

0000950170-25-01901111-0-K Alkermes plc. 2025021220250212171842171844 0 0000950170-25-019011 10-K 129 20241231 20250212 20250212 Alkermes plc. 0001520262 2834 981007018 1231 10-K 31-001-35299 25616093 CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000 00-3531-772-8000 CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000 ANTLER SCIENCE TWO PLC 20110804 Antler Science Two Ltd 20110509 10-K 1 alks-20241231.htm 10-K 10-K falseFY0001520262Alkermes plc.L2http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMemberP56Dhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMemberhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMemberP3Y0001520262us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001520262us-gaap:RetainedEarningsMember2022-12-3100015202622024-12-310001520262us-gaap:CertificatesOfDepositMember2024-12-310001520262us-gaap:CorporateDebtSecuritiesMemberalks:LongTermInvestmentsMember2024-12-310001520262us-gaap:CreditConcentrationRiskMemberalks:BiogenMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001520262alks:CardinalHealthMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2023-01-012023-12-310001520262us-gaap:SegmentContinuingOperationsMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001520262us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001520262alks:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2023-01-012023-12-310001520262us-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-12-310001520262alks:DiscountsMember2023-12-310001520262us-gaap:SegmentContinuingOperationsMemberus-gaap:CostOfSalesMember2022-01-012022-12-310001520262alks:ManufacturingRevenueMember2024-01-012024-12-310001520262us-gaap:AdditionalPaidInCapitalMember2021-12-310001520262us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001520262alks:TimeBasedRestrictedStockUnitAwardsMember2022-01-012022-12-310001520262us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001520262us-gaap:TreasuryStockCommonMember2023-12-310001520262alks:TimeBasedStockOptionsMembersrt:MaximumMember2022-01-012022-12-310001520262alks:ManufacturedProductAndRoyaltyMemberalks:LongActingINVEGAProductsMember2023-01-012023-12-310001520262alks:RISPERDALCONSTAMemberus-gaap:RoyaltyMember2024-01-012024-12-310001520262alks:ContractualAdjustmentsMember2024-12-310001520262srt:MinimumMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2023-01-012023-12-310001520262alks:LongActingINVEGAProductsMemberus-gaap:RoyaltyMember2023-01-012023-12-310001520262alks:BiogenMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2023-01-012023-12-310001520262alks:ForeignCountryExcludingSpecifiedCountryMember2024-01-012024-12-310001520262us-gaap:CorporateDebtSecuritiesMember2023-12-310001520262alks:WinterStreetLeaseTwoMember2024-12-310001520262alks:BiogenMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2024-01-012024-12-310001520262alks:ResearchAndDevelopmentMember2024-01-012024-12-310001520262us-gaap:ForeignPlanMember2023-01-012023-12-310001520262us-gaap:CorporateDebtSecuritiesMemberalks:LongTermInvestmentsMember2023-12-3100015202622022-12-310001520262us-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMemberalks:CardinalHealthMember2023-01-012023-12-310001520262alks:OtherAdjustmentsMember2024-12-310001520262alks:OtherProductsAndServicesMemberalks:ManufacturingRevenueMember2022-01-012022-12-310001520262alks:StateMedicaidRebatesMember2023-12-310001520262us-gaap:CommonStockMember2022-01-012022-12-310001520262alks:TimeBasedStockOptionsMembersrt:MinimumMember2022-01-012022-12-310001520262us-gaap:AdditionalPaidInCapitalMember2023-12-310001520262alks:DiscountsMember2023-01-012023-12-310001520262alks:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2024-01-012024-12-310001520262alks:RodinTherapeuticsIncorporationMemberus-gaap:DomesticCountryMember2024-12-310001520262us-gaap:CostOfSalesMember2023-01-012023-12-310001520262alks:JanssenMemberalks:RISPERDALCONSTAMemberalks:LicenseAgreementMember2024-01-012024-12-310001520262us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310001520262alks:AmpyraMemberus-gaap:RoyaltyMember2022-11-012022-11-300001520262alks:DiscountsMember2024-12-310001520262us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001520262us-gaap:EmployeeStockOptionMember2023-12-310001520262us-gaap:ShortTermInvestmentsMember2023-12-310001520262us-gaap:RoyaltyMemberalks:VumerityMember2022-01-012022-12-310001520262us-gaap:IntellectualPropertyMember2024-12-310001520262us-gaap:TreasuryStockCommonMember2024-01-012024-12-310001520262us-gaap:SegmentContinuingOperationsMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-310001520262alks:ContractualAdjustmentsMember2022-01-012022-12-310001520262us-gaap:BuildingAndBuildingImprovementsMember2023-12-310001520262alks:StateMedicaidRebatesMember2024-01-012024-12-310001520262alks:OtherAdjustmentsMember2024-01-012024-12-310001520262alks:ContractualAdjustmentsMember2024-01-012024-12-310001520262us-gaap:LeaseholdImprovementsMember2024-01-012024-12-310001520262alks:TimeBasedRestrictedStockUnitAwardsMember2024-12-310001520262us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001520262alks:ContractualAdjustmentsMember2023-12-310001520262us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001520262us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001520262us-gaap:ForeignPlanMember2024-01-012024-12-310001520262us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310001520262srt:MinimumMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001520262alks:PerformanceBasedRestrictedStockUnitAwardsMember2024-01-012024-12-310001520262alks:AristadaAndAristadaInitioMember2023-01-012023-12-310001520262srt:MinimumMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001520262alks:ManufacturedProductAndRoyaltyMember2023-01-012023-12-310001520262alks:SeparationAgreementMemberalks:MuralOncologyPlcMember2023-11-150001520262alks:OtherMember2024-12-310001520262us-gaap:CustomerConcentrationRiskMemberalks:CardinalHealthMemberalks:RevenuesNetMember2024-01-012024-12-310001520262us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001520262us-gaap:RoyaltyMember2024-01-012024-12-310001520262alks:CapitalPurchaseCommitmentsMember2024-12-310001520262alks:BaudaxBioIncMember2022-01-012022-09-300001520262us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-3100015202622023-11-012023-11-300001520262us-gaap:CreditConcentrationRiskMemberalks:McKessonCorporationMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001520262alks:ManufacturingRevenueMemberalks:VumerityMember2024-01-012024-12-310001520262alks:ManufacturedProductAndRoyaltyMember2023-01-012023-12-310001520262alks:OtherMember2023-12-310001520262us-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2023-01-012023-12-310001520262us-gaap:SegmentContinuingOperationsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310001520262alks:OtherAdjustmentsMember2023-01-012023-12-310001520262us-gaap:OtherNoncurrentLiabilitiesMember2024-12-310001520262us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-310001520262alks:LongActingINVEGAProductsMember2023-01-012023-12-310001520262alks:ManufacturingRevenueMemberalks:VumerityMember2022-01-012022-12-3100015202622024-06-300001520262alks:JanssenMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001520262us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001520262alks:ProductReturnsMember2022-01-012022-12-310001520262us-gaap:RoyaltyMember2023-01-012023-12-310001520262alks:StockOptionAndIncentivePlan2018Member2024-05-312024-05-310001520262us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310001520262us-gaap:LandMember2023-12-310001520262alks:ContractualAdjustmentsMember2023-01-012023-12-310001520262alks:BiogenMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2022-01-012022-12-310001520262srt:MinimumMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2022-01-012022-12-310001520262alks:McKessonCorporationMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001520262alks:RodinTherapeuticsIncorporationMemberus-gaap:StateAndLocalJurisdictionMember2024-12-310001520262us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001520262us-gaap:DomesticCountryMember2024-12-310001520262alks:FormerTermLoansMember2023-01-012023-12-3100015202622024-02-2900015202622023-11-300001520262alks:TimeBasedStockOptionsMemberalks:NonEmployeeDirectorsMember2024-01-012024-12-310001520262alks:JanssenPharmaceuticaNVMember2023-01-012023-12-3100015202622024-10-012024-12-310001520262us-gaap:IntellectualPropertyMember2023-12-310001520262alks:AmpyraMemberus-gaap:RoyaltyMember2022-10-012022-10-310001520262alks:PerformanceBasedRestrictedStockUnitAwardsMember2024-12-310001520262alks:AristadaAndAristadaInitioMember2024-01-012024-12-310001520262alks:ContractLiabilitiesMember2023-12-310001520262us-gaap:ShortTermInvestmentsMember2024-12-310001520262us-gaap:RetainedEarningsMember2023-12-310001520262alks:StockOptionAndIncentivePlan2018Member2024-12-310001520262us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001520262alks:LYBALVIMember2023-01-012023-12-310001520262alks:LongActingINVEGAProductsMemberus-gaap:RoyaltyMember2024-01-012024-12-310001520262alks:VivitrolMember2024-01-012024-12-310001520262us-gaap:SegmentContinuingOperationsMember2022-01-012022-12-310001520262us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001520262country:US2024-12-310001520262alks:JanssenMemberalks:NetSalesGreaterThan500MillionMemberalks:LicenseAgreementMemberalks:OHRisperidonePalimateMember2024-01-012024-12-310001520262alks:ForeignCountryExcludingSpecifiedCountryMember2023-01-012023-12-310001520262alks:FacilityAndCertainRelatedAssetsMember2024-01-012024-12-310001520262alks:FurnitureFixtureAndEquipmentMember2023-01-012023-12-310001520262alks:ProductReturnsMember2023-01-012023-12-310001520262us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001520262alks:ManufacturedProductAndRoyaltyMember2022-01-012022-12-310001520262alks:OtherProductsAndServicesMemberalks:ManufacturingRevenueMember2023-01-012023-12-310001520262alks:FormerTermLoansMember2023-12-310001520262alks:TimeBasedRestrictedStockUnitAwardsMember2023-01-012023-12-310001520262srt:MinimumMemberalks:FurnitureFixtureAndEquipmentMember2024-12-310001520262us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001520262alks:ManufacturedProductAndRoyaltyMemberalks:RISPERDALCONSTAMember2023-01-012023-12-310001520262alks:TimeBasedStockOptionsMembersrt:MaximumMember2024-01-012024-12-310001520262us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310001520262alks:OtherProductsAndServicesMemberalks:ManufacturedProductAndRoyaltyMember2022-01-012022-12-310001520262us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001520262alks:AmpyraMemberus-gaap:RoyaltyMember2022-04-012022-06-300001520262alks:AmpyraMemberus-gaap:RoyaltyMember2022-10-012022-12-310001520262alks:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2022-01-012022-12-310001520262alks:CardinalHealthMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2022-01-012022-12-310001520262us-gaap:LeaseholdImprovementsMember2024-12-310001520262alks:ManufacturedProductAndRoyaltyMemberalks:VumerityMember2023-01-012023-12-310001520262us-gaap:CommonStockMember2023-12-310001520262alks:LongActingINVEGAProductsMember2022-01-012022-12-310001520262us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310001520262alks:ManufacturedProductAndRoyaltyMemberalks:RISPERDALCONSTAMember2024-01-012024-12-310001520262us-gaap:CostOfSalesMember2022-01-012022-12-310001520262alks:OtherProductsAndServicesMemberalks:ManufacturingRevenueMember2024-01-012024-12-310001520262alks:MedicarePartDMember2023-12-310001520262us-gaap:LeaseholdImprovementsMember2023-12-310001520262us-gaap:ProductMember2024-01-012024-12-310001520262alks:OtherAdjustmentsMember2022-12-310001520262us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001520262us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001520262alks:VivitrolMember2022-01-012022-12-310001520262alks:ContractualAdjustmentsMember2022-12-310001520262alks:FormerTermLoansMember2024-12-012024-12-310001520262us-gaap:SegmentContinuingOperationsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-3100015202622024-01-012024-12-310001520262alks:ProductDiscountsMember2023-12-310001520262alks:OtherProductsAndServicesMemberus-gaap:RoyaltyMember2022-01-012022-12-310001520262alks:WilmingtonOhioMember2023-12-310001520262us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001520262alks:TimeBasedStockOptionsMember2022-01-012022-12-310001520262alks:JanssenMemberalks:NetSalesBetween250And500MillionMemberalks:LicenseAgreementMemberalks:OHRisperidonePalimateMember2024-01-012024-12-310001520262alks:StockOptionAndIncentivePlan2018Member2024-01-012024-12-310001520262us-gaap:SegmentContinuingOperationsMember2023-12-310001520262us-gaap:OtherCurrentLiabilitiesMember2023-12-310001520262alks:FurnitureFixtureAndEquipmentMember2022-01-012022-12-310001520262alks:ManufacturedProductAndRoyaltyMemberalks:VumerityMember2024-01-012024-12-310001520262us-gaap:SegmentContinuingOperationsMember2024-12-310001520262us-gaap:LicensingAgreementsMember2023-12-310001520262alks:ProductReturnsMember2021-12-310001520262alks:JanssenMemberus-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMember2023-01-012023-12-310001520262alks:WinterStreetLeaseTwoMember2024-01-012024-12-310001520262us-gaap:AccountsReceivableMember2023-12-310001520262alks:OtherProductsAndServicesMemberus-gaap:RoyaltyMember2023-01-012023-12-310001520262us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001520262alks:UnvestedPerformanceBasedRestrictedStockUnitsAwardsMember2024-12-310001520262alks:TimeBasedStockOptionsMemberalks:NewNonEmployeeDirectorsMember2024-01-012024-12-310001520262us-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMemberalks:CencoraIncorporationMember2024-01-012024-12-3100015202622021-12-310001520262us-gaap:CorporateDebtSecuritiesMember2024-12-310001520262us-gaap:CommonStockMember2024-12-310001520262us-gaap:CommonStockMember2024-01-012024-12-310001520262alks:OtherAdjustmentsMember2021-12-310001520262us-gaap:ConstructionInProgressMember2023-12-310001520262us-gaap:OtherCurrentLiabilitiesMember2024-12-310001520262us-gaap:LicenseMember2022-01-012022-12-310001520262us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001520262alks:DiscountsMember2021-12-310001520262alks:TimeBasedStockOptionsMembersrt:MinimumMember2024-01-012024-12-310001520262us-gaap:CustomerConcentrationRiskMemberalks:RevenuesNetMemberalks:CencoraIncorporationMember2024-01-012024-12-310001520262country:US2023-01-012023-12-310001520262us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001520262alks:RISPERDALCONSTAMemberalks:ManufacturingRevenueMember2024-01-012024-12-310001520262alks:FormerTermLoansMember2024-01-012024-12-310001520262alks:ProductDiscountsMember2024-12-310001520262us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001520262country:US2022-01-012022-12-310001520262us-gaap:AdditionalPaidInCapitalMember2022-12-310001520262us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001520262alks:AtlheneFacilityMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2023-12-310001520262us-gaap:FairValueMeasurementsRecurringMember2023-12-310001520262us-gaap:SegmentContinuingOperationsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001520262us-gaap:StateAndLocalJurisdictionMember2024-12-310001520262us-gaap:FairValueMeasurementsRecurringMember2024-12-310001520262us-gaap:CreditConcentrationRiskMemberalks:McKessonCorporationMemberus-

011024217-FURiso04217-USDXbri:sharesxbri:pusqsqfxbri:sharesalks:Agreementalks:Itemalks:Instalmentiso4217:USDalks:Investmentsecurity Á Á UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One)    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2024 OR    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from To Commission file number: 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Á Á Á Ireland(State or other jurisdiction of incorporation or organization) Á 98-1007018(I.R.S. Employer Identification No.) Connought House1 Burlington RoadDublin 4, Ireland(Address of principal executive offices) Á D04 C5Y6(Zip code) Á +353-1-772-8000 (Registrant telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Á Title of each class Á Trading Symbol(s) Á Name of each exchange on which registered Ordinary shares, \$0.01 par value Á ALKS Á Nasdaq Global Select Market Á Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes   No   Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes   No   Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   No   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer,  accelerated filer,  smaller reporting company,  and emerging growth company in Rule 12b-2 of the Exchange Act. Á Large Accelerated Filer   Á Á Á Á Á Á Á Á Á Á Á Á Á Á Accelerated Filer   Non-Accelerated Filer   Á Smaller Reporting Company   Á Á Emerging Growth Company   Á If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   Indicate by check mark whether the registrant has filed a report on and attestation to its management assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.   If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.   Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant executive officers during the relevant recovery period pursuant to 240.10D-1(b).   Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes   No   The aggregate market value of the registrant ordinary shares held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the ordinary shares were last sold as of the last business day of the registrant most recently completed second fiscal quarter was \$3,943,314,276. As of February 7, 2025, 162,614,067 ordinary shares were outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the definitive proxy statement for our 2025 Annual General Meeting of Shareholders are incorporated by reference into Part III of this report. Á Á ALKERMES PLC AND SUBSIDIARIES ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2024 INDEX Á Á Á Á Á Á Á Á Á Á PART I Á Item 1. Á Business Á 6 Item 1A. Á Risk Factors Á 30 Item 1B. Á Unresolved Staff Comments Á 51 Item 1C. Á Cybersecurity Á 51 Item 2. Á Properties Á 52 Item 3. Á Legal Proceedings Á 52 Item 4. Á Mine Safety Disclosures Á 52 PART II Á Á Á Item 5. Á Market for Registrant Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Á 53 Item 6. Á [Reserved] Á 55 Item 7. Á Management Discussion and Analysis of Financial Condition and Results of Operations Á 56 Item 7A. Á Quantitative and Qualitative Disclosures about Market Risk Á 66 Item 8. Á Financial Statements and Supplementary Data Á 67 Item 9. Á Changes in and Disagreements with Accountants on Accounting and Financial Disclosures Á 68 Item 9A. Á Controls and Procedures Á 68 Item 9B. Á Other Information Á 69 Item 9C. Á Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Á 69 PART III Á Á Á Item 10. Á Directors, Executive Officers and Corporate Governance Á 70 Item 11. Á Executive Compensation Á 70 Item 12. Á Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters Á 70 Item 13. Á Certain Relationships and Related Transactions, and Director Independence Á 70 Item 14. Á Principal Accounting Fees and Services Á 70 PART IV Á Á Á Item 15. Á Exhibits and Financial Statement Schedules Á 71 Item 16. Á Form 10-K Summary Á 77 SIGNATURES Á 78 Á Á Á 2 Á CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS This document contains and incorporates by reference forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). In some cases, these statements can be identified by the use of forward-looking terminology such as may,  will,  could,  should,  would,  expect,  anticipate,  continue,  believe,  plan,  estimate,  intend,  or other similar words. These statements discuss future expectations and contain projections of results of operations or of financial condition, or state trends and

[illegible]

use disorder or alcohol use disorder) with three categories of disorder severityâ€”mild, moderate or severe. In determining the applicability of treatments for DSM-IV conditions to persons diagnosed according to DSM-5, one study found agreement between the DSM-IV diagnoses of alcohol dependence and opioid dependence and moderate to severe alcohol use disorder and opioid use disorder, respectively, under DSM-5. A 9 A Licensed Products and Products Using Our Proprietary Technologies We have licensed products to third parties for commercialization and have licensed our proprietary technologies to third parties to enable them to develop, commercialize and/or manufacture products. See the section entitled â€œProprietary Technology Platformsâ€ and â€œPatents and Proprietary Rightsâ€ in â€œItem 1â€ Businessâ€ in this Annual Report for information with respect to our proprietary technologies and the IP protection for these products. We receive royalties and/or manufacturing and other revenues from the commercialization of these products under our collaborative arrangements with these third parties. Such arrangements include, among others, the following: Products Using Our Proprietary Technologies INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate) (collectively, the â€œlong-acting INVEGA productsâ€) are long-acting atypical antipsychotics owned and commercialized worldwide by Janssen. We believe that these products incorporate our technologies. INVEGA SUSTENNA is approved in the U.S. for the treatment of schizophrenia and for the treatment of schizoaffective disorder as either a monotherapy or adjunctive therapy. Paliperidone palmitate extended-release injectable suspension is approved in the European Union (â€œEUâ€) and other countries outside of the U.S. for the treatment of schizophrenia and is marketed and sold under the trade name XEPLION. INVEGA SUSTENNA/XEPLION is manufactured by Janssen. INVEGA TRINZA is approved in the U.S. for the treatment of schizophrenia in patients who have been adequately treated with INVEGA SUSTENNA for at least four months. TREVICTA is approved in the EU for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION. INVEGA TRINZA/TREVICTA is manufactured by Janssen. INVEGA HAFYERA is approved in the U.S. for the treatment of schizophrenia in patients who have been adequately treated with INVEGA SUSTENNA for at least four months or INVEGA TRINZA for at least three months. BYANNLI is approved in the EU for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION or TREVICTA. INVEGA HAFYERA/BYANNLI is manufactured by Janssen. For a discussion of legal proceedings related to certain of the patents covering INVEGA TRINZA, see Note 19, Commitments and Contingent Liabilities in the â€œNotes to Consolidated Financial Statementsâ€ in this Annual Report and for information about risks relating to such legal proceedings, see â€œItem 1Aâ€ Risk Factorsâ€ in this Annual Report and specifically the section entitled â€œUncertainty over IP in the biopharmaceutical industry has been the source of litigation and other legal proceedings, and we or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.â€ What is schizophrenia? See the disease state description in the section entitled â€œARISTADA and ARISTADA INITIOâ€ in â€œItem 1â€ Businessâ€ in this Annual Report. What is schizoaffective disorder? Schizoaffective disorder is a condition in which a person experiences a combination of schizophrenia symptoms, such as delusions, hallucinations or other symptoms characteristic of schizophrenia, and mood disorder symptoms, such as mania or depression. Schizoaffective disorder is a serious mental illness that affects about one in 300 people. RISPERDAL CONSTA RISPERDAL CONSTA (risperidone long-acting injection) is a long-acting atypical antipsychotic owned and commercialized worldwide by Janssen that incorporates our proprietary technologies. RISPERDAL CONSTA is approved in the U.S. for the treatment of schizophrenia and as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA is approved in numerous countries outside of the U.S. for the treatment of schizophrenia and the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one intramuscular injection every two weeks. RISPERDAL CONSTA microspheres are exclusively manufactured by us. What is schizophrenia? See the disease state description in the section entitled â€œARISTADA and ARISTADA INITIOâ€ in â€œItem 1â€ Businessâ€ in this Annual Report. 10 A Licensed Product VUMERITY VUMERITY (diroximel fumarate) is a novel, oral fumarate with a distinct chemical structure that is approved in the U.S., the EU and several other countries for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Under our license and collaboration agreement with Biogen, Biogen holds the exclusive, worldwide license to develop and commercialize VUMERITY. For more information about the license and collaboration agreement with Biogen, see the section entitled â€œCollaborative Arrangementsâ€ Biogenâ€ in â€œItem 1â€ Businessâ€ in this Annual Report. For a discussion of legal proceedings related to certain of the patents covering VUMERITY, see Note 19, Commitments and Contingent Liabilities in the â€œNotes to Consolidated Financial Statementsâ€ in this Annual Report and for information about risks relating to such legal proceedings, see â€œItem 1Aâ€ Risk Factorsâ€ in this Annual Report and specifically the section entitled â€œUncertainty over IP in the biopharmaceutical industry has been the source of litigation and other legal proceedings, and we or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.â€ What is multiple sclerosis? Multiple sclerosis (â€œMSâ€) is an unpredictable, often disabling disease of the central nervous system (â€œCNSâ€), which interrupts the flow of information within the brain, and between the brain and body. MS symptoms can vary over time and from person to person. Symptoms may include extreme fatigue, impaired vision, problems with balance and walking, numbness or pain and other sensory changes, bladder and bowel symptoms, tremors, problems with memory and concentration and mood changes, among others. Approximately 2.5 million people worldwide have MS, and most are diagnosed between the ages of 15 and 50. Key Development Program Our R&D is focused on the development of innovative medicines in the field of neuroscience that are designed to address unmet patient needs. As part of our ongoing R&D efforts, we have devoted, and will continue to devote, significant resources to conducting preclinical work and clinical studies to advance the development of new pharmaceutical products. The discussion below highlights our current key development program. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in â€œItem 1Aâ€ Risk Factorsâ€ in this Annual Report. See the section entitled â€œPatents and Proprietary Rightsâ€ in â€œItem 1â€ Businessâ€ in this Annual Report for information with respect to the IP protection for our key development program. ALKS 2680 ALKS 2680 is a novel, investigational, oral, selective orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. Orexin, a neuropeptide produced in the lateral hypothalamus, is considered to be the master regulator of wakefulness due to its activation of multiple, downstream wake-promoting pathways that project widely throughout the brain. Targeting the orexin system may address excessive daytime sleepiness across hypersomnolence disorders, whether or not deficient orexin signaling is the underlying cause of disease. Once-daily oral administration of ALKS 2680 was previously evaluated in a phase 1 study in healthy volunteers and patients with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia and is currently being evaluated in two phase 2 studies: Vibrance-1 in patients with narcolepsy type 1 and Vibrance-2 in patients with narcolepsy type 2. We expect to initiate Vibrance-3, a phase 2 study in patients with idiopathic hypersomnia, in the first half of 2025. Collaborative Arrangements We have entered into several collaborative arrangements to develop and commercialize products and, in connection with such arrangements, to access or provide access to, technological, financial, marketing, manufacturing and other resources, including the arrangements described below. Janssen INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI Under an exclusive license agreement with Janssen, we provided Janssen with rights to, and know-how, training and technical assistance in respect of, our small particle pharmaceutical compound technology, known as NanoCrystal technology, which was used to develop the long-acting INVEGA products, and we received milestone payments from Janssen upon the achievement of certain development goals. There are no further milestones to be earned under this agreement. The agreement also provides for royalty 11 A payments, which consist of a patent royalty and a know-how royalty, both of which are determined on a country-by-country basis. The patent royalty, which equals 1.5% of net sales, is payable in each country until the expiration of the last of the patents with valid claims applicable to the product in such country. The know-how royalty is a tiered royalty of 3.5% on calendar year net sales up to \$250 million; 5.5% on calendar year net sales of between \$250 million and \$500 million; and 7.5% on calendar year net sales exceeding \$500 million. The know-how royalty rate resets to 3.5% at the beginning of each calendar year and is payable until 15 years from the first commercial sale of a product in each individual country, subject to expiry of the agreement. These royalty payments may be reduced in any country based on patent litigation or on competing products achieving certain minimum sales thresholds. The license agreement, unless earlier terminated, terminates upon the expiration of the last of the patents subject to the agreement. After expiration, Janssen retains a non-exclusive, royalty free license to develop, manufacture and commercialize the products subject to certain surviving obligations. Janssen may terminate the license agreement in whole or in part upon three monthsâ€ notice to us. We and Janssen have the right to terminate the agreement upon a material breach of the other party which is not cured within a certain time period, or upon the other partyâ€s bankruptcy or insolvency. In November 2021, we received notice from Janssen of partial termination of the license agreement, following which Janssen ceased paying us royalties related to U.S. sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA. In April 2022, we commenced binding arbitration proceedings related to, among other things, Janssenâ€s partial termination of this license agreement and Janssenâ€s royalty and other obligations under the agreement. In May 2023, the arbitral tribunal (the â€œTribunalâ€) in the arbitration proceedings issued a final award (the â€œFinal Awardâ€) that served to reinstate the Janssen royalties and required payment by Janssen of back royalties and interest for amounts owed but not yet paid since the effective date of the partial termination. The Final Award also provided, among other things, that we were entitled to royalty revenues from Janssen related to net sales of INVEGA SUSTENNA through August 20, 2024, INVEGA TRINZA through the second quarter of 2030 (but no later than May 2030 when the license agreement expires) and INVEGA HAFYERA through May 2030 (when the license agreement expires). RISPERDAL CONSTA Under a product development agreement, we collaborated with Janssen on the development of RISPERDAL CONSTA. Under the development agreement, Janssen provided funding to us for the development of RISPERDAL CONSTA, and Janssen is responsible for securing all necessary regulatory approvals for the product. Under two license agreements, we granted Janssen and an affiliate of Janssen exclusive worldwide licenses to use and sell RISPERDAL CONSTA. Under our license agreements with Janssen, we receive royalty payments equal to 2.5% of Janssenâ€s end-market net sales of RISPERDAL CONSTA in each country where the license is in effect based on the quarter when the product is sold by Janssen. This royalty may be reduced in any country based on lack of patent coverage and significant competition from generic versions of the product. Janssen can terminate the license agreements upon 30 daysâ€ prior written notice to us. Either party may terminate the license agreements by written notice following a breach which continues for 90 days after the delivery of written notice thereof or upon the other partyâ€s insolvency. The licenses granted to Janssen expire on a country-by-country basis upon the later of (i) the expiration of the last patent claiming the product in such country or (ii) 15 years after the date of the first commercial sale of the product in such country, provided that in no event will the license granted to Janssen expire later than the twentieth anniversary of the first commercial sale of the product in each such country, with the exception of Canada, France, Germany, Italy, Japan, Spain and the United Kingdom, in each case, where the 15-year minimum shall pertain regardless. After expiration, Janssen retains a non-exclusive, royalty-free license to manufacture, use and sell RISPERDAL CONSTA. We exclusively manufacture RISPERDAL CONSTA at our Wilmington, Ohio facility for commercial sale. Under our manufacturing and supply agreement with Janssen, we receive manufacturing revenue based on a percentage of Janssenâ€s net unit sales price for RISPERDAL CONSTA for the applicable calendar year. This percentage is determined based on Janssenâ€s unit demand for such calendar year and varies based on the volume of units shipped, with a minimum manufacturing fee of 7.5%. Either party may terminate the manufacturing and supply agreement upon a material breach by the other party, which is not resolved within 60 days after receipt of a written notice specifying the material breach or upon written notice in the event of the other partyâ€s insolvency or bankruptcy. Janssen may terminate the agreement upon six monthsâ€ written notice to us. In the event that Janssen terminates the manufacturing and supply agreement without terminating the license agreements, the royalty rate payable to us on Janssenâ€s net sales of RISPERDAL CONSTA would increase from 2.5% to 5.0%. Revenues from our collaborative arrangements with Janssen accounted for approximately 17%, 31% and 15% of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively. 12 A Biogen Under a license and collaboration agreement with Biogen, we granted Biogen a worldwide, exclusive, sublicenseable license to develop, manufacture and commercialize VUMERITY and other products covered by patents licensed to Biogen under that agreement. Under this license and collaboration agreement, we received an upfront cash payment and milestone payments related to the achievement of certain milestones. We are also eligible to receive additional payments upon achievement of certain milestones, including milestones relating to the first two products other than VUMERITY covered by patents licensed to Biogen under the license and collaboration agreement. In addition, we receive a 15% royalty, subject to increases for VUMERITY manufactured and/or packaged by Biogen or its designees, on worldwide net sales of VUMERITY. We are also entitled to receive royalties on net sales of products other than VUMERITY covered by patents licensed to Biogen under the license and collaboration agreement, at tiered royalty rates calculated as percentages of net sales ranging from high-single digits to sub-ten double digits. All royalties are payable on a product-by-product and country-by-country basis until the later of (i) the last-to-expire patent right covering the applicable product in the applicable country and (ii) a specified period of time from the first commercial sale of the applicable product in the applicable country. Royalties for all products are subject to customary reductions, as set forth in the license and collaboration agreement. Following FDA approval of VUMERITY and except for the manufacturing responsibilities discussed below, Biogen is now responsible for all development and commercialization activities for VUMERITY and all other products covered by the patents that we licensed to Biogen. Under the license and collaboration agreement, Biogen appointed us as the toll manufacturer of clinical and commercial supplies of VUMERITY, subject to Biogenâ€s right to manufacture or have manufactured commercial supplies as a back-up manufacturer. In October 2019, we entered into a commercial supply agreement with Biogen for the commercial supply of VUMERITY, an amendment to such commercial supply agreement and an amendment to the license and collaboration agreement with Biogen, pursuant to which Biogen has conducted a technology transfer and, following an agreed manufacturing transition period, has elected to assume responsibility for the manufacture (itself or through a designee) of clinical and commercial supplies of VUMERITY in exchange for an increase in the royalty rate to be paid by Biogen to us on net sales of product that is manufactured by Biogen or its designee. In May 2024, we completed the sale of our research and development business and manufacturing facility in Athlone, Ireland (the â€œAthlone Facilityâ€) where VUMERITY is manufactured. In connection with the sale of the Athlone Facility, we have entered into a subcontracting arrangement with the purchaser of the Athlone Facility for the manufacture of VUMERITY through the manufacturing transition period, which may continue through the end of 2025. Unless earlier terminated, the license and collaboration agreement will remain in effect until the expiry of all royalty obligations. Biogen has the right to terminate the license and collaboration agreement at will, on a product-by-product basis or in its entirety upon 180 daysâ€ prior notice to us. Either party has the right to terminate the license and collaboration agreement following any governmental prohibition of the transactions effected by the agreement, or in connection with an insolvency event involving the other party. Upon termination of the license and collaboration agreement by either party, then, at our request, the VUMERITY program will revert to us. Revenues from Biogen related to this license and collaboration agreement accounted for approximately 9%, 8% and 10% of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively. Proprietary Technology Platforms We have used our proprietary technology platforms, which include technologies owned and exclusively licensed to us, to establish drug development, clinical development and regulatory expertise and in the development of our products. Injectable Extended-Release Microsphere Technology Our injectable extended-release microsphere technology allows us to encapsulate small-molecule pharmaceuticals, peptides and proteins in microspheres made of common medical polymers. The technology is designed to enable novel formulations of pharmaceuticals by providing controlled, extended release of drugs over time. Drug release from the microsphere is controlled by diffusion of the drug through the microsphere and by biodegradation of the polymer. These processes can be modulated through a number of formulation and fabrication variables, including drug substance and microsphere particle sizing and choice of polymers and excipients. 13 A LinkeRx Technology Our long-acting LinkeRx technology platform is designed to enable the creation of extended-release injectable versions of antipsychotic therapies and may also be useful in other disease areas in which extended duration of action may provide therapeutic benefits. The technology uses proprietary linker-tail chemistry to create new molecular entities derived from known agents. NanoCrystal Technology Our NanoCrystal technology is applicable to poorly water-soluble compounds and involves formulating and stabilizing drugs into particles that are nanometers in size. A drug in NanoCrystal form can be incorporated into a range of common dosage forms, including tablets, capsules, inhalation devices and sterile forms for injection, with the potential for enhanced oral bioavailability, increased therapeutic effectiveness, reduced/eliminated fed/fasted variability and sustained duration of intravenous/intramuscular release. Oral Controlled Release Technology Our oral controlled release (â€œOCRâ€) technologies are used to formulate, develop and manufacture oral dosage forms of pharmaceutical products with varied drug release profiles. Manufacturing and Product Supply We own and occupy a manufacturing facility in Wilmington, Ohio. We either purchase active pharmaceutical ingredient (â€œAPIâ€) from third parties or receive it from our third-party licensees to manufacture products using our technologies. The manufacture of our products for clinical trials and commercial use is subject to

Current Good Manufacturing Practices (cGMP) regulations and other regulations. Our manufacturing and development capabilities include formulation through process development, scale-up and full-scale commercial manufacturing and specialized capabilities for the development and manufacture of controlled substances. Although some materials and related services for our products are currently only available from a single source or a limited number of qualified sources, we attempt to acquire an adequate inventory of such materials, establish alternative sources for such materials and related services and/or negotiate long-term supply arrangements. However, we cannot be certain that we will continue to be able to obtain long-term supplies of our manufacturing materials or long-term provision of related services. Our supply chain includes an external network of third-party service providers involved in the manufacture of our products whose manufacturing facilities and processes are, like ours, subject to inspection by the FDA or comparable agencies in other jurisdictions. Any delay, interruption or other issues that arise in the acquisition of API, raw materials, or components, or in the manufacture, fill-finish, packaging, or storage of our marketed or development products, including as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection, could significantly impair our ability to manufacture and market our products or advance our development efforts, as the case may be. In May 2024, we completed the sale of our Athlone Facility and related business to Novo Nordisk (Novo) and entered into subcontracting arrangements to continue certain development and manufacturing activities performed at the Athlone Facility for a period of time after the closing of the transaction, which may continue through the end of 2025. For information about risks relating to the manufacture of our marketed products and product candidates, see Item 1A “Risk Factors” in this Annual Report and specifically those sections entitled We rely on third parties to provide goods and services in connection with the manufacture and distribution of the products we manufacture and We are subject to risks related to the manufacture of our products. Marketed Products We manufacture ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL and microspheres for RISPERDAL CONSTA at our Wilmington, Ohio facility. We outsource our packaging operations for ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL to third-party contractors. Janssen is responsible for packaging operations for RISPERDAL CONSTA. Our Wilmington, Ohio facility has been inspected by U.S., European (including the UK Medicines and Healthcare products Regulatory Agency), Chinese, Japanese, Brazilian, Turkish, Russian and Saudi Arabian regulatory authorities for compliance with required cGMP standards for continued commercial manufacturing. For more information about our Wilmington, Ohio manufacturing facility, see Item 2 “Properties” in this Annual Report. We have entered into subcontracting arrangements for the manufacture of several products in the Athlone Facility that are marketed by third parties, including VUMERITY. This facility has been inspected by regulatory authorities of numerous jurisdictions for compliance with required cGMP standards for continued commercial manufacturing. 14 Clinical Products We manufacture clinical supplies of injectable extended-release products and solid dosage form products at our Wilmington, Ohio facility. We have also contracted with third-party manufacturers to formulate certain products for clinical use. We require that our contract manufacturers adhere to cGMP in the manufacture of our products or components of our products for clinical use. Research & Development We devote significant resources to R&D programs. We focus our R&D efforts on developing novel therapeutics in areas of high unmet medical need. Our R&D efforts include, but are not limited to, areas such as pharmaceutical formulation, analytical chemistry, process development, engineering, scale-up and drug optimization/delivery. Please see Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Annual Report for additional information relating to our R&D expenditures. Permits and Regulatory Approvals We hold various permits, registrations, approvals and/or licenses in respect of our manufacturing and related activities. The primary licenses held in this regard are FDA Registrations of Drug Establishment, and licenses from the Drug Enforcement Administration of the U.S. Department of Justice (the DEA). We also hold various authorizations, licenses and certificates from the Health Products Regulatory Authority in Ireland, including an Investigational Medicinal Products Manufacturers Authorization (No. IMP074/00002) and a Manufacturers Authorization (No. M13297/00001) in respect of our offices located in Dublin, Ireland, and a Manufacturers Authorization (No. M13297/00002), in respect of the Athlone Facility, pending completion of updates to applicable product filings. We also hold current GMP certificates associated with each of these authorizations. Due to certain U.S. state law requirements, we also hold state licenses to cover distribution activities conducted in certain states where required. Additional Manufacturer Authorizations that we previously held in respect of the Athlone Facility were transferred to Novo with the sale of the facility and related business in May 2024. We do not generally act as the marketing authorization holder for products incorporating our technologies that have been developed on behalf of a licensee of such technologies. In such cases, our licensee usually holds the relevant marketing authorization from the FDA or other relevant regulatory authority, and we support this authorization as needed, including by furnishing a copy of the product’s Drug Master File, or chemistry, manufacturing and controls data, to the relevant regulator. We generally update this information annually with the relevant regulator. In other cases where we have developed proprietary products, such as VIVITROL, ARISTADA, ARISTADA INITIO and LYBALVI, we hold the marketing authorization and related regulatory documentation ourselves. Marketing, Sales and Distribution We are responsible for the marketing of VIVITROL, ARISTADA, ARISTADA INITIO, and LYBALVI in the U.S. We focus our sales and marketing efforts on physicians in private practice and in public treatment systems. We believe that we use customary pharmaceutical company practices to market our products, including through advertisements, professional symposia, selling initiatives and other methods, and to educate individual physicians, nurses, social workers, counselors and other stakeholders involved in the treatment of opioid dependence, alcohol dependence, schizophrenia and bipolar I disorder. We provide, and contract with third-party vendors to provide, customer services and other related programs for our products, such as product-specific websites, insurance research services and order, delivery and fulfillment services. Our sales force for VIVITROL in the U.S. consisted of approximately 105 individuals as of December 31, 2024. VIVITROL is primarily sold to pharmaceutical wholesalers, pharmacies, specialty distributors and treatment providers. Product sales of VIVITROL during the year ended December 31, 2024 to McKesson Corporation, Cardinal Health and Cencora, Inc. (formerly known as Amerisource Bergen, Cencora) represented approximately 34%, 21% and 16%, respectively, of total VIVITROL gross sales. Our sales force for ARISTADA, ARISTADA INITIO and LYBALVI in the U.S. consisted of approximately 355 individuals as of December 31, 2024. ARISTADA, ARISTADA INITIO and LYBALVI are primarily sold to pharmaceutical wholesalers. Product sales of ARISTADA and ARISTADA INITIO during the year ended December 31, 2024 to McKesson Corporation, Cardinal Health and Cencora represented approximately 38%, 32% and 23%, respectively, of total ARISTADA and ARISTADA INITIO gross sales. Product sales of LYBALVI during the year ended December 31, 2024 to McKesson Corporation, Cardinal Health and Cencora represented approximately 35%, 32% and 29%, respectively, of total LYBALVI gross sales. ICS, a division of Cencora, provides warehousing, shipping and administrative services for VIVITROL, ARISTADA, ARISTADA INITIO and LYBALVI. 15 Under our license agreements with Janssen, Biogen and other licensees and sublicensees, the licensees and sublicensees are typically responsible for the commercialization of any products developed under their respective agreements if and when regulatory approval is obtained. Competition We face intense competition in the development, manufacture, marketing and commercialization of our products from many and varied sources, such as research institutions and biopharmaceutical companies, including other companies with similar technologies. Some of these competitors are also our licensees, who control the commercialization of products from which we receive manufacturing and/or royalty revenues. In some cases, these competitors may be working to develop and market other products, systems, or other methods of preventing or reducing disease, or new small-molecule or other classes of drugs. The biopharmaceutical industry is characterized by intensive research, development and commercialization efforts and rapid and significant technological change. In many cases, there are already products on the market that may be in direct competition with our commercial products or products in development. In addition, there are many companies developing products for use in similar indications or with similar technologies to ours with whom we and our licensees compete, many of whom are larger and have significantly greater financial, operational and other resources than we do. Other smaller or earlier stage companies may also prove to be significant competitors, whether through focused or more abbreviated development programs, or collaborative arrangements with large, established companies. Some of the products being developed by our competitors are being designed to work differently than our products and may prove to be safer or more effective than our products or achieve regulatory approval and be commercialized earlier than our products, which may render our products or technology platforms obsolete or noncompetitive or make it more challenging for us to commercialize our products. With respect to our products, we believe that our ability to successfully compete will depend on, among other things, the existence of competing or alternative products in the marketplace, including generic competition, and the relative price of those products; the efficacy, safety and reliability of our products compared to competing or alternative products; product acceptance by, and preferences of, physicians, other healthcare providers and patients; our ability to comply with applicable laws, regulations and regulatory requirements with respect to the manufacture and/or commercialization of our products, including any changes or increases to regulatory restrictions; protection of our proprietary rights relating to our products; our ability to obtain reimbursement for our products; our ability to complete clinical development and obtain regulatory approvals for our products, and the timing and scope of any such regulatory approvals; our ability to successfully manufacture and provide a reliable supply of commercial quantities of a product to the market; and our ability to recruit, retain and develop skilled employees. With respect to our proprietary injectable product platform, we are aware that there are other companies developing extended-release delivery systems for pharmaceutical products, including but not limited to technology from Pharmathen S.A., which underpins aripiprazole formulations in development, and technology underpinning Teva’s once every two weeks injectable microsphere formulation, each for the treatment of schizophrenia. In the treatment of schizophrenia, ARISTADA, the long-acting INVEGA products and RISPERDAL CONSTA compete with each other and a number of other injectable products, including ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension), which is marketed and sold by Lilly; ABILIFY MAINTENA (aripiprazole for extended release injectable suspension), a once-monthly injectable formulation of ABILIFY (aripiprazole) developed by Otsuka Pharm. Co.; ABILIFY ASIMTUFI (aripiprazole), a once-every-two-months injectable formulation of ABILIFY (aripiprazole) developed by Otsuka Pharm. Co.; PERSERIS (risperidone for extended release injectable suspension), a once-monthly formulation of risperidone marketed by Indivior plc; RYKINDO (risperidone), a once-every-two-weeks injectable formulation of risperidone developed by Luye Pharma Group; UZEDY (risperidone) extended-release injectable suspension, for subcutaneous use, developed and marketed by MedinCell S.A. and Teva; and generic versions of branded injectable products. In the treatment of schizophrenia, LYBALVI competes with other oral antipsychotic products, including CAPLYTA (lumateperone) developed and marketed by Intra-Cellular Therapies, Inc.; REXULTI (brexipiprazole), which is co-marketed by Otsuka Pharm Co. and H. Lundbeck A/S plc; VRAYLAR (cariprazine), which is marketed and sold by Abbvie Inc.; COBENFY (xanomeline and trospium chloride), which is marketed and sold by Bristol-Myers Squibb Company; other oral compounds currently on the market; and generic versions of branded oral products. Other pharmaceutical companies are developing products for the treatment of schizophrenia that, if approved by the FDA, would compete with LYBALVI. In the treatment of bipolar I disorder, LYBALVI and RISPERDAL CONSTA compete with antipsychotics such as oral aripiprazole; VRAYLAR; ABILIFY MAINTENA; ABILIFY ASIMTUFI; CAPLYTA; RYKINDO; risperidone; quetiapine; olanzapine; and ziprasidone. Other pharmaceutical companies are developing products for the treatment of bipolar I disorder that, if approved by the FDA, would compete with LYBALVI. 16 In the treatment of alcohol dependence, VIVITROL competes with generic acamprostate calcium (also known as CAMPRAL) and generic disulfiram (also known as ANTABUSE) as well as currently marketed drugs, including generic drugs, also formulated from naltrexone. Other pharmaceutical companies are developing products that have shown some potential in treating alcohol dependence that, if approved by the FDA, would compete with VIVITROL. In the treatment of opioid dependence, VIVITROL competes with SUBOXONE (buprenorphine HCl/naloxone HCl dehydrate sublingual tablets), SUBOXONE (buprenorphine/naloxone) Sublingual Film, SUBUTEX (buprenorphine HCl sublingual tablets) and SUBLOCADE (once-monthly buprenorphine extended-release injection), each of which is marketed and sold by Indivior plc; BUNAVAIL buccal film (buprenorphine and naloxone) marketed by BioDelivery Sciences; SUBSOLV (buprenorphine and naloxone) marketed by Orexo US, Inc.; and BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), marketed by Braeburn Inc. VIVITROL also competes with methadone, oral naltrexone and generic versions of SUBUTEX and SUBOXONE sublingual tablets. Other pharmaceutical companies are developing products that have shown potential in treating opioid dependence that, if approved by the FDA, would compete with VIVITROL. In the treatment of MS, VUMERITY competes with AVONEX (interferon beta-1a), TYASABRI (natalizumab), TECFIDERA (dimethyl fumarate), and PLEGRIDY (peginterferon beta-1a) from Biogen; OCREVUS (ocrelizumab) from Genentech; BETASERON (interferon beta-1b) from Bayer HealthCare Pharmaceuticals; COPAXONE (glatiramer acetate) from Teva; REBIF (interferon beta-1a) and MAVENCLAD (cladribine) from EMD Serono, Inc.; GILENYA (fingolimod), EXTAVIA (interferon beta-1b) and MAYZENT (siponimod) from Novartis AG; AUBAGIO (teriflumonad) and LEMTRADA (alemtuzumab) from Sanofi-Aventis; ZEPOSIA (ozanimod) from Bristol-Myers Squibb Company; PONVORY (ponesimod) from Janssen; and BRIUMVI (ublituximab-xiiv) from TG Therapeutics, Inc. With respect to our NanoCrystal technology, we are aware that other technology approaches similarly address poorly water-soluble drugs. These approaches include nanoparticles, cyclodextrins, lipid-based self-emulsifying drug delivery systems, dendrimers and micelles, among others, any of which could limit the potential success and growth prospects of products incorporating our NanoCrystal technology. In addition, there are many competing technologies to our OCR technology, some of which are owned by large pharmaceutical companies with drug delivery divisions or other, smaller drug-delivery-specific companies. Patents and Proprietary Rights Our success depends, in part, on our ability to obtain and maintain patent protection for our products, including those marketed and sold by our licensees, to maintain trade secret protection and to operate without infringing upon the proprietary rights of others. We have a proprietary portfolio of patent rights and exclusive licenses to patents and patent applications, which includes numerous patents in the U.S. and in other countries directed to compositions of matter, methods of treatment and formulations, and processes of preparation. In the future, we plan to file additional patent applications in the U.S. and in other countries directed to new or improved products and processes, and we intend to continue to vigorously defend our patent positions. In addition, our licensees may own additional patents that cover those products from which we receive royalties. 17 ARISTADA and ARISTADA INITIO We have several U.S. patents and patent applications, and a number of corresponding non-U.S. counterparts, that cover ARISTADA and/or ARISTADA INITIO. Our principal U.S. patents for ARISTADA and/or ARISTADA INITIO and their expiration dates are as follows: A U.S. Patent No. A Product(s) Covered Expiration Date A 8,431,576 A ARISTADA;ARISTADA INITIO 2030 A 8,796,276 A ARISTADA;ARISTADA INITIO 2030 A 10,112,903 A ARISTADA;ARISTADA INITIO 2030 A 10,023,537 A ARISTADA 2030 A 10,351,529 A ARISTADA;ARISTADA INITIO 2030 A 11,518,745 A ARISTADA;ARISTADA INITIO 2030 A 12,180,164 A ARISTADA;ARISTADA INITIO 2030 A 11,273,158 A ARISTADA;ARISTADA INITIO 2039 A 9,034,867 A ARISTADA 2032 A 10,226,458 A ARISTADA 2032 A 9,193,685 A ARISTADA 2033 A 9,861,699 A ARISTADA 2033 A 10,342,877 A ARISTADA 2033 A 10,639,376 A ARISTADA 2033 A 11,097,006 A ARISTADA 2033 A 11,969,469 A ARISTADA 2033 A 9,452,131 A ARISTADA 2035 A 9,526,726 A ARISTADA 2035 A 10,064,859 A ARISTADA 2035 A 10,238,651 A ARISTADA 2035 A 10,478,434 A ARISTADA 2035 A 10,813,928 A ARISTADA 2035 A 10,973,816 A ARISTADA 2035 A 11,406,632 A ARISTADA 2035 A 11,883,394 A ARISTADA 2035 A 10,016,415 A ARISTADA INITIO 2035 A 10,688,091 A ARISTADA INITIO 2035 A 10,849,894 A ARISTADA INITIO 2035 A 11,115,552 A ARISTADA INITIO 2035 VIVITROL We have a number of patents and pending patent applications covering our microsphere technology throughout the world, which, to some extent, cover VIVITROL. We own one unexpired Orange-Book listed U.S. patent covering VIVITROL, which expires in the U.S. in 2029. Pursuant to the terms of a confidential settlement and license agreement entered into in August 2023 with Teva, we granted Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license under the remaining patent covering VIVITROL to market and sell a generic version of VIVITROL in the U.S. beginning on January 15, 2027 (the First Entry Date), or earlier under certain circumstances. Under the terms of a settlement and license agreement entered into in July 2019 with Amneal Pharmaceuticals LLC (Amneal), we granted Amneal a non-exclusive license under certain patents covering VIVITROL, including the remaining patent covering VIVITROL in the U.S., to market and sell a generic formulation of VIVITROL in the U.S. beginning on the earlier of the First Entry Date, sometime in 2028 or earlier under certain circumstances. 18 INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANLI Our NanoCrystal technology patent portfolio, licensed to Janssen, contains a number of granted patents and pending patent applications throughout the world, including in the U.S. and in countries outside of the U.S. The latest to expire of the patents subject to our license agreement expires in 2030 in the U.S., the EU and certain other countries. In addition, Janssen has other patents not subject to our license agreement, including, among others, one that covers INVEGA TRINZA in the U.S. and expires in 2036 and two that cover INVEGA HAFYERA in the U.S. and expire in 2041. For a discussion of legal proceedings related to patents covering INVEGA TRINZA, see Note 19, Commitments and Contingent Liabilities in the Notes to Consolidated Financial Statements in this Annual Report. VUMERITY We have U.S. patents and patent applications, and a number of corresponding non-U.S. counterparts, that cover VUMERITY. U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733, each expiring in 2033, cover compositions of, or methods of treatment for, VUMERITY. For a discussion of legal proceedings related to patents covering VUMERITY, see Note 19, Commitments and Contingent Liabilities in the Notes to Consolidated Financial Statements in this Annual Report. LYBALVI We own or have a license to U.S. and worldwide patents and patent applications that cover a class of compounds that includes the opioid modulators in LYBALVI. In addition, we own U.S. and worldwide patents and patent applications that claim

[illegible]

any other approved product. The FDA is prohibited from accepting any abbreviated new drug application (ANDA) for a generic drug or 505(b)(2) application referencing the NCE for five years from the date of approval of the NCE, or for four years in the case of an ANDA or 505(b)(2) application containing a patent challenge, and in both cases may not approve such generic drug or 505(b)(2) application until expiration of NCE marketing exclusivity. A 505(b)(2) application is an NDA in which the applicant relies, in part, on data and the FDA's findings of safety and efficacy from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Hatch-Waxman Act exclusivities will not prevent the submission or approval of a full NDA (e.g., under 505(b)(1)), as opposed to an ANDA or 505(b)(2) application, for any drug, including, for example, a drug with the same active ingredient, dosage form, route of administration, strength and conditions of use. The Hatch-Waxman Act also provides three years of exclusivity for applications containing the results of new clinical investigations, other than bioavailability studies, essential to the FDA's approval of new uses of approved products, such as new indications, dosage forms, strengths, or conditions of use. However, this exclusivity only protects against the approval of ANDAs and 505(b)(2) applications for the protected use and will not prohibit the FDA from accepting or approving ANDAs or 505(b)(2) applications for other products containing the same active ingredient. The Hatch-Waxman Act requires NDA applicants and NDA holders to provide certain information about patents related to the drug for listing in the FDA's Approved Drugs Product List, commonly referred to as the Orange Book. ANDA and 505(b)(2) applicants must then certify regarding each of the patents listed with the FDA for the reference product. A certification that a listed patent is invalid or will not be infringed by the marketing of the applicant's product is called a Paragraph IV certification. If the ANDA or 505(b)(2) applicant provides such a notification of patent invalidity or noninfringement, then the FDA may accept the ANDA or 505(b)(2) application four years after approval of the NDA for an NCE. If a Paragraph IV certification is filed and the ANDA or 505(b)(2) application has been accepted as a reviewable filing by the FDA, the ANDA or 505(b)(2) applicant must then, within 20 days, provide notice to the NDA holder and patent owner stating that the application has been submitted and providing the factual and legal basis for the applicant's opinion that the patent is invalid or not infringed. The NDA holder or patent owner may file suit against the ANDA or 505(b)(2) applicant for patent infringement. If this is done within 45 days of receiving notice of the Paragraph IV certification, a one-time, 30-month stay of the FDA's ability to approve the ANDA or 505(b)(2) application is triggered. The 30-month stay begins at the end of the NDA holder's data exclusivity period, or, if data exclusivity has expired, on the date that the patent holder is notified. The FDA may approve the proposed product before the expiration of the 30-month stay if a court finds the patent invalid or not infringed, or if the court shortens the period because the parties have failed to cooperate in expediting the litigation. 23. Orphan Drug Act Under the Orphan Drug Act, the FDA may designate drugs or biologics for relatively small patient populations as orphan drugs. FDA grants orphan drug designation to drugs intended to treat a rare disease or condition, which is one that affects fewer than 200,000 individuals in the U.S., or more than 200,000 individuals, but for which there is no reasonable expectation that the cost of developing the product and making it available in the U.S. for the disease or condition will be recovered from U.S. sales of the product. Orphan drug designation does not shorten the duration of the regulatory review process or lower the approval standards, but can provide important benefits, including consultation with the FDA. If a product is approved for its orphan designated use, it may be entitled to Orphan Drug Exclusivity (ODE), which blocks the FDA from approving for seven years any other application for a product that is the same drug for the same indication. ODE does not prevent approval of another sponsor's application for different indications or uses of the same drug, or for different drugs for the same indication. 24. Sales and Marketing We are subject to various U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback laws and false claims laws. Anti-kickback laws make it illegal for a prescription drug manufacturer to solicit, offer, receive, or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase or prescription of a particular drug. Due to the broad scope of the U.S. statutory provisions, the general absence of guidance in the form of regulations, and few court decisions addressing industry practices, it is possible that our practices might be challenged under anti-kickback or similar laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third-party payers (including Medicare and Medicaid) claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid). In addition, federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the U.S. government under the False Claims Act. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed. See "Item 1A: Risk Factors" in this Annual Report and specifically those sections entitled "If there are changes in, or we fail to comply with, the extensive legal and regulatory requirements affecting the healthcare industry, we could be subject to investigations, litigation, costs, penalties and business losses," "Revenues generated by sales of our products depend, in part, on the availability from third-party payers of reimbursement for our products and the extent of cost-sharing arrangements for patients (e.g., patient co-payment, co-insurance, deductible obligations) and cost-control measures imposed, and any reductions in payment rate or reimbursement or increases in our or in patients' financial obligation to payers could result in decreased sales of our products and/or decreased revenues" and "The clinical study or commercial use of our products may cause unintended side effects or adverse reactions, or incidents of misuse may occur, which could adversely affect our products, business and share price." Laws and regulations have been enacted by the U.S. federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and healthcare providers and require disclosure to the government and public of such interactions. The laws include federal "sunshine" or open payments, provisions enacted in 2010 as part of the comprehensive federal healthcare reform legislation and supplemented as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. Such provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments made to, or at the request of, or on behalf of, physicians or to teaching hospitals and certain payments made to physicians assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse-midwives. Certain state laws also require disclosure of pharmaceutical pricing information and marketing expenditures. Given the ambiguity found in many of these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent U.S. federal and state laws and regulations. Pricing and Reimbursement United States In the U.S., sales of our products, including those sold by our licensees, and our ability to generate revenues on such sales are dependent, in significant part, on the availability and level of reimbursement from third-party payers such as state and federal governments, including Medicare and Medicaid, managed care providers and private insurance plans. Third-party payers are increasingly challenging the prices charged for medical products and examining the medical necessity and cost-effectiveness of medical products, in addition to their safety and efficacy. 24. A Medicaid is a joint federal and state program that is administered by the states for low-income and disabled beneficiaries. Under the Medicaid rebate program, we are required to pay a rebate for each unit of product reimbursed by the state Medicaid programs. The amount of the rebate for each product is set by law as the greater of 23.1% of average manufacturer price (AMP) or the difference between AMP and the best price available from us to any commercial or non-federal governmental customer. The rebate amount must be adjusted upward where the AMP for a product's first full quarter of sales, when adjusted for increases in the Consumer Price Index (CPI) Urban, is less than the AMP for the current quarter, with this difference being the amount by which the rebate is adjusted upwards. The rebate amount is required to be recomputed each quarter based on our report of current AMP and best price for each of our products to the Centers for Medicare & Medicaid Services (CMS). The terms of our participation in the rebate program impose a requirement on us to report revisions to AMP or best price within a period not to exceed 12 quarters from the quarter in which the data was originally due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision. In addition, if we were found to have knowingly submitted false information to the government, the statute provides for civil monetary penalties per item of false information in addition to other penalties available to the government. Medicare is a federal program that is administered by the federal government that covers individuals age 65 and over as well as those with certain disabilities. Medicare Part B pays physicians who administer our products under a payment methodology using average sales price (ASP) information. Manufacturers, including us, are required to provide ASP information to CMS on a quarterly basis. This information is used to compute Medicare payment rates, with rates for Medicare Part B drugs outside the hospital outpatient setting and in the hospital outpatient setting consisting of ASP plus a specified percentage. These rates are adjusted periodically. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, the statute provides for civil monetary penalties for each misrepresentation and for each day in which the misrepresentation was applied. Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that do not need to be injected or otherwise administered by a physician) and certain physician-administered drugs reimbursed under a pharmacy benefit. Medicare Part D also covers the prescription drug benefit for dual eligible beneficiaries. Medicare Part D is administered by private prescription drug plans approved by the U.S. government and each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time-to-time. The prescription drug plans negotiate pricing with manufacturers and may condition formulary placement on the availability of manufacturer discounts. The Medicare Part D benefit has distinct phases, where the share of drug costs paid by Medicare Part D enrollees, the Medicare Part D prescription drug plan, drug manufacturers and Medicare varies. Prior to 2025, the phases consisted of the deductible phase, the initial coverage phase, the coverage gap and the catastrophic coverage phase and, except for dual eligible Medicare Part D beneficiaries who qualified for low-income subsidies, drug manufacturers, including us, were required to provide a seventy percent (70%) discount on our brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries reached the coverage gap in their drug benefits. The Inflation Reduction Act of 2022 (the "Inflation Reduction Act") made substantial changes to the Medicare Part D benefit design and replaced the manufacturer coverage-gap discount program with a new manufacturer discount program that took effect in January 2025. Under the new discount program, the Medicare Part D benefit phases consist of the deductible phase, the coverage phase and the catastrophic coverage phase, and drug manufacturers must provide a ten percent (10%) discount on their brand name prescription drugs utilized by Medicare Part D beneficiaries during the initial coverage phase and a twenty percent (20%) discount during the catastrophic coverage phase. For manufacturers that meet the definition of a "specified manufacturer," the Inflation Reduction Act provides for Medicare Part D discounts to be phased in over time, starting with a one percent (1%) discount in the initial coverage phase and a one percent (1%) discount in the catastrophic coverage phase in 2025. These discount amounts increase each year, stepping up to a ten percent (10%) discount in the initial coverage phase in 2029 and a twenty percent (20%) discount in the catastrophic coverage phase in 2031. Alkermes meets the criteria of a "specified manufacturer" and, therefore, will follow the phase-in schedule for discounts to the Medicare Part D program. Federal law also requires that any company that participates in the Medicaid Drug Rebate Program (MDRP) also participate in the Public Health Services (PHS) (including the Indian Health Services, IHS) pharmaceutical pricing program (the 340B program), in order for federal funds to be available for the manufacturer's drugs under Medicaid and Medicare Part B. The 340B program, which is administered by the Health Resources and Services Administration (HSA), requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B "ceiling price" for the manufacturer's covered drugs. These 340B covered entities include certain qualifying community health clinics, a variety of entities that receive health services grants from the Public Health Service, and multiple categories of hospitals, including children's hospitals, critical access hospitals, free standing cancer hospitals and hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the MDRP. A regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities became effective on January 1, 2019. The scope and implementation of the 340B program continue to be the subject of legislative and regulatory interest and ongoing litigation, the outcomes of which are difficult to predict. 25. We also make our products available for purchase by authorized users of the Federal Supply Schedule (FSS) of the General Services Administration pursuant to our FSS contract with the Department of Veterans Affairs. Under the Veterans Health Care Act of 1992 (the "VHCA"), we are required to offer deeply discounted FSS contract pricing to four federal agencies: the Department of Veterans Affairs; the Department of Defense; the Coast Guard; and the PHS, in order for federal funding to be made available for reimbursement of any of our products by such federal agencies and certain federal grantees. Coverage under Medicaid, the Medicare Part B program and the PHS pharmaceutical pricing program is also conditioned upon FSS participation. FSS pricing is negotiated periodically with the Department of Veterans Affairs. FSS pricing is intended not to exceed the price that we charge our most-favored, non-federal customer for a product. In addition, prices for drugs purchased by the Department of Veterans Affairs, Department of Defense (including drugs purchased by military personnel and dependents through the Tricare Retail Pharmacy (Tricare) program), Coast Guard and PHS are subject to a cap on pricing equal to 76% of the non-federal average manufacturer price (non-FAMP). An additional discount applies if non-FAMP increases more than inflation (measured by the Consumer Price Index (CPI) Urban). In addition, if we are found to have knowingly submitted false information to the government, the VHCA provides for civil monetary penalties per false item of information in addition to other penalties available to the government. In addition, in January 2016, CMS released the final Medicaid covered outpatient drug regulation, which became effective in April 2016. This regulation implements those changes made by the Patient Protection and Affordable Care Act (the "ACA") to the Medicaid drug rebate statute in 2010 and addresses a number of other issues with respect to the Medicaid program, including, but not limited to, the eligibility and calculation methodologies for AMP and best price, and the expansion of Medicaid rebate liability to include Medicaid managed care organizations. The final Medicaid covered outpatient drug regulation established two calculation methodologies for AMP: one for drugs generally dispensed through retail community pharmacies (RCP) and one for so-called "injected" drugs (inhaled, infused, instilled, implanted or injectable drugs) not generally dispensed through RCPs. The regulation further made clear that 51 drugs would qualify as "not generally dispensed" and, therefore, able to use the alternative AMP calculation, if not more than thirty percent (30%) of their sales were to RCPs or to wholesalers for RCPs. The primary difference between the two AMP calculations is the requirement to include in AMP, for those qualifying 51 drugs not generally dispensed through RCPs, certain payments, rebates and discounts related to sales to non-RCPs; such inclusion often leads to a lower AMP. The decision of which AMP calculation a product is eligible to use must be made and applied on a monthly basis based on the percentage of sales of such product to RCPs or to wholesalers for RCPs. In September 2024, CMS released a final rule titled "Medicaid Program: Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program," the provisions of which generally took effect in November 2024. The rule includes several provisions affecting manufacturers that participate in the MDRP, including, but not limited to, addressing manufacturer misclassification of their products in reports required by the MDRP, imposing a 12-quarter deadline for manufacturer disputes or audits of state rebate invoices, and modifying the definition of "covered outpatient drug" for which manufacturers are required to pay rebates to include certain drugs administered in inpatient settings where the drug is part of an inclusive payment, such inclusive payment includes an amount attributable to the drug and the number of units of the drug administered to the patient, and where the amount paid that is attributable to the drug is based on a reimbursement methodology included in the applicable state plan. U.S. federal and state governments regularly consider reforming healthcare coverage and lessening healthcare costs. Such reforms may include price controls, value-based pricing and changes to the coverage and reimbursement of our products, which may have a significant impact on our business. In August 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes several provisions

including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Recent budgetary pressures in many EU countries are causing governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates, and expanded generic substitution and patient cost-sharing. If budget pressures continue, governments may implement additional cost-containment measures. 26 Å Other Regulations Foreign Corrupt Practices Act: We are subject to the U.S. Foreign Corrupt Practices Act (the “FCPA”) and its Irish equivalent, which prohibits corporations and their representatives from paying, offering to pay, promising, authorizing, or making payments of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. In many countries, the healthcare professionals with whom we regularly interact may meet the FCPA’s definition of a foreign government official. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls. Environmental, Health and Safety Laws: Our operations are subject to complex and increasingly stringent environmental, health and safety laws and regulations in the countries where we operate and, in particular, where we have manufacturing facilities, namely the U.S. and Ireland. Environmental and health and safety authorities in the relevant jurisdictions, including the Environmental Protection Agency and the Occupational Safety and Health Administration in the U.S. and the Environmental Protection Agency and the Health and Safety Authority in Ireland, administer laws which regulate, among other matters, the emission of pollutants into the air (including the workplace), the discharge of pollutants into bodies of water, the storage, use, handling and disposal of hazardous substances, the exposure of persons to hazardous substances, and the general health, safety and welfare of employees and members of the public. In certain cases, these laws and regulations may impose strict liability for pollution of the environment and contamination resulting from spills, disposals or other releases of hazardous substances or waste and/or any migration of such hazardous substances or waste. Costs, damages and/or fines may result from the presence, investigation and remediation of contamination at properties currently or formerly owned, leased or operated by us and/or off-site locations, including where we have arranged for the disposal of hazardous substances or waste. In addition, we may be subject to third-party claims, including for natural resource damages, personal injury and property damage, in connection with such contamination. The General Data Protection Regulation (“GDPR”) The GDPR became effective in May 2018 and replaced the previous EU Data Protection Directive (95/46). The GDPR, which governs the processing of personal data (including personal health data), applies to the Company and any of its subsidiaries that are established in the EU to the extent that they process personal data as well as any of its subsidiaries that are established outside the EU to the extent that they process personal data relating to EU residents for certain purposes, including any such data relating to clinical trial participants in the EU. The GDPR imposes significant obligations on controllers and processors of personal data, including high standards for obtaining consent from individuals to process their personal data, robust notification requirements to individuals about the processing of their personal data, a strong individual data rights regime, mandatory data breach notifications, limitations on the retention of personal data, stringent requirements pertaining to health data, and strict rules and restrictions on the transfer of personal data outside of the EU, including to the U.S. The GDPR also imposes additional obligations on, and required contractual provisions to be included in, contracts between companies subject to the GDPR and their third-party processors that relate to the processing of personal data. The GDPR allows EU member states to make additional laws and regulations in order to introduce further conditions, including limitations, with regard to the processing of genetic, biometric or health data. Other Laws: We are subject to a variety of financial disclosures, securities trading regulations and U.S. and Irish or EU governmental regulations as an Irish-incorporated company publicly-listed in the U.S., including laws relating to the oversight activities of the SEC, the Irish Companies Act 2014, and the regulations of the Nasdaq Stock Market (“Nasdaq”), on which our shares are traded. We are also subject to various laws, regulations and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import and export and use and environmental matters, including disposal of hazardous or potentially hazardous substances used in connection with our research work. Human Capital Resources As a global biopharmaceutical company focused on developing innovative medicines in the field of neuroscience, we have built, and continue to devote significant resources to further develop and enhance, a comprehensive cross-functional infrastructure designed to support product development from discovery through commercialization and lifecycle management. We seek to attract, hire, develop, recognize and retain qualified and highly skilled employees with experience in areas such as R&D, including early discovery, medicinal chemistry, translational medicine, formulation development, and clinical trials operations capabilities; IP prosecution, enforcement and defense; medical affairs; manufacturing operations; U.S. federal and state government affairs; sales and marketing; and market access, among other areas. Competition for such personnel in our industry and the geographic regions in which we operate is intense, with numerous companies also developing, launching or marketing products, including products against which our products directly compete. We are committed to supporting our employees’ well-being in a transparent, diverse, inclusive, and collaborative environment and to providing them with access to training, support and resources intended to help them succeed professionally, while balancing their professional and personal lives. 27 Å As of February 7, 2025, we had approximately 1,800 full time employees, of which approximately 1,700 were based in the U.S. and 100 were based in Ireland. Our 2024 global voluntary attrition rate of 9.6% was below industry benchmarks. None of our employees are covered by a collective bargaining agreement, and we consider our relations with our employees to be good. We are an equal opportunity employer and fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. All human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination are administered in accordance with the principles of equal employment opportunity and other legitimate criteria without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable laws. In recognition of the value of our employees and their important contributions to the achievement of our business objectives, we offer market-competitive comprehensive total rewards packages, including bonus opportunities at all levels tied to individual and company performance, and for employees at certain levels, company equity opportunities. We are committed to designing and managing our pay programs and decisions to support equitable pay for all employees. We have established our compensation programs based on market and benchmark data and strive to pay all employees equitably, taking into consideration factors such as their role, skills, abilities and relevant experience. We routinely monitor our pay programs in order to respond to market trends and maintain equity within our workforce. We offer our employees healthcare and retirement savings plan benefits, paid time off, tuition reimbursement and other benefits designed to support healthy lifestyle choices, financial well-being and work-life balance. In support of our business, we seek to cultivate a work environment that reflects collaboration, respect for each voice, and unwavering commitment, and strengthens the sense of belonging among our employees. Reflecting the needs of our employees, we have established a global steering committee, comprised of representatives from all of our locations (including field-based employees), focused on creating connections, fostering conversations, and helping to support alignment of our efforts across the range of perspectives within our organization. We have collaborated with our employees to create five employee resource groups, or ERGs: Limitless, a network to support people impacted by disability or illness; MOSAIC, a multicultural network; Operation Salute, a network to support active duty military members, veterans and their families; Pride@Work, an LGBTQ+ and allies network; and Women Inspired Network (WIN), a women’s network. These ERGs, which are open to all employees, share a common purpose of supporting and enhancing the inclusiveness of our company culture and providing opportunities for professional development, networking, learning and building deeper connections within Alkermes. We encourage active employee engagement to help ensure that employees feel part of our mission and that they have a voice in the Alkermes community. Since 2017, we have conducted periodic employee engagement surveys to understand employee sentiment regarding, and satisfaction with, their work and experience at Alkermes, and have used, and plan to continue to use, the data collected to help inform and evolve our human capital management strategy and initiatives. We survey employees at least annually, which allows our employees to share their insights on a regular basis and provides us with opportunities to regularly assess and address employee feedback. As many of our office-based employees have adapted to a hybrid work model, we have continued to implement our expanded employee communications strategies to keep all employees connected and informed. We are committed to the professional growth and development of our employees. We conduct a comprehensive on-boarding experience that connects newly hired employees to our business, values, culture, and people. We encourage and support our employees in their adoption of Individual Development Plans designed to identify professional development and growth opportunities to help support their career aspirations. We frequently offer Company-hosted trainings that cover topics including performance management, problem-solving, leadership development, diversity, communication and mentorship, and as appropriate, more specialized skills-based programs. We also provide all employees access to our LinkedIn Learning platform, which provides on-demand learning opportunities. We ask our employees to help us promote and sustain workplace environments that are safe, productive and protective of the health and well-being of our people and in compliance with applicable laws, rules and regulations. We maintain extensive corporate environmental, health, safety and security policies, adhere to all health and safety standards set by regulators in the locations in which we operate, and routinely assess workplace risks, conduct employee trainings and monitor our sites to reduce the risk of workplace accidents. In 2024, employee health, safety and wellness continued to be of particular focus and importance for the Company. 28 Å Available Information and Website Disclosure Our principal executive offices are located at Connaught House, 1 Burlington Road, Dublin 4, Ireland D04 C5Y6. Our telephone number is +353-1-772-8000 and our website address is www.alkermes.com. Information found on, or accessible through, our website is not incorporated into, and does not form a part of, this Annual Report. We make available free of charge through the Investors section of our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. We also make available on the Corporate Governance page of the Investors section of our website at www.alkermes.com (i) the charters for the standing committees of our board of directors, including the audit and risk committee, compensation committee, and nominating and corporate governance committee, and (ii) our Code of Business Conduct and Ethics governing our directors, officers and employees. We intend to disclose on our website any amendments to, or waivers from, our Code of Business Conduct and Ethics that are required to be disclosed pursuant to the rules of the SEC. From time to time, we may use our website to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.alkermes.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. 29 Å Item 1A. Risk Factors You should consider carefully the risks described below in addition to the financial and other information contained in this Annual Report, including our financial statements and related notes thereto and the matters addressed under the caption “Cautionary Note Concerning Forward-Looking Statements,” and in our other public filings with the SEC. If any events described by the following risks actually occur, such events could materially adversely affect our business, financial condition, cash flows or results of operations. This could cause the market price of our ordinary shares to materially decline. The risks described below are not intended to be exhaustive and are not the only risks that we face. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations. Risks Related to Our Business and Our Industry We receive substantial revenue from our key proprietary products and our success depends on our ability to successfully manufacture and commercialize such products. Sales of our proprietary products comprise a significant portion of our revenues. We developed and exclusively manufacture VIVITROL for the treatment of adults with alcohol dependence and opioid dependence, ARISTADA for the treatment of adults with schizophrenia, ARISTADA INITIO for initiation onto ARISTADA for the treatment of adults with schizophrenia, and LYBALVI for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, and we exclusively commercialize these products in the U.S. Our success depends in large part on our ability to continue to successfully manufacture and commercialize such products in the complex markets into which they are sold. Any significant negative developments relating to these products could have a material adverse effect on our revenues from these products and, in turn, on our business, financial condition, cash flows and results of operations and the market price of our ordinary shares. We face competition in the biopharmaceutical industry. We face intense competition in the development, manufacture, marketing and commercialization of our products from many and varied sources, such as research institutions and other biopharmaceutical companies, including companies with similar technologies or medicines, and manufacturers of generic drugs. Some of these competitors are also our licensees, who control the commercialization of products from which we receive manufacturing and/or royalty revenues. For example, our proprietary products ARISTADA and LYBALVI compete with the long-acting INVEGA products and RISPERDAL CONSTA, products from which we receive manufacturing and/or royalty revenues. The biopharmaceutical industry is characterized by intensive research, development and commercialization efforts and rapid and significant technological change. In many cases, there are already products on the market that may be in direct competition with our commercial products or products in development. In addition, there are many companies with which we and our licensees compete that are developing generic versions of our products, or products with similar technologies to ours or for use in similar indications, and many of these competitors are larger and have significantly greater financial, operational and other resources than we do. Smaller or earlier stage companies may also prove to be significant competitors, whether through focused or more abbreviated development programs or collaborative arrangements with large, established companies. Some of the products being developed by our competitors are being designed to work differently than our products and may prove to be safer or more effective than our products or achieve regulatory approval and be commercialized earlier than our products, which may render our products or technologies obsolete or noncompetitive or make it more challenging for us to successfully commercialize our products. For a detailed discussion of the competition that we face with respect to our current marketed products, technologies and product indications, please see the section entitled “Competition” in “Item 1 “Business” in this Annual Report. If we are unable to compete successfully in the highly competitive biopharmaceutical industry, our business, financial condition, cash flows and results of operations could be materially adversely affected. Our revenues from sales of our products may decrease or grow at a slower than expected rate due to many factors. We cannot be assured that our products will be, or will continue to be, accepted in the U.S. or markets outside the U.S. or that we will be able to maintain or increase sales of our products. Factors that may cause revenues from our products to grow at a slower than expected rate, decrease or cease all together, include, among others: “the perception of physicians and other members of the healthcare community as to our products’ safety and efficacy relative to that of current or future competing products and the willingness or ability of physicians and other members of the healthcare community to prescribe, dispense and/or administer, and patients to use, our products; “unfavorable publicity concerning us, our licensees, our products, similar classes of drugs or our industry generally; 30 Å “the cost-effectiveness of our products and reimbursement policies of government and third-party payers that may impact use of our products; “the cost and availability of raw materials necessary for the manufacture of our products; “the successful manufacture of our products on a timely and cost-effective basis; “the size of the markets for our products, and patient and physician satisfaction with our products; “significant changes in the competitive landscape for our products, including any approvals of generic versions of our products or other branded products that may compete with our products; “adverse event information relating to our products or to similar classes of drugs; “changes to the product labels of our products, or of products within the same drug classes, to add new significant warnings or restrictions on use; “our ability to engage third parties to manufacture, package and/or distribute our products on acceptable terms, or at all; “the unfavorable outcome of investigations, arbitrations, litigation or other legal proceedings, including government requests for information related to one or more of our products, securities litigation, IP litigation, including so-called “Paragraph IV litigation relating to products from which we receive revenue, litigation or other proceedings before the USPTO Patent Trial and Appeal Board (the “PTAB”) or its equivalent in other jurisdictions outside of the U.S., and any other litigation or arbitration related to any of our products; “regulatory developments and actions related to the manufacture, commercialization or continued use of our products, including FDA actions such as the issuance of a REMS or warning letter, or conduct of an audit by the FDA or another regulatory authority in which a manufacturing or quality deficiency is identified; “the extent and effectiveness of the sales, marketing and distribution support for our products, including the size of our and our licensees’ sales forces and investments in marketing strategies, and our and our licensees’ decisions as to the timing and volume of product orders and shipments, the timing of product launches, and product pricing and discounting; “disputes with our licensees relating to the use of our technology in, and marketing and sale of, products from which we received, or currently receive, manufacturing and/or royalty revenue and the amounts and duration of payments to be made with respect to such products; “exchange rate valuations and fluctuations; “U.S. and global political and administrative changes, conflicts and/or instability, public health matters, economic conditions and/or any related changes in applicable laws and regulations or federal and state policy efforts, that may impact resources and markets for our products or the systems and environments in which we operate; and “any other material adverse developments with respect to the

commercialization of our products. Revenues generated by sales of our products depend, in part, on the availability from third-party payers of reimbursement for our products and the extent of cost-sharing arrangements for patients (e.g., patient co-payment, co-insurance, deductible obligations) and cost-control measures imposed, and any reductions in payment rate or reimbursement or increases in our or in patientsâ€™ financial obligation to payers could result in decreased sales of our products and/or decreased revenues. In both U.S. and non-U.S. markets, sales of our products depend, in part, on adequate coverage, pricing and reimbursement from third-party payers such as state and federal governments, including Medicare and Medicaid in the U.S. and similar programs in other countries, managed care providers and private insurance plans. Deterioration in the timeliness, certainty and amount of reimbursement for our products, the existence of barriers to coverage of our products (such as prior authorization, criteria for use or other requirements), increases in our financial obligation to payers, including government payers, limitations by healthcare providers on how much, or under what circumstances, they will prescribe or administer our products or unwillingness by patients to pay any required co-payments, or deductible amounts, could reduce the use of, and revenues generated from, our products and could have a material adverse effect on our business, financial condition, cash flows and results of operations. The availability of government and private reimbursement for our products and coverage restrictions that may be imposed for our products are uncertain, as is the amount for which our products will be reimbursed. Pricing and reimbursement for our products may be adversely affected by a number of factors, including: changes in, and implementation of, federal or state government regulations or private third-party payorsâ€™ reimbursement policies; pressure by employers on private health insurance plans to reduce costs; and consolidation and increasing assertiveness of payors and pharmacy benefit managers (â€œPBMâ€™s) seeking price discounts or 31 A rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value. We cannot predict the availability, amount, or consistency of reimbursement for, or the prevalence and extent of other access barriers to, our products. In the U.S., federal and state legislatures, health agencies and third-party payers continue to focus on containing the cost of healthcare. The Inflation Reduction Act includes several provisions that will impact our business to varying degrees, including the Drug Price Negotiation Program applicable to Medicare Parts D and B and those provisions that impose new manufacturer financial liability on all drugs in Medicare Part D beginning in 2025, and require companies to pay rebates to Medicare for drug prices that increase faster than inflation. The Drug Price Negotiation Program is subject to ongoing litigation, the outcome of which is difficult to predict. In addition, economic pressure on state budgets may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for drugs, including but not limited to price control initiatives, discounts and other pricing-related actions. State Medicaid programs are increasingly requesting that manufacturers pay supplemental rebates and are requiring prior authorization by the state program for use of any drug. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. U.S. government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products. Furthermore, we may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA, the Inflation Reduction Act and other legislation that impacts us, whether by legislative means or through litigation, and further potential reforms to government negotiation or regulation of drug pricing. The PPACA significantly expanded coverage of mental health and substance use disorders and provided federal parity protections to such coverage benefits. If efforts to reform or repeal PPACA, or to implement differently certain of its provisions, are successful, such efforts and proposed legislation or other future federal or state legislative or administrative changes relating to healthcare reform and drug pricing could adversely affect our business and financial results. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products. Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue, results of operations, financial condition and cash flows. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. In addition, pharmacy benefit managers have merged with or acquired specialty and mail order pharmacies and provider groups. This consolidation, and any further consolidation, among insurers, pharmacy benefit managers, other entities in the pharmaceutical supply chain and other payors has increased and will increase, respectively, the negotiating leverage such entities have over us and other drug manufacturers. In the U.S., to help patients afford our approved products, we may utilize programs to assist them, including patient assistance programs and co-pay programs for eligible patients. Government enforcement agencies have shown increased interest in pharmaceutical companies' product and patient assistance programs, including reimbursement support services, and a number of investigations into these programs have resulted in significant civil and criminal settlements. Our payment support programs could become the target of similar actions. In addition, in November 2013, CMS issued guidance to the issuers of qualified health plans sold through the PPACAâ€™s marketplaces encouraging such plans to reject patient cost-sharing support from third parties and indicating that CMS intends to monitor the provision of such support and may take regulatory action to limit it in the future. CMS subsequently issued a rule requiring individual market qualified health plans to accept third-party premium and cost-sharing payments from certain government-related entities. In September 2014, the Office of Inspector General of the U.S. Department of Health and Human Services issued a Special Advisory Bulletin warning manufacturers that they may be subject to sanctions under the federal anti-kickback statute and/or civil monetary penalty laws if they do not take appropriate steps to exclude Part D beneficiaries from using co-pay programs. It is possible that changes in insurer policies regarding co-pay programs and/or the introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively affect these patient support programs, which could result in fewer patients using affected products, and therefore could have a material adverse effect on our sales, business, and financial condition. 32 A If there are changes in, or we fail to comply with, the extensive legal and regulatory requirements affecting the healthcare industry, we could be subject to investigations, litigation, costs, penalties and business losses. Our activities, and the activities of our licensees and third-party providers, are subject to extensive government regulation. Government regulation by various national, state and local agencies includes detailed inspections of, and controls over, research and laboratory procedures, clinical investigations, product approvals and manufacturing, marketing and promotion, adverse event reporting, sampling, distribution, recordkeeping, storage, and disposal practices, among others. Achieving and maintaining compliance with these regulations substantially increases the time, difficulty and costs incurred in obtaining and maintaining approvals to market newly developed and existing products. Government regulatory actions, including audits, records requests and inspections of manufacturing facilities, can result in delay in the release of products, seizure or recall of products, suspension or revocation of the authority necessary for the manufacture and sale of products, and other regulatory enforcement actions, including the levying of civil fines or criminal penalties, the issuance of a warning letter, or the imposition of an injunction. Biopharmaceutical companies have also been the target of government lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible promotion of pharmaceutical products, improper payments intended to influence the referral of healthcare business, submission of false claims for government reimbursement, antitrust violations, violations related to anti-corruption and anti-bribery laws, and violations related to environmental matters. We have been, and may continue to be, the subject of certain government inquiries or requests for documentation. For example, we have received a subpoena and civil investigative demands from U.S. state and federal authorities for documents related to VIVITROL, and have cooperated with the government in each instance. If, as a result of government requests, proceedings are initiated, including under the U.S. federal Anti-Kickback Statute or False Claims Act, or under state False Claims Acts or other laws, and we are found to have violated one or more applicable laws, we may be subject to significant liability, including without limitation, civil fines, criminal fines and penalties, civil damages and exclusion from U.S. federal funded healthcare programs such as Medicare and Medicaid, any of which could materially affect our reputation, business, financial condition, cash flows and results of operations. Conduct giving rise to such liability could also form the basis for private civil litigation by third-party payers or other persons allegedly harmed by such conduct. Additionally, regardless of whether or not there is merit to claims underlying any investigation or legal proceedings to which we are subject, or whether or not we are found as a result of such investigations or lawsuits to have violated any applicable laws, such lawsuits and inquiries can be expensive to defend or respond to, may divert the attention of our management and other resources that would otherwise be engaged in managing our business, and may further cause significant and potentially irreparable harm to our public reputation. While we have implemented numerous risk mitigation measures, we cannot guarantee that we, our employees, our licensees, our consultants or our contractors are, or will be, in compliance with all applicable laws or regulations. If we or our agents fail to comply with any of those laws or regulations, a range of actions could result, including the suspension or termination of clinical trials, the failure to approve a product, restrictions on sales of our products or our manufacturing processes, withdrawal of our products from the market, significant fines, exclusion from government healthcare programs or other sanctions or litigation. Changes affecting the healthcare industry, including new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to patent protection and enforcement, access to healthcare, environmental issues or product pricing and marketing, could also adversely affect our revenues, our public reputation or our potential to be profitable. For example, and as discussed above, the Inflation Reduction Act includes several provisions that will impact our business to varying degrees, including those that impose new manufacturer financial liability on all drugs in Medicare Part D beginning in 2025, allow the U.S. government to negotiate prices for some drugs covered under Medicare Part B and Part D with effect beginning in 2026, and require companies to pay rebates to Medicare for drug prices that increase faster than inflation. Additionally, in its 2024 decision in Loper Bright Enterprises v. Raimondo, the U.S. Supreme Court overruled the â€œChevron doctrine,â€ which gave deference to regulatory agenciesâ€™ statutory interpretations in litigation against federal government agencies, such as the FDA, where the law was ambiguous. This U.S. Supreme Court decision may lead to challenges of longstanding decisions and policies of the FDA, and other federal agencies, which could lead to uncertainties in the industry and disrupt or alter such federal agenciesâ€™ operations. Any further changes in laws, regulations or decisions or in the interpretation of existing laws, regulations and decisions, could have a material adverse effect on our business, financial condition, cash flows and results of operations. We rely heavily on our licensees in the commercialization and continued development of products from which we receive revenue and, if our licensees are not effective, or if disputes arise in respect of our contractual arrangements, our revenues could be materially adversely affected. Our arrangements with licensees are critical to bringing to market and/or successfully commercializing products using our proprietary technologies and from which we receive manufacturing and/or royalty revenue. We rely on these licensees in various respects, including commercializing such products, conducting development activities with respect to new formulations or new indications for such products, and/or managing the regulatory approval process for such products. 33 A We earn significant royalty revenue from sales by our licensees of our licensed products and third-party products incorporating our proprietary technologies. We also earn manufacturing revenues for products that we currently manufacture on behalf of other parties. The revenues we receive from such products depend primarily upon the success of our licensees in commercializing such products. For example, we receive substantial revenue from Janssenâ€™s sales of XEPLION, INVEGA TRINZA/TRECVITA, INVEGA HAFYERA/BYANLNI and RISPERDAL CONSTA, and from Biogenâ€™s sales of VUMERITY. We have no involvement in the commercialization efforts for these and other products sold by third parties from which we receive revenue and cannot control the extent or effectiveness of such commercialization efforts. In addition, certain of these products are currently subject to ANDA litigation proceedings to which we are not a party and, if such proceedings are not resolved favorably or are settled by our licensees, generic versions of these products could be launched and there may be an adverse impact on the commercialization of these products and therefore on the revenue that we receive from sales of these products. Disputes may also arise between us and a licensee involving the ownership of technology developed under a license, the use of our technology, including know-how, in third-party products, the terms and amounts of royalty payments to be paid under a license, or other issues arising out of any licenses or other collaborative agreements. Such disputes may delay related development programs, impact commercialization or manufacturing activities for the related products, impact the timing or amount of revenue that we receive in respect of such products, or result in expensive arbitration, litigation or other dispute resolution, which may not be resolved in our favor and may adversely impact our financial condition. Further, certain of our license agreements may be terminated, with or without cause, or assigned in connection with a change in control or other event, and we cannot guarantee that any of these licensing relationships will continue or that our licensees will be able or willing to continue to perform their obligations, including development, commercialization or payment obligations, under such agreements. Any significant negative developments relating to our relationships with our licensees could have a material adverse effect on our business, financial condition, cash flows and results of operations and on the market price of our ordinary shares. For example, in November 2021 we received notice of partial termination of an exclusive license agreement with Janssen. Under this license agreement, we provided Janssen with rights to, and know-how, training and technical assistance in respect of, our small particle pharmaceutical compound technology, known as NanoCrystal technology, which was used to develop INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TRECVITA, INVEGA HAFYERA/BYANLNI, and CABENUVA. While we ultimately prevailed in arbitration proceedings related to, among other things, this partial termination and Janssenâ€™s royalty and other obligations under the license agreement, the announcement of the partial termination, expectations regarding the loss of royalty revenues, actual delays in receipt of royalty revenues that resulted from such termination, and the ultimate announcement of the resumption of payment of such royalty revenues, caused the market price of our ordinary shares to fluctuate significantly. For these and other reasons that may be outside of our control, our revenues from products sold by our licensees, and any related commercial milestone payments, may fall below our expectations, the expectations of our licensees or those of our shareholders, which could have a material adverse effect on our results of operations and the market price of our ordinary shares. Clinical trials for our products are expensive, may take several years to complete, and their outcomes are uncertain. In order to obtain regulatory approvals for the commercial sale of any product, we or our licensees must demonstrate, through preclinical testing and clinical trials, that such product is safe and effective for use in humans. Designing, conducting and completing a clinical development program is often a lengthy, time-consuming and expensive process and the risk of a product not successfully completing full clinical development and receiving marketing approval is high. We have incurred, and we will continue to incur, substantial expenses for preclinical testing, clinical trials and other activities related to our clinical development programs. Our preclinical and clinical development efforts may take several years or more, varying substantially with the type, complexity, novelty and intended use of the product and the clinical study designs and methodologies employed, and may not be successfully completed in a timely manner or at all. Timelines for the initiation, conduct and completion of clinical trials may be delayed by many factors, including: â€¢issues with the opening, operation or inspection of a new or ongoing clinical trial site, including those located in or near geographic areas of conflict or areas impacted by political, environmental, public health or economic events; â€¢delays or failures of third-party CROs and other third-party service providers and clinical investigators to manage and conduct the trials, perform oversight of the trials, including data audit and verification procedures, or to meet expected timelines; â€¢an inability to recruit, enroll and retain clinical trial participants at the expected rate or at all, or to adequately follow participants after treatment; â€¢safety or tolerability issues that may arise during clinical trials; â€¢an inability to manufacture or obtain sufficient quantities of materials used for clinical trials; and 34 A â€¢unforeseen governmental or regulatory issues or concerns, including those of the FDA and other regulatory agencies, that may impact the strategies for, and design, timelines or feasibility of, our clinical development programs. In addition, we are currently conducting and enrolling patients in clinical studies in a number of countries where our experience is more limited and in disease areas in which we have not previously conducted clinical trials. In these instances, we must depend on third parties, including independent clinical investigators, CROs and other third-party service providers, to successfully conduct our clinical trials and to audit, verify and accurately report results from such trials. Though we do not have much control over many aspects of such third-party activities, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Third parties may not complete planned activities on schedule or conduct our trials in accordance with regulatory requirements or our stated protocols. The outcome of our clinical trials is uncertain. The results from preclinical testing and early clinical trials often have not predicted results of later clinical trials. A number of products have shown promising results in early clinical trials but subsequently failed to establish sufficient safety and/or efficacy data in later clinical trials to obtain necessary regulatory approvals. If we and/or third parties fail to manage or conduct clinical trials in a timely manner or in accordance with study protocols or obligations or if a product fails to demonstrate clinical safety and efficacy or to possess features that may give such product a competitive commercial advantage over other products for the same indication, the development,

approval and/or commercialization of our products may be delayed or prevented or less successful than anticipated, and such events could materially adversely affect our business, financial condition, cash flows and results of operations. Preliminary, topline or interim data from our clinical trials that we may announce, publish or report from time to time may change as more patient data become available or based on subsequent audit and verification procedures, and may not be indicative of final data from such trials, data from future trials or real-world results. From time to time, we may announce, publish or report preliminary, topline or interim data from our clinical trials. Such data are subject to the risk that one or more of the clinical outcomes may materially change as patients continue progressing through the study, as patient enrollment continues and/or as more patient data become available, and such data may not be indicative of final data from such trials, data from future trials or real-world results. In addition, such data may remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary, topline or interim data disclosed. As a result, all preliminary, topline and interim data, and data from early clinical trials with a small number of participants, should be viewed with caution until the final data or more extensive datasets are available, as applicable. Material adverse differences between preliminary, topline or interim data and final data, or initial proof-of-concept data and data from later or larger trials, could significantly harm our business, financial condition, cash flows and results of operations. Our success depends, in part, on our ability to successfully obtain and maintain regulatory approval for our products. We must obtain government approvals before marketing or selling our products. The FDA in the U.S., and comparable regulatory agencies in other jurisdictions, impose substantial and rigorous requirements for the development, manufacture and commercialization of medicines, the satisfaction of which can take a significant number of years and can vary substantially based upon the type, complexity and novelty of the product. In addition, regulation is not static, and regulatory agencies, including the FDA, evolve in their staff, interpretations and practices, including as a result of changes in government, and may impose different or more stringent requirements than currently in effect, which may adversely affect our plans for product development, manufacture and/or commercialization. The approval procedures and the time and requirements necessary to obtain and maintain approvals may also vary among countries. Regulatory agencies may have varying interpretations of the same data, and approval by one regulatory agency does not ensure approval by regulatory agencies in other jurisdictions. In addition, the FDA or other regulatory agencies may choose not to communicate with or update us during clinical testing and regulatory review periods and the ultimate decision by the FDA or other regulatory agencies regarding drug approval or post-approval requirements may not be consistent with prior discussions with or communications from such agencies. The product approval process can last many years, be very costly and still be unsuccessful. Regulatory approval by the FDA or other regulatory agencies can be delayed, limited or not granted at all for many reasons, including: (i) a product may not demonstrate sufficient safety and efficacy or a sufficiently favorable benefit/risk profile for each target indication in accordance with applicable regulatory agencies' standards; (ii) data from preclinical testing and clinical trials may be interpreted by applicable regulatory agencies in different ways than we or our licensees interpret it; (iii) 35 (a) regulatory agencies may not agree with our or our licensees' regulatory approval strategies, plans for accelerated development timelines, components of our or our licensees' filings such as clinical trial designs, conduct and methodologies, or the sufficiency of our or our licensees' submitted data to meet their requirements for product approval; (iv) regulatory agencies might not approve our or our licensees' manufacturing processes or facilities, or those of the CROs and contract manufacturing organizations who conduct research or manufacturing work on our or our licensees' behalf; (v) failure by our clinical investigational sites and the records kept at such sites, including any clinical trial data, to be in compliance with the FDA's GCP, or EU legislation governing GCP, or to pass FDA, EMA or EU member state inspections of clinical trials; (vi) regulatory agencies may change their requirements for approval or post-approval marketing; and (vii) adverse medical events during our clinical trials or during clinical trials of other product candidates in the same class could lead to requirements that trials be repeated or extended, or that a development program be terminated or placed on clinical hold, even if other studies or trials relating to the program are successful. In addition, disruptions at the FDA and other regulatory agencies that are unrelated to our company or our products, including those relating to a prolonged U.S. government shutdown, or other global, political or economic conditions, could cause delays to the regulatory approval process for our products. Any failure to obtain, or delay in obtaining, regulatory approval for our products will prevent or delay their commercialization and could have a material adverse effect on our business, financial condition, cash flows and results of operations. In addition, any failure to obtain, or delay in obtaining, approval for our products could have a material impact on our shareholders' confidence in the strength of our development capabilities and/or our ability to generate significant revenue from our development programs and could result in a significant decline in our share price. Even if regulatory approval to market a product is granted by the FDA or other regulatory agencies, the approved label for the product may not be consistent with our initial expectations or commercial plans. For example, the FDA or other regulatory agencies may impose limitations on the clinical data that may be included in the label for the product or the indicated uses for which, or the manner in which, the product may be marketed, or may impose additional post-approval requirements, such as a REMS, with which we would need to comply in order to maintain the approval of such product. Our business could be seriously harmed if we do not complete these post-approval requirements and, as a result, the FDA or other regulatory agencies require us to change the label for such product, or if such post-approval requirements significantly restrict the marketing, sale or use of such product. In addition, legislation and regulatory policies relating to post-approval requirements and restrictions on promotional activities for pharmaceutical products, or FDA or other regulatory agency regulations, guidance or interpretations with respect to such legislation or regulatory policy may change, which may impact the development and commercialization of our products. Disruptions at the FDA, the SEC and other government agencies could negatively impact our business. Disruptions at the FDA and other regulatory agencies that are unrelated to our company or our products, including due to changes in government, could increase the time required for new drugs to be reviewed and approved, or otherwise cause delays to the regulatory approval or post-approval processes for our products, which could adversely affect our business. The ability of the FDA or other regulatory agencies to review and approve new products or manage post-approval requirements for marketed products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times for product submissions have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely is subject to the impacts of political events, which are inherently fluid and unpredictable. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, or if other global, political or economic conditions impact the regulatory agencies with which we interact, it could significantly impact the ability of the FDA and the SEC or other agencies to timely review and process our submissions, which could have a material adverse effect on our business. 36 (a) We may not be able to successfully expand our R&D pipeline or our commercial product portfolio, which could limit our growth potential. Our business is focused on the development and commercialization of medicines in the field of neuroscience, and we invest substantial resources toward the research and development of new potential product candidates to advance into clinical trials. Notwithstanding this investment, our development programs may not yield viable product candidates in a timely manner or at all, and our product candidates may not obtain regulatory approval, which could limit our growth potential. In addition to our internal development programs, our strategy for pipeline and commercial portfolio expansion includes identifying and evaluating potential transactional opportunities, including mergers and acquisitions, licenses and collaborations, and development and supply, commercialization or co-promotion arrangements, among others, to acquire or license additional products, product candidates, or technologies that could be additive to our business and to our strategy to create value for our shareholders. However, such transactions are highly competitive, and many other companies may pursue the same or similar assets to those that we may consider attractive. In particular, larger companies with greater financial resources or development or commercialization capabilities may have a competitive advantage over us. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to enter into transactions on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable products, product candidates, or technologies, the competitive business environment may result in high transaction costs, and our investment in these potential assets would remain subject to the inherent risks associated with the development and commercialization of new medicines and may not yield the growth or success that we anticipate, which could have a material adverse effect on our business and financial results and the market price of our ordinary shares. We are subject to risks related to the manufacture of our products. The manufacture of pharmaceutical products is a highly complex process in which a variety of difficulties may arise from time to time. We have in the past, and may in the future, face unanticipated interruptions or delays in manufacturing through our internal or external supply chain and resources. Such disruptions can occur for many reasons, including, but not limited to, the supply and quality of API, drug product and other product components and any potential shortages of such materials; regulatory actions; failures relating to materials, manufacturing equipment or processes, quality deviations or safety issues, vendor error, operator error, labor shortages or disputes, utility or transportation disruptions, or physical or electronic security breaches; site-specific incidents (such as fires), environmental incidents, natural disasters and other severe weather events, including those that may occur as a result of climate change; global disruptions such as the COVID-19 pandemic and ongoing conflicts in various regions of the world; and many other factors. Any such problems with manufacturing processes, whether at our facilities or those of our licensees or other third parties that manufacture or package products or components of products on our behalf, could result in product defects or shortages, manufacturing failures or products not being manufactured to their applicable specifications, which could require us to delay shipment of products or recall products previously shipped, or could impair our or our licensees' ability to receive regulatory approval for a product, commercially launch a product, expand into new markets or supply products in existing markets. We may not be able to resolve any such issues in a timely manner, or at all, which could result in declines in sales and reputational damage as well as significant remediation costs to address any issues that arise. We rely solely on our manufacturing facility in Wilmington, Ohio for the manufacture of VIVITROL, ARISTADA, ARISTADA INITIO, LYBALVI and RISPERDAL CONSTA. Due to regulatory and technical requirements, we have limited ability to shift production within our facility or to outsource any portions of our manufacturing to third parties in the event of an interruption in manufacturing or demand for manufacturing that exceeds our capacity. Any need to transition our manufacturing processes, or portions thereof, to a third party, whether due to an interruption in our manufacturing or due to demand for a product that exceeds our manufacturing capacity or otherwise, could take a significant amount of time and resources, may not be successful, and could cause significant interruption or delay in our ability to supply products. VUMERITY and other products using our NanoCrystal or OCR technologies are currently manufactured through subcontracting arrangements at the Athlone Facility, which we previously owned and sold to Novo in May 2024. Any interruption or delay in supply from the Athlone Facility, whether resulting from issues with equipment, materials, personnel, manufacturing processes, or internal or external quality audits or reviews, or issues related to the subcontracting arrangements under which these products are manufactured, could result in delays in meeting our contractual obligations and could damage our reputation and relationships with our licensees, and result in potential loss of revenues. Manufacturing facilities also require specialized personnel and are expensive to operate and maintain. Any interruption in manufacturing, delay in a regulatory approval or commercial launch, or recall or suspension of sales of products manufactured in our facilities, may cause operating losses as we continue to operate our facilities and retain the required specialized personnel. In addition, any significant personnel shortages at our manufacturing facilities or the Athlone Facility, whether temporary or prolonged, including shortages related to the labor market, may cause significant interruptions to our supply of products. 37 (a) We are also dependent in certain cases on third parties who manufacture or distribute certain products from which we receive revenue. Supply or manufacturing issues related to such products could materially and adversely affect sales of such products, and in turn our revenue from such products. We rely on third parties to provide goods and services in connection with the manufacture and distribution of the products we manufacture. We rely on third parties for the timely supply of goods and services that play a role in our manufacturing activities, including, among others, specified raw materials, equipment, contract manufacturing, formulation and packaging services, storage and product distribution services, customer service activities and product returns processing, and some of these goods and services for our products are currently only available from a single source or a limited number of qualified sources. Although we actively manage these third-party relationships to support continuity, quality and compliance with applicable regulations, events beyond our control, including natural disasters and other severe weather events, including those that may occur as a result of climate change, or global disruptions such as the COVID-19 pandemic and ongoing conflicts in various regions in the world, could negatively impact the continuity of supply of such materials and/or services, their quality and their compliance with applicable standards. Any such failure could materially adversely affect our business, financial condition, cash flows and results of operations. The manufacture of products and product components, including the procurement of bulk drug product and other materials used in the manufacture, packaging, storage and distribution of our products, requires successful coordination among us and multiple third-party providers. Lack of capacity available at such third-party providers or any other issues with the quality or operations of these third-party providers, including any issues related to regulatory permits, audits or requirements, could require us to delay shipment of saleable products, recall products previously shipped or impair our ability to supply products at all. We endeavor to qualify and register new vendors and to develop contingency plans so that production is not materially impacted by third-party provider issues. Nonetheless, any such third-party provider issues could increase our costs, cause us to lose revenue or market share and damage our reputation, and may have a material adverse effect on our business, financial condition, cash flows and results of operations. In addition, we rely heavily on the three largest pharmaceutical wholesalers in the U.S. market—Cardinal Health Inc., Cencora, and McKesson Corp—in the distribution of the products that we market and sell in the U.S. If we are unable to maintain our business relationships with these wholesalers on commercially acceptable terms, if these wholesalers experience prolonged business disruptions, if the buying patterns of these wholesalers fluctuate due to seasonality or any other reason or if wholesaler buying decisions or other factors outside of our control change, our business, financial condition, cash flows and results of operations could be materially adversely affected. If we or our third-party providers fail to meet the stringent requirements of governmental regulation in the manufacture of our products, we could incur substantial remedial costs and experience a reduction in sales and/or revenues. We and the third-party providers involved in our manufacturing activities are generally required to comply with cGMP regulations and other applicable non-U.S. standards in the manufacture of our products or components of our products. Additionally, if any of our products or components of our products in the U.S. are scheduled by the DEA as controlled substances, we would also be subject to DEA regulations. We and our third-party providers are subject to unannounced inspections by the FDA and other governmental agencies to confirm compliance with all applicable laws. Any changes to our suppliers or modifications of methods of manufacturing require submission of amendments to our marketing applications to the FDA or other applicable regulatory agencies, and ultimate acceptance by such agencies of such amendments, prior to release of product to the applicable marketplace. Our inability, or the inability of our third-party providers, to demonstrate ongoing compliance with cGMP or other regulatory requirements could require us to withdraw or recall products and interrupt clinical and commercial supply of our products. Any delay, interruption or other issues that may arise in the manufacture, formulation, packaging or storage of our products as a result of a failure of our facilities or operations or the facilities or operations of third-party providers to pass any regulatory agency inspection could significantly impair our ability to develop, obtain and maintain regulatory approval of, and commercialize or supply, products. This interruption could increase our costs, cause us to lose revenue or market share and damage our reputation with our collaboration partners or in the market generally. In March 2020, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) was signed into law in the U.S., and served to increase the FDA's existing authority with respect to drug shortage measures. Under the CARES Act, for each facility where marketed products for certain serious diseases or conditions are manufactured, or where components of such products are manufactured, we are required to have a risk management plan in place that identifies and evaluates risks to the supply of such products or product components, which plans may be subject to review during any FDA inspection. Each of our facilities operates in accordance with a comprehensive quality management system, which includes risk assessment, preventive actions and regular review of inventory levels for each of the marketed products that we manufacture; however, the FDA may not consider our risk management program to be sufficient upon inspection and we may still experience shortages in the supply of marketed products that we manufacture, which could materially adversely affect the patients who rely on such marketed products and our business, financial condition, cash flows and results of operations. The FDA and various regulatory agencies outside the U.S. have inspected and approved our commercial manufacturing facilities. However, the FDA and any other regulatory agencies may not approve any other facility that we or our third-party providers may operate and, once approved, any of these facilities may not remain in compliance with cGMP and other regulations. Any third party we use to manufacture bulk drug product for use in the U.S. must be licensed by the FDA. Failure by us or our third-party providers to gain or maintain regulatory compliance with and approvals from the FDA or other regulatory agencies could materially adversely affect our business, financial condition, cash flows and results of operations. Our

success largely depends upon our ability to attract, recognize and retain key personnel. Our ability to compete and succeed in the highly competitive biopharmaceutical industry and in the disease states in which we market and sell products depends largely upon our ability to attract, recognize and retain highly skilled technical, scientific, manufacturing, management, regulatory, legal, compliance and selling and marketing personnel. Each of our executive officers and all of our employees are employed at will, meaning we or each officer or employee may terminate the employment relationship at any time. We face intense competition for employees due to, among many factors, the geographic locations in which we operate and the competitive benefits and compensation practices in our industry, and in recent years, new competition as employees are increasingly able to work remotely. The loss of key personnel due to any of these factors or our inability to hire and retain personnel who have technical, scientific, manufacturing, management, regulatory, legal, compliance or commercial backgrounds could materially adversely impact our business, including the achievement of our manufacturing, research and development, commercial, financial and other operational and strategic business objectives. Risks Related to Intellectual Property Patent and other IP protection for our products is key to our business and our competitive position but is uncertain. Receiving and maintaining patent and/or trademark protection for our products and technologies, including those that are subject to our licensing arrangements, maintaining our trade secrets, not infringing the proprietary rights of others, and preventing others from infringing our proprietary rights are each key to our success and our competitive position. Patent protection provides rights of exclusivity for the term of the patent. We are able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. In this regard, we try to protect our proprietary position by filing patent applications in the U.S. and elsewhere related to our proprietary product inventions and improvements that are important to our business and products. Our pending patent applications, together with those we may file in the future, or those we may license to or from third parties, may not result in patents being issued. Even if issued, such patents may not provide us with sufficient proprietary protection or competitive advantages against competitors with similar products or technology. Because the patent positions of biopharmaceutical companies involve complex legal and factual questions, enforceability of patents cannot be predicted with certainty. The ultimate degree of patent protection that will be afforded to products and processes, including ours and those of our licensees, in the U.S. and in other important markets, remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts and lawmakers in these countries. The development of new technologies or products may take a number of years, and there can be no assurance that any patents which may be granted in respect of such technologies or products will not have expired or be due to expire by the time such products are commercialized, or that such patents will successfully withstand any challenges during their respective terms. Although we make reasonable efforts to protect our IP rights and to ensure that our proprietary products and technologies do not infringe the IP rights of third parties, we cannot ascertain the existence of all potentially conflicting IP claims. Therefore, there is a risk that third parties may make claims of infringement against our products or technologies. If patents exist or are issued that cover our products or technologies, we may not be able to manufacture, use, offer for sale, sell or import such products without first getting a license from the patent holder. The patent holder may not grant us a license on reasonable terms, or it may refuse to grant us a license at all. This could delay or prevent us from developing, manufacturing, selling or importing those of our products that would require the license. Claims of IP infringement may also require that we redesign affected products, enter into costly settlement or license agreements, pay costly damage awards, or face a temporary or permanent injunction prohibiting us from marketing or selling certain of our products. Even if we have an agreement that may serve to indemnify us against such costs, the indemnifying party may be unable to uphold its contractual obligations. If we cannot, or do not, license the infringed IP on reasonable terms or at all, or substitute similar IP from another source, our business, financial condition, cash flows and results of operations could be materially adversely affected. 39 Â The laws of certain countries may not protect our IP rights to the same extent as the laws of the U.S., and any patents that we own or license from others may not provide any protection against competitors. In addition, in the case of certain of our licensed products or products incorporating our licensed technology, our licensees are responsible for prosecuting, maintaining, enforcing and defending the IP related to the product(s) from which we derive revenue. Their failure to secure, maintain, enforce and defend this IP could materially and adversely affect our business, financial condition, cash flows, and results of operations. We also rely on trade secrets, know-how and inventions, which are not protected by patents, to maintain our competitive position. We try to protect this information by entering into confidentiality agreements with parties that have access to it, such as our licensees, licensors, contract manufacturers, potential business partners, employees and consultants. However, any of these parties may breach such agreements and may disclose our confidential information, or our competitors might learn of the information in some other way. To the extent that our employees, consultants or contractors use IP owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. If any trade secret, know-how or other invention not protected by a patent were to be disclosed to, or independently developed by, a competitor, such event could materially and adversely affect our business, financial condition, cash flows and results of operations. Uncertainty over IP in the biopharmaceutical industry has been the source of litigation and other legal proceedings, and we or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers. There is considerable uncertainty within the biopharmaceutical industry about the validity, scope and enforceability of many issued patents in the U.S. and elsewhere in the world. We cannot currently determine the ultimate scope, validity and enforceability of patents which may be granted to third parties in the future or which patents third parties may assert are infringed by the manufacture, use or sale of our products. Patents, if issued, may be challenged, invalidated or circumvented. As our products achieve greater commercial sales, potential competitors are more likely to seek to challenge our patents. In the biopharmaceutical industry, there has been, and we expect that there may continue to be, significant litigation, inter partes reviews (â€œIPRsâ€), post-grant reviews (â€œPGRsâ€) and administrative proceedings regarding patents and other IP rights. A third party may file an IPR, PGR, interference and/or infringement action against us, including in response to patent certifications required under the Hatch-Waxman Act, claiming that certain claims of one or more of our issued patents are invalid or that the manufacture, use, offer for sale, sale or import of our products infringed one or more of such party's patents. For example, in December 2024, Argentum Pharmaceuticals LLC filed a request with the USPTO for ex parte reexamination of the validity of certain claims of our U.S. Patent No. 7,919,499 that covers VIVITROL, which request was granted in January 2025 and is pending. And in January 2025, Apotex Inc. filed with the USPTO a petition for IPR of certain claims of U.S. Patent No. 7,919,499 that cover VIVITROL, which petition has not yet been instituted. In addition, we may need to enforce our IP rights against third parties who infringe on our patents and other IP or challenge our patents, patent applications or trademark applications. In the U.S., generic manufacturers of innovator drug products may file ANDAs and, in connection with such filings, certify that their products do not infringe the innovator's patents or that the innovator's patents are invalid. This often results in litigation between the innovator and the ANDA applicant, commonly known in the U.S. as â€œParagraph IVâ€ litigation, which can be expensive, protracted and distracting to management, with no certainty of success. For example, Teva entities filed an ANDA seeking approval to engage in the commercial manufacture, use or sale of a generic version of VIVITROL and alleged that one of our Orange-Book patents related to VIVITROL is invalid, unenforceable and/or will not be infringed by Teva's proposed product. In response, we initiated a Paragraph IV lawsuit against Teva in September 2020 to dispute such claims. We may have to expend considerable time, effort and resources to defend such actions, and litigation may be necessary in some instances to determine the validity and scope of certain of our proprietary rights. In order to avoid or resolve timely and costly IP litigation or IPR, PGR or other administrative proceedings, we may enter into settlement agreements in which we grant an adverse party certain rights with respect to our IP. For example, in August 2023, following a trial in the Teva patent infringement lawsuit discussed above, we entered into a confidential settlement and license agreement (the â€œSettlement Agreementâ€) with Teva in August 2023 to resolve the proceedings between the parties. Pursuant to the terms of the Settlement Agreement, we granted Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license to market and sell a generic version of VIVITROL in the U.S. beginning on January 15, 2027, or earlier under certain circumstances. And in July 2019, in order to resolve an IPR instituted by Amneal with the PTAB, we granted Amneal a non-exclusive license under certain patents covering VIVITROL, including the latest to expire patent covering VIVITROL in the U.S., to market and sell a generic formulation of VIVITROL in the U.S. beginning sometime in 2027 or earlier under certain circumstances. There can be no assurance that we or our licensees will prevail or settle any of our IP legal proceedings or disputes on favorable terms. Our and our licensees' existing patents could be invalidated, found unenforceable or found not to cover generic forms of our or our licensees' products. If any ANDA filers were to receive FDA approval to sell generic versions of our products or the products from which we receive revenue and/or prevail in any patent litigation with respect to such products, our business, financial condition, cash flows and results of operations could be materially adversely affected. 40 Â Risks Related to Regulatory or Legal Matters Litigation or arbitration filed against Alkermes, including securities litigation, or actions (such as citizens petitions) filed against regulatory agencies in respect of our products, may result in financial losses, harm our reputation, divert management resources, negatively impact the approval of our products, or otherwise negatively impact our business. We are, and may in the future become, involved in various legal proceedings, including those asserting violations of securities and/or fraud and abuse laws and those asserting claims related to product liability, IP and/or contractual arrangements. Such proceedings may include claims for, or the possibility of, damages or fines and penalties involving substantial amounts of money or other relief, including but not limited to civil or criminal fines and penalties. Such legal proceedings and the preparation therefor may result in substantial costs to us and diversion of management's attention and resources, which in turn could harm our business. Moreover, if any of such legal proceedings were to result in an adverse outcome, such outcome could have a material adverse effect on our business, financial condition, cash flows and results of operations. Further, our liability insurance coverage may not be sufficient to satisfy, or may not cover, any expenses or liabilities that may arise. Additionally, regardless of whether or not there is merit to the claims underlying any legal proceedings to which we are subject, or whether or not we are found as a result of such lawsuits to have violated any applicable laws, such lawsuits and inquiries can be expensive to defend or respond to, may divert the attention of our management and other resources that would otherwise be engaged in managing our business, and may further cause significant and potentially irreparable harm to our public reputation. We have been, and may again be, the subject of citizen petitions or litigation that request that the FDA refuse to approve, delay or withdraw approval of, or impose additional approval requirements on our marketing applications. If successful, such petitions can significantly delay, or even prevent, the approval of the marketing application in question or cause such marketing application approval to be withdrawn. Even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition, or may impose additional approval or post-approval requirements as a result of such petition. These outcomes and others could adversely affect our share price as well as our ability to generate revenues from the commercialization and sale of our products and products using our proprietary technologies. The clinical study or commercial use of our products may cause unintended side effects or adverse reactions, or incidents of misuse may occur, which could adversely affect our products, business and share price. We cannot predict whether the clinical or commercial use of our products will produce undesirable or unintended side effects that have not been evident in the use of, or in clinical trials conducted for, such products to date. The administration of drugs in humans carries the inherent risk of product liability claims whether or not the drugs are actually the cause of an injury. Our products may cause, may appear to have caused or may be claimed to have caused, injury or dangerous drug interactions, and we may not learn about or understand those claims or effects until the products have been administered to patients for a prolonged period of time. Additionally, incidents of product misuse may occur. These events, among others, could result in product recalls or additional regulatory controls (including additional regulatory scrutiny, REMS programs, and/or requirements for additional labeling) or product liability actions. As our development activities progress and we continue to have commercial sales, our product liability insurance coverage may be inadequate to satisfy liabilities that arise, we may be unable to obtain adequate coverage at an acceptable cost or at all, or our insurer may disclaim coverage as to a future claim. This could prevent or limit the development or commercialization of our products. In addition, the reporting of adverse safety events involving our products, including instances of product misuse, and public perceptions about such events, could cause our product sales or share price to decline or experience periods of volatility. These types of events could have a material adverse effect on our business, financial condition, cash flows and results of operations. If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We participate in the Medicaid Drug Rebate Program, the 340B program, the U.S. Department of Veterans Affairs' FSS pricing program, and the Tricare program, and have obligations to report the average sales price for certain of our drugs to the Medicare program. Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies and the courts, which can change and evolve over time. In the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are generally obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program and give rise to an obligation to refund entities participating in the 340B program for overcharges during past quarters impacted by a price recalculation. 41 Â Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. We cannot assure you that our submissions will not be found by CMS to be incomplete or incorrect. Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental programs could negatively impact our financial results. CMS issued a final regulation, which became effective in April 2016, to implement the changes to the Medicaid Drug Rebate Program under the Affordable Care Act. Since that time, CMS has issued multiple proposed and final rules that change the Medicaid Drug Rebate Program. Regulatory and legislative changes, and judicial rulings relating to the Medicaid Drug Rebate Program and related policies, have increased and will continue to increase our costs and the complexity of compliance, have been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS or another agency challenges the approach we take in our implementation. HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective in January 2019. Implementation of this regulation could affect our obligations and potential liability under the 340B program in ways we cannot anticipate. We are also required to report the 340B ceiling prices for our covered outpatient drugs to HRSA, which then publishes them to 340B covered entities. Any charge by HRSA that we have violated this regulation or other requirements of the program could negatively impact our financial results. Moreover, HRSA has established an administrative dispute resolution (â€œADRâ€) process, which is governed by a final regulation effective June 2024, for claims by covered entities that a manufacturer engaged in overcharging, including claims that a manufacturer limited the ability of a covered entity to purchase the manufacturer's drugs at the 340B ceiling price, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could potentially subject us to discovery by covered entities and other onerous procedural requirements and could result in additional liability. HRSA could also decide to terminate a manufacturer's agreement to participate in the 340B program for a violation of that agreement or other good cause shown, in which case the manufacturer's covered outpatient drugs may no longer be eligible for federal payment under the Medicaid or Medicare Part B program. Further, legislation may be introduced that, if passed, would, among other things, further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting, and any additional future changes to the definition of average manufacturer price or the Medicaid rebate amount could affect our 340B ceiling price calculations and negatively impact our results of operations. Additionally, we have implemented a policy governing the eligibility of covered entities to purchase our products at the 340B price for shipment to a contract pharmacy. We implemented this policy out of concern that contract pharmacy arrangements are diverting the benefits of the 340B program from patients to contract pharmacies and contributing to the pervasive lack of transparency within the 340B program, rendering it difficult to identify inappropriate duplicate discounts and product diversion. Certain pharmaceutical manufacturers and the industry group, Pharmaceutical Research and Manufacturers of America (â€œPhRMAâ€) are involved in ongoing litigation with the HRSA regarding manufacturer initiatives that restrict covered entities' ability to purchase products at the 340B program price for shipment through an unlimited number of contract pharmacies. Additionally, several states have enacted, and many other states are

considering, laws that prohibit manufacturer restrictions on contract pharmacies. Certain pharmaceutical manufacturers and PhRMA have initiated litigation challenging these state laws. The outcome of pending judicial proceedings and the potential impact on the way in which manufacturers extend discounts to covered entities through contract pharmacies remain uncertain and negative legal rulings, or the passage of legislation in respect of this topic, may materially adversely impact our results of operations. We have obligations to report the average sales price for certain of our drugs to the Medicare program. In addition, we are required to report the best price for our drugs, as defined under the Medicaid Drug Rebate Program, to CMS. Statutory or regulatory changes or changes in CMS guidance could affect the average sales price or best price calculations for our products and the resulting Medicare payment rate or rebates we owe to state Medicaid programs. Such changes could negatively impact our results of operations. Pursuant to applicable law, knowing provision of false information in connection with price reporting under the U.S. Department of Veterans Affairs, FSS or Tricare programs can subject a manufacturer to civil monetary penalties. These program obligations also contain extensive disclosure and certification requirements. If we overcharge the government in connection with our arrangements with FSS or Tricare, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

42. Our business involves environmental, health and safety risks. Our business involves the use of hazardous materials and chemicals and is subject to numerous environmental, health and safety laws and regulations and to periodic inspections for possible violations of these laws and regulations. Under certain of these laws and regulations, we could be liable for any contamination at our current or former properties or third-party waste disposal sites. In addition to significant remediation costs, contamination can give rise to third-party claims for fines, penalties, natural resource damages, personal injury and damage (including property damage). The costs of compliance with environmental, health and safety laws and regulations are significant. We have developed and implemented a proprietary risk mitigation program to preemptively identify and address environmental, health, safety and security risks; however, there can be no assurance that a violation of current or future environmental, health or safety laws or regulations will not occur. Any violations, even if inadvertent or accidental, or the cost of compliance with any resulting order, fine or liability that may be imposed, could materially adversely affect our business, financial condition, cash flows and results of operations. Risks Related to our Financial Condition and Tax Matters

We may not be able to maintain profitability on a sustained basis. At December 31, 2024, our accumulated deficit was \$1.0 billion, which was primarily the result of net losses incurred from continuing operations from 1987, the year Alkermes, Inc. was founded, through December 31, 2022, partially offset by net income from continuing operations over certain fiscal periods, including net income earned during the years ended December 31, 2024 and December 31, 2023. Our ability to maintain profitability on a sustained basis will depend on our ability to continue to grow and diversify our revenue and to effectively and efficiently manage our costs. Factors that may impact our future revenue, and in turn our future profitability, include, among others, our or our licensees' (as applicable) ability to:

- successfully commercialize VIVITROL, the ARISTADA product family, LYBALVI, VUMERITY, XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANLI and any other marketed products from which we earn revenue in the countries in which such products are approved;
- successfully develop, and obtain and maintain regulatory approval for, products in the U.S. and/or in other countries;
- successfully manufacture our products and third-party products efficiently and in a cost-effective manner;
- obtain adequate reimbursement coverage for our products and third-party products from insurance companies, government programs and other third-party payers;
- successfully protect and defend our confidential information and IP rights related to our technologies and our products;
- achieve product development or sales milestones under our collaborative arrangements; and
- resolve favorably any commercial disputes that may arise in respect of collaborative arrangements from which we receive revenues.

Factors that may impact our future spend, and in turn our future profitability, include, among others:

- the scope of our research and development activities, including the number of programs, products, indications or new technologies that we may pursue, and our ability, if sought, to share development costs through potential collaborations;
- the time and expense required to pursue FDA and/or other regulatory approvals for our products;
- the time and expense required to prosecute, enforce, defend and/or challenge patent and other IP rights;
- the costs of operating and maintaining our manufacturing and research facilities, including the costs and availability of raw materials or components of our products;
- the costs of doing business with third-party vendors, including suppliers, manufacturers, packagers and distributors and CROs;
- the scope and costs of our commercial activities, including expansion of our sales force and our investment in direct-to-consumer campaigns and other initiatives;
- the cost of possible business development activities, including licenses or acquisitions of technologies, compounds or product rights or the potential acquisition of other assets, including equipment, facilities or businesses;
- the costs related to potential litigation, arbitration or other legal proceedings or government requests for information;
- the costs of defending against potential or actual proxy contests or other activist shareholder actions;

43. the costs of compliance with new regulations applicable to us, including those related to the measurement, reporting and assurance of environmental performance data and other sustainability matters; and

- the costs associated with recruiting, compensating and retaining a highly-skilled workforce in an environment where competition for highly-skilled employees is intense. We have broad discretion regarding use of our cash and cash equivalents and we may not allocate our cash in ways that ultimately increase the value of our ordinary shares. We have broad discretion in the allocation of our cash and cash equivalents and we may not allocate our cash in ways that ultimately increase the value of our ordinary shares. We could make capital allocation decisions to utilize such funds in a way that our shareholders do not agree with or that do not ultimately generate shareholder value in the manner they, or we, anticipate or at all. If our cash and cash equivalents are not deployed effectively or do not generate shareholder value, we may fail to achieve expected financial results or other business objectives, which could have a material negative impact on our financial condition, results of operations or the market price of our ordinary shares. Certain U.S. holders of our ordinary shares may suffer adverse tax consequences if any of our non-U.S. subsidiaries are characterized as a controlled foreign corporation. In December 2017, the Tax Cuts and Jobs Act of 2017 (the "Tax Cuts and Jobs Act") was signed into law. This legislation significantly changed U.S. tax law by, among other things, changing the rules which determine whether a foreign corporation is treated for U.S. tax purposes as a controlled foreign corporation (the "CFC") for taxable years ended December 31, 2017 and onwards. The impact of this change on certain holders of our ordinary shares is uncertain and could be adverse, including potential income inclusions and reporting requirements for U.S. persons (as defined in the U.S. Internal Revenue Code of 1986, as amended (the "Code")) who are treated as owning (directly or indirectly) at least 10% of the value or voting power of our shares. The determination of CFC status is complex and includes attribution rules, the application of which are not entirely certain. These changes to the attribution rules relating to the determination of CFC status make it possible that one or more of our non-U.S. subsidiaries will be classified as a CFC. Existing and prospective investors should consult their tax advisers regarding the potential application of these rules to their investments in our securities. See "Certain Irish and United States Federal Income Tax Considerations" United States Federal Income Tax Considerations in our Form S-1/A, filed with the SEC on February 29, 2012, for additional discussion with respect to other potential U.S. federal income tax consequences of investments in us. If goodwill becomes impaired, we may have to take significant charges against earnings. At December 31, 2024, we had \$83.0 million of goodwill. Under accounting principles generally accepted in the U.S. (the "GAAP"), we must assess, at least annually and potentially more frequently, whether the value of goodwill has been impaired. Any reduction or impairment of the value of goodwill will result in a charge against earnings, which could materially adversely affect our results of operations and shareholders' equity in future periods. Our effective tax rate may increase. As a global biopharmaceutical company, we are subject to taxation in a number of different jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of these places. Our effective tax rate may fluctuate depending on a number of factors, including, but not limited to, the distribution of our profits or losses between the jurisdictions where we operate and differences in interpretation of tax laws. In addition, the tax laws of any jurisdiction in which we operate may change in the future, which could impact our effective tax rate. Tax authorities in the jurisdictions in which we operate may audit us. If we are unsuccessful in defending any tax positions adopted in our submitted tax returns, we may be required to pay taxes for prior periods, interest, fines or penalties, and may be obligated to pay increased taxes in the future, any of which could have a material adverse effect on our business, financial condition, cash flows and results of operations. Changes in tax rules and regulations, or interpretations thereof, may adversely affect our financial condition. The U.S. Congress, the EU, the Organization for Economic Co-operation and Development (the "OECD"), and other government agencies in jurisdictions where we and our affiliates do business are focused on the taxation of multinational corporations. As a result of this focus, the tax laws in Ireland and the U.S. could change on a prospective or retroactive basis, and any such changes could adversely affect us.

44. The Tax Cuts and Jobs Act amended Section 174 of the Code (the "Section 174") and, with effect from January 2022, eliminated the option to deduct R&D expenses in the year incurred and instead requires taxpayers to capitalize, and subsequently amortize such expenses over five years for research activities conducted in the U.S., and over fifteen years for research activities conducted outside of the U.S. As such, we expect a material decrease in cash flows provided from operations and a material increase in our net U.S. deferred tax assets over the next number of years, which could have a material adverse effect on our business, financial condition, cash flows and results of operations. In December 2022, the EU implemented a new corporate minimum tax rate of 15% on companies with combined annual revenue of at least €750.0 million, which was transposed into Irish law effective as of January 1, 2024. We do not expect such rules to have a material effect on our business in 2025; however, such minimum tax rate rules or other similar rules could have a material adverse effect on our business, financial condition, cash flows and results of operations in future years. Our deferred tax assets may not be realized. As of December 31, 2024, we had \$121.6 million of net deferred tax assets in the U.S. It is possible that some or all of the deferred tax assets will not be realized, especially if we incur losses in the U.S. in the future. Losses may arise from operating events (including clinical program progression), or the occurrence of significant excess tax benefits arising from the exercise of stock options and/or the vesting of restricted stock unit awards. Unless we are able to generate sufficient taxable income in the future, a substantial valuation allowance to reduce the carrying value of our U.S. deferred tax assets may be required, which would materially increase our expenses in the period the valuation allowance is recognized and materially adversely affect our financial condition and results of operations. Furthermore, we have included within our U.S. net deferred tax assets of \$121.6 million an amount of \$30.0 million relating to employee share-based compensation expense. It is possible that a significant portion of this deferred tax asset will not be realized, especially if the price of our ordinary shares remains at its current level (see "Item 5" Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities" in this Annual Report for details of the price of our ordinary shares). Unless the price of our ordinary shares increases, we will incur a deferred tax expense as our U.S.-based employees exercise or forfeit their stock options and their restricted stock unit awards vest. This could significantly increase our tax expense and may adversely affect our financial condition and results of operations. The disposition of the Athlone Facility may limit our ability to use our net operating losses and result in unanticipated tax liabilities. As of December 31, 2023, we had \$94.7 million of net deferred tax assets in Ireland, including \$87.5 million relating to net operating losses (the "NOLs"). These NOLs can be carried forward, without time limit, against trading income of the same trade in future accounting periods. In May 2024, we completed the sale of the Athlone Facility to Novo. The disposition of the Athlone Facility may be deemed to result in (i) a significant change to the existing trade such that the same trade is no longer continued, and (ii) a complete discontinuance of the existing trade and the commencement of a new trade. We do not believe that the disposition of the Athlone Facility would amount to a significant change or a discontinuance of our existing trade; however, the Irish Tax Authority could assert a contrary position, in which case we could become involved in tax controversy with the Irish Tax Authority regarding possible additional tax liabilities. If we were to be unsuccessful in resolving any such tax controversy in our favor, we could be liable for significant additional tax liabilities than that which we anticipate, which would materially adversely affect our financial condition, cash flows and results of operations. The IRS may not agree with our conclusion that we should be treated as a foreign corporation for U.S. federal income tax purposes. In September 2011, the business of Alkermes, Inc., a U.S. corporation, and the drug technology business of Elan Corporation, plc, an Irish-incorporated public limited company, were combined under Alkermes plc, an Irish-incorporated public limited company (the "Business Combination"). For U.S. federal income tax purposes, a corporation is generally considered tax resident in the place of its incorporation. Because we are incorporated in Ireland, we should be classified as an Irish corporation under these general rules. However, Section 7874 of the Code generally provides that a corporation organized outside the U.S. that acquires substantially all of the assets of a corporation organized in the U.S. will be treated as a U.S. corporation (and, therefore, a U.S. tax resident) for U.S. federal income tax purposes if shareholders of the acquired U.S. corporation own at least 80% (of either the voting power or the value) of the stock of the acquiring foreign corporation after the acquisition by reason of holding stock in the domestic corporation, and the expanded affiliated group (as defined in Section 7874) that includes the acquiring corporation does not have substantial business activities in the country in which it is organized.

45. We believe that Alkermes plc should be classified as an Irish tax resident corporation and should not be treated as a U.S. corporation for U.S. federal income tax purposes. However, the IRS could assert a contrary position, in which case we could become involved in tax controversy with the IRS regarding possible additional U.S. tax liability. If we were to be unsuccessful in resolving any such tax controversy in our favor, we could be liable for significant additional U.S. federal and state income tax than those we anticipate, which would materially adversely affect our financial condition, cash flows and results of operations. If the separation of our oncology business completed in November 2023 does not ultimately qualify as a transaction that is generally tax-free for U.S. federal and Irish tax purposes as we anticipate, we and/or our shareholders could be subject to significant tax liabilities. In connection with the separation of our oncology business into Mural Oncology plc completed in November 2023, we sought and received a private letter ruling from the IRS (the "IRS Ruling") and an opinion from our U.S. tax advisor (the "U.S. Tax Opinion") regarding U.S. federal income tax consequences of the separation, including that, among other things, the separation would be expected to generally qualify as tax-free for U.S. federal income tax purposes under Sections 368(a)(1)(D) and 355 of the Code. The IRS Ruling and/or the U.S. Tax Opinion were based on and relied on, among other things, certain facts, assumptions, representations, and undertakings from us and Mural Oncology plc, including those relating to past and future conduct of the companies' respective business operations and other matters. If any of these facts, assumptions, representations, statements or undertakings are, or become, inaccurate or incomplete, or if we or Mural Oncology plc breach any of our respective covenants in the separation documents, the IRS Ruling and/or the U.S. Tax Opinion may be invalid and the conclusions reached therein could be jeopardized. Notwithstanding the U.S. Tax Opinion or IRS Ruling, the IRS could determine that a distribution or any related transaction is taxable for U.S. federal income tax purposes if it determines that any of these facts, assumptions, representations or undertakings are not correct or have been violated, or that the distribution should be taxable for other reasons, including if the IRS were to disagree with the conclusions in the U.S. Tax Opinion. The U.S. Tax Opinion will not be binding on the IRS or the courts. Accordingly, the IRS or the courts may challenge the conclusions stated in the U.S. Tax Opinion and such challenge could prevail. If the separation transaction is ultimately determined to be taxable, we and/or our shareholders that are subject to U.S. federal income tax could incur significant tax liabilities. Furthermore, in connection with the separation, we sought and received an opinion from our Irish tax advisor (the "Irish Tax Opinion") regarding the Irish tax consequences of the separation. The Irish Tax Opinion was based on and relied on, among other things, certain facts, assumptions, representations, and undertakings from us, including those relating to past and future conduct of our business operations and other matters. If any of these facts, assumptions, representations, statements or undertakings are, or become, inaccurate or incomplete the Irish Tax Opinion may be invalid and the conclusions reached therein could be jeopardized. The Irish Tax Opinion will not be binding on the Irish Tax Authority or the Irish courts. Accordingly, the Irish Tax Authority or the Irish courts may challenge the conclusions stated in the Irish Tax Opinion and such challenge could prevail. In such an event, we and/or our shareholders could incur significant tax liabilities. Our business strategy may involve future transactions which may harm the market price of our ordinary shares or require us to seek additional funds, and such funding may not be available on commercially favorable terms or at all and may cause dilution to our existing shareholders. In order to achieve our business strategy, we regularly review potential transactions related to technologies, products or product rights or other assets, and businesses that are complementary to our business, including mergers and acquisitions, licenses and collaborations, and development and supply, commercialization or co-promotion arrangements, among others. We may choose to enter into one or more of these or other transactions at any time, which may cause substantial fluctuations in the market price of our ordinary shares. Moreover, depending upon the nature of any transaction, we may experience a charge to earnings, which could also materially adversely affect our results of operations and could harm the market price of our ordinary shares. In order to finance such transactions, we may require additional funds, and we may seek such funds through various sources, including debt and equity offerings, corporate collaborations, bank borrowings, arrangements relating to assets, monetization of royalty streams or other financing methods or structures. The source, timing and availability of any financing will depend on global economic conditions, credit and financial market conditions, interest rates and

other factors. If we issue additional equity securities or securities convertible into equity securities, our shareholders would suffer dilution of their investment, and it may adversely affect the market price of our ordinary shares. In addition, under Irish law, the directors of an Irish public limited company must have specific authority, as approved by the company's shareholders, to allot and issue any ordinary shares (other than pursuant to employee equity plans) and, if such directors desire to allot and issue ordinary shares for cash, such shares must first be offered on the same or more favorable terms to the Company's existing shareholders on a pro-rata basis, unless this statutory pre-emption right is disappplied by approval of the company's shareholders. In May 2024, our shareholders renewed our board of directors' general authority to allot and issue ordinary shares in an amount equal to approximately 20% of our issued ordinary share capital (as of April 10, 2024), and to issue ordinary shares for cash on a non-pre-emptive basis in an amount equal to approximately 20% of our issued share capital (as of April 10, 2024); however, these share issuance authorities were granted for eighteen months only, at which point they will lapse unless renewed by our shareholders. If we are unable to obtain renewal of share issuance authorities from our shareholders, or are otherwise limited by the terms of new share issuance authorities approved by our shareholders, our ability to use our authorized but unissued share capital to effect or to fund acquisition or other transaction opportunities, or to otherwise raise capital, could be adversely affected. In addition, future investors or lenders may demand, and may be granted, rights superior to those of existing shareholders. If we issue debt securities, we would likely be subject to restrictive covenants and debt service obligations that may impact our operations and financial condition. We cannot be certain that additional financing will be available from any of these sources when needed or, if available, will be on acceptable terms. If we fail to obtain additional capital if needed, we may not be able to execute our business strategy successfully. Even if we are able to finance potential transactions without seeking any external financing, expenditure of a significant amount of cash on such transactions may require difficult capital allocation decisions and may limit our ability to pursue other important business and strategic objectives, may significantly impact our financial condition and profitability and limit our potential to return capital to shareholders. As a result of these and other potential impacts, the market price of our ordinary shares may fluctuate significantly. Currency exchange rates may affect revenues and expenses. We conduct a large portion of our business in international markets. For example, we derive all of our XEPLION, TREVICTA and BYANLNI revenues from sales in countries other than the U.S., and these sales are denominated in non-U.S. dollar (€) currencies. We also incur substantial operating costs in Ireland and face exposure to changes in the exchange ratio of the USD and the euro arising from expenses and payables at our Irish operations that are settled in euro. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, USD, and the currencies in which we do business will affect our results of operations, often in unpredictable ways. See "Quantitative and Qualitative Disclosures about Market Risk" in this Annual Report for additional information relating to our foreign currency exchange rate risk. Risks Related to Our Ordinary Shares The market price of our ordinary shares has been volatile and may continue to be volatile in the future, and could decline significantly. The market price of our ordinary shares has fluctuated significantly from time to time. During the year ended December 31, 2024, the closing price of our ordinary shares on the Nasdaq Global Select Market ranged from \$23.01 to \$32.56 per share. The market price of our ordinary shares is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and industry factors, our results of operations, our ability to maintain and increase sales of our products, the success of our key development programs and expansion of our development pipeline and commercial portfolio, our ability to achieve and sustain profitability, the outcomes of business development transactions in which we may participate, our capital allocation decisions, and other factors, including the risk factors described in this Annual Report. We have also experienced significant volatility in the market price of our ordinary shares based on our business performance, including in relation to our commercial sales and the financial guidance that we issue for such sales, results from our clinical development programs, and events relating to regulatory actions and interactions related to our product candidates and commercial products. In addition, the stock market in general, including the market for biopharmaceutical companies, has experienced extreme price and trading volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. In particular, negative publicity regarding pricing and price increases by pharmaceutical companies, and potential legislation to regulate drug pricing, has negatively impacted, and may continue to negatively impact, the market for biopharmaceutical companies. These broad market and industry factors have harmed, and in the future may harm, the market price of our ordinary shares, regardless of our operating performance. Our business could be negatively affected as a result of the actions of activist shareholders. Proxy contests and other actions by activist shareholders have been waged against many companies in our industry over the last several years. Activist shareholders may agitate, either publicly or privately, for changes to a company's board of directors, management, structure, spend or strategic direction, among other things. Proxy contests and other actions by activist shareholders can be costly and time-consuming, disrupting operations and diverting the attention of management and employees, and can lead to perceived uncertainties as to the future direction of the Company or its business that may result in the loss of potential acquisitions, collaborations or in-licensing opportunities and make it more difficult to attract and retain qualified personnel and business partners. In addition, if individuals are elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our strategic plan in a timely manner and create additional value for our shareholders. 47. In recent years, we engaged in extensive dialogue with principals of Elliot Investment Management L.P. and Sarissa Capital Offshore Master Fund LP and their affiliates, resulting in negotiation of settlement arrangements in 2020 and 2021 pursuant to which directors were elected to our Board and a contested election in 2023. The extensive interactions and activities related to our engagement with activist shareholders required the expenditure of time, energy and expense by management and our board of directors and diverted employee and management attention from business operations. Any future activist shareholder interactions, contests, actions or requests, or the mere public presence of activist shareholders among our shareholder base, could cause the market price of our ordinary shares to experience periods of significant volatility. Risks Related to Information Security and Data Privacy Information security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer. In the ordinary course of our business, we and our third-party service providers collect, store, maintain and transmit sensitive data, including IP, proprietary business information of ours and that of our suppliers and partners, as well as personally identifiable information of persons who use our medicines, clinical trial participants and employees. In addition, we outsource some of our operations to a number of third-party vendors who may have, or could gain, access to our confidential information. The secure maintenance of all such information and the secure performance of our information technology (IT) systems are critical to our operations and business strategy. As our dependency on, and the complexity of, our IT systems increases, the confidentiality, integrity and availability of our IT systems and the data that they store is critical to managing our business. While we take prudent measures to secure our IT systems, the risk still exists that such systems may become compromised by successful breaches, malfeasance, human error or technological fault. Moreover, the revalent use of mobile devices to access confidential information, remote working practices, and the increased use of artificial intelligence present new and increased risk of security breaches. Cyber-attacks have increased in frequency, persistence, sophistication and intensity, often conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage, hacktivists and organized crime). In addition to the extraction of important information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of our information. Certain types of attacks or breaches on our IT systems or infrastructure, or those of our licensees and third-party providers, may go undetected for a prolonged period. Although to our knowledge we have not experienced any material incident or interruption to date, any breakdown, invasion, corruption, destruction or breach of our, or our partners' or our third-party providers' technology systems could compromise such IT systems, and the information stored there could be accessed, modified, publicly disclosed, lost or stolen. This could result in legal claims or proceedings and liability under laws that protect the privacy of personal information, demands for ransom or other forms of blackmail, disruptions to our development programs or commercial operations, damage to our reputation and adverse effects on our business. We retain cybersecurity insurance to cover costs and expenses related to a breach or similar event; however, there is no guarantee that such costs and expenses would not exceed the insurance that we retain. We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage. In the ordinary course of business, we may process personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, patient data and sensitive third-party data. Our data processing activities subjects us to laws and regulations covering data privacy and the protection of personal information, including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. In the U.S., numerous federal and state laws and regulations, including state security breach notification laws, federal and state consumer protection laws, and state health information privacy laws (for example, the California Consumer Privacy Act of 2018 and the California Privacy Rights Act of 2020), govern the collection, use, disclosure, and protection of personal information. Such federal and state laws and regulations may require businesses to provide specific disclosures and implement processes to permit individuals to exercise certain privacy rights, which in each case could increase our potential liability, increase our compliance costs, and affect our ability to collect and use personal information. The privacy regulation landscape is rapidly evolving, and any changes to existing legislation or adoption of new state or federal regulations may further complicate compliance efforts and further increase legal risk and compliance costs for us and the third parties upon whom we rely. In addition, each of these current and potential future laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and the third parties upon whom we rely. If we fail to comply with applicable laws and regulations, we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (HIPAA). 48. Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. The EU and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. In the EU, for example, the GDPR governs the processing of personal data. The GDPR imposes significant obligations on controllers and processors of personal data, including high standards for obtaining consent from individuals to process their personal data, robust notification requirements to individuals about the processing of their personal data, a strong individual data rights regime, mandatory data breach notifications, limitations on the retention of personal data and stringent requirements pertaining to health data, and strict rules and restrictions on the transfer of personal data outside of the EU, including to the U.S. The GDPR also imposes additional obligations on, and required contractual provisions to be included in, contracts between companies subject to the GDPR and their third-party processors that relate to the processing of personal data. The GDPR allows EU member states to adopt additional laws and regulations in order to introduce further conditions, including limitations, with regard to the processing of genetic, biometric or health data. Adoption of the GDPR increased our responsibility and liability in relation to personal data that we process and may require us to put in place additional mechanisms to ensure compliance. Any failure to comply with the requirements of GDPR and applicable national data protection laws of EU member states could lead to regulatory enforcement actions and significant administrative and/or financial penalties against us (fines of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher), and could adversely affect our business, financial condition, cash flows and results of operations. General Risk Factors A future pandemic, epidemic or outbreak of an infectious disease, may materially and adversely affect our business, financial condition and results of operations. Outbreaks of contagious diseases and other adverse public health developments affecting us and/or the third parties on which we rely could have a material and adverse effect on our business, financial condition and results of operations. For example, the COVID-19 pandemic, which impacted the operation of healthcare systems, global travel, supply and labor markets and other business and economic activity worldwide, had a disruptive and adverse impact on our financial condition and results of operations and on those of many of the third parties on which we rely. Although the acute COVID-19 public health emergency has lapsed, we will continue to monitor its long-term impacts, including impacts on market practices and on the labor market, and adjust our policies and practices as needed to mitigate any adverse impacts to our business operations and financial condition. We will also work with our internal teams and the third-parties on which we rely to assess, and seek to mitigate, the potential impacts on our business operations and financial condition of any future outbreaks of contagious diseases or other adverse public health developments that may emerge from time to time. If we identify a material weakness in our internal control over financial reporting, our ability to meet our reporting obligations and the trading price of our ordinary shares could be negatively affected. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. Accordingly, a material weakness increases the risk that the financial information we report contains material errors. We regularly review and update our internal controls, disclosure controls and procedures, and corporate governance policies. In addition, we are required under the Sarbanes-Oxley Act of 2002 to report annually on our internal control over financial reporting. Any system of internal controls, however well designed and operated, is based in part on certain assumptions and can provide only reasonable, not absolute, assurances that the objectives of the system are met. If we, or our independent registered public accounting firm, determine that our internal controls over financial reporting are not effective, or we discover areas that need improvement in the future, these shortcomings could have an adverse effect on our business and financial results, and the price of our ordinary shares could be negatively affected. If we cannot conclude that we have effective internal control over our financial reporting, or if our independent registered public accounting firm is unable to provide an unqualified opinion regarding the effectiveness of our internal control over financial reporting, investors could lose confidence in the reliability of our financial statements, which could lead to a decline in the trading price of our ordinary shares. Failure to comply with reporting requirements could also subject us to sanctions and/or investigations by Nasdaq or the SEC or other regulatory authorities. 49. The increasing use of social media platforms and artificial intelligence tools present new risks and challenges. Social media is increasingly being used as a means of corporate communications and for purposes of social networking and commentary. We use social media tools to communicate certain information about our business, our employees, our company values and initiatives, to support disease state education in our areas of focus, and to provide information about our products or development programs. Additionally, the use of artificial intelligence tools (AI) is increasing in the biopharmaceutical industry and, as with many developing technologies, presents risks and challenges that could affect its further development, adoption and use. Despite our efforts to monitor evolving guidance regarding use of social media and AI and to comply with applicable rules, regulations and regulatory guidance, such practices are evolving and can be unclear. There is a risk that the use of social media and AI by us or our employees to communicate about our products or business or for other business purposes may cause us to be found in violation of applicable requirements and could result in regulatory actions or legal claims against us related to off-label marketing or other prohibited activities. In addition, our employees may knowingly or inadvertently engage on social media and with AI in ways that may not comply with our social media policy or guidelines with respect to AI or other legal, contractual or regulatory requirements. Any misuse of social media or AI may give rise to liability, lead to the loss of trade secrets and other IP, result in public disclosure of personal information of our employees, clinical trial participants, customers, patients using our products, or others, result in reputational harm or lead to other consequences. Negative or inaccurate posts or comments about us or our products on any social media or other public platforms could also damage our reputation, brand image and goodwill. Any of these events, if they were to occur, could cause us to incur liability, face overly restrictive regulatory actions or suffer reputational or other harm to our business. 50. Item 1B. Unresolved Staff Comments None. Item 1C. CybersecurityRisk Management and Strategy In the ordinary course of our business, we collect and store sensitive data, including IP, proprietary business information of ours and that of our suppliers and licensees, and personally identifiable information of persons who use our medicines, clinical trial participants and employees. Our licensees and third-party providers also possess certain of our sensitive data. The secure maintenance of such information and the secure performance of our information technology (IT) systems are critical to our operations and business strategy. As our dependency on, and the complexity of, our IT systems increases, the confidentiality, integrity and availability of our IT systems and the data that they store is critical to managing our business.Our Information Security Management System (ISMS) is a key element of our information security program, designed to identify, assess, help mitigate, and monitor IT risks across our organization, including information security risks. The ISMS is informed by the structured principles of International Standard- ISO/IEC27001:2022 (Information security, cybersecurity, and privacy protection), which outlines guidance for the establishment, implementation, maintenance, and improvement of information security management systems. Our ISMS is comprised of processes designed to identify cybersecurity risks, safeguard information assets and preserve the confidentiality, integrity, and availability of information owned, managed and maintained by us. Our ISMS includes formal written policies and procedures, technical security controls, such as automated tools designed to detect and prevent cybersecurity

incidents, and programs designed to promote internal and third-party IT risk management, audit management, incident response and security awareness, including employee awareness trainings and other initiatives. Our ISMS includes periodic security audits, vulnerability assessments and penetration testing to proactively identify potential system vulnerabilities. Our ISMS is periodically assessed by third-party assessors and the results of such assessments, including any cybersecurity risks and related mitigations identified, are reported to the audit and risk committee of our board of directors, as described below, and are used by us to improve our ISMS and our broader information security program. As part of our information security program, we also have processes in place for management of cybersecurity risks associated with third-party handling of our confidential information, including in such third parties' provision of critical services on our behalf. We conduct due diligence of our third-party vendors through an assessment of their security practices and overall risk profile, including through their completion of vendor assessment questionnaires and ongoing monitoring of such third parties, utilizing tools such as security ratings services and periodic reassessment questionnaires. As of the date of this Annual Report, we have not experienced any information security incidents that have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition, and we have not identified any current cybersecurity threats that we believe are reasonably likely to materially affect our business strategy, results of operations, or financial condition. Governance and OversightWe have a multi-layered information security governance framework in place to provide oversight of our information security program and strategy, our ISMS, and related risks and opportunities. This governance framework includes procedures for escalation of identified information security risks, threats or incidents through various management levels, including up to our Information Security Governing Body, which is comprised of our Chief Executive Officer, Chief Information Officer, Chief Operating Officer, Chief Financial Officer, Chief Legal Officer and other members of management, and as appropriate, up to our board of directors. Our information security team is responsible for developing, implementing and overseeing our Company-wide information security strategy and related policies and practices. This team works cross-functionally throughout our organization to assess and prepare the Company for identification and mitigation of, and if necessary respond to, information security risks. The information security team is led by our Chief Information Officer, who has over 35 years of experience in various information technology roles, including 18 years at the Company serving in roles with increasing levels of responsibility. Our Vice President of Information Security and Technology, a Certified Information Systems Security Professional, with over 20 years of global experience in various information security roles, including 14 years of experience at the Company, is responsible for day-to-day management of information security team initiatives. The other members of the information security team have extensive IT, IT security and cloud industry experience, as well as certifications pertaining to information security and privacy (such as Certified Information Security Manager, Certified Information Privacy Technologist, GIAC Security Essentials and GIAC Information Security Professional certifications). 51

Our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. The audit and risk committee of our board of directors specifically oversees critical risks and opportunities facing the Company and, in this context, reviews and provides feedback on our company-wide enterprise risk management program, which encompasses risks related to IT and cybersecurity and mitigations put in place, or to be put in place, in response to such risks and opportunities. The audit and risk committee periodically reports to the full board of directors regarding its oversight of the Company's enterprise risk management program and periodic risk assessment results. In addition, our board of directors receives periodic updates from our CIO and Vice President of Information Security on our ISMS and other information security initiatives, and on our information security governance framework. Item 2. Properties We lease an approximately 14,600 square foot corporate office space in Dublin, Ireland, which is our corporate headquarters. This lease expires in 2027 and does not include an additional tenant option to further extend the term. We lease an approximately 231,000 square foot corporate office and R&D center in Waltham, Massachusetts. This lease, which commenced in January 2020, expires in 2035 and includes a tenant option to extend the term for an additional ten-year period. We serve as the guarantor of a lease assigned to Mural Oncology, Inc., a subsidiary of Mural Oncology plc, for a facility in Waltham, Massachusetts with approximately 180,000 square feet of corporate offices, administrative areas and laboratories. This lease expires in 2026 and includes a tenant option to extend the term for an additional five-year period. We lease an approximately 7,000 square foot corporate office and administrative space in Washington, DC. This lease expires in 2029 and includes a tenant option to extend the term for an additional five-year period. We own an approximately 375,000 square foot manufacturing facility in Wilmington, Ohio. We believe that our current facilities are suitable and adequate for our current and near-term preclinical, clinical and commercial requirements. Item 3. Legal Proceedings For information regarding legal proceedings, refer to the discussion under the heading "Litigation" in Note 19, Commitments and Contingent Liabilities in the "Notes to Consolidated Financial Statements" in this Annual Report, which discussion is incorporated, in relevant part, into this Item 3 by reference. Item 4. Mine Safety Disclosures Not Applicable. 52

PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market and shareholder information Our ordinary shares are traded on the Nasdaq Global Select Market under the symbol "ALKS." There were 87 shareholders of record of our ordinary shares on February 7, 2025. Dividends No dividends have been paid on our ordinary shares to date, and we do not expect to pay cash dividends thereon in the foreseeable future. We anticipate that we will generally retain a significant portion of our earnings to support our operations and our proprietary drug development programs. Any future determination as to the payment of dividends, if at all, will be at the sole discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors that our board of directors and management deem relevant. Repurchase of equity securities In February 2024, our board of directors authorized a share repurchase program to repurchase ordinary shares of the Company in an aggregate amount of up to \$400.0 million (exclusive of any fees, commissions or other expenses related to such repurchases) from time to time on the open market (the "Repurchase Program"). The timing and amount of any share repurchases under the Repurchase Program will be based on a variety of factors, including but not limited to ongoing assessments of our capital needs, alternative investment opportunities, the market price of our ordinary shares and general market conditions. The Repurchase Program has no set expiration date and may be suspended or discontinued at any time. During the year ended December 31, 2024, we repurchased approximately 7.9 million of our ordinary shares under the Repurchase Program at an average price of \$25.33, resulting in a total cost, exclusive of any fees, commissions or other expenses related to such repurchase, of \$200.0 million. All ordinary shares repurchased were returned to treasury. As of December 31, 2024, the remaining amount authorized under the Repurchase Program was \$200.0 million, exclusive of any fees, commissions or other related expenses. The following table sets forth our share repurchase activity for the three months ended December 31, 2024:

Period	Total Number of Ordinary Shares Purchased(a)	(1) Average Price Paid per Ordinary Share(b)	Total Number of Ordinary Shares Purchased as Part of Publicly Announced Program(c)
(2) Approximate Dollar Value (in millions) of Ordinary Shares that May Yet Be Purchased Under the Program (d)	(2) Approximate Dollar Value (in millions) of Ordinary Shares that May Yet Be Purchased Under the Program (d)	(2) Approximate Dollar Value (in millions) of Ordinary Shares that May Yet Be Purchased Under the Program (d)	(2) Approximate Dollar Value (in millions) of Ordinary Shares that May Yet Be Purchased Under the Program (d)
October 1, 2024	\$ 4,686	\$ 28.74	\$ 4,686
November 1, 2024	\$ 3,727	\$ 27.41	\$ 3,727
December 1, 2024	\$ 3,413	\$ 31.43	\$ 3,413
Totals	\$ 11,826	\$ 29.10	\$ 11,826

(1) Consists of ordinary shares acquired during the three months ended December 31, 2024 to satisfy tax withholding obligations related to the vesting of equity awards. (2) In February 2024, we announced approval by our board of directors of the Repurchase Program, which authorized the repurchase of our ordinary shares in an aggregate amount of up to \$400.0 million (exclusive of any fees, commissions or other expenses related to such repurchases) from time to time. The specific timing and amounts of repurchases under the Repurchase Program will depend on a variety of factors, including but not limited to ongoing assessments of our needs, alternative investment opportunities, the market price of our ordinary shares and general market conditions. The Repurchase Program has no set expiration date and may be suspended or discontinued at any time. Irish taxes applicable to U.S. holders The following is a general summary of the main Irish tax considerations applicable to the purchase, ownership and disposition of our ordinary shares by U.S. holders. It is based on existing Irish law and practices in effect on January 6, 2025, and on discussions and correspondence with the Irish Revenue Commissioners. Legislative, administrative or judicial changes may modify the tax consequences described below. 53

The statements do not constitute tax advice and are intended only as a general guide. Furthermore, this information applies only to our ordinary shares held as capital assets and does not apply to all categories of shareholders, such as dealers in securities, trustees, insurance companies, collective investment schemes and shareholders who acquire, or who are deemed to acquire, their ordinary shares by virtue of an office or employment. The statements are in reference to individuals who are considered non-resident and non-ordinarily resident of Ireland for tax purposes. This summary is not exhaustive and shareholders should consult their own tax advisers as to the tax consequences in Ireland, or other relevant jurisdictions where we operate, including the acquisition, ownership and disposition of ordinary shares. Withholding tax on dividends While we have no current plans to pay dividends, dividends on our ordinary shares would generally be subject to Irish dividend withholding tax (at 25%, unless an exemption applies. Dividends on our ordinary shares that are owned by residents of the U.S. and held beneficially through the Depository Trust Company (DTC) will not be subject to DWT provided that the address of the beneficial owner of the ordinary shares in the records of the broker is in the U.S. Dividends on our ordinary shares that are owned by residents of the U.S. and held directly (outside of DTC) will not be subject to DWT provided that the shareholder that is the beneficial owner of such ordinary shares has completed the appropriate Irish DWT form and this form remains valid. Such shareholders must provide the appropriate Irish DWT form to our transfer agent at least seven business days before the record date for the first dividend payment to which they are entitled. If any shareholder who is resident in the U.S. receives a dividend subject to DWT, they should generally be able to make an application for a refund from the Irish Revenue Commissioners on the prescribed form. Income tax on dividends Irish income tax, if any, may arise in respect of dividends paid by us. However, a shareholder who is neither resident nor ordinarily resident in Ireland and who is entitled to an exemption from DWT, generally has no liability for Irish income tax or to the universal social charge on a dividend from us, unless they holds their ordinary shares through a branch or agency in Ireland which carries out a trade on their behalf. Irish tax on capital gains A shareholder who is neither resident nor ordinarily resident in Ireland and does not hold our ordinary shares in connection with a trade or business carried on by such shareholder in Ireland through a branch or agency, should not be within the scope of the charge to Irish tax on capital gains on a disposal of our ordinary shares. A shareholder who is an individual and who is temporarily not resident in Ireland may, under Irish anti-avoidance legislation, still be liable for Irish tax on capital gains on any chargeable gain realized upon the disposal of our ordinary shares during the period in which such individual is a non-resident. Capital acquisitions tax Irish capital acquisitions tax (CAT) is comprised principally of gift tax and inheritance tax. CAT could apply to a gift or inheritance of our ordinary shares irrespective of the place of residence, ordinary residence or domicile of the parties. This is because our ordinary shares are regarded as property situated in Ireland as our share register must be held in Ireland. The person who receives the gift or inheritance has primary liability for CAT. CAT is levied at a rate of 33% above certain tax-free thresholds. The appropriate tax-free threshold is dependent upon (i) the relationship between the donor and the recipient, and (ii) the aggregation of the values of previous gifts and inheritances received by the recipient from persons within the same category of relationship for CAT purposes. Gifts and inheritances passing between spouses are exempt from CAT. Our shareholders should consult their own tax advisers as to whether CAT is creditable or deductible in computing any domestic tax liabilities. Stamp duty Irish stamp duty, if any, may become payable in respect of ordinary share transfers. However, a transfer of our ordinary shares effected by means of book-entry interests in DTC will not be subject to Irish stamp duty. A transfer of our ordinary shares (i) by a seller who holds ordinary shares outside of DTC to any buyer, or (ii) by a seller who holds the ordinary shares through DTC to a buyer who holds the acquired ordinary shares outside of DTC, may be subject to Irish stamp duty, which is currently at the rate of 1% of the price paid or the market value of the ordinary shares acquired, if greater. The person accountable for payment of stamp duty is the buyer or, in the case of a transfer by way of a gift or for less than market value, all parties to the transfer. A shareholder who holds ordinary shares outside of DTC may transfer those ordinary shares into DTC without giving rise to Irish stamp duty provided that the shareholder would be the beneficial owner of the related book-entry interest in those ordinary shares recorded in the systems of DTC, and in exactly the same proportions, as a result of the transfer and at the time of the transfer into DTC there is no sale of those book-entry interests to a third party being contemplated by the shareholder. Similarly, a shareholder who holds ordinary shares through DTC may transfer those ordinary shares out of DTC without giving rise to Irish stamp duty provided that the shareholder would be the beneficial owner of the ordinary shares, and in exactly the same proportions, as a result of the transfer, and at the time of the transfer out of DTC there is no sale of those ordinary shares to a third party being contemplated by the shareholder. In order for the share registrar to be satisfied as to the application of this Irish stamp duty treatment where relevant, the shareholder must confirm to us that the shareholder would be the beneficial owner of the related book-entry interest in those ordinary shares recorded in the systems of DTC, and in exactly the same proportions or vice-versa, as a result of the transfer and there is no agreement for the sale of the related book-entry interest or the ordinary shares or an interest in the ordinary shares, as the case may be, by the shareholder to a third party being contemplated. Stock performance graph The information contained in the performance graph and related information below shall not be deemed to be "solisiting material" or to be "filed" with the SEC, and such information shall not be incorporated by reference into any future filing under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate it by reference into such filing. The following graph compares the cumulative total shareholder return on our ordinary shares from December 31, 2019 through December 31, 2024 with the cumulative returns of the Nasdaq Composite Total Return Index and the Nasdaq Biotechnology Index. The comparison assumes \$100 was invested on December 31, 2019 in our ordinary shares and in each of the foregoing indices and further assumes reinvestment of any dividends. We did not declare or pay any dividends on our ordinary shares during the comparison period.

Year Ended	December 31, 2019	December 31, 2020	December 31, 2021	December 31, 2022	December 31, 2023	December 31, 2024
Alkermes	100	98	114	128	136	141
Nasdaq Composite Total Return	100	145	145	177	119	173
Nasdaq Biotechnology Index	100	126	114	119	118	118

Item 6. [Reserved] Not applicable. 55

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following should be read in conjunction with our consolidated financial statements and related notes beginning on page F-1 of this Annual Report. The following discussion contains forward-looking statements. Actual results may differ significantly from those projected in the forward-looking statements. See "Cautionary Note Concerning Forward-Looking Statements" on page 3 of this Annual Report. Factors that might cause future results to differ materially from those projected in the forward-looking statements also include, but are not limited to, those discussed in "Risk Factors" and elsewhere in this Annual Report. A detailed discussion of our 2022 financial condition and results of operations, and of 2023 year-over-year changes as compared to 2022, can be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 21, 2024. Overview We have a portfolio of proprietary products that we manufacture, market and sell in the U.S. "VIVITROL, ARISTADA, ARISTADA INITIO and LYBALVI. We also earn manufacturing and/or royalty revenues on net sales of products commercialized by our licensees, the most significant of which in 2024 were the long-acting INVEGA products and VUMERITY. We expect VIVITROL, ARISTADA, ARISTADA INITIO, LYBALVI and VUMERITY to generate significant revenues for us in the near- and medium-term as we believe these products are singular or competitively advantaged products in their classes. In 2024, our net income from continuing operations was \$372.1 million, as compared to \$519.2 million in 2023. The decrease in net income from continuing operations was primarily due to two significant one-time events in 2023, which were the receipt in June 2023 of back royalties and interest in respect of 2022 U.S. sales of the long-acting INVEGA products, following the successful outcome of the arbitration proceedings related to such products, and the partial release of our valuation allowance maintained against certain Irish deferred tax assets. These events were partially offset by an increase in our product sales, net and a decrease in our operating expenses in 2024. These items are discussed in further detail within the "Results of Operations" section below. Business Update In May 2024, we completed the sale of the Athlone Facility to Novo and entered into subcontracting arrangements to continue certain development and manufacturing activities performed at the Athlone Facility, which may continue through the end of 2025. In November 2023, we completed the separation of our former oncology business into a new, independent, publicly-traded company (the "Separation"), which is more fully described in Note 3, Discontinued Operations, in the "Notes to Consolidated Financial Statements" in this Annual Report. Results of Operations As a result of the Separation, the historical results of our former oncology business have been reflected as discontinued operations in our consolidated financial statements through November 15, 2023, the date of the Separation. Prior period results of operations and balance sheet information have been recast to reflect this presentation. Product Sales, Net Our product sales, net, consist of sales of VIVITROL, ARISTADA, ARISTADA INITIO, and LYBALVI, primarily to wholesalers, specialty distributors and pharmacies. The following table presents the adjustments deducted from product sales, gross to arrive at product sales, net, for sales of these products during the years ended December 31, 2024 and 2023:

Year Ended	December 31, 2024	(In millions, except for % of Sales)	December 31, 2023	(In millions, except for % of Sales)
Product sales, gross	\$ 2,119.5	% 100.0	\$ 1,855.4	% 100.0
Medicaid rebates	\$ (454.0)	% (21.4)	\$ (426.4)	% (23.0)
Chargebacks	\$ (231.5)	% (10.9)	\$ (231.5)	% (10.9)

(189.1) (10.2) % Product discounts (155.1) (7.3) (137.7) (7.4) % Medicare Part D (83.0) (3.9) (74.4) (4.0) % Other (112.4) (5.4) (107.8) (5.8) % Total adjustments (1,036.0) (48.9) (935.4) (50.4) % Product sales, net \$1,083.5 (51.1) (920.0) (49.6) (56) VIVITROL product sales, gross, increased by 10%, which was primarily due to a 7% increase in the number of units sold and a 3.2% increase in the selling price that went into effect in January 2024. ARISTADA and ARISTADA INITIO product sales, gross, increased by 5%, which was primarily due to a 3% increase in the number of units sold and a 3.0% increase in the selling price that went into effect in January 2024. LYBALVI product sales, gross, increased by 52%, which was primarily due to a 45% increase in the number of units sold and increases of 3.8% and 2.0% in the selling price that went into effect in January 2024 and July 2024, respectively. The decrease in Medicaid rebates as a percentage of sales was primarily due to the increase in sales of LYBALVI, which has lower Medicaid utilization than VIVITROL, ARISTADA and ARISTADA INITIO, and actual Medicaid utilization rates related to VIVITROL being lower than original estimates, due, in part, to \$8.7 million in actual credits received in the fourth quarter of 2024 from certain states related to duplicate Medicaid billings. The following table compares product sales, net earned during the years ended December 31, 2024 and 2023: (In millions) 2024 2023 Change VIVITROL \$ 457.3 \$ 400.4 \$ 56.9 ARISTADA and ARISTADA INITIO 346.2 \$ 327.7 \$ 18.5 LYBALVI 280.0 \$ 191.9 \$ 88.1 Product sales, net \$1,083.5 \$ 920.0 \$ 163.5 A number of companies currently market and/or are developing products to treat addiction, including alcohol and opioid dependence, that may compete with, and negatively impact, future sales of VIVITROL. Increased competition may lead to reduced unit sales of VIVITROL and increased pricing pressure. The latest to expire of our patents covering VIVITROL will expire in 2029 in the U.S. Pursuant to the terms of a confidential settlement and license agreement entered into in August 2023 with Teva, we granted Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license under the remaining patent covering VIVITROL to market and sell a generic version of VIVITROL in the U.S. beginning on the First Entry Date, or earlier under certain circumstances. Under the terms of a settlement and license agreement entered into in July 2019 with Amneal, we granted Amneal a non-exclusive license under certain patents covering VIVITROL, including the remaining patent covering VIVITROL in the U.S., to market and sell a generic formulation of VIVITROL in the U.S. beginning on the earlier of the First Entry Date, sometime in 2028 or earlier under certain circumstances. A number of companies currently market and/or are developing products to treat schizophrenia and/or bipolar I disorder that may compete with and negatively impact future sales of ARISTADA, ARISTADA INITIO and LYBALVI. Increased competition may lead to reduced unit sales of ARISTADA, ARISTADA INITIO and LYBALVI and increased pricing pressure. The latest to expire of our patents covering ARISTADA, ARISTADA INITIO and LYBALVI in the U.S. will expire in 2039, 2039 and 2041, respectively; and, as such, we do not anticipate any generic versions of these products to enter the market in the near term. Manufacturing and Royalty Revenues Manufacturing revenue from RISPERDAL CONSTA and VUMERITY are recognized at the point in time that the product has been fully manufactured. Royalties earned on our licensee's net sales of products using our proprietary technologies are recognized in the period such products are sold by our licensees. The following table compares manufacturing and royalty revenues earned in the years ended December 31, 2024 and 2023: (In millions) 2024 2023 Change Manufacturing and royalty revenues: \$ 400.4 \$ 369.0 \$ 31.4 Long-acting INVEGA products \$ 236.5 \$ 486.1 \$ (249.6) VUMERITY 134.0 \$ 129.3 \$ 4.7 RISPERDAL CONSTA 23.5 \$ 37.3 \$ (13.8) Other 80.1 \$ 90.7 \$ (10.6) Manufacturing and royalty revenues \$ 474.1 \$ 743.4 \$ (269.3) The decrease in royalty revenues related to the long-acting INVEGA products was primarily due to the receipt in June 2023 of back royalties of \$195.4 million, inclusive of \$8.1 million in late-payment interest, related to 2022 U.S. sales of the long-acting INVEGA products following the successful outcome of the arbitration proceedings related to such products and the expiration of our royalty on U.S. net sales of INVEGA SUSTENNA in August 2024. Pursuant to the Final Award issued in the arbitration proceedings, 57 we are entitled to royalty revenues from Janssen related to U.S. net sales of INVEGA TRINZA and INVEGA HAFYERA through certain specified dates in 2030. We expect royalty revenues from net sales of the long-acting INVEGA products to decrease further in 2025, as the royalty revenues related to U.S. net sales of INVEGA SUSTENNA comprised a significant portion of the overall royalty revenues for the long-acting INVEGA products. For additional discussion of our agreements with Janssen related to the long-acting INVEGA products, including the royalty provisions set forth therein and the related arbitration proceedings and outcome, see the section entitled "Collaborative Arrangements" "Janssen" in "Item 1" "Business" in this Annual Report. In addition, each of INVEGA SUSTENNA and INVEGA TRINZA is currently subject to Paragraph IV litigation in response to companies seeking to market generic versions of such product. Increased competition from new products or generic versions of any one or more of the long-acting INVEGA products may lead to reduced unit sales of the long-acting INVEGA products, including those not yet genericized, and increased pricing pressure. For a discussion of legal proceedings related to INVEGA TRINZA, see Note 19. Commitments and Contingent Liabilities In the "Notes to Consolidated Financial Statements" in this Annual Report, and for information about risks relating to these legal proceedings, see "Item 1" "Risk Factors" in this Annual Report, and specifically the section entitled "Uncertainty over IP in the biopharmaceutical industry has been the source of litigation and other legal proceedings, and we or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers." The increase in VUMERITY revenue was due to an \$8.3 million increase in royalty revenue, partially offset by a \$3.6 million decrease in manufacturing revenue. The increase in royalty revenue was primarily due to an increase in end-market sales of VUMERITY to \$628.0 million in 2024, as compared to \$576.3 million in 2023. The decrease in manufacturing revenue was primarily due to a reduction in the selling price. The manufacturing fee we earn is based on our cost to produce VUMERITY. As the assets used to manufacture VUMERITY were classified as held for sale and transferred to Novo in connection with the sale of the Athlone Facility, depreciation expense was removed from the manufacturing cost base, which had a negative impact on our manufacturing fee. For a discussion of our agreements with Biogen related to VUMERITY, including the manufacturing and royalty revenue provisions set forth therein, see the section entitled "Collaborative Arrangements" "Biogen" in "Item 1" "Business" in this Annual Report. The decrease in revenue from RISPERDAL CONSTA was primarily due to a decrease of \$13.0 million in manufacturing revenue, which was primarily due to a decrease in the number of batches made available to Janssen. The decrease in royalty revenue was due to expirations of the patents covering RISPERDAL CONSTA, which expired in the U.S. in January 2023 and in the EU in 2021. We expect revenues from RISPERDAL CONSTA to continue to decrease as patents covering RISPERDAL CONSTA continue to expire in markets where end-market net sales of RISPERDAL CONSTA occur. We are aware of potential generic and other competition to RISPERDAL CONSTA that may lead to reduced unit sales and increased pricing pressure. For a discussion of our agreements with Janssen related to RISPERDAL CONSTA, including the manufacturing provisions set forth therein, see the section entitled "Collaborative Arrangements" "Janssen" in "Item 1" "Business" in this Annual Report. During the years ended December 31, 2024 and 2023, we recognized \$36.6 million and \$49.9 million, respectively, in manufacturing and royalty revenue related to FAMPYRA which is included within "Other" in the table above. As of December 31, 2024, our manufacturing obligations related to FAMPYRA concluded. Accordingly, we do not expect to recognize any revenues related to FAMPYRA going forward. Certain of our manufacturing and royalty revenues are earned in countries outside of the U.S. and are denominated in currencies in which the product is sold. See "Item 7A" "Quantitative and Qualitative Disclosures about Market Risk" in this Annual Report for information on currency exchange rate risk related to our revenues and "Item 1" "Risk Factors" in this Annual Report, and specifically the section entitled "Currency exchange rates may affect revenues and expenses" for risks related to currency exchange rates. Costs and Expenses Cost of Goods Manufactured and Sold (In millions) 2024 2023 Change Cost of goods manufactured and sold \$ 245.3 \$ 253.0 \$ (7.7) 58 The decrease in cost of goods manufactured and sold was primarily due to lower cost of goods manufactured for certain legacy products due to a decrease in volumes of such products. This includes RISPERDAL CONSTA as well as products manufactured at the Athlone Facility. This decrease was partially offset by an increase in the cost of goods sold for certain of our proprietary products due to increases in the number of units sold as discussed above, and an increase in costs related to VIVITROL out-of-specification batches and subsequent investigation costs. Research and Development Expenses For each of our R&D programs, we incur both external and internal expenses. External R&D expenses include fees for clinical and preclinical activities performed by CROs, consulting fees, and costs related to laboratory services, the purchase of drug product materials and third-party manufacturing development activities. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. We track external R&D expenses for each of our development programs; however, internal R&D expenses are not tracked by individual program as they can benefit multiple development programs or our products or technologies in general. The following table sets forth our external R&D expenses for the years ended December 31, 2024 and 2023 relating to our then-current development programs and our internal R&D expenses, listed by the nature of such expenses: (In millions) 2024 2023 Change External R&D expenses: \$ 36.6 \$ 51.7 \$ (15.1) Total external R&D expenses \$ 101.3 \$ 98.4 \$ 2.9 Internal R&D expenses: \$ 114.5 \$ 128.3 \$ (13.8) Occupancy \$ 11.2 \$ 12.3 \$ (1.1) Depreciation \$ 5.7 \$ 9.6 \$ (3.9) Other \$ 12.6 \$ 22.2 \$ (9.6) Total internal R&D expenses \$ 144.0 \$ 172.4 \$ (28.4) Research and development expenses \$ 245.3 \$ 270.8 \$ (25.5) These amounts are not necessarily predictive of future R&D expenses. In an effort to allocate our spending most effectively, we continually evaluate our products under development based on the performance of such products in preclinical and/or clinical trials, our expectations regarding the likelihood of their regulatory approval and our view of their future potential commercial viability, among other factors. The increase in expenses related to ALKS 2680 was primarily due to an increase in spend related to the advancement of the development programs for the product, including completion of our phase 1b proof-of-concept studies, initiation of our phase 2 clinical studies, Vibrance-1 and Vibrance-2 and preparatory spend in advance of initiation of our phase 2 study for IH. The increase in expenses related to LYBALVI was primarily due to increased spend on our pediatric studies related to the product, partially offset by decreased spend following the completion of our long-term safety and tolerability studies. The decrease in other external R&D expenses was primarily due to identifying cost-effective resourcing options for clinical programming and outsourced data management services and decreases in spend on activities associated with certain of our research programs. The decrease in employee-related expenses was primarily due to a decrease in salaries and benefits related to a 10% reduction in R&D-related headcount during 2024. Selling, General and Administrative Expenses (In millions) 2024 2023 Change Selling, general and administrative expense \$ 490.2 \$ 440.2 \$ 50.0 General and administrative expense \$ 199.0 \$ 199.6 \$ (0.6) Selling, general and administrative expense \$ 645.2 \$ 689.8 \$ (44.6) 59 The decrease in selling and marketing expense was primarily due to a \$34.6 million decrease in marketing expense related primarily to decreased media spend and free goods, a \$7.1 million decrease in professional services, primarily due to the decrease in media spend, and a \$3.6 million decrease in employee related expenses, primarily due to a 7% decrease in sales and marketing headcount. Amortization of Acquired Intangible Assets (In millions) 2024 2023 Change Amortization of acquired intangible assets \$ 1.1 \$ 35.7 \$ (34.6) Our amortizable intangible assets primarily consisted of technology and collaborative arrangements acquired as part of the acquisition of Elan Drug Technologies ("EDT") in September 2011. These intangible assets were amortized over 12 to 13 years using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract, and became fully amortized during 2024. Other Income, Net (In millions) 2024 2023 Change Interest income \$ 42.5 \$ 30.9 \$ 11.6 Interest expense \$ (22.6) \$ (23.0) \$ 0.4 Other income (expense), net \$ 3.2 \$ (0.5) \$ 3.7 Total other income, net \$ 23.1 \$ 7.4 \$ 15.7 Interest income consists of interest earned on our cash and available-for-sale investments. The increase in interest income was due to an increase in our cash and investments and increases in interest rates due to the rising interest rate environment. Interest expense consists of interest incurred on our previously outstanding term loans scheduled to become due in 2026 (the "Former Term Loans") under our former amended and restated credit agreement (the "Former Credit Agreement"), which we prepaid in full and terminated on December 19, 2024. The increase in other income (expense), net was primarily due to the gain on the sale of the Athlone Facility of approximately \$1.5 million, following the completion of the sale in May 2024. Income Tax Provision (Benefit) (In millions) 2024 2023 Change Income tax provision (benefit) \$ 71.6 \$ (97.6) \$ 169.2 The income tax provision in 2024 was primarily due to taxes on income earned in Ireland. The income tax benefit in 2023 was primarily attributable to the partial release of the valuation allowance maintained against certain Irish deferred tax assets, partially offset by taxes on income earned in the U.S. and Ireland. Our effective tax rate during the year ended December 31, 2024 was 16.1%, which exceeds the Irish statutory tax rate of 12.5%, primarily due to non-deductible expenses and income that was taxable at rates higher than the Irish statutory tax rate. The new corporate minimum tax rate of 15.0% did not have a material impact on our business in 2024. Cumulative unremitted earnings of U.S. subsidiaries totaled approximately \$933.5 million as of December 31, 2024. In the event of a repatriation of those earnings in the form of dividends or otherwise, we may be liable for income taxes, subject to adjustment, if any, for foreign tax credits and foreign withholding taxes payable to foreign tax authorities. We estimate that approximately \$72.0 million of income taxes would be payable on the repatriation of the unremitted earnings to Ireland. As of December 31, 2024, we had \$393.9 million of Irish NOL carryforwards, \$14.1 million of U.S. federal NOL carryforwards, \$43.2 million of state NOL carryforwards and \$34.0 million of state tax credits which will either expire on various dates through 2039 or can be carried forward indefinitely. These loss and credit carryforwards are available to reduce certain future Irish and foreign taxable income and tax. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities, and may be subject to limitations based upon changes in the ownership of our ordinary shares. Included within these loss and credit carryforwards are \$14.1 million of U.S. federal NOL carryforwards and \$5.8 million of state NOL 60 carryforwards, acquired as part of the acquisition of Rodin Therapeutics, Inc. ("Rodin") in November 2019, each of which are subject to a \$0.5 million annual limitation. Liquidity and Capital Resources Our financial condition is summarized as follows: (In millions) 2024 2023 Change Cash and cash equivalents \$ 70.3 \$ 220.8 \$ (150.5) Investments "short-term" \$ 203.6 \$ 256.9 \$ (53.3) Investments "long-term" \$ 24.6 \$ 48.5 \$ (23.9) Total cash and investments \$ 298.5 \$ 526.2 \$ (227.7) Outstanding borrowings "short and long-term" \$ 459.1 \$ 1.5 \$ 457.6 "long-term held-to-maturity" \$ 0.1 \$ 0.1 \$ 0.0 Total \$ 757.6 \$ 528.3 \$ 229.3 Sources and Uses of Cash We generated \$439.1 million and \$401.4 million of cash from operating activities during the years ended December 31, 2024 and 2023, respectively. In December 2024, we prepaid our previously outstanding long-term debt without penalty in the amount of \$289.5 million and, during the course of 2024, repurchased approximately \$200.0 million of our ordinary shares. We expect that our existing cash, cash equivalents and investments will be sufficient to finance our anticipated working capital and other cash requirements, including capital expenditures, for at least the twelve months following the date from which our financial statements were issued. Subject to market conditions, interest rates and other factors, we may pursue opportunities to obtain financing in the future, including debt and equity offerings, corporate collaborations, bank borrowings, arrangements relating to assets or other financing methods or structures. Our investment objectives are, first, to preserve liquidity and conserve capital and, second, to generate investment income. We mitigate credit risk in our cash reserves by maintaining a well-diversified portfolio that limits the amount of investment exposure as to institution, maturity and investment type. Our available-for-sale investments consist primarily of short and long-term U.S. government and agency debt securities and corporate debt securities. Our held-to-maturity investments consist of investments that are held as collateral under certain letters of credit related to certain of our lease agreements. We classify available-for-sale investments in an unrealized loss position that do not mature within 12 months as long-term investments. We have the intent and ability to hold these investments until recovery, which may be at maturity, and it is more-likely-than-not that we would not be required to sell these securities before recovery of their amortized cost. We have no off-balance sheet arrangements that are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources in the next 12 months. In connection with our acquisition of Rodin, we may become obligated to make up to \$825.0 million in future milestone payments to the former shareholders of Rodin, \$200.0 million of which would be triggered upon

achievement of certain specified clinical milestones, \$300.0 million of which would be triggered by the achievement of certain regulatory milestones and \$325.0 million of which would be triggered upon the attainment of certain sales thresholds. At December 31, 2024, we had not recorded a liability related to these milestone payments as none of the future events that would trigger a milestone payment were considered probable of occurring. 61

Information about our cash flows, by category, is presented in the accompanying consolidated statements of cash flows. The discussion of our cash flows that follows does not include the impact of any adjustments to remove discontinued operations and is stated on a total company consolidated basis. The following table summarizes our cash flows for the years ended December 31, 2024 and 2023:

Year Ended December 31,	(In millions)	2024	2023
Cash and cash equivalents, beginning of period	\$ 457.5	\$ 292.5	
Cash flows provided by operating activities	\$ 439.1	\$ 401.4	
Cash flows (used in) provided by investing activities	\$ (111.3)	\$ 53.3	
Cash flows used in financing activities	\$ (494.1)	\$ (289.7)	
Cash and cash equivalents, end of period	\$ 291.2	\$ 457.5	

Operating Activities Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income (loss) for non-cash operating items such as depreciation, amortization and share-based compensation and changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations. Cash flows provided by operating activities during 2024 primarily consisted of net income of \$367.1 million, adjusted for non-cash items, including share-based compensation of \$96.6 million and depreciation and amortization of \$28.5 million and deferred income taxes of \$40.5 million. Cash flows provided by operating activities during 2023 primarily consisted of net income of \$355.8 million, adjusted for non-cash items, including share-based compensation of \$100.9 million and depreciation and amortization of \$74.9 million, partially offset by changes in working capital of \$36.7 million and deferred income taxes of \$99.9 million. During 2023, net income included receipt of \$195.4 million from Janssen, inclusive of \$8.1 million in late-payment interest, related to 2022 U.S. net sales of the long-acting INVEGA products following the successful outcome of the arbitration proceedings in respect of such products. Investing Activities Cash flows used in investing activities during 2024 primarily consisted of \$176.2 million in net purchases of investments and the purchase of \$33.5 million of property, plant and equipment. These outflows were offset by proceeds from the sale of the Athlone Facility and related business of \$97.9 million. Cash flows provided by investing activities during 2023 primarily consisted of \$101.1 million in net sales of investments and offset by the purchase of \$48.0 million of property, plant and equipment. We expect to spend approximately \$45.0 million to \$50.0 million during the year ending December 31, 2025 for capital expenditures. We continue to evaluate our manufacturing capacity based on expectations of demand for the products that we manufacture and will continue to record such amounts within construction in progress until such time as the underlying assets are placed into service, or we determine we have sufficient existing capacity and the assets are no longer required, at which time we would recognize an impairment charge. We continue to periodically evaluate whether facts and circumstances indicate that the carrying value of these long-lived assets to be held and used may not be recoverable. Financing Activities Cash flows used in financing activities during 2024 primarily related to the prepayment of our previously outstanding long-term debt in the full amount of \$289.5 million, payment for the repurchase of our ordinary shares and related expenses in the amount of \$200.3 million, and \$29.6 million of employee taxes paid related to net share settlements of equity awards, partially offset by \$27.6 million of cash that we received upon exercises of employee stock options. Cash flows used in financing activities during 2023 primarily related to \$275.0 million in cash distributed to Mural Oncology plc in connection with the Separation and \$28.5 million of employee taxes paid related to net share settlements of equity awards, partially offset by \$16.8 million of cash that we received upon exercises of employee stock options. Debt In December 2024, we prepaid in full all Former Term Loans under the Former Credit Agreement for a total of \$289.5 million. The Company did not incur any early termination penalties in connection with the termination of the Former Credit Agreement (other than customary breakage costs). All liens on the collateral securing the obligations under the Former Credit Agreement were released in connection with the termination. Such prepayment was accounted for as a debt extinguishment. See Note 12, Long-Term Debt, in the

Notes to Consolidated Financial Statements

in this Annual Report for additional discussion related to our Former Term Loans. 62

Discontinued Operations Net loss from discontinued operations consists of the results of our former oncology business and is reported as a separate component of income. For additional information, see Note 3, Discontinued Operations, in the

Notes to Consolidated Financial Statements

in this Annual Report. Critical Accounting Estimates Our consolidated financial statements are prepared in accordance with GAAP. In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events, and apply judgments based on historical experience, current trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, we review these accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. Our significant accounting policies are discussed in Note 2, Summary of Significant Accounting Policies, of the

Notes to Consolidated Financial Statements

in this Annual Report. We believe that the following accounting estimates are the most critical to aid in fully understanding and evaluating our reported financial results, and they require our most difficult, subjective or complex judgments, resulting from the need to make estimates about the effects of matters that are inherently uncertain. We have reviewed these critical accounting estimates and related disclosures with the audit and risk committee of our board of directors. Revenue from Contracts with Customers We recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenue following the five-step model prescribed under Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, (Topic 606): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Product Sales, Net Our product sales, net consist of sales in the U.S. of VIVITROL, ARISTADA, ARISTADA INITIO and LYBALVI, primarily to wholesalers, specialty distributors and pharmacies. Product sales, net are recognized when the customer obtains control of the product, which is when the product has been received by the customer. Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, healthcare providers or payers. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. The following are our significant categories of sales discounts and allowances:

Medicaid Rebates We record accruals for rebates to U.S. states under the Medicaid Drug Rebate Program as a reduction of sales when the product is shipped into the distribution channel using the expected value. We rebate individual U.S. states for all eligible units purchased under the Medicaid program based on a rebate per unit calculation, which is based on our average manufacturer prices. We estimate expected unit sales to individuals covered by Medicaid and rebates per unit under the Medicaid program and adjust our rebate accrual based on actual unit sales and rebates per unit and changes in trends in Medicaid utilization. In 2024, actual Medicaid utilization rates related to VIVITROL were lower than original estimates, due, in part, to \$8.7 million in actual credits received in the fourth quarter of 2024 from certain states related to duplicate Medicaid billings. Medicaid rebates for our other products have not differed materially from our estimates; Chargebacks discounts that occur when contracted indirect customers purchase directly from wholesalers and specialty distributors. Contracted customers generally purchase a product at its contracted price. The wholesaler or specialty distributor, in turn, generally charges back to us the difference between the wholesale acquisition cost and the contracted price paid to the wholesaler or specialty distributor by the customer. The allowance for chargebacks is made using the expected value and is based on actual and expected utilization of these programs. Chargebacks could exceed historical experience and our estimates of future participation in these programs. To date, actual chargebacks have not differed materially from our estimates; 63

Product Discounts cash consideration, including sales incentives, given by us under agreements with a number of wholesaler, distributor, pharmacy, and treatment provider customers that provide them with a discount on the purchase price of products. The reserve is made using the expected value and to date, actual product discounts have not differed materially from our estimates; Product Returns we record an estimate for product returns at the time our customers take control of our product. We estimate this liability using the expected returns of product sold based on our historical return levels and specifically identified anticipated returns due to known business conditions and product expiry dates. Return amounts are recorded as a reduction of sales. Once product is returned, it is destroyed. Actual product returns have not differed materially from our estimates; and Medicare Part D we record accruals for Medicare Part D liabilities under the Medicare Coverage Gap Discount Program (CGDP) as a reduction of sales. Under the CGDP, patients reaching the annual coverage gap threshold are eligible for reimbursement coverage for out-of-pocket costs for covered prescription drugs. Under an agreement with the Centers for Medicare and Medicaid Services, manufacturers are responsible for reimbursement of prescription plan sponsors for the portion of out-of-pocket expenses not covered under their Medicare plans. Actual Medicaid Part D rebates have not differed materially from our estimates. A rollforward of our provisions for sales and allowances is as follows:

(In millions)	Contractual Adjustments (1)	Discounts (2)	Product Returns (3)	Other (4)	Total Balance, December 31, 2022	\$ 226.7	\$ 26.2	\$ 29.7	\$ 7.9	\$ 290.5
Provision:	\$ 509.7	\$ 326.9	\$ 33.4	\$ 71.5	\$ 941.5	Prior year	\$ (8.8)	\$	\$ 2.8	\$
Total	\$ 500.9	\$ 326.9	\$ 36.2	\$ 71.5	\$ 935.5	Payments and credits related to:	\$	\$	\$	\$
Current year	\$ 509.7	\$ 326.9	\$ 36.2	\$ 71.5	\$ 935.5	Current year sales	\$ (308.4)	\$	\$	\$
Prior year sales	\$ (184.8)	\$ (30.6)	\$ (24.8)	\$ (13.0)	\$ (253.2)	Total	\$ (493.2)	\$ (324.4)	\$ (24.8)	\$ (69.2)
Balance, December 31, 2023	\$ 234.4	\$ 28.7	\$ 41.1	\$ 10.2	\$ 314.4	Provision:	\$	\$	\$	\$
Current year	\$ 557.7	\$ 386.6	\$ 28.6	\$ 87.4	\$ 1,060.3	Prior year	\$ (20.6)	\$	\$ (3.7)	\$
Current year sales	\$ (369.9)	\$ (353.6)	\$ (70.8)	\$ (794.3)	Prior year sales	\$ (172.6)	\$	\$	\$	\$
Total	\$ (542.5)	\$ (371.7)	\$ (15.5)	\$ (84.3)	\$ (1,014.0)	Balance, December 31, 2024	\$ 229.0	\$ 43.6	\$ 50.5	\$
Contractual Adjustments include	Medicaid Rebates	Medicare Part D accruals	Discounts include	Chargebacks	Product Discounts	Manufacturing Revenue	We recognize manufacturing revenues from the sale of products we manufacture for resale by our licensees. Substantially all of our manufacturing revenues are recognized at a point in time when control of the product passes to the licensee. The sales price for certain of our manufacturing revenues is based on the end-market sales price earned by our licensees. As end-market sales generally occur after we have recorded manufacturing revenue, we estimate the sales price for such products based on information supplied to us by our licensees, our historical transaction experience and other third-party data. Differences between actual manufacturing revenues and estimated manufacturing revenues are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The differences between our actual and estimated manufacturing revenues have not been material to date. Royalty Revenue We recognize royalty revenues related to the sale by our licensees of products that incorporate our technology. All of our royalties qualify for the sales-and-usage exemption under Topic 606 as (i) such royalties are based strictly on the sales-and-usage by 64	the licensee; and (ii) a license of IP is the sole or predominant item to which such royalties relate. Based on this exemption, such royalties are earned in the period the products are sold by our licensees and we have a present right to payment. Certain of our royalty revenues are recognized based on information supplied to us by our licensees and require estimates to be made. Differences between actual royalty revenues and estimated royalty revenues are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The differences between our actual and estimated royalty revenues have not been material to date. Discontinued operations We determined that the separation of our former oncology business, which was completed on November 15, 2023, represented a disposal plan that met the criteria for classification of the oncology business as a discontinued operation in accordance with ASC 205-20, Discontinued Operations. Accordingly, the accompanying consolidated financial statements for all periods have been updated to present the assets and liabilities associated with the oncology business separately as discontinued operations on the consolidated balance sheet and the results of such discontinued operations reported as a separate component of income in the consolidated statements of operations and comprehensive income (loss). For additional information related to discontinued operations, see Note 3, Discontinued Operations, in our	Notes to Consolidated Financial Statements	in this

our financial condition and results of operations. For information related to risks surrounding our deferred tax assets, see [Item 1A](#) “Risk Factors” in this Annual Report and specifically the section entitled “Our deferred tax assets may not be realized.” Recent Accounting Pronouncements See Note 2, Summary of Significant Accounting Policies, “New Accounting Pronouncements” in our “Notes to Consolidated Financial Statements” in this Annual Report for discussion, if any, of new accounting standards. Item 7A. Quantitative and Qualitative Disclosures about Market Risk We hold securities in our investment portfolio that are sensitive to market risks. Our securities with fixed interest rates may have their market value adversely impacted by a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectations due to a fall in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates. However, because we classify our investments in debt securities as available-for-sale, no gains or losses are recognized due to changes in interest rates unless such securities are sold prior to maturity or declines in fair value are determined to be other-than-temporary. Should interest rates fluctuate by 10%, our interest income would change by an immaterial amount over an annual period. We do not believe that we have a material exposure to interest rate risk as our investment policies specify credit quality standards for our investments and limit the amount of credit exposure from any single issue, issuer or type of investment. We do not believe our exposure to liquidity and credit risk to be significant as approximately 41% and 59% of our investments at December 31, 2024 are in corporate debt securities with a minimum rating of A2 (Moody’s) / A (Standard and Poor’s) and debt securities issued by the U.S. government or its agencies, respectively. We have the intent and ability to hold these securities until recovery, which may be at maturity. 66 Currency Exchange Rate Risk Manufacturing and royalty revenues that we receive on certain of our products and services are a percentage of the net sales made by our licensees, and a portion of these sales are made in countries outside the U.S. and are denominated in currencies in which the product is sold, which is predominantly the euro. The manufacturing and royalty payments on these non-U.S. sales are calculated initially in the currency in which the sale is made and are then converted into USD to determine the amount that our licensees pay us for manufacturing and royalty revenues. Fluctuations in the exchange ratio of the USD and these non-U.S. currencies will have the effect of increasing or decreasing our revenues even if there is a constant amount of sales in non-U.S. currencies. For example, if the USD weakens against a non-U.S. currency, then our revenues will increase given a constant amount of sales in such non-U.S. currency. For the year ended December 31, 2024, an average 10% strengthening of the USD relative to the currencies in which these products are sold would have resulted in revenues being reduced by approximately \$8.9 million, as compared to a reduction in revenues of approximately \$10.3 million for the year ended December 31, 2023. We incur significant operating costs in Ireland and face exposure to changes in the exchange ratio of the USD and the euro arising from expenses and payables at our Irish operations that are settled in euro. The impact of changes in the exchange ratio of the USD and the euro on our USD-denominated revenues earned in countries other than the U.S. is partially offset by the opposite impact of changes in the exchange ratio of the USD and the euro on operating expenses and payables incurred at our Irish operations that are settled in euro. For the year ended December 31, 2024, an average 10% weakening in the USD relative to the euro would have resulted in an increase to our expenses denominated in euro of approximately \$3.9 million, as compared to an increase in our expenses of approximately \$7.7 million for the year ended December 31, 2023. Item 8. Financial Statements and Supplementary Data A Selected Quarterly Financial Data (unaudited) A A First Quarter A A Second Quarter A A Third Quarter A A Fourth Quarter A A Total2024 A A (In thousands, except per share data) A Year Ended December 31, 2024 A A A A A A A A A A Total revenues A \$ 350,372 A A \$ 399,131 A A \$ 378,143 A A \$ 429,986 A A \$ 1,557,632 A Total operating expenses A \$ 307,063 A A \$ 289,248 A A \$ 273,387 A A \$ 267,298 A A \$ 1,136,996 A Operating income from continuing operations A \$ 43,309 A A \$ 109,883 A A \$ 104,756 A A \$ 162,688 A A \$ 420,636 A A A A A A A A Net income from continuing operations A \$ 38,948 A A \$ 94,658 A A \$ 92,795 A A \$ 145,737 A A \$ 372,138 A Net (loss) income from discontinued operations A A (2,120) A A (3,300) A A (414) A A 766 A A A (5,068) Net income A \$ 36,828 A A \$ 91,358 A A \$ 92,381 A A \$ 146,503 A A \$ 367,070 A A A A A A A A A A Earnings (loss) per share “basic: A A A A A A A A A A From continuing operations A \$ 0.23 A A \$ 0.56 A A \$ 0.57 A A \$ 0.90 A A \$ 2.24 A From discontinued operations A \$ (0.01) A \$ (0.02) A \$ (0.00) A \$ 0.00 A A \$ 0.03 A From net income A \$ 0.22 A A \$ 0.54 A A \$ 0.57 A A \$ 2.21 A A A A A A A A A A A A Earnings (loss) per share “diluted: A A A A A A A A A A From continuing operations A \$ 0.23 A A \$ 0.55 A A \$ 0.56 A A \$ 0.88 A A \$ 2.19 A From discontinued operations A \$ (0.01) A \$ (0.02) A \$ (0.00) A \$ 0.00 A A \$ 0.03 A From net income A \$ 0.21 A A \$ 0.53 A A \$ 0.55 A A \$ 2.16 A 67 A A First Quarter A A Second Quarter A A Third Quarter A A Fourth Quarter A A Total2023 A A (In thousands, except per share data) A Year Ended December 31, 2023 A A A A A A A A A A Total revenues from continuing operations A \$ 287,595 A A \$ 617,397 A A \$ 380,938 A A \$ 377,475 A A \$ 1,663,405 A Total operating expenses from continuing operations A \$ 298,567 A A \$ 336,128 A A \$ 291,744 A A \$ 322,844 A A \$ 1,249,283 A Operating (loss) income from continuing operations A A (10,972) A A 281,269 A A A 89,194 A A 54,631 A A 414,122 A A A A A A A A A A Net (loss) income from continuing operations A \$ (12,050) A \$ 279,101 A A \$ 91,554 A A \$ 160,552 A A \$ 519,157 A Net loss from discontinued operations A A (29,795) A A (42,036) A A (43,796) A A (47,773) A A (163,400) Net (loss) income A \$ (41,845) A \$ 237,065 A A \$ 47,758 A A \$ 112,779 A A \$ 355,757 A A A A A A A A A A A A (Loss) earnings per share “basic: A A A A A A A A A A From continuing operations A \$ (0.07) A A \$ 1.68 A A \$ 0.55 A A \$ 0.96 A A \$ 3.12 A From discontinued operations A \$ (0.18) A \$ (0.25) A \$ (0.26) A \$ (0.29) A A \$ (0.98) From net (loss) income A \$ (0.25) A A \$ 1.43 A A \$ 0.29 A A \$ 0.68 A A \$ 2.14 A A A A A A A A A A A A (Loss) earnings per share “diluted: A A A A A A A A A A From continuing operations A \$ (0.07) A A \$ 1.63 A A \$ 0.53 A A \$ 0.94 A A \$ 3.06 A From discontinued operations A \$ (0.18) A \$ (0.25) A \$ (0.25) A \$ (0.28) A A \$ (0.96) From net (loss) income A \$ (0.25) A A \$ 1.38 A A \$ 0.28 A A \$ 0.66 A A \$ 2.10 A A Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Not applicable. Item 9A. Controls and Procedures Disclosure Controls and Procedures and Internal Control Over Financial Reporting Controls and Procedures Our management has evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of December 31, 2024. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that (a) the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (b) such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Management’s Annual Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over our financial reporting as defined in Rules 13a-15(f) and 15d-15(f). Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, the issuer’s principal executive and principal financial officers, or persons performing similar functions, and effected by the issuer’s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that: (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of the assets of the issuer; (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and (c) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness for future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control – Integrated Framework. Based on this assessment, our management has concluded that, as of December 31, 2024, our internal control over financial reporting was effective. The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which is included in this Annual Report, beginning on page F-1. Item 9B. Other Information Trading Plans During the three months ended December 31, 2024, no officer (as defined in Rule 16a-1(f) under the Exchange Act) or director of the Company adopted, modified or terminated a contract, instruction or written plan for the purchase or sale of securities of the Company that were intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or a trading plan not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Not applicable. 69 A PART III Item 10. Directors, Executive Officers and Corporate Governance The information required by this item is incorporated herein by reference to our definitive proxy statement for our 2025 annual general meeting of shareholders. We expect this information will be provided under sections of the proxy statement entitled “Election of Directors,” “The Role of the Board and Its Committees,” “Executive Officers,” “Other Corporate Governance Matters” and “Board Nominations, Evaluations and Refreshment” and, if required, “Delinquent Section 16(a) Reports.” Item 11. Executive Compensation The information required by this item (excluding, for clarity, the information required by Item 402(v) of Regulation S-K) is incorporated herein by reference to our definitive proxy statement for our 2025 annual general meeting of shareholders. We expect this information will be provided under sections of the proxy statement entitled “The Role of the Board and Its Committees,” “Director Compensation,” “Executive Compensation,” “Compensation Discussion and Analysis,” “Executive Compensation Tables,” “Additional Compensation Information,” “Compensation Committee Report” and “Pay Ratio.” Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters The information required by this item is incorporated herein by reference to our definitive proxy statement for our 2025 annual general meeting of shareholders. We expect this information will be provided under sections of the proxy statement entitled “Ownership of the Company’s Ordinary Shares” and “Equity Compensation Plan Information.” Item 13. Certain Relationships and Related Transactions, and Director Independence The information required by this item is incorporated herein by reference to our definitive proxy statement for our 2025 annual general meeting of shareholders. We expect this information will be provided under sections of the proxy statement entitled “Certain Relationships and Related Party Transactions” and “The Board of Directors.” Item 14. Principal Accounting Fees and Services The information required by this item is incorporated herein by reference to our definitive proxy statement for our 2025 annual general meeting of shareholders. We expect this information will be provided under a section of the proxy statement entitled “Audit Fees.” 70 A PART IV Item 15. Exhibits and Financial Statement Schedules (a)(1) Consolidated Financial Statements “The consolidated financial statements of Alkermes plc, as required by this item, are submitted in a separate section beginning on page F-1 of this Annual Report, as follows: A Financial Statement A Page Number Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) A F-1 Consolidated Balance Sheets A F-3 Consolidated Statements of Operations and Comprehensive Income (Loss) A F-4 Consolidated Statements of Shareholders’ Equity A F-5 Consolidated Statements of Cash Flows A F-6 Notes to the Consolidated Financial Statements A F-7 (2) Financial Statement Schedules “All schedules have been omitted because the absence of conditions under which they are required or because the required information is included in the consolidated financial statements or notes thereto. (3) The exhibits listed in the below Exhibit Index are filed or furnished as part of this Annual Report or are incorporated into this Annual Report by reference. EXHIBIT INDEX A A A A A A A A Incorporated by reference herein Exhibit No. A Description of Exhibit A Form A Date 2.2 * A Agreement and Plan of Merger, dated November 14, 2019 by and among Alkermes, Inc., Thinker Merger Sub, Inc., Alkermes plc, Rodin Therapeutics, Inc., and Shareholder Representative Services LLC, as Company Equityholder Representative. A Exhibit 2.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) A November 25, 2019 2.3 A Separation Agreement, dated as of November 13, 2023, by and between Alkermes plc and Mural Oncology plc. A Exhibit 2.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) A November 15, 2023 3.1 A Memorandum and Articles of Association of Alkermes plc. A Exhibit 3.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) A May 1, 2024 4.1 # A Description of Securities. A A A 10.1 A Lease between Alkermes, Inc. and PDM Unit 850, LLC, dated as of April 22, 2009. A Exhibit 10.5 to the Alkermes, Inc. Annual Report on Form 10-K (File No. 001-14131) A May 28, 2009 10.1A A First Amendment to Lease between Alkermes, Inc. and PDM Unit 850, LLC, dated as of June 18, 2009. A Exhibit 10.2 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) A August 6, 2009 10.1B A Second Amendment to Lease between Alkermes, Inc. and PDM Unit 850, LLC, dated as of November 12, 2013. A Exhibit 10.74 to the Alkermes plc Transition Report on Form 10-KT (File No. 001-35299) A February 27, 2014 10.1C A Third Amendment to Lease between Alkermes, Inc. and PDM 850 Unit, LLC, dated as of May 15, 2014. A Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) A July 31, 2014 10.1D A Fourth Amendment to Lease between Alkermes, Inc. and GI TC 850 Winter Street, LLC, dated as of December 30, 2014. A Exhibit 10.7 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) A July 30, 2015 10.1E A Fifth Amendment to Lease between Alkermes, Inc. and GI TC 850 Winter Street, LLC, dated as of October 31, 2018. A Exhibit 10.15 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) A February 15, 2019 10.1F A Sixth Amendment to Lease between Alkermes, Inc. and GI TC 850 Winter Street, LLC, dated as of July 24, 2020. A Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) A October 29, 2020 71 A A A A A A Incorporated by reference herein Exhibit No. A Description of Exhibit A Form A Date 10.2 A License Agreement, dated as of February 13, 1996, between Medisorb Technologies International L.P. and Janssen Pharmaceutica Inc. (United States) (assigned to Alkermes, Inc. in July 2006). A Exhibit 10.2 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) A February 25, 2016 10.2A * A Third Amendment to Development Agreement, Second Amendment to Manufacturing and Supply Agreement and First Amendment to License Agreements by and between Janssen Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated April 1, 2000 (assigned to Alkermes, Inc. in July 2006). A Exhibit 10.5 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) A February 8, 2005 10.2B * A Second Amendment, dated as of August 16, 2012, to the License Agreement, dated as of February 13, 1996, as amended, by and between Alkermes, Inc. and Janssen Pharmaceutica Inc. and the License Agreement, dated as of February 21, 1996, as amended, by and between Alkermes, Inc. and JPI Pharmaceutica International, and the Fifth Amendment, dated as of August 16, 2012, to the Manufacturing and Supply Agreement, dated as of August 6, 1997, as amended, by and between Alkermes, Inc., Janssen Pharmaceutica Inc. and JPI Pharmaceutica International. A Exhibit 10.3 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) A November 1, 2012 10.3 A License Agreement, dated as of February 21, 1996, between Medisorb Technologies International L.P. and Janssen Pharmaceutica International (worldwide except United States) (assigned to Alkermes, Inc. in July 2006). A Exhibit 10.3 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) A February 25, 2016 10.4 A Manufacturing and Supply Agreement, dated August 6, 1997, by and among JPI Pharmaceutica International, Janssen Pharmaceutica, Inc. and Alkermes Controlled Therapeutics Inc. II (assigned to Alkermes, Inc. in July 2006). A Exhibit 10.4 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) A February 25, 2016 10.4A * A Fourth Amendment to Development Agreement and First Amendment to Manufacturing and Supply Agreement by and between Janssen Pharmaceutica International, Janssen Pharmaceutica Products, L.P. and Alkermes Controlled Therapeutics Inc. II, dated December 20, 2000 (assigned to Alkermes, Inc. in July 2006). A Exhibit 10.4 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) A February 8, 2005 10.4B A Addendum to the Manufacturing and Supply Agreement by and among JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated August 1, 2001. A Exhibit 10.4.2 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) A February 25, 2016 10.4C A Letter Agreement and Exhibits to Manufacturing and Supply Agreement, dated February 1, 2002, by and among JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II (assigned to Alkermes, Inc. in July 2006). A Exhibit 10.4.3 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) A February 25, 2016 10.4D * A Amendment to Manufacturing and Supply Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated December 22, 2003 (assigned to Alkermes, Inc. in July 2006). A Exhibit 10.6 to the

Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 30, 2015 10.4E * Á Fourth Amendment to Manufacturing and Supply Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated January 10, 2005 (assigned to Alkermes, Inc. in July 2006). Á Exhibit 10.9 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) Á February 8, 2005 10.4F * Á Sixth Amendment to Manufacturing and Supply Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II (assigned to Alkermes, Inc. in July 2006), effective as of July 1, 2018. Á Exhibit 10.11 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 72 Á Á Á Á Á Á Á Á Á Á Incorporated by reference herein Exhibit No. Á Description of Exhibit Á Form Á Date 10.5 * Á Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated December 21, 2002 (assigned to Alkermes, Inc. in July 2006). Á Exhibit 10.6 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) Á February 8, 2005 10.5A * Á Amendment to Agreement by and between JPI Pharmaceutica International, Janssen Pharmaceutica Inc. and Alkermes Controlled Therapeutics Inc. II, dated December 16, 2003 (assigned to Alkermes, Inc. in July 2006). Á Exhibit 10.7 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) Á February 8, 2005 10.6 ** Á License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems and Elan Pharma International Limited and Janssen Pharmaceutica N.V. dated as of March 31, 1999. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á April 26, 2023 10.6A Á First Amendment, dated as of July 31, 2003, to the License Agreement by and among Elan Drug Delivery, Inc. (formerly Elan Pharmaceutical Research Corp.) and Elan Pharma International Limited and Janssen Pharmaceutica NV dated March 31, 1999. Á Exhibit 10.24 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á May 23, 2013 10.6B ** Á Agreement Amendment No. 2, dated as of July 31, 2009, to the License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems and Elan Pharma International Limited and Janssen Pharmaceutica N.V. dated as of March 31, 1999, as amended by the First Amendment, dated as of July 31, 2003. Á Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á April 26, 2023 10.7 * Á License and Collaboration Agreement, dated November 27, 2017, by and between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH). Á Exhibit 10.10 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 16, 2018 10.7A * Á First Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of October 3, 2018. Á Exhibit 10.12 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 10.7B Á Second Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of January 31, 2019. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á April 25, 2019 10.7C ** Á Third Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of October 30, 2019. Á Exhibit 10.10.3 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 13, 2020 10.7D ** Á Fourth Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of August 25, 2022. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á November 2, 2022 10.7E ** Á Fifth Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH), effective as of June 7, 2024. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 24, 2024 10.8 Á Lease, dated March 23, 2018, by and between Alkermes, Inc. and PDM 900 Unit, LLC. Á Exhibit 10.4 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á April 26, 2018 10.8A Á First Amendment to Lease, dated June 21, 2018, by and between Alkermes, Inc. and PDM 900 Unit, LLC. Á Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 26, 2018 10.8B Á Second Amendment to Lease, dated May 10, 2019, by and between Alkermes, Inc. and PDM 900 Unit, LLC. Á Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 25, 2019 73 Á Á Á Á Á Á Á Á Á Á Incorporated by reference herein Exhibit No. Á Description of Exhibit Á Form Á Date 10.9 ** Á Confidential Settlement and License Agreement, dated August 29, 2023, by and among Alkermes, Inc., Alkermes Pharma Ireland Limited and Teva Pharmaceuticals USA, Inc. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 25, 2023 10.10 A\$ Á Tax Matters Agreement, dated November 13, 2023, by and between Alkermes plc and Mural Oncology plc. Á Exhibit 10.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) Á November 15, 2023 10.11 ** A\$ Á Asset Purchase Agreement, dated December 13, 2023, by and between Alkermes Pharma Ireland Limited, Novo Nordisk Production Ireland Limited and Novo Nordisk A/S. Á Exhibit 10.16 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 21, 2024 10.12 a€ Á Employment Agreement, dated as of December 12, 2007, by and between Richard F. Pops and Alkermes, Inc. Á Exhibit 10.1 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) Á February 11, 2008 10.12A a€ Á Amendment to Employment Agreement, dated as of October 7, 2008, by and between Alkermes, Inc. and Richard F. Pops. Á Exhibit 10.5 to the Alkermes, Inc. Current Report on Form 8-K (File No. 001-14131) Á October 7, 2008 10.12B a€ Á Amendment No. 2 to Employment Agreement, dated as of September 10, 2009 by and between Richard F. Pops and Alkermes, Inc. Á Exhibit 10.2 to the Alkermes, Inc. Current Report on Form 8-K (File No. 001-14131) Á September 11, 2009 10.13 a€ Á Form of Employment Agreement, as amended by the Form of Amendment to Employment Agreement set forth in 10.12.1, entered into by and between Alkermes, Inc. and Blair C. Jackson. Á Exhibit 10.3 to the Alkermes, Inc. Quarterly Report on Form 10-Q (File No. 001-14131) Á February 11, 2008 10.13A a€ Á Form of Amendment to Employment Agreement with Alkermes, Inc. Á Exhibit 10.7 to the Alkermes, Inc. Current Report on Form 8-K (File No. 001-14131) Á October 7, 2008 10.14 a€ Á Form of Employment Agreement entered into by and between Alkermes, Inc. and each of Iain M. Brown, David J. Gaffin, Craig C. Hopkinson, M.D. and Christian Todd Nichols. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á November 2, 2016 10.14Aa€ Á Offer Letter by and between Alkermes, Inc. and Craig C. Hopkinson M.D., effective as of April 24, 2017. Á Exhibit 10.17.1 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 16, 2018 10.14B a€ Á Offer Letter, dated March 29, 2019, by and between Alkermes, Inc. and Christian Todd Nichols. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 29, 2020 10.15 a€ Á Form of Indemnification Agreement entered into by and between Alkermes, Inc. and each of the Directors and Secretaries of Alkermes plc and its Irish subsidiaries. Á Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á April 29, 2020 10.16 a€ Á Form of Deed of Indemnification entered into by and between each of the Directors, Secretaries and executive officers of Alkermes plc and its subsidiaries. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á April 29, 2020 10.17a€ Á Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (File No. 001-35299) Á April 27, 2017 10.17A a€ Á Form of Stock Option Award Certificate (Non-Employee Director) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. Á Exhibit 10.4 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) Á April 28, 2016 10.17B a€ Á Form of Restricted Stock Unit Award Certificate (Time Vesting Only a€” Irish) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. Á Exhibit 10.5 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended Á April 28, 2016 74 Á Á Á Á Á Á Á Á Á Á Incorporated by reference herein Exhibit No. Á Description of Exhibit Á Form Á Date Á Á Á March 31, 2016 (File No. 001-35299) Á Á 10.17C a€ Á Form of Restricted Stock Unit Award Certificate (Time Vesting Only a€” U.S.) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. Á Exhibit 10.6 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) Á April 28, 2016 10.17D a€ Á Form of Stock Option Award Certificate (Time Vesting Non-Qualified Option a€” Irish) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. Á Exhibit 10.7 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) Á April 28, 2016 10.17E a€ Á Form of Stock Option Award Certificate (Time Vesting Non-Qualified Option a€” U.S.) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. Á Exhibit 10.8 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) Á April 28, 2016 10.17F a€ Á Form of Stock Option Award Certificate (Incentive Stock Option a€” U.S.) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. Á Exhibit 10.9 to the Alkermes plc Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (File No. 001-35299) Á April 28, 2016 10.17G a€ Á Form of 2008 Restricted Stock Unit Award Certificate (Performance Vesting Only) under the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended. Á Exhibit 10.2 to the Alkermes, Inc. Current Report on Form 8-K (File No. 001-14131) Á May 22, 2009 10.18a€ Á Alkermes plc 2011 Stock Option and Incentive Plan, as amended. Á Exhibit 10.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) Á May 24, 2017 10.18A a€ Á Form of Incentive Stock Option Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. Á Exhibit 10.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 10.18B a€ Á Form of Non-Qualified Stock Option (Employee) Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. Á Exhibit 10.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 10.18C a€ Á Form of Restricted Stock Unit (Time-Vesting) Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. Á Exhibit 10.3 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 10.18D a€ Á Form of Restricted Stock Unit (Performance-Vesting) Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. Á Exhibit 10.4 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 10.18E a€ Á Form of Non-Qualified Stock Option (Non-Employee Director) Award Certificate under the Alkermes plc 2011 Stock Option and Incentive Plan, as amended. Á Exhibit 10.5 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 10.19 a€ Á Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.1 to the Alkermes plc Current Report on Form 8-K (File No. 001-35299) Á May 31, 2024 10.19A a€ Á Form of Incentive Stock Option Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.6 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 10.19B a€ Á Form of Non-Qualified Stock Option (Employee) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.7 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 10.19C a€ Á Form of Restricted Stock Unit (Time-Vesting) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.8 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á October 23, 2018 75 Á Á Á Á Á Á Á Á Á Á Incorporated by reference herein Exhibit No. Á Description of Exhibit Á Form Á Date 10.19D a€ Á Form of Restricted Stock Unit (Performance-Vesting) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.6 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 29, 2020 10.19E a€ Á Form of Non-Qualified Stock Option (Non-Employee Director) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.4 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 29, 2020 10.19F a€ Á Form of Non-Employee Director Restricted Stock Unit (Time-Vesting) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.5 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 29, 2020 10.19G a€ Á Form of Non-Employee Director New Director Grant Non-Qualified Stock Option Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.1.1 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 27, 2022 10.19H a€ Á Form of Non-Employee Director New Director Grant Restricted Stock Unit (Time-Vesting) Award Certificate under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.1.2 to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 27, 2022 10.19I a€ Á Form of Incentive Stock Option Award Certificate for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.19.9 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 16, 2023 10.19J a€ Á Form of Non-Qualified Stock Option Award Certificate for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.19.10 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 16, 2023 10.19K a€ Á Form of Restricted Stock Unit (Time-Vesting) Award Certificate for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.19.11 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 16, 2023 10.19L a€ Á Form of Restricted Stock Unit (Performance-Vesting) Award Certificate for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.19.12 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 16, 2023 10.19M a€ Á Form of Restricted Stock Unit (Performance-Vesting) Award Certificate (rev. 2024) for Reporting Officers under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.25M to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 21, 2024 10.19N a€ Á Form of Restricted Stock Unit (Performance-Vesting) Award Certificate (rev. 2024) under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.25N to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 21, 2024 10.19O a€ Á Form of Non-Employee Director Non-Qualified Stock Option Award Certificate (rev. 2024) under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.2A to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 24, 2024 10.19P a€ Á Form of Non-Employee Director Restricted Stock Unit Award (Time-Vesting) Award Certificate (rev. 2024) under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. Á Exhibit 10.2A to the Alkermes plc Quarterly Report on Form 10-Q (File No. 001-35299) Á July 24, 2024 19.1 # Á Alkermes plc Insider Trading Policy. Á Á Á 21.1 # Á List of subsidiaries. Á Á Á 23.1 # Á Consent of PricewaterhouseCoopers LLP, an independent registered public accounting firm. Á Á Á 24.1 # Á Power of Attorney (included on the signature pages hereto). Á Á Á 31.1 # Á Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934. Á Á Á 76 Á Á Á Á Á Á Á Á Á Á Incorporated by reference herein Exhibit No. Á Description of Exhibit Á Form Á Date 31.2 # Á Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934. Á Á Á 32.1 a€ Á Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Á Á Á 97 a€ Á Alkermes plc Incentive Compensation Recoupment Policy. Á Exhibit 97 to the Alkermes plc Annual Report on Form 10-K (File No. 001-35299) Á February 21, 2024 101.SCH # Á Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document. Á Á Á 104 Á Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101). Á Á Á Á Á a€ Á Indicates a management contract or any compensatory plan, contract or arrangement. # Á Filed herewith. a€ Á Furnished herewith. * Á Confidential treatment has been granted or requested for certain portions of this exhibit. Such portions have been filed separately with the SEC pursuant to a confidential treatment request. ** Á Portions of this exhibit (indicated by a€œ**ã€”) have been omitted pursuant to Item 601(b) of Regulation S-K. The Company undertakes to furnish an unredacted copy of this exhibit upon request by the U.S. Securities and Exchange Commission. A\$ Á Schedules and similar attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish copies of any omitted schedules and similar attachments upon request by the U.S. Securities and Exchange Commission. Item 16. Form 10-K Summary None. Á 77 Á SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Á Á ALKERMES PLC Á Á Á By: /s/ Richard F. PopsRichard F. PopsChairman and Chief Executive Officer Á Á February 12, 2025 Á Á Á POWER OF ATTORNEY Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. Each person whose signature appears below in so signing also makes, constitutes and appoints Richard F. Pops and Blair C. Jackson, and each of them, his true and lawful attorney-in-fact, with full power of substitution, for him in any and all capacities, to execute and cause to be filed with the Securities and Exchange Commission any and all amendments to this Annual Report, with exhibits thereto and other documents in connection therewith, and hereby ratifies and confirms all that said attorney-in-fact or his substitute or substitutes may do or cause to be done by virtue hereof. Á Signature Á Title Á Date Á Á Á /s/ Richard F. PopsRichard F. Pops Á Chairman and Chief Executive Officer (Principal Executive Officer) Á February 12, 2025 Á Á Á /s/ Blair C. JacksonBlair C. Jackson Á Executive Vice President, Chief Operating Officer (Interim Principal Financial Officer) Á February 12, 2025 Á Á Á /s/ Samuel J. ParisiSamuel J. Parisi Á Vice President, Finance (Interim Principal Accounting Officer) Á February 12, 2025 Á Á Á /s/ Emily Peterson AlvaEmily Peterson Alva Á Director Á February 12, 2025 Á Á Á /s/ Shane M. CookeShane M. Cooke Á Director Á February 12, 2025 Á Á Á /s/ David A. Daglio, Jr. Á Director Á February 12, 2025 David A. Daglio, Jr. Á Á Á Á /s/ Richard B. GaynorRichard B. Gaynor Á Director Á February 12, 2025 Á Á Á /s/ Brian P. McKeonBrian P. McKeon Á Director Á February 12, 2025 Á Á Á /s/ Nancy L. SnydermanNancy L. Snyderman Á Director Á February 12, 2025 Á Á Á /s/ Frank Anders WilsonFrank Anders Wilson Á Director Á February 12, 2025 Á Á Á /s/ Christopher I. WrightChristopher I. Wright Á Director Á February 12, 2025 Á 78 Á Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Alkermes plc Opinions on the Financial Statements and Internal Control over Financial ReportingWe have

The accompanying consolidated balance sheets of Alkermes plc and its subsidiaries (the "Company") as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive income (loss), of shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO. Basis for Opinions The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions. Definition and Limitations of Internal Control over Financial Reporting A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements. F-1 Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Critical Audit Matters The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Rebate Accruals Medicaid Drug Rebate Program As described in Notes 2 and 11 to the consolidated financial statements, the Company's revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company's customers, health care providers or payers. The Company records accruals for rebates to U.S. states under the Medicaid Drug Rebate Program as a reduction of sales when the product is shipped into the distribution channel using the expected value method. As of December 31, 2024, accrued Medicaid rebates were \$202.0 million, of which a significant amount related to the Medicaid Drug Rebate Program. The Company rebates individual U.S. states for all eligible units purchased under the Medicaid program based on a rebate per unit calculation, which is based on the Company's average manufacturer prices. The Company estimates expected unit sales to individuals covered by Medicaid and rebates per unit under the Medicaid program and adjusts its rebate accrual based on actual unit sales and rebates per unit and changes in trends in Medicaid utilization. The principal considerations for our determination that performing procedures relating to rebate accruals for the Medicaid Drug Rebate Program is a critical audit matter are (i) the significant judgment by management due to significant measurement uncertainty involved in developing the reserves, as the reserves are based on assumptions developed using historical experience, current contractual requirements, specific known market events and payment patterns and (ii) a high degree of auditor judgment, subjectivity and effort in applying procedures and evaluating evidence related to these assumptions. Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to rebate accruals for the Medicaid Drug Rebate Program, including controls over the assumptions used to estimate the rebate accruals. These procedures also included, among others, (i) developing an independent estimate of the rebate accruals by utilizing third-party data related to product sales, the historical trend of actual rebate claims paid and consideration of contractual requirement changes and market events; (ii) comparing the independent estimate to management's estimate; and (iii) testing rebate claims processed by the Company. /s/ PricewaterhouseCoopers LLP Boston, Massachusetts February 12, 2025 We have served as the Company's auditor since 2007.

F-2 ALKERMES PLC AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

	December 31, 2024	December 31, 2023
(In thousands, except share and per share amounts)		
ASSETS		
Cash and cash equivalents	\$ 291,146	\$ 457,469
Investments	\$ 460,522	\$ 316,022
Receivables, net	\$ 384,528	\$ 332,477
Inventory	\$ 182,887	\$ 186,406
Prepaid expenses and other current assets	\$ 91,282	\$ 98,166
Contract assets	\$ 4,990	\$ 4,706
Assets held for sale	\$ 94,260	\$ 1,415,355
Total current assets	\$ 1,415,355	\$ 1,485,506
PROPERTY, PLANT AND EQUIPMENT, NET	\$ 227,564	\$ 226,943
INVESTMENTS	\$ 73,148	\$ 39,887
RIGHT-OF-USE ASSETS	\$ 84,245	\$ 91,460
INTANGIBLE ASSETS, NET AND GOODWILL	\$ 83,917	\$ 85,018
DEFERRED TAX ASSETS	\$ 154,835	\$ 195,888
OTHER ASSETS	\$ 16,503	\$ 11,521
TOTAL ASSETS	\$ 2,055,567	\$ 2,136,223
LIABILITIES AND SHAREHOLDERS' EQUITY		
Accounts payable and accrued expenses	\$ 185,332	\$ 240,561
Accrued sales discounts, allowances and reserves	\$ 272,452	\$ 263,641
Operating lease liabilities	\$ 6,166	\$ 5,746
Contract liabilities	\$ 1,249	\$ 2,730
Current portion of long-term debt	\$ 4	\$ 3,000
Liabilities related to discontinued operations	\$ 4	\$ 4,542
Total current liabilities	\$ 465,199	\$ 520,220
LONG-TERM DEBT	\$ 287,730	\$ 69,372
OPERATING LEASE LIABILITIES	\$ 69,372	\$ 75,709
OTHER LONG-TERM LIABILITIES	\$ 56,019	\$ 49,878
Total liabilities	\$ 590,590	\$ 933,537
COMMITMENTS AND CONTINGENT LIABILITIES (Note 19)	\$ 4	\$ 4
SHAREHOLDERS' EQUITY		
Preferred shares, par value, \$0.01 per share; 50,000,000 shares authorized; and zero issued and outstanding at December 31, 2024 and 2023	\$ 4	\$ 4
Ordinary shares, par value, \$0.01 per share; 450,000,000 shares authorized; 176,670,785 and 172,569,051 shares issued; and 162,176,994 and 166,979,833 shares outstanding at December 31, 2024 and 2023, respectively	\$ 1,767	\$ 1,726
Treasury shares, at cost (14,493,791 and 5,589,218 shares at December 31, 2024 and 2023, respectively)	\$ (419,255)	\$ (189,336)
Additional paid-in capital	\$ 2,860,890	\$ 2,736,934
Accumulated other comprehensive loss	\$ (1,967)	\$ (3,110)
accumulated deficit	\$ (976,458)	\$ (1,343,528)
Total shareholders' equity	\$ 1,464,977	\$ 1,202,686
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 2,055,567	\$ 2,136,223

The accompanying notes are an integral part of these consolidated financial statements.

F-3 ALKERMES PLC AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Years Ended December 31, 2024, 2023 and 2022

	2024	2023	2022
(In thousands, except per share amounts)			
REVENUES	\$ 1,083,534	\$ 919,998	\$ 777,552
Product sales, net	\$ 1,083,534	\$ 919,998	\$ 777,552
Manufacturing and royalty revenues	\$ 474,095	\$ 743,388	\$ 331,983
License revenue	\$ 4	\$ 4	\$ 2,000
Research and development revenue	\$ 3	\$ 19	\$ 260
Total revenues	\$ 1,557,632	\$ 1,663,405	\$ 1,111,795
EXPENSES:			
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	\$ 245,331	\$ 253,037	\$ 218,068
Research and development	\$ 245,326	\$ 270,806	\$ 272,702
Selling, general and administrative	\$ 645,238	\$ 689,751	\$ 590,751
Amortization of acquired intangible assets	\$ 1,101	\$ 35,689	\$ 36,363
Total expenses	\$ 1,136,996	\$ 1,249,283	\$ 1,117,884
OPERATING INCOME FROM CONTINUING OPERATIONS	\$ 420,636	\$ 414,122	\$ (6,089)
OTHER INCOME (EXPENSE), NET:			

CASH AND CASH EQUIVALENTS€“End of period \$ 291,146 Á \$ 457,469 Á \$ 292,473 SUPPLEMENTAL CASH FLOW DISCLOSURE: Á Á Á Á Á Á Á Á Cash paid for interest \$ 23,010 Á Á \$ 22,748 Á Á \$ 13,563 Á Cash paid for taxes \$ 2,592 Á Á \$ 44,243 Á Á \$ 20,749 Á Non-cash investing and financing activities: Á Á Á Á Á Á Á Á Purchased capital expenditures included in accounts payable and accrued expenses \$ 2,254 Á Á \$ 2,645 Á Á \$ 2,950 Á Á The accompanying notes are an integral part of these consolidated financial statements. F-6 Á ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATIONAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. Alkermes has a portfolio of proprietary commercial products for the treatment of alcohol dependence and opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development (€œR&D€œ) center in Massachusetts and a manufacturing facility in Ohio.In May 2024, the Company completed the sale of its development and manufacturing facility in Athlone, Ireland (the €œAthlone Facility€œ) and related business to Novo Nordisk (€œNovo€œ) pursuant to an asset purchase agreement entered into in December 2023. The Company and Novo also entered into subcontracting arrangements to continue certain development and manufacturing activities performed at the Athlone Facility for a period of time after the closing of the transaction, which activities may continue through the end of 2025. In connection with the sale of the Athlone Facility, the Company received \$97.9 million from Novo, which included a payment of approximately \$91.0 million for the facility and certain related assets, and recorded a gain of approximately \$1.5 million within €œOther income (expense), net€œ in the accompanying consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2024. As of December 31, 2023, the Company classified the assets described under the asset purchase agreement for the sale as €œAssets held for sale€œ in the accompanying consolidated balance sheet.In November 2023, the Company completed the separation of its former oncology business into Mural Oncology plc (€œMural€œ), a new, independent, publicly-traded company (the €œSeparation€œ). The Separation was effected by means of a distribution of all of the outstanding ordinary shares of Mural to the Company€œ’s shareholders (the €œDistribution€œ), in which each of the Company€œ’s shareholders received one ordinary share, nominal value \$0.01 per share, of Mural for every ten ordinary shares, par value \$0.01 per share, of the Company (the €œDistribution Ratio€œ) held by such shareholder as of the close of business on November 6, 2023, the record date for the Distribution (the €œRecord Date€œ). The historical results of the oncology business have been reflected as discontinued operations in the Company€œ’s consolidated financial statements through November 15, 2023 (the €œSeparation Date€œ). For additional information related to the Separation, see Note 3, Discontinued Operations in these €œNotes to Consolidated Financial Statements€œ in this Annual Report. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESPrinciples of ConsolidationThe consolidated financial statements include the accounts of Alkermes plc and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated. Columns and rows within tables may not sum due to rounding.ReclassificationThe Company has presented its former oncology business as discontinued operations in its consolidated financial statements as of December 31, 2023 and for the years ended December 31, 2023 and 2022. See Note 3, Discontinued Operations in these €œNotes to Consolidated Financial Statements€œ in this Annual Report for additional information.Discontinued OperationsThe Company determined that the Separation met the criteria for classification of the former oncology business as discontinued operations in accordance with Financial Accounting Standards Board (€œFASB€œ) Accounting Standards Codification (€œASC€œ) 205, Discontinued Operations. Accordingly, the accompanying consolidated financial statements have been updated to present the results of the oncology business as discontinued operations through the Separation Date for the years ended December 31, 2023 and 2022 in the consolidated statements of operations and comprehensive income (loss). Assets Held for SaleIn connection with the sale of the Athlone Facility, the Company reviewed FASB ASC 805, Business Combinations (€œTopic 805€œ) and, based on the definitions therein, determined that the Athlone Facility constituted a business. Accordingly, the assets associated with the sale of the Athlone Facility were classified as €œAssets held for sale€œ in the accompanying consolidated balance sheet as of December 31, 2023. F-7 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Use of EstimatesThe preparation of the Company€œ’s consolidated financial statements in accordance with accounting principles generally accepted in the United States (€œGAAP€œ) requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies, including but not limited to, those related to revenue from contracts with its customers and related allowances, impairment of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.Cash and Cash EquivalentsThe Company values its cash and cash equivalents at cost plus accrued interest, which the Company believes approximates its market value. The Company considers as cash equivalents only those investments that are highly liquid, readily convertible into cash and so near their maturity (three months from the date of purchase) that they present insignificant risk of change in value because of interest rate changes.InvestmentsThe Company has investments in various types of securities, consisting primarily of United States (€œU.S.€œ), government and agency obligations and corporate debt securities. The Company generally holds its interest-bearing investments with major financial institutions and in accordance with documented investment policies. The Company limits the amount of credit exposure to any one financial institution or corporate issuer. At December 31, 2024, substantially all these investments were classified as available-for-sale and were recorded at fair value. Unrealized gains and losses are included in accumulated other comprehensive loss in equity, net of related tax, unless: (i) the security has experienced a credit loss; (ii) the Company has determined that it has the intent to sell the security; or (iii) the Company has determined that it is more likely than not that it will have to sell the security before its expected recovery. Periodic reviews are conducted to identify and evaluate each investment that has an unrealized loss in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis.For available-for-sale debt securities with unrealized losses, the Company performs an analysis to assess whether it intends to sell, or whether it would more likely than not be required to sell, the security before the expected recovery of the amortized cost basis. Where the Company intends to sell a security, or may be required to do so, the security€œ’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.Regardless of the Company€œ’s intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.The Company€œ’s held-to-maturity investments are restricted investments held as collateral under letters of credit related to certain of the Company€œ’s agreements and are included in €œInvestments€œ“long-term,€œ in the accompanying consolidated balance sheets.Fair Value of Financial InstrumentsThe Company€œ’s financial assets and liabilities are recorded at fair value and are classified as Level 1, 2 or 3 within the fair value hierarchy, as described in the accounting standards for fair value measurement. At December 31, 2024, the Company€œ’s financial assets consisted of cash equivalents and investments and are classified within the fair value hierarchy as follows:€œLevel 1€œ“these valuations are based on a market approach using quoted prices in active markets for identical assets. Valuations of these products do not require a significant degree of judgment. Assets utilizing Level 1 inputs at December 31, 2024 included U.S. treasury securities, marketable securities classified as cash equivalents and a fixed term deposit account; and €œLevel 2€œ“these valuations are based on quoted prices for identical or similar assets in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models. Assets utilizing Level 2 inputs at December 31, 2024 included U.S. government agency debt securities and investments in corporate debt securities that are trading in the credit markets. F-8 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, accounts receivable, contract assets, other current assets, accounts payable and accrued expenses and accrued sales discounts, allowances and reserves approximate fair value due to their short-term nature.InventoryInventory is stated at the lower of cost and net realizable value. The Company utilizes a standard cost basis, which approximates cost determined using the first-in first-out method. Cost is determined using the first-in, first-out method. Included in inventory are raw materials used in production of preclinical and clinical products, which have alternative future use and are charged to R&D expense when consumed. The cost elements included within inventory include three primary categories for commercial products: cost of raw materials; direct labor; and overhead. Overhead is based on the normal capacity of the Company€œ’s production facility and does not include costs from abnormally low production or idle capacity, which are expensed directly to the consolidated statement of operations and comprehensive income (loss).The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management€œ’s judgment, future commercialization of the product is considered probable and future economic benefit from such product is expected to be realized. The Company assesses the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety, efficacy or quality concerns, potential labeling restrictions and other potential impediments to approval. The Company also considers the shelf life of the product in relation to the expected timeline for approval and considers issues that may prevent or delay commercialization, including issues that may arise in relation to the manufacturing of the product. The Company expenses previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by relevant regulatory agencies or other issues that may make the pre-approval inventory batches less likely or unlikely to be commercialized and to result in future economic benefit.Property, Plant and EquipmentProperty, plant and equipment are recorded at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred and major renewals and improvements are capitalized. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:Á Asset group Á Term Buildings and improvements Á 25Á years Furniture, fixtures and equipment Á 5Á - 7Á years Leasehold improvements Á Shorter of useful life or lease term Goodwill and Intangible AssetsGoodwill represents the excess cost of the Company€œ’s investment in the net assets of acquired companies over the fair value of the underlying identifiable net assets at the date of acquisition. The Company€œ’s goodwill consists solely of goodwill created as a result of the Company€œ’s acquisition of Elan Drug Technologies (€œEDT€œ) from Elan Corporation, plc (such acquisition, the €œBusiness Combination€œ) in September 2011 and has been assigned to one reporting unit. A reporting unit is an operating segment or one level below an operating segment or a component to which goodwill is assigned when initially recorded.Goodwill is not amortized but is reviewed for impairment on an annual basis, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable. The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of its reporting unit is less than its carrying amount, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative impairment test, the Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then the Company would record an impairment loss equal to the difference.When some, but not all, of a reporting unit is to be disposed of, the accounting for that reporting unit€œ’s goodwill will depend on whether the disposal group constitutes a business. If the disposal group constitutes a business, the Company attributes a portion of the reporting unit€œ’s goodwill to the disposal group based on the relative fair values of: (i) the disposal group; and (ii) the portion of the reporting unit that will be retained. F-9 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) The Company€œ’s finite-lived intangible assets, consisting of core developed technology and collaboration agreements acquired as part of the Business Combination, were recorded at fair value at the time of their acquisition and are stated within the Company€œ’s consolidated balance sheets net of accumulated amortization. The finite-lived intangible assets are amortized over their estimated useful lives using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract. The useful lives of the Company€œ’s intangible assets are primarily based on the legal or contractual life of the underlying patent or contract, which does not include additional years for the potential extension or renewal of the contract or patent.Impairment of Long-Lived AssetsThe Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset; a significant change in the extent or manner in which an asset is used; a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset; a current-period operating or cash flow loss combined with a history of operating or cash-flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset; or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell them.Revenue from Contracts with CustomersThe Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed in accordance with FASB ASC 606, Revenue from Contracts with Customers (€œTopic 606€œ): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. Product Sales, NetThe Company€œ’s product sales, net consist of sales in the U.S. of VIVITROL®, ARISTADA®, ARISTADA INITIOA® and LYBALVIA®, primarily to wholesalers, specialty distributors and pharmacies. Product sales, net are recognized when the customer obtains control of the product, which is when the product has been received by the customer.Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company€œ’s customers, healthcare providers or payers. The Company€œ’s process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company€œ’s estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. The following are the Company€œ’s significant categories of sales discounts and allowances:€œMedicaid Rebates€œ“the Company records accruals for rebates to U.S. states under the Medicaid Drug Rebate Program as a reduction of sales when the product is shipped into the distribution channel using the expected value method. The Company rebates individual U.S. states for all eligible units purchased under the Medicaid program based on a rebate per unit calculation, which is based on the Company€œ’s average manufacturer prices. The Company estimates expected unit sales to individuals covered by Medicaid and rebates per unit under the Medicaid program and adjusts its rebate accrual based on actual unit sales and rebates per unit and changes in trends in Medicaid utilization. In 2024, actual Medicaid utilization rates related to VIVITROL were lower than original estimates, due, in part, to \$8.7 million in actual credits received from certain states in the fourth quarter of 2024 related to duplicate Medicaid billings. Medicaid rebates for the Company€œ’s other products have not differed materially from the Company€œ’s estimates; €œChargebacks€œ“discounts that occur when contracted indirect customers purchase directly from wholesalers and specialty distributors. Contracted customers generally purchase a product at its contracted price. The wholesaler or specialty distributor, in turn, then generally charges back to the Company the difference between the wholesale acquisition cost and the contracted price paid to the wholesaler or specialty distributor by the customer. The allowance for chargebacks is made using the expected value method and is based on actual and expected utilization of these programs. Chargebacks could exceed historical experience and the Company€œ’s estimates of future participation in these programs. To date, actual chargebacks have not differed materially from the Company€œ’s estimates; F-10 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) €œProduct Discounts€œ“cash consideration, including sales incentives, given by the Company under agreements with a number of wholesaler, distributor, pharmacy, and treatment provider customers that provide them with a discount on the purchase price of products. The reserve is made

using the expected value method and to date, actual product discounts have not differed materially from the Company’s estimates; Product Returns the Company records an estimate for product returns at the time its customers take control of their product. The Company estimates this liability using the expected returns of product sold based on historical return levels and specifically identified anticipated returns due to known business conditions and product expiry dates. Return amounts are recorded as a reduction of sales. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from the Company’s estimates; and Medicare Part D the Company records accruals for Medicare Part D liabilities under the Medicare Coverage Gap Discount Program (the CGDP) as a reduction of sales. Under the CGDP, patients reaching the annual coverage gap threshold are eligible for reimbursement coverage for out-of-pocket costs for covered prescription drugs. Under an agreement with the Centers for Medicare and Medicaid Services, manufacturers are responsible to reimburse prescription plan sponsors for the portion of out-of-pocket expenses not covered under their Medicare plans. To date, actual Medicare Part D rebates have not differed materially from the Company’s estimates. A rollforward of the Company’s provisions for sales and allowances is as follows: December 31, 2023 \$ 234,414 \$ 28,690 \$ 41,064 \$ 10,164 \$ 314,332 Current provisions relating to sales in current year \$ 557,651 \$ 386,625 \$ 28,627 \$ 87,373 \$ 1,060,276 Adjustments relating to prior years \$ (20,562) \$ (3,700) \$ (4) \$ (24,262) Payments/credits relating to sales in current year \$ (369,869) \$ (353,629) \$ (70,752) \$ (794,250) Payments/credits relating to sales in prior years \$ (172,656) \$ (18,041) \$ (15,484) \$ (13,488) \$ (219,669) Ending balance December 31, 2024 \$ 228,978 \$ 43,645 \$ 50,507 \$ 13,297 \$ 336,427 December 31, 2023 (In thousands) Contractual Adjustments (1) Discounts (2) Product Returns (3) Other (4) Total Beginning balance December 31, 2022 \$ 226,741 \$ 26,175 \$ 29,666 \$ 7,938 \$ 290,520 Current provisions relating to sales in current year \$ 509,780 \$ 326,860 \$ 33,417 \$ 71,449 \$ 941,506 Adjustments relating to prior years \$ (8,921) \$ (2,841) \$ (6,080) Payments/credits relating to sales in current year \$ (308,353) \$ (293,785) \$ (56,224) \$ (658,362) Payments/credits relating to sales in prior years \$ (184,833) \$ (30,560) \$ (24,860) \$ (12,999) \$ (253,252) Ending balance December 31, 2023 \$ 234,414 \$ 28,690 \$ 41,064 \$ 10,164 \$ 314,332 December 31, 2022 (In thousands) Contractual Adjustments (1) Discounts (2) Product Returns (3) Other (4) Total Beginning balance December 31, 2021 \$ 209,760 \$ 24,150 \$ 24,313 \$ 9,585 \$ 267,808 Current provisions relating to sales in current year \$ 434,143 \$ 281,308 \$ 15,851 \$ 58,788 \$ 790,090 Adjustments relating to prior years \$ (22,019) \$ (3,294) \$ (18,725) Payments/credits relating to sales in current year \$ (237,521) \$ (252,896) \$ (48,834) \$ (539,251) Payments/credits relating to sales in prior years \$ (157,622) \$ (26,387) \$ (13,792) \$ (11,601) \$ (209,402) Ending balance December 31, 2022 \$ 226,741 \$ 26,175 \$ 29,666 \$ 7,938 \$ 290,520 (1) Contractual Adjustments include Medicaid Rebates and Medicare Part D accruals (2) Discounts include Chargebacks and Product Discounts (3) Total revenue-related reserves as of December 31, 2024 and 2023, included in our consolidated balance sheets, are summarized as follows: F-11 ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Year Ended December 31, (In thousands) 2024 2023 Reduction of accounts receivable \$ 22,031 \$ 11,510 Components of accrued sales discounts, allowances and reserves \$ 272,452 \$ 263,641 Components of other long-term liabilities \$ 41,944 \$ 39,181 Total revenue-related reserves \$ 336,427 \$ 314,332 Collaborative Arrangements The Company has entered into collaborative arrangements with pharmaceutical companies including, among others, Janssen Pharmaceuticals, Inc. (Janssen, Inc.), Janssen Pharmaceutica International, a division of Cilag International AG (Janssen International), and Janssen Pharmaceutica N.V. (together with Janssen, Inc., Janssen International and their affiliates, Janssen) related to INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, INVEGA HAFYERA, BYANLIA (collectively, the long-acting INVEGA products) and RISPERDAL CONSTA, and Biogen International GmbH (together with its affiliates, Biogen) related to UMERITY. Substantially all of the products developed under these arrangements are currently being marketed as approved products for which the Company received or receives payments for manufacturing services and/or royalties on net product sales. Manufacturing Revenue The Company recognizes manufacturing revenues from the sale of products it manufactures for resale by its licensees. Substantially all of the manufacturing revenues are recognized at a point in time when control of the product passes to the licensee. The sales price for certain of the Company’s manufacturing revenues is based on the end-market sales price earned by its licensees. As end-market sales generally occur after the Company has recorded manufacturing revenue, the Company estimates the sales price for such products based on information supplied to it by the Company’s licensees, its historical transaction experience and other third-party data. Differences between actual manufacturing revenues and estimated manufacturing revenues are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The differences between the Company’s actual and estimated manufacturing revenues have not been material to date. Royalty Revenue The Company recognizes royalty revenues related to the sale by its licensees of products that incorporate the Company’s technologies. All of the Company’s royalties qualify for the sales-and-usage exemption under Topic 606 as (i) such royalties are based strictly on the sales-and-usage by the licensee; and (ii) a license of IP is the sole or predominant item to which such royalties relate. Based on this exemption, these royalties are earned in the period that the products are sold by the Company’s licensee and the Company has a present right to payment. Certain of the Company’s royalty revenues are recognized by the Company based on information supplied to the Company by its licensees and require estimates to be made. Differences between actual royalty revenues and estimated royalty revenues are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The differences between the Company’s actual and estimated royalty revenues have not been material to date. Receivables, net Receivables, net, include amounts billed and amounts unbilled but currently unconditionally due from customers. The amounts due are stated at their net estimated realizable value. The Company’s unbilled receivable balance was \$69.5 million and \$103.1 million at December 31, 2024 and 2023, respectively, and related primarily to royalty revenue. The Company maintains an allowance for doubtful accounts to provide for the estimated amounts of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable. The Company’s allowance for doubtful accounts was approximately \$0.3 million and \$0.2 million at December 31, 2024 and 2023, respectively. Contract Assets Contract assets include unbilled amounts that will result in a sale under certain of the Company’s manufacturing contracts. The amounts included in the contract assets table below are classified as Current assets in the accompanying consolidated balance sheets, as they relate to manufacturing processes that are completed in ten days to eight weeks. F-12 ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Contract assets consisted of the following: (In thousands) Contract Assets Contract assets at January 1, 2023 \$ 8,929 Additions \$ 13,606 Transferred to receivables, net \$ (21,829) Contract assets at December 31, 2023 \$ 706 Additions \$ 6,615 Transferred to receivables, net \$ (2,331) Contract assets at December 31, 2024 \$ 4,990 Contract Liabilities Contract liabilities consist of contractual obligations related to deferred revenue. At December 31, 2024 and 2023, \$1.2 million and \$2.7 million of the contract liabilities, respectively, were classified as Contract liabilities “short-term” in the accompanying consolidated balance sheets and none and \$2.1 million of the contract liabilities, respectively, were classified as Other long-term liabilities in the accompanying consolidated balance sheets. Contract liabilities consisted of the following: (In thousands) Contract Liabilities Contract liabilities at January 1, 2023 \$ 10,701 Additions \$ (931) Amounts recognized into revenue \$ (4,995) Contract liabilities at December 31, 2023 \$ 4,775 Additions \$ 34 Amounts recognized into revenue \$ (3,560) Contract liabilities at December 31, 2024 \$ 1,249 Foreign Currency The Company’s functional and reporting currency is the U.S. dollar. Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction. The resulting monetary assets and liabilities are translated into U.S. dollars at exchange rates prevailing on the subsequent balance sheet date. Gains and losses as a result of translation adjustments are recorded within Other income (expense), net in the accompanying consolidated statements of operations and comprehensive income (loss). During the years ended December 31, 2024, 2023 and 2022, the Company recorded losses of \$0.8 million and \$0.5 million and a gain of \$0.7 million, respectively, on foreign currency translation. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk are receivables and marketable securities. Billings to large pharmaceutical companies and pharmaceutical wholesalers account for the majority of the Company’s receivables, and collateral is not required from these customers. To mitigate credit risk, the Company monitors the financial performance and credit-worthiness of its customers. The following represents revenue and receivables from the Company’s customers exceeding 10% of the total in each category as of, and for the years ended, December 31, 2024, 2023 and 2022: Year Ended December 31, 2024 2023 2022 Customer Receivables Revenue Receivables Revenue McKesson 36 % 25 % 14 % 12 % 16 % Cencora 17 % 15 % 16 % 12 % 18 % 14 % Cardinal Health 16 % 19 % 24 % 20 % 24 % 24 % Janssen 14 % 17 % 23 % 31 % * 15 % Biogen * 11 % * 11 % 19 % 13 % * * Indicates the revenues or receivables for the customer did not exceed 10% of the Company’s total in each category as of or for the years ended December 31, 2024, 2023 and 2022, as noted. F-13 ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) The Company holds its interest-bearing investments with major financial institutions and, in accordance with documented investment policies, the Company limits the amount of credit exposure to any one financial institution or corporate issuer. The Company’s investment objectives are, first, to ensure liquidity and conservation of capital and, second, to generate investment income. Geographic Information Company revenues by geographic location for the years ended December 31, 2024, 2023 and 2022, as determined by the location of the customer, are as follows: Year Ended December 31, (In thousands) 2024 2023 2022 Revenue by region: U.S. U.S. \$ 1,410,159 \$ 1,491,939 \$ 931,991 Ireland \$ 1,294 \$ 1,179 \$ 1,829 Rest of world \$ 146,179 \$ 170,287 \$ 177,975 The location of the Company’s assets are as follows: December 31, (In thousands) 2024 2023 Assets by region: U.S. Current assets: U.S. \$ 218,747 Other current assets \$ 129,332 \$ 143,417 Ireland \$ 256,891 \$ 128,448 Receivables, net \$ 78,269 \$ 113,730 Assets held for sale \$ (4) \$ 94,260 Other current assets \$ 149,827 \$ 141,861 Long-term assets: U.S. \$ 189,335 Ireland \$ 83,917 \$ 85,018 Other \$ 44,791 \$ 109,534 Research and Development Expenses For each of its R&D programs, the Company incurs both external and internal expenses. External R&D expenses include fees related to clinical and preclinical activities performed by contract research organizations, consulting fees and costs related to laboratory services, purchases of drug product materials and third-party manufacturing development costs. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. The Company tracks external R&D expenses for each of its development programs, however, internal R&D expenses are not tracked by individual program as they benefit multiple development programs or the Company’s products or technologies in general. Selling, General and Administrative Expenses Selling, general and administrative (SG&A) expenses are primarily comprised of employee-related expenses associated with selling and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising, financial and legal expenses and other general and administrative costs. F-14 ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Advertising costs are expensed as incurred. During the years ended December 31, 2024, 2023 and 2022, advertising costs totaled \$107.6 million, \$127.6 million and \$41.4 million, respectively. Share-Based Compensation The Company’s share-based compensation programs permit grants of awards in the form of stock options and restricted stock unit awards (RSUs), which vest with the passage of time and/or based on the achievement of certain performance criteria. The Company issues new shares upon the exercise of stock options or the vesting of RSUs. Under the terms of the Company’s stock option and incentive plans (the Plans), the Company’s employees may, at the discretion of the plan administrator, become eligible in certain circumstances set forth in the Plans for accelerated vesting of certain awards granted to them under the Plans. In such circumstances, if there are no effective future service requirements for such employees, the remaining fair value of any such accelerated awards would be expensed as of the date of acceleration. Time-Based Stock Options Except as otherwise provided in the applicable Plan or award certificate, stock option grants to employees expire ten years from the date of grant and generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Except as otherwise provided in the applicable Plan or Award Certificate (as defined in the 2018 Plan): (i) annual stock option grants to non-employee directors expire ten years from the date of grant and generally vest over a one-year period; and (ii) stock option grants to new non-employee directors expire ten years from the date of grant and generally vest over a three-year period. The estimated fair value of options is recognized over the requisite service period, which is generally the vesting period. Share-based compensation expense is based on awards ultimately expected to vest. Forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. The fair value of stock option grants is based on estimates as of the date of grant using a Black-Scholes option valuation model. The Company uses historical data as the basis for estimating stock option terms and forfeitures. Separate groups of employees that have similar historical stock option exercise and forfeiture behavior are considered separately for valuation purposes. The ranges of expected terms disclosed below reflect different expected behavior among certain groups of employees. Expected stock volatility factors are based on a weighted average of implied volatilities from traded options of the Company’s ordinary shares and historical share price volatility of the Company’s ordinary shares, which is determined based on a review of the weighted average of historical weekly price changes of the Company’s ordinary shares. The risk-free interest rate for periods commensurate with the expected term of the stock option is based on the U.S. treasury yield curve in effect at the time of grant. The dividend yield on the Company’s ordinary shares is estimated to be zero as the Company has not paid dividends and does not expect to pay dividends in the near future. The exercise price of options granted is equal to the closing price of the Company’s ordinary shares traded on the Nasdaq Global Select Market on the date of grant. The fair value of each stock option granted was estimated on the grant date with the following weighted-average assumptions: Year Ended December 31, 2024 2023 2022 Expected option term 5A - 7A years 5A - 8A years 5A - 8A years Expected stock volatility 38A % - 42A % 40A % - 44A % 43A % - 51A % Risk-free interest rate 3.64A % - 4.60A % 3.44A % - 4.75A % 1.83A % - 4.26A % Expected annual dividend yield \$ \$ \$ Time-Based Restricted Stock Unit Awards Except as otherwise provided in the applicable Plan or award certificate, time-based RSUs awarded to employees generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Shares subject to these RSUs are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of time-based RSUs is equal to the closing price of the Company’s ordinary shares traded on the Nasdaq Global Select Market on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period. F-15 ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Performance-Based Restricted Stock Unit Awards Performance-based RSUs awarded to employees vest upon the achievement of certain performance criteria, typically during or following the end of a specified performance period. The estimated fair value of these performance-based RSUs are generally based on the closing price of the Company’s ordinary shares traded on the Nasdaq Global Select Market on the date of grant, unless the performance-based RSU is also subject to a market condition. In that case, the fair value of the performance-based RSU is based on a Monte Carlo simulation model. Compensation expense for performance-based RSUs is recognized from the date the Company determines the performance criteria probable of being achieved to the date the award, or relevant portion of the award, is expected to vest. Cumulative adjustments are recorded on a quarterly basis to reflect subsequent changes to the estimated outcome of the performance criteria until the date that the final outcome of the performance criteria is determined. Income Taxes The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In evaluating the Company’s ability to recover its deferred tax assets, the Company considers all available positive and negative evidence including its past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which the Company operates and its

proceeds of future taxable income. In determining taxable income, the Company is responsible for assumptions utilized including the amount of Irish and non-Irish pre-tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company is using to manage the underlying business. The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates its tax position on a quarterly basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense. Comprehensive Income (Loss) Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized holding gains and losses on available-for-sale investments. Earnings (Loss) Per Share Basic earnings (loss) per ordinary share from continuing operations is calculated based upon net income (loss) from continuing operations available to holders of ordinary shares divided by the weighted average number of ordinary shares outstanding. Basic loss per ordinary share from discontinued operations is calculated based upon net loss from discontinued operations available to holders of ordinary shares, divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted earnings (loss) per ordinary share from continuing operations and discontinued operations, the Company utilizes the treasury stock method and adjusts the weighted average number of ordinary shares outstanding for the potential dilutive effect of outstanding ordinary share equivalents such as stock options and RSUs. Segment Information In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosure (Topic 280) to establish standards for reporting information about operating segments. Operating segments are defined as components of an enterprise engaging in business activities for which separate financial information is available and regularly reviewed by the chief operating decision maker (CODM) in deciding how to allocate resources and in assessing performance. The Company has utilized the management approach to determine that the Company is managed as one segment on a consolidated basis and is the business of developing, manufacturing and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. The Company's CODM, the Chairman and Chief Executive Officer, reviews the Company's operating results on an aggregate basis and manages the Company's operations as a single operating unit. The CODM measures profitability on a reportable segment basis using net income (loss) and utilizes this information in allocating resources and in assessing performance by monitoring budget versus actual results. Please refer to Note 18, Segment Reporting, in these Notes to Consolidated Financial Statements in this Annual Report for further information. F-16 ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Employee Benefit Plans 401(k) Plan The Company maintains a 401(k) retirement savings plan (the 401(k) Plan), which covers all of its eligible U.S.-based employees. Eligible employees may contribute up to 100% of their eligible compensation, subject to certain Internal Revenue Service (IRS) limitations. The Company matches 100% of employee contributions up to the first 5% of employee pay, up to IRS limits. Employee and Company contributions are fully vested when made. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$15.1 million, \$15.0 million and \$14.4 million, respectively, to match employee deferrals under the 401(k) Plan. Defined Contribution Plan The Company maintains a defined contribution plan for its Ireland-based employees (the Defined Contribution Plan). The Defined Contribution Plan provides for eligible employees to contribute up to a maximum of 40%, depending upon their age, of their total taxable earnings subject to an earnings cap of \$115,000. The Company provides a match of up to 18% of taxable earnings depending upon an individual's contribution level. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$3.4 million, \$5.6 million and \$5.1 million, respectively, in contributions to the Defined Contribution Plan. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures in order to provide information to assist key stakeholders in better assessing how the Company's operations and related tax risks and tax planning and operational opportunities affect the Company's tax rate and prospects for future cash flows. This ASU becomes effective for public companies for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This guidance will be applied on a prospective basis. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income-Expense Disaggregation Disclosures, to improve disclosures about a public business entity's expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly-presented expense captions, such as cost of sales, selling, general and administrative expenses, and research and development. All disclosure requirements under this guidance are required for public business entities and effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted and the amendments in this guidance will be applied prospectively to financial statements for periods after the effective dates. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures. 3. DISCONTINUED OPERATIONS Mural Oncology Separation In November 2023, the Company completed the Separation. In connection with the Separation, the Company entered into a separation agreement with Mural, dated as of November 13, 2023, that, among other things, set forth the Company's agreements with Mural regarding the principal actions taken or to be taken in connection with the Separation, including the Distribution. The separation agreement identified those assets to be transferred to, liabilities to be assumed by and contracts to be assigned to Mural, including the operating lease for the office and laboratory space at 852 Winter Street in Waltham, Massachusetts, as part of the Separation, and it provided for when and how such transfers, assumptions and assignments were to occur. The purpose of the separation agreement was to provide Mural and the Company with those assets necessary to operate their respective businesses and to retain or assume the respective liabilities related to those assets. Each of Mural and the Company agreed to releases with respect to pre-Distribution claims, and cross-indemnities with respect to post-Distribution claims, that are principally designed to place financial responsibility for the obligations and liabilities allocated to Mural under the separation agreement with Mural, and financial responsibility for the obligations and liabilities allocated to the Company under the separation agreement with the Company. The Company and Mural are also each subject to mutual six-month employee non-solicitation and non-hire restrictions, subject to certain customary exceptions, and certain confidentiality restrictions and information sharing obligations. F-17 ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) The transfer of assets and liabilities to Mural was effected through a contribution in accordance with the separation agreement, as summarized below: (In thousands) ASSETS AS OF November 15, 2023 ASSETS AS OF Current Assets: Cash and cash equivalents \$ 275,000 Total current assets \$ 275,000 Property, plant and equipment, net \$ 10,096 Right-of-use assets \$ 14,513 Goodwill \$ 7,800 Deferred tax asset \$ 1,799 Total assets \$ 309,208 LIABILITIES AS OF Current Liabilities: Operating lease liabilities-short-term \$ 6,036 Total current liabilities \$ 6,036 Operating lease liabilities-long-term \$ 9,412 Total liabilities \$ 15,448 Net assets transferred to Mural \$ 293,760 The Company determined that the Separation and related Distribution qualified as tax-free for U.S. federal income tax purposes, which required significant judgment by management. In making such determinations, the Company applied U.S. federal tax law to relevant facts and circumstances and obtained: (i) a favorable private letter ruling from the IRS; (ii) a tax opinion; and (iii) other external tax advice related to the concluded tax treatment. If the Separation and Distribution were to ultimately fail to qualify for tax-free treatment for U.S. federal income tax purposes, the Company and/or its shareholders could be subject to significant liabilities, which could have material adverse impacts on the Company's business, financial condition, results of operations and cash flows in future reporting periods. Furthermore, other than taxes recorded on the transfer of intellectual property, the Company determined that the Separation and related Distribution qualified as tax-free for Irish tax purposes which required significant judgment by management. In making such determinations, the Company applied Irish tax law to relevant facts and circumstances and obtained: (i) a tax opinion; and (ii) other external tax advice related to the concluded tax treatment. If the Separation and Distribution were to ultimately fail to qualify for tax-free treatment for Irish tax purposes, the Company and/or its shareholders could be subject to significant liabilities, which could have material adverse impacts on the Company's business, financial condition, results of operations and cash flows in future reporting periods. In connection with the Separation, the Company also entered into a tax matters agreement with Mural, dated as of November 13, 2023. The tax matters agreement governs the Company's and Mural's respective rights, responsibilities and obligations with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the Distribution, together with certain related transactions, to qualify as tax-free for U.S. federal income tax purposes), tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and assistance and cooperation in respect of tax matters. In connection with the Separation, the Company also entered into the Employee Matters Agreement. The Employee Matters Agreement, as amended, governs the Company's, Mural's and their respective subsidiaries' and affiliates' rights, responsibilities and obligations after the Separation with respect to, employment, benefits and compensation matters relating to employees and former employees (and their respective dependents and beneficiaries) who are or were associated with the Company, including those who became employees of Mural in connection with the Separation; the allocation of assets and liabilities generally relating to employees, employment or service-related matters and employee benefit plans; other human resources, employment and employee benefits matters; and the treatment of equity-based awards granted by the Company prior to the Separation. Discontinued Operations The results of the former oncology business and transaction costs related to the Separation have been reflected as loss from discontinued operations, net of taxes in the accompanying consolidated statement of operations and comprehensive income (loss) through the Separation Date. Prior periods have been recast to reflect this presentation. The transaction costs related to the Separation were \$36.0 million during 2023 and \$1.4 million during 2022, and primarily relate to professional fees for separation activities within the finance, tax, legal and information technology functions. F-18 ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) The following table summarizes expenses of the discontinued operations for the years ended December 31, 2024, 2023 and 2022: AS OF Year Ended December 31, (In thousands) 2024 2023 2022 Operating expenses from discontinued operations \$ 40,587 \$ 14,996 \$ 5,790 Research and development \$ 164,803 \$ 136,177 \$ 164,803 Selling, general and administrative \$ 5,790 \$ 164,803 \$ 136,177 Operating loss from discontinued operations \$ (722) \$ (1,403) \$ (11,061) Net loss and comprehensive loss from discontinued operations \$ (5,068) \$ (163,400) \$ (125,115) There were no assets and \$4.5 million of liabilities related to the Separation as of December 31, 2023. All assets were transferred to Mural as of the Separation Date. The \$4.5 million of liabilities classified as liabilities related to discontinued operations in the accompanying consolidated balance sheet as of December 31, 2023 related to bonus amounts accrued for employees that transferred to Mural during 2023 through the Separation Date that were paid by the Company in the first quarter of 2024, in accordance with the terms of the employee matters agreement entered into between the Company and Mural. The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2023 and 2022: AS OF Year Ended December 31, (In thousands) 2023 2022 OPERATING ACTIVITIES: Depreciation \$ 2,319 \$ 1,539 Share-based compensation expense \$ 8,188 \$ 6,577 Right-of-use assets \$ 3,803 \$ 5,909 Operating lease liabilities \$ (3,938) \$ (5,920) INVESTING ACTIVITIES: Additions of property, plant and equipment \$ (1,798) \$ (5,510) REVENUE FROM CONTRACTS WITH CUSTOMERS During the years ended December 31, 2024, 2023 and 2022, the Company recorded product sales, net, as follows: AS OF Year Ended December 31, (In thousands) 2024 2023 2022 VIVITROL \$ 457,315 \$ 400,419 \$ 379,478 ARISTADA and ARISTADA INITIO \$ 346,187 \$ 327,690 \$ 302,052 LYBALVI \$ 280,032 \$ 191,889 \$ 96,022 Total product sales, net \$ 1,083,534 \$ 919,998 \$ 777,552 F-19 ALKERMES PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) During the years ended December 31, 2024, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows: AS OF Year Ended December 31, (In thousands) 2024 2023 2022 Manufacturing Revenue \$ 23,172 \$ 23,444 \$ 56,962 INVEGA products \$ 236,386 \$ 236,386 \$ 39,292 VUMERITY \$ 94,755 \$ 134,047 \$ 134,047 RISPERDAL CONSTA \$ 23,172 \$ 23,444 \$ 56,962 Other \$ 23,256 \$ 80,218 \$ 119,426 Total \$ 354,669 \$ 474,095 \$ 474,095 AS OF Year Ended December 31, 2023 (In thousands) Manufacturing Revenue \$ 23,172 \$ 23,444 \$ 56,962 INVEGA products \$ 236,386 \$ 236,386 \$ 39,292 VUMERITY \$ 94,755 \$ 134,047 \$ 134,047 RISPERDAL CONSTA \$ 23,172 \$ 23,444 \$ 56,962 Other \$ 23,256 \$ 80,218 \$ 119,426 Total \$ 354,669 \$ 474,095 \$ 474,095 AS OF Year Ended December 31, 2022 (In thousands) Manufacturing Revenue \$ 23,172 \$ 23,444 \$ 56,962 INVEGA products \$ 236,386 \$ 236,386 \$ 39,292 VUMERITY \$ 94,755 \$ 134,047 \$ 134,047 RISPERDAL CONSTA \$ 23,172 \$ 23,444 \$ 56,962 Other \$ 23,256 \$ 80,218 \$ 119,426 Total \$ 354,669 \$ 474,095 \$ 474,095 AS OF Year Ended December 31, 2021 (In thousands) Manufacturing Revenue \$ 23,17

[illegible]

À Á 3,507 À Á æ” À Shares used in calculating diluted earnings (loss) per ordinary share À Á 169,198 À Á 169,730 À Á 163,742 À Á (1)Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.The following potential ordinary share equivalents were not included in the net income (loss) per share calculation because the effect would have been anti-dilutive:À Á Year Ended December 31, À (In thousands) 2024 À Á 2023 À Á 2022 À Á 1 Stock options 11,517 À Á 12,422 À Á 12,777 À Restricted stock unit awards 2,391 À Á 2,378 À Á 5,040 À Total 13,908 À Á 14,800 À Á 17,817 À Á (1)Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.À Á 14. SHAREHOLDERS&” EQUITYShare Repurchase ProgramIn February 2024, the Company&”s board of directors approved a share repurchase program authorizing the Company to repurchase ordinary shares of the Company in an aggregate amount of up to \$400.0 million (exclusive of any fees, commissions or other expenses related to such repurchases) from time to time on the open market (the “Repurchase Program”). The specific timing and amounts of repurchases under the Repurchase Program will depend on a variety of factors, including but not limited to ongoing assessments of the Company&”s needs, alternative investment opportunities, the market price of the Company&”s ordinary shares and general market conditions. The Repurchase Program has no set expiration date and may be suspended or discontinued at any time. During the year ended December 31, 2024, the Company repurchased approximately 7.9 million of its ordinary shares under the Repurchase Program at an average price of \$25.33 per share, resulting in a total cost, exclusive of any fees, commissions or other expenses related to such repurchase of \$200.0 million. All ordinary shares repurchased were returned to treasury. As of December 31, 2024, the remaining amount authorized under the Repurchase Program was \$200.0 million.À Á F-26 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) 15. SHARE-BASED COMPENSATIONShare-Based Compensation ExpenseThe following table presents share-based compensation expense from continuing and discontinued operations included in the Company&”s consolidated statements of operations and comprehensive income (loss):À Á À Year Ended December 31, À (In thousands) À 2024 À Á 2023 À Á 2022 À Cost of goods manufactured and sold À \$ 5,798 À Á \$ 11,353 À Á \$ 10,284 À Research and development À 28,085 À Á 25,753 À Á 23,289 À Selling, general and administrative À 62,754 À Á 55,611 À Á 54,104 À Share-based compensation expense from continuing operations À 96,637 À Á 92,717 À Á 87,677 À Cost of goods manufactured and sold À æ” À Á æ” À Á æ” À Research and development À æ” À Á 3,255 À Á 4,652 À Selling, general and administrative À æ” À Á 4,933 À Á 1,925 À Share-based compensation expense from discontinued operations À æ” À Á 8,188 À Á 6,577 À Total share-based compensation expense À 96,637 À Á \$ 100,905 À Á \$ 94,254 À Á During the years ended December 31, 2024, 2023 and 2022, \$3.1 million, \$3.2 million and \$3.3 million, respectively, of share-based compensation expense was capitalized and recorded as æInventory&” in the accompanying consolidated balance sheets.Share-Based Compensation PlanThe Company has one share-based compensation plan pursuant to which awards are currently being made: the 2018 Stock Option and Incentive Plan, as amended (the “2018 Plan”). The Company has two share-based compensation plans pursuant to which outstanding awards have been made, but from which no further awards can or will be made: the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended, (the “2008 Plan”) and the Alkermes plc 2011 Stock Option and Incentive Plan, as amended (the “2011 Plan,” and together with the 2018 Plan and the 2008 Plan, the “Alkermes Stock Option and Incentive Plans”). Effective May 20, 2020, the 2018 Plan was amended such that any shares underlying any outstanding awards granted under the 2011 Plan or the 2008 Plan that are forfeited, canceled, repurchased or otherwise terminated (other than by exercise) from and after such date will become available for issuance pursuant to the 2018 Plan, notwithstanding anything to the contrary in the terms of the 2011 Plan or the 2008 Plan.The 2018 Plan allows for the issuance of non-qualified and incentive stock options, restricted stock, restricted stock unit awards, cash-based awards and performance shares to employees, officers and directors of, and consultants to, the Company in such amounts and with such terms and conditions as may be determined by the compensation committee of the Company&”s board of directors, subject to the provisions of the 2018 Plan, as applicable.On May 31, 2024, the Company&”s shareholders approved an amended version of the then-current version of the 2018 Plan that served to, among other things, increase the number of ordinary shares authorized for issuance thereunder by 6.3 million. At December 31, 2024, there were 17.9 million ordinary shares available for issuance in the aggregate under the 2018 Plan. The 2018 Plan provides that awards other than stock options will be counted against the total number of shares available under the plan in a 1.8-to-1 ratio.Stock OptionsA summary of stock option activity is presented in the following table:À Á À Number of À Weighted Average À À Shares À À Exercise Price À Outstanding, January 1, 2024 À 18,139,903 À Á \$ 32.28 À Granted À 2,615,357 À Á \$ 29.48 À Exercised À (1,328,189) À Á \$ 20.76 À Expired À (1,427,409) À Á \$ 46.72 À Forfeited À (521,043) À Á \$ 26.65 À Outstanding, December 31, 2024 À 17,478,619 À Á \$ 31.73 À Exercisable, December 31, 2024 À 10,979,663 À Á \$ 34.53 À À F-27 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) À The weighted average grant date fair value of stock options granted during the years ended December 31, 2024, 2023 and 2022 was \$14.08, \$13.74 and \$12.62, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2024, 2023 and 2022 was \$10.9 million, \$6.0 million and \$11.6 million, respectively. At December 31, 2024, there were 6.3 million stock options expected to vest, with a weighted average exercise price of \$26.91 per share, a weighted average contractual remaining life of 7.9 years and an aggregate intrinsic value of \$15.4 million. At December 31, 2024, the aggregate intrinsic value of stock options exercisable was \$38.5 million with a weighted average remaining contractual term of 4.4 years. The number of stock options expected to vest was determined by applying the pre-vesting forfeiture rate to the total number of outstanding options. The intrinsic value of a stock option is the amount by which the market value of the underlying shares exceeds the exercise price of the stock option.At December 31, 2024, there was \$32.3 million of unrecognized share-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 1.9 years.Time-Based Restricted Stock Unit AwardsA summary of time-based RSU activity is presented in the following table:À Á À À Weighted Average À À À Number ofShares À À Grant DateFair Value À Unvested, January 1, 2024 À 5,657,578 À Á \$ 24.18 À Granted À 2,260,345 À Á \$ 29.51 À Forfeited À (775,415) À Á \$ 26.43 À Vested À (2,237,302) À Á \$ 23.05 À Unvested, December 31, 2024 À 4,905,206 À Á \$ 26.80 À The weighted average grant date fair values of time-vesting RSUs granted during the years ended December 31, 2024, 2023 and 2022 were \$29.51, \$27.65 and \$25.27, respectively. The total fair value of time-vesting RSUs that vested during the years ended December 31, 2024, 2023 and 2022, was \$51.6 million, \$63.0 million and \$54.3 million, respectively. At December 31, 2024, there was \$53.4 million of total unrecognized share-based compensation expense related to unvested time-vesting RSUs, which will be recognized over a weighted average remaining contractual term of 1.9 years.Performance-Based Restricted Stock Unit AwardsIn February 2024, 2023 and 2022, the compensation committee of the Company&”s board of directors approved the Company&”s long-term incentive plans, pursuant to which awards of performance-based RSUs are granted to employees of the Company at the Senior Vice President level and above, in each case subject to vesting based on the achievement of certain financial, commercial and/or R&D performance criteria to be assessed over a performance period of three years from the date of the grant, and subject, at the end of such three-year performance period, to upward or downward adjustment based on a market condition tied to relative share price performance over the three-year performance period. A summary of performance-based RSU activity is presented in the following table:À Á À À Weighted Average À À À Number ofShares À À Grant DateFair Value À Unvested, January 1, 2024 À 1,546,357 À Á \$ 27.95 À Granted À 498,120 À Á \$ 32.46 À Forfeited À (172,576) À Á \$ 25.88 À Vested À (536,243) À Á \$ 22.21 À Unvested, December 31, 2024 À 1,335,658 À Á \$ 32.13 À The weighted average grant date fair values of performance-based RSUs granted during the years ended December 31, 2024, 2023 and 2022 were \$32.46, \$29.91 and \$30.73, respectively. The total fair value of performance-based RSUs that vested during the years ended December 31, 2024, 2023 and 2022 were \$10.1 million, \$5.9 million and none, respectively. At December 31, 2024, there F-28 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) was \$3.0 million of unrecognized share-based compensation expense related to unvested performance-based RSUs which would be recognized in accordance with the terms of the awards when the Company deems it probable that the performance criteria will be met. During the year ended December 31, 2024, the Company recognized share-based compensation expense related to certain performance-based RSUs that were granted during 2021. As of December 31, 2023, the financial performance criteria for these awards were deemed not probable of being achieved; however, in February 2024, the compensation committee of the Company&”s board of directors determined that the Company partially achieved the financial performance criteria. This was considered a modification in accordance with FASB ASC 718, Compensation&”Stock Compensation and resulted in a modification charge of approximately \$6.8 million. In February 2024, the compensation committee of the Company&”s board of directors also determined that the Company achieved the pipeline performance criteria for these awards, resulting in a \$2.6 million incremental share-based compensation expense, as it was deemed such pipeline performance criteria had been met. The share-based compensation expense related to these achievements was recognized in 2024.À Á 16. COLLABORATIVE ARRANGEMENTSThe Company has entered into several collaborative arrangements to develop and commercialize products and, in connection with such arrangements, to access technologies, financial, marketing, manufacturing and other resources. Refer to the “Patents and Proprietary Rights&” section in “Item 1&” Business&” of this Annual Report for information with respect to IP protection for these products. The collaboration revenue the Company has earned in the years ended December 31, 2024, 2023 and 2022 is summarized in Note 4, Revenue from Contracts with Customers within the notes to the consolidated financial statements in this Annual Report. The Company&”s significant collaborative arrangements are described below:JanssenINVEGA SUSTENNA/KEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLIUnder an exclusive license agreement with Janssen, the Company provided Janssen with rights to, and know-how, training and technical assistance in respect of, the Company&”s small particle pharmaceutical compound technology, known as NanoCrystal technology, which was used to develop the long-acting INVEGA products, and the Company received milestone payments from Janssen upon the achievement of certain development goals from Janssen; there are no further milestones to be earned under this agreement. The agreement also provides for tiered royalty payments, which consist of a patent royalty and a know-how royalty, both of which are determined on a country-by-country basis. The patent royalty, which equals 1.5% of net sales, is payable in each country until the expiration of the last of the patents with valid claims applicable to the product in such country. The know-how royalty is a tiered royalty of 3.5%, 5.5% and 7.5% on aggregate worldwide net sales of below \$250 million, between \$250 million and \$500 million, and greater than \$500 million, respectively. The know-how royalty rate resets to 3.5% at the beginning of each calendar year and is payable until 15 years from first commercial sale of a product in each individual country, subject to expiry of the agreement. These royalty payments may be reduced in any country based on patent litigation or on competing products achieving certain minimum sales thresholds. The license agreement, unless earlier terminated, terminates upon the expiration of the last of the patents subject to the agreement. After expiration, Janssen retains a non-exclusive, royalty-free license to develop, manufacture and commercialize the products, subject to certain surviving obligations. Janssen may terminate the license agreement in whole or in part upon three months&” notice to the Company. The Company and Janssen have the right to terminate the agreement upon a material breach of the other party, which is not cured within a certain time period, or upon the other party&”s bankruptcy or insolvency.In November 2021, the Company received notice from Janssen of partial termination of the license agreement, following which Janssen ceased paying the Company royalties related to U.S. sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA. In April 2022, the Company commenced binding arbitration proceedings related to, among other things, Janssen&”s partial termination of this license agreement and Janssen&”s royalty and other obligations under the agreement. In May 2023, the Tribunal in the arbitration proceedings issued a Final Award that served to reinstate the Janssen royalties and required payment by Janssen of back royalties and interest for amounts owed but not yet paid since the effective date of the partial termination. The Final Award also provided, among other things, that the Company was entitled to royalty revenues from Janssen related to net sales of INVEGA SUSTENNA through August 20, 2024, INVEGA TRINZA through the second quarter of 2030 (but no later than May 2030 when the license agreement expires) and INVEGA HAFYERA through May 2030 (when the license agreement expires).RISPERDAL CONSTAUnder a product development agreement, the Company collaborated with Janssen on the development of RISPERDAL CONSTA. Under the development agreement, Janssen provided funding to the Company for the development of RISPERDAL CONSTA and Janssen is responsible for securing all necessary regulatory approvals for the product. F-29 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Under two license agreements, the Company granted Janssen and an affiliate of Janssen exclusive worldwide licenses to use and sell RISPERDAL CONSTA. Under its license agreements with Janssen, the Company receives royalty payments equal to 2.5% of Janssen&”s end-market net sales of RISPERDAL CONSTA in each country where the license is in effect based on the quarter when the product is sold by Janssen. This royalty may be reduced in any country based on lack of patent coverage and significant competition from generic versions of the product. Janssen can terminate the license agreements upon 30 days&” prior written notice to the Company. Either party may terminate the license agreements by written notice following a breach which continues for 90 days after the delivery of written notice thereof or upon the other party&”s insolvency. The licenses granted to Janssen expire on a country-by-country basis upon the later of: (i) the expiration of the last patent claiming the product in such country; or (ii) 15 years after the date of the first commercial sale of the product in such country, provided that in no event will the license granted to Janssen expire later than the twentieth anniversary of the first commercial sale of the product in each such country, with the exception of Canada, France, Germany, Italy, Japan, Spain and the United Kingdom, in each case where the fifteen-year minimum shall pertain regardless. After expiration, Janssen retains a non-exclusive, royalty-free license to manufacture, use and sell RISPERDAL CONSTA. The Company exclusively manufactures RISPERDAL CONSTA at its Wilmington, Ohio facility for commercial sale. Under its manufacturing and supply agreement with Janssen, the Company records manufacturing revenues when product is fully manufactured and approved for shipment by both Janssen and the Company. Revenue is based on a percentage of Janssen&”s net unit sales price for RISPERDAL CONSTA for the applicable calendar year. This percentage is determined based on Janssen&”s unit demand for such calendar year and varies based on the volume of units shipped, with a minimum manufacturing fee of 7.5%. Either party may terminate the manufacturing and supply agreement upon a material breach by the other party, which is not resolved within 60 days after receipt of a written notice specifying the material breach or upon written notice in the event of the other party&”s insolvency or bankruptcy. Janssen may terminate the agreement upon six months&” written notice to the Company. In the event that Janssen terminates the manufacturing and supply agreement without terminating the license agreements, the royalty rate payable to the Company on Janssen&”s net sales of RISPERDAL CONSTA would increase from 2.5% to 5.0%.BiogenUnder a license and collaboration agreement with Biogen, the Company granted Biogen a worldwide, exclusive, sublicenseable license to develop, manufacture and commercialize VUMERITY and other products covered by patents licensed to Biogen under the agreement. Under this license and collaboration agreement, the Company received an upfront cash payment and milestone payments related to the achievement of certain milestones. The Company is also eligible to receive additional payments upon achievement of certain milestones, including milestones relating to the first two products, other than VUMERITY, covered by patents licensed to Biogen under the license and collaboration agreement.In addition, the Company receives a 15% royalty on worldwide net sales of VUMERITY, subject to increases for VUMERITY manufactured and/or packaged by Biogen or its designees. The Company is also entitled to receive royalties on net sales of products other than VUMERITY covered by patents licensed to Biogen under the license and collaboration agreement, at tiered royalty rates calculated as percentages of net sales ranging from high-single digits to sub-teen double digits. All royalties are payable on a product-by-product and country-by-country basis until the later of (i) the last-to-expire patent right covering the applicable product in the applicable country and (ii) a specified period of time from the first commercial sale of the applicable product in the applicable country. Royalties for all products are subject to customary reductions, as set forth in the license and collaboration agreement.Following FDA approval of VUMERITY and, except for the manufacturing responsibilities discussed below, Biogen is now responsible for all development and commercialization activities for VUMERITY and all other products covered by the patents that we licensed to Biogen.Under the license and collaboration agreement, Biogen appointed the Company as the toll manufacturer of clinical and commercial supplies of VUMERITY, subject to Biogen&”s right to manufacture or have manufactured commercial supplies as a back-up manufacturer. In October 2019, the Company entered into a commercial supply agreement with Biogen for the commercial supply of VUMERITY, an amendment to such commercial supply agreement and an amendment to the license and collaboration agreement with Biogen, pursuant to which Biogen has conducted a technology transfer and, following an agreed transition period, has elected to assume responsibility for the manufacture (itself or through a designee) of clinical and commercial supplies of VUMERITY in exchange for an increase in the royalty rate to be paid by Biogen to the Company on net sales of product that is manufactured by Biogen or its designee. In May 2024, the Company completed the sale of the Athlone Facility where VUMERITY is manufactured. In connection with the sale of the Athlone Facility, the Company has entered into a subcontracting arrangement with the purchaser of the Athlone Facility for the manufacture of VUMERITY through the manufacturing transition period, which may continue through the end of 2025. F-30 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Unless earlier terminated, the license and collaboration agreement will remain in effect until the expiry of all royalty obligations. Biogen has the right to terminate the license and collaboration agreement at will, on a product-by-product basis or in its entirety upon 180

yas&™ prior notice to the Company. Either party has the right to terminate the license and collaboration agreement following any governmental prohibition of the transactions effected by the agreement, or in connection with an insolvency event involving the other party. Upon termination of the license and collaboration agreement by either party, then, at the Company's request, the VUMERITY program will revert to the Company.

17. INCOME TAXESThe Company's provision (benefit) for income taxes from continuing operations consists of the following:

Year Ended December 31, (In thousands)

	2024	2023	2022
(1) Current income tax provision (benefit):	\$ 25,640	\$ (981)	\$ 11,169
U.S. state & local taxes	\$ 4,259	\$ 722	\$ 4,401
Ireland & foreign taxes	\$ 1,192	\$ 4	\$ 4
Deferred income tax provision (benefit):	\$ 191,658	\$ 191,658	\$ 191,658
Total tax provision (benefit):	\$ 71,612	\$ (97,638)	\$ 2,024

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation. The income tax provision in 2024 was primarily due to taxes on income earned in Ireland. The income tax benefit in 2023 was primarily due to the partial release of the valuation allowance maintained against certain Irish deferred tax assets, partially offset by taxes on income earned in the U.S. and Ireland. The income tax expense in 2022 was primarily due to taxes on income earned in the U.S. In December 2022, the EU implemented a new corporate minimum tax rate of 15% on companies with consolidated annual revenue of at least €750.0 million, which was transposed into Irish law effective as of January 1, 2024. The Company has determined that this new minimum tax had no material impact for the year ended December 31, 2024. The income tax benefit associated with the Company's former oncology business, and the tax impact of the Separation, are discussed in further detail in Note 3, Discontinued Operations, in these Notes to Consolidated Financial Statements in this Annual Report. The tax benefits included within discontinued operations were \$0.7 million, \$1.4 million, and \$11.1 million for the years ended December 31, 2024, 2023, and 2022, respectively. No provision for income tax has been provided on undistributed earnings of the Company's foreign subsidiaries because such earnings are indefinitely reinvested in the foreign operations. Cumulative unremitted earnings of U.S. subsidiaries totaled approximately \$933.5 million at December 31, 2024. In the event of a repatriation of those earnings in the form of dividends or otherwise, the Company may be liable for income taxes, subject to adjustment, if any, for foreign tax credits and foreign withholding taxes payable to foreign tax authorities. The Company estimates that approximately \$72.0 million of income taxes would be payable on the repatriation of the unremitted earnings to Ireland. The distribution of the Company's income (loss) before the provision (benefit) for income taxes by geographical area consists of the following:

	Year Ended December 31,	(In thousands)	2024	2023	2022
Ireland	\$ 440,674	\$ 411,767	\$ (32,198)	\$ 3,076	\$ 9,752
Income (loss) from continuing operations before provision (benefit) for income taxes	\$ 443,750	\$ 421,519	\$ (31,128)	\$ 1	\$ 1

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

F-31 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) The components of the Company's net deferred tax assets consist of the following:

	December 31,	(In thousands)	2024	2023
Deferred tax assets:	\$ 80,209	\$ 195,658		
Research and development expenses	\$ 71,167	\$ 49,206		
Accrued expenses and reserves	\$ 41,189	\$ 37,367		
Operating lease liabilities	\$ 17,537	\$ 18,716		
Share-based compensation	\$ 33,773	\$ 33,727		
Tax credits	\$ 26,882	\$ 27,116		
Other	\$ 3,695	\$ 5,582		
Less: valuation allowance	\$ (79,727)	\$ (129,296)		
Total deferred tax assets	\$ 194,725	\$ 242,076		

Deferred tax liabilities:

	December 31,	(In thousands)	2024	2023
Property, plant and equipment	\$ (21,917)	\$ (26,271)		
Right-of-use assets	\$ (16,337)	\$ (17,748)		
Other	\$ (1,940)	\$ (2,716)		
Total deferred tax liabilities	\$ (40,194)	\$ (46,735)		
Net deferred tax assets	\$ 154,531	\$ 195,341		

The activity in the valuation allowance associated with deferred taxes consists of the following:

	Balance at Beginning of Period (1)	Additions / Reductions (2)	Balance at End of Period (1)
Deferred tax asset valuation allowance for the year ended December 31, 2022	\$ (249,112)	\$ (22,405)	\$ (271,517)
Deferred tax asset valuation allowance for the year ended December 31, 2023	\$ (271,517)	\$ (49,569)	\$ (321,086)
Deferred tax asset valuation allowance for the year ended December 31, 2024	\$ (321,086)	\$ (79,727)	\$ (400,813)

Inclusive of continuing and discontinued operations for the periods prior to the Separation in November 2023. (2)(Additions) reductions represent continuing and discontinued operations for the periods prior to the Separation in November 2023. The reductions during the year ended December 31, 2024 primarily relate to the abandonment of certain Irish NOLs following the sale of the Athlone Facility to Novo. These NOLs were transferred from Elan Corporation, plc as part of the combination of the drug technology business of Elan Corporation, plc with the business of Alkermes, Inc. A number of restrictions applied to these NOLs thereby restricting the Company's ability to utilize such NOLs. Following the sale of the Athlone Facility, the Company believes that its ability to utilize these NOLs is remote. The reduction during the year ended December 31, 2023 primarily relates to the partial release of the valuation allowance maintained by the Company against certain Irish net deferred tax assets. The additions in 2022 relate primarily to Irish NOLs. The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making such assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. At December 31, 2024, the Company maintained a valuation allowance of \$29.6 million against certain U.S. state deferred tax assets and \$50.1 million against certain Irish deferred tax assets, as the Company has determined that it is more-likely-than-not that these deferred tax assets will not be realized and some may be abandoned. If the Company incurs losses in the U.S. or in Ireland in the future, or fails to achieve sufficient profitability in a timely manner, the evaluation of the recoverability of the deferred tax assets could change and a valuation allowance against such deferred tax assets may be required in part or in whole. The Company will continue to monitor the need for a valuation allowance against its deferred tax assets on a quarterly basis. As of December 31, 2024, the Company had \$393.9 million of Irish NOL carryforwards, \$14.1 million of U.S. federal NOL carryforwards, \$43.2 million of state NOL carryforwards and \$34.0 million of state tax credits which will either expire on various dates through 2039 or can be carried forward indefinitely. These loss and credit carryforwards are available to reduce certain future Irish and foreign taxable income and tax. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities and may be subject to limitations based upon changes in the ownership of the Company's ordinary shares. Included within these loss and credit carryforwards are \$14.1 million of U.S. federal NOL carryforwards and \$5.8 million of state NOL carryforwards, acquired as part of the acquisition of Rodin Therapeutics, Inc. in November 2019, each of which are subject to a \$0.5 million annual limitation. F-32 ALKERMES PLC AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) A reconciliation of the Company's statutory tax rate to its effective tax rate is as follows:

	Year Ended December 31,	(In thousands, except percentage amounts)	2024	2023	2022
Statutory tax rate	12.5%	12.5%	12.5%	12.5%	12.5%
Income (loss) from continuing operations before income taxes at statutory rate	\$ 55,469	\$ 52,690	\$ (3,891)	\$ 5,607	\$ 4,177
Share-based compensation	4,347	4,347	4,347	4,347	4,347
Differential(2)	4,844	4,701	521	1,102	1,102
Intercompany amounts(3)	708	708	708	708	708
Irish rate differential(4)	5,798	5,798	5,798	5,798	5,798
Uncertain tax positions	667	667	667	667	667
Non-deductible lobbying expenses	767	705	775	347	1,272
Foreign derived intangible income	281	4,530	R&D credit	7,815	4,283
Abandonment of NOLs(5)	49,897	4,530	4,530	4,530	4,530
Other permanent items(6)	4,000	1,539	1,125	71,612	97,638
Effective tax rate	16.1%	23.2%	6.5%	16.1%	23.2%

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation. (2)Represents income or losses of U.S. subsidiaries, subject to tax at a rate other than the Irish statutory rate. (3)Intercompany amounts include cross-territory eliminations, the pre-tax effect of which has been eliminated in arriving at the Company's consolidated income (loss) before taxes from continuing operations. In 2023, this included a tax benefit of \$15.7 million related to the intercompany transfer of inventory that was owned by the Company at December 31, 2023. (4)Represents income or losses of Irish companies subject to tax at a rate other than the Irish statutory rate. (5)Represents the tax effect of the abandonment of Irish NOLs following the sale of the Athlone Facility to Novo. (6)Other permanent items include, but are not limited to, non-deductible meals and entertainment expenses and non-deductible compensation of senior officers of the Company. For the year ended December 31, 2024, permanent items also included amounts relating to the sale of the Athlone Facility. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

	Unrecognized Tax Benefits	Balance, December 31,	2021	2022	2023	2024
Reductions based on the lapse of applicable statutes of limitations	\$ 438	\$ 438	\$ 438	\$ 438	\$ 438	\$ 438
Additions based on tax positions related to prior periods	\$ 449	\$ 449	\$			

ex4 1.htm EX-4.1 EX-4.1 Exhibit 4.1 Â DESCRIPTION OF ALKERMES PLC ORDINARY SHARES The following is a summary description of the ordinary shares of Alkermes plc. This summary does not purport to be complete and is qualified in its entirety by reference to the Irish Companies Act 2014 (the "Companies Act") and the complete text of our memorandum and articles of association, as they may be amended from time to time (together, our "Constitution"). A copy of our Constitution is incorporated by reference as Exhibit 3.1 to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part. You should read the Companies Act and our Constitution carefully. Use of terms such as "euros," "euros," "euros," "euros" or the "Company" in this Exhibit 4.1 is meant to refer to Alkermes plc. Capital Structure Authorized Share Capital Our authorized share capital is \$-,40,000 and \$5,000,000, which is divided into 40,000 ordinary shares of \$-,1.00 each, 450,000,000 ordinary shares of \$0.01 each and 50,000,000 undesignated preferred shares of \$0.01 each. Our ordinary shares are registered under Section 12(b) of the Securities Exchange Act of 1934, as amended. We may issue shares subject to the maximum authorized share capital contained in our Constitution, and subject to the issuance and allotment authorities approved by our shareholders. Our authorized share capital may be increased or reduced by a resolution approved by a simple majority of the votes of our shareholders cast in person or by proxy at a general meeting (referred to under Irish law as an "ordinary resolution"). As a matter of Irish law, the board of directors of a public limited company ("company") like Alkermes may issue new ordinary or preferred shares without shareholder approval once authorized to do so by the company's constitution or by an ordinary resolution adopted by the company's shareholders at a general meeting. The authorization may be granted for a maximum period of five years, after which it must be renewed by the shareholders by an ordinary resolution. In May 2024, our shareholders authorized our board of directors (the "Board") to allot and issue ordinary shares in an amount equal to approximately 20% of our issued ordinary share capital as of April 10, 2024. This current authorization extends until November 30, 2025, at which point it will lapse unless renewed by our shareholders. The rights and restrictions applicable to our ordinary shares are prescribed in our Constitution. Our Constitution permits the Board, without shareholder approval, to determine the terms of any preferred shares issued by us. Our Board is authorized, without obtaining any vote or consent of the holders of any class or series of shares, unless expressly provided by the terms of that class or series of shares, to provide from time to time for the issuance of other classes or series of preferred shares and to establish the characteristics of each class or series, including the number of shares, designations, relative voting rights, dividend rights, liquidation and other rights, redemption, repurchase or exchange rights and any other preferences and relative, participating, optional or other rights and limitations not inconsistent with applicable law. Irish law does not recognize fractional shares held of record. Accordingly, our Constitution does not provide for the issuance of fractional shares, and our official Irish register of members (shareholders) will not reflect any fractional shares. Pre-emption Rights, Share Warrants and Share Options Under Irish law, unless otherwise authorized, when an Irish plc issues shares for cash to new shareholders, it is required to first offer those shares on the same or more favorable terms to existing shareholders of the company on a pro rata basis (commonly referred to as the "statutory pre-emption right"). However, Irish law permits such companies to opt out of the statutory pre-emption right for a period of up to five years if authorized by a resolution approved by not less than 75% of the votes of the company's shareholders cast in person or by proxy at a general meeting (referred to under Irish law as a "special resolution"). In May 2024, our shareholders authorized our Board to allot and issue shares for cash on a non-pre-emptive basis up to the amount of approximately 20% of our issued share capital as of April 10, 2024. This current authorization extends until November 30, 2025, at which point it will lapse unless renewed by our shareholders. The statutory pre-emption right does not apply where shares are issued for non-cash consideration (such as in a stock-for-stock acquisition) and does not apply to the issue of non-equity shares (that is, shares that have the right to participate only up to a specified amount in any income or capital distribution) or where shares are issued pursuant to an employee stock option or similar equity plan. Our Constitution provides that, subject to any shareholder approval requirement under any laws, regulations or the stock exchange rules to which we are subject, the Board is authorized, from time to time, in its discretion, to grant such persons, for such periods and upon such terms as the Board deems advisable, options to purchase such number of shares of any class or classes or of any series of any class as the Board may deem advisable, and to cause warrants or other appropriate instruments evidencing such options to be issued. The Companies Act provides that a board of directors may issue share warrants or options without shareholder approval once authorized to do so by its constitution or an ordinary resolution of shareholders. We are subject to the applicable rules and regulations of The Nasdaq Stock Market ("Nasdaq") and the Internal Revenue Code of 1986, as amended, that require shareholder approval of certain equity plan and share issuances. Our Board may issue shares upon exercise of warrants or options without shareholder approval or authorization (up to the relevant authorized share capital limit). Dividends Under Irish law, dividends and distributions may only be made from distributable reserves. Distributable reserves generally means accumulated realized profits less accumulated realized losses and includes reserves created by way of capital reduction. In addition, no distribution or dividend may be made unless our net assets are equal to, or in excess of, the aggregate of our called-up share capital plus undistributable reserves and the distribution does not reduce our net assets below such aggregate. Undistributable reserves include: (i) our undesignated capital; (ii) the amount by which our accumulated unrealized profits, so far as not previously utilized by any capitalization, exceed our accumulated unrealized losses, so far as not previously written off in a reduction or reorganization of capital; and (iii) any other reserve we are prohibited, at law, from distributing. The determination as to whether or not we have sufficient distributable reserves to fund a dividend must be made by reference to our "relevant accounts." The "relevant accounts" will be either the last set of unconsolidated annual audited financial statements or other financial statements properly prepared in accordance with the Companies Act, which give a "true and fair view" of our unconsolidated financial position and accord with accepted accounting practice. The relevant accounts must be filed in the Companies Registration Office (the official public registry for companies in Ireland). Our Constitution authorizes the Board to declare dividends out of funds lawfully available for distribution without shareholder approval to the extent they appear justified by the profits of the Company. The Board may also recommend a dividend to be approved and declared by the shareholders at a general meeting. The Board may direct that the payment be made by distribution of assets, shares or cash and no dividend issued may exceed the amount recommended by the Board. Dividends may be declared and paid in the form of cash or non-cash assets and may be paid in United States Dollars or any other currency. Our Board may deduct from any dividend payable to any shareholder any amounts payable by such shareholder to us in relation to our shares. The Board may also authorize us to issue shares with preferred rights to participate in dividends we declare. The holders of preferred shares may, depending on their terms, rank senior to our ordinary shares in terms of dividend rights and/or be entitled to claim arrears of a declared dividend out of subsequently declared dividends in priority to ordinary shareholders. Share Repurchases, Redemptions and Conversions Overview Our Constitution provides that any ordinary share that we have agreed to acquire shall be deemed to be a redeemable share, unless the Board elects to treat such share acquisition otherwise. Accordingly, for Irish law purposes, repurchases of ordinary shares by us are effected as redemptions of those shares as described below under "Our Repurchases and Redemptions." If our Constitution did not contain such provision, our repurchases would be subject to many of the same rules that apply to purchases of our ordinary shares by subsidiaries described below under "Purchases by Our Subsidiaries" including the shareholder approval requirements described below and the requirement that any open-market purchases be effected on a "recognized stock exchange." Except where otherwise noted, references herein to repurchasing or buying back our ordinary shares refer to our or one of our subsidiaries' redemption of ordinary shares, in each case in accordance with our Constitution and Irish law as described below. Our Repurchases and Redemptions Under Irish law, a company may issue redeemable shares and redeem them out of distributable reserves or the proceeds of a new issue of shares for that purpose. Please see also the "Dividends" section above. We may only issue redeemable shares if the nominal value of the issued share capital that is not redeemable is not less than 10% of the nominal value of our total issued share capital. All redeemable shares must also be fully-paid. Redeemable shares may, upon redemption, be canceled or held in treasury. Based on the provision of our Constitution described above, shareholder approval is not required to redeem our shares. We may also be given an additional general authority to purchase our own shares on-market which would take effect on the same terms and be subject to the same conditions as applicable to purchases by our subsidiaries as described below. Our Board may also issue preferred shares that may be redeemed at our option or the option of the preferred shareholder, depending on the terms of such preferred shares. Please see "Authorized Share Capital" above for additional information on preferred shares. Under Irish law, repurchased and redeemed shares may be canceled or held as treasury shares. The nominal value of treasury shares held by us at any time must not exceed 10% of the nominal value of our issued share capital. We may not exercise any voting rights in respect of any shares held as treasury shares. Treasury shares may be canceled by us or re-issued subject to certain conditions. Purchases by Our Subsidiaries Under Irish law, a subsidiary may purchase our shares either on-market (an overseas market purchase) or off-market. For one of our subsidiaries to make on-market purchases of our ordinary shares, our shareholders must provide general authorization for such purchase by way of ordinary resolution. However, as long as this general authority has been granted, no specific shareholder authority is required for a particular on-market purchase of our ordinary shares by one of our subsidiaries. For an off-market purchase by one of our subsidiaries, the proposed purchase contract must be authorized by special resolution of our shareholders before the contract is entered into. The person whose shares are to be bought back cannot vote in favor of the special resolution and, for at least 21 days prior to the special resolution being passed, the purchase contract must be on display or must be available for inspection by shareholders at our registered office. In order for one of our subsidiaries to make an overseas market purchase of our shares, such shares must be purchased on a "recognized stock exchange." The Nasdaq Global Select Market, on which our shares are listed, is specified as a recognized stock exchange for this purpose by Irish law. The number of shares held by our subsidiaries at any time will be included in any calculation of the permitted treasury share threshold of 10% of the nominal value of our issued share capital. While a subsidiary holds our shares, it cannot exercise any voting rights in respect of those shares. The acquisition of our shares by a subsidiary must be funded out of distributable reserves of the subsidiary. Share Repurchase Program On February 15, 2024, our Board authorized a share repurchase program to repurchase our ordinary shares in an aggregate amount of up to \$400.0 million (exclusive of any fees, commissions or other expenses related to such repurchases) from time to time on the open market (the "Repurchase Program"), with the timing and amount of any repurchases under the Repurchase Program to be based on a variety of factors, including but not limited to ongoing assessments of our capital needs, alternative investment opportunities, the market price of our ordinary shares and general market conditions. The Repurchase Program has no set expiration date and may be suspended or discontinued at any time. During the year ended December 31, 2024, we repurchased approximately 7.9 million of our ordinary shares under the Repurchase Program at an average price of \$25.33, at a total cost (exclusive of any fees, commissions or other expenses related to such repurchase) of \$200.0 million. The Repurchase Program terminated, and superseded in its entirety, the prior share repurchase program authorized by our Board in September 2011, under which we had purchased a total of 8,866,342 ordinary shares at a cost of \$114.0 million. As noted above, shareholder approval for repurchases under the Repurchase Program will not be required because all repurchases of our shares under the Repurchase Program will be effected as redemptions pursuant to our Constitution. Bonus Shares Under our Constitution, the Board may resolve to capitalize any amount standing to the credit of the reserves of the Company (including, but not limited to, the share premium account, capital redemption reserve, capital conversion reserve and profit and loss account), whether or not available for distribution, for any purpose, including, but not limited to, for the purposes of effecting any exchange of any rights and applying any such sum arising from such capitalization to pay up any shares of the Company and allot them, credited as fully paid, to any holders of such rights. Lien on Shares, Calls on Shares and Forfeiture of Shares Our Constitution provides that we will have a first and paramount lien on every share that is not a fully paid up share for all amounts payable at a fixed time or called in respect of that share. Subject to the terms of their allotment, our Board may call for any unpaid amounts in respect of any shares to be paid, and if payment is not made, the shares may be forfeited. These provisions are standard inclusions in the constitution of an Irish company limited by shares such as ours and will only be applicable to our shares that have not been fully paid up. Consolidation and Division; Subdivision Under our Constitution, we may, by ordinary resolution, consolidate and divide all or any of our share capital into shares of larger nominal value than our existing shares or subdivide our shares into smaller amounts than is fixed by our Constitution. Reduction of Share Capital We may, by ordinary resolution, reduce our authorized share capital in any way, provided that such resolution does not reduce the authorized share capital to an amount less than the issued share capital at such time. We also may, by special resolution and subject to confirmation by the Irish High Court, reduce or cancel our issued share capital in any way we think expedient. Annual Meetings of Shareholders We are required to hold annual general meetings at intervals of no more than 15 months, provided that an annual general meeting is held in each calendar year and no more than nine months after our fiscal year-end. Any annual general meeting may be held outside Ireland, provided that the Company makes all necessary arrangements to ensure that shareholders can participate in such meeting by technological means without leaving Ireland. Notice of each annual general meeting must be given to all our shareholders and to our auditors. Our Constitution provides for a minimum notice period of 21 clear days (as defined in our Constitution), which is the minimum permitted under Irish law. The only matters which must, as a matter of Irish law, be transacted at an annual general meeting are: (i) the consideration of the Company's statutory financial statements and the reports of our Board and our statutory auditors thereon; (ii) the review by our shareholders of the Company's affairs; (iii) the authorization of our Board to approve the remuneration of the statutory auditors; and (iv) the election and/or re-election of members of our Board in accordance with our Constitution. If no resolution is made in respect of the reappointment of an existing auditor at an annual general meeting, the existing auditor will be deemed to have continued in office. Extraordinary General Meetings of Shareholders Extraordinary general meetings may be convened by: (i) our Board; (ii) at the request of shareholders holding not less than 10% of our paid-up share capital carrying voting rights; or (iii) at the request of our auditors in certain circumstances in accordance with the Companies Act. Extraordinary general meetings are generally held for the purposes of approving Board or shareholder resolutions as may be required from time to time. At any extraordinary general meeting, only such business shall be conducted as is set forth in the notice thereof. Notice of an extraordinary general meeting must be given to our shareholders and to our auditors. Under Irish law and our Constitution, the minimum notice periods are 21 clear days' notice in writing for an extraordinary general meeting to approve a special resolution and 14 clear days' notice in writing for any other extraordinary general meeting. In the case of an extraordinary general meeting convened on the requisition of our shareholders, the proposed purpose of the meeting must be set out in the requisition notice. Upon receipt of this required notice, the Board has 21 days to convene a meeting of our shareholders to vote on the matters set out in the required notice. This meeting must be held within two months of the receipt of the requisition notice. If the Board does not convene the meeting within such 21-day period, the requisitioning shareholders, or any of them representing more than one half of the total voting rights of all of them, may themselves convene a meeting, which meeting must be held within three months of our receipt of the requisition notice. If the Board becomes aware that our net assets are not greater than half of the amount of our called-up share capital, our Board must convene an extraordinary general meeting of our shareholders not later than 28 days from the date that they learn of this fact to consider how to address the situation. Quorum for General Meetings Our Constitution provides that no business shall be transacted at any general meeting unless a quorum is present. One or more shareholders present in person or by proxy holding not less than a majority of our issued and outstanding shares entitled to vote at the meeting in question constitute a quorum for such meeting. Voting Our Constitution provides that the Board or the chairman of the Board may determine the manner in which the poll is to be taken at each meeting and the manner in which the votes are to be counted. Every shareholder is entitled to one vote for each ordinary share that they hold as of the record date for the meeting. Voting rights may be exercised by shareholders registered in our share register as of the record date for the meeting or by a duly appointed proxy, which proxy need not be a shareholder. Where interests in shares are held by a nominee trust company, this company may exercise the rights of the beneficial holders on their behalf as their proxy. All proxies must be appointed in the manner prescribed by our Constitution, which permit shareholders to notify us of their proxy appointments electronically in such manner as may be approved by the Board. In accordance with our Constitution, our Board may from time to time authorize us to issue preferred shares. These preferred shares may have such voting rights as may be specified in the terms of such preferred shares (e.g., they may carry more votes per share than ordinary shares or may entitle their holders to a class vote on such matters as may be specified in the terms of the preferred shares). Treasury shares or shares of the Company that are held by our subsidiaries will not be entitled to be voted at general meetings of shareholders. Irish law requires special resolutions of the shareholders at a general meeting to approve certain matters. Examples of matters requiring special resolutions include: a)amending our Constitution; b)approving a change of our name; c)authorizing the entering into of a guarantee or provision of security in connection with a loan, quasi-loan or credit transaction to a director or connected person; d)opting out of pre-emption rights on the issuance of new shares; e)creating a new class of shares; f)re-registration from a public limited company to a private company; g)variation of class rights attaching to classes of shares (where the Constitution does not provide otherwise); h)purchase of our own shares off-market; i)reduction of issued share capital; j)sanctioning a compromise/scheme of arrangement; k)resolving that we be wound up by the Irish courts; l)resolving in favor of a shareholders' voluntary winding-up; m)re-designation of shares into different share classes; and n)setting the re-issue price of treasury shares. Variation of Rights Attaching to a Class or Series of Shares Under our Constitution and the

Companies Act, any variation of class rights attaching to our issued shares must be approved by a special resolution of the shareholders of the affected class or with the consent in writing of the holders of three-quarters of all the votes of that class of shares. The provisions of our Constitution relating to general meetings apply to general meetings of the holders of any class of shares except that the necessary quorum is determined by reference to the shares of the holders of the applicable class. Accordingly, for general meetings of holders of a particular class of shares, a quorum consists of the holders present in person or by proxy representing not less than a majority of the issued shares of that class entitled to vote at the meeting. Acquisitions An Irish public limited company may be acquired in a number of ways, including: a) a court-approved scheme of arrangement under the Companies Act. A scheme of arrangement with shareholders requires a court order from the Irish High Court and the approval of a majority in number representing 75% in value of the shareholders present and voting in person or by proxy at a meeting called to approve the scheme; b) through a tender or takeover offer by a third party for all of our shares. Where the holders of 80% or more of our shares have accepted an offer for such shares, the remaining shareholders may also be statutorily required to transfer their shares. If the bidder does not exercise its “squeeze out” right, then the non-accepting shareholders also have a statutory right to require the bidder to acquire their shares on the same terms. If our shares were to be listed on the Irish Stock Exchange or another regulated stock exchange in the EU, this threshold would be increased to 90%; and c) by way of a merger with a company incorporated in the European Economic Area (“EEA”) under the EU Cross-Border Mergers Directive (EU) 2017/1132 or with another Irish company under the Companies Act. Such a merger must be approved by a special resolution of the shareholders. Under certain circumstances, shareholders also may be entitled to have their shares acquired for cash. Irish law does not generally require shareholder approval for a sale, lease or exchange of all or substantially all of a company’s property and assets. Appraisal Rights Irish law generally does not provide for appraisal rights. However, it does provide for dissenters’ rights in certain situations, as described below. Under a tender or takeover offer, the bidder may require any remaining shareholders to transfer their shares on the terms of the offer (i.e., a “squeeze out”) if it has acquired, pursuant to the offer, not less than 80% of the target shares to which the offer relates (in the case of a company like Alkermes that is not listed on an EEA regulated market). Dissenting shareholders have the right to apply to the Irish High Court for relief. A scheme of arrangement which has been approved by the requisite shareholder majority and sanctioned by the Irish High Court will be binding on all shareholders. Dissenting shareholders have the right to appear at the Irish High Court hearing and make representations in objection to the scheme. Under the European Communities (Cross-Border Mergers) Regulations 2008 governing the merger of an Irish company limited by shares such as we are and a company incorporated in the EEA, a shareholder: (i) who voted against the special resolution approving the merger; or (ii) of a company in which 90% of the shares are held by the other party to the merger, has the right to request that the company acquire its shares for cash at a price determined in accordance with the share exchange ratio set out in the merger agreement. Similar rights apply in the case of a merger of an Irish plc into another company to which the provisions of the Companies Act apply. Disclosure of Interests in Shares Under the Companies Act, shareholders must notify us if, as a result of a transaction, the shareholder will become interested in 3% or more of our shares; or if as a result of a transaction a shareholder who was interested in more than 3% of our shares ceases to be so interested. Where a shareholder is interested in more than 3% of our shares, the shareholder must notify us of any alteration of his or her interest that brings his or her total holding through the nearest whole percentage number, whether an increase or a reduction. The relevant percentage figure is calculated by reference to the aggregate nominal value of the shares in which the shareholder is interested as a proportion of the entire nominal value of our issued share capital of (or any such class of share capital in issue). Where the percentage level of the shareholder’s interest does not amount to a whole percentage this figure may be rounded down to the next whole number. We must be notified within five business days of the transaction or alteration of the shareholder’s interests that gave rise to the notification requirement. If a shareholder fails to comply with these notification requirements, the shareholder’s rights in respect of any shares it holds will not be enforceable, either directly or indirectly. However, such person may apply to the court to have the rights attaching to such shares reinstated. In addition to these disclosure requirements, we may, under the Companies Act, by notice in writing, require a person whom we know or have reasonable cause to believe to be, or at any time during the three years immediately preceding the date on which such notice is issued to have been, interested in shares comprised in our relevant share capital to: (i) indicate whether or not it is the case; and (ii) where such person holds or has during that time held an interest in our shares, to provide additional information, including the person’s own past or present interests in our shares. If the recipient of the notice fails to respond within the reasonable time period specified in the notice, we may apply to court for an order directing that the affected shares be subject to certain restrictions, as prescribed by the Companies Act, as follows: a) any transfer of those shares or, in the case of unissued shares, any transfer of the right to be issued with shares and any issue of shares, shall be void; b) no voting rights shall be exercisable in respect of those shares; c) no further shares shall be issued in right of those shares or in pursuance of any offer made to the holder of those shares; and d) no payment shall be made of any sums due from us on those shares, whether in respect of capital or otherwise. The court may also order that shares subject to any of these restrictions be sold with the restrictions terminating upon the completion of the sale. In the event that we are in an offer period pursuant to the Irish Takeover Rules made under the Irish Takeover Panel Act 1997 (the “Irish Takeover Rules”), accelerated disclosure provisions apply for persons holding an interest in our securities of 1% or more. In addition, the beneficial ownership disclosure requirements of U.S. federal securities laws apply with respect to beneficial ownership of our shares. Anti-Takeover Provisions Irish Takeover Rules and Substantial Acquisition Rules A transaction in which a third party seeks to acquire 30% or more of our voting rights will be governed by the Irish Takeover Panel Act 1997 and the Irish Takeover Rules made thereunder and will be regulated by the Irish Takeover Panel. The General Principles of the Irish Takeover Rules and certain important aspects of the Irish Takeover Rules are described below. General Principles The Irish Takeover Rules are built on the following general principles (the “General Principles”), which will apply to any transaction regulated by the Irish Takeover Panel: a) in the event of an offer, all holders of securities of the target company should be afforded equivalent treatment and, if a person acquires control of a company, the other holders of securities must be protected; b) the holders of the securities of the target company must have sufficient time and information to enable them to reach a properly informed decision on the offer; where it advises the holders of securities, the board of the target company must give its views on the effects of implementation of the offer on employment, conditions of employment and the locations of the target company’s places of business; c) the board of the target company must act in the interests of the company as a whole and must not deny the holders of securities the opportunity to decide on the merits of the offer; d) false markets must not be created in the securities of the target company, the bidder or of any other company concerned by the offer in such a way that the rise or fall of the prices of the securities becomes artificial and the normal functioning of the markets is distorted; e) a bidder must announce an offer only after ensuring that it can fulfill in full, any cash consideration if such is offered, and after taking all reasonable measures to secure the implementation of any other type of consideration; f) a target company must not be hindered in the conduct of its affairs for longer than is reasonable by an offer for its securities; and g) a substantial acquisition of securities (whether such acquisition is to be effected by one transaction or a series of transactions) shall take place only at an acceptable speed and shall be subject to adequate and timely disclosure. Mandatory Bid Under certain circumstances, a person who acquires our shares may be required under the Irish Takeover Rules to make a mandatory cash offer for our remaining outstanding shares at a price not less than the highest price paid for the shares by that acquirer (or any parties acting in concert with the acquirer) during the previous twelve months. This mandatory bid requirement is triggered if an acquisition of shares would increase the aggregate holding of an acquirer (including the holdings of any parties acting in concert with the acquirer) to shares representing 30% or more of our voting rights, unless the Irish Takeover Panel otherwise consents. An acquisition of shares by a person holding (together with its concert parties) shares representing between 30% and 50% of our voting rights would also trigger the mandatory bid requirement if, after giving effect to the acquisition, the percentage of the voting rights held by that person (together with its concert parties) would increase by 0.05% within a twelve-month period. Any person (excluding any parties acting in concert with the holder) holding shares representing more than 50% of the voting rights of a company is not subject to these mandatory offer requirements. Voluntary Bid; Requirements to Make a Cash Offer and Minimum Price Requirements If a person makes a voluntary offer to acquire our outstanding ordinary shares, the offer price must be no less than the highest price paid for our ordinary shares by the bidder or its concert parties during the three-month period prior to the commencement of the offer period. The Irish Takeover Panel has the power to extend the “look back” period to twelve months if the Irish Takeover Panel, taking into account the General Principles, believes it is appropriate to do so. If the bidder or any of its concert parties has acquired our ordinary shares: (i) during the period of twelve months prior to the commencement of the offer period which represent more than 10% of our total ordinary shares; or (ii) at any time after the commencement of the offer period, the offer must be in cash (or accompanied by a full cash alternative) and the price per ordinary share must not be less than the highest price paid by the bidder or its concert parties during, in the case of (i), the 12-month period prior to the commencement of the offer period and, in the case of (ii), the offer period. The Irish Takeover Panel may apply this rule to a bidder who, together with its concert parties, has acquired less than 10% of our total ordinary shares in the 12-month period prior to the commencement of the offer period if the Irish Takeover Panel, taking into account the General Principles, considers it just and proper to do so. An offer period will generally commence from the date of the first announcement of the offer or proposed offer. Any announcement by us which commences an offer period must identify the potential bidder with which we are in talks or from which an approach was received. Any such bidder will then have a period of 42 days following such announcement (i.e. the announcement in which they are first identified) to announce a firm intention to make an offer or announce that they do not intend to do so, in which case they will then be restricted from making an offer for six months. Substantial Acquisition Rules The Irish Takeover Rules also contain rules governing substantial acquisitions of shares which restrict the speed at which a person may increase his or her holding of shares and rights over shares to an aggregate of between 15% and 30% of our voting rights. Except in certain circumstances, an acquisition or series of acquisitions of shares or rights over shares representing 10% or more of our voting rights is prohibited, if such acquisition(s), when aggregated with shares or rights already held, would result in the acquirer holding 15% or more but less than 30% of our voting rights and such acquisitions are made within a period of seven days. These rules also require accelerated disclosure of acquisitions of shares or rights over shares relating to such holdings. Shareholder Rights Plan Under our Constitution, our Board is authorized to adopt a shareholder rights plan (a “Shareholder Rights Plan”), upon such terms and conditions as the Board deems expedient and in the best interests of the Company, subject to applicable law, including the grant of rights (including approving the execution of any documents relating to the grant of such rights) to subscribe for ordinary shares or preferred shares in the share capital of the Company in accordance with the terms of any Shareholder Rights Plan. The Board or any duly appointed committee thereof may effect an exchange of rights in accordance with such Shareholder Rights Plan. Frustrating Action Under the Irish Takeover Rules, our Board is not permitted to take any action which might frustrate an offer for our shares once the Board has received an approach which may lead to an offer or has reason to believe an offer is or may be imminent, subject to certain exceptions. Potentially frustrating actions such as: (i) the issue of shares, options or convertible securities; (ii) material acquisitions or disposals; (iii) entering into contracts other than in the ordinary course of business; or (iv) any action, other than seeking alternative offers, which may result in frustration of an offer, are prohibited during the course of an offer or at any time during which the Board has reason to believe an offer is imminent. Exceptions to this prohibition are available where: a) the action is approved by our shareholders at a general meeting; or b) the Irish Takeover Panel has given its consent, where: 1. it is satisfied the action would not constitute frustrating action; 2. the holders of 50% of the voting rights state in writing that they approve the proposed action and would vote in favor of it at a general meeting; 3. the action is taken in accordance with a contract entered into prior to the announcement of the offer; or 4. the decision to take such action was made before the announcement of the offer and either has been at least partially implemented or is in the ordinary course of business. Certain other provisions of Irish law or our Constitution may be considered to have anti-takeover effects, including those described under the following captions: “Authorized Share Capital” (regarding issuance of preferred shares), “Pre-emption Rights, Share Warrants and Share Options,” “Disclosure of Interests in Shares,” and “Corporate Governance.” Appointment of Directors of the Board At each annual general meeting of shareholders, each director who is nominated for election or re-election at that annual general meeting of shareholders shall be eligible for election for a one-year term. Except as otherwise set forth in our Constitution, directors will be elected by way of ordinary resolution at a general meeting. In the event of a contested election (where the number of persons validly nominated for election exceeds the number of available director positions to be elected), only those directors in number equal to the number of available director positions and who receive the highest number of votes in favor of their election shall be elected. In no case will a decrease in the size of the Board shorten the term of any incumbent director. A director shall hold office until the close of the annual general meeting of shareholders for the year in which their term expires and until their successor shall be elected and shall qualify, subject, however, to prior death, resignation, retirement, disqualification or removal from office. Any vacancy on the Board, including a vacancy that results from an increase in the size of the Board or from the death, resignation, retirement, disqualification or removal of a director, shall be deemed a casual vacancy, and subject to the terms of any one or more classes or series of preferred shares (if any), shall only be filled by decision of a majority of the Board then in office. Any director appointed to fill a vacancy shall hold office until the next annual general meeting. A director retiring from the Board at a general meeting shall retain office until the close or adjournment of such meeting. During any vacancy in the Board, the remaining directors have full power to act as the Board. If, at any general meeting of the Company (other than in the event of a contested election), the number of directors is reduced below the minimum prescribed by the Board due to the failure of any persons nominated to be directors to be elected, then in those circumstances, the nominee or nominees who receive the highest number of votes in favor of election shall be elected in order to maintain the prescribed minimum number of directors and each such director shall remain a director (subject to the provisions of the Companies Act and our Constitution) only until the conclusion of the next annual general meeting of the Company unless such director is re-elected by the our shareholders during such meeting. Duration; Dissolution; Rights upon Liquidation Our duration is unlimited. We may be dissolved and wound up at any time by way of a shareholders’ voluntary winding up or a creditors’ winding up. In the case of a shareholders’ voluntary winding-up, a special resolution of shareholders is required. We may also be dissolved by way of court order on the application of a creditor, or by the Companies Registration Office as an enforcement measure where we have failed to file certain returns. The rights of the shareholders to a return of our assets on dissolution or winding up, following the settlement of all claims of creditors, may be prescribed in our Constitution or the terms of any preferred shares issued by our Board from time to time. The holders of preferred shares in particular may have the right to priority in our dissolution or winding up. If the Constitution contains no specific provisions in respect of a dissolution or winding up then, subject to the priorities of any creditors, the assets will be distributed to shareholders in proportion to the paid-up nominal value of the shares held. Our Constitution provides that our ordinary shareholders are entitled to participate pro rata in a winding up, but their right to do so may be subject to the rights of any preferred shareholders to participate under the terms of any series or class of preferred shares. Uncertificated Shares Pursuant to the Companies Act, a shareholder is entitled to be issued a share certificate on request and subject to payment of a nominal fee. No Sinking Fund Our ordinary shares have no sinking fund provisions. No Liability for Further Calls or Assessments Our ordinary shares are duly and validly issued and fully-paid. Transfer and Registration of Shares Our transfer agent maintains our share register, which is determinative of ownership of our shares. Our shareholders who hold shares beneficially are not the holders of record of such shares. Instead, the depository (for example, Cede & Co., as nominee for DTC) or other nominee is the holder of record of those shares. Accordingly, a transfer of shares from a person who holds such shares beneficially to a person who also holds such shares beneficially through a depository or other nominee will not be registered in our official share register, as the depository or other nominee will remain the record holder of any such shares. A written instrument of transfer is required under Irish law in order to register on our official share register any transfer of shares: (i) from a person who holds such shares directly to any other person; (ii) from a person who holds such shares beneficially to a person who holds such shares directly; or (iii) from a person who holds such shares beneficially to another person who holds such shares beneficially where the transfer involves a change in the depository or other nominee that is the record owner of the transferred shares. An instrument of transfer is also required for a shareholder who directly holds shares to transfer those shares into his or her own broker account (or vice versa). Such instruments of transfer may give rise to Irish stamp duty, which must be paid prior to registration of the transfer on our official Irish share register. However, a shareholder who directly holds shares may transfer those shares into his or her own broker account (or vice versa) without giving rise to Irish stamp duty provided there is no change in the ultimate beneficial ownership of the shares as a result of the transfer and the transfer is not made in contemplation of a sale of the shares. Any transfer of our ordinary shares that is subject to Irish stamp duty will not be registered in the name of the buyer unless an instrument of transfer is duly stamped and provided to the transfer agent. Our Constitution allows us, in our absolute discretion, to create an instrument of transfer and pay (or procure the payment of) any stamp duty, which is the legal obligation of a buyer. In the event of any such payment, we are (on our behalf or on behalf of our affiliates) entitled to: (i) seek reimbursement from the buyer or seller (at our discretion); (ii) set-off the amount of the stamp duty against future dividends payable to the buyer or seller (at our discretion); and (iii) claim

insider against the ordinary shares on which we have not paid stamp duty. Parties to a share transfer may assume that any stamp duty arising in respect of a transaction in our ordinary shares has been paid unless one or both of such parties is otherwise notified by us. Our Constitution delegates to our secretary the authority to execute an instrument of transfer on behalf of a transferring party. In order to help ensure that the official share register is regularly updated to reflect trading of our ordinary shares occurring through normal electronic systems, we intend to regularly produce any required instruments of transfer in connection with any transactions for which we pay stamp duty (subject to the reimbursement and set-off rights described above). In the event that we notify one or both of the parties to a share transfer that we believe stamp duty is required to be paid in connection with the transfer and that we will not pay the stamp duty, the parties may either themselves arrange for the execution of the required instrument of transfer (and may request a form of instrument of transfer from us for this purpose) or request that we execute an instrument of transfer on behalf of the transferring party in a form determined by us. In either event, if the parties to the share transfer have the instrument of transfer duly stamped (to the extent required) and then provide it to our transfer agent, the buyer will be registered as the legal owner of the relevant shares on our official Irish share register (subject to the matters described below). The Board may suspend registration of transfers from time to time, with such suspensions not to exceed 30 days in aggregate each year. EX-19.1 3 alks-ex19_1.htm EX-19.1 EX-19.1 Exhibit 19.1 ALKERMES plc INSIDER TRADING POLICY

As an officer, director, employee (including contract employee) and independent contractors of Alkermes plc and its subsidiaries (the "Company") may come into possession of material, nonpublic information about the Company, its business or other companies with which the Company interacts. This information is legally considered the property of the Company. If you are in possession of any such information, you may not seek to benefit from it by transacting in any such securities yourself, or passing on the information to others to enable them to benefit. It is also the policy of the Company to transact in Company securities in compliance with all applicable securities laws and regulations. The misuse of material, nonpublic information is contrary to Company policy and U.S. securities laws and may lead to severe consequences. The purpose of this Insider Trading Policy (this "Policy") is to inform you of your legal responsibilities in this area. What is Insider Trading? Insider trading, which entails transacting in a security with knowledge of material, nonpublic information about that security or the issuer of that security, is a crime that may be penalized by civil fines of reimbursement of amounts unduly received from such trading and punitive payments of up to three times the profit gained or loss avoided by such trading, as well as criminal fines of up to \$5,000,000 (USD) and up to 20 years in jail for individuals. Under some circumstances, individuals convicted of insider trading may be subjected to civil liability in private lawsuits. In addition to these consequences to the person engaging in insider trading, employers and other controlling persons (including supervisory personnel) are at risk under federal law for the actions of their employees. Controlling persons may, among other things, face major criminal and/or civil penalties if they recklessly fail to take preventive steps to control insider trading. Even if the Company is not prosecuted, the fact that a director, officer, employee or contractor of the Company was under investigation or prosecuted for insider trading could severely damage the reputation of the Company. Thus, it is important both to you and the Company to prevent the occurrence of insider trading violations. You should be aware that stock market surveillance techniques designed to identify potential insider trading transactions have become extremely sophisticated and are being improved all the time. Insider trading cases have been successfully prosecuted against employees based on their trading through foreign accounts, trading by their family members and friends, and trading only involving a small number of shares. The chance that federal authorities or exchange regulators will detect even small-level trading is significant. The Insider Trading Laws As an officer, director, employee (including contract employee) or independent contractor of the Company, you may not seek to benefit personally by transacting in securities while in possession of material, nonpublic information. This rule applies to transacting, or your directing others to transact, in the Company's securities (whether ordinary shares, preferred shares, convertible securities, stock options or any other derivative securities that provide the economic equivalent of ownership of any of the Company's securities or an opportunity, direct or indirect, to benefit from any change in the value of the Company's securities) and in the securities of other companies if you learn something in the course of your employment or relationship with the Company that might affect the value of any such other company. ACTIVE/136096699.2A For instance, if you learned that the Company was about to acquire ABC Corporation prior to a public announcement, it would almost certainly be an insider trading violation for you to transact in ABC securities as well as the Company's securities. If you learned something about XYZ Corporation which was not publicly known while you were working for us on a collaboration with XYZ, transacting in XYZ securities might well be considered illegal, even if the information learned was not related to the collaboration. The insider trading rules apply to purchases, sales and gifts of securities. Sometimes material nonpublic information about the Company or another company with which the Company is working comes to your attention even though you are not directly involved in the project. You are nonetheless prohibited from transacting in the Company's securities or the securities of such other company. What is Material Information? Material information is information that a typical investor would likely consider significant. There is no fixed quantitative threshold amount for determining materiality; even very small quantitative changes can be qualitatively material if they would result in a movement in the price of the Company's ordinary shares. If you learn something that leads you to want to buy, sell or gift securities, that information could be considered material. Both positive and negative information may be material. It is important to keep in mind that material information need not be definitive information; information that something is likely to happen, or even just that it may happen, can be considered material. Examples of information that could be potentially material include changes in Company management, threatened litigation, Company or product performance above or below issued financial guidance, the Company's involvement in merger or licensing negotiations (even if the deal had not yet been agreed to), or the success of a feasibility or clinical study for a development compound. Keep in mind that the U.S. Securities and Exchange Commission (the "SEC") takes the view that the mere fact that you are in possession of the material, nonpublic information is enough to bar you from trading. Therefore, trading while in possession of material, nonpublic information or tipping this information to others to trade, even if such trades were not based on such information, is violative of this Policy and the law. If you have questions as to whether information in your possession may be deemed material, you may seek guidance from the Chief Financial Officer or the Chief Legal Officer to assist in that determination. It is important, however, that you bear in mind that the ultimate responsibility for determining whether you are in possession of material, nonpublic information belongs to you, and that any advice or action on the part of the Company, the Chief Financial Officer, the Chief Legal Officer or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate you from liability under applicable U.S. securities laws. What is Nonpublic Information? Nonpublic information is any information that is not reasonably accessible to the investing public. To show that information is public, it is necessary to point to some fact that establishes that the information has become publicly available, such as the filing of a report with the SEC, the distribution of a press release through a widely disseminated news or wire service, or by other means that are reasonably designed to provide broad public access. Before a person who possesses material, nonpublic information can trade, there must also be adequate time for the market as a whole to absorb the information that has been disclosed. Once the Company releases information through public channels (for instance, in a press release or an SEC filing), it may take up to 48 hours for it to be considered broadly disseminated. For purposes of this Policy, information will be considered public after the close of trading on the second full trading day following the Company's public release of the information. A 2A Policy A Prohibited Use of Material, Nonpublic Information When you are in possession of material, nonpublic information about the Company, or about any other company if such information is gained in the course of your employment or other relationship with us, or when you are in a blackout period (as described below), you are prohibited from engaging in any activity that would be considered unlawful trading or tipping under the U.S. securities laws, whether in the Company's securities or the securities of another company. These prohibitions extend to your family members living in the same home as you, family members who do not live in the same home as you but whose transactions are directed by you or subject to your influence or control and to any investment fund, trust, retirement plan, partnership, corporation or other entity over which you have the ability to influence or direct investment decisions concerning securities, and continues whenever and for as long as you know or are in possession of material, nonpublic information or the blackout period is in place. You are responsible for ensuring compliance with this Policy by all such persons affiliated with you. The SEC and federal prosecutors may presume that trading by your family members (including those that do not live in the same home as you) and friends is based on information you supplied and may treat any such transactions as if you had traded. There is no exception for small transactions or transactions that may seem necessary or justifiable for personal financial emergency or hardship. Tipping Information to Others Besides your obligation to refrain from trading or having others trade on your behalf while you are in possession of material, nonpublic information, you are also prohibited from tipping others. The concept of unlawful tipping includes passing on material, nonpublic information to friends, family members or others under circumstances that suggest that you were trying to help them make a profit or avoid a loss or enjoy some other benefit. When tipping occurs, both the tipper and the tippee may be held liable, and this liability may extend to all those to whom the tippee gives information. Besides being considered a form of insider trading, tipping is also a serious breach of corporate confidentiality. You should be careful to avoid discussing confidential information in any place (for instance, at lunch, on public transportation, on a cell phone in a public place, in elevators, etc.) where such information may be overheard or intercepted by others. You should exercise care when discussing any material, nonpublic information with other members of the Company who do not have a need to know such information, even though they are also subject to this Policy, so as to reduce the possibility of leaks. A Transacting in Company Securities If you want to buy, sell, gift (which term, as used in this Policy, includes charitable donations) or otherwise transact in any Company securities, you must first determine if you are in possession of material, nonpublic information. If so, you may not buy, sell, gift or otherwise transact in, or provide such information to others to transact in, any Company securities, no matter what position you hold with the Company. This includes the exercise of stock options using cash from the sale of shares to pay the exercise price (also known as a cashless exercise), and bona fide gifts of Company securities. If you are not sure whether or not you are in possession of material, nonpublic information, you should not buy, sell, gift or otherwise transact in, or tip others to transact in, any Company securities. From time to time, the Chief Financial Officer or Chief Legal Officer may determine that certain persons within the Company or everyone within the Company may not buy, sell, gift or otherwise transact in Company securities, also known as a blackout period. You will be notified when a blackout period is in place. A determination by the Chief Financial Officer or Chief Legal Officer that no purchases, sales or other transactions may be made is itself deemed to be material, nonpublic information that should not be discussed outside the Company. A 3A Since financial information about the Company can significantly affect trading in the Company's securities, all officers, directors, employees (including contract employees) and independent contractors are subject to a blackout period beginning at the end of the 15th day of the final month of each fiscal quarter, and ending after the close of trading on the second full trading day following the Company's public release of its quarterly or annual financial results or other financial information (the "Quarterly Blackout Period"). You may not buy, sell, gift or otherwise transact in, or tip others to transact in, any Company securities or enter into a planned sales program for transactions in Company securities during any Quarterly Blackout Period. A The Company may also issue material information to the public at other times, which may result in additional blackout periods outside of the Quarterly Blackout Periods. In such circumstances, you will be notified of the applicable blackout period. Please note that stock options issued by the Company have an expiration date. It is your responsibility to track the expiration date of any stock options which you may have been granted and to plan accordingly if you wish to exercise such options via a cashless exercise. A Transacting in Securities of Other Companies As previously discussed in this Policy, if you want to transact in any securities (including, without limitation, common or ordinary shares, preferred shares, convertible securities, or warrants) of a company that is a corporate partner, a collaborator or a possible acquisition target, or any other company about which you've received information in the course of your employment with us, you must first determine whether you are in possession of any nonpublic information related to such company and whether that information is material to that company. If you are not sure whether you are in possession of material, nonpublic information, you should not buy, sell, gift or otherwise transact in, or tip others to transact in, any securities of such other company. A Post-Termination Transactions This Policy continues to apply even after termination of your employment or other service relationship with the Company. If an individual is in possession of material, nonpublic information received in the course of their employment or other service relationship with us, when their employment or other service relationship terminates, that individual may not trade in the securities of the company to which such information relates until that information has become public or is no longer material. A Additional Prohibited Transactions Officers, directors, employees (including contract employees) and independent contractors are prohibited from engaging in speculative transactions in the Company's securities, including by way of the purchase or sale of put or call options or other derivative securities directly linked to the Company's equity; short sales of the Company's equity; the use of Company securities as a pledge or as collateral in a margin account; and trading in straddles, equity swaps, or other hedging transactions directly linked to Company securities, even if such persons do not possess material, nonpublic information. A Preclearance To provide assistance in preventing inadvertent insider trading violations and avoiding the appearance of an improper transaction (which could result, for example, when an employee engages in a trade while unaware of a pending major Company development) and for purposes of compliance with the reporting and other disclosure requirements relating to insider transactions, the Company has implemented the following preclearance policy: A Members of the Alkermes plc board of directors, management committee and disclosure committee, and officers of the Company (as such term is defined in Section 16a-1(f) of the 1934 Securities Exchange Act of 1934, as amended (the "Exchange Act"), and each such officer, and each Section 16 Reporting Officer, Company employees in a position of vice president (or equivalent) or higher, Company employees in the finance, business development, alliance management, business planning, corporate affairs, investor relations, legal, and certain employees designated by management in the research and development, commercial and information technology organizations, must obtain preclearance from the Chief Financial Officer or Chief Legal Officer before they may transact in Company securities, which, for the avoidance of doubt, also includes gifting Company securities (whether directly or through a donor advised fund), even if no blackout period is in effect such that the window for trading in Company securities is then open and transactions in Company securities would otherwise be allowed under this Policy. A Additionally, from time to time, certain additional individuals may be exposed to material, nonpublic information because of their job or other relationship with the Company and shall be required to seek preclearance from the Chief Financial Officer or Chief Legal Officer before transacting in any Company securities. A A list of individuals requiring preclearance by the Chief Financial Officer or Chief Legal Officer will be periodically generated by the legal department of the Company and communicated to the employees on the list (the "Preclearance List"). A Be advised that preclearance from the Chief Financial Officer or Chief Legal Officer does not constitute legal advice, does not constitute confirmation that you do not possess material, nonpublic information and does not relieve you of your obligations under the U.S. securities laws; it is a safeguard that the Company has put in place to help protect you and the Company. A If you are an individual who requires preclearance and you are contemplating a transaction in the Company's securities, you should contact the legal department at least two business days in advance. You can send your preclearance request to preclearance@alkermes.com. A You are responsible for ensuring that you do not have material, nonpublic information about the Company, or about other companies if you learn something in the course of your employment or relationship with the Company that might affect the value of any such other company, before engaging in a transaction involving such company's securities and that you comply with any and all other legal obligations. Therefore, before you make a request for preclearance, you should carefully consider whether you are aware of any material, nonpublic information and should describe fully any relevant circumstances in your preclearance request. The Chief Financial Officer or Chief Legal Officer is under no obligation to approve any trade submitted for preclearance. A If you are precleared to trade, your transaction must be executed within 48 hours after receiving preclearance approval but, even if so precleared, may not be executed if you acquire material, nonpublic information after preclearance approval and before executing the trade. If the transaction does not take place during that time, you must re-request preclearance through the same process. A Special Types of Permitted Transactions A Cash Exercises of Stock Options This Policy does not apply to an exercise of stock options when payment of the exercise price is made entirely in cash. However, this Policy does apply to any shares acquired through an option exercise made entirely in cash, and you may not sell any of those acquired shares for so long as you are in possession of material, nonpublic information. This Policy also applies to the use of Company shares to constitute part, or all, of the exercise price of a stock option (referred to as a cashless exercise of a stock option), or any other market sale for the purpose of generating the cash needed to pay the exercise price of a stock option. No matter how you exercise or otherwise acquire Company securities, during your employment with the Company, you may only sell Company securities, including those obtained through a stock

are a member of the Alkermes plc board of directors, management committee or disclosure committee, a Section 16 Reporting Officer, or a member of one of the functions listed above that are subject to preclearance, the Company strongly encourages you to transact in the Company's securities under a Rule 10b5-1 Plan. In addition, if you routinely have access to material, nonpublic information as part of your responsibilities with the Company, you may find a Rule 10b5-1 Plan to be useful as well. A Members of the Alkermes plc board of directors and Section 16 Reporting Officers should also be mindful of their respective share ownership and/or holding requirements under the Alkermes plc Amended and Restated Share Ownership and Holding Guidelines when considering establishing a Rule 10b5-1 Plan or any other transaction in the Company's securities. A If you intend to trade pursuant to a Rule 10b5-1 Plan, such plan, arrangement or instruction must: a) satisfy the requirements of Rule 10b5-1; b) be documented in writing and include a written representation by you that you are not aware of any material nonpublic information concerning the Company and that you are adopting the Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) and Rule 10b-5 of the Exchange Act; c) be established during an open trading window (in accordance with this Policy) and at a time when you do not possess material, nonpublic information about the Company; and d) be pre-approved by the Chief Financial Officer or the Chief Legal Officer. A In order to satisfy Rule 10b5-1, all Rule 10b5-1 Plans are subject to a mandatory cooling off period (consisting of at least 30 days or more under certain circumstances for employees other than Section 16 Reporting Officers and at least 90 days or more under certain circumstances for Section 16 Reporting Officers and members of the Alkermes plc board of directors) prior to the date of the first planned sale or other transaction under such Plan. All Rule 10b5-1 Plans must also adhere to certain prescribed limitations on the number and nature of Plans that may be in effect at a given time (e.g., minimum number of trades requirement, term limitations) and such other Plan parameters as the Chief Financial Officer or the Chief Legal Officer deems to be in the best interests of the Company. A Modifications to, or terminations of, Rule 10b5-1 Plans are highly discouraged and require the approval of the Chief Financial Officer or the Chief Legal Officer. If you are a director or a Section 16 Reporting Officer, the Company will be required to disclose any adoption, modification or termination of a 10b5-1 Plan by you and certain details relating to such Plan in its periodic reports filed with the SEC. Any questions in respect of a Rule 10b5-1 Plan, requests for approval of entry into, modification or termination of a Rule 10b5-1 Plan or the required disclosure relating to such Plans, should be submitted 6A A to preclearancerequest@alkermes.com. A Transactions effected pursuant to a pre-approved and executed Rule 10b5-1 Plan will not be subject to the Company's blackout periods or other preclearance procedures. A Investing in Mutual Funds You may invest in any mutual fund which invests in the Company's securities or the securities of any company with which the Company has a relationship without regard to this Policy. A Reports of purchases, sales and gifts for Board members and Section 16 Reporting Officers A If you are a member of the Alkermes plc board of directors or a Section 16 Reporting Officer, keep in mind the various restrictions on securities transactions imposed under Section 16 of the Exchange Act and the corresponding reporting requirements. You must immediately report to the Chief Financial Officer or the Chief Legal Officer or their designees all transactions made in the Company's securities by you, any family member, and any trusts or entities that you control, including gifts and cash exercises of stock options. The Company requires same-day reporting to it of any such transaction due to SEC requirements that certain insider reports be filed with the SEC by the second day after the date on which a reportable transaction occurs. In addition, you must comply with the preclearance procedures set forth above in respect of any such transactions. A Disclosure of Confidential Information A The confidentiality of all material, nonpublic information that you learn while working at the Company (whether or not such information is about the Company) must be strictly maintained within the Company. Only certain executive officers and certain members of the Corporate Affairs and Investor Relations departments are authorized to disclose material, nonpublic information about the Company to the public, members of the investment community (including analysts), or to shareholders, unless one of these executive officers expressly authorizes disclosure by another employee in advance. A In addition, with advances in electronic communications and the corresponding increased use of the Internet, email communications, social networking sites, video sharing websites, electronic bulletin boards, chat rooms and blogs, electronic discussions about companies and their business prospects (collectively, "Electronic and Social Media") have become common. Inappropriate communications disseminated on the Internet may pose an inherently greater risk due to the size of the audience they can reach. It is important for Company employees who choose to participate in Electronic and Social Media to understand what is recommended, expected and required when discussing Company-related topics. In this context, you are prohibited from sharing any nonpublic information about the Company and from discussing revenues, future plans, prospects, products or the share price of the Company in any comments, responses, or postings on any Electronic and Social Media and are subject in all respects to the Company's social media policy, available on the Company's internal intranet. A You should not, under any circumstances, recommend or express opinions as to the Company's securities or comment on rumors or predictions about the Company, regardless of whether the rumor is false and whether you think your recommendation, opinion or comment is being made on an anonymous basis (for example, in any Electronic and Social Media). If you are ever asked a direct question about the Company or any prevailing rumor about the Company, you should respond that it is Company policy not to comment on such matters and that any questions should be directed to the Company's Investor Relations department or Chief Financial Officer. This Policy operates in addition to any other Company policies relating to safeguarding the confidentiality of the Company's internal, proprietary information. A Reporting of Violations 7A A If you violate this Policy or any federal or state laws governing insider trading, or know of any such violation by any director, officer, employee, or independent contractor of the Company, you must report the violation immediately to your supervisor, or to the Chief Financial Officer or the Chief Legal Officer of the Company. Persons violating this Policy will be subject to disciplinary action by the Company, up to and including termination. A Modifications A The Company may at any time change this Policy or adopt such other policies or procedures which it considers appropriate to carry out the purposes of this Policy. A current copy of this Policy is maintained on the Corporate Governance section of the Investors tab of the Company's website. A Questions A You are encouraged to ask questions and seek any follow-up information that you may require with respect to the matters set forth in this Policy. Please direct all questions to preclearancerequest@alkermes.com. A * * * Your failure to observe this Policy could lead to significant legal and other consequences, including the potential termination of your employment. A A 8A EX-21.1 4 alks-ex21 1.htm EX-21.1 EX-21.1 Exhibit 21.1 SUBSIDIARIES A A A Name Jurisdiction Alkermes Ireland Holdings Limited A Ireland A Alkermes Pharma Ireland Limited A Ireland A Daravita Pharma Ireland Limited A Ireland A Alkermes Finance Ireland (No 3) Limited A Ireland A Alkermes Science Four Limited A Ireland A Alkermes Science Five Limited A Ireland A Alkermes US Holdings, Inc. A Delaware A Alkermes, Inc. A Pennsylvania A Alkermes Controlled Therapeutics, Inc. A Pennsylvania A Rodin Therapeutics, Inc. A Delaware A EX-23.1 5 alks-ex23 1.htm EX-23.1 EX-23.1 Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-179545, 333-184621, 333-200777, 333-214952, 333-226359, 333-232831, 333-240170, 333-258229, 333-266350, 333-273456 and 333-280984) of Alkermes plc of our report dated February 12, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K. /s/ PricewaterhouseCoopers LLP Boston, Massachusetts February 12, 2025 A A EX-31.1 6 alks-ex31 1.htm EX-31.1 EX-31.1 Exhibit 31.1 CERTIFICATIONS I, Richard F. Pops, certify that: 1.I have reviewed this annual report on Form 10-K of Alkermes plc; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A EX-31.2 7 alks-ex31 2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATIONS I, Blair C. Jackson, certify that: 1.I have reviewed this annual report on Form 10-K of Alkermes plc; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A EX-32.1 8 alks-ex32 1.htm EX-32.1 EX-32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 10-K of Alkermes plc (the "Company") for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Richard F. Pops, Chairman and Chief Executive Officer of the Company, and Blair C. Jackson, Executive Vice President, Chief Operating Officer and Interim Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge: (1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12, 2025 /s/ Blair C. Jackson A A Blair C. Jackson A A A A Executive Vice President, Chief Operating Officer A A (Interim Principal Financial Officer) A A A A Date: February 12, 2025 /s/ Richard F. Pops A A Richard F. Pops A A A A Chairman and Chief Executive Officer A A (Principal Executive Officer) A A A A Date: February 12,

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

R2;%PL\,D0V12,22%D&XC@9]:_81XV"5,4'3:*0[F M/'2L<1B)XFHYR/-
SO.L1GV8/&5TE)I7MMH?@U_P5#_X)G_|!6G|M;|M/OE|_M6I/(@;|J'A^WU2?3?!ACUZS6--
)AD<0,J_&4R+^|8"!WR-G %>W?|\$/!/^"< MG|9G|%O|27BSQ+^T;|!%T?
2|9\|B&SUQM4M9VAG2=6|@+&|_X8L3@ &\$9R2 M* 78Q<9QSTIWEJ!G;75+JLL.Z-
E:UCWJTW">:5LC_LI0BJ=K;)I_F1QHQ'*_MQ5*A)%+17FGO_4UUSR*=10!Y!^W7\,_&'Q?_
&_BI*O &E"^UKOQ%X U?3M M(L_,6/S|F6TECC3/)*|\$/D<@ MD5|.K:.*SD:.* M_.3=0;R
<|E/+DVD\$G.5."?SK^GIXPHZU'IE5CG"|.>*Z_|X'AF3X*^_Y(|S*.FH:L4@*@9PYDE"X_WN
MI>F?|C_@VS_X*%_\$7;<^_M_.V/^"|=;ORI(|5U19IO+P#YBK_'4C/8L#G/X_T
M3:/JQ50H'K|M2+'@_::!6W/CC45F1X|&VS;6<:A3E"N27R3W(&%OG|*?AS|/_OPF|)V
M/@7X<>\$|'1=(T^W2"UL-/MUCCC10 !A>IP.07C072*.,XI37GU|56KOWV?%Y
MKGV;9U/FO=5R|NB|/\$<+^T'HWQ3UWX)^*_%^^^H6=KXLO-\$N(= NKYBL,5TR\$ M(|D
X)ST)%?A;K'_!LY_P %'?\$.KW7B#7?'G@6|OKZX>>|N9M:N&>61CEG8 MF#DDY-?
T%;1CD4%>,BKPV-JX5>YU.K(>*,TX=YQJ;2^_ MWI!|L.VI_!/?XX7FA7%U-
XGFU"RDT2X;13%)%&I#LR*<|D/&#P: ^R%0H*=M-
MOVKGJUIUJCG+KJ>3C|=6S+&2Q-;XI-MV|PH.<<445F<9&|>Y6 %?&?| P6E_ M8(^,?|?_
SAI7PJ^"VI:/ZE8^((IZ636;IXH+56& 55CG)Z8 K|/).< 4
M\$9'2M*-65"2E#='9E^_KY9C(8JCI.+NC^>K_ (A@/^"@N|YO%7@'_P &|_|M|8K|%/A
@B!_P3X_;%_X)|Z#XP^'7Q_!5Z!/?>&=3F@N|!L|)%O))F@NOF\$Y.|
M%VJ1LX&RF#+CRW_>S;3WDDYSP2 MJJ.=HK^BUDRN%%?#/_!7C_@D5X0_;C|+2?
%GX6VMMH/O/TJS(M|K|L6M0J>+ M>?L&49V2=?X6RNTIW<.8W"X+,%4KK=6OV?F?
D'&66XW-,I<.,|4|M=UV/Y|5 M^9L|,5T7PB^&^O?&7XGZ!|/"T#R7_B#58;&U6.,N=SN%!
)QG/TJEXY|#> M_/AIXKU#P)X|/W6EZQIMPT%|8WD162*0=5(-?H+_P
&WW|+4006_ :FU;|H7 M7;|7TGX?;MM3(BL'U&Y#)%P>T6 M,\$M'9R_,UVHZ'9L&
|C.W!&0#C|2?@E|:/B+^SQ|4|)%^,WPIUQM-UW0;Q;BSN M-
@*DC&Y&4)%&7*D>AXQU'YW@8^VH>UB_>O=^OF?Z(>'>0X.7"T:F7R2Q\$'?T
MM|EKL UOZG.ZSI&K>'|7N=|UI3IK_|LYFANK6XC*O%(IP58'H0:|H|E_|JOXW
M_L017WQ^U#|#OA#_P5Z_9 MCC_;G_91T&UL?
C1H=I&/BEX)T|E4WUFU"9+A(!GDS@A_ ^6B|'Y@<_F-=6EYI M-
|+IVJ64L\$T+E)H9HRKHP.""#R"#O7H0G'\$4^6:|FOU/U'+,RP?>#GA|7!*<
MHKQG!|'W|'T9_23_,\$OO^"T/P/_ &^-'M_!GB2>V|,?\$&WA07'A^XN0!?,(<
M@TDMN3|Y0P;Y>H&,YK|'?X>^!7|3CQLWA:P.K; JZAI|G:D SU^O^UUIZ_C|T
M3O|KGA76|7Q/X7UJ|TW4K*=9K_ L,AHHH)!T=70AE;W|K|4O^"= _!RC|0?A
MU_9WPP_ ;9TV3Q;|I\$=OY,?C*PCS?1MN7;YT2@"10N|++ALA?E;)->'C,IG&|Z
M/W'X|Q=X6XC"3>(RM<|=W'JO3N?JC^V)^VAX: ^_A2^'_#5W!>^)|A=L%FKA MOLO^(-
MX;1H|BTNF^76H6_T>-.=Q8|5QM.0;_!-,OXD06
M,Y'&|. ^B6WS/Y3XNRWB*6,|G.#Y4|)*_XKN>0^#O!_B7Q|XDM!/W@_2)K|4K
MZ39;V|2|D|CBW X (M&!@CU!-?/Y>ZMXBU62_OIY|V^O)MTDDK&225V.2Q)R2Q)^M?
*1=')8N\$%S5
MWIY1|/,^9C|'8N,%S5GU_E|/S)_%7BGQ'XVUVX|1^)M7FOKVX=GFFN)"S\$
MDD_@!^0)KN_V*_B8UCXU^+*2:9H+D2K8/D&0IR>2#Z|U|>#? GAGX?>'; M?
POX/T6WL+&W0(D-O&%|I=3ZGU)Y/7.:^@X?X.Q695?K_/NH|GNSV'?!^F*TO6ZU"909KA|E
&?XP|: ^\$OA_X?G|5^./\$=GI.F6NW|1J&H M7"Q0QY8*_SL0:DD
>YK+^'GQK^\$OQ:6XD^&/Q&T77UL|?:CI&H1W'DY';83 MC/O7@O| P6+ _&:_ (G_
+77_!/'Q|_?@W|4=YXBUQ;\$6%O_,\$#&_|AE?YC MTPB-7S+_&ZG!-_P#?:?
_X)^:7|2;3H#PO;Z:WB*XL7TS|/=+)N\$8<-T/' M44!;J?IX"#THJ/S"HP%I6F"|\$+4!^
M'OC3X9OM:DN'@CTJUUB%|AI\$SN0(&W9&TY&.,&NXX|+?V%_ ^""/I=GP/_P""
MNF@_M7^// ME; ^#|'XA:MJEQ>)J",PMYUNA&=HYSF1.*_V2,"@9QR*C6A6E|!#@T
/*@|T+G&"*9YW< MTKS!>@H 7:6Y-.&1U-1^+1Y^)^OP(&>FAZIQ_VVLJ/W4T?
6|)0:9;ZSHFH0W5K=0K M+;7%O(&25&&0RD<\$=\$=ZM5XW_,\$^UV?L0?"I'W?";?^E<|
'UO2 M;%|*9YWK|*7SAC.*_/%|*6HS/@G% \$E%_|X=,4GGB@"2
MBHOM|Z8I6N0!D"@ "2@G R:C;_' ZTGGDG;R4 <5XO_::_9^'^WB"3PEX|^,W
MAG1|4AV^;I^HZS##,N0",JS_|@|>M=NTR@9%?AA_P60_X(I MU?M=?|!1;Q M/^T|&_
EE>>&|2BTX6MU)J"1L3%!&C_ "D|?,#^5?N8/WG&*.1|_M%_ G MXC>(^?\$2|
_%WPIK&J!68Z?INK133!5^|=BL3QW|*|G0TCCI
M7V&T1)W*W2GPQE\$V@UWRS+%2P7U64KONG|WZ'C4|CR^GFCQT8VG:WEJ4M<V
MV'B+2;K0=8L8;BTO+=XKBWFC#)(C AE93P00>0>W%?S9?|%J/^"9FI_L#_M M?
V_X"T>X;X>^*YI+C0|D!I%LI27XQX6MKLS|)X+XH MK<,YHIW_'P#F?/W&
D'O7YG_MA_LF_\$W|BKX|:Q|"/BGH|1WFFRAK6|53Y M5|L R2QL?O#|I="""#TJ|E#|K?

XU_L9_%:Q^+/P5\5W%C<6\R&_T_SF%OJ,M(?)F0<,I&<'&5R2#7TTZ3K?
O:3U7XG\#9IE&O%FA76FZA:2>7=65\T_X./A8/BE*I9M?!?QTT\1XQJMBV\$:5@
_3*!F=!M*I*.54@'L!^4'
M\4\I)GQS_8Z^)=U\,/CCX)NM+O(&_P!'N&C)@NXS\UXWZ,/0YX/I6N'Q4*O
MNRT:W.W(. *L/F4QJN(7LZ|=)0>C\5W0G\G\6?I0\I(WC(>._@'\1K\I0\PI?_M/AC?=#
<+Z21GY7_\$<5^L_P"QE_P<^_#W7I)?"7\I:OP^DT6Y2.-4\0>'X'N+>
M<\B0R0X+QXX(QOSD\I" #^*.W"\AX@7^T4\2?_MVEO<_I^@^_/I#?
I:WAF'XE?!+OHC_VE&MO'?^';Q&#*>H:/.>Q&0:ZC\G
MG_@GU\)_@O.OB#7IO^\$BU5#^[NKN\$+%I'K'DX\3J2<I,5_) \ (OCC\8?@%XI
M3QG\&OB\J_AO4HU9?M6EWC1\U*\2K+IUQ@G&X'!P1R:_0+IFG_@YE_:P^&-
ML:Z\|=?!NF^+6#;OV^W_P!%NB@'.1RK,<9SO\!7Q>(X&RZ,.6(ITTY:_P!+
M8_",Z\|ZF%Q#Q."C&IKUT?S6S/W^A1845(5"A>0OI3U8#J>^*._^"?7_6;_M_9E;_I
\$L'PV\|VFK:5XJ;37N\K2=0M3MB\$:H7'F+E2_6(!XSM..U?81*LF_M36=2A*C+DDK-
'Y_CLOO675W00\$7&:Z,E7&.*6D3\|M+4G&8WC?QUX9^'?@_4_M'GC+5(K'2=
(LI+O4+V=L)##&I9G/L_*_"#X\?|\%/_!0O\I\X_R?!?|\X)L?_M"EK&S^T/_9<-
GI\H:KJ"1++OE;&4CC*D/M"G&Q3NY(K\H_VR_V?M0_:H_9<_M\(:SQ9;.:?;6>H7UFEJ^G)
UOYBH\G(\$OG)D_C/E+UH"<_,'XN?_MMX?|\\$_|#=G'XZ^/.H>*M/TO4HXW6\USP\|%+:IG#
|'P3"-R_P)R,XK\7/\^"*M'_!7/1/\^"H'P9U" T\6Z+#H_Q\I
(+ #'XJTNU5OL\U&XPE\YZ1NRLIC)+1L,\$_MD%6;KO\|_@J5^T1^R"?V*?BE\|*?
B=|7_!K7VM_#;6)-%T:UB%I+NZ2TD:W,:_MALEQ,J%)_6D16N+B:YB\$P7?
U""CJH4'MSSF@/LGD7Q+_M&R?VK_@_P#\&|^G_M;W?BJZMOBE;>&-GO-2U:Q7S1-+?
QQ.7B90,I&(Y%8_M/_!N_P43_:I_:ITWXE77\3/CB'6I/#MQ9+I?DV\$<'EB17W\I
YQWKV3@X_MDBV?|_A0BL1UVZ7_.G*VKXL_P"#/?C0_C,?^GK3?_09*^R>J?|\(G_4P
M_:Y_X)^>_/A/I7\,GCZ'18?%&EZO-K"S:?'-YKP2V@C(W@XP)7Z=<|I5\H6_M_:!G_@LS_P
%%K^W^'O\|OPRO+./2-%AAUZ\T725N+B6X=%62YEF<%(@7!**M-NXYSQCL_|
@|9"_P#"QQ@.#_T!?\$'_*.L*_2?_@B|^REX(_95_P"">WP\|M\.^&=#M;?5M=|.VVK>)|0A4%
|V\F02,Q;JRKN(4'H*LC\A/A#_P<%_1%0_VM\$OC0GPQ;E\W7B*UL5CAUCP_P"(=-
%CJ4;,:L;@_%MC9:RQMB.1O\JLNY<|S7KW_!MK%\7?\$/Q0_X)6VWA/7+6-('_Q
U;P_ILR2\$O_-NMOJ6Y\Q\H0D08X"QI0'_MV3PGX??\%9/VV=<_X+_M^PYJ7Q&MV^'?
_"QK_2SI(TV(-|FCLYI\$7S;LAU'_M/600_P#X*Z?'SXH?LL?|\\$^OB%|==?@UKBZ=XCT'3XI--
O)(%D\$;&9%)VMP>#7_MXX?";_Q%(O%TBV&O+HZ2"#36MXDBMK>"/&^L=+U2:6-/\$_?
AN-|!L\$.8245=F)8V_EAF^V+\$SV\|M)GHZS*A7GK0.R/\$O^",G_!5;PW_P5\$^_%QKFL:-
%HWC\|PJT-KXRTF_N9'=<MI>6_)(ADPWRM\|R,K+R-K'X#_. "V'_!9O\N;|BO_
(*1:U\#_@Y\2X;#PAI=MCH\|S_9K:7#(Y\|VUBEE=AG))8_C7AG_!J-
X\|2>%_P#@HWJG@6PN?|\!0>|!MZ+4H6)PWDLLR\$#/4,O7'0GUKDA_@Y1TF7Q!_P_%D?
\$F@P.JM>:7X?@5F_A+MV\$*Y_6@+>|=M^TK_,'#?_!3;|JSQ;?77\|OA740!_A","*TM-
%T4WEX!QEY_MIMK+OR,84
'OUK\8\VT_P#@J5H'_!/_@G\X+^_0Q5T:XU\QGXD.T.QMM&T.
M3\TU_J+6R/*TK8_=HOS,QQ\9(%>Z_L3?L>_"?|_8K_9_P##OP2^%_A:SL_!|
M+TR&/5+Z&(>=?76P>;(-_5BSY//!%?/?_!8\|_@C\|<_1%5O^%>I#|9SX3C\#
M_P\|J%_H6LS,EVUW\DVD@\$8*?9VY/_#T/O0'NGY?_|\X*_-?|\W_!2*^U7Q
M3^RY8;G;Z#'JCNK>&|CCM;+@\$6_GR@|CJ\$KC6X+2")-3\.>)M*%C?+\$VUA-
'(H'S\3W\4YQQG(<#|D3X_-!7_M\|AO\G?
PI^S;HWB_0;4>'=+C@N)VN8;=KR;^*=E)!+,WK\5^2_P#P=;?\$?|D_
MXQ>\$\AWXH^%7Q1\.:|XVT'Q+>:/K5OH^H1336\KY3,RR>?EE0+SP"3CK0+Y_M'ZO?
%/X\|^+?BW_P3U\!1?M%?L>&4M?UKX8W6L?#U;2W\$TD\X\FTELBO_Q,7*_MKMQR:_(%?
VN/^#HK;_R1SQG_.\$')_|\\$U^FG_!!5IKG_@DU\|D968C09\$4_MLQ.%%Q*_H/2OISXN_%CP-
|#/AEKQQ;^)>N1;H/AS39;|5+R;I'&#I8GW)Q_M@
X.LC3H9;GPG\|^C:A\JHEC?4&|(_8_M(|<_M^>%?
@UKMC^RU\&_A\X\|^MS\|1=:OM5USQ3>:/;ZE'XO?P\X4MM1T\|S_U
M#XG>#IOLEOI%KH4T3)I4D1EN9\|M\XDB@|(^,WP=_P""EO\2WQ\$^#OBWXJ?
M#PGH1^%WB""ZT^|\|&^*/_NFA:|US0=3OY\|+|XK>(+BY:T_L6*6T6S\$\$B;|I
M@".=Y(|EOXG%RBH6:Y>9*VFCM?>Z3\B6B3LV\W09Z_/LUI^CO\|G.2?|A7
M_@H+XX_9RU266S^\$7Q\>TO?AW_-O/A^T3RLQ:6&DU\X97C1QI
M+J6L)IEU.1:VT!\$^AV_ W#_P_%.=5\02#^T_@W^RPL-M:\$@RZ9J&J>\$=3N
M(M+B5ANM9W\0?\$9\4UR&5HWBU;PIX:%J\O&D+#T/_@LOX:)\0_"KX5?\$PZL^MA?
%#PO|_!\$!&7_@9(=4U+2\|L+G5M7BCN;62&ZM\|O=&TG6+'5=|)IMVT_MEI"
(KK7\$E7T+_@C_.&_ ^G?LN7GB;P\?1ZEXP\5^/?\$!^ (LK(!>:5JFB.EG

MH'A^63P\1VS/SY_BF^,KTV!/?%R|\$ M^,\FEZ7?_# 'R\X\ZC_,%&?
V\OB+!*/%WBKQ%I7P#_&>XM=LTT3P->1VW MVS4O#>J6?
A749+=YX;NQ36/\$GBFXU*X;6Y=.N)X_ "FD+I=J,P@O*YGIJ#X# MO_+!-
#XA?!OIH?IG7Q#XOB))ZKXE?PQXY(ZIK"7UMJ:PPKJAT*>XAM;_7^
MC^)\\$M=;1K;4XKFXT75M-MM7TV\%R;7^S?2/^"3CM??M!/?MG:I=AFOYM%I'
WVWQN\))S0D M\I(W@[XA6\8Y'6*>3(YXYQP""=||8?
9LDUT=TFVUW;>^/P6L6^JOKUTL_P#@_M>1Y#_P
%G=5L==^#'/\NN:9,+C3=9\6ZJHNGW &!8ZCX4MKNTF\["6":_P_ MVZO3\A
^":%K\>?"DGQ&_F^+'CSQA\;_&FA)>PWN@ZI96?@[X&O^P:H_ |
MZ;K:INC77L^JO9V0)7F\ZZ)JNBZ?-^A^_!&GX@>+OPO\<_@
M\XCU.XO*^%WB'PS?>&X;BXDN8\)'B5_%EEX@TZODF)-MI8O_#%MJ%O:1\(%
MN\JOU*Z6-);J=G\1^#GPQ/_!47\H\XT_%'XO>*/%\$?P8^&FHPZ'X\+;:'J"6
M.GZM>ZFGA\3K*:>"\@T^%= 'T3^VO%MQ:6L_ JVL:K9/%=0VZM'#I?!\\$M+F>S
MO\VIKRV9EN;72-*N;=D)#K\!+|6Y8F0@\$AA(JE2_2"!@5\^_|\\$/&?I%
/WQ?;/XHU/Q7=Z1;WEEKT&C6BP6-LNH?\$_P7*UL-/EAN M-
R65Y'YLT@%T&W1)=K.D;_7:"3T25TG+?:X+:%|5KIOMM\WY'T7XL\#R?| M!;+JK7X*ZA+
_-%?B:Y^_7QUO/\!|8>&/\$FH1WR6HM-5TK2-=GG>VMK.VNY?# M4/B/1?\$_\$AW4GMH-
615U'1;B\GL9\R2_ H"K^_F?CI_P4H_8F^&'B+PE\;VL;SQ'XB^(&C^%O#
M\|MH=MJ'AY!\TCZ/_8GAFV\$JE+X:FUMEDL?WTXCUZ,M=_/&8X?W%>6?!\\$U/V
M&OA5XI_!W\J_4O\$WC^V\>Z/X\1:K#HMKJ7AR+P:TWA?Q-K.AV2W%G/X8G
MUDP2VEG'+>!\>C9IS(4D\$16)?T9_P""A\ R9C\?O\ L4+7_P\2+1*|\%_X)
MYW;JE_P3BTR\MBRW-IHGQMN;I+IR1Z?K%\J:Z\IJM+*L;2VO\7US5K2Y^V001O;G1\3
M>!\Y?^"9/\9'P6E^&_BGQ_*O#OB+4(\U8XTUFRT+7OM)M\;SMK M^7PH->T3Q-
H&IM;0;K"LUWHL\S-9W%)\J'M/_!%"")?@M\8+D*!-+|4;2"1^ M\16_A/29(E/?"-U\!7!
M=#U\6:SMVXXW*I/(\%5_R\|F_@LHV_P"W4T_6^M^@K>|S==|_#L>>?!\5W6
M/\%GA\|L7\F?7_5F=0\+;_ ^*.LWOAVS&GAE-;G6(M+.'|&&4W_ R0PWyK\;_92_X)U3_"
|XB^&/VE?C-4?%_C?|:"C?7;UJW@O M-/E\+1;MXM\;MXIZ%9B\|@MQ!8R;?;K'<M?;?|?
9+?!\%'\V%&92C-KOP7)0D\$J3|=I25)'!*G@D<<5^Z\3*34():7CKW:U
MTOV*M>3;Z\1?);C7=(T>21E2-%9W=R%1\$4%F9F)-554\$L20_23BOYXO@?|
M"IO^"HGO_P#CA7_(S>)_%OB#X2N_&PE\2;KXKN\|
(M\ZS\1OZ%I;+HNNH_\$GP7*UHFF&SN59+"ZC\ZY
MF'VPMF&)4U\LY)I\1)MVM=W>K\OU"6\5NG>Z\VV^X^B-=|&3_P#;|;?|;_ ^#
M\$7P\|5^)+S\G\X^W4>A>*/#7B;_CO(\22/5M-T+6KJ=K>VM+2\G*?| "0;#
MXBT;5A:0;LMI+?;# =3SVD\|S-?ZOP^4_L#?|!1\6\AY+G2_@9^TS\|E;PX#B+ M2M*N=?
U*ZD*(@55AB;PGXRDU;P5\$DL_ ^A^&=>AU;)\L)KS'HGX0_|\%0/V MK\A
A\#|1OV>O\^E2_#N\UN^|S^#?%/\@/2IC/KW\BF\Z^J?%S7/-6-M\|L' MMA;BU:-
Q*7:7<@C^Q_|\@L7X2\|W_P"SMX8|=ZOJ":3X\|&>/+LOA_<1*/M MVK/XCC<>(O#\|
|LTDTU>Z\5Z>2TOY'SY\5-"7\O\|_@HY)\;#>WS?|O\G;1-2TWQ
M#?:9)\$%%_HUPJ^(Y+1\B"ZLUU35?'UWIGA>1)\$F2YT7PQ+?);RK;SH?DS\HC
M\B3X7_" +|M'X\?LX^'?\$_\$CV_|\%_%6R^'=SK^KZUJ/AZ?Q18OXN^(7BCPEJ(T M>|L?
#.GZ3"EOI^B6L\|D+W1K\|>27#SM<0-;Q?H+_P\$;M\|'#X&_ \$+QS9;H
MVL_\$CQ7\1KNT^(-S>;VU2QATBRBN?#EC//.EQ?07<>LZIKW\HLVVZO\7O\1
MFDGTN5AY#^V\ P\I4OV-?^P5\|\$_ _%=GQ\IQ;4G\!2;6K;:L:OYN\OV'9-7> M\;?R;2MTZ?J?
0WB+X1>_P#@E_|\LO_M!?\$'X0^(O&FN^(O%EGX5T_2|=7G
MAW5#8^*9+V\|>'KW3X=(A-Z!;R1Z6WBF\UV^MK\|+Q+N+2\$A38IDCF^=/V6/
M^"9WP_|\CW\|M*^_G\|0?B\XD;Y\1OC\!|=^+(KW3_!%;# +I6F:E<3C\|2NKK M5-
+U;ZUS7-5M%AU\JNM2EELDBO+;3X\|S M;37EY\|&_P#|8JYG@_9+TZ*\$N(IW
MXO>#K;Z"D\3_FB>+KQ1)\@\$%/M-I;D D#S ASD 'Y\^"_QA_ ^"KFD_!\X4Z9 M\;?
V=_A+K'P_T_X;^!\P-K&H:CX<34-7\|6_AG3(O#FJ7Z2_&O2I5OM1T=;
M.\NQ+I>G2?);H\;L+|\V\922E*3O)M)M)*RN_R7S#\5FKI+32^|O\G\ MWW^@?
|SY'WCGX4_'#XX?L_#\$Q'<^)\#X82;GK'PSU_>7S;?1M)U2PL\K3 MK-)Y)Y+73M9T?
6\|2Z?HJ3-;_*FM);O*ER7'QI\AU\4_B\ P41_:R^&? MPT^(MW\+=A \$OB;XKA3_-%FD?
+XEC^&MA\2\|+J;5X9F4\|+;ZKK.MW/A_3S M\|F;A\0?LO\ P'_;F;M\|2_P_?A'I?
@BQ\4;+KUGX MKOO#WB3P=/H=M.O@;#PH\$=KHVG^.?
%&N\$7ESI&EM.2UV@O99;IVM\|+;W M\;^+ AIX"N_"!|?E(\%KXN^).E:0;>|BMYM\J;
NJ7NO+;SAXIXM)-O(LBR% M&^=_^"S_/R;SX)_|\+OX5_|\4"^)U>)_|\%KF>#_
OC_LEQ1%Q'>2_L_6\U MM/RM"GP+|57;H^#D@W-M;N;@KNC&2&V92\|H0YM7SM-
OJM&U_E^@W\O.UIHOO MU78S_P\|D\ _@F=X%^_P9TWXW_!Q?|\1\2^ (7Q;2^|5Z?

=:7X@Mf6YT?3[^ZG M LG7+VU/3=7N|ENKZ=[-::^L[3f\$;B"XNI. V0O OB7X9?A%3?
M\$O@'O=XTQ B)KGA7P[XJTF7QGJIN#JFNZ=#X%TAM"N-2-U/=7!OX-!DTVRO#
M+=W9-Q;28N|E<3R?NA LUVT%E^S\ K2V"BMW0@M\+8(=@PIBB\#Z\$B, '-
C2U5:MX;^\$'P|TVVU0Q|-%D4-?ZC% MH-0XJUC57CD\$EI>7|M!J>A>\$?
#_H6Mf:Z|JUQJ.IK;7"W%S!+R?|7/|&.D ML->&/'O|47|+7B_OOX|9|>PT^6>S
MN|5%CI'B#0;|KK2=8L-479%9&TDCOO'M-|3_+2VC?|!2/|J#5_V9? WAOX MA?\$B.H??:
>Z/XMN+"&PM/!L'B;PK9W&IP2:AXN|'0_-|>ZMM LH\$759H:W MLX73W17EM?>OCI;
/!6+|H3X6^)_A%XY_9N^&EIX8|5G1&U&Z|.Z|X.L=:@ M;0?\$.E>)+-K&|U#XTZK:P%
|H|&Y.EA.9+.2YA3R|)%FC:NG#WHJ-HMIM*|M|-M|W|H|A7NFI-
N|LTMMK:KM_GWU^F?VT?VRM0|_L.>"/B|.;V7P_XN_:M!TSPKI?A^|LIV&H^\$X_\$.@3:
|XMN:Y78|>H.);6=YX=@OX'6>PU6_M=1M7\$ MMM'(/&/@?
_P27^'|>M?|OPGXQ|=>.OB5HGQQ|4Z)I?C5?\$WA_6;6SC|#:JL
M.MZ9;VU@|BJWJ%YH|DUO'K5W-K"7=|J\$5Y+I=_L.ZVGA^-_VW?_Q^&'|O
M|'"PN^)|FDS>&_.B3_&>U|0Z3|J.F:J.->#Q)H3:*'OM&O|4M-N"VA:M%<1 M?
9;V=88Y&@?RI8Y(4_IABC@BB@A18X88TBBC486..-0B(H|*JJ%|_"I;<(MKE>|I7:W?
*TEKVZVVU|RDKMWZ6T|:)O3U_*Q^_G_2LTG7M_:|_:PT+Q3K
M9|2^)|)%M/\$VD^(_\$;_>8&U_7M.^)WV/5|;83?00=5U"&XOCY0|S_S_FOW_K M|*O^"<_
_"I^W%_V'_B/_ZN6|KKM800^"SHU?5|I&C^!6TD:C?#2V>7X)|S MIPN9?L1?
S|4\$VXVWE%O. ESGS 'R*)1YIO6*TCN|?96PH.RV;UZ?(_>OY78 MO"_QN^(_!0/|J/X?
O6G|_U|4/&/O8|&^_/%B&XB/ACX;A1=,U_Q1|JO
M;1X|JR6670=,TEOL|I|J8U/^P8989=72;A_87|D^Y_X*+S?\$Z|3|JS3_#%K
M|_QX2U5K.31W^&S79|6#4-'&EH1X2OKG5/).GG6"YDC%GN5/-82^0#|>_L1?
M|H4OVR0^P5|_O_5V?#ZG#W>?6+M%/35;_H.6JCN0>7|J9W|0?POT?_@F'^S+X MMTWX-
>/_!M|7Q*_0UOPCX+UCQ|JD^DZ>VAZ3X/T_Q7J6KZSX-M_)TZW0=#
MN;FWUZ31G>ZUC6;VS_M>U0=,OK.HL%GE|#!*_P#!';X6:G|%/|^*O%OCBW^.
M6L^&HM700\$4>IV?_C^B>,+^R6|&F-H;Z7+|?Z+IU_*MEJ\$|U|NKZDL5S>V
M|WIDEQ#;6O'?A%L)M0,W|*|C8H)SUJM;^?74|!_X)??'|Q|4/A?XY^%?Q-U*|U;Q MU|"?\$-
EX>?4M4N'N=6N?#&J+J4&D6FIWZ)J>@:|I37KR/(VG1:3#. M6FC:XN/F|_@BOOK?
|7|/3^U?A+_Z5_&"O5O^";W|/|2GPE^,?OY|>_/'X=1 M>|;3XH6\$>K1FS|1>\$|5TZ?Q%
<>*,|6;JSLK'0/\$_B&|M+:VCU2|^RM?N1!'B M\$W4TK,6^?O|_@DE"S^_DL10Y&&\$B*5.1@
MX:.'9JK:VOL|K6NWK:VFX*|X75K|M|")M(T1M;+6W-I:QZAJFKZG9 M&*Z@M@\$AV?
&'@:3_()@_M9?|35/AKXL|37/P#^_5X=|8^%_\$NHI?16J6>J M:3L.O3W#6UM9VMW-
XC^(_#>I:PZM&8|1T6>|GT^XOFO/G/_@GWXT;_MD|*^!?'L7|*7PD|"?
\$+PU>>+.,3Q3J7BN|TFW0+'7(M'@6VL;9=1^(_@J1K; M|_|=QF.RO\$ \$LK@W2MF)?
6OVG?A%_P4_&L;+P;9?\$G|GCP;I:~!;|5|0T2?
MP9XA":3SOOUZB6UTGS7;09ZZ^7E^OS^R/^"F_CSXS:YJ'P=_9>^#D/B'29/C M5K-
K:~?%NFVVJ6U@FFZEK-OX?T3PY>:_90-'8Z5>7;ZGJOB|+B&Y?2=,L| M>82Z7J%_7/B?
Q|_X)0_";X7_L|^+O'OP|9>//^%H_"OPC|/CV?7|4U*P72 M_\$#>\$K"37MW>JD2SO|
IA^U!^UG M|/V3?AY8>*_'VC5/\$NMH|GX4|#:3_-FM>)|7MK>&2|"32>9!INBZ:TT+:Q
MKDZ306*3V|-O|?ZC>6&GWGY1>A Q;_P4=_J^#/Q0^)^IOH/|W|/5G|?&
M_B;:PQ|E;3=9|=^#|_|+Z|J-YIMJUS8ZGXOU./7=(BDM#J%|<>\$O#&KVMZ;R
MPMKBW*1#.#E96:BD|6W|3OM:S;.:6G;T*:5W>|;Z+IMKY>O|P3|_|P""='Q| M|6?
&+|DJQ|6>.+|H2>*OA_JOB;P7J>K7\$C3:KXD3PU8:~K.E7-Y.V^2YU23
M1=8TW3K|F|RYU"|M7O|IY;JYFD?|OOV-_@1X?|^"CGC;XX?&|H7QMXJUS
M6M(U71K'2O"^@:W'IB:~:~^NKWMMY/VFVU"6Q|.Z7%9#3/#FEV,=M;_>9;ZG/
M?/>3D|OMK_@C/_R:IX|_|+?XM_|4.^'E>&'3|B|H+|E+XJ:W^TM^Q|?W=
M_HE|>ZCXG^%EC;"^U#3|'"N?M^IZ);>'&_<>-O|DEPIDL|*M%3Q/H;4:1%
M+M"EUB;Q:K=_I<=AX5U">POKC2;MH);G3X;CQ9::UIA M-:TGAJP\$FJZ%J^F:
|J>F1);6\$>G^+_&K3=>_;;^_>UC|FS4/%>NZ%|_"@7I ME|?>(:#0KE8)+^|T1-)LO\$>I+%
<17.GMXBN_%6OVOA73|V_M|U=)T2RN|ZOL M_/GU&"|_XOV*_P|OWP7^U7%
<>#M:S^R|/? M"OO\$|9WWCSXH0>*,+Q=-/!<1E.HP6=L4BQ;PK"H M"VRHOFJDIV?
M7_LP MP?|!RY^&G|3O|/BGQAIL.G^,K#PKXS|+^(-875+#5;2_M;S4|>"|EM|_Q
MDN/#VL1:/>Z1KFGW_P|L*75YI5_I,MA=VRRQ_O1X)|5Z9X|&>\$?'.BLSZ-X
MS|:~#XKTEF(+_IGB+2K35|!F(X+&UO(BQ'!.<5^%'|OGA_|X*L?M+?#BZ^%_M_P
0/V'KO5M*UE|GPQX@|1%:~J|=YH|SS6HBN=1^,VL6RQ.9'2=6LF=
MXV*D&3NK|@OV6?"7BSP#^SG|&|/CK3GTCQ=X3^'OAWP_KNEO>6.H-IHI-MDEE|D-
|HMW?:?<""*~*,26=W<6Y"@1R%0)G|;M.5VFTTVUTO;MKN..|232 MWU|H?
ZN|CWRBBBLRPHHHH *****"BBB@ HHHH *****"BBB@ K|_P!BB0_

MJ_@HS^UH"=2Q86GC^?6O%?AB%P8Q=)8ZT_C;PO9PH2!*R^"/&VK7)E0;<:=M/M5
Q5?W\$K19/^"E'@;Q\&_BK|SOV|OAYTES??#K7=\$|-?SBTM@T:WFC_;
M)X|&N;V2;R|37+'4|;:"M>N/;6/5/#MI&3|NRX;|T?YE9?XKIK|58F71|G M^'7STW_
%S_@M3_R;W|+_P#LLME_ZA'C*OU!^"? "1GX1_IDQ|!/?^HKI->/M??"JGGX7?
MN?"KP%8^,M4|=Z+X6DN|&^).@R^&YM;|/|SZEX=O(+*WU;V1 M^'M=^R@;?
KLK75@|C;7MO>QI'),GE2Q2?27A?P_9>\$O#/AWPKILES-IWAG0M M(|V\$MZ|4MY+9;-
HOIMK)=R0PV|,ER|%M&T|Q6|\$3REVCAB0A%3?NOCU3E? MYV_R!)|S?1K_"R/P_
."87_)X?|;?_87|1_|JT=;KG_V|V|ZY_P40_:_MCU?XIO:2?%BSU0XB+X+@UR2|/3;WD?
CB|TWQ\$F@QW>#_&CIGAZ*TTW3X|/_M \$BW|,|JB6R#3DNBGZF_K|CGX8?L^?\$CXG?
%'P5K/CG4?%'Q8N;VZ|1VOB; M5-"O=
(LY+_7KKQ#;NBV^F>&M&O+9%OKN2;,7M_J++;JB,SRAIF|H_:4_X)N_M_O|;|8R?\$BYO|
Q3|.OB|!="V.K;_X*N-.CM=>GLXXX;6_UG2=1L+N)|5MX M(884U+3;G2|F9(HS?->R1Q|/?-
%N5VTI1BKVO9I+=M'L2HM);.SO;77;|=# MYY_X+&?\$_P
!6WP(T;X4MXGTN7XB;KX|;.>(X/"5M<+GZXESJ^I6_M&|Z79/-
>6T%D|^;=M1E>46"7*6EZ|O|W;_|HJV_|,=N_P#U2|U/('T^|2|_IH4MWH_|X?T6PO9
M!)#J"PZ%-J5_:3&"JU2Y;-M)!|C;:|O"6F_|L|R?LV#6/%5YX'D^&^J_"W^U
M|R|TE_%R>&=5TB|T-G2_@T2WT<:E8Z=>&&QN&T%K9#;V|7%G;?_\$R>\$*^=M?
^"5|+K^U1^V5I=Q+'#J4FIZA-'8R;JW3Q;?|1?=\$O?2)"3O9+2>|M(KAE! M6)
|F!7(C;BY_6|/FW|G'P-^RY|)OAT|/=2|4ZKH_|B/4O\$|W7B^_TK4=6_M# M5;73K2XB6XT?
1=|M!;)%IEN88S8F57;4O/(&54^2?BY_P2|^\$7Q(^*VN_%_P
MQ|0/B5|)O\$OBF_O=6|10>"_0TZ&QN=6U1GDUG4|;.>:R74M+N=;N)|K58UU"
MYLKBYGFDAM+999\$9|T9.=VTIVL|7M9IZI?YB<7;-M7&VG?;_"|F?_@MU_R)
MG|/W_8S^/?|TU>&Z_8_Q3X83OM|+O\$?@R1D2/Q=X!UCPP|R9;.)K_AVXTIF MD
!)15NR7P"=H. 37RK|4_|@G_|(|C#|*?A;|(|&7BOXH'1|@S97=IX>UG2_M|<|.0>
(M8;_M;_VN|KQ>:EX2U:TO)Y!91RJUE8Z>1(AD,N1M^XK>|+;W@M
MHRQCMX8H\$+D%RD2+&I8@*"Q51N(4_G_|O4MKEBEO%R=_6UG^TG=M|;.=K(
M_%K_((X>_M-T7P5|8OV?_\$;|6C?\$3PI|3=1|4R^&M1FBM|5EL|S1M%|+ZS#
M;VCN)+EO#^K^\$9(M7%N)/L;FIV9G*+O M@_CZO?
Z3J%C<>1K4J|(@GU#2KW35O)/;N|1MKV^FENFI|/FI_|()^_|HFC4;_M_P
5>&)/\$WBCXCW|E?V4?Q\$|7W>FZCKFAQZE\$|_Z_AFRBTN#1=+N)T=A+>W;
MGZEJ4|;SVEQ?3;:=7-E+3<&W-W;?V+;U|)?%?;^OX!;6B|;=|J|K6WMZH^?
MBRX_:_E_X*4>\$_A) 1JOP=_9K%W=>+(QB?3+Z|V7|C>>-H|A"&1AK?BU?#OP
MZOHMRL;+2KB|MR;.3?|@+=-^PQ_P4(|-?>N?\$.|L+KQ'XB|ZMI&M;W(-
/DOYX|:VN|*T#0\$BM|F|U.|OK MXRP3W%|=M%)<3N+;W2)?VE_V_|A7^U-
<^|M2|=EXU-;|V|+R^N_#?B3X?Z
MMI.AZ|"+Z2QN'MKB|U30=>22WMKW3K2_L#%!!O-OK;W<.5|;W^7;|NWEH?
FA^Q)=V7P)_X**?M5?|;Q3<0;-'X_MJU#Q#?|_@M+V1;9-
8|OO.WC#PM86@E91+>;CX*|2W;IV|4>=>MC*|?P|AB3ZL;/3-&UGPOI236<;^;\$_
MNN:QXM6WTKST5;ZXTV|%NS&RGV?9_P"TW^P9|&VI3HFL^_|CQ)H/C_P_IEO MI-
H0_#-QIEGKVI6-J6DAMO\$5I+I^FZ%?HNR#5|'2;" MR@-QK-
LA(M+W5;W48|&017>GVMG?V|%W&*4;J;OS)+W;;M)*H=/D*SLXVF;
MWOLNUMSXO_X^V>%1X%_9K_94|\$!HW'@ZZ@|*AXL^4X|/>M-TC='D^6WV/* M9
TC(|KJR"G_(K>&O^P|H_|INMJ^?/VH?V2?AM^UKH/A;P|2-7|;:/9>\$ M=7O-
:TV7P7J>B;:=375|9"QFCO7UOP|XBBEMUA4-&D\$%O(LG+2LOR5|+Z?91 M;866G0-
(T%A:6UE"TI5I6BM84@C:1D5%;0I&"Y5\$4MDA5&-(O&*ZIR;^=A MI6DWT;MY|A
(_"_@D+86^J>./VS|O\$|RTU&|(|(6%TG3?;WFK_|2MYTY!
M'S12;_AZJ*W/^"1GB*T^&7B|HHS|F?QG>6ND>A_0O&D6H;?I5W(EK/K4WAY
MM3|;*>TTV*9E>Y?37T_2+SR8C))+8WYO(5>WMKB5/T=_9M_8Y^&|'+>M_\$?7
MOA|K7CG5;SXH7.E77B"/Q?JFA:C;6DFCW>NWEJ-(31_#6@RVZ/+XAO5G%Y-?
MLT<=J(VC9)6F|N_:9_X)R?_WH|3Q_\$_.9+1-3|2^"Y|/CCUIK" M*.WL;K7-
+U&RNH;C4K*VA@MK?5+"?3;YH(+>*|FO(|:U6"^>+B'25NTF22VL+Z1K<*|O;?
T1M3+"MX8(3=K;_|6ZW)C7SU@:0"1H1+N\$3.Y3:6;-(KX0_9N_X)U_?|G# MQ00Q
L)/\$OQ#^(T(G^P>+O'EY97LFAO=1/!JQ1R3O6=|:P7_|GWM42Y=%'6V|>C;?
ET2Z?;I7U;Z|+M_7W?>?&G_4) M_P"3;?C|_P!BA;_ ^I%HE>5?|SP_.M|7_&\$O
DWBEK35+KXH;==*.K6|HXY M|46TZC/&3%*PY|;^U?C%|*#OQN^&?
B_X5>+O6+'P|XTTV/2|5N_#|S9VFL MP6|=|:WRO87.H;?JEE%-YUI\$|:XT^Z0QEU|L;5=
<7X|? WPC^SE|+M|^\$G@> M_P#\$;I>&_#USK-U97GBF|TZ^UJ637-
8O=;NQ=7.E:5HMDZ1W=_;B+3H2EN ML:2-(K2N^9*OVD?V;_%|S:I7C

MOP|XNM=3M=&NI%M|K4I/#\FJ^%O%K6,\$K+),-+GL=\$FE\$:LQMM1CN 6A1W6A M_P
%0+JR^-O|37|D|W|-WABXAU;7|;6|N;Q1964BW)TJ#Q|K?A2UA&J"%G-G+
MIN@^&-5UV|@EV3V^CW4_-+'|GN;>1_MKH7_ OR?_JH_Q@?
B1V\$.M^R_P#|\$^O@E^R|XANO'6B7/B3QU|1;JVNK2+QCXUN;&XN-&M|I3J*
M>'|T^RLK73YM2B)AO=1NFU'5G@DNK2'4(+&|O+2>^>+/-
|2|_2|H_N_X'PK^W|_RD>_87_|#_P &/_5|S5^ZM?*7Q>_8|^&/
MQI^-7PI^_WBK6?'%CXP^#UYX9O?#-AH&J;':>';V7PKXL;QCIRZY9ZAX;U34 M;J.75&,-
X+#5M-:2Q_=00;S_.DU|6U\$D|J*5_=5G|_0I=?_HE^AG:OIEOK M>D:KHUV";35|_
OM,N@.2;>_M9;28#D<^7*V.1|;_\$_G_@D)XHM/A|K'|0G|_7 MC"|MM&^(/A|QT-
6M=\$O9X|>YU6;2(|KPKXLCTV'"5EDN)=&N=\$TN6ZC16D-KJ M_-Q&K0PW#Q_N/7Y|?
M+?|X\$/@;^TAXP;XCW- P'"*/AU0KD6PU7Q#X*N-/CM MI?
DLXXX+6|UK2M0L;J*35+;WAA@BU/3KC3+J6**);Y|TPP&(BU:4972E;5*|
MFGH|=M|VU\$T|&M6NGD|S)_/:;@UK|GWQW|*?A-|)/#/AOXF_%3Q_JRV^I>#
M|Z|O_M6EV6HW%CIOAF\$ _V5I^)-4O)18K=QW_%E|O<26R13VLTGQO|MM/7-U^VI_P
%/_A5^S%:/M^"P4S|GQ_:PDD;39;^&.PUSX@EI58,(Q;P:# M|/;"2>)Y|,U^&U%>(|J85|X?
LV?|X|O@3^S;XD/CW3)/\$OC_. (ZI<+8^,O' M5W8WMQH37D+VUW-
X>TVQ|+*PL;NZMY'AEU*|75-66*6YM|;4+>TN|FVE|_|M9Y_8U^%O|_WB_P"
(GC_PIK'CGQ9XS^)|WG>)?\$?C_5="U;4E;:5+W6|373Y= M\$|>'\$_@76|6O\$O|
5_M\$=VUS<6&GM&T @82OFC'X5=J+2E:S|K-IM;|/=GU_X)^;GA"9A"O|
@H|J_@9E71_@1^U(MG=:'&B_9M&T/5M; MU&|_|+2%(U2TME|_|^9=5|+1VYD2+3/"?
B;SU&Z"JL JE^W3/#I_P#P5%_8 MVU&^E2TL%T|X)Q->7#"V1T^-
OCI7#RL0D:QFZMS(|E4C657=E7)'Z@_M/?L MB?"O|K+2?"6F_\$>Y|5:1=>"=5O-4T#7_
5J.E:7KUL-2MHH-1TUKO5|U^V M.FWTEKIM|/%'9O7(O-*L)8KJ)\$GBGXO|H|G|A;X6?
M2>'O'!%AXZU|QE9^+|A_M|:Z1HWQ"TZ|TEO\$FIV;PVJ7D?BB&72H&L" NK5=4E-
M8:7);ZG+=2Z9)8VM M|>V=PU_-XMW3Y7&3WZ64O/S7EH.S2:7=-: ^:=O+;3UU.*_X^C^
K_P=?LE=| M^P%|4_#7Q_9_ ^#<^C:I8W%|X'|#:#|/O\$VGQW_)O-
#U3P1IT7AU8M3MU;S+ M,WVGZ9:ZM9M,JBXT^|M|E&97)&Q^S5^R/X;_&
<|&|=;2WCWQU|5S|0XM'L| M? ?XE7ECK%JNF:);:Q96^E6-E|CREA=6^N7T6H6MY+_M
/@CQ^S|K?B;4M;|>.:?B=|V-%UB69K_-);'|J&D7^E007#EI-/TJZU73)H1
MM|P2\$MM5N=;V9*B3R@D2)./*XMNU^922|D|J_W?T@L|_R6K5FK_K;|ST_X M5?MO>
(?C1^V9XT^?PZ|_|>&/\$GP<|Z?J-SK'Q/L;K4I+U)=(TFUM+N2UGBN
M)M#O|2Y|=7.:%IDD"(+|2|>YU6TEN85WCX^_8B_Y2I?ME?|_8*^-W_J|A|7 MZO|
|/'L.GPB_9@|)W'A3X5:%-9C4I8+GQ#XBU>Y74O%'B>|M8WBMKC6|4\$-
MM&Z6J2S"ST_3|33|)LFN+J6ST^":|NY)^.^%W|/PO|A)|??B7^T9X:UGQS
M=^./BL;^*+;Q%IFM:IH5SX6M\$|6^)|&|6:FVCV-EX:T_5;9XM2T2TBLC>:WJ_M"O6
=,^'7Q%U/Q M9I.B:3XLT_QC:W7@|4-)TW5&U33=)US1H(9I|9T/Q!;:8O:>(+UI8ELDG:=+
M9TN8TCDCE|5|*^ O#_A3X>>'AA!#)K'A7PUX+T?P%#;Z^MIJ\$NJ>'|T.W|
M/1PZTB6M08WTE|HUL\$U)5L8+2Y:68+;Q0N(52E91MNIWRLOSL_J|_)?G_F M?*W_3_
/C-X8^*/|)OPKN|36; ZG|O!NE> ?&EE+>0+=Z#>^"-/31(+C5 MU>4FVBU31=-
LM=M|N9A%-:7GF;ZRQ7,RZ?<@".|M1>Z7>K;WEN9+2|@B%W9S3V
MDL_S_3'B+_@CK^SQJOBZ^US0?&OQ1|&^&=5N'EO_5HFJ;-/8PVT|HEDT02
MM5U31|W4;?2|RIY4&JG6|B+'%TP\$2Q?27P_&?@)|*_C%X(^-'P|7Q=X4U
MCP%X;D|+:3X7T|5=(?P??V5QH6K:%>7NNV|HX?NO\$6J:O?QZS9-I/EO;W7O=Z|>7|_|
M\$U32_V= M?^"OOC>3QE=6WA_PW|;_S/'X?US4Y8|/3H?&FF:|JUM))W>GZ3X#|)ZO<2
MJOB/5+B^MAJ#-;V=Q;W|;=I&CF|U*^NH9(HHFAM;5YEN+ZTBFN_M/_L??|H|
MK'0|+T|XCV>J:?'KGAXW'_">_#%S:V'B72(KLH|U8>;>66H6&HZ3=2Q123Z M?J-
C<+ '(K36\$MC=2R7#?*_PL_P""2?|H|/@7O1HGBKQEX@|<_%V;1'@?2=|8 MW>F0^%
(LLGFV|ZC|G6\$=UJL%M*%9-.N=3&BSJ98;_2KV"4Q O:|K=|Q23B ME=2MMK?2ZW_
=FKI;-|WVVZ=?+|3Y8_X*(O)|1/CQ^PU^SY^T3XQ|'6OA;Q)|MWB!|7|1^'=*;JGM-
")_ \$2*YM- U622_'VJ.+45TOP9)-%<8>WO/\$,5IF01& M4_KU|\$?COX'^*7P&|(?&=?
%&AVNAW'A"PU+Q?J-JEG:V?A;6;+3H?|A*-. MUZZN)TATR?1M16ZANC>2QH8DCND=
|:;>":3UCQ9XA;_.O"VM^"?%VB6.N^%/
M\$>EW&C:SHE|S39WNFW47E26Y\$;1R0LB|7MY|:2&YM)XXKFTFAN(8I4_*^V_X M(W?
L|6_BB34#X|^+ \$O@V: ^COIO_AUC18K;Y6*4S1:=H2Z;&6:|&6.
M/6\$MB0FL+=DWI5XN*B|QLVT|75G:ZW6O9A9IW6MTD|;_|^|_|?|_|.7Q/HWB
MO|MO|K_Q%X?O\$U#0_%8|=>)|"OU2:\$7VC:E|6X|H3|O(+B.*XC2YL|2MIMD|
M44T7F*DL:/N5?WUKY#^\$'|\$ _P: ^!7QE|4?&GX;2>*=#U3Q3X5_X0VX|&)?:' M_P
(#IFAA_#;WJ"Q6WDT SX6_X+|^"-3U M#X2?"/XF;:;O.GP|?>

W^FZA*D9D^P6GC/3K22" ^N/X4M/[6|+:98.|<&ZO|* M(&Z2*2-U'3>.? _A3XE>\$?
\$'@/QSHEGXB|
M)^*-.ETO6|&O@_D7EI*5<8DB>.XMKFWFCBNK*|M98+RPO8+>|LYX+J"&9/RJ
MF_X(T? 5M8N'M?B?|8;+PE=W:W4_A2'4O#3\$A)/,2V&JR^'G\$D,/=\$=O+=;:< MWD<07?
=2S@SL)Q<4I-KE;MI>Z=K|= 'H_(6J;:5|VZVM;3|?T/|!\$TKX1_#_59K'P?XSL_P"V8-
3U|=0UJ^7PY;:A:ZC++:'4)/#-MBVJZTEGY+6%Q=V\$0;_(E_X(RV5OJ-
J^V)HVGf6M_="VRN4SC?;W M4WQC@F3.#C=&
|#. #C/2OV> ^\$GP@^'GP,| #Z7|_ACXJWICC^T7MW-
)Y<4%K#Y5G;6UO#XS^S'^QS|+_P!E M"|"^(MY|_9|VVD^-|\$|9PW^F:7>2I:SZW-
XUM9YE^MOVU_P!M_5_V<_%7PM^&?PJ|-^'?B7|5O'^LK!>> M"
|VYOfO+#2|V2VT|P_&\$TJZAF|L5|2ZS>K!| "W23QRVUA?R;-A7MYCL_M_|+M\$Y?
@=^TKXM_X6+?7OB;X>_\$.5+2/4_\$W@J?3XDU|V,4=O8W.NZ7J%E=07&I6
M5M##;6^J6\$VFW|V|-O#>3WD5K;)!/ ^S;_P \$Z?@/ ^SAXH7X@V,GB7XA_\$6'S
MSI_BWQY>65X^A/=1/!GV-C96E|<0.T4FIW_P#:FJO))/'9WUI(;ZU647VRUFTJ_P#B2O|
9NHR7J>5>6-NEGJ1 M:UA,2?JA^VY|3/ 7PY_9B^-\$?C/Q/I6@W'C'X7?
\$'P9X3L+JX0:CXB|2>)/"
M6JZ/L.EZ/|> ^|OI7O+Z!KJ2WA>#3K/SM0OY;:OMY|B.Q^U!^QS|'/VL="TJ
MS^(UGJNFZ_X>%PGAWQIX7NK;3_\$FE6|TR27.G)>V6HZ?J6DW\$T<1)YLNFS;?
<7\$| |GS3|,? ^"3G|_@B;4+|QAJ'C/XMZE<:1?;)I3^,|ZP&E> M'+2|M|) +O2-
&L;&.VEU6QBN99+"XU>35+&QNUM|ZOTRUO;>.X"YHM1;3BD MN5*Z=GNG?
2_73Y=VDTWLTW>|Z?+KY>FZ/-? ^"2>KZKHO|?%Q1UGP|H3>*M>T M3XI?\$34=(,)??
V9)X@U>P^'?@*^T_0DU\$V=^+&35KA8+*.|-C>+;-M)K MJRTNXOXX|MKO3-6|FPC_
+.O+;:|KF.WCU*Q\$OK/L,7|+?@+|D_P=KW@;X=;|
MXUUG0O\$'B67Q9Z<;A*4KW5W=2UTHKMY MJ|3|AJDK6=E9KOIT9|-?
&JW|)I_P5X^"Y^!K61U^76?!US|55|-F(V|7B;|1
MXC_X6*+C|^X6|D^&:6TOB=4&|KR74GU\$G49=0 |3|GS5-,_9|_X*J?M%^"? M&EW!H-
E|9U|3:EX2OM1F6SL-0U?QGKVB_\$G0|:"|N&2V87EO,+FRN|3L|.F
M9'N=.T*ST^QT_3|'M+IXHVNI4@N-3N57R+C4I;7%NNM^U-^Q)|&|VL|?2KKQ
MY|K.A>+M MGL=%|<>\$|FSL|>ATUYGN3HVVH)?V.HZ?
J^CBZEEN8K6|M#7D4;VUNG=.U|ET5|A6;|D|RE;|+|^L|G|N3|KEP_9*M^%EOXCTV/P_K?
Q%|0ZUINF>#O"&M7%QLU&V2ZCG|1:K=6NG7-MJ*Z9IND17, M(OTDCMH=9O=
(@F:4W MIOHSX-^*/%WC?X5^ /&/CSPL;>\$O%WBGPM|B#6O# M-
J|T6AW&KVR7T6FO|M NX|FVM9|=+V"X FMKP3V|_\$.^\$?@S_P2J_9|^%_MC#3/'7B?6?
&GQ>U|0Y|:ZT2T|G'PW87-BZR6-U+HFGV,,FIS6WU7
M4+S25(1FTMI(TD'Z<5#Y;)+5ZMMJVM\$K|+S*5^NFFV_Z!1114C"BBB@ HHH MH
**** "BBOSV|>Z_P#MG0?MN^ M%|P:TW|*<|EHS>,)H?#?@:YTE;|I*UE MM4|7KW2I?
&%L1J*:'6'6RU&)(V*)\$%BDF5FE>^J5E?5VOY+S\$W:WF|?>?H31 M112&%%?%GK|!=?|
VS|H|KSXX:3|7X-:3|FVRL_'K?"B6| |-^|M.TQ|F#QYX M;@|'_9-:T32K7Q1?EO"\$FN-
"NL7|RMQ")+B|\$M|%;RHTKINZ5E?5|^@F|=|H M:?
KY'Z%57NK2TOH3;7MK;WENSPRM!:=0QW\$)DMIH|FWD,4RNA>"XBBGA_"SX_ %'XEZ;86
^*_%|EIM| ML=G?W7A|1+W5(+2ZD@*SI;W\$EJL4KPL)%1F*\$;,17A_|\$|/26O|_|5'P6D^*
M'B3PYH_A?44|8Z|X:&F:'<7MS9&WTFUTJ>*Y,E^|S^=*VH2+(N|8!&FT9+4| M.SE;1.S?
FPZV|?PM_F?8%?%?%(HHK|F? ^"9O|3/QN_:#|3?M':?|7O&W_"76 M?@+4?|,'A_|
(1OPCH'|E1:O|'Q"@U%|,|: #HLM|HBT/2UW:D|XT/V7= MT33W!F:3;_EM?YNPKZI=|_@?
K-117YU?|%-_CO|5OV>O@%X6|: !_Q5_P (MAXFU'XM>' _#%|J?|A^'-?|H|PCXZU2ZL?
L7BC1|:T^/S;|1M-G^TQ6D=XG MV;RH|A(9IXY1*|275I?>-Z)OL?
HK17EGP+|2:UXQ^"7P=|7^)+W^T?.\$7BKX6 M?#|Q)KVH?9|2S^WZUKGA+2-
3U2|^R6\$%K8VOVJ^NIY_L|E;6H!O|JW@AA5(MU|3I/1M=@ "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BB MOSV|: _^V=/^V|X|T7QA!K2_LIP66M-X/FF|_-
^!K;26NDTK1FTOR=>LM*B|8 M7).HOJ@1;W494D8.DH:*. %5:5|ZI65|?5*R|1-VMHW?
MT|3|":***0PHHHH M *** +SX%?M_ %G1/VV_C1^RS^T%K%AJ#:W>3>)?@AJ5EI-
MHU@-%M|/.K66 M@V20JTES'JGA';J3M>7=-/9>(?#_ (AL)-0O+B|18VHMIM?
95VNMNM03D)NU MO-V^9^H=%%?)G|:7|3=M^RG|\$-5^ (L.A.:QXJU+4K3PIX\$T: ^:46%
|XGU.WO M+J*XU,6|D5RVE:3INGZCJU|'!+!)>?9(=,2|LIM0BNX1)MI+=NP|CZSHK|_
M#W@O_@KGXN|"VOQUL_C7X:T|4M4TE/%FB_"*ZL="MM5O-'N+87UCI9T\$^!)O
M"UGJ5_8M\$+|/3-4U=+|! *D>JZE8:OYZ1_?|!'|8;_M9_#K6Y?\$VE66@?% 'X>
M7|C|CG2|.2>'3;R/4X|H&+1;:W4L|S80:DVG;G:7>FSW%Q)9:CIEUME^S M7%HBTX-
)N|6D|.S>GK=+3S742=W:S7J?>-%?D! ^TI^US^T)|0OVC)?V/_P!C M6/1|,|6Z-\$=

GGQ)U>WLKN+1[B"UM[O5XK634]/5-,TC1?#T%Y;V.LZK-I M&J:Q>:J<#2-
"M+>|MK9|6|C^(OCO_@I% ^PM#HOO/^*GQ!|(_M!_"2XU>QTSQ M7IT*+*=+FOY-
L*3ZG+X4|/>(M>|*RVFC:O:2ZMH,>HO;0ZQI+RW%A9W0H-V
MUBFU=1;LWVZ6UZ7:N+F6NCTW=M//|C|VZ*|ET#XU^ O\$'P5LOC|J:6OP|NO-M
4GQ\$N+^Z15N-T*UTF75M2B08(WD"ZC|6|U9WEK%)(5O|:6WB>0A2WXZ^ MOB7-
,%#OV|J2|9?*\$3X(_\$'P| O@_H&N76B^%+ #45CM3J=Y;QQW"6MZC;V5Q82>
(=0E>SV|6|U=" #1M/>6.|MH5&+=W=12W;|JO7^F.^W6^U
MOS|'IR45^4_|\$G|7/Q@USXN>.:?V2OVJ(+&/XT>"(NYT3Q);6UA8'Q3:Z;%:MW=
|87MOI<-KI=U=OHUY:>)=U;3+*SAUCPX;FXO+>*ZM5N-0_5BE).+L|>JU M33U33|G?
^MO)A1112&%%!!1110 445S?C'Q5I/@:PCXH:Z|-|GT/PAX= MUKQ/K\$^5!BT00=-
N=4OY!N(7: .DHK|GO| @E;KWQ9^*?A? MXS_';XH^_&GB.W|=??\$*?2O"&@>(/%&O:OX?
|V>EFYUK7)/" ^D:C?3Z=IFG M3ZAXDMM%MUL::W2WA|_8H\$B@C:-
OUAIR7*VGNM_6VOW;"3NKJ^X445^>MKX M2_:'7|OO4?%<^IZW_P_B/9HMGIK>+?
#+:;+D?"2PT|MGAS=2/B1&_X6(MU. M7?3E4W.Z_#?8G69A*|H4K)O72|NB|WT!^E|5_P_?
H51112&%%?GQ_P4U^)G MC|X3?LPWGB|X;>*M7|&^)4|=>\$=.36=\$G%M?
+8WKZ@+NV\$|I|QY4XBC|Q=O.P M9?LU-
WQ7XHU6|USQ^XA^&7A+5M;UB_D|V|U+4KW2;>>|O+J M0!0||KM)(V!EB3@4|>
|S=+M?#_VK_|!/*-SX*UZ||0>,+72|JV|60:AI>C6:Z|HVJ:C M&D|E(IO9#\$FER1N8V
9Y4*|*U?:-?A%|:O| E,?|L\$>\$?_48|75=. *DY M)|MKU5B9-JUNLDOD?HA^U1^V?
X2_94|2?";P|X|*ZMKJ?%6^U:TM|5L=4T
MS3+#P|H|X;L;|H|U5|1P&ME'B.*Y>1'18H;MI_BCXKV<^H>%O U|G|#_X+-6-OJ?
CG|DS3;M6>TU"|^ (5C=(KM&SV|WK'P MS@F574AD9HY&=2&4D\$\$\$5^R^I_#
|P7X=^#NN?#70/#FE:/X&L_6N^&K7PU M8VD<>EPZ-
/HM|:3V9MR&\$PN(H6NY9S+|/>3337%U+-<32RN|1482:NYBZUHFK) M
FK^'/\$.G);R7ND:@+6:XMI'%O=V6H6=S;S/'=Z;?V5R5@FDEM8/O@_ ^VCX
M8^,'|2GQ9_9LTWP5KVCZW)|L:QA7:NO7D!G8A()\$D_>,N/B#_ ((F3RM|*/C7;-
(Q@B^(>ASQQ\$_(DMQX;2: M15Z;H4MK=7/<1(X17C_L1?|H4OVRO|L%?&
|_U=GP^IN"3J+^5)K7:|O|PN M|1?|=I/ &_ WV/N3|H|_@H!X_9F|3:3|-M_|(Z_|6_BYK-
O:W<'@3PO/B#XCEM|?PO8>+KNXO|U>|O':/3M,N+O4O#WA'5-* MU#6)5,&C"YT)|.U&
|4V*:E'?2V=M=_ (|_#OB+P;XX_:_T_:W^_Q\$U_P|9:AH MFL>
(|)|%77BC5-.TXV=MJWBN_P|'T^32WU.>\$F|TKP;X8M| \$MNV^'3;^XMV
M"QW6VNV_X+WWP^|0_"7X4_\$+PAXM|+EX|I%_%&UTNPO?#GB'2;S7++0|.28^8U&-
U!IW:5Y7=TVDJMK*Z7 MSWN+F>LKJU_A|M.O?7SU^X_3+|H?HOX;?LL?
#|^//B|/>W!O:S^R?#7AK1H MX)|>|3ZP87G^QZ?#<3V|O#;6L"-W-A97GYXZ;_P5V&F
M7NAZC|5/V5_BA|/ASXBNH8=)|>MJEWJT-Y;W""^;'>6>GZIX+|*6&H|):YO)
M8M)|OZA<&V21|6*|8(C^!|?M&^*Q^TW^VC^P+X1U^.+4/"FL?#CX0_\$36-#EC MWZ?
=77CNZF|:>*K9|'|#L+A0;FWC="V%&VF_::^#>G?'SX)?\$3 MX2WHT^&7Q9X.:*/
M/F%65HQ4>9-N6K=VK*_1=7;>Z|'M7>SV=K6WT6|_/O^#_P!OG|M'PIX7^\$^L M?
#KP|X;|1_\$#1?CW|_|>U;PY|1?#;L4GA73M*|8Z=K.BZ=?W|26|3&&*)4U.
M==T,B6L@1TCE5@/A|/|@#|N_3/V?_ (2V/PENO@|X_P#&D^J? \$34|27Q+X=:W
M&CVZ^(%T2Q6"826LK^;9&U,UQB0#RY\$Q@YK|'\$^"7C|/G;_@F|:/A%XV|5:
M5XPO?"WPD^-9TG5=(BOXK:/O|6T37=9MM/9=21+G?97E_J\$<8^:**U-M|"5C MB6-
<_X(|_|)HT_95O&G_IN|,TTXJG+2H+6|5_/75>GF+WFUK;Z|::77W M_(\$M_:1)+=?9DN9
M|>VL|+TU)K>35M7NY4MK);FUAC6ZU"|"L+|"|_#^TW_@KY;Z5?Z#=_%C|ESXG-M?
#;P)XED3^QO&8U6;6%O|*0(RZC8Z=J_@_P?::G;112+VCN MY#%)|.|?#|B)_CM^U+|*?
C|XR|<6&I_#|X;V6G6Q_"IKWPW+)|#=#S:3/J^M0 M7#;J=8ELKV/4O\$=WI_L|?\$_
MX0:|H00|VJ?.\$R:#3+GPOX2TRX;7|>TKQ7HVMZ?>6S70T6#4|X6O%M(|VWF?6
MH*|W3KJ|LW9X+UH9IBH-Q5G)O=W;Y;NVEM|;MO0;;U=|6V36^E|H|?(_3/P
MMXHT#QMX;T+Q?X5U2UUOPUXFTFQUS0M7LV9K;4=+U*WCN|*ZBWJDB"6"5&.*
M...>%|T4|<%O%?Q_|)WBMM0U&5|R(6.E7B1WGW&N:-
=^"M/TC5Y|2"74=L=;UCXC2:Q: M6%XZ-/0:H^D:6U_% Z+=|3|3S@X@CVM)151-
72LK7M>TTM_S_03NW"VC:Y M*_|P#ZY_9V_X*8^\$?B|H4H/|@M|30A9XG^?
Q&U6X%EX>TOO|J3ZI8:G|;QB M6VT.|N;|P_X3U31= M|"O_*@7Q.KS3_@LQX-
AT700@5|>= TGQIX7|=X1CUZS1(|HGL;KQAX:: M2XVEG;0-
3|,ZG=:8&)6"35+Y@#YO'0_|%9? \$B>,OV(_@QXO2-8D|5? \$|X:>) M\$B7)6)-<^%?
Q"U18U)))5!|=1DDX'))H27-3DE92DKJ|=FFNKZ.Z?7J%)|)Z MM)Z|7T_0_0/X.^
O" _PW_8_ ^#WCSQKJ|MH/A7PK^SW|,=9US5KK>8K2QM/ & M@LY2*)9)|FYF306=I#-
Z#_P37_93|)6,|D*>||#_P_\$+75T4L\$N|%|_."R'7FM90;!@->M_ M#UXH;(#V:L%+ ,OZ@?>?

40@E!-?@=!,?ASIWC;X;VNFZ#X"/Z7>V3>*/#2I
M>7|^E02Z_=W|N|H%EN|8U6XU" U,ROYN+N|N7E7+LM%DDY.+E>325VDK= NK
MO9#;,,,2=K+?3=VMH_P"K_CVWP ^/WPI_&D_ASIOQ,^&NH7%SI%W/-IVL:9J
M4,=KKGAS7+1(9+W0M=LX|F*WU"VCN+>=6@N;FTN|.YM;ZRN;BTN89G|KK|*
M_P#@F9J^G^!OVP?VQ?@9X6O+>X|C4? \$WB;PM#8W"76FQ:9X(^ (K^&HGTZ6
M*1|W+)=1V=F?,>.WA(=2HFE&320;1J^ ^J3_%&G=:JSV?R| M^YX?M.?|%\$/ WP"|?
6WP>|^ ^O\$ _QO|B_);270@SPC.;2'2'O+5+ ^TTZ_U M-?
U&77+K3Y(M2CTK20#^I/#|B7%|/9F6".;) _9N_X*1^"?C7|1X_@U|0
MOAQXI^!'Q407>'1_#GBN|?4+ #5+V.W-Y_8_JHW6C>&M2T|6Y|16N+&RU30+.
M#4%406E|+?S6EG<_/AWQ_17|'_5#^,?B7X|65U9>&/BG-XP?PWXVNK.:
M|MM#T3Q_XATKQ)X>|16K1Q32SZ380:9-X)U:~3XY;C3"M|%) ^YLVK^"3|80BQ
M^RS|_%_VH/&GP8^_Z|-/U@_M7^D:/J=C/>Z8=,GMV%;5-
1\$=X@G.+:C%13B_>CS*5^MKVMM:|E;?6|R4Y-O5 M:/X?+36^_6H?
Y%+|KS|L|PQ^R)_PK?_ (2/P7KWB_|X61>^ (K.R_L34-/L M?|_|P|_PCWGO=?;U;SEN?
^\$AA|H0X*_9Y=Y^9*^RY9!%) *02(XWD('4A%+\$ M#W.,5^%7_!:_I_FUK_L.?\$_|YI7|H7?
_I=?|>|W_HMJEI*\$^UES7^3212W M?K^B?ZGQU^QY^V;X9_;"TWQWJ7AOP7KO@Y/
E|H%C=Q:YJ&GW|W|Z_!JL|_E MNU@JB);<:5(L@ER6,J%>%:O\$?CK_,%,_"GPZ^")NK?!SX/
PC|9?M#^/_#< MUW: ^)K+PC=3V&E:9?Z>_EZGIEM=Z=X?^7:MJE|HTP-
OK;6^@)IVGW7^AG49K MN*|@M?F7_@B%_P
BM^T/_P|A_P"/_IN|7UY)^P|40#|/I&_|6'|0GPI_.;9 M?">M^.=:M--T|XA:_Y.GVUUI>MZ_J-
I/?ZG*H-EX<|?V7B"RUJ+7I773%DT M|2Y-1DMX9&N;6W""E-)7Y4FHW=W>UW?LNI-
W:.NK;5|>>FGF?IO^RC_P4 ^' M?|3?B/5?AS?>%M>^%/Q:T>WN|NX|">*)TNQ?V^GL\$U-
-&U;|I4USJ&DDB34 MM)U'1|)U**V|R|MK:
|MK34);+K/VCOVUOA| ^S)|2/ACX#|?:/J0T|XBVM_J%
MSXQBO+:+20"NfZ;=QVMW>:C9M'+?WVQ7,L=MH:H:59^'_%)BAU""TU?Q!(NF7EYJ_V
MG0=5?17>SU"S6|T:*RMHH;."*,?F?|1%5-+T_7VI?V.-%U>TAU#2=8U"Q
MT04|"Y7?:WVGZA|1/#UI>VEPF10AN;,:6&5NH:5?
*C12J%EDMKNR0;9_WEIJ.FWL%SI^I6|AF)J?.\$CX M7^%OB5|+?
%GPFU;2|/7POXG|)WWA5=/CM(8K/3+>6Q-KI<^GVT4:Q64NASI:
M7NDO:I&VGW5E:S6GE201%?P,_86^,_B+P-^PS^W)X>2|N|34?AAILVJ^Y=[MF?
0|7^)OA_6/"<1LG#\$0FQUOPRNI111GR8|Z6>Y%*KB5I#EC->ZN5IQ5KWN|
M.U|:WMMIX(+M-)N|T^FUDNW3?I<^U?B3_P55T#30B#KWP^^ GP*|<_M%7/A
M::ZM|=UOPQJ%UINDF2QF-O>7.B+H_A3QMJJ:1;SJUO_&Q
ME7L20+JVF6M^RZ=J#R6>G:CIE^|_.I:9:1WNG3WORS_P2?D^%7P|_99M=:U#
MQ7X*T3Q9|0?&'B;6? \$'H>(\$T_66M|%U&;POHEEHV5_M_IE_J?
C!O%7PYN8;YM,GDMOMADT;P|KLT3,)7U""TU*X22680*,6Y12LXIV
MEK|SC:Z:>BOY;,:|5=Z.Z=[77:|OGI?>A|Y? \$|_ (*|_"GX/?M&R_'XA:9 M?^'+2R|_
R^)=4^)5|H%F/#NGVJ>#|1|6PVO|F112ZQ>W|_|"/1-.LK&*>|U#_M5|ZSM;*WGFFCA?
YC|2_1%>|D|_Z|HVLRL?LO_%E?@WK%|MKHWQ/U>Z&@S:|0%B
M21Y|"T*|/R:|J30;Q275K:CQY#--"I:|?|&5D">' _&_P-X4^(_|P6(|^\$/ M&^BV?
B+PSJ&E^'+W4=\$U%#+I^H2:|!+=:|0Z=#?6^0EW9KJFE64MU8W-DM+Z
M".2S089|2>:&3|#/|^"F&DZ==?L0?&>.:SMV32K3P1>Z:|!%&HL+FT^(/A.&"6
MSPH%NR6|LUKF+9FUGGM_15*ZDY8IP35^=1>|5KZ-JV|_1F"N|V>S:2LM=K
M+^NY|=^&OB5X)|6?#G20BOI&O69|_OX5C|:0>(:QQ96EMX=:3CJD|H)N=A MT_|
L^T25M3BNO+DT^2WN(:I8YQ%7|K_\$/_5QT^JUC7W^#|I-/Q,^+W@/
MPO.T>M>|>|OM!L|:VCWEM2;3K'P;XK-A83Q10#/"AN+OQ7K_
_/_C|H>B6D4A%SJEOS07;MJE=700=Z:6?J?HQ^RY^U;|_OVL|!-WXL^'|E_I^H MZ'=0:~XMI
(ZXMO%KWAJ_N8Y);0W"VLUQ;7FEZG'!<2:1JUK*8+U+:ZADCM-0 ML|ZQM>
(|'_MH>&/&'|5_C#|E&V|%:19^ (/|HKJEU<^+)|0T^31KQ=+T|2|1D
M2"RC47L9E35(XT,C\$*|3EN&6NC^"W|_OPP^_P_60BA70 M|XFM-3^*|UV^
MK>%&N|_A|\$:-#=#ZG#K3)H>BV6E6UQ!+ #J(O&M)+G4;F"QL|^Y|+&UMH#S^:'
MP1_Y3'_&|_L\$>+O_ %&/'-2E%N=KV4;J^Z?N_E=H&VG%=WKY|?=?^F?H#^UK
M^WA/_V4IO#_(:OM\$UGXA?\$|Q9"EUX?^'OAJ:&WO6L9KJ2QM-1UB_EBNVTV
MTU&_AGT_2H|73M5U'4KV"=+;3VAM|BXA^?OA=_P5-T'60B)H'PX^//P+|<_L
MYZCXLN+:S|/:MXHOKO4='>XOIEMK&363J_A3P5J6E:==W3I:KJT.G:EI(H-)
M')J;JE8K+9|2%M7^' M_P
0/#E|H_Y2FY@T_Q#|H:K8+*1N2TOY|W2KFYB|VRW&EV+,"84Q7+%._
M6FW)1N|VLY=EMIUO^7=N9;)|6W2>KOTZ|_#ZW_:V_:AT|DKX::12/\$7A;

M5_%UEK'C33?!<6FZ+>65C=0W6L;)XBUM+V2:~#0M;Q1>'9X'C4>8TEQ\$P^57
MKY1^(O|P5)|&Z7'#:~!+X/>._V@=9T_0=+U|QQ_PB3WEKX5|#)J.GQ7|VF:
MGXJTWPYXJ^UZC10>2#4Y;;2%T:WG@FM_18-W;WEK:~'|>WC6|^G~!C|EC
MOGJER|YJVN>*OA+-K-Y*Q:6|UJU^%/Q\$-8NY&~)+W.IVMW.^23ND(R>I_53
MJC7P+X2|_LP_!'P|(:%8:~ZW|_O_WBW6OL<6V;50\$OB?PML.L.YK.I7+~%I
M|JR^OKZZD8RSR/Y%LEO8VPAL;2UMX5:*C=J4G&UVD|);|=~;6MOJ|+~#U;T=E
M9~;NW^BZ<~_X)K6MOHW|<~|:~@:7\$ECHUCJ'Q_M;33K<>5:P6^E?&"6RTZ*:M%
<(J6=K+)!O|N-V5,M'T:~EU/2|2;5M?T=K*_FMVM9+J&ZV~;KI
M%X)6MV:~+)N""%5FV@%B3QO|&VJS:S^RC^SM?7#%YA|'_=B|L69G_~+)|V6E_M*[LWS;
|+9|I&.2SEFRVT|*~#.~|(Z5XA3X=RZA?R:=I6I6.CZ#X<|6>(E&@FWLM1TN"Y|27=
M|&ECNH-0B:=S|=?~\$L_%?|/FL_&Y|/_3TK5_#^O|_A_5X;GXJ:3XIO|/5
MO%4_B75K7;9Z|FVFHZ#J%IITMEX?DM=+TJ*VCT|_M9M-BOHKNZO=..7
MEA)W4KV3MJHZIZOSVVMYDOWI+1JUWKI?;;^MCXZ_9XUN#X%?|%9OC|X8^(#I
MI%-10OY\$~\$|SX|/3Z%|3O",~\$%Y-B)HM4TVS;0K9\$|3:~+XPU
MO5%MSE_L6GV>B16<|WM\$=O?:O|<3.);J%6^4/~"O_B/X'ZMK/@+P7H^CZQKG
M|5%E-I"Z%J'@Z3;>:'XYO~:U#5|N=KOP9H%@L6M:~;=W:~.MO%>6=CJ8T_Q+|467_~"7^
OVHOA/K7_!3+0?B;X@T!=""T9|'D|2ZC|K.F6|E;MI9G1+K6(+4.C;>(/#VB74IG|<>&|N|?
7GU6:2Z|1P:K=2:AHVN4ES;J4TD_MW'J^6VL5?5A^M>XFKQUM?
XNU^~^ENOE|C|T^B>)/@W_P\$;/'GAG53ZM=0TG5/B?X#O+~*_L)HKFQO~;N|
M|47=E>6=S_SP3VES&~>6WGB=H98I\$>~F5E)^VOV1D5/V5OV;PHP#|#/A4Y'
M^U)X(T1W/4|79C~/~'2H;;A=|:DF_6R_S&OC:|1LOP/RO_~;%(^&'!4G|D|X
MAZ7MLCXUC^~6BZW<(=C32:GXPU|X=:U<3;~!D_X1+6~/M"),~N5((~K7|KU_M^\$G_
5"S%^UQ^Q9/'W*ZSHFT#)8F+XF>'WA_52&YD=|8().0#D5^|=\$_AI_MO^|;
|G_P=|K>2|T_O7_~|C7|H_~|;0|~#?LT?~\$;X1_#|QCX?U2|3XKWL=M'XH_MBU+2=~-
T|PK:~'7=+T2ZU37I=2EB*6%~-3&H7'OM?AS5;?4(D)AY=MG%K&J>~'+VXE/E2VMJQ&?~#A
@K9I=AKG|00I(FBZK;+>:7J|Q<:7J5H|2(EU_M8:AXW|+VEY;~|3QRHL|O+)~\$S12)
(H8E'5@&'ZG?M6^'=~!L?V/_C|X>L-'TVQ_MT+1?@A_\$&+2-
&LK*WM=,TR+0?!NI7.C0V%C!&EM:0Z7-8VDEC%|&B6S6T)A
M5/+7#Y8I4VTWS7OK;JNR|_6VD|6MT|K;^KGSIXT_P""GWP2L?"G@G4?A-X=M|9_&_P
=~/=/%?7~^&/_@W3W/B+P_~07\$|G>0>~WM8=8.~@WMK>VEU;_8K"RUV
M|G\$<6I00/H=|8:M=;~|D?~!0GP9^TWXSUSX7:QX"U_X1_~%+1K_|U!?">OZ@F
MK0:E;~9*D_JVUGJ+Z7H%|%K6E&19K|1|0T.SG6T\$MS;27*VE|MKX?_P1K|>
M&K+|G'Q1XSM=\$TZ'Q7KOO,U|1M6|0K;H=6O=(T72/#/NF73K*>~O;
MB&RB:~.W%S=W%RT;3RO(?%|5ABT_~(+=~^WLD6V.I:~TU|(0(UN99OV;=8AE
M>95PLC2+;PNQ8\$M+&LOS(P.6-YQ2=XIR3;|6TM:VS^~JA7?NN^CLK6|~9^H
M|47|6?PT_94|~;5K'C5-4UWQ'XHNIM|&>~!/?#<4-QXC|37EOY(N'A2>6*&S_MTRRDNK1+
|49V8QR7=O;V=M?7L|D)|XB_~|%D?AOX<|3*M|HWPR|~#077A|3;I;M|J-
G|O\$'CBQO8HG!C%
MU9^(=;BU2.Z0>~+C1|~2Y%K&B>L_~|%AO#.D:M^RG9:~>6|U;PG|2O"|SHUX
M8U^U1+J|MJND:E9138WK;7D%Q%|5N;M:RV|;W^0-O5IVL|6MO;?|H|Z?U;Z@_9-
~:N@~:~LTSQOXATOX:~*/~'AOPWJND_MVGAK4/%-PKW?
C'2|5MKRYCU>"U@L(K&RCA^R+&|5CJ^00%YN+X;~'|&_X*O_M
~!9/PZ_92UCPQ97)AUSXN>~(-)|"VJQ/BY31HW?Q|XEN%3(W6LVG:0F@W9?
MU^~)0H+AT^ROV;|90O\$7|/P&|0:F2VI:Y|&?A?J^H_0%WWNI>~"-#O+IPH)"A_MYYT""|~\$
@\$*00/RN:~M_XR4_X*2_L|?L|Q?Z=X4^#MM:~>~&UL?GMH|N=(/'MVO6=|JY46^J>~'
~#|%;~CM^~|6XUIHE|OS_Y45|H64;R=KOX?|VOQ^0W?ELW=
MO3:V_P#DCZ*U+QMJO_~!K|A3X1W|E|~
X_~'=WX7M_~"NF>~.|~\$D|1OX4;2|9|M^(|7;4\$|/^(FN?
LWC74(|&CM9K2W+P7T;GVJ;VJ6LWW+|&_B38?&+X4?#
MOXI:~;#3|7Q|X0T+Q.=~^U"^.D76J6\$-Q?Z~>K!;+=RZ/?M&9Y_~O?AAXW|5>\$BDC|H
M_P"S=3G@|~;=(3XO.AIX2M/\$_M7B'4|+GFDTE/~#6LMJ;Z3HVD7GB.YB-
~IQEM#!"C*9?.5MO|ML2S_MRW_P"Q_MI_PK:~(K*T2Z'Q%_X2|FDDW_~
LLOB5L_P"\$3_X1D*F&N_~|&W?~"2-D1_VA_MMRWV)?B7X#Q?|+W_~."M?
QQ^)+@W6A_~!3_~\$>CZ7.?WEI;ZIH&GZ=|K:W@S_MN4_~9)?%FMV|@S&TL,UQ\$P)A-
9NG?~|PI|=~|/4/_*RWHU6HQU5M52%_~.E7@_ML'-B;HV\$6KZU?
I9ZG<6=G=Z@)+~#2+6TTR|OM;OK;|M;6.*.UN|NV^/~(^"HO_MQC^%~^O|
AR|H+|DWQ5|~!OB|95L?~\$=JGB#3|ZU@RC7\$~L.E>~)=@MM7|~%UC|C+PM?~+74?
|87BWQY=J^@:3&~*|~\$M:UI%~@OA|PS+|AE-\$L=6M=~EU!~#!#I3?VEXD"W=A((-

N:3XF_8CM? \$F@7I0JNA>(/&?PXU01=4M',EKJ.E: MK;WUJHU;.:0"%W:3PW\$+\$
F.120#07UU^Q; P FE_LZ?IDA|\$?^F2UK\F/C MS=W%
[_P1V^!LUU*TB:AX&M%=V+,>+>PUKQ18VD0)).R"TMH((UZ+'&J@ "O MUG_8M_Y-
+_9T_P"R0^"/_3):TGI"W:I+D*+O-00%A !'TY11169H% %%% ! M1110 4444 %?
A%|:O^4Q_P \$?^P1X1_11CQ=7INU^'GOH-^-(KC_(*|_! ?7 MK?
0=:GT.WTGPHMOK,.EWTNDP-'X:15HXFU%(&LXBCNBN'F4JSJHP6_.M)I.5 MW;W)?FB9?
9_Q+13%_P""Q?1 R4C|C+|'_CG_T_?#"OV^15_P#(K>)?^P!K
M'_INN:_%O_@KKX;1:11V29=#T'6M9BL=6|_-22Z5I=|J_=FLFN?#1HVN
MLX)EMQ(L,S(9B@98I'N0C\$?M-XI5G|_^(T16=WT+5U1%!9F9M/N JJH!+,Q(M
!)P!FE+^'3_!?- OBE_V| ^1^,W_!\$O|Y)=|;O|L?O#O_J.R5RW|\$7_M "E2;_*_!7QN_+5V?
#Z00?^",?A17_1,OC1#K^AZOHZ9)/&GA^17DA2|@@:5%8A6= RJW!(/%>??L1?I4OVR0|
L%?&[_U=GP^K M27Q5O|*_)\$KX8?XE^;/FW|C|D#X5?M_-' +1J7PQ|77|507/P_+ %
<|Z5%X< MUFVT:?!1=^+ _! ?I^L_ ;EN-.U(SB*33I%4""(0_|@9G|U=OZ/M_P1^_9\$3&^
MY^*B|F5%W>=-7<|'"J_ ^&AEF/'J.2> *^9?BL_Q!_X)W?MI^/OVB;_P!K7C MCX
?'&+4|OQ+/H:J:1J?B'4+37=;MKJ^|F6QTK7|_156|UJNB1:JHET_6M!
MU6YT^TO8|R*_GTSG/CQ^T-10_P#@IQ_PAOP\$ _9P^%OC3P_X 7Q1H^O| Q!|>
M^,K:V@T^PDL8IH+5=7N=&NM4T?3='T>.|NM6-J=7N|;1:A#IMMIFFP36GE7
MZ?.VFI-OLM;JRLE>ZNM;1.O3J)66C5Y)Z+77;K_6GJR|10!>E?"C_@J=^R;
MX,TPWJ^&_#?PY^%?A/PS)J4RW-|+H^A>&_?%?@G1VNKE\$A6XNGETI8KF=885E
MNA+(L*A:_?/5-4TS0|,U'6M:U&QT?1M'L;05-6U;5+NWT_3-+TS3|>2|O|
M4=10|N2&ULK&RM89;F|N|F6*WMK>*2::1(T9A^,G|>|/1+7C?X>;^S'|=_@#
MH>I>+M;_&6=*(|(>%M3TNWM;C4|=U#POX%O;+6?"^O3V=IOO=3M+/5(=97Q7
M%;+=7+V_B%M0:-;"TU2YC|P^._!2R|_&G_ (3ZU|_?@+|SOB8W04^*.GKX
M2UZUN(+ #4|?1M*U&2.W|26VD_P!C7-S?ZF+RS-SHU_K&G^'+/3K*|N-200@
MMOL)IU%!K9+ED|VM9|N|TNM>MRDU&Z|K3>|M%^1^G_.T?X|!#? \$7|CW|H
M+7_A|XS|)^_|C^#WQ2TZ36O|OB+1_\$^DOZA;^#+^:XL'U'1+R^LUO((FVE
MFM6F\$|4=Q |HJRQEOFC_((|_P#)HT_&5;QI_Z;O#->H?#+|E+6_AE^P)X
MI_9SMC:7GQ"%4_ "?XDV^KR0SQ?8|CXA>_|"U=DLDN_W<,MGI=Y>:=X?AOCL2
MXLM,BNWQYK5^:G|?L;_ (_9;+!;Q^SO|6?AW|4(/P^)_E_GZWK&AZCL-
_IVH6\$LTS+:7:RV,X*1K<6_E7*2O":CK:2|7MM M?T'>SBWI=|WRTG/^W%|>_CA7OVA?
#_P?^SCK;WA;4|6ALO|A9OB^TNI
MI"Z6+4=%_P"\$DNM*DU:S5KO2O#6B^\$WAUCQ!)IS+J>NW-VGAR(!
(Y| #6*6=Y|34)-3TR>;PWX?BF;1 M|A'FS+:RF+4;BBD:..?6|KK7!?
M067Q'_8S_-V;|L6W|ZOXZ^\$/C.RB&NW M6DQRF/2OM?A"R|>(-'U#4UAGM|%U2"
|T^W|2Z))J<=OIVK6TBZ5#=>9;ZC-M97?VA_VU?B;^V-|_#_B'X+_9K_9|??|"O|
_A&K|4OB?110&5C9)'8:%H>S
M5KS0_#5MI5J.F7FMWTME'%&D.JZEK#VWVA;;P_%^|U73J2:Y.7X/=3NWJDK-Z=+:?B?
9W_!*;_DRGX<_1A_XA_|J;ZW7QW_,_9_M_P#D<_VO?^PO|O_
\$Z_%BOL#_@EL;C1_P!C3PM8:U8:CHU|X=12_\$""5;35_M+"|L+JW|SQ!>:XDC6MS#%/Y;Z?
J5M,C",APQV\$D8K|I?V)OB?|;V0;'Q_|M'GO!|#/_%_BKX&?\$CQ;/#CF|T^PN;/QAX4U;PG'-
KFD^(\$T^_2*;;#<0^_12 MTY|G4/LFD7^1126C:_IM|806NJJ_MN|;LM-
;SOI_74>W(^R=_N1|Y_|%IK^MWC_9L^'&F,X%U="1;^&/(W;Z=X"^(50J75A-
XEU+5|13GGT MBTUR|TK3+?1/"7AVTU#4KP7 MHZK+9_&WPHZZ?HFFW5_);6-
OX#^)%N)!;V;_KQ6L+2P0|IBQ1M)%'D%T!+./MLHO?FNUVNU:_XAOSM;6M^'WZ?KY'R-
_P47LIY/V#_P!A;455C;6OACX>V4K@_M?(L^H?S2Y|=6/9FCTVY*C'(1^F.?
K#PU_P2_9(UOPYH&LM<_%)VU?1-*U- MFB|9Z<(F_8071;.#PVP\$9,N4_9AM(PQZGL?
C3^SAKO|1A_P3G^%/P^T2R(M^ (A;X4?1OQCX1TN_
LDO%'AKP%|JE>;';OR19WVIZ+J.NZ+;&|>WAM|3N MI8WLD-O'.R_*OP@_X*J_|*>^&?
A_X.?'&7X(\$?V?XR_#S0K#P7:V%I!9ZVMK;VU)K71O\$|N;N*;4+>+_\$H6;!>35H-W4I72
M>NK33|&OPZ@TE)M|-N|JN_7SL?H=^SE^P;|"/V8?'&J?.\$#X83^_9-?U+PS?_M^#KU?
\$/B.TU:Q72|0U/1-9N% %M;Z18/">"ZT/3V21YF"1&53\$3(KHK5^1/_M 3M^
WQ=N_B9|7/VQOCUH|X4|8?%|H1M_"_@_4(+FPO;+1M:U6UUB_U2|T MBZQ=Z7:01:?
L.@>%+74E755TBUU"XNHEM|VRN;S|=JSG>^LN9V5WYVU5_+;_M7<=<=MK?
UN>\$_'W|F|X1_M*^\$CX1^*OAJ+58|<3R:%K|DZV'BCPO>7"*KWWA_
M6ECDEM'_L|Z632Y4TOQ?9&U2Y M(8O;Z|Z)X@|7?'+_
()O_M0_\$000XGV/>//BY^S7|7+H|Q-<&HZGK4^C6BW| MWJ6B6AUG4Y;RUTWQ)X/?
4|4T6+3=:N|V|3;+;ZWN89%5|_1U^_7Q;||W_HMJ_ (#_@KQ|#?&C?X/?"
IQIX|T+4M=B^#VMZS#K.E MZ-:SW^HV'AKQ'IVD0G75M(%DN)|+1|SPUIL-^|&O

M^"CWQ3_:7!*67PX_9E^_BJ3XV:UI=MI7BCQEXC;35^%_P,KJ[MUM]4\4R:
MG"!ZU!;6+M-<:59Z[8Z3))-Y")IFOW\$.Z)J4V+Z_2_|::8^ ^#/I5.@I8_\$
M+17LO%&G6LEOX;^(&@^39^*!RTDB6XNFBDAU?1/DDDET/5XKJQW33SV:V.MH2)?
1?G'_P\$ _"GQ!^*M/P6!8^(7U[PO\1;.>74KN[NEC6RM-J2:2ZV2O9^6]NHDURJZT=
I^6O!;I&3?CQ\I<MO^">?I4/A\93^+'B.3QQ\\$_B-J6DV"@O5)&N&L-
_@|4ZK)H^@^)^O#27@?#K7?!/P"^HJHMY+X@UZ\$80+/0M?7Q-?6L^MI1*=.N?
\$GB>_M/[1H=\$T:|U)=\$T^;:E6J")W+W,"@RI M[1NX^MR:>(I'7G9%/QGH?M3XR?^%3?
\$|YX\!0_!G3?V?/B;X+_&E_\$6D7G@V|T+4K M59;'P|JVKVTFN7&J^'+:
'Q3KMXJ23W7A^SDT&S@:Y-K*U|J-M PO/IK|B'|MC6Y^'/I'OB_X7_%&R?2_%7QZT|Q-<>.
I".2_P##>F>)_#W_ C6CZ(|JP4:MEH^D#^U9X\A|/UW4KZT\$S_9\$F,1_=IVC!OBIXYG|?
CQ9KE|XOM-8700%%EI^F(^B^+|8;%D\$?:_/_/@EI^R|I-?'G@_Q_P'"^CXD
M'Q'X(1Z+XMT6/4/%UA=69U+0=1M]1L6O+2/0Q;BS-U;1K/<7F)NC\$B\$Y M'Y_
+.O|5/C#_@FU'XQ_9R_:3^%?C74=!LO%>J:|X)|4>%H;-XKR&^CMX;M
MM\$;6|C1|*UWPSJKVD.L65|::M'?Z7>WFIV&IV1NB|K|OIGPGT'XK_M_?MB>"MOVG_-!
X%U_X9_'X.)I,W@:#7DN+6|I3SZ!W&MZ+;V,K1VT6LW&I>)KE=8
M127UA#QT^UGO;R*M+M|NA>*0C&^\$M>--
(ME4S7\$K@1MXETL0:Y#O6>|&N16EOH|><_LT_!Q;|4O^"6?A;X3Z=JFO_M?#WQSJNC?
\$:30=0^TZMX:U#3M>L?C)XU0O1|;4GM_L^H6^D:T8(-.U56BE|S
M1=2N)X|>=O)!^8O@9_P41|7_+_'(\$3X_M4_!WXE-XM^'RWVF>\$M6MEL8|MK5|
(CGEEL=/U6;7+RRMKO3|:46NF>*M_O_-L|_138".RE>U^VZB6ES2E!^|
MIRT5K|M|_7Z6|;5U9*2T:6NN_;0|O| ^"='|37QA3XF>./V-OVB|B|U3QY|
M.:35^,^(M5NOM^LO%X:NK6SU;PUJ>K%GE|10&SN|?7?#6NSO+\$:Z'|@'X:_%KXS?M1?
\$|N7XH>#|OP#MH?B:SU:S|\$:/:?
VUS:S;K<:S#INDVLNF"|@M;N_T/PYX3TP:7/KLME:V^NZK>
M1SZ>2;34K>W@^"_AOQ%;_P#!7GXT:|<:#K4&AW&D^*UM|9FTN^BTF=I/#7A1
M\$\$.HO_MG*7='5_DS%F1E&2I';FG:R_=Z|)^|=*W|7)U|V|_B=K|VNK7,G|_MAB-
I_X*>_MJZ;=|DN;P_&?4X%D)W/;7/QL|+W)7(-:UU.VDC7.?*Y4,JL
MP^N/^"K|S#!^Q;X|BD::|XG^'|M;CCYD|6Z;>_HY|06D|I9/R'C&2/EA
M:@|/_\$/|C'|MB'|M+PGX&U?QS|(O'NEM8?\$FST*.3?HES3:5H_C#2-3U\$1:=J&M)?;--
<6:K*WE?|1'|2_BK_@ID_@#|GG|G/X7^M-|+V/#QA8>)?'/BSQ7:V26NE?9+2|TZUN-
8DT:JU;3-*|.Z1|JFH:GNSP_XM)+_LC07*LLDGC3P%>J'ZF#4O!|Q8U&U8?|+VMU"R?
|!7'%?MS^S+_P-FW?L^M?|D0^%'_*_@>@5^<_P#P5\AK-X?_8L^#OPW|#:J^LV/|@;XE?
#CP|IM|IF
MG76HWL>B>&OACX_T.UN;B"QAF=4\$<5JDTQ01B>9%+;I%!_1|FVVN+/IG;X" M6EW!-
:W=K|%OA;:7-M"&55DAFAD5HY8I%5XW5D=0P(\$/_M6%^|27Y(I*SMVC%?F?D7_P_\$Z?|
D_|_;<_|'_Q1_|5U&OJG_@K=XBM|%_M8X|0;:-(\$D|7^_O_GAZU4D
RSVNJ2^+&102,D6OABYD()Q&3C)'SA_P3X|M-^(M*_Q_:0U/5-!UK3=-U'5OB8VGZA?
Z7?6=C?+-|9#<0M9W=Q!'!-?LA68Z9!K>ZDA_M?
&06C)RW4|_XN^,/PM|!>)?"W@|QIX|,^&/%/C>ZM|+PCH6LZI;V.I>(KN|_MOX-+MK?
2K>9E:|EFU&YM|-%CR3/-&G!<9|^RLK73;_TTZQ@CM; &PM; >RL|:%
M=L5M:VL206|\$_2_POPPOI&B|E4"OS#_X*#_(>_%SX.V5YJ7Q0^
M!>M7>M66CZ5&)=9U?0KN?2|1FFT6VV.^HZYX=U;0M.U/3=+C'G7MK/J|5G'=
M:BUE8W.:M*7O.R;=WV_I<7JEHKVMI_7EZ_-46OP<_86CC|.?!|3;JK_P?
MX<"P>%L;7XL74VFEH"V-I|WQ6|+-9+%'B.)=)EU?4M+M8|8@BN9(0>G50
M_P#!9+1?^\$(AS_SQ|?V@5LSI(1+Q06)|&2>+%B^S&1YFU)?&<-N;T&Z/A|M?#,U^J
Z7_:QD_XF=>L?|\$ROV8OB-|8OB3^T-|<+&|TSXJ?&R|DN(M(U:\$V
MVO:7H=_JL_B/6=0U^T94DT|50%FO3V|H-HZ)=:::59&|C@N|NXLK.U%PC/
MFTNDDKJ|=|TNR|H>I+M)QMTU?E_P|O|_@'S%_P_\$S?#ME|>VM/VF/VBO|2
M:OXL):REWX>@U\$"<:/JOQ!UKQ5_E_91R@F*7PYH'A>3PYI0'|O3|'#4#'\$B2
M1VKP_I%_P4.^\$WA?XJ?LG_%E|>L|9M4^'OA76?B1X4U9XT^V:1K'A"PGU>=;M.Z'>0Y,
<|%_NV?:(:6^UO%FE_%;_(F_M5^/_C)H?@'5_'WMI-
'Q>N=0NM8.AHZQ:%|JNJ/KD>FW=W'!/:Z#KO@_5;F|@|V-K&S2O\$7AR|GM
MH|Z+4IKV;1)?VA_ ^"@/B'|L|P9<_LY?LG_!_XE7VK?\$/|%IOB|5|=L=*BO|+
M06NX9;K3|:VT'5|>TS3_-U*2);?6/\$^OZUIUA8Z,M_#):*;S|=H_.I3C*-N M5*-
FFK122NGVMKHQ)H1:>|OIK=OUMOV>IYK=:OK_3/^".LVK/(\$?V+)OV5O\$%_-!
<7GB;P9XAM/%NOV<1FAC|>*>GN-3FU?3UD6\$W4'AG5Y;&+
M1D)XH'N|/0|"2ZACEDEC'YB_LV_MD>(?'^">FA^)/V9OVH/A;X|D7PMKVLZEX M"U?
PI:Z9=17=GJMTUU>V|D^OZGX>T_4_"UYJCW.MZ9X@TJJNYUDU:JM+O35F

M@6*).TU)0W4W*WDTE=?/YIC^%IOK&WH_T/0OV^U'CA_X*,?L8> K4&X>PN/
MAKJNHQOX8PV5_P#%?4+O42V<20Z/X\$;-
-&^!M,M+BP^\$FCZHDP^WRRZ(WA;2FTPW,%N=4TK00#L MVI7FL.Y';PV-
IXNU1)MDRUG?0V'I?U,WI,=^6*3]7JUIHL..MWW>GFMD?A% M_P%5_
DYGJC+_L+Q_ ^I_X3K]6/VM_^35_VD?|LA7Q7_|4&URORZ_X*E:
M+K&I_M)_L=7&G:3J>H6]HT9NI[*PNKN&V'_GOA23-Q+!%(D(V*SYD91L5 MFZ D?
J5^UA!/=?LO?M%VUM#+-=@PU(OLRGSV6'E!TB/IY"T[KGJZ[PE;SV\$]H>L?R*_!0: M|?
X,?MF? +|H+X0ZAI0B_P",\%C#I.O_4TQ=0U+Q=KVC6]KKEC']>G:-8 MZC>0V?
B+PMJ6N>&+B>9\$N;;^SM/O|+T_5(XM4:TYSXI|>. ?VD?^"D\$WP_ ^"'@ M_P#9V|?-
7^'=AXKL0\$WQ|:_ \$"RU.WL+6XL|:ZT]"U|>:-H=G);Z+9ZCJE
MS;Z):RWNK^(-1>Q9;/3H|/>5N6_-;#N_'P_*?^"B%M1AV7/%,'Q%^-_C#1= M*MO\$'PJL?
#5_XIU#PPL'A/2?#SZ?JZ1VCZ8FBZUH&F6>N3]-8TW6M 6274+L M:?.LUAS>V2?
|*%_VH?@S+#_,-1?L=ZYH>BK-%!?^+?"L'B/PIL)=Q\$7L9 M=-;\$,TB|2H9 |2=H-
|2:BN6[M?)VNDINC3ZZ"TO*[L MK|)::6UNOOZGI%:3IWA_X=>"|_
TFWD33/"O@7PO9Z=!+UG9:IJ\$7BG6-+1FR%_L71(/.EVSHSOIG|Z)V
SYOMWI4_|5_A7XD_L M\$>-/B1|\$+C6/\$#?%&)/A7IMC;Z7=?!)!HVI^(6-OXPT?7--LO=S:?
J6F>\$DU MR1GBDGM)3-IY8WMU87MG>3>^?L%?"_@O|LI_"7PO>V;66OZO H7_"
<>)XI MHC#=IKGC21M>>TOHV"E+S1|-N|-T&9" R?V4J,692S9KW82OHY/E7=):R_&R
M93UDO)-^6NW^9|@D!@58_J0000""",\$'\$@@C@@|5^"7|"BJR_9:.-;S^ M#VMG[-
X>|:/XK^)^D6|F&('>'A=J6K2PS0;@JORZMX2|5:)>R(S&WL49" MT=L|G|
|J_G9_X*3?'XY:1^U'KOQ&^"GPY^(7B|2_B_|(|\8WW@KP5XD|4
M6:S76FWO@77=&U&70=/O(|6:?PI/AZ^B\$|D;2O(LGERI('*=FY1;24EU=D
MVFFOPN\$KZ='>GX^A|+?\$S+F2|L_"| MG)|J5S?Q.2Q\$5YX@|7ZU!
0SSZ;^|\#"*)JPT|_E.'KO_8*A_P#66]&K|_ V M?*A?=?!WJEGX+^!M2T^XTK6|;P?:;
[XBTZ]|@DMM0L/\$7B^YN?%FM:=J,.RK- M%?:7?ZU-I<|.H#VYLA;@!(54?GQ8?
#:XB)_P61UKXB-X|!:+|Y-.B2/QTWA M;7|X.D*[CP1|/AD)?2?\$K4;,R%|7?PU<;
M?:^*M6UBUAF@;5X|+|0:A9^%O#/AZ:8:<=7*:YJ#. CZ7V|_|'|OI/_ .S= M^PS|1#|O
FG)XE@O_AY;W/C|7DBUOQS?F7QUX<@NY&UZZBWZ7%>QDK=:;X? MAT?2) 2!IXR<^;?
\$SPU\$/A/KWQ;^\$?Q?/B.XUAO#T%, MUI%XTU;3?\$WB#2|1N|.T_5V|_
ZQI7BW3H[W2;O4=/DT|6=(86EO=1W5SJ":9 M5_:B^+W|8|/:'P0|46GP|_9G|6^
/@OHIT+6==CUJRU'6OB|!3+VW|0:5'IF
MF^#=#&30|2_O+'2KV===U+^Pl,O8OLVAW,ESXC@9?|'"OVKWTAKM|!|= -
RUTM=I=.ZT|_ <5?C?_,H6MRK^5/&Q_5|D; M1M8|_LP?
70O\$&DZE H6N:1+|/UAJNC:S8W6F.KIE|::/1W-EJ&G7L4%W9 M7=O(K1SVUS#%-
\$X*2(K BHE|+77VDOR013YMOLKHGT511169H%%!!1110 M 4444 %%%!!1110!X-
^T9^T3X%_9A^J_\$OXAV7B6_|OKVG^'5@|*V&GZC MJG|H;G;7|S:L;?
4M6T:W%N1ITT1L8\$U7Q|1-#|86FB07P5;?4;_1M(|/=8:S+
MK;275G).L"W|JLG|MZEI6F:S:M8ZOIMAJMD|*|V>I6=O?
6K.F=CM;W47;VEI!%;6T"9)V0P0JD429).U\$49).
M,DU2E.;E;66EH|+32UOQN)JJ6NB=TO/S?_#%D@\$\$\$ @C!|Y!|Z@CN#341(U5 M(U5\$4
B%50.@50 !V %.HJ1A35C1&=E1%:0AI&50&=@ H9R "Q"@ %LD M =!3J*"F">7'O|_
V)YNW9YFU=^S.=F_&|;D |@&* =10 4444 -2-(E"1HD;+G:B*\$49))PJ@ 9)).!R2 M3U-.HHH
88T+K(40R"JR%0756QN56QN ; R 0#@9Z4^B@ HHHH.O6FHB1
MJ\$C1411A410JJ/0*H |@*=10 4U41-VQ%3:EI=C?
75BRR+,K6=Q=02S6S+,B2@P.A\$B*X.Y01<)+=&|>>+O'6IW%Cl.KG3;+M|X=|)7Z6W
MVA+NQOO/6PU*RTVRTCP?I4=G?ZCJET#2KLR:C<'6YK>V_0"BFFU=+JK/TNG^
M@K)VAM@HHHI#*WV.S%R;T6ML+PIY9N_(B^TF,# C,^SS2@'&S?MQVJS110 A M
(((!!!!&00>""#P01U%5|6RL|[%&BLK2VLXVJB7EK;7:1N)8TN8(IU2100LB+*KA7_) =0&
)P>:LT M4 %%%!!1110 4444 ?SUZ7|2=<_X)_?MS_'IQW|=A|XKUOX??&|7/\$MWX<
M^(^BZ:FH2PZ3KWB N3Q5I0TF^O9;33[V*RMI8=)|4>'(-2M-1L)=-L+FVM)|:
MTL+>^^^H_BO|_|%6OV9=9|_ ^(_ #G@#1?&7Q4|6^*M#U+P_HW@V7P7=6NF:AJ&
ML64UC!:ZZVJE3/HKO,%NK;2|+5|NZ3-O#;'S3+'^L|Y966HVTUEJ%I:W|G<+
MLGM+RWB NK:9,@|D)H)T>*1<@':Z,,@"%8.C>!?!ARY>||/>\$/'^A7D@99+K
M1O#^DZ7^-::PIJ*-|J6@Z M)HNB:-IXUBR?Y|/UC41I4E| GRAPHIC 13
img77546233_4.jpg GRAPHIC begin 644 img77546233_4.jpg M_IC_X 02D9)1@! @\$ 8
!@ #_VP|# \$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!
0\$! 0\$! 0\$! MVP|# 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!
0\$! 0\$! 0\$! 0\$! 0\$! 0\$! P 1" (^ ^L# 2(A\$: 0\$! |0 M'P 04! 0\$! 0\$ \$" P0%!@<("OH+ |0 M1

@@\$# P(\$ P4% M! 0%] 0(# 01!1(A,4\$&\$U%A!R)Q%#*!D:\$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM|BYNL+#Q,7&
MQ|C)RM+3U-76U|C9VN'BX^3EYN?HZ>KQ|O/T|?;W^/GZ_10 'P\$ P\$! 0\$! M 0\$! 0 \$"
P0%!@<("0H+_10 M1\$ @ \$"! 0#! <%! 0 0)W \$" M
Q\$\$!2\$Q|A)!40=A<1,B,H\$(%\$*1H;!'!2,S4O 58G+1"A8D-.\$E|1<8&1HF M)R@I*C4V-
S@Y.D-\$149'2\$E*4U155E=865IC9&5F9VAI;G-T=79W>'EZ@H.\$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM::WN+FZPL/\$Q<;'R,G*TM/4 MU=;7V-
G:;XN/DY>;GZ.GJ|O/T|?;W^/GZ_1H #,;! (1 Q\$ /P#^S/X4 "G0 MOB-
H7BOQ9XL|5_&JZUJZ^-7|16E,VE?M%?'_,+Z7::7X7^/_P 3/"WA_3=- M|A A;XF:+X?
TFPTGP_HNEZ79V>EZ79V|=O9QDOQF0R2/Z9_PSCV/?^AA^//_M (E1^T|_||^C|G'_))
|XA_|+S^U1_ZT|7Z|YH_|&_X9Q^'O_0P_'G_,2H M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|/?
KWFB@#P;_AG'X>_P#0P_'G_P 2 MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?KWFB@#P;_
(9Q^'O_\$,/QY_|M2H_:>_|GOT?|X_#W_H8?CS_P")4?M/?_/?KWFB@#P;_AG'X>_1##|>?
_\$J M/VGO_GOT?|X_#W_*&'X|_)4?M/?|SWZ|YHH_|&_X9Q^'O_0P_'G_,2H
M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|/?KWFB@#P;_AG'X>_P#0P_'G_P 2
MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?KWFB@#P;_(9Q^'O_\$,/QY_|M2H_:>_|GOT?
|X_#W_H8?CS_P")4?M/?_/?KWFB@#P;_AG'X>_1##|>?\$J M/VGO_GOT?|X_#W_
*&'X|_)4?M/?|SWZ|YHH_|&_X9Q^'O_0P_'G_,2H M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|
/?KWFB@#P;_AG'X>_P#0P_'G_P 2 MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?
KWFB@#P;_(9Q^'O_\$,/QY_|M2H_:>_|GOT?|X_#W_H8?CS_P")4?M/?_/?
KWFB@#P;_AG'X>_1##|>?\$J M/VGO_GOT?|X_#W_*&'X|_)4?M/?|SWZ|YHH
|&_X9Q^'O_0P_'G_,2H M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|/?
KWFB@#P;_AG'X>_P#0P_'G_P 2 MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?KWFB@#P;_
(9Q^'O_\$,/QY_|M2H_:>_|GOT?|X_#W_H8?CS_P")4?M/?_/?KWFB@#P;_AG'X>_1##|>?
_\$J M/VGO_GOT?|X_#W_*&'X|_)4?M/?|SWZ|YHH_|&_X9Q^'O_0P_'G_,2H
M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|/?KWFB@#P;_AG'X>_P#0P_'G_P 2
MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?KWFB@#P;_(9Q^'O_\$,/QY_|M2H_:>_|GOT?
|X_#W_H8?CS_P")4?M/?_/?KWFB@#P;_AG'X>_1##|>?\$J M/VGO_GOT?|X_#W_
*&'X|_)4?M/?|SWZ|YHH_|&_X9Q^'O_0P_'G_,2H M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|
/?KWFB@#P;_AG'X>_P#0P_'G_P 2 MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?
KWFB@#P;_(9Q^'O_\$,/QY_|M2H_:>_|GOT?|X_#W_H8?CS_P")4?M/?_/?
KWFB@#P;_AG'X>_1##|>?\$J M/VGO_GOT?|X_#W_*&'X|_)4?M/?|SWZ|YHH
|&_X9Q^'O_0P_'G_,2H M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|/?
KWFB@#P;_AG'X>_P#0P_'G_P 2 MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?KWFB@#P;_
(9Q^'O_\$,/QY_|M2H_:>_|GOT?|X_#W_H8?CS_P")4?M/?_/?KWFB@#P;_AG'X>_1##|>?
_\$J M/VGO_GOT?|X_#W_*&'X|_)4?M/?|SWZ|YHH_|&_X9Q^'O_0P_'G_,2H
M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|/?KWFB@#P;_AG'X>_P#0P_'G_P 2
MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?KWFB@#P;_(9Q^'O_\$,/QY_|M2H_:>_|GOT?
|X_#W_H8?CS_P")4?M/?_/?KWFB@#P;_AG'X>_1##|>?\$J M/VGO_GOT?|X_#W_
*&'X|_)4?M/?|SWZ|YHH_|&_X9Q^'O_0P_'G_,2H M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|
/?KWFB@#P;_AG'X>_P#0P_'G_P 2 MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?
KWFB@#P;_(9Q^'O_\$,/QY_|M2H_:>_|GOT?|X_#W_H8?CS_P")4?M/?_/?
KWFB@#P;_AG'X>_1##|>?\$J M/VGO_GOT?|X_#W_*&'X|_)4?M/?|SWZ|YHH
|&_X9Q^'O_0P_'G_,2H M_:>^>_1_P,X_#W_H8?CS_XE1^T|_|/?
KWFB@#P;_AG'X>_P#0P_'G_P 2 MH_:>_P#GOT?|X_#W_H8?CS_)4?M/?_/?KWFB@#P;_
(9Q^'O_\$,/QY_|M2H_:>_|GOT?|X_#W_H8?CS_P")4?M/?_/?KWFB@#P;_AG'X>_1##|>?
_\$J M/VGO_GOT?|X_#W_*&'X|_)4?M/?|SWZ|YHH_|&_X9Q^'O_0P_'G_,2H

M_>^>_1_P,X_#W_H8?CS_XE1^T|_|/?KWFB@#P;_AG'X>_P#0P_'G_P_2
MH_>_P#GOT?|X_#W_H8?CS_)4?M/?_/?KWFB@#P;_(9Q^'O_\$_/OY_|M2H_>_|GOT?
|X_#W_H8?CS_P")4?M/?_/?KWFB@#P;_AG'X>_|##|>?_\$J_M/VGO_GOT?|X_#W_
*&'X|_>)4?M/?|_SWZ|YHH_|&_X9Q^'O_0P_'G_,2H_M_>_>_1_P,X_#W_H8?CS_XE1^T|_|
/?KWFB@#P;_AG'X>_P#0P_'G_P_2_MH_>_P#GOT?|X_#W_H8?CS_)4?M/?_/?
KWFB@#P;_AG'X>_|##|>?_\$J_M/VGO_GOT?|X_#W_*&'X|_>)4?M/?|_SWZ|YHH
|&_X9Q^'O_0P_'G_,2H_M_>_>_1_P,X_#W_H8?CS_XE1^T|_|/?
KWFB@#P;_AG'X>_P#0P_'G_P_2_MH_>_P#GOT?|LW/>?
|*RN|_|U;7M;_L3XM_M#^&+"_P#\$_B'7/%>N?V'X4_-:"
M^)_AKPI8WWB+Q+J&JZ|JO|E:#I6FZ5;7JZE>WGV.RMXY+B3RP;|YKP;|G'_M_)
|XA_|+S^U1_ZT|7Z_#|G'_DGOB'_++S^U1_ZT|7Z|YKP;|G'_DGOB'_M_LO|5'_*T|7Z|YH
****_"BBB@_HHHH_****_"BBB@_HHHH_****_"BBB_M@_HHHH_****_"BBB@_HK^7_(_..?^"
|NK?|\$_L?_7A/X"?LX1_-J7|97QN|-_M77B?1-
>UNST|6|!^!GPWCU*XT6/XB:IX;U&*YLO\$GBCQ'JVGZQH_P_T'5;2?
MPZMSHFNZ_P")8=0L='L_#?B>?_@E-_P1:^^'7Q%_9^^%?|87_5>M==_Z;_
M_>7/@WP_|4_8B_:TUK5_C%X\$^#_AGQCIMMKGA7X9^&?A7XUN|3|_O:EHWAZI_MTO?
\$_UWJOAO4)-(UU|4|_|^\$_|'-VS0:B_?T|T5_-W_P6F_8(^)'PO_X)W?M1_M^/_@F=|4/?
|*FJ^\$_A%|0_8^*O|/'PVU-3^SQ|7?@>_AVX'Q@|_|>/'@YK_M-CKW@_X_,\$&W|'V^KZKX:|9_
S10A_K>LRV=YX8UZ34&UC1|<|+?TB4_%%_%_M_!1110_4444_%%_%_!1110
445|Z_M>?!SQG^T_>RS^T_|"?AW|2M2^#GCOX_MO_!SXA?#KPA|4|(-^NH^
_\$/BWPSJ.BZ7XEMVTJJTW54_LV|O(YH-*U&PU2_M.2O|UY;7BP3(?15%?SM?|!O'_
_\$_A_P|J+_|@DC|)?VBO!7|2W|07@OXL3_M?&+O_P"\$O\$O@|X?_MUGOUK_P-?
AU%X9TWO'::|XKL_0|=^&_!5^/&?Q0?_M7=(M_&%I9>\$|>SM|3X?^%W.NZ|/(NF_T2T
%%_%_!1110_4444_%%_%_!17_MXQ_|'|9_Q8_8_X)8?M%?';X%7|Z#|7IV|?#?#3P-
XN2REOG|_#W_P_3/&>C_M>%=5|96L8MKBT@UG00#=[K=SX7O=3,>FV?
BPZ%/(<)|J#)'I&H_P=/'"?_!(#_M|HC_(*T_P#!+?)
9|_:C_9S^_'@3X<_MS>\$_P!N+X|^)_B=^U)|9/&?Q3L?
MB_XS|*OI7@BST2.#XP>\$=|>>/_KG4?!6LZ5'K7AOP_>_8='CU+6O\$&L6FL:++
M|VJZQ<:V_ZZ65%RB9XK;7=1@N=4EM8W::W>Z;)&94!/A/G_!8K_@M|^U=^TS_M_P_%
"??_!&O_@E;X^U#X1Z|J_QDT+X"_%_|H+PO>&V|9ZA|1KW6|*P|6:#X_M&|1Z<&UCX?|
@;X.M#J|DWQ\$|8>'|BR|ZUJ7A_Q|I>CWFD^'_G?QH?W7T5_M^/O|O|P0L_X)N_L|^'_|
T_Q_>SUX*_>^+T^GOOX|_:0_:ET2T^_7Q|<^M*YH-FK^+HO\$_Q\$'B.7P%=WMR|T|G8?
#S_A&|32O,,L)FU2: ^U6^>=OBK^RM^MT9^SQ_P5,_X)7ZQ|+OVB/C+XK_8"|3?
%_P#:&TG03^S?|2_&%_|\$RV^\$7QM_MT_|8-
_:ED^'FM^#/B+XRAUWXXW/PRUSPM:>;,*V^'WBOQ|K'A?P%XGL+5O"
MMI%INO:)HWA\$ _H+HHHH_****_"BBB@_HHHH_*_FO|^#K|X(_+X@?|\$_/|
MVA_B|XT^'|A'O)|4O@%J7P9U7X+_|!#U31K2?QC|+KXC?M)_OP#X_B|^(_M?
+74|+TWQKX2U!|)|4Z-%%CH=J=C*|'|2^M)->^+/_B9OVR?
%NEPZ+KVC^%M)T7X4_\$74|^'=C>WE|J\$M\$/A1KG@;XJ+XX|2>\$OB;J_C700AA|3=)?
0KW2K6'Q-J?@70?&&J1ZGX2O)_|M3|_077@W7=/_GFO|4/_DTNYCMKL@'|VT5|=?
|\$_^OV<_B+^R/^Q9^SA^S9|6O_MB|J7QV^(_OP>^&NE>\$/_%/Q0U_|1D?
7|ZVGN|J3|.FUBXN=6N/#OA*QN|7P;X_M5N=4>/4KGPSX?TF>^M+&ZDELK?|I%H_****
_"BBOS#_X*Y?L|ZA_P44_9(M/V_M4(I+ZU_|>/_OC|^SGJ/Q/U32K_2=.U?
1_A%X0^+OACQ1|3=2T6?6;FWMFUN+P
MAI>J0;_D46HW2ZG<6DT6DZF(7LY0#|/**_AI_P"#IC_@G=^PE^QQ_P_\$G/AI_MJ|^+_P"R-
^S|I%?\$_ND_M2_"_P7#|0|!7PP|+6?Q5U#PM>>/_C'?7VB^(_OBU<_MZ==_\$_SQ79W|
|HVG76H#Q/XLU>6_N_.T^:|DG>QM6BYG_(-/O^"?O|_#W|8O_M_2X_:_'U#|J+|DS|G_XY>
(|G|L|XH_#^QW|0?A;X2UKXFZ+X_C^'?->J6W_MA|PK|4GTQ/B+X.L+#5=?
US5=,7PIXGT:72|5UG5-2TZ2UOK^ZN)0#^|RBOR\$_M_P""-G_!|/74?
^"9GP;_:@_9NM;2XA^%UU^VY|8?B=^S|?7NMZ?KNHZG|"O&_
M@GX3MX)75;FUOKK4\$UCPU7GZ|T_M_%%?#?|_P4/_."@?P_X)|_LR>_?VF/V@=?
@MM+T.VGT|P+X&M+VW@|7_%O_MXAW%GZUC69K=GO;_R)=A_#.AV^I^)|
<=>VT72;ZXCH_X(MV?M4_%7|MS_@FU^S;^U5|;+W3;WXE_&>#XK^)=?&BZ78:-
H^F6MK|&|&ZNUN-8U&UTJ+4M?U'5= MV5GJ5G=Z=J-
L:7^GW|M/97UC>P175G>V=U\$|%U:7=K.DD%S;7,\$CPSP3(|4T_M3O'(C(Q!_+-%?Y4?
CWX/?"IX|_|!VK|/A-|%_GAKX9?#+PI_P49_9A/A;MP'X.TV'1O"OAJ'7|A9XFU*Q|VZ-
:A;+1M*?6M9U*ZL|T(Z*VTO2XKA;#2|.MST^WMK6'_5-

OC1X6\&Z+X<^(/COPKKOP&^.FK:AI?CSQ#HMI8WGC,?A1X0NOBNF@Z?
<>&CIVFZ5\6\2\7XF>'X=-\R5=,?0/%>F M3V"3SOV_|@OIXE_8M^#_QE^+?CG\D_M"?|
;@MOV=-=^"/C;QAJWC#1-0^&?Q+^(>F^&|#U6STG7+R33;;XG>|+'Q-I M=_8^,-
&C\ZIXFU'09-.U>|BT'7\5T\|2:@ HHKX;_X*'_|%_@!_P33_9D M\:_M,?M
Z_!::7H=M/IW@7P-:7MM\XO^+?Q#N+.YG_.#GP19S>8\UK&LS6\|M/>W_
)\$NG^&=#M\3\3ZX\|MHNDWUQ& ?^+|>|UX-^SC_P D\|0_JEY_:_H_|>^+|!^SC_R
M3WQ#_P\!EY_:_H_P#6GOB_7O->#?LX_P#)?/\$/_9>?VJ/_%|XOU\|S0_4444 M% %%% %!1110
4444 %%% %!1110 4444 %%% %!1110 4444 %%% %'^1)_ P= M3:CXCO?
^"XW\|75MKEQJ\$^F:/X?| V;M_|'1WN_|-:>')?V9?A%JUU;Z1N4*=
M/:Q=JGBJ\|E\|LLG\|JW6I\|MYGF*O\|KFZ7_9G\|F:=_8OV#^QOL%I_9\|E_9_|
M_LSI\|!@_L\|D_HOV#|+Y7V3\|_H_P\|G\|OR?W>VOY\$?^#FW_(((*\$C_(*&MQ>\$_VR?V/_
'LM?| VG_AIX07P+|1/A5\J.GZ+|A &GX;:3=WVK>' +WPGJ6J7
M%CH\7Q\|76IZS;)IVKWEJGC3PSJ%MIEGJ=MJ_A70=&|1?2_!);_@ME\|'K'
MHF3X3_LO_P#|2;QA_P_,'MF_L_>|M^%7Q\|_MB6NH_L^Z9X_LO_FD)H.@_M?
\$30/&GQ5L_"GA.ZOO%&A;:_W>OZ#=:O9ZW\XF_M(V&G7FBW>CZC>@'|,M?P_MD_|
!W#_,%1/CS_|/B?|/#_^":/|_Q&|1?";3OB5X&T?XG?M^_!/NIW^B^M)?\$6C^.%FN^"/
PS&M;9<6.J:=X;AA|JXF\|::8W2#O7::OX6TRZN8M_ML\|6T_5/Z:?'G_!1*X^,=
|HGPR_XJ>\$|+|KCXAZ_XITO1_\$OQMM+?7\?|JC;X M^>#5U2TB\4^/?
&GQ^M\|*P3\2M8L\|(-^?"PL^"NO^.?&WB35X\|>?4\|0?#* M3:S)_ ,=_P=N_|\$O/C\|1/B_|\$A
@IA\|/ASXD^+GAOX<> ?#GPP_:_|\$^!= M(O=:_|6^&-_|">-?&?
C7PG\33I&FPZAJFI>&KZS\6:IX9\6ZE8:??+X-M_#^@ M:OJ<3:5?ZGJ&F %O_@XV^
'PY_X(W_!W\|@O\|JG_@F5I0_8\|^?@OXL M\|)=| M8_!T_P#" +WOOD\|(0>|!_
_8VQ^/|08>3I?QOU276?|WF:|J7Q,T\|O+>>*H-= MU>S\13ZA8M;6L'TE_P
%EOBO*O^"D_:_|6?| P4\$|9_"GP3\|6X?_/_// MCGP5KT^CVM\|K/PA^)/B;|HX-
_!OXZV'P\|0W*/K.E:|X@N+?Q7X;O+1;I8M M"+OPCIMM=4LX9;'X;:DU\XOO\|CQ%8_\$S4
MO"M_X*L/'FLZCXHLM/TSR\|Y?IG_@LC\|)OA9_P36_X=+|_@GUXV^*O@F'XO3_M^?
V>O\|/ @WP_-KL-OK'O<^)|OASH_P"#GQG^/%|A_="OFBUS5_#GAV\|NO%GB
M*XNQ9+#H7A^718=7EM+W4\|MKL_)A X(1_|\$ZOA7^VK_P0U_X""^*_CQ\|0
M/C\|JWA#X>_%3\|I6Z^%P?|+?&Q-X""^&?@KXP>%?V6O@IXO?XYZUH/|@S4\|#7
MXJ^,+R\|O"7AFP/_|3;Q9X"-Z'X9OVT3PQ::KXOU\4L&_X-5?#GQ%_:KU M3\|HS\|@_XY?
M#?'L_L2>|/!6@_&?4_P\|G;P\|3?%P\|TSQGXE00\$#>#SX9O0B
M#X.U/1OB=X4^&&H6VK7.M>+OA_|#|O9X4TKOKXCTSPWJ6N2R1Z7?6FL?6'_M;??
M>_LN_!;_@A+_P4Y^'WQ:_^/OPK^'7CS2/'_T=X_N_!B_QCH^A^*I
MO!WQ(_9E^!GPJ\|Z_I6@7US%JNNV7BCXEZ;|X#TD:);ZA/<>+)|.T+R5U'6=
M'M\|XQ_X.VOC\|\$/@C^V+^U;:_&7XN?#GX4_XS_9LB?PK\|\$?QAH7@JPU\|_M
(0;Q5%XR\|8)IVI^(|H3M.GF_|>\$_.U3Q5J\|NA/9^&|UG7)8QIFCZG=6H! MK_|!!'QOXS_
&*?^#DOXS_L_";QOXP7\|G+Q\|>_P\|NK\|GO5_!&K;W>W^DZ MWHW\|MC\|?
\$WPW\5:QITMQ\|@F\|::3_PJ>QLD\3"V;5\9ZWKU@LZV>KWBM\|C_M_!|O%|!A\|)?^"|3?
#K\|G?PIX0^_EIXNN/V9O\$=DOP\|*:1HN@Z%|1/' +Z3_M+J7CJV\|*Z=#9:*=2GUZ6/Q#J4\$-
O;0:MJ:W%U=AKF\|NIY.C_._";7\|1_P'L_
M^#KC6\VD=2^+|/@;1O@+X\|;F_P""B/B'PG\6M=UVTT'P-K&B?&KPQ^U\HWPI
MU_/7=8>QM+6T|=:KXV\|)Z?H,M\|J+B\|U_3H\|IY\|#O?^#EVIEL/^#AOPQ?0: M?>ZM-
967\|&|W#I>F_8_|1U*6V?1)H\|L\|0N\|L/MMXZ"VM?MU_96?GR1_:: MNVAWS(?;?| P<:?
| \$N_7_!|(X=_LD?M^L)?\$O\|H/X:_)_C'-|C/A;_M5^_OQ\|4?%'XI_\$;O-X-1_\$;0?
BMK_B;6O\$DVH:=XLUV3X=^_5\9:=X3L\|C M\|!;W%J-I#-X9TPPF/5_WN\|?M'_|%,_^"F_
;Z?|+X_P#_3DU#2O#_|: M'QT\|>')^ (E\|HGBCPW\|_%%U#X;|5>*A9\|>;OX+^+
>U31?"7@#QEK/CCP_M?<:EH=|J7B+P\|X9\|)W.O0^'=;TWQG:>'I5_:_S_@ZO\|VIO_'!|?
VK_BC\|+&GO;_&\$WAGXK1?%3XL_%VX M_|^)-_@%UX:T>Z^,'B&P\|!#XIV-Q92V>EW\|
<=M=VFJ^*K'4K(_*7_@KI\|'? MAE\|SO^",7\|)=U\|0?_?P+|+?%|+|@/V.?\$'AOQ?|1M5\|01>,8?
%FO?#?3;7X M?V<|W%_33_P2\|^*FM?|_!1\|_(-|/'UY^V;9;:_^T#J6K_#X^?#?'Q>?&\$^PT
M\|Q:OQ%L/A1XV\|::?X UWQ\;ZC8%+WQ/H.CZ#X/*^)+Q\|WQ'^<^*_#,'CN;6?^ M\$GNC>0?
RL_&ZUA^*7_!IU^SQX2_9W_9T^,4S_"+JINV^,W\|7'Q'U/X=^)= "T
M#_A)-1U7XMZ#)|1+7Q5K.DVJ?&2Q\16_C7P392>*O MQXFT+X<^&=&TWPI\X_
MUSPU?V?A_2-3_>W_(-SOVAOA%|_.?^#>?Q?J?Q+|4S?# 'PW\|5_::;Q_XX^)_ M?ASQ1\|_
(+?%UIX3C\|?&CQ=HNC^!/'UUIJ&-4M;+Q\|K>CZ=?_!S7_!HK\|_%\$'\|1\|<_P"T\|&|9^+O
GPI\5_ML@^,#\|<=2^?'BOQ#X^ (7B3P);?&\$\|X66UAX\|)?\$'PCJ&E^*_TWB/QAJ/AW
M4O\$6N^'M0L-2O?!GAOQ+X32_M(O\$|KG^@OP3_P_\$%M2_X\|)_|\$@O^"V'PY;_MQ\|9?"_|
:G\|ZE\|/CO^TO\|LIV4EAXAUFY^\$WBGX&?L_P#QCN_A_P#')AXH MTC2(

'Q\UUM6L+7Q9_P@,FIV46DZ)+X?N?&_BWP[XBU/28?P]_X,W?C3\)/_MA_P4C^+>A?\$_P"
(_@WX?:K\8OV:KWX9_"VT\8:_I_A\A/OB+J/QA^\$^I:5_MX\$|+SZI/6VJ^+I9M-.OGT/Pl;3-
JVMRVTMMI5I>70\$)_O(_X+9_&OX1_!+_M_O4_MY77Q<^(_@_X=Q?\$_|
90_:/^"GPW7Q9KECI%SX|^+GQ+^!7Q&T?P+|_M_!UG=2I=^)/&'B2[2ZFLM#TB"
|ODTK3=9UVZBM|t\$35|0L@#^_G_@STUWXG_M>%_V=O|_@N!XE^">DS:_|9?
#OP6_9XUWX2:%;Z='J|^M?\$_|2?_W|:NH>_M)_@_MTF4&+5)M2|56^E6<>G2
QWKS+;:"LIKXR_X)?*!_!10_()/?\$?1/BW^S|_P_M51TWQK|+_P!K;XS?\$_KQ_XO|
A|_P5ZTCQ3XFM/VC_AMX|I5V%OH6BVBGB7XSZ_M9_JRUO4?@SJ<%W=Z?|
%/PAHF@:7J&L:S|5_P_&G'|7_M_@3|E3X3?
!%B;I_'7PUTO|H"?|G/P1|9OV>OA;X_UF.RNOB_K'|-'PI_:/!^)
M'BW3=|T&+5M\$UKO?:^&+2XT/5_&.C>&-1@U^V)3ZGK4,EGI^F:EJNG>S?|_M!:_GX#?|
!_*7|NG|EC4_VY/A!;:M^QI_P53U6/P)J'C?|A;7O!7B/P+!:_?CE|
M00%|YHD'BSP0>_LV:UH.B^,?\$__BBU35KWQ1I_P"T#|+|/#EUX8|66=G
M_|+|86T=MJ6C0QK^=FG?L_ _RS_X=F_:_|DT_|/|/?#Z;|JRT_:/='TW7+;XL>&|&|
(Z7|2O@/|1?%5C+;1VQ|=;+J|DE_MO_:_T;*_ZL_BKX=:7|0EU)?%.H375M_*C_
&J/|(W@7|J|H|H|HGX3%CQE|6_M-%^\$B?LF^)-5^(|@3X5?
\$_KQ=|)3|7M,E^)|WPRT2S|\$_^/?%_P_P|5|A_C>3P_M';7VKQ^)|HPYH/B'18|?US0M_BUNYO=
MM2T35OZI_|@B1^Q5%M8|':7|./@Y|/%TMU.M+6U^(&M;UJ332>'X7?6QXG^(6C?
#V2P;Q5ILFGO_#2?|&?7|0'P/_9^_:_Y_M:0UOXY?%GX?_BT76OV;/B_VE:U1?%.D>\$-
'OSX*|>_#KXB^*XK;5-%|/'C'4;87'VB#PWX;U|6#\$_;2+^:_W/_O|_@U#^_7Q(^!?-5U
M^_G|\$_WAWQOXXKO?V??&WAOX^V4OP_U+5)+SP_#XP^#_B6UG|*>/UTUV2TL?%
M|_:1K'A|4M2TNWMI-6M-82'4H|F+3M_._G_Z75?Y2O_!N;|:?'A/X<_P"#@6U|M9^)/B#X6|+
^%?BKBX@_:5|)_#K7O\$6JV^A:=XO|5?%/4=3L_AMX9T>?5FLO/X_M@|=:_A?V&E>%M&
<1ZCK6LW|AHUC;3:I>VUI+_*_M5_'#7_'!P'^W_/_%W|H+_M_(+\$_LG?
!\$8_'7Q#|7_#_|JG*Y^_'|D)/PW_:4LO!6O:IX6U;XK>*/VEO%W@'|
MGT0Q'K6A7=GJEWX'|+?'WX@>>KPW'<06-UXGU;7-7UBWU.XTWPM)HM?_@X
MCO+7_@A7^T_,\$Z/VGO^"7^AZ!^R??_!;T;XU>'?C|!(OA+IH|%?_SXSZ'_M|_|1^"-QH-
C|4_A9X=ET_P'^+KG7--^*&N:1KWB"^T@>*YVM-&U^'7XO\$^C_M:1K.GR?|%)|V
/B_^S7_:_%G/V3_/_@LOX<|>,_OB=^S_GO|_8^_)7|2&I>_M_#NJ>)=:_\$_.N_LU^*?
A|8;G>>)=_T"RU75;:P9XD^%_PWT"XT;Q>;"73;:Q/
M;:MX=U8V%W=>%4|19G_!Q0;:_@N?^U7_,\$YOV5O^"8>M^&?VK-0^'F@_&?Q
M%|4/B|I*=:7QG|\$_?A+IOOQOO@XFF3?%+XF>' +74_"7@R7POHOPHU77/\$.CWN
ML3>*HSJFD>'H/#C^*=3T?1=6_/K'_@YF^"W|*|7W_'!|P%_P5D'PHG3X_ZU_M|(?
V2+OX.^/+KQOXZ%UX-^\$GOR|8>'?B_X,ZOV./V<-#_&*|G|NG2_AS|E_:H|8^+/_C5
M^S_XD^*7_"7^_Y_|1^\$=KXH^&_BJ#PE_PA%QXHF^'-GLU|PKH_&|8>\$;7_MQ;WV#
|*^LM975|;W&W_P(=*A^*_C;X>?!+7?"_AH^_T|6|H>Z|: ^&ETGX=ZN;WQ-"6^/?
@7XU_&/QSKW_MP=E|4Z|:'|2D^'NI-1.5MOB/;>_"|J3>)KGP_-5|2:7X;N/%HTM-'MO\$TJZ+/_<
MQW=Q9+=@'|>=?Y"W_!M=J.H:Q_P7Y_8ZU;XCW#7?B35/%W|3VH^)+OO1Y0O;
MKQM>_LP?'^Y:XOQ>JO|_Q/Y_%DL4D&56|_MQH/LRB||H5_KTU_GF_P#|5?|_MX(J?
MB_|\$|O^"E?AK_@K3_P3:^\$'B/X^_"33_CH7|1_BCX_#NQNI<^('PS_M|;/X@7Q!|3?"3>#-
&M|SQ'XC^\$7Q#;Y|0M9ZKX;TC5+GP1HOB#5O#VMZ3INE_M:%H^OZX?Z&5%?DA|
/^"Y7_3|^_P|TWQC>_M:?"^+X%^+SIL4OBKX(?M&
M>_|#^"7QL|'^(|I>>350"EQ|_B)>>_'!!XGU/2|NSO+%;KP19^)-+U::&)MM'O;T7EJ)?
8OA!^UY|5/VGOV@?#|G|?@MXAL_V+|/#ASQ#J7Q#_&H?C%X9_M|8?"^?
XK>_KJPCMO!O@C|FCX=^;=*T#QMXL|_:9?W;FM>-?C'XA|_:5|_J2M
M=_.30_AWJGBJXN+C4K<_SM/^#I/X1_##X2?|_MM'7X8>_"W@&/XE>/_@Q|7
M/'L'A32+31;:Q7|3_&_Q|C_D^&'@#|N?|G/QSX(!>%?"7B_XP?_C6?\$_?Q3|0
M>'=&LM(U+X@>(M"|:W/AW2?\$_/BR:RBA_MO7K/0;6ST9=9OEFU*73+&PL9|F6
MWL+..#K/^#Q+|GGXK>_="BO|A_^V+=>_"\$^J?_#Q5|%?ACX.F|?Z9H|W&A_M:++1?
AO|1/'VHZWX"U+48|F2ULM:O?"^K>|/\$_@'67T:/7TU+4|+2!>'PSK5
MS|AC_P#!U%^V|_V|VC?V5OBQ|\$_!GQ2L/@?IWP\$U71/'Q3^)G@/Q|;_M?
XPW=SXNDUSQ1JO@'P?XVTS1?&4W@|PC>ZE9^\$9?%VJ:/I^E^(O%EAXHL_#?
MIHZ3H;>M:F?U#_|%|?@_P#"SQS_&TVD?\$_P_8?#_PGXC^(WP/^?|/#^L_
M""QUJNBV5UXK^'&H>_B1^S/X#|:R>\$M>>(ZEH|'BWPCJUWH?B.QM;A+'6;5
M:%|0MKBXTK2YKA_\$A_X(1_|\$ZOA7^VK_P0U_X""^*_CQ|0/C)JWA#X>_%3_MH6Z^%P?
|+?\$_Q-X""^&?@KXP>%?V6O@IXO?XYZUH/@S4|7XJ^+_R!O"7AF_MPV/_!3;Q9X"|
Z'X9OVT3PQ;:KXOU|4I/V%_P""UG|57|_GB3_@UY|_:9X>_M^.?POUW4_P|H'X)?L@>\$?
@GIFD>_=%U'4OB=XF^"_P:_P!GV|^&B^\$+"TN

MYK05KWX5CP7XGL_B+'##CP7J^D3:'XC;3M9EM;""?||?^#;|HKW|EWX+?|?)?
M^"G/P^+7Q|^%?PZ|>:1X|VCO|WX+|7^='T/Q5-X.^)'L.OP,^%7@77|
M*T"^N8M5UVR|4?.\$039_>DC1+74|CQ9/IFA>2NHZSHJO? 'R?|+&JOASXB
M_MUZI^T9^P?|(&|GPS M??\$P=j>C?\$/PI,-0MM6N=:!7?#_P""WBSPI7C7Q'IGA04M-
-&"LY>(_CW^W5^SWJ_@C5M;O;_2=;T;|MG6Q^-OB;X;^*M8TZ6X^P3>--
)_X5/8V2>)A;-J@L|UZP6=;/5|Q6R/^#-KX M^!#X(_MB_M6VOQE^+GPY^%#>,_V;
(G|S_\$?QAH7@JPU|_A|O%47C+Q@FG;MGXCOM.TZ>;PYX0T|5/%6KP"Z\$|GX;TC6=?
MS?|%\$?\$/A/XM;|KMIH|@;6-\$^-7AC|H#10A3J|<
M>NZP|C;6MIXZU7QMX3T_09;Y|47%WK^G0/Y3SX!TG!X|'A9|)O|@JQX M)O?AC|/
GX!N/B|^R/X#^,'Q;-PEHMEH4?C?XI^(?CA^T1X?|\$/Q|06^MGQ06|XL|0Z7X4T"+7|>
(7NM76GC4M3ENM3N;R|N/K?_@|C^\$?PP|&_M|MI(CQ4)^_"WASXC?
&7X;_%&3XL>_|%TBTT|7_B+^;^UCC MEU_4?#/AF5?
#FDZEJ)GO|;0+73M&6Y.FZ7IMM;V?^#UO|FOXOK^UM^S;^UM; M>"_\$&H? S4/V9O#-
_!|0|=V&ESWGAWPY|10!_O: ^+_C?^PO\$6J6QFBT2||0 M: '13=,G|_Q:K'8QZT=+UE-)GU";3-
2AL/E+_(.I/V^/AG_P4%|%'CA+10"7B#QI=^(-='&ZEKVF^%IM>U(_ID_X*X_|JCEG_V9
ME_P3\$|5J?LB5|_|P#!HW%|6Y_^"(_|L'P|N?"|G|=YOVK?VDXO@I>_.%F M?
P7:_%N3|DG|FQ/AO<^+UM|>ZN&|+P>,3HTOB|8+6YF.DK=B*WFSM*|;:'7B7QUXW^
/Q M&_9@U#XX^&|T.RO)|3N=1^\$\$/AW4X?B4C6L<7@K41I^D>(9-/U76M%LM0^0
M_P#@VL:_O|0?"7_@AM_P4S|?LMZ_P"%/&|/?PX|??M#?M&_"GX!6|^FZ_|
M4+OPO_PS_P#LZ>#=\$^*FA_ "^9;K5?'.@Z|XOT>_M\$|'|2=5T_40%=GH?@_5(
MEN0%>BVFI@%SP_|LG?\$_P*_P#!?|X*F>&|@NM|_|@U|0_@"@GBKX0_MM&?M?
LC^("COP;^T=^VE967PZ^OBSQA=^-*U?X;>)_B;_P;_9|^'OC7 MPQX>O-
#ET"||^#+)M6|5^&/&NGP;5J/A'2M1|^_X,Y_VE/C1^U1^S+^WG^R M?
|=B5|0O'OPM^#?"FK'XHZQX.N?#^J2M>R?FU_P0^^*GC?|M:|_81_X+SZ+K/PO-
&AOVF/^"B?|47P\$^*7A|(^)FL>&/&BZY|2^\$=;^!/?Q
M\$|)#PSJWQ>UC3K|0/"WB7PWXEUG5-57X;:KKVD^)/B4R>#/#'@?0M-K#P|<^#?>N6-
QX_P#4.F:#XVUW0-7|237%|X/?|@Y:|1?L&^+_AG-KG|*8;8;:-^%Q^%|SX|^)45Q+X|&
M:?!\$^|Z/A0K7QC!|4+F:PNM TF>76|_&LFO:DJQU35+T7-V)_VN_P"#
ML#_@G=^Q9^Q)^P|^PU|O|+OP|(_F3PA=0%?PKVZ|97OB;Q+XU_X5UXNT MGXK?
&+6?!"N^/_&NN^)/"B|1%^).M:QXHT2T|6^(-='A:XU74K#PNVCZ3?7 M5A+|">.
|7Q%_P3Y_X.O;SXX_M1^!|B/X,^&OB;|M#XO?%SPAKFA?#SQCX|N/ M'7P|^&E>/+?
P1XA^NB^"|&US6_B_LUYXPTS3=4TSP7I^NZSIFM6NL;|/Q
MUS2;S3D_3G_@|*_:|\$_\$O|_8L_8E^&GB272/AI^T=K/Q?B^.'B'|F76?%>B
M:Y|8/AK|M8^'7CS10#VK_\$G1-#>:+PSJ-U)J.F:=J5F|UUI&|> M|767AJ|U^4 Z|X>?
|\$_N?|7_!2+@U;_9;N-%|&:=?_M2_L_>^_Q1_9R|M6VFGQ/XKN=3|_
_'CXLZ_XI^\$<%Y#|#|MOM'^+.A:3=>';/1)KJ'2X/'\$GA#Q) M'=-|,?
&3X>>+=4U"RN7N/AA|K|2_#_B^7PLPN=/U63XE> M*;^T^9_5A_1_P:|&?
X2_\$3_@CI^RS|//_OO(1%^*_|_P6T;QWX?^+O@C M0_\$F7_B|X;:OXD^-?Q9U_PU:>_#D-
PVL>&_P#A)=S)U;PY/JMG;6VO:=%< M7>D37D%MSZAI7QA^&D8W"POX0|8?
\$_4=5_9QO-">|^WK|O%.E: <6J|+" M&/WM_9&^#?|/G_!
G_@F+^V'_P5;|_LP>"_A|;_C;X|C5^UMIO@*#PQ M::5?_#?X;_%#Q!_XK_9<_9-
M6LK;PU3P%|/_SHEU|*(?B?X5T:2VMM-|=R M^*|12TFMO#OA;2|'_!W_
()@>*_@Y_P4G_8D_P""C_|2W_!1#X>?M1_MC_MR M?&?
QQ|5_AQ|\$_WA#|BS|K_H;2_@.GAWX.^%/&?POT|GGXE? WX\$\$_WX8? MLU>|
|7XG>/KJ0^&-!2^#=#1T;P|H_@V7Q#I\$?@G6K>36_P"XO_@HY^RY|/|_MO|'"7|5?
|*^AZI9Z+XE^-?P7|8>\$?|^JZE+-!-CXW-B=4|\$3;U;-PW%S%H0|
M6Z=HRZY);6|O<+I+7A@@FE"1M_|_P&^7_!2*|_."OOO_&C?^"?O_!37 MX;?
%OX">%OB1XQLO%_A|5+GX9>-/%FH^"?B_X>LU|)ZWYGA?P3HWB+Q)XY|#
M_\$WPS8^?^\$?|9_#?2_%|A)=^%|#NM-AU;PYXJEU_10#^E_(-E?C)_P4_|M:?
L; >||@W_P48^\$W|3'@?XB?_#QUI.A?"|QU^T|+ _B=|A_QH0OA+XJT66
M^TK3'UKXG;:H^J>|/HP|KND;|H=UKRW6J7UCH&J^\$M(U22,6UG->?TD5|Y_L MZ?
%SQS|==%|0_%#5?AJKOPQ^%GB#4+*+X)^?B'X6U|P;|9-|=|*6-K(FJ?.\$7 MXC>\$M>N(
|P':^-=6E;3P%|/-:T+2_&VB^#M+T|Q+X|_LOQ)XTN?A|/?HR@
M#^33_@|O_P"42_@C_LWX/?^JV^_|<;_&5/_*++X^?|G_!3_/6=?V5; M|W_X/(_VI?
V;|2_84|_?LK;3|B?M6?"GQ9XD^!>A>="USXI^\$/ M#-I)OB+JW|N>-
!>DWMYKO@C3;W2&_A'4M&NO%MGHT>O6'B#3+O1#J\$%P) M!PO_9D?M7_+-'AA
8R^+G|*?BSXZ?"_PG^T?XP;|A<^/?!7P8|4^+|' M|_|>/O'?
A3Q!"/@=I&G;IX!T+6KFQN/'+B^&WC9=2T|PE;:JZ;:?)?ZW8 MZ?87NFW-X>\$?|%K?

V\B7^V1_P7/_99_P"/>G>.0%?@_18\ M\$ LN # M7\HKPEX+10ZQX7E^VN_%37??
BSQ\HOB06-#N\U*|.:%X(13V/@00-!ED M:3\+15Q>(?!T>I73.*=)R_^-7CJ3_@@_1M_L-
M#_P#!-+0=\$_9HT3XF M?#_Q.WQM_9\^%EJG@7\GOXTZ?
!*/%ANPAM?7PI\K;>"+K40\$7A0Q?>Z+J
M'B:W\0^(K*JLM.16Z=J\$/BZV&LF\ P6A_8(^)-I&W!=0\9B_X+)X(15^M+_V,?
%G\1_ [+GQ*^/GC/P-X:UGQ. P M9^%M_X!\(^/+_OKI.@6FKZM:>'-
M8\+^\$H/'NC^(1+6/3=5\0WVM>\$%ELM3CT9-5P0\ @0\ >\$) _^"IO_!07\AW\
MFS_@FGK7AW\H:1_AQ\-\$\!0Q?_:#^%VIKXY^/PAM/BEXJT'^GN/'0QA.17
MG@S39_"/AKPE'K.J:/;^(;07K\4M=TKP78:4WC.X@T2X_F_X/!7P/^+G\ M&O\!G\?
WA'1_%#^/_C?XD\#Z5H6NZS\0_B'JFCZ=1'?&_P%0\$?Q1TOP_H_P MVO\
Q:>_"WPM>WM^VCZEKNN^%O\^E>(-;N\(:MK%_!&J5^BG_!MQ_P3)_9-M*?!\\$Z_V7_1
@H?!\(?@QH6D?M_>.?@W\>=)L_C_XH^(_QIO/#5\KM\!0OB=X M\$T9?\$7P^C\!M-U:30/
<.IK86=Q>V.=8GEN9_O^#K\HC/MXA6W_!(W\DSP3\ ? ?BSX@_#_P#8U^(_PZTKQ:VA:?
=:\KGA3X3^\$O@AXH^&M>D^-MZ:0M-NH-
"LO\$>K1))%I4NK6M_>B+3%O;VS\1_X(!_ME^-M;_X
M(@>'OAM^RM\&_WQ%^+W\+/!*"I6.LS: K?A#Q#H_@*I_:=L_B%\0/&?P\$^
M_A*:4\+LK7XOZO\1--UU?\$GB&\^'NL:EI_@.PA\.^'_\$\!UMXD\;66G:6?#_M
_"_V4/VAM)^\$7_!2330^#ASP#\!OBO\?_CUX\+=:S^Q;??\$WQWX&_:#_3U
M3Q\HGP\^)^5_XFO?V:/'"PZ\1^/+WX)?!7P&:+0_%%IJ7@00/A4GPYMY\;U'Q_MBN^#
!*230^_P"#++\L+X\^.\>:_N_9\)?_!'!4>_?A\|_A_X'^*GPNT/MQ3K5QK2?#75;CQ+=^%?
\$^C^\$Y=02YO\30#OB>VOM&OY\AU"+0+=+U/OI=1T MK2;?
4/\$.07=Y\L_1&JWQX^)^O\0_CO_@LCKOQV\?'_+5_X*A_I0?H\6H_M#
IX=^,=:!>)\233AJ&B_-%#30'OPR\6?*\$\TR#P%^SQH3>(IKX9RP:/XONO" M^A)H?
@NR\&?#?1;KQ#I6A>!/;\$'_&_'B6#X-?MW?M>>OB=H/COPAXEU3X M%1^&
IN#40AQX^?3?VM^"/&@+0>)K+XH:J9^&IG00A(NG:=I6HK\N^)^VH^\$M M-N=4M?I
M+R?7\FRTRY/&OVFO\ E<7\+_1:J\DG_TR_!BO\1.O\G\H\I MJ+JG?
7_#IW1OVI=\$^,OP_U;JG&Q_;\&_O%%U;K#Q%977PS3PKX/B^%FC M>)?
%:_+8G;2)O"ND7VB;J;GQ-!E?!\6VA3P/JVHQQ:+X>1Z\)>%;5-;DAT7 M6+;PK?ZIX?
36/T"_X/_VK?V:??%G\&'PD_97\)?'7X6^+/VC?!\W\:/@3QWXV M^"_A;OEHOB/X@^!/"NA?
;XZ:3J&J>>//#VBW=J>>"";WXB^"UT^P\5H&L:Q M;Z\!?:9WUC;7US:Z?P-V?
\$+JB#JG_@DMX\X)K_&_P?_"3Q%\0/B5\4 M/CWHGBO\FCQ?
XM\Z5\2/&_@+O7X9T+Q\$?%/@/PAJ%_!XFUZVT/3;'4=:M_% MOA&RN;WP/KOAA\
<^U:1>Z18ZA0!\V_+!M#^Q9^R\ P4@^/_5O^"NG\2/Q MNU3XX?MO>"V@O\$'Q(16?
L^S^%-*!%^"_@_13_&&MZEX\ _%Y(K77\&-7T4Z'KU\X,T77%_43_@Z_P#^"HGQS_8!_97^
M#P;_9O\1Z\H.OBE^V+K7Q.T\^+&@S36?BCP_+OA9IO@H^.(!\KV\5SX M;19^)
[_XE^%-,T\Q39M_:F@Z+'XBN=!\FTWQ"VD:WI7\B6F7?I37_:T_P#! M96>&\AUSQM\
(XY\+682+'INF_M/_+'?CC7,VVHV^W_0-A_6@SZ*EPHB8V MOA?XO^!
IC3Y)-5\)/<+KG\!%O_!R+!%+;_@M3_P\$^OV6?V_^";&OVO\5GA?
M\H7Q)\4/^\$M_"Q+GO\X^@)\)?&'00A?>^+8\GP)9Q2>*K/Q\;-I P+X*N/% MOPXO=
(@+9:5X<137/B.32O*T^6>4_^1_P!M/X-V'PW_&#?^"='QE_X(W_L MR_+!0&R_P""D?
PJ0_""7_BY\;_(9_1\$ _-O'P?XT^,?@_P6?!\0Q)XA^M+/C'XP_%?Q?
^SKH'@S\H33\6^+MEX(73;+5/%WC71+KPUXFUG2_#6E7W@_!Q
MEM9/^#K/P7I'Q:_X)Y_1\$VOV\?B?!*B%\+OVM_B\)\-?"Q1\(>.O\$'QCT3 M_A6 UKX'>
(/!\CKX7V?P1\<^(E\(_#Z^TKXBV_/#7P0TWX&_# MWX0>//S\$DOQAL?
5C#X0\\$,7^(5AHMY\;A3IR>&_T=_BOXE^-OBCX=:-X9 MU>Q\2ZU;O?Z4MI\$^!_P=U?
L_M*?&'_@ES^SKXNLO T?Q%\4?!#XV^&O^!Q M\GP@T3Q!?
>'O"EAJ/PG\>'O\$/C31\&OY=3\2P_#G2O%_::?)J6I37-J\A MJFEZAK0@M1J-U8@'1_+!N-
_P2_X)T^)^O\@G'^R_+MD^*OV9/#?B\JH7X
MV_"+XW>!\OBQXK\8>+_B9XL\+^_O""B+XF_\$?X=ZWX?UWX2>(O&V\!V;3M2\ M&Z-
INBW\$,7@&\$E;!\;C+J4UQ>2_S2_+!M?X*!(Q?!\%^?&?PZ;PYH\UX#C\+ M_MG^"F\
(ZA80:GX?N/'"*6FNZ\$?#E\HFI=6NH:/-HP_LRYL+Z.X@N\GM\H) MHY'5OZU?
^#6W\J/1/BE_P3_9?!\@%X&!\^/KZS^!\P\^+EA\9?BGK?AO6_" M_@/PW\3-3^/GB+7?
GPO\);KK>DVNG?%+6/\$G@'Q1JGCKQ#J_@35=5TGX=6& MG>'-%\626_B'QG::IG\G_I
_L1_1\$=?^#C7XD2_MM>&OB;X'T\$>)_V_-#* MZKH'PM\>.=1!?:1\2V\3W?PH\7^"??"@;3?
\$OB3Q7X?^(\Z;Z\X5L-?? M3\4U;+3\=&FG2_\$\$^D_&3^Q%\//_P)?^#MZ#X9?
#/PKHO@?X?>!\V^_P\J M?PSX_1&^&!*+3/#WA?PY\A_XRVNE:#H6F0!;;3=
(TNT2.TT\3K5(\2QLXH; M2UBBMX8HT_0_@^#^%_PY\.\$#_@G\H5M
1#^%M%^)^7Q.TC\J30?B+XYTO1; M"P\3^.=

(^&X_9K3P%8^*]8MH([S780"\$B_Q+;>'VU*6XETVTUBZL[1+7RX_M8_RB_9_:(^*Z;_P=
(6W|100XLIOV70#.N_MV_M^)%>B_'/5=\$[*E|G|_M?6'Q/T_1?#GQ0U"6^.@^%O\$5CJ?
B#2-\$|2V|SJ;6&@:|/%M:^)7PQTC|J37OB+X&T06K" |3^!M(^)M_9K?P%?
>*|'MIY+S0H0%|A#Q+<^'UU**WEU*TT>ZO+:-[7RYI_#Z;U_@A'_M^TA_P4|_X)=?
|\$>OC1X'_BO?A7^TA|_@I^SI>6R^,O&WQ)L?@_X_9P@^%_MO@K3/A?
=?'"P1X4@UVU|*_&+PCX+|^\$O'%SKU09:5JGQ|>^,O')|3_!!T
M#PQIOPWT+P3^1W_!Y;|(_A?|A_@I-|'_\$7P|>\$_!M?%O|F#2/'_3M_M0|+:)8:'+X|+=A
%GXJ:_%/XS|4+IT-O%J_BF|TC2=+T_4=?NXY-5U*WTZR6_M_NKDV|T)3^|I_-(F?
&OX1_&W_@E3^P;=?"/XC^#_(B1?##|E#|G#X*?A?"M>N6.KW/|@+XN?#3X%?
#G1_'7PX|8V=K*|WX;|8>&|M|6:|T/5X+2^?2M2T;7;M6*XT36|U"|_A'_X/+?BY|+_
(E_|%)O@_X=^'OC_P)^_M:|^\$G|&D>/_B=MI_A;6|[#7)??CI/BS|5-
=G|&>*|TZ:XBTCQ39:1JVEZAJ_|@7JZ;;ZC9-?MVML;F\$.:W_!R;^R;H_3^D_X)1?
M+?!GXQ?M_ZG^TU|6/AQ|3-9^)'Q||M:??&+QUK_(^U?QS|)+X
ZWX4|7^%);G6VTSX5OZ8?BIK&BZ-X/^%|AX2|&:M!X=TCP_INFZ&DUI>7U_
\$2_|%H_VP?VP+G_(-L?@#^U%|_%\$OC'PW|0_V@_M?
A|^Q=XE_:.*^(7@!9M%|1>&/AU|_A5I'B/Q_JUOJ^A-;77A&P|2?+\$+5_"/@_MO5-
0TB2VO|OBZYT-)(K/5)2/P_X.SOV|_VO_MO"OP/^?B|O1;_#
|Q1|OB@^&|'^^(6D_LUZ/X0FU|J*FN(M'U#5M5^&OCO3GT
M/47MM=TV|,ZE;ZMIMA*D2R_TM_+"_@H-|/|@W_P1A_ ^"1/B?PG|.J);1^M\$OC_&_LB?
L3_M.?"SX:>#|OX|>*.|T"U_9#|1VWORT&V^&?A9-9GUWQ?|M^K5?A|_:7Q|
ZYX=ULWW@720%NF3:++|JFF:|HP|^)^!SX|_|\$P?^"B>A_M?L-?!SX+:%H?_!-
W_@HK^SO|=OV//WCGP;X:|1Z|X#^\$/|/?_@O|FWXU_#KX_MC_\$;2O&6H>&(X=
^_OQ"|5Z5X3O?B5X0T7XP:)>_%O0?BOHV@VVA^,M>|_#Z?
MXN|2M_H,5_ER_P#|33_@E=^R#X|_&U?V2V_X((?%E_BA1/VA_&DFL^*O@)
M|+|:U_Q&_P"QYKVBZUX?U30_BKXFUL1-XV_9U|*6LUY?ZOJ|@KXPKHOBGP'<
M>%-1U/0730VMO#WAG_4:H_****_"BBB@_HHHH_****_"BBB@_HHHH_****_"MBBB@
HHHH_****_"BBB@_KP;|G'_))|XA_|+S^U1_ZT|7Z|YKP;|G'_DGO_MB'_LO|/5'_K3WQ?H
/V^(?^R|_M4?|_K3WQ?KWFO|OVT/Q/%?R6>B_%GX4?\$WX(?
\$+3GTS5K_1+V#Q|+_C#X3|_#_\$3P_MS*+_ \$VZ>P;7?#_A|KFD08>(|FU3PWJ^D:O?
^BT44_%%%%!!1110_4444_%M%%!!1110_4444_%%!!1110_4444_%%!!1110_4444_%%
%%!!1110_44_4444_%%!!1110_4444_%%!!1110_4444_%%!!1110_4444_%%
!!111_M0_4444_%%!!1110_4444_%%!!1110_4444_%%!!1110_4444_%%M!1110
4444_%%!!1110_4444_%%!!1110_5X-^SC_P_D|0_|EY_:H_|M:>^+|>|UX-
^SC_R3WQ#_-EY_:H_|>^+|!^SC_,D|0_|EY_:H_|6GOB_M_7O->#?LX_|)/?\$/_9>?
VJ/_6GOB_7O-!17P|^US^QOK|6=SI-|K7|7O|_M6|/7P|_|^'|W|/X?_9'^+Q^SUXGU3Q?
>SW)N_&?C7XJZ!:WWB_7-.T/2(|_M"Ti*^"+6XT+PA8WDGB+6?
&%CXYFO_#D|@WX!_8O||'_L_&_QUK/B*UD|+6^L_MZG|_?
L/Q4T|;68|O/&AZV|,OKMW>ZSXAU&|E_/W@HK^/KPK^VL_|!_|%?|_MP5_ ^+/G?|%'?!_|
P4"_96^#|/|@J/Q-^S/_P44_:X|8_M<^&?!-S|4_%T?@;X_M3_&|X,ZM?>(|GX4_\$GX9ZAXUU?
S=:|9^\$K2TNK|/|JUX9-O|>G:|;G7?OY_ ^M%Q_|\$|/VU_|
@EA_|+_|H;X_?'CP|^W|HOQE^'|5VD_#XN>_,B|IFH?;P_M%|
(HOB|X,^/|P@T7QKK&H:;|Y;GQ5IGBSP=XM^'WPMG|_*_:?P%KNC2:7|
M1XE|*V>J7@!_0/1161KWB#0?"NCZAXA|3ZWI^AS0-)MS=:KKFO:E9Z/H^F6J_MLJ-
H36|E9VZLZJ9KF>...R@MD@\$_UZ*(|40L_95G'|1GP(**RHSCX_MO?#|:KN'^*S?
|)#@_XC_#0T?|-4?LP_|'?;_|P|_P|_P#FAH_|MYHKP;_AJC|F'_HX|X#?^'?|A|_|T-'
U1^S#_-'?;_.._|/?_)H: M />:.*|&_X:H_9A_Z..^W_AW_A|_|/-#1_PU1^S#_P!''?;_P
_P##W_YH_M:/>:.*|&_P"&J/V8?^CCO@-_X=X>_|S0T?|-4?LP_|'?;_|P|_P|_P#FAH
|YHKP;_AJC|F'_*..^W_ (=X>_#0T?|-4?LP_|'?;_|P|_P|_P#FAH
|YHKP;_AJC|F'_HX|X#?^'?|A|_|T-'_U1^S#_-'?;_.._|/?_M)H: />:.*|&_X:H_9A_Z..^
W_AW_A|_|/-#1_PU1^S#_P!''?;_P_ P##MW_YH:/>:.*|&_P"&J/V8?^CCO@-_X=X>_|
S0T?|-4?LP_|'?;_|P|_P|_M?_FAH_|YHKP;_AJC|F'_*..^W_ (=X>_#0T?|-4?LP_|'?;_|P|_P|
M_P#FAH_|YHKP;_AJC|F'_HX|X#?^'?|A|_|T-'_U1^S#_-'?;_.._|M|/?_)H:
/>:.*|&_X:H_9A_Z..^W_AW_A|_|/-#1_PU1^S#_P!''?;_P_ M_P##W_YH:/>:.*|&_P"&J/V8?
^CCO@-_X=X>_|S0T?|-4?LP_|'?;_|P|_M_P|/?_FAH_|YHKP;_AJC|F'_*..^W_ (=X>_#0T?
+4?LP_|'?;_|P_M|_P|_P#FAH_|YHKP;_AJC|F'_HX|X#?^'?|A|_|T-'_U1^S#_-'?;_M_.._|/?
)H:/>:.*|&_X:H_9A_Z..^W_AW_A|_|/-#1_PU1^S#_P!''?;_M_P_ P##W_YH:
/>:.*|&_P"&J/V8?^CCO@-_X=X>_|S0T?|-4?LP_|'?M;_|P|_P|_P#FAH_|YHKP;_AJC|F'_*..^
W_ (=X>_#0T?|-4?LP_|'?M;_|P|_P|_P#FAH_|YHKP;_AJC|F'_HX|X#?^'?|A|_|T-'

U1^S# -" M?; ,. \/?)H: />.*|& X:H_9A_Z.. ^ W_AW_AI /-#1_PU1^S#_P!" M?; _P
_P##W_YH: />.*|& P"&J/V8?^CCO@- X=X> |S0T?|-4?LP_|M"?; _P|_P/?_FAH
_JYHKP;_AJC|F' *.. ^ W_ (= X> _#0T?|-4?LP_|M"?; _P|_P|_P#FAH
_JYHKP;_AJC|F' HX|X#?^'?|_A|_|T-' U1^S#_M-"?; ,. \/?)H: />.*|& X:H_9A_Z.. ^
W_AW_AI /-#1_PU1^S#_M_P!"?; _P_ P##W_YH: />.*|& P"&J/V8?^CCO@- X=X> |
S0T?|-4?MLP_|M"?; _P|_P/?_FAH_JYHKP;_AJC|F' *.. ^ W_ (= X> _#0T?|-4M?LP_|M"?
; _P|_P|_P#FAH_JYHKP;_AJC|F' HX|X#?^'?|_A|_|T-' U1^S#_M-"?; ,. \/?)H:
/>.*|& X:H_9A_Z.. ^ W_AW_AI /-#1_PU1^S#_P!"?; _P_ P##W_YH: />.*|& P"&J/V8?
^CCO@- X=X> |S0T?M|-4?LP_|M"?; _P|_P/?_FAH_JYHKP;_AJC|F' *.. ^ W_ (= X> _#0T
M?|-4?LP_|M"?; _P|_P|_P#FAH_JYHKP;_AJC|F' HX|X#?^'?|_A|_|T-' M_U1^S#_M-"?; ,. \/?
)H: />.*|& X:H_9A_Z.. ^ W_AW_AI /-#1_PU1^S#_P!"?; _P_ P##W_YH:
/>.*|& P"&J/V8?^CCO@- X=X> |MS0T?|-4?LP_|M"?; _P|_P/?_FAH_JYHKP;_AJC|F' *.. ^
W_ (= X> _M#0T?|-4?LP_|M"?; _P|_P|_P#FAH_JYHKP;_AJC|F' HX|X#?^'?|_A|_|MT-'
U1^S#_M-"?; ,. \/?)H: />.*|& X:H_9A_Z.. ^ W_AW_AI /-#1_PU1^S#_P!"?; _P
_P##W_YH: />.*|& P"&J/V8?^CCO@- X=X_M> |S0T?|-4?LP_|M"?; _P|_P/?_FAH
_JYHKP;_AJC|F' *.. ^ W_ (= MX> _#0T?|-4?LP_|M"?; _P|_P|_P#FAH
_JYHKP;_AJC|F' HX|X#?^'?|_MA|_|T-' U1^S#_M-"?; ,. \/?)H: />.*|& X:H_9A_Z.. ^ W_AW
M_AI /-#1_PU1^S#_P!"?; _P_ P##W_YH: />.*|& P"&J/V8?^CCO@- MX=X> |S0T?|-4?
LP_|M"?; _P|_P/?_FAH_JYHKP;_AJC|F' *.. ^ W_ M (= X> _#0T?|-4?LP_|M"?; _P|_P|_P#FAH
_JYHKP;_AJC|F' HX|X#?^M'?|_A|_|T-' U1^S#_M-"?; ,. \/?)H: />.*|& X:H_9A_Z.. ^
MW_AW_AI /-#1_PU1^S#_P!"?; _P_ P##W_YH: />.*|& P"&J/V8?^CCMO@- X=X> |
S0T?|-4?LP_|M"?; _P|_P/?_FAH_JYHKP;_AJC|F' *.. M^W_ (= X> _#0T?|-4?LP_|M"?
; _P|_P|_P#FAH_JYHKP;_AJC|F' HX|MX#?^'?|_A|_|T-' U1^S#_M-"?; ,. \/?)H:
/>.*|& X:H_9A_ZM.. ^ W_AW_AI /-#1_PU1^S#_P!"?; _P_ P##W_YH: />.*|& P"&J/V8M?
^CCO@- X=X> |S0T?|-4?LP_|M"?; _P|_P/?_FAH_JYHKP;_AJC|F' M*.. ^ W_ (= X> _#0T?
|-4?LP_|M"?; _P|_P|_P#FAH_JYHKP;_AJC|F' M_HX|X#?^'?|_A|_|T-' U1^S#_M-"?; ,. \/?)H:
/>.*|& X:H_M9A_Z.. ^ W_AW_AI /-#1_PU1^S#_P!"?; _P_ P##W_YH: />.*|& P"&MJ/V8?
^CCO@- X=X> |S0T?|-4?LP_|M"?; _P|_P/?_FAH_JYHKP;_AJC|MF' *.. ^ W_ (= X> _#0T?
|-4?LP_|M"?; _P|_P|_P#FAH_JYHKPZU; M=_9KOKJVL;'|H;X&WE|>7\$-K9V=K|6?
5Q=75U<2+#+;VUM;PZ^|L|Q/*Z10P MQ(TDLC*B*S, ?<; "BBB@ HHHH **** "O!OV^(?
^R|_M4?^M/?%^O> M:|&_9Q_Y)|XA_P^R|_M4?^M/?%^@_9Q_P^2>^^(?^R|_M4?^M/?
%^O>|&_9MQ_Y)|XA_|+S^U1_ZT|7Z|YH_-O|O#PK_P4=|?ZCX|^?L?^\$/V)_\$/P9N=
M,FN_C'8_M0_%|X|>|!|=|?Z@|S>V|O|.AH?PE^!OQ!LW^%DM@MEJ/BX3^+K34M?B!)
<2>=";TBT|P>)-^(>A|G_5@C_9PU2|U+0_ ^"==G^UA;?.\$W0I/#?
M@C2/\$7|24_|.\$WP2M|/ @U_0M4^)%QX4LOB3IOQ-U.)/\$UWH7B*P^\$NH^\$O#_MN_0-
*O?"?B58=0U;|/%**/R(^,?_!-!_P!M|P?^UCJG|9(\$>\$OB=^U5^R|_MH|/)=GH?P7UO7?
B'X-^!GPX|'+>|/%'QA*ZSI^C+QMX1^&6K?%GQ|;_&/Q,G MQ"NO\$.L?
#OX=Z/!9^&!/WA'2?"EC)IWB3Q7XRP/A?^Q1^V)|6_VE_P|C/X^?MM|>?*?@%|,|^%_BA:
(^+H^)'MP|_6?P|;2O!%EK_A+X5>'?^%F3Z+XS|7ZAXC?XMW4>C6&GWO|+44 %%%
M'@WB+_DY|X0?|D&_.. |6%^RO7O->#>(O^3GOA!_V0;|H|_U87|*|>|T %%% M% !1110
4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M %%% !1110 4444
 %%% !1110 4444 %%% !1110 4444 %%% !1110 M4444 %%% !1110 4444 %%%
 !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% M% !1110 4444 %%% !1110 4444 %%% !1110 4444
 %%% !1110 4444 M %>#?LX_|D|H0_|9>?VJA_UH|XOU|S7@W|A
R3WQ#_V7G|JC_P|!>^+|M|^SC_R3WQ#_-EY:_H_|>^+|>|UX-
^SC_R3WQ#_P|EY:_H_P#6GOB_7O-M!1110 4444 %%%
'@WB+_DY|X0?|D&_.. |6%^RO7O->#>(O^3GOA!_V0;|MH|_U87|*|>|T %%% !1110
4444 %%% !1110 4444 %%% !1110 4444 M %%% !1110 4444 %%% !1110 4444
 %%% !1110 4444 %%% !1110 M4444 %%% !1110 4444 %%% !1110 4444 %%%
 !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M
 %%% !1110 4444 %>#?LX_|D|H0_|9>?VJA_UH|XOU|S7@W|A R3WQ
M#_V7G|JC_P|!>^+|!^SC_R3WQ#_-EY:_H_|>^+|>|UX-^SC_R3WQ#_P|E
MY:_H_P#6GOB_7O-!1110 4444 %%% '@WB+_DY|X0?|D&_.. |6%^RO7O-M>#>
(O^3GOA!_V0;|H|_U87|*|>|T %%% !1110 4444 %%% !1110 4444 M %%% !1110
4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M4444 %%% !1110 4444
 %%% !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%%

!1110 4444 %%% !1110 4444 %%% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M %%% !7S)^VCK&K^ V2OVC=:T'5=2T36M+^#GCR|TS5|
{OKK3-4TZ|@|W MKP7=AJ%E+=V=S"X#13V|TK|MO| X+%Z MA6? OCOX*? CX?
7'^\$/&VA:IX3|0? '\$|Q|NMM4O-'U6 V>H?|(SX4TZ9=-: M>|IUM-5US4|FX|F97E|.V5R@V?
9|'<*YYGN9X#\$8'+:U: X?'86KB<95BJ6" MC2HUX3JQ|M5Y:=:C%IT*/M:KO| P|.Y^
>||C3X<^'""\$V6<1|68' |19G MP|F^"RG(L%5EC.
(*N,Q^6XBA@:BR !>TQ.!H2K582CF&-6\$P<=>5N.)YXJ+-' MK AI:|HW HO _.:/_#J^._|Y?
4?|+?M&_J%_|C9_X=7OU_P#+ZO\$Z*_L? M^S&O#T||LD||VAZ3+--
|2RS2R6%N|DLLCEGDDD=B|N[%G8EF))K#PC;;;PU!MMW;;I0 M;;;U;;W84445|TA1110
5X-^SC_R3WQ#_P!EY:_H_P#6GOB_7O->#?LX_P#) M/?\$/_9>?VJ/_%I|XOT'_|./)/?\$/A
V7G|JC_U|XOU|S7@W|./)/?\$/_M &7G|JC_-:>^+|>|T %%% !1110 4444 >#>
{O^3GOA!_V0;|H|_U87|*| M>|UX-XB_Y.>^\$'_9!OVCO_5A?LKU|S0 4444 %%% !1110
4444 %%% !1 M110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
%% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1
M7RM^T3^VE^SE^R|92M|5_B|TUIXB\$ GLO-6@%/\$'CS40ZH|E>' +*4S:=!\$YO,MQXBG:U
MU_XDZA;MM7>E|+|^A>%_.3>#%I5EJ&J6K,)+3Q&CJ&'V?#G_7\$O\$SA4P."=#
M!2:OF..YL/@^5_:I2<95<3;_*AJ59)Z2<=S|!5_I,>\$GA!'\$87B+B*GF7\$ M-
&_E'A3AWV6:Y|!1*ZIXRE" M3P>4-Z-/|9@7.#YJ.*SM%_T:_|J+X#?LV M:.*=9^,?
Q'T'PD)+;O<;X?:=M2|7:X%\$@4:+X5TU;K7+^Y4^SM?)9+IEK,Z M?;
|ZTC)D'X" M_|%OOB|X|_M'PU^S)X23X=:))YUNGQ|A96|AK?C>YB/FHM MSI7AX-
>^&/#CLIE_)XJG&|_640" *7P'_._:G|8?|6VL?|)X|T@UCP/X M>|03I?Z|A3OC/0ZUKEE-
&LEOK:&ONO|+|^!MSX,R>'@-X<8S3_%CS2>(I
M|3YC@|I_|O<%B)X>CFU1U:=JV%JY+EV3X5R;I2X@JP?.?SO?"|B?|M?|INKQ, M/B)K-
MXFETC79(X;|XR_&?5-7MM,N|Y|-4Z"^D=Z|XDLXTGG&G0>&=,N=" MM9\$;R>|TQ,;?
W+^!G_!&|EWX=>'KN'XJC6?C;XMU;2;K3K|5M4N|PMH.CM M?6OV>XN/"N@Z%J"7-
G>P;Y&L|3UC5|9O+:81W=D+"=%V_KX !@ # M@<=|2U|UGWBCQ+FZ6'P-
6.09=3Y8T<|)E4I4;BA|KDC4QD5"L^5+EY:"P MU&4=)46?KOAK|;PDX'G+>->
(|5|3>*L2YU<=GG&E.GC|)4Q-:|Q%7"Y%5EB M,!!U9MU%6S*6;9A3J-RIX^/,T?F/_P_?
_V#O^B6^(/_Y?Q!_>:*C_(<_M_L'?|\$M|0?|AR_B#_|-
%7Z<45|W_KEO;_T4V>_>'7&^7_3|R_H/U?_B_7 M@?|I&A|_|
Q#._P#Y@|OZNRO:6MO86EK8VL?E6MG;PVM%O>3R|>WC6&& M/?*SR/LC15WR.
|MC+LS\$DV***^<|NVI6V|VWU;/UN,8QC&,8J,8I1C M&*2C&*5E&*5DDDDDDDK):
(****0PHHHH *|&_9Q_Y)|XA_P'R|_M4?^M/?%^O M>:|&_9Q_Y)|XA_|+S^U1_P'M/?%^@
_9Q_Y)|XA_|+S^U1_ZT|A7Z|YKP;|G M'_DGOB'_++S^U1_ZT|A7Z|YH **^(/VM?
@U^VO|:KW1=#_9D;_*TG|BOPMI M.A75|JOC70/@+|VOC_|
\$WQAXSO+FX@L=)GTGXQ07/P|*?#|PYIUQ;W|W_9
MVD:UXQ|:ZMK#6D&M_#_3O"K|XV_(OP|_P5_:_3|_P#!*+X2?%#XB:|!|=6_
M;@^_.W|:EI_P3I^"/Q LO#M|:_!WXD_ '\$Q_ ^T/XC^!GA|H|/"-I-!-%X2NM
M|^)O&UCHT4NE:'XMUC0|M,BTGPQXGT^TMP#^E.BOYJ/VJ?^"F_OQ_X)(_\$
M'IWX6?M#?%+6?VR="TG_@G|>?MG_LW_!#^(7@;X:_#KQVOQ;|_-%70?@+X ME^
GCVW^_ '@7P%X+U7X=Z|XR|<_#|QUX1|80>!?
#GB/PGXD^B_#/QV_:_)_8^:_S_X)X_!_P#;N^/TO|IGA0|X*&^%OBIX*|_|3Q7|.&|.2%K_M
(6'X|L.ZWHO;Q?=_%F73=3UW1H0#|S****/!O\$7_)SWP@_P"R#?M'?^K"
M_97KWFO!O\$7_ "<|A(/^R#?M'?|JPOV5Z|YH **** "BBB@ HHHH **** "MBBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **_.K| MI?|X*?_++?|_V_17|4?|
"TOB#:>9%_P@WPXGL|8>SNUVCR?\$7B7S?^\$= MT'RG8"|M7O+W7+?M1ZHW@;P|_
J|PR|Z_._G: M;V_ (0|JMUXPUY+A"@T_4_%=I"/%6N7\$T9GAGLO#|A_2|0MI##=Z)/LWGI
M_AWPWXEX@C'\$?5EE>7-*5K.O'<_F/Q M5^EKX1>%|2ME7|K3XR|KC-T*?
#"'+I9EB*>+&6UG|K_HY_:_5_X\$?LQ_LNI?:=XU|<0^('5HDBI|O IMO\$7BX7*
M+)MM|7CBN8M+|, \$N@#?)|J6ESF-Q);6UUPA_GS_&CO^"O_.TU|<|JX|)_M"&_
_@AX1U.X_L^SM|D|VJ?\$K6ENI&M|>"X|8BVAN|N;EG@-O!X.T|1+^*X M)MO|4U"-
GZ7|FO ((Q_'WXK09^)_C|JD?P0|)W3K= RZ7>Q1Z|A3-4BD9W8 M?V&EPFG^'GN"-
LD_B'4?|5LWD\$LOARZ 9#_01^SG^PQ^S1^R|!;S_#X>V4O

MBN*\$Q7'Q\$!6&+Q+X|N|P"RM'K=U;QQ:) '<*J"YL?"|CH.F3F-'EL6D!<_7>T M|-.!/?
X<7QKGU+| #S| \$3E3DXSC6J<)Y7C*\$| ^PQ:70?SA_LZ_ |
M:) |J3|H2| @|8_%1I_@SX2UBX&I7^O? \$&&|U+XAZXMVZ3SW=GX-EN(-6%W<>
M:|CW'BZ_|L|DSHMX#M; ^@G|FG_@G)^R|^S&NGZMX9| %1^, '|F(Y#|1_B\$M
MMXB|107B*A-QH-K);1:%X6*2"7|/|H.EVFJK;RM;7FJWZC>?NZBOC>(\$7B7 MB-
3H5<5_9^7R3BLNR|FP| "5/91KU%)U0FDN:%2HZ+:O"C#8_?|PI^BIX1>
M%\$J&8X)?|9^*:4HU9<4|5*CFE84|2GSNOEN%E3CEV4SC4^(?^R| MM4?^M/?
%^O>:|&_9O_Y)|XA_|+S^U1_ZT|7Z_#|G'_DGOB'_LO/H5'_*|I M|7Z|YKP;|G'_))
|XA_|+S^U1_ZT|7Z|YH_-?|O3XQ?MJ>\$KWPGL-OV7OV
M\$ _BQ^TYX)|7:3*_ \$, , , =SKWC|10#AB|*^%K|+?P+K4?Q_U./Q+|+?DWX^_LY_M0?MJ_L'?
#^MPT?|C|PY^PG^T%^QI^T_|/VD/V.?V>/\$WOA^%?CWPMJFH?LH:QX9|2^#O#_M
(@UKX*QZS|_N@>-M,G|;?#GPSHEOJ7B6P|-M%X=|4>(4T^TDFTC3_-VJ M*
/YH/VI_P#@F/A 'O| X*V_ \$#|J7XL?M\$?##5/V.=#UK_@G|J|I&7L.?PR^M(?
CCX;_ \$#QY|50\$/O7T7X|Z|>?B5??L_>-B)X*TKP/H/C'P+|/?!GAOP?
MI_COQ7K7B+PRGB_O|K>B>\$=4DTC39_H|PQ|_#_P|M'|LW|KO_O|I?&_|K+|G
MR;|F7PI_P3Z|+?%/QQXT35_B5|(O_|_|1?|4WQ/^&=C|)K6_ ^%5K|'/&/BJZ M|_!#P39S>+_
|Y;:Y|1H/A|XT|0:KJ7AGPS??">#3;?5KVV_=&B@_K(U|0-M|4Z/J'A|O/HFD>(I
U:W:TU70|>TVSU?1|3M696:VU#3-0AN+*|MV959H;F M"2,LJDKD_C7HH_ ^|
=_9L_9UA_ :*^%FB0_+X*Q: +J/P5^/NJZAI\$?PL| #)I M=|JFC>.?V;+32-20-/70A:7-
I5IKNMVNFWDI+W%C;ZSJL-K)%|J-VLWM7#_M*_L/_1N/P&_|-|/|/?
YGI/\$7_)SWP@_P"R#?M'?^K" _97KWF@#P;_AE?| M9A_Z-Q^W_AH/A|_
/,|1_PRO^S#_P!&X_ ;P_-|/|/?_F>KWFB@#P;_ (97_M_9A_Z-Q^W_AH/A|_P#;|1_PRO|
LP_|&X_ ;PT'P|_ ^9ZO>:.*!/O^&5_V M8?| HW'X#?| AH/A|_|,|1_PRO^S#_T;C|!O_#0?#W_
_9ZO>:.*!/O^&5_MV8?^C_,|1_P,K_LP_P#1N/P&_P##0?#W_P"9ZO>:.*!/O^&5
M_P|F'_HW'X#?^&@^'O| |SU'_#*_L/_ \$;C|!O_T'P|_ ^9ZO>:.*!/O| MAE?|F'_HW'X#?
^&@^'O_,SU'_#*_P"S#_T;C|!O_#0?#W_YGJ|YHH_|&_X9_M7_9A_P"C_P#S/4?|,K_LP_|
1N/P&_|#0?#W_YGJ|YHH_|&_M_P"&5_V8?^C_|S/4?|,K_+/,|1N/P&_|-|/|/?_F>KWFB@#P;
M_AE?|F'_*_Q^W_(:#X>_#_/4?|,K_LP_|&X_ ;PT'P|_P#F>KWFB@#P
M;_AE?|F'_HW'X#?^&@^'O_S/4?|_#*_L/|T;C|!O|PT'P|_|F>KWFB@#MP;_AE?| 9A_Z-Q^
W_AH/A|_|,|1_PRO^S#_P!&X_ ;P_-|/|/?_F>KWFB@_M#P;_ (97_9A_Z-Q^
W_AH/A|_P#;|1_PRO|LP_|&X_ ;PT'P|_ ^9ZO>:.*M!/O^&5_V8?| HW'X#?| AH/A|_|
|,|1_PRO^S#_T;C|!O_#0?#W_ _9ZO>:.*M!/O^&5_V8?^C_,|1_P,K_LP_P#1N/P&_P##0?
#W_P"9ZO>:M*!/O^&5_P|F'_HW'X#?^&@^'O| |SU'_#*_L/_ \$;C|!O_T'P|_ ^9ZO>M:.*
!/O| AE?|F'_HW'X#?^&@^'O_,SU'_#*_P"S#_T;C|!O_#0?#W_YGJ|Y MHH
|&_X97_9A_P"C_P#S/4?|,K_LP_|1N/P&_|#0?#W_YG M|YHH_|&_P"&5_V8?^C_|S/4?|,K_
+/,|1N/P&_|-|/|/?_F>MKWFB@#P;_AE?|F'_*_Q^W_(:#X>_#_/4?|,K_LP_|&X_
;PT'P|_P#F M>KWFB@#P;_AE?|F'_HW'X#?^&@^'O_S/4?|_#*_L/|T;C|!O|PT'P|_|
MF>KWFB@#P;_AE?| 9A_Z-Q^W_AH/A|_|,|1_PRO^S#_P!&X_ ;P_-|/|/?
M_F>KWFB@#P;_ (97_9A_Z-Q^W_AH/A|_P#;|1_PRO|LP_|&X_ ;PT'P|_ M^9ZO>:.*
!/O^&5_V8?| HW'X#?| AH/A|_|,|1_PRO^S#_T;C|!O_#0?#W_M_9ZO>:.*!/O^&5_V8?
^C_,|1_P,K_LP_P#1N/P&_P##0?#W_M_P"9ZO>:.*!/O^&5_P|F'_HW'X#?^&@^'O|
|SU'_#*_L/_ \$;C|!O_T' M|P|_ ^9ZO>:.*!/O| AE?|F'_HW'X#?^&@^'O_
SU'#*_P"S#_T;C|!O_#0?M#W_YGJ|YHH_|&_X97_9A_P"C_P#S/4?|,K_LP_|1N/P&_|M#0?
#W_YGJ|YHH_|&_P"&5_V8?^C_|S/4?|,K_+/,|1N/P&_|M_-|/|/?_F>KWFB@#P;_AE?|F'_*_Q^
W_(:#X>_#_/4?|,K_LP_|&X_ ;P_MT'P|_P#F>KWFB@#P;_AE?|F'_HW'X#?^&@^'O_S/4?|
#*_L/|T;C|!O| MPT'P|_|F>KWFB@#P;_AE?| 9A_Z-Q^W_AH/A|_|,|1_PRO^S#_P!&X_ ;
M_P_-|/|/?_F>KWFB@#P;_ (97_9A_Z-Q^W_AH/A|_P#;|1_PRO|LP_|&X_
M;_PT'P|_ ^9ZO>:.*!/O^&5_V8?| HW'X#?| AH/A|_|,|1_PRO^S#_T;C|! MO_#0?#W_
_9ZO>:.*!/O^&5_V8?^C_,|1_P,K_LP_P#1N/P&_M_P##0?#W_P"9ZO>:.*
!/O^&5_P|F'_HW'X#?^&@^'O| |SU'_#*_L/_ \$;C M|!O_T'P|_ ^9ZO>:.*!/O| AE?|F'_HW'X#?
^&@^'O_,SU'_#*_P"S#_T; M C|!O_#0?#W_YGJ|YHH_|&_X97_9A_P"C_P#S/4?|,K_LP_|
M1N/P&_|#0?#W_YGJ|YHH_|&_P"&5_V8?^C_|S/4?|,K_+/,|M_1N/P&_|-|/|/?
_F>KWFI&JZKI>AZ=>:QK>I6&CZ3IT#W6H:IJMY;Z?HUA:Q#
M,ES>7MW)#;6L\$8Y>;>5(T+;|32*2>XN)_A)|.XH8(8D,DLTTLGA|8XH
MHD5GDD=E1\$4LQ!-?GG^TM_P68_9Z^\$O|H>'?@Y:S_'CQI)8!?:/=2/AOI MUR
%#W"BR:WGN/\$_C+I_"X6TV_TR^1);<^(M/FPZ_AI|2?VH?VXO^"@OBMO M
MA)XM|46&H2F2V^\$?PFTK4=-|&V-J9)"DNM6EG-/ +?V5KO?=K/CK6-1CLT#
M;:ZVB7"_I.O^%W\$.:TUC\$E*G422:DIXJ>%I

M2B[QJ2V/Y)\3/ID>%W!.*EP-PH7XI<9U:OU3"9#P<_K>">-DW&GA\3GE*EB M<+./I
M3SH!HO@7X7?#5?"=A>Q^:@CUSQ\AFITE\$6:,Q31^&[7Q/>VIF\$N:,WSO'X4
M_\$[XT_\$WJKCQG9>?%AY\#?AOX26^O&'A[X;?L^?!OP_H^J3:F6)3?ZSH.B2^
M,]>81F(WIO=530HY=|U!|6FH|*OZF_LU?|\$.|\$.IG3_\$O|4GC=/#=F3%-9H;K1--R4:*YM?
#=GK_VBWF#VOB+3|E/E->OX+_L_M|?!7|GGP^OAKX.?
#OP[X(L&CBCOKK3K4SZ|K+1*BK-KWB.^>ZU|7)QL4B75-MINC'C;\$(T4?
1_VSX<|#+^|D>?"%F>4M/[3QCC+!4*JM|]I*#HKEE|U.6"P|_M24HW@|)CCI>
MVIKV6)H0YIAJ5*LE7APVX/D/YVOV:/-^(WQ0|: #3_\$G|27BJ/X5>'Y1%<'P_M/X7DT_7_
(A7D#"-)O|3_TOPMX5:2.0LD@/BJ|BDC>VO=(LY#N3|S?AG^P/M^Q|)*?#MMXH
M_P"&5_V8?^C_|S/5|S17R|^Z'@W_#*_L/_1N/P&|_!|/?|_MYGJ/^&5_V8?^C_|_I7O-%'@W_
RO^S#_-&X_-;-|/?_M_)GJ/^&5_P|F'_HW'X#?^&@^'O|_SU>|T4>#?|_K_LP_|_1N/P&_|
#0?#_MW_YGJ|_AE?|F'_HW'X#?^&@^'O_|_SU>|T4>'6G|_7|-=A=6U|8_L|?_ZS
MO;*XAN|_|M/A-X"M|JTnk>19K>YMKB'0\$E@N(426&:)TDBD171E901|C110_M_4444
%%%%%%%%!1110_5X-^SC_|_D|H0_|EY_:H_|_6GOB_7O->#?LX_|)/?\$_M/_9>?VJ/_6GOB_0?
LX_|D|H0_|_9>?VJ|_UH|XOU|S7@W|_|_R3WQ#_V7_MG|JC_P|:;>^+|>|T_%%%%%%%%!1110_4444
>#>(O^3GOA!_V0;|H|_U87|*|>|U_MX-XB_P"3GOA!_P|D&:_P#5A?LKU|S0_4444_%%%%%%%%
!1110_4444_%%%%%%%%!_M1110_4444_%%%%%%%%!1110_4444_%%%%%%%%!1110_4444_%%%%%%%%!1110
4444_%%_M%%!1110_4444_%%%%%%%%!17G7Q=^).D?!SX7>/_BKKUCJ6IZ+|/"6N>+M3T|
M2%M7U2|L|L|L|K^>UL%O;FSM#|E'"^?
Y|2JU|HRROCJ5"HJ56=%TDH5%'347|2|WY6GHFK/<_M_|_?&3PR|_
_:@LNXZXPRWAO&YCA98W!8?'0QDIXC"PK2H2K0>&PM>*@JT90_M?_
*_KINUM3|Q**_#O_A^|_SE_P|\$B^-G_|_@/X%_|_FOK|N_.OHM3T^QU*!9\$@
MU"SM;Z%)@JRI%=P)/&LJH|B+(J2_\$D=0P(5V&&_9QPYG>0+#O_,NKX!8IU5
MA_:F_:NB|J|J|LYS^!5:=[V^-6OK;HX#|6?#KQ.GFD.^*|OXEGDL<'/(X
M&&+@|'|_B5@W5^M8;#W5=X/\$J)SV=&7/RWC>Y1117B'Z(%%%%%%%%!1110_44_M44
%%%%%%%%!1110_4444_%%%%%%%%!1110_4444_%%%%%%%%!1110_4444_%%%%%%%%!111_M0_4444_%%%%%%%%
!1110_4444_%%%%%%%%!1110_445P_Q"^)GP|^\$WAN|8?\$SQIX_M;|^"&_
(\$3ZSXGU:STFS:4J62UMFNY8WO;Z?&RUT^S2XOKN4K#;6|LK*ANG2J
M5JD*5&G.K5J24*=%G"52L.EAL-AZ--O|_B35;'1='L(%!)DN|1U&>WM(%_"%|R52|8506
M(|_"7HC_|@N'X.T:(AX:_9>|'2>-=3436Z_\$COY:WNC^%87_'B+=:;%X25|3_MQ%K2\$&.6"?
79_"XAE0K-I5|?F_)_"TT;|NW_(*1^-?MA3Q|6EM;|JVI7SQ_M^'_A5X):=G+I#
(XTOP1X=DCMY)'^QV\$?|O:C;O:(K:4K@:6_4_E|*|VO-#^T_M>
(L5A^&_J@E.K5Q|H1Q;@|/|^!.I3AAN;6+75I5(R::H5%_H?QOX@?31X(RK_|MO|5/"C)LT|8>-
<1.6'PF#X9HXBIDBQ"TLRP^'Q6(S;DNJJ628/&82M!2C+,_ML_US+|J/VE?^"VGP?|!?
VAX<_9W|_3_&'O_"9:=%VM+?>'AQ8W"-L_MM%(
MEOXG|5K&Z2(|5M|X=TZX1HKK3_\$-Y"V#^+FO_\$/INS_|_@H_XS_|_PGQU|4HX|J_M*;|P?
X6M1H'PP|)"1T6VN-1@22P|):*D1\$:1_YXKU!|1E.U9=4GE8;OV%_9F_M_P""(?PX|
(_V=XE_:8|5O|3->C|FX?P%X1GU#0_5L_OE.UOJ6N\$67BCQ.B2
M*P#6R^%+9U9HKBSO(N6_:7P5X%|_%_#?P|8>\$?'A3P_X_|_:8@2QT'PSI-EH
MVEV_R(C2+:6\$,\$37\$HC0W%S(KW%RX|R>620EC|+XKX%X+3I<'Y3_|_&YFL%RO
M/8|B3&X:HITYY?A7|L?P0_9H_X_M(<:79FP|2_M3>./H8G_CN#|_OAS=7%HB\$AF^S>(?
&|_|&I7F5=8|JR|_6&E_M>1/\$QM/\$M|_X8_NK|_?A%|_|?@OX;@|(|?"KP+X:|^'8-
K'3O#FF6|B+N9_5%_MWJ=TJM>ZO?L&;S-0U2YO+Z7).MPY)-
>BT5^;Y_Q:Q!Q+4<|VS"K6I*7-3P=-_M^QP5*VW)AJ=J:E%_*K452LU|523U/ZU|_|_PQ|
(L)&CP1PM@L!C94O98K/L_M4O|0XAQR:7M/K;XKGO4:527ORP>%EAL!"3?
L<)25DBBBBBBOfS|9"BBB@_HHH_MH_****_"BBB@_HHHH_****_"BBB@_HHHH_****_
_"O!OV^(?^R|_M4?^M/?%^@_9O_Y)|XA_|+S^U1_P"M/?%^_MO>|&_9O_P"2>^(?
^R|_M4?^M/?%^O>:"BBB@_HHHH_****_/!O\$7_)SWP@_M_P"R#?M'?^K"_97KWFO!O\$7_
_"<|(|(^R#?M'?|_JPOV5Z|YH_****_"BBB@_M_HHHH_****_"BBB@_HHHH_****_"BBB@_
HHHH_****_"BBB@_HHHH_****_"_MBBB@_HHHH_****_"BBB@_HHHH_**^5_B_P#MN?LJ?
K|5|!2/C=X)TW5|_7|_M|PSHVH-XM|6)(NX)#-X:|*1:SK-
D|TBF*.74+2TMMX8R3QQQRR)^5_Q@_P""_M|GP_TK|5I_P_|_#OB+Q=U;4|5FP%BNM3|
M-W)4EW\$;*(V^HRC@OBC/.6679+C:E&=G'\$UJ;PF\$;ZN.)Q3HT9V6K5.|&>
M*H4*5|N52,8RE'|^*(S^)/QG^\$OP=TW^UOBI2?|7P_L6B::!_%?B/2|&GO5
M5BI73;|N8|W4Y2RIJP:;W;|LK*D;%2!_(Y|0/^"F'|>O|1>JMX8|+>,-|_M,C5FE2T|_%
7PY>Z|JDHD(4QV6J;:|/Q#F*JRO|8_\$;KE@Q3>VZK_PW_P""
M5_|=7QXU+_A(_%OA67P)#JTJ3WWBOXV>)9K'6|EFV^=)=Z\$@U|QXUVD6-HU7_M1+-
_7*Q?:E*RF+|REX4X?+*<<1Q?Q5E62TVE/ZM1J1JXFI&^L(3Q\$|L.O:+7^

M!0Q:NM\$U=K^:L9]-?,^+|56ROP*!&.-/\$#%QFZ/JK9AA:V"RK"U/LUZ^'RJG
MF/O9CF6222DG-TW:~+3S|MG_@K'^RWXM^"WQ;^#POE|9?.\$?7?B!X*|M2>"
[7Q'TWA^30/!VF2ZUHQISWUS>^)Y=*UR|2U>;S(H).|.W%M>JC%+^*-H MI9/Y@Z_HMO?
^"&NG>\$OA!|0=>O/B3XG^*7QAL?!/B"!|^\$/'|.GZ)X,|,7?C
M*+39VT73KV|!0W.K7NL6K7HC"N:|PJ)Y#&LWEQ!XIOS*_P""7W|>/_10'B#_M,*CX??_
#75^G<#YEX>Y-@L;@|CSVE"E|:A+\$5|XQM+"5<565*\$?:488I8-MRI**4>;GAX4W.ZO+
≤CKZ10"?TL/^(>'L|10#C&U|=+)JM/*|LX#R#&YY@ MLFP\$L=5J/"YABO|!SX3>,""?CSX
M<^#O\$W@KQ)HGBOP_?>|(%KK'A_4K35=/E>/3|99H/M-G+-&ES:O^ZNK60I<
MVLP:&XBBE1D\;?_Z^~;Q_Z-X|0?|A4?#|_YKJADMovXO^":GQ"28KXR^M%%Q?
7,>)8VA|0?"WQ|%"?;|AY\$.H^#?\$CFVA/F0,5|1Z-!+NVZ1=,K+CQSDN M4>(%/++E'\$V3/-
|Z- 'W&_P!&#&|3YUQ5X0?|1X,XF_L#;!9UG-?A_-|GK9+4R^IFDL%6P M|S; X7+|:|1_-&
(A/"5|;@93E3I2I8J,DZ5;^VZBOQ#_&4_ ^"TOPH^(ZZ;X
M3_-/TNW^#_C.40VP|9Z:~+R_&&L7)4AIKHR-=:WX*::4HB1:D^MZ/"N^XO/\$ MEE'B)?
VJTC6=(|0Z98ZWH&JZ;KFC:G;QW>FZO|%|:ZEIFH6DHS%=6_92SVE
MW;R#F.:WEDC</P4N;FA"i6H+~#UW&4|+6KTK5'I4445XA^B!1110-4444 %%%%!1110
444 M4 %%%%!1110-4444 %%%%!1110-4444 %%%%!1110-4444 %%%%!1110-4444 %%%!
%%>-_&C|H/X,|L|>&W|5?&+X@^'_!&F,DS6,&I71EUK6I(49WM?#_M
(>LDN='PM"MB<15DH4J%"G.M6J
M2>T84Z<93G)|%&+9P9GFF69+@,5FN2|2R6X>!)95B:0HLCA0QX7_A_GXJ_M_P"C9O#_
/X=+4?_)AJ_#CXR^*=*|<_%_XK>-M"-P=\$|8?\$GOSXIT M|.E>
(/%&J:MIYNK??)Y%P;2|A,T/F/Y4FY-|;=Q|VK^N|)X8<%/ "X:6(R""K
MNA0=:FQV:1E|5TX>TYHK&I*7/S7BDDGHDKL_PKSKZ8OTAJ>/A@'2X>X.J4W@HXJL*Z
>_XF?|!%VOB3K MG@FSTSX6_!|P_P"
O'%Y%>+K7B;Q!KDOC/3M)S>2K9'PSH_|FZ)%=77V_033
M7NO&XM(KR2:W&BW<\$4=S+|&^"O@5^W_ P42|8+XON(?&OQ!@FGEMYOB;|1-1 MN-
&^F@Q.X%S:Z1?74,>E0VT\$|_VGP|X#TF|N;=S*VCJK>97ZN?|!IOV!_MV;_'P
#/'|1GQ+|('XC^--%4A@MX(D6.&&)\$CCC54154 #|US;C/AS@?&9AE7:O#>'Y
MEAL1B,+BLTQ_M*OLJM.I*G5I8=SJU,96HPDG&\$98C#T4X*7L:T7S2_KO@GZ/M_BS|
(O(>%^-'?WQ:S3%<(YME659UDW|W#7U;!O&8'%82CB<%C,SCAL%@|BR_
M'5Z4H5:TZ64YKCI1K2C|>P-2/LZ?XQ_LT?|!%KX&?#+|!XC^_VJS?&_Q=#Y
MB:%IUGI&D::;J69::PTW3X;>SL|=69F6&WAC
MC|9B%!)K6HK|BSKB+.N(;-UC_,PQ&DFW3ISDH8>C?1JAAJ:A0HIK1NG3BY;
MS%N6_V9P)PMEF04IPC#%8JA2=-,^(?^R|_M4?^M/?%^O>:|&_9Q_Y M)|XA_P"R|_M4?
^M/?%^@_9Q_P"2>^(?^R|_M4?^M/?%^O>:|&_9Q_Y)|XA_M|+S^U1_ZT|7Z|YH ****
"BBB@ HHHH |&|1?|)SWP@_|(-^T=_P"K"_97 MKWFO!O\$7_)SWP@_|(-^T=_ZL+|E>O>:
"BBB@ HHHH **** "BBB@ HHHH * M**** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH ***|W^ (WQA^%/ MP@TPZQ|4OB-X+^'^GF-I890%GB/2M\$>
|525V:~;7UU#=:C,S I':V\$-Q/(XV M1QL_%;4:-
;\$5(T:%*I6JS=H4J.)5*DWVC""E*3|DFSDQV/P.686MCLRQF\$R_
M:8>#J8C&8|\$4<)A:\$%O.MB*|Z=*E!=93G%+N>D45^/?Q?_X+6?LH^_OM5E|.
M;+OK|:-7A9XXI=#TJ3PEX5:6/74)6_?YK46#LGKKAFIXW;6ZP
MMNE|G|S|=QTM'-54PW#_Q:6><*.U?*

:0HT*(4J4%TC"\$8KH@HHHK,Z0KFO% @WPEX_MV/EX2)
<>&M#|7>&-8@:VU/0/\$6F6>KZ3?0L"-MO8WT,T#LF=T4FP20R!9(G
M2158=+150G.G.-2G.4*D)*<)PDXSA.+3C*,HM2C*+2:DEFFDTIF5?#T,50K8
M;%4:6)PV(ISHU\7IPK4*!&I%PJ4JU*I&5.I3J0;C.G.,HSBW&2;:1^W|5?
M_!\$CPGXB_M/Q?^RMXBC|ZPYFNY/A=XOO+R|)7DA,LS6_AKQ0RWFL>'Y&^2
M&UT_6HJ:T^2:15;5=\$LX_E_)3P1|90VW?^";WCY_"DZ">*OA^%N7NK_X:>|+.M;6?
AOXKAC?|?WNVFZW3Z1?6|TDJK+XG|":S:7=_\$|X2 M?
#3XT>%KOP7|5?|/A|OUX9O,L^E^(+"|J6WFOA;S3KH;+|2=0B'^HU+2|FSO
M|<|P7,9YK|3R/Q1QU'#_-D|58.EQ/DTU&G..+C3GCJ<%9*2JU8RABG#64?K
M*|NYV<<73250XP|1?H:|X|?|=?!?/<;XA>8:<|1AJF1UL3A^',57?O2IS MP6#J4|3DT*
|4:55Y5*67*CSJKDF+Y|FU\$7B+4\$G^'VN7KF*)3HWC*2.VBTF6YF9Y%T|O3;Z8EN&BM+;|
8GR|? MK5#-#<0Q7%O+|';SQI-|/|(LL,T,JAXI8I4+))'(C*Z2(Q5U(9200:_F|:_L M_P'''
(FIZ>NI>|V30\$;ZS;*);I_A)XXU'''#5D55#?9O"7C2X,%A?EG)2VTWQ M6-,>&%-
TWBB_G98S^?|+\$_VTOVR/V!_%C_#G6D|0)H6AW BU?X*?%VPU4Z9 M:VWF>49?
#C7C0:QX9CE2*9|_O?#EZOAZ^D<7|QIVM0| WJXC@+AOBNA4S#P_
MS:G&O&+J5N'|QJ2A6H|7A3G4_96_X*A_LV_M_V=X>N=7_.%2_\$Z|N'_(O/QW?VL%OJ
M=Z^_|OX2|6|;71_\$6XJJP6EQ'HNO7\$C\$1:\$8U|UOTAK|FS3*,SR7%2P>:X+\$
M8'\$QN_9UX.*G%.W/2FKTZU-O:K1G.G+D)G|N<'<<|(>(&3T<_P'''^(.H8?
%4TU|2C&Z"BBBO./JPHHHH M*****"BBB@ HHHH *****"BBB@ HHHH *****"BBB@
HHHH *****"BBB@ H MHHH *****|4^_O|1?P5_9U.MXF^,?Q"T#P79/'*^GV-|<-
UUXQ|:OVA_@O^SOX<;Q1|8_B%X?|!;G-*UA:W|R9|>-O\$O|H^%OV7 MO"W_
@6COYUM_PLCQG;6.J^,KJ(^;'|IT/PUNO?#WAI<-DD,^JR>)+ID(;I
M+IMPN%^+/@O^P|^V?^W5XD_X6/KB>(8|"U^6.XU'XS_&74M7CL|1LWD,H?P|
ME^MUX@|4P+').NG)H%A)X=MY8_L,VJ:2F"GZME7A;5H899KQIF>'X;RR-L.C
M.K2ECZJM?V:NY4:%2:^^6)Q#DG|X52/XJXS^F;@|RS>?!?T?N#|U|6>+ZO-
M3IYA1P6.I<,X*2DH/%2C3A2S#,<+0GIB,1.63Y7&FXUX9Q4I7O|,|3_P#P M6|I9>
(O|1|+?LN>%?^\$'TE_M?|A97C:TL=4|77*'S8_M.@>%MHX?T'/R2
MP7.M2^(|B2)|@7T|3+E<+|0_!K|BC|M#|N_Q_P+&UB/Q%)HFO2QS:C|:?'C' MJ>K0Z;?
632'4'P|;|+O7?|\$|M'%.NFP>&|F|/6LD9L)=1TB|/3^@7|F#_@D MW^S-^S|_&=X@|4Z8?
C?|1K3R9_^\$D|>Z?:OX;TR^B|M_|+^|JWHUEY<|4 M=Q:W6O3>)=8LKA?-
L=5M0WEK^H*(D:JB*J(BJB(BA51%"JJ@ *J@ *H M Q7;B/\$+AWA>C4P'
&2485'%TZN>YC3E.O6|SA3J/ZS5BW|I%B*E"C3G=+!<MNA|_EGT7?
%7QCQ^&XE^D|XAXZMA(5%BL'X<*<8JE0R|_ZQHXG\$8:'|D8.I"
M|/C\$2RO#9CCL50:E+B&-9VU34K?1_\$WP;U32+?4+V#2|3N
M_%'B'2KK4=,BN9(|&_N=,7PGJ"Z=<7EJL5Q-8"_O19R2-;B|N?+|Y|_(''
(O_F'K^MRBO+7C'QDDDDYY9)I*|G@-9->|<6LHW=KNR2O_MLDK(^QG|?
P"E.&;^|U/2|)U|Q9J^LV*P7EY
MIVESR2"SO8//4VBK'617?:37V7117YMF&.KYGC|9F.*Y'B<=B: ^+K^SCR0|
MKB*DJM3DC=|L>:3Y5=V5E=|G|;<+<.:9=PAPUD'"F3JNLJX;R?+LCRU8JJ^)
M^HY7A*6"POMZRC!5:WL;:/:5%""G.|E&-|(HHHKC/>"BBB@ HHHH *****"B MBB@
HHHH *****"BBB@ HHHH *****"BBB@ HHHH *****"O!OV^(?^MR|_M4?|K3WQ?
KWFO!OV^(?|LO|/ M5'_K3WQ?KWFO!OV^(?^R|_M4?|K3WQ?KWF@ HK|P?
^"ROQ|^_W|+/_ M 39_:H_:+ 9R|=Z1|/BE|(/A|?%>@Z_JO@G1O'6R4ZWI&DF.RTKQ)-
+X=A MN@NIM,EUK6A^)+(>5Y;Z3(7|Q/JK|L3XN?;\$GX\$?LP?&WXL_!SX3>,OCG|6/!
MO@74KSX;"GP#X>G|6>)_%_C:_D@T?PU:V_AVUOM-N|5TO3|7U+UUGQ+;V=_M:W@|+
::J|MI*+B.(\$ ^E**_EL^#'_!3SQ)|#/V(?^"@?|:/Q!_:I^/W|8OQ M_9+|Z;HWB7|CG|J|ID'X)?
L9?%3X!_&?Q#JD6C> M.^*/@CX5_#OP|X|33O M'/B;5|'TA=9/B+7O"EGH=EXH?
3|K4=>TZ|DT;|'|_';|LG|C|HK/_@GC|'_M-
J|X_2_M&>&_P#@H;X6^*G@KQSI^I_#X6_#Z+|FO|:_B^&OPVM?C!IME|'
MKSX6>#_#&O>(?@AXSTU/%?PX;PY|6O|_A8?CSP|K>B^%O%|W|A69=-U/7=&A
M/W,HHHH |&|1?|G/?"#_+(-^T=_ZL+|E>O>:|&|1?|)SWP@_|(-^T=_P"K M"_97KWF@
HHHH *****"BBB@ HHHH *****"BBB@ HHHH *****"BBB@ HHK
M'NO\$7A^QN)+6|US|L.ZBV^;;76IV5O<1;T65/AFG21-;I(NY1N1U<95@2X
MQE)VC%R>|HIMVO:|EYM+U9G4JTJ,5*K4ITHMJ*E4G&\$7)IM13DTFVDVEO9-|M&;%%
<_+|)9X5_Z&;P_._#G3O|Y)K4L=1T_4XFGTV^L|0@20PO-8W4%W\$D
M|JCM\$TD#R(LB|)&Y0D,%=&(PRDMPG%7E"45W<6EH1%/\$X:K+DI8BA4FTVHT
MZM.^U/5+RWT_3|_M\$ S7=|_R0VUO\$P!DFE1 2 3DBOS_P#C|_P5_-8L^#YNK2?XIQ?
\$;7+7S =" M^\$UB?&LLKQ9#1Q^(89|+P2LF_P#=_^7/XIA?=>D|=BNR|<791FE;5?

8Y9EV,QI M1-*4<)AZM=00UJ2A%QIQZN5248I:MI'SG%/'/!G ^\$^O<8<4Y!PSAG%RIU,Z
MS7!Y?*NDI[.:%I8FM"MBJC:M&EAJ=6I*7NQ@WH?H?17IS P 8/^"[WCC4OM6G M_KX-
:#X7@8-!XD^)&J77B;5&1B<7\$7A007T33-.N47&Q+G6_\$%L'&Z2.5/MW1^
M4^_O_!1!MK4+G1M+0_&OXEV%U,T%YX;^&DZAH7@BT1EPD.M67@NQ
MTCPS%;0QN(Q=^)^9)'PX:XNY)IFDD_1LO(^(ZU/ZSG&)RWA_"12E5J8W\$PK5 MH0?
VG3H2>'6FZK8NC)/1I.JOY2XI^G5X4X#%_P!D\$PW#^5 M8C X'\$5UHZA<3F-
&&9U&Y:1G@L:/:F5P8HI;VQMK8R!|TZ+%*T?Y M7_&#_@NW1.-(^U:?!#O@_P")?
&=TNZ*Q%|0-2M/"&BI(2+NWT321X@UC5+ M4G"B"[O?#-R0S.WE| DGQ-|
(/^")/47C@6U|3M>|_#_8TJ41M:-WU|_PG M'BZ)),NCT3PQA|(^Y1,^9%<^,
[*=)"D9BSYC1?JC|_|@BU^R9V_LM|
M10)/&7QHUF\$K)*GB35Y/#7AW|/^\$!-OC\$'&IK75O\$6LVO\$^'R^|
<)*4;6<98:=&A9O>,LTK)K>#6_RO| KC|_MIQ9|WA;@CAWP3R'\$_P
/_)^6IGE*G/XHUJ.;8?.,P4HP=XU*/!N!FI-N->, M^7V?XG?\$/_@IS^WE^T-
JA|_%^/%^J^\$EU9I8|/P=|"/#EYLKS;SM"66L61U
MKXA22HC!/1%|0JH8|_*#E2LWPY_X)^+? MCCXDN=-UFX9|&1|S1)!KOC|
|B.,@_P#\$PT&W1V(B^T*RR>7_%Q_#SX2_"|X M2Z6-%^&'P||&?#_3-BD):>\$?
#>DZ"MSL.1)>R:=;V|U_.S9>2YO9)|B60M)+ M*|C,O|"K.KXKTLMI\$PW"/"4Y)1:Y?
K%6G&MB9KI.<./#PH_U_JXM/=N73 MJP/T)<7Q9BJ.;>.?C'QMXAXZ,U6_LW!XNK@LKP|
|6EAZ6(S2KFM=X7622R_" M9))1=H0IZW_!;X/_/!";X6Z+|DU#XW?%SQ5XZO\$VRS^O
VGV?@00!)T:TN M=5U^^(=' \$5DUOK.CS@L'<6=Y';W)54O(+F'=\$WMU%;X;\$
MXC|UZ>)PE>MAL11DITJ|"I.C6IR6TH5*;C.+|TT>?FN4Y7GN7XK*<|RW YOE
M>.I.ACA>,XK>!2|F:;#KB+|I06'B*WA>6XMXRN4TO68-5T4 ML2|FFR/AA^L97XG4L?
A8Y1QWE='AN=HOOL:5.&88>Z4?:63I1J3BM/;8>IA M,2ES2E4K2=G_!'QC|#W&
<,YS5XZ^C9QGF'AEQ3"|6IP|6QF)K|+9FHR|H(| MJDXXRMAL-
5J7G++|TPV=Y1.H.G3PN7T8<|>%_9>_P""@7|_P"U9;6EAX)| M6+X;|?
R0*|W|,O&C6VC>+4F6.-KC^OU-Q+|WBBC=F*W&@7E|<)_HFU"RTYV M|E?
MNOY(OVH_ ^"0G|07P%N+KQM|\$J|^~?@;3)O|2@D|.6LFG_%'PTMJ3=1S MW?
ABUEDDUHV4B1K;ZEX/N;W49Y8VO9?#^CPH|G|+?|P5_&@/|@3/:^"?C
M=:WWOL|#;.*-F_X2"Z?3_BEX:2US;/#;>)KJ)WUXVDBR/<?XPM|S4YY8UM
M(\$6DPIA=P_|JX;" MRQD9T-G6Q_#V*S;#.04Y)9?E|(34/ZV:*^8?V<_VQ/V??
VIM(%_|)/'=EJ&L M0VZW&K>|!9V:;XZT-26#G4?
#MQ,T|UO&R|6U32)=4T5W(2'4I6R!|/5^2XS! M8O+|14PF.PU?!XFD^6I0Q-
*=&K!|:.\$U&5FM8RM:2LXMHG|P9%Q|D?%&5X7
M.^,WR|/,HQL/:83,LJOE#8*O'2AB,/:I3>)==:2?NM!|,V"W.MZLQDC,+3
M6ED|I:2%3>7-M'F0;X;#8G&5Z>&PE"MBL15DHTJ&'I3K5JDG|F%.G&4Y/R29
MYV;9OE60Y?BLVSO,L|D^5X*FZV,S',|7A|@<+26|3\$8K\$U*5"E"|2YISBFV MDKMI'N5>
(?&_|H_X)?LY>'CXD^,?Q"TP;:R12R:=IUV<-=^(M<:)7)AT'PW M8)%OV8O#'_ "N=!D
M|ZV_X6'XMM|'5_'5Y"?-C^T:/H6;WPYX9|Q&5D>|?Q+?+|LL,NFW"X7Y"^"/ M|/|9G|;_B'_
(6/XE77M,|/^(95O-1^,?QFU#6,ZQ;2-(XF|VM^+GQ+XKC M95FCL)-
+M%|.Q3*MI/K.FH05_5LK|+9X;#1S7C7-(N#&;5J6_V'^T_P#|%NO'?BG^T?"W M|,'A?
_A7NB/YUM_PL7QA;6.K>-KN(^;|HT7P|NO?#OAO>I5XY=0D|27FTK(MB;:<+A?C?X*?
L)?MG?MR>(O^%C^(4U^ST'Q!*EUJ/QE^,VHZPLJVKN|@E|
M07ZW7B+Q5#M|^/3SHUD?#L\$R"RGU?2T(*_T%_LP_|\$J/V8OV=O|/U|6=&_X7
M1|1K3RYO^\$N^(5A:7&CZ?>1HCY_AGP-NN|"TG8_E3VUSJK^(I(?#_#-"I@/#_)*)*(
M|HOWX+\$U*5&G*Z6!478|+*_HL^)_B|F&%XF^D|XB8_&T(5%BL'X<|*XJG0RK
M+F|50Q&*PT%E6\$G&-|B?|PN,QF)H|LWQ&ZJ&|PUX\$W7>B:=LD2.>UNM9E|2:U8W,
M?G6.L6P;RU_3E555"J JJ JH 55 P..!P!P*6BORG-XS3.|2|7FV. MQ&Q#O:=>HY1HM-
PHTE:E0IW2?LZ,*=-/51/|5X,X|X,|HAD7!/|#>5|.9 M9#E/Q&)Q,HZ2JM)(****|T^N"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@
HHHH **** "O!OV^(?^R|_M4?^M/?%^O>:|&_9Q_Y)|XA_P"R M|_M4?^M/?%^@
_9Q_P"2>^(?^R|_M4?^M/?%^O>:|&_9Q_Y)|XA_|+S^U1_Z MTH7Z|YH_*+_@MO)|/CU^T-
_P \$TOVD0V=/V:?.@?XJ^/'Q=^/7A|3_AMX>| M.>&O&'P?|#V?AF*ZU2V|0WOC;Q?K_P
90B5|_-&B|*Z9#X=_LB6V|-7GB;Q? M=:[KV@QVGA:300|A|(\$A|Z>|=_'7HK2OV*OV3?
%'QP_9^!|?QPUH-WXA?2/%VH:?!1K'QSXZ^?B/6M!TF,^*M T, M_%'1MA %.DS6UC?
^)/"?B%KK1|/Z_HH_!7H_ (OE>)O^"CGAGIN|Q|A2
M?|MU^ROXP_:R_8T^'W|*P|^'_BC6?|?B/Q;HVI?"7XC>*/C;X.^+Q^U/X.M^(-"@BZU9?
B9JGAGPYI_A3P+X|^(\$&D_#3PG=SW'B|4-1|9GPCX*V?#P/_M &T?VS?VN_|
@GM|;_VLOV?)OV9?"G_!/KPM|4_"C1-7^)^7PB|?S_M%_M3?

M\$ X9V/PMF; X56OP<18^*KKPW|\$/!-G-XO| 'EMKGO&D^'OC3Q|JN|>&?#-|M|)X--
MI6O;:|T:* "LC7M T'Q3H^H>'O\$^B:1XCT#5K=K35=#U|3:/5|'U.U M9E9K;4-
U"&XLKRW9E5FAN8)(RRJ2N0"->B@#XO>:/!O^&5_P!F' HW'X#?^&@^'O| |SU' #*_L/_
\$;C|!O M T'P| ^9ZO>:*/!O| AE?|F' HW'X#?^&@^'O ,SU' #*_P"S# T;C|!O M_#0?
#W_YGJ|YHH |& X97_9A_P"C_P#S/4?|_K_LP_|1N/P M&_|#0?#W_YGJ|YHH |&_P"&5_V8?
^C_|S/4?|_K_+/_1N/MP&_|!/? F>KWFB@#P; AE?|F' *_Q^ W_ (:#X>_#/#4?
|_K_LP_|&X_M; PT'P|_P#F>KWFB@#P; AE?|F' HW'X#?^&@^'O_S/4?|_#*_L/|T;C|_M!O|
PT'P|_|F>KWFB@#P; AE?|_9A_Z-Q^ W_AH/A|_/!1_PRO^S#_P!&MX_ ;_P-!/?
_F>KWFOF#X|_ME?LW?LTVLQ^+/Q0T'2;-2+S8!/FE2MXA|;W MA95:\$1^%|'WJ=I%
<;U\$-_JL6G:5R6EOXT1W7IP>"QF85X87 X7\$8S\$U/(@H8
M:C4KU9;7:ITXRE975W:R6K:1Y&>|09%POEM?..(YRO(:IV\$9/0Z;_AE?|F' HW'X#?
^&@^'O_S/5_'K_P%_M'_#7ASP?^VO|>/#?A+P_HGA;P|H>N^&XM,T#PYI5AHFBZ=%
X%|+74T=AI6F M06MC9QRW;|IQ(EO!&KSS2S, #)(|'|&OVAO|
@N9XZUOKW0_V:OA|9^!|_8R1 M0^_.OB)%>:
(/0DD67\$=SIWA6SGF|+Z)=+B)MNJWOC&W=#(C6T;E73|.OB%XZ|_M;?
\$SQEKOCWXBZYJ7B7QGXHR8=3US7=6"+?:C*|H;Q6LSI%!!' NGO6D5E%; M0Q6L-
E';Q6L:6Z1*/Z|_*^!|_X=S#%9OG%*C@X8K+9X.E@W653&*53%82NJE M6%)3HTX*
!Q<76=52FE.G&S/AG_H_2,|-?%3AK).!N!;;F&>5|EXKH9|C<|
MC@*F\$R*5+#Y3G&6O"X.MC)4,=B|JV8QJ*K' 0P4J5&4Z.*K100Z;;E+^|O+E;L;|8B^?
Z_|E_P""&OPT^>M_!_XG>/M;|_|^ M\$-9|;Z3|6GT?2/%VK>'=)U+Q'I&EP>\$/#%_'8:3K%
|:3W^F6OVV|N;J2*QGM MUFGD\$DPD:.(H^@|S5*I6E5BJ4JGM85J?)
M3G|SYJ537|/T/Y=^CAPAQ;QUXI9;PUP7QGB^,YQV69S*7\$V!^M_7<'E|!3 MJ8ZEA?
J6)P6)|MB:*=&|L|9A&U)IUX*|_P_8_AQ^QG^V+^TG?C6/'P8|7WN MGZL)QXCUG2-
/^'7@|@1N TD^F7FMKX;|_.;11_.;3P|%. (2WM))|S\$?|_O@_M_P#|\$(?&NH_9=0^_.OQFT+PS
0LD_AOX:Z7<^)-39&(/D2^)?\$\$>BZ;IURBY\$ MC6^@Z;|>9|L/IS5H3C%|I?GC|
(_|^"67|%/PC6">+X3VWQ(U MB%55|_|_|+X?+W_08|F|.W,%IX(#%B79|?PK_|
<%MB1HGTFG|*G|+T:A(V M;O@ (B*,*B?!|X>*JCT"CPZ !| 5|W17YUF&;YIFU3VV9YCC,?
4NVI8O\$U;ZA M?2U.-24HTU;11@HQ2T22/ZNX6X'X-X(PGU'@_A;(:&
<*XQC4IY)E6"RYUU'5_M2Q-7#4:=7%5&US2JXF=6L.7O2FY;G@W_ RO^S#_ -&X_ ;_ ;_!/?
)GJ M/^&5_P!F' HW'X#?^&@^'O| |SU>|T5YQ|2>#?|_#*_L/|T;C|!O| PT'P M|_|F>H_X97_
&8?^C_P#S/5|S10!X-_PRO^S#_P!&X_ ;_P-M!|/? F>H_P"&5_V8?^C_|S/5|S10!X-_PRO|
LP_|&X_ ;_PT M'P|_|^9ZC_AE?|F' *_Q^ W_ (:#X>_#/#5|S10!X-_PRO^S#_T;C|!O_#0 M?
#W_.9ZC_AE?|F' HW'X#?^&@^'O_S/5|S10!X-_P_K_LP_P#1N/P&_P## M0?
#W_P"9ZC_AE?|_9A_Z-Q^ W_AH/A|_/!7O-% '@W_#*_L/_ \$;C|!O M T'P|_|^9ZC_
(97_9A_Z-Q^ W_AH/A|_P#;|7O-% '@W_#*_P"S#_T;C|!O M_#0?#W_YGJ/^&5_V8?
HW'X#?| AH/A|_|!7O-% '@W_#*_L/_1N/P&_M_|!/? YGJ/^&5_V8?^C_|!7O-% '@W_
RO^S#_ -&X_ ;_M_ ;_!/?)GJ/^&5_P!F' HW'X#?^&@^'O| |SU>|T4>#?|_K_LP_|1N/P
M&_|#0?#W_YGJ| AE?|F' HW'X#?^&@^'O ,SU>|T4>#?|_K_+/_1N/MP&_|!/?
_F>H_X97_9A_P"C|T4>#?|_K_LP_|&X_M; PT'P|_P#F>KY|^/G_3/_9&^.^@/IS?"_P
/_("SQ%|!#*)|8_"31=%|S M:G9SLLA0ZEIFE:~#H'B*U;K(9X=9TRYN_)0PV&H;
<|>>OW|17;E^98_*L3#& M9;C;1@L53^&MAZDJ<|73<)5+\$T)^_1JPFE)?QH_M4?|
M\$M?VD_V9I=0|3Z#ITOQ>^&5BTMQ'XX|V-V=9T>RC8;)%G@Z.2ZUC1&5"|M MQ?:9-
KV@VD*>9=ZW;:XA'2_LI_|!03X5^_|!| (M_ LK_SXJ^%HS%;)X MT/X.?#3OB-
I5ONC02ZI9?|_"/6>@^H;:=%JE_|!UN5C)=7VLZM<\$1M_837 MYM?M4_|
!+G|FW|H@:EXAL=)'PB^)|X)9AXY|V%K#9;G?%Q/XM|(:K32/\$ M
8AGN+NTDT/7|F5@T^NNB^4WZU@_\$3)>(|/3ROQ"RBCBU%5*='EK4|??
J2P4O9U&HQE@*BN?Q!GOT5?.\$PHS7%|8_1(/#U|XU_|_K_+/_1N/P&_|!/?
_F>K^2|XT_L9?MD_L|^M+8_B+H|^(:?1-\$N"^D?
&OX1ZCJK:5;VS2EU@|1&T2WU;PW'<1PPIJ6G>);)= M OG=M/AOM: @WL_Z#_LJ_|%O-
0LUTWPA^UCX;:5(%\$5JGQ;|#:=%#J2@!|@:KQ
M=X*M_)LKPLQ5KC4?"7|GM% "@6#PM>SLTIXLX|+JU3"O-^#;PHA2Y3.|E2I5*
M?|H44DFZ?+ #EIXF<%|=,/_|^A).:~) M2J8|&X7%QX7QTY/DAB>>LJN+RG#XB=W0Q-
2IF632I1EB)9W"FXQ/W*_X97_9 MA_Z-Q^ W_AH/A|_|SU'_ RO^S#_ -&X_ ;_ ;_!/?)GJ?
X9?%CX: _&; MPM:>-
/A9XV|>_.O#%Y|L>J^'M0BO(X)@.O9ZA:@K>:5J;/2XTW4|>TO|9OEG
MMHVXKT*ORFK2JT*DZ->E4HUJ4G"12JPE3J4YQ=I0G3FE*\$D|'&233W1_-V"Q
MV"S+"8?'Y=C;+C|!C*,1A;:@L12Q6\$Q5"HN:G7P^)|H3J4:|&I%J4*E*_#/#5
MIS169U'@W_#*_P"S#_T;C|!O_#0?#W_YGJ/^&5_V8?| HW'X#?| AH/A|_|M;|7O-%

'@W_#*_L/_1N/P&_+!/?_Y GJ/^&5_V8?^C_/_J7 MO-% '@W_ RO^S#_-&X_;-!/?_)GJ/^&5_P!F'_ HW'X#?^&@^'O_ M|SU>|T4>#?_/_K_LP_+/_1N/P&_+/_#0?#W_YGJ| AE?|F'_ HW'X#?^&@^'O_ M_ ,SU>|T4>#?_/_K_+/_1N/P&_+!/?_ F>H_X97_9A_P"C|T4>#?_ +_K_LP_|&X_ ;_PT'P|_P#F>H_X97_9A_Z-Q^ W_AH/A|_|MSU>|UX+|=OVG/|@7^S7H|O? &3XAZ'X2\$T\$D^EZ&|S:AXKU|8)0J:_%X7T|:G6_M|21YHC;O>168TVTF9?|00K. (F0;X;"XG&UZ>&P>'K8K\$U9*_AAZ4ZU:|D)| (M4Z<93D_1.V|/_ S?_/_IR#+L5F^>YGE^395@J;JXS;LTQF'P&!PM).W/7Q6*J4_MJ%*-VDG.<;R:BKMI"_|_#*_L/_A T;C|!O_|PT'P|_|F>KPGXZ:._P3P_9M MT^((C)|_/_V:?"\$*->_8D_CT'POI_ANYUO5- TL9@>YM|_M(V%K*R_ ;KNUC)D'XS_M/_P#|;_XD^_/_|1|+_+_+_AO|_X5?X^&O"GfQ._ /SXFU&)U2XL|3TZ<;5^5O@;_P3Y_/_(:_4 MU|_\$_Q6- %TL)AHYKQMFN'X\$MOXIXP^F53SO-ZG|7T>_."|U|5N+)|U-9JL%C:'#&!?-R/%2@EA|? MC<+1J7C6Q6*J9'E<8N->GFE>D|>V_:_?_."B'PE|8?VCX7_9E_9+^ WPT|/R_M>=;?|+ +5_!GX7ZQX|O8&|V/S|*T;_A|WPWX6|R_-@0UPWB;_1E2>VO_.G&U_M?;*V;A @FS^U+^U3<6OB;_PX?A|X_U.074G0%^=(O(XY_LBV4NF6%OX=|P+;2ZU8+@K_17^S#_ _,\$L_P!F+|G#^S|>O=|_X6_|M1K/RYO|_A_-B/%96E|96%XFX^?X9|'? O|!T38Q26UNKM=;UVSE0;ZXOW1^DM M=6)|0|AX;HU_O|/DHT).+IU<|S&FZF*K_WX4ZC=>HF_?A|;J0I0E=?45'0|_M;*_ HK^)|7BWF&%XH^D_XB9AF=.G46)P?AWPOBX8;*,NOM0Q&*PU.&682:A_L^ M)62X2OC,1349OB.=5.1^9|/_P#P2?|_V5|/@/90WOB;PO:?'3QLT!CO?;\$?Q0 MTG3M6T")W5TE&A^+_A;WPUIT#|D>*75D|1.S:RIOMM;C5B@^O?|AE?|F'_H MW'X#? ^&@^'O_ ,SU>|T5^59IG&:9UB98S-<=B,=B'>T|14#N!>#_ ^RBGD7|7#F5<- Y73Y7+#Y;AHTIXBI"/*J^_Q4N_M?%YABN726+QU?;\$8F;TG5D>#?_/_K_+/_1N/P&_+!/?_ F>H_X97_9A_P"C_M|T5YH|8>#?_/_K_+/_1N/P&_+!/?_ F>H_X97_9A_M_P"C|T4>#?_ +_K_LP_|&X_ ;_PT'P|_P#F>H_X97_9 MA_Z-Q^ W_AH/A|_|SU>|T4>#?|_#*_L/_A T;C|!O| PT'P|_|F>H_X97_M_&8?^C_P#S/5|S7%!/|BA/OBCH|UXA^&OCCPGX_T&QUO6?#5| MK7@WQ#|7B72|7Q#X=O9-.UW1+B_T>ZO+;'.5-)O8GM|^RDE6XMWV^9&%D1FM4 MZDH3J1A-TZ;A&I449.\$)5;_V<9S2Y8N?)D4FG+EERWY7;'5IQJ0I2J0C5J1 MG*G3:*@L|&_P"&5_V8?^C_|S/4?_/_K_+/_1N/P&_+!/?_ F>KWFB@#P;_AE?|F'_*_Q^ W_ (:#_MX>_ _#/_4?_/_K_LP_|&X_ ;_PT'P|_P#F>KWFB@#P;_AE?|F'_HW'X#?^&@^'MO_S/4?|_#*_L/_A T;C|!O| PT'P|_|F>KWFB@#P;_AE?|_9A_Z-Q^ W_AH M/A|_|/J1_PRO^S#_P!&X_ ;_P -!/?_F>KWFB@#P;_ (97_9A_Z-Q^ W_A MH/A|_|P#;J1_PRO|LP_|&X_ ;_PT'P|_|^9ZO6M4|5^%|S\$W?VUXDT#2-F=_| M:FL;=I^S'7=|KN8=N.^<8KSK5/VB_P!GS1-W|M?';X:;1LSO_M3XC^"=V8Z_M|OM>N1; <=|XQ6|/'XJM;V.&KU;|>SHU*E_3EB|G/5QF\$H7|MBL/1MO|6O2IV_M|>>2L97_ RO^S#_-&X_ ;_;-!/?_)GJ/^&5_P!F'_ HW'X#?^&@^'O| M|SU<=JG|=G|\$6B;AK'|8W|+&ELN/^&5_P!F'_M'_ HW'X#?^&@^'O|_|SU'_*_L/__\$_;C|!O_ T'P|_|^9ZOD+5/^"RO_3&MTC=|K_!|^F;E'|M3S:E*N?W6E_!OX|7.RX3XEJ|_|&19I_M)? >L*U;S08|ZKOWP/00|;C+A6DUNT093%^_O%I_@?H'_PRO^S#_P!&X_ ;_M_P_-!/?_ F>H_P"&5_V8?^C_|S/5^6VJ?|'#O_!;G3|WV3XC?_M\$G7-N&_'M6W)PCGRO_ _QG4O|C|C_/AE?|F'_ HW'X#?^&@^'O_S/M4?|_#*_L/_A T;C|!O| PT'P|_|F>K|*M4_X.?- B>'<-&^"/4FHD9"G4_M?#WPGTA6(|YM_BWK#|2>A*;L'|'W>F|)'KFW/?&_'O7? 2)|/\$_K|/'N/5_P#G|5P5'MOI;%4|_|?/LSS: MOC+X8T;|_%^7NW_/JCCZ_P!WL<)4O|C|^_%^7P8_8Z^%/A_5/B1XS^\$?|_OP|_M|_>|'==? U?QOX@^'OPS|_Z1X9@L98Y(|5N|?O='L|;2_L|SY)@NGN876Y:%8_M6|JHP?HW3M1T_6- /L=6TF^L|4TK5+.UU'3-3TZZ@O=/U'3|V|+FROK&JMGEM MKNSN|;6.XM;JWDD@N()\$EB=XW5C_)TO_!3|_@K|H??"B=YH_@|3|'"NO@Y^ MS_X;DM|H_L_A99^(VUZZ|4^)H0V/%'CO7(-T2'69K+<4|/;"TT>EZ_K2W"M MJ&J3-J0^OO| @C#_ _%GM0_9=U#0/V7_-J#7|S5/V<-4O(|A">_|J0DGO=0 M^!FH7L^\$L|QSYMS="V|N92|Y:O)_!T|DFIZ9&^DO?6?*8XSP%XHPG":SKF MA6SVE*=?%<.T5"M5A@5%6C0Q-*I.GB,PIVE4J8;ES0J4Y>SP|6I7@J=?XK_ M2(X2QO&+R+DG0X?JQIX?!|2UW.C1J9@Y.L1AJU.G4PN6U>:_*EBJW)4I5(^MTQ- *EAZCJ4|J**CBEBGBCG@DCF AFC26&_)UDBEBD4/)'(A*21R(OR.I*L_I_M#*2"#4E? A)_O>^P4444%%%%%%%%!7@W|/_)/?\$_A_V7G|JC_U|XOU|S7@W|_M|/_)?\$/_&7G|JC_:->^+| !^SC_P_D|H0_|EY:_H_|>^+|>|UX-^SC_R3_MWQ#_-EY:_H_|>^+|>|T%%%%%%%%!1110_4444 >#>(O^3GOA!_V0;|H|_P!6_M%^RO7O->#>(O^3GOA!_V0;|H|_U87|*|>|T%%%%%%%%!1110 4444%%%%%%%%!11_M10_4444%%%%%%%%>1?%WX^?|CX"Z*_?|C|!2?"G@'3Y\$=|1-/1-!_MMA(N(YI M95EE>M1;M+&5\$J&"AK;7-BJSA2DX|NG2E4JV3Y:%?A11J/C7B M_+GD6\$F|SX@KIT>:FH9/@%7QM*G6NE3Q6+IX;|7=YXF\$5*2_H\$U'4

M=/TBQN\4U: LM+TRP@DN;f4=1NH+*QL[:(:l:B\N\F2*WMX(U!:26:1(T RS M
5^7'f00_!7S\JE3X+&fT?P9JEY|=O&-L9(5TWX>3VP\|)07*%P!J/C^f5f&DM MG*%?
M'A>W\6.C/'OMU4LZ?STWOB7\OC_(*+>)GTV.;XE?&"WCOP3H^E11>'
MOA9X7G=XW@^V10?V)X T&6&-X!':S-'JEQ#')/>W.-9L6@A) 6&fM-%fW097E%CXAC9
M8K@ HT> ^#^%8JM00Q'3O&+BE+^Q,IE-U)-JZC4<(O&RA;-5'2P\$\$_+fEU<
M_E.K\3QV!.*E3 ?1U!*<7E>259RH_|\$0^-Z="&&f14N6=;#0KU(fT<1AW M:4f-
#%f3XB4'fEZDXH^)?C;_,%3_P!fLGH+4F\&^f^Z^&6AZf.UCIO@KX.
M6>HOXNU<3(R):3^*XDN?&&H7DD;3++#X=?0;f1L2Z4YC5EZ;X!_|\$>_VJ_C M7=1>
(_BF;X'^&f3N&O;W40'0EUOX@:.@+f42W-W#X*M+R.^C09)))GGC\7ZO
MX9O&F5f6CE617?fIU^"7f/./P\$ _9UTM=,^#OPP\,>#G:f;f>fURWL_M_BO58P MJ
KJ_BS5'O?*\$6f1LR>8+:ZU*2TAD>0VUO""93fS7/C/%.CEE">7f#Y#@LAPK
M7*f\97HTJV.JVTC5E37-2fJEHY8JKCVUU1ZF1?0QQ_%V94.)_fI%>)G\$/B5G,7
Mf19#E^/QF!X>P?.TZN\$f18NHJ6-^fI2=VJ.2X/AF\$)6:C)7YOS;_9Z_P""5?f)
M7P%*%CJMWX.;XN^-+1Hf _^\$fI^*26FO6UO=O-Y@ETCPBMO#X5Tf8fIMDME/=;9J
M>KV;11,fKO*IE;Z;f6_LC?LO>//\$&H>* _&?P!^\$WB;Q+JOV7^TM;UCP1H-fJ M-
fHALK;3;f(f1RIQA33C%J-TC^M,fI*O#3A_);/f#V4 M^'? _)!KV?X;??"fX7?fS2+f0?A5X f)?
M#S1=3U)M7U'3/'f.AV&AV=fJCVMM9-?W4%A#"DUR;2SMK?S9 S""*%\$!_fS>f|*
M_\$CP3XVUGQIX>f|+;_:ZOK'P\UN/PfXPLK>.Y23fM7EMOM*6LCSPQ17 VK/ f
MfJfQ;fI>6=fJ8M*+NRNH8NWK'&XW.))X7,<7F4DU2JRPV,Q&*DG&fI"-:C4=&O- MJTZX
M&Q5&&+P6'A--O&6JQ;+X8f.V9O\7U. M6&YN%MK?
S(X(Pem9PW%Wf3HT;J9fE&3C);,H
MMQE&2:E&2=FFGJfFGHTf4f&5&49QC.\$HSA**E&46f1E&2O&49*Z<6FFFFTTfK
M0****104444_%%%%_!1110_4444_13P0W,,UM&_N583BGJDC9GQ"?AOP/XF9/f(
M^.>&fMXAP#4_8/f%TG'&8&f42C*OEF8T)4L?EN(:23KX'\$T*DHKDG*4&XO^)K
MQGf'_P!Mf _@fYX_Bf50MXJ^fT%U';6/Q&f#7LNM_#7Q;%\$Q.%CJ4f6KZ-J5M
M*fIKO%X9f|=;_:WC.#<_V*NR.:OUP_95_X+;_>\$/\$OIF>\$/\$VI_#L?@C6GfBT3XG M^#f2fO?fJ
f(?*A6Xf2>&@UfK7AV20fH;J^T>36f->9V<:=HEE'A/WCUG1=f' M1:7?:'X@TG3-=T35+=
f4f'UFPM=3TO4;248EM;f3fV*>TNf>0_!X+B&2)Qf MY37XH?M6?f\$6?
A7f15U+Q;^S;JMOf(?&,@fN6f\$ZJUY?_#f+6+fDKE8;-T6fUS MP3)-
*7>26Q77=&B7Rf;Rf.Z?#\$,OZM2XTXfXfTfTf'QUE<,OS'E5*CQ#fEL90Y
M7;EBZUHU:U**;TA5CC<(FY3<*\$5=?Q1C?H_>.7T?L5B<^&C?QEB.*.%G5GBf
M=X7<6U*5?VD6^>K'J<f)EV-JR2Hf\$8*IPfG^fJf+6>"/\$FA^+?
#.L6ZW6EZ_X=U.SUC2;^fP""MKZQFGMY-N=LB"3?*\$X:. M14=64=f'7f2EKJf'f^\$ M?
\$9>UAV)=VSQ>)=&MY=L<^CW9(3fPOV5_P#@LfHf&OBE_9WA7fH'3f;X)^fIO
M+MOXFCFN;WX7:OEQ+DU2+fJf3fEfC5Q;:6_=
/f#TIU%7BMO:82=:ZC*=2G16B_2O#f'Z8W!f'\$
M^8_ZH^f)67XOPCX_PU6.#QF4f4JKA,HK8RT4Z=#-,9fPLLNJU&^>.\$SRA@f'V
ME.CAL7CYOG?f4T52TW4f-UG3f/5M'U"QU72f1MXKS3f2TVf@OM/O&K2=|U9
MWEK)+;75O,A#Q3P2/f%(A#(Q!!Jf7YBTTVFFFFTTU9fK1fHZHZ-/8_L*\$X5(M1J4Y1G"
<8SA.\$E*\$X22E&49f;4HR33C)-HHV8453U'4=f/T?3fH5M6OK/2f
M*fTNSNM1U/4f1NH++3f.T^R@>YO;Z^O;EXK;TLf2VBDN+fJZN)(X+>"-Y972-& M8?
Rf_/_/_(.4?AGX2_:(TCP'X\#6WC7fD'0KFZ)*^fOBM:1Z@?'&NZS-=10
MMXf\^fFG&Z@L)_!AMXf%CTK4K%f17f9V,EUJ6GW>D%=,M;KZ3AOA#B'BVIC*>
M0Y=5QSP&&GBL3*+C3IPC&,G3HJf4<82Q6(<7'f#8>,G5K.,G&f)'fI*/R_%&O M#7fM/ U>
(LSHXf9CBZ>\$PD9*52f4E*48U*fHTU*<,)AE.,f5B915*A%Q4fI<f M2G"?f2%%?"BMX)f,?*\$?
X<>))f'f9^f!?'&>CVFO>%_&@W:7VDZSf-
MfF^"ZM9TY!fW0W%O;L5U9W44fG>0074\$T,>GK7BCPSX:Bf_Q%XBfT+0(=NfSM M:U?
3f)*BVf_-YEf<0)MXf/.<<'GBOGf4:T:LfJf52->\$Y4YT90DJL*D).,Z)K;9CONQCO7B?B7_@fI_
L\$^'=+U#5+7fHSX9>-Q8fT:R^&&LCXF7 MEQ=")Y(K*'A"8f;M(fKDIY<4Uf=V=@C.C7-
Y;PDRCTL/D.>8fIQ6&R;-<1S- M*/L2?2O#YE; M4O%VOf!f*JKH7A;3EN=:U"-YXC;f?K;f)-
G.Z?VCJfE\$3f/YZ?VGO^"V7Q4f= M_PfH^&fV;?#P^\$OAB;S;_A_=\$\$=AK?Q(U"V;f>GFV-
G_ *9X9f(&:%RCf"/\$ MNJ6fB1W6G;fHfPVK^#7BKfH+P)K/CFfU3XR?
%O7M3UG4fT7/BGQ&+75_B5XO MN&f94Jf<f|>'O\$*GD52+2fV6>A2?+=\$&?
A'fH;WJ;R+CPMX;@^f)OB/2O#T:LP M:VO)M.O_!!;\$?f| (7< 9^J?*\$'_!T_|#ZVfS_A%?V-
O&6LXSY7_ D'QFT3 MPSoHf_LWX>>+?+SWV^;CMFOOY9-Q7DE">7^'?AW6P?;O9U.
fS>fEf|f%5f6f M^f-/&XZG7FF_?
@f95C3@VUf2@M%^6X#PfPOB=f.F&XfI^E)XY3Sf4JGUG">'G"+
MS&639=S;8>MBLKRYY?Af*#^KXF.18.>*Q\$(QJ/B*M4O-_M%^S#_P2Y_9B_9N

M_L_7;C0/^%M_\$.T\N;_A-_B%9VE_!87B;CY_AGPEMFT'0MC,KVUU.FKZ\;N@_M,6N8XK\
(*_C+|0?|'3?Q4N=___"*_L@_#_1LY|O|_X2#XK>(_\$VSKMW_V;X\|_M)>9CC.WR\X_-N>/#O\$/
<|?MPW^~/P|\|_-'F#P_"V=LEUX7^)^N7T?HLG_M?XKZ=9\$COYFFN#Q@+_R#|%C/\|_P
6<_Q+QFGE_|_"53>)_LX|>;YGOF0*I_|_@LY_P5P^)\$KV^D_M_M&>-|09V*+>?!?A^|*|/ECW=
(TD|*?#2WOMPS|K23O-R/G/%;TOH|<;R7/B,Q_MX:PD%K)U<=CI22_|AY9*'WU\$O,|_"M|)?
@,;N3#9;Q3C)O2*HY?E\|_R?_'%S_M:%3|JOZ?MSGYO.VXYW8YK7_B|4_M*V@C')R|TSI&O
/WF'0UY#XA_:/_&>/'6_ (2KX|_!CPSY6?-_X2'XH^|_|_M%|O;UW_VEKMMLO@YW8QCFO|
/^L_^^)/_!6?Q_.E|JO|.7B*1GY;4/&OOA^\$ _M-G/&'P29(=;^)?|_:_O)ZL(|21QCYE!KU|P_
,&YG_!2?6=G|HZ!|&_"6_&|_M_A/(BM8W/E9_O_|_"*Z5XFSCOY?
F>V:/^^(4^'^^%_W_Q>R&;7Q4|'3RZ4H^7N_M9UBI7|:;<7_=_%_P
1A|1|7IE_@MQ#33^&IC:F9OA*|K/W\APD+;|_*K7|H<_LO_M\0?|%)O^"?
GACS:|JO|:/|_K/%GS(=)^_W@3Q%<(1U1K;P|K6J7"R#O&8|>-_MN:|_!0?
|%K/^_"7GAGS/|1_:_W|_W/EYW?|(_X0^*7BS_/|G_">+!=9\$F>WEE@_M>QQ7|V/A|_@V!_:_3O-
C^)_OC;^S)H4;X+)_I6N?%#Q#=#1_|0|<_P+_+|!MC(.?E_MCO)\$/&)>3CW'P_|+&L'O#N?
+_X2K|LGP9HV<>;_:_(_|&M<|3;|7R_|1^(7_M\A+S,=MWE9|:/|3?!#"_||XCYGB+?%)1PW-?
OR^QR?'_"MS?;/|>/'S&?|A_MX895AK_#_:_&*Y;7_)O;9WEWSOR_*S/UK|0?
|'#'_|_71=_|F_\$_XA>+|=N=O_M_"/_@|=VWF8SC9_P_)5IGAG&>WF>7U&
<)_AAH=C*>X>%/A3J-Z%/81ZE&1GEB<\$'U/Z/6\$__YFO%6:
M|3_M'??"6_^^_|+|'@7QG|#=#)|80W6G_\$/XA^(|;TMO'=_X;N(V_M@G|^*^%(/#LES;*>&?;
5XF:/7->36+G59|%Y-*T^/3HY;F\N?RH_X)Y?|_!2GX_MZ?|_!SXAZEXC^'7V?QE|_._%D:1?
\$+X/^_(M1O+3PMXI>WB:/3|:L|FV2YE|_M>+_*R\$L?;\$_-E:7+R6;2Z;J=EJ5@ZV|?)
0|^WK_P;A?#_:/_6N?&_|#%_|M0-6^)_@J&ZU+6/AKX|1Z?XA/Q,T.*
(RW%KX4OH=&T7^R_&MDJ-+ING2E|+|_M1(6TR-;#4S:S7?Y0?
|\$H/^"0/Q\$;_G^(D_B_XL:7XC^'7|-'PZ\1SZ5X|UB|_MM+K1?
\$GCGQ)HMUY>|_#|P='>PQW%K?6L|:6?C'Q_|C|^*QF2QC27Q!+#+;6_Z_M|P|FG@|#@'.OJ-
'#TN&J**L(RR',_LE3CE&'PM-)8MT9TZ-_M/'4,-AU-_P|JT\103J0FGB85Z6(H>U^Z|4_X.E?
CE-N_L7|E/X4:?.G.S^U/'
M7B_5|OIN^R6&B;|=|;_^U>_WQLS|5_35HW_!'S_@F=H44,5C^Q|+)_TMXTCC.LCQ+XCE9
M\$/B#5)KF0@_O+<22RRMEY'=V9CZ3I?|_P32_X|:/_M^R?L5?LOS;_8_M3X,>_M!-
WUG\$IW|74|UQ7S6MO_|MVA<">/_?>?%'|J5|7^JX5Z=|_OA=H>|:/
M|+^\$GAB;9_N_VT-7SC;_W^:_N%TO|BS|CG0|O|_8O)DGL_^D;|N?V7|"/A;
M|S^3;|D|^*P|<>V*|&TOX&_!30|O|B_!_P"%ND;_:/|+^_A/3|N.FWD|\$.MW';&4?
|1+|_.*|^|^\$V7U;_?6:V"?W^TP.*_4|_B%?BQ7_WGQDS*E??ZK1Q_MRMZ>SQ^\$ _0_S|K_
(+S?|%6-9D|BS_:_2@T|S';MMHWP4^!)D;_.?EBDNOAG?_MW@/H8YP_'WNM9_|P|/_."Q/C/_
(|/CM|=2|W|O|_PB_PR|_V>|/3R_|_MA&OA|_XSV|O'M7^B_8:3I6E1^5I>F:?.|L6
OEV%E;6<>T=|LMXXUP.PQBM"C_M_B,/""+_'3P@X7I6M:4I9:Y-JVKY.'8/_R=|H|_P"
()|:UO|H|:N+:R>|(_MQS2,?-+GXFJ1^ZFEUL?YR'_#3G_!:_QG_P>'C?_(*:_EYW3_A%_#?
Q=L|V_M|IY?_"_Z!:_|<|O+Q|4?V/_P7?|9_ZZV_X*JZG#-|TZA+^U5;:XML_17_R2.htm_IDEA:
XBRL_DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:		
Cash and cash equivalents	\$ 291,146	\$ 457,469
Investments—short-term	460,522	316,022
Receivables, net	384,528	332,477
Inventory	182,887	186,406
Prepaid expenses and other current assets	91,282	98,166
Contract assets	4,990	706
Assets held for sale		94,260
Total current assets	1,415,355	1,485,506
PROPERTY, PLANT AND EQUIPMENT, NET	227,564	226,943
INVESTMENTS—LONG-TERM	73,148	39,887
RIGHT-OF-USE ASSETS	84,245	91,460
INTANGIBLE ASSETS, NET AND GOODWILL	83,917	85,018
DEFERRED TAX ASSETS	154,835	195,888
OTHER ASSETS	16,503	11,521
TOTAL ASSETS	2,055,567	2,136,223
CURRENT LIABILITIES:		
Accounts payable and accrued expenses	185,332	240,561
Accrued sales discounts, allowances and reserves	272,452	263,641
Operating lease liabilities—short-term	6,166	5,746
Contract liabilities—short-term	1,249	2,730
Current portion of long-term debt		3,000
Liabilities related to discontinued operations		4,542
Total current liabilities	465,199	520,220
LONG-TERM DEBT		287,730
OPERATING LEASE LIABILITIES—LONG-TERM	69,372	75,709
OTHER LONG-TERM LIABILITIES	56,019	49,878
Total liabilities	590,590	933,537
COMMITMENTS AND CONTINGENT LIABILITIES (Note 19)		

SHAREHOLDERS' EQUITY:

Preferred shares, par value, \$0.01 per share: 50,000,000 shares authorized; zero issued and outstanding at December 31, 2024 and 2023, respectively		
Ordinary shares, par value, \$0.01 per share: 450,000,000 shares authorized; 176,670,785 and 172,569,051 shares issued; and 162,176,994 and 166,979,833 shares outstanding at December 31, 2024 and 2023, respectively	1,767	1,726
Treasury shares, at cost (14,493,791 and 5,589,218 shares at December 31, 2024 and 2023, respectively)	(419,255)	(189,336)
Additional paid-in capital	2,860,890	2,736,934
Accumulated other comprehensive loss	(1,967)	(3,110)
Accumulated deficit	(976,458)	(1,343,528)
Total shareholders' equity	1,464,977	1,202,686
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$	\$
	2,055,567	2,136,223

~~***XML 18 R3.htm IDEA: XBRL DOCUMENT***~~

CONSOLIDATED BALANCE SHEETS (Parenthetical) - \$ / shares	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Preferred stock shares, par value (in dollars per share)	\$ 0.01	\$ 0.01
Preferred stock shares, authorized	50,000,000	50,000,000
Preferred stock shares, issued	0	0
Preferred stock shares, outstanding	0	0
Ordinary shares, par value (in dollars per share)	\$ 0.01	\$ 0.01
Ordinary shares, shares authorized	450,000,000	450,000,000
Ordinary shares, shares issued	176,670,785	172,569,051
Ordinary shares, shares outstanding	162,176,994	166,979,833
Treasury shares	14,493,791	5,589,218

~~***XML 19 R4.htm IDEA: XBRL DOCUMENT***~~

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD (\$) shares in Thousands, \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
REVENUES:			
Total revenues	\$ 1,557,632	\$ 1,663,405	\$ 1,111,795
EXPENSES:			
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	245,331	253,037	218,068
Research and development	245,326	270,806	272,702
Selling, general and administrative	645,238	689,751	590,751
Amortization of acquired intangible assets	1,101	35,689	36,363
Total expenses	1,136,996	1,249,283	1,117,884
OPERATING INCOME FROM CONTINUING OPERATIONS	420,636	414,122	(6,089)
OTHER INCOME (EXPENSE), NET:			
Interest income	42,450	30,854	7,629
Interest expense	(22,578)	(23,032)	(13,040)
Change in the fair value of contingent consideration			(21,750)
Other income (expense), net	3,242	(425)	2,122
Total other income (expense), net	23,114	7,397	(25,039)
INCOME (LOSS) BEFORE INCOME TAXES	443,750	421,519	(31,128)
INCOME TAX PROVISION (BENEFIT)	71,612	(97,638)	2,024
NET INCOME (LOSS) FROM CONTINUING OPERATIONS	372,138	519,157	(33,152)
LOSS FROM DISCONTINUED OPERATIONS, NET OF TAX	(5,068)	(163,400)	(125,115)
NET INCOME (LOSS)	\$ 367,070	\$ 355,757	\$ (158,267)
EARNINGS (LOSS) PER ORDINARY SHARE:			
Earnings (loss) per ordinary share from continuing operations - basic	\$ 2.25	\$ 3.12	\$ (0.2)
Loss per ordinary share from discontinued operations - basic	(0.03)	(0.98)	(0.76)
Earnings (loss) per ordinary share - basic	2.22	2.14	(0.97)
Earnings (loss) per ordinary share from continuing operations - diluted	2.2	3.06	(0.2)
Loss per ordinary share from discontinued operations - diluted	(0.03)	(0.96)	(0.76)
Earnings (loss) per ordinary share - diluted	\$ 2.17	\$ 2.1	\$ (0.97)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:			
Basic	165,392	166,223	163,742
Diluted	169,198	169,730	163,742
COMPREHENSIVE INCOME (LOSS) :			
Net income (loss)	\$ 367,070	\$ 355,757	\$ (158,267)
Holding gain (loss), net of a tax provision (benefit) of \$292, \$1,195 and \$(973), respectively	1,143	7,779	(7,166)
COMPREHENSIVE INCOME (LOSS)	368,213	363,536	(165,433)
Product sales, net			
REVENUES:			
Total revenues	1,083,534	919,998	777,552
Manufacturing and royalty revenues			
REVENUES:			
Total revenues	474,095	743,388	331,983
License revenue			
REVENUES:			
Total revenues			2,000
Research and development revenue			
REVENUES:			
Total revenues	\$ 3	\$ 19	\$ 260

~~***XML 20 R5.htm IDEA: XBRL DOCUMENT***~~

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]			
Tax provision (benefit)	\$ 292	\$ 1,195	\$ (973)

~~***XML 21 R6.htm IDEA: XBRL DOCUMENT***~~

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD (\$) \$ in Thousands	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock

BALANCE at Dec. 31, 2021	\$ 1,112,584	\$ 1,658	\$ 2,798,325	\$ (3,723)	\$ (1,541,018)	\$ (142,658)
BALANCE (in shares) at Dec. 31, 2021		165,790,549				(3,853,222)
Issuance of ordinary shares under employee stock plans	19,630	\$ 32	19,598			
Issuance of ordinary shares under employee stock plans (in shares)		3,160,644				
Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards	(18,204)					\$ (18,204)
Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards (in shares)						(720,962)
Share-based compensation	95,176		95,176			
Unrealized gain (loss) on marketable securities, net of tax provision (benefit)	(7,166)			(7,166)		
Net Income (Loss)	(158,267)				(158,267)	
BALANCE at Dec. 31, 2022	1,043,753	\$ 1,690	2,913,099	(10,889)	(1,699,285)	\$ (160,862)
BALANCE (in shares) at Dec. 31, 2022		168,951,193				(4,574,184)
Issuance of ordinary shares under employee stock plans	16,760	\$ 36	16,724			
Issuance of ordinary shares under employee stock plans (in shares)		3,617,858				
Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards	(28,474)					\$ (28,474)
Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards (in shares)						(1,015,034)
Share-based compensation	100,871		100,871			
Unrealized gain (loss) on marketable securities, net of tax provision (benefit)	7,779			7,779		
Distribution of Mural Oncology plc	(293,760)		(293,760)			
Net Income (Loss)	355,757				355,757	
BALANCE at Dec. 31, 2023	1,202,686	\$ 1,726	2,736,934	(3,110)	(1,343,528)	\$ (189,336)
BALANCE (in shares) at Dec. 31, 2023		172,569,051				(5,589,218)
Issuance of ordinary shares under employee stock plans	27,572	\$ 41	27,531			
Issuance of ordinary shares under employee stock plans (in shares)		4,101,734				
Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards	(29,637)					\$ (29,637)
Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards (in shares)						(1,010,156)
Repurchase of Alkermes' ordinary shares	\$ (200,282)					\$ (200,282)
Repurchase of Alkermes' ordinary shares (in shares)	(7,900,000)					(7,894,417)
Share-based compensation	\$ 96,425		96,425			
Unrealized gain (loss) on marketable securities, net of tax provision (benefit)	1,143			1,143		
Net Income (Loss)	367,070				367,070	
BALANCE at Dec. 31, 2024	\$ 1,464,977	\$ 1,767	\$ 2,860,890	\$ (1,967)	\$ (976,458)	\$ (419,255)
BALANCE (in shares) at Dec. 31, 2024		176,670,785				(14,493,791)

~~***XML 22 R7.htm IDEA: XBRL DOCUMENT***~~

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) - USD (\$) \$ in Thousands			
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]			
Tax provision (benefit)	\$ 292	\$ 1,195	\$ (973)

~~***XML 23 R8.htm IDEA: XBRL DOCUMENT***~~

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD (\$) \$ in Thousands			
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income (loss)	\$ 367,070	\$ 355,757	\$ (158,267)
Adjustments to reconcile net income (loss) to cash flows from operating activities:			
Depreciation and amortization	28,533	74,927	77,862
Share-based compensation expense	96,637	100,905	94,254
Deferred income taxes	40,522	(99,902)	(32,795)
Change in the fair value of contingent consideration			21,750
Other non-cash charges	4,512	6,329	5,531
Changes in assets and liabilities:			
Receivables	(52,052)	(44,510)	25,250
Contract assets	(4,284)	8,223	4,434
Inventory	3,091	(2,712)	(31,021)
Prepaid expenses and other assets	2,254	(34,847)	(5,328)
Right-of-use assets	7,215	15,387	16,569
Accounts payable and accrued expenses	(57,967)	23,009	15,534
Accrued sales discounts, allowances and reserves	8,811	11,526	14,899
Contract liabilities	(3,525)	(5,926)	(7,129)
Operating lease liabilities	(10,123)	(16,147)	(33,225)
Other long-term liabilities	8,430	9,334	12,726
Cash flows provided by operating activities	439,124	401,353	21,044
CASH FLOWS FROM INVESTING ACTIVITIES:			
Additions of property, plant and equipment	(33,484)	(48,048)	(38,255)
Proceeds from the sale of equipment	461	354	
Proceeds from contingent consideration			1,273
Return of Fountain Healthcare Partners II, L.P. investment	43		485
Proceeds from the sale of the Athlone Facility	97,933		
Purchases of investments	(486,547)	(254,471)	(309,671)
Sales and maturities of investments	310,286	355,522	281,627
Cash flows (used in) provided by investing activities	(111,308)	53,357	(64,541)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Cash transferred to Mural Oncology plc at separation		(275,000)	
Proceeds from the issuance of ordinary shares under share-based compensation arrangements	27,572	16,760	19,630
Employee taxes paid related to net share settlement of equity awards	(29,637)	(28,474)	(18,204)
Payment for the repurchase of ordinary shares	(200,282)		
Prepayment of long-term debt	(289,542)		
Principal payments of long-term debt	(2,250)	(3,000)	(3,000)
Cash flows used in financing activities	(494,139)	(289,714)	(1,574)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(166,323)	164,996	(45,071)
CASH AND CASH EQUIVALENTS—Beginning of period	457,469	292,473	337,544
CASH AND CASH EQUIVALENTS—End of period	291,146	457,469	292,473
SUPPLEMENTAL CASH FLOW DISCLOSURE:			
Cash paid for interest	23,010	22,748	13,563
Cash paid for taxes	2,592	44,243	20,749

XML 24 R9.htm IDEA: XBRL DOCUMENT

Cybersecurity Risk Management, Strategy, and Governance Disclosure

Cybersecurity Risk Management, Strategy, and Governance [Line Items]

Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]

12 Months Ended

Dec. 31, 2024

Item 1C. Cybersecurity

Risk Management and Strategy

In the ordinary course of our business, we collect and store sensitive data, including IP, proprietary business information of ours and that of our suppliers and licensees, and personally identifiable information of persons who use our medicines, clinical trial participants and employees. Our licensees and third-party providers also possess certain of our sensitive data. The secure maintenance of such information and the secure performance of our information technology ("IT") systems are critical to our operations and business strategy. As our dependency on, and the complexity of, our IT systems increases, the confidentiality, integrity and availability of our IT systems and the data that they store is critical to managing our business.

Our Information Security Management System ("ISMS") is a key element of our information security program, designed to identify, assess, help mitigate, and monitor IT risks across our organization, including information security risks. The ISMS is informed by the structured principles of International Standard- ISO/IEC27001:2022 (Information security, cybersecurity, and privacy protection), which outlines guidance for the establishment, implementation, maintenance, and improvement of information security management systems. Our ISMS is comprised of processes designed to identify cybersecurity risks, safeguard information assets and preserve the confidentiality, integrity, and availability of information owned, managed and maintained by us. Our ISMS includes formal written policies and procedures, technical security controls, such as automated tools designed to detect and prevent cybersecurity incidents, and programs designed to promote internal and third-party IT risk management, audit management, incident response and security awareness, including employee awareness trainings and other initiatives. Our ISMS includes periodic security audits, vulnerability assessments and penetration testing to proactively identify potential system vulnerabilities. Our ISMS is periodically assessed by third-party assessors and the results of such assessments, including any cybersecurity risks and related mitigations identified, are reported to the audit and risk committee of our board of directors, as described below, and are used by us to improve our ISMS and our broader information security program.

As part of our information security program, we also have processes in place for management of cybersecurity risks associated with third-party handling of our confidential information, including in such third parties' provision of critical services on our behalf. We conduct due diligence of our third-party vendors through an assessment of their security practices and overall risk profile, including through their completion of vendor assessment questionnaires and ongoing monitoring of such third parties, utilizing tools such as security ratings services and periodic reassessment questionnaires.

As of the date of this Annual Report, we have not experienced any information security incidents that have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition, and we have not identified any current cybersecurity threats that we believe are reasonably likely to materially affect our business strategy, results of operations, or financial condition.

Governance and Oversight

We have a multi-layered information security governance framework in place to provide oversight of our information security program and strategy, our ISMS, and related risks and opportunities. This governance framework includes procedures for escalation of identified information security risks, threats or incidents through various management levels, including up to our Information Security Governing Body, which is comprised of our Chief Executive Officer, Chief Information Officer, Chief Operating Officer, Chief Financial Officer, Chief Legal Officer and other members of management, and as appropriate, up to our board of directors.

Our information security team is responsible for developing, implementing and overseeing our Company-wide information security strategy and related policies and practices. This team works cross-functionally throughout our organization to assess and prepare the Company for identification and mitigation of, and if necessary respond to, information security risks. The information security team is led by our Chief Information Officer, who has over 35 years of experience in various information technology roles, including 18 years at the Company serving in roles with increasing levels of responsibility. Our Vice President of Information Security and Technology, a Certified Information Systems Security Professional, with over 20 years of global experience in various information security roles, including 14 years of experience at the Company, is responsible for day-to-day management of information security team initiatives. The other members of the information security team have extensive IT, IT security and cloud industry experience, as well as certifications pertaining to information security and privacy (such as Certified Information Security Manager, Certified Information Privacy Technologist, GIAC Security Essentials and GIAC Information Security Professional certifications).

Our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. The audit and risk committee of our board of directors specifically oversees critical risks and opportunities facing the Company and, in this context, reviews and provides feedback on our company-wide enterprise risk management program, which encompasses risks related to IT and cybersecurity and mitigations put in place, or to be put in place, in response to such risks and opportunities. The audit and risk committee periodically reports to the full board of directors regarding its oversight of the Company's enterprise risk management program and periodic risk assessment results. In addition, our board of directors receives periodic updates from our CIO and Vice President of Information Security on our ISMS and other information security initiatives, and on our information security governance framework.

true

Our Information Security Management System ("ISMS") is a key element of our information security program, designed to identify, assess, help mitigate, and monitor IT risks across our organization, including information security risks. The ISMS is informed by the structured principles of International Standard- ISO/IEC27001:2022 (Information security, cybersecurity, and privacy protection), which outlines guidance for the establishment, implementation, maintenance, and improvement of information security management systems. Our ISMS is comprised of processes designed to identify cybersecurity risks, safeguard information assets and preserve the confidentiality, integrity, and availability of information owned, managed and maintained by us. Our ISMS includes formal written policies and procedures, technical security controls, such as automated tools designed to detect and prevent cybersecurity incidents, and programs designed to promote internal and third-party IT risk management, audit management, incident response and security awareness, including employee awareness trainings and other initiatives. Our ISMS includes periodic security audits, vulnerability assessments and penetration testing to proactively identify potential system vulnerabilities. Our ISMS is periodically assessed by third-party assessors and the results of such assessments, including any cybersecurity risks and related mitigations identified, are reported to the audit and risk committee of our board of directors, as described below, and are used by us to improve our ISMS and our broader information security program.

true

true

false

Our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. The audit and risk committee of our board of directors specifically oversees critical risks and opportunities facing the Company and, in this context, reviews and provides feedback on our company-wide enterprise risk management program, which encompasses risks related to IT and cybersecurity and mitigations put in place, or to be put in place, in response to such risks and opportunities. The audit and risk committee periodically reports to the full board of directors regarding its oversight of the Company's enterprise risk management program and periodic risk assessment results. In addition, our board of directors receives periodic updates from our CIO and Vice President of Information Security on our ISMS and other information security initiatives, and on our information security governance framework.

Our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. The audit and risk committee of our board of directors specifically oversees critical risks and opportunities facing the Company and, in this context, reviews and provides feedback on our company-wide enterprise risk management program, which encompasses risks related to IT and cybersecurity and mitigations put in place, or to be put in place, in response to such risks and opportunities.

The audit and risk committee periodically reports to the full board of directors regarding its oversight of the Company's enterprise risk management program and periodic risk assessment results. In addition, our board of directors receives periodic updates from our CIO and Vice President of Information Security on our ISMS and other information security initiatives, and on our information security governance framework.

We have a multi-layered information security governance framework in place to provide oversight of our information security program and strategy, our ISMS, and related risks and opportunities. This governance framework includes procedures for escalation of identified information security risks, threats or incidents through various management levels, including up to our Information Security Governing Body, which is comprised of our Chief Executive Officer, Chief Information Officer, Chief Operating Officer, Chief Financial Officer, Chief Legal Officer and other members of management, and as appropriate, up to our board of directors.

Our information security team is responsible for developing, implementing and overseeing our Company-wide information security strategy and related policies and practices. This team works cross-functionally throughout our organization to assess and prepare the Company for identification and mitigation of, and if necessary respond to, information security risks. The information security team is led by our Chief Information Officer, who has over 35 years of experience in various information technology roles, including 18 years at the Company serving in roles with increasing levels of responsibility. Our Vice President of Information Security and Technology, a Certified Information Systems Security Professional, with over 20 years of global experience in various information security roles, including 14 years of experience at the Company, is responsible for day-to-day management of information security team initiatives. The other members of the information security team have extensive IT, IT security and cloud industry experience, as well as certifications pertaining to information security and privacy (such as Certified Information Security Manager, Certified Information Privacy Technologist, GIAC Security Essentials and GIAC Information Security Professional certifications).

true

This governance framework includes procedures for escalation of identified information security risks, threats or incidents through various management levels, including up to our Information Security Governing Body, which is comprised of our Chief Executive Officer, Chief Information Officer, Chief Operating Officer, Chief Financial Officer, Chief Legal Officer and other members of management, and as appropriate, up to our board of directors.

Our information security team is responsible for developing, implementing and overseeing our Company-wide information security strategy and related policies and practices. This team works cross-functionally throughout our organization to assess and prepare the Company for identification and mitigation of, and if necessary respond to, information security risks. The information security team is led

Cybersecurity Risk Management Positions or Committees Responsible [Flag]

Cybersecurity Risk Management Positions or Committees Responsible [Text Block]

Cybersecurity Risk Management Expertise

[of Management Responsible \[Text Block\]](#)

by our Chief Information Officer, who has over 35 years of experience in various information technology roles, including 18 years at the Company serving in roles with increasing levels of responsibility. Our Vice President of Information Security and Technology, a Certified Information Systems Security Professional, with over 20 years of global experience in various information security roles, including 14 years of experience at the Company, is responsible for day-to-day management of information security team initiatives. The other members of the information security team have extensive IT, IT security and cloud industry experience, as well as certifications pertaining to information security and privacy (such as Certified Information Security Manager, Certified Information Privacy Technologist, GIAC Security Essentials and GIAC Information Security Professional certifications).

[Cybersecurity Risk Process for Informing Management or Committees Responsible \[Text Block\]](#)

[Cybersecurity Risk Management Positions or Committees Responsible Report to Board \[Flag\]](#)

true

Our information security team is responsible for developing, implementing and overseeing our Company-wide information security strategy and related policies and practices. This team works cross-functionally throughout our organization to assess and prepare the Company for identification and mitigation of, and if necessary respond to, information security risks.

~~XML 25 R10.htm IDEA: XBRL DOCUMENT~~

Pay vs Performance Disclosure - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure			
Net Income (Loss)	\$ 367,070	\$ 355,757	\$ (158,267)

~~XML 26 R11.htm IDEA: XBRL DOCUMENT~~

Insider Trading Arrangements	3 Months Ended Dec. 31, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

~~XML 27 R12.htm IDEA: XBRL DOCUMENT~~

Description of Business and Basis of Presentation	12 Months Ended Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
Description of Business and Basis of Presentation	
1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. Alkermes has a portfolio of proprietary commercial products for the treatment of alcohol dependence and opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development (“R&D”) center in Massachusetts and a manufacturing facility in Ohio.

In May 2024, the Company completed the sale of its development and manufacturing facility in Athlone, Ireland (the “Athlone Facility”) and related business to Novo Nordisk (“Novo”) pursuant to an asset purchase agreement entered into in December 2023. The Company and Novo also entered into subcontracting arrangements to continue certain development and manufacturing activities performed at the Athlone Facility for a period of time after the closing of the transaction, which activities may continue through the end of 2025. In connection with the sale of the Athlone Facility, the Company received \$97.9 million from Novo, which included a payment of approximately \$91.0 million for the facility and certain related assets, and recorded a gain of approximately \$1.5 million within “Other income (expense), net” in the accompanying consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2024. As of December 31, 2023, the Company classified the assets described under the asset purchase agreement for the sale as “Assets held for sale” in the accompanying consolidated balance sheet.

In November 2023, the Company completed the separation of its former oncology business into Mural Oncology plc (“Mural”), a new, independent, publicly-traded company (the “Separation”). The Separation was effected by means of a distribution of all of the outstanding ordinary shares of Mural to the Company’s shareholders (the “Distribution”), in which each of the Company’s shareholders received one ordinary share, nominal value \$0.01 per share, of Mural for every ten ordinary shares, par value \$0.01 per share, of the Company (the “Distribution Ratio”) held by such shareholder as of the close of business on November 6, 2023, the record date for the Distribution (the “Record Date”). The historical results of the oncology business have been reflected as discontinued operations in the Company’s consolidated financial statements through November 15, 2023 (the “Separation Date”). For additional information related to the Separation, see Note 3, *Discontinued Operations* in these “Notes to Consolidated Financial Statements” in this Annual Report.

~~XML 28 R13.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies	12 Months Ended Dec. 31, 2024
Accounting Policies [Abstract]	
Summary of Significant Accounting Policies	
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	

Principles of Consolidation

The consolidated financial statements include the accounts of Alkermes plc and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated. Columns and rows within tables may not sum due to rounding.

Reclassification

The Company has presented its former oncology business as discontinued operations in its consolidated financial statements as of December 31, 2023 and for the years ended December 31, 2023 and 2022. See Note 3, *Discontinued Operations* in these “Notes to Consolidated Financial Statements” in this Annual Report for additional information.

Discontinued Operations

The Company determined that the Separation met the criteria for classification of the former oncology business as discontinued operations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205, *Discontinued Operations*. Accordingly, the accompanying consolidated financial statements have been updated to present the results of the oncology business as discontinued operations through the Separation Date for the years ended December 31, 2023 and 2022 in the consolidated statements of operations and comprehensive income (loss).

Assets Held for Sale

In connection with the sale of the Athlone Facility, the Company reviewed FASB ASC 805, *Business Combinations* (“Topic 805”) and, based on the definitions therein, determined that the Athlone Facility constituted a business. Accordingly, the assets associated with the sale of the Athlone Facility were classified as “Assets held for sale” in the accompanying consolidated balance sheet as of December 31, 2023.

Use of Estimates

The preparation of the Company’s consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”) requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies, including but not limited to, those related to revenue from contracts with its customers and related allowances, impairment of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

Cash and Cash Equivalents

The Company values its cash and cash equivalents at cost plus accrued interest, which the Company believes approximates its market value. The Company considers as cash equivalents only those investments that are highly liquid, readily convertible into cash and so near their maturity (three months from the date of purchase) that they present insignificant risk of change in value because of interest rate changes.

Investments

The Company has investments in various types of securities, consisting primarily of United States (“U.S.”), government and agency obligations and corporate debt securities. The Company generally holds its interest-bearing investments with major financial institutions and in accordance with documented investment policies. The Company limits the amount of credit exposure to any one financial institution or corporate issuer. At December 31, 2024, substantially all these investments were classified as available-for-sale and were recorded at fair value.

Unrealized gains and losses are included in accumulated other comprehensive loss in equity, net of related tax, unless: (i) the security has experienced a credit loss; (ii) the Company has determined that it has the intent to sell the security; or (iii) the Company has determined that it is more likely than not that it will have to sell the security before its expected recovery. Periodic reviews are conducted to identify and evaluate each investment that has an unrealized loss in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis.

For available-for-sale debt securities with unrealized losses, the Company performs an analysis to assess whether it intends to sell, or whether it would more likely than not be required to sell, the security before the expected recovery of the amortized cost basis. Where the Company intends to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.

Regardless of the Company’s intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

The Company’s held-to-maturity investments are restricted investments held as collateral under letters of credit related to certain of the Company’s agreements and are included in “Investments—

long-term,” in the accompanying consolidated balance sheets.

Fair Value of Financial Instruments

The Company’s financial assets and liabilities are recorded at fair value and are classified as Level 1, 2 or 3 within the fair value hierarchy, as described in the accounting standards for fair value measurement. At December 31, 2024, the Company’s financial assets consisted of cash equivalents and investments and are classified within the fair value hierarchy as follows:

- *Level 1*—these valuations are based on a market approach using quoted prices in active markets for identical assets. Valuations of these products do not require a significant degree of judgment. Assets utilizing Level 1 inputs at December 31, 2024 included U.S. treasury securities, marketable securities classified as cash equivalents and a fixed term deposit account; and
- *Level 2*—these valuations are based on quoted prices for identical or similar assets in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models. Assets utilizing Level 2 inputs at December 31, 2024 included U.S. government agency debt securities and investments in corporate debt securities that are trading in the credit markets.

The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, accounts receivable, contract assets, other current assets, accounts payable and accrued expenses and accrued sales discounts, allowances and reserves approximate fair value due to their short-term nature.

Inventory

Inventory is stated at the lower of cost and net realizable value. The Company utilizes a standard cost basis, which approximates cost determined using the first-in first-out method. Cost is determined using the first-in, first-out method. Included in inventory are raw materials used in production of preclinical and clinical products, which have alternative future use and are charged to R&D expense when consumed. The cost elements included within inventory include three primary categories for commercial products: cost of raw materials; direct labor; and overhead. Overhead is based on the normal capacity of the Company’s production facility and does not include costs from abnormally low production or idle capacity, which are expensed directly to the consolidated statement of operations and comprehensive income (loss).

The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management’s judgment, future commercialization of the product is considered probable and future economic benefit from such product is expected to be realized. The Company assesses the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety, efficacy or quality concerns, potential labeling restrictions and other potential impediments to approval. The Company also considers the shelf life of the product in relation to the expected timeline for approval and considers issues that may prevent or delay commercialization, including issues that may arise in relation to the manufacturing of the product. The Company expenses previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by relevant regulatory agencies or other issues that may make the pre-approval inventory batches less likely or unlikely to be commercialized and to result in future economic benefit.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred and major renewals and improvements are capitalized. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:

Asset group	Term
Buildings and improvements	25 years
Furniture, fixtures and equipment	5 - 7 years
Leasehold improvements	Shorter of useful life or lease term

Goodwill and Intangible Assets

Goodwill represents the excess cost of the Company’s investment in the net assets of acquired companies over the fair value of the underlying identifiable net assets at the date of acquisition. The Company’s goodwill consists solely of goodwill created as a result of the Company’s acquisition of Elan Drug Technologies (“EDT”) from Elan Corporation, plc (such acquisition, the “Business Combination”) in September 2011 and has been assigned to one reporting unit. A reporting unit is an operating segment or one level below an operating segment or a component to which goodwill is assigned when initially recorded.

Goodwill is not amortized but is reviewed for impairment on an annual basis, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable. The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of its reporting unit is less than its carrying amount, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative impairment test, the Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then the Company would record an impairment loss equal to the difference.

When some, but not all, of a reporting unit is to be disposed of, the accounting for that reporting unit’s goodwill will depend on whether the disposal group constitutes a business. If the disposal group constitutes a business, the Company attributes a portion of the reporting unit’s goodwill to the disposal group based on the relative fair values of: (i) the disposal group; and (ii) the portion of the reporting unit that will be retained.

The Company’s finite-lived intangible assets, consisting of core developed technology and collaboration agreements acquired as part of the Business Combination, were recorded at fair value at the time of their acquisition and are stated within the Company’s consolidated balance sheets net of accumulated amortization. The finite-lived intangible assets are amortized over their estimated useful lives using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract. The useful lives of the Company’s intangible assets are primarily based on the legal or contractual life of the underlying patent or contract, which does not include additional years for the potential extension or renewal of the contract or patent.

Impairment of Long-Lived Assets

The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset; a significant change in the extent or manner in which an asset is used; a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset; a current-period operating or cash flow loss combined with a history of operating or cash-flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset; or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell them.

Revenue from Contracts with Customers

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed in accordance with FASB ASC 606, *Revenue from Contracts with Customers* (“Topic 606”): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.

Product Sales, Net

The Company’s product sales, net consist of sales in the U.S. of VIVITROL®, ARISTADA®, ARISTADA INITIO® and LYBALVI®, primarily to wholesalers, specialty distributors and pharmacies. Product sales, net are recognized when the customer obtains control of the product, which is when the product has been received by the customer.

Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, healthcare providers or payers. The Company’s process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company’s estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. The following are the Company’s significant categories of sales discounts and allowances:

- *Medicaid Rebates*—the Company records accruals for rebates to U.S. states under the Medicaid Drug Rebate Program as a reduction of sales when the product is shipped into the distribution channel using the expected value method. The Company rebates individual U.S. states for all eligible units purchased under the Medicaid program based on a rebate per unit calculation, which is based on the Company’s average manufacturer prices. The Company estimates expected unit sales to individuals covered by Medicaid and rebates per unit under the Medicaid program and adjusts its rebate accrual based on actual unit sales and rebates per unit and changes in trends in Medicaid utilization. In 2024, actual Medicaid utilization rates related to VIVITROL were lower than original estimates, due, in part, to \$8.7 million in actual credits received from certain states in the fourth quarter of 2024 related to duplicate Medicaid billings. Medicaid rebates for the Company’s other products have not differed materially from the Company’s estimates;
- *Chargebacks*—discounts that occur when contracted indirect customers purchase directly from wholesalers and specialty distributors. Contracted customers generally purchase a product at its contracted price. The wholesaler or specialty distributor, in turn, then generally charges back to the Company the difference between the wholesale acquisition cost and the contracted price paid to the wholesaler or specialty distributor by the customer. The allowance for chargebacks is made using the expected value method and is based on actual and expected utilization of these programs. Chargebacks could exceed historical experience and the Company’s estimates of future participation in these programs. To date, actual chargebacks have not differed materially from the Company’s estimates;
- *Product Discounts*—cash consideration, including sales incentives, given by the Company under agreements with a number of wholesaler, distributor, pharmacy, and treatment provider customers that provide them with a discount on the purchase price of products. The reserve is made using the expected value method and to date, actual product discounts have not differed materially from the Company’s estimates;
- *Product Returns*—the Company records an estimate for product returns at the time its customers take control of their product. The Company estimates this liability using the expected returns of product sold based on historical return levels and specifically identified anticipated returns due to known business conditions and product expiry dates. Return amounts are recorded as a reduction of sales. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from the Company’s estimates; and
- *Medicare Part D*—the Company records accruals for Medicare Part D liabilities under the Medicare Coverage Gap Discount Program (“CGDP”) as a reduction of sales. Under the CGDP, patients reaching the annual coverage gap threshold are eligible for reimbursement coverage for out-of-pocket costs for covered prescription drugs. Under an agreement with the Centers for Medicare and Medicaid Services, manufacturers are responsible to reimburse prescription plan sponsors for the portion of out-of-pocket expenses not covered under their Medicare plans. To date, actual Medicare Part D rebates have not differed materially from the Company’s estimates.

A rollforward of the Company’s provisions for sales and allowances is as follows:

December 31, 2024						
(In thousands)	Contractual Adjustments ⁽¹⁾	Discounts ⁽²⁾	Product Returns	Other	Total	
Beginning balance — December 31, 2023	\$ 234,414	\$ 28,690	\$ 41,064	\$ 10,164	\$	314,332
Current provisions relating to sales in current year	557,651	386,625	28,627	87,373		1,060,276
Adjustments relating to prior years	(20,562)	—	(3,700)	—		(24,262)
Payments/credits relating to sales in current year	(369,869)	(353,629)	—	(70,752)		(794,250)
Payments/credits relating to sales in prior years	(172,656)	(18,041)	(15,484)	(13,488)		(219,669)
Ending balance — December 31, 2024	\$ 228,978	\$ 43,645	\$ 50,507	\$ 13,297	\$	336,427

December 31, 2023						
(In thousands)	Contractual Adjustments ⁽¹⁾	Discounts ⁽²⁾	Product Returns	Other	Total	
Beginning balance — December 31, 2022	\$ 226,741	\$ 26,175	\$ 29,666	\$ 7,938	\$	290,520
Current provisions relating to sales in current year	509,780	326,860	33,417	71,449		941,506
Adjustments relating to prior years	(8,921)	—	2,841	—		(6,080)
Payments/credits relating to sales in current year	(308,353)	(293,785)	—	(56,224)		(658,362)
Payments/credits relating to sales in prior years	(184,833)	(30,560)	(24,860)	(12,999)		(253,252)

Ending balance — December 31, 2023	\$ 234,414	\$ 28,690	\$ 41,064	\$ 10,164	\$ 314,332

	December 31, 2022				
(In thousands)	Contractual Adjustments ⁽¹⁾	Discounts ⁽²⁾	Product Returns	Other	Total
Beginning balance — December 31, 2021	\$ 209,760	\$ 24,150	\$ 24,313	\$ 9,585	\$ 267,808
Current provisions relating to sales in current year	434,143	281,308	15,851	58,788	790,090
Adjustments relating to prior years	(22,019)	—	3,294	—	(18,725)
Payments/credits relating to sales in current year	(237,521)	(252,896)	—	(48,834)	(539,251)
Payments/credits relating to sales in prior years	(157,622)	(26,387)	(13,792)	(11,601)	(209,402)
Ending balance — December 31, 2022	\$ 226,741	\$ 26,175	\$ 29,666	\$ 7,938	\$ 290,520

⁽¹⁾ "Contractual Adjustments" include "Medicaid Rebates" and "Medicare Part D" accruals
⁽²⁾ "Discounts" include "Chargebacks" and "Product Discounts"

Total revenue-related reserves as of December 31, 2024 and 2023, included in our consolidated balance sheets, are summarized as follows:

(In thousands)	Year Ended December 31,	
	2024	2023
Reduction of accounts receivable	\$ 22,031	\$ 11,510
Components of accrued sales discounts, allowances and reserves	272,452	263,641
Components of other long-term liabilities	41,944	39,181
Total revenue-related reserves	\$ 336,427	\$ 314,332

Collaborative Arrangements

The Company has entered into collaborative arrangements with pharmaceutical companies including, among others, Janssen Pharmaceuticals, Inc. ("Janssen, Inc."), Janssen Pharmaceutica International, a division of Cilag International AG ("Janssen International"), and Janssen Pharmaceutica N.V. (together with Janssen, Inc., Janssen International and their affiliates, "Janssen") related to INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA®, INVEGA HAFYERA®/BYANCLI® (collectively, the "long-acting INVEGA products") and RISPERDAL CONSTA®, and Biogen International GmbH (together with its affiliates, "Biogen") related to VUMERITY®. Substantially all of the products developed under these arrangements are currently being marketed as approved products for which the Company received or receives payments for manufacturing services and/or royalties on net product sales.

Manufacturing Revenue

The Company recognizes manufacturing revenues from the sale of products it manufactures for resale by its licensees. Substantially all of the manufacturing revenues are recognized at a point in time when control of the product passes to the licensee. The sales price for certain of the Company's manufacturing revenues is based on the end-market sales price earned by its licensees. As end-market sales generally occur after the Company has recorded manufacturing revenue, the Company estimates the sales price for such products based on information supplied to it by the Company's licensees, its historical transaction experience and other third-party data. Differences between actual manufacturing revenues and estimated manufacturing revenues are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The differences between the Company's actual and estimated manufacturing revenues have not been material to date.

Royalty Revenue

The Company recognizes royalty revenues related to the sale by its licensees of products that incorporate the Company's technologies. All of the Company's royalties qualify for the sales-and-usage exemption under Topic 606 as (i) such royalties are based strictly on the sales-and-usage by the licensee; and (ii) a license of IP is the sole or predominant item to which such royalties relate. Based on this exemption, these royalties are earned in the period that the products are sold by the Company's licensee and the Company has a present right to payment.

Certain of the Company's royalty revenues are recognized by the Company based on information supplied to the Company by its licensees and require estimates to be made. Differences between actual royalty revenues and estimated royalty revenues are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The differences between the Company's actual and estimated royalty revenues have not been material to date.

Receivables, net

Receivables, net, include amounts billed and amounts unbilled but currently unconditionally due from customers. The amounts due are stated at their net estimated realizable value. The Company's unbilled receivable balance was \$69.5 million and \$103.1 million at December 31, 2024 and 2023, respectively, and related primarily to royalty revenue. The Company maintains an allowance for doubtful accounts to provide for the estimated amounts of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable. The Company's allowance for doubtful accounts was approximately \$0.3 million and \$0.2 million at December 31, 2024 and 2023, respectively.

Contract Assets

Contract assets include unbilled amounts that will result in a sale under certain of the Company's manufacturing contracts. The amounts included in the contract assets table below are classified as "Current assets" in the accompanying consolidated balance sheets, as they relate to manufacturing processes that are completed in ten days to eight weeks.

Contract assets consisted of the following:

(In thousands)	Contract Assets
Contract assets at January 1, 2023	\$ 8,929
Additions	13,606
Transferred to receivables, net	(21,829)
Contract assets at December 31, 2023	\$ 706
Additions	6,615
Transferred to receivables, net	(2,331)
Contract assets at December 31, 2024	\$ 4,990

Contract Liabilities

Contract liabilities consist of contractual obligations related to deferred revenue. At December 31, 2024 and 2023, \$1.2 million and \$2.7 million of the contract liabilities, respectively, were classified as "Contract liabilities-short-term" in the accompanying consolidated balance sheets and none and \$2.1 million of the contract liabilities, respectively, were classified as "Other long-term liabilities" in the accompanying consolidated balance sheets.

Contract liabilities consisted of the following:

(In thousands)	Contract Liabilities
Contract liabilities at January 1, 2023	\$ 10,701
Additions	(931)
Amounts recognized into revenue	(4,995)
Contract liabilities at December 31, 2023	\$ 4,775
Additions	34
Amounts recognized into revenue	(3,560)
Contract liabilities at December 31, 2024	\$ 1,249

Foreign Currency

The Company's functional and reporting currency is the U.S. dollar. Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction. The resulting monetary assets and liabilities are translated into U.S. dollars at exchange rates prevailing on the subsequent balance sheet date. Gains and losses as a result of translation adjustments are recorded within "Other income (expense), net" in the accompanying consolidated statements of operations and comprehensive income (loss). During the years ended December 31, 2024, 2023 and 2022, the Company recorded losses of \$0.8 million and \$0.5 million and a gain of \$0.7 million, respectively, on foreign currency translation.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk are receivables and marketable securities. Billings to large pharmaceutical companies and pharmaceutical wholesalers account for the majority of the Company's receivables, and collateral is not required from these customers. To mitigate credit risk, the Company monitors the financial performance and credit-worthiness of its customers. The following represents revenue and receivables from the Company's customers exceeding 10% of the total in each category as of, and for the years ended, December 31, 2024, 2023 and 2022:

Customer	Year Ended December 31,					
	2024		2023		2022	
	Receivables	Revenue	Receivables	Revenue	Receivables	Revenue
McKesson	36 %	25 %	14 %	14 %	12 %	16 %
Cencora	17 %	15 %	16 %	12 %	18 %	14 %
Cardinal Health	16 %	19 %	24 %	20 %	24 %	24 %
Janssen	14 %	17 %	23 %	31 %	*	15 %
Biogen	*	11 %	*	11 %	19 %	13 %

* Indicates the revenues or receivables for the customer did not exceed 10% of the Company's total in each category as of or for the years ended December 31, 2024, 2023 and 2022, as noted.

The Company holds its interest-bearing investments with major financial institutions and, in accordance with documented investment policies, the Company limits the amount of credit exposure to any one financial institution or corporate issuer. The Company's investment objectives are, first, to ensure liquidity and conservation of capital and, second, to generate investment income.

Geographic Information

Company revenues by geographic location for the years ended December 31, 2024, 2023 and 2022, as determined by the location of the customer, are as follows:

(In thousands)	Year Ended December 31,		
Revenue by region:	2024	2023	2022
U.S.	\$ 1,410,159	\$ 1,491,939	\$ 931,991
Ireland	1,294	1,179	1,829
Rest of world	146,179	170,287	177,975

The location of the Company's assets are as follows:

(In thousands)	December 31,	
Assets by region:	2024	2023
Current assets:		
U.S.:		
Cash and cash equivalents	\$ 70,303	\$ 317,850
Investments—short-term	203,631	187,574

Receivables, net		306,259		218,747
Other current assets		129,332		143,417
Ireland:				
Cash and cash equivalents	\$	220,843	\$	139,619
Investments—short-term		256,891		128,448
Receivables, net		78,269		113,730
Assets held for sale		—		94,260
Other current assets		149,827		141,861
Long-term assets:				
U.S.:				
Property, plant and equipment, net	\$	226,646	\$	225,578
Investments—long-term		24,629		17,957
Other		210,792		189,335
Ireland:				
Property, plant and equipment, net	\$	918	\$	1,365
Investments—long-term		48,519		21,930
Intangible assets, net and goodwill		83,917		85,018
Other		44,791		109,534

Research and Development Expenses

For each of its R&D programs, the Company incurs both external and internal expenses. External R&D expenses include fees related to clinical and preclinical activities performed by contract research organizations, consulting fees and costs related to laboratory services, purchases of drug product materials and third-party manufacturing development costs. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. The Company tracks external R&D expenses for each of its development programs, however, internal R&D expenses are not tracked by individual program as they benefit multiple development programs or the Company's products or technologies in general.

Selling, General and Administrative Expenses

Selling, general and administrative ("SG&A") expenses are primarily comprised of employee-related expenses associated with selling and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising, financial and legal expenses and other general and administrative costs.

Advertising costs are expensed as incurred. During the years ended December 31, 2024, 2023 and 2022, advertising costs totaled \$107.6 million, \$127.6 million and \$41.4 million, respectively.

Share-Based Compensation

The Company's share-based compensation programs permit grants of awards in the form of stock options and restricted stock unit awards ("RSUs"), which vest with the passage of time and/or based on the achievement of certain performance criteria. The Company issues new shares upon the exercise of stock options or the vesting of RSUs. Under the terms of the Company's stock option and incentive plans (the "Plans"), the Company's employees may, at the discretion of the plan administrator, become eligible in certain circumstances set forth in the Plans for accelerated vesting of certain awards granted to them under the Plans. In such circumstances, if there are no effective future service requirements for such employees, the remaining fair value of any such accelerated awards would be expensed as of the date of acceleration.

Time-Based Stock Options

Except as otherwise provided in the applicable Plan or award certificate, stock option grants to employees expire ten years from the date of grant and generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Except as otherwise provided in the applicable Plan or Award Certificate (as defined in the 2018 Plan): (i) annual stock option grants to non-employee directors expire ten years from the date of grant and generally vest over a one-year period; and (ii) stock option grants to new non-employee directors expire ten years from the date of grant and generally vest over a three-year period. The estimated fair value of options is recognized over the requisite service period, which is generally the vesting period. Share-based compensation expense is based on awards ultimately expected to vest. Forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates.

The fair value of stock option grants is based on estimates as of the date of grant using a Black-Scholes option valuation model. The Company uses historical data as the basis for estimating stock option terms and forfeitures. Separate groups of employees that have similar historical stock option exercise and forfeiture behavior are considered separately for valuation purposes. The ranges of expected terms disclosed below reflect different expected behavior among certain groups of employees. Expected stock volatility factors are based on a weighted average of implied volatilities from traded options of the Company's ordinary shares and historical share price volatility of the Company's ordinary shares, which is determined based on a review of the weighted average of historical weekly price changes of the Company's ordinary shares. The risk-free interest rate for periods commensurate with the expected term of the stock option is based on the U.S. treasury yield curve in effect at the time of grant. The dividend yield on the Company's ordinary shares is estimated to be zero as the Company has not paid dividends and does not expect to pay dividends in the near future. The exercise price of options granted is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant.

The fair value of each stock option granted was estimated on the grant date with the following weighted-average assumptions:

	Year Ended December 31,		
	2024	2023	2022
Expected option term	5 - 7 years	5 - 8 years	5 - 8 years
Expected stock volatility	38 % - 42 %	40 % - 44 %	43 % - 51 %
Risk-free interest rate	3.64 % - 4.60 %	3.34 % - 4.75 %	1.83 % - 4.26 %
Expected annual dividend yield	—	—	—

Time-Based Restricted Stock Unit Awards

Except as otherwise provided in the applicable Plan or award certificate, time-based RSUs awarded to employees generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Shares subject to these RSUs are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of time-based RSUs is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.

Performance-Based Restricted Stock Unit Awards

Performance-based RSUs awarded to employees vest upon the achievement of certain performance criteria, typically during or following the end of a specified performance period. The estimated fair value of these performance-based RSUs are generally based on the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant, unless the performance-based RSU is also subject to a market condition. In that case, the fair value of the performance-based RSU is based on a Monte Carlo simulation model. Compensation expense for performance-based RSUs is recognized from the date the Company determines the performance criteria probable of being achieved to the date the award, or relevant portion of the award, is expected to vest. Cumulative adjustments are recorded on a quarterly basis to reflect subsequent changes to the estimated outcome of the performance criteria until the date that the final outcome of the performance criteria is determined.

Income Taxes

The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In evaluating the Company's ability to recover its deferred tax assets, the Company considers all available positive and negative evidence including its past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which the Company operates and its forecast of future taxable income. In determining future taxable income, the Company is responsible for assumptions utilized including the amount of Irish and non-Irish pre-tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company is using to manage the underlying business.

The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates its tax position on a quarterly basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.

Comprehensive Income (Loss)

Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized holding gains and losses on available-for-sale investments.

Earnings (Loss) Per Share

Basic earnings (loss) per ordinary share from continuing operations is calculated based upon net income (loss) from continuing operations available to holders of ordinary shares divided by the weighted average number of ordinary shares outstanding. Basic loss per ordinary share from discontinued operations is calculated based upon net loss from discontinued operations available to holders of ordinary shares, divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted earnings (loss) per ordinary share from continuing operations and discontinuing operations, the Company utilizes the treasury stock method and adjusts the weighted average number of ordinary shares outstanding for the potential dilutive effect of outstanding ordinary share equivalents such as stock options and RSUs.

Segment Information

In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, *Segment Reporting: Improvements to Reportable Segment Disclosure* ("Topic 280") to establish standards for reporting information about operating segments. Operating segments are defined as components of an enterprise engaging in business activities for which separate financial information is available and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company has utilized the management approach to determine that the Company is managed as one segment on a consolidated basis and is the business of developing, manufacturing and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. The Company's CODM, the Chairman and Chief Executive Officer, reviews the Company's operating results on an aggregate basis and manages the Company's operations as a single operating unit. The CODM measures profitability on a reportable segment basis using net income (loss) and utilizes this information in allocating resources and in assessing performance by monitoring budget versus actual results. Please refer to Note 18, *Segment Reporting*, in these "Notes to Consolidated Financial Statements" in this Annual Report for further information.

Employee Benefit Plans

401(k) Plan

The Company maintains a 401(k) retirement savings plan (the "401(k) Plan"), which covers all of its eligible U.S.-based employees. Eligible employees may contribute up to 100% of their eligible compensation, subject to certain Internal Revenue Service ("IRS") limitations. The Company matches 100% of employee contributions up to the first 5% of employee pay, up to IRS limits. Employee and Company contributions are fully vested when made. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$15.1 million, \$15.0 million and \$14.4 million, respectively, to match employee deferrals under the 401(k) Plan.

Defined Contribution Plan

The Company maintains a defined contribution plan for its Ireland-based employees (the "Defined Contribution Plan"). The Defined Contribution Plan provides for eligible employees to contribute up to a maximum of 40%, depending upon their age, of their total taxable earnings subject to an earnings cap of €115,000. The Company provides a match of up to 18% of taxable earnings depending upon an individual's contribution level. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$3.4 million, \$5.6 million and \$5.1 million, respectively, in contributions to the Defined Contribution Plan.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes* ("Topic 740"): *Improvements to Income Tax Disclosures*, to enhance the transparency and decision usefulness of income tax disclosures in order to provide information to assist key stakeholders in better assessing how the Company's operations and related tax risks and tax planning and operational opportunities affect the Company's tax rate and prospects for future cash flows. This ASU becomes effective for public companies for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This guidance will be applied on a prospective basis. The Company is currently evaluating the impact this ASU will have on

its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, *Income Statement - Reporting Comprehensive Income-Expense Disaggregation Disclosures*, to improve disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly-presented expense captions, such as cost of sales, selling, general and administrative expenses, and research and development. All disclosure requirements under this guidance are required for public business entities and effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted and the amendments in this guidance will be applied prospectively to financial statements for periods after the effective dates. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures.

XML 29 R14.htm IDEA: XBRL DOCUMENT

Discontinued Operations

[Discontinued Operations and Disposal Groups \[Abstract\]](#)

[Discontinued Operations](#)

**12 Months Ended
Dec. 31, 2024**

3. DISCONTINUED OPERATIONS

Mural Oncology Separation

In November 2023, the Company completed the Separation. In connection with the Separation, the Company entered into a separation agreement with Mural, dated as of November 13, 2023, that, among other things, set forth the Company’s agreements with Mural regarding the principal actions taken or to be taken in connection with the Separation, including the Distribution. The separation agreement identified those assets to be transferred to, liabilities to be assumed by and contracts to be assigned to Mural, including the operating lease for the office and laboratory space at 852 Winter Street in Waltham, Massachusetts, as part of the Separation, and it provided for when and how such transfers, assumptions and assignments were to occur. The purpose of the separation agreement was to provide Mural and the Company with those assets necessary to operate their respective businesses and to retain or assume the respective liabilities related to those assets.

Each of Mural and the Company agreed to releases with respect to pre-Distribution claims, and cross-indemnities with respect to post-Distribution claims, that are principally designed to place financial responsibility for the obligations and liabilities allocated to Mural under the separation agreement with Mural, and financial responsibility for the obligations and liabilities allocated to the Company under the separation agreement with the Company. The Company and Mural are also each subject to mutual six-month employee non-solicitation and non-hire restrictions, subject to certain customary exceptions, and certain confidentiality restrictions and information sharing obligations.

The transfer of assets and liabilities to Mural was effected through a contribution in accordance with the separation agreement, as summarized below:

(In thousands)	November 15, 2023	
	ASSETS	
Current Assets:		
Cash and cash equivalents	\$	275,000
Total current assets		275,000
Property, plant and equipment, net		10,096
Right-of-use assets		14,513
Goodwill		7,800
Deferred tax asset		1,799
Total assets	\$	309,208
	LIABILITIES	
Current Liabilities:		
Operating lease liabilities—short-term	\$	6,036
Total current liabilities		6,036
Operating lease liabilities—long-term		9,412
Total liabilities		15,448
Net assets transferred to Mural	\$	293,760

The Company determined that the Separation and related Distribution qualified as tax-free for U.S. federal income tax purposes, which required significant judgment by management. In making such determinations, the Company applied U.S. federal tax law to relevant facts and circumstances and obtained: (i) a favorable private letter ruling from the IRS; (ii) a tax opinion; and (iii) other external tax advice related to the concluded tax treatment. If the Separation and Distribution were to ultimately fail to qualify for tax-free treatment for U.S. federal income tax purposes, the Company and/or its shareholders could be subject to significant liabilities, which could have material adverse impacts on the Company’s business, financial condition, results of operations and cash flows in future reporting periods. Furthermore, other than taxes recorded on the transfer of intellectual property, the Company determined that the Separation and related Distribution qualified as tax-free for Irish tax purposes, which required significant judgment by management. In making such determinations, the Company applied Irish tax law to relevant facts and circumstances and obtained: (i) a tax opinion; and (ii) other external tax advice related to the concluded tax treatment. If the Separation and Distribution were to ultimately fail to qualify for tax-free treatment for Irish tax purposes, the Company and/or its shareholders could be subject to significant liabilities, which could have material adverse impacts on the Company’s business, financial condition, results of operations and cash flows in future reporting periods.

In connection with the Separation, the Company also entered into a tax matters agreement with Mural, dated as of November 13, 2023. The tax matters agreement governs the Company’s and Mural’s respective rights, responsibilities and obligations with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the Distribution, together with certain related transactions, to qualify as tax-free for U.S. federal income tax purposes), tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and assistance and cooperation in respect of tax matters.

In connection with the Separation, the Company also entered into the Employee Matters Agreement. The Employee Matters Agreement, as amended, governs the Company’s, Mural’s and their respective subsidiaries’ and affiliates’ rights, responsibilities and obligations after the Separation with respect to, employment, benefits and compensation matters relating to employees and former employees (and their respective dependents and beneficiaries) who are or were associated with the Company, including those who became employees of Mural in connection with the Separation; the allocation of assets and liabilities generally relating to employees, employment or service-related matters and employee benefit plans; other human resources, employment and employee benefits matters; and the treatment of equity-based awards granted by the Company prior to the Separation.

Discontinued Operations

The results of the former oncology business and transaction costs related to the Separation have been reflected as “Loss from discontinued operations, net of taxes” in the accompanying consolidated statement of operations and comprehensive income (loss) through the Separation Date. Prior periods have been recast to reflect this presentation. The transaction costs related to the Separation were \$36.0 million during 2023 and \$1.4 million during 2022, and primarily relate to professional fees for separation activities within the finance, tax, legal and information technology functions.

The following table summarizes expenses of the discontinued operations for the years ended December 31, 2024, 2023 and 2022:

(In thousands)	Year Ended December 31,		
	2024	2023	2022
Operating expenses from discontinued operations			
Cost of goods manufactured	\$ —	\$ 39	\$ 40
Research and development	5,790	116,177	121,140
Selling, general and administrative	—	48,587	14,996
Total operating expenses from discontinued operations	5,790	164,803	136,176
Operating loss from discontinued operations	(5,790)	(164,803)	(136,176)
Income tax benefit from discontinued operations	(722)	(1,403)	(11,061)
Net loss and comprehensive loss from discontinued operations	\$ (5,068)	\$ (163,400)	\$ (125,115)

There were no assets and \$4.5 million of liabilities related to the Separation as of December 31, 2023. All assets were transferred to Mural as of the Separation Date. The \$4.5 million of liabilities classified as “Liabilities related to discontinued operations” in the accompanying consolidated balance sheet as of December 31, 2023 related to bonus amounts accrued for employees that transferred to Mural during 2023 through the Separation Date that were paid by the Company in the first quarter of 2024, in accordance with the terms of the employee matters agreement entered into between the Company and Mural.

The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2023 and 2022:

(In thousands)	Year Ended December 31,	
	2023	2022
OPERATING ACTIVITIES:		
Depreciation	\$ 2,319	\$ 1,539
Share-based compensation expense	8,188	6,577
Right-of-use assets	3,803	5,909
Operating lease liabilities	(3,938)	(5,920)
INVESTING ACTIVITIES:		
Additions of property, plant and equipment	\$ (1,798)	\$ (5,510)

XML 30 R15.htm IDEA: XBRL DOCUMENT

Revenue from Contracts with Customers

[Revenue from Contract with Customer \[Abstract\]](#)

[Revenue from Contracts with Customers](#)

**12 Months Ended
Dec. 31, 2024**

4. REVENUE FROM CONTRACTS WITH CUSTOMERS

During the years ended December 31, 2024, 2023 and 2022, the Company recorded product sales, net, as follows:

(In thousands)	Year Ended December 31,		
	2024	2023	2022
VIVITROL	\$ 457,315	\$ 400,419	\$ 379,478
ARISTADA and ARISTADA INITIO	346,187	327,690	302,052
LYBALVI	280,032	191,889	96,022
Total product sales, net	\$ 1,083,534	\$ 919,998	\$ 777,552

During the years ended December 31, 2024, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

(In thousands)	Year Ended December 31, 2024		
	Manufacturing Revenue	Royalty Revenue	Total
Long-acting INVEGA products ⁽¹⁾	\$ —	\$ 236,386	\$ 236,386
VUMERITY	39,292	94,755	134,047
RISPERDAL CONSTA	23,172	272	23,444
Other	56,962	23,256	80,218
	<u>\$ 119,426</u>	<u>\$ 354,669</u>	<u>\$ 474,095</u>

(In thousands)	Year Ended December 31, 2023		
	Manufacturing Revenue	Royalty Revenue	Total
Long-acting INVEGA products ⁽¹⁾	\$ —	\$ 486,101	\$ 486,101
VUMERITY	42,886	86,440	129,326
RISPERDAL CONSTA	36,123	1,153	37,276
Other	63,489	27,196	90,685
	<u>\$ 142,498</u>	<u>\$ 600,890</u>	<u>\$ 743,388</u>

(In thousands)	Year Ended December 31, 2022		
	Manufacturing Revenue	Royalty Revenue	Total
Long-acting INVEGA products ⁽¹⁾	\$ —	\$ 115,655	\$ 115,655
VUMERITY	32,493	83,003	115,496
RISPERDAL CONSTA	42,670	7,243	49,913
Other	37,211	13,708	50,919
	<u>\$ 112,374</u>	<u>\$ 219,609</u>	<u>\$ 331,983</u>

(1) "long-acting INVEGA products": INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANLI (paliperidone palmitate).

In November 2021, the Company received notice of partial termination of an exclusive license agreement with Janssen. Under this license agreement, the Company provided Janssen with rights to, and know-how, training and technical assistance in respect of, the Company's small particle pharmaceutical compound technology, known as NanoCrystal technology, which was used to develop the long-acting INVEGA products. When the partial termination became effective in February 2022, Janssen ceased paying royalties related to sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA. Accordingly, the Company ceased recognizing royalty revenue related to sales of these products in February 2022. In April 2022, the Company commenced binding arbitration proceedings related to, among other things, Janssen's partial termination of this license agreement and Janssen's royalty and other obligations under the agreement. In May 2023, the arbitral tribunal (the "Tribunal") in the arbitration proceedings issued a final award (the "Final Award") which concluded the arbitration proceedings. The Final Award provided, among other things, that the Company was due back royalties of \$195.4 million, inclusive of \$8.1 million in late-payment interest related to 2022 U.S. net sales of the long-acting INVEGA products, which amount the Company received from Janssen in the second quarter of 2023, and is entitled to 2023 and future royalty revenues from Janssen related to net sales of INVEGA SUSTENNA through August 20, 2024, INVEGA TRINZA through the second quarter of 2030 (but no later than May 2030 when the license agreement expires) and INVEGA HAFYERA through May 2030 (when the license agreement expires).

Following issuance of the Final Award, the Company recognized royalty revenues related to the back royalties noted above and resumed recognizing royalty revenue related to ongoing U.S. sales of the long-acting INVEGA products. During 2023, the Company recorded \$486.1 million in royalty revenue from sales of the long-acting INVEGA products, including \$195.4 million related to back royalties and associated interest related to net sales of the long-acting INVEGA in the U.S. in 2022 and resumed recognizing royalty revenue related to worldwide net sales of the long-acting INVEGA products of approximately \$290.7 million, as compared to royalty revenue of \$115.7 million during 2022.

In October 2022 and November 2022, an arbitration panel found that the Company must return to Acorda Therapeutics, Inc. ("Acorda") \$16.5 million (inclusive of prejudgment interest and administrative fees) and \$1.8 million (inclusive of prejudgment interest), respectively, previously paid by Acorda under a license agreement between the Company and Acorda. These amounts represented a portion of the royalty revenue paid to the Company by Acorda since July 2020 related to AMPYRA. The Company paid Acorda the aggregate \$18.3 million in the fourth quarter of 2022. In addition, during the three months ended June 30, 2022, the Company had recorded \$3.2 million of royalty revenue related to AMPYRA as the Company believed that it had met the necessary revenue recognition criteria under Topic 606. However, as a result of the arbitration ruling, the Company reversed the \$3.2 million as the panel found that the Company was no longer entitled to be paid those royalties. During the three months ended September 30, 2022, the Company recorded both the \$18.3 million in repayments and the \$3.2 million reversal as reversals of royalty revenue within "Manufacturing and royalty revenue" in the accompanying consolidated statements of operations and comprehensive income (loss). The amounts related to such arbitration ruling were included as part of "Other" within the manufacturing and royalty revenue table above for the year ended December 31, 2022. As a result of the arbitration ruling, the Company has no contractual obligation to manufacture and supply AMPYRA or contractual right to receive future manufacturing or royalty revenue related to AMPYRA. Refer to Note 19, *Commitments and Contingent Liabilities* within the "Notes to Consolidated Financial Statements" in this Annual Report for information regarding additional legal proceedings related to the arbitration with Acorda.

XML 31 R16.htm IDEA: XBRL DOCUMENT

**12 Months Ended
Dec. 31, 2024**

Investments

**Investments, Debt
and Equity Securities**
[Abstract]
Investments

5. INVESTMENTS

Investments consist of the following:

December 31, 2024	Amortized Cost	Gains	Gross Unrealized		Estimated Fair Value
			Less than One Year	Greater than One Year	
Short-term investments:					
Available-for-sale securities:					
U.S. government and agency debt securities	\$ 266,506	\$ 763	\$ (58)	\$ (6)	\$ 267,205
Corporate debt securities	192,617	762	(58)	(4)	193,317
Total short-term investments	459,123	1,525	(116)	(10)	460,522
Long-term investments:					
Available-for-sale securities:					
U.S. government and agency debt securities	48,856	—	—	(179)	48,677
Corporate debt securities	24,484	—	—	(158)	24,326
	73,340	—	—	(337)	73,003
Held-to-maturity securities:					
Certificates of deposit	145	—	—	—	145
Total long-term investments	73,485	—	—	(337)	73,148
Total investments	\$ 532,608	\$ 1,525	\$ (116)	\$ (347)	\$ 533,670

December 31, 2023					
Short-term investments:					
Available-for-sale securities:					
U.S. government and agency debt securities	\$ 199,708	\$ 758	\$ (36)	\$ (611)	\$ 199,819
Corporate debt securities	112,055	703	(15)	(536)	112,207
Non-U.S. government debt securities	4,004	—	—	(8)	3,996
Total short-term investments	315,767	1,461	(51)	(1,155)	316,022
Long-term investments:					
Available-for-sale securities:					
U.S. government and agency debt securities	19,392	—	(27)	(315)	19,050
Corporate debt securities	19,306	—	—	(289)	19,017
	38,698	—	(27)	(604)	38,067
Held-to-maturity securities:					
Certificates of deposit	1,820	—	—	—	1,820
Total long-term investments	40,518	—	(27)	(604)	39,887
Total investments	\$ 356,285	\$ 1,461	\$ (78)	\$ (1,759)	\$ 355,909

At December 31, 2024, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. Investments with unrealized losses consisted primarily of corporate debt securities and debt securities issued and backed by U.S. agencies and the U.S. government. At December 31, 2024, 77 of the Company's 320 investment securities were in an unrealized loss position and had an aggregate estimated fair value of \$112.7 million. Approximately 41% and 59% of the Company's investment securities at December 31, 2024 were in corporate debt securities, with a minimum rating of A2 (Moody's)/A (Standard and Poor's), and debt securities issued by the U.S. government or its agencies, respectively. The primary reason for the unrealized losses in the Company's investment portfolio is that its investments are fixed-rate securities acquired in a rising interest rate environment. In making the determination whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company has the intent and ability to hold these investments until recovery, which may be at maturity.

Realized gains and losses on the sales and maturities of investments, which were identified using the specific identification method, were as follows:

(In thousands)	Year Ended December 31,	
	2024	2023
Proceeds from the sales and maturities of investments	\$ 310,286	\$ 355,522
Realized gains	\$ —	\$ —
Realized losses	\$ —	\$ 529

The Company's available-for-sale and held-to-maturity securities at December 31, 2024 had contractual maturities in the following periods:

(In thousands)	Available-for-sale		Held-to-maturity	
	Amortized Cost	Estimated Fair Value	Amortized Cost	Estimated Fair Value
Within 1 year	\$ 324,897	\$ 325,566	\$ 145	\$ 145
After 1 year through 5 years	207,566	207,959	—	—
Total	<u>\$ 532,463</u>	<u>\$ 533,525</u>	<u>\$ 145</u>	<u>\$ 145</u>

XML 32 R17.htm IDEA: XBRL DOCUMENT

Fair Value

Fair Value Disclosures

[Abstract]

Fair Value

6. FAIR VALUE

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy and the valuation techniques the Company utilized to determine such fair value:

	December 31, 2024	Level 1	Level 2	Level 3
(In thousands)				
Assets:				
Cash equivalents	\$ 8,388	\$ 8,388	\$ —	\$ —
U.S. government and agency debt securities	315,882	265,090	50,792	—
Corporate debt securities	217,643	—	217,643	—
Total	\$ 541,913	\$ 273,478	\$ 268,435	\$ —

	December 31, 2023	Level 1	Level 2	Level 3
Assets:				
Cash equivalents	\$ 34,316	\$ 34,316	\$ —	\$ —
U.S. government and agency debt securities	218,869	181,041	37,828	—
Corporate debt securities	131,224	—	131,224	—
Non-U.S. government debt securities	3,996	—	3,996	—
Total	\$ 388,405	\$ 215,357	\$ 173,048	\$ —

The Company transfers its financial assets and liabilities, measured at fair value on a recurring basis, between the fair value hierarchies at the end of each reporting period.

There were no transfers of any securities between levels during the year ended December 31, 2024. At December 31, 2024, the Company had no investments with fair values that were determined using Level 3 inputs.

The Company's investments in U.S. government and agency debt securities, non-U.S. government agency debt securities and corporate debt securities classified as Level 2 within the fair value hierarchy were initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing market-observable data. The market-observable data included reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validated the prices developed using the market-observable data by obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active.

In April 2015, the Company sold its Gainesville, GA manufacturing facility, the related manufacturing and royalty revenue associated with certain products manufactured at the facility, and the rights to IV/IM and parenteral forms of Meloxicam to Recro Pharma, Inc. ("Recro") and Recro Gainesville LLC (such transaction the "Gainesville Transaction"). The Gainesville Transaction included in the purchase price contingent consideration tied to low double digit royalties on net sales of the IV/IM and parenteral forms of Meloxicam and any other product with the same active ingredient as Meloxicam IV/IM that is discovered or identified using certain of the Company's IP to which Recro was provided a right of use, through license or transfer, pursuant to the Gainesville Transaction (such products, the "Meloxicam Products"), and milestone payments upon the achievement of certain regulatory and sales milestones related to the Meloxicam Products.

In November 2019, Recro spun out its acute care segment to Baudax Bio, Inc. ("Baudax"), a publicly-traded pharmaceutical company. As part of this transaction, Recro's obligations to pay certain contingent consideration from the Gainesville Transaction were assigned and/or transferred to Baudax.

In Baudax's Quarterly Report on Form 10-Q for the period ended September 30, 2022, Baudax continued to include disclosures regarding its ability to continue as a going concern, which first appeared in its Annual Report on Form 10-K for the period ended December 31, 2021. In March 2022, Baudax reduced its workforce by approximately 80%, which was designed to reduce its operational expenses and conserve its cash resources. In light of Baudax's disclosures and the fact that, as of September 30, 2022, Baudax had only paid \$1.2 million of the \$6.4 million that was due to the Company in March 2022, the Company determined, during the three months ended September 30, 2022, that it was unlikely to collect any further proceeds under this arrangement and reduced the fair value of the contingent consideration to zero within "Change in the fair value of contingent consideration" in the accompanying consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2022. In addition, during the three months ended September 30, 2022, the Company determined that certain construction in progress related to the manufacture of ANJESO® had no future value and recorded a \$2.3 million write off within "Other income (expense), net" in the accompanying consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2022.

In December 2022, Baudax announced that it would discontinue the sale of ANJESO and the U.S. Food and Drug Administration ("FDA") acknowledged the discontinuation of sale of ANJESO via listing in the Orange Book.

XML 33 R18.htm

IDEA: XBRL DOCUMENT

Inventory

12 Months Ended

Dec. 31, 2024

Inventory Disclosure [Abstract]

Inventory

7. INVENTORY

Inventory consists of the following:

	December 31, 2024	December 31, 2023
(In thousands)		
Raw materials	\$ 72,139	\$ 71,416
Work in process	79,871	68,843
Finished goods ⁽¹⁾	30,877	46,147
Total inventory	\$ 182,887	\$ 186,406

(1)

At December 31, 2024 and 2023, the Company had \$22.7 million and \$33.9 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider.

XML 34 R19.htm

IDEA: XBRL DOCUMENT

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

8. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consists of the following:

	December 31, 2024	December 31, 2023 ⁽¹⁾
(In thousands)		
Land	\$ 957	\$ 957
Building and improvements	134,699	132,735
Furniture, fixtures and equipment	244,113	237,728
Leasehold improvements	42,416	39,893
Construction in progress	58,391	45,791
Subtotal	480,576	457,104
Less: accumulated depreciation	(253,012)	(230,161)
Total property, plant and equipment, net	\$ 227,564	\$ 226,943

(1)

In connection with the sale of the Athlone Facility, \$92.2 million of the Company's property, plant and equipment was classified as "Assets held for sale" in the accompanying consolidated balance sheet at December 31, 2023 and was not included in these amounts.

Depreciation expense was \$27.4 million, \$25.7 million and \$26.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. Also, during the years ended December 31, 2024, 2023 and 2022, the Company wrote off furniture, fixtures and equipment that had an approximate carrying value of \$0.5 million, \$1.7 million and \$0.5 million, respectively, at the time of disposition.

Amounts included as construction in progress in the consolidated balance sheets primarily include capital expenditures at the Company's manufacturing facility in Wilmington, Ohio. The Company continues to evaluate its manufacturing capacity based on expectations of demand for its products and will continue to record such amounts within construction in progress until such time as the underlying assets are placed into service. The Company continues to periodically evaluate whether facts and circumstances indicate that the carrying value of its long-lived assets to be held and used may not be recoverable.

In December 2023, the Company determined that \$2.9 million of its construction in progress at its Wilmington, Ohio manufacturing facility had no future value and was written off through "cost of goods manufactured and sold" in the accompanying consolidated statements of operations and comprehensive income (loss) during the year ended December 31, 2023.

XML 35 R20.htm

IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill

12 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

9. INTANGIBLE ASSETS AND GOODWILL

Intangible assets and goodwill consists of the following:

	Weighted Amortizable Life (Years)	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
(In thousands)							
Goodwill		\$ 83,027	\$ —	\$ 83,027	\$ 83,027	\$ —	\$ 83,027
Finite-lived intangible assets:							
Collaboration agreements	12	\$ 465,590	\$ (465,590)	\$ —	\$ 465,590	\$ (465,590)	\$ —
Capitalized IP	11-13	118,160	(117,270)	890	118,160	(116,169)	1,991
Total		\$ 583,750	\$ (582,860)	\$ 890	\$ 583,750	\$ (581,759)	\$ 1,991

In connection with the Sale of the Athlone Facility, the Company reviewed Topic 805 and determined that the Athlone Facility constituted a business and, accordingly, \$2.0 million of the Company's goodwill was allocated to the Athlone Facility and was classified as "Assets held for sale" in the accompanying consolidated balance sheet as of December 31, 2023.

The Company's finite-lived intangible assets primarily consisted of collaborative agreements and the NanoCrystal and oral controlled release technologies acquired as part of the EDT acquisition. These intangible assets were fully amortized in the year ended December 31, 2024. The Company recorded \$1.1 million, \$35.7 million and \$36.4 million of amortization expense related to its finite-lived intangible assets during the years ended December 31, 2024, 2023 and 2022, respectively.

The Company performed its annual goodwill impairment test as of October 31, 2024. The Company elected to perform a qualitative impairment test and determined that based on the weight of all available evidence, the fair value of the reporting unit more-likely-than-not exceeded its carrying value.

XML 36 R21.htm IDEA: XBRL DOCUMENT

Leases

Leases [Abstract]

Leases

12 Months Ended

Dec. 31, 2024

10. LEASES

All of the Company's leases are accounted for as operating leases. The Company leases approximately 231,000 square feet of office and laboratory space located at 900 Winter Street in Waltham, Massachusetts (the "900 Winter Street Lease"). The initial term of the lease commenced on January 20, 2020, expires in 2035 and includes an option to extend the term for an additional ten-year period.

On November 13, 2023, in connection with the Separation, Alkermes, Inc., a wholly-owned subsidiary of the Company ("Alkermes US") and Mural Oncology, Inc., a wholly-owned subsidiary of Mural ("Mural US") entered into an assignment and assumption of lease agreement (the "Assignment"), pursuant to which Alkermes US assigned to Mural US an operating lease for approximately 180,000 square feet of corporate office space, administrative areas and laboratories located at 852 Winter Street in Waltham, Massachusetts (the "852 Winter Street Lease"). Under the terms of the Assignment, Mural US assumed all of Alkermes US' obligations under the 852 Winter Street Lease. In accordance with FASB ASC 842, *Leases*, as the Company can no longer access or direct the use of the asset following the Assignment, the 852 Winter Street Lease no longer meets the definition of a lease for the Company. On November 15, 2023, the effective date of the Assignment, the Company reduced its right-of-use asset and lease liability by \$14.5 million and \$15.4 million, respectively in the accompanying consolidated balance sheet.

At December 31, 2024 and 2023, the operating leases held by the Company had a weighted average incremental borrowing rate of 4.0% and 4.4%, respectively, and a weighted average remaining lease term of 7.2 years and 8.7 years, respectively. During the years ended December 31, 2024, 2023 and 2022, cash paid for amounts included for the measurement of lease liabilities was \$10.1 million, \$10.3 million and \$27.0 million, respectively. The Company recorded operating lease expense of \$7.2 million, \$10.2 million and \$10.7 million for the years ended December 31, 2024, 2023 and 2022, respectively.

Future lease payments under non-cancelable leases as of December 31, 2024 consisted of the following:

		December 31,	
(In thousands)		2024	
2025			10,189
2026			10,259
2027			9,505
2028			9,574
Thereafter			59,695
Total operating lease payments		\$	99,222
Less: imputed interest			(23,684)
Total operating lease liabilities		\$	75,538

XML 37 R22.htm IDEA: XBRL DOCUMENT

Accounts Payable and

Accrued Expenses

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2024

11. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consists of the following:

		December 31,	
(In thousands)		2024	
Accounts payable	\$	45,630	\$ 65,649
Accrued compensation		70,960	83,107
Accrued other		68,742	91,805
Total accounts payable and accrued expenses	\$	185,332	\$ 240,561

A summary of the Company's current provision for sales discounts, allowances and reserves is as follows:

		December 31,	
(In thousands)		2024	
Medicaid rebates	\$	202,044	\$ 213,845
Product discounts		19,351	15,121
Medicare Part D		26,933	20,569
Other		24,124	14,106
Total accrued sales discounts, allowances and reserves	\$	272,452	\$ 263,641

Included in accounts payable was approximately \$11.4 million and \$34.5 million of amounts payable related to state Medicaid rebates as of December 31, 2024 and 2023, respectively.

XML 38 R23.htm IDEA: XBRL DOCUMENT

Long-term Debt

Debt Disclosure

[Abstract]

Long-term Debt

12 Months Ended

Dec. 31, 2024

12. LONG-TERM DEBT

In December 2024, the Company prepaid in full all previously outstanding term loans (the "Former Term Loans") under the Former Credit Agreement without penalty, through paying off the remaining principal amount due of \$289.5 million. The Company accounted for such prepayment as a debt extinguishment and recorded a loss of approximately \$0.8 million within "Other income (expense), net" in the accompanying consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2024.

The Former Term Loans bore interest at the Secured Overnight Financing Rate ("SOFR") plus a credit spread adjustment applicable to the interest period and an applicable margin of 2.50% with a floor of 0.5%. As of December 31, 2024 and 2023, long-term debt consisted of the following:

		December 31,	
(In thousands)		2024	
Former Term Loans (due March 12, 2026)	\$	—	\$ 290,730
Less: current portion		—	(3,000)
Long-term debt	\$	—	\$ 287,730

XML 39 R24.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per

Share

Earnings Per Share

[Abstract]

Earnings (Loss) Per

Share

12 Months Ended

Dec. 31, 2024

13. EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per ordinary share from continuing operations is calculated based upon net income (loss) from continuing operations available to holders of ordinary shares divided by the weighted average number of ordinary shares outstanding. Basic loss per ordinary share from discontinued operations is calculated based upon net loss from discontinued operations available to holders of ordinary shares, divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted earnings (loss) per ordinary share from continuing operations and discontinuing operations, the Company utilizes the treasury stock method and adjusts the weighted average number of ordinary shares outstanding for the potential dilutive effect of outstanding ordinary share equivalents such as stock options and RSUs.

		Year Ended December 31,		
(In thousands)		2024		
Numerator:		2023		
Net income (loss) from continuing operations	\$	372,138	\$ 519,157	\$ (33,152)
Net loss from discontinued operations		(5,068)	(163,400)	(125,115)
Net income (loss)	\$	367,070	\$ 355,757	\$ (158,267)
Denominator:		2022 ⁽¹⁾		
Weighted average number of ordinary shares outstanding		165,392	166,223	163,742
Effect of dilutive securities:				
Stock options		1,377	1,093	—
Restricted stock unit awards		2,429	2,414	—
Dilutive ordinary share equivalents		3,806	3,507	—
Shares used in calculating diluted earnings (loss) per ordinary share		169,198	169,730	163,742

(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The following potential ordinary share equivalents were not included in the net income (loss) per share calculation because the effect would have been anti-dilutive:

		Year Ended December 31,		
(In thousands)		2024		
Stock options		11,517	12,422	12,777
Restricted stock unit awards		2,391	2,378	5,040
Total				

	13,908	14,800	17,817
(1)	Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.		

~~***XML 40 R25.htm IDEA: XBRL DOCUMENT***~~

Shareholders' Equity

**12 Months Ended
Dec. 31, 2024**

[Equity \[Abstract\]](#)
[Shareholders' Equity](#)

14. SHAREHOLDERS' EQUITY

Share Repurchase Program

In February 2024, the Company's board of directors approved a share repurchase program authorizing the Company to repurchase ordinary shares of the Company in an aggregate amount of up to \$400.0 million (exclusive of any fees, commissions or other expenses related to such repurchases) from time to time on the open market (the "Repurchase Program"). The specific timing and amounts of repurchases under the Repurchase Program will depend on a variety of factors, including but not limited to ongoing assessments of the Company's needs, alternative investment opportunities, the market price of the Company's ordinary shares and general market conditions. The Repurchase Program has no set expiration date and may be suspended or discontinued at any time. During the year ended December 31, 2024, the Company repurchased approximately 7.9 million of its ordinary shares under the Repurchase Program at an average price of \$25.33 per share, resulting in a total cost, exclusive of any fees, commissions or other expenses related to such repurchase of \$200.0 million. All ordinary shares repurchased were returned to treasury. As of December 31, 2024, the remaining amount authorized under the Repurchase Program was \$200.0 million.

~~***XML 41 R26.htm IDEA: XBRL DOCUMENT***~~

**Share-based
Compensation**

**12 Months Ended
Dec. 31, 2024**

[Share-Based Payment
Arrangement
\[Abstract\]](#)
[Share-based
Compensation](#)

15. SHARE-BASED COMPENSATION

Share-Based Compensation Expense

The following table presents share-based compensation expense from continuing and discontinued operations included in the Company's consolidated statements of operations and comprehensive income (loss):

(In thousands)	Year Ended December 31,		
	2024	2023	2022
Cost of goods manufactured and sold	\$ 5,798	\$ 11,353	\$ 10,284
Research and development	28,085	25,753	23,289
Selling, general and administrative	62,754	55,611	54,104
Share-based compensation expense from continuing operations	96,637	92,717	87,677
Cost of goods manufactured and sold	—	—	—
Research and development	—	3,255	4,652
Selling, general and administrative	—	4,933	1,925
Share-based compensation expense from discontinued operations	—	8,188	6,577
Total share-based compensation expense	\$ 96,637	\$ 100,905	\$ 94,254

During the years ended December 31, 2024, 2023 and 2022, \$3.1 million, \$3.2 million and \$3.3 million, respectively, of share-based compensation expense was capitalized and recorded as "Inventory" in the accompanying consolidated balance sheets.

Share-Based Compensation Plans

The Company has one share-based compensation plan pursuant to which awards are currently being made: the 2018 Stock Option and Incentive Plan, as amended (the "2018 Plan"). The Company has two share-based compensation plans pursuant to which outstanding awards have been made, but from which no further awards can or will be made: the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended, (the "2008 Plan") and the Alkermes plc 2011 Stock Option and Incentive Plan, as amended (the "2011 Plan," and together with the 2018 Plan and the 2008 Plan, the "the Alkermes Stock Option and Incentive Plans"). Effective May 20, 2020, the 2018 Plan was amended such that any shares underlying any outstanding awards granted under the 2011 Plan or the 2008 Plan that are forfeited, canceled, repurchased or otherwise terminated (other than by exercise) from and after such date will become available for issuance pursuant to the 2018 Plan, notwithstanding anything to the contrary in the terms of the 2011 Plan or the 2008 Plan.

The 2018 Plan allows for the issuance of non-qualified and incentive stock options, restricted stock, restricted stock unit awards, cash-based awards and performance shares to employees, officers and directors of, and consultants to, the Company in such amounts and with such terms and conditions as may be determined by the compensation committee of the Company's board of directors, subject to the provisions of the 2018 Plan, as applicable.

On May 31, 2024, the Company's shareholders approved an amended version of the then-current version of the 2018 Plan that served to, among other things, increase the number of ordinary shares authorized for issuance thereunder by 6.3 million. At December 31, 2024, there were 17.9 million ordinary shares available for issuance in the aggregate under the 2018 Plan. The 2018 Plan provides that awards other than stock options will be counted against the total number of shares available under the plan in a 1.8-to-1 ratio.

Stock Options

A summary of stock option activity is presented in the following table:

	Number of Shares	Weighted Average Exercise Price
Outstanding, January 1, 2024	18,139,903	\$ 32.28
Granted	2,615,357	\$ 29.48
Exercised	(1,328,189)	\$ 20.76
Expired	(1,427,409)	\$ 46.72
Forfeited	(521,043)	\$ 26.65
Outstanding, December 31, 2024	17,478,619	\$ 31.73
Exercisable, December 31, 2024	10,979,663	\$ 34.53

The weighted average grant date fair value of stock options granted during the years ended December 31, 2024, 2023 and 2022 was \$14.08, \$13.74 and \$12.62, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2024, 2023 and 2022 was \$10.9 million, \$6.0 million and \$11.6 million, respectively.

At December 31, 2024, there were 6.3 million stock options expected to vest, with a weighted average exercise price of \$26.91 per share, a weighted average contractual remaining life of 7.9 years and an aggregate intrinsic value of \$15.4 million. At December 31, 2024, the aggregate intrinsic value of stock options exercisable was \$38.5 million with a weighted average remaining contractual term of 4.4 years. The number of stock options expected to vest was determined by applying the pre-vesting forfeiture rate to the total number of outstanding options. The intrinsic value of a stock option is the amount by which the market value of the underlying shares exceeds the exercise price of the stock option.

At December 31, 2024, there was \$32.3 million of unrecognized share-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 1.9 years.

Time-Based Restricted Stock Unit Awards

A summary of time-based RSU activity is presented in the following table:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested, January 1, 2024	5,657,578	\$ 24.18
Granted	2,260,345	\$ 29.51
Forfeited	(775,415)	\$ 26.43
Vested	(2,237,302)	\$ 23.05
Unvested, December 31, 2024	4,905,206	\$ 26.80

The weighted average grant date fair values of time-vesting RSUs granted during the years ended December 31, 2024, 2023 and 2022 were \$29.51, \$27.65 and \$25.27, respectively. The total fair value of time-vesting RSUs that vested during the years ended December 31, 2024, 2023 and 2022, was \$51.6 million, \$63.0 million and \$54.3 million, respectively.

At December 31, 2024, there was \$53.4 million of total unrecognized share-based compensation expense related to unvested time-vesting RSUs, which will be recognized over a weighted average remaining contractual term of 1.9 years.

Performance-Based Restricted Stock Unit Awards

In February 2024, 2023 and 2022, the compensation committee of the Company's board of directors approved the Company's long-term incentive plans, pursuant to which awards of performance-based RSUs are granted to employees of the Company at the Senior Vice President level and above, in each case subject to vesting based on the achievement of certain financial, commercial and/or R&D performance criteria to be assessed over a performance period of three years from the date of the grant, and subject, at the end of such three-year performance period, to upward or downward adjustment based on a market condition tied to relative share price performance over the three-year performance period.

A summary of performance-based RSU activity is presented in the following table:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested, January 1, 2024	1,546,357	\$ 27.95
Granted	498,120	\$ 32.46
Forfeited	(172,576)	\$ 25.88
Vested	(536,243)	\$ 22.21
Unvested, December 31, 2024	1,335,658	\$ 32.13

The weighted average grant date fair values of performance-based RSUs granted during the years ended December 31, 2024, 2023 and 2022 were \$32.46, \$29.91 and \$30.73, respectively. The total fair value of performance-based RSUs that vested during the years ended December 31, 2024, 2023 and 2022 were \$10.1 million, \$5.9 million and none, respectively. At December 31, 2024, there was \$3.0 million of unrecognized share-based compensation expense related to unvested performance-based RSUs which would be recognized in accordance with the terms of the awards when the Company

deems it probable that the performance criteria will be met.

During the year ended December 31, 2024, the Company recognized share-based compensation expense related to certain performance-based RSUs that were granted during 2021. As of December 31, 2023, the financial performance criteria for these awards were deemed not probable of being achieved, however, in February 2024, the compensation committee of the Company's board of directors determined that the Company partially achieved the financial performance criteria. This was considered a modification in accordance with FASB ASC 718, *Compensation—Stock Compensation* and resulted in a modification charge of approximately \$6.8 million. In February 2024, the compensation committee of the Company's board of directors also determined that the Company achieved the pipeline performance criteria for these awards, resulting in a \$2.6 million incremental share-based compensation expense, as it was deemed such pipeline performance criteria had been met. The share-based compensation expense related to these achievements was recognized in 2024.

XML 42 R27.htm IDEA: XBRL DOCUMENT

Collaborative Arrangements
[Collaborative Arrangements Disclosure \[Abstract\]](#)
[Collaborative Arrangements](#)

**12 Months Ended
Dec. 31, 2024**

16. COLLABORATIVE ARRANGEMENTS

The Company has entered into several collaborative arrangements to develop and commercialize products and, in connection with such arrangements, to access technologies, financial, marketing, manufacturing and other resources. Refer to the "Patents and Proprietary Rights" section in "Item 1— Business" of this Annual Report for information with respect to IP protection for these products. The collaboration revenue the Company has earned in the years ended December 31, 2024, 2023 and 2022 is summarized in Note 4, *Revenue from Contracts with Customers* within the notes to the consolidated financial statements in this Annual Report.

The Company's significant collaborative arrangements are described below:

Janssen

INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNNLI

Under an exclusive license agreement with Janssen, the Company provided Janssen with rights to, and know-how, training and technical assistance in respect of, the Company's small particle pharmaceutical compound technology, known as NanoCrystal technology, which was used to develop the long-acting INVEGA products, and the Company received milestone payments from Janssen upon the achievement of certain development goals from Janssen; there are no further milestones to be earned under this agreement. The agreement also provides for tiered royalty payments, which consist of a patent royalty and a know-how royalty, both of which are determined on a country-by-country basis. The patent royalty, which equals 1.5% of net sales, is payable in each country until the expiration of the last of the patents with valid claims applicable to the product in such country. The know-how royalty is a tiered royalty of 3.5%, 5.5% and 7.5% on aggregate worldwide net sales of below \$250 million, between \$250 million and \$500 million, and greater than \$500 million, respectively. The know-how royalty rate resets to 3.5% at the beginning of each calendar year and is payable until 15 years from first commercial sale of a product in each individual country, subject to expiry of the agreement. These royalty payments may be reduced in any country based on patent litigation or on competing products achieving certain minimum sales thresholds. The license agreement, unless earlier terminated, terminates upon the expiration of the last of the patents subject to the agreement. After expiration, Janssen retains a non-exclusive, royalty-free license to develop, manufacture and commercialize the products, subject to certain surviving obligations. Janssen may terminate the license agreement in whole or in part upon three months' notice to the Company. The Company and Janssen have the right to terminate the agreement upon a material breach of the other party, which is not cured within a certain time period, or upon the other party's bankruptcy or insolvency.

In November 2021, the Company received notice from Janssen of partial termination of the license agreement, following which Janssen ceased paying the Company royalties related to U.S. sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA. In April 2022, the Company commenced binding arbitration proceedings related to, among other things, Janssen's partial termination of this license agreement and Janssen's royalty and other obligations under the agreement. In May 2023, the Tribunal in the arbitration proceedings issued a Final Award that served to reinstate the Janssen royalties and required payment by Janssen of back royalties and interest for amounts owed but not yet paid since the effective date of the partial termination. The Final Award also provided, among other things, that the Company was entitled to royalty revenues from Janssen related to net sales of INVEGA SUSTENNA through August 20, 2024, INVEGA TRINZA through the second quarter of 2030 (but no later than May 2030 when the license agreement expires) and INVEGA HAFYERA through May 2030 (when the license agreement expires).

RISPERDAL CONSTA

Under a product development agreement, the Company collaborated with Janssen on the development of RISPERDAL CONSTA. Under the development agreement, Janssen provided funding to the Company for the development of RISPERDAL CONSTA and Janssen is responsible for securing all necessary regulatory approvals for the product.

Under two license agreements, the Company granted Janssen and an affiliate of Janssen exclusive worldwide licenses to use and sell RISPERDAL CONSTA. Under its license agreements with Janssen, the Company receives royalty payments equal to 2.5% of Janssen's end-market net sales of RISPERDAL CONSTA in each country where the license is in effect based on the quarter when the product is sold by Janssen. This royalty may be reduced in any country based on lack of patent coverage and significant competition from generic versions of the product. Janssen can terminate the license agreements upon 30 days' prior written notice to the Company. Either party may terminate the license agreements by written notice following a breach which continues for 90 days after the delivery of written notice thereof or upon the other party's insolvency. The licenses granted to Janssen expire on a country-by-country basis upon the later of: (i) the expiration of the last patent claiming the product in such country; or (ii) 15 years after the date of the first commercial sale of the product in such country, provided that in no event will the license granted to Janssen expire later than the twentieth anniversary of the first commercial sale of the product in each such country, with the exception of Canada, France, Germany, Italy, Japan, Spain and the United Kingdom, in each case where the fifteen-year minimum shall pertain regardless. After expiration, Janssen retains a non-exclusive, royalty-free license to manufacture, use and sell RISPERDAL CONSTA.

The Company exclusively manufactures RISPERDAL CONSTA at its Wilmington, Ohio facility for commercial sale. Under its manufacturing and supply agreement with Janssen, the Company records manufacturing revenues when product is fully manufactured and approved for shipment by both Janssen and the Company. Revenue is based on a percentage of Janssen's net unit sales price for RISPERDAL CONSTA for the applicable calendar year. This percentage is determined based on Janssen's unit demand for such calendar year and varies based on the volume of units shipped, with a minimum manufacturing fee of 7.5%. Either party may terminate the manufacturing and supply agreement upon a material breach by the other party, which is not resolved within 60 days after receipt of a written notice specifying the material breach or upon written notice in the event of the other party's insolvency or bankruptcy. Janssen may terminate the agreement upon six months' written notice to the Company. In the event that Janssen terminates the manufacturing and supply agreement without terminating the license agreements, the royalty rate payable to the Company on Janssen's net sales of RISPERDAL CONSTA would increase from 2.5% to 5.0%.

Biogen

Under a license and collaboration agreement with Biogen, the Company granted Biogen a worldwide, exclusive, sublicensable license to develop, manufacture and commercialize VUMERITY and other products covered by patents licensed to Biogen under the agreement.

Under this license and collaboration agreement, the Company received an upfront cash payment and milestone payments related to the achievement of certain milestones. The Company is also eligible to receive additional payments upon achievement of certain milestones, including milestones relating to the first two products, other than VUMERITY, covered by patents licensed to Biogen under the license and collaboration agreement.

In addition, the Company receives a 15% royalty on worldwide net sales of VUMERITY, subject to increases for VUMERITY manufactured and/or packaged by Biogen or its designees. The Company is also entitled to receive royalties on net sales of products other than VUMERITY covered by patents licensed to Biogen under the license and collaboration agreement, at tiered royalty rates calculated as percentages of net sales ranging from high-single digits to sub-teen double digits. All royalties are payable on a product-by-product and country-by-country basis until the later of (i) the last-to-expire patent right covering the applicable product in the applicable country and (ii) a specified period of time from the first commercial sale of the applicable product in the applicable country. Royalties for all products are subject to customary reductions, as set forth in the license and collaboration agreement.

Following FDA approval of VUMERITY and, except for the manufacturing responsibilities discussed below, Biogen is now responsible for all development and commercialization activities for VUMERITY and all other products covered by the patents that we licensed to Biogen.

Under the license and collaboration agreement, Biogen appointed the Company as the toll manufacturer of clinical and commercial supplies of VUMERITY, subject to Biogen's right to manufacture or have manufactured commercial supplies as a back-up manufacturer. In October 2019, the Company entered into a commercial supply agreement with Biogen for the commercial supply of VUMERITY, an amendment to such commercial supply agreement and an amendment to the license and collaboration agreement with Biogen, pursuant to which Biogen has conducted a technology transfer and, following an agreed transition period, has elected to assume responsibility for the manufacture (itself or through a designee) of clinical and commercial supplies of VUMERITY in exchange for an increase in the royalty rate to be paid by Biogen to the Company on net sales of product that is manufactured by Biogen or its designee. In May 2024, the Company completed the sale of the Athlone Facility where VUMERITY is manufactured. In connection with the sale of the Athlone Facility, the Company has entered into a subcontracting arrangement with the purchaser of the Athlone Facility for the manufacture of VUMERITY through the manufacturing transition period, which may continue through the end of 2025.

Unless earlier terminated, the license and collaboration agreement will remain in effect until the expiry of all royalty obligations. Biogen has the right to terminate the license and collaboration agreement at will, on a product-by-product basis or in its entirety upon 180 days' prior notice to the Company. Either party has the right to terminate the license and collaboration agreement following any governmental prohibition of the transactions effected by the agreement, or in connection with an insolvency event involving the other party. Upon termination of the license and collaboration agreement by either party, then, at the Company's request, the VUMERITY program will revert to the Company.

XML 43 R28.htm IDEA: XBRL DOCUMENT

Income Taxes
[Income Tax Disclosure \[Abstract\]](#)
[Income Taxes](#)

**12 Months Ended
Dec. 31, 2024**

17. INCOME TAXES

The Company's provision (benefit) for income taxes from continuing operations consists of the following:

(In thousands)	Year Ended December 31,		
	2024	2023	2022 ⁽¹⁾
Current income tax provision (benefit):			
U.S. federal	\$ 25,640	\$ (981)	\$ 11,169
U.S. state	4,259	722	4,401
Ireland	1,192	—	—
Deferred income tax provision (benefit):			
U.S. federal	(19,870)	10,192	(10,536)
U.S. state	(1,392)	(507)	(3,010)
Ireland	61,783	(107,064)	—
Total tax provision (benefit)	<u>\$ 71,612</u>	<u>\$ (97,638)</u>	<u>\$ 2,024</u>

(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The income tax provision in 2024 was primarily due to taxes on income earned in Ireland. The income tax benefit in 2023 was primarily due to the partial release of the valuation allowance maintained against certain Irish deferred tax assets, partially offset by taxes on income earned in the U.S. and Ireland. The income tax expense in 2022 was primarily due to taxes on income earned in the U.S.

In December 2022, the EU implemented a new corporate minimum tax rate of 15% on companies with consolidated annual revenue of at least €750.0 million, which was transposed into Irish law effective as of January 1, 2024. The Company has determined that this new minimum tax had no material impact for the year ended December 31, 2024.

The income tax benefit associated with the Company's former oncology business, and the tax impact of the Separation, are discussed in further detail in Note 3, *Discontinued Operations*, in these "Notes to Consolidated Financial Statements" in this Annual Report. The tax benefits included within discontinued operations were \$0.7 million, \$1.4 million, and \$11.1 million for the years ended December 31, 2024, 2023, and 2022, respectively.

No provision for income tax has been provided on undistributed earnings of the Company's foreign subsidiaries because such earnings are indefinitely reinvested in the foreign operations. Cumulative unremitted earnings of U.S. subsidiaries totaled approximately \$933.5 million at December 31, 2024. In the event of a repatriation of those earnings in the form of dividends or otherwise, the

Company may be liable for income taxes, subject to adjustment, if any, for foreign tax credits and foreign withholding taxes payable to foreign tax authorities. The Company estimates that approximately \$72.0 million of income taxes would be payable on the repatriation of the unremitted earnings to Ireland.

The distribution of the Company's income (loss) before the provision (benefit) for income taxes by geographical area consists of the following:

(In thousands)	Year Ended December 31,		
	2024	2023	2022 ⁽¹⁾
Ireland	\$ 440,674	\$ 411,767	\$ (32,198)
U.S.	3,076	9,752	1,070
Income (loss) from continuing operations before provision (benefit) for income taxes	\$ 443,750	\$ 421,519	\$ (31,128)

(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The components of the Company's net deferred tax assets consist of the following:

(In thousands)	December 31, 2024	December 31, 2023
Deferred tax assets:		
Net operating loss carryforwards	\$ 80,209	\$ 195,658
Research and development expenses	71,167	49,206
Accrued expenses and reserves	41,189	37,367
Operating lease liabilities	17,537	18,716
Share-based compensation	33,773	37,727
Tax credits	26,882	27,116
Other	3,695	5,582
Less: valuation allowance	(79,727)	(129,296)
Total deferred tax assets	194,725	242,076
Deferred tax liabilities:		
Property, plant and equipment	(21,917)	(26,271)
Right-of-use assets	(16,337)	(17,748)
Other	(1,940)	(2,716)
Total deferred tax liabilities	(40,194)	(46,735)
Net deferred tax assets	\$ 154,531	\$ 195,341

The activity in the valuation allowance associated with deferred taxes consists of the following:

(In thousands)	Balance at Beginning of Period ⁽¹⁾	(Additions) / Reductions ⁽²⁾	Balance at End of Period ⁽¹⁾
Deferred tax asset valuation allowance for the year ended December 31, 2022	\$ (249,112)	\$ (22,405)	\$ (271,517)
Deferred tax asset valuation allowance for the year ended December 31, 2023	\$ (271,517)	\$ 142,221	\$ (129,296)
Deferred tax asset valuation allowance for the year ended December 31, 2024	\$ (129,296)	\$ 49,569	\$ (79,727)

(1) Inclusive of continuing and discontinued operations for the periods prior to the Separation in November 2023.

(2) (Additions) reductions represent continuing and discontinued operations for the periods prior to the Separation in November 2023. The reductions during the year ended December 31, 2024 primarily relate to the abandonment of certain Irish NOLs following the sale of the Athlone Facility to Novo. These NOLs were transferred from Elan Corporation, plc as part of the combination of the drug technology business of Elan Corporation, plc with the business of Alkermes, Inc. A number of restrictions applied to these NOLs thereby restricting the Company's ability to utilize such NOLs. Following the sale of the Athlone Facility, the Company believes that its ability to utilize these NOLs is remote. The reduction during the year ended December 31, 2023 primarily relates to the partial release of the valuation allowance maintained by the Company against certain Irish net deferred tax assets. The additions in 2022 relate primarily to Irish NOLs.

The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making such assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. At December 31, 2024, the Company maintained a valuation allowance of \$29.6 million against certain U.S. state deferred tax assets and \$50.1 million against certain Irish deferred tax assets, as the Company has determined that it is more-likely-than-not that these deferred tax assets will not be realized and some may be abandoned.

If the Company incurs losses in the U.S. or in Ireland in the future, or fails to achieve sufficient profitability in a timely manner, the evaluation of the recoverability of the deferred tax assets could change and a valuation allowance against such deferred tax assets may be required in part or in whole. The Company will continue to monitor the need for a valuation allowance against its deferred tax assets on a quarterly basis.

As of December 31, 2024, the Company had \$393.9 million of Irish NOL carryforwards, \$14.1 million of U.S. federal NOL carryforwards, \$43.2 million of state NOL carryforwards and \$34.0 million of state tax credits which will either expire on various dates through 2039 or can be carried forward indefinitely. These loss and credit carryforwards are available to reduce certain future Irish and foreign taxable income and tax. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities and may be subject to limitations based upon changes in the ownership of the Company's ordinary shares. Included within these loss and credit carryforwards are \$14.1 million of U.S. federal NOL carryforwards and \$5.8 million of state NOL carryforwards, acquired as part of the acquisition of Rodin Therapeutics, Inc. in November 2019, each of which are subject to a \$0.5 million annual limitation.

A reconciliation of the Company's statutory tax rate to its effective tax rate is as follows:

(In thousands, except percentage amounts)	2024	2023	2022 ⁽¹⁾
Statutory tax rate	12.5 %	12.5 %	12.5 %
Income (loss) from continuing operations before income taxes at statutory rate	\$ 55,469	\$ 52,690	\$ (3,891)
Share-based compensation	5,607	4,177	4,347
Foreign rate differential ⁽²⁾	4,844	4,701	521
Change in valuation allowance	(49,517)	(142,424)	1,102
Intercompany amounts ⁽³⁾	708	(16,551)	(1,694)
Irish rate differential ⁽⁴⁾	5,798	235	4,926
Uncertain tax positions	(667)	(234)	602
Non-deductible lobbying expenses	767	705	775
U.S. state income taxes, net of U.S. federal benefit	2,802	347	1,272
Foreign derived intangible income	(281)	—	(4,530)
R&D credit	(7,815)	(2,823)	(2,531)
Abandonment of NOLs ⁽⁵⁾	49,897	—	—
Other permanent items ⁽⁶⁾	4,000	1,539	1,125
Income tax provision (benefit)	\$ 71,612	\$ (97,638)	\$ 2,024
Effective tax rate	16.1 %	(23.2) %	(6.5) %

(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

(2) Represents income or losses of U.S. subsidiaries, subject to tax at a rate other than the Irish statutory rate.

(3) Intercompany amounts include cross-territory eliminations, the pre-tax effect of which has been eliminated in arriving at the Company's consolidated income (loss) before taxes from continuing operations. In 2023, this included a tax benefit of \$15.7 million related to the intercompany transfer of inventory that was owned by the Company at December 31, 2023.

(4) Represents income or losses of Irish companies subject to tax at a rate other than the Irish statutory rate.

(5) Represents the tax effect of the abandonment of Irish NOLs following the sale of the Athlone Facility to Novo.

(6) Other permanent items include, but are not limited to, non-deductible meals and entertainment expenses and non-deductible compensation of senior officers of the Company. For the year ended December 31, 2024, permanent items also included amounts relating to the sale of the Athlone Facility.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

(In thousands)	Unrecognized Tax Benefits
Balance, December 31, 2021	\$ 8,372
Reductions based on the lapse of applicable statutes of limitations	(438)
Additions based on tax positions related to prior periods	449
Additions based on tax positions related to the current period	590
Balance, December 31, 2022	\$ 8,973
Reductions based on the lapse of applicable statutes of limitations	(1,073)
Additions based on tax positions related to the prior period	281
Additions based on tax positions related to the current period	558
Balance, December 31, 2023	\$ 8,739
Reductions based on the lapse of applicable statutes of limitations	(1,306)
Additions based on tax positions related to the prior period	59
Additions based on tax positions related to the current period	581
Balance, December 31, 2024	\$ 8,073

The unrecognized tax benefits at December 31, 2024, if recognized, would affect the Company's effective tax rate. The Company does not anticipate that the amount of existing unrecognized tax benefits will materially increase or decrease within the next 12 months. The Company has elected to include interest and penalties related to uncertain tax positions as a component of its provision for taxes. For the years ended December 31, 2024, 2023 and 2022, the Company's accrued interest and penalties related to uncertain tax positions were not material.

The Company's major taxing jurisdictions include Ireland and the U.S. (federal and state). These jurisdictions have varying statutes of limitations. In the U.S., the 2021 through 2024 fiscal years remain subject to examination by the respective tax authorities, however, some states have longer statutes of limitations and additional fiscal years remain subject to examination. In Ireland, the 2020 through 2024 fiscal years remain subject to examination by the Irish tax authorities. Additionally, because of the Company's Irish and U.S. loss carryforwards and credit carryforwards, certain tax returns from fiscal years 2002 onward may also be examined. These years generally remain open for three to four years after the loss carryforwards and credit carryforwards have been utilized.

XML 44 R29.htm IDEA: XBRL DOCUMENT

Segment Reporting

Segment Reporting

[Abstract]

Segment Reporting

18. SEGMENT REPORTING

Segment Information

12 Months Ended

Dec. 31, 2024

Following the adoption of ASU 2023-07, the Company is required to disclose significant segment expenses that are regularly provided to the CODM. The Company’s CODM is periodically provided R&D expenses, selling and marketing expenses, and general and administrative expenses. Other external R&D expenses are composed of general research and development expenses and other external projects. Other internal R&D expenses include allocation expenses, travel expenses, and fees, taxes and dues.

The Company’s significant segment expenses are as follows:

(In thousands)	Year Ended December 31,		
	2024	2023	2022
REVENUES:			
Total revenue	\$ 1,557,632	\$ 1,663,405	\$ 1,111,795
EXPENSES:			
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	245,331	253,037	218,068
External R&D expenses:			
Development programs:			
ALKS 2680	45,947	31,321	15,715
LYBALVI	18,737	15,379	23,056
Other external R&D expenses	36,627	51,668	57,423
Total external R&D expenses	101,311	98,368	96,194
Internal R&D expenses:			
Employee-related	114,496	128,282	129,735
Occupancy	11,206	12,299	12,449
Depreciation	5,701	9,578	10,708
Other internal R&D expenses	12,612	22,279	23,616
Total internal R&D expenses	144,015	172,438	176,508
R&D expenses	245,326	270,806	272,702
Selling, general and administrative expenses:			
Selling and marketing expense	446,214	490,154	392,211
General and administrative expense	199,024	199,597	198,540
Total selling, general and administrative expense	645,238	689,751	590,751
Other segment (expenses) income ⁽¹⁾	(49,599)	69,346	(63,426)
NET INCOME (LOSS) FROM CONTINUING OPERATIONS	372,138	519,157	(33,152)
LOSS ON DISCONTINUED OPERATIONS, NET OF TAX	(5,068)	(163,400)	(125,115)
NET INCOME (LOSS)	\$ 367,070	\$ 355,757	\$ (158,267)

(1) "Other segment (expenses) income" during the years ended December 31, 2024, 2023 and 2022 includes "Amortization of acquired intangible assets", "Other income (loss), net" and "Income tax provision (benefit)".

[XML 45 R30.htm IDEA: XBRL DOCUMENT](#)

**Commitments and
Contingent Liabilities**

[Commitments and
Contingencies
Disclosure \[Abstract\]](#)

[Commitments and
Contingent Liabilities](#)

**12 Months Ended
Dec. 31, 2024**

19. COMMITMENTS AND CONTINGENT LIABILITIES

Litigation

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company would accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on the Company’s best estimates, utilizing all available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company’s operating results. At December 31, 2024, there were no potential material losses from claims, asserted or unasserted, or legal proceedings that the Company determined were probable of occurring.

INVEGA TRINZA ANDA Litigation

In September 2020, Janssen Pharmaceutica, Janssen Pharmaceuticals, Inc., and Janssen Research & Development, LLC initiated a patent infringement lawsuit in the NJ District Court against Mylan Labs, Mylan, and Mylan Institutional LLC following the filing by Mylan Labs of an ANDA seeking approval from the FDA to market a generic version of INVEGA TRINZA before the expiration of U.S. Patent No. 10,143,693 (the “’693 Patent”). Requested judicial remedies include recovery of litigation costs and injunctive relief. In May 2023, the NJ District Court issued an opinion in favor of the Janssen entities on the issues of infringement and validity of the ‘693 Patent and the Mylan entities filed a notice of appeal of the decision. The Company is not a party to this proceeding.

VUMERITY ANDA Litigation

In July 2023, Biogen Inc., Biogen Swiss Manufacturing GmbH and Alkermes Pharma Ireland Limited filed a patent infringement lawsuit in the DE District Court against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited (collectively, “Zydus”) following the filing by Zydus of an ANDA seeking approval from the FDA to engage in the commercial manufacture, use or sale of a generic version of VUMERITY (diroximel fumarate) delayed-release capsules for oral use, 231 mg, before expiration of the Company’s U.S. Patent Nos. 8,669,281; 9,090,558; and 10,080,733. The filing of the lawsuit triggered a stay of FDA approval of the ANDA for up to 30 months in accordance with the U.S. Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”). A bench trial is scheduled to begin on July 28, 2025.

Government Matters

The Company has received a subpoena and civil investigative demands from U.S. state and federal governmental authorities for documents related to VIVITROL. The Company is cooperating with the investigations.

Product Liability and Other Legal Proceedings

The Company is involved in litigation and other legal proceedings incidental to its normal business activities, including a product liability case alleging that the FDA-approved VIVITROL labeling was inadequate and that VIVITROL caused the individual to suffer from opioid overdose and death. The Company intends to vigorously defend itself in these matters.

In addition, in January 2023, Acorda filed a petition with the U.S. District Court for the Southern District of New York (the “NY Southern District Court”) asking the court to confirm in part and modify in part the final arbitral award rendered by an arbitration panel in October 2022 and, as part of the requested modification, seeking an additional approximately \$66.0 million in damages. In August 2023, the NY Southern District Court confirmed the final arbitral award and declined to modify the final award to increase the damages awarded thereunder. In September 2023, Acorda filed a notice of appeal of the NY Southern District Court decision to the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit Court”), and the Company filed a motion to transfer the appeal to the U.S. Court of Appeals for the Second Circuit. In January 2024, the Federal Circuit Court denied without prejudice the Company’s motion to transfer the appeal and instructed the parties to brief the jurisdictional question as part of the merits appeal. Briefing in the Federal Circuit Court is complete, and the matter is pending decision.

Guarantees

In connection with the Separation, the Company entered into the Assignment related to the 852 Winter Street Lease, which is described in more detail in Note 10, *Leases* in these “Notes to Consolidated Financial Statements” in this Annual Report. Although the Assignment transferred all of the rights, title and interest in, to and under the 852 Winter Street Lease to Mural US as of November 15, 2023, the Company ratified and reaffirmed for the remainder of the lease term its guarantor obligations under that certain Guaranty dated as of May 16, 2014 related to the 852 Winter Street Lease. Upon completion of the Separation, the Assignment was accounted for as a termination of the original lease and the Company de-recognized the right-of-use asset and lease liability related to the 852 Winter Street Lease. At December 31, 2024, the fair value of the guarantee was not material to the Company.

Purchase Commitments

The Company has open purchase orders for plant and equipment as part of its normal course of business. At December 31, 2024, the Company’s open purchase orders were \$17.7 million for capital commitments.

[XML 46 R31.htm IDEA: XBRL DOCUMENT](#)

**Summary of
Significant
Accounting Policies
(Policies)**

[Accounting Policies
\[Abstract\]](#)

[Principles of
Consolidation](#)

[Reclassification](#)

[Discontinued
Operations](#)

[Assets Held for Sale](#)

[Use of Estimates](#)

12 Months Ended

Dec. 31, 2024

Principles of Consolidation

The consolidated financial statements include the accounts of Alkermes plc and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated. Columns and rows within tables may not sum due to rounding.

Reclassification

The Company has presented its former oncology business as discontinued operations in its consolidated financial statements as of December 31, 2023 and for the years ended December 31, 2023 and 2022. See Note 3, *Discontinued Operations* in these “Notes to Consolidated Financial Statements” in this Annual Report for additional information.

Discontinued Operations

The Company determined that the Separation met the criteria for classification of the former oncology business as discontinued operations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205, *Discontinued Operations*. Accordingly, the accompanying consolidated financial statements have been updated to present the results of the oncology business as discontinued operations through the Separation Date for the years ended December 31, 2023 and 2022 in the consolidated statements of operations and comprehensive income (loss).

Assets Held for Sale

In connection with the sale of the Athlone Facility, the Company reviewed FASB ASC 805, *Business Combinations* (“Topic 805”) and, based on the definitions therein, determined that the Athlone Facility constituted a business. Accordingly, the assets associated with the sale of the Athlone Facility were classified as “Assets held for sale” in the accompanying consolidated balance sheet as of December 31, 2023.

Use of Estimates

The preparation of the Company’s consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”) requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies, including but not limited to, those related to revenue from contracts with its customers and related allowances, impairment of

intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company values its cash and cash equivalents at cost plus accrued interest, which the Company believes approximates its market value. The Company considers as cash equivalents only those investments that are highly liquid, readily convertible into cash and so near their maturity (three months from the date of purchase) that they present insignificant risk of change in value because of interest rate changes.

Investments

Investments

The Company has investments in various types of securities, consisting primarily of United States (“U.S.”) government and agency obligations and corporate debt securities. The Company generally holds its interest-bearing investments with major financial institutions and in accordance with documented investment policies. The Company limits the amount of credit exposure to any one financial institution or corporate issuer. At December 31, 2024, substantially all these investments were classified as available-for-sale and were recorded at fair value.

Unrealized gains and losses are included in accumulated other comprehensive loss in equity, net of related tax, unless: (i) the security has experienced a credit loss; (ii) the Company has determined that it has the intent to sell the security; or (iii) the Company has determined that it is more likely than not that it will have to sell the security before its expected recovery. Periodic reviews are conducted to identify and evaluate each investment that has an unrealized loss in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis.

For available-for-sale debt securities with unrealized losses, the Company performs an analysis to assess whether it intends to sell, or whether it would more likely than not be required to sell, the security before the expected recovery of the amortized cost basis. Where the Company intends to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.

Regardless of the Company’s intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

The Company’s held-to-maturity investments are restricted investments held as collateral under letters of credit related to certain of the Company’s agreements and are included in “Investments—long-term,” in the accompanying consolidated balance sheets.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company’s financial assets and liabilities are recorded at fair value and are classified as Level 1, 2 or 3 within the fair value hierarchy, as described in the accounting standards for fair value measurement. At December 31, 2024, the Company’s financial assets consisted of cash equivalents and investments and are classified within the fair value hierarchy as follows:

- Level 1—these valuations are based on a market approach using quoted prices in active markets for identical assets. Valuations of these products do not require a significant degree of judgment. Assets utilizing Level 1 inputs at December 31, 2024 included U.S. treasury securities, marketable securities classified as cash equivalents and a fixed term deposit account; and
- Level 2—these valuations are based on quoted prices for identical or similar assets in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models. Assets utilizing Level 2 inputs at December 31, 2024 included U.S. government agency debt securities and investments in corporate debt securities that are trading in the credit markets.

The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, accounts receivable, contract assets, other current assets, accounts payable and accrued expenses and accrued sales discounts, allowances and reserves approximate fair value due to their short-term nature.

Inventory

Inventory

Inventory is stated at the lower of cost and net realizable value. The Company utilizes a standard cost basis, which approximates cost determined using the first-in first-out method. Cost is determined using the first-in, first-out method. Included in inventory are raw materials used in production of preclinical and clinical products, which have alternative future use and are charged to R&D expense when consumed. The cost elements included within inventory include three primary categories for commercial products: cost of raw materials; direct labor; and overhead. Overhead is based on the normal capacity of the Company’s production facility and does not include costs from abnormally low production or idle capacity, which are expensed directly to the consolidated statement of operations and comprehensive income (loss).

The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management’s judgment, future commercialization of the product is considered probable and future economic benefit from such product is expected to be realized. The Company assesses the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety, efficacy or quality concerns, potential labeling restrictions and other potential impediments to approval. The Company also considers the shelf life of the product in relation to the expected timeline for approval and considers issues that may prevent or delay commercialization, including issues that may arise in relation to the manufacturing of the product. The Company expenses previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by relevant regulatory agencies or other issues that may make the pre-approval inventory batches less likely or unlikely to be commercialized and to result in future economic benefit.

Property, Plant and Equipment

Property, Plant and Equipment

Property, plant and equipment are recorded at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred and major renewals and improvements are capitalized. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:

Asset group	Term
Buildings and improvements	25 years
Furniture, fixtures and equipment	5 - 7 years
Leasehold improvements	Shorter of useful life or lease term

Goodwill and Intangible Assets

Goodwill and Intangible Assets

Goodwill represents the excess cost of the Company’s investment in the net assets of acquired companies over the fair value of the underlying identifiable net assets at the date of acquisition. The Company’s goodwill consists solely of goodwill created as a result of the Company’s acquisition of Elan Drug Technologies (“EDT”) from Elan Corporation, plc (such acquisition, the “Business Combination”) in September 2011 and has been assigned to one reporting unit. A reporting unit is an operating segment or one level below an operating segment or a component to which goodwill is assigned when initially recorded.

Goodwill is not amortized but is reviewed for impairment on an annual basis, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable. The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of its reporting unit is less than its carrying amount, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative impairment test, the Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then the Company would record an impairment loss equal to the difference.

When some, but not all, of a reporting unit is to be disposed of, the accounting for that reporting unit’s goodwill will depend on whether the disposal group constitutes a business. If the disposal group constitutes a business, the Company attributes a portion of the reporting unit’s goodwill to the disposal group based on the relative fair values of: (i) the disposal group; and (ii) the portion of the reporting unit that will be retained.

The Company’s finite-lived intangible assets, consisting of core developed technology and collaboration agreements acquired as part of the Business Combination, were recorded at fair value at the time of their acquisition and are stated within the Company’s consolidated balance sheet net of accumulated amortization. The finite-lived intangible assets are amortized over their estimated useful lives using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract. The useful lives of the Company’s intangible assets are primarily based on the legal or contractual life of the underlying patent or contract, which does not include additional years for the potential extension or renewal of the contract or patent.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset; a significant change in the extent or manner in which an asset is used; a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset; a current-period operating or cash flow loss combined with a history of operating or cash-flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset; or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell them.

Revenue from Contracts with Customers

Revenue from Contracts with Customers

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed in accordance with FASB ASC 606, *Revenue from Contracts with Customers* (“Topic 606”): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.

Product Sales, Net

The Company’s product sales, net consist of sales in the U.S. of VIVITROL®, ARISTADA®, ARISTADA INITIO® and LYBALVI®, primarily to wholesalers, specialty distributors and pharmacies. Product sales, net are recognized when the customer obtains control of the product, which is when the product has been received by the customer.

Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, healthcare providers or payers. The Company’s process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company’s estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. The following are the Company’s significant categories of sales discounts and allowances:

- Medicaid Rebates—the Company records accruals for rebates to U.S. states under the Medicaid Drug Rebate Program as a reduction of sales when the product is shipped into the distribution channel using the expected value method. The Company rebates individual U.S. states for all eligible units purchased under the Medicaid program based on a rebate per unit calculation, which is based on the Company’s average manufacturer prices. The Company estimates expected unit sales to individuals covered by Medicaid and rebates per unit under the Medicaid program and adjusts its rebate accrual based on actual unit sales and rebates per unit and changes in trends in Medicaid utilization. In 2024, actual Medicaid utilization rates related to VIVITROL were lower than original estimates, due, in part, to \$8.7 million in actual credits received from certain states in the fourth quarter of 2024 related to duplicate Medicaid billings. Medicaid rebates for the Company’s other products have not differed materially from the Company’s estimates;
- Chargebacks—discounts that occur when contracted indirect customers purchase directly from wholesalers and specialty distributors. Contracted customers generally purchase a product at its contracted price. The wholesaler or specialty distributor, in turn, then generally charges back to the Company the difference between the wholesale acquisition cost and the contracted price paid to the wholesaler or specialty distributor by the customer. The allowance for chargebacks is made using the expected value method and is based on actual and expected utilization of these programs. Chargebacks could exceed historical experience and the Company’s estimates of future participation in these programs. To date, actual chargebacks have not differed materially from the Company’s estimates;
- Product Discounts—cash consideration, including sales incentives, given by the Company under agreements with a number of wholesaler, distributor, pharmacy, and treatment provider customers that provide them with a discount on the purchase price of products. The reserve is made using the expected value method and to date, actual product discounts have not differed materially from the Company’s estimates;
- Product Returns—the Company records an estimate for product returns at the time its customers take control of their product. The Company estimates this liability using the expected returns of product sold based on historical return levels and specifically identified anticipated returns due to known business conditions and product expiry dates. Return amounts are

recorded as a reduction of sales. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from the Company's estimates; and

- **Medicare Part D**—the Company records accruals for Medicare Part D liabilities under the Medicare Coverage Gap Discount Program ("CGDP") as a reduction of sales. Under the CGDP, patients reaching the annual coverage gap threshold are eligible for reimbursement coverage for out-of-pocket costs for covered prescription drugs. Under an agreement with the Centers for Medicare and Medicaid Services, manufacturers are responsible to reimburse prescription plan sponsors for the portion of out-of-pocket expenses not covered under their Medicare plans. To date, actual Medicare Part D rebates have not differed materially from the Company's estimates.

A rollforward of the Company's provisions for sales and allowances is as follows:

December 31, 2024					
(In thousands)	Contractual Adjustments ⁽¹⁾	Discounts ⁽²⁾	Product Returns	Other	Total
Beginning balance — December 31, 2023	\$ 234,414	\$ 28,690	\$ 41,064	\$ 10,164	\$ 314,332
Current provisions relating to sales in current year	557,651	386,625	28,627	87,373	1,060,276
Adjustments relating to prior years	(20,562)	—	(3,700)	—	(24,262)
Payments/credits relating to sales in current year	(369,869)	(353,629)	—	(70,752)	(794,250)
Payments/credits relating to sales in prior years	(172,656)	(18,041)	(15,484)	(13,488)	(219,669)
Ending balance — December 31, 2024	\$ 228,978	\$ 43,645	\$ 50,507	\$ 13,297	\$ 336,427

December 31, 2023					
(In thousands)	Contractual Adjustments ⁽¹⁾	Discounts ⁽²⁾	Product Returns	Other	Total
Beginning balance — December 31, 2022	\$ 226,741	\$ 26,175	\$ 29,666	\$ 7,938	\$ 290,520
Current provisions relating to sales in current year	509,780	326,860	33,417	71,449	941,506
Adjustments relating to prior years	(8,921)	—	2,841	—	(6,080)
Payments/credits relating to sales in current year	(308,353)	(293,785)	—	(56,224)	(658,362)
Payments/credits relating to sales in prior years	(184,833)	(30,560)	(24,860)	(12,999)	(253,252)
Ending balance — December 31, 2023	\$ 234,414	\$ 28,690	\$ 41,064	\$ 10,164	\$ 314,332

December 31, 2022					
(In thousands)	Contractual Adjustments ⁽¹⁾	Discounts ⁽²⁾	Product Returns	Other	Total
Beginning balance — December 31, 2021	\$ 209,760	\$ 24,150	\$ 24,313	\$ 9,585	\$ 267,808
Current provisions relating to sales in current year	434,143	281,308	15,851	58,788	790,090
Adjustments relating to prior years	(22,019)	—	3,294	—	(18,725)
Payments/credits relating to sales in current year	(237,521)	(252,896)	—	(48,834)	(539,251)
Payments/credits relating to sales in prior years	(157,622)	(26,387)	(13,792)	(11,601)	(209,402)
Ending balance — December 31, 2022	\$ 226,741	\$ 26,175	\$ 29,666	\$ 7,938	\$ 290,520

(1) "Contractual Adjustments" include "Medicaid Rebates" and "Medicare Part D" accruals
(2) "Discounts" include "Chargebacks" and "Product Discounts"

Total revenue-related reserves as of December 31, 2024 and 2023, included in our consolidated balance sheets, are summarized as follows:

(In thousands)	Year Ended December 31,	
	2024	2023
Reduction of accounts receivable	\$ 22,031	\$ 11,510
Components of accrued sales discounts, allowances and reserves	272,452	263,641
Components of other long-term liabilities	41,944	39,181
Total revenue-related reserves	\$ 336,427	\$ 314,332

Collaborative Arrangements

The Company has entered into collaborative arrangements with pharmaceutical companies including, among others, Janssen Pharmaceuticals, Inc. ("Janssen, Inc."), Janssen Pharmaceutica International, a division of Cilag International AG ("Janssen International"), and Janssen Pharmaceutica N.V. (together with Janssen, Inc., Janssen International and their affiliates, "Janssen") related to INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA®, INVEGA HAFYERA®/BYANLNI® (collectively, the "long-acting INVEGA products") and RISPERDAL CONSTA®, and Biogen International GmbH (together with its affiliates, "Biogen") related to VUMERITY®. Substantially all of the products developed under these arrangements are currently being marketed as approved products for which the Company received or receives payments for manufacturing services and/or royalties on net product sales.

Manufacturing Revenue

The Company recognizes manufacturing revenues from the sale of products it manufactures for resale by its licensees. Substantially all of the manufacturing revenues are recognized at a point in time when control of the product passes to the licensee. The sales price for certain of the Company's manufacturing revenues is based on the end-market sales price earned by its licensees. As end-market sales generally occur after the Company has recorded manufacturing revenue, the Company estimates the sales price for such products based on information supplied to it by the Company's licensees, its historical transaction experience and other third-party data. Differences between actual manufacturing revenues and estimated manufacturing revenues are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The differences between the Company's actual and estimated manufacturing revenues have not been material to date.

Royalty Revenue

The Company recognizes royalty revenues related to the sale by its licensees of products that incorporate the Company's technologies. All of the Company's royalties qualify for the sales-and-usage exemption under Topic 606 as (i) such royalties are based strictly on the sales-and-usage by the licensee; and (ii) a license of IP is the sole or predominant item to which such royalties relate. Based on this exemption, these royalties are earned in the period that the products are sold by the Company's licensee and the Company has a present right to payment.

Certain of the Company's royalty revenues are recognized by the Company based on information supplied to the Company by its licensees and require estimates to be made. Differences between actual royalty revenues and estimated royalty revenues are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The differences between the Company's actual and estimated royalty revenues have not been material to date.

Receivables, net

Receivables, net

Receivables, net, include amounts billed and amounts unbilled but currently unconditionally due from customers. The amounts due are stated at their net estimated realizable value. The Company's unbilled receivable balance was \$69.5 million and \$103.1 million at December 31, 2024 and 2023, respectively, and related primarily to royalty revenue. The Company maintains an allowance for doubtful accounts to provide for the estimated amounts of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable. The Company's allowance for doubtful accounts was approximately \$0.3 million and \$0.2 million at December 31, 2024 and 2023, respectively.

Contract Assets

Contract Assets

Contract assets include unbilled amounts that will result in a sale under certain of the Company's manufacturing contracts. The amounts included in the contract assets table below are classified as "Current assets" in the accompanying consolidated balance sheets, as they relate to manufacturing processes that are completed in ten days to eight weeks.

Contract assets consisted of the following:

(In thousands)	Contract Assets
Contract assets at January 1, 2023	\$ 8,929
Additions	13,606
Transferred to receivables, net	(21,829)
Contract assets at December 31, 2023	\$ 706
Additions	6,615
Transferred to receivables, net	(2,331)
Contract assets at December 31, 2024	\$ 4,990

Contract Liabilities

Contract Liabilities

Contract liabilities consist of contractual obligations related to deferred revenue. At December 31, 2024 and 2023, \$1.2 million and \$2.7 million of the contract liabilities, respectively, were classified as "Contract liabilities-short-term" in the accompanying consolidated balance sheets and none and \$2.1 million of the contract liabilities, respectively, were classified as "Other long-term liabilities" in the accompanying consolidated balance sheets.

Contract liabilities consisted of the following:

(In thousands)	Contract Liabilities
Contract liabilities at January 1, 2023	\$ 10,701
Additions	(931)
Amounts recognized into revenue	(4,995)
Contract liabilities at December 31, 2023	\$ 4,775
Additions	34
Amounts recognized into revenue	(3,560)
Contract liabilities at December 31, 2024	\$ 1,249

Foreign Currency

Foreign Currency

The Company's functional and reporting currency is the U.S. dollar. Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction. The resulting monetary assets and liabilities are translated into U.S. dollars at exchange rates prevailing on the subsequent balance sheet date. Gains and losses as a result of translation adjustments are recorded within "Other income (expense), net" in the accompanying consolidated statements of operations and comprehensive income (loss). During the years ended December 31, 2024, 2023 and 2022, the Company recorded losses of \$0.8 million and \$0.5 million and a gain of \$0.7 million, respectively, on foreign currency translation.

Concentrations

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk are receivables and marketable securities. Billings to large pharmaceutical companies and pharmaceutical wholesalers account for the majority of the Company's receivables, and collateral is not required from these customers. To mitigate credit risk, the Company monitors the financial performance and credit-worthiness of its customers. The following represents revenue and receivables from the Company's customers exceeding 10% of the total in each category as of, and for the years ended, December 31, 2024, 2023 and 2022:

Customer	Year Ended December 31,					
	2024		2023		2022	
	Receivables	Revenue	Receivables	Revenue	Receivables	Revenue
McKesson	36 %	25 %	14 %	14 %	12 %	16 %
Cencora	17 %	15 %	16 %	12 %	18 %	14 %
Cardinal Health	16 %	19 %	24 %	20 %	24 %	24 %
Janssen	14 %	17 %	23 %	31 %	*	15 %
Biogen	*	11 %	*	11 %	19 %	13 %

* Indicates the revenues or receivables for the customer did not exceed 10% of the Company's total in each category as of or for the years ended December 31, 2024, 2023 and 2022, as noted.

The Company holds its interest-bearing investments with major financial institutions and, in accordance with documented investment policies, the Company limits the amount of credit exposure to any one financial institution or corporate issuer. The Company's investment objectives are, first, to ensure liquidity and conservation of capital and, second, to generate investment income.

Geographic Information

Geographic Information

Company revenues by geographic location for the years ended December 31, 2024, 2023 and 2022, as determined by the location of the customer, are as follows:

(In thousands)	2024		Year Ended December 31, 2023		2022
Revenue by region:					
U.S.	\$	1,410,159	\$	1,491,939	\$ 931,991
Ireland		1,294		1,179	1,829
Rest of world		146,179		170,287	177,975

The location of the Company's assets are as follows:

(In thousands)	2024		December 31, 2023	
Assets by region:				
Current assets:				
U.S.:				
Cash and cash equivalents	\$	70,303	\$	317,850
Investments—short-term		203,631		187,574
Receivables, net		306,259		218,747
Other current assets		129,332		143,417
Ireland:				
Cash and cash equivalents	\$	220,843	\$	139,619
Investments—short-term		256,891		128,448
Receivables, net		78,269		113,730
Assets held for sale		—		94,260
Other current assets		149,827		141,861
Long-term assets:				
U.S.:				
Property, plant and equipment, net	\$	226,646	\$	225,578
Investments—long-term		24,629		17,957
Other		210,792		189,335
Ireland:				
Property, plant and equipment, net	\$	918	\$	1,365
Investments—long-term		48,519		21,930
Intangible assets, net and goodwill		83,917		85,018
Other		44,791		109,534

Research and Development Expenses

For each of its R&D programs, the Company incurs both external and internal expenses. External R&D expenses include fees related to clinical and preclinical activities performed by contract research organizations, consulting fees and costs related to laboratory services, purchases of drug product materials and third-party manufacturing development costs. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. The Company tracks external R&D expenses for each of its development programs, however, internal R&D expenses are not tracked by individual program as they benefit multiple development programs or the Company's products or technologies in general.

Selling, General and Administrative Expenses

Selling, general and administrative ("SG&A") expenses are primarily comprised of employee-related expenses associated with selling and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising, financial and legal expenses and other general and administrative costs.

Advertising costs are expensed as incurred. During the years ended December 31, 2024, 2023 and 2022, advertising costs totaled \$107.6 million, \$127.6 million and \$41.4 million, respectively.

Share-Based Compensation

The Company's share-based compensation programs permit grants of awards in the form of stock options and restricted stock unit awards ("RSUs"), which vest with the passage of time and/or based on the achievement of certain performance criteria. The Company issues new shares upon the exercise of stock options or the vesting of RSUs. Under the terms of the Company's stock option and incentive plans (the "Plans"), the Company's employees may, at the discretion of the plan administrator, become eligible in certain circumstances set forth in the Plans for accelerated vesting of certain awards granted to them under the Plans. In such circumstances, if there are no effective future service requirements for such employees, the remaining fair value of any such accelerated awards would be expensed as of the date of acceleration.

Time-Based Stock Options

Except as otherwise provided in the applicable Plan or award certificate, stock option grants to employees expire ten years from the date of grant and generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Except as otherwise provided in the applicable Plan or Award Certificate (as defined in the 2018 Plan): (i) annual stock option grants to non-employee directors expire ten years from the date of grant and generally vest over a one-year period; and (ii) stock option grants to new non-employee directors expire ten years from the date of grant and generally vest over a three-year period. The estimated fair value of options is recognized over the requisite service period, which is generally the vesting period. Share-based compensation expense is based on awards ultimately expected to vest. Forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates.

The fair value of stock option grants is based on estimates as of the date of grant using a Black-Scholes option valuation model. The Company uses historical data as the basis for estimating stock option terms and forfeitures. Separate groups of employees that have similar historical stock option exercise and forfeiture behavior are considered separately for valuation purposes. The ranges of expected terms disclosed below reflect different expected behavior among certain groups of employees. Expected stock volatility factors are based on a weighted average of implied volatilities from traded options of the Company's ordinary shares and historical share price volatility of the Company's ordinary shares, which is determined based on a review of the weighted average of historical weekly price changes of the Company's ordinary shares. The risk-free interest rate for periods commensurate with the expected term of the stock option is based on the U.S. treasury yield curve in effect at the time of grant. The dividend yield on the Company's ordinary shares is estimated to be zero as the Company has not paid dividends and does not expect to pay dividends in the near future. The exercise price of options granted is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant.

The fair value of each stock option granted was estimated on the grant date with the following weighted-average assumptions:

	2024		Year Ended December 31, 2023		2022
Expected option term	5 - 7 years		5 - 8 years		5 - 8 years
Expected stock volatility	38 % - 42 %		40 % - 44 %		43 % - 51 %
Risk-free interest rate	3.64 % - 4.60 %		3.34 % - 4.75 %		1.83 % - 4.26 %
Expected annual dividend yield	—		—		—

Time-Based Restricted Stock Unit Awards

Except as otherwise provided in the applicable Plan or award certificate, time-based RSUs awarded to employees generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Shares subject to these RSUs are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of time-based RSUs is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.

Performance-Based Restricted Stock Unit Awards

Performance-based RSUs awarded to employees vest upon the achievement of certain performance criteria, typically during or following the end of a specified performance period. The estimated fair value of these performance-based RSUs are generally based on the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant, unless the performance-based RSU is also subject to a market condition. In that case, the fair value of the performance-based RSU is based on a Monte Carlo simulation model. Compensation expense for performance-based RSUs is recognized from the date the Company determines the performance criteria probable of being achieved to the date the award, or relevant portion of the award, is expected to vest. Cumulative adjustments are recorded on a quarterly basis to reflect subsequent changes to the estimated outcome of the performance criteria until the date that the final outcome of the performance criteria is determined.

Income Taxes

Income Taxes

The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In evaluating the Company's ability to recover its deferred tax assets, the Company considers all available positive and negative evidence including its past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which the Company operates and its forecast of future taxable income. In determining future taxable income, the Company is responsible for assumptions utilized including the amount of Irish and non-Irish pre-tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company is using to manage the underlying business.

The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates its tax position on a quarterly basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.

Comprehensive Income (Loss)

Comprehensive Income (Loss)

Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized holding gains and losses on available-for-sale investments.

Earnings (Loss) Per Share

Basic earnings (loss) per ordinary share from continuing operations is calculated based upon net income (loss) from continuing operations available to holders of ordinary shares divided by the weighted average number of ordinary shares outstanding. Basic loss per ordinary share from discontinued operations is calculated based upon net loss from discontinued operations available to holders of ordinary shares, divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted earnings (loss) per ordinary share from continuing operations and discontinued operations, the Company utilizes the treasury stock method and adjusts the weighted average number of ordinary shares outstanding for the potential dilutive effect of outstanding ordinary share equivalents such as stock options and RSUs.

Segment Information

Segment Information

In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, *Segment Reporting: Improvements to Reportable Segment Disclosure* ("Topic 280") to establish standards for

reporting information about operating segments. Operating segments are defined as components of an enterprise engaging in business activities for which separate financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company has utilized the management approach to determine that the Company is managed as one segment on a consolidated basis and is the business of developing, manufacturing and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. The Company’s CODM, the Chairman and Chief Executive Officer, reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit. The CODM measures profitability on a reportable segment basis using net income (loss) and utilizes this information in allocating resources and in assessing performance by monitoring budget versus actual results. Please refer to Note 18, *Segment Reporting*, in these “Notes to Consolidated Financial Statements” in this Annual Report for further information.

Employee Benefit Plans

Employee Benefit Plans

401(k) Plan

The Company maintains a 401(k) retirement savings plan (the “401(k) Plan”), which covers all of its eligible U.S.-based employees. Eligible employees may contribute up to 100% of their eligible compensation, subject to certain Internal Revenue Service (“IRS”) limitations. The Company matches 100% of employee contributions up to the first 5% of employee pay, up to IRS limits. Employee and Company contributions are fully vested when made. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$15.1 million, \$15.0 million and \$14.4 million, respectively, to match employee deferrals under the 401(k) Plan.

Defined Contribution Plan

The Company maintains a defined contribution plan for its Ireland-based employees (the “Defined Contribution Plan”). The Defined Contribution Plan provides for eligible employees to contribute up to a maximum of 40%, depending upon their age, of their total taxable earnings subject to an earnings cap of €115,000. The Company provides a match of up to 18% of taxable earnings depending upon an individual’s contribution level. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$3.4 million, \$5.6 million and \$5.1 million, respectively, in contributions to the Defined Contribution Plan.

New Accounting Pronouncements

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes* (“Topic 740”): *Improvements to Income Tax Disclosures*, to enhance the transparency and decision usefulness of income tax disclosures in order to provide information to assist key stakeholders in better assessing how the Company’s operations and related tax risks and tax planning and operational opportunities affect the Company’s tax rate and prospects for future cash flows. This ASU becomes effective for public companies for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This guidance will be applied on a prospective basis. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, *Income Statement - Reporting Comprehensive Income-Expense Disaggregation Disclosures*, to improve disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly-presented expense captions, such as cost of sales, selling, general and administrative expenses, and research and development. All disclosure requirements under this guidance are required for public business entities and effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted and the amendments in this guidance will be applied prospectively to financial statements for periods after the effective dates. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures.

~~XML 47-R32.htm~~ IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

Accounting Policies [Abstract]

Schedule of Estimated Useful Life of Property, Plant and Equipment

Schedule of Provisions for Sales and Allowances

12 Months Ended

Dec. 31, 2024

Asset group	Term
Buildings and improvements	25 years
Furniture, fixtures and equipment	5 - 7 years
Leasehold improvements	Shorter of useful life or lease term

A rollforward of the Company’s provisions for sales and allowances is as follows:

December 31, 2024					
(In thousands)	Contractual Adjustments	Discounts ⁽¹⁾	Product Returns	Other	Total
Beginning balance — December 31, 2023	\$ 234,414	\$ 28,690	\$ 41,064	\$ 10,164	\$ 314,332
Current provisions relating to sales in current year	557,651	386,625	28,627	87,373	1,060,276
Adjustments relating to prior years	(20,562)	—	(3,700)	—	(24,262)
Payments/credits relating to sales in current year	(369,869)	(353,629)	—	(70,752)	(794,250)
Payments/credits relating to sales in prior years	(172,656)	(18,041)	(15,484)	(13,488)	(219,669)
Ending balance — December 31, 2024	\$ 228,978	\$ 43,645	\$ 50,507	\$ 13,297	\$ 336,427

December 31, 2023					
(In thousands)	Contractual Adjustments	Discounts ⁽²⁾	Product Returns	Other	Total
Beginning balance — December 31, 2022	\$ 226,741	\$ 26,175	\$ 29,666	\$ 7,938	\$ 290,520
Current provisions relating to sales in current year	509,780	326,860	33,417	71,449	941,506
Adjustments relating to prior years	(8,921)	—	2,841	—	(6,080)
Payments/credits relating to sales in current year	(308,353)	(293,785)	—	(56,224)	(658,362)
Payments/credits relating to sales in prior years	(184,833)	(30,560)	(24,860)	(12,999)	(253,252)
Ending balance — December 31, 2023	\$ 234,414	\$ 28,690	\$ 41,064	\$ 10,164	\$ 314,332

December 31, 2022					
(In thousands)	Contractual Adjustments	Discounts ⁽²⁾	Product Returns	Other	Total
Beginning balance — December 31, 2021	\$ 209,760	\$ 24,150	\$ 24,313	\$ 9,585	\$ 267,808
Current provisions relating to sales in current year	434,143	281,308	15,851	58,788	790,090
Adjustments relating to prior years	(22,019)	—	3,294	—	(18,725)
Payments/credits relating to sales in current year	(237,521)	(252,896)	—	(48,834)	(539,251)
Payments/credits relating to sales in prior years	(157,622)	(26,387)	(13,792)	(11,601)	(209,402)
Ending balance — December 31, 2022	\$ 226,741	\$ 26,175	\$ 29,666	\$ 7,938	\$ 290,520

- (1) “Contractual Adjustments” include “Medicaid Rebates” and “Medicare Part D” accruals
(2) “Discounts” include “Chargebacks” and “Product Discounts”

Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets

Total revenue-related reserves as of December 31, 2024 and 2023, included in our consolidated balance sheets, are summarized as follows:

(In thousands)	Year Ended December 31,	
	2024	2023
Reduction of accounts receivable	\$ 22,031	\$ 11,510
Components of accrued sales discounts, allowances and reserves	272,452	263,641
Components of other long-term liabilities	41,944	39,181
Total revenue-related reserves	\$ 336,427	\$ 314,332

Schedule of Contract Assets and Contract Liabilities

Contract assets consisted of the following:

(In thousands)	Contract Assets
Contract assets at January 1, 2023	\$ 8,929
Additions	13,606
Transferred to receivables, net	(21,829)
Contract assets at December 31, 2023	\$ 706
Additions	6,615
Transferred to receivables, net	(2,331)
Contract assets at December 31, 2024	\$ 4,990

Contract liabilities consisted of the following:

(In thousands)	Contract Liabilities
Contract liabilities at January 1, 2023	\$ 10,701
Additions	(931)
Amounts recognized into revenue	(4,995)
Contract liabilities at December 31, 2023	\$ 4,775
Additions	34
Amounts recognized into revenue	(3,560)
Contract liabilities at December 31, 2024	\$ 1,249

Schedule of Revenue and Receivables From Customers Exceeding 10% of Total in Each Category

The following represents revenue and receivables from the Company’s customers exceeding 10% of the total in each category as of, and for the years ended, December 31, 2024, 2023 and 2022:

Customer	Year Ended December 31,					
	2024		2023		2022	
	Receivables	Revenue	Receivables	Revenue	Receivables	Revenue

McKesson	36 %	25 %	14 %	14 %	12 %	16 %
Cencora	17 %	15 %	16 %	12 %	18 %	14 %
Cardinal Health	16 %	19 %	24 %	20 %	24 %	24 %
Janssen	14 %	17 %	23 %	31 %	*	15 %
Biogen	*	11 %	*	11 %	19 %	13 %
* Indicates the revenues or receivables for the customer did not exceed 10% of the Company's total in each category as of or for the years ended December 31, 2024, 2023 and 2022, as noted.						

Schedule of Revenues by Geographic Location, as Determined by the Location of the Customer

Company revenues by geographic location for the years ended December 31, 2024, 2023 and 2022, as determined by the location of the customer, are as follows:

(In thousands)	Year Ended December 31,		
	2024	2023	2022
Revenue by region:			
U.S.	\$ 1,410,159	\$ 1,491,939	\$ 931,991
Ireland	1,294	1,179	1,829
Rest of world	146,179	170,287	177,975

Summary of Location of the Assets

The location of the Company's assets are as follows:

(In thousands)	December 31,	
	2024	2023
Assets by region:		
Current assets:		
U.S.:		
Cash and cash equivalents	\$ 70,303	\$ 317,850
Investments—short-term	203,631	187,574
Receivables, net	306,259	218,747
Other current assets	129,332	143,417
Ireland:		
Cash and cash equivalents	\$ 220,843	\$ 139,619
Investments—short-term	256,891	128,448
Receivables, net	78,269	113,730
Assets held for sale	—	94,260
Other current assets	149,827	141,861
Long-term assets:		
U.S.:		
Property, plant and equipment, net	\$ 226,646	\$ 225,578
Investments—long-term	24,629	17,957
Other	210,792	189,335
Ireland:		
Property, plant and equipment, net	\$ 918	\$ 1,365
Investments—long-term	48,519	21,930
Intangible assets, net and goodwill	83,917	85,018
Other	44,791	109,534

Schedule of Fair Value of Each Stock Option Granted Estimated on The Grant Date Using Weighted-average Assumptions

The fair value of each stock option granted was estimated on the grant date with the following weighted-average assumptions:

	Year Ended December 31,		
	2024	2023	2022
Expected option term	5 - 7 years	5 - 8 years	5 - 8 years
Expected stock volatility	38 % - 42 %	40 % - 44 %	43 % - 51 %
Risk-free interest rate	3.64 % - 4.60 %	3.34 % - 4.75 %	1.83 % - 4.26 %
Expected annual dividend yield	—	—	—

~~***XML 48 R33.htm IDEA: XBRL DOCUMENT***~~

Discontinued Operations (Tables)
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Transfer of Assets and Liabilities Effected in Accordance with Separation Agreements

12 Months Ended
Dec. 31, 2024

The transfer of assets and liabilities to Mural was effected through a contribution in accordance with the separation agreement, as summarized below:

(In thousands)	ASSETS	November 15, 2023
Current Assets:		
Cash and cash equivalents	\$ 275,000	
Total current assets	275,000	
Property, plant and equipment, net	10,096	
Right-of-use assets	14,513	
Goodwill	7,800	
Deferred tax asset	1,799	
Total assets	\$ 309,208	
LIABILITIES		
Current Liabilities:		
Operating lease liabilities—short-term	\$ 6,036	
Total current liabilities	6,036	
Operating lease liabilities—long-term	9,412	
Total liabilities	15,448	
Net assets transferred to Mural	\$ 293,760	

Summary of Discontinued Operations

The following table summarizes expenses of the discontinued operations for the years ended December 31, 2024, 2023 and 2022:

(In thousands)	Year Ended December 31,		
	2024	2023	2022
Operating expenses from discontinued operations			
Cost of goods manufactured	\$ —	\$ 39	\$ 40
Research and development	5,790	116,177	121,140
Selling, general and administrative	—	48,587	14,996
Total operating expenses from discontinued operations	5,790	164,803	136,176
Operating loss from discontinued operations	(5,790)	(164,803)	(136,176)
Income tax benefit from discontinued operations	(722)	(1,403)	(11,061)
Net loss and comprehensive loss from discontinued operations	\$ (5,068)	\$ (163,400)	\$ (125,115)

Summary of Significant Non-cash Items and Capital Expenditures of Discontinued Operations

The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2023 and 2022:

(In thousands)	Year Ended December 31,	
	2023	2022
OPERATING ACTIVITIES:		
Depreciation	\$ 2,319	\$ 1,539
Share-based compensation expense	8,188	6,577
Right-of-use assets	3,803	5,909
Operating lease liabilities	(3,938)	(5,920)
INVESTING ACTIVITIES:		
Additions of property, plant and equipment	\$ (1,798)	\$ (5,510)

~~***XML 49 R34.htm IDEA: XBRL DOCUMENT***~~

Revenue from Contracts with Customers (Tables)
Product sales, net
Schedule of Disaggregation of Revenues

12 Months Ended
Dec. 31, 2024

During the years ended December 31, 2024, 2023 and 2022, the Company recorded product sales, net, as follows:

(In thousands)	Year Ended December 31,		
	2024	2023	2022
VIVITROL	\$ 457,315	\$ 400,419	\$ 379,478
ARISTADA and ARISTADA INITIO	346,187	327,690	302,052
LYBALVI	280,032	191,889	96,022
Total product sales, net	\$ 1,083,534	\$ 919,998	\$ 777,552

Manufacturing and royalty revenues
Schedule of Disaggregation of Revenues

During the years ended December 31, 2024, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

	Year Ended December 31, 2024	
	Manufacturing	Royalty

(In thousands)	Revenue	Revenue	Total
Long-acting INVEGA products ⁽¹⁾	\$ —	\$ 236,386	\$ 236,386
VUMERITY	39,292	94,755	134,047
RISPERDAL CONSTA	23,172	272	23,444
Other	56,962	23,256	80,218
	<u>\$ 119,426</u>	<u>\$ 354,669</u>	<u>\$ 474,095</u>

(In thousands)	Year Ended December 31, 2023		
	Manufacturing Revenue	Royalty Revenue	Total
Long-acting INVEGA products ⁽¹⁾	\$ —	\$ 486,101	\$ 486,101
VUMERITY	42,886	86,440	129,326
RISPERDAL CONSTA	36,123	1,153	37,276
Other	63,489	27,196	90,685
	<u>\$ 142,498</u>	<u>\$ 600,890</u>	<u>\$ 743,388</u>

(In thousands)	Year Ended December 31, 2022		
	Manufacturing Revenue	Royalty Revenue	Total
Long-acting INVEGA products ⁽¹⁾	\$ —	\$ 115,655	\$ 115,655
VUMERITY	32,493	83,003	115,496
RISPERDAL CONSTA	42,670	7,243	49,913
Other	37,211	13,708	50,919
	<u>\$ 112,374</u>	<u>\$ 219,609</u>	<u>\$ 331,983</u>

(1) "long-acting INVEGA products": INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).

XML 50 R35.htm IDEA: XBRL DOCUMENT

Investments (Tables)

[Investments, Debt and Equity Securities \[Abstract\]](#)
[Schedule of Investments](#)

**12 Months Ended
Dec. 31, 2024**

Investments consist of the following:

			Gross Unrealized Losses		Estimated Fair Value
			Less than One Year	Greater than One Year	
December 31, 2024	Amortized Cost	Gains			
Short-term investments:					
Available-for-sale securities:					
U.S. government and agency debt securities	\$ 266,506	\$ 763	\$ (58)	\$ (6)	\$ 267,205
Corporate debt securities	192,617	762	(58)	(4)	193,317
Total short-term investments	459,123	1,525	(116)	(10)	460,522
Long-term investments:					
Available-for-sale securities:					
U.S. government and agency debt securities	48,856	—	—	(179)	48,677
Corporate debt securities	24,484	—	—	(158)	24,326
	73,340	—	—	(337)	73,003
Held-to-maturity securities:					
Certificates of deposit	145	—	—	—	145
Total long-term investments	73,485	—	—	(337)	73,148
Total investments	\$ 532,608	\$ 1,525	\$ (116)	\$ (347)	\$ 533,670

December 31, 2023					
Short-term investments:					
Available-for-sale securities:					
U.S. government and agency debt securities	\$ 199,708	\$ 758	\$ (36)	\$ (611)	\$ 199,819
Corporate debt securities	112,055	703	(15)	(536)	112,207
Non-U.S. government debt securities	4,004	—	—	(8)	3,996
Total short-term investments	315,767	1,461	(51)	(1,155)	316,022
Long-term investments:					
Available-for-sale securities:					
U.S. government and agency debt securities	19,392	—	(27)	(315)	19,050
Corporate debt securities	19,306	—	—	(289)	19,017
	38,698	—	(27)	(604)	38,067
Held-to-maturity securities:					
Certificates of deposit	1,820	—	—	—	1,820
Total long-term investments	40,518	—	(27)	(604)	39,887
Total investments	\$ 356,285	\$ 1,461	\$ (78)	\$ (1,759)	\$ 355,909

Realized gains and losses on the sales and maturities of investments, which were identified using the specific identification method, were as follows:

(In thousands)	Year Ended December 31,		
	2024	2023	2022
Proceeds from the sales and maturities of investments	\$ 310,286	\$ 355,522	\$ 281,627
Realized gains	\$ —	\$ —	\$ —
Realized losses	\$ —	\$ —	\$ 529

The Company's available-for-sale and held-to-maturity securities at December 31, 2024 had contractual maturities in the following periods:

(In thousands)	Available-for-sale		Held-to-maturity	
	Amortized Cost	Estimated Fair Value	Amortized Cost	Estimated Fair Value
Within 1 year	\$ 324,897	\$ 325,566	\$ 145	\$ 145
After 1 year through 5 years	207,566	207,959	—	—
Total	<u>\$ 532,463</u>	<u>\$ 533,525</u>	<u>\$ 145</u>	<u>\$ 145</u>

XML 51 R36.htm IDEA: XBRL DOCUMENT

Fair Value (Tables)

[Fair Value Disclosures \[Abstract\]](#)
[Summary of the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis](#)

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy and the valuation techniques the Company utilized to determine such fair value:

(In thousands)	December 31, 2024	Level 1	Level 2	Level 3
Assets:				
Cash equivalents	\$ 8,388	\$ 8,388	\$ —	\$ —
U.S. government and agency debt securities	315,882	265,090	50,792	—
Corporate debt securities	217,643	—	217,643	—
Total	<u>\$ 541,913</u>	<u>\$ 273,478</u>	<u>\$ 268,435</u>	<u>\$ —</u>

(In thousands)	December 31, 2023	Level 1	Level 2	Level 3
Assets:				
Cash equivalents	\$ 34,316	\$ 34,316	\$ —	\$ —
U.S. government and agency debt securities	218,869	181,041	37,828	—
Corporate debt securities	131,224	—	131,224	—
Non-U.S. government debt securities	<u>3,996</u>	<u>—</u>	<u>3,996</u>	<u>—</u>
Total	<u>\$ 388,405</u>	<u>\$ 215,357</u>	<u>\$ 173,048</u>	<u>\$ —</u>

XML 52 R37.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

[Inventory Disclosure \[Abstract\]](#)
[Schedule of Inventories](#)

**12 Months Ended
Dec. 31, 2024**

Inventory consists of the following:

(In thousands)	December 31, 2024	December 31, 2023
Raw materials	\$ 72,139	\$ 71,416
Work in process	79,871	68,843
Finished goods ⁽¹⁾	<u>30,877</u>	<u>46,147</u>
Total inventory	<u>\$ 182,887</u>	<u>\$ 186,406</u>

(1) At December 31, 2024 and 2023, the Company had \$22.7 million and \$33.9 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider.

[XML 53 R38.htm IDEA: XBRL DOCUMENT](#)

Property, Plant and Equipment (Tables)
[Property, Plant and Equipment \[Abstract\]](#)
[Schedule of Property, Plant and Equipment](#)

12 Months Ended
Dec. 31, 2024

Property, plant and equipment consists of the following:

(In thousands)	December 31, 2024	December 31, 2023 ⁽¹⁾
Land	\$ 957	\$ 957
Building and improvements	134,699	132,735
Furniture, fixtures and equipment	244,113	237,728
Leasehold improvements	42,416	39,893
Construction in progress	58,391	45,791
Subtotal	480,576	457,104
Less: accumulated depreciation	(253,012)	(230,161)
Total property, plant and equipment, net	\$ 227,564	\$ 226,943

(1) In connection with the sale of the Athlone Facility, \$92.2 million of the Company's property, plant and equipment was classified as "Assets held for sale" in the accompanying consolidated balance sheet at December 31, 2023 and was not included in these amounts.

[XML 54 R39.htm IDEA: XBRL DOCUMENT](#)

Intangible Assets and Goodwill (Tables)
[Goodwill and Intangible Assets Disclosure \[Abstract\]](#)
[Schedule of Goodwill and Intangible Assets](#)

12 Months Ended
Dec. 31, 2024

Intangible assets and goodwill consists of the following:

(In thousands)	Weighted Amortizable Life (Years)	December 31, 2024			December 31, 2023		
		Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Goodwill		\$ 83,027	\$ —	\$ 83,027	\$ 83,027	\$ —	\$ 83,027
Finite-lived intangible assets:							
Collaboration agreements	12	\$ 465,590	\$ (465,590)	\$ —	\$ 465,590	\$ (465,590)	\$ —
Capitalized IP	11-13	118,160	(117,270)	890	118,160	(116,169)	1,991
Total		\$ 583,750	\$ (582,860)	\$ 890	\$ 583,750	\$ (581,759)	\$ 1,991

[XML 55 R40.htm IDEA: XBRL DOCUMENT](#)

Leases (Tables)
[Leases \[Abstract\]](#)

12 Months Ended
Dec. 31, 2024

[Summary of Future Lease Payments Under Non-Cancelable Leases](#)

Future lease payments under non-cancelable leases as of December 31, 2024 consisted of the following:

(In thousands)	December 31, 2024
2025	10,189
2026	10,259
2027	9,505
2028	9,574
Thereafter	59,695
Total operating lease payments	\$ 99,222
Less: imputed interest	(23,684)
Total operating lease liabilities	\$ 75,538

[XML 56 R41.htm IDEA: XBRL DOCUMENT](#)

Accounts Payable and Accrued Expenses (Tables)
[Payables and Accruals \[Abstract\]](#)
[Schedule of Accounts Payable and Accrued Expenses](#)

12 Months Ended
Dec. 31, 2024

Accounts payable and accrued expenses consists of the following:

(In thousands)	December 31, 2024	December 31, 2023
Accounts payable	\$ 45,630	\$ 65,649
Accrued compensation	70,960	83,107
Accrued other	68,742	91,805
Total accounts payable and accrued expenses	\$ 185,332	\$ 240,561

[Summary of Current Provision for Sales, Discounts, Allowances and Reserves](#)

A summary of the Company's current provision for sales discounts, allowances and reserves is as follows:

(In thousands)	December 31, 2024	December 31, 2023
Medicaid rebates	\$ 202,044	\$ 213,845
Product discounts	19,351	15,121
Medicare Part D	26,933	20,569
Other	24,124	14,106
Total accrued sales discounts, allowances and reserves	\$ 272,452	\$ 263,641

[XML 57 R42.htm IDEA: XBRL DOCUMENT](#)

Long-term Debt (Tables)
[Debt Disclosure \[Abstract\]](#)
[Schedule of Long-term Debt](#)

12 Months Ended
Dec. 31, 2024

As of December 31, 2024 and 2023, long-term debt consisted of the following:

(In thousands)	December 31, 2024	December 31, 2023
Former Term Loans (due March 12, 2026)	\$ —	\$ 290,730
Less: current portion	—	(3,000)
Long-term debt	\$ —	\$ 287,730

[XML 58 R43.htm IDEA: XBRL DOCUMENT](#)

Earnings (Loss) Per Share (Tables)
[Earnings Per Share \[Abstract\]](#)
[Schedule of Basic Earnings \(Loss\) Per Ordinary Share](#)

12 Months Ended
Dec. 31, 2024

(In thousands)	Year Ended December 31,		
	2024	2023	2022 ⁽¹⁾
Numerator:			
Net income (loss) from continuing operations	\$ 372,138	\$ 519,157	\$ (33,152)
Net loss from discontinued operations	(5,068)	(163,400)	(125,115)
Net income (loss)	\$ 367,070	\$ 355,757	\$ (158,267)
Denominator:			
Weighted average number of ordinary shares outstanding	165,392	166,223	163,742
Effect of dilutive securities:			
Stock options	1,377	1,093	—
Restricted stock unit awards	2,429	2,414	—
Dilutive ordinary share equivalents	3,806	3,507	—
Shares used in calculating diluted earnings (loss) per ordinary share	169,198	169,730	163,742

(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

[Schedule of Anti-Dilutive Potential Common Share Equivalent Excluded from Calculation of Earnings \(Loss\) Per Share](#)

The following potential ordinary share equivalents were not included in the net income (loss) per share calculation because the effect would have been anti-dilutive:

(In thousands)	Year Ended December 31,		
	2024	2023	2022 ⁽¹⁾
Stock options	11,517	12,422	12,777
Restricted stock unit awards	2,391	2,378	5,040
Total	13,908	14,800	17,817

(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

[XML 59 R44.htm IDEA: XBRL DOCUMENT](#)

Share-based Compensation (Tables)

12 Months Ended Dec. 31, 2024

[Schedule of Share-based Compensation Expense from Continuing and Discontinued Operations](#)

The following table presents share-based compensation expense from continuing and discontinued operations included in the Company's consolidated statements of operations and comprehensive income (loss):

(In thousands)	Year Ended December 31,		
	2024	2023	2022
Cost of goods manufactured and sold	\$ 5,798	\$ 11,353	\$ 10,284
Research and development	28,085	25,753	23,289
Selling, general and administrative	62,754	55,611	54,104
Share-based compensation expense from continuing operations	96,637	92,717	87,677
Cost of goods manufactured and sold	—	—	—
Research and development	—	3,255	4,652
Selling, general and administrative	—	4,933	1,925
Share-based compensation expense from discontinued operations	—	8,188	6,577
Total share-based compensation expense	\$ 96,637	\$ 100,905	\$ 94,254

A summary of stock option activity is presented in the following table:

	Number of Shares	Weighted Average Exercise Price
Outstanding, January 1, 2024	18,139,903	\$ 32.28
Granted	2,615,357	\$ 29.48
Exercised	(1,328,189)	\$ 20.76
Expired	(1,427,409)	\$ 46.72
Forfeited	(521,043)	\$ 26.65
Outstanding, December 31, 2024	17,478,619	\$ 31.73
Exercisable, December 31, 2024	10,979,663	\$ 34.53

[Time-based RSU Awards](#) [Summary of RSU Activity](#)

A summary of time-based RSU activity is presented in the following table:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested, January 1, 2024	5,657,578	\$ 24.18
Granted	2,260,345	\$ 29.51
Forfeited	(775,415)	\$ 26.43
Vested	(2,237,302)	\$ 23.05
Unvested, December 31, 2024	4,905,206	\$ 26.80

[Performance-based RSUs Awards](#) [Summary of RSU Activity](#)

A summary of performance-based RSU activity is presented in the following table:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested, January 1, 2024	1,546,357	\$ 27.95
Granted	498,120	\$ 32.46
Forfeited	(172,576)	\$ 25.88
Vested	(536,243)	\$ 22.21
Unvested, December 31, 2024	1,335,658	\$ 32.13

[XML 60 R45.htm IDEA: XBRL DOCUMENT](#)

Income Taxes (Tables)

12 Months Ended Dec. 31, 2024

[Income Tax Disclosure \[Abstract\]](#) [Schedule of Provision \(Benefit\) for Income Taxes from Continuing Operations](#)

The Company's provision (benefit) for income taxes from continuing operations consists of the following:

(In thousands)	Year Ended December 31,		
	2024	2023	2022 ⁽¹⁾
Current income tax provision (benefit):			
U.S. federal	\$ 25,640	\$ (981)	\$ 11,169
U.S. state	4,259	722	4,401
Ireland	1,192	—	—
Deferred income tax provision (benefit):			
U.S. federal	(19,870)	10,192	(10,536)
U.S. state	(1,392)	(507)	(3,010)
Ireland	61,783	(107,064)	—
Total tax provision (benefit)	\$ 71,612	\$ (97,638)	\$ 2,024

(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The distribution of the Company's income (loss) before the provision (benefit) for income taxes by geographical area consists of the following:

(In thousands)	Year Ended December 31,		
	2024	2023	2022 ⁽¹⁾
Ireland	\$ 440,674	\$ 411,767	\$ (32,198)
U.S.	3,076	9,752	1,070
Income (loss) from continuing operations before provision (benefit) for income taxes	\$ 443,750	\$ 421,519	\$ (31,128)

(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The components of the Company's net deferred tax assets consist of the following:

	December 31, 2024	December 31, 2023
(In thousands)		
Deferred tax assets:		
Net operating loss carryforwards	\$ 80,209	\$ 195,658
Research and development expenses	71,167	49,206
Accrued expenses and reserves	41,189	37,367
Operating lease liabilities	17,537	18,716
Share-based compensation	33,773	37,727
Tax credits	26,882	27,116
Other	3,695	5,582
Less: valuation allowance	(79,727)	(129,296)
Total deferred tax assets	194,725	242,076
Deferred tax liabilities:		
Property, plant and equipment	(21,917)	(26,271)
Right-of-use assets	(16,337)	(17,748)
Other	(1,940)	(2,716)
Total deferred tax liabilities	(40,194)	(46,735)
Net deferred tax assets	\$ 154,531	\$ 195,341

The activity in the valuation allowance associated with deferred taxes consists of the following:

(In thousands)	Balance at Beginning of Period ⁽¹⁾	(Additions) / Reductions ⁽²⁾	Balance at End of Period ⁽¹⁾
Deferred tax asset valuation allowance for the year ended December 31, 2022	\$ (249,112)	\$ (22,405)	\$ (271,517)
Deferred tax asset valuation allowance for the year ended December 31, 2023	\$ (271,517)	\$ 142,221	\$ (129,296)
Deferred tax asset valuation allowance for the year ended December 31, 2024	\$ (129,296)	\$ 49,569	\$ (79,727)

(1) Inclusive of continuing and discontinued operations for the periods prior to the Separation in November 2023.

(2) (Additions) reductions represent continuing and discontinued operations for the periods prior to the Separation in November 2023. The reductions during the year ended December 31, 2024 primarily relate to the

(17) (continued) reductions represent continuing and discontinued operations for the periods prior to the Separation in November 2023. The reductions during the year ended December 31, 2024 primarily relate to the abandonment of certain Irish NOLs following the sale of the Athlone Facility to Novo. These NOLs were transferred from Elan Corporation, plc as part of the combination of the drug technology business of Elan Corporation, plc with the business of Alkermes, Inc. A number of restrictions applied to these NOLs thereby restricting the Company's ability to utilize such NOLs. Following the sale of the Athlone Facility, the Company believes that its ability to utilize these NOLs is remote. The reduction during the year ended December 31, 2023 primarily relates to the partial release of the valuation allowance maintained by the Company against certain Irish net deferred tax assets. The additions in 2022 relate primarily to Irish NOLs.

Schedule of
Reconciliation of
Statutory Tax Rate to
Effective Tax Rate

A reconciliation of the Company's statutory tax rate to its effective tax rate is as follows:

(In thousands, except percentage amounts)	Year Ended December 31,					
	2024		2023		2022 ⁽¹⁾	
Statutory tax rate	12.5	%	12.5	%	12.5	%
Income (loss) from continuing operations before income taxes at statutory rate	\$	55,469	\$	52,690	\$	(3,891)
Share-based compensation		5,607		4,177		4,347
Foreign rate differential ⁽²⁾		4,844		4,701		521
Change in valuation allowance		(49,517)		(142,424)		1,102
Intercompany amounts ⁽³⁾		708		(16,551)		(1,694)
Irish rate differential ⁽⁴⁾		5,798		235		4,926
Uncertain tax positions		(667)		(234)		602
Non-deductible lobbying expenses		767		705		775
U.S. state income taxes, net of U.S. federal benefit		2,802		347		1,272
Foreign derived intangible income		(281)		—		(4,530)
R&D credit		(7,815)		(2,823)		(2,531)
Abandonment of NOLs ⁽⁵⁾		49,897		—		—
Other permanent items ⁽⁶⁾		4,000		1,539		1,125
Income tax provision (benefit)	\$	71,612	\$	(97,638)	\$	2,024
Effective tax rate	16.1	%	(23.2)	%	(6.5)	%
(1)	Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.					
(2)	Represents income or losses of U.S. subsidiaries, subject to tax at a rate other than the Irish statutory rate.					
(3)	Intercompany amounts include cross-territory eliminations, the pre-tax effect of which has been eliminated in arriving at the Company's consolidated income (loss) before taxes from continuing operations. In 2023, this included a tax benefit of \$15.7 million related to the intercompany transfer of inventory that was owned by the Company at December 31, 2023.					
(4)	Represents income or losses of Irish companies subject to tax at a rate other than the Irish statutory rate.					
(5)	Represents the tax effect of the abandonment of Irish NOLs following the sale of the Athlone Facility to Novo.					
(6)	Other permanent items include, but are not limited to, non-deductible meals and entertainment expenses and non-deductible compensation of senior officers of the Company. For the year ended December 31, 2024, permanent items also included amounts relating to the sale of the Athlone Facility.					

Schedule of
Reconciliation of
Beginning and Ending
Amount of
Unrecognized Tax
Benefits

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

(In thousands)	Unrecognized Tax Benefits
Balance, December 31, 2021	\$ 8,372
Reductions based on the lapse of applicable statutes of limitations	(438)
Additions based on tax positions related to prior periods	449
Additions based on tax positions related to the current period	590
Balance, December 31, 2022	\$ 8,973
Reductions based on the lapse of applicable statutes of limitations	(1,073)
Additions based on tax positions related to the prior period	281
Additions based on tax positions related to the current period	558
Balance, December 31, 2023	\$ 8,739
Reductions based on the lapse of applicable statutes of limitations	(1,306)
Additions based on tax positions related to the prior period	59
Additions based on tax positions related to the current period	581
Balance, December 31, 2024	\$ 8,073

XML 61 R46.htm IDEA: XBRL DOCUMENT

Segment Reporting
(Tables)

12 Months Ended
Dec. 31, 2024

Segment Reporting [Abstract]
Summary of Significant Segment
Expenses

The Company's significant segment expenses are as follows:

(In thousands)	Year Ended December 31,		
	2024	2023	2022
REVENUES:			
Total revenue	\$ 1,557,632	\$ 1,663,405	\$ 1,111,795
EXPENSES:			
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	245,331	253,037	218,068
External R&D expenses:			
Development programs:			
ALKS 2680	45,947	31,321	15,715
LYBALVI	18,737	15,379	23,056
Other external R&D expenses	36,627	51,668	57,423
Total external R&D expenses	101,311	98,368	96,194
Internal R&D expenses:			
Employee-related	114,496	128,282	129,735
Occupancy	11,206	12,299	12,449
Depreciation	5,701	9,578	10,708
Other internal R&D expenses	12,612	22,279	23,616
Total internal R&D expenses	144,015	172,438	176,508
R&D expenses	245,326	270,806	272,702
Selling, general and administrative expenses:			
Selling and marketing expense	446,214	490,154	392,211
General and administrative expense	199,024	199,597	198,540
Total selling, general and administrative expense	645,238	689,751	590,751
Other segment (expenses) income ⁽¹⁾	(49,599)	69,346	(63,426)
NET INCOME (LOSS) FROM CONTINUING OPERATIONS	372,138	519,157	(33,152)
LOSS ON DISCONTINUED OPERATIONS, NET OF TAX	(5,068)	(163,400)	(125,115)
NET INCOME (LOSS)	\$ 367,070	\$ 355,757	\$ (158,267)
(1)	"Other segment (expenses) income" during the years ended December 31, 2024, 2023 and 2022 includes "Amortization of acquired intangible assets", "Other income (loss), net" and "Income tax provision (benefit)".		

XML 62 R47.htm IDEA: XBRL DOCUMENT

Description of
Business and Basis of
Presentation -
Additional
Information (Details)
\$ / shares in Units, \$
in Millions

1 Months Ended

12 Months Ended

Nov. 30, 2023
\$ / shares

Dec. 31, 2024
USD (\$)
\$ / shares
Dec. 31, 2023
\$ / shares

Collaborative Arrangement and Arrangement Other than
Collaborative [Line Items]

Ordinary shares, par value (in dollars per share) | \$ / shares \$ 0.01
Procceds from sale of development and manufacturing facility
Gain on sale of assets
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal,
Statement of Income or Comprehensive Income [Extensible Enumeration]

\$ 0.01
\$ 97.9
\$ 1.5
Other
Nonoperating
Income (Expense)

Stock distribution by separation of business

Company's shareholders received one ordinary share, nominal value \$0.01 per share, of Mural for every ten ordinary shares, par value \$0.01 per share, of the Company 10

Stock distribution ratio by means of separation of business
Facility and Certain Related Assets [Member]

Collaborative Arrangement and Arrangement Other than
Collaborative [Line Items]

\$ 91.0

Procceds from sale of development and manufacturing facility
Mural Oncology plc [Member]

Collaborative Arrangement and Arrangement Other than
Collaborative [Line Items]

Ordinary shares, par value (in dollars per share) | \$ / shares

\$ 0.01

XML 63 R48.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details)	12 Months Ended		
Buildings and improvements			
Property Plant And Equipment [Line Items]			
Estimated useful life	25 years		
Furniture, fixtures and equipment Minimum			
Property Plant And Equipment [Line Items]			
Estimated useful life	5 years		
Furniture, fixtures and equipment Maximum			
Property Plant And Equipment [Line Items]			
Estimated useful life	7 years		
Leasehold improvements			
Property Plant And Equipment [Line Items]			
Estimated useful life	Shorter of useful life or lease term		
Property. Plant. and Equipment. Useful Life. Term. Description [Extensible Enumeration]	us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember		

XML 64 R49.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Provisions for Sales and Allowances (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Summary Of Significant Accounting Policies [Line Items]			
Beginning balance	\$ 314,332	\$ 290,520	\$ 267,808
Current provisions relating to sales in current year	1,060,276	941,506	790,090
Adjustments relating to prior years	(24,262)	(6,080)	(18,725)
Payments/credits relating to sales in current year	(794,250)	(658,362)	(539,251)
Payments/credits relating to sales in prior years	(219,669)	(253,252)	(209,402)
Ending Balance	336,427	314,332	290,520
Contractual Adjustments			
Summary Of Significant Accounting Policies [Line Items]			
Beginning balance	[1] 234,414	226,741	209,760
Current provisions relating to sales in current year	[1] 557,651	509,780	434,143
Adjustments relating to prior years	[1] (20,562)	(8,921)	(22,019)
Payments/credits relating to sales in current year	[1] (369,869)	(308,353)	(237,521)
Payments/credits relating to sales in prior years	[1] (172,656)	(184,833)	(157,622)
Ending Balance	[1] 228,978	234,414	226,741
Discounts			
Summary Of Significant Accounting Policies [Line Items]			
Beginning balance	[2] 28,690	26,175	24,150
Current provisions relating to sales in current year	[2] 386,625	326,860	281,308
Payments/credits relating to sales in current year	[2] (353,629)	(293,785)	(252,896)
Payments/credits relating to sales in prior years	[2] (18,041)	(30,560)	(26,387)
Ending Balance	[2] 43,645	28,690	26,175
Product Returns			
Summary Of Significant Accounting Policies [Line Items]			
Beginning balance	41,064	29,666	24,313
Current provisions relating to sales in current year	28,627	33,417	15,851
Adjustments relating to prior years	(3,700)	2,841	3,294
Payments/credits relating to sales in prior years	(15,484)	(24,860)	(13,792)
Ending Balance	50,507	41,064	29,666
Other			
Summary Of Significant Accounting Policies [Line Items]			
Beginning balance	10,164	7,938	9,585
Current provisions relating to sales in current year	87,373	71,449	58,788
Payments/credits relating to sales in current year	(70,752)	(56,224)	(48,834)
Payments/credits relating to sales in prior years	(13,488)	(12,999)	(11,601)
Ending Balance	\$ 13,297	\$ 10,164	\$ 7,938
[1] "Contractual Adjustments" include "Medicaid Rebates" and "Medicare Part D" accruals			
[2] "Discounts" include "Chargebacks" and "Product Discounts"			

XML 65 R50.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021			
Summary Of Significant Accounting Policies [Line Items]				
Revenue-related reserves	\$ 336,427	\$ 314,332	\$ 290,520	\$ 267,808
Reduction of Accounts Receivable				
Summary Of Significant Accounting Policies [Line Items]				
Revenue-related reserves	22,031	11,510		
Components of Accrued Sales Discounts, Allowances and Reserves				
Summary Of Significant Accounting Policies [Line Items]				
Revenue-related reserves	272,452	263,641		
Components of Other Long-term Liabilities				
Summary Of Significant Accounting Policies [Line Items]				
Revenue-related reserves	\$ 41,944	\$ 39,181		

XML 66 R51.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended			
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
	USD (\$)	EUR (€)	USD (\$)	USD (\$)
Summary Of Significant Accounting Policies [Line Items]				
Actual credits received related to duplicate billings	\$ 8,700,000			
Unbilled receivable	69,500,000		\$ 103,100,000	

Allowance for doubtful accounts	300,000		200,000	
Contract liabilities	1,249,000		4,775,000	\$ 10,701,000
Gain (loss) on foreign currency translation	\$ (800,000)		\$ (500,000)	\$ 700,000
Threshold percentage for disclosure of revenue and receivables	10.00%	10.00%	10.00%	10.00%
Advertising Expense	\$ 107,600,000		\$ 127,600,000	\$ 41,400,000
Share-based compensation expense	\$ 96,637,000		100,905,000	94,254,000
401 (K) Plan				
Summary Of Significant Accounting Policies [Line Items]				
Employee contribution limit as a percentage of their eligible compensation	100.00%	100.00%		
Percentage of employer contribution matched of the first employee pay	100.00%	100.00%		
Maximum employee contribution limit as a percentage of their total taxable earnings	5.00%	5.00%		
Employer contribution	\$ 15,100,000		15,000,000	14,400,000
Defined Contribution Plan				
Summary Of Significant Accounting Policies [Line Items]				
Maximum employee contribution limit as a percentage of their total taxable earnings	40.00%	40.00%		
Employer contribution	\$ 3,400,000		5,600,000	\$ 5,100,000
Per employee contribution limit £		€ 115,000		
Maximum percentage of employer contribution matched of employee's	18.00%	18.00%		
Time-Based Stock Options				
Summary Of Significant Accounting Policies [Line Items]				
Expiration period	10 years	10 years		
Number of equal annual installments for stock vested Installment	4	4		
Time-Based Stock Options Non-employee Directors				
Summary Of Significant Accounting Policies [Line Items]				
Expiration period	10 years	10 years		
Vesting period	1 year	1 year		
Time-Based Stock Options New Non-employee Directors				
Summary Of Significant Accounting Policies [Line Items]				
Expiration period	10 years	10 years		
Vesting period	3 years	3 years		
Time-Based RSUs				
Summary Of Significant Accounting Policies [Line Items]				
Number of equal annual installments for stock vested Installment	4	4		
Contract liabilities-short-term				
Summary Of Significant Accounting Policies [Line Items]				
Contract liabilities	\$ 1,200,000		2,700,000	
Other Long-Term Liabilities				
Summary Of Significant Accounting Policies [Line Items]				
Contract liabilities	\$ 0		\$ 2,100,000	
Minimum				
Summary Of Significant Accounting Policies [Line Items]				
Manufacturing Process period	10 days	10 days		
Maximum				
Summary Of Significant Accounting Policies [Line Items]				
Manufacturing Process period	56 days	56 days		

~~***XML 67 R52.htm IDEA: XBRL DOCUMENT***~~

Summary of Significant Accounting Policies - Schedule of Contract Assets and Contract Liabilities (Details) - USD (\$)	12 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023
\$ in Thousands		

Contract Asset [Abstract]

Contract assets	\$ 706	\$ 8,929
Additions	6,615	13,606
Transferred to receivables, net	(2,331)	(21,829)
Contract assets	4,990	706

Contract Liabilities [Abstract]

Contract liabilities at beginning of the period	4,775	10,701
Additions	34	(931)
Amounts recognized into revenue	(3,560)	(4,995)
Contract liabilities at end of the period	\$ 1,249	\$ 4,775

~~***XML 68 R53.htm IDEA: XBRL DOCUMENT***~~

Summary of Significant Accounting Policies - Schedule of Concentration (Details)	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Janssen | Accounts Receivable | Credit Concentration Risk

Product Information [Line Items]

Concentration risk percentage	14.00%	23.00%	

Janssen | Revenues Net | Customer Concentration Risk

Product Information [Line Items]

Concentration risk percentage	17.00%	31.00%	15.00%

Biogen | Accounts Receivable | Credit Concentration Risk

Product Information [Line Items]

Concentration risk percentage			19.00%

Biogen | Revenues Net | Customer Concentration Risk

Product Information [Line Items]

Concentration risk percentage	11.00%	11.00%	13.00%

Cardinal Health | Accounts Receivable | Credit Concentration Risk

Product Information [Line Items]

Concentration risk percentage	16.00%	24.00%	24.00%

Cardinal Health | Revenues Net | Customer Concentration Risk

Product Information [Line Items]

Concentration risk percentage	19.00%	20.00%	24.00%

Cencora | Accounts Receivable | Credit Concentration Risk

Product Information [Line Items]

Concentration risk percentage	17.00%	16.00%	18.00%

Cencora | Revenues Net | Customer Concentration Risk

Product Information [Line Items]

Concentration risk percentage	15.00%	12.00%	14.00%

McKesson | Accounts Receivable | Credit Concentration Risk

Product Information [Line Items]

Concentration risk percentage	36.00%	14.00%	12.00%
McKesson Revenues Net Customer Concentration Risk			
Product Information [Line Items]			
Concentration risk percentage	25.00%	14.00%	16.00%

~~***XML 69 R54.htm IDEA: XBRL DOCUMENT***~~

Summary of Significant Accounting Policies - Schedule of Concentration (Parenthetical) (Details) - Customer Concentration Risk - Minimum	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Revenues Net			
Product Information [Line Items]			
Concentration risk percentage	10.00%	10.00%	10.00%
Accounts Receivable			
Product Information [Line Items]			
Concentration risk percentage	10.00%	10.00%	10.00%

~~***XML 70 R55.htm IDEA: XBRL DOCUMENT***~~

Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Location (Details) - USD (\$)	12 Months Ended		
\$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Geographic Information			
Revenue by region: U.S.	\$ 1,557,632	\$ 1,663,405	\$ 1,111,795
Geographic Information			
Revenue by region: Ireland	1,410,159	1,491,939	931,991
Geographic Information			
Revenue by region: Rest of world	1,294	1,179	1,829
Geographic Information			
Revenue by region:	\$ 146,179	\$ 170,287	\$ 177,975

~~***XML 71 R56.htm IDEA: XBRL DOCUMENT***~~

Summary of Significant Accounting Policies - Summary of Location of the Assets (Details) - USD (\$)	Dec. 31, 2024			Dec. 31, 2023
\$ in Thousands				

Current assets:			
Cash and cash equivalents	\$ 291,146	\$ 457,469	
Investments—short-term	460,522	316,022	
Receivables, net	384,528	332,477	
Assets held for sale		94,260	
Long-term assets:			
Property, plant and equipment, net	227,564	226,943	
Investments-long-term	73,148	39,887	
Intangible assets	890	1,991	
Goodwill	83,027	83,027	
Intangible assets, net and goodwill	83,917	85,018	
Other	16,503	11,521	
U.S.			
Current assets:			
Cash and cash equivalents	70,303	317,850	
Investments—short-term	203,631	187,574	
Receivables, net	306,259	218,747	
Other current assets	129,332	143,417	
Long-term assets:			
Property, plant and equipment, net	226,646	225,578	
Investments-long-term	24,629	17,957	
Other	210,792	189,335	
Ireland			
Current assets:			
Cash and cash equivalents	220,843	139,619	
Investments—short-term	256,891	128,448	
Receivables, net	78,269	113,730	
Assets held for sale		94,260	
Other current assets	149,827	141,861	
Long-term assets:			
Property, plant and equipment, net	918	1,365	
Investments-long-term	48,519	21,930	
Intangible assets, net and goodwill	83,917	85,018	
Other	\$ 44,791	\$ 109,534	

~~***XML 72 R57.htm IDEA: XBRL DOCUMENT***~~

Summary of Significant Accounting Policies - Summary of Estimated Fair Value of Stock Option Granted on Weighted Average Assumptions (Details) - Time-Based Stock Options	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Weighted-average assumptions			
Expected stock volatility, minimum (as a percent)	38.00%	40.00%	43.00%
Expected stock volatility, maximum (as a percent)	42.00%	44.00%	51.00%
Risk-free interest rate, minimum (as a percent)	3.64%	3.34%	1.83%
Risk-free interest rate, maximum (as a percent)	4.60%	4.75%	4.26%
Minimum			

Weighted-average assumptions			
Expected option term	5 years	5 years	5 years
Maximum			

Weighted-average assumptions			
Expected option term	7 years	8 years	8 years

~~XML 73 R58.htm IDEA: XBRL DOCUMENT~~

Discontinued Operations - Additional Information (Details) - USD (\$)	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

[Discontinued Operations and Disposal Groups \[Abstract\]](#)

Discontinued operation agreement date	Nov. 13, 2023		
Transaction costs related to the Separation		\$ 36,000,000	\$ 1,400,000
Assets	\$ 0		
Liabilities related to discontinued operations		\$ 4,542,000	

~~XML 74 R59.htm IDEA: XBRL DOCUMENT~~

Discontinued Operations - Schedule of Transfer of Assets and Liabilities Effected in Accordance with Separation Agreements (Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Nov. 15, 2023

[Current Assets:](#)

Total assets	\$ 0

[Current Liabilities:](#)

Total current liabilities	\$ 4,542,000

[Mural Oncology plc | Separation Agreement](#)

[Current Assets:](#)

Cash and cash equivalents	\$ 275,000,000
Total current assets	275,000,000
Property, plant and equipment, net	10,096,000
Right-of-use assets	14,513,000
Goodwill	7,800,000
Deferred tax asset	1,799,000
Total assets	309,208,000

[Current Liabilities:](#)

Operating lease liabilities-short-term	6,036,000
Total current liabilities	6,036,000
Operating lease liabilities-long-term	9,412,000
Total liabilities	15,448,000
Net assets transferred to Mural	\$ 293,760,000

~~XML 75 R60.htm IDEA: XBRL DOCUMENT~~

Discontinued Operations - Summary of Expenses of Discontinued Operations (Details) - USD (\$)	12 Months Ended		
\$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

[Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations \[Line Items\]](#)

Total operating expenses from discontinued operations	\$ 5,790	\$ 164,803	\$ 136,176
Disposal Group, Including Discontinued Operation, Operating Income (Loss), Total	(5,790)	(164,803)	(136,176)
Income tax benefit from discontinued operations	(722)	(1,403)	(11,061)
Net loss and comprehensive loss from discontinued operations	(5,068)	(163,400)	(125,115)
Cost of goods manufactured			

[Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations \[Line Items\]](#)

Total operating expenses from discontinued operations	39	40	

[Research and development](#)

[Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations \[Line Items\]](#)

Total operating expenses from discontinued operations	\$ 5,790	116,177	121,140

[Selling, general and administrative](#)

[Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations \[Line Items\]](#)

Total operating expenses from discontinued operations	\$ 48,587	\$ 14,996	

~~XML 76 R61.htm IDEA: XBRL DOCUMENT~~

Discontinued Operations - Summary of Assets and Liabilities (Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023

[Current Assets:](#)

Total assets	\$ 0

[Current Liabilities:](#)

Total current liabilities	\$ 4,542,000

~~XML 77 R62.htm IDEA: XBRL DOCUMENT~~

Discontinued Operations - Summary of Significant Non-cash Items and Capital Expenditures of Discontinued Operations (Details) - USD (\$)	12 Months Ended	
\$ in Thousands	Dec. 31, 2023	Dec. 31, 2022

[OPERATING ACTIVITIES:](#)

Depreciation	\$ 2,319	\$ 1,539
Share-based compensation expense	8,188	6,577
Right-of-use assets	3,803	5,909
Operating lease liabilities	(3,938)	(5,920)

[INVESTING ACTIVITIES:](#)

Additions of property, plant and equipment	\$ (1,798)	\$ (5,510)

~~XML 78 R63.htm IDEA: XBRL DOCUMENT~~

Revenue from	12 Months Ended	

Contracts with
Customers - Schedule
of Disaggregation of
Revenue (Details) -
USD (\$)
\$ in Thousands

Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022

Disaggregation Of Revenue [Line Items]			
Total revenues	\$ 1,557,632	\$ 1,663,405	\$ 1,111,795
VIVITROL			
Disaggregation Of Revenue [Line Items]			
Total revenues	457,315	400,419	379,478
ARISTADA and ARISTADA INITIO			
Disaggregation Of Revenue [Line Items]			
Total revenues	346,187	327,690	302,052
LYBALVI			
Disaggregation Of Revenue [Line Items]			
Total revenues	280,032	191,889	96,022
Product sales, net			
Disaggregation Of Revenue [Line Items]			
Total revenues	\$ 1,083,534	\$ 919,998	\$ 777,552

XML 79 R64.htm IDEA: XBRL DOCUMENT

Revenue from
Contracts with
Customers - Schedule
of Manufacturing and
Royalty Revenues
(Details) - USD (\$)
\$ in Thousands

12 Months Ended
Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022

Disaggregation Of Revenue [Line Items]			
Total revenues	\$ 1,557,632	\$ 1,663,405	\$ 1,111,795
Long-Acting INVEGA Products			
Disaggregation Of Revenue [Line Items]			
Total revenues	486,100	115,700	
Manufacturing Revenue			
Disaggregation Of Revenue [Line Items]			
Total revenues	119,426	142,498	112,374
Manufacturing Revenue VUMERITY			
Disaggregation Of Revenue [Line Items]			
Total revenues	39,292	42,886	32,493
Manufacturing Revenue RISPERDAL CONSTA			
Disaggregation Of Revenue [Line Items]			
Total revenues	23,172	36,123	42,670
Manufacturing Revenue Other			
Disaggregation Of Revenue [Line Items]			
Total revenues	56,962	63,489	37,211
Royalty			
Disaggregation Of Revenue [Line Items]			
Total revenues	354,669	600,890	219,609
Royalty Long-Acting INVEGA Products			
Disaggregation Of Revenue [Line Items]			
Total revenues	236,386	486,101	115,655
Royalty VUMERITY			
Disaggregation Of Revenue [Line Items]			
Total revenues	94,755	86,440	83,003
Royalty RISPERDAL CONSTA			
Disaggregation Of Revenue [Line Items]			
Total revenues	272	1,153	7,243
Royalty Other			
Disaggregation Of Revenue [Line Items]			
Total revenues	23,256	27,196	13,708
Manufacturing and royalty revenues			
Disaggregation Of Revenue [Line Items]			
Total revenues	474,095	743,388	331,983
Manufacturing and royalty revenues Long-Acting INVEGA Products			
Disaggregation Of Revenue [Line Items]			
Total revenues	236,386	486,101	115,655
Manufacturing and royalty revenues VUMERITY			
Disaggregation Of Revenue [Line Items]			
Total revenues	134,047	129,326	115,496
Manufacturing and royalty revenues RISPERDAL CONSTA			
Disaggregation Of Revenue [Line Items]			
Total revenues	23,444	37,276	49,913
Manufacturing and royalty revenues Other			
Disaggregation Of Revenue [Line Items]			
Total revenues	\$ 80,218	\$ 90,685	\$ 50,919

XML 80 R65.htm IDEA: XBRL DOCUMENT

Revenue from
Contracts with
Customers -
Additional
Information (Details)
- USD (\$)
\$ in Thousands

1 Months Ended3 Months Ended12 Months Ended
Nov. 30, 2022Oct. 31, 2022Dec. 31, 2022Sep. 30, 2022Jun. 30, 2022Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022

Disaggregation Of Revenue [Line Items]			
Royalty revenue	\$ 1,557,632	\$ 1,663,405	\$ 1,111,795
Janssen Pharmaceutica N.V.			
Disaggregation Of Revenue [Line Items]			
Royalty revenue related to back royalties		195,400	
Back royalties late payment interest		8,100	
Long-Acting INVEGA Products			
Disaggregation Of Revenue [Line Items]			
Royalty revenue		486,100	115,700
Royalty revenue recognized		290,700	
Royalty			
Disaggregation Of Revenue [Line Items]			
Royalty revenue	354,669	600,890	219,609
Royalty AMPYRA			
Disaggregation Of Revenue [Line Items]			

Royalty revenue		\$ 16,500		\$ (3,200)	\$ 3,200
Additional award paid	\$ 1,800				
Arbitration award amount paid			\$ 18,300		
Repayment of royalty revenue				\$ 18,300	
Royalty Long-Acting INVEGA Products					
Disaggregation Of Revenue [Line Items]					
Royalty revenue				\$ 236,386	\$ 486,101 \$ 115,655

XML 81 R66.htm IDEA: XBRL DOCUMENT

Investments -			
Schedule of			
Investments (Details)	Dec. 31, 2024	Dec. 31, 2023	
- USD (\$)			
\$ in Thousands			

Available-for-sale securities:

Short-term investments, Amortized Cost	\$ 459,123	\$ 315,767
Gross Unrealized Gains	1,525	1,461
Gross Unrealized Losses less than one year	(116)	(78)
Gross Unrealized Losses greater than one year	(347)	(1,759)
Short-term investments, Estimated Fair Value	460,522	316,022
Long-term investments, Amortized Cost	73,340	38,698
Investments-long-term	73,148	39,887
Long-term investments, Estimated Fair Value	73,003	38,067
Amortized Cost	532,608	356,285
Estimated Fair Value	533,670	355,909
Short-term investments		

Available-for-sale securities:

Gross Unrealized Gains	1,525	1,461
Gross Unrealized Losses less than one year	(116)	(51)
Gross Unrealized Losses greater than one year	(10)	(1,155)
Long-term investments		

Available-for-sale securities:

Gross Unrealized Losses less than one year	0	(27)
Gross Unrealized Losses greater than one year	(337)	(604)
Investments-long-term	73,148	39,887
Amortized Cost	73,485	40,518
Certificates of deposit		

Available-for-sale securities:

Amortized Cost	145	1,820
Estimated Fair Value	145	1,820
Corporate debt securities		

Available-for-sale securities:

Short-term investments, Amortized Cost	192,617	112,055
Short-term investments, Estimated Fair Value	193,317	112,207
Long-term investments, Amortized Cost	24,484	19,306
Long-term investments, Estimated Fair Value	24,326	19,017
Corporate debt securities Short-term investments		

Available-for-sale securities:

Gross Unrealized Gains	762	703
Gross Unrealized Losses less than one year	(58)	(15)
Gross Unrealized Losses greater than one year		(536)
Corporate debt securities Long-term investments		

Available-for-sale securities:

Gross Unrealized Losses greater than one year	(158)	(289)
U.S. government and agency debt securities		
Available-for-sale securities:		
Short-term investments, Amortized Cost	266,506	199,708
Short-term investments, Estimated Fair Value	267,205	199,819
Long-term investments, Amortized Cost	48,856	19,392
Long-term investments, Estimated Fair Value	48,677	19,050
U.S. government and agency debt securities Short-term investments		

Available-for-sale securities:

Gross Unrealized Gains	763	758
Gross Unrealized Losses less than one year	(58)	(36)
Gross Unrealized Losses greater than one year	(6)	(611)
U.S. government and agency debt securities Long-term investments		

Available-for-sale securities:

Gross Unrealized Losses less than one year		(27)
Gross Unrealized Losses greater than one year	\$ (179)	(315)
Non-U.S. government debt securities		

Available-for-sale securities:

Short-term investments, Amortized Cost		4,004
Short-term investments, Estimated Fair Value		3,996
Non-U.S. government debt securities Short-term investments		

Available-for-sale securities:

Gross Unrealized Losses greater than one year		\$ (8)

XML 82 R67.htm IDEA: XBRL DOCUMENT

Investments -	12 Months Ended
Additional	Dec. 31, 2024
Information (Details)	USD (\$)
\$ in Millions	Investmentsecurity

Summary of Investment Holdings [Line Items]

Number of investment securities in an unrealized loss position	77
Number of investment securities	320
Aggregate estimated fair value of investments in unrealized loss position \$	\$ 112.7
Corporate debt securities	

Summary of Investment Holdings [Line Items]

Percentage of investment securities available for sale unrealized loss position	41.00%
U.S. government and agency debt securities	

Summary of Investment Holdings [Line Items]

Percentage of investment securities available for sale unrealized loss position	59.00%

XML 83 R68.htm IDEA: XBRL DOCUMENT

Investments -	12 Months Ended
Schedule of Proceeds	
from Sales and	
Maturities of	
Marketable Securities	
Plus Resulting	Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022

Realized Gains and Losses (Details) - USD (\$)			
\$ in Thousands			
Investments, Debt and Equity Securities [Abstract]			
Proceeds from the sales and maturities of investments	\$ 310,286	\$ 355,522	\$ 281,627
Realized losses			\$ 529

~~***XML 84 R69.htm IDEA: XBRL DOCUMENT***~~

Investments - Schedule of Contractual Maturities of Available-for-Sale and Held-to-Maturity Securities (Details) \$ in Thousands	Dec. 31, 2024 USD (\$)
Available-for-sale, Amortized Cost	
Within 1 year	\$ 324,897
After 1 year through 5 years	207,566
Total	532,463
Available-for-sale, Estimated Fair Value	
Within 1 year	325,566
After 1 year through 5 years	207,959
Total	533,525
Held-to-maturity, Amortized Cost	
Within 1 year	145
Total	145
Held-to-maturity, Estimated Fair Value	
Within 1 year	145
Total	\$ 145

~~***XML 85 R70.htm IDEA: XBRL DOCUMENT***~~

Fair Value - Summary of the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023
\$ in Thousands		
Fair value		
Debt securities	\$ 533,525	
Recurring Basis		
Fair value		
Cash equivalents	8,388	\$ 34,316
Assets, Total	541,913	388,405
Recurring Basis Level 1		
Fair value		
Cash equivalents	8,388	34,316
Assets, Total	273,478	215,357
Recurring Basis Level 2		
Fair value		
Assets, Total	268,435	173,048
U.S. government and agency debt securities Recurring Basis		
Fair value		
Debt securities	315,882	218,869
U.S. government and agency debt securities Recurring Basis Level 1		
Fair value		
Debt securities	265,090	181,041
U.S. government and agency debt securities Recurring Basis Level 2		
Fair value		
Debt securities	50,792	37,828
Corporate debt securities Recurring Basis		
Fair value		
Debt securities	217,643	131,224
Corporate debt securities Recurring Basis Level 2		
Fair value		
Debt securities	\$ 217,643	131,224
Non-U.S. government debt securities Recurring Basis		
Fair value		
Debt securities		3,996
Non-U.S. government debt securities Recurring Basis Level 2		
Fair value		
Debt securities		\$ 3,996

~~***XML 86 R71.htm IDEA: XBRL DOCUMENT***~~

Fair Value - Additional Information (Details) - USD (\$)	1 Months Ended Mar. 31, 2022	9 Months Ended Sep. 30, 2022	12 Months Ended Dec. 31, 2024	Dec. 31, 2022
Fair Value				
Transfers between Level 1 to Level 2			\$ 0	
Transfers between Level 2 to Level 1			0	
Investments determined using Level 3 inputs			\$ 0	
Net amounts write off within other income (expense), net				\$ 2,300,000
Baudax				
Fair Value				
Percentage of reduction in work force	80.00%			
Milestone payments received		\$ 1,200,000		
Milestone payment receivable	\$ 6,400,000			

~~***XML 87 R72.htm IDEA: XBRL DOCUMENT***~~

Inventory - Schedule of Inventories (Details) - USD (\$)	Dec. 31, 2024	Dec. 31, 2023
\$ in Thousands		
Inventory Disclosure [Abstract]		
Raw materials	\$ 72,139	\$ 71,416
Work in process	79,871	68,843
Finished goods	[1] 30,877	46,147
Total inventory	\$ 182,887	\$ 186,406

[1] At December 31, 2024 and 2023, the Company had \$22.7 million and \$33.9 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider.

XML 88 R73.htm IDEA: XBRL DOCUMENT

Inventory - Schedule of Inventories (Parenthetical) (Details) - USD (\$) \$ in Millions	Dec. 31, 2024	Dec. 31, 2023

[Inventory Disclosure \[Abstract\]](#)

[Finished goods inventory located at third-party warehouse and shipping service provider](#) \$ 22.7 \$ 33.9

XML 89 R74.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023

[Property, plant and equipment](#)

Property, plant and equipment, gross	\$ 480,576	\$ 457,104
Less: accumulated depreciation	(253,012)	(230,161)
Total property, plant and equipment, net	227,564	226,943

[Land](#)

[Property, plant and equipment](#)

Property, plant and equipment, gross	957	957
Building and Improvements		

[Property, plant and equipment](#)

Property, plant and equipment, gross	134,699	132,735
Furniture, Fixtures and Equipment		

[Property, plant and equipment](#)

Property, plant and equipment, gross	244,113	237,728
Leasehold Improvements		

[Property, plant and equipment](#)

Property, plant and equipment, gross	42,416	39,893
Construction in Progress		

[Property, plant and equipment](#)

Property, plant and equipment, gross	\$ 58,391	\$ 45,791

XML 90 R75.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Parenthetical) (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023

[Property, Plant and Equipment \[Line Items\]](#)

Property, plant and equipment, net	\$ 227,564	\$ 226,943

[Assets Held For Sale](#)

[Property, Plant and Equipment \[Line Items\]](#)

Property, plant and equipment, net	\$ 92,200

XML 91 R76.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment - Additional Information (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

[Property Plant And Equipment \[Line Items\]](#)

Depreciation expense	\$ 27.4	\$ 25.7	\$ 26.3
Wilmington, Ohio			

[Property Plant And Equipment \[Line Items\]](#)

Construction in progress	2.9

[Furniture, Fixtures and Equipment](#)

[Property Plant And Equipment \[Line Items\]](#)

Carrying value at the time of disposition	\$ 0.5	\$ 1.7	\$ 0.5

XML 92 R77.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Schedule of Goodwill and Intangible Assets (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023

[Goodwill](#)

Gross Carrying Amount	\$ 83,027	\$ 83,027
Net Carrying Amount	83,027	83,027

[Finite-lived intangible assets:](#)

Gross Carrying Amount	583,750	583,750
Accumulated Amortization	(582,860)	(581,759)
Net Carrying Amount	\$ 890	1,991

[Collaboration agreements](#)

[Finite-lived intangible assets:](#)

Weighted Amortizable Life	12 years	
Gross Carrying Amount	\$ 465,590	465,590
Accumulated Amortization	(465,590)	(465,590)
Net Carrying Amount	0	

[Capitalized IP](#)

[Finite-lived intangible assets:](#)

Gross Carrying Amount	118,160	118,160
Accumulated Amortization	(117,270)	(116,169)
Net Carrying Amount	\$ 890	\$ 1,991

[Capitalized IP | Minimum](#)

[Finite-lived intangible assets:](#)

Weighted Amortizable Life	11 years
Capitalized IP Maximum	

[Finite-lived intangible assets:](#)

Weighted Amortizable Life	13 years

XML 93 R78.htm IDEA: XBRL DOCUMENT

Intangible Assets and	12 Months Ended

Goodwill - Additional Information (Details)
- USD (\$)
Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022
\$ in Thousands

Goodwill [Line Items]			
Amortization of acquired intangible assets	\$ 1,101	\$ 35,689	\$ 36,363
Goodwill	\$ 83,027	83,027	
Athlone Facility Assets Held for Sale			
Goodwill [Line Items]			
Goodwill		\$ 2,000	

~~***XML 94 R79.htm IDEA: XBRL DOCUMENT***~~

Leases - Additional Information (Details) \$ in Thousands	Jan. 20, 2020 ft²	Dec. 31, 2024 USD (\$)	12 Months Ended		
			Dec. 31, 2023 USD (\$)	Dec. 31, 2022 USD (\$)	Nov. 15, 2023 Nov. 13, 2023 ft²
Lessee Lease Description [Line Items]					
Right-of-use asset		\$ 84,245	\$ 91,460		
Lease liability		75,538			
Payments for operating leases		\$ 10,100	\$ 10,300	\$ 27,000	
Weighted average incremental borrowing rate		4.00%	4.40%		
Weighted average remaining lease term		7 years 2 months 12 days	8 years 8 months 12 days		
Operating lease expense		\$ 7,200	\$ 10,200	\$ 10,700	
900 Winter Street Lease					

Lessee Lease Description [Line Items]		
Area of real estate property ft²	231,000	
Lease, commencement date	Jan. 20, 2020	
Lease agreement option to extend renewal term	10 years	
Lease, expiration year	2035	
Lessee operating lease term of option to extend	true	
852 Winter Street Lease Assignment		
Lessee Lease Description [Line Items]		
Area of real estate property ft²		180,000
Right-of-use asset		\$ 14,500
Lease liability		\$ 15,400

~~***XML 95 R80.htm IDEA: XBRL DOCUMENT***~~

Leases - Summary of Future Lease
Payments Under Non-Cancelable Leases (Details)
\$ in Thousands

Leases [Abstract]	
2025	\$ 10,189
2026	10,259
2027	9,505
2028	9,574
Thereafter	59,695
Total operating lease payments	99,222
Less: imputed interest	(23,684)
Total operating lease liabilities	\$ 75,538

~~***XML 96 R81.htm IDEA: XBRL DOCUMENT***~~

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD (\$)
\$ in Thousands

Payables and Accruals [Abstract]		
Accounts payable	\$ 45,630	\$ 65,649
Accrued compensation	70,960	83,107
Accrued other	68,742	91,805
Total accounts payable and accrued expenses	\$ 185,332	\$ 240,561

~~***XML 97 R82.htm IDEA: XBRL DOCUMENT***~~

Accounts Payable and Accrued Expenses - Summary of Current Provision for Sales, Discounts, Allowances and Reserves (Details) - USD (\$)
\$ in Thousands

Accrued Sales Discount Allowances And Reserves [Line Items]		
Total accrued sales discounts, allowances and reserves	\$ 272,452	\$ 263,641
Medicaid Rebate		
Accrued Sales Discount Allowances And Reserves [Line Items]		
Total accrued sales discounts, allowances and reserves	202,044	213,845
Product Discounts		
Accrued Sales Discount Allowances And Reserves [Line Items]		
Total accrued sales discounts, allowances and reserves	19,351	15,121
Medicare Part D		
Accrued Sales Discount Allowances And Reserves [Line Items]		
Total accrued sales discounts, allowances and reserves	26,933	20,569
Other		
Accrued Sales Discount Allowances And Reserves [Line Items]		
Total accrued sales discounts, allowances and reserves	\$ 24,124	\$ 14,106

~~***XML 98 R83.htm IDEA: XBRL DOCUMENT***~~

Accounts Payable and Accrued Expenses - Additional Information (Details) - USD (\$)
\$ in Thousands

Accounts Payable And Accrued Expenses [Line Items]		
Accounts payable	\$ 45,630	\$ 65,649
State Medicaid Rebates		
Accounts Payable And Accrued Expenses [Line Items]		
Accounts payable	\$ 11,400	\$ 34,500

XML 99 R84.htm IDEA: XBRL DOCUMENT

Long-term Debt - Schedule of Long- term Debt (Details) \$ in Thousands	Dec. 31, 2023 USD (\$)
Long-term debt	
Less: current portion	\$ (3,000)
Long-term debt	287,730
Former Term Loans, due March 12, 2026	
Long-term debt	
Term Loans	290,730
Less: current portion	(3,000)
Long-term debt	\$ 287,730

XML 100 R85.htm IDEA: XBRL DOCUMENT

Long-term Debt - Additional Information (Details) - USD (\$) \$ in Thousands	1 Months Ended Dec. 31, 2024	12 Months Ended Dec. 31, 2024	Dec. 31, 2023
Long-term debt			
Prepayment of long-term debt	\$ (289,542)		
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Former Term Loans	us- gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember	us- gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember	
Long-term debt			
Prepayment of long-term debt	\$ (289,500)		
Loss on debt extinguishment	\$ 800		
Interest rate added to base rate (as a percent)	2.50%	2.50%	
Interest rate, variable interest rate floor (as a percent)	0.50%	0.50%	

XML 101 R86.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share - Schedule of Basic Earnings (Loss) Per Ordinary Share (Details) - USD (\$) shares in Thousands, \$ in Thousands	12 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022
Numerator:	
Net income (loss) from continuing operations	\$ 372,138 \$ 519,157 \$ (33,152)
Net loss from discontinued operations	(5,068) (163,400) (125,115)
Net income (loss)	\$ 367,070 \$ 355,757 \$ (158,267)
Denominator:	
Basic	165,392 166,223 163,742
Dilutive ordinary share equivalents	3,806 3,507
Shares used in calculating diluted earnings (loss) per ordinary share	169,198 169,730 163,742
Stock Options	
Denominator:	
Dilutive ordinary share equivalents	1,377 1,093
Restricted Stock Unit Awards	
Denominator:	
Dilutive ordinary share equivalents	2,429 2,414

XML 102 R87.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share - Schedule of Anti-Dilutive Potential Common Share Equivalent Excluded from Calculation of Earnings (Loss) Per Share (Details) - shares shares in Thousands	12 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022
Denominator:	
Anti-dilutive potential common share equivalent excluded from calculation of net loss per ordinary share	13,908 14,800 17,817
Stock Options	
Denominator:	
Anti-dilutive potential common share equivalent excluded from calculation of net loss per ordinary share	11,517 12,422 12,777
Restricted Stock Unit Awards	
Denominator:	
Anti-dilutive potential common share equivalent excluded from calculation of net loss per ordinary share	2,391 2,378 5,040

XML 103 R88.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Additional Information (Details) - USD (\$) \$ / shares in Units, \$ in Thousands, shares in Millions	12 Months Ended Dec. 31, 2024 Feb. 29, 2024
Equity, Class of Treasury Stock [Line Items]	
Share repurchase aggregate amount	\$ 400,000
Share repurchase program remaining authorized amount	\$ 200,000
Shares repurchased	7.9
Shares repurchased price per share	\$ 25.33
Shares repurchased value	\$ 200,000
Cost of ordinary share acquired during share repurchase program	\$ 200,282

XML 104 R89.htm IDEA: XBRL DOCUMENT

Share-based Compensation - Schedule of Share- based Compensation Expense from	12 Months Ended

Continuing and Discontinued Operations (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based compensation Expense			
Total share-based compensation expense	\$ 96,637	\$ 100,905	\$ 94,254
Continuing Operations			
Share-based compensation Expense			
Total share-based compensation expense	96,637	92,717	87,677
Discontinued Operations			
Share-based compensation Expense			
Total share-based compensation expense		8,188	6,577
Cost of goods manufactured and sold Continuing Operations			
Share-based compensation Expense			
Total share-based compensation expense	5,798	11,353	10,284
Research and development Continuing Operations			
Share-based compensation Expense			
Total share-based compensation expense	28,085	25,753	23,289
Research and development Discontinued Operations			
Share-based compensation Expense			
Total share-based compensation expense		3,255	4,652
Selling, general and administrative Continuing Operations			
Share-based compensation Expense			
Total share-based compensation expense	\$ 62,754	55,611	54,104
Selling, general and administrative Discontinued Operations			
Share-based compensation Expense			
Total share-based compensation expense		\$ 4,933	\$ 1,925

~~***XML 105 R90.htm IDEA: XBRL DOCUMENT***~~

Share-based Compensation - Additional Information (Details) shares in Millions, \$ in Millions	12 Months Ended			
	May 31, 2024 shares	Dec. 31, 2024 USD (\$) Item shares	Dec. 31, 2023 USD (\$)	Dec. 31, 2022 USD (\$)
Share-based compensation Expense				
Share based compensation cost capitalized \$		\$ 3.1	\$ 3.2	\$ 3.3
Number of share-based compensation plan under which awards are currently made Item		1		
Number of share-based compensation plan under which no further awards will be made Item		2		
2018 Plan				
Share-based compensation Expense				
Increase in number of ordinary shares authorized shares	6.3			
Shares of common stock available for issuance shares		17.9		
Ratio of awards other than stock options counted against the total number of shares available for issuance		1.8		

~~***XML 106 R91.htm IDEA: XBRL DOCUMENT***~~

Share-based Compensation - Schedule of Stock Option Activity (Details) - Stock Options	12 Months Ended
	Dec. 31, 2024 \$ / shares shares
Number of Shares	
Outstanding at the beginning of the period (in shares) shares	18,139,903
Granted (in shares) shares	2,615,357
Exercised (in shares) shares	(1,328,189)
Expired (in shares) shares	(1,427,409)
Forfeited (in shares) shares	(521,043)
Outstanding at the end of the period (in shares) shares	17,478,619
Exercisable at the end of the period (in shares) shares	10,979,663
Weighted Average Exercise Price	
Outstanding at the beginning of the period (in dollars per share) \$ / shares	\$ 32.28
Granted (in dollars per share) \$ / shares	29.48
Exercised (in dollars per share) \$ / shares	20.76
Expired (in dollars per share) \$ / shares	46.72
Forfeited (in dollars per share) \$ / shares	26.65
Outstanding at the end of the period (in dollars per share) \$ / shares	31.73
Exercisable at the end of the period (in dollars per share) \$ / shares	\$ 34.53

~~***XML 107 R92.htm IDEA: XBRL DOCUMENT***~~

Share-based Compensation - Stock Options - Additional Information (Details) - Stock Options - USD (\$)	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based compensation Expense			
Weighted average grant-date fair value of stock options granted (in dollars per share)	\$ 14.08	\$ 13.74	\$ 12.62
Aggregate intrinsic value of stock options exercised	\$ 10,900,000	\$ 6,000,000	\$ 11,600,000
Stock options expected to vest (in shares)	6,300,000		
Weighted average exercise price (in dollars per share)	\$ 26.91		
Weighted average contractual remaining life	7 years 10 months 24 days		
Aggregate intrinsic value of stock options exercisable	\$ 38,500,000		
Weighted average remaining contractual term of stock options exercisable	4 years 4 months 24 days		
Unrecognized share-based compensation expense	\$ 32,300,000		
Weighted average period for unrecognized share-based compensation expense expected to be recognized	1 year 10 months 24 days		
Outstanding stock option	17,478,619	18,139,903	
Maximum			
Share-based compensation Expense			
Aggregate intrinsic value	\$ 15,400,000		

~~***XML 108 R93.htm IDEA: XBRL DOCUMENT***~~

Share-based Compensation - Summary of RSU Activity (Details) - Time-based RSU Awards - \$ / shares	12 Months Ended
	Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022
Number of Shares	
Unvested at the beginning of the period (in shares)	5,657,578
Granted (in shares)	2,260,345

Forfeited (in shares)	(775,415)		
Vested (in shares)	(2,237,302)		
Unvested at the end of the period (in shares)	4,905,206	5,657,578	
Weighted Average Grant Date Fair Value			
Unvested at the beginning of the period (in dollars per share)	\$ 24.18		
Granted (in dollars per share)	29.51	\$ 27.65	\$ 25.27
Forfeited (in dollars per share)	26.43		
Vested (in dollars per share)	23.05		
Unvested at the end of the period (in dollars per share)	\$ 26.8	\$ 24.18	

~~***XML 109 R94.htm IDEA: XBRL DOCUMENT***~~

Share-based Compensation - Time-Based Restricted Stock Units Award - Additional Information (Details) - Time-based RSU Awards - USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ / shares in Units, \$ in Millions			
Share-based compensation Expense			
Granted (in dollars per share)	\$ 29.51	\$ 27.65	\$ 25.27
Fair value of vesting RSU's	\$ 51.6	\$ 63.0	\$ 54.3
Unrecognized share-based compensation expense	\$ 53.4		
Weighted average period for unrecognized share-based compensation expense expected to be recognized	1 year 10 months 24 days		

~~***XML 110 R95.htm IDEA: XBRL DOCUMENT***~~

Share-based Compensation - Performance-Based Restricted Stock Units Awards - Additional Information (Details) - USD (\$)	1 Months Ended	12 Months Ended		
	Feb. 29, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based compensation Expense				
Share-based compensation, accounting modification charge	\$ 6,800,000			
Performance-based RSUs Awards				
Share-based compensation Expense				
Number of years from the date of the grant	3 years			
Granted (in dollars per share)	\$ 32.46	\$ 29.91	\$ 30.73	
Fair value of RSU's vested	\$ 10,100,000	\$ 5,900,000	\$ 0	
Incremental share-based compensation expense due to achievement of performance criteria	\$ 2,600,000			
Unvested Performance-based RSUs Awards				
Share-based compensation Expense				
Unrecognized share-based compensation expense	\$ 3,000,000			

~~***XML 111 R96.htm IDEA: XBRL DOCUMENT***~~

Share-based Compensation - Summary of PRSU Activity (Details) - Performance-based RSUs Awards - \$ / shares	12 Months Ended			
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	
Number of Shares				
Unvested at the beginning of the period (in shares)	1,546,357			
Granted (in shares)	498,120			
Forfeited (in shares)	(172,576)			
Vested (in shares)	(536,243)			
Unvested at the end of the period (in shares)	1,335,658	1,546,357		
Weighted Average Grant Date Fair Value				
Unvested at the beginning of the period (in dollars per share)	\$ 27.95			
Granted (in dollars per share)	32.46	\$ 29.91	\$ 30.73	
Forfeited (in dollars per share)	25.88			
Vested (in dollars per share)	22.21			
Unvested at the end of the period (in dollars per share)	\$ 32.13	\$ 27.95		

~~***XML 112 R97.htm IDEA: XBRL DOCUMENT***~~

Collaborative Arrangements - Additional Information (Details)	12 Months Ended			
	Dec. 31, 2024			
VUMERITY	USD (\$)			
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	Agreement			
Percentage of net sales in royalty payment	15.00%			
License agreement Janssen 9 O-H Risperidone Palimate [Member]				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Patent royalty rate (as a percent)	1.50%			
Know-how royalty rate resets (as a percent)	3.50%			
Period after the date of the first commercial sale of the product for license expiration	15 years			
License agreement Janssen 9 O-H Risperidone Palimate [Member] Net sales of below \$250.0 million				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Know-how royalty rate (as a percent)	3.50%			
License agreement Janssen 9 O-H Risperidone Palimate [Member] Net sales between \$250.0 million and 500.0 million				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Know-how royalty rate (as a percent)	5.50%			
License agreement Janssen 9 O-H Risperidone Palimate [Member] Net sales greater than \$500.0 million				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Know-how royalty rate (as a percent)	7.50%			
License agreement Janssen 9 O-H Risperidone Palimate [Member] Minimum Net sales between \$250.0 million and 500.0 million				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Aggregate worldwide net sales	\$ 250,000,000			
License agreement Janssen 9 O-H Risperidone Palimate [Member] Minimum Net sales greater than \$500.0 million				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Aggregate worldwide net sales	500,000,000			
License agreement Janssen 9 O-H Risperidone Palimate [Member] Maximum Net sales of below \$250.0 million				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Aggregate worldwide net sales	250,000,000			
License agreement Janssen 9 O-H Risperidone Palimate [Member] Maximum Net sales between \$250.0 million and 500.0 million				

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	
Aggregate worldwide net sales	\$ 500,000,000
License agreement Janssen RISPERDAL CONSTA	
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	
Royalty rate (as a percent)	2.50%
Period after the date of the first commercial sale of the product for license expiration	15 years
Number of license agreements Agreement	2
Notice period required to be given before termination of agreement	30 days
Period for resolving default or breach after the receipt of notice for termination of agreement	90 days
Manufacturing and supply agreement Janssen RISPERDAL CONSTA	
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	
Period after the date of the first commercial sale of the product for license expiration	60 days
Notice period required to be given before termination of agreement	6 months
Manufacturing and supply agreement Janssen RISPERDAL CONSTA Minimum	
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	
Royalty rate (as a percent)	7.50%
Royalty rate upon termination of manufacturing and supply agreement (as a percent)	2.50%
Manufacturing and supply agreement Janssen RISPERDAL CONSTA Maximum	
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]	
Royalty rate upon termination of manufacturing and supply agreement (as a percent)	5.00%

~~***XML 113 R98.htm IDEA: XBRL DOCUMENT***~~

Income Taxes -	12 Months Ended		
Schedule of Provision			
(Benefit) for Income			
Taxes from			
Continuing	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operations (Details) -			
USD (\$)			
\$ in Thousands			

Current income tax provision (benefit) :

U.S. federal	\$ 25,640	\$ (981)	\$ 11,169
U.S. state	4,259	722	4,401
Ireland	1,192		

Deferred income tax provision (benefit):

U.S. federal	(19,870)	10,192	(10,536)
U.S. state	(1,392)	(507)	(3,010)
Ireland	61,783	(107,064)	
Total tax provision (benefit)	\$ 71,612	\$ (97,638)	\$ 2,024

~~***XML 114 R99.htm IDEA: XBRL DOCUMENT***~~

Income Taxes -	12 Months Ended			
Additional				
Information (Details)				
- USD (\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
\$ in Thousands				

Income Taxes [Line Items]

Tax benefits included in discontinued operations	\$ 700	\$ 1,400	\$ 11,100	
Cumulative unremitted earnings of overseas subsidiaries	933,500			
Valuation allowance	79,727	129,296	\$ 271,517	\$ 249,112
State tax credits	\$ 34,000			
Minimum				

Income Taxes [Line Items]

[Period after loss carryforwards utilized that tax returns remain open to examination](#) 3 years

[Maximum](#)

Income Taxes [Line Items]

[Period after loss carryforwards utilized that tax returns remain open to examination](#) 4 years

[U.S. state](#)

Income Taxes [Line Items]

Valuation allowance	\$ 29,600
Operating loss carryforwards	\$ 43,200
U.S. state Rodin Therapeutics Incorporation	

Income Taxes [Line Items]

Operating loss carryforwards	5,800
U.S. federal	

Income Taxes [Line Items]

Operating loss carryforwards	14,100
U.S. federal Rodin Therapeutics Incorporation	

Income Taxes [Line Items]

Operating loss carryforwards	14,100
Federal research and development credits	500

[Ireland](#)

Income Taxes [Line Items]

Income taxes payable on repatriation of unremitted earnings	72,000
Valuation allowance	50,100
Operating loss carryforwards	\$ 393,900
EU	

Income Taxes [Line Items]

Corporate minimum tax rate	15.00%
Revenues	\$ 750,000

~~***XML 115 R100.htm IDEA: XBRL DOCUMENT***~~

Income Taxes -	12 Months Ended		
Schedule of Income			
(Loss) Before			
Provision (Benefit)			
for Income Taxes by	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Geographical Area			
(Details) - USD (\$)			
\$ in Thousands			

Distribution of income (loss) before provision for income taxes

Income (loss) from continuing operations before provision (benefit) for income taxes	\$ 443,750	\$ 421,519	\$ (31,128)
Ireland			

Distribution of income (loss) before provision for income taxes

Income (loss) from continuing operations before provision (benefit) for income taxes	440,674	411,767	(32,198)
U.S.			

Distribution of income (loss) before provision for income taxes

Income (loss) from continuing operations before provision (benefit) for income taxes	\$ 3,076	\$ 9,752	\$ 1,070

~~***XML 116 R101.htm IDEA: XBRL DOCUMENT***~~

Income Taxes -

Schedule of Components of Net Deferred Tax Assets (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:				
Less: valuation allowance	\$ (79,727)	\$ (129,296)	\$ (271,517)	\$ (249,112)
Continuing Operations				
Deferred tax assets:				
Net operating loss carryforwards	80,209	195,658		
Research and development expenses	71,167	49,206		
Accrued expenses and reserves	41,189	37,367		
Operating lease liabilities	17,537	18,716		
Share-based compensation	33,773	37,727		
Tax credits	26,882	27,116		
Other	3,695	5,582		
Less: valuation allowance	(79,727)	(129,296)		
Total deferred tax assets	194,725	242,076		
Deferred tax liabilities:				
Property, plant and equipment	(21,917)	(26,271)		
Right-of-use assets	(16,337)	(17,748)		
Other	(1,940)	(2,716)		
Total deferred tax liabilities	(40,194)	(46,735)		
Net deferred tax assets	\$ 154,531	\$ 195,341		

~~XML 117 R102.htm IDEA: XBRL DOCUMENT~~

Income Taxes - Schedule of Activity in Valuation Allowance Associated with Deferred taxes (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]			
Balance at Beginning of Period	\$ (129,296)	\$ (271,517)	\$ (249,112)
(Additions) / Reductions	49,569	142,221	(22,405)
Balance at End of Period	\$ (79,727)	\$ (129,296)	\$ (271,517)

~~XML 118 R103.htm IDEA: XBRL DOCUMENT~~

Income Taxes - Schedule of Reconciliation of Statutory Tax Rate to Effective Tax Rate (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of effective income tax rate			
Statutory tax rate (as a percent)	12.50%	12.50%	12.50%
Income (loss) from continuing operations before income taxes at statutory rate	\$ 55,469	\$ 52,690	\$ (3,891)
Share-based compensation	5,607	4,177	4,347
Foreign rate differential	4,844	4,701	521
Change in valuation allowance	(49,517)	(142,424)	1,102
Intercompany amounts	708	(16,551)	(1,694)
Irish rate differential	5,798	235	4,926
Uncertain tax positions	(667)	(234)	602
Non-deductible lobbying expenses	767	705	775
U.S. state income taxes, net of U.S. federal benefit	2,802	347	1,272
Foreign derived intangible income	(281)		(4,530)
R&D credit	(7,815)	(2,823)	(2,531)
Abandonment of NOLs	49,897		
Other permanent items	4,000	1,539	1,125
Total tax provision (benefit)	\$ 71,612	\$ (97,638)	\$ 2,024
Effective tax rate (as a percent)	16.10%	(23.20%)	(6.50%)

~~XML 119 R104.htm IDEA: XBRL DOCUMENT~~

Income Taxes - Schedule of Reconciliation of Statutory Tax Rate to Effective Tax Rate (Parentetical) (Details) \$ in Millions	Dec. 31, 2023
Income Tax Disclosure [Abstract]	
Tax benefit related to intercompany transfer of inventory	\$ 15.7

~~XML 120 R105.htm IDEA: XBRL DOCUMENT~~

Income Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]			
Balance at the beginning of the period	\$ 8,739	\$ 8,973	\$ 8,372
Reductions based on the lapse of applicable statutes of limitations	(1,306)	(1,073)	(438)
Additions based on tax positions related to prior periods	59	281	449
Additions based on tax positions related to the current period	581	558	590
Balance at the end of the period	\$ 8,073	\$ 8,739	\$ 8,973

~~XML 121 R106.htm IDEA: XBRL DOCUMENT~~

Segment Reporting - Summary of Significant Segment Expenses (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
REVENUES:			
Total revenues	\$ 1,557,632	\$ 1,663,405	\$ 1,111,795
EXPENSES:			
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	245,331	253,037	218,068

Development programs:			
ALKS 2680	45,947	31,321	15,715
LYBALVI	18,737	15,379	23,056
Other external R&D expenses	36,627	51,668	57,423
Total external R&D expenses	101,311	98,368	96,194
Internal R&D expenses:			
Employee-related	114,496	128,282	129,735
Occupancy	11,206	12,299	12,449
Depreciation	5,701	9,578	10,708
Other internal R&D expenses	12,612	22,279	23,616
Total internal R&D expenses	144,015	172,438	176,508
R&D expenses	245,326	270,806	272,702
Selling, general and administrative expenses:			
Selling and marketing expense	446,214	490,154	392,211
General and administrative expense	199,024	199,597	198,540
Total selling, general and administrative expense	645,238	689,751	590,751
Other segment (expenses) income	[1] (49,599)	69,346	(63,426)
NET INCOME (LOSS) FROM CONTINUING OPERATIONS	372,138	519,157	(33,152)
LOSS ON DISCONTINUED OPERATIONS, NET OF TAX	(5,068)	(163,400)	(125,115)
NET INCOME (LOSS)	\$ 367,070	\$ 355,757	\$ (158,267)

[1] "Other segment (expenses) income" during the years ended December 31, 2024, 2023 and 2022 includes "Amortization of acquired intangible assets", "Other income (loss), net" and "Income tax provision (benefit)".

XML 122 R107.htm IDEA: XBRL DOCUMENT

Commitments and Contingent Liabilities	1 Months Ended 12 Months Ended	
- Additional		
Information (Details)	Jan. 31, 2023	Dec. 31, 2024
- USD (\$)		

Commitments And Contingencies [Line Items]

Potential material losses from claims, legal proceedings probable of occurring	\$ 0
Additional sought value for damages as part of requested modification	\$ 66,000,000

Capital Commitments

Commitments And Contingencies [Line Items]

Open purchase order commitments	\$ 17,700,000
852 Winter Street Lease	

Commitments And Contingencies [Line Items]

Guaranty date	May 16, 2014
Fair value of guarantee	\$ 0

EXCEL 123 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644

Financial_Report.xlsx M4\$L#!0 (- "%*3%H'04UB@0 +\$ 0 9&|C4')O<',087!P+GAM
M;\$V./0L",1!\$ \IQO;=!P4)B0-!2L+(/>QL0D&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(-C(H(/!47BK9.7;=N')=HI6-Y
#OGDK7A.YNJQ<&4GPZ4A!0W_J=0U|R;UEA_6\#MI7E!+ P04 M " !0BDQ;:'U>&NX K @
\$0-&108U!R;W!S+V-O&ULS9+! M2L0P\$(9?17)OI\FB:.CFHGA2\$%Q00(5D=C=LTX1DI-
VW-ZVI740?P&-F_GSS M#4QKHC0AX4L*\$1,YS%>C|_HL35RS/5&4-GLT>M!RI%BZ
"4:8?/XNH%V(<_5/I-P!=DJ.V2VI81CJ837GR@X(:W:>_+:Z?|@\.B4:<5TUHN)B(X3DMY+??
4RN/_PNPCY8MW7_MV/(@LJ%KX=1?J"U!+ P04 " !0BDQ:F5R<(Q & "<)>P \$P 'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG|FT+QC:~MK03621A'^_1S80RY8-[9]-
NIL|!"SI^|Y%1^?H.'GS|BYBZ(:E/)X M8-DOV|:IMR_>X%#BVR|*+ M41B1%G|@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQFJ&&^+3&K!'@\$WVWO@C(WXV(IZMOFCU7
MH5A)VH3X\$5\$8:XIQSYG/1;/L'I4;1IE6|W*.76!4!EQC?-*HU+,76>)7 |;V<
M!/T3\$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?
F<-0HACA*FNVB<5@\$_9Y>PTG!Z(++9OVX?H;5.VPLCO='U!*=Y \FIS_LC0'
MHYI9";V\$5FJ?JH,@H%\D>/N5Z> HWEL:~4*Z">P'_T=HWPJOX@L Y M?RY|SZ7ON?
0|H=*W-R-[9]'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M|+;
<\$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;|YZ<5X&N(YV02Y?9A7;>?8T='|Y|%1L*/O/)8=QXCRHB'NH8:8S|-#
MAWE|7YAGE<90-!1M;*PD+\$.W8+C7!2P4X&1@+:'@Z|1 O)256 Q6!8#*Y"B M?
\$R,1>APYY=<7^/1DN;/IF6U;JI=QEM(E(YPFF8\$V>KRMVEL<%5'<|56_*P
MOFHJM!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?|%U#KG[VW>/Z;L!2\$R<><41 71% B.5' 86%S+D4.Z2 MD 83
>LX=SFWJXPD6L_UC6'ODRWSEPVSK> U|F M\$RQ#I|!?
8J*@!&K8KZZKT_Y)9P|M'OQ@2";_-;I/;=X Q|U*M:I60K\$3|+ M!WP?D@9CC%OT-
%^/%&*MIK&MQMHQ#F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V|0-:/8--
!R1!5XQF;8VH^1."CS<_N|-L,+ \$CN'MB|!~4\$L#!0 (- M %"*3%H!:Y&8< H.-<| 8
>&PO=V|R;W-H965T&UL
MU5M=;|LX%OTKA&@W_J)D(=:ND:K*A+%G=7;:7W8~52*2D\$@J" Q_7LB0)(E"
M@G+|78%V5M|4ANO72_0;77FHS 0+,F3)-OK+^67GK(-B,L5%(A_9X@|25>A\$ MX44L\$?
I_M"C?|?4|*"J\$9&EE#"5(:5;^Q:~5\$6L&9UZ+05 9!#~8^+T6@| R M""T.&DQZ%4&/Z>N-
VH0KZD.-%|;@#=#D+X>C?@XF0'-S_/R:&2X2>&4'% MA/^#B1V78"- '8
WF>BOF>C;TJH|/F,*N| M>
|_@E)CXL^,,DF?"4R)0GD3')L:LYKLRY@BLP=C)BK&3;1@;0D_G.(\$>'I-7 M|
(F|F3BS(WF>YY|_#^@')L*LMKL2Y@BL05A_15C?6LU57'QZRXV>93?WO:~/
M)GZL5KORXPBLP<_IBI_3|?AY()PR-73\$"

8@ (U4;D)9!036J6^UW) _ZV[#U,25\1K,9^AT0Y!P-69KCS#@>;@!LH\UJ MMS-MCM":M
4U;8&UEK?#FTF\$FSFNU,FB.T M)FFUP/>M*K@>)&|HAK.(0D0; VU\$/ _O(.5 Y9!#P= IL)-
&.W^YZ3J6^*|0F MBI78H|=2^^,Y@?AFZZ=VF'.RG*I5VA-LFJ=
|VIG|*MQI)'DC\$ L5YY3C%>9A MP8[XG9BLAG:KG5G;A];W:
I'OV^7Z:N)#\$E|.1"G%>@901OZ!%I_Z+I M8N*GS@5\NWQ?QC*6IB
TQI)%SX%UF2IUOZ!79M7P>L;B:-CYXPM((1+%@&HJNM\$(5Q>+O>@-DB M*NQ6._.V#
I4?U&H_V\$KM_162(I.85_+"W!7M2%^8D2RG:M\56L.L6NT'6ZEI M11'Z4J23%J_-:
*/O'X4GP?FYD2ZG,M\56L.N6N8'6\K|B"(B_0\$QF&9DB.= MBX/+<24X8N-DXP;T.^.*B-
UH9P+WH?B#6O\$'6RG^)_R*;F,8-.F41N4TD,7I M|)#G9T>^YYUZ_IF1!:=ZWQ5;D|U:
|P=;Z?U!'_Z.%Q>H#MX#|UG9I^S0PY9 MEN%B-I?H#U:8IS?
L"#M3N(_5@:!. "8*M4@ (SA4|+4I2_W@#IH^N"Pl.9!#=#^M9#@VDNATO<
56G/;09TDA%LM&*Q(*H|B'|/H%*,FQ_VY!PJ?V0,56PF^Z| MYV?
J4)8IPKA5DL'-6_E>&&DS(YT^|%(EM,LP15:DZPZ2PCM(O|LAX8Y.L) M^A?6!?
7#8@CKX>&)|_|1NJT+LLM|W|'G.!VINP_X4EH).GM M;J|Y
EAG2>\$=G5_QW2V/H>,RB(^-H#X1Z>GP=&9YWE&OIRF"JH0FGS5J4)H M5_FK>8Y!EA7
7+DR8.3,#M2V|W<-+B?4X3!5=H32KK1"&TJ_HE=^CC:S3'V8RT|F<_/1E M;|X-
_FGDRVE6X JMR5>=%81V";_8IN1T:B| A!:\$P_|58|L|0/V=^K M97_/KM.7++7NE;6;/W
:D066A,|5JCED+"<<,J^|!Q-S=K"=M|N0_CW:N'? ML\OU)7-*<|1MU=@<0WR5TTV?
<9"X&@.!:|HG,RUX^Q,W#Z2@%Z=!/0VS/17 MQ-WG-&OCS8Y060H\$ |"
<\$|-.&J|/+NBU^PRK'2*0E+\$Z=WU|>OU3HAO!,WO M'T%8%8|/\$&A9'4;FQ1+T0P?
=80F.|%#W!"2 0I(j8"#6^K>|:UY^F|P4\$T%C MBCF%'PX4Y&^_G 6!|Z':L*+O_
_O\$-88(Q(1I5E7IQDT\$%R\$A_I* 7"2Z!(T MBB/J6@.,ZH+: (TL.5!TXF:M3.5
FL\$|00<)\$^+=H7I=CZ=SEL30<56!./ MB/O=J)%&F<.,\$19S-\$W80J
IM!L!5U6/57'DG!."W@B&3D_+OLC+M3*BCG?|
M7*5#58*DT&M%Z_7)F%0<12S1AW|>2/*F3A 1SE5C.,70&G^-VD|7S5GSL&3V
M6#4L*"WV<^M6;?/5?#*2Z)U+ZEA^ G|4R2?
5'Q94SG54*#+M#CFT0D3S!#QW1C(H20)>"| ^3 M7):MKK|P=-,NIR-
3&2I2^&:\$CR%F@%|20Y,L:5%|'"3|(I&-8C*=EEWF_|"1 MP0W-
9VJ<3M6X0FL.W^H>J_U>.94ZTK9,|7|O'11|AA%+>8"*)&N1'|&E'AS6B\N7O56> MQ=
#YA+=WMZ6):"B\B=S@SJ=5G%*5C9H=^UDI-KQK4^80N!0W;H|)+EZNCK%M.M!G-
|OUZ^41V,j8;1@7*"0%3,/6.3T|ZB)>G2LL;R7)|SG+"I&2IOIQ#?"9< M00"_3QD,?-6-
^L#J;_5_P!02P,\$% @ 4(L,6LKUN3K|P_Y2 !@ M!X;"|W;W)K,3U_
MSO)_B@VE#/(S8)FEQT=LPMOLZ&!31AF|#XDNVHRG_YB'+MR'CM_GCH-CE-%R7
M@|;))FF/=B&<=H;GI>?W>;#|VS/DCBEMSDH|MMMF/^|I\$GV?-
&#09%G'6YH6<9:"G#Y<|;\$PZQA|8D;I4=,GX06 M-1"AW&?
9/^)FNK|HF0(136C\$A(N0_WFB8YHDPA/\;UVVCL\4POL7|IX_U8&
MSX.Y#PLZSH(_XS7;7/3<'EC3AW'"?L&7V?\$WK@(CP%V5)4?X&S|6MV0/10F#9
MMA|,\$6SCM/H;_J@3T1H_K8X|J|Z WCH UP-P&6B%K OK\$K)P>)YGSR 7UMR;
MN"AS4X|FT<2IF,85R_FW,1_'AN/%?+6832>CP)^ R|%L-!_|8'7M^|*\$|,'= M: @(^?_H-?
)Q"H)-MB_"=%V<#QA_LA@_B,JG7%9/01U/F=#H"| #0_A\$EF+X M^_W#|?P 8_W\$#0Z!
(U*?|@KZ+OETH'8+1;3B_JN*I'%AJ|V)M?2UV8400 M>GSQ%#1_HKWAK|I_VSQ31?
=!SHYBQ8=8L<|L|SFF|58"MO=AN%;1*\$3L#*9IBGMF5V!)84_FUFZ/JM"#!A)SD
M6VGH\$M*5=-CB3JBOY.7BUE|&?QO@EA.GYY/Y|/B_WTUO;SB|&&#N!TK@4,*# MD\$-
LZQ2WRL|V+-P|NV\$ _J'6PY?3J.N@000705G|V\$J46'J|R%+*@;9S.,\$UU6U
M#7?|5|AK'H5F5J|+V0O&S17#M+W4_%4QE M\$Q.?XE.808)@!
|R&T*">T8)%.)KIX,E|A\$Q"B"W-L|(08ANAKC7?^ER(^RMMQT TKPE=H,8JR/9>38!?
^%%*M5!IA%.5| MVL@/919D;H,NX;+L=+YD.V29Q.ZH*-20(-*3X* @&*8B|.NXJ
(Q0)CPQCM,
MHUHVU5E3!H%DWD.,WQ%/ @U#9V=BNVH)HZ!'IZ7&QHWG(X001))1WVB")P_LX
MB5E,WR;PD4R =EO%U?|E*|&,=(!OM8AZDCRHO7>CEGD0(LL|12U;(0=WT!|J
MR!*|TNW5LFG'\$8I3DNP!)%GZ6((%:WJOI%/T/M_=[,H,BTVS*|*&8)&>8&?-M-
/'J3T+&5P?+JJ61|B(3JR6K"BY+U>M!^X!WAZE|XG5T56BAI&1GI&U6^K
MH01R7OKV01Z4K')=@3Q%KAK4AI>1GI>/NA&./\$OE6)7| ^#=29<)' +E.|HH
M&!SI&5SH^%\$PG5^!F3_B.K-%DV^1R\$CF;=O#CK33RF8.<B5;N0(EM0JEJ5-
VLZW2(.=2P,M*S9XQ"J#WF_(X3?L(=?\$#5=U_M@*/C-#0C&;^,MJ)3AG98L;_*V4CUBK"-
Z|W#_*VW'LC03_M>@EPF|,'RC=B+L,V82X.^G9A#H'9\$|_|G|8D+_"?Z|@P0T^
T)WYJ=^U9P?B%4\$T|= _9R2%X:B>-N0VB| M'2W?=B3*PSQ|%.^ILO_OZ#C3K3-
JO6Q9Y#P18?|S38FV)F&CFW8CFDX+BF3 M"!UD\$-LS3)?

S*MY.*N^MI\$AAGB>5=_S:|J0GW@WE17J=SBR M1NI#3ZXQA1F&L\$-)X49)8;V2:L-
>TX&\$X|9JLJ1>P+(J@95N>(^578--| ^,^&X7|0 M2P,\$% @ 4(L6LB.DGLI P R0H!@
!X;|W;W)KTDW3|;.* LI.1AV?(BV.;N?|S:|H^DK(GG@ (J)RE.1|HB1#%J:|S*(\$, M|Q-:0"
|O3"G+L)!3-M-YP0#^I5.6ZI9A>'J&2:Z%_7)MS;(^G8N4Y#!FB,^S M#+.?9Y#2Y4
SM9>%>S)+A%K0PWZ|9S !;D8.SG3&Y689)!S0G/\$8#K0AN;I
MR"P=2HLO:)9|98Q4*H^4/JG)=3S0#\$4\$*41"26!Y6< (TE0I28X?M:C6Q%2. MJ^,7|9G,
(^8PHNE7\$HMDH/4T%.,4SU-Q3Y=74"?D*KV(IKS|1O*U04U M%,VYH%GM+
DRDE=7_%00Q(J#Z6QPL&H':U|NW:PRT0KLC*M#NZ0).KBXN' M"3H:8P:Y2\$"0"*?OT0?
T%NF()W*5|W4AHRL-:HCG561K V1SB\$Z0;9YC"S# M;(<)&XUB5NEGKU!;R*P %F/
M\$INB0YSB."4S2FG)3U|6WX MR 635?:|*|5*V^G65J_>*2|P!--
OEL@VD=Q"D/! *XP'E,|ED7J; >3=)M%B|1O2\VM MI=,PLBCZ)|JV-
^GAG<8M>A|/#7WO| ^BKZXX:|KW:1&=#\$>|CV0(/&O#@(/#- M51R|0C%|S_,-
O^>N07=96JX7&.Z&W3: /-^>><1#VCKJN55M(GB7Y@|!9@^|T M|0(Z-
GV|OJ54|O<2O|@6S8^; ^@|2:-UT":.9036 MGA|V^E?YO<>X?Q5MT| / ^6.,DNUZ|<6?-
SR(W|N/|U8^*_KM+L1J|_M?%> M^92G3YO'6%SU|E86_H'B1^%*.;+Z|X
7SK,RAKDB&>?OR<'GU%&Y26*_L@N MAHOKCI;UB
=|GF8F/"GC=_R(|LB7|A61CM| |S:WCX^D'GQ\$GX; M|;_YBW1UW;\$Z;.&7WC9O)|/|2|
(Z9F|>10D^?_1>X'5.FB^3=)H7306/5C| MX>ZO|U\$XXJ!-AH:D*(|D1NPA@:T:\$"/;
<"*!BSWS(Y*|@?2|W^51R|HSA# M"VO9A|R9>6M!WP^S<9^FL?C6%^W2_NUX-
!W_#J#F>N@Z4S|>7!'LRD:WZ'Q_MHSL9S(8"@_8C|!V.'OXG|KTHF@Z?
730I@XZ/3E#R8+|\$,U6T3;QPD5RCDXJU>|5'0|^_G>O.CDS:Z3I*&3F""*\$Q7"7+#!5|4
M#?0\$XSUMD7|AB@M.GQ^@2@^1T0C#.C0|?'-*=#<.:XY4;"A^T&DN3W:8&_B
M/KNC)W=Z";EVUY3|3;.T94QEO3^+4B|0B>N-
AULAN2NO9ZWS|+G6Q_KNFE0,6!OARX!<(9!F:97 M<0Z \$ _^9=HFK\$-
'W1'3EV+N_/XHIV3#V>IMCWZ8QIR5C%9<9>Y<9RK&_C9(4
M140T&D6+1"33<+L4Y6<|P42^0DE4;|_I_QC'FP349,RI+>.XM3_R|M+578|
M_W/K9W@_3+WPU7|)./*2A*>)2(#1>XA>LH)Z!@W)KFO&01@0IE.*I:@ "8#K5
MJ"D%%0#EF98<\$R9>P>92@=-A,N|>+|*W;\$0WD*44S|)8R|3'A UJ|89 M@^F\$6A(U
&;9IBZ-J%.'Z;9V""M0L_?4;"6UP=&1"3&T:WW"6)-#L0ZBNF H MT0-0AO@'L-
:*4^T((T_Q Z-X'S=&&@2H(:MBV'(ODS"86E:B %K%I6:R! MS8'8PDHVA:0;_?C23W>3|8-
05B-Q|RF|76HND"JN=8P13;A99@K@,,\$R\$3K
MN*ZA'0QME28I:1)E31K|IMW)7B(6%>KL'(W<&5BF"G,MU:E6K3EM6:NZLE1V
M6*F"^L,PY<)N*N;S/%J#::JP4(T*IFMR4-1A5+-T)L=\$'68:I"DD2KF%U7IK MSZ.8RB
15@|'0G133K@#@3A3'6G@#.\$PUIC60*2475LJ3_NU*I%:>+6K2%4=+
MSX_1FO=L84UJL.QJ;>Y+Q2?&&U M^AH+G|5%.&L9"<1K&-96@"XKG 5:5"YN-
1.6"V>2B+H<3)^DY%X46G-^| (MO1O.0/6.ZS+'Q
:NA6,=UK7%VM&2F=5QNPT)B!X895/2DU%ES*C/J8@'5+;9*"&J9GR MS(-
PNF|6|ZZ.ZV+= (H;90*?4-42|9>4.)B,1B-.O !4CAL839S@:3/Z+IO>#
MB0LJ1=+J;E:KUIRVK%4|6BHLHE98KA>'0G@DZ#2(DN0;40UBN*%'WKQYVY;
M%BWC:%T(E*V HFA3B),\$=;/=*
4940NRGX)O(^&%GQ2U72O(EB*L2_5%U.KK'X:UBK5U7&"#,'E'Q8%AC8%=ZC*B
MUF5'!;.*I0UD+&S*).U:+A(HF6+=E"*R:2G1J*:L?|^YPO_WV9G;X%EHE1|N
M&CT|W&0U|\$XJ@U.T?H-9X.1N/D#/N!1BL%OG_ "T:-.4 M_&A=IV%#H|_T&
<08B|90CB|D:4@_M91|5RSZG.6OX_5|XM51Y5|JP13_=[#ER!/U7/VL\$ MEP\$0#EH&
#CE,H"6PHVJA=M|%"RRJOWJ^6%!*-
|QR8|R4.IH\$TP)/&K3&UD6|/_S:M.6U9JSJP5(344J92|9,>
M2C7Y;.^U:/>U#@+%2SQ.R0=V0!H"BZ=FW5!^!\$ "M&; M-KU8*1V9>G?08?_
0I8YL|P71Y|>D'ZJ'V=I526V:LUIRUK5H:5*9/B?3RJF
M5)C?JEN;UIRVK%7|5FI3IM:F1SQ#59>4S&2:+6|> 3A3E!M+GE, CE*A>|L* M\$RLE*E,?
L_|TY|EQS1<9D\$NKHK15:TY;UJK>.WB6COW""!%(*VF_|K4UK3EO6
MJGXKU2|3J|C)E"K)|2M6G-87?T236LX'V:E^&5J|=OTV)ER;BI-?MM-;5IS
MVK)6=6P1/^:QZ_YF|*)&@>;<-TH3|_N|^;8Q!_@Z"=A&7SJ|=RI*,|M7|Z|
M^4/\$Q3PI3"i79BB1_'NK8G=11HMO<(7J(TC=;YQQ7W%CS..+|912E7Q?9 M#^S?
7>G_#U!+ P04 " !0BDQ:TIY""*D" "J!@ &'AL+W=OTVfy=V3E)J>1VS-N5>AZUE MEE*
<LZ-W|Y)N\$QQ:W8FX-6LF#L20?#N&LU=4&8820U U'#!@>899I(E?&G MXK3J(S5P?
|YCOS7:E98%\$3A@V<|TEDG7^FY|C\$NRSN2;,>^PTG.A^2*6"?;+
MVRJW:4&T%I+E%5A5D*>T',ESU8<|@-'Y!;!6 /8C,/)=#OS0.?PKD: M1L%X'L+D%B;38-
::#U4"|,8^#" :CZ2RX"|;A|& X5C% 33N)V%X"HTIX4AE M@C*-2'8*9_0^M

X.8432"G,\$I86A,:B8TM5LSI9CJKZ^F5I|I'Z'!=&3#\$+M"&B,\4L"6XFM%;L|Q7WW748?
HW-H.=_::KM P4-/@YO'8#|'X>|H|ZAIU??7 M,GRM(WQ#&K\$<(91\$HGJ-
\$G|U%D)R|9Q^'VIV2=8^3*8MYD84),*NI3Q\$(-^@ MY7W|XEPV?QQJU&>2^9|J\$|J*)L;J)
|??8O3EYAH*S36K,K+% BLM4GAYJ8\$ET M88BTI6X|JUK=XV: _+V|S'.?
ZXF62_S;H|J|52>5.NRIAYTC7QF#%!"Q-97E M|/Y>K3VX9ZSGU7I?>7-H?H2F,?%;Y*J8
_EXJR>7ZE2N*E69:|9(6QCP63 MRHS,-%'?%^0Z0>TO&9.|0!J0?|&|?U!+ P04 "
!0BDQ:HZT3J;0("M1 &
'AL+W=043I^R_*%8"E&B+TF<%F>C95FNWDPF1;@4"2I>9RN1RE_NLCSA MI?
R8WT^*52|XHGG9*X@DQ#N2!"@=G9_6WWW*ST^S=1E'J?B4HV*=)#S_^E;\$ MV=/9"
(^>O|B.|H=E|<7D_'3%|5J@^7B|.14;5(Q"(L*P@N7Q|5,1QA23;|=L6
M=+2+63GNOW|&|^O.R|<|D).L_@_T;7;V?>=?S7Y#WK|^7-_|%8_1Y/D,G/H"/Z,H13?
+;_%WP=%&<3DK9 MF@IS\$FXCO|U\$)|@7WR<>HB7 MLE'A:T3QKX@8!.N8WR!9-
5(U&3Z>8XR)Y9BGD|=|JC5VMN6TC69=(|=U|<:4\$=JVC56V#*Q@96P@<|0)/O-
:Z61|M)(CTKCB1P|15W"KXY*:2|J M=<%Z4ZQX*,Y&LOP*D3^*T?D_?L*V|4=-\$-N
V>V|_|>P3%=)/F18#Q+,AP0+ MN@D94|>BA! |V^:,:;7|V,.'=I6AUXJ36U3F7IGD\$\$|2# ?
\$BP FM5B|VK%KNW6JY%**5 M617+1?
P@|D04OSQ7B|Q\$(+E@0.*+R_.HJ"MJ4S+9JEJ=%*@RR%#!RZBX^UHM M_)DG:"2?
Y\$KQ*YS&)>?O|HQR,5FS5"Y55'&U1H|@?@3S_4+-+L| MZV&'&.I5NK>7 PF908)YD&
(^)%A@:U8/K=2V*HKM*HK|.!7UTK36VY6ATQHD MV P2S(.\$|R'|
M8=WHP8KGU@3>/LBM#I+<+Y7B6\$AJP.DTP;4P MLY4)IC?
>4*/"NE!AO0AP0(@L!:U|HY:MY?:SZG<-<;1|Y+9>RY'|TDL-|O
M4):BA.798U0K5">W(I7;UE(|*|B: MHL2V6A&|S1Q:\$9!@WE'MJR%#!D!@K8K
1B,0&;TU|5%2?)G*@2|02:5G:%G= M8K27\$I9#;*80VQ|L*+.@:|XHFG|L2@*HL&U^|P1
_"VZ#M'2C+N;1|.DS*(J MS5BC|+C*;G6F@2,NIH:KJ!">QG",#<=1|RMG>VZQ+'4I'<;*T-
Y|)%\$3/2Y|84=NE|:HK4E'D=>";%+518@ WN@:#XH6J!)RMBTF(F= ^MR
MW*AZN%_6@Q-ZL\$Z<8|J|&S-6E*/K3*K42*F.KI=3E0M *K4UK(|_AOT*_
M>VEGU!|T|)%#O*GK4QLSI".F@83U0-!4+8!":U=-HQ+B?IGP_VJ;KBW KDHX
M)H|)5.6GOY^#5VN@FB,HF@^*%FS1K,/Y;5=6HRCB'TA2?'&:@U34IJ/H,U T M#Q3-
!T4+L\$|E-;!ET\$|5V*B1N%^_*(\$X:X:A0W#85B=J|1?5"T M JM37*CI N%^AN>|
|:.\$*XJ|DQQERU,D|E0E T|Z@>^*Q RBT=ETT4B'NUPIG M45'FT>VZ/E\$F^?
ZPSGF,KM(PB|/|KW(A'&JHUNAGQ*6:_0VH!'AL6|TK ^* M%D"AM8_-\$(@_1"25?
UHL;|+|4|I(UE%Y0-|4S3|R(P%4U#;|C0Q(ODD& MI%J2-3*@M+4=5<8G&AF0\$56FT,
11FV7JD*%QG!,,5;&L*|SP|2D%NF<|=I M@(|Y+|Y24=CKW#LO|:150GUI0%9!H5\$!&+-
LU+*R2 *H"@J+YH&B!)BECRW)< M@@|<|2-"DB^EPI(NM(=D7,&40=85P4T.|QJH:BZ!|
|OVF#*0%5_*+0VK8T*M2/X7*F!_T,%#O:L"5J=:F3J)SD##>J!H/BA: (76KH&!20_N
H(="J@:|/. M6@U4!01%|T#1?
%"T@.A4P%9^VY75J(#D;Z0"|O=E|#0'J@*"HGF@:#XH6D#T M*J"!K4-
+W48%)|=2ERM|W#)-|76%*1RI=36!M.,\$,.,@3F>=ZH*|J)YH&@^
M*%IP1(+;K#>R.(F7!8|D_<79H2NV/.)CEKNRG">J!O5!T0(HM/;-:HWH
M1_M%O^@_M.N0(:QJ9XHZV GT,(1?..ZH\$&C. 0FO712,7TGZY"@QF':%
M.&HS@ZE3>W^LP=Q"HGF@:/Z1&0F@HK;9;=1+^DWW^H:DC4W|9JVZ3)U&ZDS
M9.HV)G&BCBVX:B'1SV-X1B|*IZO,W.9;JGHP*=H8E=8EGZRR3=N^/W3|_R
MJ|L|V FL. S*Z*3ST<.P.-|(&B^:|H@28I8VR:+F4N5FB?|H#UDH7I*QP>> MWT=RI3#
|O\$CYW|_4\$|L#!!0 (-%"*3%K>,M'UI@(-+@& 8>&PO=VJR M:W-
H965T&ULK55=3|LP%/TK5H8VD ;Y! 9K(|5-\$4A NZ9L MFJ8|N,EM8Y'8P79: ^/>SG30KT"
(>>(EH7N.HF63SHKQN|)!B#18Y%3T;4R
M*NYY%.A|D_"3P\$|LS)%6,F/L7@=7;==R=\$&00R(U U;#;\$@:0YYI(E?'0
M<%KMD1JX.5^S7QCM2LL,"QBP_!=)9=:UOEDHA3FN++WF1X.;JAI/X"QK^N+N:_D;
|8|R|R@PD27!^@ |171RA_ ;T# MM(<(1=.,50+35'1LJ:K39|A)4TF_KL3;48GKH1NFF
4.TA32YP2VDM5J|;: M^MZ;C!\$D1\AWOR+/A8(M!0W>#_>WP*/WP|TWU/CM3?
F&S|_!%TLL03TXB=@< MQ9(E|QG+4^!"W03^M;|"|=7;O+N2AQ EU+V8< O@0K
M_/S)/7&^;^O<1Y)%'T3VK*M!V|7@+?9PBA|1R=F2&!;GP&%.9\$'VQI8\$QT; M(NVFR|
|4Q>|W.S+ZQS7/3M^GA2|3CH._7;I%J'O?&F'^+XXT"):RBLGX"
M|6IKOSWC.B_6^|J6:Q?|3U-|^@WF" T(%RF&N*)VC4U42KWVR#B0KC7/,F%0^
M9*:9^K4 UPEJ?|Z87 ?Z@/9G%?X#4\$|L#!!0 (-%"*3%I@ZJ:|. @H \$ Q M 8 >&PO=VJR:W-
H965T&ULK9MKX^RZ*I|DQ)G9SPJ68|YB|).)N?7'PF(,5*#DRV^)-AI;Q-MJ_7HDK/G-
/L|WPA1H);,G/1YNBV'V93/)P(|8_YSN1"+_LDZS+2_DQ^QQ MDN|RP5=EHVT|
(9;E3+8|2D879^5WM|G%6;HOXB@1MQG*|HMSUZ^BCA|/A_A MT>L7=|CIE!?'3"

l.=0Q1+\$7Q?7>;R4^3@Y=5M!5)'J4)RL3Z?#3%7P+FJ@:E MQ8I
(/.'=UTA)>4C3O|6'Q>I|9*DG\$K\$("6"RU|/8B:B6'F2S_%/I71TN*=J M>'S|ZQVR%"_%%//!I-
NZL7R";914O_G/./A!';#3T8#4#8C>@'4TH'4#^M8&K&|RLA4
M4LHX!+S@%V=9^HPR92V|J8LRF&5K*3]*U'M?%IG|:R3;%1>SF^OES=4BF-|/M
|2\EI^ ^S: OE^CF\$LVFRS_1Y=7-7TLT1M^7 ?KPZT?T*XH2=+|)ISE/5OG9 MD)#/H#Q-
POI^7ZO|D8|I88*^I4FQR=\$|68E5V|%\$/OQ! 7E5|)7T>@Q\$^!E1 M_
D1BS#@@69O;TZ|YL';FY,>-?3P/FCICW:JCR;HEWK^X_@--
M9->+'XO|Q7SY!0HY9;|:E7U^)+O>"C.1|(Y")|S|. +WW|!CO4|%+(AG04#
M.6N%DQW"R?J|7US+RADE8;H5Z\$.KDTP5U7,NUSB9/QT\$!
MS&S;M=VV66":C;'M\$:>Q:RFQ#TKLWL28KQXKJX&LN\$6.BE26W#/-PB@6*-\$E MJC^/-
^@M2SJ.5IGZ1;)<2+C190|5H4V*B*1@VED#YE&0SH+!G+6"KYS"+|3
MFT:|D\$|B%=#5;)"?)MF1?2_@LHC)4|YR@)B&=3JF64:>4RG^@)!5BYGD/@
M=('/BMQ>1J1_ U;6_1+G&@_B.0|7'G9E6V+)|R|94 M 0-
)N>;+J8R0J0R;&|S@I0"@4>D7A.5V*:>81078=IQ1CM*->XP3/+ MY\$D6L31|
04PXY|4K'^_*;5F+AZ+PX@,XHMTM5#&R|O>1Q<9N)'8|6KP-G
MU4'3L@;UO!O;3(OCT: ^69EJ-*?.83@B0G4V)UR&MH1|@3 M Q *P;8NQK3"-
O4,+8"98SM^AY:&=W_ |S\$#,-TK>-|Q%|7|*XP+PVPOFG<' MJC-)96R|OJ-S#V!'J"0?71_
1W*(Z.I)#?G@?O29UE)R+BL;6D5Y)?<3XK<M!O DK#.SKJFP5)-D/|;'W_4B&RS")
|CHM?(=#8*&!,O MQE267ET-8&|IAK 3!:9#C6D@15R
E8.\$|-82!@_)8J8E#%'&%M;+|0RT<|1 M.2 |2@GI8%?2< OI'<9K"(O3Y'%_1&
MVY:(M&'|Q;:7U\$!NP(MEA' M(2\$-69#WK4 MKG_ EV|9@2*#+D\$-
ZBT8REL|I@WFD'|F:Y6D9J?Y6KR)I-' MIDSQ|@GM8BYG<*HJBW_VT4XM|H"!A=!%
<8">_.8 =|RSFZ9D#^?.(W=7I&Q0B MIU H#858U6M.:MJJ1B.EN5^?
B2_ T4<=P(CJP!3T|/^_?Z?@L?%)N290+<| M*Q*1Y6BQ^(2N/M|^EC-
@22U%9PZ96,6,0;'W@=X=%N".7E<7:C".|&-<=Q=2 MU|-B(X=4@2YYJ 93<-9\$3.
|R7=|8>^Q CG<'8R!O|:@U3\$CZF?|VGX4;KB9? M,E|-HL#C,\$|RS'-
LG8UFD*&4;/\$&B=2D.C75|32HG4%VMFVL@P: '?&P0SJV-&A#B;2?\$H^0ZL,^+|=M
M/|:@JA)Z&JZHR7QCC#&U/%VR:6A3:FSB0/X<9K.N-H)"7OHJO+Q?7T>O:6
M_ U>.'WW|M^0WH*AO+5C>K1E>F(M3&61G|F>;WZ7Z3HVS|C;|DPC1.'UAD
M:86(%R@7.JX|!/??YMTA!L;?B&M;EKY\$.-1MV|%KV)3VLZDYXD1YOE<+|JK2 MI-
DJ2GCV@G*U892C?2(QIOH |1|Q+%/KU=V5R41/&1-77UT%S+ #C.D;D #/? MH1V+J|3A6-
K/L?/M+DY?1+U_A,KE04S\$O*AR2^VXEA&0^504<;GV%7*+%\2? M>08?C:#
_AWQS2TTT,YCKHZ|D|WVB-4Q!Z0-R-(3(M?2E'K-"LS(A.|>H0%
M<@)4:C+CF%AR"#+>|"H.I2W=M@:I*7|2%LN!;^|ID.S^+\$2#R"T4F!ID7B^
MS8PH#4JN0WEK1ZE!7'H*;<;DC':R/-?|RM|8+6"?E1QOI=2Q@K9C@:|HRJRM
MKD%1>F)YLD&:FFC06O86J?@TQ\$|DZC-,?5TB1*:>|V*C0 "&V'8|Z@-KN)3U
M<^GU_!Y|!::SN_ET.?^(%M?5E;RH3HU-KX/J8OZ?|XL?TRMUI P|>0,N4SK4 M6,|S#+#?#
%|?IH4<,MOJ(G'6D"H|0:I=LG|H02.8_/Y5/\$9)HMZO6N\$1692N M0,\$F5S+Y/AS|#0-
VQ"?U1T#M7FUR|2H'E21|C MIL|! #LH@('HKQ61MM*&'EG_->N?
R^ ^WM57GJ<7K5G'E\$P6(YN|I9?K^;@SC:
M!F7%0;T?0WEK!_3HR%T_4)85L&0FA0|1(HNZG,..!001HD%KZ'OH,,B.NL:P)
MF&%J.UT)TM @ZZ?|MH.(T4,V-*U?7TD|ZP8(-I250 YLUS6L=W\$&K|C3F^R
M7|^>BCF:6,N>#(U0<-H/NDXYJ+=@*&_ MT#;PQT| 7TW(-:7GX7?O^*_X25(?Y&S?
5_Q9XYD<.W,4B|5T:7UVY2-E MU7'|ZD.1|LH#| H4:3;AG(CN)R'*@/Y|W6:%J|?U
T_ S1Q|7|02P,\$% M @ 4(I,6H8E:X5|# FT8 !@ !X;"|W;W)KJ%
6>I\$KGW.*M7AZ94@N>N\$EY=C2;3)X=Y5P6!|>OW6=G^OBU MJFPF"W&FF:GRG.O-
BR^KJ5<.,#F 4WXE1E?C\$KMXDKQ89<;|S|9A|2
Q96Q*@^3H4\$N" _^3WP1'?V\$69@PA!TH|BL:)7W.V M8|WIC'U2A5T9|KY(1-(7<
0#&BMFM14GLU&)|T1|R:Y/(S::S)Z,R'O<=>.6Q MD_?X!WOERT<(8G,K)01 |CYB"8MF"%.
(2Y@"2(F8K*(LRHAB^9G\$2NU*K44 MEL36@C#\$|O_QB%_\$.
(%VQ6V|JJC*,I,B/,EDC&6\$,-YD)3Y7!<^R#9/>H9(O M,K\$MV|S;+U2K"*#(#<7B8Q)C8C%
<)>Z,><:LEOB_Y-KB49FI#18|
M9)|OL|\$AZ"IU|HCF;C:(^A!NF9&L5*Y_6:QT!9\$WEC4<|0A-IR
M"@|ZC#95O.K9XA=LAL,N|RP,) ^'=T5;\$JT)E"CO|X.>?7LQFDU?S2_ =B^NHA M,QM#
<4X!,7 AO> SS# #\$(.UG!H)7G|FLN,+V3F16T+JY|R1':2_'P=E%AL/,*NKV)CB#<-1+;
M:3Z4NDBQEL!|8&|6Y M|BYOOJXB\$X9B4!_E#P&+;L9.)P3CQ*&@IC\$>K2K'SND
0X>AE0.03_//:7/6,6-)(^|7X^W"1% A!0|Y# 50|T1+L87Q6B.75/VR-2VT M;O6?
*|W2+SR'@MTT6:NC<-=KO!B,#"=&B|QA);">RSYU5BF#@X7S)XS

M?_HA_[A]);'PSG]>G22U>Y?O[PV^GD^,I(&\$!T^>O?+EC0HW5Y%GB_M+U1(@\$+A?
256/\$L/V1^,T!*D%994R=-WU)T*I>NJJ"#A-!E5UI52Z"IZ"*M)F#OI>YZD6
?:YZBQ@'P]9"DJG,1->H6JH7XFN5NE3T*W=7^[.B^%)%P0&A
ML\$"Q5"0H9.3@T\N.BEAE8>9?(CJ)6MF;+>-6|<8C=="6>M9@B
IB4*GP:H#W&!X.5_!06%5JZVK.:J,?-M+5NKDO!5%2&%7!+T=BA6Y[JF?!"D!@KF6=.B=?
9Q=|T:-3NI=^G/IZO.<(&MS-VAR0S;G/4R4%763|WB.:>J&13EZ';M1|-/UU)D;+W-
YCIFKG/:8H MUE%XT)6^|>BS1PK6V'KPH<';UH./8ME^V*DNLS'5!C|*JB'U7DFUJ1*!|N-
4=D1<|J=:U M9TDT0#0:|'3VU7B,V|:
|K4M<4^N:BI05@C(U'6MX%U%I\$MW9=XWZ.O,U2 NR M 2RQR)UFK+#+-
Y&WV^"G;".ZAT-(|L4(=%3M.!E"QBUZ 3%|)\$2;Z5;KSB,I0O
M"=P<7V"\$7IX>^%@C|1JPN.+5H^MW;.W.|.17VBH=CC_RZF6C';S.3H4.O-";M\$-
K_9N(9\CP=KA\$"(J^;<|QLTCIFF:D%XNAN_[1;=LL|3P;|W/=5-!@Q?/!(MJD?
XL57'C6"AVSP0;&Y%01W%DDLIXL;2@1->S2|C=W+2|76P?MQ#I#8X|"(;>\$@#
MKOMU_O:T%?>D>T*6A_=[N'@6EVX;)GWT-V1^O*>XR\$1H?GWC0L+6M!QW>
M<+,5|VQ12|E;|6F?H_OW|(P4XK8Z4<_%|BW<_*U(VFSE,>^'&Z#'(,|;Z2
MH(8>Z*\$JYYJN;>H^G&H+S!8B6?#XJJ|SXR|+"VK(7;|<-K+3|;C4"JS11-?L
M>\$5K_@>T@%8'TEXUU^=BH!\$L7U<-KO3"Q(78^IA8JV|N|=PA^RGR%|
|;:|K4Z11"57H(!_HJ4OG M'>#|3Ts,TXJK2FHHL,-;Y3X+S3^|;^2PP,@VHXYG(0,-AL-
PT6AM=I=J Z5 MEX>FX|DR.-=@GS^0GRTAW2GKDM>5|L
M7:#OSNCC*|V1T5|T"K^XK|)=+=N30G+EO\XT>;|W4;.KWZ'\$;|T10QR?Z|W
M)ZEOP|DOE>CG|:GKQ^;4|=98#*,F3W/LV6|3QG5*T0N.V3:=M+_2;-FO=2=U
MF+QKRNEVI^ZJN.Y8;M^#|GO0?0_Z=^|!IYW?&)U^&|V_N&==ESSW_S|PS!N=9"^?9?
>\$G|_O;^_WM|?|(^_O|_?7^_UZ_VQ M;J+|NZ_I=_WAES+2>U/HMK@UO6IV|Y'6'4O?
<5PW;2|(^H|U|_DU-MQ5+8TJ M,%PM|8N-OW6Q,8;|H|(^CTWW.^)QZPTV|7|O9
YKL"^9-J73/N2;5|R|4LF M*IG&.+V|DYW>^U)V^\$BPP^C?47F,*|/G|_18OX^|H|T?G|
H@OR>I:K_BRCCR MAC|R'BF_O^VV_*CS?2&YT\$OWK2A4|56%|5|=TGS.?//*6_H
(^UP_|4MG|A> MRH(27XJHD|G**.U_R84_|JTGW|R\$)9JW+W&PO=V|R:W-H965T
MW3VG+_&6BP=9 "CT6)5,SIQ"J7J*|W>4B0Q;U1)&2P%DDU5 M\$?
\$TAY)O9X|G|(#9NZ+I09@,G<4W6<OJKE*')>&):<5,\$DY0P)6,^?2FZ:A MR;
<)>ORALY=X:F4GN.7\PP54^C6!U2HD@2 M"|Y%PF1K-
K.P8EJT'IR<^VW2NA3JG\$J69(GM)%H"<^0BP#E%*9E5PV M Y MNKM-
T>G)&3|!E*?&?|6|D8;F.L=*U#0/.NCKSMHY_I(|GHVO.5""1%Y9#?DB M==|Y_ZN|
|G_*F,*V0@%WB?DNWXXT-#B|?|@_)Z'^>Z_.DW0WT-@^8+_N8&PO=V|R:W-
H965TG*,E:-!\$Q<4,WB-\$E&<8TIC|*I&UO);"I:S2B'E42JK6LLWQ? Q'86 M|;+|P)J6E;8#
<39M<E/H'V*VEZL:<06@-75' DH9A%|H=8F+7NP6_*&S5 M01093#9"O-C.
(YE%B14"!KfV!&P^KW /C%F0T?BS8T9^2QMXV-|3O|G<32X; MK.!>L-^4Z&H6W4:
(0(%;IM=B^QUV^0PM+Q=,N5^T|=;V)Q'*6Z5%00LV!C7E MW1>_|>IP\$&
XOP/274#JO+N-G.4#UCB;2K%%TJXV-MPJ;IH(T>Y_5.>M#2S MU,3H-
&4EX!\$SQ(3RDLTEQ+S\$DS9M9K&VNQ@U|7YCK;H;.D)6A|M!>=50E|Y M?)O?
&S,O%ZZUUND0> #Y#>HW|M":9(. KR^3|?O>/T3O&-I7J'-.WKDA+Y2
MTF)V+.L..C@.M>?F3C4XAUED#H8"^0I1|OE3;Y1|"2@/O/(@1_6+0/42S;# MZ|ZA-
IH3T>C_B|SIAH\$%9@H"8D,O-@QR?@A^?8%<&'I;N3E1A=5|1FD.47X
MA%N8>"N6BY;|H8OVH?Z#FW;W|=WGWNBVQ+"E7B\$%A0L;L3D&LGLQ MNHX6C;NE-
T*;|U*_/(@K0+S'PAA-YW|;^V0QEI 'XZ|R*F08N9(L=E;.%S+B MTZ_'H?
0DLZ14F/%L,ODX+J2V@|.3M';OSTY<%8VV=.|%J(I" ^NTY&;1%|9G)Z5XLY+I@FS0S@I|J|!
MJUMP)DOG'OGC)CL=3#@@.J0B6Y#X|T079 P;0AA_-38'G4M6|/|NK5^GW)' +
M4@:Z<.9WG<7|=/#S0&2TDI6)#V|SA9|CMB>N_|GN#PW|1F#4*LQ1W|2A%>2FC/#OQ;
RB)Z|&KH MQ;-+"LKK,B'D5N*|A (04B;B7,9=.#5>T^!;)0L=3*.,O*8|6X.*|=S%YQ
M.9V)K|&/(@KFU&V;V",>+N@9VW0Y|W+5Z2&HF#Z5#,)K/#-^P=="<)'L'
MK|B|VMH|=|OZ&X<#8XHS-9EPV Z.?)>%OK*ZW2TH@%%@DU&H/X8|X,T:/*
M_GP)HCJ PY<#X,H'\$JHZ'10LB__1(S=S|/TZ.WTCOL\$00|"WK_||9O^GB
MY02F(W%YM;AXN+G_=G-W*^ZNQ?FOBYO;J|5"S&|OQ?E|<:/@U?N'J|75L;=Y
MDI;1_(%|5\$;)1":%&OCEH|ZJ5V92S2BHB|JA17EBE+;K8BYC"(0/081'5KR
M"513"FVM>Y+<|Z*@3"O.&8N0)K'29#+.VE+E75".K*+1SG\$.2VF".P!5S@-3!
(705|H|!@|L%SO+TT0_T M_|L??H-)L=S&/N7\$6 MQ|G (-ZSK2;9E-<-
PI=0C4*1K+O9=N|S08X<&+W;.:9>5#)1\$6 MI"6X*@_)7E3 &^BN/25R\$@FO=\$
01)P@4"J6 !\$P'(S\$MOX,'\$QRC,YM3S%4 M2P4B9X|CQ*7WTJX;|L,V|VE;\$0|(1_FLZOZ-
6YK'.FIN=?)|O8?-#(C|ARJ M5+22Y;1+?1MQ,1!RQ77|LJXP#9Y)_6@M\$&JFLXW*-J|

I ZV0VUVL,?>N6N=) MC6RR#4R.4IU R#:7AXV.^5Y=O!3E?CVA&0GDDXD?Q2^?
1K|@>!O#IE;>%0GA M-K2ZZ2BUMMOVU%&"6KYKW#O(-
G&=#39V6C(IJL)AK>%02VE5 UHZKJ\%/3XNL5C9K*FH5UNIC285 EBM;>[:5,YSA45X
M^S|#@_ \$F>3:D:UPJ/=3'KD'?Y"DJI>\N)KH>1!A.P@%#./QVORBIA|I6'I1_
MUV|RD&V9)6VUU(*RP?%N>"2T8RH.@)P MYUXRK|G+?
M8ZQV3'1Y3X_JQ%\I_6=I7?/XRC+-6S"L;?V:KA^V-5LWA;LS,>0K+1P"2!|I
MV<_H|GE&H0N!Y=,TONCG|_*#98^=<-&>6UM!X('XVCL2+|T|OKUW)CAFG5|3
M#%|E8_WDI%:|!_N|?J?NQ.07_E?IUQKQ&UI!=3+Z=#00OGY!UO_1E>G5NG01
M;^#T,|=EDSP+8'_ED&GSP0ZZ_8X^P=02P,\$% @ 4(I,6LCS+_XC*@ M?H@ !D
!X;:"|W;W)K&ULU7U9<|O(EN:|?@7" M|_8-NP.BN2|EER-
D>2EUNVR'95=/S<0!0\$221!D\$> %0LOK7|_G.R14\$)=E5
M'3WS4"Z*3&2>//N6B>5'_&C3-+N?GCZMEQNU3>I>N5,% M_
(JjVW2T)_5^FF|JU22|D/;_FPWY|^W299|>C%<_|N8_7B>;EO|JQ0'ZNH
MWF^W277|4N7ES<^/!H_,%Y^R|;:!%T|?|-E:W6IFB^|CQ7|I|=3.DF9;5=19
M64256OW\Z&SPT\LOQO. WS)U4WN?(\^SDJBR_XH^+|.=?
0"D:2|72:W.R_P_LK39_/QH_BA*U2K9Y\VG M\N87I?+|1D?DZ
MMAG|G|_KNJF(6_YOUXYE0G'W?)"@G^I=LE0_/R(1J55UK1Z|^,??!M/^LSN@
M'5MHQW?-_B=I=??777\|^_1Y|>|-7KQ|?_'FXOSL_>?H|/S|PY?W MGR_>OXT^?
GAW<7|Q^C+Z6&7%,MOEA"X"YKPL:EHX35C./F|4M+3?J#1:945" MHY,\JAOZ@B2ZJ2-
Z/M^G*FIH="(X+G_|J^JVM*NWP9)44.9?3|S;:_|O3
M|J:@Z>K|59VE65+1/G011=&H:EEN=TEQZR;"@T3#HDY8|NMHDURKZ\$J|E)Y
M1F(\$P'H\$>+|?%C*<:;\$+9U#43P>|I7_.R26@#8(""
6H#Y5%94%"6RYOHVN|C51H*.UZRC-:D(8_M\$7!/@TG=5HD_39#@T?
N1F3#J2#C4|HH6T0(RXGW1PHSD6Y54=:0@B\$=&T@=P M@5+1^|)1T2B.7OF ?0@
HREK%?WC;/_ALA,XVN@Y|P'|8T%|="R@|,GLD, M61V=%
<6>!GQ2N|)J&-8D33.L0M|FA1@=^JMW%|8?|:DB9B#JTHAFDS2|TNU
M2V1LM%7RU;+*:%R6|'HM*A(>,>0'R04&K%+:M6)6\E#@ "2EAHTB3*JVCER7|
M+WJLL?CF|/*EQL^3|O'G9>H@-8^=79|:IX;|R7&J|7C2"NR;W\96\AAU6.=^ M/G-2M-
_),**YYG.>CSZ2-:P-%K|+?>M MBZ>
A4IMX&00#DDWE5L5/<|+NGY"6*MK14_JHG*1HLLD5Z1W,'VA?0LF-I:I
M\90>_5FSR=RERTQT%*ODIQ%3KS8(JP%WVI M&;+7M\$=2*DI4|Y'=LIH&6U,
(RPIFSQZB?SLD\W'RNW/&W%T1_|M=*T-1 %DDQW;&;Y(&C9OR6I%+*QE%SH85-
E::RR\$CJ,|2ZY P@S3\$N@#89 (4)RN2Z",&#JK M0WE1UTF^9^3
)A|=>GX39E"ZS"LXF;PE/N&C3G,OV@NS%_6R@(-|RY;BU95
MN66PX0>*6R"FF!UR5=7!;HF@Y0U(CP4)VJOB1H 4P05'-69M%AN2?555V\$ORS:|@
M|C-\$UX0|AR|08*U-K&|* 5 +U5 P9+;LB(3E#/ER0?#TIB(?KPF GZS\$G;MN/FTVW+
=YE^8(WB/Q.5 @T?V*PHV M1>\$G5<7J_5M6'@P)|<6|<5LGKX|^DA&:C^WFX\$24
MA7@M-/Y4F|X/?|PFF26H&% ??QJ")FIS \A07D/\$-*69=V0+T08)8U1|5EA MD"HGR&*-
(E|(-|IA&Y7E=|T|EOL/I*RI&7#2D-|9:ES-/U(0AE0\$A99VTH?DJ% M#|S>3Z^("'
#1WQGKN6WR!W&TLW.9=@KLZAW6+BV7^ZT.=NQ|T4Y'HR%4K(!K
M,>EL:9A:I+2R|CI%K_9Q#;,">^B\$1(3.8"\$C:505"75S8/?',0>,I(:3_00
MGFOI#G9^Z)DDUTF60S6=DM8Y9;\&N^>1E<+^,8Z"%M+W1JZ^%"0 >?:?|,LZ
MR0JC|&OH4DB+CGH-#O?;O5@0T9BA%XK', |2".>Q4(P|:ZV2;S&I);(L|4_1 MX^R)>%_""
<*S3D'#G=,8QJS/:+Q^P.?QMHI(H_\$UAH%KX.*7M(+@SR|U#*2@
M^1XV(>GP;4F(R+.OBA4+67U89?/434;3I67!M440J(37J|2T#@PT0<'M'44.0 M-
O,#PJU*"D@30@00\A0|.R7_\$!Q:W7IN 7'IX:SJ&RD,Y#F4CESV%9L9QUMI
MRPI:/LVNLQ2FRR*%<HN\$&0"-216I'K_DQT*TG)L.G01&P37ASS=TB"RI19|
MJN6+\$5_!;#."R/W;V&;(8RMM@?@:|P3AI;:@9@UF|GV_*/3G|G1S!W@\$| MO*E|NHL9|
T!,QA?OAL5_X&P*-A1"TZ2%L;,@PSWH 502B/+\$(;:1JB?P: MF,6C8(8?
R%,WSD\GHW#F"@F(|:"P^A%?';!BC:OX+AN'HD@J|"#;<7""|T0Q
M'!FK=5*ES"l'(IV6F/M(Z";_R|58-A"?|Z.PBI6 HV*| @H16_=\$!DW\$AAK MV UHY'
YS6;4K(@Y%/G-:G3DD:|PX1IQ.U?*JA<=E)6.3*|I7ZU@O\$JS "P
MU5&68NGT0/K<@5S\$MJ=->6I=GL_59Z-2-
^1:AT94Q\1PS;%ARS9IW\3SB/C)X3,.8*#5XQ^+SJ&'(!&_M&9WF,F079-VK_8'I94%V?
D"W3Z|QV&68|1Y#"^_7.4|@I_&1_9|"\$SSV| MR0CGY'V2\$+!-
JY=5=N4"=R_0KVVB#G&*P59!W@U6OUW.BE=1#K8L?8LX3"L M.J*%(F2%)
J,#B>,G&BS>.1_TAZ"\$9G67%;B_1U@%AG%3_3X^:BBEY&_C|L@=8 M55_KA:S62:R\$/P-
XDKR1!"3ZTLRK/GI&8\(:3!|& U"7(>816J_-|J0Q/

M'="QH@_JDE97J&0E4@H0YBJJT38Q 43'\$@1)FXSZ"I"P37^@G4FDFAGAL*8 M>E?
JH9(QX/B9X30QN\I3EZG*ZZ,\$&WX'P?QX2F*IMK_3EJL.!Y>N;"WJ9)4
MHB?/2!D,BOZWR0B33PN,I4%^E234IHXEAB(7:5+3)=D4\$S"RF9^=%BAG4GS
MK7UVE|PR59D7=7;.!Y/."+^\$HZL3|7I:W&2^=".-29Y!V!6,+IY)R%|OR'ZR
M#8D*F\$(ED7?
1E"17|A,95U308E2);PSU|D(OJ+-6964=P,GXX_(.DDV484\$NM&_+L|GHL|'KSPC&YF
M\Z6++E!=@1UJHQDH)8Q60OI9!Y%BW T16>"3|P?1DF:'7)\$E>0T&RH*UW O
M@7E,Z|S\$)JG6XCQ|\^D>RW3U|99A!XA)P*YGG5',W=JSRL)IK#8S;BJOS0A|+
M/N26&+I1ZQ(57&'T\$4>=E>F9H\$5K,MH=@/8=)8JN9+)D00K;P("'
M0?'FRJYJV:U2!K.IW@X"G_*.FM7WEJR"_%ZRRYI\$Q,#117;0=K@1/5H#2\1" MV0W>
|QIY"N9,B-H)&K.\$5WAR50B+3&-X8|-LCLHDL'|!1:|(HED)-NO\LJJ
M)ST%>7=%N:4(TH5:D4:ETG YLB;Q\$:#-LG,@4>(%HE55:WSSH<|HAMN619
M^%'\$+B'G?'F' 34KLF9AP|\^S:&Q\$R:@|G|@2 ^%J4-P6IUY4">RB\$' GR M?149|
<34Y,B5+^A).IZ*DUC@?95C"A,Q6*80A>|&4@RHN(>JD?A<@|/'1%Z7
M7A:8@RL*.E;D7*_4 8W:N_2"|X96XKB7Z_AfZ!*L9G9.U7D%J!V77)J(BQ=Y M(
\$2=W<%YE4"XH76=&X M4|LY)U#|';N_+NW,7.F\$0&Q@#&|
\$+4(15C+"I:5T%!DQE/S'5H@!V&F6?H*M-
>2<0F@DO3W^A9L#Q6K=N#;2N\$PH^.C@HG/KHEMA=|K*#)P.|?
|T3GN5\$EV;&B<|_N|*_MH.14 <30#^ M82-Y9/|S\$Z77Y#R@KA?B=>4TJ-I+U9W5-G(H-
&>Z))"W<-A8+=U"|HIET'P^+9'KC'<@TS\$ JHUR9Q|SW2ZH6_QE.56O)+(
MICHHD%L184PG#LVJU)QV47:LZ1,5/)^RP1^NJW.^BS^0(G:S<9WDJ.:DVO,.) M=':2
M)&'QM\$@.J.I!'*NRUQ) M7ZH(%F-7E7|-9%|N2ET^=W6N%Z_ ^FR|&-AB|_AS M'6:QCD>
|WV.)*|W4DA;1DW1UOMA9">N7Z*?@6'#8'PR8QLCA<|L200%U(0*&
MFI+T.@#!^P(ZZ:SU#>0%_0CBR,B9>U9_-7J,: ?^TFMU MG=JQ75_E;K&=L>
<)>YEJ@GA".FP1,\GY=Q-J M!>4&PI."M"+
(@*V63#5/3_.0*.F)/%Q1T\$<<<1=X|7T*&JX@."U37X^| M9,0'5&-7R|^J?
9V*&97\$OZU|'6J"C-V.-E>&E9Z6:8KOW:@PC2BC9^(?W) + M%1.1R&)>7C\$>,\$V?+ #B4)
<<%CWBH'P (ROH!Q:;A>|HDQH%@2H4=^^SUD*NX= M%+"K?
2;OZI"\$:;T\$>K3BEHYNCF=E|K>VK&M539V6%(5-H%RN%@WD41;\$6*M9:
(=.@H,)@D|7HTZJR5%SN(G>4XL/8=D\$E7(M;:0^W64S\NS2K=R5'=RO7
M*ZH3W=*.F32MAP^M#?^3*GA"TE&4@5 S\$| B|O@>@_KH/=0H_Y|HT/)*PW%
M1E=Z"/(I(L|X+9(#%8-4@H2<5S|E(2"=;7X|&%)5=BZ^YWP"&X9\$-;*.2T MPE>_1I
U2O>4N78SF^SSFE\$X=58AJ4DR3"8+B6=MK&|UE)9S6D5WEGDE(N.^ MH*V=F
#=I=)CN_JD#!^"R)%/0G|Y#L3)ANEP>+.MLQ6|E3W2O@M%MIV M>JUN=Z..H7
&U|AK!;X17|@YU3;F07I-?&J3^|S\$YX%KG\$E# *YP!:=+UL'N MALYDY\$
6T|F8F293;E8U;52>1TF+:@?%I(L%&UU^?4=|N,,U^04"\$BNUA+& MFG6@G?R4PIU
&80=I-Z|FK-T@YO>2@DU.K3:G6%JED;A?B\$//:6NB5BML1<1+@>55+5/B
M!/>|E8FPC8WL-?FJD-^CZ'N5V'|GK5F<#D2":\,|;?DL,/*TRB5#|I@8Z
MV_,D*>VR5MY|PG/&S2@KLX8|?T"@;RU2EXP*KP7:07Y WV<,C=\$G6G5+;L@#
M*;,E1@P)&%T+"E.KRM:D(N'@VX298=T@FJK\$NE4NS=|)C2GKG.ZXZ|F+04SE M"
(T,XADL63V;)&^BNWA00:RR>^S4/B8YI-1HS^436FCJD?CM)%*U9:|U:43
M/M:|R>YHZ-!-F%V;DJA)EZL\$2SJK1VO%G7U"<=<=\$UG36R!.8/!C|7-^K:='-M|R8J4N,?
>DG!#K6_4DBS2|QBF<)*G|0/_%(\$@6QFX4Q%84JRF:XO184B2|8 MW|)ZO%:|V-L3:
|C#DPU*F4LYCHPW (4?R<(# MU9C)N0")R 5IVG?V7 &3(!*(T)M|L&+00AVYW)|4
M**_5:=VHG13?N;?;|;D<'&LS1Y:F_6G|0 2'1YCH09.|\$8_9=F8:_ VX?F+4
ME<&Y|ENU0|GJ2^C(L/EMT|H|\$SK,|TRVJ+FO_!J@|(BKM\$AAV_83+V|KV=@PR
MT<&#EV;/_J)HT+(5H^A|NJP?19G0.I5IN/6(RMQ+IVK,CB21DSVGC1"5Y!@ M*U4R#-
ZQC@M8#W)UWYQ#0M<\$??G;Q6|7GS|I>?!|XV^#V?A9%\$=GGRXN/Y^|
M.NOXYN+|Q>>+ #^8;/?=
|R_/WOUVX<8Z)Y%S824M2PC=NZ28+4|E+&84JJ:F4Y62%X\$'9%(@N)@UR7A6T|*3FLMX'
MZXQ29YQD1# FYY3PO%F*TUY>2T6.'>%;^M0=8)HR*"#5BEN7'KMWT^C>I\$IR
MUJ%BLOG1VCGV^MB-*?\$3AS!"09-&.^S0*;4#@;2\$%'^U/K:ZUKA&Y|I73)I MCJ\$|-
HV_7H5)G#/4;|3X>LT/7NI?V\$#4A1RA;72QMIBR;8,K>0.'!PH2;J
MV@4OHL8NO&.U>&I^W,7\$;1Z:'TUE6R-=EFK_5' #|06^B:VF2| MG60T;!9+U" I+X
9!5NYG*XSK9WI5I3,I=|!\$>_ T@;!)5F+;\$:(HL\$R<'D,2J M|9FMM&N7.|TSKW-
45@&!)0MF"1:25#*J.L@Q')2EX'BO_?(JNS5H4/D30;9
M|?;:@E:D@>U683ZN6>>2";#P2|N;H,5"?,<^F:&T!\$CBF3>K><1#@XB1!TSG
M2IRNIT.U@?@C)|TWW'<96)97XK3 MO6(O%_G!&\$_/_9KW9M&6M!

7H.W6I%>R=I95#MOJ?G7-4J9)N41- NE^4JWE M'DV/QG3/QK/Q4'Z%)4ECI-Q7!G\FX&
ISC6I')U/K(6<:5+I@76Z4Q\^L^KB MG.OZ5\GRJ\443L>PPA?E;!KLV):S\HV-W?
@V\$B3ZQAC0#Q72HY7=GI3/>N7
MHP9MYW0!.WLB54E;.*%J'RH6))\$CMRP"5V+,C>0!::ZE.\$6DVX'B/+RJS&
M1C##V@79WN9&:1UGUPSR):8;U/>Y#;#\$C9FMQCP YD.O#YL-SU@O/9JBI)>D
MZCYM:CR%MI2;_2B?SQ1|+O=H3Y 0&|9L9523KKC2/:=3(HUC#O /6W93K>*M%=K?
RZYT\J#Q|%?YFL&?_E140+3&W,JZ+8+;V9AAW)\$UKA| 1*QDJIAZ=?X4("M9=XY,|2C682|%73;NS1YNA2T2\ASC*MA(/BRZI8IR&?U>&'CF8=|;|W.('|1 M6
:=H,"ATEB'&BG:1X14#^I_F%/TBIAAVL)'U Y?/=AG;C_G'_9J
MNUH5YM+>WJMD9|6(=:%-_NG|2MWTIT:MSG;5QBB0&R|=6^JJ6EVSZ%G\|E18,| M!
_FA\$/+(-RG*ULAYNRC;9@*|,O2|,.,@Q,3=UB=-CL8I^Y/BIW?U'HB W<MX(#(|<:,!UUG-
/CD0.-^8(U<|DD^C/%I M'D\7??HP'L3|*;X9|,!.?Q@-QQ%H-#PYU\48;/_2^
)%WJT!1M4)*-)I-9 M)T,HM%\&D^'\$UYG.(OFLW@T&T58JQ\|9|,3?|^K'+P0*J|CPGL>#
(=1D_L MIAV'HWC6|P??4&PSQ*"3C|DM3_C4A1GW@40S31?Q?
+J@&>GS9\$30+H+99_UX M-AGRS|,%K33I/WBE<"^#V9
P,^69!O.X/Q|(QTD\GH_EXX@^SOGC<+"(IX#J MY'61/H2Z3%-"|F(V!U%I'^,)?9@0
OLS4'<4#Q?X,|I-X_%P=L"?H_|H_ASR M#J;QC!;!#GZ;Q8(8=#(&
(*7V8Q8O1G+^@/0W|AB>_44\F_>C\$6#
M630;Q_/Q(EJ0,\$SZ#V5.009PX/*,)Z/!QIG3./^_.'TF;+_CPF=A1F6!#3
MSR_@S&_4|LP>QDOLIL#W:4(TCFCL|>SQF:8=9+-
\$.O7\D.WUPR6=; "_#J;+4^1Y|Q|HIG/<'X',Q#"3 5D.
M5XF29|OH/.0#/F8E.!P"BL|:\$TGZ41|5T80N)#:6XS'\$8G%8#XXN0?GUE0|
M|8A+BTv7)OF|9U6%+'#WK64-=WVJ3UQ?O?7K|IBRZ_7'Y^_?
Z|K:@_5^O/|Z|^/#>5'_I0X!/?7V:\$PC:;WFZO?FDCER^I.L28/-^% ML-
^_/KZT\7GW|UZO>CRX%*WL+A?>VW.-LBL6WS/W41BVK@##-N7)D:=9N'#
MD2IUDW*0>#'MHBUE<)/#G_EV|5E%+JWTSZ:.)AU@|2F>*6^3G+4#,3K*QT\$W
M02_Z-7C:|L<:?)EZJ"+@4 ;6|HM7OBBRML"L"4*WG8U2W3*B=@*70*\$?Q M?
F395H&E|AW9:8/RB'TYVH?!QT:A\$-S511W%&LP)/?GE|@Y57+WC4='X&M7
M%%61GNH^5G!5*&E MC"QUE|^ (BK=\$AU)UDU*J@|L7*V^;Q.R%J7WWKYS<.=
M^??O>UXUZ?3\$#29B# 10HI*N

_=^7>Y%RDFJBE@4;MEX&'R(<.>K|J5\$G1!H 00-@!Z?/IA/IC5+HW
MC4,%ARW@(@S7%^B#|5Z \$UR5=0.:!POL*|J3|P+|C8 4RSGY5.LG#4|O-M5
MY1>!9\$;0KC|#:4'3AFB'O#9+B<#JPR64!7!.)EH?CRUVW62;&W@BS^"=%!E5
MDF8Y#7IKJ@:) \$!|=| 3: D_.> 32K9, 7D4(PJG|T?K 7 MBT9#9|D9|A|^I8-1H\FT6|?*(^|#-
^_,W|C|FN-BN\$)+%@.M):;T(X>CP2 M>*;|QOLTN!KHC3>(-B4<7\$'BV#0F
M@PO<2DW&"|,+=GXH+";W298CISX%)GQ*HB;NGIZL#.X?GP.%&ZX_I>Q/
M:9!@GOT#?MDD6:%W8(U7"|*K6(T4A00MGB|4OD!"#05?P^>0'Z\7QB"E+V|
MDR|Q<&FX:.0OHJ?9.O:(&1,89|UIA1*V0!A'?0'/RPL^CK?%=G@:O|;'\$&M0 M_2MA!H:?
G>H%'@6,|@!X4K;E@"(/MLB+6!\$(1"BOY^E\PI()VS05L9(UO MTRT-NULA(/
L@&CN!|9|V"YHSRM1=QCD>%/M5R+N *<%/C?LR0G E9D\$F#D M'M|28G
#L+BL.U\$|D#;RXPJW)BF0FE#MO+,|Q9V=@KB,&%K=>U(28.GAJ.8+ M,
RT\$QK1:O<5W;H.M^AJ+V#Z+O-4KS)+5 IH@%#P\$#9 5,/|_D'P%?)8D
MB4'T\$QJ&#G&ZQ4%X2ZWUF99H"GB%<@H!"*3Q_!Y%%219?)2V0?B,YXV(D|9Z
MFC\$BB_?S7;D":P3(TA8(OD_=6|W(0-^=X,JMIT@^* 45,-=M1:|"+3D-+ M1FFIM:
4GBS#%5D%*C4KO%P06;P3S/ '4%Q4%NQ\$%+|HG%JCZNP_!&_.D#% M&IU\$.6|
<&452(0Z2)(&8X 1S?'P0?3";I\$H)58XH?BTR|X'0??S.SFC1@\$7T
MAS\$*9|S4J"RR0|=GOG4'QWC#M@I9NRYM\$%TXSJ9LELD<&?G=P5&G)3R%&,9(
MPUK0RB#+)3%IG:,EO=ZOUWAY%?H HM51E"+JJ);TL0.X:&XX;Z".>Y:1H4'-
WUZ2EV*Y#_X 8Z=M+)IC+&4Y5; M=Y/(IY\$1&^.7Y^AUP|_C:#2;^@Y|GP1KVBVD|
(5:|J7W06V\$N0\$*K|<0'P M=X_>:).0NE6ON1TNT0&"_U0|G@#:D0>H02#W&=B_3K(&-
R|QE@ TCF0)YT MV|:K*KMV%A;/(E-;S(JE-X0<&^AO"474Z?
XU(4^!SL6F1=%F76')E6\$*-VQ MZ0=VB!MC%RS56>6?P6ZME8DJ8:2|#[WN?'
M(:IU'E8")_P%&0E0.JP8A'+@+H)/+^B)| S&CSN#\$-8A9-\$. "YI!GE2*4X=G M
<^PI"Q'65ZCXRAA-9<@5>_A8!.GYT"2"9"XSY"+ @AN|2^4&^!(1,P"!;O> ME?(HFW;
(T\$'K5..*>)?*U.3UT0,;?6|^9H>:WEM2:Q--5EQ7(%S)H&F2E+6 MZ|SK4R'(-Y.U&JGA,Q
C#KPJ(0-GAJHQHTGL?-A|J;*I2RV+UD0G"H^(N?JM M?7>7W-.I\$BZ*Y44-
K|&7*,**NVG/TUO3I%@LR;48F&1|B-N<3:'U#=#PLJ/M

M%A5X29O>RVKL+JOO@W:%HBFK^XKZ9'O1NX3B!MDBJ>K!\$!+=HQ^S#4+)+AM
MU!59WB(P=MB=&'41./9R\09M6X%ABSZV=/F\2Q\ZJNCE%:9<^H'62S=(8 MHE
W+/GVO!=WO'CIB2.9W3O=I,D=6J[0NYL##=;\C'!L?J'"HTB./-LQ%/I
M0YFT[H!TS22'T=#I=8N"-YX\#NNNJ9NDVK!8I>\$OR7;WXI4B(VML2"T@'J1"
M7:ACDX=Q(O:"A)[43U+\$U"/=K::B+Q<>7) B"4^S-IO)U5&.)LZ#-0\$^H&\$40=E
M>Y6WAW#WJL+%E:"Y.=))A5"\71.>.[4;LX1U'Y'XK=S"1!6.B+@.SA&:017
MU#HH7&M9X_*&8A8[5B9!MHY\$JF M>'3NY#H5B#@LKE-
#%8PV+Y0XQ51E7I.>\$D7XFE%QON9A+HIME?8<#&=HJX@_MS!_?5\[@-D6;>YXEX\$=
+MD-8=PH@OV.R/VZL[.:^VM;[46\$(7A;J;N@G9: M5@2D@>HVX#H+ROI*+%Z,D,G%
[8Z@WH",)P2UY0.4 4CE(G\$WEE=JHD,+< MH9!"HOP6\X]'2P-0%U!DR9A4D=TG^4J<
TY>PM!5?L-X.+JH" M%NLF??WJHXT+(M&&GK\0?9@N0XRX?LH&_#@@!O
>"&\$3GK6^0B#"AV53M,&9S5;N"10*!<=.(S,6\$YWUFN,#R(7
M@H0&MKAP6;WAV*+12GD;+=W<"&K84-\$P#^"7P?X:S>Y17[7R;+;+GH*1MVI
MJ\$,*I3JD6&04_8IE"7+AJ\$X;>*P_3@:I%;4Q%&K8V4'#PSA_2C*0!RO0C@\$# M+@,|CR@-
I^80;5D70DN#1.(N&O\$7RFMG\$:GE/CUE>8-11[9]>L@),I+/VE@9
M.@M;|V7|X\$89:9@906!!Z@YDS1@."42;BN"(S[4:A\%"G%:=M|R*.&U3/!"
MB..&'CP^OJ%_Z48=+;_FF,J'GPH7!POW\$KTH0Q'DZ,9VGRM|
M;.,8%*=K12(Q:=2#A^F713!5MC?RMRAPT>(MSA0NTRMP5\K0QY3D-M!D8YM
M7&%"[MPUX7;Q5@03K-Z5Y(:O':AZ.*1X&COI&F]?'C;T#^I0?\$,>9)2*B\0
MOX<%LPSC(HKK(*)80/^H\33QI0(J_E\$5JF4|T?6K<%8C!K8'MAU>S6/TED
ML"Z<(WR9;3HV=*-W/0Q;6@CQ3?0%MO1\WYF3-4:B-%T I|7*>0%,9&.LT/H, M-
Q7%GH(Y+*^%W4V)_N3Q&IZ7D857S"K)ZDLQ^NZDN.^(!N56U"EED'@)U^8
M4+.=&\$D|SU)OH'/+S"WA-GZ4CMR=7O!H/^AH%>["57\$-EGM\$0'>2OE4.T0|)
M@KX:R<187XO1!7W A;L VEJEE?J|5Z>F2SP6C07.-&R;PK\U%M"3*&%2\$5#4 MKL_0Z%
(V.D(.L;AXN0" LG-A05|G0>YDV|H[Z5V4 NS_1NF%+7"RB::>.*N# M^=)(JY3XW12ZR
GWC67M7=I=-^K/A+H-(ZC?H:7|B-6CK?RN\$0.12F.F M#B*VA9ES&\$*1LL'JWT!EO|
AR,+LZ&YCV0WO==.ZX)P\Y1"A94BR43LD2SKG
MHA^~*X%8M+@7K1&6|Y'4\$)SM<9(4=ED;:SRF!!5^
MRDKGL\$E7L/2M!>J*0.&E.KB5'YSO"UJ-=JU"MXNJ-P/D\S4L*.NS;%
MNIQX.QE*8I2%N>+. +BX8R!|H==H4E\$S)DK?OJS5.C<_3*Y(56KU;+H=EI':
MH\$6*M2.+%);ZV/WC>Y)@R3H*&74*|<@:ZZ#P8JM8YR\$IT-XNM0G(WJ9.\$T-!
MML\,%/N\$R!|L(*?S(KW?FP-0%1?D93T>O|.Z>IE0F(D&0|H5&5R\Q6F*7@KK M0'.0|"2Z
3/>#I;JGQD;!*LJ.Y!WA\$F&W;>^>X=-Y1?S|O:S_YR+;
M_|G0W)_F^)#8=5T!9WI!W\$\$@HN1- MA(UL.^/<)+9A|
(*&MN\$)3^H80QGUIPIRM1^8"#S/N;&S-LP)>.@QL%#.W(F M6G9_WYK3NC\$|CBNAE
H7PG609ZRIF_/A/(X>!^ PE1->5&L7ZQ@V'%I%FJ?U M,V6E"G,)%K>/DIS\$RC:MS<|<-
\$C--H+B0MW=A82W%U= XX\$PL=NGU'DAL@% M'0^I/O7HJ4E7NGWF3B%\$JZ?
(DNLP9AWST.IU)IK^D9D&Z/0@AQ^FY@*2005N MU:5662NF>=6(U60|+F!F16=:O4-
G0|Y@ M\$EC-2JY:578W">R:|S;>^Y!G3H\$T|0/63|.HYZ+487RS(MV5TA96ZN078J>
M/'_L@:*|1!@\$(|=339;0N)_@#6#*)>|J\$S:'&Q*E.QL|Q)JC"R"R,54E
M&4*L*MG*D^S4+)4\$8Q"<X0\?4#@C2'B3+T06QV87C*L|I# M@70%1W,,
|+%&VWN.0A8RB:IVZEXH#ZBJD\$ M ET5Q=M?@R.#B?'QJ#%F*5#_-
MM"Y;C&^FP\$!TN;(3EY|/" 66S=>;BN^;4(*8.L:=U0LU3!L#GH+Q0=>O)?
RXV^"F!|@FX&; MBS,"XKF6?" V6ZH?FOCEG@N7 %V_1S1R6"Q*^|9)R&44";ZFFS@B,>
M&)B,O,5TSD0&3F?6:"HCT4UV8HZJ3*R2PA'T.GS74Q)T| 716!F;.* K9/A6G>T-
2+EI48WS|S|RL(BVP(4HCL!NC<.:W>S M"20J).>PI>|:9|NCP;#^37."5PC('2N&GQH
VWDBDCP;5\$1=R=Y-)#VZG M7G|XPK*+"PK/N\$Y6GRVG<#R&&#XS9XW=I+N<:%B:E+
!*>0YX^;C(-6 MD)17G_5B5,(O3UP|S9W1GB;C9L,|# MRCM3=
((FJ7F(FZJDT*9R+>+!_.*K\$(1J+%G(?
2RT|DTA.N8C0'D\$12*R|"8BXMHR'T8Y\$:^_"L&:UBDI(3N.X>?U0>#!-XO!7GV."0?
M754EK_H^M+#+2X,AD*JEMGWCWUWG%..@_6_W77#3B1W,V89IB=,C*'Z6 V0\ M_HHB)
(+,2^Y\$#SZ1D#>#9'1P_+ SCSMG>FXL@987U;=TPE2@BQ-K))Y&+|8 M+0QB(9|5(
GR.DP:BZJ18B1R>4_.UR.XHDO_W9CB)V;Q-0Q;>(>UE>/EIG;
M|_EYC&U1J^*Q1/K|=E9+F)%:+4_7?S|R15U.@K*3W9X?#Y&YUIF.)4H6=TH
M3DE(TDHGWL#\$F\$-14YPAI1"H2,PZ0+:|WEB16)KJQITA>6;?KO#ODM MJ:6E6W>X#
(RSC>C!G|YWXBK% MRX'JB!NXP|RCXWDGMUE=-*N5V@|,-!0'9|-#3PX2|TZ>DKN@W-
>8C?#;2F6X MO7.KSM;1T|\$S|QY.GYVP"?D<3ZL6R2_.2E 6F\X-I='#@@@%-91M/#/T7@R
MC:>C*7Y:QO.S(7R8CN+A'+|9#>,1?9B,IO%D,CZY\$\$>1MWD.%4\$**)WI4!U* MZ,2.9K-

%/) ^ - H L E R ' L ' , Y I G O (B 6 B W B R F \$ 0 X U S > + ^ 8 G _ H [4 3 F G A ? W A 3 V ' 9 M 6 P ^ C H 9 3 3 V -
) O % B . R ^ = U F C ^ = O \$ _ N : < # G 3 L U X : + D P W O P L 7 L [/ 8 \$ 3 X /) O M : L ^ " T 1 ? # > # \$: T [^ + , Y A I -
 G S T 3 . % > 1 H L Q 0 & 9 . (X V 6 [7 Z X H ^ S > + J < [L <) ? % S 2 M Q _ ' H +) [C J D Y > % ^ E C 3 I ? . %
 (!] M E C B H < (^ I C / X , , # A = X N I - X ? (8 ?) I - Y ! / T O M # O : S [J _ & S S ' M 8 ! X O
 # # P : 1 Z / % K B # , 0) B # A [6] = E D 2 5 _ G L ; # ; T 3 / X 5 F [6 Z C M " 8 R _ G , / _ / + 1 (E J , X N G T + # H # 8 I @ -
 ' X N < . S O R , . 5 < ; R . 1 I 8 V 6 M P V 4 , Z , C (<
 9 (O Y P % : # F : Q ^ , Q H [U ! H] ^ ! 0 & T T ' (Y C 9 < 3 G F B " Y # ; D . : < \$ ' T + +
 M < 7 Q V O @ 0 R ! @ (9 (S 4 [% B V _ F N D < 8 , 6 _ & B T) & 1 % K Y K A P , M H) A [F (I S = 6 3 Q : \$ H :
 M % _ % R N / P V M) P " B \$; 3 " 0 ! H % , /) (U - 8 A . % @ U T 0 U @ _ Q @ _ / A H _ E F > - X . /) Y & % + ^
 M U \$, = 8 # X + X , S ? B) C C R 0 + (; R 3 H _ # A _ - @ [0 < [H \$ = & + \$ G \$ W . % M & W X J 8 >) . , F ? , "
 M M 4 Z 6 " V 6 2 B S / ^ = C 2 * Y T - 9 " 9 S 0 = / @ 5 B / F 5 W (; 0 2 Z 7 (; @ Q T E 4 @ X J D > > ; E N - J 3 \$ K
 M) . L C 5 K B Q 3 Z @ [C , @ L C U H ,] ^ J > ! - - Y I H * . F 0 [T , ' V & J \$) = " : = J 8 W - I Z Y W U 9 : = :
 M ! G D 2 ! X Z 0 # C ! 8 P : \$ F 8 W @ Y G " > * [G Z W + X Q W " 1 3 X \$) C N = X R X Y : P [\$ Y T 1 : H " 1 0 7 8 ' M G T V D \$
 M 9 # % : C D X > @ + F [J A U W Q \$ K [& M < * [E _ G N D - H B 9 P ^ R Y M " (; + [; & V E B _ O \$ H # S 7 R " F U Z :
 (W @ = O P @ ^ 7 Q 6 I @ % 2 Y Y B K [5 S > O (R [R # @ . - D I P 2 M + 3 / F H - 0 < (Z + P 3 ^ N [
 M Y O + @ Q P ^ 7 : _ ^ 7 > ^ S C A [> _ 7 E Y V / # [X J J _ G / _ W M [0 ? W X , N _ G ; [] ^ 9 Z X 9 \ B " I B 5
 M G _ 4 @ : R 5 4 3 = @ U * F . I / K 4 G = H * 0 D ' E 1 ; M : X , 4 O + L , Q 4 . X 5 F X < * Z ? Z J Q ! . @ B U Y _ A . M > 9 _ D Q ! T
 T = % [' \$ 0 3 # *) ? @ K " B M 5 * Y W 1 / 5 9 + \$ F ' 5 7 T F / 7 M [W 1 6 . 2 P 6 5 ' = ?
 I 8 . [. L F Y , X ' 9 T K : Q 7 @ [N R ; A S O W 2 R M X V _ ' Z ; < C & & 3 " Q 3 G ' 1 K ' + 8 S L O F + ; I F < ([6 , N V L 6 G
 M & T Z " R : K T % # T) 9 , - , ! B ! ? J ! > G M F X ! ! M F (' - 4 / H @ _ \$ & > X ? H O E * ' O / B 0 " S O M # 3 ? 1 M Z
 " 7 ! \$ 2 N & J . G 7 M K / " 2 8 3 &) + C [& M ; (Z A 4 < + < ^ M Z : : P E W 3 P \$ V I R # & ; = L ; [B 6 M W ! I & Q Z (_ ! < #
 P F Y W 7 B N B ! = 7 U 4 _ B _ M * S I ' % A S 7 [7 H I 2 X E ^ B M . @ 9 " A 4 U D 1 [%
 < , > ' B A 9 . \$: & K S # ^ O Y D ' A , _ H E ^ 4 F T [^ K A 8 K " V) 7 5 ' . * N J ' ? ! L - M H H M ^ - G F
 2 2 T & W G * K / F [U @ < 1 2 2 C V Z N 7 B 1 R N - " " X H Q O Y ? X Q Q M ' . S C 9 ; 1 % X O M ^ L > , ^ E N _ ?
 + " J \$ X = : = H 9 = ? [T 0 4 ? L + J R [: + Q < & ; N C) R % ? [0 K [\$
 M 5 \$ [G J N T + Z T 4 C [* > V : X 1 Z # [5 S + [V @ [U X > ' A , _ B . V X + @ _ 4 ? 6 7 * [" G 9) 7 G Z I 2 J W
 M = P G J ; . S P C > X 7) Z ; [W 2 Z " * - H 6 9 H 0 > 4 2 H 4 (G 6 _
 M V X T J R O U U @ [D 5 5 E , F ^ Q \$ [K 9 5 / . Z A X + 4 G = H .) B T C G X X & ' _ + P ? < 2 L F O < , ^ K O N Z -
 V J K [\$ O = X 1 N K N C M 8 : U M ! E E 7 + Y , I V [* * (I ' # & E > \$ * & ' O A . _ K Y + B ; ? 1 S 2 . W M @ - O 6 R 4 ?
 N 2 : C U + H Y U 9 K H (' M " D) ^ 8 X E A J J Q - P A 3 , ") @ N 4) K _ 9 # O " H W & @) 3 . # Q : 7 + / - : K I , H ? K X S -
 V 5 V O # M ' * A [V _ C Q L - = L Y _ + [9 V T A X * % _ ! > L \$ L M . ! , ^ N C K . 3 L Y 3 # 5 X 8 3 6 (0 T T X ^ H F : @
 M G 6 [* G _ B 8 [, ? * U Z B 0 Z U K F B Y ? P 8 * [+ S K - / Z / 9 H ^ 9) 9 Y , 1 H ^ ; ! ' T - T _ C L ; - C 7
 M : V W D . L ; , ' N C S H C . ^ < 6 : ^ 3 D + K ' > 8 ! 0 0 / & = L ? G V Q 6 [A X _ 1 = E / 3 / #) K 5 9 D ; T [
 M N B H N > Z P) K C " ? C Q % G & W O Q G > V \$ Y % ; 7 * O [" . [X - K 6 M C 4 L W 7 % 4 3 [1 E + D 8 J 1 8 [D 8 7
 M / _ I C % _ N N - ' W 6 P N 4 [Y [T 5 Q & Z A S X G G 8 - V D O O H & " ^ & (X [8 G T 9 G 1 & 3 G M E J O 5 0 S (
 M O J O Y 3 4 ^) O F 8 ^ ; , 8 F Z R + [; ; Q 8 S + S 9) M - ' 3 # 1 A = ^ 6 C) R * / 8 S R > G O 4 1 _ J C U ^ 1 G W
 M = ^ K Y 2 > H W 7 T C [Y B [" _ [H A N B M C @ , C K 6 9 U = B 0 U ; . % J T 6 K , 3 U ' D 0 > W # ; [R + [] ? [" M : M -
 = ! > % 9 / (\$ 0 [(\$ 8 ' Y N D E \$ M 2 V V U * , F U 3 9 B - 8 T , 7) : 5 V " [3 6 4 " >) X [7 H Z 7 5 F
 M 2 W 2 P W O + I ^ (* E U ! U K P 9 8 Z H \$ + B 5 1 W V 0 V 0 # R L [' O 6 [: I 8 Y D ? N) J G F [U (M H = P & A
 M : S % 7 " 6 M Z 1 0 ? 0 H P G [V [N # O F * Y 8 ? O : T [Z ; 3 4 I ; 3 ? A E) U I # O J : - 7 E @ > @ : Z C \$)
 M M 1 + 2 I R W S ; _ / ([@ # 1 [G T X [T F V 8] = W 8 = S ? (> & B I) # ? G J Z _ 7 S 6 _ U V , A [W H L < \$ " O _ M U N (
 " = [F @ O D Q Z R 5 7 @ ' 6 # > 7 T P L N 9 (% . @ E 7 0 6 Q ! [\$ + R 5 Y 0 ? - T 8 U [W " _ G 9 4 C J M C T \$ V * L I 5 J . C . I
 [= 9 4 # F : J E - T G % - M M T Q N O 3 Y V O < (- Q R 2 T / C ; [I 5 7 Z L L , J Y Z M = N , W U) 3 7 & E R > O [T ; + 8 2 Q
 > W D [Z [. H = Z . S " G = ' _ & @ S H @ H X Y J [! ' & P V C _ [! , M C M R T U - B & R > 7 > (, K (Z 6 P ? ' G / ? G /
 M Z % * * M 6 @ Q : # & ' 6 9 > ; ' + & < @ [4 J [% D J U 1 _ O @ Q ? 2 Y # ^ Q # U Z 7 + . . M I R 1 N 2 O [2 A
 N Y 5 C 6 G C [M M Z = 2) - A / 4 F N [M X Q V * E 7 ! L < 1 B N 6 [M J - & X F [+ + 6 C 0 J + & 6 * [V C O Y > / Z *
 (S [> R [; # " H ? > 3 K 0 M M K > & [I Q + J : A ; Z > L > W 2 ^ / O * A _ C 7 T 5 [: - 4 L B # C N _ ? ; T -
 1 K C * # . D S + L 4 Z [4 Q > \$ [M O R = F A _ F : L B L J D [V [B ; X [(0 \$ 0 1 ? 0 I Q @ 7 . S O C S V 2 @ ^ F ^ ! G T # [
 L Q B = 7 * (R " X L ? M 4 6 # ; * ! X M S B * R , [" 8 K 7 # U 9 ' # [L , Y [8 8 Q N / E O Y ?
 Q & > + & > % E > W < ' [C ^ O = - J 1 M J . [C , 4 E B & ? - V % E J 4 > * ? P [= & F K V @) B 2 ? # " < 7 ^ + . + E ; ' A R V
 7 + : Q 0 R ' D [B ; ; # 4 M T 7 (1 S Q ; 3 D P , + _ & 0 X C [< T 3 % & _ T T 7) R S (A I U / @ , ^ ?
 4 9 C 1 : \$ I A L 0 K H _ H 6 " 6 ! P O M I Z 0 R 3 L [B ^ > C L @ 9 7 . Y O ' R # % 8 Z 7 L ; 3 Z ?) P I 8 M E /)
 [# H 6 & @ W V 2 H L R Z I - N H / @ S (M G @ ^ ; & 9 Z ! C @ ! I S X % W) B / 3 M Y 8 [3 P \ A - [B X ; P D # A 6 < 3 ^ ?
 T : 0 8 0 7 G 9 L T J G _ 0 & (8 M 1 @ X ' = S 9 3 4 ([1 H 3 X # V " X 1 Q C , ' V T ? - ? S 9 : \$ C % , Y K / > F : ?
 + > # ; " 4 P : 2 0 9 0 Y J *) 8
 M 2 % \$ C 6 R [R . 8 G / X % 9 > S N + A : " E K G 8 (V C D @ B 0 6 K C % , U O # . [" J I T . = % O " " 8 I ^ @ D I 5 [J R 0
 M / S 2 1 ! 4 N U R U > M 7 B S . + X V H 3 , ^ Z 0 3 = (; ! 6 Y # 5 8 A & % F 0 M ; F U 2 E ^ R R K # 7 E O 7 ' 1 C J Z -
 / 8 ; + P " & L I / -) C , 5 6 7 2 E Z 0 E G V N ' K M 9 ' R A " B ' U N 7 ; ' M = K " & = 0 L 5 _ T X = + @ I [[# P 1 N R . _ &

@K>E%,TI@D"N.L'-E&\1JS(U0MGA0N]QT
MSAL=R4VW(0'XNU^//+,YU;U"C:M0/^XO*/IE2/6,HY|%R CP|Q0\$@HRJSZ\$Q
MHI=0_[CA(OPOGLX"1_6N,^KG^ETSF@8'!*SF5*9I5,BIP=Q<*>GHU+|53 MVFEA+
.#RJS!Z) \BR!GA"+J4!B'\$1\$M\$K3|;3';V MIZ,ZC\$U6>W-G A8NR!CT).)>F
GU'KN1M5F0W|?(Z^5Q.\P/"4'DY"B9=@O
MOAC,G1T)OAA|7X@9:CH:3+MM3;V(|ZJ=COMKDU|=P*Y/.8H'J0|V?UR>_/:A
M.O6@FAYFW_C*?|BRA!W*X|@8(I%_J3MJG6G+8!|UCTFK3;GZ+)7=;:"Z-G#E
M'IEJ"+^MA//AZL-|H6H%A0K7!HIQE^*AYUB-25>-8B8Q'O8\$
K7!SPB1OC:T"C;OP\$W91!CL:| #J&D_9"!5/BFTCBZP&|3GHGH6YLAX-8ET!"2JR-M*
<*8QB'-'|O48A*-1K"-QI85QV9|4RN=1'|F"BX|B!\$_J8>*RMESS|GE-M M+Z434C OL#!?:
&7DNLJ3%YK.A\$FU##HXIU|-N<6\$PV&)-1"@DJKE-B|-,OT-M-
B,KYTJZUR%/\$IBZ=B'R&KL@ \$^%*_HL-)YKS^LC*|AMYOM%2H+VX/K6N
M%|M"AHJE4DXP-I32_C\$?.4 BH4VT6%A|LAD==,|WE2S1P/Q'I MD9-
F7TGY>TDP1RL+/\$+@C;FI4|R?"#2HJ_H,JH7YGCJ.!|/%;KM\$8I)<.1=;M6E8JL?
OJ13X3;RC9BL^EIDZ#H7I>Z2|&"IF*EUQH|Q*,H*"|<441/R6JQ
MSKR(RC&H,/2&%)84\$!XYLZ(L3BT@N+).6?VN_Z0JK@F:R4XI6X|W|\$6?'EL)
ML,%_VFJHL:.'N;\$745BV1|E'L/|6KKTO*UU|#2+5+PH)V1D3ZWUKFOCEU|
MVLJJ)7#G,K3.<7TKVE1AJ@XJV-M,Q**G|C754|_#VL(*_@R/6))9VGIZ'
MD3=0(V.4^(JU-W-8,*_TJ|R)LR*^CV!|BS*"&K*_6(J'TQ_M6SQI%+NJO96|Z8/1|>4?
3@ "W+R.V:;+4!Z4-8R;|)5_BG%ZS'?OE/FZ>'9:(M^DHC2V M<4S8%/R.XKOPBI/"
(*BD;CF2VKZ=63=6E2"WM')1M|Q3DI<&U7Z6L*B/E ?W M&U&1@!2!|3YN,
(NK):%W;|Y:"86U8B(S6HJ7M'K<0.=^L_GRZ
MQ@:V0<=M+CHD=,M79|VG'^SE%>"#SAF@9#M+*,QS|G7T)N\1UZ|L8BT:#XXW
M'9P\$OWBDEF|Z++:8VL<(_\4Y5*M7|/UHFJ/*9SL0';TNN\H8E+ID"4_N":5(6ZU*T4XERZ
<)>BL;Y87'|%|1FE?Q-JG3Y._1SWEY#>->M<4^F7Z3;>G'(#;M8+-
EZ#ODLJO:.)#TX9C|EJ&B""7GX^>0X.YF@4_8TFJ*#*=CKDS^AGG4|H|VP4_|R7_Q|GH2'8B|
N*:"1:\$@_34|RA'J-G,;MCNP(<-\$1: '#|_@N0(L;6RMRM|,B*J?@7=NGV""/1 M?
CTV74D:AF!GG*26');#|GE')_ "DJU^_9<"NDRHO4:36ECDB|'>AL(I"7= . M|394,
_FHY+>86<"11Y7TAQVPTGU@GJ6I=AA"6UC#N*1-MFM9G+R1*MC/*M|
M%ZX" ^M'838*5L,Q'F723X.E?\$_^|4ZE3^9X3#_8-F>H.3|=M&IL)YO|FM TF M14D|9H1
CNZU;+N>*N/^WB>7'#OZ\$;EOIS7|:|?2SV6|%1B|)YAT;7.<<4X MM;3X*TT^".
YM)9I2RM61Q\$GG_W|QT.2I3+X0A;"I_\$C0.8B_1;+2(-Pl.47Q MQ4H+3PMG#|-
H_'S08%WJ,%';Y)K|*CC;,08VX8(W2XS3Z|EYF_%NBN,.O*% M;;L#YL:P)V+M'/<,7,;
)BS|^B"Z14|%:S|\$+E&WT*#ED.M!RIHWY<>!,I> M,H_\$SBV1;EEM+|R&Z=*0?
+@RWNU)M>&QNY7KBR5=V)1QS"|H6#.|C4Y""&Q
MQ;K/&F'(:Z@P6L'O3BHBW|C|24+CE!WPVL0S3ACZS7WWG+UD0\$2"1OH*8(
M8:N\$2M;LKJ=:005U4%.3+/-=>9#2STP0GHCA80\$N0;F|T0R64_YK5YE3/'|'
M17_FH'4\$2_1EA5=A@+B2.(XF!A(*;"S4&01:#ABA((5|2BTK8"KT8A1L#4*@_M<1F
CUQ7Q=N.IG3|H19^VZ?<2SJY|EZHWN="T4U.RY5&M/W00E3ME?XR=+
MUX|K>H"7\$|L"4>(<=&_|L-6MTS5E|!F=S//&H|H7*2@0\$?:U56_-/D3|(6@>6
MZZDP32NG0G=Q?LLM4CL'_%|AC%GE^N@Z?+E;4M>T2;MDDM1GL2D0AJ|L?+D
MCM%F2R8-*R.&|V!|9M*W6IW,^'ME8UQI+_:;\$9"1>X"-;L?=4J_00-M)8+44
MZG3"S4BYK|=ZV"=2#!\$Z"3SHEV28-VM2M\$.4<.QM_YSG9)""RM00.-:88P9
MKDNG5:N)9H;^R4B:%7|PF/L=%-I6U3'Y?%K\$=9Z!0"7R#_NS|_*_"%))Y#Y_
M^@9323KE@6|>+0I_"Y)6E'R)T#X+/S5!2ST)KZ|>^@1=R%ZV(*LJ+F;/'*M
M^2*YP23B'BPF%D|D3<>5,%=6)7;3SB5"C-
H|Q3PX90"\$|WX|=Y#=\$G|3FZKU@4;'QB<;K'Q@8':U=MO>N4"!K)Q:N)Y;+=4
M\$9"6:M)'|Y=&|'W|D1N-_ZB=_J3)\$;ZS#L7^9?F>0J!^U|F3A=EN-/PQE(9\$
MW&'!U5K1V:|H|3/P&D9|XXX|NBG37DDPM?8;_X76=OTH9V4,A|\$V%('21^DN
ME7SBBIX*M'09GU+1*5P@.LC9|
MVI\$VJQ%#YU>?;)0=CG(Z7,2130=!=;'OHLLM%1X;1SH#5+^|M%M5T52U2J^?
F!=BQ=.I&XYMFP.<+!=V+MY.B!H;:TU%4 M"I?/I)!!^+A)-
CR94RB|F%U7%U"|D4&2C%M@YE,|2X(:(\$44.-A=YJ@<;29^
M|^#4K+@4YA;DK#7;X3CBZ|H"-|<6LF.F| MPY: &%FL+;364HN=*|B2';.PYQJ9HZ"Q8;-
_K9X3\$F4+8# MRU?9GR*.02Y5^X"XV=)8;:!"|SPUVUZG0F('G_A8N"QZ?
WN^_^|*B:N|,"DOVK:_.7*O)3@_M<@KEZ|HMOFF@:#H'RCH4OVQ);8^IH?T.T@U*T
KMPSK2+,K93/"3BW.|\$N<
MM9|>860I/P3S2K(F0\$%_)T;CC'/>R"2Q|=6_::1%KE36^R/J"#B04S#WS-54 MB?

GO8;L.VO18*?)IK&BQL56R3FH3C#LH=(9\$FFV_O"VW8_RNI|P.*L95J_M
+R25)6&^T";#XZKV(%8|+QY8DW6,*L#O&92PJ\$Z(S.I"9=D\A*NCHI_P8
MPX*K>OFP%O7&Q_IK.:E9|6I6Q/G8_9F139T?&)W;(N7@1UT#T(\$&F(]=9>;6MQ&
|_L_L1LCO=1-.T|K_M1_/J/5:+M-
/:VH?"M"W6JQ=3I5(?;F7O1T\JR<*(=F+-760"T"YH7HNI.VK0K*O
M#5PSMDJ'LV6F;CAJ"E&E+(YIM#U@!0CPX>8@|:M'I43J;G@XGELZL%A"=>MI\$EXG|5-
(:D;I4B,MJ6=|QVY!UFQ9M"!O"5M#YW2>G9|M%O+?HYA/J\$ \$IAB_MNE5+2--
+V1Y1'0X6LR=<MI5W_:;H=#HD5")IR2Q|QT|U4^#|OBI+1O_- ">|*ZC,M|?_"U!+P04
M"!0BDQ:0)%X?_T*M(0&0'AL+W=OOP*B;CM-!;*|Y^(97Y(VN\G48R?M|.SL
TQ"\$C<4J8*4_M'>^OW^|)'6QK"K9A|Y8(B<^SGX#N'7|
|7YTLRT;MG7>5DU;|.SMEV\#EI_MLIF>J^:X7N@*;R:UF:L6CV9ZTBR,5KG=-"/I.=%)W-
55./3UW;NRIR^KI=M_M653ZRK|F.9|K|W"NR_K^S5B,^XGK8CIK:>+D|/5"3?6-
:C|OK@R>3@8J>3'7_M55/4%3-ZAF9|EZ>"|O!KOBMT/?-
VIB1*K=U_84>WN=OOAY)ISN=M41"X>=,
M7^BR)\$J0XX^,Z'C@2107QSWU=U9Y*.*K&GU1E|I7>3M|,T|&+-<3M2S;Z_K^
M%|TI%!*|K"X;^Y?==VN|,%MC7GMXX;|!ZPFZ*:55,BDQ5+3O+
MLGI9M44U95=U662%;MC1)W5;ZN;YZY,6C&G|2=8Q.7=,Y!-,A&0?ZZJ=->QM_ME>M|D|
))!|\$EKW8YW(OQ4N='3-?<"8|&>RAYP|F"TI_PZN_3|UJEMTQJ\$
MS;|W:>SH!;OI42Z|;!8JTV_&2)9&FSL|OWQ!Q%YK_9(&PS2!ONHG|X@_-F
MJC=TE1%NS2:MLTGOE09NM>|E8"%|P>)N|0>-
|)K5Y1:UFUEM6FU(IZ53L;0J&E;2!H9W\SU&_M#0>CA@<;%;;|*ZCP-
R%CIVHLAAK\$094U6FFUT6W,_(C)FZI\$+*|I7)B4TI_MT^RBGB|4|?#C#XD4|:N&+399-
P-K-;|F|6;H_PL_P^JBK/LD7C.+HO&ACZ>Y'-2/%|F+;O6Z,
4,;\$./'4%L'D:2/1^4.F(^CSUO8T8&7-*B_MT95ZL_1/J|SHCU\$7-" +4IY\$*2AB'/J0-
MV@'GL|#J5|!':?@%'H'<|K41<02_MEHDL)9%P+Q|N&/(@="S0QS"Q0RE2'I%4(Q3G0|OK?
0ICIW%"3H4>08A!"-Z_M,7G7YS*E@>|/!)#QH_CT_^KXE%:#B,'HICQ./^:"?
1/B%R47,8L&#(&4IDB'T#@U.&%N*M5B1/('H|B)N)<<'BS;_M8>DE'. 'H@B%%T"?
A1EB&\$9?2A4T48NDW),!66"8!3WS'R*=T|QS/P-K'AJ7D
M:>H21")!)&7#H6'YS47G453|U6%I@Y&B)B+!8181=@-?D'8I#Q,;IU', \$R_YMOK,8"
(1^#"0X/|/%84\$112.C5\$08D2\EWJ'UDS)/;,%>PRCS@|700?&)49F_M,S"E'R|I!
<.B/DTV@C,(\$\$XN<_,131(KXW,.DDD:|R(EO).Z+9)RZ62%X
MY'62P\$.|IPV|^8W5QH87T9+>JR0(PUL@PF\$9_MH8>-)4:S*V5:=CFLR#
(#BZ8NZ5#A*^XL0UV%S-EIN"4?=G%J4^);3)|D%HT
M(+7H8*1VK>|TM=3X+2T(OG9@NV'OG6UR\$AMF;(#J<|OBO'/7#?5,.V'<7NZ|_MH;U-
=82:%>:%Z80QO3!:_Y#U|4%*|J+2Q7M76G'KI6'9NLA|A-DVK^&,'.C: MZ.*_>+V.!?)J6.|K
UVVZ7-,0D+6N;&UP>|P2|QNY;V|^3I@)3T'8TB@DP"5748\$'<06N=J6SK*N_MIB|(V
/KJ|NB+%KJR%#+TR!@R'61B-&?V'S_'ZN2S_8\$7SP\$7WQP\7IR6QS_MY-0C9|R(A
M<*@YC0L=^&CAK0RQ'E??8|@U|XYV\$MUI4H"0V!-K_MRAZQU"IQ-A|2KYY6-
JV+RNKMZMN1E3|<5W>+V2|#!CR.PS5N?G(|ALX,9
M67#%)4#MGO1*AO1*OKFV4UI=K_S/WIEZSB|LMS&-|_OMUTQK>Q(+
|QGM;|JHTSZ\$K;M6AE\$Y)V5Z>?#1KH-0W8_MLSX(VUX-
36IDG1KN+.&6#7T@H)4.QVB|J^ORQ>|HHZ,X: ^?09,1P*#@WW%MZP
M_>JV|6AN|'#|AVX:G"Y^!,V!9|QX//^CZ0_>#&ZT%56&X7.E6;";KI;D'3K_M1Q?
*P\$HPRB|:E>VL6Y,282(GO6%\$JY%|*A5QXH(0|-GT|1_?K),1N=%/<4*
M/'63HB<(P|UL|!-0!.\$E8"EKY|I%#7U|VG!QYX?>HS@%?8#:JN1|\$^
M+Q.'?3|^4Q=SV@|^C_>EY|ID)/IM^9DPVX?V,^ZGAJUF!49^U!#|_M_V?_#R)SR=?
GU"UI-06CEZ//QS?'MM0&U,J&J1NGP\$0^C7&.X(00H_>\$A""|
ML+V80+>1,GL>@V;3DKSWM2GQ/HC/M#9G6M_ML.U|AT|V7B+LI?ET.=
|VQ7.*|A@RS&'X>.,VJWYH6^|'5GG%\RJ9F:#)J,|_M?>"^R"F@X'P#5IMW^)^0=,ZA-WI?
:&N>CETC0UIY':(5WK_6:A2(D'|&P>C_MZVWHXWL1FMT4,_OM=1"/W->&,\$;LE,
|40E|T^O3=J0^+_8*B<>-)8(\$*0'8D_MTC^1-(S0E\$-2F?_@2|Y+&B=<1@|QZJ1|KI?E3)?
Y|'%;|:)OIBV?D/:%,D"*"M\$:/H)))(C#X,|<&F\$U9W"HOASF.X:W
BN5X|_B(|'F'A9(>2J_X#!8&^T))Q_M:=B;6A*,2V';A&P,
M.\$SK.K|ORI(E/D|QT"4A|T32R1H_Y*+O)2'?K_WN|?N#,7!|(H51CVFRJ7
M|C:.*#K&;MLZ^L%|7-B=;!HXG9+VZ|D9:U|P2XQQ3XWA'U^MS>H.G^A|K11
M4ULIEG-+97>YV"^D!6HDW%TOG#UA&RM<|82;=L+=HR|H=0&IC-B7C#IP=E|
M;6PT!NQ^6UJUDO9@B/7VZT)GEJ63Q_HH4K,CI/'X|5&AY=3=^X-.\$?F\$|H
MZ04+"#D%GAL3_I.PZ!<\$;71?/EQ<1H3=!?

&SH6#*GI'T>!VW\$Y:\$V@8I5%71)ZJ\N"MR'*OLH: 4[S-[ZW=7")ZLW6#C%)W:>WIJ MS-
"KN,OL87;X7X S=P.^6N|^D>"C,M,"O4ZD)CJ0?(Q,^YNWCVT|<+>A|_6
M+8YL.YQIE6M#"!^4@,Y=0_\$8/;/B=/_5!+ P04 " !0BDQ:HVJ@ H8% M #A#0 &0
'AL+W=O^|S|QT77V4&H,A#D9?RHI-
ZP7U!6JE;GYMVMF)WS6N6LA%M!9%T45'R_A)SO+GI^KWUQ_MQ|:9TB_ZL_.*;F\$%ZO?
J5N!3OT-)6 &E9+PD M*+WMR?7@|U>K/@"X.=W!L3 M|N\$<22&F=JSN^ ^Q4:R*-%_
=B/#\HHJ.CL7?>\$7HUH>F!<-=9(CI4Z*"LE<):AG9I= M,1GS4K&RAH3\5H&@^K
D>,>FFQSDZ7E?X2YZ;3|N\$"\M8O_#1#|@G0\$OD^2Z
M3"!Y"M!>AW'H.5X&1Q%O(+X/OE|EP1>,#B"%W8^AP8O_\$F?:9D0G*NXI#GY M*A=2?
+7?"_5P-SY^|!)V'T&A_?1>IK*BL9PT4/!2!#WT)N|?>,/O0|'O!AT
M7@R.H<|6J,^DSH'PE*P%+64*0H_G4H*RSGQB=-,RIAA@,-(4A8_.LY+,XYB+
MA)8Q8+:IC*R@HO80R'PK %!T2A|R|BCP_ZN,R|JCQY|D)?OT5.:G+BC<1CZZ05LW7-
RPJ3CL'T3|I3<|LH-DC0CTR6AKYQ%+02B-(G14Y(,I M9.B8^GC&T|:-0HOB#|S(#YV/G"
<|EN=DY(X1\PKP;(4^+OI@5Q+?'4TF#9/& MJH2\$WL0-O+'S:3F_7'Y:KI?7CP|NI
:#L7,#W;FVJ67<;W,(
M8S\$)W='0(T=T%G4ZBX|KS+8KG;L_*!R'E'(<4XLBY3FFHCX/I4OM8Y)B_C|@
MSY4XP#UU8B?|/^+'@H4|V_ZN'R%;1RYN&0+)>B0:S.: M8(-
DNESK3M|M,AB|T7BDM3.9M&G*?Z;EL5P@((+B1|J-D|2FLL7\$-XU&*I4R|1+B*
@LACMHT7S7&_H(IB5B2)EBQ0LLR)G^ ME,)S>9GKB6'K#<>
(>6+XAKB#USX%D>O|S3D|JYA)Z|A:6U8MN2I2S65?&& MEV>FPBX5%-
:|:V8CMRUCE?"=";)G|3D<2HO:-(TF#V*94N1=13CAB(HWA,
MPBJC6,L\$8\$^+|S|Q_5D;X&K)EPC_3E36>V39%HJ^K_/|^ZWL;Z_O
MYNOES4VU6&W=T-S" M1FID|/KC,7:%:#0ZV.5"
(X|(G7B38UT#4S%T)^'8)#ZN#CPMHLOUZO_)TG M& YSWGA|U;\$6;#;?SU1L&=++
(453|_T(^X>P%PK|H'AE/N(W7.&5P_PSO(!T MP/N5< MM0|Z@^Y6-_L74\$!#!!0 (
%*"3%IXA'%-P 0 .P+ 9 >&P0=V|R M:W-H965T6;F;Y4A7ZZ:-V=F.4+Y;6;02=|Y5W
M!E;|!#F66EZJJ8+9W)IWB:WF+_L"#K\$|REKU=/%|/K/+BW;21C,U
ME^O"CO331(6))W1X4UW4_AL|-7=%W\$;3=6UUN5\$&#|J:G|EUP|T/KQ02LD>! M;128|
|LQY+VDE9VSHU^0L;=!C0G^%"|_CB75^Y1|JR!TQST;&>DOJAJK=#< MZ!+U=&4-
!%2#W\$W;)>MZ|C4Z&LO'0M7'YX\$%FTXSF&|P+QM|M@>?,G0-J,L:
M|:N9FGT+\$("S.X_9UN-+=A#Q2DU/\$*<8,<+\$ 3R^8X!|/+ '\$|H:HV7|J42TA
M0HPJ9=^*B"&JYS3>B6GZJ(-I5\$K|T6U.^_?
T8B<'?!0|P4|SV|@TJRFCF!8:_1T^5*5L|0K5-MG-KJ.W(QDC6:ZP*Z07W:>@ 3369\8Z%U
ME%4 J-W|.3|CYD;|3R.?E+F'L;|?Y.T_"&O370,H3%"ORWD MHS9-\$-
(862T4_\$G!T3_(:^_4WY/|V<=;4S|1&L-=+7XU?USP4DVG/1_ZVYS
M#YHR/8;|>O|N892=@<1XA'D2O4BMR?UU?Y2-'Q!/,4L92@6.PQ!1+C 1<0LJ
MXK8_NNH.4.|F",4!>IC&##'WX5@(T;H|P@P*(YQ&?H^%\$8+"8#110<)#D@OF
M#/)0X"ARM2=BP\$| #0P3PGT6_2*"D"7V17@#@0#(H87(|@*H(H2S%GT?<\$ &|4
MAH5B&G)H(YC%T8:""/B +@#-@J812@F.DM!1,#"UWD\$|2>!/|@ (5+SBPGORB M@/V
@LV?|I:|?K?4T)IB*,P?)%>Y83SG"-H681P?RS2-RB! *.8(!"<"2@
MJU&^H<3Q0RED\$XY)@D("1ZG/"H9Y|)H@@_R(B._('\$>:
<.^>&ULO5C;:MLX\$'W75Q!N4*2 M\$HO4/4T,).X5:':#NA)MAF>&
M9X9#7VZ\$_*8RSC7Y41:5NAIE6J|OQF.UR'B9J'.QYA7,+(4L\$PU=N1JKM>1)
M:H3*8LP<)QB725Z-)I=F|S.Y.+D6MB|SB=Y*HNBP3^7##"|&Y&M'1=N!COLHT
M#HPGE^MDQ6=B-.RUI7O)*Y:(BDB^O1M?TXB; |6;|EYQOU%Z;H"5S M(YAYWUZ-
7(0\$"_X0J.&|!#[W?;J+ A4!C.^MSE&W)0KNM|?WQC;P99YHOA4
M%%_S5&=7HVA\$4KY,ZD)_%)MWO+7'1WT+42CS2S;M6F=\$%K72HFR% 4&95|TW
M^='ZX2D"K!5@!G>SD4'Y*M')Y%**#9&X&K1APYAJI %<7N&AS+2\$V1SD|.1| M=
<^5|BJK14X_)?.|JQ>78PV:<7Z|:+7<-%K83|101FY%I3-
%7E@#ZWLL,U^MQ_M|FK_AOO=:X?R(P0
M:IGKG"ORY_5<:0E<^:O/"|T>7O|>&#|7:ITL^-4(D1Q><|D^?/:."|'+#
MZRSPAK1/9A"/:5UP(I9DSYH^F(.^*F'N|V A(:4QHUTQLE2%!"Z>;6ZL-Y*
MH13Y7\$'X%_G?/+4^0)\KZ|H44N,^00Y0Y/>*DS|X(G>--
TDNR9>DJ+DURV"3,U!9DGR'|L*ZOD_R M IE|!CGJ3"7@(M4=Z(7U^7QV3E;BGLL!*|X,P
Z=7J_5#UYD1WY GC^+ M&&4ONR_"&/\$\$=E!& ZX@'FV%WE|H8=,VRP
K!'Y|3L|HU0U@%TX|C6N|X MD9YI<0;L0?4/!S9-=!NF2\ A\$*ZIGPM5*X)|?
PCO=LOS+5G4/3Y\$??UHF/Q M/5C4BUH-^W(GQ'?
AY)T(6LWQG70'B"W7"TW+=UUPGW,4".XO(3B-8SLT&\$,_M:G!M 0:4FA8NB6@|1'"*,?>

W2>BXYE-17VC"*>8\$UJ_B>KL,:CFL\$!H\$M.>+:<1P,QXI+?3L,0G"V%U
\$0)M0L:F/B%P:V,ZOB!8:VVLJO"ST!QC6-@ MUO&=P7QANTY?L+\$H;N4A:|@0F|?
J^-3LQ&;A">X*|9| MA=Y)L>|560H14EF0I#P
5062NTP"A9|P7RHYL%IF#=7*=B=1N)!/5E@-*,FWJ/I.?:;3CO*-C'K\$SD
M->|P|^JPL"1K M+G.1F?EQTEMK|CLJDK2,:8AZ:,W)63C_06UUQG (R2!^0UT
S*E"@.30L(M%R#UL*XPO|;U\$FO;=K'.I*A7&?%-%^H?)S0"^(TAC3U*JFTV; H&S|296!0T
M)4.W12_1QGL009++E7G/8L5>5|HY|6CW9/YNGDIH8W|VU(;2N,EH(O0=0Y
M#R\$SR>8-VW2T6)MWXUOH>(6:9@;/?BYO.? P? @!D
!X;|JW;W)K&ULI59M;JLV\$|N7W%0AZX%M\$BB9%M,:-Y,:\$ "31\$D:?=AV =:/EM\$)=(A
MJ;C9K^^14A0ES;)B^R+>D;R'SW-|JL960>*!-7- M|=T)5FJ_")+@ON-2;\$OK.J+E?,>W>
(7V|^Y"DQ?U*&M1HS1"2="X603'R>%) MYN;| "5|\$|LW
!J=DI=17YWQ8+X+8\$<(*"^L0.#6W>(I5Y8"(QDV'&?1+NL"A M?8_ ^WFLG+2MN| %15?
XBU+1=!L : -|RI|*7: XZ=GK'##U1E_! ?VW=PX@*(Q M5M5=,#&HA6Q; JW+P| \$L"Z >=
IM0HE&;=|.=J#|K-)C1G>*D^FL@)Z3;E
MRFH:%11GE^ ^YT/"%5PW" FVN^JM"IG4>6@-UP5'0@)RT(^P>0A,&YDK8T|\$ZN
M.F_RSP3HJB4:30: ^/-X M9:RFD_ '7D0B'K14 RVV)!%
<(10#41LGZO9!E.Y%K9PH#R+D6A3<>@@<1H0"-==%>>>G MN4'7W|*S6)12W#1=5,
<1&DMT_J:UK:);;E'3Y4-ZNXIR 'PXHH.*|0JU.ZRC M-Q|(KE2-
H57,6W|VX2/>8@5)U|*N34?M/AZ.3KDI 6!:08 ^=;| 'J9Y/FA| MOMC1@S7Z?'!U
%MUBUK2_VF|*GI"97%'7%<6C\$M.FPT&8=YSH!-QF\$|BV\$<
MA|,9ZY%.E=XI33G|(9"V*)QD,: Z\$W|TK2ROB-,X2|)9DI+ %IFF831UC-LG#
M+!T/&#_*\$R4F_2^)^2;P329#XW^EAB5YF\$|FD.1)&&<)I-,P9_E/I"8A\$8SV
MIG|U)_|HDY*_ />7OP|Z\$|FD1WCD|;FE|0^SV*61T2ZFXRE9"24YSH;XKG7
M)AI4A!KUUM<| X5JH&V+0|;E|;CMJ(3&_K|CG76R\$-5+BAT/A@.@YMI6N M=:S: ^?
JR4I;JE3=+^CU |2;0^\$8I>^ ^X! ?H?CN5W4\$L#!!0 (%"*3%IG M*U|N|P(#4& 9
>&PO=V|JR.W-H965T;8F6V@_- /<|T"IU+*7 MQ'>^|_-
W%|HEN%;ZCZD0+;S40H14%G;7\$:1*2JLF>FJ!B7MS)6NF253+R+3
M:&2E!|4B2N.X%|6;RV_|+Y|/1ZJH15-FR!CVA_-
 />:K&C/4O(:I>%*@L;Y*)@DE|/MWM05|E;-
L/-1J#=I%\$YM; ^%0|FL1QZ3|*H|6TRPEGQ|=RA=(J
MO8'3)S83;Z&D25>MQL56XYIRY%^P)&D<*>DK0Q\DR66;PDB\$K17E>Y43=.C MC-
=8=""+0DCC-#_"E^VSS#Q?|MLK|DIA#)+C?|K.C-6T|7X_5|*+6'^/J%K ME403L-)' ?
6"0;W"8/SY4|*+OQZ1F^ _EYL?8QX_4>N52(*@Y|*1S-_) /\$|T MFG>AJ(^,-8|25@AS):@?
N5Q<=JC86,10^X(?&IW36TG!;FF8+,V9_QCND74> MV)HNH47-F3|P OTT3+
(+MTC"/.EUGJD3@4MHM"K0&.A?A(-^ KU!;,BSS@V7
MG&YL"0NE2@.GR1ED,07T(> ^%2=|O/"G+!.%WXD|&@:3A8-#WJUZ8QSV/FM@W
M>EN!H-6+#+V>5ZINF-Q Q4H"IVFW3UTDA|(TKFRK'NQAJ M-7^K|5634 45H 1F@5-9;
<5U^:5AVFY@S32ZJJ\$ _PE2|:;C0X&X)+| 59<5+ MU-WW;DITT,HUZH4?
6(8^WU+;MJOWWOU,G+2CX#6|;AW3"^X-"!P3M"XVS|/
M0+=#JC6L:OQ@F"E+8|8O*YKKJ%T |<^5LCO#';#_4XS_ 5!+ P04 " !0 MBDQ:'!8 Y\$#
"8|P&0 'AL+W=O=7"&Y13-CMF4G3C))&@3:P19H@:#3W3TLJJ#83"Q4EEQ)GLS|
M^Z5DCYL6TQSV8NN#?'PD17)U5OJ;J0 L>:J%-N@LK991I\$I*JB9F:@&)-X<
ME;Z9Q:T^1;:1P\$JO5(N(QO\$|JAF7P6;ES_9ZLU*M%5S"7A/3UC73SSL0ZKP. MDN#EX
L_5=8=1)M5PT|P-/;9|H|Q%PTH);!&JXDT7!W^5BN@|@1 @&%=0@,?
X|P!T(X(*3QO<<.,H-.17+|@G|O?4=? M#LS G1)_|)6ZV>D!*.K!7VBSK_-
;T_4X=7*&'EYP|V8P&I&B-576OC QJ
M+KL_->^KC<*\$PCW^C0'L%ZGEWACS+|HRRS4JK,I%&M'C-7X9OY|S?
<.,7L=V=71TC2L@'6 A6)/T*P>?NR; 40=217?7B-^'7H'W#-=#2
J%I6BL<89M!>2H!)8TEZ?E",#|0&T MS|_E9G3S4:*P:@UBF; /G?NDY"89CSXY
V_)8HWW|&NY;) \$1&^9UXU6C^!L M&Y*D63A;+|/PSR=CNY;+;EM-
83DR)_YG0^^@180)42 MOP!G-,R2&4D7X7R1CN|01ZO;KF-P25#PA-"&3.=ANDA(-
@WS13)Z: |6629(M-H_ #:3| #|SQ,X@R-&+/\$5E.T=2N8A1(!+Z!@C:/>\$|H-UC+
(ZQ6Z=QF,P2_M,AYH|6#-M?"1&*+?DLHS=W; ^8TR6_-5;DS PI!#.&'SEZ
MBSNG2./;K3& X:T XZSPU/Q5\FM"ZRSA&J;+F,N|>E!"HT X,317(W|E
M9G|Z4|W|<32<<:DLXA6BQ2|3 QN\$KE6+V9V|5F_11;>L09_13\$ OG\$;7.(?3
M8>QLNVH0|R;69^9/G%IB(C|L:3?|H0W@\$|03P_M_JB4?=DX_|PWOP'4\$L#!!0(
%""3%K1EXB""P, \$P' 9 >&PO M=V|JR.W-H965T*_W5+!\$M M_"B%)-@:>UJ%
(8F6V+)S)E:H:2=A=(EL|3416A6&EGN0:4(DRCJAR7C,IB. MO>|63|>JLH)+O-

5@JK)D^N<%"K6>!'&P=;SCQ=(Z1S@=KUB!=V@_K&XUK<*&M)>GW'
M2Q3"\$9&.,;OO.H\$GI@+OVEOW.UTZUS)G!2R7N>6Z7DR-(,(<%JX1|H:O<%-/
MS_%E2AC_A'4=V^L\$D%7&JG(#)@4EE_6;_ =BIH7N(?7I'39I7)%HMX' |M^Y0?Y-ZO?
(>7_ ;DOQ39UIJA=#7E)CUTB+)2@MN>R&+7HAV\$Y1|U\0GCLZ;2. M;R3!5&6(U)S
O>|S&%6*FWY+W<7X35?(!Q_0J8IXJ56QL ET HG)7%QE;0P MRI*JK 3;A?
H9)):FW./@_Z=H-2= !&FG'24#,IX_2Y,X.=|U;G7NN:26SP5 M-*!RX(^/>-2BF2/87.E:
BLT(@U&.F;JLB/H|GOMWC BZ|BQ3QZD^4=\$ZY*M MN&6" _Z+T-|<0QW-*<8?
>.:9LN*H'B>-!;!@Z4\$G37WR=K2/ZX/1S&K?>*. (BX M1X4->G7"7JTTWZ=,/4B'N|&9
_JKN> ?6T1|DRX\$G7AY|BAZT;'7P^|QMO\ M*F;UA/P37O|GWC!|=<&E
X(*@T=F@%X"N9W>|L&KEY^5<69J^WES2|PZU"Z#| MA5)VNW)FA_H|# =02P,\$% @
4(L,6A&DV|Z_ @_4!D!X;"|W M;W)K&UL?53;.,MLP# 'W/5PC>.,+2 5SM.G-L2 TV| M8@7:
(>AE>QCV(-MT+%26/\$ENVK|?)2=N-J1YL4F)/.=0\$CG?2/6D2P!#7BHN M|
(KC:EG0:"S\$BJJSV0- G<*J2|JT%7K0-<*.Z2*AY\$83@**LJ\$E|S=VDHE M<|D8S@2L%-
%-55'UN@0N-PNO|^T6|MBZ-'8A2.8U7<.,|F.=ZI=+.I2<52 T MDX(H*!;,>>7^V'-
IX%_ "#P4;OV<16DDKY9)WK?.&%5A!PR(Q%H/A|A@O@W *A
MC#|;3*^CM(GH|H|RM6.M:14PX7D/UENRH4W\4@.!6VXN9;.,["M)|9XF>3: M?
|)7(J+Z FAR5S)#5\$V M&M&LX4IUV2B."7LHT;A+L,|D|P EJ3)R0-->C3>6
0U&X%V19@V0)\$|P#T M(W(KA2DU^2IRR/%%"!-)RG:25I&1Q\$O(3LC@|Y|HC
:'L\$;="4.-|@>(F_ MSE-M%+Z"WX>*;"&&AR%L9|QT33-8>/CT-:AG\)|' JC\,L1@<-.X/
8>G+? M-@21!;EJ3*_.ED15_ Q^1M-'O%D%?DNQ><+*C+@|H|&'VHEJ-LAV09|G+ '
M6^|X&|)=095BT.Z^2":Q8;6!W&Z;\$D@A.78^\$^M9;S^Z
M=W(M<%\VFHD).YHRS@P#"S:_.7@P(8=>0+#7D16HM9L|&@^G\$:9MSFZU&VWG;4>=
MA;=S!9;J-1.;%128&IZ-8X^H=M;TCI&UZ^|4&IP6SBOQ/(.R;A?2&EVCB7H M|G|R%U!+
P04 " !0BDQ;G%?2_ V # Q" &0 'AL+W=ON|M MC&FN@T 7.ZR9OI(-
"MK92%4S0U.U#72CD)7.J:Z". SSH&9<>(N96UNIQ4RV MIN("5PIT6|=,O=Q@)?
=S+(-."P|NS-V(5C,&K;%1S2_-RM%LV! *7F-0G,I M0.%F|BVCZYQ,VCN#/SCN|D-
(ZW@Z/J#_XG*G7-9,XZVL_N2EVY_Q7|?!S!0E;.: M_ <^LQUG'A2M-
K+NG8E!S47W9<_.9PX3,(W'.+>(7\NT".Y1TS;#%3<@_*
M6A.:;A4G3>1X|**|F@4|7+R,XME401#
|S\$89Q>P\$N&\$T@<70(&7I^X/F;.*@U_ +=?.*J9O\ EW"&FYQ'M;/K6
M#2MP|M%%T:B>T%M|^A#EX=<+?-.;|WH)??(H)L22FY@7>I=RZ!BR')S#\$
M:DYBL3X6|BJED'1?-5D1.-#V,B*|CT7V^L1"8?U&I43|W0R^OQ=D+%L-4'|
M+TY8^Y.,_A/S(Z29GR#"11\$A! M/O":0S3R)^\$V>B'-
*RR;.:PCMX|033(-26(:Q6GH9WD\$%P3-!D&SRX)V|Z\$| ML=M6*10&5DH^4/CS1
M!Q%OZ6R9>/GT81)'XZ|D4536YI0'EFRURQ|? V2UXP M;C'7S#AI.-T/T|2.HL2?H-
F(#K%L"W-D!-'43|((HLR/XJ@'44B71QFX@SCW
MITE"0"3L=/2;*Y8X)=,4(OJ\$^;.%87%V|.U^B-{|-UDR=4MN?K)CAYQFM4
M6|>L|)4B^Y%'U:'?KCLVL#10&NF|TOMN=!0X89&UL?91O;|HP\$;.;?RE. MZ52!O)|0T,
(H1(*Q:96H5+7=|F+;"R;DPU\7V=YE@R?24K%+2SEJDAJ9JX^M*(\$N M(72ZFX.)2XQ
MO8)HT(%%;.:N1XT;L|*G!9Z)1+72N\$7_-\$&T5_B|^GJFU8P|,L:Y6)
MKEB*,X^|H%&|HA=?7@QN@MLS2H>MTN\$Y>OQ\$ULMJCB#799U6.M<6
M31>.,98*JO61@ (K.#J ^\3:SUY9*LJ\$VF-D|DR.L)2<_%V(SZ1QA#B>=|IV@
M8%EKXNI>2"0W=K\$:X9RK-81 Z-3<|^ "7%^-P\$-|2*/P4 M|\$=1T%FAUA-
RAE(H#%12.7/OX|H0|8,@@%YG=5S_ \$6H|LB@X|5+^@95(XL8U M#\$WUU|
(TKFI7VYXT;ZSX|QI:%3-H#2.*XI-;@:77N@FB;13(RLG#\$3:._P%02P,\$% @ 4(L,6A.5\$F)8!
_PH M !D !X;"|W;W)K&ULQ59-C|LV\$+W|5Q!*\$7@! M=2U*EF4|MH'|<-
36JLMPV*H@=:&MOL4J1"4NO-O^0DA5ONW&"7GJA*(GS MYLWCS)"S@|
(/9@|@R5,|D)D>V NKZ6!@|CV4S%RJ"B3^V2I=,HNO>C*-2#.(H&@U*QF6PF/EO*
|V8J=H*+F&EB;G+DNG/UR#481|0X/CACN_VUGT8 M+&85V\$;|_*_52N/;H\$;I>
G2<"6)ANT|N*+3Z|2M|PM^XW P)W/B(MDH|>|> MWA7S('*\$0\$!N'0+#QR/<@!
_."&E|;C&#SJ4S/)T?T=_ZV#&6#3-PH|1'7MC| M|!@'I(MJX6|4X>?
H(W\$|R5,'XDAW9M%)'"-E:5K3\$R*+ELGNRIU>%|#+6
M(/:|&T>>Y2VS;# '3ZD"T6XUH;N)#|=9(CDNW*6NK|2|'.|M8,BVYW!G2_UD9 M27)*\$AB:-
X> 8OZ:)./%|RK:B_A/O'U<98C4GRYTL!-W## ME^%G.&|+ C.SR'OEAC(1:U **VY)H9GL7
M-NT777")9=6\$|U(|Y|W|#DPW^T50;2@WB(F*|_KO)+%|51LF"W3E-L-B1MB
MTJ<700|U"9I9I>|)#|A%N,Q5B>DC/+6M5B7),1NXK)\$RP6Z":|S>#?F!)%D<
MTF2,LY1.0HF..N3),%I3"X|FD-I0-IN6ARD>+3)VD8C<;D F=TE(3#*&KF
M<1I2FK8XSUFazu\$61EGD9FD:9JUKFH|#>)2AS2U(A>76A/71US:Z98_H=@=\$ MUEX?

W!!UE-TXV0W!OF>Z\$CW-S)V#^S)#KJX)*K#17VAEQA?*6JG94
MHJ@SV0"XMF^U,A7XWBT^\$U,A3T1W5KEC@37VSS\$L,1
OJ7&:NM80;^V,FY4A:UXTR0&U66>,@TO639R4J63[FH75'Y'+XY"HA+ M\$>RKS?
>E\CW\1ZCWB\!9ZS;G*KC=6;##X ?I/*UT7#DTJLG_U4O;E;,@/PD M@@WD#%/C9
/P"*Y%<;)_S,EUS/)\H\WF7\4!0U3BE7AO?
*HCXT"2<1IN80LQ\S,PO'B/N_)>;@Y"#'IKKSUQ6#_1.-V=Z M\I
f6f\$5TU%\$X\$ORYOKU'NF=QRE\$K!%T^@RP_S1S16E>;&J\ M>"C;)XR?#3/=fJ
M0+L%'^^K,(G:%^>@NR&ULO5=M;JLV\$/ZN7T&X19\$ G"Q1 MI%[2Q\$"2=EL'=
V2M,4^,A)M"Y5\$EZ3B]-_02%F*TCJ;.PS[8KV0]JQS=|^=
MS-.M5%_T6@B#NJJT6>SM3&;D_E\I
f*9+4I=NRNU.)6MJPV/+E(f7ZXW5,IMGITCVPD=U)^ML0_OBK-98 F)2N3&
(G"XW(M+4546"&A\W6'.!I?6<'S?H_J8H=8[K@6E\+Z M7!9F?39+9Z@02]Y6YEIN?Q>
f>)C%RV6EW2_-fO8&,Y2WVLAZ9PP,ZK+IKOQA
MEX=##,C.@#C>G2/\@TW?'&JY!8INQO0f(T+U5D#N;*Q1;DO"E9+L#. +FS57
MXA<;5X\$N90VUUMREZ^B6WU5""Y_.#;BOF^?Y#O*B@R3/0(8\$O9>-66OTMBE\$
M\11@#OP&DJ0G>4\$F\$=^(W\$=1B!\$")W BX:@(X='GPL:I%VTE4!RB9Y-P-L'
M>R_04LD:5AI3-FW9K!!O"O2FU'GW!JP^,(1R)GI?KB:9V)8fT1N>BL9f)06
MZE[,%K=K\HKZ!?'KS\@Z(+?;&(WTB&\^YBO&?;G?(LQ7SGP16635RW4"&Z0_M:\V
;SY\NI%2L+DM;8P6E9EP0WLT08NM2,!>1NA6_6BA)KVZWVWN+*6J"C
M2FI?+.f);CJO("fE**^\$J6TSMZ9fW*5@."/G;5M3^1_2'>I=3&>ED)66C0 M?_
_NH8=;!2C6(Q KT\$O\$<)*E<U#'+(W@28f-2fAGQQE:^\^,4fC)^\^8f(
MBH.4(0*&L)f\$#OS;fL0+(P6HD&XJJ<%2^@X4IM;f)P05\$S_@B+&?Wf]fF8^XT0+&.
(XIB1@T+N Mf2C.H@B%."/LP(B?4UR/F.
(P35&,&81*PVX_T=AO^P39FLGZWK(P#Yf\#XfJL/7f'O*\\$EV)8/P^")67D+DK5>;"^\^::&f
M<\$7_X1E.>R&*@JA(%\$&2;4M%!\&?f-YOBCL"!/3.H+ELXDGFfTf3K@0MT!_1
ML<7,T+%=#_PDA05-J7:KE"28fMTJC?V\$>/U78K2N'5&0AS0f)+_9@f93F>
M%CN>@):DP"BS/\$_B7HV-BMf+4 J28;CV\$5&?6CZ";6P02UL4BVW\,fD)f;K
MFX_H?,M5L7?^3f+L5\BK%V\$/XH6)S!(8)?8f0*?@?CK5+X@!'E'7:9>\$3f24) MPS1DO?
fHY'UR'F_)#*,\$1P'fB,_8"/Zf,VGF\$21fW4&DP);f)DJ%R6;\K MH=S?fB8?
Y59/B&T2fE^*+1W(fO^5V":!#A#;9E\>_F?-A9C1N)^*B9^Q07,T
M@WE(@fZ.TOB)XL*\$@f\$C3E3,3f-'Q;\$H0J0?A3" PTFfP=B-K.S3SDVX?ZC-
M1P>#6JB5_.f8OW5M8fHSP0fV.&&==P>+Q^W=|>Pf5ZL2/N"56(fIC'D8;*Hf
MAG0/f1f|<,>_&CBTN-LUG!*%LAM@?2FEZ1^L@^',PL \$ B 9>&PO=VfR:W-
H965T>^P"DYf>R^JS60M3L2Y&7ZL5X7=>;Lf-3E:Q% MP=54;D2)-
TM9%;S&;4Z59M*\%1/*O)3Uf;#TX)GY?C\N7fVH3f_+K=UGf7B
M0f74MBAXM;L0N;Qf,7;&f8.K;+6NZ<'I^?,-7XEK47_?;*AP=JfMDF:%*%4F
M2U:Y)8OQW#fBfBf'fO!;)fY5fYJ1)@Lf/f-9?fB;f;f@D8NDIA4XOf|\$2Y'G MM!!@_-
&L.>Y\$TL3^=;OZ&Zf|=fEP)5f*_f.196Jf?C&=CEHHEW^;UE;SfFVCT M"6Bf1.9*?
f+;9JPf9LE6U;)H)f@-fD97FFWfHf/"8"6XSP=6XC2"-fA6O^?GS M2MZRBBD9C;K0JNK9
)>5Y)3KNL+;#//fJfLRD85@'_D7H=CD(U_D0fTVfZVQ M- TX39IE+LPRf|@/+. "
fH59;U6K'792K2PP5.@;D#fYK;+MRC*fX2R91YCL5<
MV_6/K.=UBGIZ/>^KBK)7F4IRJ;;58/^<+U1=@1K_&M+9K.@/KTCAMW>/UCJYf?
(_S2;2Z87+(fE;S)=!A,+D0IEEEf MPA"/f.fYRTH6f"6Q#)'H3L0-
f3E;E:D4(UUE_*!Df|@Y&_Q",L1A<+LH%J(B MUXfFER6&RfJWB9;f.-f/HPZ;/ETV2V8;
fE!S")fBW?>D:7E<@!A&%@f#)M M%_9^SUZ)98"6-)O@S)fA3FS-(AL0'%NO.Z&+P
O921f+GEH>WHf@*K C_>U9 MMH.)':f0L:*9IQ>(+#OT;f@%fU'6\$/8_) "@?.5:(\$-
_VB*S0FVF3Nf89'&8&_M 3-X&Kf,9,IX(+ MY1*7'0.NQ88;=DR!f\$S0f4SPZ(fH F/R5BKPYPD*
f^f)Q4;38L;fN:KX9ITE ML-D)6L&=\$U%7"JW!14(<07 Mf+\$*M(DHT4?;CS\$S',V3L-
f';O>;YC464N"XY+ M@N-"KYBJAIGY0YYS8A_C ^;Z+D7JH?%f2fV-D#*A<fVSV
_Q7VOCB#^VF3fI MA"J8L<fGfXW0BD=Z;
f^J5P^W<f)\$C43@fBW;fR!">9^2A5&22EOLVV81LMXP MfKZQ)fRG8NGK.7YH15Z 2>f>
f("K(f?CPCM/0Q/==B1fJHRYJHT=f9SR1U;O
MD*#8;YV+YIV+\$+8RR3@EEMNL7K.^Q<5@!^739'+>S(f(>HP>_(30_DfJL5
M=R+U@N=FP1K5=)65I<f;Z\$Q-8J5_.YFG(#fE\1-VRfY@f3Df|Ef,1%Z'f#fM0/
/*D,%@%#NfJ(R)>V7,5"LfJ "YBVW%6. D1FFVM-f&E1f|\$E1"UQUDC3|=!05'3W*Z
MK4C65TT*06O,C0fU.R@YVYDf05@RE)G/f#(BfB&T,LJ4VOVfOU;M0f;5YQ
MDQ/H>EZO'TfBD0fBEfK(N==?5PfNfAZ>"40T^2:CfK7V,9N;UGM=!MfU<37;fU6
M4WfJGPf5PN-RYf\#MfKfK0AKJD. 5fK:A 0.T2fHGL#2O VL-4C=TX6FLA\$;&fI*

M60FR!5^)=L):QA,6!):OBT7@HL\$T MQR">-8NI>WNP;N*=L,B>F=8R
M"!PS\$ _KX^DB\$F#T S#^!(A&VJBY:1M^*W7#TJ6P#2Y^/2-5\$SH2%8=/:>H0E
M!))WLGR:FO2P--SN5CLR G[S06F1.@VHBC'H] T76+IT 5)#PZ"FFTN.N"9 M[3*8%
[JXD=L9&:- 4#I=JF%'++;T]/&"N/L)J#Z1@2C2[=#!T]3,O-L]>-5L, M:@VLF1,TC?
8,5#17U!F?C.:94XGODEP0GZ9Q=&IXR[3NX-!2_U 5PM"DP(MR?&V;0-JX,7D/S=H"?
Q?'3^-7M\3B><.@/@!N?I?I/DUP;_: MCJ8[QH%0BE&A.N^J[4]E:8;2Wf'W>|Z<6D2-
O931B&IC8EJ93IYPH[!L)UJ MP@J&0D8]7HIF %JHQA097H:JF#1- ?*:DZ5Q%.2;#0CE+?
K#.5VS94Q33M% M\$XUAKXT=;!O5I=3^C_F(V#C+/TF;DT"'65XZ#H!%YT-"EG5*P%_-:
FTX ")M MWZ81*[(I-S\SY;SN&@Z*A[U%VB:*IF7E#7RCLRMU;=04=X.5=?Z?D&?ZD3Q
M%0<;+QG1M"G[3N\&I/P)IX*&G!EK1[VQ!*5B'P[AOAH6.L*9315;*FA\$UC.&1
MP0[58"%X;DY.:+F#DNGAF0NINC/GH+@*_2FJ)7+989?/CN2T*^838296-
75CKSXARGMV>'W*AU\OZ-AM@=U[K7.Y)RA)/: ^U6_\$-5*M_W>!:B\BT/S WSWM_AXQ-
+*V\W_ZWXE5<(9L5RL<14>QH%8U:9_RN8FUIN M]!\\$%K*N9:\$OUX*CZ:0!>+^4V\XW-
R2@^]/(^7\ 4\$!#!!0 (-%"*3%HW M23K,*4_.L*9>&PO=VJR:W-
H965TU\NNM\$GQ9*Q5YG[ENV"]X5G8&Y_7=G1J]?
G6[X6,V\$^;>|4GOH'E&56B%)GL@0E5A>=(3VJ]*U+? Y M\$SMJM?
KR4+*:_8P7EYT7\$M(Y"(U%H'C\B"N1)Y;(*300<7L'\$Q:O>/!OU\ M[3OZLN!:7,G\KVQI-
A>=N-+L>)5;N[E]J-H_0DL7BIS7?-"KI'UW0ZDE3:R M;.)6109&5S;WO\JW"A MC<*W\
<[S_C9H_O-HMEY.J9:GXJ*#!:&%>A"=P;LW-'3/7N'J'[CZKZ\$/9DV9
M@%S!:+%N7V2I+.5+?NS!ZQ+K40C]'^U7@YVG/-P*N9+'EY=.-S&CT9D&?616
MMV9%:Q:X\$! UK&2.=:U/G: ^"JR;O@%D3Q4(HFSFG.RI!;&2E>;G403J1JL>S
MARY'WT>33Z-9J?.7!J>8YD_B+(2\!8H"8*(A!ZK[V'H\$=|ZCVEE\$1)X(R^
MW(TF,ZM!);6Q<5I+N=18'66UPH06"KF@5= R7T)7/*9YI;\$%6\$E>V/S_R^O.
M8,_HRJS\EEI>+G.L +0.RT,1F\$C=R4L;/M"^GY/(!"SSB>A\$P&A,WC)W1 MHQ&J1?
NW_%B>W9JB-.I\$C-.(W7I0_OZ-!Z\$S-!H,K7C()7DA"%D%@PQ8#1M%G M7AO?
EY6HBP0HA20F'FHE(:&)[XS+%_T:%=MOXM;,: M]'4B%B;\$SL,0M_E12,/6VU>4?)^X-:
(0D/;44A"=#83X)UPED(+'))[-J5
M(2OFS/!_!L'@;4HA4(3IJ'Q)7;HS/83^U=S%*M6NA;"HOXFZM[3?@??#PFC
M/OB)2VC@@@Y>@+Y0Z'WX)#31)B*THNP8)/A1,7^"IK?_Z]TE"B(XRC\$088]8"
M"@&2P;4_-H\NWN?>AC<5!8"NK0'7:2.YA/H09@0SP_QQA8LOJWGC3\$9S&\$^N
MIKO+^?WL+5=#(??SZ-)Q]@>C>Z\['TD,/ PO118:33_4\$>)X
M'FX8XEA=F\$[>@CQK=4?71ZH\$K*I>Y@/OZ!;8,L2+#5:MPZWV;,_VT?P+*NW_M6#
<1<2/7[(@)\B&C^K=4)\#F'D=5'5VUS9.[9+Z)22]S\$6%;*)AJ%X0G[HP;Q M4X.L.R)I6J)-
CVV+%B6OEOC\6G/#WVY7K67R(1%|KG*I=8| *H379BHX; M(<.,?;9|ZR.JY]IO_H/*3*]5.
(G_MKZ1P-((=2Z'K,TI+(J33.+&X/DIRP_M&6#^%V_&P%NNUEFI(1 T*105P.\K M*J\MI
Z/_!%2|H1M2AR"G'-S,A,Z+Q4A)1%4N6VQR(&5P6"@N;%?
D0U8:DZ@#WP0"T(6@'C)TSK?K8B>U;EJ8X5HT]C@<80+"53(8GY M8.%"2L+G%)5
VS6S^7R0%U2"7A_.3;.:?7Q\$3;C3-U%|M*Z%T8-CN@%'",Y63-MF)IW3(N1UQ
/^XU]!E.=^QG<|L\$,N)?^@'8V^YR=H!D5O#&K\$ M>U3'>^2,IT&*.*)@ID4&2B24J-
%"5WB9I77"RXCO)CAFE%(QN> +98R_=(6 MK7.V75=5"7:R\$?
#H>&IO_&W35%'TS>H'-54CIO4?L\$"%"B5R02L:AN71). MG%U)&OV'I.#P:
(N6CB9LT')AQPM3(:B5?T_MKI^UZ9EB&JYYD57HK2+H='W73+AY*(7Z3G!1QHL?
4N7P_O4S5IB*K2)84<> M-E)W4J?NQ.GRHQ;Q3TB8TI)-
"UM_3%\$9*6HB614STZJ8:6/7C6Z21_C+QP\G M87#\2942NA!H0E%@)8TIYC3!96_R02G*?
>"BS1<4:4N[QD57"MRWWAU6TA|
MCV43H)*A(2Z(+92&M+=!8+J@W&F2GXU25PY4%7I'>)%G6%UF0_M7+;?
_JHUH7NZG:DNT8XV\VM4K"K&9L\$K@JP@?.8,BEWH'OC#T-
JX"\7@QMU>J'F)1<%W>"M;H;7MA;VLI;#RSO?6R+G#&NL ME,
fOU#\1D=E>8U:/FB1VXO%J=!:9+:YH 1K9#, W\^\$T*L',T%JF3WY%U!+ M_P04 "
!0BDQ:X)8]:V4# #/ # &0 'AL+W=OH#X-JC\$>9 MBLSL#D3:'[S8V-(I-
M&EIPW,YWOG,Q\WFX%O)!%0 ::1CE:A046I=78:C2 M
AA69Z(\$;G9R(1G69BI7H2HEX,P9,1HF470>,DOX,!ZZM;D<#T6E*>\$PETA5 MC&'Y-
4JUJ,@#K8+7\BJT'8A' 1+O((%Z&_E7)I9V*)DA %71' D(1\%D_AJ M&O>M@3OQGOF;2@
MM%):L;:8,&"\$UT^!;1*Q9]" /&*0-:)XUT|+4Q/M9!4%>WHN36=
(=1!H&W=0\$B4|#UZWS5G7X?6. MX\$TK0C.3&N6")JR4XA%LV.I0M%XL^D)=J1*G,
K,6Z5-/D(P?O=?!H]6': M.YGV"KW"--MD9H:39[5Z/[&G\$?:-3#UXQ#QW@F(IUOB?
6^*9TH3||I!ABH% M>441)3D<(NF'2?KH";!4'D;G+:-S+|3'2G*B*PD=E).-'=3EAS:?
Z);P@FK MV"&>7O!7)G/04A^)\N\..|W 27+:+WV\O#G6!%|P5^8R MCG;-|TVJ#!?F/N>

f=4_#:=|+.X,56B),=f12+=0-"OGP%^(%>F|S= M=15W3UCX4|Q?
|>X"B|W7S\HO|HG40BI05KEL@>\$A\$34EA&9/>8CO+NX80^5 MAXLNZCP71AWTK?
9^8|QWT%?CM8.N0:62E\$ZEWL\VVFK>I5%9,UXQD-BN'RZ-
MGTFEWJ|P+|HJC|9ADX2|W|J|RU|T#W|F)4D9|:T*)?KH%M@1Y*!'AGL8TK%9. M22OD9&
(M-|O55JU/:HVZ.UY+_-5LL5X0KD_G??EY(=R2*OI&16FY?\$ MLL^|Y#G|.B)Y|93E7XN-
4B7Y:YNDQ>5L4Y:|_ F|B#9J&Q;OLIU*|2_W6;X- M2_V8|AR+7:|_="1VT3>9
J9QOPSB=+2|H|V|RQ46V+Y,X53|J4WF+BS4=9;|&:_+S>7,FY&UN@_W2?
DO>_J7.A)RJGQ1 MEA3U7_)TQ-(9B?9%F6V/P;H&VS@|_@IQ\$!X3P<|,D#T!_!C
S0#1 M\$R".>*E/T@=QD21S%JB!GY%9WT_4^417Z
M)L|>XZJ|%\$1W5W(:)AH2IFMRE>C.%Z:1?OQYIM#A:&GP@S(ARPM-P4)TK5:=Q/,-?M&
GB6 MX!H&,ZY4|YPI@|"%12H=7+PSD2'KP|'_8|*9!>9V/CS3H;^,-^OG?.I:|
M6JIM05KB\$-!B^HFL'.BUT8J*G'YBD|S\$1|TP63)2L(|!H
M!|9#V1=+|1"G:27D79A4_1R3|H#"J5-4<_7C@C/!N6|@QU-1;|CXU'_A04(
M3+H>|1H8AXC3\$'\$_&B5SO|USIKK%K1W*NDK#N(V5&BGI\$Z|\$:.'7'?5)AC7^E
MR)/,2HIN-(@: ^-|P1QJP (-YOJ4^A0G*QNRG+5*US99;G+8SU| M5=30N4A:E3D#
=)L1P0FJ692K=5Q^9R.Z M=MU<7X!C<%@A..EXW%0D0'.|!%A.%FO(>M-
0':D43VD49DO16|PQ7_.|?D
MBN&H+RC@7/V&JS_(5:|O%;%E_RSC6P5S+@6X!@|\$ADQ&@0TS)J,."T9;AT&
MYQF|7.?:\$.|!#A)P,0W3|!STVB5GTFS!5-FZ*|X-/96Z_JQ|*E4GC);,%6V
MKLK0J@S_|^*^',GQF>&J@SV^N!|,.*_5P^GE7C|CN&(XZKNR;|RV!|(-VJ>I
M?,%RD)@^F;A%RW%V1J;2_!H?'YRB6(UG|5!'8 M&N-81@3#>3Y8?0=+!Y3Y/.*TEI(-
>|DS;ARI) ^C6SG>,:E|UGK.@JD'G>X M*1,"!.XZT.-B6.M&V;=G<+!+\$?*Z),)LZ\$N2,?
TZRC0\$OZW9,*>LQ"CP%B MK;5EP|YVU (M1Q+T:6#;4P!|SQZF!@.F;,#-%|GSNX*T-I=-
NQW5W%1K^^X M6QJ,??4Z/F6V8*IL7=U:Z|S|W-
+@R|H|U2I/F2V8*EMWWZQU|C#L|%_DED9R M? 94|6-49T3IF=Q|'<5@DKF,,3XQ6+7W@
|/;\$TY#-K1R:S22#%|&C'|QM||\$K:N&84<|C2L8*:1|)-LFG^F57H+|'C @^_SU MK,Z\$
1V|?,@>G5KG#<.6>!)7,%>RV3=:+/37?.E88CFLC:04E!>2>VZ/
M1JWMAF&#/&X)1A+T"6!;8L&EL,:2#4/FI0"#=>:E+0067|.O|ZS|3XJR4=5
M|O,4=07#&5Z|7DV;+9@J6U>|UG6#?"M7 (/>^|4J3YDMF"L:5^76M,.PYW|1 M
0G8CEDP*LW-\$ 0&OI3FF0\$&\$YSUO.-#:|HAV'Y/=40"|A:QGC6LC5H\$QKE@
MKLG6AC"Z|M:A|8TP_&|W>>D8"|<7S&76I9-61_V;-VM1 4!U_@U'CK5/FP
MRYSBW(#;+E*_YPK|/+08#H3MMH|W/5|7IMY:TOYL%|.M"^027+AM AEFUAJ'P%R?
>^88LU&^X_482MX:2OXVEP"XO57J MN=SE)E?D=)|X9MD;9CCN5|/BRAO#2"?
8MMUE"NRW^E2USP77F\$X1P)8TR>" M\$Y|'^U:|UHGQ*:X&C*UZR%\$^X|
(S|TI1'/B^U:883@_,'OO"6|/&A|W:"U:| M0X+3BS1,NPMKU4-@HK@-
\$%AGW'9I5"ZL>|^H-2|B9(N,?2\$ _>|T/<|9^GU MK^R|;LTHV:_5_J#;O4HC-?Z=?
\$N+%4#JZ|H=2"Y(C=A7I)5@XBB7)=1/,: M?>BV)-
(IZGH3Y@^ZE.@K5LKS:ZN9|HN+YR>7&:=*)ZUND1:DCCOG9,U+VN!GWG-MZG;/#
|=0#P|EMJNO6=YE99EMZX|,%:Y57@'T|_ =95CX_5 4T=X\$7?P-02P,\$ M% @ 4(L,6@=+*J'8
P '!4 !D !X;"|W;W)K&ULO5A=;|LV%/TKA%8,+=!\$W_|G:.)I6\$!4C2(V^UAV,M7=M\$*=(C
M*,O|H,R,E1:4>'SR1|4:9!^YLL5K6(#ZNGT4NN6V+ #DI@\$G"&1*PFCJW M_DWJ|P901?
Q)8"\|H|%)9.9T8\$%#)E*+|^|&.E!HF/8Y_&U*G M|=, #^?^?
V7^ODM?)++&\$:=-_D5QMIL|(|03FL<\$G5\$|_ 4U"L>'|.75+|HW
ML9Z#LE(|7C1@/8*"L/J*OS>%. #XT4|_00,(S@6\$#2|_%Q_U@.A<0-P JM3= M.O>J<
E6>#81?(^\$B=9LYJ;J?H76|2+,3)2%\$OHMT3@U6|03!/\$56I U(RN2
M8::0;9;QDBG"UNB14Y(1D.@*+?0TS4L*)OH)=L!*T%>*>3Z*D'L=-@|RVB9
MZR>\$H3EG4L/S*N(.4|PR0 LS6(G>)Z PH?*)OZZ2-#I=Q_0.P/ZLN&EQ"R7 M\$U?
I#;TXW:S)YJ|.OA)-@EDURCT/Z+ "Z(>^/Q|>-@#3|Z!SWP|RXWX6| M6M56VJ"5-
JCXPE>D_?RZM|_:"RZ5U#(?_JJ7G<4|7=DO.Q&G\$&4T>;534- MG-FOO_@#
H<^#6R2)3;)4DMD';7"5JWP%/NL^9ZN1/|1-3WT?@0U4UPQF7^"
MW2P,!U\$PG+B|PT+WA/E1&;=L.1E6##VXL#KAJ4|88/AR|NU89VTHS;MZ)6T M|
|+^R|">TDQ-J4=L4RV; M9(E-LM0264>M0:O6P)IWU\$R#P|X|+\$_R#I>1OE^|!|90G)R5)
<6T!)9IX## MMH##DP6<|V++&1CKJ6U(E+J,"TSU_\$Z(K%WI(|JE>EUMUC-2Z?
5)N^3I*_ /) M_BZ=|3;)\$IMDJ26RCFBC5K316WG4R*9;-LD2FV2D);*.6N-6K;\$UCQJ_|*AA
M\$,5""Y=Y3|A KX..O"PY.:Y+2VB)K%-"W_NQ6?N|*G/;@,"/7"VOE(@ "O1
M))0HDA_54|S7SK+K;(E5ME26VQ=E0ZVU/Y;&5/3DRW-;+(E5ME26VQ=S7|L ME?
V3F|N+|*FA.MP*1?XXBH|LJ2""R9<|/6*P) MDXC"2M-
|UT.=G*B/XNJ&XMOJK&G)E>)%=;L!G(C,P ?KJBG/UW# #'5^V|Z.Q_ M4\$|L#!|0 (-

%""3%K040WI+PD/M+9>&PO=VJR:W-H965T-YC_9>/O@>3V>R^J!<38/IN)6
MR+OY3:&N^BN4*\$Y%5L9Y1@HQ.>|=TD_ ^P*D,ZA9_QN*Q7'M/JJ'RN?E>'Z^Q?
TW^O!J!'"1>ES-.EL>I!&F?-M: "T)&+-P/5>,6!+[:K@;LT<#<,&'O%P%L:>+L:#)8&|=#
|S=AKXG@@@XNS M(G|D1=5:H55O:O9K:|57G%6)SOE1=JH#[X=+I
M5>.>O>*>,G*=9W)6\$C^+1&0"!-585@-B+P.Z8B_B%^%'XM)_ \$N8PC|S=OSMQA|
|G;8C@1G1E;1|B#TB|M0+M07,RR\$^I*6JHB'0I7@2+U) M
JE>94ZBQ5S%2UV1^SA1|M/2%JO&S:|V4|TS#QG@YL+(/>NK(!:(66.BZU
MN/61W!H4#E<4#N%,3M3R)JZ8|W988M.UT8FZ+004382>6C+&=AA
MUZ2Q.696Q|ZEJ4<|('7HFM"@(\$NWLZ_0QY6HBTB8IQ5-C7P0_&6TU9W3X==
M61@#G7=FC+8+HN.<.I;J9&EZZK&!|SIC3#/&0,8\AY*C_WP@-TE@K4"P>==5_M-
2H:1T7SL=#,0&@=1|FA"BJ\$D)%XZAH/A:;&3.MAB@LA_QTGN3/0JA:HI9_M|?
VBKC5)G,:2!"4)UJF@LR#9RO;@QW8WMZ&MP_WOS/8^-!+5(HG"*NDZ>
(K31:K)ZY+H,I=!0F3P5*W,B_B*|+6|;_*R9
MG,\$F_3LUX_"8.D=@'H*:G%%877EVS+^QG(I\$A+5@9+5K4\$!-/S:|+<.:2
MAJIGEVB4K<|HM*W@.:I;'PO-#("6J@R45:L:,>^V%G^)^V6_VBN!:|YN=;&S
M3LTX/(+?.I#9C(M,ODL,W_\$J3B^JF|JW.H:#X6FADS+6<9+&?|IWE<-
#>\$5>V*||@:#1B#_M.N19K6QL7|HOVTY;-J9YWV(5J9%*X-%ZQ^+|0Y-!%7-
_U6=%PBRK'J)|3F6_MLM|2*>MJ|B#*ZNS
WUO.N5PQRV;>YNRPM0F'N|Z9:"0TDVBM>QFL>U^;&129_M?^39|6J5Q.-
"A#*WIMX5|*-S^4'5PZAH/A:;&2VMA|G|!#|U<.H:|P5S<="
M,T^G:3WLPGIXIREC"P8T9;S=E,.FG8^5|4/WNEKWNK#N_5--M4W_"9|J_U
M45:*WVC(8S"JAF:*L1CA^D"JM/YG"7JCC_JFH^%9D9L|63L_MX8|&XIZ-Q3TK;Q?>
M!MYANH!7(#CMUIRV+(SQ?L0RZX6RRZL5M|,|#YD_MM:MEM0N?
&+8=0'_|H11^KF.H:#X6FADS+<@|6!;O^K,.K|W/2VV_41G#_CISW=Z'9K9?D/E8
M;DT:M>SV8-G|3<|4)/_USZ;:/U09(E^WL(DJKE'1."J:CX5FQD6+:^|@XMI#
M%=>H:|P5S<="V.V|N-36-WN7)*|5DEJ%2/4C6V+0V;|Q2.66Y-K9H|6+I>
MQUEU<,/ *>H>-"H:1T7SL=#,&&A9|0T/5GA0Y3W!^|G7_M0;:8J,*S*.KX%'DHRA*X|
|0%CCHD"IZM|Y|>:,EAR\Z\$|T,|>UH|>|!V7IXP_MLW*+NEN-BL91T7PL-
#,&6E9|!|NM|E"%-BH:1T7SL=#,QT)HH3W8=GJ|6Z':_M
C<80EJHHWFS)8/!UIJNGJ"U67|W*:-MSZ_H)
|HY#I6&:1Z+=1T4TS@K22(F"M+Y.%++D:)YTE1S(?-Y_2BE^US*/W?
MSD00B:)JH/X^R7/Y&PO=VJR:W-H965TT&:%YND|CY^MWQV/O.F1R*^J-
#H6|FXFGF%UKL|WU=9_251MV('W'S9"%D2;:9RZZN=!)(|_MIY+Y81#?\$?
DDH|^93M_8HYU.QUXQR>)1(|T|('NBVT7?#G_M|QW9P@KTHVC-
#._08!D!@TQ; "&+^#K_\$QBR2X?%W#>HU>UK'JO@)_5Z5%63L;!B7EU3_Y5@>BY8#C
M"PYA|1|V'487'*+: (7)"*V9.U@/19#Z5XHBDM39H=N!BX|R-&LIM&E=:FJ_4_M^GYJDH?
\$ANTHEM.-S0C7*-%EHD|UY10T:-@-*.@T_U:F4.4|QE8ZZ7@6IHD
MH(52H:4B/#^M_4')FC*JK=OK!|"\$,O7&'Q:/:#7K|Z@5XAR|+\$0>V7|-7H=O/(?|
W(6CB\$#|[%X3Z|BO@_V2V*|L4_M!N%H@-#R^>|1%3I1DY;(X447,ZCBSXOULK-
OPS%JH(:#4/9>^!.|4@&:|4_MN@)Y&_ ^|T|X#MX-
Z7PAL#/5HT;UZ!KZ235Q9VI(:P4P=@#VBCK,DR">^H>V_MA+|-)W3QNB,VKBA-
KY*;9'GU-X|@Z0JU|BU81SC<8=5WPA'<80|&:VXH15?MI?51\$JXV("7D2_MSKV9_#V3-
0+U%/'00V;C'XR:,(MQA.V2%)Y>BF#1TDQ|-M<-
+:>)2F08==WRBY%,E)0VWRO(IKWUW7ZV|RDG7W0F!GVM-&>_J|M+^6=J+1
M&K:4<_L(F_M?%X|V(*G(AV*1|M.6)-T2Z!OA(GP<.)P<'K"@N^OS=JWO6DT_MZO
:L+E)HTN|6D|KOLZKM&^HLE4IS-/ZKZE1REV5'H#089_M|C.)QG'W_ ^9_MF3(97V
3"M5"=|7O;9+L.Z013=:COB32G6R\$&&P.9W":&DJR:OFJBQ<|U_M36NA31?FAH5IE\$%:_
|X1^FM@-FM9|_A|02P,\$% @_4(L,6MN)?_&ULK5IM;^HV%/XK_M5B9-F|0UQ*%
_T|J:::NW6J6FW|_V#FOBP&F)F&|B3|H^?|(|\$IXDA|?G2
M)N&A'Q1:8T^K)4C7SUEI0KWU?16NVH>I":%EJ?ED*N:':
MW,J5K|:2T3AWVB0^'@Q&_H;RU)MAV_MX+T^>.2KM^/IEJ|8\$|-
_:!^DN?,KE)AO6*JX2)%DRYEW\$UR3\$&<.N<6?
MG!W4T37*0GD6XB6|N8MGWB#K\$4M8I#,(O|MV8(E289D^O%O">I5;6:Q|>O
MZ+_DP9M@GJEB"Y|Q6.|GGD3#|5L27>)?A2'3ZP,Z#+#BT2B|K_H4-H./!3M
ME!::TMGT8,/3XC_|4A)QY!:",AQPZ8";#L.,A|!T",|U&)8.PYR9(I2W10|P1P|"C.Y%JM<*_9S&
^C>D6.Q\$)BRY0&/R+|/6SJT_M.-|J:'\$GY|MC1S1A-4)ACC?LP/M,4Z58BKZ^#HI"CRQB?
\$^?S4A|10Q)8JX;_MX_'(U4Q;4#B;RMXQUVI+(S;SS\$M\$,,EGWOS;;X+1X*|BC>|2XD6:;?
CW;|8(W6FV4?^T,3F\$9!(2C_"!64Q>5DQ>.B>K_M/0NEF85HRV3VR"PB;306<\$'Q>LH6J?</p></div>

U\Z/^6FURL1Y;\$6<77MGX*,J M\-&9*GUD>Y;NS/OR=[-J&WGF\W FSQ2HLY6^TPH2C
"!6>R.*W;'X (=0S() M"4: P"PF)Q63\$UB!3EH%.FX(M-4J#;!H";
<>ZK*RLB*ZJB*Z<\$=URL8):'ITM M\9TSD& \$" ,QB.!C42>(
7\!E)!"9H&@\$"LVF\RCG#F!%Z,,;KS24D&BG1FJJ^ M:E=U@&N2\FZ_MB"ZFZE-W60:
0*S6:X+BR"\$%[5H!4\$*!J!0K\IK(N(P)E9 MOT\5PU;E-%;-Q7EFL,LI-
!AG=\$')U)Z*F.>T@1\8C31:YB%UMUF\VD\$B4:@ MT&R^ZT(B&,&K\$K1L
\$4C4&@VG77E\$#C3Z7>H-A4Y2DS.ZPZ MC0\Y/%O5/G!9=+97.\9!(E&H-
!LJNOZ(KB"%R1H)0&*1J#0\+W9NI; SN2Z
MOR!+O.X\$LS4;37#.#3UV6'7H\$==\V\W1X7^50!B *S\$3?A!T0@4FDUGG?"[L
O958XC4KO.; " MV&\V1HD=9J.&\$OVC\$UA&1:O\))M"^8I7"%RJGE:GY6[R,V*-Y\?!-2G.O-
4P-MQ1&\>RI7/%4H84L#.;@8FX1%%J?:BALMMODYKV>AC93SRS6C,9.9@?E*81^
MO&PO=VJR M:W-H965T16K)IE=8) M@;9\F/;!)>PZMB9\4#W\W?MA PJH\$S%_#CGI-
ICE\WM)7J2:!\#G.N=!C M;VU,
<>O\ EU#3G5'%B!P9BE53@UVU)L,,;P+^,Y@J ?O"I92/ED.P_9V ML0L A-9:!\XM&_)L"Y)
<(T M?M><7O-)!"JOO\H@_.>VH94\$U3"3_P3*S'GM#CV2PI"4W,\G\##+6>&\N72JH=
M+JG6L8%'TE(;F==@S"!GHOJGS\4/>X"P?P(0U8#H):!W M"M =U+ ;T:T'/. M5%*<#PDU-
!XIN27*1B,,;3@S'1KE,V&7?6X4SC+\$F7A>+3>12S)G*!\&6+*7"
MD+LTE:4P3*S(5'*6,M#D\9GCILM*#C9Z(D4*PBCJEN\J2A7VUF 0SZ_)50*&
M,JZO\$35Q*D"!@,R8?L+91R987N8CWZ :FY.?UIG?5YE')S(/(_(H\9.:?!09
M9(<\$\MK0>!'MO+B\SC(FD'9(-WQ'HB#J'4EHP2>7 Z/SJCI-BO;=7R\ M\$WPSV(
H<=V^@CGF\EFTO6UN=4%3&'MXG6A0&_#BMV_"?O#AF#-MDB4MD1VX
MUFM_CCG9:J\)-LF2EL@.G+Q\ MG+PYN_ \.3\NRI\T 98?P.3EF8T475C>5?:XV<=
)1_YFWYY+@D)7@@\D\H\LY M_-RZAM1DQFDP#9TP8^*,\$OROWNA3;*D);(#\P:-
>8/63\6@322;) \$M:(CMP M!;28.'AFFNLB\$'9)Q? M2FEV'?N!IL:_.P)02P,\$% @
4(L,6I:##^& (P CQ !D !X;"/W M;W)K&ULK5AK;^(X%/TK5G:TFI%FR9.\$ = &I;?91
M:4;JRG;WLYM<\$FL2F\4-S\S\ M9TT\$)IF6\E\@-BYYW#\L6_P97ED_)NH "3Z
MWM14K)Q*RMV5ZXJ\@@:;+&=L!57>VC#=#8JB\$O7;'C@ L#;FHW\+S8;3"ASGH
MYN\Y>LGVLB84\CD2^Z;!,<-U.RX>*!E)74\$^YZN<,E;\$ ^\NZY&KD\I
M2T\$;H((PBCAL5\ZU?Y7YH0:8B+ \),79=)2GACH@=WQ-MB&W1AI24;\$F,J437>
<\V5!):HGM6DYR 0+^@C=IUQ;X&?T!Z!\-?WT_T\ MK.1X5Y\$P9=RS\$W'/JQ
M>EC\WD2AVH%#^>VC,3%<1AY\V%<-A*G7DEZBAN(F?=BYI-B'F>;V5CZDZCW
M+KU-
LLP2V<"MN'/T\O2FOF7AGZ: ^N.5L^BU+":UW'&HU0_4F(!)X'L7WR999HEL8%C;&Y9:
M*H\4IG\VR3)+9 /_?.IT"O,LE\$!\,JB+((TNBF_ = E;9,EML0^<^"DW>!H3+JB&R9:),ML\4V-
/0T M!\8G3XAOK;3PY;\$KBE\4R>U87.(%B^2RFL;BDC2Y/,Y9YU: \PT':\IMEJ
MNY9^MN^JKTTO>3%_H\MMTP&>:-I6_2OF):\$ "U;!\5E-XL44GQMOMM!Y+M3#_X
MQ*3J+LUE!;@ K@/4_2UC\GF@OZ#_#V+!\U!+ P04 " !0BDQ:\$X,%#8@% M !U' &0
'AL+W=09ZG>G-9<+E\K5C!'AJ6\02T'\HDXUC8TM6(/;\$L&%W M_5\ _5;R9,_R'WQ-
J4" _TB3CT\%:B,WU>,RC-4U#?L4V-)/_+%F>AD+>YJLQ
MW^0T7)1.:3(&RW+':1AGH\FD_.T^GTW85B1Q1N\SQ+=I&N:_O\!"\$!:K47QPW@VV80K.J
B<7.?R\MO'641IS3C,?D\96N-4+3E M@J65LU20QMGA._Q5-<21\9\!'!R@%, =2.5
RD0\RLJT\D(1SB8YVZ.\L);1 MBHNR;4IOF4V<%=TX%\G\+
Y9^8C8_ =\JB2S2\5UF\ C*,P\$^@FBM@V\$W&V0OBS5%-YQ3P="RK"..&?H/7C_
Y\?A)O4=QA0Y9 MLRT\LP6?C(6473Q\!%42OQPD0H_\$.QI=(8(O\$%A@:\QO3WQ;*RZQ;!\N
M,2CCD9YXM\H\H*)PC+C:UT^AP"V\D Q,;_Y)HSH="1G'J?YCHYF'\YAU_HL
MRVZ@8*U<29TK,46?W89\ C62OH:BXH#^W\2Y,9/+;7CR\$JQFT&L>U. MQKOC?
%0SV_%L-ZC-6DKM6JEM5\H MVU\$NTD+;AW<^8/C,URP7EX+FJ4\I(9H MK,*U'("6-
6;R*8\,FN)=6JQCE'L XVH;FGA/(+E%&A\$^BH3_9M!_R.0(T9 M =OS\ +=6J!K% %C-YC5-
%DBB G'9ZSJ1QBCG#G17226PP;7TF7AU)IYQMGGYGMV:HG!\I\I A*C8B\Q2JPK7 H=%
M7(*\@E4H\NR-NP1W\$ 1FZEX2KF%5;H1RP4GZ(K44%"JM/M6R0:#V,S!\^Q-
T3*RM0\$0JV"JVAKS'#7N#T#:B&M;!*
MTH**4,"6%W2'NL8.^W)*.#W*&M;""YO*G,H.7VBU#8K;H:*U\VOQ"V_&+0R* MVZ&BM?
-M<L#XA94C@)8OMWEK<8.D\#%/0<;T/ 6AN4M:'CKN'\0Y;W&#H-O MVWT+3\+
;>#MO0>6HYX.KK#FJ&<;\$(SU%##2X\3-N3SWA,(IRK4#:<<9"& MR<2\3VU>""S:
<=^,I64&N'?;=G\T(E!+!\N*!\&'%\IL/%:V=<4-A8J;P MZXH\HK(VP-VS#HT1)FX\I. M?
%\UKD#4,UW=N8+.K/\<@32L>:SW\YJL_)K'8S;GK)J:\RP%3BDNTL:'IT3
M*E\(_17FJSCC**%+Z6A=>3)"?GC'=@1;%.^GIB0K"TO%S3<\$'SPD#^OV1, M/\4;YH-
XVS_P%02P,\$% @ 4(L,6O0X CJO P UA !D !X;"/W

M;W)K&ULK5A=;^(X%/TK5E9:S4C3YHNO=@\$)2&=W
M'ZJMVVMV99S>Y@-4DSMH&VG^_UTX(!)DL17D!.|GGV.=Q+3,=^HE.7P)(C<9!D5'W-
(^6|B^,|^P3-,K95^X\$|^!5W!"ZA_BB>!/;=F M25@&N60\|P*6\$V?FWT=^J
\$FX@>#G3QJ\$RWEE?,WW?DSF3B>GA&D\$"M-0?%K
M"PM(4|V\$|_BW(G7J,37PN+UG_V|\$HYA7*F!TY|L4>N).W)(DNZ2=4SW_T!
ME:"^YHMY*LTGV56QGD/BC50|J|X@XSEY3=|KXPX_OB#,X"@_@2G@-X90%@!
MPDL!O0K0,\Z44HP/\$55T.A9\1X2.1C;=,&8;-IGN<|HBQ+XEB%.35_*?!.^
M)"|LE,,EBVFNR"R.^297+%^1)YZRF(\$D-^0H^\$JAJY#0KY3)L@/FF|D"@>
MOY&"I/4WP5R80@V?YH\$8'NV!8\$+BLPD+C43)LF7"!1EJ?R*8_R-J^IFCIE,
M&EQR|"J4JR?MOI6T>2DM."/|#|@CS|5:DH<|@:1)X*)/M5G!WJQYT,H807Q+
M00|,"R@9YG0XG)X:(%|E|.##%C5AG?K0|(5G^/8IN:%52N@A)3:W2|:>G4V?
M3>RH#%,#R)(@M.--??_\$WF|V|HDBSHB:|C8JUWLM;%/|X+/,)PM4JS
M6K<|I8JE3'U|T|N599N,?*&24%*B"%77VW6ED/XY2;51_5VZMV&H|&|/?;,
M&M5K|D7VH+,".HCLUR+|5XND|Q>*|%MG%IR(M\$>=JK1&|7V|RD&MX5GF7G9B|O
KA+K.NPO^AZ9,/H,+F_)J M9'0-
LFG#T>W2;|H_Y7EB5=Z*_S2Z90MZHJMZ5IP<"WH=|-6=%U9V25;U!5;MT\K#'===00?
Q=O@_::88M^|=6K9AU<@2Q00)\KHMV4T@>:,J*_Y&*%H#ZKXSI?U!+P04"-
!0BDO:0;8U4A"|L"@M&O'AL+W=OLQH+L96*F5Q9=LB3B'#HL<*R-
7,DO\$,2|7E*UL4"!B0!FUW7X_ML#-,58NX\$|LDJE'K##48%7,=Y M7|QRU;-KEH1DD
O"!K=AK(QW)@K\$'W;E.QE9?+P@H-MO%(S8/79P-PHU41J&7|J3JMVJ8'11W|1Q.
|BF6!!HXAEHOIA18?|1MK0-WEDH7@O)L@JL5I"10/SBQTJ'/8_3'&X%+:6K'IAA'3H%7X)-
?;/I=|>JXZ\$9Y307ZD">0-EL%4(=A|N+8^IV,D80|Y#G
M7"*W|_HM"YH|^ZUP*/GP|V.:+OZ5SS#YYVX*SA/D)HKF%|"|HFS=2'0K|E" M2*|.S^^V?
2C|^U^|DUR)0H,4|U)TF48(EM,G93?N5;7K(2|1L32:=>)/5?!,9_T%|H6" M@|Y0OW.
<"US>W3\$34J@W@"K1\$B09DBF@.12XE+5-QT|R4|.R)!L8,OW,;4(O_MZ)O?R-
|L"W9HZ/A-NX860;U^T*G%1-B0HBW,X,#ADR7-.IE/38@SD35\$&-8B
M##M%^\$+P@E#U8D-C%9+6D|8J5B?_J3DQ/%#>='_CN84J
M\$>|K'-9/F7U:%TR34RE\&1|JDJ|LO+Y3U/683>8KXAZ"2@L%66_-U0A|K*V
M*3N2%>:U7S"l:@?33%4Y"%P;J/DE8W+7T0|J_CA!U!+P04"-!0BDO: M9BR,*WX\$P&@
&0'AL+W=OFFLSL?G;!2=9FPG::7|6L3E|L6 M/\$'K?F@@X3R!AX-Y399GRK|R
R\$"/.59P5?.08CRSG5Y?"YK>T)(7|9\$=9 MCH5<97N7EXS@I'K*,|?
WO*F;X|1PULOJO0>V7M*CR-*"/##CWF.V2,IDM'S-MRH'.RON?TOU|J#?<|;+>
|(EXDOYP.2:6U.2-"<%3VD!&-FMG'MXAWQ/%51; M_)62,V|M
W4HCY1^52M_) "O'4WM\$,A(+A<#RY40V),L42>|'-PUUZN|4A>WE
M%_JOU<'|+@WG\$G&QHIG>:B,/*F3L@ (3M|S,0G>OZ=Z_*%|^F&:_^@|/>UG-
M?.2"YKI8|D&>%I=7_*1%M I@.%#@ZP+_VH) %P37%H2Z(*S,7 ZE\H"PP.LE MHV? U-
:2IA8JF56U//RT4.=|*YC|)5U8HU2'M-"l,61).!C21A6IX.#"=C* M%DN.&0%T!SXS7/
=86KYGG,B.,!% OY,|6.:I2(E'/RRV|E3*2%I>|CF+(\$ M%S&11R,.8\$M*? &#^STC1/-)+Q!1.
TXV_EEWV9(O#FQ|=+5|AC4GOFQ GK_MWUWVWQ_:?Q+?@#@#>-_SPY|RS?
7E04|Y,I=_H*=,*.^>B/IL^/79|"M>
M.,#;|F3;K3CNSX=%T#8#U"CQ!TO<4Q6CAP&.&\$GXJO_^@%.09_|Y-B\$(4NP
MCKB@%A>8Z.O/5.,X\$|G|5+=515JZ'PM:6|JFMPL@?J(2K*,BK%6\$5_50
MZ^+L,;309B/9A"%+L(Z|J+877=%(L7:8-0|H%|I18Q5&KUHTC\$)Y^_Y/HR)+
M7|JQ,ZWM3(UVWA^9M|.OD'<=NG|&91:.#?WT|SY;10186S9AR!|LHW16*YW|
MWR%_9E.<31BR!.N(F|?BYL9>W&!^J%)(K!:(MV-ZPID*%GT*C:BQ"FW" T/S5
M9>/(J_ZJR_|CH%|6S0&&S7OU&:G-,LZU5B-:U;I2%-:RN9 MS4T75Y/%H3F,
(R*GBDQ.!05^N01+KQN;B7MCE88TK=,NL|5BV\$T3SJ\$Q007YW
MHF(N'VW%:B|7M+:5P%OXWGS82Q.|861EU@*M9FZK-&2+UE789'-H#N?ZZ4VQ
M!QG!)B% Z*?)542@H'JHT/NHTVK"\$,+6!_'Q'J7A94!|U#|2K?|1%4\$|L#!0(
%*"3%H9T\$X>;00!06 M_9>&PO=V|JR:W-H965T&D) X="A2ON28#/S M>;YOl,'V=,OX-
|&F5**7+,W%S%I+6=S8MHC6-"/BFA4TAS=+QC,BH3PNRH@LJOQ:/"%IV@Q(G&*;\$_?
*05O|D="M.'A&BLHS M8|J4XR&>68Z*B*8TD@J"P-^&WM,T54@0QS|UJ-6,J1P/GW?
H/VOR0.:9"K/ MTC^36*YGUMA",5V2,I5:/LKK0D-%5|4J%_T;V=2P4E4*RK'&"+(DK_|)
M2RW\$@0,0-3NXM8-|H."?M|B M:F^@G^0J|PO)X6T"?G(>)B)BN4SRDL;H|X)RHM(AT
>TJ&8"8DOT|06FF:!" M/9|SN JD)\$DJWH/KUT6(KMZ|1^|0DJ,O:U8*DL=B:DL(6
UK1W5P=U5P|HG@ ML(L^PUAK@3|F,8W;_#8P;>BZ.|HW;B=B2*-KY.\$|OM|=M|6#C-
_D7YU-|E^?(<+T*).)OTWIK,+US>&J\$G8C M"A+1F04U2E" ^H=;|QQ|PX/QD2D6?
8&/%8*TT^4V:_"|T^1+YS- %"DYT|Q'AH M)CUN2(|2=|S(=5W<,58+.:+G)=+V+M 38U-

E#JQ+BV(?8%/8&U-)PT&D/>
MUG=KTF>.^@0+>P)KI0D/^|VA|_J|N:K'N53A&NUP;7N3H^5OL/\$=|+!'YME
MW*G'\$|1&>+36,S2F&S@V%6H"&REW0EU,N4^TL"^TMHSN7D;W;:W_MZ^_WZKA|L|Z
M*72M!F@%VS8.U-5D)#\$VVC0/M,!?GJD^TL"^T=J|V|Q;>IKN#U,=5_ZF?!5_E,QI4N
M=*Y'\$!.OKB"KAF2%OI1|9E*R3#^N*8DI5P;P?LF8W#74,U0\|Q?4\$|L#!!0 M-(
%""3%I6@G*J3@(.@& 9>&PO=V|R:W-H965T_9/UKOVLL82
MYIS^)+DJ\$^>#@W(H):J!|Y|ALZ/%9AQ*NT3-5VLYZ|L*Q60.K!64!'600%S MEX?
@=P#|7\$'2_P!IME5E;"ZOP&@O>(&&B-9L9V-Q8M'9#F*GB2@F|_M2S1.I0LB,|X485O(T;
<:|#:9E>@=6K5U1;Q MU*"D@BS"TA>\$TH400DNEJ MPH3*:QW|N%J@J|?
7L:NT*\$|M9IV NU: ?TP 9!,43-|BW_/#\$?C|?'AP"'=U M*OI|'^T^?,L7'.&;;X4
ICK+LS\$_-+4\$X3F#^NIFL<0;)HW|K"6(3OKFU?3&
M^SCF|D)D!UZ#WFMPBCW|SA6F""%NG8T9;=&31IAOL4B|V=T/U)_G_4WW8JP/_
MJM3@1(Z6*|QDN2Y\$=F XZ@U'9Y0KZVS3%|MCKD|2_:OKZ*^#\$\$:AOB=>CD-K
MR!WT(7,'?5B0W0SH5!HI#=#YKRE\$VU?;B>*U;4UKKG2CL|-27T4@3(#>+SA7
M^XGI=OWEEOX!4\$|L#!!0 (%""3%JUORVY3P,)4) 9>&PO=V|R M:W-H965T?
WEMY5SO:"OE;90":/!4Y5V,G MT|J|<%V59%|0=29*X/AE+61!-4|EQE6E!)I:IR)W
+KNP5EW)F_|J-G(Q\$ MI7/&X482514%E7|O(1?;L>_|SPNW;)-IL^!1B7=P
KTS_)&XLQM45)6 %=#, M<")A/7:F_L4L-O;6X)|!5NV,B5'R(,1O,UFF8\&R"D M:?!=-
HMC>/N^!G|J|6.6AZH@IG(?|%49V-GZ) 4UK3*|:W8?H=&3V3P\$|K M^R3;QM9S2%
(I+8K&&1D4C-=O^M3\$8XTA*_O33DSE3B>":!0I2@*'\$Y?N ME2FRX"FDKP%<#\$H;F>
Y,I?|2<0Y)&?2/3V=WR?GFW7*PNNN)4PYQWPYBB<*%*FL#8P:Q7(!_!F7QX
MY_>|+UT:WPCLE>+S5O'Y*72,((FS/XT74)K|AZFV+U. E"/QZYC|L"#HW|
M*PO>D4L:HE%)XFM,BJA9XI'2A)1X\$^O+\$D")@4\$=)&M\$?L|/(^<+A'M"H
M'PT&W63|+=G^2;*V+O?\$NEZ M|@I#?)|Z/7|0|Q|5AU44^?M'Y>|<<7(C;WX%69?
Q75=TM05MK>8VBMU;_T2 M>XZZ17B|J1N6'U1N&\$K-88V0WMD
_&ULM5A=C|HX%/TK5K;J6JF=O/G.+ " !V:I(MT|X(Z*Q6JSYXB(&H24QM |U_OXX3
@%/Q*@>'B!V|CGQ.W)_0'6V/,MP:|*UC?6'.^N35-MECC'+\$;LL&%.+,D-\$=
<#.G*9!N*42)!>6;:EN6;4H+ M8|!"3ANTPC/,OVT> MJ!B9#4N2YKA@*2D
QG1R#4LH3(3_*P23I&U:Y(ISA M!2|ID/C9X3'.LI))K.-G36HTURR!|
<|D|2O!#SA!@>D^SO-.'KOA\$:(,%+ MM,WXE.P_XUJ05_(M2;:D-
|C7L98!%EO&25Z#Q0KRM*A^T:_.B!.\$*H&V#7 M/|@>XSP"<&N!
<"W!K@"N=J:1('V+\$T:!'R1|0,EJPE0?23(D6|M.BW/<9I^)|
M*G!|,4|7&PQ6%*2@S\$I.!4|P<0B^|J,Y>4Q9>CF(D;+MEF&) EB%.&5BN*
M5TANG9@YL+R+,4=IQMX+Q+=9#-Z|>0_>@+0 |S79,E0DK&=RL>KRVN:B7N&H
M6J|S JA#;Z(=:T9^*M(<-(E,(7<1K-|T#RR.OECO+@!#OP;MV%0L:7P|W
M%/#X>KC=H<9I=M"1?,YS?.W=N#_NOK|W(A1,,|9=Y7O%:^KYBT?.+=L@Q:X
M;X@G"L-TAXW!VS^@;_V|D|PG6:R)K.6GV_C|K\$YH2C3#S2I(?*^|7">Q)? M/E=W
^AY@>^(W=R=6J*(|WW'M;QV7*R(\$Y|@.L:UA'B-\$*|3R./D<3*?WM^I
M)'0B7|KU.LEB360MQ_S&?^54LG7Z:_.LE@36H\$# MSS)DK
BS+!=&9XET&>8\$D1N\$ZCP*&Q5AIXKA=#*;#^,A\$.|OT PF7R?SR;U*
M4R2;2^|%G62Q)K*6BU'C801*N17|H%,G6:R)K.4GM(Z5F_6;V543M!+'|6\$8
MG*67*LX.,@ZRR|5G&5;GJU,.'A2A,).*7?_C(9WCQ.EAD|D2|=?*UNLBZWM
MFGUTS7ZEE*J)=9FJDRW6Q=8V|5A-P|
|B|H|LZW|TEI?;V6+=;&U33V6V+"SXKPF0_S+_T-6Z'B.>YY@EX\$1C*(H/\$^PR|@@
M"+R+UY9YTD;),5W)=A0#"|(M>-5=;&;EM=0-GK.YD=E*TRV9XXT51_M"Z*K MM&
@PTM!:=T\$8E&T:DU5 TXVLEGS1#@GN3Q<8Y1@6@:(|TM""^&%07J!|S |^ M!U!+ P04 "
!0BDQ:??20_+R0' !1.@ &0 'AL+W=O|5@GUY?GSTGZ-5L(D:-OZU6<
M70P6>;XY&PZSR4*LH^Q=LA&Q_TL2==1+I^F|V&V244T+9/6JR%Q'&^XCI;Q
M8'1>OG:7CLZ3;;Y:QN(N1=EV08|2|U=BE3Q?#/#@Y87|Y7R1%R\,1^>;:"X>
M1|Y|HZ*4+TGRM7AR M_|T8.,6*Q\$|_|@(|BDC^>Q%BL5@627,>_%>A@_YY%XN'C%_3?
RN)E,5^B3(R3-MU9_+;;ZX& 0#-!6S:+O*[Y/G/T15D%O@39)55OZ/GJM89X
FVRQ/UE6R7.%Z M&>|^1M|J(@X2L->20*H\$4D|@+0FT2J#')K J@97.
|S|HI>>|!HW.T^09I46T
M1"L>E&26V;+|95Q<|X<|E;|=RKQ|= "^>1+P5;)8F:S1.XCR55R*3B|@7:%R^
MO4@S|!8|R TWW:X\$2F;H-HJW.QFV39?Q'\$7Q%-TGWZ-5_AU5:|EZS44>+5?9
M&YGZZ8&CUZ_>H%=H&:/1;+-9\$IV/LSE|HM%#"?54J|V2R4M2|4\$W+@?
Z^|T,13>Y6&?_F'C?X3(S;O')4&.(CS+'U>.X(4|^|T,5IQ7B|@MQK86|3^+YVTOY 2O5
M>O/A|_7OE^@N3:9;*71355:PKKL!\$HP#@6DD>GL2O9|4Y4'R"0G&@<T/OT|

MG_Z)ZK+F=^5M!^8=2(L%'G:+5;FRF.\$18&M-
6\$9\0CUF5E9^,"XN\0C_0YT^WU;B\ON>7H'XXX>'OTMCA5;HSML#\$HU#H>FT*GN.W
M%)I.JK+KV.I>C|&)\$5_M33@H&H="TTE5)IQ8_>@1DJH-!&XS/-J8AD;XCS"
<)>ZW\01W#H.6&+JI3U M)7;K^+_P_4L0MIQ^V\4"ITE!H.J?*AA/6E^9
33@H&H="TTE5)IS8F^1'
M.;XU^\$6/UO_Z&AOBREXCKFNN&8>QZ\DMW7ZBK"^Q6U^E.5L3Q\2>2^_J:A
MT'0"E>T/>Q@G3<\$:1:"DW_MEH9;NKT\7TUJ\A'1>-0:#JI MRH\3>SO\U56_6BWL4;3PQ
D\TWUGHL16%4V5\JM\I*8;U-#CM"YQT_MVFR&0M/9.Y@ "Z6T;!'8.!'80I_+397EIJ?.@E0
NCLD;MTMI0QRE. S:[F7*]=(NHQ\FP75OC=C? MLO/
6U&0Z'I="MS3OL:%&@1AT4C4.AZ6.0RJBS4Z=%6'.ZP\@:;<096R.&
M.%MKA"E\S+L.B\3(T=8UL>-WW2;@:;!P*3>=6V7;6U^@(-W7SH&@<"DTG5;EY
M=NKH"&L.>V*#';7M6>((R&M3W1Q4QQVV8%%U4LY&*?N,CW2HKUC>BKV\^F
M74"[V%!\H.L?*W\.^1DD8J,<'1>-0:#JIRN.S4T=)F&F4A#%6EZ!AE,0G?D.!
MAE&2,,0M7I0I6\VZC)*T'"+"UY6(\HO\0%O:4&@ZL8Z(:Y_SX\&NW%NF\/+8
MH4FRC?/=R;/H_MSD9?E:<#;ZU?XC.].-RJ8W6'+VRB=+^,,K<1,0CKO?+FF M='^S),E?
GA1OL#\%OH/4\$L#!0 M (%""3%JE#U2)I@8 ") " 9 >&PO=V\|R:W-H965TYP SXA1DXP-
E#FGW+EXQQ\CV.DOR\|M^1|=KO MY\&2Q30_25L"A\..^IO:<%-^%BR8L%_-?
5M>9F.MO*;;P M9DD>I@G)V\R\U5/?6U0",J(KR%\R'>F2;\$J=VGZK9CQ9^<H6@1BUC
"P05_M'?LDD5101+M^+N"JK8Y""^N\!/=5=>K,P=S=EE&OT>SOCRO#?JD1F;TW7\$
M;I('CU4K9\2\((WR\|YJ&*5'@G6.4_C2BQ:\$(?)YI^KS;\$CD!PV@5:)=#V M!8-G!'HET(-
,*@ \$@V,S&)7.%9@5@)S7V^(QA6@N&Q&4:58'2L8%P)QJ4= M-K\?^>-;E-
^698^D*R(%K1BHG10J1: >9@49K_EF?@V%#H^N6'W+%DS,L_2 MF%RF"
<^\$_7+1"+XDEV5ZEN7D/9G.9F'A3AH1\|GL8X57WUJ,TS#*W XF0+|<6_M>?
OF'7E#PH3\|MDS7.4UF^5F?BV86R?I!U:2+39.T9YJDDBO1CF5.[&3&9BUZ M2Z\77]*
I+^37)("^V+|;C;P\|>0+34K\|E-Z?;\$%WYA6B*IK4TZ%(N_QQP(5>?
ME5MRN<4"J=R6RV_92MIX1R\|L\$ZD\31?T8"=|T27
ME\|LG04F/_^DFLJO;79#PBPDS\$;""3,1<(!,P'P1J&'FP-/9#1)S?I(XWX
MHQCVE#9N_11#6,H:F+|K\|KBE;XDQ3 M'RA&|YOB1-
_PW\$=U\|2L;62(;72!YKD.4O(19**T47_UCP,*|ET\O6DS552
M5E=7(6\$6\$F8C80X2YB)A'A+F@V-\$YM;\$YN0U,&;2\$,C81829B-A#A+F(F\$>M\$N:#8
U##\|>&'G;IX;5G1#F;\$9Z2.Q\|UGY?1L(L).Q&PAPD MS\$7"O W,W.WWQ\9_4?;&'Z"
<#;,>.MFX=2=UZT;-D*:Q*500Q9@DG8<*9R.C;
MC"JE=C4J\$F8A8382YB!A+A+FC0Z,.E(/; K*V+#I>&O3L=2F'\-D\7X;|#!9
M\$/_35\N=DNLLG:T#WGH8E<*ZNA,)LY P&PESD# 7"?0,|A\$;|A85>IKQ\|HK
MC78K,,C34)H%I=E0F@.EN5":!Z7Y*%K3VCME\$?7_7MB2\$SH&\$FSH#0;2G.@ M-
!=*|RK;|MAA,#(/1P|M<:IJ#?'BFK\3;M\|<^W@G21A/^T%K(NY+#.%D32 M+"C-
AM(<*,V%TKR*MFLM;;P,#RT(RMHT:EW)4J5UA2>CMKH26JR"TBPHS8;2 M""C-A=
(|*,U'T9K>K8M6ZN"UQJW0:A:49D%I-I3F0&DNE.9!:3Z*UK1V7413 MY56T8\|MT-
H9E&9!:3:4YD!|;D7;|>9U8V":X[VJ;\$NF M,GYF1%I7M%1I?
6'KJ\|D>G7\Q\VTU5+0ZA649D%I-I3F0&DNE.9!:3Z*UC1Q
M7<52AZ_5XT.+6%":!;794)H#L;E0F@>E^2A:T\HUR4N5U\|R.Z?&A\;V*UKQ1 MR-
@_H6@2>V6LJU;3^ITQ)V&.5"F^9!:3Z*UG1379E2Y:6IG?N\Z0/-9F1% MP_9+3^-
#%XSVM_2E/%OGXQVTW@2E.5":Z5Y4)J\HC50I.^+3IKTRO\DFMV% M/-
OTXQ\N+TCA=)_09H\Y78\^4)I5T9HD;Z_&|G0I Z4YD)I\I3FHVA-J\9% M).V%(A)
|NODDG5>WI4C\|3FNLU.A%24HS.YH+_C>@29UH30/2O-1M*93Z\|*3 M=ES9Z0?
I>&^*G-O9LM *)1F0VD.E.9":1Z4YJ-H36?7=2KMM1ZYTJ!E+"C-
M@M)L*,V!TEPHS8/2?!2M:>VZC*5).PG'G/G+"9T\|#*U706DVE.9:6Y%VQWM
M:;+JIC|R\|_TM<>7=)^K>M?Z6.%4U3&/_":S^SG/A,QN7DDM\$9RXH\|T\3?
G33)%@^UJ(R;|02P,\$ M% @ 4(L,6D<%&,V>!P+C< !D
!X;|JW;W)K&ULM5MK;|LV%/TKA%<,'5#XE-2EAAHD\4KT U%LW2?%9NOA3E:5M7Z?#
(I M9TN^2LHSL>:Y_.5>%*NDDA^+Q:1<%SR9;QNML@D* C99)6D^FEYLO_M<3"_\$
MILK2G\N0+E9K9+BQSN>BIR\$!|R\|;^Y%<-U@VW\$UY0_EHV_09W*G1#?Z@|?
YY>CH&\$;SZK M:HA\$ _O? KWB6U4B2QSH-T'AFG7#YMI/Z.^WR+2\T0C;
M^7VRR:H0X0%WOD^(UG@SD97;?A'C+C;\$(\$#;E)58\1M+!JLTW_V??-JW1*,! M))8&:-
|6V |PVV/3?9,=NF=9U4R?2B\$(^@J*,E6OW'MF^VK64V:5\?QINJ
MD+^FLETU_9@_+|*2\Z4JP1CR#PX=@0X=@:9XV(+W\|D\$FF-QE?"SGOKA,9">4?
+8ITBKEY;DIO1T>, >/5 MT^>^|7"-#ZMB%/KU9BJ(;5\Q8R5MZ MN.EOP-N5_#
HE\|E2@K4Q?L<.D6MUXP'J:\$QK""^P_-Y/0P#&G(PD-8BS8Y MT"9.VA\|*49;@-

I>K5[9E^4&N6L:|N,-AC>M#BFB'T"&(&BF2\4Z3"*G^1G
M7H*,RZ^K99(#D7/P@R>%B3;5&(TA9!W:AJ P,K-F!|;L*-8+^84<)<|39SHG M3,(
<4,0#&ELIAX>J(='#>7?RBJ5:[|,Y7V2%N!KDFVXB7FHD2(LH AUN.MA M6,
f%1EB+?'0@'SG)?Q+YXJAI&&ET0HQ)T"&M1^&(Q9:Q\$A\XQT|. #9489T+ M31QC T=
(H@Y'/0K'4619*-&"@1"XXIF?|CHH|>IM|\$'27.4,8C@+;,@<;\$@V=M|)?'N
YI4I1BSH=JA#E.&(FJAJ,03.@5JVKLG8\$H9F%WK!KB,*5Q8%D> MH)(Z>
(S6&:DZ@8;JNR^T=MI**B'Q|&Z@4WP'I^|)K9V^DF\$X4(>M5@'J>FKP M"J8HJUF 2G?
A<<+;SRY DZ)J?L\$416W,E>O"M^Z>;!F@+JECJ*T*IB!(;:N7 MTEUXA/
:63IQ|D|*3VCMK)5RP|CWFN#T H/3|X36WNXI3X#^, M5D/(&%G, %)F +G-
P,DS#>D>8(QQUYV;HEA +.P;FVRW3^AM%Y%N \$Q^T1#F M,
(Q(V03DM@G/6ZX|0)L@B;I*80@C 846UXV4H"/WYO>*2W|WZ4S>|I*NULSY
M6I2IF:E7)?>%ULY;*3FBOLLT3FLP.'U/;:WTE4- ;H?08USJ^@Z)-BH-01\$* M+
(-2N0#D=@%|=P%(UW\$#1T.0G:/2>N36^BM1K\$4A2|HX76 MSES|/?
*M|BKWOM":|5QX|/|^,1:\$L=^ _TKX.X+S)T\$?%"UNX291^P M;_N O=H'7VCM|)5|P
+#+-8Z"-8=0LBZ97|34*,JVB:I7 0^KI;0;V."" MVMTVF(*@;9E6U@*|K<7)6S,W_N"QIA?
|QQ3;UD1E(|"XN|:57H74MS7&)SI
M2S@+HIP%"3PO*L1H58:F|PNMG;YR)^2%*Q+\$4&N VIPU1:'(|D" *&M"W;-D
M|NSF#"S\$ R_R>K2"))^#9,'SV8|^&P0W^.;^1*G (AR.P3|'L=>GY'X0FNG
MWSA.X+9+QV|0B'YV %%&@Z|1,|3!. X#2S6(*%M#W,|W3MT@\$/UY!F*AW+IT M\$S
|HXCC"-IFH3(F0&U,CMX@\$-V"D"BB6L|;"AXOCBT/|(GR*L3M54|<(!## M>8:
(A=U|F2%;;A"HI19"E&\$A;L/2?^T;M&-P7W7PJO 251.B| |Q734A7KV- M+|3V^27E;>C
IR36'0,U'))@W2,2IB|J6?ZH0WDT=@S#N#N# M30-^K@&^,)K=T'R@+1R/<4|>IN?
*&UTU?N MAKJ+. =S @|M|/_A) MMQ Z;<"SONF4|??^Z&'YHD,YP/C6.+B6#*_3"W
M^>DQC0?9= ?E|B?M".W=.R47 6RM;%|N6LW8=*K+?O-|V)JA*K|9|+ MGLQY40?
(W^>^%J)X^U*|,'5Z1F_X/4\$|L#!|0 (%"*3%H6G*F/*P, (|* M 9 >&PO=V|R;W-
H965T&QG2P+T 883+Q|J|6BAL|YXVKFK;0NCGQ?)2O,B>J) KEYLA0R)|H,9>:K0B))G5'.
M_ "@(|GY.*/?BJ5N|DO%4E)|I1CE<25)GG1-Z>(!;F1=Z=PMO;;;2=L&/P7)
M<(|ZKNKB29N8W*BG-D2|J.\$AHM\$FS5O < MCM.4VF01!A>|>N4V=?MGJ
EEZ@#V@'X|I(R9937UM2&P.GY2>SNI0\$4|O(41 M7 JN5PI>|A33|P5|@HP1W?
|)U&GXADF/>B'SR *H@%_(Z-125?:F\$0|G- MN6;T"Z; A%)0".6J85LTE;^1|V=/_CH>CZ?
^>@OCL&\$<_@WC-HCA3Q#|*-A. M,6HH1IT4OUDE,2;:P2!04_|F&4M"):P)*_%
|I>W74F#K|'WC;ERAVDOAV'4 MVY&|<4,|HJ0^%;
(0TE*GN/A5UCJE'EB(DP9TIAG:/((Z(<-^F%GCJ|0)@;6 M?*IVGR.R-MJ
@C#5G\$ \$O4&XO3;"X/Z*#SK)KWOS'F1B MC9(|8,)3,&'PY/9WRJ5;_(%)#UO?I_ Q*Z96_|?
TT3U|+^+|B;XH6J&AS|4 MC=_J\$7*4F>N\$%"2BY+|J%YK5IMLZKGL,^>U5JW9)9\$;Y
H9+8QKTQN8>EE7W M4TVT*%S'L1#;|'|INN#(=(T|HP3Q?"J'O)M9!TX/&WP!02P,\$%_@
4(| M6HVNP)#C @/_@ !D !X;"|W;W)K&ULK59M M3|LP\$/XK5H8FD!AY;PIC;21*V(8TI(|
|<.T#VYR;2RJZ*LVAH.I(+*#\$G9F0!=4X ME7-7+230S((
|@:>UW<+RDHG'MBUL8P'HM*7#" +A8#1W?62|< MLWFNS8(;#Q9T#A/0-
XNQO)G;LF2L@%(Q41|)LZ%SYT|FD;&W!C|8K-3&F!@E
M4R%NS>0R&SJ>.1|P2+5AH/A9PCEP;HCP&'<-H.Z,-#-|9K|L|6.6J94P;G@ M/UFF\Z%SX|
,9K3B^EJLOD*CQQXP%5S97|J;#V'D)72HFC >(*"E?67WC=Q MV #X_1<00;
(G@)Z+P#"|A"^^%M!K #T;F5J*C4-"-8T'4JR(-;:(9@8VF!;-
MAEEITC|1\$G<9XG1|62Y!:"MRBH.1,S(6(H4(%-D)D5!)I2#(K3;
MR!75E62;X12MKJB|!4VGB)E NMX8|TJ1:U 8?%;.<40Y^P;9^8+WL&;Y)I1" MP_T\$P8RK
W1^,TG(_MX!V2.L)-|S42DT5 -7HTQS6#=#M)(UJ2<\$+DOR 7(E2 MYXID1" Y \$7M#K.-
#YZ^%A!SOY/3S8H29L M4QY:00#?2*3|D"4RU3OV88K5J5K0%(8. M5B,%
<@E._/Z=W_<^=<7O+CCL,0M= MX:W=1-;.*=W+./2|X*0_<)>;@>LPBZ+(7)--
L^2Y67#B|X/CUFQ+;-2*C7.*
M;9|UMX^Y2|9.@O^|D6|)ED3/0A(%'Y_ \$P|VHJP7(N>U/B|J2B*G5=/=K5M@6> MV|L7L&.*?
F3,7'TU_)>2C2@"0 M/*4|4P,K05RF=7 M5F*60J;8R(B\$V<:NB>G;F
Q8U|!BNULR8FE(D0CV9S&0|QS "#E,T)JC^ M6|(9<&XL:1Z_2Z-6Y=,=|
<;Z^=%|_#J8"55P)O@#BS\$96%V+Q#"C.<<L;J M,J""X%1P5?
R257G7L<@T5RC2\$JP9I"Q;_J.G.A\$|_;;_!*"@%?P7CLJ6(XH MTJ@OO8H0">-
Q"T2HO/Y,Q3#>H MPQ&@!JD?Y("PC-PF(E<:H_HVZB ,%7M:\$CY=\$_ ;V\$|!|)CX|A'Q*|_-
|L8C M@2H17)<(K|/H|+X,2NF@CL@P%1+9'XAU,A36<5W;-;-;" J M1"WH%:6?
C(*Y!*LZ/LW-W1^C#V*|9^D_7H@6&B<^F29Z"RCMP:'A1P|SJ7
MD>^UN|U.WU|6N&U7;MN-;HN1W|!KYY%KV+1^UB/|&IZQ_>|H-Z=

MZVRUU&GLDHT"JJ4"OD5!2I-?VQ[NCOR[GVN0\$K^;+>]+U-;L74;E7%-4K<
MV\OME=+UWUF8MSY>MU&#/UJ>K=:ZS6+[[*|EM?|^=J*J_M!=2UQ0;-I>V<<
M,-/=%95SEBG"8:91SG%P^5Z6EIO4"R*"64B4,|Q3+1\$R9(&PO=V|R:W-H
M965T7#+>,Q!+2B7XE:6Y M&#E+*5?7KBNF2YH1<<56-
%>_S!G/B%2G?,&*&:=D5@9EJ8L|+W0SDN3.>%A> MN^7C(5O+-
GI+0=BG66\$/WVB*=N.'.@\7|A+%DM97'#'PQ59T'LJ'U:W7)VY M-/RM0I^ZS"-P?
D;-7))79|Z)H!.6 IO,Y'+D1 Z8T3E9 MI_*,:?^B%:\$RP2E+1?D)ME5;SP'3M9
LJX)5!EF2|H)KVH@|@*?R(50'H MW!"2Z"ZSDM8-D60Y&P+>-%:H14'Y=B4T8I-DA?
3>"^Y^C51<7+|F20< M??"IFH(X'XWEX#-@5Q2,&'9BN1/?PCP40@J:2#Y#Q)R&.2)C*A
GRE1*PY MG0\$BP1Y0,3O@CD|7G"?Y GPB(A'@[0V5)\$G%.|7/P_T->/OF'7@#DAQ|6|*U
M4,ABZ\$I%J\$C+G5;-)?|HECTXD?T.G5P##|P!YR&|)GYP?CIOAKAK&>BQ1/9:H
MQ,-FL=P40|!&91?KM|<6J_5:K,B4CARU' 7E&^J,?_+AMZ?;<0L@35HXIHF M-
J&K87N40!336ZJ|C>L.("@"!BAO)9AQ@'!|@Z&|V61C|>24+OV;A&UDP&=78#8W:|>^A|
(U)DK:E-CA*+?!A#/%L!M@?"'78T@X&.!B.GZXNK|"'|A/%>|4|(TY>J!|*Y|^J<>7AC-3"CW#
MY9B|ZSQ|ES 4#L &/91JM\$ _=*9J":U)5=L):/839|APV.(58!!%Z%"KQ^T0 MC*
(P/J%5;2J@V57TT:K9@I@|HCR5ES A4+L0V,>&0*L^Q!9:PE9&Q%D-B)G
MJ!8=.PP4|E|L':BVI1V,H.?#=M4B;460V8I846VK*S!WW+D(8 FM.4Q|U8Y>
MY0Z|I8Y+&""D#1#J7?*H\$J:/JX@/KS5MC3#@PB=<5(^Q9D|BT3QE>,\$TE?
M9P+,Z)UGZQ+/%#J0=\$N|3|D!6_8XMM"95|7>0N>1QCC"/2QX(#D+_L*|0T@YB
MB(K":JLTM5%!9J/209HOW#V_-72>.4MHS5'1U@A%?41JU=|80FM2U?8&&3W%-M62*-
CTIN|2*-.XD4:U^"S;|D'Y9_-SW7W4G-??3=>9LH35'13LA#N(%%MU M,
L:0FE2UF\FZLXY;S6L6IH*K>\$XOA\$'0W009PQ6Y57"=E|WS7WV)GW)0H|
M6!LE|/>1M%4?9 NM257|(&RN%)TC::MFJ\$(+S))V|Y6%W|5^\$KX(LD%2.E<MA7E7
Q7/=V_?=R>2KBYR*E9-)65Z|KD@R M*+"X8"50=6?>
(&EJO*|*TH..*U%1>X&GC=W"TRH\$R|K:;<|7+)*YH3"/4>B M*@K,?ZPA9|>5XSM/%SZ3?
2;U!3=FN;|G|HBNWZ:Z=U'-|TV= M+J86GL:?
W#_5G5>=V6(!&Y;_0U*9K9Q+!Z6PPU4N|/C'|V:*,|J\$|+^AL= MF|:SA8.22DA6M&+U!
6AS2|^;\$&<")3/L"!H!<&O"B:M8)2,'|%,&T%TY>"
MZ2N"62NHN^XV?;-!15CB<,G9\$7'=6KGI0DV_5BM>A.J|B"YNDN43H:?,.'H
M*|XK0+^CFS0E.GTX1|>T&80ZF6<12\$QR<;Z:?'F(T-EOYTM7JN#:PDW:0.LF M4!/*
(!_=,2HS@6*:0CJ@WYCU5V_IHS?B!P8#5U'KT 5/Z-:|T?\$.|PLT|3^@ MP
N"H0Z9Y0|0*KGWJCPRRR-(NNC3_7G|Z_+&/2C:-)|3=Y_A!OH^M8WC;-HL9L;N!M*5R|
|SC/3?ROJ4'\$%(M4:10"P\$) M7+T,(465('3?
|IX@0LM*BB'L1O.QV&V:1?,WA|FE<#WLBPI|PHCI|+|56Q06K M-/8C)Q(0V^W4&D5FA"
(F,^*>L(*0&?PJ%:O LX_(IR*?&2&-S8-,LLFD6
M+WY*:#Q|*+=:R|3EUTF+HV96.,JQ8|#7(VZL5QMFD4VS6)+9CWX5QWJ_^Q
MO+FRF0",9I%-L|B262|!OO>|4?&X_|>>*)F?|5|55.0VJ.F5;/55/.0WHLB
MM5|)|K/3^OK^Z11|<=F?9#?FZ&.Y6W6+;;GUR9|L\$7TC^3N2JUJZ>'(H4P/?U:91-B5|+-
)O|FIWXG53G_.|MN|HDI|#ZL.79ICE&N|+3ZA_>R4I7>Q4/QY&PO=V|R:W-
H965T,*X67JUU_-|5=;8\$#41+7+S92-D0|39RJVO6HFD*N9,|R&(N=H1C@|2U*YIB#S>
(Q:'A1=Z)|\$CW=;:"OQBWI(M/J'^W#Y(
ML_-'*Q5MD"LJ.\$C<+R|<+;*K;Y3^)OB09VMP4:R%N*;W7RL%EY@"2'#4EL+
MQ+SVN\$3&K"%#X|>IC>XM.#S|HB65-%"X%^T(K72^|W(*-V3|'X M_(E|/%-
KKQ1,N2<<>MW @W*GM&AZL&'04-Z|R?<^#V>,'X%\$/6 Z!|*00*(
M>T#|JX"D!R0N,UTH+@|KHDDQE^ (TFH;:W;ADNG0)GS*|;\$_.6F^4H/3Q4>^ M1ZZ%/.)
|>#)WJMHQ!+&!DYRB@K)WA>4\$XO &HB!*1N"K7X?'S^&^R<"0AFA(0^3LQ3|
MPXJJD@FUDPA?|I9*2W,S_QF+KS.8C|NTU3I3+2EQX9ER5"CWZ!6_Q:FP1|C MT?
Y/QI|%'@^QQ|>L%X_D8&Z41DD)&SW)#CYU<-M&|D46A?'MW-^?AS"B%29A
M.F@JXY8,W)*KW+Z8IF%O6BM%B6J476<@/?=|FV?A!;N76FF>)_ \$XN^G;GJ5 MW0?
J2F|"K9"C!;!_77UW#T9DU?<(V#/,LN(GJE:1ADHU'E X1I5<9?1;
M,)/POAK&V*40SCG,HSR_I#>FEB;!*_&; MX>;92?|(\$#!1FM*I@&B@6AE?
5%;O6R+U\$0Y\$HFV0Z%RHF8MY5NPY4M+M%=Z M3RN4D|2\$|L|Z>H-
RZR:C@E+LN.XJ>Y.P_?>#:E+>39;9F/R?+9TP|K_8;Z; M|'1N:5<<-
<15,,G.&LIN>W4: +ULV3M=|F.KEE;7XX4%H%|WTCGA#YMK(A M%Z;X#U!+ P04"
!0BDQ:F;QSV|30@EL|-X8O).EUL^N_|G+/2"4&+F/.GWP:G**4G(AF->DXV;:F!
M^>=^UWKG;PLN<6IEM|)%|HH)NV*0XXK7TCWJYBOV?LX|7Z:E;:_0|+DA@ZRV
M3I<|F!240G5_M+780|P/GL#\$/6 Z+V N>TE0LZ9:VM&7<|38QNP|AL8O.#
MMC8MFMP(Y4|QX0RM"L*Y|)%YM4#EMMG *"|HB>2T1|IVP(M',^YH:!)S(N

M3^!XAHX+:4\(|28P?'1"1R!4/@I*2SL4G@2)K?(AZ&:>=C.@-&3/1A"/M/T\$41F<'X-
/WP^/7\(*,E0E&JH2M7SQ/ZLR\$S:3VM8&X>8|/_?'V-,|H03=IOS6
M6N>6CG57"JDS[FB>.W"%/,EIQ8W;0D.7HJ"U1>J!UN(JA)J#5Z6R!
JHS/1Y2.H!GL=X%^?!V[60EF0N")8
M.+H!9V"ZCNX"IZNV*9;:48NUPX(>030^@=976KM=X/ML>%;3WU!+P04 M"!0BDQ:
<&|H'-|# #|P &0 'AL+W=OGZGA>[%2*UD\|V|>RN6S6DK2E+C%0.\K2K\$?E|C
MDNX7#G0>;WPAFZU0-JQLWJ-OL/B6|-BT&1PLMR;M/L.|C/0?D
M+1>TZLE@XK4AV TT!B* &&SR3X?8+ NPE!GO!T0@_,.EDW2*!LSN@>,.!4M
MT=1%5YLN6ZHAM9K&.'D4R+S1+9BLB.8^D!5B6J!4!U 3|^:\$DCITJ |^!.
MJDW1EAC0-3#'OKW! I&2OY-9W^YNP-07|!K0&KP=4M;+F/YW!62L?I=-^_9
M71_8^<^PN\Y)0C@!/? |1/2D+W|_9BFND).0|!H5A^AQ?|LEC-4 #!6 " = MN@-
#,H#\$|H9^078,,JU MTWM C3I4|4;99>,'BY)X|NZ.I6G"H@1ZX1
V(1T.I\$,CZ<^8|ROYHLC;JBV1 MP(5)" +CWB|JZ/ @_X)7UV<#(NAGG
T\$(Z,A+|2@4K0F&M= M8VVK14|H^7X2Q>\$)?
VOR6PB66P";*9X/RV1|9^;,GC99&R4DSFF,F=-.;FJD>|V2LB#UIN/YJ9)K:8<5
M4RU'(J2YDV0);*(:>N/?N&>W07L|2^)^MH4W5YD8^\$>:M(<|HD 8A'&:GC2J M-LY/@DC?
K' T%-#XKYW=MJPFFH7X MR2!W7|H9*R|JJK;"%-JW:"Q@8+EQ
MC4|E;/66T*;J1X<"S1;EQ8W|U('X80AA<-JXFK@@2?S9,XT|.A5HMBJ?L=PI
M;6GYZY>L&>CL^;*\$-I4|^AP86^Y6JQ;(%MI4_6B"H-%IO+Q;DR==&/HA/-T%
M;,*")8^XTWAZ&"@V<(L;==)A* '&PO=V|R;W-H965T MI"(4LJ4"9^3BT\57
#XXK03\$'J^1.RGN|N\$Y&CF<30H&QL0R,AB6.40A+1&D_)Q. M^Y<6N#E?
LW^IM).6.Z9Q+,5/GIATY'QT(\$Y*X6YD:LK;/0,+%)LA:Y^8=7\$
M>@/|I38R;|40<;S>F2/C0|;@%|_&8#? /R7 H(&\$%1"ZPJ61-F6#14<@7*
M1A;G53>5&A2PW-[BC.CZ"DGG(FFB@I'F.=CF J6&V!Y A?2E|021GX #,J
MFZ04""(.NV./ITS1F*+A,1-'<#A|P|C01|1R.YO X<\$1' #/X7LJ2TU8/70-
M*;!YN'&3|66=K?|,MA.,3R#H'8/O^?T.^/CE|&;|DOK7E^:YY?A07_9=Z0
MKQ0.UP8S_;M+;LW=[^:V;^ ^Y+EB,(X=>3XUJB4|T_ETO|#YU"=|3V98-06M#
ML(MJPX;BM0'7-AQ#CJ9+?LTYJ#CM7;.,?/IT\$-*Q+C>%=86%9_V@#=#M*N=^F MW-
^9|H76:#1YD>>T9|8EL2_"@%3QXPU(=[-.&/9%MV1"V M-H104*H|.5|K/_RGH,|ZKE_U;.
|<:7;=OJ-J07/-0B<\$|X|.24"5;>H>F%D M4=WR=|)0SZBF*75U5#;
GL^E-.N%;1SM=T+T!U!+ P04 " !0BDQ;|L:% M&UT# #6#0 &0
'AL+W=ONEEQA2GOJ^3#'#J1|(| @5|V4N748%=M M?5THH*D#Y=R/(@F#FYY0);
|5P8VNU6LC2<"9@K8@N|YRJ^W/@Y_PBU0U/+ETBNW2_9U|:1Y)2&YG78%Q!SD3U3^|J
M(0X X>P)0%0#HL> R1. <0T8/Q9L'&_,0J_,L29U5KA%E+F_HBL.16&4)&2#S|+5F!L#?
F'G*4ILP&BG%R) M;IO9<+V-P5#&|3LT^7P3D|>OWY'7A ERS3A' |WP#;
|.SN\$G|4K.JY5\$3ZPD MC,BU%";3Y(-((6T3^A6XUOTX-MYU,L80S(BX_"
(1\$T\$TZ5C0Q?/AXPYX 'QX MU./-N(G4V/&-
_Q"LE!GK4|!^Q>MR96!7'_ODKZBGG13V|OE5!95. O>=|DV)%D|\$%E+TDDCZ:2/'4.\$I
FKMC3*YB/<4;M#53J,IJ-YVRCN,)J-QHU1RXMIX|6TUXNOC./%L#52')'_B;|
M/AE>&G|AR2+!R)K*3=KE)O|O2,U&U+2(>|F_\$" |WZCRBJI M8SXHE-SB+)WYH)?
H0I69%B '!RMT H1476,+%Q9?2L-
%NFNF>'#"Y0UP.;&ULM5A=;|LV%/TKA%8,+;!\$(F7)7,1T\$0^SFFA9=.JVMW(IWR4C%:
MD#L!9)GG6#R_)XQO9Q|T7BY|H:NU,A?|=+K!*W)/U-?G=|G?H.2T9P4DO(" M"+*<=>=?
P;HXB DU!%_ \$W)5NX= R/E@/?OYN0VFWF!840862@#@?77(YD3Q@R2
MYO%/#>HUOVD2|X|?T#|4XK68!RS)G+-O-%/KF9=X("-+7#+UA6|_D5I017#!
MF:P^P;,:#3RP**7B>9VL&>2TV"WCIWHA|A+@Z\$ "JA/OJ0EAG1!60G?,*EDW
M6.%T*O@6"!MTC|WKYY|HX 6H" UKR4 M.D=.;4YFU_V%S6_ |SM^Z_" &|*X!""#;
C0;2YZ>GA|UT7Z|4LURH62Y4 MX84"!%Y68\$C(+G,TG&G;4IN|(+/-
UODHA'XJ6_@+CX/DF;)H%5|UR-<0V^RF@N+>RD=).
(Z"5P_H:%B'Y;AA;:RO%XLRKQD6.D'T'D*17|@ M.UN&B(Y|# "ZB!"7Q:Z:#<7
<38:D)@W5Q\$6Y)_U6F|QFF/08PLD\$#M;,-/0F M5GIZB#+|P
7>C>:5(\$2/>C6XWUN1SBUR1V=T3!H9V?@NL5K1\$?R7:%U|>|Y M!VA|H-
|JDI37/4;|W1)|I7;L2 "SP2+H9*9VU_5F8|Z%UVIZ^FI4X^TW
MBJ.HUX)U7'PXKLNT'=S0/KG/V=%JJ,Y6-&"7;CO#H9,A;D=X0Q5F|(<=>|HN|00U.9|LKM*
|<=KK#V/F^9S4,9^MWA-;5W_H& M:#<.IV|(|3L 80)|KN%X7)=I:QN@W3>|*K2N|'?8(
MNFYZY&ANU_K_#Q> |O|YVUW 66;G"!.\$A|V./25G9;86 MDM1+^ ^|=|^K9" MG?
U|:;%UA;=F!|VW4N_A|KS|->^?/ M6*QH(0\$C2PT?7(|UKXG=JJS=B>*,ZFWH
U>*Y|7AFN",!|. @|RIY5RIGY@5K M|T(|_0|02P,\$% @ 4(L,6EO|Y0<, P-PL!D

!X;"/W;W)K&ULK59K;JHP%/TK5E9-K;0U+PBL@TBT65>D5:K*NGV8
MHL\$D%V+5L:EMH)WVXVX|O.7YP!VLN|F4*H-!C1ID<6JE2-MBS;/EG\$*&9:G?
%,S\RXR+ #273&WY4(3G)01FW/<0(|PX19X2 ?NQ'A@"\5
M)0QN!)+++,/BZ1PH7P\MU|H,W))YJLR '0X6> X34">+&Z%|=L62D-R8))PA-M;:A-
7+/HKZ)SP-^\$%C+K38R2J-M2DZK6M(MJL;JLMQCH7BI50!*\$Z@XRPXA<_ECYL=S@-
K=X^H',X)<_Z6 3@GHY,X4 M4G(?)
(JOP.!AC82)UFRFD9N9H|5\PLRV3Y30LT3C5#AF"K,YF5) (RE!2819
M@KYRGJP)I>@C&B4).3N\$*1JSXIB9-3J.0&% "Y8D.N9M\$Z/CH!!TAPM#WE"^E MYI
#6^G\|S"IV7.9R7N3B'SK-+&'HXP+1?X4 MYY?/|)/SL"0"\$GUJJSN\SM0YVG!W_?9@GW?
+7|IR1=107-4U)C%&WL_N\|ZK'/V;F9+*Q9.V%LE109BGI=F M\$|L5|R53Q_UN-5M7?
*"|Z|L:/=558%"_ :8J2\AJ+.6\$249AI2N>TI-6)HDPK M.HHO\|)ERI4N@_)FJBM;\$"9
S\|X5YN.6:"JE<- 4\$L#!0 ("%*3%K% M5S&B_@4 \$TM 9>&PO=V|JR:W-
H965T73D|S5U>,+)AO%08DFI1\$|Y5HC+WE+*U46_+V9+FA-QQE:T M4._&
<^5(=|T1&/NF#VZ3RYZC.Z(9G4F-(.K/(|VA6:9)*H_0%;17 M7U,'|KY^H4?FYM7-
/!!!;UCV-4WD\K(W|J&\$SLDZDY_9YE=:W9"O>3.6"?;,
M;2JW=3%2>G'ZG24:|3=)4DJ38'R=|M45I<6^5|0"5),_ \$!O4-I@?Y<
MLK4@12(F?:FNKAG|676EF_)*|BM7PBI|ZQ-JY%"@L\$|HT-7V5=IV|^Y+|M6LE
M_D:*,^0Z)^K'=!=|<_OP3'HU_Z!9, M>#C&M6 B.^9W|GB&L|/F-O\$A&*_"='&#?&|VGB>
7NO&D\(|2I'Q'PJHF/%T M91SW|TN2_\$BLSH94|-S8+R1|J;JJ2'3J|(:8^*(-/@6-
MX4:U<".K<%|A4|31!Z5: NJ2L,9IUI+53X^,*YP6DBE)^V2T0H_5L82AO'. M9^<^<.8.6C-
4HKS6J-2R\$S"R"A,5 L(:=XEM!5| MK-#V'\$?
HF1(ND(OR>Z:1@(|:5R1QF^30L@;C"!A,1" LX9?SVB_G
MUD_PC^94CNC3BA:B+#OR|JR:T_4'8V1L5=HT:|4WHD-G'0+"&
M8MC9|@)\$"N0>2%H#20E!;!\$J+H6A-|JA;|HC6V>:*4X+87!42JF"D0JI" M\$:VX7@+
(9_2OK9=W79%WEV^NA_>*[1M|D<|Y(6@M(B4%H,16LZ8|L6Q-;^
M4=D,.\$SEJOEQ.RL*53UU;V.>-5|X=-@|AS|@#M_X'20E!;!\$J+H6A-CVR;M@-
C>!2P?.F2ARA3C#U8^>213E::D1:*FE8)NU,SRVKKD#3YVRB5-IV4@VVX!
M*"T\$|46@M!B*UK3,ML6(#^@QGNB52,K+_VQIA3N|80>YCN=W^@*R*Q>TD)0
M6@1*BZ%H35|L.Y#8WH*LRMA6|I%,'+H^:<|LG88!|4J^D:_DZZY'80":1 A*
MBT|I,12M:9AMYQ;6Y|CW^U:)ZNB|4J(=%'H!U*G2T";GJ" T)06@M(B4%H,
M16N:9|M'Q>,?M&@&|:2"T@)06@A*BT|I,12MZ9YM5Q7;VZK_9|\$,VF<%I06@
MM!"4%H'2XHJV|V|K-8V>W== 'G_.F'PYT!>H=U!/_P-0 M2P,\$% @ 4(|,6D|6I#"_| @?@<|D
!X;"/W;W)K&ULK971;ILP%(9?Q6+5U\$IK-2<0R!*DME'52=T4->UV,>W"@9-@
MU6!FFZ1|^|F&LG0AJ;2;8&.?|_V_R3F>;+EXDCF-0L\%*^74R96JQJXKTQP*
M(B|X|:5>67%1\$*6G8NW*2@#);%#|7.QYH5L06CK)O+Z;BV3":15H"7:19%T4-M1+Q<
>|J>.|KR_NZ3I7YH6;3"JRA@6HQVHN|,SMLF2T@%)27B(|JZESZ8^O M2;|S\$V!W?
*6SESA@9*TO.G|SD2S9U/*,(&*3'I"#ZL8%K8,QDTCI^MTF=CFD"
M=|>OV6^L>6UF221<=<.:#9BJ?.I&#;EB1FJE|OKV%UE!@|J6<2?N+MNU>ST%i
M+14OVF"MH*!E|R3/|4'L!&|!("W=CJ;D:6Y8PHDDP\$WR)A=NML9F"MVf@M
MCI;FJRR4T*M4QZGD#K0EB<|1HODLB*_03:UJ-<@NH3EYT1|:2?189B#0-UZ>
M7Y,R|4:6K-TCT>D,%*%,GJ\$31\$OTD/-:DC*3\$U=IC8;DIJV>JT8/|!G!ND% M&OB?
\$/;P\$#TN9NCTY.QM&E=;|'SBSB>V>0?'??Z|7\$HE|_%A5Y^T)L6P/X6I-MC|&L2-I31Q>
!+|\$!)_GXP0^|ST<\$#CJ!@V/9\$^TWZ-/41-4VRI38)O\$|/XHG M|J8'-NQ@P_=@81^LB0K?
P'!P-|9TL_ |V*@/%NS!XL+^EEAOPK?8T5|K+" M-1KVL T8=:W24|9"#|H,K!;*/.-HC!G\$8'|
7=?|Q\$(R2)6544>CO/-Y>+8V"8!#|(|:=Z;F9OI*Q)J64C-6.LZ|&.D\$
MHFGVS43QRC;8)5>Z7=MAKB|(\$&:#7E|QKEXGIF=W5V|R!U!+ P04 " !0
MBDQ:%SX0|J," !|P&0 'AL+W=O:&EM":%\$E:1LY^<|H|3%
M#R7UH1>)CYWAS*U&FVX>)09@"+;@I5R;&5*5=>V+9, "BHO>04E|BRY**C"
MJ5C9LA) 4P,JF.TY3F07-"^M>&369B(>|5JQO(29(+ (N"BJ>;H'QS=ARK>>%
MNWR5*;U@QZ.*KF_.ZJ&:"9S9'4N:%U#*G)=\$P')LW;C7DTC'FX?.6SDSIAH
M)PO.'_7D6SJV""T(&"1*,U\|K6\$ "C&DBE/&GY;2Z(S5P=_S,_L5X1R\+*F'"
MV<|5=G8&EHDA26MF;KCFZ_0^@DU7|*9-\$^R:6,=BR2U5+QHP:B@R,OF3;=M-M'G8
;O*P&L|WJD-OP7XQFBCS-B:4D7CD>;,
(G0TLNF!R8U!HYN|U+%TJ26;TB2X8\$%JF!!=%#2GYO,5BD2#)1S+|DEKW.=+
(|IA/B7G9Q?DC.0EN<|X+1\$B1|9"!UJ'G;1J;QNUWBMJ|Y!<\$M_10#S'
M"WK@D|/A_C|RH@F,+?PH)8@U6/|=VID?.JS^Y_ (|LS|G7G_+?:7RJF;+/29;1A"PZ#|
MR3H.PLAW109ZU|5Q5!1&P547M2 =:#N.NG*3MBO+>JT16|J
MN^>*,FRR^W=L"IVV|J|TON41T=7Z@Y#WS^4?ASF!4X8N0?:|9W^IO\|MWZE8

MY:4D#)8(="X'R":?MU,%*],RUMPA0W4##AQ8'0;B_Y%P]3W07[7Z:\5]0_M2P,\$%_@
4(L6D!GDNA\ P V! !D !X; "IW;W)K&ULO5A=;YLP%/TK%INF3>H*YJM)ER!UR:9-
VK2HV#1AA4QI# @N. M1)%EA/H"RG;3RUL/3RXI7<;J1_8T61+{F
)\MMVP=7(KE\$2FD\$N*,L1A_74 MNL'7,QSH!!/QG<)>-.Z1HK)B|+<>?\$RFEJ-
G!"G\$4D,0==G!#-4(ZEY_*E MK,JF3FS>/Z"-^05F141,&/I#YK(S=0:62B!-2E2>(5K.S-
".:STFB"6=I
MQ'6T0M,W1AN3K=C07" C4G+UEJH&=W\$,2MR*=" "6K%!)#\$Z0>|@ (2I.Y> MN46
0*_1LEQFO-9H5G .N40+SG;4+*=R\$UJ2%,0%FE-1 EZ@FU1YA.2ORM>@ MMR"
HJ3@Y1PDH:EXI6" +>?HY?-7Z#FB.?JZ8850H6)B2T5-3I".*QIO2QKN
M"1ISB"^1AR^0Z[A^1_KL>E>.JU6@M:JNK6JKL'S3JMJ!#2BU)HT%;EI*O+S
MD\I'R5DXE<7H*8WUU,?^C78DMBF%KJ2S:05O3B&0Z=-UU*# 36TL6K=?'Z
MT*.O3))4?;JE.L*HDQP<0H.J>I WVJ&L\$Y@Z>JO:1>Z5ZP?NQ_XUR7:\$A5IH
MXSJL1<.O:~?B|~#Y#0F-"J0JNB(2N^?4"/7)!@)K<0UJKL\$YK1P,JR
^ZK7Q5T[CJH:\$V:2(Y6'?HHA+13_M%VT@L!;;4.P%^,C+'5\$!=D_LRM@Y M|#+.
(_9E#JJ9XI#RX3|>Z8O<@.14|>KH'0VBP/'17V MSVKE0?NOH=#:VAPZ,-S;R QIY>#_?
MC'IG&KT1&&?>R\$1U:V&+=.?>;_3/@= MS05*8:WRG,LK!
<#+8W0YD&OK3J(K)M6YUMQN@"3 =8!ZOV9,/@STX;;^,R/Z M!U!+ P04 "
!0BDQ:DE7SJ8\$ " #=#!P &0 'AL+W=OVPG#2W+IB\$J7A)?^Y[CF7%1865#L7:E;4
7%A01=W |Q*WPH0Y66KG9B)+>;H83_32#95
MA<7I)5" ^'3F^LYN8DW6IS(2;I35>PP+433T3.G)(EH)4P"3A# E8C9RQ?S%)_M3+Y-
^\$I@*_?&R%2RY/S6!%?%R/&,(**0*!. 16L#\$Z#4\$&D9/SM.I|_2 /?'
M._:/MG9=RQ)+F'#ZC12J'#EO'53 "C=4S?GV\$W3UQ(8OYU3:)HVN9Z#\D8J_M7G5@K:
BK'WCN\Z'/8_?/0((.D#P7\$#8_4);.*O,EC7%"F>IX%LD3+9F,P/K
MC47K:@@S7W&AA%XE&J>R<9(SABF)9O@>+RD@S JD)T4#!?IPIYM%@D2OT;@H
MB/\$=4W3%VN8Q7^%T"@H3*L|TRLUBBDY/SM)(@Q|*7DC-9=,7:5EFLW'L)=;4I04-
f%%B^|+D.C8<<^OY9P|'5_M@DK^&"JYW2,;WL/JA>RQCF,'/TO2A-;
<+*7+_S\$>S|DP)'(#NP(>SO"JA_MVU&W=@P5VS+\$EL\$(YLLBI/02|W-?A4/LY(XB=
JU60?RHEY>J*2|A<(*T#44_M),>D0'-8ZGBP"9_D^=LO-Q9HPB2BL-,X{?
Z,)|N9M(BM3V/EUSI MT|T.2WW_@C)>GW%N=H%YHCO;_3L%U!+ P04 " !0BDQ:D|N
f'4" !: M!P &0 'AL+W=OY)?/##((C|MDE#NI8D;NY5I(FK-*,=;":HN2R)_7"
(3VYDW|)X'INBZT'; 3Y.*K'&!^J&Z
ME;:GMRPY+9\$K*CA(7,V|CX/IY<2N=PN^4MRJO3;82)9"/-K.YWSF!=80,LRT
M92#FM|\$K9,P2&1O?=YQ>*VF!^^UG|D|N=A/+DBB|SNP;S74Q||8>Y+@B=-W M8GN-
NWB&EB|33+DO;)NU|<2#K%9:E#NP<5!2WOS)TVX?|@!A> 0|@ "A|IT(
M.9=SHDF:2+\$%:5<;_MMPH3JT,4>Y35P7XA:\$9ZKQ-?&B>7SLYWJ9;.,'E"=8W8.T>4
MPB",X&\$QA^CD|H?|-(&TW81A,ZWNC5:)CN,M7@|_HOML3,%45R7#FF1)7 M*#?
HI>_?#>+@0X^|J'47|;&G-ZC4U"152N0:*B%M77:9;&B&CL:>JDUZ%@5!
MD/B;#06+5OVB7_W5O6GP|9YL.!Z-H@.ZPU9WV*MK#P|*N+?*-X)P=0IYC?"% MR*R
0>AJ(.ZRTTO|EZF*6|/Q&PLI_@_N1JV|4>^6_MK++F>CEVF,/V|J|^J8,UY0K8+@RP.!9!A
E!+ P04 " !0BDQ: M3^,UY|<# #)#P &0 'AL+W=OF.0 UB1VUG: _ONU'(9,|RY
M2(G2KV+ARDP@B:TH3=S |R|=E%#FC(>V|4E,ASQ7"67X)\$#F:4K\$ZRTF?#UR M?&?
7|\$P72V4:W/\$P(PN_6U"EC&N'^|H|LUV|
M7LR,2)SPY"|J^7(&3@0XYSDB7KFZR^X75#/^\$4|D?87UL78?L^!*)>*IUNQ MGD%*6?
%/-EL0>P+_4&P%010!'WO'4%G*^A|5_#="KJ63+\$4RR\$DBHR'@H! MF-
_:S3Q8F%:MET^9V?>I\$KJ7:IT:/W"V.%?3N\$34
8O2YY+PF(Y=)6>CW%UHVWLVR)V|\$YL'QXY M4TL)=RS&N\$8_:/&@Q<#:*D\$>QHW:-
CB%&%|#QSR#P@F|=A'Y-'GY|C)X\$9>=7)30&?0W*08J;L10+LYXU,TE|_3X|E>|;C!T
M5_N6@I: =0K ?4: =E4<<^D\$KFA= ;?B*!DEJ!NU*10*G@F"L_@Y35#^/MN MHAQ!8?
KOF%8(FU+^J4/9&/=8E,V+R.7Y@I#L>H1+C#^+VUE|TG1)!#(4D09V6GL2;8QP
M++*MF|_9@^9=>\$'O#;;#XZI\$|N|N_L>)G,%J=PK3"JEYPKGX")S&8\$?#|6L7 M|?
T\$Y^"X HZ|5^/H@VMA:T4)\$<^9*B|X96M9C|H8*NQ-^|34J;9V^F%3%+F/
M1"PHDY#@7%MZ%Z8J%\$7=6+PHGME*:L:5KL0LXU+7VBC, -T_YUSM7DR_LGH?
M_P=02P,\$%_@ 4(L6@ /?'%*! ?A, !D !X;"IW;W)K&ULK5AM;^(X\$/XK5FYUZDK;)LXK| "I-
'NZD_:E*M>|SVYB MP&IBL|8#>_|^|20\$ \$DRV=/,%XF3F89YG/,/\$DQWC+V*-L03?
|XR'J;66^&S""ID1 MBA|X\$6>(_|^&=L-|6@M;_Q2%9KJ6_8L|D&K? "RZ?-
UQC#4#J7%OP30Q-\$UT%2>&7O1B|_3J>7HB""&\$ZDAD/K:XGN<91D MQ?
&M!K6:W|2.Q|=|H|+|HK, Q+XGF7_D52NI|;(BE>HB*3CVSW%XZ)!1HQ
M89DH|&NMG4LD!1"LKQV5A'DA%:?Z'LMQ)&#(FIV<&L'M^O@GW'P:@?OM0Y^<

M[>"7RE142AUB)-%LPMD.<&VMT/1%*6;IK>@3JO.^D%P])>\$JJV3.UV%6.)2*8>7H.G
M10RWNKT'0C\1@%#PSYH5-M%4? #06NN)+14;'9.=U)'/J\ C=,Y%##WQF5*X%
M^\$A3G+8!;"5#HX6[UV+N\B+&.+D!'OP 7,?U#0'=OH=,JC'KW=W>JAX36:J M\$LI
I@>ER#%'DO%;DI:5KV_VU6ZB8"RVV9K_!D/G#Y,N0X+% M X&U-/,:S?P^I-
D7U6@)35BN\G%6\O E9SE(U#XCM%-'ZB&JT15'J.)O3W6Z\0L@&,81&VS^~3LVO-
@X#9F+8Y!PS'X*4?-K:*6 M\$E&SP^E/R%6PX7\$X@1-VN1FL8.CYCM,A9\DS P@#;
fNP81=>ED\$3D_ T36'D M1)T0[PUF01"=I.G4\!H&(S>,S\$RBADG46f\QIDPU_+,5'
U9P4."Q0.!M50; M-.j->O-?_D^9Y\J=[#<8!M\8\>3<9!;ZNI^W=W>9;0\GWYX-(S!?
@4D2U\ U\W9'MSO?VG5#XH6#X76ULX\;.?^4K^LW8>2
M;DBT>"BTMG2'21'V#E5O\3LU;JL,O"CJ%I7!RAEW&VI_A&\5X##WP?!\!Q\$+
MR4FB6TQ5@T^42'"W0_S,JTDOW,6;:4BT>"BTMI2'1\(&OU:'O>/QO=(-B18/MA=:6[C"
fPO\A\;UU&)Y4F.N\XVX=FJR@WZW#W@@O5<^.IA0;Z.K\H!\J>I
M@LKJO;RYVQPBW95')YW\&PO=V\JR:W-H965TMF J@I*PYHY? M6R%. /fT B!H<\$Y(+H
"%M ^%Y U (BJTR3BM4AQ0HG"!\\$/2)AHS68>K)@6
MK=,GS,S\1@G\EFB<2AZQ8(3M)/KP)Y?R%\0&@38%%H!NT\$8OLKRF@/@6W3-%
M;E)":S-:,T5Z_Y,T8J7I9Z^!O+XI29\3/4K\B:T3J'"&T%+|\\$*TZRFV,ZT
M)KO\T0\I*\$RH\KM!T03(XXTPI'?!;XE9+A>NTJF;!--RL3?.A23.XD*8?H\$^<
MJ4*B1Z9'U2=PM6:=<,%1N(?@*F,*V2T*_5\1X 71P(\6\X>' _#T_?#@2C9A
MMPQ"RQ=>Y&-#,%\S\$R1\4W!\J'9/M1U0I=W M1:YG0WQM.(9FI\G9U(\;:H\Q
_GWFSAD^E'HB*9H\7CTH\HN*9'W=1/7\$F MG3B3J^)\L%,\>T%^5R6_0L5?
AW\JFQB1+1R+KR3;M9)M^EQ.G8ZHV)EDZ\$EE/MM;A3+?
YAG1C_WSW^Y,0\JC=0#44%D\NZ>\$X>BXOB"\$V>=+.KXCR!5\0D2J?; MF/(S(PK='I
8_I5>9?06)38F63H264_%>:;?B_+N_.1\3M3')TI'(>JKYWML! MT_MAK=D;
f=1/03CWSZPY&!6?_4K3@;B)%WEGUG1/CN(EB)TM::1.MF;J.5QV
MO5W9=&^+A;/^!U-.V2/^&TU3BWW"8D>81!2VFM*[C?702C3E3=-00+(_F>N
M=/E@'PM=\$H(P?K\JENM):!OF UV1F?P'4\$#\!0 (-%"*3%JW?H26/@, M &,*9
>&PO=V\JR:W-H965TJ00"0H&)=0J.?K:X0B&<\$ (7Q=:!9-%LZQ\QD_J'FIU8\HG!E1)\+3F
MBV:0(H;5@G\6>T^XIYGY/02)4S\#;N\;11 4AFKBKTS15:PZ7_9MWT>#ASZ
MXR._\XA?NDP/.(PV#L;E ?68UUQ2Q;SK7:@7;6L.8&=6YJ;Z+ATIWBVFIZ
MRLG/+MH65^ M@K=OWL\$;,"\$X%0-ZEJ?0CK*U*N#/3^0 UQ8+ MAU=;^KSZL%W=E8-
S4\(\$%P'==X-ZB\RYY_ZX^BW-O3_2>Q9(H9-(H9=ZOZE MI!I15CK)Z8X"RS*.
&:,T*E0E;1MH^2H%YL5(NY0KA=#BAWF8?;%JY1PS4Z
MC;04*M.LH"57<+G,@%4V5YK_C6D'ZNB'Z.+GT7F(SF!>>83C\G7\ZCF@#5M M_\$;_>B
9-*;O<#HW.B5&),&8W(B\IT93^CD4\NBUH;E-2>'YS/J#08ON#IW M?
B77M.&:GLJU9;)JH9G^M\>M<\-7XLP;G%DGS DH9ZPJFTBF7U(SXHZ\$>@2JJ
M)K:TTNYRF2\WKXUZUD8=3^,7U)UQG4H='OR/%ZBSNKTQD+@ZX/_2F\6F@fJH M&X?
PN\EOOVZ8SK@T('!#KE%00B3;MS1^8E59=P7WRE*/40\SZ@)1.P-ZOE'*
M/DW&PO=V\JR M:W-H965TL?24-SP\IZ%4N_G6%/N(RW.UD<.)?S?;AE*R;_
M\1\RM6PD.MNH*.6)\^_%SA_1PK"*M,V\06\L"\$:J/(fMG25*0U'G\4T.-9LPBL;O\0O\I
<%J^*>0H%N^?)WW\$D=PLC M,%#-\$-N\$AD8_ \J#NK"RI/<,T34?
Y%ISK6,M#Z('1/ZV1U\FF<59_A7*YV8B0\0WZ"+89^>BVV& M-CE/U3>9C+-
#G&U1F\$6(QF)='5%9?^Y97J8\J)8R&<:)>*<&^;BZ.V;=^@- MBC/T=<?
<5U7H\>P*=1Z%+6MFN?TP.@)SB.LT4;W:W*8V5UM; MQ\ "M7\=*T6*FWAJ0, H\$Z\GG-
?)YX";S\06\$A%\$@6\$)\OU'2_TDFJHC>#TPV M\$D5\/(BBYU&_G^N,>"IK1
6\J%I^)\8+5K0U'L#\$D;!8#T!9XV,W"7S2"5
MA(11(%A/26RUW9_UDWRF!T^5M*;UK(:#8.#'D2C/O>1'W&F!\0^>>D(63>Z6
MTBHYCH\;-1TY) K-8HV5O_D00^AJY^-^M\$F*P-)HU" TOM*D59J_6\= &0LD)
M2:-0M+Z<;4^/M8WN:JOKGSG)\6<#O\V\1&%LN_;0EB-A%@DN\]*X;;2QOM-^
M5)*%^7I7NC\B1Y;P?^/M0WQ;\SHG?F'!%;@#MTX\$N;ZYVX<";-
,+O@QK8CQ_J67./&"2VM?I#) M-Q DC4+1^@*WP(

Z+O\UV\J&69,\$KC+!;RL.F137F;ZD>;J@PH MC4+1^DJWDPB"P=U+0&
<*H#0*1>O+V;?'^!OJZ'HO6U;N<1Q(&W)NB\ M 91&H6A\.=MY \J\$O\$KS"FJ"SAYK6-
;HSLX?M\J\$@4GA%WX%^SLX*;LGQ;KD0+ M5=@AD\6287.T6>W^6*\Q#H\?
X5M;K5FWF&H)_4N8;^-,H(1M%-*Z\=4IY=6J M=+4C^;YV'W^,D MI D3,D7R"\127_/Q^?
L^VPOYHE)"-'K-&%=S)\4ZOW%=%;-W\$S3+FSF)5YCW(Q\$X5FE)-B52195B^W1\$F\G/'
M=PX93W2;;I/A+F8YWDGHG_DCQ)2;D-);\$.XHH(C239SY\;_B?S2H*SQ%R5\ MU?
I&IBMK(5Y,XCZ9.Y\QB# 2;X/\++>A M,VNLR%*POVFBT\DS=5!"-KA@^DGL_R1UARX-

+Q9,E;|H7|?U"!072HNL-@8/M,IJK?
_Q:;!Z)E\$)PR"&#X,@@')P"&N#|+B%X(3!N#88?|3@LC8HN^Y6?2|#MM
(;+V92I)\$TM8%F/LKHE|80+|K-0'G6\$DHIV.G%UX-
25/P:44TIDQ|1LK8*D0Y>J",09GZ@B|:R9FKP473D!O7 M|BPK=X(3|O@!>A!\$'QD7<
M'A?1J_DF/9|>5<1Q/|&L>#G!O/"C9IQ>\$XFC;:BRS!.OL_M>FUO7A
FT*J5/(J*7:PT:#UN17(@VZYY#N|^.0I:YJRO=:Z\FD MM?E5.@SZCZZ.-PFJCD2U:5XO61=
(?U.+)+\$U&BGIO M%N5&K5-|4\$7D9NU2(%7!-BR?S38C6|1*/K?U)) 1N2W?8NK85Y?
G)K=Y|HDM7SF.|I?F':A!GC' M5(I(#UAN04#\$R:0WN@*SLR>I>I\$EKDY\$ M::!Y'5O|#U!+
P04 " !0BDQ:9R*T=Z0# "A#0 &0 'AL+W=00:E'-EP45.FFV-JR\$D#36JC(>
(X@5U05EK+>=WW))9S MOE,Y*^%)(+DK"BJ^WD/.#PL+6|>.SVR;*=-
A+^<5W<(*U&_5D| MN|.2L@)*MR7B)!&P6UAV^O<>1\$:AG_,|@((??R+BRYOS9-
'Y)%Y9CB""1!D55+_V!|Y M;C1ICC|:I59GTP@.OX_:?ZR=U|ZLJ80'GG|AJ/8*B+)?
OS>S!##FWE68S%NRDY;AO.,@ (M!R;H(R|5)M&'H7T5(&MG>H|(T?/|LFDQD=
(9LC%WR/B\$ |HBVPDC: ^R?4U8 M<+O8N;4%=|3"K|MB#:
(.SP65#6.CP;NLP6RY6UG1!::6WE,2Q|ZLY7??X,#Y
M88+/Z_B|*>W+3SLE%2U35FX154AE@-:P965I.C2UZ:A,)ZB=ZQLX_(>_7DQ
M0HT|C<&@-F@V_'Z)(^S&L>./!T%5+|#|2=1?Q*T5/!Z#O^,@P38=_WP,D;0
M8023&|!>0"1,O@\$D. .YP2Z)R J).Y#XK8L9RO3*91R?+^/0"Z, CT0+.WTZ=5ZS
M@NA:YIU_C=G:.N%TXC_.@I%@XD':QY.YZTM=KO100=N#T.47'9<^>A(L@8LT
M^'_(99CTQ.2_S&8ISW,JL.EJ(FQ"W5>|BPXV_.\$@W"Z9D6@DUGV9P)-9_B2Y M78/5:
(^R2Z>>6-8?77 T^7A--E= ^:=@SFS,!@!ZVL!GBX&P|QW#99_AN4%MLY",8/6U
4|7A|-4> U8+5J?;\$:YO",V<6S<"S_|&4% M3|>55^?):YBC|WWLS?R_,|N#4W,!8EO?
#21*^*Y4S0&ZZ^WN"W?-J;N?WEQ> M/E*A,Y%\$.6RTJ-X#>@F*YC|O-
!2OZC/XFBM|HJ|_WV' F\$FZ/\$-Y^K8,:Z M6|GR+U!+ P04 " !0BDQ:.\$IL|WL\$ #(%0 &0
'AL+W=O!^:"2;?\$P^I"A|P-EKWP+(-!;EN9|86V% M*&YMFT=;R# ?
T0)R^69#68:%G++\$Y@4# '&NE++4|OPGM#)/<6L|ULR>VG-=
M2\$D.3PSQ799A|GX/*3TL+-:'T54V^Q0O+419!"I%0\$%C^|.!\$!TE0A
M23O^KD"M^IM*L3D^HG_5SDMG7C""!YK^)+'+8+JRIA6+8X%TJ?M##GU Y-%9X
M\$4VY_H|.E:QCH6C'!&<*,G!|P:|4_&L5 M@DHAT,R4KF@>5EC@Y9S1
V)*6J*I@293:TOW2:[BOA9,OB523RS76|S@1C\$7 MHP>;R73B6 ?D|JT% C5|1|T)-N9S?
Q3%18YRB;WF9<4KPTPH\$)BG_:%!Y7J_0 MIU|_SVTA354?
M*/K/O2+.^"6:Z"FDNMAQ|IR6.(VP"V|+%VU#LZ>NIU(JX@ M&B'?
_1UYCA<8#JX7MTWJ*^N5_U!A,C)>(@1E1 MU9=;7N (%I8L(!S8'JSE;
|^XH?.'B:TAP58#@;68#&HF@R|TY4|= &22-> |, M5CJ4.)R+FQ@+0!M,&-KC=>
(A#7R4VKY-9B4NT3R5%,TQ0SC@J0%55%QICQ MI1T3;8-
XDU2/FC2="66AFDO%'HU5(M*L8U%>-.*NZ2A\$&B M'">Y8\$36|NB2|_&+"|+?&66CI9?
&3>-,N\$YK^A(W\$%B+N&E-W+0?<9'XZ*"NW3"|,7|GIK+=="=67TH' 6I3.:DIG M |5N(+
6=ZYS.O0Y_1+RE(3-U!3 LMY|_L>G
M@RI=@RNRM1NJ+ ^5#H;4Y;QRTW4|'GW,&\$4UR|H_DG5|ZO|E|UN%W|I4S|CC
M=%O2F|>!T-J|>2?>O'ZY*K<60F,D.Q"TZ|-I:X_-43E_5#6RW6V5J|XNJ+; M#=#4|'_.AM<-
Q:CS<8:)*>N M/YLY_ME9L-N|^O^J5MPN|N%1_Q&LEUF|+93LV^#-2C::BBT-
FNGQL(=#|ZN MNIW-2F|ZAT1;#876IO/4MKC=?+|A*H?EI?1|H2|BSY_?JFE)?
G9U@RCO.1P2R25*82,AG=%\$ M4L;*:|R(FBA+|)>J! TT|MX|B8\$I#O-Y2*XT1|H+Z|7?
X+4\$|L#!!0 (M %"*3% H&@|ESY0, \$ 2_9>&PO=V|R:W-H965T\$CNH-
MOEE3EA(AFVQC|AT#\$FFC-#&Q9?EF2N+,F\$|UWR.;3^E>)'\$&CPSQ?9H2|N,>
M\$GJ<&::QVO\$4;|9"=9CSZ8YL8 'B>??(9,LL5:(XA8S'-\$.,UC/CSKX;5<9 MZ!\$O,1SYV3-
2J2PI_:H:_T8SPU(100(KH22(_#G_R2)4|D)Q?"M\$C=*G.CO_M?E5_KY.7R2P)AP>:?
(DCL9T98P-%L";|1#S1XTXU;%\$%8CY-A_(6QA MMR&@A^|F3H-YV-
T!1>,:|J?)M+KK2V8@L0J9H"03M))YR?_/?H\$EN,2"L1,X%JYQ:776E|M M8A4NXY++N-
<.:!%G4;^|97R|S)Y:.'+;|&|')J0-@TS!OAH!Q6S0N?|L(JRE7'S!/E9O|(<=>J9M7KN/?A#J54Y
MG<|7=NLA|+QX=83D7\$)R1E:|NK>|H0WI_SA)VZ>CM-WO+-U|AKD3G_|U_KOU?6(F0-
MR>1W*Y|(D|LT1PFLI:0U"N21EN77%7E#T)W^@%|2(6BJ'|=(F|J@'R_!E2|M-
I2#|M)H_A-02P,\$% @ 4(I,6K^)*>Q6_P_C0H_|D!X:"|W;W)K M&ULK59=<|HX%/TK=
|R=;C+3V|@+VBOX)D#;|4-F M,J&TSXH| 4ULB94\$)/WUU8=Q@36>9"8O(GW'-
|SKBS=X8Z+1|E"5/!4E4R.
MO)52Z^L@D/D**R)|OD:FGRRXJ(C24|\$Y% H@*2RH*H.HU^L%:'RX9V|4YD
M0|Y1)65X)T|NJHJ(YS&6?#?R0F^_<\$^7*V46@FRX)DN!0U+02MD MDG(&
ARV8H(O#+.%3#A ME=Y-DMB"7,%W7=ZKL7URCU)FBL|G"F>A*<427A9D=\$H2-

OBH(:\$"GA&W-; MT5!<3%\$16LK+/9E[S?UL[H:2K\JG4\AX=PGO(!HBO5OCJ)-
QBKD/3D\;H%/7PZ/.M3\$3>UCRQ>_H/;Y8>T_/YDOMCGN&)-V1G-
&7C+JM='P#RV>.YFT6??+3=3*^MQ\N1N4H\$:Q=UA6)I&QZIS=LPY6ZA9K7H6YL
M*W&R/M:JEFN_M"X1NV6B"5E\$DI<.;J>/!/?E'#-CYLHOK;MP-7NKFPPY7N M%U&8
/UAP;G:3\P+F@XT^PU02P,\$% @ 4(L6I"#!^TZ! ;4 !D M !X;"JW;W)K&ULK9A=;^(X%
(;_BI5=[7:D*?D" M6KJ U#;I;B\F516Q>VV2 UA-;-8VT)E?
O{834M*:3)'FP#5#U9,EYBJ2\YRA<;#C@WHK+PHR 8
M^B4FU)N.S;TG/AVSK2P(A2>.Q+8L.?I^!P7;3\SO.JOX)JNUU#?Z7B#5S # M.=H<77E-
Y2V_POJ!@TT+V.%/_10JX;>"C;"LG*6JPB* FM?O%KG8@C@>+8!5\$M MB-
X+AB<\$<2V(WPOZ)P3\6M#_K&!0"TS3_:KM)G\$)EG@ZYFR/N*ZM:+I@LF_4
M*E^\$ZHXRDUPI)4HGILUYG"i4YVC>U;J_B>P.S!%W\^F7L
M2Q6\#L'/ZD#OJD"C\$X&&Z!NCBT5<4!5'?%E"W/(&LA^+PI#SYO#RVR-//RZ..9,1-/XH-
+_Y\$AJ.^U'Z MJLM@.[PB]NU\$/4+>B W.8.*I(5 WX\$W_>V7V
MI+OH)VWYJD;HC&VI)'2%2I.3)PO"4L=01KV7+5V'+5^:G\O2T7P!%;HN^
N4!+SDHDUX!R M+\$'?UN45QU3:;.IDGVM0=Z!Q%: #-
#)=1I(Y@+3.N&S.N.JOXA ZS^CXN"\$4Y M*PIMR\$:Y(2W8UW'=?+.-
:"71U-.G'4ZP_-4T\RL58T ZHW"=JW4P@IZ5W%3 MJY6?49.?46=^'C#A:
(>+K>F9:DS_7:"=6B=;UZAWG:QS-M>!)WI>:09!|6QE&I/(\$X-MU-MRA7291,+4W6!'9&
MI7.Z>9LY4<:!)\$ZP=?\0? @_&MH6*-TAGSOLJ6EKFAMNXYV@V&G77-:J5UT
MJG*E&WONUW9*2YS24E>TMD71FT61\T5+C71ECDM:XI26NJ*US7G;!8>=NSGU M_7#
(V(J2'J=GXUW5J><;HIKVJ UY=EF"">O35W1*A/HJ.M\$M3F5!AK"F2V
MK\5I37.W.;J\0=V\^/?ZR--&ULK9AMC\HX M\$,>_BI6>3JUT2Q+G =@#)';IP\WH"2W:
I6M#!HB:V)OMH/WVM9T02 @L.>4-M)(G\YF?G?'\$HR/CW\460*(?:4+%V-
I*N7NT;,:0DI\$C^V JB=KQE,BU2W?
MV&+'@43&*\$UL\#BAG9*86L.1:9OSR8CM91)3F',DI FE*^,\G2-AQ;+G6J>\$E MWFRE;K
GHOW9P+DZV\U9U=J\$1Q"E3\$C"(Z\U=1\GKJ\3(^W&(IBXAKI M4);.?=00(KJ26(^CQ
,R2)5E)^_)>+6L68VO#R^J3^R02O@ED2 M
<L^19'<: ^+F!06UGH1@.,R+)9,39\$7'=6ZGI M"P/36*OP8ZKG?2&Y>AHK.SE9;
F'!TTN0L\L5@KHW(KT\$<:0506L%6@1;3X%.T3;E2#W5PLT%",XA.L(>)&_BA%_1'JN&26Z,
M@D9NGSFA&MMON 177/SAP,5.!4OC6&VQ="16PA(66,)&+&H'6D-!YCP"LR#
MV\=!/ZR0:1RN+9F.Q\$ID^@69?B.9M^PU^PV6_C66P NQ\U6P-(I5%DM'8B4L
M@P++H%7^1JURSR#Z\SC>4\$8#"K\$:OK59:A9H\O_\$\;P@#%LW.;^F=I,P9@>
M@*M:\$YDL@U0Y ^@3B3EZ(D>ZB@,N\SI6@CGL#=W*.UG3S7-Z_7-
2+,>%SW'A%KO5G9'AJ\APT!M4TTWSR*WGOR.U
M,J=S=>TVEJ"7>|>=D+OK2+B'W2JD3LOHKM3*D,Z%M-NNDJH?R>IDYU\O>-QS MJU5
3;>:7#1K=KPM&/OB\$SL%OC%'0%MV)H*/\NS:"V.OZ;F\$*#2_J2/2;K1 Q2'1Y-?4\$!#!!0 (
%""3%JL=G\E208-LH 9 >&PO=VJR M:W-H965T'DN>\$H3^&7&14P4W(IY5Z:"DC
K%\$==[#C\ M;DQ8TAD-LV?78C3D2O6QA%X+))=Q3,3ZC\$9\==IQ.YL'\$S9?
V@.QJF9\$YO MJ/J<7@NXZY910A;31#>(\$%GIYVQ^>,'^@"V1M?
&%W)K6ND4YER_DW?7(2G M'44AF2B1\JZ_6:;@6 MIYV3#@KIC"PC->&K\H1(J*?
C\3R2V?IH5;SK=%"PE(K'16% \$+,D_TONBH;8 M*N#AF@*X*(SW'E%&4T58)%_
NPH@Z\$# = MH*CN+*.UU3G8G3)\$\60Z%T2TO!^@"Y@+Q/ FP3.L#7B.OV.D.?^AK"##?
3Y MYARJ?/\$*C>>"9FE8:O*)O*R&OR:&KY\OGPWN?CT3U6VUD)Z1+V1*0GH:0>&
MC*3BEG9&O \BHW?+;C\I>?1?=VHIQ\$J(KG@1U;Z\!<"E)-C D^OH!(J.+ M16/Y;U62?
@M)\LHD>I;&OZ8B , P02 ^0PE,4Y)\$5"(&I;Q<9G0\6\$0Z;B%)\$ _*)\$ _L M1((> +P;T@C=
(2^)1 2E.<4J9\AINO=(Y!3QZ!!B65@Q?)7PE>O%[K,-AJ=
M.S1Y,ZA!)2BO!H3K&"EPFL8:XR\$B,T4%4@N*0@T+AIV^GC\$A%0IX',R!HJ@
MQ^'FOU3P'0.-HKM6+7UF!D(0DFL" 1HVDZX-G7>-T+LG!T(ZJ^/8-T\IC M(MQ\7,032%?
M'XYK2(>-?!\VT7X.TEVRA,7+^-DF0#OD/?L(&^N!W M\IC@-VE'NVR7&A. #V1\
;7@.;#P&MN\0\\$/Z\%Y_BWH;YM51SQ@IW/+>@*8>
MN7M\$O1T6'7:\$^W: '<1\X0#83W\";O3\N01\9IF/&,%L-T*M\$6\ M'U)>*^0\^\
I^G3GV=L@&>W 78>3BYN MKM\SL?QI7HVMA*|+:V^KT#84T;YL SYL"SIU!,=ELR%-
\$>+AEP MS9+L,^+M-6\O_10MQP8H3\AR\ (PA.P^X&JHU6--7HX)"2,A)K/4P7_ F.A
MJ&EGH\J>?3_@BBO H?M8-|>@WY=,T! I#E;F@.3\$[B H0(.B)F2?ZA#^ 3 M*U)
H9X#W;FV-JB16Z\A^SY'KGL;Q@./EDRWWQ\1?P"MX\6&P12=" LE1E
M7XWRY'79G;*S(OHT9V?TV\K\JR5)EC.8.I9"IZ7E52\3-%K_R\$3:AOSZ1G\H M Y%?
OPWY\8W\^G;Y_9D36 .4?B,A?2/DOEW(VYDO&BKMHS@I&V#+P"BY;\\$ M^,\$A9;8 *A-
IY;O_UH? _UG: ^VTL\7WC#GR\)._H4HHH3\W8\ (V.^W8UOX=C MF0+3\I ^;B;: \$^!7?

PRH,UF^\$7_?KL//.!3RM6\$Ezc:6X;fQ!;Z!;/:6SV M^18A^':\),H.*@Z,,19&!WZfP92-
L.U4G0>B6B9J?7IEPI'F>7"TI"*O0+|N,<f6Y MT164YQE' P-02P,\$% @ 4(L,6E '^8:& P
@T!D !X;"fW;W)K M&ULK5?1Z>+|+\$#95[X%\$.BUR\$L^ MLf9"5/>VS==, @?
T0I*^22EK"!#"MG&YA4#DFA0D=NNXP1V0;+2FD_UW";.M3^E.Y%D)CPSQ75\$0fM"
AF5F.4@0YK(6B(/*RAR7D MN6*2.OYM2*UV304f03^R_ZF3E|F|\$ Y+fO^3)6(fLR862B
ENUQfIH>_H\$EH MK/C6-.?Z%QV:6,="ZQT7M&C 4D&1E?650#9&G !P<;@-@ "W#_#/
+P&X+T7 MX#< 7SM3IZ)fB(D@fRFCf14M&13-fL,C9;f9Z7:fY5@fFDF<6+^4*Yf>B) M0
)'=V@ESU6RRP'1%#TRNL_T_MXLH(0T\$|=(^C34@:2,%FA)2Y&5NZSX9
MN=A%G^1B6Xf|^*!-(N@2VS+TUP#T:L' O,L:P'B\$/_X9/Q^ MN'LA&Z_=3D_S>6?
XECO&H!329;U'@KRBZFT;7Xf|>&fROF;VS(KD74<f5M' 40L|^?1:H122.2QSDVNU>BQ
M1JN7f|fNC@/fF=Kf4SN&47?1!'>#XF\$0OCB(VJB_ G&K?_QM_5P0_2;U-38X
M6=)WQU%/_# H5(>UHfU Y#O8+#UHfO<7f3fPR.5KPJ0f&"R'<=33M+S(_KUG
Mf\$ID'2/fUHCP8E7'D(*LZ^0;96VLZO":57U-LOA*9fU')ZVCDY^JZLG@?_WA
M:|+VRWH8AIW!.8Q-9,f8" fS5\$;4f1#f1V)%A36f0(8:HL1fVYfN"/<f9078
M>6LfGf|^Mf|@9YNF2 PXG74Vf(Df:&3N#W,KBLY >/&CYfL?#%3)^H(fFYHC7F MCP?
_!"\$.<' W#&%W4fAXDWfZPfBZV>ELH'W21!;-KH9YVA-=Z6HVZEVMFWX
M/^HVMS>_4f"NCEfHZF_(CX1MLED9YA#*BF=42@EL;HOKP>"5KI5?:"%"-KfZ
M=BL_9H" fT /DfI50&ULO9M=;fLV%(_ "N\$50PML ML4GY(fX< TW\$8@\$6+\$B:
fF+8f2f1L5")f\$@J3H;f|^%\$?L4Q+X;SB;#>)9?;fM%-fCDGHE"JWYP,f|>fWB M-
GEYf1T90'*,f6fU?Q^6f4Gf!%/>60*f!+/_GO@E3f."9,_CSQHZV-59f.Y_?J5_ M*AM0&/_-
+^4Z6fD);-;G@f,|fBOF*Y:fYE=N?>=V@2<&+9*K+OVA;EQT-4)1K
M(f,ZV)YfEHCJfWNNA=@+P-,W D@=0 X#QFf\$!f'5 <&S N X8'QLPJ0*fI@^K MMI?"AO_N
WJf%\$H,fKF6LF8KT8&GLV M!f7,8U35?5#63-VK&!%U+8=8:4f'SV 4,;3-V;2&O;;D@7F+
fHQ,4Xf!0&9%Q MQPE='Af|>=(2'QX>3CGfZ?
#CVBf'L\$AN4O."8Q/f|^B_T57f1F>Z3^Z,E6AQMVH
M8JPZTOL6f?_!f8PT5Tf|L/S^_SP==2E,B0LA(1f0B3C_\$N'V,??6D3@1ZX MX*O\$:-
MSHC2W%WW1A>)f\$1f8?)"*WQW8"4&67Z^Q050V3LH9BfGA:SD:CQ?fI
M7_UV&3P^+f1V%,+XLf3U-N@;Y9KLYfIXY;K,LSQEQ22"%f,B40f
M:B172#YQfI3G3=HYf|Tf\$F<,)7P3M6fJBfJ9fC9T'P:0EG/=|^EZVD#_*f'/R,-WE M8>K-
PQ>6YM4(f/ M: +2CV'B,=D5_G##52)CQ%:&*Y1*K5'\$E'JQ-f|;fF*
PGfKfJf_Vf8Y_&V#.L@1f54fJ%HKG):fPjH05^Y.f\$Z2+.^%. MR8&,89T&2%H(2J-0-#<-
C0?&\$f"1#)=S7H+20E:A.*Y66D<,0:QQ'Y*f|WOT MN-WYM/5@f!
f12"D5SA6Z<,f9;f5^KAV'BL6f/^Z%2f;_fAZ#&GE06@A*HU
Tf_U3X^6)WT3W';%fJW/X3TK@HV4f|\$;f1&CF#_Q5&XR+HSO37B-=NY@VfJ#
M.fY0&H6BN=HWCfIOX'?>5XfJf5NU-:4" f2@M!f12*YN: @|=(\$Tf\$L34" f2@M!
M:12*YBY?;+QTX/?2=59,f94->V\$/4?EZN0-,RJfGL#*5=?RL,XECfVK/2/M M-
30^D^Jf|>A'4:T/1W(0T7COP>^TCGWO7%'=&:_ 'LIZ"PWfJf:%HKM"-EPZf MKK#W'5"-
@M!f"4f1J%H;E8:QOSfRQKL^CD%+S:>%fN&R-\$)GARL*(fJU-6f|<;ZfW_G>6LLEfNY%
f|f0WNJfFN&@_6YZ M9DU@:Sf!5*V5O.,f34f95X_E;C,f6fI8*FF?&N+D@-.#:C(f<fQ0KO
A%fJ+ MF5EfX(L9fJV1.*#QP)*JBP/QY"3G;SRW7.BQf)MM,Z@5f,2OQ%E8@fL'KF9V
MRY*2_J@C"(fFEUYf|
f&KJ;fQN(K@;TX&B,=RfJQ;WKR(9U;CO8(Y;_2U*9S:T;"Z6PP54N/f|fM/f|\$--%f"#"C;
(^XME9L>F#&-\$&@5fJf\$ZfRO)U2Y1.+GX0f-6 M /J"GT"@:f12fRJM==
XO: ^ ^f|fZf'OK\$J.P\$^fINFd'8);"5%JX=WT&f762,(fDCWWV+/,<+ M>ARZ?SW<fX"KX=
f%Z+QV^SZAL_QT>\$Y&1=f1)3*25-2G.3TG6=TK)-J4YD
M8R)U(OL24A|8f|^HWU*WHL0)S"WU&A+ =V M_OS##9V_ ^L0B*PC=-*
M'5QB/Y11(^R&LP(EZF(26A&Z1>HMS;'.@7Bf^6A|7\$8_4K_V8F*f|T*_TW2(f
M_&CBS.S=L:Xf9fXf|<:=L_BEV;7ONMY:f;f18M)fJ;fFL!8=!/WMY
MAB2+!R+K":V@H6_NDK#(84>DBP>B*PC=-0*f?T655Hf\$7fJU fCX*1*>fQ< M-
PJCDRH:7;M>^fT3)7>M%K<7-3B<;P:f|_E^\$?6S-V=(LG@@LHY:TU:MZ:fN
MT>F00@f)%f@f\$UA':=;Y_D#J_19\$V;AS_ ^_E.%)f4:(5-)IX)R7:8^4ZD7-2 MH?;19WH!?
&O:;&BJZBL0U#;U;:ENC.-Q,GZ4K=:YO/_TW=fIWW"?\$N4-CEL
M%*4SCI1+O&YfZHEDI6D&UDRJUL(f;f4N M<&:G_#F#Q,f|_M fKX'Uf|+ P04 M"
f0BDQ:A@VfJL"P% !G'0 &@ 'AL+W=O&ULM9E=;Z,X%
(_BI4=K6:D2<f'W332)V0T8ZTNZW:SNZU2YP&#>," Mf23MOU^;4f|+ f03)O6E#..?f6-
CS@O3/64_ ^)H0_9Z+O.17Hf40FT0'X>F: M%)A?T fTY9D59046f|f.7S#"Y6247N(f<-
G0)GY6@VK;Zf9;fIW8Hf|DM M WQ;%fBf|?"\$YW5^_
X.CUBfOL:2W4%YfLNL%/Y)Z(fYM;)H^<f1F69%;3D&2Tf M(ZNKT36f7" f7)501_V9DSTf|^

S641TI_J(-ORZN1JRHB.4F%DL#RWX[,29XK
M)5G'SUITU/RF2CS|_*K^M1J[,PCYF1.|_ ^RI5A?C28CL"0KO,W%='W_2>H!
M:4HOI3FO_H)J'>N.0+KE@A9ULJR@R,K#?_Q<@SA)@/X;".A.0.'6"=VZ" M7R?
XYR8\$=4(U=.31G= Z:BI9KZ4-&OLB6OK%0+Y5XP>3:3>6+V MK4QI0< #?B8<\$WGJ
M8T(\$SG+ ^269_OT_QP^?P>0E>!A3;<G>YKTY/OTI\$E?G)|.V^F.G)QFAE S0ZC2|I
[4JZ\$+"1U7 MT"JU2 |JOEY%[3>7?(-3_0Y_34F3E-BN?P,V&L&K|VBO; M*#-
T&=H42VR*+2R)M>8B:.8BL+(C|#:GPJ988E-L84FL-15A,Q6A|;)|0=T5Z MN!
[DE9%3SD&* &7N1'=P>_,V|HZ 8GERA\$Q>Y<6=?Z\$?!. B#26=;,)8WE*0E
ML1;|J"\$9&4G>247,TC60+8/L|':RA=W(AE0 |BR;8DZT*;,>I C"L+O%|JA
M&+G=#=98WE"2EL1;)"<-R8F1Y'6:LJW<'5[!543KG|)%2G/3Y0#CI+LA^E!=Y
M7=;|L;2A%"V)M2C&#<782/'F>%43:41 GN''+|,|SIF<8|R_7*/'Z*U\$3-8E@
M=R4:"QO*T))8BR%TC^|"-5*|7V-&QLK)+8\$T&FI!5JV#UA.X_17F19'78:@+
MBWI|56(N;"A%6VIMC"BI#4=GQ^AWI+L MQR\$?N5&/I%6_8TNM3?+H>. RW-
R*|;Z'FC5^%A52ZRJ+6RIM6?E:'Z@V?W< M,N5|Q,MGL,FQ;-55HTE^;K,J<=?;3-
_5C!&NP|QYMJX4-ZLNFO31 |!<.2#W3'M/5>"O;3<, ^T;W"TT3AOH=NKF*PP^?
H|&!9J>CN4O|PNS OH|9^Z|S MV:6IBPLC+^CBM.IX;*FUG|8?
+0|R6O|U2.C,6WZM=|JP% @9^X'6VN;DN+@X| MO|L=FBL;_*3=JN=Q3MY1J5>0?
V/VE)5\$F8"I#G5Y2*UP/U)JOYMSK|'U|+ P04 " !0BDQ;!2F9F \$# M ""' &@
'AL+W=O&ULK5;?;|HP\$/Y7 MK*R:.FEMB EA=!)FDWK0R54VNYAVH-) #F+5L9GM0/O?
SW9"!C1E//0E|8_|MOMQW9|HEN!'R2>4 &CT7C*N1EVN|NO)IE>90\$'4I5L#-SD+
(@F@SE4M?K220 MS(\$*YN-.)_ (+0KD7#|W:5,9#46I&.4PE4F51\$/DR
28V(R_PM@MW=)EKN^#'| MPQ59P@STPVHJS,O^W6DW6N9\$P;5@/VFFIY'W
MQ4,9+\$C)|)W8_(!:3|_RI8(HI2;VK;CH;146A0UV'A04%Z|R7,=AQU \$+T! MP#4 'P+ "-
P#=#M |)%1#6@-!%H+BXI 03>*A%!LDK;5ALP,73(GXAJ>B
_1/GD&A"S0SORHK&2"Q0&.;\$JI?\$.7HD;"2N\$2-F3DIA*> MQDJ)E!(-F?
%9YRB!!4AI9MJ1G2>@ "67JDZ%|F"7H_.P3.K-<|DH%>&9&OK;
M*+!^ ^&GM|:3R%K_A;8#1K> Z5^@;SR#;|) "-|S8_WNJ?X*,";27J|M|1KB#
MPQ:'KD^'=UO@R>EP?\$1-M|EFU_%U_YM-E%"5,J%">C7>*ZT-#?L=UO\$*|:P
MG=%6G2NU(BF,/%-6%,@U>/'#T'4^=H6K?+K.3Y;,-?Q18-'>|!-?5NB%KL<#_H!?
U|NZ3-M+AP\$ 6|L|H3U&F&|H+|.QUE&[4TV%|'-=^:VNP+<>ADKIFC'A7#0BP8'@EY;
M:2'&.#C0|JKL N.PTVN7\$S5RHE/S9\$K"|0Q%KR/:'_3Q0>"O6|S:\$IFTV|TD MLE+D|U3G
N32=3F%4E%R716J9K5H&/7/P|6)Z;|5OWP'TW5G6^)-&=4(08+ M0|FY|!NO9-7QJHD6*|
<#YD*;CN*&N?E) &D-S/Y""+V=V|TOQWQ7U|+ P04 M " !0BDQ;J&F)3TX% #^\$P &@
'AL+W=O&ULK5C;CMLV\$/T5PDV##1#;(G5/O :RZQ0-T%RPFVV?:8NVA4JD2)| M^?
L.*:UD2Y2R?)BZW)FR#;S&AYR|2#DOVK/F\$:/9<'5Y62O|>'=?*XV>U92 M-
1,'QN'-5LB2:KB5N|DZ2\$8S:U06<^)YT;RD.9|L%_9-
|E'|SDN|TV#^;+Q8'NV"W3=X=O\$N|FC9!(LNWE MY -^M*|L;|(OW/VH\$ZND:&R%N)?
<_,INYOX9D:L8!MM7%#XNV?7K"B,)YC' M?|7323.F,3R|?O;^AR4/9-94L6M1_-)
G>G|Y228H8UMZ+/2->/B3U81"XV|C M"F5_T4.-|29H?5/'^M G|C@;," U :D:Q
&/BU@?|2@Z_V M"&QD*BHV#BNJZ7(AQ0.2!@W>S(4-|K4&^CDW>;_5\$M|F8*>7G_A&E
Q|HX|,MH2FZA;K*C@5#8HMNV\$;P35|DU&8(GMOJ|HH|R">#1S=4,Z0%^KC=,IN|HNG%
MBFF:%^H-N+R|7;&+5V_0*Y1S|'TOCHKR3"WF&F9OYC#?U#.|JF9*!F:*"?HL MN-
XK|)%G+ #MW, ?;#7?RS/V*C'IC-,PL7|_C1(+X.M?@|@|H(Q8VQ,)18O5W?U\$(!5_15HH20?
GHG|ISOD.P MK\$A;1@JM&2PNIO4\$?8)JDK #!54-7YX,NTP#**T\$P0'BD2IUXE!'S7UDQ2|
M0Q-U(8C&<[NGDDW-HI\$|!Q)64F4YNA4GJ+3:49>W.'2!P4X|H:6#I ?Q&XF
M<<,D'F4"*R"L;|RJSRR'SUY";>:T<(%&)^Q-(@J|#Q0&*/=RAT@>%9" G2<,D
M&65RO:=|9ZH-W=/B6'4R6H XH7SCK+*D-X=ID(:XFQH'# JSX.8X^X M.:4-
I_0'GYJ&9@\$%1OD3HJ4XV+&7='CT,5,\$XRN!_/*K6F
M%_&Z%.5#14(5ATH(AHV2^" #X%472\$Y7X-ZJT0Z_63 M:>3LT;0UYF9%^@77)^4
>;T;.4#QP_*%6SV#1U?VY=WL=F;7F?/5YRWBL!T" M>6/?UD&2U4!RQ1GVUP|>?K|
(DM.0EX3|:-.^W)-M_-")|I*7BLR|+C*>.|? M0_746@9T;1!F|F*N9-
6X"BW!'=IC8|LU+,-680^MY %HQ@L?5R,UK6A|>
MK|!&LFP@B6%_Y#C!74WE@I'\$R//S/+I@H3^P>.%64>!Q2?%A#7L;P6%?;"OT
MR|>_W%^>0P2D2=K|HD8'^^G<_2)OYZ%D)0H>URA?|9Y|
(YM+RDUXY95".8G|R,EDSM|P*1 |8,&J|X)FJ?-(=8'>W33>7YE M#K?
L@40KICH9^TSE+H=|4L&VX-*;Q9_561TV53=:'SQRUIH+4|HN6<46KT!
MP/NM\$/KYQ@S0'/DM_P=02P,\$% @ 4(L,6J(>6Q, @ DP0 !H !X M;"|W;W)K1*=-
_1_2G:S#&B|)%UNDR,/ #F|*ML8^N1B1X M:I1VTZ@F:B_CV!4U-

L*-3(N::RIC&T\$LVG7L6HNB#\$Z-BM,D.8L;(7649T\$W MMWEF.E)2X/R"ZYI&V-
TU*K.=1N/H6:&0ZYJ(LZS5JOQB?30SBU+1ZEE UJ M)XT&B|4TNAI?7D~^|?
3#X+G'K#L|@,UD9|^B%NW(:)9X0*BS((PC^;?&E?)
M3./W@!GM0WK'P_,S^M>0.^>R\$@YOC/HA2ZJGT44\$)5:B4|0PVUL<|CGU>(51
M+GOA.|@F\$12=(L,SLR@D;K_BZ>A#@<.:?J*0SHXI(%W"RBP6 D2>6;-%JRW
M9C1_"*D&;R8GM6_*DBS?2O:C_\$X7ID'X)H0P4=8'A:"\$,C EZK"4-
N_VN.YL*BIH*%4"=P/\$,24KD3. *IX5XJ MQ9 NBXE3|3B8J!|W=--7Z\$|PV(\$D_\$'2)-T
@_+&1P?G?P+\$W,%IF5(|V5(M^|DOV6
F72%,JZS"#^O5HXL#|ZOEYCVB)|>103+=.E:4>TXFUQ:##<8Y>=?
MC<^2SV_PG>SY3MY"SSW1%6JL)/%J**YYZ5LA-:'E3%JA=|#,M:00^LY)O>%^
M<.=>2J0/=1%"^27>Y./3T7D6;PX)Q@&ULK591;|LV M\$/XKA%84+;|&LB3;2F8;L*T5ZT.!
(&FVAV(/M'2VB%*D2E)QME^_(Z5HCLVX M*9
7FSQ^|^F^H^YTL|U4WW0%8,A#S86>|Y4QS548ZJ*"FNH+V8# DZU4-36X M5;M0-
PIHZ9QJ'L91-EKRD2PF#G;M5K,9&LX\$W"MB&|KFJL 5L#E?AZ,@D?#
M#M=M5QAK"Q:RA.|@%<|=<*/R% TO):A":24\$4;.:!+?/:R!4_>\$";
(ETJV&LGT+#2HQL84%GWDJR|R^)G(1S'Y+(6IM T\$RJ<\$(:9A MR\$7|F(M5?)8QA^*")*-?
21S%J2>@|3K;+UFN2
MY:|J|B23Z9#)|!S|8D4Y%040:HBI@&R&*L!WWAH:4\$R6OGQVO&/'QOP_2*;
M)I>SV/XP3Q|0Y31Y"LH|H&0:#Z GNL:#K0%973=8ZJH:MU!I4GF
MEST99\$_.REZ6)3M6C4722-V;%7|JL!(TN#-JOZ"O6(G)P&.C^_W%!)GHR.=MIY@T0?
3+G XRIZ|FT|YZT2H%V,B??YNGIUJ/A:P|F%V)-:#N8S\8K-!;/8S M)0KX>?IA<6:G)77R
JX|H),*SCV@PPKN%(4"^D:U,X-.YH4|NO9?;.&ZS!/ M+=T8<61?
X9S5C47_TW1#VF>JL#5IPF&+E-!%%\$-2W>#3;8QLW"BPD08'"|>L M<%8\$90%XOI72/&
|L X;I<_\$?4\$L#!!0 (%""3%JM:;+7Y08 @=: M >&PO=V|R:W-H965T^I%2 US3)^%5O*
<3JO-_GT9*FA)^Q%"2K4429_0^!WR=IB3_>4,3|G+5@|W-C8=X
ML13J1G|PN2(+J7BR^H^EU?|K9=9G-*,ORP#.9U?|:|A>8A|95_@OL:TA>|I M|HK*\$V/?
U<5H=M6SU(AH0B.A7!#Y|YG>TB11GN0X?E1.>|MW*L/=SQOO'POR MDLP3X?26)7_%,
|&|ZOD|,*SLD|\$ WOY@U:\$L/(7L807?|%+A;5Z(%ISP=+* M6(X@C;/R/WFM K%C.T6
U09H*!|VV)@5P9VT|L,7 J ^>M|K@R**CW2^Y% MX(9\$D,%ESEY
KM#2F_I01+^PEO&*,U4H4Y'+H&T\$X,I7?AV<|3!QM|FRR|V2W^'L*OX?A+.#TWA;8T
M=BZ7 MIG5.9T#V)!9,@-'|5*UERN5PI)4M4'_R/%J:NHO_K6.'C3)!L\$3|E%!#. MJ>"
+|E+|H48GML2DDY-'>G#)"#,1LVJLH P|9E>XVB,L"@:|F^N:~8"|
MSIH:RFF1L%71V%HH&|JH422ACH+8@RT-)=B./N@<=>>ZX_?QV9QA|H|_|I
M9DT.#2AL>T%CI#H*V19VS6.'5JUW&64MG(PMIW)VH)YS4&_AH;SM!
|)6@;|3,0W"=)6P MGY2>YC0AHJF3J_#9>DU
QPG<9DT8<,B7O|VB,,\$"SVYI0K#69|!;H\$VB:|TB M6?33R,(QL\$"61L(
0RAHMB(C3,:DA4*MS&"GBI'+J\$QS%|>JP<@&UJ%L;7T<..!Q8
MN|A|MK6P0=W"IER\$>+75>+29|<>R?4:+'GV@YJ6;Q0+8Y0MS@:AX|@-+Z=W(7@Z/-
D.CT&'Q|F=^!V,GX< MC;^,QI_Y#Y|N'X<3<93(T|=|=@>@GKF=1R&@?
R2V22JXTYM&^*6YH|J"86Z M)90B!R9C,!Q-*W+A<(?:"5"1F'P\$C|??
C#QU572*K>8WFZ\$)!M4>GM7D:0(B M#-N^3,J_)OX##V-/3IN-.(?:1Z|704>H_TZM
M25"G)C\$097(:@@_O?(2LBU_,|0(%+|!LG:LE2H+!3TIR#J@Z\$0!#&M'T23K8 M|.F76_
%0U2;L,I+LIY1OGG=|9MW|*HWG^P/M!P5.\$H8Y|X.\$@|>I+-
>AZ+X|K@#)B6|O|.Z4U*|T5Q;_9!Q:_9*>YMW>W M1W,WQ8%4X_XM/^AX?XU|LZ',J&F)
|Y|4ISR|>M7EV>\$=R1?Q|D'"9W+85AG MGJR=O#QV*R|\$6Q7G2D|,")86'Y>4S&BN
/+YG#&QN5 OV!Y^#OX'4\$|L#!!0 M (%""3%I>|?D6F_,X-: >&PO=V|R:W-H965T5
ML.SF|W=(8J|5=EUX>8A)BF>HSEG2&HXW2K|V:P!+/DJN#2S:&UM=1|IEB#
MH.9452#QR5)I02UV|2HVE09:>I#@<98DHUA0)J-|ZL?N=#Y5M>5,PITFIA:"
MZH=+X&H|B|+H<> |6ZVM&XCS:457<_V0W6GL1=W+"43(U3DFA8SJ*+|R>
M9@|@9WODL#4|;>*D+)3Z|K7Y2Q*7\$3 H;".@N+|!N;N6/'|.ZTI%'W3@?<
M;3^RO_;B47X&EC)L7.7#_15Y_NS%-+88F*./BS:(RR:(|#M! ML.067|LVY\$|90MF#G_|
GP4(8G2DLR5|M.4R"S*^I?4#-(3DB79H"^@,/P* MB@Y^%@AGT&5IX/D&_R+%
|M9*EOR_K|!Z>3:@C#_|)G?<)_U<|MSXM04M(|9 MA>|;V!*/_|MW24_-\$G_\$AD>S:<=3;:
M)G&FQ|IPT|_*,A_9P|;5>/Y1#:4UT!P.Y*2"CQV<1.C6JHM4ZKA2PW&0DF\$
M*MF2%7|+|LD>?A/I;)3XOR|@1E(POI_,JA3/PJG|.*692^LOGZM 1)#DWA MD-?
N.G'Q|3A2&1|-DPZ&R;!M+_#BH54M2|6^+4F2I>@21%> D'" M0|5/OMD;Z7B|OS?
V=+WJ=+T*ZIH,*)23S'" Z|BNT&4&&?GB#1H7J.1+;G
M.4V>RHWD%R|JEOQ(3AR+;=^*G.Y&N|O*A2_1XZ?

IS4WGENH5DP:KCB5"DI,QOEF8U7EZ^^%MLEC-^^8:+UR@W01\OE18UK0=JX+N"IF?
_"U!+P04"!0BDQ:+8.EI5\$#M#&%#0'AL+W-T>6QE1EDJB'V/SIG\IDUCM&!9ZS>G-
@E+MK3(NBI&T#I&P3%;\$\$S4IS)GJ#I%)E1)NNF@=%KBA)"B!EM/AU.E&0\$2;15
LLZM,%IY,+H4>^?TZY-G;AV3D=Z-SW/-R\$YGO0D7IW\OKK
M4NK+5YZI\ITY.NKU5VMJWA=7)WG.U\XFXN,VLD.N%X2#8I;R\$5^VZR0:G,M3(
JW\NG2K-9.)-D?R6K02FG%8I\KGW CW_VW6>4T\$5X6W3IO8/>96?I+AZ
M%SZ'Y_K9=>QTV38AWR/U?O_T\$U&AV\RC_?8W5R.G23@Y=@\B5L=_9OMGW
MF@RJDU#KN+5UV*JC'AQJ1_YG."+S)JDW73*NF:AZ"Y8D5#PX_VD^W0^%L.\#9S(.4,
M4(YEN9!)^<'RN#FQN=PSC>,PC")L12<3IX,)MFY1!#JN-W#G?11LWE-!Y_+16J02P,\$%
@4(I,6I)*NQS\$P(LM!;3T\!\$MP>:4#M.*2VBZD8_1!2:5K5N%(MB6!:(7-
>=I3W;+T!;X"O.D0Q0FE(2S,.M\W2?S+W\PPU1>5*(Y5;&GC3Y?
YVX\$G1H2)8%H%R=.B':5_J9373Y?M-J_4J40F9)
M!3F5,UMO*>7L03J0BT84N!,NM+%E?41J?ND8'Y4I>/MN4Q;7.BV5N9*E^L<4
MF\7.E\5IW*JHDH\1QV'WN@WB)--PE@L%CI15T6RR51>;N-H5%H!YG:EU\8A-M#%"/A
(#L LG-"R!\A@>P"R.D)("ZC()I-GGA1S+9_%HMQ5B9^N-
YHL25MDE:V(U1M!D/4#L>\\$+>YE;/E1%3(^?.>&)@C,RW<;24\$;J&
M6397RB9&KZOMHEB(KONKRR3)IGBO\$B5\FVGU,.HT/MDJ38.(U33.2<%K-
TJGO0Y50ZWZBYN%\KLSV\$XB';M)AUZ>E4,3"U-DXM*!M&I>I6?
&DRY6XW'B8R#\$V27%K->KJ4VXKM,-UIC@E328G9)M%:2\+,PS!4+::#[PW5.W
U?/G\4XU3N4N0_-WI=?8Y"(FVTF+UQZSH\^;+ZM4C&PU04V:LQ_BF+^I.4IM=
('"&S.\$9*6D70_1I(F16Q\$LCZVPKGV45N2IDM;J.I&KGA+XH).R7,BA@5^?+<=3(S<:5FI
(8+D1%"9B,,IQCF3E>9.Y-I MVT\VD15"[DY'D:9R5E26?
U2'TKL062)DMT129\$LY2^_/4&B")E%,5'+N@;S MH-:%<;G2DH(A.83,4?
=QEW6J=RR8AUL:-U#62'-K,=8"IL=77;M2!MM9FU@S#;%1-
IH,VOC0,HNSJ:5Z^A#TX;5+&;/P-3=O^C)FUFFY#4?1?!M#Y0-V:3-;)/7"XO&A))FUDD?
Y+Y061((&UF@<"L7IQ13.24-K-3<%Y/BU9M M9)@VLV&VB?V^B\Q:1NDP&P5F^%
ICTD%&Z3;Q<_P\T81F:3#;)*#J?Z6E&(B MDW2837(HJ7Z))\6\$(R/L)GG-
7/=>;J22#G?'Y&T*NY<0&:7#;:18U_4?::27M#K-><)+8H9A(+QWN+@O\$[%];I)
<.LUXP9D2'\$Y%NNB?MP/0H)M)-JZ0=F)AB M(NUT3SDTJ-/9%VNMS:
9@_ZF&Z/YA(UWN@_%A%/#CE!>=>16LFW1WB\$Q?IGY23&2A-MZ
@C^ONC.39%0COF\$;0)Q%YJ.X19WZ@4\$UDH8K80J?^B&>;AY0K594IZ(1
M9*\$>LX4\S'>W)I5E#UFHQVRAUP+U^>?<;>8R\$(I9@M!3'6*+)0CIE"N*A^
M3C&1A7K,%H*8?C21A7K,%L*8-/7H(0OUV"TSABC\;.(IRNP60IA>-)&%>LP6
M>AE)V==FOIDATD,6ZAUGP,HPL%)IR)HJ7
MO>8B(+Q68B(+QA6)DH9A\7&C/K\$1RZ2DF7"K#/2YT:"QU^S!13&2AF'M<
MZ#;F%5&"V4<6ZG./"Z%H>O=F'UFHSSSTN!##+(J&8R\$)HGS\$A@.F2\$8J)+-0_MU72\$W-
P6A6NPAF*!#+-MG7;1X\$ MK9XI#Q2NW0S8JW('00>)ORHR@*LW
_:ZW\$'0!_7FTL/UFP&SC2"HUWZV KB2 M,SCF\+AWH&T/%*[E#(X^5P
M"^D.4J0Q>"IA*!TJ@\".?_JKV&WG%Z/AW'I>AH7I_O=87SHMM-T^M'WXVH\MD)?CW?
\$T"\"?K(_G_7*Z+,^;_K1#X?I'QOW?X\GMW\$!#%.W>%Z>-VTT/7ON^OEL?_L'>7G;0%
MTM#>WYZL5T_=Y"3(#=_D)<@/W\0D*P?U"4H#A_4)*@-'10EJ\?U"1H#)_M4)6@.G^0-
2JC_20U6.TMLJU!7AM%6P+\$-LJV19@ME6T+4!MJVQ;@-M6X;8 MN:W2;0%V6\7;
01VJK<#Z.U4:P?0VS5_M@%Z.17;_?1VJK<#Z.U4:P?0VZG>_M#J"W4\T=0&^G>CN
WD\U=@\IO>KM_7HU=L#I/:JMP?H\9N')0"IO>KM_7H MU=L#I/:JMP?
H\550#I#;JIX>H+=703U [Z!Z!X#>0?4.+V#ZAT>@?5.P#T M#LW#;H#>0?4.+V#ZAT
>@?5.P#T#JIW_.@=5.+T#NJWA&@=U2\T#OJT' M@-Y1\8X O:/J'0%ZQ^9E)4#OJT'@-
Y1\8X O:/J'0%Z1\4\ O1.JG<"Z)U4 M\P30.ZG>".!W4KT30.^D>B>
WDGU3@"\4W/8!*!W4KT30.^D>B>WDGU3@"\ML^J=7IGU3L#I,ZJ=P;HG570#-
HJX9H'=603-[ZQZ9X#>N3DL"-HJX9 MH'=603-[Z)Z%X#>1?4N+V+ZET>A?
5NP#T+JIW>A=5.+T+NHW@6@=U&I
M"\"T#OTASV!NA=5.+T+NJWA6@=U6\T#OJGI7@-Y5I;X O:OJ70%Z5\6\ O2N
MJG<%Z%U5\PK0NZK>%:W;89U 'L;TX\K /RVIAG8,0#!K6E&=@S<&N:H1T# M4-
R:9FS'!RWIAG<,0#)K6E&=PS)N*V"L<\$&H8W\6ZW M7NP%&#&@-
"O^\$W2Y\^SFDK;2IBU9ETKXW08GM\SOX2)^\7'H\GJQ;'?IN<)>MH MY_WT20A7\VO?
N7B<I!!6MN/<5SY\G1_\$5-7\ZL\$*E21&U./@I>#7_E@CNKF^ML\OJL?.KSX?PLVO'81/-
MG/1ZO:T\9BUB:HZMJZ\F%=/W-;RGKEX0XG%SV
MN%T\N:NP(1+O)AQ7_ASP'^.17^;AQ/*X_(Y_MG?%;_0_VH2!H) ^,D@?&M*!@?
210_HH('V4D#YD0FF\$(JJDD"HHDH*JI*B MJJ2P*BFN2@JLDB*KHLBJ*+(JBJR*

(JNBR*HHLBJ*K(HBJZ+(JBBRIA194XJL M*476E")K2I\$UI J\$XJN,J'P*A.*KS*A
"N3_RGLJW'< M ^/XY1GW53N\YHOE'\@W/P%02P\$"% ,4 " !0BDQ:~T%-8H\$ "O M\$ @ \$
9&JC4')O<' ,087:P+GAM;,%!+ 0(4 Q0 (M % " *3%IL?5X:~[@ "L" 1 " :~!D;V-0&UL4\$L!
A0#% @ 4(I,6@%K MD9AP"@ YSL !@ ("!#0@ 'AL+W=ORD# #)"@ & @('D&@
>&PO=VJR:W-H965T M&UL4\$L! A0#% @ 4(I,6J?6PP9U"0 QS(!@ M ("!00X
'AL+W=OXG !X;~]W;W)K M&PO=VJR:W-H965T&UL4\$L! M A0#% @ 4(I,6MXRT?6F @ N
8 !@ ("!MS, 'AL M+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ 4(I,6DCK M-\$IF @ B08
!D ("!M4T 'AL+W=O&PO=VJR:W-H965T&N/Y!@8 -(0 9 " @>I2 !X;~]W;W)K&UL4\$L!
A0#% @ 4(I,6LCS+ _XC* @ ?H@ !D M ("!%UH 'AL+W=O&PO M=VJR:W-H965T&UL4\$L!
A0#% @ 4(I,6G\$!<==G!P TQ, !D ("! ML)L 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#%
M @ 4(I,6M:KB>>:~!0 " T !D ("!&+ 'AL+W=O&PO=VJR:W-H965T! !X
M;~]W;W)K&UL4\$L! A0#% @ 4(I,6D!P\$0*: M P \$@@ !D ("!8L\$ 'AL+W=O9.Q\ \$ "N" &0
M@(\$SQ0 >&PO=VJR:W-H965T&UL4\$L! A0#% @ 4(I,6HAP/0HK! L D !D M ("!~X
'AL+W=O&PO=VJR M:W-H965T&UL M4\$L! A0#% @ 4(I,6E!H9<#Z\$ 13, !D ("!2.~M
'AL+W=O&PO=VJR:W-H965TPL ,,, 9 M " @7H& 0!X;~]W;W)K&UL4\$L! A0#% @
M4(I,6JLFZ5A6. @ 3P !D ("!+!('AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @
4(I,6F&PO=VJR:W-H M965T&UL4\$L! M A0#% @ 4(I,6A&DVIZ_ @ _4 !D ("!SW8! 'AL
M+W=O0\$ >&PO=VJR:W-H965T&UL4\$L! A0#% @ 4(I, M6A.5\$F)8! ,PH !D ("!*8!
'AL+W=O&PO=VJR:W-H965T,PL \$ B 9 " @0Z* 0!X;~]W;W)K M&UL4\$L! A0#% @
4(I,6C=).LPH!0 ZPH M !D ("!>)4! 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @
4(I,6F-!@N8!P %RP !D M ("!K;~! 'AL+W=O&PO=VJR:W-H965T M&UL4\$L! A0# M% @
4(I,6H.~5%I_ P A@L !D ("!~;@! 'AL+W=O M&PO=VJR:W-H965T&UL4\$L! A0#% @
4(I,6L:~# M#^&(P CQ !D ("!<4! 'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @
4(I,6D&V-5#_ @ ; H !D M ("!F=('AL+W=O&PO M=VJR:W-H965T;00 M !06 9 " @83:
0!X;~]W;W)K&UL4\$L! A0#% @ 4(I,6E:"&PO=VJR:W-H965T&UL4\$L! A0#% M @
4(I,6GTD/R!D!P 43H !D ("!8>D! 'AL+W=O&UL4\$L! A0#% @ 4(I,6A:&PO=VJR:W-
H965TH% @!X;~]W;W)K&UL4\$L! A0#% @ 4(I,6A.@5.L!0 #R\$!D M ("!-PD"
'AL+W=O&PO=VJR M:W-H965T&UL M4\$L! A0#% @ 4(I,6IFW-5I@ @ 8@4 !D ("!"A8" M
'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ M4(I,6O;&A1M= P U@T !D
("!&PO=VJR:W-H965T&UL4\$L! A0#% @ 4(I,6L57;+^!0 M32T !D ("!M2H"
'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ 4(I,6D!GDNA\ P V! !D M ("!MS8"
'AL+W=O&PO=VJR:W-H M965T&UL4\$L! M A0#% @ 4(I,6D_C->>W P R0 !D ("!SC! " 'AL
M+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ 4(I, M6K=^A)8^ P 8PH !D ("!Z\$L"
'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ 4(I,6FD P H0T M !D ("!K%@"
'AL+W=O&PO=VJR:W-H965T&UL4\$L! A0#% @ 4(I,6K^)*>Q6 P C0H !D M ("!564"
'AL+W=O&PO=VJR:W-H965T M&UL4\$L! A0# M% @ 4(I,6JQV?N5)!@ VR@ !D ("!=W\$"
'AL+W=O M&PO=VJR:W-H965T&UL4\$L! A0#% @ 4(I,6@~) M2PYI P C X !H ("!LX("
'AL+W=O&UL4\$L! A0#% @ 4(I,6H8-JK L!0 9QT !H M ("!5(8" 'AL+W=O&UL4\$L! A0#%
M @ 4(I,6@4IF9@! P @@@ !H ("!N(L" 'AL+W=O&UL M4\$L! A0#% @ 4(I,6J(.>6Q, @
DP0 !H ("!=Y0" M 'AL+W=O&UL4\$L! A0#% @ 4(I,6LK+ M*#UO P B0H !H ("!^Y8"
'AL+W=O&UL4\$L! A0#% @ 4(I,6JUHHM?E!@ " !T !H M ("!HHH" 'AL+W=O&UL4\$L!
A0#% M @ 4(I,6EIQ^1:8 P S@T !H ("!OZ\$ " 'AL+W=O6QE&PO=VJR:V)O;VLN>&UL4\$L!
A0#% @ 4(I,6IC0E^X% P VCX !H M (!:~\$ " 'AL+UJR96QS+W=O XML 124 Show.js IDEA:
XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities
and Exchange Commission. Data and content created by government employees within
the scope of their employment are not subject to domestic copyright protection. 17
U.S.C. 105. var Show={};Show.LastAR=null;Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE')
{var ref=((window)?w.document:document).getElementById(r);if(ref)
{e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display)
{}else {var d,p ;if(e.style.display=='none'){d='block';p='-'}else {d='none';p='+'}
e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else {a.innerHTML=p+a.innerHTML.substring(1)}
XML 125 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 *//* v2.2.0.24 *//*

DefRef Styles */.report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a: hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a: hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 127 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html3815301true1090false10 falsefalseR1.htm100010 - Document - Document and Entity InformationSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDoc and Entity InformationCover1 falsefalseR2.htm100030 - Statement - CONSOLIDATED BALANCE SHEETSSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSO BALANCE SHEETSStatements2 falsefalseR3.htm100040 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_Statement BALANCE SHEETS (Parenthetical)Statements3 falsefalseR4.htm100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)Sheethttp://www.alkermes.com/20241231/taxonomy/role/StatementConsolidated STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)Statements4 falsefalseR5.htm100060 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)Sheethttp://www.alkermes.com/20241231/taxonomy/role/StatementConst STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)Statements5 falsefalseR6.htm100070 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITYSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSO STATEMENTS OF SHAREHOLDERS' EQUITYStatements6 falsefalseR7.htm100080 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_Statement STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical)Statements7 falsefalseR8.htm100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSO STATEMENTS OF CASH FLOWSStatements8 falsefalseR9.htm100100 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance DisclosureSheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecu

Risk Management, Strategy, and Governance Disclosure Notes9
falsefalseR10.htm995410 - Disclosure - Pay vs Performance
DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance
DisclosureNotes10 falsefalseR11.htm995445 - Disclosure - Insider Trading
ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider
Trading ArrangementsNotes11 falsefalseR12.htm995455 - Disclosure - Description of
Business and Basis of
PresentationSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureDe
of Business and Basis of PresentationNotes12 falsefalseR13.htm995465 - Disclosure -
Summary of Significant Accounting
PoliciesSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSumma
of Significant Accounting PoliciesNotes13 falsefalseR14.htm995475 - Disclosure -
Discontinued
OperationsSheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontin
OperationsNotes14 falsefalseR15.htm995485 - Disclosure - Revenue from Contracts
with
CustomersSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureReve
from Contracts with CustomersNotes15 falsefalseR16.htm995495 - Disclosure -
InvestmentsSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInv
falsefalseR17.htm995505 - Disclosure - Fair
ValueSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValue
ValueNotes17 falsefalseR18.htm995515 - Disclosure -
InventorySheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInven
falsefalseR19.htm995525 - Disclosure - Property, Plant and
EquipmentSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureProp
Plant and EquipmentNotes19 falsefalseR20.htm995535 - Disclosure - Intangible Assets
and
GoodwillSheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleA
Assets and GoodwillNotes20 falsefalseR21.htm995545 - Disclosure -
LeasesSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesLt
falsefalseR22.htm995555 - Disclosure - Accounts Payable and Accrued
ExpensesSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccou
Payable and Accrued ExpensesNotes22 falsefalseR23.htm995565 - Disclosure - Long-
term
DebtSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTerm
term DebtNotes23 falsefalseR24.htm995575 - Disclosure - Earnings (Loss) Per
ShareSheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossP
(Loss) Per ShareNotes24 falsefalseR25.htm995585 - Disclosure - Shareholders'
EquitySheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSharehol
EquityNotes25 falsefalseR26.htm995595 - Disclosure - Share-based
CompensationSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureS
based CompensationNotes26 falsefalseR27.htm995605 - Disclosure - Collaborative
ArrangementsSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureC
ArrangementsNotes27 falsefalseR28.htm995615 - Disclosure - Income
TaxesSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTa
TaxesNotes28 falsefalseR29.htm995625 - Disclosure - Segment
ReportingSheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentR
ReportingNotes29 falsefalseR30.htm995635 - Disclosure - Commitments and
Contingent
LiabilitiesSheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureComr
and Contingent LiabilitiesNotes30 falsefalseR31.htm995645 - Disclosure - Summary of
Significant Accounting Policies
(Policies)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSumn
of Significant Accounting Policies
(Policies)Policieshttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSun
falsefalseR32.htm995655 - Disclosure - Summary of Significant Accounting Policies
(Tables)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSumma
of Significant Accounting Policies

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryfalsefalseR33.htm995665 - Disclosure - Discontinued Operations

~~(Tables)Sheet~~<http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperations>

~~(Tables)Tables~~<http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedfalsefalseR34.htm995675> - Disclosure - Revenue from Contracts with Customers

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenuefromContractswithCustomers

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenuefalsefalseR35.htm995685 - Disclosure - Investments

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestment

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentfalsefalseR36.htm995695 - Disclosure - Fair Value

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValue

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValuefalsefalseR37.htm995705 - Disclosure - Inventory

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventory

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryfalsefalseR38.htm995715 - Disclosure - Property, Plant and Equipment

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantandEquipment

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantandEquipmentfalsefalseR39.htm995725 - Disclosure - Intangible Assets and Goodwill

~~(Tables)Sheet~~<http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsandGoodwill>

~~(Tables)Tables~~<http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsandGoodwillfalsefalseR40.htm995735> - Disclosure - Leases

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeases

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesfalsefalseR41.htm995745 - Disclosure - Accounts Payable and Accrued Expenses

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableandAccruedExpenses

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableandAccruedExpensesfalsefalseR42.htm995755 - Disclosure - Long-term Debt

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebt

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtfalsefalseR43.htm995765 - Disclosure - Earnings (Loss) Per Share

~~(Tables)Sheet~~<http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShare>

~~(Tables)Tables~~<http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerSharefalsefalseR44.htm995775> - Disclosure - Share-based Compensation

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationfalsefalseR45.htm995785 - Disclosure - Income Taxes

~~(Tables)Sheet~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes

~~(Tables)Tables~~http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesfalsefalseR46.htm995795 - Disclosure - Segment Reporting

~~(Tables)Sheet~~<http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReporting>

~~(Tables)Tables~~<http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingfalsefalseR47.htm995805> - Disclosure - Description of Business and Basis of Presentation - Additional Information

~~(Details)Sheet~~[http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionofBusinessandBasisofPresentation-AdditionalInformation\(Details\)Details47](http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionofBusinessandBasisofPresentation-AdditionalInformation(Details)Details47)

[falsefalseR48.htm995815 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSumm](#)
[of Significant Accounting Policies - Schedule of Property, Plant and Equipment \(Details\)Details48 falsefalseR49.htm995825 - Disclosure - Summary of Significant Accounting Policies - Schedule of Provisions for Sales and Allowances \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOf](#)
[of Significant Accounting Policies - Schedule of Provisions for Sales and Allowances \(Details\)Details49 falsefalseR50.htm995835 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOf](#)
[of Significant Accounting Policies - Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets \(Details\)Details50 falsefalseR51.htm995845 - Disclosure - Summary of Significant Accounting Policies - Additional Information \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSumm](#)
[of Significant Accounting Policies - Additional Information \(Details\)Details51 falsefalseR52.htm995855 - Disclosure - Summary of Significant Accounting Policies - Schedule of Contract Assets and Contract Liabilities \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSumm](#)
[of Significant Accounting Policies - Schedule of Contract Assets and Contract Liabilities \(Details\)Details52 falsefalseR53.htm995865 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSumm](#)
[of Significant Accounting Policies - Schedule of Concentration \(Details\)Details53 falsefalseR54.htm995875 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration \(Parenthetical\) \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSumm](#)
[of Significant Accounting Policies - Schedule of Concentration \(Parenthetical\) \(Details\)Details54 falsefalseR55.htm995885 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Location \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSumm](#)
[of Significant Accounting Policies - Schedule of Revenues by Geographic Location \(Details\)Details55 falsefalseR56.htm995895 - Disclosure - Summary of Significant Accounting Policies - Summary of Location of the Assets \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOf](#)
[of Significant Accounting Policies - Summary of Location of the Assets \(Details\)Details56 falsefalseR57.htm995905 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Fair Value of Stock Option Granted on Weighted Average Assumptions \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOf](#)
[of Significant Accounting Policies - Summary of Estimated Fair Value of Stock Option Granted on Weighted Average Assumptions \(Details\)Details57 falsefalseR58.htm995915 - Disclosure - Discontinued Operations - Additional Information \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinue](#)
[Operations - Additional Information \(Details\)Details58 falsefalseR59.htm995925 - Disclosure - Discontinued Operations - Schedule of Transfer of Assets and Liabilities Effected in Accordance with Separation Agreements \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinue](#)
[Operations - Schedule of Transfer of Assets and Liabilities Effected in Accordance with Separation Agreements \(Details\)Details59 falsefalseR60.htm995935 - Disclosure - Discontinued Operations - Summary of Expenses of Discontinued Operations \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinue](#)
[Operations - Summary of Expenses of Discontinued Operations \(Details\)Details60 falsefalseR61.htm995945 - Disclosure - Discontinued Operations - Summary of Assets and Liabilities \(Details\)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinue](#)

Operations - Summary of Assets and Liabilities (Details)Details61 falsefalseR62.htm995955 - Disclosure - Discontinued Operations - Summary of Significant Non-cash Items and Capital Expenditures of Discontinued Operations (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinue Operations - Summary of Significant Non-cash Items and Capital Expenditures of Discontinued Operations (Details)Details62 falsefalseR63.htm995965 - Disclosure - Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureReven from Contracts with Customers - Schedule of Disaggregation of Revenue (Details)Details63 falsefalseR64.htm995975 - Disclosure - Revenue from Contracts with Customers - Schedule of Manufacturing and Royalty Revenues (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureReven from Contracts with Customers - Schedule of Manufacturing and Royalty Revenues (Details)Details64 falsefalseR65.htm995985 - Disclosure - Revenue from Contracts with Customers - Additional Information (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureReven from Contracts with Customers - Additional Information (Details)Details65 falsefalseR66.htm995995 - Disclosure - Investments - Schedule of Investments (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvest - Schedule of Investments (Details)Details66 falsefalseR67.htm996005 - Disclosure - Investments - Additional Information (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvest - Additional Information (Details)Details67 falsefalseR68.htm996015 - Disclosure - Investments - Schedule of Proceeds from Sales and Maturities of Marketable Securities Plus Resulting Realized Gains and Losses (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvest - Schedule of Proceeds from Sales and Maturities of Marketable Securities Plus Resulting Realized Gains and Losses (Details)Details68 falsefalseR69.htm996025 - Disclosure - Investments - Schedule of Contractual Maturities of Available-for-Sale and Held-to-Maturity Securities (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvest - Schedule of Contractual Maturities of Available-for-Sale and Held-to-Maturity Securities (Details)Details69 falsefalseR70.htm996035 - Disclosure - Fair Value - Summary of the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairVa Value - Summary of the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)Details70 falsefalseR71.htm996045 - Disclosure - Fair Value - Additional Information (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairVa Value - Additional Information (Details)Details71 falsefalseR72.htm996055 - Disclosure - Inventory - Schedule of Inventories (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvent - Schedule of Inventories (Details)Details72 falsefalseR73.htm996065 - Disclosure - Inventory - Schedule of Inventories (Parenthetical) (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvent - Schedule of Inventories (Parenthetical) (Details)Details73 falsefalseR74.htm996075 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureProper Plant and Equipment - Schedule of Property, Plant and Equipment (Details)Details74 falsefalseR75.htm996085 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Parenthetical) (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosurePropertyPla Plant and Equipment - Schedule of Property, Plant and Equipment (Parenthetical) (Details)Details75 falsefalseR76.htm996095 - Disclosure - Property, Plant and Equipment - Additional Information (Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureProper

Plant and Equipment - Additional Information (Details)Details76
falsefalseR77.htm996105 - Disclosure - Intangible Assets and Goodwill - Schedule of
Goodwill and Intangible Assets
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleA
Assets and Goodwill - Schedule of Goodwill and Intangible Assets (Details)Details77
falsefalseR78.htm996115 - Disclosure - Intangible Assets and Goodwill - Additional
Information
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleA
Assets and Goodwill - Additional Information (Details)Details78
falsefalseR79.htm996125 - Disclosure - Leases - Additional Information
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeases
- Additional Information (Details)Details79 falsefalseR80.htm996135 - Disclosure -
Leases - Summary of Future Lease Payments Under Non-Cancelable Leases
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeases
- Summary of Future Lease Payments Under Non-Cancelable Leases (Details)Details80
falsefalseR81.htm996145 - Disclosure - Accounts Payable and Accrued Expenses -
Schedule of Accounts Payable and Accrued Expenses
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccou
Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses
(Details)Details81 falsefalseR82.htm996155 - Disclosure - Accounts Payable and
Accrued Expenses - Summary of Current Provision for Sales, Discounts, Allowances and
Reserves
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccou
Payable and Accrued Expenses - Summary of Current Provision for Sales, Discounts,
Allowances and Reserves (Details)Details82 falsefalseR83.htm996165 - Disclosure -
Accounts Payable and Accrued Expenses - Additional Information
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureAccountsPa
Payable and Accrued Expenses - Additional Information (Details)Details83
falsefalseR84.htm996175 - Disclosure - Long-term Debt - Schedule of Long-term Debt
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongT
term Debt - Schedule of Long-term Debt (Details)Details84 falsefalseR85.htm996185 -
Disclosure - Long-term Debt - Additional Information
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongT
term Debt - Additional Information (Details)Details85 falsefalseR86.htm996205 -
Disclosure - Earnings (Loss) Per Share - Schedule of Basic Earnings (Loss) Per
Ordinary Share
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLos
(Loss) Per Share - Schedule of Basic Earnings (Loss) Per Ordinary Share
(Details)Detailshttp://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsL
falsefalseR87.htm996215 - Disclosure - Earnings (Loss) Per Share - Schedule of Anti-
Dilutive Potential Common Share Equivalent Excluded from Calculation of Earnings
(Loss) Per Share
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLos
(Loss) Per Share - Schedule of Anti-Dilutive Potential Common Share Equivalent
Excluded from Calculation of Earnings (Loss) Per Share
(Details)Detailshttp://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsL
falsefalseR88.htm996225 - Disclosure - Shareholders' Equity - Additional Information
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSharel
Equity - Additional Information (Details)Details88 falsefalseR89.htm996235 -
Disclosure - Share-based Compensation - Schedule of Share-based Compensation
Expense from Continuing and Discontinued Operations
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebased
based Compensation - Schedule of Share-based Compensation Expense from
Continuing and Discontinued Operations (Details)Details89 falsefalseR90.htm996245 -
Disclosure - Share-based Compensation - Additional Information
(Details)Sheethttp://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSharel
based Compensation - Additional Information (Details)Details90
falsefalseR91.htm996255 - Disclosure - Share-based Compensation - Schedule of Stock

Option Activity

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-ScheduleofStockOptionActivity\(Details\)Details91falsefalseR92.htm996265](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-ScheduleofStockOptionActivity(Details)Details91falsefalseR92.htm996265) - Disclosure - Share-based Compensation - Stock Options -

Additional Information

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-StockOptions-AdditionalInformation\(Details\)Details92falsefalseR93.htm996275](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-StockOptions-AdditionalInformation(Details)Details92falsefalseR93.htm996275) - Disclosure - Share-based Compensation - Summary of RSU

Activity

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-SummaryofRSUActivity\(Details\)Details93falsefalseR94.htm996285](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-SummaryofRSUActivity(Details)Details93falsefalseR94.htm996285) - Disclosure - Share-based Compensation - Time-Based

Restricted Stock Units Award - Additional Information

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-TimeBasedRestrictedStockUnitsAward-AdditionalInformation\(Details\)Details94falsefalseR95.htm996295](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-TimeBasedRestrictedStockUnitsAward-AdditionalInformation(Details)Details94falsefalseR95.htm996295) - Disclosure - Share-based

Compensation - Performance-Based Restricted Stock Units Awards - Additional Information

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-PerformanceBasedRestrictedStockUnitsAwards-AdditionalInformation\(Details\)Details95falsefalseR96.htm996305](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-PerformanceBasedRestrictedStockUnitsAwards-AdditionalInformation(Details)Details95falsefalseR96.htm996305) - Disclosure - Share-based

Compensation - Summary of PRSU Activity

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-SummaryofPRSUActivity\(Details\)Details96falsefalseR97.htm996315](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation-SummaryofPRSUActivity(Details)Details96falsefalseR97.htm996315) - Disclosure - Collaborative Arrangements - Additional

Information

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollabArrangements-AdditionalInformation\(Details\)Details97falsefalseR98.htm996325](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollabArrangements-AdditionalInformation(Details)Details97falsefalseR98.htm996325) - Disclosure - Income Taxes - Schedule of Provision (Benefit) for Income Taxes from

Continuing Operations

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxTaxes-ScheduleofProvision\(Benefit\)forIncomeTaxesfromContinuingOperations\(Details\)Details98falsefalseR99.htm996335](http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxTaxes-ScheduleofProvision(Benefit)forIncomeTaxesfromContinuingOperations(Details)Details98falsefalseR99.htm996335) - Disclosure - Income Taxes - Additional

Information

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-AdditionalInformation\(Details\)Details99falsefalseR100.htm996345](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-AdditionalInformation(Details)Details99falsefalseR100.htm996345) - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision (Benefit) for

Income Taxes by Geographical Area

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxTaxes-ScheduleofIncome\(Loss\)BeforeProvision\(Benefit\)forIncomeTaxesbyGeographicalArea\(Details\)Details100falsefalseR101.htm996355](http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxTaxes-ScheduleofIncome(Loss)BeforeProvision(Benefit)forIncomeTaxesbyGeographicalArea(Details)Details100falsefalseR101.htm996355) - Disclosure - Income

Taxes - Schedule of Components of Net Deferred Tax Assets

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-ScheduleofComponentsofNetDeferredTaxAssets\(Details\)Details101falsefalseR102.htm996365](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-ScheduleofComponentsofNetDeferredTaxAssets(Details)Details101falsefalseR102.htm996365) - Disclosure - Income Taxes - Schedule of Activity in

Valuation Allowance Associated with Deferred taxes

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-ScheduleofActivityinValuationAllowanceAssociatedwithDeferredtaxes\(Details\)Details102falsefalseR103.htm996375](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-ScheduleofActivityinValuationAllowanceAssociatedwithDeferredtaxes(Details)Details102falsefalseR103.htm996375) - Disclosure - Income Taxes - Schedule

of Reconciliation of Statutory Tax Rate to Effective Tax Rate

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-ScheduleofReconciliationofStatutoryTaxRatetoEffectiveTaxRate\(Details\)Details103falsefalseR104.htm996385](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-ScheduleofReconciliationofStatutoryTaxRatetoEffectiveTaxRate(Details)Details103falsefalseR104.htm996385) - Disclosure - Income Taxes - Schedule

of Reconciliation of Statutory Tax Rate to Effective Tax Rate (Parenthetical)

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxTaxes-ScheduleofReconciliationofStatutoryTaxRatetoEffectiveTaxRate\(Parenthetical\)\(Details\)Details104falsefalseR105.htm996395](http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxTaxes-ScheduleofReconciliationofStatutoryTaxRatetoEffectiveTaxRate(Parenthetical)(Details)Details104falsefalseR105.htm996395) - Disclosure - Income

Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized

Tax Benefits

(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-ScheduleofReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefits\(Details\)Details105-falsefalseR106.htm996415](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes-ScheduleofReconciliationofBeginningandEndingAmountofUnrecognizedTaxBenefits(Details)Details105-falsefalseR106.htm996415) - Disclosure - Segment Reporting - Summary of Significant Segment Expenses
(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReporting-SummaryofSignificantSegmentExpenses\(Details\)Details106-falsefalseR107.htm996425](http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReporting-SummaryofSignificantSegmentExpenses(Details)Details106-falsefalseR107.htm996425) - Disclosure - Commitments and Contingent Liabilities - Additional Information
(Details)Sheet[http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsandContingentLiabilities-AdditionalInformation\(Details\)Details107-falsefalseAllReportsBookAllReportsalks-20241231.htmalks-20241231.xsdimg77546233_0.jpgimg77546233_1.jpgimg77546233_2.jpgimg77546233_3.jpgimg77546233_4.jpg](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsandContingentLiabilities-AdditionalInformation(Details)Details107-falsefalseAllReportsBookAllReportsalks-20241231.htmalks-20241231.xsdimg77546233_0.jpgimg77546233_1.jpgimg77546233_2.jpgimg77546233_3.jpgimg77546233_4.jpg)
<http://fasb.org/srt/2024><http://fasb.org/us-gaap/2024><http://xbrl.sec.gov/cyd/2024><http://xbrl.sec.gov/dei/2024><http://xbrl.sec.gov/ecd/2024>
JSON 130 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "alks-20241231.htm": { "nsprefix": "alks", "nsuri": "http://www.alkermes.com/20241231", "dts": { "inline": { "local": ["alks-20241231.htm"] }, "schema": { "local": ["alks-20241231.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 422, "keyCustom": 108, "axisStandard": 36, "axisCustom": 0, "memberStandard": 43, "memberCustom": 59, "hidden": { "total": 15, "http://xbrl.sec.gov/dei/2024": 5, "http://www.alkermes.com/20241231": 2, "http://fasb.org/us-gaap/2024": 8 }, "contextCount": 381, "entityCount": 1, "segmentCount": 109, "elementCount": 1013, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1126, "http://xbrl.sec.gov/dei/2024": 40, "http://xbrl.sec.gov/cyd/2024": 15, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100010 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCE SHEETS", "longName": "100030 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName":

"CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R3": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "longName": "100040 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:CostsAndExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R5": { "role": "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6", "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuring", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_fe129032-fc91-45ce-a255-8c6d11ed2b00", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null,

"decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"],
 "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true },
 "uniqueAnchor": { "contextRef": "C_fe129032-fe91-45ce-a255-8c6d11ed2b00", "name":
 "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null,
 "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"],
 "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } },
 "R7": { "role":
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
 "longName": "100080 - Statement - CONSOLIDATED STATEMENTS OF
 SHAREHOLDERS' EQUITY (Parenthetical)", "shortName": "CONSOLIDATED
 STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical)", "isDefault": "false",
 "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements",
 "order": "7", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9",
 "name": "us-
 gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuring
 "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-
 20241231.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role":
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
 "longName": "100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
 "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false",
 "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8",
 "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
 gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3",
 "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1,
 "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
 "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
 gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3",
 "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1,
 "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R9": { "role":
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag
 "longName": "100100 - Disclosure - Cybersecurity Risk Management, Strategy, and
 Governance Disclosure", "shortName": "Cybersecurity Risk Management, Strategy, and
 Governance Disclosure", "isDefault": "false", "groupType": "disclosure",
 "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef":
 "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name":
 "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThre
 "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div",
 "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true,
 "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-
 f808ef80fde9", "name":
 "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThre
 "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div",
 "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true,
 "unique": true } }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
 "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay
 vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure",
 "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef":
 "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:NetIncomeLoss",
 "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-
 20241231.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role":
 "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445-
 Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading
 Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "",
 "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_c71f8d00-570d-
 436c-ab1c-cb8cd23a9d60", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null,
 "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [

"ecd:NonRule10b51ArrAdoptedFlag", "span": "p", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c71f8d00-570d-436c-ab1c-cb8cd23a9d60", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } } , "R12": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureDescriptionOfBusiness", "longName": "995455 - Disclosure - Description of Business and Basis of Presentation", "shortName": "Description of Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } } , "R13": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } } , "R14": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperations", "longName": "995475 - Disclosure - Discontinued Operations", "shortName": "Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } } , "R15": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContractsWithCustomers", "longName": "995485 - Disclosure - Revenue from Contracts with Customers", "shortName": "Revenue from Contracts with Customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } } , "R16": { "role":

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestments",
"longName": "995495 - Disclosure - Investments", "shortName": "Investments",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "16", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div",
"body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div",
"body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true,
"unique": true } }], "R17": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValue",
"longName": "995505 - Disclosure - Fair Value", "shortName": "Fair Value", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order":
"17", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9",
"name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount":
1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef":
"alks-20241231.htm", "first": true, "unique": true } }], "R18": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventory",
"longName": "995515 - Disclosure - Inventory", "shortName": "Inventory", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order":
"18", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9",
"name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount":
1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef":
"alks-20241231.htm", "first": true, "unique": true } }], "R19": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
"longName": "995525 - Disclosure - Property, Plant and Equipment", "shortName":
"Property, Plant and Equipment", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef":
"C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"],
"reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name":
"us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"],
"reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }],
"R20": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGood
"longName": "995535 - Disclosure - Intangible Assets and Goodwill", "shortName":
"Intangible Assets and Goodwill", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef":
"C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"],
"reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name":

"us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }], "R21": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeases", "longName": "995545 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAn", "longName": "995555 - Disclosure - Accounts Payable and Accrued Expenses", "shortName": "Accounts Payable and Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebt", "longName": "995565 - Disclosure - Long-term Debt", "shortName": "Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShare1", "longName": "995575 - Disclosure - Earnings (Loss) Per Share", "shortName": "Earnings (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "longName": "995585 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }

1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation", "longName": "995595 - Disclosure - Share-based Compensation", "shortName": "Share-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrangements", "longName": "995605 - Disclosure - Collaborative Arrangements", "shortName": "Collaborative Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995615 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReporting", "longName": "995625 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingentLiabilities", "longName": "995635 - Disclosure - Commitments and Contingent Liabilities", "shortName": "Commitments and Contingent Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30",

"firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "longName": "995645 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "longName": "995655 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "alks:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "alks:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperations1", "longName": "995665 - Disclosure - Discontinued Operations (Tables)", "shortName": "Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "alks:ScheduleOfTheTransferOfAssetsAndLiabilitiesWasEffectuatedInAccordanceWithTheS", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "alks:ScheduleOfTheTransferOfAssetsAndLiabilitiesWasEffectuatedInAccordanceWithTheS", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "longName": "995675 - Disclosure - Revenue from Contracts with Customers (Tables)", "shortName": "Revenue from Contracts with Customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order":

"34", "firstAnchor": { "contextRef": "C_e6077b21-3ee7-4611-b445-bfed9a5f5a9f", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e6077b21-3ee7-4611-b445-bfed9a5f5a9f", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }}, "R35": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables", "longName": "995685 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDiscl", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDiscl", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }}, "R36": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueTables", "longName": "995695 - Disclosure - Fair Value (Tables)", "shortName": "Fair Value (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }}, "R37": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryTables", "longName": "995705 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }}, "R38": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "longName": "995715 - Disclosure - Property, Plant and Equipment (Tables)", "shortName": "Property, Plant and Equipment (Tables)", "isDefault": "false",

"groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "R39": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillTableTextBlock", "longName": "995725 - Disclosure - Intangible Assets and Goodwill (Tables)", "shortName": "Intangible Assets and Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "R40": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesTables", "longName": "995735 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "R41": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAndAccruedExpensesTableTextBlock", "longName": "995745 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "R42": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtTableTextBlock", "longName": "995755 - Disclosure - Long-term Debt (Tables)", "shortName": "Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:LongTermDebtDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:LongTermDebtDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }] }

term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "R43": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareTa", "longName": "995765 - Disclosure - Earnings (Loss) Per Share (Tables)", "shortName": "Earnings (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "R44": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "longName": "995775 - Disclosure - Share-based Compensation (Tables)", "shortName": "Share-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeri", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeri", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "R45": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "longName": "995785 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "R46": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingTables", "longName": "995795 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure",

"subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": {
"contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-
gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html"], "reportCount": 1,
"baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-
gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html"], "reportCount": 1,
"baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R47": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn
"longName": "995805 - Disclosure - Description of Business and Basis of Presentation -
Additional Information (Details)", "shortName": "Description of Business and Basis of
Presentation - Additional Information (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47",
"firstAnchor": { "contextRef": "C_c4b1f0ec-e7e0-4ea3-8d70-415c094775a6", "name":
"us-gaap:CommonStockParOrStatedValuePerShare", "unitRef":
"U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals":
"INF", "ancestors": ["span", "alks:StockDistributionBySeparationOfBusiness", "span",
"p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body",
"html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true
}, "uniqueAnchor": { "contextRef": "C_c4b1f0ec-e7e0-4ea3-8d70-415c094775a6",
"name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef":
"U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals":
"INF", "ancestors": ["span", "alks:StockDistributionBySeparationOfBusiness", "span",
"p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body",
"html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true
 } }, "R48": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
"longName": "995815 - Disclosure - Summary of Significant Accounting Policies -
Schedule of Property, Plant and Equipment (Details)", "shortName": "Summary of
Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "48", "firstAnchor": { "contextRef": "C_1d74b729-a172-4533-8009-
35d45e750252", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td",
"tr", "table", "alks:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
"div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation",
"div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_1d74b729-a172-4533-8009-
35d45e750252", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td",
"tr", "table", "alks:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
"div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation",
"div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true,
"unique": true } }, "R49": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"longName": "995825 - Disclosure - Summary of Significant Accounting Policies -
Schedule of Provisions for Sales and Allowances (Details)", "shortName": "Summary of
Significant Accounting Policies - Schedule of Provisions for Sales and Allowances
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_4749a866-1bd8-
4011-840c-5328878daedc", "name": "alks:ProvisionsForSalesAndAllowances",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
"span", "p", "td", "tr", "table", "us-
gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock", "div",
"ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1,

"baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "alks:CurrentProvisionsRelatingToSalesInCurrentYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } } , "R50": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"longName": "995835 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "alks:ProvisionsForSalesAndAllowances", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_46ab2eb3-fe89-454e-ba4e-cb11a7e0cc46", "name": "alks:ProvisionsForSalesAndAllowances", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } } , "R51": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
"longName": "995845 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "alks:ActualCreditsReceivedRelatedToDuplicateBillings", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "div", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "alks:ActualCreditsReceivedRelatedToDuplicateBillings", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "div", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } } , "R52": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
"longName": "995855 - Disclosure - Summary of Significant Accounting Policies - Schedule of Contract Assets and Contract Liabilities (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Contract Assets and Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_4749a866-1bd8-4011-840c-5328878daedc", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_93068ea9-057e-4cfb-8c02-5f4ba2a8282e", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } } , "R53": { "role":

["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
"longName": "995865 - Disclosure - Summary of Significant Accounting Policies -
Schedule of Concentration (Details)", "shortName": "Summary of Significant
Accounting Policies - Schedule of Concentration (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"53", "firstAnchor": { "contextRef": "C_bc3ea53a-9532-460c-b581-c9f548f72d6e",
"name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil":
"false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table",
"ix:continuation", "div", "us-gaap:ConcentrationRiskCreditRisk", "div",
"ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-
20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_bc3ea53a-9532-460c-b581-c9f548f72d6e", "name": "us-
gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang":
null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation",
"div", "us-gaap:ConcentrationRiskCreditRisk", "div", "ix:continuation", "div", "body",
"html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true
} }, "R54": { "role":

["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
"longName": "995875 - Disclosure - Summary of Significant Accounting Policies -
Schedule of Concentration (Parenthetical) (Details)", "shortName": "Summary of
Significant Accounting Policies - Schedule of Concentration (Parenthetical) (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical",
"menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_580fdb8-55ff-
4f21-b9a4-17ffe7af4199", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef":
"U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p",
"td", "tr", "table", "ix:continuation", "div", "us-gaap:ConcentrationRiskCreditRisk",
"div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-
20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_580fdb8-55ff-4f21-b9a4-17ffe7af4199", "name": "us-
gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang":
null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation",
"div", "us-gaap:ConcentrationRiskCreditRisk", "div", "ix:continuation", "div", "body",
"html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true
} }, "R55": { "role":

["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
"longName": "995885 - Disclosure - Summary of Significant Accounting Policies -
Schedule of Revenues by Geographic Location (Details)", "shortName": "Summary of
Significant Accounting Policies - Schedule of Revenues by Geographic Location
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-
439b-a344-f808ef80fde9", "name": "us-
gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD",
"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr",
"table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first":
true }, "uniqueAnchor": { "contextRef": "C_22cd8cbe-a487-4f0b-bfd2-73ae8051d4fb",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div",
"alks:GeographicInformationPolicyTextBlock", "div", "ix:continuation", "div", "body",
"html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R56":
{ "role":

["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc](http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc)
"longName": "995895 - Disclosure - Summary of Significant Accounting Policies -
Summary of Location of the Assets (Details)", "shortName": "Summary of Significant
Accounting Policies - Summary of Location of the Assets (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"56", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867",

"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ce2ba18e-a85e-4a70-b511-1e1dde705674", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "div", "alks:GeographicInformationPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }], "R57": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "longName": "995905 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Fair Value of Stock Option Granted on Weighted Average Assumptions (Details)", "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Fair Value of Stock Option Granted on Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_42dd1770-5ebe-49ca-904b-4a1ef4ba718d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssu", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTex", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_42dd1770-5ebe-49ca-904b-4a1ef4ba718d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssu", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTex", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsA", "longName": "995915 - Disclosure - Discontinued Operations - Additional Information (Details)", "shortName": "Discontinued Operations - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "alks:DiscontinuedOperationAgreementDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "alks:DiscontinuedOperationAgreementDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "R59": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "longName": "995925 - Disclosure - Discontinued Operations - Schedule of Transfer of Assets and Liabilities Effected in Accordance with Separation Agreements (Details)", "shortName": "Discontinued Operations - Schedule of Transfer of Assets and Liabilities Effected in Accordance with Separation Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b02bf82d-4b46-

4c30-ab75-d5b3c38c6dda", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "tr", "table", "us-gaap:ScheduleOfTheTransferOfAssetsAndLiabilitiesWasEffectuatedInAccordanceWithTheS", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R60": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "longName": "995935 - Disclosure - Discontinued Operations - Summary of Expenses of Discontinued Operations (Details)", "shortName": "Discontinued Operations - Summary of Expenses of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_eeed7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBal", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eeed7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBal", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "longName": "995945 - Disclosure - Discontinued Operations - Summary of Assets and Liabilities (Details)", "shortName": "Discontinued Operations - Summary of Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "longName": "995955 - Disclosure - Discontinued Operations - Summary of Significant Non-cash Items and Capital Expenditures of Discontinued Operations (Details)", "shortName": "Discontinued Operations - Summary of Significant Non-cash Items and Capital Expenditures of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_24ddf1d0-a511-4d8c-a5a0-8ea408a5cea6", "name": "us-gaap:DepreciationAndAmortizationDiscontinuedOperations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "tr", "table", "us-gaap:SummaryOfTheSignificantNonCashItemsAndCapitalExpendituresOfTheDiscontin", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_24ddf1d0-a511-4d8c-a5a0-8ea408a5cea6", "name": "us-gaap:DepreciationAndAmortizationDiscontinuedOperations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "tr", "table", "us-gaap:SummaryOfTheSignificantNonCashItemsAndCapitalExpendituresOfTheDiscontin", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "longName": "995965 - Disclosure - Revenue from Contracts with Customers - Schedule

of Disaggregation of Revenue (Details)", "shortName": "Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cc660b77-5fdf-4bd1-aea5-9365b33e99fb", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }}, "R64": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "longName": "995975 - Disclosure - Revenue from Contracts with Customers - Schedule of Manufacturing and Royalty Revenues (Details)", "shortName": "Revenue from Contracts with Customers - Schedule of Manufacturing and Royalty Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8746eede-b3a2-4eba-ae51-0eb6e325c59b", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }}, "R65": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "longName": "995985 - Disclosure - Revenue from Contracts with Customers - Additional Information (Details)", "shortName": "Revenue from Contracts with Customers - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c5c7f2d7-3628-4690-9882-ceb85c393ec7", "name": "alks:RoyaltyRevenueRelatedToBackRoyalties", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }}, "R66": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu", "longName": "995995 - Disclosure - Investments - Schedule of Investments (Details)", "shortName": "Investments - Schedule of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDiscl", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "unitRef": "U_USD",

"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDiscl", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }], "R67": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditio", "longName": "996005 - Disclosure - Investments - Additional Information (Details)", "shortName": "Investments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "unitRef": "U_Investmentsecurity", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDiscl", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "unitRef": "U_Investmentsecurity", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDiscl", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }], "R68": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu", "longName": "996015 - Disclosure - Investments - Schedule of Proceeds from Sales and Maturities of Marketable Securities Plus Resulting Realized Gains and Losses (Details)", "shortName": "Investments - Schedule of Proceeds from Sales and Maturities of Marketable Securities Plus Resulting Realized Gains and Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_eeed7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "alks:ProceedsAndRealizedGainLossOnMarketableSecuritiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eeed7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "alks:ProceedsAndRealizedGainLossOnMarketableSecuritiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }], "R69": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu", "longName": "996025 - Disclosure - Investments - Schedule of Contractual Maturities of Available-for-Sale and Held-to-Maturity Securities (Details)", "shortName": "Investments - Schedule of Contractual Maturities of Available-for-Sale and Held-to-Maturity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",

"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
"span", "p", "td", "tr", "table", "us-
gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div",
"ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-
20241231.htm", "first": true, "unique": true }], "R70": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary"
"longName": "996035 - Disclosure - Fair Value - Summary of the Company's Assets and
Liabilities Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair
Value - Summary of the Company's Assets and Liabilities Measured at Fair Value on a
Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": {
"contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-
gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "U_USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div",
"ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-
20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_116d88ad-6a73-
4009-98c3-84593cb9fb56", "name": "us-
gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-
gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1,
"baseRef": "alks-20241231.htm", "unique": true }], "R71": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional
"longName": "996045 - Disclosure - Fair Value - Additional Information (Details)",
"shortName": "Fair Value - Additional Information (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"71", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9",
"name":
"alks:FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelOneToLevelTwo
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [
"alks:FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelTwoToLevelOne
"span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"],
"reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name":
"alks:FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelOneToLevelTwo
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [
"alks:FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelTwoToLevelOne
"span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"],
"reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }],
"R72": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryScheduleC
"longName": "996055 - Disclosure - Inventory - Schedule of Inventories (Details)",
"shortName": "Inventory - Schedule of Inventories (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"72", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867",
"name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "U_USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-
gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1,
"baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-
gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-
gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1,
"baseRef": "alks-20241231.htm", "first": true, "unique": true }], "R73": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryScheduleC

"longName": "996065 - Disclosure - Inventory - Schedule of Inventories (Parenthetical) (Details)", "shortName": "Inventory - Schedule of Inventories (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "alks:InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippin", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "link:footnote", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "alks:InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippin", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "link:footnote", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "longName": "996075 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)", "shortName": "Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipm", "longName": "996085 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Parenthetical) (Details)", "shortName": "Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_74a6cced-7e45-4b3c-a4b1-094bcb379c08", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R76": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "longName": "996095 - Disclosure - Property, Plant and Equipment - Additional Information (Details)", "shortName": "Property, Plant and Equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:Depreciation",

"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "longName": "996105 - Disclosure - Intangible Assets and Goodwill - Schedule of Goodwill and Intangible Assets (Details)", "shortName": "Intangible Assets and Goodwill - Schedule of Goodwill and Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:GoodwillGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:GoodwillGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "longName": "996115 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)", "shortName": "Intangible Assets and Goodwill - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0f5ea468-3d57-4d81-9a20-81da478f7d7b", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R79": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInformation", "longName": "996125 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R80": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureLeasePaymentsUnderNonCancelaleLeases", "longName": "996135 - Disclosure - Leases - Summary of Future Lease Payments Under Non-Cancelable Leases (Details)", "shortName": "Leases - Summary of Future Lease Payments Under Non-Cancelable Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef":

"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAn", "longName": "996145 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)", "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R82": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAn", "longName": "996155 - Disclosure - Accounts Payable and Accrued Expenses - Summary of Current Provision for Sales, Discounts, Allowances and Reserves (Details)", "shortName": "Accounts Payable and Accrued Expenses - Summary of Current Provision for Sales, Discounts, Allowances and Reserves (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "alks:AccruedSalesDiscountsAllowancesAndReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6269066e-49ee-48dd-9253-a30e12b22011", "name": "alks:AccruedSalesDiscountsAllowancesAndReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "alks:ScheduleOfAccruedSalesDiscountsAllowancesAndReservesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R83": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccr", "longName": "996165 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Details)", "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a6a067f0-4719-4b72-8a92-be189e78674f", "name": "us-

gaap:AccountsPayableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true }], "R84": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSchedule", "longName": "996175 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details)", "shortName": "Long-term Debt - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "C_4749a866-1bd8-4011-840c-5328878daedc", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d4b929bc-2380-43e6-b73b-a70c5072d8c9", "name": "us-gaap:LongTermDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R85": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAdditional", "longName": "996185 - Disclosure - Long-term Debt - Additional Information (Details)", "shortName": "Long-term Debt - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "alks:PrepaymentOfLongTermDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ec5861dd-2186-4134-94f0-14ead99a95da", "name": "alks:PrepaymentOfLongTermDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R86": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSchedule", "longName": "996205 - Disclosure - Earnings (Loss) Per Share - Schedule of Basic Earnings (Loss) Per Ordinary Share (Details)", "shortName": "Earnings (Loss) Per Share - Schedule of Basic Earnings (Loss) Per Ordinary Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R87": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSchedule", "longName": "996215 - Disclosure - Earnings (Loss) Per Share - Schedule of Anti-Dilutive Potential Common Share Equivalent Excluded from Calculation of Earnings (Loss) Per Share (Details)", "shortName": "Earnings (Loss) Per Share - Schedule of Anti-Dilutive Potential Common Share Equivalent Excluded from Calculation of Earnings (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-

gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "longName": "996225 - Disclosure - Shareholders' Equity - Additional Information (Details)", "shortName": "Shareholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "C_c3256974-34d3-48a5-8b33-82e7618c6ad6", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c3256974-34d3-48a5-8b33-82e7618c6ad6", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensation", "longName": "996235 - Disclosure - Share-based Compensation - Schedule of Share-based Compensation Expense from Continuing and Discontinued Operations (Details)", "shortName": "Share-based Compensation - Schedule of Share-based Compensation Expense from Continuing and Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_151ece9e-d0ae-47cf-8fcc-03e3adee77f1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation", "longName": "996245 - Disclosure - Share-based Compensation - Additional Information (Details)", "shortName": "Share-based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCap", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true,

"unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCap
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [
"span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div",
"body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true,
"unique": true } }], "R91": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"longName": "996255 - Disclosure - Share-based Compensation - Schedule of Stock
Option Activity (Details)", "shortName": "Share-based Compensation - Schedule of
Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": {
"contextRef": "C_a1e02636-04c4-402d-8189-7cc7dfcbe93", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutsta
"unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [
"span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true
}, "uniqueAnchor": { "contextRef": "C_f1176253-9ec1-42c7-ac63-ab7a1ef0dc26",
"name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
"unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [
"span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique":
true } }], "R92": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"longName": "996265 - Disclosure - Share-based Compensation - Stock Options -
Additional Information (Details)", "shortName": "Share-based Compensation - Stock
Options - Additional Information (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92",
"firstAnchor": { "contextRef": "C_f1176253-9ec1-42c7-ac63-ab7a1ef0dc26", "name":
"us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
"unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null,
"decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"],
"reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_f1176253-9ec1-42c7-ac63-ab7a1ef0dc26", "name":
"us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
"unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null,
"decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"],
"reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }],
"R93": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"longName": "996275 - Disclosure - Share-based Compensation - Summary of RSU
Activity (Details)", "shortName": "Share-based Compensation - Summary of RSU
Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef":
"C_64ecb838-c7ac-4b9d-b2be-4ba4e9ac4656", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrum
"unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [
"span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableText
"div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-

20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_32f84869-7edd-4c9a-818b-c70db6176af5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrum
"unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableText
"div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R94": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"longName": "996285 - Disclosure - Share-based Compensation - Time-Based Restricted Stock Units Award - Additional Information (Details)", "shortName": "Share-based Compensation - Time-Based Restricted Stock Units Award - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "C_32f84869-7edd-4c9a-818b-c70db6176af5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrum
"unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableText
"div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_32f84869-7edd-4c9a-818b-c70db6176af5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrum
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R95": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"longName": "996295 - Disclosure - Share-based Compensation - Performance-Based Restricted Stock Units Awards - Additional Information (Details)", "shortName": "Share-based Compensation - Performance-Based Restricted Stock Units Awards - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "C_5833a363-43cf-42f3-809f-9ee6325c583b", "name": "alks:ShareBasedCompensationArrangementAccountingModificationCharge", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5833a363-43cf-42f3-809f-9ee6325c583b", "name": "alks:ShareBasedCompensationArrangementAccountingModificationCharge", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R96": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"longName": "996305 - Disclosure - Share-based Compensation - Summary of PRSU Activity (Details)", "shortName": "Share-based Compensation - Summary of PRSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "C_6b45fd92-332c-4ba1-bb59-8b959700413c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrum
"unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableText
"div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_af023d77-6110-4a60-a850-9f6e41e29d5f", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrum
"unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-

gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableText
"div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R97": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
"longName": "996315 - Disclosure - Collaborative Arrangements - Additional
Information (Details)", "shortName": "Collaborative Arrangements - Additional
Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef":
"C_4eb2968c-f1cd-4faa-a3f1-0336fef27a09", "name":
"alks:PercentageOfNetSalesInRoyaltyPayment", "unitRef": "U_pure", "xsiNil": "false",
"lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "body",
"html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true
}, "uniqueAnchor": { "contextRef": "C_4eb2968c-f1cd-4faa-a3f1-0336fef27a09",
"name": "alks:PercentageOfNetSalesInRoyaltyPayment", "unitRef": "U_pure", "xsiNil":
"false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div",
"body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true,
"unique": true } }, "R98": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfI
"longName": "996325 - Disclosure - Income Taxes - Schedule of Provision (Benefit) for
Income Taxes from Continuing Operations (Details)", "shortName": "Income Taxes -
Schedule of Provision (Benefit) for Income Taxes from Continuing Operations
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-
439b-a344-f808ef80fde9", "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
"span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-
gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1,
"baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-
gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang":
null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-
gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1,
"baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R99": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
"longName": "996335 - Disclosure - Income Taxes - Additional Information (Details)",
"shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"99", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9",
"name": "us-
gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordi
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [
"span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"],
"reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name":
"us-
gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordi
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [
"span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"],
"reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } },
"R100": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfI
"longName": "996345 - Disclosure - Income Taxes - Schedule of Income (Loss) Before
Provision (Benefit) for Income Taxes by Geographical Area (Details)", "shortName":
"Income Taxes - Schedule of Income (Loss) Before Provision (Benefit) for Income Taxes
by Geographical Area (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": {

"contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNon
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
"span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-
20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_72c77be2-44bd-
46a7-aab6-4dc52792173e", "name": "us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNon
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
"span", "p", "td", "tr", "table",
"alks:ScheduleOfNetIncomeLossBeforeProvisionForTaxesByGeographicalAreaTableText
"div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount":
1, "baseRef": "alks-20241231.htm", "unique": true } }, "R101": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
"longName": "996355 - Disclosure - Income Taxes - Schedule of Components of Net
Deferred Tax Assets (Details)", "shortName": "Income Taxes - Schedule of Components
of Net Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": {
"contextRef": "C_8221db91-6e8a-477a-a28a-c95a72c73867", "name": "us-
gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "U_USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:SummaryOfValuationAllowanceTextBlock", "div", "ix:continuation", "div", "body",
"html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true },
"uniqueAnchor": { "contextRef": "C_f7a12138-0216-4e3e-850f-732186783569", "name":
"us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "U_USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div",
"ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-
20241231.htm", "unique": true } }, "R102": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
"longName": "996365 - Disclosure - Income Taxes - Schedule of Activity in Valuation
Allowance Associated with Deferred taxes (Details)", "shortName": "Income Taxes -
Schedule of Activity in Valuation Allowance Associated with Deferred taxes (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "102", "firstAnchor": { "contextRef": "C_4749a866-1bd8-4011-840c-
5328878daedc", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef":
"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td",
"tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "div",
"ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-
20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-
439b-a344-f808ef80fde9", "name": "us-
gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "unitRef": "U_USD",
"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr",
"table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "div", "ix:continuation",
"div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique":
true } }, "R103": { "role":
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
"longName": "996375 - Disclosure - Income Taxes - Schedule of Reconciliation of
Statutory Tax Rate to Effective Tax Rate (Details)", "shortName": "Income Taxes -
Schedule of Reconciliation of Statutory Tax Rate to Effective Tax Rate (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "103", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-
f808ef80fde9", "name": "us-
gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [
"span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div",
"ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-
20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":

"C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }], "R104": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "longName": "996385 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Tax Rate to Effective Tax Rate (Parenthetical) (Details)", "shortName": "Income Taxes - Schedule of Reconciliation of Statutory Tax Rate to Effective Tax Rate (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "C_4749a866-1bd8-4011-840c-5328878daedc", "name": "alks:IncomeTaxExpenseBenefitRelatedToIntercompanyTransferOfInventory", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4749a866-1bd8-4011-840c-5328878daedc", "name": "alks:IncomeTaxExpenseBenefitRelatedToIntercompanyTransferOfInventory", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }, "R105": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu", "longName": "996395 - Disclosure - Income Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)", "shortName": "Income Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "C_4749a866-1bd8-4011-840c-5328878daedc", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_fe129032-fc91-45ce-a255-8c6d11ed2b00", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true } }, "R106": { "role": "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm", "longName": "996415 - Disclosure - Segment Reporting - Summary of Significant Segment Expenses (Details)", "shortName": "Segment Reporting - Summary of Significant Segment Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "alks:ALKSTwoSixEightZeroExternalResearchAndDevelopmentExpensesDevelopmentPro", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [

"span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "unique": true }], "R107": { "role": "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDisclosureTextBlock", "longName": "996425 - Disclosure - Commitments and Contingent Liabilities - Additional Information (Details)", "shortName": "Commitments and Contingent Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:LossContingencyAccrualProvision", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eecd7ffb-581b-439b-a344-f808ef80fde9", "name": "us-gaap:LossContingencyAccrualProvision", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "alks-20241231.htm", "first": true, "unique": true } }], "tag": { "alks_ALKSTwoSixEightZeroExternalResearchAndDevelopmentExpensesDevelopmentProgram { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ALKSTwoSixEightZeroExternalResearchAndDevelopmentExpensesDevelopmentProgram", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummary", "lang": { "en-us": { "role": { "label": "A L K S Two Six Eight Zero External Research and Development Expenses Development Programs", "documentation": "ALKS 2680 external research and development expense development programs.", "terseLabel": "ALKS 2680" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "alks_AccountsPayableAndAccruedExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AccountsPayableAndAccruedExpensesLineItems", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpenses", "lang": { "en-us": { "role": { "documentation": "Accounts payable and accrued expenses.", "label": "Accounts Payable And Accrued Expenses [Line Items]", "terseLabel": "Accounts Payable And Accrued Expenses [Line Items]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAndAccruedLiabilitiesCurrent", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBalanceSheet", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Current", "terseLabel": "Accounts payable and accrued expenses", "totalLabel": "Total accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r109", "r110"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities

Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } }], "auth_ref": ["r108", "r110", "r113", "r1416"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccr", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAnd", "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."} } }, "auth_ref": ["r108", "r1083"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable", "verboseLabel": "Reduction of Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r995"] }, "alks_AccruedSalesDiscountAllowancesAndReservesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AccruedSalesDiscountAllowancesAndReservesLineItems", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAnd", "lang": { "en-us": { "role": { "documentation": "Accrued sales discount allowances and reserves line items.", "label": "Accrued Sales Discount Allowances And Reserves [Line Items]", "terseLabel": "Accrued Sales Discount Allowances And Reserves [Line Items]" } } }, "auth_ref": [] }, "alks_AccruedSalesDiscountAllowancesAndReservesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AccruedSalesDiscountAllowancesAndReservesTable", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccr", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAnd", "lang": { "en-us": { "role": { "documentation": "Accrued sales discount allowances and reserves table.", "label": "Accrued Sales Discount Allowances And Reserves [Table]", "terseLabel": "Accrued Sales Discount Allowances And Reserves [Table]" } } }, "auth_ref": [] }, "alks_AccruedSalesDiscountsAllowancesAndReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AccruedSalesDiscountsAllowancesAndReserves", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAnd", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "verboseLabel": "Total accrued sales discounts, allowances and reserves", "documentation": "Carrying value as of the balance sheet date of obligations relating to sales discounts, allowances and reserves.", "label": "Accrued Sales Discounts Allowances And Reserves", "terseLabel": "Accrued sales discounts, allowances and reserves" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property,

Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } }], "auth_ref": ["r54", "r251", "r862"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r29", "r30", "r126", "r259", "r858", "r889", "r890"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "AOI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r18", "r30", "r705", "r708", "r768", "r885", "r886", "r1245", "r1246", "r1247", "r1257", "r1258", "r1259", "r1261"] }, "alks_ActualCreditsReceivedRelatedToDuplicateBillings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ActualCreditsReceivedRelatedToDuplicateBillings", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici", "lang": { "en-us": { "role": { "label": "Actual Credits Received Related To Duplicate Billings", "documentation": "Actual credits received related to duplicate billings.", "terseLabel": "Actual credits received related to duplicate billings" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r1163"] }, "alks_AdditionalAwardPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AdditionalAwardPaid", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri", "lang": { "en-us": { "role": { "documentation": "Additional award paid.", "label": "Additional Award Paid", "terseLabel": "Additional award paid" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } },

"auth_ref": ["r118"], "us-gaap-AdditionalPaidInCapitalMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AdditionalPaidInCapitalMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
 l, "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]",
 "terseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over
 par or stated value of the entity's capital stock and amounts received from other
 transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r903",
 "r1257", "r1258", "r1259", "r1261", "r1431", "r1494"] },
 "alks-AdditionalPremisesMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname": "AdditionalPremisesMember",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
 l, "lang": { "en-us": { "role": { "documentation": "Additional Premises.", "label":
 "Additional Premises [Member]", "terseLabel": "Additional Premises" } } }, "auth_ref":
 [] }, "alks-AdditionalSoughtValueForDamages": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "AdditionalSoughtValueForDamages", "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
 l, "lang": { "en-us": { "role": { "documentation": "Additional sought value for
 damages.", "label": "Additional Sought Value For Damages", "terseLabel": "Additional
 sought value for damages" } } }, "auth_ref": [] },
 "alks-AdditionsOfPropertyPlantAndEquipmentDiscontinuedOperations": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "AdditionsOfPropertyPlantAndEquipmentDiscontinuedOperations", "crdr": "credit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 l, "lang": { "en-us": { "role": { "negatedLabel": "Additions of property, plant and
 equipment", "label": "Additions of property, plant and equipment, discontinued
 operations", "documentation": "Additions of property, plant and equipment,
 discontinued operations" } } }, "auth_ref": [] }, "ecd-AdjToCompAmt": { "xbrltype":
 "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" },
 "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount",
 "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r1176"] },
 "ecd-AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label":
 "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } }
 }, "auth_ref": ["r1176"] }, "ecd-AdjToNonPeoNeoCompFnTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "AdjToNonPeoNeoCompFnTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label":
 "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel":
 "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r1176"] },
 "ecd-AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock",
 "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": {
 "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
 "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r1176"
] }, "alks-AdjustmentsRelatingToPriorYears": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "AdjustmentsRelatingToPriorYears", "crdr": "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 l, "lang": { "en-us": { "role": { "label": "Adjustments Relating To Prior Years",
 "documentation": "Adjustments relating to prior years.", "terseLabel": "Adjustments
 relating to prior years" } } }, "auth_ref": [] }, "us-
 gaap-AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServiceEl

{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriod", "crdr": "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENT", "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r70", "r71", "r599"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENT", "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantItems", "lang": { "en-us": { "role": { "label": "Advertising Expense", "terseLabel": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": ["r644", "r1064"] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r1221"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r1134", "r1145", "r1155", "r1188"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r1137", "r1148", "r1158", "r1191"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r1222"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r1176"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": {

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r1183"], "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r1138", "r1149", "r1159", "r1183", "r1192", "r1196", "r1204"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r1202"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensation", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r631", "r642"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": [] }, "alks_AmerisourceBergenCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AmerisourceBergenCorporationMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "documentation": "AmerisourceBergen Corporation.", "label": "Amerisource Bergen Corporation [Member]", "terseLabel": "AmerisourceBergen" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGood", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC", "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of acquired intangible assets", "verboseLabel": "Amortization of acquired intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r10", "r436", "r443", "r1041"] }, "alks_AmpyraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AmpyraMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "lang": { "en-us": { "role": { "terseLabel": "AMPYRA", "label": "AMPYRA [Member]", "documentation": "AMPYRA [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",

"presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSec", "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive potential common share equivalent excluded from calculation of net loss per ordinary share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r321" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutive": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSec"}, "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSec", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSec", "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": { "r40" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"}, "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSec", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSec", "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Denominator:", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain"}, "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSec", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSec", "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r40" } }, "alks_ArbitrationAwardAmountPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ArbitrationAwardAmountPaid", "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "lang": { "en-us": { "role": { "documentation": "Arbitration award amount paid.", "label": "Arbitration Award Amount Paid", "terseLabel": "Arbitration award amount paid" } } }, "auth_ref": { } }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty"}, "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf", "lang": { "en-us": { "role": { "label": "Area of Real Estate Property", "terseLabel": "Area of real estate property", "documentation": "Area of a real estate property." } } }, "auth_ref": { } }, "alks_AristadaAndAristadaInitioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AristadaAndAristadaInitioMember"}, "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "lang": { "en-us": { "role": { "documentation": "Aristada and Aristada Initio.", "label": "Aristada And Aristada Initio [Member]", "terseLabel": "ARISTADA and ARISTADA

INITIO" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific",], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r696"] }, "alks_AssetHeldForSaleNotPartOfDisposalGroupNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AssetHeldForSaleNotPartOfDisposalGroupNoncurrent", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc",], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Asset Held for Sale Not Part of Disposal Group Noncurrent", "documentation": "Asset held-for-sale not part of disposal group, noncurrent." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI",], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r168", "r179", "r255", "r288", "r326", "r332", "r350", "r353", "r400", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r698", "r702", "r741", "r854", "r941", "r1032", "r1033", "r1083", "r1112", "r1319", "r1320", "r1447"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI",], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI",], "lang": { "en-us": { "role": { "label": "Assets, Current", "terseLabel": "Current assets:", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r245", "r263", "r288", "r400", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r698", "r702", "r741", "r1083", "r1319", "r1320", "r1447"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI",], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary",], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets, Total", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r716", "r717", "r1070"] }, "alks_AssetsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AssetsHeldForSaleMember",

"presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipm
 }, "lang": { "en-us": { "role": { "label": "Assets Held For Sale [Member]"
 "documentation": "Assets held for sale member.", "terseLabel": "Assets Held For Sale"
 } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL
 }, "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Asset, Held-
 for-Sale, Not Part of Disposal Group, Current", "totalLabel": "Asset, Held-for-Sale, Not
 Part of Disposal Group, Current, Total", "documentation": "Amount of assets held-for-
 sale that are not part of a disposal group, expected to be sold within a year or the
 normal operating cycle, if longer." } } }, "auth_ref": ["r153", "r1083"] },
 "alks_AssetsHeldForSalePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname":
 "AssetsHeldForSalePolicyTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 }, "lang": { "en-us": { "role": { "terseLabel": "Assets Held for Sale", "label": "Assets
 Held for Sale [Policy Text Block]", "documentation": "Assets held for sale." } } },
 "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 }, "lang": { "en-us": { "role": { "terseLabel": "Long-term assets:", "label": "Assets,
 Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsA
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 }, "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Assets",
 "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation":
 "Amount classified as assets attributable to disposal group held for sale or disposed
 of." } } }, "auth_ref": ["r1", "r86", "r103", "r156", "r243", "r244"] }, "us-
 gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL
 }, "lang": { "en-us": { "role": { "terseLabel": "Assets related to discontinued
 operations", "verboseLabel": "Assets related to discontinued operations", "totalLabel":
 "Total current assets", "label": "Disposal Group, Including Discontinued Operation,
 Assets, Current", "documentation": "Amount classified as assets attributable to
 disposal group held for sale or disposed of, expected to be disposed of within one year
 or the normal operating cycle, if longer." } } }, "auth_ref": ["r1", "r86", "r103", "r154",
 "r156", "r243", "r244"] }, "us-
 gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS

], "lang": { "en-us": { "role": { "verboseLabel": "CURRENT ASSETS:", "terseLabel": "Current Assets:", "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]" } } }, "auth_ref": [] }, "alks_AssignmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AssignmentMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
], "lang": { "en-us": { "role": { "terseLabel": "Assignment", "label": "Assignment [Member]", "documentation": "Assignment." } } }, "auth_ref": [] }, "alks_AthloneFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "AthloneFacilityMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGood
], "lang": { "en-us": { "role": { "terseLabel": "Athlone Facility", "label": "Athlone Facility [Member]", "documentation": "Athlone facility." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r1117", "r1118", "r1141"] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "auth_ref": ["r1117", "r1118", "r1141"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "auth_ref": ["r1117", "r1118", "r1141"] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "terseLabel": "Auditor Opinion", "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": ["r1225"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Total", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r367", "r412", "r853"] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]", "terseLabel": "Available-for-sale securities:" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCo: { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "After 1 year through 5 years", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized

in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r1279"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "After 1 year through 5 years", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": ["r375", "r849"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]", "terseLabel": "Available-for-sale, Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Available-for-sale, Estimated Fair Value" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Within 1 year", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": ["r1278"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Within 1 year", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": [] }

approach)." } }], "auth_ref": ["r374", "r848"]], "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "totalLabel": "Total", "verboseLabel": "Debt securities", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } }], "auth_ref": ["r368", "r412", "r716", "r842", "r1070", "r1074", "r1273", "r1435", "r1436", "r1437"]], "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAssets", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCE", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Investments\u2014short-term", "verboseLabel": "Short-term investments, Estimated Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } }], "auth_ref": ["r364", "r412"]], "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Long-term investments, Estimated Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } }], "auth_ref": ["r249", "r364", "r412"]], "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation", "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } }], "auth_ref": ["r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414"]], "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation", "lang": { "en-us": { "role": { "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } }], "auth_ref": ["r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414"]], "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } }], "auth_ref": ["r1199"]], "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } }], "auth_ref": ["r1200"]],

"alks_AwardGrantedInFebruaryTwoZeroTwoOneMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"AwardGrantedInFebruaryTwoZeroTwoOneMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "terseLabel": "Award Granted in February 2021", "label":
"Award Granted in February Two zero Two One [Member]", "documentation": "Award
granted in February two zero two one." } } }, "auth_ref": [] },
"alks_AwardGrantedInFebruaryTwoZeroTwoThreeAndTwoZeroTwoFourMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"AwardGrantedInFebruaryTwoZeroTwoThreeAndTwoZeroTwoFourMember",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "terseLabel": "Award Granted in February 2023 and
2024", "label": "Award Granted in February Two zero Two Three And Two Zero Two
Four [Member]", "documentation": "Award granted in february 2023 and 2024." } } },
"auth_ref": [] },
"alks_AwardGrantedInFebruaryTwoZeroTwoTwoAndTwoZeroTwoThreeMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"AwardGrantedInFebruaryTwoZeroTwoTwoAndTwoZeroTwoThreeMember",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "terseLabel": "Award Granted in February 2022 and
2023", "label": "Award Granted in February Two zero Two Two And Two Zero Two Three
[Member]", "documentation": "Award granted in February two zero two two And two
zero two three." } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing
Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [
"r1195"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgHowMnpiCnsdrdTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award
Timing, How MNPI Considered" } } }, "auth_ref": ["r1195"] },
"ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock",
"presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-
us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award
Timing Method" } } }, "auth_ref": ["r1195"] }, "ecd_AwardTmgMnpiCnsdrdFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgMnpiCnsdrdFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI
Considered" } } }, "auth_ref": ["r1195"] }, "ecd_AwardTmgMnpiDiscTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgMnpiDiscTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing
MNPI Disclosure" } } }, "auth_ref": ["r1195"] }, "ecd_AwardTmgPredtrmndFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgPredtrmndFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing
Predetermined" } } }, "auth_ref": ["r1195"] }, "us-gaap_AwardTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AwardTypeAxis", "presentation": {

["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc](http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici)
["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"](http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure)], "lang": { "en-us": { "role": {
"label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation":
"Information by type of award under share-based payment arrangement." } } },
"auth_ref": ["r602", "r603", "r604", "r606", "r607", "r608", "r609", "r610", "r611",
"r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622",
"r623", "r626", "r627", "r628", "r629", "r630"] }, "ecd_AwardUndrlygSecuritiesAmt": {
"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardUndrlygSecuritiesAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities"
} } }, "auth_ref": ["r1198"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscIndName", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel":
"Name" } } }, "auth_ref": ["r1197"] }, "ecd_AwardsCloseToMnpiDiscTable": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTable", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards
Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r1196"] },
"ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTableTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel":
"Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r1196"] },
"alks_BackRoyaltiesLatePaymentInterest": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname":
"BackRoyaltiesLatePaymentInterest", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
l", "lang": { "en-us": { "role": { "terseLabel": "Back royalties late payment interest",
"label": "Back Royalties Late Payment Interest", "documentation": "Back royalties late
payment interest." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BalanceSheetLocationAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l", "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location,
Balance [Axis]", "terseLabel": "Balance Sheet Location", "documentation":
"Information by location in statement of financial position where disaggregated
cumulative balance has been reported." } } }, "auth_ref": ["r451", "r1461", "r1462"] },
"us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l", "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location,
Balance [Domain]", "terseLabel": "Balance Sheet Location", "documentation":

"Location in statement of financial position where disaggregated cumulative balance has been reported." } }], "auth_ref": ["r77", "r78", "r451", "r1461", "r1462"] },
"alks_BasePremisesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "BasePremisesMember",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
l, "lang": { "en-us": { "role": { "documentation": "Base premises.", "label": "Base
Premises [Member]", "terseLabel": "Base Premises" } } }, "auth_ref": [] },
"alks_BaudaxBioIncMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "BaudaxBioIncMember",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional
l, "lang": { "en-us": { "role": { "documentation": "Baudax bio, inc.", "label": "Baudax
Bio Inc [Member]", "terseLabel": "Baudax" } } }, "auth_ref": [] },
"alks_BiogenMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "BiogenMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l, "lang": { "en-us": { "role": { "documentation": "Biogen.", "label": "Biogen [Member]",
"terseLabel": "Biogen" } } }, "auth_ref": [] }, "us-
gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BuildingAndBuildingImprovementsMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l, "lang": { "en-us": { "role": { "label": "Building and Building Improvements
[Member]", "terseLabel": "Buildings and improvements", "verboseLabel": "Building and
Improvements", "documentation": "Facility held for productive use including, but not
limited to, office, production, storage and distribution facilities and any addition,
improvement, or renovation to the structure, for example, but not limited to, interior
masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-
gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
l, "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]",
"terseLabel": "Business Acquisition, Acquiree", "documentation": "Identification of the
acquiree in a material business combination (or series of individually immaterial
business combinations), which may include the name or other type of identification of
the acquiree." } } }, "auth_ref": ["r437", "r438", "r439", "r440", "r441", "r692",
"r1059", "r1060"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
l, "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "terseLabel":
"Business Acquisition", "documentation": "Information by business combination or
series of individually immaterial business combinations." } } }, "auth_ref": ["r72",
"r73", "r437", "r438", "r439", "r440", "r441", "r692", "r1059", "r1060"] }, "us-
gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfC
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContir
"crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
"http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
l, "lang": { "en-us": { "role": { "label": "Business Combination, Contingent
Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
"terseLabel": "Change in the fair value of contingent consideration", "verboseLabel":
"Increase (decrease) in fair value of contingent consideration", "negatedLabel":

"Change in the fair value of contingent consideration", "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset." } }],
"auth_ref": ["r693", "r1250"] }, "us-
gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureDescriptionOfBusin
l", "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation
[Text Block]", "terseLabel": "Description of Business and Basis of Presentation",
"documentation": "The entire disclosure for the business description and basis of
presentation concepts. Business description describes the nature and type of
organization including but not limited to organizational structure as may be applicable
to holding companies, parent and subsidiary relationships, business divisions, business
units, business segments, affiliates and information about significant ownership of the
reporting entity. Basis of presentation describes the underlying basis used to prepare
the financial statements (for example, US Generally Accepted Accounting Principles,
Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r84", "r145",
"r146"] }, "alks_CapitalPurchaseCommitmentsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"CapitalPurchaseCommitmentsMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndC
l", "lang": { "en-us": { "role": { "documentation": "Capital purchase commitments.",
"label": "Capital Purchase Commitments [Member]", "terseLabel": "Capital
Commitments" } } }, "auth_ref": [] }, "alks_CardinalHealthMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"CardinalHealthMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
l", "lang": { "en-us": { "role": { "documentation": "Cardinal Health.", "label": "Cardinal
Health [Member]", "terseLabel": "Cardinal Health" } } }, "auth_ref": [] }, "us-
gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
l", "lang": { "en-us": { "role": { "totalLabel": "Cash and Cash Equivalents, at Carrying
Value, Total", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel":
"Cash and cash equivalents", "documentation": "Amount of currency on hand as well as
demand deposits with banks or financial institutions. Includes other kinds of accounts
that have the general characteristics of demand deposits. Also includes short-term,
highly liquid investments that are both readily convertible to known amounts of cash
and so near their maturity that they present insignificant risk of changes in value
because of changes in interest rates. Excludes cash and cash equivalents within
disposal group and discontinued operation." } } }, "auth_ref": ["r34", "r248", "r1013"]
l", "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
l", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]",
"terseLabel": "Cash and Cash Equivalents", "documentation": "Information by type of
cash and cash equivalent balance." } } }, "auth_ref": ["r248"] }, "us-
gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary
l", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value
Disclosure", "terseLabel": "Cash equivalents", "documentation": "Fair value portion of
currency on hand as well as demand deposits with banks or financial institutions.
Includes other kinds of accounts that have the general characteristics of demand

deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1433", "r1434"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificati", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r35"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS\u2014End of period", "periodStartLabel": "CASH AND CASH EQUIVALENTS\u2014Beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r34", "r141", "r285"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecr", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r141"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing

Activities Disclosure [Abstract], "terseLabel": "Non-cash investing and financing activities:" } }], "auth_ref": []], "alks_CencoraIncorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "CencoraIncorporationMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "terseLabel": "Cencora", "label": "Cencora Incorporation [Member]", "documentation": "Cencora Incorporation." } } }], "auth_ref": []], "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu", "lang": { "en-us": { "role": { "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }], "auth_ref": ["r15", "r1106", "r1107", "r1108", "r1109"]], "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }], "auth_ref": ["r1174"]], "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }], "auth_ref": ["r1171"]], "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }], "auth_ref": ["r1169"]], "alks_ChristianToddNicholsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ChristianToddNicholsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Christian Todd Nichols.", "label": "Christian Todd Nichols [Member]", "terseLabel": "Christian Todd Nichols [Member]" } } }], "auth_ref": []], "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }], "auth_ref": []], "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfTreasuryStockTable", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }], "auth_ref": ["r60", "r61", "r62", "r63"]], "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {

"role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } }], "auth_ref": ["r1175"] },
 "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName",
 "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r1175"] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r195", "r197", "r208"] },
 "alks_CollaborativeArrangementEffectiveNoticePeriodRequiredToBeServedForTerminat": { "xbrltype": "durationItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "CollaborativeArrangementEffectiveNoticePeriodRequiredToBeServedForTerminationOf", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "documentation": "Represents the notice period required to be served before the termination of the agreement.", "label": "Collaborative Arrangement Effective Notice Period Required To Be Served For Termination Of Agreement", "terseLabel": "Notice period required to be given before termination of agreement" } } }, "auth_ref": [] },
 "alks_CollaborativeArrangementKnowHowRoyaltyRate": { "xbrltype": "percentItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "CollaborativeArrangementKnowHowRoyaltyRate", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "documentation": "Represents the know-how patent royalty as a percentage of net sales under the collaborative agreements.", "label": "Collaborative Arrangement Know How Royalty Rate", "terseLabel": "Know-how royalty rate (as a percent)" } } }, "auth_ref": [] },
 "alks_CollaborativeArrangementKnowHowRoyaltyRateResets": { "xbrltype": "percentItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "CollaborativeArrangementKnowHowRoyaltyRateResets", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement know how royalty rate resets.", "label": "Collaborative Arrangement Know How Royalty Rate Resets", "terseLabel": "Know-how royalty rate resets (as a percent)" } } }, "auth_ref": [] },
 "alks_CollaborativeArrangementNetSalesTiedToKnowHowRoyalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "CollaborativeArrangementNetSalesTiedToKnowHowRoyalty", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate worldwide net sales tied to know-how royalty under the collaborative agreements.", "label": "Collaborative Arrangement Net Sales Tied To Know How Royalty", "terseLabel": "Aggregate worldwide net sales" } } }, "auth_ref": [] },
 "alks_CollaborativeArrangementPatentRoyaltyRate": { "xbrltype": "percentItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "CollaborativeArrangementPatentRoyaltyRate", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang

l, "lang": { "en-us": { "role": { "documentation": "Represents the patent royalty as a percentage of net sales under the collaborative agreements.", "label": "Collaborative Arrangement Patent Royalty Rate", "terseLabel": "Patent royalty rate (as a percent)" } } }, "auth_ref": [] },

"alks_CollaborativeArrangementPeriodAfterDateOfFirstCommercialSaleOfProductForEx"
{ "xbrltype": "durationItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"CollaborativeArrangementPeriodAfterDateOfFirstCommercialSaleOfProductForExpirat
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
l, "lang": { "en-us": { "role": { "documentation": "Represents the period after the date of the first commercial sale of the product in a particular country that the agreement will expire.", "label": "Collaborative Arrangement Period After Date Of First Commercial Sale Of Product For Expiration Of Agreement", "terseLabel": "Period after the date of the first commercial sale of the product for license expiration" } } }, "auth_ref": [] },

"alks_CollaborativeArrangementPeriodForResolvingDefaultOrBreachAfterReceiptOfNoti
{ "xbrltype": "durationItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"CollaborativeArrangementPeriodForResolvingDefaultOrBreachAfterReceiptOfNoticeFo
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
l, "lang": { "en-us": { "role": { "documentation": "Represents the period for resolving default or breach after the receipt of notice for termination of agreement.", "label": "Collaborative Arrangement Period For Resolving Default Or Breach After Receipt Of Notice For Termination Of Agreement", "terseLabel": "Period for resolving default or breach after the receipt of notice for termination of agreement" } } }, "auth_ref": [] },

"alks_CollaborativeArrangementRoyaltyRate": { "xbrltype": "percentItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname":
"CollaborativeArrangementRoyaltyRate", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
l, "lang": { "en-us": { "role": { "documentation": "Represents royalty as a percentage of net sales under the collaborative agreements.", "label": "Collaborative Arrangement Royalty Rate", "terseLabel": "Royalty rate (as a percent)" } } }, "auth_ref": [] },

"alks_CollaborativeArrangementRoyaltyRateUponTerminationOfRelatedAgreement": {
"xbrltype": "percentItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"CollaborativeArrangementRoyaltyRateUponTerminationOfRelatedAgreement",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
l, "lang": { "en-us": { "role": { "documentation": "Represents royalty rate upon termination of related agreement.", "label": "Collaborative Arrangement Royalty Rate Upon Termination Of Related Agreement", "terseLabel": "Royalty rate upon termination of manufacturing and supply agreement (as a percent)" } } }, "auth_ref": [] },

"us-
gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItem
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
l, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r696"] },

"alks_CollaborativeArrangementsDisclosureAbstract": { "xbrltype": "stringItemType",

"nsuri": "http://www.alkermes.com/20241231", "localname":
 "CollaborativeArrangementsDisclosureAbstract", "lang": { "en-us": { "role": {
 "documentation": "COLLABORATIVE ARRANGEMENTS", "label": "Collaborative
 Arrangements Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr":
 "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL
 l", "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENT
 LIABILITIES (Note 19)", "label": "Commitments and Contingencies", "documentation":
 "Represents the caption on the face of the balance sheet to indicate that the entity has
 entered into (1) purchase or supply arrangements that will require expending a portion
 of its resources to meet the terms thereof, and (2) is exposed to potential losses or,
 less frequently, gains, arising from (a) possible claims against a company's resources
 due to future performance under contract terms, and (b) possible losses or likely gains
 from uncertainties that will ultimately be resolved when one or more future events that
 are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r114", "r170",
 "r855", "r928"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": {
 "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] },
 "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo
 l", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure
 [Text Block]", "terseLabel": "Commitments and Contingent Liabilities",
 "documentation": "The entire disclosure for commitments and contingencies." } } },
 "auth_ref": ["r158", "r453", "r454", "r996", "r1308", "r1313"] },
 "alks_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "CommitmentsAndContingenciesLineItems", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo
 l", "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.",
 "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments
 And Contingencies [Line Items]" } } }, "auth_ref": [] },
 "alks_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname":
 "CommitmentsAndContingenciesTable", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo
 l", "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.",
 "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And
 Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": {
 "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "CommonStockMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
 l", "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel":
 "Ordinary Shares", "documentation": "Stock that is subordinate to all other stock of
 the issuer." } } }, "auth_ref": ["r1102", "r1103", "r1104", "r1106", "r1107", "r1108",
 "r1109", "r1257", "r1258", "r1261", "r1431", "r1493", "r1494"] }, "us-
 gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "CommonStockParOrStatedValuePerShare", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL
 l", "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share",
 "terseLabel": "Ordinary shares, par value (in dollars per share)", "documentation":
 "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r117"]

], "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } } }, "auth_ref": { "r117", "r929" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } }, "auth_ref": { "r117" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Ordinary shares, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } } }, "auth_ref": { "r19", "r117", "r929", "r947", "r1494", "r1495" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares, par value, \$0.01 per share; 450,000,000 shares authorized; 176,670,785 and 172,569,051 shares issued; and 162,176,994 and 166,979,833 shares outstanding at December 31, 2024 and 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } }, "auth_ref": { "r117", "r857", "r1083" } }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } } }, "auth_ref": { "r1180" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } } }, "auth_ref": { "r1179" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel":

"Compensation Actually Paid vs. Other Measure" } }], "auth_ref": ["r1181"] },
 "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
 "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel":
 "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r1178"
] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6
], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax,
 Attributable to Parent", "totalLabel": "COMPREHENSIVE INCOME (LOSS)",
 "documentation": "Amount after tax of increase (decrease) in equity from transactions
 and other events and circumstances from net income and other comprehensive income,
 attributable to parent entity. Excludes changes in equity resulting from investments by
 owners and distributions to owners." } } }, "auth_ref": ["r31", "r268", "r270", "r276",
 "r843", "r869", "r870"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6
], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax,
 Attributable to Parent [Abstract]", "terseLabel": "COMPREHENSIVE INCOME (LOSS):"
 } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss)", "label":
 "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of
 accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-
 gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]",
 "terseLabel": "Concentration Risk Benchmark", "documentation": "The denominator in
 a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r43",
 "r44", "r80", "r81", "r361", "r995"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis":
 { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ConcentrationRiskByBenchmarkAxis", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]",
 "terseLabel": "Concentration Risk Benchmark", "documentation": "Information by
 benchmark of concentration risk." } } }, "auth_ref": ["r43", "r44", "r80", "r81", "r361",
 "r892", "r995"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ConcentrationRiskByTypeAxis", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "terseLabel":
 "Concentration Risk Type", "documentation": "Information by type of concentration
 risk, for example, but not limited to, asset, liability, net assets, geographic, customer,
 employees, supplier, lender." } } }, "auth_ref": ["r43", "r44", "r80", "r81", "r361",
 "r995", "r1230"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ConcentrationRiskCreditRisk", "presentation": [

["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica)
[l, "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy \[Policy](#)
[Text Block\]", "terseLabel": "Concentrations", "documentation": "Disclosure of](#)
[accounting policy for credit risk." } } \], "auth_ref": \["r83", "r199" \] }, "us-](#)
[gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri":](#)
["http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1",](#)
["presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica](#)
[l, "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel":](#)
["Concentration risk percentage", "documentation": "For an entity that discloses a](#)
[concentration risk in relation to quantitative amount, which serves as the](#)
[\\["benchmark\\]" \(or denominator\) in the equation, this concept represents the](#)
[concentration percentage derived from the division." } } \], "auth_ref": \["r43", "r44",](#)
["r80", "r81", "r361" \] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype":](#)
["domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["ConcentrationRiskTypeDomain", "presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica](#)
[l, "lang": { "en-us": { "role": { "label": "Concentration Risk Type \[Domain\]",](#)
["terseLabel": "Concentration Risk Type", "documentation": "For an entity that discloses](#)
[a concentration risk as a percentage of some financial balance or benchmark,](#)
[identifies the type \(for example, asset, liability, net assets, geographic, customer,](#)
[employees, supplier, lender\) of the concentration." } } \], "auth_ref": \["r43", "r44",](#)
["r80", "r81", "r361", "r995" \] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype":](#)
["textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["ConsolidationPolicyTextBlock", "presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica](#)
[l, "lang": { "en-us": { "role": { "label": "Consolidation, Policy \[Policy Text Block\]",](#)
["terseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting](#)
[policy regarding \(1\) the principles it follows in consolidating or combining the](#)
[separate financial statements, including the principles followed in determining the](#)
[inclusion or exclusion of subsidiaries or other entities in the consolidated or combined](#)
[financial statements and \(2\) its treatment of interests \(for example, common stock, a](#)
[partnership interest or other means of exerting influence\) in other entities, for](#)
[example consolidation or use of the equity or cost methods of accounting. The](#)
[accounting policy may also address the accounting treatment for intercompany](#)
[accounts and transactions, noncontrolling interest, and the income statement](#)
[treatment in consolidation for issuances of stock by a subsidiary." } } \], "auth_ref": \[](#)
["r76", "r1021" \] }, "us-gaap_ConstructionInProgressGross": { "xbrltype":](#)
["monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["ConstructionInProgressGross", "crdr": "debit", "presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq](#)
[l, "lang": { "en-us": { "role": { "label": "Construction in Progress, Gross", "terseLabel":](#)
["Construction in progress", "documentation": "Amount of structure or a modification](#)
[to a structure under construction. Includes recently completed structures or](#)
[modifications to structures that have not been placed into service." } } \], "auth_ref": \[](#)
["r155" \] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType",](#)
["nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["ConstructionInProgressMember", "presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq](#)
[l, "lang": { "en-us": { "role": { "label": "Construction in Progress \[Member\]",](#)
["terseLabel": "Construction in Progress", "documentation": "Structure or a](#)
[modification to a structure under construction. Includes recently completed structures](#)
[or modifications to structures that have not been placed into service." } } \], "auth_ref":](#)
[\[\] }, "alks_ContingentConsiderationPolicyTextBlock": { "xbrltype":](#)
["textBlockItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":](#)
["ContingentConsiderationPolicyTextBlock", "presentation": {](#)

http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for
 the Contingent consideration", "label": "Contingent Consideration Policy [Text Block]",
 "terseLabel": "Contingent Consideration" } } }, "auth_ref": [] },
 "alks_ContractAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "ContractAssetsPolicyPolicyTextBlock", "presentation": [
http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "documentation": "Contract assets policy.", "label":
 "Contract Assets Policy Policy [Text Block]", "terseLabel": "Contract Assets" } } },
 "auth_ref": [] }, "alks_ContractLiabilitiesMember": { "xbrltype": "domainItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "ContractLiabilitiesMember", "presentation": [
http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "documentation": "Contract liabilities.", "label":
 "Contract Liabilities [Member]", "terseLabel": "Contract liabilities\u2013short-term" }
 } }, "auth_ref": [] }, "alks_ContractLiabilitiesPolicyPolicyTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "ContractLiabilitiesPolicyPolicyTextBlock", "presentation": [
http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "documentation": "Contract liabilities policy.", "label":
 "Contract Liabilities Policy Policy [Text Block]", "terseLabel": "Contract Liabilities" } }
 }, "auth_ref": [] }, "us-
 gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "crdr": "credit",
 "presentation": [
http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, Allowance for
 Credit Loss", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning
 balance", "terseLabel": "Allowance for doubtful accounts", "documentation": "Amount
 of allowance for credit loss for right to consideration in exchange for good or service
 transferred to customer when right is conditioned on something other than passage of
 time." } } }, "auth_ref": ["r403", "r407", "r408", "r504"] }, "us-
 gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock", "presentation":
 [
http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provisions for Sales and
 Allowances", "label": "Contract with Customer, Asset, Allowance for Credit Loss [Table
 Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on right
 to consideration in exchange for good or service transferred to customer when right is
 conditioned on something other than passage of time." } } }, "auth_ref": ["r1289"] },
 "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [
http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset,
 Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of
 Contract Assets and Contract Liabilities", "documentation": "Tabular disclosure of
 receivable, contract asset, and contract liability from contract with customer. Includes,
 but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [
 "r1323"] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [
http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Asset, after

Allowance for Credit Loss, Total", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Contract assets", "periodStartLabel": "Contract assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r502", "r504", "r523"] }, "us-gaap_ContractWithCustomerAssetNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici", "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]", "terseLabel": "Contract Asset [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract assets", "verboseLabel": "Contract assets, current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": ["r502", "r504", "r523"] }, "us-gaap_ContractWithCustomerAssetPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetPurchase", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici", "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Contract with Customer, Asset, Purchase", "documentation": "Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time." } } }, "auth_ref": ["r405"] }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici", "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, Reclassified to Receivable", "negatedLabel": "Transferred to receivables, net", "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional." } } }, "auth_ref": ["r1048"] }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerBasisOfPricingAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "label": "Contract with Customer, Basis of Pricing [Axis]", "terseLabel": "Contract with Customer, Basis of Pricing", "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer." } } }, "auth_ref": ["r1052", "r1324"] }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerBasisOfPricingDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "label": "Contract with Customer, Basis of Pricing [Domain]", "terseLabel": "Contract with Customer, Basis of Pricing", "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts." } } }, "auth_ref": ["r1052", "r1324"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri":

["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [
 ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "totalLabel": "Contract with Customer, Liability, Total", "label": "Contract with Customer, Liability", "periodEndLabel": "Contract liabilities at end of the period", "periodStartLabel": "Contract liabilities at beginning of the period", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r502", "r503", "r523"], "us-gaap_ContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityAbstract", "presentation": [
 ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Contract Liabilities [Abstract]" } } }, "auth_ref": [] },
 "alks_ContractWithCustomerLiabilityAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ContractWithCustomerLiabilityAdditions", "crdr": "credit", "presentation": [
 ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
], "lang": { "en-us": { "role": { "documentation": "Amount of increase in contract with customer liability during the period.", "label": "Contract With Customer Liability Additions", "terseLabel": "Additions" } } }, "auth_ref": [] },
 "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [
 ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL](http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL)
], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilitiesu2014short-term", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r502", "r503", "r523"],
 "alks_ContractWithCustomerLiabilityOtherExpenseIncomeNetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ContractWithCustomerLiabilityOtherExpenseIncomeNetRecognized", "crdr": "credit", "presentation": [
 ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
], "lang": { "en-us": { "role": { "terseLabel": "Amounts recognized into other (expense) income, net", "documentation": "Contract with customer liability other (expense) income net recognized.", "label": "Contract With Customer Liability Other (Expense) Income Net Recognized" } } }, "auth_ref": [] },
 "alks_ContractWithCustomerLiabilityRecognizedThroughOtherExpenseIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ContractWithCustomerLiabilityRecognizedThroughOtherExpenseIncomeNet", "crdr": "credit", "presentation": [
 ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional)
], "lang": { "en-us": { "role": { "terseLabel": "Net amounts written off into other (expense) income, net", "documentation": "Contract with customer liability recognized through other expense income net.", "label": "Contract With Customer Liability Recognized Through Other Expense Income Net", "verboseLabel": "Net amounts write off within other income (expense), net" } } }, "auth_ref": [] },
 "alks_ContractWithCustomerLiabilityReductions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ContractWithCustomerLiabilityReductions", "crdr": "debit", "presentation": [
 ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
], "lang": { "en-us": { "role": { "negatedLabel": "Reductions", "label": "Contract with Customer Liability Reductions", "documentation": "Contract with customer liability reductions." } } }, "auth_ref": [] },
 "us-

gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica", "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Amounts recognized into revenue", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": { "r524" } } },
"alks_ContractualAdjustmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ContractualAdjustmentsMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "lang": { "en-us": { "role": { "terseLabel": "Contractual Adjustments", "label": "Contractual Adjustments [Member]", "documentation": "Contractual Adjustments." } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAddition", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": { "r1056", "r1058", "r1070", "r1084", "r1100", "r1490" } }, "alks_CorporateMinimumTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "CorporateMinimumTaxRate", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAddition", "lang": { "en-us": { "role": { "label": "Corporate Minimum Tax Rate", "documentation": "Corporate minimum tax rate." }, "terseLabel": "Corporate minimum tax rate" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummary", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6", "lang": { "en-us": { "role": { "totalLabel": "Cost of Goods and Services Sold, Total", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": { "r130", "r131", "r807" } }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperations5", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensation", "lang": { "en-us": { "role": { "verboseLabel": "Cost of goods manufactured", "label": "Cost of Sales [Member]", "terseLabel": "Cost of goods manufactured and sold", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6", "lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": { "r136" } }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"CostsAndExpensesAbstract", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
"http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
l, "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel":
"EXPENSES:" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"CounterpartyNameAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr
l, "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel":
"Counterparty Name", "documentation": "Information by name of counterparty. A
counterparty is the other party that participates in a financial transaction. Examples
include, but not limited to, the name of the financial institution." } } }, "auth_ref": {
"r235", "r236", "r290", "r291", "r471", "r489", "r769", "r787", "r852", "r1018", "r1020"
} }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role":
{ "terseLabel": "Cover", "label": "Cover [Abstract]", "documentation": "Cover page." } }
}, "auth_ref": [] }, "alks_CraigHopkinsonMDMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.alkermes.com/20241231", "localname":
"CraigHopkinsonMDMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role":
{ "documentation": "Craig Hopkinson M.D.", "label": "Craig Hopkinson M D
[Member]", "terseLabel": "Craig Hopkinson, M.D [Member]" } } }, "auth_ref": [] }, "us-
gaap_CreditConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CreditConcentrationRiskMember",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l, "lang": { "en-us": { "role": { "label": "Credit Concentration Risk [Member]",
"terseLabel": "Credit Concentration Risk", "documentation": "Reflects the percentage
that a specified receivable or amount at risk from a counterparty under a contractual
arrangement is to a specified benchmark, such as total receivables, net revenues,
pretax results. Risk is the materially adverse effects of loss attributable to (a) the
failure to collect a significant receivable from a major customer or group of
homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a
contractual arrangement." } } }, "auth_ref": ["r167"] }, "us-
gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit",
"crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfI
l, "lang": { "en-us": { "role": { "label": "Current Federal Tax Expense (Benefit)",
"terseLabel": "U.S. federal", "documentation": "Amount of current federal tax expense
(benefit) attributable to income (loss) from continuing operations. Includes, but is not
limited to, current national tax expense (benefit) for non-US (United States of America)
jurisdiction." } } }, "auth_ref": ["r1232", "r1255", "r1430"] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
l, "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "verboseLabel":
"Current Fiscal Year End Date", "documentation": "End date of current fiscal year in
the format --MM-DD." } } }, "auth_ref": [] }, "us-
gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit",
"crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfI
l, "lang": { "en-us": { "role": { "label": "Current Foreign Tax Expense (Benefit)",
"terseLabel": "Rest of world", "verboseLabel": "Ireland", "documentation": "Amount of
current foreign income tax expense (benefit) pertaining to income (loss) from

continuing operations." } }], "auth_ref": ["r1232", "r1255"]], "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current income tax provision (benefit) : " } }], "auth_ref": [] },
 "alks_CurrentProvisionsRelatingToSalesInCurrentYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "CurrentProvisionsRelatingToSalesInCurrentYear", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "lang": { "en-us": { "role": { "terseLabel": "Current provisions relating to sales in current year", "label": "Current Provisions Relating To Sales In Current Year", "documentation": "Current provisions relating to sales in current year." } }], "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "lang": { "en-us": { "role": { "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "U.S. state", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } }], "auth_ref": ["r1232", "r1255", "r1430"] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } }], "auth_ref": ["r147", "r361"] },
 "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } }], "auth_ref": ["r1126", "r1215"] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } }], "auth_ref": ["r1126", "r1215"] },
 "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } }], "auth_ref": ["r1128", "r1217"] },
 "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",

"presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag
 }, "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or
 Committees Responsible [Flag]" } } }, "auth_ref": { "r1128", "r1217" } },
 "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardI
 { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
 "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag
 }, "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or
 Committees Responsible Report to Board [Flag]" } } }, "auth_ref": { "r1130", "r1219"
 }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock":
 { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
 "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag
 }, "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or
 Committees Responsible [Text Block]" } } }, "auth_ref": { "r1128", "r1217" } },
 "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThr
 { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
 "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreats"
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag
 }, "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for
 Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": { "r1121",
 "r1210" } }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
 "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
 "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag
 }, "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes
 Integrated [Flag]" } } }, "auth_ref": { "r1122", "r1211" } },
 "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
 "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag
 }, "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes
 Integrated [Text Block]" } } }, "auth_ref": { "r1122", "r1211" } },
 "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
 "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": {
 "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance
 [Abstract]" } } }, "auth_ref": { "r1120", "r1209" } },
 "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype":
 "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
 "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag
 }, "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and
 Governance [Line Items]" } } }, "auth_ref": { "r1120", "r1209" } },
 "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype":
 "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
 "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag
 }, "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and
 Governance [Table]" } } }, "auth_ref": { "r1120", "r1209" } },
 "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype":
 "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
 "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManag

], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": ["r1123", "r1212"] },
 "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrant": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementThirdPartyEngagedOrReasonablyLikelyToMateriallyAffectRegistrant [Flag]"] }, "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": ["r1125", "r1214"] },
 "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementThirdPartyEngagedOrReasonablyLikelyToMateriallyAffectRegistrant [Text Block]"] }, "auth_ref": ["r1125", "r1214"] },
 "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversight": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversight", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementThirdPartyEngagedOrReasonablyLikelyToMateriallyAffectRegistrant [Text Block]"] }, "auth_ref": ["r1126", "r1215"] },
 "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementThirdPartyEngagedOrReasonablyLikelyToMateriallyAffectRegistrant [Text Block]"] }, "auth_ref": ["r1129", "r1218"] },
 "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementThirdPartyEngagedOrReasonablyLikelyToMateriallyAffectRegistrant [Text Block]"] }, "auth_ref": ["r1127", "r1216"] },
 "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementThirdPartyOversightAndIdentificationProcesses [Flag]"] }, "auth_ref": ["r1124", "r1213"] },
 "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] },
 "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddition [Text Block]"] }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate added to base rate (as a percent)", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] },
 "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "xbrltype": "stringItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtInstrumentDescriptionOfVariableRateBasis", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi
 l", "lang": { "en-us": { "role": { "label": "Debt Instrument, Description of Variable Rate
 Basis", "terseLabel": "Variable interest rate base", "documentation": "Description of
 reference rate used for variable rate of debt instrument." } } }, "auth_ref": { } }, "us-
 gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr":
 "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional
 l", "lang": { "en-us": { "role": { "totalLabel": "Debt Instrument, Fair Value Disclosure,
 Total", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Amount to be
 realized in future", "documentation": "Fair value portion of debt instrument payable,
 including, but not limited to, notes payable and loans payable." } } }, "auth_ref": {
 "r476", "r740", "r1043", "r1044", "r1434", "r1435", "r1436", "r1437", "r1438" } },
 "alks_DebtInstrumentIncrementalCapacitySubjectToSatisfactionOfCertainConditions":
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname":
 "DebtInstrumentIncrementalCapacitySubjectToSatisfactionOfCertainConditions",
 "crdr": "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi
 l", "lang": { "en-us": { "role": { "documentation": "Represents the amount of
 incremental capacity available so long as the entity meets certain conditions.", "label":
 "Debt Instrument Incremental Capacity Subject To Satisfaction Of Certain Conditions",
 "terseLabel": "Incremental capacity" } } }, "auth_ref": { } }, "us-
 gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche
 l", "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel":
 "Long-term debt", "documentation": "Line items represent financial concepts included
 in a table. These concepts are used to disclose reportable information associated with
 domain members defined in one or many axes to the table." } } }, "auth_ref": { "r292",
 "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478",
 "r479", "r480", "r481", "r482", "r483", "r484", "r1042", "r1043", "r1044", "r1045",
 "r1046", "r1081", "r1253", "r1441", "r1442" } }, "us-
 gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi
 l", "lang": { "en-us": { "role": { "terseLabel": "Due date of loan", "label": "Debt
 Instrument, Maturity Date", "documentation": "Date when the debt instrument is
 scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": { "r257",
 "r1042", "r1436", "r1437" } }, "us-gaap_DebtInstrumentTable": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtInstrumentTable", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche
 l", "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments
 [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of
 information about long-term debt instrument or arrangement." } } }, "auth_ref": {
 "r25", "r58", "r59", "r82", "r161", "r162", "r292", "r468", "r469", "r470", "r471", "r472",
 "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483",
 "r484", "r1042", "r1043", "r1044", "r1045", "r1046", "r1081", "r1253", "r1441", "r1442"
 } }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {

"xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi
 l, "lang": { "en-us": { "role": { "label": "Debt Instrument, Variable Interest Rate, Type
 [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate
 on debt instrument." } } }, "auth_ref": { "r851" } },
 "alks_DebtInstrumentVariableRateBasisFloor": { "xbrltype": "percentItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "DebtInstrumentVariableRateBasisFloor", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi
 l, "lang": { "en-us": { "role": { "documentation": "The floor for the variable rate base of
 the debt instrument.", "label": "Debt Instrument Variable Rate Basis Floor",
 "terseLabel": "Interest rate, variable interest rate floor (as a percent)" } } }, "auth_ref":
 { } }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
 l, "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized
 Cost, Current", "totalLabel": "Short-term investments, Amortized Cost",
 "documentation": "Amortized cost of investment in debt security measured at fair value
 with change in fair value recognized in other comprehensive income (available-for-
 sale), classified as current." } } }, "auth_ref": { "r412", "r1275" } }, "us-
 gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
 l, "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized
 Cost, Noncurrent", "totalLabel": "Long-term investments, Amortized Cost",
 "documentation": "Amortized cost of investment in debt security measured at fair value
 with change in fair value recognized in other comprehensive income (available-for-
 sale), classified as noncurrent." } } }, "auth_ref": { "r412", "r1275" } }, "us-
 gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowance
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForC
 "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
 l, "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale and Held-to-
 Maturity, Amortized Cost, before Allowance for Credit Loss", "terseLabel": "Amortized
 Cost", "totalLabel": "Amortized Cost", "documentation": "Amortized cost, before
 allowance for credit loss, of investment in debt security measured at amortized cost
 (held-to-maturity) and investment in debt security measured at fair value with change
 in fair value recognized in other comprehensive income (available-for-sale)." } } },
 "auth_ref": { "r1275", "r1280" } }, "us-
 gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain":
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain",
 "crdr": "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
 l, "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale and Held-to-
 Maturity, Cumulative Unrecognized Gain", "terseLabel": "Gross Unrealized Gains",
 "documentation": "Amount of cumulative unrecognized gain on investment in debt
 security measured at amortized cost (held-to-maturity) and investment in debt security
 measured at fair value with change in fair value recognized in other comprehensive
 income (available-for-sale)." } } }, "auth_ref": { "r1277", "r1282" } }, "us-
 gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, Fair Value", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r1276", "r1281" } }, "us-
gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedLabel": "Gross Unrealized Losses greater than one year", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": { "r189", "r416" } }, "us-
gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses less than one year", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": { "r189", "r416" } }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAddition", "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Aggregate estimated fair value of investments in unrealized loss position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": { "r187", "r414", "r1039" } }, "us-
gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAddition", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of investment securities in an unrealized loss position", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }

], "auth_ref": ["r188", "r415"]], "us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesHeldToMaturityFairValueNoncurrent", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Fair Value, Noncurrent", "terseLabel": "Estimated Fair Value", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent." } } }, "auth_ref": ["r1243"]], "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "lang": { "en-us": { "role": { "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "U.S. federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r1255", "r1429", "r1430"]], "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "lang": { "en-us": { "role": { "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Ireland", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r1255", "r1429"]], "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "DEFERRED TAX ASSETS", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r653", "r654"]], "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "totalLabel": "Deferred Income Tax Expense (Benefit), Total", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r10", "r205", "r1255"]], "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred income tax provision (benefit):" } } }, "auth_ref": []], "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "lang": { "en-us": { "role": { "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "U.S. state", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [

"r1255", "r1429", "r1430"] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Deferred Tax Asset, In-Process Research and Development", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both." } } }, "auth_ref": { "r1427"] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": { "r1422"] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": { "r1422"] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetAbstract", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "auth_ref": [] }, "alks_DeferredTaxAssetsOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Deferred Tax Assets Operating Lease Liabilities", "documentation": "Deferred tax assets, operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": { "r1427"] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "terseLabel": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": { "r1427"] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
 l", "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Tax Credit
 Carryforwards, Total", "label": "Deferred Tax Assets, Tax Credit Carryforwards",
 "terseLabel": "Tax credits", "documentation": "Amount, before allocation of a valuation
 allowances, of deferred tax assets attributable to deductible tax credit carryforwards
 including, but not limited to, research, foreign, general business, alternative minimum
 tax, and other deductible tax credit carryforwards." } } }, "auth_ref": ["r1427"] }, "us-
 gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
 l", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards,
 Research", "terseLabel": "Federal research and development credits", "documentation":
 "Amount before allocation of valuation allowances of deferred tax asset attributable to
 deductible research tax credit carryforwards." } } }, "auth_ref": ["r1427"] },
 "alks_DeferredTaxAssetsTaxCreditCarryforwardsState": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "DeferredTaxAssetsTaxCreditCarryforwardsState", "crdr": "debit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
 l", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation
 allowances of deferred tax asset attributable to deductible state tax credit
 carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards State",
 "terseLabel": "State tax credits" } } }, "auth_ref": [] }, "us-
 gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCom
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensi
 "crdr": "debit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
 l", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense,
 Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Share-
 based compensation", "documentation": "Amount before allocation of valuation
 allowances of deferred tax asset attributable to deductible temporary differences from
 share-based compensation." } } }, "auth_ref": ["r1427"] }, "us-
 gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities":
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
 "crdr": "debit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
 l", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense,
 Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued expenses and
 reserves", "documentation": "Amount before allocation of valuation allowances of
 deferred tax asset attributable to deductible temporary differences from accrued
 liabilities." } } }, "auth_ref": ["r1427"] }, "us-
 gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
 l", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance",
 "terseLabel": "Valuation allowance", "negatedLabel": "Less: valuation allowance",
 "negatedPeriodEndLabel": "Balance at End of Period", "negatedPeriodStartLabel":
 "Balance at Beginning of Period", "documentation": "Amount of deferred tax assets for
 which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref":
 ["r673"] }, "alks_DeferredTaxAssetsValuationAllowanceReleased": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":

"DeferredTaxAssetsValuationAllowanceReleased", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
l", "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance released", "label":
"Deferred Tax Assets, Valuation Allowance Released", "documentation": "Deferred tax
assets, valuation allowance released." } } }, "auth_ref": [] }, "us-
gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
l", "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Liabilities, Net, Total",
"label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Total deferred tax
liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability
attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": {
"r1422" } }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesAbstract",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
l", "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]",
"terseLabel": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "us-
gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
l", "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Leasing
Arrangements", "negatedLabel": "Right-of-use assets", "documentation": "Amount of
deferred tax liability attributable to taxable temporary differences from leasing
arrangements." } } }, "auth_ref": { "r1427" } }, "us-gaap_DeferredTaxLiabilitiesOther":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxLiabilitiesOther", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
l", "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Other",
"negatedLabel": "Other", "documentation": "Amount of deferred tax liability
attributable to taxable temporary differences classified as other." } } }, "auth_ref": {
"r1427" } }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
l", "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Property, Plant and
Equipment", "negatedLabel": "Property, plant and equipment", "documentation":
"Amount of deferred tax liability attributable to taxable temporary differences from
property, plant, and equipment." } } }, "auth_ref": { "r1427" } },
"alks_DefinedContributionPlanAnnualContributionByPerEmployeeAmount": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname": "DefinedContributionPlanAnnualContributionByPerEmployeeAmount",
"crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l", "lang": { "en-us": { "role": { "documentation": "Maximum amount per employee, by
the terms of the plan, that the employee may contribute to a defined contribution
plan.", "label": "Defined Contribution Plan Annual Contribution By Per Employee
Amount", "terseLabel": "Per employee contribution limit" } } }, "auth_ref": [] }, "us-
gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l", "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost", "terseLabel":
"Employer contribution", "documentation": "Amount of cost for defined contribution
plan." } } }, "auth_ref": { "r587" } },
"alks_DefinedContributionPlanEmployeeContributionLimitAsPercentageOfCompensatio

{ "xbrltype": "percentItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname":
 "DefinedContributionPlanEmployeeContributionLimitAsPercentageOfCompensation",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 }, "lang": { "en-us": { "role": { "documentation": "The limit of annual employee
 contributions to the plan, as a percentage of compensation.", "label": "Defined
 Contribution Plan Employee Contribution Limit As Percentage Of Compensation",
 "terseLabel": "Employee contribution limit as a percentage of their eligible
 compensation" } } }, "auth_ref": [] }, "us-
 gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype":
 "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 }, "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching
 Contribution, Percent of Employees' Gross Pay", "terseLabel": "Percentage of employer
 contribution matched of the first employee pay", "documentation": "Percentage of
 employees' gross pay for which the employer contributes a matching contribution to a
 defined contribution plan." } } }, "auth_ref": [] }, "us-
 gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
 "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 }, "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Maximum Annual
 Contributions Per Employee, Percent", "terseLabel": "Maximum percentage of
 employer contribution matched of employee's", "documentation": "Maximum
 percentage of employee gross pay the employee may contribute to a defined
 contribution plan." } } }, "auth_ref": [] },
 "alks_DefinedContributionPlanMaximumEmployeeContributionLimitAsPercentageOfTax
 { "xbrltype": "percentItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname":
 "DefinedContributionPlanMaximumEmployeeContributionLimitAsPercentageOfTaxable
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 }, "lang": { "en-us": { "role": { "documentation": "The limit of annual employee
 contributions to the plan, as a percentage of their total taxable earnings.", "label":
 "Defined Contribution Plan Maximum Employee Contribution Limit As Percentage Of
 Taxable Earnings", "terseLabel": "Maximum employee contribution limit as a
 percentage of their total taxable earnings" } } }, "auth_ref": [] }, "us-
 gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
 }, "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "label":
 "Depreciation", "terseLabel": "Depreciation expense", "documentation": "The amount
 of expense recognized in the current period that reflects the allocation of the cost of
 tangible assets over the assets' useful lives. Includes production and non-production
 related depreciation." } } }, "auth_ref": ["r10", "r53"] }, "us-
 gaap_DepreciationAndAmortizationDiscontinuedOperations": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DepreciationAndAmortizationDiscontinuedOperations", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 }, "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation and
 Amortization, Discontinued Operations", "documentation": "Amount of deprecation and
 amortization expense attributable to property, plant and equipment and intangible
 assets of discontinued operations." } } }, "auth_ref": ["r242", "r1251"] }, "us-
 gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization,
 Total", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation
 and amortization", "documentation": "The aggregate expense recognized in the current
 period that allocates the cost of tangible assets, intangible assets, or depleting assets
 to periods that benefit from use of the assets." } } }, "auth_ref": ["r10", "r326", "r337",
 "r353", "r1032", "r1033"] },
 "alks_DepreciationInternalResearchAndDevelopmentExpenses": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "DepreciationInternalResearchAndDevelopmentExpenses", "crdr": "debit",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
], "lang": { "en-us": { "role": { "label": "Depreciation internal research and
 development expenses", "documentation": "Depreciation internal research and
 development expenses.", "terseLabel": "Depreciation" } } }, "auth_ref": [] },
 "alks_DevelopmentProgramsAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname": "DevelopmentProgramsAbstract",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
], "lang": { "en-us": { "role": { "label": "Development Programs [Abstract]",
 "documentation": "Development programs.", "terseLabel": "Development programs:" }
] }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisaggregationOfRevenueAbstract", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]",
 "terseLabel": "REVENUES:" } } }, "auth_ref": [] }, "us-
 gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]",
 "terseLabel": "Disaggregation Of Revenue [Line Items]", "documentation": "Line items
 represent financial concepts included in a table. These concepts are used to disclose
 reportable information associated with domain members defined in one or many axes
 to the table." } } }, "auth_ref": ["r522", "r1049", "r1050", "r1051", "r1052", "r1053",
 "r1054", "r1055"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisaggregationOfRevenueTable", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]",
 "terseLabel": "Disaggregation Of Revenue [Table]", "documentation": "Disclosure of
 information about disaggregation of revenue into categories depicting how nature,
 amount, timing, and uncertainty of revenue and cash flows are affected by economic
 factor." } } }, "auth_ref": ["r522", "r1049", "r1050", "r1051", "r1052", "r1053",
 "r1054", "r1055"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisaggregationOfRevenueTableTextBlock", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]",
 "terseLabel": "Schedule of Disaggregation of Revenues", "documentation": "Tabular

disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } }
}, "auth_ref": ["r1324"] }, "us-
gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text
Block]", "terseLabel": "Share-based Compensation", "documentation": "The entire
disclosure for share-based payment arrangement." } } }, "auth_ref": ["r597", "r601",
"r633", "r634", "r637", "r1062"] }, "us-
gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-
us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } },
"auth_ref": [] }, "alks_DiscontinuedOperationAgreementDate": { "xbrltype":
"dateItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"DiscontinuedOperationAgreementDate", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsA
l, "lang": { "en-us": { "role": { "terseLabel": "Discontinued operation agreement date",
"label": "Discontinued Operation Agreement Date", "documentation": "Discontinued
operation agreement date." } } }, "auth_ref": [] }, "us-
gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasic:
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
l, "lang": { "en-us": { "role": { "terseLabel": "Discontinuing Operations - Basic", "label":
"Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per
Basic Share", "verboseLabel": "Loss per ordinary share from discontinued operations-
basic", "documentation": "Per basic share amount, after tax, of income (loss) from the
day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-
gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilute
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedSha
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
l, "lang": { "en-us": { "role": { "terseLabel": "Discontinuing Operations - Diluted",
"label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of
Tax, Per Diluted Share", "verboseLabel": "Loss per ordinary share from discontinued
operations - diluted", "documentation": "Per diluted share amount, after tax, of income
(loss) from the day-to-day business activities of the discontinued operation." } } },
"auth_ref": [] }, "us-
gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "presentation":
{
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsA
l, "lang": { "en-us": { "role": { "terseLabel": "Service agreement term", "label":
"Discontinued Operation, Period of Continuing Involvement after Disposal",
"documentation": "Period of expected continuing involvement with a discontinued
operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example,
'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } }
}, "auth_ref": ["r98"] }, "us-
gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": {

"label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": []
 }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DiscontinuedOperationsHeldforsaleMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill",
 "lang": { "en-us": { "role": { "terseLabel": "Assets Held for Sale", "label":
 "Discontinued Operations, Held-for-Sale [Member]", "documentation": "Component or
 group of components representing strategic shift that has or will have major effect on
 operation and financial result and business and nonprofit activity on acquisition and
 upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": ["r7", "r8",
 "r243"] }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DiscontinuedOperationsPolicyTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
 "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label":
 "Discontinued Operations, Policy [Policy Text Block]", "documentation": "Disclosure of
 accounting policy for discontinued operations. Includes, but is not limited to, method
 of interest allocation to a discontinued operation." } } }, "auth_ref": ["r14", "r27"] },
 "alks_DiscountsMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname": "DiscountsMember",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
 "lang": { "en-us": { "role": { "label": "Discounts [Member]", "documentation":
 "Discounts.", "terseLabel": "Discounts" } } }, "auth_ref": [] }, "us-
 gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill",
 "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]",
 "documentation": "Information by disposal group classification." } } }, "auth_ref": [
 "r243"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisposalGroupClassificationDomain", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill",
 "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]",
 "documentation": "Component or group of components disposed of, including but not
 limited to, disposal group held-for-sale or disposed of by sale, disposed of by means
 other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-
 gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities",
 "crdr": "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsSummary",
 "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses",
 "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and
 Accrued Liabilities, Current", "totalLabel": "Disposal Group, Including Discontinued
 Operation, Accounts Payable and Accrued Liabilities, Current, Total", "documentation":
 "Amount classified as accounts payable and accrued liabilities attributable to disposal
 group held for sale or disposed of, expected to be disposed of within one year or the
 normal operating cycle, if longer." } } }, "auth_ref": ["r1", "r86", "r103", "r154", "r156"
] }, "alks_DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet",
 "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsSummary",
 "lang": { "en-us": { "role": { "totalLabel": "Net assets transferred to Mural", "label":
 "Disposal Group Including Discontinued Operation Assets and Liabilities Net",
 "documentation": "Disposal group including discontinued operation assets and

liabilities net." } }], "auth_ref": [] }, "us-
 gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 t", "lang": { "en-us": { "role": { "verboseLabel": "Assets related to discontinued
 operations", "terseLabel": "ASSETS RELATED TO DISCONTINUED OPERATIONS-
 LONG-TERM", "label": "Disposal Group, Including Discontinued Operation, Assets,
 Noncurrent", "totalLabel": "Disposal Group, Including Discontinued Operation, Assets,
 Noncurrent, Total", "documentation": "Amount classified as assets attributable to
 disposal group held for sale or disposed of, expected to be disposed of after one year or
 the normal operating cycle, if longer." } } }, "auth_ref": ["r1", "r3", "r86", "r103",
 "r156", "r243", "r244"] }, "us-
 gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr":
 "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 l", "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label":
 "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
 "documentation": "Amount classified as cash and cash equivalents attributable to
 disposal group held for sale or disposed of." } } }, "auth_ref": ["r1", "r86", "r103",
 "r156"] }, "us-
 gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 l", "lang": { "en-us": { "role": { "verboseLabel": "DEFERRED TAX ASSET", "terseLabel":
 "Deferred tax asset", "label": "Disposal Group, Including Discontinued Operation,
 Deferred Tax Assets", "documentation": "Amount classified as deferred tax assets
 attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r1",
 "r86", "r103", "r156"] }, "us-
 gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 l", "lang": { "en-us": { "role": { "verboseLabel": "GOODWILL", "terseLabel": "Goodwill",
 "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent",
 "documentation": "Amount classified as goodwill attributable to disposal group held
 for sale or disposed of, expected to be disposed of after one year or the normal
 operating cycle, if longer." } } }, "auth_ref": ["r1", "r3", "r86", "r103", "r156"] },
 "alks_DisposalGroupIncludingDiscontinuedOperationIncomeTaxProvisionBenefit": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname":
 "DisposalGroupIncludingDiscontinuedOperationIncomeTaxProvisionBenefit", "crdr":
 "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 l", "lang": { "en-us": { "role": { "terseLabel": "Income tax benefit from discontinued
 operations", "label": "Disposal Group Including Discontinued Operation Income Tax
 Provision (Benefit)", "documentation": "Disposal group including discontinued
 operation income tax provision (benefit)." } } }, "auth_ref": [] }, "us-
 gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
l, "lang": { "en-us": { "role": { "terseLabel": "Total operating expenses from
discontinued operations", "label": "Disposal Group, Including Discontinued Operation,
Operating Expense", "documentation": "Amount of operating expense attributable to
disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref":
{ "r102" } }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr":
"credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
l, "lang": { "en-us": { "role": { "totalLabel": "Disposal Group, Including Discontinued
Operation, Operating Income (Loss), Total", "terseLabel": "Operating loss from
discontinued operations", "label": "Disposal Group, Including Discontinued Operation,
Operating Income (Loss)", "documentation": "Amount of operating income (loss)
attributable to disposal group, including, but not limited to, discontinued operation." } }
} }, "auth_ref": { "r102" } },
"alks_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent"
{ "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent",
"crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
l, "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities-short-term",
"label": "Disposal Group Including Discontinued Operation Operating Lease Liabilities
Current", "documentation": "Disposal group including discontinued operation
operating lease liabilities current." } } }, "auth_ref": { } },
"alks_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNonCurr
{ "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNonCurrent",
"crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
l, "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities-long-term",
"verboseLabel": "OPERATING LEASE LIABILITIES-LONG-TERM", "label": "Disposal
Group Including Discontinued Operation Operating Lease Liabilities Non-current",
"documentation": "Disposal group including discontinued operation operating lease
liabilities non-current." } } }, "auth_ref": { } }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
"crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
l, "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current
assets", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other
Assets, Current", "documentation": "Amount classified as prepaid and other assets
attributable to disposal group held for sale or disposed of, expected to be disposed of
within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r1", "r86",
"r103", "r154", "r156" } }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncu
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurren
"crdr": "debit", "presentation": {

["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS](http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS)
["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS](http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS)
], "lang": { "en-us": { "role": { "verboseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET", "terseLabel": "Property, plant and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1", "r3", "r86", "r103", "r156"] }, "alks_DisposalGroupIncludingDiscontinuedOperationRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationRightOfUseAssets", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "lang": { "en-us": { "role": { "verboseLabel": "RIGHT-OF-USE ASSETS", "terseLabel": "Right-of-use assets", "label": "Disposal Group Including Discontinued Operation Right Of Use Assets", "documentation": "Disposal group including discontinued operation right of use assets." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn", "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of assets", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": ["r449", "r1251", "r1307"] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncome": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExter", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn", "lang": { "en-us": { "role": { "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation." } } }, "auth_ref": ["r450"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperations", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r85", "r152"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGood", "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r1059", "r1060"] }, "alks_DistributionOfBusiness": { "xbrltype": "monetaryItemType", "nsuri":

["http://www.alkermes.com/20241231"](http://www.alkermes.com/20241231), "localname": "DistributionOfBusiness", "crdr":
 "debit", "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA](http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA)
 l, "lang": { "en-us": { "role": { "negatedLabel": "Distribution of Mural Oncology plc",
 "label": "Distribution of Business", "documentation": "Distribution of Business" } } },
 "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType",
 "nsuri": "<http://xbrl.sec.gov/dei/2024>", "localname": "DocumentAnnualReport",
 "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity](http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity)
 l, "lang": { "en-us": { "role": { "label": "Document Annual Report", "terseLabel":
 "Document Annual Report", "documentation": "Boolean flag that is true only for a form
 used as an annual report." } } }, "auth_ref": ["r1117", "r1118", "r1141"] },
 "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri":
 "<http://xbrl.sec.gov/dei/2024>", "localname": "DocumentFinStmtErrorCorrectionFlag",
 "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity](http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity)
 l, "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error
 Correction", "label": "Document Financial Statement Error Correction [Flag]",
 "documentation": "Indicates whether any of the financial statement period in the filing
 include a restatement due to error correction." } } }, "auth_ref": ["r1117", "r1118",
 "r1141", "r1184"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype":
 "fiscalPeriodItemType", "nsuri": "<http://xbrl.sec.gov/dei/2024>", "localname":
 "DocumentFiscalPeriodFocus", "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity](http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity)
 l, "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel":
 "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1,
 Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and
 Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } },
 "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType",
 "nsuri": "<http://xbrl.sec.gov/dei/2024>", "localname": "DocumentFiscalYearFocus",
 "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity](http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity)
 l, "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel":
 "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the
 document report in YYYY format. For a 2006 annual report, which may also provide
 financial information from prior periods, fiscal 2006 should be given as the fiscal year
 focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": {
 "xbrltype": "dateItemType", "nsuri": "<http://xbrl.sec.gov/dei/2024>", "localname":
 "DocumentPeriodEndDate", "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity](http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity)
 l, "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel":
 "Document Period End Date", "documentation": "For the EDGAR submission types of
 Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR
 submission types of Form N-1A: the filing date; for all other submission types: the end
 of the reporting or transition period. The format of the date is YYYY-MM-DD." } } },
 "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType",
 "nsuri": "<http://xbrl.sec.gov/dei/2024>", "localname": "DocumentTransitionReport",
 "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity](http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity)
 l, "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel":
 "Document Transition Report", "documentation": "Boolean flag that is true only for a
 form used as a transition report." } } }, "auth_ref": ["r1162"] }, "dei_DocumentType":
 { "xbrltype": "submissionTypeItemType", "nsuri": "<http://xbrl.sec.gov/dei/2024>",
 "localname": "DocumentType", "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity](http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity)
 l, "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document
 Type", "documentation": "The type of document being provided (such as 10-K, 10-Q,
 485BPOS, etc). The document type is limited to the same value as the supporting SEC

submission type, or the word 'Other.'" } }], "auth_ref": [] },
 "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
 "DocumentsIncorporatedByReferenceTextBlock", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text
 Block]", "terseLabel": "Documents Incorporated by Reference", "documentation":
 "Documents incorporated by reference." } } }, "auth_ref": ["r1115"] }, "us-
 gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]",
 "terseLabel": "U.S. federal", "documentation": "Designated federal jurisdiction entitled
 to levy and collect income tax in country of domicile. Includes, but is not limited to,
 national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": ["r656"] },
 "ecd_DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRflctdInTtlCompForCvrdYrMember":
 { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRflctdInTtlCompForCvrdYrMember",
 "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
 "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise
 Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends
 or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total
 Compensation for Covered Year" } } }, "auth_ref": ["r1173"] }, "us-
 gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS (LOSS) PER ORDINARY
 SHARE:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation":
 [
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel":
 "Basic", "totalLabel": "Earnings (loss) per ordinary share - basic", "documentation":
 "The amount of net income (loss) for the period per each share of common stock or
 unit outstanding during the reporting period." } } }, "auth_ref": ["r277", "r303",
 "r304", "r305", "r306", "r307", "r308", "r314", "r316", "r318", "r319", "r320", "r325",
 "r690", "r695", "r713", "r714", "r844", "r871", "r1024"] }, "us-
 gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel":
 "Diluted", "totalLabel": "Earnings (loss) per ordinary share - diluted", "documentation":
 "The amount of net income (loss) for the period available to each share of common
 stock or common unit outstanding during the reporting period and to each share or
 unit that would have been outstanding assuming the issuance of common shares or
 units for all dilutive potential common shares or units outstanding during the
 reporting period." } } }, "auth_ref": ["r277", "r303", "r304", "r305", "r306", "r307",
 "r308", "r316", "r318", "r319", "r320", "r325", "r690", "r695", "r713", "r714", "r844",
 "r871", "r1024"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EarningsPerSharePolicyTextBlock", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
], "lang": { "en-us": { "role": { "terseLabel": "Earnings (Loss) Per Share", "label":
 "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of

accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } }], "auth_ref": ["r40", "r41", "r322"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShare1", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r313", "r321", "r323", "r324"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate (as a percent)", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r656", "r1066"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory tax rate (as a percent)", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r289", "r656", "r681", "r1066"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationFdiiAmount", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "negatedLabel": "Foreign derived intangible income", "label": "Effective Income Tax Rate Reconciliation, FDII, Amount", "documentation": "Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)." } } }, "auth_ref": ["r1066", "r1419", "r1420"] }, "alks_EffectiveIncomeTaxReconciliationChangeInDeferredTaxAssetsIntercompanyAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "EffectiveIncomeTaxReconciliationChangeInDeferredTaxAssetsIntercompanyAmounts", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to intercompany amounts.", "label": "Effective Income Tax Reconciliation Change In Deferred Tax Assets Intercompany Amounts", "terseLabel": "Intercompany amounts" } } }, "auth_ref": [] }, "alks_EffectiveIncomeTaxReconciliationForeignIncomeTaxDifferential1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "EffectiveIncomeTaxReconciliationForeignIncomeTaxDifferential1", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule",

l, "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in specified foreign income tax contingency.", "label": "Effective Income Tax Reconciliation Foreign Income Tax Differential1", "terseLabel": "Irish rate differential" } } }, "auth_ref": [] }, "alks_EightFiveTwoWinterStreetLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "EightFiveTwoWinterStreetLeaseMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf", "lang": { "en-us": { "role": { "terseLabel": "852 Winter Street Lease", "label": "Eight Five Two Winter Street Lease [Member]", "documentation": "Eight Five Two Winter Street Lease." } } }, "auth_ref": [] }, "alks_EmployeeRelatedInternalResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "EmployeeRelatedInternalResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm", "lang": { "en-us": { "role": { "terseLabel": "Employee-related", "label": "Employee-Related Internal Research and Development Expenses", "documentation": "Employee-related internal research and development expenses." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAm", "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r110"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCap": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitali", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Share based compensation cost capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": ["r632"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLin": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItem", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensatio", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo

"crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 l, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation
 expense", "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost
 Not yet Recognized, Amount, Total", "label": "Share-Based Payment Arrangement,
 Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of
 cost not yet recognized for nonvested award under share-based payment arrangement."
 } } }, "auth_ref": { "r636" } }, "us-
 gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCo
 { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 l, "lang": { "en-us": { "role": { "terseLabel": "Weighted average period for unrecognized
 share-based compensation expense expected to be recognized", "label": "Share-Based
 Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for
 Recognition", "documentation": "Weighted-average period over which cost not yet
 recognized is expected to be recognized for award under share-based payment
 arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents
 reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r636" } },
 "us-
 gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCo
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo
 "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 l, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation
 expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding
 Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be
 recognized for nonvested award under share-based payment arrangement. Excludes
 share and unit options." } } }, "auth_ref": { "r1415" } }, "us-
 gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation":
 {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "terseLabel": "Stock Option Awards", "label": "Employee
 Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-
 efficient means by which employees of a corporation can purchase the corporation's
 stock." } } }, "auth_ref": { } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "EmployeeStockOptionMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSci
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSci
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" l, "lang": { "en-us": { "role": {
 "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option",
 "verboseLabel": "Stock Options", "documentation": "Share-based payment arrangement
 granting right, subject to vesting and other restrictions, to purchase or sell certain
 number of shares at predetermined price for specified period of time." } } },
 "auth_ref": { } }, "dei_EntityAddressAddressLine1": { "xbrltype":
 "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
 "EntityAddressAddressLine1", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
 l, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One",
 "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1

such as Attn, Building Name, Street Name" } }], "auth_ref": [] },
 "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri":
 "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two",
 "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2
 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown":
 { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
 "localname": "EntityAddressCityOrTown", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel":
 "Entity Address, City or Town", "documentation": "Name of the City or Town" } } },
 "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType",
 "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "terseLabel": "Entity
 Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } },
 "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype":
 "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
 "EntityAddressPostalZipCode", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel":
 "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" }
 } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype":
 "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
 "EntityCentralIndexKey", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity
 Central Index Key", "verboseLabel": "Entity Central Index Key", "documentation": "A
 unique 10-digit SEC-issued value to identify entities that have filed disclosures with
 the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r1114"] },
 "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
 "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding",
 "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate
 number of shares or other units outstanding of each of registrant's classes of capital or
 common stock or other ownership interests, if and as stated on cover of related
 periodic report. Where multiple classes or units exist define each class/interest by
 adding class of stock items such as Common Class A [Member], Common Class B
 [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the
 Entity Listings, Instrument." } } }, "auth_ref": [] },
 "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri":
 "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel":
 "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether
 registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the
 Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
 period that registrants were required to file such reports), and (2) have been subject to
 such filing requirements for the past 90 days. This information should be based on the
 registrant's current or most recent filing containing the related disclosure." } } },
 "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri":
 "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [

["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAnd](http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAnd)
["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS](http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS)
["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS](http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS)
], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] },
 "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r1114"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r1114"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1224"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "credit": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Public Float", "verboseLabel": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed

second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "terseLabel": "Registrant Name", "label": "Entity Registrant Name", "verboseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r1114"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r1114"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r1114"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r1114"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity", "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r1226"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r1167"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r1220"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r1220"] },

"ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r1220"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r19", "r241", "r272", "r273", "r274", "r298", "r299", "r300", "r302", "r307", "r309", "r311", "r327", "r401", "r402", "r448", "r501", "r679", "r680", "r687", "r688", "r689", "r691", "r694", "r695", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r747", "r748", "r749", "r750", "r751", "r752", "r754", "r756", "r768", "r867", "r885", "r886", "r887", "r903", "r969"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r1177"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r1134", "r1145", "r1155", "r1188"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r1131", "r1142", "r1152", "r1185"] }, "us-gaap_EuropeanUnionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EuropeanUnionMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio", "lang": { "en-us": { "role": { "label": "European Union [Member]", "terseLabel": "EU", "documentation": "Economic and political union of member states, located primarily in Europe." } } }, "auth_ref": ["r1496", "r1497", "r1498", "r1499"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r1183"] }, "alks_ExternalResearchAndDevelopmentExpenses": { "xbrltype":

"monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"ExternalResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
l", "lang": { "en-us": { "role": { "label": "External Research and Development expenses",
"documentation": "External research and development expenses.", "totalLabel": "Total
external R&D expenses" } } }, "auth_ref": [] },
"alks_ExternalResearchAndDevelopmentExpensesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"ExternalResearchAndDevelopmentExpensesAbstract", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
l", "lang": { "en-us": { "role": { "label": "External Research and Development Expenses
[Abstract]", "documentation": "External research and development expenses
[Abstract]", "terseLabel": "External R&D expenses:" } } }, "auth_ref": [] },
"alks_FacilityAndCertainRelatedAssetsMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.alkermes.com/20241231", "localname":
"FacilityAndCertainRelatedAssetsMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn
l", "lang": { "en-us": { "role": { "label": "Facility and Certain Related Assets [Member]",
"documentation": "Facility and certain related assets.", "terseLabel": "Facility and
Certain Related Assets [Member]" } } }, "auth_ref": [] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineIte
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummaryC
l", "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on
Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value",
"documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": ["r716", "r717", "r730",
"r1070"] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummaryC
l", "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring
[Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And
Nonrecurring Basis [Table]", "documentation": "Disclosure of information about asset
and liability measured at fair value on recurring and nonrecurring basis." } } },
"auth_ref": ["r716", "r717", "r730", "r1070"] }, "us-
gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueTables"l,
"lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis
[Table Text Block]", "terseLabel": "Summary of the Company's Assets and Liabilities
Measured at Fair Value on a Recurring Basis", "documentation": "Tabular disclosure of
assets, including [financial] instruments measured at fair value that are classified in
stockholders' equity, if any, by class that are measured at fair value on a recurring
basis. The disclosures contemplated herein include the fair value measurements at the
reporting date by the level within the fair value hierarchy in which the fair value
measurements in their entirety fall, segregating fair value measurements using quoted
prices in active markets for identical assets (Level 1), significant other observable
inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [
"r1433", "r1434"] }, "us-
gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAs
{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetC
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary"
l, "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "terseLabel": "Asset
Class", "documentation": "Class of asset." } } }, "auth_ref": { "r721", "r722", "r723",
"r724", "r725", "r726", "r731", "r1072" } }, "us-gaap_FairValueByAssetClassAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByAssetClassAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary"
l, "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "terseLabel": "Asset Class",
"documentation": "Information by class of asset." } } }, "auth_ref": { "r721", "r722",
"r723", "r724", "r725", "r726", "r731", "r1072" } }, "us-
gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary"
l, "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]",
"terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Information by level
within fair value hierarchy and fair value measured at net asset value per share as
practical expedient." } } }, "auth_ref": { "r476", "r549", "r550", "r551", "r552", "r553",
"r554", "r715", "r717", "r718", "r719", "r720", "r729", "r730", "r732", "r774", "r775",
"r776", "r1043", "r1044", "r1056", "r1057", "r1058", "r1070", "r1074" } }, "us-
gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary"
l, "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "terseLabel":
"Measurement Frequency", "documentation": "Information by measurement
frequency." } } }, "auth_ref": { "r716", "r717", "r718", "r720", "r1070", "r1436", "r1439"
l }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": {
"en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": { }
"us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValue"
"lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Fair Value", "documentation": "The entire disclosure for the fair value of
financial instruments (as defined), including financial assets and financial liabilities
(collectively, as defined), and the measurements of those instruments as well as
disclosures related to the fair value of non-financial assets and liabilities. Such
disclosures about the financial instruments, assets, and liabilities would include: (1)
the fair value of the required items together with their carrying amounts (as
appropriate); (2) for items for which it is not practicable to estimate fair value,
disclosure would include: (a) information pertinent to estimating fair value (including,
carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not
practicable to estimate fair value; (3) significant concentrations of credit risk
including: (a) information about the activity, region, or economic characteristics
identifying a concentration, (b) the maximum amount of loss the entity is exposed to
based on the gross fair value of the related item, (c) policy for requiring collateral or
other security and information as to accessing such collateral or security, and (d) the
nature and brief description of such collateral or security; (4) quantitative information
about market risks and how such risks are managed; (5) for items measured on both a
recurring and nonrecurring basis information regarding the inputs used to develop the
fair value measurement; and (6) for items presented in the financial statement for
which fair value measurement is elected: (a) information necessary to understand the
reasons for the election, (b) discussion of the effect of fair value changes on earnings,
(c) a description of [similar groups] items for which the election is made and the

relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } }], "auth_ref": ["r725", "r727", "r728", "r729", "r732", "r733", "r734", "r735", "r736", "r840", "r1070", "r1075"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary(l, "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r476", "r549", "r554", "r717", "r730", "r774", "r1056", "r1057", "r1058", "r1070"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary(l, "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r476", "r549", "r554", "r717", "r718", "r730", "r775", "r1043", "r1044", "r1056", "r1057", "r1058", "r1070"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary(l, "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r476", "r549", "r550", "r551", "r552", "r553", "r554", "r717", "r718", "r719", "r720", "r730", "r776", "r1043", "r1044", "r1056", "r1057", "r1058", "r1070", "r1074"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary(l, "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency", "documentation": "Measurement frequency." } } }, "auth_ref": ["r716", "r717", "r718", "r720", "r1070", "r1436", "r1439"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional l, "lang": { "en-us": { "role": { "terseLabel": "Investments determined using Level 3 inputs", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r721", "r731", "r1072"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary(l, "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [

"r476", "r549", "r550", "r551", "r552", "r553", "r554", "r715", "r717", "r718", "r719", "r720", "r729", "r730", "r732", "r774", "r775", "r776", "r1043", "r1044", "r1056", "r1057", "r1058", "r1070", "r1074"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary": { "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring Basis", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": { "r1070", "r1433", "r1434", "r1435", "r1436", "r1437", "r1439" } } }, "us-gaap_FairValueOffFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOffFinancialInstrumentsPolicy", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificance": { "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": { "r13" } } }, "alks_FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelOneToLevelTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelOneToLevelTwo", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional": { "lang": { "en-us": { "role": { "documentation": "Fair value recurring basis assets or liabilities transfers between level one to level two.", "label": "Fair Value Recurring Basis Assets Or Liabilities Transfers Between Level One To Level Two", "terseLabel": "Transfers between Level 1 to Level 2" } } }, "auth_ref": { } } }, "alks_FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelTwoToLevelOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelTwoToLevelOne", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional": { "lang": { "en-us": { "role": { "documentation": "Fair value recurring basis assets or liabilities transfers between level two to level one.", "label": "Fair Value Recurring Basis Assets Or Liabilities Transfers Between Level Two To Level One", "terseLabel": "Transfers between Level 2 to Level 1" } } }, "auth_ref": { } } }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditional": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule": { "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r404", "r406", "r409", "r410", "r411", "r413", "r417", "r418", "r484", "r499", "r710", "r737", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r868", "r1039", "r1070", "r1072", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1084", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1283", "r1284", "r1285", "r1286", "r1432", "r1435", "r1436", "r1437", "r1438", "r1439" } } }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype":

"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetUsefulLife", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life",
 "terseLabel": "Weighted Amortizable Life", "documentation": "Useful life of finite-lived
 intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents
 the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] },
 "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated
 Amortization", "negatedLabel": "Accumulated Amortization", "documentation":
 "Accumulated amount of amortization of assets, excluding financial assets and
 goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r253",
 "r422", "r442", "r1041"] }, "us-
 gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible
 Asset, Expected Amortization, Year One", "documentation": "Amount of amortization
 for assets, excluding financial assets and goodwill, lacking physical substance with
 finite life expected to be recognized in next fiscal year following current fiscal year.
 Excludes interim and annual periods when interim periods are reported from current
 statement of financial position date (rolling approach)." } } }, "auth_ref": ["r444",
 "r1008", "r1041"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class
 [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class", "documentation":
 "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [
 "r435", "r437", "r438", "r439", "r441", "r442", "r445", "r446", "r808", "r809", "r1008"]
 }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net,
 Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Expected
 amortization of intangible assets" } } }, "auth_ref": [] }, "us-
 gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross",
 "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "totalLabel": "Finite-Lived Intangible Assets, Gross,
 Total", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying
 Amount", "documentation": "Amount before amortization of assets, excluding financial
 assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [
 "r422", "r442", "r809", "r1041"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetsLineItems", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Finite-Lived Intangible
 Assets [Line Items]", "documentation": "Line items represent financial concepts
 included in a table. These concepts are used to disclose reportable information

associated with domain members defined in one or many axes to the table." } }],
 "auth_ref": ["r435", "r442", "r445", "r446", "r447", "r808", "r1008", "r1041"]], "us-
 gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill",
 "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class
 Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
 "documentation": "The major class of finite-lived intangible asset (for example,
 patents, trademarks, copyrights, etc.) A major class is composed of intangible assets
 that can be grouped together because they are similar, either by their nature or by
 their use in the operations of a company." } }], "auth_ref": ["r435", "r437", "r438",
 "r439", "r441", "r442", "r445", "r446", "r1008"]], "us-
 gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr":
 "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill",
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAssets",
 "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets", "periodEndLabel":
 "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived
 Intangible Assets, Net, Beginning Balance", "label": "Finite-Lived Intangible Assets,
 Net", "terseLabel": "INTANGIBLE ASSETS, NET", "totalLabel": "Net Carrying Amount",
 "documentation": "Amount after amortization of assets, excluding financial assets and
 goodwill, lacking physical substance with a finite life." } }], "auth_ref": ["r808",
 "r1302"]], "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FiniteLivedIntangibleAssetsNetAbstract", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill",
 "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]",
 "terseLabel": "Finite-lived intangible assets:" } }], "auth_ref": [] },
 "alks_ForeignCountryExcludingSpecifiedCountryMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "ForeignCountryExcludingSpecifiedCountryMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf",
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf",
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAssets",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssets",
 "lang": { "en-us": { "role": { "documentation": "Represents designated tax
 departments of governments entitled to levy and collect income taxes from the entity
 outside the entity's country of domicile, excluding the specified country.", "label":
 "Foreign Country Excluding Specified Country [Member]", "terseLabel": "Rest of world"
 } }], "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssets",
 "lang": { "en-us": { "role": { "totalLabel": "Gain (Loss), Foreign Currency
 Transaction, before Tax, Total", "label": "Gain (Loss), Foreign Currency Transaction,
 before Tax", "terseLabel": "Gain (loss) on foreign currency translation",
 "documentation": "Amount, before tax, of realized and unrealized gain (loss) from
 foreign currency transaction." } }], "auth_ref": ["r743", "r744", "r745", "r746", "r966"
]], "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssets",
 "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and
 Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency",
 "documentation": "Disclosure of accounting policy for (1) transactions denominated in
 a currency other than the reporting enterprise's functional currency, (2) translating

foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r742"] }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignGovernmentDebtSecuritiesMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Non-U.S. government debt securities", "documentation": "Debt security issued by government not domiciled in United States of America (US)." } } }, "auth_ref": ["r1084", "r1348", "r1490"] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignPlanMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificant", "lang": { "en-us": { "role": { "label": "Foreign Plan [Member]", "terseLabel": "Defined Contribution Plan", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": ["r1386", "r1387", "r1388"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r1138", "r1149", "r1159", "r1192"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r1138", "r1149", "r1159", "r1192"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r1138", "r1149", "r1159", "r1192"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r1138", "r1149", "r1159", "r1192"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1138", "r1149", "r1159", "r1192"] }, "alks_FormerTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "FormerTermLoansMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddition", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSchedule", "lang": { "en-us": { "role": { "label": "Former Term Loans [Member]",

"documentation": "Former Term Loans.", "terseLabel": "Former Term Loans, due March 12, 2026", "verboseLabel": "Former Term Loans" } }], "auth_ref": [] },
 "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r1172"] },
 "alks_FurnitureFixtureAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "FurnitureFixtureAndEquipmentMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica", "lang": { "en-us": { "role": { "documentation": "Represents furniture, fixtures and equipment of the entity.", "label": "Furniture Fixture And Equipment [Member]", "terseLabel": "Furniture, Fixtures and Equipment", "verboseLabel": "Furniture, fixtures and equipment" } } }, "auth_ref": [] },
 "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi", "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "negatedLabel": "Loss on debt extinguishment", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r10", "r56", "r57"] },
 "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm", "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r133", "r952"] },
 "alks_GeographicInformationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "GeographicInformationPolicyTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica", "lang": { "en-us": { "role": { "documentation": "Disclosure of the entity's accounting policy for geographic information.", "label": "Geographic Information Policy [Text Block]", "terseLabel": "Geographic Information" } } }, "auth_ref": [] },
 "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoo", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoo", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "lang": { "en-us": { "role": { "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "totalLabel": "Goodwill, Total", "terseLabel": "GOODWILL", "verboseLabel": "Net Carrying Amount", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r252", "r423", "r841", "r1033", "r1040", "r1071", "r1083", "r1293", "r1294"] },
 "alks_GoodwillAllocationAdjustment": { "xbrltype":

"monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "GoodwillAllocationAdjustment", "crdr": "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "negatedLabel": "Allocation Adjustment", "terseLabel":
 "Allocation Adjustment", "label": "Goodwill Allocation Adjustment", "documentation":
 "Goodwill Allocation Adjustment." } } }, "auth_ref": [] }, "us-
 gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label":
 "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text
 Block]", "terseLabel": "Intangible Assets and Goodwill", "documentation": "The entire
 disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r1291", "r1295"] }, "us-
 gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificance", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy
 Text Block]", "terseLabel": "Goodwill and Intangible Assets", "documentation":
 "Disclosure of accounting policy for goodwill and intangible assets. This accounting
 policy also may address how an entity assesses and measures impairment of goodwill
 and intangible assets." } } }, "auth_ref": ["r1291", "r1295"] }, "us-
 gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "GoodwillGross", "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Goodwill, Gross", "terseLabel": "Gross Carrying
 Amount", "documentation": "Amount, before accumulated impairment loss, of asset
 representing future economic benefit arising from other asset acquired in business
 combination or from joint venture formation or both, that is not individually identified
 and separately recognized." } } }, "auth_ref": ["r425", "r432", "r1040"] }, "us-
 gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "GoodwillLineItems", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Goodwill [Line Items]", "documentation": "Line
 items represent financial concepts included in a table. These concepts are used to
 disclose reportable information associated with domain members defined in one or
 many axes to the table." } } }, "auth_ref": ["r424", "r425", "r426", "r427", "r428",
 "r429", "r430", "r431", "r432", "r433", "r434", "r1040"] }, "us-
 gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "GoodwillPeriodIncreaseDecrease",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "verboseLabel": "Allocation Adjustment",
 "negatedLabel": "Reduction in Goodwill", "terseLabel": "Reduction in Goodwill",
 "label": "Goodwill, Period Increase (Decrease)", "totalLabel": "Goodwill, Period
 Increase (Decrease), Total", "documentation": "Amount of increase (decrease) of asset
 representing future economic benefit arising from other asset acquired in business
 combination or from joint venture formation or both, that is not individually identified
 and separately recognized." } } }, "auth_ref": ["r1292"] }, "us-
 gaap_GuaranteesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "GuaranteesFairValueDisclosure", "crdr":
 "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "lang": { "en-us": { "role": { "terseLabel": "Fair value of guarantee", "label":

"Guarantees, Fair Value Disclosure", "documentation": "Fair value portion of guarantee, including, but not limited to, financial standby letter of credit, fair value guarantee, guarantee of collection of scheduled contractual cash flows from financial assets, and contracts that contingently require the guarantor to make payments or perform services." } }], "auth_ref": ["r1433", "r1434", "r1438"] },
"alks_GuarantyDate": { "xbrltype": "dateItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "GuarantyDate", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo
], "lang": { "en-us": { "role": { "terseLabel": "Guaranty date", "label": "Guaranty Date",
"documentation": "Guaranty Date" } }], "auth_ref": [] }, "us-
gaap_HeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecurities", "crdr":
"debit", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Amortized
Cost, before Allowance for Credit Loss", "totalLabel": "Total", "documentation":
"Amount, before allowance for credit loss, of investment in debt security measured at
amortized cost (held-to-maturity)." } }], "auth_ref": ["r183", "r379", "r409", "r1288"]
], "us-
gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
"crdr": "debit", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Fair Value,
Maturity, Allocated and Single Maturity Date, after Year One Through Five",
"terseLabel": "After 1 year through 5 years", "documentation": "Fair value of
investment in debt security measured at amortized cost (held-to-maturity), with single
maturity date and allocated without single maturity date, maturing in second through
fifth fiscal year following current fiscal year. Excludes interim and annual periods
when interim periods are reported from current statement of financial position date
(rolling approach)." } }], "auth_ref": ["r186", "r192", "r393", "r849"] }, "us-
gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingA
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmour
"crdr": "debit", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Amortized
Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date,
after Year One through Five", "terseLabel": "After 1 year through 5 years",
"documentation": "Amount, after allowance for credit loss, of investment in debt
security measured at amortized cost (held-to-maturity) with single maturity date and
allocated without single maturity date, maturing in second through fifth fiscal year
following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling
approach)." } }], "auth_ref": ["r385", "r847"] }, "us-
gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Fair Value,
Maturity [Abstract]", "terseLabel": "Held-to-maturity, Estimated Fair Value" } }],
"auth_ref": [] }, "us-
gaap_HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecuritiesDebtMaturitiesNetCarryingAmountAbstract",
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu

], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity [Abstract]", "terseLabel": "Held-to-maturity, Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule",
], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Within 1 year", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r185", "r191", "r392", "r848"] }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule",
], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Within 1 year", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r384", "r846"] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesFairValue", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule",
], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Fair Value", "terseLabel": "Estimated Fair Value", "totalLabel": "Total", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r184", "r388", "r717", "r729", "r842", "r853"] }, "us-gaap_HeldToMaturitySecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesNoncurrent", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule",
], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent", "terseLabel": "Amortized Cost", "totalLabel": "Amortized Cost", "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent." } } }, "auth_ref": ["r364", "r1280", "r1288"] }, "country_IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IE", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf",
], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "Ireland" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
]

], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r1117", "r1118", "r1141"], "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificance"] }, "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareScheduleOfEarningsLossPerShare", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentData", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncome"] }, "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "verboseLabel": "Net income from continuing operations", "totalLabel": "NET INCOME (LOSS) FROM CONTINUING OPERATIONS", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": ["r75", "r129", "r144", "r303", "r304", "r305", "r306", "r307", "r317", "r320", "r695"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEarningsLossPerShare", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncome"] }, "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "verboseLabel": "OTHER INCOME, NET", "totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES", "terseLabel": "Income (loss) from continuing operations before provision (benefit) for income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r128", "r172", "r178", "r845", "r864", "r1026", "r1032", "r1263", "r1265", "r1266", "r1267", "r1268"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncome"] }, "lang": { "en-us": { "role": { "terseLabel": "Continuing Operations - Basic", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "verboseLabel": "Earnings (loss) per ordinary share from continuing operations - basic", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r129", "r173", "r277", "r301", "r303", "r304", "r305", "r306", "r307", "r316", "r318", "r319", "r690", "r695", "r714", "r844", "r1459"] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncome"] }, "lang": { "en-us": { "role": { "terseLabel": "Continuing Operations - Diluted", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "verboseLabel": "Earnings (loss) per ordinary share from continuing operations - diluted", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit"

outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } }], "auth_ref": ["r129", "r277", "r301", "r303", "r304", "r305", "r306", "r307", "r316", "r318", "r319", "r320", "r695", "r714", "r844", "r1459"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSe", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC", "lang": { "en-us": { "role": { "totalLabel": "Net loss and comprehensive loss from discontinued operations", "terseLabel": "LOSS FROM DISCONTINUED OPERATIONS, NET OF TAX", "verboseLabel": "Net loss from discontinued operations", "label": "LOSS ON DISCONTINUED OPERATIONS, NET OF TAX", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r90", "r91", "r92", "r93", "r94", "r101", "r105", "r166"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludi": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDi", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGooe", "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r1059", "r1060"] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludi": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDi", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional", "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Fair Value", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludi": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDi", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional", "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]",

"documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } },
"auth_ref": ["r14", "r23", "r26", "r86", "r95", "r96", "r97", "r99", "r100", "r104", "r106", "r107", "r157"] },
"us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensatio
l, "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]",
"terseLabel": "Income Statement Location", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } },
"auth_ref": ["r450", "r451", "r452", "r722", "r726", "r731", "r882", "r884", "r953", "r1008", "r1073", "r1463"] },
"us-gaap_IncomeStatementLocationDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensatio
l, "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]",
"terseLabel": "Income Statement Location", "documentation": "Location in statement of income where disaggregated amount has been reported." } } },
"auth_ref": ["r451", "r452", "r722", "r726", "r731", "r882", "r884", "r953", "r1008", "r1073", "r1463"] },
"us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
l, "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "terseLabel": "Income Tax Authority", "documentation": "Information by income tax jurisdiction." } } },
"auth_ref": ["r284", "r656", "r657", "r666", "r676", "r1066", "r1426"] },
"us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
l, "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "terseLabel": "Income Tax Authority", "documentation": "Income tax jurisdiction." } } },
"auth_ref": ["r284", "r656", "r657", "r666", "r676", "r1066", "r1426"] },
"us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
l, "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name", "documentation": "Information by name of taxing authority." } } },
"auth_ref": ["r666", "r1426"] },
"us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
l, "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } },
"auth_ref": ["r666", "r1426"] },
"us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } },
"auth_ref": [] },
"us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" },

"lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]",
 "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax."
 } } }, "auth_ref": ["r289", "r648", "r656", "r663", "r664", "r665", "r671", "r675",
 "r682", "r684", "r685", "r686", "r900", "r1066"], "us-
 gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr":
 "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
 l, "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel":
 "INCOME TAX PROVISION (BENEFIT)", "totalLabel": "Total tax provision (benefit)",
 "verboseLabel": "INCOME TAX PROVISION (BENEFIT)", "documentation": "Amount of
 current income tax expense (benefit) and deferred income tax expense (benefit)
 pertaining to continuing operations." } } }, "auth_ref": ["r193", "r206", "r310", "r311",
 "r326", "r338", "r353", "r655", "r656", "r683", "r873", "r1066"], "us-
 gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordi
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinary",
 "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
 l, "lang": { "en-us": { "role": { "terseLabel": "Tax benefits included in discontinued
 operations", "label": "Income Tax Expense (Benefit), Continuing Operations,
 Discontinued Operations", "negatedLabel": "Tax benefits included in discontinued
 operations", "documentation": "Amount of current tax expense (benefit) and deferred
 tax expense (benefit) pertaining to income (loss) from continuing operations and
 income (loss) from discontinued operations." } } }, "auth_ref": ["r1067"], "us-
 gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract
 { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
 l, "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income
 Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Reconciliation of effective
 income tax rate" } } }, "auth_ref": [] },
 "alks_IncomeTaxExpenseBenefitRelatedToIntercompanyTransferOfInventory": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "IncomeTaxExpenseBenefitRelatedToIntercompanyTransferOfInventory",
 "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf
 l, "lang": { "en-us": { "role": { "terseLabel": "Tax benefit related to intercompany
 transfer of inventory", "label": "Income Tax Expense Benefit Related to Intercompany
 Transfer of Inventory", "documentation": "Income tax expense benefit related to
 intercompany transfer of inventory." } } }, "auth_ref": [] }, "us-
 gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
 l, "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]",
 "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for
 income taxes, which may include its accounting policies for recognizing and measuring
 deferred tax assets and liabilities and related valuation allowances, recognizing
 investment tax credits, operating loss carryforwards, tax credit carryforwards, and
 other carryforwards, methodologies for determining its effective income tax rate and
 the characterization of interest and penalties in the financial statements." } } },
 "auth_ref": ["r271", "r651", "r652", "r671", "r672", "r674", "r678", "r897"],
 "alks_IncomeTaxReconciliationAbandonmentOfNetOperatingLoss": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":

"IncomeTaxReconciliationAbandonmentOfNetOperatingLoss", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "terseLabel": "Abandonment of NOLs", "label": "Income Tax Reconciliation Abandonment of Net Operating Loss", "documentation": "Income tax reconciliation abandonment of net operating loss." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": ["r661", "r1066", "r1419"] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign rate differential", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": ["r657", "r660", "r1066", "r1419"] }, "alks_IncomeTaxReconciliationInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "IncomeTaxReconciliationInProcessResearchAndDevelopment", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "terseLabel": "In-process R&D", "label": "Income Tax Reconciliation In Process Research and Development", "documentation": "Income tax reconciliation in process research and development." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from continuing operations before income taxes at statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": ["r656", "r1066"] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "terseLabel": "Other permanent items", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the

domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } }], "auth_ref": ["r1066", "r1419", "r1420"] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "terseLabel": "Share-based compensation", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": ["r1066", "r1419", "r1420"] }, "alks_IncomeTaxReconciliationNondeductibleLobbyingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "IncomeTaxReconciliationNondeductibleLobbyingExpenses", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation nondeductible lobbying expenses.", "label": "Income Tax Reconciliation Nondeductible Lobbying Expenses", "terseLabel": "Non-deductible lobbying expenses" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "U.S. state income taxes, net of U.S. federal benefit", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": ["r659", "r1066", "r1419"] }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxContingencies", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "terseLabel": "Uncertain tax positions", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": ["r662", "r1066", "r1419"] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "negatedLabel": "R&D credit", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax

rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": ["r1066", "r1419", "r1420"], "alks_IncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "IncomeTaxesLineItems", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio", "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]", "verboseLabel": "Distribution of income (loss) before provision for income taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Income Taxes Paid", "terseLabel": "Cash paid for taxes", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r36", "r143", "r1252", "r1424", "r1425"], "alks_IncomeTaxesPayableOnRepatriationOfUnremittedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "IncomeTaxesPayableOnRepatriationOfUnremittedEarnings", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio", "lang": { "en-us": { "role": { "documentation": "Income taxes payable on repatriation of unremitted earnings.", "label": "Income Taxes Payable On Repatriation Of Unremitted Earnings", "terseLabel": "Income taxes payable on repatriation of unremitted earnings" } } }, "auth_ref": [] }, "alks_IncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "IncomeTaxesTable", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio", "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r9"] }, "alks_IncreaseDecreaseInAccruedSalesDiscountAllowancesAndReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "IncreaseDecreaseInAccruedSalesDiscountAllowancesAndReserves", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued sales discount, allowances and reserves.", "label": "Increase Decrease In Accrued Sales Discount Allowances And Reserves", "terseLabel": "Accrued sales discounts, allowances and reserves" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "presentation": [

["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA](http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA)
 l, "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer Asset", "negatedLabel": "Contract assets", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r1250"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer Liability", "terseLabel": "Contract liabilities", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r804", "r1250"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Inventories, Total", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r9"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "alks_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "negatedLabel": "Decrease in operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r1231", "r1250"] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other long-term liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": ["r9"] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": ["r9"] }, "us-

gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Receivables, Total", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": { "r9" } }, "alks_IncreaseDecreaseInRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "IncreaseDecreaseInRightOfUseAsset", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "documentation": "Increase decrease in right of use asset.", "label": "Increase Decrease In Right Of Use Asset", "negatedLabel": "Right-of-use assets" } } }, "auth_ref": { } }, "alks_IncreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "IncreaseInOperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf", "lang": { "en-us": { "role": { "documentation": "Increase in operating lease right of use asset.", "label": "Increase In Operating Lease Right Of Use Asset", "terseLabel": "Increase in operating lease right of use asset" } } }, "auth_ref": { } }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": { "r1138", "r1149", "r1159", "r1183", "r1192", "r1196", "r1204" } }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": { "r1202" } }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": { "r1119", "r1208" } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": { "r1119", "r1208" } }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": { "r1119", "r1208" } }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI", "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Including Goodwill)", "totalLabel": "Intangible Assets, Net (Including Goodwill), Total", "terseLabel": "INTANGIBLE ASSETS, NET AND GOODWILL", "verboseLabel": "Intangible assets, net

and goodwill", "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets." } }], "auth_ref": ["r1290"]], "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntellectualPropertyMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Intellectual Property [Member]", "terseLabel": "Capitalized IP", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": ["r24", "r1296", "r1297", "r1298", "r1299", "r1301", "r1302", "r1304", "r1305"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncome", "lang": { "en-us": { "role": { "label": "Interest Expense, Nonoperating", "totalLabel": "Interest Expense, Nonoperating, Total", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r336", "r1249"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFINCOME", "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r279", "r282", "r283"] }, "alks_InternalResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "InternalResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummary", "lang": { "en-us": { "role": { "label": "Internal research and development expenses", "documentation": "Internal research and development expenses.", "totalLabel": "Total internal R&D expenses" } } }, "auth_ref": [] }, "alks_InternalResearchAndDevelopmentExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "InternalResearchAndDevelopmentExpensesAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummary", "lang": { "en-us": { "role": { "terseLabel": "Internal R&D expenses:", "label": "Internal Research and Development Expenses [Abstract]", "documentation": "Internal research and development expenses." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventory", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r419"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryScheduleC", "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Net of Reserves",

"terseLabel": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } }], "auth_ref": ["r151", "r1015"] },
 "alks_InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShipping": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingSer", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryScheduleC", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale, located at third party warehouse and shipping service provider.", "label": "Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider", "terseLabel": "Finished goods inventory located at third-party warehouse and shipping service provider" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryScheduleC", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r261", "r1014", "r1083"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r194", "r247", "r260", "r419", "r420", "r421", "r806", "r1022"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryScheduleC", "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r151", "r1017"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryScheduleC", "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": ["r151", "r1016"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC", "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel":

"Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } }],
"auth_ref": ["r326", "r335", "r353", "r1032", "r1248"] }, "us-
gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
l", "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]",
"terseLabel": "Investments", "documentation": "Disclosure of accounting policy for
investment in financial asset." } } }, "auth_ref": ["r872", "r893", "r894", "r895",
"r896", "r977", "r978"] }, "us-gaap_InvestmentTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentTypeAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
l", "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation":
"Information by type of investments." } } }, "auth_ref": ["r906", "r908", "r909", "r912",
"r916", "r974", "r976", "r980", "r983", "r984", "r985", "r987", "r988", "r989", "r990",
"r991", "r1104"] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentTypeCategorizationMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
l", "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation":
"Asset obtained to generate income or appreciate in value." } } }, "auth_ref": ["r906",
"r908", "r909", "r912", "r916", "r974", "r976", "r980", "r983", "r984", "r985", "r987",
"r988", "r989", "r990", "r991", "r1104"] }, "us-
gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables
l", "lang": { "en-us": { "role": { "label": "Investments Classified by Contractual Maturity
Date [Table Text Block]", "terseLabel": "Schedule of Contractual Maturities of
Available-for-Sale and Held-to-Maturity Securities", "documentation": "Tabular
disclosure of maturities of an entity's investments as well as any other information
pertinent to the investments." } } }, "auth_ref": [] }, "us-
gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label":
"Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclo
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosure
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestments"].
"lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity
Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel":
"Investments", "documentation": "The entire disclosure for investments in certain debt
and equity securities." } } }, "auth_ref": ["r175", "r209", "r363", "r365", "r738", "r739",
"r1456"] }, "alks_JanssenMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "JanssenMember", "presentation":
{
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
l", "lang": { "en-us": { "role": { "documentation": "Represents Janssen, a collaborative
partner of the entity.", "label": "Janssen [Member]", "terseLabel": "Janssen" } } },
"auth_ref": [] }, "alks_JanssenPharmaceuticaNVMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"JanssenPharmaceuticaNVMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri

], "lang": { "en-us": { "role": { "documentation": "Janssen Pharmaceutica N.V.", "label": "Janssen Pharmaceutica N V [Member]", "terseLabel": "Janssen Pharmaceutica N.V." } } }, "auth_ref": [] },
 "alks_LYBALVIExternalResearchAndDevelopmentExpensesDevelopmentPrograms": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname":
 "LYBALVIExternalResearchAndDevelopmentExpensesDevelopmentPrograms", "crdr":
 "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
], "lang": { "en-us": { "role": { "label": "L Y B A L V I External Research And
 Development Expenses Development Programs", "documentation": "LYBALVI external
 research and development expenses development programs.", "terseLabel": "LYBALVI
 } } }, "auth_ref": [] }, "alks_LYBALVIMember": { "xbrltype": "domainItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname": "LYBALVIMember",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
], "lang": { "en-us": { "role": { "documentation": "LYBALVI.", "label": "L Y B A L V I
 [Member]", "terseLabel": "LYBALVI" } } }, "auth_ref": [] }, "us-gaap_LandMember": {
 "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "LandMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
], "lang": { "en-us": { "role": { "label": "Land [Member]", "terseLabel": "Land",
 "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": {
 "r1325" } }, "alks_LeaseAgreementCommencementDate": { "xbrltype": "dateItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "LeaseAgreementCommencementDate", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
], "lang": { "en-us": { "role": { "documentation": "Lease agreement, commencement
 date.", "label": "Lease Agreement Commencement Date", "terseLabel": "Lease,
 commencement date" } } }, "auth_ref": [] },
 "alks_LeaseAgreementCommencementPeriod": { "xbrltype": "gYearMonthItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "LeaseAgreementCommencementPeriod", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
], "lang": { "en-us": { "role": { "documentation": "Lease agreement commencement
 period.", "label": "Lease Agreement Commencement Period", "terseLabel": "Lease
 agreement commencement period" } } }, "auth_ref": [] },
 "alks_LeaseAgreementLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname":
 "LeaseAgreementLeaseRenewalTerm", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
], "lang": { "en-us": { "role": { "documentation": "Lease agreement lease renewal
 term.", "label": "Lease Agreement Lease Renewal Term", "terseLabel": "Lease
 agreement option to extend renewal term" } } }, "auth_ref": [] }, "us-
 gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]",
 "terseLabel": "Leasehold Improvements", "verboseLabel": "Leasehold improvements",
 "documentation": "Additions or improvements to assets held under a lease
 arrangement." } } }, "auth_ref": { "r155", "r766" } }, "us-gaap_LeasesAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } },
 "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn

["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS](http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS)
["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS](http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS)
], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": []
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf)
], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r760", "r767"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": []
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf)
], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r760", "r767"] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": []
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf)
], "lang": { "en-us": { "role": { "terseLabel": "Lessee operating lease term of option to extend", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r761"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": []
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesTables)
], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Summary of Future Lease Payments Under Non-Cancelable Leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1445"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": []
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOff](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOff)
], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total operating lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r765"] }, "alks_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": []
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOff](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOff)
], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": []
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOff](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOff)

l, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r765"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOffF", "l, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r765"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOffF", "l, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r765"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOffF", "l, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r765"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOffF", "l, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r765"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf", "l, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease period", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1444"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock",

"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeases" {, **"lang": {**
"en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel":
"Leases", "documentation": "The entire disclosure for operating leases of lessee.
Includes, but is not limited to, description of operating lease and maturity analysis of
operating lease liability." } } }, "auth_ref": { "r755" } }, "us-gaap_Liabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"Liabilities", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
{, **"lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities",**
"documentation": "Amount of liability recognized for present obligation requiring
transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r25",
"r109", "r110", "r111", "r112", "r113", "r114", "r115", "r288", "r400", "r459", "r460",
"r461", "r462", "r463", "r464", "r465", "r466", "r467", "r699", "r702", "r703", "r741",
"r927", "r1025", "r1112", "r1319", "r1447", "r1448" } }, "us-
gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity",
"crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
{, **"lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "TOTAL**
LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "documentation": "Amount of
liabilities and equity items, including the portion of equity attributable to
noncontrolling interests, if any." } } }, "auth_ref": { "r122", "r171", "r860", "r1083",
"r1254", "r1287", "r1440" } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquityAbstract", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
{, **"lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel":**
"LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "auth_ref": { } }, "us-
gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
{, **"lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total**
current liabilities", "documentation": "Total obligations incurred as part of normal
operations that are expected to be paid during the following twelve months or within
one business cycle, if longer." } } }, "auth_ref": { "r111", "r246", "r288", "r400", "r459",
"r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r699", "r702", "r703",
"r741", "r1083", "r1319", "r1447", "r1448" } }, "us-gaap_LiabilitiesCurrentAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
{, **"lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel":**
"CURRENT LIABILITIES:" } } }, "auth_ref": { } }, "us-
gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
{, **"lang": { "en-us": { "role": { "verboseLabel": "Liabilities", "totalLabel": "Total**
liabilities", "terseLabel": "Total Liabilities", "label": "Disposal Group, Including
Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities
attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r1",
"r86", "r103", "r156", "r243", "r244" } }, "us-
gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit",

"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsA
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
}, "lang": { "en-us": { "role": { "terseLabel": "Liabilities related to discontinued
operations", "totalLabel": "Total current liabilities", "label": "Disposal Group, Including
Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as
liabilities attributable to disposal group held for sale or disposed of, expected to be
disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": {
"r1", "r86", "r103", "r154", "r156", "r243", "r244" } }, "us-
gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
}, "lang": { "en-us": { "role": { "verboseLabel": "CURRENT LIABILITIES:", "terseLabel":
"Current Liabilities:", "label": "Disposal Group, Including Discontinued Operation,
Liabilities, Current [Abstract]" } } }, "auth_ref": { } }, "alks_LicenseAgreementMember":
{ "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname": "LicenseAgreementMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
}, "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to
the license agreement included under the collaboration agreement.", "label": "License
Agreement [Member]", "terseLabel": "License agreement" } } }, "auth_ref": { } }, "us-
gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LicenseMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
}, "lang": { "en-us": { "role": { "label": "License [Member]", "terseLabel": "License
revenue", "documentation": "Right to use intangible asset. Intangible asset includes,
but is not limited to, patent, copyright, technology, manufacturing process, software or
trademark." } } }, "auth_ref": { "r1325" } }, "us-gaap_LicensingAgreementsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LicensingAgreementsMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGood
}, "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "terseLabel":
"Collaboration agreements", "documentation": "Rights, generally of limited duration,
under a license arrangement (for example, to sell or otherwise utilize specified
products or processes in a specified territory)." } } }, "auth_ref": { "r74", "r647",
"r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304",
"r1305", "r1418" } }, "dei_LocalPhoneNumber": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"LocalPhoneNumber", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
}, "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local
Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref":
{ } }, "alks_LongActingINVEGAProductsMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.alkermes.com/20241231", "localname":
"LongActingINVEGAProductsMember", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
}, "lang": { "en-us": { "role": { "documentation": "Long-Acting INVEGA Products.",
"label": "Long Acting I N V E G A Products [Member]", "terseLabel": "Long-Acting
INVEGA Products" } } }, "auth_ref": { } }, "us-
gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": {

["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica)
[l, "lang": { "en-us": { "role": { "terseLabel": "Summary of Location of the Assets",](#)
["label": "Long-Lived Assets by Geographic Areas \[Table Text Block\]", "documentation":](#)
["Tabular disclosure of long-lived assets, excluding financial instruments, long-term](#)
[customer relationships of a financial institution, mortgage rights, deferred policy](#)
[acquisition costs, and deferred tax assets, by geographic areas located in the entity's](#)
[country of domicile and foreign countries in which the entity holds assets." } } }](#)
["auth_ref": \["r149" \] }, "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": {](#)
["xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["LongLivedAssetsHeldForSaleByAssetTypeAxis", "presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn](#)
["http://www.alkermes.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipm](#)
[l, "lang": { "en-us": { "role": { "label": "Long-Lived Asset, Held-for-Sale, Type \[Axis\]",](#)
["documentation": "Information by long-lived asset held for sale." } } }](#)
["auth_ref": \[](#)
["r14" \] }, "us-gaap_LongLivedAssetsHeldForSaleNameDomain": { "xbrltype":](#)
["domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["LongLivedAssetsHeldForSaleNameDomain", "presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn](#)
["http://www.alkermes.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipm](#)
[l, "lang": { "en-us": { "role": { "label": "Long-Lived Assets Held-for-Sale, Name](#)
[\[Domain\]", "documentation": "A name of the assets to be disposed." } } }](#)
["auth_ref": \[](#)
["r14" \] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri":](#)
["http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit",](#)
["presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche](#)
[l, "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Term Loans",](#)
["terseLabel": "Long-term debt", "documentation": "Amount, after deduction of](#)
[unamortized premium \(discount\) and debt issuance cost, of long-term debt. Excludes](#)
[lease obligation." } } }](#)
["auth_ref": \["r25", "r169", "r475", "r485", "r1043", "r1044",](#)
["r1081", "r1458" \] }, "us-gaap_LongTermDebtCurrent": { "xbrltype":](#)
["monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["LongTermDebtCurrent", "crdr": "credit", "presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI](#)
[l, "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Current Maturities,](#)
[Total", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion](#)
[of long-term debt", "negatedLabel": "Less: current portion", "documentation":](#)
["Amount, after deduction of unamortized premium \(discount\) and debt issuance cost,](#)
[of long-term debt classified as current. Excludes lease obligation." } } }](#)
["auth_ref": \[](#)
["r256" \] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType",](#)
["nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr":](#)
["credit", "presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional](#)
[l, "lang": { "en-us": { "role": { "terseLabel": "long-term debt paid off", "label": "Long-](#)
[Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt](#)
[whether such amount is presented as a separate caption or as a parenthetical](#)
[disclosure. Additionally, this element may be used in connection with the fair value](#)
[disclosures required in the footnote disclosures to the financial statements. The](#)
[element may be used in both the balance sheet and disclosure in the same](#)
[submission." } } }](#)
["auth_ref": \["r1433", "r1435", "r1436", "r1437" \] }, "us-](#)
[gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {](#)
["xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr":](#)
["credit", "presentation": {](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche](#)
[l, "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt,](#)
[Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking](#)
[fund requirement, and other securities issued that are redeemable by holder at fixed or](#)

determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r292", "r479"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSchedule", "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r292", "r479"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSchedule", "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r292", "r479"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSchedule", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCE_SHEET", "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "LONG-TERM DEBT", "verboseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r258"] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtTextBlock", "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "terseLabel": "Long-term Debt", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r159"] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCE_SHEET", "lang": { "en-us": { "role": { "totalLabel": "Long-Term Investments, Total", "label": "Long-Term Investments", "terseLabel": "INVESTMENTS\u2014LONG-TERM", "verboseLabel": "Investments-long-term", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": ["r249"] }, "alks_LongTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "LongTermInvestmentsMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule"] }

], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to long-term investments.", "label": "Long Term Investments [Member]", "terseLabel": "Long-term investments" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche"] }, "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r25", "r1309", "r1310", "r1311"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche"] }, "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-Term Debt, Type", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r25", "r55", "r1309", "r1310", "r1311"] }, "us-gaap_LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo"] }, "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Provision", "terseLabel": "Potential material losses from claims, legal proceedings probable of occurring", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth_ref": ["r1314"] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo"] }, "lang": { "en-us": { "role": { "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Additional sought value for damages as part of requested modification", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": ["r1314", "r1315", "r1316"] }, "alks_LuxembourgInlandRevenueTwoThousandEighteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "LuxembourgInlandRevenueTwoThousandEighteenMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio"] }, "lang": { "en-us": { "role": { "documentation": "Luxembourg inland revenue two thousand eighteen.", "label": "Luxembourg Inland Revenue Two Thousand Eighteen [Member]", "terseLabel": "LTA 2018" } } }, "auth_ref": [] }, "alks_LuxembourgInlandRevenueTwoThousandSeventeenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "LuxembourgInlandRevenueTwoThousandSeventeenMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio"] }, "lang": { "en-us": { "role": { "documentation": "Luxembourg inland revenue two thousand seventeen.", "label": "Luxembourg Inland Revenue Two Thousand Seventeen [Member]", "terseLabel": "LTA 2017" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang

["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica)
], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer",
 "documentation": "Information by name or description of a single external customer or
 a group of external customers." } } }, "auth_ref": ["r361", "r1051", "r1094", "r1098",
 "r1324", "r1460", "r1464", "r1465", "r1467", "r1468", "r1469", "r1470", "r1471",
 "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480",
 "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489",
 "r1491", "r1492"] }, "alks_ManufacturedProductAndRoyaltyMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "ManufacturedProductAndRoyaltyMember", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by
 labor or machinery, and royalties.", "label": "Manufactured Product And Royalty
 [Member]", "terseLabel": "Manufacturing and royalty revenues" } } }, "auth_ref": [] },
 "alks_ManufacturingAndSupplyAgreementMember": { "xbrltype": "domainItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "ManufacturingAndSupplyAgreementMember", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to
 the manufacturing and supply agreement included under the collaboration
 agreement.", "label": "Manufacturing And Supply Agreement [Member]", "terseLabel":
 "Manufacturing and supply agreement" } } }, "auth_ref": [] },
 "alks_ManufacturingProcessPeriod": { "xbrltype": "durationItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname": "ManufacturingProcessPeriod",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
], "lang": { "en-us": { "role": { "documentation": "Represents the manufacturing
 process period.", "label": "Manufacturing Process Period", "terseLabel":
 "Manufacturing Process period" } } }, "auth_ref": [] },
 "alks_ManufacturingRevenueMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname": "ManufacturingRevenueMember",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
], "lang": { "en-us": { "role": { "documentation": "Manufacturing revenue.", "label":
 "Manufacturing Revenue [Member]", "terseLabel": "Manufacturing Revenue" } } },
 "auth_ref": [] }, "alks_MarketableSecuritiesRealizedGain": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "MarketableSecuritiesRealizedGain", "crdr": "credit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
], "lang": { "en-us": { "role": { "documentation": "Represents the profit realized on the
 sale of debt or equity securities categorized as held-to-maturity, trading securities and
 available-for-sale.", "label": "Marketable Securities Realized Gain", "terseLabel":
 "Realized gains" } } }, "auth_ref": [] }, "alks_MarketableSecuritiesRealizedLoss": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "MarketableSecuritiesRealizedLoss", "crdr": "debit", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
], "lang": { "en-us": { "role": { "label": "Marketable Securities Realized Loss",
 "terseLabel": "Realized losses", "documentation": "Represents the loss realized on the
 sale of debt or equity securities categorized as held-to-maturity, trading securities and
 available-for-sale." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
 "MaximumMember", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoo

"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
l, "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel":
"Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [
"r210", "r212", "r214", "r215", "r217", "r239", "r240", "r455", "r456", "r457", "r458",
"r591", "r643", "r720", "r803", "r881", "r883", "r891", "r917", "r918", "r975", "r979",
"r981", "r982", "r986", "r1006", "r1007", "r1038", "r1047", "r1061", "r1074", "r1075",
"r1079", "r1080", "r1095", "r1321", "r1449", "r1450", "r1451", "r1452", "r1453",
"r1454"] }, "alks_MaximumPercentageOfProductSuppliesOnNetSales": { "xbrltype":
"percentItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"MaximumPercentageOfProductSuppliesOnNetSales", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
l, "lang": { "en-us": { "role": { "documentation": "Maximum percentage of product
supplies on net sales.", "label": "Maximum Percentage Of Product Supplies On Net
Sales", "terseLabel": "Maximum percentage of product supplies on net sales" } } },
"auth_ref": [] }, "alks_McKessonCorporationMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.alkermes.com/20241231", "localname":
"McKessonCorporationMember", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
l, "lang": { "en-us": { "role": { "documentation": "McKesson Corporation.", "label": "Mc
Kesson Corporation [Member]", "terseLabel": "McKesson" } } }, "auth_ref": [] },
"ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r1175"] },
"ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r1175"] },
"alks_MedicaidRebateMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "MedicaidRebateMember",
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAn
l, "lang": { "en-us": { "role": { "documentation": "Medicaid rebate.", "label": "Medicaid
Rebate [Member]", "terseLabel": "Medicaid Rebate" } } }, "auth_ref": [] },
"alks_MedicarePartDMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "MedicarePartDMember",
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAn
l, "lang": { "en-us": { "role": { "documentation": "Medicare Part D.", "label": "Medicare
Part D [Member]", "terseLabel": "Medicare Part D" } } }, "auth_ref": [] },
"alks_MilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "MilestonePaymentsReceivable",
"crdr": "debit", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional
l, "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone
payments receivable.", "label": "Milestone Payments Receivable", "terseLabel":
"Milestone payment receivable" } } }, "auth_ref": [] },
"alks_MilestonePaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "MilestonePaymentsReceived",
"crdr": "credit", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional
l, "lang": { "en-us": { "role": { "documentation": "Milestone payments received.",

"label": "Milestone Payments Received", "terseLabel": "Milestone payments received" } }], "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAssets", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrangements", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditions", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssets", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssets", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssets"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" }, "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r210", "r212", "r214", "r215", "r217", "r239", "r240", "r455", "r456", "r457", "r458", "r591", "r643", "r720", "r803", "r881", "r883", "r891", "r917", "r918", "r975", "r979", "r981", "r982", "r986", "r1006", "r1007", "r1038", "r1047", "r1061", "r1074", "r1075", "r1079", "r1095", "r1321", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r1195"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r1203"] }, "alks_MuralOncologyPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "MuralOncologyPlcMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndOperations", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsSummary", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsSummary"], "lang": { "en-us": { "role": { "label": "Mural Oncology plc [Member]", "documentation": "Mural Oncology plc [Member]", "terseLabel": "Mural Oncology plc" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrangements", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssets", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssets"], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": ["r361", "r1051", "r1094", "r1098", "r1324", "r1460", "r1464", "r1465", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1491", "r1492"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r1176"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENT"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash flows used in financing activities", "documentation":

"Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r281"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash flows (used in) provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r281"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash flows provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r141", "r142", "r144"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSegmentReportingSummaries", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaries", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTS", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsComponents", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "Net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r132", "r144", "r174", "r244", "r267", "r269", "r274", "r288", "r301", "r303", "r304", "r305", "r306", "r307", "r310", "r311", "r317", "r400", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r690", "r695", "r714", "r741", "r866", "r949", "r967", "r968", "r1110", "r1319"] }, "us-

gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSec", "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "alks_NetSalesBelow250MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "NetSalesBelow250MillionMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "documentation": "Represents the maximum net sales under the collaborative arrangement to determine the know how royalty percentage.", "label": "Net Sales Below250 Million [Member]", "terseLabel": "Net sales of below \$250.0 million" } } }, "auth_ref": [] }, "alks_NetSalesBetween250And500MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "NetSalesBetween250And500MillionMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "documentation": "Represents the range of net sales under the collaborative arrangement to determine the know-how royalty percentage.", "label": "Net Sales Between250 And500 Million [Member]", "terseLabel": "Net sales between \$250.0 million and 500.0 million" } } }, "auth_ref": [] }, "alks_NetSalesGreaterThan500MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "NetSalesGreaterThan500MillionMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang", "lang": { "en-us": { "role": { "documentation": "Represents the minimum net sales under the collaborative arrangement to determine the know-how royalty percentage.", "label": "Net Sales Greater Than500 Million [Member]", "terseLabel": "Net sales greater than \$500.0 million" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "alks_NewNonEmployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "NewNonEmployeeDirectorsMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "terseLabel": "New Non-employee Directors", "label": "New Non Employee Directors [Member]", "documentation": "New non-employee directors." } } }, "auth_ref": [] }, "alks_NonEmployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "NonEmployeeDirectorsMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "documentation": "Non-employee directors.", "label": "Non Employee Directors [Member]", "terseLabel": "Non-employee Directors" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r1175"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

"NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r1138", "r1149", "r1159", "r1183", "r1192"] },
"ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO
NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r1166"] },
"ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel":
"Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r1165"] },
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r1183"]
}, "alks_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "NonRule10B51ArrModifiedFlag",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": {
"en-us": { "role": { "documentation": "Non-Rule 10b5-1 Arrangement Modified [Flag]",
"label": "Non-Rule 10b5-1 Arr Modified [Flag]", "terseLabel": "Non-Rule 10b5-1
Arrangement Modified" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role":
{ "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule
10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1203"] },
"ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": {
"en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
"terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1203"]
}, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
5", "lang": { "en-us": { "role": { "terseLabel": "INVESTING ACTIVITIES:", "label":
"Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "crdr": "credit",
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
1", "lang": { "en-us": { "role": { "totalLabel": "Noncash or Part Noncash Acquisition,
Value of Liabilities Assumed, Total", "label": "Noncash or Part Noncash Acquisition,
Value of Liabilities Assumed", "terseLabel": "Purchased capital expenditures included
in accounts payable and accrued expenses", "documentation": "The total amount of
[all] liabilities that an Entity assumes in acquiring a business or in consideration for an
asset received in a noncash (or part noncash) acquisition. Noncash is defined as
transactions during a period that affect recognized assets or liabilities but that do not
result in cash receipts or cash payments in the period. \Part noncash\ refers to that
portion of the transaction not resulting in cash receipts or cash payments in the
period." } } }, "auth_ref": ["r37", "r38", "r39"] }, "us-
gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr":
"credit", "presentation": [

["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6](http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6)
[l](#), "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel":
 "Total other income (expense), net", "terseLabel": "OTHER INCOME (EXPENSE), NET",
 "documentation": "The aggregate amount of income or expense from ancillary
 business-related activities (that is to say, excluding major activities considered part of
 the normal operations of the business)." } } }, "auth_ref": ["r134"] }, "us-
 gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract",
 "presentation": [
["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6](http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6)
[l](#), "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]",
 "terseLabel": "OTHER INCOME (EXPENSE), NET:" } } }, "auth_ref": [] },
 alks_NumberOfEqualAnnualInstallmentsForStockVested": { "xbrltype":
 "integerItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "NumberOfEqualAnnualInstallmentsForStockVested", "presentation": [
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
[l](#), "lang": { "en-us": { "role": { "documentation": "Number of equal annual installments
 for stock vested.", "label": "Number Of Equal Annual Installments For Stock Vested",
 "terseLabel": "Number of equal annual installments for stock vested" } } }, "auth_ref":
 [] }, alks_NumberOfInvestmentSecurities": { "xbrltype": "integerItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname": "NumberOfInvestmentSecurities",
 "presentation": [
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditio](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditio)
[l](#), "lang": { "en-us": { "role": { "documentation": "Number of investment securities.",
 "label": "Number Of Investment Securities", "terseLabel": "Number of investment
 securities" } } }, "auth_ref": [] }, alks_NumberOfLicenseAgreements": { "xbrltype":
 "integerItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "NumberOfLicenseAgreements", "presentation": [
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang)
[l](#), "lang": { "en-us": { "role": { "documentation": "Represents the number of license
 agreements.", "label": "Number Of License Agreements", "terseLabel": "Number of
 license agreements" } } }, "auth_ref": [] }, us-gaap_NumberOfOperatingSegments": {
 "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "NumberOfOperatingSegments", "presentation": [
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
[l](#), "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel":
 "Number of operating segment", "documentation": "Number of operating segments. An
 operating segment is a component of an enterprise: (a) that engages in business
 activities from which it may earn revenues and incur expenses (including revenues and
 expenses relating to transactions with other components of the same enterprise), (b)
 whose operating results are regularly reviewed by the enterprise's chief operating
 decision maker to make decisions about resources to be allocated to the segment and
 assess its performance, and (c) for which discrete financial information is available. An
 operating segment may engage in business activities for which it has yet to earn
 revenues, for example, start-up operations may be operating segments before earning
 revenues." } } }, "auth_ref": ["r1033", "r1264"] }, us-
 gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments",
 "presentation": [
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
[l](#), "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel":
 "Number of reportable segments", "documentation": "Number of segments reported by
 the entity. A reportable segment is a component of an entity for which there is an
 accounting requirement to report separate financial information on that component in
 the entity's financial statements." } } }, "auth_ref": ["r1027", "r1037", "r1264"] },
 alks_NumberOfSignificantOperatingLeases": { "xbrltype": "integerItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname":
 "NumberOfSignificantOperatingLeases", "presentation": [

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
l, "lang": { "en-us": { "role": { "documentation": "Number of significant operating
leases.", "label": "Number Of Significant Operating Leases", "terseLabel": "Number of
significant operating leases" } } }, "auth_ref": [] },
"alks_NumberOfTransitionServiceAgreement": { "xbrltype": "integerItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname":
"NumberOfTransitionServiceAgreement", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsA
l, "lang": { "en-us": { "role": { "terseLabel": "Number of transition service agreement",
"label": "Number of Transition Service Agreement", "documentation": "Number of
transition service agreement." } } }, "auth_ref": [] },
"alks_OHRisperidonePalimateMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "OHRisperidonePalimateMember",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
l, "lang": { "en-us": { "role": { "terseLabel": "9 O-H Risperidone Palimate [Member]",
"documentation": "9 O-H Risperidone Palimate.", "label": "O H Risperidone Palimate
[Member]" } } }, "auth_ref": [] },
"alks_OccupancyInternalResearchAndDevelopmentExpenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"OccupancyInternalResearchAndDevelopmentExpenses", "crdr": "debit",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
l, "lang": { "en-us": { "role": { "label": "Occupancy internal research and development
expenses", "documentation": "Occupancy internal research and development
expenses.", "terseLabel": "Occupancy" } } }, "auth_ref": [] },
"alks_OperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "OperatingActivitiesAbstract",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
l, "lang": { "en-us": { "role": { "terseLabel": "OPERATING ACTIVITIES:", "label":
"Operating Activities [Abstract]", "documentation": "Operating Activities." } } },
"auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr":
"credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
l, "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel":
"OPERATING INCOME FROM CONTINUING OPERATIONS", "documentation": "The net
result for the period of deducting operating expenses from operating revenues." } } },
"auth_ref": ["r178", "r1026", "r1263", "r1265", "r1266", "r1267", "r1268"] }, "us-
gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
l, "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel":
"Operating lease expense", "documentation": "Amount of operating lease expense.
Excludes sublease income." } } }, "auth_ref": ["r1443"] },
"alks_OperatingLeaseExpirationYear": { "xbrltype": "gYearItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "OperatingLeaseExpirationYear",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
l, "lang": { "en-us": { "role": { "documentation": "Operating lease expiration year.",
"label": "Operating Lease Expiration Year", "terseLabel": "Lease, expiration year" } } },
"auth_ref": [] }, "alks_OperatingLeaseLiabilitiesDiscontinuedOperatingActivities": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname": "OperatingLeaseLiabilitiesDiscontinuedOperatingActivities", "crdr":
"credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS

], "lang": { "en-us": { "role": { "negatedLabel": "Operating lease liabilities", "label": "Operating lease liabilities, discontinued operating activities", "documentation": "Operating lease liabilities, discontinued operating activities" } } }, "auth_ref": [] },
 "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesSummaryOffF",
], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "totalLabel": "Operating Lease, Liability, Total", "label": "Operating Lease, Liability", "verboseLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r758"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL",
], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities\u2014short-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r758"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL",
], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "OPERATING LEASE LIABILITIES\u2014LONG-TERM", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r758"] },
 "alks_OperatingLeaseLiabilityRemeasurementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "OperatingLeaseLiabilityRemeasurementAmount", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf",
], "lang": { "en-us": { "role": { "documentation": "Operating lease liability remeasurement amount.", "label": "Operating Lease Liability Remeasurement Amount", "terseLabel": "Operating lease liability remeasurement amount" } } }, "auth_ref": [] },
 "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf",
], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Payments for operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r759", "r762"] },
 "alks_OperatingLeaseProvisionForExtensionOfTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "OperatingLeaseProvisionForExtensionOfTerm", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf",
], "lang": { "en-us": { "role": { "documentation": "Represents the provision for extension of operating lease term.", "label": "Operating Lease Provision For Extension Of Term", "terseLabel": "Lessee operating lease term of option to extend" } } }, "auth_ref": [] },
 "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf",
], "lang": { "en-us": { "role": { "verboseLabel": "Right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "RIGHT-OF-USE ASSETS", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } },

"auth_ref": ["r757"] },
 "alks_OperatingLeaseRightOfUseAssetRemeasurementAmount": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "OperatingLeaseRightOfUseAssetRemeasurementAmount", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
 l, "lang": { "en-us": { "role": { "documentation": "Operating lease right of use asset
 remeasurement amount.", "label": "Operating Lease Right Of Use Asset
 Remeasurement Amount", "verboseLabel": "Operating lease right-of-use asset
 remeasurement amount" } } }, "auth_ref": [] }, "us-
 gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype":
 "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
 l, "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount
 Rate, Percent", "terseLabel": "Weighted average incremental borrowing rate",
 "documentation": "Weighted average discount rate for operating lease calculated at
 point in time." } } }, "auth_ref": ["r764", "r1082"] }, "us-
 gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype":
 "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
 l, "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining
 Lease Term", "terseLabel": "Weighted average remaining lease term",
 "documentation": "Weighted average remaining lease term for operating lease, in
 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one
 year, five months, and thirteen days." } } }, "auth_ref": ["r763", "r1082"] }, "us-
 gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr":
 "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
 l, "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel":
 "Operating loss carryforwards", "documentation": "Amount of operating loss
 carryforward, before tax effects, available to reduce future taxable income under
 enacted tax laws." } } }, "auth_ref": ["r677"] }, "us-
 gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": {
 "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial
 Statements [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr":
 "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAn
 l, "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current",
 "terseLabel": "Accrued other", "documentation": "Amount of expenses incurred but not
 yet paid classified as other, due within one year or the normal operating cycle, if
 longer." } } }, "auth_ref": ["r110"] }, "alks_OtherAdjustmentsMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "OtherAdjustmentsMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 l, "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Adjustments
 [Member]", "documentation": "Other adjustments." } } }, "auth_ref": [] }, "us-
 gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 l, "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other

Assets, Current", "documentation": "Amount of current assets classified as other." } }
 }, "auth_ref": ["r262", "r1083"] }, "us-gaap_OtherAssetsMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OtherAssetsMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificat
], "lang": { "en-us": { "role": { "label": "Other Assets [Member]", "terseLabel": "Other
 Assets", "documentation": "Primary financial statement caption encompassing other
 assets." } } }, "auth_ref": ["r77", "r79"] }, "us-gaap_OtherAssetsNoncurrent": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL
], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Assets,
 Noncurrent", "terseLabel": "OTHER ASSETS", "documentation": "Amount of
 noncurrent assets classified as other." } } }, "auth_ref": ["r254"] }, "us-
 gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDurin
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPer
 "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale,
 Unrealized Holding Gain (Loss), before Adjustment, after Tax", "verboseLabel":
 "Unrealized gain (loss) on marketable securities, net of tax provision (benefit)",
 "terseLabel": "Holding gain (loss), net of a tax provision (benefit) of \$292, \$1,195 and
 \$(973), respectively", "documentation": "Amount, after tax and before adjustment, of
 unrealized holding gain (loss) on investment in debt security measured at fair value
 with change in fair value recognized in other comprehensive income (available-for-
 sale). Excludes unrealized gain (loss) on investment in debt security measured at
 amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref":
 ["r264", "r266", "r396"] }, "us-
 gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDurin
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPer
 "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale,
 Unrealized Holding Gain (Loss), before Adjustment, Tax", "terseLabel": "Tax (benefit)
 provision", "verboseLabel": "Tax provision (benefit)", "documentation": "Amount,
 before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on
 investment in debt security measured at fair value with change in fair value recognized
 in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for
 unrealized gain (loss) on investment in debt security measured at amortized cost (held-
 to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r4", "r265"] },
 "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember",
 "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
], "lang": { "en-us": { "role": { "label": "Other Current Liabilities [Member]",
 "terseLabel": "Components of Accrued Sales Discounts, Allowances and Reserves",
 "documentation": "Primary financial statement caption encompassing other current
 liabilities." } } }, "auth_ref": [] },
 "alks_OtherExternalResearchAndDevelopmentExpenses": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "OtherExternalResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
], "lang": { "en-us": { "role": { "label": "Other External Research and Development

expenses", "documentation": "Other external research and Development expenses.",
"terseLabel": "Other external R&D expenses" } }], "auth_ref": []],
"alks_OtherInternalResearchAndDevelopmentExpenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"OtherInternalResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm
l, "lang": { "en-us": { "role": { "label": "Other internal research and development
expenses", "documentation": "Other internal research and development expenses.",
"terseLabel": "Other internal R&D expenses" } }], "auth_ref": []], "us-
gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr":
"credit", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
l, "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel":
"OTHER LONG-TERM LIABILITIES", "documentation": "Amount of liabilities classified
as other, due after one year or the normal operating cycle, if longer." } }], "auth_ref":
["r113"]], "alks_OtherMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "OtherMember", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAm
l, "lang": { "en-us": { "role": { "documentation": "Other.", "label": "Other [Member]",
"terseLabel": "Other" } }], "auth_ref": []], "us-gaap_OtherNoncashExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNoncashExpense", "crdr": "debit", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
l, "lang": { "en-us": { "role": { "label": "Other Noncash Expense", "terseLabel": "Other
non-cash charges", "documentation": "Amount of expense or loss included in net
income that result in no cash flow, classified as other." } }], "auth_ref": ["r144"]],
"us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNoncurrentLiabilitiesMember", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica
l, "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Member]",
"terseLabel": "Other Long-Term Liabilities", "verboseLabel": "Components of Other
Long-term Liabilities", "documentation": "Primary financial statement caption
encompassing other noncurrent liabilities." } }], "auth_ref": []], "us-
gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense",
"crdr": "credit", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC
l, "lang": { "en-us": { "role": { "totalLabel": "Other Nonoperating Income (Expense),
Total", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income
(expense), net", "verboseLabel": "Other segment (expenses) income", "documentation":
"Amount of income (expense) related to nonoperating activities, classified as other." }
] }], "auth_ref": ["r135"]], "ecd_OtherPerfMeasureAmt": { "xbrltype":
"decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"
l, "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount",
"terseLabel": "Other Performance Measure, Amount" } }], "auth_ref": ["r1175"]],
"alks_OtherProductsAndServicesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname":
"OtherProductsAndServicesMember", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
l, "lang": { "en-us": { "role": { "documentation": "Other products and services.",
"label": "Other Products And Services [Member]", "terseLabel": "Other" } }],
"auth_ref": []], "ecd_OutstandingAggtErrCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OutstandingAggtErrCompAmt", "presentation": [

"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r1136", "r1147", "r1157", "r1190"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r1139", "r1150", "r1160", "r1193"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1139", "r1150", "r1160", "r1193"] }, "alks_OutstandingTermLoansPrincipalAmountDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "OutstandingTermLoansPrincipalAmountDue", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi", "lang": { "en-us": { "role": { "label": "Outstanding Term Loans Principal Amount Due", "documentation": "Outstanding term loans principal amount due.", "terseLabel": "Outstanding term loans principal amount due" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r1164"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "alks_PaymentsCreditsRelatingToSalesInCurrentYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "PaymentsCreditsRelatingToSalesInCurrentYear", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "lang": { "en-us": { "role": { "negatedLabel": "Payments/credits relating to sales in current year", "label": "Payments Credits Relating To Sales In Current Year", "documentation": "Payments credits relating to sales in current year." } } }, "auth_ref": [] }, "alks_PaymentsCreditsRelatingToSalesInPriorYears": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "PaymentsCreditsRelatingToSalesInPriorYears", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "lang": { "en-us": { "role": { "label": "Payments Credits Relating To Sales In Prior Years", "documentation": "Payments credits relating to sales in prior years.", "negatedLabel": "Payments/credits relating to sales in prior years" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "negatedLabel": "Payment for the repurchase of ordinary shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r139"] }, "alks_PaymentsMadeInBusinessSeparation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "PaymentsMadeInBusinessSeparation", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "negatedLabel": "Cash transferred to Mural Oncology plc at separation", "label": "Payments Made In Business Separation", "documentation": "Payments made in business separation." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
l, "lang": { "en-us": { "role": { "label": "Payment for Debt Extinguishment or Debt
Prepayment Cost", "negatedLabel": "Payment made for debt extinguishment",
"documentation": "Amount of cash outflow for cost from early extinguishment and
prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and
other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes
accrued interest." } } }, "auth_ref": { "r6" } }, "us-
gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
l, "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based
Payment Arrangement", "negatedLabel": "Employee taxes paid related to net share
settlement of equity awards", "documentation": "Amount of cash outflow to satisfy
grantee's tax withholding obligation for award under share-based payment
arrangement." } } }, "auth_ref": { "r278" } }, "us-
gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
l, "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities",
"negatedLabel": "Purchases of investments", "documentation": "Amount of cash
outflow for purchase of marketable security." } } }, "auth_ref": { "r1274" } }, "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
l, "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and
Equipment, Total", "label": "Payments to Acquire Property, Plant, and Equipment",
"negatedLabel": "Additions of property, plant and equipment", "documentation": "The
cash outflow associated with the acquisition of long-lived, physical assets that are used
in the normal conduct of business to produce goods and services and not intended for
resale; includes cash outflows to pay for construction of self-constructed assets." } } },
"auth_ref": { "r138" } }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupIssuersFnTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label":
"Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers,
Footnote" } } }, "auth_ref": { "r1174" } }, "ecd_PeerGroupTotalShareholderRtnAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label":
"Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total
Shareholder Return Amount" } } }, "auth_ref": { "r1174" } }, "us-
gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l, "lang": { "en-us": { "role": { "label": "Pension and Other Postretirement Plans,
Nonpension Benefits, Policy [Policy Text Block]", "terseLabel": "Employee Benefit
Plans", "documentation": "Disclosure of accounting policy for plans, other than
pension plans, that provide postretirement benefits (including both defined benefit and
defined contribution plans). This accounting policy may address (1) the types of plans
sponsored by the entity, and the benefits provided by each plan (2) groups that
participate in (or are covered by) each plan (3) how plan assets, liabilities and
expenses are measured, including the use of any actuaries and (4) significant

assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived." } }], "auth_ref": ["r64", "r65", "r66"] },
 "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt",
 "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
 "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO
 Actually Paid Compensation Amount" } } }, "auth_ref": ["r1166"] },
 "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO
 [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r1183"] }, "ecd_PeoName": {
 "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } },
 "auth_ref": ["r1176"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType",
 "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt",
 "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
 "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total
 Compensation Amount" } } }, "auth_ref": ["r1165"] },
 "alks_PercentageOfInvestmentSecuritiesAvailableForSaleUnrealizedLossPosition2": {
 "xbrltype": "percentItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname":
 "PercentageOfInvestmentSecuritiesAvailableForSaleUnrealizedLossPosition2",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditio
], "lang": { "en-us": { "role": { "terseLabel": "Percentage of investment securities
 available for sale unrealized loss position", "label": "Percentage Of Investment
 Securities Available For Sale Unrealized Loss Position2", "documentation": "Percentage
 of investment securities available for sale unrealized loss position." } } }, "auth_ref": []
 }, "alks_PercentageOfNetSalesInRoyaltyPayment": { "xbrltype": "percentItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "PercentageOfNetSalesInRoyaltyPayment", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
], "lang": { "en-us": { "role": { "documentation": "Percentage of net sales in royalty
 payment.", "label": "Percentage Of Net Sales In Royalty Payment", "terseLabel":
 "Percentage of net sales in royalty payment" } } }, "auth_ref": [] },
 "alks_PercentageOfReductionInWorkForce": { "xbrltype": "percentItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname":
 "PercentageOfReductionInWorkForce", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional
], "lang": { "en-us": { "role": { "documentation": "Percentage Of Reduction In Work
 force", "label": "Percentage Of Reduction In Work force", "terseLabel": "Percentage of
 reduction in work force" } } }, "auth_ref": [] },
 "alks_PerformanceBasedRestrictedStockUnitAwardsMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "PerformanceBasedRestrictedStockUnitAwardsMember", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
], "lang": { "en-us": { "role": { "documentation": "Represents performance based
 restricted stock units as awarded by a company to their employees as a form of
 incentive compensation.", "label": "Performance Based Restricted Stock Unit Awards
 [Member]", "terseLabel": "Performance-based RSUs Awards" } } }, "auth_ref": [] }, "us-
 gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "terseLabel":

"Performance-based stock options", "documentation": "Share-based payment arrangement awarded for meeting performance target." } }], "auth_ref": [] },
 "alks_PeriodAfterLossCarryforwardsUtilizedThatTaxReturnsRemainOpenToExamination"
 { "xbrltype": "durationItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname":
 "PeriodAfterLossCarryforwardsUtilizedThatTaxReturnsRemainOpenToExamination",
 "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
], "lang": { "en-us": { "role": { "documentation": "Represents the period after loss
 carryforwards have been utilized that tax returns remain open to examination.",
 "label": "Period After Loss Carryforwards Utilized That Tax Returns Remain Open To
 Examination", "terseLabel": "Period after loss carryforwards utilized that tax returns
 remain open to examination" } } }, "auth_ref": [] }, "alks_Plan401KMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "Plan401KMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
], "lang": { "en-us": { "role": { "documentation": "Defined contribution 401 (k) plan.",
 "label": "Plan401 K [Member]", "terseLabel": "401 (K) Plan" } } }, "auth_ref": [] }, "us-
 gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name",
 "documentation": "Information by plan name for share-based payment arrangement." } } },
 "auth_ref": ["r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395",
 "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404",
 "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413",
 "r1414"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan
 Name", "documentation": "Plan name for share-based payment arrangement." } } },
 "auth_ref": ["r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396",
 "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405",
 "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414"] },
 "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember",
 "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
 "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel":
 "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r1167"] },
 "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation":
 ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
 "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments
 Service Cost" } } }, "auth_ref": ["r1223"] }, "ecd_PnsnBnftsAdjFnTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
 "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits
 Adjustments, Footnote" } } }, "auth_ref": ["r1166"] },
 "alks_PotentialAdditionalAwardToBePaid": { "xbrltype": "monetaryItemType", "nsuri":
 "http://www.alkermes.com/20241231", "localname":
 "PotentialAdditionalAwardToBePaid", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
], "lang": { "en-us": { "role": { "documentation": "Additional royalty revenue potentially
 to be repaid to Acorda.", "label": "Potential Additional Award To Be Paid", "terseLabel":
 "Potential additional award to be paid" } } }, "auth_ref": [] }, "us-
 gaap_PREFERREDStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"PreferredStockParOrStatedValuePerShare", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
l, "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per
Share", "terseLabel": "Preferred stock shares, par value (in dollars per share)",
"documentation": "Face amount or stated value per share of preferred stock
nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": {
"r116", "r487" } }, "us-gaap_PREFERREDStockSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockSharesAuthorized", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
l, "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized",
"terseLabel": "Preferred stock shares, authorized", "documentation": "The maximum
number of nonredeemable preferred shares (or preferred stock redeemable solely at
the option of the issuer) permitted to be issued by an entity's charter and bylaws." } }
}, "auth_ref": { "r116", "r929" } }, "us-gaap_PREFERREDStockSharesIssued": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockSharesIssued", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
l, "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel":
"Preferred stock shares, issued", "documentation": "Number of shares issued for
nonredeemable preferred shares and preferred shares redeemable solely at option of
issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held
as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": {
"r116", "r487" } }, "us-gaap_PREFERREDStockSharesOutstanding": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockSharesOutstanding", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
l, "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares
Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares
Outstanding, Beginning Balance", "label": "Preferred Stock, Shares Outstanding",
"terseLabel": "Preferred stock shares, outstanding", "documentation": "Aggregate
share number for all nonredeemable preferred stock (or preferred stock redeemable
solely at the option of the issuer) held by stockholders. Does not include preferred
shares that have been repurchased." } } }, "auth_ref": { "r116", "r929", "r947", "r1494",
"r1495" } }, "us-gaap_PREFERREDStockValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
l, "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel":
"Preferred shares, par value, \$0.01 per share; 50,000,000 shares authorized; zero
issued and outstanding at December 31, 2024 and 2023, respectively",
"documentation": "Aggregate par or stated value of issued nonredeemable preferred
stock (or preferred stock redeemable solely at the option of the issuer). This item
includes treasury stock repurchased by the entity. Note: elements for number of
nonredeemable preferred shares, par value and other disclosure concepts are in
another section within stockholders' equity." } } }, "auth_ref": { "r116", "r856", "r1083"
 } }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
l, "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current",
"terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount
of asset related to consideration paid in advance for costs that provide economic
benefits in future periods, and amount of other assets that are expected to be realized
or consumed within one year or the normal operating cycle, if longer." } } },
"auth_ref": { "r1244" } }, "alks_PrepaymentOfLongTermDebt": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"PrepaymentOfLongTermDebt", "crdr": "credit", "presentation": {

["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddi)
["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA](http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA)
], "lang": { "en-us": { "role": { "negatedLabel": "Prepayment of long-term debt", "label":
 "Prepayment Of Long Term Debt", "documentation": "Prepayment of long term debt." }
 } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
 "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "PriorPeriodReclassificationAdjustmentDescription", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici">
[\], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment
 \[Policy Text Block\]", "terseLabel": "Reclassification", "documentation": "Disclosure of
 accounting policy for reclassification affecting comparability of financial statement.
 Excludes amendment to accounting standards, other change in accounting principle,
 and correction of error." } } }, "auth_ref": \["r1242" \] },
 "alks_ProceedsAndRealizedGainLossOnMarketableSecuritiesTableTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "ProceedsAndRealizedGainLossOnMarketableSecuritiesTableTextBlock",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables">
\[\\], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the proceeds
 from sales and maturities of marketable securities, plus the resulting realized gains
 and losses.", "label": "Proceeds And Realized Gain Loss On Marketable Securities Table
 \\[Text Block\\]", "terseLabel": "Schedule of Proceeds from Sales and Maturities of
 Marketable Securities Plus Resulting Realized Gains and Losses" } } }, "auth_ref": \\[\\] },
 "alks_ProceedsFromContingentConsideration": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "ProceedsFromContingentConsideration", "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA">
\\[\\\], "lang": { "en-us": { "role": { "documentation": "Proceeds from contingent
 consideration.", "label": "Proceeds From Contingent Consideration", "terseLabel":
 "Proceeds from contingent consideration" } } }, "auth_ref": \\\[\\\] }, "us-
 gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA">
\\\[\\\\], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale of the Athlone
 Facility", "label": "Proceeds from Divestiture of Businesses", "documentation": "The
 cash inflow associated with the amount received from the sale of a portion of the
 company's business, for example a segment, division, branch or other business, during
 the period." } } }, "auth_ref": \\\\["r33" \\\\] }, "us-
 gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlan">
\\\\[\\\\\], "lang": { "en-us": { "role": { "totalLabel": "Proceeds, Issuance of Shares, Share-Based
 Payment Arrangement, Including Option Exercised, Total", "label": "Proceeds, Issuance
 of Shares, Share-Based Payment Arrangement, Including Option Exercised",
 "terseLabel": "Proceeds from the issuance of ordinary shares under share-based
 compensation arrangements", "documentation": "Amount of cash inflow from issuance
 of shares under share-based payment arrangement. Includes, but is not limited to,
 option exercised." } } }, "auth_ref": \\\\\["r5", "r22" \\\\\] }, "us-
 gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu">
\\\\\[\\\\\\], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable
 Securities", "verboseLabel": "Proceeds from the sales and maturities of investments",\\\\\]\\\\\(http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu\\\\\)\\\\]\\\\(http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA\\\\)\\\]\\\(http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA\\\)\\]\\(http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA\\)\]\(http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables\)](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici)

"documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Sales and maturities of investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": ["r32"] }, "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyHeldForSale", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn", "lang": { "en-us": { "role": { "terseLabel": "Procceds from sale of development and manufacturing facility", "label": "Proceeds from Sale, Property, Held-for-Sale", "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth." } } }, "auth_ref": ["r137"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from the sale of equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r137"] }, "alks_ProductDiscountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ProductDiscountsMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAn", "lang": { "en-us": { "role": { "documentation": "Product discounts.", "label": "Product Discounts [Member]", "terseLabel": "Product Discounts" } } }, "auth_ref": [] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici", "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC", "lang": { "en-us": { "role": { "label": "Product [Member]", "terseLabel": "Product sales, net", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r1049"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccr

["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAndAccr](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAndAccr)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC](http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC)
, "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel":
"Product and Service", "documentation": "Information by product and service, or group
of similar products and similar services." } } }, "auth_ref": ["r219", "r220", "r221",
"r222", "r223", "r224", "r237", "r357", "r807", "r874", "r875", "r876", "r877", "r878",
"r879", "r880", "r1010", "r1049", "r1093", "r1095", "r1096", "r1099", "r1101", "r1241",
"r1317", "r1318", "r1324", "r1460", "r1464", "r1465", "r1466", "r1467", "r1468",
"r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477",
"r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486",
"r1487", "r1488", "r1489", "r1491", "r1492"] }, "alks_ProductReturnsMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname": "ProductReturnsMember", "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc](http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc)
, "lang": { "en-us": { "role": { "terseLabel": "Product Returns", "label": "Product
Returns [Member]", "documentation": "Product returns." } } }, "auth_ref": [] },
"srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri":
["http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation":](http://fasb.org/srt/2024)
{
["http://www.alkermes.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccr](http://www.alkermes.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccr)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAnd](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAnd)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific](http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific)
["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC](http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC)
, "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel":
"Product and Service", "documentation": "Product or service, or a group of similar
products or similar services." } } }, "auth_ref": ["r219", "r220", "r221", "r222", "r223",
"r224", "r237", "r357", "r807", "r874", "r875", "r876", "r877", "r878", "r879", "r880",
"r1010", "r1049", "r1093", "r1095", "r1096", "r1099", "r1101", "r1241", "r1317",
"r1318", "r1324", "r1460", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469",
"r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478",
"r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487",
"r1488", "r1489", "r1491", "r1492"] }, "us-gaap_ProfitLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss",
"crdr": "credit", "presentation": {
["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA](http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA)
, "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion
Attributable to Noncontrolling Interest, Total", "label": "Net Income (Loss), Including
Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)",
"documentation": "The consolidated profit or loss for the period, net of income taxes,
including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [
"r244", "r267", "r269", "r280", "r288", "r301", "r307", "r310", "r311", "r400", "r459",
"r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r690", "r695", "r697",
"r700", "r701", "r714", "r741", "r845", "r865", "r902", "r949", "r967", "r968", "r1068",
"r1069", "r1111", "r1247", "r1319"] }, "us-gaap_PropertyPlantAndEquipmentAbstract":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property,
Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-

gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
}, "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel":
"Long-Lived Tangible Asset", "documentation": "Information by type of long-lived,
physical assets used to produce goods and services and not intended for resale." } } },
"auth_ref": { "r11", "r766" } }, "us-
gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
l, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text
Block]", "terseLabel": "Property, Plant and Equipment", "documentation": "The entire
disclosure for long-lived, physical asset used in normal conduct of business and not
intended for resale. Includes, but is not limited to, work of art, historical treasure, and
similar asset classified as collections." } } }, "auth_ref": { "r152", "r200", "r203", "r204"
l }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentDisposals", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
l, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Disposals",
"terseLabel": "Carrying value at the time of disposition", "documentation": "Amount of
divestiture of long-lived, physical assets used in the normal conduct of business and
not intended for resale. Examples include, but are not limited to, land, buildings,
machinery and equipment, office equipment, furniture and fixtures, and computer
equipment." } } }, "auth_ref": { } },
"alks_PropertyPlantAndEquipmentEstimatedUsefulLivesDescription": { "xbrltype":
"stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"PropertyPlantAndEquipmentEstimatedUsefulLivesDescription", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
l, "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life", "label": "Property
Plant And Equipment Estimated Useful Lives Description", "documentation": "Property,
plant and equipment estimated useful lives description." } } }, "auth_ref": { } },
"alks_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
l, "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the estimated
useful life of long-lived, physical assets that are used in the normal conduct of business
to produce goods and services and not intended for resale.", "label": "Property Plant
And Equipment Estimated Useful Lives Table [Text Block]", "terseLabel": "Schedule of
Estimated Useful Life of Property, Plant and Equipment" } } }, "auth_ref": { } }, "us-
gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross",
"crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
l, "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment,
Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross,
Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total",
"label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and
equipment, gross", "documentation": "Amount before accumulated depreciation,
depletion and amortization of physical assets used in the normal conduct of business
and not intended for resale. Examples include, but are not limited to, land, buildings,

machinery and equipment, office equipment, and furniture and fixtures." } } },
"auth_ref": ["r155", "r250", "r863"] }, "us-
gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipm
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]",
"terseLabel": "Property Plant And Equipment [Line Items]", "verboseLabel": "Property,
plant and equipment", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } },
"auth_ref": ["r766"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipm
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL
l, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net",
"terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET", "totalLabel": "Total
property, plant and equipment, net", "verboseLabel": "Property, plant and equipment,
net", "documentation": "Amount after accumulated depreciation, depletion and
amortization of physical assets used in the normal conduct of business to produce
goods and services and not intended for resale. Examples include, but are not limited
to, land, buildings, machinery and equipment, office equipment, and furniture and
fixtures." } } }, "auth_ref": ["r11", "r766", "r850", "r863", "r1083"] }, "us-
gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentPolicyTextBlock", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy
Text Block]", "terseLabel": "Property, Plant and Equipment", "documentation":
"Disclosure of accounting policy for long-lived, physical asset used in normal conduct
of business and not intended for resale. Includes, but is not limited to, work of art,
historical treasure, and similar asset classified as collections." } } }, "auth_ref": {
"r11", "r200", "r203", "r861"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentTextBlock", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
l, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text
Block]", "terseLabel": "Schedule of Property, Plant and Equipment", "documentation":
"Tabular disclosure of physical assets used in the normal conduct of business and not
intended for resale. Includes, but is not limited to, balances by class of assets,
depreciation and depletion expense and method used, including composite
depreciation, and accumulated deprecation." } } }, "auth_ref": ["r11"] }, "us-
gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentTypeDomain", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
l, "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]",
"terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived,

physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } }], "auth_ref": ["r155", "r766"]], "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } }], "auth_ref": []], "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici", "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life", "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]", "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value." } }], "auth_ref": ["r1306"]], "alks_ProvisionsForSalesAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ProvisionsForSalesAndAllowances", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "lang": { "en-us": { "role": { "label": "Provisions For Sales And Allowances", "documentation": "provisions for sales and allowances.", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending Balance", "terseLabel": "Revenue-related reserves" } }], "auth_ref": []], "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndC", "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } }], "auth_ref": ["r114", "r170"]], "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndC", "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } }], "auth_ref": ["r114", "r170"]], "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit",

"presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo",
 "lang": { "en-us": { "role": { "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Open purchase order commitments",
 "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } },
 "auth_ref": { "r114", "r170" }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable",
 "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } },
 "auth_ref": { "r1164" }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock",
 "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]",
 "terseLabel": "Pay vs Performance Disclosure, Table" } } },
 "auth_ref": { "r1164" },
 "alks_RISPERDALCONSTAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "RISPERDALCONSTAMember",
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr
 "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to RISPERDAL CONSTA, a product of the entity.", "label": "R I S P E R D A L C O N S T A [Member]", "terseLabel": "RISPERDAL CONSTA" } } },
 "auth_ref": { } },
 "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
 "localname": "RangeAxis", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGood
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } },
 "auth_ref": { "r210", "r212", "r214", "r215", "r217", "r239", "r240", "r455", "r456", "r457", "r458", "r547", "r591", "r627", "r628", "r629", "r643", "r720", "r777", "r786", "r803", "r881", "r883", "r891", "r917", "r918", "r975", "r979", "r981", "r982", "r986", "r1006", "r1007", "r1038", "r1047", "r1061", "r1074", "r1075", "r1079", "r1080", "r1095", "r1104", "r1312", "r1321", "r1436", "r1450", "r1451", "r1452", "r1453", "r1454" },
 "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGood
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]",
 "terseLabel": "Statistical Measurement", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } },
 "auth_ref": { "r210", "r212", "r214", "r215", "r217", "r239", "r240", "r455", "r456", "r457", "r458", "r547", "r591", "r627", "r628", "r629", "r643", "r720", "r777", "r786", "r803", "r881", "r883", "r891", "r917", "r918", "r975", "r979",

"r981", "r982", "r986", "r1006", "r1007", "r1038", "r1047", "r1061", "r1074", "r1075", "r1079", "r1080", "r1095", "r1104", "r1312", "r1321", "r1436", "r1450", "r1451", "r1452", "r1453", "r1454"] },
"alks_ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWith"
{ "xbrltype": "sharesItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdi
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
l, "lang": { "en-us": { "role": { "documentation": "This element represents receipt of
Alkermes' stock for the exercise of stock options or to satisfy minimum tax withholding
obligations related to stock based awards.", "label": "Receipt Of Company Stock For
Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related
To Stock Based Awards Shares", "terseLabel": "Receipt of Alkermes' shares for the
exercise of stock options or to satisfy minimum tax withholding obligations related to
share-based awards (in shares)" } } }, "auth_ref": [] },
"alks_ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWith"
{ "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdi
"crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
l, "lang": { "en-us": { "role": { "documentation": "This element represents receipt of
Alkermes' stock for the exercise of stock options or to satisfy minimum tax withholding
obligations related to stock based awards.", "label": "Receipt Of Company Stock For
Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related
To Stock Based Awards Value", "terseLabel": "Receipt of Alkermes' shares for the
exercise of stock options or to satisfy minimum tax withholding obligations related to
share-based awards" } } }, "auth_ref": [] }, "us-gaap_ReceivablesNetCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReceivablesNetCurrent", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI
l, "lang": { "en-us": { "role": { "totalLabel": "Receivables, Net, Current, Total", "label":
"Receivables, Net, Current", "terseLabel": "Receivables, net", "documentation": "The
total amount due to the entity within one year of the balance sheet date (or one
operating cycle, if longer) from outside sources, including trade accounts receivable,
notes and loans receivable, as well as any other types of receivables, net of allowances
established for the purpose of reducing such receivables to an amount that
approximates their net realizable value." } } }, "auth_ref": ["r1083"] },
"ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems",
"lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation
Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded
Compensation Disclosure" } } }, "auth_ref": ["r1131", "r1142", "r1152", "r1185"] },
"alks_RepaymentOfRoyaltyRevenue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.alkermes.com/20241231", "localname": "RepaymentOfRoyaltyRevenue",
"crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri
l, "lang": { "en-us": { "role": { "documentation": "Repayment Of Royalty Revenue",
"label": "Repayment Of Royalty Revenue", "terseLabel": "Repayment of royalty revenue"
} } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
l, "lang": { "en-us": { "role": { "totalLabel": "Repayments of Long-Term Debt, Total",
"label": "Repayments of Long-Term Debt", "negatedLabel": "Principal payments of
long-term debt", "documentation": "The cash outflow for debt initially having maturity

due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r140", "r898"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r235", "r236", "r290", "r291", "r471", "r489", "r769", "r787", "r852", "r1019", "r1020"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC", "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "R&D expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r646", "r1008", "r1032", "r1455"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensatio", "lang": { "en-us": { "role": { "verboseLabel": "Research and Development Expense", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r645"] }, "alks_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ResearchAndDevelopmentMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC", "lang": { "en-us": { "role": { "documentation": "Relating to research and development.", "label": "Research And Development [Member]", "terseLabel": "Research and development revenue" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r1132", "r1143", "r1153", "r1186"] },

"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } } }, "auth_ref": { "r1133", "r1144", "r1154", "r1187" } } },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } } }, "auth_ref": { "r1140", "r1151", "r1161", "r1194" } } },
"us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule": { "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, "auth_ref": { "r248" } } },
"us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSchedule": { "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Unit Awards", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } } }, "auth_ref": { } } },
"us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCE_SHEET": { "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated Deficit) Total", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } } }, "auth_ref": { "r119", "r163", "r859", "r888", "r890", "r899", "r930", "r1083" } } },
"us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENT_OF_INCOME": { "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } } }, "auth_ref": { "r241", "r298", "r299", "r300", "r302", "r307", "r309", "r311", "r401", "r402", "r448", "r679", "r680", "r687", "r688", "r689", "r691", "r694", "r695", "r704", "r706", "r707", "r709", "r712", "r754", "r756", "r885", "r887", "r903", "r1494" } } },
"us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameAxis", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantEvents": { "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } } }, "auth_ref": { "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r1061", "r1229", "r1326", "r1327", "r1328", "r1329", "r1330",

"r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385"] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameDomain", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificance", "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } } }, "auth_ref": { "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r1061", "r1229", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385"] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationAxis", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificance", "lang": { "en-us": { "role": { "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } } }, "auth_ref": { "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r1386", "r1387", "r1388"] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationDomain", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificance", "lang": { "en-us": { "role": { "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } } }, "auth_ref": { "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r1386", "r1387", "r1388"] }, "alks_ReturnOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ReturnOfInvestments", "crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENT", "lang": { "en-us": { "role": { "documentation": "Return of investment.", "label": "Return Of Investments", "terseLabel": "Return of Fountain Healthcare Partners II, L.P. investment" } } } }, "auth_ref": [] }, "alks_ReturnsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ReturnsMember", "presentation": {

["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc](http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc)
[l, "lang": { "en-us": { "role": { "terseLabel": "Returns", "label": "Returns \[Member\]",](#)
["documentation": "Returns." } } }, "auth_ref": \[\] }, "us-](#)
[gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType",](#)
["nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label":](#)
["Revenue from Contract with Customer \[Abstract\]" } } }, "auth_ref": \[\] }, "us-](#)
[gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype":](#)
["monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit",](#)
["presentation": \[](#)
["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSumm](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici](#)
["http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC](#)
[l, "lang": { "en-us": { "role": { "netLabel": "Royalty revenue", "label": "Revenue from](#)
[Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues",](#)
["verboseLabel": "Revenue by region:", "documentation": "Amount, excluding tax](#)
[collected from customer, of revenue from satisfaction of performance obligation by](#)
[transferring promised good or service to customer. Tax collected from customer is tax](#)
[assessed by governmental authority that is both imposed on and concurrent with](#)
[specific revenue-producing transaction, including, but not limited to, sales, use, value](#)
[added and excise." } } }, "auth_ref": \["r176", "r177", "r326", "r333", "r334", "r349",](#)
["r353", "r357", "r359", "r361", "r521", "r522", "r807" \] }, "us-](#)
[gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype":](#)
["textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["RevenueFromContractWithCustomerPolicyTextBlock", "presentation": \[](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici](#)
[l, "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer \[Policy](#)
[Text Block\]", "terseLabel": "Revenue from Contracts with Customers",](#)
["documentation": "Disclosure of accounting policy for revenue from contract with](#)
[customer." } } }, "auth_ref": \["r207", "r513", "r514", "r515", "r516", "r517", "r518",](#)
["r519", "r520", "r1009" \] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": {](#)
["xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["RevenueFromContractWithCustomerTextBlock", "presentation": \[](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri](#)
[l, "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer \[Text](#)
[Block\]", "terseLabel": "Revenue from Contracts with Customers", "documentation":](#)
["The entire disclosure of revenue from contract with customer to transfer good or](#)
[service and to transfer nonfinancial asset. Includes, but is not limited to,](#)
[disaggregation of revenue, credit loss recognized from contract with customer,](#)
[judgment and change in judgment related to contract with customer, and asset](#)
[recognized from cost incurred to obtain or fulfill contract with customer. Excludes](#)
[insurance and lease contracts." } } }, "auth_ref": \["r207", "r505", "r506", "r507",](#)
["r508", "r509", "r510", "r511", "r512", "r525" \] }, "us-](#)
[gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {](#)
["xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":](#)
["RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": \[](#)
["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici](#)
[l, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues by Geographic](#)
[Location, as Determined by the Location of the Customer", "label": "Revenue from](#)
[External Customers by Geographic Areas \[Table Text Block\]", "documentation":](#)
["Tabular disclosure of revenue from external customers by geographic areas attributed](#)
[to the entity's country of domicile and to foreign countries from which the entity](#)
[derives revenue." } } }, "auth_ref": \["r148" \] },](#)
["alks_RevenueRelatedReservesIncludedInConsolidatedBalanceSheetsTableTextBlock":](#)

{ "xbrltype": "textBlockItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "RevenueRelatedReservesIncludedInConsolidatedBalanceSheetsTableTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificat", "lang": { "en-us": { "role": { "label": "Revenue Related Reserves Included In Consolidated Balance Sheets [Table Text Block]", "documentation": "Revenue related reserves included in consolidated balance sheets.", "terseLabel": "Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio", "lang": { "en-us": { "role": { "label": "Revenues", "totalLabel": "Revenues, Total", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "auth_ref": ["r176", "r177", "r275", "r288", "r326", "r333", "r334", "r349", "r353", "r357", "r359", "r361", "r400", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r741", "r845", "r1032", "r1319"] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificat", "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Geographic Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": [] }, "alks_RevenuesNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "RevenuesNetMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificat", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificat", "lang": { "en-us": { "role": { "documentation": "Aggregate revenues, net, during the period in the normal course of business.", "label": "Revenues Net [Member]", "terseLabel": "Revenues Net" } } }, "auth_ref": [] }, "alks_RightOfUseAssetsDiscontinuedOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "RightOfUseAssetsDiscontinuedOperatingActivities", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS", "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Right-of-use assets, discontinued operating activities", "documentation": "Right-of-use assets, discontinued operating activities" } } }, "auth_ref": [] }, "alks_RiskAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "RiskAndUncertaintiesPolicyTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificat", "lang": { "en-us": { "role": { "documentation": "Risk and uncertainties.", "label": "Risk And Uncertainties Policy [Text Block]", "terseLabel": "Risk and Uncertainties" } } }, "auth_ref": [] }, "alks_RodinTherapeuticsIncorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "RodinTherapeuticsIncorporationMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio", "lang": { "en-us": { "role": { "documentation": "Rodin Therapeutics Incorporation.", "label": "Rodin Therapeutics Incorporation [Member]", "terseLabel": "Rodin Therapeutics Incorporation" } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"RoyaltyMember", "presentation": [

http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr

http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr

], "lang": { "en-us": { "role": { "label": "Royalty [Member]", "terseLabel": "Royalty",

 "documentation": "Money for usage-based right to asset." } } }, "auth_ref": ["r1325"]

], "alks_RoyaltyRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri":

<http://www.alkermes.com/20241231>, "localname": "RoyaltyRevenueRecognized",

 "crdr": "debit", "presentation": [

http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr

], "lang": { "en-us": { "role": { "label": "Royalty revenue recognized", "documentation":

 "Royalty revenue recognized" } } }, "auth_ref": [] },

 "alks_RoyaltyRevenueRelatedToBackRoyalties": { "xbrltype": "monetaryItemType",

 "nsuri": <http://www.alkermes.com/20241231>, "localname":

 "RoyaltyRevenueRelatedToBackRoyalties", "crdr": "credit", "presentation": [

http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr

], "lang": { "en-us": { "role": { "terseLabel": "Royalty revenue related to back royalties",

 "label": "Royalty Revenue Related to Back Royalties", "documentation": "Royalty

 revenue related to back royalties." } } }, "auth_ref": [] },

 "alks_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri":

<http://www.alkermes.com/20241231>, "localname": "Rule10B51ArrModifiedFlag",

 "presentation": [<http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements>], "lang": {

 "en-us": { "role": { "documentation": "Rule 10b5-1 Arrangement Modified [Flag] .",

 "label": "Rule 10b5-1 Arr Modified [Flag]", "terseLabel": "Rule 10b5-1 Arrangement

 Modified" } } }, "auth_ref": [] }, "alks_Rule10B51TradingPlanMember": { "xbrltype":

 "domainItemType", "nsuri": <http://www.alkermes.com/20241231>, "localname":

 "Rule10B51TradingPlanMember", "presentation": [

<http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements>], "lang": { "en-us": { "role":

 { "documentation": "Rule10b5-1 Trading plan.", "label": "Rule10 B51 Trading Plan

 [Member]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype":

 "booleanItemType", "nsuri": <http://xbrl.sec.gov/ecd/2024>, "localname":

 "Rule10b51ArrAdoptedFlag", "presentation": [

<http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements>], "lang": { "en-us": { "role":

 { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1

 Arrangement Adopted" } } }, "auth_ref": ["r1203"] }, "ecd_Rule10b51ArrTrmntdFlag":

 { "xbrltype": "booleanItemType", "nsuri": <http://xbrl.sec.gov/ecd/2024>, "localname":

 "Rule10b51ArrTrmntdFlag", "presentation": [

<http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements>], "lang": { "en-us": { "role":

 { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1

 Arrangement Terminated" } } }, "auth_ref": ["r1203"] }, "us-

 gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType",

 "nsuri": <http://fasb.org/us-gaap/2024>, "localname":

 "SaleOfStockNameOfTransactionDomain", "presentation": [

http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici

], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation":

 "Sale of the entity's stock, including, but not limited to, initial public offering (IPO)

 and private placement." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": {

 "xbrltype": "domainItemType", "nsuri": <http://fasb.org/srt/2024>, "localname":

 "ScenarioForecastMember", "presentation": [

http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen

], "lang": { "en-us": { "role": { "verboseLabel": "Scenario Forecast", "label": "Forecast

 [Member]", "terseLabel": "Forecast", "documentation": "Information reported for

 future period. Excludes information expected to be reported in future period for effect

 on historical fact." } } }, "auth_ref": ["r596", "r1240", "r1260"] },

 "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri":

<http://fasb.org/srt/2024>, "localname": "ScenarioUnspecifiedDomain", "presentation":

 [

http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen

], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario",

"documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } }],
"auth_ref": ["r238", "r312", "r596", "r1227", "r1260"] }, "us-
gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAn
L", "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued
Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and
Accrued Expenses", "documentation": "Tabular disclosure of the (a) carrying value as
of the balance sheet date of liabilities incurred (and for which invoices have typically
been received) and payable to vendors for goods and services received that are used in
an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities.
Examples include taxes, interest, rent and utilities. Used to reflect the current portion
of the liabilities (due within one year or within the normal operating cycle if longer).
An alternative caption includes accrued expenses." } }], "auth_ref": [] },
"alks_ScheduleOfAccruedSalesDiscountsAllowancesAndReservesTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"ScheduleOfAccruedSalesDiscountsAllowancesAndReservesTableTextBlock",
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureAccountsPayableAn
L", "lang": { "en-us": { "role": { "documentation": "Schedule of accrued sales discounts
allowances and reserves.", "label": "Schedule Of Accrued Sales Discounts Allowances
And Reserves Table [Text Block]", "terseLabel": "Summary of Current Provision for
Sales, Discounts, Allowances and Reserves" } }], "auth_ref": [] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareT
f": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSci
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSci
L", "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation
[Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From
Computation Of Earnings Per Share [Table]", "documentation": "Disclosure of
information about security that could potentially dilute basic earnings per share (EPS)
in future that was not included in calculation of diluted EPS." } }], "auth_ref": ["r40"
] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareT
f": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextB
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareTa
L", "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded
from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule
of Anti-Dilutive Potential Common Share Equivalent Excluded from Calculation of
Earnings (Loss) Per Share", "documentation": "Tabular disclosure of securities
(including those issuable pursuant to contingent stock agreements) that could
potentially dilute basic earnings per share (EPS) in the future that were not included
in the computation of diluted EPS because to do so would increase EPS amounts or
decrease loss per share amounts for the period presented, by antidilutive securities." }
] }, "auth_ref": ["r40"] }, "us-
gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransacti
f": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsT
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang

], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r696"] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Provision (Benefit) for Income Taxes from Continuing Operations", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": ["r1428"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtTable", "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Long-term Debt", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Components of Net Deferred Tax Assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": ["r1422"] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalance": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalance", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsTable", "lang": { "en-us": { "role": { "terseLabel": "Summary of Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r14", "r23", "r26", "r86", "r95", "r96", "r97", "r99", "r100", "r104", "r106", "r107", "r157"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareTa
l", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic Earnings (Loss) Per
Ordinary Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table
Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted
earnings per share calculations, including a reconciliation of numerators and
denominators of the basic and diluted per-share computations for income from
continuing operations." } }], "auth_ref": ["r1262"] }, "us-
gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables
l", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Statutory
Tax Rate to Effective Tax Rate", "label": "Schedule of Effective Income Tax Rate
Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the
reconciliation using percentage or dollar amounts of the reported amount of income
tax expense attributable to continuing operations for the year to the amount of income
tax expense that would result from applying domestic federal statutory tax rates to
pretax income from continuing operations." } }], "auth_ref": ["r658", "r1066", "r1419"
] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeri
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCo
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensatio
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed
and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share
Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation":
"Disclosure of information about amount recognized for award under share-based
payment arrangement. Includes, but is not limited to, amount expensed in statement of
income or comprehensive income, amount capitalized in statement of financial
position, and corresponding reporting line item in financial statements." } }],
"auth_ref": ["r69"] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeri
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCo
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation
Expense from Continuing and Discontinued Operations", "label": "Share-Based
Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized
for award under share-based payment arrangement to statement of income or
comprehensive income and statement of financial position. Includes, but is not limited
to, corresponding line item in financial statement." } }], "auth_ref": ["r69"] }, "us-
gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu
l", "lang": { "en-us": { "role": { "label": "Schedule of Equity Method Investments [Line
Items]", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } }], "auth_ref": ["r288", "r397",
"r398", "r399", "r400", "r741"] }, "us-

gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": ["r244", "r288", "r397", "r398", "r399", "r400", "r741"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r435", "r442", "r445", "r446", "r447", "r808", "r1008", "r1041"] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": ["r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r1040"] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill", "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill and Intangible Assets", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": ["r1291", "r1295"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInventoryTables", "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r28", "r123", "r124", "r125"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtTables", "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Scheduled Maturities of Term Loan Facility", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r12"] }, "alks_ScheduleOfNetIncomeLossBeforeProvisionForTaxesByGeographicalAreaTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ScheduleOfNetIncomeLossBeforeProvisionForTaxesByGeographicalAreaTableTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of net income or loss before provision for income taxes by geographical area of the entity.", "label":

"Schedule Of Net Income Loss Before Provision For Taxes By Geographical Area Table [Text Block]", "terseLabel": "Schedule of Income (Loss) Before Provision (Benefit) for Income Taxes by Geographical Area" } }], "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica", "lang": { "en-us": { "role": { "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "terseLabel": "Schedule Of Product Information [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipm", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r11", "r766"] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographical": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreas", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica", "lang": { "en-us": { "role": { "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Revenues by Geographic Location, as Determined by the Location of the Customer, and the Location of its Long-term Assets", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": ["r52", "r127"] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica", "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": ["r52", "r127"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingTables

l, "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Summary of Significant Segment Expenses", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r49", "r50", "r51"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock" } }, "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r598", "r600", "r602", "r603", "r604", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r626", "r627", "r628", "r629", "r630"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock" } }, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of RSU Activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r164"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock" } }, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r20", "r21", "r164"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssumptionsUsedDuringTheYearToEstimateTheFairValueOfStockOptions", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAssumptionsUsedDuringTheYearToEstimateTheFairValueOfStockOptions" } }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Each Stock Option Granted Estimated on The Grant Date Using Weighted-average Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [

"r165"] },
 "alks_ScheduleOfTheTransferOfAssetsAndLiabilitiesWasEffectuatedInAccordanceWithTheS
 { "xbrltype": "textBlockItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname":
 "ScheduleOfTheTransferOfAssetsAndLiabilitiesWasEffectuatedInAccordanceWithTheSepar
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsT
 }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Transfer of Assets and
 Liabilities Effectuated in Accordance with Separation Agreements", "label": "Schedule of
 the Transfer of Assets and Liabilities was Effectuated in Accordance with the Separation
 Agreements [Table Text block]", "documentation": "Schedule of the transfer of assets
 and liabilities was effectuated in accordance with the separation agreements." } } },
 "auth_ref": [] }, "us-
 gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables
 }, "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll
 Forward [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Beginning
 and Ending Amount of Unrecognized Tax Benefits", "documentation": "Tabular
 disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": ["r667",
 "r1065"] }, "alks_ScheduledMaturitiesOfTermLoanTwoThousandAndTwentySix": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "ScheduledMaturitiesOfTermLoanTwoThousandAndTwentySix", "crdr":
 "credit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche
 }, "lang": { "en-us": { "role": { "documentation": "Scheduled maturities of term loan
 two thousand and twenty six.", "label": "Scheduled Maturities Of Term Loan Two
 Thousand And Twenty Six", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-
 gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 }, "lang": { "en-us": { "role": { "label": "Schedules of Concentration of Risk, by Risk
 Factor [Table Text Block]", "terseLabel": "Schedule of Revenue and Receivables From
 Customers Exceeding 10% of Total in Each Category", "documentation": "Tabular
 disclosure of the nature of a concentration, a benchmark to which it is compared, and
 the percentage that the risk is to the benchmark." } } }, "auth_ref": ["r42", "r43",
 "r44", "r45", "r80", "r167"] }, "dei_Security12bTitle": { "xbrltype":
 "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
 "Security12bTitle", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
 }, "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of
 12(b) Security", "documentation": "Title of a 12(b) registered security." } } },
 "auth_ref": ["r1113"] }, "dei_SecurityExchangeName": { "xbrltype":
 "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
 "SecurityExchangeName", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
 }, "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel":
 "Security Exchange Name", "documentation": "Name of the Exchange on which a
 security is registered." } } }, "auth_ref": ["r1116"] }, "us-
 gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "SegmentContinuingOperationsMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensatio
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu
 }, "lang": { "en-us": { "role": { "terseLabel": "Continuing Operations", "label":
 "Continuing Operations [Member]", "documentation": "Component of an entity

expected to operate in the foreseeable future." } }], "auth_ref": [] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensation", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Discontinued Operations [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": ["r8", "r87", "r88", "r89"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical", "documentation": "Geographical area." } } }, "auth_ref": ["r211", "r213", "r216", "r218", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r359", "r360", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r907", "r911", "r913", "r976", "r980", "r984", "r987", "r994", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1011", "r1050", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1097", "r1104", "r1324", "r1460", "r1464", "r1465", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1491", "r1492"] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentOperatingActivitiesDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensation", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu", "lang": { "en-us": { "role": { "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReporting", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r179", "r326", "r328", "r329", "r330", "r331", "r332", "r339", "r340", "r341", "r351", "r352", "r353", "r354", "r355", "r357", "r358",

"r361", "r1027", "r1030", "r1031", "r1032", "r1034", "r1036", "r1037" | }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummary", "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherItemAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingOtherItemAmount", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummary", "lang": { "en-us": { "role": { "label": "Segment Reporting, Other Segment Item, Amount", "terseLabel": "Other segment (expenses) income", "negatedLabel": "Other segment (expenses) income", "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)." } } }, "auth_ref": ["r326", "r340", "r341", "r353", "r1032" |], "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r342", "r343", "r344", "r345", "r346", "r347", "r348", "r356", "r359", "r1028", "r1029", "r1035" |], "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummary", "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "totalLabel": "Selling and Marketing Expense, Total", "terseLabel": "Selling and marketing expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummary", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC", "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Total selling, general and administrative expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r133" |], "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpenseAbstract", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSegmentReportingSummary", "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense [Abstract]", "terseLabel": "Selling, general and administrative expenses:" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"SellingGeneralAndAdministrativeExpensesMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensatio
 }, "lang": { "en-us": { "role": { "verboseLabel": "Selling, General and Administrative
 Expense", "label": "Selling, General and Administrative Expenses [Member]",
 "terseLabel": "Selling, general and administrative", "documentation": "Primary
 financial statement caption encompassing selling, general and administrative
 expense." } } }, "auth_ref": [] }, "us-
 gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 }, "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses,
 Policy [Policy Text Block]", "terseLabel": "Selling, General and Administrative
 Expenses", "documentation": "Disclosure of accounting policy for inclusion of
 significant items in the selling, general and administrative (or similar) expense report
 caption." } } }, "auth_ref": ["r1417"] }, "alks_SeparationAgreementMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "SeparationAgreementMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsS
 }, "lang": { "en-us": { "role": { "terseLabel": "Separation Agreement", "label":
 "Separation Agreement [Member]", "documentation": "Separation agreement." } } },
 "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensation", "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
 }, "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement,
 Noncash Expense, Total", "label": "Share-Based Payment Arrangement, Noncash
 Expense", "terseLabel": "Share-based compensation expense", "documentation":
 "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref":
 ["r9"] },
 "alks_ShareBasedCompensationArrangementAccountingModificationCharge": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "ShareBasedCompensationArrangementAccountingModificationCharge",
 "crdr": "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, accounting
 modification charge", "label": "Share-based Compensation Arrangement Accounting
 Modification Charge", "documentation": "Share-based compensation arrangement
 accounting modification charge." } } }, "auth_ref": [] }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisi
 { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteSei
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
 Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Number
 of years from the date of the grant", "documentation": "Estimated period over which an
 employee is required to provide service in exchange for the equity-based payment
 award, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the
 reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1062"]
 }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVesting
 { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeric
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by

Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } }], "auth_ref": ["r1062"] },

"alks_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun { "xbrltype": "pureItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrument("presentation": [

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompenn", "lang": { "en-us": { "role": { "documentation": "Represents the ratio of awards other than stock options counted against the total number of shares available for issuance.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Count Against Number Of Shares Available For Grant Ratio", "terseLabel": "Ratio of awards other than stock options counted against the total number of shares available for issuance" } }], "auth_ref": [] },

"alks_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun { "xbrltype": "sharesItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments "presentation": [

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompenn", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompenn", "lang": { "en-us": { "role": { "terseLabel": "Conversion reissuance (in shares)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Conversion Reissuance Grants In Period", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than conversion reissuance grants in period." } }], "auth_ref": [] },

"alks_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun { "xbrltype": "perShareItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments "presentation": [

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompenn", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompenn", "lang": { "en-us": { "role": { "terseLabel": "Conversion reissuance (in dollars per share)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Conversion Reissuance In Period Weighted Average Grant Date Fair Value", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options conversion reissuance in period weighted average grant date fair value." } }], "auth_ref": [] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments "presentation": [

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompenn", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompenn", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } }], "auth_ref": ["r619"] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun

{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments
 presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
 Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures,
 Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per
 share)", "documentation": "Weighted average fair value as of the grant date of equity-
 based award plans other than stock (unit) option plans that were not exercised or put
 into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": {
 "r619" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun
 { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments
 presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
 Share-Based Payment Award, Equity Instruments Other than Options, Grants in
 Period", "terseLabel": "Granted (in shares)", "documentation": "The number of grants
 made during the period on other than stock (or unit) option plans (for example,
 phantom stock or unit plan, stock or unit appreciation rights plan, performance target
 plan)." } } }, "auth_ref": { "r617" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun
 { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments
 presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
 Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period,
 Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per
 share)", "documentation": "The weighted average fair value at grant date for nonvested
 equity-based awards issued during the period on other than stock (or unit) option
 plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan,
 performance target plan)." } } }, "auth_ref": { "r617" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun
 { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments
 presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
 Share-Based Payment Award, Equity Instruments Other than Options, Nonvested,
 Number", "periodEndLabel": "Unvested at the end of the period (in shares)",
 "periodStartLabel": "Unvested at the beginning of the period (in shares)",
 "documentation": "The number of non-vested equity-based payment instruments,
 excluding stock (or unit) options, that validly exist and are outstanding as of the
 balance sheet date." } } }, "auth_ref": { "r614", "r615" } }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun
 { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments
 presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen

], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at the end of the period (in dollars per share)", "periodStartLabel": "Unvested at the beginning of the period (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r614", "r615"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r618"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of RSU's vested", "verboseLabel": "Fair value of vesting RSU's", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r621"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrun { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen

l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r618"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAsst
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumpt
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Weighted-average assumptions" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAsst
{ "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumpt
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected annual dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r628"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAsst
{ "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumpt
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock volatility, maximum (as a percent)", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAsst
{ "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumpt
"presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock volatility, minimum (as a percent)", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAsst

{ "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumpt", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum (as a percent)", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssu",
 { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumpt", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum (as a percent)", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r598", "r600", "r602", "r603", "r604", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r626", "r627", "r628", "r629", "r630"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdd",
 { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAddition", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in number of ordinary shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] },
 "alks_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPla", { "xbrltype": "integerItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansUn", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "lang": { "en-us": { "role": { "documentation": "Represents the number of equity-based compensation plans under which awards are currently made.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans Under Which Awards Are Currently Made", "terseLabel": "Number of share-based compensation plan under which awards are currently made" } } }, "auth_ref": [] },
 "alks_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPla

{ "xbrltype": "integerItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansUn
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "documentation": "Represents the number of equity-
based compensation plans under which no further awards will be made.", "label":
"Share Based Compensation Arrangement By Share Based Payment Award Number Of
Plans Under Which No Further Awards Will Be Made", "terseLabel": "Number of share-
based compensation plan under which no further awards will be made" } } },
"auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSha
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesA
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel":
"Shares of common stock available for issuance", "documentation": "The difference
between the maximum number of shares (or other type of equity) authorized for
issuance under the plan (including the effects of amendments and adjustments), and
the sum of: 1) the number of shares (or other type of equity) already issued upon
exercise of options or other equity-based awards under the plan; and 2) shares (or
other type of equity) reserved for issuance on granting of outstanding awards, net of
cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r67"] },
"alks_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConve
{ "xbrltype": "sharesItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversion
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "terseLabel": "Conversion Reissuance (in shares)",
"label": "Share Based Compensation Arrangement By Share Based Payment Award
Options Conversion Reissuance In Period", "documentation": "Share based
compensation arrangement by share based payment award options conversion
reissuance in period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerci
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisabl
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Options, Exercisable, Number", "terseLabel":
"Exercisable at the end of the period (in shares)", "documentation": "The number of
shares into which fully or partially vested stock options outstanding as of the balance
sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r608"
] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerci
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisabl
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
"terseLabel": "Exercisable at the end of the period (in dollars per share)",
"documentation": "The weighted-average price as of the balance sheet date at which
grantees can acquire the shares reserved for issuance on vested portions of options
outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [

"r608"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod", "presentation": { "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of stock options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r621"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r613"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriod", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriod", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r612"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r610"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodPerShare", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodPerShare", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value of stock options granted (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r620"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInPeriod", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInPeriod", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding in Period", "terseLabel": "Outstanding (in shares)", "documentation": "Number of share options (or share units) outstanding during the reporting period." } } }, "auth_ref": ["r611"] }

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "verboseLabel": "Outstanding stock option", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r606", "r607"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r606", "r607"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value of stock options exercisable", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r623"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r622"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "credit", "presentation": {

"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding,
Number", "terseLabel": "Stock options expected to vest (in shares)", "documentation":
"Number of fully vested and expected to vest options outstanding that can be converted
into shares under option plan. Includes, but is not limited to, unvested options for
which requisite service period has not been rendered but that are expected to vest
based on achievement of performance condition, if forfeitures are recognized when
they occur." } } }, "auth_ref": { "r622" } }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAnd
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding,
Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price (in
dollars per share)", "documentation": "Weighted-average exercise price, at which
grantee can acquire shares reserved for issuance, for fully vested and expected to vest
options outstanding. Includes, but is not limited to, unvested options for which
requisite service period has not been rendered but that are expected to vest based on
achievement of performance condition, if forfeitures are recognized when they occur."
} } }, "auth_ref": { "r622" } },
"alks_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeighl
{ "xbrltype": "stringItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedA
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price",
"label": "Share-Based Compensation Arrangement By Share-Based Payment Award
Options Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average
Exercise Price" } } }, "auth_ref": { } }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificat
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIn
"crdr": "debit", "presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
l, "lang": { "en-us": { "role": { "terseLabel": "Incremental share-based compensation
expense due to achievement of performance criteria", "label": "Share-Based Payment
Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of
the fair value of the modified award over the fair value of the award immediately before
the modification." } } }, "auth_ref": { "r635" } }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeA
{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPla
"presentation": {
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": {

"label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } }], "auth_ref": ["r602", "r603", "r604", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r626", "r627", "r628", "r629", "r630"] },
 "alks_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConv
 { "xbrltype": "perShareItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname":
 "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConversio
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "terseLabel": "Conversion reissuance (in dollars per
 share)", "label": "Share Based Compensation Arrangements By Share Based Payment
 Award Options Conversion Reissuance In Period Weighted Average Exercise Price",
 "documentation": "Share based compensation arrangements by share based payment
 award options conversion reissuance in period weighted average exercise price" } } },
 "auth_ref": [] }, "us-
 gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerc
 { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercises;
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by
 Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise
 Price", "terseLabel": "Exercised (in dollars per share)", "documentation": "Weighted
 average price at which option holders acquired shares when converting their stock
 options into shares." } } }, "auth_ref": ["r611"] }, "us-
 gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpir
 { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiration
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by
 Share-Based Payment Award, Options, Expirations in Period, Weighted Average
 Exercise Price", "terseLabel": "Expired (in dollars per share)", "documentation":
 "Weighted average price at which grantees could have acquired the underlying shares
 with respect to stock options of the plan that expired." } } }, "auth_ref": ["r613"] },
 "us-
 gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfe
 { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeiture
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by
 Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average
 Exercise Price", "terseLabel": "Forfeited (in dollars per share)", "documentation":
 "Weighted average price at which grantees could have acquired the underlying shares
 with respect to stock options that were terminated." } } }, "auth_ref": ["r612"] }, "us-
 gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGran
 { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInI
 "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by
 Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise
 Price", "terseLabel": "Granted (in dollars per share)", "documentation": "Weighted
 average per share amount at which grantees can acquire shares of common stock by
 exercise of options." } } }, "auth_ref": ["r610"] },

"alks_ShareBasedCompensationExpenseDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ShareBasedCompensationExpenseDiscontinuedOperations", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperations5", "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation expense from discontinued operations", "terseLabel": "Share-based compensation expense", "label": "Share-based compensation expense discontinued operations", "documentation": "Share-based compensation expense discontinued operations" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r597", "r605", "r624", "r625", "r626", "r627", "r630", "r638", "r639", "r640", "r641"] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": ["r1322"] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": ["r1322"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeri { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1063"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssu { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumpti", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected option term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r626"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndI", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by

Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term of stock options exercisable", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } }], "auth_ref": ["r623"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAnd", "presentation": {

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average contractual remaining life", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } }], "auth_ref": ["r622"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": {

"http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "BALANCE (in shares)", "periodStartLabel": "BALANCE (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } }], "auth_ref": [] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": {

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu", "lang": { "en-us": { "role": { "label": "Short-Term Investments [Member]", "terseLabel": "Short-term investments", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } }], "auth_ref": ["r989", "r990", "r991", "r1012"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } }], "auth_ref": ["r145", "r286"] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": {

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio", "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "terseLabel": "U.S. state", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } }], "auth_ref": ["r656"] }, "alks_StateMedicaidRebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "StateMedicaidRebatesMember", "presentation": {

"http://www.alkermes.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAcer", "lang": { "en-us": { "role": { "terseLabel": "State Medicaid Rebates", "label": "State Medicaid Rebates [Member]", "documentation": "State Medicaid rebates." } }],

"auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } } }, "auth_ref": ["r19", "r117", "r120", "r121", "r241", "r272", "r273", "r274", "r298", "r299", "r300", "r302", "r307", "r309", "r311", "r327", "r401", "r402", "r448", "r501", "r679", "r680", "r687", "r688", "r689", "r691", "r694", "r695", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r747", "r748", "r749", "r750", "r751", "r752", "r754", "r756", "r768", "r867", "r885", "r886", "r887", "r903", "r969"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOf", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifica", "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical", "documentation": "Information by geographical components." } } } }, "auth_ref": ["r211", "r213", "r216", "r218", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r359", "r360", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r907", "r911", "r913", "r976", "r980", "r984", "r987", "r994", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1011", "r1050", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1097", "r1104", "r1324", "r1460", "r1464", "r1465", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1491", "r1492"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC", "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": ["r298", "r299", "r300", "r327", "r756", "r807", "r893", "r904", "r921", "r922", "r923", "r924", "r925", "r926", "r929", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r942", "r943", "r944", "r945", "r946", "r948", "r951", "r952", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r969", "r1105"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "StatementOperatingActivitiesSegmentAxis", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSharebasedCompensation",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule",
], "lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation":
 "Information by continuing and discontinuing operations." } } }, "auth_ref": [] },
 "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation",
], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario",
 "documentation": "Information by scenario reported, distinguishing information from
 actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual
 facts." } } }, "auth_ref": ["r238", "r312", "r596", "r1227", "r1228", "r1260"] }, "us-
 gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "StatementTable", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContract",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTS",
 "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsComponent",
], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement
 [Table]", "documentation": "Disclosure of information about statement of
 comprehensive income, income, other comprehensive income, financial position, cash
 flows, and shareholders' equity." } } }, "auth_ref": ["r298", "r299", "r300", "r327",
 "r362", "r756", "r807", "r893", "r904", "r921", "r922", "r923", "r924", "r925", "r926",
 "r929", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r942",
 "r943", "r944", "r945", "r946", "r948", "r951", "r952", "r954", "r955", "r956", "r957",
 "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r969", "r1105"] },
 "ecd_StkPrOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType",
 "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "StkPrOrTsrEstimationMethodTextBlock", "presentation": [
 "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label":
 "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or
 TSR Estimation Method" } } }, "auth_ref": ["r1135", "r1146", "r1156", "r1189"] }, "us-
 gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember",
 "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-
 us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel":
 "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares
 equal to appreciation of predetermined number of grantor's shares during
 predetermined time period." } } }, "auth_ref": [] },
 "alks_StockDistributionBySeparationOfBusiness": { "xbrltype": "stringItemType",
 "nsuri": "http://www.alkermes.com/20241231", "localname":
 "StockDistributionBySeparationOfBusiness", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn",
], "lang": { "en-us": { "role": { "label": "Stock distribution by separation of business",
 "documentation": "Stock distribution by separation of business." } } }, "auth_ref": [] },
 "alks_StockDistributionRatioByMeansOfSeparationOfBusiness": { "xbrltype":
 "pureItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":
 "StockDistributionRatioByMeansOfSeparationOfBusiness", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAn",
], "lang": { "en-us": { "role": { "label": "Stock distribution ratio by means of separation
 of business", "documentation": "Stock distribution ratio by means of separation of
 business." } } }, "auth_ref": [] }, "us-
 gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype":
 "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTS",
], "lang": { "en-us": { "role": { "totalLabel": "Shares Issued, Shares, Share-Based

Payment Arrangement, after Forfeiture, Total", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of ordinary shares under employee stock plans (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } }], "auth_ref": ["r19", "r116", "r117", "r163"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } }], "auth_ref": ["r19", "r116", "r117", "r163", "r611"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENT", "lang": { "en-us": { "role": { "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of ordinary shares under employee stock plans", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } }], "auth_ref": ["r68", "r116", "r117", "r163"] }, "alks_StockOptionAndIncentivePlan2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "StockOptionAndIncentivePlan2018Member", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation", "lang": { "en-us": { "role": { "documentation": "Represents the 2018 Stock Option and Incentive Plan which provides for issuance of non-qualified and incentive stock options, restricted stock, restricted stock units, cash-based awards and performance shares to employees, officers and directors of, consultants to the company.", "label": "Stock Option And Incentive Plan2018 [Member]", "terseLabel": "2018 Plan" } }], "auth_ref": [] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Stock Repurchase Program Authorized Dollar Amount", "terseLabel": "Share repurchase aggregate amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } }], "auth_ref": ["r1322"] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Remaining Authorized, Amount", "terseLabel": "Share repurchase program remaining authorized amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } }], "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENT", "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "terseLabel": "Repurchase of Alkermes' ordinary shares (in shares)", "documentation":

"Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r19", "r116", "r117", "r163", "r898", "r969", "r992"] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Value", "terseLabel": "Repurchase of Alkermes' ordinary shares", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r19", "r116", "r117", "r163", "r903", "r969", "r992", "r1111"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "BALANCE", "periodStartLabel": "BALANCE", "totalLabel": "Total shareholders\u2019 equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r117", "r120", "r121", "r150", "r931", "r947", "r970", "r971", "r1083", "r1112", "r1254", "r1287", "r1440", "r1494"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAI", "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "SHAREHOLDERS\u2019 EQUITY:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Shareholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r160", "r287", "r486", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r500", "r501", "r711", "r972", "r973", "r993"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r753", "r770"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type", "documentation": "Information by event that occurred after

the balance sheet date but before financial statements are issued or available to be issued." } }], "auth_ref": ["r753", "r770"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r753", "r770"] }, "us-gaap_SubsidarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidarySaleOfStockAxis", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfInvestmentHoldingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfInvestmentHoldingsLineItems", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAddition", "lang": { "en-us": { "role": { "label": "Summary of Investment Holdings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r901", "r905", "r906", "r907", "r908", "r909", "r910", "r912", "r913", "r914", "r915", "r916", "r919", "r920", "r950", "r1104"] }, "us-gaap_SummaryOfInvestmentHoldingsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfInvestmentHoldingsTable", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAddition", "lang": { "en-us": { "role": { "label": "Investment Holdings [Table]", "documentation": "Disclosure of information about summary of investment holding, including, but not limited to, investment with value exceeding one percent of net asset value of registrant." } } }, "auth_ref": ["r901", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r919", "r920", "r950", "r1104"] }, "alks_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "alks_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific", "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "alks_SummaryOfTheSignificantNonCashItemsAndCapitalExpendituresOfTheDiscontin", { "xbrltype": "textBlockItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "SummaryOfTheSignificantNonCashItemsAndCapitalExpendituresOfTheDiscontinuedOp", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperations1

], "lang": { "en-us": { "role": { "label": "Summary of Significant Non-cash Items and Capital Expenditures of Discontinued Operations", "documentation": "Summary of the Significant Non-cash Items and Capital Expenditures of the Discontinued Operations" } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables
], "lang": { "en-us": { "role": { "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Schedule of Activity in Valuation Allowance Associated with Deferred taxes", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": ["r1423"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA
], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURE:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r1182"] }, "alks_ThresholdForDisclosurePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "ThresholdForDisclosurePercentage", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
], "lang": { "en-us": { "role": { "documentation": "The minimum percentage of revenues or receivables from a single customer that is used as a threshold for disclosure of a concentration of risk.", "label": "Threshold For Disclosure Percentage", "terseLabel": "Threshold percentage for disclosure of revenue and receivables" } } }, "auth_ref": [] }, "alks_TimeBasedRestrictedStockUnitAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "TimeBasedRestrictedStockUnitAwardsMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
], "lang": { "en-us": { "role": { "documentation": "Represents the time-vested restricted stock units awarded by the company to its employees as a form of incentive compensation.", "label": "Time Based Restricted Stock Unit Awards [Member]", "terseLabel": "Time-based RSU Awards", "verboseLabel": "Time-Based RSUs" } } }, "auth_ref": [] }, "alks_TimeBasedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "TimeBasedStockOptionsMember", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
], "lang": { "en-us": { "role": { "documentation": "Time based stock options.", "label": "Time Based Stock Options [Member]", "terseLabel": "Time-Based Stock Options" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici
], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "terseLabel": "Title of Individual", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": ["r1269", "r1446"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": {

http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "terseLabel":
 "Title of Individual", "documentation": "Title and position of individual or group within
 organization." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype":
 "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "TotalShareholderRtnAmt", "presentation": [
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
 "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount"
 } } }, "auth_ref": ["r1174"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
 "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total
 Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r1181"] }, "us-
 gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "TradeAndOtherAccountsReceivablePolicy", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]",
 "terseLabel": "Receivables, net", "documentation": "Disclosure of accounting policy for
 accounts receivable." } } }, "auth_ref": ["r180", "r181", "r182", "r1270", "r1271",
 "r1272"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [
 "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role":
 { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } },
 "auth_ref": ["r1202"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType",
 "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable",
 "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": {
 "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]",
 "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r1204"] },
 "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "TradingSecuritiesAndCertainTradingAssetsTextBlock", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables"
], "lang": { "en-us": { "role": { "label": "Debt Securities, Trading, and Equity Securities;
 FV-NI [Table Text Block]", "terseLabel": "Schedule of Investments", "documentation":
 "Tabular disclosure of investment in debt security measured at fair value with change
 in fair value recognized in net income (trading) and investment in equity security
 measured at fair value with change in fair value recognized in net income (FV-NI)." } }
], "auth_ref": ["r737"] }, "dei_TradingSymbol": { "xbrltype":
 "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
 "TradingSymbol", "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntity
], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading
 Symbol", "documentation": "Trading symbol of an instrument as listed on an
 exchange." } } }, "auth_ref": [] }, "alks_TransactionCostsRelatedToTheSeparation": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "TransactionCostsRelatedToTheSeparation", "crdr": "debit",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureDiscontinuedOperationsA
], "lang": { "en-us": { "role": { "label": "Transaction costs related to the Separation",
 "documentation": "Transaction costs related to the Separation" } } }, "auth_ref": [] },
 "us-
 gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDoma
 { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
 "presentation": [
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditio

"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedule", "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r484", "r499", "r710", "r737", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r868", "r1070", "r1072", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1084", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1283", "r1284", "r1285", "r1286", "r1432", "r1435", "r1436", "r1437", "r1438", "r1439"], "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r1205"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r1206"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r1206"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1204"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r1204"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r1207"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r1205"] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Shares Acquired, Average Cost Per Share", "terseLabel": "Shares repurchased price per share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": ["r60"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA

l, "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r60"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r60"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDBAL", "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury shares, at cost (14,493,791 and 5,589,218 shares at December 31, 2024 and 2023, respectively)", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r60", "r63", "r120"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Shares repurchased", "negatedLabel": "Repurchase of Alkermes' ordinary shares (in shares)", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r19", "r117", "r163"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "http://www.alkermes.com/20241231/taxonomy/role/Role_StatementCONSOLIDATEDSTA", "lang": { "en-us": { "role": { "terseLabel": "Cost of ordinary share acquired during share repurchase program", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchase of Alkermes' ordinary shares", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r19", "r60", "r163"] }, "alks_TreasuryStockValueAcquiredCostMethodExcludingCommission": { "xbrltype": "monetaryItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "TreasuryStockValueAcquiredCostMethodExcludingCommission", "crdr": "debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity", "lang": { "en-us": { "role": { "label": "Treasury Stock, Value, Acquired, Cost Method Excluding commission", "documentation": "Treasury Stock, Value, Acquired, Cost Method Excluding commission.", "terseLabel": "Shares repurchased value" } } }, "auth_ref": [] }, "alks_TwentyTwentySixTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "TwentyTwentySixTermLoansMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueAdditional", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtAddit", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche", "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLongTermDebtSche", "lang": { "en-us": { "role": { "documentation": "Twenty twenty six term loans.", "label": "Twenty Twenty Six Term Loans [Member]", "terseLabel": "2026 Term Loans", "verboseLabel": "2026 Term Loans, due March 12, 2026" } } }, "auth_ref": [] }, "alks_TwoThousandAndEighteenStockOptionAndIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname":

"TwoThousandAndEighteenStockOptionAndIncentivePlanMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompen",
 "lang": { "en-us": { "role": { "documentation": "Two thousand and eighteen stock
 option and incentive plan.", "label": "Two Thousand And Eighteen Stock Option And
 Incentive Plan [Member]", "terseLabel": "2018 Stock Option and Incentive Plan" } } },
 "auth_ref": [] }, "alks_TwoThousandTwentyFourRepurchaseProgramMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231",
 "localname": "TwoThousandTwentyFourRepurchaseProgramMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareholdersEquity",
 "lang": { "en-us": { "role": { "terseLabel": "2024 Repurchase Program", "label": "Two
 Thousand Twenty Four Repurchase Program [Member]", "documentation": "Two
 thousand twenty four repurchase program." } } }, "auth_ref": [] }, "us-
 gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation":
 {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContri",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici",
 "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement
 Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and
 Arrangement Other than Collaborative", "documentation": "Information by
 collaborative arrangement and arrangement other than collaborative applicable to
 revenue-generating activity or operations." } } }, "auth_ref": ["r696"] }, "country_US":
 { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024",
 "localname": "US", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOff",
 "http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici",
 "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } },
 "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "USGovernmentAgenciesDebtSecuritiesMember", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureFairValueSummary",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsAdditio",
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureInvestmentsSchedu",
 "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities
 [Member]", "terseLabel": "U.S. government and agency debt securities",
 "documentation": "Debentures, notes, and other debt securities issued by US
 government agencies, for example, but not limited to, Government National Mortgage
 Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by
 government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal
 Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National
 Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank
 (FHLB)." } } }, "auth_ref": ["r1023", "r1056", "r1457"] }, "us-
 gaap_UnbilledContractsReceivable": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "UnbilledContractsReceivable", "crdr":
 "debit", "presentation": {
 "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignifici",
 "lang": { "en-us": { "role": { "label": "Unbilled Contracts Receivable", "terseLabel":
 "Unbilled receivable", "documentation": "Unbilled amounts due for services rendered
 or to be rendered, actions taken or to be taken, or a promise to refrain from taking
 certain actions in accordance with the terms of a legally binding agreement between
 the entity and, at a minimum, one other party. An example would be amounts
 associated with contracts or programs where the recognized revenue for performance
 thereunder exceeds the amounts billed under the terms thereof as of the date of the
 balance sheet." } } }, "auth_ref": ["r805"] }, "us-

gaap_UndistributedEarningsOfForeignSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsOfForeignSubsidiaries", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio

l, "lang": { "en-us": { "role": { "label": "Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Cumulative unremitted earnings of overseas subsidiaries", "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile." } } }, "auth_ref": { "r16", "r17", "r190", "r649" } }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": { "r1201" } }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu

l, "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": { "r650", "r667", "r1065" } }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu

l, "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reductions based on tax positions related to prior periods", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": { "r668", "r1065" } }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense", "crdr": "debit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditio

l, "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense", "terseLabel": "Notice of Assessment", "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": { "r1421" } }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu

l, "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to the current period", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": { "r669", "r1065" } }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": { "http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedu

l, "lang": { "en-us": { "role": { "terseLabel": "Additions based on tax positions related to prior periods", "negatedLabel": "Additions based on tax positions related to prior

periods", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } }], "auth_ref": ["r668", "r1065"] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "presentation": ["debit", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "negatedLabel": "Reductions based on the lapse of applicable statutes of limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": ["r670"] }, "alks_UnvestedPerformanceBasedRestrictedStockUnitsAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "UnvestedPerformanceBasedRestrictedStockUnitsAwardsMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureShareBasedCompensation", "lang": { "en-us": { "role": { "label": "Unvested Performance Based Restricted Stock Units Awards [Member]", "documentation": "Unvested: Performance Based Restricted Stock Units Awards.", "terseLabel": "Unvested Performance-based RSUs Awards" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r46", "r47", "r48", "r196", "r198", "r201", "r202"] }, "us-gaap_ValuationAllowanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceLineItems", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Valuation Allowance [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceTable", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "label": "Deferred Tax Asset, Valuation Allowance [Table]", "documentation": "Disclosure of information about valuation allowance representing portion of deferred tax asset for which it is more likely than not that tax benefit will not be realized." } } }, "auth_ref": ["r1423"] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDomain", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowances and Reserves Type [Domain]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": ["r293", "r294", "r295", "r296", "r297"] }, "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSchedule", "lang": { "en-us": { "role": { "totalLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease), Total", "label": "SEC Schedule,

12-09, Valuation Allowances and Reserves, Period Increase (Decrease)"/
"negatedLabel": "(Additions) / Reductions", "documentation": "Amount of increase
(decrease) in valuation and qualifying accounts and reserves." } }], "auth_ref": [
"r1256"]], "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ValuationAllowancesAndReservesTypeAxis", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAc
l, "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowances and Reserves Type
[Axis]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
"documentation": "Information by valuation and qualifying accounts and reserves." } } }
], "auth_ref": ["r293", "r294", "r295", "r296", "r297"]], "alks_VivitrolMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname": "VivitrolMember", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr
l, "lang": { "en-us": { "role": { "documentation": "Represents the information
pertaining to VIVITROL.", "label": "Vivitrol [Member]", "terseLabel": "VIVITROL" } } }
], "auth_ref": []], "ecd_VstngDtFrValOfEqtyAwrdGrntdAndVstdInCvrdYrMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdGrntdAndVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year
[Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and
Vested in Covered Year" } } }, "auth_ref": ["r1170"]], "alks_VumerityMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231",
"localname": "VumerityMember", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCollaborativeArrang
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureRevenueFromContr
"http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignific
l, "lang": { "en-us": { "role": { "documentation": "Represents the information
pertaining to VUMERITY.", "label": "Vumerity [Member]", "terseLabel": "VUMERITY" }
 } }], "auth_ref": []], "us-
gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSci
l, "lang": { "en-us": { "role": { "terseLabel": "Dilutive ordinary share equivalents",
"label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
"totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment,
Total", "documentation": "The sum of dilutive potential common shares or units used
in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [
"r1262"]], "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSci
"http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6
l, "lang": { "en-us": { "role": { "verboseLabel": "Shares used in calculating diluted
earnings (loss) per ordinary share", "label": "Weighted Average Number of Shares
Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Shares used in
calculating diluted earnings (loss) per ordinary share", "documentation": "The average
number of shares or units issued and outstanding that are used in calculating diluted
EPS or earnings per unit (EPU), determined based on the timing of issuance of shares
or units in the period." } } }, "auth_ref": ["r315", "r320"]], "us-
gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSci
"http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatements6
l, "lang": { "en-us": { "role": { "verboseLabel": "Denominator:", "label": "Weighted

Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:" } }], "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/DisclosureEarningsLossPerShareSec", "http://www.alkermes.com/20241231/taxonomy/role/StatementConsolidatedStatementsC", "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } }], "auth_ref": ["r314", "r320"] }, "alks_WilmingtonOhioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "WilmingtonOhioMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEq", "lang": { "en-us": { "role": { "terseLabel": "Wilmington, Ohio", "label": "Wilmington, Ohio [Member]", "documentation": "Wilmington, Ohio." } }], "auth_ref": [] }, "alks_WinterStreetLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "WinterStreetLeaseMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureLeasesAdditionalInf", "lang": { "en-us": { "role": { "documentation": "900 Winter Street Lease.", "label": "Winter Street Lease [Member]", "terseLabel": "900 Winter Street Lease" } }], "auth_ref": [] }, "alks_WinterStreetLeaseTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.alkermes.com/20241231", "localname": "WinterStreetLeaseTwoMember", "presentation": ["http://www.alkermes.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndCo", "lang": { "en-us": { "role": { "terseLabel": "852 Winter Street Lease", "label": "Winter Street Lease Two [Member]", "documentation": "852 winter street lease two." } }], "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } }], "auth_ref": ["r1168"] } }], "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14",

"Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic":

**"10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r22": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic":
"10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r23": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" },
"r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic":
"805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-
55-44" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" },
"r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99",
"Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r28": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" },
"r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph":
"14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-
14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph":
"14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-
45-14A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45",
"Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r32": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
}, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph":
"12", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r34": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" },
"r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph":
"1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph":
"2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph":
"3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph":
"4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-**

[illegible]

Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "60", "Publisher": "FASB", "URI": "https://asc.fasb.org/715-60/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "70", "Publisher": "FASB", "URI": "https://asc.fasb.org/715-70/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org/715-80/tableOfContent" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }

}, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name":

**"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher":
"FASB", "URI": "[https://asc.fasb.org/1943274/2147483475/205-20-45-4](\"https://asc.fasb.org/1943274/2147483475/205-20-45-4\")", "r94": {
"role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "205", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147483499/205-20-50-1](\"https://asc.fasb.org/1943274/2147483499/205-20-50-1\")", "r95": { "role":
[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\"), "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher":
"FASB", "URI": "[https://asc.fasb.org/1943274/2147483499/205-20-50-3A](\"https://asc.fasb.org/1943274/2147483499/205-20-50-3A\")", "r96": {
"role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "205", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A",
"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483499/205-20-50-4A](\"https://asc.fasb.org/1943274/2147483499/205-20-50-4A\")
"}, "r97": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "205",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4B", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147483499/205-20-50-4B](\"https://asc.fasb.org/1943274/2147483499/205-20-50-4B\")", "r98": { "role":
[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\"), "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147483499/205-20-50-4B](\"https://asc.fasb.org/1943274/2147483499/205-20-50-4B\")", "r99": { "role":
[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\"), "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher":
"FASB", "URI": "[https://asc.fasb.org/1943274/2147483499/205-20-50-5A](\"https://asc.fasb.org/1943274/2147483499/205-20-50-5A\")", "r100": {
"role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "205", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B",
"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483499/205-20-50-5B](\"https://asc.fasb.org/1943274/2147483499/205-20-50-5B\")
"}, "r101": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "205",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147483499/205-20-50-5B](\"https://asc.fasb.org/1943274/2147483499/205-20-50-5B\")", "r102": { "role":
[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\"), "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147483499/205-20-50-5B](\"https://asc.fasb.org/1943274/2147483499/205-20-50-5B\")", "r103": { "role":
[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\"), "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5B",
"Subparagraph": "(e)", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147483499/205-20-50-5B](\"https://asc.fasb.org/1943274/2147483499/205-20-50-5B\")", "r104": { "role":
[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\"), "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher":
"FASB", "URI": "[https://asc.fasb.org/1943274/2147483499/205-20-50-5C](\"https://asc.fasb.org/1943274/2147483499/205-20-50-5C\")", "r105": {
"role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "205", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147483499/205-20-50-5C](\"https://asc.fasb.org/1943274/2147483499/205-20-50-5C\")", "r106": { "role":
[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\"), "Topic": "205", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher":
"FASB", "URI": "[https://asc.fasb.org/1943274/2147483499/205-20-50-5D](\"https://asc.fasb.org/1943274/2147483499/205-20-50-5D\")", "r107": {
"role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "205", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483499/205-20-50-7](\"https://asc.fasb.org/1943274/2147483499/205-20-50-7\")",
"r108": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI":
[https://asc.fasb.org/1943274/2147480566/210-10-S99-1](\"https://asc.fasb.org/1943274/2147480566/210-10-S99-1\")", "r109": { "role":
[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\"), "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI:**

[illegible]

[illegible]

["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482740/230-10-45-15"](https://asc.fasb.org/1943274/2147482740/230-10-45-15) }, "r140": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482740/230-10-45-15"](https://asc.fasb.org/1943274/2147482740/230-10-45-15) }, "r141": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482740/230-10-45-24"](https://asc.fasb.org/1943274/2147482740/230-10-45-24) }, "r142": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482740/230-10-45-25"](https://asc.fasb.org/1943274/2147482740/230-10-45-25) }, "r143": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482740/230-10-45-25"](https://asc.fasb.org/1943274/2147482740/230-10-45-25) }, "r144": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482740/230-10-45-28"](https://asc.fasb.org/1943274/2147482740/230-10-45-28) }, "r145": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": ["https://asc.fasb.org/235/tableOfContent"](https://asc.fasb.org/235/tableOfContent) }, "r146": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": ["https://asc.fasb.org/275/tableOfContent"](https://asc.fasb.org/275/tableOfContent) }, "r147": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482861/275-10-50-18"](https://asc.fasb.org/1943274/2147482861/275-10-50-18) }, "r148": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482810/280-10-50-41"](https://asc.fasb.org/1943274/2147482810/280-10-50-41) }, "r149": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482810/280-10-50-41"](https://asc.fasb.org/1943274/2147482810/280-10-50-41) }, "r150": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147480418/310-10-S99-2"](https://asc.fasb.org/1943274/2147480418/310-10-S99-2) }, "r151": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147480581/330-10-S99-2"](https://asc.fasb.org/1943274/2147480581/330-10-S99-2) }, "r152": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": ["https://asc.fasb.org/360/tableOfContent"](https://asc.fasb.org/360/tableOfContent) }, "r153": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482309/360-10-15-4"](https://asc.fasb.org/1943274/2147482309/360-10-15-4) }, "r154": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482130/360-10-45-9"](https://asc.fasb.org/1943274/2147482130/360-10-45-9) }, "r155": { "role": ["http://fasb.org/us-gaap/role/ref/legacyRef"](http://fasb.org/us-gaap/role/ref/legacyRef), "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r156": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r157": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r158": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/440/tableOfContent" }, "r159": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r160": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/505/tableOfContent" }, "r161": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r162": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r163": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r164": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r165": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10",
"Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph":
"2", "Section": "50", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r166": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r167": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21
", "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r169": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r170": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r171": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r172": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r173": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r174": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r175": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/942-320/tableOfContent" }, "r176": { "role": "http://fasb.org/us-
gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r177": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r178": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r179": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r180": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r181": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r182": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" },
"r183": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r184": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(aa)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r185": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r186": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r187": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
 "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r188": { "role":
 "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
 "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r189": { "role":
 "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" },
 "r190": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740",
 "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r191": { "role":
 "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "942", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r192": { "role":
 "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "942", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r193": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
 Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic":
 "20", "Topic": "740", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r194": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
 Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic":
 "10", "Topic": "270", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r195": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic":
 "10", "Topic": "808", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r196": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic":
 "10", "Topic": "275", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r197": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic":
 "10", "Topic": "808", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r198": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic":
 "10", "Topic": "275", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r199": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic":
 "10", "Topic": "275", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r200": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic":
 "360", "Topic": "958", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/214747798/958-360-50-1" }, "r201": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
 }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting

Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",

"Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C",
 "Publisher": "SEC" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
 "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17",
 "Paragraph": "Column D", "Publisher": "SEC" }, "r223": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E",
 "Publisher": "SEC" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
 "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17",
 "Paragraph": "Column F", "Publisher": "SEC" }, "r225": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A",
 "Footnote": "2", "Publisher": "SEC" }, "r226": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B",
 "Publisher": "SEC" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
 "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28",
 "Paragraph": "Column C", "Publisher": "SEC" }, "r228": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D",
 "Publisher": "SEC" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
 "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28",
 "Paragraph": "Column E", "Publisher": "SEC" }, "r230": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F",
 "Publisher": "SEC" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
 "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28",
 "Paragraph": "Column G", "Publisher": "SEC" }, "r232": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H",
 "Publisher": "SEC" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
 "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28",
 "Paragraph": "Column I", "Publisher": "SEC" }, "r234": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A",
 "Footnote": "4", "Publisher": "SEC" }, "r235": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m",
 "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r236": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m",
 "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r237": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin
 (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r238": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin
 (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher":
 "SEC" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff
 Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph":
 "Question 2", "Publisher": "SEC" }, "r240": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin
 (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher":
 "SEC" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
 "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r242": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B",
 "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r243": { "role":

[illegible]

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r259": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r260": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r261": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r262": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r263": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r264": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A",
"Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r265": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A",
"Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r266": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
} , "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r268": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r269": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r270": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r271": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }.
"r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r273": { "role":

["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "220", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482765/220-10-50-5>" },
 "r274": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "220",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "6", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482765/220-10-50-6>" }, "r275": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "220", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147483621/220-10-S99-2>" }, "r276": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "220", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147483621/220-10-S99-2>" }, "r277": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "220", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147483621/220-10-S99-2>" }, "r278": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "230", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482740/230-10-45-15>" }, "r279": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "230", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482740/230-10-45-17>" }, "r280": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "230", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482740/230-10-45-2>" },
 "r281": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "230",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
 "Paragraph": "24", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482740/230-10-45-24>" }, "r282": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "230", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25",
 "Subparagraph": "(e)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482740/230-10-45-25>" }, "r283": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "230", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482913/230-10-50-2>" },
 "r284": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "230",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "2A", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482913/230-10-50-2A>" }, "r285": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "230", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482913/230-10-50-8>" },
 "r286": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "235",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "1", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147483426/235-10-50-1>" }, "r287": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147480678/235-10-S99-1>" }, "r288": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-1"](https://asc.fasb.org/1943274/2147480678/235-10-S99-1) }, "r289": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-1"](https://asc.fasb.org/1943274/2147480678/235-10-S99-1) }, "r290": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-1"](https://asc.fasb.org/1943274/2147480678/235-10-S99-1) }, "r291": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-1"](https://asc.fasb.org/1943274/2147480678/235-10-S99-1) }, "r292": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-3"](https://asc.fasb.org/1943274/2147480678/235-10-S99-3) }, "r293": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4",
 "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-4"](https://asc.fasb.org/1943274/2147480678/235-10-S99-4) }, "r294": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4",
 "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-4"](https://asc.fasb.org/1943274/2147480678/235-10-S99-4) }, "r295": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4",
 "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-4"](https://asc.fasb.org/1943274/2147480678/235-10-S99-4) }, "r296": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4",
 "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-4"](https://asc.fasb.org/1943274/2147480678/235-10-S99-4) }, "r297": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4",
 "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480678/235-10-S99-4"](https://asc.fasb.org/1943274/2147480678/235-10-S99-4) }, "r298": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "250", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483421/250-10-45-23"](https://asc.fasb.org/1943274/2147483421/250-10-45-23) }, "r299": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "250", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147483421/250-10-45-24>"
 }, "r300": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "250",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
 "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483421/250-10-45-5"](https://asc.fasb.org/1943274/2147483421/250-10-45-5) }, "r301": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "250", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483443/250-10-50-1"](https://asc.fasb.org/1943274/2147483443/250-10-50-1) }, "r302": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "250", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483443/250-10-50-1"](https://asc.fasb.org/1943274/2147483443/250-10-50-1) }, "r303": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "250", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r304": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r305": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" },
"r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r307": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" },
"r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r309": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r310": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" },
"r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r312": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r313": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/260/tableOfContent" }, "r314": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10
" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r316": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" },
"r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r318": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r319": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" },
"r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r321": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r322": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r323": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" },
"r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r325": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
}, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r327": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" },
"r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/280/tableOfContent" }, "r329": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
}, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r331": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r332": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
}, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r334": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r335": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",

[illegible]

"Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r351": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
}, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r353": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(ee)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r354": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r355": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
}, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "36", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r357": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
}, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "41", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r359": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r360": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r361": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
}, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "13", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r363": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/320/tableOfContent" }, "r364": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" },
"r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r366": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

[illegible]

[illegible]

"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r397": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r398": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r399": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r400": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r401": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r402": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r403": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" },
"r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r405": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r406": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
}, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r408": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r409": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
}, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r411": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" },

"r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20",

[illegible]

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r444": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r445": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r446": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r447": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r448": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r449": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r450": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r451": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r452": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r453": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r454": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r455": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r456": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r457": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r458": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r459": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r460": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r461": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r462": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r463": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r464": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r465": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r466": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r467": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r468": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r469": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r470": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r471": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r472": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

**"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r591": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r592": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r593": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r594": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r595": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r596": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r597": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/718/tableOfContent" }, "r598": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
}, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35",
"Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r600": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" },
"r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r602": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r603": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r604": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r605": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":**

[illegible]

[illegible]

["https://asc.fasb.org/1943274/2147480429/718-10-50-2"](https://asc.fasb.org/1943274/2147480429/718-10-50-2) }, "r635": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "718", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480429/718-10-50-2"](https://asc.fasb.org/1943274/2147480429/718-10-50-2) }, "r636": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "718", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(i)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480429/718-10-50-2"](https://asc.fasb.org/1943274/2147480429/718-10-50-2) }, "r637": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "718", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(l)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480429/718-10-50-2"](https://asc.fasb.org/1943274/2147480429/718-10-50-2) }, "r638": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "718", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479830/718-10-S99-1"](https://asc.fasb.org/1943274/2147479830/718-10-S99-1) }, "r639": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "718", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479830/718-10-S99-1"](https://asc.fasb.org/1943274/2147479830/718-10-S99-1) }, "r640": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "718", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479830/718-10-S99-1"](https://asc.fasb.org/1943274/2147479830/718-10-S99-1) }, "r641": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "718", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479830/718-10-S99-1"](https://asc.fasb.org/1943274/2147479830/718-10-S99-1) }, "r642": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "718", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479830/718-10-S99-1"](https://asc.fasb.org/1943274/2147479830/718-10-S99-1) }, "r643": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "720", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147483359/720-20-50-1"](https://asc.fasb.org/1943274/2147483359/720-20-50-1) },
 "r644": { "role": ["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "720",
 "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483406/720-35-50-1"](https://asc.fasb.org/1943274/2147483406/720-35-50-1) }, "r645": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "730", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483044/730-10-05-1"](https://asc.fasb.org/1943274/2147483044/730-10-05-1) }, "r646": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "730", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147482916/730-10-50-1"](https://asc.fasb.org/1943274/2147482916/730-10-50-1) },
 "r647": { "role": ["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "730",
 "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483041/730-20-50-1"](https://asc.fasb.org/1943274/2147483041/730-20-50-1) }, "r648": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "Name": "Accounting
 Standards Codification", "Publisher": "FASB", "URI":
["https://asc.fasb.org/740/tableOfContent"](https://asc.fasb.org/740/tableOfContent) }, "r649": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "3",
 "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482620/740-10-25-3"](https://asc.fasb.org/1943274/2147482620/740-10-25-3) }, "r650": { "role":

[illegible]

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482685/740-10-50-15> }, "r667": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482685/740-10-50-15A> }, "r668": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482685/740-10-50-15A> }, "r669": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482685/740-10-50-15A> }, "r670": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482685/740-10-50-15A> }, "r671": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482685/740-10-50-17> }, "r672": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19",
"Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482685/740-10-50-19>",
}, "r673": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482685/740-10-50-2> }, "r674": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20",
"Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482685/740-10-50-20>",
}, "r675": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "21", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482685/740-10-50-21> }, "r676": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482685/740-10-50-23>",
}, "r677": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482685/740-10-50-3> }, "r678": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482685/740-10-50-9>" },
"r679": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482615/740-10-65-8> }, "r680": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8",
"Subparagraph": "(d)(3)", "Publisher": "FASB", "URI":
<https://asc.fasb.org/1943274/2147482615/740-10-65-8> }, "r681": { "role":
<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.1.O1)", "Publisher": "FASB", "URI":

["https://asc.fasb.org/1943274/2147479360/740-10-S99-1"](https://asc.fasb.org/1943274/2147479360/740-10-S99-1) }, "r682": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479360/740-10-S99-1"](https://asc.fasb.org/1943274/2147479360/740-10-S99-1) }, "r683": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479360/740-10-S99-1"](https://asc.fasb.org/1943274/2147479360/740-10-S99-1) }, "r684": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479360/740-10-S99-2"](https://asc.fasb.org/1943274/2147479360/740-10-S99-2) }, "r685": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "270",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147477891/740-270-50-1>"
 }, "r686": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "740",
 "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482603/740-30-50-2"](https://asc.fasb.org/1943274/2147482603/740-30-50-2) }, "r687": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "323",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478666/740-323-65-2"](https://asc.fasb.org/1943274/2147478666/740-323-65-2) }, "r688": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "323",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478666/740-323-65-2"](https://asc.fasb.org/1943274/2147478666/740-323-65-2) }, "r689": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "323",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(e)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478666/740-323-65-2"](https://asc.fasb.org/1943274/2147478666/740-323-65-2) }, "r690": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "323",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478666/740-323-65-2"](https://asc.fasb.org/1943274/2147478666/740-323-65-2) }, "r691": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "740", "SubTopic": "323",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478666/740-323-65-2"](https://asc.fasb.org/1943274/2147478666/740-323-65-2) }, "r692": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "805", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479907/805-20-50-5"](https://asc.fasb.org/1943274/2147479907/805-20-50-5) }, "r693": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "805", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479581/805-30-50-4"](https://asc.fasb.org/1943274/2147479581/805-30-50-4) }, "r694": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "805", "SubTopic": "60",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
 "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147476176/805-60-65-1"](https://asc.fasb.org/1943274/2147476176/805-60-65-1) }, "r695": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "805", "SubTopic": "60",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
 "Subparagraph": "(g)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147476176/805-60-65-1"](https://asc.fasb.org/1943274/2147476176/805-60-65-1) }, "r696": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "808", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r697": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
}, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r699": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r700": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r701": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r702": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r703": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r704": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r705": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r706": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r707": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r708": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r709": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r710": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r711": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r712": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
 "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r713": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
 "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r714": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
 "Subparagraph": "(f)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r715": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B",
 }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r717": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r718": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r719": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r720": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r721": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r722": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r723": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r724": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r725": { "role":
 "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r726": { "role":

[illegible]

}, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r757": { "role":

["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479041/842-20-45-1"](https://asc.fasb.org/1943274/2147479041/842-20-45-1) }, "r758": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479041/842-20-45-1"](https://asc.fasb.org/1943274/2147479041/842-20-45-1) }, "r759": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479041/842-20-45-5"](https://asc.fasb.org/1943274/2147479041/842-20-45-5) }, "r760": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147478964/842-20-50-3"](https://asc.fasb.org/1943274/2147478964/842-20-50-3) },
 "r761": { "role": ["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842",
 "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478964/842-20-50-3"](https://asc.fasb.org/1943274/2147478964/842-20-50-3) }, "r762": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478964/842-20-50-4"](https://asc.fasb.org/1943274/2147478964/842-20-50-4) }, "r763": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478964/842-20-50-4"](https://asc.fasb.org/1943274/2147478964/842-20-50-4) }, "r764": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478964/842-20-50-4"](https://asc.fasb.org/1943274/2147478964/842-20-50-4) }, "r765": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
 "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147478964/842-20-50-6"](https://asc.fasb.org/1943274/2147478964/842-20-50-6) },
 "r766": { "role": ["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842",
 "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478964/842-20-50-7A"](https://asc.fasb.org/1943274/2147478964/842-20-50-7A) }, "r767": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "842", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478964/842-20-50-7A"](https://asc.fasb.org/1943274/2147478964/842-20-50-7A) }, "r768": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "848", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483550/848-10-65-2"](https://asc.fasb.org/1943274/2147483550/848-10-65-2) }, "r769": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "850", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147483326/850-10-50-3"](https://asc.fasb.org/1943274/2147483326/850-10-50-3) },
 "r770": { "role": ["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "855",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "2", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483399/855-10-50-2"](https://asc.fasb.org/1943274/2147483399/855-10-50-2) }, "r771": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "860", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147481326/860-20-50-3"](https://asc.fasb.org/1943274/2147481326/860-20-50-3) }, "r772": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "860", "SubTopic": "20",

[illegible]

[illegible]

"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r802": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r803": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r804": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r805": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2"
}, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912",
"SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r807": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r808": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" },
"r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928",
"SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r810": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
}, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r812": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r813": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r814": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
}, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r816": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r817": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235",

[illegible]

"https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }

["https://asc.fasb.org/1943274/2147477268/942-320-50-3"](https://asc.fasb.org/1943274/2147477268/942-320-50-3) }, "r847": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "942", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477268/942-320-50-3"](https://asc.fasb.org/1943274/2147477268/942-320-50-3) }, "r848": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "942", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477268/942-320-50-3A"](https://asc.fasb.org/1943274/2147477268/942-320-50-3A) }, "r849": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "942", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477268/942-320-50-3A"](https://asc.fasb.org/1943274/2147477268/942-320-50-3A) }, "r850": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "942", "SubTopic": "360",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147478451/942-360-50-1>"
 }, "r851": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "942",
 "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477734/942-470-50-3"](https://asc.fasb.org/1943274/2147477734/942-470-50-3) }, "r852": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r853": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r854": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r855": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r856": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r857": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r858": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r859": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r860": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r861": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

[illegible]

["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "235",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477965/944-235-S99-2"](https://asc.fasb.org/1943274/2147477965/944-235-S99-2) }, "r877": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "235",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477965/944-235-S99-2"](https://asc.fasb.org/1943274/2147477965/944-235-S99-2) }, "r878": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "235",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477965/944-235-S99-2"](https://asc.fasb.org/1943274/2147477965/944-235-S99-2) }, "r879": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "235",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477965/944-235-S99-2"](https://asc.fasb.org/1943274/2147477965/944-235-S99-2) }, "r880": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E",
 "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147480081/944-40-50-4E"](https://asc.fasb.org/1943274/2147480081/944-40-50-4E)
 }, "r881": { "role": ["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944",
 "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480081/944-40-50-5"](https://asc.fasb.org/1943274/2147480081/944-40-50-5) }, "r882": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
 "Subparagraph": "(e)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480081/944-40-50-5"](https://asc.fasb.org/1943274/2147480081/944-40-50-5) }, "r883": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480081/944-40-50-7A"](https://asc.fasb.org/1943274/2147480081/944-40-50-7A) }, "r884": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
 "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480081/944-40-50-9"](https://asc.fasb.org/1943274/2147480081/944-40-50-9) }, "r885": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(e)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480016/944-40-65-2"](https://asc.fasb.org/1943274/2147480016/944-40-65-2) }, "r886": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480016/944-40-65-2"](https://asc.fasb.org/1943274/2147480016/944-40-65-2) }, "r887": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480016/944-40-65-2"](https://asc.fasb.org/1943274/2147480016/944-40-65-2) }, "r888": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480016/944-40-65-2"](https://asc.fasb.org/1943274/2147480016/944-40-65-2) }, "r889": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480016/944-40-65-2"](https://asc.fasb.org/1943274/2147480016/944-40-65-2) }, "r890": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
 "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI":

["https://asc.fasb.org/1943274/2147480016/944-40-65-2"](https://asc.fasb.org/1943274/2147480016/944-40-65-2) }, "r891": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479583/944-40-S99-1"](https://asc.fasb.org/1943274/2147479583/944-40-S99-1) }, "r892": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "944", "SubTopic": "825",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147477351/944-825-50-1B>"
 }, "r893": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "946",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
 "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479886/946-10-S99-3"](https://asc.fasb.org/1943274/2147479886/946-10-S99-3) }, "r894": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479886/946-10-S99-3"](https://asc.fasb.org/1943274/2147479886/946-10-S99-3) }, "r895": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479886/946-10-S99-3"](https://asc.fasb.org/1943274/2147479886/946-10-S99-3) }, "r896": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479886/946-10-S99-3"](https://asc.fasb.org/1943274/2147479886/946-10-S99-3) }, "r897": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479886/946-10-S99-3"](https://asc.fasb.org/1943274/2147479886/946-10-S99-3) }, "r898": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479886/946-10-S99-3"](https://asc.fasb.org/1943274/2147479886/946-10-S99-3) }, "r899": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147480990/946-20-50-11>"
 }, "r900": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "946",
 "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "13", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480990/946-20-50-13"](https://asc.fasb.org/1943274/2147480990/946-20-50-13) }, "r901": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147480990/946-20-50-9>"
 }, "r902": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "946",
 "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45",
 "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478009/946-205-45-3"](https://asc.fasb.org/1943274/2147478009/946-205-45-3) }, "r903": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "205",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478009/946-205-45-4"](https://asc.fasb.org/1943274/2147478009/946-205-45-4) }, "r904": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147477796/946-210-45-4>"
 }, "r905": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "946",
 "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478795/946-210-50-1"](https://asc.fasb.org/1943274/2147478795/946-210-50-1) }, "r906": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "210",

[illegible]

[illegible]

[illegible]

[illegible]

["https://asc.fasb.org/1943274/2147479134/946-220-S99-1"](https://asc.fasb.org/1943274/2147479134/946-220-S99-1) }, "r965": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "220",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479134/946-220-S99-1"](https://asc.fasb.org/1943274/2147479134/946-220-S99-1) }, "r966": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "220",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479134/946-220-S99-1"](https://asc.fasb.org/1943274/2147479134/946-220-S99-1) }, "r967": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "220",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479134/946-220-S99-1"](https://asc.fasb.org/1943274/2147479134/946-220-S99-1) }, "r968": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "220",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479134/946-220-S99-3"](https://asc.fasb.org/1943274/2147479134/946-220-S99-3) }, "r969": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "220",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479134/946-220-S99-3"](https://asc.fasb.org/1943274/2147479134/946-220-S99-3) }, "r970": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "220",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479134/946-220-S99-3"](https://asc.fasb.org/1943274/2147479134/946-220-S99-3) }, "r971": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "220",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479134/946-220-S99-3"](https://asc.fasb.org/1943274/2147479134/946-220-S99-3) }, "r972": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "235",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477968/946-235-50-2"](https://asc.fasb.org/1943274/2147477968/946-235-50-2) }, "r973": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "235",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477968/946-235-50-2"](https://asc.fasb.org/1943274/2147477968/946-235-50-2) }, "r974": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477271/946-320-S99-1"](https://asc.fasb.org/1943274/2147477271/946-320-S99-1) }, "r975": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477271/946-320-S99-1"](https://asc.fasb.org/1943274/2147477271/946-320-S99-1) }, "r976": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477271/946-320-S99-1"](https://asc.fasb.org/1943274/2147477271/946-320-S99-1) }, "r977": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12",
 "Subparagraph": "(i)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477271/946-320-S99-12"](https://asc.fasb.org/1943274/2147477271/946-320-S99-12) }, "r978": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19",
 "Subparagraph": "(2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477271/946-320-S99-19"](https://asc.fasb.org/1943274/2147477271/946-320-S99-19) }, "r979": { "role":
["http://www.xbrl.org/2003/role/disclosureRef"](http://www.xbrl.org/2003/role/disclosureRef), "Topic": "946", "SubTopic": "320",

[illegible]

}, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" },
"r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)",
"SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1010": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic":
"40", "Topic": "944", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1011": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic":
"40", "Topic": "944", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1012": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic":
"320", "Topic": "946", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1013": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1014": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1015": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1016": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1017": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1018": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1019": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
}, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "22", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1021": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1022": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1023": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI":

["https://asc.fasb.org/1943274/2147480678/235-10-S99-1"](https://asc.fasb.org/1943274/2147480678/235-10-S99-1) }, "r1024": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "260", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher":
 "FASB", "URI": "<https://asc.fasb.org/1943274/2147482635/260-10-55-52>" }, "r1025": {
 "role": "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "280", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482810/280-10-50-30"](https://asc.fasb.org/1943274/2147482810/280-10-50-30) }, "r1026": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "280", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher":
 "FASB", "URI": "<https://asc.fasb.org/1943274/2147482810/280-10-50-31>" }, "r1027": {
 "role": "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "280", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482785/280-10-55-47"](https://asc.fasb.org/1943274/2147482785/280-10-55-47) }, "r1028": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "280", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "47",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482785/280-10-55-47"](https://asc.fasb.org/1943274/2147482785/280-10-55-47) }, "r1029": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "280", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "47",
 "Subparagraph": "(bb)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482785/280-10-55-47"](https://asc.fasb.org/1943274/2147482785/280-10-55-47) }, "r1030": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "280", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "47",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482785/280-10-55-47"](https://asc.fasb.org/1943274/2147482785/280-10-55-47) }, "r1031": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "280", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "47",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482785/280-10-55-47"](https://asc.fasb.org/1943274/2147482785/280-10-55-47) }, "r1032": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "280", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher":
 "FASB", "URI": "<https://asc.fasb.org/1943274/2147482785/280-10-55-48>" }, "r1033": {
 "role": "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "280", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482785/280-10-55-49>"
 }, "r1034": { "role": "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "280",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
 "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482785/280-10-55-54"](https://asc.fasb.org/1943274/2147482785/280-10-55-54) }, "r1035": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "280", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "54",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482785/280-10-55-54"](https://asc.fasb.org/1943274/2147482785/280-10-55-54) }, "r1036": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "280", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "54",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482785/280-10-55-54"](https://asc.fasb.org/1943274/2147482785/280-10-55-54) }, "r1037": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "280", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "54",
 "Subparagraph": "(e)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482785/280-10-55-54"](https://asc.fasb.org/1943274/2147482785/280-10-55-54) }, "r1038": { "role":
["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "310", "SubTopic": "10", "Name":
 "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher":
 "FASB", "URI": "<https://asc.fasb.org/1943274/2147481933/310-10-55-12A>" }, "r1039": {
 "role": "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "326", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" },
"r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "24", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1041": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1042": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1043": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1044": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
}, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "69E", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1046": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1047": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1048": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r1049": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1050": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1051": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1052": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1053": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1054": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1055": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1056": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1057": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1058": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1059": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1060": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1061": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1062": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1063": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1064": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r1065": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
}, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "231", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1067": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482630/740-20-55-7" }, "r1068": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" },
"r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "4K", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1070": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1071": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100",

"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1072": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1073": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
}, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "103", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1075": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1076": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1077": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1078": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1079": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1080": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1081": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1082": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
}, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1084": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1085": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
}, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "21", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1087": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"

}, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1104": { "role":

["http://www.xbrl.org/2003/role/exampleRef"](http://www.xbrl.org/2003/role/exampleRef), "Topic": "946", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147477439/946-210-55-1>"
 }, "r1105": { "role": "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "946",
 "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45",
 "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
 "<https://asc.fasb.org/1943274/2147477802/946-310-45-1>" }, "r1106": { "role":
 "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "946", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB",
 "URI": "<https://asc.fasb.org/1943274/2147477271/946-320-S99-1>" }, "r1107": { "role":
 "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "946", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB",
 "URI": "<https://asc.fasb.org/1943274/2147477271/946-320-S99-2>" }, "r1108": { "role":
 "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "946", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
 "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB",
 "URI": "<https://asc.fasb.org/1943274/2147477271/946-320-S99-3>" }, "r1109": { "role":
 "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "946", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
 "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
 "<https://asc.fasb.org/1943274/2147477271/946-320-S99-6>" }, "r1110": { "role":
 "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "946", "SubTopic": "830",
 "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147479168/946-830-55-10>"
 }, "r1111": { "role": "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "946",
 "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55",
 "Paragraph": "11", "Publisher": "FASB", "URI":
 "<https://asc.fasb.org/1943274/2147479168/946-830-55-11>" }, "r1112": { "role":
 "<http://www.xbrl.org/2003/role/exampleRef>", "Topic": "946", "SubTopic": "830",
 "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147479168/946-830-55-12>"
 }, "r1113": { "role": "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher":
 "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" },
 "r1114": { "role": "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC",
 "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" },
 "r1115": { "role": "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC",
 "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" },
 "r1116": { "role": "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC",
 "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" },
 "r1117": { "role": "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC",
 "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1118": { "role":
 "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC", "Name": "Form
 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1119": { "role":
 "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC", "Name": "Form
 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1120": { "role":
 "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC", "Name": "Form
 20-F", "Section": "16K" }, "r1121": { "role":
 "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC", "Name": "Form
 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1122": { "role":
 "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC", "Name": "Form
 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" },
 "r1123": { "role": "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC",
 "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1",
 "Subparagraph": "ii" }, "r1124": { "role":
 "<http://www.xbrl.org/2003/role/presentationRef>", "Publisher": "SEC", "Name": "Form
 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" },

[illegible]

[illegible]

[illegible]

[illegible]

"Subparagraph": "i" }, "r1218": { "role":
 "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
 "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2",
 "Subparagraph": "ii" }, "r1219": { "role":
 "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
 "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2",
 "Subparagraph": "iii" }, "r1220": { "role":
 "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
 "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph":
 "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1221": { "role":
 "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
 "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2",
 "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1222": { "role":
 "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
 "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2",
 "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1223": {
 "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
 "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2",
 "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229"
 }, "r1224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
 "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1225": {
 "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
 "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r1226": {
 "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
 "Securities Act", "Number": "230", "Section": "405" }, "r1227": { "role":
 "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450",
 "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "10", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1228": { "role":
 "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "3", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1229": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)",
 "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1230": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
 }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
 "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1232": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
 Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic":
 "10", "Topic": "740", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1233": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
 "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1234": {
 "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K
 (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)",
 "Publisher": "SEC" }, "r1235": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
 "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)",
 "Publisher": "SEC" }, "r1236": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
 "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)",

"Publisher": "SEC" }, "r1237": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
 "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)",
 "Publisher": "SEC" }, "r1238": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
 "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)",
 "Publisher": "SEC" }, "r1239": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
 "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)",
 "Publisher": "SEC" }, "r1240": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)",
 "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r1241": {
 "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting
 Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2",
 "Publisher": "SEC" }, "r1242": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" },
 "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
 "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1244": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1245": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" },
 "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "5", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1247": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" },
 "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
 "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1249": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
 "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1250": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1251": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1252": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
 }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
 "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
 "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1254": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1255": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1256": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4",
 "Subparagraph": "(SX 210.12-09)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1257": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1258": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
 }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
 "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
 "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1260": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
 }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "6", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1262": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1263": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(i)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1264": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
 }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
 "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "22", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1266": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1267": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
 "Subparagraph": "(ee)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1268": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
 "Subparagraph": "(f)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1269": { "role":

[illegible]

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1285": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1286": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1287": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1288": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" },
"r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r1290": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
}, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher":
"FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1292": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" },
"r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1294": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1295": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/350-30/tableOfContent" }, "r1296": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" },
"r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1298": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1299": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1300": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1301": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1302": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1303": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1304": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1305": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1306": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3" },
 "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
 "Paragraph": "5", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1308": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/405-30/tableOfContent" }, "r1309": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1310": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1311": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1312": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1313": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name":
 "Accounting Standards Codification", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/450/tableOfContent" }, "r1314": { "role":
 "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" },
 "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450",
 "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

["https://asc.fasb.org/1943274/2147483076/450-20-50-4"](https://asc.fasb.org/1943274/2147483076/450-20-50-4) }, "r1316": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "450", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483076/450-20-50-9"](https://asc.fasb.org/1943274/2147483076/450-20-50-9) }, "r1317": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "450", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147483076/450-20-50-9"](https://asc.fasb.org/1943274/2147483076/450-20-50-9) }, "r1318": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "450", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480102/450-20-S99-1"](https://asc.fasb.org/1943274/2147480102/450-20-S99-1) }, "r1319": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "470", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
 "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) }, "r1320": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "470", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
 "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"](https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) }, "r1321": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "470", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
 "Subparagraph": "(d)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147481139/470-20-50-1B"](https://asc.fasb.org/1943274/2147481139/470-20-50-1B) }, "r1322": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "505", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147481520/505-30-50-4>" },
 "r1323": { "role": "<http://www.xbrl.org/2009/role/commonPracticeRef>", "Topic": "606",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "10", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479806/606-10-50-10"](https://asc.fasb.org/1943274/2147479806/606-10-50-10) }, "r1324": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "606", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147479806/606-10-50-5>" },
 "r1325": { "role": "<http://www.xbrl.org/2009/role/commonPracticeRef>", "Topic": "606",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
 "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479777/606-10-55-91"](https://asc.fasb.org/1943274/2147479777/606-10-55-91) }, "r1326": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "715", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480506/715-20-50-1"](https://asc.fasb.org/1943274/2147480506/715-20-50-1) }, "r1327": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "715", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480506/715-20-50-1"](https://asc.fasb.org/1943274/2147480506/715-20-50-1) }, "r1328": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "715", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480506/715-20-50-1"](https://asc.fasb.org/1943274/2147480506/715-20-50-1) }, "r1329": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "715", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480506/715-20-50-1"](https://asc.fasb.org/1943274/2147480506/715-20-50-1) }, "r1330": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "715", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
 "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

["https://asc.fasb.org/1943274/2147483041/730-20-50-1"](https://asc.fasb.org/1943274/2147483041/730-20-50-1) }, "r1419": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482685/740-10-50-12>"
 }, "r1420": { "role": "<http://www.xbrl.org/2009/role/commonPracticeRef>", "Topic":
 "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482685/740-10-50-12A"](https://asc.fasb.org/1943274/2147482685/740-10-50-12A) }, "r1421": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15",
 "Subparagraph": "(c)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482685/740-10-50-15"](https://asc.fasb.org/1943274/2147482685/740-10-50-15) }, "r1422": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482685/740-10-50-2>" },
 "r1423": { "role": "<http://www.xbrl.org/2009/role/commonPracticeRef>", "Topic": "740",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482685/740-10-50-2"](https://asc.fasb.org/1943274/2147482685/740-10-50-2) }, "r1424": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482685/740-10-50-22>"
 }, "r1425": { "role": "<http://www.xbrl.org/2009/role/commonPracticeRef>", "Topic":
 "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "23", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482685/740-10-50-23"](https://asc.fasb.org/1943274/2147482685/740-10-50-23) }, "r1426": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482685/740-10-50-3"](https://asc.fasb.org/1943274/2147482685/740-10-50-3) }, "r1427": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482685/740-10-50-6>" },
 "r1428": { "role": "<http://www.xbrl.org/2009/role/commonPracticeRef>", "Topic": "740",
 "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "9", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482685/740-10-50-9"](https://asc.fasb.org/1943274/2147482685/740-10-50-9) }, "r1429": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482685/740-10-50-9"](https://asc.fasb.org/1943274/2147482685/740-10-50-9) }, "r1430": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "740", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479360/740-10-S99-1"](https://asc.fasb.org/1943274/2147479360/740-10-S99-1) }, "r1431": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "815", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
 "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147480175/815-40-65-1"](https://asc.fasb.org/1943274/2147480175/815-40-65-1) }, "r1432": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B",
 "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482134/820-10-35-54B>"
 }, "r1433": { "role": "<http://www.xbrl.org/2009/role/commonPracticeRef>", "Topic":
 "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
 "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147482106/820-10-50-2"](https://asc.fasb.org/1943274/2147482106/820-10-50-2) }, "r1434": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "820", "SubTopic": "10",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

**"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1435": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1436": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1437": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1438": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
}, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1440": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1441": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" },
"r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1443": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1444": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1445": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" },
"r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1447": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1448": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1449": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":**

["https://asc.fasb.org/1943274/2147481326/860-20-50-3"](https://asc.fasb.org/1943274/2147481326/860-20-50-3) }, "r1450": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "860", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147481326/860-20-50-3"](https://asc.fasb.org/1943274/2147481326/860-20-50-3) }, "r1451": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "860", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147481326/860-20-50-3"](https://asc.fasb.org/1943274/2147481326/860-20-50-3) }, "r1452": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "860", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147481326/860-20-50-4"](https://asc.fasb.org/1943274/2147481326/860-20-50-4) }, "r1453": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "860", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147481326/860-20-50-4"](https://asc.fasb.org/1943274/2147481326/860-20-50-4) }, "r1454": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "860", "SubTopic": "20",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
 "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147481326/860-20-50-4"](https://asc.fasb.org/1943274/2147481326/860-20-50-4) }, "r1455": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "912", "SubTopic": "730",
 "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
 "Publisher": "FASB", "URI": ["https://asc.fasb.org/1943274/2147479532/912-730-25-1"](https://asc.fasb.org/1943274/2147479532/912-730-25-1)
 }, "r1456": { "role": ["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic":
 "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher":
 "FASB", "URI": ["https://asc.fasb.org/940-320/tableOfContent"](https://asc.fasb.org/940-320/tableOfContent) }, "r1457": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "942", "SubTopic": "320",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
 "Subparagraph": "(b)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477268/942-320-50-2"](https://asc.fasb.org/1943274/2147477268/942-320-50-2) }, "r1458": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "944", "SubTopic": "210",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147478777/944-210-S99-1"](https://asc.fasb.org/1943274/2147478777/944-210-S99-1) }, "r1459": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "944", "SubTopic": "220",
 "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
 "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477250/944-220-S99-1"](https://asc.fasb.org/1943274/2147477250/944-220-S99-1) }, "r1460": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "944", "SubTopic": "30",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147479432/944-30-50-2B"](https://asc.fasb.org/1943274/2147479432/944-30-50-2B) }, "r1461": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "944", "SubTopic": "310",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477363/944-310-50-3"](https://asc.fasb.org/1943274/2147477363/944-310-50-3) }, "r1462": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "944", "SubTopic": "310",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477363/944-310-50-3"](https://asc.fasb.org/1943274/2147477363/944-310-50-3) }, "r1463": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "944", "SubTopic": "310",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
 "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
["https://asc.fasb.org/1943274/2147477363/944-310-50-3"](https://asc.fasb.org/1943274/2147477363/944-310-50-3) }, "r1464": { "role":
["http://www.xbrl.org/2009/role/commonPracticeRef"](http://www.xbrl.org/2009/role/commonPracticeRef), "Topic": "944", "SubTopic": "40",
 "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
 "Subparagraph": "(a)", "Publisher": "FASB", "URI":

[illegible]

[illegible]

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1495": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1496": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1497": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1498": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1499": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 131 0000950170-
25-019011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-25-019011-xbrl.zip
M4\$L#!0 (%&*3%JE=7_71G(% %9Y50_1
86QKMW4TFR)_H_@JFIH\TIVS@((JFE@8:K.G\$^)(C,C0=.R MY"/)%-R_D;(-
M@|\#4A6RL!B@>RJM7?N'9\$1OWC_Y7^].IS>>\$F+Y60^^^N_
MZ9_5OJV@69VWR>SY7_MJL'=!P_^I7_H_!Y;^W/CE_H-'QI1GS=NUJ7D M)?
TR6=;I?'F\H!O_[]>?_W&@/ETJ,;_?^?TXKU=&M MFS?_///GUN?S);SZ?&*[[7\N,,AZ4_6V>
MZ7A+!_[]+R?,7JQO_K?IW&_(MOO=L1M,IO;YQ?S+ # M69W@!;!V5W_7UYF_?G&
I>GTQE/YVO+&4UK2XB6UGT\N^F+%[X/?R6SYUY_ M+?U/^_!H?
RFSCG???"7G_'1RTJU793%MDS?GRH_K,XU2X>,)P0NGKCYXJC\Y M=77^U,F%!9P_V[]DI
[CB1Z.S\ G_ ^L3AOA@LLWHJZI_P+SR='STZ=O/K8 M=;4L0T@N%#\I?
3:./6+*+R;UPUIKJ\7-U>LCNLDGPNSDS#>K6DX^M"9^ GWS M_ SCX4%|08<((SI\Z\1*>
{QZ\^6;'95E_[]_0_?|^XLY/Y\B"W7WYF=?P= _J" MU6??Q.F_+GZ)?T&+0SKA8\F-
F_/KO/CV6KQ^B*MEU1_?CY_>?/TX(6%U=?M M(R>_A=.G+Q: 1^[]2S<|^2X^9J@;-
EGR\UYM*J,7;*9U[]JH-EL?EPS<[]M/7CAQLO%ZOUWS+^[]<-+Q:0%1-
LPW^>@;0M#DPI?F Q>?=SEW1L=/[863,[]X] MV\$?)9?
GM(*UQ+3Z#_[])Z\ _M/=^C5_SS\$Q?/)[]8>K^;_ =7)X-%_P=EK[SY_6]VR3EV=?;9/ET11?
RXXF/OJ7 MR:M;W6_[]&A%_[]_7IV5L-ID/57H.C; !5LJ!35CHD[]4KT
M[]V8X;'F#05HH"_BD"SB;"Z!U#GI2 MB?B?WBC_=_/D'?
_UR;*K3YY10TZ3EG>_6W[]WU[]N7ECFAU==4RTQ90[]HP-G M>,):
(*F2G8AA5Z5.K_J.Q5WG[]4@3I_PE>;M/O[]N^55A+?[]_W&I569K8@G)
M0^S_@FL5(0=C(2: ^9&S:%L+SJ[]PW8X9Z?9?7N<#I@UFC5W^GUU^W0L5RV#;+
M!W.IE=ID5->*());"%[]W=0^K%[@%?);3(^%=?7^E3>CY9RK99/>(C7[]?0VZ>2
M^<;1M/YJ;7VXLE6M\$#;\$A;V!/\$<@X\$QU&4BF\OU9&\$O,%[]Y_UYCY8,6ZY M>R+9[]
[]5R[]X[]?T%UC4\EFP*:665-/8@HD7W#SDTCK8:'H(5:%&<[]@
M4SUXZ^[]["R\$!9=WIXU\$28L\$1CK3>@[]EDW&Z%:RAD_)P<6@(@8_U>PQFAIM
M"BQOCV>3DR_[]L_?#WYAN;B[]Y&S[]WF45G35-3A^[]XTY M&ID_.6ED;95+53D&W=
(W/[]++F,*7H_*.4U[]")@\$_!V/_G[]>H%+[]-9_.31G[]WWB.H
M.3UG6:\$9&YD*AM^*TXA0;"XN@WGLE6J-E80:ULZIUF<\$1[]LM0
M55D34B/*T7WFE;Q=PL\$+QC*T.+G[]X_Z0V.)YO+B[]7-+J[]5DRA+[]W18:'&I MUY22L:Y&
P9[]!Q>P0TELD_*GXKRM5K4W*D%L@UO_P-EQ9[]8[]7C!9^-(556BY/ M4,%[]FX\$[]D.N,-"I?
_B'#(4TPT+*#6OPH^/#+Y59*C*TS18@-#;#X M\$5KJ"HQ:([]4R6OW'L-
363U@0VJQAC!_X&*[]3*@'O,H%+5=/F:T%9%Z.A_.
MU0=4CUE\Y)BYD8Y;=V^ ^RY+.1@WA=OCJP1S,&?>"1'OH":Q#K1J62@!0%W
M*24H#*7_5&5R<%4SO-OB.S*NM;Z; O0L^5@-5/Z\$K!T(>57H*V'8^3M"7:SM
MM@+K*2:DPP(IY@9&YYJRZ9J?X + 'GW#W[]SY5,VX"K0C-

+/:00^::%TV3M6)B7\$#+O_U%G!JWEFL?M_FQMK)<4N,M_:_^M&0S:"H.A?707BQD%?
*\$<&;6_QJV=BZ6E_#77/RIGQXOU3VNGS:W3_M1UF_5-;=JL2F?&:YB,X7UGQ-
</5EW+U5)SJ?UTIE5:PJSGR9-?NX36MQ8_M+YL^://???#WB]#W2^?76Y)SX6/3WYL?
+-71I-)G:Q...1&FQP*!IG;S?M@IE+9G3YDC#Z[5>3Y4]_SNVEK4B9]^>M#SCM0_>X
ON^19MIW;W7:SYW5/8_M3:)%UQMCLF+HIYG[WWSG/=SIT\$L_60/T&Q*L?
4VKO_&K9?/5@-5OWN_ID;.?MSIYW\P(3?(0G=/EEP140V;55A@N\K!)%:
)A%U1BB#L0;R",0@W+^>'1_M?+;&X1@R:9\NZ0Q&R3-9:#VEDGS90_O-
OGPF(@YD%4CLMC-MK**8IEK,9?@<[1>7+104Y/^\$,U_BI'VFO,L0EF13F8.7C_LOQ!C^
M());XLR-\$J<5UU&#-[V*;3B?/?\R_M)380/W0V=%-CTR\$S/Z#-
D)5.#)F0D'E\$T8>E1_NSAD^B4=2P_3R?)?=UZ_MCS#N,MJ=K-X\5MY8KE8L:GV?
^>+N\?+%9O.B^4Y?K@SF3^GV;:8[.@./>8>!
MXXM#7/SKXK/>KNN8\$./C2BR[V)C8!/LRJRU6\$EP149E*|HWUWES|W#M+>G
M7N#9LR-?Q;VLNW+4"J7SF_8\$2%59EQO,<028E*ACL:SG^07-GD:R\I:X33
MU8LM\LT'ML?IM7\1>TNR8EH\H"ZKT_L_:R_.LW2#/:1+5>99_M&SHXY1'RVDUE/?F@!_
M<7YN4!>+P_+RA\Z_KZ[YH/2\)%%43W"/7=+YV-XYZ.:GF_FJFB\$#/A3Q
M6FN\$8H*#HDJOJJ,RX*IV^+Q>5]W3L\FLY?\$ZVC_H_7GN'KJ=5\2SV:P.+M5N!:J1")IO
MS*XU-M9JAL3>3S75KG0;UC?YM:KM@Y&1+1AJOY_W>T8I#*^_2*,4\$F0L'K()
M9*AFU=VP*D6"R">X8#J=_RGI?A+H/TW57+YCO:H>KQMVWV3#N"Q\S!)49
M4WKO(45=0.<45"DI=0JC4F9O,>7=^7+UN!_@=!N!@A%@2'2!J%4H5L+5!"0
M/'^\$2B!K?&4\9C2F\$ACR9#%0OW7U>">WM2SV_L"R'U4VV19=JYR]/.;9!V_MR=A*
(0.5[,#%8B!A0!;0_M'3+Z:BT"^JB_05G.A!5\4*,RS#L&_5H6/^/3[N"2!
(2M%I.Z.DWW^WTV6:W/MOZ9:-8<88HR28\LDIFY_@>6^A>EMZ-
SYB'U8R#^_7V9\|@PI=;!V"LY+4;3T4_M3QU*5M'E7H+/"BKI+JE4GRW6(O+UFI22%+T-
4FY)/B)V+SE>OF26CY0F?(N+3:P=/[CW\Y?;#NX\?'3R[00FO\F&>?1.NQ2#JFQS6H&R3-
K6&<MEZDP,CDTF^R"J+CWV?X_W+<&I8'8A1/"Q,ID:M25V88?
CFE/STSKJ>Z_JI%GZ8AP<496[MM,#UO/WMFZ5D@X,'45;Z08E_M,
(EM\H\$13+W;X6CZW92\$=5-[H0Y"87.\$D40&5+SI6LU2O-Z2]<.!W<16AY17
MX.O=J^13*9XJ6"V(5NOJH&=_SO?&'.F9K\$8#@2\$>."U>A5X<8FU>J4=;51VN
M.:^JMZUJMZ-L^JAMB5_Y\RI99E-F5JDR;3F1C:D/%WO\CI_UPOGAUY1Z
M9+LT(ZJF2(LGS09E218RE1):R#'-7!KUSM7\3DXXBJ(-#H[FL^5\|>%\K%,H
M)N==2PB=3?2424/'X;!YWH0H'9M<;CX4=#Z%X13&CX+-[4&|,%5(A!F4CQ*.
M9GF"/+H.L.MMIKM9JTE4X\$Z&P(8LT:??RN:06K-MXD7KYF)
I&"G*T1NOG(&>K.1HD8'L*M8YZOI.B7,>E0"?^=R7:*MBK?
HAM\5UO5NTDUR#*VS30\^2A/-P,9ID;80%1LYQ3I9V^\$*9#Y#N\7_1Q^L
MBBL.>.)L7:76R-P")#103G0,36,2ZZK0\$TJPT_2.TVBNB8;?Q)?/U3E+TUAEB_MUW-
'I19C%L)A4=*41'H!F@2)5\$G8V*MP^VH(9+Z+I4DL*<1P8;/S\6\JKRW_M'?4*Q:4\$;\$7%;-
WS\6C\I3_M2V;/%+S8JPV^JP-"*XK@LS"&%SSI*VMMKKK_M
7"W6"@Z@IV"G4+W"121&%
(F"UA|@U*#\M+:/O2^/93F!T)^.LP=*'=0|=5Y.9LREMRMKB.7DK9O|A'(R1^D96W%X1,>
M25U>&!FP.6^IE#\PU>WCUED4VVJAN'DV:5Z3M22\$WKU+J'RDB"D5^+4+;8
@8\$OF*)@U'MP\$JH/^L^7RVV/FGPMU;C;9_UOG[R"V9)N/U07=^X*DFR+A&0EHJS'-D0
M*2H_FH@^-UM;&1;FGBN@?O/Q-{ZBA,1?/Y2_^\$=JJ!_CHY7R_499E.<='75
MW%^SI(^5N)_&FW^=2Y\|6<5^9HJATB9+H[\$:]&G3IA39L&XL9.FIGK,9MF\IR
M4R+H\N'1ZP5>EPQS_H+7"T:K-J\$A\$.MT\$I>N402B2Y'!6@CJUYC4LV^_2K#
M>E!';>2W@V516ZV#C"*J29W4HJ-*!"J\$(KK)K)OLJ)2YK!.LUN/#XRF?VJ:!
M*SEO02_D:B_I!|OE5H;:/:"FO@EV@#*50=.&9:Q.F6(E<5MK\50'I9:NVSZ_ML"6-
9VSU+EGH*0=P4>()002P4;&8:1WI,&Q08<,C5-B22/-E\NKWN>A@|)
MQ0+=5(NZ\$FHWG,MF4JA@(W#GCV.96'0%.&07(1^T-I6J_U"17/E:V+R\$EJ(MW1N?:I-
IN/SC#C04B3""DY_M-@(*FX59IBE6TCF4WDR*PJ&>|M7=)>JZG?
%9EV5W!242)5MS<+*/V<'1)1*M2U+(A;RV9--\$90VAA%2=ZC56IO8^I
!W5%;+&I)'18336!T_MHDMRC"\$-4Z9J"SY\$DWD7!N>&S?
G\T2U)PQ3%""O7;+.,YRM37S\|7JVZ\$NN_M6>MA.ZD-J7&W9'74'&VP'8R-B?=U.(#9LTY-
F#Q;%6-VYI@>&?C@S_VIO_C MAKG)HI+DVP9HT_ED+1QRO9QI#AH.CB9
MC4I)9E#7H*4QM2^(+;>BP_C=30\XI_R"3RA19\O#L6J
MV.GTI1UIHFY,P6@AG0S*I"P)K00E6L,LYLR*:S1J?B;*<7LQX9?7D"V,LXV/
M9E(W=BU+@+!'JW6MC"4RV_6,"0%C;&5&Y+56-8FPSF"?NB.G>N.74F;V)SK
M#EKWXD\ND09+C,C5A6P9I.&,X6W.'YH/R5.4;T9)JD/P7)M&<4**YHNMM-
M70VK")#.^XJ.I@5/3^P0LBH=K;+A-2_C"=B\|@>>X_3>^KV>Y/C!4X?|^--Y\|?

M/YG6;=L^&K3?A.U3E&UHO20X&1FJ;#6DWA)+B%1,SP9;'2ZN_QF1L(I@fTM<
MH*B*R;'M&26=V.G@V/9,'D+K)EECL\K#E1"/T6-B654'PVDE?%NG< MU2I""'.IF=,9HNT?
6]_HIEI>OWBA;';P]=T&7K9FOO?WUOLF6*R4V%+#TOO72* M#Q\$PZP2JUM*5Q^3+
<,D/LL_6_81HP6;\$ZO4C/#P/,N_@<<-7=R9SMD=&\C.K MO%*2^V*3X3).H-0L34K)-T5F-
HS&PR(-%|OV&\MM?FP2?G=%-OL)J!1;%%) M21L_*>=R!C-D;OH\$'Y,A*CV4KVPQ3K%/
M#+,C#!&<+>*V9LQ@6;#8!CDVMN:U3J['E3?-+&R?2_V!C.H2F#975,BS+9 M(#0'V"-
"*ZDF_N*#IN4SB9399KJG)H;N]>P9 MS S7O7(6NDSB<3VPX6NB@F_8'%NV@WL?
ML)DY\$+J'5\$S!6UT#F"D!-!)&^AB_M+5OH+CI?T;R0T80#CX^1KZ>-
%&_J>#>'N".E"/OI0:8J(-C4@"VD"%C#JFE
M\$/VX'I&1NTZ.L+.RU5;*MJC(I*5<.Y3._C4Q&/H@|_#!IG/Y5S]6_.N2?F(
M,=_Q8B%J/_KCWZ^VS MB9/74VXB693T4.6"S*1@O<@@I8/JQJ82@^IN?
WUGU|+'NB.763\$I2?)PBB*_M.V/8W&N \$FW,.0:B|>>^?
*GR8K0\;23MFY17M83>LO+RUK"D4]*_-6FHN7N7 M>C1MO(I+5S&X981HW8_HV4>9-
NG80@#E:V)GA.4\$BR0JIBU4PK3L(G_W^EX MEW\$,Y=I27W>HJ'84*X)D@QJ,"Y\$TLX9-
6|>W!=YG4YAO%-BM/!9K^.;>:F|R M5+!9,*FP'& CF6TP'QBFDS=&8ZE|.)?
U*%FK.|+D5()WY,&G(KNO,R8G5@W2 M>R)VY|6+P_HI2G(.
IF/YT9L|\$9|L%;3DYI:3N1&Z.BQ&^K(FF#AK>P,^>FK|5P%JF9813
8DIHQBTM2*L<'JOEJPK.@8;#KC|7_9'Y^TH.|,YL^OVH#>NZ22/07,MO:4F@U
C^@8.E8\$2>H68F^|,NJ33<.;/3GIT_%H5;|EWC.D@H%9-#?{(
M;*"##D7%G+PO>L@\$OD'2ZG\X)W>-!ZL.V7E&=M44(VE-\$1):Y!NHEGWTG<9+
MV7XL,64YF3&WWJZ,N)>3MZ'@\$|S\$;Y/9LQ>TP",Z7DWJ|DN2(B^|AI.0|#+M=?
MX|6*^>--Y(#N#>RQ>IF-2*0,R0EI;Y*UFR1&K3-DR*DX0#^&T?.;>F_M"(MWW
GWYPM&5=)4|^\$,Q!+86DJ\$8=*H!V|9S MCKZ4;|E^- 'DC?.N*
|HHJ4"3I9H\W" TJ&:|5578Q>ASLX=^I9O|&AX^Q^@K& M-MZTTE8=DT^@)Z-
LIE1HG=M @VF_0N9,4&CW:|+X)DV!&+QKQ4%1
M3>9*2"9&:1|J+D;JZR.PS9O_%3BZ^W#H|<+W(3N&B'GPUQ^(Z|/W=1&#C7U
MS#9)1IDAS9^RL86MQN9MT8QO[%|!FQWVZ=^2T9@B2?R'T79FRR-*|O(@C?Z
MK&.OI<8HH_-@9HM2&C5JN<=B164,-.JDJ,- S20':%5G
M4|NQ|12*8E'7(N|;_UL=%E1>LDSV*;UP,J-V#Q>SR>SY_FP7Q\$+>:ZC--BG7_M,E
Z7|THUZF*0JD-"Q-&2 W=TH8IME>Q4HTJC U,)4@A&0@%:PE&I1Z'G:4|
MKS+H(B84PF)YM MJRK&T(;%_U?84.O;G5H|25-LEE2AOB1%1JN)6--
:Y*MWL,58Y6,>3M.^3Q|_MA3:9'@L>?9N5<|*"G|K|Q5RZ|Q|=K|;D>|S/#
(DGM#AX@0M)_?G@!2XRQ%DP
MIAP.OIZ,0*:@9K3%FILA%T;%D\$N&4E7=6HW*ASA<=YY+|KWZ_6_/H!J!B6> ME01Z#
:3MA2IOM_6J_-\$1<;RNA5?K%V>WNX'*R?-R?+/BK+-C/MQ=|I=8!36OZZ(&.:Q;7./-
*_6,RG6XPO_.3P)'AP6Q)&YM2|G.LK|G2R%
MVQK;A4|P.CGDQ|Z>6*3;YEM*D#+#1E<3VQPHPT<_JD2AQEZ'PR*?D5)GB6\$T
M>3X(S=)|,T7FX(BJW+5M+7UO_.NQJ51K#QDHL GI?#:.61\$P|E J=B?S#\$>C MZ?E;
MUM6JRA#36E9MOK"24|X".0Q6J5K2>!.0QZB"|X2RQXPNI1G|_|R==S
MV^I>:^M"QX9L.4@#\$F,=D&8ST9F6G!G6HSIN Y(=T9+?;ZI2W-,<@W_G(V2Q
M+K*RR2;=JO<46EY6>_XFU'\$3W#2'LQ.9|!=3W):LA\$+RUG*4A|;-:1@_Y1N
MO7+*653#-= \$=>"KX;@SRYJ3|ET_04?K8!Y)24F)L%\$,,%\$*I."PL^I1MM(Y-
MG7G2F8:GM-ZB4_UK6T|NZ>9W)9M<)_L_*6DFM>X 69AO5/4JLF(>-S5@EZ4S
MV|D&.)YW<2P.FD.9K)QX|.Y S\$Z6|F3;7HXO|ZE:B*N,%MPA\$WEF^|.L|MP,)8*;9FM"?
(I:3JJ5J^T5-7Z-1M|MP8E3K;#LNVA9SHZ2*M FK4MY\$@"JS
M=,74C?:M&#|L=N(U#97L2!@D35U|A)"|9FLI2,ME+|4='G-"97"\F-GHP^R> M/CAXO)-
S6;:")KC>8,FV5:HS\$#DVY:G)7VHQ;7*E M|9'O:BU|=0FMM:?.4;) \$T6B(RC!;
|X:52DT)LHJUN%""S|,EPUR#H=S?|RR M1MA:=P52Z\$J:IRE :AZ|J&IG&-
MPQJ(0SL6OAO/5&>K-E.:DL"%[V'G N" MJ5H%8|U-?
K@@|{#4'PCM27KVEF/F*P78"Y|7%+#E#;|H\$TO V(-|U/U;+*
M75I(7!C(BVA08K12Y(F|FG-&XG!;JY18*^CK'.N-%S_P^^1-{ZDDGI3
T=L@^(:ABHN^VI5"&-*#'|8WYHZGK%3%N*2T|*PE*C'R,UU!L M"T!>Z5B53AF'\$VJ?
G@K.5OUDAM/?B(7-BQ|>QUY5FNTIA2H7;BSLH!NM!
M*6M":D1YO,3NKQN@0+BD%_-I>W!XM)B_/&E&N2_!!=*|%>,"R%P%<*TJ2!8I
M4%9:|R-%X=,,CUI#YH09;0K ;J.4!S_LB1,\$8X-(OLIWT(R065D@18S|RM"0*TZ4\$I)==-,|E
E M1|'5^=|:46YU^.=V>J@Q@5K3"<&B3DR@X@_Q.8:~D;K6(0PL^"H(JV6(=|
M>KUV\$9UXBZXG!L7L%&--("/-|"\$EP-P(=&R*T&!H93@L<:4)-Q|H1ED^/?C|
M>C)#0:T5VY&Q>R^>B_*9P0R8:IU.F8RCX=+WQFB?MC-ZH?\$U0;&V2"_+%"AD

M/DYDZ\|Z\F:|.2=#S\K>DKJL/@7=&AB= CC-IEIV78%VA"UGS'\L+B1#3!Q;
MX\NKAZ+\$(F_=M5"+^H?MJ^|>5.1F6"E:T%5TB1&LU1M1DH/2M2Z)6*9 M.1K6_
Q8.3VT+F(YWB,72U?>4"O\$. \$09< \$SE"9#UVPSELD1T0QKL(ER+[R M].T=H-
:ND%K6,NY;!K"@|E!J)*A6.652CGW,%C*?:|3W|Y,IJZGG*[8U7VQC
MBLZ6|H|6.1AO(9.,VF: +@05JL&Q(1-345:OC|MUW*D>_MOJ9KAMI9WEK,F8X M2;|,L;
UJ((+S>6D\G#F^J: +?O=4!%J?;: &JDF?^EXZI'7KED:UDC\$.QQPG M-G1+WCNT^I-
H9KQB5?VC*>_U\$%V.VVJZAO+ \$"# =5QG| \$ F7(:F|)*ZGA-LI(M\$X^&
("I@VR=125.9: ^M5*RK,LRCH,|VPS#:JFQ9SQL"1 &9Z-O#7QO3GHE
MBWNY.>B|AJ9+4,T/6WG|4F)9V>6('G5(5J),<5D??BA5 ?*|>^QYT#10^ZL3YUR
M"HI\$:G5)B?6M"K\$,ZV6Y/V%A3.M1! JF-
:>3|J43H8*W'E|8A%.IU&*L&2|6|>5X_ =|G_,R+@|5"S"D)%7_VYQ:B'R/KB013I9F
M14O.,9*%\$*#&%M*SFN3PG"RY_*V|>UZ\$G9^2I4F+Y&U_-ZH|.QM=H6@62?|
MDWV"Y%H|!|1@4=ZV3"WM9&WW= | |\$LHYM=#\$6NI*^H>% J7QIO:U6:FW=:D;
MESGR!HSC9"\$@|VP(V>@|H>50W_-"MY| (V?"1?UO>N'K,^G%Y?SYJ0'LZ/C
MU7)|AMG"8OZQ3MA?|Z#|"_K/8T8;KS^RDG.GBK [7DC%X-Z8DL52BP4!79&R
M7U,A\$7|*54:I4D\$W7CN73T5|?U|W#*#VA!9|OC@4'?6Q*1#+;8V!V!:E2@ZI
M=S"2X^)^B-Y!: #4PI4EA|",4,F_ =|4VYGTU64|: !#V9M\G+2CB|DU3RB/O_-
M9VB43('@MKB"%\$E0WP|++RYF="VJ3 MU0Z-
SJ^&NM|FXM_E5;!*ENSGRW9QW%,.)FVRL@9ZS9J54R5 X|E*DMBAIF:.*
MVGA:G>>*6KH)0_9F1L'(>HO0/358DE=K)|V,CI=6^RTXFZ|Y)BE1J+5FDQ
MGA7_F+QWQ5'R%H=UO S6TVR35.G8L 26#X8DC,56'BHBL)7!\$N\76\8M8!N! M*@-
(?'ZYIF3E(:MDP'7,D -6R!@L>=<*AF\$C6^,6ZV|0*RGC"YHLL\76PY0I M0E*I"
I(TH=MH3!EVCWU1EQ)&?Z*ZJA#TP8R_ ^GO|R|V).BJ34O('FJ)'IOE
MV(|5LK"ZI4RGKM6XF8YCIUM4\$|FUV@:(("EHXDXGU1Y*&X%F)WO,7<'N7G
M7(S1;SMQ>#<95AS"Q9D8BTK)|90)5@+5&VD7#)&&E;J?1%ZN)J: MSDW"!E>|=XKU?
7&!=ZSX M=+1D'O&75+YW-D<;ZQF182HQ#VM-8+IN M,962* W'N9^1.5ZKD|5K!@-
;H|5NPO,JLK+IQ4)/F6D595Y%8.AF:,IHBC'-
M#AO@O*13Z'9K\$|EK.'V"D_9@=A>|)BN\GDVJ5(H=99!UB*:(;,%Z%!F@J+S M597D|G-
:VY>U&A/&<^W|:FZL4@ZN5P_*E XN-P.I^"MHO>- MB?|A-
CP_<'OU8LHBYSY6B4=NK"K|PG+6"?K|4C|I!|>X&T;7V^X OL3?V-
M5CI%COK(RQSVPI A9<=L9VMTW::JZ|'9SON"| #9*KBA=E#Q@MTRN|AH4&4"G
MDO\$-%,BH0\$?8.O M:A^O7LREH|@|=!6R,SF%ZM/_?;R8+-
ND;B>0LAU|3XB3\$C8(&"TXI3+D5"TD MYUE^E|R+'|:&V! ?AO5%R8="Q-
&D)WAG=48'<=)0YP#TZW|7WP^;SL:)(Y).! MT'_4O|_R.9_=O70<|%N>>5-%?
NJ##K:9"*DDD3>1 N-|@3==@^1SWC#MQ#R>C=|E| =V^P9;512F"H8)W'M MZF5@
8/P%D-TKL5F|;"^Y*^N|N?FK;:% 7M5 M4 W0M+>RE6R;4EE23%63 M%HW9;|W?Q%;?
%)^ZH3?E-6NS3- 4RF"JVB%)&9:R9+\$1Q=B'C?Z/W:AN!(GF
MG>X%\$3(1;X.,,EI5HKZ8/#EOJ;OIR,-\$GT8@IS)MVH:M!H,*ZB8-4L*@\$&Y
MRC1U;=RYJO\O0;DP0&X:T^T+PH16==4L?>BT6R>9PO=8,18=/ T7.W)%Q8&
M/6(3:6|,FO?,6;H3;9-6+)(-4&@53LABEEQJWZ_I0Y<_OPZ/4"MV=17/FH
MHWAI4U=EL&HC\$C6P25O8U/6ARF L9KI"S4*4K JC7*EV6/3S8-V71H|TOHOF
MX,5|L9)DMKJG^|/%S1Y/GM; K6?I4|Z|)2DCU-+6N9+LF&8I+:B MJXS=:%MPW *;,\$?-
BO|S-^)|ZZSY+/M;L.,L? \$^J8'2 TSL#@QE+#Y/JY,N23H M?
DHKG,RHG4WLOIYH.T5E>I28N6=#SE<|M)8P4^;T\$OY&HOZ21>?3U57R|9
ME.K!5,FE|,%"+KTRL"XAFEY|J>.KOO&=B;O:M\V3KA%":()K;-IEA:::2#
M3|:UTCH<^"4VJ3B@H("IP;/8@:'PE>SKNY*,2(LCWC^OWQEK?>|&
|ZZ,YFS|;E5,K#9:3=&ALC;TDB+ MYFC >4:X25*?K6_.4_3*>#,:&;ZJ+>:=X|FTG60DGGU|
<'BTX!V\7^XY8@-\$ M+/Z EB5JLTYL_P(VF5"*|!@9>.P%7Z%-IL=2Y_%62-Y|)75JU.XOYH?
BP3E> MK:W|Q_W,/?>\$%@;F9+:&< M=8,:7#5!:7"L(Z@'RG\$EX|
|BEW=NNMS@Z*LIZY,S#NTTK2JEHK*D016*-R MYRA-+0<@HU&HG.Y|.0D#N>XLE%
K9(>40B??QO,V7|(/QH-|URPR8!1%M\$8F
M|:8"CI*"X|.H'TP2>54XG#HX/,L=.CUS*68W1KEC!#"LAXSK!S#JR1K? (ME+-DM1T6?
X|Z97F#<-L8BZA8^/DBC65T+E"0"NB66|*9=*W#I79O,55H(^A. MG|82|&,#|-\$?|WZ|?
3;8|W|J3U-;JH48HB?I,: "5'L;B):UI_*ZN3X<"-H M%ZD=TL(GT*SJ\$&F1#&^:
T8HR/T3,Y%F7-??"73(KYS2?|^>6S+83JFS M|K?-@8LN0B\$?P!VZEO|A+E?
2AF)|)%LSXTRJ-89*#D&^|FPG>8: M>=M,SUB'-
_P&J2+D4WI&"%%8L"DJ&+:JGC: ^E#EK|W%(Y)) MMNNF*U8%PZ:Z<|)XTV<%13EIK%=
_ILZAU<,E@@X|0'='K@T2B81V* |@V66 M""R>:1<4D)\$D^MP|2H#%V7NR(-65?

>NRU!Q9\IWB!+W7<(+?9&Q>"X(OI2 MV41KNOH1#+ #E8+:>= N'700"-: G|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|B^= M79'_H:(U1E*UCE<3\&N+|\$%CWSP0OI,?+!:ZBK2,;? D XJF.R\#FWMB@TW< M\IA*A)2=+VQOEYR&BPKM=(;SNS%7>^F8ZX6!S\^TEZ++F\$(75IBR;NE-EU5 M\:-D%%-#:EMWD>Q.[21=>&D)=/LIP8)8Z:46 LU'72.1H\|7F(5)\O(2O! M);))L1CSRC1PIDLX_ "K(I8G_03IQ7<60MB?N!%:MA";: ^1,0-U#=#E)SG+!/K5/ MWI1AD? ^/JHRQJC)V)&U*K=4:A)!3ETI%U@_1B.\|D,TQV=B&BWQ>|D1J-!ROUMC_JY*-T7; JM<(+^4Z6^1XQ,GA6'C 77DCMU7J+3;=A MP?,7M;M>.W&VVH\|!)1;C>K.>="ALAXNDJF=9#BA2=YKWTL9=|S=T%E>VXH7 M;0E.5507A0JER(S*!653;/OG._:&659LXW*|F^:HSSF)T9)SI<4_9=K1_C! MR=7>'4:Z_N5Z_#'?79,[?2K&PCO_IC\!^!E&:H8- >HR>.: =4\HISU(Q.:0*75>A)6|-2)36:#V*7;J2J*ZLN(9E3PC\JL3?(*SS- FO3"H+)D56+B0U8^2,4920#=-|XZ9=@2OY&:: X@_M%+VMQ=?@H1KB7= <26V:E*^BQ6*\Z*L+A/\$&?&?1S4G=|DBIW\|V3HS\U7=7K<M>,L='%&5N\;3 I? 2N^>=L\XGZ3IAB15=6;>18>HZ;YJC\@L-FS\$U/7&O\OD\|J_>G2\7C_O: ?KN>.CM& MH\NOD"TV<)XOG\$IE2Y\9(+*Y7XT=-HOB4EZV-YDN.&M\|@Y&3LBH10J^%Q72T M 5 S49IVY+NML<1A&X\>YBNTR?28=S>|+2('WHA\O: NWETX/? KV6\|@YFAM\Y\X'WOX+K1,KR6N2WV3A&| MTWE(W^G6IM> (H\JU#6WPQRJTI+K=9>ZY2/:=MKDCI1(LA9M6#O"NB2Z6D@, M2B 3!6MAY>- ::_3R%6J\|TX?=:;-W\Q6&1\$8VT>BN%/U,F8ISN-84@3>;/I M&"^|OS;0<6M/A7XI(;5JH:@0&>MCX4^% 8%QU@;7N^K#FMU7TM#NJU30?@7 M?;4J.D2H9*7)C(W6#::&9^W6\$PS5>|+%^:O3W08AQIL9FNM/03; TONH@!S-M"Z =FTG5:Z_U\8%A>PI#FK%8=0/\$))/.(R07X+O,MU:FD:4XWK340?-*MU,U MQP1*VE;!4)T#EXP"F>4DK;Y"<=|6U;W8'TZ\O-LL:|K?|V6<'S2X98EW:# MIFQ>6A? 10*\RFRZ59G#NI_LX*.-;<6R:D946&H! M5E5#;S\VU(SK?MB\|R4W,5#::,DHNT5SCF\LS? LUBAA\|PMD\$D%G2-I'2!6+)E M+>(JH*0"&QUU2&AJ",- Z1R_.OGVG98#\|RBG\|VL)SH\O684@|?B(_V%-#JE(MGRBK2)MBC-)#AA\|F\$*RR>UC"KE:I5=!6/?;8!K\$G*QGG(U-RQV.! V?&|G MKPS[5K1X\|@)G7FTJPW\|7O0?N;|D83D0DT)7'#(9BH;K#DVA|BRE#KTT(9H MG# ('9+6="&,\$ZM) H\|H2LU\OKHS.0:7PMYYRW?2A7='U'->=UTNE0J\|-IY/9\UH M1@N>#\$\$21+;80_#J#:L MS_F'O&+^'I3AC>E- @_7,NBZ0\NR,@9H)UL42"MIA\>EWV"MV-PE_@3RF6!HT MC0RZLBZ H3.3I%9\JDK*M\$9EDLN6Q;8V\$;V"TR'2P ;LN1_!&|/+TKG)K,B8@3G;6>1;/A'8Z). M/>>J:7O;NR\$J'I&5M?0:R_@M\|0%!K6&6BIB7TX7LOW07TG>G.J.^K, M*CH\2- +,W5\$E2%Z2X/B?'HU-.%X3@|_ \$6\OV/#&AF*&GWY\;!-X=3VWE6;@ ME905-DKB<(N %I')G=/T*).P\|E\|HA9A1N+=;!Q;.^YP(8"OE,DXUZTN'FUH-

!UAP08%JE4'25<95>|#4*K1KHD#LJCR:/M1ZO!*Q(V:)'QU#?I@AB-
!.DO!#K@*%8(AU.NHP:,OPE#G.NW%G12862:)O M17V^?3?F!I@R\$H59J\$,EYR=YA5>MD
MUD=VI18;:S7-[600*8O,F!YVIR;:H9(3WXA1|HMK&=-.P<9.+D-
\$25M5E0!M0^BI!|JKH|W+V;W M;K<=R?W@-5N5"7HI&9R-#M 4Q6:EB4S%+*T-
1Z35) 3TP_^X<_OA^P^NY|.* MTHLN>&@V:G">.F
T@=6"QZ9RM48/%S_|JB:Q++^7JP53F" Q8,9??:Z@Y=Z,
M5HC)=HDE*RWBM\$40^"BF%;>LGF^F+/KXP>?JZU!|"X".W(I8.VEF 2F(L
MO*.31H.^D8|HS4RB\$ _#">|W&QR70BGY3P3!2YQ^(&!Q07?AHE-R|)?!%Sj:
M+|!NN0<('HLRRE901D2UJ6Q1;:A,J><|JFG.!QQ=H*"MB2"L1=&+QHZ^B2:
M,DF3)0>%P:~/7;-).UQSC4UZTO3WYKS:).^4&E)3#KS+\$1PZ#25J#4&5FECF
MUN:~3*Y|D;?5V927TEZS9Y:<%5G'6L 9:44M80&*.<*)-Q5O40QIT;:6CB MQ"83'JO--
B8/1C,46/?Z*PT5V-+9</6ECJ<*/F"&,K=TRQBVGK@9*B0TM""
M<),8MNF0!P#K8P(#,K**/D&U:RKG\$ L+83A/WMI:L5G;RAR>*+I_C99SIW1+18?.|O
V:&SG^4*|B:M)J0E,P3?|M MF2I2|9?Y=(J+Y7HFU9MI-1;DC)CR_G|X)=/+>>|HLO?Z'9
M_ 'R^|H|E3|^QK&KYJ>M>N,3-BZO_|LX.C|WP!=O*X>^|TN_|LOWKO:~6IQ
M2PY|Z;763_V1M7W^E7S@BF|Z6|YWT1/1>G;X"R_|@/7LAZ|H1|T8B+:IM./MK_+
<"5_*^>_?0;?89O/(C0^D.)XC|L;YX?M,H96|N^/!-.>^G&XS9%Y|^?2,FY(3"GT^7|WF
M*_KIQFK^E/KRKS_=? 3LGSTK=-@=-*417"D,I(";\$7--&86'ZZT1?SP|O M_-,A:~P2Y>R
"XQY\$B:~#)3>8FJ>./ATX_X_BPK*NX!0N_0VTZI#|34#6=9# M(6=*34ZCC%~3|M"
|FS.10.|F@HZ'"|HN24^;1*S3E44:H7L.&BDEZ+O?)_M?<;+F6SOAK9W+!~2(C|
%'ZCXH1K_DQ7(BF6=O6:_.4\$A|D+|B9>8H^FZ! M2C
&NR%;+9^FBJF|:RO=HIK4UEE(G3Q@|Z:U_P|G4^+-6 D*PM7&9SW'9(A M?C|
(I+#T7*L|0BJ,PSPOBW^I9\$ M0E*LD1/FK\$(E1<('U9L.GOA%M75A@&4<
MEW7O8+/BOS\$KK^41&A.GD6_@UR_\$S\$F(PLM8HC|"CJ*R*Q2%|+(I&R|Z#*
(3L\$F,)HH;|J:U3)=;E:9D7?;Z^Y MJ20EAB%"J8F)8F-@%*9HM|U!"HOBK%!
<|JA+2=Z:3XZ6:J(RIO|BTT|WA|AS2=6N.C.,RI:~?*"|)X.G"#--5 ML82-
^>GBGNLJD*DE|ZN27'5I&5B,O+2>4BTI&69%8=A.*N^!,\$5?@?;5DSM
MJO^S|Z;=C>/(@NCGF5^!4WVK)VM&4FE?TO?>=Y2VLUI=3MOC);NSWWG"!R0A
MBY44J>9BI^K7OX@_0():O;JV;*,_=*4I+D_@|K4/>DFWYXY|O.7T|#:;W6:O
MT^Q7W08:GC050FAVJ@WTSK;A0-TZG?;8;:;<3K;J|V1M,=>"ZBDWJQV6WW/M'0
BN\$Z+T+~7;>#P;|SD-#A :<+7_;<1J/M8/7|@)#":S<' M@-2#+I@^;8 51U Y0:^S>D DC9:
T1D;:B|J|WVGCD0/\$O&Y/T&T|#_@% MU&-&_WAU7.1^JM=J@ZW\$ MOUVWA;C#
9\$:>%O'JZ;!A3T36L#0G?<;WH-MT:@*BJOU,==QHP)4!;./^F/@. M! "X(')X#[A8"X|
<>L.B|P^Z/9;C8|3ZFT)#J|MA|DUZD"20#{AK|D^T;Q MV>|ZG;\$|Z)=AX'K
'#L=46WT\$/E:6# &(J&*5?DM(!;8=QVQBK>ZO1Z
G(#X|0(2^XS4!1U!08M"EWQM46^T^QP%LS2H(6L!%X"! LEZ_*^H(
MJE|)5DF4Q:Y(Y)|38%|D7('2=_DI'_A/^R))TC2&;
<|_SPLH&LX_U6L*/L,AJ-.X\$CM.J*.:^_"*SXZ40R?J<*5 M'5"V9OH+8|"<|!;QL5&?
I3M3'E_":^E|_3;F\$ _J8\$|U: D|%-?L))KR4-_H M1&D:3>6S:(%5>>!?
AA|#,4|Q,|F,A_I+UQ.PG:IPQ14?9|&H7L=|MK/P^9N^ M2+|H%U1!|3&,0D\$
N;|J=|OQ|*=5L@%#_.Q?_|+HUG?^|U?|.L!U9L!VM@A9 M00'!4>#HKZ30UJ^N=:9ID
T;EG!(BB_6*@2|2+ M.W:C((H_J5_ |M9O_|KB>=.%'CF;4W!TSP|'9_AX|/1N>
|9_>'S#WPY#7 M Y;3_=WSD|'9:/^4#0_WV/X_=|V//QMG^T>??
DR.CT='1V^=EAMCNW|@X/T M'R_3**RPO=INC37!8!O<'SZM-TMDGZ-XRC1
S!7>XVL_D;X!GR%_F.^22P%4 M|>9@S!VP94"K=:05/>ARU,\$;O5Z_#W9JG?_\$E)|0=
!TYPKA>KWQV*EV^@UX MIC5P0\$T%XWH,DEV;
<9:Z&/\$S0H|6D_X'_92E'WF61CORY8UZO5;_66L|+CK!9XGXF(@9QW@|?!#>#2^/
M|9NO_1W_!|YQ_UW>HFN,O+=2!Z>:O6_=G47M4NI/KZZYJ'FK5F^_Y/#=JU MQJT?^|?
TWAQ/TKW)NQ9>:K7_)J\$PO^_2/|?Q4OK-AR2UQZ@!)Q^/5QF#<:?:=;L/Q^IOBY|P
MS'AP(F91G(*1B*W&T_ZR8?|)<(%>HP"AP=|E (^;|T|ZBE#WKM|L|M|!RP
MT|L6K!H|*2|=#^*6H;:|EM%4-W@NSP|!|>!.|H^/3L|8!G)Z?GP|(R= M'3\$P(<|3F"-
%CLZ88W.!^~7=O29G?UMGQG616Y9#?A.?&H-5>=4Z:\$<_M42Z|4IUZ'=HF??
MH(U;+G-&XU!;X_%V|AT M06=7O|\$4U8|C=HUT>_P<6=3;/F88OS|,O)?
XLL?;A2G<)7)OA8U>/S*NZ| M*L)58N@Q&ZYCC*7CB6K+
|72P6@H|M(EZ==#NML:|WJ#9=IW';G@WBV-,U*,C M_ ;|N.N>E|:
|+5BY)UR9B((9'#=*KVU5I:~?N-)KU7K->;32Z9**VJMOM M=:JH1K/3|(X|,%1|FZ*=
I<^PY5D2|\$\$BR)NTVX>:|/>C_.WRG|L|>;|1R?6
MD+.&W)8;Q%/ZL,0|>QD>'@Z(I/-6G//+-\$_*VLNS1D9DYG.E+K

M5OPOC;99DUZU8OK?!"#EPV/%@CJ3R|9\$KN@H\$TO>[U.N|MLM2|JM3|FES|Q'J0KKY=-
A7IS|F-' M;?'="UHP4_9<,MAN?ZMZ.L^:3J*!6_1_5B>|Y(OSX^:+5;L;'C;JH|AP'\$ \$P
M|E3|8|RJK/?;#='L|)WF>.,Q_MN6? ^\,'O^R=?0!_3E>'CX+<>V|G|>9Q))'W.┘A6EW?
!W938"XO&+!;7-#8U3!E/6#(3+M;:! M>

(E%O(I-'2M22XT.MG31|T7-ZJB@;6U|CNH,K' 5Y5--O-7IOW1+W??5XW
MSPB+!\$)OK1ZV"J2|H=3!|J974=4VBV(6|I,1LS^RV\$|H_G_IWHJ+EFp,GZ;;X MDH?
^G_3W+UO)=Y|V.-XPOWYFSK*#,'=G|J |.K5CH,5HL =JGVOV|R(^%Y M3;?>
|H4VXY@XXS|&JG^\$;.:R62_%G9!AT*^";MVK- IWB'┘┘<8SJW43FML M?
SH+HCEPGO)IL,,HMI*|O#L!_82NF|L(L>UV"?0\$%6OA|7K6\$?9=P;.:M=S
MO:9P&MU^M|X90AQZ'K:(5O|Y|\$/1>%9\$W(W"D&?P(M;E"7B892X#;RSU>TY
M@W;=K?(!EO3711LG;:K53J|2?1=<; MRY&
|6^9;YL!YL=O2FIX@0+"QU+9U)|CO# 'KC01W|=F)%? O|[%3=|5:?'#='|L MM|I-
/MCL"!;:7*?1:-9Q;N3 ;8,IQ>N| MVA^T>+77YZ(UYBW@,9L5+<<1MM'ZES_;C;R-
%8+>3;K4VVRW|ZV|C6K \$S,9 M #>?"C'<1K|GB&YU MT*Q|(&&3=#Z04&UU6AYS=:
BT|_T<6XV&HZ.)| |HX@BVJ30&Y4>[UFM0_+ MV*9\$JLW|JK>Y5):3/'GEKW|!:
|^WD|!4!&*&IZSR_BH8> DRU#@9!|ZP).? M9TKP)A&NF%J@LH%\$+#PVR^(DP|2@-
&)P|!F2&|T|SB|HAF\$.┘=|/VYWFJU- M"EI5,-6H=1|0,@5//2 UJ-6J-?O|K%&K7_K8S=\$/?
L;\$/78B-DLF<.&^L05 MJ;|<\$@6^|H(VVIF?|I2T*+@[82X.8|E*G|CX?|J?3YK(+
<>G|8(ID^,N3\$G M#426-7YX3E_E6NBSOXSI?_76-IW#*!-MRY7_ ^U!EDA-3%C_<"4Z&8:
MPH?@_M2J%2WC.)810\$|20*!9+HM;L;57W<.:;=S6JSTP(#>S_85_MMKU/E;K;┘O*>
MX_4>'=%69L2|T71(4#|0">_6F2 &^/-XSN2LC0K|/SB\$!@.-F5WAS+\$GJH+>
M1K|PCCGJ=M!6JSD8M|V64^UW6IC@X_2Q+WR|6N_67<_S6J)9?|174^D/4GUX
M2L(:'OO^:HG'\$L|S\$4^GP|T!|NOH;LM'/C0J'+A=*INKSON#W#P<=&C@FE?
MZ2:HL"PG?;#F|JB,CSLJ2XG'┘U^"R*!^Q4!;) -&?9-%>D|JR.X5A"-M>&X|
M_+67)7|M.X07KP,E@0"G/X3IQW:MTVK|O+,>NK?-"GC*YLV;!.8H|#!16C!G MSMR)
<+|SG;.-? DSHSK63OAGUR((JM_#Z!H6+G@"+;|@AR3#.-/F"?&?BB+
M9T^R0+!VO;A;QP:'\$3MEC2Y|T?2>JU^N|T S;|5%LUJV^N+*J|#JW0==^!V M6D|:
|J;R57Y!X#B=X3\$J0+\$B."P+>?Z321/\$&+=^#)7XL\$C5W-C%ZW|┘U2 M=^#M !TPG|
┘#N-)YDY8,HFPWXSN2I=.;+JX|FN>+L)>ECMX1?0Q4./?6C*
M/3I@TL/OSA|H:L|/="L|A*M0|Z\$)P\$RW.I_Q)&6#.O/X/"DR17W0">;@K>J M?=YQ@;.),3!
T:JVZZU.#^OW&|WQ9KB@ZOXM.Y:B\$S'EZ8,|EL|?=NYX7: MR^KI;UN
(&,%GCKUTO2X,+DOXRA\$|W4P9^)*Q',V0B|:=ZE\$:X^GG'V6VGQ)
MOA3O,-5|TWER(BXS.?N5G5;/V =T!_9V6+/5K.7N%9|E┘NLWZIGI+&D>%)Z4DQK9@
MIA415D18\$;\$%1W8_ \$4\$.|P"V)AAW71_1F,WL\$=-\$;WFX|BJ#!517_I;0;:
M5V*MOP+GFP)4YA4T2.|UH,4C&"_991Q=IQ|I,'C:93;:YT:&T\$+|H0//!UYN*W
M^[7>0Z:7M!|PO02^U7_!|),QW.X^QTP-@N|JF)",H7T"?/T:O7&H|+D&┘^>
M.K(F2Z@!>ACOB|H3QR+R5LNM|HOC>K4Y'KB>Z#8;:;&A-D#D|_P%;+V,5C6W
M\$'03L3!7W?2T*0|'Q&"!O^D%3Z!2O?T:MI3^S%O3P|Z??3PM_C(T;JC<=" #J-
9K4IQBYFM(^KCM>M5ULMP>LN|W;;G0W%IFA?G|+\$#T62 ME,?1COT?PH-
=!;F35I+;|B*-R;MJ-#_R8@M6)3EO6^*MAME&'L;|?= M;|)U|Y2,N-
MH>%ZK#;QTX#2K|5ZC_4RUU:IZP%_=>GL@1'U#V;QZ5W)3:D^O
MC"&OK(9XKP|1=QZI&-|0\$<"60'?2<4P-P6WP?3 Y-0T8EDBHPFP2AZ_
@P_8<19O3E(>>CSV\$C;+ MHRO?6U?8T?K UV2ZOIJ0VE8@RMI!H>^3;:Z=
Z(2"%74"ZO^,4G?FATV'GMM+9;8|UF%UM; M_8(+W:IZJJ<2R0;:-
C/Y|*7!\$XCAG'FX"LJ0S(HQ7SS/-3M;|H9X<|1%%H MN^
!2_3<;M/(%5)%JPT6F|>L.EQTNJ(^=AKNHU-%1NXX'N+.HGA8G_ G@%^N
MTA/2.'NHFO"R<-WZZWW/MG!F"5%;B|@^GW|PZV5M"9*2@944KEXD;+Y2'4
MOD|6U|G'5 ;OF&IH9C;Q;('RZA A#F;:;(%>^5&6!'--IZN^6KM_S<-# MB+71:S; W-J-
7K?JM.OCJNB.NUZWT>5.SWLLL>Y%;H9| ^NR'I^DT MW4=
L;@64>TCU'NGS<=QU+M0X4X;J)\$71\$HLD)"KK15&Y0(@FZ/_2);T;
M47XG"/1@GOB)&FZ&<>4K_1('=5O4?D682 T LS#A)RHCR+|NTG:N\$2SV|(|3
M,YTS!DW|EE!O@2E;YNL2*:'-MOU6J.^5VT /UI#U=N)UQ;!'Y1FEDQ\$\$&C|
MCGU848I=2J4" T?2+K0G<8;|FID6DY|1:7JX MY_2=#44@\$'.>R-
|E%=DMP=LSH'E^>0E< |G*E-JMR\$9A-PBCJ-QCC &BD BC M#-4QJH_PLE6;Z@?
T^\$19RKB'M0U2?(\$01=8\$ \$BNAUG@H?=6+4>2B<|G4<*F^ MP.6|JVL?D,V!
<;V_ ^PLONRR54A648-#)00:C!)25#R |P0Q7/?CPTN)VKN\$)
M%F" I6Q+!QGB^\$|KfJ|@<%L'= *IE) X!C"#:DT^+X%K K,A"E')3F /I-|9

M#9&G6HK>&RQQ\$:=S8KY?*;B\X2R;*+1H;;7-2K7<=K5=OC\;C;1Z(JJ.!\1
M+PWA#;I+;G?;?;LJM>[??ZH-2/!WJ8.P"V^JU>H-!KRM\$H/;?8)N?Y
MB'CZ\$M"7H[M_.+!=.IG\$&&N/P7V\U\U5Q&8RE\!8QH2U7T63IPA?:?
8JK%E0=FX;HK851-+L=T6'
M=005UGC0!!M10#7>:_JMAM.JIOCGNCT%HFEDY38;-(1QM37H-ZIM#I80IP-;
MU<;8Z8_[+6]<;Z\J8(VFTPC,V,C\?DJ\ZRA+R4\.*R\IC>1L)N&;#C_?0CJ-M;K/2!
<*I=W0;33BK&7A4@**V7&R/'<M:KO?[\?9[\@JYX\/(M/5#RX7W:7ZBU8PS>/6G.CQ)R9
PL^0?4M_[\8M^2.&:VP5.S_&0(OJ+S(KCJY0(XM^S M?(44(HRPF?
L^&89B\GO2;"\$4,_TB M\&F-!9B>!--
3/2%H*+H&R=25OW\;\$)2_8J"TV&@TRNMB512B%#=?M!00U\;P MA2!\^PE#Y+!M.40
\$U\N1;5<)01K010440\D7\IQL=K:&0?B1\7SE<<,BWRR
M.;CC^!62*5152^0=XL;PLMT5Y97P,#/(C#Z\Y/%'5/N;^MRID_N&1CQTO;65ZU45:4-
RK_102=1^G9\46KYZ&EY\!V&X3*!.#W_9,O^Z?L
M^&"7#0_W7GGKS@U"Y03\T^EH;S0\&>V?6JCD^')X>#X\ \$T(U*(S=G3(/A^=M?&&-
>05W"R,-(P)_.O;/ONV/SQA^X=[H#SN\>_N?_FT?);#3(VT\+K4:S MS'DUP\$@M)5&QK;
;%2QH*!\>W_1W44);5X&^!\4Z\!=K7;P_S<K,SA%\&??+!8-;HX\O2"YP36P3\+=5CA
M8X7/PR'6JEN\YM4)F4\6R+O9(>-<9&\$L0"!<">\B2?EX?.%&4TK8?
TF)'^.1&KGE'SEY1%N^9" MK/RQ\N>YY8\5,R\I9H6RKQ5*=.1F,71#-+L5+
(2J'GED)6V+RDL&E; M8?-6A4W\ K8J+A(^%NG\PO,3-XB2+'Y9B^<+G1*2V)
IQ9*LX+&"YVV;/UN% MI0LE-EM08_.VBFVVF_+?4L>KFPF6\K;-
ZE'*=Q=LC;X7EE.Z1S;.5F^1?C M*+XH^K\GE&\6A1?
BW\I+6B2RDS_V4CU9;DXO^T:S_7\G?CJOP!T!-4VE1M*R MI2K\@I\JL+-
JZ+\$1#H:.*V7\$6NQ.>R,I^!\EF<;Z6F8%F5YYW)M,T;.ZWM-7:L MV+NGV.M:L?
=6Q5X79%TBXBOAO:1T^W\U"+^/RMUK-1YA-3I6)OJM0F7GA4N
M;U6X\!Z*6=)Q7;R) %)<:\$.EZ,7\;F6AK4O9>OD0REH3'X\W,^1G M4DSUK91ZJU*J?
S'6MLM%/I8ON4BRV2R@?-/X):5485B=YHLC:75J+'#.JGC*
MK5BR8ND18JEGS:HW(Z\&5EZ\57DUN' G/+P4R84?HAG%+V.A9-;UGTXNN.N^
M.;.%N3CF2_?GKE A@MD0\<%?I%B^@B+00TGO)@>*.2=32VWDFTSDJUO#:Y7
M)\!L7_#M2C\^@;N+HR"15;3>2U.N\?#!\8&3=3!#(H%C;:\\$#^\$FU%N
M^=AW18RM*>)9\+)FD%L;A>WKQ;&CL5P>A9IV<8GP'<%^BP#.F/D@K-IRS@33
M1GE>[T\$S^FS0:3MEEYU*_G9E5\06&XTG8DP>?'@4R&F=HT568ED)=)S2R0K
M>%Y4\BY26\7\#00\#R\B^@Z\%-DXL\NP"1)N1\>."(4+H\V0K78FLCO3;L M';\$KE\
<^X?)\2@^7OY,95;2J4#TGUC;XLZ+,BC)K7%D9AS+.SFAZNS*NE0NT M&(4\9A2
)\$GD7*[2%\T/T)+LQ-S;271=19S,+YD*D1%%5))9R(;P6?!\B MM+Y""\ZL9?;.D)8=I01VI5;
I8A;\H>O/>(!EO*HL\I(L1'!*!6#1%ZWL/=9K M,TMV/PNAVE'0^FS-E!5)
I\':CO,5KVP;%K(T\TMZ^32\KY9=V"R\MRSAMPT: MVRY;-);>^S1K\RH-13T%LR:SH7X,?
\$=/TU6M=J\2-S)R^8\R+4M=!_N^VQ M4WG8Y^QR>G9_LGUJ2MR3_)*)_L=49_)
<[\@;!\;@\JT+<'M6@E=!\5'(W=I00OMK
P\!8WL%W/OV)NP),\$6=^E@&7'(9H/?!"6"O>H);Z M)QE^/SY66SOC0/RHRBI-E%7
=K)IN./YR2S@X_XZQ*/K'6_2^+;E'X@+_R1 M):D_GNMETJ-5\$7H\LRBA>7,?
9:K7E=AQHA\(\$\RG6B5,-IU:P MAX=PVDV?
8K/\$D^%TU/_C84YR'4QMOPH1@:@F*8_3CSQ+HYWR#P\H>5F>/2EC M? R_250*2CM!
BZ7CW>PIWH?P"F_%5M)><6A/SW"8\W7 M3V&4BHLH1!\UFL?>11!%WS\$-
I1B.L@!\>W7W)@2_EN?M1('W-+#+;9Z?C8X. MAR??V.'1V3\;/3K+))7/3@Z^AT6N\5K9:=G
MP\I+_N'9Z?KY*I^6O7,JW6SS/L:'+PW=%*V\JU6A7%8RA23ACWV>\37R\?KK\I V
M2T4E=*FW_97O'W_AYQ"87RFO?8SYLWZ(S4V@D.+IH*Y/!%)!3^0"&/O<#UD
MC@"6!_Y8Q->"<##MV9P'WOR\$6P@C.!TX/POYRS)W FN1BU@RN<5#4MUZ=H/
M@L5K;I0%WN+%9++JZO6JB^('M\H;O(I3!C%O+A7+W\DNFSINB,"7UPM70:-
M*5SZ)"A%TQ6O\A\$QBP5&8NHL6SB Z+SF*\$C):FQLT6@JS\$;)RA!9Q,>8WRL?TE?
AG/*8FJM' U?P)_HJ2X\$4/GN\V%T M';(L5*G\A&?YPA=/VVC76V/>@FLHB!"9
&T.PS"#)9P(H,04YXX47L\=(," M7.D^C:P,\$ CL, @\42%JQ(F0
AE%"MIU5K(1\$M*P(+7:D=DS:W0\RRBE\CI:ZC/+;'5@J^ICVT-
MGVW5VNW>H#%HM#N->K*C36LJ'Q5#C? ML3AO<=I
>4!\&+W/3Q\$3SA=ME954:Z7N9!V001#-\$Q0J^+H,IHG@.I,;O\2Z MJQG<>L757!
0M(1'R0YJ(;!1D8%@5U)Q.A4QD1S<#@*=)2\!(04DF\$>X ?MJ1
M;P\$%QHT2E6^BZ<\255+WZ>W8DG-DMI+D1HBKO\!7BJU!VC"5X/-M#!70A=U@*
24.Q^I!\5"@T9WF,5@B\SOB,'4;BGUT4&N4IA="I-1\$F8QNOKF M)QR@5&WSW\$
")L9;A74&JUV9\X9;&8N_..?!F& YX-"PRXHY*,R\$/@@JU" M\4QXG(QBU\H%B\#?

PR*!_9A6ACZFT\|&\$0-0,\7)8F83J)\$K!>=JZ1XFD-2EW(-R\K#9A78E2=0P%"A_C7C0C
M/5\$!5S0\$0\$(((-23\$X%5# WNDMI(\$Q\$DDRSUHF\7:YT70:1PX,**;24K(8_M"=A)-
4=5*E_2)V)\NOA#0#U.)M9Z61H45I*10\KF*0S\13D%)D(JTV4N#X
MOXN4Q7\|R'=\D!\|@C&L=\|G?=>+!#!U.CMP(\.Q;*N%"DF*2HE^AI(\ID%S^."
M4#C1PQ1A0B==_GI+%\I8L7HHL5*16\|VUB-3I<.;AF9A0'W0Q\$!\$.0EG0IN*09
M/F"YM&2\$1/(\O=@2@"6_E\2QI!\: 4\$!12DHR:WPKD'O_K\$UA?<>^3W^0N_M#
H:2"_PQW_\$Y5/P)HPEKQ>E+SX#TS4X6G>8UD22Y':Y#J'.U+M.T<[V0.!OR0"
I'ZN;1D2/Z\$K\|2T^4X>98OD%LF?%,D)9TMHKM+=_E%D(AK MC.2LSABKK4'.AR6\|J:
(8)NR7H=2_.G0\Q2%%\!T/,8_#W_%#A&H^)*%AT*;K0#T6.8)-ET5FB\ MI2Q#RD4-
:/&2>:%'\|@/\24?-XEK6(-CJ1\$0)LC""+[MN%M?8MRBC+K+<%JX<@FWY3\6&.
(Z/9@U_+O!\(X(YXS;@\C%/3O_M)2)@PR!_X"9@"Z_DN(I\%!!2H08\KMA(8
UKL0IF<#C'!+<\$8(#9,JA?200?\$1,>C_F*"MU@?_ ^&=\HL8NDU_M\(\$3P""&K0VE5>L0,
IC^<*>Z\;PEQE+N=BQ50KW>1.;!UC_G6LQ2A*2RE0BS_M03X%ODM+#_BU?(EV\<\$Y
+PC.F*JXDWY=TS;*_\O_VO",#F66P54WF,N77/F)_MO'<|T/&BO@(_RS/#93.-
(7EBFCLGZ+/YS&EFGLY0*Y;\$.B+?A*,L_)Y3WDD"*.9B?85,G2<="12C!-(#_M'_TP?:
L2(U%BKFGN,@/%%,HI,<=.3\WYSKM_K57BBT!!I,KI)1S_H^)#R0-_M(%6?E_M&>MP
5.6F)).F_,3?9YK&65L;A?6->&P*-REGW>,3P'_5R"5B0_B_M4FE;^
\$L!5B)13Q(HC(JH3+L;5Z+&?MH"L8,&49%(/.8A1_MF-+-5_""58K\#5T,I/>(*4G\$A?
DD#R!1S(P57E1F%+JJXQJ4)C4=1#_6K>"_M5=Y?L;H?)
|1US+.;>0OKF%NVC MG6,3^&X=#/*4Y40?'L,4.'\$18=[FQ-4;WJ_MNX72YXOB\|@QE"7#N)
(E9@BLOJ3U0E^36G(+,6W>L>Q;L*36\$;P9_C_M3&JVCU0:*KJ<6)8A@D\$L%.:!
(E2*2UJM\|SD\$073\|C#6+/.E/?ES/U&JT-5V"2_M-
SJ\$4BX3D%1IH=1,47_|\#M86AL=004865Z3VZ<_SV""NS.;42FPLBR,>+2Z_M0Y(1+#-
#91G=%>7:*JBA-&A>*B/<\$L'|(X(Q>F7-L@Z5E.3XT6S"XRG\G,E4
M.^T6>/9HKD7+=X:6TF\|@:/R5>XP'8KF\|/T\GG!4_E5YES&T35#)Q9+0'L
M\|OC4H%#%,S_W=URRF,R)<>S5%HLF\7X_*3XG..R=!.GTB^X&J>E%H'..ZHV
MJ.@0&:_B?J!U"N4W*YRQ5_2H.IF8)6R\|)S^+DZB81+_M'
5%!9T_G46)\%1Q7(BN97H%>IT)#/0=2;X4.2H5U:%K5K*_1*(RF190725_M)FO4-
Y6#4PIVTG&I0DSPN&8LW\J#\@L7^BLGE^6WZE"TL>SD2=F)/Y8UNS+.
MGN>24YT\$:71^@'A-(:_YN5TJ\Y;VGI3V%CNK+._BGV#/1\ST975?M^TAB5J_R?
13=AY29)WF@29Y@=|Y_M\;26=P?'^\$4>(?->G%VRH5%M""1@-
L+^O#?:5\PG0.2(UMB\$1\9702K\|O0"-4QE+#EH6Z\$Y7RJ(\ISO_MR9V_UZ7\|+;9;3^V*S:
@T2LUWF(V6S9BL5*5\$!-;"B1I'9G: 4F<8P*T?'R)=3Q<^7_M4F\A#!:-I&
(85")S08RV49+Q7^=6:1&E1H8O\X4#\|D^!5"YQ2%R*:U)\GZA1_M^), \$YWF0KISO(<^)T-
GLOF8EJ\B>F*@_.L^'+C:V?GV^PLESA=58JHDX*_M-Z>9TX104,F*'_38/A=^_Q.
(AFF43WY9>+49+=_NS^7DCJ+8!\$FOR\$TL4AEE_MSE2%(2-
03JA9IH>ZP9D(*H/7'4/Q%;+10&6%;Y723'7H8FD%9D_-ZY>U!+Q\|_M?MD\%%>:!(9>
Y&4J+;:0_&^!9#+88^+8;FP;&1\AMRHA(3Z6\|6BU>7):
M&M.)2\$W3!Z0'2N7X@1"B0)K.\$2GJ>JFO(4H6\|) \$1HX?&!Z8J\V?&@I8^%1_MYE0Q"9'-
LAAS\RT\6\IXCISUN\32-!IO_BL_!(-BZH"9TJPW6\|R+X//4;"R0_M37CRQFASB?
_4)4&J8Y)4?+,W\$V!\=8R4M402.*&8DRS;JD"WXGACF(-LOR3
M"C_(\|09JEYA\$@5<4D)23X&Z*4(2JX(&5XB76&TV,A5\|JV4\|C.<=\$!C_MHY.TI%F\|1'-
UB\O#(-JW*TPLV"<##G0AS2*"98:MZ78*|\SD=37S6\|+4:MEF-FL+|E1MDG60^?
E\|YBG:9I3!DX.26R7LN\TG@6\$^!8,"S_9?15W?7TT;W1\F0+_MN>XR-E(?AW2RKJM:>4
+P"2)_BJB\XQ_@=EA7GU*9^R\|0:TK>|!"\|@D3SR,WD_MW=KC-
*9VP1H'TWMLY\|WX8G>Z/#W\|CNT9?CX>\$W-CS<_M8\5:_M+%X!5%Z\|-S@R\|>?
9FH)R\|DV069#;SK9I8,%Z:"/">1')R_|\#O9:/_E2Q3_MSE@H>"
|64_J>CPVY\$W.H0A\$|3;+2Y&D^>00LO+@9"KL_|\%?DJ\$KLQ75006
M<5AC.\7>V>*O_:CNJ_74R9A!6:(>>\$2RQ(CE2/O@)@*=_Q*BSY8FB!@9(N;+
MUA5UA\|ZJRW?YT=G\$33&>:/A;E%ZE)'DQ0\|LZN9&!)\$^8>6OY.O:K\|T#>49_M-
NZ_95\$(C@_NFB\AVYNWT(FYX_-F.2@>9B0*5;ZVW.!OGRP#4^D7^|_MOS3
<7CP^_|\DET+WV%Y82LS8)GA6V\|D='HVW!M:Z#T&>FQT.#H;'5D@/|\@2(_M!W\|X79S\L;!
|\$\|/"^?1H>?!U9X#T\$>(<|\C';C>9+RP+_P(0!\$Y>;KZ.OH\|3H_MP\$+_P_BNR,_6_=WYD
RIC1C+V?GGT=6ICQ@1<01-22_#\$>'9_N'5K=^H*77;.X_:4MQAPR_'W\|L&3S\|#
(9N%'L:0P\$8^O7HO@0=|\V\|_-K;MXK4_M\|W\|73XZ>35F%1LFZ!'3J;S+_LGHS+_O(_0*?
WH4H1@E"K=09P.Z,OY*Z_M:O7RHT.P_|\9_-3_=|C@|\M03Q"N9\|#U*5)RX:_5!/1O\|
<|\KT:YK"-M(VY<+(X5(H\|/3\BPV*,96^FV%O0^/3\|P3LV_&_MG\|H9=/_C8'AZ?GJV?
V@34!X%Q+.3T>&_+@?%G,|OQZ=&)-G0KQ_MLC<|(\|1Z-!X8>309_SK:M=!

I<%;/_>/#T8VX/(J^3OT21,HI#1I#2F M_(1NJ93PBL2FG?8Y)>2M;B5?080(OYSP3^45-
C!P>X.V-A?|P|W#X9|VP: MK<5GZ6|_3<^!"&U_VGTV<+RX<(X G#7T^QA|@._+7U
M=;!46 07A^BLI^>?CEY3@&WKH'=^9K-D'ZSP_P.CG:'>Q;|A-"|_PK'UH
M|*CT85'53U#P?/M|=+AGBPT>#N.#;"YT&MUO<92!;?7U9/CM8'AB@?I@H-ZP
MI/X+DL:.*QHB*WZ|L."M@DHGR-0SU-VP!T|A?@M() #H-+-'2BNY\$BLW'4=\$2/W!9+
LJ0%= P@!>BH,0 WY= MT2^50WD1H44: +3;0L7.F;NWXLUUSICK&
=HY4^NA-7.F=KTOIOE?6OL9;Z' MAQ>G%_ZVMMT|'H>Q5@RCZCO<4
MTT5J;\$CS(?)H\$3B+PO-O=\$UY)AD;Q|4\$=;L.!>L-I_H:|FW| (4 RREE3.
M%S7IFA|A(C6V*2*IFMDC:| #EFP4=3>W5F+SQZ(WJMO12W=3#1P)_ZJ>DV5?4
MV|5)R5?>>1X-#2D*\$G&-:N)J4V)|AGPT1: M=%Z2SQU=H?DGKBW#*&!2&HKA
MXX2WRR|R 'V6YS*XR0HF2DJ\$ ^"Z)1ER)(H!|H71%6F+;"K 3\$+6G-.'+|J M
@(-119'B:P)KK%_ "#;A<#|GB*G MOP(S('2< WIR*FX3;Y;(NQ&M1 X|1 MRFC|7.!&DRB
Y@("I8|H@1ZN:A)|<:X|P@ M|4D|AQ7/497!|UA'+R|HA4*_ 'Q+V
+V8D7_2|E6.%DY:CE%60|V*^8BA-(>3D+"Y"63GC&^ZC,5DH
M(4'2RH&3P%WTKY72/.X8R"S,A&0%F=(FY)!R.4 <5N*G ;SB<1,HGDF1/>:I MT-
/=C@WF=T).H&WRHQGS;\$I*B@|6*(WYK\$W>&CFE#PU|8:|I5-CI&M\$G5
M<2J.GXAEI*IM\$WB8Y0/K3!\$XKRO?\$WI(W|R\$;&XY'\$ ^!M&4_SGOR.?GY0H!
M+OXW93<|&50*XT4)G=Jv8N.F|; MJP&?1YFZ17Zi4: 7ZC_K^P\$#
CY+Q,=\$S#C**@T4N'+YWI"S|W?:05JKU?C9=,*J?4HO|*|KGG0 (UNK=?K/,NG'K*Z
M9JT_N'5U_EK&B^".W=08Y!K)1(:0Y2E1OTOK\$#G0965/.M^N!AF@|M+,16X M:XWG?
\$.4MSKVL9|V'NH,3ST+#@L."PX+#@N.S8#C!ME%NM\$6B*X|_JL3!&8I MHPFZ3Q
_WF!\$?TG_OJL*C6KSTV#N6DBROXSI?_76R|#T|5'!+:QD4PJ COX M0_++&X*:Q:)7
X|WQ=//1!S|:13/|RV: WM\$, \$6?=-+//1AJK2|G"HMF.X" M)D.-
L@ "S=&A|7#;L|6|K^PS9%T<7>/7_NNGYD^/@_>*X,+SP-^?7K(D=O_K
M)_A'K|=I=YNMUD6C|L?L|B?&@W3E|06->GOV8T=|L|5JS,A;06%T?# 'PO!)R M?
3\$M|S%QPSN:D'|JRU|JA 4I5=^X,'Y,A/S>8>_7#CT;+@W7)EC9N%X
MYV>VT|L1!B4UY0+8" ^%N,
MMJJ=H7D&^6%YGX70FV!#SRH#X+^8%&>KT%|C%7K75J&_K2ITF|_Z3O-9;1!R
MZW0!"P|+ #PL/"P|+CV<16C8SPF9&V(R;+0.3Q2LK%"R=/6\$B3@|@U7EG(9>5 MR3?-
-3.)&I^6NA^H2R75T|A&VX.
M8N'Q:N"Q%1+FQ1).ML#C06554EN,JK:RU6*7Q:YM@IF%Q_NDMBT5I6|+R!8>
M%AX6'A8>%AY/|@_?#&HMZP!OM2Y::QS@K14.|%:K9SC_W7K 'H)/KTI9%+ M#?:?CA?
|:'%0@/5H;@|D|O:|X; 4+M>4DD2TGN=/A|FPYR=LJ)|'C"NX|KL % MOL|D.: =I!,?S |O:V?
*.Z ME@^|J,@I"#@CI30&P6%.G!Y2#XCD 8,1GBG,_BO|_K=5&7V!(1" _QZ=\$68>
M\$V;J01#LG##S"+#&G!-Q9F#F^|A|:FM<|C|_3*.@\$|4%:;+),-ET,|C=I+*6|
C"P|+ #PL/"P|+ #PN|_6\$/*_GP|QG M&.BPX;.%A7MU|K5|JPH+/RS6>S(Z/=X_V1L>L-
VCP|.SX;MLB;_%W.#M#J!9 MW1WCR3|W=@:EK.^ |891SY+H"V#:WWF8)")\,Y1S/.'Q%)
|Z%23"AN%;HW2 MY|1.6>D.^!F\$14B>6QY4&>"PW09FI#%=OV 7Y908 _J7?:-9W|!M+
M-J!OC9U?7A*BEI(LG+:600|1Q8\$'/ZST4|H|@2|2|M<;+6!/OT&88'7|= VW(M3L|/S_8/#X?
L5_/_>.#T='A&RYQV6)NL,4TOQD\$>W+;X.;T7#*1A63?_+Q M&"N=KL1*@^'5R|5M|;
'(O)" +|5(?S^D?U.H_-J% A(7&4QOF" ^_J8>UKC7U(
MHTN13D3,KOUTLMJPU:90A:VT4LDBAE?X,0/1X0<^3V'G9;066K+;AF 6&L|K ME;
|Z|WWU&|!^@:WT"YR=C |_A5Z|LY/|KZ|=IXHI6K? VV:ZSS#/V4KIMX0P
M*Z)5KQHX%E6L0F?UH=>O#_UM^/G;_@DJ1)^ ^#0V/#T96'|(R^I#%F&L/F11
M93M0Y7WH0V;GR(UOKM24J5-K80.|>Y6M0T@V.(N:-CF##NAY:6+RTT\$M@6*
MMNV9^KAM>_.*F.;I&Q7C;9MDK)E6N6|PCL;),7BX\$OCH&V28M'OY='/-DEY
M>WALX6'A8>%AX6'A8>%Q3Y%NP_7/%*|_>OYE_V1T|LV&Y|@13|Y".U+%J3^
M#/W@;B#B*/&3-P,GBS5/AC6?_C2AN@MIFRH,|(H|S)QG#UA2|MM-YHF#N
M72,9^70J;QJ7=CV/%3Q%T;7Y1EQQ4@Z3R2P!|@O MC=A\$!#,&|!6+), \$J09:%4Y&R4
@OP;XX,Q&A&S*UB'+\$*,%F?E5AA?&@U< M::UWY\$94X4G|T,-V5\$JHR!?
S2:Y|P3"&@@%'%;.O\$3-@S#C ?L1,RB M.&7C*"Z-021F
_R9P>\$A,N%|CHX1T5)UG/C\$XNQ#C8>U^ ^>=>W J09S-*GARU
MAB>CT|AWI!P*_|C=#@Z&QUMA/L|S2R?;-SV'S@L3_S9S'_T*.Q;X^N\$' MOS-?
Z9/|XI\$U>=58!((G A YC?DT2|P,>9(?_@\$H*U-?,D#HD!J#|1F. 05N
M1/0@&\$XS)IS&/U*PT|,I+ +Y9(G;U8H#RU(?F6^R1 4?OA=G/PH)H'.C:=P
MR40G<7.YPR+@IWH%3N3-*Z4;_ ^|";_ZT-4G>0H4!' ^.9^*ZE1X6.WMLDDWG
3+A5&)R<.|\$7P^=" _>2?4EJ8=RXL|XK|_8'/ M1ZJ'S7I1@FE\$)#+=)
(HT0\$|J4|AZ":P8K@!94HT0TZ1L _M=H--+RNLVWV" M?PGO^WW|YR_8K"WQ?P

9BN_EQ|@'='00=SEEZ'%|YU8">W_FE M/%\G(Q|&4UM/4PC|0QY&N_\$|;Y;GK:+ M/^;#?5
IL%?-8G|J5QS^C0 (DJ6U M&1RMBB@O*K@JOT>ECP@1Z2F|A(=:=:0UHE5X7Q3S178
5.++9 YX5K,^/_13 M/X=0_JUKY!A98MRXGD<2!+TL #V
T>1E/T|2XE6THBF?,P=HR0.4|1%:\.9(M|C+A4|!XX7^;^?8VSGV;T>0CD*V)UPQ=4"|-.O-
=D7JK=)898=1C36:E4: 7FF 3B21
M".21(:U6V1SL&CCM90SR1WB28|_D^R9P';B=/TVT"0AJ)0=3";9|HZD)7Q\$ _M9L#Q4,;
4EOU|;\$)M"|H(1)3U'^EN3F_V-UQG5EE-)L2D3L1UG"G)@#4FE/ M\$PCW^+LTCB3_O
(=8CZ=P>|_1)B'I>|<.;2%\$'\$| 3J|?!71;|CDH<^6D% @_M&X(VJ9H11GZ>2K2^+B\$
T8E"52.6,P\$ _7L:2?TMD09**"|YPI<|,4/?&WRI MPIP@0_)B8AH5"TDBU\$!(;?-B?
LT#L&*VY8=(1-1K?|PP31!;:91:_R,6E=N
MM|ZBF5)K'T)ECO#VK|SS37@H'4/2)>%Q^%Q%F3_I?(8!*+@_16?)W)T,;H,73'W|)=)TT8:
M6|N>|%L?67:55|#2X<#&?-PC1Y?0-HC-&?X;(Y,1|^4NUFZ|&H'FP?!?I_Z
M/Y" _S."E8/|2.Q?>PM\$|L^R,+I4<7A/C\$SZ;XPQ4/8// 6VL0Y<* W+W!@L M
%ZA=ZV\$9F7Q,._A>%5B _EEA 9?19G9TE1U?+"#@).3ERXMKZ+D?:(|@@\$) M^K?
A@\$*S/\$+;%|;9(*L73=)B";2D#GF@Z&?X3X?N0B5*W5YL|H&8|Y6Z_M9 MH|^'0"
(3AS06#NK-=9!NU)O=4H;JX;KW9135\$(C&=DO*RB6_E>-|122A_.9B).(NK1W.CM MH,
(6>17@%R*^G\$O+4Y: ^HX0;H^*&%A|/"LPKWP,T5BHE(?;248R?A/?|F+;! M|(G>)*4K?
D;RK03U,-!TT\$>9KW "%@Z8KZA9|E^4Q)2_!-%UR:X%>W5YR!EN
M&S89@|8\$7 _J3|A|Y8>2Z61S3;P^?V\$;|I.OH MZ^CLY.C FM6OF*OI0V0?0AX M?|LD2|.
N"=,FM!_9@"
M6QHK*-2*+V2)CGY'P7R*|1Z.ENW4=^,HF6&\$TP3DTN\$4.2>X\$D|\$/EH_%'U& MJP*74
8LH@\$#YD&HT+,1:H9_Q.@&)0Z|*J>&E%MX _URFA6.1W)/ZSG?|QW, MYU=-A(|1RCB
;@F|H)A;HHG-Z&I/DW#|/\$SM: EHI3@"H2/@..H>N?I\$9+2D
MOZ"+*0L0I3%|" +838FY1(H)Q5>N'.|D+X4JSP:>O1N19S|K>A!,_ =^W%5NM M|JO1L6:S
'Y:@#YYD=8(7?^-5B7GCR"!G4 S5.4CV//Y91@EJ">?HN::>=)M4,=
M'.")YTLX@:25/KHD/TLWC4T|WP&SAUMI"3-/ +*%*&<\$|D 6I"-2L(S"M9BQ
MPJY%'6.UPI|O%+XL-|H2D.8;S.L57=-#MEE%G35MH7;O>L67M"A>6%>P><"O M+
|X8/. WV@>|',L5Z^:GJQT75>I"K_.*?J*.R*:=;MGAF%,M9%M%QB'6B@
MYK74Y|7P8T|:UT)J"*;WDN>5/>4W+-8NE6J4EMX*%ZAPB)(*IM)K2|7>E057
M*7SH5|SS,ORI>;WM:R^V7H6H/PCS5_*A5W>W,;+;\$|D3M"|LA8_UCUP ^*L?
^8#,MO"48+,4MSI7 M/F'1=:B: ^I1T/8|=ZRY2&|I3 |)
(Z#@BP,IQ&5%E5NC'DFI5K|7C=M_A'8;69|74|B:74|
MZ%J',_MW)E,|Z7G="V.1M"C^K_-.*6>)/.U@/\$OO)|Z14+9J@EVL)8>2YEW(R)0^5,/(%7L,=
(Z+X#LM M|R%E:R-;NLG/?AXJQ,3| LQ5!'WG*=4^<#|. &W\$|HYIC5KJ7)6D|UI61^<(
M),"?99\$+G01E\$66060"*3>*/UY3|@*Q=Q2%\$0C5_P:.%KI/EE| PX.NP)DKF
M,46+8EF2KI8W&&RU6'(M MHWU2TE_VN5@NL-
SF:85G2G4@49EXB'9%GI&DN/1|JJ9E1L4J5GW=O'E=1(&J M\$FH+01#*5NY82Z+K6TD?
D@5:K%6OJ|*#|2'(:8R_ #,^WC_9&QZPW:-#X,N6 M(&| #OI
>)|?;V@1EX\$J(H_ ;PIXW" _>H8KHBZ#&
M1|IL=6E;QOH3|DRMJ6HE#U/V2@)LKYL_65O,VF+6%KNG+69+%5Y9J4*C;FL5
MWEVMPL)DNW+GEPL7| =B^|OZ_:5+-L&-U<=(OL A6|D8F C;_H0-0MG;(
MQEV@VA3KG_0|P_13MBUUYV(*1G521HGL@)\$|YE;9>96=&R>(E@T6B=82J5:
M:27*9D8TR@;++ZCA-+8W&+,B|E\$S@C?@|4HPI7)//3B:"HJQ8O!^IOZL@63
MUGG)LI96-6B94>BIB7*7NL&;NO%U&%KO\$M'AU(%%814KIZ|; \$CF7EA-*&W
M*Q;4?|E\$V!2LFP|M|8KAG-(O|:HDEK54TJ16XUA5@%-75H.(>,G|KW(Y%57
M6>V6RD>&1DF(MB|*0XZW :\$V8A"QC2>7: Q|@WDES|6).RW9YI78O!*;5|+*
ME|FLCEF'I@FG+|OJJXM ^*UQ:(^,%9"&OO?|F? |U|.#.|::&F.6K|5-D#
M=!:A(@U8>X5:F&2>(-/0;|I|S%^?#UQ%|U*/+ %HM4-3ECFSQ) M>V;G&-
D|CZ|B%,@'I<9CM*>:|D)W89A-'0KH1SAFU#=#Y<0*,%ELMJ5|A.#Z*>|JMCQ=-B|#(
M,,"E1%C 6_|F%*_.%<|)=8:HT@CKWB|60=L,>M^BOF6&HPW:YW%%I"%|4)Y
M^U|.=;Y((CN"%FVE3'*70W#'.*B&AM=LT?B|EV^ |KN8LSUI_I&=HQ. CZU M M!L?
0N*U|E?^72VLX=B;ARYU'96S=CU#.B1* JC*VD64G@=C2JM7HY|\$=!D
MI5|D(\$A=,4|@;VCKB02VKF:(>Q|Z:D"@3D5>V0'/"2^IL:'L4DK|<6%MP'\$B
ME*YZC6(TA!=2=>*4&")H.H2@L%FJ(>L'Z8:>L??@4|'#Y."C1|"+Y-*B|9-M".A
RES5XUMHKQ12XW?)\$ _45;-JF^K|P|TJF0"Q#")OA+6C912^(.QDYU=:E
M(U#"XQ2%0&K#U+N!AA>D| #O@KOGNF<3=FFPP:_|BAU=1<\$7);?@N^ V=\$N2>
M0QN#BAE#^)U,NDJ>RX&AVPS% @C_5W2<2-YH)#?@5'Y?I#4GF_ *%Z9\$C)4&.C
M*5HJ"-NQM&CT2*4LP"P8X/D)E316(9G MP;P

*VB*H@D!\$4A)BS&4G%PA\$I#!%,:VR1=XE0>9!C,) > ^BW\$F,Y|I*?M|
MY)L(CCS;6WM#*LR+KD,<#FG|&05%H03=U\$+@%U@PH,487"=A!TJYD&>-J@#M
V1L@UP'5!*I,AZK0*_L?30'M;XC?K@Z1,7G9%F@1 SXHNPTAA[V.?0 QC3 M0";=+1>|!
(*L/CR7*(53!'V&-"?|19RZ.G2>(("|7"V(HXQP31SN%|<|2 CIZH<3C5!MT=#M;6%2Q-
J>S|GH)?@M-&-
J7QQZ1@DON6BZ#/Y\$|W;GVBJP29:8JEY,:X2:N2PZQ9P*S\UM5|KA2Z=IS@9,M@C.>\$
MXS*MV7>7^-5&)\$OW;0@6W="2S)Z\$KC;? MKWU@NC|6JGJ-871. I2#; M<,W5!
.,8&B(9#/EZN/N!!O&:4>63FTP;87+B ?2C87C!&A*%1MG,3':_#N) M4M0%CT-1M,Q"ZT4?
E/2\$%><&;XWT6(K)R+\$W,M|5;,:O MO.H@5Z%_H?
#=R2_+G|&KP0;BP4):J0Z\OX1\H2'@CIO8%E4RTGR!'!:=GR MK?#_?J"R-
V=^X7&0KB"Y+S.ACL0V&/:^EZ<2J0D|U)V M8'WR<\$I?5.X5?
8+RQ!H=^M%H3"X|\$8412*M4:%D<"W?S|>1Z|.IF+\$DPH1Y M/G>
H"LD(MJ2KL6@8|W!W>6.1)S%;>"MQ&J%M48J&_H+0YU?1F\$_::2!D3>
M,J7|H\$=LFDT5Z+!-74*)OO+<2PHHSDD*R-"P"4LG5NEC@|J3'.*P.:=
(.CF.,\$2ZG25=NF<-K4%H81HB219? M^03#R
D4Q#/3U\$2\$"YTA1SC//6/J9A(%E%M)3L(XU=A3M%RD"%MO
M!YW"OASZFC|GF*D2(T6C;N-.%)*MPHN M9*
{3UA)R1|M4XJX2U'B.\$3FQK80D8=1B@+WC1>I#21 M>%W3(!SYW+#"0:V M0W=.0|H.
(|!."BF66V*B4C1^V|9-C >LDH(|-*|M2DLV7:+69ORWWT%|ER
M.BPP'OPM2XPY#D8J.+52R!G^@A-@P?A?8?/3#H>S&)|L;*|)VR/*"Y&Y.<@| MT2Z-'5|
{Z%>G|>2M-#LH@1=M94YC(0&&N5O,)4-^2V#WHT^R0:S M@@U^ 93'Z;D5Y8*CW<
R8M_)<(SN!R.+^TQ=+)(P0_.D)1CX29)ASQ!R\$(+1 M?LUCK_3"SW1|B-?
S=U*.)Q'OE3S\$6&!^LB;)G>: +SQ!>9TBD1\$U.)X,F7|TC>>:I40|ZL1@08-*\$83'?,"(2
UAQ*(T@*J9+C>TF_6>PCJ|MK#+-+|*_1 MK%?PV-N+9*!O4^D9\$<
M,D891J%-5IU|D&"2_8(<=D:B>"WZXE@EM&61*)
M(EG5TC_:OZ>#W=XT?;\$5|_:X6FD)-WNM|R5X5+HO9|Q.UUR\$5W9|ZYRLI<
MO\$6PU|AYSG77?6_,'>+CK-0CR?-BA+/6SY4*>D5?D(>4;1'T4X8TV!55X5A M DQ_QT
_JBSEX?JYJD)%NU%_4|":HK+R(!|7&)|, @+V,>IH9|6XVTY^_Q M'_A*:.C?"L?Y4IED(A%J
)@.+5UR%4JV|3N":OM,G%9>FQ%*2%08AW:"F3,_|<5DWDH=SF,H9 M:D5Z(W>T.@/4
D@#)>N3RISXIO*PD8JZMLH)4R;U &.:3/@JM%,|Y%NM!&9H@
MX3P^SZT\$T#&!YJYC\7RE;+-L.|VOT=D),\$.:7PJD*-YMITR'U6E)8KB7X@
M5|7(9ZK8#G7T(A? XO+P;#S0|1;|P:08# LJROD%|EG0 TKVFQU?Q=>D_@%+
M^.#_##ZW*OB@\$+0^=;ZV*YX=V5@L>KYGBH1*%:
ME\H<:?,XUP/'T+JH|O|:546!S0;"\$,^*^/H|ETD845YK/EP=G5LS#=-='G*/ M5|AG2INIL-|
%X'80(E.,8Y: ^CL'OEUAWE-#/4S""WR^:5@HN 919 M,7A\$HU,E-U?
NX9E0%\$|9K2"J0)%&5|YC?"S511^+X5JHW,)OK1PLIZJLZ:FW
M+!;XS"__AQ|@_:5X7D<3|A+\$=#G-O3R=E;#4E&|+B21)-IMA|OKZ,+.6=N5G ME0E5"
7J2(LQ.90\$*T0?RKL,|%<)/6#4KE2HEC:IM2;#"U|RWBJA97S.3TQO M?
{ZDQ270YSTQU:7/DDZ7',-7G'J"E&0)DOM:-5_X\$I"C\$W\VO_M3=2?1E%8&
MTEA6*J#7^U;QC6>.|HJRM\$&CXIL(|5N@!RV!:@\$;B_ UCP\$ZZ6_2-S220T M\O:JA>?ZCL>
4*0<6>VF4-!9I<:23|*.5^B0@S1*5B#IS7KA-16=^*\$;4S4N M:56D;+
|.K7ZSY:UEHSWDI_G+L-C3@D\$FPOP|>>F|&T MN1GO+C?C'762+W=,LI+|(S>N|F6X?
=2S!C*H*M>NSN:D;*"|#=N"4|EPVRZZF|1G
M<37DQ.:Z1QUF1E"Z#_DU./OG|F3!^WZV!C2C84;69Q 8:7P+/2K%@,"HP-D M=?
J@84YPG(F@C RLM@PM(WK8,%8=ZOF,,Q-44=-D P1+Z=4W)O^6O:0J>*S| M2A;-
/Z@6+^_X2IZZZZ5@,QY|*=R|H,6I T1'@9_ C2VEY^(-URIV9B*FS9I89
MCM7IMA9)S^|G"K1).9M%/MD868+,@L)?|SRAR1H4|H_4!GO|S_4+PO%DDR6
M'RH2ZG1:IFF2 *I2WF9)4*_Z""5QP-2S:C8K+9\ND=N&LG\$2>P^>|U0\|N7 MWK@4|%!
T12?|HIDYB!_JZ|+SNC7K3-W3:@OG0'0^L;|K.LCC)N'R!|.K M=M\$|T9V>*\$?<
0G"4%TCL9RYYY9A(H5U_Q%A@6W2|C|CJM%=|.G3=4>ZLDP4A(MB;/-5|_9(S341
<6V=E<9S/>N7^Z(7!3M_R)Y,DC>&A1|HL85J BHL>@)LUTS.(=SG4OM7L"
|T.TARQTNDTCPQTCP2*T.DLNU>WO2G MV%R-G5/6T U%!S=L"Y8D#\$@1/H45G=:
R>IUIE,(6JPKJEFC7 MQCH5|93|<'S^|T8^AS|7&%|]?BL/WO@|SVW_3';(YX5^MTQG")|
H&TL*+| MCVSVNFY:|HS--/2*)N6RM;4Y4=
<8UVOF:9EF:>^HD|_96*|.4I@>^AC&Z.2HV+:|KZ>MGNBINU^,,:R%M1D6|*4 M.R??-
*_8G&ML4!1'M04;NQ-|A"Z?>1BEHUDJM,(#ELJ9\$,MFV701-5+SWL
M@ (K)IO3(.0803|D<|XRV(@@M.04YT".75>6RL1P_M|8|N2#:#+69I*%>N#:=
MB+ZP)/+!4YHQU4RC:0,"\$W5@#0NF88&-!X'@DZ*7OFIDK&_(?<2E:=")|5;|

MFN>/QUEB:%3\$14H6C_\$X-<?XJP3;(G,O9(NI@"BR\NIDC!)A&S/[V!HK:<|
M_X5ECIWXI65F0\$8.!:>!.K*=-8W(D_K\$45J.%@@&H^@C)H&"QU+QID,PAD=K'
M)/+E'!9!>)>K#^C-J%6BSGEY[UE/+9CW9K*>WJU\<^.%W[EI<*U0O!>(:7+&8!
F)=B6=!!#/S\$KRGB8^K-D#A(&I_Y55_&9KE:GAL48_MM'?(.AAG."=,^3?R\$9SH4Y;-
*:@'D!;W7E:41\$EG"U.-_64'R+U=X>BK&?_M+BLD64*U#X4U\$B!8XFK*_4!-
J6191C9Q9T+&KF@M"8>RU0#BB.*F/)R2+-0_M'?_(E4I=5I'2M,4_M?
Z8R\$""UA55/)KZ,,)JIEC>0T2)^ZVQH=0YX6!S
MK<1,E(H+VFD4SU3%N8I14\$C"L!^!%.\$RFC0MMI/#%#6+YAK1?I+*+C=N)Z,\$B
MJUW%3!;5NQ^H5Z@!#W!(7=.H_)M%"%Q?KA"
(>,*A0EU)@<%GE\!JL0KHG5(2AJ6_LD^KMN-IM3)>FZ?(/%"F,YIT&%
MIE047\^I7YJH>XF#1-%?K>EZ>#S*Z5KYPOS8D!>4.!5Y\WZ:5&K1S=594BU
M&+N\|D\$24DS'F44_8'Z@=Z|^|N7XWS|RMU/MHK9R#^_6F-'*PNUS3@_J"7%J&H=
MLS"!|=MJKIQO_Y5!\$@B7/F\$I%OKTL"*ITQ=SQBBI8S'^EPA&O_/E5?766^/'8_MY/JYH!&
<,O#D_*L*X932T#=#S6NM=5\VZ:|%;FZ\$7'HR6"DQN!@7\$X68@R;U_MRD
YH#E3B=MZ!K8L4)I23XG"^XL|;&2F1;4(XYRR#QL_M>9,*&MD44A+_WD
I\$47G1MTC;G&F(MRCS9O(H5L7OJ/RTI;;_M*13KCV+C(?(:+?
^XJXL!2SJB.HL0<)0ZA#OMD3.1B#L8N)Y\$R6)*F1*(VG=41%\$XMC@).|"WY\$L%*/(_6<
M@"GS;S!|7';E@'42;J&GOI6L6_'/^"#"0!?EA)@&.*XOX"3-.C&9NOFOG0_MM8/,362_R(
DVDSRY"00&_K\FN3&M5;X!RH0X';"5H_#PZB_;DPQIE9DXHJ_MFZ%1-
\$BL0.>JR8;LXH0"-;6A,*PIDS<68%.K?A-CX%#&<1@05V*E
M?"6;B;B(V)6U""(>4")EN1O;):4U%>=2^?_9>]EMK\$D7?15\$'VB)NS8D\$H7
M6Y*MO7<<6I;K-&/+.I+LZH_(+DHH@T";%PDLY|^Y'5=0%"R:UPJ2D)'1f=%
M@L#"NF1^F?EEIG3N]"I5P7|CWM4T"+6<6TB#E1K5|@IV#HI1:9G:|BOJV|D*
M(6Q\$D5,JL04PC(HG*86^G=6[1%_U%9=E]L(^.BVN\7_*,79V55R('UI<2;/_
MH%G52CZM=09EE=75RF292^REB,10JB(E)9Z-0DW:>.WY;):4;CC68V*DH7@VYG_8:-
=|8!08_M&?5*1'TA;7>KI;Z|OR%#GG!8AY22@,.\$5&_B152,T!';+|IV0(8)4B'31#R
MMYHLN%Y?"W_FQM;*(O/FW"7MWJ(M-^6N;^.+6\$?_X?=G^*4Z"EZ+7>\$O\&\$
MYR<7EX.W@|C^*SHY;D|^1A'W|_WC_&7#;YY//)Y?G'J^W^255=QFQNVJE_MD4L#)
(Y:0TWI<(X/-/F=P^/6VGJ")EO:Z&I'O("4JWU)9=^?SEBJ4?;RT#
MAPST(2;D"NQA@A%6<8^C8^I4"SO@6=@S|_11JLVWM\FU^IT>DH;TLXPY8
M#0A8/8^CHRG^Q\$C-00K7FS+Y_XNTP_LNF_(+@TNU4,FR6_8T.+%D.0
MK>;I:=|H<5G_5'?PCD.V8C-C2GT#F)HJM#;^RNV^3K;%CV/|Z'Q^%|T/+Z>
MO_=X/:UUZV3,Z1H%PXIO\|H'_MON+;0Z=-SQ>Z*T%32@#|1S*;'T9OG;^NA#A
1Z;ZP)3AKQ6\$K;3/>|>%=8YBFB>DW||:AV9"5G,VNN)IOE_M.MX&!AO|X-
/A4D5D_.6E=RUAE6"!JZGN-M#E2+_1:'A#LS(T1/00S'GRD.=|MA:
(@T<)NMK64L"%L#QCJZT%NB&YR@A^95VX60
M>,-0|KD_(GP693H>*|5#2@|T^S=;8C7XD'?,2E!@9C|)N@=|-(!C6;?&L0
M'&G6|W^BT3XR0=6;M|<#C9YQ/4;\$6<\$LBO_E#YT|.R+B=Z&;#K5+|0^1?9|6_M%
AVKGASB!|G97B"V#9\FE^;2EOQ@C_3?ZIG6WAD,41D_W^\$T;|38C,Z^7"V_MM?_B9|R
.|^EW?6=/_JPO;OS:|I^M/V|8R|4DPG%E|B)'SXZ"V6#|YC|JR;?
M_ZB=YW'K6=T5@TA:4Q(M!5)EJ9OYF+LN%W5\$;"5WY5M59VI+P|@*_!_B95
M58Q2UUW.:^J*1,5@(|#F8JJ/HFON;DJ=;;/D1N&T:T3FCB\7>8W%)JA>&)#S
M8JVN*A=&|K2+<\$U#YN),ZNG;A,-@E:"".\$.N#)|()N<9=G"WM<|U@(|H>I_M%
<%*CO119+JS|M/DUJ|VZH+D#T,%/U6|,BX(E5+K-8I+9|K8D>Y=4)AFS=\$^WT_MA?
5|8|C'R8_-/0"U*2<"RR!T7Z-YL&J%|%R74A8RK:5GW7XZA0P0_MH)
(2#&^;5&04F\$#^#Q?1I"F1,\$7C@+_7|2"|PY:HR;|@,DZ)6#IS#_KR^'^_M9=TM_-
D*FZ'44E={0QGE0!_S=MD-|F>2MXAB,0"J3Q4JF*2N#R6?K
MXYCX^W'Y!YW1.+J@^HC/D4;'.EP=C0%EC|"2X.8FC_M';|2I^"W!-
(%#9(T<6:90"@HO3O#4CLBV%EM|P6=I.'(J>%N@*-HAE#75L_M3+)1;+
/JM&T_2/8CX%D)HF7*(EG1>84GF"&)&B3|0&P@&+G6Q'M;SD&KZ&
M.Q>ESQJ+9;EP!XSWFFV1"AQY!E;2A-P8EG+("JK#7;"L\$IK#GU7#;6E=&5+_MPV?
A;2NI:GDD2!EF#=#;3VY?16ZGPTT&.)?J5L*0+PZPG%Y*>;R(F,+68ULO_MO8U/E9'1
F|7U=OT;ER)>0^#Y^Z_N)?",WX#V|C@T/"@R'?\$@9"DGWKA#|P|M0.YT6+
|HDV_7>@A@OL+?J?"|WIB2JBB+|T|^Z^5ES7&S_M4|W#<,YW7_P\$@|_
V;WL_A34*8X)X!6:~VY>|*@NPD&@2^B-PUQ'X)E#XK>=C_M|^4WGH|O>RI3W|H|H'2<
'M|^7_M+|^W3N'?|8HO_5=|M?H5=9S|F5V5#7%T\$6/=|M0EL5FY*Z(?+\$.X*=".4G!C
M|HVK=FOBN7@QZ<_/7_Q.R|"O"/?0F60O>R;9(V62/4G1Z/JJ+|^;O51U|8K
MUE)S!0VX0,_0?A_4V>_XGE!)O9A+(E*7:V*Y11"517/>.<|Y9YN)I:6G(_TW_M22?

L\$IV:D*JO'9&0\$C#D^D*]HWC%1:SN:G3WJ6V[%*;-)0EOJ8S,W+SU%'S
M.@/3DCU<&MVX\AS#M.ATB+52 M!,1+KE_QX:|2F*FD78_D
HL[V,BDOCR9U=I0T(IJ4&GR0MW_JT|W^,..#4<8)FL>2Z9E02CHLOTF^P!F*K?K2|\$P%
-CFHBEP/WOVSANR.Y2T,L!0 MF4DL00U?
(2^ULHNPX4<2^IA*:=_9=RV;\$Y&>"\X\$HH2/(9%B:)>/S6OTD(>_I M:\$BN_:D:\$
_3GG"/41CP81NNQ:~G'YT1(^7*E*OE@E#<1'+ B9\12 ?A\) MWI \$84[11;H4QP=WO.
(^7QR>="L;7%\$UT3*:*\$O=BF&TG|+/\$5H.'&*QQN(8|>00T,B MR&
(D.:RDP)AK9>YRK54EP3KN!NIPT.3&-;ID2JTP00E\$YY6>FM;ZK'CUTB6
MY(:'G5",5%:H(6!@MI%3^W9^OGYI+)KUG|;5+0/@7E5@1002SD5NC|TU?3)+ MOE
A+WH9..BP9Z2#+)T/9LWXGEBXQ@^:2+BVLX*JI-KC-8+YC9?T:V8C|1\$Z-
RH6O+K%K6S"UDBP>1@ M_A! HK!IR-
?)DD,BX/M>C.I@L_U!/3>ASP>9&TE(TPWA0WBF#BVMF<:|7"-
M&=Z*=X|_T*MDA&V,*6 SU#X#Z"6: ^/2+7&08B-)VX:9 =+Q1WZ*3P&3JJA M>VV(B6.
X_QE24W3'0,ZJ)YN|OG8VEZI-T='>41?B|*NY%AR-Q;B\$*2)F#:
M3YH:.GOCPI!@(9VT>O6E@9!K;_"A;^TY?F1DI-E2:=#3&"*4W RMM_MI95)5G>7L?
==DA5=L4'=GD@@UHIO(Y":CX27NZZU|+(@G/8+E^A!3
2VNKZW|CMTJ;VLYM;MGQX!U:++>D|M! V:0U;BMZ?Z^ 7E1|2:D,G8&Y M*Q:FI->VS+-
N|6MWWI<|I>NABH')DKC(-XFF(SD U::1/ 2UE(5E0|MB.C 5 MK;N :!#:NI6#H:OP,@T.J.
|8-^YZ&)SL*DJD-P@<^PY S;B)V7R1|)%A15 M;"-
%.2Y>;7>Y!SD7_)*|Y^=NRJ7S"^I>X3;WL-A7QQ&@S_1Y|&)R<7AZ?#J)G|65>;NOC
MO4/E/S"A|01;-*^G67 @_!*<&/N3AP;/>A|BRH|UU7Q)>%=N1D?%IAOKX.+D
MP^6G=RF|5JN=TE%S4"+).("+:2HD'O83Z1)G1X.S MJ|^#C'R6-
1A_A@U#VV7U@I@X6L#5YSJ|5|JCQ*FLL"&/_|GI>7.@O@>LIX9>X74*!MQV5PJ|,HQZ-
5;Y= BRK7#RW M;RB"/3\$%30@=NT:|U#WWE#MR4"9ML;/ZW!N^C2*NZ3(C,K\$SK 5V.X
*9(K+ M\$&9YXZEH>UZ7(4P'4#A42615YJ&O|P|!HC)U2B +CI<%7'QX_L!G5G3ACST>
MRS/U..|)(ST=Y:'R4O9Z/TO-1'K>:ZLI2L\$3E\$/|J>DI&R0RD M45#'\$JN/!A_.S@?
OGP>H"T06)@&4R=+E@|/+P9M/%|?A8|M',2^E9;\$@1 MW"XGNGQ!={75<;3|79YD\,9?
_R=JRR405E,<,L7 7=,N=/13'T+TB2|_Y_G9T_&?6.49,..@\$75+1T-
3)QG8"!^3R|XL!' +KH69Y@;,_FEDRO(^/C|Z= MO#T^T3/OBD>AP4("?.Y>5S#GBG1|_
M_G0:8FZ\$3Y^#E_RB|&J-HQ6KW|3;*|1)(\$=X7,Z" MLU2A7^ILP*+|{"O\$QX!
_3XP,EMN0F|!7|?SXS01^|\#9Z M!N;56 =Y_0K?L)I<8TEB \$T_0(6_JZ
M_MX^OGC.:XT;O*^YG0FJWL_O3A,VPEE'IU@RDXPXVO;K0.?|%)M<;8WG MK9|,2)-
QB45D.OL',XT3|PP2
MZMW/M<|=M@.V78+C:~+089068S'693K>&%+_W,IDDPT#QD*53A:H!E>
MBBUC8":'4SY3 LLL'8&)@O?VB\$+\$CE@XP,4|A"C.W&KQ*|0'A@QE<5-3&SZ:
MSRI@ZBY75.F>Y|LIB 3HOP-5JP2NAN_!(7E;W)&|236XU02*>\$Z@Y
M896EX|:6(XA7;NB5+LG<,>_Z3 %|Y,Z2FKA-"783);C|YJY!+8ZZ&1*KZB|ZL)A|9VBK"<
M0@H2-/R>|EMJ/45WHJXW7X)L|FW->0W0L^3NGEB8FHO/MO'0'_H)V=+ 1(E
M^S0YR&4D^Y!_VS\$3Q95)KS3#WI(@.KRD (=QJ::1|)1>J*VXN,,NRLAU|;
M(LRDx7P1+)26P;,%JLK8|VK--KQJM_DIB8@ (3!F=A8|4Y4/\$9;48JH|>.@ M>Q?
|^SJJ*DHNY#8V\$R-D-MVD.E\$M)1"RPI&_2ZZV|MN) 4%B;_H31'(MUV
MH|OLSK!4N%\$XS'74,|WI!1+@R/(T1?E4%A=XZ_.SUZ5%UD@+J<.L"4?I?/V
MH/RJ,"M^KTSU%(F|U3J|W;|6;)(2Y95MQ4K|_?SO@>V7'GLM^QT'=MLO^!
MW,"W%6IB(.EQE"S*0Q6.[X*7;X!B!DS*E_"3MK>V-K=^TNLIX6I>F=<5XRZC M^?
Z|(|CZ(S<=|D|&7JQ)I<1LB7";TGV|A M<@.+QWK|_6MO_,! ? K@'HW_|X^=?
^C#9,%%@<|K;8BB0BQ4|0Q;H,7E%|3'
MNGY"!0%'228G9L:QYE90H#N1@X3KGOZ*2""GM^-#@|(^)P<|V-SPF*U7^SO! M?
^"Q/TCV+ZG1;RM#@<*3?0C1::90(=ZO+0#_2BZ@P|BE7|TV+|SX*X?B4>
MZOF2VF;|JN?1\$8(,^X7|E\$|I+&#CF|!?:MZBTJF&#CL@X>C29;D|'=ZK;3
M2*:E|%|S+^@EUU.M_J7 ^4<+VSLFVNZGOWHJ_U%/WQRO_/LT75_!0!|TR(=
MQ"|VM^_7^WM_8IWN%(X=)Z8_\$7_F1-PYT|X';|HIB/\$|_<7S;UOU+Y4/YX, M<.L6|
|Jk+OW|^EO7_2|V=K=^#S\$Q15T\$/4|9> M*/M|)WZUM=OCE#4^\$CU.>1CZJLW?
\$Q3/4ZY5YRRM;,,O|S=|W' M&A^)'J<| #'VER&1=EKB')&L,27K7R8.1OSTDN5=
(LOMR.WZY|ZJ')&M|)'I(M|C#T5>|Z>9KKWKM.GJ!0|G'*/>
(4P"C;:_|^BY<|3EGC(|'CE(>AKWJ<|C37 MO?>G/\$&AW..4>|0I._VP5:|O?
>BQREK?"1ZG/(P|%6/4Y|FNO?^E"&OW17RPUS-FU_E\$|##E8:BKGC'|Z)<8\$,E.
|SEY8O*W1R3WRIC=V=F+7_2> MD|4^\$CTD>1CZJHB1R0/
M0UWUB.31+S\$@DLY24;V3Y!'+WQZ1W"|5G%ZWPB>D3R,-15CT@>

M_1+\$.32^T@>C/SM\$1CZJHR?)\$Y2_M/22Y5TBRM_LJWNW;ZZSUD>@AR?
1+W'M)GJ#|V2'O:8%POCBK:T>MDJSSD>@AR?1+W'M)GJ#|V2'O4*25WNOXA=
/9=DG8!\$#TD>AKIJ M(2_(\$Y6V2>Z3W?KBY4Z\O;O=(Y(U/A\$)(GD8ZJI')(I^B0&1=.8F
MJDZ21RQ>T1RGXCDYO+_3AVW6^43TB.1AJ*L>D3SZ)?YQB*3WD3P8^=LC
MDGLEMV\MO8@/7O9AFW4^\$CTD>1CZJHR?)\$Y2_/22YWJMN?QWLL^M;K/.1Z*)
J#7_60Y-\$O<>|E>8+RMXDCR,/15 M#TD>_1+W7I(G*J
I2*OD.1@>S=^M=AWMUGG(I%#DH>AKWI(ANB7N/>2/\$'Y MVT.2>X4DK_9W
9;Tl-9U/A(I)'D8^J') (I^B7LOR1.4OSTDN=>J)"^V\N*J
M\ LZ6/219DR/10Y*H:JZ2/+HE\CWDCQ!^=M#DGN%)
<'N_'NJYY+LLY'HH_V.X\9CTD69,CT4.2AZ&O%)\$)ZV2RQLBD=Y8\&# '<(Y/H;UWIS@=?
Y2/3(Y&'HJQZ9)65_M\GTF3U_ \CD?O-O7KR*#_HPSEH?B1Z9/
Q\U2.3I+2O<_D"8KA'IG<*%D M>_ME_/ESWE=YR/1(Y.'H:JZ9)45OHN9
+_GPPS0 _\H%T'_^O)\$DKIJ_ME8Q?I-_RJC>,F89%-
FZOU&VCX40Q4:_3&D8Q^HZ)^WSR^>3R_-I_*".?*W MSXO-
E\N\JVRA_Z;;;MSAWS'+W3G/QFHFER::(DRIO9T)11,8GF"7Y914D^MCN8FQS,HGT7)?
YSGM1HD5?1J(##CE\631G-TE%95/.I*4U4F\ \$TAQ>Z6D3U
M%+ #PU;1H:OBGB0#S9N,X@O<3>_H+N#\$STP\$4P,WC_F&D2\3I\3.LO3U&^: M8-,4-
WD\$ET1;-K\T]*,HX\EDE^9C3=%\27*TJJ&CSYM7FSJSK&;19=7=D'\$ MOZ^B-*<=0K^!?
^JL\;S:C,Z:L FH2^#EL%?P6T/&LPCV:P WS28K3GB995)FZ
MSLR,MBC\6MBC)J\@5U^5AC\ E8_U#2G.X\$|Q^T%PU58U/V8UNTGH.79KK!(9D
MHBMX#QP\?H# 'HL@WS=1UE3IM8FCLE@D6;W8F,"-8_JRANNKB2E1YO(G53/D M
>!,)99BO?3,8%E")L<7Z8TLR3-O=.U-\$?XVK GOAA^K).4B-LB-;
IT?AA;'0Q\N'S^_H*".3E%D*0^!:CT" _PZBC45J.FEE5)_G(5)O1)_M6
MWA)J\ZK\9Y,M8'3;KWA-!K/39-R!KNZ(6!11>_?'T7/9.1\B1NOMX#R
MZ\82MM9!7T=E7LL_A_V MVL4D4VLXW*_,#KYU\$==9WH\3ZVB4)56%T!7\$C*!'
K<"^0B7B!C_H/D|=?? M&\N'D\Q\W1B#?!GA'+^&MVEF^>\$XK>99LGB-
WRY!T\ V7@.=P6.+5X0_ ^!= (B MG2QTA/33#="-A_.B2NG>I<&%O#8;+_B=.
K6HS\J1NMP^V=/Z\AG/-@'19P M.RSX!:/>?)?Y9,X'5?)JE-
MLJ@._&SW2;=%@ZNH;CKX^9_'9^|/H&D7OQ>7YR^M^#GR_/CS^?'%T.2/C+5\I.
MWOU^?#|X^%%E:Q*K(MOZAB =U4E\$ 7SWCO5"3%@UHX\3>&WY5_2Y5
M\4P77<(_0*R8BH_L(UZ\0<%J\%?H*;P_K2G.L"2 _H\6\I;+_9@!_SK^1*-1 MY5\I
9Z4;V&9TDD*_,JUPGBRGP'F<&)<3F*J\JZY--/_GSXQ\$#6QK!YB
M^L+7+Z.B!!DV+UBCH+E)JR'1:\HY8-HJJ\B6:KL F/^ ^,GW%:@(P^B/?V7L4I
M:I\MO\ "K>>K45OWQY0,_#Y*>#K7A_ =S<&8T\I)J*-0'3NJOML5,P4S*(93B8\I
MV/(38D06>0W8F20\$&I^Q_Y3_N=S4>_4BLO>9CTMD00_ \S>#JYY-;=L\$ZCKKW M67?
XK\$N-=RBFA9-CL20A_1M\$|W?H % ^:)^R88D4
LK?)Q_(I8V0\G7\4A'EE8\6P^0V\I4/V*TO2F>J;Y.L\IE8#W'G8L:*W,0:*/TCF(
M!Q@)R).B=/96H"3A,?I+!N\3DY;LG-BOB?(!@_0/<&KLZRXJ5Y_O\#YH;R) MO\&?
@J\+|=FN(#:YN\$+7)KX,7KZ1)0LP+?D2?M+VUM;FUD\Z\1RL+)E7YCG5E M_"
I(>!:_K=/IK,M>NT2DG'+5\K\SLH:?*XGWR?F+PB.\5^7O&3W>W-O=W\I
M5^X_!H\CS_SV-W-\8_ \I>W,/_DU-Z-IT=I("X1ZX=_|/W;^H0^3!1?'
MYDK:Q*#U8\W8@>2'T'\S+D+.GU\4U7R=!\BJ?UIN_T 27+12 M#^)\G96
I\$8UF#W7&\$\N5_51K.JQ XX8S/Y!#/Q)S!_ ('3CGH%_?PS\ 7AG M;R?
>>=6WYEKG\$|3V\IV5?9G?(1 _PKWQ/N_@'B_TQ&KBMP\O/'%SG\$|S#DH>AKGI
I\MA7&&F_O8?DB8G?'I#<'R!Y!6#D57SPHO>0 MK/.)Z_)PU!7/2!Y\ "L,@*2S
F\O(7G\$XK<')/?;F/K9;S_JA/W\XAD38Y\$ MCT@>AK\J\$T!RGX#DY?9^O--=(I4')&MR(GI
I\ C#450\('OL*IQZ2)RA^M>T!RGX#DU8M="5!ZYU/A\$|('D8ZJH')
(I\A7L/R1,4OST@N5<2R>|65KSU
MLDD3R,/15CT@>^PKW+I(G*'Y\1*OB&1_>R_>/^B#-NM\)'I\$|C#T M58\I
('OL*|SZ2)RA^>T1R0\W)#U\&+U\T'K,>D:S)D>@1R>PKW/M(
MGJ#X\1')O2*2G1?;8ON&H0\ (EF3(I\$CDH>AKWI\$|MA7N/>1/\$'QVR.2>T4D
MNR^WX^V\O1Z1K/&1Z!)P\!7/2)Y\ "O<^TB>H/CM\$AKWI\$|MA7N/>1/\$'QVR.2>T0D._'V
Q5E^_9*V/1(I('H: ^ZA') M8U_AWD?
R!,5OCTCNL\G>_OY!_&JOKR" _SB>B!R0/0UWU@.2QKS_DLY^I+V+
MY!&+WQZ0W&_09FL_?M'32-;Z2/2(Y&'HJQZ1//85WMGJSDKL722/6/SVB.1>
M\$D3R,/15CT@>^PK?A4C@_Y_A9NB?WR"(Z.!?*(OD7?>W MDO&+_5O>|8;!TK#
(QNVENFTT?"D^ZG5:PRA&WS%S@_?=1'M\!WXWOA@EOP-M\&+SY>|N3\?
LHK\HXN\(<)-\Q3\|T*|^9:)\I%K49U6F1 M1_4TJ2,8NP'@G^JHJC)!I'290WLZ\$IHV(2

MC8JR--6\R/%,1S"B#?KM""R8)UY4M;P(WK8J(!1W:Q-G6UUF&RHE5;IS!@
M,,XSMVU@Q>&O>9F:BD7T3F.I.)-<53,YJ9.ZO3VW%E1H7AY?R-[#J3Y.LJ: M"]>IY-
FKIV!07DTC6!235WB,DJO2F!G\K(INTGH*5Z3E.,+#E!HZK6E5-6;L M'U,X97/#A!#CW-
(*A4=5?A859>'UXH;P<[1GZV&5VA",CQQ?"BIN(IPMZ:YK H5PN6\$?!B
MPP4!8C2U@|3A=XOR,_H\$FZBT8^B:P3BZ,5%2PGCHW:L4E&@T<6!MOL*!549\$
M&UP!3Q;PS!P!,830!D<61PT- M#%X?G!KL.K%'(%5MHB*(>Q9&-08)P='8>|=P M*)W
8!;Q/WDXK3)XG;AJLW4:Q^EU-,J2JD+8>&4V!+GA48"APJ!"^3,_\$&G
MJ>OKC=W#26: ^;HS3D@7":SA-S2P_ '*?5/\$L6K_';)5BX^1*P%!\X+!;3P!_H
MJCJ=+/2\$T\$W8 L?SD5ZO"Y-EJ+5#Y%8\C'C&++
H^HT6VO?/GO8!33JM"UQ#;U\LK>^/7<;O ??TVSNTP/TM6X=MKHOVM!7BY13\$
M530#03E#7*U*J8&?S_X.XSW-,XO FZ?4G/YL2WLY\$
MA*, -2M%THJNLN^R&0V\EUC(C28I/#7)!4U(&R:,KI*K!-4H#)??8514-*ZQ
MF8AN)ZT(OY8?H!6(^2!&E <,"X8XA4=81<;/RPNFA MB6#ZO>|D.\(B^P:QCQ.<=?
5S#',!H!QO/PS!DGJ2\$.7'K:KZF>)9*VCTJ M9)O9>IL|
(;A6!\#4"J@QQ%#Q:L%GH/,&V^P:18[+,\$SF=YP41/P!N.'(EC/C*
MU#4A1P=&RV)&!T3.S!0L05,&QX@_LD.!*I,QFW(&KXD# MJ^E7I9D0.B^Z?
@N3!G@5'PCB!XY!A@<0P!^9\$J6Y-OP#&N<8_LR*.1U%-SWT
M)\X%OIF=#OP#7KU:GA):J!M24FG^W:2E!1%N&|@^!3T/9F9=DCX0;X!.I37: M%9BA.
>YOLID9&GMQ#=#W9;\$+/G'GD*V#PD/4)KCKK"6**QW"<>.+5Q:7#J5-MM L2-
@!OT;)Y5\$3C(X9@.>>F-OWXQHP2M2#5O:4O!A+Y/#^1V99 A3%>J1\$=B M+-%@2"
!6Q1^L%G\H&C+@9JLBQ0?O/W6+)(7>3@GQ-B3*9(\$>RS+R M*2 CN"S Q*YX3D=90Z
)H;^7K%>;EYA"W\Q:.*69H9(ZQ4-9WT%Q6,\$+T(M=
(+G@FZJ43\$W8G!J8%'AXO#H(K\$WY95 Y,&QK-<;4H9:-CU60*!5S=593SU M&9VI
|,BA5C5!&@*DL: FA!3'D)=3AL,9,8H+4?-#>+5&>,T-V3!+^SB!\S"
MP&IRO#R0GC003H3C9D3W!OWD.#(^#IVHQ.W,P%?I/V&S;B4 K\$@>?=
M*^W+\$EP<7!.N?.PZIH+OE.5@KQ*/(4)>_X=+#Q,*R@UW5SC;)8MA>@*3G=
MRW<@AT<9C1N>5EX7STFD*TO>-+D+!@G/267W+(DEA>-
X%A5AZKYWPFQO5T:A,B*KHD03!>5)F< *5694DACZDA7>7 YE4,L82
M9#N::Q;DJ2DUF6#/'3 O^T"!;T#VBG8B&^1OP5"H&\$MO*OO0V&:ECD>88G
M#XRD)^!>#_W;T W@F_!@-JE!'6HF&Y%PZF1E"O?^K9JLQ,4N:Z!U?P&(P
MJB75H*W*IJZ^_.I(AJY=TH5^#I/D MO8*L"-4AJ^HG,N4G+
@!V!5<+N"#E8YH*@C!H&>)_DH)3B1JZ!WE%33:)(5 M-SR!+*Q)*,-2G55OT/G<5&:UNX//
?_!SL!6X4EM9M'V/_:WCD\3ZLO MT3N (S#I=,'V(6L2V+T#)ICV?
&U3LO<3Q)0!J9HIB'4"E/3YY//)Y?G'!W\$T M.#^YN!R!;A_12>G)Y? MCW!91!>?
+BZ/3T!/_S^_S!R_!SY?GOY!CBX!O-?!^!^ M/SX?/_SF!VIZ?L3>@!8TK/C!>#H'1Q!,+O-
AI\$UX'6B!O!#!/_UE,<|"& MH_!(9O-#^Q<9Q!5*
L#^!#R=\$8&/^OSIP_YR>7O^H@4S>2N9^ CWJ0%!)KH M&?ZPJ7B&FDH"13)-SS>|/>
!L^ND9,,%-0U8!AAHXVV4%6C;A1'0%F=,.7 MDASVW&857(R>A-8*X*AI/"N,O-M^Y!
!5'WBXV!U1P17 U9ZD7_'U&|2UN;EQ
M+HB5HNS>Y=:V7!Q?/D7A>&_29"=FZLF0TRP6)M)64=N@DR3IPS\Y89_R%
7910WR;7\$!%GH,&K*4K4Q?0,0G_0_!ERN4!.*MK>[M],QH4(0L=C+J6?'Y-!-OE
HR&88(G>"T+=!D2CMUD9OUP2A(TC+J.76 MPT 3O32\$Z1>N5 M>.,GZ
PQXL0F08VQLXT24;3)AMUO_>|/\$+PLKC MG28-
JK^9,6C7X&8VHW22PK2!N3(OT@YRQ!H=Q+!|=IUY>_@27;/YU3J%W5!K M 1W"?
LUSBF3P*%GHO6+P!'CQ^I"*&HQMOM)7,ZS1BL;A?.&UF^%(L(JKP M..RPL E"(A 5M
N91M_PH\$8.V'CI\$!L::Y HE2X^<#R!*[1X;*]!-,>P0= M&1'(K%(-
;#JF90U!ETQ@DU^G9<\$#4.;OBZ@V6N.!%P!5JYFL4++Z_2::X5S
M@+=;OM*Z0A9PN&\$Z6+63N *Y!T(4#/4_K+YGG!S\$H),&+C%H^"2C!8!B7#97
M_&2>DYE*TYX(!;)4#M;!/1&J)T(I9G5WDE^C/+XB>062%N_Z%L79P#F6UDO_M#;
(L2JZ3-"KGC0.85!0ZS/\$?0Q:8!#;++XFLJ?%I.2;Y34SUB4SZQ3F2JSKL28*.Y<4Q9_Z
)_K0T/D_FR&DU*@ST3 V!\$R33FZ!
M9J%=="!;:U;DC'H9P2VPZ1*64&K=@/M1ZJVIE:")F+A=6EF;!) (VTWH)TJ.EG4YD
M%5KT9(S9!^!;9=.B>R?HJ:)*NG"SGEPC:%DU9-
1(3@5O#F=VP(A6=U@7,WF;T:Y>|,*4!.-<"0TD MQU0@*<4T
J7!B1D9,N*NQ+ZF#!G;@>9/ELS9HBK(B!#::S@PL5!9!*Q:*DN> M4 Z%""\$[-
_%*8)A03/,1/X88;>YY:#UJ2><85(0A%5<&'!9V<73Y37B*=6K\$ ML3
V(S(_HL*\$M3IM;%.&)2\BU@B/# V=)14\$OEL..@9S8H8XQ8!^9LQ\$!M65%\64_A?
&)Q76.2+,7,89V9G1RP8 MFJ1;9@6A-^"B/8N!J/5.&[R]M?

53ZZ[K8NR=T4'<:@L2B9*CV\Z]I&K:X9DI MG28?5D4Y9[4Z3(L-I(V7Z;1
G<%ADY'=\$4402J1,"|FL% MEEF&G+9Y9ARNO)1PSALF50|UP
;X5!COI#>QU!'%>H;N04!\$#)38\$,95NYC MCR!9>'Y_=/102&:F0!#%O":KD<(-98*I-
FPSPFEC!2|XOT57XG=S<%_L*!=!O M2,3LSV!_!N_C#.ZN.(-(X\$LYHHBMX+|
ISK9V>VY_YOE2G*:6.!_*&P?/P.?|I
M=OZ(^_,NU\|S4S!'="+5J)0J\$W1@=W|. '(O5,P!K13;C#-2OA*2QL:|L*7Y\$K0
MG"5#8Q,A>::KRAG7OHQK8B9FD1738)94<:P(:>K0LD;*Q3YK_:1Z*IC|JV
M)MU/OC;#*|7!|HKX#|BM?B?XZ0H\$#;1GR1O&MBN_5|T3;6^@1J*>5%I_L">Z
M)L=@B^C2"|4AU@BL\!8*_;Z|>L_(MD(B830+Q;1N2;G(!4
UW"|P>CN\LOKV<58",5CFZY+K& ME &>&^5MCPU>Y,|#BLF6-:G2KS)U""
(!00NM0=-=1\$ %V.P\$D>-%4W@^S!_MSGLLW!1Y1&Y!Q\$DMP!_E,4ZAG2*GIJ8#?
3/(-N8_/%NUIAI P,FOZ0DY#EZ M0X&C+7%|FAP;C"ZQZ3V9S,G| RZU
F=M+&;2M",32DRWFEF\$IR:4\$|^ M,7D"A:PB,%S0M((3GV-:<:G9LKV\$|RVN.5E^&Y
GTC7FG_A+##.1E? M(-0E)4?@B*-B7@((73*B-
&>;R>EGJW9DEZKEBLF1"@:RX&E0P6R@2S|HBJ M*8FOH;\$2S66T7#4I,
|4#F(!OAU:T.)*BRH=47T("8:U!"!I9>O'#:*K|>0KH M"80/=9C1 @H*8H)3#G,3I85-P010-
J'MZY"|.%,<|GWE(=R'%))Q/J0::X@N MZ-!?!+2PR.S_ ^<&&A&;Z90>V0<Z6?
Z3P+8<@N284,+Y ECP)+;'.V*T:-8"M'?N\$HFYAPC|G@0
M0\$2)"!*"PEN2A69/K#\#PI)UH8* H\#C0,D(A*B'?LO)W%)E_ ^X?R&ICA!6NG
MN2&H@|@MZ"|1_HS(=JFU'9:F;6FWU0R065,JT52WU=B866NV-<"H2LR-KR!
M|4*I9<"Q(&+3P(-?H63BB@B<2DV7BOQGCAQFX4JZ<(%OZ|N"OVICP|J|FXS*
M(@>H'?2NELL(FV|N90T67J-D9Y-O*')>9,+U0DHF D.;SIE;#;87K+-A+EO,J M-
<|&4_3!R8;3(-\$,T_F&3'ML64HP4'^4FR_#-DM?|Z|1Y"NXL,C,6?Z2#P MN>&*;'X|H?V-
=8WL;#T* %,G0I&L:VS(.TK_-|2#5HUN(Q7D,-NFJ8|1T:1U9Q*='*+D M|>XYX<1
/H^-3CFJ@M1Y<|1;E#H|R%,G; Y;T@ D&)P1<@P| (T|J+ZGR*\$Z
M@>"\$:I\$Y/(@1)*=MQWB*5\$GYL.<1F&2XR;\$S)^,3./PS"< MW\$L%&-A=1GQ;+
<%@-3=908CP WM|U6GFY8^NT+AP|@W=QPX.HF5F31DYL'P# MC1@|GK|O^-
'C.|8SZ>^_E,JFEJ8.2*Y(J&\$|RGPE?WT;+=&!C5'7)0ZR_00N+S; M/9?
WD7)Y'S|D='+2N0|*H|6LO"HC4E6-BPY4E)*UX>\$&U";S0C"1%B.0Q'&6
MV6HLL(R"2=R@")*D83R=A@0D;V!%"K%K=R|CQ7>36:@JE'=';+\$ M.'|H|.AMIU8I3|HO-
;KMPNHJN)ZXN+R24D\$. YR9!"6<,2G,UN1Q'@'4-N, M3@NP?
=#>2EU:O&PA=QB#!"F&3%I2:91>IU25#Z_ O"#N8I-K4><+?^Q%V1ZZ M MHD-
|Z@R|V+6+D*G84I,J9C!MU*^C|&FBC%GEH/U*Q0V?
C:16J=^XXAFG@('9D(4!5?;!_+CROT* T4B"?T@9R*3OE6X\8Q&AI"WF+T&?!\$ #%%\$ ^DP4L
)M.^-6OAO,WHWZEM7MR>0I%VMA<|?C/) \$JM5X0SU@E/V"@66V(EP<@42!*CKY@ M=
|%U=?!KLBAS\A/V-<((F|TMGD,|J1F& H9:ZL1"-N(&%=!RX+5*3MB%-;
MU%|"3A^I/@HRIB1_!R.8B.@0135\P3(.5K*DHHM32|IE\70F^5N|*J8J*
M@^%A|,:NO@T-PRP5;K ^%RMY2#-
ZU=7FTT6%NINWE21Y^Q#67'K^>EESKZ3,ZZOI8*
(QX5'VFR7QN0':076ACD1/BJ|*5C<, Y=)DW F'K47.>O.; MV^# 7>+:RAD/"N@=75A"
(PLM^\$|J:&|\$8H9%S@H)|L|^=";CLI0%|A+#!|!\$;
MHY=CY#F3YP60Q5A|YF9\$B9L'8*|/PMON MKO&*6Z|?^;(:?+UR@HUORJX-@JJ6HG?
N'U/(B(I8HRL\|F ""1| R>A3+5| MER1/Z'W;S@NYL>,-. 4(| E4RZ1;1S&3R5>7|
_3\$*60|)U!|GB5|'SA,16 MQA
!Y!=J@Y#.5WP_D7)|&.GFHC8B/EQ&*L_|1786U.A|M7NE;XPFU|^S&NR
M|L.+M!T|#EOE2+!ONT.\$HF1U W<4(\$7(F:/"E"ODFRU-|N,_K@;|\$'% M5/#9B@V52QP?
KVKGUO?LYE9M.) (U(C H8@X,)TK#|"Lj6S)>ROL<-V4QYY!O
MR5WCM%'GS*!)FU:S2FH4++-2EJC|Z|Q.LC1#Z5\$JJ4R5E&%+,M.:^R1T(8E
M*&5RZ8W&5,_>(5ZF;Y_@,=E2|0|O F_"FRD#VB|8%7E: H?N0(9,"F?C>^TGDCCHX
/*\$ _PZD#2QYR7_@EFV283_/KAS*4Z*#T#^|.X AR.:B@: M"(9)C#1Z+MS,><|8E;WT
&B3|(|JT3^4CIK1MV!A#UH-Q,?>F_?@(K?KN=|6F MM;T6;T6=',@K!F|J_-
FV,1%;2'OVWIE5WAF;*M-|S'F|.5XW3;K7T;T.?H5
MI3!\$^W(^|H|JY8!;>&QCSZV)GD79YEH|TS:A&-,*C%(3R4GCHV*T9)I6>&
M"T=Y4|J7A% HAHOGXT>()V7E%BHK,S"1M\$*=7%-RC8=9Q,"(?|T&AF#75U
M0TL0I\$^<>1=/U +Y|!%B(!7N"6:&AG|(FFJV3SZLG
M"SYTLN!.3Q9\A0*W%4R:N<9HM\$<)(9JH2V<|2&"*WR MO>/1|)I*"N
+;!BK/EDL421T+_I#%M)|D|X^537X6,|!.ZR8L MUC L<,W)>XR"2BFR\$RH'ND)V
F|7VQQEQC.%Q6XVN!WL2/F"3/37E+20%G7YI!:.Y:E M=X;8VM*B 8|\$Y"l&M(-'M5<8-

RV^1H9^,=1>OKT*.PT|E18^6 (E-"W0E8 M,SHW6"B"<3!R;F"S;K\Z>!%P;|JS|G3648%
<:Z0U4G69,7G=AT,4E?0GL^V" M2D.HYDB*H2U@RLH"4?B'0?H'?
#\L89@;>3(#L>771G=MH%EP"%3'Z##Z,J@&
M,T8G;I@>2&W5;>U\;CDNO!TJ(+,A|3=5"CBI9;Z"/*F4&(N"D ?'@PDHBBINX M5MG"A-
H|OE;W'1V.@G&>|O?INUHGZ10GR6L:(ZL!1T4)8C=J%A4^/CJUF|1ZI M3 XU;/ K*DB-
WL#,RRV#R%E\;-P5U%&ZHFW(+ \$N7#;!MBW,M+2??X|H6*05K
MT8J:4"\$7ZF"Q\$. '<7IR@^ M\DV'Q/A@3RV% C1B@+8+#H'6;.OM?#/Q"?Y*^ M+J>\$?@.?
O-QZ^6SX-G. |^ &!#FET0*1JXZ.L|OAL "PSL/=M#RER2XOL37:JR.>G7'S;
M*S>PN3(|Z>NECZ^=N?.PNAV|VW22K=2T /;3| \$3@PO2/ 'E.,IJ+F=^C_A
M@'O%|*QETCLW\$Q2T*,7_I,|+|<,&37|:>SXZ9LG-L6!|(IZ(1 /0Y4'-08GKQ MEH
#O'1X0|&>3#4L9M3V=@:.=W44RY:#A0C*.&7/S.;5IA:KD_G=?OZ_<-VSVX\$GA.CD6R?
\$7EEDI#<\$LPZY*9J;KB(^+"JO_(&J-(S F9+|' MK1=BUX|CV1^"J3,|A:%E,"_MHE#
|7L|I;|@;KS0%DFSRGSI97,@HN)'S&9HO(3
MIKL|VY9JN|BE8S+0X_"6:/_"O8O>PR|6N|GP)AY: ^5- M47S99)'?
N7%S;4W+++'9,@)DL_)8+R6Y8>H.H?-'G); MR_SA4GAR%X\$F*?7F(2(:92K+
<:%65Q/*3;+!%HIO2CX#JZ)B\8TFT^MUQIK |LNM*?/OS\$>T,#285 M:"%=B;*@:4D.-
JZTZ@7(XCLGU>Y#6U!W9POPW8(LWU|WM+&74I@IW;6|MWCRC(!N%>&UBM-
8YVMS:HWBZN@ "V=%FA^P0F6;6.^8<A8Q;P M|)4I=<| "YU"KX"J2>:> "I/Y/6'K\$#
O)/!5 _JLR2-L(-|TO>X7B9R6PM MT|XO|\$G!^WV|* G1P|Z0J&+C^4/Q21RH8O6+
(6%,K42OR8E M8Z3 =D-ABDZK/=9R'RPJ9U;P4^@NFW1|JB0:?!'4_#9?/!('MSB'&2-3
P<>WQRX>Q^L_S HLY!;Z?*R7AS*O*4-;##H_SN%9?\$O1
M%2DM0CX>UR9./W&>,EC"M|=NN=2U'(9P).S-5 |?2Q>,8)Q.R+ZO?4=@7M
MS<|OIEUC03/96_.8,:7X"2VNIA!|U>H3YG5:F)1)(^5!ABSZ7'U!\$'T;7|+1 MEV\$R^L*WH3
8J#E;7PH_Q5H*2U=2/2JDTF;L0%\$A1A6DA.Y1#;T3FJDUF3"PV5+5%)JHD43%JHL5D:2\$N
M4XN7>* _SIAS95M7^*)G,|,HU<6'7MXUU10W+(L'BIL7<.DQ8I<+L-YJVSMMW M)
<./F6,9=M75;H*VQ4FK)9W'=.3(|01#,V3#;.JYCI8V|V(|K#Y&SQ3&(Y*
M:'95WI7;,"^)9A2NQ%;;&B;67MOA'D|U)?GVO/#OVGO!13E@H1!ID<;#:#|F
MLB|L1(3_DE95%&-\$J)(TE>Q0(G_3E^B^8)_6@DJ T*RGY7@#UP0Y% MTQGME
M,2E=G3B1*\$|HCW3|7?)V#2=#9NR\$HH(ER_\$CNTCO|(-|W-48WA\$FHS|MMY=MJ.-
H|%.)|C|E'; M7/TF=VU&ENZVB;|;@V|+ #5DS(X#0|X@'
ME1R6R^;#GF|@TH4K^%,96ZH|4@;5G;6T'|%GI=<(.1'M4V?^< M7K-?
S1D>Y'P35|N\$|3#/WU#|S>M@Q>J|<0)ZB%X_O-|OE3)#6O'99-.G&|
M)AJPJ_\$Q_F(|^I@Q\$YCK)H0HU#HW!1Y!'K+3K#="E|=LT-\$N"1,E)HLR?S M\$M-
F56'L"+@ZO3"6|G8")R/:'DCS5VJCI(Z|=FC4AN871-P@S|%K?TY,
M;%Y+2>&AX|8E02HE,5MDK| ^9B+5&-5!LP5%YJRY6L=:X0\$|JK@|K.B;W>K:/
M5Y>"34|5.=|UT><.=H M"31PK.;QPWFV9F @2KCR24B^ (=/-
C_T+LVE),L2\$WEK"R"&-6(+^I9&!4;HB1P2C"A"2Q2*KXU-L3?|HH>PTPG
M\;EP3BJ&5V61N9907!OO+#4;"/0+0HNN:C*B'SAOD9A"> JJ%9*#B^X1(T,
M7:LI@E"\$5)5*#LN"BSSW(VDI:K\$*O2IWNA1 JRTI9Y8|F?I<^H1V)&PNI
MT*L%Q80.N:14.\$H :D#|+|6*TMXP!J| |%:8'C+D0| 0_1X4WP=L5F.80!Y7V
MY08(%^BNP1ABM|IA\$|9|&.;|17G+WESPS(7WJA7|G|FG64!DC+P*-(\$)X:D(
MO(&:&9+#3UF#7GW2RMIM#I,XA+F<@-^B|E|Z&LP?JX!EV S4|L<|,M3A)|\$Z
MOCF7';4IB'XS_4&KMWS=/KD MG%5-7@\$",+(YN?
_WJ.>>='BLIUW#8\$;F_CUMI4>LY;3Q5INAG|DNKP2)SZA4,2SEQWE:I&/0LN1%
M9/AR&92W/5;!C5|= <<%8TDL\$*2ZDU*"^,CJ:.*"1\VP9AOYZ50QZ"9_2B#!QO MY2P8|
>.;4|X:_0H|Q9 D(@0(G,DZ.6S|(Q-B(WE;!*|C^"%TJ@J17/B_1:G|K?R+1OJ(HN
M;5Y<68.)6E8)|+=2!3DE2"! ?M(D5UHZE*|+0_3#B|1XH1T,7TL7;.S2|0VF M
6Q&6FS.|T<\$S5"|F>PJU)&.&'E|W*H|9-G;'G#PL%^HTQC!D|DP!;N:J(|" M)-<\$)
^@_"_H(2|3YTE1;BC8VI9?5IX*F"YQQ%|W1EV_L6WWWRT6U:|4PV!4|:N8^|UF;6UJ
0YH|O?OE80-&)|+KA-*A>Y#LOB);KH7) M|@%^Y%&;U**RZ)MZ|Z#6\$XR\$(D|
|+)-5Y3=J7VUA,1OMVF0=-M4*XTOYT^+3 M(|A6Z\$%|HKI+<'^('F"3L\$.%.4|V)N49,(
D9+PV%+EXP3=@ "JO|'%.@DM MPL?EE43IM#I_8"YB,H*C.KM6Z,A-
TZDBPVZILWW|=G\$|,8MU04?:2\$|K>NBT MIA<|K>F1T|J>I'93|>3(9(O4M5RB
)Y>2\$EEF&. UJ%?_ |8S|OSQ MN2>I9W"-_5*;&&U+*,@<8KBA5FEJH.QN;O|\$P3XLD7H5
MVHBLEUR"J"MSK#W>E.8P,M83,9|R4A0C1%./; ^*(.Z2TFTJS@3W7&V<;;"SK M;JSZ &(?
5J;45MKTNC('VE(|&:-R0-.XCOG74IB5J-8PJ(!|XB5-8KHO)17^ MNP&9Q|-"B"7F?
L_VKI.V@Q/O?*1|_#G1_03EFOCL/Y7#!.PI6(),^ACDP6#(- MLR%-
U^79L1)YD*WNSZWJ?'GCX<)+R93)H\$T>3\$#5-5EI%>Q-(4;-Y@W^CO:.

MSH/M,>TL00)2RY!UH;U%MMNO[4 58_&(%&/ERFOC2?F/9#8_ =+O\0L.*MBC*
MAXNPV#16J'+(540":%34P/=JO)U';X9DK4HK!N.[(:?/O9H\$ MM!*EC6/0\$R-@7T?
8PVU[1V?-RW76>0QR>XEJ?T,,P/0*8XC8@*PQW)BAXH9I
M.A"VN2:*WWFE"96W7^+DN[P94JE!HRV!)%GU"[]+IFV
MO486B!^71PE"PEF[CX01H!K>IA-G9^AC?H,ZO_+ID3?3PAM>*!V%^6,(IP3N%N[0-
[A#U= M4?2)^ (C3GEA9.N&W7I3J48L >/&PA>F\$MC@826*KK0 K#U_PE#Q.FNH#Q@=
MM'6L3&TKD8GLO^TRZ?8GO!%U7G64.UZ#IAC;A)@\$40<5UQ[!-.Y7+NY[]/"%
M5@=#Z2ULVP-W4E[+ON=AO\$0_JGK^4FPI MT9"\$K0+4EG)OM=(J25)V9+6)CK:.\$
(5I*D86%6B)+1,J_:M.2Y^MR6GT*^ MMZ5F(6W&#[FUZ CH;R(>(%TFJ*B!Z#]#?
YTDA00"\$4I%4^&%V\<40."+2 MCP?Y[-,P[\$]-;I4W CL1S@?ED3*V7?5JN;DJZI1?GF,
)#^7P[Y\$5;"Y#V!H
M<)N1!;Y+/E;T\$/H"#\$.-3:"V(!=&>\$5U43!,=DT#%HDS((ZUBS^IBD@*F=O-T
M8=.:SJV1N;=1\A/J+HOYE-K_ ^+ "V(R?'>9= M!Z-
[MN6@\$)"@'C^DKEJ'^^R\EW(MDN69:4, 0%=&"#A[S.\$OY1\! '= _ZZ?G
M=E>H34A%TB(LDK:\/@ \$ZM1VTKKKE2ATB0@K_ *I-%,S7IYDV_[5ES&R64_R MB5
SI6\I'7E8/%W@KIR*Z[U*H6-C=\MNEU);=7!X,0:+9"*1T\IE7B'3-JH M
I-(SJUB6ND\B"5@.H[F"'[KHO@B9"2ZVH %CK!MT'3M\D M/"6WGY'E77[72>!
4L.VX^8;&7WXC9[+_)6^%&[<B;'1?5-M>\$1V@F%Y=[GE_ ;E[9XN70?TNC9\$;N3
R:3E\$E'REUUC ZO_8LAWK6\Y![@"; M4V\$%O[+1IXET%R&+B L>4'# ZB JA>"MCC[+
F[OG<<[?WV;)"7"\$YQONKV MI^SLJEQ+=]+[F&Z&PS=S2C-LYMS6\I;==?L+|--??=.&^
:7V=W>C 89P%\$\$ MJ;@-&%G!=J9.*M^P"SS6H_3\PS(+,2="<@U[IP W,XKW4TE<\W;
=VJF,1& M;QAXAL\$[<3+8NJ"VFA+G5;"?F_MZXP?.:^D\R=8#2HF6Y^S%.Q,AK\;^A[?G
MSMKG&FCN5GJG,R;N_4K\..M05?+MLS #Z 2P(DQ@Z^+85@_ZU7I?5U&45!'Y
MBG7WQ=8;_<(EAZ(8(98=E8>4.9LT5,^#Q(T7)1 '>7MC;:SMGI# ML7.%)>O044)1?
YLWE:.)#&(4^|\@XD89DX^URUT=3[2QHZRU"ZY=*3E>:IMB1#T
5[59CJN!!&IE#KT,GD=PRVMZ(3H-WWY"LES!(%EZFF;CTN3VU;VK4+1RW\ 1
MY6E[7TUPC2A#FVZ"/(^R149T?[%][X8L@8D%F]:[*EJ>>T90QY<5|> MT^#
M191R7J,FDOQM+F[4NS\$OO-VM0W:L(VW,JC'T-0/#-F0E"R[YS_CFK'A6%PD
M%\$02UCQS+#ZOF\JK/[Z57]OG^545+5*PO@*>E=ZNHLUYIMD/,^Z(JL15X[%H M.
[R6G+6EW8U%@&;*YL=M63@,O1TC)_D5KQ'G.[+-]HD\&(J\$%\$_I#FG3-[%
M)!;V).X#)2M?ZVK8Y!FB6F/LB5S1TN;:3WW!6\ZX":B/2_]=TN.R&+*)K%[V%])Z>PO-
HT)OTF68DN7#3*X_IGDI*M^_H'ERHI M+8OM MCFM-??
V,?;/043N83)*T#*A"JCL!,4A1^KSKT=A@X,./A'5", & M*_C&;JIAKP-
_H(K.X7JJG6DI4M)LY?4W0,5AQS5OS01)P(?"?@%C-OH%].3X MT&IP,!EN@?
HNTYV#8L&*MQ(*)Y'7.<5NDJ\$0)=IO%,0Z;-@7\;2A= PUMD.[MH:X>%Y[\0XK=OMM;+;
(YB MR%*Q5&,&2S=&;0_JF(.186H&C_F?/@[+J5]>9KZUVG'?&88O&!B659'GABF
EF9.E<&IH1..X++D-3X', FHDS#6RHK MY'MG[_ +*4I<1N\^Y?
PELAU8YD@1P[CRBSN"\#MB9BE*G[_ =^4M'C3^LW,.[P M\G<>[0Y90GXK).?
NHF!MA>P<_8U'57,F8VH@L\DY[3-P0;E%!Y+H-E07PSIE5AF3
MSEBT)A&\WO7@P[PY42+ M;Y6QKX3/S@9'KA=*X=-
Q_H"9#LK1<,FKJ(GF.O2X!Z+\H8:@*,*H_V75E5C
M)*T3+H[F71MGF_0B@)+PZ\$PIV1@0@%2A8&"ABY1QK>U'8U(Z2'+E,W8*T,
MFTT;8+;9S8Y,2#49V!5D+PK29(+.=FPT?_>>|,+R,+B;XN[7>DUA!*=[7/HT
MVJ>H2<96%90L_IW;2A1[ZI%.SX|+
RL9X7SWJMB0^NIRXV@PDJ,;5T,DA5D";LSF'2G8Q5,(ZDK*0D.5V(PV*\34E'_AF6L
W)*UPB-T,P&:>H53J(*3C MZ' /M495:35!GQ3L[>Z4J.RQN,50P'@N3SN;*V8M6*-
X*6\$YEG-5;:*!1%R\ M=@D\W5!\^ASOAUIP+1S3(_WVS=0LXW8AIM:%C%!7OGJ[-9U
M5;+8_#0?TQ[N2(KI"&\$%L>DP6YQWISM&+3+#*>@+^8B!JJ \$LGM2*VBM"!
M;74%6W&HPTO<\$3)#).:= "M]EG7C+(HLT8KJ]>/\$<("7?B\$@19Y-?F_R
M[V_O;&CNP!B.-SKM.">TQ0-!>BV7GL&.O'S*.L[Y8R0_+K@8!Z%2XAXID[Y
MD>@\$.1NS5SYP21>K!;EJB/A226<)U(MD2@'JUP3HKD#A
M98,+AD)R.W&=QM0L&JU)JC_B2LT\$;:,^,.GXM75%A2.^"DWFH5Q?1,048L(TO MM;?
@<%XG66,V>.7G7H6'I;Z=WH.7'&5A%K]>4NZBB2%#++15>|XCRH!@=F?>#
MY@K5/O+DXEM)1,@0QWO2)H0!9LG-[>R[VX0U>Z.OG;)#\XOD<;E7\$EQC@T'S
MCBH%?+0XS6N),>=*)SDSIJ":@K:D>@,*"W@YXI=
M4A4S+12ODM7W;Y^VEX7F6'H@/MJ,WE9)A@HNUB0PEL;Z46D@Z3)TY)4I.\$ MDE-
"5U'+[V-FR!M*-0+K##^_ (#L2@[V:D=1F7*J_-|T+[H5'I]>&60 M2/+VSS2/J_._^:*
MS1Y_BKUH(N7>I+SG*3'&HR-Q;1;)0_!:@\$NV5J<"D\D1]Q5[!?!O!JP8!+;2

M4SY7*#H;\D\$J6G71KQ!\XH=8:Z^2.8@Q<>6'+32\%04CB705.TW0:3C5?;=
M4;^'+/\$S[E7"W#HPZNCISYPM'0H"1;"IE^EM#\N*VM?;H(: '2& M'3"D:NR0LP-
782* VR) *GE3?A-JF0\,09(OC+PKI8HD*;9-N"&|;|KD'" M?S=?
Q'I^ (K#9GPEX0=14)4MK';\R7\":F(IZ.WO*IX:QI6%5W3-2OZ5L^K:
MP4J2/4"@/T+=XB;3XW6)V4=^7306M+,UI3.D=6,M>U=(UI6?I:Q&?FGOC55K
MQ\&K\$;:U|^.%IU:~4D|(>NB\$I+V>D/1("4GWC1;6L<|B1U(;YZXLY5JCK;|=
MI+X#.P+3W8Z*LFSF&&W5^L=>F|EU\$%NOH^4V,M9FO?4M@O#PNZ.S01=1?A
M29E64R1|@)7*33/8F-+.(*@|RWE1>D8?NXCIW/MK(11W|KL@|6"\$,@6?;\$;B=
MI15|IU:B|B"0+FFV*B|3|^JIE:4@2*55ER;RLIX7HYA0#ESF*W-&_K'>'(T.Z3KL MG BI)
|HIRB_B|4AR.TRDVP\J!/?DGYAQOBHV@;/9=A16P)^BY1U@B0/EF"M-|
M8SP0@A.XYC1M3<#3Q>;\$DU8VWBW3*UPX=>MC" IJOVX.X@)B5OBBS'S:~%@4
M7Q3)P:89:Q81EHR'Z15V.|*FN!-Z1EN9-E.-G"JMV9LP+6>,E7RT;TI*:(R6
M9XP,) >0P+"I+GZ\$@+F5"X%Q*S0SR4_X8?_*CE8"^75:%F)XQ4KUI/0AKJF)
M%>G72Q9^;*@DNY5(H5RDAA_FJR12>,5+JYK;*|-6-^\$|3|T|2QW1SLKVF@AI
M32:..EL!1U"|"B==U@|M/Q>XBJ;>B_EW?(.S+QYM1 ML\$A>E7Q_S+|+;*NS9.8:/>?
_@N=5F%'1|O)#KH?@YA|C:(#|U(6-+'V\$8|P| M4.0@NX*KLF5:H5??
JZIW^-8G+6_"@;P<58"1:8G|ND3RA@JNL'.I?:O(PW3.Q7RKTQV41RNT#?
9<7"B*>!U:8KB\$Z"G|251D)' M7*#C#NNR^Z=%C&LJQ0S'952W"|"O1E'D92-ZAE'K
L\$NP6Y7XDK&I"AT:A!G5_M/,TP!*43Y|Q.2BZH5LTE|0?">\$^!=NOH
:>I5>N&RJY+6|I*9*RJ>#^.)DE M5|9V'1E^YE9K0>LOK*>9@(Q\$9HADM.I.Q|+SJ9|
(B#5MOT4SM)"K M2 B/D%;-XH5P\$ZUJ,+ =K@@RB=
R/W%E;A'#H9Z|Q2J0GN!VIJ9E(|R|NQ<
MC8RUP@VW#N9OG^5HG>:*EAS6L9/<_"\$A\$O7!HQ.B5|L<_T(Z%T*AAO!&_ECG*974|=|
MQ%6,B=86WK\AD@;R8O:4>""!H#'/=RX*;O,H=9(;1 M+T@T*I*XZ)
(.V0BD<%8Z+^@2ZJ7RBZUXZ6RQ/G;)W@=;K:"NMHB5Q\$0 U)
MB@KH^"/_L62I3YAB%FY W;T"Z#"DZ6%HSV-E|PLY&'33> &8<,+ \$=)&QS11L
M6F0_KYRQ9=AP',7",7-=O3!R:\#2D*HG94+;R=^.
MN#T|+P4ZD&&SP.X.HOC!+XC\$2I=2\$1'V*--I9MW,1F:VV,BXJ*'G/P@V-9Z. M=GMEJN-
);\$3UX-9V^4='PDCD(9Y9-4.L|9:MS#?(|E
M,_5T92W3F9?!F2@|H\$>IG;ON+B0C|E*NLC'4-A.F94-\$;G03-58^>RF"&5
MG8(#**VE6R_Z(^2?C?AI|^:|EXN;"=9B3Y TB;\$8^~T|YLD)Y;VZ|CTO&5 M24ID@,%LK
T-!/?LOQB^_(LBA-|T_|IMX/KH*.""TK8Z5%^AW9NC:8|7F7% M\$&8(=%|K65|%TZ08-
<)P'V-/KV+.D9V\N.;<,6I41>X?Y02F)J/:K+EIRJ(: MI>S^40?+L\$DS8=W|G%*X>8&A#0|
E|:H%Y9\$)\$4O@Y|/#-^6^R4FKX>@ (GEMM M3!IN|TXNDTF)5?
P:8AA+M4_)VVKF=)HUTTD>X-J54;87=1!55NDR'XNHY2G8
MBHM19H35RKRSWXPENV(: 0BE&#!|2Z4\$QB3IXZS^4#^J5ZTJ%C(M6 'KR
MOU!;HN>U)\$G PHUB.M|XH,A0\LZ|5ZQ)2M53T\$%-;X*| MF;J|=94M6Y8K=:JYDA4-
|*;*CU9@|S^K|O|&)V|2. M&I=!5^,N%|H2+;|23'/U-+=KHTX>BXPk(|T;
(H&QWW/|0'Z/2H1,=#@>X|9GW%8\EMB\$UMSE*G"(MB4HV\F)|JL68\$SEBRVR0\$9C-
^2:P@E1MPX\Y9PMRSF#5|R1+F*5H\$|3L56S(MJ^F341?9GBGWP)ER^SU3H\$RY9XJS
_L|LX,2ZH"LA|+=A3AL3&GAWP%0XAH M*MOQP=86-U?
#RM%.JL=>T<+6+;A%Y3Z/|3*TT'|>WOI:QO=1SX#I@|K"KT&
M*9<39YLR+MDKB5H1GOUJ<^|G2F(;&LSJLOIU"+!GBCH/5;H5Q|+WU/+/
ML:9204J9:WC(|)5,C6K T&?CF7&'PQE(9+\$M@Y0.Q6G7:/0&(\$BJG#U:VJ? M.
Z+N#.#|X"HG0MH-OR4;\$8'%C0M*G:~! ZDC#R/A&")M"34@5R_@@\$M8:>|MDGH:VO"
80PEGHCA4)JE0&KDQ%+U M\$T*L6+"TIH/JJ|'C'=&7|URB|'(&QPM;!&T1K"J!0ZL5_H?
6C>T+K3=_)6A ME\$@P.DHC9!+ N|BQ4V08FGH*)@#|U?
K@5OGX<\$;&8NV+G"WA)T@E"C&W;& M"5DB5L^L7R,JHC-
-9YFM8^W899MSVH9%CEO:'G*R FM*B*9&ZS"XE"61%W)C>TJOK9Q4KY?;'^)P2?
TF/O|C8(V:GB)'6>7*EQB,G-V@Q7S/N1BUZIK4:/
MHH.%UU/MPBQSHZ2GD@LIC!R7@:QUS|&5&=2FISL:@A8D7"VQ/UH\$|OKK|&. M"-
TAB5":O;PP\$2V@\$ JOA|V0Q(L_ OK\$O=DAD--5;BB71N7Y !|"3>#01 MZ2O?:X0001&>::!
(1758|C7Y#9;Q3*4+0EH|Q%_AZ;FJ42HS;97*F<(0T>+ (M29:).|_*YAP2L-0OBQV_ZN6|
(OS?_O"R_K? ?SY@X*_6 *7:<5|SCIS3E!8
MR8,LL|G"9\$G7G)R|4B>Q|Y/WZ)K%UW"_65@|DNE%|X!QAVMGL#K^
MY!5(U7E%6._X_)?J=?0>Z0\$9NW=AM6K:7'X@P!38HX(KF| #-Z%-I8=TLPIUZ
M&'WX>#\$X.<+;4&<+W+'\$W92;'D8?U3L=70#J(&9VUQ,3-D;'3>WA6 &FL:)=
M'Z+0&20_^ED)BNC_0UNB(L3O?_ES>7_H_83,F("6;'@I_|5L B12=Y-2="

MR:D,Y=EO)Z=(H-S-O,Z;LA/MK|9(#@A|+NV: *|N!9JL".1 MK:BJ6.9:7H8R!4/|0H2-
!EY);T.SNMPSG|,=GT|0F-)H!5&H=,| #AN)(G+ MYQ*TS\$2\$=,!.%.2P2&
N="C)Y|H,DHFP:U,|WR!DB51X^9I3ZAZ5^*(VD0FW/V47@JVL PWX JL!0-
T%MNIH(%A<2QW5|G^9?S!CL MKO>*?S\$#1U/B27LX|BV+8>&,S(SJ+7ANZ?GK9M,:RJ?
JRK)'I^%"A.HQ-Z"&O MR#=DUK:J7Z9:3&)9M3K. X23EUL8V6 M-
ST../B6\$4K;W7FT,"V\$>5Y*I^W,: Z2/H79N_#B.LEX*B7+|20L9Q:|M LL
M,35X|A/OOG#|.06&7="+)FT(=H92@4US>EFOP&OI/C(1Z|O
M|C:M180/1GGH9%Q#GHR SB,EX|R|H_009Z4/;>C\$Z_M\$3GFS) 2U-_:7)0>
MVO@U54LE0"#MX2NQA@E^3)B548HB1D.ZQL98>=)@5LRO!7E/MJ,W38DU)VK,
MW"Z2<1R|Q:R:/ *|*&RDZ.W6B^CHY>|I3\$NJ36;F4^0325WYM(K^U^|+W8WM MC?
W|G8T#F".9V\$|319/'1-PJ:|\$_ZY#>'S-LYFHZQ)PEIU1ZZ.?-X.#V^S M|^|;-2-
)MOA786SLW.N.@#5^|',ZXA>A|F-&LWY=V=USY_ZS 9*@A#\$)< %" M:LZG_U6>?%06
\$IRM^V6:41L|+1%\$B@4JK+R;ZV?B@|'LX|KE<3 M.
@MSA"4"4|4G&C1,ER5:RFYX(6LNO!"6=|)I*Q>/WD4X|I#>#\$K/|"-ST)FD
M%A|C5|IF;C2=1#3?6|BS.^57S\$ATCIELS0>-PM|:1K-2 M(I|_VX^JT.PO
M#M+D8(^='I>)<|P|>|O|-VJ9BR72@#8 Y_%!^|IY\$X9QD|C>E1ST_!/BA|Y
M|F@|*TG8:DN6KF, BG%*H=8+ -*I|^#65,8X+, M!8J+V8U:'-&B%Q29%W;09:+/NA,Q&-
^G>*MCAB_ZY"IT*&A_="="K0|>^|J@ MA|*M%Y|L#)+4@,UL\$#MSG1G)G&D:
ML2A'|@*@IM"4*,DBXNRN+R9N2+>\$)H:F24:|_CC8>!A*#QY(C1#)U9D5@SS
MV1:P+DIH=*LWRA18C@A8MC|OX?QZ|-G08YFIV\$F;_489T_Y=_N0:|I=O@\$
M,*2_D8;FGW4W:|AE6M|6U0FIEZVO95)4)=>!">5/"ID)\$M\$QW>B?MQW4;WK
M)@(9VN063RCXN+)./%|THW/\$)3!PN';:ZP,O6M\$4XN#2*(1#Q,2IM?|@\$@6_
M17@A9'F4HT6!4(OJ,07@K2%!(U/ZX;:"NX^JVO@UU_,\$#(G%*Q=ZR*YSGS7 M(?
Y'"S%8.1&F\$?Y:#?F %\$BIQOQ^XY3S P MRS%HH@A@ER@18A|;
"MM_ \$M"^(WN!);_N#^@V|>_/#\$BJ^;C8*;;AK%GL M@Y|3.)#-B** MUD
9CZ|Y04862RWQJA>NY3| 8-++HE|'H_Q%|@*Z-"V|;K|0 ?0*=,%:>R# MI #?4D4TQ?
2'\$VG5O3T3^R\$+0;|QT_|#Q/N4^HDHH2CU4!.%#N%OA;9L'<
M\$H9BULIGX<4(T!FT=+6WZ(72#;&PM>!.L1|>^L=IAM-
QFM5=1>FE^\$"TG:3GO8L\$/LOSRA+DO/,@GH3^&KOJR#X M>|OJEY-?
3MZOWQP_/K|^FNWBO/QWO3UOBJK,W0|/7IR.7F)WRL*&EFYL\$%^|5IL_>
M^=|QLU|.WO&WUI-YY4_FY;8F',X)I0:1|/#"N C_YZ1YFJGHO:V|T#"|I 6U
M@*+H026S@?7PT/3?:DFBH@0K5K G)A("*(|I|0M& QCH*#04|6956<,460 M
UX.Z|'18|/S)WT\$EI 5AU.EZ^5I=8T;B;V_4"Y2%^\$YJVSH=ESGHQ|T.YS? M?
ZU;>JO3P!|XA?KIG>OD+|6CC5,50^0#
M=6.3|Y%O2_;7O3|5|S|V_SGU:CN9/A,|:I3*.;BH2|<#I RO-!24OU'1^\$I
M*XDAM\$;N.%AWL2;Q%-WS|21VXH!\$33"Q3|9?-#0V\$V)|TZ KCM|6S1-Z>(01
MV|O<+!G?
840(O3>MZ!4!+Q\$>1K|*/"VF<2|F|8IJ;91TL|"8G68H9Z!*:=%FU#3.Z=&H4+2AGX!
MN0%#^@VW4|JR<|0TTW-Z4S^>\$J4#6R*|>8SE!PL|S@8HJ\$|OYF',2);P*=AP
MDT,EOBMN2XE!;|A/QA|CYEJ_ %007T!>Z+%>0'M^AG)!7Z4',KW"?SD^XEG%
M0T&O@7<\$K5!L,=ES7|B%O;!Y>LY1RY^|J'EM*F+Y;@J9;#S=TO/|D(
MLF@|D/Q477FB(A8I+2AUBX<(EB\$L%2;#X%4|B /3N,_?F(_3/\$SM+@>VD!!B
MG>G1:42H-L+GFU/J-FEK\$TTPL3K<'2<3D#R?-"T!MY;LNRV\$PXAQ1 @_&-(#
M)C;:GY17/MO^AN=;|=?)N.>JTNE5:EXM(TV"4>_*A98O>U,6CNR0H&/*R|
MKLJE8*#&.UEUXED+3|9?PH=V.R|Q>Z<79@75Q6S/16^|BELEXZ#- W4|A*H
M;\$K)Q"X+:*W"6%(,YC99FU8,FJ;:):|WQ"SR^030P:6@ M,N&<6EJI&4:X0)*IORS7Z_
!B|3?_O,)/V=4*+;GJ*)\$AO\$|TQ_4S/'+GX M3&V.J9XB72SO>W1)"ET)'K!7').EU/R*.\$&-
U@X6;+2%O@/Z@78U6=PMS14 M3_5?V|'CVX|_6?;L|2?7CT|;V'7W_WW?O7%
|_8XG8"0#PRU8GA?9AG* M1(I?H=|(X|?N';2H^4>;,
<4DCOMW&GGOI^=VU6K_ "+\$UN!;!=J+EO BPL:(M5;F7=4TC3,UC8#WR*8A|
|DOX"BR+)3+U#7Q>;0/3 MP3(=+,_/5S4M'HTV^GI!;_+.6&5E(>% B=8!<<-
B=)F^|+'UH)8%0\$'1,G M:C9Y4=-
B_RB+G4'3W%J|@4237UHVD*CZ*%5)16,%>7FXU+1TIZ7|9=NS)H? MM1B9O)5
_N|E)>|>6("8!L\$BRT EBR)CZI=Y-MB9'5'.!Y0?P(12(!UAY KR,TPX*|A
MXNI8@;|:A4>M34G):7-|O,UA8'SJ#DT;:CVN?X!DJ0_F(B>#/JW9#|QFU8A'
M'GB@C\$(@6*S'D8,>FBSZ(G|M|DV!5:NK./9T7))+.)TNZ2;FUVW7D7+#Z# M4,)&Z4@Q?
5KTTZ+_H(N^UQ'&(BJ/#&&1(6PN4>"N"+<|;PXCFOV|BKY9|QW M6|ECL|(<7V5-
E9F-3SVOWJ MSP>Q-H|PKQV';AO|'|B=&YG94O\$KMRHG,|.GSQ_S3RRC")9%SL@

MGOA.+(SI>Y50f0IE\$%V;=ENE/2JQ.+:;G=?0[#!QC;S7|19^2%KH))UEL:(2 M8K5
ZY1H#I7%+^W+>(F"9P,F6>1;('PD:CK-PXHDI=9I<|>-DHW)U;U+LK_H|%P3#
M*ER0RVK5/(206+J,?S|JUUE6+J.C-;9M*VG;?V!MS6-MJMMH/VG:0MKC&O\$'J#6?
T;FEW9U^U|>A!K!U;[TDD].!C83#10_.;M1X|=A MG?,-;1C>@N2(\$")(9J<= M.^W8#UM
MCS>@. M29GT09R#(\$))7^>!Y3OU32>,L-KDRFT_(EPRWCO-C(.@
MTZ.J4:8D,@F25BCX!:@AP0M@F/*!F5+_5^)R:A\$DY"(QZ,%K|HPB|&-KR;M3
M')T=908A6|1WQ54FZWXXWV//@1(\$F!/:V*9016X_.+ #Q%I9D@Q|3DQSN?"-|C_*MM-V?
>:X8'F3L0E8?0BJH*3DM5T'N"9<3-?1&J6/*"QJ0|7Q23R=6^<<%G3+ "
MN*VW!5):"\$4614.D=*^S('X|98K\$|-%|<*26H':U6B|:6V&1Z|ESLZ?UL:
ME"/:_RW%OT53XDPT,BHKRHEL&V;WJVQH8ZZV)@=*FOKA.DS^3IS2%RY_7E;-
_M6&F0=0XNR3M=E,VBV|10FN:)V3.W@_5:SY+NZH&GVE6^UWN^
M3SJOM|1J|2LLPG71UC/LP%EX2:-D9CU-?HLS/Z+U/3S_HIA>Z"H
M^32X9|Y\$. _RF|(. ^#4 MW XS'KD\$##\$D(^|D%&?@Z6);%9&1F2LG491/R M
|LQ'18XN.71|-5AV|^_JXQJR)9\$FS57|=TH^>#LS5|<1)RI+#T'CNK"9W:\$
MU(V<*PGN(HF8=9H|1U.XJ3I6XSV+^(:D8='8Q8I3K9K>DF)^'M'"(L+PI"0
MO|C^**^P@F9#5(<6DXP9;=OP@EQIB0L<
|Q|'8:@0@U|'&OX0@GJUTTX8OKAH434U!*,',+|HE<:M*I
MC^EFL5O&T\$3/'SC;:5TYJYHQ+6DN&0#@:(YXG4ZB(BGB6J*J'H4D.10EC4O
MP.0=D4P.?L7OM!R0|\$ MR^ ^DWAE M,5H|@JC82;5B=VEVJGFKV3%(5<\$|1Z+
(%Q@C8KLVNIHP\$.7*X,,:&L1%WNOY MU9XU13\$
NSRFGHA7<%%>%&>U"K6|XF#>%T+"M2PA|"HGONO'F(2?9"KJMA@,
MC)UA|)%AXGGH79ZU+||LKT.WQ=@O;.+E9N-<|O(X*&ZL%OGW?*LD(GYE|Q M6>L|!
|J6-.6&-AA>8?S|K| MAD)=;>%!0!E>U&5@JR+>Z<:"REK LKV5_5 M;@0=Y>\$,?VLER),I?
PI>|\$28*QD2;-R-'ON M|W|UH=H+0_5N#C|BM1.+_5,#L-5>U*S2,9E>7IU8)6W?
(|Z|W)P_ I*P|O)UEWU(|1>6U"DORJP^FPYR)4
M,:4>250|3:5_JQ#:8&G)*P^FB/66B1GG=EXX^:KW&E;-RYEI&W&:@/Y
M':.#|>09PB;E=GN_|<6>J==&3AW/|8(SRJKP9O3UE"R/%9%@-<@G"7_?%9KD
M\$|R>W4720"UHU).720_*3X,,:&WD;W\$UM,:1\$|4"6"?J@=JU|HQFKM|F7C\$K|
M.LD1TLQ!RM&_2"L_""OK(\$ _GWZ;+|> FP2&Z8H+|HC /+IW)%GW*W6&>768 M_R?
9|*/9L1SRX6|F^C,|C|+TT%V'+6^0H/0_:%2J3S#44:(WGY-TQ\$WK DEM
MSG*FD86:&Q7(9BCN267;Z|TU49E?47;-E!|J1M_3"K:1L689UU.JE|UB V M6JF_3GY,)
(\$HY*QJRW.|L\$^Q7)-K0|+U=\$-Z|:4|G,SG#
MD9CFD(4+9|Z|1#>B>H_)O5@^A<+2|@QF-D%3<\$8A8BD|?@{OVY<-ZPAP^_-J
MT3C9H"1ND|NKUYNWE+3@A+MZH'=|?,EG@_PJ7RRZ#?<>A>FC1*_B+C;YKV%
MXE3JE;X*7FZB@./3|J|T<_|&R_N.>NRA1W_#/5YL("7(KV)KQ?79O6+7ZD4 M0'57?
8<:=)154G|O6C),|B03#|1,8^)|P9|VCRU4>40=?_7 KG;*:Z5QW>XUP M"Y6/B=,_JB>H-
/A9X6E@;KX4M#XE\$N2>Q.2JP3XG8&+Y9K;3O1Z3@0&)6=B MV^ ^V41?>O;@(\$5\$'H?
|Q|/7U#5TOY\$S.- (NX%W)DNB)D2"ZV=|>+ "L?6/&. MIE42W7EHO2*5(G_*%,8&X5?
VI^PUHP%/#B4^DW4DK)@>/B+|GGC/X7*8+.VA M;!S0JD3(D>D?C76&:G,D=<".W) &/)-
M6W|6PKE;H:.S**NJ#E!B@/62<\$1DILC2'8D5"X-X\$:8=
M#_'@WOV'V>S1|]=HE0TC/.N"*:Y\$>_I_LR_1C2R4L>J'AM<)"8%9#NJ+'B2
MDG0K:"V4(L*14(51AQV/OCXT|H0Z,D)_1QV6\$AK/#1@EO%X)|\$V='NN4POQH
M)!1C1,M^J8'%>GA-XC.Z!KYFV_R2@J01_X;+ # M;5B>O-
|8B(5W8<6'77GW;:EX.||Z:Q&H=3LC=>'=%I:#R*,6%'0+.% M"
<03NHX);,\$CT718@WFS'+F4/@YV)^5!-2O!G0YA#O7%4-F@%|,.5|A;1\$\$
M6MQ|6;+NP#+F,1(5ZR:|M&^35-FOC^ -KF/A\$,P|0X.@,%-,=,/4&^|"09/N
MY1C2I5&RA6HCV&":WQJ<(T'\$USCBX-K?!@/_3.V)RLG&JPAP|2N+% QDPU M)M=
|1)H*QU;A929U<@UW9.L|AEH,KQ:P758R"D|>%N9>^J.W3S'ED|9(Q&1R
MJJK9DG+=4VD@5|F0|9G\$E|2,\$(^PP5|2#NLW=|TW1M9" 8@#P75:UK>EE9< MP*,
V"12=\$6.^9X &F7=M;_*J*0SUZ"QKM\$0|H|&D 4%,XK=D/U=J/YD"7*FZ MW"(%D9F2.5^0-
9H3X\$|L;G@ED4X342|-TA%H0:\$;*(4>"A#|G2OCBH9D M3D(YVT|T%K|H|
|_#_|5^>H87&N@AG"G57|M?"0)\$X%VZ2"/\$'X'(F&L M8|>/LP?>1L1.P;E=|YU:-
J.YRC91U|M;-M'W3>FJB?.IU2EL(^D=AYA^F?0(M+L)_\$0('FR*\$|4GGVCHW|= _@;
XYLIYO&U1_ALP#'+-%U*3=|JWT.DSY_VB M7EAQ#WO/&*BN5O!PK|X|=WM
:16D88;31%=>%Q=|H<;AF&I%1AY)5I'@K6A=\$'1Q'P,)Z\$*;TP"*406|J&LFJ.-
|G&6&#,BN"6ZNO(+|0?ZQZSQP@X 69)!WBK,&5)GA7!|
M.Q+29;WHK(F:/8496LZ\$QD_(DE7013G=)MM'2P2'SPP66Z975#_88T#3B!
M@Q37L,E3;6U9I&-(9N27DU|.WIR^?,:/C7\$|L:F&96\$9D=O*0LR)?G#,11U@? MA(;

(^E"7\$3+6+&\$K9?<=:+ABZ?!=!S)'AL?1ACNDU_Y\ MU(X7.J)?
QR%/2_X*3;8C+Y9(#F%7=59@63_2O(>")!(U=LGRG\$2A&JG)!+FAOB_MU3\FS6S=[5QA-O-
G4Q9)CZKX&C%,XJ_NLPW^9E!:"@(MR9T\E8==G7;+JY
M.>UQ'6W\IS6;"S>JS9)K82M\$>T'P/MHK9X^\$X/*LA(/74'I/\$3D10RSX\$S+9_M
*C0NH&"\$E.02+<8SY8CHP6.<6_M<-"=WC59V+U-BD?
I'5JU\$T^WP3X0A91T_?;24|\$-8/D7\$JL'5PJA>H!#N,BL=BB-E@NC.XU)<& MN(07F\$!HU-
L;>1KB\G_8NLIJHUBA7_AW6#*;!U82H:3\$84=T(X6,Y#T&8& MWI!@84!5,,4-
18%A8;^=;>+25&X+SFEPI\E9%VX7?B99^\$O1MY;.:2!43\FD+ M4YT\O.B\VF(
)%;OND5<'KA=M-,^I)2;F%WH "5SKQ MAED?M23<-
C!RI8R6)KC*R)=>*%0XYN4'K)U)J,\$=.A9K6'Rf@UX@'JX.OB4E MY7!A8?ZL++J
%F#/&@:4&%OLL@\$/>NRR2_954I^*M5_E=I*H"%J\7M6W!VC M8\;#%8L;=6>=/O\JP
T^\$!/?_D20G;Y!_C L-%2F8N5YO\| "YSC8#).-W43?
M1\4_/_LN>O\6YX\>RUW">69;IF^/B%2IEUFTFRGZ)X%J9CTG%R5-:6<A\K\:_M)B?
S1^DHGE.I&+)Q8Z<I(^)_F0\VL\X=K MC"*K\|\$ZF-;!\8GNK=O@880*-2H4ED\.#/#??_I
2ZD->YM>C?NRI(;P^)* MP;\$_B&_5AM5ZAM1R3@8P3" K VW!TQ_4J+D-R;4GR%
_JFA3\IL"6_LDM*\$ M%T>ST^"J!/?>EODVIGBPNK=<=<3!"Y!\VP0ZI88)W< IG1<7#?
65U(MP
M\|5%IE(5\|%V>Y8@T@5EG@(W/2\$J.VOBQ\$9+1)WW\|%UZRL<[WSLYPBQQ\$J(KMD
MEE#B\WU\ C*\$X\$T;8(%G1V28\|L9EZ>=<&#\$M3AR#/_O/_/(MS\NIQ\$@3#O*Z#
M\OU\I'4;!\N\BALL7%;1M'-WM'C;!\NV#)+U;V@|BB57#K\$J6F\|9W.%\VPC/
MWK^ZSK*/D(X\J#(",ZX^8H3A3+ 8\CU=|? M2-
6#"RJ\$N7N=JEC4BHJ8/4I&+1ZQ9(7C=\$Q4U:\4I9%FO4\$=+>Q6BER,N1_> M4?
B:48#GB.C+RH@CQ5W6&(509YY3,\$NF(>?-EUF_4P<=M1O/_LD
MO)ITC1\$+&+=YP=FD6\$Q:EZ3F)LBSV\$VUWB?;P)?>!.4E(5LXYAEU9^3S"A\$8
MWPXWH9!'HAE;E=M6*1#VFU0+P\|C\$@^U/^J\$23\3A!2?8G\$;NU)WGZ25'%PA
MT\|3@J;7\J=JEVG01O)DEDSAXD#T"J3PJ2'O\!WNC(VH>L^~73=PPE=JYFB
MZ\|\$(R^<#T7>I#T7?1T2G#^VY7BF=R>N0CN";^'7E+3A7KSG\<'HA
M/80AI@>>^66KVf4)5OM)%<|QH/J,\$6(QE:1S4BZ)+CUVZ\ICEE^>'>""TN
M92;"2R;_M\JL**X0<^T.4%Z>Z#Y^GPP*MWM^AAM(7\O>|:MNBLBX2RO\|_WR>O
MGIV?)'-3E\|N2OQ\|WIR7;|6!_!P%CM,6"2V)3#9Z9\|1Z9DTMUT8(6LA0'A3/(X,Y;VD
MQG9@A+WN(-=);ZU,D8_S+CU7G3U^|?C8YR2NJW1L/_9\QJ-=72Q)-5L^B(5 MI-
94PE?!TSWK7A;2)K4<;-F,F6W+Q8QB%T?IX!_\$@AT1\%K&O@/C^XO-XYK^
M//2B1R8J;6.H%?I%KT\W<;H%=;VE5WH_!8?A.SN18;Z\|HXK\YP67)W2? B MZ17-
;3'/(E6WNKX,"X,TWC#|40,K0@@Y#VP7R!Q\|B(G1V+1CFB;-0+D;J)76V)
|F8P&BM/20V""H\F9V2\T%;#)84DJB73D\3N7#| MJ=Y>DS"1CV^;-
1BZFX%"X0S%@K=W*YX^J A=L=010R\;+)H?LT;R\DG9 MQ\DR6=4\IDQ2J-
J3;L+\$FNNLA%5%R#KH3QNT@/2JT5\$ZX*VW\5S@2T^L M\$-
^2\$|KKIL_5F4N^63\|#D6ZK\$MAO0U6-(Q@,#!S(.Q%2C(B&#TAPC80'G9D
MONMY);Q==/;C@+ROMC8G%Q"L&2H6SEI1 M=MZ\|=J:F\$KG>+H=SF^F,S"02?
S(B7?V_2L'6Q"V-EEE-75\4J1_O;U7\|M, M9N(/-1,^H\$D;ZA_<|QJ9=&
I("X9\3\G5%%N35PI3N2B&9H87K81#1L.?!\MO'AO_??&
'RDS\Z_NG)BY_.798LK!+2\KYZSV3 TM?D/<7DN D8DJ2_AEZ M*=49G#WJ\QYYUW3_?
ERK#F",#3W54_3OCKQLX/K":4 UT82O<'CK#&\00BO(ML;4-
P\0I&\\$M;'DAA\$6\W8U\FT\3(H(B85D&-HSIG,^@!TD\5.K\$V\RF87AI!:99,W-
(Q>@4+T>X(Q!\|%>)BQ\$LX3_9()W5;3IMTW28< M9-'PB'6,-K%-Z-19\9I%<
M1K%V^R)7Q2QR(W:%F4?RJ9GJNJ=Z,^6#4KXK9E&+I)\$CE=.8?' \|6%LAP4VH
M@.4(NXY\ P#I(KIOAS MC-*N'= G8B- H.860;)#_ ;O4.LT!*RW=;IF!GM-V=^OKV^VW12;
|X5>TJ%4A M,%0'W_I!);\$+|S67#BGN:*FT7A_-WJ@LD)E+Y=9G;H_!JF;?;0Q1/TPA
Q9;:_F62VOS"9;:F.V)X.SB^?H>8%,VA7&1WX<".L%AW_(CV2KNL0
M)NZ*88,#L8O(U@+;*V\IF9P6="=O@K)/GEK=;!ERMUL*MQG_DX@#O#)\%(W'2
MZS3)M"=\$J_\$IX:3J'<@)MQ'P\7\$4ZZ>M\5M)U#^ M(Z%-
C9P_Z>D;&V7K1GA=J"550=0X;W"DBA^M-8<:A7WJ'Y\$35+_@*@_Y+F<^
M%^8N""%R2D"8"6L/"PILBA 'A#_.INTU;:\NKW0WZ7;V@'6C1=
MN;.#H*G72N*&R+9W'G'NO=RB&YFI4N,2ID_U^G:ZS%5.84T,0>B:2R^R0L\9
M;:730IY6_|3Z/_#J\QS(L^KN7|=0_4GT3WPH4\| M7OT3TTDRG23O9Y%U1#52M
15CDWZK"CGZE:17R3\5\$.9\N5K#/\Y0HW+-+,68Q^\$?.3LD)2A@?
5&,*8V\$'A!\^%/@""UJ1(;UR((IPR^\$*1-B.U\X7Q2LH)=^8_"8TH799PKXFH-R:TU'# S\|
I(A*ARX26;@ MS3F*PN&A14"\$\|<"\$VXX\O:1GA6)

{SNW(AFCR#^,)MF6M,*T;Y%"18F40DH5-MNP%WI,)=>H_&XF'RUFC)+
(C:.&%QYG:9/G\$U91A()4_HJ'?UHG:%=%P=-"&N-M9TD+4%IPP@4JD5Q6>O"P%ZG=IF-
PL7\K.N+A(^QV\$NM'J24;I13,?:6&L(W
MJ83I[@14;P2I2M>CVW""019\$WM,M1%V/<@[=E) Y?)-#L-80)!Q:MV!E7_0X
M+3)B!"X%8\ 7 HWKV"A(Q#R1AUHQPI3HVPX5&_!S\CCUB&1
MY,\$Y/1,9QE[7JAX\$;;XI',%\$@QR3M@| #JZ@\$UUCW9(*: MZP\$(&,1SP22?
(&J\6W>V,TD:)5PHC[U3- 3+2:)(.L*R>Y6Z\OL@5;H-2_O@ MR3-A-
+X7S7%&G30Q\$X9GIU""MZUM\$HV;&OOXHP=4MJ.B.RTX->E6M^>BVOY ME"LL-
ZRE2A/+&G1N\%9BPXU,Z7S9S?Q;IWP UQQ)'(WO1 N?_=%W&@/.V_|>PFZV3I
M>U:C\O&BY)U*ZAAZDQOI'.FZ)!#L4H8VIJ\$Z4QG7JD6C\K\T!L9NF\$JCFI
M\$(ZYS/U&8EID"O37)F)XHVW@C#H^_OCK.B5%2.+=0A!. ^MM4\X8DH\$H&A)7
M\O=7#|=^6Z/P^Z M8J,\%VY+01?IY=(Z\BUCV;/^T1.H'\$MZJ4
3>:05627,MTX/,28./P2NO5 MW?! _R-5M=_ '\$<;I880.E%T!6N+.(("QER0#<1W/RK"IT?
ELC3!*Z:MHT%V&GE6PZ>S#VE\$3GV4.GZJ0/44ESXMV4.9?"="6+;<\$T.M?0NE
Q^IQJ2""R! M+L D)KR25\$-%8A/I
MPD9T'6L5927I2IX7932<9AUS1UYVY=X8S0SPGDx),-E\TE8).-J.>YW""!-@
M,2F66.IH7HQ("N&>[FME'(T.OVQ%_03%G&11I 1=0)+C43WR1Z#&DVKH2DB-MX?
&"5Q'2^T7RBYL;KII;JE5"(Q,9NQ('I358^NN=-"1N.G+O=H4QFG3;)?TS MF+X!%,LE8I-
D/3EY!-LMZV5\;=:Y;6SBH#^I\P3ACUSJH\VV":)'5;; 7^H=D M.;A8@3K>RG9GI
K,+)&:1/P\O1AXP0P;ZO%\$CJ83R/7\7R;Z#>^IZK/GDO'
MXSIO=UR'P\&9(1PAL3L2)%WS61@6-//@=%5T_%*#X+;GC5:O2#)=)7C.S6JSH
M2IV!SF#J#IC-HN, @.1?/@V":BN,AXV3\MU&.:2UM'@'#F\$CDDCK@6'6L/_C7(M,&
<4PWB%V_BJVP8/\$%QZ*DS6:V\4UHN4>"*AO^"NQG/GEB[VUIT4FNH\{C\.. M;VW\Y<3;
(*;#R(>J_9M)^G_1SV,UK=L:-%8->J)7Y 1Y<[!^=4S8H\QW42
M&+I:U<)Z%ZJ;L\IR2O"QAS&O;F-30D#>+|R'|=WB9;
I60=FBXK%NC5\B33WXF.GCP_EAJMF'H84'A';.. M\$#1-
>VW::W^05RI@L@/NUN%RCE7_ ;I@I/2W?:?G^GBRXX,4 S2!"28:12I5S M#
I,1<11>@HGQ"7!Q(*DD9?0 Q>D"@K%6+DIJ>-^(7YG#25T,&V+7*I'0,8M
MJ:2DD@IY*!%HHE2!7;8.DPEDLOV;V(8S/#\$D:#%T;3FLK4G+BRP(5-1W8/BI
MEGKE%8,5N\$J2"NGYO7K;3F2GUS_L7R"/B3;:'X# MS6\Q&K/N\VROJR<I-
#9NIZ#FTY9ZQ)>.H,H&KX1W.S*(^*8Y&OT34-1?F3X)%OF5\$:QGQ\SV8
M*W<#I\H(J3;C_Z+:^>1@2UIX#%)>IDA2IGX8&8@'I;Y:=VES\19V\I_SIA
M<\$\NKEB6&T)C1,F\$LUO!_ \GGQ=H@M7U\$P@B,B\;2 O)3A05O-#B3W5,BO3\$^ M3H"3
.WHU:NTAX9SRDZ+@DI=[KR'SLKH@QG;M /S W-QR @EI;GEM9296G(
M\K,S5YRTN()NV&JP;:8.(N4R2\;GL\GSU^+F)EQ0EQB;U<%^QM(;;"!4PY^M
UCN/&ZS)\JW-'OI+'%4XFR+1G@FJ>")FWEV!2,5\$#D,0_#_2 IFOM&EQMB M"W\$-@C?
2PUFDZEE?:?X\NG7Y;X='DW9WA!\$%#UI86"RJS42-H%6\&2Z)EMT MR'GVF;
(>I)2_6BL9>C>YLZ_&O9-#TERYI>52(I>>5*,R0O>\AG M7WN(R+FH2#<85IP=CM=GS
M*+*>CV3&) MHISIFL#B2=\$2P%A(-P7B69/:6ZJ 8!B#-*Q%-
ZT75\N9T,>7MWJ\5:V5QPR% MYRA\QNW69&7;?I\|VUV\$^C&OQ7E?
786T'\OJO)!J\4)6^(KA)>(,0=3W'L M;37%2=P'4AMV\HM=*O636?^H7UWG8:U2-
G1&Z5#[2]_ ^%\$B%CT:WFI6B5IWI\$,I\ZPF MLKM6XYIWR_5Z\W\,T*9Q)#S=G&
(H,"8,F^#=U49,NIN\;-Z\31, MI%.T3\I%4W'@E@V;<"98I2""U_&%SJ&98"IS(7(Q5/XV>>H
M>E'OR M?Q\7HJ99H5\FJW=,6N*OO\$U.&&9Z\EB\I'R-JN\$&0S%KU7*_S M<
AK7K>_@YB\;+M=H.Q+4UV\JZEFT.DV5"P+349)J6 E\N\UA@':X_(O)+R
MCB5/ABN=2TG%XKQ2"5%DFJP\$PY>Y*/1UF:\$2ANS D_ = F)ZTH(L)8=X5E;WR5
M^FCVM_J20J5,B=ALUIF\B^1^1;-4.\$B5JH227/#L.>6E9;AMB%&Z(N*FJ"P3
MMN,Z)R(YD((AHJ^1VXHDC:@84I4JWP='FZ\$A_.SDX7M'D8H\%SQ?HA:SO",
MC0,,1.-9IQ9KE-TT*;D;=TA*N\KC6NVH2-DU\0L.1N'A&?:ACL4\+M.\$W3Q M"7Y/MQ-O
50H^*TZ#'#9V:0G+Z^N)+/\$7PPC M559,3M9!7JR3%!O-!NUAMJ?;
<" +LZ+C9=4VE854\8YF6G"^%#"9Z&MVC6GT M.KUO>XRV*W?^: +C9#LA4&-
Q>ABUZH798^JC5>NG \01;3QCXL/("8V*I9H> M6:>7@I3H\$PER+9CS3"!OI#196R*9-
-/7XC3X&-I>@M>\$)0/DQ!_IYG6!W9 MT'3C1%+=WQ,H&WN>IIZ:C2*%=_@ 0""Q?
6L)1CZV)1./W76.?H_UDQ>-JQP(M>B"J5AVH'TB3SRQW?38;GKO\ID!UFL*_
W)^XZ^)7RXR9\ID=2HB#B 3H>[?|B M*;X!K3\$.)\$)@%B4BV>>M)QR1,
>EJ1H4/'#&1LYL=0RN4*7H.PTHRI1G-O\$F M\0.-V8WB^H5L("Y+A6GEQ7D;2#?
>5\|M9"#P)Z.IC#V\6LCZ^%YTE_I MQX.N9R=XH%,0VYM%V7S^(?HS2O-M1SO8;
I+>%%+ERAP6J\YE\}@CA9"DC?DJ87EB4B-11JB5-

=1.0HX;.37&X^J=PKP0&J/=^WEFU>!ZL6CN%R,6N+!*;H"11>
M6YR30&_+VZQ84/*87AF<_W9V1S/NJ^ IMU_UA+7C%[-911SY%)&4;5BSZNL+
M)UE"#&RB6IU(4LX\$36,CSQ6Y2|724|>Z/
MGXC#AU9>A1A\$;SGR/ZX*N9!9B+YMBB+C#AO-.4QFP|8QJF-3-IY 1TV!!N+> M;4T1?
@S/LI+RW"Y)VV*!=CRY^<"A;|9"OP!T%3A.BL;*YL8#Z9XM%?
A6^7S\$PD7|. @KY^YA>@N5|_E.MPJ;.=M03!>GI>U@95|+N8O)|^O'YS3\$5J;._9R8N3-
R/CY^% ^Y%^-K1|'\$GRRUN PH)*3;'V9\BDU62S@3L'#'W
M>;G:Z5*G=4)V4Q(&|FS<.EUW.W8&Q>-JK\$EZ."TP+|Y*BA,&G+Z=.|)Q9S|I-NJTG|Y>?
G3TY/WOQS M&%61PK9VZ+|(J_HLV|)%7O7EH|,T\9U*
<*9^A828;3=7,A24\$EQ67J&\Z0\N55F;)OLO M=MM"4(YT\L*JTY?E<(0C:6%?YD-#
POV/;'4N(R&VAHP0OI\$W'".W,A/^-Z|M--15DH5E*'G&92DJ;|8O\$F.H.70RW0)@T*4
E" YGMU-'0GM18MAK@?|.7H MEHC=\$9Q^T0@MF*UHP=*AON6'14|R/;*C^|9S%_94?
0BJ|DB.|WYD+ #N!FMQ@ (M9|O9P?611&)74I>DU/.,CRR!J1+*% ^IH
|K27WG+UHSZ%_N8H00.|1&1SI M7O6'99SIF,.1^'+49|1H|RJ;M"M"U-
A0.I^#.L8@^C1*0%G/6G ^B0,6/UN' M#OC6JI1L,=V|N-4'^@0>_-3 @|H-
X,/%#SX)9|)4D/\$"1R5V(FW3%#MB|PM MVH&\$.W@
>WG#8'UV33GO*,M/XZJL>23FH<<\$V'PDJ@|PT:|?|@./4G? (#NF M|UJ-M
O9Z9S|!.UNQF#\$> %JZ#Y+NW^@B9BN)C>.:!BJ4VX.#>EQ_3A_:T9#WG2N
M69|K. "^9:09|0^AMT|:9KAJX|=Z_.HB>(SU!C52_,EWR/N?;|JKU70"/Q0R
M(1OEGFU'M^* (2?-V-05679328:QIDQB=495(|O(D^I">.HE8>T!6;1@_"
MZ|TY7M.K6#XD@1S/M9&)LAY9|HFE6UN317|)&&T;%IZOI*0U4E;1QVZDQ
M>L4^+_,P>/"D*42'B2# I;|V?%FR \$*+7K0X^L!;B11^3 X5*4E-@G>W|;
M|4%P\$REB)K\$S>GWL7^R5DHB(RIA2@|%SUDTA"&XYV)@=B,4VVEJ|QEC3%H%9
M=^|PT:@D;|.=("N?J|J2L2N<1P9JN.*G_1)0M@1 <*=TZ^|#|9,).K1LJ5I
MA=2/%=!'2BL1%?KQ*!NGG7-+=TY2C+B4;.L|*12HRZR\B1C@^: <=M?'-E^>
MAXB*S&|CKB2(&W@M GWUX,='\$(T-W_Y;D0='?W92+8ZRV;.PX<)>AR>OQ^>*_
MPAH+=WQ4-UOYF5SORF_ |A@Q"2(BF/4Z&Z<|= ?ULA= M%"32 C|MYW8\W!E8+?
02|1)Z&Q4#=#B!%@:P"M4,)&_%A)".*|X* MY|Y83G1H5V|HE1,F'?/
X*)#RRDN'E,>135&.\$N#;HMKZP D>^K>713S&F/7#
M=3|#4|@60"%Z1./NH%#83EV'6OQS;;GAJ6/F4SYT_E%\$ _?C1%5I6%X2_75Z7 MJ8--9|HD-
?AFI/(>R5%APA= ??|*YWE<<.=R#F' (=W%<6/+A/LM"|.I.^KIF MQ|873)W'Y8K-
|;M<(SG)T&>V._;8QW)?1|_.89^&UME^D#V&K(O1ANKK:6N M3XU^Z>8% @&1MH1Q_-
|U&-^HAJN|N6N!=1=\$;1SL|QH\$OJ:C"P%*=K,9)H0(MC1Q?
T#J_E'R04NMYK\$ \$IP>RF7D;|.9,UD&8= _V>RC@SI8GQ\$)6& 2Y%|:;&6
MU2:3WQ&^@QYW04VU|2ZO%T5_S:F0AW3BNGKPC8;H_M+3I6Q
M@)Y^OJ2,^@CP7P#VC#")K!8|/H*8C>SMOVK/Z8)L_Y+,AZ6D.7^NK\$DC|O?
MNXP/0\$B2|^GOW%Y;-|<4IGPQQ?#X! N_G|. ?KPYL3Q6GXCZZ/O-MW*\$'2;^& MN1
)DC/M|_8@KW'4UBKK01WJ/;>6B,R|G3=,0>+>RX<,".",&&+0\$V|NMA M+QX7M*_
E"F!OJR|Q0AA>XLOY<_.!O8SY+=MPE+:%VL1!;81;1T.<&8|EB|() M2^JX7&:STR*
<(:)VGRC#WFOM>#P.108. 0ZR2O=^?'1|^N0U_17_OO_C5|+ M:9PH"\$H"%?
^|ZLNL8.2L(ZY7HK\$TH|+!A9OWF:B1J5;7CC@|I9:MHYF M/P._BZ?3X<%NS:A;.
|9B7%)_P@A?*GU3(2-"|D|Q:9&+?*6C&QS"@<&67S1%
MSY5)@2+ #GTE@|ETW24M1\$|V4)FE9HUN"=9,8H,M1#-:|A2>&4HVHP'?\$.|) MI
M4614L-S,:AO7B:18ANLCYEKL#?XX.U=^&76&M\$7\$&%|@A?LO4_2J=N*2BH#P
M;M9M\$?7902446G31L"O6:Q#AWZ?8_-0DX7C4?.)#9|<'U\$!%CR-JY,V (H%'ML@J^% M-
G) \$A.B6L#SN70^PO%U8@,D+V@10"3S>%SJYWE4;9M5(|B?FP(7)B)3(Z
M234H'\$=TT\$OKEM>E.IH|C<+077OU3) \&HHVS6@,.D@>V9LF^(9U|UTK2S!!
MC*;"RAAOK/*SH1:ZW@M2OV6GM9M9SER(EPJ9K(LS^J4ST#ID)8F-67;7*^EC
MZ>+78M%AUFJ*%HT4=KVV;T0M!FI1Y7|M-6-#!VUXE\$P2-I0VH;,>"
MR=QXY5E#CA>*R8"?|@^1M|WYEH06 <#WQF5S63=OR?^H=V\$1L@NGO=FI4HX1
M8J2N#,,/&AG@%;H|4KDEL+C>|K-FU'GN>+MV=-W=\$FN)?&-\$3ZV-1P|HK
M@VNI6,9!P3,|2 SN"8J|)%Q(|.G,UY*|'"AS6DB%/:N2VPF*Y14)SUUIQ?^KA MDLMB(?
G|OX#%_*35;:TNW_U4O)'9/T6&|32"6D_)VNBRB.F@U<-3?QN_WO< MN|HSL\$ _WN|V
.'DU?V8J2^)% "N?;5:_'J*V,=GJT)Z>';XAT M(WVNE"P9\$2)6&@=19(83B<|+FOIW5V3
7=!/EIA=B8E!;+/KE?66<>,"9^ ^M MY4Q89.)UY*ZUX'#0RZ,6X,:K5RU|!#^_
/1+7/YB?|R:EC1(Z|9.|6M8PRVA MH?:Q)3(XJP:3Q448U|-\$AD&YZ*'%A#7755)_#
<+8AO*W7HPT0\$H-3:B)*J\$ MB^R*);H@!"G?R|'E',NKJC"T!?!2OX\$!I*|?
>KGB43X*^HL&NVX+KG#UAT.3.*L2.&IL5X8(O M2!D| 1>IN2&|:(0D:-

G1P1+4*!),=V!D1),YXSY7@2W3\$9-2F?A 2TAIR30 M1E(JWU%= AI%HADR/
/XSET\TOB5Y74P."BS-,LH\|+|!%>4*JA?1)O!<-:N
M!MB;2EW_=6K"3+,A3!0E!=N=TV#0BXHRA: YVBD0XI&?"H:5Q+UBZP+|.QB? M1R4(
2D:D3<"!N::%|ZK_^F*5AM+=8T;WDKG8T\$(.B1'1<12-0;\$)IA)V&2P ML65Q1GA\NX2?
(DXG4YF4=4^I\$+2479"TORFS6#P\$P\I338 OYMILL!,H:&0(ME2U@(3:-
)-/L!O^1>NX+9"00+%B\$7QEP;+I"78,(D?0ASI!JLC.503,+!L>!=TOI 1%O\N@5(HB:N
M7PV9^8\Z2R!M'((N\$C#64C:--@:::EFB4"9"4;AJ1;G(:@M@+Q<*HDF-?+* MTX-
C!H@)C?6LTJ|SG9:I-*&@=/J:GX8RI\$&GIFZ;?ELIPZZBM5!@,U4GCUD;
|FWG%9#N/ABG9<; MWG--L8)V#F!72!\!8*G2#T)VB"8&_XYPU-XU"
(LS/:|CYKVCXLV'UW)&+(Z M\$7P,S41IZ:)HKKQ.IN=ACY4YJ9=V1*\$: +%!N@74HI!Q
K96>|C;A+23ZA#N MK=NI:<4K,.'LWL?%*_F1C@SE!>|!=I*|AZDF);J1ZN>LI(W
MAEOI<65,IC SHL\6YH@Y=SOQ#<6::OI,IZHTI6OS\$.L/CS6J14I!B46J2?UJ>&+?
IAP7AISNM+|Y14,L08)IB\$LM&0N^X\$^?AY#O)&8O<>-*^|G M0EJ=>H>C08E&+
P4!R|J9EL+HV_R_1C_9SUQ%:@BHWN@!*<57!%%W9E!40Y
M:DBO^6G25JFLI\$>3G!+IRLCNM%_U2!C##DXX&-|@I-).(21S+^!SZLTMF>#N
MR|DO|K|OQ.3X3F=F=OC0G+++'M|4N_*-0!UEX'+BQ-NJOKQ|7E|*(D>SE H\$ MI8W@|
8G;&7K9P/VA-&Z J6<>QE8\$9RF/KI<,Z_P#9 |K+01=,FO)3B,S!7G ME%@BE|2.L
AF!|I|WEQDE6B|SQ?)0,4.(1^*+Y\$ZWK*OVA:6>9P#4!05;840 M0'E4:.)
<|'\$M2Z5I>Z<|CW*P!)|O@78V(5:PY_\$MP;LB*S|9%WA@K MAH|1(OCND%.9|M?)LI(%
M*# ML9^9:JV\$ VL3@0;P-6XINY4<.SKU)\EG&LH?5FP-M;9T7|@)85!
M@):D!;0/H2Y^GR4RO|+<.#+^';W4S>|R::^,10!#|7EL9G
M:6FD,IC=Y3#V|SRGDDHA^7'ATES--9!%@E\$>;ESV0\$I_8+|#SFO(Z8|^C>H
M!%'20M)LZH)%EQ#L5=FCIG%|+|&#&@QZ8|L%8|3:SJE?U,'G,:?V@Z'G\$?G
MEH6(95VS)/(Y90_I2RBALYDJTL=MSZ(Q MY*#LP8*.(1)@NB&O\$/H?2|T+|<-):G?
%HQ^");U+8#?A: ^\$P|:@ E7|6PM MD*C--C:XJH|3CNU|HDB^!P!X.E|Q-.T_T
MLV9W!#1^|NJTU0Y_6A3M|BI73OI??/77^\$5Q_L(I2N!M\$1C% UI*A"X0F)
M|P.BS9IOS(81YBD,*IL%NXHI":KL#@ \$4O|G.+ "^=)9F6|JDYM|C2Q#GF(XF M1Z%CK?
F=L0O|+=|MSN_ ^(|U3"Z3#,"C*%56T3)15L\$A82*0T3VD|HAQ-:; M44%:G1XSX"-U-
YASJL-^9/T2.@-0FK?87*->|&V|5/(K.6\$| \$BZG&Q*% M(+&X;';
<\$%U:MYF|2C9U.WOV|!>TA+,+P" 1#;=GU^>O,2 |_=NY-4Z6EK
MWK*=2>|N9\$EX#6_PZ<_XZ(+RP#.CF#I7M1'L^ ^R'^|_D'W|PP^N'MPZ-57V M-
>S5!:/L8!M_#VN1"GUA\$7RCB!;!9%&_Y_ |8.'0.? (K""|E7?160PA)?5M(MV-
GCSW*3YQ@|AEV:#A?RY_:%C@,+,@:HKQVF4_P2?8T^'2IRV*(\$JUG7'D)#
M#.M0EL=P%|)X-6KKR5,9/CUMN,AZ18F\$>?H E*5F\$V(W|YO;Q-X?_I8|(02F
M4*_")Y8C"0-V\$?_*|V%UJ"!T?6WNDZ#EU!K6!/GA6RB=5::34:@?9|H\$)T8HU
M_ E%N|B|SR5=|P,,X5\$%\$XAC2:JY^"S"?E-!I98-Q)FN:IG+FFP4D16|U!Z M4USDE#
|E5F|YMC+;? M%6>*KL\$!RW;W):#R=W^JZ|?V EU)Q*Z!E##>:;AAY:' XLT8 F|>B^YH
N(: M:>IM|:I!V!#JVV K|V90S.)<^4)*\$@!XOGTM
MH5^P2V%/T\$&KB6YZ>>"|Y"OY=\$62GC"|Z1!MTX.L8Q&AQH|6Q(NZU%0U@+^B
M/<39,6"\$@D%W(^7C'(ZZ8X@|&!:8@>. 2@ZAY&H'0OF3HQ'" PEY.T<+^FQR
M2O4)O|@.&|JYQ|T9,36\$!/?^0B,/6Z_J286|HADL2F\$|L\$#F?DF!#MO+EU+NV MA4H?<
<|'#T^EW&AY6NKPCXFWW4-B) MAF/^D) #/+A:7=-V LK7K@JKB8|
(.W\$1X2(A!*:LM&F\$6FGJ?KW?|NZOP MDPP?0EU^Q7N#_D)V|W?%|MHOU!-
B^"\$>%VI>BFW@|:IB@ M|S)N@FZ(1U4B/7-"D4J1S17|W&Y-
3FYP0H\$ \$UUVBD|Q1JO,SR60?;ZJ"../5 M!7|UYOBG9-ID"
|V9L|= /QV4(>DU:1_..@\$|YS@G>|@)+Z^-|\$/U-XYT1"<3T)Q6DD
M,PNV|QD.N.>0CVDGLHT=Q:8OP^;|+\$F.5Q"RA09;,C+'H?V"J<@*M_5H.VX|HEDAX9)
MY8F!_E?86E00=W2\%H5G!|O_';M|;P0:V5X2R&OX8W|^3^|L0/\$|BK&EJ(=Y
ML"0;Q.11"44Y+T<0/WTN" T9\$T+|OREI53RB5&->J^&>K)N^\$\$G-.R3| OV,: M<+R0E")
<#D^|W->E"4NIOAJ5< M&I8DDT8LN*,K6E;
<\$1Q**A,F>XX,BMY=&&884FG<."VN9B5W;2(-G;P7|,+(Y\$75BM MY(U=A!WK^5
RD!"V>L!D&VYRSYW53U "S1IV:=OR)8D"A M W<9J+K;|>+%C^5?
=MN/+3DXV9K_ ^/^>=@VM-^UW4&1666D\$C8_36@*Q|=41 M,E!8%J:U7;%V3&1X-
^@S5SMX5^H-#*EM(."^A(#(=8%\$)=GC-|1;@\$XF!%
MSFW"4K\$G!@=(J_VI7#P#U\$^SA=<_IS5;\$R=@ MHUIP2TQ/H2CK_891S_2A+-
LKSCDLMZ<6=|6%2.1&1R.@OH'L&WN2!&GHFRNC<.6TP-IO8M&A%<|S@A6S_6 EPT-
IH"V!6E M1\$ \$NT|D>\$|CNMEJ(?TAC<42@8=."G.3?S&BT6E\$W9DHO_+^|Z<:*P^!5%8
M:9?23K\$'7?BKL|AF;C)0B9:0(O(&3'C\$;^1*A:J7-R88!%8&+88*/AH,,>Z!4D,/Y%?

I@|69AF1\$|4)3LL'.5K)'U; <0KRQEPQ6NA MS!^!Y<;?TYB1U:NC RYZ\$0XOH4F|T;8*UG|:-
N4"K2:7R-:W?<9;%G3:69;2 MD8){AI2(L1^#"B>|3+.N':-E2Y@H@Z):SI83=6MW77+?
8JHM1NAC@ 2E@7! M*C#L\$ED02/_9D60^ ?\$MJ0%+:LE
1RY0=^18H&SI(B#87X30*%5"&%UH,?) - M>+K<^IMOX3;?219&'
|*W>C9H)N'RZZLWRO2EP3/+9@2IFCQ97WVT0A@A=S->;?) M<;PT#70\$5!
BWY;R+D2(XV0H#4>D MPVV*W,122|V3B:4XSZ!
Q|>70C72::8%YS,0|I+D0RS#1)**+.G;XV:475 M2QS2H.7NZ;%Z6Z#OH&|3WL|V_J-
RU!^@"DOA^@6#%)FS7!E,5=K3V %E1EG2
M4VRR^0J);@>D:|O9G9B%&?|FNVBH%S^|N|,GSU^KC!BO-|-'=F|&*KWA.I7
M:|W|RBN_Q1TG2|>:13QEG),8N\AV\$U0FI# #26V/:K5J9>Q.^2,%8*|91DZ|'O,-
MPH9129.CD?&_S51'FD|>D MR_^EH7O>E"@V"PLOQZW!=M
T,7TG+%=L^+75+F;7O6'6*Z|3EQ1A_@+U M(\$ "N3.R<#12&5L.+@O2*BCK|>N-1;9*5B
M1>6L%^&(LUP|S7-RC/)R.7M,Y^AL:|E_8VC_.B.9TU|N8.?A9K7 ME,GMN=.
*"Y*0M*H%WO5 F+#+^?#K>S_I8LDB0NTOY>UVRHKZ"X%FR5<|7H5E
MW1BVZ.GKU_T%9TRHLS?A |9S|@,L\$;_842M >Q:2)W*.L*ED"^G%9^4@8\$|7
ML@_|C/%&T|+P/;+R=MB4X_4'EVNA8FY4.B0'IR'IE7X:0QVHQJB,A>X)77+4
M8:,"9S|+6FN*(,+=10FIJD>UU2+ZC1\$V^N;)1;G%\$APZSA3*@/^Q@|H24H" M1KCN!
(Y5Z%)S|8GDH42/V7^E"TO>2)Y!NOP#) C M"93PM;HISTK\$, %R)6Q)Q%(J/X>
(D\$A4Y9I+AMK.ALCIO)Q>| 2&S;5"L!,% ME!>MN-HKSRV&Q:"DQ'
MB&FC2N6B\$YWS@CNTFJ0EYOF=M(DUQ"/9F|W^70"OK&4%;EC|R_VU4'!@1I
MRXFV6MIM!|>\$4\$68D|/:#&D>LG#RV8"F,PV8X|Q-N|5/'+=Z?<(N?*6|Q2_1'
M'@\$00T@;YB@W=(|4OU'SHBKT*JV^:PZ%NC!+",GQ6:FU|E4P|1I2NR2.YST3 M=S&Z)-
G!NVR(2"RGT#_X|Z2Q5NVL;#?-(J"2-/1;|>H:|J|SW0X9'B^?W!4U
M4W'CV#QO2ZE)'!@@"PI+/C%4.14.%_8!!=':.*+"V,.6;TI(I51,A)*<@D>S
M1|J?:VF#CDQ66<,"F@D.#DQDO8X#2V-F M0=()O,2%623'YVOGP&K4\$8(\$D-ZJNA":!
<,>65-#V|?H_"H?0B|>B&Q0"16 M/?!|F/(<""Y?^(%OHQ|26_+JUEB9MA:<04;|BH-
U39WZZ+V-(L:1AZDFZM
MR5|)FJX;S9&'A*.WLC@K6SZS|:DXW/M7%ZY2\DV\$I6:=:X_ZC=ZB0D.W|9IP M8T ?
7Y@N|J#P(=J;/F8|)\$)%|(-#B.RN|A2IR9KP2-77/:S;EW06>YD6>P-YJY
MV.1FN:S19%4FWGV8W8:6Y0IO\$AP#TNI+H6^BFF+ D9Q#\$.C,J/RJ#F_4H?^B M3='?
3E|?'H4CDZ),P6#Z)R/SS0@E"4&"\$NI7UX<LA M./Z,)5F&J.\$G)/=6;/2>L-
Y;J|U>D2|'YU4L)U*B| M.>|8P_G'/6 J!=Y M+TX2'?|8)H.F@ (U^_/FX->|Z;9')Z0=SQZ(GX;
R&;3MD8?I0E(Z23YG_E MDT#/= (=Q*9W8|>-3ZVD7N2|/#<6L:1O,!@PT15|3?
NZH0RBJD>;C*/M|G4FN M*":KW&-%;3F#^CS6TN2*8|V^#P9O<@%F:?
W9H;HCBXN4B'^ (H9M%|##H77&M)GV^|NE@QNZ15%\$;19L&.G"
<4C|9K;L&)_5,%H(Y!DF|*H&I>P+_3E1MH M/A\$AR^/3<% "0,'5X^CBL(X94"8-
(5<:YED@E|PU!*45= #66(/";(U6\$76Z MD4VE?<#W,0"TUF\$=2E>SN%TK7":8EOWH:G
"TA5#/'#I9=<,H'QC:3Y7C M<|2;XIKH(Q|_ ^T|KIAZK?PPR:GGL>^%-
G3L"#5|2J|6"VY|7EU4_M#FX' |: M,XY|9D"?0*2M";8Q 1ZH=*8BSP2&\$T%CRLZ&LR?
C=0P)8%)"";&K\$2(T+?4
MR\$2ZH+3^\$MP*0WHH5*|>-'K5KV#9%VEQ=3!EB'19^>X:IYN4H;530 MQ\#-
U,04L;I!Z^NT+2 M((?CA|L_|'GF117>6?1/4G-' &;#O|&(0G)YM>?X>SGO?\$P79OLB9XJ5?
\$D M(AAIPM)%Z.*HJ=,"*5W2?ERTPUD_KOR8Y^%4VJ;J?@X0Y3:%GE#N/CP_>=|
KQCZBQ:Y)'#|?ST M^7\$D<66Z.6N_#!:CIB?NL-6^B#!B0L+V%Z;6VQU@
MW=;I@37*:V!LK48/T*O4%8MRIB.+I+_A6A*V ";;Z'-\$@+1""4H|1"J1@=#O M<
V9>PA@E%!\$Q\$.KGY7.C4X%MY!4X\Z|8+ ^|.D@|*|N=>ED;C|JY:3IESJ M9!BO-
BL2,\$SD?"PO,MK1:=&5FC,A4N>&7N4|HP.%^L;2;0/E>TF|<7Y|8WN9
MM75|TKH6*433G(XL85:LSUY*<.N MJ@^,A\$EQDB,E;G?#.75DQ?O8Q3"/.<
U2)B>KT\$6U93S"M&0U!|V/?"">A|, M)\B=N-#J!:_0|LIADU|HFUU9V+?CUMHSXU
MK8(BM"H1E_-@&X9(&YA1?3;- (4*(%S+|HAM #?#*B=_5|3DR%/O2;-#V
MQF'02BZ(9(C(7X>SYCG8DXA;!5==@C&M=X|_#HJ7WLG\$7|_/'F Y &A!W%"N
ME&A^4&,FCV-I2(H.4=^SOAD1CKA_40|XCP*AJ;=Y1.(8S9/4S2=+S |Q0H1
MO>#CA>^(H,Q' |EXYM=-19^7D=UT_D;\$)-IP|_|Z;)27|I?"1Q-%YL6%U\$Y&|
M<'CPJMMP?>#:%S**)\X9|,1-4.6"6K.VQ2)Z|LS|M"YZ-%87I*;;!%;
|T1P1B)'AH3MC;@IO^BT8SP%"!N,L4W)=YR^FN|!"4
M1@GO.6UI0|#A:%7(P5N66M=M=R)7&@=|7E&"/_WB|Q9VK/C>GK"!1T(VJ"
M0J)%7VI:)(NEKQ=\$4_C0-V/*4^|EHZ|X6)HC02:P8|E;UP,34(S@|PJO*&H MP8D%F";
\$|:V|NUL\$_,|+G._I=K/5L,U|3U9IVF)=L|1.6J_-J|FIFX5XSR:X@3|/3!1F&.%LQLDX1;MRCC;

M=|P7W/&VLP_TIG';+_)?YV80V^N>:%X5^F_-GWL8(+|JPW^0.C?-D0X.=)L M !?
Q8EU&Q|XHLURDW&|B|IP#^|G K5|MB6890@\$4&M705 /5A|/S_M|V9A
M.:P=')7'^@ZQ|,RED'G\$=K,JV F9*Z%NZ,A8",F0LVVK5DG#8'J,!>+JX:A!HWU,/,;%6V
M5*V1/G>/'7(7(W80FBAN?M*1TZ%,G"Z#*8:%ZO_UX434T7?W72'Q'2P2^Q8L
M@JFY)G49=ZAXO6'E_T'CVX|_6?:L|:??CT|_V'7W_WW??&N)%9>GXA0?OW?
O3|VKW|8=&|D)U_N\$ M':5PRC;H*S@|>?WF^/&QH2?XUMGLV3|_.G|VRTDV^7GYT|_3|
|,Y0|WR>O MGIV!?!%L_XM?GOSU>/,F|_3%_SO^|Y03|)^_FG M?
QZ_>/'LQ!!%G\$AGPL+=",=^E^A|@>-*.;RIS'6%."B=9E7)H 5',/)#+F Q+ MHQ8\$1,&
H'WAT3ARJ',W8W-A*\$JU9%,YGH:2E_V*7<)ZY+ M.:N,@.X ZF=D<<-)|51|{(9BHD|!
WE7R#>T3<0*Q?|!"AFGQ3XO_(HQ\$HTN M!_JB"@\$(DIUNJL=\$P9\$W6?
(FS?)Z.NJ9*ACJ|D6|K2P/^S"SA?G97%A(/8^ M\$RA#/<.,|BG97DZP.(|MXN:_7^;R6ADD/8?
N1UO&T5^T%7KLH9JQ3L7K!
M10%K>K&ITDT/6G|X&5^MHMH>'8H>O^SD|@URQ"VEKW|7AGC*|Y6Y<,L7_U
M+>JM45HVOD|MG'B|+VH>>|DBAZ=GNUZJ|@VT|(|@Q|061)H|VP)D"_%%%?K
M0=|L2|7!'3H|F,|:#TX\$ZJ2\$&'NAG+4+|Y_5O)'6,D&"Q9(D'\$.F%-
I3EBH2(REXL7%/XL2B=|KR<2Q_FUI+|\$|MD&Y@Q*T+IW48JO
Z319|V@=_U#Y8@C?">B^\$-2+6%T*HOZR;5%2^T-N XEW M1Q|
L+S%V_Q,*0^6Q'9&I|ZU_.|1Z5@S)H4G>%H@VY DFY-
*TASZBF^0*UIZR5GOY2)|H7|J|JB9PF.W(M,S/5GD=<)<@YJ>,JY=/2GI;V1XT
D*M|G"O|)7&1P_R3D"^MXU^Y|1AKUE8Y MGO_A1TC|G|?KI?
R1LNLW6,D3D<3Q<"+R^+R(/*:#9#L/L!ATF_4I^)^N MPJ,02=6"-|7UGF'W;|8/9)7-_T-
5V"13J-&|0!\$V;+TO MJ ^N99V0MK@>V?7185RWD6Y
.6#F39TS:VYX4:GJ2Q>E84\$9@HPD_0?E."|R M=:%DTY>1JR%LBGJA>F?XLJJ?
!E#I"=43(+8@N@3T;H*5^OL9C7=GGAGX)9_
MH40.WW|>@,*#RTQZ_&2|N*3U'|K4((4G'#MOB7IH2Z_?CU*%1\$!LV>U*M!&C
M^9;I+M'D133543|O|H?M;%GSV""2P|2B#7|5/G'#9IWC79&\$ISO|F3WN'J|_MW(-
VZ!)H,U/QH @8|P1NTVLFMREP_V4|D|L,R 5(K86'=WA,F;X;56Q4<+HQ M@|@ZD?
6(D;NG=&@QH5&@P)>M1|D|CY8|X*EZT+6DG9+@Y?9KY4.^V@#=#G*CG
MP^S>VVCME\$0>S;JZRL?G\$;NC|2+K>RKN_Q7,-M3/K\$B7:MRQ;WQ?(5PZ|NX M,P-
P>#TE=D=^HK,^.@W3>^!>'&(M?@YJ#|\$NK/-+HKD+'INGS'<\$=>N|:<3CW=,:"3^:S??
C C/XL@)96,J13<>R M8_6D@KQ)SOB-+0ER'G?A@-COBHDWW78-
|ZUO+RN7E>CUZ=W+S M|N&CUJ@D8^R:;%399#980MV%^6Z|TW)|Y0/K*
;PCP6C^HEK.W|'H_@SY M^89GOB|K^D).95A&YS4K@LF;"C^J+Q%7W.&T*I|3!-#F?
WU%AI^Z('W^?^MI!HO|:-?,MK;CFIY ;IXS#D)+Y;%@#&YHJ\$I?1#HE'.
<|=:!'I0L=7&EP0%X6E@T1"V*5J<<,=CF9/?BW;,%0@K_-
<*2CNO61#GJ0B^G;"YP@\$D^CCBWH%PZOZ|_HCS0M M-|R P_!FGY:-
Y09Z|OW_WQ.O)YK3;|0?GG|Y|\$=#4^+><,JIS_@6'G ZI1. MN8P"L Y:WJYX58Z:F?&
1EW'JR "NO)L3#PUNI5?_=UD|M|I:NU@CBB&%2; MU!9'/0'2+8)"L\$/FC:RV9S)6&0 M?
5U8501J(O)@:;%C;PV=PE,B0_. =2|9*YRL3
M<5ZU%3_ZTCJXSR93S\$2>D8B)CC8DMM#U+ G#R:Y^RG:5(I2S=3T/_LN|K'LJ
MATQ8M#=#Q)J>|0!&|YJASUP^L0DV|V;|!"<-\$N15|Q&#&Z\$YL/9C|=658E1<9-
M>:\$TPY1/V,Q=M.:KR_(C8'|"&\$8Q*+7^<(U&.:9*B!^\$.9RFS?: Q3SH%!)>
M@W>&1R5A)3*\$%_.RXBS9V7!'OFIT3(B>"<,A/:TF%&+OW@81|,K=M|JW1'V
MBH0:"E5|K-/I7#/'7@,M#9+,0X"(H-HWS.A.-K#:&O|KB;5;&R5RGA>|2SI>
MZ|?)Y)J8IPRZ?%0X2U,--4/FRV5*RW:Y,13VQ,"1%>A?(0W%|XP?|M(RNEN
M2),B21QYJ7QNI&>4HUL83NP1XI6|VYW7'-OJE=)G/73W/,PQZ7NIT!FM^JZ*
MW\$CH!XAXNO!0R('5"|"E|4Z\$@BQNWEX1WA)-+Z"F"!:'B0|+DU40&
(P=)3:XQ0U7%+FW>\$FUTTNY>&|F)9%|51WA-ZF O9. MPFTPA9,?
<%6N(2IH8B4CN310M\$%JT1N(EN5)ZA6+NHZZE".K9|I'N:E_HP') MH|HZ:
|A:A^9G_IV5SEE?EOW.#?SP)/ZTWY2)|_ZYM-2&MCVTA&MV?/+H
M<8QN(HK*X=CS\$"@MQ)(>.#&,O6.U*MS;H>|J8_4/4SD3|OE3PSY_/6&?/R_L|V|
|+W|X?Z+|_*TU@|?BSKO_>^^ MUOP1:HUZ)KC/K4J;\$Y|9ZZNQX4.
|O>|XEPZ1%L*BD@J|CU)SWZK0G-+)*|F MI_|KWVQ_?PD(^.*0BC&!&X6-
CNBGR|G%+=IZ)<"\$"PHBC,&|LJZD,I^DU MBM>:G>&-|%:0A5F1D><:|ZKVQ%?6(PD?
I%OT+JKP44?/BCX7<|?9|*94|0);3+V_7I"A(3"5|H
MQ)9E56ZZ34PV\$(C@FS!&*\$4U+R7;V"34?9:Y/0H(!=\$|O!!#S|JNL?O_OF
M7DRR>_&H'8F90WJ/H2M04"!SL@VP9ZURW5|RXTN-
M%GJXW#=#.Q&7&/C/'WF1NYPX|MJC'@E_F.UV&R-ARN>- MF5(GQ!?!L+QU.RR|S,_Z96-

YCI-@KBH[W/P_ ^M97'>FD'5L9"G6=&W_\$KT+=Q4T>[JQ5MQ(UOEFDJOV
P%3%0%93TAJO%7^ ^J.KA3 M A+|N5J#|(@3N=J5%O'9G:J/& +1L'UIDA0^YBYGU
<56R6KL@YFGL5V:R[1 MP_'SKO,\$%=:OL9 P3NSE&)B
UPX=NRD,>-8YZ8\$"!L%>6(:F%_I#|.)0W\|3\$1F4LBOR6D)CXA'H'K.
<1MMVX4^ONA!:YBW#R/BW%+|+ M<-AWS ?Q^S&GP**C(\$LJ;-PK<+U5S[U5V8OKYT?
-41HRF< MW.?
QI!0EM>O(\$@55R=WFYI#63YD.:HJ7@0)W7P&VDW='ABIZ*^+OQ'<"F&45
M^|OX/:IR_'O#/'|F9|2XL_LP.KL_?'WTW0U|72G#^.-.)_S^NZ-O1D^'T;>H M><@7+Y^IA?
M*\$?_TM^!>54#.:!R^KY\$X3VON:WYA438I;6ZB4U!'FD40+^ MSC3R=
KS*7QR^CJVB;M6:|9YDI8V@|%)=|A(Z2T;|Q2TCK>1Q@CM%IQ.WS3)
M_YKPYH;>|M4NSW7LV.U^%*&_*W3ZH%U.;4W6#3GID)7C;=623QW"?7>1*.
MYA")N%|MUPOZ*9NAN_2JI(RP#"|K'I:5X0P=&I191|ATP'IL.L|WOU|2SOB3
MCO51!'Y&%^#I#596!D.=|*U&H/|'^I@,D="SM!2*(391+|.7!EWF:/93|4B
MHIC&4RXI>3#O|21H=<+J+U: ?GP|8P9E8%R2>)|HIC<|G|0@^|WWO8IM?#(I M#|8:-?
M;U P1,5J|R?E8AWT/CLIXHJ/\$SB'&UT=*\$=F% E.|W|K)S, M)E|'#JU/<5XE>H%V?P\$
NMH???.S"ERH MB%/LD3?|">.#E\$NZ5A=E_C7 2(R8:VASE9*UK1MMJE*_UA3; E-
7>VTH8RN MA|'O|K=0V,|K|?CT&JZ| V334FO.;DW#4LL| M+61S=HK+(7".|+&H,LA9;B
MKOG1A&(:OH6T4W(^YT;|&)N/*=.0/&U.:1&2Q8%71\$^7\$|H*:"OOJK'5N/.,
MCDWXCYS\$|20\$,!)Z--- |W"+L4;J46N#NEN2R7G32&+V|^:*0 E;PXL**7;K:
M4&1,PX"X>M84A'37M?^OHM|2UJ,\$03 ?.|)E&TPWJO!W<(HXKCZ/FBDMY/\$ M6-
HEW6!.C)+7OW.*I 3/FGA*)=P#\$T?^HBA|NY|D#_/?JGWL|;\$.&UL*! M<^:E=;SK+64|A3?
7|*CW;|\$ |.2,6%-&OZ,=XZ(^VQ|%I
MM2_:V4J0>.5UGM=A;VG\$RXD^_YB:\$TO,A_V<6(J^WKL1#Z%_5;2#?'1?X#T|V'L @?
=^OAYXC5=8Z1&P@EAD+6T=LMTW^ ^4|6?3AT&|@TBO^ DDI M7\$!TY-
I0^#;QN1_:OM|&X/^EW_,\$T-T59WNALT+*4>V\$.^>5*9E9!QN.2&| MB<|L
BA!4LA"692B>..MS@6#S^*BI7_39G.|1*(TOBZD>T_4;==|SCYR2T,X
M4|H(9&|05BY8+|MUIXVX"0K*K_3W@|?X3,|I\$PH,4)6!/WUV,*!|6 &E&9-
M8<1%&6X7Z4&31>1UCQ*%556&'Q=83354Z=5&D=3H/O*! 7&D9JJO.O8IQA,R
MK!_3|_;"KUF4A&4B|'58=4K#P?=-5&6Q9+=;LNYQ52H-24T0HKOA638U5QV:
MAK!Y\$D@Z3X#%)-CDUW1T4, 514YN|3C7N:SU^8DF5V)M0CYF;G|REO_%ZR5
M=,M'+S?1-Y@|Z.H4>6(:%W=5L|*%H?5\$*(K-S(C>Z*<3E.B+|JX&.E|1VD8
M|W5;_PXN1FUFO;FM^C1.L"= &'%-1V&|;OG,*M/S9OR0D2_A&')R++OSAL(; M8|
+04>S2/6BE|6<-|U0>M;\$"B=.O/6=|XW&/*>SL*_F_J2O^KM0.*EJWD+
MEJ'8F159S9IZGZ_#|5J|4FZ=N\$JS#&%L+L MIP7)DMH|_&N3B8XD|7C"^*|PDV
3=B4W+9(EZ?|&@_JSG&\$6>1%S#-BT)B3Q MO%|'"XZVQ-S89B:4@)R&-GH
)2VDM%;="\$F@?'P_*0CF788@43M7<.-Z6_/M"@E;PL&%7|SW+J>|MQXL/QD9%MYZ7?
;E!=-45|/C;NC06L8WK9KVBYG^+EU MMLG.;|=A0PI3"B'2:(/%QUL6;C!!T5:H7'0'5AZ-
E79="/+<3^ MBVQ:0;/K2=EW#*4UX%%O+D;|0*/(NMN0JJ(08G7:%E9R!:-%)R+
(87&WX/"7 M_17P=Y8M2#KY'?#|R=ICGW??1Z+ 9KMRFJXO+_9^|=F-
M&DG31OX+P=L^X M(T@VGZ)D|VR\$VH|9S;IMK^7N.7UNW' 4@:*(-@AP4(
DSJ|_F5D/%\$A0(B6*_M_LF:V&W;)%)&HRLKZ|E'YX++V"@!\$U:6&U7TU4Y|'4)I^&
(=BH=V-B/'>Q9Z M"B= _JH|7=D>
H.@P0+HY@^6"JEL8MS.!F1UVG+M'%56PU&O7O/5?W/) &X: MZNJZ9 ^ (S837'.4WE-
@E<7|+E?@U*G;R8@<102<9*L|HF|8^5CCX82
MZFIXJF|'P>NL^K@PQ'T+0SQO88@'&H9X|*:&5K>4|J3<2F/*X+L#9FVEJP)M MJH-
WU0"8.H#UK/.X4ERAEJ4,7FD Y66W1:4S_*QA3'_I"'I!:>F=00"/6CB
M^%_UBL92SR^CYEH1ZLX0)4.TT.65E|3H7H4%QK&Z8"H|^&?DAYL%:96.D-#
M^[9\$3LFUJ=1/\$UGRI=HY6;*1R!2UK1P,YZ0|C,+ON'OER#5=+* DT6C"R;_'M
MBR9EBF.EW1C.(0|(|R3|PCS6,"A|DBM3 KM7|-.QQ5"IOU(7W6PK%Z@7\$F
M:|>TTKWX+1 |6^*\$|8H@VFCNSHUU;MY=8S,7H|MJ;FI?S@IOL4YE1U^CD6&
MIRE|CZ6PXY-?19M6ROXYCDI>(RSV'_J8:GYG4U|HJ"OK,Y"% MK+1K/\$"
Q#B5(D^(OIZ):@+A'O8NT4618033.C1 7WEJ2IW|=FFJ M|*MJ4WZH6JW379
*0;#NL8JJ*7XBLJ4"^&|,9(8#D8A<>AU|HJX,#E>|HCE28 MF/+ \$EVI-- G/TZ1|RX6J8L-
S55;L?|A M'&:RE3M.ZG|Q\$%S|^VTH_(@V&=8T0HU!52'|\$HKO|Y<'L_3,
(8/IE+6VW:2=)C'|.UC|J>;78=E8NO:VJHN_D<:4AU%1\$4^7AU)A MS>;|H492.O
.%@R|5JHC\$J.9MLBC\$=%DL9RNPH+'6&'A3XL^6|S5,=RTM-
M%62_AXHBQB370&Z\$LB7J'3%LK 0,&#';|&)^):T8 M&>^S4/D09JW#MN0*3-
5AO&E:3892 VXOPDK,Q1%4W*ZJI*EW2-+IV1C'(I)'ID7.(J>1TGA,N'H:SLB&XJXD25W*K?

N(5I) M1US@IYE"74HA,) > '%D_HVT-9R:'D4C8(BZYZ*I@ELNHX_#TAAG-=6L3XG":W
M\$BFXR.Q83IWKHWGUKELIO3<,=6E=M'B*USY%SR95=|8@A6G?%6&6F| (+H: MV5 (-
IY5O(E\YU?H/0)%156\D^@;S64" A5BP! NBDE37D.JMKL8O;<7 M.#&3\$;Z-(AZW@?&:
<.:!B=-75CPE/JLH-W IODF/R39A<5^U.!/7I0W4\$9H%# MBWQ*4A@4C#2?R=8NY?
OV(*1@9Z4085IFK*!\$"HZ3&JYN+*|S0#2"%L)XM4D M**4.D@L4ZXK;02+&">CSUV\$
|C;"|+S"IU_ ^<#+Q&5FQ6.##ANPQLK0
M!05;U+2(DI4I.J&YS908%PU!;2OT28K@=K2N7V404RVXTM.^Z,*I(Y7:/> M?
8^M'+K8R@.-K3S&\$H|7,=5T+S3I58!<.,K4@#QK00V0WEPC8#/HN0J5058
M0\$.+T;\$6J8+>49AD.0Z<|?IM9""UJ?6P23EWB/*YCW1CGA/HW'8H*RY%=0 M' %*WV-
6NE+YV=I=LRMFF\$>\$OG5+F MC/046D*\$+|N:7TC6R.:V2MM ET:D!+,JR@6I2EXKF>-
JRA(O.+ \$DJ6GF M4HA5*BVZ)YNZ-"|6|ED4_397,WM
!14@1:TDA72LU!MK)9(2N(7SQMMASQI M%24K7#5JNY<-
IO3I1B|+6UIBD8919!N%:2ZS|N6'JD+%%!E4):7)*A_2RU+- M,T5L@?
U>=!SK:&.9EKRNRFSFS?=BZ)8MYN9I1DO=G|>%OG7T3MD\$%)J
LA9>*1=7VYUX_-4!;!8,/P#94V0IV;(P"
M>01LRZH>IKAPN4"O/..E6R)H,WRS+BC92KN<7K|#D3>7\$B;WX VUC\$2!LN+
M&APWW&@"V21,@R::X7.3@*.:>%#1H0BU'/2?4:6PTMTR7;IB@+- C8OGUDIB-6%?
4(=840I2EHR K"&.0FE%!=! MJM+\$G08)I%KGEH:7A/4A2+K9XI!;SB91G%9F5&G=7-?
K+,SC!JGP4MQ0S?3 M,BI"M4XN7670519Z*^.<8AYDJU!#
IFM0X\$CEG"3J|N5:EN*2YQ|HK@U*HA"B MN+&-OW*AY2@Y560
<87+3>*Q00G"2%.ZJUUSCJQX9.&R;!%GK X^,DKTXJL)
M\$A5ST(>GTD0C8R;+X/:*W)5EG(U|D-!.\$8L.14JAIZ,JB#6SM;Q_3C!.YP9K5WY'>,NI&
<\$4H@KI5:=@_*K&T6XA|@PK)92PI2K M588_J#G*O#(JCUF(-I"M KZ:VF/;J-
X>4R1&.23I|\$ 7)HFLK^/*EIDF&V6OI=WG"C_>!K M5S6%/ZM-#/1;\$!:.Q1SD-E0\$"AU?
2"I"U!BDWTXXY"B3IR#)?4'A:WILY(&(3 M|S\$GF?Q>F\$;1Z#NLPIK+F(W +HC?
0G1.U1#*;8%Z>7^ 8H9T@OI+A BIH7VU M8;J-EYTB|+N1#K&I' W*T?
R#;:G2F4G1Z0QY0997>@;E"Z*,=|Z6S5+&OI& M#*G\$Q0P=P5>XR;!:;9^A)3D
^T|Y3R7)4G30S%)FG/I% E-I(V4%045'4R00 MNRC)4|-1=ND6F'A)CZPX1;|B"G04X>
<19L|=3;1\$ _!XG-O\$/KKAI@ (X<9,?4'D957 +|U*V3DF4NT!9!U0. MF6Y.|>?D,@Z2&RKV?
LT\$<0;6:98_QKV5*U:)RJH(MURQA&^M7^GJ)>K6HG+| M^C>67J
)O&2S\$'_:F%K@BV41(9BK"J%6%C2!&(:<3). KI\$:Q05Q(+,-|#/X
M(X,7N@F@8JGC=G\$9%O\$KC'V)6#C5Y>U|S@-9 Y5R|32|R>) \$;M12 ^_S'2I MH9FT=
NERC""%@5U+2H4;+W% (=4!E|FI7 |. _PS M8%,F" |BI%!)MT|S YDI=>ZG))+
8+4GBBNJOS\$9\$-4H4AK=V6PJ_ =T*5@;+A*>)ZF)P#2:."GH7,T0>!X:QFS\$'&Z=
MS86JX'SIO,'^L\$ ^W<-35'==G%A*T3"R IW M7I?.JTRV-2"ZW\$NMBN-LAI&_6K"/4-
S170KMC03>Y:%EL!)/I7TL0%K^9ID? M#100S%Z.|>QD"B_ "@)T\$*,|_-
_H%RKV/87QX"+KMSJDY|!;O|<^ ^R*(JYM?=
MID|-4);AE&G5/XITN%V.%U&!21QMZ\$(*)YRYEG=)-4/7HG>IKH1=L3C1&FT1
M,Q38.:QH%H (- 4PZCELKY&5C\$99E034,U\$47-&TEF5FM\$|>+|29;C=H+#+:9
MIE.N%6&Y|TN_ ()\$;D@)\$*|D6W58D\|D6!KRU>3!:NFV!>DL< *E#0Y3&("D
M)^@A^U=F>,_MT\$Q3-<<.=J?LWF2F=Y2*.&6JPX#>P|4-&|L.%6JMON1XLVR=
MLTWYY>J7AD12U2?G@|H%*5&+@#80'\$LD5:2<@C50'>6;">CMI%9&|P6GKS:<
M9':|S\$+.%@+|U9TO,>..RSJ75+#+G9JBYFFA%U7@_1Y,'1MZZ7|F<|X.,;9.)
MIN1_L|>F,'SCQ95J|BAE3GI_9D1X|*|=7PYC=;=):7Z'YH2D SI7H9H M6U@EP%
(T^FVRH_JMQS_PI@=G|\$38|DVL,5\$'IN%/1USLY.9"W8JPI%?_O?
%Y_/SGUP+TNOM6H*1\$R1?/K27_ZL:IJ7!BZ9K7#\$
M/>ILR%+ENY3R5ZH:,5WOD\$1=T'BU+T(&:BZ,GR8C+!1>,F:4&BX#,\$\$M1WE M+
|T&2_2H')SA%7)"6I0>06ZE*ND(NTB-E88V?5MA8%&_D6F8%52D6S|N
MY74LNUKPA@=4WC@KKV@F%7^5SJS4\$C5A|116"LLCXQ93%2&M-Q.KCV6X0/G%
M&&R_UHK*!\$>LK)S\$V.1%BPC"S8IOK\$R\$|LTU!S4>&ELD6Z?%RO@39%_)6"@^ZO?
A*&S&T>EN\$>(B"W.>6\$6*W4= DM|BF(55FF=5:/77, MJ,Y"OX\$9N5..VTX=-L>
<0GJ=OB!92|: BENB'7?6"!|6"JXJ%7PA7('Y8.D M;PTT?.G,ZG*+K%DN'=D1UB^S^&?
*T=X-A>QGP&.1H9MVO(HI?)06|Z*I80 M Y9GCH9E<)DZ^2@?2-
T7E\$S65A,OD,W_F7_SCMG?1?|=|L-8!7!^HU2%_U?|3| MF"48|^3I%% |^M,5LO
@IATR:1^L-T!#IDQ20P-4%)8KQ.0ML-!1=/?I(K M_E2F>15.|
(KBG0U9DG1,"*)0>;G.2GTRT>L?OQWU?D"PXB|H|*&@*N,=1?: M:9<13#?
@4Y02?|;2W^1%?%;&G&I, SHOH4%/4XX!?,C?-E=NN*G(0'T(SU=!0Q-
BQ+HVR8.T\$VWIF@*"I\$@J7<"ZXJ'15.72(Q M_!30-ZECCZP*3W5.

f5(XTR0.,Y45CS%832PZ7Y3(MBIAR8\ZEZL4IY4)&.Q
MOIS\$A>JJ(T#_IKJCP2)!NOYL;C0E?'M8K+((V7F,I\$^JYH^KRKJ)+ZN[HE6'
MD9M2IY2Q<:H>>|;9=,'IWUR)(;K=G=!WAMB,SYJXBC9=+#>^5"L_KF;_G92 MRB7W
6C1;/1^_#2%#R2K5-0B=*K'73?9LI^%O\$Z9V[+D!G9(%[.KBZK\$V8KT2IB?
V,ZK GK*G8Z>#BQ2HI0A[V%K075IU*7H#-9"GHA MUC1L_SC!/M7;)LP-
Z:9=#4OY!X=8Z^BYBFD_03."I?;>-%,Q"UC&*P%:V*\$U MYL/B8B#(4U.;R'3.E?
<2JA^,5'*6TJY0D3?^8ADOC6QWR=(1^9L?KJ-N!4O MU.Y*GQ3QG03XX!7_AF)%_M:D_4
)\$Q3KI@W04U!U#73@U ME!4@Z=Y\$!>R -I1/9X54PI)-.D8(FTE:T-
"0@0,CD40YA>\$+%1P@BF-8M)31 M-H*:/=)ORC,5?='0P?;(TS+=*J,+#"R(@:D\$40EA,LA
.L6PV"+ "1SI%7XY, MFZQB@974I#E07+6N>T33P&X"P#/T%,/5RK%1JT7]#[NK\$=XM5-
Q6O28F,+:/ M32:N1,E C>|Q2A?T1F5!%;D"3Z(1.\$!
/WA!*4CQ5ES+X6.9NCPLY6KIJ<962=,-%)&B M?
9URY,MRM3(RVS<5[NV22C14PFNO2[LH!=OGN36\$(VJ6ABX:/+OYIW^.?SES|
MTX'&/SGOBNJN825CJ\$QJE4Z+)2@8WB|G,C.0?(PKDJRS!)4Y.14ZI1HH*5. M0)_F&('M'!!
/K!!=VEP1"HMOJ).LXA|5RULF79/45%MNF!^:QSJJ2:K4&,V< MIS+^IV"\\F&D.1XU *P*,
(KO)M\$|6W M*PKAZO0%| 93?52=?
A|2)3_JODG%B*CPK/8(JW0!L%A5')ER24H+!3NT89:3 MLA<*S:UZ;KHAA/3
+,:@IUI@CTBU8'DGA((DD*Z-LKYA:F-4MI&K78ME^0W M9;09=2I6)0CHK32Q:3)A?
00A>N0CB*D+_0FLBQ8""XAJEF*R%3#G|-N6U
MLVY=L&2CGLVV|\$>S,&FX"RE,#'CVROYR>Z8+:BCN="&N6'@05-0S57%\$4@J
M@RG+UY?F1%(W!ZK-E>OXNG&2TW'PKL,D,BY.FTZVLEV\$012)MQ5-5*@CMI7^
M;@7QV)4HQ^-FQ\$9<-ZAD-[V>/'"QO\$HZHRD617|G@&"I3"A=GY7.@OD|. \$0| MS"*BFI?
4""B1^L0:L 78R>TMN*&1UJ*!?'M0E:B2+\$6/%;T,F86:\$0EMK6". M%X4CPLAF6426(I
10Y&2DK%ADULZH*:AJ&(> P&IKH0:+ "FH6SJ9*5P:3/;
M+LM=RJ^UKKJQ<):52RVM54=P*&U*"S3FEBA8J|193974! MG:)-
E*:7;)08S&-4IGDA|_)I*LD0&^JW&F3 MY25;%5%9N??(A%&-CJPRI+194)
M;)9)E%XZ/JYE<,\$SFB/,%|""OH!!V_D"CL|7|. @862|_08""CO|UAE|PR9A M BLC!-^
+;C;UJFK.+Q8=M_UHZQU%^Y|TO+N_.BX@EG^4#+_3=-Z#V;=^!=
M(E|@&Q7BBSH*SF?+WH,O*SSJ_6?X2T^2,EIH&#A>7O_#0Q<-NCTSYKC?C!N
M|H>LW62|XS?'G;/QX*P_|&'S7|B:YK?9%SI^VXLWWSCW@^%X/&H.3CNC9K|W M-
FJR7K_?)^V3SG|9QSPLO=>S*9(A'GPZHU=D@J#R8N& I|U.8;W27L.6RP MO
L5001-/8^#7U4OR*|4=TY|A7G|B7^|Q<>IYH&L,EISE^8(+@/%MW8=|Z
M3R^P>W;^9|-F&+46W5X%#Q|8%4H@297|O| M.2Y5:>0=12YLP7/_P%THK?
VN;KOHNEV+1|8OWDGI=%/15)57VG71|)_K5565
MGAJ,N*32Q>I^0: ^H1*B|ZIW7M|:Y=T UM>WCOU)'|X'|5'/|YNGO,V: _?:(M-4?=-|: Y'
Y.^N.>?|KN|':A(UX0;=#/O4H)/'(PQ:-V>+%DDV7,G31'(K+ M7R_M:R|F?
0<.XE\$|'+I4XU>/J>|9&D6_)G|E>K>,'DI\$Q|-K%04RM%6%U#
MR>K2RT_)D4YA2U11>ZDD8^44Z&D)(K@.>4V'ORN*)D*T8%N=5M=
|O>RZJF+XURH5U=|4Z67BL2O7_2(5Q) MGLEK#'/9-E;Q45QD@-NAF,AK/%.J3I'
@L6&KF5GPC1"06\$B><,3;RQ|&^P4+E%Z/L/NM9,KWDURE4I11N< MB!?
5.#7N|7H|Z)PT!^|.L-GOG@;-4O|@J#UJ=TL.NOYXT/5WBU/O(W;UPL,\$ M 000-
H,#>|N#I@*K.F"&\$3A&%)1(^U|UBKQM5 K%DL)S\$U.A<=J40%6\$D,UN
M)";DI9,@HU6%W*(NTFQ7ER|F!98Q-B35D\$2U1R((FI=EO 7&-B83-5M+,83
MV*=*IHKH\$X+W44L%NV6A>&%J;K"X?8@6),=NSZ8N-1%74P!;ZEU-
@,*9MA.0.J|0P7'07UMWCW2:5R|M/*PZDBMRRJ#Z8C|-" V# M,S;JGOC=-C_PF_WQV;
YZK-.LST,^HA/_FC)&"(=%8MDL|1"ER"8XI6|CI#V/DAN%
MO%141P,I:0E2&9&&"6XA4Y7E1WF96_,U:IC;,,ZEOF);*-V!:/1RA_<,; M|7&WR88H
I<^8081.C+/XT!Y^E6P8W\$9 M4',,AT /F'1F,-)5;I4>4@ MTA>C76'RS?;;J"DO?!NS4)
<*3^*K! =21JJBZ3*A&EZ.S7'_+740U/.T_E=L M&Q5Y%@75E-
M.ZC|H|EHQD4(W64.P;08(SMUKSJ_*Y91YM|3347CGLH|9%Q*B
MC3M|.U4>>.:^2W<R(976=V& M|JLD\$91F=:2"MU|JAVJ"GH9?&2_+V%2^D
?"/DU7SW|H|&KN^.@>^:S=M/W MVZ!7G_:&S;/N6:<9G(UZ?
CMH#P&VGD"OUCMQKG;N4_K%K/D#+?EKLOBK+Y2@
MB&V15@FR,8B#NDBR)6|;|Z5Z&^>AONKGH2+S RI_U|4,D \$,PKDPN7%|K#F
MI#_N^J?]<9.?M0?-?KMWTCP;,.8"1;A#TSOJG _JD^UCS)8GXH|%ER;L|CA4% M-
'2U/#CJ83-B|O%%5_-^&IFK@-/4:?)%;RB79;&"RP+P<,BBKP>2X|:24_5,)H4
MY4T4>J(T6*Y92L73+#LPP02NDG-(EN%-5EWS_=T4X/AE">:FGN/"?0|^_F82
M|K'W|A:>I-OX3V,PPK&WH_S""GWAJT|2KL(|%KYX;R3LPA

M#H&/18<#+J#TY&3P@3|I"&RH 1:4&W;4QL0\ /6)^=#90#,>\W^Z,SUH2E
MH,^^[W=Z9YRSL^V(P)1|ZWV2RN,%9Z@@@PJ-PY+#Y#UJJ2
MG#ISUXX<*4JBZJO6&;HKJ.RQREK'+0A+[F=Y6VRN5BAZBP(NL-4=GEQ&B:2X
MB[I',J8E'T@|=,HHB<|W@VZ)YWFZ6D|:/9/ 5K9R#|MMID?=(*@RX.3I(S MO -)I&?
O: -(+ZA%I "M"?%UNL+|)*-C"J6N0G?; VYL4(J%>H>FXEJH ?6)
M(.6P<+Q20KW2DU<\$>Z9)Q\$|J<^=4C:1J!>CS3TYY>0M"S|@|I%:O*@|2^<0+E
M#B4RH.%W++7U&;Z1(13)N%HC1_PHF@)B!:=
W/%6F0ND!%=%I'@1E821,MUT01H5>OY\^!3@M4:=?
2>6@2S2#*G^G^P:J|@%6#J_OSA_4PSQ3@AYAR?E&'U9 M^2Z;71:6J|
>"/5M^5G|H\7W;\$.^X#/'#RA#7J0,J!U,5=UH|P93R,%>F M'YSU3MLG_K #*B0_;8+9?
M8|9Z>P@C<9X/@).CT3|:N49)^^&G|5GN9S*5#_MS=WR6W
1J=K#46\,1ZD#>|4_Z:#F6?^D:Z/XW<&IW^&#)|@()G(;A?U3>IF/ M3*2:|0=
(TC4VH@X8|VEU:|U#53=2#5&5|S>DDJO:7FF0(KS0&\$_G"Y2N*A;" M?
*5:M7G(GX=5E4AEH(K>TOE@Y0^MN,S
>CBZ#R|J6'H89%67!7YMT&|PPVS|Z%'A63TX0+GS8)>BIF4\$|L-
!P:./&T0ND9KNG&:N|K|CK4L_E.JD,F^?(7-IV|?NM)UQ#RSS^Q*1^JU;^" MV&;^)!
<|RTK<5O2CP*L;OFR^|P|&PBJ=(NU&V5^| U456@51.6>6^!Y|C* M66+7)OJHE2Y
R08RM9C)GEF8APR#)M1UFFG"B")?M<H M#+|J<|"QH|CR@B?W,3+
|8;#I88#D;.QUCVFK*52F@51E/-79\F M8>(VO,X;KC-
K3!LXG9"CMC141?)%'F94ZDD""P=6R.2EK/T0?AG#69<-E&'R MNM235?
3)M(U(52,KJTKZ |KM;M'^|'VCFN|?*.Z6HYNBWF9H;^_,4 K+W;;Y
M>Y|+=G#6:\$&7|TG9/57X|F3#"L4H2|>J|K|R V(|@I<|.J (K6)CZL:D1|
M,*YR52D*1V8)T?^&/5._826J;/ZM:*I1;SG1WSLY|2MVFKQDXSV; M-C"%|
|9@"B%4AQ5.M>5U5_(N"5*4|M_"L*X2
M|/YEZ^U+D'O75P|KQ(T^";O'T#W?|;NI."&J8DL3?P*"OZ^:2.C38/W6(
MZ\$W>EJ+.AXF2>\$-D|H|*ZH2US'WKf*GZBD '9J5V2WK/D;\$ _19PBH7.MN32Y0:
M,%*D#IK.J@'JWV5^S"6G:OV*T(670\RGL-;SC|_|#^7+6U"RTZCU!_P=&CO MB\H' JO9I-
(O3@?F)Z/4KH3'3;PZF:PTE)65\$<*/YNGNXZ'XFV(\$:)QL!TP
M.90K@H^)%VC"R&2H\$<=JQ2PT,6J+S(@EATW=|10N!8FI92:|J,ZH=ZV86"-C M+
B7S9DI?C#!4MZ<+AS&.992IRMXD'K4*" +CIC(8MMSTKGA,%?K0442='YB' M-
_\$47(Q^I20M=3AEJ:P=;#6+KFC"H+J'FBX:09I?K6KZC+FI-\$TJMHS!H+HX MN?
9YPHULH9-74%A67 S!MR(2.3!B\$WI7* M8FPK:E7Y;
(;'9;E!L(Q8Q'L^63U1W1&MF(45GAEP4+2T8|!T::|?A,J3N4 M(RFU';%=;>=0
_K"\$GT@|_HKXWM9GDV2%-X>(#Q.5-UB36<=3PS'U?IT249E|5C?NBWVZVV!RN,|
R_Y+=^E%,>*48-(6C(M/LMX7T#^<5'TZD6XC"FIH\$@LD/'_9GKB)OF:G 'Q"&?
P3Z6.P/&.53-N|Z7E MVK=8Z|-4N+U!,6%K-|J &SD9,2|V)498PE^7S%:+8
M6<&C/'_Q\$<\$=\$=%=Q51;5+LFN:|TJO(HY1QQED6JL<8T!+M=<9!)L|00)V?Q&
MD0100:@4NZ3<83MG*5+T|PV&JBSBBA5C^DP,>|0S&44C)0!5^I3@.\$=ZB%Q0 M!Y|
=QKQ/5\$=!\$D0)UQ\$UO>6QE7@3.FV!GYR%ON4|ZRU^LT%+/?V'L2+,8) MM(%S7X
L+7T|)\$:0SV+&,I VF%&^9TQORM?9I M JD;14O+L6E|JC2(SSQ5,7D9!KGEJ>JF-
*XBIRR:/E69V>H\$6,AQ-|H#|Y0G MN1DA|HU05P|W&(RRCB)HN2&3@;IAM3Z!91%K%2
G;X649U:--B);%@.C6.= MY6PB5AVJ5ULA^X.=I37S\$",%%+&7E39RVIE;|P+?
#VWUPH8'UPF9OX2C^O?@2_"@RYZ'6| M=FMXI7ZY2^_H7/-?
9S2.|ULE);R>OZK9ZW5VMJ=ONM8O_|8B4K=,= M;?N|FS_U_2?/V?
IXO%5EW*\$5YB%>Y6"@ V:2J2,Z7_5(N4&0\$/>#+Z2|X/X M005L+DZV?
\$_8|H3QZVO,+|)9I!Z4&+QT40P_-!>#^NIXEGD4#N-IZ:\$W|;-@M_0|>N|6|XB6#=
|U|XKN+ETM9L&NMD-R3KNW M7QNR>@L>>IEK4QRV&
|_YVXONB|H=ALF9_3_8E(V77&'Z;U%)W_|Z#S@RO|,CSZ7)V.^-
DYK2=YW*Q|LCTY88L1);GYLUZ7=/ MBA;|QLGIB6-
4QZA/P* @.1!UOUI4WMPJBW=/6|+ 'ZE&-4QZ@.1!UO|A-O;A5\$ MR4|M.E;=)U:M
6,ZZWV|C%@^T^L3|8=Z<.21@B8|@=.D9UC.J<,XXWCX@WMVM? M#%O|CF-
4QZ@.1!UO'A%O.@_WD;-J#1C36>_P^W TWFx701W??%XJZQNBFA M M>KB7JG+5
Y%|JNB?|*" -KE""U|^K< TEYL.*UU^AW>H|9#Y#9|TYLW1|V=W#N M.-S!^;IPWFGU'9P?
(K,|.'=P?M@<|N")C<'CMV?'|!KP-Z'XENI"|Z^X=| MA&!W_|H_? \$?
9V;XIN>U5MHNUMAR(K=8'HEA|':@+MQ=X4!W-?054 13W0J098
M="CRLJRS=%M=5%J"),>V)TX!?)0"N \$QCU3<=CJ-T^ZN"|XCM|5Q|>|VJ;# M<&
<7.3#?FNUTUNKLVG::)|X_/BOW"KECZ1JSM,/P6EY!);O%XH?MD: ^7O7| MH_:PUT&*
|A71GXV@VOT.?V(CXG(YP4:=71G@BTL>.7%9YG_AKU6#UM'/Z|E

MLVFA#0=GX/PVO,C)L3?7L TILTH%%F31WR*35YQ*C.>&JBP[P+4XH)0S"(V M?
S6.^*U-T2Y,^|<9.%XKJ= OVF*C*79:R)'\$|H7HV8X%\$8|^73;!: "3:B'
MJU)RHX;ECZ%KOW5RUNOWNNVSSDFGUQ_"U*P;G>^Q6^|FS":3),(3|24CX
"&C36\$1YTU8 #X.0Y|S8&Z M^).QQ^"%V=QC-RP-
1.MP/=!5_==Q?|VXO|N/W^|1>^_Y*,V1Z9%S&|X-|YCI M
@8LE";7+/)&G8.(^X3/5Q4:WKH&A)J\$ _15B> M39(4IAW0#|/BAWCB8-#%4Q?&.,/75VE_
J;Z| IS(:ZE.4S/"H _|/B7|?8 M|5|R6S_*17A-|)X|HTY%PU0%J?34 @Z:
F!5Z>>0QVOF/!2T=/Y##+8EKB-M)V^<)>E,O Z+2R80_6|Y7F+J8<3|4O8&:')!&L++32.?>
9<(' \$21 M%W"8"= 25NI=LS3D<-QAD#\$CLC: "K J0HQ1GGEQDGD10%5-.8FO\$H!@)<)>
M/.'4S/F/(<'600*4TQ|>V H1!;AE9?,9DF:Y7&8A4@CG"" M^|BX?|D>#C=LM MW3L;^5-
+U:LP@UGXFQSP-!03%\$*XBL9/(S*)O+0;ZW+EH=2B:=B0:TR5+6C
M)9Z+JNM!XGI\$7"JX KAYG\$11 ('FU"5C|< VOCK?|"(8/(^\$)5!:@WZ+9Q..7ZXP\$S_RDQ1>
M/DN0 P =4(^AA5 M?8.< 01X41+' R9FOGW5|+TFX2W%Y
V;+IW%9)5HT5%L#L\$J1:U24E/R@ M4BL 0*MHH#9*;I%;D0.-%7:
|HE7;Z3|!=#VN6=ZVS|>@G 93!O1)NH#H2@\$C M-
>L5Z!+)Z_ (70&GYL=Q|BD=C8UCN*Q;=L+EX_>)GPR:5|@O<0XL0EO9WN|NX
MB:W>,0%K#|: MIAM%9Z,)2E|M/("V#/#C4@|+\$M+6\$,*R,LSB6@LN\$;|BE3&
M%%6R3.D|<33'5KR%C+G*08:TO/=YBAKK-\$DYZFDA(O@X2:=2B2+9 O.EQU\$A MK!
9\$QY1EU^?S5!M(&4QD|@>)%S0+'\$<&@!L'OAAQJ| 5>>D3-(H2MPTI)+, M\$(Q9!!^@.!'<
_P':C+ M5)|Y#J9Q@?@!|X%-)(X 90"@A9/Z#+NK58M0;@R_G3 4+-=|F3QBDN110/((
MHTR3X"8VC";P5|!92NU8DJBDM=!L&H5I!!_P:P9S_1-V58",EEK,#7S'T2I, M9JC9<-
LRP<%)I)R1"WJ?6E#=#I48ZO 9|WV;T/ XQAFP7|8;W4|G|:'B/8@<0%_7F%OT9.XVU?
EG3OVOR%.EDH"CW+P@K<|Z\$^K6AN)EYFU(
M@BM|JH3YVFTS9=|YN:.E,X=0&W>3H9Z8HSI'ON*[?2)X0LG_DQI7!C*8TX#N MO)D".
/4GY.6B@.)16UPFFBS*LLEC.. "I0,|LHGV*Z167MRKFT-;BKZ#2^39/I0'^X'"KKF#AW;TC4
MS0% B5A0MNS7KCY1#2U^E7J)+U-27/C)C&M559UL8X-5<8P^|^AV0"VS|BJE
MY542\$ _;XN7YZ #^':0"7XJ5Z/E:Q3WKM H-89CP-DP!7(\$&, MMLY;/EUZV7T\$IXWMX9
MH "\$,|2@+^OPG\$FW9TQLC&@((Q+/EMVV_)@%'@40:7P;M'DK3TZU41**G2
MF510"1V9B,D'U)'PR36MGC.?40Q#;, @4K-RJ>9&D6&C|O7MIRG^48_U(5:9&B
MY7C%4C2I01M"XY2GH D|M7**6+'!7- 8|"@^%8H,\$(A,7(7LNF+7TM_-PPF M\$-
(!VXQ|A).LHLZ\$WA^26|JLD@&!'G65J(P P'&QLQ*|#%?;BH:|<.0#6#|9D M
HSDPSXB<@.-L<81(BAA(+T4+DWMBMB^4?X ADTA,*4|E^)-R-4C90|W
M\$<|N.%EO?|+T/UN ZU4GYZ"D5D42ZO@8!PUV&2"^(0
ML7C>A.8B,B9*+Y%JM^0W41+K#/1X==KK\$00#|,&Q:T@V8|V-J|%-M)<:W?5FIL:I3P1)
MTH9VO?HJLM=B*:#W#9O+#|6>@0,K9PP<+GO>#8I%4\$J3N<)68SFMXTZGP%J' M
MG0|\$TV2435E1PZR.D4PP_R#+;M&H4:N10K^/;>6R!YISKB=UX+ZHCL"E"1
MO%4U47G)(K5B>NM<8%Z".7)2:P|J@-)%EE\$ _4-%*4E(Z&C+|!D9#14!-IKCS MB0-|
"D@?/%|0ZF,XB1"&?;M/;/91FWT5|FB4YL\$+QFHQ:"MS:|A_%'M*
M8NY0"BL,XO\$2K'&O"+,6NEJ(+1'S8?)K*^K;|#"X|"+V")=,(CMQTL977*B
MN4")I*%T!RIUV(Y&H"V"+5OBQ@QU>|+<90RG#O!L+'\$F>0QA8N-01KWD8@_U
M.+0J;.:Z23?"JVMU-J|SL(H"KC8"U8X<.J:D?KY\$GBD|D+)7G?5X1:%S22M
MPT;%J5GGL*T|61LEQCW-R:IC7MQEEOC?T>*EF'KT=E_!="8.G|Y#7;: 7|/#
MPK@XI\$O4HW.E3XO|*"5N(4L7/J\$BEA _H6Y_L R%'Y+|=(IN"< 6=1ND8CZ* MGX|B?>
Z2Y.7=OE.886ZT"QF4'HWQI*D>*F;Z;A(?)YASE\$.=9GF+ 7H2S M*)Y+TW2@W?
NF^/|E8FL^%G#4 IG||RC=6PN13CAX!Z4R01TTV6-1\$OS"JF M0NN0DW"R|5+|!|-
I^9")@_Z)0:S14N\$<5NKTO=\$#F2|=(.N^W=,*&R:V1(QO(2PNH%: ^*,"Y#SA>C
M6&6*.48%^.I'8YF39%Z;C" VY0MEI9|'G+WDC?;(6)O.|H%K!M>#/FO&;@Z8O?R+?=?;6
M:O^H?XXI6FPF^"O!:@=0 2.5R0/38B|5V=>A".6U|O|?;\$4? *L(AF64JS5*
MJ_SG^SH2M%O#5=T""M2.((P7JU--PR"(>%5UJA4^@V=AKR?H^; !49>G?1^1
M|;^)/=NM|G"P">67ZH+1XT_OPRE<<>'TRA.I_|<7|)?A<-_Z?9ZW_JM/V=7 M+
|&#&1N7G);8_&79GMZ|5%_=.!S/B|O4K@3E_6Q_0.E@89G>(UANV^MW|_*T"
M""%OMDP<|U6X-'O#43AX9MCH/H4=-'W'+<#V716#=#|@C5=|@F;?B<7?
-2_|M?;J#Y2|JU2 MQ(=/+BOU;V9XZ|IP M1V4W1Z7|D&9=|W%4GOD8^7\$W1?
&=B!3G|UX@YD',@XD'\$@|Y0@TW<@4Z.K*PJ/6|Z|H%28_|QUU1/T-JT M!MUC'Q/-
OUYU@|A^|E.N1S/9FE+O=|R|LG?9#7/..P|T<_OH&'AZEX5|;
M@L6B*7@;CG=|!.*DIANP|PWN'5(46W!VZKATC|BT!CSI|-1QJL/3E9I7YR\$&
MN&-3!Z@.4!VG.D!=!M2NTU#WB4UKP)0.4!VG.D!=";B|\$|>F>|2F-6!*|ZB.
M4QV@K@34_D-"E!V;/O3R7"=^NLOS'5^>WUDOKAX05--M<#?J>P_R=;E17R^2 M;J?

4KU=,IQ.L-6#-HX*&_L"QZ7ZRJ4-
0QYHU95+7)L6@,V=0CJ6+.FK'E4"#I2'JV8!,:L*E#4,>:-67-8T+0/H-R
MSQV,NB3R_,P'K^B%5@_V>D>U\$ \$0.H1WE^!.^:L)ICCE[X"@H>NBRO>431V"
M.M:L*6LZ!'5LN@=LZA#4L69-6?.H\$-35WMA7-G4(ZEBSIJQY7-CJPHCVE\$T=
M@CK6K"EK'A>"NG)%C/!\$AS_9*+TUS76T>G"OO^U%"_O8"IF#Z!>1;R@5/
MKWFPBDV&;7^CROW%E.^:XOKDNX!H>B^<&?N7F4IY/SP&SP-6SV%68EO<%(I7
C8GF_P:307MH?@VKK4",-PI!>170^_^,=IMS-!+;RWANP>BP/O7)'>2!9[MC;O?1BSV]9
MY+U)XH..BT)E)X\RG!%WJ<93QE^(5;)6F)71!"_WYKT.O\N#A_&[CO6|^>
M*\$5?)JP;)U&4W,!!/3%)BCP1MP#!Z\,;@EW_F,4E7IR,;)EZ2I_@A]9UB
M&0^L:\$JH'LF3S01GY-6?A-G&4QNO(\$<.:I\1D*4JXW.I@QV018[CR.,Q!M*
'YPS\$H@'\$6S;UQFDSA]8G@WBQ_-@0=@M.:WK\ZO\$O.??P\$'7;K!^T()YML73N@7K)D?
U\27;001KA@QKATHQ-SW9>&T+421/MU6DRJ\CC/?S)!7P'@"N"?
M/'_XBO8.B9@J.D,UHN+I+8E*M>+#@I&YV\W_P3VEO:4E@9X)BWC+?3X=-5OT.@U:>
<.,#IO8GW@TL=4S\$):S#MOR!?O:'Q^"C-!9AWY2/IU@-,MJ>1&5T^I(1&SZD2?
0*6N0\YC9.L%E'^R;T)MN^8>|Y-G09J%";(P8,XL#>\$,R_!WX/8O
MYPR0,.4IGE<@'.@,SPIU\$"MOAQ,:R=S!?'W=W\+JZ%B_C\MU_??;GX^@>M@M_
+B\OC0T*LO#8(X=L5C-M1!->FI\9-|)&+C318T1&&F'*@S"?-D&<3!\$88=-&/KA*?
R=E"EJSBF.'%_E M\$>!.DA*\$\BQ\$VQ.D\$ NNX76-CD'QA'Q7F\$I"!8HS!.%9)@&L1FR)CC
M9,JE/,>?A7%.ZJ61\$03G/_2&W58'M(0(#F#<6!1F/PPZ9ZVN_EIQ94JH'W-M00T6)(O7?
R&<;J-HK-4+3,;,GC(:G+;2S)(X@4I%0XP]=Z_M\AC+D4TG!_,15/G-.3R;(3H&>*"?
@M_TMF00KU+>%\$/3/N?HC1%&ZX>%P\,3;V2<*#X)M,|"TL\CHJY2-M7JY9E,OA&,X-5
'\$PY#T?1B/7:'>#XH>3_\$3[R(-Q02V"+0[VDIVZ^&A0?W\|
M*QU\$15TBIWHE|!\$DR'L,/\$*T8[G:QP3@%-5=)K0;M.4Z:E3@!?'ZBV'(B\$0-1X
MIW>QK|^7@Z)-25E<)RG0(4*7&D92B\$4?K3G30-.-HE812"\$@!G-M^&-RG4C+A""&H
9/I@A?D"H086F*EH(TE.!K!8|<'-8-#F.4S/'4HB650\8-MY3HD,.6!|!\$Q?>58UV21-
|BNIKW-CSPSVXXKG6)D2.\$L:84KX-M+7\$F!|26-D%)".(-_8ETF_(WWJB2<9X/5-PT-
SCB1L^'-|A\$HI-&|":R
MAA)_GCNO;00H*|1\|L3YK'P"R=)BEZ%5!R!%SX:3B2.\$|.ICUCCCL@7Y1-M-
+;5&0DJ!*|U8(2&5Y9_!E9"-OYQO80%JZ!92!M.:D3FM|R.WNH4KJH_/(
MGQX&,IZ#UJA|=5HN%P@EC6K@|BQ),3RIY-2|'R')\$S'B',V#<21JGF"K!#9-M6';4G/O|_
KR6O-O#/0'C6<*3ZY0(J6|SD-P2*&|X7)"LU_|HMS,'@:SAZV6=?UNLB|L.RP"ZE-M
?:19PX:+#=#KI8G;H&,*D(-'R-CY:WG&+|@P_);P%FZF20P\$-R6PDO0GQ"2
M5Q#P(@,=**?;%WQZ-F%P)'U0W1_SZM_@'KU58X;:LQG<|<MDB5WL!S'@|.4@3KE
"U<#|Z|&:%YDJN?R#=UVNU6^T?I>S@|!\$9L)_DJHHP<
M1\$S/O5BLQ'0=BG!\$YMAK_7Q%B27YNGZ|=H^=.\$|U'KE/\$|/Z|XKO.-1JH-MP4EW-
Z_:S2.=5N=T-POJPIL>|*)6K^V|@|V|HYZ:|VXY50>(C:K_|H9S_-M|*K?
<%^X#=>|!\$90'@RPJZ76;5+0C\N^'9)E5YK)_|B(5WJ+<|(*FEJAM0
MVZPUAPG;*9SI@+RNF_-8D0&Z'Z'6:Q0RL-?0>>1H?'=2OIM1;=NE30M8=FR0/M9KOG!
(+#+%B<0;KEI3XM!+R|B'0#@N=|86P'M,O79"Z<).JAQVLLC_)1G^|
|P|6Q/_0;Q83:L8'U+?+X*-O1-;U*?C#?M4D-MW27WJ\O9Z/3.6L-CI-C=R#TC@94#
|R(LV-#AY=4PAG#01V;|@^_/C|3/KD*_M^J.CM)-+3J%W-HH\$5.-T,&C5N->5\$U\$..!T;UI-
C00OG4*_7VSZ_\$SY/K|MQC<"3Q2Y;"><4X|W|K;3SN(N^A*H=|5?'^ANGUMU!|*DLMC
JUW=/>_1B3ND-M:RG1'E'TWWA.7>6CYY"9TX+SL#_K'>H/S-MT-B-
U84RW%6.N_AVN/G|C+D#W.QVCC5,R,%FW=50%|+J!)034\$A-MG(1RN/G|_.APY>6<*"
|K;ML!Z'P8?|R=YW@I&?M-MI>=@X*P.)SZ=U?'|.AP%QJF34-XWZ\2/#C?
W"#>'+IG+H>8>Z?4N*^%=UO6.\$JY|YFEF??V.\$')MB@D/->NJ@|B;|R2?
G1P>;>P2;KMRS0|U|4NM=5L*!|O:G;,+3'4/1""B-I^:3%A#;\$TD4-M!HY>5\$W
JO8B|8&4/%*AV^ET=VZLW+/%#JZUW:L+MSO1|P:A|L.GY-GP<.
MG1TZ|ZJH>Y#G!QT&SL5,<.CMT/BPI
MY9DS1;KMW5|PT/N.XH+G:Y*QR&!G|G(IGSW9:>@\$H1.\$|1*\$9ST7^>DH<-G
MA|L.G^N(SX.V@V<'SP=FJ#QS1D|WQQD|W:/)Z-%|1@2+N&AX,<^>%;NZ+22|
M%R3Y*).U\$|0/Q:X?GEEB;T#4XY39G4;|M+?S3NAW;E+=Y';ME=0|\$M?|;TW5
M&J9KSZH.G3?B|T%GYUVE'#0?32|*Q|G|_|""#L;Y4"EX5FW_2-
^|Y^U3NK\$|0Z:#Q>:=W?G-W|R8"?Z:P4A.NTGY)C5ZRK>=?K-M'L%QN-P@O/|AB
F!O';%F^JTX7Q@0)@K_D|-|=|T5W3|JME|/8|X;3,(4^YG-M80((F\$3Y-'X=A&(6L?
DK_-')^5H#V*O9XD(M:>R41RP+KSD-P2W2!-=L.%V!>|N;EFG>P|9|HBU-MX?
PIW;WL5!&7|A>|H_-M<3,HS"&B64LS5ZQ/\$M>E|_2LN/Y>;3!28;PW)?L>B&S<7K%SL;
M-JF\$)-Q#BR^6|G>|V|C)R>N8E+9:'KYBT|RZ|>O8?FOOZ_VX.!>;H^>;VZ/;

MZ=T1YO>+WR^?OGTP9N5|VFOTD3 'V'L U,*'GBCN==I JCP8&K^Q+MA IX(
M89'P>B_ (N9-N%>G\$!//62L9?'828P;"3P6 S_ | 5:W>?? M"Q|!T:C"T7T8=
<(R|P:F"E_ #&_AX#)"/_T'BW.6SKUNN|MO>>=?+BZ_GK| MIX'
/RX^7GR|^+3.R@;W+:RWX<+:6UK8AS|^.?_P^|5::^C>MXC^8(-5Z!|*M_*
|7.OV1/NW*E3UT033&/)(JOAI5S,4(9=|VC>6A"-QWTNOP*! U|LE>RP M% @9
LA'+8%#88N;->(KB\$80|A(Q1_7FXW|96R| "L|H|M.<,X&'H^0&.,*)
M.,_"/PW0RF"FQQ|&C(:=QZ|ACP+?I:S|JPE-9!@@DX&"9IL&C\$D:_D/.B5 M"2BR80P#
<5!7IOA< U>&)|":@6QMX.,_G+:&'I |PL'A" 5N6'2 G W*\$@=& M"S3|CL|S2;>OX
Y,WD"B\$/:3+U?-#G&9(I6YQCD,|B6\$K&BS6-0CH'8CL, M?'HX_#M.
(MA#W\$K2|ST_F<)<F<;&(9C//,|2&"@PT?" PT)/GX+
M>TLT"B"!'O_1>;87HAV122%I7Q)R1HEDV,' Q^/,FF U)KGXBW|1H@|GX
MH_X|L%'\$9H*_ \$ARV\$-B_;&'2N0Q'"X0BS^2O]?\$5DGGs=X*35/QO^
M:*NG:|U2/_UYQ7.=!SS2:0TZ@|V|JM4?GKE%U6Y1=T2;GMY97J3J:#|H!!5L
ML|6=1M7&V>E|N^Z|!OC-WUZY/+ZA8ZC-3_'%>CQQ)RR-0YC?8DC|
MXGKOE@3N1D|2+>V+<2S08&?NI?KN+ZD<,JR)#MW'H. ^G/W5%%6S^L;>'R4
MAG|M":!+:IN!I.*X/F|:(#|U"9W"L;L+J8<)OY<7L78>B-6Y8-
L\$J>6K+^4|W<0QCP8MC;6W0;_ Y|:#=L>\$M8(ZIY%H=TSQG+05FMH:V|:G6O_-!|
MFX,V|VU"!VV#DPT+L.|? SZ/D?R8WD7.2'X"3K|KKMF=@&>4|4>*O+W^2:OK
M&,|E4ZI/#3&.E9\$ZPY;0|=X#M\$YQ|YZZ0|HXZ5BG# MNV3V^P-@|O0X/!T;;Q0S=\$Q
W3W=M+|ATS&O"1MR|.O44X><|6-JAYRK5-RS
MSFYO@!QR.N1TR+D_K.>0<|5FG)YNV&" 6<|K|=6H)
MM|6S45URVL4^/89Z1PKR#VGR|H2|O.I(|U3D_5*1'90Z*'VV'C0.2!V0.B!U M0.J
M*R3GCB-=/N^A|J&)<=8Y?GS=A-I'%QV-^Q61M>2^\$N?E9PQOG60ZS.,7/
M=3|AR|LPM?3E0-0V@P...*/2WRF'Z<+W6"A_>812T?R BN++17(AX)4M#RMB
M8QEOD>%@_'86IE2U/_=FF-"|&@|7C\$-DQ9)\$G>)9%?(KU^7&B40@H*+C'KE(N/R50
ML.KH,!|X3R_RF&J6>'2.IY=>LX=UP|R|J%|!\$O|0-X#3!:(D|_";@D@=<-+ MDSF+LGES#
WZ,L.?B&/_4C(S|1 V_AE0T/V):S-IA1G)>NC2|'Z9^/A49 RX4+>|W,VEK!S8FNFJ-
T#F3)#^? MOIQ%):++CQ;)OD |/<>5;&6?KS4);=&M<3?5QTDZS2-
9XW|MRFLBPP/5&R&2 M*1S*J3X%I^ONC;_Q.L"E72W(R8|MR@|A3|_))
|_)/!TR_=0HG"412|T++P@% M:2;5|J):7"Q)"YT*UECJ,8//|HBXAXN2M8;?
KIQ9|Y7VR5T22+VS!OU7M63H M=|HM75|CYPUL5R)R?T)8%B2
7KBSH%*&."7XZWP1M(6" @ U>|_).6DVBC|T M'QNL78W0NQ|?O7I?J(&-L,V" K#32IN;4
+>M6K,(-9^!M0YU<6YV/LTD*L MB.SS12H/WAX!^>F%D2QO+XH%0E6*2/U>4<=@(:
<1X#"\$:\$QOKE M/&BI?4*|5GU;4-0#OB@UA(N_,=IMS-|3:U=#+Z9:'1FZKOV,>KEK/W,
G5H.Z!4N|Y^;|^W67VA"/=>3_|_|O60ZVMU_F9OSXX,RAC%-?CJEIWIZ0O|:D=0K0|R?
Z/&>3/:E.MVXLITY|VOL2-4+;C.G7=W MW@_|O.^VR)MEE&VO4|R|>U0J_G9\$U>,3(
K8'&AQ7'S|_ =W?STTFQP..S&-* M%=3E%.VFRL8RO;:|TT=:6:/:|FPLL;A<.P.9.\$3@V^_
T/6YM(U#8\$0'G?L(-MG?W3DPW+(1.OSKH=-!9"T9TT+F/T/FRVS|KG3B6W8AE*R,-
=|N(SKD8=NAB MT(40CO28|*>*<:2 WNGU-
ZQT|!C5Z<).%W;,>+2(V3UK/21JV#&J0TR'F\$?-
MB\$>*F/W6T+&IBT5PCH+/%35|LF^E.B0/SNH-Y=|. &'HY/G?;KM%_'B,<*F+VA M6-W"P?
W6 M2'FD N&TO?-PW0>7UCA;G>H?DA:N0-R!^3/ N1G|9W?|#H@=T#N@/P86-L!
M^2Y=-.V=9X'L\$Y(-LOMGRP\$@@@QW+B4&=Y<2."^ |ZR'KMKIXRH(DQYZ=:9,I M^Y-
!&'J|JEXZ0_|S^S06=BCV@F8VNM3|F;5_4#ZD,'ZF&_UWI(>PX'U ZH M'5 |H'9 O;_Z'2>
|SUK<+Z1^\$|_E@N?37^E1'+=Y|U^L>:REY=JNG'YK MT.O|N#5_S|9|-=NFQ|
<)|P+NIYP)|H7QDE,'_A*QC =>EG@9_#9:79/4NV\$" M_A""RF%.7I!S_5#*?1|"@8+Q_Y"W,-
F1EXR|M=J-X8PJ0@DO|Z9X-67S>^ M:|3?I2+|)K3EZ>MCOX*Q|*)-6=L/H6EP+|!
(;G(&O;X45=|?69&#_'86JN=@J"1/#,YKOL|O|I%AHOK MM|S/>2IR!@10M'X?
QBSRSF|8&GBA\$#E,!1ZY8:FCV|=V-%;)E!>.WY\$1," M\$?^*-Q5.XU1@+ #A#^
_UYW_3R;U|U>R|'D?MAF\$P'>XVE>PFGP.OPY",808 M_!5^NR0\$6@/
=:/*XAD';WL!!^=8XRS,(@G@2|)PG"93|Q|L%H+!-M*OA.VO7RX^ M_M|SPG|UR7^?
O_CW9=S0.0TR:|FG@|J*@\$%C/NA^,0Q@M@5(&@W6WWVBWO MGR0R,E63*?
TVOND&|S52/MQGF)HKGQ3=|P0'R3M+Y#!;A?/H&!!U P,^9
M)V"/84T^BJ=9DFJ9AR|)0#5G452QIB2|Q6M^JE03H%|KF/|'O@%(1^9"Q0?
MD/%^+H2E7;&KE'-4\$4%|!#;-)U?&|A|^4&AIH5#S+'Q_-'>*KA"?@2 #GPO|X
MI#@<*:WNZ=>LTA?Q=TJU;_ P7*J=4G\$IP.@O_W':|1;_L2\$|Y%?A1GLMK_!
M5KP!U9F|T"1|ZIVG*785),K72<5\$4G:Z-2>E8M*ZT:W;>8WB0G'C1<:G7D?1
M|Q.=QG.,Y_,)1 #CD=LAMZ'\$1&^!N>)R!K5RA3EB:D|*E M@*?V|\$UAC&@.)O;H3U2-

.0_LQ2@GLTFWL7O7@3#7DFP1:<&%S-:?)'H'!' M8G0W-A^TA/*#8=T#P*Q[S-
/0!T\$TDK,.\$;".^Y5W\$4GD*!R>T>RU'G93
MZ%D@E*H&8S%:^1R_GB8I7T=CF!*Y%W\$F]5\$.G|&|SA<7^X3(4|HR2,XNB->
(7\17N'!*.V:%&T?DXQ|G;.& M5V_P?9-
_IV\$F508DRQOX!AY''+|.D(U''9''Y>*YFF73P*F)'.I.O#S"GND/8\$ M/4.Q'|*.76:P
:WO3K263(\$*>1C#?Z?R/(&\$S!\$6"<5WM=WJ#;'|@;>66\$+N M?\$EBG"N1|07&+
X#UR;IA-1%I/(9LA3BWIMU@95>A3@^/G77S6!|J%R6S" M8"D^S^EF+X(Y5|>
MZ110>#,&QBSQ83(>H^X_F@,X_M!KG9CG;.:?ZM!0|J49I>8O36WA-M3^=E:?.& MXZ"H)
<1"&:9|/;?3KJGK;;M-4>W,=GZ) E3"=8_#(8GI<63CUIY.|=Z5K)BH
M%%=:!LL#\"|.35('C(0RU=8/\$;).*L%6S;4Z+&CQ:NAAEM,AB;;2O:TZA80H
MB|4.5P&T&8!N7GME.5\$)|J0|AM0_7Z<3T>@+M%5;^9/2!T* &2O61AAL \$^
MI5P=R|*F2ARJ-Q5WJ,8"FK&,<,UH4XM\$T%.G9XM;4?)HX|4T+)>!&DAWT|(8_MHN_?
.:D8:~?DBB^YX)?H378F&@URNF952+7|YEEZ4DY6;@<*>|M|4N#)3X8RS1SO-Q@-
TQ:G;,\$9X&V@%8I" ^76UCIA"LN+|F|L/K/T(=;DFL|: MY7V|2U(=M51R7L0CD-1O);,C&|H|
<1:(#<#|;|G/"7Q|G0;I_'0F\$=T;J&*# M7H'CZ ;/EQ+);|<|J:9T40#KK|A(!<|VC>6!8-
5'5=U)Z|'04H(_TY2C+UQ/%I" *G7) MK5# ^7OX1|BH>S\$ |J/TDC|.48L3R3(2!L;E(>N;
^'N@:0(SH'W!A|A+|(?R_M,EVR'VD*TL6"K"B2""C@| \$KR676F(F.P?.|R>(XQ|
_B";X%|%G#/&DG.= MS|U8K%2 A@+=|LQ?Z>< CW5:GV|;^ M|Y Q'O!
(:|!WZ|N7|545WEA=;*/JP#^H_D<8KY|B4QU">WK0>7I =_SF;R|. M7CR:?
A4+>69Z5D>>|S|SL694=!0Z_#XS)|?K3N|1|.7S4>B.PEFG=|;-.VW)'YREWKE=_:30((
M^=(I\$/NL0#RM,'MY\$>LK55%9B&/KL.'4C#7|A+:|FU4&);I8CR+*,>SK'4>GKIFZ1Y5:-
RL/.E.:I,>:1G2;G^P8172G90@/;2ZT(>* MN<^B,3L@=4!:/R =|%KMVG"R U(I
Y('9#N(9" ^&|8DO90<71WY>^/MBR= MJ|N|;W6W3UW=
|0.MNWU|E2\$7*X'X|_LV59)55I-3_9@ZTSJKR M8^6Z8#A4>=U\$)7N|*AD;9@-
TXQD6/UE> R,%E? MYA4O3,FGQ%&|UM3%|Q=?OWSZ@\$G=S63<-
'G(E'RL*;0#N11U02%=(J MJ#*6"P=;5:U) '\$\$3Z|'#W|)I1ERX U5D(|J7.I:#5-X-
7(TVUTPC1H(@K. M%VD)!!9+%3/%NKWWK9Q/9U\$RY|RIYZE_T: :2L-
(!MH)0MU_7!"5\$0)1L>: M3A/. BJXE*78WHBOI/EX87?MN>L=?NU-
0(3|J(UB/Y<&PMH76+2\$7BAW TX* MK#W(9952'\$IU=X U_%^/8+|
:MX4|VH6|P|+'6_NYO4_4|KK&WG|N^L M-
(%:W|ZL|YE*+|CFHT_1. FYTS">JW6RH^6V)XCD^ MT;#O0G4/5!;G'*Y#:36+O|Z!QT=I^
>&8+%H"TZ&8!HGX.(IR:M4R^?/VGQ M*8NQ!?!%|TH8."7T\$=R_<<\$;IW'671_/R;
|2#ER2-DL6|H|2MTA95\8VX%;
M??;B=N5V',P|K9U|3QF>/3!TGSW#>:M)HBM#O%_51"5|=G+OE;APA-U'+G6\$
M.A2N<|?9<:DCU,%PG3O.CDN?C5";6U%/%=UHY'1F|>W1W;N45%I0;VKO;6Z
M!76SNMY6Y+8Y@|M!^CX3=I^(Z0AU*%SGCK/C4D>H@^\$Z=YP=E^Z1P?68|A\$5
MMM4_7O*X|6D-N-(!IF/\$XP7,0>LA51H_8 M#W;Z0F?L@F_H|U//4"K!A!U*.
+S@45&|A2XGI15'U^OY:@D|\$GKI#Z|?G?% M%L?
M#I@=,|MJSI@WH3;|YV=.||=, #M@=L|A?S|@'D3;G_9&0Z|6'VVB'S
M0T/B*HNZ/W>H47?'+|JN|;BXOB89M;IW+BXGL)W =@+|Z6|EV|M/E-@G@5U| M=G?
(|)!Y3UC5(?FW'YVNO-X*0?,#I@=,|A?JSI@WH3;NZVS^K#Z0>*R:|'Q M-XZJB|@UZ'
5Z0Z0L/M\$3\$>H0^\$Z=YP=ESI""0S7N>/LN'2/ZL5NN1*)RX!Y
M*JOKW706)7/.FRF/6,8#Y|RL(1*Y3#R7,+K;N_Q.OS5PC+I'C%H#MG2(Z1CQ
M>!&S>^J2|/>*46O_E@XQ'2,>+6*^|/1.IT?*J,^(M1PN8+SL|+|H1%SX|J(|:SB?S9\$?
D+8>')!E81+7_ZMJ@\$Q.:#JA>;1"<^#Z_M|^P5F|: *1U>.D8|6KP|VWDM;,>F=2.4PTO'B
XOUW3*|'9>)Z(N?.H"99Q3_M9NU&/O4_J1I TJ%
(2U>8R15F>A:)V^FZ=CW|S.T.F|TP|PEK.F#>J&)>=^<1 MD_Z8'3|8#X^5G7
O)&/:O=._7T"YH,*+G+=>H|L&,EN/>&J4JA.7CMY|>2U MD|=;|'#U^ZUV?9B|= @*|HNSND-
DA|YZPJ|D/FC9|YV'7M>O:9W1TR.V3>\$U9U
MR+R1CZOK&JG5V,FUW6"MWHz=7+WC<7)|X8*SU)|X+ Z|@%_S*)E-X2OGYCH.
MD=UM=1'&@B0?1;QV00NA*/;#;T00#:AZI/*|VQ|L<' ^|3L%U _B4|_F2P7/JK69#M
M.^JW!KW>CUMS(#T8/XMWW_6Z1T!M32BP|J|:-
CV^3KC@'ILF>9P)CZ7S">,A^NQL^H+I?P4G|!%4HTOB(*O_,HG"1)@&^_3|(4?
Y%'+\$O2N<=F|+YK M.3P=1W"9IA?*JK-\$J0ZO ^6/)WRU,>_7H=L%\$9A!K2
;8#7)9B)ZHV9#R.+ M5OU8U1W69SRLP,Y^RH'YD:_UZ?-4ZT4|=^._AZ,4
M)|GLT)\$S_^S2V\$;9BR51U,N\$=JEH5CKWX3OF!.*|OX|Y;W#L\$ _/' +^8??
M+ZK)K1|.U#3PA?@V@%0&R./K!2UN@2\$I+ ,! T9,QF/! ?A@;%X>=)P UMYH MI%HF?
92@|L33J2?8F&=S(E&61#Q5R*-G(1>LA|<%2RR"TU=3;QBT7@DP_%< M,H+

(f@:P89D"9N3C-|E,XNS81F/%6UA@832C!Z M08L8QZ<%W8E.5/P|H\$
M.:7N@.2<1<'4L'Z&+X6=QA\|D6#)11CHYO^Q|ZW-;2-)MG\%X6G/RA\$DFV^* MTLZ-<-
O=H>\$;* NNUN/|/9> GJWQ4719E M=5S--&H+IS|Z8.3OM!|H\$GC.P=)0K|HR8VJ%?
8\|ODB/9OE-P_H|P3\TIM)\| MARYWHYBXFNGAYTWW|2FD>&+0J*79-@^_2.
(@7:URZ_CQU|F^O.F))9&EOD2_
Mj=.F1>O;|I"AB<6D;R*M&J4JWL!ZKXWZ^\$2MV|D:A5QE=Z_)0Y"OVI0:XUZ
M'7|?/8N)VV;Z27*_OW|SXX|J|JU|PEW/>&63FO<|K;S/T|Y!OI7|_YM"QK:
MG0VWC2>>%#WD^OMO7VW?@|H|NRUPR.OAF1%6^9N_O1F^>;|MG3DQ/+-|FK
M@|(C2!\$2J@'.LIG;Q3D(!\$I?/G@8_R?BL#W'&7VDN;/XUDN5:'9 M?;<&-S:
(|AJ2_Y4BM'IV>E8'Z4MYQ.96KU.X|5PO4|N2ZVINRK*K0(F HRN
M_|0EC*XJ&Q"O|PN/OD6|<1C+^768*H.2|8Z5_O3;.^(^;WL_QCV&%8I8\$*
M:DH%AR4Q@|H:/I68 \$!:9|CO#P^L^U\$| M!!YS0H+:0&V@MG)0V|@-:@.U@=I
;76CMHN#;PR<#P)+4-BGKL3YHA@NIKN)
MU70W;#%46%D|OJ\$..^DY>_#GI.F/7WDH;O'GZI9=G!G<4#U;J/+>3%^1H|JX)G.^926I
MNL&^S1GHT.TG-%>(AX|LB-A'>F>J4(?|P7'|L/N=8PV+\$50*(@615HA(+|<'M%F!D8)
(0:0@4A#I1OC,"?>X2D2DQRNB|IM6Q/1!'CYT8V5P|E MIK;R!::I?ZI-
H_NK9N|ZZLG|HN.&4AURSF<*)W/_VG&CA2>65_SM|JL:|(5
MMWLH^D/_D@B/F\$^;;;ZM2E|YWH11*YZMCHUW;V5Q?->,WC>|XG!30<1,1Z<
M5W;JH|D'XQ4DT_"8OWDT9|EFI>F/ZWNN3PV+16B.AE|I|@B2M/|:#KW8LQ92Z M>R6|.
|&,S&FZ112LT(P;PP(N-L;W98?OD)F7;W662&2.1C8^P1F_7ZW:8HAVY2+
(Z'#MK,SV@4|Z#P-/P5|9Z#^_G_5F-?V95=M|;_TY(M|SO6)S|6_HW+-N'|*)QR:L|7*+8
XH|H'U|!.X*OH;AMDAKH)SG6N,H' M/N%(+!R)!8E6\$9>E/*T*0E(IM#UDAM(05;"A4
^B,I10%<#"TJJ61"L@15A: M5;8:4 ^BX088SGD^&H1#P+ZKA)6 |@!%2) #B 'D\$-)R
\$5(DZV\$D2%B!=? M"SXIEDVDL6QN'LLFUF/9D(&%#"QD8)UW!E:GU2D-
CI'("AH%C8)&*TBC04%K M5!H@|T?!H^!1|&@%>?2BAP;|GH?EPP|\$*&UZ|BLGMI5-*?
*SOVD>4|T|Q M;J|(8W7W3.K/=>X|?_2S1|+X&"8WUM?TT2YUZN*O?
|GL=MO7/W_|JG|J7+_C M;-B!?'MQ Q;|!//XMX|<:)|"4).\$K| MN-
D@0>UA029S+9%0WDH_H2LC2N*T@|OCT-A MQSJ?>")M,9?6-/0HB/*>.DG(=
|O/\$O^+0/|@K;-3!;^_?5)1/Y,8OY;GWP| ME,L&/3,N=
H|Q:Y^:@(3CZB:LHC_5|M|VUQXB.|NZA(?;D&5<(136.BBB*A*J M
_Z0V'*&N"QE.;,26TJARBS\$SI!!7(? T/X;%0C9Q9=BA*MBMF|\$UJKE\$*R!% M&%U5-
B"0350QTPPY0<@FAAT&.PSD<')R0#8QR 'D')-G&)5H+(G|QM>|> M@_6)
2"CV")53!IR-*J8HU&AF/4CYU^<;6Y%O|L:U!R QYR/8#8P&YBM%,S6 M:|?&-0<@F
W;|F8|V;K=(Z;#EM19CM|#R%U)V;/X;7W\$ \$PU4R@D**0:6#IG MJHSQ|V"\$ H
MW>:|/A%'1Q|8%V8'X5W#|E?.QH%&JHQ&>CS8K*+D<;Q3(A^)SSLGK=9K=4L"
M71RT"|X\$;Y8,>N#-71L=|>|&?Y64.+ \$7 @8%|X)!GV1YGK#(0VD(M)(!&4S
MOM4;7HZ=C?C4\$;7JT<5WM=%11V;K_4Q,MB8(>*.CQ0BS1 M|:'7
5,OA)@\$3P*|@6/|AJ)T7%=N:|1T"AH%#1:-
QKMHS|GRV_BH*H9;01):MHAFFJZ9N!6NIRHY38.P&0E5E.Z6;E#5 MY%2E-WYL*
(4J^)_8_S|SK3D26DT@N|2;|E2M77E-XIOE=7QBM/)/K0V6/XX)I
MH:NJQ:U<8\$G_U@T#GO_6LM;3G;9WGEZ7A&>?1J/6S=((F)|O|913\$WB|H#5
M<|L+A|J9D3V33N+1+=24B51|Y891<|OM|M"ZX.:98GF_!.%DKTHIY M=Y(|M1
NRU:5IU/OX|ZYOGH+=3T|'+LS;JS6JBO/)*+G(A%UF=ZL#L64,WZ MO%)E8<+>"+
|35S|K,C&5&=_X|>;OTB;%77C3|7BT48W--#8DD/^:'3&J3G MWC9HNGA>
<.:2I'4A(4GT|*5V;/I5?|0RX>!O'O0'A7=T;MC(4.=8E#ZZNX MMWX+
ZZN1Y*|^\$E7S|S|ZQ7IS!-*6AZ3H%"E<=6J1Y5&|*|N_4.5QBIMA\$%F MJ-
)8(136^K#9JDBH CA#E<8SQ&4ICXE&P:|2J'+(#%4:7X9F4:6Q5M1=%>56 M
1,|1M<9XA)&5Y4-"%1HK+AIAEI+1T,SJC1"WU7":@ YG(0<4*41Y !R #F@
M2F.)5H(X)/"%UX*1-/0XMY:Y-%TD|5H.B0^(?.\$)B4JGG_@T.G(AH5HG/H%'
MP:/@T;/DT80Q"\$3Z+"S#;.@6CGAZ%8-2R,&IG.#|E@=XE8M27W*=Y?D|^8QFN
MU4HGW=PIT1G4_1TYI.*>WJ>N4K>;K'6ZYU,H/>\$|649Z^F"S|V(>VUM|K(GC
MT)TD.FG.Y*@N! %6>|8|4.6ZFI326^\$E0N68"LX|%;XMK;EP_9C^YXQM3FV- M8LLFN
O5'C>;68Z<2I58SDT1423CJ)&^@)/+IU/ZR)HL'^@8O_M?K2|ME: ^=M|?)S\$EIR.I5V|
|JCJK<=R<)>79,4N^1P.KD13I<+MS-L==ZF^>'RWI;2B=2= MNNF6XSK4K-B:"9*0
ML#B/..1Q=><\$|SA-|9\|D\$8U?%*6X>YF4|YI,T@_)//&\$@ECBAW+NQGQ2 &.3
M;E5'*"AD1LDDO\$'S2=U5(7S1Z*/HVA8+C7"7S;4#?2_I#%28-.G,FB\$ MIY_?N?%L%GCZL
@UHQ=BF7)+|6:14#="-R:|M:S_H>Y\$|L9*4GB1KHAMU6^U, M |W*WV3R:|?%-
OV;:2&I:0"Y.?(?|H=H I(.^%8/_3&O=X M."J:M/|Y^5?+%F&XI-

&^\$Z%#N/JATV|UBE>J.3.59.P0&VV|H=|K=8LWJ|-M-JJ4T/NAUU|%A|ZXB%|S
@A=8DE7G=I|.R&"BJW-&F#)+(<1<3Q+R2FOEU MM3?
F"6330!"T^*VN5##G%UN,A2GQ+L-3<3)-2"^(=(:;25K+:6W94?),.9"
MUA4RTY;3)\$|E/B+,RK5%0;SZLP2<;_2PN3FL|T(23PY0NZ3^FI?*(K)4QS M1,V|!4|
<)42>R87)VE"W&R8I/-MS:5ZIN199\$S(:."M9D'1MY?W,2"JX|V48
MS=P%CO,K'|)X75^0AHMFU-B(Z<_V\$E;9S"3ZKKVZ>2#&'(&KC MS|/UTQR(WRW;
(TN*UQXWLKEZH &1!U|@VORG(JW|JV;O>NK)^Z9#F+=YC/@|
M@F3N7SMNM/#\$|HJ_W5B1M:T)N%F&7>J_H#AXDZ7:005K4W2-|<\$*5<|F|F4 M-
68Q5SQ;VMSON7|H=)|.H|S|_T Y7:|C2)B_>31GF<_.|.?U/;+&F@3% MT!PKL?H%25I_K
=?.:|%E+|I);P|L8Q,)GX1!2M+5#6&!5QLC._+#N,AR|#! MB/I2GBV2#|H>_.:Z)\$;"FEX7|
|3EQ1PQ(0F@J5FE/M>PX8|^#PAOK*"H73*) M79MN)5Y061?
FR"YU078&&%W|S^!6FQG=-I^!)06L:WJ0UMMK6DQ8/I2+AK3O M)\3PN?
XISTE"73GJ3P:O=#C07N/WJTL#X_!Q4JSO/H@%'R9D_2XCTKVVC%|F\$
MWGTEX1T=Z|RA0#:=|&U>(I/GC@:T&Q'ZYKS8_U,C7Q^|!%5WAF*7J|;/4&|9&
M_=%3CNEI|X|R3,^H-6BWQX4_QWDM^H?^H7_HW^L=U;>|,RJO*F7.\\B|%(I
M829FIXV\$BF,E5&QL22.WHM3\$4!74@BIJ3Q7(TL2!"4V5G_@1|7-0*35'@W-M|
X%F|P|JX|A!W(X&CF8>)"|P_@!_!^V R|YPA=L /8 >P=L#2 N0 <@ Y M8&D!/?@
_@!^PM"@Q.^"TO|*|=|OQL&=)E+"P?UJY>QNI3XB->
(SZSK=ZV@6A'&3YNX98\$D@/6JDER@V%K#. !>" Y8*U\$6'09|85A&|L+V#G%VK1^
MP#I31NM<'KF>+X|76>"|Y("U:|<|H)UV|F|-Y9_@|D|ZQ5DN1ZG6&K#>A MM|L.KF|O8
"||UU1G?3X,1X5)8_7@|Y!)Y^H=-_4=7(H%/8BS.M #<>X,.3CN M/C6(\$T8HN+32:
27|MH<|1PWZ!Y<"BX%EU8:C>#270\$48W#IR6(L<+S_*=8 MJ(H1^O!|D7?S4,NL"-3?
L682|,|NBGE0(*AP#YUU-/T(_OC|N0ED116FP7'4-"2H%
ME8)*0:4EP#*H%0%0**@65@DI!|:24"FH|RIE#V)B&T#D8)(0:0@4MBDH%)0 M*:@45
J:M"Y\$F@9ET+^".J1^S/JAWN_Z#CWDJM|:|!OKW=WK4N_OF#G=J,D M?_M#KWN&
<\$HC@WWGS4M+Y'UL?92VG\$|D:/4Z#;O;
|O8;5I"\$Q8,Y++H^*9M*;!YZD(DJM=PCS2Q#@Q=M1,2MMBFL|-O!))'*1TPJWCQU-G^/*F
M)Y9|8B|1;^JTB6|?IM<3%CRQB.15)!DM3OK|_|N..N3JO|E+L.OV74&@_A3|/>_13
M;D'WT#UT|PC=>R_Z|/!|,|FVGD2>,X!_O|!&\$0'^=8 M)AEC7M=I7D,CGPN(:;\$X
PS|PQQ>3H)84.B|!(MKR PD>OIES?MY0/+Z4Sj@ MV3HKKH@JHAY?8:~E
MI&2,|=A^0_(AB&*LQ&"IG96E!G+8,P)%N/[K1:"' <_.8(?JLL.O011)T/H M ?0
>MBRL@BEX|866_(L_98_2^P8DE^\$&UK_+;Q\$@B).L*>,0A)|HWV^Z*\$<MG_)S
8K5(U31"\$O<"M=32>|3(&Q&PCMX;M1R "TWI ^_Z|G#WCBGHWGZ@W&K M4W,\$'G-
"G@&UF3;|QP>Z>1*Z_|&(A;|U(QFZ4W ?N*|ZW-=I#6J|/S ?F_, M|^;:"!AJU|H>RH #XZ?
@>"|&!U>/ \$YSG#0L0| ?V_N5@/WZPS96OZ_B MJ\$JS'^^H.JJC*BMN#C|5_%3UM)3.5\$V-
>JT><<+ '816-V"=*:;%AU^'TT"L! MT,|I=036F7+;1;OV1A|26 V,-O9,1NLM=-#KP1 Z?
5\$5AGRFFC7JL-W""# MJ5Z.GYGT'.IBX\$|Q9'>B!|&=E09P"<(|CQ/Z(\$|P9V5!G_)P CN
M/\$_H@3NQUUDZMQ_R05|9|?/*46|XBJ M1:
(<"|6\$D*MO#>P1)P*VQ14"BH%E3YYK|37&I8&R54GTM1!2/_R.8/JQSWZ
MP77:7GY6CMK"Z8|J8"7-^ZAUNA+^557;DRML ^VY<@"6UZFO =ZU|1_1|;
MK0|BFA6\$N2(SU5/7=^CNJWZ+P|IVO:60+L9'Y|D|4MM+10|CK1OIRU#\$TK%^MZ/?
&K8Y%C_3NCM.5|(D.KUVE8W7:WKYY./_0:5BBCA>0G2&_9LC|Y
M^<5|8<.ZDQ8)82%)M>%4F^4#>"&D!HFHF(.B,6BS"X M=^QND;>NY&2^|NT
MH24K_YVXM|+CU%(E(C=/:4^>9XUD5:43*>N|)=)G5AQ84WJ;/TOU1.\$3;H+ M-9IW0?
A=AWS!4T<|+:"NA?I%(|IE.K)#7J-[25.17)N+\$DV3JCU#6L:T,-C
MRY,BBI5|XCOIW4IK3DB:1?2UY5WJ>P<>K^&" '9GJF6Z5:Z|&_:L5B:#LE0
M6FX4)=)I65^2R1|)*(/%D^>|C&D,N_\$D5-5 &EN2A,50C0J=F1+X@C|2,)F+
MI47#1,|C<"Z",|Y|C4IZ9C")!8' M(-:A Q3;B+10DH_/+6\$(\$G6 ZE8P+ M>H<=A/18|AY-
6\$|,^&?=OHGPOUOT>ZC\$0!^(!3^C>EH*#T|4Z@A(HHD?40" M-1W(6C27A%E'?
17%86(KV;= 5SE=?28DY3."QO0/31P\$"!|J#J1M&<8.%3,V(M9\$@
|5P:1(>'D4>4GJ0_+DR*AA5)1JZ+R7#XEL(&<%,OH:5YHJO,885+Q?
4;A::YG'\$*|S"#YP26^0:M%(I:KJKTU"0UICK?"L|4\$G F:O#Q'7-4XC;^)ZS%X M:%1G9%
|RU|%JJV@VN1Z-OLW 73;.6F)M0=I4Q-G|:>@)1%,^HM:03#WW.ZGX M)C7;W*;5?
M)T=P%";V(Z\$&\$VJ8!71+#<-*\$R%B21AR:P!|#JZQ@UYIM-2 MAN5D!U&
<@:X,@VYA|JS, (4|V|KH#D1GC*YHIF4|JFS^B)9D 4^#13EI9& MD<(G/T0PWLBB8".+3
LR>0)_S4;*+|!R.6;|<#6SMGY/UK#T\$ZFL|F6S16R0
MD1Y*O%AOGS'3E962:S@#*6DD|CD|39:E3.WS6P-0!GL?:
M!K7I'6:~T^M_#|BHRJRSB61=2HK;4WK4T=;>=VDE"_|QA|ONH&!+<:? MT&RF(;

{68FDD'6C[+0CG1/K*S.;I:QC?O';3.-=S7T[}@FKQQZ-[<2)Z|R8*7 M
2.,)8%JZV*.:0E>H&BM;7NDT&T23|8BDMH/O;W?0G.:!4O';WQ/*FX145\$ < MD3|?
+|1Z*Y)YM"/J)3\$ _=*,OQ-F,4QI?EA<-Y/MX6JL/T00\$10QX*CNT=IKP@I(M8=LFcf7;O-
3425:~5J"|NW4CFV9;BIM"SR**XPM,F_14U'I_U>Q=3SUY3Q9C MJ"?8%?4FF?
O7CALM/+&|XF|WIKO;-1=7S3*1XOJ#;/O*R%.:?+M(7JUB9-^NM4
M+U_H7:_YPY9I_MTL^W0'=B&5V_^3&#R;9-4#6& M!5QLC._+ #N,A&YWJWB?
I/UYZV+;LE.:#=#M;6RR>?E:2R @5UU24CR"D8.IJ4CW3I'#:Q!-T4*^-)J62U&Q-
!BTW=YL)FEM(S43+G M1?&?;&.M=H!WQ?;?Z;S:95\$?
R>EPPHG(W37"7%.;J;FQE6=R)U1BTS2=(17 M?8E^4X=-K;?
H6KQOXCD5207@C<:5KU>ZKXWZVE4MV2>;B/F*KU_2WZ4?MUP
MV|J/>V^+C&KZJ2GUQOWW=5K#|A/N>L(MW=;E9.^=_WG*_|Z|?P|DVUT^F&NW
M;4HJ-0'OF8\$.E^<8YP"9/2 SPBI_|I'@ F0@!U3""*.QM]=@<3RMC019"UYL M6!-
) +57|3|'46LC0#1SD@U0Q'P2Y'GL8&N>4QI\$?C(Y|6\$-%,S1;.: V4%NE
MJ*T|/O)Q7A6EMJ.~3EF,VU!O>#D"+?JB|X 6|Z|V^\$A-3#==1S#(@QN74='
M)V|+ZH)R@W*K@=5TICI-974">##7P6AU |;Y,AHGI0-XY=LPAY7^BE;Z11*I
M@.QW*.;ZSG.\$00[M!NU6#^UVT>ET6@>
ID2N&!S/"6X#MYT=MPUZM6"0|&A3^10/LOU5!+T MUH9#\$6I?SE7%|GA|R4?
B(M*^/BH1E1=0>>'%PEH|K6YID%SUR@L@4A IB/0L MB?
3HJ4^U)E*4L'FLWD\$6C/I^F|?@|/\$^V/""@2NXZ%,M=7T77:W!EN|"5%IQ
MW&C"-5|*%30TZ<;"|+|+*PN/T|4|^&3X8@ @6/6>;EZ=EY2.9G1_)IU/2W'90
M=:/UZ99\!;_)EVGA">N"S|!_IPZ;)&\$TU?UY#TG4|B*\$GO&IRT|W\$G;%?H
M<'|O#GYD|JF3LEN3E05&SX&4_I1_F7AI/&" '6U\$E4%PAS|H/*1U_KTZ5!;
M/56SQ9WSQ8|+I5*D;ZLS|^_|*?7IH4;ZBGIL<|H8:'T@H;S!5K^CQ.!34 M*#L_P_-NH^R-
,>JV|&-KX|,-W4WMAYUCOH-3YPEI@22.K@TKP9B;G%(M<-0 M@";74>H-
1WG1J(:!,5VY@E>%TF*1G9U(Y\$>.AZWA2AFJ(JOUS8NG)UQKM"?OQ.'17R_J8BZQ1%(XY?
=G) M.%MU;3PH%(%3E;W^|/\$T*5;CG8B4F+KRLE_CDOP\$*|W4|9/2W@UBLJ5&M#5
M586X\$;HV@:D6H*K|"A3.S_|H_|OM|1H*3V/%ZP3'2?J1RHFCB<4FX=)#5
MN=7AQ(VU3N";;2EY()4X3=DY5>F(M6?Z|)VJ_P8I'R6>FCHP2/>.^MD6H+^/
MFOVA,QJVN|79Q#;DK4(8K=?%XLG/B\$|OT/30*VA%=@Z\$S|
<_F7A"3^00Z(/SL=*)/B""| MFJ&:B\$9%(MK!|X|(;2?/\$PUW5CEHA5?6)9;W;D-
V_B|/RPZ38*5:4EKJ M,N#2.?Y&RMM=8Q4J;"T* _7|X*
M+^\$R=+Q@H,XD7#52OX7N)|027K5;H?KMLJ_C3PCIRK=9TY|/#_306DQ|OY
M4B|8N\$QG|>VZ?(Y9HZG;?E%:JHROJTHJ|&K#2PV|"GBBZ9)FZA197NNH?O5Q5
MN:6Q949O94 :2NR417(PE07EJJ4TQW7W>;Z:C3Y=#V?VY7JH84"1\$8(*8L4
M'NX'2A/+, "MTUN";:7H|J-J6%43+%F=K"B:RU)EE=Q4@3;>BX(5|, \$ _R7;XH 5|
(S8WQU6P&IA+5W|.-LS MV;|"%IS;5EZ9ED.IP@J+:YAUQX5U
M/5TDYPLO6,ITE:)*!|=ZKS0WOY1(+8Z|O,J,*C_).GQ,>|O'E%JV5N-.;T YM596PR|K-
65LX/U+57A2Z9I^G_7W1!RZ|,Y+|&PH|,66.>Z^:| M#|J<|?NT7+\$NSV|*6VV00*YJ|
<%407)<)RVS|0K&D^4E0JY.JLQ\$LU,B?>\$I M-MO!.<6+S?
IO5|,N"HX2.Z'Y/F==HL("Q8U4=6^C=RWK/?7<(Z,TLDSQRD)9
M9UU)UZP(3.E099P_+ABUA"6VD|)P|B.|X3+T:B|HT|EW9'ES|;/\$3<' ^0.M
M8@EIU*\$S\$C69Z_?R%&.V? 9FFG6|/#.M+.|A/GYJ|L+"B,/4(L1Y|HC=28^M?
M+K0=|C4+5%GN'XKUVG|):N%^R0K0J1LZU_I^-|+>^WY"%_PNN=2Z'CI'E|VE
M3PN5Z0K;D V>C0E8;BBHO6HCH_!|K"\$U,E2+|3@_9Q|Y M%|/\$%7TF,1^>
?|+ZB;Z|%;ZK@JF9F,|7HYA5C&W2GL6IZ93=J'H%>&4;^E;R; M4ILHI^/'KASU)X-
7XL?|M@)#5P5Z6N_U&H*7,3^3Q<2>\$'#B2JPCUU8N3H)I M-@D*.:5NX-79SK&02W-
0H<| WHH_?W|W|K69^V+_3TC=FR59'HEI>H|D. M-M,.#YZ?
<_%=N462^2*/39/12)JZVM-\$>8'DK7Z,T)X06EW_D3@WN@.9FXGF
MT|M4">2ULVW,G5N M|&+W50DGM7-
\$>6B"@V7;LCYSQ>Q0WB2>""5Y|(>U;MU:72UAT7DH%|0LVT5
M&E@04J,H(>D)+@9VROD1"TOU9|=0I&TRU&@O+F%6,D|5,F|/\$*D%U//7|:-7"= &B*A1|H1
Z\$VT*'V8I MKPE!62JEW|YHFK*|UZZ|:70PX*2^,WTL\$R*09%:HB|LO+!CV-!8|M7-0|P*
MXUZ@\$T4=-'6"*+;L5,MRN':^G|K4.X29ATS-2>UG3N.L,R,Y9Q|SQOLI52Q3
M/:"C!_A|/(E=FZXBZSB9_,%ZA@/(@0F5<>_ (^)|J&>1R_+XN;|65!IZSK\$+X@ MI282-
WU%W&!HGSOM^C/FCUCUSC"4DJ#R|FMZEHXAZ\$PPVV58<.7Q)*(E"8=/ MY
I3)+R=JBYSH^_|3F. TU=,|J+%\$>51(:F4
&73&)E9P82G@5HROV'@F7BMNH&&^UFEDFDR\$RO@=;>#MF^6@B7>Z*04W&MB#A:
?&%N M8P^M|9.:BQ>&FG|Y_ ^4G0|KOME_ (7"4VE%|3&|H_ ^5#=#M>P/6Q8>R&VD=W_

M-5BX-M^9/N7*NG#?62Z#UITN]?C0\$RZB=_H9(AO#:[JR>*DRV&6H-B+8Q"LZ M?
MS41Z2?IFZE>_(@)V7YYIDDI(FW)5IV^XZ=;(\$)(-IR419VL>^KF1TOZ+\$I M8JA/\$;O&#/
<+!XJW+-2&X!E9-3?=#2>J84C/!OTT+C,\$CR)"6T"%G40K [V M-SN+*O9=A<8:5*M
?/KPOS_HZ>0OW^M6&I_W3EZ_O/H/?I(^_?/3UT^? M%>Y_=^?
WO_ZWY!A4@7FCYWLX">2<JE9N @>^*L>)E'N/J5J6"S03-%OE MQ_VVVFHI@)3E"3?
AZC8B* TV=78S_M+""M M-
) +9.U!=P:9D*/(&4,\$"=X!""E_A.Q>04P;S5(_F)!7,!GGH'/DFW!UA!
MW.E@TISJ#M2JW2G\$[18U8=\$6(?3.)%^9NN]"Q73'BI[8"&6I%/+,K.2-
5\$R?;T(L)Z&;>SS";\$^G6 DU-);#"MM.">Z#M
MDZ_:5&\$V@W1.4+3K[<9V2@T9#OS5>36[Q-I00;<3F2Z>F#1T)#3OMJ3^BRP5
MR9!3'LB0%77@:[H1"Z:[6*:F'*U87)5,,%%MU4.XLI'"CJ,1,88>=BBYH!Y
MHEV=J2:/5GB(P[M9P(-\$31L2J9;3#J@N<51L;RZ36.[N;.!#31[^N[1MEZ MK&5[FJYO-
)'(EWH_4J6H&1@4-I;T\$.F=)+4"!FJEX\JEEVH&941O&XA\U0_
M+!OI*"ZWS4JW*#&VEVX(-C!3X-"KM&IVAVAP!EU30)UW)0ZTE#Q!#4J*U%?
M/"UXT+H<=MZN!B6L!89MC3Y0SO)KQ5Q-E<-WQ9NN]"I?/& B(YE>JHONORT/MZ?
5:_7:O/QI=I@;C(?I'C2ND H[LLDR'V:>[!\$)@
M@'YQH U^N_:4G5(8M>W3H/10W(R@.00.F52]*B405&QH#O=Z[M4)?\$>3\$AS M6W-
^J!O,!*:L+K7G70QIR[KV,4QN3/_83+H)Q5R[=\$D?F7QCN)27N72#2J(;8B;Y6&)TLP:Z7>(-
_#E;7K@=XH M(M1\$K3<758_N!/?ZJCF^T):M+UH[E,%XA.BGI+TTA)
I))U9.+QU8:AZ_[2HK
M5*H1+REIKX.E20.3X,UB>V)*MDIE2L;)Y%JX2#P1LJFVRD'_L9CVS51QF
ME)O7:3("287,I7\G=#!;!%.=^Z!4H=G*3\$%5:**3*\$,M+@A\PA\DO=;*/TK%
MOVA4>00*.Y9E:RG=F-M%*O%GU3):T<77N=&I&J\$%;09MJEK:!(/*D^_
C5E3U=9#I/K0&B8JN42M!V;OY:M4.[H:4Z1B<)2>W\$W+W!93J1D960
M_9V9*8F,0DU\NBO'WF2O(EK|=^+J.\$H5!9IE6:ZW4:?G&#V!1U,WJBU4'S-; M7&?
(YJAB!3H7CMRH=,UUJJ4IZS3(<6!\$F6;&E4(-18X7UZ72+O.7%|>|2# MCG
H4B|_UU0<=*1/2Y\$FA^[_JZOI!WHGDSG%?MZ*,,_3O@(L*Y\$@'4/_=;U
M"K"&S06;Z[4=2!J3ZZ:\$EI=*JUW9>LI.?I:U*C M,4WKR\ PULX<[S<I=4J:+V?
=>SU")U!1_:@#FEBI6?6"@JC#0[Y+7'&7DG\ (6 MH_OJ?:(HUQH6[H9M!QSA
XNC#;K[[P9V?Y]A03W2V MC%'EFW90&JUPJ5B)"\$V/..8'6O%.
[MC!Y;AK>V7[5K>#3]W1CBV')!4&2YGI MF=8'X6#2HQZ_H!I)'=T)SXC3IG?2PW[Q5=-
VL-+QZ,O.\$<"/GD!>.E^+M8_M9&9FYLE)(^<^_/WC;UGHW4YR^%?V>+Z>3V6)77-
>M;I'G*5,*5UMIR^H1?' M,S*M9DR3W*,,5:-=4>X!_HZOTMOI,?-8-IT8*MX.T-
5^J@T!P^ MILJ2-P3FCRLXR8.=/^9;&;+AU(Z5!>51S#UHA<(<4I4B/B=V(M2'B:3%^T?;
O)HU58 JK>PC;IK;:Z5K9.4"DT9?
4FF;UJD<"2UJ7>5WK^E4IS1J\6Z'+TMKA!9OJH=|A^W"%?
MHJ7M/^&NPV\9D^+OMO_3WC\$4VY!H J=.(W7N@(N;EUH*8ND+/=H7YI"J9 MK7;'I?
2G<2K1806C7T+B6[H^XA'8 MIK)[W4)O-,+|S=_>=-^|A*0?KX9)HJEJC M
2!Q#LT%&K1Z0[IMT^=YP\$SNO.K\W:>P\ZEP=>+Y>UIV'/%0@!_!CT?AQ\ P= M7 5&
I((1P8A@1##B:S+B#C,&.?T& ??E&?0*@U(58CN5"B^H^UP\.\$_@3=B[#&L;%
V*!N4#Y7Q-.|:8:KS^J^.'IA44O%6*(@X)@JTB2B&HNJ.TQDHA:|J@SI, M9Z 4@JH-
ZC"=@5(JC:HPW0&2D\FJ%-DSQ2/RE00>>5T&B-K=2AE7JC\$-*#I
M8L=TEFT/[\$.2AGR8[5**IR2_GD^.4Q4[CF4AILK[PL_)23AH'S\4#T MFZ# MF
B&'(>AUATN N<%HV08\$P 400YGY#,.Z#,4^3Q@"77E=?K^%;A#"X5='55F=%,/2*U-D
M%AZ"JHO+UF5YL%ZZQ,*G)M0^IN)>.ISL/>' SN+DB M4 4W'W0N!XSG*H,=O
Q>K@A4P=AJEP?KI2/F M%JUQ/GG^Y^#
(SN#!V3B#GUJ/\$%JYS%JY+"Q4>IT+C5L_&PCC:E20"T!+,&8 M_.+9,B82/ZL&U!+-\$HP)
)XO8QZ_,B-P6C9!@3 !1! F\$C|KB=,2H!*\$ "2"> M+6&.>P,PYC.
BOI5E?'=_2:6<_HILH3O6'8H'9=^#J4G8NE8<8"J5D?1?3B9 M&R=S0U"U01VF,U
*0=4&=9C.0"D\$510483H#I1!4;5""Z0R4HJH5CKA[Z9W1
M8E4K*Q*>C,KADP\$7P>=2"B">J7/PHM>^/_O* SB\$#MQ9+D2".ZO\$G=UQI^CG
M%)4%J>!.<&>Y\$ GNK!!WGN8@ (4"U;(("9P*(X,PJH:*P=P\$=98+D:#. M'E'G<(!MSA.=?
(8R6!7Q\$>9EL AK*7JQ-&D.)KT-JW<JG'B?Y8WH"CP='@ MZ))R=*_=&I8'I*!H4#0H&A0-
BBX&G,""!D6#HD'1H.BR4G2GARHLH&A0-"@:
M%%U2BNX.>D>/HSE;CCYY3BDJ9;W61\$*E+.AEZ&7HY9?2R_TQI#+63N!H<#0X
MNJPOVCOY""XX&1X.CP='@:'B)0=\$EP# H&A0-BGY6.MH8.QV@:% T*!H4 M75**G
Y!PSH3(3OBT;UD=IR_E\$AE:O MT["Z[6X/VAC:N&+L]/4C T&!H, M#88&0^?
CT^T.N4!/1@:# V&!D.#H?/QZ;3A'P9#@Z'!T&#HF MZ*?

G#F!;VV>XBFO)^R!|=G1PZT9NX%_5H@)SZ=4JZH0?W5XIGS_AJ+J@#M,9M*
(6@:H,Z3&>@%(*J#>HPG8%2"*HVJ,-T!DI)BC4SZOM>8@?DC"DGU0%/7@<
M2\A"=2CF64W7\YDZ"0>#T=%CH0'4L@D*C D@@@C'W#*NX'!X\ZQY +9N@P)@
M(AAS\W0[\$&:5<%H"5((P
<2S)R0^FX\'.H/1%+QXH#5+DZBO:#2=TXJ1N"J@WJ,)V!4@BJ_M-JC#=-9*(C:H
[3&2B%H&J#.DQGH!15KG#@W4OOC!:K7%F1&14#J\,N @^MEU(\4S=@Q>|X?
AL0\PI@:XLUR(!=6BCL'O;/-=P!W@CO+A4AP9X6X\S1G M"0&J91,4.!-!&?
N:6^_VJW+,P4JS\$U09\DO">JL%'6.CW\^6EF0>N*SSU_4
MJR(^PKPH%CR\$M52=.)T4IY.>1OUV1EW4QL+R!AP-C@9'EY6C+X\^W"4H&A0-
MB@9%@Z+WI.A!:U>L(.B0=&@:% T*+I(T3U0-"@:% V*!D67E**[G3%*S9;7
M7XQ:6170%Z-6%00R\#+T\DOHY4&_B\43UD\@:' T.+JD'-T;=;!V D>#H\1
MX.B2THAOM30_HA=/.EJ5/ MD5=\M2_H2XTQ*?)YSP(#^)#SAV\A?92VG\$|D:/4Z#:O;
|CZW5&N\!Z7Z M^KC;ZC)!.4\$R\63I-/3^>F'\$ZOF Z1ZILJYVQV?6#.OC5'I='IK5\$0-8@:
M1%UWHNX?_X!D\#1X&CP-G@9/'S!'@_;)7<;@:~? T>!H\#9Y^<(0ZO1/|C<'3-MX&GP-
'@:/W@"/5ZPJ9SG5\@ZGWKU=* _@GJ\?ERL2\;FN\732KP+Q MDHUK_?VZ2RKFCI.&
|ZC<<10).O+<6\MOVQ-1\+EL,00@NY8): MZ662<7WN7E,)Z
&9<,A)%AG!HY+"0\VSTVZ_77OBR?J_6XG(RA2WW:N+=>WO<21EKGZ')\A3G,=ZWM+
M,J'Y\<3OL5="0/U
M,&ZB:9JU("GA!2!^C1M1LOZ:KH1T97TH6JR37:RH(<^W!XWLIBA'2OPU3.E
M\|S1HD+_+>.6!4H0^7;39_?1YBTWTI>ADD=@VW2YF-(ZAZ4Z\$|>Z\|V0N.MM;
MU.#K)+_HG-1@-CS%?D6)/^4\;417^00V)K" FA!2.UQ2-OB\;7EB%BTB,FF4QGR M9?
1&=J)&C2C\7>-/#TM|=B.SN?P\&W78WC0/4(9#_0+=|H5H\1-#!S^C>84
MB8,^6U(S\(#P\YW627\#?.\$61^/.I7\X1JATY\;3ZI,-7R<+1UB,9E.|=5Z M-;Y^\$-,#Z&Z^-
'190 \$+3;9*S%!\E9/G?@Z7P'"#@|X?Y/31RRF_82D^AU-#D M5N9>(?
QX)IA_B9<60FI<9435I MHC232-P0B\W+^4)Q2D*C\$UI?
@X5K6\VT!*1=>&^TTR6/X_GOJ:S*"9>BID_M_:U/GB03,)1A,*S=*^@%M;9I=@>X*?2L-
RO6\Y*N?=7S=ZULI4=E\;5979% MO4GF_NKZ8WV3IS5P?
=4L\$QBO/|AJA).2NEX\$D:N>K0#BWLKK27#/\XN N9GL8 M\WON_G2Z3Y\|^+=9?
&09PN+HSMVJ+S*UU:%9\ZA5S95(XN!Z\0N2M/Y8#\Y* M05
6P)7P\|L0RNG\|S8P:3K1M_/(8%7&R,|L.XR\$|77GMLR?O7KW@L&W9\|Q8 M0-
5>\$Q3M8+WDO")6D7Z(=|VH_8#E)\$&K"ITQ+S2R>@1PJVNV,Y9U6A#:8U M3M;JI&7|E-
O(|*B,V1O;,-S8RJNF6L&*UU=14S;M:=6!U%_6W,R(NFFH5-N
MXT(L>>.FS);4T1'P876=LV\$-K*VXGK)@4,,2RG\G;I@O3M0R;,) +14<^N\|8 M;-
&*+;VSP25? VRT^XG6/TS|-_|H8OYL4MR)&S2R"181ICF*R;_(PE2\#W/ M4\;8%8@EK"?
P;U. MTNL,5))>KT&8-M3+||B&S0@&|PB2\37KYY+_7H|=!7,|8X+&|WNU+6S\O-E
M&PUA|U\|=,N0\W06-F^0<*AFJW6^R\?J?F#9K?=L(YD\|A\$C#|OP+@,,**U MG!
(O7>@M&VJ_6-YS:MJ2\|S+H2N6Y5\0W900\9A(C:S=6/I-(C330\VG^-,2G
M*"19..FZ,|7\$WOL^&U._JPD&J^@!F7\B5G;#N6&;7P/_IODK,89C05>,"JK(1:6\$XRG
A M:'73R#P7U+B;('N7-)9V8*@H%8(Q\G*(A-X0Z\|D;X67B,UOE8^*S\|08MN?
M.9Z,'WK1#3N4?,MV0SN9LUO,5A\|PW()QYM@B#)6>Y2>KQ3DU3\68%@Q+LWI0
MJQ\Z.L.85.T%+Z;D;1K%2.=RC\6W(M'2Z M9:Q^X8G;&5U'A37/-
%\$>05M\$,VOJ\7>1=9'XCC%JF\4:*,@X?UDL@PEOUNY MODFW69_TJOYZ'C?
28\6O\NZ1YJH.VL*\$S\$|8&+,K"&+\$^UUM*
M)HJ;VH(|OYNA#\$JTO5\|KXMC3++=6HWH=BG:6\U%V2F\$|LCH0_K7F(. \$BC M<-
#B.O+UFU;OL\0\G\CL1K7(N96AL?|FPF4VL9)(3A./#-*I&6?V1/-#88\$5
M%YW,/:&|=>7=;NI9(OP^E&>QY5*%:4W*NU8\$>KU,X)1|Q&W>NH%AK59\K2Z
M5%!\89PR>(,3E/#P+J<8H\5KA2K;\$'WA_R_J'NOHH@MCM?&EZ<<*M.*BD0CEF*_0
MS!"ZT7=ZSXPWQU2DQD;C8,@\,(W^;NP/4,O*?E9J7N7VV9J9Q;^J/6VU5E"H
MJET%8%Y"\VZ%4-C^,;=!>LJ44H\O9YYIK;'Z^EV6VONU*|G0)\$&;-2E\&D;
M8UQ&I)^FK@DI^OO\|H\U+*7N5O87MMW+;WGT(O7BC<88/LONY@V+V(T37LB)
M2;VD\BY">6-2*TB1\+3>\$,RXMVK\7%1#<^05\$ 1&_A\T2()P&'CZU+PNQA
M12Y!6A!H2##!W+65W25LWM^D\|@ZV(M:O'&H62-S6='CMO1&<3T)8_U'6M^D
M+4\1G;1>4NSP9&%NOV4CLZ'8#ZAT=#.MYF(|X;|H0>^'H_A-NP)AG\9\Y0
MZDFF#/5Z2L4AFA"86#GA+8X' M"T(U8ME&/3.1LC@T&?B\$G"@2X5)MD0%#M
MT3/"O*BA\RGU\|F8ZP,76Z09K\|M'A\|H%:D)Z\G>U\$.85%_-YES(S0PU4\?0
M6\Y48V)NPSM69H"-SYOD M31P1\CE;+!>J|0K"MJ&WT7F7\@:/%/U&#;\$:_%D(T
ME>_Q?D\$|R!>0.2T;+%'O.5B+0.\$K>;,*5-&|RQ1 @1KA1T&LZ)S4@Q3T\YQ8
MU\6;)2EH'QM8\$F\$|2#\|*Q9*IC+4D\A_29\$,O%VS967*.R=@8S5\61NW:K8R

MA#+U3&K9D>I(SDW\;YHXBA::FA::/+N;#Ij5<"1'?'Z-D*K3%05B,>K>CS>M
/0%X9Q>/HSI<7\;=@/_66_DZ0N*CG,J03!KKJIA_2;I.351G<9=-;_8:9XR3 MRBTFN>E-
L=M,KJ3{ @CMM^F7:46Q7:FPB.B)TM*= [P4J\YQXPN,-[LT7]=J= M-
QFSL(/"73K0C!H;)=.I:[M*=8MH8.-H\|0@::4*.<JAT*_H6Z=D>MR8(K M%F' FGLE|
(T;XHD\|9\$4;(IR\)\ZMWL'?_9'0@M5QE=I2+H;F-6K/A:.6@|'
MM&KDFZ{(@"6VS2[C6UIE>7)*9F&X5;KED^-TBCJN7RB@?M"Z'G=TIN\$-"V4LF
MX7;_9=-PGW6/.BU^NU>?S2Z\ W&0_ZO_T)IN,H?/[P^6BKN"[*!6?=PQ&48
M"4\A5MZ\>GV80I<&G+-8;+55".?JBXBNWNO\$|@#|M\3ISPA=L@C6L*4.<
+DTD2YD=?R7%E@=AK8@S4! /G:@'22/#6+,T(28L?E MUHT>8!%8?%TL%GS)A2-
^=.85;|W%<>A.5"P0?>V&VA681.R7A^T/>+ZZ\|9E M9E/I:PXV2.9-
IG(7(AR")/:"X/O+K@4>;71% %@/_ (ZTD=I6\0EAAX'EZLSZ4 M4B_?53Q GL-N)Z&*X^7O+
(\AL-V%3FDWR9\$B,NHYI+\$26A=A#8R3SQ M3'1"(7%11N\X\|85^JE)H+_T?PIE6"?
KV1,%O.6Q4LAHZ\|S*GM*WR2J"N^|X,U&"^3ZW MVB70*RW-#2;^3D7;Y5GAA;- '3
KIUK1R/D2,GAE*>KS)CS"06H0!=L)WYL\32JNP@@TB\>
<)>15%F&A8H"J(LU4*W0V5JR*/W^*.4+K.# M3QJ6DTAU5(I?
9,\|V+P0R&BK#19SGDUV)HC4L8C!NCRR&\$)SXDJ6JY\G-6M: MW<&EG*<16436JC
VBX>?OV7-9<:;\$OC\$)P!UWJO,K^|UIYSK\80>R7EPTNO5
M\4+;ZL@'3T60\H\$4YAQ)C@WD\UO,2SYO;\AJ,+URN3NM\=-Q\TXI>;5)VY6C
M_F3P2E\$D^YV%J\7K^QSWOX6!'W >DIH^H+R"L+ZD9D*W\%; "EV2N+"R:X5H(
MBFHBK0TS*67;+9<-T2+!LL24X(M+2B(-,+G*2EJSY\1ENOHM?&WD?
A6C)C^5@CT_<8\|3-ZU_P9M>V'QO?
5V4Y_JW4=2@L)I\$A4\|DD/X1\$(^D\$=!127L*N\$J@TK;
MG(7'J5VSJ7N03%J3I!^J="VV9M*D(3=,GZ)#\87#X1\J37F^\$"KR?|+D!3L9
MBMS"U4>I?#!/*S,P+^,7\\$/8>AK&.P>*WF1QI8QL+?;+A+Z\|E;&\<19\44!*<
&SI\$V;V/QW2O"-JTH M).*L-J-E_=@CCU#C2Q\|F\^-^|
EFRS6TJ/L=.8F+KQ>%LAXN7\Y1K(Z0\K3?-HQLS\$5IH*BZ57=)H9J/
MA=:\$VN71\J0M4)S!K <^6M24#/CP'-ETWW" \6 W(V59NH\$ M=1%MSG)M/9EERM*R:?
7AQB;)9IG;|EFJ<7'0\|D .U3#/'1KC:JD0-9' MFI?J1A\$?
Z+^"=7"=KF0^L"P\\$. \$ODO\|5(9>0P /17&T/??B>OPD*D-3#T M:M
UHJ."|*|6ZT2W_9BZTH^:\PLO98/92U/:EVOGV/"ACX9N2KW;AVROJF5\|#9'M=7;97K7=J/N
M-HOMI?7SO;&&?F?M@47:@R6\U&\W^GG;J17(3D450>^OUW3*#Y17<5\AK6L;
M.UFP=.Z#<|ZS() M YVF-M\|/- ?J%:O&|Y'Y3M2S01G9B'C?--
:6\|T2T%+|KS50E9%PCN+2+ ML2G4Q05H\4HXL\|UY>/J 1@%RUF-Y^JYM1C>_=?
4H\T;) ^,6L1MR-;KVT;EQNX<.M4@O,C6?KAG*C5'P GZ;F;#OSAA=R?/01
MB9Z6A1RO+?T;L:Q@|/NI^HR)5#LCDC=! M\&
|*BN'_PV5K3!:ZYZDM8G/NN0CU.ECH^|)3Q\|G@! MX?1*;2"?M\|Y'Q6WPMMYA15C?
F03'R2IOKY1K1DEQ9C:X=|_ (H\2GJ M)E2\BDC4=@%OF?F12?
HB&N1=)+44Y3G\|B:Z<%4\^-^Q1QL\|H2F_.U8'>3E0\ M\$T\|JF'%#T^?-<
HMK*R2XKZ%)0?/GINIGN8ZU%9KG6)\%TJD\X7)KSDY3=_#)M
MS49KNQ#5^(:ZN.2\TGP2\VF^5D<4^3M93S5^!YWQ9EG*VR8@*NO9FAVA9;#!
M4+V'>*|P=+;/GCU\|TFCUNAI5'<:H\KEMRQXXEL>3\)-U;-1/XNPU\$ZUR\KY
MU#9=M17K@%DN?"E 9&E\|%+\$X',F'K-X?U8@G7+J?HKNE6;%_28_A^B\="HI8
M..)P^EK\|X;(|%* MP2SJ\|VW%9W6KDSRC7FB26MDO4E61AZJ_TV MO9Z
X(E%)*_2_ E3H:BJ;_J^-_OZ>G^V&WA+H3>SKY*|S<7T57.:M\|H0->V
MN\$=G^J@WZ7\|<<4^GU>D^X:|#;|EL=2_ A3\|/>,13;D'WT#UT\|PC=^|?XW"=
MO(P_@8_HXB.6:E2P;M,HQ*GZLUTA%I*\$M&>#/\|C">ZL>C7;|:|YDXZC=(UR
MT0IGPZ7%_@WS46A\NKN\|TQZ\NRA\|Z\9.UX5;|&+\$#6;Z& M+ G;_W?
WG2S;\$"C_8W3;1%;*AK42G>\$GB/VS N7^FEW/GUE8+9(Z,0#\3Q' M\|8;EO.?
ZCH\&_L\)^./_0:Q8S/D+?\$RT5\$Z"CGM\$KU6(NW>:PE_X_F5G\$C@ MO,H,U>MRWA<^Q-
T\Z8'T0'H@O=(,U>N2WM>9&X+SP'G@/'!>>8;JE1>W-1<5 M
NF!\\$|Z(+W2#-4K&W\|+ #Q%>1R^!+XK%=_!/U15GP9D^0K:I'/YYM4\$"VW M?;
|XQ\$&J01()WXD:JJ@?T?!"F'@*G%%Q.+=T4\$/CB\|RO\$W6Y\|0&Q^_!2Z\| M6?
Z7(Y\ WAX'#L5PFF5&%FG @NZ"DL7DJ\|Q+L\$ P#\$8X)QQ"08 CL\$ YXQ+ M;_!P#
8X9UR" 8#C\$C/ SN*B=WMQOOZ;NY6SOS&CN,S\|MH/N(>|_|>+L.QL
MDR=,@_1^ZF(10A>/RBI?_ "|Y"^Z\$J/NF6+V MR%;;Y GR!'G6B#S'XT:GUSE3S(A09ZE
"+(LY+D;:HL=/J\|4LR\|D60H@ M@CRK2)\|H\K@OOAR>*69!GB#/4@_1Y%E%\NPT\|H-
18\|C#KNR@'<:P1GLOHUZC=SD"W&L(=| W MX%PC.(|_|E\|&ITQ\|ZPAWL#?
@7",X@|VW.)(|O6%C/#YV',YY?X4J;:J M6Z\O4-NN.B3>U_9\&K&JTK+J?

<4&F!\$!AX)XT0GT.7- *N/X=S*4U#8.YQ=^| M?L(?YS7LX:V&UJXPB4%KET9K|WN-
7GLM-<0|5AR W|)U1XW+B|1 M:E1'N(<|><:P1GLO86|^XW1-ME=80|V!MPKA&Y@
M;|"Y1G &>V|Y,J+=&/9@>Y?+5?U*A>|V_- =P53|S^E@EJ7YWG"EDP9W@SE(\$=Q91>|L|
>-4>_81|.6!;.,@3Y!G M*8 (JPB>?
9&W4:GAU4|2L2='NU\|0A>>\$ \$405MO##IN9'R#TH%KL+Z:\KR2
MM)"36!HE>T\$ZMML&VE_8'>"#V\$'L(/9|B9W/6 6Q@|@K 'P0 M.X@=Q+XOL?<[?6#]?
&F|!"#K@LX!'S^#+2/AC@%JHY0!W,#SC6",YA|T_H> M--I#',!Z%/L;9>=J>Y9?G@
+5W:M57.WU66V+-4SU=.| M8>.R>UH|76|H5|PN71,F%EJ--C|:-
A|W>CIZ_6R7H@|W!YC6#--B|MFS> M;?0N.X ^V!QL?
BZ0!IO7EAR8Q|T#CJO&:1!YW6E|YPU&B/ M3ILX4&|LGS8S^X7+U-72;8JR<|73J3@Z'T?
G0U"U01VF,U *0=4&=9C.0"D\$
M510483H#I1!4;5""Z0R45K#L'+8R7VXK|TY+?!XS@&C^K-0%T7IT9,+24,X
M\$Z'\ZUANNYTNC5WDVE>UF!ZEYQJ0.\$@<@JH-ZC"=@5((JC:HPW0&2B&HVJ-
MTQDHA:|J@SL9Z"T0AN@J+*S|HY?-);S%ZZI8PK|T,6HJ%-NCCF7B')D4YP& MZZ^?
3=%N=9\$9A|PX7R,8ZK)>#R||&TN#RNG(Y2>BTQ2W+#+?S3YNO 77T*=[7C1L9C
M+1TXK*& R|!#4;!U5< 7W"T@_|61?^H"TUA6@=7!ZN?,ZET@'ZP.5@>VP>HU
M8G5X/L#JIT8Z6+TZV:KEYW50>IP9X/+SPG2X/*Z9R)%^#R|'E9P-I<'E|N1S)U^!R 6
MC'%JR5=)|VI D< O&.+7DJR1M2!*X!6.<6O)5DC8D"=R",4XM^2|N|22?'KR
M%#:F7VYC^DY+?!XS@&C^K-0%T76A1=\$T3MK(6D(9R*4?_W+9;?3O79<+XFE
MABE\$4J|><2X8 4F-._@_6C'"6%7GPNDP>4UYO(A@_|N|Y>?"Z3|Y?7E|LM+!|<#BX_
M%TB#R^O*Y=U69PS@E^PH*90|VI_Z7|Y=|;B1\5A+!PYK*. R|! 4<%T5,%<>
MQ&&.+X|U 8'J|<5VV#U*K Z2MJ|U4^-.=+!Z=;-5J|"JZ.(!E|U\$@'JU<'<
MVV#ULK,Z2!WN;,'#Y.4\$:7%Y7+F<+?'E?1|+0D8==+<>V+V+/|>U@+N'+AO:M M'
=|^!Y9=^|91EQ K*7#Y&4\$:7%Y?+A|@(|04N!Y>?#:3|Y37F5R)%^#R|'EYP-
I<'E=N;S;ZN!0L.D7|_@OJH?BS/0>CYNQ|ZW3/D MP-UUW%O+|D04,9AN9--@-
M##Z2V|@6FJ7|V7=^1|U?-WO74D=-QPVES>G/
M5P3|9.Y?.VZT|,3RBK_ =P%=K0\$#AMIDH /W!'TD4N|EVDQU:U/ZSO4BB%SU
M|!%Z(G9O):'SGF7" K|G|K#K=1\3XP*CEI/4N?
|2HS@LC1LW5@_ZH1D9/+E39IF06(NT>_K
MM(F,WZ;7\$SP|L8CD5207(A2Q7%5PZKXWZ_\$YMV|D3ES/C9=7Z?U;_F_TZ_J|MM6A-
#W58_GCCGLZK4|W""7<=?LMEJWO9+OQYPB.><@NZA^ZA>T?HW@/!A9V"!J
M22%G#Z_*Q!7E6Y(7I>KODCZV0%9@:Q 5B"KDI/5UYD:@J0 5> J<%79N>J7 M(GC&
<@*9 6R EF5G*R^!K'P%%5UVX|7NZWU;)UNX:XA(1J@#/,W#/\$)214
YQAYIXA+DNYP_@*1UP_.P&_
M!%GSKWZ4M?)^6J&|E7Y"#9_RR=:F7C/=^|2"S745_4FXXSD'%-3V@(UG(^Q<
M#|FX'#4&X|/.KZL>|H|Y)4%N(#>06RG(=|@9-7KC4I?M MQKAWV&F5U<,@R
WD|G(|W|C|C1K|9:E(#>0&|BM9N36:0R'O4:_#7|I#1=1
M&H4.%|&KNHB,)|B_L>3|00H1G\$507.6@#.BKE_81C2|;@R&V46&,@|J|ZPS
MY;1>;|CH=+%|!"DX#|H4.6&?*=UQIS'JJP\$|CB MNXSDRT&M+PKWSYFGZ,(+HNB=Y?
IV,)=P%Y5 O1UX?.7+U4;=|K:*4M0+R?.Y M:8\$?.2/TG!3L1:?=H#8_*|3)?
3H>8H'GRS|:O.@>V,)<
^2!|F#Y%|PTUAC>X_9CXWA#6H_)K7W._U&IXMM|U*ZQ5^C.,^&KQON|?
T'USIRA9Z32Z|Z M1Q>?I0#+*#0(I&HHPC2L(>H@D*JA"-PAJB#0*J&(DS#&J(. JD:BC-
:XBZ M4PD\$16M*MY7V3QDCMZ3T;%&Q|616"G(=QJ# 4|V;,>|V!M->,V B"1VZ.A
MD!7'(@-Y 9R.SMR&W1H53I/0!4KZFHKXA=1=I%Y+B1|1))!TZBBBN|VF9| MO!
|TD,NTR|_4'3=&XZ-6:"LE?"OB@=HGX;0Z2;S@GG/EWG|W4:|SQ|^OY
MP;P5A2Z8MZ+,VR,;%|Q;(^8M 6ZQM0":!\$+F@7-5@&G MH-EJTFQGV&OTVT=-\$2@E?
E^49U&|J18>T)5L.7@|JZ|KNZTNDXT3)!-/5I%M MCARZLX_TSE5Q|CN-
R_X)79^5Q_))5RAKTL,:!5@%|U:!=|N|4,;|J6:4- MNCU+B(O)JTZWOL_N
24P;9@V|)#%&Q;=:;M=+J-T>C1:IUG@&70+>BVY! % MW5=:;GN#
5FW1TW1+"F63YO&^9+5=JKN84/UG/+J-IR0C!.2ZR^0TJ,(T|'& MJ(- JH8B3,;H@X"J1J*
UKB#H(I&HHPC2L(>J|5ST'6VF';Z7=:=#3B4)'CE6+9?4*RZ M=-
Q0PTA81'57/:K|@AJ!F&Z0M@FM+U#P;=6Y MMTT:X D<"VXM000!==6GVM/6>NE-\$
&UX)K2PY1<&W5N;7ZG0!Y!|=QO', M"@2U=*J|O_3I=2A""\$(H0@?
=6%VL)L.%R98M_Y8!>N6B'6|V%<'ZX)UZX|5 ML&Z96!<|H&!=L&|H0K6+1/KHLX
6!>L6W^L@G5+Q+IC|.N>O-@ZKT M44\$=RK!T%)E6")EB.UV+\$' NF> 5;!N65BWT^KW
&3\$LX-KRPY1<&W5N19| M|!:<&T5(JNK3|7XOP1<"VXMOP0!==6G6N|K4X?
0'U|U.92H|)=2KBO#0M M^H|V|*A)Z/Y'(Q)^U(QDZ\$X/@#^JJE?

MX.Y3X_.U\$7F:D[V?))55(I/QPB)E^ MCKB%Q,X/AYCIYXA;2.S|<(B9?HZXA<3.#X>8Z>>
(V)*[.EIV7:.3WUUMZ^
M.Z=W6K*3P'.."?^5:5_2*&NC:R%I*&:B5#^J2^7W4[WVG&J));.%394*[.A
M6F\!EE%H\$C\$54(1I6\$/402!50Q&F80U1!X%4#468AC5\$'012-11A&M80=;<2 M"
(L',.+;O^35TR%";H8)29*P TU#^U&#'_58_@OJ!\$C(!FGKX!U:X\5L&Y9 M6+?
3&N+T%62I@FM+ #U%P;=6YMMT:@&O!M>#:TD,47%MJKAWC1 !P+;BVJ! %
MUU:=:WNM-NJEO?
H*R@=L2\UO\|P#TW\$CX|.4#ER84(10A% "\$6UV8'9SY"!#N823\$|KPY!0"95@B98B-'RQ!
MP+IG@%6P;EE8M\|J8=|'|>S@VM)#%%Q;=:[%'CNX%EQ;!8B":ZO/M4/LK(-K
MP;6EARBXNMIMC4>86R\QZ;|M!Q3J5 M^+'@|@>^:GW";TWJG^_N+
|P;5=XW%/-"Z(DE+L@KW#J^@X\|ZK?&O1Z;|?;
M7Y@%H^=..@J>IA)=&|3^#V!+!8F;&:_U!#;HOB ;B&_/8R(*|9L-
9U_RU!Q.%*KS)CNW+4GPQ.B<.A M17>(&V5"6#,16?)6>(F(I=/0!D4\|D\|9"/+ "7:@3-
JQ@:@5TWR)T??|L^2\MM)/8O97TU=2U"9@L|?
S!;093\WU#;/55.H+FWWP91>E3G7P^V,7QRS6*=4&M M="0J5#IL"/V>>/1AIR>:G<&%?
*>N|@P<|UM" QJJU_UAKZU5,C+B=PU+J%=^ ME+;<3^B*7J=A==O=?
LOZ243TX&1!/8UG(DX%0CUO/+??W""7;2QQZ/C\Z;802 M!MUI?ES(T VX"@M-
<;JRLJ1/W<@*U11O|"NE.[HY%[\$5!_SEK>M(>I"(IM
M!GH_/8/*'57+|0|U0+7GP;A7(JV*/^=N-P.>L)\$IF_6|4J4),0J6ZI7-
2U)"FV|%/&/43*G"418=U2O|/I%P:D>6%, MF#>2BJQH(6UWZFH|+=??OZ@JL>.KND-
"A_|.Y4U%_7DS>T5OLV4I7J3FT M9\$GFB^&1?
Q5H"PJ|Z2\$&^|[\$1|P0^*X\$:%Z9S8V.1Y:I"KHVHB8)K6B4P";1CZ.G<9:-|4@ MT?/^-
+BERY>|_4#NC4F=67-J/5WTO-,>XQ(I5\$|/PV\$6 *RL"G/FY%)LT* M8<|<>^T?B
MW*C+"4\$%@?'|[""*FQ-B*>).NMO3YPS-W 4W;1%\$DIU MPYX)#K1GSE%;?
YTQIRMBITEFY))DQ+NI1.VB1'.>"5).6H3+%-K_3DBSTV6D M?
6A";"A#/=MG@FB,IC21+3'2TA)*J? \$)H(784&A+"W/_;-S0.:R8F M3C|P_|C8+-
J|WT_R>8);YU@1CW?_E7V2\$26GZ9TL@PL&?%NLDMT;|3I7!"\$
MZ7_UNT.ZA)7U=E0SWK=-P?LU^F*_3H|UAK'|=%Y|>|_V%T&&=L@J2&6: ^W)
M4DWU_)XH(1U^|P1TH':FG=)8& M65"G\$|H6NE?K>6EX2%O(&RV8!&0EL8IV2-O;
<<#/+XRULA3HMO2-000>-9)S MRTQ;O)XK)J|GQDM^S=:1|AUMTM-'(LR63_FEA*[8;-
|JM-V;P5XD(5D69J?7 M9A-9-4"MR/| ^_OUOZLG: ^)1L==.U9(H0J|AR8R7_) 'ZU-
NL=|H;R/>J9WKQK M\$|+C|O144|H|
(Z%DQ1_)8EQX8GDU|>3|. @G\|D42Q.UVFE>GW7Z|JM2R4"0!@>F.YP8C6=&?|%/+7"_(K.
<M=?WBO'\$DW>@UU)J*+7ZV!'@5)MQ0V?HD:((<)LF8IEK+G#C 2J?E|#=X+FO!-
X_9D>5&'WZR,P)|*Z=U?-7O7:LPT7="; MKTCDR=R_7H'_ND^U-7|!)3N3)ZD_V
H&;K*NTUY=Z77\$K;R>!/<|9CP.F7/V M?D?|'.V|W,O>QE0-ER-
|EP=S5F6C&KZ8^-=FEU7(HF#Z|4O2-+Z8SWX*B-5 M3*F|5|*
|\$|OH^LV/&4RV.=G5&!9PL3&^+SN,A|B@U;WE|4)OG8+0,-P#VF8 M1_XT82K-
7#C,H5&B=O+3I4;H1M|3C)B|=6|01/Q)&-2+;/=EDO>Z ML"E*-
SFNZ3)#62D2Y3|@D"EU<3!T!(^ (VBU4D\7T;P5D: ^A^<7<=6HL+V5V M;DZ>(^C6-
M%X/=W| |G32?O+IE=_U3HP;F7=JEURA*4G:##MT%;%8 MQ#N;/A|LLVGT(9C3U(@U(+
|PUE^@=L<_AS?"^HJO@KD:=#"PA|5Z3VORZ4 M3FA??_C|Y;/ZL7-/H2H^==M=WH;&
|.!:O7_/&-LBERF M_/!*_ZR-<+ 9M;#=#L;X|G -|\$,I?F\$8H|JBWJER:W&W_TM
M=&UYQ|;|+*!9_2%(@+W)D_?JKLM9|!^:7:>X+1Z M-AX*\$9B3;T'XK1#14.
|@RY|J%WSYF?T%%6LSZ9|, #R= 9UE=JE|H=8|OWG" M?RB8M@1-M:|W"O&R>?!"/&,I?
DY?S;)=\$0PJ"D-P=H2.&AUAJ+9V>T1?:<7 MM'I?)C4#R?
L+|)G&VP.Z#1)U+WGWOXSF9-Q:BLB_ ^5;=SSH#-JC7K,_Z+>; M_:DS;\$|5\$#3%T|Y-
Q'A*/7#>*.U*(_2|G/|MS8=O|J@SO73;|>9@U::=|0
M;HD)QV|:DTQ;Z?;\$V|FVWU@^F9E_>R-MY^J?@<^H|HOG@|H.'SO!_O2AK|X MXN:-
I=F"5,I|3+*_EPZUWXODKM8.^L.VXW2:4|)UF_W^9\$RMO6PWN_V^& S\$ M9"CMX7-
;^X2FE@&J0C^RYY)2!;/WKR/A*>VPB)IDZ45N|FS*[5Z M3(A_J*>E-D5!W1?
|593O:D^G";BP_3YM>! NRO>R=T6@< M7LJ/^ ^V8X!;S9O0KO_7\$2WC|6QZ?
RUSRWRCH:*EH MCR0L|Z+^0^46|84, MO-|S-|@O6M|6_Z-) \$#FN<6THZ/HFG"&??
\$X|6:|Y?/8+M(=SDA&85;7 K#\$" ML^H5F/6:9Z*DV%4*C;-&O|FN6U:%|=O|W|^>2E?
MN77|Z=-I3WCIM+|E04G? MLD#^;S|<_YL=A(N@K*.KS)%.NX+F2);M|.6.??Y6K%>;
(2HJ+8/C!)V=%M_ M9U>@"AU_\$8/I^4 OAXK|NBOC.LW|YJEH7)*I+|V+(WM>4|W
MAN4NW26(?2)HH&>8I8\$#S.XY|<8;1\$DJ86T+R2O)7.;3/UDER9;!@&UD2|9S
M8KJK*S,7UXJD\4LA9|WC!6'A,'Z&| "4#8!?'8!'|TC^9R'|DF3EB.+6Q M/H11Q(^%E|EE?

FE49;5DH.+|R_OP>(99'L'E9?+\$19J YH8Q*&5VQ'\$T23B; M|(@ROZ*ZBQ/N,BGL5?
Z6;^+<\$CRB7D6>3S(X7|H7W57GRZ-D5(M WDW.E'^^)^L MC%>|5SWNB"=:
M_GO\$R755\$D_Q^0G|(@)=C6"9JCI-:@BEIA=X0A78W=V//20*QNF%DFDW;-3W
MA=^H8@J4^PO+<_LL2PQT1/2&ZSG-,R?>J|7ZH#;:9/K1/U_ T4XOMCMJ"A; M(%W)?
^RW;ID6:U0J9DIAGU===20*I56_2-1L6Y4I CR=Q_-\$-K*PC=TT=3= MUJQYAN+B
|_P9HIDPMK5M12/Y|=-,73=-)=BQTR PE=D&?I\$M^=4?4BW13>J*?
M;I('X"U>=^/&*|XDWHBB'-U6-.K&*9JKDM|2>450OI,..*BPT5.K*96I/U*)BXZ,MYSQ^P
^C M7?&1S3(3CH%H^=.T.=9:'4IWA'AJXTE;;WL45;|Q?R;O-O!*\$7;..%|6)ZV
MOZS3NR:D-FPZOG1=|K9*XL6ESCK9)RTC0XAE+/3!+<%S0%*5IGKQFR
M|GJ_ ^M^I(Y(5_UF7 SG9G)\$X28 VP1;WH?<KMZN)DOG'2|&!K8H.CLK.FDE/.>5G0?
|V)3@DU<\$'29A;,%<2AD4P"0.3 M,#Z0A"?522Q 3D8_V@9)AHW|'\$0NF&>W8Q/T=Z,I?|
Y@VZNK@%3#0V#B8> ME_0>|Z#9L/\$7!ZVOO@#ARALPGY<#?
8V32W;DK%=<Q3IZE/6^I3N_C+5|_-;K7 M-|&6E(CI3+|J5K|IQR&O#!&%?E&P87R:?
4SDK(P!78N"X;5K9|:> B1W\$;'K M^:"&D2=.I,^\$JKVJ,(J(VXACBQP/BN)6;
P,9YY%+^#BRX/KE-=?X97EL^=% M05?+<#|O4:\$UTF)M%+<67_6DTS:?"<+Y8!
(R>C\$H5|W'L/AE?#NP=T6'&|JK%_MA5>+KG;Y&-
|Q@KM%N=F|ZNKRRHGJWP.+9IM\$GZB|UW%7.J!>7U^Y3>WK|N)W M:6K?>.^NJCM??
4(E:|2+-7-!<S6|'IC*/Y@QY^<=<\$J<8D_2)Q5'ILQZ)<_W| M#1(!SPYS26SF|
<7CY|B|J:UW_5Q_||S%|S-DVZ(-*E=|_EI3V|XL1"MM;-?(MVS.FOPZ|99W&Z&
M3|P(3|W#_?H"!|%LBHJ7^KSFI_"4|0G'&/=EE.PI_WI7_1*"600IY_E15 FX
'HCLK"0QB@|)T/\$&4?RK|=DWTFRKZ/RKXXR5EV
MDRFQ+PC(^Q:K;T;GX3BD(4A;LG"JWV1""|Y*E=F\$LY=RZE^N4_
M9LB628)JF41Y\$5525GU6|_84#8&2,@NR:O@FROZZ&2N;4=>J_19'9XIF/G#5
M4|DUM,RP3-*I1XP_KY_&>=\$":*Z|SE2*"ZG*CO3ER;M'#)%<+WN
2|WDV|GU|+)V='Q_RQ.MF9U(4189R',G*2N\$O)FE7#ZY@!KBOA=YRR|U?
MZF"8ADN624(I7S)4|LDN'I
M|!5S|51E|6|MDQ9M@#A>XC:UKRV13JWVR1(S6^O+%'VYC_.EC\$3@!<|:._ND M?GH-
..|G5+P">?>D|B(#&0&\$@,) 828SYBO."AW|&O/YM7#SC5|.|Y+X=EPUJL=|/+?5|TO4@
MC'_R=@7B(=+5R*V^F;XO=9G_8L+5#&;\$1K#6XR>(4K*3Y|>|<|Y9|H;L.BE7 M56:ET|
#43NJ:@-=' Z8>5_<F5RQG=V>FT>/1F5Z9>6J?:7*1:RSKG0X2M.B
M1D>1M!"SWLQWDBW_7?KV/8P8-X|EV/>R9JB.LW
AAPZ3&=ENA6PWEK.J4+UXL|C/H;_) XQPB?48PB?D.VZS'83
M06<4@<@|ATYHHK_5G5N|:4-(@;FH<-^G\$4#3'JG"3UCYN^L'NX"&Q/IHK6N%R
MBO.#/;P*>I8E7DBK@&)=2\$;VF!|U-CAHH5-D/8*"/KO\$4US8-ZGYS!((?)_M(P|:
(KY;MS;^09|D12"@|DLH|0K-=CE?|DBAD0_-!L#E0!&;Q_-/\$M|*CND
MARQ#C++<N@+I@?3HVVH\$;|Y+ESPGZ#O9=PPK^_<\$MG33U;N\$|T@#B&ZIEI?
M7(0^MYPV=,|JQ%Q&D(H&G2"4Z^B'|\$8,|:|ND5V3JU*-2|,T MC"15Y78*
<1"S;+<=.6HEG!42G|=RU4C+@<LZ(J\$|_*|PB3HBN:@IX5Y+RY/2NJ
M78@L1\$AK1\$@'6|21")\$<A4BJ!A!)4Q1#!XADJKI: "2U;8#T/4RS7#JX8|\$O
MTJM;47T4_T^@G\$H-D(F5%S+0R;U%.F M;UO\$DXB;FCN01G0
48ZBPZ^ZJGZFEJJK8NJG^R1YEA=Q8>MO@Z8KQNKG-HJ=) M>J|P.BD:(BA48LL@*\$N?
F=|SG=(X\$Z6>9_F=KC&E!|EO:>|I9VX*^/Q)4BTA MNS"Q9YTHZG"+V!)15',H"F"4:7
491BJ2KY219<5S;:T&X4|*L1OW05U/OC3 M94 4X"BMDO=|'P%2:@L|H|<#I:(M8
M\$H%3@_60#%NSX ?JAI.<2I,Y7^<;&N'0R7(8L3R_?ST/1FE^6!!/7KB71| M*"#4/T-
>^DVZRE/&9F&I(^85#BF-(*)"K?8!AQ0"*F2|M0.J0FBUWY-Z5ZC. M=7Q%K\$D
JH5%)@D&C%)="<2|N-*WU7/'O8;|!"&'7NY8E 486%9R.*0E6V M#
(I27F:3"QPU=RX|@BCDO"5">@H6>UP_D/J^16R)0*H(*42HMFN:=2 U(UE
MM@VCKL+%'<(H8=2IHL"W2A!#H29;"D.A)PI9;XVL5|E^JE/(K;AQ'S"H!_RF'(+
(?|V1M/XC8H^R'*. \$*(>IC.|B M?3_AA%|VN/?OB!SWP!"|^&7L*WXX%^C+
^#IVHFXE89Y/K^,"E2"/=2%HF^ M!?'6&UN,>-
H|S+IW""UV/^U6NP<4W3|>2MZ2)O|L#SEOWPU|V-L7,XGC+F"E;,< MY\$|1 '|Z"Z|T|7&Q^
(DTP"FNT>C!_J4E>W"ZUPPMU;*)S?ALW?A@BX69WI"<,_GE,FRS9%1>4G9|)Z1/?JFN!_-;
MZ#!C>UE1%IM5U\$G%XHC|/CTWJ%SJ_-Q-\$P|F12.M8|U%DSW80;+<@KS
M|WJ33|LJF)|@3E|9IHE|WU(7OTLU^I: ^Q&UJ7|.7N*U/EIC96E^FZ'WCO;MF
MV=;+V=.K-I&6EP;8RAJ)|@<1 8B OD!B;3(RU|
%OK*OI;,)O1D@ZY2YSYO!M1R@*6LMACT@!^AG%K,F"^%2S(N.N+6/E|SY+^
M!Q78\$O3<|F|7B|M;9\$E.UF=%L4L.1>|<\$7NQM<22/'NH:B-
3ET|!M69A&BZ8T|.U2FDNH1|PZAD_-SF(Z#4\$.

M9NRU;K63M\$BM)RF.8_;&Z4T_F\JF2>I*UP;Q+PU;0@4/N\$R-1:CHI%TVK\H
M\$H^IW&6P4T7_YK>P51&?)F+O*C/O+8!O/JA_=F7Z3/-,M@\$>"3/F>0Q7&
M96(4(>87S(IJW>Y0;K@W8("@"@K7RUIN@OINL0L2(^UU+LJDN--A+!KA+!
MTE^WB#\$18WX,8\YL26/K_#05\?0=#+0GU5+FOPQ\UBYJR-VSZ)D*/ZL
+ #667=GR/C(L"A_+*K+CRY*2"TT6#'#7\$FDA#\$N*BF5XM07^O\$M@V7ED?
E6C!&+AAAB&*=\$/\$;0D2\$B&+5156)I3JZ_94JJJPX1#/*HJA:V_'MY\CO65O"HE>%
(H5\;\$+QI59;W&L)7U#^#N;WGL/!&>#WS::8B\77-X%TN_,\$P\$P8I!E+"&1U^1|=;(>I-V
M)H6D1?B\OBK89",V)@M\#U>T%^S:"!Y5AM@^S%L6JC0?I\ZQ9!;?4^#)))M_
%CPUS"\#^JY_:1(9:50\I#R/D641YVNHZXL#-R'%A'1?J\G/4JL_Y_<"M/O?_E3X_>I?
C>^Z*F<"P\BP70\$AZBD5PL.9_<217"(?(?
@<(LHSWEL\K5)O.ZUR5A>LF7F5K^5'SI%9V5R^Y\$6:~",O!XPVIA(NFCDY\INE\$LR>
M1&W<"@K\$[\\$ED/LR>W\$;"\JW^#?V\$G9\$#VX\T%_(3J\K>D\;?L(#WP<.;J;M/WNP"0?
A\PI;E%F/OI8JB_)1\$2^%IL_*;\AE\$;.0V_@%E*>[_7#U6-!(\$M I<"@1KU>3OZMI,
(61\CD\H:B/O9_PG=V7\AX\ M5@ZTK9#\BIW\PP-S\HZTDL")B7P\J4%6C\$
M=T7E+!LA'6K592"=HJ\ S#GEOC;QW\N6)"#JHA>!Z"J'!3^I&3/SJA_>2%X&P
MY*2\97+9_Y"/JX)(^87E/^4PY!>SSNR=I^\$+%'V0\3+CA\J\!41G?QOA\JF MPX@^I?
%O7Y"Y;P"A^?!\+\$%E\|*1EH?!\4S43<:L,*F9_F&2A>;*(LJE\I\Z;
M//)UX;08=VE\G/I%+X>\Z\>@ZT9)\YZ_7S+\0U7B\;F7\G\Z.V636#A-K6..+M% ^O;[\#
(NA_(1T12T\LV0WI5BR8VX\UXX,M%F9Z0W+.Y)?+L,V247E)\3Z%-MD#
I\Y\H>V#.BPXSM96Q(>2_UBC\H6\OQWZ?GYIU+O9^W:0(842\9NV@56\RS MWF3T\LQ
U45A_K17O6F&E5<,S.DKYB_U92^I4JS\UU?N4OJ6NOA=JM&W\!5N M4_N:O<1M?;+\$.S-
;Z,D70&^=->FM;H-H MQKZ=?-H?
IJ>Q%Z2#KEWGOG<69ZR@*4LH@T@)HAW)H,F&\%"S+N^B)6CM^S
MI\J!;8\$/:722"?:"IPHW1\$J<M;9\$E.UB.6>6DXY*XW'M,J.12YLP4BAQ9_M9
_F=I_A_R'^M242_6)CGM+X)\P/3G+IB5;Z-JM*6C?;3EIO/77IY8G"LC_%
M)J)OCFMO@T3U6R<*,1\$=F0\3T;>1!R@8=,11&B+(S2K=8163T'O'EPKVMCM M
0C4F*N&;Q;"-60^A&N\0'AAG/T5X=H6P+65G1M4-0_3JDYJYP9O++OM8X,O
MVKU/EU<JCN@S",8K46;PI0!>J7#/\@"LK^Y7*IW1_,F>LIS=946UUAF=SWO
MAW>BB_OK;>#/\^O_H3W6=_R'>IQ4MYOT\$9* @3EP%D'SSTAR56D?46HL\!,TC
M214&IZHA&%LC&#08(IY\$*-8<%"ZI9N.PJ&8KJI?J:HJAJ89?I)'62\$W:NME M59_UX.Q-
H:"BPE\1;M1ZE3*;!\\$=I-;Z8A%0)KTJ71#?Y R0F\HS(\^_)Q M2/>/LA\Z M\I:=I"*5
F\$@PL"9,%#\JMBD59++"\$Q6GUGN?.C=5=!\>9X\3;XO@ICOH7)+5PZC?-^O7-_XWEQ
M4C;R\9E21RX5;R_1=5EA%QELN\ZU(\V\ MQ"KBLX;Q&9Y50("V8-
%\J8:71.U6O)4KK#F@6EM(I&4Q_*JNM(:U\%%C?@ "J M?="5AF@->6\EI?_1K#4,UKY5U%
I96Z0MXGL\$@XV#0?B?ZBA:_22\$;:0-!:_@ M(?
Q@Z<9BP:HS9A%653"W#A5R&\.\$*A7IN)UT11.(NH\(% "2,VU=M-
Z9_+OR2A\WIH\#\;P>AVE.6E MA:JJ"-507Z)?#5FOZZPW220NY!8BM34BM6-
\$.HC4WD1J.K\$-V^H64@N#C09J_MOX\@TN+4A*IO%\$I\A
MK>9\$J3HY46H3K3A1JMN&00/-E8\931CO:FB:E4R\;L'1GN3_@D71S\DAQ#I
MCSC,>I+IZ>%&X:76M\3FT6-5>&EV(3;\$2\AZJR_"@><&U@J8L*@N(J;W\$)-F
MUO"3J1%1DLTC&G6=MA'3K+.>=1 EO\$=%-T_\$4*C(L)_9LEYWZ+ \$"GO-"J/5# MJ&I;Q)
(H59P,%(UG\J5#/7&;+V;IR?0244>.^(F5%Z(FY#UND*/ M%>"F.OXJPD_J1DS\ZH?WDA?
1+.-TNV4PIA0DL1@\$O! "&RR\H1_NG'(*8?MR3 MM?T@8H^R'Z8\PO'\$-IQC=I?
O^V\$VC.C3'O_V\8W\!E"9C\VS:L4'_QIE>1@I
M5=,0MAH@RO>'21:*9_T#9Y%L>\FCWQ1.!W*4<(GJB\;F7\G\Z.V636\A)K6..+%^O;[\#
(NA/(1^11T\LV0W15_MBR8VX\UXX,M%F9Z0W+.Y)?
+L,V247E)\3Y>KXS\4EWO\6RH8<;V,C:D+)8_M19U4+(ZX\I-S(JEWL_-;\$P)H?
L'8C_BGD^%.OJ)I&_?Q\FH.;B;_':J\XT
MPY8J\N;T%?.7^K*75"G6_>LK=RE\2UW\+M7H6_H2MZE\S5\BMCY98F9K?9FB
M\XWW\HIE3R\G0Z_:+%I>&I#M@R9(#"0&\$@.)@<38(6*X?NV%W-JOYS!2S6N MK42-
VPT1?K9AMM&.WZT@S4>Y9FP65HZ#85ZZA=L@VKR&?MT\FI^F)\&7I\$N
M\B\ZDZ4L8"F+/28-X&<8MR8#YEO!@HR\OHB5T_MM;ZN,HRJ"DQ.T7JU-
J\T2>SK%J#=7'8)K=D^?M='.I#^N#HIGO_,@X34JS4\% M"3.>-C?MY%W?
9\$=K\$V"^\\$S+> K09\^@QL.'UNJ&=0B3.FM;&L&;K6W5\9VI M\$V)T"=I=TT?I!AU!
(65O\+8NJP=KK_>VYIJ-?_%CE)0/(\Y)&Z?^,>(SKJU M\SI&CXZAL-1FG+IYADV LZ?
KL",T0ZY;@#83.8K8;AW83)' ^ ^E>\$9UL#SUZA
M32,E/A7+MJ=*)IMX\I.#+&.Y=#&"&=!9KK8CYLT+T6;
I\UWHZX"#Z0L9;K@M.42X&"W>N%7^I M"QI^OX\I?@!L8XWPKCGOFVWIIJF-T9UF\$%

FORM+TKZYIZX9&0_9XKY""UAUP MQW?#*D2,=47X*XHDSZ!>*(S!+%>0+S+\$-!AZDO?
^D)%LS\$=-1-15H1J"V; M)&594\$6B6\$JNJ(I"-60^19L6"B@&L%Z5VN%:@?/L-
H6L"JKM@P M+YU5HL(H<=!7A;JMG>JBB*J0\U; '>35)5WB JWJPPBL"J86"E(:Y"7+51?
D;KM"JZJ\U<\$D\5RP+3>0PEC\$;J0^""=QMAP> M%\9PW_M>KF\1#5/IL" J3KV?
61(C(\$UN P@TS\XB,R'P<.=H+R 9!@|1\$RV M9/"Pl.XY\V.LAQ#@U6R/U8*COQ.,J 57"|\$LJ
(DAYV&D<=OISM&7CN +P=<; M'0L-&U 7\$(0X1-"39J-XA1-GQ7/9<37NP+#9B*O!?
U8C'H#_JP3&L;2C\|T M+4T>XIYT1.J#7_JJ+_U*@"R"\$#PY3&MYR?J=OR?!G&&<)?/:C?
U0\Y""0AED> M CFN\$|^-7SD)O 'R#+C'4BLO@L0\6!%/PX".RWE*%)|3)(<5\$1+9.1':P68BL
MY88V.X;'Q*|CU#"OASC,4M1-47@,4L)3-IZ3OUY\$(#T.&6\0-
@(|'NUV6>6(PS2,)%478LE".(4Z;2DX9;V"J.;K(X%P"EEOR?BB*007 M>KC6BJ =4Z
96I&PY1"=%TXM1J>"DW3NLU'NHHJLJ7_T%A0F6)?,69
MY_0ANJ)0@:\$K"EEQ,UGO\Q\$P5=D1A"!N6B-N,A V(6QZ%S8ICFZ2"6Q2;Y36
M85,5#R!)|S%80-D%X5)/QP1Y&KO*\$R9ER=I<0+QBGDIRVD:LL(J;RL?9AG MT@G
KX&4C=PL|S-Q*6(O5(#+8*|71O6Q,1"RW@I9K_2V(A:/_@R\$7PA^%H4
M?"DW2NOE'RK P=<0 7IT 86J!KYDXJS<%L@0<>V3>2 0%DP">RUL008:J\$'6A MZL-
VC,AZF\1ZB+L:0UT6@BX\$76\G7EF JHN(QO5R\$HB;4'FM"S<%
M22IN^7=QE52P;Q'SUI0BZP-!%?+G1\&55; 2@JMU@JM-J. -|*J5@X:ZH ZJU M@X8EO-
)M5W,4OVUX5;FWIO#3P0.O3'K(%T/XN9CT^2R)Y>(P(IOXLKY(XL4S M\HX1IZ\$>;
NGZ:O!:2;B-.3/C^(T&||?KA^G8;X\XK2E<9KA>P;Q:5=P&D=3 M:>AQ/%5 J3|BT'HS
!LGI/0/N\H>+9W'H/?^SUJL55'VB_PMA&ZH&I<5/VOK M\|0L<,,N\C;W< ?\|^ ^\$G=B(E?
_?!>|B*:99QPMPP&GX*L%J. -|X^07E MB!/F7\G\Z.V636_A)K6..+%^O;|/(N!.(1P12T\LV
M0W95BR8VX|-UXX,M%F9Z0W+.Y)?+L,V247E)\3Z%D#[Y\H>V#.BPXSM96Q(M
1*RBCJH6!QOWZ?G-J!+O9^W:0)P32\9.Q#_%?-*;532)_SL0)5&8?ZT
M5|UIABE8#;SI^*8O\64OJ5*L^|=7|E+ZEKKX7;K1M_0E;E/|FKW\$;7VRQ,S6 M^C)%
|QOOW37+;'"<"V#5|MS&&KI(#"0&\$@.)@<1 8GR(&&^X\NW%/-
V0X2?;9AMM,=Z*TCS4:X9FX65XV"8ET\|L-H@VKZ%?-X FI^E)|"7I
MD#OMB^9C*0M8RF*/20/X&<;MR8#Y5K @XZXO8N58/DOZ'U1@2\|3*HUTHJW:
M0\9\A99DI/UB&5>&A8!-%|!0Y,XV4"ER9!561OY#_FM-(@+\$VL!DJ"ER M-
V:%KB&\L1+K?2NHL1(,^&=D1\$US*?33RRAOS9-?|\$(VOM M(;)T\T'L1?
O:K+P)3ZZAANRBJ*XAM.L1')GU_@3\$5Q|".X8\$1PBN&41G\$V9YKEF)Q!<<=--
_6^H'3LDIFOHS4;T MAOS9-?Y\$|-8>>ON.Z W1V\+HS0DT3\J"W.?QO\$S@U=26B-
M2*13/-=3F M(&I#_NP:R)J:P^U_8JH#5%;;79EFZ:&@=MQ#&(HAG\$="FV/97US),7;A
M>[Q7R\$-GLMP\$=)H\U>V"l:./@'K>=,8;PC54AQV1RV\U>RX\DA^.TI0W,7\&
MUVSY\|^F*(KFH) ##EOSI,J3Y*J/=86V4.\@%F;5@*LJ=V*;(O#
M+/U&TSH.LVHZXBV.K:)-H\>JT);J(M9#U\$6|M/>(&V-JU<5^N\I%=\$61UO&
MC:9W!6V\%3SDWU4!1.DH3!D(FQ1!5T?VTN;18U6@RT#0A:R'H&O\|<|!EX.8
M"S'7JYA+5&RP '1TU(=" B*M1LG>RZB* *60^=31M&> &L\|@@ M
JLE@)5UHW6C#|*C@B(BSD/409VT8X07.PN.!B+.6P%GVC=:9 MCM6-'P|\$F(6ZKI--
#!%F(>NM V;|3^I&3/SJA_>2%|S\XZ2\93#\%.2F& >|M\$T;,+R@'_*
<<@DA\W).U_2|BC\|O4E>YE(>IC.|B?3_AA%\VN/?OB!SWP!" M\|^&7R*
|XX%\CD.#!4S43<;L,DG=_F&2A>';*(LI%\Z;/)UX:0H1PF?S+ET
M"E^/^5=OJ@PY5PTL77;U)L-YZ_7S+|1E3"TM+\$_Y+U_-P1@^E_)8ZY|Y2P' MN;-
'1WFR/_T%4+KXN%A|@:-I -/=HJ\$#?C\OTP2@DURR=R#^*^;Y4*RKFT3^
M_GV8@::+POQIKWK3#-.K&)C35\Q?ZLM>4J58\Z^OW*7T+77QNU2C;^E+W*;V M-
7N)V_IDB9FM\66*WC?>NVN6^;V,S<+*<3#,2^|Q&T2; MUJ"OFT?ST_0D\|D)TR+WES)?
<)>REE 4L9\|R\$Z@)\AW)H.F&\%"S+N^B)6?M^S
MI\|!;8\$/:722"?:"IPHW1\$J<|M;9\$E.UB.6>6E81+B20"HY%+FS#52*%G% M3CU1"-
)TX6OWTG*)WIH\3JHF8A+2 M1KD*-TCTXIDZ9+V66._W\$3"5ZHA*:02QUCJQ%L;1*RU!-
;2 6MU!6JMN&0F M(BY4>UBG-%FO;7H@XMIXJ@O\$|1T1%R*NQ1&7<:-
TIB7,3%2%|^XV:\$|M'CVP
M6#FRWC:P'B*OUI#7KXB|\$'F|B|SX!X9=*U6N*#>*WGJY\K>Q%R?3^(I?4QKG M;
IG%\$(1U8GMM'CU65A;|E<+H",.0^58)PRP!PU2\$8>N\$8;\A#\$,8M@0,4P&&
MD8V#8>@5VYR-MGGT6\T@4Q&0(?A(-MRJ@M=H* #'9NX!;(X2\K&N S+G1
MNN,7F|M?32!"E5QYP;.E\ P^9FF&@ MUWOOE.58&MQS9F8FW#N)X1*,98 LI M
R+C+4N;\|Q- <<_28HIX):&<&N=<.MWA%L(MY:\$6VI7X-9"T46\$7-W93\VC M1YN02R&
(N9#S\$'-UC@^;QUO_1\|R%F&LYS&5TIB7SDJ%\$1%_=V58=HT>KZ&MV
MRA>B+^0\1%_A;Y.\$7TA^EH2?76FS,3*GHA".O.\NH8/5H%8;/3O!"\$(>"%?
VZ\5G;A1C;OM@&"?4W;?YX)'_X)PK\$/| M;://HL2I IAH_\$(|M+N>U!;=41< Q'>'8.N'8&

<(QA&-+P;%X^^8XB[4?JWB
MKC/\$7;O+>8B[.LN'S>.N<|1=B+OFP%VV85M3N(MV!7:|4GIBD83|7<=>KS#.MSFK-
K'7 1::0-Y;>Z\$)';7^K'7:6(OQ%|+8"^WV|AKMB.L@%WOIN\$Z*6|=8<2 ^D1ROT0!"Q
A"A*@@B=@E\$J\$K|(.TS'+NAH/I>2 ^\$ M%YL
+S2,ANP&O"C|&EH'HB&3)%*>\$7HQ2K,1;SB;)|+E*&*2HE%9T3_3+O+/-M4!6?
&'|U22"@QQ7S1FF8AT".XT=00.-;)AUXPE.B.)J.\$ 15#-(#Z;\$R"(_ MJ1LO;L?
WDM>1+.,D^B6P3!3\$(SB[? F&|F_H|S8GS+WU#[NR=I^\$+%V1>)M^%R:@@>W<7|?
I@-(JTO|H0>OW|MRVN94TL+RU/^RU=S,
(:6Y7S"F.LX.)|")2)|4ET|H|G18<;V,C:D@'E819U4+(ZX|I-S M>|2EWL_-;%L))?)
L'8C_BGD^%.OJ)I&_?Q|FH1M&8?ZT5|UIAEE2#,SI*^8O
MI64QJ5*L^|=7|E+ZEKKX7:K1M_0E;E|FKW\$;7VRQ.S6^C)%|QOOW37+-%W.
M'^%VU@;'"8B.;AT*0&\$@,) 82 XFQ0\1XPXUL+^9%?CF#EVI<6XD:MQLB_&S# M;*.
=J%M!FH|RS=@LK!P'P|STTK9!M'D-;|Y-#|1-3V(O28?<*|U|R7V24A:P ME,4>\$P'I,&Y-
!LRW@@49=WT1|H|A9TG_@PH|7I*I9%.M!4X4;HC5.:6M|B2
MG*Q'+//2L*A:D@12R:'(G6V@4N3(JH8AA_R7VL2\$2 6)N:L+S%'Q<2*YA!>-AG>|
MFLNS"K,+ #GO^84D(?K9:N:VD|C|(8.P^N;- %W.: (YE811^CD *Y7F/(1\$,ZF.6P0ZH<-
A!'3B-M!|WS"L>P,8X)X^)|N_CM_)X6;??BT2A0.P/Q5OGPTMWUW&!?I@?1>BP-,K8"
M6&SA>=G-I<8829B=0Q*=/ \$J|V?A^O6|>S8KIXJ;L!M>0>D SR64LEFX!*W-
?.>#FE/U|Q#+^1P!_>4>&L82 M3_X*DS@K#EZ\$F<0*5WA?NAIY@|G7
WK/BD<&0K=7Y5:C|+O+@YM'!|.G>N@ M'+?/&EXY%)0S:Y(S*&A0T'R03A>OR-G>
<*JPZD59K_S%UM5R?|_H>_O_B M5V7_2TUT)'=A_OSPUTG.[B23*)]=
<3S|DMV.HB)"=R7_O2|=#XJL:^X8\$.G<M.?
T)1(\$;@P*W|.;:HSAE/O7XH|UD^/1BC*,A/*X4.GR47%CO VKU@_T|B>'MX>&-
=V'&8X8HH|9FNYC6BFP7E%.[PT<|5=\$?1>6&SD(8(\$TEFN?4&W#LD16Y
M| #7A,*=XHE| ^&TM**))!7,+ O?R:ZBW9NR-=E=B|H|688|'-Y5M*%,LMA?|?
M/L&JWMTHY@W/P+A1R,^;:'0'=|H:/M\$BWD*UD9IN9" 67C'|XY33=8|2O&H0
MS(&2WB+F?*W|V(8,N3ATN)B|X";.<.WV%#QCLBR?)HZ,|I
UA|*3%:5|XNUNT!B|A?/49Y<-M:|14=H:P9(H+Q)-3-HKA+O% D(&#)
7*^/W=Q@/=Z6BV2)|RW>D|H_.*FM67 MR|2<33%W>-U|ABV=4-
XCUGS#>UH3)NW0X+UXAXJU<|&YP?Y1I&%K-"R&CV1\$+?>Q=D>C2/8
MV^|W^O++\$*S)U>^|Z6+9)C5^6#FLI#5|/DUD'DK9KIDD.5P0,,4AB8BAH>#
MD/%F2B0%7+M!8)IB+BV(V37PIG7^7 M#CH=4;R^/K|_|I?1H**|F|\$%<,'DZB@^/3(V6
T&51|E %!H,D@K|@4-*0 MI9G('(^KV&'YLEH0DAL;82P^!<.5>I.DQ:3XU!?
GP<+ %G|@@:5+ M*WM, ^1\$<06;I89!D1,IEFY.\$#C+!'?H6A\$?QQQ|-0Q='Y+_S
M45|2'>Y+0LX9SXQA|>6W"(Q\$Z;_O_4Z|G_#6GOB4|6\$4:W07DSBCY.F(B:B M^A",
(JD2;K!,"&LO|Q6'@N"K2!(2D-^>C=QB)"%_,#^\$-CO^,AY5JP8&EP|MX9(>YV76&LJ
<_XLW.Z>|44XY.'\$F*KW+Q\$CR 00_3?%1T5T^"CL?I'0S3 MOPR<:TI?5|W%
^Y*GZA+A>E;5TO4^R^0_0/Y 1PS>V"B+I-DU'LRZ5|+CH@ MK|3:_*C|I
(^&PHTZ\$9=K+7Q5:9|UFJ+-D6Q;+='-9JKK,(I6Q%#=(|^R6-LL MMDA+|/6HE?
>A|T=LM<'3#74V-RH6!%A|A>;;HD|Y;J.+!J=S59+DJYJ MX@_ID>W?
3|M)I8VGT'OAK=U1&9AOTT(6REHS|HK-PEF|CF^00UPH;-\$F|SY6V@Y;F!;! M3|0|T?
+L&+ML M-870|MQR_-;Z;GL_2.G3;|G^>WH.W9.46_2;;GQ);|UB2TD7*,E'MN%<;
MHN=#QE_XMN)(2JZ&H9WTL0@_1H&% 'Z%W| @:9TG.T(D-\$C1(\$6#M",R 0W2
M73&WT"!%@W07#=#*KU@Q2>C=BD?1|7|J %V7ASAFD5V|0_+5|^UI^DZS1YS9H
M85BR63;G@>>!C*Y;|JT:G1NJ#-'B1(L3+4|416AQHL79?16RH11"BW,;+<|6
M#,YC3BSI@N7%J?J#Z)|NG-'Y#@TP\$-H)=;|)IN>1:&Z3S"P@B)' + #H&S1)4
M:\$>B'8EV)-J1:\$=V2(5L*(70CD0|LLG W8#&3/K1EPZ3Y"?;1/R|>FC|=@) M)8_68|
<,HVXS44>(A-8C6H|H/79\$)J#UN"NV\$5J|VV\$|+L&|:#JNW70|HO>A M+QWTI2-
Z&X5)3_HH|^Z*|/D@7_S|?ZKNZ#Q%B?6.LVJ|?K?=>H6@5G;9_@ M;YROT-
Z5,|>KL1!3V30I@(+83JAX#L1VS?+O-1!TA4C?<|L# M"#84T:\$-B38DVI=8Y>MIM!FV)
8B-T\$_*0YHETW9=.Z2AEL1>^7@X6H| 8 MA<4H+\$9AM|/PBALIZ.P9J"-SZH9?
H)N^@/DDP-KL MQ^XR_=J=*CM)161'9,<.41'9\$:U=M'978^U^XX^7+OK2#^_O;|>
H|X^?|1V MT=I%:|Q?M M7;1W.X(6T-Z=U|Z%G|2-F/AUW97H7I_GY-U00>X#7,2GZX?
WDA?1+.A<|OD M4MOS|< #8:S|@G*H?PJJHK@G;_M!Q|YE7VS=,(\$%3:+17;SOA|DPHD|
|_-L7 MC-8W@-7XV\$H85G002MUJF.)6F<7^_C#)00'LE\$4T#^|9)%'3A,^SS\$F>9R3
M617U'3*NK|7TZMHV5.<#;M3_LM7C!_J4|7_Z.F:366)&K&&-+UZL;|/+N)#,
(>|KLA8WWV31 M5BEQ*MZ50O|OGU(V3-+)|@EN^H-F0"I-|G-PJ|&^IY8 WEQ:9?AM\$?

BF5W MD\A_BX3\2M+8+CTOWH92\-\@ 1)>BN%+22"=3(807\$X50#R)X*"?
M./FH(-9M'OKH\$"%\)&A&QT!QIX@E3?:TPEL%TM4&5"52+KQ'=EZA=-IES7
M(+IIV@IU/TEB%H_Y)00^JNGPAC/MX+ EOU;<65=<^>3=?EP"8V@W"GSF?
MD)C>P0A\%NX=C/P0)GH^#&-0:M?PH&J1XOW)+',HT-N_J4^YS+=MGK&
(TH+T%J_-:"W,8FI<-%Y5\$!Z)!3M\#V,:>R&-I*N-
J,AL\H5Z,9V_ ">3!O2>290S)_%,;DZOX.Q/7%A M#I<*CQWEW\HT
KHQ*1LPEK_8H(+@ (7R>C=PLJ\$.:AO#%9_-I(,76U7)_F'Q
M7/&7LO\%HN(91\QC=RXLBZ8(>TL7#X)?M)\XC3\ 0\$ 8P=1PLLE:PV.2(4MI
M+KB"W\7G +*\$Q1D@1RF,X6\F?8Z2+/O2XY=G-5'#!Z18^Q+JIRC,G\3M<(5'
MLX\$41,E#)@5)*C'J#?C'?#CY(&5,>F(4Q%18L""\V4Q\B4,+ ^64>GP\$T8BC
MWZGYO\$G.:03+'W%IZ)Y%3_!=P-*4+T;,"*52CW\3L@S\$33^A04;8OP<+2*\$M>
MKFZY!O_%!U\N#:_^ ^-R:/3:N\|=HZJ8 A,G@L;\$(OA1>D(05AQNWA\$#C\$YY1Y ML?JD\1%
(#Z>JRE(QX233_EP MSM-;&H=_EHM=+LDU&" ^V!W%75D&WTF?
#|^OSK_T/X*@5@D(=DG0G,12,DIA MDPK!W1-+JBX\3V\%_%A3@E%F'+L'-\$RC)
JZM@,CZ8X*JN,FPUA)V7%&R8/ MK8S)BEW*;;"0",I&42%JN)!D F[X1TT*#'X5T>>
<+=%TD.8#Z2)G05D 'D2 M#B-
@A5L6PT@B\$!SP/10FO<;C;-@C%KM>J,1"6@O,0_L@MD\$TA#.6I"++'07I M
JG_ELD9D%02*T-D"4@":9J4T_AP,5LZM7@+W-S\1>3UQ<J4&^:Y;8:87DX@_BLHEF
M&@+YV#J!J3,XX4 0"@UY@CUPG9)4<&JL\$;-I!O6^MA&X M+UX;)8T%&)>J
G)E!0Y+X?_2L/"3U&1X\$*9W<'OIYO\$+&<J?7KI4*EE<=B?-+O*T4Y?SKN03G
M\$A\>FOH"J8_'J4?_JB\%S.?J1J8-P)!S2%^1!^RL9J\$!83!\YB(E(ZX?N)?
MP"Q'T31>NYK!4P2.)R801WT2R) MQ?J"3!FEXMV S4;PC '+>7Q_/FS'^3-("W
_QA9\Z:M+>N,'^B,F=GJ:@C2# M_P4I#*N0;J4ERT"1!YK5@,ZK.&>'>JPFPE+
J_V_KF/=4+))15<3C_DCH&AA MU')=5(#J,/N90#PW\@BD MC84NY()*)
NF;J*D;>"SG;*!-30>X8TN@9DNV(S)GV%3J!OFTCQAP:;&C
MX+QS&H+A/X%,RSBR=TQ9'4C>,B_@&3).\$3G^P:V9J/&#"J1<,?U,V#,MX%/8 M-
JOT36#%9CH_2D0+A.!,6DG-F7I4N)>RPD,1^D0\-,)S#?# 313_2E#U&H
MD#E9J2""(.&J"KP_5Z>?PRJ<- F6)H6 F>Q6(P:9IPR/H?BA,O'\B*AUJ8\3"96D=OP@"L,8
M^2#?6ETOE>E7").*CYS3.*L)4XIC+OJYEK:#ROBY8\4H,5CX;!\\$%&_%@V\$7
MYF(1N<&05UJUCMSE1U8J*_IBP_P03#BRKD,^Q58(ANY_ZJY7R?F9SG:3(S*92)W
<;LLW_# M"J@R'T^J)IF9;C0#\MYBU@#S4N#J+9TLW'U"!AURELX!G+)E.'(7\SG#X/E
M&*PS!MVRB7TM&'2'W+WM 9.)S" _I!\V!G#L>*,JFA3>GSM!\\$Z7=Z,8/A=)
M1BQ*'\J#K/R:PL80_9,T*9S28!>(K5Z&T,>>I/DPL598/>LQ*EC9U_A7\$K9!
(^6#YXO.B6,EC" ^3Z+J M,A0@?-2A,!Q %\$01BV^%8ZL4+2!_A#
0.Y\J2O\;^;>E'+L>U*=82JV9ZP,6 M<0)CYI*11GQ!N/\$ HJGVJ2\A6(GL-;FI.?
+.86%)4>!DG\$2E\^\$2N#J_2X M)\(VN+"GLT\@F%ZI>4AK&PI*VPP\IF)H,Q_
G5=QW7/ZK8-JSW5 KEI*TR"%R!ED@?A+IZ(LP303A7#+J!(GE(/ M;ACCC!A>+ <=;D;
(T!\J\$RD#S^H-) _D!9XA#J!\X6HJF+3E>>(5KP6",GM M5I)7!*FS(N6I2""@;W^+\$0LY!*,?
C9T!;D>J!Q,U2JH"\$HI&X3#H5BV<#6U!Z"O M)\J49\
(HTBX0J!9Q1RB4Y%=8I0TSC)M!SI6S1X3N/BG6""A;:/>C3E;!
M'5\$D,=A9(K4%I#2/#XQ2F#^/6LR@^I'DJ3C,0?Y'%4)!E/.(WYBDVBL_=(YDP3\K)EEQ;
(P,;&OZN#6;FFT1&P3JYP!_M?/';^,7 @%'INJM.U30WQBR=I871)^>I4>SBE()NP:>4*
(<-FOX8+/P/? MRQJ56+Y6/H+' _&8*;-L=#/*5V@A+AT^ N84#U#V!1E
M@L&BMH40^QF;F;11!>UG9C^_72X?W?3UHQ\CAPJW4QF-&FMD9'DU5*Y53N
MR*E7SIC/5 I CRM\3C,>^8==QD5*;,#ZJ23_L9O*HWEY_,#F5/HD8),8>K+
M8\$C!C@*"T_KFF,*5!1"M"0:AGL0^K02!>(T7T?.E%JE3Z?\$_W@-7@J/L>;C M-TW)C3*,J)
(^>;6T,R<,8JYIF:A:25V/8%5<FS016QXZG*1Q9+"(4F3KH^ MAXHMF\$J^8<==&Z^(L?
Q,9U;\$:&?QG8XL_IM5MCYT/%?W-==T+5=V3<66==_5 M99<14U8\TS<J4\I4VOH>.X9?
-1>EYP.^:!\^PD""B*PX2GDV72Z>G%F.V> MGV%IGQLU9;(WV!\\$!VH:AN&J%N>
(NN6:J045SS95:AN\J352;JKB-U. MD\+WVA&6^Y; #@?K^P? %.H-
@.OR/L*MW6#1&J5AVK)*NB^UFLH%MA!Q%,=
MH!=FM%^9U2_15*6J"A84F#XJ(=9SW(B)/C(A'X'J)C(LW.)/ W74VXXDV)Y
MJAR<_OWX\I?QE71Q>B@=G!U)5W\N SHY.CFX/#F^6B/JF"J 5G<W91U4&Z*
M.BA=I>/A^=G5^>G)T<'U\9'T;0UEQ#ZRY =GA\2U6_'QJ=M+'%R?)Z68H- M\
L,T7'E4E%QH M1\$B6RAM:;A\$Y\OUP&0)2,RDN*-RF\$J,DOU?6!;!@|=9FRO M2AZIB""*2!?
W?7I>%_X^K\$ZC\U7WSZCM7KS.U/N.IOJ2UW7E/ MEJ_65^Y2^ M;CE+W+;\$+7J?&N;
<"\$Q-3^@*U\$'N= M^FIV@>CY!,GZJEN_3K/YJENODX9MU @'JN7?
_V3^NG#%'VU(X14J=M-H?G2 M(&\$YS;\R'GJC10IY1;1UK,E&U,%'28&2HNN20D-)T4)C*

11"/BV3XR;'Q?C MFT+1U0KISR<|?2T9933V>86@1W|\$ORA!7)4FJOXJJ@1|V606|Z2\$?
J5UGP=J M* !:\$M&K|YZT\$;OCX.IJVNW;+;=W@*KKUX1-00&=)& 7B88\$V30NPFVXA5S7
M%D&ZT9AXT_FUV;:V?UQ>'H=2P6\$V=LH-N|WF|2>;Z\$N&V3=-R>>'/DZ7KH MN-
DTZ@!G;?9FW4D"=I%HFXT*T*C_.DJ!&3#049P;+-
+R@&:&XE.D3J5D1).5QTCX=%V+'^8GS MG^OEL.U!EHWN|_+DW/>T*
(Y<'IT+3#.PF6'(Q T<65<"5|8-C@ENI9FFU:U=&Y42;?4CKHGV2?;:%=S3*_O9)
MAK|XY0&:_^U3^)^COQ;|V4|RN;SBT_15':6GZ&9U_JV:|?
_=|NVW3FF\$VW*==VP>KKIH%Q?IR<:|:..V&|Q=|JWW19CQ?L1_V-
^AOU|W;I;UVQ#T6Q5EQW#;|5/*;379|5Q3IK;B:0J84I;QPJ^VC/FU40&MJ3U0(BB^,1*V
M@T86CX3%>9(^H7I&|8SJ>;04LV5Y!G4L4W9|E|?RUQW9I98N!X%I>X&N\$M4W
MEK"NOD(\$E'-#6EFOU1I|=3*7=I<'=A**+6WD;%0:D^E&QJH=M\$)DS39-TW M/-
EQ/2;K1L XS|369ZAJ1;=4?*8Z5&G&^J|SR3_# M?' XRH!&I;YN/"U%|SD.087=I1W7@?
V%HGPP;&0M%^90CS;=|S31DWS.)K|N>
M|INP)+A&JYGF9IF'8CU3;6)LHMC(AA1&PG+;_ "E2\$-6.3S+2)EL'M09V^B
MSGZ_(|V&2IG5L=Y"3?QV2>^7)73!W+ECW==|7 4:AJ-E,&0^"YWP#.E74PSI+|@J;Y>7
49L,\$ MX-VO ,B'#<>N|)YJMN!V+UT6YRUB=E67LC)5UG>0TPA1#1 K=E3*(%#J"
M%'Q=43V;,-FWB"GK"C-D6_4=V6.F988?4\$=Q&JF\$N((D%J6G*T9/PS\$ INV M2SNPXU!!
|";KH8)82\$P9A&;F%1V#;^1P4349=M1/9E9S G,0-\$M|443D^5-
MR<85A&WTC);#;5NL(-8>DMM*K=|LH;|+|XOCR^O_14D7IP>|&>09D73|WW^<
M7/PX/KON26?'UZCI-U'3;ZB\$P"29|23)*!;@V<21#
<);TBB&+;N&8G|VJWQ|?/D#|3#J8=3#VZ6'/2,@ MIJ|
HJ(K8\$U10Y5=W6>R2E7'10+/T/5&K*G3)+Z|9NE=K?U@4T<,M)ZB8PGZ
M3FVQ#FPHE-W;R%@HN^O5\$FU# #Y@=R-3C=9>HKLN4&43V UWU=-20;(W84.M
M3G9K#E:ZQ7#4EEA.ER>_G8MGW^7_|@ZE@ZKNHZOKU#KHM9%K;M=6M<@OD|
MS9(#HB%UG421G@^9"G-89"GC&;LDL_V//@C8R)H""I M: ^L|56|W|Q
W&TIQ9"R4XFN6XM36 M.Q+9#(H|_&:L,7=XI1"6:13R=|3YM MPG9:AQ1WE)
|>|BFQ#=#UL&'JG!5U4TO@W=MJ-# O*?F2>Q%
(|XXOR:) Q!&45/&E=9S%'1N=FK/=6""H3#?1L9"85Y/T=95 MU|_
M32;,-64|L)GL:K8J.RJ5+4>E%M\$;,:|6*Y(Y=T|>Q-F|J<+.A|VP-
XU2=VFH=V%@HP|>1L5"&U|) MF:JJ\$|>0=9|8/#;EVW?
4V17|35A5R+^B_18LN84JN7X8|1LVVTH#!*M0T6 MU/GU;|>7;#IML-
K%X&A>;016|!0|T5MNH1P^@99KLYC&_RVJ;K=E04J"A04:"BF#0I M
4U@F;8J:S8U9=UEOFQKGBD3PV2*"W+?<%Z<+EZ^!GUCBD+1S)ZJ=LE1N&6*
M8OD8X"PN7=8R7":&7U&D|1T|D2W+;F'@M9N\$OD+|/'3DX-
O)Z;U%O7A#8|>:0;ZAT7WM^-.IM*|#;A(F6P<|))#_BNW7DV@4)0|T|N!3
M;LJE+&|/9IPJ.2W CVB;J|;M0W7;|695|QF:P'/\$7<|0R96KY*B*^ YOY0
M:5P:_7,425F#L9"!A3|92EBFM+KEMK3#;3;:K7O.K#+4*!O(V.A
M0*)=/%7B.;CFQSN:P;S)6I8O/R>PY15,-W?>7%F9|%C+66!+JH4P=#34;
ML.VBH39NYR-%O)^/%\$W|(2*?6|W/!DF:RR#Z|E"GHTY'G;Y=.EVCGNN|A,HJ
MTTU9|VS0SQXHZ< QG<#6#;TCS=1TFFH;5GE=GYKUN9H|Q311D7=ILW5@:Z\$4
MWT;&0BE>+XRN^SXU3\$-V3=.5=26@LFLI8*^9Q'4LW2-J-9IO_K@B*6|T+|VE M.;-
=M\$<.X3?;,>C'88:O!M"!37X6C2X Y87TWU"UAW7D'4#K"O;XK|YQ+0-
MS|<57VO"#JL\$S#_#?' XRH!&+V1'E=ZJNZ@'N_2ENO !D-9OHV,A;*)LL)
MB\$|=)V!^.=27=:J8LNU:EDQ<@^BVJE-J-%+R:(VR7.U9&D%9CB&R7;3)BITD M#
<'^XIL|:0HX10'4PSVD)NC#D<=CCA4W5XZ5Y!UD.!!&7:MC'6CLJTV7;)
M;A!&F>|)OJ+HLNXIGNPHCBEB3XKJFKW@N51D)\$IT".KH&<'0\$V*A9,T3K 7'0 M#,'0T Z:
(:63BE+*(HHS7|J3XFQ5G("C^A|X_MC>VG"=|(#X|":)AD-/H5T/GP):B\$5_%HOKJ.Z|
7|I.VEMXS|':N6ZQ.FDW M+&2LSAXS=L8>NTYR&DEEW|%ZOA|!"X0'/1(U"!Z
A|TR|("P|%EBU)#UJGI MR:ZC^);/7;E+ !T83>1XK>RDE:Z:?
04H|V40BW&!*@C4\$=L'>NACEA(1|@> MH|:F.G*@\$U?6=8^WU=5,L#@M08
16QJC#9N8#1_>4DE/5=N-T6VQCEA|'&K M%4^S<;GSLU_EZ^/+|+1;=K5.R;J-
@W5!I@WLSFQ|R0|5"F(6.A3%NSH>\$; M3F#
|MB7KKFO*NN&KLFNZKF08CJ.:BF8%E#2="WB6Q%ZSIY)L"|E:4@:BN5
M0K.E^"Z.+P^N3|Y^E4Z/#ZZ.ZXU#2UPR-C50(Z-&1HV|91K9|S4*VEC6=2*J
MZVJR8|BVS%Q&|=4%8| ^J%SZ.S6<&E?.IM/3+*R3WJD-UX'MA9)|&QD+)7F|
MA85BN);G>+E>X&L>Y8KNPXS9)78?N!KS**ZM)|J?(U+QQ-ZQF:A;IG8^S;*DXXBX^7-
7HW5:%-KX>< M,4;.'^5!Z(-)O??|1G5=S|4|4|9<"EO,X|O2|0-9L|3-#U"%:H^7|07#_%=
MQ5;|4Y>9XFNPMPW4F.|9"96(|K@=C-17?7JG(.3S_|>/D^L?QV?65='!V)!V> MG_%<4?

B/[L*4/AE.9,4Y\N8S6;^F!/W;"T'K ?BP/KR;_ [V2?WT80)NCB)M M);K0,3IN-
HTZP%FX67&S;OUF73YJ@:AN12CJZK>#R^/?SD^/CB^+0S76OG3|
MWW^<7/_O'HI;%+) M_XXG?Y4GWL+ FIZG5SGOR?(//O\+EEYQFDR/Y^%7?
CUN'%NF4'HWR0I"#A_*D%+|1"\$UQMV[KJ<:[V7,63==OW9-OP M=)D"5^NV:WI4?
Y'%_W&N;GOR\N'I\RU\I8=8.XQ;3D.AXDOL2C?W6F%AEA;!2_M\|@*K+,%XP|
47F@>+^&)S)))*Q^+7) M>8'G*.;+Y,+0#I;-HAFU2
R|*G##\$4W'#58%1.O?'*^:1*;*H;::#PO"M;
MI@K19#=0==6PB!\\$[H6|B3+1@OOSCGGL;%_5YFBRR8->&D&PY5=\$U;_MQ1-M-
2D%T?J"(YM:M&;F|2=+DWG\$34<\$4B@F+810,F%:B>;2\$?/8G0N*5E-ZDDI4
M75P\$OVB8SH6G?K8@3|#[KI-WDB0,SR!,URW9= D_j>,0V5:H)WN&;2@J6&6^
M;:S4)'U>OW.H.?D:126*"R|SE@;+RRU@/(@D\TY<%5_S(&GRM0/J&PZJNXZ_MIJYA1'1=-
U\$)\$@6BT/2I2YYK%J@&L0Q5|IBN\6/.%L@#0Y.F;_L@9HDC\$|*UF
MS.R6)X|^ZZE5!|O=U'2>11WPPWTV.+1+|7;%|5'&JAOTB6/%!EE^3P|KP_M
LO7#!BE99NR;E)3M@/#EXFFN*ZMN-1R|8;YN?&9Z9OAKFZ)=OT2V(8&;LT
MRX45!B#GZCZH?%N'_UG,-?Q&_HTO5G@IK^#+U54LLV=:I&?91EN+V6*@P;:H
MQZ>!*;NN_2L!JR#;OJ-S?4,U9GN*2HR5|_&5D_M&;3(A8L?;+.K5CX:UN-
M&KF!030WT&20J@Y84HHMTP"VE>H0SR!)V0KF-L,3FKNK1>>(XEJ@#.Q
)H016=>8'E.7;+E,H;KF5H+R'\,JI@_M=C@E71|E8#JUEU954U#_MUI5
EQWJ@Z%G>+9&'<_5_49|JA.I<@%"Y20^+\$1*+6S3D!97>|9)>082'4AP
MTZ\$T1VF^:8R%TKPNS5VPP%3+D->+Q7A60F1"8|^919'B4>;<(26Z,TMS2S
MYVBO)Q/CH,8_!8;8YXWNAM%'2?E/#&KK!Y|^Y_Q9GX3V3HB3##I2HR%&1
M;ZPB;MI:WN>K5"J@|KGB7F*\$|@V,RW9)*:G|HH.FM/(.>V:!!.=J0_K\NLD_M!G'&3D&
(G;^|+BFC_/CA@S6!WY|-X'/V;W\$;XS_H2I!58*J9%U6IT%GO-\$,H\$LC|^658G64Y2=|RIB=!
-TM<,4I\%H1?F"!HV_M\$33L1)MH".JU<##\#77=P-5UDSBRCJ8K;)CVZ;,+W034/SJ?
X">"QCPUZR
MG(8Q|X^I&&I6\$X)'A0QL&FLXEMG3C=?&;0L(=IL5(W&+>HIU%.HIS9(3_G4
M9@|EA|Z8P9-L;%NFO/-EL'I=S::*JGJ-E.E:OYY2>IJN|0P5-57W;_H819.G?
M7Z6"G=GMB=!A\OF!_L|&&##=CJ5M;ML|L_-J(A^Q9F3)HY)IV\$|_9TD&#_+;
MV"55E70B.MS&5EFEK"NO7YZ3F2;(JZA(B&ZO*O:'DK99NWAA#*
MU8BQKQ|HTGD?'CI"W@>7Y?^N?)*#EMYO\!'|Z-U|>.[?^L-'|2W7S@NWI!
MVQ__")5+C2;4=WT77EU-9TMFLJT|_+C8B+E9;_GRPI"|T4UR|7B(M6A8ME
M*F6Y>CB/IVX:QLV;.:NY67YN_7CS|HSCM|48>+JNNF(KQ/<|*#F_Y;W+\$W1_MO."F)?
YO.8"|@GP'_DO84XGJ=E'W|2VNCZ|Y6)8.MVGS8FX3(Z@?
_O*X7X_SN_>=>7@H&G^|FM7+#!YFGBFDJH|7.;1JY;:/_M_?SM'3LS9;_S7-8CBQ?
PD"4V;=|_2HBE9NOC;2NOB0_KMIW/%T,IZ6^UH4
MR3YQUXO9CY_^HCSVU8|72ESFP5PN;?_\$37YS|^H?'_WY@V;_!(^EH&Z)=\$UL
M|6KJ>WSFX_Z%^XR8-^ZL'Q|:._WUM|63|&7PLIE6.7CY/X>GOQR>5:|>|ELE
M"7H|>G;T_.C@|.CPK;,+0>*MPW|Q|M_!^SJS1WC9;K?RSK%?2U49^=')^=MO#QZ?
G|^6!KT0/SOEVC|/JY\$5UANKP(5:V|5L_/3@_*G>_E,*SDU|>G1|^
M?'A|=O37P^KHN/S|L/KAY(/|;EY71T6^XWKU?.77_G|&OIL_MBZW6,Z|M/NYR
/^EM7I+_'TZ!FL^3/-R*".KV?7-2U;O1\$F);_X_O6A.6W_MJDY/ZE0&A<4I/@V%E|
<|^GQVZLVX'B_CPW=/WE_A6FGU=M)|Y@S_L?;T+SY_MG"MJ_ODKU|%
I7\$(>6R&V|U;:/;O/9?BA-ONAOC27^O7YTR_UYWM-JCXFM(P4
MIYQQ>/^C#^DF^M64K-GIC&QY'LUO_O*(DD<;|@O?;*&_HDR2;2GX/T'6|_M;
|EO+,TPWUR9@!NT|HPX|CS&_+(0?Y->=9?U8NAGZ&>#|S.&_M=M;UG369"?0N';7N7(R
)M,KD^%H,F@R:#)H,ILT&88F@U\$81F&8K^Z9-?UP_M-*T6%
I/KVDUC;K2VY"*>5RE^:I21^4N2P|9U-|7/FP@CZ>7UF2_6GCV9%LCK4\$U|3
CA(VT)K;4SN@.>S3J%'OT+ND.>S3J
MM;,>_=-WC_8>4'KD5/|5W^,/O/J;_*V6->2)\$JQVBU?C@U7P6K|.BJMTDE0|Z
MFK|O1(A50SYD7V5O>L|V=D.O-UA+8A|. #NC/'^@6=D0'0P0WBH/WSH/P@8-)
M)H.D5NKF>%UMU><[H|,B6GM&@:>D02A*P0LAP><4K9-9.IO7:SB_2=/K|&(^
MNWQ6_EAS\$W|;+RZ>7=>E^=+H&V87#>|/J"N4_DO?M=!1|H3?XL8/I(/6MW
MA_KS%H8(&V92GZ#3U2AL)Z2(-E=M CF))>40P@T@R"1-<4V2\$+\$+12\$3\$;+
M;+4V3.*&>_V2L_B"90W><@G-D3C6LJ")_+Q_%VAQ5(|LO:|AP3L4&|&L"!8
M>B)%!;ON@H4R(I7V%HSC!H0U"2R3\$JR@/"%=R"+6"@ \$RDK3CS!8\$F1+G)\$/_M2R-
!4:F8(=9X+?H#%JWU2\$J&8&D1+|>>FL=47=|3=;^XZ74N7>1Z7EZZK'8P
MG|USD|6|:K|JPC5VG"&-R)!^WZ?,5)1R@RX)K)! "TQ\$^-"
MNOW(SKT<%Y.LT_M</:2743==C6|^?_#EN?3,1R7#4JL?9_FA@@H1?1-%.N0_MQ-

H'::)OHA0QM?+MU(I/1%*G(FAC\$@C!+!CA/\$27I+=*1RK6CJ\CW J5-(/D MJ041O-
- 'D@00HM)9\$":. J26F&CTGB86,%E3YA8N4,%DU0G-P\7RQ5/L?39
MR>RJ.:BHHTS+/2O)#;5C;92-#Z_*A_1(5J3N#:9I(>>G4I)W+M>(9H QFK;C)60
M6\$BL/A/+:9ZSRAJ4,84^E!HPH41Q2>>4N,M:)[*V@Y(I;X/3(%JU|@80#9H-P|9G6|.DQN
M.8DIHR>)>3Y;N\$E7^S21IDC3/M.42<8\$)10*43T(V2RCSCQ_9HDX;52A(UVK
MSI9"U#E|D(:6:|CUX'@!,17C0(P#4:Q(MKLV02S\$EI=())?%--5_0KP=EF|BV;Y)0*D5BY5J5
Q)A|). D+;:%C-%%|YYI- M04X0XV0H5-)7\$KQD2"=URE_04NZPQZ-.NVP1W>|
M;@\$W7VTL/G@VJQ?5+%>09|-85Y?UXNG#3UV,-294KD?ZBKNJ+V6_3RJ?)|+?|'-".FQ|Q
M_W(?4VO"^R""YT|CS""2E.-8>|!#R"8F*IAC;2QG;/KF2?ZIZ9D'TWB6YF_&
M(=5GI4NVM090R!'GM.O\&?;5_K74@ =N*\$7\$1A^Q\$4W6SFL#DI."!8)&-\$<
M'I>CM%0U!_NLGWAPC|4\$F|>&Y'/'-6)C+_IJ#TH(4E0G4B2CR3)D3--6_DF
MF)>% "LF!*3P_YSW7(;(0K6|C;G_S)*%F1!0>:= "+R7E,UO4|6?>U2DG871!M M.X*V8D:
<^P(GIGD\$D;P&RP@!+HS.,F?FO&MGJJ"J*Q6N/?_8D0|?7C4UWMM.
MKS&%=!MT=^U#5(3I-90BDN/;Y#_J.9^=!:&%A%,_J|3@D"\$B4QR9YH_IXVM
M.EL@AR8C0Y<^|)%=,<.&ZNRO.O<2)DG%))**,D'GD):.0P#'PA"\$1'?9_Q6,%U_M.
|MGM@\$3-M*D||H\$.|5=<45A'*> M@F=2-^?|9Y<)_GH0X|Z6':H|FJT\$<3=L'MK
M'T(FS.,A%!\$*|U/%=ZJ|=KT_#H^RVUC6;76475HEOG|WLW93_'SUG+Y>N!|/77@H%!=6
MT'@H0Q^HFK.G*C4;6SE1(*3U8+AQ\$#GUDOO"1|UV*,-|*|M?;1\$B&H0R?
^Q#*=9861.HA|9|Z=Z2>)|YZE20XURP0-(|!
M84@SP665R(*1J\$E;A>|V0CTF|(B9|P|@D7I(:0>4@^IMX?4"YRK\$*(\$K98+
M&\$4&RS(#S:D(UKKLI6VK2-|F8CVJ1|8(I%|?G**%#8|1-)6K>'DU>'IP?G1_M|4_5T?
&SDU|JQ>G)|H4STZ.R|I^;7Y||X*3X|/^%JYZW1%? X GRPQXHTe M\$&S4((*PX)*-!5#9-
N?:FK"^J^P^J=*3J|2L|)^/^|J&V65Z.:O;(F@);.\$>*
M=U|\$.>_PB"@;|J(6Y!)RJ<|BG7GN717#MT2P|T?V@_OGU?')%1,%/#9IN!N M+E3+0H-
5T95HR^?\$/6^2G&TD.:|J\$PKH|H_+=|U7|I&)'N-QL,"HB?ZNON4OKB
M.;#W7DSZ)5D_(-NYFI1M-Z%Y_O/AZ?MDY@^'_OJ|CL|\$^CZOC_P_D>7|ZC ML4X/6Q-
;F=TAST:=8H|>I=TAST:=IAC|8J3GWJ\$*V&#\$=-JB;5BV|C-|Q
MUV5/LW(#S|EUD0%SWL0<%&01"0ABFFP6"R!"2(1:XSQ;.:Q1.)J^*?VG.1ED ME0)|WZ-
:6Z@P\$|D)TG?|)"CHJU-OH|_8/J1(OLK'!3-H\$D8%F&T%\$*<#9E\$"2_M)(.0D5(KVEA2L&&
<#(R|ON7BV-"6)'18R@.ONKSKW\$2"9<9>8R,\$,+1HRV MX*42Y9|1*|H979MQ?
1|YN;WC!\$|4JSSN?B=ZJ==UVK"W-KF|0#\$24UX(F15LY"?-|I;W;L'L^FL_+=+W-HZ_M|I>-
L;S#S>R6*V_-H\$OV;|EBA!#B#T|FN-"#\$V_)DBQ!!B#T|E*D&"YQES+OP2FE.P
MF7|0U+*L@Z&^792F9N&&"T0\$|BVHA_;AG#-X%#RFL|NW/1UJL;3:G&1JNS& M|^J-
FURGYA3(YE7E#Y07-M_6X|CLL;/|OO:|W29N#|: #K2K|/_#,,IP>#@H ML?9!FGW:N(!21-
|J\$WT2Q|H|8T4H1G9CTZ73Z767FHW-A2<@O!#@=21_LA26
M6L,X69NYN\$_2Y^EU/9ZFNGXVN_3CZ3)T?/8A|'QV.Z(AF,^;,+19ZE:O(M*C
MZ<'E|'JZ.,E?NZ0YMY"V79^&T9'&'3HJR2+AZKBA9)%.%A=I?K/MM/KA9HG< MGT;5-
-"WZ4|L)J|=A|C.V|WE,+K'BZ9#UN_/_VHL(E60J+;L)K&46_M1+ \$O_|)
<@B|B^"LH;&5VM|M4?)NP:5@\$F&)"_&0FDA-I.;1WI9NVAB|I|(
M%B|LL&|TRL"C!)Q;SVM'V|F;ARD?\$1I MY|6;|HZDN)(10ST4*)|LW!R-G&6I
*F<@8A=8"F7"VH;|757GBMUTZ@OT^Z MOC^\$;/S_M@_|/O7E=2|9^_R=H|YX+G061.
(#(B0:3,P_N5@&@1_PL%7W)M&|7|JAB^ M/XWWQ7QVN=H.<5WN^>:XWMFT?
IH*O|+J=>?N;H|WR|FKIC=>.KF|XX6Z;(N ML&SN9#Z;3):X;/=<\$|%QV|3@.WM?
37\$J|"EB-S9%<.#2G%\$B;Q3\$JLE*0% MZW*"E|UE@5-NR%KY^?
L5'NP|=Q@=2=IY9(:=O7|MA=Q!*>XR=_8BD|B"(Y8X
M#U&04\$@7#3B2,M#@A)4I1F'7M@'|?S@?ZM7IR=-/3H|.CFN?GAZ>'SXXNC|H?L_
H0IP|W*6#D7',OC<3_MM2I(-_ZL_-6R9/\$OY;@GZ_5>|I^H+'B|F8=
|FJ:|W%|;BU/H2%<@|!3O7U0_M_!MB/(AH0C1A3/G)6DVJ!(LY PDJ@_"<@_W"0F"&44,=
(:E,Z"?.,|Q8-6_MCQ30/!X<%!4'OJT<|8AX1#SN1^3&'-7>6P+,VV;7&V-@/*?
C!;\$T9Q|<,PUDX7CYB"C\$U&+N/*;V8CHN^I2||0\$".99X&D|!Q1*0_M42^,9-
%Q+K:TQ+|UE9J|!+7J^|JSIVD;ZO6T.0\5RG/YT=G-UG/P^>WDIZC
MJDF1GKQH%GSVIP,ALA'9>XALITHH:R,%JBT#H4D""X@_+I60AF1+|P92KL_'
M|>H|^NL4/T+L."U_|KE|>|!8S,?^>N'|))W/3M/5;-Z4A3DL%RS>M4UV.2(*_M\$|2XY*9S"&
(C#Q%G@Z=H39@9\$*0\$O(&T%(RJ'9|@C1!D|L"81UWYNN\$<|MI8J|!.F)?
P2%8F*1\$6B(E&'3E16(M-(HP)F4P9A"TRME@J43%)%HD+FOOVD
M6WQ;:=A#UF32^)|L^OB\$ _T#^'T|R1|Z)OEW M-.MP6-X%62V3)&8#U&8%
(M,\$UF<.E@GB3(&L\$&N'&M|K&*:T^_C7ME;6*CTB MNF=AYF?"|!6>S|D'Q2YAAI?Q
04#T&E!^+|_:95)'\$R' AMM07'/;7(Z_M'QW_=/: ^;-BKP|JY/3YT?'!Z=^KLY|/3@^?

H,N@R_3198;74KW7 M'?9HU"GVZ%W2'?9HU.F0(H&'E)!8?M3Q-
)9;6T/:GCN ::IFV9=O=_M&R!K MLW^!\$SFX Y8OJZH?)K*!_5%VE>?
7^,..JOG#S5.7Y!+*ZV=%07EK-/NOIJ*#R MKAZ'/DV^X3P_SO/W:2&:-
H\$J3BVD:#4(13AX[P,X%XG-U">FUBH^;J8P\;LT M?|KTUK.F5W\Z+U^~3?
%LX1:I/LD'EVE>!/|-IFX>7WSZIM9>W)|U|H7KW_M(B&8Y5Z"5%B!
<;N#&)%@2N"/>V\$36M@%MHSQ MUN'&'?M\$%*\$&|(-X89PVTFFX|<4*
f60#4=)E(.W!H(*;#%9P!X:Q*(T3.80M M%4">!\$|OML"/&:X-7=(J|L?7K\$"<|U;*J|
<.0Q7\$|S05M4:3/'B0_\$'"CT> M*!!&7,00?8YE(&"DN"9H=06^V%67PPC"<1C1 MW3
"XW2,TWNN6!00X0>>^*5&!"-:"2"-O@UQ:R,NY5B,9P;UI)>P\90[9G M)R,@?A&_B-
+>Z1;QB_B|)WZC*W\$O#9 H%2 \H6"JIA"-R#\$J;|)?6U)UGS3Y MD/&K%>)W0\$ET7#
JE"3Z'19,8\H5E,P0Z|J05=MB;+=10\B4H99.F=+#+;R;C=<'>+YF?2SL|JCO^|MX?=
B|GOL|_UMX,X:#Q># M|,F0>E4|+XXGUXL4^Y06P!PEYBC|_-
_T6F'\$RZF:~)9Z8@LCTV)K%?2VC3?^F.V!<0;X@WQAGC#%2;M;
XL<6%,1@/AA:I" T1(J*J4@_M,ZJ8RCVS*JRBMU|YWW M6T<-4+PX6<+ #0L|&_",B%E(03X
M4\$8,(G 'MORDA--<<9*U#GJMX&Y'=?0Z'\$I@)3TLY=,'C&.TWE/=(H 1P/>M
M>)|H5%J!SZ| 5#8'R(B0062J!#6!'"EZ4DFO0P!;S)(C@!' "&\$,*XY0V9 MF5D7C0.=> 3AK
07&(/,O';>:4V-|DDMO0X!C-7T!|5,OP740TFFWZF:'J;. M<> PI(%#!OCW2OEH|
7/FY/CLHU@# #' 0K0Q!"&BYYNHIW?#Y"V5(|""KA8 M#*~?A!A";"=B&&Z|(!
M8@@QA!A"#%.X|:1PD_:Z.02E|#,6!&H&5N4\$GEKIDJ#!FU9.#=|L-K&J7L|
MJ==5|783SJV:Q=|.CW|Z^?SP>77PU|/3@Y|J^~??WEZ>%J=O*A.3I?'1^<
M_KTZ^_G@|/"L.OGU_.S|X+C|*N#&69AG2|6 MP"5#B\$K&>+VV@>\$^"R_ ^MK31%
*|W:OT'UI4_SD|S,J=4GUXMZX;:-HUL_MZ&*YBJK^D'?CM_-NP\GWT:5"~&+)QGNF!/?@P
|1-2"Y(KHV4BDG),UBL^I? M9_B! ^%60FXM3(IGK2-K92>ZPQ=;L08;EW?,2|
="&Z|B171-!;,>)6HC9)8*B'C4X,URZU8BT6CJ\$LD; MS&-N
UZ8R1Q()O/H6DSG1|~?A|=037P^KHN/S|L/KAY|/>)|AQ<+404D1D|"XRJ*2,>16 4Y-!
ML.3 TDB!DLQ8^1"UZTT|1&8B,GD@1D8\$%6|N# M5,&0IEX&8"J5&"7&)XD7;XKK-
%66\$/6('6?6?H0NINE5BI-.FD%8/M0@| M|>IW,G=;:-6').
|NY4D_SR9-.U6OW7AZD\H;5=.TJ&:Y5MOTZ+T"?E(|>;IORIM&1C>"?3LQ2NY^/%.-4"|J*"
MT|/?RS^GKU^E^7@6S|W;EL;M|OU<;:FHU%O!*&=YLPJ_4*X@BNB(IA80C|F
MI2)*:1/V|JV^X1@_14\$'5\$KNY?\$.LCNIK'Z0U|&/E1SR1,K/9V1\$IX'D<#&
MTOM)YHZ;|E|0K>S;|E0;=QL_6?WUTB1;DTAAS3S55ZF|_9LT>=?HDS2W'M5
MSR;CB.NS'|@^~|YM.9S(L.WBDDDDGE0&XW2QGY@->).2:&U=R"8'KTD?AS;0
MSTQN#V>B9V64/M'W;J|?QLSED#.7B#9\$6Y_1EIRC/')6>N"*2\$(V%2^2.HE
M531|M;*U08A2&L9;7I46(YHVR6W0+0AV@8CUIU'VU|,YRE6R!=((6'(&H1_
M&ASU"B3AA\$41F/9K<6(?LEK?#|.L|;TB"J%5!W,Y.'#E_WO\$;*WM?.W3SOD
M^|;UX2S'P;
(9&TG,1N:S%0&X2PE\$|@F|*/^TWE&E58J.^#82LU|@;H8^S|UWH^S_21R^Y&| ^OO^W
MW0 !;OJ(W^7;|78.<7J7*AJ.MR+^~;173V;+|*3NXFU96; M+S=8+"Y2G1I?
64X,N\$6*51Y/W32,RXOJ1?G!9?F|I>/O;U'Z?4VZ?'G?A13' M;ZHP<77=N-3K!#?
>TMQ/^8/E7IL7W-SJ_RUW|KQ| OS'/\$EO(8|G:6F 3XHT MKB^GA9Q?
35Q|YXTOUTSKL>R^\$|S;S?3%JL?/_Z7HSSN_>WN;P4TC3^>#6K
MQ|N_/4|3UZOD+K;WMFF3YG-^<,"W=V3|=SZZ'O>&%_#@!>4MWHHWXQ*.+5FZ^M-
M*Z^#;!1==.XX^ED/"WWM2@|H8F|7LQ^_/07Y;&O?KQ2XG*ZRN72|D_M_I|)?H51GYT'IV?
^1^&4?UC=?C_7IT_O<.E-#390H.1UK+>.5+&Z67R/MTW-5|
MG.;E4\$93L^N;EzS>B9(2ROWQ_>N+%B;NJDY/ZE3&O\4=/LU/+*|H|/FZD6;G
ML1|/QHMW3|Y?_X45(:NW8_:Q4.J/MT%Y|SE7I/SS5ZZC6|E\$;9J.^ ^TG4OD
M8|UZ>W/X>7;P|W#2VYM#|/|@YQ:G'9".?YQNK(_4W5T<.X%P4LZ=3=/MBV^VT-
M\$'4,OH ZA-|'4,OH :A-|MH)4)E;M-*X9P?7D|;2;P=E/OZ!7H%=C6J&5LNYW6)OH :AE|
+6)/H!;1A| M;:(H)9|H@.X+ 27A>"R\$+1NM.!!6??PVVX VD0?0"VC#Z
VT0>V.!UUCZ!/K\$W;:U9G_CDP)W= M5#RZ!;K%WK0UEC|!KQBR?
C'OT:>GL5DW.9|G5U|W>8_%+/P+TQYH.KMM.CA
M02WWTP=PG@SGR7">;:/6C>/%!XT7<7H,V8IF@V:SG53791GO+-!LT&S0;-!L M-
CT+YZ|&B|UN(D>W0;=!MQG(T|BLV|RRZ=M-8CZKT-J3&GIMHMXINX?
|4TTZPBZYOONCZH0 RAX<8 M_!
<_RRZZ_EV|RIT>X=.#EP?'SPZK_P/PRC|L7J>0KKT:5YQ.JH88?0>/6-O MGD17_+W|OM-
9/YOW=YINRZW4D@R_.*A?:#E*MJC,Y>N^V+X?GF*KEO'_OF^; M%|R8N|O?A'MCHE;S;
(:LJ7)"RX8"E8(Y(QC&@;TJ-J^5?>+DY3 M_LNC9_0)#AM H\$.
:6.IZB\$E;*|*B:NLOR@:YK>.WE\$O'LS+S3ZJKJ?CU5_~|H|+I->/JIC"^~)-

ZK\|.CI^\:C*L_FE6_SET?CM MXLGT^A+B; \$W+WGTWU3)D;9D)(7I?W_^\|+/+/-
W;.X71.9.2.R?I3U\|H_F_VA M'WI\$6'P5%M)\$GEBVH+PP(+27!19&0.Q>&6&\B,2W
HMF7_1%B1730#\|_5X M\>X360QZ\|KS\$WN4!ETOX;6@_SUF6)0T2
ND!=*B+S)\$6NPL+7P)(4*@0(EL M0HM00@M+!+!D'..&,<[#Y\|0H(0 'KI09A2V1C M/'=
B&:'!<>H8)\3RE%.:8DBFLB'@ B\|Q\$#\$)'!.*99&9M4GR-@E5E\|=300L=
M5/&19APQ\|2!_N,\|L(O(*>86\|0EYM;:(F4TFM\| \$XCR"8RD@^*L\|3&86,0D;MC!XQKD)8?
0JK8'TH@1\$#Y5P&D;:,\$
M9Z*#'\5/,@HN%6T%5IN\|P3#)0Y(+ "363ND1B=7WM0XZZL"^\|+2#0-(&0-H.)
MG@%EP01&%0MY;65<3I194JB3FP770H8\$CDD))JA(:8K,\$\|+/%E7&4LI\$T M'1
M6@+DNW=30=|#>_ =5,M/-9\|&!\?0/DQ_Y0JU4/.*KK M:S<-
J9KE;O;^\$.5KJ'TQM(WJW1Y-9F\|2ZF\|?>FPU=7\$3>\|3GP<'0%3BHP%3M MGHTF/?F4
A">)>\$!AO)=EH&5X8320JVE3JV\|V@64A@*DFYQK*.89\$#HKG
MY#B5)"7ZQ;%\$8V4I/K^>EYMJE>;C65QE5)=?G\|HZQ>:DU#2M77.'#\|ZTQ4=%
M@B,E<)\@OY,Z+##\$9\|D"&R)"O,J3<8Z2!)PB\$E=A2>-|\Z&W6*RIN-(TJR\|65
M(BTRY*|NZSM=2L12%\$*TIR84TVMK!&:P)&E6L8-|8QSUCDHC<\$H78D+.1R\|@9,) &"!
M9QW \R-9\|)\E9_/\BF6A K&@%#""@: T@M71@58V61ZSBO'+%6\|F@53G. L
M6'>+_A\|^A HN^M_&HO_3%-+X:M&L^3^8E"O*W?_7VNK_TM>JQ46JK\|G\|X;)T
MV>;5JRT-LZNF8\|55\|X)9U?3A.K^KRIN-+Z\|OJX5\|6_TV7EPT6WO*G50S7SZ4
M6UTQ3Q.W2"%Y6?,NX\|LOJ-QO;AYQ4P\$.9/KJA/T=R&#@AT)%OT2_W'<9HE^B M4
\$DP"WAP#8)WU1\|5P\$S*Q\$B-@W*I M 1&\|. >,*URI0JO=B'HVGOG4Z-MR*<"
M\|.8@[\\$RE2\|P-D(+ +9;BM'U5@1HQ@'4@D(9*P?WI\$B()T1"KEG66GH(3# 0
M+FI362H W&4*RJ,6HL'OV?C!))P1YVG51+B"0S\|H7&KIG-V;R-\$N+4KJA\|<
MPN'0CIG2;@^'<#H1A8I^B7ZY\|S)\$OT2A#D*HW7Y5;J\|E!>4;-/C)*S>.1\|G M\|F\|<)-
EK.P_KQ\|RFOY\|:/\|+1S\|+|S?CD%8%1TY3F+V>+O_*=Z:ZOIGALG)\$ MM<,(UX
|.S('9=@#&> (8'84Z""%V+TOT2Y0A^B4*=1A"\|5Z6Z)UFB7Z(<<|\ZW-F42LO?;+ G?
\$@A%=@\|*7@+*X2\|&Y.;IHOC<^\$TZFH;99?K8BC^OML?Y.;3EZ4\| M3Z9G'YKP8%
|\|E8=\$\|A!W"#H,## X&)=3N98E^B3)\$OT2A#D.HW+:\Z-AG'ZKUP
M>F)301\#W;E;:KLA=A7'"(8_DCKZ,OCF(H6\|8EW\$6?O-
'T0NB>\$D=)5;S67@MK\$DV)3\|!&4(AB05#@H# 0\| A.Z7#VA:PX\|183;LW,^RM
MGQ\$OS8@IW?7D^8 0B+N\|D(7(PB&Q\$&.403+HWLL=?1E\|>1!"15\|&7\|XCN;O
MHRV\|JB8.QIZ\|H@ZEJE,%*17"42,' Q)\$BP363A\|L_>M5&"W%&O\$-CMYHR' MGSNQ-
WOMU0*>'K\|.YV6-V,\$*OG*.1+G^85IZ.*\$<9PI+-; (YV>N\$WOQS\$# M'Z5L?=@08M(A2
LF9 \|"I@A&T@#66VH(U5%\|NS9\|L-PX4@8,P8HR=*!\|.@I=*
M@.1>:AZ9%5H\|FI8GE)5GUPOZH6;-D_HDY%#O?SM\|2'#T?&+WQ\|J*#.RDHZH M;?
W(%>R)=2P<5TI&R!\&F\|M\$!:\|56&2(M=I47FT@DG M,Q#&\$PA/1:\$%,Q
H\$S8;PP592T@2%XBQ@8(BJ1#&> L^DT(+0GDPA"^\|+6K"W<241G;8)7R>3/
M"14\|SX&K (QX7JX)"8PR#)1WY0)&3-:\|34+=<=Z,C(Q\|3N%R:@36\|N@1@87
M^A18QGD:9*%-8LT:#^XEN*09._=H\|D\|XM/GP#)426^|\|@124\|9%|\|B\|!"F:T M\|RDE)W\|
%@C9>V(&8G,0F8ALWJGQV'&^HBJWJ"*-PF_XO' +',%.SI"B:A\|
M\|_ (=0VT+73#&5DALKD004A0!A&P+/F7;/DE!>2!Q-C*PL+|\|L8H,9):C*@1
MR"AD%#)\J9_2(<17"ZK.%#89:8P(#GE(X1*!\|C\$YL%9K*YGA(JXM;+@7K#8?
M5RDR,HHAL9\|82*R=T2,2J^>+':AUS;20AD2=*310 IS.O+ "\$92VI"SZRSPEB M.5\$F.0M\$-
@>^ -PNP32_9;:>L6:M\|!%NKW+/\|I7%\$)\|&6N)BZO00(GG73'VJU
MZ@% '=7WMIB%5LUR51S.>NOF\|I5K*+VQ\|TJ75Y-9N\|2*FI?.FQU-7%3\|D'
M\|Q5\|=2H<2_1H+)&L44%S"LHE"X*X",Z70_-1&G+*S%NZMBR%^3*88+D,/430
M(*0MT2@1"7P.S.:FDB"U7QQ+-%:6XNTC\|589U>77IZY.L3FM+TUKU\|SA@W=M
M\|9&B>F2DP6'&@#LO,@1EV_9(D.^OE)\$,*\|HH>_2Y4TUD !61@Y)2>FE:X++
M33+DKVYRG>Z D/O'JQQ/9QURUT6"H Q\|(\$,DR%<)(FE64NL (7@&PBL#7F0+
M*AIGC6>9-O=/R5(9(J9P\|W06+@AA-1@ "6/E"S??5J"\|LJNE8==6\| M8%8U?;C.
|\|ZKR9N/+Z\|MJX=Y6OXT7%\|W6GG(GUUF7Z(T2\|1 MJ,0:O>R1+|\|\$&:)?
HE""(=3N98E^B3)\$OT2A#D.HWD81(PH>= &<#|9Q\|B#E:\$)0+,"03D)E2G3U+
MGOJ;:)U \$NZH\|1*0CR#H3\|T;M5TSFYMA0BW\|D7U@T,X'-HQ4\|KMX1!.**)0
MT2_1+_==ANB7*-1!" +5\|6;) ?H@P'E&\|>O\|+>)-3=AD\|Q1\$" YLRA\$2ITD0
M:G3(:PLB\|E,_R#^|\|H>7)9;J<|\|G\|^49-??@)\J_<.:!Y-G\|FK\|<)-EK&R_|\|R"
MR&GZ\|_6X+A_ \|+,W?C\$-:E1PY36'V>KK\|*|\|^9ZOKVP@="1D933'\$-N+R1+|\|\$&:)?
HE""(=3N98E^B3)\$OT2A#D.HWU8G;C?WG(>O\|H;
(Y=5J>TJ1<%ZO7;CRMBL.4&_Y76C@_256=PO6\|1-94 MCZH6\|T;PKP7\|UG;TK?
+J\|M/_A#+S;14)U+4\|H\$1O\$,@@8\|AF8#E"ONN4Y: M6=6&(9XL+M*\|;EYNBA6-

WZ3CJ9A=ID^MN//JRTRY76?#FKZY/IV8=&)B7
M5IN^OGUPR;E/IVY8'CJB5;3L@#BAQ0+E_THLP%&HZ)?HE_LN0_1+%.H@A-JI M+-
\$O48;HERC480BU>UFB7Z(<8+GZ_G,0*1QU\$HPG!D0E"FPP1A@6E-#3/;\$
MKI7^I9J(G@\$9U*3 V447%06K,0*"J.T5&'3^UFB7Z(T2I1J,,0:O>R1+I\$ M&6+JI^NI7Q-
I9))F(,):\$(DS\8PD-E8&G.BWN8^+F7%U&^O^S@6>.\I/EIU MD>?C>C\$?
^O%S8+I7Z[G;E*=3)LW>?VNNIJ\$?E@^CCS0E7H@0XS44*B#\$&KW
MLD2_1!FB7Z)0AR'4(F6)?HDR'%!F:~= /5J2^-B;+B[?#D)#^J|KL?35-[8DQH*]\$/MJZQ/A*'?
T9?3E71(J^C+ZAD)'7T9?7D00D5?1E_>(IFC
M+Z,O#T*HZ,OHRWLD=_1E].5!""7#OMSJW/GVY[(#%992!SXF"4)H!3;&!\$2(
M2&PTFNBU\$X1IN8 X*D\$YI4"0P,%YFR%KG;G)-CFY5G;M."U6==::DFHMS6)S
M*4=:ZJYGL9%\$2"(DT9X)%2,.\$C!#V2.IHR^C+@Q J^C+ZAD)'7T9?7D00L7,
M3=N9&QE%TB)(T,\$*\$-DS,%DFH-[;(#*A-M,V"N9CYF97.G@'M'?WAFZM=OBG
M!R\CH=5C?CL^.\$U M"!DB6)TH6"4).TXYZ]:.4T_.L&RH!)J< Z%R B>L*W^B_-
;9I2+GP\1SB|< M/-4GUXMZx;.-\$_IDF% O?
WM[?!"T_)W!@A4LY%4=D0D[7J0@)VS7^V\$C!CB M7MD_1\$./"
(NOPD*QY%7D"E@D#\$1@%HQT!H071,9L3>%*!8S,*_+F:3\$GG5
MA_^^'B_>M114TI%F"FF!M\$!:I\$6&2(N=I46PPF05@247H-A)!BL-!YZ%X()&
M70*/SVEA+2?2!@D" \$BY=" PA1D2\$^TE84Y?FNT8"/-U)J\JGC*=[W6S:B%&MU/-
L;29)%\$XXHQ10^N% MA%
(P@20G!FC370IABVNC&.\$C91!=2XF0K/>1G&YJNCNKYVTY"J6:!*HOE/MW?
Q=M+!!I,H-JL;9\$A*,>R! 9\O65C2EFXITI#8>A X)/+<6R!# MK R+0AV\$4+N7)?
HERA#I\$H4Z#*%V+TOT2Y0A^B4*=1A"[5Z6Z)2ER@)";M/*43=E.60
MAI9KN/7@N!"0#3&I?,DQ?;GB1E>S8)KA+%AWB_X?H(*+OK?QJ+_TQ32^&K1
MK/D_F)0KRMW_U|KJ_|+7JL5%JJZNY^&B=-GFU:LM+.KIF/55?."6=7TX3J_
MJ|J;C2^O+ZN%>UO|EY<-%M|RIU4,U|^E%M=,4\3MTAQ>5GS+N;+ZC<;VX>
M<5,!#F3ZZH3|/'D^PG'^?83U=3|.7US?7+M38'R^GULYL:5VV=*4!A)(1E5AFITOI
MXNXBQ-K-R\$'D(*P=QQ4+""1I04C:0"1N>?30)M?:0Q4I7Y6O'& 7!PN1"U
M|<,*F!TIKI&\$2\$(D8>_TB"1\$\$CZL@)BSVA"5@5)6(L)",7")<""I_#!XKHT5
M#|DZ@23<4>=IE81X!D_-:-SR=HS;>RR^NB.C'UC" T=&.>=1NCXYP?A&%BGZ)-M?
KGO,D2_1*\$\$.0JC=RQ+I\$F6(?HE""890NY0;!O 0O--BD!'!29D>MB|T?2'1 MWERI?
5|M1!FM70A(/S|>CQA<&'=^N1L6(D*"Y4P26;*"G^Z1\$AA9!Z\$*2" M\$|P)X\ 3+IO-
"QE,8QQXCLPY8K+I4-
JN:R/..>S>K%+VEQ,8MMU;9ZM\$5E#5IF"R\$J!2J#YHHHDHD;2U-1:6@V3L' M-
B4+PCH*7@0)QAF9A.2!NOQYFNH@_O.Z7ER66ZG/9P?E&37WX":OW#@>39^Y
MJ_""39:OLO_|-'3|_K<5T^EF:OQF'M#I_|#2%V>OI|J|9IV+;Z:XK!H)M)C'#-
>#.CLO!&?9 ACA&1Z\$.0JC=RQ+I\$F6(?HE""890NY'K(:!X;57Z=EJ?5Z=E_%1:
M|^6LKD^F9Q|!6!>6FWZ^GGYY_3UR@_W=NV=L;8UG?%X&@21Y/I-YK\$Z!N%
MBGZ)?KGO,D2_1*\$\$.0JC=RQ+I\$F6(?HE""890NY?
93,DM9=\$I8%83\$Q'<,0NJ|4%)IUEWKM-9S./MT^(DMY?
2I".J.\$|J#+B/(VI0ACV0(0I-4:B#\$&KWLD2_1!FB7Z)0AR'4(F6) M?HDR1+I\$H0Y#J-
W+\$OT298BIWZ^G?K7ABN@HP?!D0\$@:P-N4@&BFE%-!6+:6 M^NW#0E9,_?ZCV-
QI_|@KE47?VN&B|H;C^L'4<8;;F/+STMS3_|Y+&6E3U M;#*.U7OI)_;52HIVQ)C.IZ(?
85B0A'N;OHR_ODE#1E|&7|TCNZ,OHRX,0 M*OHR^O(>R1U|&7UY\$%)%7T9?
WB.YHR^C+P|!"J|OVY3V%N:>J:*STBFG0|>8TD0A(AB?9,J!@A8(2P1W)'7T9?'H10T9?
1E_=(INC+MZ,N#\$"IF;MK.W/!@J+7!@8G>@""9@O=2@K;26B^5MSFVL7!;S>
|TL\$|.&I@ M;^C6:H=_>O#RX/C9874S/GN>0KKT:5YQ.JH880*'&;L|S&"/66-\$<7;=G R! M
XTMM24.-XZU"@NI"0C98"1G0*1-0%K91EYY*Q%^957S|^U,@I99E#&UB M!&&3
DO*/XV4PHMD)'?A|Z'&GRC^N1Z42_|B<.)A\$3:@E0_|;^|M^L?\$\$V|@;I9*)"-5:K,HCD
M51,%.TC\$&NZDD5ZLK5^X%YH6L_"OB|FD/,#Z|-7X\6|UO;?:Z613<@F9!.R
M"=FT2VS2G!;!A6MJA'L0P6EP*6H@VE#&I1)J/4.KDG1&^PB1NF9M'?7@5,X0
M30S2!&*LSEMC\$QL914;&|BQ1BWQ"/B&?D\$|OJ<-'C|0R^.#HZ2Y1*O.9"F MH%"
(9,\$DEIH(C;".A+8VE'J7!HK"!/ 6;8@C.=@LC+@B!>*\$N,"S*M%B# E|LQ-+S!\$&E M
^=|!*IL=D0Z9GEJ9>W)'.-%,1*6C[2EB\$1\$(B)QAY&((2.R<8L)U9!)-)%! MX#F
"#**2Y)"M^1|BN7TMH1%O=BX\9#1D'MB\$EU=+/I|WY4,NO|U#IV+O1W7?
_TD^=MZH|>'C^W_K#1_0 M%EU|Y.|1K?8 .<7J7(AS"|+O;PKKZZFLT7Y4VY>?EP,W
M59BXNFYL^'6"&-L|J2)|_WW|@4WM_I_RW/,WCX!_F.>I+<0Q_.T=/@GIIM<
M7TY_C./Z:N+>/6E^N^;CV4QV.;>;K95KW|PS^MZ,<|OWM_F|E)(T_GCU:P>
M+_V/\$W<8OPF%5|_V|1)|SD_6/S;PX@VG|N7?7|%"E|+JKNY&?|*AHY>9K

M(ZV+ #00L:QIW)V,I^6^%L65GKCKQ>S'3W|1'00JQRLE+K?3NUS:_HF;_:>
MU3|^ ^O,'S7YQZ-(ZI9(U\36KJ: ^Q_H^ '@782_?|^ -V: ?D/ZTB_K9ZD+T/7
MS;3*PO7R675P_+PZ^_7IV='SHX/3H\,S+9+Q?3,M X\;S/4'
M1U+_(ICZXA|Y,ONM|FMS/CLY/CMY>?3\X/RP-.5Y^=|O#W&NC=_OX?'Y677R
MHGIV+ER=^Z>.8|:9N_)S>OJ|-BK+%;HBO_,K+N#,VW|#.6ZWC\$=4R
M!ON,?,OC8)=H^W1\U7R?V:-^-Z|,>3\$N(>7_]%RK3K-Y.L<>6|C->!N+-YUP1|<|?
MN8Y^_R7VL61L^*|]\$'S.%'ZE?'^E+A9: ^?O#SE|KR THN85; ^>|/RY7D TO_G+
M(9H8^WZA0_8<3M_+U@V._1^|: %EMMA7:(#W*6E; ^|BOYZ5R_U|_% ^CVDUK MJ--
|G%'H#|.(03=M|TK&,4,_'://JNVW(6R|U"L&(WTS%DI: <9: '%|HNM??<
M.WUXYYS@%U*"F_2J>|>D1C|#/ ^NSG|4S4\$(|>X"=W;-V.'K77H|B!Q CH,GT
MRF0XF@R: #)H.FLPF38:AR6_4AE%8- UDEM*.O:PT^FE: +B|EU|.:QOL|>R|X_
MA%X:D/WF"68#,"#:0*93"VIU! ^#):;5B|.37ZJ35X>G! ^='QS|5|_|.C_YZ
M='YT>/:DT^FUOCZ&8<8(&VE-; *F=T1WV:-0I|NA=TAWV:-1IASWZNV.!|Hf(
M^P_|EQ^UV7HY7:RVV&RX+,[MG34?=U?>W_#YL4|=HM78X3@MJO'RS/'JA|FL
MOE<4_9#J&KWI/,|E|,SI7!6#W0+Q7 (-3\$S1B :P4&DS,#(2\$!G34,B,3I& M/R^&DU*
(.FFD6| ^ULJO=0^2(19@ZXT4D1>|RX08E#U3AH"*6H PW(#W48)A05E3
MH\$#HVB'L3,28:8&*DY2"B":4|QP!DYP@QLF0G-H|+Z0<:=EYR:3>=%+D!?'*B
M)U)\$702Q%/7JF7_'C/.WBU%OCU!<.<|UA!"H4US(+L1OM#&9ZFYT(S:M';>M+4M"!6-
J.:@7\$HC6!T=:&63Y3&K&-?.8K|/H>YX4H,T(|:R7Z#|X @-C4.EU6|JL6LFJ?
RJS">I&KZ>2:O^753UZM:UO6|GOV M6C3K%'|Y+NL\$>C3O=X M:8#<|M(N3^1QO-
4+@ICMTP|-.58W>6LM.G_+7^PKV'Z, #/*P\G>=9!+8YSP
M\$BQ(Z<9",X,6!X4<,:9T,0:V|ST/WQUP.W^5+Z?I::@VD|N-6M6IH'8F8D
M.2!'Y|0U^&&J,S"X"35H6?B@'7HH(F2<9)972 M2=
|&7/XV^: %'1C'D1XN=|MY3^IAHZWNB|>S"E8N|JU.3SK^|2M-ZE71+;YOO M\$W8;9-
V.L(X;G6SA':C@\$PA#?(F:2JS\$@Y:><>MKTJ&>W M.E1+=+
J|A&1|NIA@=H11|(D4DQK>(X9P@VDH(E#61CE6K>1H3&,\$Q:|^< M:2.
|ME%B4\$)&EDA\$QJ#|*2(#I=@3*2(ROH\$,R9+D3"7@24003'(PWE-@0C'/ MLO6*Z382:IL-
_L2(28'\$Z#*%AFO5AI)">YYRFL|3?+| #9N'>IAK|("B)M1Y"F MF>;61@9"Q|
(H%CU89IHU:I9G\$00+:BT*NM\;M54_.EIVHW/W|G"5@GZ:J|G<
M9TML\$V0D&4X/#;N_8C2\$4NR)%(>#CKTH3J!YLE*|!-%9!2*&"\$X #FSG.2
M0606SH*XF!UMXH%UHXL06IMI&!X@OQA?A"?/4"7R)JH34'*8(#0:@#XV' M:
(6PFD15X-3.>KRMXHNSD;8X!;41?.'BO#XAM-W#=#2|<|'6JQLU)4ZG*;CRO
MWKC)=:IF>>D!Y0^4%S;?UN.X+*Z#FV-W\$|_:%?:# ^'O'9V 893A6')18^R!-
M#%M0BNB;*-8AB;4/TD3?1"D.*MW30?)%L:RXLA%DBAE\$YA9,8 &DDMI0|JCR MK10V?
GI=CZ>IKI_-+OUXNHS:GGV(YH=#N8.YO,F EQ67%T%@T?3@|L2S"|.
M|MNTH&TG"_,S;W.&AGRPNTKPI+X%E#>1P4>X/EX0A*7>&
ME#%0Q2,C\$"+E((S,X+6C8%5(FD=#A%'LB1:3%-VB1?,HE,J) RBV6N"13| %R\$P@!9?
DYB"+:5(|TV1PLU MXLPB+0;=19\$6*,6>2!%|:W80NE@(|=>"JO110*C\$)|L12:\$BI|EJJ-+
SF M: "%'DE.D19>Y,CQ3;"BYLE5:NVX6.;DF=5TOR_U/QLZ)WA\$6.JUL36RI
MG=\$=|FC4*?;H7=(=|FC4:8<|&B?9^|0A6@T<3E-(XS?.3W!F';-?N.7PWOFV
M!170@N@,C\$0@1;C4|E TM13X;U2.|F/BL*ML\$LT2Q%PZ75R"QD5E|UBY67>
O03AA@'9 M/7%*@I:\$!0W*BU1PR@-X4B#IJ">:EIC,KF^=;2>)^+X7_VV|N'AV79?GEN;+
M/;"M;11B!H|P.@,H|. ^:A(|MG/168PT>Q,-Y- <.2!#|FN|>*I29X6,L0- MY?
=:P,G=8C4S8HPC5P;=AQ\$G*,6>2!%Q|JVJRM|_|^R|:W.;N=4N^OW|BJZI MY-
2DBE!P!|K>V54:7Q+5|E@^EB>I_2F%6UO,4"3#)NW1^^L|@+ZP*5*R+J38
MI#"5V#+5|!\$8#:ZUGW1=B\$ EOCA@/#9 Y(*4W5J HG+!&2('@:|Q|SP8G=\$!|)
M,E/VZOE+J8.'XOD|&W_S/TQFUXD_\$L8="<;Q0G&D=X,A@90K#50CGF|@B\$>
M(84M\%:FM*UC7,-P^T'M,@ YJF2|K"Y-AE)B11|0HJ' R O(FC\$!>=40PFL
M|_85#6.RE54.<)8|;"#&&X;=,;?+|RC(NCOU8B!2/(D4)DJ0U5N:3)"5(.O)
MD(6M559|C*+2(P|%10X4#" \$J)PG2ID_2VMUX\$K856_HDGL^)^T2"1/'I53,5?"8I9CX'&-
6J<-K)""# MK!*\$NP*)W3@5:RZK&_.5L5G?UM/E|YBEF-
EALV|RU1(|H04#P=)7H2D)ARG M!3\$*2,."J<8I4_6U@"ECJ"H8L_G:C(KM>|!>?
AEUWVVQT(*E(F)7|C F|>DJ3 M";P2>&UA9\$8!"J9',8Y@!#N:4.TDEVHV?<8?
@Q08\$RX1=O? W MIF3%0_\$W?@X+ 9,"+\$J7/(P)6H_+PV@XU3EQ%A3(A8E0G-%%#
0Z9P0I(UC! MUW) 'N)A5*?/RTU-,+KGO>_E6XGV?AB@!%+2?0;)N,LT2*/2%'A"!WQ:@D
MS:7\$!"BE3H.VR^31"22+\$G MD)@@Y
X(01';0A4\$A!&#H7N1!I(P"HPU1HJ"0XG7!M0^Q-NV)PCA |;3U-J| MU@2GM+Y#
<,:=&N,/:EYF4W4=FG/&M#YES&SAEKE^B7<2YJ68UB-1EBD%(5<8

M,! =Z!!*I/&)2#0J:&^0D%QRM)61L)YFPX>U/%6N?CNUIQ=@?EF-&MXV^3 QR
MG@RXE*F1++F^TF1"M:SY'!&"VH!(,,:!A\$&*90L AK"TC 007V\$W2WW8Q
MYNZI=3+PYY&@Y:#9."%*(L6>D&)"E#L0A4IF1(\$1P(6E@"I2 &T\$!5(I\$161
M#"FVFTR\9T04Q 8LM0L,I0.3J_">KL+H%2PIHY69'985GPXR-1I-OJNQJ8N"
M9ZYTIV_):YC0!&C04\$"-LY8#GF@&)O.\$EM"Q 7GQOEG%F+E&TA7: FN(O M<&JK?
CMMF:U:: \$AW(@4>J,<=AIG RL1(H)(<4\$*7?-^D!<:8(UP#(7 MWL!" FB,*3#*Y*R
VB*Q5NJTA?R\YX84A 8,\X0H!\W("5,2*?:\$%!.FW%4^ M: I3,7A)TWWI@BET(/,4"\$H9?
LEM\Y!YOZ.E M_SRQ2L*IE-#W2)2%3.4B9S)X_SB@CDH@\$9;
_8^>Q!!6T+5FN+L;^MM\$Q:ZW M/X2\$X53,FQ+YD@775YL,:);0!.GIZ3EDD:L"G*#(HOF40
F/:IX:++!"4F.Q M%MK:W79:/ L\DAFD W M@>XVFAE*3H7+&9!8"P^@F@-
%)0)%7E"6&P,974MEV4)V9,O. !*=UC3C*" M6Y+@-
AF/R7CL*4TF'\$LXMH6FO"07+!2Y61L,09,#K2 &F.&<8":E4KM(R7P^
M',.#E*:H)!Q+.-9;FDPXEG#LR3B&!3\$L#S5JF'E,TL0")1T#0F#ID+2\T&L= MH:0!OIL.\$:(
*?4E)ZX/U,BZ,&X/^.PYM\$D\+Z;7>W<->DOWG0^VA.&F\6?
MA#W.RLEH:+/F/70#63U!X^UNY.& IIZ@DSLE*ZT0.*
(/ @YD/IJA!';1,FD\$H@=6@@A0RF MU'G\CB'A;35I/4A!(P 6_D>'J+!6\29E<I
<@E0-(<-7C2B"50"J!U NCU 12 MS\MV1\W@MQ2\Y1Y656C";?RVPZFWP;6FYI@
M@M@=E.Y)(Q'E!>!.>,QDI@!2%0@00ZV#WK*S>*WK_V..^F5\!""5>2"F8EU\$ H\$V)K
MV@!I80&8SE&NN>4,K=7F/<9M^?QP!=& L+T7""2X2G"5X.I%\$FN"JQU\$V0AB M,-
<,\$\$R\!=:5HL)2L TA)993F7*FU5)#'.#"?:XP&D".C*O>NS";S,I-Q/T\$
MO^9Q(N\V79*G%_(WG\X_I=%\O\S^: 9V<=_OKOXD'I#*=^7X(I76:3(B0T>#-^?
CW(IB,UGL?QF.Z_B^TRE \4NL5 M>^]-.W! ?V8NH<=;,<84*""02.&: #****!PH8\$5BKE"
(J*>-I&S\!5\LO MDU/C&7?F/M4L_2DPI.G8OF08>40>.4(&5.[-.]<89&:=!R5#G@4-)D+
'8 MDP%,&:DXRAW0\$E- N?1@Q+4#SA*.(?(!);?2= _9 8S*:0R 5@"L 1@/:7) M!&
)P)X,8#!W""OL#2FN):!:,2"E, JBG)I#9;Y&H)C_B^2TP.< LM9?:
M"8#MN\U4"6^/+3NPX-@BY^%. M(HTP5!FR?%SNWWSA*V'?0C)ML
MMD2*/2%"A"%W8 C)I:,6*U!@_P?-8GS28Z_>YZ!Q @G8DUY=LG=I"-
W4_C^P.7'6ZD)Y6&A9\ MY_Y+(HAV-7EMN;T"P&.4F>I(
XX4!)1B!:2R&CAHF4.X4(582X3=2JOQ7\7L=S=7>N0NG%G,
MMCJR5O(!HR+Y<382\OTI)G5I389) J\$7OT%+T.%@4H"F"L#J'(L#%TW #H* M,3-
%+NP:>&VES?@.P0LS.J B=:E+X)7 JZ\TF< K@=?32Q +Z3BV' @4P MB M#G*8%X
73!+!":.%VDF+1V""X'Y@?"PZDE\91# =BBNS="XLHP#%#UOU2R9 MO)P):X\ S<0RRO'!
(YL#E"@. **0*2VQQ 1A3."96(K;6&W49\5\KWKH^'=LW
MDI'(Q365NTB?)@@.L.0)!P^:B9/MEDBQ)Z28\2N6G8C!1\$Z!Y0)CPVLP\$ I
M1@#5>0%1087+Q2Y:C3\CGC V8!\@G/#EH)DYXDDBO)Z28\0N\)%2Y082D%/A M\I-
(^<@MOD!BI2Q2V#H!M^*9VQN>8(D&!*<,B2/*/,3\I\#++\@HT:5EUDQ
MFGPOLY\7I\91C^T1A Y"RB&!: "2 M4Y :J:Q.X\$B!<:Y7Z-R\@SL9GC40Y;07*_:&_]\$?G M?
_I1TU"\$!@0^?)C\?:Q4A9L@>4;1M?:(00NOE*YRN"9J0N2\$R(>)R'O 1PI=
M#I70WLSE'A^UI4 Z \V1C+5VB\N/=MMPNNX""^&\$148&A#W<-\$ZH>'1.L@2&
M"0P3&:X<&+X(\2@UCA6,. "DIJ8FS3V4>N %A686<>1R+M9BGH_Q4>_//.5T
MP.C#4TD3#0<^W43/SS!"WZ<(+!<=:I03^R\Q_ W610?H_FOV_NSCZ<:
+))8^D&9*VT^DF((P M?00"0(:I5P"8:0#%*D<:%Q@4 A2Y!QIQ.R3"L^J*>)U_XY?
E75GXV:FQ46K
M^6RK)\$"P@=^H5!*\$0\$OD2:/64)H\;M)*RGX@UM3QZ*4Z>I:%YPI)7\$16>^WP'EGXW X
MPV_N=&SCQ\!\$'GS38<%(S4N_66C13CCB_G\$ 'X^C?7+6\!/\DRD#AB'S>U\ M4/R259)
(,0'/W<"CM> %4A0P9AF@.#= !1,@1IW*1J\7>M\$ _MJ-17X\$%\ M('CRBQTVMR?
@2:38\$U),P',7!*<<@,IT-ZZ"0W\!)" :6R"(*#0T_E.V-M'C
MJ:V7>@L\^8"3!#Q\I2>FI+%#\2>^NYJ.)M?:97/UAU_X5 UM-G,C-: _RQ\9N M7KD/LI+-
YZ/H*@R.10??Q7!^G:GO:F:3ZS !:4J&>/0\ \$Z0@+AP%ENG@K/26 M8&Z(MP09\^!-
'7":.2Y.>*N;L,OJ@_C6<7UY.1H%&WDIFF_%Z6W\(@,JI MX)SI
<8)C@;="PEI(Q^P2IVTW&K+@V\%9,Q9RYZ6)F+CV3;DC&?*G, ME' XX?"3<5A8X;"E
EC%-!:&%\$"&!O,"BH(3:)\$Q:)M>4@^XGUMF/B\Y%Y-
MQC%8N2T#\$H91ERDQ,UF0R8+L*TT>-W*ENK%\$K'LGUCZ09I*;B123W\$S\$FO+C
MDHMG0\VMF\9>GDF1C2;A%-SLRIMZ>IY8YACE>_+H/(M'AQ'(.%00(!Z*=(G\$
M0\$,H@=,%ID(P8?23/#I5\$Z"6>|^+#YYWOWC6?>LY=VM9 /F T>3\$24Z<9(ST
ME2:/&ZR2,9*(=>_ \$V@?23'(SD6*2FXE84\ TY,39X,09CLUPJD99;0V6>W?F
MO.#)G5M'@C2:IQ@<0@K2PC*G@.0Y 51Q S1T#D"D-33,8E3@::3X?&Y<0N5N M?
\$(#S/;>?>#E3M=,UL\A6S\)%1,J)E1<046,\H(I Q!&%E!H9\$A\!8!Q)04G

MR%E=,*>H2/HP)"&A8D+%A(H)%1,J'CHJYA(Y+8L^F/SO_T XRG.1T@
MDB>43[,00A\$VV;X).A-D'CID>BLVA|FUH\$ & @H9!(IZ*U@1:SE6ND",...C MO# (#&GU
NV|'5&"S 29"3(39";('3(E,Y0JSU0.L90@\$P*M(8>_G2.-,&M>G-R&^|B_4\$F&K#|MZ-
JN8"YA|SA%P3"6Y40^|HJR7Y^ ^ ^|YW>G%^ ^DIU|MK|RV|V103B_ ^D9U^?%O|H.
|_ ^ ^WLGZQA2:UU(M'N_-|2LX_0"3Z"#/>
<*D@^;_!\$6)%'M"BH<#12_",E.62L\$=!4AA"ZBF!N1*MY*"N(<.JJXVH9;M*_@=||\$'C:
B40|(??.D9N^|(8;>;47N;<|1N/?*+M||L-MPFM%::1:?.L3?
DAQSQ3WW#O<.H+0KVMR2D+ S\$Y 5(:!)PU^"+|_Y M3;BE@N9*
<@Z0MOX|T!ND\$L(EA L(=B+)-:\$8#MH'\$",P5IP0+\$3 M@'(/1%H5.7".0B(PD)*O-0XH'
(Y)!@4)D<>|8P#"C/F88Q;A)S%&L(^A@A M8L!HR@H 8UD7Q
J/JM3|W8|L2=B4|P8|P|6>B1ZQ^8/C8J|*<|H^H#MC7A MZEWSE95RS.8,B"(T;R7^#VD-
|@1J\$3X@|B;N"HQ1E9|2.5.*D"%4!Y7_4|F
M9TI@XCDHH^XBG,T0'3O:3%W\$O)Q(FM"P>.Q#1.@)4#K,:!9ZRW"G#M@#?36
M(B,\$*!D20T5.12\$\$=GJMRCX%ZO*(@)4!+@)8+0%:
|P#-28NO9)BMTE0'NF2>B;2/X)#M'C|,FMBHF+WSY|^O#NUWW;QYL/YQ6^?
W|VZE5W|.L)O_083_NG%G<&^%)4>|F;:J:A
MN|31B4X31Q|3W26.3G2Z1XY.TW3|Q|#:GZTP54;C/!L&!PMWY|/9;|HZLE MG|E#?6;
<(<)XP0\$Q5@-J<@6TS#6PN<\$Y\$U BO)7I!&WXSHSDROW);!10+5MF4\$#EN.\$;D*
M2E900T@Q0<;Q0@;""M=.\$("X|>+?<0F4(3DPA"+*PPBO|0RVW UD4#K-%E!
M"3,2902,%|F""|F",F4HMY&(.100(U%0 HM@*"Z()@)+NR:F?\$XS|E.S PX
M\$'3O=9>|8=2|YIUMN0!ES9V6/&=/GMPX&0,3O&?#|3=7SOWUF1K;K&BFJV;J
M':^:2E?ZI\$7T<#?33AT-W26.3G2:./J8Z"YQ=*+30RI=V7+PG3US|)V|!|B
MTV)F+E7IO(Q1T^%-SJ=F<:2BLK1ICTYP+("UW \$F.B#!*&+>6C/:8 MR+TWYX,U?
S|H|&;S^A^GYK^+83D,J_FG&BW<>?%AJ/1P%(WZT|)<7#F+MA;C MQVSOS;%
|P|\$I7G,,6MQ1D&("E^,%%R*YI1JD!.% 76R H+ 5PN/-*PPBA%
MMQ'CWS^X<,H2N"1P2>#2+U),X*|X(*@HSES"G#JT8(B)\$%N"@*\$S(K"\$))S
MLS;^+XR M8=NO_ ^721?_>E5_+=<@<&\$_F_E9J%KQ|L:/UYD:95//WF|S_S2E2|(C3BV
M2LU=FW3@+RKG_H.KT+SVY,9^VN&WS(Q460;>^ ^I W0XVO*!_IM^*<\$&|\$_13
MG:|_O +D=3%R?P |G+G(U|_|BVNOJ_ML)R.U/6K|_LU=COAGO?"R|9NZNJ#
M_RS*^;X;MX|?A6XL7T|G52"ZM7,C=1|^,V|UL_PB:'C6N;UOYQ3VA|^ ^?G M5H?XSD-
9E&YBH-W;WZ"W_L MU<<5)
<;PA"K|WK|2H^_JNGS|TUL;FMV(%X&@.D2Z1FS;L;F'R)EE"M1C5.:=-M2|;EH?
57OGZO3E)/1G8WNW+ZX?^| ^_SKNXOLTX3_|=%>|_H7|OQOAWM=|_7C^Q6_JE_/LS?
G'B_/_M9V|/O|Q|FSU%BNUR>_//Y^?'-V^B&|^ ^.)7&_I/WZ2 CA!ZP!);J^"CU|5G
M0U,:!9|KG.>6 YH|/6@8,*;U0P;YVR2GD381OAC%|6I1>T9?G6E68VG 99
M>#JVOZAR6)X7GV9>@QA|8O*??O'/^64T;,_E/E+U=3?8SY;N-V#|5.BJSLG
M"W22O7UW|>;SV:7%+Z<79Q?ATT^?WUV\$EN7A MJJZ4;?>N&|DF)X20/H|<<'<|?
_0".|K.K5B7P_M9SKY#,@Q(=OJ1&9G(Y&?DUA=|>\$B.O4^F MP|G0=CX=>.OY(#Q
MA2|"+_R|J|^V_@/(@;\$=Z|W)"XK+#2^|FCR-5|:W+X MQUL/K=|H-
;_TLNCR>NJOG5SY=9YD_!RY|+KZFY695K^%AOWJ+1)G+1>GF_@2JW?'4MBB4F2|FX3
<3DY^R&CTA-W-M:/PX^_PL;-JUAB&F@TBX;VIN"EPU@WN'LX8;-OW^K3^>7(
M/WS0D\$/V<|A7?9|U+|W|1?:@ZVH812M4EUC4.#HCY-0X8^9)|3?6ZH(|;?
MG"YFY4+Y9?FK_ =9ZLG#S|&'D.G4UYF+=FT6*2<2JK_0K_.M.^Y*>V+RVT!;
MLB^=;0B+B0^_|+ORQ7*APSY&;U7(U9_-U/AK93B'!83?#<<+;V:|V5S=X+|U M?
5NF^H?AO;%YI_C!5K8L9M;%9E7U4|HSWOSS^+UD^|WHR|>+O65GZ7A:IM<5GYU
:9)ZW_9,NG7:GKY5KGE|/XNME_)JK1@7|/6\$GF:<3?|&X,N&S|VY
MY0I=,%KE*CUYH>2|\$+;9GS8I9>J,T90 G'L=B0K*0!HJ=J%F.15&
MPIR;:6A8GV83XYPMW|F5Q=^)X:-.?&G.K_ ^AP>F|Y-9^/!6%RM?<;&R'|A8
MUU6'R11YK|_ "F=0^ -V(/-<0.YO\$ID+J6@NJ4P^Z?_B7F|O1|2%0%1%(MTT(Q
%D1^B@:#0U.>".4XT0IKE=<^9;*(TI> X<+OB@+,=Y= !D2L(14\$A
ML6JO5(5.;O?;|XNJ:L6LQ:<@@AO1W;|-1 RO_%409((^%*CN:|CF\$F_.HHL MQCD0DA6
F& AH4!QN7<4&D)E'8;@NSML)Q.!:|W:/|-D|O_ =0(H|HZ07 MS<2_ ^UW|,"G+|W%S^9:
(\$)WK MK&.5>05H:9/<:9JYJ:H(JC'0HO\$PRR;CL/ROUTLC*IHMORY")/|^ ^67PKS3&
M5/Q58TUY%/3|SUX QH/Q7S@Z4*/AF9T#;Q1\$>BQ<;YT+;N+=D7-O2J;:OEY
MJMW3CRL*9R(17&=7SILH\$6*#^V+N:7+1O)\$:C1H+8|*8>UX:1|J\$L_/P0M3 M7JI0Z>
OJ=|OV)GL|(*D'A=5I==3D;|P|&RVK>=YRW?W5-NI7PZY?^HG_|T
MB;W)G^L8=P8C!K#R-@9EA@(EB0_62ZDE<@;-)6M#\$PTE9!9H'2P4K'*0,VP!
M9T)BYW3|M6U_6HU^+U|=S"?F|^ZK_G*|/(ISHO'U|H3^|SR|U|C.QN8J&7C\$

MF/AJ>B KX%E)6#D%%PXS!0GL-'W,I0G=U";0L,)#:0>.U>^@_OGGZA K,#?.*
M62\$IM!L2OK)K"&C!#>?<^=^+M2FVDZNRK3B2P2@I0T%D+++.7ZUR"-MSXN-
(J5+55ZM6"\$R!SG-M 3GC EFA,I*,H1H5T-L:3C@O<9PB0%H1DA.9@;D7/&P!
M=SW)G@?)GHIZTFK\$*XI#0Q9_FS*51=G0.N>C@>!507+A%:H.H=3HG|IX+>.
M|N168YUT%&'>M6LJ|TP6K(C6,%EY>'=5GZN+W_J+5S722_^-R2R&OSSW+D;S
M=BGKRO.E\O:9=BYXBXI1I;GZI=N.JZ-KV|6FSTU-YH^NU)N**=WX52I:'
MY@'DUG4M9:UOJ>P51U1G7I:'J3\$F8_IM?|,|_??MZ5^TH|B._+|'0\7O@+ M/KL0A#
|HU4NN9(3=%\$|-AEA,|MMD|(B"%Y_#O_+2J?_=O|LF?
@1FZ\K;\$E38>9D_G|UWLO|\$_+SW?!M)|G%;
|_>OKY_X:LEHNSOW|>W_VY03CE^STS9OSWSY^.?OX|^S3^8>S-ZL9
M*=_S89>\$SY'E1MG96N?|A+L1*D2#L:3N7_B569#SL\$DB\UG_!;<_!4 MMBLM!!7\$:
(D!,|2,,)9Q+RVH X@QS*6CJ*U!MV/"_0/)|-/5W#ZZ*U*|Y\$ M C^UH:HAG%XGSS))D
=*D)N|FL1&1VPT<8.0?3>M|G:=O3M2<+=A\$|H28UFD M-L>EJA:GG4MHJ|K2_Q
TBV2?|_|^J=+2-MJ>SRW8I88&N: +E 1*F%\$S
MX'6_'%C"%X+89256TH6\$|T*),^N%,>2D*|(J2MAYJ.OS!&@^M|T8YSZ,I5 M'WG-
PE|W5)%'5|&R<7D|\$_@R"=CBS,8H?TT*78F-I< <),K9J9LOLEXG_JXTX
MOS^|^*7U\$&Z|_LW\$+E?;?.WTXDWI+0Q9PH0GD|1)W/T0S?@ZJC-W;|_:V CW
M2UM@;,-6-G|6-VJ7|0\|K'?063P_/C6A^O 6.GAQHNSKDVQK@/_+9.KE
MC|_2!O|H0;&|VL-8CZ=CK^!)A8'6>20?-@CK9FXX'FQ4*-<*D_)ZSH?S10R"
MM@B^28FHQ(W_:(5AG#Y09@J^Y7TTU:W46^Z6T>BGL8JW<%O%Y"BQ1,4XN4
M7:Q&I!8I+|95R/U">GI-GW6G_<8+^9OI3LOWGG@
M")5M97)7/E#+^ZU*6FLW,/DI.WY*_X1N?C%/(;U0R) MY?
T+|P|)G9VP_K5JAKOIGM"E2!0116|_CJY"E4>W;?U!SKY'HX^-|"O=CAK MBL""X|D:?
QW&O(+XSA.OO(QB=4BSM3'5%%1V3S+_&|628^U*V|>9J|V7B1L
M2K47@6;9T=CPUM,;A8Z0/@OM4|87AQ7%\$8Y+OS MK).1&DY^-
EQVBQGI|AV&DX6_+I9+KM%;Z/:HW6CHOE6;KMJ%\$|JRJ*_(C: +1E5,<>|0\#K|G9KYHI-
6&WC! M#CTSS*JSK^*/RU>OZ@^K*VHZ;E\N1"PFXRJL6#YW)!\$5BD%:(!D|*G+!= 8
M.5! ASC-E3!L*QC)K3<'=OPUSLOAOP&A|U/D<2G07/8SDB;|8?.QB;WA!+
MK+DZ"N)FX^(/;KEQH2>-F93S;#KRDJ@9'S6,C7'*=.RHPLLM4@JN^T3JH?X M+?
K=S:O'KDK'H!;(8|6?M>7;F/KFMLZ8K;5@A>>CKS5XR&_CLVX*FR?I/" M36,SZ##
|*|;"MB|93K)QJ+'VRQX&
1AZ|LQC4>O,N>S*;|9EVCX"D;L|*_U0I@\$TYNNM|9I^>=AZ|*P*4E\$|JD*GG9R-B@O;
2^R^6=2A MK|1_O+:TM&&M9N^??H&2\I.S.*JS@EL|Y=-
ZQJ)U55%Y;ZLG.S1BHE2S2O\$ MPWG05RN+)'9?
NX|EV1M74BETS2X,O;G9EYAG*|WMQC\$M&2OXL^'E5\$W&M6: MX|J;K|
<*U#%MB1I_ ^N0&SA(O-|Z5L4?O
MD;^IC5V8&BNO+.ON|C<&7"ZN%I7)6)E(JZD;X6OANJ!*A+CMV\$7R;E"Q?
93|/_U)WUS"5+A \$R=(B"U&OFNS#75_-|Z^LO= 7/S5":OSI|"X; MQA<,K%*ZBJC;1|T._.'O=
|_;>J/M:N(W8C3|W46MR)|9,,;WW|?^MO'W)Q-
MS_(:2!&^>U0_W:QJC\$P2"AZAFJE'6O'E1A|6K+@RVV,+5!/PS4."RJ=EJ-
M"Z%JFM\$1)G\$QL?GGV.JP>Z+@=R42&&%H2-(W<,PGB4(;P;F|BJ(C=EUQP_@
M118NV1A^MX:Y:K|J&AHG%.R'-0N2\$/H|*Q|YZ<+^NB M^V*%^\$ZR-
TND:V"W\$OM|V_J^10)VXJ|*G%8Q3^7WC3U|*HN|&(6BL'(1FCV/
MZ^VHV>M6UJIZ0|5+2B2W;NNT1!928_P|@M:/L>*3CAIP;1@5C7^J4F^%M"
MIXUYL#YJM^S(S>?;!%|/4|3LN_::'YBT4W_:/JX,D-W2VVI#JF+'QF_AU|.0' M;6?PN.2>>_I-
OM!K#6%#DV9(.(\$4.8(4+F&P,"NW4(+12KP&L5/F_B?G4B.
M_KR::7B#6C>F%;DL|>1+D%X8ODJ!#2#;KH^>|,E(7*" (?US?TB:G% 8>N5)
MPG(>_N<7%WJ/5;ERKWYW;NK7.6IWAZKBYMTQZ|4K6%YV^&WXZ.O'HP@/_-
MNS|#+CQ2+-9,V"?_6&1_|+IR;A|TK M!G.JHDOQ;A3|\$@LXE2\$ _RXF@4&G M'NY=
|7ZHQL/\$JRO14.FWIF7LDX@+|5/- 8KMU!=OL@5|M|;B@J+:?"Y8%U2@
M|*TFH|YZ|D9QL9A|T1BR)1M)YY\$4K;I99J4GL)+&S8|&#?T|L MK(J756\$2RA6&?
A%JUB@,Z^+'7U,YKVOI-=&EFWU35= Z"H?804|MPT\$Q9.R9 M_SJ.L_)<_RW|*
|BP/*W7GD_CY<1T4E|;3Y^*L9BPSB:CIRX9GE@W*F^54?@!
M,JH;\$:NB83>=@C=5HN'X|@#9,L ?FD|7|;^!Z/9P9--DNKV,HYNDO#+*^1(
MLVYWLOJ9"CE2(4E_W_7HAWO<'N0A.I9:ZB_=A.\$FYWTE
MKK36AV'5@UOU*KDM\$7&P|\$M711>J+.KX;SOAJ?GN5%U'W2H: M074V8Y-
SO_)AB&G6#2H6U>;K/1V@.7L1HCUX=3M|JK4@S+R|EL'MW;V3AX
MZ=V:MWJ#6K+=7#|E!7'>^*CZ8U+\$%5#.2H +'''-.4*";207;SR?S*YWD^JW

M+Vf94ZY?W,GDA;ZY(R%D'>N%VIF9GC=#,Z.BBB\$&!@WI/E6(-#+AJSCRM0)M+-
QZBCLAR'9V9C>-.?ZZDY93N9BB^W8X*!;!U#^\$HJJ=B8TR"SG5=#^CN|-M-GSQK!,Y&
f;O'MWJZGO(6PXMGD;>9BNK.VH'55V:TAT,"5J\X_&C]6\84P7 M4B-
_MW\$U.;E8!!D5;KOT65]Z\$JDB@/5DWD9L5DDW0:Yf>6.K'8f;5#N&RJ61
M6'NfEZ^Rf%!\:7&95!N:U%_USfW42.L-6D+^= _E5f820S=7=B=-998IE(^6U
MV,J/%4S22Z?|PLfKG\|)1K/1%&(>V=6%XWA38fNfLR5;"-?S=O\$]96 MYXfK7=TI*=/OJf
<4' 4C%SfU);<9Jf965N_3LAFF=S1Q>B138Q>O#A9J4!0 MTRB@_|>5'?
JL3O)f%D5(\$6MfP=/0Zf5*:.?@:DA\$CAP:1X05.9(U.\$XYE;6%+ M5(V/>-
PW9+:O>#JEE'63PS4VY1+1+_31+<*37T+YW\N?+(KfW8^5>N2#&Z
MD3HW:5.=VM*QF\$UR8QYR3,1R95U-MOZ&TS!fM*R(:ID:,O66f= L@N.K>6*4 ML-
'A4Qf=@?:R: CML)SDWRfFO\$V\$@f|+).)6:;
M7+HfD8V&A5LfHYMOVf9S6^KV3"F4*^M:74Df>HfK+YfJR*'E81T^E&796S-
)TTD<"Yf-Af<9>PN8THUO# MHW7HT31RWVf93H=^@WLR \$SK?
KVY:.'XMfH/C6^BU=O1DIK=_?IB'\L3HKE-DW: M;7+--JTEK 2f%FM2_M/f-
8:|^"K*L\R*#2@?QL9E44A7!Q<\$LAT&Z5%JR:'OPK N MI+J2,?\$T^E9N*.^_
TAfC2=%+8NNO_"?>9.R^!XLBQFFN@MfSRSS"CL_R=ZZ M8%\:T=9"#./3%V,L31N//fJP
H@_EYEUf1MXf>5V1*N;0K#PW==L?#@/?SF MRM6M>+5#E^L/Z?
4Y@XZ(+X=%;WU@f"L3*(%,8H*GFH8MGf"H9YB!H+HW)A2G4 MDR1f
f.)YfYA0>J;8W^ (Q?PBG_"40f*V2_)ZO_ ^5YWfL X#,52R&f|+!QJK M\$fPZX
WJZf(V*X" _fO<'W-?fZ5f58_5;?;*9E&"Q^fU%N%7T09SO@W+84QU
MNWf5W&7E4G^M78W""WP""^9^fL9;ZV*M@RU_ O_#(Z\$?2QWf7f!-_ON_KK_/9
MYM>M TBASDPK_O7:.,#U'*\B/fMEN.=5(^<^O;*=*15OW=_fN
ML%DfXN^F*ACfWSW@<%;%_LU=-/M/02fI=#^9fZO:N2fT-JO\$3A!_\$VV
(49Yf)=:\$EDfY#G+-K=5*)VO-;9'5E M M<X4\$AA0;ST#Z=<""+.4.
<\$@90C>SHf&&2f|<^GALNYB%00>f9#7,=CfV^ %4 M&0\$-F=
(O,'fTH76HEMMfIU6_TK@G,!Y&^ LL:54 M(Q0KKP4H8"930\$PAM6""BN%OKHZ"45-9#
PI""TfMH8\$4" %:"""N9-3D/ M,YD?&USH#EG>(;==A/S>*O^P#6""%K)#02fS82RS_
\$J_ \$A2^W^%B:;#)M3< MW0%"YLH44%G@>.&%E+\$D1(0\&8KUKS V)DG#7-
K;/KODXD-+&L2 M4#>W?
6L;X=5E#V/7fNH/V4FF;Of5M:;)>4AM4'RE8UW5KLNZV2BF"#1fF&(H
MM//.f6@Z50<fU^5>*VD<;4+_Jf6fW H@S1 U>U/EW^SfJMRfJf_9fL.R=%O7
MG^4#XV@,+YfJSMf/%U^R+,Y?C>GfVfT;UW=LOf1"&F)H8KWf3UX'&9+;fR&O_
M5X6ORUM733GfJFVP:8M?>U>_Z11@'\$8M5,40H\$GOH2!@GEH;R^*_C*B\$BM"VM
M1C6\$#5Z,AZ%<_f8G(:\AC%.HU"BNfMUZEXV/fJ MJ@%6E>S:fO6P7"XJYE/'06TQ;fA)2-
E"WNf1L>:P2KQ>=A +4REB.fMfZ+...
M3)WfN.HT&*>8UUG^U52XVK(f0WfO7<f&4<)^=. MFYS-6""0-
\$>LA)UD9RL,'W+Z392#H45;M:ZP6TW/f\ \$F8=%=:+7V*M?S1DM34"5.
M5GT,VY:FZR)Q&!-;f|+G:@//&SE5@Q^:.\$4TE51^766\$?A^6;N/*2L6LfB/
MX;HJO:;fU(N*9=G\$Z\$97OY"Z%?7Q7JNG(V))N/KAfR3:;?7K2Z
MN(@fLSfJO^X<;#J_ =K>U+J:IB6,SM7?AJ2-OEZ-QVKL'1'5VTU+6+XYO,5YY
ME:KW9R4F-_2K#,YHS^WUHYN1f8E>=K*TW^%+2TG5Yf>Ff\$^*O98+2(SW^2U
M*K4Y-#F8Q,*&8CE O&Zf5OLH":SV=#75f2EfDLMOC1NEMJ6GGJ2E514UO?(>F-,M>
MTZM?KJf5VKf2=ZZGVMNXD_@@H2%C1T'H TG=8SIYZL:1NG'L9C5YZL:1NG&D
M;AQfHL9!M>-@H=C>/ACL 7J=+=TK U/+Z:Ef|@@,PXF%f|+/0DLO; M-9-
H!18>W*NZUK%42RRKJ2O&=PUH:5Q:H5ZR?HF M_E==3U-3FUYW NCT4KUSY.B-
KB/U6)#N-)'Gf 9XWCWUL55+)T0C2_/+_>6 MPI9EA4Q;^1>*
f:L'F:82O.Z=4M85M:\$GfWAI%-fL&6RK93:OKJG/#f\?23.4< M-
&-4XR#69MQ9QfJWH'UIfKYHV*]5N;"K2V=#Z?L,RED.65G3ED?M:%7,VSPD6
M6f>PfJLY%-1NV5HC?::: (Z):6>>T.1?%607Y<-_0fM>fOX7U5/??ZV M+8Y@:%\$A (:*
f9X+IS-WQ82Y?f4Jf= *fOAf1\$=_&R@6AW MX&8f_R@NfO6-.RS+;fL 5R-@_:fF,@P-
YW/0FJ;f?D"-LYWf|*.O?LG2=^U6" MO?%O3F;-;QJ/3&A*
<f5NfJHE;T9FAO5SYVOF^CfJMI0+MVE51M"#fI+&EW'@395 MR&XYRB>>UFSH:3V&6-
K># T^K,2S9f4W:;;LK+-Q-4Wf/3"-4fOZ4:"FK5D8 MA%*Y)\$W4@9f^fJH>
WW=:>2R_!HOU:U*U"A0f-_7-M%)C1^f|=f53B'KKN)B MZVY%\$9W"S>X8""%-f)-
WT4E7f2+>.+?N5*:Q;1S3G?X3&W2KPH7"Y"H TA)%RWU5RYYNfQ^_Y.8N,7=C
MW/f1L(f%fUFfZfJfE'/*f8 MX^Pf(RA)RUDZ;7>6VZ?GW" F\$!EVf!%&f|f?3;T>N08V-
!f16U/MfS)CJ_Rf_*@ M#2*U>V957?AL-EQ3WT=-E'PY#;L_f|>HfG_*;6@?fE^>6-
_6T^H=EKMQGT2ESY7fSMBJfD)7)?TYG'&:'13fN, MJfYWWB8.HBE\$B)(:-("Zf4fTJ

MC:+2<2J-(8PF7WOB:C1_PQLM^UJ4C0"!2^TFU8=V>-H|>5DFYLS,I^?7OR2
MG5Z|R3CD@^R9G.HY=NM!Z^:3*4ODZD"!_%3691%;UKIZ V'H*?R|TJEQ# MG?
6,V/;2Z':HXOGQ%+MSHI>|<>/=7M?C8)>I'-\$/-E/C4IFVB|+EWW|2^Q+
M6|LE&RYJ(I7W?G2,0OK;MO2ZRH_!Y6P7!U56_IJE<6P3B:XY4G|C4X>#.I&M.JC@+
(U;^JRB@7ZB,I-G75,BBWM+D(Y(&_1>HF=:>3O>UW6.U7|!"I7?O5H
MXL2NTC73Q9D9_L_GOWS|,OG|P^/Y);507EPG-@YWWYB=AF)DP?9
MZ>>SBR^G;T_3|CUEH*SCV=?SL|3)CX"3)D?OB_OYQ^.=9VK_'\$.S\$R*A0S
MHR=>1GHY&1HEM/08VXTOPY.ARI=JTF4G%XJKV6\$)HXGV:=UH=OT\HLZC.U.
MAK_=>NBT/VUB2L/4/E&M+=YY+5!8\$.7T>Z|4VKA3=V_;H>|HZK|1;K,&P|
M5L&5H=YI6%|6;EDUG7JK(HJUVZ\$,501X.9>A'1@UB4F>;4BXT6|+I=-S+4+<MV"&#|
)Y@KLT5;AR|VWJR!M#@-?^IT%4T;Y+2VIM6MQ|>#.S>J;8K"KE M6+4|VT*!|
|6|MSS1)H*;H*(I2W/;TVBANS M-\$0B3#R:V|9|T\$RU|S3*K#SFH0UEY1'M-
(O5,149%#9*9/QLLUY'8'H)(BW M::ZK(UZ).@3|9%8NP|:KCM F0/"M-63%;;D0/--A@R?
&+&)X0C6>W|J/?Y*=M5N'H9J1)>-G@!KZ|!\$AE:MMN)OM=?;Z"!-
J\$VC(I_%G_2K"Y'8H|Y;1^L|XXW^HI09152>|A^\$J<:S1SE;R MB-
:J\$D/<|VNW7WH)S|:|ZV@G;Y^O&9U::&|I?V58/&^"UJ%U|K:|=?C82J
MMJ5=|1W0&45G+>NK@IOXLC6-=+;A HS.8C8^*;D+3,7YC-7#UMH'UP-NU%M
M'+*:S03D_QD|I9>U5\$W=BV+<)I7?QRBY<=+F",!!^/:?K'I M
WAPJP7|=7CQ_:S6D.H965I;Z\$)#-X%"^QK*05Y(!A3!TJI":E:L)5L%O|5 M.0+
<2>6_*!10V|D34*07ZM^:/@QQ/&V">&VSL4MBU_46GRP_:ABK202Y*5#JB13-|)>HB"W5
M575Z\$R7;5J5;1+R^ZJHE)1 MZ13+Q|9H|*:'1F3TVLBX+F==/JP:U1#4&O-
|8PXW2LHJ_:JWN.??7:WOM<|< M25UK9^%U0WS-8CTR#|N*W'NL>6CH
M%(@N)FKAFO|Z)%E?|>4S4;Q|3&&6-C|4UA^JX7=&Z0RJ+H(YY/DC_G|H0HALI
M:VD0)D|+\$D|'9X^NV#G|U\$X;8Q1=0JB@D'?.*L>HN5FOQN+KZ7'V%>|FHN
MS;#|_FW!EMA';C1L2K.VB(KFP4LQ4Q61M>Z"CHE?75MU8^QX?\$(H.TB)IGEF
MG'A9&_6=)U2CA^MAT|OZO&6U9DPZJM?@US><74>AY<5>=<9MAL#J&-H;J3
M|RX(CIQNFH=S@|JE<;QE9/KN-\$|EO\$8|/T)PM'_VD|B;Y^/Q|?;IGT*3 MD+>'(A^|,?
P;K|*LN&&0/XLW*N.10|=35NMM0WI-R4G;_|^|E/;Q_96X?%;
M>_MP_2"TIQA&W="3F+ELI&C=Z-0T#_|J'SR_|I:'P0UM2&Z*N%VL5'4\$M;/%UW:-
JM,=H-^%PW_M&|L8!&P;B;MHZ|;ZP?M&N);3H%3'A+;)WYODT,02GRB=3VZ3S%OK,
<(Y5PQ"5YOSF%.;@)25 M:EJPG|C'1+Z-LMI-M;2QL|5I\$T1X/YE5@?\$/D_('@X%?>%
|M:>;UK)\$GZCX) MSN|J9F_K|Q1-RS(J4H\$5E|DLG?S=V 6|SE"|9=|W@PH|6\$:'|,0;"/N)2/
MGX)|ST'6&|HZV"_F)Y|CN/SOT3=Z_!36Z>W3F|HX&_|P|EK|CGGF)Y|D")
M5,U'|:@H=.N\$+Q'D;_(\$5_:V-/C?YZWCW>*9|CEWV/!!^_|>?D/QI&UO> M9@
T&203>54|GS7:|A..1>|I2|X=.;_7B;UUIHJH\$X:DA/S:W;-(?|KW^SQ
M4M#D.9EJJ_VP|G7*A>.<)-%Z2WA|B|)
MDDQM|^4.08KB)\$7WS;M)BB8IFJ3H/=/(DI1*4BI)J22E>B*ESD.|@B2;DFQ*
MLNG@9%,?SF2WTNG+9*Y&:RZ=GGA*^*^*T;18EK;>AC)>(E3F*='C.
|3#7UPRSKG/7L9HR6/)J_GNUHJAWAVZ|*T'WZ>-)3 M^G|0;=|_Z_|4)^+<*<
(KW+4GB=3L5)9L|X1EG*550_1S#&@!9!Y88 N6*YR M166.YT @C 9>G1SDQQ,
(HAQY|/"L&:;)(N).L@!"I:0'\$208T)P50#A00EA'G|!#|M|U!@A#ZRT1S(\$D5@+-
A**8\$\$/IVG@@ M*FCNX8,#I/V5U)LR0%)H "-82B&MZG8B6/=|K|
<"M=6CJ6QK&F|5LUK93KGL;544NH?>9#GLW=37 M73OU^&S,I'HDU>,%J;-)X^C.9W
DMZH00"H5A@MZ8S0G7H5 & O*!;.\$V+4T M#&\$LAK;ML1;N905!9"FT,
YQ!UGL,)#K2_H'8V+ &4KZO|&P;8*21)-|H|D\$)1THR0N-B6\$8"&@,H(4E0#&(-??2
MFIP5N='D)I2@@H1P&04:DI"_P;WQBKSI:XVU&GK|X5KO'4J(Y..68*28V;
M|!"6))OM&DPE*.E B-3\$Y9!0H#PF 4H);@0'2BMNK4&L""//5Z&\$P6A4AKD MN?#P@Y4
6A<2D((QBWBM,CW#B4AR0_?/B<|<>V!<6U"DD23?;/A"3=T:=8 M*X>T B'%#U ##=
T-X A|G*!!=PS2A17\$M=>/S F&I \$=-FX(#(XG0'I=8 M\$;IW))%B0 1)2'(L7)N0)-
%DWV@R(4D'20HH;42 N--P@ 5/8-*07(UMM'P3OZ1P)(4C*1S'JG#|_)01BT|RL^;*J6
@|H;QPXKX'42":3*<|B-@X|C
M)R=_,3B4IGY%&1BT&\$>D&Y: ^L/P/_W(PPH'C*>TTZTDBC^ ^-7;"JX17":^ M%:_J5G");
^4;).H3339-YH:H-)T7ZJ_\$065"G)9!&KQCB0%D&@A3*(YUI#
MN|;SXL\$9%L^L^L!@*F!4M+|\$UP=!G\$FN#HXN\$J:_V&3;1*EB2;|1L,05)3N M2_.'5!"H)
_TM|JB""@T< UU0RA3C'&#TYC^&YG?YT@)/3?^>J?VHZ|2(2 M&3ZIZ|BY?S4S9X?
SU'(BJ3@|D&=)Q4DJSCU5' TY9)0K8 JOI%
\$"Z"9R6A>0R,EWU1"|CGJD'D^D#Q/:D|R<";,..@CB3)B5_.N^3>@-
M4U83\$UH'(T!ASKU9|H&+0Z5RZ S7SCRY>|8>,(N1<<)LQ)F)J*

<83)) *E'QH00!=R!ZT",W-&E*SZHI,2FYML0";"GSACJ!(!# =2 FH(M%!9XPWYG>>C M"/;
[HNZ^80(/..M)U!##D2R'9O!/?L;-57B\D"3P3B2?P3."YFV1.1JE\$) =6 M* ^9N1%
248#@A8\$6RX<>OI8F><'3SF M"?3R0Y'L"3L3-AYY"2>L#-AY;F
MB0LM)3(&0.GM1^HD 5IJ"! "WSL+"Z1RM)94^N.O+|V.G&U!)\$W8F|/\$S8F4@|
M86?"SITT1\Z-QT?K@%#8 HJ< Q)*CXB*.(B4MT\$MW'E&UO:QDWCLE D|\$W8F
M|\$PDGK S8>=. I|*6:VA Q8C#"@7R.-@F)J\$"DV,0T3(-;MSZZEA6|=C/(! M|TO|_>%
(EA|ECFVK\$=&SI1H=5R|8NW%X|TRKD1H;E|5E:JE;9JR5=K..H\$&& M(:8I!>RE:.\$3X!
?!92<+/?)'(IG^U OEZ %|/^T+5HUN4%R<)-=@ R_P?E\$H+M\$
M\$1P1S8"U.G3%8QAH#CFP|B&JO=X+|5I?P@JPEWNP0|!CVL">J-<>"STR&)R M9JG3:
^X1LF 4Y9@+<@:K5\$W0G67C*LF5Q3+C\$%N2 \$4.T84!01P"&Q5#(' MK5CS-6-
D+7\$J|Y(KY<\$,>A./">N036DFB2.(X#W &H.#!D6"M01K"=82=2=8 M>|&P)@I+#+:0
8ZN|Y:4|6\$ \$6 J.8(R%HC05:=XU<4\$,*9 B2'@+#+WE0U*X M7"J1(4D#5#X|+ "&R
#G"=82K"582|2=8.U%PQIV6L.<(H"4QRCJ33>@O+D% M+(-0T4+B JX'U| "WUW2. '?
26VM***"P_|GD3 EL!)%<|'6". \$#BA.N|1'7 M5O. _+^4?|_."W5;+-\$31LB?
M|9GZ=\$8LGSV78|HPAXMJR-N1|.B;O|IM9A/ M&I():PPA:|4+@E>E6ZJ9FKN5D5/_-Y/
MFY.S E/JX6@XOW|5W.76K*OJT42><"G#L_|(&Q?66;^Y/XD_70_TUSN_C4|P
MH|_ZV" _F)Y!CN/SOT3=Z_! ?36Z>W3F|HX_ |PQ17>6>&ZR;X>7+;ZRXR*47(
M7'|YM|66MXVK|;W/5X:.<^|RYX'PN_|A.2/VUCRY|>;'+H3RGEV/SD=S7
MW/M>"1P|&=D'G-C-K&ZR>Q;|WGMFSU>"IKLVW6X6Y;Z^6R5G1#NOS:=E,/ @_WM5-
;C^YA|'V.@9N+F_M-4+3M|M#M|=!TLR-
(WP,*0H3E)TW|R;I&B2HDF*K@U!F4WLPLRSSVZ^F(T?/^+D"\$ZK%|R1
MI%224DE*W3RP|_FEFR79E&13DDT")YOZ<":|E4Y?)G,U.G#|J.13VC=7|'MD
M8VJ|H:AC_<7YY83+?MAY"Z?6_W.%GG)LV3WE?B?DOI_V#%+(%>0P@+)0U*_
M\$E|,4XF!PP55CKJ""K76|E,KA9F10!.B 36Y \$L;|Z@H##'4,6SVD=2/,1^(
MO@QFZ@O"D@A6D*1%T23"46.#464,E@P+(%|:# **E;28080HZ&P60H#Q5HC M#|
(DDOYR!|D'E\$@-E"TDL(7-H602XD+M T7X (F>|*?J"|,F\$ \$D@TC>;3"!R M;" BBB#R/I SQ(
(@4!2R8%# MAG.98TVHW0>(A&D#/1FOWA>&32"20*10-)E Y-A !!%8F(@EOB3#)@(1\$
M M+_O2_|MFC D84C?:#)AR+%AB'+0.\$@QX(A@0)7* @;) & NB-\$P69*BQ?|H'()>A+2UD
MPGD,*320!F+ "JH55A)+|/9BB, !PS"AR&Y09-#S+I-DN*C=HQ;W49\$|7G= M!<"M-
6CJ6Q;&F|5LYG_*IBW/9K-Z9&\$VGV1EX-YL.,Y;?=VU4X|/QDRJ1U(| M7H ZG#2.CL:10\2*/
2_H-3>:N4":,;%0\$1PB G"F*W-=|&%M/Y_T-NJW%NZ
M"LMQ4GBM12+C5&B\$(*M:|RU%%LJ_FMC5^LKP N#5K;7%SP=")OWC:-@V04FB MR;
|19(*2#I04D#ML= YX@4:1>&A!(>DC\$)*HZ7\$FJW-5,E580AG!N0Z1-X*
MZ\$">!U>H90X1\$I+ZS-ZAA& ^D#Q|R=&P;8*21)-|H|D\$)5T_*,^=D@4%&G)O
ME6#.0*XT P)OCR8J|O|+ FU!B46&, +0APU'HH48"B0D%#GF,H=A*B LG^H80, M*.D|_?
\$M0E)\$I(<'TTF).D@ "5>F<\$H\$#(M /7V!L@%A CZ23B*)B+3|< M"UPP2
DHXNB0@EMOR @(&.&,\$,AL4)5.CVSNZFFZ(QG0TGLYB7|?@. ?DG= M2.I&4C>.5=WX^<=-
DG>BT%#E\$(J!UH;:QI+S8!\$#@=-6"\$M\ZH)DT|_|>B(
MQ:4J|RG(Q*#|/"#9M/2'X7_Z@2XC!SE.?3BVDB7^ ^+;8":X27"6X.E:XJMO M);(J4+)-
HC319-JH\H6*TENFW1/N\$.8((.F(U\N1U|&E-(!1) A61.9ZS='X
MX.2'K>GE=Q>|!#61JBW<|_)J@(|%DWVCRA4)'TL(/FVR3*\$TIV3>:.*&B=%_<^
M=RER_ ^Z\$@\$ (2 :B"!LB"&Z"5LT0+S7*R5B_SX(2"9_:|P%,-9<|H^GY@|O
M(J7@D|J.C/M7,W-V.\$^M'Y*&TP-YEC2 TG1Q1P MK|? (BMNT7KR_4,S#!HI^:82DL|1Q
7E@#"2U)R49I PZR"(V%6PJS|CJ6R M%.>NH""W'G6HS170-.? 8.*XT(Y91)
|'+Y,0OG9"!DFBZ2,"MAUF\$09|*L M@|.L%)0|;+)-HC319-JH\H6*TGVI_Y 90G4A@'%0
LH"*S3+\$; 2"V<(80(6 M3^X7|?
SJ/^,#C&G2_I/VGR#K((@S05:"K\NV.:082(8@)0Y0)W(@2R8 H0S M%KKE08W7!D|J.
(_D^2&+,SD@'"?ZFD R2>I/<83)) *E;Q800!=R!ZT",W-
&E*SZHI:C|*UHOLD*0#27J2CG(XDN70SA| =K;*ZX4D@6"3QW YY6 M4:MR": "& E""9!&0
^>L-8,8EQ00/\$F*V#)X\$#UI?1+H088'2,V9 @5CWG+\$6@*M&/-2&D%EMP1M_,K.T|;?
\$@ MSWLRON=P!\$O"SH2=1T|B"3L3=FX1.VE1,(T 95H&Q(:D"M2@-P@Q;C#7"|
M|2P|=N=C PPZTEFV.%(EA|ECFVK\$=&SI1H=5R|8NW%X|TRKD1H;E|5E:JE;
M9JR5=K..H\$&&(28I!>RE:.\$3X! ?!92<+/?)'(IG^U OEZ %|/^T+5H\W*BS!<
M"4@XU%5>VDF+|R>SJ+""M9<):.|@B@0S@*/J: M)00;.,@,.,H9) KTMQ|=|S?.P)P1()G!@
J._4|>K*3@# M5". '6IJ0SBXDRR *E MI(5R@=:L-2IH|@&- Z1M:) ^ \$) 4&L (EE)(JYPU>X
U@NB MD%ZF_6;|H(+>?SHF|_*;683QJ2"6L,#_&O%"X'(W4|6=275,|#T-/ *GYOKO9
8J6GI7I5N MJF9JHE9%3_S>3YN3LP)3ZN%H._| ^U=SEUJRKZM%\$GG
IPI/_"!L7UEF_N3^) M/U|_|-<|OXU.|*._ ^M@OYB>08|C|H|\$W>OP7TUNGMTYO?

>!O<,45W%GANLF M^'ERVNLN,BE%R%Q^P>;>UEK>
J^V\ISU>&CG/O\!+O_83DC\|M8\N?7FS2
M\T.YK\|W01(Y>C*R#SBSFWG=>/=,TN<3VS>+_!!1Y'\$@RK\|=A\|MEJL_/QMG\|M=YV2.? 6#.&_J3<,0MU"@[M?|9E/-8(YC\N! R M;
<@)X+AVWJ!;UY6W%9V0KC_VG12#H\A%75Y/J;>PACHV?@Y0\25B\X>;<[
M?'V^ZW%:2I O^GZ%>M&C1HBN-4 ;!/:CZG,||=N<[,%JM4(VBI8J
M6JHHJ:L+|G%T&@=%-Q7=5'33SNFF-JS)XVJGD_| (=G=<.^W\|+M(CMVTLL;?6 M6M;?
(@PG7W9KJ2U2JF^U.V/D.?>3W5;R?TGLO\W'83Y&C1FBD27\$\$_'(&J>1
M\=PSK\|F2:T>PR;I<@1)1XCSA5'6GF.+;:1>)%M&\$;U46PZ:BV-)AHB\3N
MR&&T@B+/B"<+BNP;BF#O?&1&(F=1=Q@B8P(&C\$BE4_*,K=:HPIS)4R0##\$? M!>
(Z6.0D8RAZIJ)OQJXE1I5O\$-\$9\$"(@5\$6LV3!43V#42254XYP5"BC"#N M H:(Y
09R@EU/GLJ*R"25\$J8:X6"\$&G@'N&1=)A@99R4VRG@RSN,M*3% M>EL\$MH!(!
9&V\60!D7T#\$8^C9L0H9 *CB#?UX#E.*)CDJ;52Z417/!&,J3-8 M(.,UW),L@ (BTN?
>-9%'PX*R46P-1TQ%:% PI&%(PLT\63!DWS#\$4F(9X1;9 MJ%1N@Z:GE?
D\|C=+*1+GF*XY()-1@0)OD3>Z?YB.R5 BDO0R\$Q\$ =QMMP1*3J
MP/@+BCP.BFR\H=EBH:3F58^,6XO%B)KW+0X ;ZQ(4JNR,%Z/!P/XK3J?RVPU
MF+8MK\$;|:IBEMZ\|E9|>=Q'M^LF8Q?0HIL+O;%@<8"+2744 0EIP,5 M\$:R'7.
<^*/!8@TTIRI4L#,L2=B9@Y%3T8*6XA+0Q',48M00:.)Y_LDL4QU6*7
MAL=*Z\7I%;GYZJ9*XS/>(:Q\$00=&; N4%)YL&T\6*%FLU!L")3%*I#2/B\$OC
MD25>H6B\52%J(H6\|B5224Q84DABSA%W+=E43.>>N)\$\$_&M'4HH9IT6'%E
M\|T=L"Y04GFP;3Q8H6G<52IP/,@EI MP8E1 #_ \$:Z2\QHARJ2+AG&+FM@XE1'2T(
5)J\5J"Y(4GFP;3Q8D671*DL82 M:X="R*E\|GE-D\$D^(8XZ)"\$GSL-H^Q\$61(K-(6J0
D<\$BGTBP"/ODF6 VD,"W MCB1"=Y0N/LG>2&U!DL*3;>/)@B2+^7V!*4>MAVE1\|'|"#^!?
4 F_16V"-2%9 MLQ+>HI%+KS6 " ?'A)" C H6*6FB82')
<*41U3:01!GNL.V.LFU1H84GV\;3SU257F^8 M;|M//E-5NJT ?*!4A\$<(HY+Q"ESR
7!\$7QN>%36 M8;92=N|>&05/'(GNJ-HJ1WTV 'X40\A6205?+
(7C>3^Z@08%LW:#.0MF%0S5:7;O^5 M\9Q;AI%E"DQY;P+25"<4M:)"&4DE\$DI)2TB2@;
)Y(A\60)9CJT5,MK;3))
MJ5"QA\DDI5\|L\|R',AH',P_.1#GHVK8\|:AFG%;6Q3>CMA!;O*T6\$|/7*,>
M:|&|04\$FB3@C\$AF2\$F(&LWSH#@L2'CT?9>.G\|(A0'4EL.PREW=\$LN^;^_X"R MD\Q>S
IX%A8OX%G \U' 4R9- XD\$12LTXLXGY(2FB,1@G'&1*[UZ7F73B3\$;
M\|T\J.TRK@IT%.PMV%A8OV%FP\U%"|%"12KK'(OSQSS-T(9)F52)*H.*,0:64L"
MLLY('KET6C^|:|3QVRQZ8#77,!SZ^"Y\4)\$3Y9JM%^Y8&||>=Z5LUW;|!&: M'ENKWD0?
SUP<5(QT*HIS2D%) 7L>%A\$|H%EQA?|8=>/>.*|_:(5Q=_:/E/S
MZ'KC)8)W3R+X_(&2!;+HL@F\A&18,VP1)U9-5ZBLY8*KY%CS.7C6PILG1!S-M?
R//(^">K5LO,Q\+;|K#QJ#Y; 7#KO=_K>L&C=FL5#94;R5\GZ\7\GO:\$K M)"V>?
N'N@FL%UV:X1G/C>< C9!P%C,HI5S4)^&ER3';):4N\WEP2_P%J\|M?WE\|@)KSQ'6N,-8
MXV@0MBGE@S(,N20L(N"2!2X((U:M\|.FW.D*\$(WFKV"<>8PTUQ)%XJ74ACK&
MPS9@S72D;\$FMO%T2_)K!:=;VE\|L+K#U'6-/6)>DX0Y'G/=&(*3(D9R,I&5RB
M7'D75Z*04M.6TX#@+POS79C0%4(1F-2FYGAC^M6R)&IVP\|C\|M:7W(:89J9@._87
/H6BH0U: ^:X?|C"&,|2MAR,4NS&GUC7C.(^#%|_Q+M:P
MFLXLU,/SKKUXF;KQ^S(YPRB|<|K403P\U!#H
M!S1Y;| ^)O.4M\|PJ.YHWDDP_NG*\$Z=*-07\|HUY_%"<:|L\|G\|E@RVWB*&!B M\$7>.
(V,C1C8H 0H3<\$&Y%|7WL^|+KNU\|^<|7L8?^_.X6+5<+F5\ZC5\|D-7I MV';KA4Z2S;?
D557W?'<(<)OEC@=/5F M?H7W
WC'9\$DN'I+NO>%!+HGHZU/@VICS<:^33K#7PMB#7%Z9T.UB M.;6\|HS/XJ#VLT^?
VJ#9+GK/+.T\|68EQSPCU#N&J(K W\|\$K,+2-0"D:S6 E MM*
(K\|81B\|\$\$E,*^%)@YQ9ARRC'.4--81?J00S9*A_3E^C;UQ;#+08_@-VL?
CGJ@QQN;*'_|VR3H_@TQM'P)!MJ)_#FW\|H_|>+*H(%?@Y/'0W& MTZ\6#<|AZ.
|3N5/LFC(+E;6Y Q,8SA8=WQV>|95ODJBIY M(,IS#.<'J28?' M(,=>>'7>'|;-LR=57;|&
<(R^9\|F:LUH\JW=#,)75\4 M+V,K;1#&=^C!4+S!T1"RQ)67)IYZW1PQ6Z=6F*-O?
72CD?|5|M?P+I//IZP M8G.
QB8@_DO;_680AJ|>_#IGVFNC'9FC%KATA=LVRU1K:Y.'<=2WR8Q
M9U\$/W_ WV\|^_OSVN\KU_71U^>%,=_;|+=&;H\//1V^/KU7"FZ'19>WJG2#3
MAX\G0*.3C\7KCQ^./|X_>G-X\09-|>|HP^&'UT>'|ZOC\$_C@H5@:PZ2EX4^Z^??
>U92\|C.DU M(,WK'.M& RWC8!;??#D"=.N\|Y?,'<,#< VGUP-S=NWY,+X\J-
!PDNW4'0\B@*WY^_
M\X5\|L0GJ/KQTQ(P06UZ/#5M<=UJP7\$>A>MO+X8'%&,+CRT1\5^W6%7ED&2G@

MT:X2".L)UL'06ITVA\:/2\,UZ\7M;':.3^0%I6%;+M:
/IDEQAQ:I8\%@X0>S**7!I'8V.H12U05SPB)R%'I\$18E7\$WO-M')>CM(-92VIV
MM45@=^0L7 &19\23\43V#414D(SA%) .F'''NX(<6UB.6-'4,1;P2JO:I!W# ME!+D"+:
(YIR&G+N!E I:WZGJ^|I^=MP_?9WYSXGH-Q!#)G&:S'[/!!I)S86RRHVBN:(>+EK2I*
():P*. Q -IQ9 &!/?"PR@IK?.\$+1ZGPV667P\B9P+\$) M 7.K5CH0).F9\$ADM7&YY+TSN11
X2LG+0)S\$08BM5&IF'=F6#@3I)ZAE#W0/ M'-'^Z#0.JFX_DS8.SJIN;9LC)G7Q.??9;-
B=#FX[8EB4WI;*- F2)".>"08 MV\A1=:?3M9+S="V?O)V07%IHAB*#81#EMK)4H>
(I2I#1AJ%\$P1U7CD@1M\I\$3@ID.T2WOGY^CK)>MWIWT ML'I<#:NXU<%
(&EW*>1=2R\$K1= WDF9&0^1**T2MR%5_P,=VF N4.\$Y.66P3
M"5>MDUP0,SA#D(PZIYDIBRR%W[P15E&OF);:;#:#,F.QPJMIHGK1;\G?2&2G-
M/0JN%5PKN';3&1R#";=8YE;I#C!*1.2D,RA)%8*F/#(K5\I@*&ZLEG"/"X"% MF!"D.
<[A9ZJUTL'&X+>!:X1W&&M)SM,N2?YC.=ISYAXW5<^=3W2Q2&;BS\W M3P!&ZP^;+!
<|V!Q#NL^<[5K70)KK X' |O|TC006*% MGWD!
I=-8Y8UYV\NH3NVP:01Y4PY|U*_|\$@'M @&K;_7HM#H_M:!.?!PW(@V7 MY^?
4,))56UX>:>R9_W>E\EN_[3_6_;&PYCK_JT="=<=3S!|7/T|KXTZLF
MGT|KXO|RP\UP#8RXU|"5|<+|*I",1E?F+
(/7==^6;ZD.OS;U1\$Z#;/C;/PX_?'A_5&AW_Q%5/V=;*+>4^!|I%YT,X3/0;E(8LZ<\$
M9LZ42<|GO7V&Y\$/E&8+ M/\$O*3|Zj\$%|\^N= |,8!S%\,KS@6N<>.'P|&|
<|Q,4L5N!+_15'DXX|IAR> M|A5^GS|T|6&Y3VM_VKQKYLQ,:BO!=?
#M|/=A=6XO)F_)|I#TQBDWW|OD=^0| MTGIZ^O77?\$ _PG9S-
G(%GD0OCF;OFYRS81Q4)|-Y@)X8P(?-D#VH=%OW9H^84B9C
M!U&O;B1+/:QR\|J0=4>^+?8"FBBQI1=\$.^CE-F,K|#@76::9|6PU%_T 2,1J#WA|
H>OP.8%G'W&XM8_SD M>,CHM:IX\$=&X'HXLJV)\$|J-[4*<5!;.H4N#CZ%F&9ITU3;^(5>-
HLC>0Y9*A M>K|N9H:">VS3@Q7^R,2H)^N8A|AO>L7-2=CE.!\#Q_W5ZW_K=:9?
U(OKE6V1 MZ0.&%J|UQ@F% <3A@O73.@Z*DXG>:99G-
JOL>KU847RT_*E@SJ3NY^)&#> M7;=US-
R^KEL3!SXWJ'IQ%;3VF5(/087!E%QSSENPI>>H<%6|+<'\$Z-1FI0U*
MZSS'F>.UO#^*_K0',_|2-|KQ\$AZN7GAIM(&=>MTT0CO7+LAD!XT'MHOH'J_
MQ|/S1O%,+-&3_GGM*XEE MC%_KG^9J|+_YV4%,=&!PQ\$HKVR;|GO7/GFJ!6?3
MG31|_F&1|K9AWGX1Y^RDF@>T_0.0":Q-"!; 9QD;Q+!-QHDVNC&5"Y(j MMTN(@4?
-9|29FM7+@Y|BS;(B:ZB_9*\$W+2|I|W7";,I%LI? Q^8Y#(%CJF9' M+D|@:G\$?
M,E3V8"QMR=B_?K'ULV*>%^QNY9YY'8,8>GBJUIA4G7H7^,Z,^NE M9=('\$,
('_&'V+|ZTB6?G MN! 6V7R2WR6J&5,)<|R2Y7>?#LSC(?IB|?
G+DP%PQ&\$O?,QFXN&TGO+G>3GE M3WW@JXLK+9;7W2|?DJP_I\$GDNM;/G(!@J_?
BJ.C)&P@S|QN=M|>;4MZN|LX5 MR?
2C<6_ZH1N/%D):8S!V>J>A"WA|S".S\$?:@_H!Q3(83A3%|/#'Y^P:51XT* MF !V/6AB4@N:
(0+5_MWTC?QJN^.-I-WM5J-8|@0;O< MF&XEE|*MQ"WI5M(Q\$H%F?
NDXCT=:Q#,#FX^_M8NWA@M|<;K-E.S57=9H*QW)"X"B-NY<|%;+/-MD;E0YS|?
I=:|J&MF^SK97O#;E@579 X(FTW!#K M\$+,Q@N48);
(V461L\$#0%XDG@F)""F:#_'S#L7T^7^! 6?@26Y_ALW/#S;!OW
M77_PNEGH_WAS9FYH,|^(#MB#;8#;0@>:&Y \$=#FP",XS"X*8-9/B6A\$PLQ
M<;P)I&@|X|JRZ()/>|U_&@-61.\$(TL|EXB\$1|#6|06+MAL1=-
":N5'JYCW_:9.O/5KU9Z>'\$\$YW\(/&G_M;M^| ^NN*;5U#\$';AC==9BY M97SQ:&I-
9L1359B^+07J6+;>@R=V?G#N+,4KHTC4 \$Q|UF@|5.XOJ3P/F|M-
DC|S&)>=G&G;Y|'I_V5T8TFCFH\$13G)#^G"%W6J)QDATZR>UQ,/>WK/-+MG
M|L1LYS0#FXZB.770F(0S|W=X&F-3!WTXB?) -S-1L92U/-4PD'R?|QYDTS7#@
MT=TF/P7>|D#PNR&NAB53-%&#C*8*<>(ULL%9L,\$35BEZ%>)*,0\1L"&\$""19 MDME3|I
S?"*+Z&|((09;VUE+?Q:3+/3TT\$= EET#ZEV\$|R\$4=AK'7\$HZ& M?ZI@+RY%_"HPM
CT@*D>SB;+=^8E0?5W=%H'4&,OW_VI-67<*XJH3> *2YN0 MTU3DWQP7S#;
<9%MT48,*U;<8_|H#1=|?(08J=>-W%.;I; PW>'AW?-9|%>KA>==>O,S?
MKIR<.Q!UKYG\$M%#+Y(.|LU&GB|E|FEM1|(57Y_UA\$XE|V:@|,*|>N?|W3+Q;
MD/D1O.|W/%1'Z/KH^+!FHM>|G>H3,**38&>)IGHI>U^
PWZZL6OW>'3A^G@"-3CXV6?,?WQ^|.3QY^Z9Z=_3A\|KH\WU?\$)?/#|VP|G
MQ|7/KV=>U""|K|C)EZ,:Z6E32L^HDB40';CTTN3J);9,*W!T1.YKY7G'F#S M3|GB|HWI-
O7B?_WHU7?V|3;Z41N#EY\$IC,|J3=F@|I\$@;#R,W,/?-DWOE|_|@.PK,T>7G9ZZB;_8>JH7X.
M/.7G/*RN94|3T>0E:/WE|?L)_|E-9&4|B:7C;4I7PYA.L|YY>,GD?P?@
M_S2|O@G5GP_CRV\$|MSFU;;FB17/?B^N+|I.7SRQ)>#E|RHW5|R:OUOB_,OG3
M(M!.9SY!VE|_>#|>^41R_D_+(K|VUD*'^81W#ZYCS <4-P3.Z<_V+ M=E826MLLN);

(GR4HS7\|=#VPG 9P^|6=N0^!+YFIELF^/66V%,4;X)ES==
MYPOZXL%TO;U>ZJY0_G&9_0>AZ4?
@|KN4#G^"==DVMV^O=8|FT/XQ2C\$9<1V^B|_|@_C5 M;AL AV&2&;^F.5QPON#|X^B9
N|/TP36\$TT|)T@J+A|/R2-X?D!)Q42|C1@0 M_BJ|4QY"(MD&\$ (0@'C3<(RQ&
/D<:RORF;0|P_NG|<"?VN"-B?SWPWC".A++ M O(|+47D-^TZ)_DLA|I#:@:34|&# 'YPZ+-
"%|!>TQXI_73X_'EO8+IS|E| M^/DA^5D/:17+L=&)*1";A4;"\$-:>(98BLIY(1EVY%\$-
E_Q,OOYI'^^DX?W M;%U/.KH548F|;%CL4.3P!|N96PUAE#V)-?
8DKIY4*KL2^V>R|)!N*;L2VPY; MZ! C)4HCQR5&""?>DM23\$1O>@I=26ZN
M,U5DKZ09/#|C;^\$.1 LT|AX!/?=EP*!L.>[+AX 58\$EPC)CP&TT)XY')NA%>1 M:
W>.N;L4Q/_QQ5>.=J)3M9&2+|Q3(5?*UC0B MK91\$28\$EP
3GU*T43"9"B^!|Q,_%+BKA78&8X+9&5F'MM-0_I3OF_|_I0F^|J
ML#/%L'>CBCH6P!LY%U9ZE8O2!H/U6)\$?=01M(:WL8#:\$8!64|X@8X
MRUBP2+E025,%3':WL|B;Y@UZH':#-Z;5N_PUZN|JMXUO|<9:R=?
6&>|O/O\$HPHH2SB&#@1HZ4!R65\$@K,4DF=JQI_U=U^|F9!XUU59VMH;W.VZCT(>4_KR
<%X3P"UU.\$L=SEW* M@WB<')1%)
|44XVP;9NQ'E0Y.Y9R4?)*%&\$ (06\$>M#6)14<0M3|BQP!"A5&':
M@^9>/%8QSM|_#9>LU(4|"KUE/|VK?TPUW%W-R2&L";PVRT6A6G%
MN98=,NC;>F:EV!4;MRNFC;|T?>_J&!^N75V61OE0&XYD+L? M%@L-2>(8*:
(A9_YXDY"FQ"&H-:4*|O-,GG;|H0 M-:00P<8-TKM|)(?5.E/S>|!|
(|2K4!|?;%2BABFW#SOYL@;1_K09<;X=- M*7#^)'!NC(TD686|"@|>Z>1EH(BX4*
3X@V8J6_Q|KG|3>U'_%#4&>|('I) M:BB(WN;-AQ8HW#W"^;+74/8:|F.O05|J,18>F>1-
SHY(R%C-\$0W!*|X8<^|1 M:I\$ _W5X#ZPC9OEI>9: ^A'+|H^5Y#J0.Z9|9*J0-:ZH
^@5GAC5;.)XH"=1QO_M91FRV.6R-E)\$ZJCTWCY6'="-G|OH4-Z^?
J7/K1#H=24_KR|0.JN\$N6Y)DEQ;
MH!0907:U'E(A9J4P:4Q\$*^\$B(IYKQ(6)R&J/P8VP(FKCE*5J\$Z|'N_X3,|>
MZ_%@\$'O^HNG,,A'BX6\$O-'|V)Z462|'2R:7Y5?>O| #FEL%=-|JK
MUY/:4\$T)//5J6*5QKV%!VVUJF WB>1|@(%>.FE*QJH=-!9|_#HX/0,MWNW9P
M4"WR;JX|E:8DG|H4&/&#V,0= 2M"MNCs,^)W?VH7^+.XH53/:K!8"\$E_4G
MI:MRf:I9Q:#1Y2O@?:?Y8<-OMOG:&4ORE |GS_H&P,"7_(?|/9)O=(FY+DP
M_,;|6!K*)JQ#,,=N&AU!LHMU|UJ:GE0_F;^S""82|59: =C;*9P*,O39NF.Y?X&H|@G|F;
M8!#|SB8%F-(|TW#>(|/+:^&N) 6F904
M4B0Y#>+)*%0^Q&=9)C=XJR|R<(-4ZEK'5%Z#KN@;%B)NR@%0".=@4;5!RLF<
6DD,A;4A:?!1H|UHW0CX/*Z MW|OAG@G>?ZZ'?|T>Q
!+ "K|=|1^N%K|RPC_)&N|'=LJ=+F=-@F7:S_L?L?, M(:M|8#_7X&*
S0PL.+%/1Z=@AI_W|S7P5?=K*6N MJQ-+O)M|DT\$FR;#|H6\$RX&O4N:--&O3|AD.&\$531))
(8S_I@^H:Y58,<7'Z MR|8W^\$7UJ#^8^&MI3G1P AJEG5V8YN7-_7DG*WL?
<=C0M(8567C?HM*^7J|) MXKQR1"-#DD<|>;" (J9(\$TZETA\$4RH/2QV9Z|=B?QC
&RGU,2^+U,675|MM% M_OD.H*8_N"E>XY %>|53K_U2 &;|L|*\$ M|/7-OF^,..|H
|7K@S.44^!T"\$)6\$9%Y(S12%KGN:8N\$O,@^&RR%\$|. @:H@ MWP\$LIC?
UT(W.A|/\$3W&0V@Y?S73|%"U66"< 7\$V M%;DT!#DP\$)\$70>(@ P&3|_|&%(;8|195@P%
(F)!.%%5\$8!IX-8"RL5H0+H=E*
M_XS|6+Q|.D5R70;|1^TQPK^:1YCZX|:4*ZB|:>5!W#YTF_":G#!!*AF"+<0
M\$NK<&A.ZK/%JU53>3_3_F@V5.^OT4G)|TN.,WQ@R/IEPP_DVN7*S8%0NKRX
MO'B'7UP*T^|!E:|O.0B0.\$E)+S3U5R_A|@_E905S816U!U?OOKL06E4C!@
MIY:K8;!C80_K\$|/4\$+|^XG|1|X7I=Y?IUZR,59B^,/WN,CTM3%|L^TU+5SL7_M|)%
|M4TW:EL@3|NBW';!&2M0_JO M%U|?
*5XONKWP^W/B|Z+;"Z|_%UXONKWP^W/B|Z+;VQSUO*6P6^L2&K9>5VRC
MISE^|_|=A|_|^|Y'%HZ6DW 4|7^J\$+9P?
8%RP9(Q%0C*N(!):8)@PY%2(2QKK(O%)87M?:9/F4|N7Q%+*|RE,,JA(
MV*Y+X4:YYJ\$"6&V@HY%'(LX|K@X*LV,M#\$@2XP"TO*ILLF 8%KEF>+@"+(5WY\$0*XER
M(=>D2'/6*PF\$(5DDDEQD8@0U|68?GQQI\$4A!";CG2 M*NAL?29*';6.KI13B5@8XF5?
N,HS8A(|1%V%\$E\$@M:..KL5<2RAG*<5QX/CY1-
MA2*.NRV.4D27&-8@B=+D*IT4F:0UDH)2D3S1V*|T_.26.<4#18)8|.UB(LCP
M8!!+AEHBM*!.%#^MB&,1Q_MWRI.4J"@U(ExX\$"TP02V1\$FF)J4E..<)>7Q-\$!
MFB:O)6*6<,1E_W*8N"TU|/#+|S95**811R+.-Y:'\$F\$804=\$%_|V2"0R#@P
M6ZVDQG.*G73QJC@R%;V+6B&;K,VUL@4R442D&>% "V40#W|X>W|V|AXHX%G'<
M!7%DD8!!"N*8&/&(:V:1"|8@S|&(:C 7_\$H!N5>VP%,VW:K_XJV.S|HGK)0-A=V#9%8T-
BSA(QD M,|A^D&;XH2H4I:FP"3'= 61A">8&(>(R-O<7":DM0U(*.H)CQZTS>U|Q4KX

M9\$?T6C\$0GU<8\1:*0\6(4XN\|MQI&W>7(A\,6H(L78E1=IA;S6G BD/TIL3 M,4&\$M4
R)*H99090*2?3%'\$LXKC3XFB\T9:HB&)B#\$1+Y^Y:SJ%\$L!#44=Z<M/KAR@\$A(:D
DD0_9Q\O\|N"O<9043C9IHXD)6SE 5/RU(HZ\|+8X<2Q\$QEB@Y
M3?)A((Z,L@ (QD\|&1"&RQ73FQP\3GCC)D7%)PCP41\LP@P:Q43BJH>.U\+KV
M;T42F%:0L8CCCHLC8&+DTDB\$Q;&(FR20S8F?EH&=F@@)UDY
M\I2Q<|%PAJS)*30Y.\VQ(%\$4F"B/B39V*|=KBSCNR.9";'P)"OWOVUO.(RE M#%+95-
@))&*)*B,<\$B39\[*>!84AE0HP"9,(PML5AUY%BTX9<@ (1A&7V"/7 M"H
-/YS'F099M\;_19,0R?5!SA<3EB\$KP#<0Q4(D=P_M/F@T1!"KYR8D%R MD%WB.
HP)\1!GL&W\QQI(Z+\$%EP_R'U/;::DD4IP(Q#'#@);!T%%C*YS4F'&V%3^--%7\$LXKC3
MX@A6IJ=<,)FB6:TEB-O.\$CC(I6T\QO"!%74B)CC0:G M*/%H%36,KD0S%+'6@54&\R0.
!\$4L@Q,OD T,;" U*OM%.8J\|YW(ZY>DO:~ M9.5^J_M?2EB\%'+'@*B81H4CV\61-
R3D>6)%3AK,14A MZ)7(LDXF,F(IDEKB7&Q8(I<<1QKP+B;%////;*;Y1?~?B.^~*!;_*
#1+HZ\ M(454I&1R59?<\$<.#\|*""Q&;E/).F*26O M W+1>,0M,\A@HI%D-
H+QEXASY7AA\$<0%O"JW_TM@<8\Y=S;Z8^&!\T_'FL+|E/L\|>8#Y%3"??#J\VO^
M>/32CD?|5Y.W&7.YY?#(G;M^3"^^,9S"W(3E\+K"U"K_6P=G6W'EV\G-US
M8R1^|AY^8&1^S_=,H#RDZ12!XM\?O?CUA_>R \NK88<*ZWFV_=LS"PJ!O8
MF9C2NF')RX\4KZXJA-G?S8J"3"JOJB7@VNM40.RCN3PW\|X5@|R&Q*8UX8!M M\$?
QQR;OE0,'U1%WH\|XE\|CZJUK\K\X7^NZT/^H%
(,0(1C9END^=Z/AS#@.*@T+S7'U7QNX\Q5+.U6QST\HB>PKY+\$3.3 M4SL3M8@|)I\$3+
=#O/8Q>"VPN6K?"8U32\$XC(5+*B=<\$_.6,Y(BJEJ&SBO#Q*
M<:6C#^|NL?!N2)\#26\$!\VJ2@/&J&)&1.1_!9F4T2K\$U0B/LX9+J9!0/K
FXD',55M=.##@Y+ MI&S3@0-3Y&3R2)E \$ICMD6C7ICE&;K!GWH&"D/DD*,:Y;(E
_4D7A&6PONKJ M'&U2C\#O\$6-&Y'P8H(M20"8PFYFGC&O>JCDJ+S3AV" I>02^R^4WF"
*.17!0_M*J0CSWGFG#C,A Y^11YAH;VR5" 02P<^)<|%@F\$QI:'48J\X"%O2.>2Z*AF/
M\L\$J7#PBQOU4\5,#7Z_ |9_#&B_Y/S0EZA5 7G\|DNU7=JZ+UIU6&P2_ |P45E
MA_D&@+P9\|%U\$.QA6L1<ZMX+)XY@\$!&.A7%E#<_665\(|?|'_EV@,88#IYX
MFM6N>Z_-NQ_)?6UX,|?|\9VRH2A_CKGS0\|C,&MJO_CI-5<#"?|?^+?R73L<
MYF#*EXB675Z8<;Y@.N%_HOJ8YOM+Q%ZE;OR.0@U657Y>=E_'9\U7H1Z>@W\A
M,G^|8H(>9'_SSW#J"\$X^&^"?88'6ZF\$V\N14\;|XZ\|P_KYMF#V(5!~?XV+|N=F
ME(WW>:;>%)_26Q?C\VE_Z>6NS_@9YX1UZL"!N<#0Y!*7*7N M=>L>#&QD\|/PR?
(7L.Z3CR>LV\$0!;+BO\3=;_9B.TU+/+DDH/4<0"EZYP
MVV:9:FUMAC".^C:9D>MWP^,LZN'_WH^?>WQ\6G\Z^KPP\|QJN,~?CL^>G-T
M^/GH\?'B>F^81LV\NT.F#Q\|@\$8G'ZO7'S\;+8?EF1ERE#-R;9HI*>V9V)2\EQ9Y&FWT
M6#-*W9\|D45::Q'%3;(|B>7IEAU"LPVK.H1 M_'FW3@<(0?6%CP#|O@*?Y\|/-
X09(.!IG^@^S M_=7)HSU'K027!\$G-X6^'^=G@.EV^<#JO^M?1V'G46\|L.K69WDD^2-
|UA_# M=6 '^D\$,=8YT@H\$XQJ,QBI?"Q.|?BC9<(0AG/=S(+NJA-Q'!Q4)|>8GPOC
MZ;M_9L,_|JL(;@R8\A\|/?%70-6\|OUO\8UC..B,32!EL,X^#IAO3Q&>UYG
M4\8APC#"UZ&Y^4OLOQIT*"R,LR;DB M#!E.,*!Q'!\R%OY10?>#U!9:
<5O\$*76X>!:.#'.%K\|H\|;\$8&A?(V-80IY02Z,BR:B5BN?WX929@_QY\$KE\^B?O?
T.BJ1GNZ^GP7 MDSX\$ \$VEXDMV?._#0Q93S;7MO.Z*
<9\IP'@IV%Z!&YCP#|)MHG;5\XQ\A>>#M
M<#T\|C\B_LRIFSZ+,G>R+LRW\ZWV\|V?FM)76O1=H7=_8.N\|&-6W#G_5B"
M\0\W9)>VZIO\K9%*J0!5VK=G59RP(Q9^&:U\|0'2JV\|L;S^:\MD\|V*RM^|Y
MZ\|T\Z=+|O\|H0,."V)_H.0\7)7V+HHE+U5**PHE*)0BD+9!2\> M#85"BT)I@9-
:BJ<|DIMZI^6;|G#F3;~!))3LHGB<|=4_//F(QM)%TARRYS M5!';O>7
0I9=YJ@BF'O+@=LERT~)3\(|5G,+2\BICH;ZW.4N\$,,4OCG\X+ M;RR%K6U>S!\Q P?
KR<#F2-|BVFY1HRR^NM??/C7OQ85W)|%~;(/;2MVMQ?;X M-
A\$BN\$&>^82X\$P19\|"@B5N-HHN&CT\|=OYB>G MV>+!;<1N.S?=X01WB-
A4C;P=\$\VGUU=%_Q?|7_3_CNA_1PG#5%NDM/((S34?M6Z7\|#.H85_5_T M?|'_1?
|7_~|4SXN;J#E7"(L8\$* M*&A?T'XO3O@?9V*E-YG*?5E=I. 3 MNI K\BADK9.(!R^H,I2HW
N\+2\!M3P O%ME<86R%Y1^?O.9\$7E+|:CU-(2 M(R0R\$?0^)S;EVK?@K5'+7
A>|;B\B53*7*#E,VUG;&/R+)|@4=(.OHF))_ZC
MTCY/KO*)*C&\JUDIC"V2O\|Q\9\|*B\A=4OG8D2)DHHDR#GTJ/R2LU<">8LG CX9-
M)518AFX)YQ6@+T"_|T O%"72T(08(#2_-@'0QMP C;R/FRKM(XTH/'NVUXQX\|
MNABM15P&BIS5% EFH^38V*!6.DEO\$>BY+-Y=F^6Q!|=)7E/Z^,UE1^@M*WV(7
M!O,>@M?W MS\|MH#Q&AG:(!H2-9H@K\$Y%UX&(ROJO+3FNB5Z+.Z_00>=_O?7E??
XTA\^#H MGFU#KK;3NLN@'|*ZE9:/BB\^FE\05WM_W&U3Y)MEJ,T WD.S4"D/#"&K=|R
M0M*G\QA!#\|F^/*_19\4YKT\|73,,+E/98\91W-|D-QH\$&R\NOJVO)U-4'17

M2F8^:4T>>7U-GG02^_8BF3N|(H|:Q/2!'3?V9JFV+1@%0|J5@+"E#AT%:AX)
M:FXH_18W^FL'H&:-CAY|LT2M\$(C'T?'-O|BT%13&U;D59V!MF;)=JV0+2L
MP/_C&;|;WR_>Z+|=9#?B877_JYC6.X@BA;R|R|&%7/O(@47"|\>V0L?>G3J_M46RTI2-
5^?V;6|6E(U7XV1RI>CT>#."W:6I#L>B*PM|O\NX220NY|H\$#BX_7
MCFV%@+JOG=.2^RRYK_::B|SQ1L_5<6-5#4_MP"Y0>JPAYSR;(M?
^Y0=4QZ-.W<'=)_@K';4+/4!#*:8<2MPLB2\$%_B_M26"M2-
1^Y:RVC|19HB.R6L3)/4X0@H@GN480%E*M=%+)>NNP%_(;R^5UN'H_MM1T,+F#L?|?
=?.)U(Z>S%>XPS#9O.'M_)';92|^DI
MX801U=\$"%SQY'#S97HNNXK@^9>NNWM&Y!0TFN21DDB2LQT'6'+5)F;=
=1<+H|U;JE@86|4PA')66Z0_MH'GL+A
50A<29@)FR13S*^\$Q==061>TU(57SKBWR:UW0(E76R)=FNJ8DMLUP7%D1B!/6H,"J|!
M.#_T)H2=8#|IW#K=;\(%;335I+|S:7BBE2\$H_@E*#H-54WF<*MH_KBOHH:F
7J+RCI4C*GL1.F86E%\$F|_M46._O=AR=GS?H DU!8TN,4(AI+A%G!'_-#/4
!U|0H(075|FJT25F'*68>8:H(MXM0;I_DE2'&.N1!&:!6W>7:<4MS1O-0BV9OX<
ODL^!)P9.")|?CB=(N:@=MHH_2B\$M-D%/6(DRT2-\$PH^+*[H73\$N##2\$0958CS()!CC*'
%1?>"HNIV":>M\$&8ZDI0D|)9N:;!3/=2<|UU*+I!@;>Z*QBHVQ71O#;2-
8U\$A|_|#IY2@HY,#*0_M4E12D4QRRFW"9|U2+1(A.IJ46B1|(LMD-0"* (4I"Z#
<""B42F&XU5+\$P
MMFMA"*XU|A@<50|6@C<>.8LQ8B8IHX@EVJS4(EG'97W,0^5*=Z@L4?"|)\$=-6_MB&-
!C<*4!35N1_V-I<;8(?*XJ^US%\KNX4|
MY:~5TI'%QMAQ355LC.V6CE1!\$1?|J+!,@|T0.7)6&S_T#-<>S_R^VG!OG1W#
M1RP#9CJ:EC)@>R.>+1#&@AF%*0MFW(@921_F*'B63_J.>/(4:4X\$4H%:%H1@
M1*|DF:SCESXB9I.C*=@1KN/|@;IXEAJ2>UD_|M|AF3=Y=
(6LBUCQQ8!+QP;"L\$_*\$;"J4<^\$|8='<|!4.ZZH^?TB|RZ1M)!K_M'SEP""CAV%8(>\$GD?
Q9VW*='!_QQH>-&ISKLVI X;T0E/%^SP71BL'RW='<^W#_MGD(IO+IO>W|D:
(T5&\$HRPC#P08KF5*V<%UVDU.E_@G|+Z.NR%_MMS/E|2%NK_(:E1W)9=D%W)=-^A:
(98&1_B,%1FZ'\$4DI,49KY+Q@B"OLD!%2_MHY0L-JP:'G7<1/?1)X\$1T1&JU#UK63)).+9_&
MF%*8LF"S@09B%6-.(B85Z'^FP+-D-)|Z31UVD4N_M5|D)K>.-/AYF\$-4QHAR":YD/6C9-
=|H';.+85_EZV#YZ%_M*5?7.V\YMH"%|0DR^|;M\$@R0323"@633.X#()#6\$?
Z4P5.=N*5,;*)&|Q,D_MRQM2\$N7W)J3;I\$|L%(@|L\$#(|1#"??7!\$(M(P
GQ("@R.C%\$B=32.QH(7|EP_M6Z=D|Q-".DP678=6KKK4%S5G7!5RVFK8F#LA|
(J=L56|0HJG,0LJ9S&)L!&_MT!19@BUBB1*G+;8V4VXIH^7.
<|U1Y!RVFIOQ+,%PE@PHS!EP8P;,<-Y:@3V_M!)<&<2|_TOG4/"NB_Q3=*3C?
BBCWA"EW0,*|U+6^:#ENW2'?-!1|;W|7;=M..T?TVR1-
KNF7_K|*WN=MNDPEN@L(M=T6|!%5>R*|<:X<33@=R;\$?/8KG?=@_M(UB)O
B6F61#BA09)KU47-/;^C@ZZOGN."/_WZ::T.&AF8=0|JQ|KV1UQ9(
M9P&1PI0%1&X\$D8"-<,PX%#27B\$OID'%.HR8'1P62)".<Z?.\$D1\$|Y>TF|9Y
MJV7'='>|U5(:D)@2NZ::BBFQ75-"41^T%8A|DL_LX_0Y3R5*@J0_E@4+8J7&
M|3K^Z&,>|N:|HTQIE+XW_MH"<2RH49BRH;.-J&%P3!9T/F*>8,1)<,@939\$ _M-
U(&PPSS?!,Z*.6!L&F(Q@OL/\$4+B?|95TW_J|9M3^,S^*@|O!WJ+_>|&GS_M_|D)+ZU|8|O
@\$(|17D4"!N=6W.8B*RS%@@%#69>DLJ&|5)EX%9*TUV8A2P-
I1HZ@QML1)G1B|*@XQ^J!2Q-XR?^MW:7|RH_M(DC#.=PT&HSC33XQ/Q",_?0#/UC?
0H@'G=6X625|FT0C7+|;K@|N1Z.97)I?_M|;
(>P2C\|13++#XGYF(4X59BRNT0|OZTNQ.EW04'5;1_MJ7ZJZM&P^OP_|=GYJS?
5^:#_96#/AIT*M'7UNG|&8|VHZJRNAQ5,ZK2"^<+M;+>A<=V;_A&G!#X
4D_|FCUR|E5^2G<<8I4B_)&KT(QBJ\$;|RG?K7E:LS1-A_MVI=_@Q+_6H|JN/P|#C(P
WNHA&^K.'A(=|U|@^~V%|HT8KP-CA@N&X"WKB
MR^1E^<&^/OPMO;9K77|@1_W!136,@Z^UCW#G^1@>9_-H@3!A;/Z2*1+&|"X_M'|2_\$?
-TT:G|2"@V:=QY41|W;2!+|SKO|BQC1_M;'RS*SI5W_LQ+(*_F#RM_R_(*HG&K1)7HB|.
("G|P&A3J;-|!7)PMIE2OTU_MO%RVE3&D*ZRP.(%+=CCM?X//|YW+)|5|YD!W\$JM#|.-
:\$S0X@7?|UNW|OZ|_0C6%Q!@.1W<=?_G!4U^K".GJ|.I_MINO3"-OR"A5@N9%H7Q:
(9I>)|G.68XI?'^M42&'S9_DU2_+JN1|+;|_ \$8#_M#X&?PQ!H8"*NE%5YJ2N?M:++
FW&HJ.!E*,P)XTE|QU_PLU3U0IQ%4VABF_MEC&D#TH_JHN_&*|6<--?(VL7^?
Y:|Y3#_|L;%>G_|@T|/=Z\$6|MCT?#&O3Y_MPNML:|R'X<[ZRE9FO'9_U7H5Z>-
ZU%R_SMRO.MT(\$SR=SRG1G:O+!A?#49TN9DS3W(IB+|PZ|P_KYMG-
TL)L7|G^|HRAF>NF_MHX1|/NA+\$;J^1%U&!=H@4^_0;+W;.!K"E|AOPFTSWCH=7
&5N@L&*S(VD3\$/^E|7ZS%|_7+WZ=,^VU|GKFJ_4N7>&VS3+5
MV@|ZPSCJ(>AWIT4|/|_?;S__O:X^03^=77XX4UU_,=OQT=OC@X_|T|OA;<M-

D,C,M_0W0DR??AX C0Z^5B]_OCA^./[HS>')V_?5.^./AQ^>'UT^+XZ/H\$/M?
G_[X>2X^OGUS"S[945>I@Q[4T!\$)2X=UP1H:33BTEJD-0=[\$DPX&3SWUO\$_
M]8KA=Z?;S(L?QV+N;3P^1R/G!+3IWYE-EBF0:ZRBU-/IS@B[V9N(79B[D
M9Q4\,:!5CD[X>.8 ZQGI5!13WOQD#>3#+W3)<)B^9-0'\$Q;N_8_KX. >\$WV*
MKNTL!2D=1E+@@@,@,%ID(SI'S-,9D."%I):B|C@>UL!)34_S&B+)7ZX%
[E'<6D(Z68VV%CU8^'3_07>&'1H7L \$LPYD60A-(>86X20%9
MZ2C"G(<40:4)RZLL(6GDTNN,:@!'H\$4",@ITBY(F&A:2#,\$_&4MP?QABV5ZT-
C25G*-2AVGI>.*XF1H52CJ)A\$G/&W\$K_-MF;5"8Z<J;19@-,<^X-
5:X;W13S_/R%HUZV%&\$^N>[A-KMDJOFT5U&7N)B M=PGQY*5!S=I4BXM38F!3
IU<\$[>-D1S#=#M\$N0]WG<7!6CRKXHS=JMA_L M-SL(34@[&X]9%>5/AZ.^_ZOJ-
X(PB1F!<(1 0'/<_)EUFZSNV>QML_?POG M<;9.;3PIU4^I3P)E>47G-
OA\$'SP_(X13#T_ ^M?^H)H,N3\9A/6G=?P:FQ@| M7.=!L5H8WW1W)H?
5*C^HFXV2Y5V(>C@< S5f0,V&\$L-J?#Y]9OP>![X>QM7) M38/_>9C9"(C|ORP.JC^ G29?
Y?I!#:VNVR18?-ATMVJJ-)IZN4"?->4/HT> MN230=<^;11Z'U9F|/MAU%P5ZJ\$?
Q.8=TW'DAR^&[?J#3N4B+ #K,%7BU.8 *M1)L1S|<#/SX;CC+U8-!QE)<:UF2Z[LW
FDT:ZWWLQD\$3X%R@R>PYTP50^&>R
MPP6WGP\$SS(C5/"G01E7#,:S^TGLI5=T,'MR8R39.%5.:(\$:5QJ,Q?#;=)-V
M^|>X'C0|,!E7|I0Y<2:T@^|A3,T&G*T'U5?;'3<+G'FAN7YQ,M.1?^N/NP\$H
MM>1(36D;X,+F MEM0.^#:Q7.091V^Q7.FCHZ/VNJHH\,:9@@@9]FGF!'H[7B9_/@>HYUZ
M@-!=:@M@9Y"7ZH\$6^0WI*EYS*Y-E8=SERWBIDE30#))DX^GJB!6'&U.0R!*
M822BBV!Y>W#.<;|;DIBXLXKHE<9.#>B|J_8X0#F^Z71!;|=7%[RR5]DCPXS ML=
[FV3<7?X)A|,248V&T;\XT\$^@S*;09;P!OPSB=7,I>7J%DN+;/PTZ)M
MJ+@8WK|KW">=@??IW04_R3L=AM4>|!N7S%F6@#;9&(-JUQ2(Z?
3G,%0OK\$WIL9H/1AF'NN! M?3_8VL'%59QNF+!SJ5\$;0V^J\$?:
&P7#FH/7'0V#1Z;7U<_U+S,2W@+_L AH3HC);FI_|, @8@7-
ZKV\$@3LX%Q'&*X/D:AJ3%7G+F MP2E6*SUCN5/*"X|H'R:3CI#(G\$,&LO'*I&C53|H|2H?-
C_ ^/M\$=\$TXD.|"*M!W*K+@+G#A1R*:UONY!FUYDYJ\$AV|#53JFB% IFQ+ F-P3CIPR
05'2=0Q M *?2JRR:G#-2IX2HS&F!4S>&T^?#ZJ!U\$SILR9:MAQ0F!5*ZYS; M|OM?>C"
(,.'-21SN7^-Z"".>F|.3A|Y"P#;.)5LO!EMG[SZ^*6X|#+=+E)|Q#_MQ--
7L[HSF/-5OWWO.|T"4?F1Q|4X%RE6.>(XC1K8CZQ^6-:T""07,\$(-|
MJ&.,+\$_CK4UL>DDN!_%KDQQ:Y|F&|*,FQ3R9@+#+?N?GPK+3PYE"G!"2:
M2GM->#F.X?5AQ7O%R+:T%_08^QC+W'8=6B|RP)R(UX1N)PLV;O)9;/5;U_J_-MT+\$_-I7?
S88O)\$_-I)MQUU@^QN[R%,,XYL@NL<^UT|,\$>0#U|"3#9_3Y)4N# MG>P49'998-
@|WAN+"<;YR"A.1!7|H?#PX|S?G:/+4&RT|&=1EN%>3W<<%,|T|JN%Y==ZBF-
V=SV5,!&U@L|H|W|ZY M?ML&*|NY9#"=*,HDW21|J?3Y"!0"0L#O-
O#%M1>B)F4C2.,*&L2T!2ID^| M;GH+0_D6XU^P@I.Q^-/Y8MUA(-/UK8=_H020-
#E5DZV*AADS3|STUR3X,APW M7|S#TO\,'OG\$DLNBF7^H^#XP-8@6CA41?511V|H-
#'|@Z_-7M1DL^=,:%3L9_M:7.,)))*3&Z?V8N&B:1"F!Y^W:B:XN5;
(B>KLX"4LPVR/+@FYC79*:NR0#7(M-|OA+C.8K5!;2:C
M1MY;CKA0"FG/2SDQQON^ED4X'?*_#;'-;Q>|!X,4NBMJ4UR:(&Y841^IW_3_RG|^4&YHI
M-WNY+"|?,>7|_3_|V?1_R?7?R_-?XO;>6|M_K#-_G5Q<7Y05<+N
M4/FBODM/R^@G+)=R_4F1;=7U*;2|&^V_H_/W_-E"O'@P'>>'MV:'#<|'
MU;#?!1MRAM5MI?3:R9UW6HA_9%OX|H0KJNAZXN># M;=LC_41!8=9:XA?
6WFG69H6U"VOO)V03QZL_?W=S|8G,PZT7HIUH6NU#V=A
MXVLKEN/6R;H+*NB:*6R;E,L:YX9,/BZ28"D7B=4*<24LTM1&%%0^TFN"W*E
M"S/F3C#.*9+"V7P(\$R.#-49_/F-HYD7_3_M|RDZ=(OM2-0=.V+=&(B:
(F>RWMER2'2GC?OGQ.UBAB#_1629Q/_|*Z&QM! M2B()\$@VR&
Z9!'JRLK*7V96+A09+1)BCAJN%|;*/;1*#5Y10U5\$)L#R4X;[|1&?R)R8(ID)6*@(,
M+|%#"V@\$61X&F"S8!RFO!;7.1\$2T!(D= 8L!U*Z*R
M7E|=66UM\$@2003AC|STMZ,D2"JA@L0Q)%*D_"ZE_%W=;|<_K2WNM_NXWZZ&M4!?
<+KC|2%|_->Y1?P!PL.R(BHB87Y<,)U'V@&')11)R4C490=+^Y(
EF#"MBD\$M6(|XM1|H3C9R5(G|J07B8C6:T7*M(M4)2@J3AN1VLH9
M1<1GQ=5@BK1R@#Y830(0| MXZC5S@NQ+^RP7201H(-4L(%.^VO_-'|)"8*B&13-
H/N:@<#"AQS%B4%**B M(:N<0T&PA'T2*ND-*BY>RKON%|APQVW^T.>@'_EJ_R0.
|J-BAM|(#FR8N MD+0BUPX.'FFF1A&DC MI0H",9-=34L;,"81L1*CF,*1H6-
>HL|=T|I"PYX@DUDN&4|1(8Y7;U>7? M"(N(\$A.%4")Y3_-#';;-)\$H4)"E(4I#D90>4")
|:X!"8(1Q_0JET|\$@S\$!T MX!"PY9L5I'?
MGGH\$)"\$^CEZ*X.+1#*\$I@6L/>+19A/5\$Q0#&!<42# O-B+M

MN\D.VT82NMUVJKOU5L;HRL>-KFR;K*R7)2T*0E\$0NJ0@U%5CZ6JJ-G68+=LQ
M_*_7<+,,JZNW^2W_JS>OPPF:Q'\$_%>XMW%NXMW#O@W+ONJ8'?^4*OM?D_-2=
MT#M6 OE;:![OPX%W:Z2[U=EWLHWNNAV67L::C[A^YRW9M0I6NNDO]?%M==7,/
M@K;M3&[ZW5S2=!%8-NC8QP:G.\$:LL38H>M*THYC,W+,:-AEP VR^
M9N^,8=QQD*>R: R_'.SL(G?>:9I76WW"1>,EJMNN+I^J."JHNW"[TVJM?
7M*_JP5+XP2S,2=PV0H&;5MH\$|6|JKK5"EO7V6FN-/:Y7 M*?
*G+7_8=K/DST\$CJ3N!^(&=3++6)Q\$(N=9MX,5;JY!_UQ#SY25BK) (@?D%-
MGT1X7FX3,#L?O@K|R<7 7K|,WVZHAP<"%+,.18UKO5O/!OV; #.EROGGJ6U\$<
MAE<7L&KULQN6_117JJXOJBE^^4X5D|"[|@|H|-,AMRY9?
49M<.,D&MVV7J>ZLB&ZYT.:V%_7P|?|I^O#;T4GU^|O7U>&[-|7)'|^<' +Y M/OQP?'3R@-
U:ZGOWATSOWT"C4I?5Z_?OSMY_,XS>'IT9OJU^-WA^|>'Q^^MK4Y.X8/?
CMZ=GE0_OFZD;PP_,>R7EJ%K%6Y52,| #S1*7CFN"0"?3B\$M;ETQQ MR HM9?
<(('_5YO=5K_AMK>JM;EAJ+77:G(! MEDS*70E7'_4|_54:~?KBAAF!8KVT0=?;|>U P^V!'3>
(DZ:WWK4CSGHLF'.C M52W?5N?-(V|0@W\$!|7QL.F|Z6W6D*>;ZOW77K#23?
&WS!+5:SL>C'(+S=E@ MK;GG=?
KXO/7A==1>5|+7&S6064SSSHX;E% @P3|;:7*VWPVQ32&L35\U*^;H,^|>JYTM9UWF9P;
<U4@;T:YDZ&R20VC:X'?=NT *S.X_0L(|>;F.)X7/M65^Z= M"Y>YI 31-6|,|. %K%Z>?
8QPNMO|0|V|CV,MU; (DA%?!@VI!7O>SK4.ZP|0R|:R>0#Y975EL_QYTX2W%D0KXZJ|@:|
(MT",OK=Y/|?6,3,\$ =3.N9ELC>^~6*P|S,OWK\| \$%?-72J'5#-^#?"; '&|!3B
M13VG6@/4K(&P|@V: &|5B|LP/E^5>LR^|@|UIY.U@;8T|*T|U;PA=-;E064_ MV?Z@QJ3&
(O|4=),>QH\-,0ZU,7"%8|5?LN%!05J|+~IQ@=JQ&PP?U^|TH|
MZWNR,K5\$HG5*G(|RTE_,EAWP0X|F:E.JMT";|D*7FW=G!6-M">>S:<;0-FS. M(X-
EC|X>76L|V9*U#-L|E#3=HXG>?#77K5.LWI5)O>9S1J4\OUZC)157W|RP809(\$907\$?
CK+&M M,>ZP|?_FSM>U|FKGVD&*MAEGON1B/,MBKF:'BT'V+==-RC/1/O9;/^IDK0TK
MO/N_9_UQ|C|.;)R/1N#V?|W"QYH|K0/(:INZ-I2>W\$CJ>@"+)N29*:9+5W,> M3#.+9?
_VA7*P00BF=SMP.8B|W# V?UW+J<%E_F+.'@?W%_2|0LB'E/36^|R\$
M39OZV7!NV|3_U(^;";2ZR MX;O1X%/^ZX:'MX)TV6P>F.6F<:SJ?/>
|XLMU8.EGM9=N0?|WXC=>%!3QK M8#|W^^>|;CF^L.G6WS.U?|7Z""!5|+O8?
CZ7YQ\$X>CB7:3409"D& G4Z6#P7 MV":1>FJ:0.C!;MH" M7_UKE8ZE/65)G>JV;-
||P6V.5|X|!3 *:U?NZ=D@V M0|)KXVXH.5_8EJ+Y4=|)VG77;O;K-|?F&+
&Z),-9UR,,N_TZS.J-B&|%AX M2X,:=E=&-1NN(%P-V6",ICR*)=SECUOCZCM.);:JKA-,@P^"
(^..U1SP*BOP& M=9T&|A27/6S\$0I_%W4|TW(U4+&-
\$C4_Y_U8GV;7^C|5#9YU\$|.!Y;U%#A+'5>(QORC2"M,-*6"92D|@HGHP/?2-B|BZ@YLC5'
M3'Z/X_K(O4B8>TJ8.4%;J5(|89M@AB)?6@K| DJ#K^*"3LV6!U/EBONXV=BM
M#ZYVAS?F3*O.@5GG9XWFT&AVM=-|4RA|Y2E+"Q5TCRP;LKX%DNVJ&|O)RH#W M7-
8:6|-5.6D##*EL-PSKZ*3K|@2#)BM?6>@<5,W\$|ZANG&T JZUFV,1@;-ZPY7I9G
#K;MVI<|OJOGG MZ&(YZWQJ|.A 9(7 S 5D7|2(2U.?|1+\$@I"*2D)EW"A)?BE=_7-
2G33|F=RG%KPY/_JA_(Z|^J|^"L.K=*SGW|9ABL=E>5L?G M.?(S-H=Y!+-5S5DS*|^
S(7Y'7VQ74L.FR^#J>C"Q!;5./%:N1S^4F>0_:)
M3A;KU_B:YH<#_>7&:|V02Z_ID)GY!\$R6C<:-(24#PZSM,[F# QSV-A&0)8Z
MKNABG"/&X_"C_=B|;ES;GTW_=9-T0B?)_"9O_IRCG&Z@#|JU#>^,@^ KYF M5|PX?
NK'STOHSJ>_:64N.?1Y4A|66R#K@GM?OW_SVX)@_6%|60U09Z//M9|H M
'(W#RA|XV;CN74^ M6A|!7NNE;6ZJB0P\$GB| XXK*|FAN<#U7B_KM";K_OVL>|1/<0
LDKU|,19 M=I\$U41:U|RP'3(|SO1O_XWD,?5^?N(.5"G*K=9J%,,Z/FPU!>VBN@04:QACJ
M5UP_I6L&Z&E"OZR4|^A)| MHTF|3ZGOX|C7K07D^A",JRX>L="2O*6W^RO@N&
M<|9LI_D=C)FWQ?D(ACP:-Z|H|!>F@|!9O56G-4GAC7!#JK?!S"9S/(I'UF. M "6
:,\$3OG5CODICNM8=N0-=6|&2JUECS>G43_|H0?("XTP:06@'5/ &8H4D
M:>=92||T&|=..I14V*2'K)61|=R'KLH2LEY#U\$K)^_Y#U;8:-/TZ|^F;;:2QR M 2V"8N0"
<4YR+49ED)11AN0"?+|1QO4N+I3?|UG*:'@X#/4)R^^CR70C887S46_M
>KC8.E^%5N|>:9QONVA*Q3?Z^/'"RI!WE8'),?_JH M)E-Q0%T339,3;*-
L635TFJY>:N)_50|S'-D4_5CMM=:)7J%K',SOM?Z\$NK
MO284#XS3'\$01@0)U|-8?!R<';23Z(G/AH#J:|W,9CBW=53?=-QWLVE.KO=STBEC""?
M\$*\$X((ZE1-|^?UG#SP^KP,<|FP^OG;%'9TF|9,W:#\$O<^K28+?&|-MNJM)Z|<4)
<3;+8R|;8|_H8W&|X^7S.A7*+&6KS VY*JK|@UK@^|3!&6A.FES MD^=.K.,/PL?
5AW!95?BPY8;:K|_-P#|HTF6AXE129Q MC/++;!.Z1QX\$0F M\$V"F|^>N;|P=08>_Y8)!E-
8^|HAX&?&L(O2_GZ%)~6&BZK*W2?LS1/F HB MD(|6(6Y50B:7|B#*2L54P\$EL-
*W;EEQLZVU^IW@|;:)Y|!\$4VV.X|99|?EAV MN|"7O9;+0,0UHBWC|S|VDF|C+U?
8OD@B|?_LOHE|O="5OE8)0_4?W&3|(BUFR\$H44/8A4 MRT|]

3N.,J>PERQJMQ&YN461^A\L0^+R-8U9O[CY,V"E^4J*R/O+= \$I#K;; M'VOK%6K@_D\$-
ZGO-(4HSGR(&15')7.T>>,5%6&TODF":\$.G59G07Z A6&".1 M.*B9-&F
;)J0UXZ#ENF2)FS"-)M=)US2"UDJH!)!%:8L+ KN L-^1)P"X^ M(N
(86!K*++958,*AY6(&L%W+->Z4LA\$HI'5FCBOC<#\$(I1)^,%V.V(G!C) MB5)-KL0
@+.'.VP\$5=8F738(:3'LEVW#%0+X^CZ>X9_*P6HZK5EFN.&N^QUDS MCP%95<
:/TT^F,QNE^-J(C,5QTN:WZ<&^D-VP;8_;&R^:%VYI@DKCIROLOO3U
_&@>"FD(@&XS9W0-(N@R46O+5?6*!+:1+6\#D3QZ
MAJ(VH\AYB9\$#88V\$LS:DY(3\$88^LERVW6M^Z^= *#V5S\$)L1U7@2E/ZZ *+VE
MYV6T^YR(8>#71;;C\ V-N+?"OL R;YJ^YSJ?"2\$XL%TB:"C1V 5;6;
M\$04F':5:)V4W&F1LBTN;P(C53W^Y!+Z<<^UAG36\QHU'?WQ8Y4#\+66!B!\N
MN,MFW>VWD(NVU19RDNB^N+\$3I=Z#52%5BHA;1I"USB-J0@2;U1(<I\5*WU W
M6YFWR523%9ZZI4?P6RV?B>XT;_W09ORN2ZXK,L_F\$+4ZDP+HM@BH6];/!CD:
M\7FZ8B*62D46D+>)(*!T+8<,Z0\$T0#AWEKF'Y"!\2&8GMC0NT!@QBK#*?8
M(VTQ!@#5#+G\$'3)\$ \$T\$H-5AL^..H,CBOYRY"GCF70C4@/N-%\$YV201AFO=|D@_MXF"
[S:&>NR,&@ZB 7>]!# #"!>,(<61%1RF4V10B3'!\E M/M#3N"+Y8,U'!C;Z63XNC^R+.W?
=#].?7CE!:_%:K15'SN%C46GP#9T*,8 MB&.=0YH'B\##S @B8F(:%>K0\$G\%
UDF#/T^'\@U'N1D)'<%\RVRV\$F*5XPCA M*2L)6.L\$+6ZI>=0S73:R?
UZGJN;_M_5AEH2[6"-UJ4)UQMMHW)9N MF"=*H5R.ILZ5&(7^O(!2OMF&T<5T>?
>B\,MD7FEQ69QT6=NF*3WV1U//<|E+ M(^?QSB:3&-956A<'N7;E2M6F/GS19-
\$VA;T&E_-)+!.|%B/,E7PNXW3E|9|!-M=-4?G|E#->)M*DU:R81M4/37|N%D|\$/1%^
M/!XNS9<;DBI/_F@3)4W7,VI6JSUV..E1\4728[?IN9EGNJ3P2G|HY-'XXKM& MG?-
(AV=U%EE32,.X;6Y5EY3>&N16CF;Q#0;S#,.5^I5A>74LKI4)U34'4D: MY|1:=EMV?
TYRD9WJKYB+% =B_XKQB0TX?C;DJV\$J.6YVG^8W\03I1M"VRE5^ ^KJ/?.
|E57;NCAF4;@NE?-2U2V10%'M7(X:?.R MZMIHWD|JC08?:YC\G(&%\@ %S-|)BM2NBX7-
G/ 4W50H!W.DV/;)C=-B<\$J14TRGT|9^:/O\$I<"?+++-&ARI M@6(.)"Z7%VW%%|R0YC?*<
<MKRFAEHM|S,;C\N6NE.IL\6HZ)V+|_JL+82M9<1>.[U5=EAAS)A-|0%X#="<
M&\$>8|0F\$+9(I*
|3,#ZVN*X>&CMK*Y2"/YTG#>0NMB.U+6E!"=M)9@FP3N7*8VY)\$Q=AJ8I
Y8K1N:=GBM9YHQU MV/UU6=:KY0-JB+B|:"KY+H^X|)^Z|5L|_FI8CSLX>YT'!O-E^|?
|0MK|\+D8Q/S73XTA?GX^&@XN\$=PSR6EB85&('BS-MD3.O,"<
M'S6U;'.ML_QQ!/,^|>W'0!:BN12MG51U|J833N?WKQ"9|1C?|8.I\$ZPSSQV
M4|T.!BN+,2_|VLB?>6S&JIBTRXO"*@RLKUJ_7:9UQ+@E.,@V3SP;..??9?Z M.J3,*^9:F&
(XGQ@'@#F|_|CX>S2XFQ_/_= M^F:EHM;<
|A4JUE(4W.7.NMLKYGFFL=ZQY6CZ@|Y+E|!*|ZEKK=T?MX|=9!I+WPSS\$CY?525/>9J4(
MU9|X_HE?I8EP*^OFK4|C.XUXZ=M09_E>M>E|>\$APZ8RQK)6^_*2|0?5.>ZU
M@E4'JDT6EU46=-)&E:T?4K-8KVH JW%" +L9'6&|Q1CNMM:=<
<>Z_V+8OP78U#N^A=98_)7JH!?*?|+|+0*L%_E MD_6N|N"D0?AKJ9"!*\$P;?<
^OT;#2)|_86|;NSMV+>MV'46VMXT5Q1U^=O_+E- M*:3A=%S7#U|O2B U-)Z?9C+DD!<
V9QY+<117:ZHJ;(+JC%41VT(;I7?NBE' MG1G*PMQEQ05K51'NQCD MG;W:@*=M:|)4<
EN(!3#L/JYX)MO%9+|CD&L M7'^E(P*|I5W.?J6^R/\$O,HK|_|GL|H<
V:3_!0%"35=2&G)3EVR/^3:I>='I MY:Q?F|Q-|_:Y7;^1.NUG\$V#W+&%BWYRXL|BF<
UR9M59/&U-N??IL#9E#H?A|5*)^X>='-7.1B.ASE\;%Q|<
MW_|!*AK&_6D^Q/V.H+S=,6^+FYVVCV<
M\;PITKPT)W*!WL6J+ #7GZ_3JVNP'^Q:H55>0=G\$P^OSR_K;B4|G((\$7SSW^V<
ME94WTYEK06)=N|T3JL<@=3?VYSO9P_8^5"N#(L2%>_5ND#)7|854K:*3=:R<|?N94<<
M*'W'.^|XFSK@PJS|J =|_7_ ^/!U?1^!6N|NIZ_|ZOS|"-AL&U.J(5/|<+R,^<
MP|HV&N;+1L_,'|RP-FLZ)FB1G!|Z<_O\$&-U/?9@6N;!SR*<
MC;)K/_#;ASHB^;YHO+J_&@V>.R7V|Q GK/K(I-I66#<
MDK"D^=LZI?"^5%V807.S_6):U:?.@U9QE|H7N#\OHRX.5)BJ"/2B0?V55&C&'<
MV6.LRVYY_1LH4.L7FS#@@@3C)|Q &OF|=|J>9|<&&.3PY.3H|>=!=T@'*WDXO-M|B(<
/%LB=I%PNR3*W<1M1|7NG?/O5C.!7S0LJO.P_HMUT|S3K)CU1NW/.H WX6WYJ/LG*C.<
M^5YUE\$'^9:6Y|5WVR/96HT/DWIG\$67WQ<+1|6MZ*+;^?0/_Q^)RV/W#W'" 5:<
MF%1)"640)U(C+H)!C|J|+ #4\$ \$4T5AN5YAVF+FD:\$'=<(NX91M8I@8)PS#/M<
M90B;E7)7TS: ^GK61A=+A,.3_'2TETHW%6|A:1;VC>(M5'V|_-X3WJ+=, +VV MA?<
BX?|?/!O\ZTK?+9):.VQ<8'^QX;^UG>AHEM'&EL4^Q|^P|ECP73EFAZ<
M>P: ^U:%4T3DTL5% @2I!+;:=PP!0Y1BF*" =C5"DE-LJFWD7G:|Q0|H-M=(|& M%'9<
V;B)@1MFKZ|M,F|(!H/5? M-(%EPS@M^DAQ1>QB?<
3!CQCBFN1:T9DDO\$:N2PYRCY&!)V2DL1'MD# M,1=*N0CJ|!<

8CN8"Z=UHZ+>J(1#K. OMH%*YN8+5!;L+5C]=K\$Z;I& 9
M1T2+A#CG%ID7)/*1\$1^O8|EL=%)^8,-[+GJV;F>KGBZ' L7,[@JB;'5WOXGS MLG'V2V-
F%^3>9^1^-F?TY1!^EX?P7 6A:40R>8\$XE@(9D@RBR1&B4A2,,M1K M?
F#TGPNR4_MEN|9Z3QFS<_O9^R/D!50H@*W%A58'/9/396@!S0+G3":Y3HT
M.U0F|BA9X'LH6/2*%;W".6.=#;.!7X'P"0(Q#AEF#A).4>664#FQ'P7U;4B<8 M-
CV*^;^Y_WHG_7Q5BIWG>)>2&O7:OCT^_.7X[?'IE;J<)06\I("7%/!GG0)> MJF\|006-
E5*KI01'D;|%_A;YN^T4W%*"8POR^OV5KDPK!9OKYE;TU>1L-)XB
MX./SXHS;M1;Z^N**P=|WW#\$A1A"P(XCYT4^X!,\$.>XP,MO8+6"8*|^*|8/FB_M|76=
|WVN"Z;R#X|(\$K>4LE;>NR|I:@9EQJ\$N"0&<:T3LEX3T!0L=TQ9&1A| M3(|&D|IT
RKSHRXM5PP2_6YC8W^94?S<|C^.^A|I#_I/* M%%>=|_Q
/:#UCP(=P;+Y;N!KK|4*T#T_I>,-M8IR>Q>KUZ!Q&<@F;.)^? M| (=9ESFS4_@G5B?
QPC92H;Z//HX#.X7O06Y,QWTWJ|_X|QG,*_7A8SO)E6!0 M&L>8A4#UQ\|)094B|.#,
|J/I#|S|J|=;F8B|D8A%&<|'J8J3^#Q_|WK|)UJ G0 M!Q|E A_|I7/|B8SN'<^ZGJ0\,3IRHSL
MQ<4@CVMM"D_LYZVLPG?@IORN!\$)HT|>CZ8S\|GTSMT,?FDY&;VDR4E|6/
M_9J"|=^&HWS;JHNQOU/0(YJ\$*35W!/?5-^Z>BB M/X0QOJJ?"I_#%R.X;EP!;!;M4.SX5/?
QP6E893Y6;|B662WI7:FH-1/6VJD MZ|9I;7T^QW',SYD-
IB""IW%P"7/H#_) 'S=)=UHNUG+G%T|IS#=O#E3-+>|W-E M@_#R?
1*K/KPMKQC,,N7M|5&@>C6IW&P"S;.!1R5@C*/MP(%0S_3HP>TG0 M MX.Y4C>.:@-
UDV(TR#T><)|3+5*L^ELG)?B8C2N#Q_AXOXH3 ZJ7V?CO'+GHW'L MM8L(6V:8"0-
<,XX^@TN8#V|N)>07|F'G#09:|_|-!"|<'T0??A|;@A|K%_MSEN^~3Y;
|KK=LQ>;YSK"/|_M,L?;+@!>U3'@+WK/3M@_1!G|,8R-'?Y/SV| M(@FN|-
/!9%35ABH(\$1#AHU8HP4Z;YOUJA+>KW=|_|C:#|2K0BV\$;+USKML# MMYC9PG9L-?
=Y!XMH1%1!(^(%1UQ)A8P1%'FKH018&(.W#L-C|\$&EY)#00".
MC\$.6<8Z2QCK"/RE\$<|5TO,9(G,_X#4QRW>3+TT;G<,=9?@*|A)=1CM&<=B1
MQ7|W^A3/'6_8;V*8LH6F^*J|=0=N750957|>H|"/,9@TB^3K9G,5VSX^(3 M\$.
<7F>|!*&J/QZ26|!<@T_MS3&E!&'9M*^OKKFYOK%&UUG-^|_I".T'%N N M_|50<
:4(,"3|67&I@Q#L WF4%._H;ZI5_43_4Z4+^IO%KO&-NB3KXG;|",
MN1E<1@UBKT(T|_31QUCK O4P/6A4H#TLE8"L?35.AHR^2|J^K;7R4Z_1,;:-
MJ^=8#NN^ICZD?FT&Y)""U>,(H#C7CO)RCD>#>E) MU;_::??'*,OR,>8"0HW MY*_L9-
)0%*,&;T<+*|J&38+TKZJ98R#CHGX@G#|B7#YVZ/SB\H\$O;,:ZW0
M68C|1A|=_'VOWL7P&ZC=O:|)J-X5|50+AK/8'Z|**E"#)_W0!_G2!GRJQ@ZP
M*>|VV;.+3|I;L-DTK;VV-?7_BISK5;&>8#,A%X+""EOFTNDFN1 M4XO#47MG;-
^<|3\$;*XL/?|QVGB%>Q)D|F|N;_IFWC^!H@|Z1Q:"X|8L >DP
M|OU:R"W6MZ5N+4WGLOD,I%=|LXL>EF1E%" Y;NIG:?)U;GE5_VT'@Y%OYIQE M6';
(ED>Z8I'4'V'4|\$RPE*ZEQRI1|U0F<9R--C27UPMR_WXYOS5TKYNU3=Y
MU8K,LQELB4P^@!|= _Y<'7W3V9/_O5G,M6S#683|:%IY?(V4D&H<|V'& R@!YY M5&
*KVZ7"/|LQG/|6?N|P^J&6GJ)ZC;JK7|:8#0EK^;F M@?6^D:89(>#N.GJG'@>HO-,XE|I7?
4YPSSB>_?9FP&S5|!|,)*?X*GCT>SC M5>BJLHEZ4/U>B^S6)
|4V,6|GT|8W64|1;N|LEH_@1\$T8KTQOFY!MOJ?_>^>
M1O|CG#T+C!T/%!FJ&>+4"N0BH8@J|46@EFWT0*3|A_2"1A900CB07OXS6*D
MH^586^&CE6L.A,EX5YGNGUHR'8Z JHN:7;C^);<.U6WZJ1*0|N/ESNPG:M
MX/Y!7H\$P&V?.SPZ(FK/W@%VX=2)8KY\$4DB(N@'&M#I4|;P4ZUA+QT4V2N" |Q|J_T:L&|
|'A7;YS M&OW9L\$&3-!LV|H0U5T.F8HL!MB5C#B|X?ZKJ|^_E1^ N9!#.#Y&U,9>9/K!
MG(#9|@4MH?|= @_>7EXB| FG|!87^N+%*X.&#V?GP%4-6 &7+_.W&X\$=|Z(-
MK&G9QDDV'_OK-IGVT^6C27W(|,*Q5#[%5V|T);|A7I=%A,B7 M|PP#(?
3N"O3|ZJ1NF^M^15W: T2O|5D=LK+@K;-%:&Q+W?YP +H.Z-1V/'UI M9|/1J_408-
V;COM6K.-C:V? 2SOX;""GKU|O&#:Z^*;.HY:X=(-;MLN4|U9 M1=URY=UM+^KAV_|
|I.&WHY/JH>OJ-W;ZJ3/WXY.7YS?/CA2MG>+=-H6>|M M+|CT|OTIT.CT??
7Z;_N3|V^/WQR>'KVI?CU^=_CNJ?'AV^KD%#|X|>C=Z4GU
MX^NY!O|3QGZYPM"W/GE:%>RM+B|<P/0Q-28 ?Y;C#99F!CG<)_M?
QE,_%|OJ@@:W\$7FD_\$L=H-O=FG2H|%@;/K<'|E;+|)|#SK>_&1&8OV?<<
M%^;^#=#9W\$YD"W^?C5|@K^~*K-| \$WAY^,U(>?O+>T0+)R^);C7I4=;MUY|&Q+
M_|V\$VUJ-6%=F|X3RY0A4U-&LO:1Y&|X APOQY8:V O)0%EJYW'17#U^KX7 MUV4 ?
>JWIOJ7+^?/N"&UIWFM,=&_K"J@|13;I20G|IR*|GC;?B<|SR<|?G MW/&V
U;F^V3F^XU\$./UXG3@.,+E-,>CY1XOT\$W)CJH9^|IE:BXKE!%|?LOR6
MQ/UV|O*UY/^~|BF/N1R|Z(-R3U_'J|,->#6&3C;6|.-#."7K5OKL@NBZH7 M&?>(*
4@5,\$SF;)'%H\$3D<-N|?L5OAPEMW."PT|4*G|O2G+ MUR(<'U,0|M;:'|^.|Z#D2R'6WG%?
V=j%6|O6?I+<5|9VX=:;:^W=U'|=,H=- MFFV)M9|H<=.V\$=,SYMU' LH'EL8=\$K>|5\$>>

D,68;JOP03Z]\$_LAG%,L*F0" MBX@+ #5H>C1;AY+FS41E,-
QIK&V=H<)0C3UU"W&F'7'(&!4PTTSY@+ ^G5Z/^ | MM+ |Z:KRE6ZH2S=:
M(RNQ1E%;FFARQ'BSD6G&&7?&8.1Y\H!/7".M.\$4NVL!= |@R|V#VLX5MH1O!T
MJG\$WCKZ+ VL/'% @?XB3:L3^K^ G>F U M%OO| "CNX
_NU./ \$*0Q9(N192)/4JD213RIW,);2:1X(8H%&+ #G%1&W84U2R
M%'7*]3I"+N_/5>YZKY"P3LC #2PASNP8PNH%(8LH'+ | M@9
D(8J\$ \$= @K'O\$0%#)81|02V"V*J1XZKKCJ2NA9GODJ3N)@JR4IC?OS=
TSPAP>6ZD4Q>IW,%& MNF-BWOYOM0>%R_ OG23XG0-U=N-J=TR4+XQ?
#95>&2Y'5159WS/ @)Q%+J@T0Q M*(.XYQXYJPVB7M!\$F/%1I@V/FM R,\$N09%\$ @3D)
VBF+DHF<*YD2\1WTJ"=
M\$|H3#K6"706| "G8|Y8MV'5_ | (J>6Y9P0HHHC+A, '&DN/=),4R&LEY%L1')+
M;R0W(@+*48\XC1@Y3@@B6.\$HI7<.=Q"|" .\9(PMV|9-O|P&B|,0C^_:\$L_'M
MG8ZF=C"O2+,.5LC4%A0L*/PL4#L'%X'E\$R@,4H"0HX%7_ \J8MH#7_ <&+&K"31-
2(. \$9RGC#84!I+ ML*82M@S B<8- | +I-& \$.@1?+L?
#%_ ;E7|L_ MA#8^'V1\H/K; @ |&D.#%WOH4* MF'8&3'^JAAI-F4UM5|J%X<1OBS>XH+C
M!<=WC..>: |:H|B1G*92H|98:1!S8!(G| TE^C|>8COX:W(:\$&_ \$Q*G|HOMX
M|*D_@4|^::3%M|J%(M"^F1TXPBJC1)2DI)Y\$8@J8%30N:=HUI"YH6 M-
+T93;F+DFA'D*ZCG"+WR& GD6?"ZN@=#YYN(UJYNVA*18\04=!TYVBZZHB&
MW_/J_VV^+ .|FYW'<| !WZ'|:F>MJ:5Q^(!C|86OU<>|, >T73MHEQ>A;'L?
J<_ |E.8M|BG8| @7(V41'!!D+>!(3|^D6IWR;8G0I//&: MR\$23Z+/8S"<|DSA||;?
AZ\$9AV04.J6Q-C?ILY#^ZSR-@F5))I4(\$R^P:UA'I MX"5RVE\$?"9<:XZL|PA4W5DN)B N
PAAL6F GCP2C6BL=;-P\$X+=|Z_J#_K0? M;|ISC4\$ _O^@(E|' =X#NM2U78L MC+D_S+.-
T|O#M?>GK&JGLU!|YBI8SKG+ E5N,#ON(\70K.U7^9U(|UD+!'" M A=99B8PH"DWR!-
/!0\V)' ^00E1UR-?)|!SH>PD6|5D|_9+ "|O=V.'T'(M%_. MSHZG\7QR. RO|45_:@=UM"*5HB
M(*,&@|'G+'YJ<|6:U#2%TWJ|3U9DKV"9X\$9,#FK^IGR3>1.0_NFTTE+_ +DT MN4\$(-
U+, @A#KUZA7"Y7ZAC41|G" _|+HJ9|7OS;|0">U4,U77T8+\$@K>"A=O
MRN8|./B%OBP"8#|JN5^B7>=F/.WPZTX|=C8=S3TX>83Y%3"A?#D:V,O1K+VD
M>10!^ #_ ,+|>6'A@+R;QY:3!K+CNGZSO>W%=C%Z.SZPA_/+E_!DW!-|UKU7X
M@!' ">W_ LEDRR/L9TSK,&75R|^ _LJ|Y.#1;|SC;?A <_JXKWQJ4_Q&4*C^:DSH
M=;OTGH&B#W%JH_QH5FA9Z'G|ND)^+,O6Z"(I&ZM MQX.+)%|S4B_;
|17U^|&'P|/C=W^O#E^?O|Y?'T=/'R M0Q;#SJF| %QA>"|J
<%R(NZ_<6HC UU+BO;_W"K3O?VKLL6|0: 5_ Z(\$S/5?C M3.KWK0X;RWZIFM|9L(-_E^?
E44G |+)D*E;N>Z-P52-BO);.2H/S_!H\$. MDZ'Q@3H:7T*22YE0:!*U|P. R'YSDE^_-
_UGS=%*F^E|SWM M,6*ZD!O8_51'@!1=MGYKC@\$'L4A<')FX29G)
|S|>QR'DR;|L|Z@FL3N MB/0."/ N*QN%RD6E>XHV1M'D5C0YYW54A%D@P;
|/PJ*M,0,15#-C|H&A)^R8CP>@40CAH|>%|:%3O>(D1)Z|)MNTBL@B.%(0N;_-'M/\$J8<.1
M)HXBSC!&CIB(O":4*V*9NY|'8,IS|FL2F\$>XVZ-OQX"/Z5-QGJZ&SV?
RY;M(K\$*AA2&+|BR M#0R15AL3C\$9:X8 X|C1QS#"4&%;41!JH(?>V_W>#(:)G<
D&Z(SM7X(!JLCV M7^S*:A MFAKY:Z|(|@|(+:
|K%D4*A?|K>AO3T9_VU43;Z438;E_F95<(DX= M:
(B21*0LH<8';Z44|_8R+|/ #F;8;:E=X)C^5N,*R\$&VPA|+MT|RRX57"KX%8'
M<(O|8%GR"G"!#6"0L<@Y)5\$4D8;\$/9..W=NSL6/<\$CU#.|&KNBO2X4'19MX^
MSN\$!"GZM^A|H?OO#^#KH|_%U5'?<+|W;"NNGA2"=K9BT/|H+OO+P(|#XZ=+
MOPYP9!\$ 10!TG<8|H5^IG|MWZO'QNS^/3DK|W*(R/R&"EB*,A5MW7F1S|XBU
M%|Q7MG;AUIUO|9(=|^2|QH= EJ9K^"A5%^/<17QZV:LN!KD?>>|Q?'|HUK_ (M;<*<
|*3;:01_WSJ(:N<0)G|"E#"ZQPJC@|^M&|2_ MS0G^;G8>QWT/?X?
^I^;3=JEMNP|Y<|AY2895%P_\$(S|L#4_PYTA:/GNK|WN M'FB5*5!3:(UL|4:UW#!KDL@%
(,|2)J0(Q(VJC541AXH8^|J1HW1!Y620T(3 MAS@S#EG&.4H:-%3X)X5HKE;V_A
_1=B#OXY'YZ_A87FO_*_/7L|FP#YXO@4
MGO|+8.3_>E%%V(H7>:W&L|B|N=ZAJ/O>Y_D9US_BU:|VY|^?E!|>'HSZ-W M?
QQ5OWYX_UOU^OV|TP^'KT|JG|J"4#INP"46"E"6(Q M*L!B,"<=YP*Y%(Q(@G8?
QMU^_L3^_'C:'ZL)>_|U.|VTRRO;|K:G5CI77|
MF|D8KJFF9|&ZC'8|J2+;/E1OHH_G+HXK1GH5Q937_|+:+YS;=_?J.W(Q1#N| MK;1YW;:
(;N1P|Q|JPGH,)->-8S37F4GH+L;J|//DY?7|JZGOY7F:D.M-5QW
MZF!GT|&|8WD>87X%3"A?C@;V1C#H53_KP?&&=B+27PYB1<6M,JX MK007|
|VX|BCG4W_2KY,|+E_.GW'#&4WS6LD.9-X0;00EDRR/L9TSK,&75R|^
M_LJHY(#S.IYYM|OT@=3T4=|8IKA_4_S&*:=^O-28VQQ_7Z|4ZF?|VBITNT5 M"<'71Y3(-
|G;%OGQ> A6Q&@V:-B,AHPFWRWG.*

M&KP^IH^&8#1U&'E+/.+61.1X\$HA0;YURW&DFKP83>"\E=DHAD4)"W 6";+0"
M&2:%8RP:DJPM0X6.OOC!+"|4|@D_X53^V5+|7Q+!&V1Y%,A'|5Q,+B7AK^*
\$C1I+,"B4L<<5(:1 M29XC!S_! ZIX23N\$ QCW.-E"#YC|VY0%!PH.%!PH./|.) ((\$#0B'+!P!|
M#KD0%8K,) OV-=FHXUD=)80S#5220C #KC',"41|8P3;2+EMTX=>\$ <8,KT MN-
I"DNK^;T2K@O5=W(L=V'E%V#|E!BO"?K6WLQ*1&F\$0 M<2#B.8X2##NB\$/>"<|L8&'
;AIU-E#JK&+8),1%-,@R%9\$SC 9FC;%6=\$C8 M4|639@NE&|I>+,*^"/L|8|
B|>=\$O7&:Q<0-\$EYHT-)#0\$Y;AP27SE,2B-9F MXS2'&"6D ?
7?)YG+"D2D!7,@|AEH|91I&V6'A#VF/2QH\$?8ED*|X|?|VH^_M'+|H|C^C|/#^K?
#O/=8V#P<"|XJ.KZH:B\$E+RFG*+D,|B &)3J:VL\$UE7&+.O%TU EZ0+,"J-9K0"|
M0X5BCU(8OH>"1;=8T2VTH-2;)&-V",NDD#62/@'|+QDE+&<:'A!|U)#?8<&
M:P|KUA,=TR|N,*<3T'!*"A34*:@3\$&9#93!C N-I40Q24 9|Q)R%D02H2P MG"N;-
+V*,EQ'IK%32&*5B|*H="B0"<|90K|/#PW4\$90TS/;*/C8|&8@C\$% M8PK&%
(RY;3R'CPE|')%-.48 48PLC@D9P@+VQ(.MLA'J27%4EE-0.+:@Q
M+=P1BE5\$|T(-3SR6/,M7T9GU%OJ:_TH-SXM.V_6/F!G4PR
MGWV,;+WKU(NUMF_KIVS7UXB|BH-XA<4^N-
8LW%N|'|X*_'|E8'=|HK_BKK4(#'7(EKA08;7YKQUMCBF:*G;'P|Z0QC8 MU(|:3F3K7|"Z-
Q|WK%B?5=@\$Q'!|Y_MY:3MU;3*DVO"L>:H%2|=X+;M,M66
M*|YVIE/GX=O_>3AMZ.3ZO>WKZO#=V^JDS|^.3E^'1I!|-
|2;T6DRJ!FEWUIY,J;B<)TK5A:SL>V^"F'N@3THS MT"?2#%3(RK-
7=M(JL=M(TGP@68:+W_N^IPRWS+?|O27.|"D?XM&\$./%LXA
MFW.BGTW"X|O|EC|);\$_7;8Z;7D+SUE|IOOZ#U:W:DSW?86;N%NW-72
M=;H'30&.1PS\$O@LSYT#@;B|0ITJ9(FR)M'EC:U"E;1;YTU%)^H")O#7'O%PEX"XFVAV#5
M|19S&|&L)|.7|G31_Q_:K/Z;|9I"XSFEN": M.H*XU E9+3CB.>|*\$BJ,|%)'5HP8Z.F MC 2-
_.8<1X)R468L31<)%G+O+.01PY!))FAF(O&^ M0|55"LP|L7)MQ6-
Y#RGPYQ^_'7TX/OUG=|1Q1ZE>%(5NR)BB'^Q4/XBY(G@R M&-
G@-.)&2"=,@(CB.6*I=2NZH?."%8B(*@I R8KH9'+-<&R%HL\$IEB3I MCG|
3(^:+90L*%MW|UNW QNU8\$EAR((E-|B:CBMJ<|*T4H@#L ", "(9H!!3! M&D<1-
K"\$>4>Q4QPE\$^>ZVA&HH2(L?|_HYQ5N#M88GA/"5&PY"ELW0YLU((E
MA2\$+EER+)=O+38TS2"Y*F#2%;|EB;34<5_>22V;@GD1M2(@+DY O6"+G*'SJE&6J
M0S8G+4#R-/9M!W9I9+"D 5(K@<2C'ETU""5ZEK A".K/\$>1\$!MULEJ(C1|L
MD44LG57()Y%K#N. ="()SE< MJE*,= A+6XWP+_>S*UBTQEW0ONWP_/8OC
M|HCBCD|7W6#.Y8_|*+D6_#051T8I8L(C:Q\$EBR\$F:0,DPEJ@D MDPJ;+7-
YE%8P@X3+N8/.4&02J!N*D9VP5>|!,L6S-I"<|3@>4K!(S!>+.)>62PID@8+<"4Y-
*:S0+TDI,J\$!:8(PX MSN% ^>|481UX(A2Y)%24K,K7#+9I4XU2Y(B@?W|59%_W@6^L?
UI>Z|(H#VJTK/G2E;E)\$59<103G",8/TJ ME9J,&">P0UIBY52TFL2-@G%:<1EC-
KJ9!64D.K@|)^|CZ&1D5'AA7'>4\$4), MC|,.6M!76/;)ZB,%PPJ&%0PK&/:
14|5#\$QR)'RN1J>%0I9AD5,|9=*,&)7" M1K498H+!|@%R"<(^X2#XW8|?(2>R-
Y902UB\$G,!.|)Z4I&%8PK&!8P;""84|. MPTCT-
@7B\$)4X@\$VE(M*8Y,+=#&6K;2XD25"78B:ZHB8K."*44F9\$>R<5I;
M:ZGQL3L8QA7O8=.),C?/\$|-6_<+PNX79/OYDOM&DJ'WUUYW#V+,IU|/?#Z>
M=OAYJ"_M:#J:T8>87X%3"A?C@;V1C"PQ_SZT%\$#.S%)+Z'?7BYZ_<2PX40^.=|[P-
'VBF|?+GKL|H|RWS+3WAG|9Z7^AYKU:H!)=>J+ON MA?K/;?
5T3#\$4+V)/IZ|. *X8Z5444U9:IYE67;9(K4 QR.&0|QM7_UX/*RF M9Z/9Q |#Y*Y-
2)|BV4NK|><\$+|_9X2Q9/YV-X+=...?_|Z'ZD#;T!1F?C|9K_+|H31_Q_:K/Z
_OA*Z.J:2@/%%QT,9KT M|QGNRW\$7/L1|WW3E:/T_8JL*5\$SJZRK*:/F7?W-Y2Q M2-?
GP:%%NNZK=+VIBZOCQ(:(:O%0Z/E2%-%%\$36">::BY&ZC()AV01AL),(^
M=|YS-.94LAS,&"R#7P2UJD,QB5KV""9=B\$GLRB8N,%-@IML<6F#F:<&HDDX
M:R42,6+\$&0".E5(@J9FSB6"!V4:#5VVCHE%QY""*>XP32!-I\$(V:4DUB=%(6
MF.GP)MZMQ|(4MMZAO_+//WX|^G|^L_NB...4KTH"MV0,44_V*T9J@5/Q:B\$ MJ9>(
B.344F>\$M>DJ MEI"ZO|L7B,3 \$-U66;:TN;V_?L&\$#X9BCP)7"G\$*2@;0+"#*F<2.
MP*=IXW@T<&RU%1I((7PV50W2+E)DE50R2NF|9|^ (5F/ZPXVY7D>;6X+9A7,
M*BQ,;&N;F)6,2)01B826&O%((K+1842|H|(\$&1S?<*_"/!.(0)8!_+>%> M(AUH0DE8#?
|YP>Q&YSC&C(B.,N2)YX@+IY"A0B#.,:|JNB?SP+_..TL7TH5:2TL;V,;B*H-
<\$QT"0"=KD5NT&..OA' M1>VU8=A2LJ&,"\$>TY1R!VT' @#8:.09J21":&J,;#
|Q+|4F<|KC1W=-&GDL; MVX)A!<,*AA4,>S ,DQK'I(1%AF,-& 96M2'
CR9Y/,YIMX,C'(1|&D;&*+: M>ZO"/=8(5&245!|*K/)=P?#),8|,3H1)!|@6,&P@F\$%PPJ&?
<@D|68B(Z(ML) #=:/.3F&|T*=)12RM)^\$JAMFD
N<)&*^4@V^4"TB3B!%3UN<|/#-6D.QBF M..LQ7>RP3OB%X7<+LWWH_::9 6/LA|N#RG)

7QO#/2@TIT=-COEXVCGDH;ZT ML^EHSC!YA/D5L&3YTGS-H*!3WZ87PJR8V O)O'E)%
/l8L9W&=>K4 M|VXSE7 J3_IN_Z@/U.7 |XYK5"E!TGN_9)+E,;9SAH7Y\NK%SU^Y
MEQPH?L<[W@;/M!;X^7/79]3YEOF6UK%/VV=O]#S7AU2"2XM4G?=(O6?T8ZK MHV&
(H7H3?3QW<5PQTJLHIK1T3OW*LNRR,D;C;OOKQ>%A-ST:SB1V&
MR5U|DSY%LI<.W,|)7GZSPUFR?CH;PZ55Z|HN+(K7"GRILB;)RUO/HPN|6!Z M621-
D31%TA1)|X"2YG0TM8,B7SH(9<|@N|E\$;P=P:SSN2I8 L?O_CSZ^V%U M,1Z%F9|.YJM|
|OS|!\$_D_JL_L!^_^JH:AK* P4778PF_7R@^W(7!HD:|[*EUO M:/K.
(J?.8R25T@A^=;E5JT1<8XJ)"6|^= \$5"1\$^*3J2M=V43%Y@L,--M#BTP|1@AGNCM&
) *4<(XC YQ9&P\$ MK\$F"D^0M")=)A1G%3;18,.0%!4 BU"!-
;418*:^H(8|*6&"FPYMXMQ|+4N5Z
MAQ|+/-X|>C#|>D NR...TKUHBAT0\84_6"G^H%3B5/)1*"@AFJ!,CL2#3R M#O2%\$ "B-
5&|D>MO(K*8!82X%XCFY+1, ""?M%,2)|XA_8#E;6F(+ \$B*F"\$8
MHI&Y>+1R%*/+/1\$AZZ@R6:J3 N6/(DMFX'-FK!DL*0!4NNQ9((("<" HTAJ
MRP!!1\$)68XJ"HLK;.#R)&T6=G<OZ>,(19E@BCB5&3E*M"5@R&A&?>J079+I
MEKP;G0B>VMXMD99|Y|?|<'SR^|&'X=OJ|?OWYV<'G9'+>4^D5/Z(:L*7K"
M3O4\$|TW"- .9F|@EL3F8=S< M#NS3 B6%(0N47%|^F%O!K.(H)FX0Y|P
+)|@.\$,);\$;5(05^%\$B*3ULI9%#2) M8,IHGX_!"\$K8V\$0)|*E'#3,Z1@26>|ER7JR_?
3LSCNCBCN*,GW M53E0>P,&MBHA7= OGF//VX)9!;,*RQ; VJ|U7IC M&.6(*T,0)V
3&TD2)>BT5.CI!17,2MA06-P\$3F&*5C/UB_7#\$;&! MJN@?
ST+_*#UM'TH5*3UM|Z;,\$&HM)IXC9|5&W&N.M-\$Y83)HL)ZCE7\$C5Y|A M^%:- H--%
(@+"0:T<0QAA:-3B4:F.A3K2@CM,<6|IXT|EYZV!<,*AA4,*QCV
M!0LT&2L=|W!,\$L3^(.6M0%PPJ&%0PK&%8P|)X8%HT/4NCL#S8&<:P(.H+& M7*!<|4-
|6K##@L,+"WK,-+1Y,";1)"6#& P,8\$Y|LSB#MEAC)&>T9V(|GV> M&+;J%X;?
+PLMV9J\$ _N1C8RY=I\$+^L MD_-?L/_ZZ7+^|OH*)G;|?
1530F4WS=YZ>PD#OIYS%>EW&(.WT?\$/Y5HR|6_ M*TW9
<^Q&89P0;|D10VP>L;P5XP7,,S!@C3|89X?JBGT%.*LM; /*RS)GCOJ= M!.,?
KCSQ7@38)D|H2O&KP9WG'XX?O?_?Y|^N'HS^/7IX.|BN**8DEXU/8O5Z|SYC.VR
M&DU)|L7KH^ ."V3_T VCO;1Y4R^%) -1WU M:M|X"W
5G8T^PZUCV|J\$K^>1G|VS#A;@20\$ "6B'/(^ \$"8UN8A^"J->>U?= M"\$J|FE034_&S3P|
_W%F05MP<=9C=F@VIQ?Y/(YO&P;A|O>_4(AO":ZIT= MCEZ/+ ^%E@|4+8\$'16?
49KIB!L@ (C|XWD4QR,+NH1?&6;'53_.(O#^JKK*.^B M!|6IBBG!C#+|87Z_1C>>V?
%E7D_-6U#.1YM??6\$O|VO&=>?=/G!-W6*O&=,\$
MU*5)7LTK>_K*EKUF0QY4A|Z#N(1'#R|7E|!|+| #2Z..P_ ^_ERS-|U4K>M4.
M1P!;S,FP;.^#"CCW|&+<|337'OEZ!Q8Z?|G|V:VTB2=-'W|RO2=*:N59DA
M6+\$OTG2;L;3TZ(RV*;%Z;|:8B4Q!2+96"2Q?_V-2"P\$"%B*(!(- %|6+5\$ \$
M+#Y|5Z3*_AJHNVUF*;N;/MY|*;Z|8=VK|>E1LYW3| #|G+9Y-
KU2ZC0G;JK!U3RU@X2_.D;VWSV&SRG-.G MR;1Y(H?>C^O. M|\$@NA4?
B6|M41IS69=;A|_H4G6GJ.
M6W2?;V)0C||OJM/Q>0YMD4ZY4+|MALP^H=|OPI;,,CI+SV\$BX(+R=45G^
M|//L5DESOCEJHO?P3K7?W|5^7E^OL>)3EJE>HNQ^G&"Z_J7J_ ^7&RG>"&-
MASZUJP5_824F:1S)XE/>UO8%!2^W'(8FN_C3J|E/K!GFVYH MRN2WS;>AO_OS=>,P-
@'C/MB!P2H9\$Q 3(>MT2-DB(J?9&"@61FG/5I=B(++8 MB,^XP
JW.*;PBAT;:HMOK#.F;R/"SGU!!NJR3|W_N<#*.MS/>B%_ "3QN_S6 M)HWE?_U);^84>Q=
|X,UV*2,E0Q25);FE8&<'P/*ZRU MAIDGLB\$+H :?J+VP@\$Y)=I94J|U,-.VV\$NY'P&V(#-
) *FF|BS(!3"-M,QQF MG>%E2BAC?"7@CC09RJ+)L,O+5%JD2T)Y.,B3!GO&?
M<24(\$7NB4E68.|H4 MPK5VAFNO^|5|/ZJGBT432EI?&.>A-
X#A"\$V^D!|1% H;GQ\$F)&1P MZ;R=DK)4!9O|2K#BE10|.(X<#AQO'G. XP)!0GKC*,<.,*
HBA)\$G=P|@;H/2 MS@'FYZ5|<+|H_X| #^7+.KW'?0CY3=|AH8@N@>|D
=*N2:6Z./HWN>YAF^2SO&DU:U?YJ-L? MVZEZE2J0_U-5BU535_8|HFDY6+G%?
(TG2_4|_VJH_|M3Q)XUU3ZA.XB-NN:3 M|:7_>42JMNE?2>BVV|N=|K5>?
*+M65\$L1^>7=7#QMZ>-I%=?H7/7|VEB*D| M^KQH|.*K&G M=CRJGRU_D_|Y-
<356RVN-N4A?_4|C|;Z^&S)|_.E79M|6G1J_4M7=&VS2K5 M@PM)?TRC/D^>R-
6|L)V7>OKE/U_ ^_O;EQ^K#F^?5Z;L7U<<_?0OX^L7KTH? MO_RX-
B|8C(R:8_='3_>GV49G;UO!EB|?_/ZQ>G9RQ?5J|?O3M|J?WWZIOIX
MEG_Q|N6|LX_5S||GZ!O#+ROV;"N7_0>R+G@41Q@YC//RP:%5KER-
CJJA|/;:=+=UR=W|H-H@T8N%HD4'4GU>#"ZN%69;E%M.-@ MJ#/+8Y7OCRZR|UQ=YO-
=E+J-H!UW(45FU14W"l;O+"3Q/Y@3Q9B;,\$Z4D5R MX.@PXMOKY(RRB# B4L
ND;BRGS6DH%4.*)%DC1*6;4""9&3&6%#EI%5!M">W MP4|H?NAGUL2O+--

X^D)>0,;Z15.//LNR5-O>G*!9
M!6C>00_D)QOT9^B67W5!97\$|J3ZC_IS_OZ@61^PS7)5;S2#||6|X&"P97NR+=L>("2<,
(!9=V>E9"FX\$ MRRY&+!|. '*U_-M-)ME&Z=C6';A350Y7!6^BH/I!I=RTG+0 M(%
!\$ _G"R8RG_.U8_!^KA!)=)B#9-(B_M"QJ70NH5!Z+Z'=Q6K95:CLG.W3*M-
:;>/U\$RGF=WV!&G+K5!^ZU&K9N/QM%HT:T5SU^6T@RGFO!@.T@3R26<:!9Q^
MO!MS,;\$B/U7H<7YE-JN!RG/?W.>D9G4XOKK*>[4H\NWM7AHLR^NJ<:8E)?/
M!L*7'S8?|!\$U?!.3*5E,JMNOJ79U#8F(ZCY4J;|!M#NRO:|_#MW/\$KWLCF!0
MNZ_GC*CC.F6VUE.CE#AN0R(*%IF4)<"7F5%)A!GM8V9#O!JU4VF!Y620T*3 M?
PS#EG&.4H:ZYC_2"&N-!9^W?|4AQ.5>-U_\$=WHM!_>VL&?L3'ME_|<=T?7
M'Z//5E%4(W_X/Y&MML_&|@9D8R&+|!#GZ\$IF!%9OIO?>K7_|TD5,X!&@">\$75*.>8
M)4L1|R0!L4D;I(.D2%#MDV-4"KGBG#Q\$U:8J!TUMNDN"EI8)|C(IU@J8T? MT1W.&33-
=H@|W>)RRS<%|WBB6.GF,>N\$.O%'UC3M;)8)EQ>KRP.5KZ.>O:!' MTZ_,>TZOAO'I.,
<>&>KC.. M!MN3RW)^HG|:7&*K\$2+SPWP-A|!#X"A<>%Q
M!^!QOS&_0'UU5.TZ/GGP3(-N_X!O=;|G:HTNSK"AHW?(IDU#|!S2:ZO"IF^
M++VET_|H0^;D>FXZ"G Y*Y^:V3!"/&_.W!V_MC^@?G"RYUYOYVZ>#JL_
M^IGI>V4/X5;U_3|SI0_|#O #VB'7/="EKN5\$X1?|\$!M6H(
NXUZ8:>79?/^MA>RC@"8!T=.8.U'+=>|D"7(Z:|T!CAM>R\$GL/86RW7;=6=O/HOI_Q6Y!4J
M!P3F^Y\$Q797D8RUE317P6 WE=DL/OO,EQ?:^B?VB M#YNJNF#\$>'J>8M4.%#
M6.P"!S|D|_|!|?9W7SD#|@_V#_: "_M_WX_5_T0!|@_"(*FD 0(EJI MF
!AP\$!KVQW4/W=|L810.#1T!9-|!#5O+!/XDB^=96V/!9E<0.%MAOM:/!Q_MHAZ,4%:
(RZ!TX+RZ0!@7!|_|? *6EO9N#'K7VMI|_|_1Y?|!+>P6!+9-
M^@AV"W8+=KM_ ^@AV"W8+=KM_ ^@AV"W8+=KM_ ^G@\$=ONP#..V!O(O#K!I+OT@
MZ)@*N)EPTIOE|_|33=W. &^_ZZ"M&-%K*4#S&:S;V>8T+V
M>PBS7V!"E"N=K;ZLIO<7T+|JOJ+M#_UMU/;_O?NE?. '5P/!M^Y7W?"7)Z_ ^
MH86EPG*&HM_8!40\$OLCP|G&.+O,%DE?UX*/MQ7G; MV=+)X/EX,,BW_*0:|
!N32_|QCS|^OLA^3WZ|^93L208KW|VTO>?%GJ#|KU0/ M+NWH+T^Z7T9/^ ^
+%.H1FG|CR5^IE!V!Y;_NOSX?ST"FWOLF +,|!P'S&|_MYIM@"4W<(!QH1-Q+A8PV#&&-
L?>8.2K#;'74_Q3)/U!|?G_<((!G%AJA_208T M #0 - T<%PTV/-,TH|,-
(P3YIT1B"D;_M\$PBZR0' G%9?ZU%Y*X|!/-WS^ M;G|!K&R(?H8^1>OZ* M#;|_"0\$)
0D!"6T@VI%8>|XE4BS_P2.5R";J\$2:&8:6TU(;NGH1FY/-^|*;N MG!?!=DCH*--@P\$'
0:U6-."@W>;#K"!F>10M,(C+GE\$AH6\$2&*!:4V)#&P3 M:R"W.>&&+9:Y8|_|+
(*!#L3A&Y&_UBRH@&A!|<3S>G!5#|);!04/0/9MP!;@_M^\$?
A^("=|%IAA*DDB(N4D;;8(ILYWUFG0K+|L>G&*S0A"-..?8X>X)Z# MX)X'C97=,^T#F_.8
Y@!9IB|Y=NHQ.":"0\$S|ZL4!|@Y:05*0@G"92#1X4WD MTG>S7DX,ZS!
(.HQP"*M!9>3H^GE>GD19_5(|NKAFL'+0'9/S+93R>P-0^Y M9O!|=)C'HH=V|@*E-
B33!|??:TL5W(T%=R/2%*QA!GDK%>(R262UL-F)R#?, ME-3Y"!|= #4TI">S
M&|!)#KXQ^W'O_ \$8JQWH"HP%C+5WC,6\$M3):C"@FF;\$4HTC+P%#@.+HD|K5B
MO,U8WDAIDR:(_Y^C9&,9L@(\$!1)T/-L1@O IMKT @'4\$?5F@,- 8T!C0&- 8T
MMIOEK%WMS35&I60#PK%491/BD%'8(F-THH%8QC9/E&VHY2"D(?MS@7JA)5*
MX#%#@4.#0(^50@@G1D2!|- \$4)HV,9!A9P:5A21*#5|H1'Y|!#Z>_!<% H4"A M0*%
H4"A>TBA=|3;<^F"3P*)(+BF\$2DG39(>\$:|M#Q@N!|*?ZR'K?|LI-^(2
M=P1|V,XXM*U=URQM:_SR3JO\$VE:#5#S&E;(C&*,8Z8V16(P9FH%:O=43F"W
M8+=MTD>P6!|;L-O|TT>P6!|;L-O|TT>P6!|;L-O|T|T MUC6P M6!|;L%NPVW;J(|@MV"W8!|?
!HXQ'8+4PW.YC\$Y!|G'T^J|SJ+K%^*)"O;#Y4|
MCWU_#>/.H\$5K&|JLH47KX|1H)4QQ(B/"U'G\$:8I(Y(0DYX0\$QT.?J5GVD-&
MFGY'S|1W==|O=N>\$|FAQE!.M VV^, /;@7P#V&P?|_|_ :DHHJ&;5! @#00+ M(
X@|H!5\$"-_|L@;N,0MZM.08'&%*FP*!%+2E(@!_A81B08QE3IX*)?:4M+
M;6+))H&T!Q;QI!32*:@:DO\$Q'O9*4B98|P<0)4Y9!1A%NTF|L7W|;&SC62Q5##4:|^>L\$R|
MN'H'V.. "56%@^39@|!#|H|_|41%|!7(P%!|!'..##%,1\$1F-% JK1/@F!G?N ML@@!QH%|
<0>S*NR\$ M8|0'C(C##G'N';*>412#E|DD\$J);6176-#B>+&\$")HAX.?D88C3R3N-@%"<>
M?V>I>\$M6A84^QLP!K H#^0#Y'#/YW\$-3'BOF4", \$8-XP!XY;A5B/G(AC228
MF4WDBW>V*DQYAU'80@2;AV%5^,E?*V#S1V9SF.36*IG")+<8|#
MTD\$*Q\$-9TL(*!T5O9YJ(5I@FA5\$4(B%.M\$466X&(+82F2=;3M2%CW.ZK?3)8|MKE<2
M+F C>10-#F =| M@?9=%^"" ' \$ <7NL7P!QH((<0!Q!ZQ? '&@@@!Q '\$'
MK%|'"G'K|X_12*ZH(" @H|1%/#", 7B\$4*\$T)P8# \$FO8G|X_(NB>5LY"O;'?S=
MHL81DI'MLL%6S#JD>&NKB_1X-CVYN0%H)G|X\$8E3RFC;M=R\$X|8=EMV.I M
>9O,3L2|;37JS_ ;OB_ '!' \$T!UML &!8AVN'^:/P\$|.?0@L@-: UMHC4Z U M:+0&2
U(#4@-2'TT2'U' !*E%|!\$%Q+PN36);R &(|A'D9B)/';*=M!&|4T<

M#L\N\+P=VD::H*7NEQC00^* @7J QB\$! : QO : ^W 8. UX+46\JN&HA:YW3@
MRB%J642\K P:%QOB2A*: B%*K6Q/@ :B0)U? -X;/:R4T\$ 4.!0X%#MT>P\&0
M3Y>"19*7Q2EJ!-*&,D0-,YKP3U7FV"XPDQG<7#Y^F;A?7/K2H0_-;& W4-.N
MBV4VL!5_&W1WB,404/)R&\$6MRSA"3V@!DE"/<[RP2\?AH2\NOSV^,MY'@N-D
M+#+@)VMC <'+(FE2FN7.-')<.11EWCZ BZ^YT<0#M.T [0#L'3#N\6F=,FB:MHD?6
MRHBX80X961JB9:*C@43GG=T^L>VD0F>5\((@\$JH.%1. \X#S@O /F/'(8%<8E
MA#TM_!45TD9@I 2+3AB*.96\Y\Q'JJWA#ZNM
_1V.TW=M*IKVZDVUD&\OVWLV+4^7(1I."&QUZR%K# MYAD;<740?;?;
Q%|O'1Q4#^2J2BF;*L&_!MIX_]HX'YA\7K@>.\S\HS/T7 M5!MT#&P7;!=L%VP7;'?
O51)L%VP7;'< 51)L%VP7;'< 5?(8;/?YNE!;>06-M"Z(_7M2#TPM'0@&-Q+2VV1Y?
!+->P6\+9-^@AV"W8+=KM_-^@AV"W8+
M=KM_-^@AV"W8+=KM_-^G@\$=OMC0P@VG6%L1-'MAWSGDTL_"#JF BZV/#G+XFFG
M\^8,Y+SM@@HU0,TM+U8#><|S\$R Q"<-P'U P UV"W8+=@MV"W;::ET#NP6\I
M!;L%NVVG/H+=@MV"W>Z?/AZ!W?Y8Z>.F1JY0CRY4*;W).2LXHA9;8(CB1/A;->
QEQA\JU"FFJ-N\$@;:8\$|"DIQ*KSB M7KCO\!N\ WU^7@PR+>|J9\$|QG14"P:?[L F'QNF
/,!P'SVX_YS"E%)?;.(M*U;P6SED'
Z(4N:XC9P8\6YCOHW6"AD<|MORO+DFR"2.\$6/4,"88#RJV?12I M\$D #0-T
#1T8#NOJ31EED,5&&@M)<2<|LLQ)Q!53C"M"HE))<C9/-T8 M#*20Q*WA/%=*RK(?
82)P6R5J>-K\$* MG!5#|)C\24/0/9MP!;@^,=) M1CJ,J"%AQP4U) =|*Q.R0V(8.XJR"Z
0=R3CN/01,2,D MER&FO\$)|*AT(16 A@:::(H |!/? /6!/4\$9QRT!F?
8UC2',>%T%.81^*4==0WD*_,.6%\$"|@'N M
>YY?.ZQ0GI1ZK:|EAQQ;3VR+F(4C2.1\$ "N&H2B6##&\$,
<|_ ^%D0HABIBT!B<16+0KE6X/6>'8414#H1V*U3\$"_FZK M&*30PNK&-|5?
72[FP/4,QP.V\ML7'\$P_TV9G%<-ZUXW5#,%VF,!0"AWOA!-"6V3&@.4 M
I3N6@75F8"|@'9*+4P.AEO^"8R^;M9^V<=8W9?ZM526MEM M=<"&>QQ00+7J 'H
V@G+_JL'ME>-;RH!R.4X?&RZ08_Q>&HU I<0"X%"V% M(7
IVN)2*)>8+:V0L+,YIDT661UT#G&|MZ MZU&#D>%
(.T,"U9\$BJU>Z<5*F1<|Y.T*:W#J48Z.8F8PIK@\$#B1K9\|03I< M\K\|S*O _|
SPS%YJ(/,RQ;|G# #IP!/&;B4XVCR3 MM;,%A
|J@Q4_X#C@.. "X@^*XH)/E4I7F>3Y:TPPI"..B//D> I>" +72YNCQ M.>YQBEI(A\2@M2K0'
9A&3^(Q\$>A2': MN\$0WL0JUH\ (6(CN84B"6-I.VS!I?
K%/K'ZEWV6FKD;:5JA2G;:4ZY>E#|!| M@&_067YOY=._/F ^.;RW!^.VIEOU3)9\K^6?
=X|L|-%P)0J@=H M:'MQH:.W%|2P3F"C-M%=)4:|1%8D@+|I%%0BE/A%???"_4!C
MKG=UWV\VVJ?I,+/I?1% @C #VH%| |@<|!@94\$". |L@|I |63#BK=1)(^RT
M09OPC#26#A%!C221**E6-A&30\$CVM TB7EK\$G9+(T9!=;2<#58Y*7\$:Z\% ^W
M)KK\AK?0H@*XYU 5#;@'N&>)>Q*UE+.0\$-:2(JXD1UHR@@+&#"?FA-6KDUD>
MG7L>IXL2(I0OH03D ^1SJ(H&Y-2|EE/#3Q:(Q6/R#N3J<%@C\2B&*5@%98Q
M61?;)A+Y\^UMM(TL/A;X&"&'1N+8/V^1>OWS^O!53W('A4LUP/+MP%;@.4? MA>5-
%)19:U'T/DZZ\$98NN87 +?;*6RI69D/KD!C&CB*1,M5S1S*.RWPT,T)R M&6)*++1MN1\O?
D(G&". />@7@#TLUQ^7"@+@\$@7X!Q '\$'; *L2!?'@\$'\I\$#O"%B(JZ#
MD,YRH:78OU5AJLT09@Y@51C(|CGF,GGCH(A8Y,@F"*M LG@CC\$R)%EDA>!.
M:A^%89O(%^|T59@<917J;E>%-|'K>QLTEG?,*2^R?Y 8R;Z!2T@HRJ-
S@1JUXA\|9">+M>3 MF>Y(HQ_D(MRENO,Y=H|\$"(3XQ5)D
MC)91^B2P8T>T&1^8\$Y;/@*\$!0H%"CY-"HR'1.Z^1\$V43J)\$,Y?|K9#V67% @1
M+76|H#J1Z1F.' H<"AP*' H?N(8?>L31<61P6\#;-
NDCV"W8+=CM_NDCV"W8+=CM_NDCV"W8+=CM_NGC\$=@M
MC&T\F+3D\R*KF*4URK==IRK\$J\(^#BNH.X;:(TZ#)OX'V7\B3JG\$P1V908
MXM1RY%RP2&A60)H;:5>:OBK+O)-4(RJM05SQA\$SD%&G'.2%61Z/C\?7+LNAQ
M5K^+=GEL<|_ ^1U/HY-Y*PP-@!_ T"8- E3C9008 X@+@JUB^.%!!@#B N /6 M+X X4\$&.
("X |:O(X6X_8(DL@8P0EA+ /B*@1DC%\$H6F&U)4D8JC>1@5S>M)
|&S!:"LWID>U6O+D*._@|NJV_14 MAZ/+_"&,EGQLCH=|FJV2*>S3W+*7(-VGR1"%&/6J|-
D2)O@4(ZYN'2.*V)6 MUSDWWHG@M!^6'8^EIJ2_Q>Q*Q--
>K_YL^|X<|WP00W>TP28\$"<\$@7ZE;4(- MH+5V0##0&M!;BVD-^I7NW!
J=N!*H#4@-0M1NI=-5M+/DA7"LP)O=: 0H%"@4*!0O\1A6*"4(HL81AQ+@/2R3ND
M)*;&^*2(\$|NG4.A7"AP*+ISO <.:0YM,8>N9\|C,5=IPS)'&4B)NK4 NRPD M:N*UD)&
(.;!<(69SN+@|O7-&O^F&I*:CM80WNW:X&&T;|OK;*ZYC J:)=Q MA)|0
B2A'N=X89>.PT=W'H?&6\CP3!25AP\$CC3A\$:3G82H72;|\$@9'19"A M,F#E&1%ZI5AF"Y-
|=UTLPX3L4"UV7KW\5?T\|!%|"> AX'"@(>&BE:)-KFH-5 MA6A@.5C%

{0>>+%HD=;),IY"TPSO@H>>3;&OW4RSY65^?|PLI_P2D\$E?_:?O\$UHY2'?6P
M|0A'P72PC@B4!Y0'E'<E">DE)I)@'#@%G"'=+&4B1BB\$F%:"U?&07|^)3W M.*4UI*.\$
=8#U@/6]8#UMM9?M\$9H.T"4E<"ELB34C;_=\$>T+IE\$8DB8[B" M..J&L|%U+-\$Q&
CG46MB|L_E'?|U)O5WX|LXZ/K|H#|H/B/>+?|W%\$|:Y?| M\$1'-GW6QS0T_\$8S|M+%>_
QNJK|FT,\$Y'U8OHXZ6+@XJ13D4QY9UJ=!'&KY_5E MOK_K:A_=>/G&*KN:+A0LU=-U8-
1JGO=NAK5E1T.XW!8?;Z(^=!!<_QX|K|6
MO;H7!58R^>P,WA!&130,./%8BE0|3D.8C6*E_G|=G!|4KU>_*P|NEASXOPX
MP^XPN|5U2-CRB"+I P(4?6@G&04,Q:YT<(4X|KVP|KONL/A.)^A?%3*PO*/
M|KKZX^3C267/8|_/#BN/UOSVO,ZXTB_W=5*ME^*Z0.8|7N)C%%M|FJC#! 6O M#>
(R.>2",<@DS8720ANSLGZE*27!&8)DU#E.4LHB2_-/W@BKJ%=,2_5|_+(^
MTLEXE,7Y/LW^O1S;+&C%Y+S7BXSS^MVK;R7U|B|0;(-9%O5=,,)F;|UZ-MP#
ME<)>44ZX90Y%R7TIS(G)89)7R/%D<6<)>DQ66)T0>5LOQ)31SBS#AD&>P+
(&0|O|!#%BWT;*Z MFH3 V87M@!>!KCS03PO0)G/E1^|(&G*/E|UJ3AY11?_K?V*YT64-
/*L>,JP MC&6!H QO#\$DM@08A22YVAF5W^LERR46WTK+\$'K27H)|H>|J4'H
ME"FS!"1*R.K99=;Z2'FZ'ZK3L;NYPYM9SMUT32|P)_Q+O7P?ZKJW_/?E>_EJ+
(D>,ZS"SG)S)0; MS%?(AEB^,'V2?S41^Y>GB#U+O?@%A>X@-AKY-
#_C^+++'2'5SU|_1|NI+V M.1'=?G.STWU!DU_|S@|0NEZ=M_-H2CVP|.9^_1T\$"<5=L|
<_:4(J3SX/'_T MY9Y)(D*_(=>O9!%NLJ-M>*VO4)N4C)(E+6L26G/=NIAO!9M*M|OO=?
OYQD9V M,'IJOZ/ZV?('^-;U/?CU1Q68_F\$U9^\$|M|H.'|CY|NM<:==E)1N-6M#2%6W; MK%
(I._U8QKU>?)\$KNZ%+:6JWOSGR|_?0008?7CSO#H|Z+Z^,=O'U^>'WZ
M^^N7'|>F|S8C(S)O@+T78GKW_BS+Z.Q|H?S|NX_OW|Q^<7KV|D7UZO6|TW?/
M7Y^>J3Z>Y5^|??GN|&UW2U.89?5NQEJM"-R^,G7|.+F2-"A2_M)XBBV7|)
MWI<,"8&HU@DM_|M4->#^9UVOI8-=?K\$|Y5/9AD)T4XUB,.K0KJ?H6
|X'5|VW8_|3=U!/,|FO^|6E_-;|J=Q4B*4/?+<_T?S%|'9V MA LWE-,N9TKRA|E_-ALAS?
H.74>BQ'=-F6V:F|H^;F,E.\$DE8?QEZO.6*6 MO6K>U<*7R|DOZ_STO>Z?)
<|TNE7_7HT\$=/BM3|7XUY^GS&_D*\$E\$UH?-,O6 MJK)K(+_M1EA%OK_-
;=D!S6)S=M@=3E|S|/07Y2DOXN3N1|UM6M?ME5/FZUQD
MM)M*90&UC3.L|&;7RK+)|N OLOS+;10_~*ZWGBRB\$X++/L=IC*/W::^YA3& M#-
/..!=1<"8;,"\$XY*2FR-G_E+72F|'RD?"|LY4?|K6|,0Q/^>^'WJ?*701@E M+GO??VL?
|9F)>XFECLK_SS+5_RM5_L_GU0QAVA797EJ,(Y/'KI<|4T1|0G0
MSD18G6<93M9D;M:7&EW.X>SD|U|/Z4|FQ2|HWD5)F%5D5|W=?;IQ|.9Y1XFCL;7FYT^|
MY8"N/%"S(IC#M'H_|B|7,G1'/=D7=>' M3QGY)WCT=':..|HY3"XKU FG/RWZX=-
'GCCBOW|E4'+""WC@_P_#)TH^|A6/MX G%03WA-YJAZ*_.%J')3_2(
6*%Q|6O/B0|6VS!|BQ'-?'S-N79;-D|NE? MGA#|Y(?% ^EV=O%HM^ H2WLUN5!Y1-
M_(97#S.1GU^76*4>#W.8,GS0M@_@@X>3_04N>"Q%+ZN7_/S@-0)0_%!|R@8_M 4 !0_%
,6W@(("4.PXE(3NR5L))N_UXF;+B54:U)?W7??JR|SG;^*O=QZ MOO,ZFOL+;
?;RF'+^&)+2DT2EYXA*DA"7%.+=.0*42*U4""YX%8Z=WU/1<-L
M&|P,A5YE\$)IN\$|HM#W^?UA4U;&JO,,\$=JN7.|XKO|2YPP'S_?,#|+)|XHC#
MOE,42%2(&QJ1X\$@+E*DO\$MK|6.(VZU0XY(AKP@PLF@*5+-Z\$,CA
M;=&FEXO8@;2!M(&T#XJTFWUL|!AT\$2(4_#L.P|_#L.P|_#L NT/11:@E
MVK4V/UX>8K*%N@*Z KH"NAJ+W41?',.P|_#L.P|_#L NT,'NSOJOY,R
MGA""O(FZC+%DR#+)D,-24>X(27;EH|WWU(4T'>W6U7W|OM!N?\$,U((+N?B;8
M'F/|0Z9|'67+NLWVE"0V:AN<08RP;\$TQ!.02QTB2Z+FFPC&_,HCD(3LP%F;;
M/'^MTH6AK|=EYZ^Q5C&MCZ^QS?S-
>US2!_:N_)AAYD3HCF^^>^A71#A<>%QC^IQH6/; 43VT#CEX8U3 M)#1.>:S&*:'^|
MDMMD|/VV2G'+3MYL4M.^:6@+M*^%4@&|;8T4MVNW+X>C9E8ZV"W8+=CM_M@M
M|W8+=CM_MDM&V;4Q,'EXJ_"4,M0)3|PF7(3|_OM3ROAR/(2>^%P|8O"@M M<8A
|+^>_N MZ*+;KTAU'>T MIOOFC\$W;|K;#??S^WFBVH|(W(|/KO'C|53TH8PAN|IV_B&|T
M=KX_T@;D\$T', \$2 !(<\$B@D(#R02D?|8J\$ M&<3+&|KGN4, "D:Q#(<N#;2*.%9\$YUMC
!\$1T@80_D\$ 0 ! \$4 C \$<:5 ML00%2@/BW&EDL;%(VRX%=+1R#9!
&4OVED|:VMS+_A_%T?/|6|PG9|LAP/C M_J;B,(%4 !0 % 4 !00*:_%'C*)X|A2
1#RDB+7Q\$,7%,C*% "\$; (C"MAT M!
#0#V,I6|,K&S7MTY11;+J\$4XTN|@LXOZA\$T^8#;'73/|MQ?P|H3MJ>|W MU4" \$Q"-
(L;RA*30!'&J%+)\$. "0YS0X|IX|SE>;#VTP\$-GB608"S"92|ZGYJ M'(+A-A:&*%:MR
O>ITX\$;!WH!NBF?2H(=/-==,3LU);AB@V%'&K&7*2<^2U
M(808PCE|U.*#N^AFTP%HH1HC=M;_Z@&J_:H9C|5\$*CFSA>RDQE2@*6_I8"E
M^ZF"@*6_I:U?0-G)IC%:3+-53:'W%-1-N-9FE,O7FOZ%MH!|!LUD+-Z9'O MF8?#F?
2\$%K0)|;C,'MHA: ^Y1'<5|)'BD!+H^|4(35%'@8RV_7'O'3)2::0P

MT2I\$SQF1VA/E6S73>YK:1'E-SOL;FSL(Z,=+EG+TENW)/(0'D@&"8(!@@MF#7%?
#0Q7H:0RA1=XHA(V@.)3*/R)BH3')EA.GF%U9N_K4Q8F\$=07=?O? \$M L0"O +\$|JL0/I
(<2 1(M!\$@\$2.3X2,0KJHUE @G+*>(>&Z29,TA09KD)AOO@MDDBA|B?Z.#99"1+/|<
M@LZ_SJ3^;GP9!UV?_QVZGR: +: ?M|L=V^C+*|/_!_!Y?NOCJ582FS4KJQAB MA&4-
BR\$@ESA&DD3/-16.>?PAN2KIW|LX=YMGC?7_MKE?N#E+\$KSYA5,96D<
M593\$B# "V69;E#YVRUQB9#U8|@XWSMRT1A|42@X)31SBK&00&.LAM/1?>^Q
M>=^|L:|OZ':YZ752*\$S\$TD?\$ MK0N|5G0
M@|6E;7XB&/OI*^O;AM2V9)R;%H7SBYB)L%>K_Z& T+_B3/3*,*;&A |'M4SIZ3<8;E\$?
J!F?'W/7F<=F7QEG7|='...RIC)I<5^(3I M/G%_!EV=/?OW*H>2\$T@<>^;##S G1'-
_||#3//0P>%QXW/U\ M7)C&OM\M4%R;1@FT%8I;GZO-
8Y8'J7ZM'5<&H|#L4&\$:E'P5>P*3"QT|'4\$PYS"C< M"SK<%X4%H#A\$H'@3A5>10 K-"I
*P K|H\$5%+ "L *P K#B'EC! "MVG'SZ M1HNHEF6?=KXQ:|M&.:DG?KJ#|K.;M?
*'^T0FRCX\$ H^ZI-8)(JGT@E'W5 M)C#) |4^\$J^:A.8Y(%JWRZ%LK/1F|
Y^CO2"/=ZT<_M|***_QQW/|E>V40+_M771VC2H-LYWCSKD0/>;A3XC(6#/+94HF8
13XDA|4)\$QDG*.8N:K': (40& M771P%2ZL8XOG1D-\$^|B%8=Z9Y(2|W>^@ ,Q|Y2_7M|
S)J.&10J@J.|3.N= M|'9XPXW@/2 |(#T!X3TR4F>80#(E'XVG":#7-
0>42M|1F^%/66WD5|9Y(Q* M)(M":1%U,ADOB BMJ(PPB?@D B-|
(#T@_2\$J&"|JY% ^1Q/1 .P |Y-P0#L M .S:HHOMJ-N#:'V+\$O1_G'PJ<|K+++^9?Y-
TT02GL>^O|ZQDAM5PWD_:6 ^M8+X# 4!|KC:5J,B(|6%!(Y;33 %I@;(/PA*Q@@_
+":T.S7\$N# M@G(|H|51R'(FD#3*)^QYN>W;".|(YE%D+E
XE#59(9\$51B"GF8|&:NT%WS'" M4RDZV&! ^#8:8
O,#1#^D!4,\$'X!X84TDEE%D8|D(YH1GB!#6*!^8S6@@F9
M5GOX3\$5PG"\$=F4,|E|68@E*0:BD ^5)Z%U/Q,4=9<"%;Z7|M<#:./6<&.
M%.!A50*V#1SMJL3S>G!5EYE(L @!_-8*< % ^>Y0 QD7.)?3<|3I%151'<@813!L-ML
7F!@A_R IVI @/\$4Q|5+
%@"<8=|@*=J08M|Z+58%\$;:!'5\$6"N), "RQ^:R:7/PYB'7=&G?),XL|R&G)|1<+M3C
M|3.KW=HN^9^0+S?K|OW\$?"14NOZX D';F5@ >ED7%D",BYQ)\$FUAO.%/'\$
M;J)ST*2A^?;Z1PA..H8|+ %JZ2T/GHP\$>#0+F5|QCAP2("H@*B J(:L-\$):-E
MQBB"@A<1|60CLM(EY+ S07@?7/2;:'RT; *BBG6X>EBK(R J("H@*B J(*H6
M\$Q7E6A,M,*("*"2C4,@1DW)LA:50"A.YNK;,& ^&5EPG)9#-1^<20R4>BY*@3
M)FKKK'|THI*ZPYD H@*B J("H@*BVE^B^HY5-4#N;2W.Y9|+|C# WES|:Y?|?G,I-
\$(8|V"GQV/ZIEFE#LLE|@/5+Z.>O:Z'D^_ M,KD:P=G ?H|/UM-SUX-X|-
AO+)E1|NR+3; /5FW6OJL.^RZ;J|NGXZ.|<= MRZ"3RPA|PG2Y|)_?N50 M>A@|+CSN?C|N-
THK|%=W.+9L7O)C3A%O564:R.T1A|K|1/ORS"^BCY)N%|,0^@<0> MJ/.,FX79Y
6K=&N6^R'V|&0V**=NJ>G_E1T0\$H "CV""C>Q\$^Q M5O' "L *P K BGM@!06L *P K "LN
=60 RRZZS2-|J)M"RMM/- "INT:Q60' MR,=)/5W+MC|0OFC%6(:!0="V5=M I,|4.T#H>RK-
H%)JCV@5#V590) |4 M^W8I%)CVM0|IA/M-^|+ #BRK^<|S|9'OY-
S#D: ^>HLF>=B|?;,@ "Z:&^M,0UA M2L<@,+(Z.L2#2LA\$29%2GM"4HB1DI3\$-
P40K8C&*PBO\$'9(&TZ085|QQ((G MWMYN3%, YK0?RE|O;V!F>XUJ&.P(F%. C28 :@'J
>H+SW(F?6"H(P+R-Q
MA!*E3Z9&QOL0;/1^#=0SZ4*9EH.X(A%Q(RC2@GNDM))\$.6H%%0#U-/4 |0>IM8
#U;8=ZF(T#8 =@|V#7 MT#L&L?V+5C\$|BDZ#>@_ '^F.7)4+9C MA&>JH^G#YAB"_0'
| #OLX(=*<##J@1L'#C:58GG|>"J+D.58!\$" ^*T5X+|
M|CB+\$)92E:1\$"@>&.&,>6>| "E;KR)RQ(87; 8S6BD:=\$K(T.<2Q#O/W**BI\$.11PBF#8:8
O,#1#^D!7L2!\$>(ICVJ& + %XPH 5 M|\$@Q;KT7:Y-/E F%&!\$4<6|2,CX8Q#1W@44>.5M-
PWMFF-("49*=7AX)1RY8 MC)A+5M'L"3NOP(L% P2\$!P4#A L8\$>* M<>M|6"^2U3'8|_-
:A:@Q%&G/:.(F>>(LP4'2VSZLB<)|@\$.R.*|B|10GLPV*) M+%56F,|A.R1 5\$!40%1
5!LF*FFMYC@3%;,F9M)Q&%G!\$PK*,NH=YI#*.LTXCXSCXW.E#B)\6"ID1%%.M@_K"N3\$!
5\$!40%2M(*KO M6%4#Y-|6XES^N92. '5&J. &EW'0|?G?H?
MIX1\$7U|K8"6/LIXTM>#T8=F^N M;7+_8C4UCX^/Q&/^/CW;-E-"^/L(E;/Z|M)|?5:&#
|PQ0'PZH|&E:IV|=| MW|6|RC;7C.|H|>UKMMKZHPZU66TQ>4+E1U5*;N"U:?
B"U;9&75H-0C#?+E M*V>'W?QE%T>?8^Q7HWS!A2|?=. / #GS^:UA.4SZ-
^3IUJJ+U%_DT5W6VYWR: MJZRO=3CY|=>FOR&|_7EQ@UA|+G_,9+("O>
|YB.\$)=H:SI..2.J \$0^2(W+ MQ@UC' F84!|=7FH/'Z(-*R2&A20Y+F"(LY1TEC'_\$<*T|44
MO:|A|"6"*>4+P|B_2P8XZ-(?/NCBH&.E4%%-
^4IV.5G_;;8Z;0>Z%#7M@OHH%1;%V*#D1\$2#;-ZUYF<,AV5VURCL,UI-
J_!+5+8;O|3'(Z*B(;5 MYRRD!58=9AW+9-J00X@YTL@GR1HZ'A:U;K=:K^FJW6Z|_G;:?
U2&UAKWL# '93MSA|PZDJT4;JNG>Z=M<3 M1>QF4|S>9.|Z|G&8N7L-

!\$[AYBK')&YA>\$X6_P_Q_E&YP=T[N,@=JKQ*,/'
MO\IO\KO^,X\0#794P8\I256\$N_ZS?).^RYH/CEO\T&^P1;#I:O+|IQU74W
MJD+^C<.,S?+)^N"+?JV@SJ_W5\#M+V,^A\$4<623??<.;I3(I%&
M;IF8RONHK^:F/KK\0=UU5;N1\?90!#7#CC2H+Z?W4\Y;OC"LQP-?GL7V;>^Z M\$>
/LHZG8*I_C\GRZ_..PE..&N2;U4\?_S_D\$DLH=#6+F49M%,+EL_F+6CJ(MG^*2>
/AV5,WQ\+_GOR>*6#*2YQ%-(EBE_E"V8++%Z8&*I&.;X\1>Q9ZL4O M*'1S9%)T\6DVI?
%E_UGH#JJZ\OH^70E37 BNOW&1J<%K9-?_&I^1JUT/3/7 MYE"4E?+953WL-
N?.CVC+|SOS\9>"#<7>Y_F&+_*,A#Z<"R\23"U_H3:Q
M#*5+6M8D0.:Z=3&O89Y*M\OO9?)\$6:D'HZ=V/*J?+7^0W_ODUQ-5;J9;K!28L?
TZC/DR=R=2\LYZ6>OOG/ME\^_??FQ^O#F>77Z\D7U\8_?/KY^|\?KT\|L7IVF;ZN-
9_L7;E^_./E8_A\!=?N9_M>'19L9=;"OT=MSH).?SDU'8AQC".*DIR>(ROM:71LD4Z\6Q?S
>KG<'&^7^0M)T?N%[\N5Z>9>;/3A8E8#B6'66F:Q-
W?,@W'X:=NKO<|U=L.,|WVQRGSZR1J MS3^5#;!U9\;%C1.Q_)W"W(/ZVO9&U_D;V?
O(WERFV\|WFR\|WT<.;|Z\&=1C\|M?-F;4\|SX=C<7*Z=L+E@4/,7+
M/PZ\&:XG:C\J3G1^N%[\>;L\$+KGV9V<2+YXV_E;_>R7#;;|V0BEG/Z^8FO"
M@:P6,T>N>4N35U=.,|R\|J3IRC=^7AS9)B@8+IOB#E\8?RK-
E0\EN8O*//^5KYM CYUB^SL1#'*T>-A M++HYJ.?G%U4OB\|"?99FO.\$00=
(J\$A^/B0.8SCK\|R9B;O?*:G<4W?O.0'Z8? MSU\|V1%6SF>98*UMBEO+U).0:7TV5QI9L|:
83B;87<=UGOFR1>1EW3F>KO\&JM;J#7Y8\$'ELDZ\|K.N\|:J1\$F\|FX&\#S<=PL9F;H;.;SI
MI#H=%KL?38,U#:=YF19\|KZIV@U,1^7\|D\|O0.8#S
MDE'*BO\|K@FD.)NH\>3I8JEG0H\|L7WKR:_QKG=Q@'O>O\RDJ>H2#\JXSA%<'H
MOPJ:3YBDR6A,T\|X\|5HFDG&32:9=F;ZY6>.6A'^E(X:N)Z49!7H.;>#G), M=+59
K@N7YX=67#?5N=U^1UCMX'69LF8)W#\|V'FA:NK: <3DBOG..UG\|ZVW
MYN\|<_W=WTZ#DY-L\$-7;DAY:?.I9\C;.&/\$T?F*6UF:*)"^F1*FME/&F#;'"J M;'2SH?
L!6N\|M-SS(0Y*P)\$CS_?HR*Y<@.O^_&=!?>J"&XI 7\5E.=_R_\$0 M74R&TV^4XVGJK*
<9EM8U?KHI7,4\|1E=38 MY%O>#DM.<9KO:12T-W.;MGP HH'-O-OB_S8.4Z=85#
|F*U9;EG\|?M;E*\|L- MU;^U7Z.=L29ADI\|WFB\$>LC)K)@.*P0O)J?!D36TI-64\;#8+_?(
0BID#=\$ (M>^12%E8+IY8T^NW,8?HP\;LRA7LI(8\|TOE4F&I^%9AZ0EMM2H7C\|%79#
|U MH_=_+RBA\$0LN46@VNI3E/FNT0!*3+DSJ30S*\|X\|6,48T\|<5F7;C(Q0)\|MQ-
&L9R0K";N/7I2\$|H8T0Y\|>QI-S)(W6527?SH9B&P ML\|B"G2.M&*O+?)F+X5=UN@15
MPK,\|3C5UOF<'63\|UL:12O*^|D\|_W E M)%W(X)1'/7WW_UY^?/|
\$|A5ACD<9\|DMV(4\|49NLYUA6;M;M7!
|O\|X&T,)\|DRE\N6.H_GXPSQEW%>IG1=RCS.^UD>X6R2 M\$'I?.;EQ'U\|W5C;NSC:\$
'0\$|8?!\|YD"J9%|IOP>#\|Z1KR!(2F3NXOG9)# M; G:M4J9@XFR>3> F\;HZ&F
MXN1573=YHNK%8'O>G89\|\$|W,1A,ZG^7#7KTXO=>#.=3\^#F:I.#
MAH5N7?!3U^8P;=B4@4PU_'WC;E2_U?6?*T4%BV=;6-Z\|B+X'UW2NZG4F\$U; M-3AE+L
HT*^03X(B@PE\|6"KJ)6:<4P^N;S8AGN4S_M;K M_9\|JIBIX*J\|T\|X\|GR'TPX7?E7V--
I>6\|L>_|^B/6STE5NE*'= \$(6%|
MCNJ P8D@KG(,|40M)Q="KD2"#WGE'_U%#A\|Z\|7V;O_SGD\|*JLQ(0WN/U?Q?;
MRT.!^:FL)H'0<#1?4TPYB*L_EQ.TGZ"/
HDG^&^*:KTU70F;OZ_'T*Y.K\$8Q\|\$^S\|Y=XW5X-X\|AO+*E_'!YPV\|SW)-U+1T_=8?=B5/^
M='.:WHU3BXKY8DQ\|*?%8J7I,T^JE7\|IRK'D1-('OG_P^B)U@S?_/?0\|S
MKA\|VC2:A^JL\|0M>9X?K&H:L&?9\|M\|^X6UT_XE;=|:5E.^NZ#)+\|N2R+I=/
MF_6U0Y7B@SW<>PEY,86P;TK: @5LH53
=%LC13#==IKN(SE,!^<@;30!_\$\|PJM H@7H#4 !0\|50, "'7N(=|S=|5DXR?^0-
WB0'1\|W6DKSN_U,|XP/A2#AU% MM#"N5#=#QQ8W54B+B0N:%4O^F.?9(. *JUTL'&
ML#H+H^?SPGG0X@1G/^SC_I")9*,V7/;3C>|^#B\$2_Q8^M#<0"#G)7+F.-+
MD;5E+&CP&CFK\$W)>QI#067;.-AJ_%7QYW?\|P09>ML+/I:\$6_G=MH>BTP-,#V
M0U8PP\|;%H6;\$T&H03JHB'D%9%FU"-7=HL0JKS&*J.W?RCPVC\|V2\|W1_.|=MIF\|ZL
VOY'7J\|+#\|R&ZKRNPSSPNOMRY8D1\|Y:+/XGLDB^L0EGTD1@M3_N
M=|1OD0<5;1VD#NRE\|_#MLHP\|QKCMJ>!\W5; R*4)9'X'!E:E1!G+/L>'CL4
MF352,R(<4QL-+F<0^K>"H-MP0\C.P>7#YH_DOD>P@0^X\|#@D(-50>"0\|TM0
M&JRHQ1(Q'3,?1)Z0'5J@1\$C^C>\$QZ)4\$Y0\|L5OG\$X\|A.'M#+0W<2XV*+
MC.8JFV.LQ68&-P,TIM?"&VNVT\|_&*P>V5XSQJLQ4/;#L=K.(Z1ZC
S?:E*BV*OZ:C%39X>Q3'9=!:KY4Y2.E^J;8ORNOH\|(E1^(@WCC&)#)&'91_U\|7'Q
M9XQ7^2Y\|<|E;!ZV(OJ*3)96=Q?:G,Z\|(OYTZXQ3Z\$QU/>K7HSC\|S7=G_R@-
MS;E7&M\$&.;/DR# 7\$6.424S+T\$KQI\|RV7O:L_WSOSR)??3'QUW)\|M94U-%*M\$V\|>-
&.NV\|27AP>4EO7?Z\$G_K?MZC\|DTE/F0C\$?*X&X\$Q*Y@".B@3-IG')! M_-

^NZ8E_3U2J&IJ7JEGX|. +KJ#|'"KV_5_VT\$LK6#B:3\O.A>7>5')B_
MW/7QPV3.X6!3C>KIR=V15_NT;MZHOF: ^W6*(U%0)9EQ+BE#CDE+= (4NF2
M(SFH5FLF==W?,JH+G6+LY.
I=GBW2J4Z9SG45F&EO>M.Z6""78RJW,JVFHXD>UL+NG@IG7\ C|=7%F^/HI5^=
M7;^ ^=W:(D@5+,TK99GJ&ROHH.\$ Q4H\3U<1SNHG>V5EOL@|RNOZ0R6J4U>KE MA?
=J^*>?+M\^LV@P= /1?6JY>63SW?XBV=\$LA:TW7M|
+FUH5E@6Z4(#9_-VN.7W/^NSL42DWE&DO%")J(R6C4J*8"\$?<4XU,
M8@9)2J*64IK@^>UU<:\$4)4EX9)@-B M"D7;>(T\$E54)33YFX\|KXWP;U<%,I
MA(W8_8Z?/2\!'G '<=P/R\|P\T%'Y0E!1G*,>!,64X<2MP+*J2,AJ^ NTN: M)\
<3"t(FQ*7.OP3JD!*<11.BY=X"N.\?N\$/K^~8&7+^~N\WRW\$WQ6_>R%,W
M&WB@B3P0!:%Y@L#/' S,--9&Q8288_1Q&C2RTDHD#-,*84>CE+?YF03%G:(&
M6:)H#KX80SH_7SY%X"(J@:F@.^%GPGA'&ACAU4JS:X&1:X?LH(!KB_B>B0:
MBQQ*#2\&=^%D5'!(R8#Y0%I@N/*WBK+62*28.2P+7&7E,BX,OR+81H\|TRD
MW<1=A-&.8@)P'1:\VD\$:FVT>\Y?&HT'L5.EK/\YA^'R'B3@:N\JX.K_G\UW
M;6XC2;)\$O\|D5;3_-LR0\#C_9\|VUXPE43W<49%U1=;V\4\|C\10Q\0)L)""
M->NO1P* @0((4*3)!), 8&ZN&0.0KTN,<=P^/X\O+U<9Q33ES",>\F(5)0M9+
MAA013\$%,PX*)-|E:ZA"Y\0)1\("K?1#(*6>1Q#H&Z\|B<3,+8)3S'B&ET4LG
MIUT')EG!\5TVL(+K2\B.O:>.1XP"Q@YQAP/20@BD<1)1"*IC6MGPS\|S_#\$N' M?)
&CF\$864422EI9K'647*WHSST/KC/54U077" _K7\|T@C78+#J.MX\|EH4!:_ M"D%W
"D*03\+0;MD7"*"(HOES%6\$&#DF H)_88XE=C:N2.M%0BRC#@@Z\$3C&-M8(JL9
)_P6@.R\J)1?",\$S6F/D\TKQI995V"\|&%B!\0W">HR!\$H(PM9HQ#5W
MR,F\$433.2A814@_C6-=J^M9NC27;)TEUP_RRNO!3_1\?E_ M\$0_)
(NV30((RS544@H2553.EJ"9."A28_I87,2&KJ\$1""1NP\8P2N1&6%\K' M#-
DXR^|X8\|E""X4^=M8\$ "WW\&'U@ZH(7N8A=6,0Q5<@1"/@2880+QKV5*_2!
MJ7"6&H=,#'",C@HK!-R5E.9&#RG6^DL^#RY/\%3A3ZZ&4B6OL0=##Q\|FZ2
M6Q,73V&:/84MOI*2"GZ>;1#!\V>@Y0TEQ"/@T,\A1(Y%ROA-K@ @O6M-\$_ ^E8
M7N.>4&6)KY/3K@.3K.#Z+AM8P?7EZ\$TJ#1#.\$4\6(2X"1\Y(AS#35F"J\$VW\3-
&ZA;"ZZ7-;YND\$;+I95U_-JRWD_/X.F.6&(TAKR*?UPA59>I8
48\|FG8!'I2"4RU'#KC?;&_1P_MMDCA^R\$C^\$*=G3M:/!
<.984:64@OI:Y5C=9")AU"MPH8CDC:UV&/8JMN1=4 M\83YL:(\$'B@MHOSBS |=FFV\YC
M\|.?'4T1S\JW)QXW? M/UGHUQ!_7KY.@_CU^G#^|H2>|-/EXNK-+U
H>)\FV8D4+Y>=K9.@\Z^9YO_MPM;5,_|P=2\|@_A0B+KJ;_G8(>5\TC#.*#9\$\$_@8>
L_+^8X_8\|R_NQQ^OZ@GS,0?|DM=_KPNWL&-DK"1AZD0MPI_-&-2A"F M*
(F<,IH\$93T6*Z&-XE9Z'P-2D8LL\N:1Y8X@;+CSCBGCL6Z%C>0U-A+WM3<"
MX+^3BCI@0147MZ-SN*G+?_|W38EZ4W\<55\|L?4,P\|H'T,%_|H' M4OQFOZ\|C*
|X.B#D\6DLL0D3>9/W\|GUX)\|S.^R0?"FEL59N)0',SZ+
M\$;XXJ=Y%'|= '%>,|*JFW7"^C7SQX6@"Y_.#:#8#C9B>NX=3GH^EP4N|=82U,
MZ:O_SMI%T?0\COM^|>T5;2TG)3/T T)\|GR'<\S MW+,O;L7L. RW=
QVHZ\|Y\|+37SD(7Q_H7Q%ZS^!\^YUT^K>5VV^_V/7HRN+1X M-
Y1=L\|OTS#;UMGXAFLS)^N&DE_-Z63TYOH?X+W/OIZ98K.V81,,_FL|^&(O_MZS<__?
7*;&|SZ!N+6K+2%6MKUZ@>C0XM-W%O^Z7N?_C/@X^_'9Q4OW\X6^T?
MO:M._OCUY/#=X?|'PX.3Y??=\AA\6S3:BF\$Z.CZ%,3H\|KMX>'YT9=^=FI
M\7*P'R4+EA(DK=;9O1+(" @K\?J0>)Z\J)Y_2_R\$^=8,5-(=?RJGL5OU\|8=TE M8(V-
|W./)W_O\9\|E=>&!\^9RA43D\$0%H,7*>,A25LU92GG>2K>B&11\42@X)
M31SBS#AD&>%:&ZZ\LOOJR77G;J\JNY("L=?/+ "4\$<44:NEP9(" M@/B&K\|B%8TC(S;\$#
|57C6%_D")S'%SN5?N#>M2KPG2<\P4_?K*EY\$;U93R: MY_19JM)\|?;+@.#NISFR
KRM\|<3\$>?05#@*_|8^;U,5G.YAV:;R;S-|6@(-7 MA&B4MB\|D1E (W1\$CP1V-\$P?K
M(@8OE?J;EAH\0S\|@#1C&'%'P6O!_OQ>;B7#V#MP7S9FJ;3X,^UN=7)"V 0! M-799-
I\$XC:RW% @FC2_K>>9)6@IRD",4X, B,9 YRI\$0N>HI4,#&EH)2GN\$#9
MO5"V\|/T\|E\|YOD)G#BS8&B&I4GH=V:F\|AO,9\|BRY;DMG8GRV.?%LVR6LX
M=V@&+|9JHEZ>R2M\$8#-CN*?%&<\$UNNGGHNW\ C_!DM_R\5E_M%>=+KEP\|
|06G'@R\JF+VP;)3UI_/,PHP\$#,W\ N8V=6E\I4@G\B-0U5/
M_=EBE:E9=NT\|QY#^%%,#ND,4P8\|SP24S"\|A:!\Q(>ULM=V6;JY*\$8C(:?T
"F5EC<(5S2Q=FJ7C\|M_-IN;ULEN'@#WET/L=Q MK@0\|VUIC?XJ.LDQR?50),1)',.A.)#-
V\|@"MK,*,XV-1<1)AK@-"5EP@9\6 MU'+L*\$3I887ML(W!\$#B&9L?
=DH2<5Q&!C\0QU48EO!*|+PN9'^8M3LUT^KY(MR \&|WMF*VAN,2'OA!@PG/SWFF\Y%
|KF<'8X@N W0_-|SB\6U+^,^Q.X?!,=M3|
|&H^FGL\6BOA_5DWPKGT:CL(RS<88&P\#AP6O)\@\$6364.P?;,LULP1N8\$K

M.&@&JU&LOMO|(R-8\$+>#@\$4/_4\2=E5R)^AA MH."EG,(U?
AV_) | 51%FOT6&W \$T/FSME)LX;YM^/C=W|_/#A9GE>:L:AL-?
6.8L|CE_234RD4=X|3'Q2+3G M8B7G^1C;./%G,4P\3C=- VPEH7AG&.*?
H"!O\$R^7@S;E5\&D/1H/G(-BO7K
M&6QE\$JCP6#T)9_UZ1H/\$ZI0.E91M"@+;JF";ZM@;>HXKE<3Y0?*/T<#>SF:
MSGJR58&YAW|>_!XL8V OZOBZCA<6>"->K_MMC00IMNVSG_MUWS44^'IQCCOV
MQX.;GY2J0^3//RD#^ ^IUCR1Y5CSQ4|9E^7FL?=: M'O\$E/R*F._^(+^
MIM@CWB.;H+ZKNW.;W3Y% C.&)FR|5WACS,G=?/D8=O\$
M&Q_)V^L:RUB6L7R98PDHF_ZOWXB^*.C+ ^'MS5 S50JK|UWAA&V9%Y\$G/M-
T>:6L;JH+:X:E:9|S+F10=LOO!JP8_MQHAE?J60Z|0\$B!D (A!4(>HE(1
MD\4!*>A1T*.*@1PE@"GYTU(H+?NPF?I0 ID!(@9 "(26 V3;TN&>MV6Q3;W'"S M)2O-
#W/)YQN5NM("9M.#>_ =PSN_A?|R%@|VX_S|ZM1W6J(|C?GH6DGW::#|
M8YYS| #OFP|PL8|H)=D9/&N|2S:B;W8RNO|H|GZ"9A-8^&*2C)(A|+Y CR2\$? ME-
_RN2D;*-1WH)YOZ|0|6/-C#3K87JW6%*3RR"1YY M3@M>?U.1HZ,=LNB"ZP66-
VX\$198+>|YVL53'5473(A4<*CQ0>>1\$|4C(!58+K!98+;.:W/.GN>=1";C\8AH|W(O)
(UN+6\$I&WSVD=S|R&W&06USF|+<.,CEL9DRVUI3(?=|+VRIAL MJ2V5^;B3ME?
&9\$MMJR4(|^%M>HN|H+K1K#=-W93^-XZOG=RD' MZ?J" T'.(2SOK*&GVUMO"Z=)M-
0AX@5#G"F"G" *:4*5"EA92F5"U;GR;4,NS^/.US654JV'H9@H|SK>CF6A+* M.:F2F
&T4;Z0%=*@*\$A03DD=+%TO'-9M;J#@402\$P1NOT|K>"JR"|@7M"JHW
M:U/#U=M| ^+B_6HS|1MDE\$:%\$KM2-)F+\$A;7(<1J0T%)*H215JR97994A9=% MA00?;
@0'M7JK1!/(9|= (9ZRF6XK+;%XV 7H"M|MEX?H!ZOYHGI@!-R)\$;P M> 5!SG"-
C(Y:2T)4_JFOYM4,C(J@4PR>7L;Q|BY\$!%Q< AG6"HG2SZEH'U!
M^|TQKX+V)9_RB&P|9E0ZSI&C,2|N5\$*&"XJXTRX:+32G:
(, #C+|FJ<*X)U:P4A@7F"VHJ+1,A\$|QOLMKUPH9I3RR@Z55|J+_ @2N|:8JL/?"ZN7HLKM*:K
MA\$4>4XA+4DYX<8U1D%S*&\$P(Q-VD(Q92,H9|)"3+4M^8(F<|18SR%"C3VEBW
M/465Y)ZBRF<*4|'48>H=KS YQS6S%@\$A6|2I-N!1*(HB5M:&1*-+;&6IWE.< M.:!>
(2!A"\$W@A6BBL_RZ\$3 *5W:GE?(2EWL|@58|_?.W5|7|DT#N_I.%QB
MLQM%3RXZ(H)!3#B(LP10G*;&(H59<)8Y&O&*+EE3#M/)(L8L2|H|@)F;M9
M)\$&-%|8%HO*\$E(\$)T#ZOPXR':0WHME|E%29"5(^J0F=E%:KP6N&UPFL;XAG,G-7"
M,)2B4H@'C)'U4J+@DX*(R6 :5OIPM|PSCU| 6A6'|T#%0C?YI|NSN-!(H9%" M(|M*
(UI20BAVR\$0&-,)I0\$Y&^">C#&LM(V\$K:AY>"1F8IPB|Y!"71" 7*1Q(
M&5."26&P*;FV0B:%3 J9;)L|HA*9|'RN+3>ULB(H%(BC0\$0!(^V"0,I*(84/
MRK*504(MD|>Z|ST'G|>1Y@Q:86T"5"),I:4Y|CVB-G55(^,8V9O>D(:TH)
M<(8@&75>:LX|+2E||D981;UB6JH-K18(S7I*=&VU8/>:DA=N*=Q2N&6|N&7G
M%P|45S+HR!#!(2#N.4-;XJT4%@H8|B*Z^:R|2X>"\$U|NG-KX=UAM|)4&BN MT-
P+|HGGWQ\27:#<8D1EY(AKEI ECB'K@M&1)&'RC;QEFEGE^MVNT,O)7@J
MK%)8L;#*|R3F"(IX\$8FTS3T_C-;(2.=0|CIP3(.Z93<(5|E^2DI\$7,AR9H0@ MG5N-
"\$:U5CK8&'Q)S!5N*=Q2N*5P2V>X9><3<|\$: #-3CD<+&-)<1AXQ3"BGM
MHE4V*.XFKELW8DY NS6M:K>|K!;2X/.J?F.|M+;/1;|=
(9AUE/G"9PO>=8OX9>A_7GK"Y;)9ML<8 M^_G-W=-.+|RW=8#9/:YC5QJ*RPP 3 A_
M+@I_F)S9R:TGRE>N)_W)%RYRE9N6L/OZSH?WZNL|V"B MSZ%:SZCDVC!\$&%&
4<(A&YA S ICL6,JRI4T*TXB6H SQ(+ (0B&:(&,I1H\$ MRY5.*J@5F>"_C4;A2WPN!-
Y#4T\$O>@\$=V|.Y73!/?NLX/A!'N6Y,<| -KM'6 M5V_JZM-|. *HO% @QG,!CY'|E4D|'M%I=-
2#VQ=|U&UY=Y;-1_&:&|-59 M'(0|;TD:/Y\$WE3|87/;)|7-#<"-
^;|T4T5W1V8(<>9LY9C)+4KCA=|' M2L(|CWQ(D#P|;#2HTO@ ;9&8"WO_&X.TV1G(Q
MAODSALLV5M"OLPG &XCB_KB1TT MW|%/!PTJC.%(.,+*8#_?O3F=-
MJ_MYXNY5!"|P|.K=?HGC6*7I &|7SH+FYJ&:DV3MZ2K""P|K|LJ;.RY! ?89D M^_
T6P'\$0@ENG/+:P7^|L<@X*Y#"@48?P#F4YB8Q3*8V%-; M81H-V&V!=20;4D
%"R_9&ZQ1C9J@3:35AGL\$|+7BS@\$*@,Z7/AS_\$4_)8K MY|L//^J|LZ<#CDN|
<' ^/_61TMS4K|TEK'3@ M*X\$3-?_
DOC1;>!M;@GNRGVU_D./^"B)4>&|^S@+7!">M/MO!|"K'<>+;|I@ M.7G656""V<3^!%M
<)\$A&HXF8) ^QC!_?&_ 'XR8":\$|37:?"^UGS' U-5_|/M>|S6*878)*B,&*7(*;A
U"";+\$/!|9)X2H2N-N%|C-OT>+|&(_AQ=L||^R MSUN?PCE_A0CNSY^J"AWD:?
=>#J79.X|S'L3QYZD_|%'I8|W=|4G9GJ:S<: MA/78 <%|U8>#_9.#DZ?
#6:L)ON>:"JL)P@X|_J9P81|0|8X42A-P J:/9^F- MZ3"C.-HC|/'<' M\$.|/XN_C/)R3RVO>??
W/-%EVZO!|"3M@4QB9;KMU-?!XSCCD5!A8W2BE0H|- M@<^S(Z/Q9=7<2;7(V
&9&XRKO_?STE=U,AGG8_O#ZN|V "1|WJM^ R?/^K,I M>'I P: ^R)
<_S=JO'-7PR3|W|.K/9|(#GVP6?)_L-B)LQ2+7YT?H=@|:/>*+U MWM& 3"3GDR,646/

XJP&Z_\$,PUMESE#+0H@KM,H#UYX:C'(-5;J)=*.642P MB%X%CB6_HE4[^+-
^W3ST_B+E!';^5/GS.QCAZV:5D-<@2BZ5W:0GZD)ROIQ^"9U:0UO4QL@44TB-
BH2\$(>=9C'YP+(ISG2 G*\$2?8Y@4EB6CTQG#K"\$LK'4ZHQTGP))'!
MV9L&=QT91Q60(WCU(3IJXXKR_&WN^'|7G 4'Q#E.Q\UCGHX.OL(7X;8.R8U?
MWXV7%)N;K+; G#)E-?35.&?#*J_JYX\$&5EN/.7E!E6#" (BVM *?'Y2VX.*+D MI%-
<<>;UBKC:\$VFK^=?'.(Q?|. 4G076=IE9=JON#%?!_S3DN046E#,M_5'H M;L;B1>?;CH?
5T>CS+%5)V"Q)V=3CT>[W* M5E_.1H(!)1HJR9FR>NKJ?
NAG=^IZ"%B|6JQ|ST|0_7&R)H;|OIMFILWIW|Z<"N7G4Q'==3F_.%(IC%OC^KEAYL?
JE9QG%Q7S-20A;CSM!URT):.MA9G#3A#D&)9_!\$^:440=SXDZ|
_4=Q\$:A4<3A#7(B4=H+N)'EE)P%D0\$0.* M,V.#?I:0EFB|=2&M'XTOTBS(TR|?SRQ+=
_B'I3C1S_90.W M-;SJQ9GON(D| (IY 5=3\$|. UOO|DU^K_9.WE>:T=^N46L.L;<|ANC!L/<_
M+|9G^>@NV5|O9^_6H=O#/0U'8\$G#3S#Z,-BY<@Z0*T \$ZF?U=F UB|?>+)#!
M+!P,1E|62V3+EO"=E|ETE?85|GR;T-LEN(62W=+R+ETCWO5-483"T;+/XDI MS1;TK?
*DS#U||67IB09C1+*CS=[KF9^-7.#XLIU)99B"TI0KA>!O"#%9_=#:F^MP@|X|/.PL^133?
\$!O M\$*X 1IE_.'^2?S6QV-?7B+U)@_@5S5@&!NTU/.T?/@F|.N+@;U|G?^ZLM|@
M3_2'SC63WCZZ;Z H&&S?ZF@77K*PI*;BRK;K7?7YZ/:'@_X0;FOB
MOY/7=CH9O;G^!WCOLZ|GIMBHJ|L\$@_:#K|8R_K_3W^|,MK;ML,T%K5DI2O6
MUJY1/7I-^&D6M?:R@?T/_WGP|;>#D^KW#V^K_-WU(!A)R"H<\$!...!>
(>0KQ0Z/\$36|HD3^?3Z,^|1?->OF|*2CSEE%,=Y
M=E_S+B^FXWCE7B*Z|%->MYV2=WP#T|^+7;?3ABOW&BC4?+6(9YD0(Y8B2PQ
M5&-E7+0K=O*8/;;LY-N1R\$ _7P|_>K-T^"H> 1C9_O!;MGI1S|*F!66C9=+1
M(08@@KC3"AE!X1/5>;,\$2|P=2<3O6L7'Q2,W?|RK@N369<' +
|A0HJ#VZ#?'J>B:|>E,^\$J^3R.;S%Z|EL2&TKN8?+MUL3V3,+)J&24"07J
/H4N%_&!X8B|3)+A!A5LI\$|,U<=TFP;;")+9E&4!1
MZXTT'BGB|Y9\$JY'E,LNO>:^\2ERJE:+/QVQ)7*M54-7Q..WV58 |-L#?+!E9 M;%
<\$|MH"@PK<>@4VD#)%B; &G|O-.N00#M; (=%; OM8*^)%SI7 MAN6 GP@!|Q8
('\$>/7/)K_BGSZ==EHWBBV11UA\$-QO=M_Z<&SWO6WUX^!BN M|O-
<6B1|>@X#*Q=94 K1E/(J3!(CLPBX2%K3O+SY)^C@;T< M3><_F5V-8+R?
U|OA':NJCCZWI6|Q^O*YLVOWUKS+|4Y_USO^|YM3KQ3G> MW-|!?
799#7X%DS|O5PO,GWE6+O#7|QQ+|@Q_Y)& //\$SL;EE6JA/E;(6+|>+
M>!FY>T<;#G_17_1!)'0KH|BH^MK'C3(RY2Y;4:Z60-|)M3=.91M5:'G86TZ
M#G/5|&A:0XQ6/ZKIP8.'|Y;G|'2H;|0|A MSUK-^SLOXDJ>_AE>1;>!OPD<5Y'?P^
D_R207TX\$-%=IKQ?+<@3XK>QW?BW< M6K|A&:GBH1-&/&;"K*.)SL9'=BN|X*QY9|V-
A/8O;J);!JXL7#_AJ/X#*G7^+@<_P-KGG65@M0@GM\$ M;|Y'VA;/Q|?Q^B*B*[S>+5Z7A=
<+KQ=>WUU>-YZ1R)A"#@>|>+(4&>(MPIA:
M0XG0L//62&H7Y2KGKVNG|;!SOKGK|,4(W/8'O5F(J|H"\$YR^*
MSW7A||+GA<|WE|^3T8)IY1%'UB!;G44N:H*"D|K; <&E7|EEOFX^?S^:CMNC
M766TQWJS|!'^H.JTX!CYR271, M*.&H\$&=2(T?@DQ7&T"R)'|%-_BF,P|U_R,*|@/Z-
6RZZ!;#UI-A_J/Z16;XOG M#"%Q*;KH4K2HJ@I.#@BF2GQ." M./\$<_9/E>
/'2E#*K6Y%_V|/LH?PS"7|8|AX&ON4|;?:+NVY+!0UI-Z|^LC
M'758'AM_W+EWN21# =L9SN3T9LB2E7)R8W7%BZ!|-D!1&TZS&5#(B;8W@="_5H
M|M@H81B3E!,4A<)9<0XCK2A#Q";./39>J%8J*W^T8^&/>11*| 33'?;H;EC?
MKB5|X'/6?;NC76'S|7*K(U+;RVQ\$^|, WXRG,7SXYLODUD*# M4>X<<9=|YJ:I<(/H
C9J_.;?OCW^(W>L^WW_ 'N_?CAHVO_!EQ_. 'A7'?Q_ MOQ|
\$D|;XK"YM'2;>)TL\$;|-43OQ9#--!/\$X/ M,9KORJT^5C=5|DC?O?GXY=731N&S:5@U&|*%
('Z|4\$6MBRCJ+HFB2KD'KMYC M15\$E?5Y15+JG- Z+P+>VZCPL9.DT7;
(U524^=%Y+BEKRG,+|1=ZWC'_K| #R\$BMS M:X72,2+.K(-H'_C96
PT2W1@V%'&5"O2&@?G%X/198P?X|!.KA7^MDO0"O>, M+(%7)R=>!Z990?9=-K"
|!\$O(KKQAP06"3)04<>\$ETIXR1+%QGAMEDR%MQ%O/
MA>R:|0A6! =G+;E;F8N@41\$T6C^|2RJE\$|JAB'%F|P1Q M&U8"Z%
(9*6,@DH=6MO|G0%K=K=ER5E7W%"| "B%L|=SLP#PMJO&P3+/3Q0_3A MB%3)"8;@
T'<"HXT@T O&*E,4E)O"(7|9C@| %GHPY">|D_7OAVGCTZHT976 M/FU@PDR-SCY\$5:
(X\$|OC3|1=NJ)+M_X.@3YIS*-'1,-N*\$4N4@%!.|J!"8@_
MF4|B#>6;MVH*M>MF\$"UZC'4M3-U|L;K"+85;"K<4;EGEEF"4|M8A32#XY-PS
M9*SER!H+4XQ!&;;" +2V4D#X#MU".>T*2PBT=\$D)|G.3@CHCGM2LYR30CS*" M8-
|")&3P2?L(KA|,WF@82X&N=(?| \$#|P51_ ^7<|U*NNB4%D4*G=0 ML?&E/6|HJ-
QNH8|RTW|V M4DHE-
|^<6|:O=XM*54H9RE(92I1:2>XUPI)&Q!;WR!\$B4(K)R|^"#W1%H5)2

M.; "4\'.3Q59T",A0P9!E.!+J*,6\$7%O-?O@:=ELE*)CV,.,<+T'9XN*2@00%
MZ002\Q#22\>,,YXCEXQ#G+ "(K!,!,6.#LRQ)JU9V63/+N?-,Y%_F(L7 D,X'
M8BRJ,YQA3O"&D9ZPGN.;WS"WQ4A?5"P[&Y;J/AZ%J9J\JT\$K;%W8>L?T2F(*5+)(D?
78(JX)1R90A\1TBI"@HY8;3K<1T2.TX'M9&NL(>:QA
M:6P%*J*PQ=&+HP\XR=%*:&H8#XCRW\IC&9;060;R*8&1+DK010GZ&92@E<!=
R0"+D^(M)RN0UBX@((@2APDB-L;W)\0ZS8)E(2&=Y1QX903I!%!>2=C09;H/G&^9VWB-
T M\6,,RX)77BD\,C.FF#AD1_C\$6R)%\0@%SQ#W,\$G+;)\$3CBGDK7"Q97VWDYR
MYC)Q"*7A&,T",BKX7\$VO>5))XK3I53K@\$2P+CW0QCFQA):^T%F@; '*Y:"S1=
M!!ZJ!E@1 MO;L73;I@-Q466L+BLUH% UC:#JL8I7P>3<1P AH1J,H*
MA\$ _53=FFW(8"CEL6L:VR"&)C8EGDK)?35!<1'OLS8-'>->R_#=H!_!06PZ+%
ML;ZMB<7-;!CMM1805'+-="=,HVKQ2+'1"ULF<")42D)30(IC5\6\0JA-/OT M&L?
G\Z*;/""=RT8BA1\0X&O\H1&Z5WTX/OH; CWX^%OU\N#7TUL;KOR0*R)W MQ1/Y-
O7SM;M-[NIX-H7&2O 34G3P2#GK_-WG_NC:0U^R6@Z 5 99C^W@LCI MO\J;
I+ "N7N53Y\$8Y%+IY#|\@*H\&67W(?VV^)\V\^ 6P&9\BYVOPW;\< 39-J
M_ J,XQO/<6N=+/TL.3ZJ+.;+2#R66^M?%H^NDL@UN^Y"C-6O.,X\GMYT>%>^L/ M??
+BI^; '*S"-&9TVP*J-)8H8PU'2F69+&DM,DQ#5"45\$JR+D,)*2B\ZH24) M
5\$"OP2@X4"OX\$|1'FTP<#81|+70Z_?|B_SX\ZG9>|H>BNLL4\$ZP-@Y M9C;%JX"Y?
GO>JU?S5N2_J*IG,S1,P-R1KYLN(T)9_"#|S:+XHV_USA|>60; MDQQ=Q+!
CS\;=|P'C>.,9G\9\NJL+9?O\H9D\^=27T8ZK.,RFO>(:\A7Z7*SW M?
J.O:Q17N=\$X#RM08JP!)B;-@)Y\$/P6&JXX_YQ.#PU.JHP_M.#,62%X-
IAA\ X\8:GL8"UH3_GM:3&09=7 S_G\^N/KCX^3I7UX5W MWA^%65O\X?(GXA(-
X8>U=&C_E=TU@_PZE\#G\$2,#<302 6(W3A7\$3E+/%"3 M5-;I%_7A\YXD2HAYUA0%"<
\$D:-&SC":(T<*R..)3+XK1C"SU:LY<=O_=\$V M,Q\TGXPBL)%A"- '\$K5X: 32(1FDC-
/@'BGFY4H*^C%DE/GF<%A#;)3GT: ^V
M\MPZ'OY?. ^\GB9)G);G&21G\&|W^O()ZZ1Q0+CAS M\+S**;2I=
@33H4G06F^4H#L&0F,@(<8>59@I5; Y,@SC%H61,311K?YYZ5\ M MJ"OQWFX\;
(@:X38,1T.!6S)>4P+B)M\AYK!"" .%9X1P2.,K\$.;1,KMC/
MC\R7)FZX;CS+JM(8TOL\7.N>*!/+ \$DED<J*59PX>&2>_ =7@6=".!1>>-%\$V
M*#XUFBIRO-DKP7GX;9\$F7=*!FL8(@D#"@KJD"4<(VJ\Z#7\$)3&NBMP\ (E'V
MK4ERDRK\70OCYFK\X32&_>;2*\GT2BZ\DK>|5_(> M)C_2IF?QU55I#\FS#&
|S+9\$V4P=71G2=S;UV>70\W+BUH\> 8/=HM\$J\$-#Y
MT2T0L%T0T)V>SAU\<^X97\$CO9\&9M:3&Z==!_Z\^K7X?'>P-W=X+NMHA
ML*E7U('I4 "G \$Z7WD<'>TP7P'D>3W9-LARSP7W:OL?
PI&RR?;8P\LT5Z;9;Y0K=%Y\I+0E^R M\6Y@FA7=XB;*EW!%.UHI08N#/4 M.
(\HTQB.R<**BCED%?8"*QJT_ ^Z>R+;\$) SN*79;4>N+G9V;#;:>JH6_-#W;
MDT&\|H6\4&W\$#|&N7U=^MC>_NAB-|SI#DAW))WR7UX9.)OBR%LK2;|I#SJ M2_ (A-A?
&/3J=6@R_8'7\ZITPV8+5/V+UKYZRP>DI&KI*4&.91,RSA#B/'KD0 M.026/\$2G0M
TM\|V'WB=,|6A*.O\X'0A&-TFTGML.NG.5:--A->BUS%,T>N MXN5\$KM?VRA4WZ\$6X0;?
+|6|\C&TF*_|HD7VA/E%7XM>|-(JL@NV(APHT%V@ MNT#W2X'N.|1+""&O(!\$)
SQY#BR&CM\$K112QZ0B6\&W>&JP>30: ^E;C3:I5 M5Y8_7R9-W;JOWS\$-
C'5J+3>6MZP7LN@F<*<0=18F\0-;UJD"/T5T72#CIVO*M)?J MFOKOQ\IDP;O*PK\|
<6P;/&M;3,^;T*_OAC8R\YKRM&N2? MO*3S./^ MV1=9IZ^?+A;"+O:SG^AC+-GD=-K-
%+5GIBK6U:U0MU^IW1@U\|_-'GS\|>"D^OW# MVVK_Z%UUL>O)X?
O#O<-'AZ'A^="|X M?+=_>O"N>G\XM'_T\G#_0W5R"E_|=G\T>E*|>CN:2V7\LC)?
KK4#^"&)V%UA
MK1M3^@H=86K!6Z*0L,EG:CC,ID678(*IQDH0\$K/E*5XW'B*4=V.9QZ\ C
M^_3,CN\42MMT"+7)S@)\LKSK8_WAT>/0WF 8?CD\?JE^/_A8G?S'_L>#HI(\
M'Z6LG>BK.#>GA=+T11Q7P\$G\H1U?5G4VL"J-1^<+W;U^5OC_IEO=KRL(#/QT
MUL\|V1K^.\V &L8)SS!&V'XNYZVZ0X\1\|/V\SQN\> M_L
|_7UI_GLN&+>YZWHPG\|P32?|6G0\JL6?G00ZW^|WK\B.ND/P'CKYLL) M>%CU-%|@
J!5GC;1\Y@J:Q94CRE!X-"<8.F M&X\;_SGM?X8@/"NT-QT';#V_SJ'%MZ?
^>/) 'O=M8'K.VO98H_E1>+5RI\B%#(VL.2 HOK MV3VX)1'^QK2TD =9P!/'\$)9 (L8C!=|'\$
M\$")9V=I+>0B)! (RL('T\X^V=Q?PW*LK?#1RHV1B""F1X0J)%)(D)!(1PVR
MD,BVDLC&M+,CDYY@@J310#F*.N2LC"CE,(>8)"AA-VE*TLBEUQI"(PY!\$H\$@
MR:A@D9(F&A:2#,&ODZ9J>"7PZ;Z@AP%=T4)7+T\$PNZ1>UYEZO5>CHI/L47*N
MZ\|RTF"D52,N#4:VP4DR*4E!.\$D-JM3B'-SA":4CP0)KOR*YJO3T(OUL"
MVVIN\$@#R<3JU7_((ED/5\; M>Q7Z+/19Z+/09Z/'Z)/EHAV6@M\$H(#84UF((W4R'*MO-
_TL&C;3\!WB3ZI MZ!\$B"GUN9;*_U%EO6;+_6IUU=URIDMA_5FPK?==*W\5-

>5JW^T%4&*(!%L@1 M CZ-,099*RR*-K*H?1)\$KJ01'I.#!PS\Y@JU57\ M50^K#F8
7DJ\ M>)>O.A4 M06&SPF;=8C,6(@N61L0\XQ"F)X%,WF?
D@P=>HAH+MU)V\YBD^%K83(B>ZD8A
M>&&SPF;%S0J;%3;+2QX(MQ*P3U2V%#\$HZ)(*QY02#I1Q9A+KI4L^"/Y\H&9 M;:%
I5+;BW-9<=M%JW&!N^ETU52^E0QT,W\$IZ>@LKLTM6^I%K MK,J31+Q&@H>
(N,4&V90B(DD(I347B;=2;+3 Q T9!\XUZ'B<3AI(//Z&B+;
MNN^OY91GJ/G(95@B18^93@B<;%*Z3\$%!XKO#>VQ0\$E**@K4M-'Z04_21G MHD-
_,W=DJLZ^NFX/^G'NI0)E3*AE^CZ=6\ RV#MFO65J5VLM4SMG;2^,K6+
MM6Y\A>QH2XF-%N-W4XF(_JG-;HH'02Z&K^M)\G4%?S:BLQQR0K?EQ46CL@4
MJ\$;":H=X\ Q9K!,20I*4(A'1FIM9X9""P"9*Y)G+*Z9"(&.<1=03+"D33(OP
MH*SPNYOUBF\$E-,P?-GM:3\AOEO, #_>8ZL3>T1P@ V'3B3J<%S:!"P,5!MIJ RX,U!8#_?
N_:4IH,=E-5WN4#.,69!@_QGHR M\ON|=,%NDHW9\$:KL%SL.)>'X<:P8,)U/2%'A+-&&!
I&R.5%HS+" M%B7?
+, \QB2SQ'@7"HTC,*Z=H%YF.,)TG82!PG2%Z7;)H5\ M\H7GON\Y<%?Y\7\&7VPX*?
G:DJ\ MW%ZX?5-2'J U*,GGC&)93V-9HMA.PD:Q1DH4N^,F7IAN MTTP7)+7\$>
(:8!7\CTDID@1*0=U1&EV@4GJ\3.YYF4\@3FRG*\$Q7F*XPW4LS M\
<)T)5^I\B^R<+:TN'C<50Q9\THG4,57\8P5CYZ:1+?8\.,NZ+5-B5C3(T9W+V\I*1*QQ?
THS%6,MC!7Z\+FVGE" M'\$4D>)H%:0ARPCE\$C8XF*,JY=VMLX?
\$IS*48+LRUDR!0F*LPU\89;6&N5H/ M.6Z=YD;+ \$IQW,P5VG+T9E\,GRV\+1+#W-C MF
@+4%O/=V?R_OK<5&R/?;SXWFGN56^N/\$\NXIHOGZGRL_L#68.\S#.1KT
MZPF*@\Y@7U)O\N(CC*ZWGY;70^9.%?GTOL)>OTR!^71Y."O><%^;I\Z7)Q_>8W
M"&A>/*F&0N4KUB_ =K:.\@WZ^ZYLP= 44? \$P=>\P/A32FD'53QA4OB<-XXQB
M0R1A7,&M+2U_!GC!=SEX&IL^LA>*@9HN^,R4_ ^O7Y9?%N\GM96\$=S38+Q
MSS?.N+'GOVY40X_ \HW%, ^O='H;+GH^EP4E=G\G.L7(S#;APGXU%\J\$7VNXAY<
M5K8IV(BAFHS@;_ #! ?E)-SF(5FWXM=6\8DO\Y\$B_LV&8XW;NR5QB4J_.(!>P
M\JK%\ANC=J-F?Z\I\WBK_G9%MIMOCB/A45)&8RX9T!?
EEH4QPW)G<)_#H8^3\JB+PV05<8S*>QF5\7RY>R),*9O#=D'COP/T@ZO^0 M?
=Y\8<;Z"F84QH-I,J,O>=7J8I2_ \MO!=W845%\B?#<3:K^<#;X>>TKF^4P M-M^
SN/R;M?L!%=K8^ \N>CMM(Y+EEU\&4T'86EB6+@+M'C=UQH2/>YU/9;_
M>JMO9X63%GS>T/EMU&.GDJ&@"@?,=YDO ^6?(T#"T73^DRO@W/HGA>;"!@
M+ ^KXNI\A2\Q.V,UQ\IVV1\VY7_==?J"?7+Y>G...M>?9987:TX+FZW\ -OY;O
MLG8=VHIGO-UW%Y*15" X\ML\$KC1(/S ^_I'M./J8)A\A?1
MOYQ\J\CIK;O5RZ/+QY\AK6VVN*5@7'=*S\XW15X=9F=[*WM,-2_/P*V^E(
M59#P":^8LH+I'6TIN\YRB8W;^!;UP*O ,I3 (<5P"F 4P"G ,YS 0ZM%F_K
M\LOF9T=L3PEZU_ \J\$V^ ^A&4.QQR0<=C&J^SF3_ 'H<;TH%6J\$S&
(CU!.B';4.9S%P=K*Y9VBD%VTR +P2P3C*5 (I\$A MZ3T&LK &;
<<I8E8D&V5,=G4SY6.Z6G;-8+'DDY4^Y;YW,7!*@13#+(03#M* M<|%Z#7%+BB(@+E1
#G.*J'1>2L5YI.0FP?C (G8Q !59.\$8#/3EF*6+))D<9
M%LK8\A,4B6"Z8SP4#M"\2^'O;:I0V=1J>O0#LNB4O<8EC14&2J\$09\$8ACB+
M'!E!.&+..QVU(5&NA&&/Z139,9:D/69(%TCR)2KX%:I;\DBM%\CAL8\QF'/4
M66D,,QU4&I\ML)CA<<*C\TTDRT\IG0> M2\PY(8-
'FF4>^RR%1"\$ZDPQ%0S63UE(A<1N:WUVC,I73 MW=A\JC+IK B!%R'P(@3^L_?
62'P6\I%?"C2RNUJI#,)X6D4#&G%@+^I5DA+ MX'S%F*/6
GXT&@+7UP3^G_KD/_8 'OS\8=W!Q\FD\7ZDUUV/_ ^<7CZCUOEQI=A_=XY(35&=APRK(?
^&!/^*XK<"O&H\ 7:NH3_ ^M-LH7LU&N\1R-
AHWLM;+IYW1QM6OKXOY7\I"XL?|K+=?V4^?QO&3G<0Y/>5? M32_RF?
YRFZK3#XS5<I13"L)+RPD*6;,\$N4S(Q9"0H8\$J*ZUT805K/8. RRB. M&+
<6T%THX!7-.H)-%POG"5*:S'DQG.?K/TN:'OS\I #+.XB5P+G/XX>7<5 M-
Q1Q:UN"Y9)O)%I5BK'LPW.?G_ ;K. MPD%@@M4(;&YKS^ -P-E
UZS9V\X%'W\$V.GE9UUS_LVL;: \$H7#CI\$0\$G9QDCBR'@*"'>UUC;&7\$39NHTM
MK&O>;O#MJ)XLTHK7>7&8X?!D A.V/D\I3=ADW^7>;>-Z_NNY+>)E6Z3W;1L0
M>XQUVQBO6B+U_ 'JZ6"2D2\H8, -X'S#"ZDGO:IE1MT2D\6.):HX143E#9@T
M)F2Y:09P2>ZG:RGW?S4C\4U8F^:!\TL%M3\^'UY<I;B\I8G^L+FW
M>37^I(M;_ \0#MPB^;S4T.MJH>GK I?
I'"U;NEIVMIMO\7WJ\$O3C\ @=X\H.O9Z;8L*P"0;_ M1U\L9?UO'G;LDU>
M7S#.%K5DI2O6UJY1M2S\$W9ED^?Z' SSX^ -O!2?7\A\?5_M&\ZN2/7T\WQWN M?
SP\,+DUS\O.&'W;QK(5PW1T? IC='IO5VD0?Y966^S WZ\B4E\5\U. 1)^!V4V.(T,G*
M>>8I(I\BTLJ3T;?H..5\!"0738+GXRS'R(I\R+\$S\ -3N"O\O+)HUUUT)3=97V

MV9\|J"G^B[SH]2DQ7Y|"O^Z?@!6]/?M[X.CD_W3P^.C[5U9V=3R%&JLM%HV
MY.I@%C3?K)H;?&7?^SY^FY|+SPTAW]-64(SJTN?|(?TR9ZU7X8KUDWZ MOHF-
D6NLS"]V3PU,UO.F*/@8O7A6CI=!%G*?1ZI:OVS?PJ'-044=F9^AO|
MS|4:PM)9\A7RK8SC&=S!;5@J3\W|2VU7T2,,RLQW/;^V4TIU;-:(>|Q8YZW
M<3/>4TH^|R7+0V|E0SY3>|H5?'HA|6IWK1/>RQW1CK0Y|^H+*&W-U_R6.MU'
MKK0Q?T:=EK6W,5_7L&|+V|21K5;|Z,TBM_-=|J4%<K@=.Y|E\$;Q:7 *X!3 MV1W
H05P.AHZEQ;LW1,YS0NS>7GOTV@4Z@KN>)IW&DW">>|/,&2|#MV1,GK8
M!'K6%|0|6M^%|G/73?SA_->73MIJ42<*@GG'DT<
'8*0*&"3N",F61U6U(EF)2@QW%ZA,B_N;- "_4?U
MUY7IA#!L5V;M!:@!NMYF^T\$BAD4(C2TH,2DIA<\$"\$2H(XP1)9J03\,SFIA<(^
MK6P|58%(G:A!EBF,N,0,F,QSU5/,";|2D')5@OPY:820'A-W;RQ|@=.V|\$CA MD4X99.&1W>
(1Q|2+RDCDC,HQ"?7(DD!0U)Q:YIR!T&-E\$ZVT\$?|?(-GQ!^)"
M""05<8@8+;,%S6J>XJOW|K#R">U3SPB-=Z?54FMAO,*WY,;=1COW9;#=\$_!P'
MHXN|E:&3@%QRF06%NNC-%|HA65;+*^E-Q,A2SK)8.D56<(>HYU)R;0Q)*_U" M+
(LJ1JN0UCRG,#E'1C*!?"1&NA2H5GRC|@/5/:Q%|1EV8;9V8&Z6V+,89*&/
M6^F#:\$RLSHM?AF"\$F=#(4&D1I2)13PG1825UJ;DP+GJ&#),0(>) M""01SKC-
IBZIZ*F2NMR-V=J|N5GHHQADH8_-,"RBP9Y(ECW",%|\$A#;() @LI
MB4K&.>O9ZLJ79DEHG9.5F7*TC|CAF)!@A MKC>%IM;W3L|('ZU%|M|YOF:VE
M\$+|/3W-3JO#^)|@P'|J>EE|ZHR ?X>;^>C!L%N4YBK@.06MTROQ60|8P|
M)A^SIZ*X(\$HJ@S%-B!)+\$*=&((MSFP\$B=?!.44YN41WCT6@!42^S.+=.4 5|%
MQ!T\$R8YJBH3 WOA\$HK8KZW1 7H(PFZM)X4#N T.:8XFBUI8(F4S3&V*36PU\$
M3Q)2:&H'YWRAJ4)36V:RA:9:B*8P5001SF-
X"_HOF^Y4GB'04#_Z;:W1WGIB2/B|M3W)V7Y>YP;16Q.5N<M
K@NW#F(M1DPCF:!*BJM86|%W1\$D^F@B"MA&Q)5/2"?O\$6:1V1"C4HELU-TQ
MLB>9*N|. #L|Y\$|47FMHRDRTT|72:8L8K(HU +M=:<1H2(.JM!"Z3#!F7CY9.*I|<|'#-
\$5|BA2:VL4Y7VBJT-26F6RAJ;?3 ME."*"@B3\$N\$+;)85H,BOX
MK)0,FY53TZHG5:&IK4H>EXKA#2:#BW1K2?KN|A:&LN'HF5R,IODK+2:|C2;; M
0/=I5"O&&3!T(*A+|QD.V"@!4.+018,+1BZ X6 +P>@BU|EIM]*2>!T&84* M<1;B+";
|G=Q6,/2E&N0+Q=#;U|D-5=X(21"F6""NB4+&,8:(4T:S1)3^N8Z
M._?;,Z,)E04R=^=F*P=F)J%|8I!%O:X MO5N9%\$6)|@NG|!HERAK%>(|T21A1GXQE
MPMJ8=1XWR!Z)|P4M|&5I%TIP-I@TJY(-|A7:D3+W7B'?! -I<#?(G%TH5.
M"U87DRU8W6:TZ W7&LZ(5_|N(|9|<2Y(3U5!FAG%Q12 @0#49%"5*88L03
MC@/4UBJL%1AJ9=MLH6E6MAYBHE+G"1DA%&(-M6Q>1XU0@Y@,U-K
8XHIL(8Y*A,0Y(BD+)|#AND*6&(VR%5C0K|&*)|V<|9/4,|
ML2+V\$EFJJ!86U<)&M3#TZ|EP(?RLZ!;6#&KQ=XJ_4S*HN|GZ)38M6%U,MF!U
MJH6:3A':%\$>&>8JXD1AI+!D*TE#K\$E;K+;8EE(0%2,*(EC\$O0K(AH1LT9|
M|1,FFU9%ZA&M2VRZ@U.^L%1AJ2TSV<)>2+31^"4YX\$@7B@0!+82:0I2X@FK0+
MUBL5@K_)4B(EQI6E*"D"!YK\$D)-)H.B,PDY)8=1F.WG+GBC2?=N502V5HQO;
MB)Z.)G90U??D1;OCEI34Y|/B%MVC&;C":.H&L7.NR069V/#!_4L'?>8?&-GB
MM2S096\$J&2\$2%1"&;G"6I2'D\$C R I"(\$C7'CY9C'2T'&LK?+1RL|5*&/<|F"|4J&M0EN%
MM@IM%=IZ(FT%CP|TCVB#*>-|6805RVB2D!|!"">&(HMC=I2|)+(9=|P26WB!;2 MD%!
(B5--"PDV:25-QEL|1X5'>P_-E)8:SE+)|M/.W_7KR-H^EY'/<|_#OT
M/R|XG)Y*M|3C/W<6HWJHZGEV|6_-|FGC%H"O^A(-/V8+R;CN\$WU>0L5I?1
MCN|JPM.'ZEWT|=S%<<5(KZ*8|N;_K-\$|@ ^T5UW1S8KI/NP6GZ;|A*N(H|8H M"JK L7>
D#AHY+A6WCE#4^|3^/04UL'YQ6!T&>-)"_N^W@|MLZA%SX=IX_1 MCSX-89C"|S
+1R'W|:G?VHO^! P\$OMT_'TV'DSMA6%Z#87&?^M<>N1.#NV"!
M%1P_@)O:"I.R)|@;EE4>8>@ZDBP-RD7N4<,6,_S_L_>MSXWC2)|?|Z|@U&|O M=4<(:N)!
S:W0AW/>:|V^WJ+MG;^|+!|YE3LN2AY3*Y?WK+P%2LF1)+I J;&0A.->H|H M5|D"E8!-
D?'<&&/+8*MA M1C'!(>#X3*N1&AL',W|NV@SOCVJ^2;-' C87;>Z"GHS|=R|?'|IU)*|Y|E-*
M40"R90G(?@>:-OM+RETS_@EPX-N6_|D)38;-^*U0 ?)*YPJ*"DQ(TT'0(Y,DC M1@PI=;&-
<&LI5|^#_-3HS^;U%O59UVK|V852_K|<7EWRN|H,7QU5.8V_-0>U>SNK;
|AV=/F;LJO.^.'4G2WKU;.C#RM*%37. M!;4:4GH;-W|U|T"Z?
NO4K9KS'(B3G<_J9J;&TVPZR2X"C3(5B93!39F9DRG3
M+NC%,Z#6ZZ@N28YE=CR=F#^SC^?3.1 X' (= \$RCM*-^#H'9A;.:|V.XJ|! M|>9P1:>#?
QIF^R< EGLA?%)G%T!DN&|> Y&,.OP+N(UN"9?
^:AQ;071@80Q/>18=O>,0=2<8S)9Q=)<%%-3Z|41;AN,8?%|;-9 MTO-
69O>-2357>N.HRU,S'Y3E_#H&\$3)|!>&OEAZB69FPLS4- NZ)C)&+P/
M\$C**V"||NV'U/X/(A96)5|X?WU(@+|/+*BW6/!P4*0N,=<#DLD-D@/RYJZ-R;YV<M*

^PZJHS9)O@?GGP9>OV:EN!5P4.5%CI0?PF>\$NS\$7#.--S8RM[,?PXV+.
QA7_QT^S_GZO)Y\J9HX\A4SRR75=WX.'D\0I<3*M"U;^.
(f:JBIPO8GXD9-.P=>,C',>"!W9>:&(O\ /81D\NL/_OJ@#G=-_NY*; MJ%D;5X=G!5X#O@(E-
5>6;'-88A"7VJDF/C(:1R 4'@1@!91KO=#Y:C8IG=0Q M5K"B)<.S7*OF@>OZ#T2U%X;P4-
JN#-%3;A121C/D..&\$,,TT7VNHH9WF!;AO M
\$2U0PQ[C]0C#%:4.%9@9E8*QIT;RQZ8%L15Z-X77.P6(5I-DNSQTC7'Q/ M(ES#
f&"Z:0LH,E\V\$?H/^=9RB3A1@+G67!GN.>H).RBO, X\SR\$!:"JD8I M\8H"(V.I1"
MH:UX&:H. (^*?OY\$6F0, M@F7XK*IQ,VUM03S*)3I TL.?
DK6P&V^G(^'5T(79=XT\|D<4<+*G#*0-!SLC0)T M5"',-%6"EX:#\ZB^4G MP;..D8M W=
<;1?+Y)US-D\B\$3:52@309S+/V@LS#\$/ "X7+T4A=3F;=)>UH M., ^'^0_SZX\$E1NJ\
<.:|=ZY \|G5)-!XWZM-IZ>#JZVK\$.S=Z_DSMAR+;H?E M?
%C*.,S70+\$PQ>Z580F^OGGU\|PVWXB'F={SSCK?1(7WD\$8>T;A^|EC55+-\G:/0_BA0!
_F"SQ<\OGGYQZ304QV7\|X/O _[:*_+JQ5/\ MS@#W5HMQ-'=!GRO'IX";IYAZ25_L';4?
5E_5I(P+O)\$#H*;Z?-=J.\U?BJ=E
MZH03\$T\|T>#VL9VDCY0PO\$G40U/7N;D51.4CF\6X^'53GO MNZ3!
f/>Z, @\1.19\j2;5\$GTTMT8\7"<"#I#_4>!:VH;HDG53"IL>NPWUJ6#RW
MZA1/6M(V59P\|P\$Z\$!>/W(&X>#\$=B/_2GHCMCS'H@>I/,*6_*BFADZ>M&TY)B84J
M\$);AL!A3 LE"\$\0Q=-09)BE;0R<> VHA!46E,S@|M\$),!Q\6
%KWHBY'DNH_ \$2H;FR1DR^H&*XJQ?S4W\T1_T03)9 >';Y%_M>W:8EFX\46.#
<)>"12HH\$@3GR.+ MJ;.:E\$87692_ \|Z\G%Z8^+G0\%3T:K+RYVVG;>*Q?|O*J3@YW0RIZHI
12GKF# M+55>JE#5\$; -0)JR*)#.+462LEPHQXO2N3YL;\$?%&>\9X* =>.",B '+'DP>>
M//:DTYZ>QLD#?Z;&;VR^0.60MKF3#WY+!O@P;VO4'\O0 ROPG!#+'0MO\|+':>E"6
MO7\=DY<\$=H*D\)"S7AS8OG,EF3WRJ)*O_UPMY\YS9O+UG\K\;6NX;2QC\$IS\F>A>9:!
MI5<%|E@HA3\$F2O5CMWV#=#7IJ7Y_P(2_Z8-KZHAR>PW\|RS&%#U?;.*T#87^4 M?
T_78E\AR2JH)D,24+6=S\$)\H.32W\NE_PZ")E2SA&HH8\H+ZI&F1<@A+ B
M\$ZF1D+F3TCD)Q%|HML+07#"ED'%4(I:'O\$,J))+:6*&))0:+/2B2)@9,R_"
MO=@\OY&;>^=U\X6"2%;MY>#IY&P_+/\\$>%Y856IX+54B9I5#TG.!*)@E(T19
M"KK6V?J)S=)3^|\@4#T4OPL=|T0G/83_ |Y5C AS@&'J\DA _|Y:"1Y&G'\N'
M8\$8I230Q'.4<,\3 TT;*6H6P53GF4@FE3!_ S)+6W)6/G0*40XX\|P4P23YV
MLFH:-7ZPI#)QWY>9DD:SB6Q'T78>S!+V(";/3S2VE/%A<6L7-00?F*S\0^ M-AL6O3!E?
=\$)#^%CP^>PUH_,MNE\&KLFX:|S%:G@+<%5@5_K;5ERW? IG^ M%?X_,R/5-
(&S/C0409LP=Q@O%&|%;FS?G\$^.*CZ\ M=B.0\R\4-?70+|\DP4
^WI+7L7D&R2_887OU_%OURO^=TGIW;7LR%BA?=:
M7IOSUNDBPM51MQJ\JC%.;*KJZ6LUFT\|>K/X Z\Y^W;)B#',I#\1_K487ZK)Y M\^KG!=-
N5(>!HY:X=(W;=LM4.VY=>.<>DKM>U(-? _/H\>'V>__HV.SAZ MEQW_|\(U./F9O/QX=?
SU\W!R?MW MV8?#HX.CMX<'OV;')#%;^ ^/3HZS'I_"7=5XYNO/;_+2,73\$5J;13"UG"QIK
MG!0E"CU<\$/:.(8V)1TIH0PVA." E?^,67L41#J:WOHTL\ GR@:> 3N@/-YQZ
MNHOUZ+E\5^:J;\$-'TAVH9KLGs<9L^|X MT\?
80=2B\+8HD70Y18R%@A!>>H25**6UE(J<|.SLR8VUI^./IV!%A""_C6L MYV-X.9@-
+^T%J/O _X-|X\$"B&;&EQ, @\$AYGETB%)\AQ<9Z)Q:C\$XSO@Z!\J2 M"RZ\$0,Q8BY@JX)X"&-
(45'M"/J&|?@D<2(>)"19H#HS\< R941!EC04.%=@ H ML,U1*,E!ABI-K2A*+
(LU)BQ;.;HDCJ. :ASYV"FG" 8GDVIO4P"! ??Y%0J12XJH:STA4%Z-K';KSO74R3R93-
3JYK'W@|\@_M';*F\|78\$|ZQL<%L@^W6+D?*6K#\UCGM%2^(MZ86I?T0&X\|
+^_AK7PPY\|O2P@+-(%G2H_*G GD"Z\|+*2P7>IW%GL"0/Z8.
MP\|M17S\|Q&/7\|3\|PQCWB8OW*8YQ,-V\$,0"&U"&^?_T7RZ\|M\00A"*7@Z_Q
M6P9804DX)9Q+!N\CG>S#+NI?71, |=B^_QHXT8%&)V:CRD9?ORPH9\IO\$"Y-
L"7PFFD;\$D0!A4-3%U(<%5\|#"B6L@00Q7 MP.D3*V_%NU<881DY3,'(1Q>\$-
M<;@N_.T71;.:R.FAV>\$2X9\J"74L#3JXLY7S8=DX;+(%:F5Y6-.WQ.)O,QM,P M%R">.8W?
G:GZ3S>\NC+QM;5I=S;UV>#WCG&V?LNZJAF^7QTM1J=M%I?;# M*
ML!..L0(83AYCE.=**Y(@44JJ"@5(5.1GM?WIV/H<.G?LZB_6)MMJ-%D M_*55CT%A-
C\$@O/S\VTDS/9L_ ^9@)F;R>0Q\$M+LRNF1?@E @DK-QO7C_5HA1 M-#>P3E?\$BEIKW
1K/%*=HIU\|W5;X-.8U2KFDZ'6Q?#3, :;+UYS%V_W\|V M78K">.X\$|\&9>
K,1CB1W&!%;JH+B0I6:\L*N/QB#MIL;'R9U\|U6XKO>V&^ ^1
MK\|+@_2M.3V00;I/#G,AR-C9)V\|E6-
(@S;'M6+-9QN3IV=C=Q'OUF4KUX^OGMX\2: ^ ^D'8?:NFER^O,@=VY3PP5@V>WKXQVL
M1>-B%G\$UCDC23T:CR44\$RH&^KQ_PN\$&?L\|+G)\@B\$:Z=HHD\2N(QF=7#6N&%
MPN5HI"|!76@O:4?#>3L.?YA?;|*.Q7GC7C?N7 6G8_6@:;SOU:9"-5^JIM+5 M"-;N\?

P96RK0M,-R/BSE#\MG;+I7;@_9'S#K7B(^1WOO.-M=\$@?><0A)X\I
M(!G*NR!;6H1GTC>6,)X4VR=L^:1PIQ"%;^X-H#.SLR/W^Q)Z,OYO-E#TIA
MX/SP:JP83M1.'SW(Z.)>OO/GTD;I, OOM5BS#=.LF|GY+DR_M,R=4*!"07N MOR;.:
fU_!:\$O5Z/AI4,1_-JUG_5|<_ '@."S4.+QYV;XSUI"Y(44%) O5N/ MAU5
+6!R%DXF1PT4CB=G,6XMA4K;U_U=K_Z';?!JE_J/\$L| #ZE0NW] M=RA2^/(9OPY%2-
N_3A10;2 MC@JO%P->B\$ \$AMI=Q2M*^1|+> |E.YB=55\$|VZ!M'H13Q3)H22VJ%>5. B;
(B3!7L "_:4;<.7\$RMQ_0,|L+U<3K^+XRU/ M(+\AJ7._G>J_M&5>^V,I>F
7\$H;IKTI*T.5I76C+1\$%RA03CX\$)3RD-9&(.H M)85QG@HCl\$|R|O\ NJQ6\$+VW!TT&A.
<#RK;?V4|"OD?"W@/13M8G>=#) #'VC MFIx2PH)=09:K4!XJ>.,J*)
D94&ISQ5G:|7T^FR&^N%&E\B>Z&R%Z@UGL-> MZ*4\$H)Y)
3SXWUJ)MRC;VMAL,R50\$+34,&5"0%3F
MX+EK^%M3IUU!USH;|0LC+93JSKQU(8H:P|E7WX%K|%-_%\$L/U\$BR=/WAS.2T
M/(7)V|+MS0MG+&&HM*57F@XH1E8&%IPHB75A2!F+PS2#.Q./SQV/F2ISWAQ
M//:T;U"GM;B;4_IJ('AN\$Y@9@|GE?:8YWUH"Q|_ ^-?+PG_/)7++TIAI.(8_M*1UKZND'OE>
M*2KP7 WJOG-FB@H|M57R M6?T(#-!AGJ+PL@JUR9 \$K&TGLU!N M.?
G_|_ OX.@ ">LL|X"4CFF=4Z1<'OJ_PS|2%!PI7" I7:E<0Q;8#HE2)"X!(M"&MO\$!-,.(T!Z_
BIQAC(KPW^WL G0W*O!B0?'N#|KYHC=ZYZ'NA-Y*Q>SD8 M.WGFS|M:.&=#F??!S05%
M83R\$4PZ?0Y>4?UJO7&6K+W?MVR.?1JN>T%!RK8/YUB;T(FE#|4)8S=(IM%
M8Y|Y(M/QWTL;5PKYW55=?LLNVW|8"0=E,W1/B7QF|<|(' X+7;A|:(5.5% M.,Z*%/4.,
<|YDH85"%Z"BX)BQ_O:K^)^Q23W|GA1'^1CL ^\R41P0W31UB|C
M%BM48B61|=SFVG,L^1HOVB)74FB&+ M|Y'-)D)+&(" \$8-:YPU.+|9?.F&/*> M=|T.2G0/V-
.:5V)B!;.*% M!HF4=EH06RU%J6>R4*LU9C3Y:%|HS\$R(>VLLS"
MW:H0.>.)E499.&>7Y"V?/8DA\$K|ESD-6N"7V!04H3YDSA4'86H-823G2MF2(>TZ-
S0MPHG2_412ZY=_?3IKIT63Z-P O!J0D^IO+@8UI%D':ZR(W/F;3E+F#T@S%M:U0^3.KN
MJW =7N%0U#CS&MRAX ;U1-OA8;G0_-CZSV2D^@X|L!&?7-.#V2DUCH,?0>%
MXE"O*^# RGP'S8=(^N-C4.1O|_/P-&PLD'0CZ<3|V<6 AM9R^'|2H=|HKA
M./O@=!U;T6P,2X1 QHHVAC_JNG4M;\$0^#5H"C6^)=_D@2+-TVF)T#B!*.M
M0/E.)W63J?/S&K2OW7A|-IJ\$?<&@;JM0V+(&B):=C|08=/GYK&YF87,='ZK MUU5"

S5| (5)U1&#P;CW/D:;%\$4)'CG?*U:G?+ M2A;|=H|A2J9X#CYXD:/2<|>P(Z4M_,Z|H?
C)/P<^40-\$Z|Q=:Z0VFZ60N-RX M<4_D<'T:NRyBN |6RM>3L|CJ<=.UDZPH=8,H-
9V\$#.92YL:1-YL9B%|A511> M=0,'#R*Z.|^(*J3.|.1B' #|K^ =9,XT2M1 UE8&2_---|O9"\$
#K92'Z%B MT",15&G==6.L!@MBE"8V8VS&?.*Z,M6RU9?=B?<94F%\$*E&V&@*WA
W2.:2 M(Y983F79>[7P.B=A-N<.CL;N8|^LYA?F>QHL8!;EKA#GY|;T|"7D1)S")
M7T;P^ZO, @: T'DQW/7.O7KH|P#Q.CL+AGR;<L:D F7..BE:Q:J^4G MH|'D(FY>!#*_OC|
(VFFFS>,1:\$FDTG|I3;,,,P!+Q0N!R-
MU.5DUEW2CH;S?)C_,+_>A*VU|!;MRYJD&=KN;6Q?M>;3JO\ P4LG:Y&L)RO MY|_8&)?
CZYM7/-JR*AYC?|=^KM"7|F;?!8
M|>/G.6A9EX3V7|F_UQWAS^;,"XRRQ^S_,O7^_2O+|7H|'M8RM*>PLXG_5UW_M_.|Q_-
@|M'C,TSWN/(4'A2,#VBQ_5QEDO8D|0|@|:G,5"HSM3?,^A@%H+TN),XU
M\$H4#TR04067A.++&%IH:P;@1>V*:^E\$LO S+5/NY-|6?4U.H/7+\$_J*>?4B6 M(L&?:
=52B4>?UM\$N+,VE*)\$PH<2+|Q(|.J'(\$8:--Y2Q|19,CWK6YSOK'IV_
MPG,I|YBDNI=)U),YVB,>35|V|D)+VI7M%YX*^;
(WGL(>=7.U'<;6|7NK)V4|H9G_U5.+11P(U3|51 MF99&2*\$)PKRTB)6"
(J51|)RIHFWDM&U:MO|@DT+/:LSCQX+,BA\$PCT|)9Z MU"YY?
Q1+,G|M=|;9GV,DOLYLU(:BXCf)6*%8D@3RQ&65I?,V1+^VPL;-0-3 MU_N_GA1#*9-
|ZXM?G|;0|BQ;PMG)U/Q|16RW&XY)T@S%MIPJ1+)7!M4%"6AI2|,63YM3<_O|!'P|ZA 0?
F-L-T-#?JA MD'K7Q3E%#I*%W1LW(\$4.|M5;C9B IYAY MLMJJ\$>M'|(,R?
8^IR|0:SR'I("7"754.^C\$@!|J;QA9<\$1S4-OS)P;I#4F2'#P|LN<8DZ+Z_#'
M"&ZD+Q5RI0+().\$3./P:\$6\$+JC&U.>7|?"B>TF+ BUYL?MS(Y+USY/=";^RY M3MA7^|
<7'DW^ ^_,R8!0S+4E9(D*X"|?@P0TOM\$"ERG,IF1-*K'7O|*D!ZX7K
M3LD0|JR*"W1>%|1"N.WP.O5W^?;U'EZV^O/0^1">G;KW':NP-UG8+|Z' XI<@
M#S>U9NW|+.SN@HMB4Z|FBAE1A|O:%H4KC0IA!|?:A>S'HJIP8QI#&@B+&
M'4,*EP1|*QAH/TF9Z'EV|MX=:NJ#D SV@3/6B>9.4PW)|;+T/O!F5 MZ!ZPIY1:D9)R)+!'
3|H PH42(|S!|2D+HHPN 5RX("\$@)MIPB|C\$3 GEN1"ZW^!B=7,T=J;?(@|'
M|Q8,SY<9'A7?"ACFPY|K8|A_!|):"S "LQ*IRQRB A2(\$0V<8PJ M|)@AN88 M6|W&K;0N?
K7270Q_8@#KZVM\$W_B1 M^XIL5;O(*'K|.QL_,96S?E(7;X.OZX%
H=%-8|3|3)G\$^:V,C|;R!^W*CV|5FVM=:QA\$QN7M\$|7Z=2':|L!|0G|B,R!4^BS'/

M!6^=+I*.:NI6XU\$UAHE-5=VULU[]=:] ;IEQ9C9I#P0_[4:7:C+IFMJ0,R3
MJZ'JP%%+7+K&;MEJAWW4;ES:YN=MX_13_??_KM_7'V^Z|OLX.C=IGQ'f|<
M'[X]//AT^/YX8R_XW=HWKL_9#KZ>(T.OF8O?UX=/SQU\W!R?OWV4?#H|
MCMX>'OR:'9_ %|^|/SHYSGY\VT?9W|:DY=K#/T=4VU!T+)BGQ>A-M:X4+;1
M&Z,1|SK\$E(E'2FA#:#.\$X+^5_DUMJSF>R%W&AFEZABCUPX')OL2X|1;EW\$M@ (M\$V
C4R+**='8^SRW:T%?KZFS0BNDF#8(\$+1!TL\$G;HS("Z<5X^PZF'Y_=CZ:
M7#IW|.HOE7&;L?5B;S7"Z"8"X^7?WTZ:Z=%D^C<';S&3SV, @HKUZ4G03=:R|
M(Q^.#K<7!.T#JRUA(N(F%ZX7Y,EB4E47\$3-
+M,S^PLFI":O@X*)JFIW7\$QTV6MN@7;AD:1Z9J8&6=:7@Z:-1&/|,38>|6H*-M9O-
%:@J_6XVT;@^T+O/!9G6N'JJ@/|N"@#":ZU/6:8_97+|+G|9G1=F: ^
M&L/C*C7:S(CP3;BLN6+M,\$Q@9QAE/%EB:|A"NS"H,J>5^ ^+LF^QT<@?\$ZD\$0
MG0|.U|&)VA515MX: _CBKIE/GYJ+4D>Q?_DD2+-XTF9| ^."UEV;U U,(P@?
M(&Y)4YS2A#-H>W&ETNYG.+UPVA|PK>\$6PL+'13_8X..|9V<16OC(=-EG7 M
Q|.CG_)#H|?9@++1W/ZXY-?5V_*O,=?+ML;")QR9OCZ<3|F2W_T"N=\$T)V
MM6MFHVFGA5?7PX_@?8Y|LH|Z!&
|^",9LZ6/<|0":R9!8;D7/-9!BV%V>\$U5|6F6.U*;L&23&W7GBL8|
MK|Y=B&KO+,Z|+B9>>3N8'K;.&?|W_M?O+3\$ \$|8%L5|F+W|^ .NO!
|H|_1P">^8:>+0SIV,@R^?P?<+SV^0_6G_M=
&BA(CF0<#U_K+80:3\$%P+*&8RJ^\$QPPSD%;YH=7D6+Z":'_SP8_M@ZH=P<#GDWH:
(58U;LWUXL6|S=PPKS>P,2#NW:D_ME<|.KRY|N08F&9V|?
0FE:IBA*X!!*M=P*ZCR<7KC71=+H;95|K>Q|?427|
MAQHWC100(|GB\$|^+Z_3|ZQD(31U|FZ@:'H95#X_ ^ ^OXO!|GQ'|+8R^LFA-
5*+LG#WVQ!+T|K^.:EFYY/6N"XY|0&9S?=@NAG\$K\$S|/U&CUIC=M"EW4P>-)YF=U
MA).+0.:UUFX.M*)|MD9YL:XM7KM:YABNZU:T:??=%2%V/;E4H^GEXCWF|(|:
M%TVL1P7J+2RQ(QIURA#"UI4:X\$XK=Y|ZTS:DEW2?X8R6(=SY:OB"
MR'(8CW|K';|P>|OQ/FBY'P+'C=TT: ^#E@'U!"H"7XVXB")I3D9=:5@O|\$Z,H
MEN|K>=5Y,5W(>Z1:9|N^+##|U|4*"|J1JHZ:|+F\$*C0=N^|!#-
I_WLZ+@@M>%,CEP***,4H)*IAP")C?.YX4|I-IY7:.,M|08\$P!9YCI@HPO%=:;%!CFK!PZ:5-
+?B|?|\$;OZ?R<4#,#?M.W-O|GS|Q1N|M|(+@TJ#<"HZ8-
R0T1M9(:U%P*:A7>\$WO>=|KE#L+|P2|Y|5'4AJ#!"R-<80P_M)=T3|T;1=|
|8DV,HE.I08B5'AHL"L5)*X_QK\$9/J-Q9B<7:>53C#%\$6M(:\$ M!E0'
3<8RBBF"l#"J\$4R9^8/43OV2,@KL^ #^|A(7DWIDX3IW92O:;|MP_M|/=A?
Y4*6EA=&&2<BY21B)9&(%885A.L2J<7JOH1FR.P=7#J'0^'-17'FGA
M#%*YUS(GQA:2WXJ+CMST.%#LI'+V9++*4W<|A|2L|U^)\$X"S'?3B|'7N0=<
MPP":.T|X)02N\$:A5\$6,T2E+)7+/4"7|5UY7')1NA(9#ZJ*4>|160#HT:7B
MVI18YZ5/7'.7(Y|P#":T9P14"|>@>')L,@|550N6A MX '*>T|2H%)P"X"F-%)(^/'JG.Z3,PQ
|U@F#;X_M8+C%<(:JB|T#>%!:|&_M2P-J_R+"Y^TE185G-
O<>0>^_=HQ:TZT8R:;LU#JS4N'E"A+6+((<,U:|E-M|//=|+->#6/-&Z|#,
(+K7+N%W'_VPH:|94XY4D2'GK42|. \$W\$TNM2|9|+?6_MM-/.(DSK4/I3)-V+|<6S+L-
1N|_5.(:Z_4"W_29XW;%5=9O\$'Q374A2JC3K=MD|E>;35G870H|BM>8)
NSWY|F2V%^MN-@"|0/ZJFU>W4V.^M|V.DI*/#3RPAK.UP#\$.!1_MR.2!)1Q5
4O\$'0D5>QD:::)+#UEL-@5JEUX@1"AD5\$ MBUVYP9R.R,-#%F|PM5&UG&'D-F0X+
<6AFY7EFY.LF=5?JDC\$B1YU)=ZS><5_M5FU!B?:-
U_8)X2D70&:7Q42BN\$4W)UF8|!FPX&G3|>.%E!)XP)PVW>Y9NSZ+M|/#QU<;B|?
K2#ALW%^-M*|.YFD4<467A<\$8=&#LG\|5HLZ|"U!;1Z"
MPP\$C,PL1|R|H12WH,@5!"PF|H,8&X<46/+ #T|LD>#7^LYZ=3|UE2X-F,OKB
MON9R>A-Y^=RG.TP)&Q|:5.|PK&QM7-K|>Y|OQXK.Z:A,EE|VFJO^,L2N"|5
M'JS2Y"+P=+O2|P<9%|4,J*3YR;K%^%'**M7H7#KF4A7,L^V)!T_M\$,|Z')S78.%#
MOJ" T#7OCM:ZFG7(!B37.A: ^7)P1^#|C2YXX#_M
|I^;A8:9,&+6TD%_+XNNTNRMGC"|EYN.:2:EAL*:|H-GC3W|3ETK&_D|K2
MLS%,H|LDV_9V5=/,XA&X#U6X.AY': ^,-*|^TJY#|4"BIG.)7VC,Q9*UY|?^
M.:OJ=G'CB^G+9?X)'8*NW5'%1-*FS7|\$PLZ"Z|Y%QELZ8*_M.0K1
'C?.@YM8=Z%XE|C>:O1EE|H>9O=;E|*M8,R%VW":S4=928>R=M4N&U_MS((EUET)Y%
|CW**6)|//|HG!|/,W|_D|X3+58Z>7Q8F!;!K_C3|QPS>-/'#_MASMHGOW8DBH;77GB+1O
;XLSRNM,%PV@:W|:(#2+41?/^? \$6#|JL9|KE^H^_ME6_V*9GJT^'Q|^_|O3OX-
9;C.#E(*5&K*5\$+&+RT|HGH&,3^!C/|/):8E=4-V!%N1P8U5WE,=K51'
MZ|YUM,I41RO5T4IUM.Y?1VM;3:Q;'MR|TWF_E5):+Q=CL_-F_J:FU!01*UE(
M5|V1\$E(AAXG_E#*1%_GUV"%L,9;6%|@P6R#FK\$!:>8*<-T(ZX@219"5VW":O_M^ ^A_:6|

(NR{NFNP% W^CM*MTXM)KS<,UGV99A5:S@OMS+%;S*N&_.^&E6=
MZSG [2J' RJ3IWM^W+R;-6UDL'\$ ZK9AT&JZ(3S0W' &H O9-.N1WIB5O1^I
M9M08DAM@6FY#,TA=\$B2QTZCPDFN%%?'K!5*^FJ&W;9+<(?!L%ED?O=JN^+<
M1<0)@!AJ#|VN1B|6W)?K:=L7\3#\$O%CS\$Q8;'DUP
MN.U2R*BKTS3G|!MN78Q"D"D&*^,6AIETG9RB|*TUQVA# ^>S&<>.,
MKF|BC&T>5^H\JZL)JS?-Z+QW6|!P^PI2N&9-.*%_ "FU@6(F;T\$LDH7.G2?4 M4;-6-
GQGXO)^'GL|BC'B=HOQ4Q?W.YG|SNLB.OMA4H|"'V:SN1YID%OV,/ M=A/GVSGGL
@@4G6H\$33>MKGSOKK;|G-CE(31/'::Z|B^FJ^M;XC12!::!N0 M>|B^SUG!E%
<6X3)4))&E1(H '*6%|)@P2.VZ/QZZ>2|=V/J3" M*0()WSJO9 M:/JO_B42(NXJ?@KF^'SZT;?
2L<|24.Z-%&0Q6M %WD:P;V&^'5Q"\$8*OO|6 M+N+2ON'R?O559S^0JRO,%R+?-
Y^V|:\$UIN8-W|53@|;KE5052SL*A*TZ!_Z2&H^# M+HBA|^<9C1LJW-=5
(&A^=ST7VK1HKJP89@/RQ<8/L+RX4%H/+ #Z=J=!DV M#F#-
!MGQN:K&B\/*;0>T|!#^!V'9R-KB"TP|AE|"TKX#4;HQBMRMHBI^8TGK_N
MTB|/"T9':AN29G6:U+"6S#+|AM;*-LNVH9R38OU'ETN+VRS85=J&N;/ U6-
M@M69!A;Z>%I-,KBC&E73=GOKFO L|R|6JRPUL_/S4)OW%L4,0JV\4'EX|2&+
M+?;H+BZYBGXV6GT?VP9GXKY8V*+VVBGU?D|"R&>?%|.XZQ XWEYH*JY|B-5 MD+
(0C%?:?W29O;C((5S0^|=&U_D6W=+9Y)5|U,/|71JN6JEZO)C2
M|2G\$X:T|'^\|37WBV,=7UBZI#NL6*&_XE|_VYML9Z6+M J_.0\$1%72"WTS>IR M^+8":?
|C2ISGSN0:(R-HB9@O#2I=")V6)9="&(7EFJO M#&&\$H5X*7VHNPNP
M11"&1,D=+86DPMXN|?9|(DJ|AWX30?S%NIA2_8@R;_V8-U|FN\$@@?!@N'
MOFNDY!X)@DE(Z.9(6DU1SG7)(U:: I4EMLAP9@C. M>9YSG+#P\$A_Q?7;|Z|;E;
|.WK_FNVN+EF01<+KF;:: M/-7PI*OLUYORAJ_)V@,)"C>8%>
F;#>300D"X+C,)3UQ@!0IV3?ON3%|> M0("RJ;YV^=Q|("S&.4WHI.'RTP?<\$Y\$R|=
;BE&0E68*#;7F6"=O*W;::MO MY;C9_%30M=2N#?#KYDV2MKE,K%P=+_JXQ=!'X"2(XI
(0CQQV"C'M*2HMU@@| MX4+(1S,O'P,X_0'::44^/|5IM4MB^G+VZO9C\$|?NBQ-
B;Q7@|(Z(8\$B"G"+, MA*.\$4D6<6E/ZV" LJ B4!22XI8#O?
P!@:4V8|);@XG9%9IZ&M|+Z80<9 MV2^GC.@OU>3SEGJ@+S&&,\$7AC-
>*IMN;STM;!.2|_-"33M;P\$@SW-C!ME2 M(+*9Z7:8:'F_ WS=7_X|?VGPY._+1V669Q/C D
+N85S(!&=@/\$: '(WLTWG M.?HDRBFVNIMK/FE@-N*E0
!4@6=ME4<|HXKQ2>M*%TZ&JKCVTU0Z_*M?
ZZ>I*RZ9CP;.%EUT+*,2182F<.,0ZNR^6AM%.1;8X1| Q"@> QAJ?!HF^+M=32AW?
*87DR6#J#.SSL!%>:2,_AN;D%|7=PV/*9,"UX-.5WI*_I_8 XFFJ
MN0WUN61!9"C7A5\$10@VX7"PW@VU?+V8@=.D!)<">6PL8EXH"AX^#FEW#M/
MA,I7G8/?%V'PCWY>.,5PW &|KE_2;2\$<^5;IU+XC_T4)TO&V^G!7 KQTK'SN M=;;9.
OK>'V|Y.=)""F9/X'64>X|&9^TVSG6A70YMU6;+9^(|+39U=E.F/#* M-!F>
(/N>0C5,XBU0%;KN-8QA@!|8F;M.E?+FR|_2IG:++@6<?07E;4.)M.1H@.
H|M)F=S/3BEV%V;HMGW*MKV(*|;922XJ0*#+?T&I? M9%O^R*
(H|CR!9)\$_ \$K)%0\$VB;BM7IXY'M*/1)U'/I.VGI:VN:|O2G7#AMG\$ ME!+5!3"KMI%N-
8DMYN*9_\$B6;VZI?|^PP^S3@F;Q;'#8YUX4F8"W6RZ;\$%MV MM&?
BP@4A73/V_6I0WM=ZL70KS5@EE6 M'(#PA.U.P'*.
D*ZE|@9MDYCB.MZ^I=J=>WKGYYJS=A9KBG2AG"GHF399006B35,5BS@ID%40&*A3@
M,4:H/YKH"V=@6&V*IM4>OY4!T9)J+T/KU*V;SIS O3;>'RU/3\$W:
M/L;|H.KR3;=L7+\$54.'T&ABW/C8V<(N MEP%1W2BVO:)-
O9\7=XE|J4;.=&Z6;IJ0G|'B3"XW;|P'EFK:N%;ZYQ7+5+
M|/+3|W)63;Z:DY#8+%51^..K&'YG4U:V"JH&#|!% Q16"6M|V 2&NK2W9I4K MM^*PY?
H>;*V.R?G(S:5MV0(23\$|P97|, _A:?!+KEYW=?0XQO7V:|JZYNI<
MUMK#J2"L09_471>/|39&5P, HP'5FU87;)SYIL5?7KGE2AFK)FD#N|6|'9' MYYGK*_>
|L6W+:Y"BOV&@&UIVI@/^Z8#_04|I|^Z8!_N#_Q ?ATTG|&PI# MWAK-AFB,.PO!|ZLCJ=
<.:#46XK19AF|O5*HQ+B/>&&HBWF8QJYS/8&@AJ(SYM M!<>
_4*0K78PH;@G@&6;'+=Z|.VQ_UV,/=E""9?0X.;AKR0ZS/P6(OGR. M*4*N-
J3:=\$2_GUY;@|;MN< M4E>80A-2>J15T!?'*:.0*FB/BM"
%IX54Y2YZCQ^.P9=P)^KK|S<;O|T4;|ML M_GJP#V.=<\$"7*RCMQ|_>Y^='S?
5;N|A'IV<"/6DYQ3I"S#A9?E|))XTMD MA?&8><49;|M@F&-
SZNPLY!X'5H=7'T^;CW|!1N^_G@<1_6-'1#B) 1|M_%3 M:K&^IF|B ;E0C"#|4;<4_*EK%!
I(FTW5UWGUR4X68P5A|'&|*J%=C|A%*8.% M#M_<*?
@!;/\$F"C|F|BGF^9NE=P4=&_HUVG<>=B0#Q7IE%5O.;Q0N!R!#SR9
M=9>TH^\$|^'8_S*^/N:|<.:|!|8\$;N<,-'JMO>|FD|YK#PH|C;MO&NU_-G
M+%T(5|H%Z>*PA1@R(7Y8|G*Z=V|=G)|ON!|=8|WI8/A>"/.V1ZR;U|

MR7_]>5IO\$I#.VP]>38C-?ZY#DV'4:6H?_JNLJ4/>?AMQ>-W&'<(76V1K->:0
MXVK\B"Y\$#GNE%FKX-9"8"\$T7U5=U&)>/=FJ"/OHUE7%_H.DY>A<|_2?S#L
MG;7OW50JK)E|'IN>+\$GIN_F4;:#4Q@X/_SZ;ZJP_FH7Y%[\$R.8QW?-I6_TX
MF^.@O5Z0.Z/_6ZW7W\YV_?C4,?@G3-M;7V*!P\|M(C>L6:L1<_IDJ_:T(I*L MR,-
;D8<5J1_C;:#)K%%CV_R4C\$T_C U)MN:L;4W8^D^&Y4G%
(2FJ1>R|>#3ZK#AW1\$=BB)L"W|O|ETQI&&+;:#U) MZ#O|\$?S@3DA2@G=TY^
VT;H_:X|BWNr-/W^_#;='=.AOM:;!O9W7=YFS,JRDW M;66^|I'9>W+Z|YW=2|3=5VY-
Q'INW)=\$.W%K\$NUGR7U)M!.W/KEHW\T%FV^I MWL_;6LX%CO-M?-/=K==R-N#5T95N
OD->:C[|;+|,3P>9MY95ZO1'67F@1>F M1Y1_2LVT//9XTE,:?Q?GWIYP_JP?
SMP8\$WMJ7HW7/:B:V%(8BOA<">\$1P5HC
M9JA%4A&*J,4BM|13+,@N#AMT<:4/K9L:UZP4A;JC^-WBZIO=+DH%*+?*@A;
M##C;7MGS:P+ D)=0@+)(5V MB+,26^&*THJUVH6\$6>NQS9\$J,;:PMVJ4#F23K%8,H4
M66N,RHECW\$B)&_-5#&VJ!16(<%+5U+KN;7F:5P>C >8E\F2|-[EN5_V2@J=
M|DOHM)FJJ>N/KNZ!9DXHHK|.*8&')P4/@H'K*2VH>|L,8B2W2!KAD>-&4X&=
MD);N,%YZ"33P=C^_C\$/:R'8@!0)03P+6>V!9";CD1@R&8^-QJ/T6E\$#GB>S
MGB#&0E32EPH1;!B6AKN"V!U&_A_%>"AD^EX#I+: |E,IB,Q9#(=&TV'S:7\$ M7A;
(6N,1XTXA55*+!+/8*ZX<86N-N>|1M'PDOX/E:0^L-Y'+E/2Y1Y'+PW-6
M=FS|HZU|H)L3?.BO2DKPX6GA0R\$4R3E%UGN&&\$)5'(GD* ^#QZD\&0MA^8^
M:9Z3&DS-^,'V/ >X3%|GLY#2'LAD,AN)(5^|V8B%ZTEBV7UDV1XP:-*AB2&3
M#DTZM!>I=ZEPUL,\$I-XY|^JV@V+OB+47W)=\$.W%K
M\$NUGR7U)M!.W/KEHIR2"9Y|\$D"l'|8EF2K&A%,Y\,?4^)"ZL4ZQ\$5E*.F&\$:
M2:DYLJ2PV"OI>+F3ANGSB%5W0'M+X^M=E_W Y4"*5*(J5?Y()NOI:9Q,UO,R M69L-
2F\$D0X)A:3F4IFZAFS M;#)3^>"DYX19FHL2<6,-8K9T2!(^_K_ M8J7+|F*L#QM4%7C
<2|2:F_DRF<+1Y*92F8JF:EDIO8XQBJ\$U8)ICA13##\$/
MAK"TEB+A66&DR#4IU@H\$W27&^DA!U5(,)7)(J:H:C*-R30FT_@<3..6_N_8
M<*&D1\;D)6)\$,_#>@L\$%6|<*4DAMJ=M+\$|V\$|_#+(20^W/MNKAXBG@R?%;SM
MTLM<(Q.&%|K5^VT-WJ^*GZ!#2ND/=
|WE'.+NS6S5G(_4Y6L_@9JKJZ9M("Q1&:%YKU;A1%69|79,MWH(-
"RJ^2<;:JU(5'D/HK(A+RFC M)"|OQY0)F-K2YL2?SIW#+\$<+VE3C\HHDN@&FH
3@1=X+*S+G#OBF#C/?|CV MQ"=|_U6F^KVN)G4&?%)-;*,.)K/QM,E.U1>7:>?
&6>VF|:0Y=Z:O|C19:9L MH(&SV70"O'|FVDV/769|QX^-MG\$QS^/W;FJ55"GPP6_
E\$6_|8JHVAV!N.: M^;<+T5|;:@_, YRZ7?2_18HH9EO+\$_.%6|U:EZ'#L795WJ_#"|JN|N|Z=
|+-WR6+@%'G!:J1&L M\LB\C;|7|HL:S>+"9B DDPLU-BX|4|5X"O^#D=5G^/|FFADP?
2L.HV|P29W M+97"#\$!=N6DSF\HTZ\AZ\R?7G#^X2Q8^48>*FM+^=;E-
"l'/E>FLW'6%:O M+YHI#|?9.V?;2;U^01\$'KBA&E=GL|X M(/\$+X)Q-
|97OF/\$C(%IF2%DX3Q%CC"#F#::3HBVB@DEJ&'6\$K976+ HF",, ME5@
K'5\$(ED*CZ@LB)>YTUKA:.)5HS^;UV_G1/JMI1\$ VT_PUPJ0<-%%L8)GRMU'TZ: M^T:?
6B(U6YTAON(,%=_:SBK_H^@U|X|F&8U@4H,OC2G4;M/:S5NSB=-5."@
MW%M|,U(7'2(!U (&)S#2?RA@K?HRPX-H3X=9-!YO(S->N)I@%C@U9]%,S8|
M50'75\$W4;,E6)/,@96P5YJ3SH=,=F4S MV)EC\$D &\$U-
%11!5P_1J@6*FEWC31!X&FD|&8>Z?+S,l:V#%&L 3_1B\$.|(3 MNU590Z-P5>TR
)FUK0|D_E9#=?48?55-0K?'\$W:_'!1J/U !2+3WY=36&9 MS'0!V!|Q1@0JPV4<
|/\$%FT>;|JTFV8(J0&1A_4C^)|I"V"2#L|;+6_U"- M 4<&:8HGM0.N:-(^\$T+RT.#UK+|,F!
9VVP&^)=9K 3J.9|3@';K++Y)DL MR)-.=&" ?^Z_%3%4&O!1*3): QZATB\$E2(\$|3OV*M
M98Z|^O;|5|#!X#_#&M:7AR\$F<'N#+=+MMI7RXO0!, 'YC\RB|M 5|Q*X4KM4"R M")%;
!A(&98C9|#,N68YQSLYUK\$'? (6'VX._>*K8-KV@+>|8!@3(5!I&? 6 M+C0JA6+
+'G)L"^9|VO(=X>| KWB+3S\$>|%<*|BUV09=X|^T9<0V\$%"|JZA@ M K9S|JAY-
EB)W@;)+*#>X&#&F&J(9(9K9F, *M.ZTK, A\$(H"L98A%\$W@-|P
M1BYK9KJ|;*7JX\$5K9|0,(%8S Y|H|82"

O.|K98KPFK S|*>/SO<7MCTNUZ!+|DD%4PF_'E(-XPEZ @WJ9V-C@B047.OP^
MR.ED%/8QN|/SN;J,P|%#EV|6,WB?NIH""PQ7XA(@L%&@FC8DL7-
1Z5F!)6Y,27WEA1XK9R&4#H'S|>@G_B_F|242&*D6_L9T51%H!@
M5|*J"SS@FM|;^GXGOY|0%^W1;@O-V(MR5&'@!28Z!>XH<%#27X:"
M(:7T.2|HFK/R/4YPY)YC<^KL#^C&'|EIRTJ_3IKF%Q<\$|/>Y-0=E'1GLE|N_MN,EG6*[3D-
EQ4#MU\$JAW A/X930Q?|X"D37J|."?>N9>O7|%%39PO8M,=1U M8--
QYH|C(/O/P)2!|TNY/JOM355'38./R|M2L ^*NXKP,@++4G8;|RS'@C
M6GVDW)G'(_U:ML@|TR8FVFO*"@\$C-)GGQH09AB'@A<+E:*0N)|/NDD5*PS#_M87X|,-

A(G3?N==/&6MUJ*DV\|J6FPZ-A=74UJJ:7K^?/V'(JM!V6TR'C8=BO
M@6)ABMTKPO)\??/YOMNO4-^USOO=IL<%B1?^N^C/GK;>EUG\WK?N/HM;RQ
MU.4FE7//X|@/D2PN7W"N^,|*%|J?|(GI>Y4A_:@4!LX/O_|;*YR_V@6Y|U^..MH|<+
&J&0VN|>LU|_ "7OC|M8#B0XO(G4MS/,*J/:V)"O2G_(==Q.I M^V-
@;#)KP.UN|GK\ZSF2_1%-"TF6Y:DM"XGG=I(9>4*DE=1+4B_/6+W0I%Z2
M>DGJ):F7AU\$OY!99NN'=\$1V* @FSK+|Y#I&&Q9"&@Z?GDZ8*^RZOPTY=R.KX
M'E|#/|B#D91@JK6Y#|YZ:E:T5|;N88HT|*7\PG|56TFU5+Z9D5_PPCFG4)YK
MAIA1'DEC"N190> O)TBOUGL^9!H*[0AB3%O\$N!)(*,DJ7:E)>E;*KU/.FCAC6SC6|JL?"6#
|@HA<56?HB M|(\$^@%Y/U2=8G69^78GTPD|E#)E,SN8XK1=4Y+9\$1I0% N|4
M(UDZ@UB);9EC7,1C|:LF)R^|I^"M(FIDCE@>:GV!:4+\$8RNDUM+)+;65^FQR
MRH\$H>M%V+TEX'XF53\$YBR&1R=E*"E#M")=4(4|A3(4Z+-AA)."?PIK"6DW7
M3\$XIO/66(^P|@WMR@|3)"_C'%|+|TI>:|9_)P>#E;_"SDR0|;GVV|H-M-LUU MI52!/XG-
S\$)DERLM=U5|;E/!H\$|H*(I*V4R'%2U(R MO<&4WKTM1:|-*<&#
I?)E"93FDQ|J7)E"93VK><:N|*OFFE)P>_%6(%|DAK M+Y%F)3>>EV/?P8MN
M+7:RJE@\$'='+0&^!^A>3YP|61CRT>S\$@U(" PAS,TJHH|;-6K>^&3OO\I4O|?5LZ
3ZJ)S=399#>: M-MFI^N+;#EFU
WU|U5^LZ|3^O).X#X_X_|"6)_0'BCU^F_4^KU>9_\$"4Q;|K M+4;FW|Y"H9'=-N-
XPAX0FVD VG|9J_59X=6^T"|6N&N_XEM3+Z^101-Y\$5; MU2|:N|#"878V7I7PZR9H6(
E"3/N-GG;+S8RN1O;#26LELKE+W3JU0O;)GR/MM;Q?
K;!=K^T'U*.JVO68-.NT4=UO8&6?T!UKW|NF7%N+FO
M/!#_M1I=J,NF:XVPS).K("EPU!*7KG;::IEJQX7%|EQ|;M>+>O#K?|_|-|O| MX^SW7|H|F!T?
OLN_?CD^?'=X|.GP_?#\$=M&)|^X/F8X^G@"-3CYF;S|>'7_|M|?#='P'|H|FQR?
PO6_OCTZ.LO|H|;9G|;DI6/HZ'-U&15J M.4)J"DU("Z64@XQY012!|ZEK|
MM;EQ5U'BTIFU;6SX_4> M-(V;-@=C^VNE8FNARC4/TJ3K_1V=QVW1!>
|S.5PSGF|M/#IVX"-V)&X|%D8B MS|ML|5>3K6|Q|3T UC-ILL6'94GOW(>)/&
|C)S*4DN97_SUZWZEG_+Z/U#)D M7:|?2#7H5%_|N5!TQO6V|XJZ#ULO^S&;1ST6V7O
L'M\$K:0">D_=I +V2P6D M7G#|.7>SM|W@|J6?Q|ZI_M1?Y1Z"D;K#/:DX)(63%\$Z?
UB/UBWN^"N=^9|CW M!;H^>:|W3M-
*WZW0)+WND5OWY,3>_.1B+NOW)J(|=RX+XEVXM8G%^VG+(" ^
MG,,3|WK@\$WG+Z1U7J6O=|/*=Y0_U#<0=N>FW_X
M.4P49DCD11'.M5.D"VR0*%U9>E=HFO? F."R&/ B|>|Z9N5HD|?Z*%
|K)|*L\$,)X68(1^*B*V80E@03B%
M2F|Q|D1YHYDO"OLPWNK A^/=Z8ES3S%79P=B^NU)D.T(9 @|P:H;|/.2V|U*:
M#\$EBR&1(-C>3Q%P+<"!0*(&&F+8>2Q%-|!\$/|R@')4XO(MWGBK;8|UC|S5
V/JE;+YS1ZK36(:_TE>:H)8.R)HDH XVEKJY*GR8?_>^56"?..M4%2".J-H 0G8L;JM6S*^!
M'JO,FZ|/0IY|(+W)P"2&3_9FLP?K%2|R21"V3('JS72GAI\$<|RY9_1<6/\$@
M'NS3&A@J|C2%2/OCV:9|V#WR;#|>90X|U;AL="6>_='R/=#I"7;T5TTEV/&D ML-
|T8*+\$B/ \$1HQO3TJV!<";|D1@RV8_-|D-X0:DKD"NL!UM@^..5IOW6/?)*CT|5'0X*-,
|&HOANW,0>#/W1X#W0UPE2|)%=' M)4CQI)#",44=T1IA9LN0%
PNJ>,8N1QC+BSS;KWOR0-MM;Y=4E|'8_N+&SMX
M@R9JN%^"@EN^X.UD9_VK*1T(01/^> ZRW0-)3L8F,60R-INW7<\$7M81JL"Z&
M(:L1MHJCP@I-"96"T773Z |S+;KDQD;1 D!4M|X^RF+=@|*BQQ(Z(T M9P5WE!#U4"|K
|H|;58F'\$,:YP91;L\$OY=Q39AZF1'#04KL*6@|X622T!R\$LP>B
MF*Q%8LAD+387/F!E@57I\$ "E*T/R"Y0C\SO(9ZYE7.>9J@|7820W@'5J+8E"D
MV&1_?,NTP|E'ON6OKFE>9U_4:|83#S(U&DTNU-BX_BCL'JCGYX0@|MC'=H_5
MV(.R|/W; K|D%/+C?(T>&>?DO"@ (80!72DL0(YPCCK01&V&CKF!6<|GL=A-V*
M<_XZUZP'<|6ZJ^K#95_RNN|<=_D)5,I=>YC|E,QA,H?)'"9S^#S,84&4)MCG MB!D"-
E%I@63.2Z1LR4--"",<>Q"W_|,(2;E@)2|V&%^T?:P-|O1Q2.'#(H7
M\$S(XF4S5"&2S%>ULJKYF* @IWPDP@)(R6,E##28R_87JHR-TXB34N*6.X*)*VT
M")"-8%PXA|4Z@MF%0W_D=G4R"Y<,7/A>;/O\$V39"O%/5BE9I3UCV625=A|F
MQH*+CF23(8P,RW_1RX\$>,NE*,4N'/;WJ|?U""%;),#+(17*D|W++?1-/W|.I M?I8F;Z>JX-
VR)|Q4I/GU'47F65+|X4\$&K&GX|=|>D5>)N(^X/I'T\$2LY|9|
M2;03MSZY:/=F9R,E0SX4DON|GIP##2|V?E(C:>QE:3|QZR*S5Y3'*G'JBIE M;:T-
YKTO#%"J9%8B10B-)=
(Z\$MYMRC.QNUD=YFLX*H(7!7Q^@ @/9ZG+C">&!D^\$<#DQ)H7
MFQ=>FD+*+,O6%YVOZ<5K,JT;|SLRYXUX^+|B7S|(*1J1' M2(^0'B\$|V@UZY
KOG,TS0K, 7_F*+%949""YD*HS!GJ|_4E"5;\$C\$3:@^8B M-<(\$ 2(@ (B
B(" +@ (Q#0YEQ8K2AA3F@B3!#\$<*(YD6N@G8B*+F^!,&J\$##K M*8Z|YFT:

3=9*!/ZX'6E3N\$PC";WE?+<5B?10?EJXD=A,ZQG*?ZIS|U@.X|M0K*OE/#
<04=|X8W*!9%"1VQ\$);2CT)W.946R>:GF^8A5|^"Z0DA5NYRM% M3_.K
+|KGIVCIIL18"#>(5XA7CUNO&*I9QZ)1V17.9\$<">)R3@E@%8JR#3S MQ2UXM8K=?
=>#5|GL<8%XU8FM?N%W |W|C|EH'\$|.PZAT|+
|00>XY4@.9W#&'WWOCW(RGPIQ:L==<|;20)"WB-! K&,D= M"X0&R2W3.?-
R:25G",ZKHK!\$:FK!|G-+#!>"%#K5 7X4/BQ9?'D'\$1|>50L MGWEU D_>^5"Y|XD
6SW(@|L:|+>=&*@'^H(5SWL)V:453QSOCEV18WJ@)PW:% S MH/XG-LJ8,QD7,VW/?
F|LRAU_*NFO@|G)O|HP|4H+M:S/63YF.| T611;,.TSC,&W MMV_ ^|U|:5|^|
<:GW9;WJ=3IU7|/?Q3;|>|DAO|FZZ^|FW;?D= ")3GW
MKZW;;37PCYGL.XC05DUJ_3U4^L+=E'L6|>-^/GO&=BV/!H7\$7V+V<&/YM!
MR^;&R<|!&A00B)3M5V#JE4_NGR"/4B&|KR2|JSCX|M8UT15|GL%M%U5=1G:Y M-
PH#H)E?PF/LF*|>=>)||O_P"*G:O^FSOQO7;8J#H,+LU'FOF#?L@FNBLKDC#
M2EX^E=" _OH.NV5'YKST@)C6IP0T7CU:FOR2?@Y|T:<1Z&UPX0Q>.+AQ=+.KP
M%>|'X8>V2ZZRL|GG|F9!-F>6M|A*6,8;G+QA-'ZYGU|L|G:5LF"9RN;7D4BCJ70N\$!.*G
C%%-&" MPY_*YYF6|472X4P@;(Y8P4+J=\$R'@WDY)HEWE*@V|MA%F>2E_9J==Y
MCU+6A6*8;7<+N&82 :N;FHF |5H!RW!|'(WK"^)^2"(P1VQN& G6|HR%N!^R
MN0E8|+G(G(+,V&(B L3'_K/H0ZC+Z%NH_V# MH8,XK Y |)M_5X5@K"?
23BR+W'8W@0"&-9-S40 >ZT IG6>L;B/ORF4)(+; MG.0B;F7#M;(VRZTKTIL
EO,TT|D))4J\$. \$*"|6RH@LA#7;.*99V&#\$I6A/ MXCFO:P4L7*/_BA/'O#M@T=&!0QJ#-
9IS\$O2&.HUHR\$WA!D#@;40"F(9EX3:
M(J|G+S1|C33FE;H%C+L1L+J|F0A8FP:L.XY|\$9KGJ?&D"+Y)T6;Q_)B4I*QP
MJ5(N3XNE<^Z8|+Z@'B)I22E D';PFTD)0(Q(M9\$NF.QET|HUB!!^NV^YOF |
MQCJQ7+|KYKP|SX?X@OB"^+)|^+*I@ (AGG"N7,4(Y%>TDHU4*L\$R*W/;T12:\$
MFP@FE,B-SC*(FCP\$42G F!9IW)6&::VT-V%Y8O+E B+*|A|+.W%XR|:|A4X>
MS/)ZT+"C>5W1';#HZ,#=|52K7.R&#@UY#O*0Y|P2MX")7PS,NZF9"%B;|JR|=F)5N=2J(-
M0R!YH:060IG"NE7LX=B%Q* (>S++\$6IM3D@4-H!;3Q(;RZ71C\$'-V9J<_&0
MRGN*81W,2Z5|YQN&7|R4XK1Y=+9| HZ>N?6'-<6O\$^CQLH/V_CXVS-&XF|
M@:E!H:\$-YV10UF;2!N\$|;K4:VW\$1C|"?MG/:MV9#Y&G/?%E?#;SE7C\$(WQ;%
M&7=E^7U2C|OBB|@/M;I7C(-;MIUL_0ZBBG^5<(<);F*,<_,X/BW,(?X1P:T4_N'&\$S?
6_ ^M*!71_*G++R'NWQ_+H<3N"DQ0Y| @Z>?!)|4H\$NFW0IM MEM6_*&.KF ?
^"3JOGPN-TFN|&&87)8?6FS_;&"NS_7W>84@/8GZG"7=)AM MHPXO|"68C*YV|!L%>&L-
EZQ=KY.XV?_"F_UD%-|UW|Q7?&H"0^:?.P"K-W M&0O-
K(;1!!JS!*I@X*4'H|(^2PZ//M57QP TU|= <&8'!.R/SP8@K.2C<NGCI_@!&
M&W2@EX|3ZB?|"9"R*"|X"L9Q/"JGT@67,"CCU&,CK%F7X=-1L)=7ETYE|ZXZ
M|PV|_/.:\$.56|C;SL4R&<.O_P3Q35PKUG|R|<%R|2T^/;'@0,*7\$)MAODDY
MOO4|"ZTMHWJ>5^-P0W<>J#H|277JF>|L2K-(XSYM|V.WL.2A45"UX
M@EOLCCF%C^OQ#93E^U%%IXI<*W@L\$JCXNY|)2) M9_'?ESU(9#8NHW
Z&9@1R#**/OZO&;9AB"8,OLKG\$4"S+E.0&9G2;L|'S""Z%. 'X;39A"|)7^"2^-9V^&=F
MF@S*A!&SJK*MP8-@O|G=2^RW+)XKP|008-L0B^). UWMV>IM'L#QIO-%U,.
MFJ_9N_N)5_/0G0(T.5H:N<5C%#3@\$L"!CHDPVK<6FI=G8.)C**POM>.KR5|
M^V^R8=KTX,%#C9=|^G6)+5C8|4,#|_S3;3'|(S3D)?;|(:ZM%0'FL(|XW* MB4ZM)
7G12@<5;K0+|GGE3L\$(09P-M3Q?3&?QI;*5|+DI"K"!#Z|%M|+
M^|:YY/V|YSJ|8/4)W#|H=.6&* _ZM?|R'QD7/>INF1EO< HTJA.+*6TT*J4\$| M&,M
_P0G:4:MYS1G@BW->"AC4Y9R1U*FXCT.M) R2I00J9-RSJ"L=.74XS1*
MIOV|J|D|K5\$M)M^B3+W(_1;=V9FIK_RQGW&=|W08EO0|U*DV^MLXY7,36=6, M"H.
|??YY5|O"" Z*:Z-2#MT\$,'E0-7Q@>M18XR8 V)KQ:20&L4Z_*2;CR0@@ M\$KXI
#@;D#7N+)-)7@/^B*%T9XXZ+405OG;%8N-,|644?C'I(Q?05O;@*7I
M_=>S:C!EV3.-8HWBP|C|K| #3X.|Y7"JR\$YA8P+O#Y&F 64IKZAN%Y0G
M03N:B6*"30OH7|G9BL 55/#@)|@9XJ2(QT|F*MN@
M,E1P|:RWQ)MX_F<%DY|OR^<*K("DI3NC1HYU@N66X|87&75)%:18SGAC"M
M,FTD5;)8FK1;N|I0L2W4"S2F>8B0!AM!ENJ.-SYU+LT\$"Y!\$X12BN1*!4*9
MI%HZE6_@L5X86J5L*!|>N.(+W|XCMVN* MT|9|2QJS+1\$?J\$G&93#<^M
90DQBA&5);QW"BK'5_-|NLQ)0)F|\$>|'.|!
M+^_@|W)|37V.HRA7A5>BGVZ9#D6ZZAJH0!|V5@*M;AAQ*)N46?AV 30Z\$MDO
M9E16\$^"Y;7|Y;%1-3L^ (O\$|=I7# SK>9,/##YM Y8IU,:GP)T!N&3L1W,+!\$ Q8HQ?
P40YQ5)L;S.8DPL0;AOWS..UZBO\$5/59>3&+F&|.6U0C-M7P|
Z#*ISZ#M3=+6#29^>FQT^Y0|7H+? 4'3B&9S8GC&9!9Q4,DLY1HS7/* MK+
+6P*8W"KE>;#@4-+H7Z@E6A6!;%H\$)C@S@#3(3)|.3+8%9XR3N<|L(,0

M("=%)">%LB13W"L=9)XO+|UQ5.<">"UQS#*X)U-\$&V"UE*4^!Z0J%9>7'=D M7V^
ZMS!37J)<=.DS(U9Y.;S|ORF^-G"IO;-O0VC 9EVXV"7Q|HWFO208 MP"NXI06N&V|<;
(.&ICXS4N0YX4Z MH6,DCP4DDA0/*#*\$@5RO KO|D R%,O MS)0W_+B6@+)
|#/BOZ_/:!XE+*G9_F>=QS=JH?^(^F2 O+K1V!= M53|S\$W3J;WXPE>ZT=*LIT-H#LEF|O?
X%C'O|<:N*S0X(I@#A|YG!5W-9OWWS
ME|G2WEJ?#5J04N7M&VU2K7B<^J>?;#ARE/)G_[KP^=?/APGOWYZE^P?OD^ M?
_OY^.#|P?|G@P_MV;<5R.CYM|M\$=/AT0G(Z.0H>7=T>'STZ>#|_LF'|G'
M@|/|PW<^'Y^2XO/XX)YDJ=(.OBTYZ=IZ3DY.QO"#6 ME,@#@R)&|I2P8!63&9?:YA
|W4FM>O^_1%2FM.!:773M+*'>FU\$ M|HCR,<=1J!20W06BO?76Z-P;M51;|92U?|?
N#;+J03@J/A1%Q*OX:")FX\$5 M?;V|CG.V)I6R/DQA8G|;?QY4|H|W20
N#N@S,11WVZK:4 M-UQ?|M'<|^:V?8B^0*323F?OS9YQQP9#
|6NE_&\$1)*?|;5'R+|^YC_:Y>.*= M3|PM|3/VLF_LBZ=V\$86#PGG G?
=L)J: >T;\$:9|OF1N,K6.=WTN>+ZU!=8H MSZ?(\$ _0!000;RA|LPKA?
N=T|RD=NV|9|KK.-G_D<*PX8'K0>/T|+NSXL+2P M T^DW|2)|.AR5BM/Q.#N;.:Y-!?
UXT&<4*XFM1G&:9SPS07P%A=A%*W3Q'K= M\$|W3N|YWBI+J4|&_ =V5/ZXI?
1KW>AE>XD??O2!949 M*6UFB.'Q#!LA"Z+A;R*LERY-
7\$M9K*)8|2\$EBO0CC^U;L;D|NW;QM>4,%Y-1 MF*|G(&QQ0T!|H+|^#2P02EF|)BCU)%?
>\$)7E M(>>^R/SR>;2(Y6C+KP=
<7@;+GS:|LF75TKLUEDF')A.%,8!OB;O.S+>;'YEO!4\$!;S|ERAQ*L5|C8)%
(6%VH<"15^)|VHJ^\$K4!/8J^LKO"W2:|HK|V2/NP MM';K|BG'9P9N|J8.T2F?
QZ1RDVC&Q&2'/=,N|,RW=R|XE><&I83(70@|(A2*Y)8I MHE(1C/#:LVR=E;
:|@7#1HPHA?"=LN0.6VV5P02DCA.^BV2.\$+T XXSH5PFF2 M%1(|@/\$|-
_0X@/|=Y*IFG(3=JC56I&X)P+A#="|*6.V"Y6S)7,JL|Q;F2#\$R2:P1P"JUSDV0QJ:Y7>-
DSM2_7ENZ|'|!S:Z, M.&HAD#CN@O5VP%:[#"07L!M+DLF'6.DL!=3D3* M"V),"
(1E*!|QG@4 OC5.V+P0;\$N&D+T3MML!2|V2"1ID9NC>D9IU8 |Y'ZS+|LR1S&I&1""*Y#
(41#|G MN*LF#X?L ?&|4/%RP7|=A7|/MYC3W9SYSU10'B;PG*1;MX,YQ MKPC.4,I(&I
T(&EX)FE07MK,!DL*JQP1&MYS9+76Z8YFM=I;-!TD %
MZPF&%1O(&EX1GJ&4D34@:|@9UG |HJ<%HT41!&&!Q?|?QD1 GA+.N0K>*YZM
M=19H+9C^?2COT90AD.^"(7?;+=D2@C7|&QP2N@@8DSN|#\$\$%07?
=AC2>2BY|UO'>^*6*1*-7+(7;#F#MANE^\$%I8P@OHMF_TH!%?,S
M1RY(S6R:DBP7'&B"TL2R+|=4I8Q)R@S/ELI-'C-SM\$&.;|.)I*PG)58BX_S1
M*T(UE#)R|^0.R|V>R1T*9|6P)B,L,Y((JRRQ-D)9:G.;JE9H7D:'&&.;J") MDA-
C'>!,RE1>F%0Y6:Q|HNKF0OC%1?!T9<<%J1PGK';"@#M@KEU&%)0RX08N
MFCWB|N*)?URGGEM#A,X%\$9D!W\$Z%) "S-E!):T|+E:Y|.>@G<9EPB:N^"~7;
M6+N,)RAE1.U=-'M\$|4743I761!KG|AY"=06 MO9QEB-N|8,=-,A 1J8<)>F/S+9G-
GM1H|C,T+\$C,|M| M\$8|-G1'P1&(\$2XE(C2":JX)HJ@ICBUSF8IW|S<\$|^#9T/@
'X:5E^AD&>XH MAP4ZKPB4,I("Y 6("UX)BU02J09B|":OM
M@|(UNR8P'+E+9X(S;_WC/CPX;B96-EXO+E8)=2|9AG%2%4GS?1%|&)E!8L,P
MP.UH9,C5T.LC5|NW)H7F@0:7\$2,*102C&=%YFL4-0BC/N"@R|ZQS:;ZI23F.
M7FU_Z#|5,)SS:U;|&U%A/8W7*;EAM!VRTRS""4D:PWD6S1|!>+%G0J>3!H:10 MGA,1C">
WHX3*A<93SS?FL5|CJ8|U@S046+.R\$S7;0KL,(BAEA.I=-'N\$ MZ@6H-
GDFBA"WUJ2FV;":OM@|(UN MR1P(KOK8X|S(=/M!<%*C|DOP23DB=GF|^9P+/5.
MIQE)O1)\$J\$*20%"+".'|(KE#*6TX*-"*9W""9TF03YFVV\$CL*GJ2IQB|
M8O2ZY8""%2SBV;OKB|Y_-^<7;|XD;|8^+,Y#O(=|#OM<%OI=G.;)'&(!:?
0QW,R)VM:HEN3U-O!*I0R,@)D!;@(GLD(N#3*6YH2F@5%1"Y2DA<%(TKX7'!?"*^7-
LI>|;\$E M:V(\$DF,Q(S*";<2CR\$?OW_Q52RLI9T0'YH@(
M6A)-0T%T8>.Q=TQD,EW7L2H+;O6H. SCHXLP,O' NT|5O:JESR+OZ1PW*MD) MP^V
F78925#*6X|7N)(E|@T|>M5UATH"CEC4L9K1YA"F\$%18="*|V.K< M^'|X+
(R2BS""QL;|.SSLO./9|PRS|H M*DRR8?|C-/^F#0B5U-2A|E;|3/.M M7YR8P5|<\$^)|USO-
_D"!\$(-+H0(Q(5"">J%RYZW0:UP3%5FJUQ7|0BEW4|K("I 5;#DKT%1;GX9 LI0# MPJO-B-
9.\$6&=RURF)2_4&M>&K)|54-:);220%2!>=6D&"U>|;|&ZV!^""QR
M.;J^E'7TQS|. #W|J: +70?|8GT40|-4DGH'3-0+XU*6\$?^H \$WR\$9)\$++G)!
MI9RW&27;0;D3CNB9QGMQ-EVW|5* M9'T(4RCEW9\$RD@\$D
|M)!C:U+0F5LC#4QUWJ0UQHR@,Q7AM2^%06P9LB,+2
M":FGTHT:Q@%^NX= WY*J7<8V| SW#DMZMRZ?,ST-OJGI'9APP)=EAGX3;-
F_#SGB08IZ+ MJ3QE1:ZYA|H:B@5>ZAT|MQQ.H.W3 MO=;KX?6-UB|FHS"?^R)L:X=P7|
<2-@H_TC8&^^ M,C8WUOK<*|*=B(NRC2=&,0C?KHOS|TD|+HO+V=N;*T@|
J/QVT82I#EE8,^:;@S*V.;: M2CCO@^A+KNX5XD,U;GY>N+|^7U>I7T=EU9P=458^,>?

59#BN MDS/S)20VA&\$R"N-155^T>#>X3(R/,@@^&5?P'?3?C9/Q64A"@XEU//HY_GD<
M+DR+@?VYMH)09C|1:|NCM6P;M?9S@,?7(>IJV6X=!4H|J.HZ-"KX6_^XG|03 M6Y>^
*,RU+WXU^^-LE;-?+09)Z:9E\$ZJYO"4|1GT*6KNP:BLSZ|W9CP95Z/+ MYAK4X8|K,-
|&'3Z(\$2'H+K3DDG> Y\$(TT!!_2Q&%7G3?341CE)-0|S^LG!,&\$IX|!%EY;P3@">-
MK4VW<8M---MH>'#A?L'022G:>%RB|H#Y8\$(KSC1/'5\$|IJ9YRBW-T,(H42
MN=%91JCU\$FFE!(MFGN8UDH\$ZZ"R.N'?5|?8?DY'J04_\$FUJ!HG(S.LBS Z
M*@Z&7Z#EH UWKL3,KJW\$E/?-1LO^W:=^=|! \$KA_\$=\$FU,JE|=V@NN6BX8RG
MXHG:5H|K|!)U|MYV|V\$8G M?P|1:=E&|M 4Y"E|+
("RRU7X*AXUQE',18,35,"K4E48?'GT"PE -!M77 M2!7B=34@U.R>_?'9 %Z:?
#1QW^OQ9=3WP^I+A2K<<17.ME&%;ST>XF= M@)<%ECNLQDFDS"W3Z,!?
0W*U%7MR'H!5):#K23.5;S9EJ_.AI7#M5S?NB8X= MOFQ80|C\$JW:(VWIZN_-
UASMCU|V|L&R^*@E-+ M,BD%\$856Q
A%@7N|H#3P|,#"*BH|C|T9#;H@!'6_#4?!5:=#:+4'_CTEWO5G M<%4@_!JF!)_"R)W
^WX>5.Z/-TD;GT!SQ|)F\$Q6=_8>@EC!\$82S1|S=W9
MZ7L%|*R)CWL|Z=Z7|/R4H|/M=,*9@IE |1^V(27C8'XYM=&\$^,EDP6I+X:\$
M8(6@OC.DJ/<6,|O=61"T8G>TE,2?38 T|Q^W 9D!DC>;LH@-C*^_L3+"7C;
M:C*|9.Z(^^^*|I>#I@S,11WVZC8E&Z|/<#3WO;EM:4WD7| MORSK|
:7H#WK#/'E'SEE>U5-TI=0&);IM"W8W+|V'POC7UFO8:N ?(?Q%KK,K
M2KU9A7TAK_YJO/ASJ.W3;.+ '@YA JR8U|-3ZJ65 *ZL*G/7_%3JGUIQ>#A>> M?
S3>*QXLB)236:B|;IMY|KEP+S|4G48?W 2A>Y6/YN!&;K06TKCT>Y4H#|
M;EYT7+H7W;WF:NG-|/F.*RKN710I3.&LSHET|Y.1@6QE@6B9!|"LD4F|!%+V MO
B4Y2EGI' Y)4*Z0 R3DFB7>4J#9S9-;V;|/B9KV@<-WC"A<^KF&|T_/V
MH'X>75B<'&E>M&;^L)@M;|ZWV(|T92O3+,V-7L6"SKN* N; >|7.H)X-83/!%Q5)U_B|U|J-
B?N|;C MUK,>%9^NW.J*R)'HQOEI7?<*<U_ON;^5D541(Y\$!7,XR\$ _6RD|B;L=-1J-
8^|VRE\$XB M)*4=?BV)U8P;+ 'W>|S:9|2\$()\$)PW.9HH6!)>+ |B@;30(\$F@-EC-LJ#|
MTF+IM1.==ZV#7|O5D7G;.:KSY#J9+78(6 &S=?3FS@H8UAWJTM%QV%:BTA6Q
M@_4NN|4V|M1YSO) @A*6B. |51G1!D?M*\$A+Y2_R39RGF8ZF)RD4@4B7&&)
M=BDCLA#6;*.9CBM,7|;>)5>|"P2B*V.*N1+,E;S&>I<.>')D'=UU9T@V=KRZ M13(?)
2F)/5Q|POE'-%|!:0)P%"3E5*8I7<69)MVM;J&|!%*D0UK<@)WK)^:/% M&I?N8\$|D
,)\$)*A5T^&;JLR)=*L1= M(5791\$\$+TWA2*R9ID)"|WH*6#OC|7:
(D6+Z"Y2L=HS5*26|RYHAW0A(!_Q'K MO""",JDS5IB0FQ>G-
6LO7Y&=6%*\$Y2M8OK(%9;.:|A6.1&5'B4I7O-Z6K^P6
MV|B\$+KS(&2E2HXA(4T|,X161+BTX335S:ZJGQ%<5SJTOER@)F1+2(3
M6+Z"K&/C,MZ%Y >2C9DB%L'P%.1&6KVP<:9 ,(1EZ|63HCO(5(=*<9P61.3-
X0DEGE/@G:4 MZ<+IE-HU4I5-E*|)S-
%@C@;Y""%:O("!/ZI7N<1:L7EG!?!?)3MJ!.\$1G@1|PK ME^2;.>
(RHZ31,N29?'%6L_ JE6Z4Y6+U"E.O; &9N;-Z12!1>15\$A?59=\$V^
MFL0YQ:Y1E>VJ<'FR9)&U++*60C@A;\$98H3014FMB"IH"#6%A+SG|860|CR5 R/Y'R>V|
|CM ZT/N'^I2KEJQ&&="G M
6S|R@DT:1P|=0.)&2|SHEY2%LG5#;WD:S49^,0417#C)MGSKCJ'GEW^^5|T
MH^IMG83FJ_)++|X^,N/03TZNK@-#A,8/JW%BAF#.Y05<,|Q|_R*:?15U*-HMJJ?
|:CL_*MJ1H"(24):< M@SS.ZNNM.C/0|@STO,UBP;,&\$Q@7WAZJ&-C?7(1A@:"NG
MWS4!+CD:F_)F M2@R>9|!EGU_>+0|BDV^&%5?RCIZ?G"E|8X |?@8?X6V7 8S@E:
0OK;|B(6 M6#?MB|L%|FZ5O7%N-(&|G|H|LKW!?,SHSN?:O^1MP)U&;RN'\$3+U|="C@=?
X- M_DWG@4R=<-1J&\$70_WC!5/W_V5C=MSW"WQ:#|(WX^K"|&YG(O?KODX?
L2"74|&F0U7|P^P34L;B<*7MS*P%9OIWU;.:I/>@E
MX_.W:%G16N90|>V|KI^R>XSQ.YI|@>.:<4K|H7?"3/*9)9=6OX|;4##4S-=>ML
M'E=|I5L.!^40&C8VH_&>F8RKM|>_@'%O/VY5L0FN30""WS.#K^:R?OOF+W.E
MO96#1(U:T-(E:5NM4CT96U9|O6J|W7_TW|J^/S+A^/DUT_ODOW#|GQ;S|?
M'|P_V|/|.'X5DA>C8RNIF.V0DR'1R<@HY.CY-W1X?'1HX/W^RRH_NE<<64:2;L'IN?
F_1.O*1WR>CLO;EM&9Y M1A0.HB, L(W_C|C|6_^XG_Q8!' \$9M!&HN7PT|ZP!:/N\$ _GID-
OXRJR>E90Q*2HHRAVY1C,)Y!|AZ8G|OR%H%I K\$ M,VRUPEXVSP":<+ '
U|KGE6C,M%07G)6?0T0=?62NCIOJZ_#M*V#:G@:1GFOF4X:0G,>WJJFEDU-
9SON8/K>!/R#KLYO=ZR?|Q8.+GM *YV9M"7GMU&K
M1AFQ8|W0#JJZ3IP9C2Z|R'TU(|V&D@G///Z%|UDD6J-PG@R A\$5H^K|>E=8
MFK*D&L9|0.,N\$XBZ*VC5M\$!|SU2GO?H46/"HH;U3\$53-QI6>1NLA)4;M@A
MJ8,CY3=R5GIP!'L?_|=0RWG!'?"6R*\$L42KW!-&>V?
+C0OJNOS1^M:B#|U|AJL+Z1Q?"3S1' FB4F+0,#+%ZDHO&-Z:1|)C:P2

M12Z)2WU&X(^+2O_!N!PT M:2:(f\$|,M|^MUG|N5/4(-/6D^G!EH
<22U'A|OOD%="#ZC#LB"85U6346MY< MCVZF5CJD5PW7;9?1/-O/M9I=!G
CD^GH/33X>^F+ZIYL*G MDLJ",.\$*(HJ4\$Z-DS 5;0PU3TM*E';R?,F5I'\$I/H4^?
PT4UBHF5|X |H!V3 M43B!! ||J-P?;Y(>'01J=|H\$C8^~;,%!2DYU/SG^!-=
(NI//WX|^GORTGR?6G-#HJK>=4>, +M!Z1XAP*FV 9UK73OXB^?G8+/-="#\$^5H-!
M|352_2;EZ:N+AJP"|=P__JU)|Y%474OP)65DNO^8E*,V>^=;VP5.#GTKB| (9
M\$'4|)%7GX!OA:0|N:K*H918Y_.AF8\$7#%)O_HKRKUWAV|_ ^5:(G3.=^,W|;5M
M#5^<=UF|_??.?S?G%V_?S=T&(\$:#V*6(+C_?X0F>7OU??Q|REFGX0&(ZS'
MHR9|,K^PGQQ!NT;P-R!8C!UNOJGI4)-7;2H1B_E#(9!>'8M1_<0MPRJ^OR
MB%|4UY|. '8IQP_RU3>+TUM?. CV00^7;Z.*J<|+>-^WA:A^2KF>-LV3:|! M'9N(V.
TS\$H!5 :N&?*,X07"CN: ^ M-|>5X<6Y-@NAS/AR;_::.^KKVM?
*M,_S'Q9S^=,NM|G|OWSG5MKGV1/O?.)M
MO\$^52J_ ^>^ISL+_8WWOJ6/5WU_ #6=NZCO))_8JK)U&>3Y\$GZ'G|JM_? MT/3-
*H3|_!4>WSE%^B6'8|43J@|:K|I#)=|6"J.6:!=|=?,-GNH-R)&=|8| M/V@?
FSFDZM);8: ^OG_|D;6*?5L|VPM"#4.DV332/&,MT X,4>,8;WR_?X* M@&TQ
71)W1J/M;NDIVZNO0,#U %C0)?4A5% E|0IE|30)74R^+YGVX\$MB;XW MOMQ|JM?
M'AW<0^2^N_L_-,F?KCQ|%.V|/-<,ZL(I31G-B?2.*MRXG1+05%AOQW^7X|_
VD|G&%T8=O<942|&&_K@A+V|SM|*3G:14 MO8RS|FWQUV57L &_NE(A/+
D)6Y%:?!K5VM\$N->&<,%JIX54)+ "0\$J\$+1HS,
M/5&YE!!0>473)81CPON""^A2NI!1043OXS:1\$!R-2;:0+)NL2PF49|XE4(L(A
MPB""O7*U1H1|;0C'%:>9|YP\$+R01#B#+.JF)8B;+C/8LS?;")>Q(#*G-1&9
M,\$10ZDFNO"\$JRT/?.?0'!)SFQ1Z*R8DN^*K45A;IWUHVJBM:-H|J7UHVJBM&S=M+
G: ^9*@=U7= MG+ %T6E4^GM- E98|/ ^)TVZ=,CG4RJ\$HBL|*OX:'> ^T! ^T9?2 MA?
H8/."*DLA,R!|GG3AR_)69Z#4RD;XPF4B|3"808|9"@1%CUERC(YRP3N?\$ MR|
(187)'UH\95/?23"-FO(+ "E:6T*F90
MGUOH!2UCY@I40KY&B=4^@**Q=TSXT;=16-.V=U#XT;=36C9OV|RI?UARW ML?
7%;>SUQ&WO%TZZO1A5IR-SCB';:PC9MB>)N;UX|#(R|K+|EDH.L+H '08Z M#'08VT/
T0&@ T 'L.F@H+* _4_ =9RP3*>=K-EX|= \$E
MUBQ@65'GRXH|\$|;2/'5|B(P(*SW)76H(9R9W.O5,!?>|%_W4R=?J MN/SV(7;S?
|*HFM4Q? YU,"-WMC_ T"RFR#|.BAH6/?ITFS594A21D+Q=8N(J+
M(I#/#1"1MD*!\$9'6BTBI5M(KX0CS;2,B=8|DVN4DET!'X71,GO.XHBN(A*G
M/96A,F",CGUCF34,*PHB!YH5*2QQ424A6IMOHY
M2RFZBC!4|A3MQ)ZBNV;07=FZ!G.M:W,EG_|^|_ZGOQUTT|J5CIA6=%+*.CK;.
MPY@IA/&D8\$7,M:I#M(D1KC\$N%8X&FK)G9UJG7FKC3\$/W%&X+L.GL*NYCARBT
M;0J,*+3F|&IF6;I(-! 3H1D\$H8;@!@3"J-*;QDSSH>JE,H)'MEHQJ MO8-
JC5#V0"C+9;5E^O*%U|_*#N|_G&EON2D&IL!)IHQT?P*W1M2FHY3&I; MG0F:\$1Z9B3
N(I E4DE!*4Y^R4+C4/#O1_*)LAJ:T!YU!.O:./W|D3D"&RKZ MCB@Z MM#8W5A|RPM"E)
B!T/MN00IE-*%|66^L*+0JAGIYU?%-ARW> .8<7Y= MYHZXAKCV*A0=
<>VATZFIT@+|^+^*H=\$046A'#4D>H=A"L6598_?P<|,OB6M:C MN4!9,8E|;Q+9
ME,SJW!"56DJ\$3171|#=AH<@M+S(O|-(F&8^O^IFZ| ^MMYKEH5ZF"(B*GLAQ M:XR=,-
T.&&K7N"J)&))1| D6)H|JQ5AN05<2 U\$\$_| (6YMIPLGJ9#/71^Y
M42QANL3;9!|J,H@|I6|\$|-03)K|@|X\$=TN;SC| ^8|V9GWKAG&>/I9CRW F;|8"%
M8IB*"HD@OZ7=9D"\$|5B. M|Y7LA, UVP\$(11%
A\$41N|Y%":9|7<3.Y4!"A)"..D\$4|H76LC"/S_7N3\$0 M\$0)|I#-)3JSRW*(DY_L-
|G21)/H.O&/="Z*F07'6<76>Z| %VE&M(>84V14 M\$EL4B@2AE4U51D6ZM/W-H_&
(I3(G3/-0R\$)I+L;6%#PZ-|HQ M&* \$IA"^(YU)CV(-Z!:E1|MCF|N|-C7KI\$/'C.DZG-?KVZT1-
V?M.&_)BY2Q M8!@Q.DN)8!#4ZH*GA&?;D1R&0JZFF.;7WH^Z.=6"-)O|2-H|G7;):|Z!:
M(Y0|\$,HDP)7*N28^RP01%D MSW)'J"BT45;G.OVK.;;Y1:&,L1Y3G2A-0IM'
M*\$,H0|5&*%M|ED6DAEO26 6H(RIC.1,9(3J0AHGM81 :S7'-K|LE'&(RCJQ
MWN_UV7Q7ZG#QV.:U^9+VV&9,-&.B^?6Y-Z0T7;V!P%:D)O, 2,0:
MFA*1HQ8)QTI)#.,F6|6-J?Y| %IYY<%-L5Z@G>BW OM'8\$-@0T5'8%M QO/ M0;0&
(9N%7|.1GG24U. MC;G8^RYU6=7,N9 |SG#J_ %59.E:|H5KOH%HC@ #T0P%PPBANIB#
V;DV14<4.E\$ZKI9J?QV207Q; 6\$^EN*1TBW+^L^+EVU1|A0EE&K>R M6-
..@JGEXSC;|C 1;WD- S#R P2, 2)|7!Y68|'9EQ^"?..||MX3C0YSR"L" M71CY^_V_OV%O7D+
<'4?233+&;9!QE^6WM#|L;@6+#+,=|CJ|J9|UIMLEN(MK,>HZ\$*R^Y69Z%)B^27/J^DT
4",V0H%1HQ9+|98:5EF1\$;R(@@BO&=\$6U0 MEN7"%E| (U.>K* I;A;D:8|*Q)B=,-
\$.&"1B!BHD8L;M=3A>|. "L)"I5\$&/H M7!.3YD(IQ7S:4AM(5=1A| -VS. Y@|@ \$S|'L7(D-
9CVW(.OYUWLK:SKIOS'U MB46\$G2"&\$^U047@%D9|1"% M.4F)E* P: _&(QO|(?))4.5*N

MG?6_2+DZ0[E^O-1KH74!<.=TRHG7&@33\YE)-8YD[C'.Y+J2/5R?-@.-F+%^\$3X
M1/A\\$.!/\J\RD"H2A4 E>9\$YRDGJ3.*>V6H.TO@/K1L_(K K09IP6_WY>/S
M'A=XC,^KLGD\$-P2W5Z'H"&Z=B0TSPS.E@B,^I3D16@IB?%80\AE\$>M:SS"TS
M:CTMX?|2L6'&>P)/;JUP;+C):O37L^762GW#X8>3Y.#PW=\$O'Y(?/QT=_^4
M?/Q\|S\OR\NCPY.#PMX/#OR9'OW\XO'IR<'1XC-
ER9\$2=5PTGD+1.:N:(X\BH4'7&M,QELJD0FI4Z)R^&'M,\$P2\$S=3,2'-
E)6Y=WPE^ZBL\$CD?-@?..2 H0P3=PFSV:NK7,90))#\1,JC)
MT6'R_N\XFL'^\XA@=U+8KK\Z&-RLO_NI\,INC (!5"*H14:\$NHD-9>%H% MO5-
T)K@*;'Q""NF#+5!986U2TF\$YR?'WY>U:JE0\%=DZ"#,CXH3\VU_!Z5
M=C(V=A!,JOG\ P>X87RY:L8D>VF&J70L#4=X1?U&>\$5X72V\RD)PRI0G5!0I
M\$866Q"i%B99EJ\ 1=PA>.:R02W&35P18!%C4:P18!-@5G^K!O3:O M!+THG"" E-B.?
4D8R'U>6;3X(K5I_*[!+!,JBB5"++;F/+ '08-IOR7"M@Q ML?|JB!'KQW-E\$U\ P#WOC&?
Z4P. G5S1F5;7HF>JEJH/Q?;?-? LCH!L"Q= >51L1#!&L
M+46W*5/*9H3Y+"4B+K;2)AAB=ZF+5>;?-'!\$, M\$6Q'51L1;) <1;%.9ZL)2+9W4Q(O,\$)%!
!&92EQ)KK3&!"L)*NHL,1,Q\H'9 M9JE[+\$.P[%*^&7Z/,PT+O;HA+0H\6U5'\SQ7S=TQ?
N<IQ^>CF;M5MVSAM_1 MN.?@GB^)&Y@:E!-;.,Y&93UF(1!B%L.-
>VX"* ,WLW9.-\;LTC\MF2_KBX&Y MW"L&X=NB.!FT^?
=)/2Z+R\G\FVM(/3:C\=M&%B2^L=ZSI@Z#,K;ZIL^<|T+T M)5?
WBO&AWJL1JGZ&4\$4_R\G@+,UI1KE0T+2%R8L_0KB_5@|FLBF'L7ND\$=%W
M9')M1_4X+C/M:-Y)T_2'T^<^MBBJL;#:AQ:!\WMX\K^2:U>HS)(!%"QNI_@A
M118XD1!*Z,S+PN7Z3?+M?+ W,,/3?W\3AN2WXTW)\J:":L;2M_?LB\|<1=F M?
C")R9P<7(9S*A.PM 'G\P/+IQ;> "G082E3#0_>7/D*_S"XE,&\$P\G+YN M_SQ.3?
ZSF;Y,JB(O\A^3<@1/*H=CD%_9?2F82!C7TS?WDFL-G>|6_^, H.:G
M7C,(XUD+XRNGE\9HE(S-M^1B5'TIZ_BR'VT8!A#!3!;.^O,M_ ^R,++P%^C# M_&
<+.H>3|S JW7<_!=?XXD\^EUIWKTF;Q:\N^#0+LQI(%-/'=L##WQSS;+<
MV9PP\6VA+>-7H8\;(|T#I)^?#Z\|M)OCV):!H;-MT=K\IX%8#!|V\Y:@%
M6WV+,HG\G.)MP?B,F7WB/\$\HW;|TMU'6?P*1_\$C>0X3775KN+C&-;|, +NK6
MV>@&\$DX|>^_ \QD7+V\ _@6,>_MQJXK-K+8I0\A\90#57-9OW_QEKK2WTL.H
M40M:NJ1MJU6J)_N!YVG4U\9'MAKX\0SJ_J?_ ^O#YEP_R: ^?WB7\A^ ^3X\| ^M/CYX?
|_#_ ^>##M5W95BPC.C\JE?2O\$='AT C(Z.8J\UQT??3IXOW_RX7WR|>!P M_#=P?
ZGY/(@\$/OCEP^_)QJ&K@QUK%H"D)Z,P@F\ MX^=!Y?YXDP0("'_@_O%H,EWSW/1N?
S01O\OW7A M4'5H7D?M.:77PY.60V(M1M:N(TK)U\MC_ ^>#3P2
TT\$-7DLEPIE99M/C!)H<)0F\$JJZ&<,\$E."0MVD>N\|C\K\5D_#UR#OPZ2&I0&EL.
MRO%ES.|U%|\O:YK>3WX.SDQ:*4^&#A\J(@\$U\$@:A@67P:A-QR>V:3 W@E\| M%C.
+T8ACD3L|'"Q-3'(H^IM#4VOQ_,WPWA-QM"HR-D2,Q@DYHL\ITVORV&; MAH3'3X?Z
K"TI@@"GTYS\A\#8@C/\$*D."/!?"&_65T\KY#UO5GT17!S\)'R) M(
E"*0IA6C6D)N,F5@497/4OW@TA\+C-#<7O6C\$LJW@X?RBQ9CQ-7OR_1X-38#|&QV<.T2P
MO\JYR2AFP/H\05N:1X)Z5.TZ@KT)<(<=1#*.GF?6UC.+!X=|^_ '4_?<
E\|HJF"*H\3'X\,V#" +DSB=-4='P_ # Z& MKM\K'/SLDL_@W,T(/F?S?
G%6_ "I7*@NHA>NY=|@D"!|!|2-C@!L&=B2R*^ M17UO\$6A@OM:3_5,:)^84L!N \H?+
8CPD\0C:,W MMAWMOP=P13F>3
\$TOK>H\H\JZRRQ7)3QN.7\$7BX\ILD1#UMMJ4/XHP'NBYC5_MC32IX8!PYT?X%M 'AOB/
(U)3N.1S0"X\$:.FB>;KVF<#N,/0LD)O%^5HGH_ ^
MK7_<3WYM17\8\1.:|JC@02SGR8_QZFF&>0IN\>\VXFE2^:<^R/H?S\!1D.7O M\$V
/T5>-0(H^\$IMI-AP^N^.42CK>A+'\$IR_4,:L6J8%.8+ ^+^J98\SA8C>M*%:4\;4W-D(^JX
MQZ: H\$L?J<3T\$4M=GQ/&=M3FCX;A;!1J6(%B-EXT3G&!. *8/BO!4-W3K9,\$+ M
RF%&QHI',%+&TX!GUUY\ML\|**KF,Z7=(^+??_A+A?|Y<>XLK_KD8##UV*W\Y\ZXW_?
0&% "0_M_G:|_U/3@:9\|46?RB+4K@0V&>IYTWX\$D0\|XW\$&E_ YM^:&F6N\TUNWCWV,
MHP\|4W,:9GV%_ .@|C%Q+|V:"A1BJB0TA\$C(M\|O5K<|5^D=?CJIO,/+PM@FH
M&XCX)W_Q_W,9/(%Q@\$_)WF0N(*)OBFZO!&\$-X!X0>GR?ELX8*UQ'AMI#F M.DI 0*-
|69;WF*9OD\|R7YFE/2MU.20* I#KM*J.DGW7A)TTU^(:|OU?,W9GY+_-
MMW/37'0%>Q%3A\ PQ@T\|X|=N\|@)X,V\K0!S#^"36M>N@GY9+|3008R^Z>* M\J^1S
P;_-9+FUY_1)F*9I':G)F8VG(!?&QCYQ-[486A:?.0Y9J% %B.G*,JJ\$>5RH@>"KM*W
M!@+J'Q/MPY@*&|Q3^TE,>7UIS*8W#=#\$:JA*?T@S953K5119A@ "F=MC1HFD("'
MJ"8M5\$/+9@8&X&Y#_9?36R%|1_9SNRW75^99,'|U.#\|_6\VE;6T^* CK5_M>_"
(Z:H2N@D&\ZNZ?8P/9GQVPY*CY'R3C?U2GE:C:E(/8G*K"#&N'-=A4\$R) MUU4V>
(OM>@TAP"S+'Y4A1LR3."/4A@3\|#<6Z(O(S+G6#<%UG\K\YC^_J\$E5T
M>/4\4*S8QK\7HS^NT:S#O\|RFYS M_)4OB\OY1RUSC_D7,|+E.\$*(^6I&.

<<.:>!:1, LV^;SL&HA(A-R9\$;5].T M%(L/;^9\$FL=.Z>EHGOMH7@M!2"O">4
P7)O":2SF6S/A !KZI^IG_\$T(VKK M",M32D3<94UG7!!F:9%[1_." +RV;IB+U67
9*2C/B9#>\$U/;UJFJ5>4L;GD MJ^3\WYMSB)9JT A L+ ^902R;N"/KGUW+^LO{3B+
^G>OH^Z",29P_V":Q_*M M%)I\$V/ID= *A\\$(N\{Z#F1G%U+W>JONM)W6#)O#%-
F:3ZOQK/7C\RPCM#4S!2W"7A0JXZ! M=L'3IR\N!+7@8MM9P*6FS\H_+./D#/A:\$!"@I
M9D0_%HESC%9'96@'X_?)J*SA'5./U7BWAF\<JWNQ\IF;IN'JY.?X_W-#/OP M.JUI*/?
YQ2",PY7\$H4!,>.)#CD^8YXF05;J=5<),M;D8DWN'K0HXM'B'Y6VO+=ANU-
(^5<@&@;^"+=G6%ZHEO@%
MUWC=7(3XM.!^(Y74:XCLX8)A2W&N(G:@Z68TC5,7.6_CK-J%:2VOW;JC\$6>3
MY;Y>59=HR9+_CGF747(\H4P3C\%(&%61=DSH?:C4K;YJW.XR23#V/39'R3
MP\B@D*:J6XO>UB"LI8@QR\5+J7(!S5IGL:;I4U_D@V!!_?<9'*;0?HX+Z8J
MCNGS)B\$^6S38/'&9W\XC\FW=N?4?K(_B""&Z=G-<9^%\$LU\$W6>LC4KD&-U
M9CF>UL\VR A K3\NH557S61,9?D\?XH6_3&*@-MQC#!B=JCZTH:05/86PMUY
MP3'H:5&&-H(%>E5,(JU9L#4*YZ9L7CN;VS?Z?I8L!RVKK#.!EJ\LD_IRA
M!H+GMBHWF?K-RZ05;=NX9R9LWMR^;\$4\$DW\$;-FI=D2((\$E.E2 J552G+DL-
M7UJV4FCC MF'J_Z9X7K#&FU>.DIV0XGNI_"!HJSBOS=J78*%-(J?5_YOI#1J(K,@Z'4+?
M_95%DZH@L0:A68_G#X<;NKG\=71<-7*^Q74(O\BJC_MKY.1.XOFN\!>\$8. UQ8\$W*S'J'
f'," +F8J4:3,6ISU1<#,RUM#?^8E!=M.>Q5_MUG=A&OFVM6)W_Q:5L)\$::J-R(I
MYORF\|=,9'F>45(X\W@1%/A^*3*2V>V6ZGQMF"W^!7Z> M3\WF\5J\?> R"N:(*.J?
_?.4UU0Y_D\$65199RZB5VSJ*.;FG28#&J=-O.M)90S"!O>S_0E@%-
'.'7TG*FC\6GCO\M+J;RE_Q?_J\M+V?C\|_%_'J02P,\$ M% @ 48L,6J3T-"J;@(\W_D !\$
JA;&MS+3(P,C0Q,C,Q+GAS9.RJ
M>7(CR)40^O_J%CL;COWORMU+>VWV7\CN4%M51I+HB\ZIX>OPT'1"0IN\$"
MQB(5Y_/+E@(\7+!DD!";4YXNB@R\^2>>=?^;?_J747, \H3OPH_LWH_
MJXV#PG7D^>'V+J\H7H-EA\MI9&2-^\$2,7OGU>J%NT/L;H2IUOU\Y4_NW'88H"-#!N?9#
M-US\N_L>:MOG)MP_;TS"P)G =429X\$2%#C\WM*J&OB_3FA@TC=>(O2>W>'
MDKV\IG_YIC04-_B"8OP#&05N\JO?O/_SP_AO'3=/8?
+Q2=!W%NTNT<;,@_P4OCL_2P1TFEEZ1:%&_?XI_?PLJ0YV/9NQ_.H+.T)EH9TGV*&Z*_5AI
M"G\G+5PIB*>RTIN7'TA?/KQ\H_[M?H=JTW""P=^&\$7<=US^A\?P\Z;H'R\MR!=W
OJ0\03^T4NK91G5'J_2\|M%?44?;9-17*^J^2"8"U"=L3#;?1!U MX<.[M^AKBL+\$?
PS0&11#,3D%R=D'.(RT>A(7_=^XR2.IC+^LM)\$E9UO7W=<+
MLA\JA?'N39IL9S8OM;5A*_G^IY\^>DM^>;?_X?CD+/\C_91G#KT"-U&S(<
MQ:3"7V=J9L_@*WSF\?;'A/\Q@F%AT^R+&_J=8)OL4Z=R/=GUT\PS0BM_RAK M5\A\&
J68J"X1_L<9_*%L6W@%=>L_ORWX'=.;OY;34;X-N:J\$O3?
C0?!\WRJ\;C6,LW\$QTO^Z;9F"L76\=M('6 MR=J)HX,O>E0\D;V8,"%H>0/S,&#F";PI?
SX\WP=NT&ZRP@Q<J>?R^>99.C MTU;K5>J &X912GZ_K_B7^IT?;B+Z#?X;;N@_QU&
5GC)/CP>7&C?P3?IN\7 M*(QVA\=0Y>T*[\?X#^@6'CW'QPQ
Y1O>&F_/0YCE\4G/WK^#_.,<8DWYG4= MJ/QO;X^K'!'+\$N3-PW\GG_0ZDY)7*G552N
M8B\$TWB+,+B7+;+=SX\+1\$B+Z8WR_GMS>7L\75Y?GL=G9_<;7\='6U6L;N@ :%:-O^M
ZQZ3@9_+E-R&"F'TCHMGXGE>W\C_/32GT\TE9K6:VI6=C?MUA8Y\I*Z>J.
M"ZU(J>0)AZ1C=HD(VP2P5TQ_%W-JOG#(-OG=.<8>ER*!9A?+S_-J3/R^O
M%LNK_WY9O6K\H'1U-9LC3^VV\IEZK\IS*/W3H@^RZ*U8C#:D--OA3SVWP^E.M&&!
J7,R6GZY0Y\JHY09Q)%K:A(N'B\CB*VSV\/"S_Y M&\L;J3+%SSS:'O
K_S%Z1C&8@TMVZV,%0@/J*ZBWP_EU-<5!IRX'&G**U M-PYO\PU1,Q5-EHB<-D@#?
6\$^6Y\UT^UJ2I5/JU*FU6Y=OWX9S?(D'-BE_5*_+CN\J*0%6'U#TM2-MC M\$J91?)
>\$QJK9D">"X\J7L;CS;K\1!"^#%/P^!2_T%_IGY>[AHA.LC+ZU9
MKP^UJ>*DWCBS&'4OX.1.-JBO";S\XPZWX)
(W2Q*4)D1>C\P7/PB..4%54W\>6A\J8\+4.;96"R;/+@'L!7
M!1V/_\$V,Q9VKKWL4RE9(7TNS>'7M""?L.)KD: #&J#B=[6MM61RP*MRL\$2B/
MXH>M4D"S8G7M!M0^2W%U!^J?EJ;AXW7EOJ\$?;A-B?D;O\LF-T?OC9TM<2+-\$ M=?
T%)^+X2^"A.@%M+Q7R\H)AFO>HZBC*-WSF4 MRFFQ6B_6.>8\$B;+?C;DZGY)4';+
Q%% 3N8P0Z_MUF6KU?ZAK-2JDG#*MTP*VTW*_6J7*_2KA&LN_:Q9)J.F MR@ZI?
5J6AKS&\$FUA'R\0Q.Y@1N"8S:C\KEF6ND*#47!R\$J>U:7?G\78^57\$3_M)T5B%<1_W?
KNHQ_@CDJ.4I-ZFK6LJS=*1(GT59!U2G1/"VS>*FW.MW02OV' MNMJDN97;^99_.GFD#;
+5J#WZ+; '&' -#JCK7MKL -K&: ?W\2R4E\IA6%TQ(.X\6@.+U-ZVJ6N\!?:>31<%KPOJX-
BJ6ME\J(L8EWE4R)Q6JH^M_@Z*A3HNHUFFNI*G\TXK5(_PC-<2J74:_2'^NZG)S
:9';>D8H%DU71\.(M=5V/TDOBM+ &W27\$?B^@F9)ZWHBM>O\$:4U\^% H3F:E@&;-
ZOH@CEMQ6ILA M""L4R\;TKF9%ZZJ>1DX6IP7O\6VA.I+U8HEK.MKJIX7I_4RX8(A?

@D5)36K M5M?2)TQ3@MHT-"04J*J*FB6LZY[D1G]3ZO9UWBLE ^/2VG63:1N*0S)H[7J
M:U\$67YN24IJU\$CC6%'N73PO6VO[0/*1YYGFDSVY0@CIDH'4U4X4ALNHM|:>Z
M@J=U%#6PO7D/RB".!2#?:3.9-V8"|+N7!0CV@D0]5-E:0S>BV6AU)50+H^B9 MPSM"-
Y]2>W7:==&V?G/9;X=F'9!?)=1007?Q:@ =!-\$+8&LDD@MMH%8TVT|@ M4-5CV|\$.?<
B*35@&JSMW M UB6Y1-"J:EMV;M]S8:M:PD|:UAN0&9]Y3E:\$H?WUO%#H?Q?
AW78H3T^|>8A MWV|,VB>K&;O|7)=.W&! =KE |HV26Y3X%R774L,,89OV-/NNE|<-|
<[CG2@; MP?+02CTH|MMTXVX|QT 4_7%XATZ;;RA1EY?B,SW?K)Z8GU_&;8!85%=)ZN|
UL_==7'-%I F1_-|<85X=A ((@KROR9L|H=K>P2| (= <
M*6%#H#YKKAWK+_E0W<'3=LGF7RY|*0 2Z|=!^ZSC#O|(N^ZPOCNESIVNJ\$X
MGU8FM?84-)NK;M20Q02=M",#;X2"C5KA(YAL4#S?Y*J)DN!_M=F@=0J:6CCP ML0?
Z3@@56J*]2TG-MC&BZ-2M]M&0'!=!LP|J10|X-RRP>|RA|+NE+RFH2WEM0
M%1?H0%018^=HLNG#6UJ0^=^/7;;G6_\$! =OMTK94-5NO;JY0;+W26I=8?%G
M:1CE:2.9W4BBVZC;YE%1TFR8NHVAT8:17\$^G/6)XCY0X8I+A,WfZ2=&J/?= MO9^Z
3FYF)/! S?2\$;:UNQ"0?*(K)KNP+|"| #E+HIS-Z20T-M)|.N:.G&V|_M2/&"%<
<.5W"WF3;9,X<&JJK1VYJAK|F#=&M\$LVKS*PU7|4#;|GW;7T+OKS@VS M#?
X|B UPB^~^I171P@_3-:;>&=EG#5C2|K2NV076W5?I"|CS6FT)=?-IVPVR|
MU0XB_2AJME/'Y!|G/8CQ|X|J5_P/|2H\$.6*GX|XX\$?|(8|6"D)W.|<.:?
K.A7<9Y&)@&N(O>+8? M |2DV1\$|P2|(D@5*L@", 'OD!OY_ (^~CZYAS1
RJ699;/1#LQ%'^5K\$5P_0
M*7V@"N_MHK>4P>|'=8H..|!C)^^RP_OLDSY3I03HFF+&|SBG(? (W*"|HV;/_M>()A@5A8
-XSGU#@K2)6Z%"L6^O=;*Y)S<85X7?(-FZI4T>;->_7&;YDSZ|G M9"|W|
|2Z(SWKKR33QNT'P!6KJV"B&0W/"Q%JM |Y\$(E;Y86UNUP 8L 8A,) MHE-
MS<\$:TVS*NBZ_9.BNZ,' 8X/UZ7>)3#?+.^:X:<5B'CJND_>/A12>MF6_M;=F:\$VQ64|
AZKK|RH8YL8&#H+M5937XJL%3IZ^I6>NZQKQ @JO+>(SV::V'
M6.O&GL|=R&AV05UGW6@7G/R6|X4.|!D*;H*N9M_4M<_J(.Y3P/>0-N ^"RZ_M?
:DK|E==66TP=UUNKL&O;M;/#4XKK@W^?C|M+ M|B|39-4;Y|U(%:X\$8JW>/?G74*9>|
|2;#.ZF-J|B7TPD.L<*XYOR#J|<^AA^+|*+P 3W:B/J=U M|!N@#U7-_I""0U?
TKK1=^I/#6W9(T|0?L6@|QY8^|:)|P*4+'D);5+6OAFa' ML|.Z@E97&9>&0->GW3?;|LL-
0UD,TFD.3<;ATHC',9 HL,G &0040'KORMT|^K'%MS7:H*ZB/<@!4G|_C!
&GM>^|JNUELJ:5 M-2M?5Q|75OYTXH<^|16?0?CQ-G+#:W<-OB2'MA=
(V*:75%7"\$OO@V,70FC1 M@28=WN9HQC)(%)<|. TM#XJ.H|A2,'RDJX2@,4570G0|UG;
|TGU62\$|M\$);F>)34X;RNB&FH6H_E|EOK/Z"%*|23Y;@#IVJ.0E 3+SS.6&|+TZB0%
MSB5A-<6TS#>B|CIMPX|HMF|=15UT|T+_3Z|9|UW|IX|M.NL2M%YA_>>10P5 M_2<
>)MWSF9SU,4>"A.8!"20WL XG8D-'M-@,Q>HO|A|9PXK|,78%D M?
A^/TS,5%X_X=R;Y|C|"^AQH&&JKTAQF|L.P' NBS15/5^DQ9CW2PB'VE' MB?
|@%/H_0DJR;C=9.S*:726 3I?OJM.--OR>*TM!:S@;(UY\$XU\$V8.<9H|(
M8,X;WCQEA\$>Z&F|&-TNQ:IVR,S0CZ1FVPA0RQ7;IK153LKJD?8.MX@MEIH MW#
**IH=TB)W9L4^AELZ72?#)\$GU=_3+!4K2V<\$17(R/^N)|L7-_8,73(|M&|)L+ &NX,-:C9
MD0(\$Z,%|.+V8_7?%110\$|F,\$ MFI;G-(MC-JRB;G VW2A|JD9=
5YIQBFW<|HQ3'KNYYG'!4E SU&(NYI>1W&I
M7%4QJ%5"#M""9B^)|8#Y*R=\$E^46=;UE?OB/^:I4JOSK&DTJQ?ZQUOMH=|+2:
MU=5LD|H*^FB;G"Z9(2|9^B78&<|1GERDOA+*V9G<8!8CM|U8ZHMS8ZJJZ,5
M%P_|B5E::;^:W4:5U%|X+-0_!3K:'|+JCM0|Y MC ,MK0!=" RYMO1;#
(1V(ATD^52F1Z>6<*SWZGZ_Z%L VW8\$J(G7:?N=VW M0.LH!,|YHVTO!.4 40,+K?*<
|'"%:89+\$VQ;UIOO.Y-:/9<796NV'/57E!+ M'>L'N=F@72>-
G+POQ;>G_6:\$=6N_#YK@EPS9E&;_U37N ^V_\$ZS):/??.=KZ M84A=EZY"#S|L(-
)HOODR4WG03KNSO:|?VH*&^8WPLT|92ZDY_=
MZ3>&6W91;H229DO4%>RB+2')NL2+GD+,^QIA=CN?90((/:I0WN*_
M2@"^'OYN|>LS%LW"+YQOA(*3S':5+9D7NG#NW<_\$A)>M>@:??
O_>:/HWJ6:*N_N7;O)_MP_0-V|-J0Q_OK<#GK S/'=N%J0=^RFE,W2O
MHYWKA_T|72\$S3)I)\$V<|M'M\$<=
<.BV@,TMLG3#1>9X_H+)^DCGU64.K3Y3%T1|^^(2V_Q3?.)A_%B^~A^"QTXSAZ:3+I01SC
L#C^~|G|> MOS_|)Z,24RW|W""2|DK@5^F'O!.)O.UPGYWY*=K5!Y#4EP#7+EV?
9^~_IUT6 M4U)WF?>WWTL:K3."?|O^)|8)62E2A^?M2'1@FG9QODJ3SK0F,-"Y0(!#?
AHOY M_7)^>W,Y6UU=GL|N9_<75|M/5U>K9:-1-2QHBTY%81(% MON<2|SOV93+?
E++>A|29*D9/<'D|H|(N|J1N^T49>P7RTVAO#M6CKG"Q7^+|W M5_>KY?
QZ^6FVN/HFO|V6BRO_O?GF|6OW<|*,|K3'+6AZZ)#(U.8CXO9|M/U MI?
R7'B^!DMRP8RR)JP?;B8T-=)AX2=?|MS0I8Y|RQ0?4K0|\$-C79Q2'8\$(L M:NH&;K*;-K-

!."?<[O?;Z/DM6GMTI[#?XHL\$LBWIBV4JXY,@HYL%J5&"4\(\$,MEPQ53W(.9BR?
M4N4K&-S[3@6>*&(&EF09 F> 0G10QIWUH3SJR\$7Z.89H MAA?F
;1%:QH'=>1,=YFJR6_:!5&WV^24Z>#K-=J3=JKZ6)'5J.0DMGK'M* 2+?_+)J0&345.*X
MTBV7I%HU/YJ041;#J4QO7%7I02#UW9M!%7'.B\$BG*KWS<^&LOJXW%<-&JDM
MIR4E,/XX:J%V7<8B)3+J>*018BVT*4S\ON>^P"U?N%K-<[L;-2!E2XKL^\$))ZMN2*-ON
M-77IT?CNYH9%M4=V8Q;=;(-3E,U:Y*T?0GYKW_QH)Z9I_RD(1,*3N\&;F6=+ M:
fWUAFU_JK/(A,4%"L;C&>7PIAYM=4SR9X M!_2Y*P=K<(+S5(8&H8J,7:(A7Y04DN-NQ,'Z
MXTVL0-V*('\$WNW>2G>V_EF182.X)8,AC-FYSH7%TE MJ;+#+B%70%82)7R,
<76(5_P%-=LG_&GVC&)W"TI/=A2K?NBI=Y#NW890Z)@ M9IV1U|<,RN\LD&Q?--
SBR4F 0?*<+.R,V,&%LPT2[1W*:G9-D;4DF|H M\D;HFN6YST\44YK.-
^*"IB.T8WL3F271VIN>F09M3&0V2G?U/6:TW.3DD4I_MPN*|>S|U|+|^/K!I\$;;6\$-
T:EHV[N)2PI7<+;Y8MHS/8%6|83&VYWJK-VY M8;;!OV6A)U=:(-
M#:Y|2ZKVU_@ACM8(>01 GBNNRVG)|ISX"^|S8X"6-#H0O-Z"+%F@) M @%D@ M-P
@M(^N3V%P2#;|:QV\$/|*|%OBLP-RL;:/>-NPNB890\$/X!,*O%7\$"AV*
M41N<=..=L>.:3E;-.8,IVP|-2Q('(>(1;T\$+G#!0P\$7C%B;>PVL-TWP|Z< M&KPM6|&TXQ-
7?;?@JUX'K3'-'8W6@*|>P/3|",ZRE89O M>1H|S."|VJN-"?BU%NO)O|\$_'I=007T;-
SB!>3*C7_9@ 5?88-'I3E!'"^/, M^<;K+.5?/K@'PJM_#CT4WT?A!2CD'4|.Z_29!@/M39>-
J*,M=B"
MXN"40^UXN[6E:VW4)E^VEF2MKW1%JP<_WD9N>.U"9H92WMW>"|^F&9L1*<5&
M!=W/^JC(//\;\$%|H&CKJ|%L>|.8I5F8^IX?9(|!|"E^#7PW0!BUZ.0E 0A MZ!F_"9'@/H-
\$ _M, =8|WX@;.#RWX_32,J:(29_F3L1'|SZ#WCW6,G|GJRW^
MG;V_U9R|^'DVY\$5@H5,3B'4SO>2BM<^\$U6,M>;V^VC0TA7DL.FDT MYL)
(8U.8'RY*+9;?!|DN>OH3F(65OZ-?8A\$QC?TU0<7&:_DY|+\$,^>+&WN!|
MQTP7)C"7F#I^*9(XG"/<0:1>PW)LE!O,8N2:V3F& M>V%K#
I7/6M|Y8W5NRO|<|.WUWG_*S/3 _DSVR%O>?Q)|-V|UWC.5A|O7M6>V M\$|/;C|WS2)O?
GGW|8@LCR(P)L M56R-NDP*XZ_C;MS\$UI%ZCTHZ1ULPF_O'P M"^UE;I#,P^
(F|Q5MA|A'9-=%602ZM7E"KT:N6X|W|C)(A+E+25G6|)?=TYXC MY.W>7GU-
(9W;8X"NPFS'A+);/U&F6*K1H|(T@2^>)),2!HIO|I*F _A|/T?
2#=%U(;H|B|*WOR7;00%WW;L='U9X9N_WZW_ MBK!<'EY\$|3ZB3|1=)?DVZY&F<-
=>|9|*6S?TA!T6%##222_1X'KFQ!W'O6!K"Q)/Y,_X=H&56>">>XR:_'6|*Q5KJP!1\$/?
N#EU6_MLLP?K<11(6N=S87;JB";?|W\$%":MSM)KA*T-|A5"\$5|?#@E8S7;AK6I8H*;
MV\$%%>>R:U#1|E8XRRBMXMN>*BH(23,X/^(|E+C|QSC*|@PO%@O9\$CBQ
MK|Z,U1FI<6N3RY0/1?0^*(10C+GBD.LEB%)=Z|:T|\$VY"AO/L,|MY+|,Q%
M'G&)2.99BN|YJC/V_I%1C 3)P+M2LS;|(O1> 450PA_!;#@@%?@@" @.061" MS-
\$W_!#G':M"*|NSN-2+SDN7G*.TA>\$PEOTC(+52|2*R*=Y>#QV_1'907@
MDLM%)W+778"E)#XH>0)U+<.+ =^YFGOOUW(|PJW)F2E#*VCF|P+P2|X|YNHQ M(<
JDF,C+6|QW4T1OK|2|I?W|H&LW|>E#*|HS;NASKW)#Y7\$NFREY_K"TIY43F M&|9I
F^VK22\$/9HB>7G#1|I:2RZ=2_D|WY:\$M44@X8<%3WP,HK4#X_1_PRY, M4A;
(+%F=#H3LB>?B*)K"7GI^*(HP#3U9+G9FKKZB>.TG,+XC|HK|@A|P8LMN MQ;:%:-
WPJ%EF WK|_|\$|NE=Y/D;'WG7@;L5;7H6?O*RUF6/D6@;|#J7955 M|.l
I=LLBFVF65)FEIA,)^R+I^2'_^,G'9RY>/QV(2*30T#2L;)-
MKH#L8"8YUPAQM!TY;ZVO.I^D,,M8AIP1@428?E7BX|M9?:9U4)BU9 ^L(TJ M6QL<4R-
L*KI%M6J1,0(:P=, 8?L7QTVXQUT?E 8@58W7QS#)KG^#A*V? M9GP&RWZ)ZLVLJ611Q
^W*4HBJM11|?0H37S8CBD\$<-R31F972YC@M<| M|0^!'XD28OGZ(&(A39\$V/&
(.;5T&Y.>WQ&&!O&PM4B&UJFI: ^|G|3%;&OH#)J%H%?!^D!8!
(#5^'VWY6413FZA"M#O)|_P+>>&|;1E)|J_5KS^O8X;B3(;?OZ*NB+|C(0E;3E
MO7|GABZ|A4CB-DBU!LYAVYA\$K+;Q4V|(R2:S"<|*59 0Q_H#EE073SLW_J)F
M,|75K+OZ,6,7/N41E^LT;G^B&G9?G ID|V4HN;"3O/ZH|+?*P@;|4TJAS:0 M|_-
BI>X7XK;J5IF4H)\KFG7^E WJ6OO>G)SS&1PE ">(^?6E0;!!A4MGG+N
M>GF!&4.2D3QY*K#L\$ _&W2J:F%TF+;RC+=/A+%'^Y"1GG@J|%/#1K#/2MU1?
MTUX,-8#%\$%F:&\$P@_C1&J1|3|@Q+U0E^>T\$%?>\$|10<)-J MHP9671!VA <&?
KZ5W1|(N3EK.V'>GA,.6L65<'D%|'|KPB|@C>.N7/E',PN:>;XSW#^B/9.Q8@UJ6C5?
LWPJ5.E _MDR19+B#;T=L>|*S7F GD"DM +KK#E^HN MVYE^7|HV;X_9:>
|^E|_1ZONP#T7|6C&E|N6XE+7N|DOY\$B7KV.<6|MQ/!3/6 M(76 TTEQ'0A-
SINKI;>6<0'U*S|.H1N..!9I N#T))HGT945K"\$76A,!7T
M)3V3)ROM>|JY|V3A7*X(%I<7MBIMWH1X;C+HCL|H4%;:M'M|/K;3|^BQ|F
M47AW*9|124G+>Q3D7UG.(2HSE_(&X,.7NQ%+;4L|%"U>P'41",P-[KY7|
M?)@6S=KO*20/L^3/TIV?/K%WV^NCLWRQ0^&=UD!F58"*LB.4,O\$6TW797I M^

%H0[M4->RYFQ!3M\@/YE837/BDY@!7/Z3SP0?F_N>KCS/F=*JY_Q4UIFGI M9-
:00CSK80*L\$QG(5GZ.^9:7#S\VMY*+*XSJ54\$=>-F4B=R)86,OPG1Z\$BP M?
&D)!PIR@(FJ;\#AR=N)WI&98Y='\$?4D9:J,\!FMG80*W\$NEJO3W/!P9=*
M3QW18C%L%/GY'I+%B1ICQ-&BG0PM\$E(6G2G*AG MA(ZTN"DS#5UHJ,TG02A2QV
M@SF6,8)HB\!\$!6ZFL.1\$+H"J4B>7?T%!\H&9IJ8@8'NSJ)1(?+H/T M+0)0EZ0&9L51!8?
(RX)DP[V(GE\$L48/5?|>/R%9-J8"WNT=#JR\$!&-4RBGD(ML 0IM1J!:=NT+.YCJ
0N9LJ,0T/JF9HY036N;D^@=V-(? E.-GS^_5,A!>6
MG9103&XT.0*QLHKA\$5_1W=S**V&QX4)^5R^XK<-UE,5%>"?>="=08W36*|J77GX(L M
7PGT[Z4;9!:TUEC O: 00PU/.KJS&:5,E/C?_7%1"+=AQ.K;J2_PHH/4
M=|-5Y'GW_OHI"A2OBZ*T:4G2#;,-B*!L8<8!03Z@R MC'N93=7X
#:K;%&9M\$;^,V@8(09\$-72)RTX"1TEVS4P")ZN67P+/7G.(RGH5 MP^>VIG,I6Z_C#&J9,.
(0JZP,/ _XB!WW1:>Y#SJ9.U?5#Y'%!!W4.L, _/:P!&"E
M>\$EU=2:#=:BY7*3%7Y)C\$G+)8A\K(:*"JDWHYEJ.\VZ-V# '*W 4>
(J2#E_/390+VP,8PMRCFSP1L%@/+%^? \$PA\55J
M<,1Y5@VH!8%10SE9!ER6XDZ@2A\$6>WW7+E4Z%.ZFM8Q6I?"YH_PX'S'Q%'1^ M.H?
6B73.!H8B\,0L."<1V0;59>VJ207S2^9<8 0!%PH"6H#O(MEKU9+*I!!Q M0=J<;
IB25R:6ZBN:=JA-GX(H1-S50LIDB@M.O ?^5N-I*BL)"=S-(Q,<9YG
MZ<#:TK\$VY&)^70^))_XX/FR@F?:8D8U-4L!DM*_1E!L8E54F=47EUB;V:":7
M&46CCC*INKXMF0DP\W!2L3E7P%WK,/A;\$_(?I(FEOR;I*C<9ZE9MB9558O.
MRT3JEJ0*\$P4%Z?#+NA,TIY5.DWTD5%,6>-%"L2MQ/E=6F0*0P(,SV,2G>B1 M;
<6=7N2>/MJ:IB,JHI#'\%_ZF#'_J11Z2T7L:8#74K&L.81MI?P\$@&R91W@R
MCZE..\$4(\$I+L\5>^PAO8&%G3^82*"&/F-J&4585M\>%2@3'PI?_4Q20#)E8 M8
;&Y764^DQWHS%-M+ZTNIEFV'57RD/ES-X#W4T#%CM3XE9U\^
M!+5HLOJ:%MWF70JQ#\$V6U#DIO#B4")S-ZEI\$!6;,<;X!&><:WXM")(!?
9XAYE7//JN(C>6"Y=\$&+6JKF>9YF5N20HPZ+C()OS>=\$4U<=AJ88IAQ%#(#!8_,B\NT
MXAVIF;Y0UNMLCV^O P%GT:(U"2^9EB0L>AH1&)J/*,33&Q#F;^>'?I+2VX=W
M4"G+MZ,OJOU>>"?5?C:MS6%!JJ(DR\$)ICJK\2\$_27/HY5/T4GIB8,>FDK3(
M+6D8UV=LP\$.32';^8P:7 AAIN\$JI_#W)#SM+RJFIR\X'8O6',>I3<"9B@<'
M\#U3::%S3_(-^;P54+.2=UE4TC2B\$)B\I \$ \$JB&^57X?"EARS0U\(\$M.#)<)
M\T#,V4*>0+GGF\J.X:D^)_%::.?+A)9*1NN7NR?6(SIWN0\O2IEIX Y+(KJ M:8X#&&\XX
V@++I2LVYY8&)IR1J2?RBK_<;=.,C_G"#0>VW;=Z6J8?EVKF.
MXIMP\$!609_D\POW/S3+S>)D\KOE?)1L-KC)_QL3 R;"5&IVTH3<|+ZE;CH>@HOD8-
PZQBF\@ MV"WS<('V+N80

\$_3/#!C5 M9WT\AZRT=3G,G+-0'XJF;<|_ (HG48:%WW,4;U%X\$<7|B#;J\!\$?6U\+GJ%?*<
M9TLG6!T++B\JO_>6:;\0:JZNOU%I# :QW^ROEU\POMH<3C#6T&#P!9A+L;\$5 M\$)I,M5-
-P-ODU2;@#8NY: 886KDP9KJ M#8I6^#* R4+>, &KK=L?57GR+DN)QIXS=3/6M@M-5E
M1YHX_!'"&'DGM\$+C'^=;KOT_*YXJ6+AJ7)?L5M:
MRZ88(40*5XT\$DM/(&JITB\$M>JR^GFDN!5^\$^!'" *J!SHPERPA=Z(H M;MDYE\Y/28^J-
!JKZY@/;A3'N907B L);!Q"1)<(.VFG&F\2MDB2N;%!D3 M2D"TI S-0YY.04P
M*91=4H'I@.A*ARKSZHP)U)ELJZ_H1\$5TS()&&[FF\I)*L3A(Z9TJQ2QG(@J2UE8_.
<."K#E:J&1>,"*CE_&G\H"Z"D#, MB3RE3'M"KT^)^4QT"K-R@Z&+U=BSB(2K\3Y7,2Y:-E!
(D;,>9!K0)E%K5G?4 M.!+PAYJO*NG'T!!K(3,#X +!2W4A09;+<%LLF QIOBMN"2)U'69?
+YJ& MF9*?@56(HT!N!CDJ8<^H^J@J PR\$9<=J00OX&D0SNKQKR.G!,"2VC+=I5=Q
MC.^+*,8 'SA273/#2I9VQ";, /)UM#5LNESD^N8\B09K>2;-A1,NP T!8*^ ME3@0=:5B-
5;+>*Q12:P<-J\+@6M4U=K /H=8,@X8.X1?'+D>NDD-NZKHMGX< MFDK6J1_\$6Q^?
@UO<2B#Q_-H/OJ1L"00/>H%K<>:53Q'/I=I!NA;^&=J*&4 M4P\;@K,7;E,4\XJ?
E/=0%TH6KR6/AP,5#ICS#;XXD;+P>'/IWPWEB,+MR!@
M#WD(S\GO:L%AMME@%@MY\WB!W"0*!5UZN/6_H.! 9! M=|#@7-9"O-O4M(A
4DO\$J=0>R@+!KB,1X\>|24"!I^L)06;DMU&Z0E5*C 1/:.?|4,(>YI,,4I2
MB.\$&+ _JKKRFBT4A7(2XHJ)@P0='B6N5\,KZGJ-&#&D.D:R>M,!&?)^X@U,C1
M*2JLW)V%.PL7ZLX%0J#
I6&=1F\49"1*!6>ZD0"15<581*-4&Q(3"6CN%Y\FTG@U%H4,O> M,T!# F&,2@EW4
7CZ6J85U05/5X:8@!4JOQVL"E2K" 7(->8U;7YK=?J#& MC\$-IK+_0P-6V/+>X:?
9P<_9*="T=2;"L&ATM,*R-AG&/Y263JR6,UR7C8Y
MYZBM.7G#=_ZZ&3)ZU^FJ/N>B8@Q8#MA1#R 2WH^?MK+XPURT3?LFJ-M3:6+:6%PJ
M%EZ!," N:Q&J<4NOR.II_QK\$1ETIPWS+,MOMW/@PWV#Y;^EO0W_CKJTP08J!"
M0&XF-GV(J8.J^1H.C)(C4:I=8:KAV+L29B_4#S.XV%*8(UBX=EKS&%#+,

M4'U@R98C'X>|RCB!AN+@:'EA>PFEY&A1U DVHN\$%7|W@Q@_TOTO_:VX0E^N8-
34FY+VS0'''_0#X|_%|LCU';/H<# ME)J=6M.9B\$FM90ZVAI6GH&&ECP>6
*G|7&R5UJM=FY&QCSRGQON3.N H-44& M&YA8;HS&2%CG!S\$!A3PZ9(NF0TI
S*|,57U48D+HL(67C(F4@/T:F!XZ*-< MM48'+2I:O|B9/V@WYVI-Y0DPAV(&' ^ ^ O-
/:!!Y0|LY^Q:)00MH!%DA|:,HQF M6ADH&T=)'52U)2ESD.L2I<7'!U"1Y,|N?IN
2H4>F3N4/D5>"2>_6>HC9>5I MB:|TQ)/T14P3CSL9!M&I
M0?)Q21114/_|=6,S|*/T5E7!W2R'PY" LH=YR/ MVU(G+&()DF>AF1|8/'&F)-
|HA,Y'H>NUE2@%,|/U&TC=W|D| ^>-6I0,VZF M'1'K?
B:YIU_)1E3W2VY::YIPXM3:)1E2DYJ&V8QY R6>JH95G2P)NZHH1A6C4%0PO#
<@7%|/)B7:*PUK6E:2*#4BKQ#P4Q3E M#',-NC;P|I?Q",V:%&75P|<(>(<(\$#
|:XC"51EO&U@Z)7RCH*2|4|NR@E?*X::Y1&6U?H-">M7D;-GB:3.GUDO) MPRF.00Q03?
6=31S3.I,9U2|RYGDQPG(J_CB/5|'+|9NE*FG:0VVP'74!*H@X M(=I7'W,38"|LJH.:=%?
M|:Q%"FF:7|:.\$Z#TR&M>WW(^'(WW^%&AD8|R+,,| M6!1SF5-PA(J+V |GK%I%C@-Y
"-ITM|@?A,?SE_JX="5V@2|6_KWZOD&=&G
MTG5(WM60S&M%V&^.JFV@G=|@*|>@LBQR<_4>3\$IL)X(LOCT?<3?^" ::O/O
MM*=C6J^:?'<6/893%VYLP<,\$%DO|HO\$2KIRA+7' 7@CS1""E0@=L3,3R*PF!
MHW&I>YH^V*-1/=..\$U0*S,7QA&@2(=%\$1,((D)6-D)DA*X3K0B85H0I07+
MA0(ENE;H|2DI*Q(D!#QS?6\$ \$7Y6RPAZQTCF6!S_:F1L,HM0TWT%|'_&<9|N
M^#F4@8^K2EI47F'!8NVK\$RF4BOP&F8*J@H48Y*
<2WW#4FK)Q|2+,3I84Z490C%Q&_JC0=2/H2H4NA;EEVIJ2C9GJAIOIB%W4\$F5N9\$
MX/TCHX\$J0GY85=YJ2_MU":9X=@4H"='RD1#(VI.1-/!X|T5U_BG#HL2GT(UB
MO*\$%VN.CM8K.(|"!MT|FUIJ|37\$/QUQ7H+G.H>Z M4(Y"7MX>LP614C2-
UF4&WNF4':>R6+F3|8I=J|DVR1_81%.KV|1/!#R5H6R::H5F|ZU?L@R MD4.F7^"-
C=DCN\$QYA|73UQKP7|!5H)S-F5X\$2RZ1Q|GB@=(B@U\$-O3<;> M@(LD\$|J'KE|.?
E18P4JD,"452R+XJ!)8/+:?92"M'(D2S<1OQL3,9^ ^KJG0 M+XZ6!"6)3,,P1
NC>N0|9(^!O|X.(E<.3U8N,YW(BA:A%'UB*#1PDU?_S-Q@_M%H;XOZ|V=(. <-BPT8\$UI?
I&T:9I1!|TD@@WS#:@UP>6F9EBY#HI16G+@=+D M%%VB9!W|A+N|U6
_Z6I9%.KRFx!= YKG0E'!IEL6_3DH3-\$Z+RQQ|9\$NP,MH M31V%,47!W5?
Y>0(N/,=ASU@*Y+JXEEEX|S2E9&_GY<<(LZ(AD=X@H)\$|B-MU-ML7)K-
:YN6KU_LWRX6ES.;B_F|O53*'F%Q8<:;>.S63B|_"X|M.:XXFPR-2" MRG*CER/4(
MMPG,O8S#Z\$?+HB8VSVM,V.VG*/#P&|!Y'S>K._)C?HVE+C?@\$?WK|'B=U&6G
M\$F/0P#W?;*|_D_9>L6Z9IF=-*FX?-Z#2"Q_-/8@C2INFIR-2BR,L>>1S4VE;M0V6:8
:2P:GK6(<)SB-,|9R#QP15!&RM:9W)6045X|\$!159CZY|?&3QS_>|/9Q|-S_UZ197?
MF.6XE)%B*WOP(M)K\$&JEB|9|/I#D):Q.0CQ4<|/+ #:Z>ZH365K'J\$18'O-
8@\$:E3%=K:74GR2 MS@ZBJF&/9|CP,?AG!OSU,|JH.22,L/E8Y\$D:&F5F8"%@,QWT-T-3P<
M|.ME%|J4(|Z)P/LT8C%QR|!&Q^0\$W>/?L@0(AF((B2E37R/6>|+,073_#Q)J0!
M\$QS=OEX%|FU94-<8+9N&/<<7^_.?O?^K NZ|6F(JZC1Y6)! (XU65"(SJV7IU
MQ"9_7|I%J'9P*8%S_"N|T?6VH04-UH01"^P5_E-#8.Y.'S_XY85H(<-*XH
M=@K4H+O(RT-A'T3;|N!TB@)3DWW40&K+KWE|30P4BK3 R'(-|HU%%.M\$:@ "M-
WK|^|&T-A4|OVB1WP2RS6^N?;#%^=3|BMW*< @3|4|*CM1H\$Z8=UM#+?<0|
MF|&E'Z,UKJJ(1%17F,9C|XTF/.?3CW_|Y>8NXARGXYQ"H\$@|Y
MYX?/"03HTVQIE5RCFBW>@9!%+H3G@H-WX)<0Z+8_V|ROV@RH6LKFH:7)5\$5
M>8BOXL&0E+3GSK^F);Y|N|\$(4AV;W+6S;|D9<4^B|=/F
|G(N@FYPJ7(%2_48.CJ6%MT|J)+M0%XJ|:4
MC9W^*UEP326+OACD"8876"1.7'UE!Q%.&OX?.)=(/33:4QI./RQ3O,O+65R"
MU*>)Q\$!K=^_N5\$H+2>\$)<(^MM\$A':3/*_K28|YMY'D\$S<(-2#%YSMG*|GMC7
MGC37|BFKV(LO",_|1/N&XN?3_C%"!XT60!<(PK#_CNC)G_GOLUQ|R0Q1Z8
M(&WXA0H/|1WGP*>L5I@_L?ZBD"FYG#,#%;WV.&IE=C7@>1\$G=EDE_O4L;?
M1+|#)10\$!\$C_E(:F&"*,!5W:EA9#SM,|^L6-\$<"!@A)U^>3O|_B8L'1O_M3*X3|M|A&GM-
&&A*U4|J2J8=X-P8M^4&GY;|S_R6TA8SMYE1/,#?|07>PA
MNOA5WL'^2JDO7J|DPKK*H6M0OHN\$%_)&P,P:D*F5%?%+DA0(:56|'V4/OO:
M>B.Y=Y9|,S_O|=."XATS|,U1#RMC:|63)^R51^YK*EF&((&4
MFLBK1UZK0MSDE6PD7F'_@/3Y01_8)2_|^AS)10G=(-4|2|B+P|BK3:|826-MIX-W-
Q/V|'_QM5'COZCM_Q5Z%W6O>GEY2;N:5Z!0JW|J?9R.|>0GH1B%G+MR|:
<=L8@\$0'3CC:%YR,N8:G87?,U":?7CW_D|RYK=9Q:FXU#'?SB/<,|HO_M"
(DE95+J>.T:9ZZY4NXA1CN(ZE28-61E1|H0|:;F&5AFJ4I2E*:J:@_*HI_M;
_O7ZBLH>ZN&7C5Y)I4R0W0@H!E=:H2@S'A((QX90@\$ (5%01118%P^#LFQ*
MW:L)^L9%ICRO1"/3LK*|/1T-

GAL/(@#Q+BM>6&IQ0AZU2.WV6+1\$!:#+\$&&.OKTI*C;R*B]J M%ZZ/'\|+=^G;B#._+)
F.E.L*#.M96\$FUU0JP.44.[H]/7IV8U M6':XRTGPW'401<(KHU\$|^X:T1N#/LM(3/-
XZ/T1I1?MK.LNPI YBD\8HKJA@ M3W**PC46?.8QF#C8'L,U/:C\B,XW9?D=E!3(DX4I=:
|BEVP8RP/N\?H M.'%G_??I.>(_.#UU6V?|O)Y=!7U%|:/2R%<+6O28W>W<^ @B-R3|A-
%.9'Z M|K2J:OCU._>CK8L7Y01.GV:3F\$+|V-R&-2%%"CPE-^6VJ3X|1ND>Z(*9&5>W:
MB*N(_NJX,T6%B=W08JM\$0@%06EW2:DHVH0'3V(?4N(17_1P"B-KRLS(41UW' M-+
T8*3O4YJ&S@T|A\$G|0"#!POE8L_8/(8\SZF?; YW?NCOLET5T&_ ^&/@4 M=JN
_"/UR7J1IS(1Z9"L=L7XC.XI9S#?<(<:&DD@'K.LL'W<90"W5KJBB4L. MP,-7^KZ*>(H6U2?
JN2L:6WLH_=1^BM*%WF<@5=E S=&UNSZ)W%:6GO\5S\$1^_*2A8>O201J|L3B&Z:PA-
X|J=R"*U,CCT MAC-'S6TDYW"+F!/?#[9EV/V(=|0J+
|7P##LVWD1NN7J(5OQ>X^%R&WNH%|7# MTC^.
^U.9QH0)@37,X='4N@C=+6LP\BWLVGJ:HU|P_XS K2A^2"D9:=F-3>
MW)N.)ID#)AJOP9K(8/ 5D^B U9PQI&8T2MJ\$|OTQ+B3BZR0L6WR\$BC=1,8N9
M|2#*5.? 72TTT+4^W|RCM!'".T>;**Q=0!T>!W%)!:_^C|^C#.P/)30F6 M*G!1R0(!_.4R-
4(>B:V#;O%:@:Q NHB" Z\$-P@% HC_I0FDC0 MHBB@\$F\|V|--
=DWVJC)UH3L7P|KQSPVP# 84\$&P:F/TGD^3X4I4?E\$0JS5@|P M<@'2\$XKW
&@%EZ,0G|Y=W2D(:L.LGH11UG;>JZA40@,_^8A70YWU75O/M|LJ
M/8/AEFB)CV"/L01%|B1AT>JH&A-8PI0M#4P^++BN#G2?!^*TW.4:F=GY?YL
M4M.NFQRP4C%ZPMQ4C@<*)TN41"P&)Z/N)OP',W#4DQBI(-^I(P@)|@O@W7KN|MT".
(N5(UF+"9@3B887; ME D?|>F\OV;,+WYD0*_ _@0:#JXC;/%|836A3BFGK#(
1%QV5(&0F9V%W:S_M/L6@:Z6SOZ|:%.*A?
B'LGM'5VUJ>/BY<|X#PD(,12!2A9JT)F;O@@\$SX0EP MX0CSX5A*PYL*"]=/-
,8'@M%EH0W:>O9\$'97(+1-.E'5>?1;,>90D+GN6^F+O M\$MYCB08VJAN
||MU\$+V4\$L#KT';UIY(.ILEA"Q\$|2WS:U?J+YK4-.|5-55 MBGG1.KYIV|J&^TWHY_IC>F?
@._|/%#<#97M1730U|H5A'@'F7@+4G#Z22E+;K MY N7S|UN'T?/2(Z?
V*3&%/|H//QV4|UX|&I8SH:BA|JMEI@9;+4A!*"AE""P*&#|/*WU'T70!K0/D7
M^>EH7'>BR2@TK\$ _#RB/|3|/#-#BJJ+@X4Y>H#1#_@IHB!.4P@C1)5G#<+@&A0
MHG^"|41_F<>JJ2>QI7M|4'&YJPBYA)UY|9?\$\$EB4,R|;|VJCNH;U5) MNA4 ?
2H\$AGZT;*)31|P_U"C # &.*T-?;Z0WB;-'UWB"W0"89WFN*6E1^TH# M^IB4@@(-A)1
GCS< &;'_R0< \$|3'_DV#OWFI DLVV;VWK5F;:>|JD^(: M"
(SZ"(%V1=_45O)V5N4JZT9J89-%*1AC>4:>50:!=<,|%Z19JB34!FG8 MWX:E+/"X
MR+OAL|19+I0U|F99R4>603)B7|S'65Q=S9626|467>!M@1|+DPEX7#"8J9M M?
+^>SVY_OI'/9|6 /5XR@_8!L0Q2E5&N?:N*LE)4F R7/? OV9XJ7WI3|92
MJ^.|Y.4GDA^#1<)Y(8&%4:|D*YV*-Y"R\$(B^)|2|NTQA51AKG^
M917ACNVBL.Q|1^(-=2)H1VK6AG_D9
6(XH*6|HR_QI&+Y^B%PX)7C_/:6M/S5C\$^;YD@9(L M
'D"@MI('4>I/00T9C\$EI:E=J0G|\$!3%UV:Q;T4B*U3B+0@8#S)"^1+S0W
MP*^#B9ZY)UYF^P#@0|&Y3T"0A8)E6Q*6@|+SB*%S-P#<@^43(E@719K+4M3-
M^:&"J)JH4RYIUWG,IC':&*0;L<>QF!&|@)?XEB|(@5XU1HZQCWF"QS1.3R
MX,ZH>W<-*>ZSQW^@=E(!O*XM,S9GQ.T"8+;OV-3 YM4M.>QS|EG-
5)FBIE)@.5A*>2"_60;J&Y MR;HUG>E@S6H3|JFJV+>9WH1|+._>A;C>^664|6P-
@QP75|/%?*"4^P,XGR)G M D'2G(=H|83YT>W3->;V"
<86<4N.XP/8:U6&0-.M3,A&,EL3&V:"GV""/X|9
M>IH!4Q_"T)&856UE(:5HU&*2PO:LVE&XA<@BZ)=.4RPN^_IX4776A)*.K@48 MX40Z-
9*V^S):TX3 (-S\$>|#50?3% A'3|EH#=#9ZEJC8T\VS21 M^7\$>WH0!9DP9AF3G%?Z44#.
(&L+)?\$,6T0PQ"W"3)/@Z*>-T M\$EU;.Y_B|H2,6|,*H,ONN4HZ4!D4CP2L!B!Q\$4=
|*9BWMHZ|Z,')5ZJ*!&@ M1,J"!95U;+X8A6%;:=
<6Y^./2/QH|Z1K5*+1(WKR(@DI:Y58IFN65#1\HSH^3 M:Y?8M%GFX/S
B(Y4@UK6=N(J)D%'%. "+VA552)?2XJ9OX.8;611)=2_&;C5
MU9|VY"A"MFH^T)K&&E>WB6,-DB.|Z|6|+5)6A45IHBD&NW4:/CV"D4J=QZT!G N*
F/TL0R&R.)F":@,\$#;M MZQ:E-%:L|,BC00|1.9*EK-36,<|5-
H.G)H94,)U"O)*8U>U"R+X/6V/KHZJ& M:8"L0A EJHG<"W;UA-^:O1M+LU0VK/DZ?
+|95/LPWM|RXA;W)&|H1_%AX;|< MX66+|34
?!)XO2:8R558_45|6HR*LC3.O17>05|/D8,A1:41_AC@9\$7>LP: M5<.:|'RE|"9K^-|!
|P.Q>"FT2N?107G(8&0.?:+LU:_=0G2NUH MM9"|SM(X6!H8R|6-0S.3;.:ZT_-|
|0SA,1AKJD,^N" 94&_"&OPST;VN;:@E M|9P3RB1&Z4_(->|AQDR4G|M?
B46ML2N>L)T'764B(0+1!,\$|J9|&Q+|4-.6 MW:E|U_GT92C&DTECI_G698SBFFNG.H=-
"TTI@Y#IRC|6A|./|W O?WSW M|@|' B.%P;191=.N!|G(E6NGY3V4%S8|AU&XR

+T MWYC^ QGKB+/' C(^VZ
M<+?"F5,4M C6LI>C3:B/IM(0WAKX:0<='G!0V\O!5NMJ3\$ _OHB<).\$/X &
MV2[T]4:'=Z7F(X%K::W(9#CDYFBN36L:E:&/#*0%ACLSH%:_*)6D3WZ=I6*R MV=77-
6\$H(021LIX*B7O\$3EC,4).G!>8O,J00XJF!-7J)IK4GXW&K&8^TN,V(MM?JT@@ \$@4E*J-
+F-2V&+13SHO/OF-A384A#CRMIO1("Z+"EP4 #-&4.5480 M);E@"9H!VD?\$(
VCKF&914Y)VN9R\$6<&A*\$K;5YNW.,7(:JC7XLTW>80#-TIH M5>8-
JDZ#>U2K4Z6*,#T"NME&QH:9?(DJH) \$)K("RJ2"W:3R;+TW;7SKZ))H MCH IZM:F)[>
<%\AODJ&*2DXB!K8(N!82"+/XSS/OK N;(ZR@NGHL"DDAHA=?5&57L73ZA(-
#A*58*#9"D MZ9AES5U#6% *8=CHAL;,
/!"WXXN#BGK0LOK84K;CQPO.+Z*8V>2%;>GL,G=;'5.'E6"/F4?B%@D^&X\$>0B
ME"3XM9: ^>:H:JO%:2FOW\$8K*CJ?,\$.51W5'/&.%PJ.&C_8L/S,HRO?(S32B.I6FY
M7*XH/27MF&ZG**M,U:31C)%N261"GD=*H:>Q"Y*:RKAPEJ18^1\$!;N4>OSYN
M(>ZE)8=&;2IR+!VC;+1,4>RDI!/@P3M"7T)2AR2_,UH4->>'(%[0B4PHO7#
MG&CBBQULFM28B" ^+*F)45/(UZ/6;L%IJL^= C5E\SOIM9EG?*7VW);6G&)R)
MISO;94374PZGE\$G"[0E-(";(F+3=*X\$0H:F6Y,LU'5"0A:DB"J110\$ ^+I/
MFHQAOXO#AR8UW\AIE*6[_F>YYD99?@HN\$VKN>\$J<[DL*>< \MPH\QO\$;F+! ^8%
<#"9#7Q0&[D]H=B1G M7V%/4>2]^\$%@THU00'-BOB6PM391C(7MZ F.KA_%8*JY
,=93MP5RR0XK74/S^ZWB, M%@3LN8!&6S=DNC%PE, \AGC0PT.,\$GC?
>1 _[FJ2>XSK7(;T!Y)PKK%-('' MIRB4A_G5BDQ\$ZU]+<[S(
E"094\Q@Q\0SP\RN"F*N_3J*SRAR*,&U\T^X\OE
M."3K5I/RU!AYBQK_U*>Y/H\$S7^[A,,6P'36*&7V]B;[++\$MGE"7P3;813#PR
M!1#C(%7#^P_4<[ND]5=XOP_IG\$@-[W2G^YA IVPV_E)(D5VZT;*/L(>B[/ M#XI-
+BELO_,--1&RXA9=;/\$.2#GH/3T66Q2N6\&3M;)A/R%E&5"+[N;G@+N(M%3\H[F!
[.M.P0_)I@&\$&QP'7 G[TFMDA5=6L#A_N/G!!\$+U =G,5MIFL]&2L
M5\$>/5MD^=.XFTAW9FLP\$[,>UN.PJ]'=+XW\$[J;INLNNPN! 0@"\$B+8\$ _\$OR MS990T
@"M*D).>5E" \TN+3 MTE86P:P@S F+\$ \$1;8+)0#-?
=6O7\$F6W#IM#H@F&'R/[J!.3BPA;!C),;OL1 MA: :!#\; ^>'?I+2S\$O-\$/M;\$C\$-
X5XRCW\$\$N9N0):IC 36B>Z11/7L<_,E M7\$6, ^9/&ALA8Y>8\$C,<22V42\$8?8K,
I(3N1%ZAH:/*?P(J\5-?U:LBP#2>'9 M+8P/:I8BL0E<'8.5MJEISP6G85H+-HUEN3"-
F.:R6)@1V2]4:0_6=YZ\$(M\$ \$TO9?%V)=*&YV5?
GI0H8GLGASABM]H17SQ7X"O#!U#CV"D>:_A3^ M6KJ5Q^W\$E+\$4^>7*0YS<(*F'.DGM:
(-(#QUQW2+H3DB&T3N#ZBH,)H-N34SF'3)PQ_\$S%<"LF%Q9SUZA9,4;,<:
MSQ/3K5@/;VL\$JZ>19[H0&D\3)%O2YO7L60X;!"\W1_+H2FVZ*':&M],G+IEM
MMS':NBFZ@5B(-/7*O=I>_UY?4M_D_650,P(%"-X6[']N(I(N"PZ9K@)DBU\$ M?
>B"*2;1M0GI9G1/EZJ&O1LN3VP+^6QOP@MW[Z=NH&0ZU'5&1@E&6111^E>;92DL,4U
C@3O-#IF+EB=I%"LM!FIK
F;/)J<\6KR'94!;2N.G546M9AA2.1LD:=N+;PNBC)BSPT#!*=PV6O:Q5?B
M*2ZE(4'Q)3B4(\$ _ED-V>SO3_UK%0M8DX>8!LZD"W5E\L*C3N3*3RD3\OG/OI>Y
2#+DT1/<*4_ ^?M5 M1)HKZ?2VI3
%#PF5D:I6S&*Q4(CW*"@O)#\7%8CZ_@6HTU8A3RC>D7*I9_,
M94B*#RLM;F^E>;RHWSEN_FIKC%7L%"^(4;QX<-Q=I0!"*NH#!%
MH:L%@R:K85YLH@I13\$QCR0I8(M151#B'-CZ\ _?F&:Z#4"8M+7S%#B%!N[TWSE:+I
<<2]>0P<&8K'0/O3M6EM*H^+ M3+DNIZS^;H %VI:*O:L?
LT3D#L77*O5(AV!U<\$F#P\$N=L;=9Y0FHPEF6PCPC MADU(W!!@)^('AOI8W*
[=CMKK>]8;>+@+L7Q';W[R|ED|W;&FY,/ \$N=4V7DOE M.D:-U^N#1T>!/Q2=QW_+>*-
T9"7Z<#A&S>N:+'%)Q//N8>W3@I7(5;_)UW M';C'UW@G\$E-
H[FJOC,8+H349\WIR8MOK59+Z.^,N!&V\$9A?'W*FH7QN_H<
MO41+_^L53/%_H3@RRK@:I3^=\$&TL/Z^?
=F\I1>FZJZTVJK_,=I^;ASV\LPYT(:I\$R'\&U8T\>BHRI>= 9V*_ST8U
M+6)*4N<:R83G/HM6M@O"FCB\$SSG"%P'H?
5H'1M4I3(CO%>TSD"NV2HJAJ&+SU^;D#+\$AIR^/LEIWMBAC#2]H1
ML.GA2=#!P+ \0XG\$A5(0+(9]##\4WA-T#IY70\$ZL8@_,ODDN2M6\$J!;G7YX!M M6G\+
&KHJZEB^SN2FJP#3XY'M?>8";1<6K5TW)F?O:I:<6XFY1ZDH
M%)BE9VL1==R!T'0/H6;SES1/0YP\0ZW;YL@_1KA7(4W=7;;+-7&)T=0=&I
M3"8=00@D5:T'@V%N5VHWK9:9J,E8;+3E*F'^=S?3<%/:4W"4(ZS,1> F23/W MN*/R-
F/=FHI=-51Q<=Y(6 VO=%!'F=.T&_X%W9.+Y1-N@AK70U+*_ -45^
MF\$HU>9.: \$S#4,Q"DDCJY65B:K)X\;P9!BZT9)I0 GLHZTW%7K8.7-753%=0T MS5YT9?
CR!P@D>2+U_+DKY_NH^LL)O'FQ)OV%_QRGZ,[UQ/B"HS7^(2#CI4. M@ ^"FSA\UOE-

\$)Z 49:S^/.8.ORG",)^ M\$LB?#: '4[1UR&E<"G"P!C%17/CUJ6\, KLNHB"XIN\$ LIM4\ 7R-
0A^ ^35? MO,S[13\148L>10D)).+N3E(/HJ-BIDUW61SZ*9:YKOV0\\$_ 9&4UAK\7FLJ-
M)@00;W7-*2F(A@G4G*^ \ ' *MW_Y!H5GGY??5\$8>HR3*8KEB.,=ZY'JOP>/ M 2\
<1P&B\X2GZ>7EY7LR53!+ \Z\^ ^\$M_/R6\$/SFWW-"SM^ E\$-H_9\>ULT
M.LWNI "8WMH8 JG>= ^N HB2! *TCKJWM.#R6CY""[OP\H^N4"" .D;"-M3= MVJD/P?
D;I?E*%J6\N3C1H8_\$K1MZ028>" P^S_U[6YY;H#)43X4\JWD\$MK'- MH1^C-
7Y7DCGFAA)@C')WQHZ37VG)@:82R.I9>HT\ R#T-[U<&,=1% M??R@/1DQ)>1\&V
& \CMG\$T<[9YVKK)PHUUDYC\1;T?%I^13B71TW=1+>(P=@ M1G_3T\;V=XYWZ\ "YP^0?
A M,N YD+K!/? G\B\CK?&D1@@ZC^,;A-!U,U &JKV,LY26P-*#\YLEV.S<^S#=U MQ7-
?H&1!GXP)^[DU#\$ ""H\$9T2N<(BQ5H1R9MR&\$3.'O@/F,X2CGV\$!;^U#
M4*/SXJ=/#C<\$4(9D? DAU\+/XV7VN.9_E57R43R\I)!WPXEB\HP1\H03\;S-P
ME@2+H\0CYVY,R,@!!&K16JM N4O.3\4M+&)6AU+W)"ZO_6D'8\XA1+,>PG!B[<< \^
GYI3M/+&8=3?.*)H*;!RN_7/Y_ = MWUBX:@:??\$-
F\4TKK,_08A>'G,L"4(NU2/_8<4P>))8HQ47A<\$FC(0070YF\ID MU&S#\8.*P?6\;C+&-Z-
S\$<:8:[HUM2DX(L#Z T\]-T"

"?6!A+!* "A%.@WKF*(PM75./P-&FSXTDCW1EZZJA=,;=75Z:"P4C&I;YSC,+D'*40 M"
(7\$R6GU\$JTB\FD>MIZZ(S&N*D+Y&31NR/*\$3#BO8V9\;V%\$N;BNXAM@_G<64;YCUQ6%
<Z)\$;TD)>@\^M\$;L"@,>XWU\SW;=*S7F!(L MR3@:R_Z=+VH2FUHCN78SXC'9G;5>@
Y*JDR@E@ \9R0'Y\Y,C:5RK/_SX>I^ M>;7\ \J%YH5 H!\U'7^>=4""#SQLD1%1R6
ATBW!Q>Z(V3> \8Y173NQ =: M7AR(-W;VF
Y1E_F,\!*GO(\$W\ P(%X(;N\1E9H4\UP/E^L.W;)D"0@% M*6&)N_HL8;L.B?
;AY%V*&VZW(/;?8P/KWQ "SVXDQ""*3&:\$B\ACHW43?#G% M*2AM2% C>&P\NQ(^-
S<+7;!\\$!D:R^/LMN7'-(SYW):3P7T1H=H\7?1^FO M* 6?B6T(3TA!B58Z=E#O,
L,0BLW;H;K/LT=HR5F7.N4@^L:~90#(((\$GFB\!U M6\$B\4XHX>./D?
75(NV46@;,\QH'NXG*I9%H7+>@?SZ',HKAF,Y#(U\,@K M\J)%4^P162P_)VRT0Q\^->
((R\H*+TF2LJ@24R;CO*TS//HS:(UF=X\^SPF#\P)IR>^\$T-Q@GE2X3L98!'*_2OS
M"7!\ "ED)RC.P?@+SD/?TC5.S6?+>.J2\ _Z*S7E\$F%4V QS%^DQP4DF@"^+@G
M('K.MW\H>) (-280'V6!OQOT1EYD_7K_[OS\WBV:/XJFCZ@ \Q,..#A00WSW^
M>/:^LKEX\$ \?H)' XPS\T)H: '#L^1X,Z'LRK&\$IY3^H6;0P@5F6XMO;3P^ \MHUI*?
OLYT3?CAKF8')4@!\$0PM%&NU*C2Y_G\!S|=)4J3[SJHF: \ "CYMF9K>S M^XLK-
3\$OC15,///**>^BTAB\ 88NACN2R.LB(RSS: 6IV_'F_/* MF2V75ZLE'O'5RIG=7SH?
Y_/+7VYN;U_C\$+ \$L_!B5&-%\6;DM,\3+"D=SRQH8 MTIEKAH>21C\$POAV/(*,P*._^,
(W3U&R&01T9*(\;F?QYO71)H6 /
MMZR)P2^_849:L69^O_S>V5#R0X^&^:QVR&_3U5.J>B=+NC5.\V^*X^S?Y,\IG:#P'0!\$
ZH=> \K-R> DE M^B;WRQX+EAPDJHE*!5ABXT'G7GM#^1-
2ZN7P@G^1":H_GP(OU36X4JZ'GOON5P5N;,X6S3<%1D+;G\$OI;L2Y0MSK>"2?)>^&XO!C
HO3%=1F:EZ&M"CY M<15N7,XU0,7_3!6=<(B7?=Z-
W^)4'5GT#&^N8"P1Y@5JY>?]\\$IR1\$ M6P\48L>MH\JQG(<,DBI4Y
H3C\GP0_.ZO\ET2:NCG;-1QODHXWSEH;=H"T4
M2;E:E.3V3"#'87_%Z\$T.3NH\4FH4T=0K:Y4*3-/?W%P(U6M:[5I96Y\W8'A\I
MN;59.HZAX\;U);EY\;EWC4E!%S@W_ELL?WVW> !=BS:8X'VX'X<;DF0#^A(
M^O'DE*J3DWWC4%A_.@.T,)#8K:DAUI \>62+ \RV+ ^\$J^8ZOZ6D8F?+DMC8UR
MSA%C7HP#,^9_T,F5,Z\B M',=<Q\ TS!!;MXX@TO'0@7,6\&!W_*<58\!)1(7 M.
 \>ES<%3^ \DO:'LVRV?R*)' #%&=?'L\WCR6SY""!T*)C-2VW;M\AL>50G6.X
M+QD8ET217A_2*QB+R"9/7FR\T=[B\$R,1WA?W:(D^;SKHYK\%'@1A&J9MSL
MC6M+B98A9RC=4;&-S8ZL:DT'4D\W_Q,*O%7\$SN>A4,#!/?BM.+6@P_'>HE^1 M&^?>
Z:"2Z\$/9VETOGGOQOBD\213?;A4\?CK_*7")IOL_! ?QGYI(DU(-.#HGP
M9V/>RKN"4G3>.P=,<7CX*P_2)Q&O_6<(Y_.'L\MPYD4C9%TKS3A%.Z,>
MZV%'7GEA9,-/RSX#PX^WKJHDJ)60< \Y? \LH@"L3\V#4/RQ\$ \J:V*D&(-A
MQEI=TV8#'E3Z^ \4/=KB--KG3W\4W\NKH(>?7\$QO\IT/O/T>!\Y+"Q_".Y.\C
M@0PF:R=Q^O>'.)Y;!XSHWB\X\ \T4>;4AOXI) L:0,4071_%X&Z:~NBGZ-9_
M1MYQ^,7YX< \1Q1?!\&(2)_D%;>&,-'4XFK EY\$TXY!VQ@H!\&V\4E3BP-D,?
MWD%O'Z,US1R'/P>(>)R\$'D,9(=_W4364Z;\Q\A:(9BZW,9+"88CA!NU&^A\'
M6'6\+.B3P;DC#(Z\;(!/_A1E"6X4D'\$)K@D*" = 2Q3W!W\YP^"M\J6GD\0,\$
M\Y0U2\;+6,,,KBO:YS-18&_M<>O#VKQ'F@RVN0F,/9\ \$2* \&V3_6\1)\DO>
M\J\$.RFH\ " \XPT&>5C\.' =^S\5!^_6\C^ \OVCNO9C0\!MN\0T\X7??_7-27@"_MSR.!@:
(^ES1?\$.: \$W1#4\$236QD14 MR,W\SU?+U/B4<8KL71UI8^9.^-!H_X>ARA"-@LYI8

1L*3@EO@(# M,V_!"*=W;NC2I_,ACM9@Y4H@S\(\$\$KUI ZOR+=IS\@:*=HL61M?^\$@:0N?
R3; MZ^\$NGG1M_Z:<'+'BR!*Z<|'BZ;Z,C.)Z2XT>M IH6R+JBDPI>G'BZ. &^ (I=YY&
P^J+ M!Y@P+I|B&2&D'4;;8<0=1GT<'? ZQD*LG7?S'N\ (Q3@!(A:|7O)@Q-
XY&L7^+D7\$Y9@I&P<8I|YIYQX>+SQP>F: M;PB?!LA|H #*%>J|0%!(
#AD@ZR6XI&/KS(ASF5-(H/OT3OEYN0*7CP90Y8&@F* MGSM;07+*;OR@|?@A5O|15%B"
(4-;>(6#K/C?L>'M*=VA1_.)6AJLB66,RSM MI#%*_9BJ!#5! ON>UJ(1_\$02.RND#^L0;
(J;&NVB:QY29\$8!&:=8KH(=JR M\S?V|XB_ GCS5,G|PC7\$C"2="NN69\3M,F"6W_3U?
J@=,=ZXU#Z#C3P&@=9 M.<=Y4B/FL0/#'&-@^?U\$MU|?
B;MT\|H|?;:&5,618#0'%92(>|PUWF6KE^@7
MDFAZB2\.) *PG_Y/_9|^_!0L@ZE2X.C7MN0N"84*#M V@\$?*, ' QI%N!QCA
MD;Y#/_|+!%|2_+7X5IEA,NB!FG. F|_#7OZ*N#SJEY3!B#J'F8'*3|W_EH7VM
M@Z@":8|_|#X_UW.?@T<89X>IE|!_N:/W2)Z+^|TC5>73C<0>>_+|_#V;N? MA*G@::P5|
<;YC/E|*XXW_+.C)5"8HR)"H::HU<|.4)3XK<|&WORG?-V!+RP MALE-0Z|:=UK)=GJ.-
E&|BG"=2YBA\$6#))JE'|XGAWTDG2LV M%T'3H_TCN(/_*A_:84=-8?L9&:@=%V_KBRZ>-
@;Y./I 5N080I(O9\$*7,K",_|_(1Z0\$<&39^1A-%|!|P-AQT^5J&'|Q'Z!O
1<6"Y|XO.,_|_5|!|@B?Y0!%0%0%9A(1|D"
MT69G8)>|Q|S(>1Z"/&_#2.\$BDYBTBE,KZO!@?|;Q&PSN0IX-*>|7U"MZQI4M
MI&^CS6E7ICY'MIKA |.C'#|X_U_'"&G|_5FUN^H|YX|H:F4_+?4U3J'GX,JF\$HQ_A)7+|+
M6^B2PR%N3DU?;VH&RMKF00UYU#_@*|Y6H1N:0E)4:;|O-CLXNL; MB,X;
<7@K9)^6VN\$W|!ANR2,,^|A#@@|_+@_? *PT?_::&7_%&R)?^_W%W^_O
M,A_JX*HXFG\%<-<)/|I?IPI95')R8ZT41|,N4HYU|*J61RGY(;XI=_3%A/2. MF&
IB>-2L#A1::Q@5,R&1LO6|46)XCBN5|:&4LN4>KPD8QAB;T*|W|_O93M/_BATD4WET:N06
G1#0R"J|2K0=^G(O-S"@J MAKQJ4-XX=|/Y8JHP-B H|H|L,DEWEVA#J3)(G=\$,)YFIBER-
Z\$1@EP%J" M,+LH" |JB>F;^C\$;WT*?OBN"16FW"A5%PF6>(B\$>HN\$FI:
|D^L%_H6FL>I+. M5Y^N%LI_<7|@K/SM7J7V@F*E J9 ;PKIHOE|YYU?7|45FQ9G-?
O/J^6_MTKS4LW|^&Q2G;5V+1%H;E-P/C^N6BV%1LHRMA=S@\$B
MZL<9RR%A1N=\$=!>4ND/).YS^|SHE&JBK9>|CKRIS\$*:4W|<,TPG^31D:|7#I' M0?
3RX<=|X;?=_8OK# MXVP!Y"%-|,-|/J |N;H?X/#-;ODHWX"=!M:|XG)3|6^
M9<7\$@*|&V8|T,8L*_|X F;2R"ZJZ(. \$!Q<'4OX*|Z8"#"_=U,MK@0*8=YH_MM!?
7P&G3&"M*W6'D>7|2443+009YQ!E6!KMF@XW98&G<;Z@4\$&62!A)V9P GD-
T_1)G!"I58=WBP+M2 M MCPTD.-;\$",&1TMF ^?;E|:PNZ4WL-
!C|Q=%KO!/%Q'0;3%DN2ZUVU'B#F< M&I8/U^<;F8&<72;O>|HE#=#F?23C,DW5
)#Z|_|^&(-7#4@=|8UO|%#! 2A)*P*OKXS>,2DCY!L|_@OIZC|6A!|8"*>8A
M6D7DT^HEZLUOY&QQS#OC/)(@+X9R\$L5ED!;GY3UR'FF7G !ZX@_|7CUDS_2
MEVAH+L7>#.9L:>YXG7>"A<5Y(BY#UO6%<"G/6)_X/|9B>N M\$CA%@O'HT|*XJ|?
Q1N'DAPK|_|QT527B0TI&70, M@,%U\$3VCV\$Q&DN?AS\$2|>QJ4.CDN1A9U>P4#?
P@2&'D_|/J431/S\$VST#RQ MPA/B8+LZ(&TV:\$W,X(40.0&4<*J=
(>Q%T9TB*Z,6AH7Z&_PFY|"6*?
#LD(&O#,W.@I@#S!F'F*VTXE2"%USJ|0#XRFTD"KMP88C !*)AO
M4W_ =|6@S6@#00X_I&|(#2X=&1E\$>?^|HEZ7K"#Y_+, @SV8@2HV(>,L/_.#
M#TWD7\$;XRG04*!|\$YDG',J&X&T@((.5E&,G08W+P@8EQOZ8!|PFVUU7H':|X M%4!?
WU"6J1NGXPZ&R'8K?T=Y#B(",&AA(WH|H.O00B,A/N,1)3ZLD&|P/%Q"
M@W%0/I+ZOC.BXV@E#8ZGFKUXQYGC RJ"&#=#,MN|>6>'\$*U#>#VPDL_/_M1|G
M*8BC%0|_|D#S-3)?|^LHQORRSZ"X-K-MC @1LUZZ|%"R&Q.^|S#T8,BJ&^@>M,-L?
Q78U3WM)H|=?:X4/OK+!CAP6B0;+5E!1T><_Q;1T\$ \$/BQP/|DYJ M ?
Y_|MZUN7'D2!O|*Q6Q>^SN",K'W?8>V^M/E\$1U|4D:DFJ9^>=#PX(*)+P M@"-
BR3ZUY_*K#L(2FH"5234CK"G=;\$R*Q.%NN3E>=2>9=8|FX4^_K|1A|5S
M6I,%P9\$1/32L&X9?B-%AYY<>_'_Q&C?#'|.V%\$MQZ*B|PG!O""95/4T|7R!T&EQX2=CX<+
(1J9=(QS_F_X|^=/G_|K+*|1.06EW&O2|',#M.T M GBG#5-Z:-|B")
<%N""3GWP%DB>5POX^>\$IFZ^RJ@C2:/|5\$&^OV\$>97O;Y M%=O^V;JSS(-
U^P/%YH_|B/1="AS?4# M/+.|E+:7W/8%V)YKVS=1#5L#:>F% P(QK@#T7-@U81X
MC+Y?|QVW74NHV+5|U4;U&K/5ZRD&|KCY|Y4H/?L!|P594O;#=#LB9;T|HP"^T
MVJW,5'@*2SERQ7>G=?9XH:??FFW//44UFB6S498-|YZK_*X*,@G6=1=!N'
MJRS|LJC!|.03(1HQ|?8SHR1|X%&(SOAEW5FC\$T|=#R+;H*T6D-)E2*L)UZ
M5FTVR5;=9?VAA?)V:V.PN*<7.!PC_!(C|#ITSC4U8@,>M_RHVVGMO&|BAENR
ML9V22|?!D1|/|#:OF|M7G|1PTG_.1T*@YGW|@:8"-(+A5!/1|A.#\$I>L:47
M1ECD,Z8E*75N@\$2;ALMT"T2C_|3*|B&G/&"+(P\$&?)T%|DEK6HVX\$<,|N#G
M2|J@;#9'|\$|2XC9_&X9O9\$B|=;(A>+;ZC%<.4"1B<2Z@K*G@)/^%+S>_&

{U:W=. "N*O=/ "0U,V MNW?22-;6L?%5ZPK[4]D+'(=QRP,5ETYTZ9ZA@ @-'[T=K[JV-?
DN, MG7VWF M*HLB+L[H"ZI(XZ[A]=35!3_3H&T010/1);@RZ=H
LF72W2[%7=HEYI^V!V6: M920@M3?F6\$<[\$#>H/QK7KY!.\$IF@!.F>
43A%G>MBR%:YC1RWVZ@QIPV^\$WE8 M*">*.R1C\$N*)RO.&6H'CV'['ALD(OS!
(RB6&8\$!Q_HX-LZ+!PCI#J'.\$*[H\$ M;/R"!6*Y!2YP0AQ1\CS>W
X&ZQ(ULY.J+\$IVV&2CYO!=QT, _FT@V9F-, \$A/M MW;NOWA-
@""2BYI:R*X\$;N1ED1_8%9/WJ3H_5YZ(@\Q.@P87/!=!EG&(&[<=U
M5(VNOW"2V+CA&@-I!&@'IVE\$W0V9(E'F"2ZS"ZN:T@AU@T!#:+\$A>!L7J#CC*
(L"#NV>;\CA5\0X@/'AL\I @S0,: MB%0!9^0/H(7\$Z4>B@SI:4W\MMKJ

A%DCT5G %.F)XI@P/G!D.3Q"@M ?HQ MBMAGB@NQFAJ8'8JBB)
%8#@H[=1';^&^"36A]9&95\AK7MYBPL\I^7P5L.(P M?97E"OH#G6[Q\$XV7*T#U9(?
*8\$F_..\$E]+2UY2?NX.(K"O4-.P@: NV6J;X6 M&|8,B#2""L(&L0I[#=V#NO7[R5G@K%P/Y7?
\$"\$HG(P)1)?""^Z.RZ""PAD@ * M2@EI_AB'M&B%ABR[2""W* 0Z!T/NU XK%+UKC/
[DLYNX71L@.D!J FV04X6 M]*#390LS\$VG\77\!#HA7@P"/7?#LZ63JV!5)2R_TW/Q]*=4,?
1!:/D@|\@)M< ML|V>4CN+!Z59DX5LP3VT!\@X%#T@M.L)F4K?
=+8"*=;T=L686EGO#4MV M;<*CHJEI0\$Q=1"MS;;W>9]CF?
1'D^7:1Y7#M.=1,8_1\$MA9+9'^.,2>C47X% M%H4^+=K+@7)WFM^.0[HFI)*/_MN1_?
W8QNYRRT;Q7ENV\$EC""!(H>*R MHE I'& @7=|S#%"D,B,/E-P%<33
BDB\$0NFI_344FS_12R-V Q6LY1T3(+@S MJVR^0@7*DJSS6.KAW@U4(,9Q)5?
7DY\FY&HZN2&P30\GX\LO M9'@Q'W;S!*Z:(E"YUFP=%|'H >%P85FLH-1E;
MG\$/E\0(=GK>/TOLG0)1W,XD)ZFOKDS!; 0UNW=!/LG9-&'J<4^4; J'\W,P
MR9*TB0D'RC,N70!|*7*+'AH19EL=0
!8%H+|C>_Z7Z,0%NP*2DE\$B723UZG.V/,V6<|%B77.>6* MT&A@|A|F2@VUR0?2?KB-
_GZQ?0?(FCI=AH70]X\$;2#@R"7Q2 M4&S8C^(J(HMU01T\$ZUK^.%L4-;
|.S=KB'.PPO[BE_NTYP&2?PO&GW-\$CCD M?0GB%/) #D]0 -<[9B2Q=7B*:'0?R;UDO-
+D8"WQCD\!WEQQ\0/0 B1@A@2&J M4J('RCY+R3#Z1R7#CYQCP\$-QT:DXU5]?#8\MT5.
<7XMMRN\@_Y662,A>&&Y/ M>376GMOSC^)\$\Q65,|WPGW)3L#?,P'YGY_1GE_O/3X-
?_@OOL_YX2]_M^@/|8^:\$#8<<3AR7YD";&'!B^O3;5:R|SASR67;-C=VT?
Z29]6F&_9I01\ M8MK4-;|7QB6&74@GCF8AMPM3!1SU4(J=USV]2%?2-4)OXYQY
_V@D4D]&L/@P08F;|2M5T;M MI1\$TV>N#
<2!HKX^9P]CKT5F=M.NS8IG3M*XYC=UC0YXF@^ ^3\ M9J?
P,4&DOBA#V01'R?;J:IS\$&"@YW|:V^ ^)T'-|P:L.GW]8<[V_L81F691X_
M5/Q2469P1/(+B^# !|;)8')S-QU]'=W.QM]&9'S+OA\Q1TQF,X=I16G;/\B MRN8F7I&&
(0>7U_#*O,3E\X=%\$>T0&,4|#@Q\9AXTVJ)F2R@A.4*&J;/HE*I
M500Z;*!H!Z5Z>,F@)Q!;AVD.Q_YM2S_14Y0/4+VNAFI]?\$6HV.+WSB93EE&,U&T#Z;^!
[BR2"0IRS">TC\5YFFV#I-P"4UUWS%4Y%TJ" JC""1L2^|02WTX(>?/:
MK\$92JD>#/MPU(&OW'E&'DGW,WT(V\$@/AVS3CK""SLR&' ^?C ?L_/DSI!=CJ,X MJ<
PG;6!8U,K?_Q3K)5!Y(=*QT@9KHRS4BL06>@VZRU9#%JMGTJ*GP6SY:#K
MI092FN/Z@G:#MFH*I"B?7#^=P/8D5ILVV00QQ+@70;!#S'6;'VK@\$;6IEODK
M&Z.G.F\N/HF>6'Q19;BL0#3X9@#?B>&-H;:|YC|:0|U#LOB%""+%.WQ|TP
MK#;L\$K0=0R@B#1*X-05YN\JFD5%=)'HP#FY5EUK8%8RKP;LLZ,'2ALBH8Q(<
M@8ZO8V\KM.*&' ^XUN.6_NM#+=B3-+ZI6%|8"ESC^?9ZHXC
M(#Q=7V9XU3SBTT\6NM-97SG:=C2@:#@IQ\H06EF&.U-[S\C(X2^_A;FCU]S9Z,\$
CL=F7;Z6A'>P(CVO,K4TA6|/^Y&2|) M4>EQ8EM=N>#50!;1-
|TK,OH;YQ"9;G!..Q\$OLQ0H].&LO@3)6IG3|Y""I8U!@ARPKH0N
MARWCH6IN3!;G5<\$F;G\$H]80.C.KYQF;63067@4D:9DFVW+(5+3QEDW;"4I8M
M4EP/+@-L/NW!"&[AC)?"6V?- WQZ\OV^50.*RRH0.DJI3R2>0\|ZM<3*P
MC48HJ<04BP0%/3*I@8UVYQ%YJPWDI FPN68IY,Y;U-0)R@DMRQ./4Z>V6\$>%
MND%).QGP6=SE=|T?"6J+03G"" N)+H|Y|N/7.JC:\$%P1DLE.*AQAE!|:1#SDRR"U+
(G:PLEB%.300E1(|E MAPLA4P)5%7
P=E'.B\$J(5"WS@#@#"HP!LO*#Q>')#LNL!9;M""AH(KT \$7FCU
M6!A=UZ:/4_5\5:M#4BB7DBO&_&|O(L9)OW M59:/TT66K]FZ?
IXQ%RC(I\$D^JOY""^9T!G\3^9/+(A '?FP,L)S\$P1&=00R,X M-HWGA%AXQO-L>"?
X2S5"+V!/NUOS59S&);V.'Z'OHF3B8&0\6M>F45C+XB" M
>&*SE"3K|Y4=V8VGKTF"V\$EX5;6G>"M)U>.J\$!""HA|TJQR0)F|CF^5UHJ!|V6UH6--4S/
)9F?&&XQB,I'0Q"O)4_W U7"G6VN:\$67MI**294:'8;?//A"[6A2^1WY@.AC\$Q28JJ#5-K
M5+?PWKN@ <3CD+G@!P*%N8)M-&R;8W=2',UMED84R&_A("*&|ODDT>+!0>1 M,|D

1+&.J1=*U@W-LLY3Y)X'P*U6N;^LNW;*3G8;J@C608J_+#+.C_<5+M6WDA"
<*.&N6<_4V+3(Z61E<_7F^LCG=6&(=Q9K;|57VX(^>0Y5XG#8_AT?'
MV%BWPCLO,W2X)>@8LG-^S'H|3O,E32^R?)-Q*[LA?JTK((8&M|>0|FT3|JH0 M3':-
|D32V|EQ5KBW+MTYJU669I+!BK^'XB4|'&=?R5,874*D||NHS9)7+D MY.EBQ?
@@>JL^>D%OZLX|VPR_SJ:*NRPT?->C6YGHX|>&#=U%*ZY67WTS%%6
M("8" MJPRQ3AGMYV(@=#%ABAT<-ISBL>,9IU/'N"W;!,>,XNI5/O MLI+M3C%
|ER1###H,(A&/08)',MO701)6R:ZOC?RUT|0UKO8W05H MV'FC8N>% MNSR#&|
(PC40/0#?|=%|&88*)@8*=3DO\$=\$J@*DZ F\$ S_0OZ'82K.*7Y=H#A
M%=XRX+Q=R8\$'Q.MG2B9"-(:9,>'E_W<@7WF^Z#%PX;HG|N6Y#P4["\$,H)A" MQRF
3#S;A3H/L|<&N#U:71|!S*(4T!!!%I+S%1H|-'N.%DQL8I|""^_6/229
MG356X0_P"3\$N(@8F6JV7D'K*1;P\$|^2H|-5|V M)8|XAW5|3A7D@#_&SHU=K!"O=11=
3KYD8Y'6_|<\$>|^\$|793Y+4LJ=FK) MMU=QPI:<=L6E2ACATDY^^
WUI+Y LX!"9HNU4(F6&V3(%'H#453M0PC|5PKL
MA15UX\$#OUL"|&K(11#"JR18'A|1XC(("#G9T=9"5;Z&_!+; QZ=AB&; A56
M7"HFUJLLOV#'^+B\$*V+!'!ZB;\$GIPFHM KHV NO?CB.,0|1|+SJ/P(_LWUGJ#
MK3D<9=5#N:@2\$H1^X/I\$5?05C0_\$9R?M<^A|*VC7A=CFG%?/3#.?VOWO9K|C
M"R|80Y(|AW;\$2|K_':<3&8#&-L6V3\$E2/OD@-7R\$6(|20GB3IS?BL|M;:>|H
M%N+!5ITD2?'|B2|;JUC6FI^N|O L2B_W9'3.K+-R)G>CZ7^OOU"KD?#V8A< MCX?
GX^OQ?#R: >8_ OSYT^>_7D|NOYS-1|;MR%+=MU@>P6@BN,MU> FZ0Z! M&ZZ9
9;DP*5S+55"C1,/A>1*J>,='?6RL"S,D:*-&IQ^V*+%62N/QWCX?BA M2N4OE|'ZU|H'|L
28;UXQ"E(IS M!@JGDQ;6&A4|\$0AU-XL\$>,@+>)(U_
^T7%ZD;H|@"Y4.9|Y12MPN)PZL%+-6 M6<+>+^;5UEO"^&5TQ!>JY6P5
MJFHP4|N1J"R\$.BCV5904KE.Q|FQ7.5ENLPT,)L.S4@T4>@/A'FKJK|3\$0006;N P27B-V
M*P^O,C&(@%3%J'E6J+(|L92VU;.:3;IA>7R8L=P7XUOC!(!?
KY5V"K@3D|5|075Q6HW0)ET.H=>O M-
;H|JCK+%F<5(%0ZI>OQ85JRUZH|B4R2'AWV#Y2R/AM>CQ^?E-4 P4M>=_\$
M08E3HQ7D=C2WZ=9/>N1VASX<4V7|2@(|5|,|9S"A|_O2;Y|6*,(^Q6*X-B R7 M.)
)D.J+R"5#FVRL5|!K,AZ'L\$|/(B.BX*|H)=8J,YAHK PD:K&G+Y'\$=<&K-
C59|0P5OLC4'|B8O,TR;^%#!R9;-X0|O(8>|G|_
MW"0765&VKKK>R|,"0:FBGZ8U,*KD%J.*ZN*O/P|/\$\$/%C?|/|)3
M0IPSW'4Z>"OV+B3YZSJ&P%?GB,T8|CMF+W5|J_9U1>N@'N@X;L#R)BAE?^(Z
MRTMX_V\$U:T_|X:8K5*(20^D58HP2,C|-\$G8EA;CU@T7OUDQ?MWQ0-OG\$:
M'_H&,1@VJ\$YZV6OE@S&BX)|#^X8WOT+@|S(M_&W|7PZN79;+|'-C&9H|_
MW>CMAFS.*^EBY^CG-M5*.WK9&LV*|VVX4R->(HQQ>8Z8PHVR'2TSO;|0G<\$6
MX|L:0#OZVH?|6X|>VF&;37#9472(9
MZ=I&D_1@+V\$|H7X>H%G9"^=3K(L)O=N/DR|PA<4P96EEGP?V-EW3X_7H0>2
MPXWOL=7|*|OA|X(|_V4'HA&"*SCE6T0N@<")E\$;=OUH7CE==@MT7F|I;P|
M10VM3H'==Y\$+K20|J';\$|W4,G>G<#V*N-W>>F'TG0Z/OQ M602<'-\$KG9-7
M5*HY2Y=(&|+K-K|2)!*A"8@;MKIF802*4Y('A*0;M;3,0W>|E|WZ4.<)"(L
M'80=|/|=)B42)|-#?Y|/J5=Q4=AJ;|*4|P LSWG.@N#9|N>MO:6M2!QQO4 M|B|
(?)_MWND6*DH??-I00?'P>MW'PPI,W;FY@V41V='5"/OR7MX#)_9-3+* MZHT7J|^8|U;_
(DX.R(LG_9T"08"0U2A|I7K0Y|4A|1|@9\$*>,9R3ED)/7O MO1W_|'C|NNA^OROWY1F9_
M<2"6L|F2S,Z?,KF Q%@#^%9\$,^Z@C|B.|R6_;V,Y;NY 3H%I*>R.)">84
M6G@LY#C0|*1|FT_76'-%|MZ|470FO'D6|N^I1(:GT0#_0;|7\$T.T^6IFKA
4|J_&7|X0?'#-D4|+ MX.F/RR1<:'_L8N)I\$T%B|5-I0,2>|')AH"60+M=H5I+>?
VPPGHJ\$NL80/|K M|..N01PE*YKNJIG2((\$.ER|Q|/?)|CK9X(K+-GBN #
;S7HVA*1C'J'"|0E^# MTY&0+2_++,<_"@JR@|H8,CM;BV:D_2D%|9SQ_
U@0NM/|XQH&M%MWB|JEN\$/_9 M8(12,_)O3++;B865BR9(+>3_8(=;
('Q\$W,/1@J3)RBOLIR=<|/DDDBMYRNO# <_@(4A MEZ-C+PH.#|Z5!QP@"6"\$^
E'BK)|I"#=?LZG*;#Y57;)R5 M@N?
#@PP<40,D8H1DDA,^1H*#)&*4\$'#@X|2_,T8*OU%C_0'=:6UT;F>S8X(T
MML/,5VQSWM""#:6>TY+?OD=LK0(2%0-'<12X09M=6&@>-=>,|Q|/Z<+ ZVM
M|!4K71|,H508D|)X*);-4!1(A)E5TWC7|7YZT:=O_RA779NI%5H=3XSNX-M,F)03J-
&O"M=UBV1=@Z;M_|#0N0&(1!=Q|T=|8T0|XHQ>!2%&,>G/O8| MP,7;^TX-
;_|S%)UW+ADKV/+O-.Q"74"DCY)|8>>K(OJ3|-"59'S;)|9?|_
MJZT%;WIZ|O;|P18NO|CA&U)0=(VUR,E|M9<(=,CIDHS;#)6VG>.#XU2^V!0
M(|"CG|'Q28K@N1+GE4;=O|J?*|@T@+9BDDJ/ZYZ|B<+V6|A0^_7<7%P-X*0 M3G-T
.%>DN:E9H"A)Y'I@6B>_-.:1?+F@B(X2H>M-3E

:)))+X02X8A7J6^PXN^7\$N,2P2\DE(%@U
M*+C.VCFOJL;O.6Y.=|L|/1"RW:W>H|\$\$Z9%)S9897(U3E9OT X4CK_" +;| MXVI
W,06I%G",FJK00.;S1;2BPV2_T&8X,+&6<\$0{9>T&&IJAH8*%PS"
MP/>BR*EKMP^D/1UEZ W*7FO_O(:P=XP8S,&(T-H;15&M.3PT5.5=L?N)69(A
M2.R.USBH?4F.H0YX"2&ME|+(4\HWK>9D0I?CU:@(_D(8#DZ*.UH";|+\$+!U
M31(4'A\%OG@%OYR|X0L:LQ<:BE)Y2N8G"00@-!H^LGUV226Z_5T>AX>>/=XR
M:8NWHL0;0|:< @,BATW\$N!7S ,&1 ^A/PF*/XZH\$84\$J<*&|@#G+:X# M'V-
QOO?.,9/&GU6K==!OITLYBLZBY=IO(C#("UOL_0B*%8(P<66*T&G MB??*B&|Q^!>-
JJRA|{(8"L08C9%_0?E9R,;"FH=7GKK/9C\IEW#
MPS,UD@4!5X!DRO/@^>!GV)!^D(TJ@BV:21_LM*C1\$OMAASG;7G@J MKE^@JSB-
2XH@ME,V2|{(E)/9YP(S:B5!4;1&RN5:!.%:NUJ,B\$ZB*H"Z_H+FE.
MS;=B>M_I@Z/'0U\|AQHK|92=.J^R"YY B2E)DK++S T(L;FGO;L)%QJ-3PC MY2E>N7\$#
<|S2PJ&.:?XK+E>3/D_5=6|V,.%_E6;5<8=A*9++5|;EMNI%V%66A(CKZ>W|FTXV
MOG/I):/XBL'4BE,Q:8Z":T9)Q576"\$++7<0D#NGV=0ZC0K*1B#HHY)Q.G?- M/J|.NSO|C
O8S|4CH#=#0>XH*RA2O<7|I>9/S"%;_M|9_*R@XSH\$N1B2)G S?.|6+:K5EBS@MSQ#|,K
EOZ"6?T:U9YGS|_/O/_Y|A3H^LL%?HFAT# M0"-DEPO
:/KT>4#@U_ZQJ*=TS5E+;|A_U|6:PS'RWY>'@|XT@5_K543HDFB;
M2EOOS:\5VZ9D(QV1Y1'2ADO%SL/^_O+/-79|/._H"M2'R8?& M!*Y!5,@Q'?
QRTT|3WP+XLV%F/Z*Q1RH'TOTZ/%HQ3@5Z83/87#N(D5< Y?IN
MK)C;5@L6*H+BGC.A:B^LH&OK|OP+FTHB|L))MP16W'IX'I_1J0;^4 \$V8;6 M#WL0
|GH^ZO)/I|G|-'0MD&XD'ELM@ X; X#)DAD=Q4H%N7:#..2)H!\$2, MT& MB,4&88I3=K-
<*P*.4AP&RXQ\N|93O-K9)F:J%._+G4M5NR.9DDB|V MBM\L|LRK+!_CLX=SML)9GN3RF
TP;4FX|VK#C@_Y;- QMB("B,V^I%6,A
MQF"\5B+MY;V5I<:'KJXU@M|ZN;\$2WS|#K0JK(,^W|&#Y@3PH<=\$IXS5'1405 ML0\ (7F
%(0_CDCN)+/1*9#;=6NIA52>4S8X|_QL*A+;G"ED2T*9QT_6A%?, M^S0N"\P/#N\$
QO::;@+733E4G:.\$"(HF|HU,K!SXQ"X|KW7;_MNSWO=FL;LV26A8_M5D\$B#TRM;BRF0"
(E>B/?Z6@T;.@5@6"CV8'8%LOJ3\L' MCS:-S8;>F\$OT|CY?
T3D|B|0+6"SY6P%DQAH CZJ>@&_D^Q7\$Z#,,LCZ!T&LHA MH#^';H:(K%GA)J\$M1PE?
B|<7B:#U2(D<)|1_ZY'R*AP|4_T_Y|B-Z71|G.RZ
M%ZY4;W#Q4_"RF|{\$JLG5UA'VP3VYY@E|O|Y;5GL*I?;\$4_OT4DMI3H,93"|J> M0J&?
@H(#='>>C&C|Q%;X\HM@DL\$&/Z^#_J@72|V%TD,F0#:&+CNJ^|:&@M# M|S@F?
2^_S4|87S9)*0#N=(Z0_!K8CT9.'B;L%JK|TUS6-JC"3|5KU_-)
M(+6TR|PTN6CYCS=^:5>FUD\$#ZO9ZB#9'55BVNCL)&=YN2ZW&;!>L|(\$#&%CA
MOIA>|>(<10X(E5PGUGB1&)/_"|VTOTM|F9,)5#*^/(0NPZ*.;18'KN%I;7P
MF%9"i!;7W*RN#6Z*XA|?;MW)6I3;GB1NJ@"!7\$P>Y=9%A5D';35@BV,5>Z^
M^K&U(8EM_4KRM C2V'KV|^U|'"A^+++?;X'. MFS8%S6UC|93#BL1Q>K:157FO_WO-
\$SO'J57*PX9E5Q.#FG3)#X0I>CFW11/X8 MD>7X1T%=?|QMY J05J^#B!;5(,EM=2X-
E'FM*Y;)|:D'*|H(|G4=(&:HY MBCGSPWP5I*
(/^ALM,/S9"++YALZY)0;=SW_S'GS|_ ^OS7\$:#N+@2S|3OTA_7:J8HO-&*7-X|(:+#9BM+R
M&E(/L#X?W@!A\$?U6J-Z,I,F|>'6X!"E66N+"GR M\N|3V#9;/IVX*&-@EKBA_8!"XK-
R^PQ:C=R*J34/WU|M*#^5W-!RE;&CQR-; M*1^_-"4+S_@<9E\$"_45%6R&&<>E!^
<9&L9&UB6/'<+::!CEH4|K1XGS1^!
MPUG3|P%TP3LS6*.\$|V&I8*!A.6,6GQ(JOWO|W2*VR21+V>8JT/3
M|A|X)Z8W4N|_43K(?H!551BQ2IF6?+|D_KFW4J|\$5\$NK_00D@F(|G5EZLRV MY\$UF|
<>>|TRQ_!)5F%2((@U5;LL+^_J?|H(&1|?{|A&560+2K=BE7VE!*F M)WMR'DG@M8
J(j)QP0_M=1:PD@:7E);9&V/;UU):Y)XF790UX*D_D,XZV3MD MK40DI;K=%+JQ068(Q-B5-
#^|?#SK/!DIV@EZ*K?TH?*3ME=E(Q_M;D|LW%=|O|=P#PPQ20)9|!#2Z"?);
*>2*VI&^"H&X62F10IA? MN|/&7*=?-,G3X:E#RZPKL;9LK2SS1&|
|3=G^1^VV007|*6N0.UE7N*9!O45R MH/%0!P"G\0#8ZW\$T_A002|
|IRRI_GW|JH)3)O>,QJ"_3P%_#5AX+N!&E*_M/#28J|.7*?
31Z|'^L7JM|.3Z>G@^F0|GP\$|RG\$Z'MU|&-Q_E|ZN|ZGJTCSK'
MX@SRAB>E3L|&+!4J|^_3|*%@MR>86N-T4R\$%@5&J,H4^@)R|#.=!\$1=X:&Z=
M8S6BJ22B\$>,4W9C8GF:E_8/_|@^K"4S6U6_DQ+35C"/<<6#?;\$C^_RG5CW*!//2?
MC;EA6&L'DU#E*H(9.S8DLF77'3TH56P!3|@8 MF/;(\$CO"\.)*4W#|3_.2)=X
M_N6GWO/M%YHM|V"SBL-ASBY|3L*#LMY07MBX|GZ;JN9VNA27&H'+PXX-6A%! M3<=
(0=6!^PT4@,IP79Q^HN!2YHO1|;85V_@|(JD6=#K%GB9G,T=>R(MPU\$@
M#GQ&^QH4=))HEV(?SW.2@=6|Z7+:##=;=KAFIU+F!*%1=4UGOM^+=84Q.N
MW:A0C5,;L^.>!'>2R@|TZFPQ@D^Y;XHAN_R/56F*FD^2F^Z,8&UY^7 M'TH.U?

30=0.%Z!8^5M-\$A!;9N1ZT2EOJNG7"/YAJV2MK:??%P\)&+E@7ZQU=
MGAY0=P;9H*1[K*Z&HR>V1C2('EQ.SOT04GA>Y\$&G),.:2QMKLI6_?!"A;
MW6Y1;HPUCYD8BX"&>0%L.7:&-QXO?FIN53U[FD.T?#R9#Z_)<#8;N:N_L.*G
M#Z_'3Q_J!5,5^&3V5FL>,AV)J!H05781>SHPI&U41QN#&Q Y/"32_'\$<:T&# M2A=D*
A+JU<3037FUB>+NSP.V=F.%6J1384N%0QX!0;G*48ESI&,7-O;"(KX MBM%.=YN=:;
[XH)IY>8/6:W/ Q?XZ&SY08KBA>*/!/[AH?DWHK<7UJF7SJ;HJ:TZS;9"46U&W/J4)(/!
L_,@_)7_*F! M"2+DLU,F[PC(N09,8C\$=))=*=F=E8ALH6QZFVD_03Z:|>#GOKDW2f!
@U MUBJ=)7E<)-("SZ@-\$-MVR.&ZD(X)4JL(\$DDUP@P>4GOI S.E:P;W.%0(- M&U\$Z
+74Y;G4K;U61!#>+JQN?)'_"_.29!0?O/,...'.ZS*,5JJ1K83Y,O_4
M1!\$SRV=H4BTM\M!;C4SO""D*=?!U?";7PAW-(VRH 3>(I6.%||7AECX9".AYEK(O
M0!Z9U"59!%-CX9!;BHZ907=MOT6E^)(3W!/\#*(?:X8%!GGV=&B@BTLC M0MR @\$"
!061/;"B@:'(JRF6|LR,1X?-HX!&KGE;/'+;-_3P^VS@:##ZZA M1CRPSUR%|3F)E!|@Z;|
f(=1^N3< M1G,I-I2(HU20ZXH ?R%Z|E|H080|PWQ\A8UA%<9GELBSIT\$G&I3BO;NI@
MQ-
:4|31LN\ALAX9#W/#U;|D:0*^BFA/0_NN,'1VN@A"Q;EQ9'6ZCOUJL'V!,2"^ZG<;%KS>BZR:
9#@>7O M|R2?TJ#(4F;Y|CK^E2;;>5;_U)0N8|@>TO(J"9:'AFO-L1_8#-%ZB!P.P1XR
M.2#"1P2GB)W/\$CTJ|@N,J|>T*6Q16-"X3R%&->+W\$&4W/V-@4;M&X^QQJ:"
M)*RZ8%M;\$A1%O(@AO\V^H_%CB_S8OJ(DU(7@.\$H;O+9;7W|=T/B0)1=|SNW;
ME5@/;*K7U3.|P;|?+|BJ1!YO.(N%XG-;HJ^_EB>VT5H)D5K(/!,\$P^_4R,_JW&NCZWB=!SQO
MMRN4Q&J^I=WT"P!%/%#25YPE^=AJ0J\$)|18V7!W;"=RFU_EA2S9|,V M?P_D
M2UHX+J%L;;B8SU(.P!#X.2ZT'KE=D:2'?|*M-5;ER#" -5%M-!C!:/=,|C LX MJ-
=R3U.ZYDWJ|B)1!YSJ!3UPW!P9H\$;P8^AX4B8U '8ILXAAUVDW1QW|
M";X(1Y4KAX:&0V7A*P>ZDVE!JL?J!M4Y=F&!NE|RC2W6J2D)(*BO.7M.C#
MJCZY=U^;NV&W_OBPQ)#1"6K*!02;VF;HR>ZH3WFX=OFSEN,+_-|7;23.F_Y M3>X2:
f!'.DN'XF5-%0E(DB9,KO_!4\$X-M^?;5;;FY|"_P\$NS5ZS;6|OM(D MPPOP99KEF/
L5TP*2BSH1R(f/\$GJ9Y|E;%G%@/E4K&Q
8QEF9G_'I>6@QZB3;1:X3OUM0@WG@3/#O/?&DP|9|'.8'3V*RD'RD7_*I
MVHP1\$PM:R9NH545XH%5)"F!1-OH2(Y-.9J!/%I^##?7BE^0 ?LXKS(^)\$?
M+\$_ELK%42@BJ&E E"ZRC SM88D4*08|C,VS!23O@QQ."3G>PB35.7|&O%@/>
M:6|&6>YK= T@?H@H|L'(<|=IY.40JA9|5:P675UBE C.6.G@S,8R^XYPCAA
M<+P.\$::L1@>HS@#YW&TM%ZHFJ)LHY3@5;/5\$Z7=TY+UOE?"O2
M91.3A7G|!V@IL\$X6.|?_HG4%\MQ\$&,@
MA(|\$X81@+)Z*@R|R#^6%,+HQ;+)+Z'IM=50V16*D5_CUEI+ITJ9:-VNC8ZW0-
2|C3"M|^TYDQ|H-IQ%QWS|X:-=Q4;"^"76?O"H,,<1 M:XY!MR*ZYQQD7.%_D+<-
FM:;)B4.CYJ*^FZV*?CBQ';OG:1;O|P#CUC(ZK*C M%Z"M|BA.@2N&%_8+P@(|*)|
\$<"&&59X+?_GL2J\$0F17/F@R3+H&6N(XBW"E
M0_%!5SJUE#S6=;_O8|!#A1ZLKFUB0(CD5|^OA|0Q,#@%F.J@>|01VXLC\$| M@ +|= @
UOLYY#RND|*|R;-WXD5M:3A;L%6)F7|9)O6Q_5|4JM%|ZX""D-!7D MC
@5|!P92=T/=H9!|#Y_@%|Y-1K^SX*E:+0-QH(|^>|!|_%=^Y%^UD'3+S M_4B3L|
MK\45\$E,B_95L"19*B=1J?0CG\$2B&>26I*HO?/AF!;X'KBJ-M-
!WJ)E(99!2F(|5A"Q3T'U4PB|WF;E9"3J|5;=%<|M&*J
ML'@,VI'Z;5UB&"9*Z'3>&VB/015L#?6*\$L=U(IZ>K1\$>.|@%CN-AG%7B|85#
MJG9BTK!V4CZG=U\$.?IYH!6<)|@-VX)-XY_5_8Q_/)W6@ZG(|0OY#KT7_V(M?C MX?
GX>CP?CV9GUY/;+V?ST?3F'7M#7_F,-^/5:C-2.XH18RS P'X6>BA".Z|C
M=GOUN0.7Z;!8;#YBK=#06"\A235#G26+-?HN7?50Q*'5TD6'(S&QR%SN2""
MDDYZV/8*X" T>[FVNZ<+A^WNFV*?4A7S?;!LM];7(WDXKBRW%=P()HO1/ZL@
M&:8I^R^TA_1)|@FE%,,A OH3W@K1<,+@NO-R#-A*@.D1NE?KX214S-+Q|QFW;
MN%/KQ;055D!6!+40KH:8>I"#!C6)MJO^&FTAOA_PO)U:?A.DU0+Z@2\$A*7KE
M.RDJM@1+K_2W4|<|6|0|M6V02\$|>JL"|L!6#+L09Z(<^X<|L.:6&
M=EZWIR|FV#>4*.">"Y2R\$'JV"R|EV-/G|(. '7E&\$" (R3G6L5AV CP'OPCN/MVX M-
QQ^|B5CKWN*M3U+FH:BW4LW?[5:U.|G1,LG4@&I=WB',_N1M/+X?
7%Y'8V'W;4S:G(:@V_3R@O*06Z\$X_72!6\$ M:QZ0_-#X8 ^Q<40=H|JU8;^8Q5,R)C-
R1T9D2B|)D##3R(3)G'(((\$7>*CP0_|#V3&"I" 95SG|PM#!WOR22#4P^HM^)-MS-|/LX
%T%F0I'AG9>V>867HR|Y4.W5D)M8K+ M+5|SX,P.+|W!T5.Y1;S4CCL@4N=
W'JE6J|Q5;4>3A:86EIE2<0&W0D_GK76 MFM)_2|Q2YE(RE5: ^@9J
MU(|H@J'<6SG1+MOI-)U#GK2OI40;H84&;
MCJ'+)"WB|,CPO\$;;IABFB<&K1GGB0+P.76WEO10_1:PO?29V75A M| L.W(HWY466@X,
F84&>;CJLA@.OA88L98N8'WCVGINO_6Y3-DICYTEO/72PE6|WRV200K@6|US|@+!G"&

<.F)TR44[W4]-R+4;7%T/J MXDCO_=,&B [3M0 M2YLY;O-"PIE\$5OS+DB8-V.DIZ-Z-
D)#4=FW!'LIY=9!I>W(:(3EV_\$@ER 0LK= R36R%YG%.'^ 0X+=RO[YV/X7&
M!55NG_RL=NK7F2_9:[N,@C'< (713XJY:((L!G&E1BX(X/W@^G&A2_\$) M4L/J.S:
[TW*::8.DW,)KW5T=#+(MHGB2<_DD**#BQ0+.P\$, (4D)RX#/XJ]<
MK(\$:Z+8LOIF+9.K#LLI<[!&(E3@ZMI/2RU%/O10UZ'?# G@+JT!\$7*#3
M="%Z*MJ2XUA2D3I)-HXJY3OV#+KRCOZ-KJHU C_S9V'@6JX9I22(-MG#!;
M46M_O,Q2-"K">(WW0W_T:>=5C)?@81K)++=K("GN %%7"L0 COK&%.^M1L*)
MF599BY#**|9C0W8O3;_O5=#:"NT3;|P I(H R>:).X0V%7CUV8HR+^S1|
M*&B.71_C=.%5|D7D?(M_?I\$ \$1=&J5@0%\$)3CK0KK5%RP Q?\$_>|= @<|LGFY
M!4PYH#^!:@V,QOYT">!9QU\$JKY12^@"QJGA-O-(@[D9L74YQ\HO*M3Y:/N#
MO/PNF|_L,D|3WHMAB3?9K"74&2W1B90MZI?AEDW&67=1EE'M75+!8!O4&6
MQ!&G7&)?A=NV76>62;/D4"C Y1?SKL<_L2|OLYQ:S|6<#L05V2|.T>)B,T-4S MUJU
URT+)X5\$8HCT6A39H46U=^NH9LTJ=F;Y9P79U4?1H-JNEED)(R@0.U6|
MG=0ZL;JR&PRR6E|2D7S:8&-I2UCDB)Q@4E0MR'\$M@_7DTAG6J'"&R6Y;.%K
M.VZ+V+CX'=[E)MC^%AH+7G")?86NT)4:_XS-^W+!GHK(&_X4J@)O&1\$)D#
MT\$ \$7|L/YBO)?(4EN4 MU@=5_QEJSX6FUA_097;H;PPXZH"S|"&B_*N/X,%>^|_
)0NG-.7PK 'W|S_^M_M/?_H%=_D*05%NL"DTX^_/H1;^MNSWOM;)\$W.RZ\$_T/7\$*
|_9NK&?KY;Q|Q MYG.:?2J|I6Z,|)#XXF&7Y9R|\$DVM*W;)1T?|4GF/^J5|NDL>
|_%HW4HFV26/4 MHI<6QKVG04K40UXEY7/QI%Y^Y4H(HZ-
QY+A8RGAL30W92U5:9BGWBP+J+OX M&F|T PM)=*1-
00|/347+F|CRZ(O+L/R*?/9|_RZ_) =R_M^6|;F@6F(YNF-UD4+V(.%
<+.U/FR59#,) &WU|PGN+3M>(+CM00JAS"IO1Z",W M(W3EDV9R82 V45F.
995LOL^_GXA6D|?)FOAW0N5B9"?|M%591L5)S/3:WV M5UG.VS* @M-|/TNSO|C N.|@-
D_PPISF!9ZRWE7?M Y?=1)GIA2(K6*X.M M&X|.\$;W7R(|/R@^9VM8L6"/C|T2,
|_MQR%;PR8+A3|FW'O@.% T_ZI5LE9C
MG9FW1U_)VE,ZP.L;_*"6TH/^G2;27Y6>AGG;"A@Y*8)E@)+E2%*M*=G_L M22Q3%*&N-
L5/F+!3F^K,.LRVU'Q,D13O|;_|NU7T"1UU!4JP+R-JNL|%-/O MR-6P>YL-
IK/R'1T/9R/+LE|0B|LXO)|7Q|>|^%^VQ_DUL/Y'Y'|\$1C%.3U M(A \$X_(*V.);!>N\51"6S>
|BU8&?'QGF^_T&R9!YL5NS8G0T@N=UZN
M(KL#%VQ(1(Y'G)T>A|>U_0;)R.4Z#/@XXQB.I@8V/+|0>(-1&1
M6ZJ"Y_P|M)\$X_4B40J(U>ER@W+O!RCX/9U_)U?7DIQFYFDYNR/CVVVB&3,K#
MB_GXFQ|*+&Z;)AVY %3?+(-A6|4JXN1%NS^JHXW(2V!%JJVP*A|SA,3Z'\$=|)@*P/?
7EHRDXV_?)V?3:|8 M:\$>\$W|W>BZ\$66@'(.LL69U5!?? />S2S|+ ^767YE&|8!U=!0:'>
<|V&A-#WG((J\$ME*12\$|^',FBLE M8&B6,W^P|Z.H.NN1L8VPCCR5,|5.Y,+YF=;I|^N-
|L|Z(#|N;NYZDS2JG6 M0TW,4?K9Y|L,M|8D^!RVG)0W043'J:P#G|%-D'<
W8EWF5)DB'(>,+Z|((L| M2<,LR99;LDE"H%4JE,9^F+OGU0:Y4)"I.E)F_2K-B.5?
6NP+T|)@|1//S?G MNY#DT>2EH;*?XE)T4|3,:R2)C)/HLWI/#&K&>%2,-PBF?_3|W_F
M)!;.!#W,N=(^VU8'Q3?B_OOJN3@+/_M'_0#3.(E6VF=Q5;KO?K7AR)PU XI((?\$(
@ND!R_E2Q461 4,=(-F: |S"D M3@)20C;G=|"P7E#|&>@'J0I=X9
P1X'4+,:/6^S(|!*>,0U0#X'O18317++& MTWM!(M'X9A1P?M^L#F|'%1_) V3RE0,_-
ZT@QIF#6V+I?Q\HXY|'|3,1M ML&|3AZ&%8;4H Z@?Q=K4?
|>2NZ1),)=IA&PRA";MH@T4U"13>9Y6J| MAI 9FQ!"ZM#J@<,:8|_
O:>HZ0@CBZ:V8SFA".U*/6I5'JUG;7-MRG.0VS M91K_"PIAY|P|H9"W":!LJ|+(CL-
1|H|=B7)!RA8|2VKJ0Y=#4S4^1JE|0*1Z MHM3S\$SP.0-|X\$_4&-
Z5GUX.B12BU9=MAVP)!LIWBQKW:"C> .OV|33_PE2 M=H_L)I@/V^!.\$#M@1UR;B&
3Y&5*|-T%YS|Z7OR3K+K
MF+>V_7D|51S"F=ZRM.U@RG3GY6WB8@:@D&RN7L5I7+""!Y',X|:64#'*^|FQ
MDD)&PW*^BO/HCBVCVY^"G*ZRJH"&R-DJWFS8_L6;H*BHDFN|HB.#)R+&8|.G
M:HE|5-WGN6PW!|<9)4%8,2H6^0=^C"8%G*-)!'/_69-(0.=1G&!88DE6\$Q6 M-%'5I="N"
|&*\$|&-48G'A|0Y%;YJT 2|*2KS1(RE4G-QEB_%:IO6V\$|_X3=B/EU|H"H
.&-9;P|H=|AMJ.Q9O M(7Q A'@.EV H\$7H|<9.Z_XEC5T:Q@:6EIX:N;-;%:^;*OG
W=;YZ1,VTF"S M,V98@Q9)Y)N)U*+E/5M4+&@WKKMC=&E.G M|N/215^_890"2@!
(+K_,?BX,-IG|WF2R=V*_JU.WFOJO^RRZ@!NY|/+^/S M:|D|RNPN9S7MFCW\$3XO
(B'@!P62MR^'85|1Z#H.'N(\$&_PO6@\$ (B59L+I48 M8@?DP@|4+=F6?|I(|
M@H!;_G_*>F&+^22.99"ZN!R*F&|R%4N^IV\$.W=!RE478-=GTO&U.QAWN|
?|YFOP\$'6#>[3JRR)V.@X-T/+ MV62(5Y2YI<|'|H^"|JEL/#P?7R/H#|G>7I+9U^%T|'5R?
3F:SG|S'W_^.E/ M?R6C_|D?SW|VN4Y>BFO|G3RC |O>H9DE(4M6-S)I2-9W|N.WZ"
<|&R&GW%>: M1//L)BBQG&7&RUK8_+ND#Z7X*?L..G;B=))2B#

(B>A(N_&CVZ/'C:D@6N. MP%C.RNQ,C@8!PO,2JT(OLH)=58)%">>M?;#) V+!:: (RY5!9P
:++@/RU^C: M 8:C"/J/3K96K-1,OF\$4=PC@6L)6&,37,L-MIA29&" +=F\I:\$1B_8W"IX
M2Q>P|BEC ^?&<@(&32_*MJAQ"D\$N=D&\$+I;/O_TYZZ+?Z%X"^3.3*WP1BO5
MO(/F:16*UGFPI%)(I1MD!XXWJ601(O8K\$BQ.KO"Q2=2992IKK,XQ!6#OS-M|DI
(E6)M>LB>A^"#0)(E?FK8T!Q;ZGB9&@3=(8LBL979GV6+11Q*J\$D%M9MM16YGA@C>
<7! MOFJ-3J'737?58!Q#W>%WEI,UTID-8*(62Z1K(#KMD M8L<8EY?
<;C(AQ53F>7#LJ0%GQ-72; \M'K|XFI*A\$1BB"0@LQ^66%F28Y@C MKP#-
'3F<2;H")AG5=-OF"O!VYJT|GH#VA%'CSOKD0,/I:|5^E=F0X,GEB7X
MK2_@UD%P! =I9FUO=L56".8"]<@C@@"UGV11!H@G>/JB;;H08"#PQ@07HIRN
MV&D#W((QH|@(&W',I!9E!W,A/@XGM87#!?3"979#|WW?K\$;MZ14V:'W)V M);,\$F-
P>%|ME=8P=1OI#2*U2P0Z MI1J,J4(X/3"|" ^ ^V%&/XBKK\$14&<*8Z"O?PP2B(10
MRXJAD(15HOR8RD5_+05NVSWPO;DRGGJ3&3,B1D^N/'3F',VSUC1%^WD*
MC93"^O_RTQ=A+)WSS AD!' \$T3B^"33;8RJ/Y>;!%>0P+% (0
V",BZLDR|H>GN8K"ME>|K0EG<2C4,,# 0^B MV0=^\$|B'ZOO.&;1<6"
|N8EIV40*YZ\$>%\$|0?N\,M&'=V'>40<\$Y;JWJL<;F
MS|6S/T:XAUU&1;NK0#=#K#\PGY)\$/(OF)?++&K\|F-R.X*Y.|Z>3;>;,NT,R@
MT>WH:CSOC4\$|/#!#0.MNN'|+DP%D@9! NY&1'Y%>@>!FRG(5-S!?'82"EG2A=5 M*,
|4)U;4|/FL?IM#:Q7PCP?3.A!2|;@CP4)K0WH|XX M?
SZ|'MY>C/HR<+;!OC=#;|")6B&D(J4C5D493NWAG,N3!::V_LK&P>D?:Y; M4JX8=
Y.;)'2_=&7G;?9LB.H#-S=G))W.;.0.1=X(?)R/?IN,%Z/OCBXJX2?O/2B5B_XRGP5I*+?A-W_
MX&/A+V (M\$9:<+C*%EP=COK|U1|GM+"F*>)F"71UTE"A9)SWDI#Y:3ST+8==
|Z52XARW M4/%P'J1*"EQ?*_9>2 P#0/J0--(F|+6*!\$|A,1)PF3H2*"T882TV"H<;Q;'5J=Q-
4UVD8+|>+NQSJL,LM=\$0# MYR'L AN^3:9&B>R-0?^MCXZ286*G-AT:OE|X?
|:NIBEM:MN7_>CE;|0I\$D<? ,6|B*)^DF#TF|Y(VK GF??1| ^'B@DOZ=
MZO>X(#3A+W)NT#IP:VR6"PI+) \$A9-XRF,ZLI&ZQHA6=
|9HB"U")N'/FT^A,Z|S0,^E,O=SZ,'(NJG.#FT+%O^M^:D.LUYG*N7X9F%J-
WZSW%1;X)U4Z5 CS-H>/7POS2H'#|E8N;Y,)I< C: ^O M3W6LNYA4GGB/+&@?
(|S8*:Z/60?FFCVQ(TOJ47RS)|DKW%)K2QIC|<8#P:+Q M3W|M5EE>G@&/H7-(1(%Q+I
>FD.AJM2'WVUQH3%_#|@6MUGY,RT%1L2_.*M2 MH/LT5W*LVZ@)%>&;BK.?
%LVXOO|Z/QF|2;&P+=M_BB9MC)'|,,6Z?'V' M9XYT\0+U>8G!3?W#*2TV65I
>4K;R?'B/8PH|1#E,7YN#(#=R-Q/D2(O>7Y/
MDVVSR_(R#|8M:IDXV+|WRU\$>BIETM&%-RVG BE.\$"_+!8MC.L%J5G3S1LAP
MA"S@%5NV56@M\$64\$G*+\$7<;WHF*W6,XZLC.?.N.)'S(Y XE AX_U MEQ-*"
=&&M1OL@"V|^LL2.=A7R5504;*UN6YT_,@NTL?FYIE5\$JR5KI1%0M
MH4D3"TIGX")ARM&1Y6HFA3QLV-6'@_>2.PW+B):%P0#01L! =<S2J1"# IR
ME83H+T3=OJ;G#??F1T^%TE0%/\$BYDM|BZW\$|NHAMEQ/^|DE7= !|_*SSM&J
MI&CR\$JR8H|M'QV8FWV%ASTRS2"ZE?3&WKPR>W1UI;3&5GG?
ZMOC8^RBO!4K;SU*A"FI(E\$F.? MF! ?KJM^6H_ =KBJ1SK^"2U 0I^0K#9)R%
<|)5'8#\$4J#O'(|Y/IW=|S'T'S M-G\$ @&X+)LF%>;,(5?'B6UIJ,I1SNLAR>B=A1Z^R?
Z'@?.MM=7E-, +Z,\$7 MX7I1:?!0)4&;9%)5E0YE:0!XD22Y9P^X
&'9|B(J&L<6J!76!IG@;8U_@D M&C-%RA8_EVC^+5V;827'7*;XMR*C2Y)\$0-!0M!<3#
<6F=I& |A\$<?:3Q M3L! ^Z)=PH\$?8"@? =UVH+@\$X' 4M@<_"9|ZR6-
B|X^(A|>,BN_+,@>H@FQ0 MNI|%-+SUXL,TK2#SJG|)%\$(R3"XX
M&P|FX!F8DK'ZD7@N\$'MA*NW/L&YEN0(O/%&'L%-YJR0#A&\$ D"*S";)8*?/ M@8!>NY!-
&|B:C_0W_KHW(6!8P-9 +OU\$@/!2FV1&)V43UM)K5!/M566L.J M'"F&W|&
8QR&L\$_(T7-U5&E @5"2DHA|?BC|DN.S'8>IS|K';=-*X&NTN M0^=;8QTZC/2M=KJ3*U'
,XU V\$;58LQ.LW"1@B1<(6|5&US1RU50|DN6^#!; MIK9ZW4*@W8!\$8DNPUC,0X)H9QY|
|7|O|FO8|N'F9NYZ/&E2?/K% V(T)9<^# M)%|'CO&UH=8K,P8+^76
%M66W0G+9BWTZG7A|EV#./4F4UBYIJVH\$19= R M>V**%9A^Z=DXMBS8>70_ZPY#?
CV_%|/||&5.9X'ST9Q.X2;XW1I9)4.1U\$6 MZ6/(BUMH+4*'F;;S<= MV-J_<&M3S&
|IJAIO%R59|GBK&+W^!K:-"M"5X|4#:<9U8@QVH&N"|B1_6\$@07!^7.>;J|!R\$Z_L
M>53R!PJ)Q@|/KE6/-V.J K8|J.M.G|)\$")|EA&V&;=L>9R>CE%+^/'*)I!|/T MA)
<% .4Q<% 'XX1SBJ++=6-|MIT4T^P#EK53ZL;W M2CW')T&4KT=11>.K;<>CF;5S-
0+*S")TM#>|Y*74E @;T?/X0K>&2#"/;A1 M5K1!2EE.676|&KS=T.K3 EI-
|=H"5KQ2RGP!O=DY%#E-:9ZZ&2<\$G'|EZ,G80@:RA(-^/=C:6J|1*|WH&P\$ MYN-
AYZ/'^* \$|N.9\$UG!'S: ^ (NP-\$?') EX 0%X%(SEQOGC\$0XO.+H|A^ ^, MTR7@?
2:T8'YF(Q_9C?W0Z|(4H' CQ?0IQ#G1LA4X/J B0IJ".KIJ;FUZ;/, M#H79N30;84@39-
"&Y|O,WH(^Q|;|NUN#/1+//?_O6|WVP'(24AH55WfV!EM% M

RZ@[IUP_8F=R1'@ME77A1&+DNIX0S\H',AFY*TXTTFE-GULX:GGTX,_DK:N M>
<^L\$Z2..W!8KLY/_9GL6X-)LUSH1&E6#[*,,"DAKCMM.V=%B-66CHY0S[8
ML.=VJC2"V=]0A^[0NK!DQO.#W\$]-]^-&1P%>8\UQ\2],<|,|BE.@QN:'M(G1-
J%V3F1/BP>6\$P\$W0)DBK!;L_LW)+7Q3\W-AM6G=MZH%V*U D#G=N MM_7N+!13VQ)
(A\$1QC>B))7:A>),Y&Z?F0+!:(R\$-ESG%N\(%5%1?;/DY18B
M"9<9Y%4Y#\,ZLLO>/FFD>2V\X[(UIP8_)5LJ^\$]/\$*O@M2@;XM>#4LA1Y!O_HV.SD
(M\JK%MUJ:<5T6*^H#@CIVPQ M#:"3&X-?730F*4D-7TD!X5PZU
5>%#AHY6*_E_'M(V.?2!FLK8=]1!4!-W=MT\$W(>?XL93X:"%R;I-
&Y^~57_9^/3=TY(AJ0E<3D;/O%Q'IMFLYG1H^R|<MY-G\$\$\$JMYN1:8!@.F'?
)866'6Q(\$2T\|M>RBT>.^ATY3+P[0B._NDF=RMZZ MVU#O\$1*U^TE\$V%^WV@5?
8&7VM_\$ZL.VH0,P65P_D@'ZHFG;1L#=#%8!MS@\$!MOW(6KB_,0HAA3%*1@XUI-1T&
!%>7_'J(]S=VY#IT?[@8#]A+_E2K8"=AZ#M.(&)?,8.A&<|7JG'1L3@"
(Q.A'X&\$F%E&/VCXI\$V.3^_)ZLGWT_/A.#X4V M\P-
XP=YTP0!;T=YQ&W8A%TPPB".IO0!2A6[Z]22(MD)-60Z#F!U,'X9NI+C MYK+!-
\$%U,7XK8&4;X?H=&H;LT5?(:D% MV0=F(T>9D0>*""@#K.DDJ+#W'C
7FL^__RGDVUH\$I737[@'RV)/K33^|I+-M6;46GP#+?4^>A#DQ?ZH7DRI!_%D\$#EN P_;
MS./'V)_Y|=Q0#JX>"OK/'CK'"|E_6@6"M"R"PIQ'@CHUPDI
\$&IYKA|<>;P.8J/O)L5X'^=:L*A;QZ:(-^;N6)C,4A2JB=Z,KD5U^9|":MK-
@0F&OA(EQN#SU@&%S&|O9?;OMFC50,9D/K\GU>'@^OAJ/QZ,9&=Y>DMG7
MX73T=7)|.9K.D.7X3W\EH_^Y\|_=@|/;+)SX-G<=>*ZD.YH&"7A"H',<
MBDAMDA9#>MWVI\$JH=|G;WVMTK8W;"C>)FK4CB)6|@P0Y*X K#O|=
!R=GQWM@V^|1^2HN"\$WXW3G7W28Y M-PM(DDTS;RYDW.
M^,9%|2YG|&YVW+#:EP!/V%QH3:|BG7^WAC,W_RIP0@+M5^XAK++9|/%4D2
"2_RK)GL8L,WG-UCM.-A,Z1SQ'^030X\$'?C;'IEKAF/N|
MN^O1S>@6KG,7P|E7O%_XAX|RK%U M8HXV-)75TU^H+
(<&UL|"BJC8<,)1"==MO!NSV6H7&J^Y/?#FA*GX(\$V.Q;MFLJ?
8""ER|X5+A|I5/IDG,J7@A%*JFQ)\$D:|X!|99#42U)X6/RYQK.@2D W-M!^=ZUY!@!' # %Q
M1B(_YN%TA\^>
U%_AS_JU6V3\$DDIDA0V|"N/LZK/) #VU>:1%=9CB!0K=AX^&\$40&'\$!P1Z8N'IOHXZ6Q*W
M9P7V0(\$D-O(&B4|)DOJQAR+3*CAV7BK;[W1/=:%^N'7F)W>|W"U;75C-|IX ME4|,F-
|.OWF|K3LUM+FP=|=YVT!:(N*G8-
!P=0MSD>D^HM'YIKZ@T3CE)3I63|*!DX@IX'06J0+J M*C^%A*G'XE29/0H-
=F\VFBT8LD>V)7@4J;NS&<\$"O3 ^>FXT8UC|>|VG/*
M\8Q0/MCWN(^C7GEYX&GSY>1YDJF|0PLI7"|EH|%OJ)*75DPP:N2(4V2AV M+8??
2B|1@B#?"(3'.10ET(|\$C|2".G:[U;ORH'A70+O(CFD%(F<&*F3*S,LI MS96M5AL^S V>:)K.
|H5Y0;2JUE8/=IU+NYP0:%PTY0@;?EMA: MUS)COH4+^
TM7B&DP0+O+V7FQE3KU,;M3=#>6-OK^#3Q)LAK<##^ZM'TT-BGAL66=
()%^E8|:AE;NH MW;NF.F5T\$P1L5UE.PZ XL%_&/BPH0CH|/0-D\$<#
(<1+|TPW(|=V>L?^?J5Z MO^L6A9Z84%!:-5...@/%_WSC M\$0K>_KI>-
VVG#M*C,8QMOLI>,YBUW8EI<@,;@5(\$ED^4Y5P9^:7,=TT2 IW#9(
MI:A=J(Y!KB.5VP=MZ;3W;79"\$U\TG-R6,;H:!)F-0.8Q.@=-M?
@9@J42G%7EQ@4,&^VE1WF9IV"H|^28P7*62@,X!T5K?A2O,?!.)/N&9L,
M;8'W!9"P+GG"|D&*7|"&O@GP|?K^+|TS|L|D|:(T D^"0@N\$KJ0>|OGW MGS_UT|D-
=.8FXLK=>N8-V+QOL+J7=|\$66N@/V50NTB);. M.T&P<1/DO|
(2WES|,K<-0;.3G9!.M'AC*>N7D.V8.2&2H-&YTGNIH:?'GB%;J:T-"(*G+)4J66
MXX0(:)"61TU3KL1\$^2!\$?_1XU.S(XZ3/V^:/Q1,5004|SY@0|T&CT#=#6LK6KBW(-
>:*@G7Z9@=MSH|G7@":C|>;BM|5V:R@|C.XS:F@-
M&:QER73BWQ2!54\$(M3C2<(KVX,;W|6*@-#LT|
M!02.T6):X5),%9@E.P2R=8'IQMD'13KQ,E6_O8S9^|J(Z2|TZKUP./N'')M>HQ(2-ZA5J-
|HC0%&+,LYOL-7G0!ST*|V@9|)P^X*?AJY^\$-0(WKHXX?EC5S(|CWHHWY5R1 M!:(|/;
<+:/ZO*^*5W&D-M)RJM@W0KC7DLB(K4ARX/K+PJL6>#MY,X?FW@<'(-
MGP^OQXT|>1F\$+,>8?FT&+/'Y&=R3H;DFGPC8S|K5*MA6Y7A7)#S#'(% YTL
MIGC)Y|402+MY,-0%"H1P@A9)LS^6&.1@2B3EN+%)A9?%\$="YH5&)>NFPC7D==<=
|ZU/G@4U|7A(-O>MT7F,,LU'0?4X98<&W(|O@A(%0;,>'E)580*,5)<@S MR-|Q)
N<-0|W;X688U@&KR4.B)3IO,J'^5&:YHOV83XDF=/Y4H0++0|X\$J1
MA,N4|!0|L:6AC|BS00;.%8|-PYNJ.A#F&5._SE*3+P|J:|(N"N?8>0&2#EGN M"7-
DW'R:\$=+5>S(USVE\$O(I7"DQM0ZPRBKT6!%9HVB5!T).13*IRJ)D=W51 M3!6VB6+N|-
OJ4R)71@QMP@^>XII.?9<;GZO|39?<*?6X#7RAD9QR(9|%^3E

M92>7=BF1@\$ARZ?;RWL'PQ3RK#=O/);Z#X5M\$M;8-CA%G\$O9M!CGO1VK<+?Z6
M9D!LZ=IM@V24 M;2,<)27?.\$K/74F A/8 *PG00H81,'1Y4'1MKS06_MR7D@)P
FT#^8T\Y>=9^HEA,B!536E0)E'1>="=D:H MYP5.. "!,/F.48_
76.+WV#2U76:3)S%LW>)CQ1JZ"5!AB7/J@TLGDD%%ZZ&%E2V5+5=*40H0@T1;ID<; Q'
MB4EY/4X#U053%'*HA(15UUH^6F(E^CQ>NT5.V'W-L\N\$6*51<(R.U%50@6 MC-?
LAP8;..V=QDM'E(U2@\$40(*.H.^V6@>\$7>GV%6 YQOU!GG199&AQT=7[Z,!ZJD/I9#
M(j\$8\$PE4U+;(2))!S1?-N>0B#\$"(H= MQ!@T^3T\$W"/?3X#!XUD\$Y
8S<O!^RUOD#)J4VK@W%@3=":#:KT1SN)I8MR0.&'/FD(.JX\$S_&Z.I2NMP-I
M78.JS!CL@,CA\$CU>#-="F0\$.^<=UOI7GEV\BK\$:/2OZ
K+ETSW%@(PO.&61UO5K,O&S"\\W)X-PPA+0'9>P *\\#2fO)L MF0?
K5@R+O.LRR1"J#=#VQ;WP'<%753)=;PX^\$.W.N(OET\00IMM%:3HHS7
M&/ZJN\$V)!YM\$JQ5QEHF'S10;<:LJ4/P@5YF#18Z"V<:.\$#@F+))V_K9(=6V0P.:
(-KT0,+|CR3"X5>"',=->X^&" M#6V2TODJSZKEZBI^H(
06"#9:YX#TD8K)*X=N'\$8UEF9GPAP!77)#"5CZSA^!
ME3%\$+WQ"ICKE@_";X_07S\DU'(%NWG"S@7YJ3#,*QJU0>5Y'3!JB5"+T_X
M<UQK32H2 M;S7T0*(PI_D:1M"V^PL)&4 807M\=GYU8H:UU2MR"1!YLD\$_3IU4?
\$.V<;B8 MB|C<.HK 3&7;E!O (APPM EAG^>&!W%^PT M(TA3"-KR|R>U;T8KOP7"
<50Z;@.BR0=(.\$#=<%Y U)8'!IW%;:.\$'[5(DMJ%Z M)/XW9ZH\$(*[Z\$@GB7MKP*LDZ@1L
MA|;U&D(AQ+9#O-8OJZP#=#|VT@+/H(!RUM#'HH8UVJ/1TK+R*TR-XR#113|M
MPJ5*FEGQY"=6VI\$A5A5J@S6^<24ZO'L&KI\$QS8E-7.4'<=@9L"BN8-/ZKP3
M1<^N2;FB^7P5I&*O(#@PW 9Q.P3=M^Q27J(.JP4='9;|XD) ER>8*P%R6!T
M|#=!*FHQ.(JP021!0L!'BG^,D3:2JO9MF?Q71:(0L8V+HH+PK=L2T-X^'O,8
M^0K(S\L8/Z+CR5B4T10"ML@3)D%KB#!'-MY/5..!F5@-O'3*\$&K_OWL7DV!
M>WN1'/8:OQJ2'1DQ=*O'9D.C*WL9P M^FD8O:JW_9:64\$)1S&.(FMF=
!|VW5"R7.1;H0FM)\$CW%\$36 #,J8QR9_K7>_MGRK"09>.2V2QPCZL|
-0FT\$U\$'O1!WJH/<^L-Z=EZ;*\$?9@;|HVUZVWNQZ_M1OW#BXX\EZS|A|=X&I8JB-
2!ASY#B_TNVMSZQ3':#:59N>OF>UV1W=H MMJ438!L|_4VPWOSUTE\EA;|F"S,MUH
,\$!H68%OX8-QG2Q:5ER\0M7GH0*# M0XA7SW3|P'Z|'*=,0#1E3Y8M)\$APD%4%^D(\$S
T|0;-7:DC,>IC,OP5DO(I M8T=7KI)0H=,OZKMCV\63-FSF>HA0)(@NA,U2ER?
H>,>V6Z4L\R'Y_/M/?_8' M%|30%%YPEN-
PSZ_G|*N"|RX7;6#,|H|.L\$3.^'ZB8S|V'WF'+C^6R_9AF_U M88'A@?
J0+*^:@_+F20C9C8N'"<(N*V#0YOEK+)W1&9;\$*YO(*O=7Z5_Y07-
M5UF^H'%9Y=XX;IW|)NG4+?WWAX6;(*+ \$";.I.Y+\$3*BZTV2;2D5<><-L|LU
MGL0FIR'G5!RG#F\1IB+.7;USJHY\7R;<&U|!=!WH!-
<(+*Z|8!6F&=KPE@53E@+>|@LJ>,>Z M5.*W5@67>
5#C'#9C1_C\$.|.'=#KE8J^:3@"O0*W3,#D|IM6C01LO7.VC/; M:L>?MST_9R<@N6;-
H<^PRK=XC^,X.;A9'/CDI#@)|<,E#MQ"G79F2S.BF#1) MHOP\$<.XI2O+ATQ|'?
S+'P9^LLG7\$O_::!?? |+X/G/ZL*ID)/\$WVYJ_M);^OTKE1'@@3(& M7NO-I_KB_V?
O390;5K(TX;^"B.F80A4AUJBN=BU3GRB)\F67).HE:7MN54QT
M0\$221%T08&&1S/IU;YZ3"Q))@@26\IW(KKKRD1N)|>S/H?\$.7/I>,CB_C0V M(U&N?9-
//LD\K%WAI(_N(#\8/-3%NC%/&UQGGPY3WI3L-A(\$^!D\AZ?^J M5-
TFP0&FB&30&G>G@A\$A^WNWB>)WT.-;I5"|#0;1TO9%2-&+!U'?DKN
:&_"MTEX'J6HTAXHJSE@2S+MJA MG|68LBNX;240"
|MN>+|4C*;7\$;VE\$!%0JO\F).EQ:9T2P%=@\5QX3,E8687 MA#X*:WKKXT>H|!CZ.5T'/?
1S.@Q'2D:>8HO)!E)RYTZH1JKT| NQU(USS\$ M3/#3HN 0%SMS"KTYHCOIW_SF)Z
@9T?AN|KE'CLC-PH|/1C M(\$O9C03-Q6 MFW+2U,@ZI1B>9&UI6@Z.(4|\$_KE0'N\$?
TS64>RY_=Z!75/-|QL M5LU^P|++5I%\$S#6DH_7Y--
UT35DCZ(:ES<^HP7(NOX:%OZNX)910(ER?#+=J2 MA"QY%*Z(MQE!D#9@M.YH4ZV-C-
"GD!_IM1V@!4N(CD<(P&*>.:|I=V,QY L'A M-K30OLV/ TR'M\$GB-.C.'&:(D|V)"SYQ(*7|).
<*A#|?_BP4D|L2\$OPH0?+ MC= 9M)G"D0T*<(8KI7BBH1NQS.E&9W1)
|_ ^XC;>3TC@J5PL)+2\$,.A#1)9 MNI0L(/:B|)TW61Q+-X)Q\$GCR(8R2PG.G^_#)C8>)
>F>LH*L|_D,?UY?G|I M72S_Y_XH'GJ&R?@@GQR|SD9.CBL| M|FVG(.MR%|5|\$_@-
PZWU\$^8MVN//8EH/XL|C;.)\$|G9!08K8J|/0KU75"0L\$M ML3S^*Q15'|#?^<-
'|KXH_TD%2UG%:(&='WT=V35GF42L9_&^P%\$HR M|7&;J"_9R'
A1VU&77BH!Q|ZV4)W"W("QDWSAZ|@8#C;3NR\3\$0X'HEM+!T MG-
I9N*WPR#RK\$95|N5J|TW-H*E|'M'39:06LH?;BFFPWSIS/8"&|V8+R: MA;>\$N:#1
LR\$CD\$|_ \$CAAD>69*0UP)?,) URN.=O!\$;V,TE?(3(ZQE.\$@*C2 MSBQ0,'|B'4Q_AW-'A
F^MB2,/N, U>|A\$*"- \$ONF=2A;NG8VA\$I\$|S\$U*Z!@S M\$&+5!@'<.@%Q|1 3^#?_!%.

0)JH>EGGB6=S9['+8E[OC*5)]\VSQS7F*LN M9%\Q!,=L,V?#@ SR8B!8BO0J6-
Q^&!^V%DK9L*N\I?ALZPL,0.F\!? 4/9N M,\SP'J2/Q!6+EW\CI&H=I 5IPB,";RV&
#D,Q//%\$)KX/PN(\$\$K\E' '?Z:R M_3!>(@\F3T_-<3-
V466&4F6H\''%RH#_MX(799\9*!,8RIGM M, \$OBY'B0)#7C*?]\^D\IG9E/\H_ ^\$%
9ZL3\5T%L1N8*KH/V0F3A39"K M+ ^2I?Z.=_/Z\H^=D8CS6>^67?
I\$4I;U>1@>VIS%O=*"0Q\ZH",P\$#+/+_J.D MC%^94Y1C(/1\7T3A(@O(A_?
7GS\0=^HA\OR-3\RP-VV#4"-PG?0M//A_?.G
M=O*/(H#HOOD'=/1_WPR)XB*LDE8FZ:U05#8UGEJQ_O6(7"&_9G:>3R!+=U\$,
M;C\$7*TN%2H2'#8N,#++AMT56P>|6TL80J604<>^TY;"G3W\$ \$ 0P0O,GELFYI
MJPSR\!;QT>71I />::&55\%S)J1*L(S2?:'>;9Z\J"BKMH#;6F\!-\$GHC MK7&K=&E-
+::W3EY-S6!\$&;ESXL5B#NR\K\TJ\I,8.&22 M(@X;^FH(0K0(-,5G;?
IS6(Z64Y_YP>V5_T#^=FLOS9F3S>LC_U?+KY\IZ MN%KV/7L\9N?
IFXRRK_M2=S2JU+@93-O=MZ^TH\<\$0/ SLEA,7 M=A(R/ED\ SAX_+YV?IN?+Y>^@
)TH9F\$8PVT/U!3\3\$OT7(F(F-Y%H;+7!\$0\AM^XY;U@_M@_H\!\$4VD-|I"-+
K%L\$(5;Y,K%D\$H/DB,DX))\$/B?://|+:#F\$D?T69K-)TJH> ME0,/OPK03>K'+YH0=P-
\$AP!5VX(?)F%>PI1S2,E\N;(JL04"6H _"VGF%) MNJ:CW@P*!#FQ(_ ".F/8! #TZ@'L%3T?
2(L)VX.4.6L*=-.^94I'>B,Z,Q)X M\I+HW9\|C&5T!\A*+4H=S\$Q:0"*#?GK.9PP^W
_T=5V\I54GL\$YL0.#&K3J MB&8=WNX;(22HHV\$@JUIGQ)3-
:D6B8M9T\WA^,IJSP_A\WN(X87_R\&&^X6%O M;B#BCMNF^))1%?
2"D8W+V.L\B3P#L=+H\PYQ@EVPET^+.95N5\|<.4_WD\<5_MJBM
4_T,'U<73F/T\6//1M%.Y=P^S\|MW\BNK@"?YT?>RZTQHFF6.RU\1(L M\K9?
H86EQP8O-TP&#PB#=#^0YSMSXN'J_-D\B"%*IO49TGI1_[V]"VK_)S->5
M\PM^TJ)G"&O*,&2?Q32@U-40QH_Z;=L'OZ\/_!"@G_;\O\!\$7H?YL\$?<&+*MX3,X05O-
!*5B@C#)(I^@XH\|PBMZ9!P4\$>;XY)_\$#.\N7/L%\$+!46. M6<9CJWZ"QGK#R^<0_%7-
#GSB9#5\ _PVKOG#U+E;S\!T+_,P+S\|H MMV_=1^\$67-
!O9HC&.:N0B#AS3=/L4_9^X;.,S,)\CU=O9+@A3S07;9KI8Z! M\|<_%'\AT*?I Q#*
'J\DO#05PQ";Q\|VZX4\KVX">#=#W49R+G4_2G\TM6-F. M.'L_||/?
97G&2!S&0PX\$FH&N*R9KX+Z BX@\$ZKI\0PQ, !A6W;J8\|W7\Q,D2
MIGUR\;7&D;YON,9U;Y#1 MXV\3&?4DHBVMZK M1F+P>2C=V45CMKR!
<|1;_9Q@4%4^??W>M4-.3\G&_ZW@;L.CX#(X)^F8EHX MQPG11GGG ZBQ-
)A\$'<*LZ\$6&(2"8NJG(6;J%GI<)&T%(/,0>E;+R^R#0FP0 Q+USS MN_"5!T>58JN#>"?
XFA+*R2?X\|MU8&J+#+\$R&M7GE8*MOB"*2LV&J@-ON/=<6B+/
MMF(FG^%04\$7\$6(5+@5/S;-L%0\G2_I@0?KV07DFB7D\ _S8:&)HG9%/\$R_YF@, @I
(CH4;/C+!(VC"JK/E)F\ M\$!.8Z1A86\L:Q.B0-Q*FLQ-F=/_! _=;G&!\^ MIEC8S@GHJVL?>
>5HH*\XB^|,-^BGDS@X4 ='RDHDM"WBR,\$Z,-K?X(3KL=L2
M@||;M\FNW>X9(,6Y"YPS,%%28H_\$&5%37W>38U"!S16=.KQ7E.5YOX6<
MX&.F6>Q_9DRPPK73T\]?*YR2*O47M'TS\ _^NBP MEAW6-\$N!\^\$8HX4NB(0!J0@?
Q!NV.FA+/"TOSRBA+&&4L26?Z&HT1_|+V M<' M@0QX67=)4Q&JF\<L, @)#-
T)V(R"&X35T_=)>C(|43\$!2G(\$1H-AK_0*ZQ60W MQ?S+|MX|X|=K(_B!GU/LB+XE3@7?
TF43;V#U0P7ZP"%ZTYK#F1&7K=K_:!(QH*GB^#\$Z((4&M"O 3N
M=5"F@A\|R\$W44#6M+R6F\I\AVPZSP/!<|=4"6VKMAM@&@!|@SZKKK0:ZY7HC/
MQ65LF\|\$-:#D1== ^QJSW:0J09E+;)\H8XP(P;2\K?A\|M4583MYF\ _Q^#Q05
MWJ(261YK>%B,5S12=H57BXU=::,DR8;&JKV(#@- +8>F/=!\A851\|&_O? _^M
|AVLX\|=3Z\IOWK_'O^?%U>;/_* @O\G 66!29/C."X*=V_;\P\SA\^8-I* M_Y!GE?
@PG1@&8F"W B^D, ^*WFB@.\P!>DMK-@Z+=+=EVDPRDW;1C6@33<7;(
M6U,%^F!@77;,IQJ&-L"D#H0\$IX9TJ4%?;68G;Q->I8K^|RV1%9RFR'I2#,G& M>/B>HU(6
&6@|T;PH\Z\J/S03\DI?;K |YG-4;M\|PQ.@7?2QZ%R!5B;+CSFC-5G_*_-C,+@G
ME!&FC\$^KD"5H!;90%-,|&-D*6B\|S\KQ/&8G,9^C?)U&:\;^\$ M>9C7ROTNX!
(741!0<1P<,#IW;U"[1_|XT:D#03J\|VU&=&_J>%9-K0RE3+/WE
MFFS|\$).XH06<"5!Y3F'C7 X57@^FH"3%Y\<-PY4S)\$J# W%:'9 2U%#O!H9? ML.T\|?
ITN5P!;MOR? _^/'S\ _O\ _/'SN\5T\? &*FBXB@-O9,8>^0X\5\|MRO0!*)
|L_|WV2%N\YS0RXCXVY#RNC%RAG\&.) WC=*,).DVH 46>SHRKF\|
MGS"2@\$+E;NL<|;4.(3(|P\|Y2%8*FEO=W>4#K V))Q\9;S%Q9#.
MSZF"UDM)+^"S,B6X\ A9*165!%#,UZY(WKID,!WBLW+OPB\;DKEVC-49KKV96K
M8T+4==%1,\0CA?)N)2SB^H@ _=>%LQ^1\GG&@8+H:Q/L.C*XW\J84'GH)KK8 MTQZ:
\$|XUX%&;\UL00P?9,2Y^<;/8I9EASYDA61F\$^>?&>-<;DFRCOU#"JU1 MN6T&\|^&
NLB\VL,-Z>^)Z'HZ%3LH%&|:3SGST=O5CA%^/A9V-63X4QD\$.W,IZ3)\$?XFV^H\|
PRE4AEU@\$H9 _"=(%1C&&9T>Q\$^\$!NE"-) MG#3"2%8(|MBL(|%%\$GZT:~B%9\|E

W2(7R4_3YL-LRKE.AQ*(I:&89_7PT MCAA.L0@.B.Y!!4D2
E3YH!POJA|^&M6C*F9,NQ_YKCUS'_8Z?YIS%W#.CZ!X M:>5:S-MQ/-
J0M2,,2H.JM7FPI5MOD\$'G2<^>TUSU55:*34(/% 2K2.CM)+)+ M*V"0)/7WJ!G,
<5Q^%#J;ZTY1+?HSSXV5JTV'FQ(9:/5(6F_KSG0RFZU!|@?MA9*UR @:>
(M/.THM!@[UJS)JX\$D_2.>'1G M!XA/!P!MH7#O_@5NZO!.'(\$Y4I70@3_2>LG\$2530
5DIT8INLG59KN/3&/ M>)GHJ=|K_ =IJ3T4'>\$|8I1/MCW0=(Z2GO_>|2_'6#;E|
P#\$4KHAD=7|B4'C MX3\5 %.9F|0MLK':YA+E=YQ,M3^B_"F^1
&P\$4&T_ =|M':#IUT4DE8HV|B, M@^T,@*O==M!%<*6A1JX/NT1@O62>OS>>2|P!C= _3,
JL*<64LAXD4 <,0"!LR.' M "^(& 0PCQQZ)!|P\$ = 'TC^R_DA35L#D(&&TIP!Y2E|3^*Y(*D?
XSL-%JKE M 5|X&%Z2EOZ5>;O,.,=;=D33_E:=DY>T8NJGL9Q9>0;I@.)LB078"%GITA0
M?T^29+5SPP!6:I):+PK-2>6G_ |BN0,3=*C'X"3:DH=8!+;-AW|8D7>"M MG@^M/(^.&
V5 M\$R3IR&X!7IGW^R/,1=GS!V<|)Q!|=)A)*6AD&!^9AP=|#+QE /ZIE*, "8 M|
CB!56T:?) +XK\$|<#|S=D%*T9\$IZ9)N#4=&1%Z\$D850_P(Z(TB|_ UZA M>,99,.(D|
@SMR7A&L*9)#QK2|V5T@?JJ0J|%%!H!|O9|<3OHGQH|M83\$-7Y
MIQ;WANC'R5N[4J|]/#0W_S|0G=+|#!3\$|_G85!4!?\$ (3EY(|&X)O(5"B&R3 MSR-1WGW>-
'O_I3C|5JD||<?8G|>B)*ZJTR'@','G)W\$|,0C'E:/+1/SXJC%Q_T
M!|=)YC;XC4L040>PE7WRX243;*|IPHJ/R#!29V2Y>Z MMCEQ+-6)\$J;
(X7>2'7U|>T6N85D>&V_L=N|!#S%':<->F:| -TIZZ0VX<>/X M"&N-
:CF(/6+A1LXSLV=3'AZ2WD#8#H(!/@?^EGEQ.ICH':JF4>-)Z_?=Z&_6 MA!WUO#?
AC1);PGZVXE28M:&M,G<85;L|)_HFIROU;M;/W(V\$+!|@:5>6X3R MW1A?^41BD.+6K?
41>2|P,^4^Y|X|!SOXH2 M6@5JB,9RGY^A8C*Z(:/T8DF;X1_K_M/WK\$D ?UY^YF\$X-
<.^/C>W@|L.&> M|Q)/-O2D,(|N7)X-PSLOM"12#4|H"VE7|(+(|>@?
Z00|Q;I%|DH>G/60LY+ MQ0:@MPYR8+-P\$1W=(#WR5-8MV?*G00A_2&|CQH#YH1.S?
@3\$?+|<=1^D"NM8 M 14"AS&5<|!A|@&ID/?C ME#(G7Q53)P^\$J=P?
^<&EE+|!DO4I\$#S/9|P/W>('23+ ZK#4;J1OBO\$HU|@S M7&02+*M*2IX,;|6#?
J_AKBGC.U:E:#+QS>C9Q-D+8<4\$%B-2IR;)7,5NR-Q\$
M% ^00Q1<'RHL\$D7E|!#FOP+1"A374Y&"5,8R;NJ3S'8^4BU ?\$ _Q#7XP#DE|2E
MC>F^,DG3AB\$E%X2VR?&8%M:D#TZ%&&@Q67P^:6).)F:CDZL|N6XV%F_;VQ_ M1.N-
AKG-T"GTT7.N@)Y|6)(U*|NKP0OLH!|>_ |Z0-|<#K\$\$\$ N_ |9@T_ M?WKWP>%-
XS'N=ZMV1XW0_V&##FU14H%Q5'UK_3&7.7@GYDFHGECEZL(E,W,KV
MX8=+M688|:GDN.+M.WD'SFT4!&|<|GKD=2*/Z::CLW=;F/D1GH^9A(PF20)
M(88+1@BDMQFFPUB|1I=B V O5TH3BTX8E Q_)FNM^M|5RQ9".WNC5.OKO3'
M|Q_.+QOK6I7;F^JU'C6%KV#>&J):RQ?9 K|J'IC2-
Y@0E@|S#_V@X4|O.GZ6*RFCU^=B8WJ|G7V6HV7?:KF.^0D K/EC=.;H
!2'Q7:1_6TT7CH@A.-5CH,P?5HZ-VZP1@@S|,9QLU_ MW+G1NDB#!^PIU(B|,FK\$7(A;8
BD?)2:T(|=E^S"&V B, +_CQ|<.-?20J# MR*GHU).-I8!"^GEX6S|
Q|5|!ICI!V|XO4P5|B7WB|^< 02|G3MFA_ MB
M#SP|H"&I)>6|JHE#8:_H9>X*MMI#;K# #9/%H\$MUF_UPJMH!YO"40 M)(A0!|:-
G*XXJ|:|&R3+RSOJ66COD#@AM@M"X'PHC0Z3J:A+@HI@+OKEH>OV
M0L+^L0/PT;J&4\$9XVDB8,)\$@CFE|!#\$?O^IB7X4+=!#(PSS\$=&'VM2;SV\$ _C
M8%G\$OA%_NTME|*7X_@2!DFU"3_-A"!QUF(XZ3N?YZ*%@%^5@="P(SQR.5PX8
MO!+8D*|<,6@9O"I*.3CNW_8J%!(3|(8|YR#0|08)=^Q6XNPZBYB%+-
GT;_F!#^(|%VO1=8T/Y\$I&6MT/EP|K MK#G3N=8+|I7AHDN^ ^2\$=R#*.
"4E11=7)\$ _N7|^|=UK+ #FF8ZN7Y?U8Y(X7M9 M_ QAWM*.R%"WEV\$Y^L<4"<?<
C9DI%W|RZPT|4GX?*UWLI:*TZ\$!#5PYKE|/C M/ "8#HDM>JXHS0YV%^:Q*!@C7H?
15|:B0*?Q@&2/C2'3T%GY7IW72QF-XZ M|G_ <2;+Y72U|/M9I+1?
13%=WZ|GWF7*KM8&PXTXLQNK1UNX5\$<9LQ@C7OP-M0\C%UNK!X&T,8BAM-
=Y"\$CK6T!#H4E&(-L|6<|S:89AZ@|6EM!Y|P1(BPH<8 M6D|O61AXP??"HTPKJ4P7-
)|DK,AL<0TMR#GS+UVQ5W2A@4>|D N0"/"Q!W!N_ "4?XMH?T MA+OX >P-PKA(H?
|)Z9K!F6_+T1P1HA|!P%_4J.#|G6EB1ZT+-^Y4DH,-46VWIG^N(OA)21TQ\$1YP
M,TBU";^NDV.UB.*|Z9Z=S9V%A/&1P_V?*CYHAG1-+@2"*&2??Z9I:GL+^E
M;/ERM@:|G;YXMB#>(#W.PB2-,|:0I#L2 |X|G|?*'S!J2Q9,3Y#TF=(^=PV M|W
|^YH1X2A4.\$@&@|67NUZ2HK\$Q(3F8PGK_E,9O<=7*&9J^|(X@'R!XC!|Z
MIP@7%"PZDG'JHMT5)LSCL &&' MM^?P!JT?>Z =|C"&W2|&7|:&X73\$K,W>;?+2-
RYUV 1D|L=I&JS3\$S#8*OV M3'\$1K |X"V1P!@-7'8C,(|:4I)%A3)).Q4:DM3?(UC7<P_I9?
RC"&C:WU\$ M% (7@1|!YX;_9/|_'65MYOTYHD-'|1'%?|7/\$?T9!|L8|0B49Z=?V&RPZ-T"
M8IC_G*7!M!S?7P@+N +,G|C;DIZ#I+*,=|<6HY9J_TE*X<;!F\$Z#WT!K)# M(ON#?
SWS'M_Z#)1QYB^?B?X?-.^ ^?&;^+5I%(5\$|>29HC3JZB&S?9(;RY1|SK MXY<\$?

\$NZCS53A@):0#D8Q\$8K8G?2SS F1PP*9O(G&!>]6W_GC!2T9M.4%#H6C
MPKS&5W#O&ZHT,O#*" (YF:X<5>^Y8/&Q!!NBPATXGW9ZXM6 M2:7)P03?IN@LA?
H6(IA(N7I')#_95(=LN.EBT!GH:1C:NP-5PIS+D]M M78@KV.2;&'>@##AWLY7-
00D:"LYRJY^GBYX!;)6;#G+DD50" DMY\$ " G/R\$M
M(CT43%31C?.3Z.AW\$&G%EDRY)/+>!L)\$!9'^X%+2WS#-A6V,%;:@#(8<2C<
MA4\DW3D3Q'G@&YG#:3FV:M\;]5P=C&SLBI 3'+)KD;JD)2J?1H7]8O1NP##Y'
M#*M<,&%, -QL"L@5YC%)_39CCZ8*P?)VKZ!JJ5XEW%|7 00LAE\XGVYB0#K#& M% ^0
46N<:HO%Q:NFX'&5@",0AAO::F\$ UN#|6;<8M
M'5,H|V)Q'!H3UD5N@5DVS"-8I&#K?;|GK(#:0@9-6UGM_2:0"U\$+SV^FWSW MQP?
8^X1'QZS<[POZKXLO]Z:(R*\$(@.&GP+1%3\004Q>TY,2HF!' J^X#NA
MINCL:"*E|W.CO7Y<\$-"I@,I3@D#F95HB7R+V4A7Y\$!+P>:<*" .95S_ "7PTI# M+2KF@:;
QG(JW!P!=!B@3\$5P|B)DXH;7/QVW%ZS%W='@59W,9"1_W,4>:J^ M #F+902J"]<^N-
WC&'(^Y8F'=\$'VGCS7D02;C74H?S3.[@L,OV,K%*|<9N MY|:EAFI>"6E1:?
UMT::OX!J+0"4YG@#TY>&*" (ETW|+?L|@LL%V\X4&|/KLF MKI074J5P/@Z%Q32&-
S)199Y9@\$I7MP"Y2+S6J3!O# 'DP>?MOGM9S# 'MU MKM#TNY4.6>R,/ &AN'
M.*Y0!W7E*:-Q_I&/Q5\$&,Z#*#@=_9>)Q@,"H!C=9DM)3%H.'&L1>W_LOQ!:@
M7IRXS^U2|C%/ _OW\$K|Z#7CNW? _%C4<\$@6ZK%I&G3#Q4O,9;J)H:>X.K((4'=-:O
MJJPGBLM&W%E8]FEQL >X &@?;.W?(J\$E+Z4SUK77?#%K0GDW/_H2)O0P^1N?
M>.W;^|I-2:0%J:DMG|094,K=@:;*6 =
MY4:KGE%4.B.0|RO6'EP"O,7<8MFOT:8S0@HVQYIUZ?/K/R4F=4|_17W,C?X
MYJ<|AEM.Y;.=?UA%3 O5Z@| 7I!A?8IXZLTA;H.>B5/7CU&(ID/1V8!H<6TP M&
(K:16SIB@6(JBZ4MZ5 "W>'.@?(8T%YOA=&S;^| _W| #WEL_%^=_ CT_NK|
M>_O_7EX0Q?S5^?"G/UI|4 _OK_|TYT^X:3_|Z>/5IS_ ^Y>K|IP^BN(3I%?V M^8|?
KZ#*7_|R'_S?|_|>7JSW_X@R@>Y=I:.">_)6MT*G+^|.'* 68=Z|\$_ M_G %8,P'YOH0|:5E" ^
WOL"Y#9PK#1|5D.TVFJ!S1XL" RD_%N!|2A6&E*9 M.N:,%?6LAFEC,F|Y*(6)+
0"#JN)%@\$33\$DY Z!H^LO%\$H)HCH=|*0!8-^ |HX^A5";M'XI?D9L)+#S;\$-#%H2?
J'TL65\$G2K M6"/?++V%8PFTDKSY7AE1.N1#E+C!YSC*#G0?!AF|+|KDT?
KPBVZBR4T9=VGK MI_J(*Q|)G)C)H|
P2\$X<@R..HC<,%31.*A@#@#W| (HP|8R4!5<|<%F?.ES.G
M3T)>T8XHVTXVXHO0>P"MO#;:O?&!YI;UYN #\@I@.|MI_ *1U"+^|)Z^\$ZEIT MY4!6
M&9@|V-X)?9|SP4M##9?@_ \/??W!F0O-SS^>R)F!LTAREZ0,T7Y;>7!
MH?/FEF?./B#@'97|;<_3.P05_"B< CB&IGMW/=|,+99I_MBCOJW0H\$29E87 M;CI(,%E'-
6GR'DC=|2|,W %Z|,P5X(O/J "QGNACL(J@#8E&CK2!8'C 2:-5Z)Y
UH&&!@O::SWX@ML>V?@A82CE M\$CP&FAX|05Q^)^T1)IH^KI3-YO'5NYH^KV>-G^F_G
M?C:YGMW/5K|TOGL4J)|^\$006/B=DBG8IQ1LUX4VNS;YX\$E,N.-/6:"6&H4-Z
352&Y|6RI=%=^|RZM<:70Q+ MCFQ-Y/D;GR\$7H;0SD"@M@1IHUK|(+%FF=U2ET-
+3+&7\$9A6=[WSR8N\$D3HH MN UK*I^3V'=_B|/*3^_) '%S()*MC
!-6O@K0==_3|S;.)Z!\$5^I0<@+4U.% % M7!=Z>I=&|W+=#7?
31%X;TH_PL/H<_YW^4Z1=!:YE2(RA|N>E@ |8H/P-TJ(P
MVL/2(A|D@ "06>MWE20(B&;YL"M&Q@-M!(| "DWV^KS?_W(IN?|Z\$^|U"Y(0 M-UZ#;?
667OU!A(\$<(G63|A./L|X8T,|YQ;EV)LZ|H|69Y<|HGGOTD|NWA./4<%+30KNW_!
M7@4P+P.=|TB|*N^A#%AJ3;A31,>D1|^LLB(>0RV#A)/UG21,^1?H5BO"/=R M:\$X^
J8F\$*.|YY*Z8F\$R|(:|MDf2+V,LH|^CAF#@G;6;K"&264V M?|;Y2DY&B;|Q&>"K9);+/?
KKL;M7PT5%=TS|<60|Q^"(H6|?1.|>^EO0Y0A MJ6C+\$FS2|6"Z!|I-MH8#RQMW|M8=T?
R@&40| (=3@9W*|.%B;)=D"|S0@AQ
MT@JWLQ"U+/"F71_YQRY!WWB3CNS047J|PHR,O,286"!|SDJ#+2'FX,?)6LON MT3>5I)8-
^;7P@46A?A:\$D:(91S%O6<:ZINR5L+X@\$FK^IX'E3OX-IU|_GDU
MO74F7Z>+R>>I|_CEX7JZ<.9WSGQQ.WN<+'YQEC|/%M.E,_ ^R6JXFC_3'S|UM M!9&G5
I-)8&R!\$85Y6#:(3V75.:T,2K\$QQACPL\$P>5P!T6%T85P^>* ' #QS MY1QVQX3*"/7=7NH
U)G0\$C!;>RJ;!|AIE3E01SP)T<,*\$J<;91Y#'?
M'H"Y|>\$_2,4G19""1&IAYZ#RZ0<_8QP.N!S^BHD>XF'=FIDJ538H31 M?
ATF<0ZA=|AZ4DOPY)J)8'NRA*U6A%;K=58F|W|;KEZCI?|H"G?8WTD<#6T?
M!_O@WYRE0X=|Q?+O#@| \$@9%HC(6N-<;",6>N= O"4)R/?_SS^ ^:FPQ\$LA V-
M6,%E0|Q6_VZDX9J.F<4| C|Z3<+U;N_&O|8"82DTR_A"#0&>< MD(|O;8&_5-R%R\$H?I+
!|CTB|Y@N00>EB8_@DADF|:VAA4+RW+|2#/*D=T
MY2AC8@BP8E@.|>@5B1P(YB%5*C"UO!C@)<'.@00'GYU8Q^8.\$CZ<6D6#'2Z MR-
N_XO'9K N(0!:=|)J+PGA"^&GGUPJUX!A%&|HWA30 M/(-+B-
(R@'T))%BID)UX'KJ"M&:=,%T\Q_/D1070&OGE?;MK'GG>7ROXV48

M=0|B(4LOU7',L22|5%|P/I,F4|PU+I&U_.5^|T-5= 83PIPY8A 6-&I
MBKLE7=UIAV| "H(6U+|ALM4|@M'.W'_H|_AU*|%/|1AQ% R2=|QJ|H%|=D9U
M,Q=-6S>%UT|T=-400'.?5&M-7Y+*8?)=*9 VX_-6&+6I V O%4U'B:33XS+| M.HI-
V:K%FJUDM1 MBGF+Q4Q;X.3.FGU#%%%7R\$ "9*(L(W08CV|E422U+):Q+|2N(|2?
Z|Y&R;#. 'K MA+*8"Y %HR/T^ _|G"P%|CS_
MZ,6+|O|:A^@1(LC&LA)W7Q3N5|+M=07XO2!964Z|H,61W|}\$^T>G4L
M0*5#% _LUBH,A4G2M"?\$PD1#@CT, L'"&^!)Z))ZA>A^ E4-/Y)5M!\$/E=X M_7
'S#:/OO@8@T7'N&3IOG*E=V=58|SSYY.-A>X?S|_J|!P|!I\K)K8H.O@:A M#4G3V 9ER*
U88.^BF+@#H|_M|X2!3,S=\$5G"MA\#|)("/H&6Z/(>/W8"!_Z"S6K#S(/4?,\$"/J",|D_XS|X?
P4>2 JP' M?<1?J-3E71^_))!7|8X^VN\$:#/F0\$89-03NG: !_1 1T15<6S|H87ZKOW-D
MAT|>XX>T?U/0% A:++|V:F|GW|_:G>+^8-S-WN84,V%PFM>S!O%E#&>|%5GI4=Z:|JV>
MP67JOJEY#I_)U@|_#S\$5NP4QR=M7*H2!_ZR<2,QJ"T \N3Z*R:>D:R|)/:5Y
MN'83V8\$:7_(6R2QIN\|AMW?@SL|1Y+WZ08 0/YHA%_0"L42+ M1JX0_=
|&A7G2@SN)Z#GO|UX1L|PP67F,H1S(#SE,^N2U?IZ2+|HU0:)'X,2L7=?+9GBB850N^"
M\$>5A"&KIUV|PG_0.3#P?'0Y;,:?+8*K=-0.2QVO!@/'S'I*G|/%SGW)!T@'D+> MIKK4/:TB|
PIB08*K>N!KM&3\$N5@7T|8+Y|JMBF,M:Y4"PH:932,*G<%/|Z*(M=58,*J05,.2)P9X-
B'76\$?G:"//Y1D?Z4#0R>)/=*7&BKRY)#OFL"0H>Z*3NE MJJ"S-I\$V>-HBN&N8SD_
|7>9KDBVGF<#>,(4JBN74^2^18JT#ID ?O: G9?5 MMYV_WCU&=UF<|DB,A9)O?A!
SHZ0"K@)W! MF<>Q.CA8YS%R^!'9X<2! /=|L"0?YL3KU?A&7T"83N?
L9N'2:@".DUPD^/0 M_3>D@Q|ZQR9W#^>1_6AN^!:=C-
@Y%/WE/(COY/@L)!-1F#>>BX90=HE@G|@ M&*TZ29E-!@\$,T@BP\$0<(|^E^\$HJ:0F7!?
Z255OW8'Z_ M8UXO+&OF%W!|F3|-%Y/5:/ZX'\$Q9,0L/69K< U33'|H%:2A>;ZS1*P>;=?XP
MG(V|_ZJ*6>*1C&\$SD)><,A8\$%\$CBXXK\$^T0142JPS157(-D7*^%_:V^=^ (6
MIR#8Y03'DF"&|)SV2#_#S2#TIHE=N&_B0|3NE@YT\$ZS5-S+RH#!H|H#B,'%<
MW=%2\$E:T-/7N)B%3W"T(?3W7?N"S8.0=,+JSJA&H,P72=+,AX!A*"5=+F:M.
<617#EL+&"0UBB==#JGJX\$|'H:?'N|+|E=,RH"KG%+29|_R8ORP+=DI(LB#) M@?
|D@WM#7XC?LF-(=)9W|2A|_#X0 SG:/)%0H!&:| R0#T: + #FY31^@.%(G9#
M47""F+=!1<\$90Y!R8\$U:Z|P|16U7#B>7S\$'^7|'|@|OU/D;H D3*P3^?:=,IM1)E('GD1!
<%==%\$.KXSFG,WH4L+|_S08I8NC|HNBZITG"K2!D&T"B1-P/&3+SQ
MM=0RQK5S:Y%CBY0:<#SY2R4W*ZT9<0538C 1,- M.PE!QSNE?A#G)\$UXXBL Y;X8:)
(V(_!#9%MK>W JP|2L.>1,VR0+ Y|<&ZY M|_#?|2,!5WCT&Q\$7U?AO7&EHC(%
XBJ08"R/2,-,YX4*Q*|IV>,NE-17# M0+YT3IUZF|H"WFEG+N0PN22ZIZVHVK|
|M4T'EA2Z^0FI-OE=|=|WPY|: ^41<3NB>!*O"S2Z|5H,CYY8FR|QA"514Y
MI_8+N35@1.U|+|^&TF2*+PI*V=5 NI+ MCDJ\$|)&D.Z0Z|.K740>K509>1Q
NO+GU8|).HSB9TWL|0E1)C%0*,JP"2O6 M""P|MT|86|:NG4JEK|BT:=M?R9<|
|7)"0:/YVD=|2C(D@_9SV#W)%Y?7KX
M=31WVH\$54|83BFB%P|12|M4&_ ^1.V1X894OHTZT#SGS<3SZ+,.|9#T5?V| M?|B)O.
(>K"|HOV9B:C=D#BE#S+_Q(RSM:?'O|\$:L(%V;J|9GS*WFJ_7^F;\$H<-T\$7-B4
M%=@#1YLC2_4,I?Q>(2<-P|7L+@QR|_U&(6Q^"J=4@JS\$27C5O"C10<=? NY1C.
M9K:DMLKX.^#:S3SW^|4?T7\$F,)J\$2O.>%GQ+PRYNB-K*FL%(2(IVY/K>X|\$ M_ Y2D?
&W30-'P5!)TFOLI_J&O%^H#|C?EX:S%\$VIW3YS!9 NODBO>;5E|S MJH(5I\$WWAR
Z\$K)D.7W_Z0&E|B#S,'@*NK9738RIHQ4Z1>MY)ENXBT.G4Z|+K MREM!4\$4,-
FY2M=#XVTEJ%I<^?2\$W_MJEYX(9+.GXGJ+ 7L;:Z%YG";RDOA5K MI8"SR3|_INEAC|>
I(XJ9)LU9LYI6\$G\$GE!'KU@0J4<=945I!*.P\$U:9 O3M8; M702?
T.&D40QW0%G45CY9L0Y"Q.&6+H,E3,|\$-*EH!9%.:QO7/M!P,' M0@WHC7OP4X;MR|
(E+U;#G-_5^%PO'1U@L5'L;KZ920#D"3>M^5^AI6\$-4LCQR|*XX#S%|G)21="2W:
<^*"6%>;6C\$ M_4|C:3H\$&J1+5NVJG|>")417.0=T\$@SD91|SR1F4AS:BAJ!1ET(ZW=9,=4
M|S?52:"125MG2:T<64K2,5;?|Y9Q>CE>|1|9EPS8V\$K2)%J|AB6^=+0%+,O MYD1!
(XNC-0@_"7A;:F. 46|>7=*L&2M6KY*QXOI(Q?7U;N_&O|:PS+5UK"!;
M>+IR>R>|B(AQAH,UZ;B5I'"#QV87!1|=:0S'Z3%*24.!KG'ET66%E9|&J|WV M_!??
R|J*+X6QD!6KM" O),R('_NRY6UB|2T|OAL|"-)P?R0?*8/4LH<8#^| M?_|
>0ESR'R#.E:L(%J%_7_,=/D5"E@QY%JK27TP0X.*5I (6V>^P6L,7'. M%Y)2AMF>?+J6%
<3ECLDWE(\$%C1O|_#US3+W3|(5A =;^.:TV|5DQ(<#AQ#/ M_RV?*YV%G(>B-
PB8B!,2O^B%M0;5K"#OB3(83\$> 5BZ(X|)ZK-4>YCI@W(?
M!U9(F\$|0%5+K;7!Y:U9,AEE!|B4AFRRX|S?ZV,D&|:P@4.Y*-NFU+("H/A/
M/NJX|NALKUZC;S|PRDNZS4B*%B'#D|^@SNBNH"RT|@:EF8 RE.3|WTCAF!D+
M6;&YJ@%OH) 3MQW34W"-2@.R"UA_15MO\$O:L6("3H2ZA%|1G%>(?:DFFR@F
MDF):A^5:|&<:O8Z|G|ZLF,BV\$3"4H@U|T+V\$/KVX8;0L6??=C'Z'<)_ Q^8\$^

M25&HO>!KBFEQ^N6S/U/5HYKU+*BL\$C
M5TL\\$:UZZ.N&T\#?'.=T:&BJE'+)9ZN9@5YX'H0,4L:LZ,DB0CVJO\$4-0*M,G(K2S=.I
W,.1UV9,<470I2J*@JV9X]&Z"DOJ.\H#R C\<[V']JF^TU?J
MS+ZMF.A+X,OK\LT6S5DQ'5*_9\8KE8I8,6QQC\^29!W\IP@E!.C(A@#=#+(U\G M@)\/?
BA7\$FWSV="2:REH@8W^G%T3H\B\VT3J@H\N%*T(\:OKT&DNJ&!\%NI6@
MY\$(PF+JBXZ^:6J86A=90)'QU^(F=OWMS\A5S\,MHO#AUK 0^F)6K,+IA+!,DR
#0\$A"SWWL1C%J9=WXB)XNX H#HTH"#U",J MS*>JE^[\&=>Y@R&C_-9L6?#7DK^
OU1PG4X%RNHMBN\4V\,GRENQ>2M^(?7A MGC7%K2">4KHG*_NZV*1&U0;?
_O!6S198V:BQZ_3SQ/N?UWW=)F+6\%:)V(\ MT;\:,7EQA_!41D M-
YA94S6+S31)_3TX^PECY M19:K*XES:D\TGCR*Y3XWNRBN_
B.NNM9_I0\O.M8&0G4\$D!4EY\TZ,BT MO?
%7^R&+W6\Q:L@VM+'R03LK"JFQ7H6KXNB\DJ+D"";0JG>,*)\5>M)5\Z
M/'0<+WWU&FF_-6\%#"B(\:RH:*,A4?W0KB)7DBLTZ\6/EHQZX943_08
M>0PE@EZ\$7&>MYXS_7&E6\;5LV(HI@D'%9>NFR\<+?|AMX\$C:M:P6A4S<_.MZ3T"?
F9B2?RUCBIM02M(T.D.\\$HTX\#7E1_5GY>W8NE)!F\$VM74W9\0FZB
M@'I"G\DO1)&EF,?#9).2&-BN^>\:CY,4\G_-Z82%\$8.<"T7%2WHA>%SF_5F
MLHT)*>>ZZ;\W:\f>Y5)'5(\:TJ3?Z"WK+|UY/PC_#,RI_494?4EV9\;Y@D>P
M>J6C.JY%69R'K=.=M8W=_6DP@Y.5K=B\$BD@%K#E7EZV\I#2M7'?_ \$W>QB/TE_
UQ%GO?HKW=18'H@S47' M)^!\#;\:J"%X>K%E=C@\$1_GFF,3\K6LV(K\08HN\JF
M1GD>76Q0Y7)HT985\JL@H)XFGI_UZ>BS?8,*:KJ(_EJ/MG^ZUOBK7(1QS(4,
M@#"L+&-=820621A&3"ZZO?QYY\|P3QQIE!6#1Q#2NA005-8.
M0EJ&I2E)>9@YME,+KZD3*Z\:/6>-|W'8E&)#^--^6:KCS7^U8GYS>17>W1%6_L
MSGWB>3&|G*-X#,H*,%T9*U;IXMN5J7\|R?_9*5D\EYKB4W.\S;3P%E6ZMN\|P=
M(QO=Q4_XC(+["@,4H)E4'F-J"5NPSA;\Y=|8VL#U"&%GZ&6F?0G/\:(*LG5(
M\""1SS="MZ^5VT_6&AUGZ2\(\J)<%\$R\:/4E:L3#\$:YH\.-=U0U!(R<@3I M\$G"T-
GC40."9C5A\>GX^(->W&|?'311C:F(=C>;25A\C=&4V6,+KREM\|D.X.
MD\9+_EPGMQG+!|!%E>B/-F6U807@N4S2\$KM(6MH*4YDQX+<3TV:U80;QD_1_0
M=XWAMD0000:|)&OJ64\$@URD84ISJHAIK43\$O;FU\7D:F TNX/SPPT;FNO<+5
MG"A0Q^KF."|/\:CR\0;'?10S\':8L=_T0V.OYJ+@'Q0@*IJ8"J1V^~^IK_!V!"GT(
MA^!OQV.4THLV+67 M5Y@G#\$BNCX4U2NJ!GLSX90-U;<4T:RX!
<9CK4=I/5K."0%7L>D3_4\$ _6:\$9+ M/!5_5&2W_OI!\$*2 N&Y#<;&NB1<|6
Q51PJ09U^)=BTZ15YB^T,?!7 M;FXS\;@_.W:NO%#,V0R;I'XY5=LJ8A/T_Z.=
|7.>R>KC4^>Z-@P\;\#O;\:/%R0@TNY9;XR8.K&8RG#8RL,T"6-6+&N M9\|_
&26C<|NP@G\ZVR;D7QEPW2\G@M,1:T@0TBE'3D/MFAN_).\V5-F(XFR
M>\$W'&V\)>|/%AX@-TQ06<;*%0:M,CU(DO'39TM1?Q@+6T%*_NSKC4'3\Q<MR1)Z\|
J9RB_0LM#24;\JH?QMW<.6T-Y<19C\N 33/MX\$NK&6,>*7:&@6LU"
MCFOUX,\:DA3>T@K"E81A|M\+|%Q'9C%WLF*:=QI7U9,9\2';U68-Z(UP-"
MP+F=6Z)=^AH%&158XN.=|U)3;J9*A4:_OX1\HJZG"*U!4>???HJAO\|F\|K<
M;7G6"Q^M.)&L%0ED+9Y&N_+6\|C;ICJ\8YX8+"M<)A:BNNK6\$%630\H8K2<
M08\J5MD*4@UCJP>A\UEI_'OO@=|/\#B\!%|E1Q(IQ\XJ7V4N\|<:H=<^FUE%
M\|VWVHZBM,\|J\F_)90FB*.)\W%!\M+)&#>J,3\B#^QTR*:LVP8ON<""?
2\;035:P@2\78R:1B MS66Y,ZJ/?V%#+T(\#_J\;#/\ M%5;FDD;&)UW):.P&O>1&R9/L4_'Z"
<|A\XL=NLZCS0K)H5=X\$F7\Q9:V'5)3\$X6:0; 3RG9@N'9*TNZE\4P_GEK
M\|FOBA/4K\H5FY8N0<;L"IA_M6*PQ?0,7^DC#V<%9YTD*>!C0.C,\M*6&3C M-
*0%\AX\|31GQ70\Q5)&H\|Z: +@!\;!\%R<;-@G0>7\,WFM\&WJ(\ M4,UP_,8J2GUT%09NQ
_Y>R=|BH3,TRWXT_O(J(LVFI'M_!9'2L_*5X,J*L M224K3C3HSU#\$0
X@W^*U""(G*XV_:KGC%FH8P'NKJCFMEAE_X%J@.GD""+W/6\!/@J)Q.\BY#:#1
0<6ZEW\B=W\ MB5YIVDM/XY<:W?|*PN6H@M\|3P?+N1\|JU;\:D*5NR+2@IMH\|I?5\|
*\$BA3 M?;\W.Q^2Q.A6,_D:>/%3U:P@KZG;AGR=N_!J31FQ51<|Z#7DT.%K3WSI4,0
M%OJ\JK(FC\4P6C\&Z/MM3'1RPE%12?HJX%*R5^%|^=33.6#BR:\XS%8,?&%
MQ\,^:02_OQK?=QTU;<4T@4Z(2I'Y7C"ANF@+6D""DFP9N&45;*4."/E\$|?'9
MI&6VW\OQ<;ZAXO'2WX;\^QE^|8?H8A9!=AU4 &V\!=K@X^NQ,XHU3F=1\T3
M*W:%2>O2\$/7BC.J6D&M,&Z,GSUC<%G)\$W\|C3\2I&0,JQO+CGV1#^+,&0\8
MTHI5J4\$>9,\L@9N<2&EQ9A-6D-TVUD39BPMZK=RQ_,V=LL:U/8U_'0@'\!+4
M(_@6.TH1\7=(C.O\$|4EY-VG4ZJW;M&-
WR?")',E::&XJOG'G1&.9!MD|=R5KG6NZ5>M6'!5C#)+0 MNIV'G"UK64&_<%_13U-
:T@,N=|>(\W7H\(\3-S\O7ZA F*OPV\$T MCN\$WJ6<%@6!Y"@*R3C,W M\$-
>06>|L+FT%,7J%+N:Z49-PUV*BG\?/\$^& M*.

=<9,H#4&8AY*Z./0@>!14\$Z_)P2WY%)W*03Q@WZ.'ES-17S34NG-DULWM=35FME-
EK3@H3Y#H M0T).5K*"- (O?26#H):+KQ2R8NCI)5|XBED7#\$Y2F.0/O.QK^0!K!F?
%4H\$7 M"OP_\$/=" +VTTB00A'CXPW!;E!Z6DJOYOTZ 54W+M!L#X+W>\$I("C@=O#H DV
ME;4#\$JL\ZL(*^9:20*+I^N!I+O(4U+B-,C76%?3"B+UGHMX26#:16YRH6./M@A?
F^P>1.4*>;ZP\$:-[D^*S+%YYAXX9].APB/#"-6H633;J2QNR8F=T|(#(-
CA74C5_"Z!F@\$1F@Q"%#MU1%\$E^JA(
MRNG+YB=X=1K%FZ|HL&/BS.,JS|!\$C>14'2L(NU@8E=9)!.96==LH:'8J^)[H
MZVU/Y\$F!FDTQ66-K7(XR5//D:5K&"K%H<-&.KU)'6 MH-
KX7.X|O68@=E_X#AAD2GTQ*U:'&8DD|L4IQ6A-<2O(X9KHDO|91(VY|/A; M"!|'3L
(5K9:LVI6K!6|L3'FM YU :8?5)<0<:/E8/KKS8K)U,6> MH5P*.13\-.!&,WV3>N.?
W(KCS+|@Z7'OG'C^+AAT84)7J*5|WM.Y?%)>+>=N MQ|3@JZ@-/00AL4FE\4DK 4P*H@*
1P7"A2I<+0J|#6N:<69+.*?FG&*J6L M&+
I(VL|I^|J*|&ZH8@590WDSC.E)8<5\$Y)7Q3BT\NS7%OK^;^|NA-Z =BA-4G/N4E0*
|T4Z0IO':<7! MHRX/<.YN_0WEL>F|O5..!>3#?/*4& XSTU,VJP-^X*%
MV^:J:9C)HGTG=NR9WEXI#H X%KM9Z=Z*Z=8I,E#4I|<-H#CY&Q_\$X?IL?
FH|4NRA(77-H+RDA)M#|LUL8G^C-
B|!2OY&@)@>R3448)C0+>0D(N*OZ^)Q3>WQB^58#HYHI
M(T.YA:67S<4*Y8+\$#L@00ID7?K1CP4(HN|#&Q(GBI.!(K%L&4ZZ48
MO4UO5;1_@+'KIBAFQ# M?|5BY M2P)Z Z,4W U_YZC,I"!U?(<'S
M+)&-9/*S6QO->XM0WTD0"&<:/Y|9"W:K2@8UA:W8_+F'/@-2S9&E4%F+8=B5
MERPY%;S2IDG|MKV2 C5*? 9 K(>86Y #/<"KZ#H"%X\STZN>V|85^X?RY<#*
MK"50P19L3W6P%.;R5A#\$7/^ QY#X0F9JC(6M(4#+EFRT-L,0DH83|G"!_0<
MK);7/;|9*|CG#!%ZW@#\$\$%+V @W/A#>HK6D%B6QQU2I(OX65|T/B:N|!%B^K1|M-
+,7@=,|,AJBX@4\$D\0R1UD\$-ML@GCNN L|IHWN_Q#V0IC&_G.&/%K@ACR: M(Z:|
|7HG5#;B.XG79E3H"UNS8C**SF,E|94(2@;38|T4G-N&'83GB9|.#V2E
MD!5#UX2|UT(|UI6W@B VPZ!&X=+F8Y2"5%52()Q4.#1M87PH S%B#X0&Q1*
M6A5,#|V|/A_"",>LN? 7|!%D6O H50*6+&M*|H53:JQ@ZE* @ 73_ ^5N<\$D
M#.G_@M|7#0(4%."<6?-%+Z5'7A6|?&)I7)LM@'|#_@ (W+1FT":BUJQZ1AZ M
Q|F6Y*L8Q|YV/LZ|+<35>P@'|^8^*U4|^*92UM!#/?>37)WB5K70VW9T2_E MVVC-?/-
I#^7|6/UFQ8SG/F9E\$ XPV!QM*Q0JX:L6%L9(S_?(&>|BP*/DG,Z%J!1Q='O1!%1
MW%\$9U@T\$0,HZ2TRL1Z7@^.|J36SUT71!.Y9GKLS,|GQKK3YZ|9&DX*PT S5M
MF|CK|GVGSNC7B@EN&!HND!A::3;JF|""|!%HD"OV1M16L("G/4LUCW^DR@...
M7/64VP)E3&-SZJ5M63\$1:E!1SM-H-0C:DE8088@7DT>K|D0VKFP%J6WOVB*N
MG1'CL8=NQN,8-G\A|5E?%"K*:.17G.#RM M_9,K35DQ#=>9C^!|*?5S%G|/J(8Y>3ODV-
:IH!8DJEA(:FA%PUYN7L'0KR+O% M&_SZB-5O(!K/K*#HJR|K)M*87=9X|=77L((H|#B, M|
|%R74 M4*N1:5#<"G*6&3TI_|J XW_A%H^:7&"FPN.S"Y(Q-*69*Q>P8_8U&895!@TU
M6B(TB=Y|C+'+,>LNRV%|>0|63-IUEM C!B| ^V<_Y"C\$* WA?O#|HASB J& M?
|. #/V!ET\$9?#M#M^,<(7I+>/_A;Z9L'X7/XP^WAT! G>*P
M*"!UIZML,PHKCF(QV7*|IY:2CN)4 \$NK-JV8F/PJ#8+H%58O81G?%0=*R#:
MMPEDMUG--W#T13'3S8"-6F&I56#5DR)2+">IR>CNW: ^N?/|L.HS1T)^W\Q3O2?
MS%QXE^V?X\DM?'2,0:D%L_)NLTBDWQR|6EK5C|,WR7N;=LK2*_17-63\$=Y M4'6*/E-
9*PC)!2D!70/10P(-7MQ4"=|3QEP.;M P'T=_O=DQF=DSE7U\SY" ML
/WW#|Q1;,"5I""N!C)#I&9/.)='|D_"#"4K 6|J77;?WS6|&""^#S1++PT M-^!D%,7^?^-U9-
9MGZXU_K/\$0Jc404KMLPF647J_HK.;&7^,*N+UO&F>J*W*UI77P|T'27QG000P/6)H1@2
3G_HTI+;4\$KUN5BKR1=M_ I1\$-'(|(V9AMYM*>#&6,B* M-6H6.5+_*
W.O6KXMKV9@@@|F1^XNH9L#H=_ALO8EY"LI)FI(D9>D92_#H|26MN*ST"CKF4)^!"YQ
M 4AQ(E""Z6(A-B|J)R.&5\$|I8NRI66??0>/CGT|A6@28QI/>&G6%K5CU"9U5 M#P"GZ3|
V0IF*B4>,Z7N#UG*A=RI&T-VKH1R7GC5FCF63AJV8XH:9G:9;%(2
M4^9KM8NC;+N|HX2C^J7T7*^ ^3ZE)6Y<0| ^Z@;ZG'(+0N60 MQ\$^)^T%4C:|I@|BXH8)
!|GOL<_!;G9#|47|U8Q|V##PF&'M\%T11|>9I4LF* M/2-?
QI.)&@Q%K2##?)!K'9!/UK*".#GQDRS=12""UKEZF\$M;00RX>U,A^BETPD2V/^ ^P8?+;?
N_\$1'Z%C_7/#-E*|I|V3KWQG|YK M|H:~574CU:L1?'-5Z#)YYL*
Z!;DW/J6T&PJ4PQ*WF+TIM,U:03|J3&OMK2.\$'+/N7\$;\$!" MEU_,T8FU%
<.:#"1RB%ER7W=|(B#I.^PL)_Q^%C^6L_C5;2D*Y5LC@|^Z.^S M?1'O=OX<^ Q&,D?
\$Q?JXTL@1)!5=WYCCL&\$!#HQ?FF^\$ QJ+=-),D:&D%0=# M9D: +!9F+U%-
_2N&GSON&_F#"N-T,MTWY^!H?CB1J088Q\$|J5M#|6W\|T&P M-;7Y2.I+6C';
E6%VU_T#|X4_|B=C.#_ZG?(+_|8I;^0="&CH|3F^+XZLV(|
MF|G6)PWP4"|KR>:+ "X8(BF<*VNVAQU8I(X96QT|L-/WY|IM M|.

!+HFHJ23NV>!XXU^0H@VIB+7WSQ6%E-EXXQDV#<3ON;/S70Y#FY=X%|PV\$
M,MQ';KAZC580/N;2ZJX|+_WOE8;FD\$2MV43&L0!R2VP_DSKH1!4I
MR.*)8\ZPH^H,O[%)4+: "_A2NGO+5-"*E6GKME&%JKVQJA?5E+%B#V&JX5I'DF*)\6<[?
S!>29H M?UZ3312S0&2 &KZ+8@0UJ6+(F>/H>VA^_D21N+VD"&GZ2NYX*&AO\Y0[=E
MDSI"?7DK3J&2_E+16)_O\%|2I*+.GGF9.7QUXXI!M"G\B60FI/+RD=,2-|
M[=P4D=F!)4T6!,"SY1E7T73\ZZ':BL@_CS4Y3K^O,644!&FHM)G*CARG-R:28M<[751
MXE4|Q%#@C&7!1!%RR3(L@*_009328,;+:E[5BCOB*8[6A'@8N@PC%#<(/9%
M00!!WN!P9-(LMFC&"O*+L=NZ^'6Z72\$F8(T[74?ZF4V,O[D?W##;0-PVXIW!MPB6)
(1>;N>CH;\$JNRY6H9#<@P)+X%"1<)E7D_Z<5=&*#:H(?DP7*L\$%\2?
M\$S)C754KR!2(!\$IX(?Y)%|B= MVX 5JZF U5>2[*CVBH;I>UHT9\5TF-
TBCW7Y@1M4LX(!&D%%C\$F.|HE2E 8 M@/1V42G#@O|_TQ'#.SD/E5#PV
<5E@J^:TS=#"_)71=U@S7F_X=\$!|)0&^E..79B(P;6K?<7;4JNBAZ
M3[9NP,\$M2YH9S6K%F5:T@4RISFF:QJ*TP_F52 MSG\S*V>0TNB33|2P8IWN(,;-
*7)"40\$DY.W;#\$CO*_>F=2,YLO K2V_HT M%:-
@AW3GCTGY%\9V%1>M%'0M05'EXVYRT5UV)6/ELRV M\$2[#"1THHX5A)U")M;,>4R?
J6\$&8(5N/I+9I(E1&8YAXQE"X<JNP@G"0+1(0
M+@+@5+Z@P2O=;YB<[%I8(\$",Z2D|6LH*T6DV#5B"KJS ^-S1\2"T^@SK'VW\$&
M8L6N6F8*K#!5G<#\"|.I"Z+76;B)XCUC(^JP|YM5M8+,8@;)41*1?;\$|#YLQ
MJW@:5!O_(%7TR'HfVM=L_>95QR<31R1- NQ.HV_2JQM Z\$^%M/KB5FS*,N|L
M+4#6&@)(I46M(-G%FZ_V?X01R_\$@\$G""5I(T,Q/,UX M4+IR5LRWE"P?
I0S5"Y6D'&QFAG_YRN|YYF.61NEU67[5DR8SJ_Q_>XG*:%5YQNF3H"P!_J#
MEN<_JX'1S:C,1'KG!R2^ 92E*"ZH3PU%K%@I:Z\$P'!%ZUA6OCS6K""*:*!
MON|M/UG)"M) 9:NXEI32""O!:(Q/*4ZK,N+&AJ?(<:,\$2UWF*"./,>9&Q|7 MKI?
21S1_Q#HYS8M*85ZRRXM%7\$W0H?W/A7@KF;\E73;N,F%<=?1Z,R3H,% M;I+
6C5DQ2K3DQ6)H3'C\$S*.KH ;@!"AR#=J*F?%VJCA M5O2M4P*.\$P/U3'>/%S_H0+//EJ
KDPL_HE@_O=UF1HZ|<"**3,^H0WB_906 MM8+06H>>+Z"4=R)-T.800F;&X7-
63%%.AEFN;2S_A/4-4!K;EQZ8RZXQ.J M29A)H X=(L+&L7\$WX;RZZU/*\#%
I+O!APKIK5H;?S(-)(5>+U|HJ3AU_1"6
MZ)0ZJ4\$=*|ZDOJ42|AOP/R9,HJ9*XR_5J=8=0251"1\$|,Q@*H(U"?EPF-FV-ML:??
FTE80D|.Y71Y0W0!|O67C5DQ5V0NAEEDU%K:"E&*Z,1\$.71; 3I>VY-; M|DFA=BJ.'I-
=JR137_Y:8M:L28%.\$6L;5M%=(S|*%1=;3%=R7L\I80&Y/ MZO-XUF^/_;L??
W_EX*P@,7@9(M/,PF|1##|Y&ABD4Q7&)ZG(/>+E)KSF#^Z: MGO=E|OQ/LDY%8(&
I9LD<;I@FY28*O>H5VFW+%AVS2C('62/?AM/OU,N+HKI M/G?CXXGCU&DW5DS?
\$)B*+ #:Q4_ ^=LWNW8K(508+QU9.,OMFQ*0%43?'Q/>RT MJ7?TX\$QU9:U8%Z.)|S"M"-
EEP|V^T GZ#:E:0QP6#FGR>:@\$KAER&GJ.S*Q0H MD+^JHWNCHHKB-Z)(0UQ? 2G
Z/INN,NK)BVJGUL MLD8#?\$?)=)U>T@HC|*Q",0,L5:5 MKRUH!0D|Y912E*1-(7GM&-
'HYHC;:(VR*)\$Q ?0<\$*|UX*#@?|:;S(ZJ^+; MV'>GL)=K47?;:
I+NNK=BNE4D.8"4*;K8ZV:HOH851-WYD(#:=X-<@V/B#_U%
MK2"C;:=MX,=XHLKX&KN++W&FO\J7"4\$Q5SLWE)#KE+V9; %P)BW:Y=3H CR=
M"^BSHO&S9F3C+Y*1611Y5K1*|3.KCD^FR51(I0.,1EWYP",4#8>-I8UUC8Q/
MNGZS\572ZV8;IC:-L8G'^GP%(^,P?1&76M>#|RX8@A,(DEXC9!S&"-B_BI
M7&FU^4C;M3C^ZM|GWG^_6A5F2T'M,Q=!&|=L940AGMS+^85'!
MIR_VG9^\$^_3782W O,2",D8"Z1/%7*J@A7; ^'/FHO,Y2310SKH=6UO!"I(* M?
ACU;ACZ=*Z&%ZY=HZ-.S?KH_=?-D;X|"<_P|;.:1027H;NOR>U0F0Y|4<_M_Y0*00H?#?
2T6)+XQ5_G![%R3D|7L6);KV(,OF1@FZ M-1'#61|^R:M6-|RV\$'1=E5OK&U:UPY"F2H
F!W00H\$YKD:T.)>V@I@;:*Z| M+ 7|DZ(6;1!&WZ;J\4^W(?B2,O<>|Q.DQ-
Q'S|I@8*U)Z7M^(U;LA5.A1RJH
M,8=|:)!LM'VKX^^+IRAEH;:YZRP+M(JNB385^ZD*XY/4-'L&NAJ O\>PA>|@D5"4P^-
:=J64%<-6|&+=*|ML;05Q CP>|:TC|S5-
00XX9;%52IV0W5MLWOKS'_.)#&Y#|Q&|F0RJ:FTI M*U;UK :?
3K;EDU9,0TR|,BL4B^4L&/0#&" (0X(8>W8P#.A444K2#1G'IT(M0N#&@/M-
C#;!#6L:060|<. %8?FG"=>D|H9";.C(GBE\DW9'_JZ0/=HP^1YV|XMT%
|K;Z+N:R5MP+LYG+UWC6;Z M&N.O#CY;E-\$!
I2SF:&27L4D"J2JNQ1H5Y(>;P\$T2NH=.Y2X|66GT6(\$<#YX9 M/54J=-^M6(NRA-
0C;Y!-2O(-|U#R5<@3V?#?0F*/R@E&;J3Y2NYO#O|OD;N M&F*Y&1|NTGP,-
P(K)HW|YZ%.DK,CD%'R)DM2*J/\$=7JBAE6M(+/L|E|'EZFL M%81H9QJD1(C8-*<3:;%#-
"O(JLB\82OAO7#8L<.FA)_3L>O\$)S!':%ZJ'?L9G M/W31Z OB!L <
1I=A0\$Y56%\DE##QR#8?'KW/M_-F;@I 9WE1&U>:)"'^=JC#^63T)X?P:%0"<\$=+Y

M4CAH9A[X20HU8YU6SU#8 MBJW*?+KW,+):P8-+T@(+2?
HY\B,!)\$LJ1Z!_SFN)6D"/#N10))01AGMOWCOY2X?|,Q:S8>&5<9E"-L9=(8?
_#|;IBE:0"+D2 MF)2*JE[*?
R>^QF>M07\$KR"EZ;QEC|C7%K!C^.>'U#5C!&FM|/SU9,8FJ*EM5 M=NM?
0WU9*PBIB4^G*Y#M,|2BJ4|J6I7|V:U807P!5H-ET%A3MC|F"&*)\$GP2N(. *0:5
M@*&H%63,<0!L:+MO#|B3Z=THTJCR|!W\$ H-GU,;B*ODFI;_6;%FBCY(^FM M47"
(GWC_S-AM>4N2=>P?3*S"N6V,KZKZ3S>D6R9|VKGQWEV3+*7#??QJ4%;5
M%:9B#9NQ|H:RW,;/|P?5C=+N+A73|F&KEM\$M)H|R*-HYA|J&;|: ?Q+6710GBG
MPC3VGS-TQPO\$ \$V9S|?_JO_?32:*FAZ0| SR6PK>|LOW|Z&3|J>,8F97D
MYI6/5AR2(D19YVVS&Z92H8^1*HE_-L4Q=M6X M%5/51(J=I'?
\$HRL>H(|"/% "X4N%XQ/-6C\$|XAS39=4S)K6<3_-:5A |C|=N MR#6*X(I%A^B)2*>GF"3
4;#|1=*3209NU+JG==+PZ,+E?;1V@Z==%:K"@|O?
MK5A377"|@D)QVM12J6(%61/Z\$GE^D,\$5DU_&T^_P)A./FONNVK9BHA8D|5D2=I
36=\$7|(N(IHH9POEK2 \$-TPI#8+HE?*[O(AE M:2AJ!1GE!|/#T/*JFO&LWT>_4<|NP@O#
<"LIL9G%@H>|N!; MA&!OJ"0"SR.Y71.&CH-(S^;IZ*A)*W:~
:Z^QCQ47VAM6Z^")4U;5|5BK6K M,G5F/#-362L(T6IK|SAY\$&*U11"9';A!\$L-
|NS8^N)UV8,644:'7|6N;D.- MJG|!22N(6)*_KK|3\$)0K(+CH?W0Q|87%:|G-
\$BQE5:ZE)I6L6\$^1Y&05<;:6&%BEE0,:UQY_'6M\$M0IWW*C"Z|B\$2>19|YC
MP;)EO;&IW/AK(M(+)7DTA#:@KT':Z|N;&G|: #/S9@NQ1Z\$1%:=5/|,RJXY,I M88'I1@15
:J:Z/VRS\$7'C|,"#0-|0%P%@D@|"|C|'V:S70#|/J.:%8|"T|18 MX%*|>HVT'FGG-
6\$%V55=B"H_F|GU)O7&/WUR+?(L.CHV|519*U9*D>3;V=(; MI\$WOHH?
Q5U^\$'^+&9+8CZ@_Y3^A26K8W_H3H\$89,SU%-83L.Q"DH
MC<2\$|<'S24R_4XG%3T!*8=|>I?01XOM3|*_U|V;0\$5@QZ0W@?,4C(" (DW2" I
M1DKJ3<'=M#W^0:O@033%C;#H>-U D3|E @.D8+^AR^"G|)?>*F@L;@4Y8B/E M&D;
<8@:_6W/IT27@24:G-8KO_'@_*X1^5CZ,+C8|^""XU%IK;"Z(PO@TC|1H+@;V'T&BZI
MO!2%E\$5/DLP\$0&PH//|3RU/1+0CE%8QILW6%|-A8M8@4^;|JW'/:,(*LNE0
MZ37&LSNLCVA:=!%<&5@A_&?0&/\XL;&W|PH_-R"|P/(D%|_0*^/#\0%4V2> MTW.^\$?
=5;^T|JNP8@_D !#)*A*A=X#\$G|OIK"+(5T_Z^"4!|/4)# M4T2?
_5@Q@X50YHO2+T^_HSJ5I#|1.)-%.^!\$64|&#P22Z1K4< 0@IN"W|D+^=,JNV1H_3
M3T=6|(34|T0'U=&_9*?(%)%R5KH\$.J"MGQTH7806!-Y#8&*D MKU!>1N-
LU+XU*R9#>4GJ(ALJL:P8? TN0|.XPK;:L\$0;H5B#:F\$ FM6P8AWI M7+M
|>Z2UJT8E+JP+,5Q&SNL--\$-&S7XOB|EY"-%(4+BK<+L/, M-W3K(S\$57JQAO=%=-
Y9K\$KJ4|?|2)@>R|C<^|0R9-TP%QU|CD3+KGLHQ\$%XE M1)2J-M)8
1"V8.!+>FIU_6\$6,K|"OSIG5K;AL% |) M:+(LE| %DX'J1&JYVT
P9|JNJ_UHNJ|OVK9BP7*G+V"K,A\$KT*.BFLE80 HIX M|(:A_P'NY|4-
8%FD<3L77|3+VK3R^#?J&6"=>JVOWBC8==M6|_FY@(RK>6"Q M:=X|7(!Q,Z:C1_"
>B/AF6U80?CYSG |^MQVXU8'+5DQ"0:CAU: ?HR|J!1ER M
Z)E5@17WL7D7QE8K4U820VJV4\$>,|+K@S*-A:P8>B58(M|&49+"PC3V;H0
\$;OKJ|VI(IN1TK;_R SE!M,^8,+,K!)Z1/&C;T>SBK*3NFH?>X
MDBHZ_=:|J6S'133WZVG@#6D%HU?=-|,N-G>64"J,2M#YZ_W5SI#LH8<_<\$6*R
M'|S0Y>KAG4^Y63=.C|-P2W_S|@*W|A<4M^*-32|6I7GJLXIY=PVON;X
M:9+Z>^!,A%W^-|LB|;&GXC)_ =^6J|=HZ7^?PAK^G<11=|QVEXU;<5@J^W7
M)%SO|F|J|F;_50=2YRTEGLW""21*(8B5JQ'#1-V7VEB8_@G: ?C?5|_+|H6+%|@ "I-
8^|12/0|D# 'Z_P4'ZAD<5G!;\$GY3D&"7X9>5N;E;-BG44'F&Z=1+?
MK!BH.5Q10*!=\$WK1@(*MOH;2I+H5Y%:Y>=VFJKAX75#="G(5\$SIH=1H;XINE
M9|ZD22NFI9 A;|(|@V*CN2: XN/?I>(\$@CHK/LK4-4OAM,<_&\$+1SZIMQ=H)
ML\$;PM86H?PCU\$G+;E|_C|0QY5W""5"CV|#@>DGCR'-JXJU|GH5K_7#JY8TC/=
MEVO9U\$O;LF(B.L|!|/@@|7&|!\$|,FSQF#%Q)O,D44'H M7*|WT@NEO?CW!7X
#1NV8HH4YTMDGFX"-TD:>&H6"UM!RAER8|6A4;O(+ =K|_M_|JE|U^;&
<6MMJ*^1%*XDB !JS:|.V 1!XL+"P;EA+"T#RS#&Y>.PZP?|_8DTV/S>C
M4%+HT+MHL:R:"G'1PF3_T|TEC6B@=B4BUAXTQ1BVWK||#Y(A\$,5&_?OIS
MZGQ\$870|_SD' K(&4)<(KOZ+=B0!/FPHVO4:41Z5_Y3=PY_:NT)0\$FM/:#I
M";.47O|BHY44TEAQCLBD4D/O/M_M4>3B+;*@=QTX.7Q%9&/HSC"&F%2!8(L,^+FX?
ILW,\$F+EAFTTZQ=O<_!|MP@W|^%|P|LZQVVZB2=;UJ^&(F+FU_CSQE I?
|7WHW362C6+FUFXWT217|M> M;@=L2+"-R;7_/M&D2H|W
"JF)T#^8C)XQ*.3'@YLQ/35T6BWF62"|T<0H^!< M*/E|3P^WQ=MVXD3QK2>.:*.
|B|NR?"NH%R7%|4\$@3TKCB4_Y@Q|NTV-Z|<1 MU.D@4;J4:7-TFI9^#R (6%31:C3MW5;
<|CI&'|EH,O(Y(S2?=:IY#@DG3PP. MV9'3\$0&OIDQH/NF4'_P Q+>0=^X;23.N9MIN-

>D\$7/*WP*K(3%_R'S/N[/2;GH.V/[UCV63:9^#YJ."/R M\$(PM_Z0-442E5K.I MK7;H?
6/N\$65. \ZKI1%,M8UW/GWY\RY.\$8Z9XU63BJ=U_N+FWG6!#QC::RLQ8
MV&@>_ /CXZ&'FUO[H(M),BP-7\Z[03JJHL)7K6< MF*\$D%\D5O<39H.@3\$+K7J5LP'(;=%
I.8HJ=+BN_QY" +T'^Y!S^H#\PE40?6 ME\5.T='U*46Q!^+ M/??OGA+W_Z?
TY0(4.X+ !&6\+(\$3BDY%)6OTMS)6 MYZG ACC5?)YP'F\1 O*VP#FRI-
5(O/37^Q%INT^JP#Y)!>0%(5#S0J.CNNN MPN5'6W'I>
LK//YJ*QYD1V4%S= LY2E8UVB%RT^VD@S5'UNA\W=;T:\$Y?RMP
M_F\$K.#RNY@JDGVT%">?0KD"1+/K.#122&[V\$Y^2Y=^YP4-RV5?P6"L-8\,#
M*E2LE84Q,0D5)I+EX?D)??1@B_HFR;+Q?\$B'&')1(6.M=\$R)\.BPL58V\H24
M5'A8*PXS HEDJ?"R7A*! "9RI<+!>&F\\$(Z)23_L%X IL8(52A9+@<3 Y\$J?"R7
MB+\$0304VUEJ**2%6%3;6BL/\$B*X*&60%87P(606+M9(P+6RM L=:L;@=)%?!
M8:T4?;V@5T%BK0",#PPL8?G96B&8'(Q806.MY'L= %A!8JVPBP^ZK&"Q5L\|M
M!'I6>%@KV\9B3"LTK)5GKP)<*T2L%66)D;45.M;*L0*AO!56DPBY9=Z=;FJ; MT=/OY
8Y\,CM^GF\GJ\6\W>WIVLGE;/M_?;7^_O7\5DL>9^IHS(/H!#_T\$YJ=Z=-'I
M*KUUXAA5PVL5S>@LA:^OLJ5=YYUB; VE@{ }%]\\$C*U24X@1%TV"M4(@EYVP\1 M
%EA4F0%Y-\Y>G=E"Q1>DHZ+>*GNG'QR-: :ZD0^_*Z6>_*"C9.4*4M9>X"
M1U=US"&_2\@N' TFVZFKT;ZS= /F)P#T%B=-,)UJ(* M+MUF"CDJHZ6C\| #8Q.
MNBV&>9+9_90MJ55;M3BZM,--;*Z5&K MB4*N3RGZ33_&7%W5'6:4
+VAV\!/:;F#.KFOK+H.!6?'IQ\#6^?DIT\0N(-)
MHAZ\HR9L=H/2T;\W7Q/0* @M.9;'=/BJ5NA/\$M\RP#@6*G(A:9BJRDL?LJ9SI
M(M&4O@Q<2QT,(6Q;AU*S5'; F3'SC<=O4^+P0'2@?\.+G4&X+6PWKTZ'V33 ME-
H"J_"U GWJ)Q)0=UP1G7-A:I0)O&*Y.BJU=69SY,IQ//TU.\$4K7<"I3(8
MC&+@J\$K58K\0)Y&\I/_@'H0NFBC4,5/'#X%W\|2HI%;28!\W8.>|/EGA
M9'94MJBJFE1==*IF\$X3%4#HH-D1*/&H#!M2!Z7#S\$>63OG8S#>Q=3@36+=?
3FZ=Z\ZB\HGIR/)1# M(8P)PV:P<|*%T-1""5^L0AE"8V:L\$?D.H2\$G%\$5@&WY<0=--
&G86P&>&%S8 MJ %+<.(//&@=UXY?WPJPL,\$.U\#8>>2X+TGA,(L2OD\&P\=W70J'>-
B&G?A5 M28@FL0(X,:BN8U+K+,-.'\$>3XGCLP(\,;AX(@:M@(W-Y!EQB!;AQ,'-N"(=JH"
M1D,F=@M@0REMPVF(EV@DM"+(%'5"2Y#+BX:06D%Q;);/%XMJ\$5@|Y=BK,->J
MM(;1D_ER_J%QM+9A*GO+4\$-SK4!/#"^>&& K8&-?%+3(8HL@XO&9#PA?KG+0
M&UHE9?"I,2I0VHG 0ZX"#A^F7//T.Z\#X;*\$QCB\0OCX>"N(2)#IT?B5\F6
MC49/DL&#\$T_"H3S.Y\5*P*+X.^C\WC\O\XX.B;!\?,E1<4MJUZ0?%\TB)
M:6S.M78T.JRA=9Q/V,OC#UY G%<))"R-LLFBROJ';ZR\#/WW^ Q\6HJTY;
M+2:OJ":RD+*#5HMH5:#D7DFSEPX)V@2/#D\|'9;%>6AH/?19!O6XD%KK,WWV
M0:%VT2GC63\$[PBK(I?60 ?O&>//>M5.+)(#XC5\LB+R6R9X%5.T(I92)G"X
MRMEFAR;U18\|+3++"Q2\!02++\,|O\0VY#K\SVWPL#34\|B,?
7OTS6N\K97(2&8,/C9FH5A',#C_"?)(T&TU!=AC8_ MODCS4JPZ\9Y2.
(S94N8+U#H8ZYGPG\$ M\|X+DFT4D T5Q YR%Y'\$:6,!\?+Y.\$/Z 6NE\DI%.>*:P^"
H\$YNIF&@3 MK;OHZ/@A>::8M@JSM2+N6+,0!H&36JLO5_.*B"S&&312&4!"
{3\7T!1D)A@ MC6ZV46D>[-Z@57 YDP>R>R\;5A'_W1\$'.@MHMU&8P#6_Q^@V(B+R+
I_*"/N MD"L8_I'SAS=9R1U.P2%ONJ=5K\$-U1,D.MFQ^RFM#5\$|*BXF\AA"L1K^ALAC
M'R)D1^ MAY4TU\RLB/Z=4/\6L VJ3: YY:1^PW=6/*='V3(F@UC3D-\HZB=
<|9:\$<=9EOT5Q2<= MSJC&6J5H\+|E*7% MOD8;<\$*R5KB_AQV(1;DC3!?
S\^WGW4+%7OJQ@&U\$IBP F^LB/MGQ>NTHQ#) MH3%&@|4*KT\$@,2);C,:GS?
6(H3'M_!KM,!\2C\>&*>NI44VC&O1@-#H=|CD9(
MG6MJ#* @T3)C\$&37:SFW6(SS&"LKCCJ#I9G?'QZA8@1D^C+!S\$78N2RN 887^
MM&E(,K&\$N\6-QRGB:U@A(L5M,FG&)%5 BL>|XIH1(S8(J/QXA9J^8..4KKZWPF:G\I
8D?;8 MD!E>="(O"P'U\|I5+JTEO(G3\!E!-H\$3<*ZY@6=)D&M# MJZ;^U_73W?
WF^W__U\?6?^ (C MLTPXCBN=2ICT54/U68N+B:#3&(7HKL)DN>;KH^XY>'LVV-
37\+8ZE\$"CYHBZ M;J>><*!\S*PW3"(@:E_U2YM#)F_>_ '4:9:A;>9Y?
7,00CN\IAK?.R8=*.97R MZ7W4\ORBTDY3\$LE+/E5!&B-7)*&
D\^VM#M!;"!U^>ZV3\$+D&Y#\$N'H>|G= M7\|=|+0Z1C(VECJ0PI6*
|T'@5=8BZC82&DO/B>8" Y2'BQU/3EB4&WJ(XOL/ M\$+M^ LHK9)V+|LDZ?
HVV\$,1D=_|BA_XQ.T^E+W&/12:Q/HM\ (NGO^V/&*D)?P2)X<*U"B4YE:M\I
(HS\QTVP\N,J5XF*P 2DM*K0SJ
M5KP\$X\N1^%Q>4E\XS2\!S'3JD76>:U%=+*PU\WRDNF>1Y%'E?@|J9L.F_?
M\@9JTF2RIF>FY)"(2/I,"B(Y*O3<;Q5\ 8Y/-FM^=!=L#9%4E.;P)-^;Z0@
MK,NW1DFJ6D!&:49OK&;|<-/@UQS+HTZ%\M\EB>=8\.=VM?WUX6G\^W9>C 9N
M/I(+@#M0_!Q&@#J2,QYUS99 JC*)PU/ KI^25P0E3!!|VM>7Y9\$@GR M#Z".1+/3*

<@)S@DJ@GL,=U%|+(07!K5RJE;(YHN3U"0:1=N5P!:IJ/72(X,,JGE %W M!Z"@!?
HY)X+ #D#.DD*OF4Z= 175|UN8\Q1|G<;TP:2..ZENB*..!X4IRL| M\19 ?1>W/WQ|-%
(J<-6&|3|W"H&>025LK<+@);(=BA@Y^:&@!|=2/(H#*L'<^D6C9>')N-['DM'??|AY
MH;0-I:|W0Y0%>|)R\$|A4N:Q7G%*60OR\$|PCC'CFBG;|HLIZMYA|WJ*+RN_
M\$""KOL3UY?'.U=M:|NNG=)1,M1@O#4H9OMY!)H5303@|S9.1C<&7|-2|OS< MB E9#
|(\$F!%O+)Z>:L,?2F-D76N('+|0::F<)ZQW=^ MO?|?"OSDT.17#TA
M\$A^|GT9BW|IU\$6.&NOT9N7F1#=#!UXPOX#1LQMOC(=C":*J6W| #92Q0Y_|XX
M\1|@K_!RB7|A|?MA^TK7JJ&*<2X|QT|1N^|1%1&=+|PJ36@|^E55^ M)G0<5D\$0?4?
&EZ0@!A" _X|X#1E.BSL+S?.+DR(*..?)8(BNWYFS"*D#UD M)
(5I2D\UFZ>0(|.Y1E6!%C9 B@EXDUJVCY|\$94C MCH| #5NS*G#A,L*7*;U8
*4FP%0D7M0+707)M)RC5"L"FDK\$8B2O-!GF85#51 M)*15.R%;)FL% \$M-
8FNZ%":R\$W9E!QXF6U&9BA5 #L.M^ /IK0!S.AL,(|S? M"K0E"0J|WQA8|!"=A'S99@;#
<&XKRPLH2WBI;%^9|UF57=9TIKJUO
M/XV#JH8IW\$>*|6_1).*JKZ,0\$;H% _EG"482I7V!5|T2:V|90H|Y8X%L0*| M<2*.N-YR1C?
H|>08Q.,+CTK!&>O 00G.X/^ ^C|S^|9*Q|A MPW|HFW^@GJJR?
D6WT+P\$,4#UAZW_%5@<*@Y:=N'4(:-QCJ5HL
MKBPBYP_<#>2P3%!!LT& WR%WW;21(@4Y'Q(4S8?234%Q@T ME*9+?
44&5PGK+,910\B:&M%+^3V.J/<0./N>)-T91-7RROG U:8T.!1&IO5
MR_ZDEI0QE./A1E*UT\$V\$GB!>)BFT-G)G|?OV>O!C#R5L.-^>_B|'N<9/X3Z
ML;U\$1,*)9!W7YRI|B5QSL4SHJJ%7|A9A#P#BE%!=|M'LG5T@3GVL4'U7_?
M^_(E|F'500"U7|)|@O,JCV0&WCK>0"THVVH#|CZ2HL*4 M_T!
(^YZ.D'!17'J)RW>|)Q.^(>=*YT(B/K8QK)AY>-E<%CAGU_4%B<<8-
M.\$5Q^AKE(|H6_=Z>+66U('6,61.'<'^-\$.:IT #N|44JQ01F8H)!VBK,)9"OJ!E|C&?
|VN(|#4WW,,A;
MM0N34ODU^Y;ZEE1;D*=BWS(A#U9MC%3J%W!EC/&04EN0YT'|MN|..+J_B&|F
MC.=;)|L_|R.X'.VM*|>_#X8B5L<=@C-@,|OJ8
M77&7RG/QMP4H)B>NL/H"JP40*I\$7IEOEP>2=R!Q8S|?U"4C'U3E;YS\$3U#)
MH,N7U4GG?:H:K^.|\$Y;U^5#2UBCP08(60Z^YJO6N?/:M!'4JA*O'X^7%+'=L M906?
JVUN|#U^OTDQF,&TN.)ME3BP*4,%H%VNMJ1ZMG-CL>G?B|WFW|?9C|_M<,*T3
J(!\$.X#VZCS/@|,WU_!GL@|)!&4^@|@>+ #W!VUN/LL|>KE2>,\$Q>C M#W%#7\$"IYA
&&?#*E!1Y?: YG5?|&B";AG|X18D3?(ZCL0ZQ**C*#09|?G4 M91OP|
|_L-.O.#OY6#V|0DQA:U8D& VPT|^A(!OP#B D5?SL!&K2S+|V,V:" M64ZK!#.=B?
#V5L8|&|-D,0GN|GHP|^-,.=FY 7*IL/>RO0YIV/=F#C*L%D6 M2T|/E|3/C),M,("RP|V8XV-
8SO*2Y?|JOJ%W""^+4|#FJ>9@8--1|J@GV>UY&LIXW+8\$R|WD@|E%|QG4GQ7-
/\$+GH<1X|-Z=ZM M9!!L.HPO<83"G,|H J.24\$Y(Z)C7X20N@W%\$V?V4'53BU/@/KM
0>AQD|HWL ME)D0@,KHX|V|9E,GW*.XX4(5R)|@1|YW/PCF=::K6:.'7ITU<5_%8F,H._<
MTV2=>L%|]#CWO3:YR0-\$H3:."W0N^3SM_LSL;<6<&<>ZTTC9N7U"SZ! N|P!
M4|UE=-+C7.*WH7GP6&NWZ: 1JUF615=G=@;+9235.IR =2|I/92=3IX:H_S7
M:|_1|C/'%O:/-R|H;/TU+\$G4+Z:H'| M'*6 7UCE|Z_)><1N3BO|FA|1ZT|E#52|48L.I&O.|
(6937K77,5&Q"@Q(NW M49(F^3K?T#I?RLK""9 P95&:3--
^ ^,YKPY8K0'C:H'EY!#*)V(|6%HV|1K
M4.EVYRU" |KYWH"Q;"RE?!FER3#U7N+LRWD":)+|<(#*"VC/?=U;,%S>G4MZ: 8/1Q;:CO
M8%_DET0IWOQP/Z_CV)T|XRP2FZO3LSLS\$M"P.7KJ<2Q9F|32LGGP,/H7LF|
M*""CH4>\$WFW^C',/?VKXP>9U9 D+AL8@E|F4N6#"8*SWTCCT|^K3|/E%.Z* P%AV?H!
<#_13; #9PDJ8L= MK+Q_9<4KP4:"(6(XN. P2HV?UYD2^+:0KZ_D5)Y%H.FO(/>HGCK!{
^5|X^ MRN#_BI+>WR>I?W12T,W;2FBD|H0|R0'=3? _R! T#H%\$ 4M|QYVKKP;/L?F6
M0VZO_OUG(W'.8PAOANQX@9JP'+Z^ZE_2|6|.MKE^+XSX%L3=779&
|%KY0KU)*I\$2>L="FU|_M^!5|RVSIF\$7P;G MB1OA2|KFW>%#1'
098M%.2Q0L/\$Z/8"XBD&&.BN_5_1;)2@1ULC7=P2>A-#D M)U+N;B/-
M&&X\$IXNLZ|Z<2.*=3&;|X|B&<4>R\$"9QPF<\$M_S\$042;ZCZ=2 MZW4|VJ<|?L%/_KB-
@>>GZ%|DI9?80S+U?0;1/G9.!!AM:@OQWMQ<_13RY@0X
ML8M4B3O(88/H5!40"Q,ZL^+IJ= I\$|L#A|H|!" 4E)%_LO*,?Y@6VD".|>M/\$
M=Y)Z#J9N|=B NG65P/DQ/S)PXDCCZL:LO?492|Y'F56H(S54: ^T|Q.\$"8(3%
M|S1D1N|NVH3@|ZV+U4L;SZO(90'U5:=?(RK*SW@NB|Y\$D-F|U(^+8F_HM#|' MX:EH=
/YXLYG&\$0&#"B|G!*"4#> TOD+>E2>=NXB"U&NC#@* MX3|=T# U|1&E|#!'ZN
K%D|J#37203>0%G YBX"ZHOSQPYBF-OC/|+),T>+TX6N@%Q6BM^ ^XQG!1*D1| MTY?JO
MT_'|R2YW>!35!=WT-W;)UR'#|UW NJ@A?D\$S-V**.B,0|U+ MBHA8
M1\$5M(5X4D<\$!&C66BU(R+.2C!G)1.CCB2VJT%O6B1_!*"C=ZB8?""R-2@+0J& M:

A.#=VB8\$B)YJGQ7#0,@2D*EKPURXWJ'K>:,O?7=B;T15WQA=4M0
%DAA2=)=BQ^)WA8I'QD M3CK"<&%L>0F R69P\$=Q5^6&+F1&A
@58H8NKPEN#:2/I%KEP<'1!S' M\$)275PI7<
+2J9=W#%=XBLKFRX,&"@>0(%/IPQ":79Y_/).5JM\2M!P3YE MI/?G.,I./\$6A1\$:1:/J4/'K
>21A)"\UKN"+31D*W@8?G>2^|T.N"F29=%9 MB3TDPB*)#/:= GC "AK?QZ#PVK#-HU-
^7@/;0'M/ZZ<>!HHHB:VD/ISY30U MACPD"FIE.5.XG"UFS2T5,Y%-
L)47#&WZQ1'V'(7H|>'MPY^:D3Y)%B
M<'9H1GD/-/JPE#G&= 2XYWHRKEK/G91G6&&V&; C2IE,%1:@P<=E%(XUAHTH
MT\$!2| 0|8)YZ)4T;T"PEQ JXP;F!G !(J_5U0Y6))T|9-/IREY4| R7XX*O MK|RE)7':6!;AZ;(D^
/R)7B9FZ|C+8C??1>L/OSN+A";J9@HXA'E')*[Z.CX MW=
(*|+8J.WNC*7T!QS<0\$|BCW49AA>ORM.5TR3J212,=G.O8VSA=Z^3M+5EX
M_~*\$V0Z."QF|5VXZ)-5-=':|"(PE\$>YN>L@*9,|>21|/%PTJ-%GU9/!CAQ6!-
MMN!#9OV=G""-1FLT.'2.W2&=#GE9_8S@|=!2)#N8&HT7|RGCO|ZLT(G)!X|V
M\$TX'C7K%|9)7;98J:F/Z=^"M"K9*SUO@9G%NVF,6N>8>0&EM#S_<-Z84>K?%
MHYWR3X5-DZ7>BH|C_Y6""X""OKL!3N#_!WB?X<=1T-8Z_.+?\$X 4T>!E@EPO-M%08-
J4&ELN2V3&X+O)MS=0UF3O#%2=&00W&9+P8-J0?#%C_/W61!|@>?%
M:+%A&*IRCJP5.(G/%\$>\$A|'CK/-L(S87+S=:I4\$K_/MSO%\$UY,GEX:'
MB&BD'AH\$ _M33*W*XI8+/?1C=|3B_)N&#UA@/@6/3L24^<9KC,28NAG&8V?WT
M*U38>|.X\$|;L|J0ZL#THVG=8J_ Z+(H@>"W&*TIUGEEU&|O/P6SB=6YV@H7 A%
ML@&1%U>|1|6#N7\$0,5XNZ4,L5GBS.!&51HPVA8.@|J>OL!/R8LWORD#SYM;W-M"
(TUN"AJ^ 5>2EYWT6 AI6SFHU="5|3%OSC.8?3@3W0:.)#R&PV!B!3/O-Q8O M41G-
N"^@55G844Q&E8E|CKR|FTV>P;V)S35@>|VY(0^OFS_%#+(4>(+<3VPT M#9:_"E/?
0Y/SWQ10?;K2|EU)=WT"VH^L#^G!#%DG_!;!8G-MBFNE'Y+RZ-
;HJZ>C,^!+|SQ!IKE@^<&(SB>@N@,0/D\!+|O2.5UZP=|;K0/ M44PG)&\$ _@NT2=A3Y>-
|3^6;|I&64;O R|S)%9C|-'?5OC>Q9/!F3!|@RZ/|" F M*LF
4IB|P@|@WL7CVVAP30\$'I9F<|>7""XC7|2-A8&U|V0|X"R4ER=?Q=?0
MAT<\$|:=4A\$2_H@XN/(N-8R?<%WF);L|X-'^70Q|Z*/KEV3D";'Z&43|EV?7P
MZA^+SV,V.)|%0GZLS|U7|ALH\$.?E24.W|1%AJ!#).?+.3"B-&.%XB-'E+'V
MH35="&K"TI\$|/\$%0|PCW%W2L>#6F^ ^MT': 91&G"TI,=%0UP.A.|%O-0*/|" M|@?
#>>2((GH=UL O^%:U)1;4AZ,N++I7!2FF %^|;BN/#|/;-Z^@*/^<@| M-
+"HH).0A8CV49|I.=4R'K2LCBQH/1\$?<;18PV>0%C- 7N|;_|E>I/V|J/2
MSP|1G%/A=0T3D;A#*5_0@_SN2MX")XQ+?2T<9B0RFKKE5\F,+R4MJE_YE|Y
MNFJPKT7"0<->SN&ACJ;-&Y M!C)G=VZ/86X90L#?G,L_"D0E"
(VFOQ%G;2;|3B^&F|%/>!O%!D'BQOZI<&/? M9(D?@>2)-
'EBL/7N|F|=;FC|G1W('7|0"\$W2(#|PSYZ_L'_.(XNDH&^L%Q|P?YEZRK9=1!E?F.A#M?
1PW8_BV40YRW"&4A>=-|P*<M^7.\$" ?|Y|SX'.2-?
E5"E./2*NE#4D!C'^|GL'>"XA!C(C%Q+30|5#?G_%>,
M<%+^_LJ6N(IW#A2A<|Y_"TDA"GRON#U"KWF9K'J:ME>-VL'Y2SZ|@SWJ/WIR_M
_,@7)|@DJ1"N7'1=|FPZA5!6%Y-:61>ZF;|882E%S3|ATB849#V;&/?C3&'\$& M-
I\$VISYI=#@'Q0!8B0AMT7:&7(K.R M'^Y?H-KI^B"Y7-?\$"C'*8RRDE@%B^; X.NI7V^AK
G99|.30* X<9D^YRTKB MM+\$D^--
E.:BF^P8==&Q<1/>ODT|KBQ_ZQ^Q(G%CH|,CAO'.M_ ^F'VW>G!EA
M!3PH|5L6FAHU#HFGIP:!/1Z=LQP'49W90N|R:|\$@H(S0Z_ZY^/Q%\$?OA?"! M/>!B?
=5E?KNZQ!F!*Y0.|LO>BB)- (Z5TW+ICALM'-%(\$DCD##2K!U0=(WP
M5Q@9#4,/(<9R03&Q#W+4"0%\$)F0O%)OA6H"B@/C4!Y)3>K8"0+>|C@T!89&L%
M>&*""Q4=QFA7-T04.:M!1D,QY(KHB"E6X"1X"7"KMF. |P|BMV@F\ U5CG@U M:=#/
(T81|9|^9^R'GLE;_1SI@*O-<2'NJRW2*B5EG%U>\$K8NZ;K"8TMZ
MUL*ULBM.UGK2(CB\$?)LV#6N"Z9K;1?;3(2Z |*K)|7N9I:A8OI'D;.
MSIHNCNIEY.JZN*JN#|UM%.;C9DZP|OZ5)2G9CLYN+WMN68RNVPL;R=|PH=Q'
M4#V6TB>0:-#;HL_6)\$&B|6);-ZB)YAAL ME9J0@E"
|@>PKK2Q^<@N%)C|5IBZ1|O(O8R|S4R9|V'83HT@G.('>DN>|3@|@_MYN)YA);;"UC??
E*L% T1?9N&2#HN8UAP3WD!J6WJQ*D.VF5?^;:I8O**CE88 MQ,7D:'X8K?(-
|KEDQ&G7"O!\$E)T:1KJT;C1N4NX208W":+?\$D#NEWV88#>>@ MT61M<8F(0
_7Q/SDM:P^B/9/,QNB;#%#:8;S^~|Z"XL/_D-RM'|0:| M@S_#90ZZBD@?0S?(./-|A)@
>_&"1"DVP, Z>+"EKF"Q86M@PN|2=|/Z N(M Y*=UL3F6BV ZIRF=%#MDH:BA
O|=T01U+=3Q.:J%Z#4ISX|3SN21TKMH5&^ MC+H51#YJEX(RF?
18#:V;^;+38KAE^JH(=X;1T/%>F2RHK)*L;_G)ESD>W, ML#0,JU^<>
(001#6<_8XN0WA:\$.;C1I71#|JT"LWG#85|XPUS*SRB(:;N(UN M8F0ERXUEK|%=H+?

A_^^\0,XUAX?N"HXQ*39<4JWQSK>@OC==TGIR[#-5\$P4 MZ2?
E'!/A\ 2VZFP"5WDU'7PJ3;JM0W 4R8?A-
_3D\$#)>OY[[Z'XI#PM(QOIW:JO_OIH7"=PW548.&Y#Z<R<@/'IV=@:'\23/
:;/H#D#REUM^7++QJL_*'\$P4+;_>M-:0FBC5'VJ\$H34#.>Z;+
<:HS&Z@34["WQ/1]>JX;\$2.%7@J:-=>*(6O M 143(VS\$@
\$5FY2_:B8ZMM5NLEDWFIJG[DK_]L0>(_=2NXTZ.1R5VKUQ\$G0I M'\$\@3\$IGI
<7C<7.^M"F?G>1SORP@I+@,<*!;LS[*Z_DFB00^9,#YOW5;BUY M7J_ ^L8 EUW06)
I+3BME<*WY:749G 99YZ3,6R!N *N>Y:8G?U\ OZ)'<59?
MU:I1\$1_CGAM^G:H&Y@W8P3:OS@==;>(:0?;6P+|F*!TFG,,E7.->-1=%5^RQ
M9CMF'W7W@<_XM1/(->X_T"*.R|Y-YO7>X-9^X7*7.QG%3^
M^++EV0P=W/7N_M(:OV&&8K[25(G"/)+ "X5PHY/^&SSX 'M-B V@KRA 09[I M|-
\$MF&_!HXB@, @GE %5[6=91#C<;!\$^WTG"JLGME2JA TY1G")+ .<.:!UD
MITD\$.S\LC15E[5HD\U7J8?W3_X1WJ)A:6CXNH7NL*=18FC*JL\^AKB+TJJ M'B"5M?
Y>+(*PN0,&G&;S2P,,YRY!^0,1Z+T3AZ3HP%&^HOM!W\$9)N@%NM_I
M_US=3&))HJGFXFYL_O;F# &OMF-U1'9O@>WD&T^W;2N)\^KR26/NO0ZTT,CJ
MI.,@'QS6N1)W*^(J\$8::?X+"BJJL;Y2 9J/Q&1@175-= MUW)L-
&C,^.:*JH0CBXV&33P(N?DF"1OE:S1>I(#ABL8HT;I&H.;[GMY7=I)
MP#4:.'Y'.C4T7+'!QN/%C'NO\6I*!L/S%(RN<5QJ",K9P!HD*5T?->0M/ M%N.-
AHPWB'O)Z[4-. WXH5-&X%5,R@|U;%; [M90S4 HT HX>X-|B2^=V M842-
I&|"AHE4M^(+NF%QJ(UOJ-)(%"CX1OP^+|F1EI(LJ'@#756<+U,,#HW M4U;S?43"N-
AHED@VH\TC(9BJ K=4(^,ODE,!)^)_1V,T:%)N0_H;'Z/QDW4A M#GE?
9'2)'K'\N\JEDMG@R,B>3#!L&XW;@*NB_?C,"I2P+|A:UK%1WHU5V/ZP
MJ%+\$N"_:.\$S6C"V=-|62Q1IGZX*X">2'3_@GZS:31,67#QEM)H\N3J3GGS#>? M%>9R#
|U&!0"&&AUP(6Q&\$ZJLPR|T,G>,HGIS1)1XW1\$UP4OED#)?EM=8OAW
MVS'\$LCU"@/B"&0?GPSV\$+X'|A^W \$1DM!VMV4/Q68BQE*E(HYBL+W:3*F3VIOE.J
MRCOWRKY;JP"||+,C%K<(!7|1^K4(AW9210|MBDJZY;+JS'@NPNV\H#88_IF7Q^E'/2Q:
|!X>8%9#=#;|HM MV 4VMYK#QI=|=L\$J'@\$3I+ VQ5E(&26)1(?1ZLE_-8D?Z/'S+0J.
(A6BQW MHK_)|=+=#E4?LEU+N8P@%1/,R%EPAX^GU38-
DG:^^:1)X*>0B"H>-2052W+*M?5K;U(E3';3(O(CUYNT_.Q;!'!?'F@HQN(U.\$|#|
|)K\$8_+!WM\%ZD8ROP M&WYV,01K!7(C'-ZFLB/UZ>00!88AV"-
KI^XH#CJ_9,7*8D2'2X08Q\ZA8CO*,R R;<|2WX6|K\$58^UP=6Y<5 M;/SDCYOS#0C=
X3A#TH=7F8WE0:>SLRJ>5'+|[#*|Z;,@|!I; "V-'NJ6D>?A
MN9H:M3@UO<_\$Q>Y)E2;*1.;33D)9HK^QES);27;G?_'':&T\$Y*+ +<;*"/0 M,G?
28|B+XF/%KML1(QWRI/70AUU_)> MQ\$7BN;Y5XJSDMU/I;XT|JE2KR)B1Y?7'_%R1)Q
<;N;\$V5@,NS:|C,& H M5|9XZU@J60LUNNIC-&1+E3YY==4ZFI31R
AH950&U=)^K\$",0V^B(M;D958 M)N;XYE"%K\$"-U|:;>F5#U+FL@(Q;B^;
(#6@V4J("DL5-CH,14)Q5C.:Z<J M2)8#*X 28E#|>J31V(F=/KPUR(KD^+*
(ZRI)J9FPB=\$5CV7/BBBM7E1&53*- MADV0>U'LLD9'6HG!1#\$33Y=7>>;!5"-Y7AQ
"KL%2V35\$EFU1%;-PQ'<*W-)
M4|"R\$:K4_.NT05|^V"R>>36Q|M^G1XP0AG;YVQ),M013+<%42S 58TEZ!-#T
MC,OIH+/HUM|5\$^X8T69:&%27T!&UG@TS06/5-F^+9W9_@0N?:6%D-Q+6,@2
M%K*\$A6B,FD1?JJE C>MK-1,IECS0U@6,=CN/&H9E-F2C.: (7V*ZE4@L|2:X MGN?
G+:SDAIOS9Q#M8^=T-VJG*,^_D*&|6H+9Y,7 KNLH;J\$>F7)(K>=U.!6
M%B|J3H+XQIS<5K4ASA0+_*S+R|YF7
M>PTJ!8P\$N#_LH_<_YY# 'YP*+|H<+ #.40OGW==I;2^(.RO1\$\$(|ILT=F5WL.I M!@!-&)=?
Z/I##3('BV2JFO?%;|VH MMB?@YFGNRC^0035B ZC7|I@79"5L4JXEHU7BH=:J?A>
(T9|R23D(S>8|9#0B MO=Z 6UZ6,.\$C%4Y%_S6)\$6RP;|;M.AM+/AWU
M#N|A*4J&51+2@LYTY=7Z|!%8/P'(6NP!9BFJL,
MX85@IF=4(Q^Q|EBWWP0S|%^:7^"!7_<_|#4BH/;E&G8712MIB\|S U+|2D"XD0V_\$H3E
M\$4|KG='N|#Z"!|8T. 9*&A'7\$KEB: ^2*V9<\$|L1;0;|6JNH"=^*EW4B|4@ MK|8;,
|Q7M\$|'\$TY)7(<9O)?P^ADPB+'M:>OQ2+|N&V<_-X;HW,T|DL6|ZA
M,0#3Z#X0)CB(CJHN?: QH=-(01%#A\ZR5B/W=B@/'!QS!@^/'N5\$-
|DPC|X|U#LK6&:'|.D#X.Y1M#-!?'|AH M9X^C,COF+>;Y7&!
|@\$1WXR1(+ #^>0)B4Y!RC)"Q(X+|Y7YJ|. &?TJ|5W)_:N
MU/9N|.KP@=6%|_:=>T|[#;.)8A=X7D!XB+PJB_9D1W#S\$EY<_|4N&|H%GXXU-
MH6|%'K_<0(N9*;(4\$|*C#|B!S5X+|+|GIQ/|'1@ZOKH(PWP.|)%SS|3;+
M\$Q9A+CB/).A2+|6*_P6!7"8_J_&RCUE?Q^BEN9/@&C02|(22'(Y03T!9G(
MC2^L+O10+!VJ*D8M.33*IR3'S+_ZQ^+S#44K(3|H#77=TM%R!8E""V(7B\$

MNB;4&I.)61/MP8#/#U;HGW>#(KQGOGO_L>"#VTPBD9?NNI>ACMY)E86E&P
M4I@HC(X.7:J\$7\$.Q5_F9V/YW=:1',JW8L6^RS2HMIWG;(&\$%H'T?9@R&WVAT
MEW(46G'"^38(7M#V;>H), (M?#+T=BMH?\$SRK=AWS2I455^&JH.I
9<"U<1M19BVL;08N=C-#A3YG2!!9IU[A.4QR MJ"^~UW0?U5W#PY>JG,DGB-X0N';%:
IVZ+ MO_CA_C%\CX+W?*ZK'3SE%5F(D)/J+(\$!#PD&SA)&ZC!%4V#5 (^&OT>@!; M
"^\?I86_2^GG/*I4X*5NLQDKJ\$L+ISABP-/I'91W|HJ'I(+ #TOA%H#X^'% M1MOM90')0<
2T:\H"U0BN6I)\?0WW5ZN"B!8'M=S%9HU!+'7S! M6ZW|7JSI^7G?H3NJ(%>4M><"I?
UNEYL-'D,4'Q|I3N@"5#7NP@GJBVR>CR(A ML41'4.?YNW\$"M,3M_0"4PO1B(K@
FMR\$JAEHH_KD7Z?-55FF'O? MT>:DF(D4\QHTL!XTP9@S-A\B#W7T&E=A1O&QV0#M
>%47Y=:@L4#?H\$\$_<,% M4/C#MR>P=X)I.(?TC.&\N!833: SX(I;#7?
U9LNWK208IPIKN,W(YO_0N^=T- MH.5>IDEM+=LSX_1/C%P.4Y,I5C9%
(RH9,;S|6@R3@#LD:7I_7AG4GYCW#_ M!!RH95W6@I?
H2A|^AG*D=/EQ%G(CN1"%Q.I>!/!^9*RN9SCO8H\$1.Z|W7 MI,PL-I!57 TWAU-
195"3>0@P8\X!BK02IO?J?&#10%*FM5|3LZB+&'=-KYPCS^S,VDIR6YJ
M1<3&Q,94M\$58LZ.I5\$XR9=8!!"1CHQ74)\&Q/1D!FTJA"HVI&8 MALM+3;-?24F
IPE!|)TT|M>KK1|+@R&ENT9|1TOOH|M2EK=/RL.D:Z&UO\$^& M1TE?C:@,!I3;9+W,;.@'
5R\$CMY05SA4D_10E\$D+<<8,J_V,#914HUJ(XOSOP_M#H(H|V59\$7=49Z>ZF*8"VQ?
G8^7.'KW\$ _B;&Q""G3|TBID\KKIB9"" P^T_ MPWG\$3I!SV*,?^NA*3?UW4
FQU,T4&T/QW89.S -4MPB130 R&F0\$3=/8?M2 M) Z^1AMPBN*<8^8>.(K)-6-
+6|107H|F6PXV/61R"5_59R\X%#(.NK7ET<5|_M_%W74K45,9%U-07;8R=8|,E+L73
MBKC/F?B**JUC<%;; H7U,MM!'%J5B|1?C!*|_OL/*OX!_(LO:)+CM\$EQZ@>
MWC5CO.=+CM\$EQZ@I(0.+GUV0=\$SSR.8YY16-*@|D\|I
<3OG/GIFC)_IX/G|;^/O1WONL4>H>3""*H<_SR8>KR9_WP4U\$ M&V=4_LAJN>\$I2-
!)ADM^|\$(O.C92:OI_DP);J3,'M(J0^'W'";\$;
M&&UYH3%D&^LK9.6F_GO.P0@39C97MQ\$ 'G+7+^X;R.V/Z&WI?PHU@(<"^X|C
M>3.V|WC1W<"KW+N-CN@|<_Z9\FDS_VJ,XSDE71I-)BO-FD(MPK1(<8Z&%W9
MJL=2>H^EAW E?;\$?5LNR02T*J>_R70B_)P1Y*B)Y.DNN 8!|V SW\$!;\$9?*IGQYNLR2-CG#
|M^X!>%D A7\X1L4U|S,3=?Q%L300@LP&26(S>0J@GP317=5 M.8<\$FVF"WE:R|O
+B"0@LCD)CHM5!HQ<'1*2YM"|:(P|?K5V6P>3885AK>W M;OMT997FVZLG|9DH&(C??
Y1VX<=2;8Q-/;3U/\$9+9@|L+DG^/3/F|73;X_D^;0;*.+DD53T^NWWZB5M5AW)9*Q&-
>4T0HF MUQ5="Z+=>|H:\$2NX X9=4C-"I@\$_+_A.W! %8200XY4?VDF%>US11J,IQLV8
M4H'11AQ1|L9/J4;#)D9B';+,-6-S(\$67*Z"-U96;J^.&&V@W_/XL)H0XG.
M3I">RQ\$TBJI9+%8R+%;#T_/\$L1/N|S |*UG>&PNOWF%_TH@,2\$G!56'\$QU%
MMCH<%7;L0G;>V>2C+HTC)74MNK90!;GZ&Q5X>X)6WW\$4LY+F\$R-
UDQ^BAC|X8\$8D|248/;12<M099,>I_?
3P*|*,T,X<|H\$,7L"S0YU&B8%N.|\\$\$Q4(GU0%3TI%HI^W^+;6'P; MNJ
Y|;MROV+M;Y%=VTQVFAP^GJ ")>)%5@-/7T\$57)Q#&%%\$6HIZ:S1>HWMF
MS89MZ!%E62T6/V7#3WE)W?_8|J+X6";W67R2BT_2_)DZG@ZQPXE8KCY=PN;
MY;T(^1;EWP8QY.+I^=DYDDX4XO\$52^4M)+NKZ_1#7AQ?.ST"=+6L3&H^W;-
LKVA_0W)X, M(HKOG*.SQ^=C8G49^40&*+T!)&/'_:/X\$RD#%D|_R7-M#?X\$/_A2I.(CTBY
M@DT*Q^RCC7EX";L9T;I9ME|8#9DDMY^YX-#,-5Y\$|'"&(T7|FD24X4X05
M4"U164M4EI(#2>;P!%./T4#ULF/7|@+=%F4T<\$O*J3<| M>&L)=!OG|#+LFJ;7?
14E*Z(B845XEC!AL8W3-N.&U:GPZKT5)?"\$R0OK5|_9 MJN'QI6:7|!.G.
(J_:\$,\$,*TN0/5FC%".IG:=IH'Q15B-7SR^INQJ_U"(JQ-9@R02X M?
7('=>_AWJ\$PB&X2J*)MX4GBOH Y.BHL|JDD^Y,RU)^J(A:DM;%S|&+I#&0
MOM+&E0(E*G\$|J7|?|7|.7H'<9A?6WL N1M(!#@)=_<17@+P< I&8UT/5.C| M"@+O-?
KBH/1?Z?DV.V8!E(W>P=[?%F7_HBQ|F^\$\$. "N>HB1Y07HFLB:)D|..&G|_
EH=DY;K%|A7->E'\$ MT&_.%,IJ.>L8|0@03P\$EZYL:2B|M!=-O>-
%1E"VWS0\$O\$T/%=*DKY.BHZ7%H MR5?;=?8;2|G2,;
<|86&XEIKL6)NV'AP_SMT|@GO%'D5I)L-<<8^!-ECIC36 M.EHW8 >%F5401-
^=T\$5|;F/@^6GO^VG Y^8"8\$WQ<@"Z#*>'T^&|Z89_-\$%U M@5@1SBSN/6D%_7&Z)<:
4J=@2;('HxD6C|O =*3\$'%E-I(B^"2O.*=NUT7YP M,
(1/6@'H&&Z6UM5"JY8@3&_C|1UJ5"<(5; QN|C:06R|O!4C_)GE#J!3G"* M>S-;KU0Y-
L,*JF3\$!K2>&\$GEK5:@VU\NHDD&5CSJ&OLFYW<46@&WV*7.|EE: M =DH%
IJ(H0*E/NS4)SZ/L;S.YT4|;&Y)J<3VXI7CF.<_|&^%JI\$|=00<|,\$ 6IH.M+P?
VP%XYI&./1)N3|Y\$)O)@G9&*4 M1YRZ&5-&MTUA\$)7|OM,1+\$Q'V.|Z33F" N'FTSWTG-
V6/;)92GA_&6!1R|('8CXRF_+3|A/ZM^?T:|?O\$GD.4.;L=Y5/_>+@^4=>WF& M;M7+PHH
+J?E|D70"X"6H7@U""EU=I1?\$ M1Q?4%R?^ Z0(R@NZ+T&6;\$"2!;@:RZ8\$%@6?

HLX(8##/+,%6.JZ&W[9]S-^MMPEK%1]LK4\$IXTF,>+,(P^\$X1DH
KX|>?'N8#:8'%8ZA06@8|-(/5X3 M885X.O*" (T12SU%@J(K:94|0E!.8(17-L*0%-M!3-
J'">EVVNQ64U#OA*|^8 MVD.!:COZX3H\$ P1.W%K#0#PH VL/2AT^)^8DVKL?
3'H+6|K\$R-0T<5+OD@NU9 M/X/TUHGCRIZFA>.8E#%T%\$UAZ.UB5>K&(0)8VC-
@>'E&GU'TWSY0A0CT):#. M|^5#HK\$<-JOAQ@5 WOPW_5)#+O5|YOS!8J65<.>WS-
CQ5I 7(Y+_|79@J7 M'(:D,35U#T3'9=-ZAN\$DQ !%X6&T63#I74|O|J)#="")
4I6+|%|V+NF5X M'69"'FBLL"(@18I|P_H-+/(@CR/TC,8|>LW;&8C+LD8P9,)0\$RA7|
7H_9A MZK(5:\$|SV=A.>%NB,JZ|XO,LAG>(R(RN+ M5CRNJ)=?
OV>YC8XG)SQ05TD"TOQEA.^|^4\$.UA?@H\$|>*JW|K<,-0C:&+ "*" MFV89)7DA
IJB&RN%#9XCE,&|L7!:NB)YXZO+=U(MX>:<+^(V<)*\$EO&\$V%Z' M)=3_-4',61(A_3>
SY2:6\$IL#|5+O; Q5A0SM8OZ MA11L <,(I/-8S>\$A" (P;P&)ZR%/XY"EW(/G)^VCQ@?-
LK^W-+%J/1*23? MB"3G,Y^H:Z+U4+^,??
\$R.3FMQOJ\$N+ARV5A.%?!CX^ZNGAIMSXZ)YB,&_M.W@&SWR7,+&G^F7AIB9|
|W9|:K6LI#Y%?+R(UG5)0#G.-?&C|#7QH^IE!:_MOUEP"+|C7'VU(L&_"I/@7U4OHQ
>^*|;R-@S*^&8)|"+&.2RMX^P=D\$HTX3 KE&,E03L M IRMI;-NMBLMV#8
+1X3RF4FD3G;A37;|L(4PZYL&W8A.+*B0.8E5L3G32F\$
M|:4SMP1OF9+7CW9").;D)1R;)Q50#7/I3<6+J48+*T)YIV3'2|7YD=GR7^V\$
M<#2V3#:%6Q%|. @T7EK-[5H:LFE|J\$U7*AG ?T8V *FQ0HP4(C26G@'|I#O\$Z
M%_@|3|0>^GR GQ/DJ>'LI<>H|AI"VPA9N?7S,W3H"*\$&|/ "*" (|@L1-=P. M-V?
XPRE*G.!S'&6G! X19"BW/VH3A:D?9O!TGN ME9GYVC@ 3LD-L-NE\$-^"404'"2Z*
(V\$)/.3&R3SGX|/:(63^0:FE<&|XDKDFIQ?/ T.6I MD'#6<4/
J0M.W8#T.P!A+KZCU|M1_J_7|Q&.4*2.KXS\$NM\$?8M/;XZAEM0U|F5RN#-)VS* 630M
YKTSXQ8Z74#O,Q%W|,?X_B M/OXB^" << 3#|R*Y=X@<@2:,00#CGR|I#_'?@X29';CS-
K#"((.YY)E5A1\$0 MG=UF|*-'4)_*,R*S?8@>GY>)%=;I <3W'R<0)J"XJHY!5|20-
JQ2'OU:,EY6 MUD)|6Z6UI2|)%&5F3|76PP)#5XOKZB/MF*|:\$IUDZ>0) HK0%(@
M(M#WOXKPF1ESDHYQ9|FN<0_)I)1B18R\$HK,WGM5PV;61.2;PCE=J(6E6T Q
MX);8 VW!;EKL6WKR3POZ(Z\$OQ11?|M+?#8^15GRU\$SP\$)?C_6(|(>-3/1PE M^#_;\$
2)4J.&:12?+Q7JU_Y,RY5GB_ILDJ.VN2D'@I#B,I);9SO7^ 1B7TG
M0(F4D3R)A'YB^AJ.CNH7A03AQ_ECER0B*V*TE/|LA|T\$ _@0?H<19|8LB@|
MU2_KVC>/:;+M<(|_VUK"?N<66+6|8<;|2A;8NKK!QR-65ABH.D'7%,_D6L_
MP;X=TEU*>|F|/H#4=Z&PO(ALD@/;.|K\$QH.I;-/?
B0IX*3'!GZZ"UT|X"KA@IQ>GZ!ZG55 M^~*5-X+,R\$VF24W(-|FRAS082H<'97)XL2Y?
8ZC1'A!12?|)%G-S9CQEX.FI MW|*8;S%Y>BI;%@>?
H+U+ZY=/K4P!RF23TRJ)U^>^)*R&L7-KPR@"ZR: @5;S:K |Y>#Q!*:9(
M=\$&E6;Z^~I\$SV=9\$|2+|.5L6AWZ*L@3X'^@_S<^1GZ!R|)%+'Y("30.\$X|+@I MB-
9#8;;|W&53QE- DMA#8925;) _210^UB%|D;1I\$6#*A%69+ 5F2"SOKEGE%
MQ3LN%)O@6X&B@.S?|O|W1\$^|<.)9?OE)U&X,J;>%/&E;JE?GEP+D\$.S1S'2"
M>13&^'05.FUZ%LJ>G)%3|I\$=O'X"8M.#9G;V/4JXU;^K'#0|A5J:*JF%7'O M/8&C*|?
31:TK<%K)|5?-WQ5NE_-J8F.?E(0N3^@-2?'T|5<0>&6R<6(*0*&N
MDJV85Y|BFRY)31>OT_2T5.8!Y|CJQM=?OW,_AL|*IVM^N%0NU8*AH4(CPDEK
MP9S(SZPP^PRO1P@PFS&P#2"<8862)W@\$|ZV^,API#16.D\$X1|B%7X;|S: MD|I#?
2&VPZ7T@3+_|51#_Q=0E37,(4)2V047B@?AW|&43|V#D=D&&+4":!W'; M*8-
I=Q+\$V@CDMDL|ETZZ|1#H?_>#HQ_NTRA<'_R(##:VG7|P5@D(A%G_I:-F
MP7.T%P2T'GH(T_UL,&T9Q
KSP1(HIZ/:9DV@')1CCS)RQ29P4VBHVA@)*9,F<|,S!Q@V@JU<+X|*|N
M7R>=UA<(TC\$|B?6_KNZ6"S?|6&"7AM4A6T83V.)|74|R%=2 O_I?5+O+JPN
M%IJ9LMUF^H-^A<_J8C63P#EJ^L|&B_N:@%T6//D|8HE4GJH*.1XG3/&F M2!;8H|P?
F@WPJMORO,?YJ"(!NFCE!I0Y0KP5*|E.M7IS@|P74JF|?V5) MBDF'PFZOX?FE.J68W92?
6:1U!+QOOO@YCM@|3T@#:3CHLD/4|B=|I#|P|I%|2
M6X6%1)4_*^R|XCHB)Z;76V(TG@2UM++G=E1#HZ\$8:&UIA5"3557;(:1:PSMJ MI-%88?
72NIYT|T@:#4_'9B/F3<53"M [*62XMWL|&O5"D3|R1F=LVVTRY@E M0;3-"\$9#
(5&"H)DU;,<0*T)P6%PL28DUQDW:B4@PF_1&TRV?+"O)/%0-&+M|_Q2-R3S%%8O'9?#?
^RQ_73T_#YD^4NI|FG=?YQ F+#+":@8-J2,0 MF/D^PUO_13L(WL\$7R+@//>(P>
:5G>PP/011"!XY'E%J M)"BX):2DC:*IE5|2/3:(TKX691RJUCU3%;327Y+EX^=@^#&FJ;>?
+PGF5D H,?ZG(P^8SC4%!'"F MM61ZI@,N"8:E9UD2C"% 5QA8QW!_SY:2%C@DR'?
3:W5YY|.2UPEYGA95W&, MXBSSYP3PAG^&;
|K|YA7^*W'R/#+T9_&BH|@O=^/O0WI*UZLV"@MRPX-5\$-(= M2-S8SX|(S0%)ZZ%?
HM1Y)|E&,UCO&@1-60B^K6:\$=<7XN8CK;:#+F"!6GS-T M^M:|+3R-

N8P;IJ6.%>X+YHH[01R]H#L(ATZK7MYT=- -JY'T#-(AE.V:0Q MFG^)ED0:WU1=P/42=:
[7^P39MZN]MZ@A.:2(WW[X?T 0IZK|C 7AY MNDf>:3YT_=;Q-
CK"-|CYO^|@/KA),G|GM|- -A+#(X^/!DX#"M1L4L_VD#
M00#="5ZA<,O&Z;J;.&LEI79:;!;2IY3^~Z "HU?&/G^"1SLO*CME;&8JJPV
MZ(BN=U^30G\$C!EZ"TV6\N0L;|FMFFL1E|C4DG|F0T|-@[2!7.)|QAE^,PK M
KU'G7=GCWO-GF,,34CGQ3GG6B@7Y=2-)6| 99E|#6.J%!7A;FIVE;7|D19
M9Y>_OV(IJCTM=#.N=[12)>&F1TG\$Y(*&|F8F%3V&94=0<'VW4_@W?D0Q??(
M^I7DX0@D686_LU;D MY&Y3>!5LD/H"8O/.B?^BP8-XPf"RY_-5RKJMKJX?;H
M:==N5ASNf)2MKR7 -=G>U2LR"#3YR1R>7NL
M0\$ _P5#+)TXI<.Z*B&%THB'D^Z7+P\QP(@\$4"> M (\$2QI^7HTL_NI?P@Q*Q7Q;":Q
>=V!\$I9/;:"JBDIM ^\$6%H>G/X7J@R!/A M4<&W*&|!GX5<+%+AMB@4Y"N7&@13
;BH%ORGEA)H4^\$H5=|P 4?Q*)X*RD4/ M\$8\$2&Q|40;EH)%0HZ|BC"B^JH?
>KXNWV?H0.?UKGA|W5(LOH80CN')JJA|> &0C??T>#5QW- M_8<+FV)?-PT;2Y.X;
(D/Y#2.N^MSUUh28B8+P/JNMB0(2"INO:5029R&3.2* M^|:2P_2<\$-
\$%4L"\$&31W#BA!_C"4/,%C"Q 28U"T-F1Q,*/Y6N3:M0C^JB,P;D)>CK
ZC#Q+Z.MC|U"EYZ0'\$Y?G@7@^C MDR|\$=3GYW"L3&4&/&X2#+|1>M!#.GQ5*K"!6'?
="AU6\$#862|%">QUV+.F<MR^B2L\|R7^6Y+.%IQKEL';@#571!L@J"Z#OR8;-)V<
9Q^|ZR8))G#;N./C3 MY7Z#|Z 7&|[FINMX"^?MN|ADM1FZM+L.J%S#24C M7)KO/B-
(GG|Y|NN)Q|*0LM16\$0,7IPX06-QB'8SV=G+D !%GD'SSVJ%'=;|
MA"0 _T>:4@835FU<:#6J?*[8CXOEMCO+|IR5Y&EUC2|#"T'GE MK<5N-
*+=**|3WA;;*8HJI?5BPS#1AL'D'2P3'F|O75RJLOSUBY%BIA("C2\$:
M#=.B5RJZM4+4!*|9ZT,^)"G;W+!/IV2K|D_1>\$>/2V_ V_D>RR^5M|JM".1 MIUYP-6FY
&8=34)CR?+EZW>(U|GXWZW_@>|HBAQ"962>'LKD2(338PCOR2S/
MHLDH\$MJK>X98(.X*111-|S\$9UJ%9UQ+I?@VCQ.E C*VJ5*|&|8DNF9-:"R9
M:3Q\$D)_" +P"WU"+,T;7,W\$MM9CV::|QNMf?#=\$V0L%A:@1%-+*"1D16&.T&V31+
MC/8.#^35XSSST/CT6(TFLIH1'P;_DY%_M+I6V7P\$W(6);9=O|&?+VY"E*\$I"LP_L/E+PC|Y-
#,46*!9G=3Q,|<5),R2U M%"76.!A%JX,FBV@D"5|O?G-B'S\$SE(+ZQDF(?
\$1H"\$T6FD|F"4|QUN'S5F2 M2L=S=|D@=6D'E&U29#D>
<01DR_3W, _W(>P85%.BVO-8B-*9G|XJ=1D|1!\$ M\$98S<_4;=:YYI1#T#R>X=4Z."T_+
GO|W#3UV@+L4IV1:'Q|>X6Q%#F#V^C ML-
'L/%Q|@;70W/4V+X^1RU;2"BW\$+3%Z+X8W1>CNS5&|WFZ2!GJWF)X7PSO
M/0SO'JX5|O|7"B+"AI-Q|((@HK??B"A><=.(
MG|_#B00A;R|I#QZ!VEKW&/+6L1LTIB8|N7C9A!;E9=JVG/#*'_89Z@9+9Q6 M"+'?
8+*3B-!N?@CVZR*\$B?T5J%7WS^X*ZK7.'K(F8OK:_0 TQZWJX5P+DZQ
MQ2FV,,5FQKGL*AFY.(-4DYI%539Y#8#|9%BC*Y5TT6<>>'SKQ.6|Z2Z/?
*DQ|SP^RU'|6^"6-/L'.GF/V8WY<7= MMFGD_K'.B1-
K+62W5Y>L#PON_8<;9)!4'N#!OXV.IZR@J?6NHLF*9&_.^ \$H M%AQOZ@,QF>
/!S1\$:#\$NGJ'9Q/=P;17,HQ"O/H/D0!Y&Q)?K09EJ6^HRE; M_F6VQ?
|!'0HSN&ME)=+K8%V|CNI.=X?R&)M&;*YL 8WZIL/.,WP+/DC%'BK=W@T|^Y0Q?
7>I=+/VG\$5#..B? PVB|XY|\$#5UN, MH6RI&P#!|ETXT?QR^1KZ;:+9?
J4*,_0^FEQ%>0K'_%(|WN5.@?O|(D
M14JIR&GD&\$VOY:|WT"F+,2'B*J8&7BU15SY78Q"9DF*L0GTN5:B8.8FC8&| M3A&\$
S6_)H@|6I053@&6YM4\$3;:28SJRM9SFG01^RQ80=7CJ.-L;BR)^9M^ M_/KJMT-
\$%09K2#|/G(<0Q^UPETYFF Q2">VY!GJF+>D.*.Q!'3M+|BG<2,F M=+H-)7*?CKEIRD6-
G\$0'JN8%?\$I"G@WV2"WA+-TV/E+E,+/^TY0C@^UV"8); B25@8@F8D M0D8EN"3*
ML(FC?>P<,38:1F-UYI6ZFQ(V5L" _ITA6_8|>HM-3W|\$JW3|*EV:7)|Q>>\$ M97QL-|
(%;ZH%|-|6
R:*I1|F<^GY^~H7Y<5S\H&8J84!E(+2NL,+ING+A@892(V&5M!YZ+*.:3NE9OHV2M)*A
M>=9\$ZRH|H#6_ ^YL39*#Z./KJ%P)QBOT T@_R,OK)XE_545IT%|Z;:EAPCS;
M1>JJAU;)E"/1@LB2J4V/%Q80QVNX>,5>*VP^#\$FY97|F2Z5VD!G-.\$|YK::#
MP|16*\$1D18)(/L,'G9V;?M)X|9I&RE\$13<-H^A*2&)B,W_2@:D&108;.9X47
M1(CZN#9AC\$|I RB1JGA;\$5PN SBJJF|V2Q!%(>9':PHI26#+HGVC.E*:BE|MQ)"?
P#>X>WK(I0W")!_ _XF+_ _W^ _T3M%,VK\$(/_|QREA|?"P1UL"*(WWWV
M0.RFB|@JR*>1QP-L@!OM0R2<0;G1SE9)7SAT3*_I3@=U19N;5|JZJF<+,4E M2.NASNT
IGDES(*.(7VJ?^>1X+008.L;JH7A\$NR00?!,?O11FK4#;+W4>CE M*B>\$H9QR!VA.=
<|>ZLH,U5?>M=D9AL0H&*P.=^Z7#809=)Q5CFB88.J?S|V MB,U?
23FD5V>2OJ+N54DQQ_*QZ=422FF\$|&R\$K|.RQ2&0H9SE!(#.A.;J;Y(M|(->SU5"
|:GRA0Z_VL66A9V MQ\$%L5CWC\$A25,51'H51377YR!7|2SFIC-8*4AY)\$VBI9N&4GJW

F\M@T(HT MN1;/K0!J,NF)FYF;[BD?(\$31-3\$K_.'!YM+V[, "NLF.NO3+S@KWNS!E"RK[
MTX&HR105:Y(SYIWJ2^"\$S+QJG4;C04F"t">?YPX\$82/3" PM)&D((LJ;Z?" M13Q):"@-
DFDM3N.>E\$OQ<;6:+(ZLQ9\$U.T>6G(7<.B<=8++ZYE18;O^FN0+ M@|+/?_S+IY_)UP-?
1HFSQ;8QTZXS^6SF_.E27E05]^=V*ORYJ+D)5^AE!#_ M?O"A^H'^EJQB<)O%2!
(.SE\#O"HG\N*U6DW)O##CJ;16;.%!C.N-4XE<-#ES|.>8
MO3TCLID)+13+9FFX613SB!7.T@GN\5\$M+G8\A9!;)A'M.78\K=;5\N;^=ILE
DN""*RA9S<7A9/L!#;A=YO?)1 MN 3N2_K"1CRGV-6,P70ESD S&>
V"N\$LD_OT^4F2.:.\$+JG6,50S!*)|2\YLZWYKF^50>(9D"IRZ+H31:\$&IA_VG,
M,ZEHE:B|B@|T0X+OK\$T928V"7W!9B|SY)>O,PD7WIA?TA-,8.
MG0J%.77B5(=JFMQU.=*6T7FC!1LYFD>OE3&M|0NS@H.-^1QE!|99L0-RK_4)
M.9X5@>#SN>&O'EVC|TCOVUVF)IGH;9SD;I?I9>W8A=\$9W@2Q!\$._>5""|E0'
M.1B|H|1@/#F7#BW*H<+V!|L%|0\$A(MCGL=<1%=4S+[E(PP/S%LT;WEBZ0PZ|
)Y:++>-2K'@Y.1|M%|OI(O7MY'+>9)|WP1@;*U|" MSN?\$86-VI+YN74Z4N_<-
(ECCKH|8=TC7=%FJ;@;-AGC"G&E2#6.VK|&3.&U.\$_YTF2+|
MX=L&L0#LZ|N7R>=UA?GPS|F1^+\$VG^?'C',9K;_MCRIU^%)_5+41&\$&@HZH
MD/_Q#I++@^/'OSE!-E8(N.@LIF5L?DAG;*V_SY82KBS^KU&*Q* T|L/\$=|?<M?
JY/ZPOL|JA|'(K|#22("X0>*IKHPG^1NA74ST|X_Z|^KMROED#1M|D!2^: M!DY*71E
\$.=*;UA*1 F5FDBMU=+2&WO;WF1MVP8@!|@M_?QN%N=B<.<\$KB(^? M:'2EQP0-
/O"K_3|.G623R"|HYV/:%C1,CEIL <=|3&-59*NO)JRJSP35BU"Q0"!@O_9V0-
%|6""%D=\$P3/'H>;G!HU'1\$66^
M"BLV;O1;J.VC'Y_R;JMVJX@HZ&8\$6/@=%#X>P'0]*C>"!1.^J%2|4Y|N% M/
|R;=Z|6;N%>OBOS7XE-^&>CNB/+|?HYV6+--TB@K^_W+=?EGU3>^.1|1>?
M)E&KM7U;FAV/3GR&6|+|NA1U#V0&DSS-^/'5_!S2_B/89+&6;ZOK|.#B%|/
M3EB>IYI%8M|TRP*PWR1;!GN>.!UH_ITH"T+=VO/C"<(G6J62N<"+Z\$KRAS^NG(T/Q
MM|L;J#U5"7OR*M_+):P@9=SI"-G0;Y&|C7TB^7@GTF+|=7W^/7>Q#+!*"O"4 MW>G7,S
79I3'5K|76AR!FY.X494=@_ZGS<>8/T.@.C|/#-PBS&X|>(NLV\$=
MKECUO\$S1NVU=V=Q<)0TQ2K/C|:W!HDC7;6"ABZUL'78!=V8F;ISQW|W+B0Q
M#J=5Z2JVXD7XDB%AY@>G+R_5VJ5LQ|D;Q2CWF)^=_HXF1GFA_J,U09,#(#A
M9=|GP&DU<_L063OF?LJH40Z&5YI?CGB?P_LK|HN8?JOXRA&23AB5I5F\$XZZ_M4
#Q#2AZ|-OFI:3%"K34FIX*36|/"/>=YW/2I4JM)G&/RZ,V|;>HK2GDV7YT
MBIB*33;NB<=F^T MN"&SMW3VU5';#NN:|8FCJSEC|^&-2:6Z*V9GX_Q"YTHH\$|?_
P%F=.'?|I'OT?\$\$?P/_#_X*79^!F.!LCVS2'#J;|?|T!_|X@_M|H_A_#V Y2:YVF3W=3\$-
OKL@0L?=';RIUZ\$J>-.<.?+E-&M8JW|+))_ZA)PG03/A"D-IQ9,D.30DB4>HBP>
(G0QM/|R/=1C2|C M%9VZ)M>I;/:^4Q,7NMP@)1|Z:PO|UO"7I9X,JV2Q'/8I%CI-
:)#&\$ADYD<\$ M\$LCG;WGG|LVR734>ZRI\$|:O7#?*PM0/|UAB#RILA4A^"
|OM^Z65IPXXO^." M+I7F0AY#-|X|7 LDL@^'R*?UV|1@#>17<6--
L_08@2V!1KZO)2)O"G(C>&(' M6::M0)!AMV|%AI!MQ,8?8I9YG(*3%>3\$M&@C@!BV9-.):
D?UH%2YQ#;2#<> M&|T|7/ZF+C|FIO'0\$C#;.YI1CX/?2U/DRF#M_5WME=
|L#"YODO.1F2_%2=|YXM& M*#!AC+2?|WJON,V.1ZA\$KW=A,E@ZU&-7(<'L?
VE;Y'L\$/'M^#AZ_(&6;^&EX^V#*/DY|OUS/P%R8.)4JWV5|9FR_17|F
|#!V^1%3N@PQ6KGI%"Z/<&=^6UJ<|@SUA|P(0"2'V|^DNQIR'8(U.69;NJK_
J%|H@QYMD@T|Y-|A! MZMO-Y8AK><2%XR^L>-
!K|BF_#J<8Y=EO8;^_#Y>CKLM1%XXCF)|@FU#|OX7;
MXKQ%,1S|315)G/|TD(5.O<%=^ZGA|LL2;CB"\$9^YZ3HN,TL0J|C|BFZF8;+
(*O7(;"X(|FMNC?" MS?,>>I!3.I??O,)_)9 T\$ ^EU@L5'47R|XO0;|S M(|
(^)'F|GT&Z=0*0W(@^O|C3W_YX@ER&EM=L|TR|.F.T@'%F,E"TH/&>G4W#F\$/?X.DJ>
|>9Q^W*_MN5L|W;Z?MZ|K|NSP#2>613_HEW#K|Z/QD?0|_"%D#"^+?
OJ+"#^A=9SHN+Q M@N|;X|2Y|U;QF4QOWT3 :STV*D/?X<|BZW"@GLL.T;A/M|^&T?
=?H^|J M-QC3>Z)Y5Q""^L|!C=KS\$%D!=1QE>|_'4B|MVZ;B\$|D)>+6#Y(Q,SNO=
M@Q|GZ6UTA;?|I9T @8Q;KF)Z"&|S|.EQF3:UO+"">(N6#LOE!|GI9|HJ&
M&.Q6DAM/M&?WNQU F5#!=Y;X\$P7D%|;AVS7X6Y/2 M,9P&/#Y1|
(|LPV#G9\$&ZCF|@MW8/;<5M@_O|4|K>%;N1@I#D+T|O3G|16%K M,N4+MEYH"
(TK|V,B|P|>|A JOOA,2QG5+KF<&OAZB==>|B'07P|GKYB|J^F#Y?
6;JLIS49P_1N,ST'M41|22'#=& M@T?W_56D17' &|.TZ=:\$Q#5(V0|3DPG78U3QSI|E/#
(8GU=UL#I^)Z.AX')B MM=)+B#)TH^'#.M0J.FJ1F-\$P|/7QX3-NR'?
&0UZW^BNFN4SO'16@#>>T|9) MVP3N:@7"8_A0:Q+F|E!;-?
-018O3@VKT\$WPQS8+@Q34>(9KDW'86&PV%Q.N7 MZMRV
L1QKV&2/<4*.)7BA0\$FK#J*L+0"LRG M(G.9.SM=R7;:#H.D4-

5E@X9N\$ "5:M@3W|PNXLJE >-!ON3? 6/9F',XD+ BX MW*F?EYT:T4?'\$?
9<|L,ORS|TW0> ^D.S*3&NVMW14H,7BR2O)S",*|@D=8G| M>82H'L&K|P&2BRX!
<7GW4>+B&Q""G8|\$Q4:|!|AG2/"UPPSR?4)%")D,L, M4UF,J+)>'A2)D<16+ARW3\$)&!
D#JGM07|SY 4":=X*K2=-72NPE^3U(@P)Q M:1CP;29|E+V%5)XSI,|@VL?:Z>"|3D#
(Z4%N.OYL5|R1-W3X,P%_> #^RX@ MQ-1%Y+; *#E\$-(-#-Y"D\VR50 .3CP|^%ME(5I?+
|_<(/,@TOH>P*NO_-1YL,|
M#^2'W6(#J.9D^>F"0L,3_ (@H/V/TE;*T!+@_ |*/W/|L%:L7*RA|NBRI_|>WQ
MOC/COA|4(UW2A>B=0>|E;#EWI1PG3O 8,J)R&,I+G3!WOHH9G94OKG7"^RV1
M:PCE"RV/6<|=I'=6?|RK49@^BH4WL':1|M-PQ+CC0ZYIBH)5?@!142W"ARL
MF40&51J-(I>25Y,:69TQ&B0!?:BVS5T?6Z,AXM)V:W \$=3>CD1OUXF1IC4:'
M2C.O3|H58C0PW(>UJ:X;CP(E)T'+O9!A0K MHA/'@9;/?&-'\$-
LXM,LP&|D1PB856A:6L@W|+H2,LBN|1.|@'UPBB+|X|AX(3>!KR#,.OWZ/70Y0E#GH5
M"7^3 EH1%/!%|ED(I:@NEZ%AM9 G@& K;E=5VX@".X5X;:-P80""*7P/O|MO|
M#WB9PM01#YWX3"O5,<:7U,/6NAHHI8LH'9;@'7|<:|(\$GIDD6;G_SOPD%TWR M?|:-?
I6S^|DN4A)!GT|0-H|@2SUW0010'R*"EJFU"SAZ:>>|D)7&3ID6HH,C
M3C(G(:563Q0U:Q/B@|H-7E E4,T16U:6_ |EB/_%|E|AC>'M-KMW|X3^U>I^GL,H&R1
M|UD>MP TX.W/|RH=G7 M, 9'/VV0 D/CX1|'>5>8O()2E&
"M<7%LT@B+X|H4NJ+,G34WH1E\$(V!*61 M GZ:7\$ \$\$+WU09T"4#)W&:^L^2(>/8I0T(@),
#P>C2'=ET)9*<|A BI+DUHGC MARZ*OSNO1P*;TD&?@PC_<0M_ |M/6!%\$>\$2=V#
|R'DC*V-2& WPNCW&1&ZV_ M_ "I\$59J**|+XFOJ!_ O|XKX.3(DX"TBP.(8I(&
(:\$%+Y&|Q|.|2(9MS!Y@RL4 MIF+@1OLPGZKS41JTDOJZ>P&A\$Z10%"HM7D212G
8/1QO/ Z52R\$:&T?%Q M2PV-:RB6(A!+6+R,L/A17!I2X?VE@#<\$>Y2F0P> ^?
T:6*2Q5X#1%+D\,1"@ M*FZOS:4Z)?|Q KPEO<9HX1FXD(ITNIR<0Y#J<5D-
'=6/1KSW* @K@|X_ @RS4: M)V|V1!1.C:|=P<6?!OC=K0+/ZIHE0C<=5SB#57)B\$T7XZ?
1|T#Y61,QWL0J M?'KD7##S?:L0)|K\$^XR!23
7,,2#D(Q^ORM\$0K2X)J.+0@R|EF!4T97:1AP M**FQ6D:75. '36*0F-
G%\$P3M4Z*A95870BA^B>CO!D#B_ 3""#?GEL,^!HZ* MC
:+Z^N18+LZ6+J_ OD9T2RK64=!S8|;7P4EYQ94PA><\$3FW_&,)#"Q+Z>|QQ
MOK@|9%Y>TLH22LVG:|;PG3@'XRKT:"3Z6,)2O4*2QV)UOL-|O)KN80++N&"
MFAJVI>J;&J5Y%286)(\$8|=^?(AOZ!-YKK?(K-NO""T|1"+^8Y/5%KVR1LTRZ
MV% C%D^ ^|^8&/:%:'LO1JUAR|CVQ>,L:S6&DV?9!'GZ:\$#VVY
V(CI%1_F45L!API@ \$L,#UUF=YG-=|L|\$^D|HM@(!&X\$F
MKA,^:Q4ATI+|)&1)&AD>VQ\$U8I4CT-=,CXRH-: ?UV)YM,+ \$#.S\$K"P9""NQC
M(*C#VP5!_ S'35F(Z3@PCT542#!YZM ^S*|L4J59HW2)6L#)9(@G6;:,56VVP
M,,*TRAGM|N_ |!CG? RPS&|RV!-N!6W)8G.E*4|J,(G!C*VWV=KH7!-RI)6N MS7L4T+
E9/6@R4\$G67).BO8A?M48->D)%C;|&YW88T0^V,,S8'0&#)E08WT1 M1J?)D&
<6;7V*R2S/=^3&|IB6(M4^3Z:,- |J-# T PSU!M0V+W# '6P7L|%J6B5ME;DX(#|2,|
X4^4.|N,8 MRLS|_/:C)OQ:T.DBHZBI<+ \$!;A2Z4%,O<|HB+V\$&&>BYS*GX&MW0=@!)
(*#|S;SE"G8UIKH M&QI>,63X!|15+*YV^C)#N-^=6:8/)X>)Z@)I=68@ (Z,D9?
W))6T8:=0+C| M|EGN-W2#ZCE"/"R#A/P6@'(IPE&^ .K1#>^CZU0\$#.9H MNBW_ |H
"&A|_#_ GJ"A(\$EQ_9C>#;:?U)|,+#+R0G/|R-Z8(^- |*|JEJ9VV87OJ/0N60+D14OPTIV1-00
M946@K)*=8-N|K(A|5(*)|D-'BKC(<;9A!&N@%7&6"G>#89^T(G)3"4^ZMHP: M71!L
E+O9|TUNL:84@HG&Y2-+D6FCM*YW_ TNJN^X)IZF^5UNG;:9!:-?8EV M_0 5X*: _|HV>OS"
<%Q7PBP(|B1FG_::JTZ*O2D"|Z|6IP)6K?NKVFE?%A8GW M,55X3Z!OZE<45#S
^O^R|Z|-K>/&NO!?:97OV9F99'+9|>XAFV=|PLOY+6 M3.5|F:(I2&*&
(C4@:5OY|0<@*8FD<"5!HD&S*C7QL@\$0_:#1Z!L:+_ G2|E":
MOV0B=+:UU8Q960R_ OB|6*"PNY5<=5BOL10EA2OJVZOL!G"R;,)S?1LVN+*0F
'TC|H7NS^)>\$VG|B>!*'7\$R-#0@%D46GHC_ |M<C)44UT^.)L)|HZ"O9!*DRQZ>-+T&
|75OL@9_ TAG8#F-L,TR.Z'VCX@T,# M1X_ :7W|T2WN2\$M^'8G08Q4UL,Z?6=-':
|MN!|H G*8;H!FK-P_)SI17U@*S@ MM/U!) *8O|G-P1!0D:-/DO="E,H;YIG9TS^7J_ =X&7S8
M&DYI&(!)A=E,K^|K).2S:3R7VL0V|22"7|U&|H MO>3VB@EC=3 L19|^=3-|^OG1J-
3O/*9A&N>^GQV|R#^VEY&Z0UAC-X/"; MK)?I:;%986KLP5P,C>|&E6QB(?
JG3:-V!+08Q;:L:L=7BIVM6'+M+;A>MD,'
MV:31'8QA5\$R:V#3""C"R7E9,@O:F@.T2(#0%^J0>*M;4.AH4746@,U5DD5|
M@*P/=6P62*/U!6B:S+ZA%U'3% >O64HC5:OXO#?N28>TF<|G?GQK\$)'I7:C@ MD%EO
R,R(?/95L,2(O?HJ"N"=/# 5IYP\$CA 1XV>JON4|2BSQ%,YUL=S53WF
M9^8RZRD=-3=V|*Y>*@*TN"E_ <^R00JL>|
M:L|;R/CX4Z"GHAZVTHY&7:|,^_ SN|N<>/YX=SVQM-_NH\$35WP\$A=KY|\$QW:G

M#%^^^?@K8E(17W+5D1K-!U/\$G:1-E&#:IQ:T7U3#\$(+)|2:\$CJN
M65WH1WVC05L^:HI&LZA!83LC2K9.K'C4/-AN\$TNBT\$;ORL"IXV6" S69S^RU
M(RA;N0WSJ<3@>ZDD# 6TCMRG&/8?-83=^:Y3;D\$?E98AA /;P-K(1^BE, #*3 MI>Q7 +J-
J_L@I;N.@G6N\$)T^!=YK\$ 9I0) S?I705M|)2T9DC9=4B#Z'RY|B M:\$NDV?
IRH|MX|P41)SNES4B&,|QNO4->.IZ)LE7M'^|>NM*K8^UE"!B=A-) MEAY?
0B|*Z;;|/0ORP^#FN"*?G7T\$O\$0AE9|PR*)3\$W.80D_#'/5+0_T98H1 M2I_HO?
35>|SG)4%KBW=2F=*,UKM7+NNE-X;I3Y,Q-+>MCC_MUI*1H MBVN/;JRR7\$4L%)?FJ?-
%T,|+0|6=RYS.,| '&3D<E&9?9=I?2AW=X><3R?H:YZ4OF82+4R9>NGJN_KN|ZT?
%+!|*KP YT!< MY!_O|I&P#R YM\$#T "4K_I7|=Y^53J/B|RGB53#0'P>&+=1!
|SW|BN3JYJ? (M|= '04ZL6H(>.-8,W1;*|)GM1#KIV"X5BKM9==*|K< MIU9@<^SV9|
Y%R?DMICR|;JULQ6FB/ (^MH*&|6ANG MN; "|_YQ&4SFWJ4*KM 0!EP3#%5K91"0XK1!
_G69/D'-0H=?|G|7B2F|HR=7S8F)Y"BKY#8<2;G-K!-Q|F-H4 MR00"RYTG34;A-
@=2WHJ5^DSF>N,E@9|/F+LP>J-8(<71&O\$H/7LC4QLBYXS M>I;,-
_FLDGF6)JE7/(DH7D?M8< 3G"!1VJ+;,:B<|Q\$D:|>E&T(-V08K4ME
MAGQW\$1^|, #WR, -4NED#;/^GPU!LZ#,N7D@?A|1,ZF F\$+=Y&>X M2\$7&04+^=\$?
^&6V+!W)."A%GO7K|G\$4!7)QA)<|5#VNNL.7WL.DLN+Z|H'"_MX;0_*J>,V6|
\$|EW09A1!UO3JNH)9>XH|B1\$7?<4F!>LEE-UY5YR*XGM3R8@ M-+?
K;2":V_IFMCTR;C)R|" ::V_!E\$NEBZW&P%Q,8++^>%,JGK/"K^QWU-T6U#
MM#2%QG\$43+V@_1J&8\$|= "7" TQW4ML;) 0I;?0A&0Y&DX0GR9(F*6^G/F"6P4
M^#M!*>G<5>FFNGB*-DZ*2T,\$|K))HZ#,-2S#X|/#DR_4B^1QP5_?\$L0"5JQ-
4E\$|YHA4RX AO(4F;T"O,UXH:;8|,V/:6*F6;&1Q^(75LD
ME05POHJ_/DZ"K@DA91))05,/44'\$>1Z*B3|9?)XSB>+?4605J/XX#HG."&
MAX(<1Z|'|YV?/M0'9C|
.^&964:.4V|^\$01G(=%VLSORG!PEN^.1+LR==|T>6S>8H%'K6I3A?SE\$(.@E<
M6>Z=XY@8|V76LWWZ0.8"!..@>P#B+ _!!J)3VF0?>/T#&E|+=;+
MQOI(^|FZ=U&SQOF*% "4 U)"YO5KYXP?HO*E^O\$2(N|F-77#XF"5&EJ|DR>6WG
M4PP%Y=5VB=*0*|HB<;HWD+WU|_ULGX6TP# OS4B|ELK|H:UKL8E,+*QP)(M%
MMU(BA|'Z9)EY'3V'C5 A|%ASQ.NS|XT3"|R'&|Q|(^T&"B%E"?S//=>QD MCE?QDH"8;
(YE97"BF|<_%V1|39_#8,BL3|9H)P#270:/U^\$V;N'UPGK.3JK M4|'&#BN,O"3#!:'%F2?
D"Y|YYFBV*|PN**<"PRVR%ETYA-|#E,IEJ1?4;J+ M>=>DE;K"(*Q
^30|%7H:/>P>7@MT%|N%8H1\$>5L!|(DIA;4Z.C13WXWUEQ M&RI9Q1P%-Y_C:U-
#6"# "8TF0HC*%H:"2*)X6_B+1,O<^V>G|I66RE=R3LL|MFCA*?YI-
L|I:XYUEG%:NEW&*?J|/;&G"K1USY)T(0+:POH.2UK42FV?AT1 M)%@%:|Q"X7SU
25':B,>U7170B;=P#UJ18YQ_*1HE@|(\$*V)WMN/(*#,+S^GM>(:IF#|L^M8=AU:9
MM00.=,>S4\$%RU|D3^"FR6|6|)|BOU7HM^|#@;|!#0T#!Y?|I,G=5X@2?(X>W
M_#^"Y|CY=:R0#A@S51AYZ(5T<%97J|J8(!+ #Z141@F&&T>WQE;YZGS/T<1\$D
MOWWU(J^HI+"DU4C0|CB+UE_B-X0C+_+1L:>1)"RY?:QF|_|H_K(EY\$?KB\$ MB<@_?
M6=X-6*E>&D;F,9B9"9)Y:5<=Y^%M\$WL1\$N:#)G\$PKH3=4 M5H39;|@G?
U,A46\$4JP12|S!:(4X3F>)F|_J=_+5!RH'5)R (0VZD#Z6W'M|_:
M+SCV:=W0XK6>6/RXXI|VR:CPXZ9CX\$""9Z87Y+ M=_Z(?2: ^> M!|/%%7CD?
LB"/T2;&>UKJM.? =8OJ3(#FCZPYAC62+4'J-;ZY M3%*+-
GYG^^NVV@5X_>+A|'@?;V%XG&TV1-% MZSE>("A|MIK>'P*?D/A<14W6RW0-
J_Z&*7J&|+= ^SS"2W:@=,|2G#Y97<^ M41_653|1!;:4QP#IAY>%-2%CNBW
_D:22<;BPL@:|3)1 MOV '#P|DM#Z!O|2C.X<+6C<3<\$Q@|L"G=PMX|36@ =*!_BF|?
1M,Z^=K|Q MG|'8|#4F\$%06:IS 6=OM/2,|0&RXKRT09#C8'0T|P1|@P7Y
M@U3'">UHCK|HXSANP:09%GSV2_-7:14/D;KX"U89V05YE%X-)H=23|25-/P M*X\$|AH|?
9V%8^3"S>|>WF>\$J)+?8"18_Q8??@HB(G*|WS,F(6J>SPX3P19X MT2I>KY|?Q=S
) *UANS7E/' .5.;MSJ.>GC4Z19P 5A9LL)>7GZ|JK=L#% M,0&1:.\$W-UT7,
O1|I=_/A|^<67T&-7+)2U=F!|2|?@J5G^Y M7|!;RC*T.EI#UI/Z'W16^S)
(WW1*7(0Z?)5*M^M+7J"2|XVRU&V_*=PI(C M|EQO^<>52C?GDFNF|G=2HA7%'&@L
MA!7Q9,*|@B&1.Z")- _@0>D-V02;;0+4W/F,X:I;J/4"L=\$ZXJ|S ZTY-600(
MM?:EOT/KC*9SW_|87Q\$ISH3;'X@EF|LGT^ ^O ;?%|AVR&LIY(_DRC3|_KYG M|V?ZYE7/
\$WQTN;%^|(?Y>72,K_LR)3(X*\$N@&>03T2/M34RZ<,Z|,K", 'OY*|P|#
ACHG%+/=I|\$. ^3XO;L|E|@X.-1+ M8A*6(G
\$R7SS@E%"@ "RX|ERVM<@KS7|Y1|O5A_8|I+=Q2 R/&)/O*'JOB\$T
M/_>1S_GSBOR4>'XN6F2^5:.? &#U&:!'Z-DU_R&C=206*"CP(C|<8"+_ ^/4^
M2LGV93IZKOYL.@B?82^<4TCB|?E|_5Q=W9+:WSU%\$?;)|* :WI!(\$U^0N'Z
M(<9++T12KYE25|-/WA^\$))E)"QXBS!|J.LWU_,@8^[6L>!/4);:VPX\$>& M'Y;5

MX6LN ?Y//?S3' E<3/K=X?((E&=J?]-:Pl.O?BX3G.=; BD0&B|N:: M'?
=8E->TF17F(11.:#XIA9QJ8C&|C7:LK_6TRAK|T|R4.<>.\$7'&>'YSBE MNFA,Y\$*4H?
6<3#-7*R_EZT_-^9F3K49SC?RS33/?%7<|ZD=D-|>@J2U"PZ
MLH9/I/S/5@MSD|L7G3PL%>W2EBGLFK7OF>|H!^|.7Y%1'4E!F7;V2L,XVP< MI
|+C6W/FS-P(#L?|8X0GB9VR>7BF|N.TMM&VSECH6@1@(9&& (1& P4A&MF
M<8145M!|D|:QA1EZ|_&NBH21Q'0!)% 7M'R8VMJ' (M|:WG*%F|D,-B0,19"|Z&C"H
SE1T6C@>7>P;Q=;^\$4<+00"5>IX<;1L6=^P MZWVW*V?
90=\$%6>30|D(S8M8V7|OX2,A+-A&>;W%*)WY?IS1O;|HB*KNW4!.|\$K|ZVH\$OZP@@C8
|2|7D \$EWFY\$7|KR^ M)6B3A4_!1A|WD?8^KC.9TC;RBH&VR HNMQQKV(/ ^Q=!
|>^F\$|S\$R3)1: MHF| ^!! T_ZHH";+ Y+W@;>B+ _E'+|ET1S?QBS-Y'V;XT@MOK-
XKCVTN'0EZ" M=G&X5A8%HA|AN+5+1-
V@%VF^CONP6|CY+AX"@R'\$7T5!6GH=&#)E);^ ^G* M!CA160/
\$1I9(3U5(AV)R"D%>35,\$Z4|7=61'4%'-%-WM#QXWF*A%2%+-_:6\$
M5A5DR"AU.3JOC|:I?_LC|+9^M|9DO(|RO+V MIN>688SR1_S*C9K?:Z%O|<7Y?
GV,RA;_0AY|LEH#&)Y|GIZ7"<%L-C\$|@|H" M70A_H><_I9XS.C|.F8E(X"U8E7V):K
MHU<0|V&9QJ7+@%, ^ M>=P|>-SYRYD:-1|I#*=0H;#B'SI9J_8C<|W_U8)"H(XH
M.5M@(-=1G")&M*I6U,?329./ 9R/89;"', ^>2"H J=Q.|9<@
MW15Q#K)XN^"PB@7/+K498=SDV7>V%<5Q|J.M #V?%/9C4/(HD)':T2=G_"F
MLQ,*)E;+@0L/_3LFRGF2QD0)9R=SV@TZ"2+!|:-@KL#^&W=F|+|H:E:8#S
M4Y+|L&Z#G;G-34>PR.A_>|I?PKRU>LM3+|1Z479AJ;|\$>6T5)IH^#D^>J'H ME%?
I9GBF-T&|11%_2K6_PZSF^'E*;!YD5A).*KTM\$;6 M0XQ1L(WHS(2'|4|>UK%67WD;X-
Z&YA,H|R+6?U@DM1U'_15A(+HC">7VAV9 M@T_Z"O-|:-
&VS"A7<7=+_+0T.K|I%06\$DJYBILKZ?(3^SDUA |YJ20=C|&MRG+4ZC.B=7ON'\$6HL_
=GFN_B(UG|EJ?J4AOF+CTGR@G 0 MKZ72L-X:%#^=-N-1@V4N?
6SKMT6>F7^LF'>GAPQOT(:T67D?8LU7:033AP3Y M:T+K+)(Y7!'J"?
X1#IZ6V9RC|2//;U|_89P&B2\$S^|J_.8HDP&MIUJ+|* MO-RED_NUZ>0F,P^**J',06| ^?--
G8T9EXWQS_SM-Z8BBC&;F):D7AKDCEB; M4YWC9Z*"(*9@TQL ;L1\$&,6@LZ=R.U^"
|HM&2G0^80VHTWJ6+|I%&VV5QB86G M0_#;6R=A@0XQ3JDEI\$@#HX/I8GXT*;-
#BZM<43TX">JF_(UQ6^WM!!&=Q.PPXS.*7|JCB*A'|@S+H0837M|AEKDX&ZN_O3D2P\$
Y50; M#|JRE4QX/?FD,O=6&UIK9'O:<9B/B|9L;4&B,;MUGJZW3M=;1;6G="|G@_9+
M^HR9Z*|&Z041P34)T,3++ZBUS,TY,TOS|@)H.*2|(+SL<&(&|3Q|1S#A/8'7
M|RCBN?.KGG)2O>C)O (&@GIUN%?%3BQB"#IW1'2>3ND ^VCV0BR#)|+|8Q&
M=KZC="O=GCP3K70EP&\$DI!:=SDC4KQPX3/)(GOE5..)ZO\$QP9@MABCYH)6*
MQ@BS|VM5073U<4>P\$961Z0L<-|I67@LR|0UX1O,)NJHR.|!H&
M:!"46%YZ1Z/*|RJFJ2.0B\$X/PYBX<6BHL8OXR@5%|HUY@@*(@|H#H.C3*%K
MI003|JNX,*Z'@_9":7T:F;7D*W2S2!'L6GK8|V^?N0P "(_8_WJDJ-\$VO\$S2B|<04:S
M=Y|1Q:L &0>P%7C|P6'DJ|?7?DW.T5+.I |C+|3O(T WR8 G! 9EWYD3_WF
MHJ,O|QE)0Q3=GX2,RP@?V'#@B4/%.ZN0T>E=J6.E*?4!R(_NL(O6O6#(6 TB
M=1H>TS|P^"M|WE&|DPT9G=Y%#2=GN |, @:78T17WR%#,HA047"8|X'1W|UA
M&X/%!R C:8';+K'|@/H#Y!WP6:U/C 3)4@_"0(..D%^^@ Q<' ^RFCT0N:#L7T M!+4V>H'&
(6^KJ(9'+|BXXC8S64&D%R=%9ZK&32"ZO..!PT M*YWT
I,#5K;!XBJ|0.>0I6FD*\$LO(#I@2^F6SWNR%319!|MO-|09% M_H|PFN@A\$FDW0
2=YB6LD" _M-C:"|[#_K<35#&N72HZG2PQX9>4|1U=2\$A;#% M?;:G1F\$|-|J|*?
B_7I0DHI<0FZ/D+1H1#SAD=)%| M|L5XJ816|CZ(GO3D-
;=>W'J64T!3ADEXNOAK+^79YKR-Y1BE_M>-3+_UY^%U M0_RUGY
7ICO!;W^L=H;G;J,%^)(X(T+Q!F\$"&V,#W"! _R9*?0RC1G1^<@' M'NE_Y?,3M#;|3H?
3Y0DL1H.,.%575L(=K\$3ZYW0GZ@J+2#5=52|21>2JQ MC1S!172|M0|@G+_9JJ%,U7
1&VN@P?C\$Y2!-%<)&KF&R.TMSR%!'!;@:"Q:'N MB"|-
""6'(VAH'ALMX1CO8<%QI=8B2USS%C(8TIP|I9#&T!:=;!KRNK*M#R/P%
MCL(!K:;L30X0":>2P0R!V(W4#Q=\$|Q7H|@NV@@DSZX&S1|SVV=)%|3A"
MQ4T(^7:LN:TA|\$-"ON%I#_"|P_3IB2|>+38RPZEI%LXY2=-^4E3?M)(I,<
M3>,!%05NE27#J%I7R8NI_G78#*/ZRQQ7\$ZO_?7C\$.#E/E|_!V5I3YDZ7|8"1 MWM
R2^|)#O(=J?Q|C+M_4V(?G99X"^Z/V.4^/>DVOQDPOZ2DF/>X8"^R0J|T8
MRU1N_;;E(#@;<>PWM 0|XM:J>OP8(@JG(^+F^ 7%6^P==H%_+OIL.:9PFML# M6==
|@A4F^%_R9J+U4QQMGX(WM"|*3U^I20U;N?5P*(1FG-7"U6T&G10|TR
M|+=^_#;,\$UD,MUN80 M/BM!1DOH5IS\$K>5!@'9I6%R9U%M|*?
P@2M;70=AUP7VEZ+4ZN3@V*^6>U0 ML9\$F7|7DJ^C95Z&3Q9%/HGB?)YV|)KGLYJ5P,-
M:GOA0S;G(4Z|N.L|-C M5\$H=NF5CNBDSM"|K>|?E.T1B^EH-:F\$RXN:2DO(&Z-@!

<<\$S#3(ZV#FI+M M\$0(NTQ>/V>|?B-PG=UZR8YP(T_RH5O7DA+Y_26P_C(Q\$:
M/WMAOCLRU/I:(XV>4RNB&3U&;RA)R|+_3\$)8+4?BU>LNG|^(LD>/>/K*BT=? M42"2-
W_P^ Z|H=_24XFS5&LD:MQ=#:/(@|I74825&\$2.R1 S'% MAJ>
Z#7S3P'1X0.B'*L:,A3^ZA1=(N- @ZU4X7I37.4?C 1| '7VKQP8/&-
MHVD"^JHKE=T%, "H28I.+E1'<0*09P*N_)SVIN*X;4=!OGCKM'02.UJ.KZ7A
MK^Y0'@4N:L)6YGYVM&"A-HNP/->CH%V-#2YNY#Z(N)|#9\$J_G5^P!D@,>N MVP#"|
<=_ACS5^R0-J01-Y0(9_4(4KQWY:79& M5- M99QLG|>PGM;:*?
@QZAC&|*TT5RYOCI^UEJC4S.|L/#"#5 M54I%PB-
#+>NUZ_CV(&J|O.>=4MD\$LCV|%:6|>|V"|?8HR<4C9BH@VO/) >^*,G^_0#!,2 M=7U!U-
E2M IQ (LG,&J0"W:R""(Y@7& 3\$MV/EX):1Z<@* 7A&E.MY,ZUY+QK?:VI"!
M:Y%K;"C@4.MCJ|^,HOF%GZH(MDT!-Y!K"?(*V=VWK4I5@|M-_2L?')^.)XJ M.
(85\$GK_'\$,&^WZ|+E_!LR8&|ZL'V/3J9P,5/^*P|BK A R0;A^:;(6:.W M4 +OE8KU
"7WFTT.Q&-\$T|HPVHM1&MR+M!'*V|; D?YR>Z|=PM^E;X'IUO
M%MYX(9WM#X,M9_)7YC>|4P+YIU#^+'U.B&%TUC)N4/T?8)
M\$3.M0@^|(\$)KQX1T|DHP?14X<0?SR2@8K@:AQ%51TH|(L2@Z%01*V7SS+2G0
M(784%5?#N; K30 X)/-^GU:TC H4N?RQK!F9\$'^.KT#'(1Y+PIB 8XC9#A*<\$:, MJ",> 6U!
AM;I(:|3_/0=(S|=7H0=0;"O Y?M/"\$J-W MCULY?G_"'0'#"IH^|#|Z/'W5C|?SQWV|
|ER#_H/<"2\$QD-IPMKTX6UZ<*:87B? MZ\$>HI%&^95;K
8T,X0TH<9_QD&+_RE8;+;|4_|T3/Z|&M ;#;9RD|PU|?(E= MQ)S?
SJF5*YCO*4X,9.VR!K4&Q@(EB"B5-'E#KVA,,|HV25;"5=4I:>|M,P"
MVY7W|8+CMX"&AVY01-3 KHF9_"MU;A%84B?-B+SP%Z8'^%|HNY22SX-WM!)
MYQ0NIMX8EL|1NF/H>Z6< #TB@H;Z|-(4|Z|92G615;Q AQCG\$C//1&>.2;&
MGO)UIT3=SO3ZKVE'C0E_.@\$JFUI3B,D3006 =CFL!Y%RI:3U.J4#=-K1LC M|NL8PV.L6.
4\$IM"8E-(: "HP-Q68FPK,C;K G.WZ2|!+N0VYVVEEZ8SLPQ?O
M2,4V/0)|Y,6TOIO/7_,!?!>,#IXP9K0,4IW"!<'A#&TA*-/M;ZF H@ 5";C MJH(C^WXJ@#BF
HA3F4 K4\$QE J8F&J)|5D^I2|IN-Y-;/7+'#TW%T'4GH&:9FC=MEF-RH
MN#=@KM3GJ|+@W_NR_OIS5CJ_&9ZOD|GG2"#MZUJ>*8@.!/U44LV|@3A7%IHIB
M#B_#5%\$,S%)T#V8YE+._(|Y|0+@ KTA0@R|M7|+""|.ODE2'>W69*2M<#)
MTM^A=1:B'!%ON|5H6_#CINOJ.X^?,ZVKE;X.LXN|V;G<|Q\$^"WP\$2/|F-
O,QD3H91R#@DS+5GYDIN5,7&_4K|HJ'25G?;|IWR\$3K9R|H:*O-!B@P22085:|9DI;
M\$K0Z/QT-?>GM\$>EA|*CW7@^%QH'OJ%M=F6:._O H|JO7I1MR-|S3|=|M%|\$
M1R|C^4(UN_)3_;U9%|I9U|WO|^L1=M<|N!3NN9R)S+;U;DIX3L6.I1%)HZ
MNJ.8MAIC(E#|O#S3|_W7V8GG 5FI+B'Z2O955 M91;4(F>WG3PX1AQG&?D0410\$CK-
Z"WNP%Z>|N)SK8UAJ!:/RY?|Q=WLZ7;^ MO%S-^(BQ&_8F M"Z%#87%4A%%O"
|&9YIG@/.*GXDY3TF#Q?D^?+8<|71TWI M8NE*E!1'X=\$S|T6:\$&0
)B>A1NEIH;)|8RX;2W5*@L9DGE:.#!%' (C+X1|R@NZ9:/T2;& M^S+Q?0I&3,&
(*1@Q|2/TD^SVAR/V!!EUU;|_O=L*T: ^I;?_\$3YX.#T^>WO>
MCF,V&W2B"W3(L+_S\$C0CHBIGL>:DN#M00>_X2++_NDR>TW0|QE|P>2-"@;R
M*4%0B|<:TO2%K|'RV|M/@GUF|_|U78?@H|?X8\$BWHJV0+Y|38*_G,Q)&OA7EY;PW-
ZB8DQFP9>>#\$P M9^|>7J_B&_3B|VB%F|7=:EYQT9>BFB
M:.SY0Q5_"MC35.IG>*ZUP9-(|U^*57RD>BM*F(5MI7VFK(FAX0QP% M V(@;K@-
(/+%G#: AL_\$3!83TD;1|.1=Z25LCXD_I3:DYU|P|1'\$0/C9L MP@W&F+*BIJRH|BJ&U
THV#&.0|*#W7|6K<2,.DX,3LW&|OFQGI8(=(G*|U*LV*O)@E+NYV(_1&Z\$@-U4N
M96\$JO|2==7V9%'U.@?KOTUV|KDSP;MF: ^3'J |C+|Y'-4923K=C98M9-DN+ M)X*\$\$_9
@^|?B+-@N0UH#XA;A--@\$9.B|R#,ZQ\$D@SNT2|;!&QH6S)/F9C(9 M)GU+-T2@?V?_
00+H%"QS\$293|)|R&(O,@/Z!4@LMDS20(GK|6|S4#NE'
31=KYA<%|!"=U;"_I,PH|KH)^RQ?XP|,3&XT1UZ M39?(SW#^MH'XM!|VL:>
<|6*75&IQ!G9_|VKG&|\$2V>ZH'\$NEV2/76! MM_DD5_/FEKRC00N,-3YISG2V)|M
7>.W<9*>GREA\$MEBH\$D\$J7W"OLS^MOP2 MOR\$KS-JEE(M%-
W|W"YZC6%SZ3FAO?GHH;8Q1LHPM_;"E6E^@JW|O&,49PE=#"^D2_\$4
M)|D+M6^IYPLER6KG1=_|)6TW"4SWR^6KVC6BB.Z?M-1*\$_DS#&5\$0@/;7L
MFP"UH#K!8FU!=Q1KY-8EX&5BU7<|F10J=-2Z'6JZFI3.=F-9(YUQRG,(8|4\$
MLF)UWGKP IQ'W3372CX*>"\$CL;C%0\$#66*J-U;6#=-H09686AO\$|?7.1|+G%
M:|VDK<^G#HS!< SQYL|Z#*C%|N00L6-<\$'&16WCR*?|3L"7:22(VB)
MMM9P<+FQ^11.LC|'XI=?>/1=|8S7@?>AV6#^3+AR_VN" M:Q0R.?I Z1_046J3-
*+\$>2Z_|1#UD@O>(|JPDDB8SB CO(9|.6V7|OX6/U M4OU/<4A+GLFOKJMTM?
A(!7=VPNOJLF|3S9KI;T|; M)2FJCCU=P/Y4U|Y.#""1CIR4:U/7,Q7ZK?7&^#RDVJ|NU1
@#)&1RXAO4?R:\$-V;BHK'Z)"E|.40 MHBf'01XDJvY%-71.?V|R\$_.?(E")+E\$^EY<6TK0

UA!U?-4+^H:+P"EW-^M2MT<*!+G>9'F#Q@).7P>OA@!*)2Z9X/,&R43=E=N\$4?043P.
M#./CR F@RT3LX*! K55X8C@ "I"* V4/2\$=9L=XYRG+=23>[*EP9\H6>Y.9(M_G&
(\$R_!@N/LD) APhRFM],V19\$QP@;D&,@)E&8P#SD#BT^(HTVD*/MYJ*];
M?;\$K)1N3GDGT;I,P!8;3V/!=YM4I0?I8_'<9?-#"5D^Q%PD>%Y7T, MN@M,*ML.1?
%U#)/XBADT4\$HX.'T^.'SMT>,G#ANLT\$GND""C)S(7H)F6XQR|FY.BLD, M>GT-||-
EZV|CYL@)KN*SP^,5H;G<3Z:ZOIB<0S/<>5T/!MO\$!T)1KM?, M(I2*Y|6|S&+
J/C@Q\$N@OQ09E,P\$V!A%3NGI?7#>80?2LX@/-(#Y|7'MY^K M5+%&?
@G2W95!E|0M. @;1HD?LC'^FO|(@ "I3.?/KQQ^B7&/!&K%?*R0#2/H;G
M^#4(49+&\$7KQCB=O-OK>+J9\$=7+|QL/,BJ\$J2IL;GAFM1DS+ZU\$^NW(1_?H
MO"N/BW/I|=6.:);W3S=(7S_<4!1@|IE|ADUG_,TJSU=V>I")8|/,EN:|40
MT:6(@,JKF:S6Sj8B6K"BZ|7Y!|!(N'8|&BA6B|U|F>D&&05E_O_'@D*+M^P-MA(RH.
%#9BR?Z:-P4T&#P=JDK;SQ|YYCF<2.FY4.C!L@>|\$\$KY42(;OEF# MGG5".(*
*+&I&P0C>|C-PNDG7@?(J(Y;UC5|28|:'U;(N8|5HX7|Y,>1^M,|>?+=()KL#AY_@34
!|I<|_+4C9Q->)N=?Q5*LM'(|>|Z_@#5Y9|Y?J= MW|\$QH3T|OA-D*8;T!MPA+P9Z?
KN5V|1V-AEW8E>+V(@(*2T|P"/"?A M0SRJW:T1R)T7V9^)|HH5G> 1S5
M6KF|A'N'#ACY09FZ>PA1?A23@ZYX,B_/1=P#HG&AK<&T\$T6Y/6MR6Q./S|N
M#SA^*_+GA0NLUA?>OKM.0%#J8CJ/*L-\$-:%9YL\$'_;JY_B9A0JH|\$D\$Y"5H
M%X=K90X2|;!8M"W72DN7"V&)+=%|937;!%V<38U05PEKKPXIZUR@(S-R^ZD= M/#*
#30H2@|\$|35."1A7@GGJCP9I6B5**%?|A8Q2EXW%3OQA*:2.Q^3:B19S MRNY8X1,SD*
(N|'B8T?"OU9M|&0(D@DQ#%?7=|0:H6SDL,@,<#UNVA\$1L4CCD
M|;CZW|Q,/GOCAQ*OA=.CN_)|>VN<|?(S9\$GFGQ0)#W|A,)U646&>P%6JZMA
MK|75I_BN*EY3@%"7=504KHBj|9|N5(\$,AB#^'ZY.@EMPB-|V|&D!G'G^\$H3|(-JF
M<33?|3%_9LQV|#;<*.|56XQ<.@)+6!|E (IZ3+;K9+MRCC_8\$\$\$S)"-:5_>3 M\$Z0%
(Z1JSJEJAS"Y (W N**E Q7/D&J29R#8:M-8|RW:N44KNAAD8'H5J1)9
M,|:\$"R'#/5F.;T&_+'9GO;7K|' MBA/*O;#-J";Y+
(.M|TU\$DY'H|C756|S/'|R?."7OT&4%,|HG;TF>=T)?0%1|0R0N&|)
MVF3A4|A#M56Z3JL1/\$^Q!*E|G>+3Z6D* R1GV9>>%+QA2)%T,%PN.*L1(=Y
M+VH*K?^=)2GC.6Z3?5:C?X:|:"2#0_05;2 MR=FPDHz-
RPXLR4U(T*Y/M5>L|6W)60%!7:/%\$<2\$SU4/"ID;|U*W|*FJ.F@4
ML;N&'C)>Lj+>UP;RR;G<,%(=);*CTZ.63|HWA|<+CO \$:UC7H%&0:FZO;/%S M>?
J'@%-8Z>59ECT:A*Q:BZ/+!RG @R\$AT.A;J?P5\$B#1X*(H&>-%A
MG@H*;I3Q(M):>Nj%T|\$&|+Nj\$&,&H#UO<#U(CA>.;LMJB"/%Y|VO*1QE|2=
M)!B05|U.D|MB98|S^@E2.LMI4FJY*_76%N-*?5W<=;8JS1MI
M.YJ|'L&5@W>^:IGPRAG|HK:>3O&"B"% ^,3'M!;'2K^ M7Z*G;NY09;M!U>&N
MHGX|#F=?Z|E1A|;Q1|3.B+|N|\$7U:P&R '0/M0#J5R##(BI^=3"
MP/G8G!*UW4XLAX)TC9*4>67_!&10|@D1^(L)WJ'\$Q|&A1\$48HI/ULOB4&FMB
MHJ"=J(>|X K&--DL3Z8E|N(S89K+;U;DH3+JSF(+Y|JCF*^Y'FPC<3U|Z|:
MP*MPYW.E3#J#^;""0)"V&T-<|5S1M=YOEF2=<^5GB@M5<-H6|A)%|H|(+'
M.5:;+D7++3T8IPLL4(Y3FP(DJ4+*;6I2*R)M0%L@+|Q/J63O!QQ5_G.:&(;T/
MMKOT@2@UJ_=8 UZ5;H9GF@|HOJ9Q&^_)_GYSW<\$|8D)3T,S^&?P.HWU
M|C,?.\$:K7G'*_|5-\$7KWPA51_>0X7?4P?;*->4DY6MRVAN=4%|=\$>0|*<_J?
MR&./2|C>FHBISVI!M^A||RTIC!2.G!'W 4+*4^"|YOXH)2(NK7OEDO-G%F3;
M>-12RK6.?9RQBPMH|.YUWHTU;C5|A3&L,Z+=|Q-""7..3-@2E+AJ-13D|H^08HC
MHMB^!=0Q_1#C>^J^2O)(*4|74>|,BEWNB3&4ECGFWGAHXGS^387I-T80&3M
M+X@*);2>09'?;E\$>0%"P8*+PC|UT5W6@| #DV!R#!*CM|K1OV|#,&L8(27
M;FTEJdYMG!QD;AY41UH:+L<08-R?1 Q_/+W=N9 S,J2N!Q1!!D*|LW)\$'H%P
M'(LV6T0H|N%X\$H_N62.+L#@.1QLV805U|\$|VZL85U_\$DQ^%HPQ7|/%8?8/P%
M+F^(XV9|@/\$C2# 4(W!|/)7AP"IQ+Z@.)O(*0#AWV T'\$&7U6
M&)KN!1K8VJUF8+L7A%Q2=U7BX;V !%,1;A|#[P4DF"JQ).|N|C6RF9|S?T*4
M5^|HX4D?|!G:%W2EBRS_=[#1W(@9QC3,Z@B?9=>B)+3_DEH'>)|W6I*"1@P7
M*\$'X#75|/%967K%S,L?9|YN>O%K.6QJP_BNFD;|49L&Z;M1EAT)?2"*NL,S^=
MXR690>#S7M|C-K,Q40I7.8>\$>=&W-8P;WQ%Z|#W K* K^1DXB?C;|L-P?*L M_:
|*HYS>AN==+M;YHWP4.2U|65.,7CRNCM'=Y9|&CZ0A0!T3CX'0W1ZU%>4S0830USP
_Q'!&0\$U.ZABPX_\$?U|6L|#9IVK20#.F>PX|2TWOJ9! M""Z|U)"|H(P#I,89*7|R2*&8 M-
%K%T?Q,L35(OHH|G;_T@H/(&PY>6%S@ MN|N8<3?
%GF"8X7.;QMS|1W0H;B76/8FL"7;VGMTE&S4Y"E.\$I3,H_L/FG:? M!,O/4|JLZ25TY2N3L0
D^3>J1U=U"2WXBB868:(!|I=Q5&C'S+0?9:HR-S QVO.M<:%Y'5Z'CAN=;8
M:|J;CA>E4SUFU.Q5Q|O0M0.CDT\$|COC7*25T71XW-3F(-R>-|(% 0FN(3?&P

M*1XVQ<.,@WO:@Y>MMSA9!&03GET#CJ\$SD0*\$A/-?8VC="<*1+4?PR?#15J M&W8-
:9'DU7ML8NE.0SE\$./DP|U7|=H.9OBTH.@<)V*M=G"5>M)Y%Z|P8WNO
T?:S1H|J_M#&|16J:Q_UM1=ISHY&W|I8FRAQU\$#&@TE/_)E&ML)L4?T<@+4T5%S
JVU6PL95OWH|F M6>/=1JFIXSA:~9XJK5<"J:*H<-^_*#R+6U(@D!>
P6^:FO05_'5M)\$=#W:V M47HDIK7CB/1VDG0RW|T'M<|1W_3.QZ-|BA#;^)X|
,SF4J;AO'|MPOZ_1S+(*S_1CF'?+E+GQPUZ-,CR*+FQ=1N0R^AJU P|LC
M:-7O_NR%&3HJG'IU*R(LRLXL'L(-&X5)%63K+;G6@X%8\DX\$U99+EY79|V1
M&H9"U;X3*.*C|A(#8W3F|XBU1XR\$@IVOR9K;-D,H*%1J5*;(B:6YZOKX/&
M0E)1)T34_Y\$3+ WN74#3|I_\$WP*_(/FF M2=(LS#^>!
|X7R(^W\$3UAB)0(XGR5DRLX:4|&OH*@\$Q?,R2I)?R:);ERB?+
MU\$MS3|93.5E|V\$W4POX'%/ZW<@>3G>VGP5N>#R&.P.FZV2:(=3=:)23|H/&
M:L(%\$O>QJ)\3@G'(%1(%KQ=ZVF<_T;K)?8JZ4QN7-IRMA72H)/(4.JM+
MPB""5%_O!)"1<1U.JN.QE;"5.2O>5YB"6LY2MF|X8|H;O^E'@V9<*C"JJ MD#V|+1*3>S
(KNL/<-1GR%"J|)\$4M8_4|K55M"H*(48%6PF!1YQ+,(D"KGJ M:<.,?A"PF"/PB"J2|8B|Y&Y
0|,5>7?<225S.Q:SM"UW0_YB@="/5#>WY|A M|5.4|\$/X|+:H&A:EP|%KEA7U:|%#|CK:E,
<:HI#&#0+=2^A% MTFHSC4;|77@ATN<^+YR%HDK! ?);(M5H_:@W1*>B=/=%:RCK|
NB%K4FUB>J MP2?VPPYF=NBM=PA2+|SD_ A*XD7?+,,OSSFJ/(6COR^Z M"V-
)RJE\$|\$,OY""^/'@|XB7?'R,NN<|HK5SHL*>9W\$K;ZRKIWHF2"088'GL*U;Y"Q4PO
L:PW%KTC MBJGID3R%R=0%=V_&JN->?HGH5C1G'0>A1_X;U;QV/+CBVC((K'?7|_H-
H\$GW M:>J|?I70_?BY+@+7KR9"04+FG1!C"S97;DM6U)8BG>-H.^C<>MUE<68#_P;(M+4NI2'ADJ(63NX|OGB^W% N5=Y#()@J)"*!-,U+XH_!!8^|ZL72TP(@T5HI
M.MO+I^S'=MU|9|8@+Q?':?|H|OP.E+!'.<:&:VOW'PC| 2T'0|2CYAN!1B(: M.M|=WN)".V?
Z81?MW>G|2P4!>|ZU=HXRPFY2IX|1H7Y| 7G+VKVLN|JL+|&% MC7M@,JGI8Q,9G
\$PF7X;1V26-""Q0\$&29%|DHQ,=?&QD:VK*+);K"9 MY).""+27S M\$)27=3A"K|OP85-
SAY7U-CA4KUIP_5<0NA#C#O.IH*:B|:PLS|ARL M8AUC!
|M#%&.,KQ'WR*Y*0;2>6/ATE#J*->"QAYZ607P|@UXZ69YV+2Q;
MB1_(P+7(|3>4OU"K|%-?&=S;.,UJ#,*E|^*^*^!"S,.YBCZL|_DY\$UQW/. M^|>
+3K'%T#*Y0\$=HC0|9L! QXG+<*(CH+K|FFA&;ET_&Z&_H4,|KI*JN M|Q#-
N*GC=VC|@|O%3\$>'37^BJZ M_E1/=JHGVR3I\$|63M7TK(L%I99KD7Y^)-?
|ZZ+2^>A_!MMS M)U;_JR4HNFRHEN7%55V"V,CU_|&EQV|!!R|IYY*7KP IR_Y#S(E2?
Y+(85_M3\$2Y\$@JFVM_M5:=&->UHO+8%+^%QVOM+"?^3=7<4KUSQ0'41+X?
7*0TJ>= M|!9GE-"|&*WI*Q@^7\$5TU|-=?%:~2,C|MA"IG"2=E=C%|ION7+_)G^
USXX40 M**\$,+|RC1\$YW|@QLC,T:LPHUJ+45^\$&6J%8\$2T M7+T4,*K|Q_W|+\$X?
YT6QTQ4SM'+N|+N5;QNCY6Z^^C6JT> W=|@/^/"?P. M(:|>3,O)D6:DY)E#5YBR_=
|1X+N|MOT(-GT(-FG?)^L^8!ATGS!"RV>WRH MK-TDX(|TCM!G*
<|5L&^^/R"+!\$.J*J;|T:_\$0E?G/7,JPEZ?>\$N=G>F|B?S M100|G_8")2QND
8M00ABK5E^ZN4"O\$9C7)AZ:L#@X#<^/WJ X;_4)=+33|" MQR>,5==0R.86)P(???
UBD5*F|CW5\$8J@LBP56EL3|Z3'O@@=TW4U;5C1|_7 M<,C|_.\$4U33=9SIM:-
0|7:...|'%AN.7XH:LT*CQSV?=94<.*;WMEIJ=P5 MG""NE YXXOK09/YD6K:|= "CHXXOJ-
O#\$?HHPHS|1:|IZC>M\$DQ^|ACGE? M-B-
/TU*YNRFU@UQCNP0BMUF>MUF>MUF#,G9TIV,Z5|&E.Z@B6J MJRWY56(HB3B-
R8RO#',776&J9|VY5|G:C2RQJ2PSD#2\$J2SSE/8UI1)! L|M M@B1N!&BGRJ0F-'?H|
NEUIR/KCF,OB=ZERYXVROU(H6^|RG)^4GI_NG=|I3
MK47F=#^WL3|5H;^|V7A>EGB,)P@G@GYX+DR3;6W!_2*,P|?5^_Q
M_T4X)O|_D?,HLJ_R6B('U_H,IP|@9:|)NCWC*BU|V_D/Y+EX+6&-'UQC(O; M'FY\$X7-
%^!3T*5F@3W<(*-PK?.V>W=;LU!<5J9-_G69,GU,9IF2TX.RQ-)' MD4?T"H:DX+
<:=JKEE|I%R0'YP29_~;.\$+=U;|KV3_76;I;|/PO"XD\$2I"=5 MMU!?
A:|&O^6E54G=C+R080M P0-AU;)|J,Y2TV(>X@QWT(E\$XQFF|5OIPU"W MV/ETM1YK?
(?RTA%IZ9W=.,@8L'0^ V^9>=3:9KAT=D^@3TE)|B_1^).2VA;I
MF_E^G\$5I\$&V_QFNB@16NMUO2;=NNE)YP0/=8BUJ)54(>(Q_G':XEN&E&TOGT
ME!LTY0:U2|AHNK*O\$GJJ'EE':"Z-1R-\$GTU1T,1/R6#|1K YL8ES'E7U%U|>B!=X'5UA'K6
MF=V=?#=.|RE_UNGH"11.R.(%@K(4#'D8"L%+IQJMQ94P\$@?M
H=1H#ML='EL5|Z6V7Y|H(OYYF6Q_M_#;ST^"-.\$&?|(EGKI;OB\$%-I.\$^0KHNU-
S_5KHAU'='|!)-.546'?|C8C;>C MHLFH|UKTC^+GQYOLK7%RN|_@@N+G!#FP+!-
^3=T-N#_*\$M@U&N/'""|I# M'_SSHP<8'OL/=?M@N%?
J5=ZLN=:P|\$P\$|HFWHH9!&|C4QVA"&*|!C.PD+F> MP7AA5GREQ
M9_X#NR?'OLB3'_52@B>5_MB8_RU MT9W5:_2XY|ND@-G|! /BX|KJ> *3A!)T-FK-
O;ES;#*-.B|;5#0<=(7\$^U M'_AR@CV3*OE|CFJ%U1R_*+%F/=E,P

U+96[FU(IUN7NU9!;@K'W&F."W1NJ M>L5 /C/\$GVVT)GSE<_Z(C\EGI^O\94WHQ&A-
/H) #-=&#-"C=G7\$V(>L@4:4 MYA23J?P2I+O;+ \$GC/<)\$> 3)?/." S^(MH*,.,7.@(D3WL-
0\CYV GMZ&D%2 MW_1%Q^O,3^>XO\$7)>3*#V0<)^?X+>U=_?B2FY;,%\$E?&1%=Q3#
M6:)/!,DH0;,M1OD7^>=,.. "T"Y9BOWK\IC?-IQ"8>Q&8T&G20-D,XWM5EPV9K? MUO
ZSW\!;F!Z*CK.\$(O7A@0)4WP2("HN>&9_2\A\01%_+G4&PRZE NZ\$;GO
MHU3_.NPV(%K_/MMS)U;_NS4!2\TVU=@(%?)6*W"7ZQ.3+E\IC?#W/^,TJ47
MHN0&A?"[#S]^]S4(OR+M^;M\W;'P\AZ^B(^>F%Z7!"AP)JC2C?#;_WJ1=F&
MG)09IMHS41*RPR\$|*AOK:AT-SW;ON'RY7\IS-GF\GS\O5C#| |=L.!S\|P/L;"I
M;_VW\9&^(Q01?B=+|.-W.MM\$U'&@{?)"&+[UIKGN;'C6/V=\$ZPC2(Q_,1HN>
MUO@+1H2ZW+>FL*B;@.M\|S^C^/VG^+WE C-Z#S3O\$X2K *U7<7T>.A0(Q\&V
M!\@N4H+1YF+<;8R@YD?N09QO"SM1\|!#A);^,JV7Y^X(449.IBR\$WAAQC? M?
QP"7%9".H86K+%R=-RX,|*W>^;1JXW&T3K(:'G.#U7A,[K
M1&.Z&6\|R6E9H3,A5V.JG2YF76P,|2N;1:2YL&T*CO|.7R?H(J+&OE9F+
M0X'.MU>ZV:\$7.*KBJ1\|D<0ET5-A_<,TAN=)9.&A4TUM060&-/\$*=:7;!6W. M:9B|>
EH6*0\|P8^KG#A"\$-0 3;KX\|1-I/|/*\|L+XB<,(2(-59P0:<1J':69\$
M=4YLWHBL@"9227T0QF\|J%Q5U!;.[V#""#/2<J#\$':!KEAYUNFLMYKTNB4I!A
M:7'MUW3:6W5;VFA P>5*G\$RDZ!/? T8\$!-6O 20\$8/*>>+|(LBW7H'PH&YT"S*D4)F4
MGSCF^&-Z=E1@,REL?4#_UY%_+|B/ZP.VOXT\$MOX2^/I_>|C\|UTBF?;_"/
MD: ^!7MIA+PZAL<0LU+(= >X%P+\$XUO21,AZJH7 JH/!*(JFCE?:#D8C<0(M" M:F#!
6V#\"(9/+\" MJTF+*>7V&O2VXS(EQQX56E\|0O,7>81?
X7LBY%,QO.^R4BT3OZB2X\|0;X;0WO M7B+%4+\";-NE;|?AX_ ^&'V9IPZ_*_& 3T#)
<^1_XU_OT!K#-|CDKD%/PB7Q\$ ME_ \$E?8V0EB#_O\;QVY_|K6"LO(?%Z+*7_SZ>-
^8<>4/M\|N^4)7N/!Z62.' MF#N(3&UM\|L3H,J)U&\$KISYF\|A&))9^O\$U79X.O*5AK!;+G-
6JZBN+,UXO2H MT9@^|&M?4H/|@;+E=:^JNIS=V5N9KP1N95@P9+6D@3&BKG>*H
JT;O\$"5E': M'2;X"30^TC1\|J3EUYA"^\$0;: 7\$*E=0T.\M037O)|>R\|@2LS 9S%#-E/JH:
M;Z\|G2?5R_'.M1|=S>XRBUNWZ(FN=E8G4Q72(\^R"\"I M;
<|P\|C\$*O6B\|0&\HRM#J\|5\|MXBSQZ/40\|L4B8HXZP\R%7JV6^C9;K7DT<1N
MN_N9F=D?1-87OT;KRV_OA@I1\|C(/+P4?1N31\|?L@|;310*2HT+. @ CHO41 M8.?
A\$;N)")W7X"9+B#Z2)#/_|RQ("HW7S\|.O0LA\|V>Z>GA,-MYJ1S;C 65I MX">4%?
A+C;GH)BX2K\|W8" JGR9PFL-.OI&F+DGT=))5FH)>VB"7E/(VY:2
MA@BPST8U\|/ _9CA(UH'/%:"JO0:WO>|S|R>|F5Z,-4;XO\$1G;OD6K8,DQ<%K
MEJ+UO8\|G>JFU(R2M_)HLPF1!4J_9-
8!A.&7*TQKFEDZR80.72;7U(OO/@E99;1'@\$B>N'WQQKT3^,O.GV
M_P"W_S_#367* @KSR\| 5K5D"^SL'('PR(4L+R9&K;QXC(/I2(JVKV\|7/>D<6 MV"5-
O>E\|6W*F0_XPNE+ F4Y+JE+P')S;:(GFOIZ,"-(!3?I8#B4B0HF75H\W1 MV B
FK<@3#A^0;;J>|'|0QS1U\|R)\.N7" (=|;3.2OZUUY)GV*GTL&:K7\$^_
M91/*6D.XR_<4>*J!&% "WAN)+OQ.P(AYH\|9<*BJDK4
M\4>!0&ZQI9'_/UI7R%!=S\;#PP&H.BMRC*O2W>@%@1RMU3.Q%JHU(2Y:!\\$VG
MX\$|3MS<\$T'F\|@-J-YA+*R5:GV*?RYV"TOU-*JDVN(VY(95>/@4*.\$9&@086 MK-
YPR%,\|JJ-X4P>1&&H7LP\|#;/.O4"/AF>H&@+>@>F <=5\|KN68XB6\|J_H_Q M(1U@
@3Y8;.'!P0&U5G0^V&H=R>!\XV*TB5<30N?@8\ 4\CP2./-BB\|MJSNI M*F\!"D9A-
VD>26+!Y&B@T?2YQ/0ZC0>;=B>2U%GE.\$#M-Q*3UQR-8YO>2J6U M-
AXTVFV>UAY#QX'K>CHU'8F.WIHTO:O&!(1P0VD\|QV\|2JFCH&GA-77T6J9)
M\$)D>5\$K@'93FS\|0\)%3.E?L: ?D^!\^DWL%3=K'6F3C)2.&K9=4^.&TO# "Q;<'%?DLX+
<)>Y6>|,BB M4Q-SF\$)/POSU2T!OH"Q3C%":Z\|ZK\|YC/2X+6;FQP\$4HC^,&R:9EFOW7\|O(
MVOF(.9;_EO/=<0ZILEY0R+GS\|MX6) '.@;AHA1PHQ7T \?B5_99\;+NTFQ/\|Q45?T^OWJH
M\XYS^1S:6G:EE)5,W74\|GMCAM+B_) %4\08.D%*S74\$>KAK.2N@<:'0464E=I
MSRPCTBQ\|PZ'&+&VUSAKKM-F9CF G*LIN"SPW2KFKU6\|0\|= (HB:JJA(,C:R2
M@ZX"H&Q10,Z\$Z)%?J/=HT+ ^|5EVW%1V;-7?B"HD=ZFA8NQ.D M+>Q9 &H*|L\|QPBA\|?
Y/H1?A#Q>1JE^S)_ ^2E(4GNE+HKZ'.=<6X\|6TX#TR\|9R@318^!1MTAQ(?!SGGSC.|
|+O*;L*G(=!K)8=P4'5\$>B)&(/D_T\$ \$0>\$='1EDYN&6_P^2^/1/1\|+-^|_V+DA"ES%U!;;O
MA7X6>D-4\|V9+EEF^|V'C_/_OY:>?OGB'?.#|AOY&I4Q/LT.">DB%WW*?(\$? M&*_,G_FJ?
SF9S0N=&A_A@06/%05TU_ X17?=<6Y>J.TXAP^E5-4\|T:!\|HJ*1)<#_V MI-H=)H%!?
M6GECN6/1V)QY!LY8C3^EH;-^3MX.(XS^ ZZZ*W\ ^?E_.GO;K:Z MO\|N9/;^ ^7\|W?
KY80)&V1(L>2%L5?;C.,\$4<^ _M=WWT\$4D&JKL0RSS!O'GIW7"R&KV7\|16\|F6C>XDJ1*J
M-OI_=&7?O##W5A3YWT08N\|RY K*K\|H0V1+T\|Q(D7?L%Q=B F<>&YI4IO<>F:
M*/*G.\|3XS0V4#NMYJLHEZRN*((8L=H+\"-+!9X'ATEG1U0
MB+:YLP>|HM3D;&Q:!\PB4RN?9&\&J17\|\$.E\$07_ \$LJ"3IB:2%IA8F1E^)BW

M+H1S72Y7*/TC5%+;"&96*W<65R*/.28T0S0I0*M4-"^0CXC"3(0200/6E\$\$.
M4"@6P'D\$LY2U1.1)IDKW3G*^_\$?9-G2;WR7"^<*WSL\$+2L9\RU!>8IJ2!TZ
MB6K2Z'*S\4+UHJ1F;Y:T99=HEFZ8^F1&J4Q/CZ[M9AJFA)'^C8%DP/T*C*O MIV=
I.B\BG\/-KW-C\&.)AJH16"X1<'I. M\$"GW3="WGSP_25(=I=9DI(%+<+=C./6
7K5=C&+;.Y>=H\JM;V\H-'A"*WO M/4RSG)+*WKY#F\ /+C3_")IFN56?-
_@)A>O2K'^.TQ^RKJQ',GZ M<:JA,ASJ\#42&LH_6IY<8_RQ\%6J_9L\F\VL3IB;*|=Z.^'Q?
(P\&0-JC9A-I:G*^F&^=G:E.8H M\LC5">JS2=48P3I+UD+Y0GZLMK0V;7YPGCEW;G-
HB=I2J2#09XTD3K"920:I MK>\$B5SJ1X=HL=7L#X:*K6+"!S7IV).W"G%>MIB5=
I1&5#V:RYQ^K0D01KH. MYNC((NMGFG;4E7=I:XUB\YXU)I3*7C=^!XL:OD(@E:/IRWN"
(DMQ=REUM7C8 MRZ.AG)-?
VM&R.U@IYBGP%RL/8EWSK\4XI9:H\6EW"5T*ULLM3Y1:").C;RAT
MM1DPD\$0\$\$:4_K;_*R8I-;:@0=I.H9UP%(OHIQU1;>/>7+%>4X2N(P6--S MZ/Q+
(A4N3YGF;D2F"@CA%O-E-@_DJZRG6&_0)L;HS% HN?I@^D6,R<;W\# \$O MI\$27BFH=
<1CFE7=2A%"S"S"J8U\OSY"@X=-/SI'R\('OZ:BGP673*825#Y+WS M<9RY="DMR\3,22X\?
D73"V.XL^+%,7=FU38K\B MNR#,*I73M?=QV=^MG1T-K\$U*R:(UU?
WQQP4*P+ES8!@8:IVT+E*4;6\KY9D@0H&W11 MW,C2EC27\R8\1;F*UD4S#,B8-\$?
TCBCP87PH*O<IT2H\$+M\$N4+UA;PE\D*:. M+K7>!U%
RUBG1\$0VJ7;@ \$K^6;G"3\$;&.Z/;#^U>B;.9QAO-3M\0\&:S++3'# MV". S3V4MSOZXV-
4%+*<;WA=J"OV>Y;:YJ1#9>HU>(4 M66'UUC=OARQKWZL1QBR-W\H7I:?
L7&L'O#R=2DMKTQ::DXV)L\JL"9MR&="N2 M&>NC6"-7\^D&@*V\",7G*7A-
+>W!BQ;NXE\K0W@W=%Z0UB\>"(S*!OGG:I M@!&Z#6-;
(G9/K0&SUI6)WU\TUL:QF%_7(E\#)+K-2!;W&UOKO\HDC696)\R+
MBW"GSNE@+SW)K.>>2;?9;JC.O.-\#E"A\|#B\$3MY*)7D+1=OK>;IM: +DYDM
MI/7U.9>EBL*9;OHKEK)F9B(SQ)?M74N0N**9B\$@ZC?7E3B"YW_PWJH8K\ M^O\I^KY?
SA=K;\Z>%I M_@N(MZKHE38OV>6OF1/R;X\I?\$GI'X.S@G?
E\$QG\KLDNY(AP+O\$!HL&.#FW+! *IR6\H4O<5C%,_W+,"(6Y:& MC0A0SJ"(-
\$HG\$8V"&!,^T>;*TDKU7U1:%EHRD5&T-2Z0\7_GZ\W7_X^<%#
MWSR\WVR0ST\PT\B\SN\X12ESAX@)XP?Y1C/((>61"^4TC?H^9N\I\$ "B*X9/;
MWJZW\A:FP./S)AF\$FX)1N;S-*I03&M83J5=-\XS%ZXFF@:B
M7ILMR8^<"R(NO*/=#I';1(I'E#I4K^!2\$'7I,TRBJL(N3B MMZV_ =^!JPB'.GW.IW LR?
QTK,ASF8=?GKNTG\U\I\TL^>ES@8:%BK\|=,IAM M,\$THKJ^*J0Y@IY6E
MVD*P\K"W)33RM\A;1GT J^_H#1^B9#S(-^D+!;D5DG28D*DU-7FZ=%GOA7O
M0.KQFR"@E.9<28&1C6#OM@?E5\#0YK0U/"=FVL/U=%C-
HM3O7S9N@C33UX0"C;MX4"< ML\I\$4!.GYRNMI?
5T%>0;"!>3WLWC'E93/P(@.FOA;47"JGT
MD<(.4"02Q.QL6%I6"")?:_R3H"60"T.K+@D2H/UOD0:P5N5Q5,?#M"R2D*S
M'>3A993>%U(02%59.'YW0 LE"(LJ+A)_!'BU'^C^">,DH\4-6;6IEOX.K3/J ML5P1@SK9\$;
(V154.LL\JH\5^?;K*H2('K^E6I\$QZ"8W-MA@5\O@=??DV\!/%;
M8/='5!0O,RB/4H10&H\$39Q\;:H%;1\;.3D67\QT!*S*.NF,6-NQ;AW!+ #\Y M-.ABR: +*;
I*U(OEM>!8X7;8HI%#I3\$\$\U!WA>7LR31N\$) AY*" T6-"R!EC
MO>=K@0<500X%7OLE<>4%MHY;5A?IAM>?4%_A#BU\$&VGT.IYQ79G+G;PJJ+
M9='N^NU \1T\6TS-VH_M\I19T;>KH<=.B.@\KDM88XAG. \$E@7;E0L88UJ#
MHJL&V\$"A\7#. 2"6CUU'->P4-J>J5GW%ID:U1Z?< NY\$L'1X%X2?DJG;51JJ M?
0@FSSS1\$?7\!' I7UU(G8J^%"^OIRM\STGY^8S AQQ\$^/@\& M@3&\^&3R0%_=?+?
CH\$Z!(4X\I\C*B/25-L-\Z7\<1W68UA&*B#>Q5K;2YDB M2H#)DZ2*>7S20+&!"
%TI*;,ERF5P\I\$=:BPN##7I8\$K:,%G/;<;35D)&DFD MGR0MP4@*QY28;
(+ \$!+\$JWCT4(QC=)1X90Y+""%)F?(O.CB%B/-
PCYV^5G@>_>+XKM28NET,KOP3DYJ8U9BZU369O9%XTTD9+'WDA*NLT
MTNI'22IR;XM'B=8_H7"JBD^U.6ZS?4\D&_H68>3'VXA^XXL7./3*MB;)-21O MT";&Z'P?
G_2Y)0Q>+V3<=X'+_>V'&#->#I+,_PNIUQ*5#PL' PB\$=D++?
2YP\$N9Q\$2;+;>='W/WPE+7?)S/>+35LT<I;I"'+ M\$X9S3"M\I\$4N?@R5T9Z0&EN*
V^QZ&;3^"8D/\$N@C\&983A6C9CQ_ ^&*HTPL2 MM+!?\$,TC\]_DX?S=*
(R/0;0M"NPS75%_S5D>O5>*9\$>0Q%Y+H."H\G5\W_, M*#7.PIJ-Y26!;1J0\N\$F'F!-
ND"!-85CL<9\O=0_"6(Y3P9=/W\I)D0#;Q M\+K>@ \@-(28&C5@?
4HL'G\IX:4/GETOC*;O\1X\>GJ=%K%:0X,#1N9)E/<# M1Y*:XF5JC0\$
H7LPM#1UH1+8\L1"8%DMHWP+NDSZMZ+B=I'W^?THN.2 M55;B*_)HI_4L/?>;TW?
P,HR)@,G/*\$#.Z(*\TPO1+;,3:-6V9G=IQ?6@BH MJ\#
+6@IUK\@0KS7BPFF"+X\#SCL7\%H7RQ\$9 \4^4 M\I P;\$^>I+IYT>.\%2F\I<8_T8?

I(Q)E'#(=K&*0^X/0 |&%HU7%?4J3>Q/5+"3Q-/G=[1/E&C#B*D2]+1/EFACB,D2 M|
1_>G'OGEY.,VX30&<;_PHM6OQRVW !O**X0 6 +N65L(I=,#(#|K;I8<0 MY;..UJ4-++Z;S"
f="NFX4\$'F^A%U?A=XA)3,JD=*TW6",_JAVA:GAX4GN MJLF1>M\$VH*/TG|P|IWOR%
f%|^@WY8L|I(,%-S|X4/05OZ&J6' \$FZ.&<| #9* M?87UJRP.7U"KH=#8Z)).\$(D1B6MI-
X@\$<3E.ET3>0/"\$<\$-|SLO;7&HY/V3I MZ9!5|_E@>H4'(7;)GN.)CCMV\$J%JWV>"_NH=
MA6^HN./BDI0> A|:??%J|QRZYG :#A0@RU,\$Y-5I@'N(,NU00H TN>>\$QU8YY
M4/<*F;|"+\$&JBT6SGJ|J= \$7A|,G0B^&@X| &?)WXGNTRAND%M(I.X\$Y^,X
M07(AD3I3G |CN"!D2^E;HZ7#0.!U?&*+ +-C@%K?8#|_2&,CP@M4'%#G_ |\$A@.Z?
\$S1I)LUS#ID70"?YK2TB8KTBE/ M\SH?G-7? CHCJ|-B6NN5OSMX
NJ0QZA!"#6!E\$564^>N-@\$Q4?&N9|4\$,6UI MW1M.8R?EU+I.X87^|2GVH@?/SPT<-&
(KM|*\$DUV|OZM=G"5>1-|6;V3I3@N M@P_9YK|,M4"'TI"CB4%!Y<' +WR,7'3OVT/+
(6>_99 ZNOZ|N\$6Z\$%WUBK0: M|X1L;|'KI4>_IAN0"'QXK89RB"'1?
|<=H/!TP|NJL&JAZ,@VB9Y|4:\$ESL/ MHXLI0Z_1^8TF<|P.(@|?|Z8 %
(73XOR2BU.TGKTA|&W1<|9_)9/=W 5A1GZ;_MSS:99VF2\$OE\$R&')=,X05WUS6)QY>J
O8'@#S-;_SHK2@FU?%|A&-+3\$I2\$3 M=\$>!1BZ/N76(Y8P!BU05=E4G6F\$TR&+_,2+-
T,K|J\$9|7G#|%B3DZSCXA.*KVXSLU09J*,A.&R89LEZVR9\$=(R*B)'UMD|8_)80K
MQ>ME|;4#-?'/I\$JOLW7BU,2|D\$2E(:P3*A/BXE44=X9GK5S5)F&8++1"5!P5
MOK=GE%Z|*PO(. *G,K9+K(#JSZRWE MY<=L%6N%JCZG#;|EN!5E|R=PR2KTGE)
M/HV3)*^|0P^5=N^V&ESM|I|W:IUJ5 MX<_E5&C)?%)%6C;L#KVA,.96:8"^[*U8/D^+<|D?
(50Q/'8LD&_5Y/HJM_9 MG876XW3RP^EWI1IVJK)SRK;UPN0Z,=(E'X5!;_*B21_|?
*VM>E!IKDOO>;PCK MK*L-:@|KZ+LSC,*I>*J4K1KHOQGL#NEU ?FW\$5-
*2V06|SR|4'LF^~^|02V"(MCS^.=IH#&SRNI5|= \$>!0*Y(0^63Q^P% AQP-
&F!-7&3J=\$C&-\$F3(33V-? ML?I#(%'1JE%;3MDP\$
B^MF\$T5K'H83CQ5&0IRBRJHWA3)YE**A1PNCI9BQH@?PXHO>7|GG, M-
S2FE|&:QJ3=PDO1*K|?;)"?|F^H_V@Z)!&2L>Y:9U@S@BS4_|&8Y+?P*!
M2Z&\$|A@|QY03,|(#KR\$J1U%P(XTK\$8Z#33,^G&^0@.P8FMD0\$#(=;Y6S4=Y4;>@!_C-
",7< M&#Z|RI4_|6!'(|^5/%Z7_|*1F|W^F;L1_%1!OY!C2H=,U('8@TOX8&C=R* MU
%#.AHT\K7,1ATD= 8V'\$,Q:PM>1UF,CC|P|1(|3Y|8|8#0V/W:MM/AZ:O>
MAA>OG55V06:MQH&V5'P#3&?)N*/8JZ6I:6DOJ=4<9!@^E1A+RGPJ'@<;G|I(L
M(UVATN@/C42!Z=-54|P*2P*)WUU"=TNTI9RX0?Z-E*T|;WM"3'7K)??"|* MRS8
"XV3|5.L1G4/7EN|J*^|>AG@ZP85>@I9=4QFPLXV:IZ69|_/L.F?R|5| MO P^|BEE_Q?
A6&VDRJ|><+S%WAX^4*D_?*\$XIN|A|@JGGM(NP!\$HS|Q6^Z11R5MU%."(Z
C!;WY8\$(JC#)VZ M8,|/?PG2W6V6I&0T?/_AAUE>8HD8?^1_U YT!A'-EP5J:'T!+7^FUJ_
M:8J#URREM>Q7|?DDO2<=TB/X6W)=CI>G?|W,GGY^|'ZD0_6GW9&B*3Z@\$|_<
M2"E|DBY?/?P;2B|&.7CBNYPF<|_/#E|D'T?&".W.\$>H7+YZ,IBG)2X3?A|E MRSABJ6
D/DVO: >Z)MI*1 M|@E-)H!^Z|P=\$Z@>JM<@P.*&KBC404\%?Y"/-!)Q_J)_C#^1*85T7
6UMM8 M=GVJ+_3V2GL:#K&IW7LC^V:*J/C6V-)0NJP7OB/M9(T;:'
M&C0I=K9&7#NJ^B*'|&Z%K*R(4>YH6:>WVANEX7W2'LE1_6^)^8
MRR#H8'H9=%Q\$C"70Z&Z|D(.^4^>:@!;C|+\$""3:1IG>+0F9_Q.L+VE5 MF);|>
(SJY3|6U#J;:|XE*\$|'_;\$\$.7@Q_ =QA%('RF|*+| M/_R?)'M-
R)&9T;E|P7%V.#4M72+YS^0#0;Q>Y0,%\$7V#ADXC"\$-Z^O|/'U*<
MD9&|UR377_|G#QLOS,^"O.^K%)|LX?_YPOJHGJXCL '(5^(KHL_>G(BL_:H@ M9)WB/I*?
DOJ>QWLOB#J0LLX*I4)\$2_YOP:1OX_T^R!_BH4*UEF>ZHB.>*)&W MJZX3^3KYLY2T=?
K?_)W|&>OZ+%'(K^2,<(YT<|">'M|"?WZ(O'^"G*|B|A\$ M<|D6*,UPE-0)8?|
)!E\$#5YZ(4IN4/J.4/3#C|1KOKQN^^^DA')T'6Z%!N# M))0^;9CLB(|R\$.+|=M+X7G2S-
N>|Y>|79.|0_&WGNDK9%*H)Y_SZBC M(AL|=8JU#SV%BS:\$4GJPGQ=?JXLSIS_9
MM(3"?_5&Y^9+<&2\$C8|G#1%~|*N0
3)W#Q.&MLCX*TA2;F/;R|/R96:DH0XZ(7IL;CT>M(=
M%9H"/=XJ;U:>'O!;SJ|7%R;777:F5+6U,U*->T%94JSS;..UZNV.Y/HYVY;/
MIO\$J;4%2>;)'OJ"\$1&=>+7S(IGD)&P*DLCS<_'SS>F<*&)-YP7D-W!' M?
IP=*2GY*0G6I5;W\$H>! ?URAC_0F)';0Y2!5;JU= MHZ;S_@J2E)("_,H/61>+66UN|5P|?
=+N&+U|+P<|?|).P#Y4R1LO8LW85D?@|>..;|@GG MCR"9F:P"TS|8Q_~|@Q*E>%8/H
YY M>D;26#'_Z_ S+" +Z@Q<2\$404F_2XS%|_C?R4QE73(*&1HH ^B#Q@:\$HBS*MP:/9)+
|L&L_(B,=YA=P%D*>3|!';T 0;N:9CTN"0* M6#P?'3)<3,N9P_RLT')U3N8ZN|JKN"^>?
G!7H1;H@BM"|%U+MF2W.KUM5_M"3|-UO:BG2R_QXBHO2P%4M_I/KUC-Z?
X^AT+^8NP\$2"QCAI1B>\$C4_2IO-4 M'L?A(.@!Y0312|DH_R^"/(U&"Y_KJYIN?
K(1U%J#\$;|R#U+A^DN(SD_';U3-M>'Z3|H|J;#GD;
K!9>46S(D7|N4MI!^;,\$YSR^X)T3Q>T.89EPM4) D&47Y M.;I;%OU^HP8I'2:Q?

8S=EA%T|#6(@GVV/U>_/ZF0G#|#M35F^\,1>PU7:NUW M(79+ |>G/-
,"|N|O)JZBN^R0QCXY.>:(+ 65MG-FMV@%'%9RQ;%2@KGFBS^ M/6! ?XR(+T??W?
SX/9\$?7^-UL G0^B'TMN>\$".[?JT2]QG&(/.L*;SUEX\QE M-
Y|_6_&GB@*EUA;_02MGQSS|#:T+5W<12?U"Q 9U(XC5KPU9\ZK=)#.PX#-
M\$U&|>UG@H-H:.(=(5;&6A0E*.-IU=@<=8E 103* A'9RS]'0Q(GNZN^?@GV0
MSI++/9KYIJ)54PT8R,"U67RY/+RAECU_C0C!5W0"J2^PZH\<;*JR:F1UWZO
M.'R5F[NS(AB*D2^E1|JT*5FV^|)^SH-C>9(I*^6^)?^ONZMM:AQ'PC_I;J?J
MJN[|U58E,)GA%@@@%8?@L8B513;|RL@/DWU^W)-NR_"8!|MK|97>(6TID2?WZ
M=#??'/?7XK5%F R?@JP@R2&#Y6->^9CDN2[72@QT&>%W34Q"2C0G1|QW@"OA2=?
PX|\$,*.(M (!O2R_A92V84/HTG>W/^.B?5|. =^H=|7XVAY80';|(%U4I8@&??/6J7.4G
MRS"XBNTMLIN>RY4@6J+7|<>1X6\$|N9M5_HS:UEPH)K8_Y>&WB!_9WWC@|J:G M),5?
&_8|=P0@+*A(R, NUT#HW'8*H-%E-V6H9PF#[X@I'AU-;_>I.KG3PF+(|0 M8-
!"FL=Z:6:/X=.K&/DX:&5H5Y29T>#A)+G52KR8.P :)NSJ&005093'6)C| MX)D@X?
0DEUM\$='6&W|!NB&-6&|*!+>0DESD^743K7YW|CQD)%BG"><|Z|=R
M&Z,D;G+F%|^GL|8R9/ 74P*G1_,2;K1(%GLI"U=#\$ "U1_?=AO>/1<6|4|Z*|
MZ9QOI.)YQ1\$0TSJ\$-C_|X'A@#SNQ90N9XJS>U33VK&2|3Z|MDSL6K^(GJ7|.#
MZM:|SD:JIR-Z/BYV"G08P>*5C*);L=|)O9_XT\$)!DN>OWN#|D_GO@WC/RWCX
MNDL|U3T_V.0AJQ4T*M,!8T@N.|"E&5N(,%|Z MCYK=?XB\$C|2WOR(%-G4?A#M
408RX(|JR,<M)Q|UV&P')=Z;G*&|R_> 80QMO&<*4CN=%8X^Y)G!;2#|ZD=V./P*:9CIF?
G M';2%.-&7V<)>95? ?@|>#A 6?
W|H|IR^3.2K*P5B66[;BS:)Q\$MSRM^A/FX/,"0^HM=\$ER5!RE609FH |H6'K
M'"3/T+AM_NQK&G5,,F?NPFGGND/J')*|MFUZ@|SH6M?&'Y 75|N1-
:TT5"S+H&PC3|WNZ('3 M0DB&>01 5X+*R97RKWH-&7
Y/ZT,E%5"G%QN4Y2UI9!K&#W9V)9Q^/SDNF,) M:L|-2^VFH|M\$!?
+2.B|1<3(%W\$|L%-5HHR-S<;N,)0W0L8IB-;?|Y%:,5|F/
M760D!8|.9#VD)DN'Q2<=!8*C^/T=V()(. />)RZT5%F9GU.1HXRF!;FP6YK
MSWNQU;|IR?,0|7@=83*X'0-BRX7TEWU_B5^22 |W<.[9!E1|#/B7ZFT^ID(C M-
E<|ENK*:|J)U3W'(|0\$|7H%*CA|7\$|;VO\$ "40Q"")587KEY%SR9*W\$H?1Z
M!H_=\$6X|UW|J_|:N7>Z|3@?4J2! ?V7Q2 \$/?>,|R')UYCSOI5P5)R)E3 M><;(/08^|
=I\$)8MRZ,<=4Q|@C=<94WKGK&=RYBOI/|7ZBT'2(|YW2T!HPB MQ:E4IP4VEM_Q2'?
FU?VM 7J:'GSIQD.K?1|U|5H+|B|0Q?10D!U'O8=-Y(EE00W;#4 M8IJ6FPR774XURV';?
D)"O|3YUE.783'@XQQQ=8?@BJVUJB"65._N7QMBT@^
M0T#)VLG5JPU'=SEUR>D(5+;RKW;X|R(ZEW6(N#QRK9?@|A
TDN<^#AL|G0/A)F_5(6O=;:4SQYCY71/NY.&;_BM M+A?
LK.G&9|!'|S'8C/#TD6!C(F0V=)_ #W*ZP+4E)L=01DMS|+ QE5-8@
MH&0K*5V^6W6I^OB)5A)R^ D'-6|HOB\$!_C@P^&W6U8?FZ(M(P2#YSE3LMI<8 M-
I:.*%=>M5XWA\$OL +|L\$76P6&G6W8^J%K3G|C6|_54+GVJ@ (F;9C)O;R 8=MP
M7:)|\$C*O:VASH5D<8W,|Y|Y">Y0A@4H|ZO.FV,Z|PJ!9|(\$N3\$>I2_,EL>8 MLUE)N ZC)6?
Q6L28+E:N3M_?K0WV<.!KW6#//JAXXOH,(LE:M7|LJ,>W,D5|
M_7)3,DIO9;PNVZS|QU\$Q3\$.Z+-E@D%T;GN2B5HR3==5.1F7!W: +CAKUC#J*+ M2;
AOX?CX;!'G'R<13N+A(0^8|9'*8S3MZ73;GK 3X887)6!) *|_J;GF-4NY
M|0|HESOHBD7DOHN.C#@;JBG9.\$*[M3%*H*)E7TXVN377A2|<,IF=0M%&0/.\$Z
M/8/A4ML7,DF+?.K5CA?|-|+EA5)/9TOK@V9>A9E6&I+;K;3TUC!;|6M(WU_
M^D@7:|.W\$?2O-A@Y5OP'MDY=L7?|>C|6|/#%S\$|4UEC_0036&62/@%W=LKS/S
MO;L;20DKV%KJF'NF@M*3'2HR7#73VSD5;1*K.N1J(OY)5FGQ+/9TGE?7K+> M250PI-
045?ZZVKE|PE>2Q7J\$89%|^\$??4>3|8YV<)>FEB-?T;OV8ED^Z46(=K M8!_W
VKT"1)-9R|X##>+(>|&':29T.O*TT)!DJW=PNYDS3|@;TV(@4>+|=LZ MF7G-
,Z|>99RS|F7)SQGH&I4|*_BK,MCU?+LHN05K1=QB9 M5S*XY;EA0 NI8*ER_XJX+
|YAQWVZ5'/%&2P=\$^;RZG*W,@6>A#W3W,3;GH4% MQOLV|_U3J3 P Z-")/(1M^3
MI9U&)|YN,#B_MU;W!W\$|")509\$IO%\$&/6P<-'.S4|)
V5(X5'OTH5.4|R3VS;XJ0\$#Y0Y(-/"S/T_==|1U%SG>EJV7R%*DH^9(# MTE*L&
(E50LM&> CI=-BH+8;M7|/2AR1/:M\$*_ "K6^&4=&JS/'0RC)>M0SB+\$
M3FN,,ERYTI6GC7+</(8E6"Z:O5=|%"\$7<67?.,5*+18\$(*V@>T-CJ_P0&<9@*2XUY?|
|5"!AR2WH9OT73Q+9/EJ(2!Y M(|HDF?>Z"A "CQ-KZ
MUC;F|4&G#9R*K@C>LUE>U4J@_/XKEF|_Y9OU_7;I2NUCR1RA(N;UGW_@
MNTE@GU_8G_+4\$|L#!0 (-%&*3%K3QSA;7RL!0| 0/
86QK#\$Y7S\$N:'1M|5UK>|M&=O|<_@ITM^E*?2A%|BVQY*9UO,|6S^;B6D|;|L0 M&)
(3@0 6%U+<7|_SGC,S&('4*,F23%K<9Y-(C#W.=?WG/-J4D_3|_XQ>C71 M*J'_1JJ4Z?

ZN[?>W#|O#XU=?R*[WPM7WCU3!//%E%5+U+J;WH5)*8;'SR M;7%Q.E7EV&0GJJGS?
S+3(B|KE=6G?^!&\$S/K?7)0Y\7)T>-%SDYW^_5^30Z'.9EHLL#^@MU
M\JHP[8_RK,8K^N3XJ*CMJ*2W4WXV4E.3+DX^FJFNHI_U//J03U7F7ASF=9U/
MZ=U:7|0'*C5CZAT#0B?XW043YVE>GOSQB/IW.I^86A|4A8KU25'J@WFI"NEN
M+M.9YFERVAQ;5ZS##5+.,TK|W<)/7D9&3J@YB>:U|?MQ<3.S1U)/N%
M|HY|75!_|B|^+?Y|+\$.-9=WO:'_9VKS^|:JO/_ST|BPJTMBS48.-IV
M|H|J03PY9KNMW??WOU|N|/:S|'\$S^_|O.|G_|20?_EQW=O?KOY&AT=/GE^
M^T5*|6CIVE^~*>|!O_RQ^,71Z>WF/._IFM_+X7F'AX_^_:K=4MPW5-
RYX'!W'TV_R::&RA?R:G.Y'4|6@)J>: ^JCSB%A;16,FYH:V MIXINHU'I@&:7%F%?
DWU6*4H!IK10'2I\$ _ZZ*/- "E_4"8PU:
M.XS>C:.)%WD2JO+1ZDT)W54/H|WT.^'4L19;3@=+Z/*+%&.I,TUY'HS*?TL2B
MX2*BE<|J&B*^J5WF0<^'G|(<-H 7W/N=7S/|=9QH1_5N3_5JW\$N55KGB2|
M"X/:XOX<7!;Z*VA#:#E06:R\$.=-\$C5="78KX2P/W0,6O|8|F?# M_\$&&S5PJ9|Y6"D^DJU
58(I#D_H:Q>T1|U.WN1R'1S<537P?QWS_S^JPY#=#|NV6G8(GKI#D(M!V%@)7-
ZJ\$Q: +4F|CA0NA%.?9_D| MU6QF)HU&4#C00JG-= @!/?I=">+^_
&|R4DJ: +&E(@R#|2YL9?"^0 O<9E.P)#,I-8V#U|HJ'U.QHJZ3C"5E-2,2,UR6E\$>6=CX
M(%*D^VB(-A7/R-4VE%+#_ |?.\$#;CW^BO5_/_BRJGSQZ-F6M60J4C3#%X#DYJ9N,:
1_2@L_MN>4EY M_%WS.|2Q+="_)9|Q@%JQ.E69&F\W,L"%|
|HY%L*UG)@_"4S^C_0.VD(R6IRF^D38Z-I,JH3_.3)63
M%">/,YWNL^Y/)*,TU3GN/K4ST01ONG5T;OGZ8\$P@;FA/%!=3MH:70Y('E_NE_M*S(
28%*SX,C62L;TR4;T4+3T|^I77^|:0I?XW>^0DRT1\$+COI@4G:>ZJH@J
MC7"EL4SJ'(2%!.J,J5!5ZX+7SZY!?!\$.H|?TJFVQ:-94:,8@_@522A=YP(|'
M4,.8CBI0B/+&J=8@!5+6VICZ*MU<578Y33;356W&0MYAZ_#|6>K4I2YQWJ2)
M%99IRHF:JC%:/&@ABJ:VS70-.30* V ML&TO2_JV!GMO^,|Y3\$)\$"JSBM/-3.
|L!|%OU%(@UX<-)S\$_-03A\$#JGS^)SN M='FNZ9>FG&F3IFRGJ'4R0R1MRI*=\$5K)
|S2P#YK1M_@,0T2AI8Z|A(5B,E\$ MT14?:K.^TC:4)+/0Q:CR@02WVL0*-
PG3Q(B&FDGFE"X9I!<823!-B".T;O^ M55.5|LT3?2!)A.AP-
6I@0PVNJ8+P4@76YFA(7R;66FF"84_*O!E/<*)1R&"
M|R|= %43X>.C(|*H|. \$7N8|LO_D60H8I;G,Q: ^HFJ*264- MOL.>51.:M|6DXXFL.
|:;%D7'5U)/7Q.&T8|I-M%L'.U#TH\$4':" +;NA @LEK4NZ
MPNFU1CNW7K>RH6_9|FZE|K8;|F:QW5\$6P#@)N//B0,R/?DYBQGQY6H5#W)M/ M-
O.>4EK|N.KD/H!&A(E#NN;|715E;J>@('ES7EAI?>2/7\$BD=|A7|*
MXG/;*,...\$^ZUSQ"8KM9/J5E(#6%WD^MN2"?9S2GB2F>QSBS^|H1ZT?
G3H**6#RJZ0J.;D,@W'|_H|NOCY^~.'KYXL7+EX=/0L37 MX^&4CVFJC-
KT7R3THW)3L%D|N|?CH%L7U|T.&0C"M2|9+%RSHOG> M*10=/9L5--
#>'#WR>E^=H"8-N*M@1%+|^-*6676N0(ZB+05^&1;?! MA\$2RX#D-
=8C|(|4>CN^!*/36|ADZFMR|W(B9_HB!1D2>8#AB7>@O/L3@BN5@
M,2LU)8EI%8N=BI^0| #4V(W\$.A2M|AJ7D8^GD|>L"YT2&|A*ET+E*K_,L!O5
MUB!&W|=L=8*)'4M33|ADXW!P6_H1F;S=17L9D@1CN'S\$&"9O9Y#189|&0X9R
M.Z=9;^_N(1TOBZGK1<,-8Z7;9NO=%FN+@R0X^,M/|N(X \$STKKTVM|\$IW+F=
MZ@L|)WV_61CN?:E)Z0'Z>I@:,7;52!*\$|,U'BXK(DC"BU-SK@-0<<<.,#8
M|#!X2#0R%T3|_M;0 U.+ :0%H@&J2@Z,SP(|9'DS-)8U?G.DR3%,03H4@SS1, M'6SE|C0E-
H JHG|!Z^A9:A_!CNX8B?;RM"IR:M!90QS6> "=O#\$W,276Q%Z M1|>N.!(
|QT@+A53OR8PP4#(T:S(\$X(SDQ3!A_L6&XNW /8N="9BXF|5A
M|U<.B*MSS1SUDR/95W"1BPTH?WN7<|U1.,ZU|K &M &) XOXA8O:"K3-!P
M0VHOT2-C_1_!*\$?+9RBPG%3NW%"7\$Q(2=,:V,=YB6!3L"@A:Q;U@|W;E\$KR| M4-
_B%;ZXU+%?/>|3ZAP*-CRV1R@ V=+E(L5*I\$|<5OH\$4A%0@F.+>0|D#^+Q M21.SF9\$'
&|+ "2DS|@8/=9K/!;63 +-"3|'YN#&)B- K#YJ5,=S)G.IRS#8_ M&D*L,T;%TU;G-"4QXNV%
EVBJ8.)DHU:Z%K|6&I<:|D|@=>K!#7%IN1|7|5-LN
;JJAENE=Y,15;+)V?)DL.H|NG1TTSO#/LT*#IH=O MG9^))CPU8F#M1%B1?&:(YOF6IR
NK4/^TF %?G<|C%5G+.OA MA3V|QK\$DYT*Z5|,|1LU-K*H|; MN!R/04U;'6C6-FC?
MA<+\$RJY|Y|L;,3'EDY3(K'X S-G=7*1%H.IFV)2Z+I
ML"9^'Z<|/M/:Y|DV|TZ_76G<@ (G1H^@?'S|^\$9>!.ZGR^\$=&|;I'4!AI#)6E MW702'
NQZDF/S VB23X'@F+0GILA\$>|EHTOBDN:GT?I3D6O1%&|8S5R(9\$)MN';C7MOYD,X(+
|N+UN+D1+| M3!##L I&?@M|9ZTP|:4H 3^|DW976L#C4@
^FV_ ^OD3^Y?/0XW|20M@3G8RS M_RAX3H"1(C=" M8AB!VW)V:IVZ-M7\$^2#
|YJH)L2J+ ?*V-353)@7E& AGM%:|D6\$L(HLZI09+ M:-
UR)'4(D4R(FY1FV#@XG8)7E02D4L,P7VD/Y5'T;<) /!)B-',GL,H8#4=H*%S7K:%,

(W1R)!EMJHDF!J@49Y6&>%L0%2RYZD_U7PRHO MA\MQF9B:|J)+K0Z<9J3F'(8_2(0I-
829Y>TKW+*^MJ10UC,=\$KBJ:AK=|MZ&/T@C!#A2%5/ MG!ITAL^0J6Z+;O?
@G!\$3:NJBFCR6RYGX|JP.\$7&_ ^4'N^M#N4 X/|J6-Q+S|PPX,|:C \$%|N MX%G\$P-
OPWIUK|7|WGUM(2*H6M,()&Y9, \$C+3,U|'8?6W?^KB.,_>8W,*^*A M0>;FZ_CL|,4GQD-
N+ES!R8ZN|TU=45&):B%-?6SND0(LZNWC-3V)#DZV!| ML:UEI"^BKV
&Z\$U&>1/=,%7Q.49%O-CDB3?,|F.B8I+,X0R"L_1_L WT8>2
MA+&@;|F|74&\$RHKX?,5GL,F2|6<-,Q6|VP=\$F)W|8Z;GL%U\$+@#;@=:Z0%T
MV*U2M9-BQP,=2ITE'I/3BX9*S2Q S51JJDE;IW^I2HSGO==A&\$ERMF*EXJ-<
M^5TTI'V@=V'=">+/L.*B\$TA.FI|QR-M:PWHD0"D'91%TP<#
(:)H*IXD#3B6>|EQ0VAF(O)&HZ*T|G<)A*.AAM%>X\$@ M7KN+/Q1;O-
G;5GI7#C8DF!S:E0"A2|Z;|5Q#0); M:CE>|*):?R+WP|@_K(3W|
(4+AY6O&@XW27Q6G1JNZC9\H'N@?3P#7,-L!\$RZ M2 U|\$>O"XR8%;-
%I(B^|O_N|\$I76T|D2^ ^),FR4VRL7@A.XP#5|M;:8WY^H
M,L'9_IQ(MAMQOKL3JNX|/R6RE,?+7=ZU_64_|*>|MO(3L^_\$._.|OL71(F M1CF1U;%?
G%*/2A)B.B@&N6*S,/,!"#*K4-J"IPKR0Z|@++8AY=-%I\$G'9R"B># H8#|=
_Q'34^(+E=;OB;&CD;X;=|M" OGJ8-HT?
5CCL1D&FFVAB@8*.H#.-6R""|L>P=SU!;U@*ED!T3." MJ0N
|>|HP6*ATG:|^|#+5=**SRQBMMI+)C RE0O\B5L&(84X>@9?>L(OR-=
M5QK.0R44+&FLNQ \$R*/21L!4GN|R)NU\$ X@&W4@*=VY;Q.%C%@\LL&|)=3P0
MS/&>C8S1Y923JS65,WET/-N6W8DG)N:1?DD%W!=M>_Y)Q!@G>@JL,)RMEJ+M
3<8&3*J@7K::>6W\$;D8 ACE7?#_ NS06RD PO>9;#%\$FGN S+;KRZ;(*E0
M4|0103U'P+SU'(C.;|H/P|BV(XCV/:|\$G?&2 Y'S=\$>1RJY#SS^5D2&(>UX!%;:1FTMS|V3-
)PS M, #3"F&RJ D\$B?Y)8:5G?C?>W1C:"F^SCCKML&'>Y%P+Y |@3HZ9\W^OA-#B
M(*T" T(+BM'1,8@XD.-7;FG#GNS93&_!0+B ^KGA|4S*VDA9==MU|AK9#++!!
MO'3X)>K=C&!78M%276V=BUYW<=NV8%KW 8^W8%K=N":;CF M<8!KO@1Q|QP-
)@7%J|.JP 4>Q!O#-" S:+EFE*N=5(/V-QY?A6E5*E#.J>R
M##74M" L>;5Q#;#"6AO<|7/2\$P'^MK^/."/RE)IG
RD;2DCJ\$|>|DDV#H0XU9OC0&S|.QRL:|XJMC|UTF>|M14CNU"-PQ2?
03I#>P*:6IX9ZY*?R"HXE M,9>>1=AV; (QOKS3"8I7&:)L+XC?
|&N>C*LNVNV@;L,OOA5W1&>TD)W=V59N; MP9DM|(T4IU<6Z8O"6"160K?
2196SU|P7'B|LA%H6^VOG.Y_6L|U"^.2?!O60S8 M!
S^F)H<2B#.)|.+:S|GF>@4%6)4@)W'4C3B<8Y!^6 E\$>;&\$|J(-.UL%<MDD18-
SP27".H_5KU;1|NAYTTTBX+D1K|P3.*1\$SW5:1ZL\$RKL9;>V3UI6|\$ MM=DX,*S5IN
@S:.(FX26>*;7173|N4TELU4W:*;K_*;:0C;)=B<|S;Y|M*047P%"5)) (BQKAY:X)'J>Y?3
MVPEI7V&<9JA(8*Z&V6FG*AF6'3|G*191>HRJN2|S M%Y\$|3ZAQTR_FMF+&JT
MG7R(#F!C0\$IV7RM.PAKKDE0RK9>DO:%E" M'@H=L3_TH"Z8!5W;)|R|>?
M7%GW4(WTJ|@&<-C3GDQ#M!/?=8*87!"H='KT|?'+%R^?O/CV^*O3>5XF 00Y05)P&F;J
ME|N"@GC5KE@HFW\$RR1._,0\$^2#H^/CKZJM?LIM##G|H!4:|3^@IM%6D<#7,.
MTAJ%|FR;+)S-MJ:N M21C#|B#?S#PDJ'#GK3283<_"D@)(J;NH<*ROG614<_
M\$S1E=/Q""1SOC?;=M_Z6=%%?.^CF|D WG^V@FSOHY@ZZN?W0S9V(D0?
Q\$IDI7Q!T.Z*:8U|\$BC08B)H?.P 0\$8=CM/GD@)M.6&.
M+YW0"470*QMSP%B.W|B.!+FGT"W8XBO:'%A/1?_*L,XV0/?L'5:*1,R29
M6^W(>R@&D:V=Q|F1;)17.R))X*ULT'X@\$|JATCQ)BT,^9'2RQL#6CE5F_N|&PA|P?"BA9J
4! M9JRR#WR2<;ZG9Z?Y,VPMC%H/K@5'FJ=,;))MS3L-#|>+|G?
*1:"?AWH^|NA5W=9|E2X&EG1T
M8F(=G0N0Q*U3UD=AZ@N8SMALO|B3:R:T+7|>SZ|*I=BJ!'CVE43)8AC:W 3 MS
YJ"MTI%>P"X|8%BF_ME7UR|&QW9;?LRD8X3Y) MF>A'>MS&_5QRYZYE G_VT-
4.UN9XWC1/7C|3|;7(?)>>XF0|L|(?^ ^CMDE MQ2SH|Z2?ZJ-
#>EVG%#!DLL|Q.KF7|X:0IFZ& M7%|+> 7ME&2^_Q2^C)-KLKR7T9A4YC+G<,R%Q?
I4S9#|Z<^_MV5B:%P@|HD!8K5,*7O)H#6|V|J#9?(4<_|88 !UK7R92-C8D.&))MY9#B=#Z
MI@Z@J7G0^:#-4!"TXM)=QBPVK;^|1WU_->GS\$#I#|90*RWT3(;?
O6YBG@(W/&Z1)^*;;EI-PC0NHAJ"G|M S:408<1EIZ)270EUUJZ(G,RH|<+M0C-
U+WR|S,G6@NLE2BLK?).'7&8?2?
M^1S96@>=JD(A@*!S%Y|ON'K2NJ|S.XRVQY4=#;S%Q,D, ".R6P/J1K=
M<9F>O%.,Z79)M.,UE;H,7%BH90?GAWD1| M/IM!G5|S,36WLLF&EQW<=GO@ML|W<-
L=W'8'MJU^N.UC%HU"CKK?R|=#TSC7 M\$AWLP7HVVU@V,U+KUG=V
JTN@P(PY\$N*22RQ|JR"%%HSQ,K,/QVCLY.2|BQ=B)BTJKE^_45!2X:B65<4<0,>N(RLG%I
MMB3L"L#>1MH9=XK(9U-C/^BJHFL".X>HK|HFIHY>SU'A,MISXNV'LU|JZ-?^

MS5=WW?YN,36[6M%C9P^M,&:820A MG9-
J1!VIB\Z787CO0YLXK[-77Y@!ZPNB!N|MLN@S3L_Q7D)%.T_7AX:X|O'1
M\G\A6:SDV^V^P!MLMOJ;5:7"Y=:W 4A2\$UP3MYHPTALH:
M46R(GW"SE"@,E|B%K70WMEUME""HP2\$XG^|HVG)!<9-O=HB:LV56/RVI0%Y> MDE-
15>%Y8E&&(P A<=<:8DFLS%,@&\$CY?002 LF+|T:%ETX2@C)(.*4*S|)(.1Y.\$!5U2=
<=<P/U\G! 7 M5U76'GS4R>+-<5N7*IPC W#/T@!MP:&FXG+\$U/Z<=-+
HDP;>"UWA&D|,IRP M8^HJ^E(Y|B|CE|YCZX);H(Al(50P/(\$9OB<244T\$FKQT
MM3O&M)L|E|YKRC(IY|665(=CUK1|6AO*/DVW?T|>+|*+.6|LKLK^YFNK%<&Z,
|Z0HVK;)>9(76XK M@=Q@JT|K1,^\$..E7'-?65Y19IEZ35"V*#&11(G9 MNS|RB<'VV/#CG?
X^7/SID02)TZ&=(I9*|XN|U\$W|)&C:-L4)JXT6+;&0F;9 M@?
3W\H;|K6|Z>B.+WCYP7"UFPM6GE(OZ**H65CANLS.%UB|9,MLJO\$3_>N7^M<
R9(H3A+TR9MS.\$Q(OQYHF0>D|GQ4F:|A;P=*GJAL1>Z51\7U*ZJDVT1LS
MV|&!)Y%9|HX^'|.8(LTTV;JVK.UL'45*HT#R;\$B%:G|-3QV?
H0=T=Y0HOU3GI@1LC00Q:US M 6*U|74&WD|K3%-5E*/9|>RM=|0@)>L(U:"TD6'AG-
R&BQ);S5\$|HG;-T20:5PYLPWR%XX1+KSU MY1K36^4_"4QT2;=FQHHY5@/G31H&8?Z;3
-WX3|;\$^|S8A?N|R!3W87|(|.)| MMCK<9Y/%KILD)MM,../&VR>0;>A#"-
!H6#28)JPLPZ!CM.+N RT.S)*JOF&NS
MU01&E94HEU|.|"F9;=@&+)"3LW7_4Q"92|JAC22 MGYH:221_H)X?
IDQNG|B_V%PB_YN%G\$HA"i>%?"HKA AH(ML"U/+|.75NGBG6K
M9J/5V.NY|!*\$L_U4L6HY*Q|N?TG;=FE3.V|+|.1|B@;>M6YMWM/^/3!6B/H
M5+E*R=#F.?)G <50,2||#V;|D)W1>BV^=+//T|8),WTBN,%)OF|?07\$=\$Q|<MN:;|@O;)*
(DRS0PODD\$K_-!!2S6_9E*G4OQ!D2=+8JY,KETB9^*Q\$%N_L
MAM4),>4"P|=I3HRJ\$>@@+WN9|.:^!WED2ENM"!XL^-4ZDYK:6*YUW\$2, MEP-
F(++1=H"1J&Z0M|8&LHTA#H,!%8)Z&3 M32|JV9//XT|A
>)6@2+B@*|=2L\$N/A%CF&964%8K MQ6P: 2>|/7"+(WEZAM|5R| #QHOF.7|/=?
US:XKGY%|9B"NQ@9:|.S%(FWTX M=LSW'O,PV-
(6|E"8FE/1@6&L@ZUY*B_IOZ4R^SPOSQE1URU\$X8N_Y:6DO6M8 MJVD;0R6+/@QNWR?
O%4X-YD/\$VB9XL7E|0R=Z| MRQ?BR?9(L=Z9=A<.JXX3K MH2G>^/* KZ4|(+|SE4(-
4HZ_4@?@X54:4DG;T048WACTYSB^O#OHCT|4
M0!KVF38J;V6KZ|,I0MBQ|LN40;'8"B2B/4M,DXS5X;%%KI50ND+P#8J)-4
MW\$VK"KUY0V"+Q03D\#%AU85=+-1CIB4=F492Y2H_M(MRK3R,5-
I"#MM41Z:,Y2,KWA"%%LZ<',R)PD@BZ%2BPW.,G6;K M;U%"A^@O+XVRTNS
H6TP"NWCFQ|*@3A0"L.|%8&.CNFI>>TZ*8Z=Q(TB|YT M9-Q>*"
(6M*\$ZP776BE15)9&PX6)H#<1|F MP/Al"ZY8";S-NAC ZNU%QB%3&C Y Q,9,')-\$|
ENS|HB|0=L|&+R M79A89',V=/'|OJ@'0<9Y"7I 10(4GW+'1.|+I7'B/CC8" E4F,T.
(ZCAE%P MA6_D_('A'Y,FKEO|WD0&9#.UA3U8*Z(L|ZUL>|;A+-
\$V2@=4UJDL=|_8:LE)+<'>2 KCC&XL*T3Y)8HGH^_D_"14%UT_>*+Y MIR|?.1)MDV-M?
VN+HY,,G"D)'#60S3MH*4%;>40D2:BRYT)L|BW';LZ/8& MX;B6S=3:FZBQQ%F-
5I3*\$5NYR%HC7|'"P5%H I1J|)*2F>%|5P@S)Z|7!5V
M^\$I8J1UY."0#\$P5(!QMR^"9#,,L64YBVAJJB_88Q7RAB.+J@:.*5|SV_0Z0
M#NFP.:G.042MQ>|8HF"&C>6W8LJ|(?7L7(-"-:2(M11YN!;L.DH8R*.
*C.D"X%EPF(V|+4RYM^942?EO%9LD"U|VGG1=<-|.6(!,9 MR"4-%W&Y,R^C>^
_5|+/|A<5LFND)C,((@;Z%HQ C&Y==)F:O:/T"/|D&X:
M&P/QWR:W9WN':MQ:5.,W.U3C#M6X0S7N4(W;^|Y"GS6)L*RY5 T1RYFAK*3
MKOD6/NQN=%ST*:\$A|RYKO2=-!J#71L6X=N==G%% =@2IA|3\$"V&L&X=PR|4
MVBU^4XC^D 2^|R 09|/E^B=;1E6V1:|O1./MW"WWSETV&#P:PF-@QK=6\$(Z+
MMI"D/L=|!&8|.R-\$6S8|O 2"SJM?0|%*@K|'|#J)) (ES/MV%(CUE?90D2C
MUU'RSEV+P_UQN%G1_V+|P%&?I26=25|P*)S:.*:C6|U#9BG3RW M!|9BS@*A|;E(
MY'F:YO.#IEB-=9DJCT44%|?#W5E9UQFF6X1>KZ)0!|H09QAFMUH4CN*>CK MH9G^_
EMU\OH|Z|1A|O5&3|O:<'V?|#=, +MT56C=^@Z8^421M)|9,/*U+Z MN|)FS/XWHF-
:,@%#9ZTE0W*DL:U|+R(H1\$R0.?|CUMSL?W#(Q7S\$N:'1M|5Q= M;|LV%'WOK|:=B
RI82-#,D+T"W|JB'(2CB%N@K+5Y97"A2H.BO_OI=4I*7
MNG;J:9CM_1#'\$N7O.3AX>%A'+&?Z9Q?/?/Z&1"*|UY?;|WAZOJ3?QYVP6ZW
M^H@!W3JB/Y)TX95ZP>'WYP6AE(EQU"OF<4|4F(F(3+3|B>6%5)H('3^WE5(V
M;8A|HF@,(_|BSAGPL^C3,=!9U>CXFXD"733(I(2>:30'+|H M8VM92-'6D M4FB_9)|A"H-
"UYE|+8LHB.V|E.2,+Z/(+?2NX&9=RMS(HK D=1:YE%XCF4U
MS+5/!MC3M,2D|!4T:1*)#U|>|ZN*),B,,38/K3G)(M25I|)*@K*-DF"V(|G"SD MI
Z|H5|T E>-/'8<4Z*\$J(2"J*(A@8^RY^JG&4|YE=-|BDKMZY|&U7,KS<.FG8IAC^HE9!

M6<[HWY,;QDT0\CID0)R%IF?OKFP!KA:ARJJHXY,06F6\$%XSN")VW\$35/#>.!MV,)ULV?
IR1/8]\$W;\$,;07L7Q/%2LH2LS4Y0LJ>K@:LI>M>A7E\$DKNODA-!
M,;IK20*0IOJN%ENIPY+%4Z?W-M!Z(QWJ3?4)Z\$+.V+5(M
M&'J*S*L)=VB+>Y(T.JC'=8K93C'?9T3E9"F<+?72\?G_>+4/X=GBS.2)T#H M-T21*=-
D2UET-M+92">DIRRD3B^WLY%OF2_B@:5@_G(CO8M?G9UT=M*IX.FI MH+.3.Y;'8<+
R,;5'.3#HSZ63T2&CDS.3Q\9KM613G?WTT='7 M.4:L^3T(42[XE A&'&6>6O&<;=RQ;?
P3+RG).5#00P98"4P0)FRNQ&UNHI2.R,Y1N^IR=[N&I]>=YI'R<(/*)SNSX=X"L?
5Y%RF/N4*,-/ID'^2>YB"DK"TX6D,F\YDB+?R:E9NFB M:9(-\T'0!\ZZ^_ \$BVRX,M4
+&90.0T4?51 U_>P(JKRU6_!])%4@TJ(GQ& M%J5=JOI=>!\?P\66DK*,WQKA?
YY*';X9!X45JA\K;6D3?Q#'*-;&2H9*)!
M<(MW0/*S(4DW6NI>1Z&DI00^@B3P.JM9JHJ\$SJM: 604!R36ZS L!7LV5I5
M7/;,&V6MJH(@)%D+!^MQ@5NRZ3QQ:IV*WE2FA-+)B=_\TGV)%CQ3\PR26H.W
MU\QN+>[;.#9*Y.DH]_I-HX;V\$;1T*\$HEH0%ECIDMDP*MEQ\$=&A@7AQ(W:%EI
M+4Z.D*D?Y>,' #19(&97ZUN%JM;=G7!EJNWB^L%?6B\7KQ;WMPNUHNWI/K#
MFIOEG+V>SZ\^K&Z7JW?L8KE^_T\@-I&I')4VF0PFD^G/I_W^1K@**/YSNGUK
M\$'\#5H*&S9'1F:\$S9A6S)3"4F=)4S-R5)2.ZAH(89>9(#<<:MFALQW!CN86*MY
VCW872%;MY<7((2!(8_9RI XR&J1N;W::8K/M2Z64QPYNX"-WG%/19 'Y\$?KAF+6-26YI?
J47&:(M!=W@YI"=*4>\$HH#,M3\$)QC@#Z"D)\$K-
#7BO!U!WHO^AHC9/Z4T9WGY6,US5P M;5JLT;2(!GX/Z:^#QVT%3REEAV;(KC5FL"?
<=:EV!N9*U4!H75Y>?U\<_*<*MRAMEK)*GI#TWAF(DF/CI/1#<<)8)2A@WSVV! M/-!{P
/0#;^W1V\F/C+49 M_[]DK=,17%@%*(@).T(4F7.SYT31/E-G0 M/6O.G\!\$SQSV(_@102P,\$%
@ 48L.6K;%AHFM" 64@+!A;&MS M+65X,S%?,2YH=&WM7-
UOVS@2?I^_@I=%KRE@.7.*U)*4/_:OOOE2CAW'2=TD#>Q6?K
M:88<#N#B@LA\2CH9H-2VY' M4J>+|N8?
LJR,15S\X4%H5,C)@N7O1&H!LS09#\$NIDS'(T=BGO>ZIU,/*.FE MT:D%Q;V<
+*?'2%S:*1,-%\$8\I,G_X:TWZM\TW'B397VAN%9P4NIYNEG68)C MO\4?
3(EUPO"S'AO2J3U,/)5W*\$'9(4U!OQ+_K)C3(V_:D7/L/H6'I(7,5S
M2"L+R=3R*G8WC6/(C!+#+=D>\$B<\NP:K28/:: @*F4KAQVDA?9+CLE1+{JYB+RT^?
KSY>77SX?/7\I_Y6=4H M*!YM,<^MAZL.^R3S,;,>"?
>RR/TWE.BP'ZV4Q9WI,;JF&L)CKKASOOZ@B&6B MI/)*"B!9@W%K, >+
;5Z(#&FPZZ@'\@U5!(5RD^3PL%LSOZ_% MJ..%>(\$H M<9Y;/PR:2ZA+EV;
<@9(TJ#4+=P=YTCT=O'NU.TH_Z;YI/S@9/?>H_V!R?O
M4+;IL2+)+/#K\J@0C'5C7:DIO\$E04D/*_7@O-I=S,^*HXQ=JGN\5VL-IHS1 ML3&?
+,PD3_%@88F'>-:UUSA30H S&CVT=B2\7O)OYDIV>%+5_EE M38?W!
J#72J*C\0'\$>32YG6)9!K941(!EJ'&C%S-7TM^:=@H6F\$!E!*IS Y M0Z6PJ?1C'"K(
+!4KN(%VD\$#G,;O)E\U4UM"C<"Q0.OB\4 BND1CLGR"SM
MNH,01')\;,%>>2UU@".%4%^#_7-4"VT3LK!AQ!W\$GK9HS'(XCU!*:E5K"LD&\$
M6^L;16AX.@01:V0+%HT+1#=#R\ (DW,W9H4R4\< JH41HL%B><,XW8QRHY2=
M%;RYA3!WI&TAMQ>0.JE+R'V^99^O70.GIAB@&&&*0N+EH7L3S/*<0L!(&CP M,E-
ALP M9"A 8Z)@|A*C) 4)>D:1YXKXVKDHXZM41\$IE34Y"+SMV"\$"0P B
M+5K_Y0R+\$ST'I@'#TJ=:(45_P)/^Z2%\$*?JG(EI%2TE5IXX(I?89Q:X5X\$8@
MD2Q;=U3&+_W8OALO,'X'/0?=<;K'I>/A-^5X"
MJ#=#P."=HK2&I^S*4.I1OYKQVVI-0XIL.W#>/M1MC6KT!;,I"*S<&@6;I&N%*8A=9@U
ZIJ6R&F7K(N*Z(C MY; FSV M+5K^2,-YJKS3.XQW:UL167(Y-_%6C8K'1PSO\$!4(68\4:72-
FCC89 M5H?U\3V/-U&2,7XEI!^QTA3V"\7"%726P8ABXRHTEW&)(/85R?
6=,A7EXEBD>F/=328; M;F!C92F\!]\@8\3-#F^GX1\$B4*;?(G01&(Z"-
_Y2D;SP,?!7+5'DX%5JG8?% MXS?M(M(>A-
/17\$3ZH+LPEF1"#!;MZ05T?P"PJ')0F\6!K%EWB:O&&Z(8%\CHX":(0!D4W
B,6(+9\3LUJ'*:VK2\1* M5%<81L,D;-P,;C/6/8'8?JHO?,#\$M+
8*CIH\!|"&T(E;+P\&JHWVW5C=RQV)>|D9 M^>?/_;>|X=NS<
38B_LX^JWWC^3L'C^2\7WWW5:L^,>N:Z4Y\AS,(Y MJZ**OJ7Y-'YU<:=
I6J'4M'FZ\X9UY(I63Z)O4F'K&E\N M2M@/@.@V8NR7
IQW3+4N;J>FHW5Q/RBH6Q>W&+3.KO6V;5J:9W:KAO)Q9A+
M6X8C&X)=C"44\('&>4V'K\@?<;OZ,?IM26\7N>X-W.T&UE+J\J)7 MW^
TUJ5>.X0@UUZ4LW&_1XX TZRXWA\4T(-_3;I.2'_JXFW?I 38<+!A
MA5C&"P\|VY6K*YR\SM+,C>C'0^4\G1^&500\4\$L#!0 (-%&*3%J;V31% MLP@-%\(-/
86QK#,Q7S(N:'1M\5QM;JLX\$OZ^OX*71;\I8#EV MG+2IG V0S:9
IH#MH5LL\BLEC6Q>*%) +4G\97W\SI/P:)W6;I+;^8-M23.<

MX7">F>\$+=#YTA;SXB9T/@6?XRIZ=.*S*;-N M*N&7@Y)GF5"#^*R<|
MN!D+%O'+Z'Z(HM7%Q3V^&FQ7Z57!AVU6;-XNFMU:K%4C!.Y%/F MAMS%:
!8A0*.26_O+>I81%)8%X&\$ FC84,12S,&L5[41J,-QKJWK]5[U,V%+
MR:=Q+F%RQZ#_JRP)GNGB2+KN"%I;|J(1-HXX1:DH%ZM&7G1RUK:SEB|USXY M>?
>^^[Y|J/18FBQ(#_#:#^!2A133FWCE#40\|@;Z0&C"%QTV|/Q
M68J4062WTFWUUN#.>|T;A\$P R;18\C0T81E7*F*2|Q)&8!IQ3YH4|!N)_HW MTSF|E-
@RR2MEV|_D)\$7X19QO?'.G?/-X+WWS5QS C-ROF+);I<<2L@&T@HO6
MOIEL;%MIOXB+"X6N.V65&4\$NG7.4|OEF"XP'3L=Z.X0
M*\$C!6FZF1%+P6T"Y2VU:O)>A,BA24H(D&420"I-6!9(I9\$=-,C,+98.F:WH M:|\$!@-
U(!2!0EB)U1D:A8V%&V(:0FI5Y#:#1;P(G6\$W1|B6L62Z;(8&A7N!
MPMZ/A4)@N5#HYP29A5^W\$(CH_-TG.AT;2"W%Y|V4O(?5|OS|>VAE,1&:-4H?-<
MX.6A?>/=|H9Q QX@Z/ BD4".S "MD* ##HF#R K,D)0EZ1|GDIM*^0CP4;+
M@)32Z!0RO&W9(0(C T1:|/K23KD:@#L\$M/2ITHB1;?'H^|H(00MNJ=9N J7
M@J:=*B"4VF>4NY: &X!\$NFPM*%|1E*,@ZNV>U9J/!+&%12PJEI*X,-H..A+6 MISRD
N7;H26"1;)<3KAA)0YQ5M>2"ZRTZF1,#P4F3M3%:BDR|KRBB169X\$90
M!T2H>'T)H*BERE(5ZB.3|26K3Y#:#BKD,"\$34XF#+-)*""G4R%L+!"NC0Q|:7#I.Y0
M69D2,6U|-9ZFZ"i> 3|%'8#" (ELBM/\$)E!0SB 2GWP&^&%M\$B=FI ?> #C= M2P!?
C|BL?+8B|X8|QPF&*>V@T3/2RDM|B|X7+SK,|C%1DQ9|HPMTQTY>Z7 MO4UEP.?
40!/G_,O+/2R93QYO@B9#;N<5-64Y#W'(?/KWO:|3|Y1)<0NR7BI>HV| MPB#/
NAFI>DY5H.|O+2W|/2Y/<+LUDH:"V2\$>7&96@N|A)!|"N*ZSO35-2+
MXR35:6/GE:R_@8T5A7.8&.V3S16R?0D\$ZB39S|\$Z"(P+"5O_*5)|BS&P%^5
M0)5|5*E4ZA>/WS2+2'N03O=S\$>E2XK0+1T4@P&C=DE9 4P\$(A|H*G2_FC-\$|
M5%:&:9@O+/T\$TN|BSC8ZO@ID|I+6#7>D.5XAHP6YDEL R#K"2<2(|9P%NA
MJK58TMJJ0*\$<_ENU\$7"QLV@IF+= \$XCMY_K.)1:FN<%4T4*!|Y:.\$#)^N|W&
M5BM4>D*-M!P!E7N*#^I3 Z;:AE"44D!|GXZ'.N0_OH)<1-HC*|_V/1AXSO.2 MFSSU^PW-
/W_NONWTO_ZXWX_47>>7|39\$,#J VT|0MV"|=M0|=H;((T29KFJ2
M.0#;,"&:'K\$F>6DAMF&I;QZ^_/G8P.=/|*)|,Q-"X|AH,|QBQYWCTQ_&8(IT7.Z3QU<9W?:I
M8N|W&Q/V B#=#I(S|BH#|CJDFQNW6>#0Q|H6BNHEQN^\$|3;|K@EUCB:H|J3
M7\$|@K>AD%?M3L,#^8|"*#.CP|M500,X^AATP-6 ?PU|UMP2|16T>R/EW@S8
M;I0PC1U?6)QHHN:S11>.WS /1XWH!3@XG%6AUDXBB+77Y6S<=>5/?>G<7N
M|'">RFK|UMOY?M,^|/2M/L"&P^W0+9_H>(Y^\$G,YYE/K<|OY\$;T>Z.*G|R/_ M8J'_U!+
P04 "-1BDQ:3(XW+9@&!!5P #P &%L:W,M97@S,E|Q M+FAT; >U<:U/C-
A3|WE^ALL,NS,0FS@,6)|M,-H0I;8R'4(VT"Q-=QT0PQ!C75U)Q^<>/3"W.581._L)-
<<\$!_)FHHJ1LXZ MGYUJQ?6:1^FO8""4630'<3!4LT9^;"7X""@?2_3V:-"
(L1Y3Z>J/AG&B6Q M4)BKQIYO&M"|O,H7A_*S'RGVH@H=|:.\$CL;*+|MURAM)+*FB,?
<%85C1.P+5 MFT=0V3A)^5\$90T|*D|& M@UBI.
M2L^F3L\$A|MZC3V|/;;NHUVD;F+QJO5RR.4 M7JH==ZH|G?.+8'6X9/3YK1|
MC+H7J|/!+!_5:-Q|;5YV>T_W|>^=/U&KW=4FE7*X|!L9KA9^KOR:6Z|6|U<|
MNR7!8B1|MHYO&|E+CN 73H9Z3D-3JL9(C0EJ<3|!#-
T0/4!B5&L(2A91!T:+M'AE!;RQX!_S '5FPS'F(X+ ?42EU/V\$;VT98\$70 MF
@"?;KO1MKIM!|M0_W%_WA(ID(.8&% "U(Q6I+.|!D: MZ=2PXB!:%_"
|_)X;Z4#)_/>P&&!.I.=,3)'K:'2)3I02E".3;5X(M MCZ?P MG\$;\$7PD@O7
;BSEASU@;>0P*I5#&(F(#GU@+B"PE_)"PL= G|5K>H@"ZA, M&)|H(2.SY1
|!I+_-9%ZS#EAC8TC%1;J86+)T2U*?X E8533?"7J|FF?-5;8 M,*RZM=K)J7?
JU>I>^;AZ>K+?E,8B<:"X%O_EI \$NLD6X%"NQ^<8C)X_9>_I
MP#O,G|_2BC9MTRN7|U<|D6'^L#;\$3&W""6-S4*4H85H#%KH@R-|3* @RMI*:H M7!#^
!B4!NO?A <+FA|KR(+!Z|;FVF0 M=,^R40+J.W/ZHH+':GKNZ3-
KNI5G5CQU3S:j"A=B%97L|G08 KS)&()SQP M,MT*S=>RDIJ?
CKZQ7LV^1C0I#4N937GC3B|JAYAEG(7;C=PDYS180;>+\$RF9
M_W=MJ#P0|%U)8BX="0H9_I?X6/M,=P:N3:>VC; YAR#V-1+H@@S\$!(LY|BIF
MOU9_,8#M,K|RXIN?1V\$NZ2=;^K|DG=1@|)61\$H M@_A8N(H.UU:#|HFJ;)5P8PZ_1HI:-
"P:WQT-NWJSJS>|'+%P%1NNK0;=)G|P MME)H=+&OH5K|^#::M
=W+|3|Y5\$MIM|RYM>Y??J/J;KT.0_QV\$B_G;+B MULLG^P|#4'@87"W>Y"|LP MKYM?
+_L5F-
5_,|EU|2S\$*M\$>#;XX%:!P%1VNK0;=B^56"U4VKFU8(+%R!|I=VWXC9(%O,QF_&6*VT6O
MV?QR8+&:N"-PY3H(GSJCO6O,/_*AKN4MBG!(^(|3&VR=_9(ME>3;"B@(|LTL

MI3.33***^DL.)KB2\$79NPB/#@B4RQJ^EVQHMY.<,W2X5D\$AZEJ5,>%H#CJ'8Z
M+ #,YXQ"FA^S*9Y+,O\WCW0"W+?.?FDX_4\$L#!0 (%&*3%L;U8 3 MTC\)FC 0.
86QK#1?,2YH=&WM?>MSW,;5I_?I*W"3>(NL&M*D M'GZ(OJF297GCVMCRE>S-W8\J0
^G+0PPQH.CR5^_Y\ID/\$-2CKSA1\$A5RN(MIK01??J\IS^|M>XVY9_+?
MJ;4T!_IV^ZEQ7VC^_/IG3\X00_J4_X+O/Y4' MOEK6Q3YKNWUI_ ^|?MJ8H7'7I
{(OMNZN-::Y=|N^H6|>NO?LA>?9L|_ ^M_OGS|_OW=-S||?_W?
MV9N_/_|HVA3:-7Q2M8=<^>G#|H_/B3JP>WCQ\ZVWY:VVQ5EV6|@T!H^UZY- S/'Q\|+F
=GWY;Y>?:3&H;P M |3P<55WV;9OD.EE79TM;9;7FVUL.YN9JL_9?
^UA6U;:PA|5YKHV@Y6YQG;| M;+G/&KNRC:URBS_&)7S7N':=O8
Q3.5@_.=YESVZN'R2G>"W_ |'=_!'?I5\ MSQ\65Z)_3|KZVL*CS8+&#VNK6I
=|8|FEW;>|8=5_M;?>ZF/@AW"17Y35NHNE@JF1?8#G* 1^?7^HV/:|JV-;LM:6-AS&^K9M-
=GEQ MJ\X |!7OH;G7/@M<\$|_ ^BV\^'GVWW4/AUSW90%3&=ZU=-OCT8KS8\$L5GU9
MHL^SGUM+9_/4@20!|!%*=0_Z=J&O|C_ ;V?%G,,'X0R4Y_T7=9./#W_NO@:RF
M7G5C00KC?M%>XC|26IY9J_*(%V;K.B"F-UW3YUW?V(|B:VBJ9_CB+G^/S7K>
M=^NZ@6F*| TRR4QV;Q8Z88|> =LP89|(F #K8"ISPB5,?O7D8@\$+ (T|SIZ?X
M3_J_<"|X#K1?5Y#<@,LK#T^(*!WN\AR^MR9?+|(G3R|TO*E?_.GB_.*2J7) MHX=
|. *D6|H/X\|8X1Z.O./CI>8;O.1P=7|6QUZX%Q@@_O/&:|(W-B7U>/CI9
MGJJPA0_|G1^BYPK7YOJVA+CA:|OOWS|A 21")^#S.ICI*Z_61+-KFU|JO> MJLM?
8(|5.F|_|=!:7^(" "\$TXRK62892;D%\$,1@2IS,DCU%W (6J@Z/I= 8Z M1;/=-O4-RV\0!^?
0YCV;@C|8N60;' MTX_VYU#5@0%^P67LE;ANZH|I=;@0F++M|*VW|_ =J?@V.
R.^@|'@?;)K6|D& MEV1MASKCB;| \$L!-,SJRCE69')%H%::YW(:PV5H!0^|B8#BX&+LP/LJ
%+VO3 M%/AY ;IAWM4-*V:@6RZ!06>EVSBI DCG+_NQ\$YP11'O2_TKVU0N5N;+:W
MIFF|X%=X*L)XNV53_XTLD9'!SH7E);LY^%+GV7=5|CVLX='%HR>+,0%&.XG?
M31Q\HNI_C=^'(X;-|HGU@6>|I % W'#RLRF|N&"6C0_Z%=XG+ 'P-E+7-LG M>CMHD&
(PBK^9AJV@;;>-*4*|7I%)B|P|;B(>(+L/3!-X=@M7I8.?_W=;.\$ MO7W,OWVZP&/DC=|6(-
APNW>N+.\$F;\$&C|BLP2=IXXT><9)8%J7E+WJN6Z %. MOVL/-
WYPP9|U\$08;.&D=#MH|@L&+C|7_#%A,|.0+I3_|#O>E+4DRL!(F/, OOEL#(=|R\$KRV
M_';"=%Z)2>>E*MY%-*5Y1#L8<|1)9.C7&1PWG" *\$>*>|)W)88&@?
+F6_I9U=,%C9:N*B"2T2)3ARQN+OZ&Z6TAVBE2G7Q0NE|H5S_7
M(.N97DB_A=7;S9;UB|9N^P:6V)A6=7^(DK&8^+?;|TK0&F_\$;ELT-
J0M:BE5AW14GQ=0"C/7";B,D'?|2X0\$%7U M=07S_'&;7#9>B'-
M2Q)H^\$Q3@.*3Y1YKLO|8N02"5XT02T3=V,TR<+|9^K5 M"H@ ON!5JNV!O|J0Z
%Y&LN/4Q8W_! *KTI*K9S^>84@!&,B@FX2QCVL+Q|;
M<+3_|&IP4M.1#ICAW1F+=HQNPI'VF^JJ<.VV-/MG^&T<#+ETU=4OH'RXU5|W
MGYXY@WMV2X@D!\$K6C;Y|J,M5)?!=L;/ALE"\$YBK| @;FC_FE0/U^>T;:T#-3 M|LR^/;
(PSH-V,OT(TPG_RUX+2V0'RM|,@YHJ|RG^Z!4|U|X|*.S?SZGEY24U ML-
|HBR\|L2)1M:CB|E;FI&|;|2%E 0?T.93((S|02\$.U\$;3H4
MF|@%L|9T)EL:\$\$_9"7RYJ;M2/.*R";1>Q;|+C_8WJXA9>M_<*U"TSB'T5|*I^RSNFUE7F5K'
|;:&YHR|)^X?|AKM(6EZ
M,#R_PXG&:M!;AKGJ_.T9/'Y&_|L,#I>>11B'TP831MXP4DQP\$N03G3>J3L@P M<,:!&Y
/Z>VUNV/CAUT#CP&NO,!!><#Y/6!*2&<4+Y5S)GM^3RLI<1LVM @P M|Y8|K|9N#FX':-
NH2|&|<+%;@2|MZ;RV_O2C.9"" EER;)I,W A6EFA7A@6,_ M-
8999^5#7L0^4SRQ26^:B!7RGC*|P4>|V9"-=-V78J6(%LQ%'\$RDOF0&S==L
M9^F89=Y%,J'YO+(!%UH-|J(*&|LVV7P'7G-6" P|X5EX6W23X#)LZ;2;^'|MZ5.6|./?
CRT/DF00RU?!+@X)K.C Q|7 M\$"|+;.<|##S3E4N;RK2|0 CQ-
OHX(';'@^HS2S9N#F);EQN|!Y+O5|L,M=+H M<4(8<*DGO'P#)WZZ*)GF-
_ME|62';M@#;/EC=>L^#_Y80E1W##Z8MS*_9&Z+;|TWSUG;|6|U?
CA,6OH;:UE04T+^Q58^|65B.! 'WQ61P) M6O"&RB4ZL"^K++<-
NH5B1L9|C;5R1;0L\$_ 2**9"!&|?V29W'.I_P_J|O+S M),ALL(_LC8DD|@\$@ZD|OB=
(|3AQ0H<3C=-M%M=I&ZY?B"QBH"LOS2-988,5// MI'^&+
|<%_GJ#=#^;R<|5@891,,\$ILGS?H-%>^>=U!*0(C>6,U&
MN/<5<".4+1WK2AHI6>!OD7>|R^G)%8M5WE7A9+%1FXUC'D.5|>T9;V3"-
=Q7GV|Z\$I9#N?92?NE(9"-:J@8)H M3V6=5_U?|_9#|C9I%7@;^(SZZOAN2Y0S*Q
4S3JNP-!6??H,(DLPZCASH#0&I0\$>@|ZC %\$-U@"LG2%AVF3+P>)7H4X"*2=7L
5^0C0AK6L0GH= M<);5#MM0X\$F"R8AA^\$,>"U938R-=07Q|>|.9J4Y)J9&^_
*NIPKDJ>1R+I5|14=E|Q%'6<3PW<6 MF#D'-UR(|ZJB(+X|R6UEP@J*N2G;FN))&S0#8L|
AIAW(I+.PV|WG;9A.J68 MAW|BV1QD^HB"3!^;:>@YD0T5.\$")(-
IGILID|^9TB29HJS2M1;WS4OW0>*)(MQ99K)XY%G\$04NDB1|!EQ0KS^4EW0R|XY,U5

MC3WHJ?JSGRL2PFJ0N+;9-W59802A;B)EC|W: ^7X6&P.Q\$30.4)=FG1)B|*P.08
YM6NH5@| \$H! ?GN(NP
M@ (E>N;@XEF^&JUMRI0>H07N9/,5!GJ3:J*JF9"4MS0(.P#*/9L)Y=
M^!%\$<6GJ90L& //R\W(^?HMFWC>,485Q@LKB|, @L? '*WHJXV3D-X|= .TX(A?
M^_PM9KZ@: -I IMV6I_ OM6^_L5|F%6P2&F(S:JMO&(W%=9J-3)^K!| %<-U;R
M('(?!F"K'; ^UAL%E'-H-R2.:!R?-1*L(8L98,0G._0Y1C(KC@6'-)! .AO:
M15\$^!1:"TFT)&8YD#@AJ!WG6TXEAKH81EQ#\H3"MY- M2!:'V0^= MO6.9SS'9,@/AP&?
H4PN'N2"24Z@O8AU./@DILY<7/F5V-#@RR*[F\$030%*#7
MEN7\$4BF40W2#\1R,"IRAO^V:L*2Y(V+^F#U5_|@_0GD=9_6E
M98W;6%\$|A'>PXX\WZ<,4PDT E08# M\4T=.Q*#9U#J'3Z1(8=E^@Z!)?
R("49,56NYP@WWU48BI%0\$CR-
YL5)U'0J#.;R#10R=3|B.UC;Y9H.7&.X*OP^E=IWIRH*ZSV&F_&M+;:JF
SO+VVZJZ"22=S_PLX4: ?>BJ*,(OD((PQ)!G\$J8%L-*S\$FHI Z5=U8V5
MFE\$9T!' ^IFT\$5HW%JM2*|H* 2V,ECK2L>ZS9(T:2/+K,">#-'H|V9,_|ETE*B)6:
|%(+) +!S>'PA\$DE:@&6;ZL>'Z&V41ZFG56|& .#BJ|.46=I40*N99^7AC2)L- M.N/INO6C
JS_*.LE@EI2@%,*L1894;GF^\$>47N+1 Z\$AO&VH\VTIAGI@5G\$U
MPB_\$U8B\$Y5G|3#R#7)Y1H:.JZF.01:2X:SJZU'046@R7Q6!^XNT M!TTR|RG1|
|_N;:|H_,Y^O,>Z3_9CTT-VL9FOM.1ZS*OK7+ID=2O'RZB(? MV*46:2Q&KE,\$>
|7E#4WBJO90WARZ8GWU60!|X&+2/SVYN#B_R.!M2BHQ! ?9<
MJBW6A8CUO;)X.3\$C%^ZVEI9S.JO|M|552| %:KL*"|4@@19D+IQ/P9>*UPI" T
MRK<\$LW!...;|D=Q\$J6F HQFTK8@2+;:I_D37#V CX^'E3ULR J;Y"#, @KHRE"9
M=8QV!ER!XR4" IHFQZ>JZID5@R5DK!3M:W|>QEPH#;J"8EU2B3 P@"H M|181R/N*(%
7@K|*\$K|O^4%-&E_:)V_S|Y'_ @CCAQ/NNJ1.:.I@Z)O4T!1& MP,:%;|+V|9:3K|EH
VG653U|;%6RG&??|(VF*R!_2!8_ ^<;F NIOJ32JLZD? M*|\$8^?S\2TH!|HUUB.D)8&N"CMQ;
<.:>_>G1T_/'CQ<,V<)1J|P&?O^AR?N4
M)XNOT,'=UQ(W* @TDA%RT&VPQ1097LP95_(-7/S5I N.L=Y@Q16= ER:RX7L
MH(=|6)LBTA%U?^!%OEA||=EGB|=/'HWIK:.P-(\$897^ZO'P2O>^#|D'/(B;" M6F|Y(>?
6.:>J;N|/,#WTW=(&A|#2,BJ&H0#PR"%RGUOIJR8/9#/#& #0CC-&/ M0A.
|UX%_75=|RX&BV8TX)9PG>YSZ/WI>A4 M" T5UD8Q=6C.& HYYNAC651^NT13/4|57
SW2A:9?1:\$W-8^9(&3I2BO KC?^ M556+(%LQ8U6?8|<&|D7C*&&0E\$C&F4L
:A"A="OHE#1X @|YCRE2BWDX)C- M<*4JYJ0LM#0I*F1A<4^+G*_*.*
L+22SD%#)XDQ2*2!&8B_HYJ!;BBS#P ML&:1M.25>X?
LT"G67BD8!HG;RDCE^SF&_N*,I0@?'.OC?*>,V#6 P@K'J?RY
MKVA|NIR#\$72V=YG7\$7#.RI?TROMB66\DDGPL?<64*&!E;91HQ_Y? \$HUL?9|J
MA9|+)6X*(|8*L*J;Y:H29.G7J1"+|,I|\$>@8%7EH#\$P_0DID%16.-CF|65/T M-
^>%1_ '05'=',DL5SNT**+.2/F=GN+O=3H=E%%@&F"*06!7|Q_FIM
M>60HA3Y/V+0IJ#,E;)-M!CYWRMG%GZ;XP S6SZ=8))%Q'G2#/*GQ|()&@?O/
MC\$M"|,.%-4D\$KP-2U&IN8'9|0O#A*Q'!E!WN<|:JAV.XYMHL.!D%YP/=0_1
MS|JU/3PL(|BJ|/>)|POB#04.%.T5<+(!1@SY@AVFP(,;AG#FG'KN8+D*?
Q1=>MV>&L)075J M0!0|6M4A%7JE1662PPJ"!-FJ+ /\$,|A?;?PLJQ<"|^CGZ)>YX|)
|M_!F0@&*3)D(' *Q%;V\$D^=|9^G6R<"071P@UO#
M48?;V!10"4.BJES;>@*D|L:HL83O1#")W1AJMC\$&I,F\$O^7_D1A#"5(_\$UC
MT5+S"*R(:OJ;-M\$2X>#;S I' MLK 32-E2839|^\$5A.,D2?S: ?IJV;CA2I@
MZ@T/3YEDHB)|RMGX_J.HVU(R|ST*M<|17Z&J8QT,NUU|=VZDH6D!#(:&*K+I
Y@SW2MA':+@H.9G.;2?L |I+Q+Y9(TPCH5^ MM3&=0Y*\$05RDLPL;D,OX,FC:6-YBU?
%U^2X)N|WZ%S,)97I+F3;|^R.O<&5 M!@ART@&GPE;|7#YS(CJA*U&S(:J1'UIH^;
(#U.>0!_M) !VR^H6+;)(,5SV M+6@*10 B3#!|J?H.";6FJ>|+L@GE;1/U@|K&;U8%)')
(9_RQF,%<7|*8F# M4A40O|
<1YTEUD0DS41@|LHD|' ">,R.44#:V;AYQU,X=&_Y5#HQ\NN\,P--ZU?
(|H\$2E#O/S.L>DNM+HG\$B+|W31P6KA|G9+|",3;_S=*GH= M|Q/7%XFW468A-
>/1Y5F!990DA!;#P8 +J'KEUX|:-M='6<5W:75LWW_/H
MGL=4M\$0@;O1Y|GQ>Q\$3C&R2S:VJXT_#IQR:=7)L-H+^5_7N|M&UVE2>16#:OS
O0D)^OU|TSEJHZPNX;.BC'MT!0:4WV*Y|"UE0R6S|/ M7E6ALW!R3>2)
|UNIVU_|*+^PB7A;:T?6SN=SY#52OP(CILDI9C^/O139>0#
MP)WP>4(VO(BO@|I+)7MPA/|7|C_(F\$ZWZU|WZT@UL3=DZ|-1N:|SON8<"U
M.J(VF0JN&QD1H("0IEJ7!|3'&74(358A:5_R@<,Q+T_|7MN2!TP B@YV|YQ
MO<3)&7(RQ>OF4HZ"6B9Q%603M/53L-|DY#F@':O3V"*_*_'U_OD>*/^5J*GB MVM.2Y&
(\$?Q#A'DA43TNV^//|32O,UV1%7U*W(PQ2<.,|=WM5?9DU8T&A%N&8

M>"U89XUXO!2=!ZY*M.H2%\KQ@VGD5D4+:QM46QHP1H0##JJ"[%H5YOO[^6
M((.DVY8/-6E7AZ4E%9",ZL+?M&Y&B*3:OPBK(+RIJ^+;@M))@??&&6E^OR@V
M.C+*4*!?,>C3*EY""@5_6HY'-6#DY.0*]A%Y7D#PZL8=YCV?F&JJZARX*THW
MS%|>%P5/=R<98_EI_O&XPX@V"(1#3\$W-<)8!G,+=!SDP.'GU^<+YB<=MT@ M=
J4IS"@0(#LZE&=9.H>>\$!8JXEM!A1JI^T^I&\$ IDA)IECV!DMB>CB'1 M:FI".BB-
X=R:>O'C,YWTX9,/ _HK.[@SG:Y|AE3YZX2?..6RT
M3/9@#O[Q^9,GGW|Y^>7EDZ>7%Y|_O+S3ZYVP"(X=O#LK;5;6&;I-T?B#+1'
MMVS+' _YL3O5XHF #3WEYT,PC.2D2|/K M6YOW#+Y(OK%*,N6XJ7)6U@9TZE|
|T|HS_#?5#G |NOH+I3K;2!O/FDJ^922T M+,GI-/ _4=|_<93TCV#N).X|:0IYYF\$,Q)
<0*F_ (=,1J IB'397|D.:<7O(- MTTOfZ_ V0KK<|RNN=8J|"7%2N|M>S)| "55|-
@.0+*6QTEY<'@|%Z7\$@3N-IUM
M^V7I<@|HH)YL4H*VC;M!O|M..L|1T&>UT=)G@@CZ6MCF"VJ)|KK3+X6KQU|
M8R.6F9UP0T5VT,:-JS2=2V'C?:*MY2DR."D|(\$AF:+NEQ<:8%<'2)< R.6+*W,M|
E/C/YT:RR.GOKB)49*, M%|HJP;NJRKSLBMDYBO^>|=N9.H^".C='2IUGA6WA5+P-'L/?
%6ZU B.|ZE21 M9"N|\$1B"9|8REU<09-OC>.J:|62-
T%MR!ZW|NS""F89+D|3.H)RNXIW(=M8!0 M6T+D>K@>^,KAJ2"2C:I*VVZT
MCMMK|9(BZ|L*|H8HID|JO|,<;ZZN|O3_ /+01G(5' _JLJ3H8#H58MFW|@|Z1U# K_I|I#
MIM0&OXHS,(1Y|BJ6|U%@L,S<+@K9 !5=<\$X=2X M\$?X-
R3=" @%|&P%/8C@0|F_*O5|Q=7%BL(*LL78\$O|3,Z?(DM-H#4|JCMK|VU M?T>\$_,
|WYB:3BQ:G:' _5&;,_)6T0NEZ\$V|9:0#N&\$N+C9>#,"#WG|H0+|JR08>
<>X/H3YGYOJ.7W2|_U"|&#&'JKL=<|=|47 M/TL|_IR|:JVM/?N:%8KO:
<(V^X93U^%6G|S|^11;NW|^Z>7EXT?>)Z)7*VVO=%#3>4-=E01| M_A%?C:)?
3L*V+B9XDX(J1/8HL:N\$|W@C8D5|,=KU(:?H7_ P>\$F/T:K-E1D M>
|\$(=(056A|LG@NWQ)1V@4|B+8FXI,DEMWG"BGJX#IVC(465|=PCH+(C J)%
MC8=:5A+&VNR5"=X'V';C8+?%_ SH9J9H.)#N*&T8R56EC_ &;RH<-
\$1>@D_(8|>^!0:94R!@B_!(-B("I/41>2|T7B@#F8LMZ|EPOCL<TD# MRV"\$H-
|U|GED9W"VNDY*%*M.E=2O'MS\$R\$=B6N\$ Q>3_AQNG5XZ&|6'P)! M#=&X'Z|
^.#RX9#OC@@@J9::@@X!G102-I7QWB|'"=TD\$S3|:\$0-V@)DZ03D MHB(YG^K)
|T5ZU/ZJFYM#5|JR|PVI@H^0Z,X+EE-7>BD##QX|XZ#6#|>49"8 MCF"\$S;?H%?'DAU-
FX6GVFCDZ!@G5,AE/|@;=|>(ZP6.T5L30,R?SJ"G*OG3.WHDBSP:0=3%#ZMLPYZTH(U%-:
(3F MF>0VC%PE/-JLA_GC "F6EW4K?>F_B^\$FYWRKPTQ|D%J5!A;0_19P*|U*NM;!
M9O8E=RJ+@5VB'NVBKHCZ@8#M'@"4.=+C_ \$0XK)N=>L*6LGKKXS|6""@/O_ M^)-
!R"5'GXC"Y+9U|\$. -WJ03N/N//=Z"P1Y*,I\$INZA3'484X+77!,C+\$S'C M7S:4UA-|STT+%
A;PU:H.D4C;%RUWBQ\$(G5E+G8+E,I3>8:9,4UUK2G7<%3R9C #A_>
M:B("ZK_1Q%Y>U%6:B0D.|B>&|TZD1P3I\$FDN5-S&F'Y^&@?QHDV;,'EA*LY
M>,K|Z7DGA|0:H\$S0T|VZG+@-JXT16BV&4W|)9XVSN)27N-1D%#|+NR.IH_-Y)Q1|H)
MZ0H8E\$LOTLJX4CJ9;%!8JB|2'AYE?*/|"RH*)VJH2(110MF\$Q\$C8*YL%Q4/LV, MK3U&
|'T*%QF'0!A%\$.LI6>RDG_N!4!*U0A^U6EH\$1Y6>)URL#0|VMJIWQ&6)
MP(\$|UA4G7YJ^E6ARZ>R_-);SG#G T(*+OI&|05N^O)=GX\$&-QM;.#CJ\$A-> M;&X+?8H
MVMEA\$0>NMQ6V9@2%7H(%@,AI,("T) UR OCW|'O:89QL(Z3O' MJ54.*?
@1I#%0S)&>&\$,0(|7 MN?;>6SUMXKUP+;DC?
92+IQP89@W7'CGCUF"/QB;*48W4O3@;XSL/ M69ULM>=(R\$'J*NK9D|_O9BT4!|!'FO?)B;
(P!MR|X|C#&8|M?|6.*5_*L M6D|<7_RX)D(8\$^K6/3G|Z#)(# 8O:>/R\$(5),?
6GBCW0P5&6|:Z=,W,?I/<-6|>%JS,1Y%,1YG(F-0)PK M4)W7UGOL/'4*_
W4"UCO!L:G,@(-_VEM|+R"C2F|UT(\$B.R|MX|4_814/9Q M8D|#96_-?
B,X#TS21)7JN.HW:%%;KM?D)34FT&=PXJ:LV3LZFP#">&>U_L?H
M8OK)^^M|T00'KLF,|?%F;L:\$ML*M36P7#AU(DU|Q%T3?ML;O'(**F6H?
5RHC1%'S#%#BX.K/VF>VNL>6PS1|0HNPL\$S M/YK*EA1-O?
SRR|^S\$WQ\$4|VFAO.Y9PLJV2DMIQU\$/LHH:LN.(/3_L>K|6&; M*>|8-
U80@ (A+'OV;J6/:02P)B*?7|VK8)?7;GO(8XS|^O/YF_-L90NJFH^V MO#0|/2^ZS|I:R82;F"
(M^9IC|*\$2NW-GX7;YN_!1|!-|0SEL,O?.T=ZP+;0 M1?
FI.=G4>D_/S&SA3C#,HYL^MAR6JW96ONVC4L*X|+,E.36',G.7-MF&1Y M2(9H/?
5A:80*FF619"CBP-.\$G.;YN\$(O8HH;6K^8^JW&TC:4*QD'B4G^L
MVV|P':6H(9;7WO|+QMX|;?|!D=T_X6Z/#VB^MZDR?I#,EKW#U!_6!SD @' =3 M(6^V?
D=3K>WPE3C5_KQTX7R4SOMOA7W5HA5T M%\$18 JFI\$!6O:|HN|::=+-
:H7E;9*@"WX"QB=82-LC9"#;:'@G+M-+OHA&3 M"JJNJ=-ZP\$64PSR|&LU(
ANHHU#@|'"4^BOMRG"&,"-P5T M.0W=X7TK0^)^9?JU21/&VYSM3|5?
E&;=%HP@HH4B'Q_A=6|^/&-JY+

MZUCG"W\$4%^ (X8THK4[96ZHA#R0;J8=0*,>0IWB4=DYIN <-'\$=2H@3SYHDW
MA*4+YJ,R<@M"TOB<,,H3KS'QN_2)\U2?-B6RN4X\$K3]*!4>WEPJC"N5RF:WZ MT/I\$?
J_OC6"K<'G@6MY/[9QS'.<>K?!"+.LX>[0:CQQ!PKJJZAZ3-7R KZX0 MCP8I&)3P-
DHP!V4ZAZ=6?;E")XZC?Y:V.VWY\$.)HE_E%,ZQN#8S^J@M>"8P4)/I@DQ3&Y
MKF9(!0&U_,@E2O("X^5.RONNIP,86%'6IC?)(4B(O<+4!8F!#%WV^-8XS-
MJ&I*9:EO\$WCB[JIS06!R*^4*H02'F.(POM@^K8_79+ Z#\$\$OE!8_
MRE,>.."!7A556*TXCL#;[IHP]I.:9L#V0X^R53;W6!WDD.[0]BM4>DH3G32
MU=?,N&G9J%WH>|@;GDXN?6GAJ&O%KX <|>G%)Y.O(%M/'9YR5N(N.'BH"&Y!
M=L&U(^0?EAL>UR"VF*("R"NB'0! ?C'=/KVJWGK R-;4TENZS3F&U9^C;5AK^/,1MC=
IYDWOT". (IV%J_'I)*-. T&LR& MI: F>5HE(\$7AHYWPDW*@GD_%=\A:16Y1E64#JN)-(
MHPG20=7;&KRS\$|OCA\$&0, F:06&7;>L<; M-Z=JQ5&K:3AE7;-EB9_ZO/29!\$X?
2QL47X>\$C,+== \$P6%:>,Y0*/#W.|EDH M/\$,K2_8\$X;,%'G%4U. **SG9.J4ZE.*DEJ*
< **L56GR).A)6+-BD\;"2LY MI?>B0XS(M)@00&L+|;H\$+_?/:.+|%>7Q2=R%Y)Z\QSJ5(7
M3'KT0PH(!+J5.0X/_4!#+GA=KASB>/F3N;P'DQ@5+@;|!00=?GH'V+DC,T
M'0K'OB<'B6_R4--N^M(R0I*|&9@LB!-RAZZT2,DR|-Y=Q*K_|=VXH,Q+G4; M\$^?
ZA3WBA:29S*SK0,.WE\$|@," @C.O1A:Y7C+7#![9R311T&!OHB3>>N3K=^G>|I M@AV-
G)41B(TZ?FX"4@,QOLC+B6FAXK.[?;H^N|<'?;GV)(-6RI'+3N&3NV!
MC|&)@C<'7KYNH:9^+8N|ZH\$<|1L9.V6"\$R^|&D%T8PG+967V.C54|R?L_Q3
MPNX6>W(0+L3=)T"WHI=Z7|/N.NZ<+G#9QX|S0WO)|:C!
(KFPAFK00#=#.@.6B%9T%VJ|'1TGESEP-%&%&6\$| M\$55S-QLJM0RIJN(YXY44UFZPC?
S6%DXS|X4#+!D98)"Y_\$+S-./XX)L%X3,'SN4|(Q<\$|H8XN(J^-)|#C;M+ M+
<(WKNNL5.7">"@!)?0#AQ|W30MPP\,%T4X<6L3,T0Y?UV|; (-)J_G9#G, MS&P*I|'+1PP-
>JHAJ@S72<=?|G\$W&>2Z|*.WH9@LU:R|S:U"J/L@)HM4:T|
MZ|C.3@UP'A4N30E:C:A_WJKEGV%260R@|)|@_5(2\$=P&VY5@;=(\$;*@ES1!Y
MZ'GVHWH.\$%TE(B!)W-%V,>R3IMS-(Q0_M,U:LJ=T<6(" @&=&#|*1%7NT|?E0^::@HBQ-
\$*;J.BL.4+R(\$?M/0IT4.:UO M3J-C6\1#((8!HZOZ%S/O9+N(#B(HDWYWE*_|BE)&JA&--
G;MJJ+T#*IHWQI4DUJB;BZX?L@YAL=9<,VFEB8+
MQOW7/!_T_8%1053H@8VUR&_PMLX9L\$= G<=;WGPP_(Z5P)7&Q%H2FLPF/WA.
MIN7%QTN.GU|CO_WV0>BQ|OS8Z1'SJHH09EHJ?E!Q#W9AX4*.*Y&MYW0S#Y|
M1!)^I9-;.*>-43)L\$D7) M8N0K|B6|EKS!KKV'2V8&T9XXOA?BE)-^QDF?
6C992D.MU(9Q&'7U:<9;U.\$, M(IAGG5HZ@FF4AC,0!CV 3X9RI9#"DQOV*@4SZ'?
>KM_HJM9X\$O_WR=7S\$)"B_M*\$+V@F,A&EAZ4'W#3C"|W="9H&-5VRP,@SNGBR,
|A!|A?K09^N@5\$|K"HQC.JNU-;21?41.+/<%/US(MME+A,@4VJ9.&Y=HHL#-
|Z3XR;AW32+N(^TT5M;N"3:/@7S(X->U\$M(S|.) * MR08^.|VT4?EK:ZG#)Q8H5!-
|DX4G\$47YIBDXRH!(69B|H=HG" 7@+|HV(Y?" M>?;=\$"&63#QN".N7?K+SK;NY630)9VE
<0,T4I3|0WN*459;M(.?AU"|D:&0S"\$TG>.OM|4Y'U9UQI_3HICPA#HF6D3UPP|
MYZ*7BXZ<%DO|6=6<1D7ZV,)_*,|H(=4RNF%3E-T_13 M.<+)R,&N|4N*2#) 6. A@?CRD?
@%K%PZ87L/0F%-M|9VRBUP'>G;V|A.ZDN1_M|%L>1HMZTX7=U#>
(XX9IZ;P/G+1_8W*0VWN%4*2MCI5_XY^@2|X1|H;'B=09_M'SPVK2!@R_.WKYQNG9YJU+
1<|EP"Y&:>N|)3|M=2!YF7_2=IBXA(HFF=D)J MPJE2(:UUE#1U0H@#^U.=G6X<)ET!"3-
C"7BT*X)K^_5LBVZ?;@@5"|@J.05/ MK2\$_"L:XJNA!W-)5.C^FD*3FX#
|3:>JS|37M04VY,)X2?&+W=|>6#-Q2_ M?RL5SN1-T+EGF1QD|C>26X?
_#"@>@8F3F4YECK|P%YV+<4HCMMM> M:++(! N+|_I.QJDQMPHVJ3
#|2+YAY4O2YMJ1@I FMI!<:;\$|T-\$%E-#Q/BRDP%+2WU_X9BEB3,-/|2.3IES
M15>Y1GZOC.L.?C(D)T\$L29=/A'\$6J5SD|1LF=TA"TTXQH-C#|^|T0A0O_,
MOW&M*JA7FN%^*^H2A;)%&W<:1Y_LVJ*|2@3;T1_M|6M7|ZBO;9.\$NV
J)\$GJK4*P1U@5.1>0%# "63"@%A4.+|A_-CSA|0DMX|H0
MZ&?|)%N&EL%T0YD9&9LM02Z7|Q^79_IVIG"1Y!?!^W)F1&9FH@I+?|E,8_2LM_M_U">-
?VVOG4QY?L;)@J!S5(EJ_1|\$XU,0^G=69!N(:_RV*AC?0=ZQ>_*
ME(^1M#&M/J#^!Q^/7>JY>=|T^H DU&P|ZEE0!#:"1Q@(@_M((%V;|H
E|H1X_K\$;B|L&0_LH_*BK>0Y1U|_%&-8BR_M#;.*&BCJE/>EX?
1FHJ|N'76&)R,*M7)9L,%=09U*B#QZ':D&1"6%+R)0>BR%
MT_ PYO#PI+PLAB.*K\$XKZQ!=-VPX74L^3O5J|0V|TORE+*!"K.IVBT|HDF M,*X
/B(Z%MI+96|36F(\$K?/LU?_DZ2T+0N('+CD&(_\$YFW"U,4^|D TO-1^*V
MZ"J&,3)@\$H8"YPD)8GD=6|K^J*CL6LELL%\$1|-68H*+K\$|>(E<)-:K)U|=
M.\$59LUKB.=#|!7"-KJ&S>9JXFB#?AQTOTT4|L6@W@T\$=7Q50J-UH|598;S
M:I+V:V|%J"2Z\$=K;FEB.7NV5'36QG>,P/;<4_U!H3MAOF0X**R\$&&2D@|Y2<|LRJ|HN?
HD/HDQH>NP0HAQ9/-T<_J'M"OMG%%SL#EOL8|R' MSZF@HJ,P""LWN?H*C%%GD"Q?

T.B:R/T"-#(^.6\$PU=FQ-*Y9+O^Y K6Q&A M
I2DLM)H/CI'Z,ZPLJ.NEOG:6*EWN?X6B1,17& 0-7P#.VA.SLWU"7*KD)-EHF>'VH2MWL8'
F73 # M-UO0<+JJ+H7_L>(U>KK+)J!%\$.84CF,G1"l.?97S3[XKZ;@TO^4+M#Y21U
MWRDN_J%=4,=R/U'_3D%RV"X:0JK&Y,22@6J M&6"(^PYIVD9Q@I:4 P?CS,\$'N)XQ0YW"
(-?;'WE\1D1P6\$!30=-L "\$L^SU, M)7%;GL;>/1:2""4"!^0V2RQYH97/9!P^
M&_BD,"&N(=>L4 2YAK5<1B_ [W"S"H=G5P&S M@G?B#MOU_:??
f6?)2<\$@V+G2\$>H>SY&4W@HFP K2IX0XLJA@>?9CP*=31*< MF6_" 0U8K1NK";:
fY.7@_DA?C23@\$G>94NUTY>16B5:CUP\$R0<#AK'VUH(B_M>[LX\Q3N&&'-
_@#OS,L&5F%R_0M;\$B0CG3#9=ICG23%MHEPNO^%FSHR\$=AL' M2"Y;.)@HB02/:C\?
1MQF(-+NU\;<!*%D8B3#'.J4N9,D1;AMA)T#+5P9EG? MV-.!]*-W@FCV\9"XNLPVQ/?ZU
3M%"8UN.@T7\$P";>?T)GXU&JEK U^X&X M6"1+(S0^)YF"
<%2631:LQJIV/@LZ02_DO1L=5G)6)]3QW>Q#(O'HF3N I\@ MX=AKXC4"504-8@2<RG0
PD"] MKEYM098EJYNXUD+::D2\R5MLX?KX?)H#URNQ&\$YD#&I3U'G>X)NS^)^02!/,0
M!2&U*!:1?JHI+Y%Q8Q+%/O:'P';&PS"!U7T3G-) C 8.XH3S4D,F.6\^F< MD3;
(2..\$+63K;0^J. *4#WTOY\O%'Q.HJE5SK37#;X8J_?'#\!'>55%%\$2 B_#PB M_!X' "ZIR!H
[*VI;FU@^-31RL;2Y?+*@[F I=UA01N" 'X<> E<.K4*?)3
MY&?)R,Z>I:"@.'ON+.\$XIWIQ\$)TB)ZOO# C.RJ\T5A_YAWY.QRI9_I'O;M<-Q_"R
@I*>X1(C\$^P?&)E;6/KXOK& M1\Z/CLW.S2\L+BVOK*[M(O?
V#PZ/4.AC&@++Q*2D)*1D/U@F(G;_,1:TE-7
MA\$[3RCX@,W.^<%78G_RB7,R\TL\4\#982-N;<^9KOCLE_E":(X\D<&I\YX(\$9-
>R7AL*05<42W)DD-)6) MBP:4?FWBY%HX'KB6NVF#!R1A.YRXQQZ&ZUXZ#"?
5@DA!)9>SF4(U-" I3]. ML4A5\G\$#_J/5KQ*JPJ;Y&<9A&;?H_4L;_I'O\$?:
9U^;P'"D,#A9WQ"Q8X)\W\GS(K47S&ZST?1YI655\DIK\3\$.I
MXODU=I>KGR7I);_01B^RY 0IK+EL_+ #5\274\$9N\$AJLH7<[GE;P[Z]-9B"%(
M#PLK'F@Y>:)WJ9K:S-U5PLJ.68TD"/JGES;0GN,_Z MF9\TE<\$2\A\$S\RAP'?
L)WUQ<1\UA&ZOZ275BXA@C3-H->[-H>23U3P_%-< M20)_+"9ZLGW*?
Y0B;LWZC\$!+WZ0:T21S#508\$!\WU'WU,T"FDRZ1*+VE/2.6+UD%I_OUO!>D_VO\I9
M_TO^[PDEH"7S\KI G\^>>T 3TR)!4S\4.&>?S1,\R\Q41IP\6EG\LTQPPK!
MXT&'KW,7XXPOM+1)R.NA0"J!G>MS_-PE5E3(Z84HIN\$&=MN:BH=B&!\$EE/EZ ME-L:
[*S>6YZ!M(A1-T.035"7\$KN507B%"3CM@J'IY'RT\I6;&:2Y\OJ3T5 M% RY.1?
3QTY?//M;1;TH))_0P9Y#=8ZX?-JW<-J3N!:=!@W+PJ11U*QC'1F&
M'R?:IU&6O_)VY(G/H2#WNI"Z\HWF")X@73 #AX(W?!1 *58SWN 1.R;2TH!
M@ZFI1*E^151G\!W6A\5/LKNUI5PC1UJR^J:INAOL5'_E@1/(R5"KGKZ7UY'
MH\$EXC3%L;L\$GYTQGUR>< NEGZ\W RDVC.JHKKJ#471I;KQ)1. ITA7F"
M&OFD(4."8!MX1I)7G6X%SOIAI?'?PN/I^Q\$B&4KK_% M9_08C.\0<I6?J M+XZAJ*J-
>:QP(E_)!'K>I2O"VU+F5(GEKK@JA&N)'CSL&&!UD8)KQFF?E
M@(\CT0P"6V:&!SY&#=>E)BQ*T<> Y3Y;#.X4+8\OE.Q9)=Y,NL3I M(JJECJ7QP(I F%Y=
H;-&);+0U7H)) (H;EJ&HIV'#^?IS_#L2@@\IANQ M^BL2""9_&TSG\3;0;/086-U5B28?
TI"E)+LY7%4PHGWR?5WP,\PD*KUQ,4&H M2!T3CT@I.@'WH!%&
(R6BJ^%'D4:8PCYM+Z)OOEYPP\U%+C%/VH^#H-16H M2PBIU:Z=&\$3T9VW\JD\
<08P"FY1H/U60%%!P\3"FAZK>,.ZW\$=@<9<5%I0SH
M#N\TY6"7T5COQ\^Z%T.6PFDZ+6T7'ZWAPJ?/R>O+";N%CGMN>IEU>0K,7+- M;?
M9S+[6E8J;14++GYK-%-S4N55:\$ M.D\ XD>_@0_7S"N^<0M#KWG0"26'3;?D"J9G'&?:
fV?Z0<4;=fDD\$S\T.N M\$UTGYC93"6K7L90*(84JOLO:MV%2U*#:M0=?Z^M<@YHJ.
fBW\6J\NCGW@Q)* MLHAM=5&CUC#B!?.#ST691EJ%-6-OV@O\$CNO. (#
<=9_E;JX1M/E+\$NT:@8(W\ MX\$C>(-)7U;Q(6U#Z;XF.WDY'2ZXY\DF'3?;T*
M,K\=KSTW,Y3G".4J=5-^ M@RUDE,>V9(JUHP?*FG,+""-023?<F;WPHWZ>
ME7C@)M*GG7A'U!#2G%*@*MRJR_8\LI>?E_W/I^Y)3'?.%>
I_PJ1I*8_S4E;LZ%7I>/J?"DW/S\?4\$*W@\$,,%>*9,)QA70-KQR MX1X,Y%A\D)<I
<=I+C>5*!5\$K0,36^V1AVD>C')=-OC6K&09.0D*1E\XCS\?=-M>)5"D)91+W>I.6=S:0?
fY993PPUJ:/290\ \$M M;(E%@^*VZL1>D_ ^I&_2_3)'TYUS;AT5X^1W8SRW8SG\ R\INP-
BG\GDM#E"ZK MP??9""K3I-::G@JPVTV M/+ \$C?
#_8C.WJ5%2K5>IM.+9Z@)2Y0=\$377<6;TEC.7>EJT,,I
3PU?I>A("=U(EI_0/_DPN(SNYEUS\R/D)CU5I M!)YS#-[**
Y7:!.P5Z3<7(F=0\$^W@Y/-;YY1&?G?J=[61XW7/T4>C^RV-/MB,\32T:W+A=OX\K>@*;
<\$?.S\O?;94=&W\$A;-7%74 M*WGI?%GCGU250&0%\$ MVV*K,(2N\T%-G/T;.^1R\I
fUX^<@P_T/Y7R38A7K\!(D4DW/RE\%)*V"3<./MUPZB
O^GC>_ (fD(Y"2_S+KQUY=0CK@I&R@:.#3=_F:90 /DQY./A/&IXHERLU:.# >;IKZJVO\

H^5#MZ!-Q>:G.50<[8/),44F!C-NB[NH9Q M55J^03&6Pl_.,G416^8XA O.!LB(Z\^521L;
H9_ '5_2^M^XL5_,P2!L8HJ MFM]RXWH6NXNZ3=B)35-ZXRB MTT2-
E<:80*2SK\5XTBT87WIS(7*^"JMH&[=HJ_:N.R2318&[+ZU?%[TOW5%:
MJH;"7A6^R^F_F6T>ZU&2\;*Z/W8T<|>K;)*Q*SZQU)Z!5_!O(0#_3@2X3YQ*MRDGREQ?
PFI@H6%[00\$D:0<37!O=#EB_\$!\$;NB[JKZY\RADWT)S(P:@!T
M/?)+WI@'^^Q/XP9@LJ9TAL4\$L/GQ:))RG&B4V^Z*S;-PR+MA2GEO*^&K/R^Q
MG1N4;L=D.M3XQFE>2![(%C3L3NK86W\$=MA)B^Q+^Q.1^9!>J?Q^WH.-J.Q]M*>
(!63!9:W^EW5023Z2S\(#J8?Y!*IK+5P>G, M?Y7!C?
<+LZ9UM5X@2F@CER*74K@6IRZ5XASWXF%DQ)U"\$#=#JOFESMK;_)Q
MOX;LJVL(GC2W M/.Y-?:%/-6!>%4N\$>[YN9I7Y8K6D\$YYJE0RS--+.
!+EA[4@OD^5WNME^83\ M/?SQOO^YSZ\$%Z<.>.:^5*Y0APBJW_JLP8J,UUX(\$!BVI+!A8?
O\$FW_!MH[IF M=;W"51"J\^MHM2@Y4-CQNUO9CJ*-VF(L^91)Y.T&N-K *5K_54N-
!YG2* M_SKIP8)X)2F==OF#|V.R9"+K|9HJ%BC9N\BP|&3+-=)VR@CHE<>\$GWYAZ:Q
M)GU(D1VILHB++^S:6O796EB8=GRBOK-SWLYOUOX:Z=EJ8+:%C|:T6+=3/#NK M?
@!VQP-LK:[WDS@51E>A,!G29:IX(JFSNPBL*=)5; 5Q,B |7X#T9..Q05
M&EF(Q:XQ)|;T5W\KVDI6.(=4HO/:0\<|&2/%[LCNO7|((80TB*<&V('B- M!K!%:YYP)
*,A=B69-@O=BP?FB?-'GXC&G')|!0"D>B)++W<|D!|N|>*3 MAKY;F@UFS_G\$M/("X-8U-
4C--) H^S-MI7+7+ MQP/3A69XH-*U?BO4=QL;+E\!M|;I<+RA838H0VXS?
^7%6NQ[7AYG& U?I M36^N6-IX>+E;6; "P+8^IHP2?&3FW=4*UB!/Y!7<@_P
)56W&^IP,>3J22G MYJ<" VH/S-ZX)<+HLN\$IP\K/E|Q;-US 1;543|Z|IHR?L00JXZP-!EG
MUWUJZ6|.R/A%; "4^6I+VK%AFAA%%#=#1ZV!O9+<=&*S>D;G7OMS*THN&X-
1P9HY@PLX|A/9/ M487|E;CAUIJ@K=S(,B!X3<* E7L^4*,Q#E
X%|36(VI260>B(19:LCWB M/) >PH9 AVO@)^@*/+!08[BO1GBV!],Y<+E2D)*.B1KNQ
B&U-&L'_WGEER! MC94TIT.WNA|P|
<6.*BT)&*&A(MXGF4<(W%V^MPVBL;+O)JKFUOH&|GZG M9(41\9;MR/+':1\$<8K8'#;:
|HZ.U:"/AB,ANX:K_2='K MBC"RDQ8P)BPM70S^U" |H&A|B P?Z#G"CY?
202<|SYVI%|2^ZHV|+\$>%I-V6B'LKW%KJ\$ \$PK@0>ZY< O05M1 MPW6&!_69BU%"-
#ZNV-!K<0"BL=V)5/|0/#^VN,TI?ZJJ |1CR|2+310(SR M8W M2" (#G8C?63K1H^L
2YXUMP|!5&|+^CP.*OR7Y3|J>\$ _W?W23- MYY0BH!U4"8^GZ|Q"WVL@B;
(!H^P|79=+;J(K?E*06.0?=SBQ&'KB.D:ZL+Z M,D|)7R|5&OCA|74B:X(TV*!A9ZC+I
0%XXH&. M?9-#6# Z)|/ ?_%4U:Q7+N:S6FW:KS/T:|&"00I\$0W2^I'&)ROL(P@:I8(
M)|4NHY0+#JB;' ^G0V|XZ\$=+SQ>/2B431_74<4;|VH%|B85P7R^H: +5KWM%C|
IRAT#0M>O-9|,"I,AG1@*+;:DVHI^&0%I8<03& MX14Y%S_!2B^6|
UL/DNO/,@JU^%+R2 V5RQ|H|3%SL90;1DQ|U)?/++<|(LN
MDTH^)|D!CP6W@;:DK|Q0DZ.TJ6AV8KU;R:%; \$SCG'ZXY|QN.(@|EKYK7'XI
MK/2/&|63;UYF\$==(| ?6QC&@C'#GI|^VCRM5)^F<38YH.C;VO/+|Q1"A_ M84.!
<>Y3%/086P,E|8W.!>=).KX65M"\$>:2RC7K\$G=T5R|@|1/X'3BHJV%AMETO8BT(+K8T+
|R>4R;%J7_Y;^+; _M?G+BO).VF H41H?FV#>UB-E!DZP3)W>|1^B|&KX|:Y^#!4@|S5*
M6FK8E\$PJS?E..^Y)&Z?JO1U3H;:ZIL*5SY5?|%;1=.:!/?
ZLZD+#I/Q8<6|U<4UW#,2O&_#/'1|Y MCC8=%\$E;.=+NUU16AS8\$L(OMO=16RRW
X*#UB>L='=|>^J_%I^CBKF)*.P
MZ_QC|5*>8Y)|H1F|Y8+FT2_M.>M|&)+^5QIT"081=|1I:3SS;'2NO=KR)9\$
M%6C|+&RC?/2E5Y=T.+KABTA?U">@F 6Z7E:9PL/E3;-X_%MA&#F: 0_L;_E\$'
M"4Z@'&\$)HT3?.DIC3W%ZXOC1*0%8(>6WTFMG:>YSA,J:00|Z4*?PU^O!'1UGX
M^NHJ_X|P|I^:O.N,"M>|EWQE*+7YN2H|Q?[*1.8\$>);S154%-!SKAG7^B^-3QBR?
TL@L3;NDX44>PG%Q2|Z?#L|^D9O9M\$6(M6B0V.!8*^VN_-9,A4P7V-8E00G6R-ZJK2
WO>F|61ZH.^VFKBWSIXE1*%N|Q+J@WDB299|\$MNX6K%%V4DDT@Y2J;K.3^GZOMT#
|M716CH|;KJEC'0<==NK0^;V(Y-).*3O9<_A95+LLZVW)G 6F1TN'I_5\$|/"N=")
ME;F.M._%O#>C<#A90H/-&RJ\$Y/O- M7LFYC#LF!R,\$F,0?A&&U-,@S1/M?
|H|1>Z0A'7XAD\$D<7BL-J%4G(WM(?>U M,37W#&FC73P0-
M|"\$1)A;YBH8"JO|OZ^/"PU8/.UEO%Q(?7|AC;_2QCO)S
M_W+JR<;&=.R&\$|U77W+"H*S@0\$E1L5!'>E)2N2H;"*9P1:K7=OC|<|YN\$,K"
M4W_#PDGDS>*NU-5;:|%+ZPT 9RK6#=#GA43NE2(PD:[C(Q4D|^G?,2/^%:WD&?O
MN6UME|;B#*_|F|HTI"D|2J%;& Y&
|<_|HJ|ZM9D|BXW5;S_K@5?;*PB4P7U|@4;)U13_P^"K|)0E|4XA? M0,<1,4AEFB?
|VOU%.6BA6L=>GK AC"O"?A/K;D4<\$#^P<|3407VLK IGHQ M<\$ZD00?GM_H<-
",BR|K|KPP"8_S|Q9B^1N04QW%RZCVJX|H4V2O5|'@1.= M;|U+?Y3B<5;";2)3S1#5*/9-
7YQJ83|?AP^C,11IY M2E|35<2#+1-S??4A-Q,TTYWD|&:65E27D

.,8(C'=R%+4M1ITMQ8KKA9;|.L MRE 01Y|^|?6*7>-A/49G .,B8(V;*'VGQ2=>
E\KLA#\KS\K8S+WZ1HJ?H5?+./&)3 M\%=-JWNA_7;H\%RD0W+;X5G
F\$U30EK4IO+XTIP<%D5%-M ^[5 MGK17R8V3B]>!51D&D1-I>XU9?
OO!LM@;@*|WW&PPU<9DU.'PIJ&NR!6>CM*K.W+8F%N46MH'X MV_H3?
)G^%HA4S!|313|N/QRS>_ "2^+PPW3J\$03U&F_A:F)J@.|XK;75 MI?
U\$46<||\$|7N8|S7+-6MOY+V+=H@@B>O4_J'HP?XL M.-UL: MJ,11+N(_T9E?
B;MG\ _E,B8^| "(.>JGJ)#@W6FS3"2SR>"TX:|# M.:|TR63+0.6P >,NR@IPN|B_J.
(F+YS_F|0<<'97!00. \$D0\$/P!>_NY>))| M6Q'7ZUZRCF?/Y*1?HF-)BWHNSA.VX-
|CY%L'<<"|Z/_!K'FWY\J91-0M)B MN&
*^AB|95IPX|5D\CYH<\$34,"S>N&;_0(J%C4F JS23M::A.Q_)|LY;(-OI
M2.MMOVIKZ/\$A6Z,3|V>'K6V70Q|M>3F;.'5#(5T%C?B(#_@9F.Z4C_X!/*
M28R#Z)D\$//*#R%GH?MI@*6O,>*OK.MMSDK!WO= >+?!7" _KPH7SPY.?UDV6<
MAH%HKJ?^ Z1CQU_%00)EN!C%^8|=NJ#L>S'+O,/|L^CBW-?>S^9C52ZJH*S M'F H
(Q*,&4 4#"PXE5.0VBJ8' &'Z9&M63;P'@SY7LKJ"7WZ*9)-Z
MQ"9/_3GS:H.4WFOL|G%\$6LP_HC>BO32\$XZ'@L;9Y?X|2VUBGW(O'J(_\$8P
MSY0|SE.BO4XAX5B,<6|F;Q38-%_ /D3.;!>C!\$MODMBS.;Y2_4N_OT_:^M@
MSE60Y(0*A?V3_03VIX|5FJ?H^OUIV/:?Y_M 2OC:OL|14'@|DMTF;"VF
MQ+|!"56Y<9MQ'ZH:84|8;|0+!'1<:(#L.8CG!5<,O"=:3: EV2;1UY^AE.6^L
M\$|*HO,S\|ITM9X!W35L9LI*U?_I3DL)DR1XL@!N4N%3V.VU^ZN&M' <9+*'M
MNAU|Z)&N.V;DF#SK'GU#-?W.ZYA TA^>VAD-*AIS@%/V9V+^!@R6Q%Z-4))
M07F0QW?H%0QT+|7_|HYIO^VHLG)K#DKNVWX?-YE)CBY<,9+7=H_E9G8V ML>I;-P?
&ZIB&I++*4+JOL+V#R'"&(>N". \$A=6DFG*V3)|XL+2/4'L,OQN;V3 M>S@T,BY
=BQ:VM&!03XGF:#*W2DNN'B258|200,+/@V.D<=%8'-U'-)N*|IE M-9!9D4S6=
TLZ+4F|3M\$|P_UC|P="2^2/).E7C@9|5-;<7WOA4@/=1+MB69/
M"TF%J/MG2KM;FQG3N0>+> #(:IA'#K0P;4Z'.BX/B9|>\$Q#(\$A;?N-FHPS)+
M(W/7&%N0|E;HEF!_%/6G#A-0)O03X?|J'9,R|Z*R(R%X?DHV|F%88*TI+(-Y
MQ;OU'^\$760AJ:|HJ|&RU?3<>TFK1>T W_YBN('=J.N7(P'C;OT5K(PN'2ILF
M|=QY|X^1V2QW7|3 =EYYZ.(.* S2+CA2,=M1"%#',FH:M|TM|CQD0I5VI
M1327S#P=E&_3XE(!|Y?P<2;R>7G/EQ|P%LK4\$7C_%D'K
M5|'&%AJD8C>:|+81^/:Y|H|ZM|?#(:ATT'MV/^|H8 H#1K"N*V7VK_SM@N8(' M1L:86,-
G+X/H|/"MV%7LWE|*3?WC&! M=1P;9Y(=%\$SUVQVY'D =,Z1-N;BX|M?
LVL%:XS+I9C(1_""U)(/:R*|523&E M^ZR=AR1%#S74%>|>DUC>-OP69&6
MU10\CQD4+_XS^|DI^9N;A9.EK?:) M-+OIW%,:/+S+:| |H25|. @:Z:9LKM0(APW2E;7|!*
(DN?LPBMX@)N\$K%|6C4-@;QE0C2UJ_3|X3D_X#K1+M)FP9SZE_,9E'?
6=^5/#&=>4N0>0?IOIB1K30R?0@=AM<7@PMT ME1;_XKDO AY.*U|V>-
TG'SJ!4|S>'N.,(82X8\$*4|+6T3'+95J/_H;/AR" M90HZ"1I"1'W1#UN-
:IZ#H%1|)=&!N10V7LF|H|V|^LY(CYH =JVF)|@\$_+-YF7
M8|A\$!CZ;T|GM^B|'BB8U;J(<=AKD9-\$8K,%JND0;T")EY,BB#L;2(|_OAI%=': OT8DTJV
6.60|EQ> MSE1'OY!+|N=<3>ECC3^\$7B+Q,LD<>G|=QZS!E %|ZZC1GJU7|HY ^_^=A).
M%*@O09/MZ.T)%L,IB1JDI=|G=DVGSFRXA#+ 'W!K',XZ2S6BB5C>P|Z5GI#5
M>R7;NIW,KU>^0Q>|1|P.21>I8Z)1=3^JM;,-S=J&F9M|37D)9F^<,;%\$'8F?4/!8+ 1+W?
NM*"K\$3080 MYDTV@OAH0|5=I-L3A^DHRB;IW|JS-
\$>A7Z&I5:/*ZD\$KTL%C!Q;_B@R+6#@_MMG-_?M4#
<7P&M&H*O6)'O#>\$+W3WTU?;WP/D/A&MA*U M,3Z+V("8TM|W+^J!6HH|Q&-S@3DX
M+_/;T8=Q@,U*|3_G|OF-)>SIM=*W^!??#ADLG(%#U|?-?
8&3+>%6|PL= _Q^|OE.#W"18VA5VU M%IA9&=/3L'7G(E||I?03I |N@V<4,H+R|_5,?
K)0=-MRV<^6KL7ZP.F^N4OLW M'F^K\$&0W:1*ZB|X@&
<2=P:|HROA29X*K#IMEY|9<./CU.)S M!=(|_ ^H@&S&+Z4=(L'&9O3
K;=NT1@6S65G0;7.V5TRDH\$@RZ0.A/AAD>/Y) M|D|4|1.#T?9XO3%\RY#TKD-
-0G\$.48,9"|N%;%*-|E8!/|>|Z|56#;4\$%-!Z MA|JOS_%|D_0M+GGW;JS.
(C9|Z16>S=|8=98:L'R6C0KC|5XA/0LT,0B;|-8 MW*U1JL72(Q8:S
U!F8_SY'XJ*@M9BR,+ 'FBJ'U L/OQHVL2AOT C|2X*1KE9 M15-6<4\$J)?
|1#;SQ1W70&"J?!,L\$ M;TJH:;%WBA3K0;I8+07P*;ILD"UORLK6Q_'\$>F*@EM
996!90'FI7L'XD3L M1|R++>3S*=>^*^|,*)\$^\$^8VV8= X4LXS.G@<#M(N<;G9P:NM;Q&
(E).6IS- M_FLWS.Z=//|RNW"C |V8RDYE+?#^|KJ
M<(<,M|NW&>UJDJ_N/6BH(C6GG>B99WMMT-%>P8UL?9HTP2"^=S/M_71*P7F*
MMQ(W20Y\$B(IR/9)T^KZZ8KH+|/%Z*19?X0\$92ZROK;'6I&"5-RLN8K>|3>(:
MO92PH+QJUOX@+ FJH*NQO%VOL1^ PACD*>DZ+.WZ>FL9GB*C?:O.:QM3F-FG|Z

M,|HXF'AG/:@Z|K M_ZT;9YR;MES2NKP'*^WI-JRDH8YC|9K+#DE.OC5ZA=1>!"ZGQ>Q
M:~44X:Z!7-QLGZGL3RLX'+7;P@>,^&W>(_;|MMZSI M_Y:G|Z-619HQ>Q
+J:~2!A4WLG DY|4W6^<0A-#/I"PY\$^~|F
M;L!4P,R/+VG"J/((@OG|Q#Q:;)NO(%MR|,B|./BY5Y|%1T;>'!WP=3JXO|IFY
MK""|I3E&L&990>_M|OCR^7Z!>^YZ>F08-J|>+:HV9|R?AVXX)6JYI8D8U7U
M3|A,HRYL|"Y6D3R,XLECX+Y\$K 9 4HUOK^1|S,8PAQAC;|*Q7N-58=9YXUPQ
M8|/"8I7R/:3CZ-678R=;A^FFAA/PN78|!Q|T"710^@J"TI6*WW5E#UEZ>NX^M>,JW%
|L,/F4%&+*SE5(|MY'M<^?4ZE4+YCD*CM;0,|SP*:8&^55|50S9I<_G)D;)
(U@C"~12PS2VSOP4/-=TP3~|PH7*_HFV^N4;E"N"2M=MJ:|ZJ"X
MLJ+32%2J(B5P#/6W>^J#SH<_NM\$|%3L?-=TBN|8#:=75'!(@;Y7)5MT\$CL|
M,Q,FM=6|BP+?T @DCB@UE+|59S"X67N\$2RQE>D/NR=|8/*D6|Z_^(!QKLS_MK#J.E.
!PF?#\$<:P!+72#HHUHV3KS1?VJ;'
M#3(IQJYA)9Y25|Q_XUK<#=-FT%*+X'M06I2+YRLFJ=V_W"(RP4002|K04|=-,
MZZT)#JTO^3PBOYJ_00AV(|E'KS;7UJ2FG^P?%-)'R9VOZ;J
M%K:M*1);*>5DDAP^Q)'8>85Q53(FNJ,GZQDYQWE?V0T;_Q40LM9>.@_G9D-;
M;:HPH45C|:HHQR,Y|3H""%G:QV1=E>963EDJU/(P'SB*L|4|TW6PIQ5=MCE^~MY'O|R-
DKA5*BU20U/K7!IH|H\$9VX|U@,3C%?)D_ G%5|NW;I0^N3?11W4
M<[TAJ=0!6FXE|BS"YKS\$;_<^2-UJ2?&YT#9'3+7!>V??\$"&X-TKG&+/'%4J0
MXA3|,E/64NT'C:F|KX2.SKP-E?0S/^3|/:UNQV#-|BU6#-P>*X8JRL(JOJ!_.3Y|MS:G
M+~#I*2_FHH?'G,|CL>/^&:K V'Y"*Z"BV%KS^P:AT3@S|IWED#%PFT2H|-UO^OGS|O4U
M++#&W+UQZ9FH|V'BWI5'X|@/V_ :1Q.MSCF\$E9QB?V|LO?Y6;Z&;&|2/2) Y M!"C%V;|+?
%5=?U!3|RB|9/, \$MJW""7NN^U9*VO">JJV9I1N?3=N#8,T#LX6A5 M6BGD^-I/2-K?
-0|4AK4PX|D'P8:KJ%R57GLRXUF+FP53JCP4#L*/%Q1*GW(M_:PX;"H5*E^|)#F4YR?
51R/F@;LCKJ|&;7<<76K""Y"!I?<.5E/ZF 01\$| ML/X6M:|%,,) -
C'27>*00WMWJ,S1F_82_=#_ ;D%Y61T|VX(=Y25.+|2E(;O M2)LYM)>0K.I>L?
ESQSNOWXUR!.UJ&G.(9J&)K"7C|+U^/N|HX^N/SX L23': MMQ+?>O.WOW|*'.-WD);
N*_D\$5'L4TQK/@W+Z M0&KK*P%7I2-+0|E.CI1XUF'U@5|5Y^= H<5!H^4F"H,'6H.+U
4P-DWLOTC M)F!C:4N4M|!BVEGD8V5A1P_LUK6WL=|5M'C9U,26;/P|(I:F4|)/79#8?P(B
M: 83,%*V>ZO\$S_-VOU@)76_<\$WZM?'CW 0WB-.AV&-4REP>=*LDW_EDO7H<
M#|BY*/%L!&RL;N"D/(8|I)E"8WPY|;D"5Y1Y X>V%TSSK=_30"-90,P6|+\$+
M8WZ53QJ3>6OWGBDN|ZJXP18DQ_U'\$8W22ADVD/+ UX|LO2R^'9?7K0K.T=Y| M 5)?
7E>JX5"EIA *AYW6@^A8@-:>@.Z.I4);_6^JH>KLA:U*5^~I<>C//&> M:~8;7\$V?
|HG.W0@W|NQD/Z"3RP_8TC1362UDW N.0-CP7VC^*)H3Q3BT=3|Z M:R1|Q4.).9-
BBS;88NI%*=*4KUQZ'S|2/+G@WH=#20|KY#W5M0PV=N MXQ/_=FL|7"25QM
MJ7S#7W&()42'B'3|3E3\$/IQY|*12|LN5M5S#\$I MGCE0IT=#U@/U T5:~*~|@/Q?
B4N3HG.DOV|^4R)YBM 9W|< PU-"SMRB=C| MD4@;05T?|SDILX-NM"/+3H|<|5V0H|
|7+HV'S|P_'1I?8S6|WA3NQ>|KNM&2 M=Z?)CTZ|E\$A1Y3*U<5P8Z62Y-_O:-!*"U0.F(3-
M/=8A=I)>18VPQYVN+./ M9G?/A/6#;~|(P8R*T9|J:C=P(?IM57%\$S-U?
U#UR8;ZG4QPY)P?>WY")X(@5 M:LJXS->C, @. <5I=W8T2'|NK-
L4R?/TBJ0|=VG6VUH@\$_NPQ%7YI3":'F>BBM M/2"G<\$S5CHX!A|0BWA|
|M)B/<.N9IA+WMS4>T1QP??W.MW\$/M6*F3KUN M.GE803T9.|Y7-!;|C&QKH_P-
@TM^;R-Y+;)U9IO2"B|ML|/HTT79@<(3K
MDGE@0LY+/#!NY*FC=*HFV%D,PFUMCX18=&Y0I7S2|FMA.~+SM;:~<7LP6=0
M1VHP|WCGQ/!-9W7|LO>X?8)\$MOI\$ _SHHDF%3;^X!75%P|~R|:|_H0N,M?
U:FHELZQ0|RXM.(/L^J"".(EW0Y4QN|K)-N(3'|L(HZW:1GUZU=.TP7 MMHQ?
7#D99\$|C.1W=E5O|>"|A &^6+)LN<>T!7WUL^;_(Y_7\$Q5IRH\$'7B:U MCGQD=PCJ#
(PW-C|S^NZ+>:~@%AM|LVPD\$WH,1Y(FGT,-^|8^UWZ N0+|9YB ME7
_7A|*~@71@E.D!3';=[RD/E|;"#VXQ&+|RW|V3ZX/_OSP.52!19|'#.X M0LIX3T3;H'UVPH*?
J|=8MSZ>,ILBU?(NT/X;|Z999_(S0J"|Z|AU#11X.'/%>V|AFE%GD4;#N442|5O M@|
|&*2.ER62KNUFHFF^S%L2J*.2"S_Z??|S%7=A-S)_YG5?GLT%\$=JS9|KW
MGN6!GVECBNN=T|3?=N@TFO%#L,?O-J"A6'Y4D=DNVPCEJ8I+' %OQ^:\$/YYSNI
_N=Z4,U3K) M>RA|6;Z0V3/.HNMQ*?:4SILBR\$D
MZS|Z,7MGMJF59M69!H1>9;^A8*~!;H9WX(\$=|3/B1|8A*^73SIHR?I8A2+E8
M4HV(9F\$T#7=6IL@\$K>SPP_56E6=GA2K80Q&K=9F7;~9\$SG%=>N07E%<+HYX^
M<433\$<(&^7E(Z/%1% L!"QG?J|BJV_7|E E#JHE6|8\$/U|4F\$|_ =+O@@9K)
MM/N)#9*DM^"75G+6RF8\$6??|6|=QY:BKXA"?+?#B&XH|U:EVOZZ4F=KK4C_?
MJ4CO|>L%K95Z<#6Y)|UZ|TCM#OC;J#~0UY-QYOF#-N+;RX ;W3F#ZT<#6#QP-M)L|H
ZH|G/7""H(7N,F1\$M9D/F?'+S587J.R/.%3F|3YXBB|^Y?%I_X<@H9 M'6V?@0,|J0EE'O

K2NCPBYS_ ^05#8HKER%\$F P/S""(G;E=T9!:@YDV< ,HZZ
M!/ILJMY\$W!5PCW*)GOZS86\AL5C8 M#/5='^845/ESF^[M0?(Y+?^\$"&U;85GQ:_T/OE.Y
M_8>9!;L@K!"A'SV*/Y=):.6C>O#|0<|^A75"JDI*QJE-3"T=4>(+U*_KH6L:1
MFLV!W*0DM\$|H0VZ_Z#_>"B2Z3I*JQGN"CJM^KR|2S_+)M7 J'&5:H3?CK M5!<5&9\,:?
BXFD8|HBBL=-'GP*S3_6_G3#BV(3E,,AJH/#X4|Q?2U00/U72TL.0V4F|DO+S"IFQA\$
MF1|PSVZ';V(I,SX7CL|;M'7.DTEKKT<)4?M8!-U#FEN8#^=(I:W/!;4U/X<\$63_M9?
^%OXL3TW6B_V@T2S0MB/MX(X*/#T!RAT6CRBCGY%+!I#/?
(B3ZN3Z!MI9J_R^K4,CWF_&OVZ75W/GHM&! M06-*D'G%J^6J:.#?
>2^RV;T!ONW)DF3^U*ASSPXH7|5';;;"RG-JBI,H^'=?? M6C'5SIS=Q\$(I
IV^UP^LDLZCJ28,9<|NQO0ME!'MS|'EZ""0)@4S8NH@.+7PT
MUKS2W5YBV';>PGJMR^1Z|'W7('B';JN7""Q1_9ZS\8C3Q_M#0|#3*JE)9JP8=-
C(Q4!*U/\$.-YVZ-&^|N"/KZ>K2:5^@/6S^Z(_;4^OOI
M9QT,VR*!,48A;=K*_>..ZK7V>X|HF&;S2LA84O/YN=L;Y31,,V<5;&| /6<.
MWY|U)9&2XLXK+S,G^(W#=WNPDP9Z)%ZW21*CO".&Y&XZ,F0&5-&@@&&>J4NM#X M-
#WF%#JM:*H%BR^|1KF"J>/'!(HN"@*WGP|TBAXOA66T|5K?TV|KL6,*^2| M147U
S_E>:=+O=TBWI> A%WK?;OC&EQ=8\$6A^;;@:53&2)NA>L,G2USQHA@=
MUS4Q|JJKJ,*2DI^UY5(MCNK%W4'%|.#&*2)&-T=3G40Q#
<,7|2931|)>R.UYQA0<+1@#WJJ+G/_4;J9 M#-NKG>GFZ7\$FOS2='OHJMUXY/-
"\$&#SAS8D VXBDE=>OAE+XLH1"%|P^=W=ZJ M,|2N|>8!|73;H(17?'|HP'J=9
X^)C|7|;8A3=N_<#)O5O0; MV+?#C.'LY%
M+7!S;U,^()+*;;LI|H0(/@)&|M31OU;VR.JP%*A'/BX%O@TG-|6-YCN-R^F
M.90VWOSH/E+.#8YW"|IX&8Y@UDU@;V" _#/H MWOV1FOZ-,HPR
'%QV|RT3IAT5X!5%1VLC3??L/(/SNQ"i??/I_Z+KN;+C7KOM#
M&!%;B!Y,&"51HT5OT8,HT6M\$M BB=R,1+3|!D.B|MQ A)H+HG>B|H|GE/&1
MW/O>Y+|OMY:UYB^S9N;W/.?L?<|9^X#6C5|D2"^1UAD-H?JCK<009'O;^|!
MUK9K(FIRPZ<|SX|10'?X7S#S!^45VM=4|154XM1;1\$|B^P@7M

K6%|0^B MS)>0^CWH;J94+(6.58<643|N>1)CJ) B\$ _K|\$^3@A|X;8Y^K-
6)XGVK@T7YR M;I25|W|@FX1|/=?.5MB,OEWE^HV@\$*S%)CAO?U1HT#R(5."|45(5\$T|?
5H-MB/:9W4@!Y(;;Q0T_ G&J7#|@WOWSQ('G)BO+O@8M&"!2;G|D,B;|J*+=+FG,
MCN:LS3F%K\$N,FR|'.RQ4\$"L,APPO(|6<5#XLW_SGQ=^\$<\$YUFF|Z>9|JW**
M8O814M%WKG+4MG(05DYG!OM!IA@MTY\$S>01S*+N7?<;X.EG*[01|-
OMW_I<4=5IT;|G@\$6; M07O&ZHO^LV?0CR=PI-
W7G)&=Q/_2LWJV;&S|JB#EZQ|13!1|'E>0F8CZEU#%|IG
|J)CIB5:\$|:+"7,5E6TCE+WY/=2SQ1T/L3M96G)Q9BM9N M&I71|@V:\$@?,NUAY#;,!5^JQ:
NALQ)N42KH(|,55'RHKMHOP_OD(XC WXSH^ MA1OQG(@'N\$:"G9%E?
6KLBCHZ_2)7U=*I^3<=W?\$RBI|A!P-LI+)M C2F|_(3(@?|N U:22Y|=RB/6=,JHCO|
|C>D<=<= MG='5=IBKQ0V:P/<=I M^PA2KHD6.BCRR&TLO\$AXT@"/.1\$1*|E ?
QM##4<2JU7>,17 ^Z49KKP3N<@X(9F>Z* MK>QE8(O0"QYG2:&@X*S @R(#
9MI<\$'81,T(&GCP8 ML6S>|. (. @3G!|J1XG<6"O7U)K5H7,+. @W;BNU)1#*,X6-
*AGBS8(=PTQ3|D M9>QXV/5D23\$/QR500!IS2?0|58Y"@!(W_RJEH""?PNT-
D.#_ 'DK%VN@9A<|Y M193|07BYJ552@FB4T|P9B/R&6U)=22_Z'U|EK&
M4VA&OB|K*A*= !GJE4&|NLE/-^LD4>2'_KTP6;9=H(' MG0D&^!|*5?
3: ^DGH&1&E>2TZJ;A_ @\$)RD\$,6YPV-/P>DWT. M#\$_^D'#/T'=:K|\$D.+ #G!074W9C>-
&^+(A<(_F(J4MX@G|8A\$AYR,*DJ9?\$O MW;N;?
CB@\$G)M&VJ,|F|46K5<>+L=&;FD8?NP<#.
!K7'U.LBLOCCVZ@LKLFM!1;V8(QA9D;N|J5SQ M+@N'6'B?5(&W1?7;L/72A ':@|
<^RF|HONWW/"0'AA|A9Z0>"_G"+:Y1|@M H+P|5&,AM>ABCK*8G392 M?YNV8-
X)TN7?N"WL\$:25)7J5;\$C= CF8V|HHH5_NY\$1?L'D>[XZ4#8]5O"\$
M@V/*'7T0=VAJF%E5R YL\$75LJ|72|+F^S+-X4O0P0R1>F_A|9729N5BC"\$OH
MK*;\$Y@49>U.9W8?;J?^KWIP?G7"XE14ZZZ>_E;Y*P8B2K^OLV(G-(P2HHDI
MEXO9AR^S"MIX|G(+26Q90FGXS%M^D MG|',53TP| ^1QY;/= \$A&%.^=
7'34Q&E!JP28E MAGA;?V^8O=*MG-BBLQOH?,'Z85\$X#
M35\$YF^K7\$&K+#+P@7Y;|E|VW 8P1|.+RTHCNF%D M)BCH5-?
998;8@EI95VUK1SE24Z+H0%MMH|6OR#|_QW4'J,-')#;R9|.H|S1
MUQ"LIGO#36+T!W1|36A|N.JG<6IT,Y|D|J>.7ZB= #&:4+,58.*Z|_E4+
MP+36#ZA,8%+YY/(@-U0IHX|D^Y\$'0QI?KHBV:07=^#E;WR|_-.5@-
M\$"HP_"RB81,,:XE+S1F'0BKQ\$U_&2",*PTA+VU6|7@|_=?H)YF)"GDC'9"+.

<,C@LS^SC!UE M;QB<0X7,V!ZUK!QR\Y7)&ELKQ81^>77GJZAVIT3S0X^V:(T3
MOTE,JAU.5592("G%: ^|SWW=:6ZIX@-2|7 MZ2KN*I307%!56@+5&W^OQ#;D
)9^YN)I&1\$30+ ^JA_O@_QU|!-?#S,'7S@&S M%1YK;@|&
(:90M&B9&LOA\$J5VI5:&MK!70 WY'B_8LF1LVN\Y)9/^ ^=74L7&NE7\!KK!)#L73|9;
M0L-UN:NG?N(P;67@P-@'GNIDX7VB;9^Y"C\X8D; X:T?;D-;"M%*SD;|K+^U
M8Q>8.K2_/J+\$?PW*F%FNY'LEMM?W?IUG0F0DKB;JOJ2-Y=!F=W-(;|Z70HF
M7X@*/C*/MTBKF\B5-^)9/+? =WF:QNOJ% ^A)=S6!C;)@9/G(/SPQW:),Q?^!A
M,K\$S\$|AW",3&2|Y6'XS_K*)J.E|E,| R=:|3UJVC'RTYKCRQ|)?=X=VT_D MVJ?
+G0NJLO(F(FIH*KE2"J,K.*OEDTZ7"O+W8:F?(2^HTJ40K35NB
MQ63SXMJS3V-0R;1/"C| |Z&X!0V= *QTXCLMM+ZZ>OY?%L#1_7>X'>L+>*/
M+@|R'.F8!GO^S!H:VF@=?+,WZDCC3-E)+5"DWY/=N!6U,7|CX+EPJ&&.N+/-MX?
\$|>R,42N++G?_J)&?B/*PNTG/S:+Y@)8D^%AHKD!Q3/A2;D>8FN46ZD.0
MYI5(%OUR*KE%>!|XYB3R1"=)ZS.*M%Z>KEOZ|AUA*"@T65'XL:V+.8)6.D/
MYW8S_938W|Z"N(VU+S4#:80@| ^_W;"I+WEM+?(/9WICD1DA)M_!4^,4>>/O* M?
1|:I.YGVP,YEW6Z^-S#WF/P1.*|H,K,+:P8.6| #C|)D21?#3,,,7|VY2*C3 MMJ-
'74HNU4FG|2+)?|:|CIL16PN32%.%|U6'WD*=%:|LAVZ-%M,NCMMJY-D? MODZ2)/:%6?
X5,R\$|/H-HAA.R&*NT)GG/U<|^F8@#K1D3'>?&#GKNPT|F_@QW M#|:3J1 \$?\$JK%:F?|:
<(:+0>T|T.32Q.KF>GBEB=+3&|,D_|J#1|0+1+1P M+A_QV.3^2#^U?
*,G5J3^-^4VO#K3QW3U&=<"1Y%K>+6;?%C;\$5XX9C MU(SJY^DRQ%AC?%_!<5^|V='G
QN>\$XTZB'A0?O|G79|<_Y3O/"DI9XL-CQ M8V:5M=L)S9'X)XHC6A.
|)BQM'W#Z5,R7A_|H<+?CL1:'>FL< G5VN&QZ#M4 M,;6=UU,9XCVVHHV0:|)?
KH8'7C*NR6MEF?:??M)WH3M!\$)=5U|H-47)9I2G M^U.*MGW7C6!38(Y1X-
TX7GXRVI!MW0(V5J9^ (?B.D|H:@J:G2&:)C_5|SC& M%VA|(@%\$8S-M"!L@;|Y-MX3T4-
0E:@7U6&3B%_!/)JXG*[T3#+_1|P3\$)OCV M=\$J/H:2P7K\$;!5|UI1V#+AO|;@.(W?#76H;?
0|T4B'W VO\$=(L@3JAZAA MFD!30%T>YR,>15D?/>/UR=G/9|B-
U2QN2>"U8@2NU7@PTX4*<> BV|Z4G M-
C>R8URTJ39\|EK|4+.*Z|/5+VZUR9#/4!N%JN:+8P|JBK\$Z2C5*8Q09*<66!#J@!LM?
(JB(P|CH@@-*" C| #NB/XCZ#\$'M>%2M3!1?J| |3T9H>Y MDWVP8Y|88-#:J0MO|24BJ:BQ
3"O*J|47X5\$ "77G,'V\$.>8I8;:YBU03@B0& MY/OOTGXMRW_000&-Q^/1O_+LI+@%'
_V36'NG:V9X8|C|:3J5D8EO|67CGWZ M7?2:/6HW7G@\$Q0|1EOF9(7 M:*=@_GD|>
|3R#6E'VNC Y|&A!9.E(LL"|"!.0SZ_-E4 ^N#)O2PI0G.LE"Z*5 M^+KYHVZ\$CBRW&H/;
+J:&B(8==4!7Q MSJ*(GC-'H_H=FH7\$@!SAB0DEA^YE\$1=-++PW-2@UX
+PDUHQIF/1_|!Q'IR M^??G1|R(YGPBN8|(S>.+H.X>
|L&4C\$KS"YJ^W@SX;/7;=' _BU)A^'AD%4594JX:T>F?3/EY!=_L(IN4(V!)QM'\$T
M=^8C+E@T/S!OAJVD?R(^G WBC\$!ET8Z* @V2)ZK"XHVV.|D|C,; M6HO!HHP8B#=-
|+!84H>L_7:%V&!2|"@G' U832Q|A(T&-@MYU,4YZ\$|GGPV& M:X5K'|/U95X YE-
/D\$NURF+ ^9?P6I9P3.O)WMKO6<>AMU._)WPUZ|YK5%.W>
MUBXOVO?.7JXE=T4*^M7?P"|2^B;C?H:ZTW-/>:.*+I@T,UD65R_<3:)
M#5&WS&F6VE&,"Q8|208AM*KZK%GE57;^E+ANPZ|_|3(UXD%,M-PG1CUV+C: M@P-
/OWOY35R| BRRDA300=HA3D.<2G\$!O@|6Z9=3 N1:*|J5CR@W3|A^/"*F M95M8C**
<\$ZXAIN^HMC+H:2H:O&&|*!"|PWW1C/G)!J3_|"2K*F+|"9F:PHLM MGYX;
|3M+|'BM90%^S25O8?&KRX"EYV?T|KUUSJ M1-XD+X<,V?6DA>VLA@!DE>>\$N+RJ:T-
VXN"8|SL9PU-&Z>OFPUM/N?D9|R M^'B0=*8Z3N.%D7"@S-/|M7|:|Z^"H.Q%RL.L8?
T>6<@1;UL^"9TA^6J3:%4S4<=UZF&)|_#R6Y:>L"_6C*:2T.F*V> Z#=#,DYE|N^A\$2
MWWRO|V,M1@0=|QQ6Y?>E=6K!:XV5S@&B4Y7=\$LQ*U+8J&6|W+J@+&1MQ(RI
MZ,Y)S|XFU^?)MZ0FC=E'5_BFO&^BR/C/L1F|T5"#X.0^Z!JP0|B*E\$5%DI;#|
MW9ZO/1HOYRC#+VJE?^OY|:"A:|H=1|"4GMT#3ANQO26AWE_N%|?ZAQY((RIE
MV,6_Z:G|',+-^N#OG&;O@L23_73R9>#|D#SM2R|8V>L^VN)>G>|QEY51!64J>1S
\$.2IL-6V>|(|X M!ZZ!F<\$(SF*4ZH89#\$07.JY(AWOE8K|I'(M\$DSX6Z(2*A\$/=|3B;SP'CH\$.Y
MH9|O!<_SL96G7:|PVJ|'A/T)DD,F,RC,0S2G4K+H4^6IR!8VNQ/E\$Q M*8!;6;@R6O"
|HD2PV>5 MT.LZ4=|/;>:"=;;)E-|R;Z6D28L|P9_.E&DW)M/'N*M+|H M.9|K>)|1S*5MA'4'-
SZ5L+)NS9PZ),!7A|^:YEDUT1^U(.NYR,0B)I2)"%W783IX*>_:=G)QEOP"OO\$O-;7B
M":>:T02S(Z'|CLB(2X2AG#|V;^:V,_F E*LA ^9C.2|@%L4E|'X7"Z#>_) M_A(3"EJF"?:
(UY4H9|,'*BQ3DPXJ.SRT9+Q&_)5I-HO8|J &^J37XR^1J\$2 M=FI.D5X|>U'Y:<;U\$2+-D6-
-) \$M*8U.80W12IA-&+|Y^46L=G#C|)=(>L=^% MD#2!OEZ,_&\$'M894U/|)2IWS:-
VO*,PEJY&^&ST\$=#)HE@0QS9^%K,*14:GL M|1:K9Z|N|Y8)YU7SEY;|RP<|!@#5V-
C78FO|U>,QI9X\$RDUH^475%=6&O\$+
M"_*2QFN2UY835R3Z1#%/WR#SJZ>)=:QG@7.5N0_J+48RN)>?

H\BL@TGO;7S: NKY&SG-MQX: MI/K>E<8E**_JL
^Z;G;N*98F/&DHOZ?"0QXM|Z1|HX6MLR5:0=1: MNBB=2.M_+=%^B.%;RAGM!*10&O:-
M=HNB+[5SW,RW5QV5SPP46,OFE;9.^7@ MI?
EP04:NMGR\B8\$H:8&!'NK'J>"O<)|#J=+CMEM0\9W=-?=@ "EC'%>BR25/G
M71Z*SNB/0YM|/O#%;|VJ\$93>__0(,'8%*|X?'<<'!6H\$%2J:O%
<*CIWZE/MW%6LH+/0X=-7:ZF8;/R\$I-\$Q1N&PC/S7:VW>UBVGS
M\$|00>>W09(43D275?8AA:Y^:2LUM8I:X_FT|>F.;H|MV3&QV60I_&HL:/
M\$1E.T_YBQ/VIA"8BLN'FU+A^1"Z0\$!Y7P:.*++
()@FU1K|E1;0#_DH^37@@.V#?'V)ZL:RS@-/Z&A.G'AO@BZG:Q M:N!^6"
\$SRDET*6=O<^6MXW*_G=G*[7(LL@Y<
MB<&,.9X%7A|/H015/IW"BZ|@OP2/MVT9.BI:'|HK34_B?6?E&1YG:37T6Q
M,/4T>|S*A>R)5R%K'BF"11ZPJWA5Q|Q#&*.|JQ=[J1-=0|KK^!Z8|9EA+EEMCC,PU
MN+U*&|N80?Y%8;:D^? %3GQ(B_/;OP\$*MDZLH/I8-9"&S3_(-)-3+|E
M;3:YCN%:FFUO"%L2: M\$ _=T9+.&!2Q#6'-W M.SX'-!N|L|M_1!2,*.(3#&T?0&L%=:5:
7=YQ\$M-VVJCCPB\AG^J_-'>NGE MBDP6(B(1E*4JRO.B5.C)RC/CW*JO(+-.B3A0_?;
Y&K#X|?TY;V2M'Z8U#=#/;LWBYQ^50_ MUS-VNR7I<|!Y+L#XC&JS7)L'Y:S(A;8K_DW-
_T%>47GBAS\$|5?Y\$RL_C508_M;1"YLS4U7R*D6L;A;L9,G^T-T'2W.*;49SIO4*AA|&#LR?
Z8?41|K|MD M!TGS_A9>":4Y&C2>)|@,T"AN@>=FO/J5(K.;:;F0TG|P*|J2>8S9UBR*;*|
M&T9U.33OM^'RL\B/M50RYMH\$&_6A"7D05L:1)X/H@S ES|3/_=T3"BVKH+"
M"3TK:ZV/.0>+HA#8EG|U_UIO_J;|H=F%K+V+<"XLFMU<1Q|1(#N^)QI
M<880'E2T=KULLV)D'%#8:_R:"<>,I\$X)|S*TF@EC|39"SM(9T#M9F=E"@|7'
M7.9%25V%332#XC;3)S?4Y18#@YP|2HC7>-.JN^KGMF2C>@0H5T+>1P:ETF,^
M)5HP|SCT'R*P_>W#0|.;:P-SM&|&=2|YKDN6_KK)ANW|.;:O,>S'YV*;NZ%
M3:_|CB_RF)|MDDUZG<)|MK:TQ@|S^K @_KKTO;>R,>3QPOP-*A"+;S|G9|"
MCXW3N=/4800"@A:F_M*JNA/^JCHOU2?A'9_ZQ?G0=|Q4ZY!AL*5|CP=FS,FJ M1D_RW?
886@AXPC-?^"T|M5M*BJ8/NX#MSUWU_R|0(MUD?H@N&)\$SUXRM3R3
MH.I^FW=7E| (6 F|@H(A;A'U2'H^*.3Q|MUI&?@"S|U@WZV?6&=#5YD|_@8
MJC5J^U"6E|?1'G&"%XF,(4:9X;7EP/7*KU9_Z7(I**Q#VG7/'R(N!U^|0.' M*58VQW7Y&
<*O#YX"A_#@H=%B|3)P"K|&D*SV^T\$573Y|T7<.5-.9XJ;J;C M<@:8)PO|UU.JF7NPTL?
^MOY?BU/6K?<8(QWN9RD M>TIFU-X);IWR"IP@(@)_VZMIG&12H(20LL*MY!"_N+
MSH\$?1LK4M|X!)V&@S\$;JV<%?RINTJ V).A|.MD*LWHL<&2>('&NF5BM)ETTC
M|0'PWA86C1_|L8#ND+?\$I8"=\$OB\$X MS1-
6V+KQ>F|_FH^)|6Z#QEQWVT|'L#+K\$N=D0'B>L4&RUT|L%_IK4 '"90#'^_MUS L"
<:A|4.;:"3V.1#T5*U-G^*F2"AVX@S|JE^2=|'&5|=!:B)#<=6,&C9*98%>9">^I0WJ_.R(UJ
M&21|_%UT;6X9(^"LM_U?OWO/DCB7=EC.-S5!|@++6+/3|"PE6W&GC2L?C5V^|D
M4+1_LV0%KI9B|?1K&"SA @L:(1=W"M!\$63"P)3=6|J=Q>Z'W9|'R)T%RI|4F
MW;#%R%MGN_=:FG-4>M 8^AXIN,(Q#I;S-\$*;6W+@&@<'15>X_S|G%:)9MUE
MSC1A;VWXFk;(!7K-\$H)7-T#J#S%SV9H 9;:- C"#3|@I U+2 K\$|9&M|?^+9 M'O-
VSG=IB5T3OY-(<1Y\$?U3 M5)D\YTU:8Q|'2+JK(^?9G97;=-
Z8O;++@|_PA68/HB;KP^F%6&VOS|0EZ< MS0((|JCJINQ4IGSH2P?
*+,50D#D5&HSV:BFTUFI+);K2Q|H1W5|66V(R M9_DB&C|_Q|G1^)?;?B@N!IZ
X|G;|K#|12@PGNG+SBI|6|V#.S!\$.+<57)-
MOU=ZL=9+1A5E7UE_4=&P3RB;>S4E+E'!&T&WW;8+!79|=2X>>>47XU6TZ2C\$
MYN+7OW,Y3 *YZS/X^5,%XJSJ/2'M(8*+MNOKZ 6CCZ*%1K1|E-- I7R6^9"950V%V(;U-
"5%|LEN?%|B4/5EQ7A M7138!IR6_|S_=:W?NI!AG)|@U7?2'G|GZY8|K;GBSZUR5-
DS|TK^8M&L(E M)Q-=/GM_?.7N4B:"9X-(R7?5<7F(ZFZ7|N.N+-!)W.7I/<"X+SU14R'C-
5? M\$7IJ4;+|()<R_!J;MU8SG|/7PF6D+NE|S2,&1S7IXZ;5!OX0SSD1!|@LA20*|
(3QMYZ0 M\$#/66E:O|\$9TJ) AT_>^"IT_H+JK 9'IGXH2YVE5Y&6^1:~/>|C*&R1C/ M4?
-2JH\$IGVYE(\$<5YW*+)?>7IUNT/\$"8V0M:56FP"RA G /R! X9)^H(MGCE MX0Z*L|G/*?
(OA8.Z5RE;GZ1Q)0|MBEQECO_ZP>82U\$C'WK|4G) M-IP_TVS:L1CH"H-(F*:-
;Q+XB|G%V-{D0%_=:C;/9ES?
5*DL64;#&B+1#@C_&KS#VF#Z,X|9|/EG/(UX6_%DU63/&J>/U4INKO?DD*ZTZ9M/1-#5|
M^LC|I83S5CCT'#|D8?Q8NXJ&^7^/&*3|_O>P\$^0#I-(N6+9F+J(|.HB/Y5_\$@XN8-
|;C,H(C%SXXVY M?VTH=K)|>\$.U_CR|W<,U<(<QU'@;G3(E&G4H|Z#HE|K>-
RUO36M,M+*ZNIR! M|'#%2(%Z5E-.7647*_H%P/!&=>P^T|?ZU B9(=
|DKMG0,RQX<'HYMY1WJY\$B000)(;L;&1@9J7 M@R5X1|HJNM)'-SXWX|_N@=;@Y;ZYQ|-
##5P07!4 /S%N,W?#Q|+ '%G&V71M MNT*71RY33W#W1BR/P/PF,2&A/(-
TIMGUE#D+C,L/R+ENOYDN(O;/6;:I:9S& MFG0|!|1#%#ZB2-"|H091^'AR"704"

IND&%^M*\$DBKJ+K+XH^(FKGHJGCB*?M?*/A5 Z5LGG^4DUNJ;.E0+B,;&MH8@?;:
{Y'4?/-O>3JF:K|>JO7?8|*==T.B0R3|A?->'HG.T9UPHL>>A9(O-MF!R/LW"X""+
{Z}50(:*->"7^N!4KD&NG=|Z!JQ%!*Y7?U7MYT_4C5.@A4_)7M-^O,)!MH<&V4.OZCN-
3V8@AKM<4*|C7E*|!|,L86^FQV|4^U7?6OD;".X38G5?J7|Z,O6!-&>4_A,AWX;
<\$O|0GFG"^O+^%;MX%,SX(R^@G@|=>|D9,E=-J!#%9T M&A QE'0-E|?#K7|30P:
|SIK\$L@Y;6C4_8P3 OJJK(|-^-=8|:7|7?"Q&TW6 M91'LXM@^CW7T&C,J8HOMU4HMN"|:
<=4=Y)-UOI1|(&=TX#*P9/D MXT;"
|BG%VAR=U&K9;#E3WZ#4"BXO7TO+V_8YN27F9N,@5|CU@|ZX>AV_!:+ MJ|P+(;?
B3=Z|ET=2*3E|RY:7X9TK*KB@S5J42S^5;%C%O76@\$F3LE<^:_D.#
MTJ7\$F@1%JRM_:LMA8S(#CJ@0D/^7:*?LY@.L:XX40|@?4M/.=?5_9F#4|
M6@!LH^(%=|N|:F,4):K<@ "3PN6%^!%|G,+9^GQM,J>1,*KBZ,O'NU""@SA
M#IT;"D|4:OBL|*7I|S% Z(%DBV(9+^M&IJ7BE|@+ BE:8P6@342NEF3YE
MZ2\$|>S)PX24%7W|XAPPOAW!#|E|KZMUD-|BP>;0CSO(12:P;|/B"%W0SX MO/,"
(99/H?5\$%819Y063|AS>%BW0+783;+"('FE!D2&E/%S5..@S.:?U|I M OH^|H|O#Y|:++?
M=Q0IOGR#:P1G!FNTL3;9S|MWR*ENF|JP;M24!<)|Z,: MW:745<(M|GDM79TF_53|N?
/B5#RX+5Y*\$Q|!3H;8D_U-RABIB<MLNJ\$C7GZH|4V9<96D:G5"2')SQN|1,W*"I2:#
(^044|W,N^BXLX+Y,XNHLW MGGH_AQ241TZ|319V|F|O|CCI_"!?!>M>MW4Z-
O+U7+'6%'M|"ES/O23JPSX-N0B:4TL117^)|B|7|N*+^;JPD,GXS|R*Z?
L3DOV@DV2NYDWV M>|5BKQ@;V-I0P<*6XZQDQ_%)XU R.'NAP:|E0G -:A 3:XP&2U?
W1L>VBM MV|9"|&ZJ=.FW@=:R6QV">*.:@=0\$!4E!46)ML=;>RJ%^-L,*5=!:7VJ8)Z4I
MLDK9F^#VB<#M0|WC W'R9BVW-P.%Z,\$/7^X9OZS0?T_W+Y!&X(+|4;*/JZ6
ML52//>V&|NLHB0JRE\$Z)C'@8349(-I@K,4!F"&|XY06>_7U3 MV-
7WZEA|8&O739*RVXK.P9|V?+LRY(:.?("H5(|B,/E)0HMD)S|=;E M|L.:N'I1O?GX-
DF^!1E483>OC.E3?HL2LLK@,AY6\$ULN_QL^?" MP^?|9\$"R,D9UT\$S1VI+
<*5KP*U9U'MM#S/Q7G4TLKYKPCX:\$ (1^FR>003GK= M_W3"GGQB0P_JM+<
|JR9LRKU. <"%85U!6SOW|DUC8X|K8:8-V:1ZT1GU|O,9|^O,D=|0%5J>|ZZ9MR4AM;
M=0|8'WY.E0:F""V=2!5T=8F%DK_A_45D;YVEB|1R&HCXJ+/@15\$*7E_WCF@
MS_ (^Q!D:%E7:^=JA'WA_Y7'OEVW/")5+(Y:ZHDHQQ=|X='Y6\$\$"L@NDKKNAS
M|53(&./RC2TY52OZM#B8.@?4X3?>KB4,7|V0|B.8ZW==>0!;YC>NCD@-?J+
M:*EB,3Q^|J?FI38^|E'CTIYV2) /'2W+#EE:??@|7A_'6SFWC";5E.,|H|U7
MWI0;PZ9SN|G_V5)\$Y<\$18U||U9 |FN<9DD=|>SA9=P3CO06>V!|MF|28_A@7
M,:R#D&-'5VC)^C>=0HSH*_RA((H)"=3\$.5"YI3M^ELW'T:6W?>RWR_|3\$@_J
M\$J|("H)7B B3Q5 V)6;:W.V^&C!-#\$?+W 6G|:5H_"P^%@?^:PD#UB;GJ/&W
M>@WR>FB"C Y6.|GCT71>.468ST:%W375.EN|7B8-'?O \$-/O#D5OSL.:9F>|
M>4|&\$&KX..5|QBI!"I0:&NK>N4;S/9_ZM7Z;\$A>B
M#*%.:5EA(-O'TJ/D53V!6TP+AGEE|0E?TN.S_&4N:*^7BHXIS*,
M""V9+GJ_8R;>CXV\$S>,I9_AN906M|V+4.?#PPZ>LCB7TB8_6-12E'GSC;*9+
M3=|LJB(R#U/1*NM^>PU7EW:G10/EZJNTX-SP |9V(J*F6/>6,|#:O\$AEK8
M//Q^5|>7@R-=;2+|M.+V6A?M36J4I-1=P:(=|S/Q&1|C\$|N68G1G,@C=,6"^MP|B^F:.)Z-
E00QVISTZM3?+TR(U*.E?CN3/_DSY|NB2 ^|T#&|C*X4-33_Z!' MH!:
<|U700>U7S4W6H/=':##=,2:BU-C)D08//D@44='T6O|W),3-,&|KNM
M4R50JZ5OP3^;GB|>W?|P#,P?-GL#D97Y|-Z\$D9^GN#%<0-UW.4WG MBGSC2;N*PZ|
Q6?|>Q>G|MLY8*42;&1Z 13H1XA8,(:M2** ^3KTBB: K0H 3@ A0 /08*L_***\$*#&'#GNS
MT/%"+Y?KR'&7:|)H|X5Z8REPVE;NK;(J"VD+*/EO!X(O'!CS|*F'J'2EUG8."DU.):|L3'.?
@&E,<;Q: MOV:S+S-J9(C%E%EO3&7!AK'HV"-W=FW.-L\$#Z%7;DMM781+|;?),|IL'BUMK-
M7X-:\$'6EJ1G+QWI35>+ZJ4R+V/MF *&IY4AXM^S|%;ZE2F?=:71V4 M#@2>1U"=AR-
|DG&NM87#|&3T3AMFLM0S6@?|5/=-U,0LK4|2|PF3L89|ZF' M9N=
:Q:2A|4DO;IDTEL<,WDY^?!F@9?
6Y&2Q"2K"2'WJ"P48<"KB=TM2+@*YW|ESOHDSS65&ZGN;0'NKNW7WC MD OTZE
EU_B|Z@)K4WS4KL\$ _EUP!|V0^8,-NWGB@Q3<@=+KGL3NQ!9\$B)D-H*HY! M?
Z!BF.^IOOC+@P(|VGV!3'&" ;W4G@'F|=\$V_T'9"C-; 5B:NI#PRDJ:AL^
MN9:~)7<5P,|*LQW/ZUF^)|91M|/#ZXXX^>PM+MK83_ \$I8|V15?=T.+|66C'=:K\$
MD+CTO&8\$V|EOX^N2M <-=HPGZAHAXV8L<,HA(@ M%WF6MME)+8)/^C.|<0?
ZZM|H%YB)?|3*5,KG>D|T:|!#9|+F|^%|^W^HCX'?G M@&5\$,7="|>Y""F"V?
6Y6V6!:=F|K;=1VA)WT4?73 MR^< H5;+UX-?V0>KSX?"#1,6Y-'IX6&KJ-:O:5V#K#-
@B*OMNXQG\$2|GGJYO>:&<;0JU6@D\$\$. *KM8|%*AD|TF|P M_&=SS|XY\$&&6^B?
A@VBPX<. M7TX@H9L9W6)#!)W&!O?|7Z*:47/4AJ*P&9|,<;G+QM9_OCRET%8!F5_.Q)HV
MB\$BW@:%G/^S:== 'NNR# '9NE*/N!H94W<@NV?|G?&B;Y.LN5Z0|2 M,PN+1F2\$?

C..NO@5#L1GY0+.,@5E21'W*X|;G|1*))J&0>P|F+R:Y5>L|DU^D
MNN1&^%S@R_13G/W>?;V?(VNH|<.8'>9#30^NUS95-EI/?1_/H!1.1B-Z_77& MOY1H"
QB=L=@IK8KZMMR,I@Q7|RIRO(#SOZZL@H)Y&-<2M\$V;W#-RV6-M&PQO=Y8>R-
T,^H:I"4PL)FI=5NOH4-.EK^7"!L,I*^':E=(?O;;9B'4.&8PYBK,M.P%
MGZ&DKDG+U"NNIGC;)HNGNM-
MF^MF6A+8FU&3ZMAT7I6Q!WAPJB,'U>J4L_X'4J7 +&\$8\$R3IS%7A5-|!T"\$>;T>
f'/D(-\FI9O[Z#2 MJT64|H1,3EQ|(-8ZSEQ=Z3D+I ZE-0|O@QF*/AA_M/?Y|W0',4-W7EPC/-
L=
MG|1W#+Q:>%^=!'6+0?;))J\$+U.ZC5|BIPB8_<.:@00Y:\$PNV,T,4?..2<_LFP%NKO%>^L)U
MOKO1P|A7!KF&:=)&MUG7'#F8LR((OTQ&='50XG,W_IN\?%|F1?,7=@KB%#K
M=GS0W\$. _9OPX+_CO+8OS\$-MP:-JMS0EZI&\$#3F)4B.*LN?7F@?T@VB67A9CITS1_#GB
M^VG7KVC.L/@"QQA?TUB?7WG|(\$TIW0RI|@F'E(KR?G|I4&:H|A|X<;@LD;G5< MK9-
^|4HH|R!LS/#C&?G!@E;KZ?S?V>8STFK6<1Y,I&LE3?9&0;IG\XIQ73QS
MU8*Z|SG@'I>MO\X_2G I>"7Q<@8W=N\$|HE1.?-IEAXI2F3^JW\$00/*.\$I(f5
M.EQCE^KO,T:TBO1TK-?FV65|)|@5:F2>,*="\$ZWYH,W_B&:W |/'!&!WI"l;^
M_=X2\$3E/LJ3LIF%RGJH!&4@2EPC+|0Z>*E(-XLL>',KYL4^8UQVDG"EB;43I MQ)9/-
Z&0=011@.75++679^|Q|R9.,^!W,C8@@VE|O<>|F#BR!|&J(\$|N\$<
MLJ:Y@'60^KGM<_2DKH5//?4OODI3HY !FI3?5*,MZ5&)/|T9.PH1^3VB@JMA M9K!K-
ZU9IZ^WWQU69R^|4@R.)^|A977597"66NDE4JO=|YT^!7=Z0F|>QB.C M:@)?
|QZA9\$-4K9RHN";LCC+J D:&FLV V/V;_9FR. EI:G" _RAJCG
MK,HW_>V@(|_N=1L6G.;F;AP%"C&EFR)|M |Q),F7+X2*Q>PF3Z|NP?|D2\$N
MNP|&Z|@|Z1855@RV*4JCT% ;/ # (W00@N'<+ \$G>X,O;'P3NU|:Z^U:FO"VZ|RMF
F;^E|)B;UYHQLQ@|&;5/YIV'07HC^HKPVO&62X.;0|9QU &Z!+=5|<<|"
M7+&TL_WWHY;NK9:*H^7,SG3D*QWWHW@3JXV)4^=K-)04#T^V*+7K=^UMX) M?
;^U?.9|YVYV&?T YH>S?2JSNGC7AV62F+S1\BUX0;X5/+1? 84|V| \$P%_&f
M|2Q>|U/F:\$N/LMU|RNY1*.;!\$J)7ZJEK_T,'CEO;_UM^=E#^|_TY|8(8H* M=MGA8Y-
Z"MG.X;QJ<:X.D|R#IT26(.| ^|.ED'QO0I&;X)>|K-Y,=L,U#(f(
MX;O|LZC8SY@2XBP645IAX7#KK7H0OY1FDG+7Z40C?JZ0.7JZ*W%'|=O79:8 M_34D=-
^E2& P9=4;RM9"XE*(3ZV8PP_&PS3|V!A06JT3)-5*00TT">5/348G M
^2;B2X8ZO#Q*4XWSC^|E|;BE0C4==|;B("V|?K O: ^:009*= MO7?
V.CCC>T|U>C|3^_FY_"X_ |POEP?'XW\$>|W&|7F_C>HMQ5B4QO'7#X'
MF&BA|5./=.Y6QB *)/R,3C MRR90AX|-3|_
O0Z5J.YC%V1ZU=7@0ZCG>RGIW0)WW((OE_UUC_|.'EQ6M&.)M M/'"0^=D?
7'NW0/HM_U+LD6YL6'P.4|E)3W4;UQ/-|T-#8K|((f(J M|H))A I+OK=|RZ^_.B(|"R@+9?
\$|WT|BU++_6OV+0MUL|VM M_D9I%&RM.;&R+1J82+Z+?X?
(+1|BW?/=^:8"G(Q|M&GR>54;N8<=V|U#=#56(:M"QFZVZ Y|U|K6R+3R? MSNF=X=-
LUAYY>8<3\$.V^,FAIH@Y/Q "-&M.GX44LW5>_)/Y91":4=_TDA?
M5GWNZ|/|_NKD|)QX-S:<90*>_ML/8?IG^6,F(QI#350P;0I17!@_K1Z.;8
M%1\$3MFTJL^WL^)Y.XYK|^3T#VWV_.V#|6B!?'4THK0J% %M8)"RV.VHWEK-\$3&
M5U@Y7L'LO@A)OV|5ECG&|4:B_ UYC5YP|N"I"@>*S9F\$8,@,SS9OT.O&9QKW
M"J^W*,92F+|'R|0%WEAM',(>|%+2V^G|I@IGB6RHROUWF;184@F\$|(X.3U01
ML2>:3:&9+6IQF3(Y"NZ|'|H\$|>B;NQH+;W|F!VY?C2&Q7)'&\$+:EXN?!_ZD<
M2A02>\$L,(GU<#HRXV1;>_|LT^G^Z#1)W:|VF.1%QRW5^&E"/WJV|MUR&=*8
M|F)4K?'U#10"9F08C5?K_<|5|7HM;K',T,|AF2+-UYI7.E>16^|X|(CQF
M&SC6CKGX*V(DL(^R'VYTO;":T+TP-MK2)|HYO%?+*=XL4|Y|A85"5=:5'L)3
M:S?;64B_NKMVZ470.|@;LS*E7*TBU0&>;@\$PWIS!|C3&0,?X|5>-?P|(\$|
I8!0G.Z=AIT;_2XV|H3K1'6X,(5+HQ,#V_ZP/W!TM5^|H52R|A#:
M^>\$(V7+"G(1+6_JH!D0QN#1L%7<&6W>Q@@@"\$|F @FA.)|HM|="V3>#R-?234?
PUA??;E0.4:BEX|"ERW)".M?AF;77TVH1 M\$>?4JB?HPO<_%?8R0>^)|SQ-FZ/ R<:E%2\$8H
QY' 7VQ9&!UE6;&|&+'01| MG_8D#+C&ZLQ.;5|00_EKT;_|L:57|X-
O1U:M|HC"8X:Q!?!/UVS9O;"E)X2S|0E9\$NM':L)/UL;>=5'?C MBT@A.O9DE)|V4'+C?
\$YJR74@*FEA,#@&HE1W /#|: @OXS2,*Y"46_3G|C-0&N,CG)@PDS(G_*^1|B =ZP&_6CH?
7%+DJOA|H#K M&KERC-QPL?^&HD^03HS.7KB(@!V<|PAO!%-9Z6|L.LP-
:7Z<5S9XUDW^VZ- M,D| %Q|371;-IABGY|O +!;3LMYY5;^? \$@ @F+91F-S;C=<@RC+
(OD*;/|H8
M>;Y?;..6TL"FXQ2WI* @==K8,VJ)GZSKS3B)9IRDW@BAU\$EVZY8S4G\$>ZJQ35|Q
M(*Q|M<|H|Q#:4(13CUBGR0DO,J=7 MH9C|JPW7!1C7#,G6R|JKS\$KI62HH'\$NW'\$ (9"l'

=J78\\$\!#PF2FXF#)MJ72HO^>>*>#E7V['Y(:N3WPL5F0-;1F\$3P+!%7%LDJ# MP-7J?
98Y2JPFZH?W'Q8NH!VV*!\$|W|C3;O!HC%K*[KJ=EE;09D=-%:5I0C/ M95;V!-1)
(LW4+MYP=Y/S7NG]=')WK6|1CB50%@(40J)8W%D 3XH6CN9JF;1
MD^_E/G08250>W+G;V2 HP(+^K3|":TYX0Q9N3@27\JHR_S,EE)>4:CWC?:F M1CQ(
3V;NKFNM3J<*MSHZ)VQ6K|L:>+9IAL<6!M&#Y4F(B\$|V!)I9%B>7#Y MX/^.=U(
X7#P8:MQS\$;\$ \$VGCG9L=49J!%QA/92#8/?RLJ(80/.&7/\$BF;-RS M!QU.5&S?
ZNL6NK##*2%83,XIJ5^Q80UE8AYQ5<#5C7!L7F(GT-N6S3!O: MHD*!&IBS!
+|0T31RD7)N?R6;|L SOK#O*@(IR_4|5LO@/(|),_<-W^E/+ 'DI6 M#D,T!*O?
AI=V|S=.Y":)H'7=8&AX311C|Q M! \WPUL 8XP|?KZ*=W4\$^
V8SI==>9M(CQ>/|6XQ+ _6:F:#MUD0)?|4>'O+{(
M2|:WA7EJ;PB&K1XB\$^31OF8|BE&_-9IT%((\$E@K*K&&9OWLSU#:Y1IU/3K|
M4;CD>AF=VW4)-KJ.@@.V:X'.7J-?|>A6Z2*V&G)4)MBV(^@|0 MSD/2!@Q 5M\$
W;L8@\$8D88"(?GCL2> C#! X@T_)KV% ;Q5,4#+|N(.U/\$'
M&/OY2QC@EA)D,O&.F+B\$O9;WQ|50|/7&2;4-I@#T)0!>O/1B-
8J25?'"CNWY>G_(X#%J\$16C)2G5\$ _BQ|HO"XX.V.P_Z\$LO%AKGE3E,>^OI*|?&LM!OE|H?
FDV M|-"V6+|99T=?JE);&|_278(^P;D;/28*/1+I4MQF^5.X!E,!3NL?|C_N_J4A
MLE8XHMFH|*1FW5=>XE&\$|8Q91.8|JW|15S?6#-G460OI5V|C^@L?TT@+(& GR@^?
X&&-EEP49FX3HT#XBCJ M/-%&BY*?SV;2XJN(3,;@OL6:-X::,K^8= 8F+>3IVN= /=QH/-
|'5)G|;8QR M.WNR,B?GYW|UX7(R0TA)V*?Q5JV^@S|XTJ* _#H|NJRHVU?RXYFY>?
E)Q@R+= M57=(2|MDDBD8R=|BM+AK7NOF^L"I5(3W36ZK"#S+
(\$#HD=RWO)6=W*@#V M.6L\$5KN:2ACCV=|DY'|JL!G|=U++|6?
Y1Y_4M94J9%|+VT3S,8A.X M|.LVZU JT@3F|U>*|CNL<^"W?L=U3|K-:3\$:UD3!8\$"|.?
P|VIZ _L0!YO&1M|7G13K9|FYLR<|EB)_?U|F<'@('S9A^I71
M>2Q>P4#^)5:F3H<+W;SY_ GX&JP|LL@
MXG|YG1!5H\$8&E|VLT^&^7TGVMBW"4ES|W36.9|HRYIW*#,_=Z"
(S'4@CWVM@YUM^?? MT-&/:U5W:T6DY.'X=26|(-'9KT:PGQ-*.##^QK>LU@T|:"=|!>-5
@%K_C M8<|(|3S3U15?ZKDMZ!%W3+\$2><+TF):VN'I;|BV!>8R F=>A!8:
|.YX,3N)HAM6^KOTY&_+7U*W6)O/G1 MF6|LM2*%"\$I*&+FS&6.4ZYM|JC(H>H3
5@PX>,CXR6?M6+UJXTGX_3|WB\$| MJ=,=C2BSYX/W>81S%Z\$YPF^,A<-
A1CW=GG|BHF>^E\$.I6Y.%3W+&ZQW82A(M M=D1# #HO-TX|ZQ/>D|8NB
._%=&V)/+F|9TLE8&%3U!O25Q|43RH7EY3=9J08
ME>R9+#L:L"1A5L;:LW\$N#46^\$5R9R3*STLZ=
(N;@K:F9|0*QJPKD,'_6NPNOJ9SH:Z|AP@V7|K|9@|,>TF|-P *OL?;MM36)?,.#
MP!ZA)U^7\$.|ZKK5^E'ST2./5"XE/ P|GQ2O|+92UI5G3;QR#9;O7|HJ0O)&
M':1<(!|HTL|#RE98VO+>?JH3B>5X;?DQBAU_H@Y|PUM|'/_|9:"4RB|/^>WZ
MNA9%LM@?5>-JCT@R)N):YWTK5|H%K..+| TCHL84HA7J0NE?W\$=P7<1._=V:
MNXJ4VV0MZN7Y"H'EQKNB\$NPCIO MBNHIVE7Q!^M=%9>H)
(O%5|_.EX|M8|R7;U)POY2'R'/_N8Y6EAH<2## %|:9 M)RH>E^RZ^U %|?|AIZ8@A?
|738QUR3"|8%@*W4J>"B+7F9Q,3VKJA)CP'MR^3M"|8J"+I5*&)?@?_HR &2!KANUI
M0UK0)9_FT(E7>0|;QQ*:5W# F'GRPP!@6QJ>#%> U)YZYFO^#?|9_'UB0E= MY4|QP+4-
MDZYD8;+RAU*,A,+S|_LWV&UHZAP|X)9CLM!QUV(AZ|JEK-DA2|
M|0SD@C>|C(|_8ESC;Z5?>K\$TS7QV,)LWU2Y, EB_T*+;4|3&7C6YA_
M8R;P# 'VN'UZZ|V6E="0;|) #F/=5%VD>Y^,IL(OFAB>XJPB9VK;/O:-G^RS/
M&W|Q+BGQ_.X>0)S",1|WT).Q()SI6K7PMU)HS^Z0OP(|BK,G;/_MF|7B|?>|!-
E":HB.V4>|Y#G>GJG"|UJISHT4^|*E:_2H|4 MAH;B\$^'AG5_K!D)@E1BS1FZ|S;3BH(%-
V|*?#_GOF^Z.&TQJ3@),,MXAUH5'L)WN3>/E7:|GS;=A(7RG5O, M=>
(=7T|)UN^UN^>.:>D=%_9E%KY.T)O)\$%7\$B2=HFPJ-J(L6RX|_P3@8H+BBD9ZOE
MC'=Z/5M4WF"W?FPV^*|=0GJ\$,W6N/Q)WTH|J_9&| #G=F27?2BP1ZDD M"
(Q|>HX!7\$>QWXO'DV^H%QJ|^LVP:|\$0RXX+B0T890_&L"=3Y7T,\$+WP OW*
M:\$|GOV+%R=:CI>)\$-^6=D-UU"H@;|_C(TN!TJ")^K_U9'WF:A!@DM'.':3C M0606:
HJ3>EYUEK#1JK'QGP7KYD1ZEY=8DVNC%>&W+H=9KBVAM+CWY'L%#:E M|OLM
4R0"M)#6&XE:2)>.KUN*.J/MU5U774--|M*A0M1/HJ=NO#=#D9ZA_"5T MS6EL
R*/O#K#*|\$03Y)E?9_X_3U|F."=I4UEGFD:UPUWP\$2=FSN;JOSS;0S@_MU#?
X2P006%\$"/8?:@@"@Q@-7:EC7EV|8L0_^YOB?A\$DX8X\$\$(W,ZNX^Y_2_.
MX%Q>+&V>^W>=
P,8PGK>'ZND6QV|.9=AX/) "A:"L^D6D|^*JRUH|^T)BZ+4N%0'V6%4>
MXH'_"\$DPDYW(NR><\$'V)&6T9LQB85|N-;ZVJ P|R1(2B!WKH@8|JX.Z(:GB
M0Y#SN>=+3VUX;O|HA(#/PM:%;<36.,|LKPV+L'B"2*|8>UEH"0;^_K.U0;&

M4B=DE8I'>X2*@@N\ZK%*2+6NC;#50#I1GW+QWS>EP#1=^QE9*8&&MR4?
Y#.N/=1ZP M:|=&J\$#P:|&(^WCM4E^I96|P"4YQ|?07XKDSM|;3/ 8T|IOPH|<.P5M|I4>O
ML,<(O(PM AXZ*K_Z5?1-,)4|C/;A_6-5D5\$9E2@G\$97:RKP;/8'D3#O3BZL
M#1F_G1|BW.PYN%ATV6&O?5(.%-%)X|H(-|Z,:NEA@|I#D0_^,@/|I^:|I M!SSRH3NY@7
X,6|*ZA4|?).8\$9/1K|1%5Y\$.ODIQ6OSLVE&E|ZA-Q\$BN.X8 MS-E1.&|*%-
TG??F06DU=4E*|8HX*&#G>= MARE;T+8/6<'=
<7|F<"Y+|IQ|=5R69E/PZ;M/V@WG#=#KL0#VAU!/?D(X_)8|#MYH M?
N((6KKFO(^6VD_,M=-%0%|;|NOB +;:@0:A--O7M;M;WA^.= (Y;7Q|(|@4XJ5 MMAA@3-
I'GGG_F&,5N|'YNX0D@YM22GM"71Q|K3|Z9,I-D#|9ND?D:)YP:"F= M>X;R^|C;
<6/=0RMXS_:YBOR&BC/P|)E|I|-O8;>8P,09_IJ"?I M?834%A^(F@_PDG#QQ
O'184UB|EL@^'"&:>9/OJ5=,O2_,>+,-|D'7H|O7R MI3ZQYGT MW^ ^1ZHH,+-O+YR,?
EKT9>GK|F> #27+5W5RWF^ Y3RM_O&,2)L, M"1LMPJ@:TH !&I'H.|+|*|VGB_BY@*|
<^%5;(-@^+C:VJE^Y7MM8,?3HS; M 8?&O7Z S21 M,B|R06*V(TZ98VKG+V;*%_E?
H_NI-C|T#|S|L.SVAHAC M-=<6|PZK!4A ML'2D2W%%)
|'F%*ZY7.SY'YK50M2|)7J33|@/8RTDQ_P1"VR;E T|LT3>;\|SI_
M6@8ZTD4*HLNOND&N.Q1F#12PUU0|O8;K8%,QZ?:TZO5)C/+Z'A//_T-8YS|'
M_'W.Z8U,5.XTBML)29-+-&=K,(X!EG-"\$%?9=;/&_F;,(+E
M<|/OG#N5'B:X\$<,BTZZ|W9G:HHT;V_H86VRFN";GE'>'\$M!6!_#| %J HEX|
MKI3R"O<+6IR%"8#8|%.AX(;EO68.\$RN?'*+P,0!OP?4FRF^SU"\$!Z#%0'N_8
M\$=1X^';YMR/?T|H^?TLTL@?|A|2>IV>?E:'B\$#PK3_(E+A-
".|X900>816|FH2^E#UT0<2A%1O|O'P9!4)61*N|"IW\$40\$=P|X9_&8_.ME-VE-
;0Q*_8)14X_X2N@JODO1*M,SB^1YW0U>L(_)_M:5Y079|59|6|_>UGI&F
D2|:UIQY91NU+=_+D !G+N, M|?
>YK310(B"&XQH'N*+,'TD_(&P|BLW5:X@DO=K!%);)|IG)87B=.L_562A;;;JL;|J(449HO*\$!-
|P9IVABQ;!O?|@-(M>#SW+XBN-O'JO7%^SP,'BS0Q*KM6\$?6^|%;ZP@A,U>|&X5U5IV"
(|7@>NZ>|MB4:%PWR|=|=,=G%FZ=T_7!^1?Z1W9E+!^D?
PEQ>|X^8VG|_H>R#8/.S3R? MZX@ (8B-@VCF# ;C3CA+A'COY./%5--0M?4QSX|R
KJE|_6?CQ\$TZ|YNZ|Y M*+HE|T?3-'XP7@;
<^4/%XRJ2@=3|E9=F1Y|VAS8|IF=W9I6U'_BWTYFR MAD>W;LP1!XO8A2TH0W57;
|S+|.05>| (N+4^XG2QC*67|('!*;NQ5O:1:H+A\$# M/=Z3\$G|D&X=D01@3-
>9?|VAX/;@79| #QD&)|RC< 2|= 'Z+>7(ZNAI2_/=/KM= M2,PZ|B#\$|C^&?
CE/M(!N\$>OLZ|<->)*(K\$|JP#0J&6X|GY|3<8@.;^;L#) MM'>?Q#9IFX+\$|/N-|TC?
H3(51?+Q=#3*#@G@|8EBD'P(J0_*I/EC)&.6Y*\$ MZZ<@5I/O>QYLSLK6F;K-EZ^AWIHZM
M@S_K94W8&P^*-ETB.F:S|I;.YP4:6K@Y1ESZCX|NUAQ KA;8L|?+\$+26^;.>Y
M47,A|JN|Y,*&,OO)X'H:Y;D_-TKR/'".|_JKP.MMY9P"VZ>"|2?9,W/N=|MS;:#/,K|J|A6(N(
EW0+;NA503OS3Y+*

@C+HU|0\BH!S0L#D&F>UNS@4WM&X|7L|:WH|OXX2^TTT:FO% T\$Y MVL|<6?YP>/?
63F>'JW?A_G.!**WC|B>|_BY/U^4GAS|0V|6P&>|Z9&KW M#GI15<%)|J2_LES,IQRQ'6>
|K^~B;7-B7|I M!_RS\$9\$#S% (|BC<0|#O-0_DO>%?IS17@)|XG|V7PK)#|^>
M3*YIY)Y3W|4WC|. >%A.)?(RP>T(G&A9YK%-^F:4TMAK8)|I#Q;|ATKF38TS
MR>G9ABLB?9-&U8V\$M7;7(L>YT|YTM2X3#676G,G8(+;)8'WK>'C-7M>D>; M7Z|?
EO1P#&AX1')&&=1SA60^D%R;YJUVQ<0FRN/<\$;/3?_=&^J!18M* C;JE@6+<:I2?
|H|ZMX6_SKMV;5 MUIE|S|\$+WO5| #%0V &I.H0QK)|\$D1!..?5|UJ?
L>Z91=|Y|L@&D@IG@I"3^5- M/-'@;_10SQH>Y;3T@\$KP0Y8&NV-
CX;;6=01KKTQ<,=5:FQ?8|1?U";/6(+!F M?Q02I|8"> T.@%
4'F9V|"XLJ<=00MD+GG|YUD"T,WZ0>31Q-Z0_A^2G-;"J.S20|&90KKY" X)BX87
M9UW802P*=|*Y|J8>SH:-3X_Z@Q|<9KAT:,@,24(K(:ZR",%)'K?^K#,FY:~T
MUWO*R\$3J2:YRO:3|F@I"-ML%1-+45M>.M<|U;9:~QV;'Q@O5W4*YSPS=Z8
MICH;J9WS174X5243T3OF>E-L:<*Q@ #VW|I.AP6CK.|'?@\$%|" M9|D|I?2 -^|
CM3CPP'N0B5(F3PO7VJW@=|BHYP/E*N:|I_|G>*P|V8(@
MML*+*IMDR8:/TH=:AA%7*Q%DIODW%_QC.B! ^,SWA3;ER+"U!:@EGHB)%55
M&C6OUL6#^~@3N)WS T.K/5('GCZ+A"=,H02^GSRI!Q,+|0>OLI?"UD4K&XV^
MXBNWS2M(^#VF#DI*^9J:Q&7-(@|9|G&S -:|Y%P!E\$STGV;|GVD+*6ZW;WM-
^\$KF<,3!;G*0YI9"Z*B,^|7^W:19<@|+*|T?T7^L4WOO6M4%+9AR(Q|A6B
MJM(Q)&#W6FM:3GB)P(P6E?O96-?|Y|=>6W/U_,8@H8S^?(6C,=|3<;|0/V7| M@?
Q)\$>=6*EUGO,6+;EPC%OZU|*G'GF>Y_VW4|>|('J|MI:.)R|J4/MZ"\$^"B M8X_U QAC1S-
KKIRFJB;%1|D M)7!_ ^NIZ*MB+|^I+|LT;|NRQ?|N&.8OI_;/M<^HK5K+I%X4>RK<|HV

M(DXJYUEH M*5\$H=(81YU@G\$TF3?V4V<(S U>@!/:=>R9&N)@=[W@K'65AA\|6O:
(8+D/-1D&[ARYC-'*NPFOM,Q@#E+#3HK7?U(2,Y|MY428T^C!#|W|NCC\$, "?2"=4;T#%
<^9>9G6#L0<-(S:F' MA-TDU 8 *2#GSAAQQ=U;=_OJ90K87D.R6_G_%+HQE5E-A?
RR'!B8T5I&|T' XX>+6M?R7#0+D2S_>J))'>"OC*|I7-+5#6;-VRN&;D|*;-JN2J?_>|ORV
M\$B@\$.K49B@\$<7B-4|GHWXI^MF+OX3PO8 MF">W_A^3_A|#!FZ0S?GF!<5=;
(U&1JR=^\$6/3|8CP\$9%I&Y8QP 790.'G1Y M_#-|E.#2A'MR;,"O<4*9&2*
ME|F1E;2W3P|AWY>Z:<2Z|83,C^:) _N,@F9M\$\$1W7B?I9I@_7M-X-I<'TO|Q M!
(F2525'J5759@Q?JIN"Q?C7L;E;FPL;XTEH'H2.+//MM4^>3^Z1OE(:/LY M-^S(4M"
|^,G"HKQ'?53>^?*"BEI,OB0B(C)OI
MOY!3U&GX'FCN2>B(K#6E1,A.|">JR.Y^>2_)VU^#8=&GJH%%0T.NC*IDV1=A
M%ZW9S89)0|@NP&XIEY9Y\$KW?|*5")=4J%JXG:9)D&%|7/-E,G@Y?3^/_#!H
MX9|H+*WA3+ +Y49=VE\,ME\;|5%,T4\$L;|8SEQF7V\$2MNT#<|3|W*:5F0& M39@;7W=
|JH)E4!>.,.'3R"|WP_.5TYK_U!:_>/EX))#FR!E;J'GFE'Q 0S> M;W"
SDW/6+>12_U1E.V'21,A1J4GU@?P|_EQ|B3K=|(<|H^V<5K;-0.G|5%|<@+O'OPEN+I<:
I.Y2NU_B_7 MU3_#-APFS<;N!6QV\$=0;VO ()"6!|XA1!D>#U7/U3IV<\$.;11W_);*Y)
M7IA>FV*T^;1"0|;X:9|F4|/E, C|JX6=ZL>W+2@|MW%;;A@'+-+=QP| R'3
M0TBH!BOUZSX668EH38CNX;|6^%X;\$2|&@*K?:W&_B/OL&;+R6R@0NX&(T.^
M5TY|2^S2%)XROP,ELF !X#"M&&2CJ2@: QB=DW-SF(<7KIG6PA).6P.PJC>
MN.NMZES'.IC^~K*TW@Q/E>EA' < MV('7@J!A2%E?7*6G-
4E\$Y<.W;;ZDX8JVB*9YUR,'&=NMRGP2|C|T MN4J_WX+^J#!YK#/7E,#KP2)^ (E5D|?
Y8J/8N!M#:49(N|>|H|E\$PJ_W@E67
MCZF#@_.'>E0JPOH(5ABYLJNDE.OIS"8B|9*5KP0R>!ZN7A)>#?T/|/7+5AEL
M?5I@2_06)GK_+**USLZG.GTJ(A9_+D-ZL*|;+WQMY.FP^O(70?WM#R>!4,\$
MS^BO,WPR=>XF0=.17/NP\$!5;EJQ9LI#0CF5H 4>P;K"X:>E?^'=Y(OU1FVMQ MU"TB
LIO =|C4P|200.;@D&5*J6_XDRGJJ_.#NMW@!F1!2LK5>7#4S<2JP_QG|^K-NM.JEZZ+
ML;KO/I"S45|+5RSN^>;NG?;|HK(%WO.R,N#\$XJ|+F>U.=DE/=4T42C;W\$ M9GK#@?
*D\$(!GA;5*0R4-Q|XC>G#:=9;1_M^0#C&4?E;SEX%D"G=|I4+IK.K?
E=9C|!\$SF%C)!|LR@'X&W.G'O+GG4 84! M4C! =#8%|@GIPHHJK9GJ/U+
PP=80!CNA?'D\$:D?60F01)?SY+IW"LG T(M|F"|^#^5\$0%|3(0677D*6RLP_0)|S;|IC-N@
&"FQ;(@_ZH9M(#/#_MXY|X;+JGS2F|8ZI8>(\$EDCO"EW:@P4=^T\$8^|Q*TES7|\$
U%*Z2AU;8PP'40 MPKR!'MIC)XK& #T8H&W N!T-7L3|_ ^>I&3EAOJ
U8PH|T|^##P=G*Q;U4K; MV.);J-&/MA6+|DO4FPN# T|VK?
|61P&^NDW:/_9EJLL>:2F)KO*W-=;59
MX|)5\$4|RU1T#.7L+8.OOZ_5P|\$&,D*E4YD=#7,|Y#|!0'LSY5|?ZMZB\$6F%4
M>J%:7MN'SGZ6T>#4W0)1EN-9RNMLY002<;|!"@6LT_?6IN(?#W1?774-|&A
M9S|219_-Q|K27CA"|W5.)E6|1US4|_:"\$TF?G!*P9HJ%*KVBW|WO> 8X_M')AN5_6|T-
4*.W|4#_|Y)\$:V5-ZY.K9F|VD|S&-KR|"*CH."ID|T|'WJWS M/L,Z/W6.5V3
!+X#;P|'RD|LK C(X6Q^|3U3(K;Z,QNM(^3G.C0SKT_\$X/"GW1;_8-V5XC*@<
MX79@LC69&#S(7CDP#SR^X9/;>/PB))3H6|>7ERJ?/T.FL;SZ'.4F/7|0*9Q" M?
MY:YY.^@@ MX/'=BMML39;-OFSP03Q>Q@KR3|80-*T27W+TT)
(0_&CU(JB_!|)4L2)^08? M0* 9UX'BIC<_>KR:F7.0#0/(ED#WY\$R>"W|H|Hf>STM13S=!?
1L?&>S*\$JU6"&|<M-0BL|2E%&|<4A<7|;C|=TQQ,PS0URO;MH;J+4>EPA|2/24
8H%BA/4(((MV:T./KA8LA-H\$;-X^V=^?,9=+'E+|T^|1Z|9:Z4CTKEN8K<
MSZ,Y6"YJ|0_'LD>|S8UIRI(Q|ZSN='PO/_XEUGQ&|_%5|K|M;O#%UT3I0LV M
Z*B5'R24>1*\$DE48-T\$E(6"i<:>:VSX6C.7G=;BV4P9@39"1ZH)1|O\2(3%
MOU_=G!^CB;BU)^V4\$CEG?:RP7C?J"Y^7BMZ;T.=,JM89!@5+|GPTOMR87R)/
MMRP7&WWF^J%.E.B;?F<:=D_8(ST4=&IR;-Y#AHUN='XR&@?^RO|EDLL;^Q&L".
<MZRC,|0>0|=X|/|@9>NIWY3-MVV",V\$7@|^S+TP-+,D&E0IBV/IL+=T<|M3D;
;4XP7DEEGU&^OC"=|I^L^G" M"#@!|,7(_@0)W5X%>SPYW|F0=GJPEOC)O\$NOT*D;H-
6&2',4>TO+I-?.%^LH)T1.>N6E,-;S0:|4EKT;%W*@&8O,5>+IX.GVM4R\$
MI91|&4PXI#_IW4?0%J9#&)C^U9ZFK6,9MI\82+|,5LL;'20K.9"3ZHV07A- M\$7\$8A7|;_?
9L^TGX|!XR3_E9N;T9OH%TR^W.?>B=)EM.6Q)-SJV60+M?SUY\$
M._ZC^WEE&*Z_YXWPGXY8"CF^V|D_.L>0+%4!OA&(LD0CR5).GT*|@5R M5DD+I9^>_
EMCJNRY737!!UR1+8VG?)|W_'G39VII%UEGAB7#F?_)4:2?HC|8 MHOMGA!/H1(:_*>^_
QS0?'Z5TL.?XYNZC2 W!R:~?K/4!|4 N&(KO9H9"W/FE? MW.OW+|D'"E VL|I#8?WS#9|
P=C?M\$%,M^!2?83G5S+|W(C*EQW=Y|W=|_U M2SW)4"
(^2)C\$68A|Z'"T(9C|+|L'0R76BJ(^SNH,CVEB<,7XT1|J;U.A
M.A8.INEKJWEM<<:/X9R5KS|I_@M> 4).\$1&60S_C9J|VZ>>JD09E9IGFU"

M='Z,QN),E_%^,\2-&,DJA[26U^?# +GCEN#34 +%A\$J6%\$8JGQ&S9W+MSI\$P
MJBAB^7):.HA=%[_HJ7I^V)'/U):.1%R5VI3F-8P8I1I)@P%(0(&9U1%N#ZSO M44IC1)
/KRYE&W,&QX1F<6QUQ:YY:72SW=\Z#<83A1V
MELJB.2(^,I\$*IF0ILE6V2=*K&NEY@7,GSVU?8^;O77=Y:4M0'2+P<(6EHY/N
M4)DZ5FH\NB';4'^C@BBK];Z.DB8>Z&*0K\ZWT6"*_K9OKN,<-I.D.+3FR4MS
M2\$C(A0W5NZYJ=7#?=?,NW@Z=?I@A"? ,OA"YHJRPK/W=4N'FP\X\$JM/1!BP!3
M4Q'7V,7LVFMF;QI'?=C\N&"^S^=HWWZP>W4Y/F6P1\MAXY+"^/0#UJH\XXL8A
M.&&4.^|\SWH@,./6(23OF20J(7+I_OG1(#J/+.04(!T,*A9R/X)\CEXP^6 W= ME/;JE^)
F&&&8 EE-3Y9H%9<48ES)7LC8UIH*OJW%I02;K/3O&9VV'[29/EE MDF:
/RKZZHL&2J(G)/;\$@71>BX)H>R(QV?WL!/D)[^LV,P#^NYPB1#2V^19U MR1*&CP55)?
*|XFFR|9." :7EE4VYK>Z;^2I>^G.E2<5.B^)\$95BW7,*F
M|XH03+8I.K"=Y4=&JEH.//8^*5VE8.-ZSM.^|HP7(5!|CD%2RY>OI%5^D%
M21FC7@L6P=8?C4.JSOPEFD+\U4F?GNN>\$'=?\6,)C% ,:Z0LT2(;C\4H+)Y
M&B<|U5X^08^Z<34))@,A/W3H5!M&!A=+O|WE-/F=%\MT%9>3K3)K7+XZ5,VH
M>E)#|+TB@R4+;AO/D/L.LS^FFL.%0X+;'.|Q|Z%?SHM.,LJ8C8>5SQ7Z>3)
M82WD2&S35B<29_<#5JT|;>I1JEMUP>"@TB35*U2D(X;-%-G-KG|;D1)U)B/ MH;
(X|^6>/?2"Z^825<%UV!8=1A.T:)(9*HK.!==^OJT%_LPHT-:=HL|8Y%N9
M?:+LJAKW#4%U6D-R!4+L+64^6TBMWW+SK<43%5BI1W3PLW&VLF3MHW1SHVT
M9%I+6LG^E|6J6!'V,A: 1S:9!T#/'>#(Z,U+2?0X'DPV|W6::C_WMSKTDI# M=
(UD/ZS#@QV_H+|23K-3J(AEZ\$Y|YN'7D><8 MG65ZH,R|N
|L@_1LS6%IEXL*A|OZ'<(4+%2YK0@WF5A M#X^E-"F-45'8CK?P:7EEK%B-
U'4Z2F_|JX&QNF|')VZRY|##%3>2U"S;,>J8,
M0|Y05,Y+IL3)3D",VRPGX_YCH9,"# =MW,8!%7T'&7I",=*82^&,>3YV\|QZR M1Q:?
V5N5"P/X|F^X28L6)D.L27|VQ#8C2BJXK:8TI(!6HG!'PO>D!U&'Z'O
M'HTO/G@MGCG8#)WO6!K8WTQY|<|M+HMEW)@&CUZ:=4.R'RXU'MOB.B|.'79|M"-
W0#>AQGU|0)2)?^+Y!1G>^|+|N<_<(3|H3'8QYU>|IZ^Z(^U+?B)S0_W M=(V|(R-
UO)3!%QY.^XQR-\$* M_ (= #APCF|5\$L.DDZ\$.757?3+9=P=,+,0V* MSR_ =/*PUDUP%DM
M|:-#G-\$>W9'H7^EZ\$OAM?4',>TNCNLT|JS4\$BR:L(VF;'BPYE!(+K|T7:\$N
M(N)MA/HI|+DG>F'|=-;RX|ZS|)4G:6AM+YVO!G MNX&U-B|>L"S.^FK@=_H*
(EZ|&WYQ.^1NL\$CF+V|O&T6FQD@1:| MH2W+9%>8-|%D)P='KVH.
(/RG_?|GZYYGJ!2NZE0_(+)-J*"4R?"_G?C@RBR1 MA*Y\$M-S<29K47.G(W!O?
NX+"A\$#>^:/M% ^ =G%<2YC72>R*[|8|S"S|3|Y4WS)(SOJ:5\$ M2|8<+|;W!)XMX|5-
A:T+TRUB#CWBUGAF=G?M2H1I8V=V=-0L9 MRGDNJ3*>\$*&CC1|(>
<>S3+9W*KT7G;)P2'YBD1>5>E\>|;Q&9N'H? K0EA* MJ5OXT:C;@_X,%Q8E5/-
UN"O=>.FA"NP/|BOU.5;XAOEW"V? M_|&|FSX3 M3>"
N"JBE9,=\8US%J6O\$KP@7Z92)SLW4%#-Y3NG.^+|J|BM2-26NGY |)V
MRY(|YT%L^ ^M&*;HH0B,">:H\$SMT=^VN 116O'I! J>^&5<\$5@?
FT|H1E|41Z;:.)60YQ,K=[HWTWZVDSAI+6^M"9#|J=N;0VYY(;R;0L;
M9U1.|#E'!2PTTQ>2%B%A@M=LL@E:K9;8PY3+/TMOP'U36'Q_EKGLB*F#O&T6
M\$I,91%N|Q>=\$;.@CH>N^YZJ| R9TWMN@J.LPP(K/@BTL_*_(1X5O3QTM,^NV
M>6TOW_*SYB>M7Q6|Z/XI!3 M@P>L!8S%|U_X9U1.RCC,XR_840R-?
E%)&0_2'!8(\$MS^>GZV!&O2T0SP^LRI MHB,G
V*#/#R%G%=P\A1P%NUL|_/B!U(|OQ*'|G0|R>)X?.U4ZS\$6D/;_:F-9_M.E
<+|/M?|!_OICK1%T@9.!0|D6=HY02>6-F*_,?_!D)'V_*E4Z_@J/%B|C
M+V5_7J>U4_O/F.N3)QY\|RKN%VN+J|.X=_3' [7QJ|C|B/)!JGK@_\$GJ;_V-
M:|H9L93DY3K;C36TDVVIO^S8^)^N07+X)8ZP1^_8/H@VSUB&P9K|H|^|'^<>)
M?|8)>Y+BLN&\$OR,3?OJ|#08W"D|@?1M,WP3H|\$K*V<7FYD-8H?568<45^U@ M)W
0GR8OA0\$Q2((N|S"8JW| =J>7KG,<"|: A:8,-4Z|@4VWBI86E"
MS82WV8G!7;+EK|L%"4)-
MK(D9(1=01^N+SXF0)//:S(M9!KR2<('TO3UM*M|_PD7G'XPK6C-@X=;|5(YW
MW|FSF91-9?#^WVI5V+74PO"V8>L,,ST4&P&JO+D3_%848XZ*AP7\$+,8.HFCCK<9BQ5?
N9+.70J7Y\$.5#HZO&Q2OQ+R95GU@9L(|J*DW(X)W
MAR6^%"MLF#U2IBRTMAG|;%BQNCXFMS_593UFMA|=*6|;JRR&3Z, 4.Z|IF
MZ.P6\$M.L-PB6-|Z4V(7*1"JU<=J&CR|Q" Q|T|F|_|1NAW|RS8M9!%ZF&!H|
M6=JOUB<1C0\$J%-ZEN"&@4=|P&_-!|X4#ZJ R:|>=Y!L+/>SZ*V_/CM-?12;
M*Q#GY50#|GA_>@;K\$P-YI*<\$?|>,>,D&NX7FMPP>&L..@H(F8.O:&>/4RJ5C
M36Z7;S=M=<;X_96H>USJ9DYZXC";T+2V9J5^/ULF0:##WYK:6*G>*MPE/V
MJO&72Y<(?_OQ?"|I@%/48HJO1' &.YXL|C TPGT#&W,B0\$(61.T?!W_8DU?

M4+&VMQ)T/K,LZ Q=M'7:I4N6 3F+*"BM1R>GO4>JM\$/ZT<3'8&OMFAS@=A3
M124B6#3Z_8,415P,X',S;+YI1?6XL.M@Y_6NV=5"W<,KWDD/*8^W<#4*N5MA
MO,=Y^1A SASJ/KW#8+# M#/%VU5J-
P^C#\$;50"N@&JU*U1*E8+04F|,P&JJP.G8AFZ4%|.8[ZKL5HM30 M91=WUM7TE4N?X?
RMB8Q?BW":JDH!KPE8.YI?Q@#Z3Z\SRIZ)_OO9M/RV@GA7
M>!6#+*6@ZYAO@.+JE8@,@V4:)^LARCRIH3:VB(N/"! ?Q7->ZW+N:BJA4A:.*
M^93X|: ZA?^9EC!\$M(5#+7|.38!;,, % M&)G|O1UM%E7W%-
_75%KOE82,'QDW(L\$BVBL=Y&^ZIV#0=FCRE&#"TUWFTQ\$7 M97+LOE(BL7R4
_Q6^IN-!\$-Y|PI5EDJ0V8E,26N_I91)7"MGUWJ00\$0JZ/4F M9#EA\$O4P|5 8%{O3P)}-&.?
=7VI7LP>.MJ8/"4+"6HW<^JUE'1X&E>_3LFE,H_<0@(FTBMEH5 MG?2?
V3)6*Q!KF7=W'9^CW!4!MC4C+5V_U-US^2>_!5O UDD/N\$|'T1U=B1 MTU>_!N'U4^
D)) 80*W6!Q2;>QIS% 3FC;M|HJ2O MW:+=JJ"AY4|R|4WU)UO?3PA+XXIMA42|7
/P^\$13#-Z\$"BB1 =P4|SLC*A:98[X%5]"8 \$<*_R5:(1V">HMTNQ3HJ%O4X|C
M*X|2OZ@^LVSHJENM0D>_! ?>=T9%M2WK+I(H49"LT.0<)"@2
M&T2R""A1T!91R2*24S>(@ 2) H)*@^0DDDB6V2 Z"),DY2,ZAH=-KW/OLHV|O M>_?/>^>|
<<^08O18|JU9LVJ^FI6?:52%IF(OH520R8TJ3V#4N%/6@E=JRY M9A!N|>|.7
M0CD|*^"((:M7O%GW""7,%&R?'#C"LG>L/A(L'_A&S=:)MPO+4|1M6*"^| M=,#(X.Y,
|Y|IR>>Q.XDZ8_>FD# #NTO>JH')UMZ Z|-T"&1UB;2|@;D_ "1
MWBS69'3^A&)QZ?"J6|Z15?5NW\8 -F 8I#OPVT*9XT41QN3Z7&/3!E\$UP@:."
M:EX3LZ4.D^Q?WAU+N+#?7GWP.KMOKUC"E7UEA^IP @,M:-RC_D*^F.'OJ>S
M|V^"@AD_W:2,CR(;JM0CTW!1NR;%DJ(3|N-N) D"FF,=|#PN4A.8HX#Z-4EE@JS#E?
E?")?U1BC M#"K.(VT|V!(8L_C.?6/8.E_?159RS7Z|J'G MN4%V2YH86GHN^7SQP!!=L >
H7^,1N;:^%JEN=RGOM4H0:2|V=#\$2B_I+/@ M2&/C8ZYGC@FDJ'?K?
CB@C%J!1'UD%P(--MB:SWJ&>*,EP
MLV6=;.*#D0SDVR=Z'&|JUIELL1U6\GMW2&'EK!OYC0/J#_+^P S4W\IM/%>S)
M'MJ=@ACN0.>Q#BD;/X5'C2A US:XOQT6CTC50#?_?)H&C8)V|L\$ZD'|2^|P^
M*IHAG!!^LIYLU#)L+\$^55D/.Y|LY(SLW+,0=S=!2'ESU Z/?#VA_IS#TL:?? M6>J-#A:|
(J@?&5,):=FAM;>M>N=LD67SH!MT*R.LAEX|C'OM3=??2,..N%H)
MTU!"C^ONOD.+X9U;PU':#-(?NQR#Q0'8D>Z4O&&P|)IK+4TJ|O,7T-B|_)9
M*C^IZ=.;M"?E1>5*B2WLE3@@7C|YW='I/4DL.\$SUC^DZW4+_H%6JGS@|A;3
M>>RVC|_O|:7/U.U/?|.4VL%&=5Q(FL#Z?%&!E?TM"6+" R5YHJX 5+NI(MC
MU'VZ3T&4LTCWM'Q:.\$@>U%?N*%\$ 1JVAB<*A+\$CUJ.NV\$|WBP&>|/#7!"# Z0-M'EQ?
E!|:R_TM?.,+O?|F>4)D|/1P@^?>DO\$8|_B%|%' M
*6/S%M+*GCG3PX2_20I_1%E)XOHCN+2:0J%S_# R&%>%@R A(YF+| 09=
M0>ID7"R9&1<<5K*_K2Y)|"6C\$J7R#4M_,9MNV2\$K0%1Y%U.PVZ4 MJ92J*<5LIM.?
+,M;4(E5\$*Q(7E1L|E:);S\H8)/J9?9?%R3=@:K|V%:IC8 M#AK&L9:Z*_ (G1?OV1CB4
0<|K?AT\$&|=G>6O..#H'T|;G_#)'WV=%QF.
<U\$L65OXX05P+=|>"O+W>SK|;R2!)%^X0BB9B"J+O&XY+(AMRUT3YTW7H3R,
(FJ2RYB&S<9D?5E1PSS.'J"@Z-MD9"+2\$-K-%K|^|JXEZA8.
MH2(M;/PFO2(*8Z,SBJ|)8R)FSRL\$5QZ\$+3|92FCR35'*^_%G2&HD
M*JVK5GM;%6VX&.\$='@_6(G4:RXG)1&OFKD=>U9#Z\$#G.7^+_
F9.37C):J6|J4D|0>5>+WIR%IL9|";HS^L(D: MS_GC:=(.'&"XH4'JYM;UVZV5
=HAZZFLT/00I-L>|J7 M 0>
((N9W6/IN;*,|_+1%R!G*>V|KQ6|*Q)C>LGS.F'=,7|VN">B7IT#+/6Y< MCFQ@44V.I1:R
7ILRU4Q>Q @RU+T:TKACYS|@Y,2'D2O M,=^;&MK!SR9X%<6V2-
;S3XE_EA16_**.^@!JVIQK O-(KL4CZD\$H0KSDV8|IM M#6QEF^IX=QWK4=|.0-
Q@C0/L7_B=)'<,UAG&,KYJ#TEKNV8Q#|+*J?=K'|@Y^7T|C(L+6RM7.VM9LK|+O
M!U5TI=7@BW8_#H\$4 7R'42(>=JNRJE|K.:7+S'\$7XV\$,)NO;3Y+|')H M8=(*WNT)
(KGJCA79X8%1YM9^R",.'XP4\$12!\$>6FV9RPC|B4^%UPX|"O1'",TX.-
!;K331LC|DX7:C*@/:9SSQ;T%SW% M6PGD>(
U/HIWB2HBD%M)K*O0)TBAF8I@|.-085\$&H,9.J_<1B|UCHO
M6<7K2I1#&HLYW,3"H\$=#HD,|>8?&1|J|T(?;G,"T!>\$+Z|A|
M/_FP162KKPFR&8J|OC9|IV22NDAE4.8U#0?3)V?5KOW>4@JVS)X(&'A:7(M!;"DCO4?
BZD8@DETB?:=*7%;UGA?DF1H_ZA81H,1?CU&,*KfV(RVU8-OHL
M)2CUK|S^28|TR9GND8_6|5L*B,""<^+^=7V>X:R%I?DTM%3*)
|NY\$R;UMD(\$#,I0.TS(|6I9F MOA#JD9:ASX+JJG" \$^SE7^"-#)@*@/+ =R@Y*30,5CQ&
(LU0'A_K/D66,74+
M9XH#|QNJWP2OZ.L;:QGNL+X2^I!G:2OSD=L_ ^O7ZA06HSGHTY2,*@L*NMF0/--_Y

5^2L=^(4Y7Q! MNUQS>,93^G1;Z;N"0A?_L;^\$ BQ/.*TJA6R1)F:Y*LQYW=?
LR+N\$T%NAO M|J00A^|L#!010/6*91:0DH\4LLAB2WJ-L'EB9G@UGDOLS?Q:9|-2*C-K"
XP M:JPW#K?D8S|5/9RQ|8YA?%2\Z%7VT|3:/X33Q*6MC 0_EY:!/1JNQHCH?"<'M"3F-
(0*B8@'VA|Q3*J67>)ZXZ6J(%E;2%G@"W46MP3YB9TQ;C!RF?OPZ)|^
MAJ=8+1ZYV&"LG48BUTP+=)J>|!ZI@WW+TY%I09.D,!T*V3/>TL?"%,>6I>K
M=S(F&Y|BC()2G7UTNL'D@P5D4D\2KM\$Q! ?QK>"ZD=\$J9|D/)# FFA1EP#|
MY2CK22G2Q;VTHK:TC*((O:UZD7EXLQO5R,|P:88CD&DA+:!@#:(PJCL'RNCS
MH!R9*!4?-6Q^4|>1\940@R:|>=7;E!=TCS<^% ?0/LG^)G\GKW1U;1X'4.*M ME0*U14U-
Z*=3HN^8U"E.JFJL?S'@JX4J|+ZV^>K-D4SDYJ>J(@T:BV_M=753XKZ>_RA&;7A\$@|0-X
00S,-:#AU=;MDOKE;" +RY=P2R06(#JN/A#,D.Q??5E7E*0_EZ*18@C MN+IL?
XHJST)9MT@F|N8+C@H/#\$?N>3"QZ-++&)F#:&X|ZCDSPF?LH+L<9& ME)&9+MTC#?
J!2OTN'=Y|K%?/:#X\$;R2816+(,KOKDL.P=MMLP3T@"JRP*5H' M=7GXYMA(65+S?
8G#!_ (=U;9L:3\$MWG>|_1S10U*5-@<946|P M2/(V>@GH,JA<,XA(N-^;L1L_*5IE*^1Q-J
Y?%66D81_,&LR|E&93
M:Y;!2KOYN67K_A7GY,/MH>%_&;Q6EL\$E1Z\$!:\.02;DH>CH1'&Z.Y-!;!^ MR)F/
THKPA^@(FVH4?'X=|K8XB7C,SF-5=Y6% /=:FFN.*2UC4E12(TXZ;0K M?N7YT0)<<
6|=). #^X"ZP#Y#YY-A',1DTLO(3 M_#,_@X_W@AM@P|FL"<91U)
(&;T++'_N\$;ZKYPOV_98L^R0SS0U= BH'@HX|> MLBOPT|!^K* TXUI?
VQTS0J"+@<<|CK*F|FS,H0,>H-@IDLOE^=B!^>L;'2\|C+0+L"MH0W
M)5^#EY3^JR,C=OF V>TJ,RV,_(%GT<2W%E M9_(:|L%J8RD3.HH|@RM?PQW4JC+?\$
<=*4Z*B/DHLS?HK?(?79%|O%BO=_=)/\$T6J|5)DN6G"FO\X|TFZ2+275G|;
M!|"%;C+|Y^5B9*7DFA64PEN?0?R:@:~V60OS+S|HB:L&L5,>033Q^- M-F^WMKQ|*_#
,&.,+(#;NYUM7Z55+>|;N%0&P?(8A
M|M>6)STP_BO:./%:|45\$AEZ.T,G>T_J%EU*\$"U2:_02H,07.|>OR*R!\$MOSM^A;6X|!
M_>I6.6.'=GZT=RO(@%7B%=Z>U0|?E_3;JVR6LN;DWLR!2KO#9LZ:#VOYWAX+ MP
\$16@&|:0F?CRLXN+4F2|(^%O;Q#3G_L'_>A>L)0/9 3>@ ^;"Y29'SC97
M^/!LFT4>W7=X"#9^/|@0EUN\81R#0^:3..3XZ6|?R3U8-)KJ&FL|(-GKV-
M7@OUR:N8+%Q@O)1C%3-=T:|&Q9;?6 0.X1YP>/|L9BTZ@|%|ZVC|;!TC7=
M|TE8'W=PNGB".6(,68-F*J;81A?^=6C>_THQ-2T/3=K/>1 0A;:GJ8|H70G?
|ZP5.ANN+"SPGJGV;,'7-|4K,LUW1/M07L4&;?
(AMU|+|8^'B(15;LKK*9|J03\$>;^M*D=N^/I,YMK#.CM(ZP2K%=A M.6I_050A.H="^_
:M*^_LS+17P)O+E_P|Z*P71Z;258VN7' MROS7Y^8VN,ZY8,FD
+;|HYB+5C2;OU5GPN>GA?0W;Z/UX3|Y.1C9'C>#;4 MN*O+'10C;_<+|XS^5S|%'(!Y
ST+HEC*@B|T*HZ2J\$5;?+Z,S\$E0)1|JGC%F MYKKS| #33>>;UC1X'+.SMX0';"\$C+I>
4PV|2.G0\$|Q FCY|Y|%'#8B@-VK^XU MA"\$9D0ESW?GXCPYR<,!@ (FS)H?
M57A/X*MD)NI|B ?'1?P\$.3;+23D.0X(MWE-O="*MUT;K;EO5#A9#?>B %M<0|:.*1W%/?
#W9|_7*|A");T1G(YS-IL|JG M;|L!"P(90D |TQ/P>\$.< E-S;A>XKM-[ZGCZ204>;"
(('<'Y4YL1P1\$|ZKOU M01;RK08AW8G^AW,N%OT-)TT,0.DYBJ2IW-
Q?;U_"^HLT;:ON:*MF^TN3%D<059L3X2^CI,H?|ON|UET(@WM_\$XGAL
ML86)+Z5^O^CN54)X5J_R9.7BW?+K|&8LOC[X/6(F9*)VZ&3WRN=|Z |; (X
MX*G|HZ1QJ:~%XP90DK|KEB)R=3/Y81-^FS(F6W\3TUB:SVZFQFI
MU3T2W\$1T_6O!KL9+IMU6_*X|KZQ?+ #)BE8C*OZ|YYYDOUU^ WS;;DUOH4/RV M.?
KY:/L+N 06A"A'7Z_HDJ2*(Q|H|Z@?J!-L;C.GE-KM>"J.RJ*U7JW9LW
ML6X0|0+J|HXF_7|4R;|H>(|XH-L=#L.^6CUDV=3G*UDR#0%>.|%AIPC4:<5 MN|1Q-
<7Y>JG;QF\$A\$A1UY 6B^S5@X"?E= NWQ?OW??5 U94GW/WK/*^BGW"%
M'YY4A%=;D=:A(X2.VRM(|B5*=ZMBN#Q@AN^^Z|UFCZ /#|R)7%L<%)D
M;W"RSP2OUSU\XPN>@KT4;5E Z-K^1C_7PH&\$9'TVB0Y#V4;7M?G=!0Q7?4&
M@,1C32+_PUX06|(|5|R I#;1TQDT;_3L9<35Z_%M|3VAL5W9R1&\$E@J,P=NPBT98|'U8-
B;U_<.HLL;:O|'L+>_F9U M=3|JF&|7"0H<_2VA ^9X;M'X?._|L;|L'W)+-
CNGH>N.2>X^S.'F?%(H9# M7*N"VM)M08;4|?ZOWAU|N@C(-G|A(-*C?
CNVYP7!9N2:Z@R|PG9_A\$(\$52LK M)JM'?<(N_#235SJ'%ESSU=?4AY-M4\$3D<0;U%\P)-
E8|B|3WT&Z(9|'7*U8A M+/WHLL.F1L|P,R6GUH+|9*#U"FD93|J^Y_95W(\$@Z*;+
|VCA_3#;|>TPSK MTY6(|Y.=RGG8|JN!CMKB+1-|5B978
3;2XAM\$P>-3S0&LK5^T%|'|OPL^1.% M_1X.|
(>R*)/L.205QPF|_5\$6FZOS'3|W|MD0"C\$Y)C)A"1_KF8R MA^_
C.C|Q|RN!5&L M*|JWH7+.\$#|B,WJO|>>0ET,NP^FC-S%.:>U:M#E>A=A MXTE3#OA?
H#CD>."W;M6(#J"04'3%GU|LR=5,D8^>S|R4W\$XT|'%YI9N>ZM| M*B7)8?
@4*.8V|H?;+;8LU|PQ6'Y-LN8S|/H^_-^^ZJ?(P(9|RU>EOZC() *5

MG !SP>J^*=YW)13J_5X=/^7G!-A\$+6SK&!*FT#TPT"1I<\$4E?I;A_8I/V8
MMT%V1G%%9H_4'D)EEGG0SG90"5;<'KRC>N.HIIT&NTI*GXL,OC\$(Z>Q?7Q=C
MJ7>+A0A MNJ!R ("IF%HQ*RX/V/2Z-JP>C&,&CHL?GN" J7VV\$7A*.V\$X@9_@FL-3V=I.
M0L#I,SCCH*R\5>^Z)#Z8S@1I_2.(A2#,73BGB=1N2!D;QER9\$[I2J@9?.W8 M%
TK4BF*B=[XR@I(C(SH:A#)J(C:QV<@Z=DA5)@Y.-;#E8V+H2YT!#,0D(^) M0-
BTW;_9APK9A*-SMU/OD799M,I?/DEN M2INJ1S?.-MF="-2-I(>K8&Q4+;-C)?
#U<7YU4<4,1D M-
B_5XG)5.5^AL#2+JIT?"&%\$L#IUPZLCAI^ZQU9T"O>DK:>P5I_S9,M0*MQB<(!6*
JM8)8\$>V.)>B+JHO;N-Q ').PXQELE(?5J:X>C@@DMI,+^C^;>/
MO*QI5OY6/\$J&,JA<"98-54(&@)*@4U1IDN7G5TLI3!U%*5J=4C#6Y5AKNNK,!+BOH?
M,OKH MV"W1"NEG>WBC,JMX?VIHJC+VI*16RKIJ2*X<@(_OR5I?R9+V27?OI
MK&^CZ%WNYE/K?8Q2/B ^;=NH_M.)MXOWIZE%74Y8RXNCH;NWC\$*(LWA)E#I
M'"U\$.JM'-AS=STPXQ2-<,.OLFFB%OHJXE*)1_KYRLND,C);,E!\$>(&I/4(
M\$):FSM^5+13E65O?.MRWWU9RWV9L>XKJBD31>/*5QS\$(P1L;#N^ZE4-8PMX7
MJ%7'4 MJRN^VOJ_&Q@%),.V^11VZENDBXI"YL*Y6A)ZR8^AF8@YI#UI3#9R
MT8D6>QNOFY#MP^?N8,TJPY;NI\$3QQ&.W:<\$FL;1AQ=HA6?K@<"H,^(MYIY"
MG',NPED19=1_EL#8Z>A^?NS|"_5.TLB\$=L|UDP8U,>>OZ\D1M_1+&L2/B^I_M
RU%@I5TR:V_>EWQ%5Z;?1YY)I? HRFNMSIB|<;BY803?&._F_@#^E!\$9#|^B
MDZWP0N^87@?Z8YSIY5B_00FB0^9^ZGE1*JXE:G7HSA\Q>?#!Z8MP1,XIOH
M.D&>LNJE SQ_9@'K^I5H_=6/H\$?J#^U)%E
\$;>';.UT83N/0VKVCY;.D&S9(HIU/W\9=_.>KX9I?2M1=^Z#U,1HT^IFS&L(_SCD7O
M79HM_+WF&V//X8#J>0I61,JK7HB\$-EAIH9FUS|K?-BGU>_!I\$:#F*.C#2J-U MO)-T-?
SB'87S#"#4SSI#NAI^XJ_10QNDJD_MVRG4_8Y/%9D4;3?+GH>'%;N'='^VM/L@8L!'0M-
@BK*T21=2E W'\$ A71F M\F4IDDR"FOE1T0-SK-R_W&[US7>EI?
A=6K:0V>)64<\$)L"C(#B56\$<[HUE4V\3IAE/)) M#(9#TX^U+Q?-^:ICX)/NX1(!%08(IK7:
(=&=0X3*X<@3B@ZLAK3L_'|"G'?N/MU&H;=MA3J+MU1W2;\$*)G"P&(JH.>33 N*D:2T6Y-
WUYQN5%WLJ"JYX=1P5_MXQVNZ3SI^V;EYM\$;@H[XD\$)WMM/?N>4BJF/MW75
MRDOSHP&2)_8=_.%3AK0CX|=CJ/N+FHQ&3QX>[I\$=N&>I3:XJJ/B\?L^TE?R09
MM&U\$/N^14I)X|6(,4*>I@(.T&V!1.V#Y7|N3&'(%\|H?A96G&KSUPC6@TO-MXVR-
U,M2J7D9D|6D35.P-5L9O.R<< M#\$_^PWT!P;U1H*1)D(A0#CC9';K.=F'4,>?NMNAY(@V-
EU:9/O-N'Q??52Z? M>KFTOH^NHD,E" _UL&/8F_;U(IW% N+#ABY?
YPX7WN)#0+FDUW2)X^XV5UP;.: M=NYI!;Q
_MP: ^NJX|%G9R9&^WY&BO5B=\X7+'693\$XNX%YO*I,1L)Z>V---W M+8>0=C.#JRBG-
*DD1."LIRO1F|H7.G1(:U3BXSDP\$ _>4_7?>F3Y_5VD_Q_? M1@K\$?V/8^%\$P-
0^VUEBV_AIEL>B,D6Y/HKE|&OFGU\$8C)_77&ZF|M=(YK#_I@E-C..NZ!
(M|,31M|MM0AW?.M: ^=T2C9M7@2,9+TJ1N%#|_D24'E MKGH@#K
"DWOXY%=\$M^5V9B&I=)#C*H6C| MHJQO>2+9J&D3:XTXD'-.H^@M_R*| 8F>
D"8L.F0|J|#99|FDWI-9L8_=%_E\$
MA(VW\^;52TY/Q!4^FH*2P^533XCW5(009,I5;.,=Y%A!*;9,T?;GTB5OZ8^Z
ME)\$T'E6#G02I?0VW6ZDQXH* <+3F,U,267UA""!YN;(YC67R:2\':MFV_2^<<
MEQ>=V0_=4D=S81EBNGA'G7(_X)'1^;_3FJ.L_6V=2*2'OQV=F_AC_@U)UK: M36\$K>N\$7?
V2%;8>R#+/B@&?|P^@|F>OCSO:Q#1G+HB=NR-=#?8 M6E&G#?|DDT\AYHT")>.
4@0>_Y7|:%3=TZEBY:5A9GVZ<|=40P&KRZ;:>EEV M(5,!B>C_)?#WA\B_1S|@+,W+-
\$A8HO"(IJ-U\$-8=-@ZB&;2V3|^TL+LZF) M;_!3"W?"JSU1|@,X:AKL>K-
A,*\$|2|LWV.;3(\$E??>/%1F^31VG/R*,FQ
M6: + ^UP::PS8(72.IR#9*R(U7IK5PO2JYS*HDS73PFL9\JW3,(SDJP9CB8B+%
MO|DB: +P/P7&*@C1@M2-%L|B0C-RYHSTN@GJE6MPQ+C0A3S'INV^G0\3P:7? M0|<7?
EN3H8B3PHI<'WFOB|A|)X>|XJE|ARPI^C*48K>J>YL?@>HWJ8F0EZ M\$(:D\93\;Q3*)
M6";F_I=;X00_@2'YZ5P)7259+*&?@G\$#G\$3>=,9Z|^?*' M'9,
I\W2;I\YU9.)A=,6,G\$|D2HTX2NAF?3GD|.V:U?-7&<+FL|ZT3U438=NO M3
3%S:\$1C%C(2^O(MS47|"I:=, #,QPWDRQ-U.O>H%|6^4J*H,IV2UA=)%_
M_18K'KV+!\$)'6".UWH-EP=;==#C@D_);<'%(A=D2O|@+IXHNL/S:RINFNS)X M_
_IYW9*W<2AVC(AKI>2I_FOB+#J"QRVZ'_JSM+4OI7I(OE'&%6(Z'K)*KVR) M_#ZU=W"2
O9@|HQZ#O(#U?FV._A62/W;I_MG%Q+,[I\$PC+C4+I@)Y.:F\$1BJ
7HG@', \$O4F:UD|U>E|&_GX\$.M|5!2_3&!-3 MK|\$^|1@Y4GWWLE?
QTRF0>:/X,JQV@G,U!=XD)! =18-""LR|FH+|6T>B>RU
M.OO'TGF4AC7M|#+\$DE>+9/5Q4#Y>&&7EUF|+-UEY@P+XKQ
M#F\$S/;=G%1TFQS;|@'O+("XN*M3C|X2YBGZ8I%W(FAA#09_HC6OE23|I5%-*

M:2LAIL&HRF5)?=&P[NW!G?<11WR10QGY00K-?8UC!KXV>895D7?11"PH2KRO
M*Y;V&C1M+CS"KVDO.Z("I"PVXX?(>A1;1AN/WS(^IL"#_>E:TOA\$_M"H
MA3V7GCJG=KR<="M0!+!P>\$RVY(WGP,;C*O@\$LW0D_\$HBFJ0V1,GSYD*EI
M7:21%;U18^\$E:54"4:W(I\U*PP@
MUK0YXR8BY%D1.VY1J7(W%MC^GC!ANWAK95=AEYDU1:(2A-X=(+/09'W_WI-
@'5(R&!2\$ MF!GBC7K*B%=<1>807B:@WF129NSO7)E'JX5XG)K\$@U"@L0+J'MI_IDY_::
M21+;ETSALZ?K>1TYAC5!J=O&-5ZDS%-IH_L!BZ""PSM^!F<1"W!RF<,-8&
M\$I_<-2T9:90"UPG2
MB92Z&9"!FW*7MJJ12V1DV8I2;RC7ZXVM^#AH7F*CZ=>1QH=,JGS,H9Y)'0=
MO@D6X1BHW!H,5R3Q@'_B26?XIE=J'JV0(F&A+N/AMV,Y&R1GR@A_'6&SX^(%
MA7B8%%%;-N/RA673_E>O!P#WF3ZK"NQY'Y<-U>T
MZD61FO%X'F+6;QD""Q72&!Z*5);J)H1#QCY@78ZGK_Q1_+?.QHHDF::F7G.V
M=E004D_TFG@DLQ=,1MA1"=.E;JE:6 T3 80 3M>6*WCUMDI\XJDH>1X>)/XT M0LI
E2TTEH!_1<3WIN3^\$KPI6%(B.219YGN-E:'1+_<6M!7=ZH(V;6P@E
M6^15=XAW#1KHZ\$%7SS+,Y61W*G&F:=4K#3W5&M3^1-8H'.9NE(*.1JOYD2
MQ(7>^75;\$*U/#CLV1+;H5WV=8_*!;\$%G2H31J5.^K !HNSK/K5,16?6?30 W
M=@M._=:MTWX?"PP/C:B<@:P.O3100W/2J5G^T(F1D_IV\$/_0&1>-KG\$2./M
M0S&DM,!2ZDZ78.,O!-0S?F*#+V"98&3&%BTUG->SKD 2MZJ438+QEEND^T
MF.)"1K1!L^1%1AUKEKY\AZ?H<_U+;?21/K07U,O,Z8SMM;Q5M^-G>6PV*
M/N0HL(VU2SA@B60K"36E,0!M5P,1-X44U1^#XE,C)2>G#WY<^F@C3'AVFS
M;4L13%BDO2AH1+>L4XE8T&Q&=?SU1TC^4-X-5)>"13'0QL("FQ%<>1.1?1\$.
MG71MDBZYL#%BUZ2BL;GJ=>6>YTAIO8DSG).PN/5C1/#G;<;DW,1-QY/10^1W M-*.^+
<&BI*5ZVJ".6U%7T'S@^JD2UR@M?9I1L5A+L7^516.11&1@1Z*1:P2 M(V?E1M,T.-
"JLD2\$1F>KZJ_2\$5R/B1%U4M@5_9X^TX_0?VL1BS3XUW_D.W^ MUOC'8?
9+AI/A.JDF3PFB?T6VS_2\$M1?;\$Y.H,3A>9@4#(R7U(=:F811-
MW0"COLVC1EBJRE,7&63D1EP*1Q1XO;,Z,KD!F<="GF!Q%>@K/TUTM+ #KF8V
M^?.K)6IM'1QRN.PB1U1\$>;D1PU=%+=Y1F,K*\$*21,>)\$.!N08"SG%A75
MJZQ;7>&/N\$17-RUARSXU*VR/N>O>1(1HE1O-+G*",MZ1-44\$'^8^X
M9<*QDE0VSHHAZ.1A,<&:(ALFP0>1T_N-YL?#*!J4SC KZ7*8BT\$F1)1 M #?S@M7C
1:%C@;LR21U@JDN86>1+^>5=&H,?KZ_Z_F2&3)67;3P6=%P<&MP M?6V;-(VNUMO+?
E00@-.4!\$53;,*8UVC1&X/%JXO>1:SZ9#WOHJKM!Y,-2BQ#R"KW78.(;ZD<\$1\$Y8X@
@JA1R MR!965H4JHU9IOH (QG)L3ES+R!HWRWW-*"ZI"CI:216F/30^19U,1@NN903
MLDGO:0K)SYNJ">17*I(_;@=".\$=-.Q6Z_1E1JCJ_\$HI^>1,,2=UP?42G: MM7J*N%^-
>EOB\$3%O1M1WNRNZ;-=B>BY9N@.U+&^?#2#S 750QR7SH4"OQRCL;'1UNJ6 ?
P@!K6+T8VL M,O:#MM)11,Y-AA#+/K7LN2)\$T1=/?RVFQLV'^.;! NI#PIN:QC(K'@45S>1
M&B=#OYN--LVS?F GRY/PS.%FPXU T8)TP9L")_1#HSJB)RF(J!1V^KPI=@1 MP3>SY4'X
15&'6 P8SVJL1M1%8?QQ %H!?-U3)3@ <3?"U M^_BX<'1BT1_RPF#E%
^Q*YMY;R15B2QG82M=Y4RGL08@.YHHA?UM6118UE MH7%W?
X5/M'Z7R!&14/JZ).U7;R2^FF:ZQ:B1=,A5"G-M&C;&
^M/*9LP#*\$1#M@8RNI8P.XS1E(C#=#BH<4"*#AR#HGO1F/# J:\$ P*5 MIW# \$?
\$P#1@L4A=<__X016L+_)"&1XW1.YT%?'K=9X@4\$RG(B\$3
M@#41RROTXX%+9NI*C6&A%N1HMFAC1#;09D_5P!WC-%CWZ/SC@KU#::H%1K0@ M-
2D.^,;C<6\$RAB1'1Q1,1^>)EI<>XP;_(CTO1?+C/'*100Y,N*%(AR*9DQ ML, ES"-
_AK=K)%@+6IH1'0PDJOH91@=1;SD1C1W\$=P,V.UV1DHZ;V5%>O MQAJ;Z?
A0B>2Y;=,01@.^"1^>^ZQ;1S^NA^1_RH'1F1"6*S5-><,BP^44 MYV(19\$2:S1YE>U-
732&""\$M/&H #%L18X0!H")D)W?@?FS8HA^O'3IG- O&;P
MM)X'&.M_\$7:PJG1LC0+_7URV*J5#1+LYCA@JS>8JK;"=(2X05MHGHV\X=1=
M)O7"C;:HSZ-=+24..HK9&M7-G88ZH;::!?)%UUJ)\$-T1GIR^>6ZLOJ>1,>?5O M9Y0GP^??
KWMD5J)\$/*"1-4GW118#*L;5!..0%5NGC>+DP2VT':88EN@.PA,,3 MP8FVD.+X(J
+GGW3'&^116/8<^2?.\$2W'06X#_AVHU=9SKWI7AV)/E07UQ1P5Y+N "C1SAKL-ZRR
MX_+L6PQ\$XS%1J1UN(NO26S6;6XV)=+FHD17_"1+6J1X#?H/X
M'-1B9H/B552N&O@(F3%9H1)H_::Z>@%6\$M,M V/_:9.1+MG83OJ&M<8Q:1 M4?F^+
M#M@3*)'W_N-4D(PE,=\$NWTSSOB1+M^/Y4>Z'\$OF5L3NS*QR_-7) 4/3B'^J M@1VX61
<'?S?TBQ71);FZ="R+\$J7/Z4Y1_11.R6FA6@1!'S=)L/AJ?7
MWN,_DCF=V1H,G@8ZR5KYQ5(?+7YYA:CR29?(A?3V>G<1H 1=ME.1=B1YL7A
M@'^^EQO_\$#L->LIUIR-1^\$GZ:9_4_L<"?1Z&171CWE#?R4U""1N1(FX
MAMD(.Z:9KBVR9(CT0='DCP;A7_1^D M00L!41?(/1^UWJDG@+_O#;B1YBHZS_)JMAE
M;GG7R_*\$1J#YC4%(1/L-21)*?#61/

M/@5GP@00Q=\$<6NO:7VVQV)@4U@N1/1<4N\$J/Y!WX6K?)OJ M3L?
M!X3Q,@#X*=>2ZEP5WTI%M-5A4#"I.^J|O|LON*#VJ8|+Q9YTT;L>=\$3X M*|DBB|J'H-
VLUT,6#)=GUR_94;=,(6QR1.JOR>#WN 4.^%@-MPFIE_<-@+WX)VW?>2H=[?
64ZAEUY>4T2.UNQA'R0('T/.U542+I:/S.LN#.D MNCH("UN-4I
IYIAN6'#9!Q<'9;&#/'K74A|.|_|"7WXQ6J;|AT*"IY|R1J1 MB.*WT7|W@55MW6VO(H*?
=)YO1%
<7JJO8|SVA00&;8^'Z(H48'JWW>BS8821T<39R0UB\$0EVA)2%BJ(7.=,^Q3Q<):U2@6?
(R?K(K0I&W))7|I5T MP4Q%" B+(CL?'ZRI'L'B<*>X7|7H)R!IROW^B>G'R)O#7<94>X76
2|I4@6E? MYA;DX|B).M,R5L6N^3DF&|;3G8BGU3X??4_>4=457,I*>|_>+3\$ LP*=6!8H
MAGWWG%C=\$Q#=_Z1E3*2?R9,,7*C DW@\$T%DB'DA=>C9YRKW3&;.7.7<(<K2
MSM|W\$?3-XD&"8Q/LY2X6D>XT\$KR;EM=(/>1Z5K;0D*%;.O'IW;-!04_')*2 MR4\$|
#.J'E"&(|;-+^&U;EK+_9CS.'F,Q%AI!#9958;&;L(/ MH73.HMWK%I8/)O?O;_E,^IBJ8#\$_(-
PCW00\MS6@/TU8Z6=!VV5+TS!@_=(M QO:@68;PK TO5B_6'6"-*.E0FI@X*3-
7T(CO08(HM;)6T|/@43N1ALCL*!%;.M#1Z,#X)=P?
(*4F0*0X)WGN_;D42N7:AW|\$;&Z715R|&WA?--YVIT0@A\$A17 MWJU=OUS6C1T%H9*
_,\$7X!+1T U-=0=B30,.K^O |H/C_VB2S|E6WL^SL0!O MJS##-C*XC0IU;HMX2MI*
|+MR@.=C8;Z56U=Z7L|=DW>X"^94|>E!|;TU X|! M/UL4YB?
HJ8BO#|Z,@@F>LEUZMX@"JU8S|I W)X)+<#LV9G_VI9=QOBS6!@J| M:X-B&1!8ZQ
0:QPHB#C_WRFA^W\NHDC.T HQ1)U2(K|*O*1|K|H9?|*P2M M(?!, /|WZ D10C) 5H_@-
S.\$_A1:2G0?Q34L0HGI@+O^0>)*704MU_8_WTX M|^4@NG>W2!RE5D\$PS
KV+@JF\$E?B!ZT6M2*H?09&Q3.8/N,|0*53-EZFU0 MV)LWWM.^|2;_6P-
_6_4^./D>J'R)G\$;&SOV>X@?P>;1,DQ?2|+:H GQJ#RS:
ME8T2UDX:L0\$G=^|F|NJ^'_=8^?^(7^M6.L|N-;=KHHOR*2!'1Q |)!Z/O)KS9B!
|X!HUZ3G7B*|HJ4S ME^2^R)G(5U|&.=7=|3|_|# MA*_HNM 'Y/FJ'C.;3!-
M(ZB4=*B|V!Z7E|< MLP/WX"&4;|A(6M.;V)WF=7HHDV469UTH|4)HS')D4VZ?
BY7@|0F1K&W1K_ ^N MUO=_LB#TH_O")6E<=\$NKR|Z8F39-
;\$8=|SY(/;6*2+Z_1R%;V%H4T'_86 MC&A6*,^M-'\$J-NAY*/SC3)VS_7(-,^E9J?
A=.PV&25>RXA|JR3>S("C#/)L8 M4/+DPM4|?F_81|N^3_T3K_8@.8=?/0/W71D\$R367Q+;
<#Y/K>VM59O|C)_|M MQ/\$T>&*I7OY#^\$Q\$&.9-CF_!";
|JLY&96PU02]*=0K(:&=ZUD@%HUC*S*._^H
MWKX\$=\$_.;79H1W!>,07_WY1PZA5::^FB"54<(#RZ_)JXT4"\$-%2|1JDEEQ9, M'OPA^" *
|(|>O;==J|,AWU^O%*==3X^=RF4"%C@VIA:E/7|RD5|\$C##,\$S|0) MY&F)=M;.>?#W|?
U3C1,*HIO^HT?|+00=D^I_JC>H2:Y&EWE|Y+;5%;IC!P4 MZJ<^"%)UFN'H)B_XFE49?
| ^H\NCC956UMN.18#R%';V|=Q&-JJ8 M&"/H-W@&W/?4>YCIUT"OR7_L&/Z;
(+O.\$*,1E>-Y406V)A|_H.=5W'/X.|<MX=UW\$VU;_B-ARQ'0=K)1@87KBCB@U+)O
"&X\$#ZNOFY#OU|H|Q/9T,5|6LU_& MTDN^>MC1W3D)%+HL/VWSN|;#_XC_*X)
B|A8Z=CTR8P MQ31AWF_-#^UH;77DM_6".YB7I_|ZZ7!;W4.%;?SG(ZI)-Z%ASZ!ERWH%
M.\$#TVS8L|;#9+EZ6UB.)_,#1*&\$8-N:E/PR M^|Q"|IG%W'#@!;#F1T7B)? XC^>>3H#G?
*|Y39U^BOD_+PX7^./@)=AI M_9|9,X<4+KY?^?KXI@Y:17!|(/@RF*UN(/"F;;JGU^ZV%?
3,&6%6DZ_!H.N M R#.Y2KSD0L=(^:\$A=4//E2L;A4O5/;6H MP2QMFGU!_'@A#D@|7+|!
(;LS^"FOP9TJKZ|UGYX|/*#)*ZP5V9(9|OJ;^0'7 M"?B)0(:#|J4FG0DQ^4HNS(>1/5Y?)7-
88&M|%(O22!L82Q+U6*-H# MR<.6RB+(D
0N^RAH+K3/:U+Z|X|@F6YHP<;AL:HP6*SVAG\$MHF!X;M99W= 7 M;@(54>\$Y
M2S7N*AB%E2>U;*|=H! H>%,WHWV'-!>DHT#7\$5P0!4*KW<|YH4EKQ,OO|O M|
DU,"P|QKQD8H|2| M H8.B+X,&LKV9F5NK6'5.VM&VPC(;F+WE_#9LPH7:5'M/*|4R^Y
M'N4LU)H8/M<-|WDIP2OR0XI&Y;9..NK;XC2W.+-.GG|1A\$FF02'G3E+,8|
MY*+9F)|J1+K2)0&(+D.7RVUZ#976MT^W7L_52*|BBZ|.J2>9
MVOD)RSX|,SZ=M1UPOQL^PE7T".G00.5UP&I0%!?5M=YDA/ALE/?(8*@_C12&
M|B9MSH=&Y|D/CMY9QT:0|4H#VO;V%X<;I@WWYN2CMI)' +X)Q=L6"TR/WI MUIH
Y+NB>C@KI:5(6_JK|6A+I;.-GG+W5U%)B,?AIT-H1L:|0F';RZXLNG|
M>VC\$ _R|QC'LY|\$"@=))&XKM;E8/R@METO%*/",1QBE1U!"U7865SX67L6CI MY6H<
G92WQ@O5F@|VY#<_6H!4NP\$|=4\$Q_#|!Z#>#P-03H?8A#.^9|_|7
M+|\$|>4JK*RL>W(1"6;+.?T3!-WC M"OW(CB M,=H/CDCUD>&@WFJNT,@1'2|
|_.89;WK^QJ>=N\$ O++@=C%9K%<,UC^,AUZ\$ M#O CMI%%PZ5:NH*5K 6/
0FTH5C\$BSHM!#WV6/OK*F.YEO'|&>PZ +/V5Y| M5\$ _CXD#\$|D*M)<_1&4RF:/4@:(-
Z*^LSV|K&%6|9""\$@A^>KLNP8YQ(XCEJ M33M, M^"V|@NEJFEC;S&ZL/F|HLC"|5*
<("9Z|F6M'4<|S72M*I_=C_AVR'K MHXISM CYT63M&Z%5G:3A=J9WYLR3;-H

!;"R L;9UQ!X6?JC)K'+7=M3EGN?1PA73'O;=)!"XBUH",?1RB?7+F=
M!M4WP@&2W:Y@)MNJ2G/Y39541SP5J'E\$PX@ MYRP==)'CW M=@E&
!U9U_@,0G@V2M%4'?; M%%ZVPIAV M.Y/D@==?MWWBQU94!
<;"D9IE!\$WFHU&137OK@%Z,J<@JHA|EM<+9,F3IE|<7U_UM^A;./:-RSL
IV#U2:^W7&U)0>%%I=N_ =V'Y\FN:/&58XM:%+7IOB6|%O)-3M31Y9NJV8^BK(EO-W?X
BLV)|OPRKMO8KZO7RJN7X6| MC_C,HJ+M-+O,2GHITJ!G2:)Q1|=!LM.O^"AY,
fW#:2X3Z%5*Y")NMV|_H!\$ MK27EGY-Q3OHXR>K5;D*;UOU;+(^E?
E9QIS67N|HOG9W|KV_!7OB*27W+M&TW:IV<"PI_\$_'B
MO|}#6_V7LA4.W'|>K_DL_|&>Y1RE:}E6Q M&2U'%=N0MX\$^U_VGG*E1K>Q:|J3N=U
M'?^Q^"?_ ^U9\$55%+_ -|> /ZTKL6+M\$RV^T=4KB|GGU-RLGM|R+V,A|F/_Y
MYCSGGTV_+|X-?L2U|=)2B|_G,W_D|_I_R'K|+S+6->W.Z%|A|2'S*_|9/RD_
MWI'Y=U703Y.0_PRMYPBN8CY|=9_U1_ =M|U>3W|OO!?'9"U_ \ZZ/RO%BA|LOZG
M4L8_WMC_#*>|5S3|9TB-_5H_E7U>_:/P5^M\$V_N=1^=O_/6=_^,|_ID'_|
M;LYOI<8_KZX)_EU9>^+)?('3_V(OQ9O|9W!>MNE'_.*HA%TF1^IK^ ^S?SYNZ_MZ=#!O-
M_ ^/66E7;-FYC%?3+|^|RITH3E_-NV^ J('WP'YIJ=L4Q0|'E8^N
M|fP;';5YRM|(I3UARS6212*P; '\$9%1IQ0F)8CT,:I083Q?S_)@!02P,\$% M @
48L6HDGAL2RZ@\$ U0X" !\$!L;63Q4 M<=PV//:=R+X-
\$4K28BO+I+*ETJZ(4102DF2\$.9:0=2Q%4::BA#3V/6-?*XFL M,3.&9)G,B.DP,V>>TWW?
|_./?|R?^WG>|ST^O_F,F;_U^M|7>2\$=M. MV#K8(GAX>|_X!|\$=PIQ#,'+|V_|H|K|;^/G^_
M0H*"PF+ "(J+_-OB=N)BH^+|?_IWD/P_E%>#C\$Q_5\$A02_7^|<5L1TL*)(*|
M"!|!*|T#Y|T#|<3@40@>_3^PSP>Q'|M/+Q|_ "*"0K_98O_- =M@|_GX8*,%
M8(OA;R/A|Q^T@(RFONM!; >?02:T(TCV0'3&*V&MHQ5M&Z-H'K|^-\$1&5
M5U!44MZHZNW:|>1L8FIV: '#QX|_V-K9.YPX?^'B)>?+5UP|06|<|/:QO15|
M+ ^1^*";L0>S#N/B\$1XE)F5F/GV3G/'V6^|J@|_W;HG?%)955U36U=?4-C>T=
MG5W=/_U|_ =^&1|Z/CHU/3%)FJ7/S/Q=^+2XQUOZL;S#_@IM;_SB0?#Q_%_; M_Z-?TK!?
O/IR((3/+Q|>T'|2/;+.:X7E+\$^*W0M;N. |'"LD7NWYW2%1>VXBRD_ '/M?
_PI/_L9C_3Y|I3|?^EU^3"\$^'CAY?-((%((# MOD|20|P=>_&L'&2F|_%%Q7>C^+(1PA
VC:E:|@.FFT'XY&3|*|_SG7;* MJU|Q9:(#8!RSY@@,YX,AC;Y3RC,J| = ME2ML8G1_E*:MC?
KBXB_:S|VG\$ W36N^2!_L;G3J1/_M M55Y>5E9_)
<','T./)/G\.&QJH7Z\$3'^@+,K297:);2@5ZW?E%*XSX|]="N>+G;EVBG|PT^+AT4_|1Y?
L|E|R"8F/_H^X*U7A;ZFGK04Y"
ML(_|WCSD(LCOT/2SI/%PYDP576IED6771P&\$E_*WU317?:/0H6?W;+HWY;T-
M@OVUG|H#NA1Y4&+ _^(BZ&@<:&":8FP?L>LE=NQPS0;SE4;;Z)>>M@<'3QVI
MXSFS,XW68^&9NY4#26|26YX48;_A1=EG?6|A!5CCM+V%OX1^5'Q(^JIFJ" I
M^H^_A(M#A=X)0|_YR+.;EN\$>|<#| O J!_3KL3J|>X|IV<7*AOWGN
M;C2|OAD0H3F|,^|2| QCV^/4PEX#E8SR> /;%;+;0|A4.%9Y/V><_LJ|C 3 M1P|E?J9?
Q8HS|A: B|R>ZE)V#?BF0XI&YJJNUEV?/^B'R\$4JFVX?#%UNO85 M?
VAMJ(C103W,7&J?K\$2OW0;_SW"K+?;4 U*TL_91;"4|UB8YSWZ5;MI+|O=
M=C_UM_3@W*")@:MRT#"^2KZ*=3CB+\$-XQ)@4+V,MGV.1|_/7Z)GU6DIJG=_M
M\$S\$;GJO1O=UZLG6H<|65:Q|WM<| =C%||@OM)8,YS\$3&30)LGX(V;IU-;,%
M)H%\$7V^S4=34\$U_.WV|2TU(^!UYC)OA9-ZQ,/ %6YGOB|?X|U?^:I!W5L:6| (M=
#N\$7M.+9|.E|(5&(S-H18RG1'P;ST\$=/9&SU\$|>G!F6%>7VA|= _5C3,R
MSC|HU|K3|21\$Y2) PV-|+ 'WP0GN-6AFS;S,B:Y,I'.7O;QL:Z|,E M,J6RC9"=*YB+2MJY-
/R'H67T%X"M9L"Z|0|/M#>_UZ16N=;ZNC\$CDBK,5IN M1)2=VDQQL_@/(Y(^?
K^|DN;%/;+Q?VSWQVOJGW_/:2"2EU&3!WM'F=I' KNS2T^+-R|J=2\9)K#XD#:XU|445-
\$<2=;!-IYV*\$F3K\$% MRJ2A,,(+7)R5V/V3_L.X.R\$4J(A/1-|+;TT93GNZ_9'1'<|_Z&BQ
PN#091-D8^&(7/*IM_/AH6T70A|P_6T^J:Z*0X+:-
M9X.C#WJWYZO1|Z<*QE'P94V"FG1>V.\$M33IZ >2S@SY^!
M=D#|RWZOP2IF*CA,N>@:;=ELM>_|X42?YB\$N(N=%VY^T"YG"0BG.WXGE7_1;
M=1DV?|MP1#"%"BWA(5%B7\$F>?)|@^ ^6C=,"ZS1V9|1&V-|@14C M@96#O|+H
23;>;H3).I\$(2E!O6CA01;'Z+E3W2ZGJP+?F31XJRS>*1NYZ|17 M6&FG)|WS4;Y9F*M.
MNE>|^:XP<#+|,PNKZ|>,^U(" <#2!C M@&%;
|*6&%H_ ^PSB3H|+JA7H(1H|JXCU6"0>:;|4-B:L.0RN'-EGR)(=2F:"P,
M5Y)PV^6L8B=R.J'YZ>U<1'KIECT8S!+ "=J-%_@-"4/&DRK'H|?#D^LY0&1=, M
&GORSF^)|;:8_"ASA'&8#B9BQCW;G^ B|/(@>;WH+(/9TO9=G|ZKJ\$J8F"_
M/F,/P|\$G(O@H%(X=%V&7%PYG-2"!B^B|4 !)*L'%T9MO1WL2^>_31/C3BPS7 M!7|
C:YP;D/%-B:L^-/3F"|HO\$W

LGO#)/AWPW_M>I:JC ?-PB\$Q>3-4;>0")-VHRT5H.H>QU(VWVW3 ZA&T;{3#2EU7?
A)+@+=M\ C4\$E:*N4CFR/J5FU=UN/N"[88YY&Q]8:2V=;6H8_=@ MS0*KFWI=BRP[-
C25@+ M3#+3BO.R1<VTG.2O5);3(ETL,R={UH9'3MCN.IQZ<73AQCH-M_?]* ^0B\J
M#:D8<8-ES?9@Z'8/(J?#)GL2-(VQ-;>=YTMO'Y_IZSKK1@Y:UV\$: W+DNW/
M&%R99A1U(-6LU&Z=9I3-;.*\@O^=*<5\U\@%KWB\IE4>96N-5>KDW%
V';)DE*X^(YN;::?'P_\$ M[GL[D*6"!W! ?7AV\SEE,&)&KD;3KQ GPIF%8#3+ZA:R-
KY("X/JJMT^]\@U M&+UN-O-S9M5V+! ^]\\$[:H3WC_N-L:>*Y09HUUUV ?
M4\C\$8DEQ)5Y&=U4NJ2 MOH_=I>[VOZ;!\\$284P49\\$W-U' 3UB&D\FFK2;B#Y-
WCE\3L00,UZ6MC+KYO- MV\!D2W35UG(N(CP89P] #-!?!D',^!Y=:'IS+&Y"R0^ L3AH:
12KQU_6GU>= M_-S5DS[X/\$[_L"*),J// \$14.75>XGCV410G\$BY@M4#?>FL\MR3N0I);*"
M6\G\NZ\X!U;/OTF-YE=7E/Z.86W1\|>;::@A)PET7\YJMWY3.MF7@\$[-\7\SV MW\=UNB-
C)GWBVWGM=F:VES25\HP\9-;JH8XZCO*!\^A5^8-D!\J27;:'&Y/
MI0^BZ\ZH3"V.!"A\64@_9';*\$FJT\>1S\1P;G!\@))H,DPTY!3?&^7\6K4
MUG&46(1;8.#=T2H?DV4.'CBHM\ _L\$ _^=DHY5VXM1H^LYB" _&4 M8.'\<@K;:W?AY!
<5S=BUC&YU4VXDW8#6*C.%!_X_B3F J &B2T?VX.J0'>=
M,F7Z@].SSPQ;MH,YYRZ'HAWVI%*F\$E5X,2;Z>(.G; 95R#Q>&&[?SY="[]?=
MSYB>_)HMT/?3MO_B<>#;9\$2_%EG#K0\4R.=:XB_M_>XL;ADFK/<1-
AR7\$WD+SW3&321;=>#.MQ+FA)@T3ED\$FG4;&FLQX;R+<.*=
M^()U';^LS54C_NTOW;4OV2F M\$-CJ\$C@.089+CP1,??C+!./\$K
/@R9!+C0S0\OJZ@S9;_XR30/=9?QS4JN=
MYPVB3/4ENUMHO1N\$>1(D0>6T)*R<9V\$6L=*,_\$(ZJ#L;;D-9W0; :H(D;WJ9 M&O?
LX>W@M1Z+U/C= L"9,ZKI3L/+1^QSD_1>IO\3-/ [H4A3,D),6%\$(O0!X
MN)3)0LT,C9.=U\'-ESC5&
M76HSBOZW;;LNC7T14/OP\7B'_22PD&SBTF*Z4T5>XX@=F=F'B',23'7.>|C
M0E@1V/&9?9S7%HZRGTT30\XF6W_+=CJXW(>%_PK^<_VRY@\$10.!+ MJ5*/
V7MXYIO^H4BOJ;PG9D'8%9POFZ81S;T+*D^O;7+IWB^ZFRF#N',)Z& M>FYG?Y4.?V\
[Z#E_3L\Y M.L+VR%69\V,+=FRU;:9_LNNJ!\$3"\G_#7HGQ<3=>8_QM,*GCCS2U==)F?
T2\ M?/?Z4R9Y8E\IMS*Z2RV45G; &R25X?'WP M\$&GJ*(9L957BE^U7L6 MRE
;R@LWZ=1*JBE:H5%0DV(4YNNL14CGVXZ&W27.07B?/X B&JO"%\$.6V3BT@H9
OU<&0_MP^+5-HG%@J0\$N8C,>7H@U&4)B\ID3V2T(&)\$LJJ'!W7:MP5S\$Q8,GN8BAU\'
MMA;4=N%T%))LG\AZY'_0V++%C!705\6#_1)71-LHQK*7#GV7LW*)T+WS0_[MT*7#T
K?,\L3B@K0!) MSP,ZKD<<5W9ZP8'IA_%>LH:L<8F50,%OU?
Q&^,|+>'.\X9)S8\OP>'.K804 MBV\WA\&W^?\$PR:B3VV<3-/9\WJ\G7L0(UEFU?
DN#IMWUL'B7J5*357A'@^1FZ)1/+9ML_"?7>/YFV7.QN*U^H*DG> MPT%;+U?
IL2\$!\H&X3BR^Q6;!2=F"1\&N,H#\DE1%9.J\QROKK":F"19F1O)X
M7""53*E\55SOE&*F+VC&"X9Z1&^G9T\$B6O U)\$9@\$;H%:B5P/5D% R4^A^.?
MF23/ENU5XJUF'K2X*W^5T7)(\UZV/S\$G* QYSPTR\$542\4\30933#(8>')= MBD\$(4=-/
Q645R9(ES.XP?F<&A8IN3PC,_K\XM\LY(X%IY\$|WCX?
MRO86\.^33;IS\7%*C\$0D'!K^1MCR)NQ76.W#A82T@QA8G@YGV^\$0,WJA*0:
MLL0.BY=:.#/\$7ZK^YI.HYN014'%&O8^R5GK=S,>4@H\AP9(|#/\$>/D62U":
MVA06V#*P?=E=J2E\)_3DX*Y\8KGR"=/QA\ (P/F=|KKDB+FNWTT0F3/'A'
M7@+;)DEKU\#2<"9BI:"L 71)R.85F!\S\ 7UQH!W4+X\|:>?1W9!\$=9 M
HZ4W2\NHF\U(0'PYJ=3PG"!.\$+2KC@IS,TUG\|&RIUM7H\5JZR81TY_8RO7
MOP!6V/T1>@QB:V!2RP\0D*%ODW.:(12WD;C^V:7_HD:/T=XSG M4S03Q0NET
M:|*R)R12P-)RQ78"%<[1@#>CR/58\6+C"<=9W;H+G'DVWJ+K&4+RF%I3PY>A
M/M4Q*IJM=IXE8-H^.*GBR*F+D"J2&V(#RN/@:S/_+^/&E\7:/UV.(+;\$7?!O M-
7^E:T",VA&.9"M\L\ 2?D<8"NSMK%GY!M%IWU*!=!K)M8W/'9\X#G)(OOH'-M9W'/Y>[>-
TI0.9/+>;|=DYP+&1\$|G29-.Y&52-H\,FK2M2.;\$(R*93L\$OCMU M0VWP"7/\@SGC^5-
@ET9UQA;C\HU-\$C90\$X", MK\E6V@L3:ZL+%0D(VZLU"H,W-2L<;PBRB
MMP)C/C9!\$SHIPZZ>!5*@W_Q47412YH\ID)DC099%L.S\Y\$+;3E!&-
!#P'P5M(R#6P9Y!_D8N0L1(&>RA065%? MBA'#/I,>7TM;M6^L\39 'C14P;P.#TS%2WJ-
#/C45OH>?FP2KB 6HI>OFV4V MW7\,L?N.R8*2=OI=5*!U\^<;F*:N1J\$8"J\UW,&Z/#?
B\730YX\$:ZZO!-K^#H MIYY?/&5GHAP(WCPL#YSO@ZFHM>7T1,Y;59\|X>
|2'+&4CMFQ0X5IEVN5HQ? MKMM3P..5U1M5<."9O\$-009:H"\$H&
(+|%U1H^XB("N8@IURY S6(@\7W@!K(< MI61B7(HQ)G>-(" MY3%?
S)+EZQTFW4J;GGG,1JM)VMYN#\F\VD#Y'P/D3_MUPK.T%A9EVSM:-;: MK>JPTF#
(@65(P^_1P|M(?SZ90=Q*!\^|8XCGTMMYA)\::MK+OU;J\0<\$75\,P+6*^_^M\UZL^!
<70CX&GOYJY%<6\Q@;^!O M,!F>^*P^S5A)&^*-0NT%R+_P4Y-.4?

C*:=P*GOSQZ.4(:!^JE0.IG_B3+8N MG+3HM.0B,%/.Y:T>P;GLCW#51@#7DP5JLM3_F6?
G?@!GMX2+D(,!:NX#VY5T\$*W&,RFO//&WC1IKC,PN3L5&_M^R^WJQOZ^(\$MY-
_PQ50UQ\$AN#G#/^,SIO.83!>= *J\$D@%O M)Y5-'5*GRX4,EQ\Q:??<>!J5HE842?
H"t@"X9X\$C %G!\$YAUB8N@ M/C:-!A5+U"U6!3P7Y(I?I#Z'9ZF&+!\$RC'0G6BA%DU?
F(!@+R&A6@+'^0W2OKWIDQ#*P60=6RMWN':/9D(Q3N M=
>E24Z(+J#V:WBH8NTC@D !UA7PJ#DN"9[INAT\$Q38FJMO_1^V&I%
MU<#LJJG793>T&1>!&U*33CWPH\$32E"C(25/*FS_'2C#.EY-HGE?I&Q^:KI:1
MM'X/*OD, GB->\$14;O!HX/'YIZO\$-K@9;#L?,FGM*@1/NO&B M=|BN;\$%'%LFL,-
*G8%CR|:1<7%LUU>7EW(#7C\$43L>SG\$;|SV\$"M'R/^\$RK MRMW0>J<1;_UJ
ZJ#I_15+&ELZ|2;_?"TA;9:4WGZD|9FUT->IA(3CSP?;HF" MYXD?..?5\$7_Q4SJPHVY93B-
6^NIOSIENKHNKB6MGM,1|^&QEV<>8;|^VLL9>\$
MI8)N%/TD;GO[C|H20R'>&#VAT+J_8S990O:|3A7|D_P?.?VHH3Z9TJ,=|WSZ
MT|.^^&W&P @\$9|'-LD4':#/E(GQ?N)+Q*9TYDQ9I8U;:&0H3_78EE|>OF0WR
MC&EZG4U75)4QR91YQB2PMQV#A'W)I"G=\$T-73#+W%0)G\Z48N
2+,\$H9JMM=^CMYQ.CCN6_F959; MHT>&/HN|_ *P*TFWX=%R@25IUF8X7+:/@?
DJ6",NHMPJCMX|3=,) ^C-^W_ M/D*M/"4!BQ??A.'8JJ\!ZNW_;I_N-
'_MC)SHNMPRE<'NBE;C@ 'A:X/B>Y| M|<8^3G?|2(C#ZKF.-U|VNT|_1-
M0,BWEN5|B=3NU7QNYC_1EA0?|98P6R9*\$ MON'+!SL=
(#4(YJ42A&K?;&|'-9NLD#+V+7LI)=(G'K8J2C|X5*(LG)DF0P'7
M.YF\$_9Q2E"*K=:A0S|N_:TDT|P|RLWWSP&Y|5-|,=>?!*>' M4<)7TL_VH";VTZVZUE-05?
I=C8ADP&^YK!WF%#W82^2 "VER7&O|=RUH72J M@'T;X5<3)%P&X|X>8@3>5;:/
|H|54>K M"H0@W9I Y89G29/SFC?>-A296_J*GT<|3!|#&6|L:4VO>6+P&P@&N)B^#
MY6')R=I#"\$-%_2@JCX=?O*QY56Q|UNJ37V&15<;4^NG3<98MEOSO<^";4#
M2;_2#/3Z4?|'4C6:T"%K>@|; M|&Z/^:6*/-V;|(?O\$9JS:L?::T@,%U\$-E|6*H3*;R(-
:=_9(>Z!%05M847_>B>N'+M M"5|!GJA|N27PU|O_@8
/:@6H/S&;|_/15C<(W).V|PG8\$=2@'Z|B" NPN0?
MG9#AE@QW&.F\$5)#@5%'G)^3FM3=PW;6(.HF@D0<.Q*RFP9HO5Q>>,"3|E|7(
MH5.R9ZTU+QJK3)TR^>)_%J)5_3TU7DV)?I.T\$&WG.^CZV?,*HW!H'9P\$55V
M*T\$,+:I=XEZM-#6%=M/4_.USEQOS\$@NBA57)_;V2A|7S1WC8#|GN'VM&L:8
MUU#_C4RE9AL,H|D@ (UDITWIY6%#P3'|68S?CN;LQ)L|BBD;;FZ%|H_*+RT1"?
MU^|3D.>ZXMZ. &HYK0VMJV/W<)(^=?D:8X\$%-17EM>')|_R;MDH|IYWS(*
MD;5.F"N"1*FL.TNP@!RC?9PEIB07_T ET/;>SJ&H"KN7S_N;|=1Y5WX5YJ MWP#JH?
4M!1X2(5)J>!D QZ<8Q23V'<"#+M.VJ15?D5?K;V_K?)L4"R^;2U- M>"?|P=B?(I8%|
(FD#MQ:576@#S+#P!LEF*JK"4Z96_|F#G4|+-_19=JCU6
M../PNV,T"A>|M1N>%|)%KT@QYE%.|H7H0@2KU0F=!)E=\$|=WSJD<|'|((DG M4\$7%?
S3,HV1Q!&TVD.O-6.8X+F(Z\$3(F/U:ERWM"8E^D;Z(B2HE43_M2E@ MT\$?:
^1D@'XIM9Z+B#=#GK\$*|N!7AZTLN!0N0+TN4EVXB=4.4@T7T>&VHYUU
ME6Z|.LYV#04,4GI1G9BFE1\$5^.+Z|^C6/:JOZLZ?LR/GQ\$8@SKWYEZ/|ZP
M0/H*G"i3N;=X|K|7VPBR@6^N6SUOPY MBF++=#"IRCE- (RE?-BO0TY(YHO?
^;OQ44JY\$(8@#R*FF)2R3B:6BG4U6(^:D|?L2O\$Z5\$"C=O;|3G**KMTWUX MV|(!U"
|XFC|U,2TF/7E#D:#&2B\$2#FHY"O,|9*K:D8 MIGG5?VQ|500^|.OLF|KEB.WH?
F>V?"ES08%#Y"("T-LBC@^%..>UN\|@GV@8 M>VWFA)C9TY|>9C^OB-
F?/AC#HZW7*FC'EN8BF#M&4(&&4_AVM\$C |0FV>9&;
MA&=7EB2O+_UPE4ZX@G|)%&GC=|@148|3R|_|.?+OLFG27N)_J_A+R|N@H(;+^
M6@\$D<9:3M@>2A?JV>FAN99VD*;1T")_C>?1ZOB 'FAUR4TQY%5QYZ6MU|MZ MU4?
D-\$<|U01@|4X!Z&<)\$P?;B;4|*V'4P E6E|+?U;X27QG'UXV1K,BCFC|= M>_.IK=1Z;74)0
/:3?|).W+UE).JSRC+/?)%(DNM:|(> MUD+I-H#_N70X?;=@N;!
G!#L889QFJA@'|51CS(\$Z2|Z%3NH>LR:_OK,">4V1@P6R|AR%"V::CCNRBRC%|)%TR?
79OD:NT|EQI<#_Y^>Q7@RO M-%--,ZO7Q ^KL2CY9DW&
_5^+,.O|?!CYURG1T:|@;=_QAQ9NOA5K4%(Z7QZ M9!>/%D,(DA)".2*M_L>PXAZ;JP53;
<#-D_8M0*L7;G>4*HM-D\$-VW": M)%\$&8W)'C7_|*N5VOG>GV9"NNVU:DVV_N2R-V
6&L8^T0S:L.Y%|_1SBL;M M0DQPU&D3#.UM>DD?:T-1VULM4DV|ZH*+D\$YXC")_0-)/&?
+|+-:>B|CIN(IP MLY\$K2E|'S#73|I?_|K43V|8\$S.UGI?00VL9|OQ|JR?J_-M?;A^Z*=)OK;
|V|^DJH5XU&PUG99-4O:MK2A)=3Z=ZJ|P>QL=4AY>?T? MQ&:AZ^6Y/?
6Z|YW)8T*9C_F0!+&\$%;%ZC9@8G|+S.9*3VP2(+&|LE|03\$UB MJMFWOOL9G!8;
\$"'EF#=>F'_|Z9PXI:*64%NQ22TJ_8Q.)T:P"%-Z|"M M?FO::%6\$3?^QC)+,|?
|*|VE%2G|U7D"5>B=08
MJCQT/^8&IZ+9AJ7_JX5'V:"LH250"\$SR/X|9*XBY6|*NDRIN0U'W.>>@-&D; M1JAN06%

{5!PNFXW?ENSU="5Z] H/\$"M^1RK"O4PX[I 245!YI>9NM\$ZC. M%&(G096MR?
B2PS"D%"42C-S";9L=7YB>*Z_?/R">%)QNO?HUMDU)*#:)IS\$T
M'MU;8+QI"*=S#BZX?)0W.LF*JQN;C^7K;OHPPM;/6J8TEUZ'FIA\G!>CY,S_M-%'@-
KC77WC#WNKKN=7N?EE 2=*CE M0 2J'CS%\PDB0?,_U\$Y,K;W'A=Q\&I=TQU/TDWI|>
<0&,OE+3\$X+9E 6Q^L MY5?;|_YJMOTBUZQ&<-7KPZOU|
M(I".VH<_J>UWC7^P^XCV,|H*;;#/8JWA9OL|RR LX: ^NS*'; WXA9)P6J_ MPSP::(=9DC
MINHVZJ8"R4=;?/V/Q< M;#58#.DH4) LO7TPC% C4;+W>G.K".L&--
Y6O!V.>!W%|AM9(2G'&6MUJ2ZN ML;&L.0!L=;|_SO?KT90!6S@H7\$A
\$L>:.\$|#P+5HY|O\$&\$%#8EP9M5T.TGE MI#:.LTVS8_)|T/NU;27AOJ/>V01R?WJDEX
J4_"ZU2J"GQ1X>(!)'6F1Q7Z! MD)PT"Z%98=J&X:-@8U+2J?
B+!U)UY%6N:YD_N9\$'UHMK7,NW)WQ'/6JQI./;
M5_EO\$;>Q0S|,+39;)7ON_/DJ,ECC0KSLN4!.VI*QH|0,+@+
<-4A|1L!..S_6ZQ&OQQA=3|Y>44&|Q M\$2FAKC;NB<:O8Z MD'G8^=?
2AZ\$D7M=D&|DS6O, N\$=H97\AED0J'TOND;+S%./D.=7Z>|>99D9) MM+P)2+EHBFRL?
(6YO,#CU30+-5M5C(1. 2EKC.G4X4;7W;|3UJ7/GX:N.\N/?!P4A%^4
M|Q1H|L3N\$|3;K;N4PU81@:;&-'Z9J&9RLGYPG6 TP1LG"C5YV3L+X)IZS@XLX M?O?D
8_GY7%5?- (O2N<6LOLXQ_?<_X/N!=@R=T;R.? MU5)XQH?LWKN#*-C6P\$ _T-
\$3\$33('OKWQ|336S81,"<5*!E9IZ\$AT2)&Y;IC M/9"0ID@-&2QIK,P8CS%W?@T?
WD*JLV L#QA68/T=:="(>\$+,' M.B -\$'CG<^|6V;
<47_VK+FY.^U33NP<|%/E_6D^9B:**3P|E@H-P<|0PX>/W M&K)WZ28-
.^4>V/RO33K-Y5O\$+'O;8P(,4CR*KR;)T: (|/Q;DSU>YJ M_9GC+MB<-
TWVM.J.,1YK"V+|UR1>>|?>S(%S"P;/F-5X%-^QM,O!?!*#8S9Y MD B#KMLI/UGT)"
(3Y"+.U0UHRQP/M?-)DU2JO L**?)IS#GC(!*?:L^)^MHMU
MQ/=|A"7G2821E=JOT.R_V|W)0+|X\ ME.;\$PD2<2&A""6"1MUP*<|)^\$T<_7
_R\$|YC.K#G<|Y* M'<..^8GSLMF491FA|76NY70-\N?WQ5\$&M)'
W)L6B&+F*IG39H1E(M,'%',3 M)X+)AG%8'E!RU&R=*.|N')J'/HYQOH_*-"C(W<.
<"VP.0"(*,%Q%@C;P M:R|X?2RL=JQ%R^|,|Q*7O&!SEV#LK4#&9(BEFX-
%AZ2:\$B2%PYC|F5L!|HB MK9@,RX>EG&W@GUGC-|VIE(8|
>+G%G_U):Z&&GYZ(PW9J|>T\$B1062 @7 = M5' ^:G-:B %\$:WP:9VUD94OL
M^CU\$V2YP WP@>A2.LK4HI*FIUESGK4N90|F#JR-K4Y5Z,P\$ _TY|8FEV+3^& MZ-
O;VT:PX!1;(4!'YBM.?C.:9052G)B!R48.|W4|G'Z/IQ0^!^X?*4MC!1U! M|@AUX-
2726(M&K|&00#NU^77.1+)3922CKE,G?Q\$9;,G9D"+# 'LR(PLIXJ+ MN(\$7@H;R)6|>CK
N+)|@Y0@Z(6;2=>*VQ_ =N1|86,6|JZAXOH)/+ZH<6Q6LLD MB0@|G|&M^_
CW5R^CK37FM9-L;<^O9J!+|70_ .|8LV@FT8:#/<.):=MX*%7N+
MF5PD1&@%&0_ ^|@V'^5,@OZ3R|(%O+6?^9SS3=F"4\$#,M@N9.5" M"#S)AAKF\$BE?
VQ.=UW>OKA|ZYOMMX/1|Z7|I%*=3YK+4%U18>8A+I%);Z|/GR,*P#YRR#O/FWHQU:=.S"
\$PED(/YAJ M\$R>6J,P'>=3N BK-J0OL#H|J9BC/"B:V|BGM=9+7: ^1|C|C\$|)*.);OA?T
M)E_G#L4?,N+9;(-ML(:K*+):"MSE33/E(B24RJ"1W)PX%9;@V\$F<34*|;ZC|
M=9FY^OLO#D5.FZ1X?L0@XU#DKZN"&*>NPX%)94# J6N%PX:O&H^C^;O?Y)I*
MI'!*4Z@\$.|)\$;=QECUQ^AR-R|UR5C,J4!T_Z9>VOJ TU#&C>V?.<+I:9|QB4
M/7M\$+G!ESX;8H?>\$EPZ:SY1TTF\$S/Q1Z% N|VT'4O!Z\$D>X-7@R|F^W&T.U,
M%6+6C%B8>QAG)4?*JL18@LRS37WQ'TZT3T7O)9Y6.H-MEU57<+XNLTAWBB4
MZ'RF5=URS!;/<-QNV3|WF,RU\6-|W^S>* _X|*OW|>-_|F(I0B?!HXU<:GK)P4,*5G1W/;
(E1DDV^/.1|X M|2G!S*C?E15PYV *X|FS+TL\$:*N51Y8'TBY24)-9<)JW8M+W# !/X_IY.C&
MSL8%:F2;)%UVY+Q*BD|JZL4;UDL8>9-XP4/YTA&.#^|+Z,E;O\9|6Z=+|=6Z
MRCI/R74U#_V^LBU%S@.CD29,B"">.,@1-8(HE TL8ZVO?NUHPJW7(U:B/O|Y><
M%OGZ"=X3=N(>=|HF&TZ;|BI>AMO|98HO-&R+>M|*=7*122AZ3YV/6K&XVQ5
M3@G|8(D=|XVTU#;?K\$G3K.K,3SMD)-JBR*K;@C-2U&T|A!NZGDJB=Z"58:Y
MM,TJ%Z%(^!7>CSX1(A",C\$;) >2ON\$FQ,J^?61W CF!EA_ =D7^ L)*SLW?M3 M+|A);'?W
;/NTY).|F(=T!Y(%NZB EG*P:+HPW&M0A (PRC|J;X-G4L\$NS
MR|L+|R=K;8O7GM.;|Y"YH|^,W!7&1?CEAH|6DQMOXRWN=K2^|RKLO>^BQI/1/<
M*|>LX(F7,/A>\$B6!R3HLI5(Y(M7ZVA#I0!%"IX|.YV77R=6V)5=O5Q6Y:1X7_ _HZ=|>
<3^)|H-/MB(/,AF/MN^T<\$ MOI0M&|P|4,|AHFZ4>3.J<+..?
_|90QO;Z3ZY>KJC:7G5,-7I2)N|K@183?)|B MR@/GGW?
@%C1G"V/_T@:_Y|5IYW>@9EYYGCVB:K="HMJ%3BPSL72GUE*WD VS
M9A6*GX2RI:W)-K;>2V9=#'WY&1^W3^ _P?N"='V3+U4'" M. L,<7?7=2*%P647SLM
"|49F:'?>|1J:^A;|I\$O'?=E!1GL|N_>GZ*Z06BN MLI?ERT6P+Z/HWNCHBL'_6S@6<>SM
TRS%DXLC/G^"DSO%K#I'>:'3_ /%;? M<|5KVMOZ-

&HMO(+.&KCNB)_GJ/\$/IV!0XMD5\$%21P

K!DP|O-|7|U3!B-M<7;6.F#Y(C'K OWN,=F-"MLMOC4I%ET_|*4GKB=?-|)
Z!;H<1%8SG02)M_\$:US\$'-A5^"3I3(SIUQW@^:D>C>8|WJ#AQ"!'
{Q8,>\$X>AD*)J9M>"N|G//Z M5.*4J5-=U5K?%2.11)|14U-
\$Y6%QK\$7XV.14S3.G3_\$VH0ZA;I) \$Q0D.D!W MT;=TZIF\5\$>EG9L^6X1W;UZCS3WF^;-
GO^>MS(/559)W|NJOHN/Q0EC%"!7Z M'8;>)9LH-O1>!6UM'(O7#9F/ZBA|.9!8WV)!?
>E5NVT0>3P XF&{9)#=N/ MH_%I6QC^X"+5"<5UR7YR=OW+S\$?Z!!4+PUU?
VRW<(JW9+2M\$ZIH7MHM\$%>(
M,)9,0^VDRH0>DB@T!\$A:H*3D3&X/"2S&L4PGG1C4S!="/U|ZI=\$MB)|?P1Z;>N
M\$=0E>X8'U@4|IS)1^>><.IR\$8)/+O@D'5 K6AG: ^90D4G-O@Q1R_-=RO-?
MBM_9^)^8=*7_I_|;NBA;&9:D_!RZ87(U21D.GC7M'_|<M+ WU8>4GKG/;KBM:=SHR
J3.?A&>)9|19)?+.;IS._+OS?+,110;|OD!YV MA%BUVF: 18JQ74'B2Q XTU"CL&|BJ3'FF%;
|E<=FE|2T|DKCS_@-29V (@'R M*B"R\$36\$-M):G9&|=0+8+C|Z&*S:/6D?JOU&-
*8%_^5)|K,*DP9+9X?W M5!|@:|YK|JZPR'=N=OZ>?
I(5VRV&S1)>/Z.BG7F\$KX'@DCJ!5RG=1,+). 3J M=I"VH:E-WEU|GO|6|?Z5-(@L3)L
M(W(UTWZGZ*.I(-JMYCF?OHJ87L-H
|T+Q;W;WKQE,ECK3VF2RZ?,E=TU(P_<7ZE^WF8I(NKWEA&:L\$Y0P#B?H|
<2K|E|3ROR-'Y# M>|_|&?|<2^O:YQO|ZV9QNO'\$0A.(>!C".Y"5|7?RXO!;LM3?
@MO|H7|=L3OC|VO^>H-<_G_WDWF; M"|H1M6,K1;
@|U*8\$6/4|9#\$\$W, Y|VTB2R:7AK2+C>#Y/GGD)|N!/3 *EN5-M2->AD@ELN82N?(U+M?
+H;=4&![N4|YG, 4YTV7YC7Q;J>|S\$628H(U'AQQFA M|3=T C6A'9^F?
&JT@9X|*Y@SJV+N2*CZ|6;QU.^ CU8UWJ|T8^U/A>P:WF*UD-*O'5_::>|;GJ_1|
M>'_|5R%|O#G.NO9\$A-28=N8\$3S|X'"6BY%5|M.+N7&'%T|UI#SB>?1SE!|
M:VDGU|P:1|BNS#|T'"^%|RP\$33|XK|'\$"E\$T6PW77)|@|+;CFD7E1=^Q|H7 M|\$"U9Y;|+-
;?7>^05&|H;|SN B*@P|(DUGN0A;KV.!JFI.1CQ_Z#D1H?&O5I<
KXS^3WEUSB*P\$'K%P;<(+V=##F=(JR:SMGX M3)CT+PLY9:T9IOG#&2-NIQ*MM'"8%?'
TVD6QH:;!%|!<16P'-O,VD)?KCP-WH M5%R|U,2?;G6=;VS#HL5)=|Q|_|.UJ3;AAUZE'GJ7'O
M *4%M_W|_P.8\$2;|X2(28'>1Z|\$M_ ^DM%3WH)!|(GC0\$=YLF&@W2Q%83#MMF'
MS_C9,<-IMRQ;@_|<>>|<-|WGD#3.-&FB!MTT=|MD|HUU"V8|E,%#R8*.1_
M#RMS5!=@V*>'*(!#,*42YB2A?BU\$P+T5^X|837PB-37&U %Q,))L<0J,I29*
M9|H2W|YRZ<87N;@|AA16*9YPDM| E N9+?>XK.-!G1RVC!9UC"TGv,.5"E_;
MPI_"V1FOFY+. 5V6)JH_H XZ+>9!ZM(L66#H"XB"1=U9(%67 M;.'UCRX40*
#D"2LSV=+Z<1.V#;?5=KF:Y|ZY7P<0ZMUZTWG;O'D)G|S"QQI
M%05&|PW5_1|('TX)DUH^@4@;M(KMQK@IXY1XG|;:#^0?*6Z1B?=TSATDZGV
M3BV#8Q2A#X|!-1R0BGK4(@.R!D2+|K:8F:ICDU7,@_QOE8_T17B1W838,\$|MJQQ;
(@_:+O?@I2TU*E-;KO/&V/5XE;N;_'JJ=X_N?>"|MB&;+5E\$N)3;
(\$#S=&#(@*X9\$!)3P<3O&#(@H)3ZO-)LRJA^4H!2YF=::C)L|:"
MT?|9ZQK>D/) 503;KPET9F11;#_0=P|L^5X|1KV%<|00*)5T(1(L2%T2('I.C V6'/ND;&S;
{2O|:'&;78 MKVMN1M*|D5(9_' ">%X:>*Z6Z+WMGSI_Z*7 S5;R=XE@|/#<+2X^M_(:2J8FI
MJC?S^4LW4N6.S&6&.W>CZ!>)H &f%07J_ (TM_+IG=85|GK%C|U835%*7X_A/W
M|S.FCC;CGMIB?ZE47J4J?>.;|U|W8WA"HGEP#<*N(|&YWG|_3!;U_';OS#Q@
MIW+KT5QEE/VF0S>?*60K: %B;B^*&.T@|\$"&WN?7;K6P_3|H Q 7X.H|0"S
MF*_!H;>@OW:&P_"|&M/0/4V/_'|CS|B+VHHL?PZ_5 SG|A%;>)=D_2E|9MZH
M5M,^TXG"O%-D_<.EYS M(RV;.-E1&COP|>*9FF_3/E7&+;|4?4J^S%RZ:V_>:-
Q)++|F#E4IQ9;O@\$3% M6.*8?K4=R|.2KV8E#\$|)^\$924/)5O24O^2>R-
X<>1|E98BQ|D+LXETN|0MX0 M4E'DIVCZE<")*DC4FF(>J77T^_60%I&!(M
(/9*|H)M>\$Q,_%H:66H-%6L03
MK)W(NW.Y(FH9R|9^W4"@X>18!Q=1/K;RC.HTF=#9>#SWH95BN6W+|QY>MK)
MZ(YK5W|;VPS9_%;|!"78H^_2>N@J#|IMUX3?SW@%X&DGX.GXI7A?0Q>4P# M3H5!|2|(
^/=L1501YD.=THI=-?YME^|8D)VOE^;PT;/H 3^PV!;LBX,P*L9YZ_"G^IQ@_|=5WD
MP%CSJ3W"1<0/@/7|N0ACV+*G+76';
M(&)9S9'ZD5.VKLT!O48+G=&L^50>;1+= "0GJH;D)H*YASQ0ZA21<8Y0YC7JC M+LD"9?
30=8GIVK;_|+KX(3WPQ|G=RXCE|XSY3B-6"&(A.8WXB)2X"RRCZGV
M&>UNK'VB'4M3|F_ENW?.;+9ZPBO5).@N0"X'Z;,\$)!(^:O61(|50RL7-#RT6 M8;/?
GZ|31.GS.BV;)=<*"2%894,)|3N:<9 (+\$H\$|L\$%N%|70.H-AB?%Y.V8 M-F|KFH|SO|QS?
^WW'=|SO||?SQ^TX,|/? MUW5>YWG^?K|KSNNGACWD76LM/4|FE&8"7-
;ABH2TCO^E4-'A193+^*UY?@/9|&W)C42?;VMODX@S M)K HU0H!+26Z._K?

V54R6VJ!DBWE1GJC >JEPM9F%!)KOX, &8M3C!VLXA3 M7=R\ "Z";+48; M;D(2
CXALVAZ!T;P\$N9OML46*F?G(4{I02IL.!ON@YF!>H)#%LMCG231%DF M;YS
1V&85A^W4+T"W HQ!6 #80AV2!641465^%OGCGT^PI29!8[VF0?O%=""
MA#X>>'..VK/GC:5|X|PK|!@[CILW3?IS|H5CF\$K2:ZM0]+36ZC|ZVW+FS " MS:M"
<1M|L&CX%NIY.9@)MZHA,".)OSYG3=T" 6MEE\$+D\H!|O;)B(8.UHW' M<^?Y/NRZ;-
HCP^?.?PSWSW=J| UN!"O0? "Z='(+E?&P")@3|H=F%4+\$-(M1EUF*=
<.,PDE=1N@V7!"60#>FT\$|'2EEZ,W=R"!ZJQ9'.QLWG0B:
MU0UW@C5=9DGWZZ/'",HM%MBN&\$A>A'7-"4)X<<1CG:|O9)V.SY*\$ T-JLL:E M?
GA_ ^AEQ/_/7Y_/1QV>M8KC%CO_ O^;V MI?9+*DHX-8J;|4<#B34K MV,A##N)@
|2/XJBQ:970&YT%%ZX2#|!V/I MF<'Y67;&J 1| ^|
(IP.C#EP9K=SW/8(UUDVGS<|MWQ,|P*.3 MZ7?X('.,KUNH"LM&VAEF)OL-
)#Z\$;I\$;U\$+RC/);?I<7'^S=NK5K7,H@Z;4 M>NRRMN#K*=7O!;X75PCG7(Q<|N,|I
9#;U+Y*_GL ?N MH@T/-?P*._
V7B@H=WZWS9ZI"+L1@YIG1|^'WD@RYB7E^X.*W="ND#.<7@VX
MCE.8%MF%D2!&0ZR_9 S^!&AD);|2+#Q?
K>>:>2/Y_ "4NUPH7Z[8=QP|:Y#FW#P;,%R+@!:96<606F0@1I+X MU2 E8A4=R=!T//>[<
B?YG?49?RB;)2=JV&,.SAP=_L|!@>N%NPDZ,YS)X M,+>%^ 0K4%Y)8O"TR(3#F3?
CTVJ|#K1.1&:7".|?#25GA8/PD ML=WRJ:%!ZM<'
Z_H6), ^WU7Y,W8L(8LBAXLEYOXG!%&O^\$|W:E:8V4!;,+6\$
M/9^;\$VR30|N9HNS\$AGVAT=16G#;|!%22;YV5KD1F_4+3S8(K-ZZG7=|TZUMZF
M_K.%^3T+(-=V)>!W@Q4X3Q#TT|>DD+DA|3|;|1|&3Q\$TK.JJGFEHI1J4|B8G
M3%SE06M*)_/?3,<|@F3I?;CZ8+POYE*5W?OXV8+-S8'I_ ^/^ MJ'_UDN1
*5^2.TN#>;|= @D(+ME#&O;K, =).\$F5%&D?<#<2M 2\)|#|ZAPJ
M#%EFWJDMU'<'6&X+-2AB@B0")>+|)5);-ZBC#%L/TF?@+UZ83;,#@'6@Y+|2 MF4X,?
H4XI3&)0\$QB@7! CTPG|. (W02X/V=+@B|XC.@\$Y M+7@HSU 4/HGQ:1S MP'\$TW8X
*E;U\$)&8.^FH,YNH=2ORG<@J'^QZYYTD).OTFIT5%CX@CS_?7@18 M#^M
\$45W@>DQS*JX4W?;<@1:&/# 1R-|#I-@*%8^J(I'-FC4:BA.%HH%C#; M7"9J_%;;;?>4&
B9+B%|!0W|(ST HN!(LH^=>2W\$VG!|0V!F*,|TK.E=OW0U
M9OWKSX'YW!\$MMAFNB51E@D3CR#K%Cl @4HA/73-T\$3PI|U!">_3Y;,:%75V|
MJUKAR5W5C1_ (/1&EU"C;<)"CO!M4S(B@FVK700F_BCN6,6%&/4LIOQ#!J#"H
MAVC^.T4|7|>ZD)0+2;3#@HH,,BS0P6@;G%QNI-W.*7F1IB\$>ZC=YAFGA,)(
M_ :TA6_>:7 \$J_.GNAEPF*D=|9? ?(N3X|@+?S?2EME"WS"TX!9(EV"_ YT%: M#UV1"8.RN9
GB)X|D":=+93O>=R4Y-6GKM=X|%D"INZD8C(V|J'"R&I ^OC& M&,Q_8-
XN;LM^9.7|8"MC>A5 B--PDQ_281\$D#=#>_, ^5S9#EHN"OY"%1O7!F*D2 (P MK6:
(V+'\$""37F,L%FC,PJRHDPD2?OD:9WDGE(BX|H6Z@+,|1H7E+!,KAW'7KQ
M2*EBQ|_ =0LTYK4HJ+L0&E&7 6AA?HC0V| R|#')?WH? DJ;1ZCX_ ^((/
N@TZVM%U:"\$,R|:&?5&NI#|#_ =|!@T|3|_ F MA1^N%/LMLUUY(0:2_F(R@KCS)G4",U-
HNR2)0X*W)|@'6!?!+|ICI:WXAQ(#5YI&A>|?RXX&OZUTX(|C;1:6.KMQ.Y G|
M_MT^Q5>C-2.|MZ+NHT|3J*(D=^ WZFP MA)##XW,|WD|UA-PMO/"ND@MB"
M?|P@7|L(:2/SAU|K8G;EA>9:5B;&I?'W.NV/_ CI%2;JD=|D#|,B2|8^NG6#) M^|Y8:9U^?
6|&#&|M_5|+9/_ ^3WO!"/6JB""FXVI(64DT;_ (#S;- "A-YRC^." M")_Y;|D@;|2?OHE!%|90|H1-
D&\$+1^;8TBIP>SG,O>;-DUB6H:= B'1-;)WE MB3160U
BJ;2ITD#@/)HN8826!!JK,2MH|C,6C-"\$GO-5#=3B=,\$6.17;808
MA|2GI5UU_C4O6/M2F%|JUCY RKN=)!\$GF/0?U/L;ML5RXT)#/?)HOJ M5&X;
M<:'774A6;G"%CX&U*>G%4#YE'>@/TGL>,3Q"I4T-2GR|4|)6,Z+IMKH'B<>%
MP?,8QB'\$6XE(HE@5O^:%C_';5 -K<::JA8MV94+; F3TZ2_QLEE|V%U0FM|) M3 3=|V@?
43CK|NQ@-JPI*=>B|7C@*Q|WIB;NKRDEZ)@4?<(7'R9 @D@9WT
MR5+Zl:9>@8|VZ.^146@H26/):GZK?(VO:7Y?,E&R@.WG0:)=UI/TF2_-Y3V
M(O,U'\$6RMP,=KG9C#DN@3;Y9MJ\$W%9>^F+O>@RKSLAU^1?
NN^KB:1Q*KOY8'8Y+ *3,>5; MJ&9@&\$W)*G3K*VX0|F361#W/EO <|,B?3U0KS&;-
ERH&--K:C)A\$33?!
MQA+H%OZQZS+KT6|K!AJD%Z0NC;.'PTJ|W-.4"X"#=DHS8F8^C"3KW(X8'0
M/TP^DM>Z":#2%JH;PMU20>|;:!.PQ6P2+_D\$1T*4RM'0)'@=EU8GGLURY>
MIRD,)|"DD4R/1?^?H*|:R&.X7,2V,+;-T(< &+>1Z\$34=)7"002"X46TRF MY^W_|?
<|M4':#R/XT7NK&5SYO_AZ^=,G%3>-2|@>/R<5G>G\$?H' 9+;!*B^ M_|X7Z
M3N'%6C6^)|AQR-=MZ?<1I^MFF(@SIEX\$D71R:|T!>:YT04_!3XSW
*)/"!+1RQNY_|G@@P!;MUX M>>-L5;_ZS_YN|?'|8SDB'5%;=0,1<@*6'@K_-S8&J4DP|
|SE^.@UU)E&G" MD*4-R.G3M'_0)| G+.-

M*0I=K(BQ*_D2=^3T>0Q.D^"W>.HQC8RQCI<9\N7
M.X^J4KM!_3Y(PO8BAWK""8,XH9Z>&XS\EZ(V8\$|E0GK'74_M=6=WVO5.;)H?BL("J
M_)F.GMLPC\$XYN! B.#5B5>RGM#3 M>8P@'(NA/ +H=MT\N \$"|ZKE4 A5)VXW>=
(\O4;;5_:IA&FDG;S'!3;H MBM9@/^_A<|0MTSNKNLVQ M#8IH3!'|79C4VXZ
?,=V=6NA@O2Q"#WM%B=8|M_)%)O/.KZ +M>!=G4W/O@^
MVQV0#4H36F3*NT3!F^+J^VV\N0(3WHHY;A3V\LP<4"E"4V2&.;,N*(CDQM;
MYUFL3W:MM%'T2R:%<+M*H/U>C8C-[A*0)QW/V)8!SRHK+'8-)S;HGK5/U;A
MY,JR_I7YQK2VHYB_6S'L1W=G;DL6WT=4XVM-+J@@^'L7YL." X4*M\$F>685\$6
MXWQJ..LJ=(CN6VO&L.E\U9&R-2^;%N\Z,"?-UW#QF!OI|9ENR2;(A)V!VQ9V
M!AUW^)\$J.R-7_FN7/'CZ:C/P2&I5|2?V>@X"l
Y5D#YAJ\$Y(OS!0HG\I5|=AJU^WF,2%%/4_1,U>S\$WB_MD&KS9FLQZ1WN9Y9864-
)C7F\7FVXJ&2*M%6D:IY0H_VOA+)N4Z)0S_G4063
MAAW7XHMND3*L42%42<*1JM#CB\$|!2
MD#W#Y9^EN6Z=Y:0YS<7<|\$_IUT\$=,4VCAX^6SZ/RW/3.1S+(F;
M_IDR;NI'^XB_:R&;=^T\7WZ2J>(7K6DJ4XR=B+#2U-MT+
FRH6^A&"=\$%VM>Z!>;6*T5.-S3>J#F6(J>G,*+L0\$@)LS@/6AY
MKH).C@G\YE/.D@VL*BNK3%"Z&TF(V\0CYI6#58!&+4-ELTFL MZ(C3
E:HHK/M%"^"+=K"/RX,C1(F\O")}<20L/-Q7Q_1@>5JD0|T"(5V"?
MGK\|GL6A@\$_.5A\8JZ\NZZB\$#DW6\X!O?#%3DAU;(D.S-\$X!4478/CA_B+OE-NY7A7>^
|3_RH\$MP_|C(<.,?B,Q?ZPY?X#|@+MN*8L@||@EN45I@S&%QI+
<8S)\$QJOG@>%_|_|W+>?+>^"A>RHK9K?0Q5IB\H
MQ(BQCVS!2N)V@\$"+S@"S:5BVR!%Q0L68>|H?|>34_RK+Q\M\|?|CPM2ZT;|8
M02G90MV%,) %ZL&'VIBK0?#AM.PX#=#4HC_I%|+\$+*(T&?0IY3&3,*NF_%ID)@
M(7FJ"*8=H-LL)QHJ|18?3!NWE!E54C,|@WIL@PJ6YFUH0YB-J7|_.P|TY3)>
M_T">V=XZ!E_S/X6LDH|77QJ|?|&N0%8YN48<9=|C:K!3ZRP*G<"8%J",|,2?
MN.OV.,OYS.-.74JU|H\$6HE+&+_A2P/N!@0XW4\$%L,T:D0JROX(T#KQC^:7G_MM
O7RN8O73ZY|K9@-J1\$KMCS=YQV@O4O4|M8Q*|G<\$JSR%NV4->)"=@=%:_>
M.8;K3%1^;G1_XVI_ZZ&9XK.J9FTSP5>L^E\|DE829'Y09;0W(|HSS(Q>3XX(M R;BY=U-
ZU?@_H_SUQ:./(<)2@XY1)GHMWNPNP0%|.+.D\N WR+ /| (=IPU(MD"BI:#'?F|^+_M;0?
|+F\UXHLWV'5>M5DI\$|L\NX/W>L)EL^V+P#-V%*WJ%7
M?!0XG_IS(|8.)HDTB\$.G0+WW'1/\$J"S>7@B3VQTZ:&_I^TM?/?B|_Q;A|^*
MM%KQAN|Z<-G&W=SBA7T;SZDX_4Y-08A82SPH?XJ=M?IY!BC&O*|C|*B|_-
W2P|+RHKWWZ2N/#X|Y>O!@MZ+3@)^DS|:EZ@AJ3'M0"7K2:TB6OE?+BF3%.FIYK'-
*\$KT!%J=?=O^(M^J_!P M7%QO+&U7?X"Y7+X\$E1<5#X@_L M4;
R0G@\$%1AR;*ZLLL5+6.1|!&^A;M:PO|<_5K+;>QUE\$N"B3\$3N|IE,-P^W MN=*W'\$CB
N,M(P8H!OV%AO M>10TO<1?LUI5OW|-,WJ8VXDM1T/R73F5R4&Y
MH|'7GPR,GJW|KFX5*W_)H4F_C\$XOH|!+;.*S,: QX9;' ^ZUOPN)_L(#* M0
MR+N3_UX%,@/45JV.7F_L5SHIS" |WV\$|2:Y"\$3H%6|S2B#65"52_ ^"NP/#G#/ M&5+27%
(^ \GMK:DLRQ.(VB\$|M!_Q1!Y.|&^:&P0TXX=%O7&2D"FINLCYPL:
M.LWIW@|8KXL.)N1|_.;>AVW|7CH,L/DZ?(V+|OU34O#)VSD!D-<@EC<'3:
M0KEU@RH(+6Q|?FCRM'3T4%H6FR&%5>HV#:#*'|&@VMVY!XE;KG/2.>79=;
M'K>BI-|WJ(%J2'+L9\<:ZL&_TS"EZ,=K:IYU|N%\$9T|M1EFHD9+&/_?<MI0Q\$V?
_#/C3G#QXA+L8@C \$ \$WD(M5G.V_AFI D1.DX9WK5^*H+=#2
MG.:HEF7_C,^&%V6%_JV_Q_1"&)((ZPHD3"?3>.A-|B-&C'/QSIZ)0:(=PC?/
M6|X,UK4Q4GA|#C7EEH!W0*EDGW#
|WZ1A%Z<)AO1_SE29ZP3*+0ZTH0Y"2_|ZC|_|XJY^WV#, M3N*T2T1H_
RMA+'|U1+Z8)+E)|F5|2^R:XK6:&.)\$WRK_NBGZ|4//_!;VZ_M_:MP1G=_V+GLV.:R1?
|7*LIBKV;^J/YBUX::FGY*"2G&,%^!U/=P%|9L.;Y! M'TOUM0^U-;
|^|68OEU^=B+O2|=M=?V|B7J3|4S" M^SGM7GEKCZ4L>9W3I:|R/-
ZM_\$I<8MF;W/L|-7&.Z|G.:N8-A00\$O|S_2AGW
M%K7=DQ/PXN5YJ^,Z%)FJM+OW1U4W>MA5&_H9/V+.E_8U\W%|:!' (QZ_RP%T M(=,;
(JG? MMV@H_7#9I?R_A8Y/%?Z|/ &KD(|TR?I9Y>_I7J08\$W/F4|V!)21!"Q'QD*7P(
M,J>+T5+IX|U?88/^U:.*H, >| #E#V|0JF75ZT6^? *3=%|)MM|Q:*JV\$|D\W M
\$J%3'#&L%CBFA9=)Z;(M|QN38AF1@O|8|W'ZFA^7??>J|+M>4I3"7%|WW\$|L MH-
\$(B3|Q.9A,+LF-);D'@SWKAGU1UH\$)YX+DJN6B?%XVK2V|'\$=|
M%|'L\$1<|T'3S\$8R,@P=67JHMLM7&|01YUE-JJ.|MU_!@Q#;Y|@HC_QW0! ?9 M<0!E+_
RZ^PTN;;GD+AMKTW!C?E(460^6^Q9NI"HXN+DHWROIDGW:V;"=;(?D^QC' M)|\$(-
C_%<+VC8Q*#+|J%:%==%0_CM<9>MK|!'PY)+U7(F\$S8Z.,>93-.2#^

M@4!W!#P'OF.@J1!SWX-HXS+!Q=Z@-Y?,!M2^8/\$'5MR-/F'1/8MM=R!|ZC8
M9E.1_V!%XBH!5\$!T!|S0BQR;(;!SJ3N_+ #39:4!6NAR"(H60C;GL;VOC
MW"!Q69DS@/%Y2!1=V!URS_!-ODO8KN^D=4G3VJF7#KJO:G*?@QXU6LP1!AXM?
2Z6U9S#W2%B?*" -6OJK'!.JVCA!M:6;W&M"^M:?.?#"/KMT!;RK/3D1&/\$P3@
MGP#|F7V/#/UO3CL!|-%5_M;CS!O!FA;YQC/G!PW>XBGU!G@?O'1@^=W7Q-
N78ID^\$X!;L^1;L7U3J!Y
M_\$1FLHK/\$6&E\$;XX!H&0")JY#Z5_9CD#L0K*/JJV@U_#809WV/.<0>7E<8
M!8YVO6F2/(<^B'-S?61&'2'Y68+!+&ESB%|R0"MEF@%%)F.BU)?N>SMS!8I-M&?
G?|#'/SA<_!FMC0_N?=@K!VQ!:'G9RU50QAT./"%H?&T;!<^DR!Y@<5#.7NU!MV%)=Y?
A2V4PQ^@_6%CH\$)ZA3O@7IPNF*Q-F+#P
MFOY)R/_^58ZLT^'NK0IRX_!1KQ_OBLDOK\$K!0IQ:>WX0<3WN.G9.@PS\$!3H7M!
D#)KO0K&/R#_23/?UOB)0Z7ZS&W/_QK2#K1WO^+T.;U6Q!;)4B)C8:'N_
M*\$YUUIQ"184X//(\$@)!^P!6@X0:~*C=Y""8,9S9?E!~*MZY:FYV!H+0!|3\$@/M
MB&&N(&X1%::2A_'TCR>4AZ_'%(89"SEY+!0Z.UG>#|B!&&MZ1+O@!OG!|@!-'M!7
O61A#>8^A&Y.&8!R&_5"*:ICVZ.FSXKO MN!7NH*:=UZ2UAD>:!B4NY#|5<'!
#J1_85A&QS\$F5=&0L"6#F%FG1ZWW MAP6=D2D7?F'8-
HW="%"3SG|QMJBWPEFUS:WOSR/"3F+^WOJ!A?J*0*!,KR-%+<=4"^X6-M%B4U#Y-2ME
CZ1;M!LL<=SON|B.!|DT00+.\$1!MO%VT:/1A?!_9;:_!R5TO7DI!5@00?G45!|1%
MB*ZLLY@K-X5YRP;D;|V!YT!X6022DASX(@+T9(2SV6>GL@_=WP
MN.+|X*"4C5IBMJ:L6M'\$:3Y^@7:??>QU^_B,\$6\$+>8LHIW-?J)O&:'BFL;M MD!>"5-
!R#287>&0!H7??UOQJDI;_IF?I0(A!0L(S,J1=0B_"L76F_%Y_"|B<MA@NV4+("!)=|L&?
BNRU41V<-
^QIR/P7D7^8:&\$H.4(J'#BBTJMOHKE9J%%^>=45(BS:OX5Z'A5J"7>\$Y!)ISK_\$,6|Q\$8)2
ME,\$GEX"_MGU;J-6,4!/^6D*^ANARES&37>%3R4V?(M!&+[E?9]!^0F!D5?7M3E+I%?
&FM%\$SI?>PW>LT3L<28?9G@/(9716&*95:O#KIN(1^+-@/>2A.;O>MY9?
>*.M3\$!4<<5R!=V+V!/?5;OR!|AB.*.IR3_*>8Y^?_?
S8XA^."3B/PY4SR)6!+T!M"/5F>2*>9^1>64V#M-!,S^!R8L\$|H!EF=1/Q86^3'0ET?W!
(.IN9W(?QEO4'E:MHCI,%M)O=UW2N MG1(9*-!^\$;5NM(\$*"M!G6YB-X92CAZ)C!0?;/"
M/?#1,/6'C!T,%6?=W(C)NR!W;2A-LW:XE#B#!D61_0RCR*;B*PJAG!Y"OLI
M<(LD,^Z)0UR4C!9Y,^72:V,_YUNU^/:YVGE0;O@\$3WGX%V=3,C01&6
MOP/78E,"%H|B_5@K71:E_ZV M^?FY-L!C'_Z8-)?PYBT;HG^1SSX=G72K9AGVG-*=?
(P\$|C46F5P!9\$!L%P(-%M<553-QE/MV;H7?UJ1-YM+R49W>EG2;/L_8?
IO*EWB3D!0EU%L;_ "\$C(JSD-M#>|>*Y?F/5?%1>9?DZ3BZVU*|/F.L1!;Z=8Q7;#D=+?
BQ7!86S#I4-4/MF)MI*.;MZY8@Y\$F\$0N+-EX#G4=/'BV?WX/^>_!B\$9WH2\$.ELJ
53V72JC;HB/M(T.@>O^6DEH748UJ"JN^>8G7^Y!\$+/2*907=T609:P&4R?
%8DCB0>97Z7#V MQ\$@1QI+E0W SD=G!&M2G)H6KOE0Z.*WK4Y
M>+5NBY8'_J0908/3^ZH"5<=)KTF16/I%-('@D!))T6VIGIH&M#\$Jv:~@@@FS M_?
ZDVLVKX!E_ST(CI#J!MJ<->>P*8J2V!>"V F*ZHHKLQ!+39/>\$RWVQE&4/O:X-
0RXNV4#\$TR+0(F/@3!+"CV,J?|<.VUIHFQO)#NEQY*(E!R<;0M@G8,1W+HD)@?
>R'-23&TRX*+!)<,O7A'^^*#Z1<&%WL^!T"0R<%Q?IOJ2WVO
M;T946!Y%+%A5ECP9)3NW"GO=N95F5+"1X9M6D>OE2"JKX%?7=@52CU6.KOX!
M9=N-D:K3HEB"A_TAB:';"4+"@9)2,&KB99"&B/=NG812N!\$7HYE9QPPHGGD
MPZ!^GK!D)H6AQ&^AJF(X-6WKT*Z_+*8'.Q^Z5R@OU)*1>K8DE937J3SIX)_
M^G;9%!F?5F<30K?#Z\$GT?!#_MTD?
+T3N:Z!"-5W:/%QJ)7210%T%11\$R4DA93L;Z*Q33LS>AKPXI/'2UJ39Q)MUXK.2I"Q+2^!-!
!7D^!MH*#*:7(BRU;L3SPSW1!I6T!1B8TFN4_QD@83!U MI!+X!_
Q5>Z56=,WW.K/VF9764G^B6K4-."C-6K'-Z\$KQ&CWJ9;#H>9-:74
MNA/T+0!F#^LP+_KY_D@02T^A9\$7R26X.[1\$.%F!%#!'1A8Y'2Y1;@B=930TB-MO6%
H<.?@X&K!.'A1F#"UL&EO6&ID">+R/X_Z_MU:4\$8!0:~,)TV1!P.T(C*=C6KOT69YH-
#Y9XJWG!E,W;Z_G^VX&SR4F=W^0B-M1,
(P!|5V+/T,&=Q'>AIF^!HDFI0G1JWY2XS:#8>FFDPZ0N!JDB9WWG
M_9M^QC!_F;7SS<5!-Y'PV01*4R,W%;*\$_L_-#^("=K1V!0=XF3B7!@
M;JAP_J)BUN5_!H\$>)=^.!51G7&V4Y=|G93C,+@8HT!N@!DPK9H@!Z=^(X?/\$
M':UN8\$A%K!5)F-6GFIV+-BM6.Q!Q2/36Z(ZR@L"?>FYURK PJ-Q+X=LDE>';
MCFCV(2UF.@TA)!P&R\$#G4!'\$CY+-:&Y00V+N/\$N"HN).7^Y?R-5*>1RT_1XQX
M,LSL8!LNA7LSJ7!XA:J!T5%F UG,Q?X)D4U88=|DC:%7S"K(+G+<@0
MGH(%A(T93J>N!,-""&/-!2#S'G@,&!S"W4VPZC!%1.~RV;)QB&!5O@XC
M*KZG4G*3<^3H-^@^H?&\$_-F_B<%ZEUR?"B+Y; \$K+6Y!)3!H&^(3Y.:FE#4U

M.+4,*1PS@8Y@'Z.9/P^./\$S\0_FS^/G<#M!^\$XS?#9<9PMEUON(I3RS#LFG M3PA9.#
(%Z(-OEC&|WHG*[7>>\$A/T,H9NQS:C@)A@WO 9SY()IVAT6:HBZR+ MLS.2(6KBNMPIY-
C-RL2WYROG&|E)-F3GRL)5^M(K:M5EQK=J=YVA1|1E0MB M4O,R8I
\$KMNH/%HIQH[1|3Q\$N/D%?K1=JH|EN|12X3TO-L>1A|GU%ISFGO+
M&&QC6L8:2NO&I';Q2_3F\$9E<.'-)=>TAC-#1+93**[!B"W7|\$V;U_2GH+7B1
MS.COOP%/_WL1-OV_\$LYW|*TL85*M AS0%|A0UV,K?+L|9HA!C&ED:\$X>+J9
MZ0/F,8:.-49%X3.RV|&-TH/NQ@?^Y.7%U8;1;S|!_6B&+W6!/?N(JQ'\$L-
M#BY.4,G1NS>/G\$IHV\$O'?<@=^3/*,Z2?ZM ALV^L3>BH'.;0:|N'WX2%K4
M8,B:/6/NKHF<_%W:|57&I130|= 'N'|&-RX6N2;R*W-G;?E'7T":K\$FFP-'2<
M(=7R,).W%M||+^>JU9XU|\$%^Z_14*(+,GF'\$0"2/#;V=8""MMM"39V*#@47W(Q1YS(NP
MUMZ,V33S-X)|V.A0Q48<&@RBU"M_S=K5ES)HT:;XK|RLZMG1=XJ)IY_QX7C" MR,A@-
T";G,:?F)|1(C|J=VTDHE7!P\$1#^|T\$S1T:RNE+Z1.UX5C;DHI@
M+\$UO(0_;*HQ3|ROT!#\$6 M\$=T7>IJ%/(DA+?R7X_6@PBNW4KJS|
#@3GTD"#0ZD%R7P4/8INYML^1MT(&B M,Y-HX=
(SZ4@\$6_+9P=W6QM=:2DLO"2<*>#"|UW,B^4/"W!Z!/:BVG%|P#.4
MY3A"A7KDI|F#FUHSH5(7L3W,.4/DKX?/Z8N^_Y7Q|!ZL-!|:A M(Y?
K#I_5_F9Y/GC/3U&4.V0"&A%#\$?S'ME#-'V"Q%/(+B1A7+A-|3_4V>8
M\$ WP2;A/!KUX@/YCS,D>U:;8ZJ?Y'O@GLE1DJA%JI>C3O|N.,*#?YB&4B
MC223|>P7\$*)T>79Q.M.#DHJ4_XGCY)O.3+BXS=T1A0|J=C; M@*C>""XZ50()#'#W\$LG-
L:Z^H-F6OSGRZAF4|-F>KB%TNVU^UZNDUP||E8 MBEGW-Q(IY(852P
R0&*WZS)^"V6Q'L@W;("15Z#>N|T=E@.T'8^6\$T1")T
MT.FW5FR.HV_BCG^X'R42J23_I|B:&/57E6#%25:GZ(CR/3+;H3%?CZ(/6:
MMGL!%MG_W MO*^@ANMU?4HZ9*7_XTZNX9N<_&|S!GT&:#3&'1J'O-DOAFIACGV!
MW_R5Z_4^>.;9)/C&:UTAY9*F?8#\$A4QO: N50"CC6UQCV89V4C&T XR'E01L3UC<
MT8*GPNR%:TW*I/_X,V.|%ZY.U_'U/Q_B5J!;MS!T"^*.Z1@H&4&AU0'O#0JR
MEKN!1AV,.Z?GCW^;F RD#I*IX6?,4L_|ND|JN=Z|E*+K%_L|9_1HY^'BOG: +
M|55N2|(QXEBQ""#/IV&0M/T\$0TK,J90N%0FS|Q)J.4E:9%.+=%H> M2,49&LSZNN?
9M>GCE2_71(H#(Y9NTM3E:LD_-<E#|,'SO"QB%8:POU=189 M1<9?F%A)X5,\$4|J
VCW*;7ULLSAJBU45!2%_-%3FZD#FA-ZRE#W|H|/U^JA M?14>./CO"U?GEQUJCV|
<*1BH||HF=(G_|XQ5J8@8"FPA3H0P^G;&F|+WK3" M?
B#33R,T0B:54_C|W7|+|>'>X%|L,#?#N)-<+ 7P=.|X-L)O(TZ!->2)
M+10DCIWPQVM(!9Y"-|V;EP)NAWM_8J?LGEH2>6PB=0D^0|+YD>LP%T\$TKQ9
M7J'#W@!?:*|TD/P9BR^_PZ|>#U#JUC^>0Y//OM"XDG*!5RI:T7^OJ|0D'R0O
MP&GC0L=|KK&-J<#O N-XG^@V|*Z>3H|6W0@XKNJ.OV@|A5GLHC^DND-2?;"@
M=^\$<:0=.=1Q:..S^E.MVFX,W|5>Q2_/M)X-'1^&ZM^X_(E|L&.X*.1%2O
M";23.F\$;F4UO^|R= #?3SB&U50|75*8#/%!W5=^G/Q53IAA%(R1Q-PF)8SO
M8+|K#VA(106##|TUI=1CB=Y2/8'?O++%MAOK#41=.WR'5'9) &%%ZQMR-HB
MJ_|=):A0"V63AL1RM@/I \$XH|'0=VX0&==&FH"-|QCCRP|P-|YBFC|QQ%U
MQ\$1SPQ0Q \$B>\$HD!CH5|S0#NZNAMU#GZ|GFR':U\$L*RN;ZC#"O MO
)@3BWQ@10DAT"E2BB(>..H-<3A+;6#9DAT+PDQ.)CW73?4;^&(!T?|UAD
MRO1HS\$0W6@*A,"_3'F^AN381\$S!-E|JR<"?M7 HA702F6"ABTB/X7Z@ ML>|!KIG#R+
|&,2>;E!+90Q55KE,6GS0)MA M"0#=#KH8)/_1K*" M9\$|QX(Z,.E3+Z\$|DA<3?
8NF1N|HHQ)MQU_=N%01P>*4\$?%M#3)3S&TG91%CD)8C/ M!Q=@
8,)>9PGKTNB3=8(GK14=2)ZSAD|4'>?P<79)_"%I>HM145:>-.J:T2JNE%*I5,/I6J0;Y
MYN?D%Y=T3KD_|H%0Z,Y)0;(&#VZ075;:|>F>4>8-X-GO.CV^|G-^XSHO(";
MLY&F95>PJG_|28:"|O""S'W6,""V+\$9BNMAH>&1G)V5|+;)/^_Y!*,!ZD>T"(%N_|S7X|=
M3NMO|=!=ZY"L+0(S>"2G?19|BGD#F|Y:|HY?HOT^H:AV|&6@+|??|591N&1!T/
Q2B+@|KP@+A*#XFM,CJ0%U_(!*YAW.NPCXK3NV^1Y.I
M"2@SW|K'V#0TW:|=DOQ'P2Q*3FC(PC^!'M%W0,|L9N5GK7K9*|&#YX)\$0_L MS1 0-
|KC?#,VOFKEZ\$D#X%WUNV>3VA&31SOVTV|?_K:7:5AGVT*2)U'(:/"@ M!HV'H6H%%E
U'JHK9WPL.F|Q23VFV&GHS(G"UE<_DX:F>DG83Z@PA NR,(- MF6F|
(3|DQGZSAA_*9BI6UP|6;.C.+7_T=EBMQ_L.#_VH58K3FE|Q_9#T|)%F
MVST7)&GP1H6V%F*|_6/'N:4=2>7ZV|/AW_TS-#5^J|D/TFVVP<*:.\$-/C/V|S
M"W7;AW'EF|_|-|U;RCB=0B78M;?>BXF9ZO|!MR& M+0'PR|_R_)|\$2|,W*/3*|XS|MQ|
(L%E^>STT1_G=?9GO?FD.H:11U+5,J(P MI#!0H|5_|^E8_-|L.%^W M6H1,VSB%Y\$+R
(98\$|8T8SKA*GB_06PJ67"1'=BM^B-W4TU&"_/R0GS|*#|K)3R|E#NAZ4+?)X?ZM MJH?
)#&,.S 7?C."LZ%C8F<|@!!S#"4" M2|<AG,IZ0@!2 !V&O)W>A=[N0CTD:W3C0?
4CUC/NST|WKG?:+YHWY&|?SH@ M'IY S\$D,A8(%5?TC2)3W|\$Z?O\$?

ZT@FS;SIE,C@<\$ZMX_V=%K96S/G/(N(K MJO(.5*,>7I*EAZ"Z%_NUO@U+A7,HQG!7F
2C+?7 LRKW|WAA4=,H5)3B/C MEJ\$,0TPL3WO:P\00-#MLZ3*THY03HT@Q=),\&=-
\$>FQ6.NNDWGGD_?PD\%E MSX,-1H&F3<:#30'&AK.WHJ|'% 1T,J_-DEN>F0"R0>/F\$ #
(C8<8BVY68_X M/4=2/I_(Z8;V^0IZTTK^@0*GS6L#.VX5.XR'954M00U/=(LE+58+
YIRK_BS MS-|EYHS42@^W!!+U\$6?=0AW%T,T(7:8?YPO>+V@^%:LF0SNC8\$D|9H)=
OL ML(339|/(4#Y\$;S/<=@A-&ZR_XR9JT'91=^E*T'7&\+RO_-|BZ4(2+ QJM
M\$2>EB@V=L6'C(0MZ'Q/#B&I_JG^#*F_H+.^6T61ZLZ_H(Y6G_P8UE72ZL_K MUU&-
*VA0)Q<6:&502A@1MD%YHZ#Y:POE28CZY2WAB=FC'IU9X/B#N5|Y;=@O
MK40&4MJ60_7|)%CD'-8WU!8606A#A%6H>8MVUOX82E9N&//>_7CW/#!K97+<
MACV8.'5X(:OE9L2JH2'BU>>1"!;3|:@BB&-|1F|I,R_/(^D\LBW8\$^%=H M//I>UGU8HI-
'LZ5:&JH|\$H*^<07!"DXQ&R1#=-;N/*S+|=&C; M&\$2*;W'%9,>YTHX" LZ#|9??Y"|#;'FV
JS!_<0?J+HJ*T/,\$=:D%"TCECTC=Z*LUV/4HY_H6J9T:<==OI
MN*QVAURNLTBF.S)SP7OWZ)E4;_*,R?;)>|HER8',L8=,GU4SKQYVH8-'C==5. M,P:.#"
(2SJ"/:/^(R;LC7D-!%0/ZFA-S)Y91H=KF|1C!(R4\$|2G3K^4K67%+ MBMANY=??
GV/I(AR/MQUH5"GV5ZI|J+P9|;Q2\$BD=G:#QP@039/3\^L/ U@?| MZY"X'BQ0!-
KNRE47.>PW /YM%SV^|I-A2EF=ZW2PYZ)SNC9/_ =30ITWB*CO
M:|H"7<_4QD:P4&0SILP))TR;'6-QDEV%/304K/)+NOWH|H%4VL|
MF0M)W&,^9;_15T4"A*^270SX)5Y:F6^VZ",ZH<8/).\$|5B4G_\$/NT63-%, M5;|1<+)=|>-
;5&9IG6&I5BU>1;C"DC;HQX3/A-XO5E+9_Z|E),3|Y\$|4@U6H MH"4=%EGGN)WO#-
,1H3ST8P"L_GC^/J=79@^&?C&(XM7_Z;2!*,9\$O+XA^"| M7*#1ED1)|_NS9;|N?
YAH/:VV"+E36/:%7|I4Q^UL"GVDNZ^K|L?I9_81Q'LN MCS
4,A\$|L&|&EO:^A.BD#A*8OQE#66|DH2_^\,9|2_Z|,3&|2A8%<:U'RHL, MJ4N;M|I(I=P-
L:8QYJ|/=(D9Y*\$O07,6;ZAC"|F43+-@TC2:JOQR:CZF%R@A M=V7;?
@D:0#=#D0AJM"V,LJ8.OT8-_05,M@S5(>|0-K M=W6>5EU:SQ_/B<@+,4I2GB9+S-
41DL%C5CKS.6(#(4|6 |PP3T/0N^|I8?RL M@R6A70?
8|3\$5APIWSY|V.V::5%J@|JRLX,TW80G)8V4XGSK?_IJ;Z@YBYE|Z'.WOX"S M,M>2;
|SS|/\$|9?A&I*BB9C%B?/CHI\C/*!2*R,W.QU#2@1)+6AYU!!M++@|H M?(@5|H|FX&7G,#
|J9|JEUO^F"9434#WR|ZWY05_0<?C)&WIV^N4F9V(?
6_BVK90517UG|C9#>+&^2YV;1WN^0X_FG;|H(' MSI8D_3FYQE0|&
f(4JAP/4*8XA|HCZA2#BCW(NRK4K%>\$PNF>GSU65'^ WRYF
M)>F|D50PE#18",Q\$1H@DPPCR"#QP+W2_RFJBQB2*T1VGE/AJ;|I3:VE?B;U3
MU1DJCYO>O_!AO(;S-"|9263ELN+. >5>+|I:8F38^%'2S C;_P^2P-&R\$@9 M>?
\$>A1OT9NF%>N#|ZJ|DY=+(%7W)12;B67_KC|,-7H86ZN8YKF/VN;F|P: M)^8%, 'P
A>X\$-%%:0T2M)7NQ\$;!1756&!20I&PV6_(-.2RS*'#E8P#OR,|:/W74RW|^A6=*I
M=W\$QB69?H92U4P>FIDX'TMWG-"23>C+|?XXKISYA@EJMRW.VG<6?>O>G!M
MX#E;H;A^!Q(D3H_%0_*|&&6-Z^)S3_8V5*|H=^|IB_ZBS-'FO5|2;HG,'2@7
M&SWQ|+=PDLD"@::!R&=-W%>2L.%NE|!(BE01IU!R2Z)?_F+OS9*H0,6N3XI M"#U
|_TE>LE|/%CLB!/?/L+APHPVJ6'18*'AHUS#+M"B@V&,|Y<^8,X|)%?FF'
MD*KINX<2OP7_86*0K.*|A8)V9DZ0XXH@*U_Z|H6K'CA:5CW1V<41R8!>AVX= M:L2-
'8|3TV&!,@:F%;N31"DA"|(T)6!80NL"UCOG>=M.|A57K;*Q
MTW:9",GOL0Q#_S\$Y4W8*W4(U8T56_-PK?+F'P0B#4^,&OL?
<3D@QIXJTM,Z3O)N/T0K:M\VG|*,JX_68*|R')S|? MX56=E|YNGQWJIVAKOZM
53B: ^WHD+*|R8 /=G0O)5G/ZP8-B+!H,-<8AE MM3"8<2T^J|#P
8'+T=T_GOT:/V\$V>2<|V\$|HED22=A;O?<+_ZF<|AUA5QKN MXG1H7HP'/KF?
A:G#6S;"ZG%@I6,ZDFD&PK M|I@)G&,H6X/9D\0(J6NGTHAWUW5Z9A^L=;VI_?'#.6?
E_9W|V9*C|L?S!GN M_!J% \$H&EB=,C!@JU40HJWC32HH-
'/C<3PSRSO,KSJGRY\$|Y(I)N< M6RKRI+?\$0#H>U#H4^G=!8'?_W_0-
0VJZ"!L9K.#,\$7=YQX#"UXW(S>_ =7GMFNTUMRORS*\$\W|)(@"%AOU#
M;:6%#|"QM.P)M(IY0.Z9CV|D6M,'J?K\$H DU8U-|Z3G/'^FC++58R>)Z|PNQ
M"J!\$ \$W9GG?*G4*EVG'19_ZKSI3':FH@V/'8K+O3-G>_?"|QD"&T2)0W9/I=
MJ45/S")A0DP0|L>=JO\%|;V=3?(<7A_YD*4ZM)|7|J0NBO_9:ZJ/N+3Y.#T6 MI?
QA00|'73\$|2HR@|BI@9TT|^8\C_IV4|G@C(=^_V&%&5=E9>(WV.37Z?I MHB9)5_1-
\$(+0AQ"\$,*OB4>|2:%?_\$8=YY|^#%HQSBSo_GJL;@EFSZKV;Z%N M:8"*P*(P=84?>0?
IQ2>&I.N^0%'Y>7KNXM%ML>46XB M0"&(@P#,CW!"|IMT6F|+&X=^+8 ;5'L2G)
|J_5@^D>*4T7H>T+S-A1E.Z? M^H>#TU+0CA"F_1B/>*@:L@XQ|T!E%4WV@QDQ%-
M44YXQ4_DFW8K0"O2%/'V M.G9W0O|J|V5GY0&1H/_|V)7_0_7|_RFR1;=E'V7;)&,-DN2-
H08)5DF)I4, M,==2R#9%I52&LE1(=F498TV2?1O++(JR9(9,MV;QO?/^_/?7SRX|KWGG-
=Y MG=?K|3SW=5Y/L'+.A\$1@ZG%>;,!'<,(AK0*<(BS|&,W(Y'@K*_!%^X_.'|

IF^G#>8"%8;0QXMJ 3Y9UK'4-?2I=@MW08%G JH911HQ81H_6
MLV#W7IWOIP2W)IQ\$0):%LK0%FY0R468;# 'AY.T Y8IQS3C 2LJ07W0(U M+@D/IJ"-
OLID) 2TQ\$!+##().^00=3HK;Q&!>-5> TP3U1B_HZ)E=\$2 A<4U
M:3:).||*30NO)L"OHWX'T((ZD\$)L/_!V.=L(O%O@LQ0C3BCI#WC|X^(B*O8
M: >'7.&D4;68B13N%S(OBD4S\$> +>#=-!IE204B) %&A5>_3YL;G79LS^B;
M2^)QQ.YM,D+L \$B A5)D^@WX'7 +EO>,@N;H5E?^Z#!(^SM-0L.EEIFZ8 O+
MR9L(CMQE)TL:4K.M'BU'KT9.: =^W03%5;2X&NQHHALJR[HH3\$! TF,@39+HM
M"G)WEI\$0E&KYR2U8P?|V-8*O-WM^!6IRV5(U3#7.0ZYQ0X|; K##Z"9"VC4L
M0C1T|XQ3SU7RLH#"@XTX@Q^-W>2'@WM&_UE)AXLN^XK6 K>-GHN+\$+J6_C/
MXR/=I?R#?!L.U.73SNHV5*0L8Z(# /4%*AAGN2+|Q*@CEH*G30WX\$PW2>.:
ME6'2EJCY-.9J8>+|- =W576_V2NXY^FSP@07MS%/I?|L.B^CX'(>_Z<8)1C|
M&R2J%IY3UTW>:J9<-:DIL'P^| M.Q8WQ+*-/3|F)|D6I>/:.\$+!NF5\$F#,>#L.XR
H_O(1>)JVDK&#W\$S1|SB MFKW\$RZ>+);-3!0,*7'U81&"/D1|?I!FG\$?-OJQ0;%>^>)2>06?
J=5TA>Z;WR M^<3Q?YSS/8I>HEAS;IEUZ/8*M&|,B^<"L!?(H4L&DF>T,L
M=S9.";R|V"/CL6":_OJR.:+:' NOT3H?@2U&&Q?!=!M,XI |7 <@2A HS_#2
.4)%#4@|H6*L,|RIG/?(5%8 MZUR?Y'GGS"SN^6K_I-
16S"Y'XH\$RN'6L9*_;Y;=%WN6|27ZE7,5^_ =^RKJ5 MA'R>@R4#=><>L0QPHHDO!-
#H'H@|H VFZTX|X((|PN*Y_6D>_04):35Z*? MK&9\$V,-?M24-
#KEF.BF:TS|;Y,%T2_X.+2J^HK;VLO70!>U=7JJ_TU5VP0 M0/0#*(7XNH&52D@0>IP|
((B00)":'V)K,22|1HS87B7U*8'7)ZKZRCO"=DOU M2_?#7;STP>&_V8-
/_3#LTZ\$34B_914.+ #IA9:"+RKF1\$F@_97L7\$P++3T\$J MHAN6|<5?/@G*B
Q%6DC\$P")E103Y\$MN?*Z@EQX0A0|OV;ROU.?4-U|DH*A; ML)47#+YNPG8Y
#012Q;N8"YYOWS9Z0.J>VO9>=2WQX(SS|;\$!#8B/A=0"H+
MA1V\$5W7UX!!HB|'<'DGP,Y.\$6'43/U+|V=#X(|KXMI6AHWG-)SK|."L#L MNOMEE?
H4*\$K(@V9L.SWY8|H'F0P3H%J:5K,Q2X|&BBHR\$=I3,/HK@RJNP|
MS\$2>B8!W/ZK>Q3*Z)G:0_UKT.R>@,VU_95#=_)M R)ASL?,3Z04OHKYK1V0
MZD"QR4/GY=>UQAYS @^| MRS\$|SBG2(^;;9LO*,IK7K;NQ)PQT;PN|!S\$V<9
26YQF|&&HN+V,>/M_3UU2/ZM^"735)5=#W5E:|--@,<7U|K,8C)7
M%17S#H<9+'HI6G9;L3CM<)9(Z|2Q^=W120*
|=^MJD31N<|4+6M|^O=I1Y58=,"+ #|9+ MM^/>Z^!*@K-G/\$DNG@C1|;\$?9L-
H_RW/OS&#D=<./GV-BD%W#.P*QP+49!(5?07P|XKQ'Q0_4-0E#5PC^"J)*0>
IR7=H*8D4X\$_=2/NF#VH0#: M6/V@IP>|N#Y|86"EJJK|D-CA0PMR?U-U,H)4/&?
G8K&UL'JZ+X|= +&O8(W7 M7ZTC<| +%2Z?\$E1DL.8|HR""@,17?#|?%DQSHE>C|
|%=.07_(|H_NLVNB M*KI_+, Q"H+TBB0.^|I= _O,ZKX1 U?
0L)^B!|/"LUQ#+78>Y=O^|K#_MZLVWGT|5'TX.D5\$3)|<0*
+|B\$'\$90M*18FW7UPV|=4&);H- M@^(I N4)L(W@#|R%B|>@8B%!.^.\$Q<|R.J9ZR\$*N|
MCNCZB=O;'BE;|UXSZL;8Q8O (!5)/ @0?5H/0#4XR53^!'!|D|AA6
M;B,BITVO>@&3KPCZ%5QTH6Z9O(!|H./@=FSPU3Q00'*/8(Z;6P^1@<%V>T&
MV@AVD*5Y^|)IEC9_4IH/40@&'F/-B->V|_TNB#KS5YE^B2PO_H)2>ALQH8'
M0*P:F3MX16P#L?A=,|X0ESLE*N1NM>F&ZM#"&=UGI|HV^W.BX6-WS1JJ>(
M!O^K,I<-(!/T#K,70V<)X"&?Y(R@N@RJ'A97U"B58S7J;2Q/QABIQ0IP*J
M8!%D|Z/X(@7-2T&'B/X&|1|F:S;)FR5LXQO/'8J+?IG<&3EULL?X)MSTYP<
MEG'/+:OM5C=7D2E(A|H6'|\$88&M9E?#/_QV.MP^|63+F'%% MJEAG "(4\$
6@|V+%&7|2;JK>9F:#=|DX_|Q_&M-RP5+4HNU8|Q'S!PH|>4N
M*NP|&>M.FQ>_D2W08M@IY|L?4"@8JA)O^|^0S9LF>7NEZ#
MO9V7HF+|XD&9ND@|W0-08^022|DJ+JS|R_#;W\$Z0;44!-F(&H8@|^|WX2XT
M*EJ56Z909F9P|7(V:58A=(XUB3,5&BI_L^>*T3_X.MR?V)W_#?9^#BF
YW9R3X|T@<&1ZJ|&D+5AIF8O'O'N1P|S_C2)V2"/3CY#NW ML#L;'@!4=?
J7&.X;=7ZB;)D.^4|1JW,18\$TEN-2X-.2FCNO)' M2NJZHP;LAOVF'0^<3G\$'\$?
0SLQ&VDBPC'LU;LVCQ-,IOU^|;'DN)=5Z.*%|(WV11_&%BS3/%W5
MC%B_ WS8H8;SV/;S\$F(18+=0CV&G^*.-7+;J-/T4"EZ#;(>-
&PSGI%RJ!T=#@Q3:YUOMT|SUK.6-?56V\$-
KK62PH/*O:66+GC%B=_+7V=%&R8(UXK|\$GFYS|>_P.MWTRK_E<^,EK7)0UEK/9 MS-
L;XY%->V#2V_-R4SR9O|XQ=:1DOH-H*XF|T??X#|9O@CR#3D#JX.DFT,
MW2G/'84+L:UHHL"N8+-8_Q%S(Y,S|D)ETT_Y:4L'6V(J@MA.0E|8'1=R=^\$ ME346--
O\$3@+|= -'3C4A,#C6K_0#/S'VKKP6+S*;ZE|>BN^V|+KW+/\$A\$?|MY6WAFM*/PHUV-
(FS#=@,2L ('9C54 BHX&Z#@9U#8'(|.QQU|UW*_R|_J1 M/?WI5H-|JM-N)|6R31Q7:
(!BC54%B;:M F!;F-(<|3M|9W|!(.GM6P)I(W+A M14'@<|<%S47.S?-B3:L-

A0@60\$/6I'5T/RJL?<3I>.J(45M+O'X,&-@VI> M/B*ORJ2N7W>I'C,HN,*!@12!G&,\$#Z
(I#=#T),L)W"\$=2!4*>Q=W>UY5-@^
MZN9!"^-7EFO\ZWM%9H),*P^BABT0H"\$B)8=1G6&(JVFD)KVSDQ_&9PYHEV1
MG'5T?Z!MY">-9:0LI-8O"\$6N#'(23INPL_V!?!7F6PYT/\$GOG.S3#4SA%YMNZN)_PI%-
NH#&" +1,P7PHX#TU?E ODDLE./: M# ^D6X39D\$ACZ'*I)S)KE^J?C2I9|V|RK8-
7C<|S^L'S=|C@'@.4D6@=JW3 M9&J1*VS|SQA'P?,A+6KG;+)HIDR"|>'\$P(_^??
>|+G17)2K92LI_,#%URJ; M).#I+DW|N5+3VHD?)8AR34/<|B9LW|Z?
#OI+S|GM;L_L6LHVW+@|RSEU!'_R ME#OS',2SV Q|73RG5C/=YA?(<;F<;?/2C9,J3?
WHBH M&YQ%+AS.4MC8@IG)96|!WHC)B,[9-4' &(\$F| S;|;+2L6%4O"A,B7X8Q-&"
M.EU^EK/AQ;UAFJ|?&B5ZI>VVN^CQV\$+XOM<+S&XE\$SDSZ5H#K3N83G3M*E8\$
MVWWL9IQ/.V.J!ZC\$')OG^3++RU'WO?7YA#+\$#AB89KI(QY?W0G'3>:KY8^MUWR>
|5ZVL0\$!(1XUCZ,3QZUSH3@R|F3OB;0U?BPR.6|,T/P2M ;8"RVV.U M?!,%%=F"W?FG
M7#)T>>Q=V,O,3N7TL@|U?9=?Z_!7|)%K30B**5PNB,.U)%(N E,|8J)UZJE
ME(;XR7L9KOS>*;X^|OYG*|ATJM|.S\$TOW/_ZB^5BM|A!E 4HE\$@)C*\$)F MJQ4G
PB#B_XD!756|B!;=*|BW% W(E7,4DL|#K')OT,_3.)ZV;|T9ZK/-H M"4I7#4EAYP
M0L|0/J+MJG@05SB7,4)!KO*8H^LDR'99;V4'D|QUIK8I^_XJ!5GQN0.L5
S:W&AL/KHNYHC|3"&;>|/|XM*H|3GN*/|. M.*IK.OOOC@D_.,\$-
'D'+3084M5;NW_@)7LDK@.@)7'63PDZ| M!XC| =>1@//UJPI075V|4#MV3;?LU=>G(M-
O7GP,UO\$XLXME09LY_S""L&\$'T1H6L9B#IT)R""T4;-WEH^2=_D?M O"TIY
MG;=X1E'(L'E;|PILW72"#W:|&|>V17)%H17)GPCF4(W@7)'3(27@,J1G&1;7
MX%ZLRV>=);4M'BO|.GWNE?J>^QHE|9J7%%Y, U>;|6BJ.EVMRE4,CZ1;QH:1
M!OM_E2^<\$=^3 MBPLG?6:%WS5H-N9"H-7X|)<32TX: ^E^**!O_H-
7(7P/FTB0RD/23Y"2"E.UI M-\$J6^X9R0+ Q|HOR_,B|F2XI/U75'F4C<1#2E=
XKL'1R|!Y0GA>-5E&|+|.Sj: M^8=I,?8N7<5CF>FR7RL|5N,|.N_PR9@L@V4R(@F\$S4(E#>
(NOO0HNH0(@0J|_M-1Z#PO380|)=9^+7D"GE|V:5EIGR9.GP5^U410_|PB>-GU02H+B-
6*\$F/62^ M!FKU5Z9>-6|U3S6'%9F67B-\$'-#N3RDZ0=>=|ZT(KIA|2!U5MD!|,@FEK9*S
M/VUTLU(O#*(R|TE+8OPR_RW=@ONS&>?O.G'J+|"|1CVYA9RTP>J<+ M|AA""* TSPE"?
+2!;.|A3^I+|5_OME"R;;K,62Y+;|2=0Q3+K1BOM<9*QV%;T)E-1|&7;_K:.*@4K-
#O=Y>'B*|L@K84K/Z|N|)|8UIUO,V09.E=) MA|FF!,^R%2Q?
EBRIN!|>T)CN;1KIV*M;E1TA"D.L>|/\$<|#,|Y_+?(AQ^GNN504% M9#L(ENBJ-KU
)R+|".#^!N82796|VL+:|V/&#H+|SDOR.3|:%6L:\$L0KQ;+) M(CV|36(TNO=Y1>W?
\$R59WYH|I(\$+<<0E&*?A2*FH|X@8^*23|)NYIE*48W
M3C*2VW;LO5.7;|000SSC)H@T)W<4DBY'3A0VZ1M"|9S M*>KQAK-
51POB%|G|HLE\$@^5MLCOV^ ^=)S,>|MNR7|_MC'FD7TW6?
-1|KMH>BWZ!NS""*7PH>=#Q@ZFV<|*|7D7GIPOS'03_@82:"4"/.!.+T%Z.Z5
MH#9N%4U!3AEP1>X5>8\$-|HQ(SMM#-.5;62Z5V@M74@=DV_7_MH|+;GH5*2CY
MB#|HP^V8/>JSLLVV4K?D"TS MDM\$-JX343/U/E0))3AH!73FUX3QHM|J|1;I#;
<^8X8+C@92G)>3IZ -NV|S# M4F-LIK"596D#XJ|5QC^&C/1|_VEHW?
H_G,T(TSS4_J/^W)\$KT2 M==-)IW02_%,|H6|-8)7O8?N058!|FJZ24AK:.*@#W75GW0>S%
|&T*?&QY M1L-L?Y2)^O|K;Y|IM3Q35:S.%1&)A&Q!-W^#N3-6'YD4-G'YTUC=|#%UAD.JQ
MH5&3FK,%B|O|+0'N-F'+(+C"5)8Q0#1KUJ'3>4Q!>A2D_%BUF7EIN=,|'68 M&*F)
ZQR-(F>AMVS%|TO.:^/'=B?TA4U0W.%DR"-#N740&XO; I!>8J@GT4(
M_&1BS5FBVBF5WK6GZT:'2C8EWJ|^<5&J31A_-EQ/\$6|C>--R&1H\$DRF)9CA
M_WVZ*^)_VAOB,DFE322P-Z-T4LTY?)UF(1K|. ?+R+T=NKCQSD4U<<#;QO'5_
MOP&1|_GJG85\$MWX)T #)ED4SWX,'6;Z@"5>X_S_N%+HX/HX!|WKOTZM=57%8
M*TO@18.ZNMKV|M.?UIVFVT|G/-(.)3HDICNXHD:|2L^.U70I8PZ:2GQ1_Y|K5\$ MRA/|@-
"B6/E+;4K%|@VUJ4|O(-/I%X*YY(RBB4M|MB9^?U+NV9|=O.O'-4
M2*RS1H*Z:++;\$686YSE >0.O<5MY1:|Q'RZD UW*R^?9|CL6LK,'U'M?"RGW
MW7_>PVK=_P-%YNT/U7IV;L&F-+C"+(8.,QVTC@H|T|B/^L;E"Y,C"=B'N4S
MY^1F%:FMSD|M4|B=^"\$D(AA/OS P>?MHW8PU|L^X(@=9)XZ4+JMI
MUC<2&I('W.X9%C8|OU!K.90P>.OK-IWG(F#W%HQ9!YE-'%8_5C2=*Q)!;4&>
M'&Y5^_\$/%7H?|.LF*3S>@KEF>6A_KU 4SC-5-LLU+GZ9OEL%%M4JAOW*M>\$4
M0X9K|'E;E#|OVM@Z5KNV"XER#D2K_=7)&CD3771J'R)>ND=#1>2?(%<("77M
M!N>QG36WSTZ4DIJ#;;WM0.|_|0QP9S749EC2Z.7;JGZ8ZZTG9\$)_O9U%|+
M_/B.4YYZ0S_(|,|J7 E@)+2:LXA<.6F0TB(3K0@J0?)QMO%_TIM0ROKJJ3<
M.:R|JDM|U@^)Q!M|E\$GEUX|9_XPFV+)|;I?SDO|A+7%W-5;C%>D(;4W!89#4 M%_=FU=-
M-%|=*[H%-1P.CWE|J;LWE-"\$H^0A^!.49@7Z8C\$, *PD5H|,V6
M#Q|9'O@(|L'KZ_M068R-S?QJ(^@8WC?<%911|?&Y&"U^T_8_5V@>D@:&4V2W

MCSMLMQN:\DA>IB9;1^T9X^RAY*B12-;[H=NCG\N044?];G_27J?L,RJOW+K
MI"2A08(MJ\P5465T,)<9@KQ2\,(NE'YMR\$BTU00!TYN\XOC#ZZMK@_KMJJRMM#*?
PORMGO(9S\PSP'%><650<\$"\$90E_H5F*%+4YP R%00/9E3\?G\QZOSO
M9\O1Q\HAXGY.50"6!\7Y,=%(JBY19@_G(7<'Y;STLX6.PFOC;IK:T"KE,-4
MN^DN9SS>0\$8WG)VY37Q8Z!\Z\QOP&AFXB4":7P0CJK4TF>24A;T7B?ADK_X?
\$S)ZOY\8':-SZQ M;:K+'0#E.P+"-+LX98@_0/"H8(=A,&^SK_F726H8IKA\9-
=-3R@>*GS(2 MUG/7S^%JZQ9YVX8#\$C^1M0.KD2P8&&>Y% '%<\$Q@'T!;/%X2:3\3Q?
PO-O_H M&O'!V/%'1'X5-5WYSDB\,@%?!JT%#X&105!/%7+;:6XE4&3K;D\RX:2?98;U
M>;'5\;WAJXH4H23-T31\KO?^JESA#A/(.4H(XAC30"BX3LH;!\;7U4_0J6O MI:"-
:=U>3<_M-EV2>W9_6GN^P\6X*!\.' V\5126#(\\$ZAD&Y,N17_LP#\$BB/
M,J/B@3MU0K_4Q3QC.\$\9&9+@C35D.D!W=IOJZX37-K!W\7;<)"G\^MXB01K7
M56UVEW5C_O":U/:S.4,1>^98XTY#=#A?8F"S3\T7-X6L*4=Q8NL2DQ#3"O
M#)EGRD.H+"52M"J\IZ/^?EMUZ/U.@NUA\1V_VDW>^!9VY09QSMCS4M0+(I
MN")\+',"*1UF;N'S:%8F\;LU.U\$S>G=|F>JWB3/_ZM_7SU*^I\$OF+!0\%5 MBPV
K=P#"2R:@R\!.'\$N41X+3PCMSW?DM\UFW0KWN+1>:UPA"7(@,=A2<'M;!\%2L5(?
!7K 7= #?9S\@D4/\$(<:XLA4-"IMJ?C(AD(Q\PM6*-%?I\$ \$KLWE8ZZ3W%(BF\$N\^
MLGT2&O(L36WXC#IA1TQOUSX;:=C65\BS'!\;RNNT-J\|@_OL2Q\8G7;O+)H
M\)\$VSW'&\$1))>N^;IO,2&%MHS%Z,&4DKG-/AN00K^
M0KV^;M+TQ2L!QV^PD\|N),0;7H*L@_V!\FX+5D\0:#KH8Y;/+I.8;.%YA@_R"!F2<-
R4#E?D-M!DUB*H\JE5P+2->?KFC)3;&U-/83QM#\I?.CH6SOJ;6?-.DOQD86HL\SXHHG?
Q^Y\N6><.\$3^SKJ MV2C\8#\$FB2O^N2K)\WT6->S\!/?MJ@/_
<6\=3VQ6=_QW7>X04\IGJ_"0S'3^ M!+." _97LTD9B.CTOEQQ:#&EXE7:
!8,'F^LXDTZCRI>HXN?E=O1RZ953_U,3 MW*9K\$-L03\N1V)G=%@0K6+
!D)F&\4#QMUKV74?XDI(>_:=1&\$E?^W !;4C8KOLB0(?UT"-BY#;#:#8YT M)M0?^X(H
M<(@@CMI!4FMA2?H+F&*J\72!W67\?XD=X1(J:6P\CSF\$FAS>Z1_ ^5E")7"6X
MVL"RP7R\H7N\YOLYLFRW2K!\X00)T! MMB2*J02\)!X#0,NT735\PP6<1H?4S>&H?
>1=R)E/X^OM?^JGZ2;)B\?;! M3J#0<*G<@YPZQ%7@+J^0*3F!BYS67-J9TO@_MU2P?
62\ "%+R;IC..LF=QDLC*"WPVL6\%A)";&LZ(N770/+JE;!;'Z8D,W>G
M6AG+.O/KBEQ^J/^H\Q>!,D-(G8!(3@2>MZ3+=LT'Y\GO=B5K\DZ8FO"*5!<
M;CVD@IA5YJ;:;L T>M)AFEA(:P2/S"%!GHDLWT@"I
MR#896VA_OHW2GW2V=3AGOAUL1O).R(RJOW.;:_@5SUFU?H0@1O,|H^;:
M+R<|+RX:6)U"TOB@)IHMGI\X.KT\;MGU6.JA1Q\$+G?
5&DXC_(V38\$04*TLV815!'4K\$"L0*<5T^=AV: MVQV/^H;|6!\096\|=WA9\?W)744?
V\Z,;:&5>>(L;6=\$F MM("^-=":LF5TD9UY2\NN8D#'\!/-
W339P\A*Q=2R8\$(4!C8*687GK&!\ZX;<\$ \$OL3:@VB&FV/V1)>:
M;C)2;BGOY)KI"FEQI4\%3' V,DWAC\F!\^H\N\!0F\$:\$=Q#_2RZ5\$*NJKF;: M#7<8B.V*32
6:&*08?0%!=FJN8Q3P,B+1>ZS"TM!H-3-.S\JM^+.\$TG1_4+EJ>)\?N)^HX!\%W
K8X\$Q!\HM^2Z7GH"%U\$'^FL4
MOHYLP:26U3@&274@@@Z',WB.DX5\HAX%J'G)E#P5(D8^Z^K&^@7%X M;@OFEM)\J?
H0*O!FCNG5L#;E2\NV\$?=DF24AC:%!N@-!+R3F&\AR.LP0,)*! M;B?E8 YTDW?
&6I<,7,V_.BG\UP+BVRY\NS^=G:\U'O(A\X0:9J1P&GBLMC
MD3C;K%/(^6N%/,@|3!!E(#\$R&#)_?6^;Y\$C>)>9V3 M!\$>0+4\|@G@8WYTVF6!23U1;6P1+
>TT%,X.B=C9M4FINJ_1G;5 /73/5-T8
M^|OWD+5ZD\0!\WF7"9#GAG;"%ZD5S(O,\$\|@I>KZ15G6LH\NUZ>M!\=6_WB3
M>S\Z<_W=3-TM. ^5:5IU^5IOA6XP?"@F72;"K;AYD_3'^Y;J;9!\SM"L\|@;D
MM5LG?''+89_TQ/9M1&MK6-RK7Y6@9E"F26P4I\$X\H#3-Z#A)X3(R.<87GXM^
MT614X!\-HF\|_@C\>D1"5ZP\|T43H\ZNA=HH(B\VS9<&0+)C3"Y\|<'>AB* M;1+7,--
MW?/P\$ZP\,1HOB&#\$ \$Q.A\OC3\|@-#"?TF774MC.M'X=KW'MD?"KWA(UTVY%
M)Y@_:_S->2\KR17V)R1-&.-21014+;:SD/6T?_VN\$VJN&A/R!\&BG')V(^J">@B@E0DS
M@_%G98AU,E9I# *CL.7<_HB2\;S REQF?>JCM/4Y!V5?M7U\W3ZZ3NS#+^,R M&8M0W
7U5Y"3TGR(>C!\@?G;\#?5 /W!\NF@JLPN5"SW"J%P0R\TY6HQ(Q&_Y
M&B,7FN>YHK_0SAR;:*+L'1IB+"IGMC\K)LLAS4&B-U(^AF)NTP_1#Q#D13
M_G08'=:K*YM^|3\J*=V&LU+^>8+2)/^<@<(V^V,?F\X8M"=
MFN&5^\$+2G99=O(Q+02_:T2P+XT6N MM
_YH;@SHOEWI0\O0RAPV0TG\Y?RD,WGP2N_*A2LP:>O\4J>2:YZB4&WR
MK0H_FFB86;AG>"4LYFB<=V\;:DPHN@9LLJU"H5W9\V;|8_12:6X:YE|E/
MY(;M9\DOXWE3Q3V2;!(E0<>-SDL3#\7&W1/Q\IX#L0X(NAA M7H.G\$CK=UC?
P%2;E?,V8\??L<><'#6\;AI-J&8FE5_8'+/N507/'(TF3YG9(ML)1:;>8=D\$.G#=0;:\$

E864=-5)?6D2=G'G[,?F6P^Z7A3MOG0B\W'0%6N8 M?
F7F3S+|&'Y+ #8IPDH"Z@60KK&13#BWY#4TA-L@JN6+:3+;4JMDYL;N.S4/
MHU|O+LXZ03*_0G!PC8@HEQ/Q&D\$8& ##G6@2|^N%6EJBZ3W_13/9@X&^BX
M_6CDMM.Y|&BS_&#%G_CW..+ '<(V7@!HLMd\X#E^4 M|! .J:6!|N^34R0E;|R-
\$.NKD!NX.ATH%<.,1-6VL6Q(I+DQ;218EQ5%;O M;2<)>9^@O%?O&|HRB^,R#X?*)-R|1:A-
?@4)?("QV DG-73D*J\$SV.[T@7/C MD3X^J;\$UV_+7W"YGO#XE\W;|7\5W0%K"/,&
:04F@Y;^0_TG#!(I(PWX.^ M;^=B|BY>R|/|+ M JZ,0;*ECFZN6'ZVR?-0S)+B#MFNM=D
MK)2A^6J|YNL&M@|*\$\$_#03W/U=-4!"FE=_CXB J7B'4,^9XR+ _F:09O>6^
M&E(!NQL^"Pl:+)%KY,IB4#LB\$8L6]-?|AB^/D'^LT MUH?HU+NRCN=F+QV-
LC^?.IB1V/X!1SK;B5<#**EPNA=.ACMA%FLS87N,7DES
M,2<|S#NZ4L;YS5ZO(2G!W,4N|1K8Y*?KAWK-!0M_ UF5@/H*AYJ3P7X&=H;:
M|<4.>CLT4/%BI M'=G2_B:9QC@U;:X6|;LRHN=S QY?&&F%J#P%|9 GL9S_ ^
M(2#0%6#9AMI.,^5M#,.#K!+#+,Z7O""I=TO\$/*40%I:F^;VA;L |H3SO' MC%))-
!&)U1PV7T;Y.(8| #C1OZ;A_/O9F4,GQR|H|FW'4%7 !G@;|V7/H75K M;:=OGG0'9X##
|HD@P99BX\!D068J|+*:+9AK?=T_GE3=O1;^8QH,2-YQY0K= M:\$'6P?GO,6P 0#0UK!-
"4"8)))*5A'VFT/\$S "KB4Q:K1_2K>8?
Q<=-49^W|N^MA|3^U2WMSW'(3A: ^K#1I*7O&U"O+7;
M2SM|'OX(@E4Q"2>B*2C+Y/DV=)KG:MEL>8XFD79SP8"JO%99(=O|V+F'YAUQ^+K
MGHM=U^-!+;|>?IH0GXNOBEIQ9)F##:S;/9|(?M7AY>/?^Y_I;JAGGM64 M\$NY|<
>6/P^_!/9QA0_2UGAI0?R%G/@5|TR|D9|'6+F&T95YW.K"<>|SWVK3
M(XGK|73YJQO&|+^OO\$_^N|\$5OD>KX.M"TD^Z)7@/I&S?*Q'WOFW|7QM_8;
M!>^3A7/X(|TT(G|_FD^#8A-T)>!.|S7+!#K!*^E"
M2CM7HWY4^>2CE5^6131!M!XN5YO/ T7F#|3Z%HRV%|*N|9L#H\$|N"H1CQ%P9 M
|Q+##C;4")E.;HHN-@^36HNX*,A=[?_"K;OR'1'##&%5M7CF6\$%
(P^_5ZFDBTZ?.Y9|TVWN:35?UE.N|);;%PV(= M2R 1O-5"4*<|DVR!|F@@YV>|9R^>|HB?
1':0Z=Z568-L 8T\$=8W&"VFHVTC)
MGJ"B'Z@W^Z9KNUR>8.)^|FBV.Q&B9K_G8|59+SS= 0_J2W1* @-K?YW*A_E#
M,9;N,F/9&|+(Y=LF#3-.8:3^2N. !L,?2_O>|EP+U-S|S<-QQ8MUD7V2=|(9 M\$8I,P|=
(K|Z@XSN|)Y+8AU|'51|&-U N6?_V(*SRXDSWP9JCD|>:|GSL^/_MJ4 |9ZN067+2_PD'\$?
5|0|NI!+|EXD M9OJTD7P-X=(^&%3;K8|IGZIGW")EYU3*TO|?|G748ZT0|H&? 8B#\$ZVZ
M#)VN@:D.ZI^_G3;_EKN001NU3RHN7|=(*K K%SGPN?V%QAB9S|Y|I#_NGWJ M
@|<>+@%FT|FB "4++BX|0N8LN**|&2DN:0|*#*|U6|&_E!0|'#;N#)Y?DCX@ MV;
L,K;:7^JZPJ|A_!4@C8V(76DVO>%=)M!IB>#+L<1L&/U9>^/N2@E?J/ MN?_N.?
%)99<:RL3?Z#ZTT +|H")+,O8D)Y/G|PC*+#+_Y:P7V-\$SMXWAEFJ1
MKOS&VR65W;|V.=4Y_ ^A=F*'X23?;04E;0;:1300|E-CU+|!|*2QG_GE?@0?5
M)_XKW;#,"@6(!YKE60ZQ473QNCAYI4-CRSN4E|GKN6G98%7\$?S^CLH|+FB&
M|N?;/^""&H4:CM^"|96"&Y!&|&DMC7UMG;H|D>JOS)Z+N!;CPZ| #-|YWKI MVV0BV^|
M3&LV7=:(Y|2<&3C-P5%U9(+#_C|@(^L++_-A6_Y|CR|8%|H|S MOU
D)Y;P:K_QA7QG3;F4R3PR6VJ"*P1GB6-'@9V_\$4JA_W#)K>I^&)SKJ"U? M|9*:SNB"5=2;:
(7Z-M|/AQI%|GX3CZ81SCQ/3)\$%;| T,7WS\$VRY,JZH)&5@ M^JP/"(L9FN
7HN6F=J5Q66'R|.Z-8. QU|L/UZ'3CSYK\$>)1_U|I-;8?4K5
M#0:VS)M,'F!V0BCU'H\$".0|Y|&|.3!K^IC2.P+|%|W"W0S9IU/98>-)#4D:%
MH>: ^5FKCM7TH1A^SB_/\$SA @?MB"U>?>V8%*XJ92>G*'8S48R>_K&_)<.|NC
MAV7|_|CMZ_YBNS8;'ERLZ9|A)=3+-_U2M/M(&!/U\$=0ZFRLV#(+ (VTQ)4WT
MB>X|VQB3U%RW3,L|9>|V?W/!_*|G=D:R)(G#(2M#8:N5 19>BTYJ)>>^|AT)|Z|LB|=9-
WB>NSR>@WNRQL^#KY?(JX(Z|M*(Z|)"ZFI;*P,^)?N,R^XPL,FTJ.U:N.8T7EKR(MC=?
3:VN|GFC|O"Z|KX^? M>9|U+\$1"B'CC3|>M&U=\$BW?^YK|SVDZ<|,VU*3SS\$"?
7|C0ZQ/ (^J;*SQ6|=
MTO"6=V2>GQWMQKSF(L'_26<0FA*WMS7K!=X5UQ|L2^PNE7YQ.N_\$GG.ZP=.#DM6+
M#!Z3\$X|Q%WC5JH:=0\$ "N&(4\$+4WF+5|Q*OWB?-SH1;?^6;167&OKOX%2Y3Q(
M=;IFM2^I(4(S?S&-(P6-2|TL/"9UP4|LO+K?>A M;6.W8+?.OY"X^J9'H?(KD
RO3NG"3:&X.Q/ /OGN@^)A&N<8H5WE1U|-'AV: M|6Z+%#5'6BALS|J54QMOK|Y<^;|!"^?
<9/6RI(;U%(K)JC-=HLN|(=G668'A MV.'K|V72H?HF|UD5;.,#5|R=2AW>&(5FO"
|S1HWT.7M@|7E^UP"WLPX|*DIFSJE&-P7#;.=@ #A83*HC5@Y|K4I
MRY#OGH16"UQ|*2:_CCH@Y|C|!4RNBPD)SG@OUQ2W^_S*#KQG.59|Q"5V?*L
M0P#1"4\$ILS/DD7W%HD' *H5M5?2S,HSJT>^ZM<793_\$K<>? M7(2I>3>:|&*? Z% 2>
?;TN(JX&!?)5EMM\$1|'>E4:|=M1^49RJ<2|A|Y MBBGL4514%*YOOUC|+D%_&_@)
|@B"?F0 W)VR\$D\$Q0*?|: ^M:JZ@'!3;:N5J2 MSQ 8MXK5#XZ|^E1%V|>CI?

Z@V@%VYJ!!#T_I(=N#X-S15ZQMOU\$;%MK':"T
MQ5DYXSJL!+S@7ZJ5C7"AF'ICWITHCX\+48LV,V\$8I)#!:CVQ7>W##S:N.%PW;5^<)5#>
M.3ZF/%T\7:5!KE6E9MA\X,7LJ5OTQ:J34@2/>/Y2O1^?(PI6FL4N/!JRS MJ^52%NH6
8IOV8COQ%:QKYW!BF*:J;_A19<4VI:Y&9M@&.0')CDYMA=9O@!Q M!R&D,M%/?/!(T.#
I8X_1U\HIG?V1F1(6.D%H=&H\$#FKS!O\$(.5Y64T4(0"N\$POX,(W_6^'=+'ZKP4/I7^
M^6R5U70!9L#+|N'G3I(5[0YPB01EX H")^T7RBN;X6L79J-Z_1^|W|/#>2JXA M7;;L<6|
WJ27PIHDY=UMNBX8W,L:++GR8\R8 IRT6OR4Q/S\$RO*|+CN:HGP| MTZZI'|*C6E=F-
3XGVG;:=Q_Y/.N0PK+?
Z:4YJPU;C9,%!)N0.?:J>6=M:X*&I17KSTD53+|HZS&SLRI#M@L-'U2E"S/JD<|XJH
MLYWSTAPN_G,U,CJR"/AB,C>ODL=45@;00'6>|DG#:615">V,2C_ ^G'5'*S M)R<.|BK.@*
(N8_+4=A4CJ@-0^@DYVRO+<|HC-SD.X@%1#?FSEW(\$WV:7.|2D M_?5AJG)JL48
L0DNQ57'?@+J"&V9P_7ZN^+RNBUS MSDU^X0L_#%./9^E HTXC-
Tf8KP%"ZZ<.MMFZC/ 9 &[0CW7K4] ?U+4./+J M|//%:\'/;-V.%E_-
=VC"1!)EFR@KYS|+S2[BG"E!34?Q99/X8INHR*F'3:H M|LPD.HKR9=
X/^|.RI7E*-3KB_Y3SN':^4=#MF|+=>#/#W*>3NO>1%!6;M|> M"33)87HYOOC^@K
NDD,XSK<0/Y?'?(9@O\$5GX)F&|&Z&|P|\$)0NQ#L%#*-Q@ MGH3FAK/|PQIH?+T?LKG|+|
NL5TU'^A-%|V=-?^F^|+9DMUZO&10GUCAQ,N! M@>-?
T6O:XZ|HA_AQZ,/#|KR|W840XLJ#-;Y# /7T2|_KK'N8|;"W/RI8=JC M^:?'|<4^G_S.'W|
|*.W'CP*4(R/?8J+C8JW;-|D^PZOB|FJA)S\$RW38;(WG/ M7_9_OY
:NLE1/M%0DW#^P(:.'KOQA&=6K2,6|N<|Y,/YT8T1/UFCWV'&(VZ^ ^A.N#?
#\$\$L8,K%6PS.J21&_Q)4AT10CVT|+#+;|!^U',+2/WND^U
MROO7B@:>8AZ_U@J?:53&|8V7@03J6J(M4.K|"IQOMPFO0AF&*?LL>9A^:?)Y
MW9\$TD0"*D%|&F_J#_.59F+B\$Z#2(|#MW'2MRN6;7PV<M)J?K:KP.?COW?
*:DG1%FD!'6MYT@-B6.V@XTD6.QE ML8B)4E6#PVFP4(==BQ9NGH,WT;M|TEVCG.I:
|OK\$=\$6'5^M>#=#CO'|W|ES6V MI+M=
(6Q/HFQ|XMX'W07J;RDP&|@!X(2'6X:="BA!DWM"LL+9*I&>5%DS-S/B|M_PC+_ =Y35)0
|7K^/_D@,'45#_DGV"WVD\$E^!N7K6L MKOZV+|S2F'S7=1QT(I>>H0A-FO0VH9E|G3C
M=RZZ|F#TN|PT6*%|BOE^"X<)_Z&*@-;:2W:=.7SI0CB-2O)^P?&3!1BK>@2
MG4;6M7A5T,|E/.RH4+D:.\$%WY9N!14^WH"1R>P|5+S@S|_&3HF_E/Q0Z
M;|7\$57=R.@;X=7%U*R,H0&_8* MC|N%NS(F GG0RM2|O)UFB6; H^+TQ17WX|V3|J?
*NU+|RU|Q.^XIDODS3W=ZR M@_|Y?42K>+AQ A'U6R|+%WA-G=FX)S;|U!MXY;-E?S+/
I*|2:G*AG(:HO M#=#T>)#WB\$|2HE"TI!CL|6KXW#F^V;P;7/S;=YW M_)W.WD!&?D-
:8|69IDMJ?B+D|J<|(XG3R7T"|(VBO;:=:<1^R*U2B-/4RW
MK*.H>CMKU\$V8/WLF^F8/ZU/.T:\$.B6L*#^SAJ60YNST8'68R+SV;JX1IH.#2
M#&W/EAS1SA|&_H@RN""2T?K(X&14H890P6+^&.LI4!1"*GXV&9IWTVJODZFF
ME62*Q^_/#|((=V.C(4.W"MDT36X/F7Y2 KX\$_S_VW@.LZ6|+|%PZB(D40I;>H
M@'01Z37Z(OV% "\$J1%A&4)DVD22"BTIN @-*|)(Y(+Q)Z0,1(1WH(17I""8\$4
M;GC/G'O?,|HWY|S,G3LSW_>\$LO+T)_NAORTH/&H.(Q*;&R_3,Z;:(HX-R\$8RQ>#S&&*O8
M&<2BT|4X+QU;?AYPT?'A;=%%,ZD?\$OS|_^PW_7BV8GO1^G,\$,E<+;%N4\$
M.+HNO,C68\$1MVK^|F,E0Z3*Y/QYGV|TJ38 +|!V M?^3N6<.55RV"12ZN97,\$*W
:3E?"1SC&|;+@QVEM_Z-1("|4B/ 8)W8E?H&S MXO0FJ'>.63U6D4&%/A3|77VYW
MPCO91|3LE&C3+.(Q(F,IQ(Y@GE'WCX@1\$LC12|V9UD.^NT2U0UNFYJWN2I9, M?.\$?-
KVQF1^,3|3#?'22%B?;!AD_P|Y4Y#|G6Y"DF7#%F3MM|N>:=L>2?-UE>4
MN6UM+M8VA0C%67PUX,U^|"/(=3F&=2K?
(N>EZ*HE=W5LMG<(84PGEL)*NDGXX"X5?(6D-EC;96926K):!8XM7""NO>|+V'+-
MIW)P%A 8)(&>R&VRZ-=7U|+?O6=/59V/93?Y9";*X>J:.*4\$OSNX|Y43/F2>
MR;+Q#>*>M75TX|GF;-N"B|_2"8EF"(1:%|7CO#SY-H|P4=F2DF9,*==S+ MO.<>?
=&DCI>'>'(B_=N;|-.R7X|5066PI>CZ5|_7RP7;
M*32#>|U6RPG;4AMR\$SEZ_8E6_G<5'9(RCM)^%64SO+"-S'-*>874'KY<\$VJ1
M'#9Y)|NARB_*X/*|2Y"C6#8P!|K+S_)E:C^ITV";T!79_*V#C;EZI9G= MH("@"B@
89W".'|>1A2!DWM-!1^K'!ZF#:LK5Q:E1NSTZO!,>SUI(|3X@F+JRK/;|SNB-|7_&>U
M:#!>BY@*%C562|;|M,*Q(K'9*3=Z.YG*LL-L,5G(M,)|_T#-'Y<#;>BT:S_'
M+LX)^=;U|U3;|T;J\$=Y M|'CMQEK@0KUH-M/FI4X!
(+8;CO<+JY\$PU)CSU#|_MSUHW5ZH)&\$?A2@');O?)2?D<*3&4,JO!H2>2->MEP9>;
(LQF5C%6|HD^/+XO//4O+@9QW7W:O8>S:TV=JH(9HK-V;R@@?@PS8-
M*N>"69KSAQL;=AX-AN_GH.U&|GE2:NS(3@T6?|U|G8-?2Y%E71LX%AWZ7TEH
MXL;O.T2|327W_-3,J3QE|A|T'B=|>H&;+PD9L>|*P29G.,DOTN%H\$:W_|B MVVEIV--
GED3N/)ABJ%T+:@T"5B#;*.&/'*<1L< Q"@ \$7_H|Y?NLA!#L MFQ2"Y8/K;I\$H?

VE.,M=H|/<7R?E&9E5'JL>|_)854K4|&|@N4'5D?*_KH/QOL4!RS_H_T'_WX|'^EVC;'EN0
MF7KGNLE&;!6U8C?!.3A#DA_0?Y?STY+Y7|P%(0>"J>0=J10>UWD_,IN_*N488+XB
M0%>XJDUM,J/VTOJUUY&_5DARXVW;1Z)-?F1*[C|H_|I?Y+@NG@7W"'?VP>M
CL,HCT&_,I=/08<\$,Q7KOU!G@|TC?<|&FD&YK|&?R#PG_6A'ZW.'1PU_1G|MQSLUE(9Y+;
IM>|Y|*(AGC_VM7#21:-NL!=KO?VAV?MB|7E1K>C!P=84W-^83,%G;
M@O;U5'E0+@8VZ8H/(M!5(#JE.-N.4Y69C^#R.D>' +UY:/TJD>6G-TI_NV5
MG.0*J#E1PS|-BN<8@.9(=:!IT4AT@;4:F-ENIXBYD3@=^F@8UYE2WC#QT8R_ML8?Q;-
/A.3=SOP1)?0P>FZM6^)#SE^JH%2D,K@|J\$M&S=\$(-YJ-SGQU?06EQM
NI2U&4)F".2>X6YR4U+5:LSM+D>)Y#T_)#+^^MSXMO(=|A_DC'#T:O(X!
AP(#'B2.+;\$^?G_XQNT|=Q^?D4|HC".Q(_C73@|M*XP5"454|1U*+=RIVAE4^%S\$Y)GQ+
(#BT|ME/#)6O"MXK5SBBE/>=&M-R\$C,M|OM0ZAMWB"587MTY&*
(/L!130.Z|G/*2033GW|>{(@11Z:O_NI_A,AF24EJO_M5-
8CYK/F=C0?P,^=:O.E2NV:EN)9|=D^U2FJA|U<MRXWP*4Z|"Q8HA&
<37^I@P;F5B|ZN#7^?M@9'/U+^G5'(LOZ>U|A_XC@\$+H#BYN=/.X0>I_MX|!|:#5.?F
H\$&-M9:2RZ_^A134,>!T3>5K VW.M%A|24F-G)C3|-^|"=X"^M:H%+|2Y(EV@;_/Z@O?
(L.5M#=(|T MD)!;|-JJ\$.;JMGQ>12/+IFE1_!BP@1RIVC0GZ;>&N1X|)X,-R9\$4\$(\$6S5|7
MFT.8W;&"U=W(XAY3|_|^I8"#KK=J&SZ/8@|LA|&KZL^>&U2ZY>GC|W8@;>^#V
M4PV/-%6>'Z/&R6&XY:2LLR|BSW;5>1X/XS-*7054B390_M^L|\$81S%:#YRO
|%!O) '\$L)*9L*&\$NU_M?.Y7;QI^X\$80#(=TKA,TOF,I=K%|4<-U8.2/VW|/#UED,UI9!N|&>:|:|
MTVVL?47PJ5U_4!7|2&UEW4KGP_!(CW5)0?A@JSH6M!&(|5Q0CW_98H@.X-B|_M'_K
0I8+??IM.F)6&8CEROM;!BN|&GFE@B_MLGC(T&.AV5J=O'.89E|3L6DT?
R?,IM,3M7T;TM!4RF^:MTOX|+.&P;U8;6|W|27_M8^WG0X4N=
(+|@C%8|H004.J0JK^402|08()R82LW-@L)1'3F^Z3-M(RK_)K?
MA%J,A)1(X!|0Z(1&|CYJTR|7W|435K4))D6#_J9C*DI|+;_+@_6_C^
MO57|I*7VV_|>P_.'Z4,LA04?^PB\$8GC7?+X|*E_M<9'YIPU46YA^*/5LH?42%
(1CON!+5!&.\$|@46C526DBA(KKGCD^/TH/X8A@_MMYKJ&M*=O'?FCG72K01M2-
;KW|90K=QI.0:TF1|/H&"Q@H:F1L_ME)?U<(#U>+HX)D;CP&WK%"D,S!L186#|
|/>4BU+2OLXZ!=CP#'|@926%#?9P_M';YWYJ|E-_^@^*+86A:K0909JPTWQ|*|JE|
F5%3*-!PC+?@SH>)V|_L:>MR+%/|#"!|D\$27;SMS9A/"5-
6/C5UN.#LJA*T^:8ALMX2V9BV@W_2V-R8^(#|
MAY!N=_KZP(.3/U=9'0.RI58HM""22RM-2UPXI_\$YXZU_810^G3;>(^5,T0_MXE,Y5"N
/VL(<0JH!Q;|H9|_E!;4*W-.5MC.HETOO|OP\$W2'9Y'SBCCS=/
M"TOWKS|RFW|>T;9CT8S.G57DY4%E0C**ZZN"\$Z7BSHBS.7)P1W2V!_GE?
MQGD/RLM4V%^\$N5G\$%|CR|V8<4D1D%U5NZ.SM5SB##+3W_-'/ZQZG.W5&=TL<
M^6>!SR726?|E9J<0A'LM6OU7FK(.*)93UTM<>?+&.<^Q20|K|@ACH1495BYT
MM<0C%D3B;/PL&EJ5UQ0V0"_Q;+GQ3+8'HP?E;R-O4|NU#|/ZY***AVI2W3Y|\$(|&69|8
V^S@E*P0YX|T&MV=MPY|MIL)TI<+TH,*D/8\$|_|
<&W&^XEV"2C3@"E0H;&|GUWZO/3UK7\$Z4GLE",O|SQ?+E/V;3*--
%4N\$!VMHU3_#V8U_1/*DL;|!P5MAEI|/"<0^=VAA7^%8:M.@F?
JO|=U6)%.|YB=#2,2V41Z/+2B4?T&/#>L)Y,@&!+WYG#_0:S8E/OFU(Z_M!Q&_+KD=
X(Y2;)_OA#_#L|GUGAG;|.9|"L!L_LUMT=?1XT@&:F0_W3!|A+E_MQVPZ44H.SX7|N#9%
(4E39?%_O3?-@.O?#!+|>TP<189BX/K2U|?%F|D1G_8|MCDY/P>9"J>L!^O-%==*J-
CB?,|5SR29J;N*%(OF4&V*[XQ@0"OSSA65.)G4P_MJD_Y=T8S_SM|'O3MY8H,1?R5"0?
W\$H_?^|1%|E.QG*_|.9?)|;+H&87_M_M*?
9C%5_7MS0UF>>:L1G|6_Q0V7,^AC.JAZ&)A^P&>O:_7NBBO_K|73(V\$MM_MV5MGV-
P%:J@O@+\$V>IWZ^B_|@.N|4_:D)_|W&=Q!2TH_&?<|48TZ!5/SQ?T_MS&|&5D50Q#7_>
(D4|C@+EI6)J6JO%-"F6?9A#0>ZYH|I?AJY;F:IL|EK,6|PO;-'??WS2|&&QX|8-
&BS>|G/KZ3_^&Z5_4Y16L8M3_MI3PLWL00XRK|;7/<3;O:786
V*P/%6K^NQC;&|L(I3SG"2)_'JOO_WNOR|+MF".)P'E@O^*E*>?-252;_687
R:S+IT|G4)5V|<LR5@^U^F_M%;:BJG/%QC\$L_COH@A@#;ECP*_A,1323
^!M"O|,"|*D1|.N30G=|:O7Y_MW!|ZZKD;K@5.#: +Y'H,R\$!3Z#|
|_A*.Q'I6@)6_C400/|ZTG|76J@S%:T:M@B!|55_*)50L:\$|G|1APMI3"_BO_0_F|+M_G0EU#
J\$5B,,|P/N|,"P+M3C_MZ|P)|ILS+Y|_\$44'_|I\$)D%ZPC
%5(B=DZ215%/J+|!8_YQZ8MH_PO C3>##_M@WBU?SX+X-^J=2D\$J;LY4YJM&|+!|SS6?
PM'-MP*J'4JDY-T.M9M=V_F07;
MW^+YPB*UJFTU%|_95&W!O_GQ(@8'3(KU=5LSZ;>Y44B>/'"+4(%X*J+H|9U
M:VAH>8?QYI?7*.&,9|/M2|V|!;J|!U9||=|+Z43RI=B%!6"X0"2\$'7HER)6E_M;#_-H&|I-
M*Q|HHT=0GP?%|I|#8>*.E&9C(^BI#C_>O/<(PZ_M3#/XN@P38*A7-

4DH'@=UV#3H [U!UAM?T6_<60FOSLGA[T%"]3<(CFY<*@ MYIYZ@E32HA)1JA
!D@M_,\$LAA6F<)>#9'U0^GO^@'4SA5(!Z^,%C.TS[99CW ME^U
(JO_*OF,TB[JG7?/#0AU)N.PL\$_AUT"\$W9R^]_<>^_CSS.Q<+V=#!4 MMCG_.I;Y_P8(A?
+_59_RC.)YON7.6%Q*SU5P_,IL/D?L-#GLZRC+>!29Y@+
M3B>L)IU[F17ODZ&K@%#F;13]N6GP(=18*2-
5*@VEN:SUI_15YW_^&;H>!G#!LCS"C%^Y;LIA|MAK<\$C
M%L+S'/@F'^@ZU6=FT&=.YABP2@6A+4T*U;2TSDEI?_KD9MS9UZ5F9E'3FQ8Y
MQ2*UNJ_Y\$B!B_H+X45Q<9A\$KOE!%8EWY6J13FU!"93;R-(L7';^J,\$/A6#!
M75^4/5H4BTMO+!@\$<\$E&!3&,/Y\$0[WE(7D4:D5D\$)19^SU5(E>))P[^0+)]3"5[8
MHVLOUQX=XCH;..W.C6\./Q M>^T+|CJ32JT0S8\$XC|3[W4&VI?@JE^OS
V[A9OZ+4,>,K'LZ1^Q2F;+V;A MKJOYRFOL)8-8^D0:1,Y>*90.V#B_H%4W"
<:+'.+)2=*) 3Y9Q,L_B#MJBH MJU%;H)I
*"GI>T.6!\$@#;JY6:%WTN,#LY<)U9D55#A[JX"^H9V-1IAM\#)2_MCOL6&V!-
_*0H>#5SN1R@\$A59_9@W"2I6=SKE(BI?P-0(U(I?U51*)X
M:C&*B7!EJ_6)%J1>2_7,/I/SRK\W|PGCV\$N.J-@"RJ:RT.F'I?H '18GN8DV
M82^%LB%54\$=S>CAK8A M%>^_
_DW=ZE<3UUZ.)\$;%#ZB#\L62U\$5IHSAEK)_D5WV"XVGYTW20_E_G=(7
M:XX\$B7W,F_0!0!4+SH+5G\$*
MU1(\$'0MKROU464"1I7SM7'A2KQBYJ6;ES;A7OABULA)I'O_.SWB||5VFX|R M
&)78Y%6\$81,;+@|KO|H6+\$AN?N9?>74U/1:P<"N(H"KE=%L,MK0-\$I EJ\$ M@J>J-
N!;X5!MD-7MEKAC@#8B;@K(XM^RSQ%Z
M^'4|O%#R0|O%#1R)=\$'Y_V|DN&&+_KBEQ;X-R#^%@@V!V=7EUE1T^,QY(RKV)T
VN"H>1W)\H2Y=;% "0X5M=4_MCX^*,CG."IS\$&3?
3JV|P|YM(>O5SWU7!YHO:XB|NK86|&8*9?784Q0<|>% M+^=?
JZD9,%ZJ,U6_3X&%+'^H#D&,+6<)VK|HD,BSEGRNEF""3JH|=VXQ>0
MVGON^_,|=0G%O|+>3&I4/1;^TMV|D29FSE1.@=UP1;!\$="ZS98H#T@H?4&Q_M
\$.0#@U%"|I:8HM#G7!OQ,1:&27.N."2)@42>?C=&G95[7>N|N70KXFC,NW
MEG611G&@-I:8R?_Z4O9C*ZIZZR!&(B:>B-/?6PTI S
MS7%.3V+4O+5_FIG1C#VLLU)COE+Y&7|,\$.3'<2XP/%@^#ZJK220;E!XX M.Y=?
8J&W:VAO8U^\$WS70DH>H.|W*WF+.,@S4;Z")IAP%WGIWULE4E^E-&>10W
M/(AB_IWxEV,FW\$(_IL94W%J&3W-RNOMJ"NBJU;SQ>FW;I:WUWBE7|I"Z%&4JN M?
XPS|QH X@6PIGNO4)V#G:7^3;H>&GH5#B9NFQ_H#BY=S%@A/WO(Y(!->-U M*<+X5Y
(O4,2:O>KA4-%90_LU#T O#%P#*!C#9X9@|4XOMD'3HI@SB2OO%S&
MG79>*%B:QC.J"OBZ'PH|!9X+(+;U7_JA=|S0"%<_M3V(L6#I(%1"O&5JN'?
T11W0A16SfVS>"W|.);+(@;W*TD/4V5;)DT<9IP)G MI"GTBCA|?
M#O:6M.L*KEQ_4O>_LNNN |!.<=0BU&,_I-S2A(I:1;V;4M(HJ?
M_EQWD/M\$B%EAT6_QH#<2J|RV\$1P)*@TXTN4IX@J_D#@_NSV,2!N7'DAGJ"B M@U
<|3F3WG\$,8-0_KGXZY|LB:S%C+>.)E&I&V>;2"HP>YB#%QA!Y*(O: ".4 M*.U?
3:%'8N%=K6)D>,N58A?6?:XP/Y-S4|KJ%:W-:#S!EZH:3IC.>;\$(.8 MW%?
MP|O/C^!-7D_NM9.NA!9&D)P'?YB"2>PW'C:CYP@JLOB-81^++9(F=@6-M_@:-
N/*D>G#>"F&!;Y)5SC4VD"FAA;S*_"?PMU56|S+1
M6+G'>3Q<,D:A&=#;Z1|2R+U|JO@PXV\$2GA-921#VVY BWO(76&^W%2-G0A4=
MJJWZ^!0GKZ7R9PXTW|S>?BY/6CA)6@NRAU^@=,!J12(0CK%^MHRT)|MS&P=H"
I+D"N^&|^?HVMHU|H5O^BRKQ=>)C5>UN9>_DU:#O|.I_3 ME?#""?B^?EPS\$|R
M:5/0^.T=/NEKK2F,/Q|CFUV|VWG|@8U=6((CNSK6_NW4,(&P&?Z+1;"1S"U>
+LJ/L8P_ OJPZTP"F&2LJKWS.(M?&#V?2'P>8KN2U@ZPS?
SY94X0YB@V=O|@1&%;S>\$ \$N|"?|PWR=B%3OPK1<(MRF@XXT_=(V""7PHIN%
I"=+N=Z;37-*;^Q9YLC#R3VJ./O) J_*RHYY;V^'L M3_<;K=._5'ZN/PTN)E-3-X9WZ1*!D?
UWC"@/RX:\$U M%J3U2\$^OW?KI-XXQS;3MXEROQ+=)|*EX=#K^#/FM?&7.)'OYE_&(Z|
<%AZ'R MKL_GFEV+10XG""X616UYC13QG=*E//+90D#8QH"|Q.3GV-8/+%\$1:EI%E9/2
MM8ROAJRM#;_=_;F?K+R;_M5;./!F*=,2M0'(*JZ84=K-I(-L V XGR/C(
M\$.=-84XGE_EL7Z0Z|>%#MHO"-6<@|>QZ1UVI"WOUFYF+0E/F:L&|7L,WK3(H
M)WE,U\$'S89#/.AN;6&^M+X1:I(\$|KCZF@D."#+88+8?VCCVB/8>)C32-#3JG
MO)BOPKX'BT;9X&J@'R'AN0"Y3^608GM;9C0_.6=*\$G<\$_.6.1.EK5A84U M3A4O|!
I|A*AF?=B83\$ _%'(U>T/,FK|X@81/RNFTCX* SZTF-E05@|/_L?+ M?W^?
B.GT&W;>U6;|Y+.*@H7CHYM5+"Z?&PQ,&^&V""G6?3A-NSG%36)PG M:S/?
*&X^|G\$MM|H|W4S5#A8Y^&MR.7((ES6_L\$X7(>" %^!1U@WO2A)?& MPS8G|=2TT!"E
>&HZJ3EJ94D+CJ/U'Z:&\$L;Q>8WG&|W,8O""!OHU(5!C5^B^_8OJN M.Z2UCL_(>R./

1YS!"40/I\$PY/T62YON'6NAM7(W MW@;?N%M\YQ9P'(+P\$B)"U\XKU-)\$DV-
>08@+UZGYSI"6L*L!U_?R_7\MX"QOB\FZD\$X 9X =1ZY M3A%V(3B-B.NQLX0M1&UH
ZN;M;8IYVD'&10D_8=90G'RO8(DA!XV7J>7; M3C3/8AT9_HTL=@R(*\$.XO_4MSK2P'-
"..&D9_&\$J'Y\B1JL4U?9'7E#PC+ MH/D9V 0\$[T2NJ;V,-H/7.';Z0EAUT!,U"D-
F"SH0013EQZY7;?CLCOV16^4@ ME2D"ZR%-NJ2*3/&M&X.?Jl@#50=^&W)2J?E4\Y-KZ
MY(S\V&VA 9%7E6_Q8='N34= S)!^=/(X?0Jl1
MN\$:9A7Q6KT1610,8)3TNF7&M'YM\,OCQ>>C5J\$?%G
;1+BI2Z**%2'FIZ\INMNS5H3FO:N5EFWT.DK\SCYO,F6\&/'\|*7GH ME^>:R#K3Y7#PJ6.?
^0>GX2\ (P76\X30TS D6(P DT& (=NZ@[8NS-I*#!.^B(M^%#P5KP^)?
354@2M\$,WX%Jl8">D7)SG/7F?#W"/VMEF<8)*0VK/CZOD%%1C M(-
)YOK_F)ZT6_0+8\^O&SF'6^.,965@DM7PN+?H\BI1FK;J2K!4\%M,*3M4_MU*0RB8;-
Y\TEF53A()\$.8A,#Z:2)O_H0?A'!)>7<_8KX8&F27T7F9#O.[?G MXOP\J
77\>.@>KK7,JWH\1R/R";LC8G8>>7V^?
M9AWAH:A^YWK;:P);_L KYL9\X:\$'-50A&#XM1O&U4XA7'^?#4U4B5(7\&_MV7-
QQ&\R),'LD\;YS\$ALWJ5M8%A+"V=+3)P\WS8GD?|I'-0K72S(J M&L\$L=>NE'896\$?
3X\$,I):@G:#^L73M8&=:N2.\$AZ"SX=52&-@\$CG@X/D@W M'*N0CUR\$?/[V:/>RZ;FU
83#H=+E 'NE7M3D1.^B^4HAB:|UWD<@35;|U\O
ME@|XVF)38.!|4EIZL_VFW73@315\0PV=UCY^IS0@6&.=GA'BPQ*\$7L_F92 M;=L\$9*
<:2WOB?7M!O#<61*8TGP@;RK^0PAQ;/JB5TG*2F,1:\$JZQV)H(K>D
M>^\$3*ES\@7FU5GUTEVU065\$+O@D<|9>4>0B:1#BI,",%4_NSO3\$NI*O-G M-
&P>J;R0\A;:56_B\%5>TUMNC>8\$T\Q^E?1JA(R(NIE%C^935ZGUA)*V)D'P M>|OYL/E?+
11\$-4\$+M"E?="Z""G)1N0U:'Z-99*H5Q0ICS4NB\J9VV&-"!CV&,=:5ZA%9:U-X\$^
M@7L,KZ2CQ\J6NA+SR;DM\|8XNHQN_%2,I+_A*\$|_?"2M5?WDH\|5%_CYO1YY&E*-%2,,
(-=Q:2&V>"X 1*N"(FI^M2UM)T*0>EH+| M64&EAVDGN<5/4@,AG"H)
(M(1F_DX\$NNZ\71ZP\QNCBS=,;WC,6\49XZ6X\E MOA:+^/*Z^|8I@2>F|+_ (V2"|^,B\T-
L\$L875\|?#3VCY!;Z,EFNL8GUQ\U=| M>Z>5S\84)IOAV,CY=#OJ4%BX\|C6O5++WU?
+A.S/#0DFD)JDPJ=QJRSDM:377QQ#;<:_O^0(_V6?+#LZ\3
MKV69\&NA^|HJWDL)A!0)1LB9B&2>_A3CP1Q\>H"W\6'XV,=61-S7P6V19/LX
M.6E\|F3936J&DB?M2OC?BOP@E8&\$D3A3^_\$>W84\4FR(\$HOTB*O90O/Y3=ZT,
M:2@|TBI-S+)BY,KO3&?,4X-J-M=\$&Y3\5;.^)&Q M2CE^MPHU\$30W4!>
|H'/#R8&UZN+W!@SS_/S..>)/5KWJEL:A;?2H'#\$L;'GV M<
M@|JEN_2T(N7^YJ2+=A4\GN&/#HD)\1,X@/VLWY.N2D!56J\$7\|<|/+,|9D>
M7&V;^GMS.ZKS(4Y@7X!/FN,%"/'8>^U>S2Z3*^\$.|> HA;N/DVT<+-H?.;O M>0C1H!W"
|7DLXAVOXT'PI52RN=)1A8B!GLBJ\XXW1H3\$#L8/\$<@+|C:|2\$A-M03-
6^M;HE,OB3O;4^:<4K_6U0W/Z-'63U09 M-8>UFP8K0,&\$*7NB1\|H4W)\1%.
{<(G/@S.*IA-"M(4R0TX3N 6QJ(T5-&^_QT7_MDCXOMT"8RO=(-O"?!
UO!.LDVI92\94Z%O)V+)%..2;%..1 M_V7\|R<+P^D#A;#!&.
PD/9;U1<;XM\97MPKI&%R7P3T!3_5^?U3F">+1>G96
M(JP@EM\FV\|L80_N\$HIQX3T*EM>B"SH<&IJ;WY\JDCX7/3J=%95=I4Y34DA-
M\|'87+;4+)-+><37H'%<3\W8/=&H;1?|CE7913(99MP?67#G"A#TJLG//*0 M!W-
H+XBRP?0R7J7A^U\7383DF4TW\|M\$7MZ^/_|CJ)&7"1.*PS=IH\|P00?D MY\X"IB/X#-
\$,:%+WKKO(13=&5\|CFVXG\|ZT I\$8R%O8*>AX#BJ3<&"1STN?
MGW7EF2U_GH)7X!/,300@P@ATJNMA^!+IY^X(0S>)CY5EE'8R<+GG,KS:E&T%(M(-
T59X\|;-KO?(/O)90AU.X)J9EZG\|6)9B'_C6MY/*R*7Z#'R9IO;U6/C& MZC&
CAR"F(AN04%X5"=*0(WL)2/+YX8G+MO\7Z4'_F3\>7#(CHG)A:CVN>>
MRLG<^A;TRB;Q.N_YKL6=M2"E#IE7X4Z^T1-?;<-UOF9BN=|X=/W^4MU(K?Y
MML\59\$&L/+|WCV/ T?L,*UWPT%R5(HFMLT/S'N'!C%/L).RBM0^M'<=<^+
M+VTEEU+5MDQZ%>V5Y\U@7"!\$ |4+&&?]=(:CYEG?1UNY2N76B|=^* I<-R=
M4;G0LK"JHE'D)UPQW;- @LY@|NVX*?;0ZACA&V)2WC(NF6/ M9U_I6=;L5\|^,XT&\$
MA>?|I'U7?6QB\|;'OK7;A54.BE(06O=M1%:XB774OI#WT,W;|R^&K.
|DY73XBY6^7R*TU,*"PP0%/PN8/=W,2XO.|P
MP*=GN::67B3@H4'80*T\W\>/D1^ONYC\ /#G\NK\2FOP9'9= 4W-X7-Q(AO8
M5L\X\|F>WQE,M\$|*VZ%LW4GXUB_|ZF\|BL\|>J2,RA2P"B-4W\$4/(=5,|<%
MB*I,J#/@NTXEEY"OQNCA=\$?:@N.!M9<+Y9*[M>SR\U4.,F\|C5?:9122K%
M4A2^N3A8<-|6-6R6;B%;*:\$P<)QUUZ/^58=L6-I:%8Q4VZ^688A_|L6'
M4LMP61:5;?#6)\H=SR#75E,FV:S:0SJL+ 8>JTF COP#D\JCL>GSCV!EX?^@G
MI/"HG6=IP_LT=!U_7WV#J\$X(^F+)E##? L\FF"Y7+|U,6ED=_V7+27G,&"@&'@&Q&-
?;SC2)8CT9(4C-W> MZ"0J\$9HQB,A)D\$CG"_|N:=^=OAKKWXN@#;?W

QA\$J/P9@\$BF^QP VQ-/M28 ^ M1/N@!53\$K.1-0U%KB1F;{P_2:4.M&S'9
!H(\$1SKC=B<N#T/9-41 M\BUKJHP5K/IN9A2,HA4(?S7\$?
AJS!%T)E7F2"WNNRJ:PAR7^Z\F/#H%<# M Y3Y-IU.LM*JDI_@I
/U&+WDC>Y77^E%GT2\I64B*YR5:7^8;VGU)7Y&"<0" M?
D,PJO.RLJ&WG\MD^!V5B>Y1J=,50"2Y+H:X\$470T02823PU5^M5T/<%2[' MF1GS#
<"36^HG P1C,N+"8P49E9R>/E)WKB)TKN\$7'2TKDZ4!K=0TTQ9P!@&,I7.>+
/RG*3G5DMA5;:VO^CP4OC\XYS4.HIYQS)3XK MW/Q(9',V(43AU\ W&Q*51KJ?Y?
\$E)U\2V0+?W#V'\$WZ)M?\$ MI^56,*O^?7\$EC?!=#>>0H0G!#=&33.L((O(J,-Z"L,R'%
<.BQ68!8S J02. M 2,1(IH#*=ZD56M)S4K N6LZ>|.J\$#+A3R^6!T1GE=8#M*&4? Q#
>#7 M7=:8\7U!ZLHZ44 :5PY0?EK*FW78\BBI/E/'?N6:)N7E:<"#:G9/5*JKX.Z-NP=*J*Y
=RH3S:9P'Q=JRXBK#KJ>XUZ=!X&L:P?NH&6.:@:H\4+ZPTD79?'..+I-/2*.,.)DQ0R
M1O.+F!EZ0)PY%\Z1L=TD)(%ESVNWSC7\LSF<,H"9F*6\$":E=PS"V)81;EH
MC<28X=6WN:HL7GRHY3\$FY'+ "TG\ (MA'D;JI<6() /A)Y\4><-=<\$B&I.6.\$ M.
(J:QTKL'+F8?Z)@J4:XDM.F3JH.'J\$Z^ M2_H)R?
F6C'UV"L,=1C:_W+=A&W3_OS&F:C\>9;NU>23I?.^YFP)\^S-;"4
MS=UH*GBA<6FY04W\WCW)HDVYJ?KGJ-5."OT@|2E)FMR >%+.LN#7.?!H?//
M1*?;@B&'LI!>1'7'I_VX\MOY=T.B_4Q0!.\$-9PC2(VEOYP4: *0*IQ MA1\D-U=WJP?
8)_F>I<^:?!M.8X;!SH+G;,TOWS"YI? '\$+G6D<|0\K,IQ9=JC
MK6\$CG%U\SUR>8RMM;P&M*M1EC8KMN#T..9F%K>%@|"+1\G5576?:5+J\$KJ^
M^/9\O\$TJ\9"Q\6/5!| QVH(5#?9!JBWOW+R@>:0:-
HP!U>2K!9,E4A"5;EI>|@J@E728..4WF%/&,:#S_|= M"E+JWC% ?ZDRKS=8#!H_K<9Q#
(!VO|#9=5Q#D'A,D1!'JBQ'=NC*E1+SS2LV M7UDP)W7'G"&D& @_8CT\#)%5#*F9?
BHA31%WM'D)\$0> X3=!4=AJZ(QXABY MDAN>6F*F(8*3QZ\H*#"E>'1\LD0:P\N\X6IX-
LRO!5N?ZZ<""@R*;WYD4A M\$SVD\X:R2 CDJ_2F#"ZI!U:GN&F^X!M5Z^8%I:/D;ZD/(QI?
-IW57M\::I- M=M!8K<:4BR\$;<%9B?YO"!\\$1NOD: 89OUR%'J9JGH9F)8%N.
FKFR_3GBEP
M7%.>5NM3M>>|NPOA.LD;CJAJ324:|4)X41Z>*SK>5@Z&;EJ_6RRNR:C>|V& M%\$7(?
8H08H)JV^#DZ0*^:YS6\$1NX4%>|J!&KSH;J!\$69)T<9D#7P A,1& MI-
!7E\;57VV3ZW6IWT9W=,0Q\8HFJ.>|08/%(N>6F!WX!+GBFUQY!_PFJ.*
MS.2Z,3D2!)3E',FS+D:OL#;(K_[BHNZNY)-#8=)|_L\7O:M)\$ 0<^P RX4WA M=<2+C;>
(H--99+MM^33+ "/>>B@|9>C\$DCGT%@UI_SP:\$(.S4I& RY4Q1/&(C MI=)?
VU,+U>*")!!T\$7&JS".MCC\|@_W L4K!%;OLAP45>_+VP)=K):CAJ08|BPF>#+-
?).&R%_9!F-U M+0"S0>7?/C |W\75=SWK4&&7:=-|X+&
(^D0D:TNAJH*3|N%=-^QS_J>J@C,W(W MS"=E|*NL?H-
^U/1GF/P/G^!|@ZH)_G=N)F;&B\1*'P.TTBG*E%S!&6J%O54 M^|B#EIU.Z@@YES|
!|AP40+TCPML>FXN\0/+ HW9'KU|UJ3JJ=>DY;;^X*W0_17IX\$
MH'XP',@BJ>94%@_D+M%<4W\OCCT|^*K.W=IMR92H(;L2) M?TTXCQW")Q'T*J""W)M?
8/3.'|D\\$_V3M:;+JQ\(|H!P\ MJ8(RB?B\0FREY\TZX94UT=6I*W6G+|5-0|^)
(OU^-3J5KU'OU5GO^EI W M9&PE)<|N|(_R'2-S|"V@-)
((1#WI&>,JH(VECE0XO"B=)9IU.|JWP(WF=I8
M\$WCM8D+PD;UU:TO9*N.C*TZ%I6C=YD84|>A=?N5D_(L(IM^E90!4'U*|+RS MM)T
+R&F/V?|H\K3C4GJ2F|B"|MA%:*R&9LPFG;@D.TZ#(9G0!!@D-|2N=8 M_-U<&
<35'7!'\\$NL4!Y";C6E95%MV\$#6(42EQYLF\G:T\K<_K"LMO=0:XE17
MSWG&G#;PJVP"OUR#\$NV19QN_5|V\49"">S,_JO-8('T):%3ZY+E(9>U)ZM@S
M@^3/UT\$.H F)+DY;|K&'M3CS&&\$;NL|^J^/G3L#=DJV|KU|J.OYC/9=|T//MX&+
F5L2.MZQ>)-!>3@F WS.!-+|V2765<-Y5 M;Z;0AQ#Y"C?|B0|^KO-QY2NP1P&Q1?
XINJ845U/;8&ERX70?7MX/240@D(M3|!-O"S=3";GL2U0VOJM5F;9:K3?
P^CA;|HEH!+^Q>QF6GCC%W+-&F_O2 MB 94!
<&ZT6W8:ERD#/#\$;ZIBSM\VCJL%^)O_GK@P+9FP6G7QDC.=JLV!XA7=
MJ=6H%=C|"G#B&2P"0;|F5)MM|1"X M?88ATD1,<%U\$%NH@;J5'G^J;IEMMZG*9|?
4S#3'TM&J;W;*3-|1OZNS)\B)5XM2/_:A:
M&.^14650MHMO\$SXV2/C+3&:M:6U5;|D)H%7_&OGQ\GSBVRIE&H#O)\&J@V
MZIP/1B8+48"*JDW4B3\$5/|=>R>Y M3-G\$:MVW9M63<%O2 KG\$
2JC3AQ8\$-9,^ARL':1V50/HK_&S5CHR#9^\$SV0! MHQ04(=-R4?
X1^#BS3:QOK+K"6R%XI-S)/4OOFJLJ2@;5Y\ M'J3)#9X#84WB?
Q\@Z;|WFN!=4E|2)#UY1JNOW:/%|Y_+D/4X\ZM%\V>,G%& M\$EA._.(?
F92AY%:*8&\$,1=IUUC;|L*8/OCF F++0W'1-E, @ U MVX)
MJO;:6;)!+*6\$Y@ (2!T\$67>PC97_K,:3>:9,<'M

1/F=VWTB1\$A7UJU9UY,2;W\$+Q&P;_1"/\$(JK'21=VVUA)"@2KG%1;JN3<6@-
MRBS.KA)N>/RFQI=*C-S\$23#TFD(M!/+1L*VMC<&RGEIXJ8RZD:N^?EV
1D!!D523|XO# +1;+_'PXO1)A4'02>! M1Q4FGI=00^8021-
1"=V*5H65)7.ZOD50V;U'5('C1_1SH0R1J=.*EQ\WF;
MZE1/'BQLP;&_1_5A:423%L1Q3J8|37OF>9Z_IRP)G!4O=@ "GOX#MP%?'@(L(M)UB4"J@=1
<:6LV%,GOOL_605IUJ!KNJJ7T5%91M=+TOR\$@'7\$'DL!;\$ (Z=(4
MVF^# 'OL(U4|A^A2VTI7Z RD2N;1=1C&>1;H>N4(-T5<|HX791.EB/;^C-M?
\$,1"2>\$F7.G5#5B@ M;:%\$|U|KFXP+;:@9G0);(590*<_;"(M:Q90/O_ WW2OG&D+"-#6YD;-
16^XS M*HLL:2W<.(D>!\$N+OIH-&G;1>FKVL'DIP4\$I/>/M/'G^!=1^RH74 ;/H'O4I
M("1'3_T6QT(:L?S+F@DZ#&N'W^G=D1MFYTD'?HPG;=@:/Q-<(H| U|:T|C
M=#=#S)G|@="1%19/TIA|AQIC*55^JN:ZB?G?@;:&5/H"Y)M3) Q2|BY,*8 M5
+_U_B%F(P5_G%EE'XS|@#O|8-RS<*PG/!B5L+F&?#8|,5/P\K/*&@&0;R MDT")VSTI?
L0_UH?7X(ULN!YW;|W|H6E!K=+@G=N4(255B=V1TZI;D=1N(>"A9U9H8|(?
@ZEPE,EZY/6(E)GVKEF MSRJ?C@/_%K"F5RD_)I=I<&ND<+ V75EJJ|Q!3,U\$6K1MO"*XA|
<1PETMR"O(M)9:F%7>QM"A_3A|SAY&8OXC6^_M3A0 MO%Q+R\$.8;HTKP|<
!|3/ZQAKQ/"@S|EJY,^A6SR!9JRI>;X""O8E7H!YLOO M@WNSUGT!?
E>HC(\$N(=,7ZW6EX;T&'M;W)WQV M+30ZQX\79- PDV6R3|J9510X
|M*",EHF5+R!;_ \$CG\|8A;L&L+_Z#)7D_ M?/OZY*:8@AKEV_E)/1WVTK@Z**>DW6,/PW-
#X>6@NUE|WS^/B08DG 082J\$ MZ|16VAU^U%C>*^K::8^?,I
S%U: ^HF%FOO&.M57B4%B/O#O0+B20P(0=H) MXD/_O3-(Z&|B+?
I\$=)AUHKI*\$*!,2>1:EEVDI\$+2.\$G">|<1'T?HQRF M6/_?J"/SWS-*+=/OX<\$3;6X./HA*??
C6*GLQD=,%/SW|4C:*D@;:_P#|S!* M>.0QL=(|/|V9C|D3|JFI#XJW+ N_CWCRNP;
1|\$G;L1KQ-E(?VI'7.1MM(\$ M11RC-
B%_GO?|E;\$.WJ7FH96&ZCCTE0_*YC_%/U=Q|_8JJ>\$KRY(HS'0G92(Z M>?)@-
<((+F+KQ6%\$&?M>PX:4_H_|OQ.WC(%?I_EC?^;_FZ MQ?
*W&.\$#_FS;J+*HHL"+KL\$4UK;Z54|7I(#BUI&42F/KP/7|Y'U|RIDH*YX MTEUJ@|H?
W@|8^5^5!\$9.V_-:13|Z@CR3_V*4I=MRY;P<^F3Q@ (RK*O6RC:%T
MXE/6Q+K!KBH6|JUE>#+C5?*51:WVPR?)O|L|?4M9=M)AHZ!*6LXHD M20*J0|
|C8>12AT@XF@1|^TE8Z&?|ZY,*LS&1-U|_:9TS/!;#0JW?-AD+M7Y M&TP*^)H^8F-B%+
(/_WK@X+""X-1RZ710XO-_PW*6>_30<-<4'VWU7^S=14
M,.2'=R*S>!A3(1VT|@G%PT\$).D:F/*U?Y8-@_M<(>T+C)_3F>&M;0L5AUMH
MLB@@B)5)I(D#W|=VNK9I^V-G\$|ZBB4D3+E;|SD"(\$@Y((NGZ=%P;IPT1W_|*C2R^?<
Z=4.8;B|;2/G,9QUNM MB|2\$|&;/_@9L\$IO|:9@V|>!OA:VQMK|GL?>(!:M4.L)!4#Z=X\$-!85
M>R&Q6#0U685;&JT;VYX)U\$O@+=Q.7KYB:1\$C5?
MM&Q>.N@V/_4=P\$/ISOX,V>>L9428!Q3CF0%J
MXU,>@Z:WP==NHL5F>B@|L1<.FA*:8\$.TBL+F3Z'8S^A3<&PNF(.WK5DET1|YSKT.S@'
E.. M&K,>?'<'GK^(B7*&):X9E/1|.R+1'!=! TMJR@<9:\$/9^,<17X97#-#H7WD)1(
MC=0Y/X!%)>J<2?=?OS2;|3|5@N5.1"*PZ?FA,F|K|17GT!)=)*@CPMP(DYVO M8-J
#R|KSIV)_2/M/BX+H_H@!FC\$BXG B;X+49',/PQZ6WACQ)(8-8W&CF9XF!^()TNTRG0A
MIN-NVG;_GTC1OQ&371/C@3|JRW6.K.02R^YW:<@B-
X"E.9/-2,_AZS|:*P,MF+\$*D,"+&:QXAH>A;%2:PY\$|64Z4K0NOB9\$ ME@I8%U_F|<.J?
P-V;GUQ1KI"&X5 26|U+|R*#0?#^.=P;-RCSTKUV6_
MCIV%=G7;41=*710|@%9CPYB68.W6E:CA*_%6X+\$G8XTP8R\$ESWJKP.^;9?
M>N1|M^=)9|+N6DZ/A/JY"\$S?3Z^_16_NA3*+FZ\$|;R5D!AN'?|DDJ88&*SW M:KL1,
MQ|!8W<_A-%+-\$M*)&WX%F)&\$!-+*^#ZO|9=;G=@6C<5W0H_|+?.@ZO!RN"M
M^6XT6<4D|,'_7MU/25.RB/&*%L#|#!&.CQXO^|K4CP_|&Y0"52\$&^)O#3C M.8-
BRG0P9ROS)(IC3A!'6TA:8J-E|1V7|^MJ2G|V|!-X:C0<\$SD:RK=.1)K_ M+%,++|B
OO9OFJ;WK|I \$)660_7N(T*\$|HZUBQ|=|T1F;,_|NX<:AY9KTBG!&KB7T-R=H+Z*U 1|(8
MK2U;D-#YMT3FK;:IT&2CV8A^<=LV3D7'6MQ*Y6""TRM0>\$6FENC,*|HX5V
M9;31;7'8*X!+EJ35H%9?9;3T.#GJRK-E*VL0Z8EN9WBH)P-#F1@.|G1|=)Z;
M@Y_0F'PN"QB8"4D@-|1|H.8);>,H?96BJH2%O^54UBX|Y<^NCQW 5_O^LHU&
M6C|XU6#K#RO81_EQ^K;_|<|UX%1'5|.5_PV6!\$|QX,MI9|;-1H=_Z%1!5)B/
MU*.*%0E;3KRIP7!YT#7BEN6C99GGK|6ZAE|?DV68,8JA;-E;_S(MUOIH#>?
MLNB@+CG,_X8U74;A@|D^|B)FT61CX'C!H7;8*V/5|_F^G*W|A5>F97OM(N4/
M>/|TB#&N?|LVST&C!M_&_UHR%8|24">>?G;J^1A\$;N9|8BQS?%T+D/R1^K"
M)M,8!2|0/X(|D.!HJ|CDUKDV|7W|K|):K!O?2SSBH@GW?'E>>K_!'=&'B
M#9+X|1'1|J.)0|<\$(|D&LL/"9%L&W+ |NWR|N!%(|CR/_FXLO:0ZMKMVR=
M%^&"&RM+G1">983^>'KNU\$A;T9=@;I#5I6M,F\$/?8\$W-U2#;3DN\$J? @;I4' MXJ?

RK0IP\6Y%!\F&JNE6/J QGR/Z:[S8PCJ]":BD!IB:J'NV%_N,(8(EZY2>\$ M<'?
%KROX@X UIA,9*RB"3-&*7A#!RWGMM%!29!TRH1RP<"J\LE\%"W_3!
MA\#_ =A%:H=|;/&@_@2Y! I<4WU;O"),;=6C<+)CYD:VN\$ "JWX12N\B\8* MT:=|O',K3?
V\|D+KX/8@#;0-)5A"!>4ILO^GV%-SC\$O\7,NRJ?*"ZMX!M'B> M4WB ^Y\|+;'H0NTK-
@C.D@3-7\$D), 'SW8.H3./^!41XJR?2!,-4\6\A89J M\1UY!L*V3O1&E&=Z.2=ER0WW?J,U.
(I6KD/4 *(WNQ*/C#-|A*BM;POW.K3C7>\$5MGR:@Q>RAW\IB;106YH/M@DNMH@BL.V
M+B"HGA*4VG&6RR9HMXO#E/Q#0>Q@IGS*"82X&7>,HG&+4&NEJ=_IH!?QJ"B=
M<^,H:0*Z_3'8\|G#S>3!8I8+*Y;"?2>E>CEOD1&U?Y\|@EG8B&*H<|LP\|OD<&
M^@[*5.T)UQV7K@QUF5#Y;/_T6IV5;"GK;4N_J(& OX#UG=/3/="5<-:3!.I=
M9+2;5N'\$CRK?8;DRGDVM162\$M@P!U1*BWHX\Z7YO_=@LOD#/K6"Z\=-11I6\|
M)+4'&R"=.I827_B\|J;-*,|T<>'C'#BG\7U*=B<>4BR?CD@4E_1'>U\YP3W
MZ6\|L\FK%EB9A2@>=NH\!5R\$ZO,E4=3J(UX"B74!CSYZKQ4L116ET4!\=U#&9
M14U5=!\C0I%\$SXCVM-
PR2,IUV9SG43XK\|/%\|*#*OXY@Z#JHYDWZ/Z0C1AF906VDX+BO5(8J\UV\$&
M%*DVRD61Z\UDIK2.3"N2Y7EAO8KN&GR\|
&Y6"_KA_6Y!/, #4SV9E2N;68SWV+F8:T"23\$EX&F+1
M);0\F0QK9Y2PA1CX"Y\|I^#9(E6#,T\|H')?%\$91\|V2;)A:~?US"|(J"G>1'O
MEYDQDB("1;SS1?R7,QR\|+T.QPWGFSV)HSG"|\J@VY8KX(I8NYDD0VP.-PU
M7(OTCN"0M;H)Y5Q)\;PMY,1BDJC@%&F17=#K8G0MB-T% AV>IK)=+.D;
(N\|&^PI\$)'U%EO^1.?MBK5!L%J+@5+? M:FR:);-/2=DY"8"|(S:|\@44"
(\$UUJO:T\|VJSC9*I+;C M=R N@X!,8 L\$D%:D7\$7-FB\EE7N^S##MQ
\$:~D'B955=6KG1VD,-/)PUSC\$ M\|S+;J=#WZ!HT/I ()LU3_12^Y53S@%|W103B MZU-
3Y=H95'&GBQV6XQK0*8SU;#H)(I(M('8E^L/&X\FLL9#='S34UU7T&9AD M\$
97D%BM^#8;0N2:*"KU\$|3V*X3.WW4P>NJD"MO\61.,5J2^/|9UIL%;8C&+C!6Y BL\$HW-
9VIQ!;,\$ M\|?3&K4W\|I(\$ _1+,O@GK!6U_+,IH"F\|1/3=-6NW!L|TNS_*4"GL*(J-W
ME^(0G*Z?:3F7-,N\|'3\|P'+\|MJ6^_GRX,VF"6B!#;,O#LFN?+E\$)J6YSMFB(I=DO.1|R
M5\|'3/X\1+T RGX L6U(;M5\$O\|:0P%\$E5#MLKTM6UG)HO)(W\$68%.:B!1#>K
ML>H_3DO6\$PHVM@U%&4;+WHUVV:&_1Z2
MH:%OQ4JZVK^>=,X/KR3+T"9N!~8VZ4!8@-/\(UZGA+C89XFG5M\|:|1<|/V)
MY@N.R7\$S@+;/SDO@=S(QI;3LI6?55<!*CGM.MUH/S.NWH:F>KS.=2-JIB#@4S
MR*J=+RS_EA'O"9OMT7C(2LY9VI5I"K7Z,!.#_&9+!|7=">6KO6^+FE5PMG\KIWB5
MU3&#\H?;C'8WTE&G//S2+B%>#R\$@_)AK3=N85/M4>-VMGU*;Q_@76+JBQJ?(E"!;
<:U35,|6L\|K/&_!78JO6?O"D19\G#?9CV+D M\|6_TH/L/4<EP;TEM;*2/N)AYXW
8_'!\$.N8=7"U3"LB%BGL#YTV;U?3?1)E;AO07/UR:~:~Y=Q(7,+!%>2.C*A5:'NC?>*4YU?
E&"E)V^E<3V>K/C>10!-64.:~:2AJL/X*H/C4U3!~!7\$^|\MC%Y%HFQF^C?
6OQO\|D.)/DWEJTOR!G\|MZ+=R(|PUEO:\HO@|*.
M8F|R4\|6|.>.)P;1AA>Q2:BPC#_ ^#MUZ#L5\$N4-|2+L\$T**<(\$V6XH"Y_4=M.
|3H4V/#PBU\XY6^7N972VQ\|D@|HQ\|&-1KF:A#UDXX\$;0H\|LO@JB6C9?(C
M\|_R1TC.%.8H2XX\|68KC&&U/%X\|+J_8.82L\|:QAG&0>+P%3OP/SIOU*D\U0\$
MTQ+)%@AEH(@G@@X2*:Z?W_*3Q3:.;|H^0K:~L\$SB'8J\|1|"SE58S?5&1Y9\$|
MOR23.@)03CHY%I>LKNS&W>^PHKGZ&5SKZC(J1NRX\|=J2_VG\|M+4)/CS!6'8
M(\$VZUD7\$K'3G^|V^"!^7R^=T+Q\|WZ8>S246RH4H9+'N.#IKU83_7\YD\|&A\|K
MG+>EMCH1/F5&+6/)R7;#D"=ECG_7N5\$^EO+:30-5!L&N(:=F(\$ (4,&\$2_W'Q
MIA#\|>9#9FKN.3+;:&M7_|\TZV\|"@/((Q>?;:'FP9G/Q%I6(K@|6VHR3!PGKM79
M+#+N6CZV_V7-6V6V+YB\|Q\|'---:(/_AQPIG#+39CWL?)\$&8W9K*|B_%2L7\|
M09N1\|K+Q\|W_PG^VL%#DU/X#KKJ;@=: T01K*RCPIK;+%T-SI^4R^*Q-*;Q5-MB0YB*)?
3_VZ/K\B.(J+TJ5UY=38CAD/#=?*,2<|7D4Q/DWNQ-;+F^|\+9#7 M@*)Y0@~*F0YJ00*
|~^IPFT?3(2Z'4'Z\|C),SLRE%F/#\$1L"QQ5ZF;~;>-TM^1K
MCY7+HQ^O.D5MP\|7^_I*=TKF4&U-8IC\$6YT&;-|B3|=M\|.GEPGH'A|B_@K=>;
MN>F@J2_>E!GT)TH,PAVUP4QC2\|=Q276@"28\|P1GY+\$90A15DI%X\|FICI^|\M:
(+PV30"*00&'13(X-C/B7\$00F),|1XLMHHV\|JXT;^>96<#^J"/(X4CQI#^" M=E6\^8_F2\|J
ACG\|D5KVA1M M-.Z<4'HC*|E-X(0R60K@'GMX.)&PC
M\;R7=CC;+TY&'QB=O\|+|0JHK;NNP*(DQ):^K7KV^_7/G;_TR!HDF@(@^)^7
MVZBKZ^5S#HGJAO.((Z8FS9K/H'*9-M1_5"P9N\|. "NS@1N+1\$PBT\|K<<~;+4O
M#ST&U5DN554%19\|":#7/F/E>_YM4M\|3=)TA^JCA'04>Z\|Q;P+7I2-@D0'O\|A
M\|CNV00=?783LGX=.I;W.@BRR#/#/DTF<7-"W>AG;CQ:4D4<UQ?RCJY7,T DY
M,@M@4?8H*&H1&7M0=LE1OFPBT4.^,7YXK"/W-MD1WZFO+|\@PON!4_8/W=<>
M)>4P\$ "R&U@TO7WB\|S^!_L&&DD'R8>G")3?7 FT"U44CZ&:=|*O\$)%VQR;J\|

M.5T_Kf0SAOE/0;E7?AN4P2%H@A|=E,C;:YU?;>H45VX(@*.>F(DKWNJ+/(
MYB\X;J1(\$YG&5LOP-0,4)\$C:!? (K&(:49O)=:#" _&&8N^S>R?P>9Q4W.QB
MY6fOZR>:+0',D&L7?UU,,UKDMX&KT@PZ<4\$|P@K"N1F.WCJ>+A)%_AYUY#-,M&\|%-
S6|G|SA,^%1TI%H@#,-fE4_I2HC%V,+1.)NQI?M1::H_E#L(W(GX+1:\$0_PY M"
fNUY/"KSU ?X&X0D4TH%_P9F#GL%F\$@ZV\G+1Z'OT&:F,=0_0?%>S7^\$X)H M.7O?
Z;:>6" XP('+@>T+LY6DM!%_>-1H_,YIX\$302A?FT:XQ?'1LKI^8OGS;
M?.#_KV,M2B9M3A&RG.ZRN M:CJF%>Q373%;|H%^(JE'#!2%K@??OPK_ f*8.G=-#K?0
;-20YX\VR8D>AI! M5?+^" ^TVP/-fELYKfV,HOVT*;!_fH)/YE.(: "P8@:G^!?(2?
AU1=+>|CWPI: M>83T12>HWDYH8B/-4X,/=7JE:VAI:ZRF|^:f.5_FNSZ4@!:_#U_W<;7,?
B MJV1H')S@;MEOA\$,D?=JY4*):&S-M'2C-,M8*B3%8A58fO,3TATRR>/fO,N@
MWJ*7Y#N@f91D),X>;DIHC@f\$B3NM.U97UKIO7TfJN*,Y0))VZfD+|3:.QfY.=M-
M"UK/A\$'" +A7_-E\$:Z&X\$Q> >_"W?<>#U-fYKfTB294A;>43/_MfPQ8<
M*8R:J\$|C7f_Q(<#>4YLO:9fIKMXZ'%\$?3#RUP.T9\$N/ JM8,I#*&@XBf8,K
MM1K^POPD;9"W+YCf2fESF/=;A=*=Tf&%RWDVTLT7*PNYUM^/B,^ ^==J5GT5C6!@=5
M'>2(FEKQ#Q)EL(fP/84_f.VD.f70_fO-4fCRHYH>;YG+01Q5E/SfU&?G;fO%
M)@Q*P0C84Xf4Y#QJf,1S1Sf,OGQD?D&WOIXV2NCC.S)-6*[XE@EZ)=YMN/8P_M;@>-
C8'7S'" +T7A4WA0023U/0"&D\$7J3\$N8-)Y/HH+4fMOKIMDOBC\$P.:G00 MT(20%"Nf5;
(8@TD9K%W_261M6Z=-f(@Y-Hf|_fTNW@N^C91N67Y=WGW-Y"E<Mf|?
1*-7;>T%>M)>,0A'OHXND@,QOK)8'^2\$U?H@V+IXf%|?'FWX= 64HfA MW?
=fF7;V*E'CfJ_M,R'.T0)f.5W1Q3O_15\$>X-5.JS+RZ'Nf.2WU(EQ6Pf6.&3f60#F'P@E&XfF\$
M+!_f:FN%:)=P:9+T:(f&_fE+,@FU\$8MV-AP:?=D?X=L?/C:
MC+4fK/_91&95/(2YW:4N1N%:M,@#fQfE-7,Q_ 'V+HfBM"A8&OE@DC9J;-.75 M-
=>G_RS_+fH,N,OET&O4726,/f3Nf,|SfJ&E2R%(WX7_)5*%#N\$fLSSSHSR8F&M>07f|f)@">
(=%QfJf8,)RP\$O:\$VfJS"H+AA:B->VJ*\$Q3SK7S_=66>KK:SfT, fMG;Y=?_V?27+VHUK1f
+;Z4Y&SK8#?QC'L@%9/+%AUPOLUN9Y*|f?#f/f;V2(O
M"9&EGU*/1_f|*'^"CIA_#SfFf(>)5Y*J#S8.NMVEH&43fKfRK=+OO/*f3f6W48 M.1?
E!7\$RM5U"X"T5f;HX3R'U:)A8f;_%*VAE7K3(KP^YW9Y(CG2Q64K@?'@63 MEf|
Hf:F=Z")TU,:f&fD)UAS<,JCZ\$^6'T8B;P35G>F^f[*C92O9R)SA2U;DRfLC MJGD*40;4=
(CK8#2D0KTU40:+:\$5SMN:OU?^G86EF\$fRC9"HE83f|=f7,W.S:
M*9@XO!6S4(.CA%\$+f' WQ*D@)%Y"! CEN\$AMY"+7f!>A#&EV7..^_*EQ^'?@D
MTE#;O4^E7f|'"H&?XH_<98-@48H=*K,H041@4P_@9\$f2L\$4H,
f8#7<#=#>E/3%J=\$#8<f|>KN, M%"^"NM3f*C0AZ=G"/CN#4: OH/"YGD'-
(P5^NX.E5C2WPfHfB#MB MNG)Q_2f|\$V\$G_CSR-6E?L%Y"GAJ^*7>D#ZP3
MXfU0D(X2@,3&Q@O;WBfWf#KS9?4fTf|f&EO3L6LY23"C## 7"T@";5:.)2+>01@,0X_:
<' ^MDRFf7=Wf&C/>1,S#QSNJ1_Y<7E2V=f'RF#5^V7QCP3R\$ID-C#fLAFK>8QV>+M
CW8>+2,%>\$WZA3U0_R?i9=34K^D)),R)Pf"R-*P\$0E6:@G;;8&3XDL0Rf4C
MA:QfX1OY)O'D"UCf/PE=ZUfRTGRf9GOHC>SQ%XJPS._CfIXfH9+AV fTK1VD'+R%#_f/;
<3C=H14ZM5C3IXW MGfYf|KEfEL5QH_fFUUG;F4f2M#,OLGfNfLH_5>
(.;X4(fU_4\$ \$1VQP/T5.# MN3,83!@: ^VT26@7MTH2XfL0H!)*=>,\$_9?(%&K
MfYAXF(GY*48%62N_TO/R-/f,HQXY@U4J MRK>*A-QNTAPT4:.(V4-2"4&0:)? MIAf*K%f|5-
U";.#G1>(?&54F-P^fW@1VH-8WAWs"K=D<9fE%/ZRT^X&)>R_K ML-
XOf|\$6%Vf|0TG)' +D?5(ZMD.A!);.(fE*!
fMOKP0:*,&2%A(#OZO004#C)B^U(#WT)+4WfJ*CRV*+%@3DW?
4M.f:GB0)ZK'XUO4D)KU" MGWfM5?Q>\$SPK13)M'-Y1U)\$f/TRf7>M2/OU12f
Z^=GWS0@1%>Y?5K.D&7&?A M)Pf?28223@/D HH?8*G4;P6f, BX.Z=7f*BRQ(A9f-QfV?
Q'OJ6L+Z*HTK0V M).\$>P.+PQG>BPF#Bf|_/&fN91: "B;PS6#Bf8f|:=
M/O&f<5BfJ^QOX1VfM_*fSf|_+?W)Q-CU(&fYMFf|_"&Z&3MfJUZ_ ^3Z0RVZ565
MTIBC_/#_:V8EJ?<)IU=;G9B7HLfDE>C;;X0Q)ON1-*GI7P'+Q;f|3#S#f|:\$/
MHH6E@f@>;%Gf|H%WU&#.LT+B>PBR- W3A_4#=#T#>31C/U.SL<fTfLC4GS9;f
M3<%Y)NfY9@U(fJ%&T*Z-JR#>G_OT3%/7 "F%:_fS<7=/:Gf|/S@UGfJf@Y5' MNB-
fX_'#0CP_fFG*B^&%N1'Of|07:f|Q0#_#_f_HH.J?f!#-&*)QL9"YVMAISGBVQ M^T^7?
+/Nf!!Y<58G4R'<5X>%-:NfCOfYZTfJ%=H9@fHf6fW9f;NQ.>Mf77fH M9?
GR4fL'BNAEfA(585*0f\$CK;74#% ^YJ?.1C=f|98fAH6OULfJ0_M4L2M):6R+.G10S
*/MBG1MfJM&AYD0'9L57GCfT0?J.,CE,U+OGODB M%!fF1ER-
0Cf|1/P,\$P<f"W4AB:K_68_M2-E5/4U0Z8>fV;<f|&4KZ;CL3)LNH
MMWZ4*QZS/64'B+D^Bf|@Hf|'">OC:2+NfVR_:f\$ICL: +XfT07%!_0GZ MTG&<-
YEVf)*NH/#=#Lf|?GK_ QBH0OKYGL5@JfT;^X%T9_%=#2;-VPUfPKMfJ M,M42FB7-
^86VP0_WF2VfJf5CfTHf|<:MX\$f|_\$&ET%_.RNUNKHD0C5B9fJN(Sf|_ M0)4;12@*1%3G#Ef|

I(S5./!N!0NW.I?)A M99-
*V\$O2^3%4=6HR7206RAR>G+Q/IB9^HFG38WUOSP:5I2N&2X T?EO&0NZ
MOF9FQN(Q3Z"NF)JX&OI_1 &LQITB]+YM6GFJ6-P1"M8+,_9OB140\$C!V!3
M9J;O/UOO9IEVU+W.=U2!43RHI#S-.[C*[L8080\CI M*N#K>YHPN:U::5QIN?Z5D0UF7I
(%D-[=Y0-C"1KZ*EMI1FS*Y?:6/F.M>I) MI>F ^Z^(2CIAMI G,O H%9&-;T6*4<&I4_FPIX
GX: ^V!3I"'+?+5U)#OUKJ,"3L>_)NS?QK+^C&ZE^1'I(IJ;'OD)
(N6IN#CXSG^=NV)WTVJ436'IP9/DBB CNYU9-C40(A
(S: ^JLN\$_JK.^5K>J=L7W]>X/WX8<6.V1CFS M)"83JD;HZ#7Y>O+GAA^_NN51>I(-I)?
XGZE\Y& XJ/(O9&@'HH/(8#!V\$ L-X:D)Q!8<%X/;(2K'V=H\$SZ3O@O1""?027Y
MH06Q6Q.;PNE5TS5VL:IO/O.2TK=CI<_PO6J%N"LM/^\$92>UKZ9*SLW*QX#=#/
M>L_G=IE]>G0B01-JSM+S2Y5Z@?I
MH[3L2^7/IV44H7SN"P3='4"6E%IDNREBOD7T\PCP4#(YU8E^=S5Y*4"3L_12
MM^0NV[(= %0XX6-+WJXN0P;)EQQG8KSMJ2RH[+*\$Z5T^GS7L"D)N?S>P?:S
M.SHW&6=BM !O-<(P:5!RC1V46QHJ%:9@)9AF&H>,5I+U4V\$O^'ON4&!>QI
MHI<4Q%>%@GAR\$*=RWS)# M\$-ALOK?DN8M#WPMK?)5_/6&?EOXC:.DBIT%-W-
C1%O@,HKF2/^S-EFC^8FP M^MRC#JZ 9""%WZ1OB>0.IUR^"@<.X'?0Y0LOM M!\$)
(5\$+B(B,IPF@)RS0E> M7S01TWEQ;:(=-
?H9'KP\#4V(5(7/Y!5F>"GW\;\$@;\$I== "I4;IB_05/1Z-+
M.O&_*QA/H1&^:F;>VXM\$((%'02<IVXWGR5CS(D-I<@S"HV*2VZU21Q?BJ3V
MRGY12U3H@%:!'JINO;,@I:G@YIO_JI-'8I 00!*NW,#O-TT())HHA>Y#W M/9TY N<#?
DI,N>27'9X5NV?3*G1)'ID>.5O)JQ36;UJN2^9)>G5CX@:W3ZRH=*]_DO: @'X&<49,16\$-
MFX2>G2\$*=R\$ MS%?W>F2^%#X_M_A#,9I&021D ^*LWO GAKT*0U>H>W%[1*\$-
X.WH*X->MSG'
M+!_VOQUF0W_TGJ&QE\$YF9KH>CI(QIX0,2_;>7P;V9S972MK%?'!Y>_K&R700/T
MP77IZ/=>4A%(&^J;H*F+=^_YSUSA7M'V+ _41>H=[KMF]YI>X>1;IRB-L?_'2 M1WQ-
+'2PLI#._W049KNU&JT)T0XS"85^R(C-A9_8+2_P")TL*F;J/+YJ0^S
MK\$KKAVYTTY.7@=W3+2#K6G@K\$P2;B:QQV(I(E&P55=J"KO%OTAO>;W-J<1&_Z
M5)L+GA\$>?"6O.K5SQQSU0S\$Y@JK/+9I X!%..FV> B5+)5:U<%X!'
MAR4^!^ZV4K3>>W\$%'L\RX.EBSSI\T9T\ODH_&'9P)S*9!@Q>R-(#!;/B)PF#
M76!!AKB\$Q""9&YGR.?>'0Z@17WA<'^1Q1RNN?%)6Y#MF_4YPIH,UDZ" C
MNR/9_L&^,TVX"\$W(*:>#EL:I:GQ7I?74G_Q6QDPT_R.MA,+=AP[WA99NCL: MO?Y;R%
(@:S30_'068/L"(VF\&I2V'O(I+3)#.5X5<5(E0:6>FK'*PGUQI6; MU@F/&.\$)K=T9X-
L_YI:JO, ""HZM@96MATE^%4 MD6T1-QQT:EF%(/;ODHHI'UZ60,L;EF-
IT>:.)F37VFFCL*3G\Y?=%-2^&F>" M+3-
^Z#3/#0N!:#6K6=AS\$NV.\$I@#ENX_3EXJKOFHSGS.IY=I:.WG9K?0_1WD M"#(6PJG-0?
C2IDKG%."SJ"4N:#B*'^&PY=+YXYRD<@DY%# C'+0FC3,3)P3_"OIA9K'2.^ZN-
9UMHPV%J'?>#.0BXU2@D,_*P- M4H118 0ACCM)"S_-MP:**(+ 80!7.WM37'
UQQ45DYCDNP_T1-YO=1=HO2=& MM:(J^-G97XV:89ZOEM@%\$&OV_2A(16"L^LM3.B:
O-E7>^S31ZIRK1Y*YW,-3Z]?0+!YC0T>_,'ML3*D^QX=1(RC\C%2B &X.I
74\$"F.6J))Q8*IECG0(/<+ # (XFE@&I1I37",W M5WA3FP2?)U=&9+XWA;UVK-
G_7B_QO>&Z!>ILIR/IX/M9I.4^=8"%UPGI' M 5)ILNG\ E UXJP|=Y+I#"QNB@VH1;
f50%NKY>>8:I_*&JD*O1"EHUU*W9LV# MI5>USQ7G9GU#?YNX^X//NAU"L\$8
TM9O(%X0#B.BVZ)G64TJ\$6)<>6%^<[NS M]'9!?'#"9Y7Y62@!-
H!=_Y4_[YSD%CFN6/."75SVWQG6&6\$!T>* M@E9;YJ!'
fKBF.RW96@3J1%JH>RW7J8/\$9;VG<;KCAJK" R++<#Z'E"LJ\$75
MWC."JC^M1V!@JP;/NV]+P??K.)-?!O=V5=0Y#KTY.\$G+3W*TXMN1,SY-
+L!._\$=;LOO=ZU;K0S6"D"SJ2'IAS68_?ASU#1I5I3Z??TB1A_YT!._FWVE7I% D+/FFI*
fF:=EYPP@%U'02 M9!9)NC_D^0*F\NQ5,B+.X?3H]-YSJM/?
QD2A)=_L\&/GC6"/XO1G.UM-'S5_M1J9G\ C+_7XD"&<*[O6@HWDD8SJ#F3Z<-WY-
J8034?^WO8^T(TEPDO3^ MUNC&.GRX'RY,E6:DF2(6_5OHKMWHL1":
f9TfPI^ (SGHJH/(CG^_:D)MB@C M^3I(!V6HY"(A)7F-GALRDX+T)4/J4N^RGf
:8C>66\N0F;1(0M/9-S_C MD="4&:K&PC!._*S(\L=[1B+\$4U-3.NVW!%P+/%YOI
MYK2S,WUSZTBHWP@P19<8VPGFGPL:Q8CTHU\$3X3U7-2^0<%&.C=3P&)P0(. M!>-
T.& I4,(I.+ =U+8(B!(EVDR--X;M-D1,1HKE!66IY8V1,73 M'0L\$6*[AG_5=5IHE\$HX>7S
(%;EJ+FNFB6C5&%7%WK923N_9W MOMF&#?I54>@+BGLTZ*:A\W
K!8UKR+Z#W6\$%TC#STE6\$P*C]=ZAJN74UVfF. MOM1)&7(.R\$@&!#+"-6QLWVI7^L;?
_N)4RY=A/F MG\$F00TXR%-M-Z@>*G'JH^?2Q2;A!YP.%/I9=^B<=ST)"&J97I,)"4F+4*U
MYQTVYB^,/T4W9X?.;O;4&DF7/DVQ=DHIR\$SI0):%Y=F+?5(X8S<^GWU_?T_'

M50=S)3Y!4-5M\BA=CP0)0 3+3RF?_G2Y9C >[69UMX-.@@3T3.<<:!!H0M!70X#OTN
MT7D)&G_E4GL.W;FR6#D_W!:#I65A=M!@R>,.!%B0>DNV,!""^_.OG"!ZM3_+
M.V^!XVIT#_W0*1C+-K=::8Z*!;3XTRV/?^MLW,S>(ODZ""0X;X0!B^:%!L_)MW-
98F:TE+,!TPXG)08&MQTY535!5IS!(_P"+5:K=|#DT8*X.\$9C7+/B/>+!:
M=VORSB1;X(_DJB.E7_6R1C&C5I_)!KKE!D_G^HN?NF^X)??:3#HM!M??%:[A!-
L^&9(%O(/19X@K;'HF(L#8SLA&D0Q;-30!O@R?I?"^VNW!-8E?7 M.L-B! K-Z
."B:A%Q<[!7ZF+B_Y/0:BM=GCANLB;0_DS_Z8:W@3R9"0C^9SH M(%#&8!1";:_W^?
%!"G>U91V^55F:A'<>/-.=1MD2H\$N;:/4@"_M0^//P&FGC_(H1E74/&U%[^^^U;W!
<"J0&3=2""\$!WJ(%)@&,+G!:/S>)C;PI
M._DH>EODO!_+;:*O!\$>3DZYY_\$*U+4Q!:6RYY%=AC,2(K"!&J88CM#E
2DBTZ*QX!P!|S4687G!|0.V?\$_=C@!"!7<!)MM!W7*O#%\$_!G\$&S MNM5\$|Z@#LJF%:5-
"CWNX!XT>OKX4=;DKD@E1(V@Q.@A+ 8ILN816_UEPDT MSYS-Y-
P"X7;WOWT!"P")O/"%T!6TCX.W& MX
35VR|KKTWLFPM/)O!>M&JW&@E+AX/.OW*S;+3.!OGS^W=)3.//B
MY8V1X.6LT@!,G4%#H4@85V0QF,/_303M+ZC'^X0_\$F!V0A907VI663RB5MNSR
M2%3/506RZ,&\$X*U/!(=@X>*TU/H#!.P6(\$#PKP;OEDW6VZ-BWT>BRL8Q(_8!-
MD!_HH"O:82TT2_)G2'#79>9D_A002)#!J;^%+YXC!^0N<&^*Y%@Y%ZS75UG<
MY8<1TK-Q:ER%3^*E&K*X:GJGW 0%CT(62/BJ0 TP.Y\$XPZ,>
M.FAS;&Q2;#E#L%Y@90BPIK\$O,DSYCE" 1R!;P63"9"JK1V"7W&OHH+5:KK>X M!??Q
MHLK\$M>/HWBU=X9-W1*ZSOA_16(!HKR!W+QP;F<*5(GA!^; MGSP3S%K+3V&
(E^<0;'H& MOLWMLM!:"7"!L.N+'AZ5\$"-
L!^6R=LU06710H(R!HL+F\$,T>_10^4XN#;WD0 MVPV:4*E5<:54B!;LOZ BYS 5!|? K70
ZV8-W@NH\$TA'HB!21*<@1=M-!(_MPASZIV7^=R21O!S:&S
)\$SSW=KGAH!5_!A9S^MZA\$A:XN (27:D!;!YX4XH MA
VF!1\$7\$FH0_+U79(+X!BZ9HM9NKNRYOMIBQD^@ZI%I@D"U.LRH%*M@G5GH("ZP-
YY!"AE1> X07*U)YV5,|^5=@NA2M<9?W&0E/> ?0=E20#Q7<@ MUUR!5!9WW'B!+
!D0ZRD8#C>#B!J#;1/YB8QL=?!|=WKH.R!<<_!LN+E:L? M/K8!*5+
(&J B+IA53"XC6;="!4!HW""BD*! MF^/J+VJR&WE M0P?UM1;\$G6R>?
(_8SMNH!GF1.7RW1@E/NLG&K^BM38R1!AK5VE!F:YK!F#8\$
MKE!/B\$VB,5"TFX=VN!=TA!;|U3G6I=W^PCM!H*5T4'D:18Q,.(160\$_#9M|M><-
>#S3&M747_0G5^2&O#!^C!;|L7VFO!;!?!F!OV\$T>.=Z M!S0A?
@G1!7!M<,5)CV'C^?,JH6,_1DK1_5VGN!_07OI(BE!/_M4#/@V!7H3/MB8GYS+'&RM=X!4?
!)#-J;(?;TZB^S:HJ57_ RPPQ9=^(T!162 MKCM=&36SI8-,G
D)FRWUG^WN=&!S13(.ABD3_51:M_#?P^C;T-QN3-IMX!C!9!KGO_Y,2T
MI&6F93WU7!DE4!<';PK!4HP'P,BE" HJ5O?U0AUZ71^Y%.^Z!M,?YY
L^EHPUL!(8!|Z%GP M\$@5YB@'C7!#L-EV#>!YJ&E=V*O5K!
<.;L,*>V2(FWHCZ@L2E0@L'@_M27BKM/;=)80(4+NDEHP3'12P=2=-A\$0?9-
@T9!Y7Q7PNW/8!V>S!H(3R7T4;_M5O'!?G_!LC:6(F9.YIK&+*\$0-V+CJJB*#Y+4;0?|VH=-
GJ>W;UWE99M!W9*9 M@\$-;Y:3+"^R4MCCR"XW:LB>L5S(XA2;1R<,-
D10&7S8(!HPD5!|\$G8%R"+"6!O"RRAJ\$!|+ #_AX#3@!(IV^OR MTAY^(C\$!|DI?!>
""4L!/9:Z=UAJ.(I9T.X!/_YC+J!+D),^MU M82'M)+5!S*G9_R#20:P78 MTD&A9%?
H\$K*N9!H/O:7/"WX0;I";NUY/6AS.O M: ^!7/QOR@K4\$NJ,IE&-030V)UO"X09-&<,9"4-
0=6TG!PPIYR5(ET#W,AR MM%8PC!F?|-^!D)#-&4P<4VL!*=^+ 2N.Y&;N>>YK%V%9?
@O!N!%HBD!C4/Y M7V5&UP*A9!;*4F,EPG#8,=:A<=C_XZ!?
GQ:'K4S275!^D+0!P>:;6J!5S) M^.^NVPR>W05P!U"9PG3IH-
Q2N7TDC:V) _&|"G27#;Z%AVH2=&!"MVW!; >P*^ MI@P7?IO_U(!W)5VIZUZE);^B67-
RKB*ZS1EJ!R64PL!#.@<,(3GA7E#6/T%Q M\$YW.L8!(-=
!;_V'GHCNBU_RN>H%.U:@SQ8SN)B29PBC_'UEO'@C5!_ ^/#RHA M9-
!B*HI"*ELA0!T*J:9-9)L*689DRJ*8:R?;B"+\$5"D)3+(5.O:I%\$+6F\$61 M_4X8-S-S?:_WY_??
!X!H_!K;.>?Q?#P?CW//PA."F S)D1.,P03X*\$_G1^,8 M(N,%6 M-
!9!%BN^S_W'KJCP+,=.E1M'5;B0.S!\$_1RD_UO<J\$\$_P3L(B3'-8X(! MJ0FIW=!?;Z\$
M#TZJ;1)Y^G@^3K3ZF>3C(>+*O/^P^FKO%.U.H;?F,JF74SK3D:_H_%D9ED* M-
%RL(VMZ7+TG&'K>YZ!H2Y5D2M;4-;,&)Q;(FDLN4ZW8%OUWY@END!N%(Z MB%M'_?
NON!T<,RDG# #^PLBB<^D5K(4%'M6%1TPE MPG<6/8!1-
RQC69>5.4@J4_KWG"O3GMZ)4M'TQ^*1S4F7W\$!7ZZ;5RAN2&M;K:/<' \$HYR(4S;T%
ME7<-S/C)*XM3_.D MS47Q:X(S;LY@&LMA!_U_/D4F6/U>R-
_OKZR+ZR2^,36@!0U>7).K0!X&1NE MH#Q9472R*
(S;4B9.2:UZ)+G@'NK!XC=5(!FJE5"VI*ZMIXY'1R'<6H,&KU)'

MASD;S/P#H(5@R/OZIUG)X;)S9>7B/?O_A%=KQ2'P&4MH'P;D;F-Y
MG/TW5NAUJ60.\$Y++AVR'CG_@>XG=I?EQ3V_17@/_2_XCE>VU@[AW>O\$A>L+0 M18.
HJZJ^!U!\$*Q-6"G\YTDE55SR/\$J8ZJ_QJY#WEC@*V1(L B?04VGR@7C
MT^YV\$#5ZYORJ_ "2P8X;PLX%/?ZO*2&//>%H:DWNT:ZS7!DBC2JRCKI!13QM
M*W53HP+DV-7-U3N3<.SBFF)B063(V_!*:IY#Y: ^EIDWVW0#HL BIKW0C=0G+
MS9Q@/X;,:3L^,C'O_GZ^E:;!HUCKJF.1'@05RSCI*|O^ \$,J3 M3>;:L;%S'ZZ7C/XY-
,^,ZIR?2)H#J)6L90ING0G\$F@7+=\$=%,T!EE*ZC MWI(ZDLQ5X=%"Z?
<#C*H8C7I>49:2E@=-YVQUW/= /3PA<I.W+4SLU5>%. /I! MOJ_11X5?P-O'-?HSKM?
C9Y48_)QOJ#I>BW^,S7YSD5+G6^S|C,=1084ML& M#&,F%.+,5:\$BIGT|6@(_M1#L
TOFKVR9OY4MLJY-^9K^ BIWX_%%QJTI@H M\$ _R'+J7+PJ90+8O.DQELPU79SX7=
I*_FXYEI Q7@BIJN6RVC..WYYT.T;^ MI?
QG(/I09@!/@DSP_KS|W4KK**8(>ATE@WM)!BVOY\$W!(H9@A(W'377+^/!*5
M.O\$*TE'FL;V-CZ%ZMEL37NDTPT&/:OMOU<9I7-QX\$<&! E MK)\$AO#
<:W46BD2'=')X"EG.-'4F-HGDRKA V*MU%4Z=D<97P8:#7T#|PR*" M#_I<5?3|<9:XR-O!?
UFU* 8WJ:'Y:P OJFR|Y^;:*V5;EF?2JTH#_QAL*/ M=%DM)8VHP|:4J5E.,*+
I61(3X\$GOYG@QC8_\$?+T6ZE-B4_VTKZ_P6-;1BY^ MOUIN(OCB\$O_EG6.SRQ.P1#;
I,4X\$P|@QP;9@1)P,\$_)9&)7I"/MA;"BK*PJ M.?'S_X!@,ZF#"%.6:5>&<0_\$+5P2^52?
B5LK+ MZ93(5YWR\$ _I48;7I2D2+1H"5CN?Q7R'57\$(S7D|\$SBZK>.4 -.K|ZK+UE
M_GG/3%IGLES!?'9#4;95B'):L>K6+I57Q|3G2)#!%,SN@J1VCB(O>6>"%OB
MXP3^H_G=?H04;C@YT>3IK69C/(ZJ'M:>781T<'K+XG?\$8B?DE:H(4*:27.C3V'>W#;
MBO^*_KQ)=_B^X*!4=O&LG92M3!+4+T<.Z/I-Q26E%U'91: &NNH?DG7==3W M
3MA'H*-B;\$0 ;W4|@WE3VE;M^/G9_<5AB@9EI1;LP' M->\$FQU68I.Z)^H>U>2|J|I
<'#6"Z(WT'R=RF!2DS%;B\$=|R!6U MDOYCCF)F:)4B# M11(109\$T:+,KY3ADY0_LO&?
I5^'P|I'\$5#+/!"&FK0)UES(@Z+#IZEWUWPKJV MOJHK.-
*_+6#;9<*K_WEND)&DDAI^HJ_6TE(SB\$49T88E@B /)IXTXM0>89Q:
MMAOLL|>N)K_U;=6=BOVJO0T"QKNON1^:R+@/|. \$P%3RQ">@G%W%!H>AWE01D)
M.MX7#"2)%7_LB"T9NGG\$ L%EZTH%C_+/@LL*(R+;7OJRIY=;|EY#MQ;&YOWU
MYMS3K;_8R'3%NU@?O93U:9*:_J&MR<1JXX>YL&Z8_<8.@O/S@S;DB>S|\$F2_
M3>3ZF,'+'I)%MKMQ2P*G5(I(O=A,(\$U|J_1.9N>5QD|I-(G!=N@,POL(IFT
MR%4RI/*E|+@@H%ET'?5;FKZ).G<)X&L7-B)M%MNZCOJ5P9-S%(6XAJ^RU>O
M&O.VE|D@:<*6(#4!>QAOK"/R9|I5.Q6|BH&. "R%.2;:+=S; M>TN^NTUM7R-IWE:|LZ-
YWH|Y\$7-7Y1UA/D-)=.Y:H+D|&SN/<(:P48"

/YRZG\$F_//U3I.SE%CR> M%TH+=;3S'+^6<)=K M|03%:&.4L!2ZUJK+AQJNG4G_I5Z?
*;*Y^?/"/,^I_#7>YYQ_++48P(UQ@2TZ0 MXH,C.=T.C8/AY1:ED|9CN(_I\$^QV@A878"1!
("W|=NH(Y@)7!?'X6S5%|ZM>-MQ6S;U+|I\$)*?X,<0"M3+VQCAJ2O O-M<3%0|C'-MBN-
&GUO6 W9PQZX_5<5CXPTI9\DJ0.0I|JGT : =D%F:./-|LP MDCCB=|*|Z,BBAW>#;JTN?&*
I_ =YO^6D^F1^TL464V^@Z:M.S0?U!6\$873>;Z M|
OO&T0(@4JM4:"11K.XB@W0#^Y_T+-C3FW;(>|Y/ND9|+,Z MV?&?/2R.J|'UWQV-|N_Z
N9W=|7(+%*.LHK0+H.XWW91W%==TO8N8&BW?R M/V*|@=\$E!J8-
JP3WPH<3K_8;H!6|=IS047_7'^PIGEPK M+!; #8)I:-.K<+; H6P=YL"
I#;A9|AX(>|S.P3_@=RW(N)R_H9WMHLSJ ML& \$G)+!4M2|I9
M#2!>;_RX9.2BQ==17M0THT\H1E; M(3KX@N>3L=,|R1=_>+Q-MOGZV\$;H?
*HJ'7WZ;4@CB<_Y:!.ZE;JK!Q:&&> MMM^+;:-^5.?
1HQJ%X906.F1Z=T**K3D/|QCC')J8S#B MD.G|ZI4Y(-"I_F%-
W3JJNL9(&'%1#6X0&A;UV%@|FEJ:T/=2|I|G#E#ZZJ| MMF_@98|3W<|#M<^:+
<.JVB\$:^YZ5>-B;OH'.8F#CJ2Q5GEIS>:C?(0|HQY M%"8XP|6">Q)4
UE<:_Q9)YN4>.^L@ (FKUIE.R:6KF7%4X8QD"9U;@*88
M*,F.:*/I=VG+^TZ*%\$_A@8_MLJHORH"MJA|Z|?R",VI/VWVY:X&3 M9ML#5>8
R"B'14J"\$40;K,73+ Y+JT4LH!Z3DR4 MA."SB1=\$3Z"9!KQ%W-Z<#=?
#"UV#;2H0G3T#TM,, -U/OUAN.2A2PMI*_NE|T MGWKTY\$S1|VFWA9X|/1;NB
'FU'!^Z00,>|=?"H./C6HVIWD2IVLR3PO-I M@O*1Q8M;_86 MJB?TG:FM^MFU>?
DI<3@"OO|RP-|EI=N0+T>DH=^MHZ*H;ICARA9,I7UK6&X5 M7T|V9M0|ZPY|E?
|O_BTKK"NN6X1RKFCWX#3'#@Y8, M:Z^>"FM9!R)K-Z4_7
*9QUEUF-.6|JCMKR8QWUQ6V1.B?\$DIS"|8I&CL#^ M5,8(|=^9R%5^%,&2-[MFB:VWL
WP4E??DJRE<:LY^;BXX-DU'XCX<5HZ/*# MOJ4@BXV1.AM=VKGF.Q
"7BP|S)K/O@Q.0HVM^/_#HZ?^T.99Z|.6_&J
MG;>I393=O7K+8R4|\$NVXB_YGNV.FW,8X*<,KZ2LH|1!!0:Y@Y),KUQM*"P

M_)L!^7&O.GYJ!%SM%=W.._OMBTH6GF^/U%Z=Y6@-OL\$P*LD58QTI"/JUBL3
MLK5EK|2MC)4D'#MMJ?*TOBHCZON|VD>B?|E%UZ<6ZA?&?HS|,(KXF;B=;6>UHK'=|
<>#;4MH@2R.;|JX7++Z8M!6X+|&Y!3J34J^+U?W_U3F5N%WQ,>G
_QD(5ZP*&#PZ7K19.B8557\$QU.V%HMC^NJ_5?TKOKU_K,O=VTPG&M_(93P.
Q*2:X9DH,K)QS|4>U4M1-.W.7*J!=M)XVG5909J3T+)./
6ZOSTPQ2FB/0*KGUSQV3!5*IRZ-YPH5MHW|S/4%U:M9M0DO'M#E86.0^4J?-\$.*T-
_V%SJHE%CFVEH15GD|)#M|GNSCS4&&{Z//RWNE*3
M*_L'5;E:5EOU_QZ<|H|PNDOMX_Z%(KZO+IDYZ>_(QA/**"9ZAQ'AN,98-M:W9MV=
<=2J?6K\$Q|Y|'B=R:_#6/73CU(LE.U4IS;V.1Z=|L:U^*;B|)(CDM?
R;5FHY%#TB3J7=,I1ZQ7B25_WRA>:YU/?4WN\G;P86|D%:1(A?;H;ABA,
MNO|B/P_YE6#5L|R!.ZOSC|1|S)B+T6MG0Z)P!+R9H/1)XB\$"6|N&);E\AXJ_M_PZ0W
YWEN%P/GK^S|W#U3_7ILN9VE|SN"S8IGY(.POW%@_#RQ^6^"*WX:L
MC*197=IP==GA<%Z5|N^V6E3ECN+/SD;?:|Z!\$LHXL\$YB.Z|3,%2K3M(UP/M8OU9*3
?F6&ZY=M5WPU|LD_1U_O<|)"NN7C@&^;V,U:B&?4FJ\$T9T;/<.MAXJY>)
<<7A8\$LPN*SM1/*U|@.L47U65&9SZ6;NT?E-1#2@<,4>W@;1>'KH
M5"O,TOXA&#.M84|'@RYH:)|QL^0PFF/"SFG)ITI?G5\$S8*F+%;)HRVK<|TS_M|
|R/:C58VHRIM|.1T(|QDOLWAM!+.321>.A%XPKOK|P|>=.*IPH>FIV%VK_M3W-!|
|<%"DNP#E-!D-?B7-|>8>Z^=(|?0|)"..\$JLNO"9VD+?^E/P(MEKH_M(I4*;;E88F_UP
_4H(F7!+V?Q?2B6V)F(K\$%C/@NUZ/,'SIR1,-PA22FF40_MKR^1""&&W7F9RC_J9-^.
3T;@0IS|G_ZS74GO>'CCQ-Y)FHLXKY01M;\$OSVMP|D"S>1MFJB_3
XD+^.>O+9(C(K;Z/+SP|;YA_U:QW5H|)"&7C/JH%|'W-B" M!FGT;>QUU'%SY+GTS@2
(8-+'TFFYC_HBQ)/DJUW'^2.UOHC**R-L_7_00
M%='^XA2>2_%H&+>ISMGO%/7IM|LE9M.B-|3?|T|\$FAQ8."Q;*LG\AH)E-EY:
M9*AJT@V+!)1<'?MYJM(EK-O6R2ZH_ZDM#&3&>I'VX"FHT(WK'K*/ZBTAE
MG"*YJB,%=R3^Q&PE>(|3S>NH=;M5-FA69.&B.|#AM-O;LE|S;LY<-KR^~|_
M3)&V>A&9|K|A3MW2<#<=/\$W:XCH^|.PT0|YNJ+TH|Y/108CGGG@C_|4P>>!.
M#25V+|^*JSGIWQ)\$@DQ^-^+^O5\$NAO,7M%?NPF(;JYIJY4+5ZZAKKS#+STQX
M3Z!S0T@!RAV_|=^((U2KKT"P&+|;IXTGM5#X|4|0?)3TA_) *D(?|@%);|=1M"<)0;'3?
Q.9N.&|YAN_X/FPB|<7#W;V.M|&QZF%BY!A%BPJ"2YQ@J#*";WA_M2Q/&J1/?
EZE)EX;('(<>9M6O9/3,9;THT/\$BB?1T|Y2P+74*%|)P;5OTJD3R<|X3_M|^|0+O)-
-4C6;NU|ZKN.^OJT%/A3%PM+;\$S!8B&O/>\$P"!J-KJSWY&I\$3E
M32'IQA>M1.S)/U4AXWE|1_!|0GUM='EJJ9PO,>OIS11=<I%FDT-!85PF" M1H(^
I;L9>\$1S(OX;X35_MVO6-'X0N\$O;5XXAUS-WG=+/4-HYLU1U=N6"UI2M5PU!
(XHC#)TL)&5|\$1_M"|6.HHU2M@W/^NT8|&YE>;7'9_I;23|<"YX0M%^'Q4T_2V"CJ2H-
UZ&_V.MV53A!G4VM@50JR8K.(<5M4M|!SG-Y)G=8>UQ4,,=//RI_9YVJEH'-0)SG3RB
MS:"U8X;H3413,+3-12W2:+YS|T>"3.O_|QINYMW|/'H)"Y*:^M|2RW<3#P(M-
_='3P8O8>%PU.KU!FZM+V,Y6S?|X%+CG+5U'GCC1#@+;)A>4:07O>Z8"D"W_M!?
0K"!L@-+5U!Q(#>|TE)=>BOZVC7AP>I&'\$,|YKE|K8KPC9DX77&K3E2AA_M=;C8MG?
ZIZ8=4UD|?VB^T?)|^O-3Q|Y&;BS(&P15,,C15/_2B*@8*Z.Y|2Y_MIC"1*AUS|5\$8S-J4?
J0W*OYDQ%YEGB,^#DOLILG'P2+H0/8^1-=)9Z>S",K_ML>6S
3/&WCNDO&NZGHU_"H^3)(L^ER@*1Y"T5H8@Z3?0;+POD=S='>IC2WP6
M3F<|SCJ\$WJ!77^V3|2_JJ;KX/#?|.6WG6Z)W|Q|+_|GI_'O1+3!*40|\$|78,@C'8_M="IH*
l:8Y+JMEG0%L;J;6O\$CYP4)4(SY_W/X.2VETQ*5%?(S9=;.9*LNH.M-XR3B(HE0/-
>QI51|NXJ_DGZOK|S-|Z|^X6>_DS_3_"BF_&S#1CFM<3E2V_M"A!>#>@07-X0)T9?
N./KA_8D!HU0D;3(Z">/8ID""KC'PLB<_JB)R6^"/JZU
M96O4#>2K+G=N;4A@7E#4/B20Z|CGGY799&E@M,EXC!2,JJG/Z29V\$;:XF-^MM
(G%U;?^MU004Q)<4EMHT\$G>192L0:|O)R.*G9'VK3>@|H_MD|0->TP4R_\$-
X*|JPHDL3YZ,>C-5XD"LX@H|LX((<9H),PZ1S&A(=P9(PF_M#^@!-I;|O|SI64=Y#
|ILD7.BB|P.RNQS?_O|^|Y0I>0_S|F=GD<U)A5|9)0<*7MH>;B|N+I@V/6V7U_!|?
+VIHG5_NW:@C7?NO:XJ7|@2^O.59|Z497EW>-'%C_MR!821'^MB<+T&|%#.(S7?
P<%5)/U?^)/\$|>7&|44L8@DV#68#WA_M^N;H+KBZL,2-(E>TV3Q7.0+!SS@3A>QM4F?
G'5_|%,\$1_+'WF;2X\$+*00_M:=;1@I3Q,>OW-^|LNG_/5\$ZF>!/Y+H2
=|M|WCFV7)P|4\$6;|Y3/KG0LK2\$S_M1Q4;,D66OE0|?+A5|346<_H?'MZ*X5H1#O"S_0;%
|0HTZG_=TXVE54V6.%F_MD_!/"W6B4G<*2(!?_X9B\$MUY\$4K'M=)9D.EW=|B9T%19|
|H|MV=M9.+I/0S|O_L_M&0!/1107S,=1CT9)7\$=5->8PXV|?%V?"GA%=|8J'9.=NU|Q:_\$?
M_P=D;YX?G:WKBH?HV9Y|TWQX?0\AA?TI>?1490N-&2JE.KYA2|FH/=&03
MW|_KU^?-3OM#>X3GN:G9XA/XBFP_\$7#!FW5-"IZYH/74;)AP+QHK;QCW\$&M
MW/_<%_;|S;Z"BGF.=N0A(1/|%A*|>-'P,5HP!U(=-6K'C_4QUS)=V1K3UV&@-

!F6O")F0%VRY#90I;'<1A(9W"RCG)EF!E+V^/X4\$%6"(&07/
GW64D)D'\$XLD#080DW\67'CA+Y'&MVAI<>CY|+?+K0I1PB>|_5GWW9/4%!O
M(B23KWM7FGU6%O +FRC?D^H6&JZ>&179W4F"JFNBP2#AN'747'\$8-N+1)Z;H;ZL!%?
MUU#Y2XSKJ
MK602I@ "PWK>* _<1N=YG%#9&1)X300+P!'.R%GHV:LK>| \$B)EGKB6">C%+Q
M!0MQ+=/SNRP.G7L6I?SVV>VB9%/QWVOGFS:+ ^ESZIYCP4G4<3_60@.W/T4Y
MG0S7A0@/70@/\$?L8I>7ZX,))E"QR(E&QEPY#,...AUS8R:2EJU#Q!5<^WZ_
M^Z%S\WRGSN\$# XIFGN^/,!@<2AMEY!(L;@U|9I 43DOT#\5R8E(;(O(Z)=ZO-M?
QY|.);\$GP@ON1T7^/Q4T2:C5S!%.Q%949.Y-JOYZ.'%/PL%-)P/HAFOG+JOU^|J^?R+9)0GI
M%/.V3W20P L@ M%6R&AD6O! ?6.Z"!F%3F27@1/-U*K\$N4-<
MBYI<@.)E%!KH'9H7EVUO!'C5N)EW/OKTA3<:D&\$=5*CO0N>ITD **|0-2,((
M34*AX)+CH'2?U6#V=%7: :=H\$6_?TPE#Q;6*<-ZS,;|
MDN%, _P#A6(_DS%>7QI=UI8"F=\$OMIOI=MX+@2)PZ<.8?:T-;TV|*CDA&XC MU^
1C."|LFUZ3A+E7X&&D*ZZ&B)T^P06V8Z^@A?88|3Z::X4=M6HO:.W// M=Q"-
_ [%BVR\$>5.(J: ^?|_!8|V, ^R)5WXJ"8+"^W3XZG,3G2/UG+FZOB49?|1
M(9N>^5L*I|'#"HZ\$=|94| ^0CW5^+=CSXM#8X*2SS#OXL|
M.7U8Q!O\$PZ(A8\$)W.|&L+LN: +1^KD0G9MPW,?IAS/-OH|DMM5XFS:'VU?^LT
M|M)FU" _1K=L.GD01!1R!YE)M8FU0M)K)M M;
|_30Z/ON_ |*/%C|&=Z\$B^" _!'V|3JI^DH|E|QM&@V>QB4A&;A9|0!"#Q'T M#O\$#?
N=B>|1Y&|@|P_CNGV|A!J086R-/C?Q&K(2_8-Z%D)M(M0T4MY(K5M0I9C-S5/XW2<.N
>|;.@M?X;|NX94*9|6CY|)+A0 \$S\$A<1+IU|6#TYA/OJ2:98X*%T?"IT @FA
M4B25R102H3/K&Z/31Y+1U6+=!UA: GO|R\MU>PVD:@MV|0QZ,((5C54M7;WK
MLSQJ+65U|LF!|*FY3JXA82|_LU\$<262"L&B8HZJFY??YMMNMRKS>SZ0>TS;
M7+C&*H6\$<\$X5'3R%4P2:|0CV#,GM8?B)_E,#|EX:F_@?U H"TG*Q |Z*%U
MA/8@B.S(WS1R;%^C(W GZ@@PW,>,'VQ:1T7!4I#IW1):I%X"P13 |G.X|L.K MJ1?B=
3^2)C8-R-.9AT%&?LS|>:7V.98\$D:4\$(")EQ_Y:>|= (R2ZPE4W|ZC MU?#FT8S5>%/W:?
|^D:9|W;M 97Z#3>5VU5=H"E39?N+)V\$O'KB 2-V;6Q)4",9W<(>PO| MO+D.^<*-6-
9\$+8XQUH5;W"YG60/GJ/W0D6A-^;#HXPI/Y.L MG0')SISV360)I)%|.(RLPHT15"70B2:B
CC8'HEI*6.,G5N;L=\$K4|M^ ^X#Z
M/91*A%OGY|7!1F(3M=*HB*M,I#4*|1^%D&0LRYPAC#5^7|6M5ZXT(|?P;#-V
MYW6VZ|?+:M;/M1(SJP3^;4PT/8Z4T(N YEXAV+"%YZ6XA|,X?2V-&@,NY8L-
MIB\$^|AVLB2^8F2_ _||'@C:**OJ_9QO&,2|P&K|BB&RNS:4N4>|?'-\$,#_B|D>?
W.Z5\$*&*>)00Q2&(! M&_!@<|K._JR^O%08^YJ@|8M0>/|3/26_42(|>3
MJQ#*JV9W(L"0Q:9AAK0G'M^I>>YGR0R^K|"\$|ZF;4"3>95OP.: =4. |NQV?9P^_EBKBI/
ME?^A47"&6DFGB1^PJ2JPIU,|XUR#I735OQ./WfY.'LG9+U=^9 M?*;73,%TI#
(6QJ*ZB9>X/G0NI(|PRNK2U4JHSGY7^HB9\$.=U@ (MD79_',DP2NV|
<.H/&A4WK_JJ|W#LJ\$C=O2!V|/7/690),-*HB*+:AKQ4FZ?""C?4DQ^" MBMIAG;H_ M5_?
G4W5TZC^:+=)|H/?2B#ZV%%5 M\$4J_2|KTJ?;E)Y):%TQ4-ZLH'!VU0#|B@|;+T\$YL.L
@TVM> MT.: =R@F\$WFKNU2K^Z5_N_MX6AU|;?
H&CC|S25|8"9&3Z^SAZURW.?|R,VM#4 MF_ |QWD'H6245E%HM2SJPLG_ |WCOJ?
1F42ZLM!46 W^LHU(:+KP^Z5GL79/I M3'?Y.N1P_.1.%_8):O
WIW8=)6Q!.#C0X\$:9QE4NSKFQ95A;8I|^E<=>9^^ MIY*ZW?EE|WEI2FKA|\$F,=M3W,
MOUU-"W_FM'=5@G^RU,5"L"9 A#MO3WPXF MK.12"/CG?|I>S0:THA?F9'5N57R
N1JOFR1^-,?R: =.99<.35?RB /G<)M MQH_09A>GQ5=4DTZFN>C*7W6XZ?Q7L"-
-6^J|@.&_2+809VEC8<|-*QL+E!+- M")
|0?:8XWK&B|EUUW|#@|=JEO1)K'O=^6JV>TA):?:F)"O3F#L;C?|\$WAN!3 MAA,9BW-
Z3|H,6M7O|&87OL(0&92MYUYXF/_5Z;J>,5::@SM66S62.-I #+! M-RF+>C?
N@>YQ10G6/03#US9_.(>@0S5*"G MQO2| |0" ^ _%|3E\$??
|5@|IDFNH.%#')4DGC|E^;1H5P-4-PS"MDAKWAHV,75=NS&'>L>0H
M:;AT"FBH|LYKM5M9|IYZ""4PBP:O^\$-:6?|;#?QFF2DG=AT5'S&^APNDE@7K
MS;\$#=#X|.CHZ=G9P:G8-H7+MESV@>(CE\$ _&.K 'D5G";WTIF8N1/_Q'= ?9 T M0RL%
5CLZO|0M| %>IACR.1\$TL*6|*6(JFA?"I*;DN72|8-"EM10\$Z7,F;F7
MHP|+ %5Q>|XC\$KY1.T.8_@C@.BI|4C";15:I%9+#5("=_1O<^ZG(
M=2HF,NH;*E+I;_3COE5*&?\$T&C));#'*\$Z>05A:'9%C'R/'EY0T/V=MRI"(? ME|
\$Q&NWG1HXTNV&*|(AB,.;>,Y#?D\$P=83\$'+SW%!"';<;3%V8:811,|*DH.
M/Z>.N8^\$20KV"!>?L8^&*11D!)8|V_XAXVE,^N1>KF&S7VRCO(&6K
SLD;KTY2>#W53P @!|;::0H;V+S;:2Z6@%,TS)C*/? M:M*N7K?
8TW:'==Y9J2<5_/ADS#SYND.Y6(UAW6U|3|.=|W!K\$V"A&_

MXJJVT2L56LAQ:AI0&60^8!T^FRCEH7U!Z:R/*E_1A56!1WFZTA
1"7&*A'34CDJ.:!W,XDD:3BH2?@/RV^HIY5T\N M"JF#NS *D6K30(?
F3F!J6TX<<+M<4_N336G4NPQ/DQ:BA/_'^3)V3R M)P#:V>-3(9^73(Q*FY3H+L-
B&I"#>C MI:NH8O2Q_2=8VO?4MS^ZAVEP?C7V<-!<&%5#_YD^M;^&D%LI(+2.Q
QC^ M0N.4@?YIU_PWC7NEO:XL_65!YIE:3!"1&=M4XJ(>1Z\$*XQ(Y*E*@7UMC?L'
MENE1U KJ-G_5/WD&H^<^OIBI/_/"HRA>_08>:&1S9+<4SM\$;)D)95/JN
M2\$^XB3Y4//\$+VXQGB@-I:#LT]-E(VU/@:U:1GOZ#YJJB\T5S6BW8\$CEH;A|
MMXMNS^)\$D2I\$1"7C T88|= (RK5SG6IX&FR%5K*J-R?0Y:J7ZYH2HN9AW+M
MK(5\DI\UOQ+F_(D!':G1N(TIU))_R*(K@,"LFB\$|^,MS5IP(>:/ M1H+TJ-
WCQXRLOJO<65&5YGW;Q+5V+AO^2P3S80D7R/@-[U9/H_C&FA|OUE%I MC7*4)
(UD4UVWMA=F+IPUAE*:M';I9SC5:"\M+!4CT^U#YT3_1/*.)Z>^=6?MT)N\M;H4-
F_)X3W\$Q2>\$A38 MGDE\$!;P0Q>A,^#;T!%R\^*(1JJ\$N0?
3HR\$;W<(1GQKQX66>'Z\$3_398'K M>C+\$OG54I7WS<(F@RSNXYA%_W-
IF";6>:RZX>*7F9*_OO^|ZHZZLEA9:J0W MJ\$|T IPT0A*PL#QFEB=+"X)|_":L<-
M'F.-8^6,!4W6_(M4O=7D,W/Q%C M5/'9")O11+::\J3P# P/-DLUJT2\&(KLZ.:
"V70"HLVHK\$^=XPZ-0@#KQ_+&,%9<_TV@F/=WKYI. MW,(HA\$@O/S5\8*
M7^M#I;\$_78GL"/S\H!*H, #,:=7*%|<|&&)%CC"91X IN.KL"U83?|<9Q@_MH;?H*G\5Q+
::JW#%'');+RC9CM358V5_2A:@68A.&P+JXNT=49M&CA=?^ M;L|L|/"^_-=4 !./"LD?
)T9>5C^L/CLZ_/'A2|^*^2N;J,P&4E|R&PX, M\$6Z>'7-RK8,.<54)Q|DY"
<%&%P)83I@#BBT,0E>UDZ6DQ8YASU:+X\5RK65L.^ ^ M)LI=A471R+|%8X7A(>
=+J7!ZA7+^6TN5EU0|_>WB/6 MUU/.5X?OO||;+Y(CED3?
H693!)&'X\$;Q2"%\$2PB=X1"ZF?&#(&|.CBV) M W73N*/#T+B1M>_"#|RU#'G<_F)39.-
:_04C"U#EUKWW1,S+_L, MM3C.(I_!HR%%D<_F9H4'C-
16Q;XC0&MNZ%J5S=VMN9)#)H?0B>*,|ES_MM5 MJ>=NSG8M88(I5 RH0Y1;?>
F;QL1E(0;'>ULR^>U@NA*)U|IW"AZI43I*08 ? M>H3I20>B"9
M&_0+!H7:\$UT|K&N3PBP09\ZV:@Q?CYOHVP8ST5H|ZF'15<)%KV&DAM>U))L M!9:G?
SFP-TG::%(SSF7V;03Y*44\$0AR0"Z".A3-/0'=Y1 A-O<@U,=TAK4> M7NL-PIVY?
R3J&_QXCW26N+8WH^M VD31RAY5&\LM"^T>7\$XD?,> MLN>JA;6V.E:/?V3|L!2K3&<-
+VW:8DNNG-UEQE(FW?M9M-8+|-;49Q2J,Q ME->%3S-N;E3J-
_QV?'R4|_6T>ESP.YR(.GU|F/?4"\$;,>58%.0B+7&.@V8JX MA?B=6G&2-
C^*E^/\$,D:M_5_6PS_\$IJQ42|H:.)JON505RK!ORZ/S5#%@C:WX MI0ZJ)' #2-
H8EV30^2+&7Z|M>|O@XR>F?XNO=TJ(P+MF+=!OZN.-
(^YGX*SP|[\$3HG'XI<1PC4=S0""8E%HVYSHQ<.U^;3;GU(7.+;W33I%","..% ^
M&5*W2*'IO%59I">0((3(I)");YX7WN:M7NE9?O30H|;+,79I(E M/C5Z5_4;J8^W;5|E7C|
M|IW>6^NL8&4.*V9;<>N;4*|S+|_ZHX^|0*1CP(L(<#_@5IN42&'GG.W7K(;B
M*8TY;I%NM5^JW |NY%V,V'G5|M.<."IRSZ36D;TQ,H_2UFA/%4E,*C%A%-1
M&B;&L6\$)A/\$7LX>|N8T8BJ#DSNXUU&?|G.B"W./|K==90//;VG1-T|T+?
Y(="TPY!6WTIC^RC1YL|@=9J+4X".1U0-&L 9= M"&|^<'LX?=C1Y=M45KT*
|WTN!SXB2-5K<\$& >YJPTUR#00F#U)#;.@H-#;8V MHK/;|=|3UO)C^UP#7"BNG9<_+
OU&<4HHGVZ%7=+U?*)A#&|=6.2 &)%I_S|K#MVY; SPU(
MWMJ*3QH\$S=4;X2V:'M2H7OI=G L_VNWW6S\$(@|W(O92W^FI9C8L.W\$S^3-
M@|T10!S/|T!*N>.+U-NZ/WY=>'4XJN#43XEP5D,.Y|/&?JH\$0>(W*GH!
I8ZNOP9U";N_7.FPZX+N|5P(@7>:W\$0\$HLA/K0-/)@Q!#\$JF A8;
M!H4Y#&@^@'LXC,1,3#)7"?LEDIY3%);|@/_A67/8PR@5CQT9<>|O;B-UY)'1
MC3D36C#B,JH:-7.U|(YN^XJ&:K!GX.6_6YKCSX|KX1?ET.'/(,OA|YT%/S*
MQ=Q^L2.51=4*P4(F5LR<>,.SQI>A6*|TAFW5+!T3*(;>K;-NT)|F|Z=2;H
MZ|MVKF6WX5HD6,O"Q38>Y)E)^X+|\$9/YX<7|ZB5'5^@N?>?GKZD*K^KT>8
MAO#E|=IV?T4"DHOBKA!;_.IW=%=,+Q3V7M@|U1@<|!&Z;H^K_!@9Y4D*<
MVZ!";Q81+*UBQS1;E7W&P|):_#*/WJ=2NY^OB60=?B0DN^6)N\$H\$WL\$ L(&
M|S&@#47!#4|055|'G3Y)J.>J(!&K 3"*;3)4#|U\$|O9&-:#9?H6R|8C/>X-MQ8
LV8H_ZF(^QKJ8D6IT;/WZA/*T=0."H8&\$:\$QY'RM2QC>%6;_&WU0VBR-M!CNVB|
<@!HEB J0XFX|<8?NH\$/LT|OQ*S"N5GOI.JJ%5&AT\$)L Z5|WW1CZ:"'
M8B9'72MC#-.M9\$QM9?J|_5#QZ|W!>=<0+KJ.#)G8|1NU=;D>J16G37M6C
M%C3GP6FK^5CN'H(!8VW*P/'|E!,VY/CW3@GA+Q=^
M2"IV_3_O@02&9X=MB24%"^':0G.CVN77W%|JUP2+GU MT(CEO_M*YJGXOG*
D4P&KZCD>^N64QGO3"9.Z.B|TFNG/=0WR;Y|>?Y"TO8 MN0!6)("
(0+Q>1YJ^?;^R5S!.T>>*8T2M|77MZX+;I;=3C75KWV.I_ '>6_UP:/240RKSAO;?
Y9|GPW#M MI"!_ZTZK\|FMS)TZ H&=&7#!8IY!;_LQ8EW!DL7N_2TTFB3;J=LND_)K1KS

MI'XCSG/[3>VA;P#K*('@9Z'?5]=PRVVO_1@17Y\HVNO'"9IF+<7.ZP1^%V\=E
MZ@;.*@KF& O+C7BQ?-P@@@O*L1MFAY@T3&^T)9G%(2 MUG/R.35S*?^,@CXVX/
!YO#)NBTS@MM-!XOP5#V>ZH7KZRCW8T"6O>;&6!JL M,&|?/?U|>%%\$|f|:G=Q?
DI74(ANS_|L;#Q_!0J9NG+/@P\$/&8B*NNCB.H.GF M>7OD5YWD/?
^RZP/CS%|I735ZT4N/3V TN44#M0"CJE&%/+ \$Z+|3=#G/R56|
M!.;3:/EPE.K38ZCN|#0=+R.+|ARD;G=>4M71I2MZU&'2%752:V9'>J,=I'
M7W_U*YK^:NIGQ" BOHOF:N&S;(&\$8*4XAE 'FP)K"A^K3O>O::78"6:'6E^ M0X>M)?
28Y".H.:O93AX.8B!*>+C5D5|0+9EH(_#ZW)W|NUU3PJCRN.!%4*&KR2J0BT_EY9>+2.
(MF2X/V_-OR/B"88WQ@O MCA!
(.QK6|C;?"4VYL:6Y|3@%@S1/NQ|&LS>OU&:Y5WS(F<3HFP|B=|28|AS#
MH"@G:2YWR"52>-)4YAE"R2FJ4(#NS!^;RG+|H/?PT+8YO>C^8R)2=%4=&W MCI
3YSH_G|>/JX.|Y4<601_<\$R4)|*PC((Z_|NK3RM|XMF M)|W
15@ZTNERW@|7%F=:9V2.R(YVGXI.O=%X%L&,'2Q|=>.G=AM|-(CE>E^B
MC\$65#NO%'^%91CRS2|*.O|UDG?F1 7 M"?ZAY\$2C5GE>D?D-M;_381(AI.&|+4*;Z57-
BHX9?.K86ZVXB0)7C M\$J22!+8XBNG @4.P76J!;NOVI6.?
YG%5Y14U@8,Z_>STWE+|BFM=C)?<%Y M>|A!G%>XRRR#P)3ZU!LSE3F1!
<>5;SCL';EQ0<'D^#7A%||^MQGO;.:;?7W M.)L8W |DH0*\$PG4K6;?
E=+TY2|ZIA:&Q9/JS=>K)/1KY|((X1Z7+HX7P05RRKA'E4FB;Z(B:|)\$E
MW5.|^AC9|(C^|S|<2AY>2KSX|!DPJYNL+QIB^41K,^A5|>_4KZ;/F11P9Q0ND7\$
\$(<+|-C1'|PIK-M%DBNP%8M'MLW,TNOA|.Q4KOCV?TM)UIZJ|+D|
(VF*N#D204H_>E7W*'K)+ "SRS:T6:#A8^\$/=[F8?|\$CJV0"|:%8"J
%\$X9;X8|PH2S=0/EFJ>32G!G23J*/ MA1|ZE-2=HB?!7=\$GR|,WGN0AHX'^^V?TPG-
<6IC9VN+^51;/|YV_*NX:%GR MCM97781+|M8_KTBey>P|O/86!*E\$-A)HF0
Q9.+K|)FAGDP=TR<'WH^EW\$A8\$&3\$T6N-'4WJ+6.G/VZ@#>TS\$ M:~?O/-
P4#,,P|GI&L47@#EFQ|*%|.3)D,%|N|1Z*=.G,='4U=J2\$E)|J9)|"\$
MNLJ:%U|2WO'K;M'J1TQWGY#<_RDJO\$Y_C?B11'F%%ELCO|,OTR;B\$49|8"6Y5|E7K8W;
MZRDNU?RZ9?SLKIWD%)Z'6XC=J\$\$\$SBC0,A8J\$&Y>&QMAVWD3M<+;VCM?^>6(C
M8N/?(8;QO2V=^5ODK9AM\$|R_P'S"QN'A:>BI!>8EFGZ&|=F?6('*,(W"TM1@9^KR_
<|A)PP'Z%M!Q28B2|1F2H*|^S,2C%|J9\$\$.NB#%,H#3O&07N2G1+
MDBMVBSNI2+R8=7D6+|FSJ&|S0^|9|V&)&QE5>H6,J|C%| M/P78=S" _WRI%4|*C'2
A>T|BQB;B:|X_C029++QBZ;(#.:| "BUA-^X\$YPW:
MW8\$8Z7QP\$Q&!\$>L&WW5(OG9X1WRU8VIXY"AZ*75KZPR1+2|*=-;|&2R(KY:!
M:@@F1VCT5W:Q%7T_!-|HG?_"/*)78,KXZQ57X|MW,Q_|/XA;B(\$%2=& %!C M:(KET.H?
FD<,GZ@L>YEG;U&AN0/\$.PPL>_6)LJ>&5|_1RS=8BT_E,ITAS\$33H4PU1.8O+ 8W,?
P_1)H|TB MT*9Z:A4>9!QOSD(A@MSS)|@|SE3H+YO*_:CB8M3>-!MNUM;Z-
7WL9'7!9S4|'+.&C|FX/U7A=FI.0.0K!|'G|OD"L=3V>H#W4C1(8M&
M|&Y\$QR9BOUXM8:UY1CQG"LN6;J2@=W@|!|(NLN_|C|%/U0X 24EW9YOJ'LH
MHL'+OL_'54?2E7ZBKR6<\$-G0|(L,L6,9ARX84#-)(06%/M|0_X4M=82J9:
MZ2OC3T1J<0^LMTPR>LIV*#V'Q6#52P /CS'1,|&ULJ&)M1?I?Q_'BK4
=|AI^:.*\$8NR64|9K M*/ D@;I4QR(A<"C..WT!FKD8+N@=
|DR'4:WYL67QRI"@:|FN'E>%*#="3NU| MUIK:V W/'?"D6|)A"9 "NI(W_'YH4_?K"?
ZZX|R|NF^D^|P87*CMS7ZIR MP|HCH#S\$U%2!RTFJ|'(ZLL3*!\$OC*CRO=#3_E%RIO\$.
(17LKF_>E+L,A96D M.8PE=^_
E=C1R>)VIE.PA=A7G_UY=7<8;B2W^9AB^=_NK#3WJ)F*02+%.84D/ M0U|%<-H|
(PW)T%XGY7NY^;V13;;CHWX'@-?ECBN8-#+= "X:1T;6RX#0SGO.< MJ,D)H2(E3OMZ?H|
<|A#L?PZP;QL)G I"?-Y=M9X#;;>)<%9:1D*"W?
D7381/QVY^S193|WA)@N|*\$HY#TL|1AT5:|9,6ROZ *ZTHMZNY>D< ME7TA|9FC-A5?
3ZFN#6*K<|:..H|O&EYX1)\$9!LSDM_>&|YLD*-Z+V1Y77U< M*
(FLB:>"LPJ2OVPZT70C6B:TTX)EMM5B8|%J\$V'^V|&3O4S>:6=(N"|%(B5)'@3P*\$Y.
|L%:#7O6QU#.Q8G?7_AO73P MS=O'Q71,^P@Y46EMZ,?E#Q)6|&E(0.QC8_5R981I2-
ITPMRA0E1M1>?'10# MM#CW'W%)_>O92Y&X7-
45R2#*KWBO>0M0&6"+)C41Z):HL/&=#.WYZF%AJ'4 MPZ5RF9E@6J?(5\$?
*G;.'0RGGK.4>W:HA0/S7_|Z@"\$/A|=J@B1>=1:MR|*AL MB5\$?#<0T#>/U.8;6(S5W@-?
(R0M"F7", \$D8_EH|H)O-&483CH0%LACLD&|90JH_7"A'B
M9WP8F270G9"#45=*0G^.>4K=^US^L:P@"_EU8":%O?=>)*UNO:N)G)|L+V NK
MU/NIL/OHH_B=PYX!&+H'Z?&F5WJV;0K'OJO?^WO?7+#+=V2@--0)9OHX0W\$^
MCF4)U!_5 !X8|O|TCMJ3G%H2'->7 M"K-
%76@|WK+@.*9>!9+W9&X8O|+8B,RDMDL..GD|7;JRN?G|%KG3D=L^2\$|+

M(VS7D4,C\$-|8^?D)8QG-Q:8=RM@=O^@(+BE8UJ.IDIR0FMNBDNL\JS.O
MK3O94ETL&5"=NCZ_BU0J1WSG,9"ZWI3O=TEKH,@A.GG\$O/2+%ZHXT40ZI^S-
M#YUCI0YH01(E,^Y?F^>EV3?7)J@RGACL00R;,T&KD-BS MN_4A?LXY<*Q-
:XN!^^(?:N40V5?@X%M%^>)#?!.SX K=K8Y<9,*6Y:&[-.:?S M|BJ7F&O3|J
M+\$NH&RE9TNYD8TU7C\$:58(4<1L\HO/<=J XY-WEI2/J1|=PF8NLM39CR|H+/M-;T
A6(Q."5|OI\$|J9Q5&_UVRP6?|P(1Y|Y84U/?W8=E| M,D,X M.-
&545"2*>;5)H+N*5M:NC1_EF'_8V/-1(F_-)X:[*U>>^W6W!>SKI)Z" M@_!!PF-
T40|LC*Y+)|SRT5R%DEL<=|'^=+B"T9:;=ELV9&IXZ>&%++L'C.B"B8
M^/O|JC82R(%_ISD9D*&GLV*_QI^ST1,)BKJ0#%V_3#*4K=(JF>E1:U36AZ MN!:>/
|3@7K>6G5|)TG4'S62_&YT-(Z>="5)H;LAI.FM='F|W-#.\$%UZ+
M;E7|IA|LTX>A&V'!8_%5L-@E..EXTU2+V++|0|@+(%Z^F*'|@&T<:WEUR|'|,M!
<7EX+F" &K\$'PT/BO61T,XMC!V81X2B|84@AK.R@<|(PR9BKR;'R=N.^:2C M|)%G:K1"?
H|',#E=8GKGD|:L\$&;8J^(9U@WV&OC'KK#S |CCT#DR\$Q()D_N#|
M6Q|"Q8/'L|^HNG&UCP0'XMUI^8FXGL2;8FC:|Q6+-#L7UO7ZB-|'EB4..4?
I'A&X!C/NU66C0B_F)&U|@9=A'&2JI MJS;W?CRL4_G|:LMYK-
|Q5+U>^YCZ)'J"/|0MEJ==OE0A@|'#|> M^G%-|?1UD|SULM&?
R_..QO|K5T!X)O_*WK,2/#P1/|@I.|)-H-Z;=\$LXBB0&
MQZPI@ (B^SOB>GAN&HO0E9DH4_TB\$^!Z'+>7M=7^,Z|ME59M=@/I*.7V&6Q;&
M5,AI#.D4=X|)U1CR5U;|B)YPS2_|H;DA'3S+8S#'W6R4FX.D7P1BR
M'&575AHT."M%F1T@|F!M'@#UL%^C?86CA(^*T88|L'=!>>R04PS6?B> MY()F'-
KY:8-S_T_UXUVJ^YX&'3"|O.+3%J\$HR3&H+HYD#IOIC=Q,EGR6:#QJ
MZF2Q3614|!EGP)B#!"FP2MYFX|"(((:2+8@)R)R5>M\$XBFE|RN(W56D|HIV
MC1*Z'8%S9&MNY(57;BH|.9XHXNW#=#P*%BHTA"1'(8NR# W0HP3_7%/#? M>UW2G+
_&\$04,TF+OG'&^M75,S/4I,T^<7 HTH &CA9)F# @URA|S<<%(?)?
FL\$4MF&E9%&6#QD+4|)%JT#7SKZ?W:|F%"J@N70&|. A|+P5RS?P1R--8D&2
M'BGK8MMS&_|"XB-,H;5=VQ/F(|O|:Y%P(%' M#:.9**=
)PL,C|K)GTUEU+*3LWWU&I82DGY\$,AY8MTP:MYS2814SR|@F'VI M|R*YQ)E-
8|JQ<:G(:T:EI-?8AJ@?855:./?TU=82A9@'7<=OD|5E;J+:TTM7
MM7)9//CVU.GY'"Q+W(LDL("ME1ORF'-SS736?5H7;6IM@E:K3#SG^U5S19&;
M2':8!!Y6#&<'>\$VX@:X?"/V CX>^U7AC=B5(^6:CS\XYMNF(!R4VO#|LJ8)A M,C|)
|8RNQ+"EQAA>S82|T|4OJB_3!#A61E|Z5:1,#Q5N(HS*,:Y4(-JW#'(%VIW48 M'+_YZ
M)9:|)OP/+NJ_%HZ:-
\$1BLN%K^: HTUN>L9*OF!L>|)9|!HJM((4)PO8LEB|MMEW4NNO\75PS0MADL+!0L.=XW
M 0<.-|=|D\$+V)66&V|L>"F3:;B+B\$OM#LZNP|8J87.(7_0.P?&\$A| |T(KR
MB;Q5FI(SLSB6-V62)F'ZJ>=3=HW\$?L 2B7F ML_C|\$U)P!TIR |M6EI3MFI'?L(9|)X:N(=
<./++| ^1@AUAO|3F7;B.! MC|^6?
VWPLXQ.P4/H!NOC2WN)&'G&|4V\$D' (5Y=765+>_:7RI^X*[8U=WN\$'
MVHS)|8(>%%+D^,XBT)N"YA_|2^4YL7T1AK?
J1YQU|N.)1=|PS&:^'I":7H8RQ.H|U1BP*ADSZAIQJP4OM";^J?@&@I)_QWW
MY4;1%_IQ;1D#,Q(M:%;_E,3)IS>O--6Y4_\$T_X.I?UOKV?-"@I^*E9/
MN2|2+^&K'Q:F/\$%YYOVO N%\$&LH "Y1@/#|P:C'\$)FPHS>|>/%@;|K92,'
MO>|Y|O'9.>X94D!>|ZWX@BS)'03|O>@|S"3WIY<)M93)56Y?>GZ#_.@4*C(3^W8Z+D
M=I2";UE"(\$ M'5L9:.*A(K0J\$^6N<2JG+.VT|FT:W?0?*K1E&|
MM1OD)'MP!S(<@K1.7HW5NN|KWIERRUUD1PCU%#("U|R^HE89B6,\$)L,6,H
M3I@TBF-\$@H|N&NY/NNO|EU3=ZMYM:ZDO_ T7K\$5M#::4H0JPWGDGF?,%O
M@UI(G|)%QY*9\$C|KOG7E>)PW?*FBM6.AWY34XQ&9=&B|YQ(XU;34B^'&7:MLZ
M>|!#+.9-G4S8"+_9|J%M^|E_<|F;C.+*B'OP|<#|SNDH0F(M_|27=P
ZZI|D@6|_5|K7E9GJV/OK/(K|YQ8A^A,H9@1H:XL_*V=6D)PFW,GMN+/:0'S>E*J\$QV2IU1HA
K>_BL"*^<5:#TNORO4=<_|K\$?ZBLN M^?
B"FA>0ZD9TJX)4/5|H+!9>./3WRX7\$QH9PZ@AZP\$?LF)|BQ:M5A%-|H9@
MBVZO#H:TDJB163|K>B|<"_TC8D'HB19M;V|W|\$H:&<'Z|HP?@B@WT\$W60RK
M0:CY-(PXSJ#|A|S?SQ'+(8 M#MB4)M;G?5G^|%M?>I90.(|M?
NJ&+>RYK|8!0EMQ&F91*I|+_DLH4|W|FW; M3XF%|@<*0WP8EBA;C?-.@S"<5(?
A|5XE|G_C|G9071|45(^4L2G?^00HE-
MQ)7O)P.ZI:UV8%|:;@GR'E:B7_X!6N|OD6>&@+8@V&M_.+6Y(
MSP_|%OM|3SDAW!A)+%I*0I9GL.6|6,9>I'"THG98")J:T?*)CFW/U+F4,&=;=B7"W4"NUS
D\$Z6) M(IBOMVH"G9Z_"NNK759L4VG::H\$|X #R?,\$UB N_4&9D&4/BOX9OG;&8_A
MR>*71&4KW2-%00?E9@,UX\$%1@H3X8/D2|9TP5IYO|V7MQ|>3|E\$9J(3JJP7#

MJC &Q:K4#L4J'3Q7_ZB@.F+LU<4E^0"#Y+.HBF\$300?VXRNSCP.NM%36H(I
MFJ\^M^"9'V3+RLK.U)6@ZVGW@[XJ)S14*S'A*.CA=J!>E^3: ^5B+) (I3I">: M. JCV%
(B'JDO@JKU>E#XS\$?I 5IFGALV?(I:1?3(ADUZR='< MS\$P\O)R-"YL"Q!JN*LW&"&21M
JH+@P>(V:; 3Z(#E'.GS6O5B.G*2(%\ "XGO+7B(AOYT* @&\$',8M_&5C'\$M>)ENE>'=T
M'BZJOK#V0#JH3@?-=CZDWX71ZU^T' U\$G=M#^B)TRLLB3K\/<%_0Y%:4, M@8?
CEOKS+X5!73>FV03DJH?E*/7_-2!1LM#[V%R\0.5JC+XPRS5P6;H*NP7, M:
ISS. 5JKNPK\XYOLW2A8>=M%E&8\$J!1"2GR^ /7 MFR6L,PO) 4:QU1=USYRJ:
IWL!7=ID8Y\ MZXB\ VU+\$!8>W\ 15C@/C8:VZ:%":R,* 5"0<%\07!Y6'Z
M=MY!\^%VE@';+V=X5EEQV'(GT7JMA]=/GW##[N\$1I+I:6.Q #Q+62\K()@(\ M'-!
DAL*W\$!'2@PWE4D(:\$CA2W/U^L;;XK'TNM>>C5,=;9Z#KYID*8KIUN@4VW\$C?
C/F"\SZ;DT/R MP\$8C\^B?+@@T')/5PU;BY*N7&/LOTYY4OU 4*#JJW(A
3/Y\ \$*BYVMHJ#&H' M0'SY#!)-S@MOV M"U4I%VCWKU\YX0N\1/;:6FH M'
X4Y^OI2>8@DFY3;QV,BES\@*L*D0Z\$ _LA)1KUC9&>)!Q^@#I(C0+(X)'. M^1BZ--,1.Q1.
(S>+=>E\Y.).+;_6')\ MOS!N,%IHQ&J\O^;^2T_5#NS?9%T M;,""
(CT\$XBME6;*#.3\$DSR6)\$1!C6\W8=L)N\F3F'ZTB\ ?? D2-37^056_M M.;JXSS%
;..5NX3G+/-=[8SOC!VKX< J%K";G23\HK% YUM/+6O M!ZU*\ RCW3N\$#4LZ1RR@G<4L0?
Q8.C\EM)B\$;6GD88Z>J.RKR0D\$WNH6V7A MG5.UKG0M8SKV\$N^O3K;_V_-?
I"U87H'D.J!X?;YK8L= M32%X\ R<^Q?<+GN
M'9+;MLWWF#C/09WJ>9E=KQSIRFHPD%!A/Q:'RL?_J%7H\$B3+S4. ML3B.,%,Z\ P#-
/Z2C\)#W,5?K23M+)^A6M)R%T EAH6\>00RSUL3V\IV,=AZ?2 MVY0\A\J3\Z0)_P<|+
<32:2.O MK%77+Q&H,EOJB"60+\$Z#M"0L,W2:A6+C\XQ+3K7MI?93WSQR?X9"Y_J-LG
MRV&EN\N-(!,P=)_.1@."6VVR/1\$;P,@7+YQO^;CK):U<[H2\QD10+R.[0GC
M8B3\$;PK;C;UW"1(PHPM0 N;J)EAIG;L"A9NT*B.K"NS5_.7AA;.%EW&(
MT^Y,HF;=/N++XDC\Q 72U>(V:PYI9PXC<1UW06"TBPED7NMI=B"F:<^Y% M=E;?E-
U\;00C:Q?_QM&G8G49%IB>G"*2YR;B,?ES*UOF-\$58"N<)EA)_;R)X
MV;=S6A7ZU9Q/_NXZU/+&J\;M(VK\ S7?;E7R?%<|XIK!EQEA7H\$Y""; (1\$T4N
MPM01Y6;P:HS^O(F=AR)EMV\H99?%KJO-130K#O">7N;%%UYDN
MG%I"2*:=B(.G^R.OAVIT\J/3+ F_9S)N';F+2D%KG5Q6.+CCKL;B+378
ME'1,D4U3"";&>3MH=SB3Z% \9JAIJB)P8&OW!9\$;D5JGOF*7\%-!\$'XZ;.: M"?
10&C.7\W03<5L\$Z\ M\$"J0S0W(SRF\Y*;4HI9E" ?67;MJEW4BW2#H@6=J: M 10I
S\!+ZH98(N2'>DF\Q,;C\DC(-80%7C+7,+H9\ D+;?5#;-I(>\$'C\3I MQ/TZ:ZDMH00;N?
7RA;L%;8XI\0S)DM";Y3S R T\5_4OM_!T5>VG>\ZUG; MN;KX?7?50*:%AY*@G8?
@05G@)\7!PDHUA/X%7I+'W?UMTP\5GN%W;1U^?Y8
MFY\RSR=3<; P= 8&>#D7!LE+;*E"9(SA\JL 4RV\--Q+- Q(JGE)7&YLU\A?.
M1OVHO^A;LH+QA6\O;8L>+&X\Z!<6T\!+S&NE"E%. \$51V!
\$,K3G/_1\$;P_,#4BP^>V7S57 M_H5Y_6G>TOMDNC>*+6;&Q(&AK,-
CT%=DB4WSF'KCR:CP-:\Y6\$2FGTQ_-6J\ M4M56>_+
(10A@^M#M+&#PEP9;)HR)C,#Q+V7TX M7GI5X\HOYZ7\$@77-?
I'8/KEGBV+BV\$7EN_J3,0N#4DP4^G3\#WAD,!:Q@HU M8<&J0%"B@;17D\5@W=XD(;
IXV819E5-3EE1Q\ (GSGD;YN\ C&M1BF)G=_+1. M^ R\$ _Z(3YN?
H;9VFB9/W9T^6Q\$PY.U,2\8YA?VT-EG(A^5:RTD@83\X MNW">0A*G\W@F:TT)R-[M-
Q+I4J@K\$@D5B@|\-PV\6#9\$ 'CL,*@?5<4)\>%^I= MX!ET39^71HK\$"
\$4@B&"T;1L6)P%;B+,R_JD;IC%1)STH0?I1W\53 _=:2!A"
M0SMMN+L?.\$^K_;P9ZG7(G4\)]>GKOM._*]_7W\LP=SM*2I6F\ MV\QXZDU
MXFU.UB;B\N\$;LO1\,843,I\$0GG:UDB\W11,0^%IN@1Q2:6RIAZQ6_/;(R.ED
M7)BKU6Z+HD3%-E\$O+*YM(GH=B,VDL'#,L ^#"3(YN05X+UI#QXO_+0
MIQV97\00/<\$*O="84JM.7I9/F91)#\ _+WE5;B<\7I4F"7D^72RM*4TP9CV!>EZYQ"9J4H7
M\;-QN*Q.AJ^A#CQ6&K\!;\$FW++C94'4TE(C#2&8B\ S\7E"N)020 !I,\I8\$
MZ;R\Z;XFL_A2\ SJ.T??'9=> 72*0'\$@MHM^ \23M(MY*-4M\JE,(BO^"=..ZO!I;RP MV-
'GAF&0XUK00F7;7TG\#_X04C<1=)_ I\ZO8;P6P+,STEE!K8! 0\4,JZ?@
MKX<6'A2NHSQF!\^QI3")8K *!0.W,9%DNH7P8XP8FD).+HNLRO\$5;4;Y:3 MD56UDI?
R+V\IF0+E@+.).0<&=[&:R1E\ "S782-&>#W.CF0D_@':?U'^/I#5
MH_L\J3ZEL\HW,FE*W^VG33)^&.#.2A?F/;,*>K>A.NZX+?M,J\YO+Y.7PYUW
M,S.>\$S>^WU=\ELKSE=T+B_T=_B=9&* 0 ?I5Y-Z\Q(G\$7<9\7@5V#ZWQXSH MQ;S?
G\PJ\$!Y?/* H\10+UH,G\+K6\$#BSR<\TX"W7\3\6""\AG 4H=Y.>\$% M>4O 8 +\$%\ (Z
A^A)P+P/>LLF9W_ \ZYFG5/-\2TCN98'K1N7'<@+V7Y.: M62,,ZC%!S817DK"(J@K=-
TD\>VA;AU,'D\$^>N1,2-BZ W)_ ^OO\0=_7I+H M5X;V0KM.\$Y>D1L 5BGQ%
<"L6J_ \JH\KL^WLY39\SA/W!/?2I MKFKM\JZ..YAXWW#SN.W1+*NC>3K=

IDI4I2%K]*@IXEWD?>I>G Z4Y V@/ (MN O JK KIV/L/? J:P2B#@S;
T8D0"1J&HX=F@Y.C@KORG,7EOZ:UB7 O)R8U"8?AQ7N5%_R%Q0.M5RX4?
ZGL3)%);+IJ5_ACBV8IW*&CP\$VB M-,3I

&R4G02.<.=K)DA>Q>-K ME83W_ ^4 2^5,,1.8+. .X#/KTW\$R@8ZV !U)_,.4>,_ M?M?:V#-
MJ>&*_)K4/0N P>")\$\$\$3)EX;"B5I09>K 7\XR\JYE""^7OJBD HUV;/%-Q-I7
MI*7&_ U9!#ZY0\$<5R9 !PY2:(IE\6'KH'?&>200%%\$&Y<6)B30IH)P;*W)[&56J#Q-
H#+D@>G M,!GN0=JZ^O27X*XOP0.10&,3VI6\{0<'_%MN;B+XT50:LFB=(^P-&Z\B((Y
M,F3!YB2,(TC9FXBHQ AVTJI! M,:3U&
I07\)E\$KS#1@8"7*VEE+72Z8E&NQ\$>NE\$J@,Y!# 5#4>UB#I--"6!@ M O=
IGU\$/0#E.H)HPF5:P6%S6\$U@.L X0\I8,,N^L9=Y9(PK^> O: I3_KUYW M_G.'=?V;&JE,C?
QGHW9EM%R8>P0-O9/;? 7<_ A 48";9^N,,!W_Z?,>"WHF M*^0H3*20ULW_/@B37
V.A%P?QX#;:@+,*Q\#C%!\^&^"L#%3RZ_YA%_.3'/M3CS_;N#I MNIRY3/P;
(S('CHH7N7;OM_WS85=RJ\B=J3I)&:^ KPVV#JV\H%\$A=64?N\$'
MB5I-35=N>%&;WT*]I&O\RO\I\$-K\$DKH\O7\$&/0_%4@;
M*M\I<<15@^)#ZKZ+"@8DT@/(1@ IGS=H2)UV!/+MU#D\GW&6WX4"-P/-)#K;
M% '@8PY\$PAHT>S#?;' D7\$<'#V/I89-4,' 'R@OZ\KJU&%8;UOE8)3<>0P.,>
MKY'Q"?I&F9KHF4IMB!\^&/C3W_Z%H(UWI#V84.3L>NHDXM<+50V:ZX#Y-
MAAL;00\OI<#\$.DATJI^)_<>2?Y\$OQ+0U(C!.R/I,?'VE5NR8;M9%-
?)XC09(O>2<=KPS*:@CON M.9\$I47_V\UR&QS13;:"^(KA8>K@D2W
MT8:'RXR%.@/N+NL<%8/(D)7:S.S^6P?099\$+(8%A\$)=X-PR)^*T=J?Q?)
MXK7*_^;'6K_CIX>K:7 QI/K#U;F91OB&FH-X)%=@\$EJD6;*_GD2MIDL#-V<
MN*^<16I_ (M9F%?@;UX%_A\Y_6I5_Q\$20&4! ?Q\XYSG8;N('V*)8*,8/H!1@ MH<,)I6-
4&C\HO#"?"8\$F"P9-G I_3YOS\VI\W7O\I3E,I7-Q&&DI_8O\IC MCPC7??96R)4RAF
ZIT"J\NE6-O>8Z?HKL'Q#N:'6-8X*4Z^_E:R:.T.\$5I MG"Q*KJ
EYRP1T7MQ.#:H\QKOH&!U?"S3JDKZ\<(\$D8GK\J&JD#^5S%ZTE M,;:@5VC!0+423?
7AB>VA))9I+N8A?CIRE0:L'L#L?L23'QK%7T6=8L,6=I G8_MXY@9G_-
I(U+X7<_GVN>73%>)>3_9G: ^>44-,C"6@H\$O+U_Q; ^\NDZ_!:"4;: MB\$?
I%KO&5=Y,+K%F=H1T;:U >_ /HG..A&"A^G MZYR R\&4*>V/T7:O/F?
X)=D\$OFI1>_XIG"Q@W,7IRS<'ZL95Z,'Z7V3 MKI4,!WHB7%7S+?J*C' -EE)&_85U8_!
I;75.G*3"CRA"UZZ?0WMA%.>HXM M>JY6I0P<<2T-S955EJU*3\OI"Z
M74;8C^\$O5W(L;L"C/V\H8:VKTGW-+CI7(?15>9UQODCLD1C?0>I()\$/C("%?
#9*59R)M?9E64T;T;O4 !9BK7 MMJ\I.E\GG2U0Z/JZB8!=+>LB29=A YVKG\TC: ?A?
FU2TD^I_./J=&IHYNG,T
M2&.O\X,0&T:"1L+=I2\9*OCKQKVRLTM1^JHTE(37;A!HJ#S4_S;DCJI@S>O#
MQEBKL,\$ @^W^ZM!W,G(AP^L)7L2KW\6I(T9"4>Z+V)@%;QQ1*!/TZ: XZ\$#'
MJ^XK9Y2)"KXZ%DN7\I>O.C9JOFET<#+N^B8MEJ@KL>N3SO\X)KE6L;Y:/I\$
MTR;BL5:1,XBL_ D^9Y=YF6F^M^13I?>+CQAS=CV9T7F7&T2\ "QZ_M&RZ0E"P
MPL;&!WAN0,I?8C#=#E>A\;"2828\$?EF7ER)=&%Y_NH@)*5?
S/.VJGODT\NWI<14U33)LWH"<7 M#CAC*Z0"%FY\$BG\I'+U3*\TON646\$UD86I@Q
MV\J3,6MQO?AQ!9^T+_U8LY\3Z_KA8%>(:8Z&TF6\0<3& </B(?K67RS9DC
M)*@>IYI^Q247?HIB""G(1AZCH@JA:>->(2COYAAMU-C6LJ\ZP;NPU\HL;O<M\AYI@-
#47Q:HI>VN8#4\;I\W=4^=(X3?EU17KBGK)A"E<8I"7&OSY-
A,XA+3F/A5G^F@X8,)R%P-C1E
M@I"3D6GOV@I5Z.X\VR\I M^U#HE\$(12*MRU;EWOMAZ7UXBO+XUM>2Y3<#;Z2#Y
MPLP0Y)+-6I8CYQG@B7HPK(&7!_I19L-97D) M?J"ID,J.C\JZNNOGAP\2VW2'1E_,O
M^GQ\I%O5=;=I*|I6YMK'4F_?R<4KF-
VW'7/Y_FE;RG%=>>@+X#)>CY==DLLHSA+C"A@4\$N5GX\W/) *M0?5I\W>?GB=
I;RJUK&;\$R M-Y+<>1>I,BI1=C=2,5'I0GV:'>"V4M8R:6?E.7QR+B62E0D9F?M4;8G
M@Q\TH2HVVZ)A5U" _U5"1)0/5!&#-,0((B"1.9U
MOHMTPIVJ@H(THQ?)FA!C6(B7=#K>IWS@)V7=NVVFA@,JZ<+2UC+T<*)*D\1%
MX/S%T*.FKGI.YY_.6V_4+L;ZB @(:1T(IV&ROM8_T)E"&I\$H6OUVV%;I="?
MWW=L,7PT59!IV^#(BGE6U:N>MX_S#<^=+1^2N>B@TWS@ZVSI++!I\$W\$#.IQ\$
M14<>YB:7'&IO'C9.10&Z-05JQ#"4,I?%R(6IB\$#*4*/!I*36Q&\W<2H)N/5-M87OX?
E3S\4G/9UZ\JE"S)-;(7FXO/2<:YT\30N\,1#6NIH/_7#A0.'GPG*/ MP^E&75=Y%0;,&
S%)Q@H<>&X/A;JE9\3FY?VN6X\!:#&QUO/?HN\BL\ICS\ MTQ=R7O5#QC#IAHN)R#&?
=S&33L\$R_1V_33I^&_?!=I\H+\$(+I\A7.7I\M3C>X" M5<93T.I\RT_IJ7N3V\K0.=0!-:
2QJ,A"63\3)2VG\I=I;9,"8WP:I1Q+*A5 ME\I)6\H"!RD_8"Q\^CQ\GT!8I,"2!5O:,1S:=W

=:C4C<I8K=)IA,X"&J'D MJ!^8D12+^>(%BV%; FAIOXG@!!(X.VV:)G3"W 4I6"!@2&_*
P>/QA??5%L M\$^&?0IP)-CP\$D*Q6^;U\$XCU,ZVB5F'",T @M*GX!I^(\$8E>2U&6OYZJ.?
M1 MJS7^%3&::*13;/F!;3+IH+!!>>#&F^KWSSKASK(6QUH?"\$W/@+BPGM<,,#
MJ#!EO"Q;HN=:64FB5OR&Q0F3QXRX:&!X.L"HU=GFBO9^2TCRQET-
\$M5G;I%@W6\$:0Y7V<1ASD M)X8IHU'Q,M)->0?LAH!Q@ (BITH+"W=X7?F".
(HPZ[B]DG!ZSI:T%>U6P;9B MH"YUZJL<,^&-
NAE'7)A("DB3%S_V8!,1,/D+DOTFE\TZ"RI."">P"3M!;:-X M\MD(=%!;LT4)TKSFP>J2I
IA7JG&QK>?=TG6LE7.EFX+4(I@2AWBU EE JG M8R_)^UM&-
>B5.6XW<3LUL6B7_PXUKV@.@>2NHR^1Y8\$4HM(S\WJ\HY;JEI M;J5%\$@M.HJ.#
Q:0I.)FO 'HF^7N+%,;MWC\OP//,>GT1^>W7T^Q?/NDS?
7B179^%=Y&3WW46!M%.V J6.6JH6V-M
VJW"HSA)8K'^0VLB0PS>%V#N%3=DO&>DO%DGE5L*@
M::5AZ'\$XZ/T9X8LI&O70;JE1.9IRIT4:|+X@L/N
MT'J2@ "JF8'OH62(I M+M:E!%&IH;FA' LWUS3_LEZW"3-YN?SUE*6>H;8:7V_MA4LX.
|'+2@Q+URRGYT3I\WK;Y*7+-/:!9:KKBVT6CK\$F> MG7..NOG%3/F1XI@B-
47I_MP0\$G72W\$OIK)I RVRSO::CVK->D=EC#>X;HAD/M_JQ+RJPQ-
GZGW/OEV@_5!/R+5;<6X0@Y"0:F%;ECI-/6?6M-;Y8R;5N&Q+?9
M2,HDO;X\$<@CJTMDA# 3\$Z@YL9L(ZA;Z|,-/MPH^N0K67_=Q%KJ7FE!R!;Y
MV9OHYSDD;|P-|H&,+;DG=3>^N8.9S7>+824X1;|3SX2|QJW<-&XTPX5V#R.
MP.O)W\$C#G,+WJX0RQ#Z+HH+;B74.(E|2+3*2A&Z+?|M|=(FLZ+B6Q_L?5NROR
M4"#,|K.)X 6N M<7AI%_R\E>#L1>LL=Q=;7W(JY>-=UA9%_+>.BGZ|T W!#@4?
B6EO0T2=P M*#"BRY(W^C'37_J(Y067 MRZ\G<@=SE>2YGD'R"785L\$0YMT>C
M=Y,G=O776H\$J7CP0346S|^.=CJIG7AYV))#?JE-'=?9O?*U7I8SV=0FB=V
M6M;\$H_6>;9|TXM M7F&+8W6T8S>.W>WX|
<,4;V(H+"Q3Q>N<'9R<|N)U(CM!'NQA^>';!VKY/9%" MT"&<0I)9?^E96Y?:U.^?
Y.R0JE0J_R3HU.MTWC B&'HIA%H+2+'VH5H-|Y78DHJ'_%L=;|_/E7+-?
FFJT"2/2D2_2>!N0J& M4CNCT"7IQ/?@#?*WTNIHO8FMJ_&F:HZHPFL.LL6M/ GOV4>SV-
Q..5CVL30K MAF&F4 YMP;+K5;*XTJ'1C%U_O4JG#@G_?AW4J2^31-
R+R0_QSTM;AL043_M-'|9E9|_YVX0D0J=FI<|5.4C-
ESXULBT;Y4GD|/N%\$C*VJJ&L'#@DY+B N: M.33"V)P\A&EK\7TSV(H)WAB!^_
#8|&+VJ2|HRN+G;LMZ7H6K!#:/^SH_8:E" M?;6"G S|_2_D#C35UM9NYC|SXCW@|
EK,WIODHY." 7A"9U2;C5!;P-|JJJM MO>:Q@4E_5%M^2(DO)1_0C&
|LSK4D*J6WM=9KI8LQK-^Z<')=J#5GO*Q>.QK= M7)#DR?VZKZZ^|
|V@VZ)NG>8&'WV.64?+V9=&;6W#Z;:!:25=|3,3E\H3=5I M6: O6NN9M.TN^BS+!|_0)-
_"|F+? BZ0RB?A2/GT#Z8A,G|8'&V6N)^AT!TW M=4GHSFG;|WN2.@MQV?6KL^?1-
A)-6UL@H.4H42?E M)V!LYSK MBKI"0T|=N\CYO!0E^+8|;|WOK^=|M%;?G?|S6YO59&
S%:B#7&|;#;)A7?|09 M/)!G!O4D+2)F&FT72O|+ _><|N1-Q!?
+300_)P5WD0O'VKD'KJ7J%\$MEN4O MO!ZG\$;S-#Q=H*RZ|'B%?%B
|W7(809NWHS1LNOB'^.8|ICEP:E5'CV1.4WG M|YR?
*H%0WP8!NQM9^7Z@!KF@O7=)\$OC+7=|N9_XQ\,ON:"S|Q5N^8.V-
|2GA/OJ?'=Y%_N8|ER!GC/;0;:!7>#^5H|OM_L MA
INN@T_(#E4#^=%2VYLI>E|*|PZH!!9\WTA,L!^QG7\%)MU_!9^YE?&-;=
MJ9510V@)P*|TH6K^|VPA&<,TI+Z|4-%NT|J*FUN;=E;F7W(,"=0&?
C>I=2<.9.UU/C.6G>\$| "XEBU/0)8M6=0'Q"D@5RG\$?QUF'HMN|<4+5\$
M;:/E*N8(YT|00.)F OP&00&AL63|R^MP2?Y5,XW3B+60JB|")GR^,7Z">Z=4
M_WAOO2Z6M<.UWOS32SX98A(5.0_12#U)HGXF?6N:1/U!TWRN=(##<_?3!COO
M3\$7K|)>9/8R0|Y..3VWA!O"B|KV(^CN6E7/=*SW:/"@FX+'Q.A*6 #G8 T5
M_(8DI2|HLWC2@-SB."7_/_@T;=SK0=R>.IM02F/_C3O\$=N.Y2E/_4|>6B\$V
M|'\ASJ|T*Q34^T R*4J\ M.|KL1'^G-E1|_XU'HXT0,..\$>2DT8&I@\$Y5|^P#
M&DFJB6EK;IW*;JUBOT^HO;|046IQK| M+%S)%SR_=F_E_-TD|3RH>A|BLU+W?;#)
<&CL#*HE(O3IQ?*(2*S/PWEWEQ M IPBS,ST8.ERY'FP7NA|"*LVO4W|T/
MER_(ZA#H_EOT>3;:705%!(.9BL6 M2,348-=N8=NI'R\$&E IKH^\$-
MH+I4|)%VS(;000'YFEK_A^(!WLO)*L/5KSN M,A/^_
_F+Q|*X0>>)_EARB7GABJ+Y6F'P4Y3@ (F<_?35F\$XX67L(?_EV^>:;@| M+U|W33|:F'?
5V)|7K9B\$?|:\$3.EC7.19D|G(@?;L|)3-'L=3|29"%P8_>5W
M2EM2DJGO+./V<'RYP SZHMNT(+LM_>XI#(A;X@U.VL\$)5WS2|4UK107T!CL
M*:>Q5ZIWW?F%Y!V7O'L_C/8-X-4 &^;N|-\$@WG.<#;G!_J"U&GW2.P9B/I5|M:.*E/?
&C<^!EN8YIU|=B=1:&^/*?BRI^Z:OW66CW2_Q;|5274Z#MB7O_Y_-;2N

MJKGV5YA:K#)#^&;2X"XD&UB\VC!41JF;J8^!W1#/+ "GFV+EJWC%/=:8!
[4Q'I^Q%9E+!F'W?OZ?W5Z)-,FJ-)NTR^/N=|"ZEMQM|^=-Z
MJ'EQQGX^PNP.XY9G(WA:(3<)*#V>O+X>648>:2&+L(->W:DLEBRNA\$IGY"!
MJ2IB+D)*_(@VY7&*CM><7^_)E!|C13Y/=-I^1\!|S,I/>5JN(!BBV\$-&A M6?N^W=(::
()Y^J|^4S/#"CTM]*1H<\$4&T!LG%Q.#|MCC8J#3:L)4+N@#
MX2',E(<(>QU;\S@AH4KHZ?I"+LB1,!NZ^S,GFB?M(j0W0XOF"NQ-F;JHKZMD
MXGKJ%7HQC\%/A_XV7:FEZGB#Y(4I4EW\LD_.;27Lj;^;"@@%JLW'8!/:W|
MH^,T|3+4%GC-SC\$!\$!%?=6. @2Q'-\$WU)/LG@8@LU=/US*LT%,7W-97Y:F Y M'"0AEO-
P;;1>-E=\$O|J#JT&3;V.8=H%6NRZJ;|CWH8=8,YKQCPGN)=CWP5-P M|^9'(!-
!HRRU5RW*7J4+92 N=!*.'|LC0Y2 \$)|.K|UEA\$OUHBH_N\4'AGIT8HL) M1^A,?08%#
(A0VTE'|@2/48\$|B*8>41|Z\$/2_QUI3O.\$_OHK;\AQB/S&HA M\I06NP/S6)DS)ZQ|ZJX8 I.?
N*"X))#"I;F7|FCQ' M=R>;!#OH=W<;'>EOO^CE7:P>;J0B,!W6NP\D.+7;
I;Q59<3#D>B&*@*W6ZGK/J"CN\R8C#&I++B;L MYZ/_I: ^>%A,TW)=2FQN#Z10+7
5NEO>I')GTF|D<|5:8//IE.H!5&J?!=!SD? MH^W-0@ZE<,%-0QV@)DJ;NTX<> X^P/GX
)M*S1EJXADQLO*LGGHKP;+A,|*#,80*69,|3D2_%A7:&*,V|'CZYQ!\$TGS\$ _RA^ZW'S>+7
M/.)D^0|M(BR,&CQYTV;1MC|E0(HKNGD8!;@BQ!-^GRN/?5.02S*ZX701=#@ M|JE'OT-
4E7X4"L&5&3^8(64Q5#C.-; M)*:.N!WZ^)|^5&N=#(?+"TWW|_Z"F%#)/84R"-=PA/|B?
|XDMW5RUQ04Y@'F65WIU5 #N@F4&;J4S&GZ|J M_078C|3G+EG4NF6_P7^6J6N\D59X
M4JRI6/) ?8*IUVZ)CR'0>-D;6;:_|SGX_7ZB*/3/6:W:M6HQHU-8MK*VU,V:W>KK
MJ@)U42/>H#)TF9=8*L@;W@>8>HCENH^;R@%'D5ZI)-I;_G0;IGA|J7Y(P
M(<1OSH.F+|EDK|9=(#|XCDBS)-Z^PQ^Z;YDYZ?O1G>HT2B4L5?_54HGH? MA,K_4?
ZH27'GB5CCU*?FM8\W GYE-2M)IP<\$-M^?S90V6_-@X*5BX"UP&@(-M-/!.;Y6=F-
&Z(V@|53HG35BU!J1@7)""<#_7Y%JXR@E/;?S&,8 RUI0|2-NR
MZ+RE@F#%ZTD^*X(\$+L;M8NQ!#FA1KZB@G_;ZE@RG,P7Z0
M19;ERM!5OY!E'/4".CY|C>8EQV@H|JA.|*F>J<&_0VR'+*UYSYWE|1UM+|O46-DM%Y
M1.*AF;Z.1H&_|8"Z8_J,M\$Y9^@YO|^B'Z"B9|)|G6_;&U;_IO(8P"XL%I M:_LJ;=LW-
LK\$,5F\$-%4CW\6\$ _QW90)K\$OD_X/PH(EG2G1@I?=-|E\$R%'33L
MMW8>>*\$^TJSJ|IG4Y|7N MQKJZ',7'KEA*C;0|Q,"L|J'C8+>NY\UHH/-T!PBMG-
_2%_V=WWSG@H\ADU|MP=O@N)G=?
Y#^CTR*,.N*E|+8;V.V|=7;*48YJJYR#2.-5<6LVJ/WM+D@_-.2 MF8V%*3PN5,M:'??
>JB);>#|L.2\$YJ=YSA4Z)L9/F/B T'TYJ."%YU*E|5V" MR?
L|5LJ\$|HN&8Q<>DQ,LR?|AHQ0Q^><*NRX08\$S<#NF^IRQ2V!>#U#'^@?1
M_J"@W>5QN#+GZ6W|08-O/%V<+^D\|9?ZU&+&\$4AMG9*ETV,H |EE2-Q76VQ'
MZ&T|8R|(-/DA'&D37W/PVLTGV^V&HB7A 9(N B)B#_?"Q
M9XU0|.R^VOBM%9CF@FUE_H?%^W"=A|L,?+Q)/4M>U+?B/|7NF.G.<@&<;FOA
M1HG9SY<;TW7=,3UF->|ZH6L"<|NMSJG+|MAB+|@D<7!PN^(?;/6;^GRN#@
MR@Y/&M8|?%CNCG>YH"/%?%;|&*Z0P>%J=?9^\$FI#|N@MXV+6Q0|X5&!G
MD(|L/_Y("RVQ&\$VQR1"U|GJB MC+|4XSCBXORE|H|ZNPQU|/&-
#Y=\$/+,%QQH'DHSP|PZV0R5@\$"I2W;9Q9,| M07TA'D^0IZ+B#Q?
S@R^*T8PD.;799CW21QO8|H#>LZ!8#_C|>#BJ0;B9KU|(>2%27|SZ0KR? M7-
PH.YES&=4'YM<7>L)(H#I<|K%M&28W\$FP_-;J_-EH|X:_0D#;)Z@C^#VZ MU7?
TS'@:N_G B0K^|,"O4@A5^FA)=6M0@PAWB+TSN?A\$TIH:5%Y60)\W3SJ M5|HG
M@CPM?|@^|H8^C^|8<26Z!@RJ3T!VI/\$9'4=7>BQ_%23V-DOM55H,+ #L)'M|
M\$UC*YK\$7-&|\$LVX?3\$A!OND) G1"LSU%;M6,BR3,9.P+6W"4WOY|J_R3RAE,|/,OUA!?
06DW"7VYU6\PM-EDAX1A;=V8.<=B'@4E|NOD9Q#I5U|K"\Z_0+8;_="KP" _ZF*QD9
MG"P/FU0*V?LPVTM|,|F?8"M\$VSI|D(:A&G;JA>\$50,4 G1'QD343M(*SO-(9
M\$|GKQ+8PF6M73^@S%;Z|X,B7W/XG?@.CFS;R..=X2#|_)|EB"#+^O>+W8#WD
M*+9FD)4>--R)%6Y|C!;|23F40:I5Z8?@L|. #/_ND=E75?ZZ23\.(6HC\$ 6+0 M3G';C|XVU"
LK6-8T#LY.-,K<-O3|7F|A&?_MX\$K\$>-6#EN Z# C_MZ&G|
(/MJ3|A72@N\$|KJ1\$Z|S3/|2M,KA3,,W>7|< M:_^:D4D>HQ)6)|KAH|)<0|6|&#?
E6E*;O%@5-*7)T4(+|7|_|*)=L%C5HBB
M6X_D;A^_1R/0NXGD"LU+CZ9.Z%=VNDL|SHY!;\$5BE%\W6AV!#L2+43YZ2W0?
\$Z#);RVBJ%=WC|:9)2&&YK|F%|QM09AE2O?.E MKP|%>>OKM:5#F?(\$0\$*13(J
DB|SE5G/C>2#%-|LLDWL:N@2R8\MD^G|&>(I M9^+37/K;OBJJ6,8|8?
HV38OEAD67P8ZAPJ)N.M52|86)2"ZK#M*N%H9^AF0|VA-|
<7^|F%I4S@17Z7HCV",48LDQK#!"U M:NGO2>'8<|V&VHI+;
4FB0P%I'POAY4^/0GMU!-"F%|:|R5JG
M?|CME2)K)\T4|Z%ZN=9H@=5(>H)I_6P|&M*#"6T @+@RCL|3UU&O8OMI,5 M B'-

9+::6-!H[@#,%L%J9T+DD'SW-%^E&B(\$K.L>,GQ%.U/+6=T&' \$KW,2A
M_LSEB:9KY&@=PNP3^|UFCKJ*=8|AG|U^7Z27G&OXB46|<|L.6PE6SM-^!1@
M|J6N#FJH+|<9(=5T|UZ>CXF\$,FR'1146UI",;X|\$)IB(AP SA>6X:(_-(T M6"W|&
(D!1\$B,%G8.2@S=)L&!H 8=|9B%Q0MX=,JFSL|YV/D?@+*/U/4'-&>
MMITC)IV80VG5_#=A5%0Z%VO|K|UYWBU!7W)E|NUO&^37\$)=BDK|43|O"Z!2*
MJ>1C&^I5-B%3Q%#)/KECKE=,LD>,)P5TFTNKE_>865L-
<(593.PS164AQGMDOT0<)>5>T|:1 M&|\$=GQPTHUMA?0-|%'Q\$C7RE=+%,>W!#)*:V,H/
SN""GL+"H<* 'L^S|&53 M3";4ND3L879_RC.C+|>?/|%ZO1M):3W/SVT8YR',2=9P!#H2=)
<^.@4Y|6(4+81 |D_#<^;UQ M1%XB'=UV.&^/TAF?.CH@ER>)>|Q|N#M70WVW:YV9A-
=C2E'J4TK@UB,(OX)M MV|S?BO5Q=T/>_K|WC%>;?0R(IS5'VI6TG;MTZZ\$JN6FS(^0LK?
-|H07YDGHN MN9BF97)C>|W)BSS&DC/U'9" D0L>(*7L)CA@Q< W.5?%5-TT&YO;H|V #
MZ_:9FJ.|B(SJ.6\$4T)WIH^"(O)LT6&H%X EY=@L0LV#X_PB18GG#T_7%Z*8Y
MWT1N!FB^|?->|;SHCNK>MW)>K"K^\$%4WZ5KK;^CO=#XNMZ%LF;".8*F//JJ3X?
%00QI.*IJ M";D1>\$0YE&!G7C4|>M@ET";W2DDW' |H7&EG>;3J|M&I1I7Q7R#"F?
=TXGY&< M_M?Q=F",B,NGG\$|%+3FNU8GI^DW_61|7P&ZRIH%#7:BB<6||"L2S0HBL_K
M>|54Q@+S^|?WOAS+VC'D'-H=)VKPB9G\$!1WD@GBO.|J/D>1@V'&2%+UY""SR MC^?
YD*81>|J_4|LY?|IA*%9|: ?WK|G<|W^RC90,GC FZS<)>0;K5S_) "|ACE
M69^31W3JV.SB)#YF"\$PS4GL# \$T(=1\$VB#C'3Z'9=5CNJ,2X\$*/Q79<0SS\$O5 M?-
WKD%P=ZR+4,+H6UN:|N_?!)X,11R-T'E(>W(|YB40M<8Z?Z-C6OZL3FOH" M+ _BWO?
E9<6(IC**Q9H"X6>#6,6SRK1GEF7UFV|26BT.Z_09"40G9>W?0GC6|!)%C^*_|-
:*AYI9M2FVL' |\$""A<'U=)HFAR/Z'<|J& M.0|&5FJW0'D)UW M5|H^U%1N4=B!|G^;
(7\$QJN\$7KEFG'6YU* &' ^3)J<(@28A|JXKN^|C MGYB-7>D) JZS/T
" |#| %P/E3BL=4/,4J,C)4+6.8#U"DJQ|Z,\$ZE,T3F' M\$XE"3|@O|=(%Q)(>|H>| MW9|!M)
|&,*:"MN8'8>/> |' |^M<|H;^KR8^B69=+NCT.S28 MS?>Y|!RNZ%_H!
DWC|Z%&IMM7_!\$ \$^J VHT3-'3|!|: +F|J#_ |QS)|3&<'&MZ
M|D|XTSOUQQ!!D>+^)^ DO6UZ=WA+C/6;|_:\$_.15 -=&4%S1_ |4\$ L#!!0 (-%&*3%H!GO?
3K0L" *|C @_1 M :6UG-SL NFB=Z_XHL,0?1. M1!TR>N|A>@N"Z-
&C303>>X|Z,>J,WHTR|H,KO_ |UK>M^8 %6_EZ QV6 \$@#K?|C^_|C_ =RL MQQX
*3|6X! ,7,*Q7@ ">D6-BD6(|# &8 OW?R<_ D_#>H*-_L4#Y_@&>'? MA,87@="=8V-
A/<+!Q<7%P_08&_>T'X)#BDK\$(*SXEUT;">^5&|?IS<@ \$^ZY0:
M7DJ=F3,VD8_N803/J*AI:.G8.3BYN'E\$Q<0E)*6DE?Y55E%| "U33U=,W,#0R M-
K&VL;6S=P Y>GAZ>?OX^OF'?XF(C(J.B4U)_9:6GO\$|ZNPJ+BDM.QG>45= M?4-C4W-
+:UM?_ |#@T/|(Z-CLW/S"(O3/\$@R.V-S:WMG=VS| GE|<7J&NT3>W M_|&%!
<#^O|+_7W61_M7U! <'&P?O/|JPGOC|)X\$4!Y=%^"F9HC:>E1OYJ|>? M|2G>):!?
4|A*PBNB<47YTGWE&Q28*9T?^1H_*?O_)BSLOZ7L_PK|?W3! \$38 M6'W#YL4H!X>. JC
7|_Q(0&21D|/3+(^!YWH"=#|Y Y/O,|. ^OEE!601< M?S!-^G&:|)"IT56GVN)#0=#%
<|Q0W@|J:7XX?J9MN"?PW^ZVV;7-P7RJ|=A M/.E)?7GTR(S8JK(5
OT&J"@SB:6O_ |:9\$DVCCG9ZL#>#\$DS%_R|C:::(^IQ*+ M7<"0P<|J2|H69HTMD|E"
258!4"+\$;|:=O=1UQDA/6|!,EG|>% M6UK<+|A:+WX7Z?|TU">;*18S5:%S1MN)Q8|
G#MT<1GZZIP2QP,\$.HE8Y?) M?WS%U<%28&S>|,E
0D0)D>MB&\$90VT'UFVG|10*JH"|HS|;R\$="K+ZL84089
MWOW%GR3*2|+3:#JV0|OBX/=739KJ5 <+G N|+;#G0|A.1&-|3:2B?-,CK D M;W9
*VU,J_ ^JIGMB@(|4(FLS(_B6V|A.MEW2.A+E)T1"SH\$5#9^.OWCO8W M9\$ L5,?
72JF667@7"@&60LS*" =MG)4@GE'(N17E#8^&')=(5^&=:G18!6V|1
MF2Q\$FY_H_=Q+|*JPI+T='TO%H:)"CF"QO=YVT|Q#L.O\$=|_Q-X-KW\$TOUT!
M|J^%MCFG N0(0(%R+AMWB|\$YP2<&-HS>*4|3^;\$8&0\$'N.M2*0|(>6B>2Z>,
MX|BX1%:K(1RX>J\$|-WOL/X^A1*2-|D)#JFH4K*0%|;ATT";N6?
XQ!|WGA%G,)YS34C|)Q|7"R1V&+H=TXDP)! MB
9U.%HEICP4<9'0.P583FAH,Q@9*T71(71M1B|ZYX8K)T7.66LX(.3
M|73A*7|&^|D:5L\$4^>|CB*9L6B(5:|PICQP& @MVW4JJOJ#%;N|ZEQ2\$5WLO+ M-
R/O+*TJQ_8;|T|?)Y9;=^JTABS/QI,!9Q>UZ@ M6--=B/SE"0"@ZIBV|:O;S@4U7DH
(!&IJQ8;%>V)M&Z@1U^*8'W? MAQ|PC8L|_YA53E|8"
<=Q|&+0XJF1KU7:8+=3TD1%=4;=;35' |@-4C&|?7(YR MSMRE|CJOY.X-
1J|VI4E323SAY<^7GD|U0S\$KB)9*9)|G|E8>
M78;8|' :_%MC|33WTB%J|VI>Y?|BU@2|!Q@XKNBE-":4YO(-(/\$S)9IWNNB
M|..5VZSKE% C800?53?H_4+97G4G7A|ZK7A/"!:*SP;3*X|<\$J?5P G^!ME
MBB9%"BUK11+(G48S&S1-8|'TEX%0SGO\$/K@M1#VAXANIYVN5(_H*4'8K3+G
MM>\$; '\$DH/2V7^|CHWV)6A8MLOQ|!|H1E|ZH'GN2YP=|?Z;7'@%?|T(#-JTX

MDQN2+>5B-IFX-'KM=&-3 JSQ1T#RH M\L+ZPKA\U);_ETW?O%:\|F?T:W)
(P"UCH;8\$7N21/W<+-2 KS-N;^9.11H MQ0/D?)|R,(LLN//!N*1(%33^?
J\;IC80JR'.1NBU1.TP=|3*Z1HZ?>PO72I(M^X3',5;|^LRDUM:B-
>_L5CR0=Y^0|UI8AK1NH/!U\ MZB2+XRX_R%"E1YJ4&2A|(TDS8GU!_@?+4B0&|
<"E,6AOM.!56:1#O'K">;9N MZ#LD6"<_C0L_Q6Y7,Q-
+'ZTQZ*I5*XRKUUHMS>=+6\W* @06HW:ZO7FDM\Z*^ ML:AF"3(N@48\XLQE^D-
(3EY99GX'2Y?FBDUC-3T_3ZX3Y;|A;G:F?' ?K #Z M\|FHB|VRG/9F./2!RW"\$=
(XT'TO"3CZY|%;ZJ4S+ MN9_LIUE^*"W\|S2;5H>?S3@*./."
!|J;&65/!K@:\#2_#|,B("UPNGOA8CYDU
MO;^<#%SDC4&G23BS3WU<:S)>E!>TL*Q|HBOLL!#\$;!^<^D4CD%IOQ|&RKR+,U
M_FVB,&,^92O?WUZIPVDHO4X"WK_UK>XB|A?;=#H<|OS<.;L|=**QH
MF^5G;=6IF""OPU37_3L071)H;W)?&N(POD\|S6^@'B" T-!(4!BRX)UY-9&M
M3OXTM<+T#?FV-AT%+_7D=D44>\$5L-6%KV*NFW?<'C0) MRRAO+V6R7/K/"YD"+B?
2.;7)9V\HZ2T'5LH9TEC=-|B7F8@YY1\$,RO==/CE0
M\$^.% "62C04XU^W1,AI9&3;Y37|/3O27|N(&|8T6=H'I(K)>N/X(-\$&'\$^#EG\$P5<-
U^0.X/,Y2L'RLC,<*D MP;,*U/F >%4D9'AOPM4CXB)
|>PI_E,'FA7#60#>U*YWMH\DLV>V9+'D\LO4 M&C4;AJWC*;DI83.F E|6!87(W=V?5
9P51R&MX+;>E(Y;.'AZD|6N*3&9A) M\$=RZ1T# (,BF|<|4ZS+
P9^7920?,UJ7|0CP/&)^!'#+F;.#HE Q6+\$/\R, MEGFXW4/3S*Y2A|D1C%%8G|?
N59G+'V8L&;T((UKF@R4#;/MRW_^\LHHO0N9N
MQ9'52P_4:04Sj\$!86^*%WD\=AQF%#YD?I#|"7C=%L#DJ8D\ V-"5|9AY,!0M9 M+;-
"YFA|6KJ:/RH@+"|6.^M&C6|-C7PRG3PA_QV6GGLEHH;TD%)*6VS1AWJ
MT%7_5#ZZN#O AH=,PP!4_KOC4X_.4C8\$(7<^M=9635R1I7@N-S|^\6\$9-
'W"^M.85T89-? MIA8I!!VA^08I';|AQ" _PID_CJQ2^Z=8.C/UTA^VF3SW8)D\$V;ZU9D|;?
J%Q:5V&?PT(DFS0 ME:OSVRQ'=.6C">X\$ FWN"|72Y|J80!H":?9"4;:
(Q*IK;R:RWYI@|>&02EH|
M:NDP53|7Z;TL;/K\$=K'B!#^J+)3KBIG2>FC/I@>1!A|3'J\$E=6PU.YU1H"RG
M3M6VS6H1?;N*Q+>M^S_*4AI#W(V|.U*)EFE6O':T>3+//_=:P;=-R6/+GXF" M5
X1.3"S6>_XEYW|DS|5I<2HMUIPKT 8A,NR^1)KAQE<;=|/OQ,'FIV/CH9
MP'E/\;\$?;%G#@^NC_D<SBPR*GY=\$YDQ?-KL2|T7YF3:|@+H*R=)" 3:LW|O
M4ZR::B8GP?G3<&'2ZV7M0;3&E_9AX?+F2);7LRVXYA%0%+/?"1W5H0"QT)-
MHH&;ZS&U<8,9"";N3V<;MI1'PK|1)|@+22.JR J>|>%8K|R^Y;&.CH2+,1K;
M|EIDO&V/4V^|>|-=V"+1"Y-TL?WN9AK)T>96KL59(A_(SY&2P10*J>2F_!?!Z<;E7!
MNU\$^QGV,J"7UA=+%S!5|K@;J97!N)#WQE8\$W1S:LXZ')^JLL(S_2Q7U?ET#^
M^BV1?,5N |<^'L(!U;HZ;:>>+YDH&|;M|U|YID|ZW.B6\$|0*.;>PT*J?;*WC67
MXOUP)\$U%;4%\$P=|'YJSBX1\$YCW&SG58Z^G0-.5*H^ UC&X M;(A8|_:MJ7N4>?
1.^>U#&#C=:M|1*!'YL)FS17"ENGA4E|(NP(U\$Z_?HCY ME5O?
J\$"U..3>#_H5HW|_(Q@'0R-4-C@=WTW813OMX2*VD):?V.\$'3R)TI/M"
MM;^C!K/+KCKPIKG-YMDD-3(U&SL;2RZ2J#8"JTDPM<|F|!8:ZEX8JL.7|CL:L'5 "
MXUR(I9\XIX|E;SD- IN|H5)*H>V!8HS+*.C^^,F53 V)
|VGLY%TY_6FUR%V8GV*4'@'AD6PYCHN6>(A N|V/,O' MS)2!JLBM##>L|4=
|6('*5SN*0O3TEMF^T9TW,50_ (X>7Y(R##U-O'Z,2# M;::'03KQ'VX>O |\$AVW*
#V<P'GX\$ML2:G)I9-3FC2|> M|60@L>TF"?VF7CHS9=@8XM*MYP-H3)/?
O:'''D^|V+1;0L:3@)L_@6A0^'<, M0|<12|XW8.766HR8TYD07M#I?@U|Z7|7,)5*3:J0QY?
>"RZ!D%9#W6?F20M M%PWK|G)\$ (4Z?8/C#QWWM?J%#SN|^;|K)RZ@
|ET^,MS""S6<_+3FUC|H>1O M-61YAJE\$0&!%J%1T!E69/1)O\$S*81 |R/THO(|'"/Q!JKA
:FN/>,4='1. M|I'>L/D-/V^#6R)QAPI*_IE_L+>>RZM'.2Q0%-;?CE.8\$ _"L1|U*U|1'FJ2
MDH*|/#7K#C+|6%5(1I3"H@P'9NU|^\/\$L2LQ);*";BJ<"-G8W1 0X\$7PSZG=* MLI-
N;FFG:DT*Y#P\$0/=15>(*B\$=M4F5G(|+)|GV^U*JA&>+>HCSHW"N/DW9 MIDI5P;
|A%SF4GJ|<0S#CYFSK|O W_*L |H9(%X0=BPFXOZ#"#|PZ0=1*""U>2<+N'S5X,^
MVLO\#M#"TW4'P&^*#"K3E/*Q\$|OK^9>L*!1FWH MNL:RZ9B\$=%I""PN/= _ZO6AIZ|>|?
|HBC MRMFU/5FS(F?4B|(% MZQV2P?2*/%/EE" _#4L2QY#E+S)4<4.)0\$3;Q< _"=0'41D"F?
RZ7#X&|/(7, M_ ^E3,<;/6Z2',-E#L=O!GWW0^!>!&;9S!6U;?1=|.1#+R/MB8(*.+E>)GY
MMT@9#ZH@X>D3TJ*M#+-A_-03Q:W@M39F9Z1;R#8Z-3T_ISZC(J0#GS;;KT MMBB|
/D\$MP#97_VELDW-|67'375K_P<.-<|RXVRE6H?^ Q8L+##|Z_/);X
M!|TZD&KBT.R0S48TZ3@W ASE>;|CLSY\$W;=D"@87/%RL^FKUH
M+_T5IO\$=D&@4V,+P>7KI |L7I=|2>R.|+55*XVQSO;MWYUM--<-%Z3_HE4_
M7>|X4\$"UZ.JWZ@ UC;9\$GGW=G(^;3AX<_E5/U#-?FANM+O<_ ^T+M9KQF!NM>

MPYHXKK14BF/F=-)Z5-PL1<^3\$6Z-4Y
MOXD3!.^!)^~9*UFR1#^.06OP(I^&!'^6/P)"M=MC11-+Z4TZ2JTIAGHOKG M^3")8
-;4DJP*E'=.JM46'(3P1.*3ZY\65GR64V8)M11@LI-! M2JHA#XT35'M&NJQ65M>NDE-
/=*Y,);XCVKYKEV<.*>E/K/LI*?UN_Z5>'MUWLL<<.+^U?4E-
X:>ZO<,C<:KWCS/Z\$A,%/\$P!G)1C-4O2V;Z3?DYA_^I7
MT=IP8)"^JL)2T?!"N\64F3/\$=4\GV1X:5Y35JGL.N6":TC=>'M%":7;&P'
M7UO3fV7MAC=G;9?3K_NN^Y1.\$0>H2VU;+W^Y#>S9SIOU>NOQ!H+!^?J.'&5 M-
W>A8/Z#@7A6@X/*Z/*OH8,1U6/Y>)N7I>+Z\$:@6?%\$,@4\$M?N,?BS?#;/F9*5
7/LPX62H&R100-FXW%W\&O5U.J5QT0SIJ_6& MN6BU'JF.*4-
Z;ZO<_JSL!NV;&G/-49U"6)W,K7=S5ALFZ"IDR\ C20#YNI!CAJCMO)(SDAW=BQ&MI#
MME+ 0\$9"NW\$.Y.@*>5%"=9F6H7>@X=F9&ENGY1*@)P=9\$Z\$ZY*:AEIT>LR:Z
M/WYT.LIQ6G8>F%=&7ZX%7\RC2.GOTBJS^933TV>506\$.N*/3B-)XPWS'<4M
MJ+_5JCA\#WO-\$;L2FIMXTRKUAN2 &AO7:1|B1?@%UJ8I&ME:-[-?+Z"X'+KN MC/?
IA+9'LN?03*7 RX4#+E!@2ZMPL?RN_A/6E+SIW/PFP%-!>#_VG)>K'2,Q
MY_M&T*!JZO:&MZ9BMU'9?3G &,P!&I1_Z|VP>NHR<3Z^*J.E&V>ND<')FZNK
MP9GHCCWOK!F/1(X11U18W(0P*%'.L^Y!3MRG9>/:O!+8.T-;WOQRZIIY/MU^>^J)47
"Z'AK'FZUKKAZA|17?|1X*Z?DW5|LGA\$D>%,MC^)*H#!ANA:WA/JT@0V+NM6?
^J&G&.28UX?).J>GPHL%CMWT8M|S\$'GD/1NB=9M_*"IQ-#.5X@0/?5O:XY|
M)l&N66#,P0^>R\FYG&RY'I+O:ISD;7>I:CML6UTN MS5J|#@H-|9QS/XC|JKC*PGG8)
IA|KUCZNBBDRI>:-?9A11!R3AO,(-Y(F^?NSAYHX0.M;_,^@T-
<\$.%098J46)HD3MAD&OWEP9;:.'"6-;RH269K!)NYW0,.)',@|F!=
MC>5Y=Z2HGXE!W!VOBI')P2(I.U30:WSYWWGZRQJBLSE91+,ZM:1L/:?SJ?#
M7*K71E56#WSY"Y*_'>*XK?6B;FEJ(3?ML!TEI6O5!"&3T"POOT* @9+?==1Z:"& M26D'G?
-AN&9"D(=3M1E)(^M?)TQOT^XD?RTAICBIM/|K|X!("K_",J5P!?
MF!9\$#X^9M%84GJ/M^_.(9T0? <|HU15G,.,+P51XIECE1?FR-^EG1./SM/-/
ME&FM7Y&\$ZFYB\$QH;G)6N_HMU MS+!XSMG_J&J|HE\$X;OS/:KN8J3E2D,YY@9*+25
?_JL-#> M|\$Y8)Y)GJ!X(9D?JASD:|.F#233X*YU>;?-KS!MD4:F|LBX9|V,;,,@V3M6H
M2|O2@#IDY_HA)3L\$B+|5(I_4KO/62'V(45Y6:5ZEGML>WV#;OM>YL*77FN1
M9S/|UQ;XNU>63YG\$*-+.Q#SS-XJHP4JFUMHN%_@YV-CVLX?WN2E_B&
M:!.*6Z@WJF=O"U6JTW^WQKX0>(GTB'+WG9+D;:K:).7DY2&P19F>)^A9?"?6(R%I\$=J?
4|D22\$G|J- MU#Z:78(D\O8TDN4>
|L%HC;E|@X*=2UB<%TFB/!_:X|YN^4Z%XVPZTB9|B(G5_M|X,*^_
=QYRL&%7I+>/1;%ICLSQKJDJ#4UB?:4M1V(Y1"\$_7ZT=KS/_T<_J
MU1GOQGR&!AVL\$1(KS^,8_\$Y;AN5.SR<8_RQAI8XF<(*_>A?#B2K9U&5;=*N_
M<7L012>NXJ2|CH7*:ZO)&._W|2+=>=2^%V(&ZE-/|JN;AZM-0|DK?EAK@:-MS)*
<2D|GH;Q,FZ+;;&R|SO"KGN^B'S^)'IY%|TGDO:U6;|E;?|K0,BZ1*W^2C
MHD@1L_\$E5|!'@%ZO2K%ML*.O+%&Y5OKB3EGX6,!PVE(0/;+^X1GPS@%C MGKXMH#
Q*F\$@N5,#3H8D(-I)^=#XW1_YQ|6D?7'&5;AQ3O+J'0;8(,/%! MXP-*W-*|HW?
6FF6OH1+4SMZ)*G\$M_?/(-N6P/>@.*,M|. +UI5-Y->63Q5415;=F2R_M,R/I0,H.LBSC^
BG|HJ2D!7=?%:QX(WX>J8XK;8)>66|IO=S@IO/_44%9WP|
M35D|IOK5QO&"U^Q|W|,EH:'9J?_07N=8X#:G: ?LCAM=ST"Y-+:?0S;VCLA
MT3W).J%NZ&=%N_84 &|I\$)K\$UH_/W|:@I@_\$4KZX%|,ZF|RLCGWX,
MXZ#QD9N|:U|'=E3|HYF/I=D=KJ>X7VHJ_|*XY-R.OUR6_91=AU>OK#22,%IR
M,.)=L\$)9B_J^=H!6T^AL)H_-)IHQ9;ZC6_6OQJ\$)W" F?9'ODO|5Z|I7P@W) M_T2<, +
(&@+0 RK(U1@(A+U2?M*MCBRAC:|U6%:N'I/G^.|%V_-E!2%C,\$(3 M= YP!|*
(>4>..DQ_|+*WAS@UA34T>3/!B_Z|3/|8MJ/,9M-9&\$2Y=LI0T1YA+.&2A;KJ1U
M!^CLH*B<'G*TOCGNT3+(D:+/E;(Xp:IB:/*FJGR,UZB,WG)ODA_3CE|N1-;
M'5!C2|2/G"+X2B21Y@%F/!8P-I> LIBMXOMF| V\$D@/NZ0P|_R_CSTPVOGH MX_?
U@%1K2QPE|53J|\$W:*HJSAZ N,36W#GT|-O)"8:0P!&R-LX?^W:*Z4%H
M^I21LM<+I6L?GSUPB(|LLU3DN?1;)PB^(VM68ON%)|W_JR"H;+|GIUKWZ|
M?"&>3M3M\$WJ+%|3KP?6|7*NOHL51|;\$;|H|N;RY,-6Y77(8R!'*PQ|,32PMQ=
MDDKIL4DN2U6D|SH,^U)US-8B+82J_"/O>|W@:<&-!_D)5A-MRZ?,M)%POY9G_M*3D-
"5K5*N\$S;:23J?|!;:@*G!Q(CD8N|O|*21-E\$ \$VHPIU>;N(0)?,F M6Z(IY)
GVO_OL|ACBFIB=1R?0GCW T?S(P!>|<_JF YS M3MNH|@,O%
|2,7:H0E>1^9A;MUU^XDC2+9TKFDOG^0N5W=^%V2'W4OK"!7I&E
MP,8\$D3U7N1;EX'<_E:12T.*7G>#L"^=O:_|/4XIHx|*';04+85+/90**>\$ \$A|G;Q7
M;VP&.QD9RQ78V3)7|7|2^%*19D@XW^AWLOP":IS>*.Z5'2OSTW;W|D!)UMG
M51,0E#P?D9T<+R|%'&*JD(?V23ZRG|B*XG'0*S@?|V3R>T|Z-(0\$-1. %W_67|>Q_-/?

LXU6E4<B-V9D36\,O MY&@*B9"?7G:S_)96%K"J0AP=O-
2^S;GE*6WT?)*SR_%)9T!!7;2D6Bj8;*_M,^A*?1TZ/G*##G-N7ZS%KP*"-N?
+6>#T,SGM#R(M9H"I=H,U?6!1R%OLCQZ M426O>"G;;7&6G=ZLK6V^-/-?
8DD[V9IWOA>;8(#IE-+*4V-Y^/K9]"6@:OX?8 M&9W+GZ3R;B;WY"1? Z=9;[FH]+0-
QY"V0I4NXE@YMK900%J2A6CYG&FKX0" M\$'X,CU"!7F#%#
[W43>@P;Q2Y!C(;495BS[*H(YSOZ=W[T9*]&T1>W].3?%C MRYY?
P0LE2\$H7N9Q#@03E>Bj;\$;UV'O!:@Z2j#3R%&IDKXLEGS6G;@_4S@Q=,
MB7)5&3@CI8CW+ZA3 :G0A#^S??FRJ+I!V&7|.?. M=TR+;_5B@3T?
FZF;W,A7/LIZ|+!|&IR2%!'ST/)678TIX7_U.&*.PH*DX_#//5AT
M|=7M9NQ0FZDHGEMC8WX.XR+J>%K.@'='Q1/86-:UD.5S5? W%DZ#.T+V:SG43
M;5V|KN|X9_K5@;|L4:.\$8G9%|+ER9AG+1)#W|4*^P%_.|W30
M_'WVU(LEH!2CIU>|H>@H_0S3)U#S*F5M-W5IN4&Y)-7Q'H(EAV'2WN&Y4/C
ML8_>7G1Z6)P=M|AV+H#Y; P<5E8;%|K8Z&/,AW4;=39!8Y3/SU,3"2#;IKGC
7P+5#GPHVMO\$15AE;=8%-EKOFE ?16L,|>7KV.:0/#7A ML_J05-_8H2?)\$0(3CX!/T-
7WN/0Q;J\$_\$G.@C.6!_YZ|^@&458?|(X8LR"IMOSA3RY&89J>X\$WM?+2?#NO&K"?9/2
Z4/<6+GW1A@D-#E,P|K-D9?"|G1!# M/MRFAJH1=;?"J;_HA'?K+S9|(.PS>&KE,JRR?
PLO?=#BA,=N):6|<&OE^9NZ?:7<|_F^2TTA:3V
MX4V;C&Z8ZO9Q8DBNGUB(73|>T\$DPIQO;6C>QXYJS?J=<@|;TY 0;;N*S M_G43|/9?
R#_WY;W^*DZD?X^DL,@D="052'T\$"#P(&^(0KSA6N*V|>*WU#B)V M/EC;+|@4(HO\$/
|_J|J#S^|/RA|!|=;>|Y,USX!_474<43KG|*!_*VTP9RK!
M<7+IWX62BU2&31_8:|H>@1DG@2N+|6WQ;JMY75J&;5WAH%7WBXGR5MT MS=D
9&JHW|0CIY(V^>VAM&.YPOJ;%EOM:68)4KC+KS%*R7!FR?*&FV6DP^=
M83ZKB5S9=&DBV7|\$+\$+HFH|V-KXK=Z-C&'3WSG.*BDQ,IE_@Q>37APX8-@V
M&IWX13HNNG-D&#J'XD|4/*@J@)M.QF8KX-Z'ZV4VR>\$RB*P|XW#D%16>;5XY
MIUOS/QV|J7.Y27FY*GC0|GI3=|6KX8=Q2U#PY".@|G20&?94W=QD:OV!E"0J
MNYB:27;QF"U IA|LS2_'RA22@|NZ0 &4(Q|)IY|@ J7-:S|0#^=# P/74!N MYF/|@-
_4_1;TXP<|F=.QF0^6GW|<2Z-SVGGC;3FR\$Z3?Q^>J796-
"J_B>"|*P.5C#|/GTLDW#_4:DVJ2XB,XH
M4\$Y"|LL,X%4)GQS%7*4.J8^"B*S4V?"P|3^43U8*'H+O"QF01E5+-<|Y)G#V
MF90L'*|4TD|@)*WFMMA?A7\$|CZM@#XE4P!*UGY,E+,P_YFW@K?
*%&#JX8'2K;08"VU'#Z>6S4W"P@*D=4^LPY|+7M>RLDWL,N@-'K?
M4D6->"8I*|NC|Z5D,J8RM(|H|A0|286H.&6ELFJ65_G%E.A>R/N/P5|M_-V8-MB6?
H%IDX|Y<|.FD#M=0#_PE=6Z='*OQ+T69FSD|?<66,I"8OM|%\$MPJN<^Z MIG(J\$%P@?
X/,@OVVX(3"-44Z^:3BI640S"*U9&EY_J8YNVRI+QWE+1V44.P* M6UJ"|3*XFHIL#S*|>|!
#|3:ZHO">PG-/&6|-25-"|@U) Q4\$58;96L |L.9 ML!_M8*5/HOM!6I@#|M|L."X0 M!-=Z
A*L|>VVF&MX+FR|F1APTS3JXYI^81X4H|D0#_2K<"1Q;N)2GOGNG@%
M22MQ1ZYI)"3%R-K??5P|F)VT.EM6H.-35="R+E+9)|76G/79-J"AUF./|+
(YWH|79Y0K6_I+0S"@1-<2S^ZUK2!|S|W#ULJL2XQ/S|,1#P?T1EO?A|G&70C2YJ?=D?
V|PV|!QVW2|@QZ MRE==ODB?8T'XO;!=|UE>AAMD!=S,Q+WY^?>|3R7:|=W.HH-H
MDI#RR|!+7E5A=.'N@|/Z#"1?!JH?NSR_BN%4|S^5O|8FU|)IN9\$56XPF.%<
M%|H4JWS89X+!RU XV|7P\$O\$|'-;E(Z94P5|VWX@G7/%8W;DM_8(*+7-H|_<
WSC5^VW0ZFCJ0=J
MM3J+;5>H9X^N')_5+.'J|L776CN"/KKA!3B%A&PZP'R_50/D5(_TW&@M_B5*>)Z!Q7N*
|HJ;\$G?S|L%|H"CMZ.0+TE\$9P|'2<6)2V6;!.F|KSRZ28S5L9K7, MG!CK^X(NG\$"&.S-
+L@<^-'O?T33M|N>&;%|GV#|Y|66=:6W/1=M;-B"0@B MUZ9X\$0+&+ MBD'\$*|LU?
+%OBWGJL6Z7Q=OP=R%;4I@WA-|ZHNL|H>|<7;'.":&JUW*-M
^1==N*PD*6=MXFVV^J|CP!\$G-'|B=EWE.^=T'RY-HSDEG3,IA&%-83M+M;|?
J3N(OVD>,E@|S|E.#^4)Z34+L^(G5QTEP>C>G8Z!X6BDG8X|I3.8KU-?
M4@66Z|M?'1E#N@YT1^|7)'5#)#_L_M&-L5L:(+<61U3P|V,I\$? 1F4(V=5A MMMV98+|C
>M-B9C%^O;H5|N%"S9?6'6G02N MHRUX2E.X;K|53?OFJ|??
2.#0\$J)T6,P+M*:21(|K(BR24(|R.5_9| MT TS5E_<=J(Z9KUP?>8G?
Y2);I>K3(E1=,AGO7EVN!,TC!6U-: 22RHXL!_J7ZJO.I MXK;K/(E_5IG_E1
|1D!U:YL|)F#N0?'.@FI9Y(5P575.8 |(X8Q.Y\$6NKI M#7(M7B-EHNAN;D7"OJEQ&T'=+
(2'#A5|GA%*_M)BWB^.|05"N*9OZA>|XX8
MT+U.&D.GHN)T>,Y_?;&P%59ULUC4WU2?:Q=.^ MBC>W@*T7T_<)-*Y^<1(?H1H?%?
+%ZFX8@Q*K|)U&8#T"%')#5,ZZCQ|G"CSQ M//:MTXQN*IO++?,1@5"!;?
>=^XH<1^U^6S|HOB"|"FT|NXJ=|/\$:FB50^W)* M2.PQTH|?
(%)MZE!S/&+OXS!=Y*U1%1B=Z.8_L|:(U3A_?) M>@MP?^JFFVR

M;#8UOF4Z+:Z"ET:18K.-IJ?8+< D^-.%/3 &OD'*1&/-\$-K1H?2/6%)IQ1,\$3 M7
R\OY=EL>C JFWAYXZ^"1,B_-/H@*GYA^9N69\$9A;Z%O;N#7;IH8WK'U(&TB6-.S57_S3;\$\$
=0D;M"CF_2ONIE#;+228L< MX4*NZP6J>":%RX='/*DBHIM4G_%\XW7;UTH?
>XN<(HOW:CD5:@3_QF"4J\|V. M+AH)(E="K4B7A:??@%V)U_TY?)_\$97B,-,B(T+K-
U,774FQ\$X!1FVDOO^O@58)A@J=_)-JU 7*W&A6E9,
MJ.6K9A+!V\CFG&HFB7+MM>\$[O. 5: ^<0:P58BUMX_M(RXNSX\$? QI#JX/=DF
MC|PUYZ=JU'D2,=K.R\$ \$OD4E'*CNR#F0UOXRJ+?RE|VLJ):=\$T.%'T<1*:|VR M
CF"87=0@=U*C>)OHMAC7'-L;/|_!JBM)/47G6*^|U#8N^JW92O8>|FYIL
M\$Y!9Q#1/^/CP[V2+U32)XO=O,;4EX/=1ZQWKH*6?Z"H*F;+I4W\$WL,UY O/ M;7#?
>A/B^?0=PI/"LPIWXV|[[CA'2E6VE,"7 .P4X,;S.Y- |7X#2V2RC;G@ M(^#94O
HY#9ZO^A207+@;)|JT^ ^:K/=C2\$JTV C%)_"/3+%U,>DAN^V&E(+6=:
MW|V!_K((GF|N:\$IE\#CHKA|>EGM-P#P6"U:%"R95%:9H1'0TI.SV(XND|+WQ M"<
5IC0XB=0Z9X;QE|QD32D#^*.\5B8O!FL7OJM
M^8.E_-"*V#=#VA@V:I2>9(&JZ4#KSC!FSMCPN'H-\$+M= M%.:Y:2?>'M)%EG-
)H6|VHTR@X+EH%4A;(\$H#|I9 M<^B)-R.Y,)<\$>ONL+=|W6&%D@69*\$4.RF|62WX|V-
)>HZ#H.EGF(BHDYO_A M_I'?_PC >DCSD|_#A.3:0U:9=SLM-;..|W&|E!X!*8^
92VRMO4QZ,5"X>PE MLR*FXL'3|2|JY?'\$WL||^+L96F^1'^!=U42'G%O>@38-
9D:|F_?,*RF_-4E^ M/A;_==S|GGSP>5=-R1S9Q'=73/2^BE\$Z?
ZY)U5U3D|X_NZ|4VZ3;/(OR67U MG<|3|6_%AF<| U M@B;9I)|*RO|5Y@|&R/+S1*NZ3
MZP1?+VNEV_.=754W,2;/C7L6S|IR8S!^"\$;./@OBWU>"9+X99BUW_AE%(/\$Z
M\W7SD:_C;C)LVN';RS 31;> (!1522R*V.XO3:).KN!7E1^W0; M7 F2;OJS/'7G|H4.A-
\$N:.U|F1|@|T)X9"HKE&WP)=@GX';JGY=I&5T:7,8 M#9F&J:%OX9*S;'Z#D3?Y-^R
)0X03YX?:M.WS ML@\$&=6:0QC;:6:Q5+6#./D1V?"^|I F M"J@O^_K|S/C!\$PIG&D&\$??
LEOE!4J|@>)_%*AH1V'=K%Z=4T/.\$IDF:U@8FG M*\PP:O#Z:TM#V*Y:(R|
<.7U=NZ\$U8XC._))CXQ(|.:UD M%;_K#6I(W9L2\$|IV? "-0E8_\$H.GHH'TPOY,6|V
M@J'YH@ "9:OW00)GB_K8+HT6!6=I24U.C)7X^.,0K2,V)D5YSWHOPG;!1E3@A
MB2EU/\$25,*)?->3"BNI#L7/F1(-*| MVJ2*=CYV+/KZBGP#H0"VK|C!CH%^?
YD|&BW1=RUA08IF\$UUG1B?| ^W75=W#U M))"D6(-
R./4Q*HI:TV+>K5*>+SI8.A|KC_-|W,S8C*.ZB|)|FK+YUCX\$8#| M IUQIW5
O49_=@U|8,30FBMV#<+59:(T @90Z9MC32W(DQ(0AQB M/MK"|B7 M2Y0ER?
X#"34_Y9DED_Y;P|JZ)U M7A:CWP0S:*XQ""0\$|FJ!)
L,91BF"@7"CJ|/;T(Z_|TOO=@E;MT0Q&KXZ MN|.+'QB4ZJM04B4PZ!
(DI1E5T1D_B|TIB2RPFQOZ:'6XN|W7I M96B./+|U4T88R&!'>\$>H&8M| O)\$S|G5LTCG4
F%EO%#GC=IE,5%?BZ3S4) MB+&K,96\$;#X"J /?+&XAJ1,Z%,MJB|Q:=6E;NULN6,-
(Q(%;0V.PMMBQ?JU\$ M!&(;,7NYK.XOL&B MI_3|.5%LSLNJ_-ZV?
FL/7!I@+@+1:I*JLG#*M)DV2S?Y|_O;NH!::1_7(ZLR M,%JPB^|/H!
(47(5H#^ ^WQ'HR6QFR98Z^FGQMV^29IY@%,H0=?|&F7WN*I|Z M_K7&^P8A: GH^?
>E7|K4?B^K4MRZ;D2BN>O?/| (Z3A%YM%9|H8#;?*CS M(\$F,OT6YS8>O_T+ 9W?O?G>
(P36LV'U+OYO|/|@(&O;65:2.^Y/F/4U|5G16A MWMUGR..LFQZL/U6P5_C)"" 4:P?
+>38@J4.|J-|?0|<60/_-\$T_/XWQ3*"" M6LR;("@">0>BCS<_>W.M+|S%>|PB!
|9G%8<\$XB%>(H+|LSJX2(XMH5VP&/MLG#=#9KXTV?"701M"4VDIKHDRS-
_/6R?;6V9='P*F)2L"EB^S2\$F|_C_KNU> M-^+|K18YE|ED6^:01|P05%|:S5>6
TN,9HGM@/OOJFYWC_|B_H3X+GF-OVR M@3(D|U^_0'C8%K|D-AZ\$+
((SIRO@|Q<>*MKDK0_) \$Z#%\$\$\$!98\$6QD&1D@\$9(M;IMBNQ.AAMV97Y('H6<(??
&XBFL2&>Q(!P!.6:|4_5Z:_N/J:#|!H1: ^3 M>_W|6-X:X^)|:RY3YWW6GSC#@-TV?
Y)U&7UL?*^:|:RU KC@YBH?'8FRY|Z M9O|TH|7,.A*>1|>W|5-Y35-
+O%5J|<"7BMXI#0GUI69N"8U6D8MW6I'&J 8 MHZE7D|HYL<*!4-X1X#7:Y;OK,^IM
C1;S M@8MG5JI*#(; |A"<"9XOF2?GNI@"^<^@<^-SP"*H4/+ =B0EH/+DF\$7'>+A
MPB%PA|M|73@)6CSI@6_97FVP_'ZO|12FBJ_L)C8Q)QSZ2WF MA>>!) -45Q\$-
S1HVT"Y,ABI>&40G(-\$&B@&^5R'20QAA#TH%V|W8YOU>|^Y\$
ME5!>|T!8/JZ0;4@|FPS3"B6)X-XPWY

BS'H8DMF!W4J5|\$ZPM_>(>CHP-C M=9|4N-
K53|N@|JK|E|V"4.\$/L3,0%|AG@&45'B+3YIS0:9>MB-/GBT?3UQ*0 MF-
OMN|S+;FM%9%;3/S4W-ES/NW KC|M\$;Y-7Q 42)G&NF\$U0-T/HRN/430UT M*Z=OE'R'-
JTOKH4*1WOD!B5,< C*RD?\$2UY=5IHOSIHM"1^UM"Y_"UF; >+8 M"9-
|+O+O3IOM"1=3JUF8U MYV>|A\$@4D7>1&\$31*\$|9F_ |W:7G6EM%QEFT,'_ '4D+
(-3Y;##Z7HN>|T1 M&Q_S(^.H7._>>39C9A/6,^OH\$|N|)%&29_0"N9G\$>?

VF(K0\$4A)8#CW[+H M9[!!LBHLBD^,J&59^&OU7A72'Q!
/JPVR\$*0&4@+JBZR:>Z.@E/GJYWGIFG"V M,\$B'0BU"UPO@U-/RV@0D0!
(W;9!/R)3;I0H^/J7 LE-R@/UH9HKCU7XOF#R,'L=P.W+J3N0.7"5[B"#)
M):Z5=I\$6&4@-9M3P-8/42K !F#@18\$B>|,V7@U?=(OD6^;
M*Z1.'GWJ|<%SEIERU&76'9J EM5_.8\$?>.&E).5VD M/I<.FLKYLHQ-
\$)JW33YUP|SSH|U^@ZL9>YTP12"WNEDDXN(7Z.4|/\$2OP7?Y
M^PE:HRA/ZHL+DFM.#\$<|*SP!(2'0D;6&7T(I2)JXX6*PH%82@(2^4:3X;NEE
M4>EZ#N3X!7Z)F:;?G! V1P?G|8G2|H85|T?,A7Y7W&LZ0N^X&7\$|7|
/T.T4WJ&5DYUO7G|;OP%##9,\$UA: ^O-9"HSDY2R"=H/#55.
MAPPXTC9,)@8084_RE;NP8&GLWXN*#PRGGMX0*>P1G_:O9SA266-
PDRW08_\$"9/BZIASL MRPRC4YT9O_>|O_K8NS;|-U*5WZW#!P?
\$""\$AF|=*82<;R,TK^E'?@>|6=X+ M+C-
HI;'.AP^,S))L4'5^13=0/:60X?/=7NNJC\$/0J:HCVT7@#D8&XU=&Q'):
M,:0BK>/,J'&A*N:F"1?H19#N88Y5UK:<_<^';7.^U^L^0MM5%_#VAX:M./Y M:=
/*XEMD/WC6\$|YO18H|.#?S:H4#T#S:^7Q,Z18&NH/%*FZ#%-V/X>969WV47
M_OO362|T&BS+_ ^"GS>J',W!QLK*<)HX;OENVK:@&1/WWGBSE,JV0;K>|U-
M!.H8N(9\$JP_)_I+C6K@V(W|OVR*H'T1<3C/_-8+5%_&J|+MAG%B0G2\$#27Z_W)B4Z-
_=)EBU4F:VZ13<5"O(&J+|QW:2_ME|J-8Y"|K\$Y3
ML:GBG+EU4<4=MQ@T?|;^#;WR:_GI1(66-5N!*BORX#E|!8-O+I>E2.TW077V ML :|>
=;>:;%7Z4X"-|/"Q2#3LYH?"/ M87-E1S+8SNR9IDV0-U7(G\$^_DWS=Z65Y+6,+
(Z@|%=STK2LGG7<JUX/?;5 M|>C.+&25#A B<I&ILFKEZ=M
M7E2CC|NJH%,EC"V*^RP??|"Z-JL?|. @^ ^F_ ^2D%U2/GNM^P*RBBA*?L,"KU6
M:NCZNBUI#88YFGI@B,PM-9V|G7\$:_K&7JT7.QCAA3IOY7=Q>|%3-->^|7<3
M::F=LHHNO?2MW+_.%3AHWZ!87<.T@|0TU=;<?;"Z3;";X^FA/F4SO%Y,6=?
M(6\$A/;)NWE.(MO:/ZX|#;MHJ3&GLUR?S2OM2+*OPB)-)ZQXM_ ^,Z|OC,0;|SVX5@-(V7-
_TQ8G,S;BH.MHCW/4.)3ELVB"D7W,*\$W66;FEE&,Y,O4P9ZJ(\$+
P3L1VA>0MRW%|KNA|SSA M%F?MCE?%(OR;J5P/4C7'C%99?CKO32MG72
+PYY4/&+T)BC/:8BQ2,(H9.:U
MLOVD4004_@|F4N*!&-/U|VIDUCK6SJO9!^F^FK#QQ7?!5;@|AR=Y|;FL!*Y#
MPZ\$+WF6SV^|MR2P?@8Y1Q7>%5HLMIPA5T:KERM-
F|^=8|"GAWYGG3NNRQW'83Q/9*71!#NR\$'7;2QIB)PLMYM!ZG_E\$X0<|_*[9YT\$A_STH-
K0474'>.EO%-(F-|1"3V\$(?#?#&+VC/ES_D^K+6! M?1?X)H\$DP1U|PQ+-
/JX6X^1)H5="#|:L33.D|5)O62Z17>6^*4\$Q)C4F\$<M1\$T|OK|EVX?
+F5H%OQTWOGF%?V!+Y/T=ZB8-WE4TOU(9*A38:QC#@R\$X_TAI
M%3<^@UEP'L2JBS+>%>-\$>41A/Q>:\$R,I5=(VN-122P;M9V/"E4&L63T3&;D
MUX)6GI>KY)KXP=(A3-"2.AQZDF-#3/Q*|E;FPO"M)F<3N7|T.W2TPJOC|HO M\$UO3'R+)
(7C=KUE%SJ/DN|OW&B7
MY|5XC|=I#=#4|APRKYNP0.O|,%W31G+GJEHC!L2*6DG"2??)BBVT-T'JF%LN
M:I@*OJTL7_8,KV(#CZV>MYY-.U*EQHR7'WJ3Z91LQUHRM|T\$7PLKPUW|_G! M8;
|\$_S|QIR<.ZA6;S/393%PNY\$FE*HR"3"EMU0<(2XBNFP)FFT @X<,+^
MH5SU_)4Z8:P8J1D;8/SX5N*IC1_4;%5F67V|L;@42_@CTGG-P^=#3=_4M
MC;H\$WD3=)_J+-F#|AHEA6 MO=|9L%&"W 3M^>+ 'F#0G+\$!%J(C
M+;)J2YT+7;AC(CFQ\$ND|GNR2*|<(B VKQ*WG'8A+"K)O6Y@Q5AL/F""| ^5WG
M_%PNO,.,>.(QS^ M#X|/T5|R)SGKU|F,URD++@8WZD|4OE.8=(+@IA#6;;4_+!\$S?
D.T5|%\$+++=LW-0 MG^@I+-KJ3?I;=D1W MV|DWY:%CFR R;_&0,\$A<96W0-'N1S4;
A7*B|'5'.PE87|/42@IW-.RJC*5 MV^69.W?O^T;|R7%'VR&3O=GET:'F*
|V|L8B0Y;#)1(DMON,T9#MVNVBBL\$O2 M'M2|'3J C:Z|9DK>Z|2S;ITPUZJ^8?
J/18*.0>>'K7?KN4>/L=9OM@|%-3ZQ MBR5POGCXYRA@E9Y:5_1/E E|0A|M;R8_O(I?
-.LM7C#|(^3LM MJ+R\$6/=M@),F=@10\$M_O\$ WA|C3G-@5T:SA&|57|T(@
A6L=/5F51@Q MT\$7<4A=O?+\$0=,*DZW4USO'VWK,7IU#_TML IA-5@7MZH
/V&:?)=2/(H5 M9D8|P#93^Y<|%"\$|&AA5:L6=#%<\$B/CM^@6PN=O_OL>O\$@<
O='!1,@A3)OX ML:Q(&A|K%28K(NB2M_4|BK_?PJ:%MPQ<13H'@S1_'-U<\$(A&^|",K-
Y_CC7 M*0B'/NI%;7Z;#|7'A_?YM.6Z02I?:C=4)GAU&0X|H57D%_);3O5&=4L/U
M=:R86* 65#@X@YF^>YJ_KP"l;Z&:>? F>YV:K(K;^=4KRYQ0^:|W0BOQ,|%=
M(#,Q@8|8^R?=:;H|)'6::ED%9D8YG<<%BQ&4?C/7-ZVI,VYOFFE.5D(ENG8F6
M/_J.FC1Z3D)MIGB;E9F|MV3EIC:W_ ^4VQ|U|CUSHI3TWN4POW9/#A8FGAC=| MH7-
J3\$0)"OP-PX#12)8|T8G=Q(X)9|_23*766|_ *V8@XNLAA?% PH|VA1_ME.4I,'
TJ3>K1/Y)0I^4J5"L# #CCD|9&F#|>3A";SL&(H.P:P|JMUQYZ/3V M|L>MSSC>V_|A/82&+

.&|?X.6:WDFa+IXNJH!*0M;-||8BIZ.O7_5Bf8G+ M0K^!O^=B-"PM/6,+98^O:|-V
0AYaOMj40^-/-^2)M3B0)74_|#T^E4*25_KJOWE)U;9>IRI>,,M-&>5X\$/R/SX^LT|^*
f,CSIWNNN;W^-D(?!KJ%)"9#FWX(8\$QI99JN M98+W 6SG'!*?
A""DT,A11WX'6\$1!7VE,^OB#,%f@Z?_.|7-5@+JD|60@W/NGE M!f\WXK5E9S%FGI"J6*.:
(*ZK M3L:1|1,^ 9Cf|?I(U5Y?B-FT6V-T9%5
M""^3O,K8V!_V\$PvF;f_FKEE9=|12:N*R6,KE#YN&OXCJ,6
M\AU,'7BH(2*3QR>_X.0QG3.NI.&6RHA"40KfHHOW\%P+J)0;_60fEFWK(8
MY5BE4G>R>2CHf;87fM\$O%!\$YW_H&X\$J<<>|Y3;&HD>'*1)4Q!+Z@(^/|7P
M:G(OAY=B\$JCU=|I?8WW5WR\$'AZ.Y_^B/V=)SHO=*&V5ELY/V\$J0X7X&-Jf#*
ML@KI'S@|O_DC)X!(D6f4L|f|WUGR^M4DT3BT6S.R#*;M;S8<*O\$G4+.,/*F
MV\$)FKM\$*)H^_L>NF0@>6O/>:(*D:@M3A8OM?&V23E@A1\$|TV@6K0f8YT()F
M8"7:F5E:D|)K|1D8O M|L9X8|9-R/#Uuw;459>^)T6LEHfU(ZA&OL!*^Y5B1
MV^Y1F:BjVZ1\$XC|B/G|H*^<^"|f:=P|3YB+IS'D.4 S AZTQ+K>VU+SB8&#%|-|f("R*8
MMH368->0Q\$5A1Y!>Z=>#Y-'O&6K+<A+MU5(RM1E_Y%?X)0>A2Q5S%#@WF39%R
M4H,Y(%C|:3R3K02;0%X=,HYXF>?13\$Tf|>&QH=2'KU+SWRW1TV2KSET>9GL^"
MHZIO;NW%|>=B)L5#SK9:PPUE+I&&X@'96PO2V'HO?C=.#:LG'\$B5&T@|1/+Z
MYHW"Y.6&9?EPU5BXE88U.C40.N9UAGUH+9#G07OF31R!/?D@UC5587KNG|f#
M'@6'K?6/"FK_-VT%W)2<|f(5R<8>Q:Sl6BBSJf9Z2Q|f#3V4P_(,GWYA^=)|f;
MDX7B3D=^W&H_3N(:H-OZW&L2W!0J56N;#2204:
_#TG%)X&;G,RKGDWW4\$CZ7Z_F(HP>+=BA+)GI=O#_8'3|D+_)IC?0^',4(&R;8PV)! "XfU6
M/9#EQAK#GHQB88KV4?<=B_/f**!UQ;=|>|7L&IUX1SFR"A!_PSUY6>;V*L M>1TP5
OP^U_VF|f\$ICSLZF_>*6QI"Y2M|4C*|@KYN9|<V40+Z8+B2)Wf"P
M^M52^Q:1Yf|HJ5)/A?JO4 0^W-JSD_3;>Y5SW\$+'HF\$M41G>;(U:+6A%+8KL
M0f7_H;Jf3/F|fSY9FR:GP@_J6<8IA&4PF<(2;T>.*_7Q5Pl,*f\$5VPVJ! M2*&%7/-
+1@N0FQZH)"U)QS K7Q?^ZD7QWSI31)D@'UPO>'PV*5M:?!>A0\$?L M;UE*f|V7E+^:=
T3IK|f+HY-6W/V;^Y.3(WWBM1|@O673C_-3/V>Ff|MPf(VZ&
fB%'YK&%29YDSHC=Q%^|f3F|BMB\$!-|f:T@P3.L|G4B8*VBEE%Q|96HN
MX28|"_'2NX/KA|f|IBI2P5:f|U|<)|LX+5Q_H.D-.L\$V4ZP=X+VC458<5%'?G
MT_-#@L4V52G#|)9\$C1?(N,C\$;5T7=^8>5f|7DSY5f_@Vf|LH(P(E;B,T_9GR M=)ZRN?
fMG^)-4*?OD1>5|+D;%_f|6LE>K2-Z72MWf|)?SBA/+-!QG)?NAS7
M<|C+,%D/*:06PFH+63YBY^>LZ4LAMN2.8!H-/RP)3;'1,L4:1WLXDB9," M-
U#Z+2FQ.3F,6V8_KQ8*%#C|fRF+M|f\$&_7O-X(619)3V&.RYS:&=Z==4GP/MC
2Y%2@I/'BF5XN_4_<10QHEB|_|=F3MPEYR1\$&M<>>"UM@+C-XWV!;U<2>
M*EY9<@264WB- YV;H(?E8)R^?+!;P0;&3N3DU\$@/fXLTB@BAA>K#Z00U;KI
MAH,TGfKFG*#@;2+T9C.&8J+*,M*-(XKJ?|5J*_-Jf;CM?^00;YPl_#A27^
M<.221L1H+/-;)NB=?2f|Z+,) ^FE1_NM_8f|&\$)/G?<+4Z37\$;\$%NCD%SR73!A
MJ0^GYMR5'f|)O1^NfO\$ =|(<;@?;W#;BZ_G#fM7?<<>&*#"Wf|f%Q0BP
M8=B.535QD:R(ME7BB=EQ#8@6;;J+00)>(B#&;&D0,GI*,<f1'7UEV'S"t&-P
MfU3\$6JERET;.+7'9;^V(6S"|4H)3J--SUEG=PF<929,N_^2T-
M%*S%5#OXW0WNP@*BQND5!F_22"U/6S-TB>V9ZT6f|f+,S+f|R Q?_&
(P|BB0K+J\$BG_NF<#.;@;=&=;FW/(NWG%PFM7_M87;T%+A-GJ?&f|UU_,E|=_.WMV!7
XZ)NQWf|H6;T/+|=f96!-/R>Z#L ME:& N=@Z=%S\$;7)f|TM'84'-Q+O.Tf|"3?#-E+8f|>
:T2OTf|8f|B^@WYH..((M3(\$>8<756;:/+5D?|f|<6!1_=_OV(=f|J^XE-G3"M(2D
M\$E|<+HWO_UB56,-(#RKXYID|N73>52_) "V.*M%JvJZS/fUSGRF%Q>0@C#N1
MH)#&A:L#f|G.fDZR4OP4B6Z5U^/E.0D6\A079-OV33=6N#6CA"N0>6GB@,^N^L_-
=*_#=K\$Q0,3f8FY*B0;9UZ MJ-1X7-X4=-?ANNHK(\$?A8fNUDBW:2f|O;)0C.E6QTM-
% "S>V,Xf|7;.*^B"#/B ML>)E 50"QAZfU4?9FET'5Q_77 M>(=;P|UVNEMX"J"-FS\AVCQL-
G*|?V?/*/_/Nf|, &f|0-^f|G.0T5E7,C*A/AKV%7U?.NMPSU9%H7f|3)8f|&#^> M=2EUK%
3NO7X^4/\$9BIK ?N)GSNSN0Z-Z(4RU#f|F@,<3)>!D22Q;B!f|_)<*
f<#JL8G&"LU(G7N58"-F3A8f|> QR>;6(7Q=CN:YU,"%A M8'fWHNC7*^X;T+
fF=X'fA/8f|<*TGfC1E33DBW',1;;;"%>1f|J;P; ?-ZP M%HfZLHNX@7K5:Yf|EZV7;Z
D(2PC:HNTQ9V)M-,R\$ "AMT< M_>RV:1>5N5@MRZ:7_5W.f4LET9KY^BTJY'fL7_VD+f\$Q
'&TAEYUI0fFD|@f|6 MN7R0H'=V\$41FfHNL75F(%_5L\$1^7ZX6'ATQf|R8V>)ZX-
H@8M1f|7,HY_V'HG MN/C7X&S;0)/T7?4F8U95 ::_FXJ:4.?f|3@+T:00#
<0\$,BfIOA+,^CU58@E^f| M19 L/H.+%C-
\$FFG+:C<^23UMHOF)NV5N87;BK%HL+%OB0G,PU(&\$+,W1.EfL+"Yf|>_"2f|);)^+NO#M
(f|W"W MU09ZZHHCH%Z<*@,f|OK>L>BW?^=RGO#6%07M?
UW*Hf|Y+^_1f|NB:N%ZHDEP5 MFP@42JY@D#ZB?EXVY'<8f|)+;Y1M">17F!=\$@NV@

Y5=\$ (=4|H|SLSLU?DWD=W%&|QE|OIXNHB3\$F0^D,*::Y#N'UI0?EN^4
M&R".EZVOYT0R>4G-U:=%D |\$C*TUR|&L 9IB J703*HISU&WS|L _/V7LI\$W M9?
88LD6DX+Y2Y1F#0KZSAMFOX9,'D|M&BX< \$A#[RE]P, 7;AE&4DO?V3J6 M"Q?S:H&?
FL/TVR0| ^=|/@_1CE7FO|D|*D^"/&|L_4V|)7)?*=@T)U M2F8:12@7I?
9U>L4BHZ\$11X=HYET|_YU"GS5-_U-19*R"K-WMN9*T+T@D3A"
(D/E;8_.'KZ2SQNCLV*.GVQWU6 M5Q9/)S|>)>8TM*^(..8+=
(X04"I>G<|),L!;3B<9|HWP|5|;|X;SQ.Y(08EVX
MHG)+.'5Y/,9B9U@G.7XM7M;/>1F*85"@YR6G)0K\$D.!:4J,1|3R?1;EA^=9 M6.>WPK6/
/J187.3J^?LA4-T08*.J<5&"1S.2+7*L/BERBS(I)*[WH]?W>
MDV^Q@Y3+>5?|:'52,|C/=MG%CR+4Y"BC/PIZAC'U5'Z4#,!G7#CGQ,&B4D%S
MWDR_6L^?O+EB_R^U2_C5*#@U|4SB04>B<&N+Y-O?=Y^<CG0>007\$A3%*^7!"@
M0HMPS3+*)@E@XLC15Z=0%3|;IK5-"=KT|#[U]=KEBFUM|"1?7M-Q4ZHX\$T=11L
":)| M'N0<=Y%5\$H'=-|9^|M9IS_K85C6OX77#+|S3|Q,3A7|E|5S:-Z=9"B==XM2) M+R|
%|F*Z|_#E"5G,"|POWU^SX<_P|L\$ _OA8SN<="?)@#Q<=|71//W=J|
M*"@8D7|W*|DM/'83Q"FN=|03C?%|+T3:F(|_S3O7AL)JL,;TV|4+/.?+SW+? M-)3K
M33|H2C|1|:AO;|_|12C MH|K?_QK)6 LW!H753GN?/C>^|:SWYQJG%OYIH41DYMP+?
N@<_E5?>A\$|R M&#*C!=8H;--DU=U*>%BQ_!OXQTBX#"91BY|;|J:I=73.5 MY|8V 9+6-
Y-2*>/'>_Y>40# '6FLL6M-2:|D&@VZE(8D^>|R(YMFUM9^#K7
M:J.P3X9U|ZUFBUXB>Q^A^.'D|Z-DEPRXBH6.+G-7HJS()%%@G(:;@N=O:HW
MY%P*_.9Y004VKJ|96F7>&34ZT?S|:|3|:0/&4<:_.9AG3C,'599#TLK"!
M'=Q_:'S'6G%S)/V4=\$R>)9R#H34|(|S!)G^=HPK63G)JB)9/(W|KE@9JC^ M,KU)
(G4|UR8F5Q+!-|@F\$;,%L_,'K'_@; M|PD\$|8=51A/^\$T|^YZK;XNK(DM1:(Y|QGX:-J%
F7(LH-2@7>N4D?9M"^NC@_M_\$;
|1J|7LP07;1F.GV0#P6|7|XLXM_"QB""|LAT0P|MSHJ_XYIJ]*%HT#F7 ML1|>;&@H_B=(-"
<*M?R|_A|#[!L*5PL/4*4/A<#.|:WD)2IK?REU_"3XN^WM M|>;
_.'0D*4S|ZHW|AQ|UQ_Z^Q0RQ'?= WH=-'JA/'9|1=(5L#_'3^2233\$Z
M:R|)T<9TSGY8=F|B5|J.*#UWL8F|&"6#V|:;17(6C>EK.M?O?YY.U1%Z6Y= MP
WQ&@T|5=;15^T/J;P|5O&%J/@AS'79S|!.*0YQY5|_M|:1
M*C)K@ULR1E8^C8|YVW+G8EL3X \$49F3F>O37+Z|ME;8ZZ-C45Z?/= %OL;|
M96:|ME/X"!?:+%-|%?!|V|TMH!7L)2*B-329=I3HYW=G")4|?U9J|VK"
M=V|4DI,Q5QSQ5/W?8S*|:(Y.R+I#4LBS<24\$ _3%Q<_1Q/"FX?=M@F8&|G\$Q
M3MV3)X3->?R|2*8E*4H4%JO5_@9N5|W@GF_+GN6,) \$2U)TWM(I)^%2_N(R<
M:B=#A5=)8^O3^,?F SJ8.)R0D>MV@L3P>AK
X#JP+&W=O_+R3.SS/#>=R+Y/>_#@!;RA&;X? M<+5S^'^?"S#ZP>UMW00)2G<(VJ9,-
#N\$2&?)B8'@"JO'!FE,W/86EN?<*C&8 MXG(NH)U5)4HU,I !(|TN::KWWDK?|UU9Y%.5,) ^?
OO;#R/VA%D,MH4|B'@|: M'4@|X HO8_P2O0GB0B1B&C!=*84G^|J,-7|8Z"4*7|
(&|@+:U|E'9I6/8"*4 M=|CR? ?-Z^ 'X 7"A|4S%UN|91_&+^J|:5>=|\$_;MY0TNKI;S|W4#
2T|L M_2_N!DPSV)MJ*\$2D I7,K'"N&WHY/C%V|W%YTKB|K@;O<"8'LO ^#5|K|XX
M>Z/NY>M&NZ/_UQ);_>LF2)N6D"!LFEKN!J?'HU(:.FLP.|Y|C\$2)!278E=Y0 M?/2T0'7=
(XDU|H#|8|&ZJF^|&|U8SR/D^*5? L"2_7*6KR),KD)?EXPC>L+9 MG.E\$.YN@!B
_A:S3+>A_2F6AHFKY+;?@;0/?KG(>9AY;^OPK@GR;Z^=S<">,&MC*B|L|Q)K-
*9R/4MY+;|H/GZH| M!;,K11|12: ^-94SAFESM<-'X#F?
Y.:FGK(S^"P;6P|@AO:G0EFGI%!'F %C8 MO420I4WWXS|^6J;ISA#=#YGL7
XX/KA\$A4\$O)%7:HY)KGTTC#,5K-DNHA0K;K M\$;G0LW#2ZB6Z<PY(GZ"7B%.I:H|C|_|
V6K|W__U|3B M_|D8MK1M)/D86|ZEV|PYB |>3&6_ ^TO!E8R (FM44\$J7?
D'=UL,1|)7K!Y'>S M@WYY-?0:%73T(;BS6E(/GV
MDSK'R".UTSJ M>920\$U)QP%'A)NC1';TA,U/3P:|PD^K1,2|DL97+KB|FAT";H MH?,Z!
|S>ES<7"JO0DA/2_<.X8|Q 1#VFSFV(|-BREGK9Y6&)MUP2+!L^O+M M4#?MJ5|S?
N5<*ZZB+J#WU|>.<6*"J*ZV-R4W,I94#A.,8NV.?7?24RH,L9, MOOL;?WD+1QK=!
(Q.\$|^Y#9L_\$X5D"C/F>R|V#Z/_\$S(#\$X.J2G|5-%*/O-> M8I/|36P+9W^S3U>?SK?
FIY*^5>)1|@YPL|9|!+^/TH)UKO()Q_ '8%_GCMR MEK7ZI4S'XJ,TNBFZ&-GY'F,G M.
|9U5RXN3I91G5PLAAPG./WQY9A!^!,PF2"(E%S\$7I15Z,MR-D%!WJN)HM;
MS5TV0;N^=94&3'Y8^N|S)UA">X"1C|4Y6_ =K+|.X|H4X=%#|?!"J|HQC|N2W
M5_I+NSDO!EJ7V,EC:JA\$7LQ.6;D!"5:8Y\$7 M43!;Q7G;4M!J:Q7# 'EB"QGPGZ7^"6
!*>!M=^B0CEH*B=E&^L51I,J7SZE' MF\$ _L'G4L|!QZV9YD|<2THJJJ?;CT:|V;@Z><
|.473Q-G2'=I^MO@CHN,="V M3CUP%FJ|?@.B\$.?3AV5Z@E(70:K|H0/UF!#KX;
M:/@H>E? '-DW>OB7FV7N"!;<|H5DXD).Q/N,G=T(X@^@:8P(+W+^NH_722J
MN%'H08N!S+*SLEQ&^"/C(&!PZM'24I2+*@SF|0T^P)EKA\$U,?@|@SOW)F8OU

M0E<\$^&(*SP^3^XS.1.?LTR)[L,T\$#UG;LB\J_3XBX)YBK.MN\MK0_P"VD!M1D?
_GX;Y7E8S8'4\$9+LP)P.+)#F+\$Y4[C^B,T%SJ7?*WfYA=8\$=\$._W
MQ^%||%#JY8_M<7_OR\VOEFV"DGP7>!JX\$PK%#^U%9T"L1(1'FFT:'>B4:~6
MCD'^ON6P!#T.NW\%;(O'>*A MG@,XB7OAW&57D=J&&743M.>1.*PY'HFA
M,DTJE)X*7WKE1X8Y8?FT-5P_UJ5F0(H/A'>0==WT<'87W<.O?P7_M#&Z2M3"_9>GS5=?
>_#,9T),Q/UY'PB_) / ^#T1VG!\$@OI7A\$|PP+6'MF%.PH\$ M3YO 8"-
F7WZ@HTV NKC M2RY96YL\?L/GQ0:"7\!;!J=VM;/\$B2^APYY>2%?
M;8(>R\$,_;^CK/BP_C/*W\$O,(JR.BE8M8K5=D\$O;9_B%|I_M*(KV/U-|UI!E0KIYZS:'TOK>
|.G&T?|.LE59?DVCL(2ID*4-!;"-TP@2^+M=|-QV+S_%),Y&+8NUVYL;1^&N|Y#|A_1S?
CZQ=XN0_OLOX^WG@#_#^NJ6' 2 M)I09RVGG=8(P/=#++#GA.T+/"EQ@!0*>3&-
WNKKUS.?6VKDKJ_OIZZG/%AM ME..219S-61WVZP07R\$=8PGNILES)(@A="WP37V-
'#)>Q;|" E*"H#(&V;?MD MH_#CKGO_A|LAV5=^&4IUN_"K"OS-1CES>1L0.[74(API+YS-
KP"T!M|Y+J<2 ML19|B;/Q?M;F&R:"2G'(>*J:TJ/J_(:O?_79?F\$|WXTV'E5S,FJSNZ(:ON0W
M.EQU6|.X&4_#OB!;KO-9\$DJ'O|;Z1B6LP7'YNT07TZ7_R))I#P>'8TWL;P_M?
|AE7'Y8M.^O@I6_..W|E&(^QUYC/<8W|;2?-J S68(O N>YJ|)@1-D @\$K"
M@*"9'8(3HE#Q'396G12VP>M,0!_TFS^B3Q|R_[E*],&"^3*E3LT3P8B(ETM; MXR(:NN-
^*7WD|_M3/=F,*>2_&3H&+D;8X|#H'=;))+-\8=%72|_Y(YC4+K%
M=@\$/JIR0T9'CEY,!NWO01DUIU?|F'|MU;_L|R|7KGVK-V_VU9\$8T|XUU2@
M.5&ID#HR,>2+K(XQ)?<1D*R(YEPIM63;Z)*D,*"EGLN9Z)AR41JO>LX6K&TW
MJK;0#|,JO?CSOLVVTR<=F23G6\$W"D;#)X8L8T9|HPK'=-^A@1/X%+F>|I#I+
MOE<*!^QGP&,S?.5'7ZE487M;9L;2V6I_@%C\$L3UW|6W;\$,UV6L?|ZI!%ND= '
MA5+IKE7!%8%S1K@KSRD4%;L"73S'-JL.S(A7942YE?3RJ-0VN":LN/?1:ODV M?
TR%!YL|\$XJPS1L@BZRO|!X|F6J\$;ND|< MWGE5;C,0Q95DQBCIC' \$C*G7
M5COEVB5AX;1+E|E.#+634YB#U11=&75ZW2|JBBJ|I>WZ51|V1'JU%8.>V
M@K5CY%\$;B|!'B6H<,,_N9TUDQLT:W%PX@(A)O|K;|3'!57?4#B0D%FT8%0'
MGUYADQ*O;Y(8 (A|CHP3MY+ M8-ZU;:=9CKS6|9N/+QT?|/6&+;JO |8_ ^P3@,,'H5=@=
<#W^)QNES\$X/XV9 MDP8YUIJ8|A+?.4_VD2-FY6HO.UK/P5QJRS0.N9(|+D_2T6|E*
G_;MIX); M;7|DF^37_J<6Q|<|ZBTK0.|@Q%>3<2O ^R7WTYQ/QL\$(PX8|9FD=K85Z-
M"3X&6<8W/)B6|>NF06I^4"0N\$2L<",\$+!;0%ZE-FWQG3Q=VEQUN(W|:
M7M..O(MX"10/VRVG1A=F6R"&S=LC)GOFW>|.CMY|F4.)-#3|/%'7%Z\$+S6F
MGC08'3.Y|(GHORB.H5 'T7A;Y>1-\$+J<:|J9I@FXU&.MA>O)-O:BK7; NE Y
M8)AV5J3)/-5MF!(E.,JOCFEZ.3>Z+M!ONQ:8H>|V7IB3SKR-WN'KYY;IZ&? MMXJ7%<92
17-T%T1|'W)J@G;|YLT/4+5LFT%'D0YJ2<%ZM>39L>T MW2UZ|+;V/3V97"PI|)
(4<%I6RI@J86A#5##<;E^OQV98\$V">C |KVO^8\$4"L M^+2&4O.?09%'_HZJWQ+SOI?'
Z;S3!R1_VJ'Y0>=#U2OG-|S V20|97EH|7P M8#15WH^_N)J; >L\$&*(M10;IMIV640?
RO)\$!:(7*W?VU7R> MXS"2I6!\$+=?N0&;DG^:ED3?R41T)84M?3G8;LLL/0V\9
@*)F_0\$,#=C=M@| M'*,UQY#C#" \$M22LE?&3B?
|*@;J%&WZ6KZ+3|Y""AFCVL57|;X3WY_:1U?
MU5;|NWZR/OHK7NBV"T!|E|FWQRS2RFYPMG@P=(;|H\$|;S2_UC4^UA(<|KK-
1##=9CD05+ M'%A"!/<3JMU?@J#S24NC_XC.RVD9I@K;V/0%T7XE&@G?S0SP(!U)|I?
R;LI M!(FR=QHBSK2|:%QDF10VD|92EVH3^V#L|OJ5(8B^|Z03\$WJ;)X)"_R@N*#/\$
M\$E|KWC1'GG/>;7KC!%;"E*L-F_M'NCY.KN0\$A&4A:CYL^|LWB3>. M\$!?'2S*0:>+ES:
=4'&"C^:D:S:|Y'RZ <6JRX&"4V0/XD2B0>;D6!M|K,GUP M; <'<87DLM+%5E);*<U
M+0;10*IH38Q/6UP5T^R;8"YV;02E(K68Y<&?.CH6|.7D:OEL^@-|3
M71KIV3IYB|Q(%FY/^NAVO;!Q*2+D7H\$XQG.P+S8QSEPCYDE_I(TK|OP@%1|
MQ>FG!7H_H"MV 2KX RG6^N-/YN\$JVC|W%W<:H%|Q^R(L@_N9TE_6^TE/GWT/'
MT#;!*AY1/T(>Z3 'H&B25L!WJ- 9/^;2Z7GZ_6|,|^8FZ%>3Z"BW#M-5^#ZI M<5H TN?
|NS|L%O*#'='SB!^C8>,"%N"HL|A7+!* =9QV;1M3ESK|(A.FR:<#-OC>#M_/R
M,O_ L+P01A;FJCK|1B^R 1/I1W:XW?Z)PCU#;G@W6C.YD|&AYE&H\$P7EU#H^H8(
M\$|/(ED#8_ ;N\$'<#AZ;1?0DYOV39=TT:"F65KNBJ|NK;|H
M(P#M4'Z|X,21;J>|!D=R"\$U;C0=6RL_.0,|6'.Q-7TJD/F))06?4,A&EP) MT.^:QJ1MX#
(P^9OTP*5W/! M\$25,Z)!O\$4%|D&9*_8H_>5D&|VSY#2'A#X/ M!IE-6CMHWH|W+?
1K97_) =,NYRJ)!-VLL>EW\$VV+"G;_OI>5,*8J<;N 4=\$1 M;#)|V_TPAC|EW^TTBHG"|"T"-
:4|KJ)ST7&R7)D%=\$5&*0;F|(B4&|POD-Q
MWO)Q|P6/'X@\$^E(02P4!;3V;G@MWM T\$;L\$|/+A.9Y>G@\$' 8+58S_39|G;
M5+S"031H@^?K&'65'1&IUI'D?8 U4?KY0|3Q5ZIL(.1MAWDD==)24&'W6D|T"
M&B7&4DU9C0U"S%UUBB.T&1)MKK;?8> EYWH;8'5?
9NU|5|PQ7/80D6'O^NC24VWW1E&O,T'KP4DA^LK|N3!QI|X0Z'

MR<\$F%G09.@' U\$E,DS713DJ.X3L5EN5A3D?|>N8F:/IV)#QL4^B=H.JB&^"
M,1G"G+CE:/\$.^FP\$?OIHVH?|4Z2QKY.XVZ0W7Y_8'3!T\$.W+N7(MOUI37E*-
CD**6>6JVV"UHNJEE)XTGA_ "B-MV'RR0?J_L3@?GR>XP\$JCO\$2 M7RL:78R3A "AXDXV-
K86@^Z(7Tl.>U?(V98U|CO|@L!KERP(PYN8^FW>OS|J M&\$>X&2?
Y%9QZ\$!>UX6S_F_@K_2\$<(\$?011&3FV".J&'<)_D4.'X: S=X(TP M:TBLY5F\$)S *.^<*1N-
CTZ3^=>&%/'-WW 44^F^#4L(\$_D7I%>3;ABG*ST+Y MSI3_VGH)E/^O?VX:="_
"E!AGN'A.Y,2\$-C(\$@9*+V!.RBD-80R+PS9?,CEI^ MY"O%72|'15S/
MC&HYNZLI2DYDF_Q|45EKMx0N=3>GA5|G\$CK:T,B
MVY#.%V&F3>)L&84.QOU;K@HY""CWK&)CBTA M_%FD/=W27.P=|)?US^+I_N-
7U(JOSEG\$D)H"\$KU.K_5\$|'|0684|'"J6\$?A=N(1RC14?6ZA:N'U(>O *PT?DX9% M\$JHO:
XNR1AV|?R6| ^29_3 F(^*WPE'.L P?*1Z7 EK(^PO).UNB9DI\$|L- M\$Z=OLF?
(J4:VIR9A:LBj 0+73JL|V#3-VC=@SBS|:7-Y=#?2@I'OIZ(NW2-+ MH9|&_M_Q7@|
(WD|_H:61AW '\$4WA='A0M&J+9R/3EO+V=5UYZ^3^TMTT\$RC M6KL#H>^S-
WR6KF|S:|&V2QU.#YUTU20NTY. R9@"+D*I%9\$>LNU2-.5.<-
M/XD7WT6J|G6>3?|M@:|=,WX+=+1H0J\$=.(QJ(:Q-HIE;*2\$EED7&(Y7JA|;'O M|@.BYHI7"
(T?=:!-T|V_SW,Q5FX|K,^V\$YG<@/%\$,XF^G(O?RT#NM) 976&M
MY6S%7A%FL,*Z"G|TD?84YU<1.-N>%9?E)ZB>;VTN0N+Z".'*^F6E-7.%RWNL
M"XH0.DNEMLM|4*C3X@ZUD96@(INO|2-VSUHXR/:T7/\$8_1|05;+UU%S&?'E
MV0V%"O2@R/5OWZQNCL&@R&|-\$%=7,*'=RJH8^/2H5+UO
MBI%)UT%JZ'LK/8LVS"7*TAUUF9R%@=/ M|X+?R&"|O774?TZK> O|YM:4\$5-
Y'54!QO|!-5+;LYF3TW.>I/OI<52N/! M<=CK"C[0"%/;257^H0| ^!I%^.D^)|.I?7Q_=Y-
+8L0FW,\$#B%Y#:S!1,J*
M#K@M:%+7>SIMU;Z_:J2!7P|.XULO.5X)%'I(DTH+=Y>N8P^4.C97-'H-|=U|_8_X3
MPS0I6FB5 M'|K|>/C=*TLO;W9MPQX<<75<|'|==#!BP.GYC8>%N_HG\$!V64=9 MC?
S<%1O26IT?;#*<|2Z7M;'S2U-|:H+C;*K+IP'@1&H>P1_7!3XT4_QQ(NJ
M66BW5/RK:|WK% C*0/"WFCX*!W=O:J&E-OK,F192R!/R:6VM>P8D."URT9ILG
M/:LN8A.D;+!|29Q@F?MF%&FVT++&2Z7K8PR|R_=%D3*UKK2'8'^I SRA6A?X
MVKT:G@63.J@S|WF|<(-O@>Q-4)- U7.(W|KRA?V%^C9U+BAWESK>2/I?3|>|
M|.7HK|/|>^_ ^S_0?Q@_O4W224SD4L4)4#JN9
M/!CWF&NW8:8"36Q|\$,|B&ZQW"WUS+Y88,6_T\$U1HLP^Y:.".)9J|U16X#.
M|%0UOR28TN;BW<7M@#[A9\$|Q+8=M|=C"4'_F!Q3G#[2/6*OK6.9S&%P"!T M%Z9'-
N8:? M'OWKZ9;I1"7^)|JZU7D*RJ+8'2LVHV09-"(G\$Y%I&^?RRB6!7>7J2-Z)@0808 M5.Q
0G9":)WMIO_*2P|*BZHF(^|A;8L8/ MUZ;8GD_B|QT|/KVH>|)|<#?5W |JP(I=
(N\$9:7O&BU5^0&?L%L4E*^(/8/5 M8=V14;_9&|#-H'EY-EQP3_BWZ'D99PL03R
Z!;%4NU95SF?|?G1S,K"QC;X
MP9J26N(H*N7WS1:\$&=65\$A|#OOQDW'D,I7&9MWMDTB48L6)TY+> &2E4-K>A
MD;6"@7+65D(9|M#RCPI^8L^U\$EO3;5K&MHK(#*?. '33.K^6|MD*P7Y;|3 M%I
:O%Q>)|8Q'=3B4D|KST+|7C9@M &0QYLR%RN-
SC.362=\$GQKZFGKU9"H0>&=Q&TAIYTPI:%3EV*V &*9G;QH"YP M75MC2A_QCH1+V
(H6)V)*6?|OASZ#U5X@5<@%|(@/79@0UY2+|T=%-6'QLQ\$M6RMD2|L(2C3_(*/^N
M\$>+H|EWIBF@?3RXJJW;.R;P| #-9L^_.U%VJ@Y)"N)98@_WF MV;|1 M6,"YDCX1T!-5.C
300^13-XW^';F?G!!24+ #DB6U M|_65-VIAJR "H:8DP. G^F=+)Y9A|JZHP_:O:@XHF;T-
2(BL|YGG>H#F5Q< M>|>.M ^|Q5MAS#>+>LT%A|43U@
107B|JYY8(0\$VL,OZ/#T,":;KRP;%353V9_I3I\$5D6.|+W>|SS68>.%I'
M+7JBW""FSZ@HP"@M*1->/Z5"(9*MLB+B#8%?Z'TC-=KM>9K<*\$%/3%,| #N|_M|(M?U-
NYO.AP(!1,V5WJ6|2>^|_&6K\$D)(&!(RAB2ECKCIAEN&^:K&X M"S?E2.7|/|/#&-
N2@1+4>+,JZS|_(M|_|HOY"FF%?'#I8(|+ MY!HL-Z'|7K?
IA0.KK6XD!"X.SA^K_Q=)IC16CKV:H% MU5B/QMLINK-
Q'H@W*CI<2FU#M5F|X)CXT_CX7C|_#NY#A-&RMX2ZU6'_@:7Z M+>8?/PW<4K,I8-
MU_!U02G|K-OP8O|2^:Q*S"O%DY/#J=|?'PN.NB4G+21 M.HA8!F0?*SX1D9\$D1;/%?
I8@K@O-_SMP"?_Z@%D?H2/M;J# MDU!PWX8H|B>|?U
9/<1"KA!6|AC(_&T8WG9"/WBM>L";^(50U-+<1LW.VA=Y MK2VSHR"V4PP|M
HH6L3^XB%QB-6D*;X"YXM>37"@V^|#"TW,@(>I=G5H3%2ZK0 MD6N;+3PJWB-J(.I?
@G+<#'|>RD(DFTI^)|09|+N\$;%. ^K+?"9|2E|&Y\$2#>V*
M\$2QY^>#L:Z^\$8P&X|VSAUW4EG*HKL U>.<1-J MCK_/#>'2QODM4'+6TK>?
UFO|E_DZ?/)HMSAE,>CW.Z5+8E/?&X|<_P)S7U M 80Q:V?
7*V%X^_. "HNU,ESV^#J4^4+ZJPT4:VNZ=SM<<>*)/X1C78>;V?4
M4CZD6=./H&@N|\$I1J^W;.*6>BP:BEFWLSS.!

6F7(^7,KCD=3C^&%5^HJL@FON(\$T&VG9VJT9X9D6>-&X_M6_KQJHS/?59\$0%>)?
=HK;P14E=TA_(1/@CQG?D(IN\|:-)U)2|%/M'E"=:CD=_KQ4?
@;5^;^RA0K&@:X\$/Z3DZ^.!Q;#6U>YSM(7071RBI=JG;M2MM<^U\|KF^FS?
YKY@;CZ6OJ;_2X;N/;/XZKDRO9VHZQ,KN XX6HSCH/@M-MP':U-118
(|=PA4)"L*K;GI">N.1#XA6H.(/99R;2116KZC(<%W9,T1MI^:7?2U+*TMENYM:W-
3PNTMOV4%!@8?5?E]@_87*1TSZJW97AS0!_DDA@)VMO_=B@F,SO^U,,R<|A3H6
S3F=\$40!-,?6+.'|?5|'T-Z:ED#DPFN;PPQ%!F?-T,+*JMN>
|\$(F)Y*0GE7X%F=/'RLSYOK>X6#2\$-MGAG;:ETJ3++W^"MA,9+MPYS>TBFTNFZY
MTX/N3&MT7D(N_OB4;R)YJ0+,OEI.>2P*^A&@UOOLP70X&_8QMR[P@^8G3X|ME-
@*1DAW12?*HJ?9_C2Y1|P:|@*SM.7,8Q8"3L\$>:Y@G1#C7^V+%/A.%<+M=F"I6.-
Q;U6XYK9QL+PVO#;590T)Y|2H8O?48HHN_OTL8\$6E;(0);T.H3V-
MY4T@QERX4)^D&HT&|F!+_U)Y^.\$BH0./4ZT6N,ZYRE|W|GA.ZHU:|!:+NQ MUO,-
|RCXM+;MB)6Y679IUI0YFO1RV83+Q3%,SN'ISN'K"C|O\|JH|YHA(
M/FN:'|A#/&DM(PXWJ&@|?/JMB@7E1AX|6_=28I2)G:~OP=U3|>.|Q7SFLF
MS&'F>)^9P,<1,@FF5"DSFE>+ZT@MOPLJP"15=A"RKO.Z7GQ%CUFZA39A3W6
MG.O""7J(5_LPANC/S2<((++SA\$9&JS2HMK&@GGVO)/^F)D98>E|
|=;>.&N6P|F0#3*4W87&|Z"R14L6=2\$JRN5\$<78TYS3%3|M-*FAF1^):FD%G:L*:%8/|CK
|UC:8FH|Z1+*T_O%|W9UU_|"NE)6@)SO)!|M%|0:E|L#"3,^U#(W<++G+9/;>@
*.EB(Q5S?C)>|EJU=4^M=09(Y2<\$PCF_4%#|V|9;9:0M5=.@D3CEZ<|A=|'"3?
X32Q900-U?M9WTR" MIX4V+)^X*VFT>AC|?+YK9T?QEE7W|P/%^CSD#1DJZW
"K.#NZ/.,03RH|T@
M;IAIDN:\$5V)UK|0VOSOFZ>%/W+L9=H:#!X_/2>L\$57CYHZ"9TLHJ8W+&ZJ;MD7'6-
-,^+&U!!E=Z*%D9',M:-R>A7S+81VN.M^5V!;4>|QR".L|GG519Z?5(,=G/|?U;-TAMO.-
>L|<@M))5>^I9Q5ZC.S_3GIC#M.RG)\$,0;*AL3S925Z?IQ17"5;&%+J_27|1:G'5ULMO|
X=WZ#?;_,Z6X#;=6:66Y9WJL|L</'YW5!:=A6|YJCE/-6X!;:@M% ^H'C^CK7VP&*N*8H-
L93EL &0/RT3M;@,,877>FT. |6?|75'6V:=\$WTK)
ME6|@FY\$=^G"T<9/+Y*WL|HSIUD>GB.|&P_9O|S?-+7C6?""= </@E^'|M'|5G6!
|B0_TL9%#HJQY9?/M731&0S|8N,^^NW?ES;S1>3=BB#_9F&2';M)7:+2_BTDM
M+0W|GV#^"5_/.X/'|655!N,90Q)R72O|R|EJM1A7|D0B8|.C: ^K|4G>T0
M.WFCN3;^8M86X'***^PC*,M@|'\$X|GX&6HM*_S+0(4GEI%<@VH*YCZJBORP MI,>\$({
6'V;RHSM/+V@>=-K7ZT&BE8XJM,L|9|#!=&0B_0|ND&N:S?XD%*M0';B.&X4.H-
WDY_.77A=EH=G6L#|3(44)'9EJ.G;5:70LMW%#SE|8R%GG_M5?&^+@M%,SP_-
S.>VM\$DSMA7"05|^W4LE-|<0)PYX31IY^:Z1F)(GH\$+GT.M.XT4,=UB:-KX6S3/^|.-
>::IA)_+TR9Q=1_BD%7S?H>Y!9UI2-LQPT-|H(H%M"+YMG9<7<^?K-HXOW46VR^"
<|AFEI_+*Z^/+|EL_W6R!!6|B",=>_,H0_C-@
M3H+YJT+%R=D|X|=1W0+9^&VD3<_&BZ;\$I2|Z|=WZRS'CM!W:~NE' IY P 0
M:~+@OC6(G\$")<0NLOS*:+3D-&HLY/5SG^/)2.KFJ).%>,6=LE3QN/|15NOK7
M_UK0QU|URK<_78-PRXL,H,C.RA?:0N+?YQ9W8K7>2|J.U!U'+^F\$1(COW#@
M%\$W|3RY\$CBR<-,&J<2%_Y|I>40ND|62^1C/PQ*>J?|VVXW4S7TRW|6|44
M<\$&CW7_:F6|^B|I*;Q:~LT5B,"8DX3)5>4MP'|X%EO @,W0YL(W12^/B%>M:\$O
7|1E!'Y>TX|I)=Z<.NACJ6P2'IJ!%RWB3-<#"^OCPULW&=@?/I@|@ZO_M\$OVGJ?
9L|V3W@DYK|8L>D3\$RGM=MI5^|(@H>5%7|9?#Q\$@#@H>X_9R2X")F
M"#^#DJ&|U:|88US|/@FH9?^I2JH5=%(VG_3=:/P_7%1:_*U@0FD+8|YC1_
M6(Y2N*1V:%S3DB-LX,+5_E=>Z7#+\$|YZ9BBUQ>YXH9SH\$;ZW:FJ?O/(QO|6
M!E/M@'&G=%!T+O/IQ4=_UW|G?|GBG>.|"ZX(|XHJ,:>X**&|I)\$6)0_;5|W
M.T1#&\$&BX4B)&%)=V!R:S)IS'DUE'3<1*)^+/*|H>\$KX=CDIC6#8|ZH7B*
M_(-5M!)H.SWG:QH>>A\$*C|X|"6GZHS>_WOT.0A|D|Q|FD|C"_@)=5R=I#F MTA|
#|T<71\$Z6L<_J2P)P1X9-32=#J40"OJR>B^/KZTJ^TR'.M RB?"17";
ML=|P@>.752U*P94?UE;8SPP%=":4_SGQ0BG1:VL5/K53#(JP21|W074Y/?3
MZ;+6'8X'RF+4-%Y:DO7A|>F@?9/?BYYF)5|MM"\$MA47RB9A.7?V0^Y|+OQJ_MR,F6D=;
|_S6USR65NB5KS(2O-SF">-AU)H^6;N.KM49X=Z?
P3DFADHGO=3YT)CPR:FR|&A1KE^QZ_V93G'Q?8O.^_M=V^P#>&KH^9#,I?
&47AX;ZUPVL(S9|5ZV,DQ+45A@O5L,W8I3%C900@.HI<
M^1H/Z^_HQT,#5U9"4R>H<|!&YJRA+Q|/7-(QGLIUTS?:M*(D^5X-I'=3K3>D?K?
_&M3L;:0%@\$CC?'A? \$"1(NN:=|LD6T3Q?'U(|V,|MW1|J'B7B|2VRA
Z)D"Q|P8XJQ>//GOZGY7|E-5R"P=J2_D#:Y;7##0)+W3S;M'0V.6=:9VH6(F<'?M<8
%V'0:"WM)^|0A&E.6-E^|LUNN3F MJPT"R<&2D#TK"=EB"<,,|.DIV SE#\$8E=
((F"WX@8)MZ'+>00:S|_*%5C=. M 4H@X2\XL)|279" 4SK,Y?!?X>Z5? DF VNC,|.(144+=Q?

49@KP2VJ: MQ26,!7K4\$8 M)IH_Q(WFQ7\$D*,4_+UDC/9Q&RNLVP+\$Y;
(\$CI7+1EF&H(@?YRQ=#G3HIZC M9:35M(COO*19V>B^JA<:C2',?H<.G'.JH!Q-EW7R
MSV?8CAUNH;,%CD4.E;W(A#;B-\$+V?%7R(K!P\$A>@HB\$U15_86P7'^^&#>'!1 M 29F"
!G"R!6K&8!LG!=R(->\$SH1:BH)11ZMGX6FB%)HB\$7@!88P^=A=D!7
MF!/>1C!;DCY;L&@IW-)SM=O_+/CNGFDYN87#.>4E18IE_N6C567!Q=&Z%B!
M"0;G,O+WZ8(\$,_ (3!@")5)(H1I;@/:#K")R+@ED&?13V M_#;\$45UDO.>:D_2HIF,?
<)S">[,\$.0.C92.1<\$C!#YZD#9GJ5!+!+&R^(17 M?-@A(1 M-@R4?
KKKC""^TCY@!\$;T^"N=?_OHZF:0<1VSY!;^@C_J8 @E*IMC;^;L K MD&J%(T!B9E?
WV;77&;><(2CQ!T5J\$ELXDFVQAAPLA!;;6>E!/\$ ^&\$X4T9R
MJPU>2EXZOO+E;YZ\$,003.-!2W&ZNV&9:KCFLAL=0;TZ2I">:LOY-(U/^_1F
M\$THOX'B!Y!;,*OXTDS-JEL&MJ"\$#. @I-46#;P@+T\$ MY;>&!@H!O!3:C=AjVH1+U;?
7I3!RV!\$M'A26^B!2"<^V<22!/?JC<%RCCW_1
M<1#DC!U3R,1XJTU)R!8E*L"SGW'%.GO7BWTYV:3ISZSW[A"?8=9URXSY)W
MB28!P9N>(_K_.DY;()WR@\$=7.C0->.Z7/OX5NGR";_@>^H4'6!&
M2)11<K*)QR!D\$^;O9'#S06N#^(\A#Y M=?X=QQU4@<7Y.! V'PQ\$.^"D@GKN^!D)10TE^
MO*QR4C73XU'DM1I-R#7\$!GAH%6A4^!Y/(WP0!A+M%+3%@5
MYAS?'YQV:WP=M)?!MUC'7&!9.D&ZPHNN V;YL:IT#9M'_6BC8AGSV;8OXH
M&.BF>%J_G#!V^T!S/#9?EANQR@KJ!H4GZ.E1S-=#F"@;7;#K!Z.&F=VUU
MPR2!Q!@790QDDO+6=R'BJ6WY@L7..\$/445_W!3?ZS%HXUM=4VMHHBW/Z*7 MC(("
(W!@W(4-%-!>C8;&128F&(B!O?H81R0!3G^,/<\$;/?2P#+/*4.'<6O)G
MIM.1E,EYS226O"KFK@3VD>)1!#XADH631_JB_5@>Y!Y=6-U_0^U) M.=ZE&&
(HFBDM@F@\$N67!'"BZCUBN(V9>!&G0U8Z)KOH!CV;_!V/*D.=?T'3 MH/NM_E3\$>/'+.?
7.WG9&/%F?T!@!E0K)CB3K+\$^NOGK).V(? M=-
!B3DYH9H".M09'1;,'5"QE;^ROWQ>G_8YV'*_NG.F)H:AK@GM9P=..Z@3.NWL!0!N?5MR
M^IV.@LTASY6!_!L+L>1QJ2803H\$7VF7JZ^=)Y6 MSU@TTU3C:N:5G\$>-\$1->>I_8-
_*H>7*"CH/U4';<;S?+PP0R-##A4P" _JA& M-Y@.I=H'%;@+TU-6P:XSKW2LYK4-1X M
!V(>@/F\$<5^DJF3>7!7SFU*F-I!SO.)?H7&B;O78I3I,(I6329L'4:P+*\$0 M^#O_DFSL^2W
_Y!_U_#?_1D@*3)'DRF.\$BI!^"8'6*[O2E-[S)47FYU+8?T
M(9F41#7YS"!6VTY#G:10HYSC1!;6<-8..MD7OEC-M=,FOR;P3PJUH+;_XP*
MO,MQEHB4"[S,82LW"9XJ194190%G_5:HUS^'UARV@*8BC,JH1J7)(PLZB5?*<
M+*OMO?EZ!+/)T!QK;W;1Y"&I!SI2")L@!+!%\$9SRKN R6#IU@"6ZG@KB*OR
MZ3Y*OZ6E-.T.WG30TIUF=&0\$.6H(M7OD5,=UB3>5#7 ACZS+6HRP1B*(>S;K
M,^Y6ZJE6.90T3^A/_\$;&%CG=K<9KK'XCK!/LG#C:O8Q#E-E!\$G^L82,@%,T MM3-
!@5)B!1"(4T+LNH;_!ZW)?U9N57W%1!ZG!'"P3!PPLT4*!'";,S)!4J MGS@(0L&-
PX<"JO;_"\$*)_A\$[S_%T)<84IVP!JHT!37_D1%1R9<1!_@3_"7X
MV6!P%N.8_1R9V39>RGU0HNF!6-
(RQYEE29A!T)=^@'KGVH4@%N'0TGB+W8IU7WEB">K'+3=N?@+;);6 U=M);R
@C%Z%5?'OT@\$8MYJ9 M\$PYGOQ.6OWZ^,PO/A.M#0!P^GVS=A/..B-) "L8?
\$O600!JUZUNC*&.BJ*U. M87,M.T,B;-&!24))11R%RV!R+);6BTKO42>[3WW7PS8=Y2
EQKB77S9A8LH M,\$OK5_=\$=O94;174!OP!="9G>W!+N(1A*!=^4Y^N!)?!17CR8OX-?.?
=*B+7R MKO'CDZE>OC+=*A#LR_0B/N7&B(&*S)EPR!H# :7>7ZS::V!IT@UZ><="B81
MX1)!Q3!;OMS&&>_EY?@7H*1M0Y0D: _=%05*"?=:EU?U!O7.<!091:RKJ!02
MT!_%^J08HQ!J0VJ#JB!SB_<=.0.L^'.9FNTV)!_7'<6>\$KVFP;!Q6-/1<'60
MF+.;BS&E1E!9T;_V1O8SR;.\$=;8G1!^5!N(175+Q;_@A1F!ZLK^7^U=. MJ!?
QFI%E&+W/6'TQ@!&@%TN1"('!:%4H/XBSRD&D!O!M'UQ^86&OGIY9W,!')KJ!*-&V?N-
>H&E5#6,Z/ M7ZH^NQF^-!W!C>H43GZR!&14P7!%M\$K _A;_KTMP#!R2-
\$U/WU""WBV%/CS M%DY#HF!E M!K7X&0;_5G#BGT26#Z!3^_M6M-
X!;3#L,!\$X\$TJB,9H64&W&'E M%NKAY"/V:4.YL@VM7!P!QJVV(+FL"SQ6JAO=5BB:8_9,
(^T;'A-FH43MDC M\$ZUA38N>[!N(4!Z:A*K#@_ ^EG_MF;U.C>*!M!\$K7!QO!N?2Y)/P?
>_102N M<9XDU4 E"B,5(!<%;Z6A.(CEO2! M(X?Y'3!>V%CT!K?7\$9^%I_L")MA%T
MM6/C9"&Z^&HJ!C&;>JG!W?C&Y5F!F;C76I?+6G1PS6V,&3Y^&OQ(%A;Z,-U
M%.1.8B(?;T94\$C!GN9^JBS%VF3:CUM1J-/PJE;0\$3,TWI:U%(QS8XJ\$*GP6U
MX5A92W>/9*BQ!6B-WI.9B)!VOU-F@X1*H+OJHT"/-P_*!VXT2RW-"-S)!
M6/Z^,7Q6CR4>>NG)_+O21*\$ M%D%NC#P'MI8;*A,&8H1CFS!URF,9&<.E-2V!SW^_B?
3LV;.<.&M=I!S/3%2T M D*Y:&+.\$,> G=9:8Z%DQMM6/!5F4OU8JVGE8G<^5/'
MK0BW%_)SACSJ.7;L,0!N%EUV-O.L@6SNH58GHQ/BTB^,W!_4>V=80A"SRY
MI6K&WCK?@3B*9!_R04R*HH^\$!/?EA3>#C:G*D'0EA)7P!8OT5L66>^(KN(HMV
M5;A0T2H3=#S2_OIN8Y5;@0=/G--H*H>#IA>S^@2-EQEC?>/3;6(!^"J!^D:?

M*%X/QEB)UH0LM 8G?&=(PP:G?7>/<4;!ZM;@7"!;SS8!?=UIE\:/_SZ6K
MV\ZE=/X)T<>3V&ZR9:(=?8.LQ!\$N8D'HK_?D6 M(\$1>7GA!E(I#). (0H-U|=4_N4=(_?
M0MJ+ D5\MWG-+#!#EXX+ <6+S M\$:&5E;+ "WJ(7H)=T>
+XW)&%EU)KVGZ7Q>12&,+W-6GNVHK B)/#T34K8% M\":G7*FEFFP!&MZ>I&LQ/^;B?
+UHW!\MSI>A M+*=)H?UZ:5924<5;KXT!4D)O4817K@Z7N/5.MP\ST.>[*E@2V\K3
&C>A MP'?= E1H/H2^_M-83Q)/J6@A*F9Z MB\!P9GKZFJ5;/J*!_ZLOJ3!
("55).>F\K6&S\+;HJ? M)K0CXQK&S<9/6:FJC"N@U<\G!\^O%NWL?R3FH7)QU7-
G/W./^ZH>^E\0-@?L MI9*W;/HIZ*O?JG^:D&P!K<HD;P,HC\9_B>*Z\$*_XN?T6H4O?
=I\J8<JWJ^T%>*!!_SS4@MR""\E(H/SAQ?V9@#44L#P?T&0^J_7LCB%)71Z+>89LL'=
FU;XC-=;5-1%="/@!TV2"E' MX:G.O3 U4.!5_5_RXCUA
E/A.7\3K"2G452MY2;0J!*UM)+GE%C6>FE=D=I MJ)@I*SS@UQR\$RF0 N;@&'>GQFH1-
AQ@&!MS+(9:N6NI. M,Y +HN\%K&1>0\%X-N&CR);0/O0%\K?PE"0SF(D(0B#SPSLTQ
>:HNH&:WAC MF%:R&=F-E#'-Z%5"/SDZ\$CBV;FA\$LIJY^;68T 4ZJH\$*&X1H?
SS<@G@#T- M(%WZSJ<,*Y"2BEY\!KKVIN#4L^(\(!TR0;%/CGE^#.;8=/.-!917FRG612U)
M^"1A(H5EWOF2K"/^S#AD@#092BY0-_KZ/N726*\$9G9==R%BLYZ=[CYH*[*YG
M.H^U>A- KZDFJNX9R'4LRFELBIXT&R#,E+OX]
MTZ98*\$<"N0\PW7_:FW/8V;WI="K0L:BH%;FMD>=@V_OC+3;.@>:V,7DE&LY/;0^*!THW!
MUVGBN_#\$&FD&(B>B\GBP=LX.\#FZEL/%\$#ZDI#9R^H++?
K'L_7_WNZ46AUXOOIU#O'9Y@=?0?\$KW.22Z90\$ _N=X@ MRB_/F0\Y<|H\Q-
=.K0\9NH=A\!3KPW)LTT8 _KP<+N.R'T:S"#&N'?"!_1H4DO\>?DS-6
F=#FL&&W/;CE>7"EA:JJ^;JH84<_:6E\;HYL&Q;[4I=AGH-
I\$M9^4Z'"L"LAP"@!"H4CV;Q:0 MKU>6P*9R.6\X?O,3:AVT'GUE6@93TYIS2N4\G1^=?
BX9P//A;"(U:2N@V7\ M0M+OX1?R#X\00G\XF\ (G'=M;S^|F63IY'!9:Y_W^3%^%#Y2I%*
|D)Z%/CS M&FB2;9^Z!9@M!M8F/;#;O(^628\OKBD^A Z0?;\$%Z(XYO^H^"!;QP*|673%
MFF'0K(WVN8PX.=4>BG+2A\I9IK_X7EICCY1-VT@A7\%@|_)1VXL,^F\X'Z\$>V-
'6QC"O3R3\|SXX?;2Z686\T9/7Y>*# M<|Z/9#%:@M,%9\.;3Y=2EH2EQI6EQJ?
4HANQC7L);G!9%J*3&%>_%3A0 M*,&@QQ;QN:PM0"K'J\D26)1D^Y14Y JG&
I:5M,4H\$G0S"OV6C1_.L%/Z:G M-3%3DKY?;&H0?Z*NKK6!KS\Q=,6?&7HR=PJ2: ^)R:
I@'O>8DOOK+P+ MG3(I'Z\5R%L75)=I)?HN"#U0+SFZP' YOH1.D,W_/+L,TK--5?T;<*-
#MO@6(PH2RP\QD=IAB\]\$'4?Q@7YB"\$61!2FH'N MZ3*^E, ^<7 |, >=
R+40_:R5\$:@>O(0W3UUZ0VRM62;406"(4(IF^;)'9CD: MQQR/79O6G;E(M=*?AH=|JGZ-
C2,K2#:=|I5D:TPQ5ZS+RGF-SC|>='*ZK&G.0=TOVG'^RW"0:|3 M"S7\X-
'?:+G%=VO',W@TX)Q9G??\$<@ |RZP+.W6C.Q\$+8XZ(O.#FFO;24* M-
H#87>U2FKNT8^6E/&>SE_58U:). ^!J%4L#P\;GM'DZ*:S*\$F;MJTK_HGH
M2&9\$;:7CWL^A>VH'JM&.W9"CRXG;3S76VIT?GK0LF%D41T@|BR&%/0.#DC1;
MN.JSY9T%B7Y&(V*0\#Z.6\;1FRK,LM%R?OM. 2Q^A UK>Z;:4-=U2;EX.06
MK#7)B2XZ"/W_ZN\?+;F\|_A\$DRWQ>;G+3J,T,'4GQ^W_|W WP0ZXMH/831B
M\#K\|DBTAC<%00\FX?>0/X_5&MKJ.6VO_HU9%L85;)K/V9/"\$3N=UDGO=6(B_D5;V
/K0S.+E5SVYRH66D^1WY>.C>R&SS9RR./40)<\$F;T MWW/LVX?B,Z
.7'W7^M.J8XQ.3\480C)<9-V\ W"\|RRH2RVN(*|5F+E0IA8V
MU@_/>028WX0B!7!O+Z5^"|\|+=@K0-B6;=U=KI?T#X5-'WEOCGU?BR:APWD
MCB<<;GE&6JH7-CSZ\|D\#2,#\$^Q'*=0>EJ>^_MW8-22+N?OGN!Y!2<01RQ\;
M\U\B\J(@5A5\K\?;\$;I+|(X\$BAEY0KCK/*"N,@'UC+SY>=IJ" K MU8;V\$/Y#
|FD>HTOM>M3MW-GI@R:6CH(\C1\U#@*M'SV-|4'OQY^@;_R0\H
MLCZ/\$(6I^7RC<4R_I0:^5-U&<3+J+F\+GR*-C,/5XBK&I8*T/#LUF*)'5A5>Y\|H
<";PP9I\$M 5 MR\F|=):3UN0UC@YV)\
<2W=|_5J\;?"K>IX6P5\9@Z5^ZPQU:X_#TV8S)OJ#| M\+N\$;R\JP#'PA+H=S
M\1\$B\HJ^:KOA. _D?_A#O/&3W2;:>RXE?TA.PABB>!G"II;6""*_L"A&^7\K
MA/B?:^4A\|C8PH9H+8FED)R&%UIN\ N;8HXX&-6QQ%2XX)&)|P^PM
M8MW0QZY1Y2N.;J\3<,%ST)_6)\$-1AFQKBY2O\013_N'<3LSWN7GEG**J2 M2.=*&.1V?
0C-@ISK7S5AJ=^67QJ\$C GY\H+&XDZ5&MLY\$PI=OGK;.HH+2LB-M)X9HYJ'20/;
(6/@V28?8*).(NS,B+DB=>';QE0\|HFN&\VFG:R^*CR("2U?K MJ(X^W/+5;47'W*J: M2%|%
"(-?SD7E?@|>0T?G'!5+CE2\$GCUX!= X>L',@IO_#XZ@)TVSD4\|@1E
M:VX!S&_>;XFXG^N)_?CCMC!T\JGB9,#Q>!.C.J4+
M6K'51Z\ZNM^W_'A/ZGM#_.?;_|H/4_'UYQ:=A5R=|5Z43%VIXW@+;/
MREW/29NZ\H_HNC\5\1D2-|7>R'NWP\NEMN_LH(7DH0?=QUZ,GGYWHO_#Z;IG
ML0<.Q>Z:C3UI#X\$<^PNP9UO%GBJ.P. #XZP/@7\#L'J'^GQK2+4#?%+;+
MP0.,X\9OHV\34'#5:QQ& BJEVI(-M1E&^4R?>03;R,G*#HA!W1S0^H@/("D-) MU?

N<_IAT[*2%HI;^HR8;U=UW'7/&AZO])H4OU/=C!3N\I:(#(!/?C0N^4AJP(<'>=.=#ZU
MLJE18/L_C.?FK^!?M7OTOA:U\J2V\?*ORW_U#
K"Z&^';0%')!E22L%&ZI8"^O"C=BF4LA^M_U.WMFKZ^(_SOB8H&F\5?8K/?##JVZ>5?
1C@%>N\PT7Y=C+@!&DPKW2QR\RZ5L2_M>C3-Z)IDE(.20IU6?
XWR\YV=5PJL^-=^MUV-V\$A\I**0R@I'N4P"NL9%&7;!@=R6175I2^ZG>X47**'O
MREZFNK\+=GK7U\$#,IX\TS_@6P_AI'MG#8\@5%%P+Z&6_O
M\$#J=XA*5B,04J8NVO%/AZRR*X_J@O7LDVW_VPDOWOL@K/N?^9F='&B"D=^O
MSAD%#CGN_N'C"4\CCBS=*KY?>?_)Z1W5XG_2>#CB3L-"U^[MM4M)(!N=PW_MV5S?
D%<@W%WOX^@4Z1D#GA6)HK_X7+LA=CO&AJJL%P\A7&@@C"6!.\$Y+GXU
M#=%ZO*+8IC+8PBK**D8-N=5ARMPH9DJECK\$W/_Z5-M><9D"<I'DW;5X_VW_M
)>#BPH;=2>G6YX3'2(D/O=4^O_9/^K_7_7^?6,"MB?+4\$!#!!0(-%&*M3%I695)'BX\!;!0!
@_1:6UG-SUZ\S6?_R)G_^F@'\V\X9LV\XC_M=,>NKR*^WG\@N"N'AJ*/?
Q1V+3TA..G4ZY4PJ^VQ:YL6L;%Y.[J4?"WZZ5ECT_MC^O%M\ONE-
^MN%=YOZ:VKKZA\]_MO!D=&Y\GSW?E8_!_Z:_O"7&6'A?X;^+^_RO^_
:_L&C1PD46'^^(R6Y#ZX0#I_M18M7?6;NL'6OQ9&3CJL_/HJV9=7;SUNL_3TW0<{??
M#CY7S&C_-6N1#;A1_MV7\OL_O_H\C^,I#_)RXE8>E",WSS%MH3:
3L5VP9^O%+L6="K#<2GT>)1.Y/M1C6!=.\$!A?
3ZFH4@#4T\$1XJ/QA@0#IL(6>)U"6)2\W\$_7&L
M*;8H/KY_,P99'BHXV_'0M:PQP7P"QH1&CL"WID(N7L-=.B=JDQ_TD3X,5U+
M,I\H:%8W9Q\?JZ8+-/(DG>?I>M9\$D-TS5DC^FNDQ\$9;JX#DLF\2G@6ND
MNCD3(1@_=OW"-HGF9ZZ'B?!2BHR:"YE^E(38502BOKRI:KYY5R*B:#JFMNG
M0NWX9_K_G?M:_WFO^IYG^O^=JK_LU3_TV)X?)R\4I.C\9DH-\$0_KYMQZ?
#5BDHD0^A_M(R!"?P\$(-\$+;5RIVGJPINTJ8)!F*LKUV=_R(O!A>?I9?9
W^_A%F0B95R!U05IVZS6S"-^)(M_X;3Z30;4
J!M0&H/5.CD#&&#!K&=):)L#BV7@&QA,..^D4FAX:\$',S3UPW6_M0Y=C%X'/_
(+EXPW*T2SN"A"08>2?F*41Y)4)(Q\?2XR19HP>I;2+S\EEFX+MZ
:2I,QS\|MF1DH/X|D*=2\I+P%780EF^=JP%Y@(F,4-)*03JKE;I:%=9-CY
M\R|):CNER>'T*01)5:>#;VK.-_HCVK+W!0XEXDM1;V^LB9&://Q52U_*UJCS9M&5Q#N\I
M\6XV^IY8)*R(C8\=X/B11<_7D>_J301SW(*UX?N=1_9K^_T,I7<;HZYQ>K%:_MDN?
(^1;_/*(H3#W#,Q&L4P3N3!/!ANN^77,C0':F>.[2E#_1';#:(G4=T#)2
M3*\|>B0Q3A.4'I1.YV\$NIQY.UM)7CTMZ?/YK-)Z\$KK2S!"/C1F2M2%I+K(
M3M;YR)F;..P-D0WQCEJ\UIH,EC"IC1^Y'KCWX5JGMM8G_\$GHM0&4
M)OWUWSKO#H%'8Q&_K;OYS./J/1/G?9(@#HLU.>8"!J)!\3(1XE9*O/P7:
MU'0>K3'@HHEP@LRG>H\$;AGV<IQ"!/(B4A_G"5>.Q2VIH/#-U%A=/DSS8\Z-I
MX0.UY:'.5;)9T3G*D1\=?+I1C.A=WY%4E-
4"K5]*U\$W2NI3IWWQ8C6#!:B\\$,UDV':#R;J\#O7HH7H_SC_M'1&9G2R*O\?
9T3(X\8!RZ"9PDZ5\GWQ48R*<%JO6!=Y1V5...+KRR*Z3444\I
M=&OYV%POG>=W5M5QC00ZPPD8#)_CN;"FJ4LDM=T7WK^FR52UB@N2Q)F\OG%\$
MPJF_".G\;\$?H?9-X=I_IY_M^I&!>(!EO@,J#)XR.I_I6<^LYN@M5=*9@;
BGI_U<I_R.#S"FQO?/(Z\9908#5"J>J_MMI_4T\OV;EGLA"+.X+CDNVT'\$8A+1
JF\FID)"K)7JK+Y6R/N.NT"[&GP*R\5W7KYG+7?_M-
9M_M".0QC,0P1=>F&6,82<^IT\$HKCM;8DX\G.EU\I?&U=Q7\3R94G#^-&EYTM4)KH-
(8*!+_Q\#HCl&\6SM.?FMZW
M1QN:/R*UX.W%@.G"H6XM>8IO<.:^(-7&RX5YRJ).5H\50NPZ'FN'T.4VX;_K_M2
QQ0^G;"7?:H*#3YX./%0\$;;S=FAGFX,#HU^Q9;\%2.TJG>_MF-AUO!J3_MWUQP:3T^O-
+1;:_L_#;0)\$KR7/K2Z3\G4M@D8RG;H)N;&KV'T@?JHQ>NP?>_M0Q=C\4"SAK^,\$IY?
=VBVI"3IV*_6SBZZO\5LS=ZD@+*WZ+"G0LJ(-\$G"N\$M3WU_I*IK"B6K1SR#Q'K<+9Z:
*2,<*6NB3X?!)6W?HUO@2"G1_M^A"ZOY_B?YG66_HJG,9U\I_M;@?
RKN/3TR5J@>31W'0>/OT3XZU9HC)/_S>C-O,OC*J?P'*8(SDCFX%T1H?_MIO9\$GOJ?
F\GV/*VD2?R1G:JEX\$H:2U321#X1_S&>=C;89K#G_8\$IXV.X?
M!^>Q">T>XML_+Z\$X\%S8!+4%IY#_NO@VB3)3?Z*^I@E/DZ*8?HKPM*E3AHST
MZO_YMV65J\4BNY)V<=W_MU_\$?C<4"82G"7L9-GBYA)@(ZIL0@:8NAFJJ\J%\$OM*"
<6\$X\5T19_(6LT_M&TZ@,!6UEU^XU?,9Q2YVT6=38-
^E^O'HAAH;FG<0DR=F9>D#O;V=!SNF0R_M!ZW
E@P9OD;W&QMQLVJ;W(S5SX2V@""DE7L+6*CKRRE\E**G7F4RD2WLB
M4R.Q'=DFF+_(.PN8+0W\+^<0GC-&?S0/#S-I^MZVTW?=N
M5\4.'9HxD)IVIBPO&:I0#=/C,HZF+XH\D-J0NI?B/MSF*:4X_M>LK\=B/_O'OY*Z%V.W2-
Q.<2.1N!A8E@D8120#C;."UU!7%P5\I_WBL8N@BB_M6\FV?4=Z1-Z:>RGC5&=VR;I';):?Y-

RUHU<0-9CB717LN?O2<%BOJDFTS<87 MW?3&AGJ>.(#L20
46EWV&A: ^<0FJY9B2N@CVRA?I ML:/FL@|ZD=@IKUIH5UL;CA5CEX)POT* <|?
S?|G"TA1- 3-H ?FQ>5EPV-| M#H|-%6X"!A41*O@XQ#J6*2W- IZKJ
|C26FPA'54,*G5<>)13IT@5DS9)S M2C\#>S76PDOCL?G/%P#SY24J>YZIA<|X!/?KYT>?
4F)O\$O _|J#; _>=' M=|YYGX.8|R/ .HYUT1K(TWA*%N\$.|<(INTCO VA(D59U!?
K.\$F<|:|907PSP MU+&6)XU\VN-/S(87L)!7H=%!>\$-X(8ZC.28F*JG?MJ#%WNE-CET
M:|'N@9G5+U.,D71H=MV'JM9(P'H(74946Z".=/UWB'#Z,|.623@Z,U#X52"6V'/OX@'|,1774
#=L51\$(|8E> MN;\$@X^1RBH^BGO#1NUK|94XF9R
VC9)CJF45;JXMR7I"%E'(3FA8<)\E|!' M/749GPJ=\$6RUQ92KG00<,)YL&B<%B2=3K?
47HF())Y|D'2IJ:OHPHEJR:: M_A@IJWR-W=ACMGW9_WS\$VAB^,!&>!2-\$8Y%
668B1*5KC>G/V0%3.A-AS9R, MIH^%DOA&G\$#?|@O:' 2.7C|Q8WJ<04R6 HDL> _ ^
QA;V3=OQ|052_4/?P> MN#'*6><;8J*91:X7YX_Q<=(?:MX-
GTYMQIXG:IY!QQ@7H^H'Q%>??GDC6!1S MGWW_+6-
##93T.NF;ONMO/C\$1'IXH,EXW7J^ OC5F&MRFG 5#M"\$H'OL5^|5 M@:
|!7AB\YLFOJ%U_9!1,J<9PN?0G*G@|+?PI%+--QNO)"L6YZ\$*V7\$,,|M)3 M>J9PK:B\$-
!4775HE|E0G^KWQ^0TF@BO7+3\$@5=G((W.|*L.*G ,I#^O4/J5R
MF\$LS*NM"*Y"D1N|1%M?R|!:(OZSCXDT|)=|B^ _@P'L%VB
M(S@|(D0S'L,X1|Y=4)\Y6N'LZEWD/ZVZ*YT^)+. ^LR|S)V?:2DH@Y9 M7,XJN%;|4*(3N+\$+
(J^,9.SNW@K_ \$O|@&=H)M0U+X+!NOLJ>2D;M/V3_@T, MH|3TO%(W<%) -LN5|:KQ)
<53'K)Z+0EC9?C,+V H9UQ|6R|KN)#Z:<+U;KJF: MI#DGE:Y 3I0?
J>@B9B:CM)M)\S^'ES,FTK+_8<;,"#3|(R|(|X%J
M\$^\$XXS(WF(+Q#L*3M6;2LB=|M'VFSI,L&6|0N>|HL>(X=VE2>(:68.#:
M'T3_UB_RAM151"MF(/_2ACJ|C;Y>8<1=2U|LO/FYIMQ(^14UH6C_9|E@A68)18=/
+8;/'J4C9&'O7\$1?|L-6VAJU&XFIS-M0)M&L804UV1H*5UM|\$OA\$O%5KA9?)+\$OV
M,:G41%@V+|= (P-"7Z'LIGR?=QT.F_HY&H!QBVG.W&IEFZTE=/'\80CCI MM,=>YRE.-
|X?KR|60LXX4BH|+EO!W>M&%G(IH!C|BTQLS|839N:15V>Y*RL M?
U&O_6#UB*)#FG#O#K%G'R6@DOGC,X^BC,0'&7B/FJNX"DG-3!L+K"*CRT8U
MME+DCGCJX| *N*JU";MVDW%8?G^R
M(78|*+K;K0Y>DU#8=" .8X/|@;R|%U_I3;GB,&'0DX,O4S;01+WP@M6@FSF.C
M4D&6C8XV5.,%/S 1|-\$CM|B?2&-Q2^HFW|ONZK"L2.)ZBOOJQM_HQ?|HB/D M4:
(%8_1X38OG(<7:RXG%U(J4)#,A7BCVB.2RB?"M &PFZVA3"^&2#N03QE"7
M#,+K^X1P:"82WE%=/(:#QS)-P2^0L1 "GDQ'0|W4CZ|J2CF(Y^DNZV!OFT
M(7G/H.=%'(>U;Q'O _|T|_!D2 _|HAY_K79_JVPIL> MW^8DP9W36|LX'?
K%"F|QW7U=/&66.@Q9^E'-LYS#:F MN5"*V;K!+>|=,|Y6^U|KFF*EVA;=-?(-H?L*A|
|O*NN;HM5M?&|@-HP\$6C,9 MC8RA0W_|&:HO:4Y(_?4<"2_WM@X|!"8Q@|H|Q>
|8,U+CS-1:A*S|!\$SD&?;9 M(F&|%|2+)D"VV#1)O,E!4DN;F^0|H1W<\$?G+@*
M|N|NG;|SHW-9XM*1%7U+UP4SYIH|5'6XP.C&K%AXC>VG7OLW5\FU07V1|/W4I\$GD)
<^<|<;<9AZWGZUSV2+K,=0&9 M\$?UBGM>)19^_MOA^4AT66;H-\$"M> _&;"J-_Z#%
MTX=NS|D|2"!34V4BV+)=|\$_+<4CRN\$ UBCNQX;1W#B;H!C7D"S^3Z+5FLR*Y+
M%U|V6/4(M@,51T_&^90602O/*,X4"R|J2/'^B/|@+ WA7M*FR&8LDZLN,FAB%
MC&2&.JM(U'FA_GN@@K0;&?61C"+ M8J1,<>86S52-Q07<,<+;Z7#Z'"&N!.|VK 10?
_!NCCXXZ6&COXER_M&&^S S<41F.#25*ZFS+JU!?!?(TI7V?A&A-
)/V6^3XS&'|+*S%G_6(DV#|SL,_%\$QA6CP M=>I/|DONMIX=UKLRU60|&=I/|
|:EW5\$|L,O?/5(|DNDE"V,X,0/#|W.^>XPX M2?(YCG%>ET36)|7)UIKN|_|
5(Q34'QA^(U1L|((ZXS,T)|\$E@7&;0>@1R MF8_9G"9^!^GB?.\$U M-
=VZ^SX|^0/9"*KK\$PI"X.FZYU7,'X;#DLNC8F/,++\$ _>H&R!6S1QUPK/H: M&XEDN%_|
4WS&P./*HZHI*DKI"G(L:='|QP&<|H1F>0|P|X.6H|^ _?
PB=6G!|@E2))4LEL3GIVK69;\$J0JNZJSF|>SDVAJ0)CP6|W_3&F?OL2PZ3 M'YC?
_W/:Z7.=:>|:B_4% -HI9Q>3|NN4!RXJ*/#?|3|77 MO;%=T?
WQ|D9774|P37VU@,F=0# 'LI^Y"FR1|1K5\$6K|H2@DV%S M6J)< UUMY%62.*%66+;X-
&:)B|YP'U.LH*.DW(|?/I.NYO|1&|,%#&8FKRP M?&(D>XR%4 MS^+RHW-D%Q^73|H|K
MA9QNV,2,LLW3D1S! M|0%_IFH9#O!UQ/9NVQCV47GAF=0
E5W<@+ #^S@!G@YEA%7Z6;&C|5.HS152
M9T&|!6V,3)6|GYM*R9"KS*%XR1!)"KF*%F:L\$|Y.C\$J5"LZ|^A3)R9WDEQ_CO8CE+G
MIXJ)/Q|CJ=%@>9G@|KW-"6\$+1'B!N(E#3X^N4/TP_#9(J;%CR^!/? U|55 MM/OL>|
<<9LDV5(2M8+<^4K@'F=^:T.D,Y4&Q|<+7-#@O'#X9&I3PP#7M00N
MW/FH9'|SKS;01;1^'%C1U(CSX|L9LJC:P('GS*&OL-D^>7@/)0X_PZ&ZD#D
M\$Q,AB^H7@#Q|6=3:+\$IKPKGE(UAWTV-IH)8|= .723=(=!KQ--1P%@0T5J'V) M/A?

\$&\$Z!="GD@2ODK\B.'\$J0*\$& UC(SA=+ KV?TQ M,IA7-;16HG Z<,'V"
<@I1S\,F87)^>>\$HRBOO.MONTFH#ST/&983H^,QTY MVL%PIF--OY#(6?SP*?
\$V_FMC3TUX5'SU?@C;*&*X\DP3MF@="M>@7" MT(JT"#8I8.Q\AN\$*)?D;AJA#D[I>4-
9'LZ#%/=RW'-MAM_)>U_O\IDGF?L2, M&KS3MTL#8F8?:Z&=3QXG03P4\
QRNFS6".GFL40XDV+,%V17(+ MT"5U,4SH^"<|D |XB(/#+WHE_Y.+?1 T&>|DEU??
@/\$|^TA^5;M,8N0T(O MH@=.:G/H01H6M(/?N;FOAIC?D\|@;/'!FPS9R=PP2LX!8P;'-
FI'9AWBU' M2=9(^ W|4%I_ 2XRA4;|3"6"PD'(BFT|K?BN|C&R!7YS|0\$|?5|_77-ZHC|S
M_,BJ_K*G>;O|: 58T7YLGPO^P>H07,16XF#&=E6.AVN&M_3D M;UN/IF@SH@|V.S.9E|
:;%PW7%/A#XXIJ?"FQ)I &W:6V!-+R\$UV*|F|QG'|YL M\6/EQ|J#-
CA/L|&8X@3|ZJ@|F+P7>)Z|^0J- (Q4Q'SE75
M+N!PC'SO6FZO:|SY-,@^NR@*A#S\$GG, !NE'*D?81:\$O-|3"!AN*UT#&+!J
MRY,>4>SQM7W)(GIR%3OUP":7U%@GNOTQJ\$UN/HQ9"PS|5-LEL2QP#J/1HU
M6;L'G,7-#EXRQ#R554HJ(F@C76QB=;K-9.;>#4?"M/\$\GQ2:)?MSQM(\$B95_
MS"E98/#;OP&7R@+O7M6,4;|/NY_G^%R@##?B=D> SZ&|5R%"@Z=P87O(8OV
MW#X=5@_S|N;09"N2|B2/1;##M!X=9*7LU,|?V#O&&TO9N3ZX;SABK|ITQZH
M7Z1|^UC=|3KF.U%\34M=&'1_9A\$ 4+X2J?_ B5N1IH%PO5AX)2>H2SKH&X M P8:*.
6H6NQ(((\$A5.,NO\$1U->)EE"|_4EMKGCET)1"Y'U392*P#K)W*&3/ M|<0:
<=1D2V5YJ: P|UQWU!(S| M;-Y7/*TD7^S!<5!PR)HR71V\MF7V;0M34|/+ =9|X,R=3?
\$JT#7UPZ'#"R4G? MB6E6(E6%KN@R?(DZ(1:H(R_"6/+>1,@MM63QN8N!
N%W!LZU#7\$B;H8B'U,| M)L+A/Y+%GDKV1TGA6J:
8!;I*V9DOZ5\$^=7U3(O"/QFK_:TS|>1WC=^0%#>@ MOS>B;C'W)EP|49=1?>" V/,W?
U6N|V%VZ?DYVY\$|_YA/2QTB|5^)^9'>1FG1 MV/L?
OMZ&G,.6_3WNP(SAY\$W#YWG=ZR/GWRO^PFU1&UX"ZDN"!C+JV(5916J\$
MP)N..C(U%CD8%5W3AP4FXI;J\$M46#7KFO5?!"S/H: M3K=M8 :>"4?
R9Z83X3PU(^|)%R3+Q)V"580>|.P2L16K;L(^NC)SU9UD=Y@2! MW+.X-+-C"R)ZWT|
:;#@PV>;,7=,|FW@KMRY|N.=LTEH|^2*I?E1.5Z;KS|& M02OIPBJ6F,>Q5?
3;3?|L,.5'^ER| J\$U_X7YWLW^9:(|B&4.//4)(%7G|KT% M:>.PJNJ8F9)!=*ND667UZX|
<2&TL2B5M@|HPNVI)7J|U_HR> M4O/-V)'ML60<.SP/(20YS8Z=NJ.FUY^JAA=C+8 M?+!
|1|RQOX|UE_=M.+XA_FGA2/N++P*|_25.?Q94JVE@O1#7M8907|/)LOF*
M5J(3QPD<58^+H+L),R=O)4CLN6|H-D1?5@VL|_4???KC8%=4"RRNQG,V9G\$H
MPS4XP|HG=|=.%YXT<.!7DB=>)|V,ACFI9%B|SS=>\$V_@.,+Q>0CL8+@D%5,%
MY2!|7NBQOA:'X2L%-SNKD|XA|=-0ETZUB=#>C7-"6YTR%%?4RSDT6)"#>7*(MP,)
G*0MX:3<'VN(C/4&)^^Q9|2A4|UJFNLSC<|9;6 AWR*/XUD5,;U?%S_
M),S|V,|QOIZ&)T|ZZYX^P&OG_YO+1|8LG&|&N0.,VOA/AT3N@_S"N_I'@72=F(S8*H3C5!1
|W"V=R6.0 MN\$YH(/+FJ@YWY4&==3C-Y;Q\$_S|BN.B_8B
MY"!;|K.'T4R|>40|3KMYZWYL,#&Z!+9|AT)>HZ4*9Y I/*H)87?K
MC^>BWC09M#PAUNJ10J(Q1|Z._1RYD*@4Y,S430>>%6W6V
1|C1P0\$IH*HL@;E..S/%5|,NDQRCVZ-|K-(^=C' M@*?C3=M_0#YT")|8+%CF/#>R
:;\$MTH0O\(&BV%EOZU,J|L,B"BDZZYB@'=\$%=|?3DNNK!2"8I6<"L:2^ M<6K8\$|V-
@XDKK_5YB/X8KGI;T(ZS|@>GBMUAT=E+ LT"DATT!39/JFP(Z\$N MK-LN 7(|_OP-W/>W|
(C->+4\$?< M/A^HF,IE!./@4G:2\$RW EO-)H@|V%V/>3^QE@%)7XAMHIE:XY!BY5H=(%
ME|'\$4=/2G39W|^<+P;,>%M,LPR?3M+@
M)*JV^J(\$%8FZC.GA"_H,OIB,9BMV8H=|A33P*ME%G;\$!8"BIO^FG_H%8&UY
M.27TZG^;0KIH!U(C>-H_@|LKWVWG*O:E?X&2.C>H|7\$_.(Y:R6RF1D2PA M=;8*C|J
MY':EX0:); XKFF <^KFF,=G/3/3#B|Z=PV<-H;)SZ21,F=W%D|*TWSNWC4|A9=>32H.
MLU9X3G"9J:XL78Z7Y20G /@C1,S*4BN|2*N+GS8S>)^IT<0S)IV-R0>.L0) M!-:;
|N4QH.^K=S2"|2^J*NQ%/, "JFA^CE'R_) '&MUU|H!4:2&|SH.)T;Q
M+YZN#E7AL@U21NA"I_<:/L=&H!JH\$|IEV(G2X4:U"OVXBL3|/)9MD#"7'67|0|_E+%/C
IQ0V^/|&@1/=V=R+!X>_(UM(DCWC!<3|^M?+XQ\$UBA<7K)_Z-XO MV#EPM):
XG!NL.%VE>(%FEDHVFXP|Q+-S|K1J;NT9+XR0',2,\$|H5+E|X>I M(?-\$W&3,<
+*NA\$K1<>GG#U/B|LGM_3&%T4).FJ8R@+EXP'_L)Y39|R,#_) M'GVX|^Q_-0N X\$KC6)-
<-;+VVE6W\&T3I83Z@UC+7'6I8#4&!.BKPZP275
MAGJ|Q:28ACQLUM)7LINW,7(#!Q|K|QWZY.)5@YU9#_UCOI*V3Y>-!R@..*"6
MNF:&/=1&A=23P|U7:/6D\U1/X*L1YDJ2;IXP8YD;>9@N545_3S0:HI
M^|T.6"|J\$O+;|'\$D0^=Y|O>O>>/&9\F/O8A*_|Y64|3?9K%@DI2A:F/+7EL 9 MG@
.\$RR&VG9*U/TS0R=TV^%C-R#&O@^W+%F(@|'|QIH%T8D5,LS|:3|:@.BT
M+R1:P<7O8T.(PZPZ*"0N2!%,QSLP+QW^@GEI=%R|X??O\$+=4"303S|F| MI|I>-
F(">&_NQ1-SW)ORS@|V%..L5N3OT<@_R(5'-+M"HYBMBG| M& &8N^

:J(8LCW&4JQJ|C?Z^1=+O^R'ONOVZ+Z7R%C.)23M.OKJ(AE%RA&\$ MMG< BG=
L:OD6&Y\$011'ES#GG^S^V+U|XUZC? 0(.5*AME43|#TD#"75B2FFU M%AI M:HH85JN
0!/:C&L9,#NC| 0CWANVJ%#@5IDLFAJ#L.6-^PA>I1=)E OP9_P|=Z
M<7HF|@3UI&F^X0=.- (IAWBD16B&AOBJ5B|QEM=)SHUK5)GB98A ZAZ\$2^5K
M<(":+E-EDVHCY7NSYB1!-OH5,;-- FF4|AMD4R0*W<2T'JW|?-.!&>2,#Z
MT:FG|S"EY%'1=*3!>RRMO#1/R|B%'J-' "2+B::?:K?>>05^>W4CHLV1&1\$M
M/7G*^2(ENB*AZ^&N9-;)|YO"8I= _5+SG:B_ UV>SH.^L= NIW>"J7'D5"?- _33#
M#MTSP"4Q)4NYSNS./35Y:@&/NPI\$Q|*LCO#4|L)-->LJ\$1=MP,7ZR1R6R(*I MBXDZ4-#*
(/I76X@N*AW\$*#P|>7&DEGRJP@H::A M
.G2G* @W|!H3U,>W"YS9!>K8+%V,|6%0H2\$N57+6@:PJZ 1;U986/OVF69V_
M:2X,D5Q,|7&=E#>D^:7-|G+|NEKL)NP.6UK@5&+^'7? 1* @-O6@B""7G"6H\$ M>=1
#AD63)-TQ&%;)S48CFSC+P.24'B4+TK5T.TX2X#|G41EQ;G3/DEO.G2= M&|EB-
_90BD|0.V,X|"\$O^=8SJ/K5N-ZE*?FYVN(BU,:\$6% NU!"*NM#TA _|B M#AX?"408F?
CD\$NQ'EK-C)2A|&Z/M49L'VO.E9725/C\$S9V3P48 M0O D^M6Y.^H3>JCK.#0DB),_|
|AS5,5Y*%Z2'PBU|Y>Q3|2|,=PY'|/SP^S5 MD_L0EVR4D7Y|PF=-(_R>NKJFI:9/%%V19
>:7C'7S:'.//T2(#"X06UG3(1C M9+!A =M3SB4;+W.,&4*Q+H&#F,KN;AUQ'>3L-
A\$(18*L1LP,YO/)*/.F'.O MN#I1|_OH.^:0V=E\$R/E3SP|?X(1D5+.WOM7TZWH*|K?
C&3\$1V%|"8"/>)BYZ M=V,.)35V4|MB%0/I,\$%,IO,(EH*OJ0+FV>L%|.M|!#I<._1Y8N
M|8N'^=FBM1ZU|Q/TV*IFA;#>)_4K."|;|HQ'?)YG;GA#&)&6J8N!|@WFT|KEB;
MH"NXFEH&8V!|8""UOD#60|G:7;8JHEBZ@TX%:_^O:)0)#0,QOBPTD20-TJL
M.3|HZ5PEM?SAI-@9YE|3VIQX^V)5%=,%WE')N"V DSM11R|!.%R!..@KU>%->
MX*&KP&>W\$DF-X-NC9WN.8+|M,2^LHZ;9A,!M5=F(OMN,.ACV'RN|,|&(
M#|Y|WAV+|>A+2?0CFDDKJ|NR*>OL.3^|53PJT0|.?.J6^04B#H\$Z|&TUM)
M>%5HB3AZOE)H:)=J;WGUK<2YJ+|=/?2+F-8I>5GI'SZ|ON:E:
MPWKN8."O2JQ10|0;PQ8T&RN.8ZLX6Q!!*_T45P+:=9 L@V;MH=D"8-
290K,/ #D(R%*+|/N7B(F*7WPSXXE0K;8'8 M&X7
K%KESJ0|3IZ3J=R|FS|3>&>6;I<@(' +7,D#QG#X|YDF%|N#/.751&|.L MQ(F+4+?
C.2P=J+7!JG\$FM^#"=>P>%O@^0XF<|4DB29H:|.G%#
M)=JK\$UPD\$3\$2(&DKVJ>)|L"!CCJ|34HTW^\$UB)3-TR| ^T>_PQD38#<_D3@OK
MF'^|7Y*RI,Z='&RO/|T|3K5'L2V)?7LG|VHVVM<&,"FB3H)V""E&1EN)9%
MA\$0&6&|B3%L8@I-H1+|\$|Z(R"4W-GU_1EW|J-|NG#%6^77& G|/LG9;&!DA"N
M#1)F_!|6|L23|?.. "5SK&CA>FN\$|*0L|D*6FVQ_!>|3\$8VVF6C|VA#+MM:>
MR=1)EK"+O@9.I.RWZG|Q2O9?|U463.X2Y"9BD?M O)XYR'5|^E+LL/%&16+4
M)6.S|DR9QF?3Z-?U6&N=2,|X6M.W<0N%J2|V\$:|)4;RP\$EV,/T+ON^!O)?V| M)<^Z|4S?
D|1G0)CMC1Y)4HRCBPU1NM//C.*|9:>61;#.?\$(<JFD/K|PDPM
M.%3&+I(SM:|NU.6*O.P\$HHKGR)^+IG)!^-VU1M@S8=Z,))Y)L PJDXL_@
MMYG:F2632O(ED9>VVB4,|)31UY M#Q(:#RBSB^XGS@4X|V;ERUS.%#QG^?WPJ<6?
FW&)|5@7|LD%L9B(CF0CH!A-A M.,5XOPJ9PROS|>'
M|XNLQAAFXL#\$P.Q*7370ZJ@XU31N4|T_)82%Y_JUOU4AVJ)KCCLT,4CY*[6)^)|%AUO?
_7X:1- M|NBEGXG@GN |5OG| |76;Q"Y HD|/I^|R9U@&MT|*>ECHRCQXWS:F'6\$B+)HW
M%D(L&EC7(6\$:#K_9^CC\$2TX\$81P2_'@C9ZMNC+(6X7T)&.G:5V|YE0'+2C^I
M1>:DT3,+P"&T Z Y3IW5=[R>|L)6;&N"%;GU-|C2J|USY|BL MPD\$|=UM::%R"? 2?+AR-
0L\$<(76I7U&J=). "6PXJY#0=H| Q*(CV!%S.C#NVDKF8L0:GB70'JH7|6-Y0?40=;=
|AV)6Y*%B85|62%S&?@ M20KZ#^|E>(%FPPK<|?-(.0+K=\$67):SN<|\$\$6-
%F\$Z!F2547/2C(|LGRXYS% M1XD7*8XZ%Y!UY/8(9S.(J/#*)GONCGF#
(AWK\$M4|863%P!0GK#JZ!|?NIX2K5 M G4?,-
"P7L%R2%U\$JQ7F/1#9D&2,91P|,*P1KN2^_) /S40|E:X9FQNI@\$LT2 M3=3,V(&^T!
|A'_UH&%%ZPUL^IR_F%|>6^S_7%QRYGYB67?=106O^0(Y%*%XO-M.JC-\$_? U
_7W\$YB^"XTT")CM%M0+, ^"PS#>;K4|^(-;&&'!QEP)>BF\$WV|!_ZZ_?*<
M!Q|>*GM>1HSJ*K\$>>_M1PY73>:4Z|:@_O0PJK|4U-J7?*H|)2 M,V1'I4YH-X\$M&DB)|=
(,9-_0/'>1_Q@->!UGBD|<1P58:Z_,@D,9X N%=IND M09\$M7@=(6SV|C)5^_
*N))HMVE2M|="^BOXKXB.BI<)>D:O+!<@L|>+LQ>WW?^R",F D8|*A48\$=3EPJ@J=
(|2U|D4I&?HYP_L*M3&:^@XVU39< M|>\$|.8K>-A;0\$OA6XQ+X=%:CM!NB_84UE"X-
G)D>-FP! GD:N3,XP|F,A.PI|&-49|3I2H76QG,;XM/RXNZ@JWES| M!;J7?F1|>"P94
M@\$K4|J0">W0+7F9IG(|?4DYJDIG:2*FH_Z.0KP:N(4-/B"C='6RIW:+L5C5 M&CGBW3-
=|>.|+/_D, B1-5)),5|YGTWQ#O>8^%,94/_GF|O'&^!L"6AAIU0 M&QUO#
8<*LSWL##>\$W*=L%Z2#6;%?5%4V*4CNW%V/08T=?=0.S%+;-5'=7G-
M606'9GVD2.9X(WGM5!NX^Z+HY"EA|%!B5(5,Y0&Z.KUDN HZ35R.*+%Y3UZ\$ MA4)M?

TB68"XH#IL7"C@DQ\$6J(K#L:8\$*N60H||=J;+ID';EVFP>F4\YC8,4 M\Y.\$"-
MMZX(83D+M26O/?UOC>&IJOA\$?N: ^O\4(A- #\1980!W_D+ZSA, M\$(HT8I81!O/7'\$-
QT\$NYRKG4^-/M'CB!8WO:'U>\$H2XH*A+N9L\|D%3 M8%W'IC,U+:ILW%,W-
l87SX4,J.O\$&=H>NJ'#S\T"V?M\I"=#%TF TJ@=Q5U! M+@3O8V5B\B!=\^%B^G 4V&7X-
-&# &Y4@.CH1XJU..E*:@;9:'GX&F?JAM MN+J7\$A%W)TD9>^O>F.L/H??
QDLXO8"B'W?X1R=%?D\$LB41*1O,XH\$X%?#ZU\$USP&"ZM!A!Q;5C@:G>RK
M.9QV!%0^2&@*R,1<7K'#VHHM>*?YQ/&F\$JD%4;\$,7/IOD\1M&\$+?>M37)P> MYQ*P?
L9B-\$Q'LD%#C#>Y=ESYR%KC;?\$JMMFO'LYV#9_-'<.,<\$CT\\$.R:5346
MGIRB<2,Z<+X<0#W5+1%[>M53L9K ^0TC,A>)N)-;0 M&:7L8\X5;3-DF-UQ3=L)NS
22J#1)^K'=?G35CB"@[HUI9Y\;*YCJ' M\M(E9L(5O4,GDK)L.,L?,A.C0X86=PKBKX;?
KMM8^5=9M/W%EH(=:C5J5!'
M"\S*ZQ97RK"@6B=\$D5#^5,S*VQ"\$GC'R*1DZ@3E@RM)FSF%VF JS-I9P_=% MP\$?
B72.PU39 J-!NA MI0I\$^3TISW539O(MT!4+4P7: M&8?&^:61?_V
+SVI%@5K!+.N ^OYOO_F^%>/D\5PZRA3FS73 XT)<(&2/-I*IU+_ ^/AC?X34C^%DB8
F4)9KT/2F*<8SP*19=Y:6FM,PN3H-J.:R=U MR;[Z%<:*]Y.0?
1A<&+,*9*JB79/UUPIN#=1 -TI98PRT?4G >"F8MUPR>O/ MH_-7O^G\$RI3
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M1"0##64A@[5;[T;4']:#"7M%/"^:U2^J;[1!:@BR: W?%A(? -/J:V<%UJ*MKDM M7K. &QY/
M.U-Y(D4E\$6 N.+K4ZA4X645QOI 8;XEI#8]-IUS%XT#IH;(1-I*W#=V;H> MO\7S8V
M'W>_INSPA&OI+?^6:S>::N\]?QA_Y=-?;S;L7+0PJA)\WK /^S7N4.?T"OBC MVS5E7X
6V)#4S%O_0 7_7>V;[IO]@L(EOR\8H' Z1:HG%E:BL+Q44\|\$?KK MUO_%WGM-
=FUZZ+Q0T5!P\$*1&D5ZE5Y\$|ED 0\$!::%\$0&I\$0\$2"A\$1%>E.J M@H (B-1(EQHA
41Z%Y"21*1+(A!>2>'& ^XSQMGC ^ZX_SGW\W.W>;:@S5@
MD;[XWK76G.MYYLJ<[S5/Z)L68:90 =5U'U20\O3KM%HPN8^2%T=C;N)ZH-L M\X?P)
(W?Y?;^!H\UZ.+W.+(-X)L!%!W%9TL\O@X;[MD8?W03@L>7X#WMS4?S0_A3;|^T=
<6(KF&TCML'&8F2 MA?!=!W*P_F&=Z>[/->6-^5P9YQWB\7B:UL:\$.)\HKA/1S@?^&_3?
LOV' #?MO MV' _# AOVW\#_R\!>@TV'4.%M3?
5552QB>7C.9<[H"MS+"TIQ^F@G8&=G=U)! MDSHQ05\5-
@H7F%[SP^4:);[8V\&BB\Z\^7_OIG";@V\V'_E.AL==L_YJ M7)OS9MORIY+)&#IO2/=>
<@1=E 8&KE"E*3SMV3FJ<&S" T@=3^=FTASD)!+I M\F+_1BL6EY\EP2\$*8?IF?
RFM^JAR?%/F4JU8Z@SOH'23X);O4<_!B RS8#H M_\$)CEBJXE4P-&%?
64.1A'IWTHMD\ (LV&"LGS3\233Z!&K)D#IY G:YD?(V!# M=1:Q F*\U4#J6\K9&-
'BE/.RB_A\|P/0=8(IKWN:2V^U 2=H' M(I'(^B664-JD9T\H%F^DZ)T@?;.U\FM-
H\F\COX"&X\W<&HA?F^=OLOCY M("I+7%;6%)ZN^9. !YE2 ?*IK8+I M'*
(%'\# +1D"O6\+3;^:;%[S). #6L_::0NMZE14/E\$ M+: A6"S1M7B.V?M_:SXQ+J+R+YW-
IV#J):SW)L,>5MWZ6\?%8+MM1U'3QUF M%&!W7%&?
_R'C#^C_RP^|B'^|&@@(-\$^Z>+)E\J_P; 3V7/_/^=|S_AYOWUY
M\4E590::L(H"&YEMQFK-8.; CJDWEDUNQ'ERMI^:_.6"-PNYM\L5+Z'@L"# MD/,?
N'BI6T8*=PX8L6=M@^/G19D\2#;R&J*8Q('.<"\$XC<0MJNOKD(>+2GM.
M_DB9N3Q4<7+);7+SA.J&QYN5R=U+;-=EZZP+BGG%Y/49&B'8W?
PUXNJ)P6j:^[PPT6C2R+[*])*WJ2**=!T*VBCH?Z
M3&0E0._+T*"5K&.UIA%@3\97!X((W4<"-1WP2(? "RG\7KC&-D\93^JM/!*(
M'!_Z4(XQ^8_?5=,%:O\$+WB9U\B8Z41JNYP,7\VKG(MYANS&C_ ^T%C-^J0U M2-
=M8QW BSM@|LA\K3\#8!^4F <\$ (X/W0;VK%%UY&IBFI;0/>GV,KW9RM5:O M
B/5, #/H#R-K,>X0_9D@_9!+=+W0\$/KHMS82XX2>BD*#F!!Y>ZM78JL_?T6U
M7WU@I%>JVMZQ):7W7\$;HO/,OSGI>9XCLSXM6@;Z(DUIRF2>CWEV92)7_/C1\99#KWL
MR!J=A11?N!K:8U W MR918Y=^H"RG:?
M\624#K:\$7PIWN\|TH\|S"U.%'PSI6*U/GH9(H?X#NO+7WE MD!3F!:GQ/;!O1RTQ\K()U-
P'O?.U27EHW!U\$!O,Q4\5.(BZ)& K\$?(C+I<"K
MNTN*\1+F;,*6VH;E2Q&?;U18L*=I%5AH==UR6OCUKJ.F%K8-IQ0WP!<-\$WO
M8@>@FP*^1"Y,F6GMRB90<^J4!>"/KSXVC"J>\$3JQ0V+MLJ4+SB3_<I'T5!|O M"Y-
M\FDZC0/K9^(TL'E+JT%N7/L .L2E42_G'T"=K3>_ =HK1\WDQT?C4%3 MVP>U*F
+J=FUH5F_+&-Y"7:J>4Z5+@\$QN*&L+"G5?D9L\!"*TL;:(C>@VR
MBD7CWW0G&CW4X9)M\5%M:S0M'.KPIJG:4+0-&R++3I!#':YE*9QJUA/+J0#

M,98DUR97E)+2;@@%|Y?%ZV>@KRVN VK2T8_F1-S5|T'V6|9\$68J^~Y,|>FN|
MFW1T0?,-8) I>OY*T|S;@)W4BFF,7/M6WL!N! A+'G62T=1R75|G-U|
ZX+N>J<0@&D3*@GAM8?(F0H|ITN>ZY4,_F?7S7 M_%?LXSRR(60JA# 974D
2C7R\$ML4QVNS*W1IMN-*FRV*KY9FB'O_9^7|UQTMYP5WQ|8G:*|^CP
V;:O_5@.0QB>P02;,%2,H5IY"\$* M|(U-JD@N^V^"P?KVPQT>5NE"<+7H?="OB-ZI
M9OEIZ,P7*/3+=/|5\$&'C+;(#9+|V%YT.TW('Z08RRKD&D|B;P!Q+Y&ZHQC|_(D MS=
<7%=-/0%2|DXSF5N>>A=%\$@E<*.GZ^%Q#/(RRHR19|LT.#B-,UOXD8V); M_-
P+ #)32|X\$&^Z'U|.00ON3NV&V;:0#/BGDS/Y|T"F680P 8/#B&
(ZL5QTFR'4T#F@G2R'Q.\$ M\$/CHPCF.\$EV;4Z4,XC9%\$49=QQ\$ "N-QSY+QH)3T/
NP\$O\$U|K+SVXD,+W0U MEH?J821CX1!.KE|S3=3-K&UGI%L9Q'?AL_4+* \$5G9R|.!
(|\$.Q490|LA M1V&Y*E#G?>IA|!A|?@0\$)I0:@SJ"SX*-K^W,CH?N@R&C2(/?0^7(%E@(
MQ=-9RWKROO>?D*#?2T|V/X'N&42>8:T9%|T(O=K!2/^|DBT&^R#IB^0(YB>M
M#=%|4|DGU>X?2_D<,WZ?^2@K |C;"IF/>| ^CR5P4=G;6A.4R)7|4L!^IEY
M,NF:,"&|C0?)TG@7R2TT070(67Q+,*"#W?P" TRN=>GIG|3|+|Z|!|&6W:
MP|6,GXD&1UP7X;J4KTQWBMT*G" 0N2/O_9L>)2G))|QR(%4ZE#(48HKC|U\$#
M|E|5|FCWG76L.G*<5*OXM0214Y&.3K0,'LZC"+T0CZX!KS>E#D=DH@,Y(FA
M!WNGR"\$UR;+U%('XR,|*V7X|"&)CO"FY7>F1%ETB*R-3)Q&?,3I=):).9.GM
M34!^'|2A01E8)76@C|BCGXB=&L|J5G?T!|4FR|&5_C<+82'(93TW!3SFT=
MW'58T"0C+I@/*Q,_2,W0K&|D,E&95/@^Z(D*/1RHI**D@952(_*5CA#SAGLK
M(55&&.3U:/9"88/"&H|8S4^5HI4>W(4-&ZTNT8ZA^ M?8R.%NAJW%%N4+|H\$-?P=1T)?
=18V=MA<^M.F5!HVUY MD7I:(TLK9ROERO6344(DR&(GI&*4N-|9EU(S.71QYO?
\$.2GBCI'"51?;JY MKN(3-C|7E!QU,991 O\$V_Z+E3+
(L!-8*BVX*OW=XN_K2_AG+,0^)|LD|7%
MV;P(CP|1M@ (A8O!|NV)*6#+M0JNXL(%Q|VCC"STPJN|ZMWUKB94!2'OD!\$) M
IZ*^08YP3RKV!#38G"(*T<6W854K MK_D=)I\$(.8'(C|E;MNE\$>RW^_
)=7ZFUORUIX2&TPYN#O.RCY'WSW7(|ANA M%|8^J"/O3?%3%UZ3*/>
(^O0\$2K9(9CR3EV)5D.7)2Y'=OIUE_|F*=-#+=%(MVJ3M%\$?-
D0ZG|H@/D@U3@;S%%+XY#_M@Q3T24:KO@|J.O=D*SD/Y\$|51CT% M5-
_,\$\$*=TV;|FYW86# W:UO"I@H6_*@1|3T7|;GS7,BS(90((C:"|EZ,P.#/
MXT0'6DD;PK@H90X RE"D^C9N|#XK1P#RI6H,< MHW.^1LQ M|(/\$6-
|JL,NGDL!_L(Y#KR@ZN|C8|PX&=.BFJM,=SP M!F%T,_7J-?
>|1R8;1_D|Y|1HC:SS" T,Z<|HOWKU8#UA'AV_19%BD6WF+H9
MC&C7H0P>I|DPQ^9/,06_T*7JL(-G!S4I2_71)YOYSDXU4|D(7:\$YTH!;)(
M%L=|FS*CD&KAY%PNS7G;UGK&|)M")|F:|G8.W7U|PF;IY:SC&*VN:"S%1K.
M|/"ZC=W;"P=9UGK9POR07Q|Y^J&YI+3QC/I^|DQ"JY3N?;@R>;4&MG8EM-
*OXN8;FJ!>J0^/DF7V0|;N0 UCR\$)W1/AA|E|< M9|Z_NU2D|X,|P7M:X\$?S@+?
^|V#U12.Z*O9WL-J0|#M8S<6.FV=ZE?VWSAIV
MOV/57U%L;+KW|J|I8R_KP|JN%A""=|*>K@WG0OW+_6V,-V#|BU8&_8|51
M\$;|CU6IC?X'LWUIK>* "GHIF)W0M:3"&>:"Q|D&4/QS#_B+!_H/^L%_Z'6%_MN?
IOO37^1OTWZK|1_XWZ;|1_H_X;|7|"ZE*ARK*BY8?!WZLJ5FV%|%+_|R% M1I64SCFN|
5'EE|1=9ISF>WAJBL_D>3BLWAMZ%|?(?5760G6|_PD4OSJ9U., M?6<>2M3=>3G-2|!-
EQ:ZO|E76)U|;3LP<790>L?%42W++3LHTE9GS.=:+_MX@\$L+6C*J%|;H?Z@(-
H%Y(&&AH8XXQ|*TH Q^8?;K2@)55/UD1|"3I+,&P.O M%"/JP8*>)
9*O1W0KY#|M0:09D:'8WBA@Y22%W/CMX2F+XX/*(OO#)YYA!/
M(+&G8ND#!9309:"XA_UW^|J9NPW&%|Z_T:X\$-A45'&!^S"ZS9Y_S^&&|/G
M>>U|3|Y4;#M!EQJ|5|JK|=|:|QA6@%UZ=-KH-HVSS^H(56X6R;ULZFTU<<& M8
N_Z0L\$4G|<|#|^|JKCU8P39|VG3D%(5_W?|0/FA9B?|(\$8|!"R2:A>Z!-X M(01G0|Z)7\$?
Y'MD9!\$.B|FZG&62H0X#>R?QN_4_797N;&RUH'CIYL H18OZ
M@9*3&8D20W(|_@3)MA97PF;4?,U2.Y9G>:_P_:6;-;A65>B36WRA:&;UMM=
M&S,.G9#92T4^|H;+|K)I&NAV;KTK)3D0/+9..G\$4|^|V9P|KJS)%9Z&^T/7'
M3BJU%/9\$SZBUJZ/W+-|TUI%G<|'4^-"(:2#>HM\$B'S@%VGD.VHH>0|+ZP MA,-R
^+M!7\$7UBITQP8KUQ1/OBF?WHW9S%USF906YHT--C-<|DZL.C)T"&S\$
MJ"\$,LM\$:Q8Y2/\$--+3;TW!/>WY0K"|N6,^&.6|OL;=7N&ALHA71+5WR"| (7
MN5VQ9XC:Q=|/ &_U\$7|1= WGN>4>%_IF^|J9S2:Z1Q;%)NB|3653|+.25+-<2
MJ_)T1,!,Q#=(#F:J@'DDD7*E*|*" (KTA27S'Y\$.@+|G:R9#(Z;|+!UD|^Q|
M(CV;8<%0|HCC|SGWK/H:3Q5&+46KOG5\$X=N%U%TM0MXZ#PV,E"5O-\$2K|SP"
M'AP" MOW 5|_/*2X3U|_UD_Q\$=|5=:XY|N6P8@QA %-
X#A(F|&H'U2==@OW|WVD4D=TUK|8>H'P,_1PE:CR|^5"A5 M?'H^.%7>7;HI+W2F?

23]HZQ(I<*>YI>!P;2_S?T4'DK^D-!;FQ!=!J;G MI7W0;6%JTCYH/)
(F/IDR/^-I(\$H9JGNO>-,IH4K0:J7W>,W!;
[C!1^@Q^'= @\W'7IWJD2K/IR+|A5\0/!+;72E#72:(! 5YDZ=EPCO
MZXBORPQO(\$<2*K/KZB"!A@<%D#MKB_N@Z|&D[R8;+^+PF8+;3Z;8MZ;,-\$
M30X|/S.FL.&?;_RDO(3OZU\$|N%S:IWCOPD?:Q)7_N#[XIK@).:3|XV3>RNA MJ>V 6XY-
'4@FUH9|W;U'4UG<,'&9XX*C&,JFK1Y.O.X6\QS?:C9B"W86*^4
M;G;J\$>W3;@ODP#XQR5NSL K7|HLV"B<1" <-,YX69*-'Y0".' L4VP^J!%.9!G6S-
R9|J*^5BJG(Q<=, N*O7 M6;|?2;ER49ZKKJ6Z.K I?JEM"<=-GX\$*:,J-8I-7DE:%2|+>78
MI":(IW|;N1"WU&)#W.0 !"Z-Z5F38">|74Z2)U(YG7P?|H-B-1Q%!8S>/|XD M9=H9)D|-W)
(^RRRYV:SZTW^,^ .V+0|DS-Z8>.(KY@0(I-%5#HQ6..4(P:? M+
:=6V;R1>Z#\$/!^0ACEU\$|=2X>|1G2FZTMETCOXBV)\H_OY.,V'JON_\$
M96!R(U(OC.+CY^YO@A) = \$NR?0! =6CB6I8P\B'ES;^/:T*IE(+_\$_% M5-
3)/Z|WNA!RO=7J4-J\$?%|T82\$TJ/F%4|(?!"B|KFP57K*.%L^WD!V_1K M/6_?
W82"N|7.A*LC SLGU8<#-|9%2/%>1+G;|<=KJ_O> TC;
M\4IY.GK9CS'4*\$F\PC%NSH'!J4XP &C'T*XQF MR\$(|4TWWF'0WC+
<@:56V@(R.K#!|3,9U7#8RJ/AP=LM804_R3>%5P^?P7/DQ ML&7:AD.P|:)K,U6-ZLF:H+-
T;7(R-206|9/A|7W/X1(\$>B'"(|7#P?;5.5 MTS;|2^!/'1%^44>=!\$+|'4R|:
|4F%3?!"KA^1;@|VB:Y\$WHI|B#Q_L> U
MG)#;P:HA|KAE/>T_93S(ABT=/S5R=/Q@Q|=?J\$";Q'ZLMUD)!K@8PCQ&*
MND|@M'W07<_W3IB+;PYVOW>2P:??>5=|G#5D"#(+LF90DU::,N (0G+|V=XE
M|/S8MH\$(3*=M:P'F|L&M^.NO+@S&2\$=@|'6G.D1WH>|_,Z4/B2Y"J>QH
M+BP2M8X^"/%!,LYV97K>T3.E62-(-+> PG>-XAO>:|O3RLC=! \$<^ E3.*(S-"2<<
!YPE=_? MY/;)H(K_N'W(8*[X?NED4ROML+;C7\$E?^6B'M6O.A*3;X9AV4MT1|H(J>6@
M9I<1&%1OP6|&4V\$3|ZO)ZK8|ZXE5*Z.SZ0?:2.Q ZE JH\$A/"1|+VD44
MGWQT|S"=6QY.@+1T!DK M_N/HL3DA(H_HMUL|_@82,M(T7TX! M%XC*
DXEWJ|I8+R9^63'P|O:| (WO(5D)^O|S,>S#|@UC=&U|MW,#!2626PK
MD%EHDQG4|CPOK5HM^;&6.F3C?X&O@P M79P46,QVJU#8N*V@)D 5QF MDWZ)S+-
(E2G?+|_J(%XGKDPAS)TB7&F08K;1A/E=4N6)'7,6)J:A#%RC.Q(<
MD\$>Y*^0LPHG8Q%S)K&|'1L^9)>._#_.3+8A)'W|-1+NK-<9.Y3!J^H7;3|S
M(|61U:|"16"=#K:F9D60,LL2H0|9S|O>/Z68+J|LR0
M@_ \$4FVKL'RVG21;'50*S"Q@5+USAMZK+%2UJ7-K UR=29N>.AG&\$H6O
M9K6|L:;#.UY,CFZ:(M"PT-")C0!S+E(R|>\$A1/8G+<8+S;3*W/@U#_)#UXJ
MU15_|1D,#PHCAMZON\$=1=/%7E=G>Y/|JZ%*J8@H4>|>E_HK+-?O,H_BQ&F
M!'A;,,MHD4L4Q;I6D6VB%%&LA-XCJSL24?HJ8209&JG9@Q&?YZ5X+*7-;X
M*QZ>X_A.ZW@3>@RNE7D<|9;.\$KK1,-0<9-M?C+7W.PH(+\$.J;X7PQ;=1>S; M%X6|/;
<&?2YG3N0K&"!)Pj9|?@1F%|+T(X|U;UG8-5X|YZ2JZQ/5YYES,T
M*WP^EQ:\$|P=JOQ@)O)(W!KG|*T=V!T@."%C9/(>3Q6=)Q=\$@X@7\$& MNB8&'JO0<-
:W2|:H=WA-,WM58YBIN4DK*W/@<)>KN\$Q*.>9,NR\$YIV=QMS%;
MT,MS>BSZ&&F\$VV3"2P45L7>5 :EBO,0+3\$(KQ/J3O6W1MYB=S0/7P9.7CV
MVY5W@!8^R2|?_8Q_ Q#|9_9@J=5:M)W3I^EL1#>EC.M\$#-ZUM.K>YRA(#W
M782J&YU=+0&EU7GC93%=++9^S/_4DE,0 M@0=L%*&=36,|E..E
:"U>M9NUZGNO2Q|;-^4_CX1X=CD={NYW5DT3>/6R=
MKFM5%)>06N1(N_L&>YQ%IB& HG)'0!!BRYWE-RLY25F:?A M I+7?"H3\$H,K-
FW:6|DH*EK#_7DVXA;^ Q+HB2C=\$0CYQQ>UR.IX;5OT|W& M M\ 'E-F5IK;GX?
2GZS(P@ (59_OY*=.+1;M\$2^^-V1<^WJO-/ZK68_0MQ:M M
K'M)_|3_\$KM8\$NX=Q.TNR1UW7>3=C6I"1)=PO-3S9!)G
I^_D8V|O04|:4ZA4%9O!R"SMO8F,^1_D|A8HB@!2>T5?|F MPYN6!HCHY;E>^H2M">^|
M&|6ZXZ7&&Z>MBP7-|X7SNDVUO_S^TM/T4:=GXX#[X]_W^OBD'05??+=O.BW" M?
3+A3HZ3N?(IJW0.WE\$?G;&2T|-%8;4H*?H-EN A)F\$3?Q@3.Z!"K|H9UK M>CPDC
!"7|0\$%AM""5D|@?#"T7%BV|7|RP|TLR9UE8|1C^63'?SX5!(XE4A MH E,E-
P^J.!W=5^FJ*+1/NB%+UT;Z"7FR'=#!)CRB)G+6NQ7660X3P0H-M(*
M8.2NK|B=YP;R9G1KF|Q4YC:TDYYX.L.X@%,5| M.E/6Q"MZ|X#|\$P.W.QT2QYH91,B
8QQ7@YI1G2T;*V\$K|=5?SJ^U!OBUGY M3|3=P251);6\$V;X|N+>-8&=7OP|*8TJAVQ^T
M2:SE'JT9U>>GB|P/VH)#.4CKKE(40XW*B=L;TAKI50|)P|D,|+?& 0'4P|<M''59ZR*.R/=
(-0@I?CUA%*3OY45ZO<=R*:< MLOPPW";FK7+A<1"|\$_.9|12R=J_8D#CR-
O+AP48KZ?;O7GU2Z9P'JA+=+HN| MA9|'=N^#V/3.T@R1HN3'0#+)+,B)K;>Y_F5ZZ8<-
F(L0^JJ:D=W5_L5U#T*[HSIX)05U-=|T0> M;FKJB)B04:RH(-
R,XD2(&R2==KN:I#UNR7<3!-'H_S-8K0T6?.'A)(Q#/-S-

M\$#X1TT&LN8ZN+5LO'2V1" 9Q ;HZUF5;<%3ZM*%JPD7>A:)UN,&6Z=[F\$U0R
M4X\$A_E-,@ 0#(Z/'*D|GLCT<:(-3 T*XPAT/4UZ(V)Y,DCZ4T\$>*K_U4P\$K
MZI*6;UN|XJ%3J6M9(<,(8|/2'\@C@=>'|T\$'H8 @N7==[!RP4=I/P78. 0K*
M8>_I,-0F|+/+V?@.\$|6\$ H7;'MF3(ZP*_ M&^|).#2.'J|+5%B+@3/H&I42))6|I1@EE17+
(5@@7FRLY|O?, MYGUE@@\$.PFYDHS_5ZX^
>H=G5J_.';5BY1VU.C341BK49CGDYO*N%BBY-U| M*J|\$/-7/,E)
|FL7*Y#LAE_Y='L|_V @/R-/Y|YMWL_TU'0&,,N5IUQ:O_KH/H8+2 1\$HTP:*#Z_P:F+?
M'\$*9P,QUIW'-|LP|-U)K MU&PC^<"'.CEY8|973>V/Y\$-?K@3J)6D:"4/XBH0TJOC.&4,*I9?
V3_.^Z|'1 M,Z,FG"F2A4ADZZA\H7,[1%8D]56J|N(X)!U1\$M/E7L4;|)ZW'&@7KQE9:3H
MT(3U*ZL?#PWX@%T*FLGI0),!.#=L8=QW6N"4 KO(7.VBH>T2/4F";<,%SROZ
MK<1/Y30^RGT'W|M'D8JETWW-,Z.80_F7;(WP46OZ#&|75I-IDX/^5V|^*M
MV/01P>T<#:0'0LI56Y-LYGXKGCX|-,/<7#P\$9|&%9U0JP"F9?3FO61.H%?S M6U:OF/-
E6P83;GEK/;>)D)6KY7?W??U*6%X?/7"|F|SSY&*=&=&OO|J'4R|
M\H0|>'\$I<&2XW^:Z%@|=ZK#\$;?|/(IOPAS&-&#%#O#A:AE,Y>SS!(X:/6 M=FUUH_?
7M"^!>H/#0A4T)RA/_E16?_?ZF5H_*ISNRL)=BNK,,Z(_Z3M_JAO? M>F^R'_P%??
0.3P+4*U|.5ODD9R*D75!)\$S0G:|B^XVAEK,^POFS@6_F"+-=#BRT/*"VTP">>!R
MC8&_|T|(QOSK/;?|1'\$E-IH2OF4>9)A/&'YFH.2G@:YV|21>|&"-Q,R
MZMXU%1NQ,F:F:GV#@);C0/P|<1+;|Z&1KD^%V|2N\$CS*V>N6H M54+=WH0@L32
:2&41AQK35? 7;0PM2I=%/+@20"3G>?!JWF^H|S#2!'R|M.*
M+^HW\$,E\$J>)|@8JOS<&OGGOAXV#RRR"=3|L-1OHD2XH5;'YO+XSHT &%+8'?
M=,@DH|&_GXBQ_68I5PO;|XAM+!|(#(ZA?&.(?L@;|^PYW:%IWJXY9R_Q_: MD4ITP|Z/
5+-H<5>F7L.(3ETIH9|2CN;'BS|M.)O.,:O>|'"7&ABW0SPG6@7 MSR52?
+DU;KX|X'KRRX-4%X':|-"#C?8\$>^:OT=K9"T95=2/;|9R*RF;5L;>J
M1VO7|!7N^)UQVHB:&)G6KM@@.N54=0J=Z?DH6, (7Z@\$|R(L(GOL|%>N>3K@
M\$LH,33=P6?9|U@FY+56=KKIASZOC(\$2H_K,V:>9NUR98Y8-"?>N')-X%^_'B
MOV6&%HRYIGS3,SWYMJ^H^O*TKR@|OCH456L,^0|GT0(*Z|<8'D7SU'MZ*
M'S./^5@?F0Z|\$(A%+/2<^B)DKSOS_6UD|M_)K"C Q;7GVIDIR3NJ.T<(^ MB'XBC'H-
"*,Z;HHI)Z#4X>?34RX1*SS-V'#Z#T%|&RT7")HC/Z"BN##HFM"/ MAH-/|)=
(,^8398PE6P@|L|J^Z19;J4+||DR3UIE|A=<1-?2O2I4%2P=EPI M@|@OH/.7'B%YUN'6"|
(ZQ?#BRRZ+*:,UV/:B 1;9=A9|6JC5*UVTTJ^;2^% M*7FF62V@P'0YP(-<8"(\$QBE'
|G(AU/X^-:19PFMYW#DK|PKBO-4CZ(:EZJ|
M)W|^G.V=/&4RJ%#=#DM07MBJ#B2BSK7B84@8M,AGW_%5L5;YH5?AMH|ZKF;2|
M;+^|D0|Z_#Q*,MV#^"Z)CM|D)/BZ(Y;RU8XUW?6CI<3.8Y'RMUP/G?\$4/X-
MRS'6Z%YNQ @ 6ATN\$#*UB* L@H!?'H81\$:<0(S5@/Z1F|=5C=,JM6.#(3Z!Y^
M;.B"5(B!5+N\$ZJ\$4.6,^ ^_NU-I>#BK7'BG4N%TH4'^TP5WM*\$THD*F3^:PH
M59CE4SC:F(Z|>,R&X|L=&R'|5YKBKY8G<9/%'&RPR4'"&EE5B6"UB7FA<() M*P,J"
<2OM|AP(FZV#T\$^:|CJCO|FGR+L#(\$F0T>_91G8CM|WU6;">BP.(CT9#>B%|E|-(=Y
MKAR_XE_|@6\$*(7X.^'D1L'&\$Q'T0.NSM3,7HBL#\$EK%<>9LT6:K&)^1W|
M4O2..3A:Q6:^52ZH_=J-?|;4.68CTWHS:),,;W52N/XH'26G\$1|P #YI74&
M992FUC'/FZ7|&'WB!S+;4B"F|F >@=KX|+M,VO*<:LH%|J7=SV|GM_?Y)U9
MB;TK)&_JYVZ?IS1?<.:?"Z_BY-@K0MWJ2KVDIZKPOO|8J9BL6SJGQ/-/"94I
MY_B"SZ8|NX3YODDM9_EP<=^'#U==SC-26PSW^JMC|^81D),TCIP9?VYS)3R|
MPT7|PWE|6,8|JQDSBOVHV&GK^W,RV)P,M5_|(+(%=811#;F%YH?
@*V;DN@=Q7F0Y,F(W7&|N&MC&G/TOW+";5F=2)W M;M4"?9@5->+@D|
D@AQ.ZC^|B(1M7|@-(,AZ17 M!;0|L>6,DV|G2'4-|KH9@L+MB)REW9YS!>,>XTG:?
0+ %XC-,UO\$'^ZK;Z M9S6|3#X%,?@3_*U_E69J|_*QF'=CT,1W>|W:W|?62_?>BA3Z;D"
('"#DZ1O"B M"&MZ@6@%HM|;NLR)ZJH?29OX1\$+;, (DXXRL"F402_RLR8O4TTD9|LK9
^#6+ MP WHE_/U;YJL2;Y;PB0|:C|Y#5\$-@F,5V1K?V A@BG^,O=58P!;T6*R/N0M
M)E)EFN,/S9:QB1S^1D#C!%_F1|D D:XX/KO2+5+C"T?>|M)C5^"|
|Z(:T+;IFZWQOO:3X;|LD0T+>;SWF3H):|-\$_-8TW;'&(&CYW6YV=D
MMBCN@X|P)S&#&^@*R8(S|JMMJDTQOZH8Q5?(\$VOS/(BP@"D)M=5J1,K*LRB: M4G;
!UB\B<3AZU';XP3+0#|/2(BZB(G+,-"HA\$)TN5L:IBR?KI>Y M%DSDX?U8U.:
|T0/:W|@P\$^L.S;|N6%|Z|<#\$/>MHCB_+6*YK04JV96J!;
M6Y1<6H'VK%PTC#3&/#GJ%LAMW\$ZXF4RL5-OS7-A2F\$,*,*,6Z).=N:Y
MKD:'DHIPVK*R,GHW"QY:XYU')^NR#|J#&F69D>.| M("">9M0Q7|T4B2:PC|
&ZE@G3#H);BIJW3DI@_S""V-<S?C-X6H:>T!U68 M\$B_\$BM^"F8|JV7%2>-
HQ7PJH0XQFNMD^B%/8/AEOY9VU7=7_CNX#>=>L#JTF
M3)B=20/S"&|W3R(M_\$2LS9ONB F/?B?OE#_//AHL*J|RWR,JN0!);:7^VGZ M^R

01\$2GKBLP3Q\$:[J*]\$TN@="=|+M%C<9 WA+|!NCTG M.:%0*=?->YW)12^JR3F>>D;N3?
BI>+BD3<-0*EC Y@?:T#:@4!L?#,%YH MA\$OB=7:0[317R]
[1LMSOZH NZ.T#O*N0|O%X%)U?O(A#?>G^>ZAGR 6\JC_/4
M7KW4|Q#;V>9_\$1PW1YQV5HL+PB!-TM@JDT^T009!^A MI"W)#)\$X
M.*),U%CI!69K.7N=-^461T&O-*5A.LTWV.S1/"4Q#T0/I*FA M^O2/)R|PBZIW0<-
|2K!U)M2MB:9(F+E>=%0I6/?\$N<5 M0@M_V!;PUKRLO"SJ|+Y7*^M7"DF=B_)HFG1DP|:
MP|_G;>|A0N>IZ;QGBB_T&&I5LUP*Z>+?"R?D_J7Q5JE-?WV7 (+|B|E1OV6A
M_!8|DU.>LD5J6*|A.9\$|1BG\$&SO5V_W0"#<8!SNB#P;S+>LRR09RA+L=)77G
MGA>^6*_%G#13CG9MXBRH0FN\$9)5(O99>Q=CZ3C|JH>*1(KU@M-Y.:2.
MM@| ^G5,%EBCN|6V'QC#ZPG19,D|T,<4KE@XCP7^=&:9KP/T).XX;FILV(JL,MF&7=|!
+4WPL-1^AIO%W|.6VB="|F.\$^1#&:Q9J&;SKN%SV.#N(\$!&?!&86=MN@(P:&
|T/QDI=+:WRW.2C"2T+V2*?2%SW8-BO0#N0A|??>X|H=HFPQPC@## M87D0.^J;
(D"VW5!MY(1%3-TFA|/R Q>9!=P MU8>4B5VGX?4?;V:^SSC|/K#=#/>%OD*[WR3-
'PHS2=*TY|:Z1G:#MP0|=5@|2 MG*'I<7|3U-;,-/OEV-E)@DW2|>*313?
E=Q|Y2H@E6UL;B8U;5;4FAHN6&40 MQ*'F&0@[9I0_#VM*ELSW0=^ROJK&|C/I?
+,VFK&SA@?4|9(!,(E"A|MW* MF.WWG?_SQLM7#MUW._9-."5S>)1@Y! G_-
\$Q:GHLJ43.SC^*1&?=571U|E M01MZ!;583';&-
%.F5.AM1='RP_"YBH15*"JYR/ZJ5|O8CFEO.,2BYM'Q8Y,A M#?>N^/D?5SB0XF-
YX,RI%/FM?1")GY-|D;ZL@|EG>'SI'|ZDA;P MXF'=F)|\$8;Z 4.#JHI5E'+3^>=8KZVX|P8^
!28PFO>;B%I4X+UB;|W^@%!D M6>\$Z*;(HMH+C2VEBF6&&4 XT);/YM%;^'M@
K;8/,@U9:)|3'OM|)%<8!:+P& M7 YSB8A),|+G1'9-V^|!08*1&T+#+*OWZRX")|
<A_8=&W18A;|J.XB M"4NV!;_ ;S0.U|X?|L.!3-=@M4NA!&RTD'E^/D)|6##@V9JM"V?
5B)X:7ZW* MAP1G(.,8S"U\$ _&'|UD>"(:S,8D=KUGL#&@;&|"/11WB+;MUJG.;SV:DYNB<1
MP6|7ZY424H<+-_T7E63W@A'6CSKW0;<#^*T|4=)+Z;=7".>_0M+=SFN+& 07 M%
(F8NQL*YA@N%GH|_D09^XZ1.;%L9"HSI_J|S|^#^;!8Q/;CHQHP")
MYQ|RE*WT92F^UUYR|K;QDVL?=C7|>@2XQ3G."/=/SX2/ONF4-_H%HT0P.1O(
MI<VSSR!9;XC\$5ZW6|^\$XV"=>0MSCB77+F8'QS^"ECL3,3&J96_6\XF^>/M?
7W6M|&X?E0:/W|\$LA +J1-(E2WB|)(^|@/JQ>D^X MRDN4\$,U<++@03@/_+0/(")F2Z
% _&'SOBH?TM+4;J|PS;M+8AU70I0FO0 ML1G1SA>?PP@_:=U'90TG C.\$|GL|M)(41JKA"
WLYWU0)<1LDS|CG|A291L M<98%A\$>=B(*^7)0+ @J@27|1?6J'9-KG-
&3(=P_|FGV83/@5GD<,P4,V<&-
M1=H5WVB+DL_A,K/.,9L;M9(95;>#;3%6)C'MD&'DY5+|MS9|1Z?);N#Q
LGMCEK)KS6+9R9VY)UO(UQ_6/N|-(XGZ4LTC@9G1R\$%Q::N M/H.W0<)B2"Q?
@|=:=:C!R\$Z==KNYA"6TG-(_2;H28%J4*\$"(Q@T>1D)&->6, M?
0A@KA5=CJ_K.B==>HJA,_WH"YHNIME3TA|R+H^8RG_JZQXJTVV3'^GU&>3J
MT%-.^Y8&7=SKA_96Q&:MZ.!X1/0N%C/09?*\$6#Q9'R|BV)3LIGG))J2!.*0?
M44Q7S09;\$X|H^J" X;D M7|HGS!2"78*G?<3K%|1%1V#>=WN"!%:PLO^
MD4W*4QHAB?,">C:D,OR,_E.,K)GGM=*,AZN4 IV_A.(=AI7#,S86L_\$.2ET
M_GFB|'SFCA&!?=V?=A|)SC|!"5P;D%|+9;M;.>^*4OV3(*9RCW%-!1EOP(|+, M8'A+?
2<|J42@Z/Y(|\$?>I@J!|@^?V|H"QR@XQ4|P+K2LSI7WR#^86/C"Z3
M|I@8|JVH#BJ6=7PP\$|)|N8 ^H"=&7OHR1E "\$>B'-;/EB|/=R!CM_9(D? \$"P M*U
/Y6'PV33K1GYLD6G6UUIB_6^+C9IY4@M@+|*&(DTN:L6OV4FAH*G+8;^@,5|
M#FH8,M>1*R:1VDH|9'35+Z(. LZ--DG*\$GE0/E>3UMD%\$JD&E=8>?T/#T2F?
^9/WL|V7YVRS|O_*C2H5R08 M;@EQ-T@SUM7-;3CT)/.#&=D8Q?>YM79K2>78W#S,>?
7P">0 @1:VJ@&+ K- M.U#R%L|V|+!YPD79\0\3R|O.D1?|+%\0HDTF_33Z^3|M*|0-
S5\$:Z/==G|N M;@C31%"#>77Z*1,0_A9.K|!"**W?|MC&BWE\$73W4_%*
<7'8J.J2"\$WE4DR:>- M|+S0<.:M4L;*|D>(7A.\$Q8Y5 ?;+
(B'IPX,_E|R|A85N\$EZX_D@++THM\$DJ- M&YUQ7755D0TRL9\$WGMH'G:
D#^T*XG3Z773W--S70F90|T|O@\$;=SREL)R> MOJK4Y".EYMJ?O|S1@&:^JJ:/)M%\$S?|!
(7&*YQZX-0@=6MSH^/.- MW^5>|P<_|3::F->POA!_0GKC\$)F?N-8U?_
'IDT#\$+Z>33,YJJ<#E|JC&.% M?|A>&DO2M4
M177T"@H.34UTDZGRFCC='1W)S\$7RTS%(19;A=_#4(!7/R\$/|^IV!T24HLQGY MY5?N-
@@U/-|D5).JM60C,@QPC6<4M|RI.JMJS,3=|8V"#E|=JSHSN/M'91I
M0KO;3|K|!=:D+7#%#VV,)?OC?P(SE"|A-U|C4\$'2K-NH4
M=|&X0.B;5QI43;AS|>TIU<|5+!N0H|,3B?HK5H'1>SZ6M^SD373#3XGV-G)
M:VD0)/A7RM&@O#O|D|+T20\$PA;1.4\$|/M,'N|@FKOVQ6|4W5+L<\$3"<:T M"G:
<)F=0Q6K?|82.4:C#Q:++2+/%_MK09_Y1.+? !|7"^S1YMRJ^VP4F46)I M:
|8ETE17|U<>.A")ETN>4VTVSQ:|ID+?>|%|>V>0%US5Q,9%(C^23(V%\$Y M76YFM!3DC

M)\$I4DCRGNL04NM6INY",_6YD+Q^BN:)FF&R=\$AD,M%FLG:0!XBR:1E#J=
IQS02UOA'U).D MR(P*EF!0CB-Y.!2\3S6MA7%WJE84I@UD/>5C.,J3ZQ%WU(-<-
/H#Z#H99<:.\$ M6:A5GUP%(!MO(%\$H-;G= \$0G400CZ%IP#BA+0+V\KX:
< *SX4+09!2X/B'N\; M9)WD97\$HL0!WFK_H\$!4JP?
T*._+ECJ.3')XRUS3=D%N#D&U;A/V"KMT'T?G7 MNE&RS&%RPWHI_0W8-
9W[-3%/KD*Z^KF7(:9_G/O>34T4P,U@D!<(K:LVI,P; MJ?C,;)/L6^_*@F0T\$ _RWF=NY-
#N(>*9_)8:UC-\$/*2G+,01!"EYJO;@2N= M;FYY N.YA&IP\$: ?8?
1"R2?)4//4!8*6"\$AULH^0.F;6?MH4I>>^'?PI+S""EL=YN':G.2%RW\@DJO.3N|PB^>
M3D"_"7!|OOT3=/XP:.' \$()&AX1C:..K77I+AJ.G),I^UA^H#"TQFD;1V(/M*YJQ91F|RY4:
6:XAHN.GH@1BVU+GQ-TIM68&7|U1)&+^!; M7/R2\Y5W-
2ZQ4"Z+=GK|_UB%M\$8@22\6Z!JDDH2/76\$?NED7E M _R5Z'!0#<: ?\4Q.?
W(J:7*#BR7%1QB%6""^+J>(%=%R;'M(9V""L0 @-T2TZ M!,QD)A\2_*K6E5*&,E?8&T?)-
@FB50??D.N?,D3C:Z6K">+/+6VP((K MUZ://#&QO;!NM"C:IT*>&D >
I/O=Z^7!9K*>#Z7@QGB+ED < M!O8|+S* D==RB**,@W+-Q| "N41|D%|,-
JRB#26T'@&3HT/T7@W&U7,?HEL,L
MR^%=47.TGP=2.U!GX15B@VM|,FQDNW|\$&#T0V4P.'4+>3',W|B12.)BF@,;!1
MJQF)^F#49S W\$PP4.)!A,73' E_84=0Y1')/Z)- 8D:8W+;C%I&D^D^A9
M0LCC|F'RD16346X^-/NAKB|DJ,4_"%790_6R3>745#G^,TKX;|>;D;X|V9UL|NP?5T/KG
MW|Q:+CT/Z*\$.1/UEN0_W2M7;3NG.J "W&D^9&HXDBLM8)LN*>OP|DI>KO_I
MT|O;NO _F'84EC,Y!"9/1NN!;7 Z@CS_M_7R|N&(:W)DGRH|6?#9=E\$Q;Y9
M&39;@ '\$ZFXE&I;^|!'?W\$FE0&PP4=VP7:MDR56.32.K>AE.C6%;Y;'F!)_E MH?
H"X5X+X1H)SZ^0,#'/H8B(SA2#S!-?5^;X:G+L.9+M!/)DI|E0C|;P8Y7& MJ%"8)+%)|
(>67M(?;T^)IROH6|_RP'!&5"2D'WL@UU+FJ?*NM/O_,=X2R|1E
M8EG051)|F2<;7&L7V\8/L#N2E;/H1|DPRVRG2: ^)|Q1L(O,\$H\$R43MS>R3-| M/_I_D??
>44UNW|IH|K:@6!"17J(B(EV03B!;\$1_0D-Z)BG0A("!! E&D2%?J
MID:E1*1\$>B="*\$H1Z5)#@H T203""VDW?N?><<_YG?V->|X?WQC?'=|?&0/&
M6'DSYS/G>N8S5|+60E7M^!KW:KKCBE>;(<;W)U|=YWH9\&D_EKRPT/N*Z#7
M#|S8X_G1E8&0"CH8R%_<|/G8?F8""2^B.X2#V9Q<09R3M*" (O2KN('*=A/7>
M*UKGKT|CK&;B?-N:FE-E!#NX)6WA-1K:Q0_), MD8@>5+W""IF2\$2LHQI E_"?Z_6U),?
&)H"0H<3+RL\A0YWLT IL#%U|8MA@_M.|?L=+?6K|/S(X9%MP@|Z|I: 'FMJV|
<;L|S^TI=Y*,>UIHFGTW,7,6XX|;D^0XX ?/?ZUX^E&6? M?UOW>D^B.%W/(?
U>|T),O<>>R+*)<3-ONKOT|G%("D;%TU0I12EK):43"DAD M;5B2D^X6*\$11"6=57EA;
|V(30F)|%?S/W!5LU0H\@HD|Q"SZ|Q| MLY?5.!*
ZXL3NL8KWX3+F:I(7!FU&=;G5#2^F0HM:W1!|JA%7D6;+S#Y|JE|
M<"X*C&%2W>QDFR;-OXUY;\$ _IYSM9ZT|JOR=YV!0M;1GY.13|H|XA?:._3?? M|= _<%+A
^, _<7/A/M#R^I7R'XW^7K8S_IUK='@;LLW7H\$. -5N|8/+HQ:)PO\$
M19>EG#03IXP6H%|: #H(=|GX<6/WISIJ#>P8&_QH1|/WR2/6?E3>CYY^|9NW_M4&!#
2YBV+DIPBVEK^|JCUOC@/X)7C-B16RI=&#=#J'^63.UJ7W|!WECIH->5
MNC?;LV:=R&L|V?KB%T@#";(D\$?0Y7/C30?_TJB"- \$6_>4NE7C _DKT U |H8 M#%F3X|0=
|TX00Y006U33STY2TQC9Q6,0L|>K(W07P.W^R*S!8LH?W^;R/0RJ MDV(^T^T7?
GOOGE#6MU*0ZZ9FJ|:|GKY1X#;?V#G!5&%#0R|X|T&;!>@&X1C MS%%H->
|C4'P|7V+WPP+H5^9H.)HN|B7#:WPNGPIFY2|/18\7|SB^|;Y/8S&
MX9B1F&4|_:7"_Z8O(VIR>7+S|S6B38QS4D1,KR'X6+OD_'%W,0VR7'2Y
MJD/^=G074XX*G"#!91|,|&"&BR4Z;T727JC =.#W8&>64P M.FZX|18_MA8,^V@1PM?
<* &GW-0X1U^H7%Z8-YGZMRRLZ8FZ-_ *Z;I=L&:& M5("8F)_J#CA2B(O.LT)-
)M<;@C/F#6X*14J=>|1+7SG_MS MM0")
HU: #?,YLP|'=AR\1A\$.!8QH2/L:W&\$VP'3C30D -:Q;>N6/9V4D, @*
M>JY,YX!UI0KX.,JCLYK.XA(UE079;0YP_\$S7WM&BO-?C!2+'A?(K|S-J%L%OM?
58>;3\$&D M'>!#R>V<*& &|!?
A7(AU/#|:|@DVMNX85CSRKA+U272C3&BQH6=QM% @K3!C MFON^1WU2(_8&ML|
|H.O&T8_)8HLD;PO_4J-R"=-BC>|L_D:Q5<,M44>D)D% MH7SN5GV3|3|>V|OT;4
>^D=BX4E|'N'(+HON>XI6TO+>P60@AZ=4OTWHE?>= M4J-'46FM#X;_.1@XV'^?
RK|_9/5DY'TOPR,SA'FX!,NZEZ/V8LGX*BHKX8Z M66!;!|AL"|I?)#AS^*
W=ILF=B^%OE7="N7|>|3WLAOS:WO-B^RCP\$-Y26&7 M
F&.V(KXKO'4)&F!)Y85#D7H6|W>I@-;_D-J:E|4N%CA)2F9&#O"#RP5
UNW""0G\$MD|,6K+ J|/+8#/NG%%&;;C+2OWRNG7 M<<|:O|\$9UXP&MV):I9:
|%K6&XNH\$|BU(0Y:C&&';)?@S'-
D,/2-.'9L*X:4;:Z_&9NV\|TC0N*KYZP|C.H8"C4|XWSPUJWNJ_:F=+ %?%

MM+SB0;Tl>C#WY|+K;XY1"!0SB9K0*U":IFW%E=CNEVH7_1V2RAH,:%+-4\B M-
Jj>*:7(56(-V5(KI8_9))\81-J0/FI\VK_OO(BJQ9EOPH,I0R.U<,:!@"ZE&A"NI'E,:!
(W(8@A9A/H,: 75(#/4A6Z|_M9(I\AZDRZL7%OR\$0@,:.&4Z?5@R2[8B|=
/FO+H<)|KD!CX"4_NC|V3+Q9?RB:X MR6??@Q.)5^5Jf\NR3@TLYZP9|J%WP?J?
L)X9UT&_=[M|>^X>G-PX\$!/:FD|E@%80IM|\$H>+ #N4 MWB'HI*"85/ # "E^-CS2|?
J+0YHI.V_D#(M|&Z|J^R)RW8#DZ(O>N^+;D+T M#"2.-81P*H^7WL&\$6TM?
C589N<(<7_AYA-TN<%7'A_(?|5^VQH|[%+XW8M08C|2_|&(Z_^N|P@FU.^+W_/9C/"?
9,1YRN M Q06SB%BB=ADB.0BXVBOXP12):P"H=:E:1L7U (I SRFFF@Y#\LK|(25|7L&
MFURF2C;@JE.M&QO"VQ_<>Z#08|5FQ%,J8#):0A3*./>->-QJF1J0-[*4@+ZT M?
R|GT5*6W+|SFW&,T,MBZ9=) #J_R2D<#XTLME/=Y#6^U,&??V_L8X2.?3_PR6:|
|'"DL,XQ)88SA-"G8Q3/B7N'L("">?L(/4;7B(:\$ M5RZ+-F|EW6|=MV*|98\$|G\ZH4_ =|?V&*.
>B%?*B|YD^:2Q/?;,@71Y*:E7&?SUUG!Z7 MTAY'=#E<|H9?"-4|V3VYQ6S0)M'R#D3MY/?
7|SM+A57NQM?'+'?PI|7%3- M^O?-E|?FJ+@97>KC7/= 1A9%#9|S^| @;#@.ZJ+J|Z2X-K
M|+A'YJ(T;#0S_3+=:HB05=BLV_OC=|P,3HU1-"HSZZP<.MJR2K85M&FH)NI(O"OX(LCG
M);%7+F.SW9:BB14E:Y^@^2D1'4S|,%V"MV',/RE>3(X?X/^JN(API\$;3;?H
M/)F>8T|7CB@6S%|H-85*Q;H>09T(?|@8JO: M\$UW|N*E!G=D/^!
|0Q9IN|D8|PI2HY|1#F|O9,70PVQF|31;|'"&9MO:P+@9 M_?
QVCWS;:O#I=P1TDGKP##/X)"Q12E6|,3_G& OU7,Y|N/OY=6&&!OA6(-MXO4!
<9J%|Z4'4F-(;3+ZEHUXNR|3;OWDN8*HDHU'="9_V9Q\$?,/W18:/|4! MZ'CGJ@6M@|Q;:
.'E&Q5&U3Z#B'AO6TA(^2T+F|<%^?B. NTLNG\$*S9#>VBM M|9|&.37>AG|JR^?
P#1%3RR| ML7,<|NPX4#,"=V*XFE6-U^:N:UL:CLORM?-TVNBNJ0SW<5-U>U58?
MZENY|7.S.)DTL390>+XQ|F:F)&+.C@7*5Z"?HS\$Y&900)J=D:"&@9?:ULOUT
MQ!|3.)5@7@/8>Y|4)RM;+4F>N|H=8EJ3YT>#;@5GES><(U-CQ?+%LE|+&/M7
MO/-4RW2^7V9^>|B|5"-15RYRN4W19./X>UCD,|3EG|TH9^+-:NU2P=P<0
M?.7:VE*;UMZ>UR2'/3+L'3U57QJWH0457WH#T3A|4X?S>7H MA|1T#
(P77VLE8QUS1,|65'YO6F|^%6,EU5I3/\$@9_K2!GG7VS82_R-|@-Y* M/MM#2?
C4)*D;N|93.;HJIO|,5SZMX96/W=,A6G^;7E'VQSETOMECEZR*+71&
M>8PRQ0I+=6GOWA;&VV'B-192-=[D*&<*O@U.E;K_2K?WTJ,+4NS7R>2B,JF3
M19&G#&%1Z*|A&_/T4B|_W#M|/_D1I*_./Z+UQ;_RR%*',|1'4S3,"('XR5|_M6HL%LN'?
P/X^M^D?+C3Y#Z7|2ND,|/!=EV0CU=A@1+!9Y%2"Z(Z-T-J M30(MDE2<+?
M/NFCS7*_GU_S9HGGXT<2T:FZX/Z|H:|D,-Y!-NX'J"(O)H8Q(8 M'%1/P!/?
Z00Y|JD#\$>>3M|=I'70-I|B0.9VHS/,(BXA|CS;:J(5*FO&-Y,D M1-
+0@15|:C1XT9CLY6;O|F3,L;8JX^R;R)CZ+%7IFF@H9^K(QE&|6:9>06Q
MWPLN(5:)L.ASWCHJ)'K# 'RE).D|'^<|'"KY\$XZV|R%<0A#S7/5Z%3)I|J|Y(6N
D^UPS>.^F*/#(+|GB MY;B#H|)Y*)O|K9L,&':AV17Z|0-07,Q^:I-
_*T47SIZSZM//0X9OC'O;:: M820T2-#%W)4D,'6_\$5IH|2 1M|O"!|QCW;=)Z7CJI2R3<;20-
=41"Y2JJ,F MOD5E#_.P0%F#3DS+LIUTRDQ/?95L
&.,R#4Q=#F42\$+Q,V5M/HU1BC=JLG# M|13GKCA^)^T
@Q,OLU\$D8#TF"H|2EB)02%Z'*GK;6+-!#|+2Q!PH<|JY3LR, MK?PRH0F;#|MOZ9
VG2ZG1CG:8TG&,%O/E3|4=E/P#!.(RM0^-BS62|)_MGZ+(!KAI|^+SF(LX4.+;S@'
+1M|9N;,>V|XPTF'7|N|G9V=PR^4&7_.*FO+ M-,P| (=,)*M7SFS0|A8)*R&ZZ/9U*2Q|
|6%+3S7283&|)&&UDFY M#2;!U&9S|1WG&E-V7&RORR|X>?
E\$SX51L:W'H2>JFN|,&76.JESK5M3P^WX M\$|WKY4*UB(P35M E2?
K;6OV(BAL|T:FEQDOQ92F^P0;EK)/!M"=L^04\$6P
MN#Q=DDT@_R;?;M8BY6|QL8|MVC6BU/TU:3M"J>'<>PUYKIA|Q^W??8;E;L/_
M1P2MF9|A?^@EEX4L+ ,MB|;Z|2C *\$)*HJ3-%Q|"\$QKI+-XI ^>*#MJ-|TV=
M,@LN|7|2EJO<|GR5VE&>RX%OI%\$4T|L=PG%QM,|R!Q\$M;A6X_>,+)JQXP2\$
M^_7|FAKN7G7|Z\$|F<*!L3!TL((^6E*Y|'2DJ_/523X MEUK(UUBFHJ38Q?
(\$LX<%VGF(.LSN:>8!MH9|Z3/%%\$9>!)S)@;?:OT:P(@YU MPKB4G4I-G>1_|V7?4"GZ/I
|VU,37!@QB0>?;I6J M1,ST.)0|*,1 M-SAN^&F=GY^?
-,\$@>1CG8|V^("00,@>CZZOKX_/X4E^-1Z| MP|R0:NG<8J/B)^D_AC&:=66FYTHM,
(*FO0X9E|YP|A'/+6E|,='GCC^4GF.H M.ISO/>:_XTU2Y/7Z^N9&WKI-A4,
QBA)R#RPU*;_"L(XS:+53*6_EU+Q M\$*4WR7;N|7|-JYH-Y"JO_-|H|?
=F508SPK36;:Q0^1#BR_'6BW)17ID&9+V MY|S57#SU1 !YRZDE|%"E"HI#3Z+:I<:8U)-
VSEX;A2|:9*4 MNMZ((GTH#A^7YT)7%Y)(5&LY\$C8V")G
U|7BO# 'R>IUU"FDX|G;M_DTTS>| M#U2+?
67ZMOACD,&%#O/7G@Q5PV6YFVD2,8|=UEW\$4W5;78LVQ0S@9N\$YN=Y34ND(|SFM3W
MANEZQ03/B/,C08,A-|?EYHT&Q0'7P1O'0|9^N7(U?&9PVO|)?

Z)@5QV3BJJH+ASXGA\GB\$X;1#W+|FG=0#JYD_2XF-MAH01&6K=!<M,T;&-W:3+3
Y0:'U|54Y8J.K*PQ>7"#PQ MR7H&-N;#DQ0IGW<1LU"R"?
A%Q6G(/7*|3W|HJ*Q?!E051,/.W'NZ| ^Z6\$KP5 MA=1WF1"-WE(063I-V0|#/RQJR"*T-
GYF^)^FPH10%&23L(.|&?'W+'?7 M?LI!(JU.>"69!_+F:0 U
M_0>Q"K'?D*SU+,8#=#96LQ_=V/4%WZD:#VK3GY<9A%J, ^BVTCVY52/Y%GK.?
M=_@L5S?
>^DFW&W(68G'A9.+UHY63RW+*TUXEN28J|CG#_S:376F2Q8V|R\.;+?;+26=D5LF7IP0%
6U;-&R>4E<6)1\X?F|=W%M>_1V^C MLR7#|_0(0<"8^FD\$PK&
_N2(F*1>_UKIURJSN!4_16J-HU?H9XW*V)V&%!TQ MKYZU\$|?I/2&>+T4H| %RF"TE/S'+
(1,=4L0|*N?7GA8#Z+Y U)AF6?=" MC@HARF^_733-\$Q?X//KVO55
5)5=++^ (JIA2L(-ZYQI(R|K=-RY.PI?U_ (M*9>+
S|6^%P3,%&=^D;6TE;IQ0)CE:NC%GE7_W93'^*-2|>6Y@ZPR-(V\D?O M7M +8(&XF.
<1DJ2&2*0B!4SLC=M!'0+V/4^T2JH(J'.>:E|A1>N:)K_@D6L3
M0=_/A.@&P)6Z@SV"SU%#7EX//ORU%U.!*,3K""4,4?A?U,K|*=K2NNEC.[KS
MKGyl.S1K|LSE>2Z-7HX"F95B_5K00JA2JR2\$J=6*_IW4,LZ7:8FK?;E.E+P'
M>6Y|Z8671@T+5UU=\$G_@N3G'BF\4B=OD(:BWGW)(Q5S0GR7&_5&O>[*%Z6 M=
>OVN\$6/>0Z"3S- E&-R5G9+-!QV*8>31/PZ!O*9?
#U3,4DZ.0E=SN0^4I<5E9#EWR1^"%07*^|7|R597.K7ZBF_K7\QS MG;K|
<|;P|K3!_/@"5 SE#7X&K3&-9C11TDB7XXCZ!?.&.UBN;\$<+RF/J@7N*L)15?4 M%
|_7_.91SFBT."(?U+(L3LNKOV|H=3/*2R%|N2/RFJ"3WN3>9W0-6,KVON&P=/-M-
VYLU&C MX5-93|H|F4_6L!\$?:PBONS5\$L54I721I^A@#I>*CL?4 M8094L?
V\$/W\$+!=!ZA4TT5JT+Q|A4B'<1HXBLH|XCG8#^T/*A|S|?#"V F#(QMR33W?>#
(9PP)Y<\$W#%|I%= M9:*IV!0=680'40SMY?,D|U,CN2%F<@E;JJDV.O
M:V&9"Q#M3B#_V(C9M5P,7V|V @SX5|@Y|PX);F-CMS;_U^=6O3\$N!U!5I&
M!YMEKQ5|_B;A;LD_10.NJ@:Q6(%1;^ (J^;" M,X0U?K% Q/- !0G*|W"|
46%/Z=+++LF;O|: ?H4M(AOU66!." 1LVHTMM#M M8'?ZS_ 'D^L>?
@XFHN(.EG8A<253|0? K<5QV22/DKL)Y.M|U|B"^0+IQCX>R MEU67L9E7RI\$8.
M>H1\GR5S4&F(-|S0ZK)*#+41%WS1/?PFOI=4+"J9T#N!C7^7M25SB|GJB=W^
MP79#A,W=1^0G6MFA\$ \$1>(6?2-UF@*!11_EG@D@^U7;5KK M;\$H>Q7'D
!)0GJ4CKD@LO\17'1SP;=50@1;;;00.O|DZ=*A!|9T4?ZVJF.W
M^N>VB^^6|H'BDBQ00*"G%:WT|S|XQY0>*B^\$KLO/Y^G/?A_Z'=QA-
0WT79I(3#-A**W2^=5(6/0;)00M?QWG1V%W+ M|X@!O>,V 8=%L_V9QV\$VOT3 M?
PTYD)|8, SX|L8X'F M%=6U6S=_*,) <<|S)9EZ.B*4B'NHV#UY_DWF9DROPX%O(\$-
(0>'A#B"VQOPY MW3.A|Z"IM4#&4UPDKW544|_UT-|?02K?
=2XPV%VW1|HQ.!O0LL6ACI23^_;; M*.(%H' AG+|_9A)%S6SOK1'0F\$MTS6&!H.M0X*
(9G1?=NUW|LXRF@8C7CW" |M0|V@*-4 WO A|,O3# E6""?LT| ^)(8".RG"^UN<;&
|H28TV2+Q*81-YL#T|)%H@|M@OIDHV*G-4U@<:4J)9X"!A1:_9^B5R2PQI5H,("
M:8KL9#F7RSR^3TRYZHVK3|GH&^)#?@I")\X?IO!V"G)TK|JT|3_MY;
M26K"GF:/YZMA'@|EHJ_1#*@-Y/"AK'P".070)64E7\$OYB>J46W!^8%@P;W|W
M3,1VY6X!;AR4\$=;OS\$O S,T)4_S|A.7,RJ1=RBGQOI:Y6*3X(D=8=?S*TO) MOVY"
|KN8:O>RXT;VX>C20BLPSV)G)#MR5.66:!. *-G'B:(Z!%.@&9#XHUH' M'L|M>;1/0|
<(AZ_BMMK%EQ\$)2)@Y/A"&4ZCZ3&&!9 *1>:"LBW()!)CK&-P M>;,;^*4Z%BAWQB,TY
L=)W-M%|L%)OOWTGGX|0B,7 J4Q)_P> 5.%V?C"PGQ
M77959Q>;XS;9Q#R/ANRE7<%>=? (6F_8&<1|LLMNUV3)G\SK)*P;9Y-O*3288 M?T
&\$71**=XG?N # \$KU213S\+4!0+0#%/.4*/K6L#UA5_;>@R^*_^9*(;Y=
MD+!>0S/HT6'3Y\$Q(C(O(^|A%YCR|,1>/Z|C"M"R: |F(3KM'?<|R8.*: YV.E M B+1+%HSZ8?
E-X-2??
W0^_|7=Z&%\$SQ;|U;KG\$CB:&'F|J^57X7,XTOLATH|JRS0X0T@MA210IR:MM>2&>)?
YRREF\$^4_?5.78:<1-4: ?C,%GIAR<6C-|Y7-+HQM3M>SX_87 MN %+%X|^?
4@5^Z&52#CM)(S^UWB|)" M7&%L!_@L#G&O,B|>935WRK-.@_6
M!Z+">LQ^2D5JH7')ZDC6"/UF=.VG";RE:HTS|PZJXPITX264&^J'>I\$&X\$@|
M621H+*S&(-E'BI&;-FUU#8/(PT7T6<|&UQ<,,2ACN%YO&AWQ6XYI0Z=B/R+
M_#==1C"U1SFKZRS>%WZP=7JY@\$OW:2#VW3|^A/@^,#VPI;2K4.J@#E|HO-I
M5:E#B73|Q99(YD!I;/FX1@?#)4CZ:44&CI_T\$_.S77#Q.VR:M|H:|;9<7#;V
M:K^\$J88^^(2)1\$*0AVD21.*DJJ@)"^0|VG7'M.ARP67>U?M7PF#-NV: INUB
M^@RN"N4&C1.*""RA6?:Z*(Q3#_QH\$C%Q.%%*C<|X|R^(1(_0W=;;/P+MAO=
MF!4M;)TR*KZYG6!">40|G:ZQF@V>Z,%Z(ZP-"%|.ES=|H=:6"D;+
|N^ND%:/92)DM.Z9U"-41 MW; :D1G%E\$VSYV*)Z^E,*%|/9O9.B*<5D-0V>

<6%W(!^A3E%V?PB^GOO MGJ!***<(#D,NU C;C=WP5%N=)EQPJ@*
/*\$G9QSV*!O2;N)-74"V 2=9X/<^&(A%JOU(PMWY?<|&J9OMC^ U:50" M6FU
WWS!\$#B*P;7JBTW0D=NH#AN5;\$@="=KH%&3@<45|\$MERP?!5#3I32IX]
M^LN(220V,MJW<,G&K%;=5.AP!XDV:_KOUK%]:^.@|8YJU@|<%WU;f=?T-^DG^PAS
M B!S:<><78+ZN8P90_@OO'A^~R-W_MK|33|T<|_ESUN1|9>5|M"=PAC8S&"
M!>KN(4\$MZ=^AQ"3H0KW8;TA8('9VU2|7KX10 480V&*+|DSS/HJ<"KR=%!S2 M<=?
^P0+%LMWJ<*&|L4!:@%JBFM_N4|1<:@9Q&MP<"/%I"Z+ML!--(I77".|M;:C"!_HKLZ
4PHID)\$)Y5Z%NA!K|!\$T=G|W^|_SAL;UZ*1+=F M*E '#K.+/-
'=+/%0/KZ#@XX#Z;SJM V9H>*F.->'U5RATVBA",|^&N@|LX?R M\$SO:/C<_A=4?
8<=S=@B0TF82Z@#4PGQ^C"A;|X&^KQ-
@7DJ|W=T8+YJZ#-0MWQ>TQ,GV)&%GL6|_O#G-P0T204' MM+B4I:|'.+ #M3A
99%:EP6G3FX>IVE^|Q|F@:IG2"|8ADGX-)WK+;SWX<90
M'0H^9HNV|,6=64.JMU;G,,+Z?FBA%E9L*=I",/X*:D9|)%<6|:)3?478)/?
MI*1*80"QFQH|"/DC!MH/M06(/A>'IP|?6 D9QB|DNTXYB8A>6H*
|9Q,8D'NY@YN:D!ATG>.T'OTX.14V-Y'9NN/2LX"-426!;WUNFEJN-22
MH,+ "FMNN\$&UK^8E5ZR%R97Y3HU^Q>_XEQI"M^5:~?>!"EP&W%? UK!':Y 7
M\$WX|!%L#N#W08&>M&5R+W0&KY|9EQO<;0PZW>MB?ROP>V,CHW61.,U|C/.=T
M!0B,+ 6|MGC(:SNYG&8*I@|@I3YC9|I_ZF(1Y|7&@\$2. 6Y|7EF?+O!)__X9/
M.UX(.6*X|"/_Y./L8)|J-&DA5& M:W^>8;82|AL%=^@"NE|89"4%ZFWR,)%/
M**4+&GM&O&|1R*!C4W'<|,?AZ*:Q;|3MO,-;+%+3;I00R:F&|;NL-ZVJS=D\$_I
MY#>V|M+C B|&9K-54-9F\$LT58;R'^N%R"0"3H5V9T'6=I?DTBB3)-.TQ>HT%
M&H%N9:6WG|J5W2J^E'QK M|ERJQIF,H+O6Z1EWKU|LPF*Z@?
%NX,O9E%-6E9GRID&*&G1O\$W>|O*,N*|0' M(T;J<6%D;\$HBH^Z)R(>_)
|;:MNEJQ&'5U.):9W6|V#<1PYJ<|3*V'\$)=.Y M|.UGT=VAH091|N7|&|E^AWI.4634(N.
(P:F;:~E*-O4#_ ^+ #Q/Z=QLD(<)= ML% ^!A&/0C><1PX2##SBW)|^W/?
|35K5_>KH.JUWD7 8J4IFK,0SSP,-^). M|GAD6D@EHM#^P|>=3|FNS=W4-OTPA
O).HF>X#GU4U|@8:242+2::=|:%^75 M&|'2ID97,;:R@7FYU8FNYY:DU-
X;JLY_PO/\$X>^2=ZL0 WHG+ _SF097">29 M. 1=W9&R-+4L4
M4|XLD&"KW@GC/Q&O=QRO"1H0|9P__::QO8Z.(|/_|G(&U|G?C2;),WZ"\$^M
M8T7>6M/= @ 0:C#F':S!|X496S2A%3#I5CQM+TZ|,F^| #V"Q-GT>P6X30LJV M+>-UOI?
EEC#-E)*Z|U,,E^Z'>CR|L,VSDY?6V2XQL%KNXBH\$@6;I0W85-0JI
MP86&/E*|'(CQ%.EQAK?+=+97WV?0,\$GC4H-/T3#DY7NAPU2=7QP1?5Z?:L5>7MB^,
M_D0VF /.M.NH#B^H)R'^5.AKNM"(O;90%|3J!RQ?30Q0AJ(#3V<+|X7|_Q8
M^=N1'4S!54\$>73*CO=A-MO*E3|:1BW|_)M00Z&=8H\$6NQ.B8%MIU1+|18/S6 MN-
JK59PXZD7:\$AODUG.%!X<=|NUT.)PL|K QGM9|MFOX,V|/%@^O-V.8@4;=
M'9H*I'KRA>!.1PBN-NC(UG*BB%*#,S\$92HUIL=FT;|"OD6K#5XGP5_NO\$ |X M&
|6/GDU_ ^1EB|;GL-POY'Q%XHV/?6I MBCVV93YHYT9U:.)\MZ;7'<6T*.Y96"#,9+
(X>=T<0%,6;2,45.66^\$'69%|R)|_93P|@U|5K\$ (\$S.J:&8N%KNXA+ M*4;K9)X-
;F>5ORTMLV%<7AE60R^NUCUR@7*XY.S%-T7ZA?4'WIF9?<@?K|U
MKUOLRA=Q656A5J7;N*Q4@=NEFCQ6(|7W(.L.#YO@X)|\$#SMNHJ+"GA%-Q-ZO M,QU?
#E>#3@4LE|&^60U(N2/6 M+|<*DWWK?RF#N7|H|(X|K.4ZZ9EC\$*LLAH-
QW@VG|YU*US51()2SU>|!@&^ M&YOW#J>*1PI/7O+*S,*,2+VY=?
J7M=2M/K9V+5I1KP-:+%"5%W>=M=%8@1\$E^*,\$_U|C>?|???7K|I M|J-E.'K^Z).V|"??
8RK.:Q+=#7VSI*" _")> <.:@FF>40<5,! 9*GYD|I M:'RBUT@_N7WTS!M3*?VK&-
U,J2M%M0:K*KR ^&|C&KH9'E^>?XS@('M\$RCV0 M%6|:.*V!+M8,!F4^ZH@,5;U>%8Q|_
/X|V+WH*,L|G: Y2'*GCC+=+J3,FD^U7 M@9&)98/D,
(7#W|QS;&/_NE0FL8N+DJT=Y%07O_0F_*|C7Q?#MC2@P<_)82^*
MS=8%V|6D/I&':TIE,;1LRTQT*NZ8G2AI6.XQZ#NHVZ^_M|ANR#L;QA^)M\$!(
MMYTJW^&/1"*|51P>5R,RJYI7_9S:(QX_0^CDMH5Z5* 7_*|%I"P0.#|E-"R M|63HA?
*,B9&+VOT9(Y_GIEQB\$,QX45R6I@|VNN1C9<^NIC J'(I MT|5_DN"=LCW4
26;P*=|>KA\$)U|A%Q;\$:/)V2Y!=Q=%V"Y4| #P\$1S:(1:I1#I&4';1+'V!>>Q-5K
M!|F|'%3<5W9C;U@6&|%P95SS?4BZ!UU|DEFQSO(I|;) "0Y0XD<+AR|GPFE
M.TQ.\$8P\$ALO!3=1P<"<.,(C^Q0*|UYJD_-)19/<|S6SQU8Y:ME!|
M*#X&_&C:5K ^>&U*'P;N|4!'UR"|.09BS0|D3*)O8(^T->D,\$?-%O#W,H-,F"?@-
_Y_B1B8O <|:|BB|X.9383<#'.*M!Q|9(LT+:/P;|F W2<4&3 X,^38C>T"!CS M.5
M"ENUB+&3XS5^\$?S00Y&_?_%#UN#^|_H_\$-&,*?),&:<&%NT=^:P0 R>V(.6 MG1?
L(=O14'(*.S.^WJ.D_,> |R=0,8S6W:%IXPXAV--RY'\$V# 'LW8QU,/%RL
M*%X4Y8+S8>KQJZJ|N(G8TPG&6L)Q'NV9XM2.D,>9/*C"NJ?;:

(M69JH)YB'9FAWQ*9@#AG@: ^@_#64JT=2'GV)K! ME(84\QFS'TPV=^8@60'1R\IY
M!%#?!?"ED(N_EY\N09#QAMK%5-7TX82.WF&9[DUUJLYG\TY5##6LNJN2)#3_F
M##FZB^GR9(N=UX^VN@1G"/W;VC6P6#\$.0)PBS#PK=P:;!6]CKL8?(3A?'(Z(I
M(XY11"NKFZ_-ZC@YLKD/FZ\>'THM2'LMU- 2Y- MXON[MB\$J%'A/L]&G9R2AO=B=
<+^;IP|=R=&R(<^>RJ.?/BR.:L^NKY \$J_ M+M&/^K!%WA<[UT?IUU%=L: '(Y-
YM/"C':3"6*I%,K=^!5+?459/Q32Q M5#J%6_H5UWCL,14V9@G4)Z^IA9T3-
\$K*9F,PH2KMAH[<0V*O5Q@ M[8S&K?
C=39Y%_D[HV0TV+"&D+'Q;T.>DA\$)@\$O\D+145ZU92?"U&L./&FW3R M70#;09|+
#A3,IX.PL\$&.A<11A;JR\QF\|C3/F+@N4EA9D+7TD\B-6U.7Y_QI/"EO)%.^|'Q&DSJ5?
D%78N- M42?L\U,V;ZLPP9M"RHMP2AA2QWX;I_"V:@^UOI?8A*(G(16*\$Y< 7+7,1;M
M%P/&FT>O&-J&OKWU/?F!_?U7\$DEC2H;,"H6E/_K6C*H+NLZ>TL%E&T)=MV9T
M/Y|^M8KC@L Q2HKWU)XC+8M@+8NO+G*=0,2O+60*G!>8,!|^9<=[DNU_"W47
M".Y>+J3=|GQY?>|HF^|B;4Z%%|42OYZYEQ-XXVK@|^?<&E|V>STPOQY-^H3
MDAF\NHKK\$S"NIWK*!'JJG&A^B.:PV:+KT084N;29K;:,'_TW\|D"KG!M!A+V_M1E,/>1_||
U(ZRC@"4U/?NM5^+4\ M^(:I561_M?YQH.&NTD\3,YBR@'^OH\.+W/>U.QZ;
<0B+W=AH(1'!#9Y9,Z MTP\$K&!%;5?
&.9(4BK'Z)>:*)"|2V9_QY:ABJE>A/F8'%50[F_PTK400#UEL| MWIX)N|2I4.\$VYO|V@
5J6@RP|\$|TZ&8Z1XN(1NPF-W"-.*@UX\$-5-%R3;R>Q@8>.S M)CX/#9T.BD'>
(\YI++EP9:MF0P|_>?OP&=NQCX!;:^-/6T9N9*>^36U5=H\U M!W;:HC
!^R*EZ!WF>V@C"R1*O_9Q^|J*7=[#Q3#\D73W&EMG<9MV\|H8C-/U M"9\6_ZJ4'@K-
WP4'Y WHO*,V1NYO09\$S^9 +FI(-,00K7GL;S_ ^88F"B;J MU:SB!NW%,>HD9?
8|2\$+C+C*+R0^G|ZU3\$Q=04FSIY1|ZD-8H'4>XI<,2H>
M5\EX4YQ/"I&97>AY8VCY,*/49EC'1NMQ*=C: ^?;+^4W0E,X;G*[K=|:DJR+ M=.W;YH;-
JXT.\H2YRLF|5|_&(U(AUUS\DHWO\$O<"8!FHO+U.I\$C8Q|EU|@"H 0??
4,R>XKC|N^%"#CC1:(D #, M;C8UR!_S6DX@J:7(UB4M*)Y^_348=/WIS=GX V-
V'^0+8T/2-7^|0&(2ZH&+
MO5H_40#EINM23E>|NXG9DKV#D/DX+UE5X+9:M7OKHCH4)^)A|D2|@)>F5W1D
M'VRG_C_@5HY7KUC Q1' K8^R6K9|B4!\$";/WU?N.+;VT5VVN/4^#R4|Y^A7_KC|/;
(B;1M5ET M' LWUKM|_OZI6O5*8@PL;E""B @_89KVT2'HVNW;64_ |2I8\$4?\$EFEU'5NG
MORI%N';:VBHIRKS_U14 HN\$ZP&0?KB0_9';\$. /; =^PZJ;71BLW^;D-Q2!|
M-.C.6LY>S^|V4W&U:HEEB2< M) ,1*|2MR*"9&%\$;GS#T403NCITC.I5@&WGW,6D1%'-
P,D&)'|@IW5?IV)-G MG6TR-IDQ4NA@O_FK#BL+^86|+&117>O|_E?
9X4VA88.E|LL(5Q(TV>|80N,0 M7HRSH|G_>_IV@T, _XOJ;TT:"N^7:P/+W37S)=2&(*)D
|J16G8YQ4/4CX3 MIB29G!R4%NICU8.L#O
+LD_!D9S%H;\$(,>#9"H7C*;8H%:9)=O|UE3?1IXO M?@3XM##^7;
MQ'2BA!%HRUMTW";X+-(=P/C*/HWDFl:EBY+0Q|W40*^|?|_S&OVK'-D5|_|J
M&,#^CPM)Q(\$T7MZCYHN%?(#Q;|C|5D%_A_QI\$6""B9_*P@:DV +#L=04 M(W|URZ-
R9>LE1O|S|@7R;KK|M)6Z|I=%L(^1|7LWGA3EH>5U:AK;4G81|HB.
MAB\$<|H\$=T|E(M|D5(8;(+|2Y0);\$8P|C0CKO^-1/F|KIY|?R|'_FZDPINSV
M8;L>9)P487*1UI>T:RQ3XWM";S|O|E6L>'%H&K80/ (^L46'46*)X?P&W-
HYV;1(JTZ.5C(L) M%NYO|IU#_AF-0J\$ "M9=V=Y=?8>9<7%RBHJ8Q8H4* M'7*Q,,Z:-
N*.0F|CN1GBDMFNXI8Z'P-<7//OD3XT_O!H;P/'-6F4K|)P|D= MN5V4R4#I_?OV,*J13H-
/UQF47PEU.,C|H9D|. #4D:LC"ZGGP%4*-LV@#\$V M-U7;VO3/L3=:I\$?FUT31>:|=J2
)S>?%30P(+9;RIYOT>H;(61YHSWJ0| M0/&RLRL+6A_;
(>|CZ|@X^;Q5D%SM|/AP0M5%!A@B8QPI?J4\GRZHU<^?(ILE MMOY?S+UG4%-
=%#8:*RHE@E118D,4Q B"M)"|%D!_07H3HB(B(D0\$)\$!(7ND=
M!>DE*DVDA(X4\$TDH"M)|D9!\$0\$H@_80#A/'"%|HMWYOMQ|HPI<^>;N3_.G)F3
ML_=9>ZVUUWZ>G'7V>LAP35>?J.500)^.VD@,KV 9FF)^\$ 20CS'CX;1KG|% M|>>|"
(>76Y0E MBONJO,/R,#J7H|)#Q.O_OF\NL<(' #&K%?%?QZMN6YRK9N
M)UGKU_E.FR&#M+97D6AB-K""0P4&MPD(UZ_.7'&^&"MKEEHH1N=%6F@AVY A
MNMD|P&|55XRV*^2R6^2VF!%CXIX=#N->J|_JM?+=?B(I/?T\$7&BOW3SQN#=
M"9&10;JT.|_""S7R(3,F'N2DEXC9SAJWFJ2+<^_BIDR/!!98&MP|Z&+PM7Y
METLB5|BG)DOO:|_PQQ.LZW"Q=|3;+.N0I+Z:459\5YAM*VDI?V\$?|;)B9
M62_TG6N<_#BK,8TNT.B+HZD%(H|\$@6=E+):BW7=
M#.D^X@UH*TH5LAKT|L)5K/9<&"5(A!>!/QPI1H|+E MFIX28(H/<<^;
(_% "Z&>MA@WL@Q|\$ (F'MK@.JEU:UWK0Y#M2J<|_N?E,+G=-; M:-ZZN@-
RGD^:X\$66D'3V\;|V9"Z/V(9;KJ7E=B32%W>3_2G,ODH6#LM?M=" M?|OB5Q?
8)^JFODLA/OP%6L71| ^%-G5|J/D+3"2Y/-*(5#_0TG\$<>OM"L?>(9 M7?;G8.*5'W/8'=

WR/6?2Q\$*#RMV0!!TO7!,O\$>Q82#:4;2=F7(:DV=,R'*
MN)&NOP73\$4C@E_K1;"0U96 'M5+% 6IR=. =8-0Jl:RS9F\$6,YNB_1T,F%:>Z
MLZY&MWJ7S"\$E5NOKH_ ^JR5*|3^ ^ W"<4#_ +_SY2A!(9X1;00B14'
MZ#4Z_)IRFW#7FB85R"NL;* ;Z0IA%6""!B'P-Q2G6CAD>L80&J,/ M7\Z8DAO #VU
>L8:LTZ0*7P)+#C?X; 00-Q0122Q5U^6J>#_ O 4\FJWO:5|0 MH;%=<'6#RL-<'&G5+9
+W&Z,JIF=#S,|U9BHBH>|D|P|H"S>|Y%WM+LJ-W M0-
Z\$7(J.V3|7W;SF|B|B(5).H:HQ(+10\WU2KN9:M\$X\$6;#N/<*@B;&E@CU MR.):)3,CMPD?
&SYSS|'7SG#|HBK^4'\$/4ZS(VU3+1&E,48 |A+PD5%J|AI&@ ME%=3K=M?
"32O\$%4PXBGLXC.):)'Z&6R_U;@FEPV|W9TOX(HH|S M|G>SI:VB5?%JU
YJU@;|@|7..9: _=I!%;.DA.8)'0B|^:DWV|F?=I\$V4^4M) M-
AHR'2GKZ^ ^C+|O5GRS>#4C500| V1%E5IM#PLY?TI>8*QARU79-WADK|9^(
MPR_R1*CFM"P9\ABJ|^>MF|2=JS|,Q6T9ELPS%8BX'S!VYIPA'<"*,YMKXFK'ZG""K^B*S?
=1%_84<0:A" <_A"J\$GFAVN:
M\$2U_)K;M.VBUX"E|IMCO|U2'0Y5M+S6M6+|_<6O"K6(L.Y1"8|2'?=-?C65_M;2":
{3X8_ "@P|D)13.#_6OTB_;"!|,WK2=N/TXR+?O8DF|"91;G1&&J&NM@JR!NB\$F7PY_8?-
G,K)TF9-EWF6C!1_ MK:K*|'\$0&"Q)7WAAU^B*0IT(HJ@5;R>H4@KOZSMY?_PZ7C%AZ
'+&I0X|9.=M>LTHSN|(G)F|6O9 &H(XQ=-'T,'GF?X7M C^>+9(1|JFO=1C8OPE^G@#
M=W3JQ-6(H=|1B:DI2*^|5;Z:F<)>ZIK&V-1>-,N2E:=:&"C'N#ST\$)Z.9ASJ M6I6)O\$
0W3SU_ZJ8#-%ENPB.N+FEB3D|@%'SD|'TPO'ZNWY&OV,W= M#E^A%Y.6^?
T+M0JMJ|:|Z;-%A?/N6"|1),^1)H^"5')H1E3,^*8^?3?(*(
MY_ZTG(M|C,W>R9N\OVP5EJ>"7DM=1WQ_F3NFE1D,_.1,<2X
=,"A>L"D/RD>#CZKX%%|V:G&L|S#.)=Z1 MO?U#;FG7>!)0.CA<<#IBZQIZ;SN-
F|),#VO9_1T|4\Z6B_H=O;2|^!RFA#K'
M%>U>M%IWRNXOP3B|3ZH/AR0FT*!V"Y\$33*31_2T<%(N|FO&)RSS|DBG_CQ_M_%R-
G|IKE7:75RKM'^:_.X89NTI^#_Z1@Y:X0T+|Z#+NF+>#QQ"AR IGCLC, MFO:R*D0432
CQ;FG7-(?)IBR\$P=(3=LW^N|%72|(1T/(==ALVMAO>9.<2>|2S29|CN
M";,19"*=6F0IEWUIR'VZ9QR4G3U+)M95X|OZB MF!/5ION%>(+
(D04QZ@"UVG##8JLUFI<<18XS(U++0Q|)G4'D;D"+-I4=:NW4LXID M?
K47KN|6;S7U/4O#Q(->E%_/MG6;\$|TFZ7NT&^&&&KV|F-7%T(OS&AM_'F|J
M|WB7|7!%V8_-|N6LP|\$;2|Y+I2G)|E(MW8*^(G|V"5^2="8+Q67VUB8|8F6 MZHL&
(0>KUE^|X^8GM9A8WT|7EH|O|TROHC(:P|F BT:48&189\$D8CM.(IQ@
MI>|_ \$^|0(>+OKL*9#\$25>F"Q9KR1L=?"O_='UO'CQ|_Q?U#U-C.QSD0A7)?
MHDET:N#J5OV+EH#+|19W<791|NB\$&ZRYN3JRR/5#QYLD'K2E1|Z|J|&|.&)>Z
MDWEATXV3N,/HH58?C|7EQGA|!\$ \$W<_F|:6'&?+|6LG5KQ'V?
V_QAGX|YW|/8&CZD^&T# MZ|&FIYHTF4@|H(*0QTD#-2U\$K;HX5"H*|9@<7*G/7E|?&=;
|Y'KQ2UQR&_NX MF^GUB29E8 M"+O
@,*W:X3ZMB^&"G&BKB|F0CJFR^3_1#X_ \$0UXO!ROMIHB'-9<9Q9OWY+OKX/Z9.+B=0G
M"CLH!3O-2FCT"_CUO>1@@7|.JE8IT92:3|KM)N5|8W;|JH>O?%)X@O;I_
M10_PW_ ^Y(:X>YQ96_WVMJSX4V&|3S M+T9XM1@'!&-<|5OCKG1+I_!;H7>=,,3EX|?>
#R7/_A3'_;6\$2T69|_U^LR|I-N!)G_NU),%\$ MR./=)OJL"H-E9Q|&8)
(HEMH>RM&G|Z|PE6*8 \$|MR)!Q^=BV_2N#>XF1E< M|_F|X|W9K\$.6BHYP90=@?
T3%_4?^@|7A@Q^1%1FDPFP!|GL4.(BL4\$?|=ZYG%M M?#/X"!#5=
(4Y/XU&46QCRPCG;ANG|H6EM,W+3.ONJ^!+?B(5O)VU;U|TJ_G7
MVBMH6R"56J,H:62U7\$;)^;D|7BW3I_3SBOJ15Z3*%OJ?AP_=-.0-S9C\$-BP&)
M.MAS'!XF"@K&3:8Z|%UM_<@Q9L|T*T0%-*#Y,AAYMA_?6|_6 TMQ3!A?|OAC M5L5-
|%KQ@+/"BA49QP-(D|/(P#1<%ND(P@D1Z0#=:G=3:T*<1!O3.CW)^MJD MT
7X14>40'>KEX_C@R|W-J+6K,'F.L_!|\$B1|3 M,+^|.3YVZ*|V^=6*
|23^/SRD9<%@*E6|A.6EW1^0N:j4:7-#&|DE)"VA7S5C
MJ|3'T*,X\$MJR(0^G%EBB%1QZ#EY1|77|:8-CR3I<:F3CH/X.Z%7PU#9E6\U
M@Z>UP!YN)E3/?1J_55ORA)F'ZL" MV9>G7SQ5DWJ3L|M@3*"CE&W0V*/BAU^797:/-)Y
U63U_*U=|B)=5'U/+;Q/HQ!5OFV\$9\$ M%7|!':18RJP@LP!'V=&O7|J1O5S7BT-)?
|'*MGR_L2?/G10H^9,>*6AHM_@ MF633/S5^P9I1-IH3%)1BR6SR*GP?*SFXW/T4Q:
(3)RB7Q|_VQ?%M#&R\$93SF%;#V6;EPN!Z9>E MVN27*3SF<))4GO^10I|J3)G9?
VYZIFN08SRA69P)Q)H/'(L"A?RU"6(/"6M6545=W-O7R=|A4'2OKH\$S%'|9Y* M./3!|_
^C@TS|X*>&/UTOH/I(O_X1'0|&TE0'DCY!%1>Q1>P:SHD87K?
8#L&@GG1'.D2D20(7!A.DA0S"5&"& MVJ%3;CBS_ ^CWDI5-
_=YCTW4%1\$;N8M@17H8O_C0|G51):(>)BHT|D!'LP M?).B*7\$-1UUMK9J<(R375LX|R-
^S\$EHB!*51|Y9C3_ ^T=\$V=KE1:_OR9_O)2 M^JCYM|FY_LAWLV9>RK,W|2_ ^J\$|@-

S3/||%OFWPP'.ES"#O 5NL%:J&*RJ:D M+\$W"V/U>\CL@Z!*S'XJ;NTQXLJNZ3K=)B>?
2C72+(YB53T2::S^DQ-9<'E MLRU4EA>5O 75P)I ?L=JLZ\$3=KX;-FQ#RL2AEI?
B^L65D".8?SHGI-X;?B = M5/*OP30N||60)O_\$C>)-5DIU
4FZQCY|H8UOGD(=Q3FZ|&W6GVTK|XA(O_QDD >,9F!!W,2WF-;J'M+1@7S+L(<)^=1
MX;V%YZ_5)M-%LRXD_C;==_CD"\$5PK,83J.8)1.EC#CRY9!O(H4;JU+Y6C,L01;U^+9E"R-
+>_8EP\$=T#F@.%|CD7W MZ@8C^1.:*_8G3?7?2J>NE).6_3KU/_K1A
M8V=A=:=!DMF18@+,O"%M#MT.IQB^T>PWR:WAI*+O"IDUM_SKDCML5IN
M;%8XWS>"ROA,Y"FYE1>SVC%N#6&F_41!:'==[N_.\DQ#>FO3MAHY^:VX5O2*
M/AO1.GKY?6Q&_868\$OT#IFKO@A%/. \$+*PZ=D
MU%VWFWN.SRT1SQMW&>+;ARA0X'OKD^2RA@.L2:Q|B_NI><'OY2S=D#?"E'A
MH7<;*DWFLX.8/9AZENO:UT1 'G\$"&K_OO <5PX>JOE,RR0 M\$OET
LPB!'XXYKC|L!Q*?W OZ|Z_*2-UD: 5|+ "?PF^/B4L>TOI\$S)PD>F). M!E*%/-F.2S=IU*U,?C?
7?G.>Y7 8<'EMF!PF?OY514',SXKG9GYV@+=='9S 2 MN*A'F9-Z_!!C#S-_WWR%;|+-
A"H^NKD/H-C'GMR+-K!\$|87 M*&A"J|K_Q2?|;"7+=0IU@?W5?V8,P0:%),LYM9'L\$|C7\$|?
D);2W XT_EBZ= M=TEM7((AU_YPI7|Q*+V_QRTJ |@R2>|<*D3ZK4"GQFHB
M1KB|E>#|J&|-I^=C0YV|!|<;\$'|%8R;ZVGOEP.C'N_DP:JVUA|B '/\$D0V4V^B2/+2
RMS^#6J&&K MF598OZ4M|YRM"J|&|Y)SBWB|>38-|1UOF0 4WN.1UB'_BU-9??8|H
GQT76> MRX=KM4B>?(D41T>!)3GJ&(-6H^3DJ_D9_G)NI%^0=F?@|4=|*"-1_O5Y-
*^|MW0@.6;"EDG23G<;XA:.-?/+%MFL05UTDW1THO7#_A
M%CLY4DAR|R1RLVC.K|G<_|R-LR<31'=@^!#9:0ES.FT26=H35_OPOG@.J:R
MPE:X?);;|;V^_H\ 9NB+L+|XY^H,'9 EU<\$8-I%O2.>EC^4E._^Y>';"!U
MQD|NMS00NO_5^<+W&"/6:IC,XV1;H3#3^.?I60)08TT,P2.38Y2.2+)DS\$3 MZ|T8|f::
IMME"Z@|YVJO:8O_@B,5NXOT1,>L@N00ALMNK#_1GO|?LD&3(-- M/NR9F51'?
7TN")6WM046'5_LNAFCJA3-&?D&_S#9J379Z;GPV11PU/2>\$=W2 M;U=L*?
2MZT%.2*SE|THH.* M=E%V0)L|O,F;I_);H'F|;% <4/#L-*4\$V%7?:OW03,Q;
(^71E>|Y2VS+IO/
M09WU+_99IY18B#U5OY;@O)&Z&LSR;R(JLATCT/5JWQYCM)\$1XA;1^3/&H/SV MPT^1-
TV)4_|@/*3|G:.*"DW71KM""%(N|/?@&^L=&YP8':Y+9H_9-IG.B69/?
M_A@>YY:6<)>4X9TJ|OKCR&/7RL8QM0JN,9'6+YDSGP#')I33N?9)SW/"O5IOH
MY1CU).94=Z5"Nj%".UX(V56 |AT=G6Z;;ZOX&L\?H|RV:/AIT%JV.HT_Z/FC M5/XBY:O-
RGI_8_(YQ_:MI7QIS812H@3^;B\$CEY"HH05-P1FC+1_)R1-1E%8 ML.?
X9AY4E?"LDTX5YV4\$'R1(C!UF=-M-ILZ:+9N|^&;G<""Z)LQOG\$C:5
M>|A0,D|P(FL:0B\$P1Q@5&11-F&#UL,TCW<>;RBF'R!NEZJ#" MG0|^=53/U
MB,24N9R/&W,EC=JM^91WC<(U,6<\$OH"Pl_.U;|QEV16V>3P#9<8YWJJX:HA
M"XU.>"T&ZC5\$JFM\$|H=69-|K(G,WJF"FLPBFN|2(3_")E((,MW_|5=H5?
MJ7N+_8P11LG@?B6&??4:Q+/T"1&\$N.J,!4NV9IWX(P|(7(<8|W |(G84H/XU
M)LA6QD-.H:HA0LZV^,L+UY+JZ;-|58T'ZQ5\$FFQ*I-DT= 9R-4 EVV::V
MSQ8:^R)9H6HY&(OC'CZ9DP?_Q1XSJ9VM7|+|,8LJYN.T6GR M4_5P4-V2|&E8=O7
M1I91' |<+|XQ*_A'>S: !B4X^_&TR|+ C+22ST#%L38\$<|^")DB46_:|6P M:C4O\$,Q4^
#%%M=X'BN|*Y-CRSIB8NO|V_4:VP'=> ME1*N+)>4AQ?-IKZ9??|? 89?JUL?
BGEL9N_"@PNAVHF+9#-JJJ09HP0XO|@9<M_!E.)#L+167|B<"5S%35LTJ1?
B^G|>0NV 4B|A_D!&=D#_20S|3^+930%7 M8|P<@ 3?
=NO>, %KB'IF>.=,Z>9R0DXP|QC_3=X4R>:Y%.U|CMD79=U=>JQ@D MX@&@0?-|>3-
MOS:_.02CSXO#E200%1&3>&2Y:MXAX\$Z-\$")VJ85T-+|K!|K;_M.F@Y'&O-
|X:U|N)166_.1*L>D;^Z,P@;RU&U#RKT2*=Z-DF3?Z%3K)>>9O^ MHYIW|7
M&THQSIcM,-H0A9|G43.|?CP @Q<>=F8U>TK@6.9+HYHS<*/7K#2*MB AM,'P M-
0XR3#|9CS@P4267|.7XQ>&G.+D)E\$4B5;>>/1NDSC<7VZ>|=P#;:/%|V8
MPZ6MPT1^S/F*L>XQC 8+L|H_6O&DD7|"1L(C>QM#U9O,DO|H(5B34WQW6W.
M7P_)JPG&26K'9_O6U>T?ML.;&/7%Q|JL;H!";"LG,S0 B?3V?&+!R?V"(VJX5E-
W|B9;QJW5XYMXU@&6|-NL-A1TU,00|M;1JXL*BTGZ%PBF3T
_C;ENDQZSJ,+>:DTJ_A_.4F/J)21YH\$PS@VL.L.J %HSNHE M|H
L|U.A|0DP,C=L16<')BP|70>SV:R(2UJ=INXQ|!-2KWG=6@OC86 M|PP)V\$-
J7O&4+S,A"VOYD_+7C.+HUE?QBSL@)Y<7C#%W|<+-9Q_C@\$@;5<OZ
M"JSN%^=VI;R&R|_VB?MZ!W34*OS9#HB(+FM&IR^5:*KM;@(S?99=RVGSI;+N
MV7LNUC|JO*7_+KY(H((9\$U@Y|J2SI|J4K^| M&|TA_/H(UWY|G-
|_0Q6|9*5F#HA#I<_8YR|Z-G M?HQN&5J^S@FC%^,8=4)C#<0"5|SHZ\$Z%" MY;>
|;^,RB@_/*4|VWQ*H&5)|56T*QSL|NKNM_BD1;_EQ2_IC14W@F86SH3E M21K-
Z(&FHTWTTZ?6-RS@D?

^H81+HD[&5E1TG4S+91_ ^7.CH"U75'_ @%%1SE#':T;!7P9S1R9Z)4@G;UJ&YH M=4
'PCY>L4Z|2^GB3I612K3#.(8U_%YT(07DND8R;J5L5TIE,&8%Q'@/1A>R
MB,YKXO4G%I+!K4,CMSWN\#HL/U CZF&I ZIM MD)@-U%M1V
\$=X5O[8Y1U#!A6VO[E;X'8%"H/0"1705C9)/? *61HNEK+=X>K MNUSD^E\8B*[-
=SC)T^Z9!S7@<*579&UW 6(VRED;\$ICW/*)%8>R1W81*,8 M0.NZ:MPQ?/N33YX
#|T>25|;4KC8XH@Q@.N7+<|0R/+<&LG_1.Q0F|79U:\$"=&P4GB;/'(<8|V|X@50E7|'C|
0?FX.G MZ3'5\$>,D()!WL0_99R&*.WK8XDW#ROCCVM.^ (I@SRPL0-N@%O|L*O6H'Y"F*
MNWUV@T> @Z%K7*,T%--:;N|*T)O!W2| #EZ)(T-Y|&B/41*B"KT#>CE#3^5I
MUUU(X;|11P&Q#1=Y=J89PP-&2;2J;|R& MN"AG7HUK8R|.3=E4_LE;@Z@+N77E
X0FRXKWNUS65?6>_4F/7Q@0E; 8,IV%JB| MV!L1V|0,+J:<58^ (=N\$G&&GWVD@FJ|FJ?
#CTPW3|DI'N<=TPK^L?(<639) MPB+CM\$9+HN;JN|DV)3>SH_*'1%6-
JG8)TQ>!"4:FT6:N&^?977'8"T U304? MX:#*7HI8;-#RQ;F)IS/B1-
!A=OB;)&598O|^5VE_F7VS-4_L;D|28|Z&/EK| M(49>#+ 'Z9,FD_\$G2309-
K:&I>;P=20'&.H8XD!FVL.9#5;YMF"FMB9\$^9^" M|?J/HT5SG|^H^9TXVI+GRJC/2>
>ODB_F./K!,SF_KA4TJM_+NL T?>A> M)%|UO\K8)X*BK"3|P7B:R@4'Y5??
T|V6I|BOFZ"V=\$Z?2G#XS\$SU@;"A.L- M5W.3GIC//F278@=#T#7_G06I
M01I).!Z/-(R00C43AOW7!+8_ \#A|5Q!<#;/F@'4Y8JR'|L>.:DWS!)%66L\$' MS9+TW"?
V6N1BQ|^NID6C|XRWL|+.LL@-^F=QKBTT1VP8|XCLU|X89|U=|C= M(6+R#UP68P7\$L
UIJ(65+3A'N6Z@)8;M.:6?J0@|C|(%F))/*(-T(&4+-A-9 . M/:@87%5T_Q?Q^E'4A8>N QI!D?
@P1C#+&/NRO0&\$#ZAO MDI&*NI
MHO|9A(G;F4|Y,B:'MTD'B^1G1!^|W@C44|L2=&OOU7X;.;@2.C68A;.,KS2=
M>&41WEDZ(GOG<^:=FL_1N<\$ \$^ ^E:(M^%H!"_KF^L+(L3=6+>F!%?'Q
MVEEL"4|&.AF|=8I:Z<,M@HXX?)TF=6T:CTHP%NI"2@C05G"TR+/J;U;:WDGY
MARR|7RA=|+O/#:/O76CK MLOG!_'CFH\$%)GW@\$CV>|MR=.'*;;JLR_W7JQR"OBH7|
<|L:~7R!?'N|_0" MJ0\$/2Y^Z?+D>O0*.5'JP"N0=8^+X MZZN7L="(+ #5<=<3,
<3%,KP^:)RV9PC6+;|*/2G#YL|-MD)E|:Z Z^4J=9%&
MB29PQ(1;:;\$IT+6KEC(Z^U;W(\$2S%6V M&MTH-X
!>GJ5S4PL!)0;6.:U)\$W6OH+VF5+7%?JHI8|+8CZUW4;@|'OIRF
M6=18&=+XH2/\$%JZ"O0|#258H-M (IE%&)|!105YNEUNN_|N|EK%)'96ZET"|
MV#PO'%.|)%1*0=7.2"TYZ&RNG48C4(MR|:"1B2G'J_QV/^Y8K9UN5A2;NOI6(TQ>P|4;MW|
W&.)0E@XKM|:O&J6,I3|KZ> MQRZBV;: IV&<.:LYNC0_"? <_UK_3*1D1--?
T'#*DZ(>P#@OXOVAD:"Z5-Q M?>DRN!@K*|>9Y|:;J4"|:??;UIUZ"|AYIH_Y;|M37
MAAK6+2/6^2GP!+LA0+.NH>L^58MC1E/2C3Q-XIN@|6P?4A!C':>U+M
!H!^ ^CN+:M(X9;-08&JDP/?VL21'5;VU M2G;)'\$AI-
#3&@2.B*XU3D4AH,#9J(S8@M>0<(^M<^Y="6%;;F.MTAELS&J8C M-6
9GXCA&ZJXWR6UL,A86-%!@DTU8>=>(8^C%=>;>L"D "4.8@N.YJ,E?YMW M_=3;YJ;7*";
<9<-N(>SS?5HZ#|=D-W\$OL8T*56(COT6-H1FJ47%3!^W\$C(O M-%83F&*7?
#237K.#6D)JE"^|<0!XT<2LMT%SS^F@X?MHXOJ=;D;@U94#?>\$O MA|2.X?C6P+0=\$%-
Z!|3_.TM>ER2X WJ*&@Z|_M9JPH%+|7ER|N|JMF_-D. M^/!7H49^|T:RA)G&/8E7W0?
|G0A,W)8LU7\$!626QP/2M7|Q.9CA3|*)G|F"\$ M8W!/)C*%;O1|*#0O/@M\$ "
|DG^W|HEOM818>,M @*S#BP|YK^+;N4/G\$& ME|XSI|-W=!!8S-
LYFV9D|\$PN3FHRR.9*J6-E/8F,KCK#NZ|N)_*G3Y=Y&RME_M;U^|G4,I;^,%YMI-KG!
|YY\$Q|#/AVU?0H7S_|* :7PTK.\$3'D&_4KC|Z&CK MZ75T)"KYZ8U@<110<\$^71J:W((
^%=:C%?76\$1X(DF%HS,8IW,2,5"MD5P%? M66F|W|@+;|X_-J"QF!4/?
#YB05\$W!&@.*@)G.!+ MV@&U.ZAPJOL(\$:_^|F|?E>6M7.%|>;EXT*NMM>VN6ZQW-
Z9FI6'^18/9J(C M|_|A_+4O)4%?\$T\$<4<#U-
^DU5P*M0%E_X;:|US#@2!O#3AH^O>VWJ57O#Y_ M&GEM@|6<@OG9M/G7)<-L-
4C>R=*+N?:5B'MG6U-TS-5\$Q_/DZ_|ED7:/CE@K;SU\8D/
M@1|F(YIPX5RY'H|4)/+@TW6_|4B8"<\$^-S8AV^7:1:_) 80\$U7G|_|&N#@N+
M5'^IS4BC=C^+(MN7;UIVS3W|\$"A|4>^4:9ZF|>|><:|AX=N7&SSSS\$C|;_AN'I&7/>XYQ^
8QS@6C.9#CE7:W;QA%
MN:VY6K"28RX_B628|&).^O@4='Q^VGLK:33(|=60|>WMXB3K|Y'Z>?'J#T/5
MDFR3DO)|:F/'|KR|+.&# MGO-153H!4Y6>:_0B0U;3TZXO+?CWK&6(@9BH@EG!(6
#+/P;8_PZR>G-M/7S MK@-'_I;V\$<+>%1!|?+_TYYN*G3WR|E>QJ="+R\$)=K_E>SVS+C-
^;"M/(@<%SU MT((/*|W+.)2!?'D&X;_W6Q1Q|1MJQN|FW_ ^ (W-6*+"N/ZWC9U10G9;_X?
LR M1P)U,')L,)=_@#?9R2P^O""H;L>_6 VJAZ;SEJAU31H.V.5);X/_C46^H,5 M^S)QG?
W/*>?WN?Z^JZL4XH-&WD*|2C;5;=>V,!1,9KJ;Z?Q.M3;P8D"6# M9W!GN&,SY^*
|E4M=\$2|/L_ ^"K-T>YUM.9_SM+.N|"+NU967RXA'?PC39^D0 MSDGPUA67@VBN|!+:3=

+F?TII#@9G/"2S-5D@V.(LN-VA8V/BCSU0?(7 M3Z7N:=,;184_\$)1MB\$CI> DV!#(.VR;V G->S64SBOI@FVXZ8 LI6;H8AQ M+3=B&'D:K@D\3%Z!_HUQ?*:I
ZIK+^>TBG6@IDI*2\GUJ\33R(J1+6F F>1 MX)C<#;IH,!,P\!47\!'=S&BFA R-
42&+W;YU0N#1L> XC\R"NPI M\|MFR\,;"G-^7,;@'O\0MX #?%*8\7G-L\|T-#"=U^[-):-
%5R%1'6->.JC*N4 M\>;PH,;WPKKD?0Q\J.9EFD\$LC+^=F.\$-_\$
7ND#+B(^R>IEUOLI%5\|MNLOEV M0'R0).BKM_6+J)O?JW:FN=,
<[1D,\$.!%>/GH*Y47R*A\Z, #G:=6%5:"4G;SN MOP/Z4!-+O((Y\|COL?< 7)9,
[2!&H<1PL*:\$&)W.FN;7MOE==UD M.O6E#Q^PP797,TYG/8Z\|C(@SWLMK!\)-?
H((Y\|OM@ (0QEUCYE+))"/SY O95 M>E?
0N2_OVEZN2U1CA08P'H3FTQK*LM\|T)ZG\4XS,;\9)8,3D(#7N>/+(&)W\$ M-&0E-
'ZHED\A0M!;+1 1\Z5&KTACX;NLXL#W;-2M M=R40^B;0?
2W'QZ.HY,#I%QPHC)V5\|&QO Q&F+!_Z%K#/\7) M(/\$,QNX+;>4JV9MR7'&+IH:
HH@#!A5-/?D7%3,8L"?&XGAS5I_M#@CL"KFW>7L&V=RI M;A7BTL7(-
Y" T'3@KL?;PP@/\VH++L>J?M!\$1U(UP((O'O\|PK'N++\YCAS%
M4J\|H+5NOUD^%/\,=ZZHQJ%>8S:D*4NM+,O\|1\$6,LJ14J,YG:#M2\$S*&X_)K M;5F(9
GS@.(C8\$/US#T=%H1,E&?|JB*WO>AIE?BV Q) 8X?_F4Q\$,RS^;3\$H MWW@4X,O(T40K;
=G#.>SA5MF*H^&"N0=[52V\|MLJ]"D>?>LPE MFT7068LJ_)_%_ZH+RT??@;#\$\$+
<_E_/!\^7__ROF+D "#0)4@>|X-N+Y^@0#|>M
MTI,;+!MXOK'8OL&EG@1IVZ&|JL*A@%|E\|18!=G4(NJ#'HMN2!S2JEFEM"*3
MJM6"TX%,-RON*1Z8\$!A:LDHXBBDN(R^59P7>\$=B_4GN?C8A#TBS<59)5BN/ MA^;'-
UN#,+_F>Q67Q>*K=92C3WG(UMV\|E6=6P?UI^'-2@UD"5<&UUA.JN&+ M@\$7%03
&VWBLM,V\|FLZJW3R%%ADE\|GZI*5*W"O)@X_OV4H\|E|"=W=[\VE:%U
M1QT\1_@;F*NE3#N4_%A#1\|+0S/K^=N*P+_CPK00>(NR@ASF7^U2I&ZB_MR
M\$6XI#/\4HC6(YO_*6)RI/^S+JZA\>>:=T&+'TR\FZ\|DQ1.D"5)._608>)E\|"
M#F&A0^UNKL5:M\|DR4Y\|K)\$5A%-Q9#CS%A>RVG\|QXL;Z6F MQSU,F"2< A(H"
FX(DSK3AB=K\|G>[*YAZ\|UCTZVLNE;:ET--+\|F2FKIPO*V M*G0PKQ#-
J*,K,BA4LTVBK,+LOU\|*|9=[?+U/7\$JL@|N\|%)>+"FBQG\|P!A:8B
M%2BL4"N+EM%I!>%T^Y+B)XEL#Q^_L>3DC_I/;(\|S_<|\|X#M |PA;"MI
M3TA'29_K)W3V-S^KN+|VS@|BUJHXB\|I=S4CJ&X,I_*OHM_C!&U*OMO 4HAB+
M%*RRVHN1I7WE(V^;HY=7NX3^;&(C\|ELKW>R3;)V^5I4S'0X.A_+MBYSX2+PJ
MG3:=^JZVXD0\)"YQJ2.FY9&2*JD" 8;;R#6\|!"5/70A>W M)45(1^G JIN=45:757?
55\|U'CTL'5?SG%77\|*PM.?@OU920,_REY#C\|)#%/\Z
MPDB\ZCY<#FPJHLGJ@ZE7H4FAD8'77&\AGU1?P6'9"SP>%QWODA?;H"L-COY@
MQQ_U0>|8;)IY@E=B+ 1KTFVZ66QBY:Y)@9B%_NC/#+D)*1T*OON,+@0#H)E
M3;O!QOIK90X@;=< 18T2,7_+A^9*|'M)M*JWU.9+CI RH+CH\|ISBVET^L.D
MN>4YFR6H7-;<;UY"ZZAW;/C;N\$O^2OY1L(&5X+/O'.4S)5L/A>O M?^ICI\$S__|K1Z/_5
8=O\$Q\|XG@4S4BN-&:B\|E=S4*\$52H:|(!L!E9G.0B/ MHA@?GL' M1#ZRO@-
*^|Q=|9'8);/>TG#M.QG42/S"F+LMK0,Z(N_44K=P:C?2^8
MOAR_EZ\|>BWQR+WH4^DQ\|B\|TS\|UY4P\|WQ\$;/;_%79)8-NYLF= #E7L>8,= M#2_VM-
L6";P\$"|C/(MCJ?4LB;@K6L7/V6*Y*?=@@&T/0\|S(.9;C\|GVEQ6K) M\|P)AGWJGH
6Q\$RYOYY,O%;I0BY^>N\|#V(SY^X*^EZ\$RF?+N)L&.0CXRSI+- MU_HMB-EA
\$Z>%ET>;QS?71#:_LFHV\$#=#+Z7(\$CJB^?>D\|6\|BVA94U-|
MA=EOTW<9CS(RVRY\|*@8_7\|RQO^GXW_#OYK\|V'0N\|JN93CJ&Y3;-DB0JA@
MK\|3F,4\|B*S_0P2\|T((3XAQ@ (2;\|FB\$QV\$L#'+-/AY;P4\|K\|7LB0+!&VVTQ(M@YI+-
H"R^M(9N5OBW\$YJ M)6)AB\$6EX)AN"TH=PA2_6'.3N)?0X2YTL#0)*\$9&>ZZISB)
M7"JI#-+"@XMR33N@40+=F0(.Q4D0\|3\|76&&<8PB;\|53LO@EN#XZ?X\|E ?0Q
MK)AZ\|+C8">'M\|WF\|DP".42%%P;VZ\|9 MTXH*(FH#4#=#G-I4N0>;'A3@(-GRLR\FZ3,
(CDH25_1M>0<,'D?@ABJY?>YH K>5HL#4.*=|VY)?) MG\|PS+1-7.IN@@"HK_#CQENM93
J2/3FP9JB M7\|#Y(>OR\|L>|&)/BIXHL>JS#,LU,VZ#G\|KT#,V?05=HC\|2K,M6/2
MMB+HYR>?|H0.@RRHQ\|SQ'^3@N%\$H\|AA&!6AT8=UL2IHx
M.@BSWP\$=+J8&O6>7/%>)8LJ09VY7\|^7U>|64UGU-L*G)5/6WJZJK,M1X\$&-@
M_JU\|_0@8C(!7Q;";P6'9?;\$%-1(5D6\|T%,VX\|2DVE\|1D\|(!\$*I?GX8)LGV\|Q M9Z^G:67\|S-
P4^OH7\|I-L&LA*R37\|NHG907N)3ERNT@L8_Q(^MHCIF^J"%P\$ M<&|2M(K,
|U8%"ZI.Y#,@1UVO40P'+GMMU7_G40Q?K1'.MN?9/8^W_BW\|H(MV>7?
QF.>R./*>LF.X@85!E*%Q"?+))JF /EW%^E>;R^+CWQ)6YTZ0%!\|/H6
M=4%;F(L#7%>%V#?#&@/7@E9++S:OK6J\$O?X?CNXL3<4&9,%>G=VC>W^@@";R
M_87Q6\|7*F3L4MI\|?E""R*!X1HKD96XZ!G7.&'N+S\|PU-2\$/3B" V;8!4>O M">NHQ:BJ%
|_5.WSBT*>@*9TC(.5NAU0D\|WJ7G7;.D9),A*!O^,18A96)G%

MG]=:P\$J7+2%'\18HAP/MDR:B0U1N/EYEG%B1;I
(+P4HHEI:I\$T.10W^N/J&G148LWGRWQ<%8|<5M&5AR\$<0#I2
MI5J_>B8C6<_!S&^I6Q(MA!%31A_3X2)0[XR_LX\$XB"H#W%N_XCQ7K>Y@?-GB
M6HSEV1U0E#R9L'U&22_U8?5:>>TD8E@/0%J4!S!+C8B:(P_7#/F'MF#PBO0
MY1;R_6/Q3D(^H: 'R_9=FW Y)IWGV>&XXC:D2%6Q9L:2\$=|T>PY|\$1_IVQ
MV;5|PY3:74+@V/OU>K_D<^|5\$W=U#TCI*~A4NW/_/JC:"D35 !F>.XF*Z5_M|5VE021-
Y@QN+%= "@|2&9|>0D8,1^/PQ+__P=Z|1S5UK6OC\8*(";\$14!!2 MM8I*,5I
%#"IM4H5,5HO" BH,<|H=WQC|CV^|_OVZ1|3,T; (MFN|K|S9_).NLKI:10D;50C^Z|S?
V/.EWC\;2HJ6.(S83I9%CNE@Y|5Y|X4 M=+H(5CRQ|Q""A|@G%E*GS^*EG5-
^G#/>#Y:&D)\$7A_TMI+)? "NA/6T?QN;,(MBKR|7GD%L96|G9XJGS|';7+ (FHL9
4#PZ_#TEM"*IUSS7FVJ?FPNJM|JNZ_M|(VXLGK8(|I?I/N7K/8*)HX<:M>T\$G-
|_VJ;5/TK='VM'8G"PE9^@M5^LVO_M4^__R;9WL|BYZ|SFI/EE_Q;2S+_^/#\$)7|_H"##
(N#U-!A0-7X)"A-KRHU, MN2BK((8RB+>#Z^L@S>92W/TN(=U?..B"|6E-
O6/&WOVEA|7P@>&TA'0>OF3*V ME0E2O3T,V^W0V_8:MS2+ XF"=-
S60MKUXQT&%L*PD8&E.^43CZ&Z7T06TL<_MC_B'B9(U/W+Z-I?HVK+ #55_>^K%H,2-
&Q1MYFNZ:TF&>EHWY3RQ@B-5+N;@_M3+JFM&X@_#HV*G00;Z4_-E^|%R),?
\$2LFGU+ _1|W| #YS4N|JL,FVC)HY&""M-192VB|'9^'O:#0%UG!\$A\$|3GY<3B?CX_MA/(-
_IQ>H|%-/(Q#0XF8Y')(X:QQ=BNZ>GVO;_*I-[TDQ|)%^\$7?*:Q)2_M)%NXR:@RPVU??
8|U9A"D4SH.QKE\$E&4?KVU|U)EL4UH#-|Q_W_=Y|85C\$2<"9_MP&Z4PO?
SV_%=1|/#.6T?|_R>*(|H<(W|T77,H=?/KJMC7;4\$GM"6>7Q|34J>,"|?M|A%E,I_7KES;K?
E9:Y5S|ZE9F1CJOW+XA636J9-> MZUJU1W7*!2_FU7G_DKEZE0|7*LNC!D:*2:RF)%?
\$-5X5)?L6X\$(|_TC?4%|T9%""<^&7_MA0Z*+>(?%P;
|_N|XJN7ERWOT@Q."YQ3N9CV1/M;*>+ON&W|5Z|**
(|Z3@RT^!|=^LM7H|D\$=R9)4YF.I;SZ|33KFMUQ|8YC,7|T'CTDTW_63O7VZN_M"?
Z98_O2<"T&V?1M(^OK%V>I7MC:T-^EBPH?OXW-Q=PM)*E8C>YG.OSER9.'|JGNJQ-
W>ZQ\$|0W?13G;%D%E*8ZW0|FFKSFG5/XF?..SE2(&.^50*%"&O1MN|?@0>FHQ|/M?
Z'3U5^FO)#G\$0@7Z-@+07|4GZGR!6?GJ?SAS<_IHGE>O|Z#+DF6Z|I<6;JF
MNMH;J9AQ|:AO5&G0B0WBF%'77.80G=DF\$90L^?1,U_F1>|&NC;4U2U5+*J..
M,68\$62TYTWK@)|IAH5)-.R-2MOF1.LP6|*NFQ:(?PNJBK))5>R;*_3!OM!'MT'@_DDM'1!?
|O#ANE%..3E==4GN;5;/TK@PL^_X_@R/7/YH<->-7ER>&\$7|N|T_M8V=#BR='_..:)?
W1*U;=U8E"6_6>R":|Q;NN11?? M^*J@ZQ(FSPH|@9?Q77.QSRW"G:Y5|?%EG#E-K
UZ7&WA)87G3UIB=E|3^4_M1114?K+GU^*=/R05C*_9^M&-|KF&Q?'79
MSU|N>&\$8./F^70/"%U+CO_'4R<@V29LBX5TDZ|7XBN##<1+)>_)B|QTY1R" M#9P"!
S>1E8(L5V"?N)EB9F"/*63H9='P1LB>XS,: W:M&9Z3LO_NDGDQ_V
MB*7PX8GUV!D+J:7"7|_-DX@COEZY"V>11'0P15*+4\$ZMQ_L904L*:SIAN=A
M(3V3H42R6UAJ++&0AN'@WU7)?#(?;O|A|Q|R_R'S'+_3Y-YE-\$WVG0H)|#J
MSZ,6TM+HR,CLDY^%P/TIQK_XOAW+A;_NB!!-0D'3MS|L<;H:P4H;JEF,W MO|LZ7-
SQI/5_Z1+V?_,_4?^>XP^-_Z'Q?_?QK|*XZ"_P27)_H4SX@#U6B5XW
M7D&|_|)0:LL8MGXO+I?*RSD9|Z.8|K/MDT(^=T5,13C80TO5N\$?B05O14SL@
M<'E59)|9E4#S0#(ECW6;)BI?3N1|^B=R99RH5?@|TF@_I>@*8S1X8V+A'70Q
M!7.TD(OIYB)|_9>&N@A.CR_"FSU(0*6|;B'9'L8V(.K|QE@T0JV|(FH=S|/Z
M=T|40PRD/>ORF5+.QC;K9PH2Y ME\$CR? MI9I"?
R0N2AN*>'&MM6#/Q%C>H\$SM'45#|2EN\$M6&9?K_|_0048:B_M8?A2,CP;2|C0G;Q2-
H(O->?QI2_6^9"915N/VE|A|CZPW8_KB?QWG1L7S1#_M_|3<0BHH
5LMI_ =C)9"87^IA121JC.GMO_NYWU)84IF;;W!CF7RX=CN!#D5F)OY)L|OQ%_B
MCZ@R)L^1C?@\$@Y!YV\$AW/K+60'+;|_4P'0(IVO"!U@8X/VVEH=@Q3:4
MG3/6.=692K5|M;MC%_YL|HUEK:%9/-B(54N^_QA63U.AXIQ@<3)
|<\$^:'C:FHOY9^\$5N!1\$KO|YIXUCT3MG:.6J;|M.&E/'6*MV_S'T3WZ. G#6K-
2*ER(!=M)MW+ M3_VH!O405,2=O=#_1'RU_&2ORO%E
/Y8F_C9ZKXK>?X_J2U|_#9K*K1H<:!
MD;/%Q9W5OX2GUP2;2=Q_:NQF8@OLS:LN7U9\GC^|4Z31J1HWQ5_>_J\$*.Z:
M^*/O.AN33!LC^A6Q56WHSLEJ@.;#D|?KNFLK;4V)U/#O^+L>|XR-5T|X+TRD
MIQ.8CD:|GBG0T;|NF("TCT)^;T>GQPJYL.7C4|MQK= TS@/QMY6\$!#03^<M?
\$H"M\$TQ\$LA(-YD:@|1?C#RE\$*&7|:
R;_AO#T6TINA4GR)3/O6/!_R@*'+2"*0GT*NFD1X1E|JS A!+YJLG-F!G_P.80K^_ASW9
MIX&' +8%.M8@)SZ(+F-/H=)Q_IZ_HO|.(Z,GM?|C|A|Q_R/R'S'(-'1_9JH@_M&'|_R(<+73*I_|
(|@K)EJ?_JX7T>'K_0B1_\$_WF_SYM_%,6|/^[S)(@H:F!_M4,84E|GH?|_#?0?4|K1E|!@_Z\$-
E0|HPT/_J|S.;?|2FJK'C_P^|WU,I_??V_MP?|F=?|_Z.@O?|?'4|L7S=#V"FM4Y^|55XF6J?|:-

C77U"WYJ*81JOPUKH(3. MK'? '#KX/7/BCJ?3V4&IG=MNW4_>!I:GY_7G)<2(MOMG(?
L\$ MZ7=ZQ\$ W=? =!Y#^L^!L.#X9L_#TL60'USS*7PY%>#I\X?>)UG\K)?\O
M_Y0^QJ_T/M?ZC\ UVU9?\$. \$R/X\>@Z^ \KI1@8K&ENGH&61M_K\$@2CG^
M(U'^Z'\$4*XR1T9JH<[=JH"?IHF)TA?)Q#_#)N,R!LX^!;TY-3-G+0Q'W\&7"
MK0T/NQ,G\J(^?/KFI=3J&S,?^ADVOCG<,6GGPT#GB+21 VU)=079IQ>?=LN/ MV?
GGAY>3RZ6ZO* @Q\Y+BM%=18;')HU/EI;G0\G?>>ZDL\OX' B.7\3/ / ^3;>OZ\$M
M1\OBA_ ?"OI:HD0K;JBCFTM@B>94XU\$+Z>6I4MS)NH4Z M%2 @8
2#IR/=; .\W\K07.@-JO@\$R+;3@?=-0PF:\CT^ F%;!'S+_ \$S+_ ZI+> MZ('3)0J-WB&F>_0-
H?'X\; ?X?#;%;M:PQC8EU!V+-JW!%;CY8\O9GLIQH
MX^ORUH%S78XO\HPZON=29\OWZ3;6\$N^!O0\ E#8\F&' ^H_?IMF5E*&I6S0FUW;J:R4RL
MXO%UL"FH6I@X\HP5F?44 M=P\$K\ -9YF/^W"9(5T\X2?S93V,+(D\ C4U=4AA6,#QY8VD--
I7J\+6N+<'>%F M(?6\>)\$B#\$>IMU.J \J=>ZL+=A!\VE8K^O31UJU?4*\$I* LNH\X
M6,WKXLKHB 1_XY?&E(T-T3>/5ORTS4<>*1C^W_C0_ ^JF_Z8)73Q
ML(&)LHSGS&46DD9(L<%6:IG\")%,U# \ @3\$=-D)#^*+Z\ ?56YH>5L9U!=?1 M7?
WZ9M=#15-[,C\Q"!%]"DK60&";*O.!)5S!_A"?F\%-YN^K1(1X?-@_6"P
MC"X680LS#G71YN'=ZD6G&>ET\2\$8K=\$-9 -FX=|+;_D*I3VPUMZI1RCZX;:(
MT*0(U%HZGN7AV_&B)P9EY_IV)6O.K7K\ "4BSSX+J8:U3X0OC(<*)/-L\UD
M"EAM\6.).Z:(H\ VUQWW.@_AXOUY%RZ^+;:%M%:L(_)^8"+|+*1< MV(G^*5,
U_HKF.EG/0GGZ \Q?@:J3%MY/Y8\$@3"-@;6W1^*!\3*7T>9RGC*S M7#WY-'O
W\HN9%WH^F>C945)4I:\ARAU MQC+3>JLURCG\$@ZP-
E\\$,7WA0K2ZD6G:P\NK<#\$\WMM32\J*Q%ZNPW9617%\ MFHN\$&<9;0\,5V'=TQGJ'-
BSO1N/5- \A!1\G/9MBCE4A M@1KUF-#\$Q-L)1XMM)N?1-@ %.@-FD=-*.
@&_2O#V""%AC(')T3Z\X\$RE0,!"KIOI^ M,ZW%?
QQ"9OH#G#;N\!YX8Q;;T@'RT7\PI\O0Y%IF+5M>3):I*,AE#E/\-A-? MP&G3?GD9:0M#K^
73_JZ#61SM5M7Z\IONASF\$@ \PW3)C7)\A\$%1KHICCN.>!C M(XKDCY!7P3B#&&
(N,&1YTZG>XB)B*OH-M05<"6W\$J2*G>
M=O/YR%F\ _A\8' _JH\$7*A;N\$@V/SSH_KOX(;N>Y_7X&U/\I'3-S8#A,3ZJ_T0%
MQT# \D)Q MID(F'B1/3TC,2A)PUC,\3<& 0&;IQ6K\ _P>1\%",CX&1U\$BB>#%
MW\;#LWD;XM%(1OD@H"U9#78?>E;.)=-('=LD^ \. \3&=, < \(&LHGIP&(2?I
M.40X,BX&,%H)AZ\$:*U7PY\0%W%FUSVA.6""X8MJ%\>C&SN@;;BW>&I'U: &V
M""G,>UW^\$/'.;KVF\$2\@ \NW1UR ^0^#LDA?H\ C>C15X)390GKF\$MQ:MDFM\K
M**2;4WX;Q'Q8 V)B4<_6_A^KO.ID:@VKU,T/@+"EZ)O\H\K\ _\$;H471@X&A
M6WZ\WS=0\&Y-0"&\S3M6 2\$1;&?N8B2,H,W46;C".7IY-S8C!>5'= \)98I#- M9>H24W1?
EHNP78AB\!>-DLQUZ@FRO+0!Z^= 3G7=DN+D,CJ'VI6@%F31W\BSH\$#33A9\KX0.I.)
MKR+2Q\TWDNAPB\$V%"W=7+ #39\^)+IW&B+NC5+%J.QZ;Z" \ "%GL%\G.A^PYZ\;
M;FW;=G1'&1K;'&X,\$EVX"2U1-C?_9:P2?VP01&/*.6? \Y,-+T/2;?A*T%, M:\3#
(W8>TPDZ1GG>9

U< \BF(M/Q: S(VT%\TD+7>0E:X\$W\ E@F6:#B_MLDZ4N\$>YM90\$=DY29\?
O'>0&HY\AU>;+\$\$N46T(UWX'BQY_&(7U@.5I
M<#+YOX3FT\;\$\>A@JQ9>!!RU\0KF>0MI<57RY\CPI<9_9+A5X@^*=1 ??P<)
MRZVU8S5!"X+ \4E%/Q=FX\JZ/>B>HCH.1K,* /1E(N6&SEO"Z3T\$4\$4LUYD?P
M<;@OV)B)4#+H&J&%5/MC0)EZK\$# /2\K(9%I@?WX#X7X M1_ %B?' \8\$U_S\I
MIT_S(THBORE@9EST^R 1Z3Q\6N (2IN*\$G\N8&.)QL>Y\J6OAO0F)\P/9\$S_
M5)\IABK>0I#O\$;C\LO+!M=U0H9:"4X_/.W@4-1\$)F_2W\=DU3\I? \$WOT\OM9&\$3
ME82QN\6""0FNHY&AU: \SD/4Q@?QIR\$\3G2G;DO \N=+*PM_9&?6LL%:H8&E
MA=+4#V*Q1=/Y\8J\ "Q\5# 3JE#+FC%=,>V*" \>R&, 51.).DE%J:9(K=BI"2@?
 ;V&W00;I+GA,8.8.YS7)JR\IE&;ZF.7A: \ 'F\A7HB%E,VF M>8R^O0\!&=-F
D/,Q=A(C';2\4VD5^ \J\74?_G@(.@S^ ^>MUP*JP/X_-6F(*P/81!A63"+QZH M6Z#SM 5(U-
OSK\FA=Z-94\Q6\OE\H5Z ^E:3+9\8L#)="%?&G0/V>CF4\C"QN MX E1^=!3-*JJ> \I 1
 \L2\>4,!=0)P5@S3CF- \S6S;/E\7C,) J5,(=20\Y(MFX\H &L,*WF=D W-#?
OHF<06_V':L6VYVX7;IWL 09F\$NHK+AB\KE79# \$2,! MT4\JXZ:\$ ^;YG#-AV32IC8=R?
7X4U< .8P#093PO1UL/3/&/8?@2\ C\ D*\$TG3+-&# NKPHQMO?@"T&\F0\4O\QX_-@O-
G3%J%OK^WBGND9(Y\+2*T/9\ C,Q MJ\>:NW3/^A,7O0(-4(I?T)U\8\J\XN=.F\$J\T/H'
K/6=H#DK+ ^W:D\WE" M6(-
U,R7;\6#9\ _6%>^, @;SAN*\$SFGP\ZBJ;:M,1:A< \= \F5J)>6TL3(.4O) M;?1C(\.X3;MI-
^>Z%':5K,\$VP8)(1"Q6 ^ \<7\ S M/Y3+/,UD\6 1BEN \$C&KN;E\ -H/;S1X\9&?
XSQ\JH^ \32%(' @./99%61#1O\4B;N1<\J?)Y\$7<9%2A4"^,(O9Z

8X6;#!E1#A@P'@76J&>S^J%_GL29UY6\$[1%&M@V D"IQ@<2>8Y6:
<1O@=0AE9^&>W'#TF(5T42SD|P*0^?W%5_)IY8'&*|A MH|HZ 5G
#2|J6;*@EWL@NC4JYB5|1*SY|&|. #|W!OF4CDSUWD3W= YM#;)Y/2I2
M;OONRK'.X>Y;EQ1O;'44&26+65|H8)H6XRK*0_48VW2(|SU<%RQ3|Q=JX8L\$ MO(
NJ9?A*0YT.,|<*H/7=+I ICOSL<=N)A2Z,F1D/A0/9.C3J4BR0_@R:ICIHIF:F2.(Y\$
MM.L&Y#-;OY'7#5G!;5(R1;Y/ M)|("W|X V>%9ET|RO_\$7 K'BI9PXP0'"|4O:O1,-
MAKT/'MSD))Z.VLY; M.!\6)VAE.!'PH"\$E#8J%,@[1 MK23.1Y3:|E/#:' :R!-
B=#JZXF89)+E;U.I'-8/WPIB(E20I'8"UR?NT. >:1WPDQAHIF| M&64\$8HC1,5VB6"G&J?
HU|Y"/@DG7SUT3D?"%7MX1L|O)|- M,AP).AZL9A
B)QUUS7>E|\$25AX#W=6Z9\$1"|G:E4A8 M 6&9&%/+=N?
N*12JYPO2Q,416T)T.|%5;2B!%PY| Y((U,\$4;IOWA\$G#PP M/D;|C15@\$I6T:2<' ^9?
|&'ULXV'PR,0,*W| UTB% WXJ/5>U20EB^;^!)"_ MAI1G-QY-
T5)FO4PI6=;%F2GQ,96|;039:WHF0S9.W| \#B2-L9#BED# '4EG,
M;"&)Y_K20D+VNN|GD;W1#U8U;A9DVC=,K1<:\$Q&_0UV9=&'V^|A*5WL|27X M,F&?
OIG GMU8N&CDSZ\$5G.H0H03LU!2J?/.(B'_\$)|U6(|5U4\$E.H6|
MMS769&@/#AMF(/5;JDS0'Z)5MXC22YQ0@4S-9|K12-SM*C_EK&C65:%=4+)>
MF8N00#QS>&|<4.3I70WL&-&.TELCHF'|FS=&&T)|K|W;?X=_AQ?)C4+*\$@6U
M;|RX%1A,*WBM4)TRXQY!ZHNFEZ+D0|7,?,DB7H>%-+Q.U*('@S<0!-,I CQD
MJZ|^<19L5P?T;Q,,NTEM=!68J|Q4401#TOTNRX+N Z&A;2P3U5 MP0J LL1SP!E-
59+|U_Y7Y!O|1UX5SASOC6&YES7VQO>_OH8BOCK-E|65,6T!)2GT1R?X2RH3
MIK+|\$|WZ00(?2KB\$#305 N_=477T3GD.QJX ^V6J \$ _^+5506&IY<'*^A63E
MV|MN0@D|APWY=^*C|4 Q:MW""S!_0WN?B'4H@|: NQ;DH06*Z&5H>8N(SUN!
MA%VH'0R43GL:BW4W+ M>|V|%M(|H_U|0"N%-\$_;?%S0JZ|?|L"S^#Z M(\$9R:
(Y(%93(M;8>;7B|^Q /PHMC^3H0|L|09OQWR#(Q^)*EG2)O3|H-BO= M7 BQU
.C'Q\$&3ANEW*;<:U!IR7V&T! T>D|_#NXG8E6S&_U|'=SI-GDO-:01"
M7:9K6%"HAIY3,@|T+=%647|V4=|&QF)9|K=8;JYK-D-^;|<-EG4Y=N)L|1
M3)1GX5Z|+L@|S-|#/2;|1DOY!4N-^V!9Y+C|TNS\$7|^,03^;@MV' |DDL# M(C1\$L0#L|
(6S/8+2W^I5%R34^XJ_|3088#L,)(2+;*>JR!|-6@L'4CD|1|
MS_S8C^DR"KOB*SDNOEG\$,O(|#65HH.:7H9Q;*4^;(R."K7^3>-S!%;|HV^X
M"X'G'8Y,YUV2L0665=)S|,VI0D=6\$2^?GH/MO|?;|('BJ2ZLDL6| M02LJXFC3YF9IZ9F)?
NP%')%4LCR*AK-S544,?E#,W82S|7E%(89987D'N|>M
M(+UA@U7#AG#3;KS3&1+'9L%O6|@:EQPOU*?2UZIMN':F#W@_?@+:0LS%<)S7 M+
UC/FC |= (ZFA_A98P%(P\$*63Z+"?%AQ^@N^="&CM-J|_B&<7|MZ-U)\OQ7
MSSR4N(W6=)A|P%Q9*^S_#?<&L01XS!0K^Q3&6 VK8FK@^V%+2FN>|JU4\$:O
M9&X4_4@/M3\$TQ?M%J>A5BF19|R|&FNI&NGE;@?O|H09|Q|>M^XD?H!0Z?X
M#Y*EYNMX(&|0|0+%6DA9%\$<,(P=LA8LQ:W.U9"F<0Z2|&VJQR)"H":3G"A^|7@CU::Z
M8"G98X"S7"^=4LDF00X"R|83|FP8*YIS-YZ%U+4FH1|&?OV9?S0YO?|UYXM/
MR0|E|V*1YH>-|2C+F(ZH0LZ5|7A5IJ)OXNF*&!K#GDIK.OHQV<@GW;|JNL#Z/^ M?
%HR41 TMZ#:%'|0=(>"\$4JL@7UN\$T'HB+(:4Q\$BTW1N|J*)K(%%D&6)29X,|?
V8N&|HG>_+\$R*K|E: M=GA|Q:MH.44^|H1+F?>5F03O5FL|%>/Y,(6VFC5%) L/S--
:*&"U|5B;EMG79OP%N*/^QGI@A::WZ8,-GJ9H_'O) M%G-1XP8=L20L'(11FR'|<\$XT-
30%Q;5|Z+J&:>-.#47"TKAK|G"N|T88YX-< MW#B5S.|&V&I&-?
AY9J&,#M8P#;\$WXYD(@|'O8RP!\$+)"QGQ8CRU2ZU+.|YRX M5"18UDY5=&!?
F(N"=IJV<_9'HJJQ;X2+L-1JSG DPFBMH*T:B8@6:H799*TR
M"YJ|\$L3HR0M&#AGK<+_SAFLE&!UH>\$R886#YKP@1S3)V(|E4+/92WP-|@)
M7M2\$>P+O:B#0M:L,B7KHPJ&2|VH(MLBM,<^|B.B.I*9+G%3)OXT00PE"XDZ0
MEE:77H|YCO|6|8K?Z,LE""X5W|^EVS:AO<*Y|(U>90')'I?2P5>*.VOEGF M6T2:SA?
6A0EXJS!|5'B|9|O92'Y;|J2|V|Q?4"-=7Q04,D,.QOL-8/4.V. M8/1'P\$?'S#;64)
H171G%>CLD+CPRVB7K78'UMDV|1|SRNOES -=-<2+J/ MH\$|L+P0;46G;V9|XV!7-
|+R%0A+^A(6"1)TM=1\$X:>9^Q/6|5^DEL(DSL". M#K%Y8:!/ _&2>%S00
PH3'Z2+W|J%?45OC,Z|0:H&GI7 M6VRN@!)%?0/&3|%1;|MM-
5|N<4+&6Z^)!_)W6\$BR(??=SO'#%AHV<@0I:'^ MTG!4| ^LJW|%/=!N2M.V'W;
|!\$%\$SP8"NZ1@0|8-NK00IN\$U=1ZF!#;=T)@)(
M\$>CK0^AS47|J035HBWEM!\$#;:"/*TGLT4_I=#*[X#F?|T=
(MC9^Z'MCWWP|GI@>|/@ZN\$8D@NZGMK+"1R|>@!H69//<\$V!YFL?NM
M6YA66*H(Y(ZVU-AGF5=05@ZMMR+)9@;|\$. "7#*"0^:P8JE5=U|17O'96?E
MD6U8MR\$:R^J5P-I10!>ECY3!27N
M"%D6RM;06P47ZHI>B'7D#/7|H/C2|F|5.O6B^#NC35.AK|O0F>|S+20VU+RV

M_1A0(>VFT<6@-;3F I;HNB==61RTUU&=1TEZFB-RU@.FF'JH/G M"
(ZKGZ:/MO3UJ#*"UMP%&|F+? HOPELA:8IG IKGHW>@6Z|2_XXKJLMA:2
MQS+3&D@:C*_%#IC3>#3|F=J=9_-22+A(+403U=OL#*|SWFC96:(JH8=JFH
ME_\$08)E^,VIQ7,E2\$*AS_VCGW5-!3:WS/,|C4/3%M(VJRX" M)#N4QQ4^OZ\$;CX#AU
M7@ "%7TW7+B=JR;@M|@Y:V&Q8H;TJTGN9%|4YU^_.1ZAE+UMU"!%F)0,C
M4Y|VK_L.ZAMHH2TUWYR^R(U*5*XCvZ\$S=#W\$P> MW& @1_K'Y46#U>
(RZ6WN>D|AS\$+:T^_K3J/;M@KC4)S+8V&+2&|?!"H,*(-=#O_ F9H*7>#:15(,;>@;"DE
MKY^?NZ*+YP&^&M9*BO60"Q:H6O9L|/03*+*7N^;>3S^!#R-M3F)+?STR|!-S
M_.'0^\$6TK\$AL|Z,N|S|,TN'G;:WTDXR|CR|;)G;8065%RL)UW_JK5EKREKN|V7YFAJ|;KIS
|XD?OA_C<1)S,="|?%.RDP""?P\$ M,>(_"!>?%A)0O)9I"/Q_AK|K".OT'DU!3".ZZ
_+O@C;S?/SM2&DU6>8+M M6JK+(-.8AF&7|R.F00-N5BIB-;/%D F?
=MVU897OH1|);ZASU3V14_V@<.PQ
MHF@6VN,^<1|NYMMB819DPWM_!|(DJ,A>\$*J#^4)KKDL9B|;"?/,T-2_:"N1K MF?,Y-
5+7X!;V+7<-&M;D|GD G7/EV"U0^@FHT7K'-)E9S=NUGE;'^CY((@?
MCJHQY^MRX9P@)SU160DS/Y 7\$DF-%(4=5=4*^@V|Y12"|T2!XKO3/|/%HW&#:
MS/&1J:V2&3-?,NT-^%P.-1(12D,\$N9"C7S\$|!7F^=J%A*NXGG9EM_%-:(H=
MBZAW/)3>0D SW\$:%MFF#18.>.XALKKDS%(#0FAGI0A0)|EV|'87(DM=QTR?
L%/|3K@R0_:@7I>FG@2(G4|X|_M3%O|2'6: M'FN&Z2<#&5FM07&&'9?
3Z/|@E)E'N|C^6W<"%|I6HVW"FLI|BI*""+*|MY^ M&R8WDE&JE+:8OS5#05O=6?
WZ9@|6KF4OB&9R-W9%0&.C>93LA<^/<&)^@?N3 MF@E;2I'N\$VL*8G7#CT4&&PU=
(+(TXET|'5R"-SGV2JT&L<|N"EB|Q4JMDS' M|E,J7\$5I4.Q?3Y|D\$FNW(9|/?
M9XS%D0'O|_HB')QJ K'! M/>=I#|!*4SROTY40%PUX&=>!8@WS@M
|.F\$A|15(F?:|500"?B"NQT)T2@, M*Y:26CUW7@-
>TFQHZ)D+9#K1!DHA|S:OZY*8R%=O&JK)^?M?SX0W@?X32+= M8'
\$GP#KP8C:V\$J\$4@%WL?D1|LC|*U1/:6;WL72',DU|N4O ;VB@\$0)Y)A>1 MG&QW)"YZC?
F;L4:O*LZ_%I9O(>L++_I5OK"-C9?X(W>N:Y79#Q(D|L_6<7>*MXOK/11:.'\$H(_N 7?*,
A6YX0AA|C%1+4>E41I*B)I9#4&6E4_2JXR^>!#->"36^/Q/80\,N-F# 26F%78!U"VUN
M/5K8_C_WUPO3<"?N'."M;0MEZ*[6:/(#Y82I:W_N3J8N2AA:0N2=??3,B:@P
MG4NK(/M|'8E(H%SJM WV<).U;ON^G<|G|33\$)\$/B\$D(W2'V|/#**6V&R3RWK67A<0U7&|
\$|O M C+ VEK:6D24+Z;SU36W/=::S_A.2NTHN9)<.6,M6S<@9N J@2T=R(X(=(2
MBHJ|51OR^&L_M@NGZ=-FA9;9_"2X|7?K7&>ERN6F)NF@H6|)JV_E_L/4/-7
M%F*":D_H2OQG(8'5@K\$W:&"SVIZH1Q70 XX"6R3I@S->H1N+ #LC&H&62&9P
M6/IS%F8V!+=L MF:4H^K+*1;HZ**::R9JBY!IX+C+-^,*-
A:=>K;G5KC,S6M9';9M3CCFVZ:SP M!X3AMTQ? ?|J2B|E|Y&PH/2I
|&4>KN\$\$(^6+BB>1Q4CC#-AY?@P|S: ^F4|U|_K33V_#? MS9@J0*DZ_XO'S&5P+#T-
G|\$SL"OW5X4NEHC4_!I%S.U7:Y*0#"EM*9N/NR.| M?TT(.#?1;W|7#UV\$'!OM=,=
<#G:5W>|6G29?H" _PK0PI8*^|!0QSH!O.F+B< M64:C^6O>#&PG4C^6KQO/%-
;^9"\$YEJLD#M@RH6Z|VK#3M!8\$-O/F|31&:N\$< MM3,W'-)
|QVK5EQIG;2P_5LJEHWN>W.\$&@,12F5|M'#?E><%/Z.3RH/"P:9;Q
MY'V4G4M;SNNBB*TO83/TS-FO)\$&|C7Y(@5:1AC%O2|LX^E"PP11X&*3W=MIM
M"PX9K9Q5P2G5BR|1:.*#@@U|?|D_>?(*SD|"'X|LXI%\$-,<706(SI"*|-(J!%N&D5WD--
M^>3JI^0N|;_@L*/ *G*)X/(E8U";*\$MF*;B?\$L8&HC.6VXA
M%4%US!9;%O>#Q;2A|55+DS4WY")!NL|HKM M4_)3=K:P3H
Y|1LCP:AIV2NUF"IE/U<=-A/LY02Y'|*.CSTLF0MLJ|"CW7#<M>-|H*|
U1<|Q<.8>4+7B:V'Z?,E|<=%N42|H#DI!,CWO% UEE|E|^4GGREM M;J@=NDL\$?
*|91%O/ZU+7N8Q-FJQ C&;1B&DFQU"|"Z:\$0%0(M8HH|T/X,:# M*DT|0Q>6"
<<*+P@0E8Z2I@6QJPH T3|Y0I2SA1J"A<,MP!S=*9_-ZH!YL@SSX M=|71H\$>+6)
(85="C|M752).2KP>8_O1G,W 4\$%AV5D=R4S@6>|0FB#T9#Q M|,83G5S?1^WO<
%"^|B+M%2YK|*D;BH_)|0@U78T>0;(TP;R6)0*%=%#)HE M5;K0L|ZVR_EQQL?
T,H0V#.%(|_I'X8-E9C"B:*FU_0&@++|3+,-"E1|"/M4>9%F%6U32%9@13*;VT4/KVQR
T5L/LZ!=D!47IA:|!>@?=(/D-2L?>Y3DA MES)8FKR!GW%UH|JW??
FZ,&.@60PE"ON5Q@@@@?5<|5S(#|S3?MY!BE?U*G7HL M&3X%8WPN.5A.5
A7F4VMMO7W"LL:P5-M)4V3>@&K<MV^ZEQ+7;0M)^BFVH1>N>Z Q? M=+H|1O:*(?
Z0= SIE"4>VHPX57>!N+1|9>N>|HM:I'V03\$M@%UOR%_C"Y<\$R+
M,HP&E"B0?/H'"@EO8;KA|W#?44&\$#OL&=/:Y.L',G1HSJLS#IG=,LH4;@D:2
MM>MMV00_7V.PS?T^@;FNS3A&|JX:W2'US4N^Y99GQ:T0OL8GA_,&W|Q|X-
M7)4IAAN)JLH??N-V6-8&?@0*?F=X?
^,YE9ZG;88/WBZ|=X^L'OWV>^<9K9!=@XO/B|T6-!"&&C&QJH(V=CR:9-W&-

\$H%M(<|CO@(.HB|HS4N,V/2.:8|%.T0V\0TIZ3P7 M3JR\9/57G_R^|ZV8H-B/&\$|=
S|G1/70RJ?G|(6H|28 &MG\$^M|#)IP/4%\$&*2,VOIK5"?7L-N25PAC5!D\$TR'ZWD?
5AY3SJTSR-NK.=5O|UP:U0OZ4HQ/S)).:ECM M|< T\$Q_\$2>9KR:/CBW@_1B@-
#"15+QS+BT'#/D#2 :L9=N!2D:Z6H5G@FD:4 MY|\$*O?/H-B?
+G=5B5!4OF_%1(TH\$O;E:40R|F+NK/OF @D|DM?IKUZ(62\$J:8E=;Z.:5IA^
M5G7>5^0&TMSD#AN+\$_7Y_KN%VM*^X!2=|WJ+|\$|NG6YS'N((|P: +1'F3ZGQH M8.:M:
<;T|ZX*C)V@&/EB_*.H%BTTD@!2N2Z)B4C.-V0_)O\$ANO8%704=59N
M+5%K>X0M%M+2)\H<<3M|A|_%7L;M\$|G(>4.K>|H|\$3&9<|&Z/-)-L)4@LQ9^CL;-
(H=P0N!UY7: +/*K;LK9+J|FOXI*U P1> ZUM1+9(AGK M\$=8J#
(=)WQ#)!N1YF+N8%AB%*3>I:ZS\$Y|6(MW#=@3+|/FXTH|T2O M@|QB|,P%W(10^X)
|W\$V|XK<@%?4S\$"G0W244|;U>#5+W-CW(D^K9DP(>
|YT*UZ|9#VA<>7Y")%AI7\$^DZDZ5CNP\$_%M"RM7M.;2;G>Y&PEH0D-F"T2!L.NA
M8P0#;+>0W.&3XWEP C84D(^?-?5CGF@IOD@B1F*;R2@_K9&MF64M9UC'E02Q
M!71GR5+>4_R|SC%!.=<52;GD&(:X|"(E#;D@/!S@Q@B\$-+B|B4^LXN|+89
M2MP|ZQ4,|F&H^A^8S7!=(9!O5;(QYU5|)%C*0 U1@,IN|6,|D,-A0""3)P< M 9;=-
B<=D*!^/|4778+O#A\$!|=7X:|<>|/A|5#S7-^\$^>3X>U!|-8/
M: +E=N"/PU|YK!4NY+) &TIM'98: M|=!MB@;F!8D+*-!8IV'N&O|,T8:U"
<(%W%31=EUH|(>=M>XQ+4-+@0J?:T+I M>Y|Y0YH%|H&0#9%<3=#CH2O;
(59S/Z|IB^)!7!TSWA^IC5*U"-(|MM0AVQ49 MDR+^*JHA;(^18/SDOM|
|3H5&D3+P|K+J2L;SG92+\$2#Y;|J-X7C*;H?MA M8SY:1@|-
|B@)CU;HQZWXS#E,+)'D"6Q!F;=.I_ ^<")Z\$V4.;3F7C(Z? MERS'=HB|?
YX<40OX>FB1W=IF|^!|MM+PEA#IV64BL+;;\$O^EG>1W"VK32! MOG"L0?
H|VHN4E^"/_|9E.L'DO0!ZG2>WU;4?U?GA(4T'_L LN?Z@&54&64Q
MA|^K7ER/WIOS8O\$Z;'5/D+L|!9O^N!YWH|2)_W|\$EFFMH18D'GF8O?D_@2
M\$%4|/G9=K^ZKE'E040M)+LS|K-&>@HS=8!_ZM2|P1&)%7*Y:0UK_3XU?
XFU'QHF@CH/ZN|36F\$.;T:.'H.A. 60E6<9K M@FJ#QXK1&L+IOE04%W?
A*A|H0ZQD:H|O7T'-R6)5D!;|D-D1RUUJD|SW,Y1SJ*8,7U\$8=:M.(,|'M>;E_Y1*,BA|F<4
S)_GIU2>JQ%5<,#+>2"D_MY,P_3:S9%+T/,88" 1HJ;;P M_'*0@_92+C =:|R-X!8W7?
4L=H|.Q^M,K,*"|&S*=B!^OMPEU^B#X&19*E1 M(1^)^4>^JDO*R!
+_Y0>%:"L@)/B6ZRAH,|D5/I5>@(:K'8YCX6C*5& BOH8 M%Q"6*<7V@)5(C(Z<-?
D|N7D<>*880/7465@JN(X,M#A'KT\$&IT V8'S0*X9?^1^AQ?.WISQ)X+;|SSN3/1
M%P_0_1J&E)F#+ZOK.C%I(65;2#;|I9PW1VHZ;C;4=QB2!2X@<=J7YY8%JF.
M3O"_'W|^I6//;NQ?W./5J_WV/S//F?NX5+=.8? MOP+|/V|7@/3W|MH|"7IGVU_ ^K;H=
|?!5M^2'#'?ATZ0TRVD^V^EYX+U0L66 MX @Q4E8M+@.Q(9V-
/F5W;G30(HXP/*0MGRX;|NAZ3?4=L!\$O.>\$|&+;_N26 ML) NPX1YW91.-
T5=||F>;SS(3E|_ =A|LM?>HIB|)JYRW^(3?W(KE0'ODRT/J|!MV<=32G-
\$/ZZ4NE0Z|,T_7TW'|RO|VC|)O MZ>*R5X-?A=8*NT^'O;EL(3D\$X5+*Q,=\$-
E=C|_#F6TAO|&-/"K"EOYGF;R|7 MHR-+3'?8RTOPX,W#LRTIOBLGQ3M:AJ
MHOB3U(=7R_O\$GV>GUAF2M8RLQ-O?|??|W\$|:|X:UF##W96#=#5|-/J.;OJ*1
MCE7JQ;|X|WSB&?|S\$KV.M= W/!>S/JZ&/3X>AQTRK(6D;9:\$O.0|VG*0..\$I3
M"!K GKX|T%.:BJA2 UGFI5-F_"I=^N542N;L;+ \$AIOE0B2_RY)?;A*7BU9SK M+?LX60-
ACJ^,*?O!R5|RLMZ|/C|VCFKC"M|!%85%3R%U!2.L-%2%50!1#
M4D6DB!@5A0I"JA:YB:D52I0XHW() %R&M|J%104D5\$0(C(324D0\$)2M8ARBP0E
MMRJ"Q,Q4#%,R&<|P.^L|ZYQUOK/6^2,K8:TP>V;_ ^WG>Y|G9|X|/AMG@Z|6
MF/@@=&&F1*=|J6>;|>_KR.OO#A@L&+A@,)|_=\$|B|U7?@V(F'_W:I=|_ZI
MVE=R=5W=E>6/5>|'^LK6I<2.Q ";D*3B(_9K8;N%C4|.*RD>|7ON.MA>75=@ M534J|?
YQ-)SCGK_ /X@;=*_OP,?M->O 5ZUVJ(GM-TU(+Z2I>.*M,#|+X)RF
M9BK|U3I1CG>>|S)\$)@-F(V<<,I(=^CR.->9.\$QB|#M!>\$,F/C/_MZ;K&M_U%
MG"|F2?%.O+NTHT|T6(P(C(85-'C54?;/7>I?G5P(!R64H<,|X-K53M*KJ
MPRLT&O|UZOT\$C>' \$M35_UQ|LRGT\$O/1G(S@|37UO'6)TH++R48MW0^LTE^H|8M+^
MQ-JRLL(>TWZMJ5VF*685"_QN_%@?+=1USY**C.KN|93JG?0O5'7L|KQ8=2MT M|F^?
245^P*:YY<;6NT@<|2&;A#G&29,N4)|-*D_R4/@ "H=,O(U4@SI+56J^ M5RN(?W*
|L88<|!CT#FLV)QW*RI^F-RK3|F?._#O/(_N+&|PT=@O\$9+F.BG-MO(%
|:9K00/T=|FR7^QNNFVXWN@>WXZH_N48T?B,EGZ'1YY\$;>;98M|VRF5H\$ M#9 S2C?
T.|+D%#Z!-S<^|=8;UH;C#5#YNWRL,O';7IBVDJS#NIY|-\$:_@4* MSL-
SYD#AN913QL#XJ;|V(M=E-F)C|AD3>Y%|HRQR"M@;J=Q|5B3R-(K\$ES;
MDC)GL9K%X#(X3M)%|5#C>K9S+1+>"2R&N^19E".WHCZL*\$*.MX%?
W1F*TR@*AK:F4'0.1#+=-/!K-P)U9+R:?

500&HHHT&&N8\$!EX;&+U/Y+09"YUW2'V;.:@6!&:E
M<"^"2SR\$EJSJMK.&YM/PT:\$!08*8RH^+_37DA2N;.:5!^PK#SHU(IT_HU,B+&
MW"\$&1WBI"4_1=UG6'!7V5R\$K6@QW:#4YE|=8:/<_FQ@0_U*L2C+_G>LAT9<
MGW+.*4!^DFU6>Q@/GO<=\$E_-BAZ1.*X?=NVA)?B%&M(>OSK1&+7ZO3XAT?\$I
M\$<'TW6V1S\RV9.W/1+*'7%(1.4.43YS'"M9ZW+J'C&@#<|'CO(7_BV_UW3+\$_M&)A
:RA*]^8/[Q+NL0I9@#G5PSI^T!C:Z_FJD+,:)^+QOI_MV=10X(%"E6[KWH&D4P)O/
J'D3DU/[#6X3#|'1|<@D|!'#7F\|F:H^6W=ET3U_MY@445U6V**
!/*02.3XB2)N';09@G6WHT7+D&X&FYF\3N>C&C%#H:2.'CL1Z<)_M=O\|@2??\JX.J/HIL?
#GA1_ZA;P(B|CYQ&R\$|MA@XCTRW&L_DX*R_.EP;QT;TMSS:8<
M9@52(H|>TK^8N!\$BLD|X_3HQNM4#V1&Z9_"G>QSC4P7#_5O-UV=)IPDYRNM
MI@D_.1/5_#S;|0-C#G4^\$BLY.M(FLDD6+?OHR\OGD|(T|!PAL4\$^D;1:UE;T
M,&KTW^<5K&H)Y\ #DB6Z55MWE_58.VLJ=8_8#\$_@%S5&E\#5N+2|N|JWH0|Y
M.FZ./<|AFN1-?0VY1QE!.(O4QR+WK:N?2*UDXFX|<9-N.4N|A)60LV&_M/-BGG6X.O!
(ZFRYC*X%^C_C1+Z80!S^K9;)IPF+D6G?|?I9#5-\$!Y.IM|AL_MZ|(4;KH5J^<ZLL1J?
KO>&7'H\$&ZZ1C65Q\$3%8737C|V7B8W?CKST<5@|07A'^6V=2XNSZ|ZVZ^XQL);P
MYN+|@>\$?|YSYK2PFL/\$*|.E;.:57/LXU_AU\$W\Z3WYP7;?LN|'K'QALWCG6M
M6NIM^9^;4|S\$Z\4CK6\$GHMEU!<_SD;)IOY|++SX+O*"*|;|X,ZK/:S5B|3
MW'ASX*0N|2VIO_"|23CJ%VM@31-N^6AIF(T0#|-(7O2&&K;|_|13JBA:U51?D?
VEI.7|8STNEKX6D33D>|T1_M0?/C_1=X1|>/2<|T2W6SX|%58>25\$K6IU*45.!&%-G4>@-
X|'|M^O7!_P?>^UU0|_MYJOV(-J/=:YKMUY(^;|@JM;C|'G|E|=L-C73A/%Z6IX(|S#G1?
6N,G|6%%G,'^SM=/&%HEMA4!N.MY6!|\$A&5R@|_GPRQ,ICO*1^C<2&0^>D1?|>_MO-
WKKE5&1KMFJ>N2U<7AY|2M|?1%;LGR!:=5I9GFTO<#52))!@=^9:D7Q|'FL%6IGY4P_
M%7.D4<0.A2B|49D3ULQ8C+.A3#+IR^_PP_|DR:7|@6ZFZ(\$E+Y_R0ZF4Z'V,@BZ?FM-
70#(5(ZQ&C+^N8^GC+_M*:A%|;Y%0W1!&|W"U0/W_5?VC|B^*J0#M_5GY1W=.:?
8*GPRJ=3S.R&C\,NK" M?
N87+C'>|YR4FU+Y|@/\$X_XKQ&P_:_RT76S+V@HLW|J6L61F1O,E4"&|B'D%7&
MS1|9BW\$QV6LXU_CY-3>OH;IZ5|J0'5MN99OC|1H*L113,RZ-4(N0,..:\$7
)G#Q,:CE'8);XKTPZ34'6^!|H9A#Q3|=TC_!H)-%PS/:_E
M.Z&^0%MA<2EH,^*AR""5'Z'^>5*J_M8YI1:8_N2I=00^EK'IV-Z/+R9>@CEG&W@
@!HG%%C0:?= %M"-HR8Y'0M7\$ M?-".'6QD))3Z0=.\$-OK@|PZJ%=3)U9EK^_
:L%0,IHD5H7\$_.*(4VPQQQ'RS
MU^A2N<"O*FZ:8\$,YI05SA"Y(O/KM=_%A2JCX:9"&OC#_6#|X5#DDQHWSS\$|_#O_M-
6NKNDC*RP#6FXJI9#I\$QD?T!6#S!Y?Y+P5TM3YG\$|7I%3ND.L|_5Y&R;=:4_MK?
<'XW|5Z&IN%+|OTEC4.(0^*8CD\$Y6)OBN;?%M5YD,3X:IN'8S;=:|@-!M)K(:;*-
GB)IC960<LJW!-XF"ZA_6FJKE"6KKKW_VVPR(1<|;K|)_M8Y('>|5%XY-PH>9.1%I3
|J BX^WMXJ'|R(=D2.&|+OL52:K%6X|XQT6)|
MPQ|OL%"U^D)2K2).X2JF+_|@8YOC^=YSKA|UA\$B<9Y&#SH8'6:N2YQ-\$U*|G/
M/XK3FX0CI5)H.4_A&6-&%?3Q4?BS6-GH,WX0>H6M0;>9|@&W\$.ATF|(NI7O^
MF(M+BQQUP|MH(%DUJ)V,PW<"1S_S6K!5%1?9IU7Z_M"|"I%|'8?+J4Y-
S015,I.W@D|G|3+!+0.Z7R4HK2=*HGSUAO-(
M/A0IBSA940SX>@LNYZ2=J&_|Z3PN.X|^7&7#*NOC;\$|LPQ&M+2E1G3NH8
MOG7H;E,OJ'I(>I_Z_M88SEXD5|B_@_M*ER_YL'|_|\$V6VP%G30CM?ZHG4J4F7
M7+Y"EAS7:MI,Y2*VI:IBW+"#;V|_M;|HU%_P(^-?T|315G"W%,PLW01QQ;I
643S>9RY0SM=O"!B/N9,S%+:_E|C
M=,D3U|QDVAO6C&6O1<64>R0:P8X\$=2@M!;,HMMG,S,J+A1=@*5G=PI//^_Z8)2_'Q50O
MHEK0I"3;872%Z8X_-%*Q%R2;P':EPM|0@|2J>+,0CBJU;9J0?2TBJ_|N2|0#
M#B@H@_W|\$;7F.2VKN?A|22+L*1'-PQ:B01#_(GEX|ON!QD?>K:2(WF05L=_7
M#>Y5P;.:C1.8&^*V_WD*FTG!KP1'9BKZ\$00C=E9D6ZJ0TN^MS/1EY_EB_MC;O9QZ"?
AC="KEG6*M;I;/Z3Z>REZ@;'QIK|B|:8*_MO(:>(1IPO\$D5T,6+_#K1;HD^*_/GX+_#OX>
<3+ZL|@#FKFA2+&_N\$2|?^_ME="X_TCTCE3FT1J('73|L>9ANQ8X=>:L\$&
<6+MH7#V"XGSL@G|'Y24K)O8VK_M2WN(*9>M06#^|D?M8TX4'J)?
GKJ);3>YDYN"X3"%R?4GYP/)(|_|R%>IB_MB5,|IR\$8C|UHNM3%W'17D%2)|*2
&5R4G&*1)4L>^@^V>X_43B_M8LC:'X|82^QQ='M'&V08JAI-52<
CX2SL7A0|WGF\$|H,QE+*.H!VU>H2:1A-J4%"8%|3:>P3BVR0_J_|Z-LN#A4,Q5Q;Z*DD7
MV|?@=W8H&&V#:1+2T%PQ9E%Q%_|L|C-O|@|)F\$|/H\$K'V:7|@_ %2M)F|W
M3W'V,INLS443(7/4?L3P,Y)7|G1%>_8_9L!K!:-#J4@UY-(>P>:E>|CL@DGB+@N-
0^;\$YL;.:3D'P_MIWJ5WL&C67W3<^ON%.:0WA),5?Q%9,J6KL^2|E(EI+S;+-%L(APY5?
%3!5=\$=L_J%E|;WDG/>A+-OX<,282.V/\$B_M-7%1!\$LFX=EA*Q-*|>|34&HZ)8"8*?_==?

8S*6I&FCUG R*L]{\$*C<1'3@=3 MX::I&/B3&-QU,J+PL583S3A%6:A0!TAD(NM9.6.B"-
BSV/>"3PK;#/J!S/\$ M9.NXR8%PT5#P/62[-OO+&O&!EP).=2+FUN/-(X2.\$^AAOPC-
3H)]+%JLEV MR.<=" GFJUW3DVF."*=JV 8F=[9#R:.D)4D4SYJ\$)Y:3\$F)&,V\^!"W\ASP)
MN-#;0K/'-VFSO=0//L7 MZYGJZ5K15R\$HC:)"IM^AJKOJH1G+WFOG/7Y! MCUDB7?
MX5TA RMFRD4<5>9N9%WY3+.CMYI%K03=_M.O((X#5UG&79
ML32:M%%\RCO:JY):!"OJWUJ+|@S9|3|8!|6:.N*WDGU==?^M=MR|8+|XT#+|L
MSH84M_L|W2R6J\$?VT"3LQYKO|5|M0BUDQO^|J4N9UGL1Z|(#)?M@HCB?)BUU M\$"
(7U":2FM.>|7WN=/NFXG>7L'6O)A!AHYSUOL65-P*!&-BU|YJY,|92,
M5L6/SWE#JR5!)L;@ "BQ'J<-[*8,KIF%IC6>;,P?N=I7MJ=TT;4351VA*1N0
M#|3LR=O_|H_|L->WER^|@P-V>G(|:H,^G(:HO?0V8\$.MF|S?:-3NW7|T;40
M"QSR'R#+YKHMJPI<5EAMK#,LWOM-7%OXF#?U82&U55>97OV37(5N|S^?:X.
M1VTC5:!.G*HAGR?-1<_08;3"%_#LTRH9|G)>A&RVJXH^%CUSJKJNAAA-K; MV31-8?C4
#'%_*RS/C(C?|"HY4AH%TK=\$6|M M.)<5*#X+|BIDV2;I49)^,
)Z4L6N7R@+N_QVCC5G*/M5<&QDN-G|L04-M'@4JBG^L5IVBOK"
|NFS'LE7K0G_96^G<=|MU:6"Q>VW<'O?|.X/ '3|SG'XN
M(KTC#;U9RGLG"+RR_N")A?|@3\$IT/N6XB|=|L6A".|UFK6|-3NKR|,6|^H M=CLJPB|
<|TS2M&)|J->KSL(\$PV'D"#C"335|)"6-"I6&|Y^@|>4"+#5\$@E MLA:CRU_-
(CLE5M9^C8E46B%I(E|&6WZB|JOY!*EG7_%2ZSQN*|6I47|G%PO M'B>|+KYHH-CU?
(U|2NNN:<+83,7Z/F#.&#;;U,".A&GJ21EQ4"X1072CFW.D MX282!*>+H^?
V"5<@_OYR(8F74VHL;U@*S\$=G*C_T,M_H%'D342-M)!6NR= M|;BU|5%|W^V>?
P|\$4SZ/T7O.NGW.92)K&6+|',1*XD3G20WZ<1|32(UC
M+\$CIBA6+G"AK(5\$3)3|BBBK65PQ;@#|H"@A 64@:G5WCLL&F)DG|&7;Q:N=
MW23|6|>?2QT' (MD-N1DRD4+(HFTOFV2Z M0|7Z0&NL\$(Y,XN1|7FB):@:|P
|Q|^N"P)N<:K0<0'H32\$|ADIH("JYWG@ M_(1KI9L>| #>B+DZNJ82V;FC7|?^CO60V(=
<"::".?|P\$!G#=1@!&S 4=3& M4/
_7(1I7(|UDQJ/EZA\$&=60JZ99HLP%*\$V00V8*D3@T!CIYZ?/#: (OXM8OX MFB2RAIZ-
+8HK)<)%Z>C6JD3&HA3ZTM81SOHO*J|RfV\$.+-EV76(/AYO)*,I MIDIL>42"
(R|=F|>!),E|N\$|>W;'5|,N1MD_+=D%#12M5PUMJv05'2JDOSSA
M<1*.34R)|S|&DVRK15|!3PK78 C+!|H5-M\$HJ|=|5MT%6)CI+*"# 2K:7Q365+H?
H8F5NN,B.NH158N#@D+? M"|?I@E#U?12K9>'LYNA479MFNZJCWP-
=H*/2V6|+|YBT\$|-&M2\$#% MJ(*?D6+AILR961#A>6^0NP2)|/#9GS#L^TC0V_W|&|I"?
RIFL\$A60)?TU6@ M(BB%M Q0.#J,S|
(|768|5#J@U8RT|11Y#/G|Y*T,SC1AB>";),W3LL:BIWW? MR._7
LYC|"MZSL2.&|AJHFW"RZ:KWY\$>)(?_TZI|9ZW#3B0&HF9|TP%TX23 M2P\$R('MR,AV<
%CMDY@#FW22AW-.T|;A+X7;LX2?ALO,DS9-\$(7_CSD'3Q
ME\$ _V22_ZPD'T)YI#8V+W0E99|,DYE0E6J_EMH)V|4\$I%:X^%<)|H3M/K&IAXC+UT)|>-
G*JV S2RM(0XI M@-E,(Y2QCP;PX4|=:K.|A;JP|T/B|IG|ZWL26'DT(CL4"A04R3MY@!K
M>P0^U=E>?-L/>UG/E%(AJ<_CLCP4\$EA')BS_RVS",1=MPZ6K+:<#7"8@58|U
M*>M==760MLUEH^D/2I QA.V*|.^Q/-7|!7A\$J007"XF|ZU\$Z=/FC6B%\LUU6
M0),%WLZ>&MG)3!LD:&P* 9:)+HL MA|Z7|9'G8D=2'GN+EC2757:P4#U>_\$Z6/D|QO|5
T@X.G\$S^XXM3/K4C/B7X M6^*9VZ(:N.L(,)Y"*F;FA|8!'6ZX%M|JM|JIV8)F2!"Z<)>1T69I:?
#,\$/RKDB M5?%DJ2^835L,KMQ<9HE<|)CWPJ|U0A6Sj>+ZCKJ7^U427^7<#BM%:R?:
MUMU,=|\$.0: Q+H%7_YR|R53,|L<5MY:K\$QN/L.B&GR%.)Y;X3K>KB9F&|17 M2W-B|
(#|N|8(@PR.)E9"/X^!;|(|&>8!DU>8K21+-DK*H=Q)R|AEB?:#R|& M3F_BE5LM,?
_PQ0Z),0:|!4=J"@V_F"Z-65K;*SJ+EQ1PP|F56*6B-;|K_YTJ5|2.Z0TP5^7RT-^(\$R0QW
M\$=E=%D/55(W#G8&4P/H@R)ZOYIFQ|Q3W:EN0WL|FX27IFMB+?R(7-+3ST1:(
M*Q7)|O#':T?8C'O;*#;/9DV-! #;T7UPJH1.Q)F|A/XU:C(5KBJ\$Q)KZ.-; MC#_@MT:~
TU0>;+U3\$CN9@SN@V958XP.D\$HW=_+=Z5P95T=?++EY).N+ZWO MQO<-
_W7MLN).X7H:'75HT3^ MAP@'L?
(|;3';#>ZZ#>F&Y6J|H^!/|1\$N\$PU*>EB|.I"9B:CS7'.AR&+08\$ M;CH9B1^RVK9#1_==
\$/&6*NR|1#C0C-4&DJHwx%MA^GXC?:3BDWW??F#XG4 M#E+EX\$=-
A424NQC=#KF._W>;G63BHML@C10G7#%U%3W5WFT*"=: "MZ5%4*SAB!!I/%>#NICN
M"->R/4PWO,D+1TF-9!F8#LR&4G, 6ZQ+490SH5_\$RES/!EVS<=WE+V/(K9|
MG3VS9)|E\$*MBSP-D|F+6_7S3DT)<\$ADG|WDP^*WY:+X=(H.=L 5'8-YW>-!-
MCU<^Y'5,\$UY_U;JYD-9I<-J!#X;|VVE+@Z|?;7;'8)Z\$Q|T(ME^YQ^O1-
C@PO.%LOA,@Z?,(FSTX 6V%>'AKL4E;.H6T/5F4KSV7^A#BH_9. MJMA+P\$*@3=DP|W?
(QW"39"%2W:(Y|^+._G3M,.NTJK^UNX.6FSI,D0,DUNE@ M1'<'|(+ #|S"99-
=0JDU?.W6G021I3NP+D(1'VW;%YC|OU^@HM3C_+=XD"5

MV\|C\$AYT\$,QZ\$JXCPA6&8U#1>#NN7:.1(B.501U9H:+ECJA);:85G4(2U,B1
MM5@&'X"8DI+6G732:.\$PIA.?!#9*?.!|?K0R!MO>3|@H*GUB^-*27!IF9JW
M\$3F\$T\4C4XG0_1#P%#WZ17\$,"R\FOD\I M<^GVJJ?4HYI>!9(?0CL MPVD@\$ =|_V\!4?
+_70_OI4G_ ^P5=?YK\ _U08\|U?C6_B':^"J:H!+IQ!!C M'YY?N_<,U K6IM3\$
ZM\&ND+QW+*6+P.S/75Y7^5=)C(,;3(|\O5X;|3R3+X M8*^+'WU7OYF1=A|)#)900)
MFPG>|8UK#F1H>O>'G/5.|@TI*W*^T/H^!H>QA\|FF_>&9IUCSX%'VSG+' MB80:?
+8J|*#G4%3%<>+X[W1?T#)M\H'@2:|;L7D-,%"GTY#58GJ-N6W
M7Y,N\|V\$*,0'F@|UZ0I/\$00J\$4G"/N\K5IZ:ET.Q8?*KF_|<7%)MD\Y'4|T M\|E>U8:T^O+
9^F2O+0-PY)3(,3;|0TUU@,N+\$X>^ZL\UCW\|QWUYJZ=9;?V M6Y^Z?
#DTX\|C%XL&KJR||5-M<7P# (-BJ=9R7>A-GXZE!PY^OVO1@?ZS*KVCS((>
M%+L=6L|>U;/_U"Q'N3O M.2(HB8?:3+8!WI#\|L,=:OR>O3U=?
+8SZP';62MR9E.*AP_CTYNB HXHK\$ MYZ,KH6LM*7=#5NXJ^K4I BL|>80\^^\$?-
Z|8&3G_5^PH4SVH^E.XI=5T#XP%
M%84JT7B7<2M\O0#J'L^\$TW\$A=I74|D0G(9,2;+VIR\$G_K/49/V?^_|
M\G.AT1|KYC7*Q^?C5.%AJD.|H73#%E.9 *>.V0.F>RD,"S0H7>-0(|I77F#8 MX,J4ID@/?
JEY15W!|M0_7J(U@CE"&B)O QU\W\|G4^BU;/_'+_%+KG+PJBK'(7EL0PRUZ/%0V"1>
|0_|=Q)HOWGYBJ)|@B"5/EMD+5)E3Q/J7,PP\X_ '(2E!"S
M2&>#1P3M%_U(SGE"TFW5Z)W8IZ"1"X+5/.=IPK&:|.|@8B;FA_7RK&CQ;F\|V
M.+!"8\AN@K#,VXC#CB419(H5KU\|Q>=" _JBBSP0)T(D/H:N^@=X\$|>.<9\$
M.A\^A:9T4=000,'3P*MK>\$=0YV_2T%9(8._I7XV(C>8WT|Z?6:/>PDN/>/NX M1^#'-
#)>3'VZH-Z";R-IR|O=^??+DVK"=O*6S0Z|?9J|2_%&_?=R1|T71 MS%YXS:0GJQ+E0
M3858/P|-Z0V4B.S9^Q"1*I'&H&> "-M_Z_'FU5GOZ?/0,&0%I!AJHW|;*|Q!G-QIPW="(
"+9\$+"M4GU-"%W51|EY_ J MF"3^3Q"K)<^3J5MBZ|!3FKOP;:9=<"W0#W)5N+|');VB
M\X I6Y0(SL;Z>0V<7,;1L.(6GJUJ5>TX1%|[#328H\$=-!F"3,)%JA=EFN"G M\|"-
&_S%_|9WMS_?T>*K5/>1EFA(R*|4*\$2"F8LO\$*DJ2'6R?-Q7O_|8=;S
M+K|CC#0TV'0AT5/(TN-K&8ICU.)P>J5D_JH+3X".|D)Y.R04+*\$F|2+FX4 M*J\$AB&-5V#|
|^O>_7,DQ+VU6;./#,_^0J|5?3KV_=G M7"GKLEN|;N65^^-
#\$22_4HAG"7N*GU.?|MAR!\JH-W-OY_|WE3N|#T=|O_W4 M*=[*_|O?
++MODI_XEE<@|ZV%N/MLG%?XHC5|9X|7/(+*8NUJA
M%W74LIHQAV CG_SXN*X'6.9M'/VUN>A4|)C.3+P_|MID|_X|Z,)Z*UI0N8W
MV|Z>JQ;M^OTE:%%?;E3\$WK'Z#R<|<_&6|V0B8|W\$PU\|2ERUL?W=;|>4 M(|'-#3?>Y52'-
;:XN)KON?)CT4H|:HQ^3RKZW4R|(|_3)SFL27^&EK.8C05_M,L|?|
|X9&"|/3BLL8Z72|=12IX|TWT/S%?|P|=WGG#AX\$&#VE3RT7(| ME18-TKP)|
|3)\$1|QNI.%G-T:"0GK3GW_VU>67I1Y7 M\|4 BR\$/|W*|>L/U19'7-0|>GTU./&|WH*E-
3L**Y_|M%T.-/W3:"P@'|>EVE.|+|SERLB6 M+;OV)ST+;1J*3VP9F_|R|,|?X*?
V)6^9XLE|PU.V^N\UK3X36ZOWQ>^9+0
MBCT;:KZQ+502N?)RX+|5_U.5=|\$J|1*H*GN@424;01%2@P<3F?I0@3\$R:(/
M#BLW^K.|H(KQCY|L6R_JK#X\$?,Z2KHx-<*=V&K;:KC>#WS=KDE|ZZF12>@<
M7VGAN;M1@_'%X5)FEN_J|)B*C|P(L/T|H2W0#RX3A,1KB1SP;'3W<'>6BZ
MYA7)'6PV2\$W%#H@32>= 2<,->D|JB'VOT;.%C^+UAU("C8@8DG|4@..?;X_ ^MCFZ
R9Y(?R5D(|^ M#XDD#',TJXX+PBG==!M667B:T(WR#4;HKE@^29H-V#|?5*
PU13PXJO>_&!O/YGZ;|CM|D|E?_SP)CIBO4|1
M2705KAA_ ;IR%_4VKP|4%X(Z(_/5HIQ2%Y@IN_DKW8|Z,,S22#6PUN:Q#ZC
M&;V3.0*7UM|FOR./88MM+EZE;FEH|\$CL7V7,L^_M9_P7C M8=UE*A5NPGHT-YNQ#4V-
X6\$K_ZA-\$TXP7VM-| \$N+I6%NQ-Q+71^ H^*U"C MT\N8Y|_&IF/+XDOG(
'&G4|/Z9Q"29E;+PE.=#[6Z0/-)"^DMT9*R4U#:"+ MA&O2_#9B(ZX&-
U..D(JZX2"^AC0;KB-\$H|,8".T&7T>#YZ?D',P5>_JQ=R-6
M533=0;@C>.@N%%LPT7U>5#_22<0Y1=;N%|A^=F|S';?S+,B=J&'L#V8EQS;E M!<'D7
|=K>P)'MC54.HX|DWF6,F%2\882TZ(?M*EJ5UU\XV^8'L2=3/80@>S M0>V0"KC0|M?
T_AHZ+K+#3<|;HM/H(XF7'*D95!BJ*4*
MCL1"1\$06#1V.|EO_160UJJ@M/Z>FOW+V-Q\$3,80H\$_91;Q80>5H=KH/L:S
MQ1U^R>^X^O:C6K"7(85:1J9P SQ0Z7%+H^EV5 BX4A-5AFT54JRQ5Q8Q^C4
M53"8(5BK,LU4(+ (3JX?C'#<|KD\$N*L63&^/K@/#^P:7ITZS'1@ (F#^?- E6%
M#&N4B8LJ*>)|J#&.)#_ZF*W*#"S)-,"|>H8WFZY1CKE*B LJ+@#S/X0I&|QQ M\H0|H6?
3S-BN&N8B5K>JO3|YFX9H%\$S\$C3(AY*42+J"6QWMC5*Y^E')^8"G
MVWH;Z&8|%;D8@V8&3|LUC,!.FEB24;&D-,+2K_7OT(H4.B-NIR:'4+U+P/
ML=)V9^(|U1Y=J@;GH!M\$R&<-XZL\$=TTU/T=14%QJ_V%U/U-LXN\CW=L@>I9W
M: ^J4|^WSM)O\|5|PS&^Y0,|TP4(40U|;:9S%NH'DM2F;Y>-IQJ"W0->PE>D6 M+28J7

);4!V!9S3K:8+Z*#)R \$F'Z5*>+>"(D\C5^';4,T(F+33K+TIF5'
M+X(&|E60046VR(AX2BHZ4T8C:AA9M.9D45.J:B?6_EJ(H^4Z183<'DRCIR MQS3A
FV.^Y"6/.YY+)7/#IE9H)5=NG@C4K&|T-!Z2MVZ--K@M|^4.A>MK8V MOIQ0+@Y*+1|
<2XTXF5<-!C?L-?_WY|LPSY;."?8'OKV;|RO(%/R,=CJ?A|
M_|L)NB70TTV2BEY'_MBV, <*>+!5'*DGV*Q\$1BH_|RJ=?IHHK"F@AEUH|WV
M@.WCW*>7)-1M)V^@_'ZHV\$"|3;BXY8N4I4(%YE*CB)R2&P81/*_D;BRKT_5
M12;|B2IHM_)70.%ZYKC:V6:?\$|#+@3F"F+*T;B|3M+L%*Y-8K\$N7|^NS"M
MO:JS#_6ZUX1V7#;=36..N42,";#3PC-9AW="K#S:EIQB|T*#@2PV9(CUHS
M52!J\$^MOJGR'I:LW=B96)RIG>RNSA|<4:N;E+(R||6=>I6B*EN/90C3%7^
M<@TYZZRP)1:V'E|;"/Z/8-,>/X)+>?|VL MX#:&'6;-HN|UM4|0FE1*GI6?G:KD #IP%15R.>
M'=>4EC|B8"VZMD=@LTCB-X|=YNN? "-7CPP%YSN!7V5REU|C!'6Z%|H",F
MXWY!*E)PL?DCL-C0/0"L1+ #F;|,>J03A,L9R9#8CM)LXXA9|1,FX12*A(#
M/^@PXJ/&AMV\$N)7PP*U08@=S%4'9F#?L-(|S,1/A|J|AI06PG(^5@ZV!|&S
MP7CBZVH#|@4N9@%/?
W\$|+TI09@E|3=OM)7/&Z&)J4D,S22(W;QZYFX>>A(XT!RR(J)8P4,TT5
M%)KQF!+|NH_T""#B|1G>MFIG&H%+0;:82B@|.)A/,'(MMD#R3OUKWNX!-\$#K'FS(?
(EM.<0R=@C-X6;=/C5|<1"\$01>+FS!' +F;|1% ^JL MG=WW92G3@^V;=.0H|VH"R" R|P-
>V=VU7L#M|J7_:0?|_|C|T5P%?\$2:\$93 ME2_&^H;7-
30@D;YT:RCD^H0GHX#NQG*+^,BPX'46%:"|L/<.!UI#FC4ZND MO"3;TE4008-;3(&
|7W|RZMK^><(B-D|NIU\$G9&A%M)G8<|9RI M5
E(0"J^0_A&&LM5"M9SI8.XQFDA7IB:|!RIWRXU-5QG\$BHH>BL" _?>*, "-
MN%6C/SQX658P-J#<,3"W|00|_/O^..O |1 ^MD|9#V#=4^!X*FRA:4:MTPW1
M^(/E1;B..T!;AEW(*&2F)>6!;7ZQ&H?Q+|_"X>P Y?0YM3*/M|!R#N;OD-,N
M42PG601)\$HE;9VP1Q,P^F3+4Y2|^LDGD;JA?Q+T5;X4|9!|T_8XM9T-6X(VR7IY/=7F+=?
O|R|Z*V, #*3NI6TTTTZ)QQ&WON2S(SF9Y9 M+"M W:!
'#.2YUPS|*=7%)N|'WX%%^L|KC\$M\$WWRY|:7L|K" ^D|V5BO)U| M6CE*TYSS>/_L!?
9IZE.7MO='P<6H|="YFMLESQF/XFK?B#;*WfVN8HTW.T3. MR;MSYU9TQIO599L?
O7#7K7GF7KDSJ+-F0-9|BCX?DCOH|*C46?-WT2S>|W| MW5>9_?
ST.BL^Y^9N|Q_DMPZZQH=6|HR_PC<9G-%/W&G MUO
:8C\$|Y<)IPG^OPC5*73P.A_ ^01JC\$< '^GYTA&'/.%\$.8\'+#4#"1 D
M31,6:"7"C9@"ZX?".=XU3&P=W1PAAT#ORTPW-7Z|X3V@)BJ&^!IK-UB(-DX-
MC(5C/60XK7^A!S0WJAU"K?(| ^UZ,THF^&SJT58|Z*08?C.LZNGQT6U!?!0R>
M&Z%L0>/=X2;:=31@RH'E+;V^VL%-C199J#_Y\$(M?_KUNY/#6BYDG3KI9!;AO M\$>
|52|+.M/S0|274P=.G;X2WG#PP0%K=BW^!(M(YC@A=2M6=+.R 7-
@!7PBIQIPCQ1|J/(>K28F?VE6WM_|JMZ/V7+U>&#FUK7,-/657A8=K#L,0R,"*TQV)C!
|R(\$2R)>#U^ M<-E.D|D#|?
DQ'=|E: ^21S+%ZRU9VP|4=1GC'U>L|KK|*|T3^VIF@RXP5O1: M*2F6XVDFJY@N)>6)K-
C>:KIU<|:\$99IDFD#|Y-U2|G0B|5&M%W-.31>W@S|W MB%76:9!%6L;+L!|QO^,:MDX>|
|,U/J+E4.IAK& M3(68&_!W<|%<1S;N1A.04|6)H#5@A|1)L45R(1GKY3F*XHCIRB5"
(J+\$W7DK M'(A9X=9|_GWABE'|B++\$ _%L|V=L6U?^IJ,BG\$*L20A-(35|A;>_/-
7|NX|N|U)%VAX8/NAU=%UJVL|Z|#2OKFOG MIN6*73=6H'*\$9@C\$D5Z+XM&_ ^
N;@015(&7AR&/COH_3A&8-2Z^A%U"MV#LA MGW91|C2A@3|^09*E57|HEO-7HVN1=
W3*OX)L6V:4\$ "RHRZ)>_)':8:B<':+. MCVV/=BV2^+BXR|A4NCC*R8>,OH 4;
(@=5|*AV(+GU:C/3'O(4J\$9UL^:TV(
M|0M5*=NYN20GH1VKME=S3:0B9T;H+P|_P:5|YVS, |Y3LCYJYHSD?AGBY@Q| MP?
Q+E&VJ6U5OHMZ^9F|#VIDH|CK91\$7 F9\$ ^WC/S E!5*FJ>E- X).OD:<*@
M4AW(Q=N@79S91WB83|0|\$7V<>T;X&-(2_|Z\$EB*
M*95VH*K27MF|'GOH7V?'7&G=|)#DG|R|5
MSWE14<:V0_+A\$J@*C%1N2CRM6+LVD:91W6%'5T%ZNPDPWKJ@N%TC1\$ M2,M |_
|Q#T&_7DBL9#7U:@JN MJMP#O^|O'G9?+F:\$|/SB11QO\$FXSWP%2-2G|&#
(78A'|\$'N.INM,2DB: M&BW.\$F+S^|SFPC|9!?=FO<(&E0^G"1FB)/H@7:L?+|?F1^
\$A#DA>NBY1\$2L M%025MS6?
Y6:1&Q.W*|BY)^|_|*B!L^|Q|*)U|O7:SO(W;|KC*YM*08R|RO>
MAY%XM#JEA(>LI8TKH17JD?%F^+-A%APKY9/8>G: A;/5,,A2V>.^ A3S@*^
M9:6U33'1%2|VR 5MOJ=FI%/X9&H#F.^61? *XPH14<@KP(*|_W%2V+G@ Z|T
M4:OSMM6;_GC8D-OQHD=J_OBRA5N<^S=I0T=-NV!-4XW^9^ ^..|J|F.O?M|
M5JEA:NS|OV/|/|^E>_U+R3|^GF:#DRT)ER"&%Q"H:S3:SVPO1G5F;X3T.CL-
MDR/"88/|36MDC'^!>)VX^2-G|J2R3J95'+B8O473?;|T: ^2SEL0!YL%AU9!2

M&KVLMT%I%PC;R\$A\$DDSA=J1QID@FT>-R2-<.:(-M+B9\$Y'>M\!9%XR[<-{P
MA4>XU&_8*3B0^X!G2FB?,H=F3G&"N8:(AWV&=!-JBNXH!:9(VEM0C),E-#S ME40*2N
AQ%NI\B,,@L> M4G<9;M5^.,01,8^EJ1D+\$=S.:KUYV>C:0)\JO ME@CGJ
(()S\$%_ "0B=T(N9SH",9*W':.%@WSW*:<)*6X;(!,;N+'C 51TJIK@^A
MYO%NR/A_M'>N44V<:1Q/!45!B+)"*BD9;AI:P6RW*%4@4V!%K)@NO5"A\$JFU
M!EC(NLIA+\$/&*@B(2-6S99651"5&JOB! %4A8V\F=.F6(D4@5G)K!;>!S%0(
M<|S,9(?/NU_WT_)IOOYFSON|___/?.^CX&.PM4&=80);W;:NE22PT=*R'2% M1+:>N(3-
9@V!'26'Z!-
\$!#V9^6E63ZPXG)QKM5@AZY,#J\$1DA%+;!*X0V2#@&;5CWW*+VB9X"XB#>+4>"5&
(5N;JI\$IRS3ZT3^4(=1&SC0(W:(0W:KZJ9<":GIMWZBD!9X!75Uf@f8f6=/VEG"@^
M'N"Z|C:O#PGXD/();*:Q@=2RXCJAF+"W#IE\$Q!;6?40S*(, !W7ID\$;E2_M"7WX?,?
M1W"Z4QU(())LLYL)4U.I8?;@Y(R>L!>!TS|+;+|R2"JDUX!U9F: M^<0J|V)80GTE7%
(\$M,L?M*YQREVO'_1NEWV'+),M)3.HZSWO@2>*A>&%\MOJ M:A&PL!|JZIVS%T^,;TH-
K':C|O_M@TH>>OH.U"#,C*TDESNEW7W\$D5?
_JZLOHELOK*XD>+;5:=CATI:4Z.#Y8Q'K%WV\ACO\MS M"697Q=Y>&PWDS#V
M>6Y2C8CMFCA\;BKB,91%;O'N)@.I5B9|^5A5UD!M(IQ&2)W6X|R%A
%K52QXASF#E|WGO1*Y#OA2ZE_6P=\$3C8W&?0-9MPQ?&/^@>\$&CZ
MK&Y,9;B8XC";\$1:BVPO/_1LD)*S8EKGQ MO,N5??OM;!B)@G!>&% M-!=/L*R|X<^Q1-
ZD&3>ST)^J0FV7@*X#E:|-80&,[M%WC&@\$'5\XMI'8QN2T
M(!,'T5CU7#9C1T#=#Q7"W#:V!|V##|EG|9)&9CCSW-G7U"AY2A_/Z3-"61O|
M6SKQX>K2-_9=)?=BGCH%@>CS^'3'A()M;*@1ODS=[F&LV\("JA:5J*B3PIAW ML-
S|3*68^H^#X70<5.X\$7'W7F>T\$|Y|,=C14YL6'6B9DL839AM9J!5BW?H@X M\$\$\$8BA=?:
|KY--KA#",O8PRF08YQ@=24AM/I89J)1S!\$Z|TLH5KB4W_#C3Y&-%
M6J"LYYLQ|46;FTUH|W,S2|0OBZ&L@^|*KP?H#HW@0+)&AA M/|':ZEJS^D)WK6RTK>
Y/0I@F;M)J34WG5DQ@_%)7L'A(FP|Z"A*V5_M^5U<./5\$&H-S=/(04MR#P66?
MVID\$0TH|M4)8GMVM_,D^.,F:P |(NY,KIU! MB%CFE>|%X'54.[WZF57#-|@;K)K.?
I>R@/%4(EQU.M7/|B3 \$:"S-G0U_QY3 M&T4KH<=V524L5HB))H,:BWAN_BUG4_G-
CY|H5M3(B|F3OIENN:9@FR7@9T@# MLABQ?0VR9*D0WQ|>A=X*D-LLS?9P|?
33Y'L)C|)DH866)"JF3T"??.*,T1AC-'|JSP(M^<3'(EYMK\$0_99|!E?M=9GIQ0Y@)(
.,+!,!#=#H8XAI3ARK=%W;W*71Q:@K> MZ!PW1CNE)^A7-\$J.J.EX(<)GG PL;-5X/#G(|Y|
MA(\$S=|:Q9#S9=V,=5O&0709B*T5C"3W>Y>2N<=MX^;^8'+)D-8/F<00!>W)-
<)>7/H:R=V%&.>J=2_YF"S^45T|(ZJ,Z#;FB@*>K;_P?AMP
MJA%8|#:9ZKM_R:Y"/W43KX;V=G"#:#E MGF/JC!(NHRJG#G/12F2Q,
(WP.K<.0NE&1N+WM^AN\$T|B;:0P_D(Z85+^7|XTC)S_C@Z;:HPO.I5WXG|15T^|&2NJ|
MV^_|3BG.DE4S10P++K|!-Y)Z)QIL3E#LC>A.-^!U@MCGF&%.<\$J
ME|MQ(W.CC|5+@|^_LR|\$78 MA-^81+UH;HBXI|G'NKP)X_I8H2D.CH^UN1?
OJ0'K=/:A7Z((QW>|&--9"08 M1R|W<.E0P%).UP;)"'/=2GO:-K3DYB4 MV(X4N%_-\$
2^A>*PV&IE>,S!//\$|3SQ//\$|3SQ//\$|3_S_1/S?+05<^0^H
MF5XL7<^+QT1'Y1GXWW."T=I2D\$?NP;7*_9Z;O#TVD@'9YM0KGDUH|!A-+6
M|+>P3OHZU9CO:-HC?.I!V 7"BE|Z#2;)EW\;0KZ1O|-4\$L! A0#% @ M48I,6J5U?|=&<@4
5GE5!\$(-!&%L:W,M,C R-#\$R M,S\$N:'1M4\$L! A0#% @ 48I,6J3T-")|;@(-W_,D!\$ M(
!=7(%&%L:W,M,C R-#\$R,S\$N>'D4\$L! A0#% @ 48I,6M/'%M? M*P %P!|(-!(.S'
&%L:W,M97@Q.5|Q+FAT;5!+ 0(4 M Q0 (-%&*3%H6M*P63 0 1\$/":P,"!A;&MS
M+65X,C%?,2YH=&U02P\$"%.,4"!1BDQ;:=YRQ%\$# 7#0 #P M @ \$E\$0@ 86QK#
(S7S\$N:'1M4\$L! A0#% @ 48I,6K;% MAHFM" 64@+(-!HQ0(
&%L:W,M97@S,5|Q+FAT;5!+ M 0(4 Q0 (-%&*3%J;V31%LP@ %|(-/"7T="!A
M;&MS+65X,S%?,BYH=&U02P\$"%.,4"!1BDQ:3(XW+9@&!!5P #P M @ %=)@@
86QK#,R7S\$N:'1M4\$L! A0#% @ 48I, M6EO5@!|/2/P F;.! X(-!(BT(
&%L:W,M97@T7S\$N:'1M M4\$L! A0#% @ 48I,6O8 V--O#P\$?&\$! !\$(-!(&T(M
&EM9S|H.M"P(KR,"!\$(-!GV<+&EM9SW,-&EM9S+CP\$ % \$"!\$(-!FT.&EM9S XML
132 alks-20241231_htm.xml IDEA: XBRL DOCUMENT 0001520262 us-
gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember 2023-
12-31 0001520262 us-gaap:RetainedEarningsMember 2022-12-31 0001520262 2024-
12-31 0001520262 us-gaap:CertificatesOfDepositMember 2024-12-31 0001520262 us-
gaap:CorporateDebtSecuritiesMemberalks:LongTermInvestmentsMember 2024-12-31
0001520262 alks:BiogenMemberus-gaap:AccountsReceivableMemberus-
gaap:CreditConcentrationRiskMember 2022-01-012022-12-31 0001520262
alks:CardinalHealthMemberalks:RevenuesNetMemberus-

gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001520262 us-
gaap:ResearchAndDevelopmentExpenseMemberus-
gaap:SegmentContinuingOperationsMember 2023-01-012023-12-31 0001520262 us-
gaap:EmployeeStockOptionMember 2022-01-012022-12-31 0001520262
alks:McKessonCorporationMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001520262 us-
gaap:SegmentDiscontinuedOperationsMember 2023-01-012023-12-31 0001520262
alks:DiscountsMember 2023-12-31 0001520262 us-gaap:CostOfSalesMemberus-
gaap:SegmentContinuingOperationsMember 2022-01-012022-12-31 0001520262
alks:ManufacturingRevenueMember 2024-01-012024-12-31 0001520262 us-
gaap:AdditionalPaidInCapitalMember 2021-12-31 0001520262 us-
gaap:CorporateDebtSecuritiesMemberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001520262
alks:TimeBasedRestrictedStockUnitAwardsMember 2022-01-012022-12-31
0001520262 us-gaap:EmployeeStockOptionMember 2023-01-012023-12-31
0001520262 us-gaap:TreasuryStockCommonMember 2023-12-31 0001520262
srt:MaximumMemberalks:TimeBasedStockOptionsMember 2022-01-012022-12-31
0001520262
alks:ManufacturedProductAndRoyaltyMemberalks:LongActingINVEGAProductsMember
2023-01-012023-12-31 0001520262 us-
gaap:RoyaltyMemberalks:RISPERDALCONSTAMember 2024-01-012024-12-31
0001520262 alks:ContractualAdjustmentsMember 2024-12-31 0001520262
srt:MinimumMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001520262 us-
gaap:RoyaltyMemberalks:LongActingINVEGAProductsMember 2023-01-012023-12-31
0001520262 alks:BiogenMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001520262
alks:ForeignCountryExcludingSpecifiedCountryMember 2024-01-012024-12-31
0001520262 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001520262
alks:WinterStreetLeaseTwoMember 2024-12-31 0001520262
alks:BiogenMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2024-01-012024-12-31 0001520262
alks:ResearchAndDevelopmentMember 2024-01-012024-12-31 0001520262 us-
gaap:ForeignPlanMember 2023-01-012023-12-31 0001520262 us-
gaap:CorporateDebtSecuritiesMemberalks:LongTermInvestmentsMember 2023-12-31
0001520262 2022-12-31 0001520262 alks:CardinalHealthMemberus-
gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2023-01-
012023-12-31 0001520262 alks:OtherAdjustmentsMember 2024-12-31 0001520262
alks:ManufacturingRevenueMemberalks:OtherProductsAndServicesMember 2022-01-
012022-12-31 0001520262 alks:StateMedicaidRebatesMember 2023-12-31
0001520262 us-gaap:CommonStockMember 2022-01-012022-12-31 0001520262
srt:MinimumMemberalks:TimeBasedStockOptionsMember 2022-01-012022-12-31
0001520262 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001520262
alks:DiscountsMember 2023-01-012023-12-31 0001520262
alks:McKessonCorporationMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2024-01-012024-12-31 0001520262
alks:RodinTherapeuticsIncorporationMemberus-gaap:DomesticCountryMember 2024-
12-31 0001520262 us-gaap:CostOfSalesMember 2023-01-012023-12-31 0001520262
alks:JanssenMemberalks:RISPERDALCONSTAMemberalks:LicenseAgreementMember
2024-01-012024-12-31 0001520262 us-
gaap:ForeignGovernmentDebtSecuritiesMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember
2023-12-31 0001520262 us-gaap:RoyaltyMemberalks:AmpyraMember 2022-11-012022-
11-30 0001520262 alks:DiscountsMember 2024-12-31 0001520262 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001520262 us-
gaap:EmployeeStockOptionMember 2023-12-31 0001520262 us-
gaap:ShortTermInvestmentsMember 2023-12-31 0001520262 us-
gaap:RoyaltyMemberalks:VumerityMember 2022-01-012022-12-31 0001520262 us-

gaap:IntellectualPropertyMember 2024-12-31 0001520262 us-
gaap:TreasuryStockCommonMember 2024-01-012024-12-31 0001520262 us-
gaap:ResearchAndDevelopmentExpenseMemberus-
gaap:SegmentContinuingOperationsMember 2024-01-012024-12-31 0001520262
alks:ContractualAdjustmentsMember 2022-01-012022-12-31 0001520262 us-
gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0001520262
alks:StateMedicaidRebatesMember 2024-12-31 0001520262
alks:OtherAdjustmentsMember 2024-01-012024-12-31 0001520262
alks:ContractualAdjustmentsMember 2024-01-012024-12-31 0001520262 us-
gaap:LeaseholdImprovementsMember 2024-01-012024-12-31 0001520262
alks:TimeBasedRestrictedStockUnitAwardsMember 2024-12-31 0001520262 us-
gaap:CorporateDebtSecuritiesMemberus-
gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001520262
alks:ContractualAdjustmentsMember 2023-12-31 0001520262 us-
gaap:ResearchAndDevelopmentExpenseMember 2022-01-012022-12-31 0001520262
us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001520262 us-
gaap:ForeignPlanMember 2024-01-012024-12-31 0001520262 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:ShortTermInvestmentsMember 2023-12-31 0001520262 srt:MinimumMemberus-
gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2022-
01-012022-12-31 0001520262
alks:PerformanceBasedRestrictedStockUnitAwardsMember 2024-01-012024-12-31
0001520262 alks:AristadaAndAristadaInitioMember 2023-01-012023-12-31
0001520262 srt:MinimumMemberus-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMember 2024-01-012024-12-31 0001520262
alks:ManufacturedProductAndRoyaltyMember 2023-01-012023-12-31 0001520262
alks:SeparationAgreementMemberalks:MuralOncologyPlcMember 2023-11-15
0001520262 alks:OtherMember 2024-12-31 0001520262
alks:CardinalHealthMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2024-01-012024-12-31 0001520262 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember
2024-12-31 0001520262 us-gaap:RoyaltyMember 2024-01-012024-12-31 0001520262
alks:CapitalPurchaseCommitmentsMember 2024-12-31 0001520262
alks:BaudaxBioIncMember 2022-01-012022-09-30 0001520262 us-
gaap:ResearchAndDevelopmentExpenseMemberus-
gaap:SegmentDiscontinuedOperationsMember 2022-01-012022-12-31 0001520262
2023-11-012023-11-30 0001520262 alks:McKessonCorporationMemberus-
gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2024-01-
012024-12-31 0001520262 alks:ManufacturingRevenueMemberalks:VumerityMember
2024-01-012024-12-31 0001520262
alks:ManufacturedProductAndRoyaltyMemberalks:VumerityMember 2022-01-012022-
12-31 0001520262 alks:OtherMember 2023-12-31 0001520262
alks:CencoraIncorporationMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001520262 us-
gaap:SellingGeneralAndAdministrativeExpensesMemberus-
gaap:SegmentContinuingOperationsMember 2023-01-012023-12-31 0001520262
alks:OtherAdjustmentsMember 2023-01-012023-12-31 0001520262 country:IE 2023-
12-31 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-
012023-12-31 0001520262 us-gaap:OtherNoncurrentLiabilitiesMember 2024-12-31
0001520262 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-12-31
0001520262 alks:LongActingINVEGAProductsMember 2023-01-012023-12-31
0001520262 alks:ManufacturingRevenueMemberalks:VumerityMember 2022-01-
012022-12-31 0001520262 2024-06-30 0001520262 alks:JanssenMemberus-
gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2024-01-
012024-12-31 0001520262 us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001520262

alks:ProductReturnsMember 2022-01-012022-12-31 0001520262 us-
gaap:RoyaltyMember 2023-01-012023-12-31 0001520262
alks:StockOptionAndIncentivePlan2018Member 2024-05-312024-05-31 0001520262
us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0001520262 us-
gaap:LandMember 2023-12-31 0001520262 alks:ContractualAdjustmentsMember
2023-01-012023-12-31 0001520262 alks:BiogenMember alks:RevenuesNetMember us-
gaap:CustomerConcentrationRiskMember 2022-01-012022-12-31 0001520262
srt:MinimumMember alks:RevenuesNetMember us-
gaap:CustomerConcentrationRiskMember 2022-01-012022-12-31 0001520262
alks:McKessonCorporationMember us-gaap:AccountsReceivableMember us-
gaap:CreditConcentrationRiskMember 2023-01-012023-12-31 0001520262
alks:RodinTherapeuticsIncorporationMember us-
gaap:StateAndLocalJurisdictionMember 2024-12-31 0001520262 us-
gaap:USGovernmentAgenciesDebtSecuritiesMember us-
gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember
2023-12-31 0001520262 us-gaap:DomesticCountryMember 2024-12-31 0001520262
alks:FormerTermLoansMember 2023-01-012023-12-31 0001520262 2024-02-29
0001520262 2023-11-30 0001520262
alks:NonEmployeeDirectorsMember alks:TimeBasedStockOptionsMember 2024-01-
012024-12-31 0001520262 alks:JanssenPharmaceuticaNVMember 2023-01-012023-12-
31 0001520262 2024-10-012024-12-31 0001520262 us-
gaap:IntellectualPropertyMember 2023-12-31 0001520262 us-
gaap:RoyaltyMember alks:AmpyraMember 2022-10-012022-10-31 0001520262
alks:PerformanceBasedRestrictedStockUnitAwardsMember 2024-12-31 0001520262
alks:AristadaAndAristadaInitioMember 2024-01-012024-12-31 0001520262
alks:ContractLiabilitiesMember 2023-12-31 0001520262 us-
gaap:ShortTermInvestmentsMember 2024-12-31 0001520262 us-
gaap:RetainedEarningsMember 2023-12-31 0001520262
alks:StockOptionAndIncentivePlan2018Member 2024-12-31 0001520262 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001520262
alks:LYBALVIMember 2023-01-012023-12-31 0001520262 us-
gaap:RoyaltyMember alks:LongActingINVEGAPProductsMember 2024-01-012024-12-31
0001520262 alks:VivitrolMember 2024-01-012024-12-31 0001520262 us-
gaap:SegmentContinuingOperationsMember 2022-01-012022-12-31 0001520262 us-
gaap:EmployeeStockOptionMember 2022-01-012022-12-31 0001520262 country:US
2024-12-31 0001520262
alks:JanssenMember alks:OHRisperidonePalimateMember alks:NetSalesGreaterThan500
2024-01-012024-12-31 0001520262
alks:ForeignCountryExcludingSpecifiedCountryMember 2023-01-012023-12-31
0001520262 alks:FacilityAndCertainRelatedAssetsMember 2024-01-012024-12-31
0001520262 alks:FurnitureFixtureAndEquipmentMember 2023-01-012023-12-31
0001520262 alks:ProductReturnsMember 2023-01-012023-12-31 0001520262 us-
gaap:AdditionalPaidInCapitalMember 2023-01-012023-12-31 0001520262
alks:ManufacturedProductAndRoyaltyMember 2022-01-012022-12-31 0001520262
alks:ManufacturingRevenueMember alks:OtherProductsAndServicesMember 2023-01-
012023-12-31 0001520262 alks:FormerTermLoansMember 2023-12-31 0001520262
alks:TimeBasedRestrictedStockUnitAwardsMember 2023-01-012023-12-31
0001520262 srt:MinimumMember alks:FurnitureFixtureAndEquipmentMember 2024-
12-31 0001520262 us-gaap:EmployeeStockOptionMember 2023-01-012023-12-31
0001520262
alks:ManufacturedProductAndRoyaltyMember alks:RISPERDALCONSTAMember 2023-
01-012023-12-31 0001520262
srt:MaximumMember alks:TimeBasedStockOptionsMember 2024-01-012024-12-31
0001520262 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-
gaap:SegmentDiscontinuedOperationsMember 2023-01-012023-12-31 0001520262
alks:ManufacturedProductAndRoyaltyMember alks:OtherProductsAndServicesMember
2022-01-012022-12-31 0001520262 us-gaap:EmployeeStockOptionMember 2024-01-
012024-12-31 0001520262 us-gaap:RoyaltyMember alks:AmpyraMember 2022-04-

012022-06-30 0001520262 us-gaap:RoyaltyMemberalks:AmpyraMember 2022-10-012022-12-31 0001520262
alks:McKessonCorporationMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2022-01-012022-12-31 0001520262
alks:CardinalHealthMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2022-01-012022-12-31 0001520262 us-
gaap:LeaseholdImprovementsMember 2024-12-31 0001520262
alks:ManufacturedProductAndRoyaltyMemberalks:VumerityMember 2023-01-012023-
12-31 0001520262 us-gaap:CommonStockMember 2023-12-31 0001520262
alks:LongActingINVEGAProductsMember 2022-01-012022-12-31 0001520262 us-
gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember 2024-
12-31 0001520262
alks:ManufacturedProductAndRoyaltyMemberalks:RISPERDALCONSTAMember 2024-
01-012024-12-31 0001520262 us-gaap:CostOfSalesMember 2022-01-012022-12-31
0001520262
alks:ManufacturingRevenueMemberalks:OtherProductsAndServicesMember 2024-01-
012024-12-31 0001520262 alks:MedicarePartDMember 2023-12-31 0001520262 us-
gaap:LeaseholdImprovementsMember 2023-12-31 0001520262 us-
gaap:ProductMember 2024-01-012024-12-31 0001520262
alks:OtherAdjustmentsMember 2022-12-31 0001520262 us-
gaap:TreasuryStockCommonMember 2022-01-012022-12-31 0001520262 us-
gaap:RestrictedStockUnitsRSUMember 2022-01-012022-12-31 0001520262
alks:VivitrolMember 2022-01-012022-12-31 0001520262
alks:ContractualAdjustmentsMember 2022-12-31 0001520262
alks:FormerTermLoansMember 2024-12-012024-12-31 0001520262 us-
gaap:SellingGeneralAndAdministrativeExpensesMemberus-
gaap:SegmentContinuingOperationsMember 2024-01-012024-12-31 0001520262 2024-
01-012024-12-31 0001520262 alks:ProductDiscountsMember 2023-12-31 0001520262
us-gaap:RoyaltyMemberalks:OtherProductsAndServicesMember 2022-01-012022-12-31
0001520262 alks:WilmingtonOhioMember 2023-12-31 0001520262 us-
gaap:EmployeeStockOptionMember 2024-01-012024-12-31 0001520262
alks:TimeBasedStockOptionsMember 2022-01-012022-12-31 0001520262
alks:JanssenMemberalks:OHRisperidonePalimateMemberalks:NetSalesBetween250And:
2024-01-012024-12-31 0001520262 alks:StockOptionAndIncentivePlan2018Member
2024-01-012024-12-31 0001520262 us-gaap:SegmentContinuingOperationsMember
2023-12-31 0001520262 us-gaap:OtherCurrentLiabilitiesMember 2023-12-31
0001520262 alks:FurnitureFixtureAndEquipmentMember 2022-01-012022-12-31
0001520262 alks:ManufacturedProductAndRoyaltyMemberalks:VumerityMember
2024-01-012024-12-31 0001520262 us-gaap:SegmentContinuingOperationsMember
2024-12-31 0001520262 us-gaap:LicensingAgreementsMember 2023-12-31
0001520262 alks:ProductReturnsMember 2021-12-31 0001520262
alks:JanssenMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001520262
alks:WinterStreetLeaseTwoMember 2024-01-012024-12-31 0001520262 us-
gaap:AccountsReceivableMember 2023-12-31 0001520262 us-
gaap:RoyaltyMemberalks:OtherProductsAndServicesMember 2023-01-012023-12-31
0001520262 us-gaap:CorporateDebtSecuritiesMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember
2024-12-31 0001520262
alks:UnvestedPerformanceBasedRestrictedStockUnitsAwardsMember 2024-12-31
0001520262
alks:NewNonEmployeeDirectorsMemberalks:TimeBasedStockOptionsMember 2024-01-
012024-12-31 0001520262 alks:CencoraIncorporationMemberus-
gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2024-01-
012024-12-31 0001520262 2021-12-31 0001520262 us-
gaap:CorporateDebtSecuritiesMember 2024-12-31 0001520262 us-
gaap:CommonStockMember 2024-12-31 0001520262 us-gaap:CommonStockMember
2024-01-012024-12-31 0001520262 alks:OtherAdjustmentsMember 2021-12-31

0001520262 us-gaap:ConstructionInProgressMember 2023-12-31 0001520262 us-gaap:OtherCurrentLiabilitiesMember 2024-12-31 0001520262 us-gaap:LicenseMember 2022-01-012022-12-31 0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001520262 alks:DiscountsMember 2021-12-31 0001520262 srt:MinimumMember alks:TimeBasedStockOptionsMember 2024-01-012024-12-31 0001520262 alks:CencoraIncorporationMember alks:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-012024-12-31 0001520262 country:US 2023-01-012023-12-31 0001520262 us-gaap:AdditionalPaidInCapitalMember 2022-01-012022-12-31 0001520262 alks:ManufacturingRevenueMember alks:RISPERDALCONSTAMember 2024-01-012024-12-31 0001520262 alks:FormerTermLoansMember 2024-01-012024-12-31 0001520262 alks:ProductDiscountsMember 2024-12-31 0001520262 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001520262 country:US 2022-01-012022-12-31 0001520262 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001520262 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:SegmentDiscontinuedOperationsMember 2022-01-012022-12-31 0001520262 us-gaap:DiscontinuedOperationsHeldforsaleMember alks:AthloneFacilityMember 2023-12-31 0001520262 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001520262 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:SegmentContinuingOperationsMember 2022-01-012022-12-31 0001520262 us-gaap:StateAndLocalJurisdictionMember 2024-12-31 0001520262 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001520262 alks:McKessonCorporationMember us-gaap:AccountsReivableMember us-gaap:CreditConcentrationRiskMember 2022-01-012022-12-31 0001520262 alks:JanssenMember alks:RISPERDALCONSTAMembersrt:MaximumMember alks:Manufa 2024-01-012024-12-31 0001520262 us-gaap:TreasuryStockCommonMember 2023-01-012023-12-31 0001520262 2023-01-012023-01-31 0001520262 us-gaap:SegmentContinuingOperationsMember 2024-01-012024-12-31 0001520262 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-12-31 0001520262 alks:ContractLiabilitiesMember 2024-12-31 0001520262 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0001520262 us-gaap:RoyaltyMember alks:AmpyraMember 2022-07-012022-09-30 0001520262 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:RISPERDALCONSTAMember 2022-01-012022-12-31 0001520262 us-gaap:RetainedEarningsMember 2024-01-012024-12-31 0001520262 alks:LongTermInvestmentsMember 2024-12-31 0001520262 us-gaap:RetainedEarningsMember 2023-01-012023-12-31 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-012022-12-31 0001520262 us-gaap:SegmentContinuingOperationsMember 2023-01-012023-12-31 0001520262 alks:MedicarePartDMember 2024-12-31 0001520262 us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0001520262 us-gaap:RoyaltyMember alks:VumerityMember 2023-01-012023-12-31 0001520262 alks:JanssenMember alks:OHRisperidonePalimateMembersrt:MaximumMember alks:Net 2024-01-012024-12-31 0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember alks:LongTermInvestmentsMember 2023-12-31 0001520262 alks:BaudaxBioIncMember 2022-03-31 0001520262 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0001520262 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-12-31 0001520262 alks:JanssenMember alks:RISPERDALCONSTAMember alks:ManufacturingAndSupplyAgr 2024-01-012024-12-31 0001520262 alks:DiscountsMember 2024-01-012024-12-31 0001520262 country:IE 2022-01-012022-12-31 0001520262 us-gaap:ProductMember 2022-01-012022-12-31 0001520262 alks:ProductReturnsMember 2024-12-31 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:LongActingINVEGAProductsMember 2024-01-012024-12-31 0001520262 country:US 2024-01-012024-12-31 0001520262

alks:DiscountsMember 2022-12-31 0001520262 2023-01-012023-12-31 0001520262
alks:LYBALVIMember 2022-01-012022-12-31 0001520262 us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-12-31
0001520262 alks:Plan401KMember 2022-01-012022-12-31 0001520262 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-12-31 0001520262
srt:MaximumMemberalks:TimeBasedStockOptionsMember 2023-01-012023-12-31
0001520262 us-gaap:RoyaltyMember 2022-01-012022-12-31 0001520262 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberalks:LongTermInvestmentsMember
2024-12-31 0001520262 us-gaap:CommonStockMember 2023-01-012023-12-31
0001520262 alks:ManufacturedProductAndRoyaltyMember 2024-01-012024-12-31
0001520262 alks:WinterStreetLeaseMember 2024-01-012024-12-31 0001520262
alks:JanssenMemberalks:OHRisperidonePalimateMembersrt:MaximumMemberalks:Net:
2024-01-012024-12-31 0001520262 alks:ContractualAdjustmentsMember 2021-12-31
0001520262 alks:ProductReturnsMember 2023-12-31 0001520262
alks:ManufacturingRevenueMember 2022-01-012022-12-31 0001520262
alks:JanssenMemberalks:OHRisperidonePalimateMembersrt:MinimumMemberalks:Net:
2024-01-012024-12-31 0001520262 country:US 2023-12-31 0001520262
alks:EightFiveTwoWinterStreetLeaseMemberalks:AssignmentMember 2023-11-15
0001520262 alks:TimeBasedRestrictedStockUnitAwardsMember 2024-01-012024-12-
31 0001520262 us-gaap:RetainedEarningsMember 2021-12-31 0001520262
alks:ManufacturedProductAndRoyaltyMemberalks:OtherProductsAndServicesMember
2023-01-012023-12-31 0001520262 alks:MuralOncologyPlcMember 2023-11-30
0001520262 alks:FurnitureFixtureAndEquipmentMember 2024-01-012024-12-31
0001520262 alks:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-
gaap:CreditConcentrationRiskMember 2022-01-012022-12-31 0001520262 us-
gaap:ForeignPlanMember 2022-01-012022-12-31 0001520262 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001520262 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001520262
alks:ManufacturingRevenueMember 2023-01-012023-12-31 0001520262 us-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember
2023-12-31 0001520262 us-gaap:StateAndLocalJurisdictionMember 2023-12-31
0001520262 alks:JanssenMemberus-gaap:AccountsReceivableMemberus-
gaap:CreditConcentrationRiskMember 2023-01-012023-12-31 0001520262
alks:CencoraIncorporationMemberus-gaap:AccountsReceivableMemberus-
gaap:CreditConcentrationRiskMember 2022-01-012022-12-31 0001520262
alks:ManufacturingRevenueMemberalks:RISPERDALCONSTAMember 2023-01-012023-
12-31 0001520262 alks:PerformanceBasedRestrictedStockUnitAwardsMember 2024-
02-012024-02-29 0001520262 alks:MedicaidRebateMember 2023-12-31 0001520262
alks:ManufacturingRevenueMemberalks:RISPERDALCONSTAMember 2022-01-012022-
12-31 0001520262 2025-02-07 0001520262 us-
gaap:RoyaltyMemberalks:LongActingINVEGAProductsMember 2022-01-012022-12-31
0001520262 alks:FurnitureFixtureAndEquipmentMember 2023-12-31 0001520262 us-
gaap:RoyaltyMemberalks:VumerityMember 2024-01-012024-12-31 0001520262
alks:PerformanceBasedRestrictedStockUnitAwardsMember 2023-01-012023-12-31
0001520262 srt:MinimumMemberus-gaap:IntellectualPropertyMember 2024-12-31
0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:ShortTermInvestmentsMember 2024-12-31 0001520262
alks:JanssenMemberalks:OHRisperidonePalimateMemberalks:LicenseAgreementMembe
2024-01-012024-12-31 0001520262 alks:ResearchAndDevelopmentMember 2023-01-
012023-12-31 0001520262 alks:TimeBasedStockOptionsMember 2024-01-012024-12-
31 0001520262 srt:MinimumMemberalks:TimeBasedStockOptionsMember 2023-01-
012023-12-31 0001520262 srt:MaximumMember 2024-01-012024-12-31 0001520262
alks:ManufacturedProductAndRoyaltyMemberalks:OtherProductsAndServicesMember
2024-01-012024-12-31 0001520262 us-
gaap:ForeignGovernmentDebtSecuritiesMemberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001520262 us-
gaap:RoyaltyMemberalks:OtherProductsAndServicesMember 2024-01-012024-12-31
0001520262 us-gaap:AccountsReceivableMember 2024-12-31 0001520262

alks:BaudaxBioIncMember 2022-03-012022-03-31 0001520262 2023-12-31
0001520262 us-gaap:RoyaltyMemberalks:RISPERDALCONSTAMember 2022-01-
012022-12-31 0001520262 us-gaap:ProductMember 2023-01-012023-12-31
0001520262 us-gaap:LicensingAgreementsMember 2024-12-31 0001520262
alks:CencoraIncorporationMemberus-gaap:AccountsReceivableMemberus-
gaap:CreditConcentrationRiskMember 2023-01-012023-12-31 0001520262
alks:JanssenMemberalks:RISPERDALCONSTAMembersrt:MinimumMemberalks:Manufa
2024-01-012024-12-31 0001520262 alks:OtherAdjustmentsMember 2022-01-012022-
12-31 0001520262 srt:MaximumMemberus-gaap:IntellectualPropertyMember 2024-12-
31 0001520262 us-gaap:ResearchAndDevelopmentExpenseMemberus-
gaap:SegmentDiscontinuedOperationsMember 2023-01-012023-12-31 0001520262
srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2024-12-31 0001520262
alks:WinterStreetLeaseMember 2020-01-202020-01-20 0001520262
alks:VumerityMember 2024-01-012024-12-31 0001520262
alks:JanssenMemberalks:OHRisperidonePalimateMemberalks:NetSalesBelow250Million
2024-01-012024-12-31 0001520262 alks:ProductReturnsMember 2022-12-31
0001520262 us-gaap:RetainedEarningsMember 2024-12-31 0001520262 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-12-31
0001520262 alks:ForeignCountryExcludingSpecifiedCountryMember 2022-01-012022-
12-31 0001520262 alks:PerformanceBasedRestrictedStockUnitAwardsMember 2022-
01-012022-12-31 0001520262 us-gaap:EuropeanUnionMember 2022-01-012022-12-31
0001520262 us-gaap:CostOfSalesMemberus-
gaap:SegmentContinuingOperationsMember 2024-01-012024-12-31 0001520262 us-
gaap:LandMember 2024-12-31 0001520262 us-gaap:RestrictedStockUnitsRSUMember
2023-01-012023-12-31 0001520262 srt:MinimumMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2024-01-012024-12-31 0001520262 2024-
02-012024-02-29 0001520262
alks:ManufacturingRevenueMemberalks:VumerityMember 2023-01-012023-12-31
0001520262 srt:MaximumMemberalks:FurnitureFixtureAndEquipmentMember 2024-
12-31 0001520262 us-gaap:EmployeeStockOptionMember 2024-12-31 0001520262
srt:MinimumMember 2024-01-012024-12-31 0001520262
alks:OtherAdjustmentsMember 2023-12-31 0001520262 us-
gaap:TreasuryStockCommonMember 2022-12-31 0001520262 us-
gaap:SegmentDiscontinuedOperationsMember 2022-01-012022-12-31 0001520262 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember
2024-12-31 0001520262 alks:Plan401KMember 2024-01-012024-12-31 0001520262
alks:MedicaidRebateMember 2024-12-31 0001520262
alks:JanssenMemberalks:OHRisperidonePalimateMembersrt:MinimumMemberalks:Net
2024-01-012024-12-31 0001520262 2022-01-012022-12-31 0001520262
alks:ResearchAndDevelopmentMember 2022-01-012022-12-31 0001520262
alks:JanssenMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2024-01-012024-12-31 0001520262
alks:TimeBasedRestrictedStockUnitAwardsMember 2023-12-31 0001520262
alks:DiscountsMember 2022-01-012022-12-31 0001520262
alks:FurnitureFixtureAndEquipmentMember 2024-12-31 0001520262 us-
gaap:CommonStockMember 2022-12-31 0001520262
alks:PerformanceBasedRestrictedStockUnitAwardsMember 2023-12-31 0001520262
us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-012022-12-31
0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001520262 us-
gaap:RoyaltyMemberalks:RISPERDALCONSTAMember 2023-01-012023-12-31
0001520262 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001520262
alks:ProductReturnsMember 2024-01-012024-12-31 0001520262
alks:WinterStreetLeaseMember 2020-01-20 0001520262
alks:CencoraIncorporationMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2022-01-012022-12-31 0001520262 us-
gaap:CommonStockMember 2021-12-31 0001520262

alks:AristadaAndAristadaInitioMember 2022-01-012022-12-31 0001520262
alks:JanssenMemberalks:RevenuesNetMemberus-
gaap:CustomerConcentrationRiskMember 2022-01-012022-12-31 0001520262
country:IE 2024-01-012024-12-31 0001520262 us-gaap:TreasuryStockCommonMember
2024-12-31 0001520262 alks:TimeBasedStockOptionsMember 2023-01-012023-12-31
0001520262 us-gaap:RetainedEarningsMember 2022-01-012022-12-31 0001520262
alks:ManufacturedProductAndRoyaltyMemberalks:LongActingINVEGAProductsMember
2022-01-012022-12-31 0001520262 alks:AssetsHeldForSaleMember 2023-12-31
0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember
2023-12-31 0001520262 alks:VivitrolMember 2023-01-012023-12-31 0001520262
alks:LongTermInvestmentsMember 2023-12-31 0001520262
alks:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-
gaap:CreditConcentrationRiskMember 2024-01-012024-12-31 0001520262 country:IE
2023-01-012023-12-31 0001520262 alks:LYBALVIMember 2024-01-012024-12-31
0001520262 us-gaap:ConstructionInProgressMember 2024-12-31 0001520262 us-
gaap:ResearchAndDevelopmentExpenseMemberus-
gaap:SegmentContinuingOperationsMember 2022-01-012022-12-31 0001520262 us-
gaap:CertificatesOfDepositMember 2023-12-31 0001520262 country:IE 2024-12-31
0001520262 us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001520262
srt:MinimumMemberus-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001520262 us-
gaap:TreasuryStockCommonMember 2021-12-31 0001520262 us-
gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001520262 us-
gaap:CostOfSalesMemberus-gaap:SegmentContinuingOperationsMember 2023-01-
012023-12-31 0001520262
alks:EightFiveTwoWinterStreetLeaseMemberalks:AssignmentMember 2023-11-13
0001520262 alks:Plan401KMember 2023-01-012023-12-31 iso4217:EUR iso4217:USD
shares pure utr:sqft shares alks:Agreement alks:Item alks:Installment iso4217:USD
alks:InvestmentsecurityfalseFY0001520262Alkermes plc.L2 [http://fasb.org/us-](http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense)
[http://fasb.org/us-](http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMemberP56D)
[http://fasb.org/us-](http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberP3Y1H)
[http://fasb.org/us-](http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberP3Y1H)
Ktrue2024-12-31--12-312024false001-3529998-1007018Connaught House1 Burlington
RoadDublin 4IED04 C5Y63531-772-8000Ordinary shares, \$0.01 par
valueALKSNASDAQYesNoYesYesLarge Accelerated
Filerfalsefalsefalsefalse3943314276162614067<p style="text-indent:4.533%;font-
size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-
align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-
family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the
definitive proxy statement for our 2025 Annual General Meeting of Shareholders are
incorporated by reference into Part III of this report.</p><p
id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times
New Roman;margin-bottom:0;text-align:left;"><span style="color:#0070c0;white-
space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;">Item <span style="color:#0070c0;white-
space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;">1C. <span style="color:#0070c0;white-
space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-
style:italic;font-kerning:none;min-width:fit-content;">Cy<span
style="color:#0070c0;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-
family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-
content;">bersecurity</p><p style="text-indent:4.533%;font-size:10pt;margin-
top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Risk Management and Strategy

In the ordinary course of our business, we collect and store sensitive data, including IP, proprietary business information of ours and that of our suppliers and licensees, and personally identifiable information of persons who use our medicines, clinical trial participants and employees. Our licensees and third-party providers also possess certain of our sensitive data. The secure maintenance of such information and the secure performance of our information technology ("IT") systems are critical to our operations and business strategy. As our dependency on, and the complexity of, our IT systems increases, the confidentiality, integrity and availability of our IT systems and the data that they store is critical to managing our business.

Our Information Security Management System ("ISMS") is a key element of our information security program, designed to identify, assess, help mitigate, and monitor IT risks across our organization, including information security risks. The ISMS is informed by the structured principles of International Standard-ISO/IEC27001:2022 (Information security, cybersecurity, and privacy protection), which outlines guidance for the establishment, implementation, maintenance, and improvement of information security management systems. Our ISMS is comprised of processes designed to identify cybersecurity risks, safeguard information assets and preserve the confidentiality, integrity, and availability of information owned, managed and maintained by us. Our ISMS includes formal written policies and procedures, technical security controls, such as automated tools designed to detect and prevent cybersecurity incidents, and programs designed to promote internal and third-party IT risk management, audit management, incident response and security awareness, including employee awareness trainings and other initiatives. Our ISMS includes periodic security audits, vulnerability assessments and penetration testing to proactively identify potential system vulnerabilities.

Our ISMS is periodically assessed by third-party assessors and the results of such assessments, including any cybersecurity risks and related mitigations identified, are reported to the audit and risk committee of our board of directors, as described below, and are used by us to improve our ISMS and our broader information security program.

As part of our information security program, we also have processes in place for management of cybersecurity risks associated with third-party handling of our confidential information, including in such third parties' provision of critical services on our behalf. We conduct due diligence of our third-party vendors through an assessment of their security practices and overall risk profile, including

through their completion of vendor assessment questionnaires and ongoing monitoring of such third parties, utilizing tools such as security ratings services and periodic reassessment questionnaires.

As of the date of this Annual Report, we have not experienced any information security incidents that have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition, and we have not identified any current cybersecurity threats that we believe are reasonably likely to materially affect our business strategy, results of operations, or financial condition.

Governance and Oversight

We have a multi-layered information security governance framework in place to provide oversight of our information security program and strategy, our ISMS, and related risks and opportunities.

This governance framework includes procedures for escalation of identified information security risks, threats or incidents through various management levels, including up to our Information Security Governing Body, which is comprised of our Chief Executive Officer, Chief Information Officer, Chief Operating Officer, Chief Financial Officer, Chief Legal Officer and other members of management, and as appropriate, up to our board of directors.

Our information security team is responsible for developing, implementing and overseeing our Company-wide information security strategy and related policies and practices. This team works cross-functionally throughout our organization to assess and prepare the Company for identification and mitigation of, and if necessary respond to, information security risks.

The information security team is led by our Chief Information Officer, who has over 35 years of experience in various information technology roles, including

18 years at the Company serving in roles with increasing levels of responsibility. Our Vice President of Information Security and Technology, a Certified Information Systems Security Professional, with over 20 years of global experience in various information security roles, including 14 years of experience at the Company, is responsible for day-to-day management of information security team initiatives. The other members of the information security team have extensive IT, IT security and cloud industry experience, as well as certifications pertaining to information security and privacy (such as Certified Information Security Manager, Certified Information Privacy Technologist, GIAC Security Essentials and GIAC Information Security Professional certifications).

Our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. The audit and risk committee of our board of directors specifically oversees critical risks and opportunities facing the Company and, in this context, reviews and provides feedback on our company-wide enterprise risk management program, which encompasses risks related to IT and cybersecurity and mitigations put in place, or to be put in place, in response to such risks and opportunities.

The audit and risk committee periodically reports to the full board of directors regarding its oversight of the Company's enterprise risk management program and periodic risk assessment results. In addition, our board of directors receives periodic updates from our CIO and Vice President of Information Security on our ISMS and other information security initiatives, and on our information security governance framework.

Our Information Security Management System ("ISMS") is a key element of our information security program, designed to identify, assess, help mitigate, and monitor IT risks across our organization, including information security risks. The ISMS is informed by the structured principles of International Standard- ISO/IEC27001:2022 (Information security, cybersecurity, and privacy protection), which outlines guidance for the establishment, implementation, maintenance, and improvement of information security management systems. Our ISMS is comprised of processes designed to identify cybersecurity risks, safeguard information assets and preserve the confidentiality, integrity, and availability of information owned, managed and maintained by us. Our ISMS includes formal written policies and procedures, technical security controls, such as automated tools designed to detect and prevent cybersecurity incidents, and programs designed to promote internal and third-party IT risk management, audit management, incident response and security awareness, including employee awareness trainings and other initiatives. Our ISMS includes periodic security audits, vulnerability assessments and penetration testing to proactively identify potential system vulnerabilities.

Our ISMS is periodically assessed by third-party assessors

and the results of such assessments, including any cybersecurity risks and related mitigations identified, are reported to the audit and risk committee of our board of directors, as described below, and are used by us to improve our ISMS and our broader information security program.

We have a multi-layered information security governance framework in place to provide oversight of our information security program and strategy, our ISMS, and related risks and opportunities.

This governance framework includes procedures for escalation of identified information security risks, threats or incidents through various management levels, including up to our Information Security Governing Body, which is comprised of our Chief Executive Officer, Chief Information Officer, Chief Operating Officer, Chief Financial Officer, Chief Legal Officer and other members of management, and as appropriate, up to our board of directors.

Our information security team is responsible for developing, implementing and overseeing our Company-wide information security strategy and related policies and practices.

This team works cross-functionally throughout our organization to assess and prepare the Company for identification and mitigation of, and if necessary respond to, information security risks.

The information security team is led by our Chief Information Officer, who has over 35 years of experience in various information technology roles, including 18 years at the Company serving in roles with increasing levels of responsibility. Our Vice President of Information Security and Technology, a Certified Information Systems Security Professional, with over 20 years of global experience in various information security roles, including 14 years of experience at the Company, is responsible for day-to-day management of information security team initiatives. The other members of the information security team have extensive IT, IT security and cloud industry experience, as well as certifications pertaining to information security and privacy (such as Certified Information Security Manager, Certified Information Privacy Technologist, GIAC Security Essentials and GIAC Information Security Professional certifications).

This governance framework includes procedures for escalation of identified information security risks, threats or incidents through various management levels, including up to our Information Security Governing Body, which is comprised of our

Chief Executive Officer, Chief Information Officer, Chief Operating Officer, Chief Financial Officer, Chief Legal Officer and other members of management, and as appropriate, up to our board of directors.

Our information security team is responsible for developing, implementing and overseeing our Company-wide information security strategy and related policies and practices.

This team works cross-functionally throughout our organization to assess and prepare the Company for identification and mitigation of, and if necessary respond to, information security risks.

The information security team is led by our Chief Information Officer

, who has over 35 years of experience in various information technology roles, including 18 years at the Company serving in roles with increasing levels of responsibility. Our Vice President of Information Security and Technology, a Certified Information Systems Security Professional, with over 20 years of global experience in various information security roles, including 14 years of experience at the Company, is responsible for day-to-day management of information security team initiatives. The other members of the information security team have extensive IT, IT security and cloud industry experience, as well as certifications pertaining to information security and privacy (such as Certified Information Security Manager, Certified Information Privacy Technologist, GIAC Security Essentials and GIAC Information Security Professional certifications).

Our information security team is responsible for developing, implementing and overseeing our Company-wide information security strategy and related policies and practices.

This team works cross-functionally throughout our organization to assess and prepare the Company for identification and mitigation of, and if necessary respond to, information security risks.

Our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. The audit and risk committee of our board of directors specifically oversees critical risks and opportunities facing the Company and, in this context, reviews and provides feedback on our company-wide enterprise risk management program, which encompasses risks related to IT and cybersecurity and mitigations put in place, or to be put in place, in response to such risks and opportunities.

The audit and risk committee periodically reports to the full board of directors regarding its oversight of the Company's enterprise risk management program and periodic risk assessment results. In addition, our board of directors receives periodic updates from our CIO and Vice President of Information Security on our ISMS and other information security

initiatives, and on our information security governance framework.

Our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. The audit and risk committee of our board of directors specifically oversees critical risks and opportunities facing the Company and, in this context, reviews and provides feedback on our company-wide enterprise risk management program, which encompasses risks related to IT and cybersecurity and mitigations put in place, or to be put in place, in response to such risks and opportunities.

The audit and risk committee periodically reports to the full board of directors regarding its oversight of the Company's enterprise risk management program and periodic risk assessment results. In addition, our board of directors receives periodic updates from our CIO and Vice President of Information Security on our ISMS and other information security initiatives, and on our information security governance framework.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Alkermes plc and its subsidiaries (the "Company") as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive income (loss), of shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

PricewaterhouseCoopers LLP
Boston,
Massachusetts

29114600045746900046052200031602200038452800033247700018288-1967000-3110000-976458000-13435280001464977000120268600020555670002136223000108353400091999800077608900042450000308540007629000225780002303200013040000-217500003242000-4250002122000231140007397000-25039000443750000421519000-3112800071612000-976380002024000372138000519157000-33152000-5068000-163400000-125115000367070000355757000-1582670002.253.12-0.2-0.03-0.98-0.762.222.14-0.972.23.06-0.2-0.03-0.96-0.762.172.1-0.97165392000166223000163742000169198000169730000163742000367070000355751582670002920001195000-97300011430007779000-7166000368213000363536000-16543300016579054916580002798325000-3723000-1541018000-3853222-

~~14265800011125840003160644320001959800019630000-720962-18204000-182040009517600095176000-973000-7166000-7166000-158267000-15826700016895119316900002913099000-10889000-1699285000-4574184-16086200010437530003617858360001672400016760000-1015034-28474000-284740001008710001008710001195000777900077790002937600002937600003557573110000-1343528000-5589218-18933600012026860004101734410002753100027572000-1010156-29637000-296370007894417200282000200282000964250009642500029200011430001143000361967000-976458000-14493791-4192550001464977000367070000355757000-158267000285330007492700077862000966370001009050009425400040522000-99902000-32795000-217500004512000632900055310005205200044510000-252500004284000-8223000-4434000-3091000271200031021000-2254000348470005328000-7215000-15387000-16569000-57967000230090001553400088110001152600014899000-3525000-5926000-7129000-10123000-16147000-3322500084300009334000127260004391240004013530002104400033484000480480011130800053357000-64541000275000000275720001676000019630000296370002847400018204000200282494139000-289714000-1574000-166323000164996000-45071000457469000292473000337544000291146000457469000292473000230100002.~~

~~style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</p><p style="text-indent:3.33%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. Alkermes has a portfolio of proprietary commercial products for the treatment of alcohol dependence and opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development ("R&D") center in Massachusetts and a manufacturing facility in Ohio.</p><p style="text-indent:4.53%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In May 2024, the Company completed the sale of its development and manufacturing facility in Athlone, Ireland (the "Athlone Facility") and related business to Novo Nordisk ("Novo") pursuant to an asset purchase agreement entered into in December 2023. The Company and Novo also entered into subcontracting arrangements to continue certain development and manufacturing activities performed at the Athlone Facility for a period of time after the closing of the transaction, which activities may continue through the end of 2025. In connection with the sale of the Athlone Facility, the Company received \$97.9 million from Novo, which included a payment of approximately \$91.0 million for the facility and certain related assets, and recorded a gain of approximately \$1.5<span style="color:#000000;white-space:pre-wrap;font-~~

size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million within "Other income (expense), net" in the accompanying consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2024. As of December 31, 2023, the Company classified the assets described under the asset purchase agreement for the sale as "Assets held for sale" in the accompanying consolidated balance sheet.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In November 2023, the Company completed the separation of its former oncology business into Mural Oncology plc ("Mural"), a new, independent, publicly-traded company (the "Separation"). The Separation was effected by means of a distribution of all of the outstanding ordinary shares of Mural to the Company's shareholders (the "Distribution"), in which each of the Company's shareholders received one ordinary share, nominal value \$0.01 per share, of Mural for every ten ordinary shares, par value \$0.01 per share, of the Company (the "Distribution Ratio") held by such shareholder as of the close of business on November 6, 2023, the record date for the Distribution (the "Record Date"). The historical results of the oncology business have been reflected as discontinued operations in the Company's consolidated financial statements through November 15, 2023 (the "Separation Date"). For additional information related to the Separation, see Note 3, Discontinued Operations in these "Notes to Consolidated Financial Statements" in this Annual Report. </p>97900000910000001500000Company's shareholders received one ordinary share, nominal value \$0.01 per share, of Mural for every ten ordinary shares, par value \$0.01 per share, of the Company0.01100.01<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span

Principles of Consolidation

The consolidated financial statements include the accounts of Alkermes plc and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated. Columns and rows within tables may not sum due to rounding.

Reclassification

The Company has presented its former oncology business as discontinued operations in its consolidated financial statements as of December 31, 2023 and for the years ended December 31, 2023 and 2022. See Note 3, ***Discontinued Operations*** in these “Notes to Consolidated Financial Statements” in this Annual Report for additional information.

Discontinued Operations

The Company determined that the Separation met the criteria for classification of the former oncology business as discontinued operations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205, ***Discontinued Operations***. Accordingly, the accompanying consolidated financial statements have been updated to present the results of the oncology business as discontinued operations through the Separation Date for the years ended December 31, 2023 and 2022 in the consolidated statements of operations and comprehensive income (loss).

Assets Held for Sale

In connection with the sale of the Athlone Facility, the Company reviewed FASB ASC 805, ***Business***

Combinations and, based on the definitions therein, determined that the Athlone Facility constituted a business. Accordingly, the assets associated with the sale of the Athlone Facility were classified as "Assets held for sale" in the accompanying consolidated balance sheet as of December 31, 2023.

Use of Estimates

The preparation of the Company's consolidated financial statements in accordance with accounting principles generally accepted in the United States ("GAAP") requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies, including but not limited to, those related to revenue from contracts with its customers and related allowances, impairment of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

Cash and Cash Equivalents

The Company values its cash and cash equivalents at cost plus accrued interest, which the Company believes approximates its market value. The Company considers as cash equivalents only those investments that are highly liquid, readily convertible into cash and so near their maturity (three months from the date of purchase) that they present insignificant risk of change in value because of interest rate changes.

Investments

The Company has investments in various types of securities, consisting primarily of United States ("U.S.") government and agency obligations and corporate debt securities. The Company generally holds its interest-bearing investments with major financial institutions and in accordance with documented investment policies. The Company limits the amount of credit exposure to any one financial institution or corporate

issuer. At December 31, 2024, substantially all these investments were classified as available-for-sale and were recorded at fair value.

Unrealized gains and losses are included in accumulated other comprehensive loss in equity, net of related tax, unless: (i) the security has experienced a credit loss; (ii) the Company has determined that it has the intent to sell the security; or (iii) the Company has determined that it is more likely than not that it will have to sell the security before its expected recovery. Periodic reviews are conducted to identify and evaluate each investment that has an unrealized loss in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis.

For available-for-sale debt securities with unrealized losses, the Company performs an analysis to assess whether it intends to sell, or whether it would more likely than not be required to sell, the security before the expected recovery of the amortized cost basis. Where the Company intends to sell a security, or may be required to do so, the security's decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.

Regardless of the Company's intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

The Company's held-to-maturity investments are restricted investments held as collateral under letters of credit related to certain of the Company's agreements and are included in "Investments—long-term," in the accompanying consolidated balance sheets.

Fair Value of Financial Instruments

The Company's financial assets and liabilities are recorded at fair value and are classified as Level 1, 2 or 3 within the fair value hierarchy, as described in the accounting standards for fair value measurement. At December 31, 2024, the Company's financial assets consisted of cash equivalents and investments and are classified within the fair value hierarchy as follows:

-

Level 1—these valuations are based on a market approach using quoted prices in active markets for identical assets. Valuations of these products do not require a significant degree of judgment. Assets utilizing Level 1 inputs at December 31, 2024 included U.S. treasury securities, marketable securities classified as cash equivalents and a fixed term deposit account; and

•

Level 2—these valuations are based on quoted prices for identical or similar assets in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models. Assets utilizing Level 2 inputs at December 31, 2024 included U.S. government agency debt securities and investments in corporate debt securities that are trading in the credit markets.

The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, accounts receivable, contract assets, other current assets, accounts payable and accrued expenses and accrued sales discounts, allowances and reserves approximate fair value due to their short-term nature.

Inventory

Inventory is stated at the lower of cost and net realizable value. The Company utilizes a standard cost basis, which approximates cost determined using the first-in first-out method. Cost is determined using the first-in, first-out method. Included in inventory are raw materials used in production of preclinical and clinical products, which have alternative future use and are charged to R&D expense when consumed. The cost elements included within inventory include three primary categories for commercial products: cost of raw materials; direct labor; and overhead. Overhead is based on the normal capacity of the Company's production facility and does not include costs from abnormally low production or idle capacity, which are expensed directly to the consolidated statement of operations and comprehensive income (loss).

The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management's judgment, future commercialization of the product is considered probable and future economic benefit from such product is expected to be realized. The Company assesses the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety,

efficacy or quality concerns, potential labeling restrictions and other potential impediments to approval. The Company also considers the shelf life of the product in relation to the expected timeline for approval and considers issues that may prevent or delay commercialization, including issues that may arise in relation to the manufacturing of the product. The Company expenses previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by relevant regulatory agencies or other issues that may make the pre-approval inventory batches less likely or unlikely to be commercialized and to result in future economic benefit.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred and major renewals and improvements are capitalized. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:

Asset group	Term	Buildings and improvements

25	years
Furniture, fixtures and equipment	Leasehold improvements
5	7
-	-
Shorter of useful life or lease term	Goodwill and Intangible Assets

Goodwill and Intangible Assets

Goodwill represents the excess cost of the Company's investment in the net assets of acquired companies over the fair value of the underlying identifiable net assets at the date of acquisition. The Company's goodwill consists solely of goodwill created as a result of the Company's acquisition of Elan Drug Technologies ("EDT") from Elan Corporation, plc (such acquisition, the "Business Combination") in September 2011 and has been assigned to one reporting unit. A reporting unit is an operating segment or one level below an operating segment or a component to which goodwill is assigned when initially recorded.

Goodwill represents the excess cost of the Company's investment in the net assets of acquired companies over the fair value of the underlying identifiable net assets at the date of acquisition. The Company's goodwill consists solely of goodwill created as a result of the Company's acquisition of Elan Drug Technologies ("EDT") from Elan Corporation, plc (such acquisition, the "Business Combination") in September 2011 and has been assigned to one reporting unit. A reporting unit is an operating segment or one level below an operating segment or a component to which goodwill is assigned when initially recorded.

size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill is not amortized but is reviewed for impairment on an annual basis, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable. The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of its reporting unit is less than its carrying amount, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative impairment test, the Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then the Company would record an impairment loss equal to the difference.

style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">When some, but not all, of a reporting unit is to be disposed of, the accounting for that reporting unit's goodwill will depend on whether the disposal group constitutes a business. If the disposal group constitutes a business, the Company attributes a portion of the reporting unit's goodwill to the disposal group based on the relative fair values of: (i) the disposal group; and (ii) the portion of the reporting unit that will be retained.

style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's finite-lived intangible assets, consisting of core developed technology and collaboration agreements acquired as part of the Business Combination, were recorded at fair value at the time of their acquisition and are stated within the Company's consolidated balance sheets net of accumulated amortization. The finite-lived intangible assets are amortized over their estimated useful lives using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract. The useful lives of the Company's intangible assets are primarily based on the legal or contractual life of the underlying patent or contract, which does not include additional years for the potential extension or renewal of the contract or patent.

style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Impairment of Long-Lived Assets

style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset; a significant change in the extent or manner in which an asset is used; a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset; a current-period operating or cash flow loss combined with a history of operating or cash-flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset; or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its

previously estimated useful life. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell them.

Revenue from Contracts with Customers

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed in accordance with FASB ASC 606, **Revenue from Contracts with Customers** (“Topic 606”): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.

Product Sales, Net

The Company’s product sales, net consist of sales in the U.S. of VIVITROL®, ARISTADA®, ARISTADA INITIO®, and LYBALVI®, primarily to wholesalers, specialty distributors and pharmacies. Product sales, net are recognized when the customer obtains control of the product, which is when the product has been received by the customer.

Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company's customers, healthcare providers or payers. The Company's process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. The following are the Company's significant categories of sales discounts and allowances:

• *Medicaid Rebates*—the Company records accruals for rebates to U.S. states under the Medicaid Drug Rebate Program as a reduction of sales when the product is shipped into the distribution channel using the expected value method. The Company rebates individual U.S. states for all eligible units purchased under the Medicaid program based on a rebate per unit calculation, which is based on the Company's average manufacturer prices. The Company estimates expected unit sales to individuals covered by Medicaid and rebates per unit under the Medicaid program and adjusts its rebate accrual based on actual unit sales and rebates per unit and changes in trends in Medicaid utilization. In 2024, actual Medicaid utilization rates related to VIVITROL were lower than original estimates, due, in part, to \$8.7 million in actual credits received from certain states in the fourth quarter of 2024 related to duplicate Medicaid billings. Medicaid rebates for the Company's other products have not differed materially from the Company's estimates;

• *Chargebacks*—discounts that occur when contracted indirect customers purchase directly from wholesalers and specialty distributors. Contracted customers generally purchase a product at its contracted price. The wholesaler or specialty distributor, in turn, then generally charges back to the Company the difference between the wholesale acquisition cost and the contracted price paid to the wholesaler or specialty distributor by the customer. The allowance for chargebacks is made using the expected value method and is based on actual and expected utilization of these programs. Chargebacks could exceed historical experience and the Company's estimates of future participation in these programs. To date, actual

chargebacks have not differed materially from the Company's estimates;

• *Product Discounts*—cash consideration, including sales incentives, given by the Company under agreements with a number of wholesaler, distributor, pharmacy, and treatment provider customers that provide them with a discount on the purchase price of products. The reserve is made using the expected value method and to date, actual product discounts have not differed materially from the Company's estimates;

• *Product Returns*—the Company records an estimate for product returns at the time its customers take control of their product. The Company estimates this liability using the expected returns of product sold based on historical return levels and specifically identified anticipated returns due to known business conditions and product expiry dates. Return amounts are recorded as a reduction of sales. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from the Company's estimates; and

• *Medicare Part D*—the Company records accruals for Medicare Part D liabilities under the Medicare Coverage Gap Discount Program ("CGDP") as a reduction of sales. Under the CGDP, patients reaching the annual coverage gap threshold are eligible for reimbursement coverage for out-of-pocket costs for covered prescription drugs. Under an agreement with the Centers for Medicare and Medicaid Services, manufacturers are responsible to reimburse prescription plan sponsors for the portion of out-of-pocket expenses not covered under their Medicare plans. To date, actual Medicare Part D rebates have not differed materially from the Company's estimates.

A rollforward of the Company's provisions

[illegible]

Contractual Adjustments (1)

Discounts (2)

Product Returns

Other

size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Total</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Beginning balance—December 31, 2023</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">234,414</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">28,690</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-	

[illegible]

[illegible]

bottom:0;text-align:left;"> </p></td> padding-top:0.01in;white-space:pre- wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text- align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> 87,373</p></td> padding-top:0.01in;white- space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;"> </p></td> padding-top:0.01in;white-space:pre- wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font- size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin- right:0.009722222222222222in;text-align:left;"> </p></td> padding- bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> padding- right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;margin- right:0.009722222222222222in;text-align:right;">1,060,276</p> </td> padding-top:0.01in;white-space:nowrap;vertical- align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font- size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text- align:left;"> </p> </td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break- word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical- align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin- left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> Adjustments relating to prior years</p></td> padding- right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> padding-top:0.01in;white- space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;"> </p></td> padding-top:0.01in;white-space:pre- wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text- align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> (20,562</p></td> padding- right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> padding- right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">

content;"></p></td>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >—<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >(<="" >3,700<="" p="" p><="" span><="" span><span="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><p="" ><span="" >)<="" p="" p><="" span><="" style="color:#000000;font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >—<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>

[illegible]

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">— </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(70,752</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(794,250</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New

[illegible]

right:0.0097222222222222in;text-align:right;">(15,484</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(13,488</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(219,669</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Ending balance — December 31, 2024</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-

[illegible]

wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">13,297</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">336,427</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.688%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.0620000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.0620000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.0620000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.0620000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-

[illegible]

(2)	
Product Returns	
Other	
Total	
Beginning balance —	

December 31, 2022	

space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">7,938</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">290,520</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Current provisions relating to sales in current year</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">509,780</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">

[illegible]

[illegible]

bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,841</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(6,080</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr><td colspan="6" style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Payments/credits relating to sales in current year</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-

[illegible]

space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(56,224 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">) </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(658,362 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">) </p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Payments/credits relating to sales in prior years </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(184,833 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid

[illegible]

[illegible]

[illegible]

#ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">314,332</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:38.688%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:7pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="18" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">December 31, 2022</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;">

[illegible]

</td>	Other		</td>	Total		Beginning balance — December 31, 2021	\$	209,760	</td>	</td>		</td>

\$	24,150
\$	24,313
\$	9,585
\$	\$

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">15,851</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">58,788</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">790,090</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;">Adjustments relating to prior years</p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-

<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>	(22,019</p></td>
</p></td>	
</p></td>	
</p></td>	
—</p></td>	
</p></td>	
</p></td>	
</p></td>	
3,294</p></td>	
</p></td>	
</p></td>	
</p></td>	

[illegible]

252,896	48,834

bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(539,251</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Payments/credits relating to sales in prior years</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(157,622</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(26,387</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid

[illegible]

[illegible]

wrap;font-kerning:none;min-width:fit-content;"/>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">29,666</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">7,938</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">290,520</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:83.333%;text-align:left;"><span style="white-

space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">"Contractual Adjustments" include "Medicaid Rebates" and "Medicare Part D" accruals</div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(2)<div style="width:100%;display:inline;">"Discounts" include "Chargebacks" and "Product Discounts"</div></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total revenue-related reserves as of December 31, 2024 and 2023, included in our consolidated balance sheets, are summarized as follows:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div style="font-size:10pt;font-family:Times New Roman;"><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-

weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,	
padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">(In thousands)</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">	
padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2024</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">	
padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2023</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Reduction of accounts receivable</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">	
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-	

bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">22,031</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">11,510</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Components of accrued sales discounts, allowances and reserves</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">272,452</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">263,641</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Components of other long-term liabilities</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">41,944</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue-related reserves

336,427	314,332

Collaborative Arrangements

The Company has entered into collaborative arrangements with pharmaceutical companies including, among others, Janssen Pharmaceuticals, Inc. (“Janssen, Inc.”), Janssen Pharmaceutica International, a division of Cilag International AG (“Janssen International”), and Janssen Pharmaceutica N.V. (together with Janssen, Inc., Janssen International and their affiliates, “Janssen”) related to INVEGA SUSTENNA® XEPLION

wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;">@<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-
width:fit-content;">, INVEGA TRINZA<span style="color:#000000;white-
space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;">@<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-
width:fit-content;">/TREVICTA<span style="color:#000000;white-space:pre-
wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;">@<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-
width:fit-content;">, INVEGA HAFYERA<span style="color:#000000;white-
space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;">@<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-
width:fit-content;">/BYANNLI<span style="color:#000000;white-space:pre-
wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-
kerning:none;min-width:fit-content;">@<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-
width:fit-content;">(collectively, the "long-acting INVEGA products") and RISPERDAL
CONSTA<span style="color:#000000;white-space:pre-wrap;vertical-
align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-
width:fit-content;">@<span style="color:#000000;white-space:pre-wrap;font-
size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,
and Biogen International GmbH (together with its affiliates, "Biogen") related to
VUMERITY<span style="color:#000000;white-space:pre-wrap;vertical-
align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-
width:fit-content;">@<span style="color:#000000;white-space:pre-wrap;font-
size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.
Substantially all of the products developed under these arrangements are currently
being marketed as approved products for which the Company received or receives
payments for manufacturing services and/or royalties on net product sales.
</p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times
New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-
kerning:none;min-width:fit-content;">Manufacturing Revenue<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;font-style:italic;font-kerning:none;min-width:fit-content;"></p><p
style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-
content;">The Company recognizes manufacturing revenues from the sale of products
it manufactures for resale by its licensees. Substantially all of the manufacturing
revenues are recognized at a point in time when control of the product passes to the
licensee. The sales price for certain of the Company's manufacturing revenues is based
on the end-market sales price earned by its licensees. As end-market sales generally
occur after the Company has recorded manufacturing revenue, the Company estimates
the sales price for such products based on information supplied to it by the Company's
licensees, its historical transaction experience and other third-party data. Differences
between actual manufacturing revenues and estimated manufacturing revenues are
reconciled and adjusted for in the period in which they become known, which is
generally within the same quarter. The differences between the Company's actual and
estimated manufacturing revenues have not been material to date.</p><p
style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-
kerning:none;min-width:fit-content;">Royalty Revenue</p><p style="text-
indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-

bottom:0;text-align:left;">The Company recognizes royalty revenues related to the sale by its licensees of products that incorporate the Company's technologies. All of the Company's royalties qualify for the sales-and-usage exemption under Topic 606 as (i) such royalties are based strictly on the sales-and-usage by the licensee; and (ii) a license of IP is the sole or predominant item to which such royalties relate. Based on this exemption, these royalties are earned in the period that the products are sold by the Company's licensee and the Company has a present right to payment. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Certain of the Company's royalty revenues are recognized by the Company based on information supplied to the Company by its licensees and require estimates to be made. Differences between actual royalty revenues and estimated royalty revenues are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The differences between the Company's actual and estimated royalty revenues have not been material to date.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Receivables, net</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Receivables, net, include amounts billed and amounts unbilled but currently unconditionally due from customers. The amounts due are stated at their net estimated realizable value. The Company's unbilled receivable balance was \$69.5 million and \$103.1 million at December 31, 2024 and 2023, respectively, and related primarily to royalty revenue. The Company maintains an allowance for doubtful accounts to provide for the estimated amounts of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable. The Company's allowance for doubtful accounts was approximately \$0.3 million and \$0.2 million at December 31, 2024 and 2023, respectively.</p></div><div><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract Assets</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New

Contract assets include unbilled amounts that will result in a sale under certain of the Company's manufacturing contracts. The amounts included in the contract assets table below are classified as "Current assets" in the accompanying consolidated balance sheets, as they relate to manufacturing processes that are completed in

ten days

to

eight weeks

.

Contract assets consisted of the following:			
(In thousands)			
Contract Assets			
Contract assets at January 1, 2023			

[illegible]

[illegible]

2,331

Contract assets at December 31, 2024	4,990
Contract liabilities	1.2

Contract Liabilities

Contract liabilities consist of contractual obligations related to deferred revenue. At December 31, 2024 and 2023, \$1.2 million and \$

2.7 million of the contract liabilities, respectively, were classified as "Contract liabilities-short-term" in the accompanying consolidated balance sheets and none and \$ 2.1 million of the contract liabilities, respectively, were classified as "Other long-term liabilities" in the accompanying consolidated balance sheets.

Contract liabilities consisted of the following:

(In thousands)	Contract Liabilities	Contract liabilities at January 1, 2023

[illegible]

4,995	
Contract liabilities at December 31, 2023	4,775
Additions	34
Amounts recognized into revenue	

bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(3,560</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Contract liabilities at December 31, 2024</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,249</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table></div></div><div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign Currency</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's functional and reporting currency is the U.S. dollar. Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction. The resulting monetary assets and liabilities are translated into U.S. dollars at exchange rates prevailing on the subsequent balance sheet date. Gains and losses as a result of translation adjustments are recorded within "Other income (expense), net" in the accompanying consolidated statements of operations and

comprehensive income (loss). During the years ended December 31, 2024, 2023 and 2022, the Company recorded losses of \$0.8 million and \$0.5 million and a gain of \$0.7 million, respectively, on foreign currency translation.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk are receivables and marketable securities. Billings to large pharmaceutical companies and pharmaceutical wholesalers account for the majority of the Company's receivables, and collateral is not required from these customers. To mitigate credit risk, the Company monitors the financial performance and credit-worthiness of its customers.

The following represents revenue and receivables from the Company's customers exceeding 10% of the total in each category as of, and for the years ended, December 31, 2024, 2023 and 2022:

	2024	2023	2022
Pharmaceutical companies	30.914%	1.66%	9.578%
Pharmaceutical wholesalers	1.66%	9.578%	1.66%
Other customers	9.578%	1.66%	9.578%
Marketable securities	1.66%	9.578%	1.66%

[illegible]

[illegible]

McKesson	36	%	25	14	14	14	12

[illegible]

[illegible]

[illegible]

[illegible]

align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">11</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">19</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">13</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:1%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:4.96%;box-sizing:content-box;"></td><td style="width:3.3%;box-sizing:content-box;"></td><td style="width:91.74%;box-sizing:content-box;"></td></tr><tr style="height:9pt;white-space:pre-wrap;word-break:break-word;"><td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">*</p></td><td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Indicates the revenues or receivables for the customer did not exceed10% of the Company's total in each category as of or for the years ended December 31, 2024, 2023 and 2022, as noted.<span style="color:#000000;white-space:pre-wrap;font-

The Company holds its interest-bearing investments with major financial institutions and, in accordance with documented investment policies, the Company limits the amount of credit exposure to any one financial institution or corporate issuer. The Company's investment objectives are, first, to ensure liquidity and conservation of capital and, second, to generate investment income.

Geographic Information

Company revenues by geographic location for the years ended December 31, 2024, 2023 and 2022, as determined by the location of the customer, are as follows:

Year Ended December 31,	2024	2023	2022
United States	100.0%	100.0%	100.0%
Foreign	0.0%	0.0%	0.0%
Total	100.0%	100.0%	100.0%

[illegible]

[illegible]

[illegible]

[illegible]

		177,975	

The location of the Company's assets are as follows:

	December 31,	December 31,						
								

[illegible]

[illegible]

[illegible]

Investments—short-term	203,631	187,574
Receivables, net		

right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">306,259</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">218,747</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#fff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other current assets</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">129,332</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>

content;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">143,417</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Ireland:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Cash and cash equivalents</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">128,448</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Receivables, net</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">78,269</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">113,730</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="color:#000000;white-

[illegible]

bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">141,861</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Long-term assets:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-

right:0.009722222222222222in;text-align:left;">U.S.:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Property, plant and equipment, net</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">226,646</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td></tr>

bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">225,578</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Investments—long-term</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">24,629</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">17,957</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New					

Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">Other</p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">210,792</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">189,335</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> </tr> <tr style="height:10pt;background-
color:#c0c0c0;white-space:pre-wrap;word-break:break-word;"> <td style="padding-
top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">Ireland:</p></td>
<td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p

Property, plant and equipment, net	
918	1,365

Investments—long-term	
48,519	
21,930	
Intangible assets, net and goodwill	

content;">83,917</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">85,018</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">44,791</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">

109,534	

Research and Development Expenses

For each of its R&D programs, the Company incurs both external and internal expenses. External R&D expenses include fees related to clinical and preclinical activities performed by contract research organizations, consulting fees and costs related to laboratory services, purchases of drug product materials and third-party manufacturing development costs. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. The Company tracks external R&D expenses for each of its development programs, however, internal R&D expenses are not tracked by individual program as they benefit multiple development programs or the Company's products or technologies in general.

Selling, General and Administrative Expenses

Selling, general and administrative ("SG&A") expenses are primarily comprised of employee-related expenses associated with selling and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising, financial and legal expenses and other general and administrative costs.

Advertising costs are expensed as incurred. During the years ended December 31, 2024, 2023 and 2022, advertising costs totaled \$

107.6	million, \$	127.6	million and \$	41.4	million, respectively.

Share-Based Compensation

size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's share-based compensation programs permit grants of awards in the form of stock options and restricted stock unit awards ("RSUs"), which vest with the passage of time and/or based on the achievement of certain performance criteria. The Company issues new shares upon the exercise of stock options or the vesting of RSUs. Under the terms of the Company's stock option and incentive plans (the "Plans"), the Company's employees may, at the discretion of the plan administrator, become eligible in certain circumstances set forth in the Plans for accelerated vesting of certain awards granted to them under the Plans. In such circumstances, if there are no effective future service requirements for such employees, the remaining fair value of any such accelerated awards would be expensed as of the date of acceleration.</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Time-Based Stock Options</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Except as otherwise provided in the applicable Plan or award certificate, stock option grants to employees expire ten years from the date of grant and generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Except as otherwise provided in the applicable Plan or Award Certificate (as defined in the 2018 Plan): (i) annual stock option grants to non-employee directors expire ten years from the date of grant and generally vest over a one-year period; and (ii) stock option grants to new non-employee directors expire ten years from the date of grant and generally vest over a three-year period. The estimated fair value of options is recognized over the requisite service period, which is generally the vesting period. Share-based compensation expense is based on awards ultimately expected to

vest. Forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates.

The fair value of stock option grants is based on estimates as of the date of grant using a Black-Scholes option valuation model. The Company uses historical data as the basis for estimating stock option terms and forfeitures. Separate groups of employees that have similar historical stock option exercise and forfeiture behavior are considered separately for valuation purposes. The ranges of expected terms disclosed below reflect different expected behavior among certain groups of employees. Expected stock volatility factors are based on a weighted average of implied volatilities from traded options of the Company's ordinary shares and historical share price volatility of the Company's ordinary shares, which is determined based on a review of the weighted average of historical weekly price changes of the Company's ordinary shares. The risk-free interest rate for periods commensurate with the expected term of the stock option is based on the U.S. treasury yield curve in effect at the time of grant. The dividend yield on the Company's ordinary shares is estimated to be zero as the Company has not paid dividends and does not expect to pay dividends in the near future. The exercise price of options granted is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant.

The fair value of each stock option granted was estimated on the grant date with the following weighted-average assumptions:

Expected term	Expected stock price	Expected volatility	Expected dividend yield	Expected risk-free interest rate
3.5 years	\$12.76	12.76%	0.00%	1.40%

Year Ended December 31,

2024

2023

2022

Expected option term	5	7	years
	5		

[illegible]

Risk-free interest rate	
3.64 % -	4.60 %
3.34 % -	4.75 %
1.83 % -	4.26 %
Expected annual dividend yield	

right:0.009722222222222222in;text-align:center;">—</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">—</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">—</p></td></tr></table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Time-Based Restricted Stock Unit Awards</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Except as otherwise provided in the applicable Plan or award certificate, time-based RSUs awarded to employees generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Shares subject to these RSUs are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of time-based RSUs is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Performance-Based Restricted Stock Unit Awards</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Performance-based RSUs awarded to employees vest upon the achievement of certain performance criteria, typically during or following the end of a specified performance period. The estimated fair value of these performance-based RSUs are generally based on the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant, unless the performance-based RSU is also subject to a market condition. In that case, the fair value of the performance-

based RSU is based on a Monte Carlo simulation model. Compensation expense for performance-based RSUs is recognized from the date the Company determines the performance criteria probable of being achieved to the date the award, or relevant portion of the award, is expected to vest. Cumulative adjustments are recorded on a quarterly basis to reflect subsequent changes to the estimated outcome of the performance criteria until the date that the final outcome of the performance criteria is determined.

Income Taxes

The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In evaluating the Company's ability to recover its deferred tax assets, the Company considers all available positive and negative evidence including its past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which the Company operates and its forecast of future taxable income. In determining future taxable income, the Company is responsible for assumptions utilized including the amount of Irish and non-Irish pre-tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company is using to manage the underlying business.

The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates its tax position on a quarterly basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.

Comprehensive Income (Loss)

Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized holding gains and losses on available-for-sale investments.

Earnings (Loss) Per Share

Basic earnings (loss) per ordinary share from continuing operations is calculated based upon net income (loss) from continuing operations available to holders of ordinary shares divided by the weighted average number of ordinary shares outstanding. Basic loss per ordinary share from discontinued operations is calculated based upon net loss from discontinued operations available to holders of ordinary shares, divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted earnings (loss) per ordinary share from continuing operations and discontinuing operations, the Company utilizes the treasury stock method and adjusts the weighted average number of ordinary shares outstanding for the potential dilutive effect of outstanding ordinary share equivalents such as stock options and RSUs.

Segment Information

In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosure (“Topic 280”) to establish standards for reporting information about operating segments. Operating segments are defined as components of an enterprise engaging in business activities for which separate financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company has utilized the management approach to determine that the Company is managed as one segment on a consolidated basis and is the business of developing, manufacturing and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. The Company’s CODM, the Chairman and Chief Executive Officer, reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit. The CODM measures profitability on a reportable segment basis using net income (loss) and utilizes this information in allocating resources and in assessing performance by monitoring budget versus actual results. Please refer to Note 18,

Segment Reporting

, in these “Notes to Consolidated Financial Statements” in this Annual Report for further information.

Employee Benefit Plans

401(k) Plan

family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a 401(k) retirement savings plan (the “401(k) Plan”), which covers all of its eligible U.S.-based employees. Eligible employees may contribute up to 100% of their eligible compensation, subject to certain Internal Revenue Service (“IRS”) limitations. The Company matches 100% of employee contributions up to the first 5% of employee pay, up to IRS limits. Employee and Company contributions are fully vested when made. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$15.1 million, \$15.0 million and \$14.4 million, respectively, to match employee deferrals under the 401(k) Plan.

margin-left:4.53%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Defined Contribution Plan

text-indent:4.53%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company maintains a defined contribution plan for its Ireland-based employees (the “Defined Contribution Plan”). The Defined Contribution Plan provides for eligible employees to contribute up to a maximum of 40%, depending upon their age, of their total taxable earnings subject to an earnings cap of €115,000. The Company provides a match of up to 18% of taxable earnings depending upon an individual’s contribution level. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$3.4

million, \$5.6 million and \$5.1 million, respectively, in contributions to the Defined Contribution Plan.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

In December 2023, the FASB issued ASU 2023-09, ***Income Taxes*** (“Topic 740”): ***Improvements to Income Tax Disclosures***, to enhance the transparency and decision usefulness of income tax disclosures in order to provide information to assist key stakeholders in better assessing how the Company’s operations and related tax risks and tax planning and operational opportunities affect the Company’s tax rate and prospects for future cash flows. This ASU becomes effective for public companies for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This guidance will be applied on a prospective basis. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, ***Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures***, to improve disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly-presented expense captions, such as cost of sales, selling, general and administrative expenses, and research and development. All disclosure requirements under this

guidance are required for public business entities and effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted and the amendments in this guidance will be applied prospectively to financial statements for periods after the effective dates. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures.

Principles of Consolidation

The consolidated financial statements include the accounts of Alkermes plc and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated. Columns and rows within tables may not sum due to rounding.

Reclassification

The Company has presented its former oncology business as discontinued operations in its consolidated financial statements as of December 31, 2023 and for the years ended December 31, 2023 and 2022. See Note 3,

Discontinued Operations

in these “Notes to Consolidated Financial Statements” in this Annual Report for additional information.

Discontinued Operations

The Company determined that the Separation met the criteria for classification of the former oncology business as discontinued operations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205,

Discontinued Operations

. Accordingly, the accompanying consolidated financial statements have been updated to present the results of the oncology business as discontinued operations through the Separation Date for the years ended December 31, 2023 and 2022 in the consolidated statements of operations and comprehensive income (loss).

Assets Held for Sale

In connection with the sale of the Athlone Facility, the Company reviewed FASB ASC 805, Business Combinations ("Topic 805") and, based on the definitions therein, determined that the Athlone Facility constituted a business. Accordingly, the assets associated with the sale of the Athlone Facility were classified as "Assets held for sale" in the accompanying consolidated balance sheet as of December 31, 2023.

Use of Estimates

The preparation of the Company's consolidated financial statements in accordance with accounting principles generally accepted in the United States ("GAAP") requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies, including but not limited to, those related to revenue from contracts with its customers and related allowances, impairment of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

Cash and Cash Equivalents

The Company values its cash and cash equivalents at cost plus accrued interest, which the Company believes approximates its market value. The Company considers as cash equivalents only those investments that are highly liquid, readily convertible into cash and so near their maturity (three months from the date of purchase) that they present insignificant risk of change in value because of interest rate changes.

Investments

The Company has investments in various types of securities, consisting primarily of United States ("U.S.") government and agency obligations and corporate debt securities. The Company generally holds its interest-bearing investments with major financial institutions and in accordance with documented investment policies.

The Company limits the amount of credit exposure to any one financial institution or corporate issuer. At December 31, 2024, substantially all these investments were classified as available-for-sale and were recorded at fair value.

Unrealized gains and losses are included in accumulated other comprehensive loss in equity, net of related tax, unless: (i) the security has experienced a credit loss; (ii) the Company has determined that it has the intent to sell the security; or (iii) the Company has determined that it is more likely than not that it will have to sell the security before its expected recovery. Periodic reviews are conducted to identify and evaluate each investment that has an unrealized loss in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis.

For available-for-sale debt securities with unrealized losses, the Company performs an analysis to assess whether it intends to sell, or whether it would more likely than not be required to sell, the security before the expected recovery of the amortized cost basis. Where the Company intends to sell a security, or may be required to do so, the security's decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.

Regardless of the Company's intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

The Company's held-to-maturity investments are restricted investments held as collateral under letters of credit related to certain of the Company's agreements and are included in "Investments—long-term," in the accompanying consolidated balance sheets.

Fair Value of Financial Instruments

The Company's financial assets and liabilities are recorded at fair value and are classified as Level 1, 2 or 3 within the fair value hierarchy, as described in the accounting standards for fair value measurement. At December 31, 2024, the Company's financial assets consisted of cash equivalents and investments and are classified within the fair value hierarchy as follows:

•

Level 1—these valuations are based on a market approach using quoted prices in active markets for identical assets. Valuations of these products do not require a significant degree of judgment. Assets utilizing Level 1 inputs at December 31, 2024 included U.S. treasury securities, marketable securities classified as cash equivalents and a fixed term deposit account; and

•

Level 2—these valuations are based on quoted prices for identical or similar assets in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models. Assets utilizing Level 2 inputs at December 31, 2024 included U.S. government agency debt securities and investments in corporate debt securities that are trading in the credit markets.

The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, accounts receivable, contract assets, other current assets, accounts payable and accrued expenses and accrued sales discounts, allowances and reserves approximate fair value due to their short-term nature.

Inventory

Inventory is stated at the lower of cost and net realizable value. The Company utilizes a standard cost basis, which approximates cost determined using the first-in-first-out method. Cost is determined using the first-in, first-out method. Included in inventory are raw materials used in production of preclinical and clinical products, which have alternative future use and are charged to R&D expense when consumed. The cost elements included within inventory include three primary categories for commercial products: cost of raw materials; direct labor; and overhead. Overhead is based on the normal capacity of the Company's production facility and does not include costs from abnormally low production or idle capacity, which are expensed directly to the consolidated statement of operations and comprehensive income (loss).

The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management's judgment, future commercialization of the product is considered probable and future economic benefit from such product is expected to be realized. The Company assesses the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety, efficacy or quality concerns, potential labeling restrictions and other potential

impediments to approval. The Company also considers the shelf life of the product in relation to the expected timeline for approval and considers issues that may prevent or delay commercialization, including issues that may arise in relation to the manufacturing of the product. The Company expenses previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by relevant regulatory agencies or other issues that may make the pre-approval inventory batches less likely or unlikely to be commercialized and to result in future economic benefit.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred and major renewals and improvements are capitalized. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:

	Useful life	Depreciation method
Buildings and improvements	10 years	Straight-line
Equipment	5 years	Straight-line

25 years

Furniture, fixtures and equipment	
5	-
7	years

Leasehold improvements	
Shorter of useful life or lease term	

Asset group	Term

Buildings and improvements	25 years
Furniture, fixtures and equipment	5 - 7 years
Leasehold improvements	Shorter of useful life or lease term
Shorter of useful life or lease term	

P25YP5YP7YShorter of useful life or lease term

 Goodwill and Intangible Assets

wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill represents the excess cost of the Company's investment in the net assets of acquired companies over the fair value of the underlying identifiable net assets at the date of acquisition. The Company's goodwill consists solely of goodwill created as a result of the Company's acquisition of Elan Drug Technologies ("EDT") from Elan Corporation, plc (such acquisition, the "Business Combination") in September 2011 and has been assigned to one reporting unit. A reporting unit is an operating segment or one level below an operating segment or a component to which goodwill is assigned when initially recorded.

Goodwill is not amortized but is reviewed for impairment on an annual basis, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable. The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of its reporting unit is less than its carrying amount, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative impairment test, the Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then the Company would record an impairment loss equal to the difference.

When some, but not all, of a reporting unit is to be disposed of, the accounting for that reporting unit's goodwill will depend on whether the disposal group constitutes a business. If the disposal group constitutes a business, the Company attributes a portion of the reporting unit's goodwill to the disposal group based on the relative fair values of: (i) the disposal group; and (ii) the portion of the reporting unit that will be retained.

The Company's finite-lived intangible assets, consisting of core developed technology and collaboration agreements acquired as part of the Business Combination, were recorded at fair value at the time of their acquisition and are stated within the Company's consolidated balance sheets net of accumulated amortization. The finite-lived intangible assets are amortized over their estimated useful lives using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract. The useful lives of the Company's intangible assets are primarily based on the legal or contractual life of the underlying patent or contract, which does not include additional years for the potential extension or renewal of the contract or patent.

Impairment of Long-Lived Assets

The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of the

assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset; a significant change in the extent or manner in which an asset is used; a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset; a current-period operating or cash flow loss combined with a history of operating or cash-flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset; or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell them.

Revenue from Contracts with Customers

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed in accordance with FASB ASC 606,

Revenue from Contracts with Customers (“Topic 606”): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations.

Product Sales, Net

The Company’s product sales, net consist of sales in the U.S. of VIVITROL®

®, ARISTADA®

®, ARISTADA INITIO®

®

and LYBALVI

@

primarily to wholesalers, specialty distributors and pharmacies. Product sales, net are recognized when the customer obtains control of the product, which is when the product has been received by the customer.

Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company's customers, healthcare providers or payers. The Company's process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. The following are the Company's significant categories of sales discounts and allowances:

- Medicaid Rebates—the Company records accruals for rebates to U.S. states under the Medicaid Drug Rebate Program as a reduction of sales when the product is shipped into the distribution channel using the expected value method. The Company rebates individual U.S. states for all eligible units purchased under the Medicaid program based on a rebate per unit calculation, which is based on the Company's average manufacturer prices. The Company estimates expected unit sales to individuals covered by Medicaid and rebates per unit under the Medicaid program and adjusts its rebate accrual based on actual unit sales and rebates per unit and changes in trends in Medicaid utilization. In 2024, actual Medicaid utilization rates related to VIVITROL were lower than original estimates, due, in part, to \$8.7 million in actual credits received from certain states in the fourth quarter of 2024 related to duplicate Medicaid billings. Medicaid rebates for the Company's other products have not differed materially from the Company's estimates;
- Chargebacks

discounts that occur when contracted indirect customers purchase directly from wholesalers and specialty distributors. Contracted customers generally purchase a product at its contracted price. The wholesaler or specialty distributor, in turn, then generally charges back to the Company the difference between the wholesale acquisition cost and the contracted price paid to the wholesaler or specialty distributor by the customer. The allowance for chargebacks is made using the expected value method and is based on actual and expected utilization of these programs. Chargebacks could exceed historical experience and the Company's estimates of future participation in these programs. To date, actual chargebacks have not differed materially from the Company's estimates;

Product Discounts—cash consideration, including sales incentives, given by the Company under agreements with a number of wholesaler, distributor, pharmacy, and treatment provider customers that provide them with a discount on the purchase price of products. The reserve is made using the expected value method and to date, actual product discounts have not differed materially from the Company's estimates;

Product Returns—the Company records an estimate for product returns at the time its customers take control of their product. The Company estimates this liability using the expected returns of product sold based on historical return levels and specifically identified anticipated returns due to known business conditions and product expiry dates. Return amounts are recorded as a reduction of sales. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from the Company's estimates; and

Medicare Part D—the Company records accruals for Medicare Part D liabilities under the Medicare Coverage Gap Discount Program ("CGDP") as a reduction of sales. Under the CGDP, patients reaching the annual coverage gap threshold are eligible for reimbursement coverage for out-of-pocket costs for covered prescription drugs. Under an agreement with the Centers for Medicare and

[illegible]

(In thousands)

Contractual Adjustments	(1)
Discounts	(2)
Product Returns	

[illegible]

Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">28,690</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-kerning:none;min-width:fit-content;">\$</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">41,064</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-
width:fit-content;">\$</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">10,164</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-kerning:none;min-width:fit-content;">\$</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">314,332</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-

Current provisions relating to sales in current year	557,651	386,625	28,627

bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">87,373</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,060,276</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Adjustments relating to prior years</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(24,262</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Payments/credits relating to sales in current year</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(369,869</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

[illegible]

content;">(794,250</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr><td style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Payments/credits relating to sales in prior years</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(172,656</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(18,041</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Ending balance — December 31, 2024</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">228,978</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">43,645</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-

space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">50,507</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">13,297</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">336,427</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:38.688%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td

[illegible]

Discounts (2)	
	
	
Product Returns	
	
	
Other	
	
	
Total	

align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2022</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">226,741</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">26,175</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">29,666</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">7,938</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">290,520</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Current provisions relating to sales in current year</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

[illegible]

bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">941,506</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Adjustments relating to prior years</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(8,921</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

[illegible]

>></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Payments/credits relating to sales in current year</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(308,353</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(293,785</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">—	
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(
	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">56,224
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(
	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">658,362
height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Payments/credits relating to sales in prior years	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-	

184,833	30,560
24,860	

right:0.009722222222222222in;text-align:left;">	
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> font-kerning:none;min-width:fit-content;">
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> color:#000000;font-kerning:none;min-width:fit-content;">
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">	font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> font-kerning:none;min-width:fit-content;">
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> color:#000000;font-kerning:none;min-width:fit-content;">
height:10pt;background-color:#ffffff;word-break:break-word;">	
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> color:#000000;font-kerning:none;min-width:fit-content;">
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">

234,414</p></td>
 </td>
 </td>
\$ </td>
28,690 </td>
 </td>
 </td>
\$ </td>
41,064 </td>
 </td>
 </td>
\$ </td>

#000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">10,164</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">314,332</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:38.688%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.062000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="18" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">December 31, 2022</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">(In thousands)</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Contractual Adjustments(1)</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Discounts(2)</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"><span style="white-space:pre-

Product Returns Other Total		Beginning balance — December 31, 2021 \$

[illegible]

bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">267,808</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Current provisions relating to sales in current year</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">434,143</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">281,308</p></td> <td style="padding-top:0.01in;white-

[illegible]

Adjustments relating to prior years	22,019	3,294

18,725	Payments/credits relating to sales in current year
18,725	Payments/credits relating to sales in current year

[illegible]

right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(539,251</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Payments/credits relating to sales in prior years</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(157,622</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

26,387	13,792
11,601	

right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(209,402</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Ending balance — December 31, 2022</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">226,741</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">290,520</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:83.333%;text-align:left;"> </p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">"Contractual Adjustments" include "Medicaid Rebates" and "Medicare Part D" accruals</div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(2)<div style="width:100%;display:inline;">"Discounts" include "Chargebacks" and "Product Discounts"</div></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total revenue-related reserves as of December 31, 2024 and 2023, included in our consolidated balance sheets, are summarized as follows:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div><div style="font-size:10pt;font-family:Times New Roman;"><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.8830000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.8830000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td>

[illegible]

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">22,031</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">11,510</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Components of accrued sales discounts, allowances and reserves</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">272,452</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-

content;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">263,641</p></td> </td></td></td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">263,641</p></td> </td></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">263,641</p></td> </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">263,641</p></td>						
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Components of other long-term liabilities</p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">41,944</p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td> </td></td></td></td></td></td></td></td></td>	<tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Components of other long-term liabilities</p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">41,944</p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td> </td></td></td></td></td></td></td></td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Components of other long-term liabilities</p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">41,944</p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td> </td></td></td></td></td></td></td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">41,944</p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td> </td></td></td></td></td></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">41,944</p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td> </td></td></td></td></td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">41,944</p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td> </td></td></td></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td> </td></td></td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td> </td></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td> </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td>

Total revenue-related reserves	\$336,427
	\$314,332
Collaborative Arrangements	
The Company has entered into collaborative arrangements with	

pharmaceutical companies including, among others, Janssen Pharmaceuticals, Inc. ("Janssen, Inc."), Janssen Pharmaceutica International, a division of Cilag International AG ("Janssen International"), and Janssen Pharmaceutica N.V. (together with Janssen, Inc., Janssen International and their affiliates, "Janssen") related to INVEGA SUSTENNA@/XEPLION@, INVEGA TRINZA@/TREVICTA@, INVEGA HAFYERA@/BYANNLI@(collectively, the "long-acting INVEGA products") and RISPERDAL CONSTA@, and Biogen International GmbH (together with its affiliates, "Biogen") related to VUMERITY@.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Manufacturing Revenue</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company recognizes manufacturing revenues from the sale of products it manufactures for resale by its licensees. Substantially all of the manufacturing revenues are recognized at a point in time when control of the product passes to the licensee. The sales price for certain of the Company's manufacturing revenues is based on the end-market sales price earned by its licensees. As end-market sales generally occur after the Company has recorded manufacturing revenue, the Company estimates the sales price for such products based on information supplied to it by the Company's licensees, its historical transaction experience and other third-party data. Differences

[illegible]

word;">	
bottom:0in;padding-right:0.01in;">	
right:0.009722222222222222in;text-align:left;">	
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;">	
style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">	
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;">	
style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">	
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
colspan="18" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;">	
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">	
style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">	
December 31, 2024	
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;">	
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">	
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">	
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">	
style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">	
(In thousands)	
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;">	
style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">	
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;">	
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">	
style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">	
Contractual Adjustments	
style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">	
(1)	
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;">	
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;">	
style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">	
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;">	
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">	
style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">	
Discounts	
style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">	
(2)	
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-	

right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Product Returns</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Other</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Product Returns</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Other</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Product Returns</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Other</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td> </td> </td> </td> </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Other</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td> </td> </td> </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Other</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td> </td> </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Other</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td> </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td> </td>	style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td> </td>	style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Beginning balance — December 31, 2023</p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre- </td>	style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-

[illegible]

space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">10,164</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">314,332</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Current provisions relating to sales in current year</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">557,651</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

[illegible]

[illegible]

[illegible]

369,869	353,629

bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(70,752</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(794,250</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Payments/credits relating to sales in prior years</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(172,656</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span

[illegible]

[illegible]

[illegible]

right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">336,427</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.688%;box-sizing:content-box;"> </td> <td style="width:1.2%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:9.062000000000001%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:1.2%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:9.062000000000001%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:1.2%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:9.062000000000001%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:1.2%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:9.062000000000001%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:1.2%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:9.062000000000001%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="18" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">December 31, 2023 </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-

[illegible]

bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2"> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Other</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2"> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </td> </td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Other</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2"> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </td> </td> </td> </td>		style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2"> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2"> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </td> </td>	style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Total</p></td> <td> style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </td>		style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td>								
style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Beginning balance — December 31, 2022</p></td> <td colspan="2"> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td colspan="2"> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">226,741</p></td> <td> style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> </td> </td> </td> </td> </td> </td> </td>							style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td colspan="2"> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">226,741</p></td> <td> style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> </td> </td> </td> </td> </td> </td>		style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td colspan="2"> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">226,741</p></td> <td> style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> </td> </td> </td> </td> </td>	style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">226,741</p></td> <td> style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> </td> </td> </td> </td>		style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> </td> </td> </td>	style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> </td> </td>	style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> </td>	style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td>

[illegible]

Current provisions relating to sales in current year	509,780	326,860
Current provisions relating to sales in current year	509,780	326,860

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">33,417</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
71,449</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">941,506</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
Adjustments relating to prior years</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

[illegible]

[illegible]

[illegible]

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(658,362</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Payments/credits relating to sales in prior years</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(184,833</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(30,560</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span

[illegible]

253,252	Ending balance — December 31, 2023
234,414	28,690
\$	\$

bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">41,064</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">10,164</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">314,332</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-

[illegible]

[illegible]

Total

Beginning balance — December 31, 2021	
\$	
209,760	
\$	
24,150	
\$	

24,313	
\$	9,585
\$	
267,808	
Current provisions relating to sales in current year	

[illegible]

[illegible]

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">3,294</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

content;">18,725</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Payments/credits relating to sales in current year</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(237,521</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(252,896</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(48,834</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(539,251</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Payments/credits relating to sales in prior years</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-

wrap;font-kerning:none;min-width:fit-content;"/> 	td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;">)(157,622
td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">)	td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">
td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">	td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;">)(26,387
td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">)	td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;">
td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">	td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;">)(13,792
td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">	td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">)(

11,601	209,402	Ending balance — December 31, 2022

226,741	26,175
226,741	29,666

\$

7,938	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520	290,520

\$

290,520

2426200036986900035362900070752000794250000172656000180410001548400013489210002841000-60800003083530002937850005622400065836200018483300030560000248600001299220190003294000-18725000237521000252896000488340005392510001576220002638700013792000116

Total revenue-related reserves as of December 31, 2024 and 2023, included in our consolidated balance sheets, are summarized as follows:</p><p style="text-indent: 4.533%; font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p><table style="margin-left: auto; border-spacing: 0; table-layout: auto; width: 100.0%; border-collapse: separate; margin-right: auto;"><tr style="visibility: collapse;"><td style="width: 66.993%; box-sizing: content-box;"></td><td style="width: 1.62%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td><td style="width: 12.8830000000000001%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td><td style="width: 1.62%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td><td style="width: 12.8830000000000001%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td></tr><tr style="height: 8pt; background-color: #ffffff; white-space: pre-wrap; word-break: break-word;"><td style="padding-top: 0.01in; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: left;"></p></td><td style="padding-top: 0.01in; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: left;"></p></td><td colspan="6" style="padding-top: 0.01in; vertical-align: bottom; padding-bottom: 0in; border-bottom: 0.5pt solid #000000; padding-right: 0.01in; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: center;">Year Ended December 31,</p></td><td style="padding-top: 0.01in; vertical-align: bottom; padding-bottom: 0in; border-bottom: 0.5pt solid #000000; padding-right: 0.01in; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;"></p></td></tr><tr style="height: 8pt; background-color: #ffffff; white-space: pre-wrap; word-break: break-word;"><td style="padding-top: 0.01in; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: left;">(In thousands)</p></td><td style="padding-top: 0.01in; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: left;"><p style="font-size: 7.5pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: center;"></p></td><td colspan="2" style="padding-top: 0.01in; vertical-align: bottom; padding-bottom: 0in; border-bottom: 0.5pt solid #000000; padding-right: 0.01in; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: center;"><span style="color: #000000; white-

[illegible]

content;">11,510</p></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>
</tr>	<tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Components of accrued sales discounts, allowances and reserves </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 272,452 </td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 263,641 </td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>	</tr>
<tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;">	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Components of other long-term liabilities </td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-

bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">41,944</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39,181</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total revenue-related reserves</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">336,427</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-

wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">314,332</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>2203100011510000272452000263641000419440003918100033642700031433.

style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Receivables, net</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Receivables, net, include amounts billed and amounts unbilled but currently unconditionally due from customers. The amounts due are stated at their net estimated realizable value. The Company's unbilled receivable balance was \$69.5 million and \$103.1 million at December 31, 2024 and 2023, respectively, and related primarily to royalty revenue. The Company maintains an allowance for doubtful accounts to provide for the estimated amounts of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable. The Company's allowance for doubtful accounts was approximately \$0.3 million and \$0.2 million at December 31, 2024 and 2023, respectively.</p>69500000103100000300000200000<p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract Assets</p><p style="text-indent:4.533%;font-

Contract assets include unbilled amounts that will result in a sale under certain of the Company's manufacturing contracts. The amounts included in the contract assets table below are classified as "Current assets" in the accompanying consolidated balance sheets, as they relate to manufacturing processes that are completed in

ten days to eight weeks

Contract assets consisted of the following:

(In thousands)			
Contract Assets			
Contract Assets			
Contract assets at January 1, 2023			

[illegible]

[illegible]

space:pre-wrap;font-kerning:none;min-width:fit-content;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(2,331 </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Contract assets at December 31, 2024</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$ </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">4,990 </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> </table> </div> P10D <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract assets consisted of the following:</p> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-

[illegible]

Transferred to receivables, net	
21,829	
Contract assets at December 31, 2023	
\$706	
Additions	

[illegible]

top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract liabilities consisted of the following:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">(In thousands)</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Contract Liabilities</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Contract liabilities at January 1, 2023</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">10,701</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>

Additions	
931	
Amounts recognized into revenue	
4,995	
Contract liabilities at December 31, 2023	

[illegible]

space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Contract liabilities at December 31, 2024</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,249</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>89290001360600021829000706000661500023310004990000<p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract Liabilities</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract liabilities consist of contractual obligations related to deferred revenue. At December 31, 2024 and 2023,1.2 million and \$2.7 million of the contract liabilities, respectively, were classified as "Contract liabilities-short-term" in the accompanying consolidated balance sheets andnone and \$2.1 million of the contract liabilities, respectively, were classified as

“Other long-term liabilities” in the accompanying consolidated balance sheets.

Contract liabilities consisted of the following:

(In thousands)	Contract Liabilities	Contract Liabilities		
Contract liabilities at January 1, 2023	Contract liabilities	\$		
10,701	10,701			

931	Amounts recognized into revenue
	4,995
	Contract liabilities at December 31, 2023

[illegible]

space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Contract liabilities at December 31, 2024</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,249</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table></div>120000027000000210000010701000-931000-4995000477500034000-35600001249000<p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign Currency</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's functional and reporting currency is the U.S. dollar. Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction. The resulting monetary assets and liabilities are translated into U.S. dollars at exchange rates prevailing on the subsequent balance sheet date. Gains and losses as a result of translation adjustments are recorded within "Other income (expense), net" in the accompanying consolidated statements of operations and comprehensive income (loss). During the years ended December 31, 2024, 2023 and 2022, the Company recorded losses of \$0.8million and \$0.5million and a gain of \$0.7million, respectively, on foreign currency translation.</p>-800000-500000700000<p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-

family:Times New Roman;margin-bottom:0;text-align:left;">Concentrations</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financial instruments that potentially subject the Company to concentrations of credit risk are receivables and marketable securities. Billings to large pharmaceutical companies and pharmaceutical wholesalers account for the majority of the Company's receivables, and collateral is not required from these customers. To mitigate credit risk, the Company monitors the financial performance and credit-worthiness of its customers. The following represents revenue and receivables from the Company's customers exceeding 10% of the total in each category as of, and for the years ended, December 31, 2024, 2023 and 2022:</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:30.914%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:9.578%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:9.578%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:9.578%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:9.578%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:9.578%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:9.578%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td><td colspan="11" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Year Ended December 31,</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

[illegible]

[illegible]

36	%
25	%
14	%
14	%
12	%
16	%
Cencora	

<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: right;">17</p>	%</p>
<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: right;">15</p>	%</p>
<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: right;">16</p>	%</p>
<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: right;">12</p>	%</p>
<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: right;">18</p>	%</p>
<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: right;">14</p>	%</p>
<tr style="height: 10pt; background-color: #cfff0f; white-space: pre-wrap; word-break: break-word;"><td style="padding-top: 0in; vertical-align: bottom; padding-	

[illegible]

align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Janssen</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">14</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">17</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">23</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">31</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-

[illegible]

bottom:0;margin-right:0.0097222222222222in;text-align:right;">19</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">13</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:1%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:4.96%;box-sizing:content-box;"></td> <td style="width:3.3%;box-sizing:content-box;"></td> <td style="width:91.74%;box-sizing:content-box;"></td> </tr> <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;"> <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">*</p></td> <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Indicates the revenues or receivables for the customer did not exceed 10% of the Company's total in each category as of or for the years ended December 31, 2024, 2023 and 2022, as noted. </p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company holds its interest-bearing investments with major financial institutions and, in accordance with documented investment policies, the Company limits the amount of credit exposure to any one financial institution or corporate issuer. The Company's investment objectives are, first, to ensure liquidity and conservation of capital and, second, to generate investment income.</p>The following represents revenue and receivables from the Company's customers exceeding

10 % of the total in each category as of, and for the years ended, December 31, 2024, 2023 and 2022:										
</										

2023	2022			
Customer	Receivables	Revenue		
Receivables				

Revenue	
Receivables	
Revenue	
McKesson	
36	
%	
25	
%	

[illegible]

16	12	18	14
Cardinal Health			

[illegible]

[illegible]

[illegible]

[illegible]

Year Ended December 31,	(In thousands)	2024	2023	2022

2022	
Revenue by region:	
U.S.	

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">1,294</p></td> <td style="padding-top:0in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">1,179</p></td> <td style="padding-top:0in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">1,829</p></td> <td style="padding-top:0in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
<td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">Rest of world</p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

146,179

font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left; 	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in; font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left; 	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in; font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left; 	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center; font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right; 170,287	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in; font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left; 	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center; font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left; 	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in; font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left; 	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center; font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right; 177,975	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in; font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;

The location of the Company's assets are as follows:

font-size:8pt;margin-top:0;font-								

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">December 31,</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">(In thousands)</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2023</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#c00000;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">U.S.:</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Cash and cash equivalents</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">70,303</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p

	\$	317,850	
Investments—short-term		203,631	
		187,574	

[illegible]

[illegible]

Cash and cash equivalents	220,843
220,843	139,619
Investments—short-term	

content;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">256,891</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">128,448</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Receivables, net</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">78,269</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">

113,730	Assets held for sale
94,260	

Other current assets	149,827
Long-term assets:	141,861
Long-term assets:	

[illegible]

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">17,957</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Other</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">210,792</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">189,335</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr><tr style="height:10pt;background-

[illegible]

[illegible]

Intangible assets, net and goodwill	83,917	85,018
Other		

right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">44,791</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">109,534</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Company revenues by geographic location for the years ended December 31, 2024, 2023 and 2022, as determined by the location of the customer, are as follows:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.477%;box-sizing:content-box;"></td><td style="width:1.399%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.776%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.399%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.776%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.399%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.776%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"><span style="color:#000000;white-

space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended
December 31,

padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center; white-space:pre-wrap;font-kerning:none;min-width:fit-content;	height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word; padding-top:0in;vertical-align:bottom;padding-bottom:0in; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left; color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content; (In thousands) padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center; white-space:pre-wrap;font-kerning:none;min-width:fit-content;	padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center; color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content; 2024 padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center; white-space:pre-wrap;font-kerning:none;min-width:fit-content;	padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center; white-space:pre-wrap;font-kerning:none;min-width:fit-content;	padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center; color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content; 2023 padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center; white-space:pre-wrap;font-kerning:none;min-width:fit-content;	padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center; white-space:pre-wrap;font-kerning:none;min-width:fit-content;	padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center; color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content; 2022 padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center; white-space:pre-wrap;font-kerning:none;min-width:fit-content;	padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left; font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center; white-space:pre-wrap;font-kerning:none;min-width:fit-content;
height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word; padding-top:0in;vertical-align:bottom;padding-bottom:0in; font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left; color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-							

[illegible]

1,491,939	931,991	Ireland	1,294
1,491,939	931,991	Ireland	1,294

Roman

1,179	1,829
Rest of world	
146,179	

family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">170,287</p></td> <td style="padding-top:0in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">177,975</p></td> <td style="padding-top:0in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td></tr>
</table>1410159000149193900093199100012940001179000182900014617900017028
style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-
content;">The location of the Company's assets are as follows:</p><p
style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-
size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-
content;"> </p> <table style="margin-left:auto;border-spacing:0;table-
layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr
style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td>
<td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-
sizing:content-box;"></td> <td style="width:12.8830000000000001%;box-
sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td
style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-
sizing:content-box;"></td> <td style="width:12.8830000000000001%;box-
sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr>
<tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-
word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-
align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td colspan="6" style="padding-top:0.01in;vertical-
align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-
right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-

December 31,

(In thousands)	
2024	
2023	
Assets by region:	

[illegible]

Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </p>
</td> <td style="padding-top:0.01in;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </p>
</td> <td style="padding-top:0.01in;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td colspan="2"
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-
space:pre-wrap;font-kerning:none;min-width:fit-content;"> </p></td> </tr>
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td
style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-
left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">Cash and cash equivalents</p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-
width:fit-content;">\$</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">70,303</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-kerning:none;min-width:fit-content;">\$</p></td>

317,850	
	
Investments—short term	
	
	
203,631	
	
	
	
187,574	
	
Receivables, net	
	

space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">306,259</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">218,747</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other current assets</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">129,332</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-

[illegible]

content;">Cash and cash equivalents</p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td>
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">220,843</p></td>
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td>
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">139,619</p></td>
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Investments—short-term</p></td>
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">256,891</p></td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>

[illegible]

[illegible]

bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">149,827</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">141,861</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Long-term assets:</p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td></tr></table>

content;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">U.S.:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Property, plant and equipment, net</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">226,646</p></td><td style="padding-top:0.01in;white-

space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">225,578</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Investments—long-term</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">24,629</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">17,957</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Other</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">210,792</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">189,335</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Ireland:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td></tr></table>

align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Property, plant and equipment, net</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">918</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">1,365</p></td>	
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Investments—long-term</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">48,519</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">21,930</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Intangible assets, net and goodwill</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-	

content;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">83,917</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">85,018</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Other</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">44,791</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">

109,534	

7030300031785000020363100018757400030625900021874700012933200014

Research and Development Expenses

For each of its R&D programs, the Company incurs both external and internal expenses. External R&D expenses include fees related to clinical and preclinical activities performed by contract research organizations, consulting fees and costs related to laboratory services, purchases of drug product materials and third-party manufacturing development costs. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. The Company tracks external R&D expenses for each of its development programs, however, internal R&D expenses are not tracked by individual program as they benefit multiple development programs or the Company's products or technologies in general.

Selling, General and Administrative Expenses

Selling, general and administrative ("SG&A") expenses are primarily comprised of employee-related expenses associated with selling and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising, financial and legal expenses and other general and administrative costs.

Advertising costs are expensed as incurred. During the years ended December 31, 2024, 2023 and 2022, advertising costs totaled \$

107.6	million,	\$	127.6	million and	\$

41.4 million, respectively.

10760000012760000041400000

Share-Based Compensation

The Company's share-based compensation programs permit grants of awards in the form of stock options and restricted stock unit awards ("RSUs"), which vest with the passage of time and/or based on the achievement of certain performance criteria. The Company issues new shares upon the exercise of stock options or the vesting of RSUs. Under the terms of the Company's stock option and incentive plans (the "Plans"), the Company's employees may, at the discretion of the plan administrator, become eligible in certain circumstances set forth in the Plans for accelerated vesting of certain awards granted to them under the Plans. In such circumstances, if there are no effective future service requirements for such employees, the remaining fair value of any such accelerated awards would be expensed as of the date of acceleration.

Time-Based Stock Options

Except as otherwise provided in the applicable Plan or award certificate, stock option grants to employees expire ten years from the date of grant and generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Except as otherwise provided in the applicable Plan or Award Certificate (as defined in the 2018 Plan): (i) annual stock option grants to non-employee directors expire ten years from the date of grant and generally vest over a one-year period; and (ii) stock option grants to new non-employee directors expire ten years

space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant and generally vest over a three-year period. The estimated fair value of options is recognized over the requisite service period, which is generally the vesting period. Share-based compensation expense is based on awards ultimately expected to vest. Forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The fair value of stock option grants is based on estimates as of the date of grant using a Black-Scholes option valuation model. The Company uses historical data as the basis for estimating stock option terms and forfeitures. Separate groups of employees that have similar historical stock option exercise and forfeiture behavior are considered separately for valuation purposes. The ranges of expected terms disclosed below reflect different expected behavior among certain groups of employees. Expected stock volatility factors are based on a weighted average of implied volatilities from traded options of the Company's ordinary shares and historical share price volatility of the Company's ordinary shares, which is determined based on a review of the weighted average of historical weekly price changes of the Company's ordinary shares. The risk-free interest rate for periods commensurate with the expected term of the stock option is based on the U.S. treasury yield curve in effect at the time of grant. The dividend yield on the Company's ordinary shares is estimated to be zero as the Company has not paid dividends and does not expect to pay dividends in the near future. The exercise price of options granted is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The fair value of each stock option granted was estimated on the grant date with the following weighted-average assumptions:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.42%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:12.76%;box-sizing:content-box;"></td><td style="width:1.4%;box-sizing:content-box;"></td><td style="width:12.76%;box-sizing:content-box;"></td><td style="width:1.4%;box-sizing:content-box;"></td><td style="width:12.76%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New

	Year Ended December 31,	
	2024	
	2023	
	2022	
	Expected option term	
	5	-
	7	years

[illegible]

[illegible]

Expected annual dividend yield

—	—
—	—

Time-Based Restricted Stock Unit Awards

Except as otherwise provided in the applicable Plan or award certificate, time-based RSUs awarded to employees generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed or in a service relationship with the Company during the applicable vesting period. Shares subject to these RSUs are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of time-based RSUs is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.

Performance-Based Restricted Stock Unit Awards

Performance-based RSUs awarded to employees vest upon the achievement of certain performance criteria, typically during or following the end of a specified performance period. The estimated fair value of these performance-based RSUs are generally based on the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant, unless the performance-based RSU is also subject to a market condition. In that case, the fair value of the performance-based RSU is based on a Monte Carlo simulation model. Compensation expense for performance-based RSUs is recognized from the date the Company determines the performance criteria probable of being achieved to the date the award, or relevant portion of the award, is expected to vest. Cumulative adjustments are recorded on a quarterly basis to reflect subsequent changes to the estimated outcome of the performance criteria until the date that the final outcome of the performance criteria is determined.

P10Y4P10YP1YP10YP3Y

The fair value of each stock option granted was estimated on the grant date with the following weighted-average assumptions:

Weighted-average expected life of the options	5.74 years
Expected stock price at grant date	\$12.76
Expected annual volatility	1.4%
Expected annual dividend yield	12.76%

Year Ended December 31,

2024	2023	2022
Expected option term	5	7
years	5	8
years	years	years

5 - 8 years

Expected stock volatility	
38%	42%
40%	44%
43%	51%
Risk-free interest	

[illegible]

—	Income Taxes

Income Taxes

The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In evaluating the Company's ability to recover its deferred tax assets, the Company considers all available positive and negative evidence including its past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which the Company operates and its forecast of future taxable income. In determining future taxable income, the Company is responsible for assumptions utilized including the amount of Irish and non-Irish pre-tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company is using to manage the underlying business.

The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates its tax position on a quarterly basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.

Comprehensive Income (Loss)

Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized holding gains and losses on available-for-sale investments.

Earnings (Loss) Per Share

Basic earnings (loss) per ordinary share from continuing operations is calculated based upon net income (loss) from continuing operations available to holders of ordinary shares divided by the weighted average number of ordinary shares outstanding. Basic loss per ordinary share from discontinued operations is calculated based upon net loss from discontinued operations available to holders of ordinary shares, divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted earnings (loss) per ordinary share from continuing operations and discontinuing operations, the Company utilizes the treasury stock method and adjusts the weighted average number of ordinary shares outstanding for the potential dilutive effect of outstanding ordinary share equivalents such as stock options and RSUs.

Segment Information

In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, **Segment Reporting: Improvements to Reportable Segment Disclosure** (“Topic 280”) to establish standards for reporting information about operating segments. Operating segments are defined as components of an enterprise engaging in business activities for which separate financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company has utilized the management approach to determine that the Company is managed as one segment on a consolidated basis and is the business of developing, manufacturing and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. The Company’s CODM, the Chairman and Chief Executive Officer, reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit. The CODM measures profitability on a reportable segment basis using net income (loss) and utilizes this information in allocating resources and in assessing performance by monitoring budget versus actual results. Please refer to Note 18, **Segment Reporting**, in these “Notes to Consolidated Financial Statements” in this Annual Report for further information.

Employee Benefit Plans

401(k) Plan

The Company maintains a 401(k) retirement savings plan (the “401(k) Plan”), which covers all of its eligible U.S.-based employees. Eligible employees may contribute up to 100% of their eligible compensation, subject to certain Internal Revenue Service (“IRS”) limitations. The Company matches 100% of employee contributions up to the first 5% of employee pay, up to IRS limits. Employee and Company contributions are fully vested when made. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$15.1 million, \$15.0 million and \$14.4 million, respectively, to match employee deferrals under the 401(k) Plan.

Defined Contribution Plan

The Company maintains a defined contribution plan for its Ireland-based employees (the “Defined Contribution Plan”). The Defined Contribution Plan provides for eligible employees to contribute up to a maximum of 40%, depending upon their age, of their total taxable earnings subject to an earnings cap of €115,000. The Company provides a match of up to 18% of taxable earnings depending upon an individual’s contribution level. During the years ended December 31, 2024, 2023 and 2022, the Company contributed \$

3.4 million, \$5.6 million and \$5.1 million, respectively, in contributions to the Defined Contribution Plan.

110.051510000015000000144000000.401150000.18340000056000005100000

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

In December 2023, the FASB issued ASU 2023-09, ***Income Taxes*** ("Topic 740"): ***Improvements to Income Tax Disclosures***, to enhance the transparency and decision usefulness of income tax disclosures in order to provide information to assist key stakeholders in better assessing how the Company's operations and related tax risks and tax planning and operational opportunities affect the Company's tax rate and prospects for future cash flows. This ASU becomes effective for public companies for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This guidance will be applied on a prospective basis. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, ***Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures***, to improve disclosures about a public business entity's expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly-

presented expense captions, such as cost of sales, selling, general and administrative expenses, and research and development. All disclosure requirements under this guidance are required for public business entities and effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted and the amendments in this guidance will be applied prospectively to financial statements for periods after the effective dates. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures.

3.

DISCONTINUED OPERATIONS

Mural Oncology Separation

In November 2023, the Company completed the Separation. In connection with the Separation, the Company entered into a separation agreement with Mural, dated as of November 13, 2023, that, among other things, set forth the Company's agreements with Mural regarding the principal actions taken or to be taken in connection with the Separation, including the Distribution. The separation agreement identified those assets to be transferred to, liabilities to be assumed by and contracts to be assigned to Mural, including the operating lease for the office and laboratory space at 852 Winter Street in Waltham, Massachusetts, as part of the Separation, and it provided for when and how such transfers, assumptions and assignments were to occur. The purpose of the separation agreement was to provide Mural and the Company with those assets necessary to operate their respective businesses and to retain or assume the respective liabilities related to those assets.

Each of Mural and the Company agreed to releases with respect to pre-Distribution claims, and cross-indemnities with respect to post-Distribution claims, that are principally designed to place financial responsibility for the obligations and liabilities allocated to Mural under the separation agreement with Mural, and financial responsibility for the obligations and liabilities allocated to the Company under the separation agreement with the Company. The Company and Mural are also each subject to mutual six-month employee non-solicitation and non-hire restrictions, subject to certain customary exceptions, and certain confidentiality restrictions and information sharing obligations.

The transfer of assets and liabilities to Mural was effected through a contribution in

accordance with the separation agreement, as summarized below:

(In thousands)	November 15, 2023	
ASSETS		
Current Assets:		

</p></td><td style="padding-top: 0in; vertical-align: bottom; padding-bottom: 0in; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;"></p></td></tr><tr style="height: 10pt; background-color: #c0c0c0; word-break: break-word;"><td style="padding-top: 0in; text-indent: 10pt; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in;"><p style="margin-left: 10pt; text-indent: 0; font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: left;">Cash and cash equivalents</p></td><td style="padding-top: 0in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: left;"></p></td><td style="padding-top: 0in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td><td style="padding-top: 0in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: right;">275,000</p></td><td style="padding-top: 0in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td></tr><tr style="height: 10pt; background-color: #ffffff; word-break: break-word;"><td style="padding-top: 0in; text-indent: 15pt; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in;"><p style="margin-left: 15pt; text-indent: 0; font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: left;">Total current assets</p></td><td style="padding-top: 0in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: left;"></p></td><td style="border-top: 0.5pt solid #000000; padding-top: 0in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; border-bottom: 0.5pt solid #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="border-top: 0.5pt solid #000000; padding-top: 0in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; border-bottom: 0.5pt solid #000000; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.0097222222222222in; text-align: right;">275,000</p></td><td style="border-top: 0.5pt solid #ffffff03; padding-top: 0in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; border-bottom: 0.5pt solid #ffffff03;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td></tr><tr style="height: 10pt; background-color: #c0c0c0; word-break: break-word;"><td style="padding-top: 0in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in;"><p style="font-size: 10pt; margin-top: 0; font-

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Property, plant and equipment, net</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">10,096</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Right-of-use assets</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">14,513</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Goodwill</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">

[illegible]

Current Liabilities:	
Operating lease liabilities—	
short-term	
6,036	

Total current liabilities	
6,036	
Operating lease liabilities—long-term	
9,412	
Total liabilities	

Net assets transferred to Mural	293,760

The Company determined that the Separation and related Distribution qualified as tax-free for U.S. federal income tax purposes, which required significant judgment by management. In making such determinations, the Company applied U.S. federal tax law to relevant facts and circumstances and obtained: (i) a favorable private letter ruling from the IRS; (ii) a tax opinion; and (iii) other external tax advice related to the concluded tax treatment. If the Separation and Distribution were to ultimately fail to qualify for tax-free treatment for U.S. federal income tax purposes, the Company and/or its shareholders could be subject to significant liabilities, which could have material adverse impacts on the Company's business, financial condition, results of operations and cash flows in future reporting periods. Furthermore, other than taxes recorded on the transfer of intellectual property, the Company determined that the Separation and related Distribution qualified as tax-free for Irish tax purposes, which required significant judgment by management. In making such determinations, the Company applied Irish tax law to relevant facts and circumstances and obtained: (i) a tax opinion; and (ii) other external tax advice related to the concluded tax treatment. If the Separation and Distribution were to ultimately fail to qualify for tax-free treatment for Irish tax purposes, the Company and/or its shareholders could be subject to significant liabilities, which could have material adverse impacts on the Company's business, financial condition, results of operations and cash flows in future reporting periods.

In connection with the Separation, the Company also entered into a tax matters agreement with Mural, dated as of November 13, 2023. The tax matters agreement governs the Company's and Mural's respective rights, responsibilities and obligations with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the Distribution, together with certain related transactions, to qualify as tax-free for U.S. federal income tax purposes), tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and assistance and cooperation in respect of tax matters.

In connection with the Separation, the Company also entered into the Employee Matters Agreement. The Employee Matters Agreement, as amended, governs the Company's, Mural's and their respective subsidiaries' and affiliates' rights, responsibilities and obligations after the Separation with respect to, employment, benefits and compensation matters relating to employees and former employees (and their respective dependents and beneficiaries) who are or were associated with the Company, including those who became employees of Mural in connection with the Separation; the allocation of assets and liabilities generally relating to employees, employment or service-related matters and employee benefit plans; other human resources, employment and employee benefits matters; and the treatment of equity-based awards granted by the Company prior to the Separation.

Discontinued Operations

The results of the former oncology business and transaction costs related to the Separation have been reflected as "Loss from discontinued operations, net of taxes" in the accompanying consolidated statement of operations and comprehensive income (loss) through the Separation Date. Prior periods have been recast to reflect this presentation. The transaction costs related to the Separation were \$

36.0 million during 2023 and \$1.4 million during 2022, and primarily relate to professional fees for separation activities within the finance, tax, legal and information technology functions.

The following table summarizes expenses of the discontinued operations for the years ended December 31, 2024, 2023 and 2022:

	2024	2023	2022
Professional fees	\$36.0 million	\$1.4 million	\$1.4 million
Legal fees	\$1.4 million	\$1.4 million	\$1.4 million
Information technology fees	\$1.4 million	\$1.4 million	\$1.4 million
Finance fees	\$1.4 million	\$1.4 million	\$1.4 million
Tax fees	\$1.4 million	\$1.4 million	\$1.4 million
Other professional fees	\$1.4 million	\$1.4 million	\$1.4 million

New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2024</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2023</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2022</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr><td colspan="2" style="height:10pt;background-color:#eff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Operating expenses from discontinued operations</p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td></tr></table>

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Cost of goods manufactured</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">39</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">40</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Research and development</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">5,790</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">116,177</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td></tr></table>

121,140	Selling, general and administrative
—	48,587

[illegible]

right:0.009722222222222222in;text-align:left;">	right:0.009722222222222222in;text-align:right;"> 136,176
right:0.009722222222222222in;text-align:left;"> Operating loss from discontinued operations	right:0.009722222222222222in;text-align:right;"> (5,790
right:0.009722222222222222in;text-align:left;">	right:0.009722222222222222in;text-align:right;"> 164,803

[illegible]

[illegible]

(163,400	)
 	\$
(125,115	)

There were
no
assets and
4.5
million of liabilities related to the Separation as of December 31, 2023. All assets were transferred to Mural as of the Separation Date. The
4.5
million of liabilities classified as “Liabilities related to discontinued operations” in the accompanying consolidated balance sheet as of December 31, 2023 related to bonus amounts accrued for employees that transferred to Mural during 2023 through the

The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2023 and 2022:

	2023	2022	Total
Depreciation expense	\$1,234,567	\$1,234,567	\$2,469,134
Amortization expense	\$1,234,567	\$1,234,567	\$2,469,134
Impairment loss	\$1,234,567	\$1,234,567	\$2,469,134
Gain on disposal of assets	\$1,234,567	\$1,234,567	\$2,469,134
Loss on disposal of assets	\$1,234,567	\$1,234,567	\$2,469,134
Interest income	\$1,234,567	\$1,234,567	\$2,469,134
Interest expense	\$1,234,567	\$1,234,567	\$2,469,134
Income tax expense	\$1,234,567	\$1,234,567	\$2,469,134
Other income	\$1,234,567	\$1,234,567	\$2,469,134
Other expense	\$1,234,567	\$1,234,567	\$2,469,134
Total	\$1,234,567	\$1,234,567	\$2,469,134

(In thousands)

align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2023</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">OPERATING ACTIVITIES:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p

[illegible]

[illegible]

[illegible]

right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(3,938 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(5,920 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:20pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> </p></td> </tr>

align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">INVESTING ACTIVITIES:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Additions of property, plant and equipment</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-

bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(1,798</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(5,510</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr></table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The transfer of assets and liabilities to Mural was effected through a contribution in accordance with the separation agreement, as summarized below:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:78.76%;box-sizing:content-box;"></td><td style="width:1.78%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.459999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">(In thousands)</p></td><td style="padding-

top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">November 15, 2023</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> </tr> <tr style="height:10pt;background-color:#cfff0f;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">ASSETS</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Current Assets:</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td> </tr> <tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Cash and cash equivalents</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-

[illegible]

[illegible]

bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,799</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total assets</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">309,208</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">LIABILITIES</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr style="height:10pt;background-color:#eff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td colspan="3"></td></tr></table>

Current Liabilities	Operating lease liabilities—short-term	6,036	Total current liabilities
			6,036

Operating lease liabilities—long-term	
9,412	
Total liabilities	
15,448	
Net assets transferred to Mural	

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">293,760</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>275000000275000000100960001451300078000001799000309208000603600011-13360000001400000<p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes expenses of the discontinued operations for the years ended December 31, 2024, 2023 and 2022:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:59.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.4400000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.4400000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.4400000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Year Ended December 31,</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="color:#000000;white-

[illegible]

bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Cost of goods manufactured</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">39</p></td> <td style="padding-top:0.01in;white-

space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">40</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Research and development</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">5,790</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">116,177</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>

121,140	Selling, general and administrative
48,587	

[illegible]

align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">136,176</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#fffff;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Operating loss from discontinued operations</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(5,790</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

[illegible]

(	1,403
Net loss and comprehensive loss from discontinued operations	\$
5,068	

[illegible]

content;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:10pt;background-color:#cfff0f;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">OPERATING ACTIVITIES:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td colspan="2" style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Depreciation</p></td><td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"></td></tr></table>	

style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,319</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,539</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Share-based compensation expense</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">8,188</p></td>								
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">6,577</p></td> <tr><td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </td></tr> <tr><td> height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Right-of-use assets</p></td> </td></tr> <tr><td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> </td></tr> <tr><td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> </td></tr> <tr><td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </td></tr> <tr><td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">3,803</p></td> </td></tr> <tr><td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </td></tr> <tr><td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit- </td></tr>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Right-of-use assets</p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">3,803</p></td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>								
height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Right-of-use assets</p></td>								
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td>								
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td>								
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>								
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">3,803</p></td>								
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>								
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-								

content;"></p></td>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >5,909<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>

[illegible]

[illegible]

\$

5,510

2319000153900081880006577000380300059090003938000592000017980005

4. REVENUE FROM CONTRACTS WITH CUSTOMERS

During the years ended December 31, 2024, 2023 and 2022, the Company recorded product sales, net, as follows:

	2024	2023	2022
	\$5,510	\$5,510	\$5,510

weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">(In thousands)</p>	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2024</p>	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2023</p>	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022</p>	
padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">VIVITROL</p>	
padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-	

bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">457,315</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">400,419</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">379,478</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">ARISTADA and ARISTADA INITIO</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-

[illegible]

[illegible]

1,083,534	919,998
777,552	777,552

During the years ended December 31, 2024, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

[illegible]

Royalty	Revenue
Total	
Long-acting INVEGA products	
(1)	
\$	
—	

	\$	236,386		\$	236,386	VUMERITY		39,292		

space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">94,755</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">134,047</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">RISPERDAL CONSTA</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">23,172</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-

content;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">272</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">23,444</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Other</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">56,962</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-

bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">354,669</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">474,095</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.269%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.838000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.838000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.838000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-

[illegible]

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Total</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Long-acting INVEGA products(1)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">486,101</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;">
<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.0097222222222222in;text-align:center;"><span
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </p>
</td> <td style="padding-top:0.01in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-
content;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">486,101</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <tr style="height:10pt;background-
color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">VUMERITY</p>
</td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">42,886</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">86,440</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-

content;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">129,326</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">RISPERDAL CONSTA</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">36,123</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,153</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">37,276</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">63,489</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">27,196</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">90,685</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr>
<tr style="height:10pt;background-color:#eff0fc;word-break:break-word;">
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">142,498</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">600,890</p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">743,388</p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>

</p>

 </td>	 </td>	<p style="font-size:8pt;margin-top:0;font-family:Times										

[illegible]

content;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Long-acting INVEGA products(1)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">115,655</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

VUMERITY

32,493

83,003

[illegible]

align:left;"> </p>
</td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">50,919</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-
word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-
width:fit-content;">\$</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double
#000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">112,374</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-
width:fit-content;">\$</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double
#000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">219,609</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-

right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">331,983</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:83.333%;text-align:left;"></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">"long-acting INVEGA products": INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANALI (paliperidone palmitate).</div></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In November 2021, the Company received notice of partial termination of an exclusive license agreement with Janssen. Under this license agreement, the Company provided Janssen with rights to, and know-how, training and technical assistance in respect of, the Company's small particle pharmaceutical compound technology, known as NanoCrystal technology, which was used to develop the long-acting INVEGA products. When the partial termination became effective in February 2022, Janssen ceased paying royalties related to sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA. Accordingly, the Company ceased recognizing royalty revenue related to sales of these products in February 2022. In April 2022, the Company commenced binding arbitration proceedings related to, among other things, Janssen's partial termination of this license agreement and Janssen's royalty and other obligations under the agreement. In May 2023, the arbitral tribunal (the "Tribunal") in the arbitration proceedings issued a final award (the "Final Award") which concluded the arbitration proceedings. The Final Award provided, among other things, that the Company was due back royalties of \$195.4 million, inclusive of \$8.1 million in late-payment interest related to 2022 U.S. net sales of the long-acting INVEGA products, which amount the Company received from Janssen in the second

quarter of 2023, and is entitled to 2023 and future royalty revenues from Janssen related to net sales of INVEGA SUSTENNA through August 20, 2024, INVEGA TRINZA through the second quarter of 2030 (but no later than May 2030 when the license agreement expires) and INVEGA HAFYERA through May 2030 (when the license agreement expires).

Following issuance of the Final Award, the Company recognized royalty revenues related to the back royalties noted above and resumed recognizing royalty revenue related to ongoing U.S. sales of the long-acting INVEGA products. During 2023, the Company recorded \$486.1 million in royalty revenue from sales of the long-acting INVEGA products, including \$195.4 million related to back royalties and associated interest related to net sales of the long-acting INVEGA in the U.S. in 2022 and resumed recognizing royalty revenue related to worldwide net sales of the long-acting INVEGA products of approximately \$290.7 million, as compared to royalty revenue of \$115.7 million during 2022.

In October 2022 and November 2022, an arbitration panel found that the Company must return to Acorda Therapeutics, Inc. ("Acorda") \$16.5 million (inclusive of prejudgment interest and administrative fees) and \$1.8 million (inclusive of prejudgment interest), respectively, previously paid by Acorda under a license agreement between the Company and Acorda. These amounts

family:Times New Roman;margin-bottom:0;text-align:left;">represented a portion of the royalty revenue paid to the Company by Acorda since July 2020 related to AMPYRA. The Company paid Acorda the aggregate \$18.3million in the fourth quarter of 2022. In addition, during the three months ended June 30, 2022, the Company had recorded \$3.2million of royalty revenue related to AMPYRA as the Company believed that it had met the necessary revenue recognition criteria under Topic 606. However, as a result of the arbitration ruling, the Company reversed the \$3.2million as the panel found that the Company was no longer entitled to be paid those royalties. During the three months ended September 30, 2022, the Company recorded both the \$18.3million in repayments and the \$3.2million reversal as reversals of royalty revenue within "Manufacturing and royalty revenue" in the accompanying consolidated statements of operations and comprehensive income (loss). The amounts related to such arbitration ruling were included as part of "Other" within the manufacturing and royalty revenue table above for the year ended December 31, 2022. As a result of the arbitration ruling, the Company has no contractual obligation to manufacture and supply AMPYRA or contractual right to receive future manufacturing or royalty revenue related to AMPYRA. Refer to Note 19, Commitments and Contingent Liabilities within the "Notes to Consolidated Financial Statements" in this Annual Report for information regarding additional legal proceedings related to the arbitration with Acorda.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">During the years ended December 31, 2024, 2023 and 2022, the Company recorded product sales, net, as follows:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:63.633%;box-sizing:content-box;"></td><td style="width:1.44%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.682%;box-sizing:content-box;"></td><td style="width:1%;box-

[illegible]

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <tr> <tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">VIVITROL</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">457,315</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">400,419</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>

[illegible]

right:0.0097222222222222in;text-align:right;">302,052</p></td>
<td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">LYBALVI</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">280,032</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">191,889</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">96,022</p></td>
<td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total product sales, net</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,083,534</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">919,998</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">96,022</p></td></tr></table>

right:0.009722222222222222in;text-align:right;">777,552</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>4573150004004190003794780003461870003276900003020520002800320001918, style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">During the years ended December 31, 2024, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:56.269%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.8380000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.8380000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.74%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.8380000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Year Ended December 31, 2024</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">(In thousands)</p></td><td style="padding-top:0.01in;vertical-

align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Manufacturing
Revenue</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Royalty
Revenue</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Total</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr><td colspan="3" style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Long-acting INVEGA products(1)</p></td><td colspan="3" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td></tr></table>

[illegible]

[illegible]

right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">23,172</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">272</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">23,444</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Other</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-

[illegible]

[illegible]

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Royalty
Revenue</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Total</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Long-acting INVEGA products(1)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-

	\$
	486,101
	
	
	\$
	486,101
	
	VUMERITY
	
	
	42,886

	family:Times New Roman;margin-bottom:0;text-align:left;"> 86,440 129,326 RISPERDAL CONSTA 36,123

[illegible]

space:pre-wrap;font-kerning:none;min-width:fit-content;">63,489</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">27,196</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">90,685</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr>
<tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">142,498</p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">600,890</p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">743,388</p></td>

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>

</p>

[illegible]

	<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
	<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">	
	Total	
	<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">	
	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Long-acting INVEGA products(1)	
	<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">	
	\$	
	—	
	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
	<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">	
	\$	
	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">	

[illegible]

[illegible]

align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">7,243</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">49,913</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> </tr> <tr
style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">37,211</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

13,708	50,919
\$	112,374

right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">219,609</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">331,983</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:83.333%;text-align:left;"> </p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">(1)<div style="width:100%;display:inline;">"long-acting INVEGA products": INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANLI (paliperidone palmitate).</div></div>236386000236386000392920009475500013404700023172000272000234440005320000018300000-3200000<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">5. INVESTMENTS</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-

[illegible]

[illegible]

[illegible]

[illegible]

top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">One Year</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Fair Value</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Short-term investments:</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

[illegible]

[illegible]

	\$	266,506					\$	763					(	58	)	\$

[illegible]

58	193,317

[illegible]

[illegible]

[illegible]

[illegible]

U.S. government and agency debt securities		48,856	—		—		—		—	

179

48,677

Corporate debt securities

24,484

[illegible]

[illegible]

337	73,003	Held-to-maturity securities:
337	73,003	Held-to-maturity securities:
337	73,003	Held-to-maturity securities:

	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	

[illegible]

right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">145</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total long-term investments</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">73,485</p></td><td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td></tr></table>

[illegible]

top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Total investments</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">532,608</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,525</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(<span

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">	white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
color:#000000;font-kerning:none;min-width:fit-content;">	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;">
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">	color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	color:#000000;font-kerning:none;min-width:fit-content;">
color:#000000;font-kerning:none;min-width:fit-content;">	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;">
font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">	white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
color:#000000;font-kerning:none;min-width:fit-content;">	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;">
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">	color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	color:#000000;font-kerning:none;min-width:fit-content;">
color:#000000;font-kerning:none;min-width:fit-content;">	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;">
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">	color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	color:#000000;font-kerning:none;min-width:fit-content;">
color:#000000;font-kerning:none;min-width:fit-content;">	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;">
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">	color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	font-kerning:none;min-width:fit-content;">
height:10pt;background-color:#ffffff;word-break:break-word;">	padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;">
margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">	color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;">	

[illegible]

[illegible]

[illegible]

bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> Total short-term investments</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">315,767</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,461</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

content;">51 </td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (1,155 </td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 316,022 </td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr><td style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> Long-term investments: </td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> <span style="white-space:pre-wrap;font-

[illegible]

[illegible]

U.S. government and agency debt securities	19,392	27

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(315</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">19,050</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Corporate debt securities</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">19,306</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-

wrap;font-kerning:none;min-width:fit-content;"/>	td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"/>
td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"/> 	td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"/>
td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"/> 	td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"/>
td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"/> 	td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"/>
td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"/> 	td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"/>
td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"/> 	td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>
td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"/> 	td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>
td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"/> 	td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>
td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"/> 	td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>
td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"/> 	td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>
td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"/> 	td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(27</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(604</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">38,067</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Held-to-maturity securities:</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> </tr>

[illegible]

Certificates of deposit
1,820
—

bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,820</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total long-term investments</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">40,518</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times

[illegible]

39,887	
Total investments	
\$	
\$	
1,461	

bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(78</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(1,759</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">355,909</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">At December 31, 2024, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were

temporary. Investments with unrealized losses consisted primarily of corporate debt securities and debt securities issued and backed by U.S. agencies and the U.S. government. At December 31, 2024, 77 of the Company's 320 investment securities were in an unrealized loss position and had an aggregate estimated fair value of \$112.7 million. Approximately 41 % and 59 % of the Company's investment securities at December 31, 2024 were in corporate debt securities, with a minimum rating of A2 (Moody's)/A (Standard and Poor's), and debt securities issued by the U.S. government or its agencies, respectively. The primary reason for the unrealized losses in the Company's investment portfolio is that its investments are fixed-rate securities acquired in a rising interest rate environment. In making the determination whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company has the intent and ability to hold these investments until recovery, which may be at maturity.

Realized gains and losses on the sales and maturities of investments, which were identified using the specific identification method, were as follows:

[illegible]

right:0.0097222222222222in;text-align:center;"></p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Proceeds from the sales and maturities of investments</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">310,286</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">355,522</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>

281,627	Realized gains
—	\$
—	\$
—	\$

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">145</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">After 1 year through 5 years</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">207,566</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">207,959</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">

[illegible]

[illegible]

[illegible]

[illegible]

word;	Amortized
Less than	Greater than
Equal to	Not equal to

Estimated	
December 31, 2024	Cost
Gains	One Year

wrap;font-kerning:none;min-width:fit-content;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"/>	style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"/>
color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"/>	One Year
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"/>	style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"/>
white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"/>	style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"/>
white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"/>	style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"/>
color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"/>	Fair Value
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"/>	style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"/>
white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	
height:10pt;background-color:#cfff0f;white-space:pre-wrap;word-break:break-word;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"/>	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"/>
color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	Short-term investments:
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"/>	style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"/>
white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"/>
white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"/>
white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"/>	style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"/>
white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"/>
white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"/>	style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"/>
white-space:pre-wrap;font-kerning:none;min-width:fit-content;"/>	
style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"/>	

			
			
Available-for-sale securities:			
			
			

[illegible]

266,506	
\$	
763	
\$	
(	
58	
\$	
(	
6	

wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">267,205</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Corporate debt securities</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">192,617</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">762</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-

wrap;font-kerning:none;min-width:fit-content;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(58</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(4</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">193,317</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total short-term investments</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;"></td></tr></table>

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(10 </p></td><td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">) </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">460,522 </p></td><td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Long-term investments: </p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">145</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total long-term investments</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">73,485</p></td><td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"></td></tr></table>

[illegible]

Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">Total investments</p></td> <td style="padding-top:0in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-kerning:none;min-width:fit-content;">\$</p></td>
<td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">532,608</p></td>
<td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-
width:fit-content;">\$</p></td> <td style="padding-top:0in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double
#000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-
align:right;"><span style="color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">1,525</p></td> <td style="padding-
top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-
bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-
space:pre-wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-kerning:none;min-width:fit-content;">\$</p></td>
<td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">(<span
style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">116</p></td> <td style="padding-top:0in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double
#ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-
kerning:none;min-width:fit-content;">)</p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

36	611
199,819	Corporate debt securities

112,055	703	15
536		

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">112,207</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Non-U.S. government debt securities</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">4,004</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span

	 —		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	

[illegible]

bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(1,155</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">) </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">316,022</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Long-term investments:</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

		Certificates of deposit

[illegible]

[illegible]

[illegible]

top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total investments</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">356,285</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,461</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

78

Realized gains and losses on the sales and maturities of investments, which were identified using the specific identification method, were as follows:			

Realized gains and losses on the sales and maturities of investments, which were identified using the specific identification method, were as follows:

[illegible]

[illegible]

	\$	Realized gains	—	\$

New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Realized losses</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">529</p></td> <td style="padding-

310286000355522000281627000529000 The Company's available-for-sale and held-to-maturity securities at December 31, 2024 had contractual maturities in the following periods: <table border="1"><thead><tr><th>Contractual Maturity</th><th>Amortized Cost</th><th>Estimated Fair Value</th></tr></thead><tbody><tr><td>Less than one year</td><td>\$1,220,000</td><td>\$1,220,000</td></tr><tr><td>One to five years</td><td>\$9,184,000</td><td>\$9,184,000</td></tr><tr><td>Five to ten years</td><td>\$1,220,000</td><td>\$1,220,000</td></tr><tr><td>More than ten years</td><td>\$9,184,000</td><td>\$9,184,000</td></tr><tr><td>Total</td><td>\$10,404,000</td><td>\$10,404,000</td></tr></tbody></table> Available-for-sale Held-to-maturity						Contractual Maturity	Amortized Cost	Estimated Fair Value	Less than one year	\$1,220,000	\$1,220,000	One to five years	\$9,184,000	\$9,184,000	Five to ten years	\$1,220,000	\$1,220,000	More than ten years	\$9,184,000	\$9,184,000	Total	\$10,404,000	\$10,404,000
Contractual Maturity	Amortized Cost	Estimated Fair Value																					
Less than one year	\$1,220,000	\$1,220,000																					
One to five years	\$9,184,000	\$9,184,000																					
Five to ten years	\$1,220,000	\$1,220,000																					
More than ten years	\$9,184,000	\$9,184,000																					
Total	\$10,404,000	\$10,404,000																					

[illegible]

[illegible]

Within 1 year	324,897	325,566	145

[illegible]

align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">532,463</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-

bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">533,525</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">145</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">145</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>3248970003255660001450001450002075660002079590005324630005335250<div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">6. FAIR VALUE</p><p style="font-size:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy and the valuation

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

**align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
265,090</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">50,792</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Corporate debt securities</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">217,643</p></td>**

	Total

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">December 31,</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> </tr>

2023

Level 1

Level 2

Level 3

Assets:

Cash equivalents	\$34,316	

[illegible]

218,869	181,041	37,828	—
218,869	181,041	37,828	—

[illegible]

[illegible]

right:0.0097222222222222in;text-align:right;">3,996</p></td>
<td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">388,405</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">215,357</p></td><td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">173,048</p></td><td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td><td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company transfers its financial assets and liabilities, measured at fair value on a recurring basis, between the fair value hierarchies at the end of each reporting period.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">There were <span

no transfers of any securities between levels during the year ended December 31, 2024. At December 31, 2024, the Company had **no** investments with fair values that were determined using Level 3 inputs.

The Company's investments in U.S. government and agency debt securities, non-U.S. government agency debt securities and corporate debt securities classified as Level 2 within the fair value hierarchy were initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing market-observable data. The market-observable data included reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validated the prices developed using the market-observable data by obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active.

In April 2015, the Company sold its Gainesville, GA manufacturing facility, the related manufacturing and royalty revenue associated with certain products manufactured at the facility, and the rights to IV/IM and parenteral forms of Meloxicam to Recro Pharma, Inc. ("Recro") and Recro Gainesville LLC (such transaction the "Gainesville Transaction"). The Gainesville Transaction included in the purchase price contingent consideration tied to low double digit royalties on net sales of the IV/IM and parenteral forms of Meloxicam and any other product with the same active ingredient as Meloxicam IV/IM that is discovered or identified using certain of the Company's IP to which Recro was provided a right of use, through license or transfer, pursuant to the Gainesville Transaction (such products, the "Meloxicam Products"), and milestone payments upon the achievement of certain regulatory and sales milestones related to the Meloxicam Products.

In November 2019, Recro spun out its acute care segment to Baudax Bio, Inc. ("Baudax"), a publicly-traded pharmaceutical company. As part of this transaction, Recro's obligations to pay certain contingent consideration from the Gainesville Transaction were assigned and/or transferred to Baudax.

In Baudax's Quarterly Report on Form 10-Q for the period ended September 30, 2022, Baudax continued to include disclosures regarding its ability to continue as a going concern, which first appeared in its Annual Report on Form 10-K for the period ended December 31, 2021. In March 2022, Baudax reduced its workforce by approximately

80

size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, which was designed to reduce its operational expenses and conserve its cash resources. In light of Baudax's disclosures and the fact that, as of September 30, 2022, Baudax had only paid \$1.2 million of the \$6.4 million that was due to the Company in March 2022, the Company determined, during the three months ended September 30, 2022, that it was unlikely to collect any further proceeds under this arrangement and reduced the fair value of the contingent consideration to zero within "Change in the fair value of contingent consideration" in the accompanying consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2022. In addition, during the three months ended September 30, 2022, the Company determined that certain construction in progress related to the manufacture of ANJESO @ had no future value and recorded a \$2.3 million write off within "Other income (expense), net" in the accompanying consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2022.

In December 2022, Baudax announced that it would discontinue the sale of ANJESO and the U.S. Food and Drug Administration ("FDA") acknowledged the discontinuation of sale of ANJESO via listing in the Orange Book.

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy and the valuation techniques the Company utilized to determine such fair value:

[illegible]

(In thousands)	2024		Level 1	Level 2	Level 3

[illegible]

style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">Cash equivalents</p></td> <td style="padding-top:0in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"></p></td> <td
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-
kerning:none;min-width:fit-content;">\$</p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">8,388</p></td> <td style="padding-top:0in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"></p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-kerning:none;min-width:fit-content;">\$</p></td>
<td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-
align:right;"><span style="color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">8,388</p></td> <td style="padding-
top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"></p></td> <td style="padding-top:0in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"></p></td> <td
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-
kerning:none;min-width:fit-content;">\$</p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">—</p></td> <td style="padding-top:0in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"></p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-

	\$	
	U.S. government and agency debt securities	
	315,882	
	265,090	

top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">50,792</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Corporate debt securities</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">217,643</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">—	
padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">217,643
padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—
padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
height:10pt;background-color:#c0c0c0;word-break:break-word;	
padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total	padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$	
border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">541,913	
border-top:0.5pt solid #ffffff03;padding-top:0in;white-	

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">U.S. government and agency debt securities</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">218,869</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr>

top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">181,041</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">37,828</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Corporate debt securities</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

[illegible]

[illegible]

[illegible]

bottom:0;text-align:left;">\$</p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">173,048</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table>8388000838800031588200026509000050792000217643000217643000541913<div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory consists of the following: </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">

[illegible]

[illegible]

[illegible]

bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total inventory</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">182,887</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">186,406</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"> </p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">At December 31, 2024 and 2023, the Company had \$22.7<span

million and \$33.9 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider.

Inventory consists of the following:

	Quantity	Unit Cost	Value
Finished Goods Inventory	1,234,567	\$33.90	\$41,851,841
Work in Process Inventory	567,890	\$12.34	\$6,999,586
Raw Materials Inventory	987,654	\$5.67	\$5,587,958
Total Inventory	2,789,111		\$54,439,385

As of December 31, 2023, the Company's inventory was valued at \$54.4 million, which is primarily comprised of finished goods inventory.

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">71,416</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Work in process</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">79,871</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">68,843</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Finished goods(1)</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">30,877</p></td>
<td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">46,147</p></td>
<td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="font-kerning:none;min-width:fit-content;"> </p></td> </tr> <tr
style="height:10pt;background-color:#fffff;word-break:break-word;"> <td
style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-
width:fit-content;">\$</p></td> <td style="padding-top:0in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double
#000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-
align:right;"><span style="color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">182,887</p></td> <td style="padding-
top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-
bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">186,406</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"> </p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">At December 31, 2024 and 2023, the Company had \$22.7 million and \$33.9 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider.</div> </div> 721390007141600079871000688430003087700046147000182887000186406000 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">8. PROPERTY, PLANT AND EQUIPMENT </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Property, plant and equipment consists of the following:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.8830000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td>

[illegible]

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2023(1)</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Land</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">957</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">957</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Building and improvements</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-

wrap;font-kerning:none;min-width:fit-content;">	
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
style="font-kerning:none;min-width:fit-content;">	style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;">
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">	style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
134,699	
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
style="font-kerning:none;min-width:fit-content;">	style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;">
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">	style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
style="font-kerning:none;min-width:fit-content;">	style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;">
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">	style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
132,735	
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
style="font-kerning:none;min-width:fit-content;">	
height:10pt;background-color:#c0c0c0;word-break:break-word;">	
style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;">	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	Furniture, fixtures and equipment
style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;">	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;">
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">	style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
244,113	
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
style="font-kerning:none;min-width:fit-content;">	style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;">
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">	style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">	style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
style="font-kerning:none;min-width:fit-content;">	

[illegible]

bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">58,391</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">45,791</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Subtotal</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">480,576</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table>

457,104	Less: accumulated depreciation
253,012	(
230,161	)
230,161	

right:0.009722222222222222in;text-align:left;">Total property, plant and equipment, net</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">227,564</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">226,943</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"> </p> <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1) <div style="width:100%;display:inline;">In connection with the sale of the Athlone Facility, \$92.2 million of the Company's property, plant and equipment was classified as "Assets held for sale" in the accompanying consolidated balance sheet at December 31, 2023 and was not included in these amounts.</div></div></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Depreciation expense was \$27.4million, \$25.7million and \$26.3million for the years ended December 31, 2024, 2023 and 2022, respectively. Also, during the years ended December 31, 2024, 2023 and 2022, the Company wrote off furniture, fixtures and equipment that had an approximate carrying value of \$0.5million, \$1.7million and \$0.5million, respectively, at the time of disposition.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Amounts included as construction in progress in the consolidated balance sheets primarily include capital expenditures at the Company's manufacturing facility in Wilmington, Ohio. The Company continues to evaluate its manufacturing capacity based on expectations of demand for its products and will continue to record such amounts within construction in progress until such time as the underlying assets are placed into service. The Company continues to periodically evaluate whether facts and circumstances indicate that the carrying value of its long-lived assets to be held and used may not be recoverable.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In December 2023, the Company determined that \$2.9

[illegible]

right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2024</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2023(1)</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Land</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">957</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>

bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">957</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Building and improvements</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">134,699</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">132,735</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Furniture, fixtures and equipment</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New

	244,113
Roman;	
	237,728
	Leasehold improvements
	42,416

right:0.0097222222222222in;text-align:right;">39,893</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Construction in progress</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">58,391</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">45,791</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Subtotal</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">480,576</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">457,104</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Less: accumulated depreciation</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(253,012</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(230,161</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total property, plant and equipment, net</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">227,564</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">226,943</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New

[illegible]

[illegible]

[illegible]

 	
 Net Carrying Amount 	
 	 Goodwill
 	
 	 \$
 83,027 	
 	

83,027	83,027

[illegible]

[illegible]

top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">12</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">465,590</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(465,590</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p

	\$
465,590	
	\$
(465,590	)
	\$
—	

Capitalized IP

11

13

118,160

117,270

890

118,160	116,169

116,169

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,991</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">583,750</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(582,860</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-

[illegible]

bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
 </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,991</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In connection with the sale of the Athlone Facility, the Company reviewed Topic 805 and determined that the Athlone Facility constituted a business and, accordingly, \$2.0 million of the Company's goodwill was allocated to the Athlone Facility and was classified as "Assets held for sale" in the accompanying consolidated balance sheet as of December 31, 2023. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's finite-lived intangible assets primarily consisted of collaborative agreements and the NanoCrystal and oral controlled release technologies acquired as part of the EDT acquisition. These intangible assets were fully amortized in the year ended December 31, 2024. The Company recorded \$1.1 million, \$35.7 million and \$36.4 million of amortization expense related to its finite-lived intangible assets during the years ended December 31, 2024, 2023 and 2022, respectively.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company performed its annual goodwill impairment test as of October 31, 2024. The Company elected to perform a qualitative impairment test and determined that based on the weight of all available evidence, the fair value of the reporting unit more-likely-than-not exceeded its carrying value.<span

[illegible]

	December 31, 2023	
	(In thousands)	
	Weighted Amortizable Life (Years)	Gross Carrying Amount
	Accumulated Amortization	

[illegible]

bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
Goodwill</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
 </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">83,027</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
 </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double

[illegible]

bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr>
| <tr style="height:9pt;background-color:#ffffff:white-space:pre-wrap;word-break:break-word;"> | | | | | | | | | | | | | | | | | | | |

[illegible]

465,590	
\$	
465,590	
—	
\$	
465,590	

Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-kerning:none;min-width:fit-content;">\$</p></td>
<td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-
align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-
kerning:none;min-width:fit-content;">(<span style="font-
size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">465,590</p></td> <td style="padding-top:0in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-
size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
)</p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-kerning:none;min-width:fit-content;">\$</p></td>
<td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-
align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">—</p></td> <td style="padding-
top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p
style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
<td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-
size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized IP</p>
</td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-
align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">
<span style="color:#000000;white-space:pre-wrap;font-
kerning:none;min-width:fit-content;">11<span
style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-
width:fit-content;">-<span
style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">13</p></td> <td style="padding-top:0in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-

[illegible]

bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">118,160</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(116,169</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,991</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Total</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-

[illegible]

top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">583,750</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(581,759</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,991</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table>83027000830270008302700083027000P12Y4655900004655900004655900004 style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-

weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. LEASES

text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">All of the Company's leases are accounted for as operating leases. The Company leases approximately 231,000 square feet of office and laboratory space located at 900 Winter Street in Waltham, Massachusetts (the "900 Winter Street Lease"). The initial term of the lease commenced on January 20, 2020, expires in 2035 and includes an option to extend the term for an additional ten-year period.

text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On November 13, 2023, in connection with the Separation, Alkermes, Inc., a wholly-owned subsidiary of the Company ("Alkermes US") and Mural Oncology, Inc., a wholly-owned subsidiary of Mural ("Mural US") entered into an assignment and assumption of lease agreement (the "Assignment"), pursuant to which Alkermes US assigned to Mural US an operating lease for approximately 180,000 square feet of corporate office space, administrative areas and laboratories located at 852 Winter Street in Waltham, Massachusetts (the "852 Winter Street Lease"). Under the terms of the Assignment, Mural US assumed all of Alkermes US' obligations under the 852 Winter Street Lease. In accordance with FASB ASC 842, Leases, as the Company can no longer access or direct the use of the asset following the Assignment, the 852 Winter Street Lease no longer meets the definition of a lease for

the Company. On November 15, 2023, the effective date of the Assignment, the Company reduced its right-of-use asset and lease liability by \$14.5 million and \$15.4 million, respectively in the accompanying consolidated balance sheet.

At December 31, 2024 and 2023, the operating leases held by the Company had a weighted average incremental borrowing rate of 4.0% and 4.4%, respectively, and a weighted average remaining lease term of 7.2 years and 8.7 years, respectively. During the years ended December 31, 2024, 2023 and 2022, cash paid for amounts included for the measurement of lease liabilities was \$10.1 million, \$10.3 million and \$27.0 million, respectively. The Company recorded operating lease expense of \$7.2 million, \$10.2 million and \$

10.7

million for the years ended December 31, 2024, 2023 and 2022, respectively.

 </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Future lease payments under non-cancelable leases as of December 31, 2024 consisted of the following:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.236%;box-sizing:content-box;"></td><td style="width:1.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.823%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">December 31,</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">(In thousands)</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2024</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-

 </

9,505	2028	9,574	Thereafter	59,695
2028	9,574	Thereafter	59,695	

right:0.0097222222222222in;text-align:left;">Total operating lease payments</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">99,222</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <tr> <tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"> <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Less: imputed interest</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(23,684</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total operating lease liabilities</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-

bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">75,538</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table></div>2310002020-01-202035trueP10Y18000014500000154000000.040.044P7Y2M12DP8Y8M12D1010000010

2024

2025	2026	2027

Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">9,505</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">2028</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">9,574</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Thereafter</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">59,695</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span

Total operating lease payments	\$99,222	Less: imputed interest	23,684	Total operating lease liabilities

align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">75,538</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>10189000102590009505000957400059695000992220002368400075538000<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">11. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts payable and accrued expenses consists of the following:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.8830000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.8830000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">December 31,</p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">December 31,</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">(In thousands)</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2024</p><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Accounts payable</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-

[illegible]

	83,107
	68,742
	91,805
Total accounts payable and accrued expenses	

A summary of the Company's current provision for sales discounts, allowances and reserves is as follows:

December 31,	
December 31,	
December 31,	
(In thousands)	
2024	
2023	

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in; 15,121
padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;text-align:center; Medicare Part D	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;text-align:center; 26,933
padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;text-align:center; 20,569	padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;text-align:center; Other

[illegible]

 								
 								
 								

December 31,	
December 31,	December 31,
(In thousands)	
2024	
2023	
Accounts payable	

[illegible]

[illegible]

accrued expenses

\$	185,332	\$	240,561

A summary of the Company's current provision for sales discounts, allowances and reserves is as follows:

[illegible]

[illegible]

[illegible]

color:#ffffff;word-break:break-word;"><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">24,124</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">14,106</p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total accrued sales discounts, allowances and reserves</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

[illegible]

2.50

% with a floor of

0.5

%.

As of December 31, 2024 and 2023, long-term debt consisted of the following:

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	162

(In thousands)		2024		2023	
Former Term Loans (due March 12, 2026)		\$		—	

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">290,730</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Less: current portion</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(<span

[illegible]

bottom:0;text-align:left;"> </p>
<table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td>
<td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr>
<tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">December 31,</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">December 31,</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr>
<tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">(In thousands)</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-

space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2023</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Former Term Loans (due March 12, 2026)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

content;">290,730</p></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>
</tr>	<tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
<td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Less: current portion </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> — </td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"> </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> (3,000 </td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"> </td>	</tr>
<tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;">	<td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Long-term debt </td>
<td style="padding-top:0.01in;white-	

[illegible]

options and RSUs.

 	 	 										 							
 	 	 		 															
 	 	 		 															
 	 	 		 															
 	 	 		 															
 	 																		

right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2023</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022(1)</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr><td colspan="2" style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Numerator:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td></tr></table>

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(33,152</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Net loss from discontinued operations</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(5,068</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>

163,400	125,115
Net income (loss)	367,070

kerning:none;min-width:fit-content;"></p></td><td style="padding-top:0.01in;text-indent:10pt:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">355,757</p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;text-indent:10pt:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in:white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(158,267</p></td><td style="padding-top:0.01in:white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc:white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Denominator:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-

[illegible]

[illegible]

[illegible]

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,093</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Restricted stock unit awards</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,429</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,414</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Dilutive ordinary share equivalents</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">3,806</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New

[illegible]

#ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">169,730</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">163,742</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following potential ordinary

[illegible]

[illegible]

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">12,777</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Restricted stock unit awards</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,391</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,378</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-

[illegible]

right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">17,817</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.33%;text-align:left;"> </p><div class="item-list-element-wrapper" style="margin-left:3.33%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</div></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-

Year Ended December 31,	
(In thousands)	
2024	2023
2022	(1)

	 Numerator:
	
 	
	
	
 	
	
	
 	
	
	
 	
	
	
 	
	 Net income (loss) from continuing operations
 	

space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">372,138</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">519,157</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(33,152</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Net loss from discontinued operations</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-

[illegible]

#ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Net income (loss)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">367,070</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">355,757</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>

[illegible]

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Weighted average number of ordinary shares outstanding</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">165,392</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">166,223</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

content;">163,742</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fc;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Effect of dilutive securities:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Stock options</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-

[illegible]

[illegible]

Dilutive ordinary share equivalents	
	3,806
	3,507

[illegible]

163,742

(1)

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

372138000519157000-33152000-5068000-163400000-125115000367070000355757000-15826700016539200016622300016374200013770001093000242900024140003806000

The following potential ordinary share equivalents were not included in the net income (loss) per share calculation because the effect would have been anti-dilutive:

57.852%	1%	11.362%	1%	1%	1%	1%	1%	1%	11.422%	1%

Year Ended December 31,

right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">(In thousands)</p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2023</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022 (1)</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Stock options</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Stock options</p></td> </tr>

align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">11,517</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">12,422</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">12,777</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Restricted stock unit awards</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-

wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,391</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,378</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">5,040</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">13,908</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">14,800</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">17,817</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"> </p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-

wrap;font-size:8pt;font-family:Times New Roman;font-kerining:none;min-width:fit-content;">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</div>

</div>115170001242200012777000239100023780005040000139080001480000017817

The following table presents share-based compensation expense from continuing and discontinued operations included in the Company's consolidated statements of operations and comprehensive income (loss):

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	1592	1591	1590	1589	1588	1587	1586	1585	1584	1583	1582	1581	1580	1579	1578	1577	1576	1575	1574	1573	1572	1571	1570	1569	1568	1567	1566	1565	1564	1563	1562	1561	1560	1559	1558	1557	1556	1555	1554	1553	1552	1551	1550	1549	1548	1547	1546	1545	1544	1543	1542	1541	1540	1539	1538	1537	1536	1535	1534	1533	1532	1531	1530	1529	1528	1527	1526	1525	1524	1523	1522	1521	1520	1519	1518	1517	1516	1515	1514	1513	1512	1511	1510	1509	1508	1507	1506	1505	1504	1503	1502	1501	1500	1499	1498	1497	1496	1495	1494	1493	1492	1491	1490	1489	1488	1487	1486	1485	1484	1483	1482	1481	1480	1479	1478	1477	1476	1475	1474	1473	1472	1471	1470	1469	1468	1467	1466	1465	1464	1463	1462	1461	1460	1459	1458	1457	1456	1455	1454	1453	1452	1451	1450	1449	1448	1447	1446	1445	1444	1443	1442	1441	1440	1439	1438	1437	1436	1435	1434	1433	1432	1431	1430	1429	1428	1427	1426	1425	1424	1423	1422	1421	1420	1419	1418	1417	1416	1415	1414	1413	1412	1411	1410	1409	1408	1407	1406	1405	1404	1403	1402	1401	1400	1399	1398	1397	1396	1395	1394	1393	1392	1391	1390	1389	1388	1387	1386	1385	1384	1383	1382	1381	1380	1379	1378	1377	1376	1375	1374	1373	1372	1371	1370	1369	1368	1367	1366	1365	1364	1363	1362	1361	1360	1359	1358	1357	1356	1355	1354	1353	1352	1351	1350	1349	1348	1347	1346	1345	1344	1343	1342	1341	1340	1339	1338	1337	1336	1335	1334	1333	1332	1331	1330	1329	1328	1327	1326	1325	1324	1323	1322	1321	1320	1319	1318	1317	1316	1315	1314	1313	1312	1311	1310	1309	1308	1307	1306	1305	1304	1303	1302	1301	1300	1299	1298	1297	1296	1295	1294	1293	1292	1291	1290	1289	1288	1287	1286	1285	1284	1283	1282	1281	1280	1279	1278	1277	1276	1275	1274	1273	1272	1271	1270	1269	1268	1267	1266	1265	1264	1263	1262	1261	1260	1259	1258	1257	1256	1255	1254	1253	1252	1251	1250	1249	1248	1247	1246	1245	1244	1243	1242	1241	1240	1239	1238	1237	1236	1235	1234	1233	1232	1231	1230	1229	1228	1227	1226	1225	1224	1223	1222	1221	1220	1219	1218	1217	1216	1215	1214	1213	1212	1211	1210	1209	1208	1207	1206	1205	1204	1203	1202	1201	1200	1199	1198	1197	1196	1195	1194	1193	1192	1191	1190	1189	1188	1187	1186	1185	1184	1183	1182	1181	1180	1179	1178	1177	1176	1175	1174	1173	1172	1171	1170	1169	1168	1167	1166	1165	1164	1163	1162	1161	1160	1159	1158	1157	1156	1155	1154	1153	1152	1151	1150	1149	1148	1147	1146	1145	1144	1143	1142	1141	1140	1139	1138	1137	1136	1135	1134	1133	1132	1131	1130	1129	1128	1127	1126	1125	1124	1123	1122	1121	1120	1119	1118	1117	1116	1115	1114	1113	1112	1111	1110	1109	1108	1107	1106	1105	1104	1103	1102	1101	1100	1099	1098	1097	1096	1095	1094	1093	1092	1091	1090	1089	1088	1087	1086	1085	1084	1083	1082	1081	1080	1079	1078	1077	1076	1075	1074	1073	1072	1071	1070	1069	1068	1067	1066	1065	1064	1063	1062	1061	1060	1059	1058	1057	1056	1055	1054	1053	1052	1051	1050	1049	1048	1047	1046	1045	1044	1043	1042	1041	1040	1039	1038	1037	1036	1035	1034	1033	1032	1031	1030	1029	1028	1027	1026	1025	1024	1023	1022	1021	1020	1019	1018	1017	1016	1015	1014	1013	1012	1011	1010	1009	1008	1007	1006	1005	1004	1003	1002	1001	1000	999	998	997	996	995	994	993	992	991	990	989	988	987	986	985	984	983	982	981	980	979	978	977	976	975	974	973	972	971	970	969	968	967	966	965	964	963	962	961	960	959	958	957	956	955	954	953	952	951	950	949	948	947	946	945	944	943	942	941	940	939	938	937	936	935	934	933	932	931	930	929	928	927	926	925	924	923	922	921	920	919	918	917	916	915	914	913	912	911	910	909	908	907	906	905	904	903	902	901	900	899	898	897	896	895	894	893	892	891	890	889	888	887	886	885	884	883	882	881	880	879	878	877	876	875	874	873	872	871	870	869	868	867	866	865	864	863	862	861	860	859	858	857	856	855	854	853	852	851	850	849	848	847	846	845	844	843	842	841	840	839	838	837	836	835	834	833	832	831	830	829	828	827	826	825	824	823	822	821	820	819	818	817	816	815	814	813	812	811	810	809	808	807	806	805	804	803	802	801	800	799	798	797	796	795	794	793	792	791	790	789	788	787	786	785	784	783	782	781	780	779	778	777	776	775	774	773	772	771	770	769	768	767	766	765	764	763	762	761	760	759	758	757	756	755	754	753	752	751	750	749	748	747	746	745	744	743	742	741	740	739	738	737	736	735	734	733	732	731	730	729	728	727	726	725	724	723	722	721	720	719	718	717	716	715	714	713	712	711	710	709	708	707	706	705	704	703	702	701	700	699	698	697	696	695	694	693	692	691	690	689	688	687	686	685	684	683	682	681	680	679	678	677	676	675	674	673	672	671	670	669	668	667	666	665	664	663	662	661	660	659	658	657	656	655	654	653	652	651	650	649	648	647	646	645	644	643	642	641	640	639	638	637	636	635	634	633	632	631	630	629	628	627	626	625	624	623	622	621	620	619	618	617	616	615	614	613	61

[illegible]

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">11,353</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">10,284</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Research and development</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">28,085</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-

content;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">25,753</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">23,289</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Selling, general and administrative</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">62,754</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-

[illegible]

[illegible]

	—	
	Research and development	

</td>	—	</td>	</td>	</td>	3,255</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>	</td>

align:center;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">4,933</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,925</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">

[illegible]

[illegible]

94,254

During the years ended December 31, 2024, 2023 and 2022, \$3.1 million, \$3.2 million and \$3.3 million, respectively, of share-based compensation expense was capitalized and recorded as "Inventory" in the accompanying consolidated balance sheets.

Share-Based Compensation Plans

The Company has one share-based compensation plan pursuant to which awards are currently being made: the 2018 Stock Option and Incentive Plan, as amended (the "2018 Plan"). The Company has two share-based compensation plans pursuant to which outstanding awards have been made, but from which no further awards can or will be made: the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended, (the "2008 Plan") and the Alkermes plc 2011 Stock Option and Incentive Plan, as amended (the "2011 Plan," and together with the 2018 Plan and the 2008 Plan, the "the Alkermes Stock Option and Incentive Plans"). Effective May 20, 2020, the 2018 Plan was amended such that any shares underlying any outstanding awards granted under the 2011 Plan or the 2008 Plan that are forfeited, canceled, repurchased or otherwise terminated (other than by exercise) from and after such date will become available for issuance pursuant to the 2018 Plan, notwithstanding anything to the contrary in the terms of the 2011 Plan or the 2008 Plan.

The 2018 Plan allows for the issuance of non-qualified and incentive stock options, restricted stock, restricted stock unit awards, cash-based awards and performance shares to employees, officers and directors of, and consultants to, the Company in such amounts and with such terms and conditions as may be determined by the compensation committee of the Company's board of directors, subject to the provisions of the 2018 Plan, as applicable.

On May 31, 2024, the Company's shareholders approved an amended version of the then-current version of the 2018 Plan that served to, among other things, increase the number of ordinary shares authorized for issuance thereunder by 6.3 million. At December 31, 2024, there were 17.9 million ordinary shares available for issuance in the aggregate under the 2018 Plan. The 2018 Plan provides that awards other than stock options will be counted against the total number of shares available under the plan in a 1.8-to-1 ratio.

Stock Options

A summary of stock option activity is presented in the following table:

content;"></p></td> <td colspan="2"> Number of</p></td> <td> Weighted Average</p></td> </td> </td>	Number of</p></td> <td> Weighted Average</p></td> </td>		Weighted Average</p></td>
Exercise Price</p></td> <td colspan="2"> Shares</p></td> </td>	Shares</p></td>		

Outstanding, January 1, 2024	18,139,903	
Granted		

right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,615,357</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">29.48</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Exercised</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(1,328,189</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr>

family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">20.76</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr>
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Expired</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(1,427,409</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">46.72</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr>
<tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New

Roman; margin-bottom: 0; margin-right: 0.009722222222222222in; text-align: left; ">Forfeited</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.009722222222222222in; text-align: left;"></p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; border-bottom: 0.5pt solid #000000; padding-right: 0.01in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; border-bottom: 0.5pt solid #000000; padding-right: 0.01in; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.009722222222222222in; text-align: right;">(521,043</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; border-bottom: 0.5pt solid #ffffff03; padding-right: 0.01in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.009722222222222222in; text-align: left;"></p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.009722222222222222in; text-align: right;">26.65</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td></tr><tr><td style="height: 10pt; background-color: #ffffff; word-break: break-word;"><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.009722222222222222in; text-align: left;">Outstanding, December 31, 2024</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; margin-right: 0.009722222222222222in; text-align: left;"></p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; border-bottom: 2.25pt double #000000; padding-right: 0.01in;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; border-bottom: 2.25pt double

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">34.53</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The weighted average grant date fair value of stock options granted during the years ended December 31, 2024, 2023 and 2022 was \$14.08, \$13.74 and \$12.62, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2024, 2023 and 2022 was \$10.9 million, \$6.0 million and \$11.6 million, respectively.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">At December 31, 2024, there were6.3 million stock options expected to vest, with a weighted average exercise price of \$<span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

26.91

per share, a weighted average contractual remaining life of 7.9 years and an aggregate intrinsic value of \$15.4 million. At December 31, 2024, the aggregate intrinsic value of stock options exercisable was \$38.5 million with a weighted average remaining contractual term of 4.4 years. The number of stock options expected to vest was determined by applying the pre-vesting forfeiture rate to the total number of outstanding options. The intrinsic value of a stock option is the amount by which the market value of the underlying shares exceeds the exercise price of the stock option.

At December 31, 2024, there was \$32.3 million of unrecognized share-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 1.9 years.

Time-Based Restricted Stock Unit Awards

A summary of time-based RSU activity is presented in the following table:

[illegible]

[illegible]

Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">Granted</p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">2,260,345</p>
</td> <td style="padding-top:0.01in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;font-kerning:none;min-width:fit-content;">\$</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">29.51</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> </tr> <tr
style="height:10pt;background-color:#cfff0f;word-break:break-word;"> <td
style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-
left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">Forfeited</p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">(<span

775,415	\$26.43
Vested	2,237,302
2,237,302	(
(	)

	\$
	Unvested, December 31, 2024
	4,905,206
	\$
	26.80

The weighted average grant date fair values of time-vesting RSUs granted during the years ended December 31, 2024, 2023 and 2022 were \$

29.51

, \$

27.65

and \$

25.27

, respectively. The total fair value of time-vesting RSUs that vested during the years ended December 31, 2024, 2023 and 2022, was \$

51.6

million, \$

63.0

million and \$

54.3

million, respectively.

At December 31, 2024, there was \$

53.4

million of total unrecognized share-based compensation expense related to unvested time-vesting RSUs, which will be recognized over a weighted average remaining contractual term of

1.9

years.

Performance-Based Restricted Stock Unit Awards

In February 2024, 2023 and 2022, the compensation committee of the Company's board of directors approved the Company's long-term incentive plans, pursuant to which awards of performance-based RSUs are granted to employees of the Company at the Senior Vice President level and above, in each case subject to vesting based on the achievement of certain financial, commercial and/or R&D performance criteria to be assessed over a performance period of

three years

from the date of the grant, and

subject, at the end of such three-year performance period, to upward or downward adjustment based on a market condition tied to relative share price performance over the three-year performance period.

A summary of performance-based RSU activity is presented in the following table:

Year	Number of Shares	Weighted Average
2017	1,160,000	1.16%
2018	13,360,000	13.36%
2019	1,620,000	1.62%
2020	12,880,000	12.88%
2021	1,009,722,222	1.0097222222222222
2022	1,009,722,222	1.0097222222222222
2023	1,009,722,222	1.0097222222222222
2024	1,009,722,222	1.0097222222222222
2025	1,009,722,222	1.0097222222222222
2026	1,009,722,222	1.0097222222222222
2027	1,009,722,222	1.0097222222222222
2028	1,009,722,222	1.0097222222222222
2029	1,009,722,222	1.0097222222222222
2030	1,009,722,222	1.0097222222222222
2031	1,009,722,222	1.0097222222222222
2032	1,009,722,222	1.0097222222222222
2033	1,009,722,222	1.0097222222222222
2034	1,009,722,222	1.0097222222222222
2035	1,009,722,222	1.0097222222222222
2036	1,009,722,222	1.0097222222222222
2037	1,009,722,222	1.0097222222222222
2038	1,009,722,222	1.0097222222222222
2039	1,009,722,222	1.0097222222222222
2040	1,009,722,222	1.0097222222222222
2041	1,009,722,222	1.0097222222222222
2042	1,009,722,222	1.0097222222222222
2043	1,009,722,222	1.0097222222222222
2044	1,009,722,222	1.0097222222222222
2045	1,009,722,222	1.0097222222222222
2046	1,009,722,222	1.0097222222222222
2047	1,009,722,222	1.0097222222222222
2048	1,009,722,222	1.0097222222222222
2049	1,009,722,222	1.0097222222222222
2050	1,009,722,222	1.0097222222222222
2051	1,009,722,222	1.0097222222222222
2052	1,009,722,222	1.0097222222222222
2053	1,009,722,222	1.0097222222222222
2054	1,009,722,222	1.0097222222222222
2055	1,009,722,222	1.0097222222222222
2056	1,009,722,222	1.0097222222222222
2057	1,009,722,222	1.0097222222222222
2058	1,009,722,222	1.0097222222222222
2059	1,009,722,222	1.0097222222222222
2060	1,009,722,222	1.0097222222222222
2061	1,009,722,222	1.0097222222222222
2062	1,009,722,222	1.0097222222222222
2063	1,009,722,222	1.0097222222222222
2064	1,009,722,222	1.0097222222222222
2065	1,009,722,222	1.0097222222222222
2066	1,009,722,222	1.0097222222222222
2067	1,009,722,222	1.0097222222222222
2068	1,009,722,222	1.0097222222222222
2069	1,009,722,222	1.0097222222222222
2070	1,009,722,222	1.0097222222222222
2071	1,009,722,222	1.0097222222222222
2072	1,009,722,222	1.0097222222222222
2073	1,009,722,222	1.0097222222222222
2074	1,009,722,222	1.0097222222222222
2075	1,009,722,222	1.0097222222222222
2076	1,009,722,222	1.0097222222222222
2077	1,009,722,222	1.0097222222222222
2078	1,009,722,222	1.0097222222222222
2079	1,009,722,222	1.0097222222222222
2080	1,009,722,222	1.0097222222222222
2081	1,009,722,222	1.0097222222222222
2082	1,009,722,222	1.0097222222222222
2083	1,009,722,222	1.0097222222222222
2084	1,009,72	

space:pre-wrap;font-kerning:none;min-width:fit-content;">	
padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
<div>padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"></div> <div>font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></div> <div>color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"></div> Number of Shares</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #fffff03;padding-right:0.01in;text-align:left;">	
font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"> font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
<div>padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"></div> <div>font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></div> <div>color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"></div> Grant Date Fair Value</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #fffff03;padding-right:0.01in;text-align:left;">	
font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	
</tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> Unvested, January 1, 2024 </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"> 1,546,357 </td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> </td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New	

Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">27.95</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Granted</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">498,120</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">32.46</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </tr>

Forfeited	
172,576 \$ 25.88	
Vested	

family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(536,243</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">22.21</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Unvested, December 31, 2024</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,335,658</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">32.13</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The weighted average grant date fair values of performance-based RSUs granted during the years ended December 31, 2024, 2023 and 2022 were \$32.46, \$29.91 and \$30.73, respectively. The total fair value of performance-based RSUs that vested during the years ended December 31, 2024, 2023 and 2022 were \$10.1 million, \$5.9 million and none, respectively. At December 31, 2024, there was \$

3.0 million of unrecognized share-based compensation expense related to unvested performance-based RSUs which would be recognized in accordance with the terms of the awards when the Company deems it probable that the performance criteria will be met.

During the year ended December 31, 2024, the Company recognized share-based compensation expense related to certain performance-based RSUs that were granted during 2021. As of December 31, 2023, the financial performance criteria for these awards were deemed not probable of being achieved; however, in February 2024, the compensation committee of the Company's board of directors determined that the Company partially achieved the financial performance criteria. This was considered a modification in accordance with FASB ASC 718, Compensation—Stock Compensation and resulted in a modification charge of approximately \$6.8 million. In February 2024, the compensation committee of the Company's board of directors also determined that the Company achieved the pipeline performance criteria for these awards, resulting in a \$2.6 million incremental share-based compensation expense, as it was deemed such pipeline performance criteria had been met. The share-based compensation expense related to these achievements was recognized in 2024.

The following table presents share-based compensation expense from continuing and discontinued operations included in the Company's consolidated statements of operations and comprehensive income (loss):

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	1592	1591	1590	1589	1588	1587	1586	1585	1584	1583	1582	1581	1580	1579	1578	1577	1576	1575	1574	1573	1572	1571	1570	1569	1568	1567	1566	1565	1564	1563	1562	1561	1560	1559	1558	1557	1556	1555	1554	1553	1552	1551	1550	1549	1548	1547	1546	1545	1544	1543	1542	1541	1540	1539	1538	1537	1536	1535	1534	1533	1532	1531	1530	1529	1528	1527	1526	1525	1524	1523	1522	1521	1520	1519	1518	1517	1516	1515	1514	1513	1512	1511	1510	1509	1508	1507	1506	1505	1504	1503	1502	1501	1500	1499	1498	1497	1496	1495	1494	1493	1492	1491	1490	1489	1488	1487	1486	1485	1484	1483	1482	1481	1480	1479	1478	1477	1476	1475	1474	1473	1472	1471	1470	1469	1468	1467	1466	1465	1464	1463	1462	1461	1460	1459	1458	1457	1456	1455	1454	1453	1452	1451	1450	1449	1448	1447	1446	1445	1444	1443	1442	1441	1440	1439	1438	1437	1436	1435	1434	1433	1432	1431	1430	1429	1428	1427	1426	1425	1424	1423	1422	1421	1420	1419	1418	1417	1416	1415	1414	1413	1412	1411	1410	1409	1408	1407	1406	1405	1404	1403	1402	1401	1400	1399	1398	1397	1396	1395	1394	1393	1392	1391	1390	1389	1388	1387	1386	1385	1384	1383	1382	1381	1380	1379	1378	1377	1376	1375	1374	1373	1372	1371	1370	1369	1368	1367	1366	1365	1364	1363	1362	1361	1360	1359	1358	1357	1356	1355	1354	1353	1352	1351	1350	1349	1348	1347	1346	1345	1344	1343	1342	1341	1340	1339	1338	1337	1336	1335	1334	1333	1332	1331	1330	1329	1328	1327	1326	1325	1324	1323	1322	1321	1320	1319	1318	1317	1316	1315	1314	1313	1312	1311	1310	1309	1308	1307	1306	1305	1304	1303	1302	1301	1300	1299	1298	1297	1296	1295	1294	1293	1292	1291	1290	1289	1288	1287	1286	1285	1284	1283	1282	1281	1280	1279	1278	1277	1276	1275	1274	1273	1272	1271	1270	1269	1268	1267	1266	1265	1264	1263	1262	1261	1260	1259	1258	1257	1256	1255	1254	1253	1252	1251	1250	1249	1248	1247	1246	1245	1244	1243	1242	1241	1240	1239	1238	1237	1236	1235	1234	1233	1232	1231	1230	1229	1228	1227	1226	1225	1224	1223	1222	1221	1220	1219	1218	1217	1216	1215	1214	1213	1212	1211	1210	1209	1208	1207	1206	1205	1204	1203	1202	1201	1200	1199	1198	1197	1196	1195	1194	1193	1192	1191	1190	1189	1188	1187	1186	1185	1184	1183	1182	1181	1180	1179	1178	1177	1176	1175	1174	1173	1172	1171	1170	1169	1168	1167	1166	1165	1164	1163	1162	1161	1160	1159	1158	1157	1156	1155	1154	1153	1152	1151	1150	1149	1148	1147	1146	1145	1144	1143	1142	1141	1140	1139	1138	1137	1136	1135	1134	1133	1132	1131	1130	1129	1128	1127	1126	1125	1124	1123	1122	1121	1120	1119	1118	1117	1116	1115	1114	1113	1112	1111	1110	1109	1108	1107	1106	1105	1104	1103	1102	1101	1100	1099	1098	1097	1096	1095	1094	1093	1092	1091	1090	1089	1088	1087	1086	1085	1084	1083	1082	1081	1080	1079	1078	1077	1076	1075	1074	1073	1072	1071	1070	1069	1068	1067	1066	1065	1064	1063	1062	1061	1060	1059	1058	1057	1056	1055	1054	1053	1052	1051	1050	1049	1048	1047	1046	1045	1044	1043	1042	1041	1040	1039	1038	1037	1036	1035	1034	1033	1032	1031	1030	1029	1028	1027	1026	1025	1024	1023	1022	1021	1020	1019	1018	1017	1016	1015	1014	1013	1012	1011	1010	1009	1008	1007	1006	1005	1004	1003	1002	1001	1000	999	998	997	996	995	994	993	992	991	990	989	988	987	986	985	984	983	982	981	980	979	978	977	976	975	974	973	972	971	970	969	968	967	966	965	964	963	962	961	960	959	958	957	956	955	954	953	952	951	950	949	948	947	946	945	944	943	942	941	940	939	938	937	936	935	934	933	932	931	930	929	928	927	926	925	924	923	922	921	920	919	918	917	916	915	914	913	912	911	910	909	908	907	906	905	904	903	902	901	900	899	898	897	896	895	894	893	892	891	890	889	888	887	886	885	884	883	882	881	880	879	878	877	876	875	874	873	872	871	870	869	868	867	866	865	864	863	862	861	860	859	858	857	856	855	854	853	852	851	850	849	848	847	846	845	844	843	842	841	840	839	838	837	836	835	834	833	832	831	830	829	828	827	826	825	824	823	822	821	820	819	818	817	816	815	814	813	812	811	810	809	808	807	806	805	804	803	802	801	800	799	798	797	796	795	794	793	792	791	790	789	788	787	786	785	784	783	782	781	780	779	778	777	776	775	774	773	772	771	770	769	768	767	766	765	764	763	762	761	760	759	758	757	756	755	754	753	752	751	750	749	748	747	746	745	744	743	742	741	740	739	738	737	736	735	734	733	732	731	730	729	728	727	726	725	724	723	722	721	720	719	718	717	716	715	714	713	712	711	710	709	708	707	706	705	704	703	702	701	700	699	698	697	696	695	694	693	692	691	690	689	688	687	686	685	684	683	682	681	680	679	678	677	676	675	674	673	672	671	670	669	668	667	666	665	664	663	662	661	660	659	658	657	656	655	654	653	652	651	650	649	648	647	646

[illegible]

right:0.0097222222222222in;text-align:center;"></p></td> <td colspan="2"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022</p></td> </td>	<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022</p></td>	
<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> <td colspan="2"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Cost of goods manufactured and sold</p></td> </td>	<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Cost of goods manufactured and sold</p></td>	
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td> <td colspan="2"> \$</p></td> </td>	\$</p></td>	
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">5,798</p></td> <td colspan="2"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td colspan="2"> \$</p></td> </td>	\$</p></td>	
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">11,353</p></td> <td colspan="2"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit- <td colspan="2"></td>		

content;"></p></td>	<p >\$<="" ><p="" ><span="" p="" p><="" span><="" style="color:#000000;font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >10,284<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><="" p="" style="height:10pt;background-color:#ffffff;word-break:break-word;"></p>	
<p ><p="" ><span="" >research="" and="" development<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><p="" ><span="" >28,085<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >25,753<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >25,753<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >25,753<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>

[illegible]

[illegible]

right:0.0097222222222222in;text-align:right;">92,717</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">87,677</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Cost of goods manufactured and sold</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-

[illegible]

3,255	
4,652	
Selling, general and administrative	
—	
03	

bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">4,933</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,925</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Share-based compensation expense from discontinued operations</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table>

[illegible]

[illegible]

[illegible]

right:0.009722222222222222in;text-align:center;"></p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Exercise Price</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> </tr> <tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Outstanding, January 1, 2024</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">18,139,903</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">32.28</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New

[illegible]

 </

46.72	
Forfeited	White-space:pre-wrap;font-kerning:none;min-width:fit-content;
521,043	\$
26.65	
	White-space:pre-wrap;font-kerning:none;min-width:fit-content;

space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, December 31, 2024</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">17,478,619</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">31.73</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr><td style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Exercisable, December 31, 2024</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">10,979,663</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">34.53</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>1813990332.28261535729.48132818920.76142740946.7252104326.651747861931 style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">A summary of time-based RSU activity is presented in the following table:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.98%;box-sizing:content-box;"></td><td style="width:1.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:12.88%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-

right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Weighted Average</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Number of
Shares</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Grant Date
Fair Value</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Unvested, January 1,

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">29.51</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Forfeited</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(775,415</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

space:pre-wrap;font-kerning:none;min-width:fit-content;">26.43</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Vested</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(2,237,302</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">23.05</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Unvested, December 31, 2024</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">4,905,206</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">26.80</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>565757824.18226034529.5177541526.43223730223.05490520626.829.5127.65

[illegible]

bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;">
<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-
kerning:none;min-width:fit-content;"> </p></td> </tr> <tr
style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td
style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested, January 1,
2024</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">1,546,357</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-
width:fit-content;">\$</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">27.95</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> </tr> <tr style="height:10pt;background-
color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-
indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</p></td>

<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td

</p>	498,120</p>
</p>	</p>
\$</p>	32.46</p>
</p>	
<td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Forfeited</p>	
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p>	<p ><="" ><p="" ><span="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td=""></p>
(172,576</p>	<p ><p="" ><span="" >)<="" p><="" span><="" style="color:#000000;font-kerning:none;min-width:fit-content;" td=""></p>
<p ><p="" ><span="" >)<="" p="" p><="" span><="" style="color:#000000;font-kerning:none;min-width:fit-content;"></p>	

right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">25.88</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Vested</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(536,243</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">22.21</p></td>

	Unvested, December 31, 2024
	1,335,658
	32.13
\$	
32.13	

16. COLLABORATIVE ARRANGEMENTS

The Company has entered into several collaborative arrangements to develop and commercialize products and, in connection with such arrangements, to

access technologies, financial, marketing, manufacturing and other resources. Refer to the "Patents and Proprietary Rights" section in "Item 1— Business" of this Annual Report for information with respect to IP protection for these products. The collaboration revenue the Company has earned in the years ended December 31, 2024, 2023 and 2022 is summarized in Note 4.

Revenue from Contracts with Customers within the notes to the consolidated financial statements in this Annual Report.

The Company's significant collaborative arrangements are described below:

Janssen

INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANLLI

Under an exclusive license agreement with Janssen, the Company provided Janssen with rights to, and know-how, training and technical assistance in respect of, the Company's small particle pharmaceutical compound technology, known as NanoCrystal technology, which was used to develop the long-acting INVEGA products, and the Company received milestone payments from Janssen upon the achievement of certain development goals from Janssen; there are no further milestones to be earned under this agreement. The agreement also provides for tiered royalty payments, which consist of a patent royalty and a know-how royalty, both of which are determined on a country-by-country basis. The patent royalty, which equals 1.5% of net sales, is payable in each country until the expiration of the last of the patents with valid claims applicable to the product in such country. The know-how royalty is a tiered royalty of 3.5% and 5.5% and 7.5% on aggregate worldwide net sales of below \$250

million, between \$250 million and \$500 million, and greater than \$500 million, respectively. The know-how royalty rate resets to 3.5% at the beginning of each calendar year and is payable until 15 years from first commercial sale of a product in each individual country, subject to expiry of the agreement. These royalty payments may be reduced in any country based on patent litigation or on competing products achieving certain minimum sales thresholds. The license agreement, unless earlier terminated, terminates upon the expiration of the last of the patents subject to the agreement. After expiration, Janssen retains a non-exclusive, royalty-free license to develop, manufacture and commercialize the products, subject to certain surviving obligations. Janssen may terminate the license agreement in whole or in part upon three months' notice to the Company. The Company and Janssen have the right to terminate the agreement upon a material breach of the other party, which is not cured within a certain time period, or upon the other party's bankruptcy or insolvency.

In November 2021, the Company received notice from Janssen of partial termination of the license agreement, following which Janssen ceased paying the Company royalties related to U.S. sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA. In April 2022, the Company commenced binding arbitration proceedings related to, among other things, Janssen's partial termination of this license agreement and Janssen's royalty and other obligations under the agreement. In May 2023, the Tribunal in the arbitration proceedings issued a Final Award that served to reinstate the Janssen royalties and required payment by Janssen of back royalties and interest for amounts owed but not yet paid since the effective date of the partial termination. The Final Award also provided, among other things, that the Company was entitled to royalty revenues from Janssen related to net sales of INVEGA SUSTENNA through August 20, 2024, INVEGA TRINZA through the second quarter of 2030 (but no later than May 2030 when the license agreement expires) and INVEGA HAFYERA through May 2030 (when the license agreement expires).

RISPERDAL CONSTA

Under a product development agreement, the Company collaborated with Janssen on the development of

RISPERDAL CONSTA. Under the development agreement, Janssen provided funding to the Company for the development of RISPERDAL CONSTA and Janssen is responsible for securing all necessary regulatory approvals for the product.

Under two license agreements, the Company granted Janssen and an affiliate of Janssen exclusive worldwide licenses to use and sell RISPERDAL CONSTA. Under its license agreements with Janssen, the Company receives royalty payments equal to 2.5% of Janssen's end-market net sales of RISPERDAL CONSTA in each country where the license is in effect based on the quarter when the product is sold by Janssen. This royalty may be reduced in any country based on lack of patent coverage and significant competition from generic versions of the product. Janssen can terminate the license agreements upon 30 days' prior written notice to the Company. Either party may terminate the license agreements by written notice following a breach which continues for 90 days after the delivery of written notice thereof or upon the other party's insolvency. The licenses granted to Janssen expire on a country-by-country basis upon the later of: (i) the expiration of the last patent claiming the product in such country; or (ii) 15 years after the date of the first commercial sale of the product in such country, provided that in no event will the license granted to Janssen expire later than the twentieth anniversary of the first commercial sale of the product in each such country, with the exception of Canada, France, Germany, Italy, Japan, Spain and the United Kingdom, in each case where the fifteen-year minimum shall pertain regardless. After expiration, Janssen retains a non-exclusive, royalty-free license to manufacture, use and sell RISPERDAL CONSTA.

The Company exclusively manufactures RISPERDAL CONSTA at its Wilmington, Ohio facility for commercial sale. Under its manufacturing and supply agreement with Janssen, the Company records manufacturing revenues when product is fully manufactured and approved for shipment by both Janssen and the Company. Revenue is based on a percentage of Janssen's net unit sales price for RISPERDAL CONSTA for the applicable calendar year. This percentage is determined based on Janssen's unit demand for such calendar year and varies based on the volume of units

shipped, with a minimum manufacturing fee of 7.5%. Either party may terminate the manufacturing and supply agreement upon a material breach by the other party, which is not resolved within 60 days after receipt of a written notice specifying the material breach or upon written notice in the event of the other party's insolvency or bankruptcy. Janssen may terminate the agreement upon six months' written notice to the Company. In the event that Janssen terminates the manufacturing and supply agreement without terminating the license agreements, the royalty rate payable to the Company on Janssen's net sales of RISPERDAL CONSTA would increase from 2.5% to 5.0%.

Biogen

Under a license and collaboration agreement with Biogen, the Company granted Biogen a worldwide, exclusive, sublicensable license to develop, manufacture and commercialize VUMERITY and other products covered by patents licensed to Biogen under the agreement.

Under this license and collaboration agreement, the Company received an upfront cash payment and milestone payments related to the achievement of certain milestones. The Company is also eligible to receive additional payments upon achievement of certain milestones, including milestones relating to the first two products, other than VUMERITY, covered by patents licensed to Biogen under the license and collaboration agreement.

In addition, the Company receives a 15% royalty on worldwide net sales of VUMERITY, subject to increases for VUMERITY

manufactured and/or packaged by Biogen or its designees. The Company is also entitled to receive royalties on net sales of products other than VUMERITY covered by patents licensed to Biogen under the license and collaboration agreement, at tiered royalty rates calculated as percentages of net sales ranging from high-single digits to sub-teen double digits. All royalties are payable on a product-by-product and country-by-country basis until the later of (i) the last-to-expire patent right covering the applicable product in the applicable country and (ii) a specified period of time from the first commercial sale of the applicable product in the applicable country. Royalties for all products are subject to customary reductions, as set forth in the license and collaboration agreement.

Following FDA approval of VUMERITY and, except for the manufacturing responsibilities discussed below, Biogen is now responsible for all development and commercialization activities for VUMERITY and all other products covered by the patents that we licensed to Biogen.

Under the license and collaboration agreement, Biogen appointed the Company as the toll manufacturer of clinical and commercial supplies of VUMERITY, subject to Biogen's right to manufacture or have manufactured commercial supplies as a back-up manufacturer. In October 2019, the Company entered into a commercial supply agreement with Biogen for the commercial supply of VUMERITY, an amendment to such commercial supply agreement and an amendment to the license and collaboration agreement with Biogen, pursuant to which Biogen has conducted a technology transfer and, following an agreed transition period, has elected to assume responsibility for the manufacture (itself or through a designee) of clinical and commercial supplies of VUMERITY in exchange for an increase in the royalty rate to be paid by Biogen to the Company on net sales of product that is manufactured by Biogen or its designee. In May 2024, the Company completed the sale of the Athlone Facility where VUMERITY is manufactured. In connection with the sale of the Athlone Facility, the Company has entered into a subcontracting arrangement with the purchaser of the Athlone Facility for the manufacture of VUMERITY through the manufacturing transition period, which may continue through the end of 2025.

Unless earlier terminated, the license and collaboration agreement will remain in effect until the expiry of all royalty obligations. Biogen has the right to terminate the license and collaboration agreement at will, on a product-by-product basis or in its entirety upon 180 days' prior notice to the Company. Either party has the right to terminate the license and collaboration agreement following any governmental prohibition of the transactions effected by the agreement, or in connection with an insolvency event involving the other party. Upon termination of the license and collaboration agreement by either party, then, at the Company's request, the VUMERITY program will revert to the Company.

0.0150.0350.0550.0752500000002500000005000000005000000000.035P15Y20.02.

17. INCOME TAXES

The Company's provision (benefit)

[illegible]

right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2023</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022(1)</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Current income tax provision (benefit):</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td>

[illegible]

right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$ </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">11,169</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">U.S. state</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">4,259</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

[illegible]

[illegible]

right:0.009722222222222222in;text-align:left;"></p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">U.S. federal</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(19,870</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">10,192</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-

content;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(10,536</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">U.S. state</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(1,392</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(507</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(3,010</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Ireland</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">61,783</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

[illegible]

97,638

2,024	(1)

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

The income tax provision in 2024 was primarily due to taxes on income earned in Ireland. The income tax benefit in 2023 was primarily due to the partial release of the valuation allowance maintained against certain Irish deferred tax assets, partially offset by taxes on income earned in the U.S. and Ireland. The income tax expense in 2022 was primarily due to taxes on income earned in the U.S.

bottom:0;text-align:left;">In December 2022, the EU implemented a new corporate minimum tax rate of 15% on companies with consolidated annual revenue of at least €750.0 million, which was transposed into Irish law effective as of January 1, 2024. The Company has determined that this new minimum tax had no material impact for the year ended December 31, 2024.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The income tax benefit associated with the Company's former oncology business, and the tax impact of the Separation, are discussed in further detail in Note 3, Discontinued Operations, in these "Notes to Consolidated Financial Statements" in this Annual Report. The tax benefits included within discontinued operations were \$0.7 million, \$1.4 million, and \$11.1 million for the years ended December 31, 2024, 2023, and 2022, respectively.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">No provision for income tax has been provided on undistributed earnings of the Company's foreign subsidiaries because such earnings are indefinitely reinvested in the foreign operations. Cumulative unremitted earnings of U.S. subsidiaries totaled approximately \$933.5 million at December 31, 2024. In the event of a repatriation of those earnings in the form of dividends or otherwise, the Company may be liable for income taxes, subject to adjustment, if any, for foreign tax credits and foreign withholding taxes payable to foreign tax authorities. The Company estimates that approximately \$72.0 million of income taxes would be payable on the repatriation of the unremitted earnings to Ireland.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-

bottom:0;text-align:left;">The distribution of the Company's income (loss) before the provision (benefit) for income taxes by geographical area consists of the following:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.46%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.520000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.520000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.520000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Year Ended December 31,</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">(In thousands)</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-

right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2023</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2022(1)</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Ireland</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">440,674</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> 411,767</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(32,198</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">U.S.</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">3,076</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">9,752</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,070</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">9,752</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,070</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">9,752</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,070</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">9,752</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,070</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td> </td> </td> </td> </td> </td> </td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,070</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td> </td> </td> </td> </td> </td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,070</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td> </td> </td> </td> </td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,070</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td> </td> </td> </td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,070</p></td> <td> padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td> </td> </td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td> height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td> </td>	height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Income (loss) from continuing operations before provision (benefit) for income taxes</p></td> <td> padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td> </td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td> </td>	border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td> border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </td>	border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">

443,750

\$	\$
421,519	\$
31,128	(1)

(1)

wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</div></div></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The components of the Company's net deferred tax assets consist of the following:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">December 31,</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">December 31,</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td></tr></table>

[illegible]

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Net operating loss carryforwards</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">80,209</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">195,658</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Research and development expenses</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">71,167</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">49,206</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> </tr> <tr
style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td
style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-
left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">Accrued expenses and reserves</p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">41,189</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">37,367</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Operating lease liabilities</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">17,537</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">18,716</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>

Share-based compensation	33,773	37,727	Tax credits

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">26,882</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">27,116</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
</tr>
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
<td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">3,695</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </p></td>	<p ><p="" ><span="" >5,582<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>
<p >="" ><p="" ><span="" <="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>	
<p ><="" p="" style="height:10pt;background-color:#c0c0c0;word-break:break-word;"></p>	
<p ><p="" ><span="" >less:="" allowance<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><="" valuation=""></p>	<p >="" ><p="" ><span="" <="" p="" p><="" span><="" style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>
<p >="" ><p="" ><span="" <="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><p="" ><span="" >(<="" >79,727<="" p="" p><="" span><="" span><span="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >)<="" p="" p><="" span><="" style="color:#000000;font-kerning:none;min-width:fit-content;" td><=""></p>	<p >="" ><p="" ><span="" <="" p="" p><="" span><="" style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>
<p >="" ><p="" ><span="" <="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><p="" ><span="" >(<="" >129,296<="" p="" p><="" span><="" span><span="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span<="" p="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>	

[illegible]

[illegible]

26,271	Right-of-use assets	16,337	17,748	Other

1,940	2,716
Total deferred tax liabilities	

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(40,194</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(46,735</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Net deferred tax assets</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">154,531</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$ </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">195,341 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The activity in the valuation allowance associated with deferred taxes consists of the following:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:62.028%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.158000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.158000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.158000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">(In thousands)</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Balance at

Beginning of Period (1)	
Additions / Reductions	
(2)	
Balance at End of Period	
(1)	
	Deferred tax asset valuation allowance for the year ended December 31, 2022

[illegible]

[illegible]

right:0.009722222222222222in;text-align:left;">Deferred tax asset valuation allowance for the year ended December 31, 2024</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(129,296</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">49,569</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(79,727</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">)</p></td></tr></table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">Inclusive of continuing and discontinued operations for the periods prior to the Separation in November 2023.</div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(2)<div style="width:100%;display:inline;">(Additions) reductions represent continuing and discontinued operations for the periods prior to the Separation in November 2023. The reductions during the year ended December 31, 2024 primarily relate to the abandonment of certain Irish NOLs following the sale of the Athlone Facility to Novo. These NOLs were transferred from Elan Corporation, plc as part of the combination of the drug technology business of Elan Corporation, plc with the business of Alkermes, Inc. A number of restrictions applied to these NOLs thereby restricting the Company's ability to utilize such NOLs. Following the sale of the Athlone Facility, the Company believes that its ability to utilize these NOLs is remote. The reduction during the year ended December 31, 2023 primarily relates to the partial release of the valuation allowance maintained by the Company against certain Irish net deferred tax assets. The additions in 2022 relate primarily to Irish NOLs.</div></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making such assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. At December 31, 2024, the Company maintained a valuation allowance of \$29.6 million against certain U.S. state deferred tax assets and \$50.1 million against certain Irish deferred tax assets, as the Company has determined that it is more-likely-than-not that these deferred tax assets will not be realized and some may be abandoned.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">If the Company incurs losses in the U.S. or in Ireland in the future, or fails to achieve sufficient profitability in a timely manner, the evaluation of the

recoverability of the deferred tax assets could change and a valuation allowance against such deferred tax assets may be required in part or in whole. The Company will continue to monitor the need for a valuation allowance against its deferred tax assets on a quarterly basis.

As of December 31, 2024, the Company had \$393.9 million of Irish NOL carryforwards, \$14.1 million of U.S. federal NOL carryforwards, \$43.2 million of state NOL carryforwards and \$34.0 million of state tax credits which will either expire on various dates through 2039 or can be carried forward indefinitely. These loss and credit carryforwards are available to reduce certain future Irish and foreign taxable income and tax. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities and may be subject to limitations based upon changes in the ownership of the Company's ordinary shares. Included within these loss and credit carryforwards are \$14.1 million of U.S. federal NOL carryforwards and \$5.8 million of state NOL carryforwards, acquired as part of the acquisition of Rodin Therapeutics, Inc. in November 2019, each of which are subject to a \$0.5 million annual limitation.

A reconciliation of the Company's statutory tax rate to its effective tax rate is as follows:

[illegible]

[illegible]

[illegible]

[illegible]

Income (loss) from continuing operations before income taxes at statutory rate	55,469
Income (loss) from continuing operations after income taxes at statutory rate	52,690

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">775</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">U.S. state income taxes, net of U.S. federal benefit</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">2,802</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

[illegible]

</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> —</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> (4,530</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td> </td> </td> </td> </td> </td> </td> </td> </td> </td>	</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> —</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> (4,530</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td> </td> </td> </td> </td> </td> </td> </td> </td>	</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> —</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> (4,530</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td> </td> </td> </td> </td> </td> </td> </td>	—</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> (4,530</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td> </td> </td> </td> </td> </td> </td>	</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> (4,530</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td> </td> </td> </td> </td> </td>	</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> (4,530</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td> </td> </td> </td> </td>	</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> (4,530</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td> </td> </td> </td>	</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in; text-align: center;"> (4,530</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td> </td> </td>	(4,530</p></td><td style="padding-top: 0.01in; white-space: nowrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;">)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td> </td>	)</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> </p></td> </td>	</p></td>
						R&D credit</p></td><td style="padding-top: 0.01in; white-space: pre-wrap; vertical-align: bottom; padding-bottom: 0in; padding-right: 0.01in;"> R&D credit</p></td> </td>	R&D credit</p></td>			

[illegible]

space:pre-wrap;font-kerning:none;min-width:fit-content;")(2,531</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Abandonment of NOLs(5)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">49,897</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">—</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-

[illegible]

wrap;font-kerning:none;min-width:fit-content;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,539</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,125</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Income tax provision (benefit)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-

	 \$
 71,612	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
 	
	

[illegible]

[illegible]

bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">%</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(6.5</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">%</p></td></tr></table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(2)<div style="width:100%;display:inline;">Represents income or losses of U.S. subsidiaries, subject to tax at a rate other than the Irish statutory rate.</div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(3)<div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-

wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercompany amounts include cross-territory eliminations, the pre-tax effect of which has been eliminated in arriving at the Company's consolidated income (loss) before taxes from continuing operations. In 2023, this included a tax benefit of \$

15.7 million related to the intercompany transfer of inventory that was owned by the Company at December 31, 2023.

(4) Represents income or losses of Irish companies subject to tax at a rate other than the Irish statutory rate.

(5) Represents the tax effect of the abandonment of Irish NOLs following the sale of the Athlone Facility to Novo.

(6) Other permanent items include, but are not limited to, non-deductible meals and entertainment expenses and non-deductible compensation of senior officers of the Company. For the year ended December 31, 2024, permanent items also included amounts relating to the sale of the Athlone Facility.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical- align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin- left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> Reductions based on the lapse of applicable statutes of limitations </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical- align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font- size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin- right:0.009722222222222222in;text-align:center;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding- bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding- top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding- right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;margin- right:0.009722222222222222in;text-align:right;">(438</p></td><td style="padding-top:0.01in;white- space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background- color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text- indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding- right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin- top:0;font-family:Times New Roman;margin-bottom:0;margin- right:0.009722222222222222in;text-align:left;">Additions based on tax positions related to prior periods</p></td><td style="padding- top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding- right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text- align:center;"> </p></td><td style="padding-top:0.01in;white- space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre- wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text- align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> 449</p></td><td style="padding-top:0.01in;white- space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background- color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text- indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding- right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin- top:0;font-family:Times New Roman;margin-bottom:0;margin-				

right:0.0097222222222222in;text-align:left;">Additions based on tax positions related to the current period	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;">590
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;">Balance, December 31, 2022	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">\$
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;">8,973	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">\$
padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;">Reductions based on the lapse of applicable statutes of limitations	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;

bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(1,073</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Additions based on tax positions related to the prior period</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">281</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Additions based on tax positions related to the current period</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-

[illegible]

indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Additions based on tax positions related to the prior period</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">59</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Additions based on tax positions related to the current period</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">581</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Balance, December 31, 2024</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-

right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">8,073</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The unrecognized tax benefits at December 31, 2024, if recognized, would affect the Company's effective tax rate. The Company does not anticipate that the amount of existing unrecognized tax benefits will materially increase or decrease within the next 12 months. The Company has elected to include interest and penalties related to uncertain tax positions as a component of its provision for taxes. For the years ended December 31, 2024, 2023 and 2022, the Company's accrued interest and penalties related to uncertain tax positions were not material.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's major taxing jurisdictions include Ireland and the U.S. (federal and state). These jurisdictions have varying statutes of limitations. In the U.S., the 2021 through 2024 fiscal years remain subject to examination by the respective tax authorities, however, some states have longer statutes of limitations and additional fiscal years remain subject to examination. In Ireland, the 2020 through 2024 fiscal years remain subject to examination by the Irish tax authorities. Additionally, because of the Company's Irish and U.S. loss carryforwards and credit carryforwards, certain tax returns from fiscal years 2002 onward may also be examined. These years generally remain open for threetofour yearsafter the loss carryforwards and credit carryforwards have been utilized.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's provision (benefit) for income taxes from continuing operations consists of the following:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </p>
<table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td>
<td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td>
<td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr>
<tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Year Ended December 31,</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">(In thousands)</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">2024</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td>

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">U.S. federal</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">25,640</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(981</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-

kerning:none;min-width:fit-content;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">11,169</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">U.S. state</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">4,259</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">722</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">4,401</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Ireland</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">1,192</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">—</p></td> <td style="padding-top:0.01in;white-

[illegible]

U.S. federal 19,870 10,192	U.S. federal 19,870 10,192

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(10,536</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">U.S. state</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(1,392</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(507</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(3,010</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Ireland</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">61,783</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-

)	()
	
	
Total tax provision (benefit) \$71,612	
	
	
	
	

\$

	(97,638)

\$

	2,024

(1)

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

25640000-98100011169000425900072200044010001192000-1987000010192000-10536000-1392000-507000-301000061783000-10706400071612000-9763800020240000.157500000000-700000-1400000-1110000093350000072000000

The distribution of the Company's income (loss) before the provision (benefit) for income taxes by geographical area consists of the following:

[illegible]

content;	2023	
2022	(1)	
Ireland	\$	
440,674		

bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">411,767</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(32,198</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">U.S.</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">3,076</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-

[illegible]

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">421,519</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(31,128</p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</div></div>440674000411767000-32198000307600097520001070000443750000421519000-31128000<p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The

components of the Company's net deferred tax assets consist of the following:

(In thousands)								
\$12.8 million								

[illegible]

[illegible]

[illegible]

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">37,367</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Operating lease liabilities</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">17,537</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">18,716</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Share-based compensation</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">33,773</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">37,727</p></td>

<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> </tr> <tr
style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td
style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-
left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">Tax credits</p></td> <td style="padding-top:0.01in;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.0097222222222222in;text-align:left;"><span style="white-
space:pre-wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">26,882</p></td>

<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-

right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">27,116</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">3,695</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">5,582</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-

[illegible]

[illegible]

[illegible]

[illegible]

align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(1,940</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(2,716</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total deferred tax liabilities</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(40,194</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span

[illegible]

#000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">195,341</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>8020900019565800071167000492060004118900037367000175370001871600, style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The activity in the valuation allowance associated with deferred taxes consists of the following:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:62.028%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.158000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.158000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.158000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">(In thousands)</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Balance at Beginning of Period(1)</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td></tr></table>

Align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">(Additions)/ Reductions(2)</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;">Balance at End of Period(1)</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Deferred tax asset valuation allowance for the year ended December 31, 2022</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(249,112</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-

[illegible]

[illegible]

129,296	49,569	79,727

(1)

[illegible]

[illegible]

New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">2022(1)</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Statutory tax rate</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">12.5</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">%</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Foreign rate differential(2)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">4,844</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">4,701</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(234 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">602 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Non-deductible lobbying expenses </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">767 </p></td> <td style="padding-top:0.01in;white-

[illegible]

[illegible]

[illegible]

right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(4,530</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td></tr><tr><td style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">R&D credit</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(7,815</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td></tr></table>

family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(2,823</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(2,531</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td></tr><tr><td style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Abandonment of NOLs(5)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td></tr></table>

[illegible]

wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other permanent items(6)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">4,000</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">1,539</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-

[illegible]

family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">	
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> color:#000000;font-kerning:none;min-width:fit-content;\$	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;(color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;97,638
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> color:#000000;font-kerning:none;min-width:fit-content;)	
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> color:#000000;font-kerning:none;min-width:fit-content;\$
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;2,024	
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> font-kerning:none;min-width:fit-content;	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;
height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;	padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> white-space:pre-wrap;font-kerning:none;min-width:fit-

[illegible]

[illegible]

(1)

Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

(2)

Represents income or losses of U.S. subsidiaries, subject to tax at a rate other than the Irish statutory rate.

(3)

Intercompany amounts include cross-territory eliminations, the pre-tax effect of which has been eliminated in arriving at the Company's consolidated income (loss) before taxes from continuing operations. In 2023, this included a tax benefit of \$15.7million related to the intercompany transfer of inventory that was owned by the Company at December 31, 2023.

(4)

Represents income or losses of Irish companies subject to tax at a rate other than the Irish statutory rate.

(5) Represents the tax effect of the abandonment of Irish NOLs following the sale of the Athlone Facility to Novo.

(6) Other permanent items include, but are not limited to, non-deductible meals and entertainment expenses and non-deductible compensation of senior officers of the Company. For the year ended December 31, 2024, permanent items also included amounts relating to the sale of the Athlone Facility.

0.1250-1250.1255546900052690000-
389100056070004177000434700048440004701000521000-49517000-
1424240001102000708000-16551000-169400057980002350004926000-667000-
23400060200076700070500077500028020003470001272000281000453000078150002-
9763800020240000.161-0.232-0.06515700000

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

	December 31, 2024	December 31, 2023	December 31, 2022	December 31, 2021
Unrecognized	\$0.1250 million	\$1250.1255 million	\$546.90 million	\$526.90 million

(In thousands)	Tax Benefits
Balance, December 31, 2021	Balance, December 31, 2021
8,372	8,372
Reductions based on the lapse of applicable statutes of limitations	Reductions based on the lapse of applicable statutes of limitations

right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(438 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">) </p></td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Additions based on tax positions related to prior periods </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">449 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Additions based on tax positions related to the current period </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">590 </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-

[illegible]

space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to the prior period	
space:pre-wrap;font-kerning:none;min-width:fit-content;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">281</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Additions based on tax positions related to the current period</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">558</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Balance, December 31, 2023</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;font-	

family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">8,739</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Reductions based on the lapse of applicable statutes of limitations</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(1,306</p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Additions based on tax positions related to the prior period</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-

content;">59</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Additions based on tax positions related to the current period</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">581</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Balance, December 31, 2024</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">8,073</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>8372000438000449000590000897300010730002810005580008739000130600<div style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">18. SEGMENT REPORTING</p><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Segment Information</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Following the adoption of ASU 2023-07, the Company is required to disclose significant segment expenses that are regularly provided to the CODM. The Company's CODM is periodically provided R&D expenses, selling and marketing expenses, and general and administrative expenses. Other external R&D expenses are composed of general research and development expenses and other external projects. Other internal R&D expenses include allocation expenses, travel expenses, and fees, taxes and dues.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's significant segment expenses are as follows:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.39%;box-sizing:content-box;"></td><td style="width:1.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.177000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.177000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.177000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;">Year Ended December 31,</p></td></tr></table></div></div>

	(In thousands)	2024	2023		2022

REVENUES:	
Total revenue	

wrap;font-kerning:none;min-width:fit-content;">	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> color:#000000;font-kerning:none;min-width:fit-content;">
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,557,632	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> font-kerning:none;min-width:fit-content;">
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> color:#000000;font-kerning:none;min-width:fit-content;">
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,663,405	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> font-kerning:none;min-width:fit-content;">
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"> white-space:pre-wrap;font-kerning:none;min-width:fit-content;">	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> color:#000000;font-kerning:none;min-width:fit-content;">
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"> color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,111,795	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"> font-kerning:none;min-width:fit-content;">

EXPENSES:	
Cost of goods manufactured	
and sold (exclusive of amortization of acquired intangible assets shown below)	

245,331	253,037
218,068	External R&D expenses:
2	

right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">
 </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:25pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Development programs:</p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"> </p></td> <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-

wrap;font-kerning:none;min-width:fit-content;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td colspan="2" style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">ALKS 2680</p></td><td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">45,947</p></td><td colspan="2" style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td></tr></table>	

align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">31,321</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:left;"><span style="white-space:pre-
wrap;font-kerning:none;min-width:fit-content;"> </p></td> <td
style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> <td style="padding-
top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-
right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;margin-
right:0.0097222222222222in;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;font-kerning:none;min-width:fit-content;">15,715</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-
bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-
kerning:none;min-width:fit-content;"> </p></td> </tr> <tr
style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td
style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-
left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">LYBALVI</p></td> <td style="padding-top:0.01in;white-space:pre-
wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;">
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.0097222222222222in;text-align:center;"><span
style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </p>
</td> <td style="padding-top:0.01in;white-space:nowrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-
align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;margin-right:0.0097222222222222in;text-align:right;"><span
style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-
content;">18,737</p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;text-indent:15pt;white-
space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">
<span style="white-space:pre-wrap;font-kerning:none;min-width:fit-
content;"> </p></td> <td style="padding-top:0.01in;white-
space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-

[illegible]

space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">51,668</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">57,423</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:50pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:50pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total external R&D expenses</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">101,311</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table>

[illegible]

[illegible]

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">128,282</p></td>
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">129,735</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Occupancy</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">11,206</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">12,299</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">12,449</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Depreciation</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">5,701</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-

space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">9,578</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">10,708</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Other internal R&D expenses</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">12,612</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New

[illegible]

[illegible]

[illegible]

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Selling and marketing expense</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">446,214</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-

content;"></p></td><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">490,154</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">392,211</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">General and administrative expense</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">199,024</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-

[illegible]

align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">645,238</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">689,751</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">590,751</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Other segment (expenses) income(1)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font

[illegible]

[illegible]

right:0.009722222222222222in;text-align:right;">(33,152</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">LOSS ON DISCONTINUED OPERATIONS, NET OF TAX</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(5,068</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(163,400</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-

[illegible]

355,757

(1)					

The Company's significant segment expenses are as follows:

Other segment (expenses) income during the years ended December 31, 2024, 2023 and 2022 includes "Amortization of acquired intangible assets", "Other income (loss), net" and "Income tax provision (benefit)".					

[illegible]

[illegible]

	Total revenue	\$1,557,632		\$1,663,405

[illegible]

Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">245,331</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">253,037</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-

content;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">218,068</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#c0c0c0;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">External R&D expenses:</p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;text-indent:25pt;vertical-align:bottom;padding-bottom:0in;padding-

[illegible]

45,947	31,321	15,715	LYBALVI

18,737	15,379	23,056	
Other external R&D expenses			

[illegible]

[illegible]

[illegible]

content;"></p></td>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >114,496<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >128,282<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><p="" ><span="" >129,735<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >occupancy<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>	<p ><p="" ><span="" >occupancy<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;" td><=""></p>

right:0.009722222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">11,206</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">12,299</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">12,449</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">Depreciation</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-

align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">5,701</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">9,578</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">10,708</p></td> <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr> <td style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">

content;">Other internal R&D expenses</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">12,612</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">22,279</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">23,616</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td colspan="6"></td></tr></table>

Total internal R&D expenses	
	144,015
	172,438
	176,508

R&D expenses	245,326
	270,806

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">272,702</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Selling, general and administrative expenses:</p><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr><td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td><td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr><td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;"> </p></td><td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td colspan="3"></td></tr></table>

Selling and marketing expense	
446,214	
490,154	
392,211	

General and administrative expense	199,024
	199,597

space:pre-wrap;font-kerning:none;min-width:fit-content;">198,540</p></td>	
<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	
<tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">	<td style="padding-top:0.01in;text-indent:50pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:50pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Total selling, general and administrative expense</p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">645,238</p></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">689,751</p></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"> </p></td>	<td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">590,751</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;">Other segment (expenses) income(1)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(49,599</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:center;"></p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">69,346</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-

[illegible]

top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">519,157</p></td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"> </p></td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(33,152</p></td>	padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">) </p></td>
height:10pt;background-color:#ffffff;word-break:break-word;"><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;">LOSS ON DISCONTINUED OPERATIONS, NET OF TAX</p></td>					
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"> </p></td>					
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>					
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;">(5,068</p></td>					
padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">) </p></td>					
padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;					

(	163,400
)	125,115
NET INCOME (LOSS)	
\$	

#000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">367,070</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">355,757</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:left;"> </p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0097222222222222in;text-align:right;">(158,267</p></td><td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr></table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"> </p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-

width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)<div style="width:100%;display:inline;">"Other segment (expenses) income" during the years ended December 31, 2024, 2023 and 2022 includes "Amortization of acquired intangible assets", "Other income (loss), net" and "Income tax provision (benefit)". </div>

</div>1557632000166340500011117950002453310002530370002180680004594700036934600063426000372138000519157000-33152000-5068000-163400000-

125115000367070000355757000-158267000<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">19.

COMMITMENTS AND CONTINGENT LIABILITIES</p><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-

style:italic;font-kerning:none;min-width:fit-content;">Litigation</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-

content;">From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If

the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company would accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on the Company's best estimates, utilizing all available

information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's

operating results. At December 31, 2024, there were no<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-

width:fit-content;"> potential material losses from claims, asserted or unasserted, or legal proceedings that the Company determined were probable of occurring.</p><p style="margin-left:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-

space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVEGA TRINZA ANDA Litigation</p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;font-kerning:none;min-width:fit-content;">In September 2020, Janssen Pharmaceutica, Janssen Pharmaceuticals, Inc., and Janssen Research & Development, LLC initiated a patent infringement lawsuit in the NJ District Court against Mylan Labs, Mylan, and Mylan Institutional LLC following the filing by Mylan

Labs of an ANDA seeking approval from the FDA to market a generic version of INVEGA TRINZA before the expiration of U.S. Patent No. 10,143,693 (the "'693 Patent"). Requested judicial remedies include recovery of litigation costs and injunctive relief. In May 2023, the NJ District Court issued an opinion in favor of the

Janssen entities on the issues of infringement and validity of the '693 Patent and the Mylan entities filed a notice of appeal of the decision. The Company is not a party to this proceeding.</p><p style="text-indent:3.333%;font-size:10pt;margin-

VUMERITY ANDA Litigation

In July 2023, Biogen Inc., Biogen Swiss Manufacturing GmbH and Alkermes Pharma Ireland Limited filed a patent infringement lawsuit in the DE District Court against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited (collectively, “Zydus”) following the filing by Zydus of an ANDA seeking approval from the FDA to engage in the commercial manufacture, use or sale of a generic version of VUMERITY (diroximel fumarate) delayed-release capsules for oral use, 231 mg, before expiration of the Company’s U.S. Patent Nos. 8,669,281; 9,090,558; and 10,080,733. The filing of the lawsuit triggered a stay of FDA approval of the ANDA for up to 30 months in accordance with the U.S. Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”). A bench trial is scheduled to begin on July 28, 2025.

Government Matters

The Company has received a subpoena and civil investigative demands from U.S. state and federal governmental authorities for documents related to VIVITROL. The Company is cooperating with the investigations.

Product Liability and Other Legal Proceedings

The Company is involved in litigation and other legal proceedings incidental to its normal business activities, including a product liability case alleging that the FDA-approved VIVITROL labeling was inadequate and that VIVITROL caused the individual to suffer from opioid overdose and death. The Company intends to vigorously defend itself in these matters.

In addition, in January 2023, Acorda filed a petition with the U.S. District Court for the Southern District of New York (the “NY Southern District Court”) asking the court to confirm in part and modify in part the final arbitral award rendered by an arbitration panel in October 2022 and, as part of the requested modification, seeking an additional approximately \$66.0 million in damages. In August 2023, the NY Southern District Court confirmed the final arbitral award and declined to modify the final award to increase the damages awarded thereunder. In September 2023, Acorda filed a notice of appeal of the NY Southern District Court decision to the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit Court”), and the Company filed a motion to transfer the appeal to the U.S. Court of Appeals for the

Second Circuit. In January 2024, the Federal Circuit Court denied without prejudice the Company's motion to transfer the appeal and instructed the parties to brief the jurisdictional question as part of the merits appeal. Briefing in the Federal Circuit Court is complete, and the matter is pending decision.

Guarantees

In connection with the Separation, the Company entered into the Assignment related to the 852 Winter Street Lease, which is described in more detail in Note 10, Leases in these "Notes to Consolidated Financial Statements" in this Annual Report. Although the Assignment transferred all of the rights, title and interest in, to and under the 852 Winter Street Lease to Mural US as of November 15, 2023, the Company ratified and reaffirmed for the remainder of the lease term its guarantor obligations under that certain Guaranty dated as of May 16, 2014 related to the 852 Winter Street Lease. Upon completion of the Separation, the Assignment was accounted for as a termination of the original lease and the Company de-recognized the right-of-use asset and lease liability related to the 852 Winter Street Lease. At December 31, 2024, the fair value of the guarantee was no material to the Company.

Purchase Commitments

The Company has open purchase orders for plant and equipment as part of its normal course of business. At December 31, 2024, the Company's open purchase orders were \$17.7 million for capital commitments.

0660000002014-05-16017700000

Adjustments include "Medicaid Rebates" and "Medicare Part D" accruals. "Discounts" include "Chargebacks" and "Product Discounts." At December 31, 2024 and 2023, the Company had \$22.7 million and \$33.9 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider. "Other segment (expenses) income" during the years ended December 31, 2024, 2023 and 2022 includes "Amortization of acquired intangible assets", "Other income (loss), net" and "Income tax provision (benefit)".

MOY07^'OM%D6VZU.;Y"M;59#JQ2W)D?;?@:W*^KOV_MB'G/H*:V-
VXTQX921'HGH00J'"*,Y'"@'\$!B-?0(2F(@(\$!*+TSI\$J74H(M/=(%0@!(B"121%
((B@104J\$D\$S^JWZX,^JOW?F?>?.WJK?=@S:J:SWZ>
M7UEH4W&;^6JH&1+4I<I0=O'S#[E4MN*?E=?UZIZDRPT5&_L?
CV4%R5J,X5R4L:2ADA%D6=Y'^HNOS6J6BA/M11+-'
:WFIX:#LMM"NJ2'@I+7_ORI4>ZN+*F1.D#T!KL6^NA9D&K\8DD_>OO M.P;?E3ZG1C?L
3LGJIT=-)VX,V5CTKKZ3/1#??348Z&\$"<0CT M,3^C#"YD-QCL#.2=JTVI/&A,3>JL?-
%LH9JD7I&^%S9H;OSK*H'IS5^J+
M+W>5U(B3#\$#W=>1*@;I".V1N9.YJD/R,;:6G>T89ZF' TW ^NI(*SQAW
M7&+H;G6\\$_LK&"E"R3J7%Q1 MC\Y MVF+TB5LRZJR.*E2W+U@=J9XK90Q
5JGS(GOZDBG,0)(RVL_*)F\$8&I<(U2B? M1W3,=#E!H4\$AWX\B:V9RI4S+F@P4V+/P8<
_KJ^>I=J2636TN."2'X*U@8HH MM*? BYXQR">+21^K!7 A.^=99+J0I,_K?B
OA4ITJ8P\NZ)MV1I/%_4H5.BX M7W@A>QX:"K#BJXS7"?
_('6;"+)/MEQ"@%SJV3\MFGHIF#/:X4:M=W(HR\A M2;>5GZ/3_0Q
O*A,>VLW@%U)K_V+/&+^/)1 '3:23LC7&ME6EH_Q=VQ0 KH MS_>O;
I_ \$5((GN=JQW)!B9F8XD881S)HVO@=)PH==ZTKE/((-V+9FI.P_9'
M\$DT4>JK,LA=0L:@B_2M,?#7.Y+WRPI2\Y\$GZ(ZFSLF:ASU2*V4'BBQIKR.R? M)/#Q=
(GYP>_A^\HTZ0Y=DHA4N/_Z:"(BG7YYX23DE_H+VW4D6X<"Z:'S7?/' MY-%>
I'G;N1%UCG9Q2DHCX2IY/0_6A_108^IY6_ZB#2FX7/8I0Z7\N'!#H31 M\<3DSL*
S\$F5I:#I;+6;),W+U4-S1>)H047YKW(OB*|M-Y-1LJ2V5F\$C.15_+P
I'C+UFYSE!WGF=@LT*I;,%CYQ##"ZX14TM7(M\$B M65Z6GXS4L,,S-
3I*^Q\^UD\5_0TZ,*SLF9-Y5"F7:ZE;)W/JI2E=8K&[MSJ
MYZLH_73*+O^3RH_T#8\$L/HEAJ2MSM\;R3KXY(\$IZQ:!(I-0M
MXGD(%|_U&K8C0%X?"%6Z928.R6?SY;).@M+NWGZXM5KPKI'30&W_(ZQ\#>9H
M1A\G\PI\$6JDW?9(LJG>TZLQ=R4'/K#V=!!<9?%|Y|Y^0L1ZS\B'I,D:DE, M.2^DZ#
L,BHM6%@APXGGN:/ONV8EJH-!L\GZE^-,TSC;MKEW^VP/2\TOM-
1MGJ4_*5@R%\KI,9/F:H1Y=LXGLFLS\A MJMX\ (R)R:K08.?214=
<.+1;IG.)#*U0_FD)F6(>0^:PM-AT*)!2J6I-::[Z1ZSJJ;
M7S,RH5YQXSTC%P\LDU!O5+H*BB?T\UW6!SH#;|PB=YG.9%"=BN_%%;>[6.\$
MZ>.1\$IK8M1+J4,8VW;1MC8S^?NB?V)S:F\VTY3/P:-KYT\RN:_3A<'YM
:H=H6+_CR*IF;Y,T2ZC;&@K4HR':QYH M\#2?/L.Q?
*U:\XI3K;ZL>GK>Y..GSG2#"55*D&_#JVS\$DF%JYGS%"K22JA+-:
M%PI_D0BQJ&=2@VA_7=J66IK(S[*,*2QJZYDJ5/1+W?5J\B\8MYP1/BK*%<2%>
M1:I\$C2+^\$#30\4Y#MEG6\I\$?(2^96XZNGPOYZ-B.*!46[E(SB"+1,^,^_9*?@
M+D^_E"1<+HWA)\7PNSPL21"W)B9(3XG\X04\A8+7F>/>RU8POP=OWHF\I\30#\&R
GTCWR46"J?R.T;B3LT7V^JHW78 MABR=HS;T<5GDY1W%I\.(APS 6XEE<;5NC+;#>1
9!\^B3ZMH@? 3O?#QAD5' MZA\$>#.RZA4-YA#.1P8>J.(NFJ5">E:~
@0XQ\LE#LO9;%/P:7&M\ _R@HG+=U M;-JGRG?J35P#.N;,Q-*1GLM403-V9
!B^;0PD5@W)>:BY"79)O67+Q G#EDG M9XZ_.6#AU^MDR(TAEHBO M+A !XIT7#
<^!4:=UL!X-UG\027@3-C6H6G74869\X,S;@!?!Y&^*A_=.)(7 M>F);?*W4A3(-ZUAPH+
<_0_7-1(=ND4 X%H((9):K7Q)BK)Y:61Q=1KF77," MO@(+S_Y89>%!CZ"/8LDF/G.E*VS-
R8O:W+!X;97FAS8T)XK@76,_E3;=QNR7 MT01,(YX0QBSG=;+W:6*,'+38?"TES+MJ|--
I43\$<6I M+X;-/7&KR@R, /+/:I\$M\ -LZDFA7BA*)*21"V;@A^*)O!8?
S@CJ:ZWV3>;Q.VP\I\$?1\$RLLUK!TCK M7C>5VKNM9K+&I3OK",U"RAU9S2(@)?RN2MI
(;>I6>D&P:5*^+5I'(#D1J2!W M0HDJ9LCE :_CB(D,<)JOMXBJI+/IG00?X.7P2S1#:K2?R-
S\AZZ M'W\='T'JG'2=A!+O5_=S?S/@7#8=W\ _I.KG%Z<+KVE (<9>JR+>)*XK;76(M\$-
C/Y-5U9.V\TV?-I78O9:D*"8YS\I/;=G;L^_H^GZ\$ CU_ ^M(S0X^S^0& M-=Z3?
TI@7\CX>B8>4I+?J-?\$H6)\7_YY<_CZX>*G'E(62-%\$[EL ^P4CV0?K M7-
41U_@N9!9.,>EY9_KD9#%Q1=V\DCWDL,BIS7*,XI+BSR=QVFK.9+RU!P27S:5[Z!
ISU)^TIT6<-^DC%/9M#I*=F%IHL'Z/\$6\$YH4C M@P\$PB!IZ1=[4(3=37)X@#70\=,^2OJ
B<+;/7:'NY\$1S# 'B-SB\0+|6N1%/%/
M*>UAFK591IV%"A2^7AC0<JXG*L#XSLXWV(:9M3TUV?U3GFE"0*K)!;?>@%J!
MGA>+7'6M5M\NH)V2.%67S-Y;=*T#2DAE1N@8JB\=GVW6\$)N0_RQJEIU3N+V
M\ _!J5\Z6K?#8=_7X0%#@#BXB< 1^4=>=#/7:N\5\HD%E/_0BWZ":JISQ&ZWQ MG-
2MHB\W^1=[V_457N?@?E6=4P:7B#2J9U?HBBXMBYE\U!0,X_*\$SI<7(W<1
M2%RH\$3ZG:;9W_K)F9=J3GY"3\RTW;^--ZL\2G).?F4?"UNQ%1JZD/I/L+"(("
(6,MDE@F#7I;JL%%VE2DPXV"!Z6?4ZRQK6AAQX
M6M5: ^>0&RDZG%QBF^P2;O'B1OK' +%W2I'+6O?I_ M5'8YV\>QE =3A1#I2A2

M_>#\$/H5U41/RO@\$W/TM3W2 BD-MKUNOZ!\$B"<\$_1+M&TBIJERN5,+)DE&?\$
M!42L(AVGW45M/'<7;1_0PI'=O@R AQ('7:)(2BV/PI/C#TKZ=?MVJGG MUA\OV4'*.
Y'70IV?*W7)SM!;5>9QW,G^Z%^V2XDK)W8BAJH^CBL&^'! T)WQ M%-
%::ZD^RBY/'3MA_D^9&/'P6;X2L-&(%<*@DCF)ZT^:+I-%-0M1J:89I: M%\$#2-
:Q:DA^^C-OA#-'70?1=:Y9\ISR-HJ?PGT_!%DB?^_ (. RA%N^_2\$:L=F
M3^Z;DF6550TU!#7C'A@/?1Y+?@Q+1;8'K ML;%-OL2I7D)GB;BLI^,>2"KB7IAI_)@_-
@U5+ZXY&5,N"?4,R.X5%P^1#\$N M3)G@GL\19_NVLF=Q?
M3^A_L&I#;PI2C0/=R\1/3"/OD\$W\JK4,R_!J#ZV38S7\KKY/I>Y\ S&S10(C/AH5!V_1AVM
M"H;ZQMCI"/O\7T?_IW'\$V\JKL+N#,N=FN\B>=:C\$&GK+^L'G&0*MXHT ZUG>
MUF=B7RY8W\A)NLI7@)**\$W_!8*;>,JX8\$/XBWC1\4*W/X2!VXY7(7=X&B &R%9??:?
@H_:K=M\(!&5C6Z22:<'>=?)D'Y\ (V4T2JU< MG>_?X8K\I>M:L)2FQ'C;B?
G+!JYRO7HD*!_CE:D"WFMDC"P^E'E^P W^)LK M8AF/>;-T^;28+K")9:4%?<
GX.57*:GHI+WUD<%\ MBFJE)?H@9&))U4\U8R0OE\X#<
<;4US8>W^Y^RX+10OU\P4Q,>XC*TW%MTX,MV
M\XW^;HLPG*Z81E1Q0,UKHROU>"SO8%\96Y;R7;%(?HADIP/)JL.Z%R(NG>+X M?UR4=,
(=SHM*Y#8KD=81;I7ZZ\<3\NNGRZG%'7+D=KTL%>I(E?8T#&\AV_?R'X9Q<:OMG\2
%+6A&*4JSG,4NXDV_+LBP0 MG)+M-ZTF;):9&\DG3GCZ><I- PHPLR=U:\$Y7!L"R-
'YHTZS7B<(-GRV.1TF8 M%82HP7L"JB9SVWWS;>&'70^,WL,,;K<\XG\<(R:P"%5^ M:-
Q1M_HPFMM\$'(.BR9 /+&\F+;#?..==_;%L_!#*XX?K3?D*%/_.^=YME\? M>
<*L6\I4H)XLJ_*"/@C\<(M?8T!9TO(<)-X\X-S&^EBB BYTWBR^4I3N"(V
MU6ZF!;\$%31PTF:D7>,*AU\&NS5 Y)RCW\!ATS8\SL)-C9_(+= '78YA\+I)
MCQQQQ'!&BX8T"QH>/I@V/H(RL-F;+.!!\$B_,2G*1L57Z_5R2)*J M%\7K4I^Y M*&V:/&\
I@M(ODYZ(/CW.=V1_F\SV_#%8_,_HPK'!%+K&E4E%HRIN^*AAQB
MKZRG%=O4K2WL;6174=I;L;CC#T-*RN8SZLLFWZ(6I"311\H5-\$@Q&L0\$U03I
MMRX)TM-F&B1=YK?I">=*;KRNJCI7\1H ^N"6>I
(E>AYJL&D)HOCL57Y09/V7WR1U?)=8+OAHDI MFJT-;FX:0G7RA1ZF<0M\
{DD0>Z;=NC_9S_Q_5_ZX>|*F"YT\I"#_2BM/"T# MDZDT\$P9@K225^BQU_C<I!7WX+P.
(U'N,@"Y"?1-!B">ASAZK\$@-8@#8VK(9 M (G-TWO@\$0RU GV1
1AO(Z;2M%9AM%3,_CZ=)HU92Z1?1E%(I-0^V#P7;261 MHD-2I_)%)IQ31/;>O8_IZ6U\1*
{YGA-T7O(GT@;+V4S>EWR;31>69Y&V1=RLN;_!6 MI7&I#X)?BA%^:EK@4;_!9=FJG%
C_0I379X_! ?O3'6#U?&0F'E\WW)4EP8U MF+
V^=!MND\$VW;100@TN^_Y%"&NE&X"Y=V75;HAM>;>L)6VA:>S2P1N MNOJR5=|0N_!1-
"D&+6.5*0BM-KW?D^N?IB_J N.)J\RI_*;%HSA\9\IOC M.H8Q8@&%2YY)B>*
(&"D.3_Y@YZI^!IN.GRS@AB65EA5ZQB'#/+0;M(>GQ>#G M9U,'4=QQ\$"!IG
%H&HWM<%VI?7\TI^Q^B8%R-5JMS3W\$#K2DA/ZV*EKTJ=8
M&;NA2H==JJ&!UF%%!;Y^;D\$^8#R(0\^MO!#
(("^0W#G:T)JR+!N+NDR42NOP16T6:6=LABU M!1;CYQ,#/F4?
Q\>F\ID^6MV'=CBKDT5\ (980\OI!UNO9@^0H5_V29\$ 8=IYS
M2Q'1UYN1)W9];+^VB+XW3C@HR+@_7PE8F_"^W#6\HX?={T4052%*M#;Q4IL
MB%O\UJ'HE^5NX=DAZ9<JWFO6@Q>*S3\14W@A59!-ZN_6\$+4>
I_5P0JQ;L*9G_G53;+U)W%!:M%V<@R8X%FB6+!+
Q_7\VOW\$MPA0Z&@VALX^%*O_!+JYL2YW\$48R48M5<.4I-
MHOXT>MBFWSIGK'4P=:_IZI"=I\JX9A8X*+W"9@-8-!/.0Q_,K*W;%J_OK,< M?
GX\2_/ZOPCK*Q%><&*HE@%+;>|OTO#|=IFGF;B'2%AU=Y<<#:BMAOTPLZ^I
M\ "S0+7=^U.:VS,,=,AS@W@== 'PSQ>;KR8U:<&W6@I P6%\T5_S!,US_2B
MEKQ>%PNX3"0IJY;R5SJOM+DP9\TZ>1\2XURTB(>DU\$N9Y6?K;W!U6!O^74
M29H_0@)D@A)RRA\7;&K.0Z7,7#R&MPS3?UD^,E_M=DS/?8KF+5+Q!ZQ;VGC/C+A?
\$)'TOGC@ (3W\^G\!ATFE0\ MY8,T331\JLYL.N&W8K'SN#\G\4^I P7?
_NM*=U8KF/RZZ\JA(%\RG8>P8<5 MKLT^!AUP3Y!==G\1)\N=^;E/W7<+2-
@KV:H_K="+?/Y.+F>4;/I=K#GBLLLO MKT7"8DR64?
31E%1*+3=%+0TK.U\%G3=M%OE\?5NR\4?:XR1MKT1J.9;3I1-O MEF47DVX-
4BW(+ZRRKJ*8C'1;-DR;ED\KM'PWF)+&X(NHNBM>BJ8 MC.M5SU7J7TYR3FBUBFX<I
<81C@#X(H=MX8IFA\$|2+B\$ 3":\3_*\|@DDC%\9 MN..KI^?6TB4SL\|-9@%W2LS
/^6.X/FMR>.R/\$I^@20&AHNA?QM"OO6Q1O& M\Q';N\3VC<^!F))>(CR,7>_8=FBT\
QO7.Z<.\$194;-^F^!\&3/Z+5JHU^: M0_-66:*UEI?',@4SD5\$@YV,7.C@JU!46X?
I6;=\$\9Y7Z2.W94HMEXF<"N>VY M\$@^?;:&-&2);QK+?O;IR-^Z6P93\GB_8#
MP4VQ=" P?IDV!=TJHG'RZ9Q6@3V6XX\1_:D)V"9_"ER!=V32\$';49\$VU&6*
MJN8CRF\O@(*WTE: L9&1=XB=L1U.FWMBU\ M#A^BM3=^97W\B\$9&X

MXZ+X9T\.\$:/_9><@@GMRL'SNB\A_1?_*(ORB/Z"R7>B-*7T6&7 G%9JPIT64
M>T*_LQ2S:@:*7R=GIE8V0&:ZDIT%EUI>;DE\$"OP(Y<*"U+D&^4WN;8*:/3 MLT+-
%;LG\$FM3OE(FT8;^Z,C/A&*K3BC_(,KDX>-BYG<)>4Y5#QPXE"71M!F"E M'-PTNBVV
EZ()+5&T=A.[H<^)]M'!R3K=,N44=U[D#RT,U1A7X<'D4>[[@XX, MT!
[SVIWN:;!N%X8/IZ>V>!:;M_)#^U%:/[6E\LY74=15A_(!:UYL3R[;:UL4B-MB4L4#I+.:?
2#RXA6M6,S/_ZF1J<-+1]*.P07\G7 LQG4GE MZVESYW&;DP3?PZV%WHA4)U4MO2
;+:9STP<TT0&2OK>H50L[R\$H6-M;DS@0WKW_YHH>/O?14\$FF%B2S<Z/U,_)W,Y%
[VMC)R1-R"?8U_#?[@,F M-(!1H^UBN9U&_#VU-Y=NJ?T?|TS^_1\$/;POS!E,U\$4TTA.
[1,XN/3]3S0,A M# !\$ARXKTXWA>3=7E^*% 09-T|_9+O '"F\U M_*!5>5.3H6U?
=G5=6^_O\2RTP7V\4@)B.#1O_1#Y1)ZJU\|C,=_J#JUC5-MX?[P<5T/-
MB%D1Z8,WP,16KJZ^0?*\$*@Z/NJVX@62/'\GU+SWR>:/MFB/>YJV
M.*M^U_%\GW#W@W>#,HZW\HX@.VX)!"D*YBJJ\3ZE %7\IZ6D43*P^JUXDM MJ-
WNDD%PWC/[^9EB()8QCROMV;-3PXE ;R7'B?WO_C133:=>_1P\DS|P
%I/^"@TBRA93AP(((<[8P,AX M2OY\|L1QS_&\$Q_.:706WK*6U)>N?*\$?KOTZE|NT"J2_^2@-
OC(01>'),UQ#\$J M?U6+,T9.[JN3<1U\Q9\5A(ZME99Y8.F|EPER%%63.75GUYU*0,
[2!:EM9]B7 M&&SY:/-QTCV7#S;@#!.J9+Y'8@D5VFJ_=-!-P\$U2E6(AIJGG6YJ0)/NDW@P%
MW7A7M9\$/W8FJ%<@\$P_^KY=8|+UTB;\$. 0+F&A77)Y@AJ\X3*E..L21!X<4\$ MB-
^9MXHNMK;WS.U"^8H9N-VR7C|LY3_7)JF(VQ<+_ *A?-VLTA:EI0H?J?5L
MC):UJ'Q@*6M9:69X"VW"86*>_V/*Z3):QJ LW?NF5CA,@31|>/3BQ"=:D%I%T1
M#O@P7(O*W(-E2#<31K'FWWYC/8"C.7G MX;5!WBB;Z4*3;G17|&>
[05YH\|C_9_7(G41>V1Q7A4*>I0QE2&U*^6SVY-MA|_)=9C(5ST9=AS1<-K|K'&6DC<(-D-
I34K,U,8',P>[O'Q'TQ-T4M0+V MOG:>E.(+|;Q|PI@^QDU!\6':K7R#NL|KPJT5VN>?
C3:=#7ZY"&AP_?)6G8 M&S|/"Y/E3B,V&U1K.*^UL=*7+;|,^>O.\$Y_Q"K9(1LN;J-
C\$V#EJ&/+([O#4FQ4;:D\TX"8S-MHM3H\3 MA\|*JL|G1VW#A>@2\$:3E-BHK_KH?
%.U!T5L"(S.1*@\$X;OSUT9;SWG>3TX^
M56<6KEJK_5)DOUJJPJ6\$N4\$2_FJ%Y=6D>Q3:+-DPPPO|P+9)K16(-PBJMBL MX*%!?
|&#-P-#KJCT)(X2D RUU@56#FWJ>[H_ GMYZPS|C_ILV!Y#E@|1|3\$>X:8:S^DL|
IUU>T|T#>I0OY*|&-9H|D 4PBJD)RQE:^OIU92W(GNO5|"IO\$1|MOEP==P<0B M@;
[2(608*:KW2BU-Z2N+ #KC(>:5V=)JDQCGPG)Z|;J7;|X,8D| ME.S_G_6_QO|LE"
<#IUCPZ#EGJU&R)#RT*W@?&Z9FIV+!GRDCVWS+ MO/JJ99D4_1#2HS,O2^7:_I
0MW2)!AW44B75=HMM1&|KHV M\$)%YUB.FW?'846IK3V";BA"D>" EWLQ-=LV|0%%--
OSHFS?MD>%%O+ #&|5_M:162|QF, @=|+|1|?
CK\OU78<78/MH0.)V(O.R%:)4F/TIE,RF|+99-4MJR8 M1*|V2Z^EF990
XME4.S3'N%1X|:Z9\$,0%#?V)H7KX+|14)./%;FNR23 GE M*?
+EN^:R,='|Y#;H*CSJZXMC:|!"D\$GZ|PT_#W"E6D_5+Z"^+N4=Q
MH09U5*/^1D_'&^27;1A\$K'WN|@\$+(8P|,53!^T)0HY%K*<+(4%WY"|4G:20E
M'GIBJ"D!=GF:Q&H2EN7^35@1?#2/SY\$?C?(XVNA/%' K+'1V*O.I+.)88F
MVYK4J23:^MO!+FF_XF1@\$*F*Z%*5|T6U=^15!;#
[RI@N:CZ\60=!/FF'.=VU)/DUHA|_0I3K)J#EL'^ ML-4Z"%:YV2XRFD=_6TJ%F-Y0_B&
O/A?|C<|1.60+EH<9WST'X<7%|^8EL M^7@N.Z8W^!5* QQER<|XQB
MD"+N|FSFT8UU_-J>J02,X|T\$GM_|2^=R;LD"5:'9^(W'0Q?5\$9:QXWU?D*Q
M/I(=AQMFU/ZGY/Y|,2-=D&2(ST6:,1FY54SNV21))7>|(F'CPT&3D-Y4K@T8
M:\B.B.'=#&C|F@H==PC5/R@1_W5Q?K%R-,586,H:CQ=[7R-#.0SLNW0HDG
M.>5_L/Q=*7.QD<%7805N-(,M^;&1P.N'X4;ST?TF_9.^&F>XE^)HCX"GVV
MZ&@MWV|QE))7/.Z^WK1P|8'VI3#IAE\$11/KM+R|,KHSL>6HFAO/WAIN% YG
M|N),R)*,X6.)?(R|/V)=XVK8|&F:Z)OZH<>Y2M,Q-ZIKNJ2#|H|R1@W)_I^/
MQ)!Q("5IY9H9S'M(K6|QB-W*37,O|SS6!MSIE(H/#MY5?"0S(P/CO#CE*+@ M"^HOU6?
2=?SA_JSFw?(O^E/ <47_+>E7R>Z_N13A|/<;0IM>C7=C" 2>=">R
M&MR%_+'FG|U1CEA\$M%D>KIF_7|F^ULCJ<&R;AG=[2V"/?>'@)4/3J ES|P|
M1+&)%IO|>9L|D:4W_|1K0FTE4;&JHSQ:*ZBEGC-P=3_7&-BBV%4L:.^W40P
M;^CM\$UW|4 MJ,86+;|L^8D|+|+K\$R>J1E%*0DW9319_4
MRK:WX|:"H,1'+P_!)VO|@Z>0^&5=[>ODH8C&YZIXBJ-QKM.+G-6QRHB>)_5-M?
CR%+CE/HKYI6-1|UZ@*5/:K500F7,KNF.X"|X#+H:S4-OR<^E^NBP%J_P=
M:X5PLT*G9/SJ_7F*%YKI4318?XIND/G/3IY?S>J1<5VN [9 M(|BP|1?|RP41L*/!VSKA9G,
|ADERG\$W3S>!:QM01#*RVWU^8UG(+2Y|B(UO MC|@>*7*Q1^)
+^&Y:URU1@J#OLR=K+)|+E(QO0E|D'DBO=J>E^|*1(_+;=;P MNSPQW4|N(?
(=0BQ<3^_WT5PRR6X..D+OS/I=_#1HMD-[H7GRZ =U7@5N2NQQ
M_2#1<_PU>NQ,D&|K'|YUA*L+O7/QU72SRR8HV\2XIO0\1J4X_8WSM1PE|@&

MLA'3F\KQ*X2H!T*5U\^V4<*'N1U/@S354T\$V&&#T,390Q\UQWXF!R.*N-U3 MR#^!/?6
TUU>8N*)'B<+X^!KSS\$G#@PW*1U?.\$='V, >)N0B>VI6_\$GMNCH
M&J3OY503H\$ "H*C6' (TU(J.W+ZYXF1V&9&'0'NDLD"V?.\$'03'9VN RYKL#+
MFT4'7K=QK)CH1\$@6E3O9;2;"KC2"\$MF2:V/P5GW\$O: ^LOQ_AQ(<107%4B'!:*
MJ6\$9'#JR1_L4IV+KOG!#DNJ/KE:IBXZ(+1\$)<|H\$H8HG'C-JYM2KW!2T#%>
MZER*DF)Q1+?;GVA0J1R1-2! Y:L3SXNZ=")S#V-V@VYC8HZ% Q*""MOOQ
MUUO|>UMA4".F-|/* C\$W8JZB*7_IDF=L3=TW^'ED\A'>RPZ0+D6^CX)H;=C3>(U7#(E
M&;R>;L*STT8!9),UY#^*7'T+JAWYX&VWW^G;BM
M;_%AO..BCX_2WBKLUW:8BVOEG".\;..@KACMR=O*JW|(-T-QF(/9./0>'ED% M9;5>\$>>
|TWK+0%R=H|<>Q9BKX\7-FRI%Q)MT9O43X:5P?;!%0C8U=M|\$.?+DC
M7*G#DIQNEK&J\H3 N!K-27?O@#_I5HOGV59?^&_5W)CBL"#R3*KUWP^
MQ7&SP;;;GAEV-=0YN,4!S/PQDGLUY^F^+)&JUQF,EG>\$F!PHYZB#BE0W5Q4A
M7!'1AV5M^P\$TF)=27C1Z@---PZ_N3QVP|=F/JPDIP/1F O*&"NY:3@0Z MW%F3&
IYK/JG&HBGVZ<.40))8S;.@WHO'G?=SYO2\$N(&I-1)*+2 @H'+#9\$I^
ZT_1;5K8F7"G^"7(2K%!.6)\D^2&RCJU^9 MY!4@=/M4D)/:Z<1@ECH(LC=6;:?
OV\$C)LYJX&%J8Y+29:/U&SZO5A22Z/Z M9?
T+!961OPBZH1)G6:E_ ^J\$)L\U(OJ6F+>9=UE;EJK\C"9\?^|M:U)_1HB M0V=:&L
48D8^3 MO./=8W/HC;/9X;4&+4CTSWPF5:@AUBE'WF:%.35QO2: ^_8Z>>&.\$EJMI;K
MKB1&N8)*HYW"!W9B1H!?(OC8I6I-TTP\44;:342G?-.;:8WU.557O
MGKD)^LP|U5MX.6U43*'\$\$_:0*3"!4+X3|5!) "KY?*8|/; \$!^SPOWXY:0%.B M/J5F-
R>>JHWIOIN+8U?8@:D4V/_|5>|F?VH_-SPY)?@WL;\$N'M;XHS<'V\$&
M(*7/J|#PO1E4B^N*)@^U^:F<<_L\$&?J:DD%8A2?OCR+3Q.!0Q3QD6K_JKL
M%4R'00\$P3_X5:90?;LARW<7O:DFH??@?|@Z/1WNB?:!K|_11AE-7(-
|Z8F|&LM_@=U9:HR;:#J<0_4;|. #@.3\$.P70^|^ M1:291(>+X?
U7|26R+-0#B,4|O)UHNRL4EPN*6QT:VO@KY)ZQ/H",M*9^6/ M|DI?@:E((1#\1#?4X2P
\$. B7CV.YEUC4&'@|4P@X)3O483&5A/X*OSAG|Y\$F\$TL0'|=6V^CAI>)
|TXOT^|H|)F56_R@ZO,10RI;:O*BL&PG
M7ZKP5&CXMC<.,1\$|P5XVAFWX1YY8<,P% _\GA@OIL&;4&U;Q:_ M9E-
XF^N=&_BH^ ^|&X+)=6"|.2X'\$MG_JMG*|6:Q0R?LOM 0'T*XC9PR1J
MYPHR\$L: ^O9+=VW5GNB\)"DV|'+ M|*@YPEO?D<);+2,V^XAI&|'UCCV/6N\$ M?
<>YS=@ZH XK_ =U= 4Y7:>Q4S17LW D!_*;K:JAV2ULK&?UZWWJ_0-MH_4:>
MV53=T)7IRX.T^410G;PP-1KF|#E|2K'_H9R<'\$1R!O@UE2K. MM&7% #3N|LAHWZ\$R
:YHT0&H+ _SQB!"|510OMLGE)W\941-A.F?9*+;LV!
MD@""\$W&4>Q|RBDN76Y1C/%"\$SW V|':5\$;:;(.@SYZYI%P')D|WV(C*6!(4 MV?
NL2JK&*G|J:|+Y*PF4N80,6&-US.>^J:\$7#4U3DJ-F|UC-+Z),A:*(G|ZC)3BX.+3SEIA1Q<)
(|5A^,!D M_M.&+;;0>_ (F-E:6S/2;R)7JHKU_V>>|!|'OQB :.=,50_IB-37Y+)_KD(-
M@SV0)U<03&?DH?|&;O|X*@.P,\$&\$G%R_#3SU^/B\$#/: TG)VN, "D)G) &PJ M|>%_)G-
#QV\$-/I^5J|I>1;"S|I%5",PX1(#\$+7GP|'" %R!'/+1Q)?G8.14 MJDZOJ-
SWT|C31@(#T|J&.6'9XJ?/-IZ Y|NF=O#C:"=M4P M!:-4D.4MCJ7^\$/+ZE.
|O|O541*YFF*8,\$\$71^7V%(S=\$.Q8:UG?D=&Y0/-Z/T-7O=_%40.)W0U9;WLZWPO-
3@A|+Y&."F399|BKB,Z&K/J%:AT5G M@5@|@=JN5ZL80PV\VM9J^6Z,CC1!|HP-
>.ST*R<"8E+S E'%|FLXF P#U M80#>G9\$G7C?|K.>R60&>|A7H;:*(GX^G/A?^S&7J?
MCP. MFV#Z'T8"*>R84P1_9J8P|>.,@!_WH!|
=!5Z;GR7F: ^6DSZ!+S|7: ^KE:S|S?|/V|!F19|>E\$BMA|Z M1C4&|XXU9,*9,-_T?
&LN_EDFP6\$VV<"G2U8M|KCE7 M>6L%K3OP|GD0W^C2Q2>FWK)CUQ:|J>I?
JPFW#N1&"BXF|)JA8PX//,8#+6VG MBL'1OM6:6E
MGG<\$^U.1KU">|Y;:=2C41JWU*%62EI%MU&1ZX!4HH
B_OS,QKD_Y92I^8X^7ZLBLR>!8|DH5OQNQ|&|=-A2RXIC>|9JV3?|R_IR%X!|L:!
M*X>R4^|3;-=\$M&>.B.HX|_7\$|G|1)W@)F12#95@N3G ERSRR="+R;
MUZE;WP8MS1=^I%ZV'I3#5-%O^D_LS;"F0|\$|8H"%:KFO<3RLO**HFWFM\$/ MFC1+
Q5M,U9%G|Z_:#|3RR5)GX#1PR|HE^!O*C96&N5Y^8"15<25#2>_#+\$X MW)1?
FEEB@>R_V?)IGH>>O|L_NK=|U@1|\$HSK\$G^K(ZOKB? Z!">_2Q'F=/W MS0,T-?
E_NTJ|_EQH|S)8&O*XDSVC!GN7%=Q8# !2,53*_#\$Z%(U893';RPL MUU2H UP?2#-B
+K-&0 /Z|,&7F#|S|KJ;BP AE @>J02^2%32_1_?|: @/|D|H MG-
Y6,K5*2O('O'F_0_JEB;8)-82XU11(5?6|N-|*U5Z^K\$LF>EXE|@%3>HS M/E
MEA3>4F|TW|WE0Z68@*@NRM5./^ZG-A|MKJ=;_*+6M|GH?VD6VTOV?G>N51/
MXIY|T/"D?G63K&Z6U^9C,0RD|&RH%E1.G)%|7F.3|_ =4ROF_7O>|O=OBM*Y|C2
MQ#1?O #%FSN>X^S|+4E4BB.J:|PRML_):QKG|'M00K"*N1%M8%:K5R.>46R6

M^7"0*]@WQ1>77K|^XQ=9.EG7A|VZ-Q!-:YU-/GCLZ=V*3B*\$U|CHOV#J:-M%/-
K=\$(1;=/>YQ+05!WL34*/PPZX4.|V#CBZ@20=N7
ME@'@9TJQ>Y|JU5XKHPDCX1P(##SDP0@GZ,-)KI9+WBGUEO^4B;I%81MM,+S
M2!1>3UXLO)ZB>FY"!|:@AOP7:%CWEST'L0N>U&-Z&SFQYVZ?W|1/|5.I2Z
ML^XREZ6E@FX_A/;+^AJ8H#(&5O;7OF14AQ:SRD%WA))8GW#K9Y5(,7?5R:
MXV|XX+GRP0(^|47YN4+;'D2J\$'A>MC\$#!1/((GFV883I\$NP>>P;*R4)TN=IMR|I*\$AB
XDBZT^BO1#K;*0/PMNCP/0/P@;TG|50#<8Q%;=JD"O+RW|\$&!/M|A,39H!F(Q-
K3YVQ%FUUT8"E2TAGKXEG/.KFTHIWLL4|T4_QK!F#K9B+R MH&&T)T\$:-/F|O_-/
/|+DI<9@6I4="\$H%0Z%|6+0RDV_#K5W);<@KJQ,+>X
M^\$VQVE6ALZ6Q'\$7CLZKWTN(AV6UJ22S^~W!&L#;Z<_~^6VMR-HW6\$;92=(VF
M2AE-"A=|M;S<5>)&'J'LKP!|MO;7>0
M|:\$/R&PQ1;5?)HGI"GFK|7M;RXM&&;|8;\$LOXD0CISE3Y_S\$UA M|!_#^%SR?7#D40O|
|JE(Q8C+U>|SPT|!9QCS14_F8_IAB7GMG\$07";!ER M""W ?AY-'N%@VTL7O|
-/C|>^ZHA)|BP2'P07) &|H*H)|-!WIE%9WAPLW"TE/4O/JA2
M010Q&"J@MC|D%H",+|TW>S|.G\$|=PT5|Q"BO."H21FX-PFC2ODM^;X8_|"N
MBL4=HQ_6U9&UTN4S0*"I%CW.G)#<;^WC9VI^|B2KG|.H|\$>?B<0^E12|C,MTD).('\$I
\$G5I=^H.D+G\$;^B&2UTNQ5#WH9|NRQ|;H"4;^UE9)2A)+H+J.
M@_11LOC5IN<,@,L%5STM"V6|6DBR!EA|?X#G29=DK8'5>8ZAJ0'H\$ M<*S07ATYKL-
'4>;X--)'7F807J"L;J.50N3AG8/XB&;4ED%;Y?J=BT'3XM MS"R#|ZJ'E%=7>?
(IVWR#MWM'=V0'S1|-|K\$+|;|?%EOY.?O?|OLL8|0T,TJ
M.8X0K!1V|;ZHR2B4^S1=#7+^5VZ259ED4|)8.Y?(|. &'5*|^Y|7ZC?.3=RZL#-29A MN01?
T6FY&D5!_Y|X%|>:!=3K;AV.Y)H2E)+K@|Z_%H^2I<8I1!&6#Y/T1=R M2P9)77U*
|U@S# MRXW.&QW&4NLI=6MW\$U_Y""/JUG|B#J%9AS.M|T&137FOPLYW;
|F5LF4Z3=M66W4WW:OSRUGQC5EN%^~M\$5U>#ZS<.|WOO#F\$#*F|T6S0&?
3V\$+)UY>0N=0ONB46H\$M4G^,GL\$GOCM'YR MN+A/Z|>/C1|<'#0&-
/W&,OFVUT4R0%N&=|Z4HK-N7QLP,PUS<3RYX,GYTE M+!-
R);JHL3>?!=A_NUX5:STB28R-VW&)&#!3H0*KLL5V8|V|(1_S2
MSI(2)V+MG@YD>O|D.|Z!|E?)DEY*FK|8*1&S%|0>B%_>1"98)Z5>@9"LK5SJ8YL31-
T|;|\$!"|LFV|L'>=S.S>4KI&EW" MWZ5P<5V|V6OHMUHKG)(O%4NHN?
O2T\$+VR6KI^Y!#C1DWZN^ECHEQP#(X6 M80#F=+(8@(T6|H|VV<&*0V'0YY(-
J:>VIHRT|^=H?KN'QXP?/F\$/YR' 5AO MQ5O21J|!.;@S"@AOU2>F# WW|D#-
@W*6%F>W* N|Y44?I6/(HO=E&AAH| MUDHW4W^#W>(|P_G44ZE,JJUL6! M'-
@//P6C/^A9)G GZFH)_>%|;XL'S5|E>2|^D>=\$#)8%\$^XZ3WM*%:-B!@|
M<(|T^2502)LC?"P0?&A?+5>6E|&/=1S>F2I\$E1>!K^:5D2GV|Z M5-
U+>9YXF3Y'\$=D_.KHS@-ELWXFO0)RG#9 7!")J8T<17AS)/:X?%V<%<+|
MYG%X9U|J^1=9QF9JCOHTB.'->-L<^KFKV=I'H>,B()SO\$SM)KGV08>Z8.
|4!6G|>XE>TU^Q#|L\$*YJW_N,"6^D-|DR28H"Z2H*WZFO+2,|3\$C
MVM^!1J#BOOI+I;LTT!2!(C&#Y&|= (P**7KG\$#PCYI^1=-N@*EM,3*|RE2!|8 M_C"
|E4SA(^!QX.BBBUB/,*F5V4@0^..2?)6J>#65Z+6N)=XQVEXADM9|_-49U
MN3_9P4|1)RJ49|VK1^TGZ|A.;S?7|Q.!|U'(V_1TCHX ^"&|/9_#O(K|RIJ M4&P^T=8-
#CZOLZ8H!;XD(-/K0.;587G8.%2LY"2;!Q^%%"0%ZZESM3Q-M0G>XR>S+S/7=-
KFOB/^#MO>.:JK|VD5C12FBTFM4E%Y\$>LU/\$1_0D-Z)|@-2(
M@(|&"\$3I:|4I45\$"#TH55H\$ J@TZ4U*0F^2"(0MI)SXW7/N..-^|HECW#_N
M'V0P,M;*WGNM.9_Y/-.O-51%('SN>R@;&VR0;V;3|K VQ&N3U|% M!|8SHS7X'N(-?
CDOA/ D9R|2&F@5VWL,T#E@WIA\$QRO IQB@!|=&LRFE@1!|@ M6? W?
9_H,+Z/XM=T1EVDNI+ #/K"83E#M/K@4-/YX5.?F?^LWL==V6%N\$M\$G)
M'=\$I2G7_4M^X,9=%K8%(\$"(Z.46O4!U%3N5A.F>:A
D9+*R\$Q|X9G=)|HAYXQ2!*7WZ'BY;C^65'(AYK,T"*1"J2YSY" MO#>?
=G9LCA*U8L8+X|TIG5@10L8VYFO@@+R7=P=&: MI(^>""7M;PS0Q:<6^LAR0V @?
(49IT|AEY;Y)G^Q|H*(T>?=FG.4S|K>;| M|XGS)<,1%KKY(Z8R=S<39;HQ@I.RN;.&
\$G24I%3_-\$,T&'&PM|FH+\$OI? M5<<0KXX"Z=|U6;8C29QX'N;I?;HI PD\$-
Q@<|^!P!/@?LFM8WHNZ&KE<0
MFW*.6|P;&IM(%#!;4.J)QO"86QS|>GF4'&|)ZW9;+|0)Y1%!|BV#EE MR/M|?
A#4@|Q)CFWU?4>.016885G'QHNV&%EFV3MBF=M>DD2C6.=Q(OF|4*
M=%2JFT%6E8CFYV#YG&3>5H("UWI6B\$0|QJ'2+U^?\$"X9"|+-DEZT/X(NB7;QJ18F?A
(JRD|727ERZS@!UB+SP_8#_!UYHBUQ9P*D\$|H++2,C6+U.%22OM8863TEY"IO?
QY|GH|)+E.NT|URK6.U0^8G4=P)/=2E|L,HINZ1HD_:.O9T!(&I M@T@NA!\$;|XVDI#|:?
A4PA\$XPQ4H&IGVBB8-XY&|BD76W8:2V58;0\$Q?@7W=Z

M3(4!NM#_1/7U8JB_DNFGFA\M?&+Z5-S>5U*RMX,J\$'XKD:4_9RF1,RM(3EA%MRKC>
(VT"RZY\0GA\Q,SFHx,M4R/N7RW\70%\RT\|V.G\4\|#8\ (ERU_)@
M4/@%,J\6VE4B2T(_W+)-^E,R.U:GTVTUON_3LFWYOT6+I!=\BQA8
MY%*!\@7W%2NWR/H;*XT091\$Y!%RQ(N(@ZA4\4;Z#W-):.SWHKT-K/8A":'&T M!,(;B"?Y;
(^+>9>NG_@#8%&LVUHAOT@BU?Z5TUVe4T!4,>/D&Z=,*LC'_KP MX>"VQ\%M^
YQ>R_K-3QD@|P"(:T:M\I=RNJLE?@&(5?<^V Z\$|N14A3* M/B%ZA2S7FE*@FTV7FU
Y:M76AP5S*U(KH9\H8&VI H(YZ'Z>K:BLVF^04I M%W^BA\$I*N6F+KH. WQ@|FM-
JXW5">ND@+WFERR4^&EP!>17Z82)I\$"2",^Y2\$ MY5|T1C6&V/PVX^QT*0N0+
|*1M0V0\&FKR2>6TIY9\28|PJE+93MMG!\|7\9 MXA;2H1\J2HLW06+|Z)K2\|
A\3^>|!"6?%4S,T\JD/\$1RR_L##PA"%4N5E;2 M\$CYAXQ
>#^6"G0*VA\$S,,3DZ!,-22K=O1I*@\|,34\I%V"#(YS'YDP:R%CDP+,
<50KR%O=F\$S"7EU.7<+&O%\4|E""*7A?(_ M/"BLGQD@*1"M@*EDKRV:3:B)
|;WW%Q\X#T M*O7#"4HL4R-GO43N6\,OXFK"(W&_GS:FT;^R|S!
CO+|D\$CDOR2EPQ.0\1*0 MY4OHF@E,,,*"?0WR<=QFIM;T\$FV1B3\|%NKW9:P M\,C,G-
#R6:2BCZ3=KCG1:D7?Z:*=<|Y054P=N_G.XUL\|V\ M"HJD13P|E@,-KEG\$1!+(-G+B@JF;
|H'P5ML\5 %,9UN:R.6I;:M(6.7C3,D M#:Q*+8.BK-*8RDB^Y5K/PB9U3\6J\$ M8291T;
|%)N13LB8_0H4U6,:VTM(B6C,P??4:2SWR^5.|90Q5UYS"SE37R40<M535?
E0%:U@>3_D FE>@):@D,\$&D:/L, 9?#0F1B"YR4_IR>CA1D@HF(. |1| MF?
X+B0\|E&=)3)F*10-8#)'5F\0_%>|. %YP^3UW"FT2(A:X5P)A/EP"3C_E@8
M_MNER*=:7)@:S|L'_B1Y,4#4KV"R*)4)W85UA'GZM2DP_Z3ZAQ|V|C+FL(4 M_Z\$P*0;
(@T/9 I(V0>0YMJ\$GX6QN\8OVCS>K#9*_S&|HG?V;+|;B=35
MG8%P0;@8LBM+N96.+ =MXVC9C8C&V'R"G#XW#+B\$N52|L""X)0(0##|B|\$29I
M8\>MV!C:|A5@QV(BC48EGC\X"E-, \$+/F5DW350+U|ZFV@7+U1+%XD:\$7% MO\$^H?<
|143+GZ'L85M1/H\Z>&U55>^9!+|(?1\$L?=?U\?_N)%*5S|^X)_V
MDY*_^V4^!|5J@9#CJJ-6Z=E)|CGI.497,V;|UU(=Z_>8|L2^+*7"
MWRWUV=ATRD#*|7|&Z&K57!Q\G,D14Y^80JA<|Q3\$B^54;WNZ9=6-EGLC#|=
MF6K0T!"GE'H|T*F+^WSWNQ3\,6>=|U!086SP+@3_SZGR:%C^^>D_//FU7 P('+-
N02F5%6NN1 M\7A\|%S6.MH)K1YY_|E|K*RL:|<_ \$^L9W0QI_8RU_N\|F+?(S
MUJQ=J=:XMQ)/N2WT\$,:6)B0T8#:/H>KX=RJ(YL0HS.6;|EZ5\9H"ASPO#;
MK<+/:3USDGTY^EO 'IL\7M6;EWF5M-T%BZM2_VLQ>09XYF6KT
MM|9/6JK14JKYU;31B1T|*I=)2ZM")\#93E277/:8LE-1LE=L|HU#1\;KXC M3F:
DF0CX>\$|UA|S^<=<_&704UC"GGW9IV>BD7+N;W+&6H5W@(U6\,%\$#T MN-
P3\!*XBZ%NUP^* T|\$72S?)KVPUU%#17(@YN8M)?
MGSWH\$F%J"&9%RH4V_E&UKS^F|96IWELB<%%RT+9PQ9"/-'YMLU,LA^|Q.VQ
M\VV7+-T\|V8Z|=| #S\!EM;U-!N@L&&|>AZP=;W7_Y LY5P\$F3+R|UOC)R#VK
M1U2R)F&G*|L>72)>(#RN&1O=PB=7E1@\$4WT;=+K(C2RWE/!|VD61B":=.6X& M^J8-
TDQ;A\XAMR!'.NU'BN%|8-8V|GZ,GALQ1^CVWD7W58AJ66 "=179(O-_ RFWM\$%")
TA\;L:-(7&/Z2L&"X"503I MF1,T)^Z@HB)PS59#7L
2OSKV+C\58YM\$>FOZ=%'&LO\#D:|RM@?ZCNGP0XM0 MO@)\XY9691H\."HFS.*|W%
^,C'#68'C1^G5+#ECF|+%)|E:*\F;#SZ:FN7D
M@G=WF;#QG98_1X4!\$J%>8T\4|>JW3SF3=-E##!,>>;C<(K(%Q.6?K/DTG.GT M.9NKV-
<("UP%@I23=:6&PXQW.N9D1ON;_5T&YF/&(-,:*A_:F%2,?#;G MGQJNT)U?#.:!TZ"\$+?\$
64\^0H0D)5#Z>_CU-L|0WL@VM..C+?F'GY)L\,QO/#.E'|3?C
MZLN4>4^92_'|BVGVSQ23(S,XAQOZK3|TJ:X6-,G*C3U(/SR02PN@L09R:&4
MQQO2PB;130VJEU?.Y0>YE/PN67TJUB\56D)!FZ>WXVIO@VL/MNI(S43\|O=9
M=/E80U0\4V+|F7MVB/#**E;,:1%T>^|I 9I UZ1E\| ^LN/ 1B\|J)",X3D\8G98)_,UV^>A
M(UNR5VI3+P0142>Z=\$M+_ =34GGUCAYRKW90L,,S>/XE@@\$S:0\$P'H,I7YA,D
M0YWG7\&M=|3N#=ZQ2OY|Q%9I>IAC\$Q,6#5JAV^;^E7S5OV;%*|Z;KQP"=IC-
7P>/|B\$G60B&|%SM,,CP/C(%:0+^ Q'V9H!+1=G_O>,2@'LMT YQT ^""G9(C>\$;6S
MJO|FW7A->" += "\$|7UA8B=|%8*+|V416D*^C;9Y', (RR;<4D(XUDSE<5'I^= MFD-?
4.|E;7KKC.55#7|VP0;\$|%(|H^&1UXAWRPJ+WBPYY+,IMW_?K"IMH^S
M2Y8N13R5D=143\!LD;E7^E^O9-*AK|H0:IE!*;/5GU*YPS:2VJY\#_JC|EK M9E&
ZK3N_%|)RP#%QKU,*2>4ZY>E*W*OVV(D1Z,>X/KI"4>==%;S(RT&J%.%
M/(&|V")10%Y_Z|V\|Z,XZ8+.TWI?;"?U"-P"KG,#XIG%/L*ZN""UJ;-HZAV
MGD34*5\5OG\| #Q|HY@O6CEIV:|S="6_7=RW2DU:M\,PGZ|_-V.ND@.8%|!:".|I-SM>
M\|S8*!%^SH/3%|L2G8'5ZMGI^NTB@: @..*3Q.(ZQA(S-(&0VG*K\|6!&|@V M,.D6:OH2
"7^/4|&JS_4"KZ'C#|T E: _/NN9B<^!Q\$%;GU%7?2=|HRR'?|2 M,"=.T@XHW|
|4./|6H_DV*JT|MZ#OC,L1&N.K|HIGFFT# MTU21/Q28#"5%&T)6^Y+/#J

(60&/J(J+@VP^HM=)^UUX\;D5%R%\MDL5%B-4 M\MXWWN
^_.M:4\VS&T\;9^GK29'(J.AIO(@>L=B14/*=60AZ\+>D12'J+P
M\;C@IQ#KP#%/>2<#1,3CGE?E9VJ+H!=B>B96(5D3(N5THYQ/V M6_F>7^I
9D&C\/,1RK=3!B28=V_P"6\$NXOW)V^E!,#YDCL#=Q07A1\$T,*8 M?M/-R! K8E-CD-
->XM-T:P) M!-J= R1F?>=2S3B\$H!"*9IGW"PG^-+,Y,?B*JO&"9Y:6_HR/AW8O?!(K*F3.
MA\4,J&A^XFPFF9/(OF^-SYCXT*91H\JC'17)3 VDG8J&MVM_*/(-!8?
M4IP71KQ3\$7PFF+!%Q;O"9;)B@O<,%P-TXCD?U^R@SMCHKO.L<^UKOY^/\$KY
M@*MO^~^K(H'+2L(GR)R5F!%;23NGKZXI7H6WO75XXE=C?B,(G^?.N+2NC.98L
MTZTB^X)JUJUKDNZ*IB8_(7*BEID4#L\W\$}63%V)2(#Y)/L-6Y1@! 8
M*B(=1"T'XUXIZ%X"=LW:1A0DZAI3(%M'0(O6PK,)N?UD3:*52MU@\$D*QQ)#7
MXJKYKP"NO@E.PORQ(
B_N8U\4+9(@.A^M_X<=R:|AB+)T'MT9&=CUNJY7/NQ*Y\K64>KQI.6!
MDW/;"\$<&@1PL:?!(L3S.VF>W:_0N/;>-EZD)VND QH!/
DX\$2546RG6ZE!,BOW^HD3>L"UL"\$8<4\$X\5 M\QD6NJD\$Y0-303X%F,*L; 0_1CUE=
(!Y=)!|^O:!/HJF/\$(+(<=X=FXEV4, MD%%;!.ZW<=|+5TC@%|NA4R?
K\6BFW!R,.5K\@!DW_>VS*\$; Q2)Q"U9TS#(M+3? C@\$JGA>QV\6!CG!2A6@,T!7,-A-
&/3@|<#158 /G>FC/O%#L(N3OZWQ(MX=@##!%|:-|/G;G33.7K*L< C4-T(
6'DN\Q/7JT'W_K8\$&8<"R)/>2'K C3 M^IDFPUJGBO, <'K;_ZJZI=AB
M2)CEZJ*+3K1(\$/UO3#B2YA.4_:TZVRX-80MW'P;|,OW3@CG@:=08\$ZE M^SO'-
M2R%'W)&WR\OB>AI'^ <"(FA.>H""|+."H?ZIEJV9UMLQ=KP3P;H
MN0K)G,IM1=&NIE7301OYPL/;_A\ QP5H \R9(%Y!6B\DL?QI,G\7D%E,*,*H-'\$-
H2+"C/)##) !FO\;(4!(CRV;&(9F M";I-^A,>MGU-P2-SPBJH=W>RB\$0S*#(:|JY%JH
N=18ZZH!3_RLBCVU4=R M;.?AF\X3^3DF?V/>,N#872:SD/>IL\$QN6
M9\VP,@G3%,4@BZ\$SC5(JE;E!G>NI&"* _1SEBTA#KO1H1\V#DWY_YF(#,J
M_JYQ*K4WOU9)02,|@X7M5)_7/UF&* =K7I& I\$VA8|:=K1'+:,.GB5,8 ?W\NTS-{Z8)&)-
SKSEQO'>.M7B? M-4L.X2DU,120\$P0&\F>51^XZ"+(*HD=" @#\$8|=|U;9#R;^&.2|Z**
/T_GK MWQ)Q"6G*#;K%4|?GBA0Q>C'ZAMK+#1=X0.4|@V9B91-T\R9CB;O>.S#8"U_
M\JQCF!T\4WBN\I2K%**U.!L.WWQW=Y\|CZ2?|<+%|@8|'Y(ZKHE!W3T37M
MG: ^)^C1-9H^6BN>.Z\$9&P@VU% @>DO@*0V.OS3@-/J&&RIUG35JS?K;X8\W+W
MYN!;E^H_E&9U#VQE%HO5>!88WJSD&).-/ ^Q,,9\$PX*F,XABOX3OSB8\$/*?
M>L##,Y1C>!:N1(A>- R.Y78BJK" ^L^IG*>FUY76FSXY
N=|0P6U/B#CC89,BZ9YLJHZ8;".F M;V/#"BHMI^J2A5!*J(OP3G4B=_K/_O_MG^L\Z1RT
NAO\T8K^H M\$|LJ<'S@?&4FBRWU!G|_|U7A>8Z,&* "33@ ;Z3G1 MKN8ZQ-
B,K=%JM);ZT*2W5X#|R6')>U,QE|BCYY/;25
MMZ=331,35SO/ZS0)Y#@ASTZNM8&9*GR" * @>H4.40W9H_GI-1++!'#&QVD;O
M_'B;JF*Q/ED'FE|8#W|/+ "LH68?/"KQEU6R?/QNY\HT#?_'#ZZ:(" @X\$- ZA
M^(:,/D7F9%O6H(C%?)P:A|J=,%?M_%\$4ER\$=7"EL(%H\6^ ^,3E|KICS@K:; M,7^9-'D*(P
_@Z'H1KO?V1Y_T4F.% _D-9O|%W M/TF3V2J^NN:5|Q59,|78S'E,+D24NT9)N5?
O2YG9,K\$D1&9A\$) (V(|U/?* @ M'JLFNU92G:02=,AT1|;C>)3C'BG_)ZHW)+|1#AB5FO?
WRM'Q6+@'GMA+DW M:(9%UU6U,FGRN?7*4B?XPXWGR!<30 _^12,G, 69\$S@>&G-
8|)^Z"+L?5*N1 MOE V'&)=.:&H\$KB_WFC7:8MJ=HPV#G;|U0_>4^E 6*62&S@>M#AT-
A8E?WM" M/<7>HX!_W&@Z5-
&Z8;.NNFS(\$U.N^.:ARUE=A*YXAJ/206EUE181G\$+5(>&^ MN"H#:<29>' ^\$XH("Z^;
<=?) "CGL_ ;HRZISO<|H;SK=@&\$4'^33X-!UTMP8%0\FZ8\9|Y<)%@7.4 M3IOK
_DA\^N\;/H-Y+F\&^1+L- CSG-PC-D+C=><. +Z%%'|UN(_P(5HNV1
MZ_74=Q%F!9"F;\$5, ^'+<"PN=@8?U,=*5DM^ \GQ&BI=%GP\FD&&HP#9^(*CK M9U
|Y4F^?KIM>=:/LFUVUZ#XP/8'C1H3I:.'MK#X#HM*22GC/('1LD)Y_0N M%SF "(T+OT&|!
|PB.W698?#@|U07++S!;D;J"E-7G>4TZMV*,AK)H_2W^SE
MB<|9/ZV\FWTX4CTK;>O3Y0AZI'5= OHKRHNMM@OA,!)61%^-|(:;1UA>=YH
M%; ^GUX&0H,);R2J5!<;I8F?*FPVDP+OER=WN-<)>"M=|H\$H3NA?)*N0W?:9V
M_787\$KIL\A#Z(:F?6HWK,)HS^S20ID>E4U#BP,|1^YP/LNV!B\2LMT2
MS=|B|J|%*F31!\$F!B@LNTN,;)J4|TZ,;!'G-MP-^07YL=|I"P|=:#.*Z_YA73.@ACXDO,6
YX8|O91|#:|T&)M*%9E<*XKL MLBY0|R)\G-SRE^"
|DM6')0S26>V.M/6.5.D3R(O,;H63AABX3/<3?;FVJ^|
M8.\X\03WZ&Y0J_FY|A@6D\|KHF5,&DR4I9H3=\$2'B EN13ZJ5DT\>5?3CI*P M>
8(8)*"+QU|_*F.4-_M^LQ)1':\$1!UWBI-3SKL8P+
Q+OR%TLR>V2*3'2ET.9|V2*C<^AVN^J\$Q@!^C
MZ_AT5|".QSF6I_ =|1L#VR4^3&BK\%OV*7#6I"=I,XH>**41<9O>-5-WBOC2XU-

;*1E###UZD M"@ Y"PH)D3SV#GI(81=D6R:JYYOJ.KK,(11)K/BA_ (/?V&&ZLH?Y-P9
MWRK\|.4GJ+ ^\G52Y\|.9_X0=+-8@2VFQRU(7=A3\$)XDKL3IQ);0.892D08> MZFM88
T^A(HUF(DS70\Q%%DL5-)79Z3?>)NK\!6;;E?B#X>U^9-Y;+8\O<
M_#K:1%NEPK+38;=X+LNG)G@?2B\$@Y)\8-G& JQU\H47BB=QJ-/4%P?I\$MZCH
MYWS> ^L8<-D)X%JQ\O3(8)K\$C)_V\?GYIMJLBI_S\HM'\S>:X)QP%9B\$'7 MRNH
ES\$^:E=^Z;:1,Z(Z:VF^9C+R*VC)R\(!ST3!XMOFL MK?J^Q\$15MU(4I+H&ONE;XY?'2&-
^W>\$?W7P>:E#U5!)AZP<;9O>SJWTSR MY4,I>L>,R#^:&> KJ_NZ?!\D/*D'_-
)P'K>Q\9H#1R-W)_0:YG_-'_!D MC_ ("D7NG'"4IX\$?6Z\W=>TN_ \KTH:+,4!_2\5Z-1
(OA0_J"@\\$['VZQ MQ+6=@JT'5+Z^>CUQ)Q9W7J&VE>T>!\W>(9Q<=4\+6IH#J4'-
+8%YJOSYMFU@" M'SZTKWHD'MM+-JVD\2+|\%W8XJ;=)WHF(8\09\=\$6F444^<^;<>);!\?
I:JGG8 M.WB62=-07:.)RZZ?L.4K_KZ='W&6&P-P^\$'"QF L_-V_"?
BW94M5DIMO9NH7JF9 ML3:<|\@EV+(?F7N3;FRFM4<^;R\64!EWR'CGJM\$L-
:M.GNAY/2#F15 V3&B@Z MTVQ%E\$V)UH2'!=Y\ M"*4L,<,\X89ILYR-
+H,E+P/4G\CBN?!\R\W;+,Q0&=7 MOYCS(\$Z,
[WB\$(1_F=%7&>P<%)F#;GS49\V):1LM_H%PS\H:K#I MSLE?RVR"*E-
<_FJI""EI)>\$B;M\$8H"2 VY?T5A-[#08\J3\VSU""#?:J M!,>U\9!%+6+>E:|*>/+@-=BM-
39ZE;I?MFT86U\X0WNSX)W\?7V3OW310TJ% MO^;/YEH7T9+4W*W+.T"V1Y40O:CSHJ
:2>@:6WS;;4KWH<\$N*/PA9ZPH_Z: MU:5_6% ^G71E^2KR2;J%O:@;V2!R 6VI:S6/L-
193;EMA_2I48P9F<'@B54" _H:QB;&DC5OZ8?VE::8D;N<^?
XD=ZGP#\$9*.4\$BN\Q@_T2>(9(1Y&P7E)=C\:%"!Q M^W)FK\;-G6FX!ZZZ&A1\>?
SOA.*2\;308(3+^^.5_+THV.1PL@#"DE^PIQ
MKO)CP4""_Z;=9K>4%'.%EV(A'>,O.DW\>8X9UZ\@FI" 1-;6+XA7P!2\$@'I9QZ%2 M.R\
(RWY.E07'*P\Z44)>D@>3WM7CVD:"G9Y\;DKR\$^4:IAA"
<_A6*P_;;0C5B.@0HYOWMP1&><8KKUV(0H;\$YMI5C%[\\$8Z VO(HF/ZW/=8_N"&]'D8
M(#T6:B?Z,XYT\$ I'(R 11\%30.IKDG20ML'48N2_+E+I8"FW N"T"M6_@Z*
GCB0UX=_;_EMIA3%_IH.4A^\$C8 M16@G
Y34QIDR;XRFO*HA)_1J%A97ZNDFTPEZUG\$CN(P<'-.98L\["*.8UU*K0^+K?
ONFVR\CTV>F+(EG6_NM'Q<<;* M^E!B+D9-"D(R7X>E>[X%#X/QN: ^VM47Q9
MOZ%7ULL;U>TA;.:4>KJE^MVB0\VM\HJM<!\?)(I*+3FJ\N6Y&EAFS4 M3;
O)DOP8\Y&0"3XMV\$;-W)*A:1 ?W\H\$ZSMJ9"!L+Y%^Z6,76\$+.\&P!.\$
M&83M\..1+MO>P#<|\\$1DPF#J\Waj?+M6P-6O4_>'AF61)%*?/O"S4 Y/?A\W
M>4#LK\$&I=|8#!\W\$N^:Y1E,I=\$?8)H3):00RSC@> M>@R\>H4@Z_-0UD\$5->J3\$-
-/5@Q-0O.U2)BB>Y2,&[')J^RE23A=LC=J:Z M4M_33'4\$80;YJY1*VJL"Y
+^(R:T!*;9(("HQ.W&*!WFD,4.0FA*ID.&H' MV&TSP7AP P?
<0*X@AR!CS""X2T3169FC<.4! W3?!IW:AA)(--1,MT MI.)^Z@:%3J=LW*FLV*K8?H)W-
@@@VB\T1&A:AP;EZT7NI9>4CV+-62_<>/S*5X(PWEG-!YH/Q M@!\?IT&SA5Q\$W
<_*05AP)4*3C\$N@GBV?M: ^IRQ@H)8@P1Z\\$. (KB?^5#;DOE M#BV;N;51Y?9
MB#^1!S6C59-17\|-0\$8('O\$1*3W M_0F3\!L?GJ_X0D SP MAT\K)%!AE9M-
%LWULBMS2Y/S7\Q?UO_7S8NNS*0MCM&!I;&@NM\))96V>IL-I
M_;\&P<9#;1%O(IVC':!V,VIF+Y/GL8HZ?8R6CHQ\2M9Y)^#C^TGC:RM?MJJ0?(Q17
MB4%99)N48#*G^YF:MJR1;H\;B&\2*<8)B"=IM0L/9@"7*=PFYFXKYS%LL)JR@(?MPM-
-=)1\B76RN\3\|/P- MH@1=BYO0\$0B=\$-RY<&'34WU\1?A"NUI+O;MI>MVIVX>RS\$A>
I6JXA9#%:JG M^G#A5R;IR.W\T(WRO\KX-GBJ@:(/O"8FWSAT @O"IV?#>1&ZV7.P&9-&?>
-% M)Y/-T&3;GJW6IKY*\$*! #._"*^Y^SFCX-6^#NOWKX/"#?_ \$T\$5D*\$@F8P Y
M:IL0S31C/C'\#GH\IPXM?6MA^|39&BL MD#X/8QV8??Q%R3I_8_5"_13U15S3\>3SIV\?
=KA5)OVRK QTI\A\;_KL_.T MIE3&!
(#N'08(960#DU7\J#0A!GQ.JG)F5>;&TVK\8:6>>E;L,%<3--\|33 MP5_J_RS3C#<>9-15
I@;JHJDK64N?KZ6\A3\ M>D,P^>^AI_JKYZH_I2Q\$W^ MBFE):Q\,L\$JS'I,W47WZ_3>SA?
C6F-ND&\$+ UDIK?5W+9P_-X,0?W,2! !.F1VD%Y14VC\T00\C,UH5 M;"X\$EV8!;_@7-
RAAKH?TQ:\L\75\$1Q.5F\I;_"XU@B^JPKX-3M.% 8\$!06 M0*LDRLQ(-,FM\J9K\$4G/%?
X\!)PT&*!NK/L1N=&&M,S5\;4 /U\$|#GJ') ^
M"QM\$/(D7O\>42HM800^?;+F8L1_"@6#F\$3\I0@LDE_5\U::'8\/(Y\Y%YC0_ M1E%
<=5,NIGVZUQ_DE\^8\$#N7_I>)21R&(W-HW!;0O>O(/@W:!\60\#O=;B3X*
MIAP#+!\@#@#"?8;J\5VL\))%3IB@,0@VS>9> R.!A\&DO>1)F-TS3!9Y!(U"\$V# M\$J
TS\=6M.%#/N1W=1*8%A440*JW_/ZNL5\]"6OW?IWLC%: D%_346(L&68BP
MLZWT;GU=|#69MP,2FZ^;/SW;_PD1!EP'G-"L?MG)BZZU!Q-T"9*SFJ9*K:(O
MN1,SB5#5T_F9"FV_B+Q7\SM@N_-(Y^:1>7@?A)O.K>_+,Y@@OZ=&YNN<>N-+
M'H2163KPF\J*7-'EA'PIR7\O;U>I*J:DMN7\YMS;!\Z.M=A=#ROX_*Z&7^@9

M!\$1QJ\B9.RL.V0#Z"UGVK?IM&J/?4X\$RH=9G7OMF"=NV+KH4TLOHY_UB)MPIT[-(-
-;+ \$FQ28 7C'@38%Q!%E::Z>OXDI%#35;J!> MH-M,6@AA.1!AFLT\$[3V4DDYI
M31<"L#9MH3N"@("H+X\$)F[5UL:6IN))M';#_T)XQA=[>AFVC+1;\$4!P'T&R=
MSR77\$!*)>^&5IC1[AVIY\$)" +W>90Z!-Y=P%I MF6I'Q#) /QV,7WEIWDK>4 M9JC:I-
#UZ8FD!_6M-4T- =^15=,QV.EP%/I>TJHR,V))6FHE.'L=J%I]Q-W + ML?.U8E1=6D&+
(4G!H541@"UFOMQ=^Z=WI>79_4\$!PQ9L5XL=;4Y9= LTH%4 M")0-T,;'G5JA-A))&0E?
M>,*D1E,YR[!U5X)_S%?SX?7,3%J2SEJ1W,X0J+" MSV9S?FQM[GJ@S"6W57=D8L?
DTWA(01DRV,Q@;MCS(%VD:NM AUQ)D M2\6./_2Y,1>19^D"4MOAP-7*E[HY'I=;(L,_\$
+5XI+?5N=5\$Q^ ^RGI8/H MF?N/-S?B&B+U&P
M((^3XW;9V+AB\C.L8D0(P0SM4VJ.%DHZ:/KI: >KJ 8.>NDFI;A-
C\$.@W++TNA>7TG"IPKN7*? \$ M3#:Y@NB.IQ:
(3QD2U\C@/2>"JW&"MC+I(*I1Z/2ZV=J*'J3&ICWW17.!I+&5
MKE5^P,#XAD7/2F.2E[QBZDH23++5_6|^SN)@=0!=STG--M[FDE&O=7(#4R1@
MXLL!5NS.!.6OR#*BE4*V9G55&:"-6K(*I@-/9/&U&3IBI@CR A2[V_-,"7VZ-W?K-[AK"-
MD,<@ON;)R!J^ ^#HD/^(<&4.J+ "HV42M!&JL88 Z- B0BS3L;1I'=\$>[?R M%7I4'?
\$KA15/F5-R8:/>M*6S^)^OF BC;9FD[R=RH0"Z%PCIDZ![ALF8Z[I]MAS)+2BC.1K:XCR-
J0&2\$NIYV7IFM/.FW,4&=#JK>*7F.BDM%90"61ZRM+VZE
MZTP'9ACR&XFF.AM_X9P(>X0\$&T"YASPR&ZJ5H9EJ6V==HT8L>5(JG=J#"L? M,N86I
<6#!/A85ZJNV@9I*+)TW9L)07\ DP[@*0=39B/[HZ*%@ "WF<|0V|@T MSENXM07<+C?B
@.TZ@ -V;/+8H#.)W8@#U5%19%\$GDXD=4L'!23/*3% 0I-D M" /\$14N&V?
3C(=.R.8.H3D:.=2.7)\$ \$Q!B@@6D4\$(JB2XF5= EXNBAX/I^C^6' M<7ICA(9B"7/4-0_;
(=\$1L'(4B3=Q)PA/L,4 !L?DI3-);" &U!\$L+52"O, MFI^(.^?;D)L(HICP&8Y4,\$
_JC:1D"TFOC;N5JWDOT!&A\ G(0NOYW^CH%,' MI
TZ:G6")K=36WG1;L\DI:SJ7)L+A/00>L#FX7\8H,@(W,HP
MY%T&\$KID,4A>".8FE+;7K9DNDVMX^%\NPT,U8%J1 M'63Y\$K@60H MJ8=Y(6>&7#-
IG.S+3.06'>GGXG"RE@FY7IJ#H=;,KC3SB;)H!()6/U
5.R!Y'ERWRA8%RU;F7AAN"Y=|A/5/WBC4.5B6GE/%OZ"%J3 M\-\$P=V%|Y=[\$-
_QGCH!432F[OA?%PO>PC5P;JS:IQ.9Y/:B6LC>\$(0_*ZIMA@7>[-ZR%">
(!"RYZUI4S(6M3Z&T;@5E/Y@A &Z5&W_ TLIJ<-+XYD"3I.* M0+@.9S+3O>P3&IVIV
2BRUD!9U.*-S+!+KJGG86J MTT-GY6%^S9S(-X4+*&93/PCA%X1T#WNHKD#M
H\$ _IFQ6Z%Q_ I=?/\$\$7>YI\$ M.TI1Y@S0/BC!
;HSU;XAC_CD\7@=XC)'T2"J9*2;QJ DZ8&D\$W\$X1B%4K@
MR#M#+6(+R5H.MJR#8,0S+2R\$'7;T!7M#V>L_18HWDTOL;SIGM@N<,7PB^%U7
M\WT329HLF"SN@\$O-E5@!A6X<<>!Y1U#=#ST:>7,[EW5U29>/<1" \MI BI+1?7
M6YN"N\$)(G5FE1H>+>T>"S!Z8WNZYFY;PNHDSI+7%.;KFJXCXT-
F2I>1.S>)3UZ&^J+!2+FUG<06DR=P1VJ M;8I_PW=ZR2'V8I"XFY[LM]_?
Y>ME>%S^E(P4W,H-L+J0@+<.*HSN&\$K:),H, M<)?>LDHU;R>
(7B#*:Q%E:Z+A=K)XKS\K_G\$18);(SA[Z7'D M/*5:P!E)! \N_(!"VE5/B+4U-
HJ=8DJMC4.!>QI5#SM23DBU%45*6W8'F1I
M3(7O3:@MS)^!/R\$<1"\$4%LQ9UE^OM7&1O&/WD&QPV)V\$T/(A(HB)\P;AO=R
M+@2'Z8SM#15IK(O@;6IK^MSZ^8'2I[\$ _SH*NI. DREHB+H9^B7F,B+K)K^,H:
MF!,A50YD;DS..4P.ECO;SR@.4W4P/Z&I'!C*8'PPD[C08T]^4IC>3S;N'E(S
MTI1B!@CM6I2^P2[T1:7!*T51E;)^0KE7NZVJ5'7C.VF&B\$PHREAP>WPL?@!=%
M%485N@8N1R,\RJ&&-C7TEPC%A0L.Y+UDRAO97*!,-9!_DKI(>B#0E;?@T/V&(0?
TBP!B:FW2 %;&,@2;^/6V@\$UUY%G\?Y(#D1;\$,I
M:H#W@E=\$ZJ;B[;NWFX#\$Q7)3B..8H)%I2^:@1?U0BW0^ \>/WK41NW?&Y:DN
MIK\U?VI*\$#V?SJF0PUO)+-VNG%\$?7T;X7YD3;A0H)=0YZ_3A'S.CJ8GJ*IO
M:S^Z)HI\$|=UK-?L*R8\$N(=34Q04L0GX6S="EA?1P9DK@)JQ_91=ZHIF2L1
MOLI;IG>\$5./&M;MM&AD7'QJVA/&.KDM25CZ%W M1U3D8)8C>_ZB'0)):XQ9;R[HV-
@ZFIC"^_7ZZ +B:H":>1AJ\$#R"4-1^;1.40D MZ4OXXK&VFO(G+K*I M<60!Q+ITG;)#
(4:V6;YBPRKW'.E14 8LV24YBLDFS/B/U"*;Z=%HP_SSBZ+L M@XVI>#/^HJ#3?
&KJ8AF!J7S*T=[&F9P2-F+97ND\TNF+ENIHP@VH(EJOISBM[I?I71_ZTM#23T,4"X-
3"+,3W'2\$J3^%HN/1G:"Z4_VMC[STD>),V.R
CS&Q5R@.1WH&9H#>4G&Z6W_/D8KW(+ '1DP.8M&4[N MO0>D^1)<0C:_A#Q/0-B1-
LPY-L+EZT?DO4GTMU5A*\$)^XA/>K)*-US,.KC\ MRQQT/G"U_L@ZGQZPG'UG*
<;H8J;4A=0I2P;2Y*!))\0*CUC.\$;0+1>7)H80R!X3SZ#XP&31'4E+;J>WG:"HDF1Y/4 MH
^M?9GUE,0GL\$43%V_KAA%95Z*.0F?V:@PA5=_W%FH3IHX\^:=IUT\JO+!0
MCP!%0:N;2.+>31'M6EPU'8^JOOBTYFI;Q:C+VSIUK #"G_\QUEN85_61)>6U M! ?W*

(2P,##>)@'O\$-.YTS@FW!J)/G'HSJA5 G\KL*"NTU\$BW<48KY_I9HVLH M_+FZ\$@IX
I='#BL""&Z/K:75/SG0>C").?#3[%0MVGNJ'DG+[A\4)R+D!R=% M\X^KVR<@DD0?
M)VH?7R@M)%9W_3L;3E@B^1?/V@S0)=L:&+CKI#\TZ'>#2E\$
M/0#MHA;1XD8\$Q^8KDM"H%C%\$\$S2!RDET8>NB"XQFCP_>?U;;5-
I9\MN\3NVYZHL6?%DDT/\$UHN;G@*K%-<%P;K=4 MU;'+^94VP9T'\$E-DI+I-
I374I^I*J^I\N\3KVZ9SH='GH;/,;!QI"VW"?(: M'=(U#)#=;I*NA-
"M1..J):FJHLB/P.N/(@R+RM:3Q'M>KT^=E)6R5D&?IB=9V M;Q \0"5A, 5Z-
ER\$.6FY_I1'DSDI/-7BMRO?XSZ-+@W+I/=F;:MTA/I2!GHZ+(6'(*."GJ(Q\M_MOJKI
X6.CL"E" M5('3XIH59T*G31Z\OF":OJZ3=1ZO_APNDL.9*WF6\$J'UQMA7N\LHA21))#"
MQ9'RA5BJNNX>^*;I.I-|<<|8-067C\$;?44T+2FTRU_N?=:G>|=(?H-XCF11V
M&K=XL%473\$R M<^9\ZSE_?6ME9U\$6._>^K^OZE7MSI5NZ?7@H-
_7MZ9'3'I\$;GR(7&'NO%1H MY=\$5>.*P1M%=1:&\KX3D8I=__^2I
6YU/7*G\$ZX_%F,+OWOKZ8\?;6K^ZT5 MAJ!/^%4=Y2P??UWX|P_
H3ZGF@P=V7I:4MF(QW"L"ZDAV>E5A#<=|HCY9E(!BAM:Y0%-6*\$Q2Q!O_36-GUR12O/
MG: E.G56^=[90/J)+#C=3ZV#8I99U1U|;7>U\1'N0K%V)/#C2O6JG*5=I6_
MT\Z==Y(U^7);. ?B"ZZU2CP251VGY9\I*8,&B;0@K0"J-XL\T90*SJ=CB7J%
MW""%,9O\$=GKK6I^ ^5B@'FX| M^_% "U<6>'_63RR>"=|W=R6#Q?0@8|+>5>&QG:!
|XAI5*5LF0^? MCTZG5"\E91ITOWG4/I:O6J%_P'>^Z7.HDLO7E|GUOJQTXE^X|X^X|^!3?
I^9KH\33Y2P1T0+^ METI,"^R(RV!UX9MUS> 5.>EW5^'=3\$ (=P;K W(_-;=
(9G@(FKMWTT6>_MGV)+)CVTEJE'QNO<7U"-+,-
O/'JKUT,/A|JL,V%Z7:+GG(=G)I5B*9CMH/ M/I9)H*\?2\$O5\$C?|C7CH7'K Z*9/_?
==:F<|XTR<>|H|G>F?|<\$9+"=J7NVU\|)EF| M!|L|GSOZ\9A+|NU^TK:OEX\S_5RB-#G?
|U=YN!4F9?MD)AS/1KL636O9Y?L MQ3N9EQVH%|VJ=IFK*P;O*W?
+V'DJ+^R)@IWX'G+|:;&.+%C.--? #|2('KC, MXKP#\$Y!+.4?
K|YX;I'\$6972<^9P'>@;YRG&SG"#F+4XR M.|UHM9&CH*V/LW?;F,|XT-FI+
MTSNN/_Q"37,K\7TH4NM;SL#F+.(+H8(^4I?
(T2D_K46=TSI,JW)\,RMON'O'EGLK_4NOE:\5%1SH\#?#8BE,?
CI4>K#;VCG&NGF^888*QQ M%IG9X5J|^|I+)XZ?(65|^N-;>M'0\$:V2\$I*CZP-
JR<;S'7*0|(U=8#;_K|MK M|/_N;OF\?|W36/X> ?TXM1\$IC5\$4&D!-;1Q;-
(8";'D5PZL8\$E4L@;AD34 M3DX*33A3L?:IB%8N@?
\$B<6\$0B8C5H<_8IBJ!/25XXCW\$)H!24X*46L)7"#93 M|'0DL"?\$=UG"LS<%+9 @>
I@.X077%\$"&,%(1\$H&|H'EQJLT"!*)&9?;M= M% RI-
\$=|2*7|Z1SP=SKA6^_<|OMNX<6F.Z@?>I"8M(US"40\$OQ'^^|@VG|N M/ OUPP49#!?
JX"\$M^;V(/&^2BOS'D2)Y5I1?)+"#&'GH4NPA>)_4^A8(R=(;<6-
J\$ITB*ORK>=Y(CK%MK_58C@>W5-M'5<62;^!I.E>/RA0VO_3U(H3);#+Q#MC>J)GR"!B
F>S,+8K;+,\$#K1,<;IB-P|HEN:*N"LO5>#R_ T9H=R;|OIQ& M: ^0(CW%=
|P&&,E=!CU0_#ID\$XW|>|B89K^8)8'M(IUEA=H"UF@#>)(0C|RO M9,A/F4-
BUH._(CF/= "W8=^UII%_ =_I/\$^ZY3%"\02PO',V^ 177:WS|Q^U MX:1YFBLI|=W,E1JY-
?EU ^>C|EJM0%K R*42WMV6\$M??\$EP1"0P/HL.^|I
MP5:CB>O'VH;ZK|.S|\$#RN_UZHSS^|4?>TYZ.ZH.&_&.>5;R| DO
K"N;_ \$|^ (V%NO6K8A5^5N(/Z=G* N\34Y2^>K2NR92O MK5;B6'#C(W0P5AV-/1J2:O
GX^ ^BE4'/CV#VA;_!L,92FP|@C^B1G30|TJON
M>AUH>;JU"SMS>985Y7_.GJUUP%#/?;?|SUR.4P6?^!8IBU-F!'M52|&OO;G=
M+#H@LZMSZERI7=I4DZOO.NNPJ)\$P_I|6|I-X=/T2S@UDC1-4A7O|<;H3;:1=7T--
"E"JXE6_3V^+|/& MB3+8ZS-A1BTV|(R;CBDEU+
|JTB8E=M47M.W!6!7MW(N'Q2EEY,^(<|"95-R) M3S6QJSLVIT_G&KV|RNBU'PY&QB*4
P/D%5U.57JXNQ<-C|^YX)\$H>_M_1VI(-OR#LT_6I;->9?W>+ #YQ;|R?T710I)_ "KP#P|)%-
JUC\75%T9>?A_P"6A MJEC#%|)YRI%(L<8;LMB%H(G|I_#C1J G(='D-6UX7998D29/^_
GGN9)O!0?. M4@T)GPFR!Y|")1|D\4T'3AP>&P3X7-KB@0&'TD?'O||J0_X4_Q/XR>5CFW
ML;UD)U AO@|I'=F_7/HS86^3_T^O?A|Y; 9!4.UJB;@QV\YT@MQ9| M>&,+E,H"\$R"S*?
SYY2H#&52'^=::ML!/'IB|L^_.XZ:UX,P@Q7S42^6;.&TW
MTB|6X<)>S'F3810@O;/EE6/Q#A?|+=IC| M|:M"JY2\$>(V*'+ZY/:AD\8+?+H.' MR
NCXZI_&:+2"TX!2=T1+NRIE<>VW|+H3K_X>7_C\$SMH_EA*JEIC!
MEOEY6/U>'*\$/=*Y|^JB1>YP\$4UN0E_NS03C M@,,)S_V11L\$%|Q^0\$(:
I'"XZO|VLY0H^;I_|RPZ+;HADMI7CC!2>C*JO4/^
MN@)WGP1VG@|/%*#%!CZHN#_N*A>&|TON6-?I:-2MMW/IZ<5%A?*)^IP47X> MZ
R2|9C;+ |H*2\4>XBES|G|B15"\$ (1R11_0L&189Q|;* =VPKV"0V|T+? M\$W!_V@K
G0%.LM"^_./5FC\G(M/%^VH'*&;C*&4)+-0G)MICY2;4X|Q9)_ (

M#9I^|,KX@6SF*FOZB"2*J)D*Q,0A.W-E?&L#|!|>>HYUT^!TOH4DG-W3B
M6#G"+)8|>4R|5|:|6|ZBV6=?JMLK0|T ST4@23J(\$D\$ _Q|H1K!@Y6%L)B6%7
MO0!%_JE8A|O,K\$V|UXA5|RTCM|";KGQWQ1XC6'#F.4D9<.CPK^@POFO9>#|
M3|R(&HI2%,G _PLV?5O|+XPM%\$.SCG|+?SIQ3'O _G=WVR_Z4|A|4<5 MSBZDC|H,LD_
2KBC9OT<+| (PU|'Z<)>7=TRS#AU8*GO?B|VWL?N@Y+254(O4 MF82(K_3|
|CZA7#G6B2Z!|*9BK@XT.*+K):GJUX8C _?J%Q|1?1_2|S P43%VJ& M7M:I5 X%J
P54TRVE1NSA?JAI*XA)7;V8K|XJP|EV8%S?<[WE ORFG| _ ,P@S+
|=-Y7|7)4:0@W.OPXU*W0HT35CV4>F'\$6>6A" MK/P)BTOYG:7ZT+WI0P;N|+RH=
(4^E"ACW'V 4=EQ0N).C+>FK-7C@V4 M/9ZL^5_&5N:~8OM=|K_&=A6*
|1_XCQOUPE7HJY;>=G)&@ 8?GOICT;AS=>P@ M&!,_GK47)/FF7>RC6&
|Q5%E.U!H0VHZ3=U0_#D+SCNGC;(.)G25&>I:=MZ>_M|*.3#\$.M.AR\$+%9Q1GX3.C_
@DYZ0=|D<#*N\$/*_J|'J?6 M.K&7TDM5;C*8+@S/NOIY9KE!4>E|6AD6F5 |MH|/|=!
|>V_V,|<+>Z1(<,*:&\$FT@?,TY4SSX>|8|^3+|7Y "X5<"@P_X.ZS@*?
HU1H,|@D&K|= \$HF31"8G.PM|
MB('19OPWVKH>|6@_ ;?|7H53XQ|/%6\$AAIV*T2V(4E+0F,D0-1RCNG_QW?%HNU
ME+O(:|+<9>')R|2?P2LQDX' #M&ZBV3\$=.0FBO_Z:7P/4IHJ!7YWX8^1>;0M
MT.DC1!5EH/6R*Y6_TBW4(KA_'GS| (7UJN"+GZ.T<57&J+HRXLF#BH|9JH#
MDWKO'F|.FS?1&4=8 |L,?8500^G+ M=U=*IR?O_NL_COM|OM)P|7J&:U#|Q
MVF#R>|VTUO&PQ,LICOF5D|=Z%C3PV5Q,7Q,+=H6|OY_Q5?G|IV/7_EK(DWMX
M1>NO:RLU/P)0J5V3/Q_|NC+L(M/|*#(|>"9&O|B>VGO49B-Z06'ZBA7|!V^X6-M@62+
(:.\$^S^%TKP|_<4@P_X|JS|B@N*;U|QZ_RN?(DS=!O2K.-IF^:*,#X*F
MDZ|'3IQN,=Z%_OD|("O<\$RS(RT*QCO!)G;)WC?%*#H&N3C+^V"0&89?.&=<*
DZA2D|!8Z4"2#C4T-96QOU3;V!;*,:"VWCWRYO%:8Q'-E<_J M@G-D5N=X!?
<3YJ/7IYW(;F3 |JUMY'WR;0?0|/9V M-Q>|VW.D&A#XEBB+ "!%WYAP(K|:A=^?|^N|L.7?
=O-H_>\$\$?:Y7_D*#G7-. M4|\$V|Y@;:;>=#?%?
|1_*S<6'O2?|+L^0Y1_P'%84_|P_%DL<9UA)OA^015V|1
MC9_ '(W7!E84'6\$)I_GRG';3M"W?*15!T\$|>0EAR1^RKG-KE?6S*<>;|R?2G
M:S\$954+DJ|!+?G.O.Z->>ONS\$9XZYH>KUV PH5A\$!2PK9V_L3;G='Z,LF=
M0<.W>_YXP0?R&G|=7Q9_A:IYT^OVC2?F-1ZET14>_5';_86. 8O|CJXW>#W
M_.%T|/;H|D.^HZQB8L>U9WD?(QLBP>9 (+L&Z4|G'T)*+=| ^N:.@XA5U?%_|
M9;N|<(>+;/_T'_R-58'WY@BLLB=8S#>=,*;:_3+M6,?"Q8> U/& M_?^5.<2XV,(7^7)E
^EK\$|W*SI)>%L=ORMTX5|FH;V/\$^*-H=7DM1RCG|MZH(\$|N%_GN3Y,54L|HM
8;SN!.U!Y+F(7481J<7I72>B?>W5SGD6VO:|G/U4 M4C3;|=SXW"-
COAG,2N78<';CKG5/GLM1Y=X, RMSD)+?C@?XYS)|N"K|YKTST%'D8E|>PGL"X9'6W
NPET9P&N#:=\$I9"TPX16H MMVY-@(51-
9B'&I+H3PLT|JU\$&0'*#X0G^.|TYI6ZF!&!;9Y>TV<06P.|D6YE MY)@,|2-S+>QJNG?
2#D!|=7ZOB|=2-|E|/%79K.EM(|3ILSZ!-|83;7^)|BO?*\$I MMG=HB1<01?G?:Z3\$#KI|2G
WB?6\$FZ4%YQJ?YB9-|F8%W&)-O MB*%)^6>| (K@U44|4T8^NG_'TW
HQS#UX_Z'_M|5\$45@91E3!GR()#S0H=RB M=< I<_E|&QM+?CLNEI<-8EV6Q#S?
&QVN*Y.-Q.2!|@H;/%2MR|;-2W/Q_'BKRCX?.SXL0;9;@!XE|+T(B MLC&)093"_VL(6:~
^:5^497|8TSA5M4G=%C0(N^;4T">YN|=37%*BNMFKH7 M?|5_P9FW?
^50K#0ZYG#7@L/5|NNOI;\$26,7M9HM,JR;E#|6/8M"+OSP%W-M/YLKQ|
MA'3I!41_@;=ZJ>>0NU>=E \$E(7R@8R @T#,@ORZ)C:O|_92'8^P%TW<@E,L
MFX=^OKL|K@J=VU482=+YB@K+;2PU^R@NC#7%#?C|?W5_5'TWK9FBCI8P|_SS
M4#?WQMBN>D+C_K/C|_9;_|V'2!+&T%9 GFP7^NO&N|O6=OD+ '-P"^9D)T
M@JYMS^_FJN5THJSP0ZJK&:O\$#OX8X6P!APW2SI2/6^&>/G4PX,Q,|2S67Y5U MOK?
3+N%X%OU6T"8#/D:Z, 79F;N:~7F MH,
|AZK>KSL=KCK@"BN+BN&W/MBX5EP587E:812LR19,=O|;..B|;R72X4A^&
M^@|J5U' (O&JX&QU_C_/O|>2NE!;&|77)8P_HQ63TX3;N;U|@7AG2TV0NW> M!:("UM*?
B3#DZ>HO;C0N*L|&2&#&#|+&TJ*#RX?BFW|HH |7BCS>5V>'7EZHT
M.1A\$3;,\$ML43(*;:'R*TGR%<(RM#8RXX"G2G11%/P)|H|B ;WV%S6'XD+Z8
M(X5N_0O(^JBVL+E5U|9UI6=!P22?^)=3J#HOMJ^/9>W8|F+|OT4<,S'G*&UQ M#/W5"
<9QI9E\$U%FFT-D2?+T-W=(;U*5,*FM8NU7P^*IV.E;8=6I)UV\$#H
MBV>BU|2;N,&0Q<2YQI6OAQ#:~Y%>;,7|1*5\$8)DV?*|C&6&T_R?14N+W0*M)#=FO\$
;.*^%W*|T>:H)8I|I^/*=/X>J3QC.-T^|/!>@=H\$W7@?;JCNL1C?G/^#QAW,##|*
|F_A0*ATCW"E09@8QOE6 M_P,ED,|CK'"&%-MH<><;,MU|.-4B3"8OV&FX81RF+)M>
(K'PK|^GW9 YV.?K MZVNEL;HL_Z|_V|?
L*;8|,6!_Y\$2DE4)8KT;F^ ^34#Q|4Y%U8@"4@@742ZY%" M)0E,O--

R@C8L_1:EX\$30'4X:_U0SD1+AZ40SU^'D1Z(%>>UQ_.6,U5(B1\$-M63L! ?
U.=4,@NN|E"/:T|!HNXX1:LON|0AMS&M?B26D4IU?3VV|V11?QJWCO-MY*NOT80IF|O?
KEXO6HA:R&O RY/5<59Y+C)#,=| #7+O/ M|
|Y5|OU,2=?3/E26|Q^Z8IC|H7R2AZ73F|7ZR2HNI%X X9)ZZ@
MD@0>J^9:E/ZEQ6H.YA:;L.*Z-:!6W5#B%8+7V'B.Y|US^.\$Q U&3!'9E48H'
M9S!|B2D0VPN#JX4JX%W>L?#%'^M.^?^Q2GW",SPUT|/7T;L-8Q8+;0'PLM<
M&GB1(??E2R_O"| (BIF3VMF-&)"FTL>%XJ\$W!WJF,A:7* @5F2V|KP05Y;;EU#
M+ /X1!0AF2.+0+|E=MS5S.%JD58.B..R57GOR3SXXN4=+VVJ8O|,E%:80#*
MAE58WF0&S^DUN|?EUUM^M7|BD|+ 8T; -IY:-0"(<2?B1\$M30-B\$VP>@| #-M-
#NS."2.ZX*SJ ITH*(B;1=A4.;SKM)(>B\$6SCM'O3D%Y10<^O;^K2/*F-MS76U!6-
\$2HB>>|CN8UX6L%Y,UFW@9:\$;:1.7Z% W|H|HxD| MD#8(>8<|X8JB&8=B>XLK:8L;S
C|A78*'8S9H|@E7ASDP9OM/O3W0|,W?C>
M:=#L&S:+J;JL;IBOOC=U79"QL\$A;D9(LEED2U>' /SHOUP;;U3<+X
M%D"SJ5PHQ|^6P%*HZE^QU9YO #A|L.S; MT^JAIVFFO44!8P9D^((87<;DH6
M&N\$42^M/PW<.SU*U^I16UW?KRX2:((?A?% J6G\$O&NN\$= !AV1=1)8+?2ZCB-N
MT!HDL) > :?Q_YEL?
&.CU9'HS2>/Z966%73F*LJV@57P;IU.RQ1!*|!"HJ\$,^BK'TESVCF+K(MJS(OA(?>
\$H;W|=I M%;|H-8K_K.P|LQ:QFHJP*K&LF@|ES.V:;".S;|FAA?--I=FE6G%*YXT|O%
MN'9475(W.:ME(LQ(!=6UG\$Q5X|,2;HW:)K;|6F53MOZ8_2V*5EE9FV!9:U| MTYY)
<06D&&-RSW07#C;U&Q*26NIURU!^?GX^H8YN+PJUNTBG'71NG!UMK&^
MEZ=^D(^H^A?YUBN>0|&J2\$OOJ8PH|K9OJ_#52|H P:ZEK/2>M(QYIBV;YI
M%3T|:EC;:/V|)+.FYYP^5=FNU?"(4=DJOZN&5J|C?# MT?
7K0DL5&@/26P:B1WA9|C*F9;;LRX?7PI-^#)+%66S!-EZ,V1|X^V/TTG+ M5!|A|JZP2BX
I;LR|I>V)AD!X2SHPL)W"PIK#YW<)0F5# 6;^=4\$=J-|*IL M,9M8*|4H"US8AY='|RC=
|Y2NYLSFRC*0.V65T*'CZT|*6%2W^BZ4='=|X,TJ M|#Z=NG|P8|_C|?
VCJFH|\$ICSFR%#F1;|H9|-K;7+| \$@GV'+J'&.*O6I>5O M/RNJ@ROL9J.6102/+V+F#/D>;?
P9L0%/6H=,)4>*>@Y|'MH'%IEF5N3XJ!1C MB*I="Z;PWAC6R'P4W,,9|:??>|L|(F+H@IR
4WV+NM<-X;| @=I1VGA7X^9. M1Y?GOLY_.+3.U4?%?%LS'6T^B0^-\$(N0!4|_
(O@._KY"|AU,#3^LGR(I)? M\$#);J0:_ NE#UZ1:E".Q0>3\$AJ,U#1E+O|Y>|=LG-|69++||
|/E->|V2T%Z? MPB7?-9' TL120@)
9'#8LAUK>H4|7|YN2!OX6.=P:6DF&>DN'-2,N8*#N6#5 MAX|*,7S@/4*O14-
LFG'"4.V6=|A:5V&1=UB.^;\$^ZIO\$=A|'B""G(!O@ "ZN M*=>S2R:.\$6,?H|?8>A&6;\$8,KG-
GI@.2E&!8>)'3X!#54|G#&TRG*R MT+@2J|EE./SLOC
(8IQ#%='(U>PU'/IC9|;Q+^F=WP_5E^2.QDFJ+-;MAZE M^K:%:RY?JXIO(7|6511N;
SG0YA\$(F_<=;K| \$7AA!3%-2XD6|Y(8\$ _\$S5"-*L-'X';K5-M=X)W2R0P#%:V4ZP,-
"8)GE5*8(VX(SP9+4:N\$WNQ8_|BH?X6NG4\$6?|6;=?G
MV+'PRP.WJ|E\$GKQX1|+&CMW@QCA/B8@_.+N\$MB# DX4L3T\$Q5Z35F7LT(2==;%&*?
22MH|:M1N+ MLFQJ|@"9%=ZH1L| %UW4K0KL_|J3PF.@E|1HA(W4N4"WK:\$P#>U'
M'(P=!J|C:8.&A>F5\$U554U#V.B|UH|6I\$P(F<848H,+8O<>*:(57.W50_B MJ_(:B0!GG-
" ^G-'BD6>41L+Y@Y?'D2G1MX| ^_.#9Y*-A?I9/S>%9|54OC5_D M-K?
V\$^HSB5\$(Y^X#34K|)H>U=R+3*WI0F9_R12V#QY090*T^.'^F4'K|F/"P
M^1\$61>W8YZB/EAT!EL <^+@SLVNZJUV\$-)>P(P&#&)P_V2OL
MJ4QQ9|UL+L1N2>;PD(=E5RG9^ ^7GY|T?%(5=|NN)WIE/7\$2|>LAL!&TCG.2 M
S;:8&1KW#F0/=|8=1+MJ/N|0;X-C#"C#+:'CGTC'&6_ZUC=J4>./%ZU1;
MI0LO|M_LK^Z@I2R/S(MWP-\$H!8*Y\$5*"45\$Z+<0IY;07|A2+8G:9MY|A&"%_
M'EB|HJR|DB4|\$AV@W0AL2S)**|6VMH="|j)D'TK/L0WH"KF!B>A7"NL>*B=
M)=9;DU_ZS(QI)OQ\$3!7N,LE+5M|IK8NZ"U|J M&\$HE|HEZ!QO'QM:6E@+C-|F?=
<=>K/%*;*S87<8^2I"?NS2*:^+@0|HFJB'|J^M-M6>'LP#F! X\$QO%Y5|/VHPA==
^RE:E2H0I%RF+=?SND+3NV/6=)YNJ2|&0 M^51>%#"CAZBRL:K?.F-X/G6%*S8?
PLY'6=*JN%8| ^\$=^8D5:_LBXHKCE;,>'WODQ-"^Q0&
MQH|O=>B\$T\$CK79V5OMK%K^A7W(|WZLX<|Q%3R|I?E3KB*IM M=;W|1RVW;(OM|
(O9\$1?TC"9K\$>\$ _C3\$.|FS._ME;#@+D264.R/(5?7SXC9 M*#D);#R;4PI/7<8YO
CUX,@)S?B?NB*KY|_B|X/^2TZHW&N|J^:?.&K8G5,^ MB|Q.B>>O7P",TWZ(3%WZN0-
Y+K7|,?*+4/4#@SA_WA"K_E;1A-:|V=UZGG, M_E%2#"E'%%U|+;>E05!'>R>!H?#3*P-
>Y|J 9X)0N7@4F|9EKO\$9H<5=|/!*/
MPL(Y5(:R=V>%!\$>N##ORM33#:_Z4'NZ&YYG@KFA>(.Q4XR#ACI%_'D*_H H MB!
|_*H\$QSP\$|ZGX15"W640EPGCQAIQJQT @VNBTJ 7(T|5W-8#>14*D*!^_
M!QM|7LX?:|Q%W?GA+ _TV8:L@34L=#%&124HSX&R7W=-3BL5TQ#A-?#R^#E'6

M'@PNFIW9%D-BEPVDW7M.>M\./+J2\$LC>WY(1*\$_&^W4J]?1=PZP265,IU2\$%
M1-O##9=WHU50R09F+J/7?WQ\$_SJH.^BOY=QPXX+?ES C>.:?@V.N37B>&OMNJ
M|CD?>-|G6Z@96B/^C.2?UP>/P>|B%., C_EN6ETWHX<@-4IU13O(.@_@= M MKE%-
J5A|G6|2J|LX3\$8,TR@_K.C^1C@*X.ZOTHDS4?D9B_MVE?5-
P!V=XNW@+\$_D|TK<>8#|@")3|M5/H|D**1UG6PP&.^8N,O,CKK0-D<.,K
M2MY<|0BZ>S34KN*DRR9#4\$H"D|O)\E#|IT@9;RZ%L|L6\$E8773F+RV|%WS" M5D?
HZ^KAY7"8W+&YH:EMV.NZTPG|7M=2QLX%1MVZYK%%;(+OH+U&=M% W9A.
M>!JG(7C1"JA@L/7OU&'E %^->|.,&LQ I@5U5?DM<"=99U-W0+|_R
ME<#>FQ("LJ8/4K=(8-76&/,7F0FBIX>R|;M!:%7@^BR\$^""9Q_P:L M/N5-
R*!^K6L=6C*7PYF#-F46\$|A|DGYV,"*|E=@IFZ,Q5 U|DBQI:H0\$H|; M:* F/\$'YE-
!\$5(:SC@?>=6W%PWB @<%|\$=0\$^>_J6QH25L|T(92NB"X"Y M5R|JR7%U0JIN?
Y^FK^X4Y:"I3KOG^?=6NES24WWF|O17,)K|JN/#WC5LS:C
MI46("NCU;T0!U9:RJB/2.#!V47Z0"9MZT"R!(HB4JBL0:"63S9M_"5QG4 MK8,4?T&^?>
<./!%AS&MUVHRS!&-Y'#E_OYZ;95KW<)Y5X!7D=IOR!D%%\4*M=,O.,"(
|3031RS|Z#D6!;5XY&SYDA0'Y(X?-\$SC&&;5!<27I^U>V|L#!.G M6TXOQE9T>4
9@@AJA3,%X_AIEL >Y@E5^FU"BN&BO >Q.P |^PW=\$C2=.:!
M58'9B<)|VV|D8M3GU@AC_KRTWV\$).C/URZ5K2Z0:QQSR>PW),^A&EU8E*+!M M>+@I
<.,2M,W8E/8RZ_7&7NKJ3F>U#(V|JC=&V>SIMY\$D=
M.TBT_HZ0U6KWM8_"'(!?)*BHM|B*BXBMD E7Y#V7N-*O,48^/;:N0DO<4? MO0?FV
X4/#XE@E>.>BRN;)B MPWC+|JH7XPMFF^OPO*|HM?.\$%?
QE?|B0D:>FY1I+CL3<|W!'6'+;1#W-0T* M#3%'YQAI;VO^0&MHHS@LIFU;
IU%QHYZI_|H_@OLL;\$^|5XYEC%VMS|9R^?
M9);.:%KBX!4;O^XT7,1X+RQ4BJ%N"L0D(A!25'U0BJ@"FU#1%.,2Z1I(N5QK M;'E:%Q-
T3>|ZHAF10&LLO!7>8|W^(G:FC<_2?M:@U|LYHM57P6_AX&%.)P\$|MANI
:A(/TAH%|_|.,@SX'NH2J"74!;.&A_5^I7Y@Y9(W.%J64=(B+0W*BP?
MFS7*A7Q8TM\$ZEN|;'S@1X:WKW,|NDM=OQ6|2|:6G|"R0SPL/_|E>? TV7K
MH=SYAI'^L=_7NKW1/4B|*_<+S#HCUNAV+19>%LA,JVE821!D,SVC/ M(<|
(#4'3TYA+B#_IV%_-6|Z?K4|TFG@^,AZ(:TR5E8)\$AKH<=./HY+P.Y
M&7OF\$LO/JL@+6|?9(I6\$,7RVJQR69=8.7MNB&AO<52!'&:(H&A67V+|"93M5G#)/D-V0
M.X41_"ZJ*_SX+\$\$+V?H+5U)D:4!|/#&9X-^(#+QL,U_00MR#DX|XZ3='+%%? M
^54A*\$SEDJ0Q>/X@>0#>0LJ44+8)LJ1AY,%9OM|N7MSN"2|X9%MM|_|4L| M-
=2P+\$|+%A|G|QX+1'R2-'J6OSLRIO*#V:40>G%%1G'_U=_=ENO?H)98V3
MHR.EY%!'5|/^BVJW.:3)-?C0GH-W+;:(_6ESV|G^U|5=,!%"--A#<@U7^%
M!AZ334.:0VI6+4H5,MHL-C'KE|JL#=&=2NE#.:9)8+NQ|EY@>3%VA#O:149C
M"++TY=0"8\$EPV,X|ULB^+KU=,>8&A#>:&)>5G"PCBF>@ZXM%_DWG;I7 AO^
MBI65P-PXW2U)=LPCNZ|.+DOH-*4-LR6P!"@U*IO(JMPBF"E"(&*');0<1N:
MD62*>_7,V'Z^.'O|F|\$5SIZP:!'^C#-+YJQ,S8JBA= EOX*H9H:TZ'Q/J6%,/E9"#Y*"?
P6&^GK#2IRO:A MO6XD/&AN-"C<^NIE0M6-KD(O,|@
M)R6OY!_AO:*ZDEHSK/FZR=0=NQ7P7V*R3EQ&;!CS?77+D'3N'NWA|V#?R5M MG#C
\$2HL,|0J0)907D?0!"@_P%D6@A7TM:1VC%Q;8BOWHP_ =KV_YD6G>Q;_1
M9DZ_06FL;79J|&(<\$OQ'=66ZY2|2T|-"50@,-=4 M/C31#=@|:7X%|HX|6? M\$%
(!|).@JV\$1D7H""ELV,D1?|22-TU(16B3A*5&Q^3YP;N!BF@N-3TA02*:<
MN|P|\$U>D=@;R&-7/>/EH^BOI=J*C4062"-7!Q(#&H17=PQ.^=76B_5"H@B0P
M*%:Z!"A4WS="|=.:V77|P<^@C|GAX=?-K:\$KJ"2'U_WJ3!'#8I3=>Y_-M<6
MG@(".:58UPZ.'\$6*AU*8>:>12TNLEU4&="ZL'V6|AU>R5W3ACH/7HU05,CVA MJZT(R=:
(LC|TUV8AE&_"BXW%_?!&S.+J>!:H.?T6O@>%M>_0U|JW(#XRW!EK
ME!\$XX0313,=3CE)4/*&+-<2.:+Q|H|\$NG2&<>/R_4YW|8,R2>'Z(8!Z)+<|_
M"G6OM%07EN,|H1JF\$A>[V:PZ1+;M)7XBY<_E+9|9,34%N.\$94.S4X8[*]=+ MIJMCGT?
G'S2'VF'&_*ZMN(KAOV|O%112ONI/RN!\$5=85GBEC8UL=:?)ZN(O MR#KC=(O|D-
>9@S<".|=P,<7^%W%O"JH3T#|E|A:2 @*Q))CX_I4C|48*LK
M=)XX589%=^./,|L2O!KR|7_C#|VOQM8Z^:'J#%7PS#_1RR|)#SQ!74@+/(6
M_65^"D0|41AY(1'03.^,B|XZ4?5%=/F^@PG7SZ|FY8JUNZO%WGH2.?I_+PU
M,B(Z+HV>62#KZHT-V7JPIW:DVCT(:7)Q&ZE+O2YH\$Z!?'C4U,>4Q!%|&M6Q#)
MPRB#3NW1)^<*3@\$V23BMEWX:JS8!FN7T5SE,93(I46B|+<5@-=| ^0Y"9AP#6N+T
MWM^2P':@;|/^R>A^*7F2PELJL.P_\$U8'2MS*|ND"O+BYD*T^L+7B_>#.@
MU|_1.I.W74C|KN&^#BVH\$;D"|*ZS7>|:5ZK1.O-THK0QM>R1.!65:IVXZ|?1HO-
VCVZ+X-C@,K;/G,I_Z.<5BO%3
MS|;G9"H#+VIA\$3A;ZYF6*LM+JGQ7X7O|7SQ'6RZNG76C|O@!903?IL=&|N

ME04C"S=VX6027T1.C,BF(/0Q@
MZZ+0TD+|CED_ZFVNAKTOTG%S!G.SK+J.%V'3J4(EQUS^WKT@.Z&_L5AAFP4>
MCV@2RG_G!3-(-(M(E L0HTW M>K/3.\$ 1) RE<%, (7)G4_*/^&!GP 34|Z#JHL-
KTUR++J1NLR ^F+7<3>X0;-+1?0"YXO=.|TQZH6(A#RDI@DJ.)B|F'MNTT0
MYH3\$3?'X*N# 5%L?V4#&N-,D M-
%0S1RU5Z@&ON/&F7FZ|ADNGEX_SZI|J: "2X^:B)=-'&PZ_8,X/;S,#M"
MV1E)@KPR<1 ^ESI1#IF&|L6N0"TG*A\$WZ=%"WEQ)'=K*6D9LE:)W@SD'(H=U
M!QM|*KYB805=|@/>P=HB|H1_ZN3VE5L_8_U0!L%X3|0IZ5KN|L|Y@^5;S%RS M^XR
H_SI|P9Q'#EL'4-%*T&(?%G44S9//LA\AS%=B*GDA@ (010W|@+DC:T>N*B\$_"8
M82X'&H|Q|Z2-H70|C7|H&3RE+SK=C:Y W601;/FZ'(B10|R@=O!N'4=%|I
MN<\$^_J:OH-X*7#9@7H4 &6>60ZLNQB!"\$#%!(H)UT+L?@.SH94|(+ \$40A# '&
M#PP)JB.@DF_&98./QIWF:BQ'2,OL",CF9NW+4\$(|:8EW15BX D(A|CRV:8Q MV?
Y;IAI/X0;Q8=T>>B|.LOYHXZCSAZ3,0(8EM_BG^9BAL976"%\$>P! M9+.*3@?
AFFRF20"BSKHI3A'6>K-#OT3YPUBN\$XJHS.-)G|-55'.5VYTN-#|P/R;7+W0NG%/7ZML2
MGG*(^4/:?K;|W^!(S|YF2OT#G8NI7_1>***\$5|0C-#ZF\$|)5#7QX@*B\$=HV8 M%7
:2(+0)@3.KT&\$>M*Z^#8L60AA/@CR!F M/"=|"@SEH?;X?|W+VH-
MH1<:G_-E^XB'5CWX59/S#G&\$ZC%0 M|SOC=L-@;D'-+4;VV;*;|@Y(7ET,E2T;+-6M;)E=
(%)=(B!2\$04@O_09Z7X MT&+C&;P=#%;C %F3B<9/"&|V ?K\$5-G3|_5K?
9|_V=6_LZ:=D/139P#|SH;4.8V,>!)|_4G)@4I\$^3-8%T|
MNRL_4M5^6V\$IEFA!ZS.4UN8YY5Z|QJC_|MY%UM2MAT|N6!%44/SP7_<8+_JN
M6_@;G#+|@*S|V>-'?8-*YZ5W(KT8K!#[2^4]4+5\$>;3P?5=.TD#:QO!:=W252
WZU%7U8#6^FK M8TK;BHN'K#LK\$7-J#QM* 43UQU|X0?
\$0;:/1507D4O)TZ#9|I.C1_ENO= MV?Q(>?T*|3%RI\$(-BM|0PB6PD<<,-
_1"=3")#=@DDS@|Q\$695AEGA0#)\$|D!6JKFFWC/9%+\$BSAA\$|62.8W:4|17^1!>
<*V!YOFX< M-#|H RAWJ&^Z7_12\$NCM\$Z %:>5J= '%!|E0&) MY9AVY!;J,;"IT4_9GX&XH
3_4TBB&7N 7-9J4@E;|/_^|*B|HP6W8RA
MK)M*S=S6>/,YG=F(Y86C|:=/;#PSK+V&^"T\$J8Y<^!M#6_'"F53YN84X:&O' M|3'!2,,?
QUMMIZM6OV.(JT\$3L!3MC|BM'|>N|&B4P8L=Y V#9Z4A2^@QW|>
M^6/|08;A_ ^5P51S?Y((RUJ(IF4Z)7.^U5M#RB:0T|1!>IO9PF,77W#D"MS
MR#|G!#2&!&;Y\$YJC>YU^D+E'O'.W8K/+.7\$7?,17 O.Y26>*|@P.@2SP\$)1/A9;| MVM'?
H|N?D7U33,Y"NM3GG!<|Q'-3^4: YQ)G(2C:0;W C)+=PPGHU60@ MD|>7KCEX?D3S*/
MM(RG\$?#(-901J;NOFF@DDH:4(3SAVBMM.15SG#K/.B M'%K0|GUD7>;3W%M#-
!FJ6JCY?F#K4F9NPDLB3U|YP/=.,2(|?,'7"=3N%2J3NPCJ07G6 +P#?@^O M"8\$R-
L'++\$07>X?AMX+RFFG|:0%^2'AJU|JXHC*N3&3/"ZK\$W)B)H,MN|/* MIDY\$M;W&7GU,-
X;\$1(8|*MI@MDK%KQ|UH3UW4Z<|B#J1DY^3E'3=.\$WY\$+-M^@|Q>UJ-DU"+P|I
DT9R?0@=/9"3"Q3+8|_J1%LSSI:O(<#7B1P526P1WKP)\$M@_|):@(>O\$|8(&|I/D
!30!BO*|N"8+!+5*7(J)/=!GJ_
M#=#JUN1LXTH|7^NV>|U>C/*WGJE^|MX"QN%G=4/G1!10;Q);AOY@?\$CVBC3^'
M|UD6RPOA("&NDD-, "5 "\$HOY4ZN=)O
_*SKZLF\$H)=QE0(_M/DTJQOIY4O#J'36CRO#;3YF9?A_O MBJH6
G&E160%Y1@&.:G>TBMZ|L0@BJSQZIZ33@O/T%N|A0>*@Q;)'<4|5R*JEPZSN3E|E:3;G';@
M2UC9#|:BGL)KC865>8"IN,=F,50"*Y-E^! P|N+||^N\$;|N3:W"V%4&5P,=,
MY?!0|^%|%_* (JP"C4C6"C>G@|*8>F|4??/U4LTDE)P4OC8OC|A1FKT:|7UW M8*|ES.5
'D>IXR%"S@_UHGRJ/O+/2X2KV?|Q:_LH;>/6MJO^H4C"B|P8>H:CC? M/^NG%6K100*
|90E5KC%7)F2U TH.VIJ;M8#8*X'9VJ1!XVAY(0MJJ6??V88W M\$+IH??V9N^?
=REE8/\$RMHF?C'E/6SY/+ #VB"&/7-\$AC3&%AJLQ3+0*|I2>0L
M4N!CKDV8&=U)H8EWAVR@+V@O@05'CB-%K@3U.<*4EIB'+R)(O4<6KL(7VH'-M;B
TEBVW0'? U7)/8P_-0+|"|;Q;HMNA|73Q%=9XO*T|^0> N*'QD**Y|)!L
M|HAZYEV\$|WY;UXU.JFUU7|X>)2YVEE,_.^OA|%7|4&'U?3L|Y4Y,VT=#Y|Z'-
M^R|9*17^/CFJ=|Q^4AP2*F.Q&T%@C084@M5/#A|X>GG_9#%Q|?;_LE8Y_
MP9D9I14|D-C7|+?F=/0FG^+8W|JQCY|HFWK.?^&V;E#(*)I0|AXUZ|WWW%%T M:?
WCT9'>,G*P|\$+QS^+U75"AO,2J6OW'4M"J:.'#Y'S9"!N|V@9?Z>X10J MC^8F)
E/T&1Z"W@L1L#>_FIO0L9EG3':6=HXV|HCU5ET%W|P>-3IQ.L05(C_Q M0TW' (=V_Q#
|/2:1L"WJW<\$ \$KX<*#F7SQJN:|AW|JH|^R?AV#BF%_TSDHP@I
M2#7Q+T+T!DKO!H#N!KW#Z\$FF,*GB?<20-|
<03.DWY>%6E0YIO"\$ (6N5WY,2^_OH,X7TJA9&S8^O"23L^XK7#W@|E@:&'LC
CAT^Z.J01|VMK^*V:SZM;S45,FNN:/#G3W%C|E%EZ+7%0#8M#<|
A@;M^|X_<3|V^4^3++W'(OH:.*4|QX&Q|_M7|^_|8%;05)AYM*

^4G7&W8RY68&\$:%#B|>6C*F"Y A|S|5'D|"R%1NSU<|3A;*QXBE8R#Z|H K4R%":K?
\$Z^\$V4<&T M<%Q@!'_9#1P%IEA=)E*"E97%F1H
_P|B2"QW>900./3\$6(+@%"U\$.6@GOB^MLIURK@(D=*A0"19QYV5S()XGW.^*G\$1A@-
M%?BG&|WNIAS:%^?K>!K /K0TWL""\$ %C ? A|=W#H5K_O 'I**F40A%3R:&D
MV14I9'9;DL3L*\$1.)3E,S"()R)A5RCEF1|@14R3)8<(.O9C)N9+DS(@QHYPG
M,V(L9LV:W|(_S_7|/<_S?9|K^O|U4|^B9R|P2K"P=,S6 "'36I"3#Z|!-MV\$|V\$?O (|@L,EK\$
DW8PXW-G&@71P-.6IV6M0#X4;QY8B7=R=NG/#<M=W%4L\$-CN|.|K8L<#6_P0L\$U@-
)'5(JLD+S|W-^*2*^L31M. M^GY|J|#YT1=%+47Z: ^S0 S6!J@!/=5B<+
Q9G38NV:E5|.A|'? (B=&|P6' (M^A7Y|Z,WW|9^ATJ0##L ?(PD_R9'E;U96G"3F&BBR-
M,AV2\$G|EV(C3""Q6 MU6P!K\$B4HPR\$LD3L5
2X68ZRC|>N=1@_PIUU5):\$T9L|MKJ7YJ(RX;YFP= M U9@AT8-
T5LAV|IW;18FQ21>G89V1N\$W|N?4H&^0IROQY'T4=M.3KTSX|&:L?
MQFT97|3++|@7U60GU<|7_?RJ,J#=1L:L(@B!5.=A12/D1E8I?F4MU>Z),,:?P
MJRCMP/K9\$G|1KE|!SWJAN@QE&49YVCGDFL&|H |&\$ (7YZ|FV W^&HET.LFP
MWBP@4D;C,CV.O:N|OU&K.,O23GO\$9;|+P.&2I=6?-CC M-?TT3!
|XO22Q9_IM|P|'4Z.G\$)3J"#Z&KF_WAQ11J_,L_:C*U_U5(+@AM>
M|=UK@DO6SJY@;|Q%+^.,|.|>3|.9EX8ZGNYX;G_XV?_8>6'XG+1"#RH:E 3.
MEZ?/0|1Q#%|H:I5T'Z0D>VZI"W=RUK'1O#&TIB7&;O@)"Q#DLPC#'E=ZW)(%
MIO%3K|!#|, #K:)),B1|6E7^IDX?(N3&PJ3LOMBU|5/75|.??C|XJK8 K""0NR
MOV\$,_)6B+'MMJ4/6|39!H:(-^4,|A%I+,R &N^46LXV)B>*RS.8C1JFU7\$P"
M@|=J0"^AH\$9KG,D1";M>YNK_D|Y2%|L;WPQS>4_EKACB"4U\$O%-@A4B_B:M?
M3T01;MH3"45C+<'K4M,C7|?/IUM6Y\$PX2|QXT<'|N|H6)/WZHX\$J0;+0\$2)*-_D.+@-
W2LU;7N8)-<4^|K3ZUF+>V"-2""X*M1GF<'OZC::X(WM782|C;/;%^|):8-
|\$DEW3;Z&2_1P=#"BB1(N?"5|O2&8KX M(Z^3:'MO.C\$S
EXFN5OF|RY?"0J=2DM|;&>=Y5-T@6_9.5NH*;!IHW:O5KV M# A|_O0)EF>V/K-C<|
9>| ^+D-,%|!%|IVF@4;1B1:F?@)J+\$_D:|V+()U) MTP9V+<%2ORWT
M%K,SR<#+!G2!%?6'>.ID,^1I^02L,KR#U/AK:7/|<-8+J=6VU@,YX3F3Y@A
MGW:|7ZW35&D:0_8(?T5P&B"8|F3M|HKZ.1>?4>TV,>KX+ET|PLXBI*6>Y|/V
MT,NYXR&O|(A>'G%SJW8|W5%'S/7!X7\$-WB0;UTV;=I6-H%G_9*!|I'^2H
MT09=KW=1ON!7JF|Z_?QY?!1EZ|K7SU#(|+/"E6H&ZCI 'Y=XC!^VE"?
+R*O!R)RSMKVBB0P6\$2UWV@N_O1K| 3|'&6(|LL%"JA42DRC? M=M|K(\$YJ8;W/;?
OCH*/4COHDJ|U.DNDJ#RU;EY.K+M@ZKMGM(KF!;W2!U'8
M|8<4P=6^O;),8.XE!=,C(5CC(Z@>LP\$T<4#'\$58CJ|'+&9UA>RA-J*HNI7;
M"H14|&@.?:8A*|38Z*A7UE:V31D!=1- TKGI5:0+|7C?2|YY1PHB"OFQ9@\$:<-.B#J MD
829Y|B.+WS:2+L3\$8>:2_L;94_2_FB*U?>F D)._?75JXU
MXD^AYC^713U7NXDR7ZVX8WCVU_NRE@_DZ|9GC7#| GXBG#;TC_;1+,6A1X)T
MQ6Q9IH75;B>K?=Z>1|V"71)/>-|*7O=BXWH*@F(U11,Y-?ARIU6:U#B*XI|K
MZQM<.,%_SMM.)%ZY=G3Y9|MG%*(U?0H;GS|MC.|L(T>RF="'_YBI() (+Z MRL*
(L:D5Z!A6FU\$RYG=ZO?(7_|L&+YBCICOWT.J|>^GWBTQGLE!4'F&D1Q
M(>2HQIGZ:1&ZO(U#NI0EJ^ B1_W8#I2KRQY1-P)CDWNAH?|C\$?_?1/YWRE';
M@>,RCC1DSG)H)5# CRK&PQMVR(K(WH*CWI6=|!92AZ2B<|:6^|E+W^0Z"@:|
MC/'_0|A:XI8N@+;?4.1%->=I_@/UV10A>LG%S8AE_CS=06DG@>OM;AP|C%'
MQMBFB'KL)74C|53:8U&PY=K%APB;??T;*)XXG_D#O?C37*_%
<@B'2%!\$5KJX3')\$'#=2_EO;Z@IN_V|47O)*&J)P?|'= MB!?(%2IU)?OCIAHGQBTW?
&V(LLTBG25|/WD26^+'FB3LOU|1(A\$ M?(0|APK:-8M3QG"<./L*Y+XC_)(^|/^P(/N-
ZR6|3=.MC-N%)SZN,7W8E)) M-M_F,D)<>,3DS (UB-V?G)=@D'@O%
|<\$9DY^+&;0YQO68I5E+(XQX,|UO| MSSGZE|L,%N%J) =:XN2H@2|RU'2U|U9@V
H>E*%;KYZ#U6>@-MF?9+W\$(Q15_MR#AJ:|M!-
@@,|0KB3,XE'NFH2_ =_X1NW/'O7W=>OE|^ ^BT*YS+@C=-!;\$VO_M4P8-.5-
:XF02+V'*JTB\$|+8_OM?5||\$L|2E|M_)L6|KW^<|H/E|GUYN^N!M M_|H%Z<('XF?
L8,UY:C>2"1F9#;,"?@09V@4MV!.OTN3!!ZF+991=IR_S'S5
M0VJ>U7/XBL=|DJ.>2V7_U63=(U?B
M3NF>Q+IPKM*CM=>!G"5W*TMEJY%/M+7&D!7\$2D)=X'J^|E9?*|C!H"!
<9G!#DRDDY_FVVI4G/L%AP3N<|ZQ4^5?))Y%H"Y-
XB|;&I"C+YO@K>/XH%%R5&VER+)*,"E:4U4ZD.ZGB;B\$|+ M)7^JQ
|S<0+,5H@M7Z1H4UYQ\$_8T#%UN\$+=S8UQ0<%&K2|?T:VA|S MFB?">6PMS=|CM28?
OKH^5EJE.6NG=|Z/TM.>G^HX7ZN5E28^=(CR4+/"@>H
M|>/X8K1|>26<>EF0Q!-4%CT7L!CAA@),.*S""=-P>+>_A,@GT&-A#\$A0HR,: MD#3'<-C

MA A_#?.X+GR(M)G"D/^6K45*;N)M9=F_K!\$8X4Z+C;HS!28=4(@@P/V\$NH9W
M>>8KMX.;Y81P#?^#^U1>W'2@OIC#?;%18G_82\/'V%ZR>%3OW@>9
M9::02IGDPK[/I9C&KE6QN_?C7V>OE#_MU"K*.B0362B@[C/' +R<1X-/@_P_G:+"EKX_KB-
^W?G69CH8VTI;*FON00"3^M6]>LQMI#W@^4HZ_7S9)T1%D#8(<58
00S5F<>TCRI1@7=>-MI^BC|?#ZO^2H1SJ2CW)42<%0'IQNJ=LS:R7UD.;^9BTQA"0
KP7,N9!>>Y:/AQ'+%\$\$\$Y_@(M>9<>|?I8TH1_1B M(&3B%"D#:\$;:(71/77?%_=@
^/-5^_T_?._[YT341N6H2J/Z387C*^/5,UH|_M*#H+N.9WV_Y8^T>M:ZND(OB&:B:SX503|
<-O/&|8>I_<%7\$XU2K-^_@#QYN?_M7YN5+40")K;VVC0L\$J?
H2+*NIG1SE"F&KL>'EJE4S|HDS\D*0UXA^;YN@510_M3_,^UG*[H]FEBNT-
BXHVM[VD^1JN7GPVR*)\$X=|<@="= M!:2)|U\H>DZ@|:
<*>DTTW'I>:N%OKC6CNK\$P>_E:AR/C-:L36YWK_\$SM,R@/O_M#?
S|B?|EQN@T1W0=4_N1@>T;E22#S8>,0038!MXZ",LL3QHD94|!FTFV>4B|.I
I#&_0%U4(-XFO|)"(B_M8#W+.EP47_^(4+K0814@&FT EE_'^@";2%Q7HYU06:FMM7?
@1|.:55V=F\$9_MDZ_)(DBGL'ZUKL/D=#-O,0,?)WGP|HVO#L24H<7Z,U6=
<.ODTF#K_4: ^A'#=[3*<>5NN>I;J_Q'J-@*RR9V#T
M|YV%+K)D:'X6|7XNO3A<5ZS,J*I*//4H:#02!/
MH&8Y>T^=5(I RR&/X3(6(PYR^0GN*R,C+@=NOBR\A'WP"6G3=!TI7;J)*CVL
MRYS1&PIF;6_E!>EILJ4L\$WN)R%V+WNJO1A5@\$| #KR021*;!GTGK"G:"M*U:O_MGH
(UDNSCL|J#.W|1ZJ5G;GB%/?|<\$M*Z1Q;.%H=PZXF"<\$&A
;UO:.*",EVUB.DFK#;HA@V\$8Z_MR2FIA(I:Z@"?VC0_&150_N8>LG3P00-I^Q'6I)^%(K
\$"#>+I4XCYA_*:X77_M*BXMHRLDLJ.*CO(G9", (Z)7_'5C1)^-OHD>XW:-
KO=HF*8"^L%:R>SFB^^M%?VL0B>R|?9E;6-
TLPZ|=K/1_>:Y4|0_,I@.V98D|CW+. @5M^TNGJNS2_FP(M\$=@1KL"GI4D#SVB2WV_N;
| \$C2QN!.= \$-8@-O"W1=|DR.|L;U*O"=V!4"I00; M&W%@\$;_?"#BMIC':@(|/YT+FH
V_VL;NM-^1;W;ZM1T(:2NT?*#@7D&N;QA
M7ZTH#;YZ6^SI_Q7GO=5V|>2>R'J5\$4>GFB@+R| \$8HFY8/E4=DS_MYI\$X
L"@URMZM0T:G?!PMQ4-_WX4C4D5/S1;=J^MVI>^| (CO;M8U^4Q+N
MPFSX1ID_"1|*2MFA0HPD;32:*&YV+Q6?;.:6;9OG?HESFO*4J|)=|?#W9T4
M7XM>#|D)UJL(!'U/U_1K@HW,N+:7|F6|=N7L6W'U-F>EY692R)!I#2<26&6A
M:|35&L7>#%F*J4M:A+90@ZGSD*RS6/7L10^W'D).# /E<7HC7:*3/_&KWW= M.BC?
8^#BO@,+5Y>1*I|@'S1(WUZZ;*0I:YWXT%9,+7=N;_N&SDNN=1ZP3'?62_M&G7V^0?
PK|DBD"YM0;@284<"3JJRM/Y|@7|>=!NI_M7_5'4=I|HUBK^/Z,E&,N6@3F@3J;.:?
DJ+7@'|D6;+G%NKY!.ZK1|>D6E9-@QKB^?LL
M@XJT4T7:F7ZAPT:\$NF|U.|QQZIGVHOUYG29V&>2';+A!;:K_ DW\$|)^=TR|J.F:EA(S^M?
W;|N^CC_2N6VYL\$V#.@|_M%G_#A1K,\$/(C|7C1VJLKWYY/JJ9E:718\$4_.L,*2_1X>N!;-:2*
M:##<#DPQR(YR5%NE:B@_ ;6|;X@)1&OQE^#VP^! (^AAC?SSA9O>P\$K/P8L)K
M1O|FT@IMC.CN6SWZ%DF5JZ3LE8X'M^7*,DU>=6|ZHJD"-8<1R!;1Y"<|7=3CT\$0%
(A:W;#;P|VU_EY;B|OZ9@SW!-W_M|&W!
|^|^>3_V|S5VW;X*FD2"G'&N#UU#;EZ:Y3|'\$UE=%(8VXK?TDYV,Z
M==R!+T_R6(.ZLBPF/38=6T|<4;:Z_)ERHQ|6|A(7FF|Z^UW<*HA5;B8D=\$C)EOX/S%_M-
NTZEVLBX_'9|E7S"_#=#X*|JLA+7^G"R9YA_3%<0'*8#;9*SY->#S<.ZHJQ
MC;CM;I'9V|C>+ '*Y+^BD;".%G11%1P^KW0FY9V'.3|@U,=@JV)\A5JMA*F5:
M>IRVJR(47"C^SBPKBUL7BM;)OY6=VUS053WKW#.JW5LU&5C^;E&.;^1!JB/I
M)\!=+"B5F/^|)6KF;Z|VB*OO"B7M2_MMUWBO!%|SX)TJQ7(9>W#PY88J5V.(Z9!ZG-
01T05#^>@2NM_55JWFB-B1_M?-H|I&XR^7F1%42?
0C;.:!2#^N)YC+K_AEV;+:NYY'6FJ>\$*B2E_WB8.)94_M//";%4?
_NUJVJO<4F\$P@\$1#';KO/*#C!'SJ1!C5XY(\$ZD6=H#|28)9R/-M:Q;E
0:2HV8|BXT"*|78!WGJD_0= M|_K3_R"WX65_S5_<>^6'?R%!%= _IRZ); ?\>"1J|(@)!_1<
BHD>H\$F;8!_M|QJW7&;NA*9=-H1=3OF,WT31)JE|-\$|=#<|EM(|1-
&1QAY7)CK^+&-6EU=6_MIVL6D'OL=1SC;A<*LW_.91X;.*L=8KAB_7SL(D)D"HB"^1@#
|49_M5R\$@?;_M|J+|Z0HX&/TT@(^\$E_D>_B|_ \$E!'E_Q_Z7_/6:(%;8#>?K@!GP_LAH!^
M^#+|^?X4+RL'_KPK\$D^Q=FD?5P:D|=#|^H#V?IB1'|?|":BRP!;ZJPINX&|HU
M| \$W@1&VW9NC/8HP)/E*9(:R+6&6E|OJ9|U(G43>N9E/S^8<^M:ZL69E=Q'W
MB+/\$D?CSL56A3/U|ZU/L4\$3(OQ_DK-);\$7M)V^WS| \$3U_X6'+FL|%;;UK|
M)V&+^=;_IE=-!TZZ?@SUM(_TN_JD_T.CF(7?Z%%HR6WMI7W\$|<6-;Y|X^(>
MIF/B@*O*L;35^TTFH"|107#EF7%5OP2MODD)H-%+3H3K4Q_M7|ER+CG,FW_-?
XN8(<+|Q7DG1P7VS|*-MYCG!UT)5DV_MXOM;\$>W!#*D5\$O@*3?@5XY9'1-?HE2.#AF.|-
"JBF_UEK))2,?Z!R2--/(G0_MX.;! ?AZV/JHB| ^/Z=G=/O-

!ZN\$SG29*AO31/_"@08C01&JRM,#""^O29(M MRJE=)GML@H_)TK-
7Z:CWW".*BN9K*=325%E*K|""H2(66[14%/F2*/R 172 M_5KVFBX+NU>\$G-
_=@;=:7,Z*'4JT4E,*!JOEMA.+!&2^3-^IARG\$,:09!OL M4-TUE^GC4EW><2M3Q[8C()?
5&7P,=Y:5JFF^WJSVR[;B:6+@2!RWF[OGWR]" M?
SOZOY[A8!)CR[2>P*N,IT"F%_U,J%,VEPO? 3IZIBL76+TU)(\$L):JE*,N M&UDU<%-
+AA(<)P73\$<;!A(PCUXT@F^'6>UE[WM)J!\WM+=C/N":-12*>O9@Q M?
_BPB\#P%?.8B8GB=/^)=JZJ[)5QE1R5P!'=K*C#+",EGZ^\$FT"B6%,2S!)! M/U,K,/?
0YX_6HM?"7^!;6K&C,29K!??UWH?J)V!\$1O!0*2"4#
MR68F\$5)7D*3!B!=W<\$Q1C>JKXY>T,518+_D8@CK;==FZ[O;"-X#+3LVB12[2N+G
9MX;#%1X M0'01Y=%H\$|
MLGAE\BRI&*2=/'1NBGZIW\$TU9'9!:PJI=/\$)I=BHY'4/5[78!U@Z#%Z\RP.
M:=N+HY67^93XGWA,K*!;4!6_778SJYKF5?F4%YT"Q994OT+WWD%_
MM3_JR[FW\P,VY*AFRN8*0V/(N@!>K%7QJ4TB,S,9?Q)&PSG+Z=)6#>[_
M;M6@N[150YTQ#MP2[B-'Y?[VGUK.>6 ("8J9-\$QO\$ _S190HEZ)#8@JGS T^
MR/F_O+,7V@*!EZ..T^/PDNGO !K60[1SKI S=0F12F\H"?CKP'^56&2<@+C@ MYMD/-
RHK I,*8UV2IO^JK[HX D0"3@Y@.I-\$K1#NETTW9R5D-
DW*^9BU0^OFL\$;2P%NWE5XYZ=V>(W78+'U[!#K\$4 ?*'6&?G<;SSB!)QOWH#[HZ&Z_!
!=-"7W4#EY?*1:FU>"X M>\$FU+)FMIX?%'K%[0SH0-5AGW35G?{#
!N(#6[PL/WGL&2FO4G%MON;N*3VP\$ M1T;=I&J)/4EZ[X?H6_R+B_+&DP=^3P[,VG7L!:
(XDB?G=V._ST+MV.?*X%XD M&7*H\$D3&EAX0*,NT0/%/T;+K'.B?D
:ZU)RJ#4QD@(IX;P3,KE,P)!L^%M[M7_+@?OV=E 0V76QZHAU6 W6LLWZ:
(^R]":0VW\G)4&TI3JD,13B.430J>E@7 MPC7N)6!^KS9_\$+4;2;
J0\$+OTW\XR4AVA9+7IT2J;PTE&4163WR!HROM M&W;.0Y<#J5?
:W4VJZZ6NLH80JO-SVP_C3%P;_?K@Q4O/;JYWNN9F:OPB)(
M\99=3&HO3WP!EOQ\$;%^#+J6HPP?(,WCX?;N.;NC1.;R#XX?.O)^PQVML^J M.1Z_D8-
ZC.U7>US^QY5[IT<_41>-!QNW05N%N6IQ#@)RELO(>F"L.\$[P\F4E
M[AZ\C63G)HZ.*7Z0&AMLDD7UT?WD=^><2X6S\SP7KKA5OF@?:?8O&M\$;(D#?.
MM7[.J.H[FW)UX5DWJY-/"6XST@;UF_VR'@'10,URUF_6P3\X'JC450P+Z* M;D[!+AXM%
!QU9O(!B%2FH0*6A>ZV^WKHK0,D(WVYG%A[Z(^C.INNKCEK#)
M3LX0(L)FLJ@@\$ODR"MP@1RUV#QXMHH\$F/?PN49GL#1LSX;GUJ2O/D[P+;.;C M-
'&!UM4MOPZOY[C\$1:2-Q.<=28!_KQK7G8#JW[;_W<_X?I2\$)\$H M[;!FNUQSX'N)!6UA:
(ZJKN0NXCN"0!T\$(OZ/Y=|+ZK^!Y6B*#3X58ZJX,P^
M4<5&0AQCX!RPEO,]#4(^H\$2!KEOJE\7= NH^;"HVXJX14!;7W)-^NWAUZ3X M(7PDP!
!..M%&BHNA_ ;*4:=+^!;3F/:%LA(=#7M3;JG7;CLOL!N_=HF![%+I(GB3A_7.6 M M&-?
C^-6\$<-LFI[Q@F)X(_XAC0@;8.*-J=QD6\$DJU2.;@H1K%E>1HK!PEYJ1
M3<7<|;3*P(*7K=B[E@;D^!1#;;7DY2>&/U!TJP9U.F<;54;_6VTUA(K-7> MU;Z_R'GQ
W=MW<"Y9+_ (?T'07%R:Q'F)Q=I*RP[DJ/_ MJ>2W3%/C.;;570?K2?/0JA!
(2H:*#.\$O+F>0/40[V73P%A1(S%^:=81\$0&- M;LWXC&DP1*\$&OW6|_/9?
WRX.^FO0Z[!#W+5>!;;E^Y;>[!D!8?F^UMN*G_# M*(3)|3'Q_"CEX^6QJI*11FRC
JE,ZT>>!\$*;2)/#-/10DR\66;)/ZGP3 MFF%#GXZ^MQ7Q;4EGUE:T% M8NNR,&VK"XK[;
<)>DN3FE,1!.8^XOS;IV_A(AV=T?N@.R\$WS2K+M !;!/3/ M+^@"XA#"YB:G%DE>
T.T:T%LE3@)!*IDRD&MI.T[.63LT,\$".(X?3[P) SB
T3D#)B1A#Z;.&'9_3(N2H1HP,2>I5X\!7 M%P0TVGMI4-
4")7HNL;19G\&W*0MI2P\$@=4\$<#Y,\$6?P3+F! ^ZI@#8E\VV\$ MKO'G9-&P.7&#?
@S91(RQ[KB>2_V[@QSVW"WBCBZ7 MP-V7[_,2\60;C?O'F03TNM!T-
68.J;S.5A10\$0D<'\$+H83EE+_ =A+IAC%-N M"FU9/MP(K&/TW"X;N[V15#>LW-
ARL;%SJ]/ZY#Y"[CH 0"-6EWHM*4>]/. MEV6X41UVK=!5-!?(fF
+8HS=.W.WY)TQZ@XF=#&L(N[;|K)<[3X;194WO M,5\$O)\7-%RU#**BE^(F<<. ^NG9-
JE>V[@VJPU46OP MG>!8V-G..=FU,(
[H7[GG""JC:NK:WR8@66(K(HSE,DK&X6VJ+]/=XFD'.B= MU#"-A?3F*
[118.;09+PY>AMH-OSG8?JK"W5ZS[U?C:*LJ4],MKMFU3,J.B[IRS)TBOLWA@<6!Z?
NZGN:!\Z6EZ%8N.8X%;E">V-XF/?-IERP?ON[8%,>T.7>%RT(ZW6
MIGZ>.QUC0AOD[ITN<@BD\$\$.+3+TK"&Z\NS<+W+B[P\$!6NS0@);92%,399?L M-
>"[!#J9"#XI@O:*7>Y.;G[!^&PR!%8'/01:Q#I+'9'DWK#" _A-X"?B)L@: MO\+3?
S\$DEJ7/CZ%;;H\FS6F[1JTR[<)>7IF?*L43G<&#^C3(G,17H"Y]8Z1V
M4(Z*_ (CI"=2^BND*X0<(MS& M&)!PRF0QH=IDWHO9LWN9N[;?%V03REH1;[34]-
I@Y?O8_#1W*Y[|D,TL1\H MY?!W_N+P5Q'+0I%\$LSP'NT@>TTH89YWVG'8>"?
EQVO!\$86JS[<*\$<5)U9174 MVH2URHEPU_Q%>H0A@!:_PP?

ZS&M!S%=P5JBY!>)L*;B.!%[/&;& M= SL NEQ1"7!T)6T(92(TL8 6IU<^0HP@*!V!%,80
VB.8:>F*5!FQ.5\$!Y,H!FZ!TU4!.)! MR"O5C06&8N!R^&K(ORE:W\$S:1T" T#/K?A9L1)55!-
?)3IOX4OL!@*SZ\4!//7 MQ=WSB7FAH=&1Y5%#^A_8_#B9YJ@=90H\$2_M^,9&4!HYZI"-
!#AY M.Z35-6Q.U%/BL;)R\$
MDN!P8G;'H=7<_='OH6D!U.C>SVJ>9HB'KR^6U0*X@7=%=+CE';V#K!_'\$N@_M?
L!\$LX9T2+"ABF^/.R_BU1;9G"^AVJ8US/BZ\1!>RAZI(PS[3K)JJ(?7RH\$
M^/7C9NNK9^>=TY5(!QT0DQEC#(R!Q:GZY^_.S69FIDP5Y0H1O\#S"7YVLZD" MJ
>58<4JZ7J@CHWU*6B!B_ " \L/#*<+,+\$6X4@4NT !L:*!["X#H! \$LK0Y. M*?
&B8W!8D17(&KN4BB!/"?B&>'T9NEV;9LGIC-. =)#9*SL#6?H'8!GQ*+ M#WNX==32-
EKNHW2VV;[V-37T*)U:XSE YJDZ+IT2<;N6%U6A89E=:Y?S\BG MF3V%)ELOI>\$X4>
!F^*!/\$W.V7OK;!,Z1,!25A 8>>ROF^_@5!8
MF!V<|*S_:%ASJYKMIETEX("F_1*1^\$66)GA,P,-M/(> M>P:P9[K?D!AQKN
MJ#0>NX93\DLG*U_V"^9S!IEE%;V"L&W3MX1F%XH*C87F I-,UF^G)#?;XM.
MM>#;@*GCTJW0/ME!>+DO;SE%M;7 O_S&1 !L)*;&!X_KF/4D6H04N8V7NS7%
MTH4!\$7Z+5P/RQA8MXU^,FY&O;)D>;!M5X%Z0Z>*4*\$==Z&2SLLLR+
!08E!AAM'/Y*CF'1(!0G62): (9\$!X 730DR.Z#!29 ;5/Y*AX MQ"^M;8)5B. 9@'^6?%6LWT!?
V(!TPF52&+OI>FF&%*+P'@"PM7V05'^^QN6(M#TIM)-?1%RD#M-(FZ'##%5(\$8)T&N!F
:5LV#JG' /!""\O_,M<),X4\$KB@!D) M2J Q2.=##D)!1V!";<%&U!N3>*!0#6WA>D%M"
(BV\$@@ 5 G!)*7E-L8S\$. \$7E!1.8?F;(MJ'9'82JJ.!WR 2TM3N(-.:%>D:18!;@;/HU>0Q/?PY04
W),WI21*!N#RGQ, M!%Y4CN4!(.<:B8..@WE(,)!"VC_61MWB*-<VB\$\$I(X!P@I9FA
O>@KX OX MX6(HM@^X"G!)\$W+!&+(MR"V_>S<H3E?RJLN(KI?5Q1(^TZ*GFH3\$>!M/
D9 M/"#2@55PX!DLTK*16EU// T!PEL/@(, #Z+A30':/:9P#UP'=W8C_ \$T9D! 9 MX?
>E7DY2A -A16:Y\$;H!H+344O+Z; V2YT@EVI9+M:'&!LO-8-N=_Y!)E:(M%;J<8KT381+
(Q+QO!O9YI(G!R>.<#N9T%'PXZU3D: QD\!P-C.BH-RM*267#
MFB7BX/E8R\$F@S./N.;SY\&FV4#^LRHA84-F_ ^5?.I.:39Y&FJB&C67J-REK
MC&G(4<(%Z2T"386!7I=2P7PC&HUCZT!NXLC!!--7\XO!8X>)#TO\N@=7N">O
M9!S!J;R65#XPJ)IHO_M-X@AF LVGUF&70=O <21('K+ [E@>9!>HN0U-Y
M/0E7YX;/ZJ!T?)1W8E>\$WEM6^H0<J2I^Y4RE)UKJI9^FW#N*Y?J!\$':P4)>C5G>
<*NCI8*X2=A2^ UN MS:LW"XDQ(2J F/?<[OA\4K%[6,95=M
S?J!B!F!R9C!_8FNL>8SRM^JT/G&/T
M/R!W8QP!S>5!2)Y%#XU"FP!Q.>^500/U",YUW@AYD*+;:))OB1Y=0*?UM>*M
SV%6LQ*2FL2I%S-J@)S3.M=*CN9F<1S!H@E3!B!M!M,2=+;S2M?^0*F
M)&UCL_2>M>_DN1!6A8/1A=T=S-GRG_W3?=FA5RI#Y!FG*&7M#?ZD-5^R.8!
M!;: 6_ \$! ME^7)"FYAEZ.NA2=+++?ELI<=D!0^)'Q!(, @N4K844@\$#ES:59%!"!]=!T32
M1,D @@@17@%IKY-A!3:7I TX%4 (P@H\$!JG#H3S%\$08X3:%H?J2A.D4R9/P
MFW&M3_L+NIQW0+G?XV9&_(*L-J=%X9Z"1^ M*F2P9?LE\$VHN1+8V.H9LJT(+2;?
H@7X3#<8/8JRYP" [1%?"39 MJ@B=YRXQME\$&U&M !/R_ M-I9IOM! =ZKWKQO1-
D.U7IARUQ3_!"STXA^=)MA6?9&-VM4%[GH/ 'R(@^O); M!ININR/-K>P.Y5A_7YA)Z>
[^F%T4<-';9[A6+7R2EDJK(#H;1/*%JYJ&)&3 MM8B+4\R#JN*7^7JN0<"H#
(&Z3:W@*6R)421'0!H2\JK92F2IT2INN1+[G<9 MC!D\7S_XEET:4-
X_4,5Q=F!ZT0IM2885SXM^F;B)HN 5\^OT8JYH)\H!%?=:4+?
N7_JU@OB:M.O_NFGL;JH1<9' M+JDRR380:W/J@9H32U-!%8"A;YZ!G8M*\$>=H;8--
RZK+EH\$, *-+Z4%*PY
MO=9S4E+^!T2W1D7TSU%FJ=@F,CB44:TVZ=IF+TG(;JY/O7J+MFDLR:2S_OV!
MAUQ078U>!(OH.AE72FS*,JKP0!\$%/CJ+!C=;(741N)_>Z>8H7W MZ
W@\$V8_)HJ2I15\F*0<,7Z;:)@IKN_GH+IAG1%_7JCRY^JM H>GE_./:\$ MT\7^J*"=
KVDS4N#WQ'Z)"O)6=D!GJ0*!,39:Z#U>9S\$0FBG2*6?_'[CA:6: MB!?'_@#P-S2/XV/-J
U&86>[->N48:9S08&@(9\$ 'V1Q1+L_ C43B M%SDJW0MA=#2L@ @===\$1:G Q//2-
AM.\$%9YXFGYVVY\ _J%759+V#GYKMJJH# -9M%XXSY2 \@-S"
M*0X80...#C4)S!I1ZY',6=L*JZI'6FJ!O.-./\6H0HIUHKY*.4ZWE;R=;2
MD*62K:B4M4>6+\$-!C2)>@D7LDW8G7"-1%BHS/,+I@!SRLZ=M7K!(CNC,HYQ
MRPV3U#/R/X &D?L(A\$:<_?=:).QR'D;J3@=K%&7*UE2T' 3!\$X:RM^PJP;V/ MPT1XND#[!-
UGXJ= D3)B'IZL&!TT>R_ ^-A@&!:#M388R_A01+G/!(5D'^ MMV0)FQ&3%9^NW(
%;3G!E=;G "I?=Y8!H:%'Z1/BS6ZZM!9!D;BLS:YO,! [Q\J<,4T,% M?
7!JTT.M!P'0%LM"&2DM6BTEHT8!@<%4O3_T(-;VHMF6X7\$*.S0 Y&00K8- M#6F4!+NI?
HA>_BW@EZ;X\$+Q6\$Z&3'6!D.91#_GC&/'(I7>Q!!7>Q>XK8F+L
MK!8.UXF093'T>T55"2M:H'= ?*R^)!&9QF!8Y>_!;&P>77!UJ*J\$+*"A;Q
MTE)V2W;E='.RW0P2;!L=SMX.G.JWG_A9#C.4!H"E\$?4.P 1L:=!>Z.2SSY

MO#08|H/W@P/BJ%_OW9"FAS4|+_+7X*T:\$L-?|/@_69USM_[NJUEL01ZA678/X
^@ET'N(CM8K0G:MCP%/4_83>(BMY^LAC:(95IWN|J?A9Y9MD9U_DG?=ABV-_F'00C
^|EH!|W#|@_M\$CBKMI6*>N+V6WB\$B3*&H^_4D\$;LJEX;|.)^/K%VWE|G-|X2+)IE%
|6DC MFU|7K2H|J>S*|_5'TFS?0F0_W*\$:/;5\$0%-Y1J,-Q_M-
>&U2@'%Y+6BIV_L^0FJD(NX0#!%081H=<3_L+P3\$NC5K^^(M4YE2
VB|+|Y>2PH:X|;5G|!10WL("C"18XNFYV%>NY+VZG.A-OE=|N3|!-?3D&:
|7M8|1N&\$NW3/\$2|81XI#T0ZHFBF:JQ_MU^2H_A|8G0/M6-I4)QE2SX!5J=!>.0JT!?
B(N(ZT\$A,O@GD5|&8PP7T_M_|K.6L'B\$/T|&_(D*,R5.6HJDPYBG>GZ#+7S-&T("'
<0>.%JFS_F|.*B|AM8_MQ7^XR&QZR#!YUVEB'JYC*|8|&..T&3*|
H68#:UF+2,20%8,1AY1Z92J_MX_G|_1*7\$P34R5WTVS9::QC^>.+R|JA;2(.KMM(I?
FBI,*HUTUX;S8DGZM_MAVO/2PATJOM%73=1&1TU!6&|B4#AP"2^A/=?JB"#
|<&03^|W&IN_5L5\$%+5_MWS75OZ;A_M;F5ZFEC:P*ZTT%_XA|+@+;5#,"?CS(\$=>
\$0/@(8-'*:(+TE_ME(F"3HJBZY47U)!0V"G*DZ1)TJ!=M#|L#|J-%_TA^4";|D(NT;0K!K'5.
MTKV(-WX"|_W_8_C6=L";;"(L|15|P-3*0\$Q9C&#&/'>'!+6+!^VV-(1;8"3_
M'M"E^K#5O!QU7;K0+T>U4;HDAL1B@U!.K=W;|3_M_H:|P
1\$2)QZ_W!E2"BB91"X"TI:"=>1!2#@6KMB;7<=*6YJ4%V,B5KR_M;J4K>8O9/+PQ,&?
V,SXEKK*98|K*"0PM8|KGN_M+O>(+F1B5/W@W7"J;|S|QIKONYUEF9LILGRF!^7U^|L;-
IHH1,E6J"#>C10W8_M4GIM:U|:O)FS%"A%6#X2;"|!"8J:
64<_@'P02!'!6#GC%:HED!9XHWA5AG_MI/&|!UA_TOHFG"-3%^*OE(-H6)&'1'|
(DO>*LI<4/;@-\$/+5A18@(X'N1L6(J_M@L:
(\$ (BT0<(0(S&%+=.P(GPBP,0NC6E\$9@ZC\$3^"@,();"E<)XOVDM"%Z(KP
MTOXIVM5WLC?9.5F>\$@ZZ(C'7=+AV:V5FAY0,L+9!FLM#=#&"Q|1>?*RD"=+A
MB1HR2_I\$*"AO38ZEUD\$UD)HJ_#DEQ4N0EY"#&B>L&|).I9>'E
M'9|_#4,_|F=@VBK;A<_48/35@|!-I!=WOT".|L4L6#F,R"#DUN4H:&=W
MEBYSQH(&XJ_068\$L!TDS|2==|2PD|@NTJ"JX("H_M92T^GCB;
|YCB%|3K_|B'0|>1X_W.N4K'OF2>)M;QU4=ZY|/*KQ>.+DH0=|70,'E=-
GG^JJ#1M|_CKR|7"ZW|N.M0;9SY:F_J'^M?7%4L4-EG(K1)G1062V^#|?<C-
6|5K*7H(@ (7D|<%&L|H"2|!K?B*KOTVB|3KQ_S?T|#!8IQB8O+8::62)B57XS?K;)D9,E0
MY|IRNMN\$4RL%+Y7<;/J4G;MIRU|=N?\$ISL7YA0?0%TZ8O(Z|(N36.Y6*4=IN
MWM"|.3IQDQ77XER!DVOPRJF1R:-A)DKCGW|0YHY%Q2VX2_Z2O<5>I7-'MK5.
MC8NG^?/UPM/MGZ3GV**7&:_M7I#D*/NVV?Y)K8._+G99;@?3^T^(1YX|_WHU_M<2?
X|9V?S_G-;M&1N_OFH2^K!%\$FYQK2WS05?K9_HRV=T3##_"30|=?;Z=,MKNO|0L=
(TE.!0H_#)|577GSEOM;_27Q\$;*G=C;+D%_@1#|)8.UM?|S7'=3_M7=
7<6!%75\$_'Q#*40(<.+";)B8T;>0|A&P%O-A!(|H|
<|S7^P!S/*PNQO%IZ7.7+Z;*>26_53R^&;V6^2Z&E3P6VW^;8_M1|09O/CM_XWPLN
B@HUHA%|BJXW*|JX-J:Q(0,H(J2/,_%["MCB86HNMSD|M?X);GA>^3|WM=D;>A>|/?
LADWT5^SH:?!-@EXDJF@:W@/=>C+N5E\$>)-(3<_C'W%W*2CKM,^05KWP:
M|2VV9XB^|D)K)M0G(B;IWB#QSQL_Y2^/A|6|>U/7SEFVN^IS3VO|J"2T;H
M<7):WYDOYU|U%AI*CK2G;_M=.8>A|U%I^J&'^^I:;%H\$AYYF/=E-?F>4\$,M#?\$
7M/9):S'#O\$3T%@L%449-K9#1.W\$<<6%;_+35.^80BC8_VR7X>BO4A%#E
MTPU9A|P(!3JB,_EL1@??#<%4AT
M9%YKUSHY,UFKEA|9&@WOZ/=+|L,87/R|^"+YB#@@ZHP!_+15=WTEUQE%5M^
MP|=K5:PH+N|LZNT#B96A)P/'_MQ:_M27>";M|^.&%==MPX<7|2Z.Q.=O/NQ9XGA/-I'
<=M*2AX^_|PIAY036W=OVBL2#-(EY9CHPJA2C&08P\$!\$*1WHB_B341\$@X1\$17H|
M%D!1B(AT\$)\$J(C\$DP%%Z;TH*"M)D1R!L2>%NOCON'>.|J_W'>&,DC.P0\$M9:
M<_*SMISDJM#N92%%%HRB_K'J,"2JN8_/3^?9/7;HBZAEU>/E#"I4G:/DKA?)K4|8G'6N
I(+2KR\$\$,0-1A\$OK|_TNQ1A|,((1XG_|LY&OF,;P:&_CPY(B
M)BH/;+Y9X_RK%_O7A3KB30%>X(H_|!^<("J)@L|TJHY\$7>-SZU9DB9V
MA;>+QQ<%7V\$3:/O!(!+&WRSK_MCA<-S.%C&JF
/<1;2@5R"P&++CEGBCA/6;BX;X+)F:%O+S*H,F\$Q|LDY|;Y>Y3|M_C;|M
M6DM|'NMU8)U0Q1&BN42U0JDQ^T)PV^Q4J6,K3>5,<,(#5SA:U_#V,3DY3N@P
MRZE8S.00F|W%0,/0H0MO7|O6EU+0M?;1C_B8|^.\$4|_95ZH;L,0'_\$_^D_M-
1SZG0#_:"YDQ|6|A:06<|D';YL*X|B/CMV#U|DL,UI%.SXTITENN#|V9
M@1;!76+V!'*0MBVC4>@EXGYL3+M<1DWT%BSPZN:M@@|L;,\$9O^+N@!L,<,26?
MJLK?);'G\$U&%=D7!\$R="K+-4K8L|ZW67+JL-E>Q;M2NR^I*2=FA?B9J=K86.
M6YBFW;DK|P.LVO)073LA1\$M_M|RE?B@R_@^"8)XB_\$?\$|NY9"J2CU62X;D30KE4%
|&1T;C|T)TX0@.1Y3^42_M7BUDI"3X8IA&PE5"J\$8T8H(&W)_@Y2R-
KY|HBYPC5*20|^6'#2J5_U@4+ON_MRGTP>\$=/AN)YU%<.F+W'^%?

ET:SHKK.#=>>N77&QNG9XL/)B34:TBGY(^>[MYQ:(JE<,.87=%E#QU?93U6ML2
ML4#.A/I?NPBA%A=&WT/N!7.B&&0TKD7&| (9" 'L!CA?@N"62U97%#:D'EQ
M6@'82(KZ>-)M=)3C9CFX-'6^MEG&),4@|=@09ZI9XDE&*.U0K_IEHW*\$>_=/MAK;
IEW&<2 @ST"+_Y(XSNB5"#|G:N14VPLE%J-,7GJA9?=\$*Z|"-/G@E.F?V
MV4Tl:RG3C+U1+-E@EQ|O'W#V?)2;@)JHYH?I<9;KP7*:7ZV?F5MK?\$.WIU
M5:OX|N5X>XQY=|T.X.S>@L8L ?9;\$/V2>Z9E=*7%(*.PDRD)6HDZQA1%NN:<
M&;F)2>*K KR&"@8Z?
C+-<3G9M+@BD(7P!NHV0TZA5!\$|5X7V.FD/BDY6BCY/.QH|Y+OR5UW
M'P3|USSUEC+NU6O,,|K3J>E_EH747J1T.7 M(635ZPQF+|HC-L:KJ*C5Q:R9
/_WWDYI!6JG(YZH0')>PDXW|=7DDP#IQVFO MAFSU(;G^YF:'PQ-
_U<_6NM8.3SPCGG@V0|>@XMR@B:H+\$#\$>^7|W0T<_PX! (M.&5E'|Z3|PY-
3R<(X ^:1TSQ=X.9G+^QM\$ _3>OVMM+)YS)29- M#Q4S|R5=&VP7EC18JQG=>G-
|AMQX|>_ ^L#KU5SQ&'ZZ_19, MCI@,)4U?0JL6Y
*GP50*7XS7C*.G*!UG77E?"|JW31.2VU%DVI#W>E|.+B|L@E_6|+8AS78|<6O5Q|=6|L#)
MZA%?A2U8W%TT_9G9,; D#!B2-S5D-B;Q%;#54,(*.ZV;6BP, MJD*
(V+@I1\$N"=Y1G6W^%LN\$2V// _UDY(2\$W2:4@0F|;8<@|\$B/Y!|&M:!"! M'|=-?
7429."/ (K14|+SUDGI5^|.V8&,B|T|Y:@^UA^RBOAGU35@\$NY3822D: M-
3D|S_R^!6,E6J8:47B!B?N|GCI?;Y*SX^RT2IS==B"N=UH-.K'CEM'O"Y1 M7?
URHN1@+VK9.H*T8/|@)X5|F" _#_19" M)A-JT8QC+*T:)B^X.55UA:.65:#R-
1AIM/U&+|V4&4KQ9|:F+%M,^Z(IE&,_G*!4|NU>A4
MY|UAT|*" _&K/V|YBR9;V4V=EDS>>0_F)|M?XM: M-
=A(WH*)%VDYQD_\$&MOG);1() ^19|8|A<"CL,UL.)2>WS'R-)| MI5\$G:Z X|QZ0RA>"3-
F>:U#8OAT_MP5|:YG(W| _5VD/Z/4*ZT=CYG1@DMIF M2@=-ZX,D,^+1,.
3%PXM#")"\$E|4-^U;B0491|.F\$(D;A*3<'HE|W>N%#)7 MDB>QK.I\$'+*(("9K4 F(5" W-
NP'O@6B&|3_'G9G5F_ ;S^BM X|&80FY-/(\$4)7 M)!/?E42AXT
_"^<0.D!' /2J^SE:|B9/C:8.WL.'?|1,<%MK2OOHWQ(59BPGKU MGJNM8L
<)>29=HUU)BZ4#S%|O*B_L31S '/OYD=D9|V8(O#)RZ2>8R*6=B"
MC>J&!*2^1#35J(GX3RO+9AKM/'V-V1UIHD_)Y(7AMQF/?AS0CZTNW(\$M|M
MS_99%7_,<_CU?"2^8|7#?GU?+J>|HXC|?M0Y;X'|HXTYC*&&1-,?G..&L
MI!MKD7, #/T4\$O!&@|AP%*81UFEG)--N/.S5B=A3+/,!W);M(<4V+352EV|2
M:=G/-0|@KMSE'P=:2X"<3|.(!=2_ER;F2G0^E|EWIKFA?%YO'+\$,IFYL/M
ML9LKB9AQEVBKN|(S|NO_.(@D6K%AS/E,U?|CCROV6,OXVCW M1D;8Q('=-
#Z0;O(VX;!"!ZEAZL*1S4//|RKB#+UNUX!|1?>|=GN8MF#_F|G
M|N5D@^OR+RF<_WE*/6JQHY"-#7)^,O_%V5O=|>;"|+5@1-?&;N46L:Z3JR#X MGVJ
^1)4F49?2=X+KF\$|1^+HS2G5-W*0|++LSTPS0_D<6UW*G59%.13@3H|J
MEZ)T4HYE:W!L#-^OOKYKOD1H("Y|X|PBD&U(H9E*^^^>6|"D=?N|).!7|SD M'\$68I
2A|FCX: ^QS|MWA-|@|H.IDM^:|H5JO!%H=JL_02'Q|O>+S2
MCN\$Z#8QL2*Y*.OXPIHPYT+/O\$ _HA|9XMV/(A*/O>0#TFC|R6T;NV&PR4.>+
MVSDH|SGLUR/V"59"#K#Q":|R&/XRY|/.5ZPP.V1\$>H\$I.|NYRE):O5%_6T8/
MC>#CV|VMDNFA0_\$WNC|(WBU|!HPE1HOM3?>^HI2OPH\$GU4XX,5\$4(|+#"RG\$
MLHEVH|19WV|V2>>6I\$5E3;V-I6|L4;>?A@U_,M1?:Z|'6G*<_M5+
|,|"NF.-7;F%72':.EQJHMGMI|B48#N|N.T%;C=UNQ4?X', ^|N 6K<_:
MXY=5WZVGZW&UP.TRE4?^PUA7"0FTND>+:'\$S8?YGVAZ_9C 0^+*P=#5?FC|! MO")Z-
MBS%G'6G." LH6^0HY3!DJ-*N|O|0,3L9|(SC4 KWI50N>C91E4RXB
M>H4&A&QPGV(ZX)R3)\$7"0BXH|.NPW1MX"Y:5B*878=C6>(B\$%P9Y>2&+D299
MUWW_M>?7U(?IEPQOBTZB|JR15J!B?R"N+*7S_.;."%!?&-R\$.T/Y4B0|5FCD
M\$F|RXG_PV_D\$ED-9|W48FL4+ICM'3"VVS+D&#U79N|<'JMY?>CF4'3SN5V-
EIMBMM%|:OY>6T;G=!.HESV|Z%1#Y-@J|; ^"JB=H-*A.-N MU@&-R3@D,#MT
6B,XWH<;Q7Y,+)|V.Y5R1|GB\$H, @-_)O/UI6AT(S&S18Y#@_M|D%\$|9OAB&
B|+BJN|399&R|!|CQE6\$D\$;9|D#S>XD4TF89'NFV5H')C<@V ME,G%1C.R_9|R6=JHR3-
A-;U#AEX0+.|A6D?PZF7Z^/,%"H<"F,RSXI^7:@_MS#A&*,I"5A|HKB/O!=(VL5033>%?
QD=2@35\$%Q)848X5RHA?'R1?7&@187E M9<|W|IA0&+ #'@R%_W28UZ@
W|4O(U,"F_Q86;*3GG-YR.W|Q&2R|++L4/>M|^+:/<_#BZZ.2;_!@3.-O)|T1-
O*%H>#9_684K|_X=7A#W&%>57H0*0L MMA@.
XD68.PKT.;4|@9&%|*W:B|*0,4|8A|>&.P|Q|(7,%:V@UDXG?+IH%9C
MD"!+O4\$|H|TKZQ0|+H\$&=*Q:86/C0*|U2P5J=%F|B;_ZH;:13@FA#V_T.Y8
MX2J+Q"D9|EABY;R#-9;+.1%?6MOOGWZXNR|F_-YRR1C5Z5B_Y|LN1'M|V;^
M&,V>2+F#-|7IVE+7U|6&LH)'_)/9CU_R7A\$YINHC|TZ^0P=.IP6:#_/?;E.W

MY:9X%IB% XK8OX(.L9\H:2?L0@<0X_)5AJ)X7O3&)0Y34;Y-+I%*0X"&=ME; M;
<@) G(*%Z9J1B/XNH!!<&F5-G!NJW8.+8+H9A7(N%?A=29AQT:!.+C.E#
MSX:@7Z(!2P)DUE)(I)>\$??@C\ULP691:\$.1;)3@9W,'00;40I_=A=Y?6TF6<
M!UO.Y5+S15B.5S>7(C\STJ_IGJ/X:@%JR2U'FZ?K-3/JZ1RBV,RI(9S+:Q!C
MOJI7+;J:IERU6RISV4RIY)(CYMMOL\DRQ.O:L.YBE2_A2!1TP>K#!,*\$QWR M=77);=
[2*O)6?C/J=OBEW.4N;)=6=ZV(F;J.&W\2_QH78.R=UO-83C>WXR
MZ!4NV3NMZZU\N"DKJ3!RBV_<&O,LK0XW(:?YR OF6(R_X_<4^Q\$*QPGT
MW'PS\$,U!;LQ.J*X!KLJE8P72^FBY*XDX#6ZZ%LP\$?
IPTB6X5)^SBSXJA.Z+\$22H:I01+U M");FS6CJ&\$!1!47%6)O+9X?
TD39,NP/D",8D)T+M^_4;J%IV3A_F+*Z==\M>1/>!O3<>)\$J037NW-
R6MOWI@5)^"Z_U\$'?73/X&9WZ99F2+#;^B7-9_/6NU<17=?
X4B11J4KO)+)=T3(8R;:=\JL_MF9*4>IH(EM!Y"[U_S:L+L,E)KC<5YKCVCV/O
MR'M5[P!W_CH%*K T41L,IWA14"Y<"4)U'S%+C@9<)_N:~S @97W\J(
M72(4YIK4\VOOMF!B8"#BN,41F?2>(%:8I3I+(LRQK9)"-RO(892I+/UD7->O
M&\$Z3I,_SK/(\$4)XJ69A4P+03X^0LN9+A?.%UEB7I)JXRL>R'6*LSJ5X8)%88)W(
M9#/IH&Q?!>!\$Y6-0IL-,BP2;;M^"[8M-'TU'4ZX,KH3IATG8#J%"7H.? MJ
WYIK4LW<1;/_LBPA7,'X\ OM!V'XM\$^@K/NTG1^J;A>\$\$(94>^6[!-Z ML]@,/3;^?:(A|
P5O:~)GW#R@.4AZG7+?0R6L:9)QD%7I>SH?W@A1AE(9/K;
MIV57W'.JM/*DHI;9LP08R\F*E2TK&@UT7
M#Y\J9BDG7Z\O-5HTD<.^IB^5#.W\$K2R\$KQ\$S\$Z\40I7^9:(#5PN"0!O>0I
M0%B;"L/TSFTOB) >)Q+?2P*<,N_3:A%+'Q@.?Y9FSCUE(^JUGL2)Q^T?T-7<*
M\$R2X+JSZS@YI(2R!;C*7[ME!HTZZ/<#)5_R/"+[Q4!%"IFB|^185Y>N\J(C%E+
B>H8NK0R|N|GB<@O/(CM,ESSO*' M"6*\$P)7)3C9N!,<#CV)I_GQFO3-LC=%
(;00&T=QQ; MX\3Z4_C|6\$^Z6\$?(S68-->TS>0).P^M(H2#?0VNI\#0HSL*G-
LB;G#O"!RE8J\X/E'95'O/GS+>_)CB MR+0*;\$KZ@9B\D)7O8G"_LKUSMJ?L9*7DO2<F
M4=,/CO@6GW_7K-MM5G*T*C/5?>O^MD1>1XYN1PPF3'70^<6WS/G1%"[Z?>1 M\$-
:=A7S|5Z4=(!F88)>#;=%T^TE_M@M+)9\$+9Z5<'DA,U,||'5Q3\$EG2+|B
MD2C|S5O4C;Q|/=XW)\9&2ATAB2\1:T8|4S.RM%1/@-OXA|WY"B+)A%V+M\$8!
MKN0*7|B0X|6-!'"\$V=T*W@,RZ8F?PB?BW#|"C4E\2S-#C!,7EM):JZ:+8IY M%632TU%2
6K,F+=/9S%M+%664M@|"I9VXD0FP_RY,XM?E|-9DKCV|61W
M(8,HAED)TO7&JRA_+FQ;4_6+K)PSZ%8|_E@XL8,CD^WBWFT@XN))F^R22(R.
M,C\$*&JM:~E5B_~30X|5HDT;GUB2*Z;K+_M?=5!
M9BR.4(:*U@4LWG78%6&2I:~SQB7"" 7#J?P|?0)H"HDL2(9IES)1+8U+Q\$= MG&?
#Z\$SLK6""=V(#.W/"J\$0C.5E\$U.(M.PH&S-"2F^M?
R+=P/NI\I4:P;D0P093'W(GEF^6^65>OG%B0|XA0_(U^;3
M!\$F\$J8LZ<40B:_8&\$Z6(NN7DIMQA(Y|(92PRRR|_W8I.OU H4;B?IY1^Y?^
M%U)N=N5EUHK/#"5^_/FFT%NO;K0D_IDE3O&?GS6*2JBPJ\$*A=*0>E\AE!03K
M/"P53|G:!)||ZNZ_9_MOCBA|3&<[=8'\$01Z*;)>M*VY:N""^CANQ?0
M!POX)UTMWK|=PMF_"GZTH,'TL1Z%*^|1IWL6**O0#UZ9WRK#!A#)921@% H
M;"J(<'X'2:K5"!MGDX7S8"W.)*NMZHV/_7V!;O):/B:CXYH):6\L7 R\$LL
M81>PYD#0|RLOSU/+|F+TZX@!|'(4Z87&MXH0%+NB&J>|+?"@"+C_
M|HL79D(EPZMV.^C'E4-=;P7B,8%J->|7=?S7*U*K\$|&C>?*
M&HVV#>U<1%/O1>1V'LX(872HZ'=K^/G5&"EL,M!H:AC=@EZVMW2&O+9?CHW
M4AXL4'98ZR|Z%A0)->78M0S/6(CE-\$#3K4|ZH8"12>3|@X H9|XF!"CA|TOF
MJ,TH"6)L^&<)Y#/,,"*,+8V^QTL)'9-RG@!KBFO^1:~8:W6-)I@F:/Z:(" MWJ-
O+@&|H6|6!|(LI>3;A3@;8.X!2HJ!\$<=B+KP%/5|A3O0|D7-<.T*P:YG?
MPL%C;MS"5+;V%NS=+CJ:=T(3?XE KMZ"_Y(DB\$LK7 AQUGN3|^#JXMH;JE6
M975I=|5(73?Z\$^%KF7W\EO2U!%U9\$7PTM3YBW-JI'%'_LI_#?E>|>ZECV9ZD M>-
G!BCZK+^(:2O+PC&Z4=IN_ZE#|?)_9K&T"K>4BL1LI#VY3I@/+D_-|ZY
M(C%#^4.!^C^/BTPRBLP\2C_CMF_6KS27FCH800R;^;J|#+17@"B\$|KDUUT M_P72 3-
I4I+0?L\N4:92H_*\$2O!4G7_+I6|L98-CGIK"!LJ0!ETC9?3 MJK?..F+QPM|K\Q0|LT52;??
0"%S86&^(\$_#\$4A9IG"4>1WYQ+;5DM!B1E, MACY)&'<;?C(A%_E|^?E\J5Q)UD;U#
|1XIS(=-8"8R2+HM(36T'M.(8'XCB M5_/1I-I:H#.YVHW:O0B<.MM74|@:_%U%Q!
|T/0",RD O>P3 MQ()_B8EM0IQ3X\$A14%F4JD>+%QS0'U)0AUI_|*T)(^|>|R-)C+?JH/*T!(
M:CW_\$J#D'6'Z/E;^\$#2C*. ZS#5"J15B%V!. 5;U/EW7|W"VIY6KM.U_Q0C
M\$DOG|(P|I'8DM?6W|_SAE@<>% "3\$%5K7Y7F?T)!*:&|B+|JL A8O*8J80PO- M/JYIE
AS'MO|!F-S1%OT=#I8L^B'\$;-S8H1"D=N1'6LPM.ZR#KB0M7I^%"3
M+,^;Y2XE22Y7A_A-JM4_,#.TM"8?29SX@,CNXCC!|*8@4L;3 P,ZQ=BGT03 M(UQ!|

/D/G)#""7C;J\$^+;WW(^K%5F?OK8,\$H"X()N:49\$';S\VT6&8Y
MA>1(IA\$WH/SJY)5Z)@<|07I!|S"\$Q!BT\$?D29, \P!;(P+8'@OS\$P&'.LT M.PKX%L;_=
S1QN8P9AN9B+TA^'W=-5M00&\R3=:U&HGG?
=^WV>7:Q%Q26_-9X9P4N+N;3WT%0JV>^Z1X--M"IE^+/->1+/6U'_I%U@LX4D&=V^|"
M#HH!;7#%@S_K56:Q'O7NA-GQ7N!%|<)CJ+L*X+1(NC+9C<5;Q8_EAGKLS=
M>L&;IO84\$XL/R+8^&9;I@Q!;Y"N,HG2J0EHUP1)@YL('UM'FW@)&&5>"X=;_
MJZX:PN7|5@3R.70H9I+#+LXKQ8OR!P_X^'|?!FL,..C?=QHO@SPBQ@)3#%E
M\$EH/0Y+=|VC_4994<1XB.>J^#?L':)4S.-
V9,^.'U'@DN/B,%25@1)TAY/<6POKRD1>F%D9MH5!?
1%:9R70|SDG^|Z|UV:J|X.ZP0)12O'O*C4 M(A>_\$E7&G+5VV1|7/-19AF?6.
<97A2+XO%""*:G579A,ZC0:JH9<&..'XL>F=M/_@50:.
<.:RX0VS;|B!760*9=>\$3"";L4.BUNC56?AR#E"3.1??S518|-7G=
M<7;06!9YNN!|>Z60AHUI93!5L;N/OHC8QU4G?AKLXD#KL1LR'4_L|5|(&|Y;
ML/77K=IC4,(&\$'!(DAH\$>|(CX#Q:E*9O^'HW8KQ%NR_7U,J6=VI(H%|43LZ M,-GCED?
6CPF|DBQ.2WC7F0>10BE*"^RG:>9WUDA:K M9Q=9R14C\6?*(.=7:9_|
MNZ'ANM<6|!1M!X'^" '8AT^D,COCS8RX^WE\$F,?6\$3/7*:YMO5)X2|9F|_M|^N@-
\$.AF@X_V@^\$GQ<#=#|:6&Y5'%N//&H'^&O!';7D^MH*)ZZ0|K?
YAE>_|P:5UHA3W!,LW/99ACP C;3|V<8|>'H766#+S3X/OS7*
MSDVHI_.|J+E*.=&\$8H|@D|RJV9)+>SH+F,L\$B7F6C!RSE E.*TCQBI*|?JBI|
M=_'G5RWKBMC5%S*,OIQAY*OUF9A.=0-E\$'4,2\$G|X4 MH+LI9|%)9)R(-^'.Y-
K/2J4Q|>%MR_/VV"M".M6V93'8-ITJ^=|JG;^:5:N_
MJS\$(RQL00=SFE6W!@DE3J>R3O&=1|O&T2=|J=X,A,GEX;2|7*'S!O(Y=*D2V?
3<*U=+3;0^4G;CX=NUZ4Z7S|=8)9V<- MM7(MNRIKZY&%-K,N01NIE#P%_O6/J-
.,@7^&NTJ9VA,)6JTAGJV(6>0%\$L) MUZ(|DHJ\$*_2%H8@HQPL/;+!5/J2RDX_"9-
7'|F3C@RO5U5:OL|\$Q0H!SB MP7KX?31P(5,(E&>_:0#CZ3Y>5,*>UK^X^H-K1*'.2K
Y5G>RCV*"2:S'"&%E M/IV06TG0IOW|>UH&3&0@Q'!&_QC|XZ+#+#/:_5&Q3I00AJE|IVE?
9_5!Z!;Z M\$;7A%\$T;=CN+1*5-K%*G84#++*/\$ _R|^MZ|@(|CVA*.,)30;|:
(UP)SM_@!^JF;_J>SN0CK.RRPJ#58>"%/I.3Q#I0CI#Q-W\$//1RIH882,O?L&-M*
3J&>ZO'6NY=M01T)^O,OM07|S=RG*SG;?&^Q(YZI?X:FA"BN|>IFXJM0L M:_T%9X+
|B^5LNAI=OID\@?T(T8N*1Z-#JNULP<=*5+=@#VL|U:O'@R4P*
MXJZ2;C_WD\$%)IK|HCF")JY|S\$A+K88/OX:1W6V#CN#!,NNF@F-VI DL6Y@)&E MW|
I/A@'X\$?G?:Z*G7 MCG^I"WS,"Q F2E*ZF@SNC,2?(-|J1RPN:|%)JB@M+D?
>J(#X@"I@=PUF^?=>2;Z2YKFE/;MT_BCI5-' ^=|M5 MC,MPJ&;=3|H|>A?A0FHSX?5N-
N%YLY!/\$D(M9_<@K&9\$%'NQT-\$F0_OASR. ML_ '3/IZ27P+NO@;
I@2X32AX20"3K"^(.Q568LD,L|94XL|0Y6YXA4PVE*'^ M|FB|I99SJV9GI
%BXM0U2)O|VE|SD)0."LOA_F&("2G<|HTI7|U>!P^L=J8 M!'+_B*#@0%,6|E9-
27569|SIW|-7TSP_>*K-!L=GN1|DAQ=2QZC M7G'GWF,J|6RIP5ZE1UI|CFGX?NK-|G=<
MSXZ@/H57.A;>;YLM SQDM4Y?*U|@E5_?R(|' \$AZ2E';\$UMDZ)-L|_5"WZT-M
UC.MZKR_R4 YIGIQ#I.VTJB-\$;2#;D|)^;-P*5Q?P&A8WWS2*K@:=-,EX'E6J7!3^YR"
MDT^EU8XH5LOM@)C"A*)R2P""N\$T9_7R< (CX//J<3Q M3JY\$)_T|!D:X1)IP8ISJAV97?
@1E")SY=#O_^\$"\$;_@Z24E|X"4KD4HPI#KK M9-J7&061|+>O9H-|J-^H|*-IO:14!'
=S7V|Y(KK|7OUVDF;S_D|YLD@8AO MN*YV2-(WZ?0&9;)D:TZ5/|3(#0^P2|HY|?A
O|8E%W8N9!/%LON%&=18 MC|*9" WXLGJ,PG&U/GI3:OS|15!8K3JY*BGK?(X6H|DH%
(XJ>\$"9=^DP6J/ MMSGG:%0E5XC8GM=\$7GMQ?3C_ZY'28\$L1?#@ (1R0A)%!P8|AK5%
|5KFQVZ,-!B57)5"3FB MU6+|9G|C N:GYG(GOB9 W<=>=&L(D@LHKW-0>\$NW|
|R118(TOR|(&(&F4&Z MVG>?#P/S6;),F13|Y6"XY">2V%HC>_.E3U_!\$3=J8W,)10VE6
V=)|C|ZQ0-M%&W(-=/Z2DJ-K+T?A;YH0RXM";#E:G@.YAR7-G?1+9@HX|4PQD=LBFL|D
MPJ45CCY|HF0+YMOYOV(5IO3R|'K^*7%|R#7UR6I&V71Z=C!?!>PKNW>XJ)0 MG?
@NU YSND\$#KH Y-|F_SBV AZ82NWOZ0FXW!)X_>H2W;7.1?|C3-D
MX)F%#^A+OX%AG2<%R06GBT|=JLR%X8%|.R>|!#-5&:4.92YG)DVTV=|3O4YI
M)\$D"_9Y);Q60.D/C2I+8TK4L=#+*!BAD1X'K%9U+OI 0U9\$3-&90MP9_L8
M:S<<&VMP/;%_C*_U%LB|9Z#1):RJV8(JPAJ|BTJGK|3,-I86K^R-H7I&N,>M/(=R#J?
@XY|O76D2V8YTGF-SP;XD11_D-D>S3O)+6X^"N"XE6K#Z*_5VB M-"J*(>K(|ARCK-C(>_
;#E2%>&HN35XKVM-+)\$@U%:_&ZTU,3_6%7" U:THX ME_?6\$J3VJS241-)*56_U4J9?
<.,5CE:.)4|:/;H*A5|D!A5,S>,A*L+2R+> MV#I*Q:\$BK40EFG|^_/479S-?Z@>
(_107!0:X4K&P<M<')FF28TXE\$1S'2+L-MMTSL_@6>@:8K:|B0\$3GFQ!+@2|SGTP/M#?
%3|\$P\$ M8S;/%4X|L6D63Z_>AT5;|T5I5@,YR% GZ|0V;:%!;)1J&+K(R'W#-Z5TA
M*PGYIOU14VIKZ,3F|DF|1,9*RI@;.:?|P?.B0L V*ON1J>*C*@\$@O#?SLIWM> MU.1=B9-

AMVFK>+SLCJH@#J,T&\HHU?_ZS?+3^<@J9R1+\$N^7,\$\XJ&/E5K^
M*0GR!B4R67!/\R*GOF5V.DE8!XXUT@%MP18&5JG5-AERQ\PLL;B;#WW2O7Q
M(APPGU>H*U.6?&'(#^PN@M+U>2>D;HDRN).\BBU8 "E9[AF0F6R>6 F"5QI
MTBH|\$A"2.E^%0U?/\$X5:JRVXHB5#ZWQT5ZEX!+"2MK2"@|4|1S"#%0:Q&JX
MU0|C:;C5XPA0?8,K>7J*+ -B-H^%LP9F4UIA^YAC5(PXF6|_P\$QJM/J(W)F%
MH:;#;D|T5,;B0=G-#3E,42=ROL10J+^M'1INQ7Y.%%N<%NM_\$UYG@Q\$|T7B)
MZ8_2|_LYBS+(^3'^@IA4T%ZO,?!O|?%4Q>-V/BG5#RJ\$W#\$
MNA*G@^MH!JL.109&O<%Z%|;?>@W,>7X M\$U'^B;(^?-
J\$4WK.8;!XX%2+,5T>F8(6OBFHSRI?|)#4+PB.XQP!X@A;N###9
MJF5VQ:F^CK4%HJJ+4((TUWMH\2C;D*!CHUF;D;::?8Y7U6K,GT34C-:S;K/C M6:.)J2VW
UBU':TBC2,W5T1!0EL_,G\$M7!24=QA:WO^,477R_%#NN6OK\TG MYZO2NRMT7|HK-
A=SRP,CGU|^ (ZV7)!..JT\$,D%7H%,URHWX_F|\$CO\Q.=U#
MW3HO=|TD&A,>|ATK*A,J&ZN?CLPV8#0|J|.FU7C(L1*F59@>|HT5)Q59E%
ME@9D!PJR?. FEA*:.|Y|:W33HJR4?\$/NCD;_@Y- M+|?4E"QQ6+OX@N|9A)DS
!J3F#\$.V^N MU8?|E@.B"6G9K;(#+5=QVGPUC7BJZF),Q5!)E6SJZ*;'K3)6"?6*OL|N(=C
MP+W,(|:NQCF,M%CZLX39N2S31"@V/8.4Y%I|;MX(0XL=&+++H1#IFG(O|3B+
M>_75\$Q,ZINW_JOYC94#^|<=-+T_?LBJ1'.RQ58UMP^V|E1OUF,H>)L;/B'
M+/8Z1|QWQ3RZ8J!Q&=OD3'4J>L:+20X>Z_"=-SWM*Z*OA|F)634UJ94Y9<
MHV.9###>33Q6QF_URSIO=E+F&4-ML\$?|=-_K!87*LV|\$B&|&\$)UD+I^SR3+#C
M:K^;AG/+1/T/(A|)'B6>=L",,\$>8\$.:>+1*E1LMJ@|OE7C+VJ'|7S\$PC YH M&\$3!688=R;
(/X>/ M|YQFJL|=)V2T:B5@E=,#\$JX&)(V;21KC"X_,C|P|&CZ<\$69^J?|YK';A51^MN?
MZ;%| V:KPU4=&.Y@HWHJDS4|1"|Q?X'4_#"F8SZJ>)D|*1;&4=[*B\$_YV MMU-
V^2/!W^~|/S |Y&#@U4H;CK<:,I%B3Q<_K7D>&K"DO?/GY2\$VKDI
M19^8>IQK|1C6,!7VBV!|DV.DS-#'VIM44HSI1\$9.YJ'<@P|OIUQ|;#;PI?V1^M_
K!HQEG_3(RBGRL7'>+:P!HOB@TF,=[P |;L\$#"S K/'0'3V|B:07(?0J:=
MOK9MB=R"E:;68>X1@) M&/Y*.KZ>#@VJ*(U6H(|SPB<=D=J3B)X3N0E|;HAN M|;
<\$#|^CQ^_J+). "PO|XA|,%E|=@5^|_8'CFZ&MRJUNP<81E*|)'53"\$4E)C
M(HYY>342AQ?E:4OJ!|/'N1:SF F^JC-WB|><7|^1X>>OWLCKG&4_(_L+FU M*P7|2M?
L_(E814!=CC/=X1V3&K5471DNY|W;VY<550MV|7%N/|J:0;O4V&&Z
MEF6\$+O&R:%8>PS_TT:;%F0Z|YK M>* _ZZWMD|=K4IPAUA@SGDA&W\$?
+|O6#I>W+W'&'03=(Q|7^RI.7>L0?^F0F M/L)UB0R05SU>?7O_(^#0!7?|NW?
M|N"WRV+U(Z!DVT=:6N'NVLZU&5ZL)33. M=9_",PL'E=TZTLTT?>>F.ML2T|(*)4?
&U.D<3!1THCKC M6G_ 'J^N6.5XSZ3CP)+MTT^3/_2^1)/'(\$|.^
HG8&"GAJ>D*2T&B79K,B0RG M|H)D)85/'L40#0GD.H)@-4Z-'?0!T@^9:,46APIW,"Z?
^X"9(EQ MPJ|_|L6'+K&""|JY^N, M:3XPOYOLYSYJE'76:B,*9Y_TK*VO:3%EU;TK-
T,%U4D1UHPB7PJQ\$;@W|,4U M1"#Q9:YM!_*
M!+94:|3^:84B%D/ZWL;7)DQ|VZ|1Y#SVR?-W)JA2PJTTAM9#^1*53BSD%LPU
M9VG1M_J_|3K|@0#L|?^X1_*0H)BY7,+|\$|*N0\$Z.DD#|'|H>;D.*;,(0;>3-M67Q@-
H1*I@PX+^_J86'_Y3N(|ZM|G_::I?-0G"?PR&!OQ3&A/-?Q;:'FAN
M|G8SC8L*\$|<6ZSW^\$SA5P(&-!\$X|C=+VNY=5>/:>UGN9-3W;3:CIK0H;^| M!5-
<&YN:&G4M7+KU>@Z8>;^I6M_@*IA+WB"0=?!'40|+ZQ#B9F(VPB8:~KH(
M.8^VRTG_G+|V*=<|M4#\$/_O:;^NE^9QCV+AM43?
EN#UUOMJ=J_W3E)^D@|AOAS%.6^!:O9 MD-V"+4C+|G;_!T8^W^=3:RKB%I|?
EGF'C>F)5<|E;I"SYRDV=+LUY'1/'A7)D=>|S):9?8|D6TWE+*+9D92VDQ|CN7=B^Z
MBGN:5U?7Y7BVUHOZ=_Z|T2/L\$3YWX(T/E+5.1|S8UT58#|V;Y;7SX^/63(:
M|D)S8|TC"D?%NA5\$DQ"_R\$"??SJ |);>+L*E"9L
MR:;H5ZWYAX&)?ZF5H7IRV7PYA|3V|U^PT7IPK|CQHIDP|<4YE MOW\$|
B(BF'AMV|K5MA|&X2*VD:&YDR MQ3^TDCBZ!2O8\$ RC<7QEN.\$\$O4W+L:B/2(JG+
MGX6N?50?#.%PBA,FC=|V"& G"^|P?"6C2V
M8(|"2C32ONC^0A68#J|F";R3@;HJ@|8|F\$ES9Y.UF&P4ZN6LAI|7(P;QK;JEI_B|!;
|8D2&8S)Q%G M&O4*#'\$:OAE2W=GD?
_#3>&A.JBK+SNG9|;%I%:UT,XGVBS7B10E=JTKGS_MX
M>QD|:B9N^;OK|SS=%^X47#ZH|% B;_#FU80B+VF607LLH\$N"B|LF'VAPSJ;
M)V*KVMN %.@Y58Z-MH%(E)E\$4\$_%F#P-LJCR=JR.HV;:_PR^6
MKW=R(3*6)"U=8FSP*_6&>GJW8-^;Z.&
<70^_7XF/AW+|Q1PF_0%@R.7G_V&I=@R+>%O"F!78\$5SG|3 M3#B3?V+|M")@F
CKY(VPOJYJS38<=#;YZ(O\$3D&1!G"0BWO|>*F
9#)3;S*M"_ \$@B+5CBEZ@HT_07B=R9I_#&_ MQYZ.X%? 149=2-|H VCL2+UJ7L"

IG?/0%+1W\$":D(!?V#! 0X.@IR=\$,BV M!'J#(S,?
E*E_8; <'5G7V9HK,G#OM%F!&BP8C5TB)?-PAYZ.[96;F KB>D
MK#WGV1XR;VT9TL<|0.RIUG\NG'H7-1%V<[!\$JQK.I-GZJ&6R:NUA?,@SFT@2
M8%&GNUM!B\X043U-F\$2T)[V?SP8W6,L6! F?*"
IK^IXSG\#/RE/Z;J(S1Y DN'0_J5QKV(*%,ES&J^,C%E,=O^&@VHW=9!&&: <'V7QIB(_E-
:NS_\$%_8\$4&OTV5^(#^Q2P M6VQ!NI9X?UJ6-5T34-ZI;Y)
9(GWTIACJ7J3SU5,8OZ\$-2JPFJMNIC!>W<(M=GD0H:5JWP!8
;4:N:^(!H(O6ZWV?,P1*%|)?SI:>%S?|77WY2E-'T9MKO%,)D)Y|,\$T2O-MXW\$:U9!|-
YV*%|@22G3#83Y-G[5+I3O\$U|MO<@;,"D\NB;(-+OSKJ7RS?J|M<<[2AH J|DAXZL+
ZNFM7V|.\$_7DYZFQ|Z*MZ68^0@*X|;\$G3!OY@E VJ3)Y M:>BEN|L|=VU3,4\Q_|TNE)
Z^H_EC)+ER I(")L!GJR6W;%E00+I'Q6E!; MTT#.JIG'3T*;+>'&XC*WO\|D5#HNJW M,M#
(IV%+;,'0BH/NM:7|Z/4P M_I@D#=#2Z4<&?0@-G'T2Y6?+*6OY^D[9+0P/GR7M(T5#;K?
OVJ-BIW>+[VD_^ M|S\GD&| H|M TY-H|"@H"_E5I DEDD4FEPCARN576|
Q\$|QM|F0FIYH G\$5? M(=%?7D2,(JE3NR|C)F38CWTG9|\$1#0W\$H ZJ@^3R<&UV<,<|
ME1X6I/"N)3GD&JT>0P|IN/|,84L#%'/USJ'^#,1\$;AVW.77M_@EVYU?;|O
M\$1MH0%SD|L6?Y2\$=4=PJG#XDJ,AO""6'^"L=H+\$JX!XM,Z_|+;'T0R> V|
|LYOAFH_**2BG M8_G4;L,M8E"Q1Q|'C;MKM+CA7?Q?"3Y>5*
((3H^I&7/AYM^|?|8V9|M*%QI7 M\$?G,33:3>=K7504@|5-12Y
_X6F5ZB).+2EE^N)N|WMTU'VX*X)S#KS!9#J6 MPG3M4>|LJ1XV>UR.5JC|H,|/#7W@G7|
(%S'CN/O|C|JUBI>,*(#*C#,3WAU| M:O>|?MP_(!|^%6| G\$/*ZHA=79W+X=9B\$D"_E.
|A+O|I\$C-VL-.V?%& MV!='G\$OB-<=P-
^6IL(|>X>^_Y7;H5#"4ZPLM0MD7S^RUCA4^9K(FQ;66|)-T-
B0|RD/5|/:F5L;%8UI%=Y3U!>3^,@%;P;6M7| M'T\$WOI!'*FK\$|%V4N3%?XOIN+/\$!
M%Z%%+/O97#|E'CQ|L.OMDH&=#8=&"IV|A|%QPMIS*@F4'B)5\$3X:A?*)/>E M^<('N?
^+L?<.:FK|_WUQ6U_0\$.DU*DHO*B MDJT(;&JD=|(1J0'T\$B60KR*| M;:E*BX!T0D2:TB(DP
:D=U!#&@DJ7%9&PA"2<|MS|_S.N6?NO7^L&89)9E:>
MY_F|WZ_W*L|G"ICL7S#S|5("ZAOH55N:2A=#3FXUO?D\Y^JT_MB^NL+_1JYS M5T*|
|JZ,^)_9F4*D?_ %N'(?|#?#MB,T:T|+|:9G28K 'N#Y/6)K ME_Z|R>^TO"3-
|?/(8D6:="=OBG|MC=A*B^@Z=_C)^>ELHW1)XMRG_M4&@9?
M%G&N|,>7BN|V":CV!;OHGQF|^JC8)M|A.7D^|LQ7)QS7SWBWN|JRL?2F|L&N
M|JURAV|TUB3V6&(1O,ZCS!3':1FAP#12Y^D5H+KB^9_V+_D%|T*O.'Y_(=Z4
MW9!#"J|0'@FOW'UD84SN^1E*K>J3'FROYNJ@/6-@6-QLA)3O9;Z|;1,8=;|M*/X|&/
"GE\$;1;3 7:'%|=|K|_M<5S+DYSUV|N?|I%L0-*@29B! M,?
8BNR|I="=|4N\$W6|!;::)3ZWW0> F63&Z";_ \$#\$GWN)YFO\$%0DR\$GY@:4U M4F)J*9#SH-
*|_K|8P|>(+TQT2%++4.H8W0@|H'O5PCZ@U0 V4 M(;):\$9I?^1T1POE(PXD.M|
(!J06LJLGKXG-+ITQ@NPE@|I"+WV%Q|;%7-&H" M5VX2(0%+AO'NFM4:7A|B>7;
(T<09FR|1?*HA&,\$9;7YQ8*"QX,+)|\$|QB Y*K M :E8/@2S/Q3?Z|7;6"| K6O5&E
:%1!WE)252 C1K|H2+R>MU#>ML04IZG= MVX=SFK"6=M!1KQ?ZEME
<9|&\$ _[DI3*)|Y7G6UCVM&*<5R_CM\$LOZ*[9/ M,PO7>^HH6F*.BL%I6H^#K1!3*AA-
#&_WUS%%099189/3GDJ VBO|.O61/R M">#%2D;Q"D-XA352|B<|%+8>N#JL,-
C3>YDO!497H*@Q |XVKH.Q+-.N8VQC M9EU@,V6D)
1P|75@MAQU!UQ=%W.A5|U.Y_S'RRLH!?-66_'#5W88>7KZPM+L MYBQ#D|L|ITY?
Y*QD7%<|>A;_2(S!8;9O#|YR9'UFZ| E|NJ:VB#OM|+N/V: ^
M9/_C"68@/F810_.NI89331!0#GRIHEGF1|WZN0|:_8#S>|D4AYZ|>
MTVAC@\$C4OSC;S'GGF.VPZRFA;\$=X47:GLALJ|9Y@3P
M56>24_.5(\$>VTGV2%:"TC_W_%NU?, LE|U|_M_%7-+OZ+D|U- M-
RM^&.@69DH6(*1|/U=82&A21*2Z;>GUY(^;BC|WK/Y%FM#JL;OKX_%)?
A4O&@@&Q5>1|SI_'A|JR_0K3)L8DOGW M6|%A@O|LS_?-
X;'|;8;G9V|!M+KK5M)T,\$JUB6-#TB/OWK8+G&*|+N2H- M&| (0L/K
?WGT|C0307\$E,NAK_ ^AJH7V8AK G"2JDQZF1HK?0 MI5I8)-)2B MK.J0=_N' '.S8;|HC)6?
PNW7,O;T2IE_2P*,3TT,V'^Z116644V#/ZXSV3>^,M1^\$%X<YU5
MJ|0|XTADV.! "P2P|Q|)#BE78F8|.?X ?0+,9)BLE\$S,'8;/(AE(1-HH*8SS-
MG<,>,NX_9)PR.=A"6.A\$_D|87&EFK|JRF0.|U?3;T'%VJE>4^X,/,OXH9ANU7
M0(40%S#=#CPG?!,C-/LRQ4::?6NST+IL8!199YB)T:39_QJV7U4"\$F
4:8WZ;|\$.#.@UA"!E,'TW4Z) M.#AZT95=1MG11V7C3Y#&| #J|F00!PE(J&P-
S,D|E,C,/DP39'R<+;| #|65SL MB"F_?U2|F|,Q4#8U-M*N1,NQ3V-
@|E_,1G|"9K_BWPR),S7)|.PC96CX-&O MH<^FWJ=LPAR4(WC!#NHQ^Q,
(4205/L|DQ|NE|_C%I)="^;#YL|ZXF->)OA4* M9O.)6/CE|W6>F7|

J9XQ CAB9N QKLM TK,/P2Z#(V=M%T"7G_-8V3%|&/F1MFBNOOR(V\6BQ?%P?H
_7N&X_F!_M,T/_PO-""&A+D.PS+NF6D6F0*=%<@@&V-Y4L:9@^_5+;D S+-1E/:=F),6<
MF^@P|*C!+P;NXO1<:/!-)Y_:^763:YZ1O.6!82\$|U\$&749/7YP4Z5LCL|:". M^7W4/0ERH
=/(.17=^DX)&"Z3:1D0';H/?7)1*8ND)_F0|E|S|YQY"6L&G^
M1%@_=:HXJ&||T_)Z#PI5+E+G?,CAY%N1_UC3>Y)@=(=D|MJ/ZL%:|!L/0H*
M\$;19'#U08T3_7W=K0!LJ*5?A7O#_96N9ZR82M4JU0G_?ND2X1%ABA|??QI@D
MV.:WKBN8=0F@A^". "<3|5HF_%9B*E|*MD-, 'CC:38F'8PW04_7RV^*GS|\$_LHA;|;T
0*Q1SB=4+\$;E,&RD#9LV!;WN) MN_AS:Y'N%T',,@^GJZY14HW?%UF,:!P%
(C0>CO)9DANE+O2Z#G7-?T;7;/MWR.:MCB=IP2HB
5/%G=@+8N,:%Q)QGC"YX;H5LQ250(I?F3H2!X8BZLYA=G
M4'!FM\$H2F=TX^@Y!"_MO2TZ06VBM:*CV<67=DL1P-'|EY"%|@RX=PN1_M'|I-
+O'2IS%^H1SO13N^4WD!\$B^OZ*L46.:6BY"\$ZL\O7S-<7-1(#?D)+J,MCR3H:S4"-
'SPH&7B-ZI.G=P*UDYN5AA2PJNP/MW12\$0E=PE,K.-^2>^;Y?|,2TJ\$.5+|(\$8M7)IJB\$
MY"\"NG_D,:6HIFA82=Z8>J3|:%:1|1FIV|;P|OW|W E(/PS4|NIVOTY+;|T4 MALI0U_10K|
<0DAU6\$35\O+ZZ|>_""_UD_.&A%';9#YGA&SZP;-MEW_U<#E(T
MOS8WQ\KSQ?,E@+,262%-J&6AA,J7W|_W>|^G*Z;61%L7RPD5C/5-D\$:+BW2|_M!A1?
K.>4B4YF|MD*9;7|VG&7(I+;H#><7Y+;Y|W+%W-5I2/>C1>DC=-M\$QI
MY*4=942)B|OQ:7)ZR+Z.L4%EJ+NBKX|E04&"6;P(E|'X,2Y,C.-23,*SD(F M67Y,?
>|R^F|B8GE1H MV)?Y2_2A9/.9"0_A4YX\$(|3C|*1A^%-SF'1,'C:BZ_M58DJN#/5)/&
H@IX\$Y^_HC07L&N&=\$E2N?RNN>VI7G9:R2-<_24'M;|A+|_M0KU/J\$Y+*
<8)>)>9G.FC'QY9GBN|S84^|;GPW1%GJ|+J04T|{#*|+3_>?|_|" M9?
J|NB%.&B\$Z/^R*.NZ4*./O/3P3+"=*G/RAME_+Z@=*912JZTUO.W*^/'C
MONSOK|PR|\$7|T"BH3.:?HJ5AXQB&\$10L;H9+1=;@ZI9O#-5"7PIP,BQR3-0
M>_GME.:.*QY8_OS716=|PO?UW5>|G)?L95=|R:7&_.9P\$4(0,RQ@U&@_"\$-P
M@^X(RBWS+6_H_7V",?6L#PL?88*8%D078|JFY"<*.B;KV?N-P S#Z#&E/A
MW"@#VTEL32,5H_XR*:T|J8M(|8/A5|VNZWDDX5.1?-,2OSX@T&^|9%|C
MSN%A2WB,%&RI&"&T!|I0,/%?Q,&H2C;LG|_|<%|JU861X%+@I"V|I%*.8/. M.PI3:&O-
B'#|!^70JZ_?*,QO'!NDA(Y-3!5=TBKP0QYY|MS>=ROJ&OD;Y*&F8OAPA|AJ|\$RW^?
OJ;|Z8|7;<\$0|0+97N_6+P%Q3_*7+W;
M6\$"|7C\$8H5#X|=%#WH+RY.%K+Z#V47U3ZJY82%R9"5QE9/WOB\8\H:UU4;-M8F;?J
KP16+F6|)@;\$5!*G:'|:0G2X^:2/.19%Z,%@R#),DO4OX1P|IV#F M4|HADN%%?
TST+Y^8;2F&@K6T!|"#"XVL1D6Y3*)A.%"O)Q^7%X<6H/!^IV#
MZ&E/W5?;XLNI6)5=O:W;,Q9Z1|K!!#<^VVE#Y|TR_%8;^YF-%.=CZ#2'?! MC*O!^M/9
U6^F>O.V|%= "W:122HXC+=&\$8@H6#PY)/L*%;P7CGF_8DL3E
MSY!>|FF"%WY>H(<7:D4C4_.V>"AD:=""|CU^H!|5O&\$|V7%M.2->5WWHM7-'
M7DM9+^LZF.97_IK4!R|/#^=?%U1*WFA+: "HCL;YU996C|HQ;\$1|_0\$Y;*,|0
MEE|IRX+%|Q'_8?
V1T2W.UIT""*O/^8CWG5M|Y#FI>%9((+T+K61AZAMCN>AUNLE_"O4#IG;
M2^H?/9.S|/:1'>E>U_OD6AN1_%.1V_1UK.7%3WL-!4=_?DK(;FXS.^/TCW|_M030E
P/6NW0)?WB\$!41'/NLYD%0.\$=VT|!2U?O7FEP*1|S^VU4-G;IGQRSN\$ M^9<_?
EM(+N4+|H_1.NJA'VJ5XT>>>R?)E=Y_W2_K^8LL\$5F^*,2\$6K4=7.K\$="FA/2|\$N3'1:E_L|
MO^C7&1=L2"IS1OYY24HY_-=:9O2Z|
MX/UDF7|9D:#+EZ81A94P*0.5^A;44B)@9WSWF1F).\$TWAQ|"M*0?B3CSLNI
M95YYJJN|<4+OMT|><;W?YK|80_?AU3G+5|Y5JN("NC+T9XF4JMFN^_B\$QJB
MGLV72N|B>|+&5)W|1;WNVE3*.,(MZ\$%98X_MQYDZ)C>M4YA-MI.I.7>H&S>?
EJ4WPLV|(|@/^TF0_K\$T&?M-%+@^&UN47W_HG>%T_%M|ZB|Q&&E29*WX|
<'7L|HTJ|Z(A5R<7|7=X|%JZS*3-,4K5(?,*\$I%VMS|/#V M@)M|C^H#"Z:(T?7*-5+50?*/
KCW90W<|H1BGUQXN>H|=JG:ZUQILV*M@6A MD|KV@%\$*IPAV5@.CJ'|I|N(4#6S)
|V|UB\$>5YQ"\$EX15T|&UV:XA9J|<_M@97P%Y.V'?VQ.WKH'N&NAJ-|<%|:-
*DP8TZW9==FW2VA,DR"_%\$#?_LTT=.\$)MOVJW?
&QRE3#B_=?|I+|L9='G@LE'8M4?)7/K"KMY.R?1HP+EHUF
MOH1CG_PD17KCX,V|PYT_/;3BZI<+'PPE>1YAC00V/DM9ZMHT#@&\$&8D,_MD?
S'=1\$N&79+(TBP*CVU|">="=?KSTB&'\$!A)7V<+PJ?UF\$|_(3%<18UTR-%<
M5'I(D:#)@V3|Y#"I(MAJ\$(6)BCX<+|V#4>5722L<5U8H"#EC.K%GT&|5|2^M?>H99?
+:N5!0_?A3A73: ^JF9)<>|2.Y/'^64)-;@W@V:Z|S)S;:1AHIXO2'C
MW*O_YEU5/V/SL:0WK#)V.4!DZM6L>+2%;D?F%GZ%T!64"*&\$^H%E)G,_M-
"^V0|X(V'0I7QKR>:R:QB1U" M="S7^HTV;"IZKYMPGN!'3B4#"P%Q7%?
GHE>U+8KG29EL\$0A%\$X>V^Z+&L2>D:YT0|_YKNLL%4%X2A.0FU_M>F7L

WQG!XP8R?=-:/*FE\$PO2YF66S4K7IF=9^O^EA@U9"26N!Q=M" M7%I9@\$WKB'C%8#-
WI N8SQ3H;ISVBSP?1GL,PS^)^N884/U^!+P4-W"<9?=-
MCE;Q&%LU(5.T^1(8#K2R#UVG9L3*^4K!_1(+K)*2Z=GF_?MJ!Z0\$#C(0=-
M<.&M'C%+SI2K^I(T0U59JKFLS-7JW0&#!(H!=V)E?+6;%TIW'F>RU%FOQI-@
MTS>%5>\$!^0^I2,B9_N!A;L-IE8FAIVUOY6!/?#;ID:R%>-IYB'UJHX|HHA,
MG!K^GL+214FS.*YIU^"QM/4=78U/L,K'I B1R_?Y#T*!&G@CJKOX*N"P.7!@ MZ(0:ZBF^
N1LK6R=:V86RP|UFQQ:GUJDL4.CG\$E!W;-7;5(/V4Z*R!(I.B\ M1LP|W0>?
7O.MW4C>#VA-DLL+'A4 %GJ,ZK3S^/|O*%:9"<|E_ ^J8&H'JT|/#3 M41PZ3ZN_J 5A.1R#
(6*_KZLV5%-S DI0GTYF_JBP'; MB7C9:98(BDM\6B)9CC|\$=L"V7)8/N0 U2H:
34ZG)D:PX%V!E8^\$'@8#N/H M:%K>?_1N4C&OK.,
4B7754"45IYEB+WV+18#C)/1=GC5Y|'+ "AT(MFHOS^T03C-
ZNHM/5S5#!X3O3^HYP8@>YE%#\$^- %E'U9AD_:%! MXVI3\#OEF^:R3BZ0YS:O@-
Q6JH\$V JJK0::XV\5>ZE'*?Q9WD?EU'278L MQ;RYT8G\$8'K\$"|N/C>9%?U=-
XZVI9)NNB2Z@7"BB%|N=X,M";^0%^LB/D8H|0PU>\$05+(>A@J"=V91^K="SCZ, M7-
A\B"M?<(.NQ#TS";HY%=J4-^-;Y?R=37OC14(0Y,4H1W:\$N8LZDC|\$D)\ MM,T|:-
E4'77:|Z6PM))B85.U#N>MW)(QJ:K!A;:|TSE:1**\A'\N1Y:#VRH MCH1V?%'5F(-
|*3<*2)H';^D89&H^>B0YJ_XT\FY.78PYICLLG">R%P*8P192
M;@,C2;5@BDL7>V7*T54D;D\&:4;:|VR2FQQZ|(:P;|?VT5HBD1"?IM9W;=B!
M.\$:MKVRQ1<.=3<+=0XYN:/B6@3&333">4DKV;SHF=BVTZ&Z@D&?56EM:='=V!
M+M)"X\$%K\4P7L77?, 09\$7@=JKXX*AEFH*@1>JGM'_V^TFPP.8QR%G:&::I8
M#\$FZ5GBGXHN\$@2\B\ 6. 7SIO9YV&.1HI +4K&+M0"/S:9Y>4 Y&"P\$8DT^AB\$0"
M8)T!*EBP:&7L("A7P/7
MED_2,GH1Y_QHT9)*|V/HXOHU2\$4S=9IC32!OMRVR,3P0PZ>C5#4\?XO4K21
M#,HAQSE4XUT@,H%A1|GF-Z\$4R0K3\$+N?PF+3.|I>5_ |Q7?W7O_NSR|:,|P(L M+J=E_&
(C\$2O!.\$#HP7"7S=8G'3,%.=LGXB|MW BD|H(TS-.@L.V\$YW.K;>;B M+66440C8V%M\H0
Q'G-Q\$35*U%=/7_AYFG%-\$65=-)KXU;|EW^?F|M#3M1| M?EA?FZK;H?Z?X7?.%3;=
|XT%V1)#%+.TVH_C, MF')3UNV':AK"@K@2>F.|I#\$4.I\$NP"/?FE(+M??Y
M#|Y88*O*MM(^_CI_G-P5ZT9BE*_V@<?*#\$DP@Q9)SV2^@BVUD
\$X(I7Q|220"^)K|FIQ75J'F=OU MW&_ OBR5R)7KCD;GTB5EH&
(5\WN5RZ%_5465HIUGS!/|!'=T ML OXNV,P7S*HO4Q7 >#;\$:0%G|
(G^,;36^&LP1_7YV=:9&!Y:)'%H-(T@\$I'&
MZ3"E@O..EZC^54L^OMIJ6(FTT':Q84K0:OK+HD*%-G;+|I_Z,3|,R';U&)
MCFL9|)%8#1|B\7:6|HX2R>INDLDO-4UY7& MQM8)*!^%J?_33(HGXA/*GG_7'CT9\@C!
MJ_6%LTZ.(^4;R6E&AO/V79)#CO^A%!'3R4S@0R2 M7?UC'1M-QD\ADK4FX@
MI"Q1ZH7'FEWURR6 =9E"FV_Q<:_@Y6T*1;^_OU2:(VY:>+GFNS5QTC:XR56^
MAS||KRGG^(E(16K!GS*|>+&0M7#9:F?M:T&|?|"6|5/ZQ3,F)U9V_9.^7 M\|WT?
HWNM8_!HA_/ULI7MYF))%0G1 A*EE8LU83)OS689/!3PHG;0U"WSD%2FI=:.Q#Y4I
M1C4Y!PSR8/3(:V>W)&@B+)I?-&Q_OGP"0054H\$7UD|HNW7)(("<")>/^C'A|MX3%IB
"RT>^A|XFW@;13|:4H=_I>;Q:BVJ9HOY'?+JO1X.K"USK7|5'3XQSXL9'W_&I=?^AS36Z|)\$
UL4@ M\$C|X3|W9K:%L_+WN>4WPI;?X:C.:|VVF\$54+9GD?^H,|G:>NG_GV&V?>KDG Y
MI'FA7(WO2.ES#XN0.6LZO5Y2"X-YF M(E:2L%3%COOV..8;A-V)/BRZ#.P176*
(8G0NTTOW):_|JX|PZ5J;I=H(E MXU?,ESGSW6S<X_*1 BAS6G&).|X>|?<
J<|>#>"4D_ ,HX|K:1W|5"=|H(X|PU M,|3Z&A(IB,&)?CJQ^FTJ%-
TH.QC\7M8B9PSO(OCFT(O/MHY M@_FI#:+5_J_7!_VBM*L,I1/XOF+F4 &VBNS4)?
J|X)0_ |@P|6=3LIOZX))@ M|:#MFU^+|>+/%.Z66^:<'O\$OO\$>&%A; "K?!2QBVQU*PBS
6-ZP:E='S109@ M%5'A"U&WNX M5FO)^F.|7.)|K!#!?WYAOI"-T-P:|L&F\$UO9(J87*)AE-
_%MX+RKC5C A8\3U4XBMV_8_+6P\$H(^*|47\|FZ=,6K'YDN;&>V M4(?SPLZ37?
(:OQURV&*F88&|V-H=Q/PA1|O/*(DPUG)!WEYE'JO*YI##CC"=
M@8=G;9#=#JE>FET(17<,B(EH>
MYI7/NZT|%Y,VXL_+/(U/RVR|Q=Z>\$3=5EP9TGXA#I<-|X9',3
M_X#&SE_/HZ1NUF#.'|T43GYK5)?6QSQQLBSAF#G-
"38"1F)\$6#GSM1|/Q0!0=RG55=0JE9T!;(>'C%F#Q:(_*5!AI@2^1
M8499TQ"FK<2%DZ61NE^R*#?#B(|WUF*\$@)."\$D,NVA,(&|>75F7SE_I%9F M|8:(V\$
"%TW:#Z|6\$ _P ;I2F/*2Q;"DYTS|7\$QF|B\U+_E&.';^WD*)M|Q(J2'N(ID+T+AW/_Y14=2_ \$
M.L7&)|N9+AV^,*1!;@HF_D0#BC1+S/?PY9*"6^"N@,%Z)?!:K9FOV.^UM=\$
MS5)DR^M12 HVM4-)-6!N/ CK@8YF|;GX9#|?5_(-#):|H8T3;HKUL3Z MNWAI0J-
Q)4!\$15+I4*DC+'Y7"N.PPT;ABQ?!.CF&4!2+BR>2-FHV_DLM31P; MIZ^1
B'J_!>4;B2AA&L_KZH(T#K3BE;#2P:D/X|5J;<6)0!(_N|.9NVKV/ MW0'8^|/-

>D&*^YC50PZZ.!. /ECIP8_T+X2+X7:/".7NC:E#B??#4YZL[^FF4
Ml81##D&H3ID+IF=J3+5NMl/%9H#_-;60\p+"7UP7E6'WKJV@V^\$Q9R+Y;M>D
M)O*F|39-8)V.%"ZBY;&XCAZ&1S!K.J|4|. (8NC/Z5|""VX!QXL6&SN9&FM\$3
MFL\$R+!WM|K?2#01K!7(-./:DMOY|:O-+U\16BTP)KD_QIV_"C+=50|HNZ^O_M.=4+Q""
(.J^#M9TEC5-Z|(-=K.JPQ*52H/F3.ICR=9\$-|H6|5YY"BG;@.ZF8-MF5FMF%EV6Q%RXNV
QPZ"Q|, @, >31%R|'FMW0_/U+Q7_D3?_,%|OI7_|ZW<-W_M\$! =2;9E, '.*?
OOEX^42@H9/HVE%7I6YK.\H'YP=BROX10N|%_A8"RA"UDZ:JX
M97D|4CR|V"X:H%\$DW;=A.|7M+7T-^!BO9,8M7|GV_A^CC(M_W7MX.I44:&U<
MC.D^V\03V7/T;A)L/O(V|08;C2-=&MAH/\$_+.\$V&:219C^Z!6MRZ|T:"FKV
MVW|V8^_A(8=OT|O6MMB1..BB'Z7XYKAI*KGNE\TJGS^4A*F*)L5O;:OBL|
M,%B\$^5::R>.RZR#33*R:3)J\VPQ|UC|Y5TLQ|?N5|/!\&W,)JZP>?BT8QJ\$+?
G('R3JQ)0VBGDJB)FK| |^CV\$S&JF&Y'S%*M-+L|GZ:|L4N(M1)8
ZUJ8(-)Y&U0(9K&9_A^>M&*8U0|?DJB-RIEB2U8S|OP"ZJ!?!_P*8_M5NM?
S*N|S\$HN&!%*B^3Z(|+R_M(B@4H&67B(?7V!M2LR
OE+, =&S|Y0(##+H5+7_&|3ZX#ZMM+L:V:S?;_<-|_6"0K04_M*_A+#+L._>?
_.EL2H26|P8_Y|Q;%>O_?+:J+;5\$.W(|P;H|.HZ=R_H6Q7S" M|_A4:T;.(>DC|
"@U&EF,T7PXEM0)%L.UJE4='01NCK-6|O<469*2F;AF=3U_M'^O4OY9:6H|JR;|
|G9=_7I0#G_|EX/9_I=KEV=0Y,DSAY-09+G-XD'<>/E
M5@#MX*^#RVJ8(Q'%4J&#K1J>6U(%7QVM_|T(%R'-X>L&NB|OMT)O9H=V0VH
M+W9|?V6\$V0KU._")L|S^Z9^GSO)F5^L+R%O|O|H3O|L<|+7'PMB0.K1%K.L
MZTY@C)JXW_XA1X)1PK(9CX|1#494\$UAO|0L*JNO**'W#(#OG9%GA7=4R|TJ
M1KW_;HM_="&K#W8O:)&M92H'G_R1<=@|1#(9,...N&"|CTF+XUW7)|3%BX&CW
M.\$A"1;F-;:H|W'&8_.7FTW=#_Q28M/39|#:0|%)>|>@G#04B\$^O1*IRQ_+|
MSEL(P#\$|_KHLW,\$:6R%*P4,.=D)Q8J;JZ|2,(8X?O;B_0W7HV8(0|2|.LOTR
MD),4@=,*;1QS2KN5%Y,"T@+UGZ#|WLM7NA"R_.;Q.7
M0QGFP9/TAJ=|'6I7Y\$PKI" T8V=^R?6+
%P@:1">+LNN(&1/3"1!_JJ:\$70BQ;TUIBJ3^|S\$Z#*9Q)>TT/J,M\$4D9A|SQ;G5J\$D)(#
<%*^:.OEU|R-'O+@?&48/\$\$;Y7P7N!40C:65W+','&4DENU&PUSQA4@_MDM@E-?ZG>/-
+6^"U;9/8+9A7|/#K4BJKW+_HL*CP+,WKf=?_MU9;D=3'0'?80S|), \$X|A'^B=?C.-A
N(&H5_NB)B'P*|@CUW=D;JT+G|Z|\$.TZ+_68W*G"7|6#_)FK_\$V*?3%9J5.3=)#|KYH,A8P
MW8_18LM|0NCHHZ;B;B"BI_@*|4H|,%M5.V.V_LQ#14;Q|:QP,NTRLUMY4CG
MIH4(W,?'\$>W|/I&7X* @QT@_RE)+ "F>@K)&UE50%Y|:6EU>|: MN>(11:>GG-(=TH:NR-
EKK+| |D%^6NO|>HE?QZI-M8=ZZI\$&6<>+U5\$|L|Z)TW
M#22|:MN(90N|8!3TH81D9L6*!QN)|4L=B6W|C|E."9L2A'MV"6;L+|
MX4<^1M!MR4U/E^6%##RO!1M")#CMUX?|=^JMB46@3.^-?.+VZH0TJNVY/D_M?
AX@|+KP"3JME040:-+?1^() "3@83EQIAO+CZE_H(YW_\$P+AF:2Z9CJJ'0T.MK_Z>|A|:
<&RADE:~B7)P_&V-90KJ%,-?SN!4?(SP^F*4|5C->>5|! =|J/\$
M4H85?)STPZ|YZHZ<.51%^'&SZ1|:Q0|&FO+E%7|IV3.&D'XK7&FVHFV;79R
MEJ|5;:*2&PVR6"|X0LB;/H)6TD'?C%3,#X7B@,)LVA,K63(YAL3AVT,IAA: M5-BOGV^R?
FM|A(:DODV_&N-4WA#|H_M^AQD0NA@_LE>)XEK"_\$-!R=8|POV61Y1-?
|Y>9L\$VF"_Y63XAM-VT;V@RX) M,%D"J:>DY_ OM75O;NY<3|BI+Z2;>.3/:XR____,
<=|49%:'N=*FYNB3W>*S9_MQ6LIDZR&@)%PH.GJ>T.H*N3XDW*%
Y.JFYZ_5ZUR|L5ABV;RH:U!&I5*0Q|
M)^+VA1+WIK4AGK0R&Q\$G(|OUV8|7W.N5A+3|,U5M(FU5K>@N?4E5!IG;?
IL/A#CK=WKCO-;:OUKL^+#+_RVZ|=|!"Q-GT|H7H_M7_&%O|'CY4*+TMJUDBL9.YC-
|0>ND4|'W|CY1GN|OO>,1J0=B89LG35G_M/M-7B)G!_G#,O\$TO|@^T'J8J9@+3R)<0(XF:
|&YSRRV+*\$5U|1#%L?_IT/&A_M<1+=!4VV?
PV)=B|.X5^!|\$GWV2JBANG^_/_%^K\$. 'X#83^&O+8%|8WT|_%3,8_M@@;45H;
2A^L(;ZS#%3O>8S=W*Y4&=JEPXY%FSZ65>_R+0.LRH4-U\$|IAKX_M|?;+
|.07T*77'3*I<<@A|L|ZW0'B<+Z/'W96H(J;JQFB7L_7@;^BG;_LKWZ_M#I*LG<*?
N!0C04D|)>PTRKL"O57TM^*|ANNV8?#Z;X/U6DKX6T8%=TE_!XNF_M7O;:J%^G?
E&:LZ%'7!%FQ,C^^_.QQCNLS@C-;L:MT&O>R"4ECNM:Q%68?5|4_M|;-'
>%2D7'.CM)@^PU>8H|J0JH|D!HE&LJNB^* @U|AQ;9YO6>T#^%|F
M(QHC@#:B03YD).IR|O.EZL,F&6%+A%C|8T"_.^>4_Y6N: ^/W>&|2=K0-,*;,0,+20\GG";L|
MH>B#-8(=((/!T|;-/=8E;I7T&@5GJJV1|S&B: ^@43!S.H_MD42K>BW|4-
C,6&Z:UPZ+R@DBJ\ 01Q_M\$@,-/B-;) \$D'5Y?F%_B"0BGA8%1L/?
C_ ^H+T_/*Q;:!5@L+)#U>CLIQ44(D(S,HQ1@+G54E/8"
M)|J/EQ,M3_18:Y_M\$5=B6>A'|:T):ZJH(A1S/I5_QL0_:25J-EAT"9FWBS

MN!W=9B7[LJ=\$9?WSCAU2DGHDE*Z(:%X^[\#LC:FPHL@'J B4FAC'+5H9"X,7I
M5U:&@AS_7!8T=KZS!Z<)>F8V9JD\$
Z2N\$R3"\$8)@%)4O=K/OZ()||B"6I#/%+G'.6VDL02%);:Q)?!4>5@\$QL,/ #X;9M /,SZP&6-
QVDPIT M%KZE>E_ =|+&394C^5^UJL0J+C%ZOE_%20W-4(*+U0YMR=|3Z"07T6Z6-
YUPWZ1<+C_3 M6JUC8GK=0C9&G|7/3BV0N4JZ#EC&V4?@,Z,I+80T\BBZ(
FG0>QR1E(3Y#S^ MB:9HX/:6SS1#10SETN/,5|@V/[TYX7\UJ2Z#K-
JWT: &:T8T:;Q!UVSFN1- M(4\WROG5@K-TISBH_,JU5WOE7.=PZ7B%--
SN"*_EAF)VY28F%IC&|M.WYHJ M,DU7+3<9=/)Z:>2422D64/Q
40C=>QRH#T'=IAN3C8D;2J44NGMM#XZ(@5Q,N8"JNOGG@-M
MNA#69#-0OER:6CCZK=2#KW.(f%4_\$G41!^1Y/S.R7MF&ZT,U0NB2MGO6-/X
M\$C=W,_CIVXIOCW:--J79\SK-S,4L8<5Y6ST"-YVW8*U.X/Y! K21)N2^2 ML/P=|(I%?X?
+W*+7;H@YOWR^A"8W"!SY|I6;6H^ ^./MO4KCLRJ;R<|AQ:%\MVL)37@#WBDI
M<:%*ZS0YRZQGEU8GO@+!C&O\$.?/!1UT2\U0T&%0&OA?A@J1UTH K
L>L76C2M>8(8#L09S<
MA0@.^2SIH+UHL&5HC.8!3RL1&0|&5C/N3/Y:8YPJYIV"M81O')CA\$_)U-S+! M68.?
S4\$0@|,3W\5M/1V9M_\$.&@/JT!POO'I/AQJJR^|9R,I?&W=K%7H|ZTP|
MFMND<35|W7*PI=&V(BG:,,%7'\$QL:DW#*!^ ^ .RH/;6"M\5ML+*)-__SD8KO> M;=U'L=-
?%5N7RB\$|J2\$,,M7;=>^5Y1H|,3DH1(@S7G,<|5TJ68=5U|/IJ MEN|20
N!650DT\9UM(J/7J0X 9|/#*6W|JWC":.H\$ALI0 3%IXE-1#S%M7 M-
W_GC&A.R?/7J)"I^)#00N_BM5K*?2.9%?9 MU<;B%-T7GBV\$EKF+3^+-
|J_E5SH+//_+70IYZ_:9M!)N<&=.FCP^WI.GHP2 M|>>U7*AD_YB1N@=EUME-
18K)JE9AE?(#/=Q#\YG8HHA;RH9YP_H=X_>7@A+0AG7@7F|+;(YU!6RF*3DTT-
1(G!B404-'&?<%CZ\4X+-|;\$O_TFGZ;IVKXJL|S1|A-<%C6TG)<|<,WE+.C9#NW MP
MR#;A)&J:@",PFM04K41REZ)YU3YNE| 6.V5" |HLNVE_O0LO_WZC#H_YV=:
MPN+%.=5SKJY_ N+16QWTO):LX<"PLV\&5Q>:,%++SQ@%9Z663I7)MXH9645:
MH|C|5619:\$PZW/8ST1Z0\$|W>SUIX511G*99!C?6.GOAP"!";3J^ ^ *SF MZ%D03|+%
|2C,4!<'3\$+7"3""8D8^06;EO+ #8H|+4GI&(Y84^6A8KR?|Y1M,) M0|E\$|TET5|HH?|:
5#K1^+):F\$TC5QS)B@P|2*:T@OP_@A=O|K_W^PL'FW;ROB^>Y7V!;66^>5< MTS|F2;-
Q>GV:-%6<|XZMO|H4U3?*MXYKQ'E|V7IUI0% 5-+"=U EU B:F%3 M^|I%LJBIS-
3:9#!'R++@V|.0IDO/CRJZ>/5_%|^<^E5GN60-"T^BONSX+SP_M*HCD;%|2@HHE|O=
^M6NYO|(JEVPJ%QOTV\H|S_WR=' L7VE1TB(5Y7?7LO. M@OL"7+/YXW6B4EG,
<12905/+7J8QJ,I>|>_O*5@AU@29ZQYB#_M=A0O/_M.L01_S7,K-@J?|F%I49|
()1|R56OZ+L8?&9*6%;4=\$0#V0;/SUX?RR\2FW| MJ3/'|XP85,M:GFM6E,-
H8OC/\$8P\YO!"SD4N1FQ@:P*J',!0XD.?NDY.J@4UIQ2@ZE5W
M;_J0W&6FT4|JV3|HYL+42MLTPY J=5O/1<^(,%5?<<#|O-)/6FKBTF2'3LEJ
MFQ'VUTE!AZ247FH#6 -^>BC;I2Z67*L+%MK+UFU0KPG5F R6.T_7F-HIVA86
MA!9^_ ;K8|L.NH+&>N^7Q/>-'?U6*V|I/? .S+C<|8R2X-OGT|C,9P6Q/P4R7
M"Z7)2H5S_ |VYM!*;G/WXYO.6(K>"@%9;4//@%LAI"<:Q(Y'ME;GO_WR(IV+
M.ZN&JEU\WO&57^ ^Z=*@S2DD-Z3 M:IW4Y-4>*LU1TN*L-|< @C.E9SH.?
4.)V|G\K)%TLXZ"3:U1L|+M0'563SO>U6|_9:U2:0QLL3B;||JNU+W L5QVLM_?K"UR?
SL^7.&#;+ #ZI> MMOS6P-R,X6-30Q|A"|? N2DCIOH21?2Y:Y<>7K,2Q4)'&!QD:5@+ "
M>_ *EGU.PW"A/XTGH30J>|!18-(|_@O"MBJMDBS_(*%G--RKBZ<*6^QUUE@WT
MJ%AKN0\$XS""<_73LD9%^3T%Q5J-^ -|H)H_XI'#ET86U"_A9S25V7X MS80?%+D8@P8
L9|LJ!FH.&C|=,=F\$GV,8N'2&|D0_7KB|7-B6|3R|5#@B;=&
M:Y)O9=JN/ZVV,|Q7^MHJ^!1& M-/4SWU(0D1#71HH!3L#&O?D2PVG%^#=#49:CO?
L.)P>.ZH5D.P=OO W KB\$ MA""I\|C1\$Y|1A%YI&5L.&=6J:G:<
)@BD@B2A/MJH#Q^ZZC=938X3%086883 M\$<= 4N:UH>;/KW6&Y'|?4GZ.>S4%O_F"C#
|A"\$E6QD2'4+!|Q"BI"4W)'% MOY ;HZ= &Q*\$KT*? RDTTWPP*L2BLP;8:7F/WN.3P#.:#?
18I+=<&B#Q| M@#;+*!M=YK&>=*(='Z(?!-99RE.LQ:JYM?
R;=4>OPZ!;2F_J'Q=Z%2|R04UC M%-0ZX)|SPS95,D0VCCH^F:_JBT:1.=!
<0%%K|XL(HO.>>?S>;;"|PI\$! R_R MEKQ>HS^NFQ7/?
4G%22RU|HM,1/Q%:6^.)>X)6|16Y-3Z+WCA,+9\$#CGXH2Y+?"
(H@QYD)6DYUOB|&0VI2%(6VIXU|PZ_)4+AKS: ^ M0(#^IPQ^/U@"&N)!19Q#9;G-
O..F\$\$\$XSPMB3R,&L.N3P"A)%'P/7:\$'|L(A M+<|EQ>W3Z/N@_4V52B3=T
U)7OY@+ZTZ*SWZ9T;WE_.=M&|H"4G",!*;SXL M'GV-JG)IY<,D"D'2K>|<^@QWFM
(GW4..06_84CV!;D7P56/Z%|FW'W* M.F4L\$|RFVR&'#W<-90VF%|
(NOF^&"82I44FTR%,XWZ@PBV^_ |YU|H(7B CB M*L7Y9;J,!AY66_-V^,M-
HHADMZ5VXG3Y2;\$JG=ON0JZ:N@RYHI".ST&|6&XL M=<,CS#"1H/CNL:,YO9@W_51V-

//2T R &2 P0#6K4L==U3Z35;1:2N"\$^<%!
M55@"P7MT47VY9OM/H<5^1180DOIRW"B"QIB|"^C;ZVV;AFERW/
M'F#T_A4@XFO;ZO>E\L(D!V\$^H?AEC2?/LC\\$.M,%FUH&,*91C'976Q'+(C8
M=M*P<>\$8491-#SP*21T5<|Y5@;Y,<|^A8'E6G=-3J*(14M8KSC3!QU?2S+337>@*Z?
OR-5 M2,L^SCG.R./&0E#\$CQ4M0^N4J@X1*B>7O"5B0;S7&%%\$Z\$V*TG"QA^'M<|6Z
MTV|WG^QO26KX357*)5??UHX<%;U)#[S#RI+'I#^QBQF4"(9@@+TJ)(D8*./I
MY"Z>|T5\$|?8)QI^<>(HVDH)TW\$<+(IS<89(-,|HMZJ0&'-'M7=QS6'CY/
M_G34M.!TGDROK00C2< &2V@,HO1S|9"C.P(:MJR63CZG?X|U=O_EW'(\$8@|
MRY!K2^_OPPHR1*@JJV"17|@J7ZIH,72&3U='+3F?X#F7PMV4^|G:<6U|8O|
MRR:|\$6(=L%=N?O8MCRMJE|T8QWO?%_L4?!-%5|@VO#^.U'5DV'.J|'S+6#@X
MK>RN=Y5\$>6/|~7'7#S'E.|6*"E-\$Q:IBDYEA-!7465AQ
N|_KX*"/,P|H%)LPCS_#CB*:%1CB\$B9|PLOP3@_MV63=2=AL/W(M-
3".,BIN3/,2M2_UC4.=0"TJ*W\$T=,,2YIQBK|8N00Q_HCT_MA"5|MAQRQ\$5|'&4D?
J7QQ05)#_4^+_FA+S36S;2P|SHP>\$33;&|>R'.@S8@"M%||*YT4B3K-
X&*9@1N4C|>'#5TN=A\$V^MMZ6+-
BHG|JF&=|R)OZN<,GRT0DX:@YCS)/XP6,EL<>|!#J*|KW<=YW&R|7\$@
MV3S|ZR|=U136?0_&L<.0D1ZS2@"4B-*)Y!11Q_0D-Z)@(B-B#0)&L1Z75\$
MBM2(2!=#"44(!AE!&EA:*0(B)-;A3B%9+PXO?|WOEC|?>>VMQ^2.L=3GG
M9.J/N>>>O=5|ITZ5"<>8V_X'ON)B^:N!?'^+M|4#2:A9;CG4H_89X>)U|%'0:UOTT?
FK;DD008|2?*^RR/=6N/<6\$-Q(AZ" M'>%)U;|>J-EJ\$Z,XJ?
#5N;^#|;B&6C*7B6@E9'(TN_B2*2@9#;7F/R/ER/2:CIR:|K;|V#@ZCTQ>.(D)?>M|Z_P=W
"H+T0E.Y5@:_ZCW;X@:T\$6G*VC(L?>.*[O5^\$O6)2RE?%SXFRD-|M%P%+
|@.*@M0'(EX8'4PI08)*S|\$E#GAXH"7M^X+)|X,UE|9L4DO"S3"Z+%E
MO)^6SWC,SZS,1:63).XYW|T4C|ZCDRFMSU6|P87&H.DS0Z?*Y4IVL=?LN;
MF1EH1N2IO;V|U5BTXG,V2|OYCV/W3F7%RSE=5O6?Q+::Q=XA!D#?KBT9K-LF
MV&K7/O.|T?(6^;8/O.Y.YYC^,65,TK|<:R9VO?
&B.Q(L:M:LH^3I9.N>#FU|_ZW.GKJF|B:..@"S)*?^E+Z|'B; &W=O5|<0YHX8(-GX
76%"3^|02Q|X.F1R>B,@>XIUH8<%2\$CJX M)BX_1)FX7V|+M)_"*E-
'&DX,^H2AER_&J7XH=Y&HCZOU<:SN%26HY8@Y%)HL'(@HCV,<>^~8 MBI"R|G?K>'
M%T0V6%8.|>62J|^2&|WL&L?2L3BH&|;WT24@++M^3PONX(|M+XT7K>)|&#
(P@57|A|0D&YOC"9V=5_Y*'IAZJ+2I?R)E:>?V.<M(G(%XBV3/<(E,-|!|,AB?
Z560M='8.|HDPJ(&_/Z@C:@:B1=<:5\$X|6S^M\$S4F@"9|MK#\$,YI?NJ&?6N|!XNR7>
|5'&/F8T(.U%P*5G3CR+)|@P2VR9|K1\$M7?|,VBQ6|MQ;5GY1X&2=P/&^0F^*LYK/AM?
8BKD.1*@G\$SLIFMETVLQPN M8F#46&ZPK)TNL&I3HM4BJ\$VA%=%MG/S-7-^9G!;)Z/E
_%3@,,'C&3M&O9^S1CXK6RE_MH|_2W'?@"M7@P|B=^/|@.WJO-WU#L8:-A%!?K)D,U
LA|SN-*J|&ZC,@RS:Q<,Q5|:OLA MJB,\$|F'T,U5Q:NNA/J5+G%1/9"F4,^11UL|J8&V=E|F?
MT)TMZ<+90|RFZD| M-%E:Y*OT>#C8OVV=;%B:..M;N3)|T*;++G70WK7?
_N5).9UEF2EY;K9RF7+G MU::41HWYM=K#Z6&Y7F8&.:?Z(FY*2>4ZE"=G^!|@Q_JH.E"57
Z-GL8G3_1(I5 MB5V(RI:X..<|&LD3G-V|C.91',Q&AE42APD2V#_FS-
MJ)&W94(3MCMQ;E,A M*GJS_UNDZQBIQ;4(*?
@1"^#-9)5=|P|S.5:V;%%1QZ7.VZ<&MGL,|#5MTC M|_CE'1%^PLW_3^W|)X DHF<*<
|L,N/3^PHC3%F?7^GA"XQPE9B-G()HPPD)1 M3(VFL&?<;YFJ%O;^Y|T
'O|AQQ|O"48'UEH|UX 4|X=9AV=>*WUO/!*&\$W M(O-8&_7D|(|CU'-
#@?;=_FJQ(|BYV|7RC3NM*4YPPY:";56QK|3%J|B+"7W-M7ZL
LB|WDP;L:|6"TM6:3X|DA1&\$;K:1E|??98HJZPRC7+|3SDG|/S|0Q|
ME5'C3!D3C2NWJ9"_5FH?U(YO##\$3N%-N>1>_VHFUP,XC_7N|*)9OU5IPZVZ|
MZBLP@2VX=""J.2"-)|\$1_Z#\$@DYG<+*1R#8CTAH-UI1S#@DV;|3IBOW"(NY5Z-MB-?
VE1=O2\$UNE?\$A^>|ZYS*GYWA"9-ISQGE6*OL7|Q|L".%^X^I*N8(-MF
S@|O'"S:&)R/TD6T9QL_+/FA|Z3(X1E|472E026A6'XM7D.B8T(KBA@_-
M|HTNH%^_5|O+L?E:\$BTFA8>WD2";9GK.|!&UE8WN9C1^%0IL.C7,A*Z
M;0SFWGCH(&K*U1P&Z-KH)(IT@D,=A%\$!QK2_C(CJVRTO*-A+#\$0ITH9\$THF M)
PP&D"|#5RXAA;YD2Y&\$YC(J|3X/8F2%TT*|@8TVVBUNOMH\$"-4ZH=|_LM
MPCO;61J&\$5WZX;|W.B|R;N'0"@;"U2D,P;|R#)|1HO))!0L#7\$N
MDBRW9FHP&9D*!1UYAZ?|<7|\$+HA,5'1,;|G#1%?
OD(H4)C8TUDM)\$KDI|>:>G*:9!4:~2Z86|%M|
3HOY17F.B3:&@O|J,L2%.QBE8O8OX=>X"^GB.(?F8KU\$:137X'\$,|P<\$K
MU8|+,_LGQOH%W+PTS\$S3M*6N:FHP*|@+D")(|=98O85/_LZ'M:DO/G%*,(#OO-M7,4T|
(0I8._|KYN7Z|S|&73L^Y.3%HDR'QJHJA/CG,C\$6OFPA\$1.6U|/FL M.:1X3BX9M+5RU:C?

A_<@AWK0RP,+^F#\$KM<(TU8*7=D_\$ (7D0T|7 MM&|.O)!IV9;U92O85 78F
6X^&3D7S0>="SH;D :YKR#.AMO*6|@KKS,,||0 M3P41NKP<59>07.T@FUIG=?
@2=#OH3E/?L*B<29:0^?,#ZIU\$+1,G ^?(S=+)!^&D)LNH:~T&S_(<7FH*?,\$|!=C>?"
00'O M+R^R'2SA3^ '\$MZ3YY|<.:|)HR-7(?Q8RTMDUW(?;\$|-K/&3N46DH)W%7D3
M>C(A7|KIFP?13?:3S:X(%V|>|TS)H(*KTP6+<1Q|E)@;:GG-2:@U&TAT*~@K ME0\$|K-J
(F0K#E++!1RH 2_O'N80>1-S|4NT|"AI+WX-MT:TI9U%SAGIN-
EW"KI6/2CU\$GRW%A%+~#AK0+>Y: =PUMELXEFEE|UT-IH/L
MT^1K++5O3H5A=RYD^6(KGS\$#K(Y7:3BY1|Y%KP=,U;^V41=)S84*)26<2,WV
MJDS*T1D|UX-1TUHE47>CMQ=F|J@Z.|V|9/&C1SA\$%K,10G(OU(5XW^=WE|D
MPYGD3|L>N|CUY^|7@;:&CO//@)X9MPHY^|~ZF(.862|*WC2@\$|9/L.DTD\$3|@
MH!;_X>U\$RC4RMR-#YZ>ULSD|9/((0NG4VT3_-/+HJ_-|@LU%|_1TF9M0CA1X
MD)7(UN1F8<)|V'V|TN2|02LSB|.6^/8@@@R:'FUC6;L|/4J#S-3Z\$D?I0G4|H
M<|L^O;DM%-&WHT=X'K1;.:^.)UV@P45N&95WK.:VQ|?D<+|A>B1Q=|AS!+8O M-
P-Q@_9_19LX*EX/O#&->,RNU19V#*6>K>I% C52"";)Q<O; M6V./%X^'+\$T21|_|-:
|HZS7*O3E_V,=(|IX|Z7VIP5NGC 8D'^S2+!?:OUJ MTWZY+R7!63Z-R\$#3!*O!'"
CS.9DBJO=,FAIVH31S6EG:Z;7); M;_IQ5N24VG: 6OY#2V+U@|MR#G%%IW!A8BZ?
ESEBZCR!!CITIG!@\$YC|:9'."99WT89BW^5|/#|ZQ^RFM|V,*3RM:=EKTSD.@@'_Z\$|P7(F&
<+Q|V.)|T5TASA5N M"L>09;_Z4+|G#R)!>8*^T!|N<855%;V,"
MPU!|NDHK5W:F2DHK@K/0;J+5G"N36|=(ZL^B4% TW+TY%ZE9G+>, T|2UA-A
MZV6|!S'&9*J&!#0%1CSSF#G8I_K%(Q"N48?PJ9B%)9J*>R2^~)WK=&:~R1;_P
M#>!^JZ9WWO%RVX(F>?)QD9R+|R*DF)DTF#@F9AV_@"S<#T>N)N9H(IR\$74N
ML1LU6R)EJH^=U,NE|%F|7,V+-KJ3PRCV,&.=="/16'_YW)C7(XD| #'K1X5(K
MN)M4DB0#GU&B'6<=WC<@)HT@!S;|X|!)'+_EA3+-W0>\$SPA#VZ0LIP#E3
M.F!Z_.4Y=|46R3A_#2QV&C(E;RD:=1C3"3P&X%F>?
1&SN621X%RR1@8=>Q!5)&".^G5UD"-Y0WI
M;QS<@|0YU%)Q>Y##.KBW<&XJ>9T>9P75D@YR'C>#+OMQ=!(TEVX>1VB)\$@7Z.?PD
!OBK# MG(|XJVRMZ/F&6X@+(!^QK9JC_=TECXFCGYLJ?0(=G/R&V1?2CVO3/U7YN_2
MM.K&V!D4^PY6;@|RI;BKZ;*D(&USC8(NH*M>)@NB8X7ZB1^#;I*01_N;0^_=
MS2Y5(I;I2\$;F?Y(+Y-VIN6'Z>?IV";|J@S? MNW+~#W|L*KX|6?^M./
EKO_7*)'G.MC>@&)_X M;NAT|/XF&)N|,U|OK@_<;00A%_FK;&X|;|N3W(*@GL1#7@&G"
<_7UXCW(MS0E 90_B%|T?7&F8368< QQCV|="Q7Z%C4|\$RG69B1"YS|2BESM-
&NW;>Y"D M|+ZL1O).YY,U_X?|C GJ0T<_+*=A/?;+/N^H.;%B%_|;9JU5: MJ-N;B4:7-
Y;Z/TN=FV>44/'^EXN+RPJJ!%<_QGD:"AI2>?W(=-2.#|N%;|9(+;|3Z29;|F#J M6-2HSSG|_
_=|OZ&E(31D)KNHE@GB*0)2|Y(F@;Q6JS% MZ?SO^&XX%=0001ZC-
^#^&MZ7)FH6V^&RF'^X-MRA\$. \$P,&G+M009,#BG&V/ M|T|Z/.18G@@ZH%=?!
MQD)DLSLN/6CV8Q:#V.1L|;O;<'4:FY9-%. CK|?MY M YM)L&.F)VY1G<-
)2AVA5,PL:BP2#NISMQ2NFV"Z:D/E4G\$P#.3.=*S%BFH
M/*P)/|M&%AN0W\$)8RAYDVP%+%1_A*V2,&|Q 0&O3LI?
BAS"&W|H|^*+L+;003MMG'+>|8TN+AQYK>QBT8U)
MV1PCFP|Y&23G4V@;:9:1E+|40YOC|VP)C=9R?4,=O3NKL_|'N0A|TZYFZ7J MB'N4^~
R;W=_G#;9 SP\$Y|XZT)'%|P'1NOHF;\$*^|~P|B7O-DXCCV-L7R# M'0R#|X|G9|*)E22>?
3=M>(?_+3P|<|U|S@RS!KDYMG&XG:QF|(H+ M/?3_~JE_M|3J;&4*!Y|O*|^2SI2F-
4Q|6E*?|O|2+._+TP^*-Y8|JS1L?2S9:
M(S;038*V^|MC%@12FN5@PKYWB3E9S0C3H^_Q1'NK3|\$?3N?|_605_~.?L=T^
M*.|7/!K*D?7_79 =MPM?%\$-NS=*&?F|^Z@|@;@|O03"|H,|H<8|2'88DINW
MF0+;N0WX/W36YUE7)O&M9N1=Y\$ZP#@(|Y^1ZRN|;NB|IT%LKD;/LLB<5S^ M!
|R190<^6HFS+,F503Q?3"@?Q1"B00>9#.B&+>JYX|3)/!Y@E\$*|0LE8UGI4F(F#-
_HIDN"23= MFB_TX<+R73;_>ZK!0?CBC:~\$W?Y#AR=Q=" 1*|&W#E|<)_A8/7=[3*EQ/
M-)F6EQD1*&L"< O+,_VE=MW>DP,)=(C^,>9,F8#%C!=Y8-V3V(.WPP:F?#LAF6
M67)R9+(PBSZJE/+T:8A9GL'"=(.%GTN54A9F5TMK=6X1DB-^~BU\$<M^H')L ZOC7
SN|>=>;P;)CYDX4'EPXVD9.FN\$0-R% MOY:
<9#TDJ2/82|J;B1,SX,_>U@2K&4G>38L_K|O/#|YEDOS8:6-QD>@>7|M|"C
I9%%FS,A0=;CVP<2|A(|;S 2F5B"<"@6Y;?%Y*1:>+N7|SWB^+K<:&* M\$|<3|4'K%W-
_~*X|E'3KIY-HHN?|),9SW) Q,L1VEV|V4L@|*OBG +>!.H MG3Y'E,H;_3&
W'G*FY|B@A>...X)2Y2Z&64'@HM/?_GGMXY3K"-/Q_TOE9J
M82CHM2Q47^E5L0R&>LTB&HQ7,=<;4YO-Y*C0Y2 M)|N|K2Y*)^;B.WE02@3. G MY:?
10F6C^@.4T9K;= !Y:EMP|KI5G?FUK09)>+37Q|\$. \$,4G63Y?^UT S#<< M?CM+
("">..PE25\$0X3XG':1G"M|BVVGHN=L|?HXQX|9&UBE>)<;_|=*Y1>9A

M>6<=Z.@W)WE=2X=R<><%^#<9*!^7VY,O'=Y72ZDY\ M.^ZMAYY)^N))O//?8/9-^Z.
(AE!|-(-RD)9NV.F5H|14Q.A)AS-7R,O_&;K.LDG5H|9!=^(^7I|+F_^O_L-H9"T3|3;MF2>
(6|-%:Y%K9'@N9%HC|'O>&*A(Y>:08Q=W)A8\$7X<>0GXFYG&?>O(MXZMO
MUR/1Z7N0TW-|L3(&Y5/Q|@'L+^Q'9.,?C<8.TP60|ZT=ADH2*1|0C*"0.T|
M&%3YRO'@UCE+\$.F OG\$PJ<(Y\$;B*"?:LTLDK)7#E+;^4'P\$O'"<|EE8C=MLYS|
&&|==>\$^6<"39%I&PN(4#|SFGVXLK,H.?|T%Z+5ZYS1|E63/5/RD/
MN6W4Z>)ET05,%|:|SD;&TO+T=N?%+|&U^159,8A"GH#DKN,G7C^J87 0.F=K
M|9ZX*8K.I/;>09P'+UV<6K|B4(|#V|5WY..TBVBGFF&\$H=WN8JOFKRW.;
J+!|6"N|>W(^=)+<&;+!V;UC_MWH#GP2:PJF@K^F;/6(J,_B.2*BWS*+I?
UA7HJY_1RV3"#GM Q=#>RY=8:N@' M/5TB@*>
|E"CEQA5^0DU^_\$_DK2R4 (@X.0^NRQF3^<=H|!TF(|I#R^^#DA|
M9U#PVBW1M>:9IX*\$3JV|3W@5O:LAJ9|YAGZKAKA"IR,NWT_>^N*Z(^6M%(|H
M4JPN#)/AWS(6+>*S=|?\$.|C6TF|V.N/2Y1%24H^351M/5L|GK#XP"U59I;M
MOHJC)1G=+|!^P0#/*UA5QJ:QK>*5=B-XSHC|*L3&_2F^@GB&C0-UORI+B<|
MO;S=_&!<3G1SF/>@R)SZ8#V2|L7+VHRB|FTJ8=JO,WJ)N(@<@?
^C%V&|MD\\$_H/QJFHKPI/."Z M&5_@W,RP/1&(\$|+=LOT#O=^:)9G6+!65*;DVK2
\$9NZZH.^-N;.<"2'^E1ZK M):>G-+=F-IM'S!9MZQ-V'4M6OZBK.^9?ED:??!,546SA8K?
Y.^CV@HRH7_P MD|0=1^-G@@S)4&<.E6/,UD9IFVIUW'SF(M%_|L#3|
#0NH*HSQOD)/5F1LA_YRMZ+ V!;?D-M/9>|W_+1IC;K_"Z6?VM!
M7^\$\$1RY!ZP.:HOI\$,8HNY|4T*\$6-^98=5VSEON*CSACV?K M@R^8|YM>>DZ:
|D/G6O\$M2,+O)D-!0L&768OQBEU=S?54!GX0U=0:2|_Z8FS(
M0(80^0ZE#R89V"+YX=%#'^&.JKIL0+::|9@._>4GLG1(LSBV7&@Z>;BZ*|
MHQP|0*@H-9 |JOG*<:\$.5AUZ:((34'9#4U/P4O|W1N935'ZHS'"T?B#DW/'" M|D^>|#Y
HICEP*|/^;0P9Z=UR2?0P5?X(7(!_:/O3*)(UM%>8DF4W:BTTP5
ML4.F"EW3'/5:3|>@:X'8T^-US=*A6R9F#XUXLIKV@A|Y&J^SE&-M*|GT|L5| MR*|_?
E=FA8%/O(_M099U42>3RK-P55TG?)M,E0G_4K0?,V|?\$.|B1R^@*\$.9BB-M2C'?L.R+-6|*Z-
0H;.:89V6KJ\$Z46AB&|VJC+IA5!/"6-MR\$E96NN4I=5GT M,%VUFY'U)RHM@&|G)L6"?
-8L|^<"7:Z9ZJ&7LZY/ V-YZOH".Q),, #US- M%_#%/4H60L|3)0?&TF!0!\$Q:
|^-V!W"ZY29(^,3'EYS6OH9>%PPFLT+X|B-C' MNG>/O\$+NA-1!9H/28C)!/F'PKDHR-
G|W(LLD;U_%0 A3L)D.|G'P|O^(S:/, ML=C%@QOS%JR/|23|,XL\$QY>Q!&
H&>'HQ*1\$V39.FA_I_P><(G.'R279|:9JM2>>1B1-TC9G-G^I5>(%2Z:WZJK+NWRU^R@-
O|+YN;MV(;YOU->|B.-PNK;UV?WXW&F+2"#W."/AB<^W
M|,=Y|D'W^PO<%H.PQUB(NYZZ56|V3?%155|E.BN::5SL3_/WRRQXPG9966!M M".
<+.#?/IO'GBR'9TH1PMF!=-9:/E|::4F@:VG2YFZ>2KLD'VX&'@|VCU/*
MOCKKS|7W@LB^|J|.NOGA6G\$R=I+ '5@YU-"9Q@3?Q!MZS9)TJ#|&|1C@E%Q
M#1SUXBX8"QX??K5)>?A|VE".6OZ=&+G'1XT,C'YIF38;S5PU|4,)2=0LN94H M&-
QV5GZ9(U.#^%|E!_R@U|CQ)\$V&G4-Z8KX%I+|KR\$|0CDC05X|H1MN*V)|K
MG2A&7/:45_NVQ0+5Q@D7TT2KK;M=E|).EMF.8%C4>&^)|J/0 M<.-
;U69@=6!>2VO+Z'|HT?C">*N;T8B3Z#|^@J|9BU|'V O!
<_XVN2/Z0;VMVPO66;_W\$@'TOYK2VF'|*F0UVM/RV M3M!E:KE-
1='3:@M+D9*BQB"08V\$B=6KBS,2B0(:2VINM8X2H%99|3SEDPZ/!&N M@*|8",R:-^?
*_6X\$&%N.|<\$3^7PS J-M=N/G^-+A9U|Z=LR5/(XX'T(+33&2
M:|TM\$,Z/>!4TH57&P.W_6H"X.&:=|*;J1MND;Y:=2,8GI?PLO8T|"/T3JOXP
M5QJZGL.GSDT@:P^2K_8-*|<1#::|^-Q!O&?1FW3D>L^N*><K_|5V:<:4'^N/<,KSB*|W2
MD7ZV)VK:K^74U&1%F,HF?+?1_.N&ZPK"Z/KH45Q"N|WS!#5CW? M2*R%?
J;Z:+G;KL6'R,G/!-LL-94?FH '|@_/F9:|!P\$|"?-F8^P*:B5@2|&= M:UGLYYD"A_O5N?
L=;85.XR6|3J|LBB,-3GL|/++G&^)+#!!:%F_-C*W R27R@K=M<2?//P M-
<>2M1BGT|&!ZL'*6;N'"KD+,21K@2I R7&4SI6P9O0F16| M%1'7M?L)=
<*MY2NPR;R|3;Y=4|E0H<_C|/# 8|+PD|&0Z!N*LFAA4>.WZNXO
M_|4V^=PJ>&WSV&K>O' MW6#95-CL&@U%R8RW1|F95ZRV+R9@C(-*
*DZX|VACQ*FIUC-0"<+E|01|LUU M+.30F|=!(AY#T=T-!=OU/&7@L_8L2HKZMJF@*";
|+E?CJ7|I:K>6;)|O..OD MB1V800 MQ&A3+DSL1X&.NM_%|W&H?-.734KHT1Y
Z8R|Y6J|4N9074X|JR3J':X'|LMM MGOW|4|\$,,BKALT&D2L%OL_#'|BT>W'"*GW*
<.:NK352A>2*9MTM8,,?0XQK,1
M0";48976"OZ6D+).Y17"S*\$=!%652005|H%\$RO|_6J1T+EM0AY/%1I-?
7Y4EG8WI=S(8LFG6T).5O>@8^)|VCJZ3A>*,< M'G5F:(>(E<+UC*"^9X8>V(/,?N
8|D&F8ECWR;Y|\$/|K_/D66/>2"7-EE>S M*4"MQ-B!AL!39F+BGP!N)<
@W9IHFVHSBW4.I(V2Z5G<;J>A1:-^OA/3N| M=OPK|_3\$MJ:HLWTA-VD9LCF^*

<[I:U='0F&SL;):;06HG]_()U_L:(@"WQY M60'55
'@Y55^+1".+W/S""PP2RT+=/YW)O"^34ZEVZ!0";YB9?I_#GNX4!2;
MRU|H7S@0UB|SABK?!V)0^V|@5.0T;_F&IVWJCZ@QE@R,Q*N_-.835|8K#^|^-M-
UI8JJ(/CZK6|LJ7|LRJ\$U89B5AQJ50S3'#+H_E<./.>+@*BU\$>C5%2^&8PX
M6ZH&O?'ZB7P&!T\AXW1LDY P)*T-NX^E6;_1@SP7<,ZZ21#4.53X^;?+'@Z
M,MA\$TJDYY%5="Z.7C2X,5O<9E5(P_TJWBE,
I.ODU1XF)D_KJ3BP82^1(TX?)PAZ!)4>!W [!\$4VM\$)*N/W/S M(-
CMZH5V&30|P7(/NF>4'G?VUA@#M;J&^X,#Y>:2E%C#3'T*_I&W)/"M+(J^M*<*Q_!/@
=|!\$6?^2FQS9"033?F_KL9D|2A@X-A#|8W&-!6+//='RM.<M"!'+0;GJU0N?!\\$ _W(#
<7DU^UF1SQ;HGBFB%'3\$|J96@I?ZL7^"3G?(Q,\$>
M5%R)&FLL85M(8>PB2YY7>'/B\$|;..+'U8!XENN+^|OC,VI!*<)EN?|'YAYL?
M6(C@6,81UFN_0F Z.H6&80%W9*516H/T^C>Y%L6?#77ER/N|T|TGM=&&YMH9
MLK)'Q_MARJ4_Y"C7F+V&9>'DS1-8AE;T5PJH8G^B0:%ZIH@S97S
1YW:P/4@CZ,+*>WXA%#34QQ3->-FE.TZ (?^_C5Z..UXE|S MS&QA|
|<|R^8Q@FG9Y6F.TOQ M3GJO="GS(Z((>7,#VBO!'I_CB'&+ME""Z,9!JV:|!R@!)6HW/,-H-
"0(7(P M=OJC*|8:|'5_J=U_P"|8Z&'|GR98)|V@_F3,-7%OMN#-\$,W-G9ML_|/8#1(M+)|4-
6Y8TOX%VI\$|L|G=I7*_|OD|?/+YM#RUX94OV67':EI4NCT+3|+7|2))&2JR9|(D
M16ZZ|C4K>HT_9TD52*NT|!\$:#1"COXZ_X5GKGJ"&VKJ/S|5#Y?@U/NR_L=
(WX_+++,_D6YV6O_|_OR|2:_8|>2U=[6D6W-U_?MP\$KPLZ0?_SV-+((>=03-JR#5ZB|?
U''2>JEX#_E6G(NLNMA_<=E:3;44)Z'K6JY>!=|DCFB0|PB9|!+N_
MUW!*2XZ1|MB48%;AG&%;>+U)INV^?5K0=(((\$26VHV-
#V8|J7LEMO;A5.M.0408E|UZLNZQZL:AV/\$?7L&IW5/O.AF9(S#6#8W/^GV>M)?
8"1PQ4.E13(+8'D2+3"O%"/(E+= "XB447 MR=_VJ5S1:7|_9^?&=W0(7;A0M_SAK3
OHW9WZRFUC?"G>-;Z@%ZN#(=&A ME|_2FUNC%'A)*8K421
_RCW>84UH/;>9!>=^C=3<|L\$V M@7Y4^M0|&J4T#X=LHS7A9=:(_K6DQP_ ^DIDINCJ
MCM*+FV>(|@|_I ^8BELE/67W'+;?F\$O?B.AAW;S0UR8W5W&A;W;D&#L>4|B
M+%WA|,PGF%%N\$U:9|KB7J>H%JR))&)9|NY9,G2^|,QH>!80QC','Q3Y|^8;
M/95|QZA*PS5+3H%?
=%@GNIGU.2L^3%U5^N=:^JH=7:~+3K=&SU2.C3&#+CVNR*X;5_HW"XMV|UX>7V#O!|*A
)C"MRG%T^39LWT?. MN0|A"|(|S*|*-59T\$N(RDR
.6@Z|/;XR!4<(TMY^T|54L9PNZYPXR2,\$CW5) M<91_#|"A-Y=W\$#0!EKOW(((8R<="(L
>'X|\$PM,??0,(_>3|HM6.J6G*>S|JZ M#5RN|:~?RW-J,UB|;)NQ_0(?P9O
M.Z%|PU+A0W2'K!:_|3C7'0,=^1C"5D%2WOC)0).|D*6P7F|UI(_TV^';PC/L
M60&:1#G_C05FP,|704:A713|HR94*YX631V:U ^W(S/&+)L,HH:RD|#/7.
MA2/#CPKEXMV_^;1.&=R#U,SW-"S1:43|I?-)N?\$.|YM>9#J5|0EW%26 M/<21
\$5>!GG#0"7@*;VR5^BPVR2Y)>JA)#WS\$4>79JWN.-7_2N*2XZ3.'N18 M8(%_W9?
G&AMU&P?YZLE3|_)Q'??F9?%.1|_81HJ\$X.C(U/X4E07:|U BB\$. MZ;|HN*2N,P
TOGE3#D0\$&N4,_)5G'D,3',>-8|<"&SO_#1=|:03L89J#-(
MOW!AZ:/5Z73V"9;Z/K@(&I_N)&Z4_\$P|R8H8P-/E|34|GW%QD.G*QU_/_3
MC5+GK""^Y""ENPI_*Q_JUCK|U""%UKPX7F^)U;=|HJV3KYVR@05E|FJ;|ZA|5
M^_Q|M)_ZBIGEB^&_|B#9|H|S>'8(Z|QV^*3ZD_B?7%|D9\$YA^_)90*2L:8P
M|. +R(.P\$YPQ9A_|'^RD|&'V7^U_?^%IH;|B!+67<0AA6N@Z:~?&E@>.Q!\$D71
MBQ;O==35/6HWHITF0R(?FBY8|!\$X4O3.BITL/^)+(|Q|'P,*K
M'1|PYG2<:~*"ST7)B,U>|H\$:-=Y<+.L0NVP|N;7VGSRI|O;&SM6".H7QK*?U#
M\$E(<_PDC)H|_X,-(|=|RYG!3CTM0=T<_|H)-_481>O@(Y>J8!Z%?@&AQ
M/R#FCC4E7|+~#0|9/A_/W6W23IEVU^"5Q1>|_WIKHU Y.J0:WLS4SH5+M8
MTBCZ2Y81F|JUS?L34)8@9|JO3\$92 CXU|CK=A=9,7_//|_+3<>LSBSK00 M))@.N?
>64I%*9%|D"|=5Z+9SN!HF_%=9|':5,H^_%PH/U,Z))>Y*C6_RKI M")|ZS-
^371*~@OA7PY4DM&MYOI)_!X@~@8:G5BV%M@VLS&2,~L+DM;?WBOL4
MX|_T1(G:%&F")T1FP5,Y@:P.GD=\$Y9DJM^&9&9BW%C|FR=C0NG&'8*?U-8H M"G
JQF|WVFD)\$K_|FEH^GY&<=B+-7V7|MO3,G%A"|_O;T_ O-(T>"IS\$1>/
M/(*|@4Q5I%,W\$FF\$V7E:#7J1D9>46=E4F_2FUAAC%\$3V/8>_-'-|K_J5L\$ MQ^?-
VEER"J<*+T|16|HZ\$E%OBM1'@EHG>GX@Z=4F+:E2_C7R_~;7,*H9TTPE<1?
SWS.OX*+HJ.L=\$<:;0|DB5VPWR|_NC>MS2+\$EU:~7S2;YWZ?16-?
J157V.7/(>YKR7XJ*88&G7W_8#^*8H7+GT+3\$Z^TO,Q#*VH/=^%BV
MES!EP#TWAT\$6T\$|AW+|Q?FOLN!?:P;PC;|>ESUTH8QKZ&2U*RCO//#SZN1Z
MG:Z|OAVQK7Y29W<7':H1NAYZ|L&##05YH|BLA=7QU06+|M:2PQ/ED@KJ-H|MR;?|
|'G=-TY7.-43@'?(|#%+TW|F>>>|J.I\$UW>_!'X3_AEX|YH2Y%#JS%=1 M%M?JL,9F7=*

LN*O#%S+^XHPSWK|YY"V8<"T4ERUL^M|+9CX\$ 3A5&/+G E
MZ;I8AIB|\$@|ZZQ3XQGS./IM6>517B?-|9X^/%T&ALU2>P&|BK^76E7.?D"Q>
M8RQ8H=T;AVG4?KXU0)MN4DR5>=.FNP5!.IP|O;7;3X;649VPO|B'=B;4<@" M&
=25V)/^W**SDHHYOR?XU%"EA9;H1M:8VP^\$L<.8KN|?Q^=P7(\$FL\$?+B\$87WS=
MV(/TVIN*8_2!;H4"!8^,IF0R&TK.?&!&#>%;\$2VZ.+6QUI>+?H85;P((34|
M"+!|_.E;_CNAGZCAW4;^Q|JG|. @|X_FSRXLC,E|QH>|E|0_-G?|.3#Q=K2>
MU|-0,>|!QE&,ZXZ_6OV,|;% MJAQEN>WVO;|!^!,W:LDU#;|%J@L&-
=D5^9#5*O)/0/2_DJ);NF.*Y|=REU)S2| MFLQ6N6Q@F<>PYQE-IN!^=^4F M76)N2G
_0#=@L|M4#;Q|I4CBJ;."?|I0< S83HC:32O|TV AP|(H8V&E)KW1#
M@;4N7N9|V#_)7N;>)3OKWL\$%G?|5CD|>60@5FR1?SYQYZ@0^?;51;>-F|4\$"
M4D,3|_.;0ADF#KWWD;W(VB<95|?=(\$7.|F?47CC/3'\$*,2XWUG&M+IZY3XN
MF3A;|HFA+S616R;_#/V6^33^7YT<>|L.>|XV5|9%XKLWH(+F?M|OKX?9LV@
M7B^)|@>;P!;D2|0;'U8E^"VJE9;F44|K#SB,V.4%\$-4>GZE_9!BJ|(G&Z41MB
M'E|H#!BQ4:FS?PT7|*(W'0T|H.7TR|R;F4TUK'27ESI*-+?V;|.1MP'&H!<
M=F%&#V8>Y">B X|6C*MOC<7=-, '^&/R|87A#R(S*&\$OM4EHI4*CIDC;.:?(0)
MJ.1|G_CMG\$GV%S>\$=|4*.*9'4TS4^UWN&=W#UX_3?9JAY1^|O_Z+|Q:084' M|.KL?
_".N*'1CFWB\$O|@1=|J#.%HMDAK.7'T%B."X,@'BO|>US=|!'CS78 MV^E_22+?
UM"55Z10L1)|@9F @MMU_&6KBF17@?8,H-
NAK1&1ZH6Z,+T!)|99SEB+.1R!AR@G6E%DW2E?8#|= (S7+5_5B7*! M&30"X2=|:=
|2<8<|^8HB^FB H3V;*R%GD CIWN.|^*J&9*TJ9<^DC/"Z1 M!S37|W;|^"Q=70?
7&'6S>"&J\$V_Z4""2_6OAU|9>|P04ML|!(9>8^J<.XLI"4 ML>-S?*ZRW+&IV(."=
MGUK8%%SYX3|4-.|J^0/LA5A M'XBSB|UAX3M)1 H%
|L1>21D.%X@UO/O1K=OU5=.9H?;I/0T;'|M?+FUI10AV.@9YP#|#"XO#*^HK/X2JC'24:
|U\$?* MV:\$FN=Q<%= -NFFJ=|I/P|*P8/YU_!0DV%?32WZY7|I2|N7|7E#3:=2|3N1
M"= 'IR#XX.Y5L(E|\$"#WP>+ #| MO70ZX<#*B%Y%S<0*|L|F8&.SCR#|T?
VQ7U0|^_.F;FX,B>3T=S8W&A)PD801;A,<|PN,NDD:|8)5BMJ0CCUT'W*Q-
(!VFU!*AR'MWV MZ&J74M;\$MCRLUTBR#YK(T^4-M0/X#(0L0W5;N_K6DWDP\$FS=E2%
(@(1=?>SH M'D1:2R=U+ .VKTL(XT<"N)U+%8|B6%;TS% @2+J;4??
7\$!5UN2VHTHU/4J6W|
M>6?!W)Q'VZO3K5;YFK28G+G3ZF|?=_A19.8GG"1&^+>%P:>K2OX(%2@006_M|L
5^_S115Z8!O_1U|^*O#S7+.&KGU\$>M^)|Y|XN3+3/9L|ADV37,10*ES"YC" ME.E67IZ/YC?
VL|KHZ^EBDYE?V5(5NH*9I M%\$|'XE_8)=/@_M4.T377*?@N;8.;0Z7=UY8ZO-8^!P+U8-
N\$DH1T=8V1|_.H?L,X'VSY43W24Z MC|5^#.!(U/(\$1('H%I0G(Z?<6";L/2>|MIP|H(_6>?
IG|K=.#JQMB)?N^3& MB<7N|WU&UYM800,%XF.I45SLO/D'YH1.X=K8NA<\$;-
GL_UDB>T5G_F'PSE6P M!SA/&|083W<"D(P^)|8#|I3"C5F?@>^R?H8L9RQE>LJ?
H_K.BO6Q\$)8N=9 MEZVU|& KJV;=U^Y|N >UM%|_CO_J5_ ^W1#|BC|T*>Z_./:W?0
&G2=|0S2 M"4G?ZC;7*UCWGM!! NGVW)U*WE28(^N&N_PD.S=KN+3_5<6_WM.S MN?
)HN= -PR00WM3@2S\$4M9/C'#D)VGF+8%7|6#|4KKL;1%Z S<=HQS2+|*
MA2|ZVF>7RAQ@YL>6CT7=UZZJ|6&JU=?V|H.QI^NL#-_6SP|LNR'|#2|HW7G;
M2|X)L|POX=WIHSNZWCB3K'EN4Y7GR!GNUR)" AR|J+U|;@LY7TFZ7 >78X MN
^P=9G2V!YQH?W|0<:C!5-@FT3@A|(^5T#'|*L#>ZM)>G=_8\$)VEL"Q:?
M|NBX%>"G<^U=LJK6J^#Y,R_(BGT;-::V09I7C'I+OTMM4IV2N+A;|ZIEG<69
M_C|AF^;I5|FOCV-?70Q'6\$B8W#?HL91U;'.6N_SE-&U:
|AT2%5_Q<9>+_UTIM_S|>00XNSN9.D5%|7|O/-=:?S,F.E78|<>3/V*,'?;G)2/!, M "4S
P=Z#H)6NT|!//W)NBZ!X)+C0&M&9&@ "LU>"=RRG M|OF4Z>E,^<
2|:*/.XTK<| #DUQC%%^CEJT!&<3GXH ^KSBJ?"Y)AO|!#=\$='0
ME%|7S'">);|Y-.T_@PRI&L,OMAF|F&_L|/'.C3?:8.'DWJ99ZCE&W>?M8?5
M7B0I"DS^JIE(OVS9?;N1,|H0=+RR|QGI2UJMSP_/M?|^3=|XOM<>AE ^#S
M+OJJ>SD*.I_12ULJICTJT&*H;./FCL)XCN\$E-I WE*|X#OP:QQX"|Z/F\$QE(
MOLR7QKY'\$M?(<?!#|_4_#2U1H40*?66<0O_J|4^WBBRRK|R8("I*&- M_0Y/?
OBW;_ ^TFXWOXA?_%"|K77E3&LOWZ;-/
MV_\$C5GK;%|;|LG)|Z5J2;|@QAT^;M^_@|=5MQQ(^BA1&Q/A*|BK=|&..K<>U
MA7%3'F/F/Z|?R M8_LY|XD>?5SMW_9/^K+I>KX7|Z76_)M|L|O)'3RJBZ^SUU1J'.?|A-S
MS+Q_UQ^=JO|V|7G%= _G?9Z<;/8W|@+HC)FQ MJ3'HT.%#H+|X&X@| S('\$?H?
OO|MY'_:QR%V&XC_Y'')PR^/'+H(LQ_Z_C_M(78G" P'"3KVOQN_H_7H<- 'CAX|?
N+D*2YNCD'M&=#A0T>.'#YZY-BOHT\$1D5'1;.%S*V|2TH(QW|S_YA?
@"O%%A.*JZIK:NOI/#8T=I,ZN|HY_MOO2.C(Z-3TQ^FYHF4Q9_+"VO_%Q=HVW_K-
#WP7VJO_UZQ#HR|JR_3_UBY_C MU^&C1XV/752<%;;_(JVT|)7|.F M"CUX-LPE?

\$F=+\$/U7\|_R_YMCK_Y9G\|NQ\|NO:1#/D4.\$'P0!L5CR M'^-_[JKY2&=+!4J]G4
H79(#,"2YOB'E7^OK\$0)3=3,'C\$+!U7^KN6U7QX9 MT9.'-3-"93HW+ZI
ZG.X3ZDR/IT81_?@5L:D6R;%AYXVN)9.C M|U\$M\$H\$F(NWS4WLG50^?VFA-
^3W:1KTQ3_+31\$/B/V=Z,E;V=.)0Y! R% |: * M: * LNM!;I36KPQJ_??U_NMM,
RPXR.,L973.K74KI4|P(M-"\$H3+@Q)^UB?%?+\$=K\$^T./V*#
<1EQH-8?'SLX)>6W57WR<.(S\$YU>&16' M993\$!C\$6)SC<_.D2-BWW,U|!"45;%=I)-
VC.9/V!%-3W<5HJA;&U|X^MXIT M^M88@%?0E2!:-!,M7G2LQHJM-+*9Z",5@\$:
<)+^9&0G|!C:<.,2>|:,6*C*V M!L-
OZ#WRVEH:Z.D*;/R\$SEMDRC,'3/K!:6D"/^'C/V8=I73*-5V.UXG/2\$?C9V|
|H|M=I6@348&S#Z9Z9H|W|A:GV4R!K/^#/'C0A'UUYGJ|GBC+. #Q^J:K8 M1W>
<-92SY^/CL;|HJ/B^DW^BVFSL?*X|?E%X9&L/+/:VS\F+SL5CD|O^R5:
M+_33:|AQ).^|G&N2S!PK7,6|DL7=V@L|D^04;3JHCQ-!5;5OH4'Q0.
|Y@A^|H|\$V<|AQ6I21_VMG|Q>-) M#+B/XSB3\$VV?|@I"-I%7-|H(P=JVIJH.^R?
|NH*63*BW//+PM%|"-G,03'J| M*&2<*|W|_B\$J0=_AMTV9N5!|SO5N>K/'N2.6
^KCOS(14X49/QR&)#|YJG3! MVL;%1(07:;|0!SK 8V-
X^DB9V7/+T8C?;:U:%F8J\$ZGG/(47+PW|:?!8^@XY M54T/98/"HUN4 !|RM
L3"Z;>4XUH.4;%Q|>A91;C6P^YH*3;&K\$);SL:&U?W
M^WY.KP&>"S*%K|Q+7'_^KKDZ@|A5'/M8F1)H&"K48?8W&P35H.WENO T%BB8
MJ/7|J5EK6&0IV=T9SA-2W1|+>Q_LF6Y_/2A6NR>;+3N|C|YX:Y=D->MIU0
MZ<%G3M|JGD:>ZA4!B@_RG*YB|<51|Y|<|:,=2=8I+_JB|8JX2,OZSC%=)S0_MC_U
AGAH|I3|@\$>@4.+AS>^R\$NO;|.Y5K_NZDA.6H|R^DQVB9G@FS M*?
KF"5(516B;%3OX,3H@M;&O%|H MH+_?11(2^?@"H+|K_WU(J<#JDM%*NHGMC?
XV<\$,?("1.9+SN\$G|G|H 0E|* M 8&B1AA-*T|E7_YLJ07S>V9J*O=H8W-/G#QN!VI=M7-?
U"4PJ|C|C-)O>|! M++57XV-!OIQQZ36"34F?;+|&*=.N3|HE^HFL| #8
B=FD60H0T3\$HBEUB|B M-^8^|=?.O.=D/Z|>MA,N3|I;W
M|W|EK_^E:%L2G;""%S&U)1@GZ^7W%BR=|,U*6\$34|^?O2QEFC0U2E23U)|I?
M4M>T1SM6U+W<:&D*(3IVTC%T035MHJ?9DP)"MP;LBI'X;=U0K#;Q3BE;0P=
MX.0)GJ'+?%.NTB(!"%A4 'FTKS.7;UY PNS:|'E*YOG=430TMA|LR('+ATX_W.
MO7%Q1HG<39^TSNQ*7|<9JY%7J6D(|\$N()78L_9&)|H|/%+<:^?7+^JU%T2W%
M|>S9G'S|V;=/OF@VYVHO#@|0%Z,K|UMU.PY*R'RAEJLS:Y^|2*MTR(RS3.(^
M%)\$O_B|N695Q*R>IGB:6?;?|\$|4(NP(?"/P6(@ 2XH!ID81%N=C65>^_O.1
M>:6N|.YOQ:A^K*IQ%%6+&IERR\$HTM&YZJ:.->('6C5CL:SGYV+L.^61N* MV|Q|-
CU=3;CO?+=T7^55B/"19--|@,K|%-F\$<:,|4++ZM')B,6_-F6#*#@/D MA^B8"
(;JKR|O1)|@X=99@H74WH?N-D?ZW.!>8U1DCE;(B;Q%%3X@7JZ.5:@Z-
MQ|1&3F0M8B1ZBAF*@\$"+4A3-
=R/MXBZ|(ZSY=R%/TXW4*B,T@S5R%3||13'^7#&YND,T=4
MMM8/%O@VD@_T6/V9%BTYU"!R1C1:*RP|A%*6=V4'D?|EZG,SVM64I@W/2=^ M65-
N_-Z-@-GO6S3|L^J&=|H9)|1_J^E*-K|8V.ZU'KL2>VCF4|*4TLXRT>E: MCO%^JR>?|*
|!?'C+2VT|EVJXT*<#K8%J|/T):"/MYF=GGMS8,F\$ M_OM+@=;%?
4UQ.TC9KQ|H|F|4(N.,TN+L3J|H(C01>ZI92|=|N8ZZ\$QW??/_! M)0|K4V3-
T.GN^T|O;2=4EGCVI=@=RF2#8EL77K:*^RK+O&V?EVH1|=DM;HB;
MZ7S!%|>L@)1VEW':LDCN5@7K*1Q(OPZC#Z=")E*W^Z#W|AO,UU+GM?K=DXL
M|U1E1K)!FWW!X#J3G^9_0D)\$UK:B_(GEL_V_WS"ZSN43'JG_-UM=KI*.JILU"(CL((+
(VCK2E*LC.^% MA5J|(<%/^E)(9&2E5E"64;-FAD#C#3;H\$6L00H7Q)<-|JOZ!G&3-LD%
<>O!" M0-6ZN>FK^E#|-11?9XLP3>5|T4|UDF=Q>YG7=&3"|UP-G="AOS7JAHT8FH(
M3V0RET<=T|V4I5DI2OTMEQ@B@_4M^D|SUQ9YM"XU.2F@;|VQ="6ZTTDF|4^'
MV.9RK;+O"QKWNE*,=*Y)57-U0WW3Z*|(6)W C*MSNYX?-&HEHV_ZQU22-+?^
MDN'913BW8V%|4UC7CF)KB^NWFOW4N'DOL,XK79(!X:9'KN."JK|M"@H5= MU|-
=0=N|3KT+.781"V3HU?9|'0LEHS@=J1D^ ^|R<\$GHM#4QO)-<3&:#0HC4 M=8K)*P-
E0;A|1V|!>V13.4*L_-ZAXM,CNOYJ M>+?
U|:3UZ)/%|\$'6Q/2:F)OE=*NHGMW!!88U,US)HC60|H\$RTW&;BK:Z)M
M@8\$#+4|N%|;F"HR579Z3UX#R |"N7(56K.5P8.'(8GW@A)Y%N1?F6|7JIF8> MQ<6\$Y#|
7L=,0*:-J"J C 4X#VH=6M4T>ID!Q9!^ M.J0WL5'3X|GM-L0!_4C;4(-9DM"-GQ'#?U
M|^R:N/AL5MZ6P<1HF|L^0! #MDN*>F-Y31XH 0<|4 MEQ)|CYW!#(+*>^)JO8|=
6(-)ZLK" |7+OM>.+(<>>7K|K1H#,ZYN(5:) ^ M1Z.P08RSX'8XU3)K*PHBR.("1KL-%
(&;M" 7&E_4ECHR1D0|C\$#|' 5&+:O# M|J?6PL|BZL1O.|'B*V.JG\$=7
MVA|H;QB+!X(|+D\$|UDCBZ=LLZ5D+?WR9\$1UC6T|-C6LLCU|<7LK,0SSSOM*
M;|8&GNF5'\$O&W50E|J"AWK-'6AO.|QQFMW+0L*0R"G;XM0E'EM)X52|,4XE

MF+1_GI/;@6Q0NU_M%B"/WURD@%^V<\$:/1UX 0.?8Y&3*SQA77N[KZH]OKP
M<:5N03_D*N\^P69\A\JS^:CTM_YXG\G50*(KNI9%Q*J;M(*&/1R3QF\$CL"G_M5^A--
&1'(JP+?-J!R%UHF&)057.CG+)2ZP9*C81+4(FE%NO=-D; M*-
("NO//#9%#GOINTHY;I'LP[E0XW%=WC\|/<%.Z%9Z\I7&R;?E%P?;) \$H=>Z
MZ"=Y"2:B/E/((AY\:^0J \^APH0\IR8\IVGVJ_TF)'5YOD\2+E11)\|@ \$R)..
MZ0!WE4\;1R@;..Y0^OC+E*R=:/-F-NU7@JRS?_KK!(68CQ"M4E@VR'Z?0)J,Q
MWBZJ'1C>QV':C\O M="# A9 >U"V3J(?#ZM? ME_NMHB>L7,,TMTU7E17IFW1K?
L3;!GIK\|@E^TA\WP/./HVV*^3*6
MY,)MRPF38(9=QN*)'EX8\;43>=@;0X7.1\2;6TVRL1_0\;%Q\B\|^R%DL^
MJ4(>PE_|;G_**W/(/(@FML60"<:A#I.,QXFUOCXDFC>LL:LK*CI1:T>5?A&P MHF!?!8:OX-
J:H3W\;S/ 4!OX;..4>4OHFV/OVV\ 61?JOG(4V%?UU<6@I% M MTN3VT\$?\$/?<_0DG\|-
D/=D_S5_PS18TL-:AKIW12.6H1>P1_SM;#V*93U?-6
M&I?."0K%QJHS\;S63FJQ3CK^VB\ME;A\LOKJNU4\?UL_H4I1\|^=|H2,P5S9
MM,N"GUM4^1,Z>Z_C3E\$4NX74\! 1:U?33@ZOE%F\$FAH)P@:Q3P2MC\$#_G19V MDY-
A3UO=9U2G?|-L4&T1Z-WAQ?'#.08_*. 6K31*HUQW\T)B2;MPEHBN;K4
M'6SZL8%_.;A7&/%\$>4_GWZ;:ATG7\U&XV^D*
M5ODIUX5L#^R:4BJFWR+TF\|4+R,Y&9\51AR*KV;7)?+HZS9UJ?|A>/Y:*VQ\$&%NS
MRQ#(H/O0\EW+YF.;119*H.\$&NHD%HKG:9X==SY2_;\^OR9RR^TR3>H7_*:6F
MJ,D&Y0,ILW'&#MU8_#A#AS.999C:3\2@;DP\AR/7QP:J*MT&NCYBXUIYE(G\X\|;
IN/6\71BF\JYUY\1 M)F:2GNA\$%(D:~?
*UL\Y:46O6.HMPB\|EZC8\A1;W6,VUOT+P^8"X43>H\|BF9_M,Q=
|F>!E:3..NVPD8R+RY\$VGB5&5_>XO>I?0UF0Q\EQTY"V^2D(/1EH(.H9_M0JDGVN\$QK
MG\|J?Y\5-S_:%Q&3&S^DO_N\Z\$|7-RH\;:%
5#Z8&N\|E2P+"@J:2KLB3#>J=O@X4UD#4W9"N:@.A ?Y4T:M:==VE(
ME5^|S_6A/>F7R)>0T;JO_2C-=68!F/:OX)J?@.>!% /"S*IQ,?F"!MZ4602(
MZ)L^@OA^9\3\|&X4;5\|@|%,TA:IO.V81*=HDYH-J<4;JV8@/FV-+|C%C:B-
_ ^LBSNG#&85VGN_MJDWJL\840+*G^3IW1KHRMI&32&'PGZ\$/<>T6\|!|/M@S8?_JH-
;Y*E&F0,T M\A\6^63R;KB&>4Q^;D\|^>Z^<4GQ%"V\|> 4GVBCJ-KGA,0?RIM(V\|+HJ:E-
@M@!|4V")T\$T\|^P5M<J**T0M=1IXP\17X@)GWF=N;9R\|S|<&MMHH
3?!QE0\U\|>&;6M;W7>#>F1\$VWB\BAJ=F\|^?Q(:Y(K5TLS8;,1U)-9)UI MI(*|B,>|#/2H;:/I
(L1\^SK6* XK\|P"Y-N5:."V9::?::37U22,R\L9J9+/.? M>9\^1>E&QE\$>H\^A6)!3\A0H\|!%
(L^K4T=(LW*67TR_VRIS_4E?=>^^(=;E M/-9A_-
>/OO&=8.7\|E#N;SM8MC9J5=V@S>W6B6R2Z(XH>?B0S_1>1P?BP#2=.Z.%#-
TL:|H+DVN\A M3DNVCW::7,^+>^;?S\|^*+>DY7\#W<+?>H?G
B#DTUUL<5\39\NQLC\G9B7+>AV\|^VR! MY\|2"%|&
1'X*F/GAHO(M\|4+4A\$=5RQ\O_1^N6Y>DIKUUK=NQA<|UJS1@;|6
M/N5\|+C^RZES)^;XB:YRQZ&/BD>CV#K\|J3N6S44=&FH:F4_LU\$1CQXGV!7CK
M,M.O\|^4.FRT;RN.2__CRW\;?YNCH:*ATN+3TD+WU%;M7_YO_??/H7TFP1K) M)#A@^_
MG0>QC!75@ (A^A-W>Z);AP!*UN\$N_=!+>#_ /1 7K%8L10QGHG;6-LVG\|T! ?S('X6*+?
U)ZL=;GJ M:|9E',4:M'#M&.EE'=PUC\EDC?18\|E#>B4KQ"L\$.|/\|7ASI0Q3%6>(?
MRO,01)KJQ.WITVD&36X41V43^EQ6X9J.?MF^J?HS7E6\3Z._MDH?)5YR>A7
MRKIY14/R)K\90?J&TSA91.16Z O<0-EF4VW6A+Y*YO"O3 N\SRP\#6D^P\|JQ
MMZTI@;@K6H8QCZ=^6#/\V0U\|)TP8!QXP<#(42=L_&N!E9'@P*VX\|:'\$5G&# M1\|
@M1+Q9M1DM\|B8%,>|L\Y)!|N-/B)F+SHVM MOE<0T^:J^DMD3S5(G#5\N6GKQWT>
(|L2NPM<(J?XMI@N6QK0/W-S'!& 7F6 M@Q9F 8L0\$2'LTK>|*TK_*
H\|Z _MC6H\$7@CN/5PE4VT\|G\|&2X)6KL&;QP2M;OP_-LP5-
H@:>|/<.QFWKY6^A_C>L\5QP MK(1<1!99I&OEC5^VY "/R:6SFM0;9?HBU3
2^V;"\K3%@CZ\|;\$ (Q-"W,R*|>C.^: (>D6P+5%;M48
M.%_82<#&@C;WUM?/D^V@1\9\;SAG?|16C4UE;!GS+|C!"NH>|E95E>OV3=
<+%'V;/LLN>IUA,G?8 MIR3\X;_|7\$UISX!31W\$<\$@S<-
>|E7&16HZ_A\|C+GVYDN\|H)HR\;ZZ&OFU)4> M\?!9E*K=F*ST*7#
MH<7;4,#\$0!EUI#_.JZGQ2EEGIM%\$&;Y/*IDBH9T=Z6M.2;
|0H1.XZXG*7=MGRJQ4SC8PF.3AV"!4D-K9Z*&B\|KEH8.Q>@6\6H#.W\|
MJ&OH=#.#2:'(U(IG:2GX\|_C;.&\W,KD"8711./)ZG%QO2WD%X8'0&L4\|3 M;^DO
1+EWV,@"X\|+7*/ MNA7W)T3?W\AYNI0LO@AMJ7^S.->MJ2@AQ79R\|PSC+A\|\$ (4;
^9N#J24\OZK M\|NH 3@/!"55U?=-SVA\|CJD*_>JC:IL)20M,"\$8 MJB\|XTX-
S\|7JZ\|#@+!\$3;'. 26STP0071H91\4M-OQ@77IUH M\|@V*4*R'P:TB'B?
_G(Y3H@P\|M&;IH@#.58W! SQLO\|4%P^G(E^K7FX^@GQV

MJG8KD\$ \$AN% 'K2>LVC_ =\FKP8=B6K&=,%:OE57G5...147.. K0\$ ZER)7Y#
MIEMZ.Y5"A*|X|#+!WOL,;#785'; "<,6O?(3NNE8?+^:ORWUTSD-M.O%_ /! MIW|PIJ6-
+D4W:QH_ZV!|X)N|H46<3'?"'+#2ZBC#?-RL%^X=2>|@K"0')4WO\$
MFJGL'CP@30Z<*&T3@MT/6UVK#'_67L;.>.5>L,8MGVP?;4PM^|387U?9PUQ?
M%;=_|_P&A|RCRXS>GU1>:|7A'A(IE>W0'H<==Y'^-T7W_<%
MA|6@9701S|;^ZNOSU|_9R.49|JU|H^Z?W^T4IH%Y-\$+U(OA;8FBTQ,%F^Z_
MJLY=;JAX?_QT.K|&|5V7.|=0Q>73_F9CBQHCI=|_K|5N:XXQ.T|>T6BS2X MVY?
PVVPORWK" |MFTG;)U7|7:&N-O:Z+U6WMKTE@>OO'U)V@L1C!;@B%&M: ^E
M@2GSR7HRU,DV\FD4QI#HL B?%3O&GG@BLNLH;N'Y\$19R??HJ1X_#;:/UPT_ MO5>XF:
|X0F_-|.;HJR4(V(13>DZH+^|XVIB M<;F!3G(E?:RE8JU8:D1J=M@J.\$W%8U-
21DM4)T|DAXVWBKTUP@5;|*"EJN);-M|&M;F02Z1EC).=MB\$Q|:N12Z\$K^B58|/#
<.!U.T>;B,*|?K*(DC1UAI|_0:_T MUK^0X;%%J_#C90S,115-
3D0|PVE:X)MF^=KF3IM>!.SF'QN:LK|T?=/,|+Y M9.PQ5%6WW_L+F7?J= ^2&?
Q9+"X,S9#%A?C &F;)_ '4E3;XZ:CJ.Y/\$7#Y| |^E?^,#3U253|HW>64!-1_0T//6T=\$|G"G0M
M?V&X8|H?0A:P+>(<,O |;|)*K2;_JBU9QW*UG\$>)W_*J O :R^BQNP1DPF-
M5GY4D!4UB5A\$XJWRKA<7KB?GW"P-%/#AF13GI2?25QK&1O:7D3_Y6+Q:G/KI MZC)?
N,^C*1>=,W%I>:|(AA)O!_58@B+EITUV
M:&IHCBS&ORIHI%ER_7W!>|9FQV,P|XQ;)QHF 1%_ -M|29Y+O|VU2XDJ>2?)
MC3G|6,*&AH^-9'W&>24C|QP*;&H|Z0A""?|9T;MG.[K7
M#%|&1G^V@|J>.|%ZPSUX;I8|M6|EF.?.DNE+ZU |Z%6", M'ERP+Y3ZK*>|/(\$1C\$OE*?
K9/J&NI63YT;*-1V.*|PJ?QNC^WM>6EMY6>V|O M\$C#M(_/5W.\$|TK'A| #-
NB\$%:MW/VVS/.M#6#^XIJ6: |Z5HC%=|2> MMMC<6>HL\$;1/KZMS51F3RPUV3#L?)
|J4CG|T=|B^R8&>A>76:T@C(/E WPM<
MAW_=K.|KTIG|ZD7N6S(Q=CH*BQ!W!3(6V*"X6M&:1(.M.|2|H: +|*+YNV|/-M49?
4>.4CG2RY3XWOG!R<2|!PQ^W45P..O\$?RA%#Z(PL#;7W@PI1U4|_%Z!
M\$G|2RE^5,FRIY0U4-H@D_MVFG|<>XD&3BPEXAR06R*ULL<|8>NL M_/,UB^7-
KL+G|1N!|T'UF^/DUIA<&7 UOGM^:HWOT+J3|ND!PU_2T=R*UYZ
M|K(JLCO_@|F/VQG"SP|N#6CYCQ,GY1U,|2'<*QI-JCV(:0RH^VS^6+B4 "VSD-M0
D!|I"IXU,B":_|,MK9NT"7U_!;P7A4D8:M3VF_BT|!0;.-0WU*==.B:3 M9&YUZ>&SR*K|GY
I5=;I8P#LX '#C|K7CHP"5R5O2H@#HUTZF*=@5R7;.2=|Z4Y-QAV',#H1U|*I|HS/JR@
M+S/3PD0,/=PHSD."T1(C";B,K+Q5TJH#A0H9BFA6KN=VB(/C6VAP=2W7<(B
MS|(R@F>@U.WTM|L7G4F"|.GD-OC+5B|(V2D%|^@1(6U|!-?AX%1GJ_%7^)*MI=%?
|G7\$Q<*|PR_CT&9M|65F)*=@E M/:5\$&K<>Y?
+N*7CL4_@WM\$96G2|RPN@XPKN=)LL4E M|K8>|HDX|23+.;K%@|F
10TN'4*2;_Q=2.0#9J&+@:|A&870LZ|HWKQ9/6 MHCY_"I:_O?=S"J#),4|
|+L#%0'2=4|TU";M_%'FN^?,B2WW3VJ?^|GE1NVH MT,T5-NCH
O,|)U'S6(=KJ<0>"*^+\$.65UV&-PR\$!/+FD07U>@J'_>7SBB)|!
MEQ:CT9TR60IE9,3%A!1VL7JLOF?^@D<2M|Z1W;(XZFE2P69T=
<2Y"Y|9(,7AK=N00\$/^&*=:XY MR=/:P@95J&YR4X:FF^C:3&RK5|(D0DKJ*|J-
YMSVG'6))O66K*VAA.1U7,NW MYK#LM&'EVD2HX|ARS9XK:>CU|
(|6+GO!%S6?"8EUP>3KM4#CM29;.,F0D0, M3J%2UN8..L\$G#611Z^2D^M!'R9(Y+,("1&
M5Z2EI=I4;./QUI. !I4R0|WZ MJ:7DRSW+D-40SI2|LT&I+JQN.-VTAU7 ND <1DU&7|V?
(=VWOA3@,133/6K= M-59B7>8TYAE99JVU|)WM+B=J-K8Z"C.=|:|=N<7U:B?M4\$N|?G?
FP0?"7|O% M(U\$NAGPF?-\$=%,0C4;-K""SFA4AG;^?E;G6E\$Y;UY;M!|HJT;HKP&M@RMH
M-1I?MVH2R^!KRSF&/G7L G%G|ADYK;S|AZGXD/&P^DP UH9V(B90,Y8R4L,K M/'@
&|/9F^M>-VN9?TB,@SPF G(|&TT'(=^ (Q;0K1D.=#=#0TZ;C|EJEQ;-M!^:|6D|'6YU/?
U9M|^YBR#|PLU=+\$TO?%4'-IT8EH|M7;@-SS0W_L9HM9>> MJ|2U-
T#%H0Q""*#1D3KODFYG+>'\$J_'03%|Y?S|/UV^QE_>"90|*\$9<'Q<(4 M'34N"ST>G9HY
54K^ZUU(0E"==B*Q% M^"(Q
M(BPPXP9PDW:"8K';B8W1@28|5F5(EJ#|+6M'R|2W3M_|J)_SX|5WFH5,Y|O;
MCTPB1#L?'@YZ"\$OAT!|@R_.H!|019C\$L',2|PLAA(!&QC761F-5^@B=B-
M!L(%4=%=|0(\$0;DT,))6I-?"*B,>V/\$A2@7Z0X=H<8I(QTG8_H(|)R21O^6
MW'682!/@T|!|Z> LM MYUO|W;G|AYSC>;>^Z!_#Q>28:74O=ZAY)
M.+TG"KV%SB=MV@?MO+XF5_1>ES?DF=73UXB("ZH|\$Y3%//SO7Y4PCUKW-9*3 M((-
BIL->JM\$)|%.:6:#CAVGFC \$WRX\$Q:5<1YUHDU(\$ _/!&*6N@?IQY38M
ME/ZFR#O(*3>:S'<8:/&U/U7C*%/K++.)#01\$"%I?^>0<+X\$Y&^ ^S0AE@|ZL
M8=H5V*"?T4 ?&|0'|*R?)3^(.FWF/%LD.26-SB9PPS>TT'4D"LQA'6U' /Y&^0R_01V*0A+?
6M-4|@CP=IY&DX@ I<"JN('Q,V"7&U| MG_=ST-

Hj;)/CMFV\UV5/7,M+IJ=^|WY0N&0^)^7?0.3FI%#+@G/%!;K^,|V>N
M<#L*9Z@9:7EYH(KGD66104U^AHU59\A^3=3R\$: .H.8_W76# @+YW\EL. |\$7 MRI
A)Q_ |*4Z,8WA2|\$|T& A_ +;04.L\$PIX3"H5_5><6|+P?7-Y97%WJW0DR' M% @1+>0S,|E|I-
%X1\$ _H,3X%3|3" C&4T9RK5J+ # (RP7 +\$>11| #4 "2B'!) ^ MN?2'11#9H)K@W3WMYK=
(/%SM>'|NC5|_U5X'\$ZN> ^*COWG I4K7>P4=^>(HO MN|VJ
|8UC\$OJZCL2F5WF+ "1^ME/'JKJ: ?B_50ZG)J&9>\$?V|JEH('M%X/U? MV|H=Y>3|K(>J1,
(;E5|E-4%|YBL5!NH@+U Q/6+2U;&9@; #/5.\$|B|6:. F# M9YCV7@|W9(:6C8>-8EYV!Z=-
>|5Q-UMYWW| (Z6,4?,1|SLX/' + MY('F#Y" I9@5/= _*FY6R|(^J7IH3/3@|B%D=P">
(;8>P!;)FX#5AM0082!U(MC \$7@*%\$=|
!;#|1KE,) #D)7.>0:'ZWX4#R6YR/(W+)DO_ V*Y, FP=ZZ./;?|ENS7QU M|D;# @3I*H,L&?
9@9P08|Y(MV/46-|B3&3,|E^! ?;IR8'Y35Y;?T;IZ(9,@A M,3C5. CY&A@?*B(F004?B3
XN2:;#%6!;FCM|ED|+4,8C\|J%YL6YKR=-@ ME44X1#I?'50:2W;:|=!|E9W.
|EMA@ONY2>-Y!G5* CW7DN0G?^= <0H@=(NU M!;.=RZP6M\UAU0TB/
L_.SAB|*_O^RB/5@H6VL;XA1P)=7=J5!+(+Y+OOM,
M0)Z.38F%5.3!70Y(C^NS"C**;J,|@I"" |R1"6-N-P
MM(S5%EVJ:B+C2""%#%=BCDNZ,,LS+?LY)CJEJ@(^CAMIW=PDX4PJ6J|OPU\$='
MZ>=T|/WI41.9Z?3;3C/<_NO6X| #->|XB=9D0TU*F.;N|4/F05T3+2)N\$B/!\$>0/7_ '0
M|JR<(U^+5F1J<(?%@VB^PU%GM3I=T&1L3?5/<7 7-";OP|P(2='AYV;?_QL
MB598F)A4'Q) 11UTB=/?R R^"BSSR9P()_ |L|Y|G VRK1E5WU0,B<^Q|JS# M-'5@QP-
-7GJ0THJ7-.1+ R&>YY2+88Z19KT% @LO:KDU+6|SIH.N|F?E"9<(%
M>0)3Y/NPA+|7LS7;L?(47*H|?;0?&=W>)YL?%;!HEC&NAG(P2U7J(%8EZMBN
M|PEH_*XR^NDP\$;YQQNH|VW|S_9?<'N+Q.>7>_LFB6A?O*YW9E*EP,R;JQ@ULON|7W|:
M6+.-1XD7_-!;#|F+;");GM7B%E&ZIH9:S!2U'G:OFC\$|H8IG\$|;AO.\$P3G\$9"-
QDYM6;91.Z; '0JA5N08L\$K6PY(D+ ^"YM MI=.;&WOK*Y*4:|)K3FZX?'\$|D,B'.'B3W-
W*BUG 8:@N|.DFHSH@ M^D"5T|>&2|
)3^O/CN/"G(&5BF2S_K7IEVZ)ZM;AK<8IC3H@MU|D)^#(@?|
MNOH|E+6O|.;A3+'70C9|USE1M(YIO\90.K!E6-+@FVZT>=)SE@* @3|W6*>P\$ M?
JVG4.XLLQQ..| (H/3VSGC)4/OW|K Q MMYKYI!KGR@:A%8N+A6|8W1.RN| %5?!P\$>@HZ!|
(^|@INET,Z3|DE'V47F.2 M_SNK!"DMR?
>#S46W"A;/%#L2U|VIXGVF,MWZ;^F/UM^*S'\$>%;5901YKV4'(%
M=OVT9P|E\$ _Q2EVU153;^ BX\ZFHMEW|;I.Q!|;GG B+.Z38)>:(.=J32VE> M-GF6MF,
<3DF;!U.=((#B|L9-/P.MCZ:(0!OUS0XWMP2U0GTD)%Q@4QPAX5^ M'V5Z6 ^#!Z(7)|.5
T-B.E,9D:T+=?.5X,W1 M8H3K4>I*7" D BP>:/VW
T,&^)09%EN,B@)*1&J|JK&/B4BT\N*I=R6UA6F^ M1=^
JK6C(6_) *+>X1_\$|;Y<;FIR)_ (4\$-V6JT^=B%T\$'P.JS9J_-EN0D6<1
M=9G=D>4_ =VGJ6IG/"85P(XVRI;+.QW:43\$VQZ?5H.S>6-X?(L4&-G&|/0^ M
MO8S53;TP;M+6&O=|W,F|-CZM>^SYB%Y,X|S7> 8|)"& \$K/EM74'(+CX^S>9
M6L;:H=| E?PJA|9)N>^!OJ8V4@'Q59H M122B<|PX7|&O> M!|/=@H==T6AF_U-
1M!Z>:YLYIC26IOC@8Y9SG;S66 QEJLL3EP58O ?_+B5 M9= +A|M;W;>FH9TCZ_.2S4?
(JX'\$"/9P/B<.:&N9)#7NN"+PD2*+F\$^K(QV MH0V>Z; %1|_ =OK6B>D<>ZRXI--
O(Q#;^F4-N%B64O:S1E@9|5N(6:3+_L
M)ZL3.&7\$1.&T18=/H^55ZXB4U(<9: ^AKG<%!0C^ ^W5^ _G)T+ /IOM;4WP<.: MP7-
VK@JUXC4%\$P/=|3)<=-|)8Q'OX?UPAJ05&R1|C2K'&B21,/M%|FJ3?U;_
MA^|Q_?'5>TT0|;=T_)L4&40;^,>1 BR| V^9RK" MG%N&|;L+RG^,
X|0GWZ,DP?| #|H1X!@;%;|1MP^3 1MXG594*X+O- +|B K? M-
""CZGRL9TA5\$Y.4(5*3|S422R\$Q76;:M|4>K0H)U_ B#X/'W;NR?DV^>46KW
M5|@S9YV4.W#\$D)0Q|88L44>?%|AO|E*LKWZM;5#QV,(ICV,K"<32-B"DI+>*
MWU"0F*.LSM8,,INM\$L&2'E<^JT>/?TP7)(;\$?M*%^_!XYSQ? M-\$|;3-MTX|S?
-1_ =OL|ZOR;0531|JFJL;B|W;L|@E#^5::RB7/<+ /<@U_ # (IEPIJK4+6PW;X*?
^G/41G\,733/@M)7 M!6_UYTHHT#.S<.#(PDJ4O;:H<.L; /*T\7S/_U-
_O++F_LL)|\SA.%ZAL!O M>M/75A_P-Y| %XN;U4N_ |P)PY G6COLNGH3|JL;F;?YE?L/7;-
DA5%EEP,#U MP%D^NXF-R+8\$U>BM@/603G,H'&;I!;L4-F\0K6#
|KS7<09|ZYT\$1@;Q&UP M&H6|!_3EMQ-
N#1Q+U3GW90\$YE=R1P=46;P\$WK1@)V!) +K"0)#;!!)*8KS&&I MX2%F"&5S>/M|G^:
/Q?";\$K^@9SUV=;+U<)K;A5C L|W|5:V/S+;XK*J&GWH MK?S5R,W0|5%
D\$SI+/*,&DH|P)M\$P:?(#_>X5_K*3B?J6).**P|L/5QUIO#;
M\$!8)7JV2?"#)^H(YW.J|+./KBHEB'1U|W&R%>?3A9AEJ%X9 *V'YKS+ /GC_G#)?ZS2
MX2,+L\$X3.6JLBYG3NC%|G@T:Q|&.MXQSOTQTA& MYC1X9^4\$Q|D)N+99

ZP!="095LJ4"WJD;Q5'(C62AGY.9RC_H">0(+?H;5XG/!DM^RK@
MFKM7JLRY=#@(.M0-CVQ19^:\$:++O!*R2!CD1C>>H9ALO#9>GD87Q.P@0:7
MWU_J4K+J7W*YSP=%]_NU-^XRJ^13<|(WZXR/1?-#%D'%#E.8S\$/:=0F.I*
MMVE\$GM7ZAJJZ*4/F+P"J0E_8/[XN>"0\TELD'Z?\5%-?*"4T08J.MVOL71R
M=_I\$S%:0X/K3!TPMDMIDVEZNG&*)S\$:UN.%(!):YI:*ZWT['')7MWAIO-%V
M/+FM.90\F?C/%3VC6IR4JW>A%9V\2O_B\Q4N\IV<^L_VU2E*1L=*_#8_R?TJ
M#DCXL<:>ADU!*J\$;S(,;H"AF+U'!=|*J1N&Z=A52CS:D1HRAHST]?&U/[M8_
QZKXF=J/*/^|UF(RIKXY|X:&9RXUBA,-D>A"/8<(QV!\$FH/#U(>.,:Y0_M8;-'(90L?1
J1TNJ\IP/*W"7(&#?HX(^K?S_M)A2+VYU3C>_#OG(F-8,-
+08U).JN<&0>W81Z;A<&Y|=XLT'B4S/>F<8IE!V_M663\JUI):O&4J\$@?
RHD,J9^|TMLEI1>"FU_M="-+%4&E17?K\|2X7+A=Z",;RPF.P"<=W-
\$^N\$7)2;_R1".AYX0'TC+^*W!*YD<'=>*F)\VI_?^
MOX(FUXK?'(D@B9KO;#D*H#WY_'S@U_MU6\|Z=M08+\$%&9WS9P*/-
=RM':J&\$>W&E0,(.BFPZ-NUHY>'&5D:.6'11+F8_MW_++|UM4^8W\N"VM.A;*H,1|W<8X-
Z;|)._M3A#,,=4D-E_85GG4S-YK_N#\$KHS!UC,V|.>G)/T0N5(@KS;+I69V37%2-
MKPU\0E7T;%VF?:*[07|1_8IS::|IA%WSOT=P<4&2;=.&RY&QV\$0\&2,2(L!_M:A#QD
;NPH*!C.|)BCZU;\$3Z_B|:.?|=|W'NE,(<|*|TA?CKCS)|RGTV=B:.'
MI*W@:R\$'2)4\Y5:FZA&Z+M>V8&"Z+R|L+I1ZRO\$"ZTP^7F/-&K8@8C|M^D
MC^VZ_S4;QP;)O&#&=Y3J&JQ=%|X)**[XA&J|Q'O7/GJ|:7T_R36_@E%E7JRL
M91)Y/'HMW#|GNB=F"Z|KE7Z|%=FDI@|,%ZX5Z8\0#7ZR0??X@(|OS|5E\KR'4
MN\E3JC=K:|Q#./#!T*P!>LKO|FI:"B;+PJ-#W7J.F=U@*Z:(S|X|*LD/MG0
M4L'BIF|Y+SUD%<#^88,J3A/_JC6&J;_6WS<.5!QL=(_9WUS
M\X=IZ=%_(?*)\AG:&&F2VXCME3UC9^.,Y,*-U86?W2KK80_+Y|9|ZV:"N!B' M.!#(X;B>
Q#%D,@JQ,L<*\$B"2G\$&F#I4X,Z762WM<,Y1;7C.L7"=90\E%|3
M5#!MMKH|@|*|TU1PHO+G_./!!YTS,3^8+.)0*Z"X68X-9H..?F/67QCKD'C(MS
Z3=3%:|L\$,:O7<:/@|SE>-@1>C5JS9ZG@0-DD@VMMP_V?H#%4NY&G96|?
+5YW+++++CR*X1KH\$ M?|;_LSJ>C+AYC3\$,>9B9A?FC6#_3W#:%R"%V4GLV+|+*+7PC
MD_E|23-=+!'&K|>;#88YV3S'AS0=8575/*&3TZ_8>_1*&^2)>Z0'<52?VQMM>/Q+3A:.)
|2D^OPQ1#X^A|5:=1JE'4:+5LQ_M/CYJ7P5X+NA:6#VT-Q6QJ|6I?
&N_9/@F#:Q),-3VI7VZFC**>*(GEV>A;EL
M9T&:8X_\$+6@I813U(G42=|VV:#+'Y#M#|>=Z_E\$1;?/RV5N23:Y=AY<;?G9
M:|%K(L79WQX?_0&:=NS;GUI6_S9H82UY3PW|'D)_+B7!R=Z;M*16O-E_?J!%
M)+SU!_Y+ZX8R9K4Q>CU7'O/E4! ?XWQ2?C3M!P3,DN#F0>W\$2LS%M(<&K3E2
M1UJ_AK4.A?|G2UQ^0EPG8R';UI_#4 (4'8/&W2G(Y*#GZ"P_MP?_N.H7_LVG|;XR|:5227?
CV38.EJ9GSE%J.J2F54X|<6DZ94LXSJ9FB(96: MEBC=SD-
J:6H23GF@&2"FA,YIV;F2((3F)DS."JX,|/_#^'|HW>=;|@<4'
MU@+VWN=Y_(|CNJZ|AQ4M,LQ=+)TM+6H^_NU2EW|J*2KD*35N5A3"1VV&X3J
M!)|4/03XSI(P|YCV=) M#/0U.S*=?0ZAPBN9,MM)A#*KEJE5NM>TVPY|:"*)
ML&YJ2+LR0!WM)5#_IY:?
QG>==6.X4(0U7_I+Y2@O4IR^9\|C,==L\|28&RDM^BQ<.T|6E+:>|4MODY_
MSD"JP<=TI-S2=8B")17SR@=W5AL(>P36*|!<6:\$*BV-.Y|X=NH75Z'0AQ6'_M
"@BH\$ZRU1CF_M4%'65|@<-%'
A"S(6;>37&14;U.|>7|E)9(_PFUVEL5|_L0@.O|BIH2<8NL=|C4-H^ZH
M>,P.|N>VK4JGN^9+|N_Q,&XD3..8S>BVK?B-VI0|GT>UWZF-2,L8@NL28EOA
M|ZOG\$HDS2GM^J=JF7S%-%#G!Q*_V;B%":N\0LR)UGGW=*U=_EH+YD|(@?
7|P:2'HGJK(16:@EZR*6_A;AC_M+_B>3UJ<7?Z5'P8;L!;XUB+S6|@?|
(.D6!;UQ4+=G!)DDL0>+!%CND#|!_M:Q"&|BS;.F*-\$_O|=MMG69:(''
@*0@V#9S(E*:.D.)*4@N0XB77)=7P#!^0_MKF))RZG)_B^K-
+Y=*:4QMO;A*M/JM8I^8Q.Q&H7L.G8PS1_!SXY@_J_YCWJ_M^C3K4<9I+F_|JY\VPH;P3Z-
@EH>6U=7|U74/MR,!.@V\7U1YHQGNJATU6?UA0H'-?
%UN.V%Z;UKM^JQQ(RFE^N0PR4:P6|_MJ*!:=/7#NS>|A%Q8T^D\G2GT#?H\$:
ML(HQ|@: ^8C'C)#::XO>.)JU4RM"M%*@V^<*K)P3Q0@4J_V(:T|@'*GS,I'H" M6N/LG*
GV@*+KJ1>3;YLZ7|9VOICV%A#YR&Q_IU=K9WROF7C^?XF6#;D>=5
M>?;/&I=/CS_(67))K+?H8"X4,%&IJ_M)'7.G*%-9Z#FMY.^(W\$('=HAT@PA<|B\DI#J?
#P6U<1T:71W_X/\$W&8.&H_M+5RDEJ->*Z0\QQ'C46V?XU197S|W\$U!3C;0Y3.D,T|
S.4AD4B'>@:XRA,*_M.GU0%.AWQ=VS=QZ4;E#XA19@%2HV;=E!-
!^LRJ:'9>\$+P0PUO56::K-6QNF_M|WU*TC\$RF^|00*HSJM%W_M/EK\$R3_N08V4
=;-'<.,.=+'0<..<'UIS|H-@,0G|T*?4U0?:!KH|C^2/8<2_M_+/M'@*4SE:|IT%

(^I<|*W%|*B.9.%NA,DXEAO-S?9SLO)4*U9JAIZ9R?C M34#XQV67W*;*/*_C>7IY!
(9HA01PZQTH;+IJ3%RKB%6D>MWKHO5L.FI.T>T M%4F?7>#7<|?
HPE!EDK72XYD4I69XD>4>QSBWW\0OR",;I%CO\GHW6&YL9\$NW==Z73'D.A,0<5D' J:P!
X2DBF_ O MXV J+&{D7)+<&::@/(JA#%RMR*;UDOG,%Q!)D*TF+SR9=T&J?)\$A'EI
M9\$/7I6FH_ W=6?234J\66ZZ=DHB?7PE- @L9Y4%*GUOK"!\$J^RWA%-WK3NL
M1}&Q3D#Q==#J?BUV>Q>BUXS&C8;N0=J?CI52@.*-XV7C"\$VHFH8=D-AI_ J;?
H#4M\$&#&@B?JF5QQ4"9ZS89^P\$%O'%.&\$VIT&=&<4-- 3I2,(ADZ M8E9#JL,'CETR-
RMHS1V?C>ZD#YOM.I;@.I7OP>M#CN.VLMZO#Y@A)..@N=UJ M(6DM^I"
(.5\$XXDB=347>|P!S05VZ)4P?UD2>I*"ZO"*ZQ%IV6_3D_NCD6*2R M+I?
\$TH'O|P&L2MONFK*=<E2U*LU94N@#IZC%3OW?7,"S=3=') J&)&IZV|IZ(O\W
MWW+3I}BR\ZT4DI;6?EOMP.UGEM=|%QRZ7H'=JP_&@WXXWRK6'RLJ=;8U
M.U.Q%J!D=R7K\$& NI;ZI-2_%>Q>=*I:>WB,9? 1(I.I/#&1-JZ&/(80JEV
MW,A_7B9FI?I*9UDG3*:T,/V|YV!Z&5)BQ5MZ= XY/>5M?MD*M8KZU4"/I1T"
MULP/C|F&||@N^+,9-=9;7*8TN'IV2>XTPK_*/6B?%&D4Y)#)S2AT.U\W@JFF MT#3CI^I
(^J #|W6+CP|JOW3WA I#GJ84,W8059<[R+E T3A,0F=39;Q*2EQG M?ZFEI-
U8A?/O*B>+RXBMK|4#JU\MW!!UV|D.9F+VG,"R*>1 MZAJ4I8]..#CF!\$DZ+5VNO'
2_NI99J#",;*|OARQ) M33^WQTWD/2T56^.&^_Z|OGV09FSQR|_ "6|>GA8S MSQZJD
:#P|JW;((^&0|WN?A8 M1KK&N;2^?F-0I?
G<)&FW5;G/5^8_L'WB=,,\$Y2\).AJ"1&+Z>.1GB3<8> ^!D3 M E-)J;M+^5@U5#
<"!DQDVL(DVZ4B4IEZ)MD4+I50#IH%5>XVN(@UN94/D\$\$, M4SR-S;U7'3/9)-K
J4>|P/I="+;|F9%)OF5:BS#|M|LM#?.UZ58NS\$3&P(W/ M>1-A07WU""R6J%F2
1;^JVF2P_*6%X|H4= CK9YSYD_W'ZU-B?FBMP)?VJ
MP2C4+\$,Y.^_3.VOC|S>"2F^\$%J9>R=\$?_&AA#WG.&&Y_W7;AVZ|>*19%W|@N-
4M_ZCB^<-4,9_PQ_W%|J9Y-O\JSC L M\$)"I-K.)K7Q%|(TC?P.I!EQ7:B31C;W-
P5PFCDG/@@!3F5P(C5H*>5Z<2V6
M98%B>7+;>N)M4N\VN@(P|4OL)9>|0@X4Y\$%S'V+^_O_ASTA|9&!*F'D#LOM M=
(G'D0EKO'-?MIL/X((|VCAVTVVTCTI9%+R^S\$0684!KYP.JIT-K/-@-:W\ M,XYP*#\$-8-
4|++>&L5_B3|9EJJ_ ;U2BK=Q^AW48IM M6T|X.T>VZ\$16C=)S4%B,>5I4I5NU?
OMX.%K2|#:^I7@ITKJ|T?L|^?YIB#W6 M|^U=UZ=N(8;|^DI>POW=MSM\QV3*#
<(#+=ZJVA#R740#NA5& &0:|_|+Y&=Y"<|.ARF@*+UPTLN+Z\WN9 LOS,8(T M1^
YTEF"*6**Q|LA560 TY("H@\$F4X8.5\$&(RRIO8E&QN5>*U*|@.06TPJW
MO_NR*26_S';%B87HRF5ACU|+=+"M!:"2T1H_RXU8B_-\$=E_-!)J_A(8+M,(&<^XC')?
W;QL?^3@2GM#RAH\$3/T3/8>*>ZB6%1=L?>#P--ZN/-U/D=F| M4A%),/2/4N.:Q)68_:#
M=5/&GE4:|>U;OFHM=V,P*9A3#UOM;AJ?RCD;= %+.YV@N+=|G;G|J90',0-/
M&|8R#X(01QFB>4VR/?!;?HCN-GDS|46-M%Z9&1B)-+G,C9\$'M3L,6T|! M!FH0|)F3N.
(YMHV^*EY(ER@Y!#&@_ ^V\CZ#':<"Q|<^B3*|#@"+3E??DN% M*3Q*-
JF@"5/&VPJ0|PY,OY%J7UK=Y"#|XR3S,O5^J'F%*T)S&&:\$T9;|C1AN|CR+#@XHRM??
V98&X?Y%1ZOS^|N" @'#I_V5\$1 M;:0I|4J)3TRLA?Y&^Z1VUD9%O"Y9;EL|J8C/4_ "
Q3\$WFJ4@D M&=/%+VQ/N#K@CR! MW9<>YZ-2,>%RW"MT*46|B*Q...O#1I?(4<=N"+
|U-W@R8>R8FO4H+L?H8E%)=LN3HK&1!CU4#^J007RTKH!..?
%W|C@HIJWED/5I|BA5;|ZEEX=*|_*O/56L90'
M>+5/N64XYZE(K;:Z3|5HNKM\$JM,%YU*=R+%2Y|/O;CSR\KMZXW;6<@\$(A60H
MPIF")|,Y4- CUPR7CKF',*=2N@!2@2SN1JHXO|ZF%)SB\DD)/=24R%&###TO
MS>\$_+MSK=HV.AFL@6V84>U!@"E,J?*M#@M|TKC|FDJ/
M:&N;_./XLWOG|=1\$*,42/2+S\$N9*5;=36|Z6K)/@ |^N(E7);^L+');|VBIB
M2^W13K9C5>Z/JMQ#PE7L<="Q*GM;HNH/>*Y@O\$*@F.K(?, 'LM|<%C?65O|W
M=404.*Y8"MSI)3Q/KZ|IV8VRQ8)D5<9:#.4Z4<)+)E+!S9EB'H'U35DKMI61
MP5T06*K\$MK3R9RNN-XD6C5#WA_(7D>|=72S\$19,Y:3*UPIE03M"Z;Q1MN_GC
M|U7BI1|;Z%7D.P_9^|.Z&>,O?Q5SJ&>^[4GCK5)M7R9,G)<=FL6F0>^RK(
M(7XDVC=SL4R.H>O YBD7>K%V8.8H|\$@*GMH4|&E>XNAL^RU-6_'M|OG'MJR
MY\$,\$S"IMD^V%KS8PX^?D#+K\$ |#FSB=Q"U")D|2R@P|6.?)QS%P7=.-!
<&|1VKGX\$#=0HQHJ@P1(+H285&FT)) M#>V;|ZYX#K;:18>;BU)
<.,|ZB|F4* @O9.51,%%<|5TXOZ RZJ)N@=\$|S)N(X% MAK0\$1=%3D?>5Q=X&DJG;Q0-
VZ1?4+X*FGM.!#)% M,|3D5TC*/K(+;4CV;J#^Z3AH1PEB5* @+/5|^1LZ26XBLW-
92J(%M=RLK"^J. M3PH)8=
IAPVN1M1G#5|B1Z^G!=0CB1O\D:'7J!%)1B'R'!\TMPF8V*)>!/4^
M2Z5GWBWTRLW^|/?Q&6B^W1NH+#@OV,UQ0,\$|A|B MA3^24Y|^?
Z^JL&W;.&D|4C2FI&*74ZR\K'8Y%GV|"?=D;:K=7,2%9Y4K1C=F M D6J!OS53!|F',S+&\$?

7F-6MIWR)7>NALR?IQ[.:IR%VS880Z7"[!2*4XTM"6 M/3BJB1"MF"7'-
GDG^!DO93NAAO!;?TSYKO"&L;+FB D)^HH-48?+;WE:. M8:7VS|J+_-7?
>ON>>*!Y*RZX*M7H.TFIOVY*^|*3GFAK\G0B41YD M8K@=RT|5
NT".!|6Y<1'7N!%'&AN\$LE03JVL4ED|ES&=5"KO!O)M6*S^)^4!.ASQ88AJ|
M/2/LP2'OPPZN*^,94ZU0M+GM;*[ZDN:P1#HXSCW/@&X|X"^*.T5_-?VM3NLR/B13O
M|99HK|/\$PW0> H0*'F-A+IV|A,=Y\$Z'NL^ZU=1/;QO;|NU83&L!
(*A!/)BHU^?/NS7Z=O:#R=&'XMDN%A(Y!2!|W= M/5-Q851H04!TX-PKTT#%35_V|
5,E#KE^:YR\4432.:|BX:ORE<#;J0_??@* M|ZJBH|6@<+!O1>FD1%^#JC(IH/>A0-*400?
5CWYUU86%*I+<@%@7=|EV^U/!* MA|27"= [*S_IR^K3<97E5\TO=-S.2"*?
7%7G_+.#F!Y|+2\$9"T_QUBYP896U M ?IJM4<71693|++++EMJXJ#U504M*|75D>*)N:-!3A
\$.^TWSX@;3I2:R?|&F M.8-W3K.F8MQ\$|14D/4@|EN7_ZWXS?PS4+%
|V*W4W|X5^H70Y=C00*8^5N&0 M-IN,UD8EL^5& MF2!H-2.7M2-
C)B/4WG+R8:A_N:71|_KZK=F9&R|A:B\$J_LYR7|"W_U>N^=O M/?|5=|5'S3\$U?
M\$|1.B5L/T"+#CD|KLFTNT->Z=M4?:EU_0"GS)D1*5"=*N M#WWOW)TZ+FIL
M#=@!Y_0H|M8E-4E.CW!PUWDU.V:%GEH;;B^(CE%;;GS)OG|#_7 N*E&(|_DC
MOSV+6PL-2+-MEU(V|J\$*ZW2=0*\$|+)J\$|+Y/15)D'@!90E^ US6H%9U5#|J
M4Q)3"\$,YA1E1&0>1275Y-
@*2ES'YA"0TJ2<|)X1*Y|B96|K+8Y>ROGXFQIV&UO"Z!X2J|+KHJD=YE\ MRYB" 0ZB_-?
N#*+?R_F:'FGJ?PM*CJ3I@'S6,*NDME'&2RWPLYZ*NK-&K|MC
M.>X9ER=^A*NH#K24_.+(|O<(5,%L?1Y3*(JNP&J1C8;/NW1TC|_5^X)R7R#| M&+ GI
#FS MC>&|3+N5>N93;_@3ZK+D!R<_OMJJUX3|H*+6|W)" :YG0>,7YOV-E&<=N^T_
MI'>6U#|I"RYQ,L75EZZ;:W2'-!W#|;|:5>|!&|5'KG^\$RNL%QG-OIXQ7 M,QGAE_70*?
X5Q.'^|&5NM4%GYW9?DO_C|J=8|4<J#UGT>1_Q#;:='+LWD
M&*ZIH:F1\$4K./#\$+)8K^_FGUN?<|)GU1#YCUJ>\$9YR++|)X\$=/|L'XNA|YRZIC
M%3Z!_U7.YD\$>2+._3@!"|7R&)MSF@#7|_R-XP50-G("GMQHO@TMP;FN9R>L:
M,!@G1,UP9:X1|>*T47Q_(X;XM&:@=5/7/V?^=|=|/;:6|H/AP!'=%H8-?K! MZQO:EURA-
IPAWWQJ=0ET(SJ%Q?|JTSLM!\$G|@.VE8"6TR,1%PH2J6!JTQ@+/0AP!^5>
BHYP!6@OT#+X9I M2IC"/2*>XLW3X0P^:LF
|V5TYE*E%;Q'JD@UZ"GB=EH(JE7M^*#6R="SO9-M66U4LF^DTDM-
>69\$/2=3WD7.Y7|"*#6RBN F|EJA-+"%F;7^5\$SOG(=IH\ K MP-
'YRMR|JGVIHE9/L8B"!Q_TM=|SM5*DF/A_G8)EMS|)<7<^LW1Y5(TC93
M3:|TR"920Y^%8,9|B*TL(4W|J^X|FKD+(>.,?^@;96@BUJ+FX-M/>3T:=|_ST\$KWU+
(|B?BSEV;/MEMJ_HZ%W "%\$0U|U^X=(-LEF5'G0=\$+QQP MQ+|H
(N@>AJ&BBZ\$!71E'JIC.^)*S3MRNE;7XUE!A\$|1(^L'48!G:L7E:5B^ MMCLDP4A?
X^V63CJZH?F1&TXC^:6Z|46??M:|J??3@S|NM;@=NY*\$S MT)B+5'H"Y=UI:(TV1"B0>|?
@|U?U+N"2X+%KL5)"8,+E_6I3#?.JQ"A.Y-ZV7+2!0|E)(MYW7YJ>(>(|O/ER_!\$!<\$|!\$;
M=OGW7S>IW50FD.QA%2X@\$IG|W4ZH:L*#H_"!\$|SH0:K>LI7H:UM.E#JAC
MU*4,#4^;073XJQ63&CNO/+%/Y!U0+X@;:/R8%158U|C! M7/Y%GV+(MV53>|_
!W4WZD!VNL6U,NHX|J1.3!|%)_4:*J\$)4| M>#1BM9RJKW@*4.>)RC0**\$;H4RV?FYR+?
#XM(!0Z#382 NO|P,TM4J!D|_#
M|SQNZ^;V6"5T#TUF*&V>O|*CE!U>&H*)!BYD5'':69,%U@HRP=|P<@|231DOW-
H|O),L7U0X.REPF4 M\$^6KK-3I@FKE,FCUP5)+/>
GV|'+,M*AV*6JDHA2"@T=T(|XBK.INK3G4V< M.EP3HBT.O_R8_XVQ2YS))80Z(ZUJ9?
_D_9Y|JA':C:AY')D|@WJ'WOY\$&%? M)'8Y2CX?C<|H&IFU%\$?6-
^UG/0CT96|>4GNG1S5LKD@"CZI<#OJ#;G!@M\$^ M+R)@5"\$D;B_7;W5KY\$|LE_J9|XN
MW>D|N;9!|Y/H/ #FYA)H/%XBZHFFYGSZ MG|(+ \$Z:.)|=M-.WW|T'"9=|5.O|H^J/^6K#
VO|?ZW\$S^H@ONE8-)6J49,V:.\$9(Y0QB M@=_|B(%U'<06NI>=>GLV3"A_|GT>|.Y.?
GX_-%G>G|_JC35XTX1 M|YX5 F)EN=?O7;FBMD;2=-SC_|HZ_9EQ'6WB5#?
ZA)DU6AZ22U:7*NS-76H M+JF)@N)K\$0\ RKQ0'>F"NX7WKZ#4E"/:3|+EGQE(J5U02?
PC40,K2Z7,4"|"A
MB8U4M/;)EW0TLN^^Z)|E56+ADG'IGHNH/5QJ7X"PIH|R^OZ#MQ%I*>1!|6M
M:F6N>8U?#\$L35(^UUXKX"(:.*-ZI=C(:_"|RXCO_;;S5VSN2@RHT/#I9/X
M(P<##V|^O9>E|C;1'R&>5ZKP;:#@XW57TV4M>.JU M(|3*MU!?
050G|.0!Q:5K|C1"AXJ*:|OLW9"*|/C T+*AW6V3H*|A\$_,<:6(5
MIU^6>D|J&,T'WITW&K|4ZF|5:./&G#5Z#X#?'23H8,8%\$S6)^_&HX;5|BPR=Q
MC2DI8F+5F|XBI?X:;I48R\$1WF-5Y#;A?(FU9K/TB_+<95E5CVQA\$UZ;R>FB^
M"ZX(|E:BT3|4<@^V1.2G;YM<&@|K#BXH/6YC1%M|J"D%!A100>01;*5S|K'-T
M)%;AV|8MQ F-+EVW":&|0Y&|?MMEJ=V\$EO\FV0T)9: @PPC|LKTT<7IB:~6O M)3'OX%.

(-RR,*G|SR5GM<)/E"/G|DCEF1.P("7RTI&A-M(. \$OSGG^2_7"X MM+%|A--
N.O&Q7N%TY-7|+A>Y'S|)BG*)85U%/)R|ISX8" 4+C*2(VBN.%SR M60R6JH#^VC
7F?,X+G?/ BR:|THT0M&3T8&+79)*>&3=RXL%-A1F?NX>(-I MYBU3X^|CDU!|3PW6V
.2AZ?G#:J|?"|7R^87P6Z%"R>F19R56RGPTY'. P4E9;E/ MG|
EZ.X>X3Y|)U|_5NS'SQY=6.G<-4?IPUN'=|9E#W/.*=B.F*T?L;(;% 4
MN3BL@&QDJ?:>D1Z9WP,R>M_(O.:R*DC|UOG?
VPXZ.WR+.UBNDMBMH:=YHQ37RP&MCZT3OZL8%_N#T.KSVY3XJX|/|^('24'
MAY%C"">Z4*">"C1./);?_N|YW&@XAD-G)|.W5VO/VP.BH|BZ.BS(?|_A7:|_M'GN^\$ECB|.
(4=J?_ZY7/+_K|.|^>A|/+?2Z6Y_C9U\$3#*C?_+.Z.:UF1=7|Z MSPZWU*|=0?
^QJ/;2K3T5<23QG*PM
&P>ZFRB37U>T'6NU2:XY&5WPX)A|_A:1J=N+HE6!ON.OWY1|2B,U/SRV.7C1S0|K*Z>=7
G;; M<|Q;FOJVS RP42>HNE"SHOE2EW2:5YCWRFT!QO*: _S;_B)6,N>D;<=^*KVM&N
M9UK_R(I2,^EU#%L:AI+4A8GW/(@470HDC5)O&5YG..C#)B|KMNB D42:/+4.R" MIPT-
)%XXD.JK!YNO#BAEGVY|9|3_?YX*8J/*UID. SR\$@^1"P_P6NONM< M";5P|G"+406-
O:X?GT5NGKI029LF#FB1ND/ABK20*|1VXKFS0ES6YJGJ
C8T4.+P*"#W;#1M0\K4HE)BH+!S@;:>.)^/WH&;4|@. MDF6EA|NGK0E*J=-
MNIKG|0LL.OB! M^=O)"|^#.(KM--;6(%/>PS:5V#;E_-; M9/*ZFK2?KMCU|Y:XG^J&
(YC_9RH= M=?Y_J,17D&S_SSF|/ M"&%CPEWDE(IM!+?V/WJ)D|;|'W\$OM= MI4=:S|?
XQHM2?|)W.SY*^G*!/? MHY26C?Q=#;#G7|1*|\$D!5CX6?9D|P|W> LF|F:*119WMDDT-
(6*8MGG)|8'_M0:130*6+8|UN_)E4?OCET<1 VE5;^1C1;.:
(_KD:ZPD^T2./\$Y=1!A2.;.:T<93PRGVS-., M(B+1|)4RW|DT4X VA7-F2K|L-
"3\$+|4"D&MZ?K,2N)\$D|K_1Q|VC\$V3|)(9 M1OK!+39)|NQ&4D%T*.5)6/05\N8?8|,>MB|
#A|: #|_|HR|!|/RGW_/"-: + MU-|ZA9%KV&&|Y\$3T(FB'+|^NW|
|5%F%%GX:3K|)O64>8^|P!>Z8)X@);_0*6((09&T;Q% C.CF,WK< A0WJ7BV0;:>>P/LE?
*F(;_2XA MQOR) M5J;S% C0;BM45./B+L MHB9;DP_)4|3.(L8|?E*_F0|YL,?
Y|'@|H7EH#LTYQ(67"J_88LY#;LR9|1 MJ9
&E;66V3KCF0_S|9X)A&EX,">.D1@IV&|A|02=@_ /1P;R!6RW#Y|VPI880S8Z>F-
O*YOMTX#@AQ9??UCV,)Y_SNJPI#L1Y MN?Q(C%;OR+|)K5@6RS(|#7U20H9"IT=Q6,?
NX2H0Q9@%IO\$;385/#T^J8+Q MJ)E-;Q7X 23|Z;K#'+%"BY,7UR0/M|B\$7A.)L6VDY-
*,U#AZ1R9(>|U#;PZ M7_9L.XZ&GZL;_9X?W96OO>^2'*9A87S-;MQW3\$/A0-
L9&LW5NZ+7G7FVH6N# MH7((Z (G;!DWA::L+):P|JU45*Q9|;:<.CT%?2|HU@**
|H1.E|LW%7<|Z M63|E;*V|AJB_W>|<&9375_ ^KES5!'XSM?X04"?3S)E\$H(|0 MN.D751U-
#W38|&1;_49|<=IN_HW^OLEU-/P|HX NOLIKX3EP97>(<1#(|A?L MK?%S.UV
GD8#/H>%M,@|*9X,LE|V|N8=U;9"KRM-;:|L_':|V)W@W9UG-8U-#
MC9Q7&WBE!D3P|NON9*U(VRV|N1Q-;FR66&I(?|6|Q<,>.C*\$5 M\$(LVE8GM?
XA=30V)X05NLZM-=X6\$_.%W\(%//."Y|HHL6TY7&!P"^DJ7(727
M%K|)#0!F8VV4(0KV1N:>)/(NFQ.S:1RTA*?|FJBO-@E38A&Z:LG/>EC(XO|)4^
M|'#Y,>|!%3#D&SX\$2|Q)UX4|%|D.D|&*|K.P()OP+3&6|YOYJ6.9I1?ME85<. M:Q|Y?@*U!
=+NZ8|F\$4=G_UO3##P3S),L|="=|5MH'*@LB_B MHM\$L4VR%?
7UH|H#=@Y3E"\$%59_A^!6USF3) |V&,1@6Y>KDC3C#2P^_?2GCX
M\$|!|=S:U%3M\$8,+Z(6#N|2&-4RJ=J(08 M29K)%PR'?
MCG|H^SH|EX4<|KT:*YI9@|@ATAGY:9-|%K8T@:6_Y&M|_R*@EVB
M!XIG>>LO,8FHE+YS@IKY2Z\$7U+"8\$,,?7_-Z3C')|T8,Z)":>+N;>/A0R(S M@?3J5S%
I\$|D/>GVZ+"0.K,Z8+5W"W\$F@3MF_F.+R5# DA16BGR<2,F6O|M M=XS-
98_"|J<9C10RK|*|/RU)\$7?IP?WUG|*0#OI %;%/ MC*4LH\$&UOKG#|JN\$E
^>*;S|G>F/3^GN5Q,+SGNC#BW&|3:|&W-3#^4WHB97
MME8G4.D9AP!Z:.;REPO|%.|YN2_8ZX*|XB)SNR2YXB7+E4U|"\$+V1OD0^N
M;|;)Y4KWZ6PDNJ2?A6J65BN_"=<7J_|L:)|(\$/P3P=W(*3G|<87J|/@0L&Q=?
D1BK,T.@|Y|F\$1|>"9Z)Q.&6|1)7|(6J>57#068/," MR1B>:|0JLDM79Y5)
NT:IVW.%"M2_0?_S9)QL!_9D>9|Y^&2;EC@=KX)R^YH
M'<:|^|^UUFNDKF;FODBNP77E1/.RN3FRB#^V-/MY83&EQ3A:MG1>0)2QVW62
M!|9(R;GM9_L\$^2RB>:3|W(!)D*SWCDYBR|&UW6,OC(6'MU_M
:E37C5Z|R(.O+Z'5|XKG65>WMQ(18#^_|24_@F')^-/&7E1,()0". 0\$-"(M(VD/&X&>R#20=
(#|R|DQHF-W&YZ0FVMM_;H*51O';J0|NP:"T&GH+REQ!8M_M;J#Z&|9'DV.|/|9"10X?
0DUCO\$-0Jc1:62D<.|/(_B7FGJ@'|@|!?.I5|J< MBDJ&W>|F9U*BA0CN%O5CE""^_
P^\$P79++.\$AW"XX|N)W)4)S'|YQ'00\$Y?GD MLV&NA>R;KZ)|@#|(|O2|B/BF W*Q
OX!OQS^?-I@G<2K|,|4HUY?Q+;R9\$;EX|JC,K)\$/_7ZVE|P(##?=T+;+5>VQC,%X M<;+
W!|9:YSU?3=^/WPV3JYN_4O934WMZ8#NIK*JJDC_QIG%)-M@INMGZTJ

MQ09.G295C6X? AC*9A>U"EKFC2]C%\$[/R2!@-/XO,^S?PU*,WA1/NSZ)W: MYI\$P? Z_H=#1|O#R0.R#JHCCCWXYMY66HB#D_MRG7!Z^B62*N"!;P*IO.VM? KD7E3;\$Q9!)=)DJEK>GT=@B<R>R*E@*G=T=SM^\$?;"\$;-?0#*AK M8;5B--[D_B%8C=3)GE.U|4#N|_XWCTG)&%5Z?C,ZMP=ER\$|%3PDR9Z:\$;6* M9|RS7K&% (@4HX@D;,"A|H4QIDM\$B<>,6_#/P(DTKO3/RW*"3'0U#WX3UQ+MI9S?;? ='CH1)AUD_KJM0G!YRU& MICE-+BEJ_&?H2\$SL:#J!PS1NP9;<|%"B\$#,D\L M^7W- :^JF)SV<&Q)A"%LW;>:\$L;|P7%--J.H!P9 NE-!.SVL/O*W|V(GCV M<:_Q0R/SBU2X&-B M4E)V^XA))BN%7.!.C_*I-JL##/ZMW=S1YY^ ^ %Y/VFLSJ?A+ %':@2S&<*"@ M4X95M0,4CF23>IM_J0CSRLXBXK+WV;1VM%X"TI;Z|V.;AP&@1)6)FT)\$MUZ- M.=NGNM#OF2(OKCLKL23_N|G-P?AK9LPAH-;,< BPUQ!J\$6?S+(8:YS&%TVZV MU%|LT,U7Z2\$5/\$HZK1+7U78E5SX^S\$=>U>'7W+BJS:2Z'FV3^>7QMF6>R31P MJVVQB|-\$;E.GN2ZSOK UD4X,GHI<%%,AUR2'ITHUSEI*O!HUE*?+*K:>SGX M/90^,D7R|O8Y;J'9PD)3DFJQ!CQG4'WD<6U%Z;2I'=RPI&R\$(8R>.TEU1V2 MR%:EZ? 1^SVZW18O/'""Z+EZ/?YD)%=S):>JKV9K'7XKCJ\$KM8<:F;M5KI P|M>OO MHI#- K4E|;+_N(:#! 3RQ/_L>O;X5/G,(.)1|PAFVUX21&WF#)\$X/(#"Y|H4+ MG/T; (TE|7#LW<.1>N' T95"+DE\$7129=+D|T0(2\$)UAD'TCXZQDR7W3&!|N M3-JP> <9!'1O);1*LTA@MO&T;OT0\$'AAUG-BIRH2J+V'T!|!#4V;Y@V;_CM-_ M>9:6>%FA77EB8E+3_:85;LM/15|WQTZ9^BFC0FJG\$(L'T5FSU-M#OVZ_N:\$5 MC.?J,S- 5_="K>TMCU?,O>P5/< XJ.IP*Y7.8Q|C1EBIN-^DO|L0I8^\$L'19 M:TE|;>> (B/.W!4WOW?/|Q|GI>*TBX(@B!5|(-<0<*J ?2J%=@B8!W'6^?F,M'LT3R6UTI/+>R: (6ICR41-5W^OX94S;; 2F|*6A->EF?>W/I<9PL\$A?0\$#P MQV#W|=K@,,WW*2'G,#.05#V'2806(R4JR"TS9L1+6:EZ? W71=|_|>&BN8=" M, (-@C;?/SY|-P#\$G.9P#(8(/PB-=R\$/I=U@Y)H*1O!2!^!KF?26;*JWABI4S;..? NIZ;,"U|>1W^JITEQ%|HG0^~7O 8 M-SV#&=CA@8LV131MP-KF_Z9'M&=S? N+R(>""^0)P@PI@&20&" C8R&V|_|Y M):1@YELR1JQV8'IF\$S7EP5'!-C9? F!Q)YSD11|&0=A9|/\$30 U:#'A1O1LZ<& MD574/? J/Z<89"=,9&W>> <"UK3HSM2YJVDW1FK"63>6P.:?DN9P2E:FHYR7C M+;)-"J!|N<3PO^!|(S<_Y6_) \$0/(DS18_3J0T#|&:8%J|!%KM2&NK|ET49E MLOEIX&?;% <_W=^FJ+7J82H0GP6@|2M|LEZ,,E|4/5QWB-N-H?CL=T,FW8| M3K9H2#2*J%KF*6%LM1>"1E;;Y*:N%Z|1ZQ@9>K+R5.:CJHOU5.0|J"KE!9?; M/QF+'? 1/%6"<|G+3KD.0';3#5GN_QMHPW&L&K=&WOCIBJQ.%<5KZC<6_W%KL MMN5!PC<8%WZC^/C7MA#2K'=86QM; &C_!C:*L3O|015%7T.6PENE,ZX#D?-. M*A1_J6B=M6A.|6KH@ZL1?R3|'B(JT!49\$&H:~9C!=7"5\$=\$58XRG0KH|@\$D1 M!FP;_LA\$%M4M!J1L);6(+=(.ZI9CFH_Z8JO/QO;MTD|H04L_1WGH"AYS_# M|Y|&X|LA/Q\$G#4YP32C#>9^)YU98HR+9JQC+C0)ZTX&XFPM LU""T_HZV6 M//&? 7KW5R_F|)=4A7+FSV<;|W|Q?6)P!HGA:G:L|*1JZ)4RT. 2T"7U\$.8 M=;NQ@ABZOB* (-;+.2KH|/K-6O@E3#UO:1UV+3".+|^,XD#S.+NM<=%.D@62 M6Z UC+1NCM|_W4ZBC2|FA5_SH|P!PHWTR203)C(*G4^Y6EXNP2@%@X_WB2R@ MT+K&^?VJ72@+3B7| MU@3\$T6U&B^(-;W8INW'HFMAL|- =|E32,B/4S4S"6Z/&"Y|AW|M 71_:VYO < MU6:H_? C'_H9|=DN!-3;K'Z3C2VP%=_FD6^1|;K&T7/HQ) 9TVNQG2"SA49AE*B!;!%@|V=AK;L1:V M8-LP%<=/=4VCU2-/5+((=A- AT7!3FB;JJ&005GPC?|2CI>*1)P)*W2(3ND%I M"F3(PZ049W@Y 8D+V>2A!@%E#HFF';OY28C%Y18+R>T75<)|99|<|_&7KEB M,#V4M+UE)*Z;SO^-S0< M|>UF)>,7U"#U+JS8-CWD|BHCVM8P%#N*>!DR\$5Q@LU:VOY_FH4' ^T?+X+5Z MD/#,7ZBO^-K;..!QY@,&/P4C&SAS?I1|?JE-IJEY?&J'\$||20=-=XF%=/Y;.:G>V1|M PV3QI:*/+710=NSHKHSFBEV.2724=_0?V;Y*MYK5D1A-*K)E\$(-1=*WSQ<3 MI!>1# (Z/9N8/Q2)76R)=#@&W@"GC%"3UEQJ;8Z.^+|'E|WM'P"7&7!P|%; MJ'D\$+|V)6#SW.RX4%C)_KN9OCQ7LCT#46|&|M&|T:%ES)B9R86+4"B010G6<%6*<|) |1 MQC-2:B)=.MO41OQIA94AIRMJEGXRQ*U@I^;M|1RF;49VI+;)/5.C>E);\$1 MW_6%AT:H1DZK>F%('7E7|5M|A3-D.8:.GZ=_W6H\$*+P?Y2R=5^-|K6BLN M*F998|(-)LIMY@NDHNC)C"K7<6_1MX|EY>?2?04_%XQ\$@5BF').^#"%(99? 4\$WH>AQUM0:Z\$'\$DN@3X1\$(_6#VS\$# MWD!;Y+.(> (H_SZ:(N-#WKE6|)(CN5BK64) M_JC.0*(P&9|"%HQI;DD0^:571%F0AG M=AD<)VZDA=Q?=_ 'K_1B8.Q%1*|/+NFVJN- QX&4QWE4_,W(-P|)%(*09W!4 M>\$?.91HAHTTI\$'46X5_\$C=&!' \$ITU WESA5CGOFY@NR-#X<5)ZPRN/T<|%|? MV;SPZDG93NJ(87-TSJ?WJ_5P;Y0"O1"? |ZL%2&NF#"!%!C%#"|JT!W)%PP1 M,?*C^;6W;=|I9,S\$TVD05U>6A":124<)FM8I93K=? +FB;2J>O:RGP.|/=5 M?WPD|!#@@|Q|@&)<:)D5Q@C3JT>9EX.IWR-

MG(+UM2,8]PD!W7&WAGMRXR-O M!\"Z;MH5AL?^L>HN7 #KQ+?I
Y)E=T\$VM@R,%YD@ZN,!IL&3KSAP#I((@0' LH/IS#AG3 "5X)+
MEM8^+)D(C#)=*H+VA^>@VN\,9G:O??G2|+_X^O=XIOO_#QS?55='E1"*M*N<
MZG)Z5PXEMDY"DAQR&G9)#K-F5SD-LQ4AA""\$ "U4P-C&OI."WZ_/HXWO|WFZ_V^~/UH
I05Z/Y^-Q/SSW?#T>HY6#I4N4K!#Q M@"1@9/TZO:G|M<_75>AN!;WJT#7"! =L6E3-
HL)E,?+;00.K+X66:W1%"Z"9H MISQI1DFBWZX5%(:NZK.59Q+@'YH' Z FY)JC;VLFM?
C:Q?NY_j*>\$+8+LI6 MJT52T*VDR,@ZK&?Q.9^=&N06*6U2D|0.0U/1;W00IKH?
0=W&;=\$'PK^;^<" MIJA#|TW0AB4Z&0Z<%BJ\$'005HB_7Q-
'0@'L/8874RU^_RB%)|01"5+,<|0I& M*>(1>6*T|0|Y+G^1I*?| \$03^#8-[YJX^L-3-
/JN?A8)F|-Q&UZ*1I9OB<|ML_9"i6|X| #UR|KQFJP'A;V2K>P M1Q;UW72%_4QR|L(?B&?
|'KH M+IAE.PIM^|N,.M.GFH 08|M|5PXZ9'A|^6-J-
BWD%8|@NY43K67|Z4.\$@10(D(W0TQ=\$EB[*\$<))N!@*" +0VY=EN6O)N?O C&=
M/0C!;FKQ&\$KW,@K=3;4L;)S7JB;5CAUL^+OYEZ-CHK0'E8I'^4,^ MJFX9)* M-
Q99#+R#9GNEG1?EISB=;JI6/6M#7R&LK|?;F\$P^Y\$ _W0?
7N6|7%PCK(R&^TJT@,T)?'2Y?*LA-"@|Q|H2,OV2_:-_-XS6C.XX=9PD" M?
MD"LW:H_WGU1|G1

XD;W!AZI?B6 M!\$((>B5E1R_ON\$&=;)4I/ K#I1T;ZBQ">|6=^W9C-=[@31|+R8|+F%!H?
_UK=V00@ M|^XIX>:4W+@UTO)*|M'56MJV!T+_HC&0F=O-
YVXZDJL/(&1%Y|R:Q|UVO0,X MB?D2X%|Y#-/&^X6YA/#.W*92G3T0DDU:NM.;
I9@\$23WHI=,@?#M\$WT'L38Y M(?;DX1L:GO|+3W8/>:RQ-
VBVB|TR;V5|F|MA+MWG\$NX
MG/QEP.7M:Y+G"QZ+\$A>8&>BRIL\$P=)TT908CA/L!LFE46_@ONNZ,/?PNQV;
M4SRFN8|OXLCE7K%VMX+U;>1NDL(_VX/3*Z9-MGW%9APT7XKB|*R^|O)?*UWC MX?
MOQ*HY*.UY0KFQ,FQ_!=VOW92^#VTWQC?_9GH5_Q|U>Z,6Z?N|X8|0W07*ME/-?
Y^&|;E9|+\$.;2CG2N'M0\$C&^8MV^RT>UO;VA2+7;35NWOLG+B|S=!,?> MMW\$>W
GW@W=Y|BEXUH|B)J!RN 7=/.PW,&|J7)E;|B#I| MJJ:-
|^#JR|;O|OSI6'98D^ ^D/14|0K'Y'E<\$N 0U\$OF+D|/4E.8'HYBL\$H|&@X/UQM&
>/K/W85JODA.4YE#,8V;?B<_MK<6ZY&H< MSV83;|71^ \$+C:36|>"0%N%P5#|
<+W*;EYN>F|M-N^S8BMPE+U7H3OG;*U%U
MZ,'=U"G,;5Q&_15UN\$DK0\$>UZZICL:WZ5!B';SBXF&1|2YQY+Y0^==B\$1RAL MOYD^:
I@E+F_X)O+CMRSSXZ(&*\$>^(RV_)2Z Q:|DH'|?EB@|.5-XL*^/7AW
M0NNV%;T^:Q.O(!:@1;OD@8"9:Q)U+|H35J|/%K ??X78*S&'F/ZN5YB-6R|R M;
|AQ3_,';Y=L9,S/W!|0A|XX5=1F-%6Z;9U4WG :+<^GEF=H,?2|/E-|H.
MR|99EB;|WLC4ESE+V. MUS&|V7FQZ!|6KQ+ZXCSA6MW7!8:6.F6NZOO:
|+O" _#>*>0'2N0NR>N7E+_|MUNTZ99)G4<;_UTH_I%
7IR?/PWOR0_Z*=N'9+Q;SHQ""7E|'ZT>Y3|2 =>>5|54! M/Z#R\$I:|=|G6M?
^4;C.*N,|UWO| (HE,G_QE<8=;D1'CPE:U.N+R5R8V)5RW\$; M,CQ|OAX!+^ (R%Q?
#?;%V#GMAA5P0*4BHD0O+^6%S94QXD2%,&!ECA0;:W29;
M\$DNY))|W(8HPUA5>.&6'|@'J3(S*CS&!=Y>V2>66X4M:#<|*|&?Z2_0K6&4 M
=^LNJ:%?CIASP8^WQA=2I.%?%X,XL4(G|FA)5=U<'!|Z(B 'W";S2 >S!81
MOX4TIX15DAS^GT|E=|F_7@XG|'_9_%B-F&JMW=WD!3QKB4ZTF-ZO\$-"9S*| MG849-
DI?7OT772(7.-1?2="+-X/NF?'+X>Q+O;?=BG")H4UF ^BR>S|))\$C\$TM1+A%A.#ZB\$B
MM_7A=@X<3QQN'|3^8C!G81A-)W>N|)'DP&H3" (#ECFXH:S0UYC8R|?FHWA! M-
F|^B?N#N89U3.\$=2-1?Q)/1F\$QTK?#&\$G|PE13Z66F|-DWF>-L5FR7M!|DK M|V*?
EU);:9WQP|M8AN-@P2VUNY>-B E)5?/#7-ZJ8=N7K-G.C|N0(G:|O+R5KD6)_?>6-3(B0A+
M?2<|WE7L75S,G""E%N^B?|S *: ^UHYL|S"L6JS@;|"QPZ;|P6G|V)"8")S
M60ZOJ+L|W(GHG3NKK6M&C(@51;|A30_16ZF3U(B5>U<^P3 MDXD6!
%99RG9S(RO9\$(@:@7"#EY|@Y-PL.FDNGS+6S^SK3@!"EPMA&/>3%_-M|8|_%_WX-WJ
M_2>R LG!(NR**REXS7I3%^33%T/O"YTC&|ZX^Y\$ '\$50Y!8:MKGW@N).UW3
M8V|O=@R^@Q.'2|3TVMYPZ_(LB>|R4;@W%53+K_JJW9MKZ5Y'9K|*??Y6G#
MJ9|NO|@.-5.8A2UR)Z'00J1K5=QNI%NN@J8?'.E2U_9-&Z9*X|?8RRIC|1CJ M'GVU?
J%N!|.UE-HD'8?A:7'(-R<%OEK9:_EQ"|.VJW.2.CXZ7#0_/QH|K|%Q2@_/SH;
M_'0V?/24GG3#7SS?;\$>Y^3:HU\$G*Y6M&C_=YL|D@:"|P?3;G#E+"?Y)#S1^AI M56\$
_XJ*:#3?V !&ULY5L;|LX%G|WKR RP: ! ME,37V\$|: FF2F0W0ID63F<%BL0^T1-GJ7T%
L0PK*95&:-WL+:ZO3XV.3+L22FR-5B1)|V|?NWN?|-O7JK:%+,4GS4R|7'+|^\$X4:O5F
MK|<7;WR6|X6E&|=07U=|+FZ%_:7Z|%UW%#)Y%*41J2:9&-V30OG;X;TGJW MX%W?
MD?I/3G;(:N-&7*CB-YG9Q9N|R1|+1,|KPGY6J|^((,^(Z*6J,XO6_FUH|\$>

M2VMCU3)L!@+=6?K_""HH;5ATGUB0SJLZ#N^_4&.RTMN^=076JV8IM6@1C^<
MJ&XWF).E&>76:CR5V&??7DJ3JM+*LA89^U@)S4E9Y06Q!7%:5,KQ@/VM55X;I
I7QFK(+;_V7)OPYPIWG4!B=FBHJGXL>XL0(M?2_VWOIX0^D>_%;-
&BN%SU+_8;13&ARQR^O;BX\W=JRZ9#?J7BQG0I-9!@FS"\$NU++BY2-+ M\A0%HS1W?
6V(IH'KLLOBBMI%UM+-@F)T@H_-K*TBG%FU@SPN18"H&-I\$<=I MPC).AW+#5+
IFKS=(&AZY31A?JG+.%[1N"/+N4E V3(@6V G/_C#Y-^;WQF MUH>9UFF HCG7&?:
I/96692HKW.>IHR?+OXB2*1RBV\$R\$2_FR D"GJ\NZL+/5_M0S64@K15R!Y?42
M3V>+/+@I(M W%5"(C*=/?SW.9"D>SX#. %4H_-A<6 MC%LV&?79;Y*LS."3E'R@H-IX
4LM\$ _8!Q_)T44,2"R/!KI#-&APMR%NM J+&&P,GR-!59K6VNNJG5%6@U' M/W9\$IK05>
A.0K3;ATLWK(0?%\$ 3&B%CG1J%+1%:GB8J81+5VQ6&10M=GAV
ML50+BUQ+_N5MYXYH6C;6(O"10:VM<|^8E=0+PFUFUDG6SC,F37X?SC%2RL
MVRJ*TH++I?;\$62;4RYE B#RQ+S\A7VY6QN_=3K#*N6X%5/"+-KMVP*LB"\$?
EP[X*R0!Q;"M\4"FBJ-BO\$JJ,&L?L;&+; A;G_>|6V! ?PL3 MK?
7>11NCX91@3FB/%T8Q058V|>P?0>O+VM9X;N3#X9)R-1/_: 4H!"M5>6A4 M(5-
IPZF@1C<74COO@J\$|O"5M@JG0SAEJH4*^+!Y2486%SA7B"E7F'JNXTU.;
MI(BTE>8+=A9<\$V0TE*BES4&,KEN"*-MY386L; 4>0Y.'38BK\|7R"4.X:+3
M22H+4Z4S&%.L;M+^PZ&?.DJ TF 2?7L:><5,AM"JS;@PORTDL_OY_-^>WM
MU=UMYZ(&".&YX/KT\X%-PNO(/HA?J_E/2|<"NVS_GB4+=O=SIVRD",-X.|
M\>\$G39AA'Q,*""H,6D2F\LR6@-1>-^E.3SJNT#Y4^6&|H_>.!GU!IV?EM|-
RE\$NR_3.S0/8|1!Y8@NY)TAV<;(G=MJU_C+1 HG>TYPEPUX_
M4&Q3@GF&PTGG1C1ZW4R5P8=@B^D@&9|T-R(M\$T1;.CPBM-I,2LX2\$7@W(.YW
M!)|/U90Q^,-A#M|RB/'+T>T1RP6B'X<"|A3!.FP0T@|B;:60*2\$H+\$P<\$AR"
M5\$J6_T>=S1T^((8E6BJYU@?-;J=-Z:2Q%CK^C9A3I(CMEK^0!(BWG|C|L)!^3UE-
J2&E/%U M71!7N59+Q\7UY|LS|'&;Z%!5R1(GCFJN('OFH3#|A>!M9X=D\5QD:.*\$Q3>
M5)X\$'T9IP6W0QG;Q\$.O^M7UB_D=#)X%\$ HDGY|*@6|YT=ZCY1KJWVA#NXG6
MQ|@DH4U"-I%0!78:1%|7!"YME&T;N^7\$T2G|E@5|B>N-64E* 74!);XC2RF
MRIT%;JPNDE9"@P8SZ:LK@#1TX:IJM=DO.=3*@8"&,#1'7G%IHD(PDV\FQ6*H;
MH/U3KO"3%N/*\$L!>V"NRUX9V*PX)Z=|I850-V|C:A|=0J|_
M1N2M3_YW0FY7|/O/!;|NO?|?ALMWMLF^R-OLE4F'D,N2=OY L|O"H;63RARK-M-
76XNWKE6'XV=UH|B:82Q"2;Q;)LG'A=*F_W"1XG7K5Z3G<#-9BA*^GMI*@=
MI^H3MM6^6XNF|KT;4+GBJ*Q?'0=;.WR/'3 @|5<15EZGR7CA(O|>+009H+
M%TN.S5C;-D%\$Z,5CE=SR^_^|@>)CU'KCXZQ@)9K(-QRZ=(H<8K5: MK'='%
M%;FJ<\$)!;P\$ _O|225JEZ/#|#"2VP1Y8PAB@<6#F)/0&"4<%Q_@3W)6>7L4>
MY\$/PM_/H;|X5GW|N2G*.7T"LY#GG3+8_-2|FYTV\$,3(3,*U0ATY|A#*F7NX#8*1R_2/-40C|
<# M+;|U^7(FA'L34_BF&M%'(='OGKU7(.GJ^:S-VSH+^H;4XX!-. M9#
(C=M,@PBAG_MX8L5Z;+TWI+79=J:ON0*H;GR69C:Nf8:8E!<\$E*)QN^><(-F//8H
M.,+/(3>[%*FO0>*[GF2M&M+";>>O6.U?*VTLWAZ^T%Z_E;:UY@0-=| ^Y:.<"
MIB3^YXK\ F%?4^E=4|+;9V&R0*:=ZW7M\$LS!8KC?M_3 M2(:16B_IG01
C&8QCJFO@_ME7O<=M|V3"6CN.WX'.*\$.K_JCI<;X0INC'AT
M05FJ=G*!28|&30S""YXYCNC7>,E;KY^IQ% BN+M M69|2@FJVV,5&'|-|!-
:^V88GO""E8;^X\$G9&X?.%-E3:69JEV9D;:Z#B|G MUG6!;JEWJ:6-C|@N:?
@M%MQ^57Z;:"/(ZQ1BFOK!PL>89Z8_%*CWABER>U?
M=T(5>Q.V!4ED*V&U40S(G2Z@7.K9:6IN^L7)5)?;|K21C@ (A_E/#I1:1M MWJ/(V-
'A>Q.L(Y>JTW|%J#^8Q=T=F;K|YF9U?W%W_ZH;(YU+@;"G>I., MO,_ZR:!'<-M+1H-
IYY8Z_U Z;=3& 1'9).E-)NPD&8W'.Z?> X=AHV3:G3XW'
M109B#)+I8.+P":O|7<*ZFU^O;K_B|SSSS;|37_7<2-X#\$0 U0M0H&?5>-
M|SE00LW=5RMNV%%:_VE'<|?Y;..Y?@=)L33E5'(F7KARN4AQGHI2/E*QX-KNU'R *DK
A"0U_6O'^ M^GT-D-1AV4FF=C_\$ 4F@TF89"4R M;MIJ+7)|62B=|0*/>MDQ:RWXW"
I*TD|H^|U.QF7>.GMMWWW29Z|56:0R%YT M,V66M4?
#R;4SS|80|*39F9|S(DIE27^EA/'_3|DDAD8JD(D<_IV+1U?(=+_C9 M:ZTV3--L2*.-!
=6NAG(RIZ#<%AI?)=859Q-Q+_)2L(56&3M7>:'A)P,EBA4|
MM|L+;5YW"FQ%"SD)??:M\$QL^(38(V16\$K0R|R.=BOB^@ OT;1<-:T;?ALQ+? MB:3-
HL!CH1_&S|B+&L,C*R_Z&_A+T_%?/:!|WVL?/2?_K87M>;-QFDXN|B^O/%^S|Y:.*G=|<
M3R>C|^DM^V,|_<#./H;:ZXN)K?L7:EEOF3%2K 'P;5A@L+,\$"21S>"Y.E#V M;1X/J=|Z-
D5YRI;| P!;9TH3_-P5|B/Y;+P&#=#LH5)PAGEY|@5;
M."#M|7|R.LXA4)4&|LT+NZ';C_8ZN10?C:>3FTOV-Q9W^UX4=&GD^UX<##&*
M^D,O|@|1H|Q|73T;F25;|I&U^/I^(9%<|+!|GT6A7VO_-19Y(>>WPU/+K^|
M'5W>C5DX\#T_"EDP#+S!8,B&/8^VGJJ"IT?;PK:|YP|BKQO%& ^#H3<<#C#J

MJ M>MQO^C V:;Q< !A.*\$W6ZH&G!4VQ^#\$.0!+0 9&D?*8T=V2I-<^7 NR+
M3S!0"JO483RN!K:25%M;WYQ &7 /K+(S" M5QB%4<^+!KWMZ.3N,U XGGYAT=
+AR\$;QEZ_VV5!%'M^W#!;#|=3-Z-+@G MB"?6>4\$ 9""JB[PXCD]NX##-
NCUOV+/OPFZ/(99A,#A!C!"7.*0-HV[LI7H\$ ME![@/VH\$LN@.#80K.'C!D ^@!I',I@^=<\$!'
M!15MU:ZHGW->)4'0!7K=[G:T@PG2/&+(M^/I.=X>.0E,+ #7!QE!\$442!D!0
\$U>WQ^PKH/0XN*T(OZE+/6R?G!+/KVXOAYU_G!QZ7)
<+U.USR5:Z'E7.6"X2&3!2_\$"Z!>,9V,K_!Q MZDS!TN-S&'4 IOLU9H/H_=?
+B.CSMLOH^OKR_&3;IH,H:M6!RZ@"&;PB%8\$ M.J@YRU4A\$!^4
HMU(<%TA=#H31QUX#7/F?B6I*7!)=)9B;FX\$XTLM+*X*O61 MY!:(O,T^T@:&TGS>J^
G#CO23456N=(\$UJEV&%JS17W.U^6VE-EBJT9/6 MQ%>(9)7+!+IR8Z0!>
X+!/659HT&\$5KO!66!UG!EE,EXFCH!DQ3>6G&T@HDH
M"RLKP6Q5UN)5JH8/GM4@)!*YKDZUP^FL!;3MBL9+)B&PH#:PI%-K(>[3'
M:ZO!,_AILS!6(K>SCGE^A*>"286"V%[7;+OO9CI\$MUV529JSR6"TI9K_D#;
MN*H@40ZT2_\$%JY.M6A3-!>8/\$(TMILE%-%@NCT83^\$U;Y4H9:Y_,IVZ8D M'54!
!("@+A@P.;+(!:VU3(!40!0(4\$H@<2;SN<6#GLFB*G20F0A!KW>-!Y0R MA(\$IRP?
)CXWSFNP!03ZCT/9^NE00FT!7-!J5DJEU84T%%EQHX4: ^D5MV9'
MSL!*&JBAY:S,,3BEUQ4:3:N7%?6!(- MK'KD VE,"1=PMI DBF^XGN!)?&_? MC^A!
(!,.E\$YD-,6N'DRM.L.8,B^.\$ZAMNN!4K)BD!) P9! =4\$X6%0A)FA(Z@,+6:2-8JHU
M6Y2HJ^*)IJZ6OV/1GAT':0TEM"J7*S8JESA 8).ZT!Q/IWK:4SI'/CN=E06*
MA/4P19+7D,6W34U@CO-\$?%M+O.!8!6IV;>2<_H"@-GMOVU:*\$N':B9K\$D69YQY6TY
""*(N4.3-44-=K"U-F/TYV@)2B*19Q/XJV=GUBV/+! MWBF 43K:MK\$"/ZO0?ZB(AC
/^03%%^52#OA6,K!2*)5 M^6+=A+'-TK_@!HW2Z7P#XOFI!+=S1H/WV0&2>D#=#-
#OIW?L@XWMBW@VNUS MJ((CJJ"!70(ZJT/H*ME-4JBJ!7.F!39E(5""/KOR7*0XH=D^Y)
NL!)Z&#R1 MDS8CJLN<.%CSM>UB\$,QQGK39:<7Q;D9#
I="UU^XVJHN<>I:BW^7!^4^@!HP MSU\$0L;\$:8NI"U&D-
<>W!3TA#YUMU:)A\$S00FW4N<+N#Y-9>HZ0^U3:Y;B-!M,;/%1E1L4?
O%'O;M0EN1:+XE;\$IR>U^3VV1F:Z6W=?T1U3H=*CJH16!5,I(8
MYV.9VGKM!)O=/7I"W5*T!W^EH152UW5APEH!@2Y;=".=JL7?4?(-1K@_9+A
M(,3GMTYZ5 M2?:H7ZM=64NJ?_?.C!5!AI.@J_,+I9O+NB?NZI"0HYI'YAK!*ZFN=DN\$;'LT
M(+NW>KINPY3K-7BF2CZHM;04GI%M-7(M:-TY[AN+1=I-ZS;;B 5U=0I5"4('JL&+'OX
M0CLRG.R:R*(GVT49.Y^H7(H7W+MCGH5#V)NBI?I\$^>]1R&Q-PM5?3AV7=_9
M^<4E\$WII?U>BP@!XNAI?FK?-3UN*ZZ5\$ J1B@:5H);HM%Z_Z MH5!K^_L-KY0F1VN!
<3T@1!7RBXL7J@#9H?!,I^"U!+ P04 " !0BDQ: M<0%QUV<' #3\$P &0 'AL+W=OO(-QL:
%UOV2)@'<-.L"K%W0!OAV ,MT1812?1(JHWZW<.=;%B
MR^XP8'N1*)+G!#OW0UUNA'Q4.6.:?"N+2EV-
Q&%%!YIO.K<3PF&500=:\$ _BLW/K)\$G0'ZI*)1YDDV!-X 3T!72 MHFR(X;OD5?VFWQH!
AB^PB!VQ"X!G=]D\$'YEFIZ?2G%ADC<#=#QP8\$0UU"
M5VB4!RUAEO.=OKZKGIC2H&6M+J<:&.+T+V(W!3\$!A%BOR701:5S16ZKC&7/
M&4P!20?';>&!<4JR?,O2"?\$8:?)WWQ+/*6S36A549N_UQS MO24/+%U+KCE3Y/?
97&D)+O+'D!;J_ SA,S!L+M2*INQJ#&AF'QBX^L?7SBA M_?
J\$!'XG@7^*^_<=))X&%HP(7(-";O*,<%X?
L=*YHP8CJ;'HQ^CQYF)"E>&*R0@)C>D@T5;J%N 57 MV.TE9!0-
0RNP0QA%H0?/ER2(R2LS",W;#2/+M8/1C9 K(4&B R9.XEJA\$P\$# MMR5_Z)8@1L
N>/@L?"VX>6'-DR!H/1J M^9 JP8^M. C)CR!BUW%?=V^ \$26((!;"#JA M>W_-@?HC?
J@&7/#4<1Z,.W M!W9Y7@2!8-FVO='K,C.M3@!T'VVV;'!WS; M-ZPU-BB&!
(CG^O\$A>0^6X!<-AS!&=0D!L+P=PZ@VWUEG0!QY?F1&@>>!^NR#
M0/#^%P=WDL2*#,8HB&M<+<#0<R@X!\$MF>.,EPT,(QPR;6C MT0=1G>|#.W
S,/"0EZ"/>:%2A*=CQ7,"*PHC4+8?.@C J4/%<@)\$Y#FA9?^? MT>(DEI>X/?
QN9(!X1C&P:@?VR7QA>?90L+EQTM!#UO @YI+X!)#0QMP"JW88 M_.";\$H%BQ% M-
CD#4FGHUUT! Q%QF4"CB#SHH8_T1=@PR8AF)1I6;B?;NB&ZWR <5-:86(E
MH2!*7FS1%NE1!T" VY_C2JV! R!-?H(P_F6&
!@U!!GX1D^5/11&>@X==;4O)S&.9;IM@)%3A K0EI(M4436!@)D@<7!
M"8L!G^&R6,207!;@*TJP+!2?'-!4U^0!YP3_\$O_CA&-QAJ'1 Z!_4=U; MM1\$I-MR!7)<\$-
D\$7A\$?/H+2_%R+K#GXUG9&7#QK@45E;YEX(V;U:I^P(QALP
M%1&RJL^!I:XMUHQKGK@4C0_>57!W><1- M""ICF%)X18W"!;R8RFVLLCVN:?
HGJ&8\$/5+A")P6&5,;6M:0!Q @?86!@M+5B0CZV3K,TO3BRWZ5#(P
DP'J^(>)U)>'!ZU7- MOPZN#*:@Y #+M6K-
C3Z,9:A;36O#EZ!OD5DU)0A:WSJ@;IEK@+E9/@OBT_&UWWMR,#IF3P'S")<2.#

&^\$Z@9>YU-TY+47;M0
M+G08F==I>W<\$&;H3WL_6DHFE^9W\$M9VB+7ZGTLWV_VOFM4_:G::ZH=[ZE<
MHB\5; &DJB0*QI! S2^D^D.+E?EM,Q=:B\(.00"G9U*2*HX.2;7E\5,F>F<2;.9RY\F%K
M'R 2\$E&F" X 2JA^OVZ05+T(6>2?=D7BP?0QI]?I=3?HLXVQMRY3RHMOJHQP
MY\W,^_+,%8."23*VDZYM2%7BS,'8E/6\MO1D_
MN\79Z;RN2\4C16N6JVDW5ZJW&S.>Z->|^"#7F:>'@PNSDJY5!^5_US>6-P-
M6BF17JG":.5;(JQ;GO=GHQ>6\$UO."+UIM7.=:D"=S8V\IYCH\|PW)(06KQ).\$
MB9^UNE)Y3H)@QM=:9H521N\UXWTU^P\?)E+IZY,_B^=^NR\^-V)5"UDE?L/
M9O.KJO TY)'F)R1W_%9NP=CSIB:1RWJSJS;.!@I8OP*[_5.'0V3(=[-L3UAICM M#HK8RI?
2RXLS:S;"TFI(HPMVE7?#.%U04#YZB\<:^_S%:ZFM^"+S2IT-/31
MTT%2\IT,>^,^>T>Q>&L*GSGQJDA5>E?(-TUL2--9?ODO)?JJ00QJ-(Q,-X MH2\|
<>O=F.6-_J0\5*P)#>NLLJ)?_FSELDQ\><| ML, INU:JBY\^&!T-3YIP>-
(:/E*^I^\$X^F\1WWQ>G;J07R9O?G\2GS*E%B8 M'*33Q5)X.<^58(+\X0N IV9%W-
P57@LOS*K4A;GWZ8QJ/C4R>D!_.|2K)"?ZWJ7:6-HO(PYP_H\|@8D\J"&PJE)
HJX//_8JL31K9004+|>H<(5R1:VSKUP!\$X C MZ&0TOE5\|(XFQV1Q?#2-)N/#CL5W<
(PX\#S'@2C4='W8O_"9IX-(VF1R=B M-!U%P\|E(C(^C:3S\#FA&
<"&.!OM\^X\WIGB^7T\|L0E.CDY:B7\$QKD8
>3CHL6G3M:BZ!1NH2P8",06NI!%HB'K<:9%?X5AD9@K MOU&JV\$;W0
M%&'74HT\U7OCN T^ZP(B9)YOP^NTB2W'2X:1H0Z46R"J^8.9(6A\8;H>|(A
MJ@LM/<'0=JO\&#|;+*|W=TOA5F\|C\$# MIX\JTG1AS:JVA^32_FY=8ZSU4D?IE!
M3E\$M("P&5=4CK91HXQ1NKN&3+-F*W._Q0K BW1%8A04-EK,S&T<*JU)JP1J
M=R)VR;M3U@P"EJ9J1UW^^LO@^BT_+R6%'&S(!8TQ7)G>(E+?,%VL:.D'E5@C
M;C*)&2<"!A@JGQ'OX^\$IO^+KT>G/+ "TL\H @WKRY\$L\XE.B2B:RIA707?JHM M:<2&U-
JS;,>)FN(ELFV"%5 M5QJ0>X,1M)3;T%.JLDX:2;UWK;A+P-|&<:N6%
(N8^"X"=1#94K*P"+J9\H+9,*G2>AJN#4DJV R\$M9I?*;N-3F'D"BXYW M@&|.6//MVK
VN@82EYS63&U@ MUL*R-_YCCX5\FZ+US^7- @ TT\$G"VQ,GC'R.T<99-^KV"
HFB/'A7\$9GH MW"]&P^>_ \$V\$"6;DKUI/-1U7Z>H@9\A 31PVNP8LJ**T9SXQHCJ"
(OK0I\$8%CMQ"/?EA8W.XE:\$@,&<|6@ UB@&/B %N! O;+ \$D!7J",F8%46%<#RT_K?'K;+
M@8T8E;09\8(-UU"AT/%ECD);Z1"K!-A^(?C87\$533Y\$ DX M%42P\|33\$%#8JKZ5Q-
:VM_%IFENBVG0-ZBM"!6-FJ: Z74*4WP_9AHF%-*U<7H1W'4G\0/P\Q)'B)*.3N;IJKO(MA\|
MM1M2H^ZDCJE,%:|RC\|RI4U:"WPM'_EB#G=,GI Q>7\|D5EF^*=*)720K G
MD%%:;\$&&IVM&V">J\(-V>^|3,N/(1<4XC*AUS;C*2+9X.+2N=LCJXPS2:9
MU'6DSG=,) 5 AOG'JU!2(:Y-GR9I5I@6,_I(R(T)\TH0SK@?-|D_1-GD9@S M2Z88.
IE*_9VX\!;A\$*Y.2<,46C7MG^*#!NH>E/C.1\$2NSM\|J7'J\!X=#PY M;4Y\$BXI?!WA#
(^&|""T1Y\^#N\$W3#DV_44S: MIW>X*HO"5\$72
\$Q\;|7&6)XUZKH9H6|"V%3%OC,|MH8\|@|BI:V68I8B8)J^ M!H81H ;JRM #O%P9'K?
J&#+3_(KCX+U!+ P04 M' !0BDQ::0+Q+O\$" K!@ &0 'AL+W=OY-A:.'6QWI?J M9Z?
M.FDK+XGOG*%0ZTF0 M!#O'+5_6UCFBZ;AE2\Q#^|6\T61%>Y:.*
R@-5Q(T+B;|+!F=Y2|>!WSCN#8' M:W"9S)7Z\8S+:A+\$3A
*+*UC8/1ZP',4PA&1C#|;SF" _I0,>KG?LGWSNE,N< M&3Q7XCNO;#T)A@%4N&
K86_5^C-N\SEQ?*42QC\AW<5F:0#EREC5;,&DH.&R M>|_ VSH<(-Q"X\T"TB\|
HFXCK_*"638=;|4&|;*)S2U\JAY-XKATAW)G-7WE MA+/32_F TB\|&4>6Z)PS*K?
0LPZ:O@!-4KA2TM8&/LH*JZ<\$>G8BTEW8L\2 MHXP76/8A2T)(XS0_PI?
MD\|L7_:Y."FU(HL\|(V=S8S7=AE_/I=P1YL\3 MN@X9F9:5.
FH!0SJ!PRF;UXE@_C#\$;GY7FY^C\WX61R"%GVXO\|V?K^R^T/M>\$R\5-0\QAI0"|\
UPD()ZD(NEZ,>U1J;.6I?|T.C\924K!;&28K\|Z?A7MD MO5NVIJMG47,F#+R&
(@V3\0MDC\!|KWOU_);1:E6@,%*?AL\$A@, R'>=;|MQ"6G>UK!4JG*P-OD'60Q!120#|
(D+WKWRC)!^)WXUY,TW X+/QJ\$;QP*-F M\HG>3B\|I2)#G^>Y:EHF-
U"SBL\IVB^H=X3P8T Z5Y;U3W>ND(:+:=&|!\$) M7:T63\4^:A*JI)4P"QP*JNMN:
|>MTS;#:R91E\$ENJ(A M IU_|F+\$ATT<(-ZZ<>4H>-;2=OU\MZ\GX2S;@-|AG=C\|
(K\|9<&|"X(&O>+ MDP\T-YHZPZK6CX.YLC1<_+*F:8\!:=#WA5)V9\|@-|O^'Z3\02P,\$%@
M4(L6M:KB>>:|0 " T!D!X;"JW;W)K&UL MG5?;MLX\$'WW5Q\N422
UK8NON4&.&F*%NC%FZ9;+!;|0\$NT190259**D\ _? M,Y3L.FGLW>Z+34J<,S-
G+AR=K;7Y9G,A'+LO5&G/N\ESU4F;|-<%-SV="5* MO%EJ4W"K5GU;64\$S\Q0H?
K18#J%UR6W8LS_VQN+LYT\90LQ=PP6Q<%-P^7 M0NGU>3?L;A\2URM?
<|8LSH\?T&F@T<*|ZJ5A MG"PI*)^=P5L).7.L;+C%U_KV4%XMU9WT\$%>RG+=QE Q?
M M@0LC\|D&7+K?LNLQ\$|AB@#|NV\|D8; R^C@XBO1=IC<1BP;! E!_#BK<.QQXO_
MC\|LKJG".H-4^?LYWQODY'ED*|A36_%4G'=1'U:8.|&|>/4B' U.#|B=;U. M#J'_>J

.PTUZ;[S:7Y]<_LG\$-//MZRV,FFPW"SV[FLI!IV/M<+IQU7+)D,@N%XA.?
C(!PD4&+M"=I.6A>U MXDYDZ!9(C%1RCWC\$HF\$<#% QQ[2.!T\$X"MEQY!:#58?
H#UB)=OV21=\$X&(X2 MOQH%T0SR<
RPE.V;6\|M7>Y#9+D2FW#-7*YT*=@;GDHE20LXCWH1.HQ2)-6>
MNI)%QM8FMN6;JXM7(IX2UV)!@-3F?6"M";"Q".>|2;XE^% MIT0L:0)-
C2Z*.&675C+SI"TX5*6PW||1W#W*J29_R Q27FH'O%35:#TML 5T MH6M\$MP?!'?
K%/>XURX07!(C7K+QGMB(AKWQEHF:-1+|X^(C?(f@?!#5"H MV?
UD6+)|C'A91@%O.5L+?0^JAOV;*ZH!EM2&??QUL)T!L;;2CZ"[9|E^+P>4@ M;.>(<(\$#RK\$-
)|B=M-L)0;X^F_XZIF/E=>LD%ON\$M+^!,KCP|L^A=0K,A&ATN< MP#)I*VTEL0=?
FZ#|"!?ESKZ":W-D?UI09L0(I7#!A'N5)(JR0*-B)3N*2)L M 280:8#
(6)M^J?.IZ)MHAEFK;*I#>G=T:B*.T*U!|U85:4(6:Y-AD\$KS37;| M.I?E?@YQ2*I&Q<?\$!;3-
9+-*!|VWE0I-X*J_4E!&5TD; M:(FPEU((T/NG*;(OFZCD2HT"i51L?
=QTKK61SHG25|#+C:Y7^:9YIMHZ,F6E
M=::;5Z+Q'A61->=>"NY=>|!^TY0&6FDR9'2%G?UDR:U MIT?%O><&G?I.=%H(L_(S.-
&*E&P&U>W3|9@_:Z;;'|>;X0/W*PDS%5B"=%! M;SSL,M/,W&PO=V|R:W-
H965TD,A+4Z0TC9K<5:??3?3"| UCUIVAO; M&TI_3WVLAO2D%2Z^P)>>^:9%S|SGN.5-
M_MDLBQ'YE4|J2Y="X_|1LLJ2, MV|.;2>%DKDW&'3|HF-S0SP-2IGLO-WN?B?
C0C7'QV'OQHR/= >&D4'1CF"VR MC)OU*4F|.FE&S6KCJU@LG=_HC(|SOJ!;-
KWAD'@3T\$KN|5F/T*9UM_JQS0|:7:|0R0|<1Z|X^!SDA*#P0W|C>8S=JD M5|Q>5^@?
0^R(9<8MG6GY3:1N>=(<-5E*M2ME! MK|F2PCJ=;93A0294^<|_/;*PI3#JOJ
0;Q3BX'=I*'AYSAT?'QN|8L9+|TO M0JA!&|X)Y2_EUAF<"NBY\50YKA9B)HE-
K"5G&5Q|BGE/29KVHQ>)|NW\%KU=' MW MX01?
PJMA"H_#/Q2BO|W59|+1W:G"=TTD2Q M6#(U|R_>Q/M=X|>B:%?Q|!_#?T_W-
JK>+N|/6BSZ?7=Y|IR>GIUP2:WMQ=W MMVQR?B3FQ|W\1-Y"X--I=:L:- M6<.
(ERN48Y,D*;)")FW5T!"NT?)^%?|_\$(V:7V_9J-?JQD,LWKT9Q5%\M+WU
MXEGCHU#"T9Y\$MTJ9^#7%APTT(EGVION\4A0I=\$FE%|;UE_?|:"2Q>E^O
M/SPQ\QN)QAG/A>-2 (3YZ0V+(K;HA|^1RW0%TI1-&S%0Z|T@NKV_CY6!|B/ M6@<'4>-
P;P0V')0&|Z.X=HO#8Z"\$T|/(ZP/PFG;4|C=2FAZ^\$6P8J
M68Z\$;&@U<4NI%;&||%2N'4K|)H+.=JC8?C 9TYRXU?&P|" M6H='|K\$N5AP8*
(4D\$,KIW<:|EUXRD;AX,1?>|QLN*>X>;|I^23)%69F0CW 4 M'8\$R =
|&|SPW/21:"G28"&)5<)>DAA>?1|JUGYM=G=CACFKW*3Y4;@:1=R M7=4^I
">|/#+V@;89ZV/TOEYSI<_VGJ^>#V(AO;A##2!8?"*X^EECI*ETE(O
M!;\$YN2^\$*=.2<^JO%>D_20U|T2 '"C;CBH2>|T!NUA30H?
%K;VV_UMGO#M;D(, &K!4T1; M,4.XW^8|+8R_X(^| 5@;XD3K^:ZHT;| 5NE!>T"LI!
MR*0_RQ^XD.%%0+FG!':776.4/; 95%W" T.Y3SDR5B"M#/GWJ?V.'S|B-I3
MVN\$B\$J)T\$WY2|?<TV;|GN_U@ "6D5F\$,1J_D\$H9[%ZMYD)^4 |RA>CL&?
MN5D(99FD.52|I>&@R4PY6I8?3N=AG)MIA^\$P+)>8QLEX 9S/M7;5AS=0S_?C M?
P%02P,\$% @ 4(I,6LUAO-'T!0 3 X !D
!X;"|W;W)K&ULG5=M;|LV\$/Z>7W%PVZ\$%%F6K<1Y!9R^8!V:M:C;|<.P M#
|1\$6T0I4B.I./|WNR,M17828|L76Z3NY;F|YX|4Y5J;G|;DW,%|)96|&I3. MU>?#H^BE7I:&-
X?5FS%9|SHW^8G_U|*P4HN+* M"JW|.758#8ZOYF00!?
X0_"U|3T#1;+0^B6*>KK3(BJ(0*_^Q^FX>>PC1Y1B'=*J0>=W#D4;YCCEU?
M&KT&0)HC1Y|J%X;P0E%19D|@V|%ZK GK3QQ#LI=#A|9H9YAO|6Z"7QJ,WBB%
M6ZU<:>&|*GBQ:V"((#HD:8OD)CUH\1W/8QB/(DB3='+ WKB+;:SMC0|&|G_.
M%M89+/Y?3P493\$R>-D\$-<6YKEO.K 3+>_O!B=)!<' \$XZ@)-#U@^D M_J#>TZA&20R?
WL_F|^&.:%66ZD8OCU8Z#3KVNA|@=W Y092+%>2)-A*#9E;@@=<|(*7-
PAIH_!\$(P@.&1KE#P@TE7LBJ"6V8MR|O&M_&)Q('35\$(M\$O'>U?
&&,P.86Z&+&#XK^%W?A6J!X\$=C|Q_ T56NE=H.JK5PI3\$@T:O-OS(?
5%K#8=6SRJDTG)*&.:)|6"M6"G/NO\$-<-E7((=H*-6\$K
MK*.7Z!=ZUBFVMB.H&V;AH)H>UV*O(1>8%M7Z!O?MKA"S7:X'2JU0^71-'F* MRKDV-
1&8MZ3V+;|%#B+|0T6.E2HH9C=);Q 1#VR3|/T?Y'|L=X>V;_C^#4= M!VU;_H?
<1;U,4.H)3Y@0>Y3 "0%Z(<7*4|Y" TUE^!D2,9/%SQ!0,&RH0|L M?
@.S^5N83M((MD,XH@'39V6.15\$:\$Z16:11M<(O0#138>KGSIB,-AC\$C3Z7
M2\$B|HB+N|W@ 8|+A9L!!9|:CX\$"K(>*7H8|YHU:YN51/ARR?UU HK
C2!Q09>PF@29WCF2^FO+RB% M6UD|.;+>4*)PJ5DM1>!8NF/1E|I>%&&8.;@-T;7'
MKO?R\$;^D0 EEP5AZT=7LH+&A;_ ^\$+?N4&=% S@WOJ61>M@2)E1NVTHPB1-X
MY;U-,*!7NZ%\$84X|MHD&|9KYT;M<#^4Z Q&UIP&I^&U;|5&-XUIF5/D.9T
M=7FG;0^%HB-.A:":\$/3#:&MK2O-@C5V-4SB MT4,-

7J5^;T%/S9)EW3V5L%FP^..LKV!AP>8GAQJJE^Z=.SZR=IU6".6NW
MVG#^6XYV07YH^9B"Z9F&|D..U&45L3=S<*/KL>,)KCH*480Y=U M8^#|J"HH/HG-
8!N+&*R;[SR\$?YD&%PTFH|1PDHYE_/H6S*\$LR>IS2X^GD M"#.+"O<.&RW^UVGTJS|
(7P M(|Z^LVZ960E%=-|SEJF+ALT&82NW"Z=I_+RRTPZV_ UCBYQXW)(#OEUIJ=D\$.
MN@_(ZW|4\$L#!0(("%*3%L.!\$ "F@, !((9->&PO=V|JR:W-H
M965TY93U14E*_# +5LB<;AS*G:=*R6AJ@W+N!;|?|W*:%99P5825)7G5!YGC(O#V"".:>
(^V^VUF? FHY+NV)KIAW(E<=>2U*&F6 MLT)EH@#)MF-G2JYGD?&W#E|S=E!G-IA,-
D)|X;.=.SXAA#C+-\$&@>+KD*AO00?P6OR5<|)4Z|@O^E&:8E;Y?^W
;M7RC2^B_7JC+L(1T83J??WZX^|*&U?3?Z>RQ
M)4SO%F;R_F&Y@.4_J^7=>KF&ED!Y1H V!%A# !*!YU6AE|B"WC/8"H|G/BMV
MUOVL(LW3-HJG@|ZO|T4Z"PJA9#J=UMA|P@|K|:|@BAV>Z&/1@^-:~@Y29"(
MW%"@|JSW?7?8|V\$0NL3OMRX""4GH#=#Q^%, "0N_,|GP1FG*3QD_D=@5D\$+MA M&*
51+X;|PA,3^WLE/ <=>=#B^/'#(" #|3RA()24K-)12/&:VE6\$G!47-UDLS M5:_K C4RT2)H-
F2S?Q1D.%:-BNJ7-+QE:9:0S&!NJ+9IX+SK1Y&Q2.@.HKBS
MDB*M\$OW,,"C0#6,")'9)0!H0R7#W20T+"KN, P1"\$48=CY;88,(72,@^/)|
MS|):#7|Z7Z34#|PHMAKW0BPQ@9LBX15V\$W|""|8=2-VRDL%4KG+"@6<;3'4
M|_9C|V1|14#+4K;|3="XQUBS3U>VDP:|_R^%4*?|F:|JC=@|@-02P,\$% M @
4(I,6L;F3L?! K@@ !D !X;|W;W)K&ULC59;;^LV#|OKR!|+DB G-
AQ>LEIDP"|;@72M6B|H6'8@V(SL79DR9/D MIOGW(^7\$)T4OV\$;2R(_?
00\$BAVOC/WA"D0/SZ72;A(5WE?'<=>RR DOA^J9"
M32<+8TOA:6F7L:LLBCPXE2L.D^0P+H74T70<|N|L=&QJKZ3&.PNN+DMAUV>H
MS&H2#:+MQKU<%IXWXNFX\$DM\0/H=6=I%;# M/R2NW,XW<"9S8W|PXCJ?1
D30H699P1!Y|P')5B(*+Q|P8S:D.RX^|W%O|TJ MY\$ZYS(7#7";U@UMNE1!%GMO"DW
MSL2@E+KY*YXW.NPXC))W'-.0QIX-X\$"RPOAQ71LS0HL6Q.:?X14@S>1DYHO
MY<%:;I7DYZ.?ON, 2.'&:%\XN-0YYB|! M8B+3,DJWC,|2#Q\$O,,O#<-"#-\$GWA;MAD.-|
|P7;RYAPOL F5<;1'^.ITI M;ZD;_GXKVP9K_VTL|H;C5XD;)Q&U@\$|A-'TZZ?!87+R
=|HENG^1^C_XRX^ M|^;W2#MP^SVMU^/^/5|>W|#%Y=DC7&L*D&\$Y1QM\$|H\$O\$,Y-
60F|!G*MA,Q!
M:EC42H&@|H|D|9V:~@W4V,X+G4N|A;!5&:\$=;!CBZZ=1FB8GW"X\$;:."S@7V+&3Q8)?
S2=L S'1;DB5H=:?!@ M@2|!:=|JR4(:2INV\$%N%+'TZ#9J^R#HCT,>S1G6Z;.!0
*R|=RVZ;PEL818,, M,CS>>P&SN|CK7/,E4L,0+@D?0C#|WFMA.URN-
|)2!0|2P.:P2R7\$:@W2\$Z|B M|TGO:~)CLS="Y8QH)UK)
(E;%A|FWM.C#L)4D"W;W9RP1>0(V.& K>>JOBG1E"
M%)=A4CH(;=* ,DW:W'<;GS0SZ:=Y,|IMP&0X4+L@UZ1|=1&";Z=@LO*G"1)H;
M3_,M?|94!&C9@,X7QOCM@@.T_Z),_P-02P,\$% @ 4(I,6F7-!3&-! MAPP!D
!X;|W;W)K&ULO5=M;|LV\$|N7W%0 MAR(!-%LOEF6GB8&DR=8 :Q;8|8IAV
=:.EM<*5\$EJ;C9K|^1DA6G+VZ|HOM" MD33ON>=X+SR?;J5ZJPM\$ ^|+4>DSKS"F/AF-
=%9@R?10UEC1+VNI2F9HJ38C
M72MDN1,JQ2@*~@LFH9+SRYJ=N|U;-3V5C!*_P5H%NRI*I^PL4|X=^(WC5N_-P5JR
MDO*M75SG9UY@":' S%@\$1H|?(Y"6""B:|H|J55G!_OD/_R=E.MJR8QN=2 MO.&Y*^|
M>|@3F'Y.(H\$(L>|5>187C+#YJ=*,D'9TX1F)|Y4)TWD>&6=LC2?*N4D9^97
M3%6|VF@X^D5J?0RWJ&!9,(6G(T|P|M HZZ N6JCH,U!A!"|E90H-5U6.^6. M\$?JR44|
A7YXN; MZYN?EP3WZW))<%<+6+XX7US!!=,|^S5":>N)G52Y;RB5_7M|FJM9_D9N9A7
M#1T%J@R*V=S2P#5D3&2-8_9SER8Y-#5E745UA5>9+'\$'? "%W3\$NV\$H@&F%
M%#DJ#7+|0|-.;_CN=5S#Z9 V+K4HS6|(Z@-0M64*TO_8TDJ2|JPBC8WP|YP
MR^JSUN9<=U0)_FOM=8@'Q;_24/^_LI0*F)?<;UD&1R+AJ+|GV^)R5|AC|^
MT7=JG|NR9M4|-(8+_C>1LYN&WA#=#6_5&9F^A1%/(W(&Q_"|J?/H|+(9U9W M
M#1(M)EL;Z0\$ 7*_I17>P(?F(OO&G|^!,EJ>J^R ICN>,KZP>K%|K4>#GZG
MZVM+'E#!0D>/BM;@Z+HB#K+1=)0NU=8P.|1VB. H/|!<-*6|**E.!C??DB<_ M0)Q&?
AA/:9:\$,S|,4IH=01S3-(CA;_E*#R"Q |F4SBF63B)_7\$0M/,H|<,P MZ7
>LR+5D|0/TL#.DL1/|5A,06C24HREUA)>JA:L|H|_>%D|2/9Q%)WY\$ M-V;9I>-
H<-7|KG>GQJQ1W'#4)X/E(P^%?IRF-:S&)X^F49A|&RP0*KV/+,.,
M6GA79,IS:3QL^@E31T/V|LSP)RVICB@GR6^E/"_5|<|JFV
M8|37%'*YV;@6F)XOJ|WM\$ _O=OLL^;YO+A^_MB_Z2J0VGJQ*X)M%~@F"8>J+;M
M;1=&UJH57\$E#C:N;%01/ 94|0+^O)051M|_*^O|>|W|4\$L#!0(("%* M3%J(<#T**P0+)
9->&PO=V|JR:W-H965TUZ%K |(OL-%EB&|A;D0_KEB7MAF'8!UHZ2T0D4CU2?MFOWQTE
M.VJ:&/LPP+!\$|>ZYN^>=R.G:TJ/+ \$3ULRL*X691|7YT.!B|)L52N;RLTO+.T
M5"K/2|H&KB)4:5_JBT\$|^X#?8HJ2|1.&T-\$"YGT?GH|&(B|D'@=XUK MUWD'B61A|;L;M-

9-!2'L,#\$"X+BQPHOL2@\$B-WXUF)&>Y.BV'W?H7*L7,L M"^7PTA9_Z-
3GL^@D@A27JB\O5W?8!O/D>EMG#A'!:-,P6DHY6L,*O"ZU
M:9YJT_+043@9OJ(0MPIQ\+LQ%+R4E\IV370"+-:(20@W:!)PVDI0'3(RK M6<_/'W)%F-
LB17(_P?6W6OOM=. 96?8'28MRT:#\$KZ",8OALC<|=7)L4T^!|
M\NS2WJ\XYI=%?!#Q"L^C\$<|B(?QY #>>|_G.."-7!%K(H_ SA?.\$Y?"WR|_%
MV4!,7H:0\CAUE4IP%G'!.Z051O-W;T8?AV<")SL'9P<0O_/B3B,,IKTX>'F M_/ZYM=?
KJ\O'ZI.8E'QV=P_=07VR\ 0C "IUC5E.1P*L67-4^MMZ3_T2;KPH*W76E+J39B/^
X,=.5UMS!_,LRPDQY!%7:VGB1JBM!>@N3X;_MY!XI"FGW\HA)BMIQRXN,
("P170\26Y;:R4QA\$P26;1#@AH><8Z.\$!8.G NCJ M). _XYS\ DFP)GD>2;(ZD3
A!QETC:N\$'I'-.3<5Q2,09"|-W!6|_%6VV#M2:SP0/'QAP/7?| | ?LB,(@IPZG"(QDE,Y6A5^B|
M:#\$5E25?&^VUL"T+3\$5Z01? WV>?&\$B0X.DBIU^8DVJ99*[AKP7>._%!P.:
MI3FCFE08_&DH%P8LU186S'KMA"D.G/?.L? 7IM::MB'0I'4\N&JIEW!;E%Q
MC005GDM8+C@5N\GT7:=T4I8VK;'1?')@L87C_L_[VF02MAQZ(Y#KZ!6C\$E
M&3Z1^1;BH_YX#!5K!I@>^ ^#X2!+?I6Z)UH-MW?3CG6GP>_M69>6-
88IX6LR#:CGRX2K:A>H9A0\ABA2)O6WXT51CG<'5P5S\U:6/
M.J=HB92%NX)C7UKK=PLQL+^DS?%4\$L#!!0 (- %"*3%ID M&=SC9@P %,F-9
>&P0=V\JR:W-H965T:7I@W@I.6V!\0-DNTN#H?|0,NTS:TL>DDZKN_7WR0_M>K,=-
VF#^!|&ELCAS/'9>68HO=HH_=4LA+#LV|(HS>O3A;6KE^?G)E^Q3>A
M6HD2GLR47G(+/_7\W*RTX%.:M"S.XUZO?|HDLCR|? \$7WKO7E*[6VA2S%M69F
MO5QRO;T2A=J\HU.JOLW.A|M6*S\6ML%|6UQI^G==2IG(I2B-5R;28 MO3X=1R^O4AQ/
_Z08F:_UPPMF2CU%7|F+X^!:%"HA"Y10D<_MR)-Z(H4!"H
M|>7>5HOB1;UY7T\V0\V#+A1KQ1Q9\R:A>O3X>G;"IF?%W8&[7Y37A\I27
M\+0_VSCQJ;)*1-B/R\$FO=U"i.5;:OGE M*ZTV3.-HD(879"K-
!N5DB9MR:S4\E3#/7MXNN!9G:->4O5%+V&O#T5VOSBU(
MQS'GN9=TY23%|TB*8O91E79AV+MR*J9=->>@5JU;7.EV%1^5^%;D(4NB@,6|
M.#TB+ZEM34A>;E7-#UO|<38S7@Y#^'K'>RT\,R,79> MFA7/Q>M3"
XC|)TXO7SV2\3O71S1/*TU3X|)?|0N'95T6,\H"|GM;^.;=V=7 MX\MW;|F;SQ^OWWVZ'?
X?,GUO9:>VWV\AM>":|0K"9*B"|93EGED|*P4AV M:0TS+#"X-
BC"KDE%L88RS\69(2:M:6@BN@*EHL,+G<"92KEH(|+Y0Q M+UZ>_ \$MPI4#;
(B.1\$:87CR_ N\J8&))@7A\$K|+|'_XI,WREA<.:|4U\$"(MENL90&FM00JN"(I-V:|L"P:C(?R-
HB#)\$KSH!?\$P;|D!W&=+YS\X@ZRY8I
M&0^#WC!C,4R\$|7\$"HT,>AG>2L&DE+U=:XH5P/67&"8V\$,:P2MP^\$)3\$6,12\$C""@_?
%|S.N M?M(PO),T R_5X*(K|@&N\$_?57O#(8\X2H*-|K|^%|7(E48%N?-(W+OX4-|!
M3BE-P1=%U5\ICQW08GV=>)QP@M>YH(15YGP_KQR#>,,914?WVP!ZZI2W*_|
M"J:PU5J;-0?X6,4V"XFXVG-J(1)0*5:|@|+_%EDT\$JK;D4_&2-(Y|T9#=#6I5_
M99\7MO+C!U"U)%"A.:@%:SI=NEY|C+.\&FHPCO!M>A'N*VXTZKK@YH#F43Y"
MRBEE1&?%@H,R\$R%*TCU@D\5UV'4S2L5F:PVJZ6I"#CY1&N\J)HH!Y+8O'Q5>A
MEP+6+7(VIE:AT1"0EO8*2KI'^238<4JOZQ2:O:|<_"O/M/"?L/FO@0G%\$-?*47_SNQ)+
(AP; \$RP#E\$ S;\$@D*]=\$WUAO:L Q M9O+5| # MY:B)43LQ@;*\$"VIP=K_A\I"-|:&"@":P#?
X7#<)|13?YI"QZ.P8JFYW,MYABW MG81R.&IHMZ:(3\HK#L*M!-\$)CYIO;L*?*JU^I-:
M>1@Z|F3PN7_U)/2U/@NR:XAU/(G)C*,@SJ/ZQ,HQ'83H\J01#W@4!28S5YHB|P.>|<-
"YRNI_=,T'@1I MSSU_^^\$@/GE?)7EXGL51T\$L3-[S W>!? K\$ /F5^GX*BWIR?
5+'71"lJV@H M.Y5|%(7|PZ7|Y)!*W7L&8!R*(5!JC,V<%3 H>L,A6B13I6)!2-(B0K%ZS!
MH7F.G:'M@^#6 H" T4\I20#LY3S%|4_Y7'G@QNR,'U %OR!/:04XW8C&899 M|:_I-
'8TK80V1&72\$%-LLM!JI75CKJ?%.AR+-+=MH(69*HS'(>_??T&|33F M/E'1YVX;:=>+?
EFGTP"|&Z.E;:YD@H%U,5U\$W@/*|5J/K<+;|E M0DR=E'WX-WV>M\!LMN:N 5ED+\$NL?
^W^U?M2BX|_Z1#_6-5E=OSD3 M97=K)H*UEH'R01|'!',2!5%3<1!6JP=-R636R-
TTAZ%CJ"Q:"8T>9':R.,G9 M<7/|Y9%WHO*Z MZ:|>\$IP?
2O9>3#2%R4'?/T4CU+0FA\87T%VT9=R5YK>BE- H_(&)^QH P4_+%?
@J:SC|0GHC>T.\$QR6S\|E M:75UU:XZ!51U&+B0((#.=&%5:&8M\|V;0:-2YI(7 ?D0.
<.=YYZ# C?/^')U M;:3'N<:|H^6W.=I;HPPIH%(>VB3H.U"BRJ^Z-0"-:)\$XAU
SG&|M#ZZ(2#+/L|N%J+SSA\$J> &#&#@|@H4^HL2"/ M4P5_*'75Q_#"AKOO?^|?
C_:/^B>*NL>PPEM\ZF08\$(M\$|!&5+-94SF3M-#R#N_?CVBHUOW\!|-PZ
M;|+|RT=7JW1>D;F7,Q=MX?UQC>Y!#" -7CH,&Q;Z\|V2ASU5
MD5,8==2_':^NY\$K@5PH/PU#@|4:PD.&0.IMJV)W&(NT^X TMG33+JA\G4!+A
M'U=HP:?'^+1P&B;EQP2C-Z6IBQQ@NCD)|R)DASX;6HZ -UTYP^9S+NJ-5|M AU/?
K;^8&KL/A9KA|G.KCP 164+1*68P%1@G.V7:?'<+D?EBUHL^&)LI:M:3+ MA>" :AP
SV=*V>H'+E!_1W;Y/U!+ P04 " !0BDQ:C19B"),/_", M&0 'AL+W=OSMNR09,_V3LP'L

HD,2X6JH\$JT=Q?OR\31Z%X28Z8_6*+54 B M\WR9J!G1_%
M!S=ZOF CIP>FK%XV'DW.G\U^2NMYP1>M M5B\H6Y
D4V.^TH^KIN71&3&D*E6T1\$'BOWOU1E45\$0(:?P2:1^E(VIC_:F_M8\ DARU0Z\<94_!|ENWAY\,N1*-5,=E5\8U9_4T&>"Z)7F,KQOV+EUS\H4@4 MG6O-
_FP&:TM=^_EMZ""_,O9WLVC_,&?,/M#V(NW\I6OGIAS4I86@UJ\>+MRKO!G*
f)*+>MQ5N-?>TK2%/)J:&2E",FULIZKJ#TUKTX;4&?5IT6@=9K3VN\
MAJ;Y6'PP=;MPXK(N53DD< K&\$G?CR-WK\4&*;U5Q(IZX3*((>N486ZN41@L0I>Z^
M7OWU3^<_G3T_P/_3O/_30\2_TUJ':9W_=">?'S_?O+ZX\WD\NK+I9C?9,00.0=DNK3
_K%UJ8GT MU(:S:#48=;WR3MA&F0DX3=ZKNE,LTL!ZTM9L/'ZSQD^R*
04(,34<@I%Q##C M?
Y^P!O#*6(!OG\%A.*9P#9X\$EMV\$LV;6+'%8S2'CO!AO_:IZW^&8VML=%'A
ML+@SE2ZA\+*WH7 M'G@/XEV;6CO)'9/U_?S,*CGM9\H0M;M(9^4".Y2N<+J
M*0Z=4D5Z)OXN:^=4+:ZNOUS^A&WGV_O+J^O)Z?_??GI_=7'ZU%\<7=S=?T_ MD\
f\LO5V_N)JR@|.IODW>_7\Y,3E_/KF^?G\|E/D.S%@N\$^E94\7P4>D"
ME0S\ S*UB;KR>PN&C@<%@X'M-MHFL><|@%X3Z1GSTUJLCA=FA:T6M3=Z.<<&
M%\$\$)Z9R&-NM"D2:C7YG9X*Q>@TM95:*1MM5%!1\;2+AEH;J6:2%Z&|-%A1Z
MZQ%S@++JQ+6LS1N\QF'58,%JH1'%*ZSH'*3),@)Q4)EZ?DQ%&9P/4;/IA+F
M*K'P4JBQ1 FL%%RK!HMR\;W*_A=5U37&.YLL%AJGL:H1?X6R+=04.># '>C6',BM68M
MJW:=Y(CZHL" X8AIB9>4C):4HM,IH^/1V**Y\$8;/7OYDC7P_LXB+/J'8(
MT/7Q='T<_B0PHT,2&1X3.5%_*=2@|Y,+|>B7@,C.EE1TH7\$X%M.*W8N)9EO
M3Q;_ZHI-H+XU.N0ESH"PN?2"M>G,D"_N41=0)"JIE\ETR\WC\G%Z\$*L/O/M'5M5J-9
MAN"!O>J9MJY+#5_N."NP%4:PR?3?H6BQS=?1QL.H0/K;='K4Z34%%\$S5%;Z\
M4+AG+NH=.#AHI5L\#QYEZ3DE)JX&:3@P*=',>81!GK9+8,YVP7TN#!5&7Q_
M*S./H***<;T4VFR&4<2%:I1_[?K4\WC_#Q3TH9J)C/RC)**&4SJT@ IFHRB'HJG() (DZ\
LCG_4#OR5Q90;F""J# #CX7K,2S;0**H>^(E\DM:0) M+_ %6?0.5%=2L!_,
<+BU19<3TDCN%4\(&H! U\$W(^H_:SU+\$\Q?RWA_+19&W M#;CIN>3)1C&
G+LJ640#K;QF)!82TD/D0)FT'I1\|@C@12:JM&A(10-2!KX
MP9(9)1239W*^JOMFK98>QT \P Q%9#KBE#40<== %GGH\W%+FAE4.#.5=I
MKK5>YMSQMIUY!COD5F1*+V D5"@.+D0BO1NHVQ!09! M\62FN4N\!DTRP5U4P\
f;+9BZ6*.2EUY^5141" (-XAJ0?\$" \$H[V<=P"<70TV M A#>)YUVKE-
4X=|H6CU924LP""F>&TFV@U5PI#8Z>DH4R63\$IT7EUM8;EP6; MKG/_F!G
N5HZ)RMRE9\MO+5KX+U6T5-!%KH^|H-H!@YKJ#4K\AN92-3#=?
MB\$DW1\|H\4N:.C1<1DQA;/0&= 1Y82-XB.SYZO)V\1X_?8M>)30DJ9CG*#A+%<.8
MC&U4R(.J\WD&:9)^'0S:79<9%@ZG=FG8_ ^81F(K>|H)PXJA'8,JPA+ M\$^@A\$C!;F
:@TZD5C1*HM0?RZV R@S\!/, \$*P7AR*"P),S*;"O>#14W1V9 M9LT;8W;|YOI2H_Z_K
'GH\$^X\|S.^>KM%%C>IV'=[LAE\ID!_&>J+VT9C MC/CIX"\$_)OI\$+CRV(I9AF&U98S-
MF#%C57NN9I;?)\|>J1*'V)D)6=/(!0P
M"L@MRV>46G0OR2/A9\$49D"LIP\K" T#AK'G0\F"4PO/0#&,HN,+G6/-QZ#QARI;(-F
M#PQDA\$6I P6D\|D*|^FO@3\|:%,X5W,>C_ \$T^R M.:MXK1;JB4H\VM9RI%X9VG>-
!*_P1OAIRBBK:S6E.GAMB-QVTA=H\G.YUJ3 M^A%Y9=F.>HS\J(T2Q^V)\M\H,93W4Z*%4
MG'S\|#UV1"l;\$\|<>%-@(|4"Q:7_HV\|D)2G_>TIM^N:|L<^
M9LR(F\LN4DDH2E.OEGBG7754)\2ES:Nf52\J<0N=!,!)\^D\B(X2&!Q>*Q=
MGY4E&13::RD5\Z@|5' Z.\$VH.DB4A:_L6WJ-Y3N;) UF(J%J9.?A5S8R2RQM
MLL#EVD)\K# WW>5-V2Y2(BCG75\$/AE"\GDVD-SS!10X5'5
M@VG_\$>ZPIQ^&O0\WPW104MWW+?%/\@ZK B*(O,\N-DD"S+3U+3>96)QXJQ<:N
MT"G_Y+<C=K>\H)\$2H\|@/S2HVM.'TMS"-2#7X@>H\E3/'23L>EHV"FD0TJ=| MXY#;I:"G?
3!S;|&_,|T-P+S#<0^#M97I*D)+A:6A@(:VVM?E(KD?CCX5)^!
f61>_R^W1@YT)0\!V)+#&|;NJ/82&_?|SUY?.'RYNKN\^S MYCV-
"1GS*8:2<4(7#N#J&CC;V=|_|L?^C\|#"GMF.I+L**)H@B'2+U*H3I1V7
M'%D\|>^!VH\^H&%8DFHA3QPW@-M?!80(G0I8E UQ9\;?Y+/'0&52R82MNV;(K
M\$F8U:_,\VJ#6J1\YQE8?6HA&&GVW21ZA?(I5*.&>+D@2JOM+?U-0\H%Z#G-
M)J8Q:#Q83AZW62=|#66NXBMJ#0L8A#&^CI>*N@ZUUVSYU".8K9_?@.\$!F\G%
M=RCY_T/(\Z(&%ZW6\$Z*(Q%Y_U6YM76#6Z3\!-W04/@QH4!1FFZ:W@#M
8QEDRS;IT2)\PJJ%V(2,8+LJ^+2'=7L8U(703U M#,>M.0YP.|Z8?
R9E1H3=X8Y,BB\B4;"L<0--Q8RU\$E-4SN>+W/5HW\$SJ^5!
MV\X\QP)^)9WQP(^P=+H_@73YC0#?Y/M!"2V@KG=\$YG2*IX7M(HSJ"!EYK
M=V\G:>"21Y?)L2W%PG(;6+4,-DAD\$Q"E-J\3Q4Y1.R1X59K)9-8\3O_O/K\$8\X6FS.
MDP_|<%T\$W 0% /1O2!Y.9/\&?A\;8E+|M0#5_-'##+>KD,DI5J:/1JWS8!% M3M(?)

Bl;XZY#S7X>)>O#ED=PBO=7L!#5%UJE>/Y"61G/86_)^SC3<[NX_(fS
M!DV/-,\$0\$#6==9WT!#S6#IS3!SLT889;16U_TT%?>M1NOE_7%+F5SLRG%+Z
M%7YB%>^I^_,@^@S2>YITCAJ101"M=T2:0F9JT>[R-"=.HF6J53]^KV=Q@_ ^M M6-
#W.#X,ZQYRAAPR0+?^6PN^=,@KYC;4W57\PBC%#;UR;|W-[VR>;MU--96*
MT99GW\$FfJ BC080-NH9!.(3^XCFD)>Mf_D!6L1/KWRIV;I9_@K_ ^+9Z. M^S SX4!
fGDW0HE\$YJ^F%9""P0*+(9ZAL>.GQ0%:Z7_RR MHN5%W?1f#OW4N?M&6M?W>!!A5-
;LPTUXNGO@NON 6&!)99IBQZI'8GBYV)'1L:f7_)_R(^6=1E!#9H+VQZ^O>T^Rf; &3&.7H
fCP*|YIHIZ?I_>) M_ZZf7^Z_CO|@f9R&EY6:8>09R<|71H6|4=K&O!*>VI:X#7^DS_Y?
_1f02P,\$% @ 4(f,6E|f9<#Z\$ 13, !D !X; "|W M;W)K&ULO5Mf;fO*U?
ZN7S%PTUL;8&2NHf0-<#;4 M16|29'D7%/TP(D<6;RB.+A?+?
G_ f^YPS0XJ4*=Mf;@LDMBS-G#GK5"f/UG6f?79^7B5KM9'55&f5@4f6NMS(&G^65^?
5ME0RY4V; M_QWW=GY1F;%R:L7_
ZG|M4+W=1Y5JA/f:B:S4:6MZf5KG44FSC2JJ3!>B5*N7)Q?>Lj<%_Y6f7=5f M+4B2f=;?
Z8_+f.6)2PRI7"4U49#X=;W>J#PG0F#C=TOSf#N2-O9?Mf3?L^R0 M92DKf4;G_YVEf?
KER?Q\$!&HEFfS^K'=_55;>B.@E.J_XfJB9M4%P(f*fJO7& M;@8'FZPP0^6-U4-
OPfPjLL&W&WSFVQS\$7+Z5M7S UHM0f4=)J4*,7+"KO!G-9 M04;Y4f?X;.. ^ ^M5ED>B-
\$E_EC:f>G->@2.^?)W;W:f;/f/++;160NJC7E7A7 Mf"H=\$C@' *QT_?LO/-_f>BFf5;A6:fYPC?f
<-fZ 6=? '3"QZ43fS-JB3755_J M8^+9567(fA_CLEL*
(;C%"E*GE5;F:B7)PB#2f77ZN35+W_R9NfS>_@-.Wf# M^Z@_:(f=W0Q5%Q^> //QUW?
BZf7_O/LBOJZ5>*W6UG<_O*GN>_%SRN0+?5U
MOD%UNE2%6F7UF4;TB\p<7=/18E7JC4A@VZQHfLN)* 5*27%4T;M55M65T"M1
M@_Y*YPAM+'HV^5fE2^,*
H94FZ4JR9B3TfL"2W53R2*MSMBVf".@'fXXf3;fL04f%2*;C)Q1/A1\XfL="/B5"SFGCC#*fJSO
G"+*QJ M62L1.GZT\$#%."fW0f2;7fL-ZV-CQ-?.<>!XP@=AQ9R\$6M-TO(fWPHf*
H&P2KE#V IMR09'R&(/6*LS* UT%."f MY?E:YHTTB8'<5Q;) \$f3\$;OS'R?
(*OZM;)*JD=|f&5fJ)fHU0\$>RJE1=,>T! M.%605GA++&_OD8?9Gf|@2Qf33MT@Z5;*N?
J,ZZ,QfV71P2(8<>O=-9)MM MKf!;R;92%\$B>B2ZWNB0719;)-
LV&&>\$WH#\$0\$G^FHQ+&D@SGfK)ZS5"@fRR5
M3*"fLBIGV(@R=7L%&MR@T;L5Y+M>L8@Gf(-WG-# 5Jf M;f;_K.
YM=%+3R\$5*2EO4JL;f\$Kf|+/4RRDYfK"?>G<9fWP"03/fGZ0>PO:f MUFXW;%9US%Kf,S#
f300@9W<-X6V>A US(+L30R+O(+ (8TU30(fZS)8-;8EB M#fFO0f
(1>Z,N+;%#S+fJLLS1"_BF@FLH^'JP;>WU\$@TV808@4WK0E\Lf;X5@R_ M-
J9;:GO53<6;9M/DD@.D*4JUR>f#ODSVZ3-04Q:AB-U"LIN,H@#G/f1&+()A& MG7X1.R/?
VE8H2fG#Y7@f; ^C3-2)4H_P24K/7.LfH=K& .E6WO)Q(-K?
+f!O(4V8Uf#;f\$&EB&-5<9F#G49>SOD8fD'Ef17 M.fWD*8G8'fJ-DNZJf)3fP\$.
(1*S=#WG;A;&&900_f49/WGBBM*fP;H@ M.#YfZ0(UR\$BETHKQ%J#.' ^40?9EfOZ_9Y,f/-
EfJ+&HF"XA\$EN4Mf|+F394fZ MG+N.fY+RO 5JfV@^ ^8Q4)\$Lf@ (1Df|:
fD>DOQW!9f!%16U'HP?+KfS-KE(fDf+R M1_Sf&)4YfPYDfLS29?UO#H MfH3?
fZQAD#91&,#L<4 \$8S^>?.WfB3fSYG-?^+'C@132?JO M@8);1%'-RE&-YE1Z;F
fRXfQ#S5JZ>4E.R)X&O f!(%E\$<*f M%')&2.fIA%f%KB)#VQGG0*_M4A-
05A;PGG#EO\$&'3AR.. "N>(0EC'LVX2A;Zf M/HfPLOfJVS2ECNCVLP0KTU;W-
ZX&KOY;Y(5B+U^HJ*fPJ&CY7X9.*; O fT(H4G M\$)B@LH
MR_ P4BE^Y:257fZ9M%WO12)D5;O_ 5*KfV/D;#"1U8)R+<_ ^S_8;f1&0fJWCf;Kf.*>;G
MTG5;BW*Q>_><'K<9N><&C=^f|SS2=8(fKE/fW+B%1B8f|<<;G+T?J&B.";&P
M&Yf8GfJYSVLT5C*
fHQ7RIKMf!%E525@2;f8WX*fL;AE0)X4fJTV)LG*fU_HU;W)2Q/337f|@7U')fN"
M&WCU:f4E&>4)M%%HG5K4P5XfTf|f3Gf|.1f.%*QXX-fEM9KRA5@EQ6MA00f96\$
MF^8\$2KHRH7%_4'+\$C=&Q"BJf+#9S?IM@6/K=6N=J" ZLfS9CD_@;762U3=8_
Mf!Q\$4=%+fWNf|f1>B#2,R &Q>-f|>3 MH?
8&8W1'&\$Sf|_@X3+W>6VF@)PN'fPZSNcv#LQ)<4JC(&\$K10L+fIX1HHC>fL;
Mf';H4NKF:@VY@P69)D\$>Af7HV,QHG\$X>3;S;\$H/f3N+(G'K(*Df; (QOWWDA^
MJHfMJX^f6C?V1\$>3@+78PP-; >?/X0WM3JQ* JG;f'&! ?941VfAEJLR&fE+8T
M#F(EBAfHfQA+>TM'*\$;K3%N;JfX22/f7LS4C,fWRN=ZD:"M(*JM '0'6J81&J M(K?
fBQ8<0\$&RO_+H/D&fD&W573URN@91;A*UK;F?2.!6DF#33*5&fVf|fC+D
M^5.Z^!Gf^N\$!VV"0fJ5f!=PZ? 5M'3LB=7.0fLX6YS0V<^8)f\$T?
G,fSS1CB9^QZ;,>;O#%Y)"N.3&BHO;2# M\$NfM0YfF%YfCN3X4
+f!.VE+5SOE.@S,1NW,S.(DBS^R\$/'"?f! *8C# 6GD&0 M>#\$7?A"!N84_fWPK6B3B^U-
=V;+V5,QF=G 3\$ "fS0Q8_fCLE8Q4L MAXO@CV_BVWMUJ-*) KK?_OR+W&R?OVVQ

GV/_82FM5'KP/_2+?KD MW=W@/I&8 N#^S8:8T@J&7LVED7OU'YL+DX)_:
<4,WZL>AML@;NP4:7*-P15+3 M90Y?^+(RJ1SEDXSW#L-
VR@X_&@GVU@/FQN%/L:;,>)LBE"S:6TAS\Z">\G4W M2\8'W>
/BK=UBJC1*_=>L^HOZE&MY#CUIT//!4"=JYJJ0KS:[JTLYN./E MML*+|A>5A|U8UM=
(.^\$P|S|T8\;H2M4\77I3\$K\;^M|M?6C,%#YH8&.E_07\ M3UHW&AS8WDSO+34R)_K)^1
%ZW@86V.@46UJSLC4_#'.9<4#P88XN\$%39 H) M>L*!P71XH\"-|7#/(+E0Q:*\$BEI-
#0YUYL,L3L:AV>6SAU)P)?N^9:-&/8A M5I9^4%_'"XQE-Z4VDO/=ICF"EM |8J*O"NX6A|?
TP^+B6V_AX5"<|C|>VWT3 M.^%V|@A.8^"Y\$R!=|&;B@R%#+K=F-
L3#M(3K:N."QIG|52P2""PD)NR|D@- M,F00%+<|R*U\$&"Y^:#?/&>T#:1:VHX5|7%Z?
Y5W\$P1\D+UUD!C\HL<'37J)! M%OYIH:/Y<:.\$#%CH.%G^8T(\$|^UFAHY\W--1V5.:092;C?
+4W\^,1-?;H\#^?ML-@V(<
I\$'4L0|A;A|PG\$ND&GHD*)1(:\$FVY1;"CHYZ@;|NLHK1Y3B_W)"W M#T/E/("JS?
26GBRRK >-'RK&FQKM U"ZG5U|QDL?NC:J+BM!C@QJLK<2)I
M9R)H=\$OQ:YG_=:;YCH.L MT^IU.OHT|D;^9O@G" W6((6F|45#JHIV(-
<^(L:EW&E;J?/@CZKZLW84,:3" MA>8U6GD>0X^'7_=8#Y\$V"F\$8WP|AX/JKK*
(G/XQN2T4CV'Z1H6YD6|ZU-NX|*731<9C?.MT37T=&?
M9\$YMY+V)8R,61_2=#YU\$4Q:VS!V(XKOHXG3! M(S.:&7\$=LE16()6VKF-
67P\$72@8"JP+Z#HB|GBR5?42J*>UJN;J5";L?8+S7
M_JCKJ70Z|OC|>>^K#1M570\$7.'@67-3F6P|=N|UW1"|L,5R/VR\T73'Z5)0JD
M2N1JA:WN-(Y.1&F^M&^'J/66ORBOU'6M_-QRK22BC!;@|Y76=?L"=|J<^;5 M_P-02P,\$%
@_4(I,6N1P%\$XO*!0 |PP |D |X;"|W;W)K&ULC5=9;|LX\$|WKQBX11\$#;"Q2E^4<@),X76,3.
|'3;H0% M/C 2;6LKB2Y)Y|A?OT-*=I(VUXO%:[|YYB2|?RO5#[|T4PL!=653ZH+TT9M7O
M=G6Z%"77NW(E*MR92U5R@U.UZ,J5\$CQS0F7199X7=4N>5^W#?;=VH0|WY=H4
M>24N%.AU67)U?R0*>700INW-PC1?+(U=Z!|NK_A"S(2Y6ETHG'6W*%E>BDKG
ML@(|EY@?M>T?|?;|_ U%|?ZT1BL)=2_K"347;0|BPA48C46 2.GQMQ+(K" M B&-
GPUF>ZO2"CX>;|/G>UHR577XE@6?^6961ZT>VW(Q)RO"S.5MW^(Q|H0
MXJ6RT.X7;NNS+&E#NM9&EHTP,BCSJO|RN\8/CP1ZW@L"K!%;@CG>MR+\$|X88?
M|BMY"|J>1C0|<*8Z:2275S8H,Z-P-TB??CI XV|O5>X M!ENNP60H|PO(JQ#/\$Z2|79@-
OYP/QYC|1?8:;M5=7W;0CF5|9;J M|9)9"N"97+EE.8?;
|J&Q/_LQ<1M'LMRQ:M|R#46Z;|UKD0&1D*6Z|206H#. M%U4^SU..*G2C2MQA0|%"(P
WP)5 T<6ZX*JXAY62-WE6@SC|RRU450>U%8DWB58?FH*EP<.^75^ (M2BA>N#'/L-
ARFR.V:VP/|L(\$>2F<&Z\$J/NK)F=0BF31_,SZ;-J|_%5NG3H
MF;C!=KAZZ@^| (9^BHT'_800;JLVKE|3F55JL,PP7QBZMX_A@%'J|^GZQ=B|<
M%K|K5&=K;|YSOGXUBM9>KF'NDD;W6|_1RKH1):Q**^1-I9R;V=484CE6J,N
MW7&5|7+) _K#6=/AU.+X:SOJM2VFYM4BORZL=5H8|.)2WE9P;|OI|^\$Q/\$J
4DA|Q42J)"\$V" MUNBEQ.NWAN6JD/="?:BX 9=1VE @B0"RCJ\$|1A^\$R0?
MB9INL:|2N_Q!&&> M/4:8DMA/\$"3H'VQ6:5Z' JWWD.)XQXRPDFO|58%(\$R\$5Q%#T-
I%\$8T:;U|1 M"@+BT1!HC"1U!5')\$1EOOUT 6<1L-
@C/(<|^&;)BK5G=5|A|FD= <_KY+@1! M\$!%& P@2C| P #|!6RAM?
7D3&FB2\$%M1|ALFF"@8OC#P&OOU^TE"A(8R|)\$34
MPZB%\$\$(D@|_&_9ORW|G8U+&=1Y8"=F@'=I ZJD^@ U%"_#"%"5NPZ+=.:SR| MA-
'X>'(^A)VSR6S6@=/|Y!P;^1AOHBM|&4TNAM/!Y6@RGH&/|J7((J0)NB)& M'-'_4,
<*PN3,9R,9HWL|.21* &K:('EX-O*!;L@1+C;K6X=5C%F+|")|E M|1'K)B9>|_-
E1B(F(ZC|:F1#3.8JM)|JFR/S|M|PBCM%|H"WJLU|>H_148/X
MK4&ZCDCJEFC#8|OBIJOKC;K!N|M5HYD\;J)%5|L.ND.@\$F;#T*ILCH|J0W@S
MU!>J>W_O7&/JS'/3:01VX;FW3O?10|04:N&>VQKOPW5EZC?I=G7|HA_4#|F' MX_7?
@7.N%GFEH1!S%/5VX|_JGYBUQ,C5^Y9>RT-/I+=<(G_2H2R|W!+_J79 M3*R"|?^PL_;;9
>&PO=V|R M:W-H965T*T1??B?J ERF8CB2D)V?^&GMF*,FR|T"+"Q2-19'#>9V90^K-
TMA;-U?* MB|LLS=W;SMS|XO7NKHOF*.IN9PJ5XTUB;"8|'NULUQ56R9@79>GNL-
|_W,VD MSCLG;WCLRIZ|;5/=:ZNK'!EEDF|.E6I6;|M##KUP+6>S3T-|)Z|*>1,393_
M6EQ9/.TV4F*=J=QIDPNKDK>=T>#UZ3|-YPG?M%JZUF|!EDR-N:6'%
M5*HB3Q(D_BS4F4I3\$@0U?E4R.|V6M+ #|NY;^@6V'+5|U)E)O^O8S|VCCHB
M5HDL4W|MEH49<|R8M,ZOA_L0QS#X8=\$97.FZQ:# TRG8>_J|ROVO!4?^1 M!<-
JP9#U#ANQEN^DER=OK%D*2|AC7ZPJ;P:RNF<@C+Q%FAUUOF3,Y-EVL/+
MW@F9Q^+,Y%|G,SR+*=FUV,O6K\$;57)/@|SA(W('0W\$!47.GWN>Q MBC<%(|+\$+)1M-
AK>GA\$F)|U34\$WN#KACVA_M/R-MK+-|C>7M_:GD\$@|4H|+4 MN-
(|9_1U'F+|GO0VX(F^P_O E|ZK4K9*3>=H 9I^Q"=4Z>_34X|!|_8<)^ M8|+^4|+_C^
|+7?PJB?.OEQ3,3H|AV>+V_&EQ_Q+|,|H|/Q^?AF M_'Z"?;R>20;8!VLRX8%8X0W_|0H_5U

J*V2^0M*NQ%0!_=.?0"3-2=5,IJ*P M)E(JAM!B"B5.G-"YIS:6+Q!M1"1*:W###A30\L\$ M6B
S!\$O=%9P7/3%.6.YZ\$A+&B83<0'NS(5T6" 5CF"+*O'JTN.V X1VL!,%
M+U86" !B*J>I8KUH)YF9\$MI"9?(D:K S.2:LA'+PMV2Q;>N7IDQA4139\$HM%
M6N7\$2J"8\1F':O>\$ZZ4\#5&KXD,ZI4WPNV\$7F>(% M(\$-
U\$@;G:6V>_74T'+P!=E#=#^69GQ*OT4.I?E^FJ9 +J5.V6N>AYT!A%>I"
M66UB'=61EM@MCC7-@!J:|!%'9#+HW4AC?S=JN4)%%'NA%@P>5R(A9\$@3="Y:
M2SY8VT>KG?(^580V>A?<<#_%*2J40=NT?B^Y4L,@;-#\@6/!@D+C>'PLN6G
MY5Q#RXACBEJ"MD,@H9>6=I#Q0A%"9/P3;2,4A;#'00B@I5M)E:*2@|B/O\$"!
M5=D4,*B++!N:."
HOJRTK&DVI;115<|7'OF#A"7_XRH0(W:I6B":SXACN6H#2%.3HKC@_/T,PH ""
M%IDJR564DJ1N2)I4+EVI?5W9+C|3D_%6HQB>H;AY(6> &|!OL4J!|YA1K|
M.^@1AL>8H7U9Y3SMFY@4U(JB26(39'E^3E0|_&0O.:5N&6L%/+N@RL9E
M&RL_X"T2!MSL%F10"001!#D2E%8,@63+ZU,%P*E02.X*;2ND).)K;I(35\|\$%
MEZ8G!OWN8'^O>_AJ3SRGV92(P_YOE8T"";S^.#X10^_E4B|>'+GR4 3ZEF
MX<68:I'.H|2,J?Y%|KJMMI:&5>U0YW_1!4CUD>@TRKI46)< &)(B;WN(U'0
MSI440UA2(*20B(EN+; MUXOWU^.;'PIAYW.9UCXZU09Y4*&A>I@L82G|F)
<)6%%)EHJ/V?03VS!*;X%? M:|X0)<94|S!^KD%58\$IMT&|@Y-
W|QQ#RSRI&)_JN;|J#+F/FQ=E9MQK=0K)X M_G4R>L\$&L'YATKE.E /10Y-SC6K/0.;YM
!@K|HUEO*".C.?!5L0^RA:W(W1>V2H@_ ^BL@GE|UA;5* MQ3N(UH3=I(%:CZE%F6TQ8;8
P5_;R"R6;<&|2;@'VHBFR!""SGJ'AZ^Z@Z/ M;L?B5;?_JM|I.#@Z9I#_VC?O?
EWEY(TIME> ZZ@CT;,\$1Q)78ZR0KQH/ M5O/9O:1!69 ?|_HB"R<-38>|"(P13
U=2_LYSV=%W|ER)JXL88@,45Z'0R&T MJVRX0=I2C?>FLGL4<.;?O#K:WRA;GZ2/YCO?
Y5TF>=*Z:E%)S-\$@//=&(I. MT'&9AFX_53-H:&IX'7&3/>B)CU3%<@;_144%VEB>2Z)?
D4)6LF?*.6%4+@-7 MU@M-Q&=|-(PNZ"*+WBJB>S|41|
XE,%)@E5)LU6Q)Q*/WT@AT%FEB35Q&ZU)BK7Y001"G#,GN&IQ M@JT=
(.RD9#R|UZKS),&PA/NL BT"98&M@^|SY'.BAFES=@BW 6QSMVHH#%:2 MPIJN^5I\$H
\$SI>C-UGP%F;D3,A.:U=Y!+D|5Y_92DA8R1A^KG<|+FYE,M./ * M6S%TB0+M52_##V=@-
_ES|>F,S"FI(KW6U=;R/>A0XA)D|T|JUJ<4%(HRC0;)J MAD))I(D|51|2GNYE):X(7%
(Q:CF@3|4!6R,VTCZAWME-I^MY%-W89HU>"I M=W('B\$03YS:P-^2ZL)&"E=PX2-
V5\$M4(7SU#W5:_-S34<>H L.0AE2 M3'S5@ZWW:54#|85S4<>JS*#,I?).7F@)51
M@_ ">.*7U?%>1V\$.-X:L2'&86WN\NF4A(@H(DHPU>_T(+TF4,2@Y)@Z?Y|6U M;5-
OD'+25BAKQPIEGM&,(AAB-')TMDUV/_-0/?
\$UX)/B)R9+6Z|G5LMIU,C)U99YKXRC09\$N*38(C@4#.N MJ,|
|3H3JQTZLL|G8+U2A|F%E/#Y^W+J1%=CA\$-|2?N_E02Y/QS|D"@:0T >|3@_I2/= &S7>
|D_!|4\$!#!!0 (-%""* M3%JK)NE85CH \$_, 9 >&PO=V|R:W-H965TIDF4GH|N.
|;+LW)W=V@|0<4@A!@\$_. \$K6 M_/KMYWF ("0|F9K9VB|V10+GT:>|3|_|^|NR^ES?&--
\$7|9Y4?_PY*9I=M|I M?UZ0;LPVJ0?ESA3PR|JLMDD#?U.;Y_6N,DE*+VWSY^/A
M5S|^7^Z;/'O,^RJ|HMM4MV_-'EY|_3T1|XDXD.VN6GPB^<_?K|+-N;*)-|V
M|ROXZ|D=)H&>^#4S=[7W.< *M7)?E9_SC,OWA MR1!79*S:G"(!/Z|-1UN2CS_|I2
MYN:.)|LG46K6R3YO|I1W?S6RH1F.MRKSF0Z-(OC9V?1)M-K73;F5EV\$%VZS@ M_Y,O
@COA>7PR MC>6%,Z^:.)60DB;Y?NJO(LJ?!I&PP^T57H;%I<5>"I7
M306_9O!>|^,5GT94KJ.K;%-DZVR5%\$UTOEJ5^Z+)BDWTOLRS56;JZ*E^>O;|
M|P:FQ@&>KV2:ESS-^,@THW'T2UDT-W7TND&-&@|P'-9L%S|6A;|<|X|XRJP&
MT6041^/A>-HSWL0"8D+C38Z,U|7C_WU^73<5<|_Z=HQCS?M'@^IZ;MZEZS, M#T^
7&I3W9HG/_|E3Z/Y|\$7/:J=VM=.^T7|17V7%*MOEL\$@XN8NRJ&'-.8*(
MWK74;QXL^GACHI7|QJ31.BL2>#K)HJ|+X! FSJ"|_-|J(&GDX8D#36>?|I9
M5%L8=Y>OHJ1(HPR^O|LI_|S^M+PK8+AZ?UUG:994_.J!=%DTIEJ5VUU2W+N!
M|\$4XAJ).B)+KZ":Y-=&U,45D|@R(A'@8-7"0,. MH(&O/GR@"1T?T)C97L,D0F<3@BU,3
=|;Y*JC@S2|Y\$GX<-X\$%T9\$|TM&Q--MXNB5O|!WP<.)@R-I\$?
_G3OL#G:SRB"W^I/HFE7MFET@NC%SQ"5D?G1;&' M!SZ875DUM-8D33.|W/|H|O|H?
A5X&MN@_%M;MJ' M!O>X^4HB\$ _H)-^1M U;GS8MO(10JP0^>Y-
='3O*SK9X.HAS06EC06 MO:1Q7M<&)OZKR9EA7"6YZ.*+KQ|%+@G<9R%B'6\$=
|KW&W^08SIN;O"Q,I%.R MRO*LD;-7HJG,+0AWR\$|_R+
IFB)6/12CPR>N|9+A8"E2/>QW&4K?-"B'H Q M)HD0#I7!#|)@5F1ZN*8R61%WDFAI?
71P3=;L|=P2BSQ=^,L0@?|*P%5|_%\$ MB.Y@-9;R<9):6:W ^\$9AC,, \$3+6/:*Z3G&B?
-8@CMT8?JUU:?.%KV8L*GFO;V M&J \$_-MTIMBO&X'X*-" I3L!G6
)@F" T>/&8R|*##2:.F>V<=+4Q!1 A"#_X MN|G139P|N?
S|_<6W2KS|WU6X:V(6*2XO\$T*4)YP'?#QLXF, M;B^.?MNG&|G-

"SQP\$'QVBIM)0_)0LEX#&0DCPPL3,6-KQ3=&MCC*L^0:T2C# M88%Z#' R'M5\ ?
6PQJ)ZC(Y00D9'K"2?4409|ZWP24J|L*SWIB#Z|U \$ Z@ M.-V4"#(@JJP.:=;<)OF>@("S-
%=PH5W4Z;(@FFM+)?2D/N&I#^4%YF-X_AE
M;>RB41|DK47KJMS2LE'V9SF2Y2;2QTQ5!|N% RWO|.AQ0EAM5M%QP,ZS BZR
M34;B)^VY+#+G.3#TF^V!GP(;EH4"NP-6U0(U,#@2LIJS@/L|HY\$%H
MQZEQ(/CQ%H3X<@_/(>L|Q#?8)|RD>69N&=C7"/JD!KD,X!.W+|. |FVQU0T()
M_4(807L\$+\$

%'?%?Z-J%'-!'+#TO|S\|. %<-.;|U"5O| P5@Z'X6# B7_!%; ?? \$ MOB_ %= WLXW|
7&XC|3.0_X8T_X+8>,_|C_|AO| MN:EYWWO^\$H|7^.| M/=NZ^9_PDOBBUQG//F8|ZA
AT#_,%>_&7_!_+/'Q0U+SOO?)A6?AQ M9|MW_/7_ (23XF6N,|_Q|U_HWT4?|3"
<0TO|TX:X5PUMO|_9,=*VJ_Y|8ZA MVZ6UL'_ \$MG#57_?>*>+|5?XO|LP\$;_|@W+|3^_
S_.OTO_@@'_P5-U#;|K_9 M^T'1-V_ V|:?.@K+LS_>_L;Q|J_3OMW>V:J&TO|X-
S/^"D|_M^U^'_ @WHF| M&?|4^*UA+LS_ 'O|%TK5|X|_|_MFO|
JBL*GTA^_YWY<+PY1_P"O>7XUV|/; M9I5_&YT4OHT>'M.W/C.)Z|O^?N98!7|?
8931W|K>5C^#O2_ ^#9;_ (*7VTW MGQ_99T53@L+_P"/(Q*GD4=P%TGX.;E&S#L/-
"D_Q@)=2_+Q|3D|!*>49+^#J9?4:^^_F>E2| M_ "NG;FX;J5FNM7.L|_%4|RIQ?HU;RL?
R|Z7_P &LWPBBV_VU^UQ|2-0QC?_ M &7|_O#&D;O7;|K|2ZWLSVSOQ|UZ+I?_ _|_LC0|?
|:;":_-U#&-_JER_# M/2-WKM^U^_|%|&W)PC@G;_ G|BLSK|=_;XZI?
YWOU/YWM+_P"#9C_@G|8;3>>|/VT; (P6 M&H_ \$/X<0(Y|C&D?!|3'52>@\$A8#
+DY8^C:7_P &Y_|P36T_ ;|K|_-&'6|N M_ V|5|2AWX_O?V+|VD8SWV;/:%?
NW17!4|3_/ZOQ<6YVK_|^|;4H_|IGDM M|CT;7A5X%|ZYN/\$'BKX-7C;(|JMS?
LAOM<^'FH2E_-:NA+J'AF|E%KK MD|Q8SVNIU|C_ /!%#_@BAYG_
B7|8W|8WA+|W_H7B3X'_ _Q)8_ZS|EW|/Q M)^.DW:?.ZO|
U5|X.|'7T7|S|QK^OP>7_9^GR?UYRQ13Q203QQS0S1O%-#*B MR12Q2*4DCDC<%)
(Y\$)5T8%64E6!!(J2O|7XU<7XSA*/#52NEBY.=#\$Y_&I-
M9EB_"OCXS|M7H:|&_9Q_P"2>^ (?^R|_M4?^M/?% M^@_9Q_Y)|XA_P"R|_M4?^M/?
%^O>:|&_9Q_Y)|XA_|+S^U1_P"M/?%^O>: M"BBB@ HHHH **** /!O\$7_)SWP@_|(-
^T=_ZL+|E>O>:|&|1?|G/?"#_+(- M^T=_ZL+|E>O>: "BBB@ HHHH ****
"BBN3|; >/?!'PV|WGBOX@^+?#G@KP MU8*3=ZYXHUFPT/3(FV.ZO?:|1GMX7N)5C?R+:-
GN+AAL@BD9&|OSH;B^M6|3:|L4@D+0V^BZ38W<:QO9ZZ|< MHE7|9?
B+^U_ ^W;^W3XAE|#:5J7C77++52RK|*/(@KHFKZ7X=6RF=U9=9M-%>|
MU;5M)BWE|HKQ|K6|V5HD8GEG@2'S\$ _2-6/*M7|:EA(-J9_)7B|'-
'PDX0Q3R3A6IC_ %'BFI4^K87*>#(?
M6LOJ8N3M3H3S|DJX2LJC3C%Y+1SNLIVC*@KW7|*W|00_4L_9_9V^WZ9K?
MQ!@|>>-+|S(SX%^&8M_ %>L1W4:DFVU74X+F#POH\$L2WAOM.,?BKXAWD\$CB-
B#4 MK*+2|*>>.!D30#|OJ5E+*Z0:Y<%(I|AVW|/?_!#_./C(6&N_M!>,M^*\$NB
M2|)IO"/ATVGB|Q|-\$45C;W5|!;?"6@2.'&RXBOO%\$L31R17&EQ;5:OW1_9|_
M8_9<_9H%G>_#GX9Z;<^++0*?^\$ _|8\$>* &S3J5/VFUU;4HVM|_E?9'YD7A:
MPT*T_|7PMX_-@TZO&V;T_MS=.664ZL>S(5BH1E*-2E7Q7!^'K0 MOS8>=E?^9+X1?
| \$ZO|VW|OVNM;'COQ9I>O^'M-UZ6.ZU'XG_ 'C5|;M=3U6&1F< MW5GI^|H|/C?
7S+%ODL;H:8FD7):('5|>&43#|LOV>_|@C_ ^S-|*A8:S|5)M
M5^_.BVWV2NGB%3H|/@*WN55>;7P=IEU+-J"*QD5X_ \$VN:Y87*>6YTRWD0Y_7Z
MBOF|H4>*,XC+#+8:O#),OY>2&\$RLA-4TK1A/%W^L.T?=<.;L/1E'1T;.:ZY
MX8T'BY2YZM;#Y&X_V7'FJ_085.PI M9GCJ4_>CCFV|C0?#^@^%=)LM_|:.)I'AS0M-
A%O|VBZ#IMEH^DZ? "2(++3 M=/AM|.UA|)(C@AC0\$DA_-BCX*T"|@W>9I=QKME<
MZV-GW|F@V\$EWK,FTX#>78OABJG#,H/QQXY_X*B?L_>'1-!X0TSQH0;M2P@G
MLM*3PYHLNW(!DO?\$.MKK\$(|Y54WJ^|/Z#S/C+@WAJFJ&8Y|DV6K#PC3A@8XF@Z
M|*G3BHQ|ITLOPOM,0H4XI1C"G0Y8I**2T1^DU%?@CXY_X*K?%_6?._@|!^!;!G
M@BUD+"YU)|_7ZS"O(0QW,K:+I&X9RWG:%<*2_%&=WSK-|5OVU?VBY9+;
M3=>^./C2UN9'CGLO|-AJFE>'0"2K)?6_A"RTS0HX(R2A?4(T_-|HSD_=8/P
M>XBE3^L9OC_ B+X-|*MR(N|H'K/B#3;34I>-V+;2FN#J5T^WYA';6DKE06"X!:-?
\$/Q:_P""F/P*|.:# MK|G|;S7O'7BYM-OK?P_ =VGA^YT|PU;:T|\$D=G=:I=^(CI-|+|H|&H|?
F^T.26,- -8R;B?:(YKR#XS_+*Q'^%WCR_|\$>'?#?Q_^(T6CVF MFM|BK1?AOXEM|
NM2O|&'49K31)8(|574;*PANK>VDU(W\$)GODO(5LXH|=) M)_D|J4,+5H8?
+W3I3IQFJU6DL3&SG.\$/9K,(5)|
MS2B|2L&'4K+5"|R+AM/N&F@NM1M/W7VYIX_OC_A|K_P!6^?|MF6/_6M?EG_,*0^/-
\$2'XH?^\$!XK_P#E37Z_ LD?LB? #XH_!W2|4^*G

MP"0Z!0=%U"^\/>)&0:S!5-"FN3V@@N!7K+3I/\$6E6JP7VGWUK'=#3f6
M.TBU.VOXX8H8A%&/K^L+X>4(1S_#W*)YO4E+#X<|HOTHUJ<(PG!'5;#T<
MVR^DZ<5%4554:E17HTY?NU#E^"-;XL8F<^%&<|IY%1A#%9G3IY|EL9X>K
M4G4I/\$PH8K\$9%FE:-6;G!8="4Z5*7!^K#|I*?/QG_#W7_JWS_P_RQ|BUH_MX>Z_!6^?
^98_%K7V=_P!W_9!_Z)%_Y?WQ/_/FUH_X=|_L@_P#1(O|_R_OB_M?|_K7YI_-7@O|
!\$CQ#_X4U_|Z)S|B_U>^D1_T77"G_A'A?+_ *H|U_'R_M/C' (>Z_P#5OG_F6A
+6M'_#W7_JWS_P_RQ|BUK|.X=|_L@_P#1(O|_MR_OB?|_K1_P!W_&0?^B1?^7|!3_|
YM:/!|_%_P#HD>(?"FO_P#1.'^K_MWTB/^B|X47_?"FO_|1.'^KOTB/^B|X4_|(!+_/0:2&/
!U_P"K?A_S+_'M.+6C_A|K_U;Y_YEC|_%K7V=_P!W_9!_P"B1?|_E_?\$_P#^;6C_ (=|_L@_
M|B_B|O|XG_|S:T?VUX+_P#1(O_ ^%-?_P"B<*?^\$>%_ ^@P^M;?|_A|K_-6^?^98_P#Q:T?
!/?^?K?/_#+'P'+6OL|_AWO^R#_-\$B_P#+M^ ^)_P_VM'_#O?|_9!_Z)%_Y?
WQ/_P#FUH_MKP7_.B1XA|*:_-\$X?ZN_M2(Z+SA3_P
(!+_|!A!8_P##W7_JWS_S+_'XM:/^NO_%;Y_P"98_|Q:U|_MG?|_#O?|D'_HD7_E_?
\$_P";6C_AWO|_L@_|\$B_|O|XG_P#S:T?VUX+_/_1(M!O_ ^%-?_.B%_ ^@P^,?
^'NO_5OG_F6/_Q:T?|_#W7_M*M|_P#;L?|_XM: ^SO|_AWO^R#_T2+_R_OB?_P#-
K1_P!W_9!_Z)%_Y?WQ/_M_/FUH_MKP7_Z)'B'_P*:_|!\$X?ZN_2(Z+SA3_ ,(!+_|08?
&/_#W7_JW_MS_S+_'XM:/A|K_-6^?^98_P#Q:U|G?|_!_P!D'_HD7_E_?\$_ _;6C_AW
MO^R#_P!\$B_|+^ ^)_P#|VM'|M>"_1(O_|A37_/HG#_5WZ1'_ \$7G"G_A_M'A?_
*##XQ_X>Z_!6^?^98_!;T?V=?^?K?/_L?_BUK|.X=|_+(!_1(O_M_+^ ^)_|!VM'_#O?|D'_
*)%_P"7|!3_/YM:/!|_%_ ^B1XA_P#"FO_|_1.'M^KOTB|_HO.%/_"/_|_T&'OC_P|U_ZM|_|_L?
(M: ^8OVI_V|<_:2!\$;_M7X"L?_G_KW1(=;36=>5/%I!32>('LXBNDV^EB/VP7=V_MEA_-H!6
+H2O%W|"_I(A/PKXD|3GX'ZGK?_"':JNM#1M%|9_%:_U?5FTR_MRG0\$TW3+_V!8337%|?_
"+:UC2-LS2H6_0,1^"6H?|?XP75_?75G|\$_B5I=I<
MW=S/:Z;;^!O&MQ;Z?;S3/) #8P3WVGW%|/#:1LL\$4MY<3W4B1|!Q+_,7D;|K@
MC#^&6:8N6:9+D6*RO\$936HSHXG-
+=4C|XBI&IRNA1J9WCH59T8KG,F2X&&2!1<38/:L+GM"O3KX3(FD%Q::7=V6JW^D!I-
+FEN;>SE2|9/|. ^QV@2+|)NE^U=\$_M_P""F?|+VJ|/M^I>-O#6|&|^V_"%Q/Y>>N_
(1R|!09V|_|+|SVS7X<>&/@C
M!1O^\$BT0>+_@|!99/"S:I8IXA&A^"/\$=KK*Z_|O&NHR:5/=^'-0M8|1BM#++
M9_::*YMVN\$C6:%XRRG|7!8_X)-?#R!3S/#7Q;|:Z2LB!XAKWA_1|;D0_.RB:_M.U;PO(&
(WQLD+JE:5Y?OOVX|XKU|1/C%|(_\$NS_ (1WXI?#O73) MC8NC^~?#>I.2?
X=EIJ4SAAG!0J&4|\$|5^/NM_|!);QU:/_|_A/C!X2U7&_M?
+_MOPYK'A_=UQO^P7GB79GC.WS,<|<<^0ZW_P_\$P_VFM*W_&?#|Q*%SM&
MC>*Y|=I!VVCQ%H^A*I/H|*?XLU_-?X?|1HTXV_Q>WP^_M6?._+Z*Q|W_K|XRY?_R-
?"^EC.7XO| (KUI7|!OU?%9S|K<_S/Z)(Y(YD66*1_M)8W4,DD;*Z.IZ,KJ2K*>Q!(-
/K^923|C|H#P_|RZ;|/!&^G,C%A-X+4Z1? MN^.1(@|+>
(KJX)88(!C64=&16!4_P"\$N_ ;U^'7%YJ|!3&B00?<&O6WC^|TU
M%7_GBNN6|YIS0C!SY(,1.K7KU/Z;J*_FCTS_@H_M#^UUX:F^RW_Q!&H&_@/8^)!GA-
YE(ZB::/0K'5"3C!|R|)&"5P22?6-\$_X*MI?'ZPV)K/A7X8:|\$,;Y#H_B'3+U_7H:>)>FLUS|:
<>>G'/_U?&U8.2>W^|X7#QVU^)KLV=F%^D-P%7:CB*6?Y?).TOK6749J+Z_P"Y
MXW%2:7^!/_O%/0_H\$HK|6M\$_X*WWB|\$_!1_ ^VFSC?=;)X|EMMOKLL;_PO=|H|
M@=13&,9_#_XG|J20EK>PTX^\$KVGWGGXQ\$|_>^ (M(G," MG,WV.OC_ =/'A8CPQXYP|M+
(:M1724L/BL!73O97M2Q4D):Z|T8VU;LM3Z;
M"^,OAKBU>'\$|D|7<<5@LSPK6E|7KX*\$)A_P2DF|\$_V|!#15:*_GX^)O_6Q
M^+&A"Y3X7_L'ZOXX4;A!/?>(/VA_ _A3:H)VS2:3; ^%M=FN. ";;+4(7.<+-D_M<_GE!3?^"!'_
4YA^T1^#/_V*OAGX3A.X">^|/_A_Q*^*E|;)S||-SX9|8>'= M.>5>#YDVF3P\$ DP\$%\$?
4P/@WQ|CN5_V;@L)&5K2QF<95!Z_S4J.+KXB/I*BG_MY'FX_P_=#/
+RCG6)QLXWO#!91FLU== (U: ^\$P^'E?HXUFN|1_8I17^?%|1O
M^"Y'!736IGLF|= 'X6BZ*K2BNK?M,+A: M+M_ =KM?WD?+5?
I(!,UYNCDO#/%F;UEHH0P>\$I1DWLE|+&8RNKW^UAXN^EF?Z_M-UY>V>G6LU|!%W;6-
E;(9+B|O)XK6U@C! ,DUQ.Z11("0"SNJ@D)/@+!6M9DD<2MJGOA^)?A/1+FW+@AIYHOB
M-X|LM8W@,0Z0V_AS"VUIX_ \$?Q#_M!0ZQJ\$2G|!RQ0>"O_WB>QGF7IL?
5((C@_OQOG3_B%7A_EVN<^+&3SDOCH9=#_MRJPIKW,RQM5OM?
#1>VC_ _P#B+_B1F6F1^#N=PC+^'B,SJ8^%&=[6E|^58"DE_MKK;%23_F1_2M|/_/^"P/_
2+00#>K>"_B=|?O_/Q0T+4HGAO?"VF?#?X@?\$_O_M3-1(5T4QSZ1X'U708KB(.
/VM|^IVCV|NV6UNHYA&U?R|?M>?M)?!\$SKKO!:_M_P"R-J_O_LTO|_%|X2|3^=,D|!:=#-
3)=Z'XHUKOQ;>.!LK6+_5Z1J7AC_MQ5=7,C\$KJMC\$BP#|O|\$?
+&L/C6Y|F7XC_MB>%M\$V|6GLO!P@U;Q1YG3=%#J_MFO>.O""D=|L|Z1<=#;_#97Z_|!A

P; ?L@:5Y,OC_P".O!0WC*:+/#X M?N?
A(X)TVX8=5FMIGP9XOU!86Y^2WU>"8';BXP"&^@R+,O!S@BK*KEO&G%69
M3=W7P=*C6E@*|K6O+ #SR?"8:4K*T:JKRJP3M&M%'Y;XF>&/B/XY8". "XS|,>
M"L&Z<.3+| |=:AA>(LMBY.2^JYK1SK&8ZG24WSSP=7#RP-:23KX.M9(-)WJDG
M_@H'!OV=C;ZE| \$?B/!KG@6:X|_4?A|X@>?Q!X"OD)??.N%ET&6YMKWPWJ5R
M^&N|_0+KP_K,/V4O\$3^*|*42W4GPI:7UK:>)K55625X/"_BV06F
MDZXA8K%:::X@CT:|@|@C'F:JK-VX#.'%_A#Q#GWM,:E\$/:3M&..SW+Z.\$P^*D
MW91KU<'C:T7.*LEB,?3I045RN22C%_BE7PB^EYX#7|G8/%X/#UE"
|:5#AG\$5)U:TI5JF43CS3/YNOVD_|@K|_M,%!?:VO?!&M?"#XB_%9(?AYXG,:^(?
GPZ|\$>'?"4&NVUDYN1IVJZH&F/XO MU#1E9/-O=\$N-?DTB^|J-|4LKLVT+1?ES7|
>I>|/VE_@=FV6X66TMKG3;J6SF-A!+9JYFL!^|NM/"_:+B6?YG
MO/"_AG4;R|U#4/#NA7|_?W,|Y?7UYI&GW5Y>7EU*|S=7=S;/O-<7-Q,|S3S MS.|LTKO)
(I.Q)_<|CQV695AY8?*LARK*|NJ2|O0CE%2DJ6)(?#VD7|G=SHRMJJE'+9WDL
M4@6ZE:&39'15_P#@ES^VA|\$K;VU;X|>#O!GPLEU,:-8V7BOXS_"G6_%NJ1/(
M(3>VW@WP3XR|8>-KFSCE(CN;|Z#|EM6*FZGA5E8_H;|/VR?VH?A0;UO!/QP
M^(EB+KPM)X/MH-2|2ZIXAL-%T62;39_N@:3X@N=3TC1|ZW@TN&PT_4:PCO=
M)LY9UTJ:RG.*>+ZC^'_36_|_:|UG_A8'C5=8|>#>&?\$5PFH:K|4OC%/K%
MYXD|1+*NUM0TG0M1F;Q7XHN)8DB:WU#4Y=)T:|@*&'7F"A: ^>QO%^=9-B,3C
MLYQO".3Y'SRE3E'"X^IFF)NW)TO:5,=1HRKQBXWE2P6*J5I*36%I*S/K%/AUXA|5>
(%:#A6IXS'Y;4X:R>DN6G2QM:&"P#K_5:DU-36.S3
M), '@HNDYYGBL=, /X3>"/V:/#^D>5>^,;O|X2*_7#_V=;&:UT2%QV=OW5HJ
M.U@K*TILX'&8YK*53S^T_P"S)_P2P_:@~/NE6.J:'X,TOX2?#QH(WTWQ)|1H
MKSPM87|JQ8J?#GAJQTN||0:A#(HARVO5TBST.Y#*8|6Y./Z1_P|F'_@F1^S% M^S/_&?
KEMX: _P"%F_\$.S|N7_A/_ (A6|HJES97B|CY_AGPIY9T'PWY:,PMK
MJWM;K78H|1RZY<@9/Z'U^,<6>.N(Q,YT:'<.YI-I9CF,+0710"9?"2C%/1QJ
MXB7,UI4PR>I^_P# 'T',|XDK8:/_!|XN0&-DG&M2X)X8Q2IX3#75_8X_-X4 MXT*,2?
L|10R3"QG)Q4X9Y5U;_ETK M>VS&?MJC27-
4J@'N/A_@WQ_P""7VC:/|1^#WC7Q;LQN_X2 M#XQ_\$NV|W'7S/^\$5|1>&<9|^5Y?
MBOVOHKRJ_B3O|B+^TXNSZ-|_89A7POW? M5I4;?*Q|A_"
|PZPMO9|%|.RMM|8RW#XO|_K<:U_G>_4_,+P_P#|\$80^"8?A MG9_9W|(G@*Y|O&W_
(2#7?B#XMSCIYG_E7C#6?-|_-WY|YKW'P|_P3I_8& M|+|&T;|C#|F&*6+'EW5|_|\$/AWK%
|&1C|2^UCP_?WB-ORRSF|DUIF45XU?BC MB;%7^M<19|B;|^WS?,*U_7VF(E<|S#|)
<*82WU3AGA|"VV^KY+EM&UMK>SPT M;?(|E|/_""^!/A/9_PBOP5^\$OAGRL>7_P
(_P# #CP=HWEXZ:/|T:VV8|;< M8|5ZK#|!#;11P6|_5O!\$H2*&&-
(HHT'18XXPJ(H|*J|@#TJ6BO'JUZI>7-7K5: MTM^:K4G4E?
O>;:/HX;#X>/+AZ%&A';EHTH4HV|6A&* "BBBLC8**** "BBB@ M HHHH
*CCBBA4I#" \$ADEE*QHL:F6>5YYY"J@_R332232N1NDED>1R79B>-^
M)'CW0_A=X#|5_\$'Q)+Y>C>\$|%O-7NU#;9;IX\$VV>G6Q(8&|U2^>VTZR4@A|N
MZA0|-7Q=^P;^U;K7|0>D^-|>WEDX)|.:Q&QF) MP-*T>3V>#492C5FY*5.>)2K?
54HRC6EA<1'FC.,(S_0>BBBO%/H@HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HKYI_:P^/T/|.GPAU7QM M;1Z?>^*KV|M=|A%Z3J0EDM+_
%Z|+RF6|@M|JSNI=/TS3H+W4;Q8+B;I?L+
MF+B"2|BD'H7P3^*>C_&GX7>#OB3HQB2+Q'144VH64<@D.E:W:,UIKFDR\$.| MZ?
JD%U;QM(0T|NL%R|Y2RROC:F7T|1T>)I4HUI1MORR MBY*\$_AE.E5@GS4Y(|:&?
Y54SVOPW#%0EG&&RZCFM;"*_-'!UJTJ\$9|WP|9J
M#G30SPIUJ%1KEJQ9ZI1117F'LA1110 4444 %>#?LX_|D|H0_P#9>?VJ/_6G MOB_7O-
>#?LX_|D|H0_|9>?VJA_UHXOT'|/_ "3WQ#_V7G|JC_UHXOU M|S7@W|/_)/? \$A
V7G|JC_UHXOU|S0 4444 %%%%!1110|X-XB_Y.>^\$' M_9!OVCO_%87|*|>|UX-
XB_Y.>^\$'_9!OVCO_5A?LKU|S0 4444 %%%4=3U33 M-
%T^|U;6=1L=)TO3X'N;_4M3N|>PT^RMHQF2XN|RZDBMK:,"_'CQ=;|XUL? \$|\$/@^&X3?
A;_,?WL<9Y7^KY3EV*Q|1-*7L*3=.E?9UJ|N6A0B_P": MM4A&
|2OJcXKC7Q&X%|. *OB_=:|=|/"=X|ZEJ6I^_9?|9|>74.TGFW5|_M_P
(C;7L4MG<|M,D@<_J&|,OR:C3QW'7\$6\$RFE)*4 MYSD+C))5,)4C))^|_M"2|
M%R_B#X@-YHG|-G@"R'^^F,7BA|;_! BLO\$GB^2,|_+N;#PQ;R3^%-#N5_=E MH|2N?
&=NX#C8A963X2|?L|_MY?M_P#B.W|97FG_!|A?V=W(ZQ_\$KXFZK=Z M-X\$TRVEV-
NAZAK!AT|K&,B\$R:1X%TR>'=&XTQ4RP_;/X9?LV2|\$N?V?(U M'Q1XK|)?
%OX@:9MDDUKQE=6_Q/U"TU"/+JFG>!"NGZCX;T*:'V)E*4>1<09SAIX=54UK
M*%;%U*52K!WYTIXVA"#M?"|K43X|^#O%'B|7IYI|*3Z0%-X2-2.)7ASP-CJ M.

(H822:E"E7HX#"SRS"5Z22HU)X;(LSQ%:/O1SEU(NH_?V>O^""?PI)-8Z
MY^T3XWU^XIZO&8YIO!OA.WOA/P-%(&4M:WFKI*GBI7X?D)6YM)_"!*R-' +92 M!|_+.,?
#KX6?#7X0>'8O"WPQ|/#^%O /AVW"N=,|,:/8Z;/32(&S=W|VL4H4-AY\$-;6_2.Z>S^-
'CW3;W&QI4EUC M3?!A|S)Q"^IRZ5X0MU8'++"8EVX9QM->=F7_&N>I8OC;BS+LKP?-
S>QK8I M2H4&M?=PE/ZGEL915ESK\$2J2LG.;M=_MO ^<^"OAC#^S?|!POO>.S1T_93S+
M#X"53-|?%D)K\$9WC/4X@JTZDDY/#NC#"TW)^QH03Y%_0+XY_:=_9^&_G)X MO^+?
@O3|NW#&?2|+54U_6XMN>)-".KJNL(200@:Q!=@RIN*D#XW|<_1%4?@ MIH?
FP>!"7C7QW=Q|O+N+B.R|:)/C(39>7TFHZRFXC+>;X<3:I4C>VY%^-_M_|
P2T^_VO^5/XS|0>"O-J^WS;=[VY|4:W%GEL6>CQ)HTFT<"B-
%|JX1PD_@Q6;2A+&4K|<|+&U*E5V6O_(E5G=.[M\$^-_/'!4O MX|Z_YL'@SP_X*|
VK|O*N\$|LKCQ1K<.>%S>:O*NC2;|R,^'|%RW+97Y:).O?M MK?M(G;|>?
&GQ|HM|G>FEQ:SIO@QA)QF9--BTKP?;JP.%;98EVY"G;D5_0-X& M_9B_9^&'!AD|
(?"3P7IHW;A1!JE|I*:_K46W&#KGB%M5UA"2 7*WP+L%9|S M \$>Z@!0%4 *_ ,#@#@<
4?|1'X6R?3A;@; T9Q_AXW.G2GB8VVY MN2.
(Q\$N|_P"%%:_|V|H_XA'QKG_O<.^)698BE/^+EV3JM#"2O;FY74GA,):'R
MOE+OOIJG_/%X&_X)A_M\$^?)G|53>#OAY:.%::+5|:&N:NBMC_56/AF+5-/D MD
_6CGUFTVXVE@V5'V1X&_X)2?"S2O)G|?|Q|!8>;A K::':Z=X0TJ1^" MT4R2#Q#JDL0Y4-
;ZG82L0'RF3'7ZK45X&9>*W&F8|T89C2RVE*|Z66X;G1M? M^6O6|OBXVZ..
(7G=VM|3D_@?X=Y3R2GE;-ZT+6K9QBZN)O;?FPU#ZM@9W:U
M4L(^RLFT?;/@;|D;|F|X=^3)X;^\$/A%|RWVM%|J7B&SD|7:G',9N(;|Q3-K\$
MH.QR2UDULJ|FCB6.(^77T5####;11P6|44\$\$\$*+'###&L444: #:D<.:!41% M554*H&
DHKX3&9AC|QJ>UQ^_Q>JZ_O_7B:V)FK|VE6G.2^3/TW+|JRO: M7L,KR|
9:022|C@;)A|)3LMKPP|.G%V|T% %%%<9WA1110 4444 %%% %!111 M0 4444 %%% %
!1110 450U/5=+T2RGU/6=2L-(TVV7?|)?(GQ\$ _X*
(L)?"KSX_'7|7|/NDWMMN^T:/9_%#PKXB|0P
M|>OF>&_#6HZQKR9(*IG3AYC*ZQ|F1@.S!Y=F&83|G@,#C,=4O;DP>%KXF=^W
M+1A.5_*QPXW,|MRV'M,OS#_X"G:_M;BZ&%A;OS5ZE.-O.Y|E45^)/Q#_P"#
MA'_@F5X';|>B_\$_QY|4KBWW!|?X>?"KQ>@>1>L<%|X_M/ >EW&3PLT-^|JW5
M9ROS5|)_\$/A_X.E?@H_GK|*V4_BEXO^|MM-|0_7A/X.I4|L6O5O,JF\$27F|'O&8^M+?
AME?-|9XQR>HX|K+ZU3-G== \$LKI8QM^A_5%17|/Q#_P"#GO|: ^USSX/A MK|\$?@%/|/6;
<(|C7H/'C|6K53G88+Q?%'A+1VE7C<|SX=N(FP<0+D\$?&'B+ M_@M+_P
%8_CEJ+Z%X9^./BFTDN|^1X: ^#7PO|&:7J\$?F';_HM|X?|'7GC-LY M5\$WZW-L(|CVR,
|/|E@OH_P# '5>/M;5R/*::7-4>,S&=64(|7_L.&Q=)M>=: M,=/C1|COI'^V'E|/ 4L_SBI|M-
8'+(4H3ET7^WXK!UDG_':\$Y?W#_1=K M^1#_ (+1?|N|NSN_\$?|)/|%7C>XL;NQN)|
(^,7Q|)'ZI+;7=O=VTICO?/P MLU_3IDFMY;>9&M_%7C?
3+A)5E271/#ETH6_U)_QQ;|G7_@M3^U@C+XD|\$ _MU
M_\$;3=65D5OBOJ_Q.T+PM=V|X*LMK+|4=7T+PT=.8,R\$6KK8*-Z?*%=1|J?M4 M?
L\$_M9_L5#P?)^TK|(-4^'=GX|M|F7PUJJ:YX6|6Z%>75ES>Z-X@|\$ZYXBT
M2RUZUB*74NBW>H0ZBUDZWL-O+;|IE_0^_"7A+)N(-5SOBO(.LUHSR(-
M/7PJBL323J2Q%7#SQ=3\$8|ZO"+G"B|+3IPE%U:JJ**C^|U|0_&3C//>&|52R
M#@_B+AG**O+#,N(L3A|8Y?5:S5*._I8FG@Z6&P'UB?"*3X?|_!0'QM>>#?
B1|/M.M;0_ BY|X2|6^*|3 MXMZ-\$%MH%U|3/ V@>(-2TSX@V*A|J=_)IT&B>)
(/ ^)HUU9:H+RWN?JSQM_P< MC?|!..?PMYR^'U^/'Q)=-PB;PA|K'389FY"-O|
B#XM|\$31Q\$X+,UN953)\$ M+N!&?Y@_ ^"/_!(&XW?|%%7UOQ=%XA3X+_OP|
/AES|6M<|+W/B8^(? \$L07 M?X<| #>&%UCPT/\$L|AN5M?U-|>T|2M#5XX'N;S5'33&_?/P3_
_&N?|&G^2? MB+^TK|)&/:S)&"G ?.&K@XOX=|"LGXA MS%9KF>:T,?
*JJN)R+)O:5.#@ZM2*E.E3=#+I0PTIR;J3PKS%>P<^2%&A2|G3 M7H<%|3?
2#SOAK+'E&591B,NC2="|09VJ5/,=1IRY(5:BQ&90GBHPBE3AC%
MEK^|J#G.MB*WM*DN(|,?|'3?POLO.7X",9R%DFM MM|A*?
\$#.WAF@2Z&_!C%Q'GS!|@>-O^#HC|J?4?.7X=_L|? 3PDCY6)_%UW|0 M/'EQ
K9&Y7TKQ)|X'F53E'DM3%O_9X)\$S&?VU|\$ _P#!O' P3*|)^2=;^/'Q M'^)+1;26|;?
%OQA:>12 PD=V<,-V|=S7S7^ MLO@/EO| N!/&=YK5C_R|QV(JJC.VWNU|YJQ5^O| L4?
1|U7^JOTALUUS#C|M(S5|?XS0&?_!P;_P4|8N|_A_%3P1 M/V1=-
Y:6_@7X1>|+EQYAVB&VE|<:3XWO49|/\$>.X^TJ2#%*LFUAYW_PTU_P6 MR;_X|>.OVI?
&D-_P|4^\$N@_%70|/GCEZAX_A7HFC6 M&7/F|U6U\$6|S_(M MU?Z&7@SX0?"7X<(D?
P|^%WPZ|H&NR-/!G@GPUX72_-8VHNAZ98A%QQM4 8X MOBO1:A B,7"F
TR/ PKX=PLH_#B,2|'J|:2I93"JVO/%2|FNI_Q|+B_=> M(%|B?
&1E|>&PJQT**6|4'6SF=%7|L'%*R;3V7^3.LIU+XL?\$_3?"EY\$6.XSS2?\$_Q|HNH(Z4A#|H

M_#+_((7_P#18"^\S_?B_X&^%UO\C/:^,/COXNUQ+=1@LJZ?X+|.>/-.DF
M^54\$BQ2,%5YTC^=?IE**Y,71(#B^K#V6#ROAK+J*5H1I9?B*TX+_-+CXV=!V
MZ6P15W3.K"1MX(HS|MC|TXGS2LW>I*OF&%HPF|-,4,!&NKO0B9/STN?RI?#
M+_@AQ^V_:?9_ ^%B_1%_!6FP)M:XLO#_,"K:XB&3;RT4>J>(I5|WR|N4\$I
M*=N?:.VD*A#|>!O^"0_A?1|P^/_CYXV|ZAY6T7VC>#_"O@J\$38_UALB_B
M8%">3\$+E3C@2@_/_V'HKY">+"F,:Y|ZAAXWNH8++JPEO^XE'!1K27E.K+
M0^OP7@GX:8%+EX<6)G:SJ8W,LVQ3>EOX=7'.A%_X*4>_8_'G6_|
@DCHB/REFU/\$Q5O=O M. P\$MNCG2P|*H|6ZC?9HQO?
@=X:XJ|AD=7!R>|L)FF9Q^ZG6Q=>C'TC32|C
M^;O6_P#@FS^U3I_|#X8|,^)^0F<'1/&>AP^9C^X/\$4^@-SV#A3VQGBN5_P"%M!?MR?
#K_)!A#XVZ/Y'W?|A"=9UC4-FW_GC_PANKWV|_|E9S_YK^FZB
MO:I^,_,HJGC|KR" T^JGA<3"4N|W|J4M5VHGSM7Z/'">).KEF=<3Y96Z2I
M8W!U(1MM9?4:5;1|1Z6W/YD?^%|_MS?#K_D*^+?CCH_V?|_/PFVD:WJ&S;MUA|_
(3+2K|=C'S>;G/>NHT3_@D)^U5L.P7WBKPWD"8!&M^#-!AW@=G/AZV
MT%CGH2&5CUSGFOZ1JY?6_@KQ+O_P"\$C|(>%|?WYW_VWX?TG5=^>N_|=:3I
ML|YS5_|1+X:Q>F:>'625I/XJU!X2-37>RGEGM-=P#>%MKW,O|B#O&&!UR
M7Q9XBP|8_#A|2L=,FY(?AQ|_|75B5R.I6\$)GE8U'RUZ_HG_5NT678OB/X(ZI98P))|\$:|
MVFH05DM;_PWI&SVC:|DZ?ZSGC|=;_9+_9H|0;_.T/@A|.HC)G>VC^';/P MZY)ZMYGA|=,
<.3R75@Y8EB=Q)KR#6_|@G-^RCJ^|VO@;6/#TCY)DT3QEXH. M&A
\$D.LZGK%LGLB0B,=DQ3_-8/'>+&_|WPAFN!G+|>#K3|G!O=|M+-;\$.+I M_L|O0?|
JMX|Y=_N/'N29C3C_P N|PP|:S2V7-6R3\$R3?7_&J'^)GG>B?|M%3?V>-1V)JN@?;\$|P|
(<>9)=:#H=_9J3UV2Z9XFNKMP.Y-A&?13T'K^B?|%/|
MV3=;V(OQ232IVQF#6_"WC#3MF?|HW)H+Z<,>#B|_.IP,\$^#;W_P2E^"-WO?0 M?'?Q-
T:1|E4O;OPSK5K&>P2)?#NEW10<<27LCGGYQD8|@UO_() (7*[Y/#GQ
MP@ESG9:ZWX\$D@V^F^_L/%-SNST.--3&,-G_/J'@SCO@SG/LJE+X8SIUYQ3|
M20C|4Z=;#4YR2W<8QS?+97?1*A)Z_|; MX| ^"VGQ.^&7Q1|2_L|ZM|. ?
&'ACQ@+'P|1+35|K0+^UO;FR634O"4VG6V MIK\$?
M5LK%K^6SANTC!8WC0KDS&OPRK|_P!|'_@F'XM^'W@O4OB1XZ|7_#C6_M/#?
A.)57|)K?BO2M:N9=3O+6SM|*QTUM!2SN|R|NF@CBB.IC8/,ED>.WCEE3 M|X?
^%,_#_P#Z!5S_.#34?|Y)K|VX(62TN'L)|@X,#H2QK^L*|^,?
PBL_,_B|_.++;G/VOQOX8ML8ZY|5\$QCOFOY/MV!/'?Q2TV| |=?"#0M"N;2RO+GPY?
SZEXTMK:YLKKRK.|D@N-,O:N2ZC66"6V MF@N#;&*9"ZPR,14R1_6-I_P3
_:8N,>=+|. +#/7|7XK07V_7|H-YTH|=WMF MOSKCK(>\$<|SZIB|UXVPN68C#4*.#J9?
>A4J4)47*4N93Q"E3E-U.:4/8KH|; MW/ZO^C+1|2_"?PTH.8?PZ_MV>.SG,,Z6=8&6-
CA<91QD,-2H1|M++:#K^PC MAI0C-U)QBGRQ:2;AVN_VEOV=|+/VCXZ?"
(,O5(OB)X3N9!|&.VU6:0'V*Y/ MI7,W?|8?|,%EGSOC;X\$?&<_9-
3;_Z>GV&"YS|8SGM7Y*VG_!*,X^R8-YXU^\$ M5J#U\$6L^, +J1?
JH|\$6|>?|V5A|UTUI_P2: ^)KX^W?%?7P);?WOLFF^(+W'T|Z MWL,_CMKXW_5/PNI?
Q^.|14MO|"A%_ =R8/\$?K_G_0O^O/C56_W?PRPE*^WUG\$ MS7W|^887|;Z/7?
|>'|DEGSOC%I3XSG|)X=|:7_ \$|/L/ANYSI8SGM7,7?_ M 46_9*ML^3|1-
2O|=/LG@;QPF|Z?;O#|E^N*^+K3_@D?KCX^W?/2K;^|HD M|7=|
|CZ>=XML,_CMKIK3_@D=I*8^W?;4;GIN^R?#NVLL^N/|9W^/;|'O1
M_8O@U2_B<69|7DNE/#UE%_-#>^.?BW=\$=1;ZKX.LT/L0_@N|;|G!|1#1|P7 MI?
;Q#B;?W*|;_/EIA_T#ZS|(BO|_|R_A3!7_+^%G;_*CL7Y|^OD9E
MW_P5A^#R9^P_#;XE7A =^UGPO99|,^3KE_M_#=CWKF;O_@K7X03/V'X,>)+
MGT^U^+=+LL_7R='O|?ANKU^T_P""7G|--OCSK0XEW^,9^U^*=,3=|?L/ARRZ
MHN/:%=/:?!-K|E2VOYWA7Q+?XQG|7XTU|_7|H#=677OC'MBCZYX+T?^95
MQ#BK?|/,1&_)DL/^@?V?|2(K_/_|X4P5_P#ISA9VV_ZD^+|^_6W0^4|O
M_@KFYR+'X|JO|=,\$POGTS##X"3&/:9N_ ^"M7C5|_8/@YX7MO3|7X
MHU:|Q|?)TW3|_ABO0BT_X)|?LC6F"/A,MPX_CN_&OO"GS|8V|5B#|HA^6*Z:
MT_8F_96LL>3|%_"|XZ?:Y|;O_P_MVJW_|M3?W|M|7\$?
J'^H'C%7_P!Y|484N_U;#UE;TY*&%_3Y'X17?_!3#|J.YSY.K>#+#.^??-!?:D9|*;WPW>-|.
M2WHF6_L=.L; M;#H+6TM|<#Z"&-,?A1_Q\$+@JE_!|
_HJ6V|O4P3^_GRFO^OXA_Q"GQ%K_P"|M^,6>TK|_%:GF2^|DSS"_H?S1?|_#9|/:N?
|>WQ|8W6_I_9/A#P|G|W^ MR_".|;CUI?^%T?MW:|_P
>WB7X^W6_I_9.C^)|8,Y_N_P!E:7#CVVX|J_H MHH_XBEDU/_=O#SAZCVTPLK?^"|JH_H'_
!!7B&K_+YXL<5XF^N.C?_,&Y MYB/QN?S*>=_P4%US|K?M=W4;|?
+'Q>AM#G^|Y8BM1|9QQG&:4?"/JO'7A MCX|/?M#76_K_&MJOBV#.?</p></div>

[W]JZE#C @6* JHH XC!7I [MPIP]0[?NINW M (+5[X@'AJO OG"">)OO^ IQO
^#7B/ON?R(?\$O0?BAX)UZ?PA\4/^ M\$@T 7[>"SO;O1=*B%S9O=1)?
WJ02S0,ES%.4N!!+ #/Y8CFB= - MU+ @J2#V*D@ ACFOZ?'B' P38^&/Q+!
<^* ' B/XD_ \$ ^360%NN:AKE\ \$N?##
MPVS7LIR0V%IYOAUYSL=.MS#86\$3.WD65M!"#MC%<; PZ@ ^"W_11/BA_W P#" MG_S-
5^FX+Q*AA/Q6(E#V?#N2WO+ ^MXIJ MSNX'7QC||-Q;RQ31-@;D=3CFKW_ "#?|8|?
3X6:L/JSQOX%/ _ *!XO-?T0?"# MX:V?P?|
AUX: ^& ^G: JKGB33?"UM<66G:GXBDLI=4^PRWUS=VME(^GV=C;FWT
MZ*X6OLE\$&Z*SMX(B["-0/2J_<5XU<00Q.(AAL#P_B_-"O5CAZIL%F5.5:A&
M;5*K*K*G+, ^:G*I3492@J8M\O37|;P7T=>%;F#PE7&9EQ3A,94PU">+PT,RRBM
M##XF5*\$J|"6&3??_9(S1_PRI^VZG3P-|3 MO_N>)H3_ .@>(#7|-5%_ \$;:
|>^1\\O_LV+ _7&./^>.&UMQ)Q6O^YO ?IE MZ/YE?^&.:?VX\$Y'@KXLC'JSQ'(?|
T#7C1_PSK^W(G3P=|8A_N^(:P_|H.N' MTK^FJBC_ (C-
G#WR#AY_IR^*_7%./^>L@6W%':_P"YO! ?I@D?S*_| "@?V MZ\$Z>\$ _C8,?
W=>U4_ ^@ZR?3^7M1_PH|NM.GA?X|_# _'>'GW_<8C_Y>P_XE|R5;
<6<5K_N:PGZ89\RO_ "FOV\X^GAOX_C'IS6/ M\$Y_+9JAS^%_ J;IO-.F@?M\$C_?_0=2-?
TU44?|1CS|!|->W_+FKT_|>?R|_ Q _'+M;C3BM?|..*U_W'I_ MHT?S*_V'_P_%;4Z6O|7
_P|R?XMG_P!!F|I|@_X*\$ITB_;"^X_QE/_**Y MI*_JHKG0%VG:WK'A7Q)H/AK6D|_
^ (=3T/5=/T/Q#)9G4%T/5;RRGM|#5OL0N M+4W3: ?E34YM^)[KPI>7|M%IOCCQ)XAUN?
0|R M);ZG|'::|>W3Z;=F6TC@OHTCAF+VR17" |H55?TF_X)>?';_A'O%^M_ W7KW9
MI/C7S=?|^?+B.V\5Z=:#^T|A|R0*G|NZ+:K.JJN#=#Z'!#&IFOCNZ23_@DI
MXBFD>67XZ:7)+*|2222>!:YY)'4L*W&DY>|3JPI3C%>SBE^R|%-C#A\$ \$K(|@11(|: &-&<
:V2-D6C1FR51|M9"H(4R.1N+J_ED_MC|Z|@HHHH ****_ "O!OV^ (?^R|_M4?^M/?%^O>
M:|&_9Q_Y)|XA_P"R|_M4?^M/?%^@_9Q_P"2>^ (?^R|_M4?^M/?%^O>:|&_9 MO_Y)
|XA_|+S^U1_ZT|7Z|YH **_/A X*J?M6_%K|A|@S|H?|:L^#/A7X
M=>./&P5|&'O9#HWQ.NO\$ L?AJ:\$ZKINE9ET|PJUCJFM2K-J43_V>GB/PPKQ)
M(WIKQN% C?H?^"B7|9H_8=_9XA^)>B>#H/B5|5_B+4OA;^SS^S|,KK5QH-E M|0?
CO|;O%=GX-^'V@ZIK AN9M/T&RN+F|3^)|.VN-1_P"\$:/:NFFPR:@| ML*
/NNBOP<^*G_!5_P"(7_!/_P_9_M+_M_X*V_P'_&7B'X4?L62?MR?! M|XB?LX>%_&'PG|*?%
|POI7C:U^\$?B|X"WG@GXK?\$?XKZAX>^+>A_ %?6O:6F^ M&M>T_P"
(/B#0_ '/@WQS8^*+SP|X\$O/#^M: WJ7PP_:::Y^%W|2'|%WP4_ ;G M|_&RTW_@H3|A
XAZH(|KX'^^OB#X4U/HG|XX?#+P58?%36OV?/B_J/Q M^(/CC1_BG%KWP|OM1B)?
%WPE;_"V74_'O@W6?"|OPA@L|;T+6Z/V1HHK^> MG_@N'|4/B9|/?\$O|.D'@#XB>.O
|&J:|2Y=2A|^+O\$'AF+4)::P#|:6TM M|HNH627\$91D^94G%6:LW?
6UG^8^,7B9A/!_P|SSO!QV58C.L-DE3*J=3+<) MB:6\$KUWFN;X'*
(.%>M3JTX>QGCHUI*4)<|:;@K.2DOV=|1?|G/?"#_L@W|1W
M_JPOV5Z|YK_/_D_:%^/LNH6NKR_ '#XP2:K8V5_IUEJ_9|4""QOKJQNIY--M?\$EUJUH^J%
|'&*WU>SMXM4L MXI+A; &|MWG9Z_5:G@9FB@W2S|_3J6O&,+B*< &|KXJD9U7%6=
|JG|H%J?Q7 MA?VCW!TZ|.&,+>))J&&,'6MZM=75 M|WVK5_&/Q"UO4+S4KL)/B;X-
T;2|&08#M-ISZW|H94).^*<7K\$8VV^X5|GD/@ MWP_ED8XG.:M?.Z|_*4X24L-EU.22?
|'E)UJUG|^Q#IU%92PZNXGQ7\$OTH/I
M'^*TY8'PYX>PGA9P|BFX4|XQW^W<18FA*T7.EB|9A.2C&K||)Y7DD:E"*&,W%U=2IO/1_
M->'4OB@_B+Q5)&|\$^%?">I6?A M;37*.S00>^*|_3->U*[MI5\$:WFG6/AS1KK:TJ6FOP.
(|BOLKX:>'?V*=4AM!
MXT_X*)_LC^"K%54C2_#OC;3=8NX(|D_9F.K77A#3;:0G(+V|M_!\$3O_FY0_>
M/P|T_@C;H7V>;7OVT_@%|0+Q=KR#Q5^TU|-?#VF&92"#%8:%XA|,3|!G#&W
MOM1OU<|EE>2(E,?2X_B;(19!C|-3C'M3KO#X+#P4M/M?P^)^C+1/F5|?+X1^B_F.?
9FN)..>),NXJSS\$RA5KYIQMQ7@|11G55I*5?_?7 MLUS/&>SNX^SS15V4CH)'9?
&G@K|H#Q'|).?P_ ^SYX|^&7P.MKJ-+*;4?! M'A&+6?'&KP-Y: + #K/CKQQ/XL|4ZK-
(Z*P(O;>..9F:RM|7=MKL(?A1^VK^T5_M+'+|W3_#C@C/S!=.(C0@| \$W'| M|@_A_P#M&_|
!,CP*D:_#?| :&_8AT&15P+SPY|9_@>FI39&-T^J6_BA|2NW M*^+YEQ=3.5_7=M
%>V6O|7_D)=|C|%^U%^SM>;ON_9?C9|;C.>F/*|3/G/M M7YCC/\$+\$8*M4K9'X?
3PV*DVY9GFV%Q6(QM5|)5YPH0Q4Y*U|SS&H_-;O^PLF M&LOE@<-
EN<^)&&648>*A0X>X9J8#+ "+60J9+;34O_ %^LPKP7\$EM\$NBZ10Y(7R==N%)! M)(&-
WV1X&_X)=_L_>'?)G|7ZGXT^(5VNWSX+W54|:.)+MP<1V7AV*TUB\$;:
|'V+X|_!B|SC'V7XH^|HC.>F/*UQ|Y|8KH|7X MO?"_.^Q|B^*P|O-WW?LOC7PU<9^GE:F^?
PKXK-?\$'Q!Q_-&IC;E)W_ '67 MX-X'EO| RUXT_K:|KXEV|=3|,R7PG|+"O#|W|M|O5+?
0K*XUL;N;|>OH| MK69=I^9?-OGPQ9A|S,3Z|7/6OBWPI?

8^Q>)_#UYGIHEUK3;C/TJY?/X501R MQS('BD25#T>-
U=#/1&4D\1#7Y_B\1C,55=;'5\3B*TMZN+J5:M5]=9UI2F_FS
M\1P6%R_!450RW#8/'8>/PT<%1H4*,?2G0C"FM.T1\%%%"?A3X)\3_.\$?
XC^)\1!&>!?!FCW>O>*/%&07:6.DZ-I-BF^
M>ZNIWY))VPV\O"LMU>74L%G9P3W4\,ETZ=2K4A2I0G5JU9OITZ=.,IU*E2<
ME&\$(0BG*IVJ0?&K1;2\$).BVWV:U7PEXTN9HKC4=)\7=WJKG?#^
M<|.8R.7YWEV(R/&3H4<1"C7BKSHUXJ5.<)PE.G-;TYJ\$Y.E6A4H5%"M3J0CX
M^0\1Y'O/@99ED.98;,%%"06PTZ^'E*T*^FXU*=2%2,*E-VM4@YPBJM&=.02-M"H)%?"?
Q#_X+U?!\,+P\Y\O\>|1^(&HV^|?IOP\^&W MQ#UG?C(7R-;U3P\H?A6XWD\$+Y.OR
8#2;\$9&?<*|3YIRO+>|I\QT9;3PV5-MXVM22?656%%TXQ_O2FH^9SYCQ?PIE/,LSXER'
2C03Q6;8&C5NND;ZZJRE_M=C\R\C\BZ*_F(^(?
_!T/^S\H\GC^%W\I.OQP|=2Q;EAE\9:GX'^%C"\$DW+"_CKQ
M#XV^)=Q;JV0&\$FAW7PNMY9D\RCO:>3Y@#26\B9C/VF\|_%.\$?|\LED#P=.5OW MF/QV
PW+?^:B\3+%+S<.,VV^A\+F/CKX89?S+_6-8VI&_P"ZRI+|OQ7-;^6N
ML+="#N_2^(5\JM3^V.B0\|OO\I_P %Y_|@J5\4;L:3X=^,&E^"CJ4C10Z\|+?
MA1X'CO)V<\$K\8WVMZ\XK\4QNHR4^Q:NDY"Y9WP:XC^Q_ ^"VG\5V?.MO^"@?Q
M%T;4?N_VC-|8\#^'S^=U\G^T)=#\|V_FCS)\G,83?^|5,?54_'.<+"-7B
M#BCAG)*+5W*>)\K5I1CU;^L4\!1;6OPUY1_O=OD:GTC'.\$^*|\^K)\J
MC#"T*,)OIR_5JN8U\|3XL/&7\WO_*&WCKXP?"3X70-=?\$SXI?#GX=6R1^:U
MOXZ\;^&?,"Q8W>8TWB#4\|C\$>WG>6"XYSBOAGXA_P#|8;_@FA\O/&O_M>_
M##5Y(-P\KX>'Q#|53,ZYQ'!\,|#\66LF\|@%67\0MN,AGF2/+C^/3P+_, \$ M?^"H'Q&G6_
\$7PL|*?#L:@_GR:\3\BSX,DN)3*,N#P7X9^/OQ2NUW"VN-
#\#Z\X;T24KG#3WGC3QAH6L6\X&UH_#MS M(-"N#7PG\1/^#IW4Y//MOA/^Q\86N-
WV;6OB)\6\B_|\S/">?X9\->="=|K M;@,WE^+9O,W;1Y>S>_T_||/^#7_JDS13!-|3?
CS\>O'MQ#M9X/#"^\?A\I-T MXX9;BUNO#GCG51 W)"6NNVLZMM/VD@,K_=GP\X(4?
|,|X>^3,/V=%|,ZE M#M_XF7Q#\|?| Q#\3^=MY_?:(WB>S*ON/+8\|KG.W\GRTOKWT?%:
<_CITH86M4C M%_9A*&!SN:DNCCBH/3^)W_F(^(?_YUN_A0Y"-
)A1_\$GC>QGG4\80."5>.-5@,9*LOEDBO\|?AY^ MQ\^R?)?(\X9?LT? ?P)<6VTQW_A?
X3^!M(U5G3\LL^KVFAOZI=3C 'VBZO) MIR_H,A"@#Z,5550J@*J@*JJ_%50, #@#@<
<"G_Q%O@G*|.'O'O)*YM\W\$OB\GM6\$OXF#RV.-AAY7WY M7+,L-075*^7O3HEH?YRFF?
|!)G_(*|?M&7T&K>*O@;\7\7EE?S9-<^.?Q& MT'P_>VHE^|//;_\$WQK9^)*AN;@?+|J?
W8T5Q_M8SZ0/&M6'LLOPF0Y11BK4UAK+&9C1HTYRZNV\$PE#\$/^|B9R_O\G7P\X-9?
5H()OBQ^UWXO MU\MM:ZT\X>?"|10"(A_OPP:UXD\5>-OM/
)6YDT&UQNP;4\=S_=GP\X-T?^
M":_@KR#XD\,_%SXM/#M,A^('Q5U334N&7\|FO_"ZO^&X",1RD948.TD\D_NS
M17QVA50\$/,>;V_%694E*^F=#++++M%Y=1PLE;H^;FZMMW9\QEW@_P"&F5\K
MP_"&5U7&VN8K\$9M=KJUFE?%Q=WK;EY>B26A)?#S_@F'_P \$|OA:8\(|?L>_M 87-KM-
KJ'BCP'I7C_5;9UX66#5_T?B;4X9P./M\$=VLY\8&0AF!^S_#OA7P-MOX0T\|
)\>&|!+Z5'CRI\,Z\I^B:?'M&U=EEIEQ;6R\5X&V(8' XK>HKXS
M&YKFF92YLO\$+'X^5\|V-QF(Q4KH\UZE1W\|GW&!RC*" -+|??#WQ,D)U#1=2;ZMI
M; >|M\|VPU?1M6TZ>SU?0M;TZ8F2PUC\|ZRU&U+2I'<"&>>.3V.BN;#XBOA:|
M'\$X6M5P^)\P\2%:A7H5)TJU&K3DITZM*K\|QG3J0DE*\$X24HR2:::O\$8;#XRA
M6PN+H4<3AL12G1Q&'Q%.:A7HU(N%2E6I5%*%2G4BW&<)Q<91;333./^'_P_
M\|\$_"GP3X8^'PX\;|X\|^#-'M-|+^%|!M\$|=)T;2;%-D%K:P)R23NFN+B
M9L;ANI9\RI GGNIIYH.PHHJ*E2=6L.K5G.I5J3E4J5*DG.I4G-N4YSG)N4IR MDW*4I-
N3:::|+ITZ=&G3I4J<*5*E"-E2IQC"G3IPBHPITX12C"\$ (I1C&*48
MQ22222"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^/OVO
M/V:/%7\3>A>\$O"^E?\$BV\#^'M"U*_P\9U?3I_#\|QK(UW5'MX;31\F22'6=,|MI-
)MY=72.!HY5D?4FE9MT,6SX_-X=(;|_P\!%QTC_,(*)|_FJK\JZ*^SR?C
M_BK(,6K&>._&YU,,97\WHHKP,XSG,,^Q\3,LTJ MPKXVM&G"K6A0H8?
G5*"TTW*&TTJ;E&\$8PYW'F<8Q3;45;ZCA_A_*N&,LHY/
MDM"IALNH3JU*.'J8K%8OV3KU'5JJ%3%UJU6,)5)2G\3Y%*4G&*^(?^R\|M4?^M/?
%^O>:|&_9Q_Y)\XA_P"R\|M4?^M/?%^@ M_9Q_P"2>^(?^R\|M4?^M/?%^O>:|&_9Q_Y)
\XA_|+S^U1_ZT\|7Z\YH_'# M_@OQ9^*_ \$W_!|_|S^%WPI|^&7QD^+_Q*^,_A#3_
(9_#OP%|_#_@S\4?C7XL MU?Q3J.M6/B\!&U'1?
A9X2\6WGA;PW::\X;U>XU#QGXLCT3PA97D>FZ%-K:^(O M\$7A02-
7S/^"F'@3Q\^VE^Q;^SM^T/^S7_-B?X@|?_LO_M"?@1+1
M_AOXU^"OQ5^(:_LU_\$J;4/&/POU/XEZK>?M%10!_)7^W\^Q\9_ ^"TGQA_VJ_B9\,/AG\7

MO@Q|/'"!_6?V9?@/>_M%_"QM^SGXT^-7/4?BCX/>\$?V@IM+@^'_QC|. ^
M'_.'A_";PO8_"[PSX#U000XC|*>&#4_%/C2>|!^J^-|.ZE>HD<_&3
M_@H_ ^V|_P2Z^*,O|.7Q|_9_|%?L::|9/CU^U#JWQV^#OCWX+VUG|= _B%|(+ M?X5>#?
@'(KGXAZ38K|75TKQ/K/BGQ/XM^^(P|A|7?"|^#/#VGPZ1|2)-=|0 M:?.R?T&44_%?S6?
|%|D4>+OV:).ON?PY|3D(|DAC"OZGX*92L18Q(Y,K;Y\$1
M9)5\$:R,ZPQ!/Z4Z^4VD_P|BOX!_M8WOA+4?C/H&MZS=^";76++09-)|4:UH
M"06^N3:??/H!|HUU%!.S2Z9:,DK1"8_,C2.@C6/Z|@:/.'PYQ-E^;X^->6%P
MT,9&K'#0A4K/ZO@L1AX+'A|O/P)P MS5RRAG6<5LAJ82KF^(KX7_1CEG\$.5YIB/;5|
A;6A)X;|UHTE'#S4JCC&3C M%N2_A.KZ@_9)_94^(/|8GQ00?A-|/C!;?|#Q);>\$-8|7?|".W?
@Z#QKFPT MB^T>PN=(MM.FU'2WL+J|DUFWG35|6|6ZM4LY8(U*7(OA3|9?%>J6|>/_
!|*T|NL^#?%WP(TC09H|HW?G0Q6|CX|_M1|_QL(KE|F"296>T@*_8_|/O_|/G|F;|F+QY-
|2/A+X9|0Z5XJGT#4/#37> MI^,?\$&LVPT05+G3|N|C^PWMV|J|CRZ9;))8Y!&
S(HE|N1|VW-?&C)'EV,6 M2K-*&:NA/ZA5Q.7X*I0IXG3V/'8C_49@^+Y=Y=#XG|#^_
:A(SV\$44WC34XK9%"1P(MJ(/E10H KS"Z_P"#6|H5,_8OVH?
@U<>GVKPKXWL|^F?)COL?ANQ|U_:S17P
M%/QQ|1Z:45F^\$<5LGD^5Q7W4|)!+Y6|/|"1_P#"Z::_+\$Q<6^L*?B|9Y|,^3|&;|X;L>|?
W/T5TQ|>?\$6.^/RZ?| BRK" MK_TB,3FG|'?PSEME^9T_|&:XMV_|#<_Q/X/:K_@V3_X*6^?
^(G|=[C|HE M^(7Q03=|/MOP5M/_!|%(DW?3|;|K/M_P>Q7|)M%=?\$_Q CO4R:??^+;?;
^D8B)S3^CCX;RV|YY#_#FM|?^!X:~?XW/
M|>Z_P"#/(|T_|XLOO2_P#2,Q@'DML1Q+##_#F6#?_*7EDS_.QNO^"/_5,M|^5|
O#|H|C|E^-/P83=|/M MOCJS_P#L5@R?
|\$_)P#@K!ICF6#|EZY!'2;3_C;^SZ|G'HL'Q:\$'_;8|J_T M; **WC| (OC=:2RSA>HNO-
@O^"O.C?ZC|G;XEVS|_9?Q: ^&DV,?W?|^-^)|N?^ YH_X= MJ?|!931?^/?X+?M(VVS|_9?
Q&M)L8_N_P|F^Y?PV_A7^C?15?|3#<3R_B| M/<*U_|LF8+_P!|S*9/_\$M/"N'?;?
&/|O|F:Q+GVVY|J_T;Z*/^(_9G+^-PAPK4|_|B%_Z55J|_Q+ MGE4/X/&O%|+M_M.&=O|
P"C3AY#^P/^"|FC<06G_!6&V"L_|%6K3;U^W3_M:IC')S|JZ>^:_P!'VBC_M (C|H_ON.%;O?|
=)7_|/V4#_(E|E#^!XC|7TNW|YNW_(!B:~?Z'^;7-M|:~^"UNFY^U^/_|@I7:|>OVW4?
VDDQCU^U?KFLF;|JG_@L-IN?M?QE_|M- MO7|=K?QO3&.3G|5T|U_1544?|1LRF?
|_POX5|J|=PRO_P'|Y54#_B_V<0_@_M>*_%|+M|V*?_*1FL_S/YOVY_|@J_IN?M?
|17|9EIMZ_;O\$OQ,3&/7|4/Y MUX5|;OVO_P|M/XS^%8O_GQ^>^/7QU|
<^#&U&WU0>%/'_BSQ/=!:=:I8AFM+RY MTG4)H|_ NK R-
)9O=0S09N|2V_E.Y8_ZFM>)_M#?L|_"3|J:X2>*_@G|/'E
MIXN!|^+K3R;NTFQ#J.DZC";3/\$?AS4U1KC1|\$FB7#?:|)U:TQ;S!HI5GLY
M|JUG|LL|;_%L-F&#Q,_"(<"Z5>G)YAESR_Z|A(N2C.OA5_8M"4JU.#DX06) MH<|HSVU--
R7GYKX#<6XK+L;A8>+/\$.8*MAZD5EV9K,7@,9)+FAA|6_|=Q\$8T
M*DU&,YO"8CD7OJc4<>5_Y1VGZA?Z3?V6JZ5>W>F:GIEW;:AINL:?(9
M\$NK>2*YM7FCEB=_Z)?V\$O^#>/P1^SM^TCXI^+_|0'B|P|;O:G@3Q.MY^SQX
M_|LZX6VOXXS'>Z;XR^+>EWM|IT^O>'Y66TT|PMIDN|>'|G5;-O\$-Y=20?8=
M'B_IKZKC?Q|R_!8S#4N\$,!EV=5*!=5*F;9E0Q'L;J|85(X?"4HRPN*14JN)E2IY-E>
(PSKUX8>_"7BC2;F=?|&L4 M0|FY^+|'84C_'?M&C?
#SX2+'CN_D^)|O\$OC:7=G|J^9X27&-YSG8/Z|**_*L M?XZ^(N-
YE1S/!9;&6|U_+OH^>&6!Y76RO'9I* M-K2S'-<9JUUE3P\$!|1EYQE3<'UB?
S|_#S_@VS_X)Z>\$1!+XNU#X|_%6X7:US M%XJ^(>FZ#IDWI@ARVM_\$74,N" V<<-
R,5^JU%?%8_COC3,|K M&|4Y|5A*_2CF6*H4'?>^H5*5#R_AZ+1:'W67>'G
N5|G^"OV)/V=?AM:'3_AUX?^(7@&P,8B-EX*^/G|_M0'A:T,2D%8S;:'|4+"\$QJ54A-
FT%00.!7;_|X_#W_H8?CS_)4?M/?_/?K MWFBOEJE2I6G*|5J3JU).|IU)RG.3|RE)N3?
FVSZ^G2IT8|IT:<*5.*M&G3A&_M\$(KM&,4H|>22/!O^&_>_1_PSCV?|H8?CS_XE1^T|
M_P#/?KWFBBH+!|O|AG'X>_|0P_'G_Q*CH|_P">_1_PSCV/?^AA^//_(E1 M^T|_|J^O>:.*
/!O^&_>_1_PSCV/?|H8?CS_XE1^T|_M_P#/?KWFB@#P;_AG'X>_|##|>?|Q*CH|_Y|_|
SCV/?^AA^//_B5'|3W_M_P|J^O>:.*!/O^&?_*!CH|_.>_1_PSCV/?^AA^//_XE1^MT|_|J^O>:.*
/!O|AG'X>_|0P_'G_Q*CH|_P">_1_PSCV/?^AA^//_(E1 M^T|_|J^O>:.*!/O^&_>_1_PSCV/?|H8?
H8?CS_XE1^T|_M_P#/?KWFB@#P;_AG'X>_|##|>?|Q*CH|_Y|_|SCV/?^AA^//_B5'|3W_M_P
|J^O>:.*!/O^&?_*!CH|_.>_1_PSCV/?^AA^//_XE1^MT|_|J^O>:.*!/O|AG'X>_|
0P_'G_Q*CH|_P">_1_PSCV/?^AA^//_(E1 M^T|_|J^O>:.*!/O^&_>_1_PSCV/?|H8?
CS_XE1^T|_M_P#/?KWFB@#P;_AG'X>_|##|>?|Q*CH|_Y|_|SCV/?^AA^//_B5'|3W_M_P
|J^O>:.*!/O^&?_*!CH|_.>_1_PSCV/?^AA^//_XE1^MT|_|J^O>:.*!/O|AG'X>_|
0P_'G_Q*CH|_P">_1_PSCV/?^AA^//_(E1 M^T|_|J^O>:.*!/O^&_>_1_PSCV/?|H8?
CS_XE1^T|_M_P#/?KWFB@#P;_AG'X>_|##|>?|Q*CH|_Y|_|SCV/?^AA^//_B5'|3W_M_P

I^O>.*!/O^&?_!*C|H_.>=1_PSCV/?^AA^//\XE1^MTI_|I^O>.*!/O|AG'X>|=
0P_'G_Q*C|H_P">=1_PSCV/?^AA^// (E1 M^TI_|I^O>.*!/O^&_^>=1_PSCV/?| H8?
CS_XE1^TI_M_P#/?KWF@#P; AG'X> |##|>?| Q*C|H_YH'_ SCV/?^AA^// B5|3W_M_P
I^O>.*!/O^&?_!*C|H_.>=1_PSCV/?^AA^//\XE1^MTI_|I^O>.*!/O|AG'X>|=
0P_'G_Q*C|H_P">=1_PSCV/?^AA^// (E1 M^TI_|I^O>.*!/O^&_^>=1_PSCV/?| H8?
CS_XE1^TI_M_P#/?KWF@#P; AG'X> |##|>?| Q*C|H_YH'_ SCV/?^AA^// B5|3W_M_P
I^O>.*!/O^&?_!*C|H_.>=1_PSCV/?^AA^//\XE1^MTI_|I^O>.*!/O|AG'X>|=
0P_'G_Q*C|H_P">=1_PSCV/?^AA^// (E1 M^TI_|I^O>.*!/O^&_^>=1_PSCV/?| H8?
CS_XE1^TI_M_P#/?KWF@#P; AG'X> |##|>?| Q*C|H_YH'_ SCV/?^AA^// B5|3W_M_P
I^O>.*!/O^&?_!*C|H_.>=1_PSCV/?^AA^//\XE1^MTI_|I^O>.*!/O|AG'X>|=
0P_'G_Q*C|H_P">=1_PSCV/?^AA^// (E1 M^TI_|I^O>.*!/O^&_^>=1_PSCV/?| H8?
CS_XE1^TI_M_P#/?KWF@#P; AG'X> |##|>?| Q*C|H_YH'_ SCV/?^AA^// B5|3W_M_P
I^O>.*!/O^&?_!*C|H_.>=1_PSCV/?^AA^//\XE1^MTI_|I^O>.*!/O|AG'X>|=
0P_'G_Q*C|H_P">=1_PSCV/?^AA^// (E1 M^TI_|I^O>.*!/O^&_^>=1_PSCV/?| H8?
CS_XE1^TI_M_P#/?KWF@#PZT_9Z!65U;7D.O_
!Q>6UN(:F)+OIWHI2_M6D@D65%N;&^M^+-S97ENS*!
-W=O:-W\$9:&XAEB=T;-W&BB@ HHHH **** "BBB@ KP;|G'_ D MG OB'_ LO/|5'_
*T|A7Z|YKP;|G'_))|XA |+S^U1_ZT|A7Z #|G'_ DG OB'_ M
++S^U1_ZT|A7Z|YKP;|G'_ DG OB'_ LO/|5'_ *T|A7Z|YH **** "BBB@ HH MHH |&+1?
|G/'?"# _L@W|1W_JPOV5Z|YKP;Q%_R<|A(A_L@W|1W_JPOV5Z|YH M **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "B MB B@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ MHHHH *|&_9Q_Y)|XA |+S^U1_P"M/?
%^O>:|&_9Q_P"2>^(?^R|M4?^M/?%M^@_9Q_Y)|XA_P"R|M4?^M/?%^O>:|&_9Q_Y)
|XA |+S^U1_P"M/?%^O>: M"BBB@ HHHH **** /!O\$7_)SWP@|(-^T=_ZL+|E>O>:|&+1?
|G/'?"# _+((-M^T=_ZL+|E>O>:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MB B@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "O!OV^(?^R|M4?)
K3WQ?KWFO!OV^(?|LO/|5'_ K3WQ?KWFO!OV^(?^R|M M4?| K3WQ?KWF@ HHHH
**** "BBB@#P;Q%_R<|A(/^R#?M'?^K" 97KWFO!O M\$7_)SWP@_P"R#?M'?
^K" 97KWF@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "B MB B@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@
KP;|G'_ DG OB'_ LO/|5'_ *T|A7Z|MYKP;|G'_))|XA |+S^U1_ZT|A7Z #|G'_ DG OB'_
++S^U1_ZT|A7Z|YKP;|MG'_ DG OB'_ LO/|5'_ *T|A7Z|YH ***^4OVXVI?
#G|%/O!*OO F_:5|2V4NJ6_MPT|+->:1H|6G>(-575_%>LWUGX=|(V.H6?
A32M>|3KX>/B/5M-N/%^J:#H6M M:CX>|(6^N^(X)*OH|(E@<
^K:* &G|A;|NW XH_\$C|E|X| MK_M\$ M1_|\$|MH'|FOX8?#|Q%X|T|Q3^PAX ^-?AF_|
"UC|.?#?B+QG|5K?XI6OON^+_C#4 MD)U_3_-
AI%YHW@V|V/^\$=: @BN9=1U>=>;&_TLR>7?#/_(*5_M9Z%i7_3T M_:,:>^'_ P
"/#7|*W_!3?XG> ?A5|+_1|-+|?1_+'|FCQ)^T5X4UOQU^ MRZYXYUOP3|:H/B;I6EZ?
X9^(#'^/AG|\$)?ACXP|0Z5;VMOXU@-S# M?O/1110!X-XB_P"3GOA! P|D&:_ P#5A?
LKU|S7@WB+_DY|X0?|D&:_+M5A?LKU|S0_4444 %%%%!1110_4444 %%%%!1110
4444 %%%%!1110_44 M44 %%%%!1110_4444 %%%%!1110_4444 %%%%!1110_4444
%%%%!111 M0_4444 %%%%!1110_4444 %%%%!1110_4444 %%%%!1110_4444 %%%%
M!1110_4444 %%%%!1110_4444 %%%%!1110_4444 %%%%!1110_4444 % M%%%!1110
4444 %%%%!1110_4444 %%%%!1110_4444 %%%%!1110_44 M44 %%%%!1110_5X-
^SC_P D|A0_|EY_:H |:>^+|>|UX-^SC_R3WQ#_-EY M_:H |:>^+|!^SC_,D|A0_|EY_:H_|
6GOB_7O->#?LX|)/?\$/_9>?V|/M_6GOB_7O-!7SU^TM^T:-LS>

M)^ (FH !OJH7XUZ3> ^_ #7@ 5]# 9I^ \$NL M_ &I O[X6T_P 1/=QR^ /M6^? /
A6=O&NK^"/#S2^M)I+POJ M-LMY-:20M% 'X3Z5^PGI_P" T1KO_
5D^ (PF) %Z_P#LU?"3_@I#^QQH7I-M MMH7C?X?^ (OA/XA|= &IO!7I1'A/QK^U_
XD^ \$/B31I) \6_#V'4?#7Q?I AIX+ MM I+QIX+ _ \$:Q3JGP+ %_ B?Q_
X3M I2^ \.ZKXF^0_#O@?IH?IK3X0?I !%C I MB?5_V9?CW\%OB% ^P'^T1^R= _ VRO'OO_
^ \$ _C/PC\%O:L I' ?@?5I L_ \$ ^%? MQ9US3K;P\ CZA H>H3;O;66IV\6UQ/H.OZIX6UB*_
F5BVG^ (?#&I:1K^DW M^C;=Z7J=G=*NY5F"LP.O10! \Z I O T7I17PLTA=> ^-9M+
IX* 'S4HHVD M_P!HF;5\$N_*I
< LV6MK'9ZW+ \4GUK3K"6/6;MM2TJPOI;2I9N(=*N I7LIZIT M+1)M/HJ_X9P^'W_0Q_ 'K_P
2H_:= _P#G04OB+ _DYIX0?ID& _:_J6%^RO7O- M '@O_#.'P^_Z&/X I?^ ^)4?
M_ />H_P"&O_ \$J/VG?_)IU>I44 M>" \X?#I_H8_CU_P")4?M_ P#SWJ/^&I705% 'M@O I
PSA\O I_H8_CU_XE1^TI_P#/>H_X9P^'W_0Q_ 'K_2H_:= ^>I705% M '@O_
SA\O^AC^/7_B5'I3O_P IZC_AG#X??I#'\>O_ !*C IHW_ .>I705% M '@O_#.'P^_Z&/X I?^ ^)4?
M_ />H_P"&O_ \$J/VG?_)IU>I44 M>" \X?#I_H8_CU_P")4?M_ P#SWJ/^&I705% 'M@O I
PSA\O I_H8_CU_XE1^TI_P#/>H_X9P^'W_0Q_ 'K_2H_:= ^>I705% M '@O_
SA\O^AC^/7_B5'I3O_P IZC_AG#X??I#'\>O_ !*C IHW_ .>I705% M '@O_#.'P^_Z&/X I?^ ^)4?
M_ />H_P"&O_ \$J/VG?_)IU>I44 M>" \X?#I_H8_CU_P")4?M_ P#SWJ/^&I705% 'M@O I
PSA\O I_H8_CU_XE1^TI_P#/>H_X9P^'W_0Q_ 'K_2H_:= ^>I705% M '@O_
SA\O^AC^/7_B5'I3O_P IZC_AG#X??I#'\>O_ !*C IHW_ .>I705% M '@O_#.'P^_Z&/X I?^ ^)4?
M_ />H_P"&O_ \$J/VG?_)IU>I44 M>" \X?#I_H8_CU_P")4?M_ P#SWJ/^&I705% 'M@O I
PSA\O I_H8_CU_XE1^TI_P#/>H_X9P^'W_0Q_ 'K_2H_:= ^>I705% M '@O_
SA\O^AC^/7_B5'I3O_P IZC_AG#X??I#'\>O_ !*C IHW_ .>I705% M '@O_#.'P^_Z&/X I?^ ^)4?
M_ />H_P"&O_ \$J/VG?_)IU>I44 M>" \X?#I_H8_CU_P")4?M_ P#SWJ/^&I705% 'M@O I
PSA\O I_H8_CU_XE1^TI_P#/>H_X9P^'W_0Q_ 'K_2H_:= ^>I705% M '@O_
SA\O^AC^/7_B5'I3O_P IZC_AG#X??I#'\>O_ !*C IHW_ .>I705% M '@O_#.'P^_Z&/X I?^ ^)4?
M_ />H_P"&O_ \$J/VG?_)IU>I44 M>" \X?#I_H8_CU_P")4?M_ P#SWJ/^&I705% 'M@O I
PSA\O I_H8_CU_XE1^TI_P#/>H_X9P^'W_0Q_ 'K_2H_:= ^>I705% M '@O_
SA\O^AC^/7_B5'I3O_P IZC_AG#X??I#'\>O_ !*C IHW_ .>I705% M '@O_#.'P^_Z&/X I?^ ^)4?
M_ />H_P"&O_ \$J/VG?_)IU>I44 M>" \X?#I_H8_CU_P")4?M_ P#SWJ/^&I705% 'M@O I
PSA\O I_H8_CU_XE1^TI_P#/>H_X9P^'W_0Q_ 'K_2H_:= ^>I705% M '@O_
SA\O^AC^/7_B5'I3O_P IZC_AG#X??I#'\>O_ !*C IHW_ .>I705% M '@O_#.'P^_Z&/X I?^ ^)4?
M_ />H_P"&O_ \$J/VG?_)IU>I44 M>" \X?#I_H8_CU_P")4?M_ P#SWJ/^&I705% 'M@O I
PSA\O I_H8_CU_XE1^TI_P#/>H_X9P^'W_0Q_ 'K_2H_:= ^>I705% M '@O_
SA\O^AB^/1_ JNH_:= I7A2_ \X_ #W_H8?CS_)4?M/? /?KWFB@ M#P;_ (9Q^'O_
\$/OY_ \2H_:= \GOT? \X_ #W_H8?CS_P")4?M/? /?KWFB M@#P;_ AG'X>_ I##\>?
_ \$J/VGO_GOT? \X?#I_ *&+X I C_ +NH_:= K I7S7O-% M '@O_#.'P^_Z&/X I?^ ^)4?
M_ />H_P"&O_ \$J/VG?_)IU>I44 M>" \X?#I_H8_CU_P")4?M_ P#SWJ/^&I705% 'M@O I
PSA\O I_H8_CU_XE1^TI_P#/>H_X9P^'W_0Q_ 'K_2H_:= ^>I705% M '@O_
SA\O^AC^/7_B5'I3O_P IZC_AG#X??I#'\>O_ !*C IHW_ .>I705% M
'@W_#.'P^_Z&+X I G_NZCH I^GQ?%'_ #./PI_P"AA^//_B5'I3W_ ,I^O>:* M /!O^&I44 >"
M_P##.'P^_P"AC^/7_B5'I3O_ ,IZC_AG#X??I#'\>O I Q*CHW_YIU>I44 >M" \
#.'P^_Z&/X I?^ ^)4?M_ #WJ/^&I44 M>" \X?#I_H8_CU_XE1^TI_ \IZC_ (9P^'W_ \$,?
QZ_ \2H_:= \G05IU10! MX+ _PSA\O^AC^/7_ (E1^TI_
//>H_X9P^'W_0Q_ 'K_Q*CHW_YIU>I44 >" M_P##.'P^_P"AC^/7_B5'I3O_
_IZC_AG#X??I#'\>O I Q*CHW_YIU>I44 >M" \#.'P^_Z&/X I?^ ^)4?M_#
WJ7_AG'X>_ I##\>?I Q*CH I_YI I>I T4 >M#?I #./PI_Z&'X I^ ^)4?M/?_ #WZ/^&?_ !*CH I_
_>_7O-% M '@W_#./PI_Z&'X I_P#B5'I3W_SWZ A AG'X>_ \0P_ 'G_Q*CH I_P">_7O- M%
'AUI^SUX" LKJVO(=?^_+RVMQ#XT44 %%% %!1110 4444 %>#?LX_P#) /?\$/_9>? MVJ/_
%HXOUIS7@WI/_ "3WQ#_V7G IJC_UH XOT 'I./)/?\$/_&7G IJC_M_:= ^+I> \UX_ ^SC_
DI0 J EY_ :H_ \6G0B_7O_ !1110 4444 %%% %'@W MB+_DYIX0?ID& _:_J6%^RO7O->#>
(O I_DYIX0?I 9!OVCO I_U87I* I> \T %%% M%% %!1110 4444 %%% %!1110 4444 %%% %!1110
4444 %%% %!1110 444 M4 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444
%% %!1110 M 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %
! M1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% M%%
!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 444 M4 %>#?LX_P#) /?

\$/_9>?VJ/_%HXOUI\$7@W/_/"3WQ#_V7GJJC_UHXOT'M'/_)/?\$/_&7GJJC_-:>^+|>|UX-
^SC_,D|H0_JEY_:H|6GOB_7O-M!1110 4444 %%%%'@WB+_DY[X0?|D&_:_16%^RO7O-
>#>(O|DY[X0?|M9!OVCO|U87[*]|>|T %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!
!1110 M 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!
M1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %M%%!1110
4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 444 M4 %%%%'!1110 4444
%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 M 4444 %%%%'!1110 4444 %>#?
LX_P#)/?\$/_9>?VJ/_%HXOUI\$7@W/_/M"3WQ#_V7GJJC_UHXOT'M'/_)/?\$/_&7GJJC_-
:>^+|>|UX-^SC_,D|M|H0_JEY_:H|6GOB_7O-!1110 4444 %%%%'
'@WB+_DY[X0?|D&_:_16%^MRO7O->#>(O|DY[X0?|9!OVCO|U87[*]|>|T %%%%'!1110
4444 %%%%'!M1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444
%%M%%!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 444 M4
%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 M 4444 %%%%'
!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!M1110 4444 %%%%'!1110
4444 %%%%'!1110 4444 %>#?LX_P#)/?\$/_9>?MVJ/_%HXOUI\$7@W/_/
"3WQ#_V7GJJC_UHXOT'M'/_)/?\$/_&7GJJC_M-:>^+|>|UX-^SC_,D|H0_JEY_:H|
6GOB_7O-!1110 4444 %%%%'@W MB+_DY[X0?|D&_:_16%^RO7O->#>(O|DY[X0?|
9!OVCO|U87[*]|>|T %%M%%!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'
!1110 444 M4 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110
M 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %%%%'!M1110 4444
%%%'!1110 4444 %%%%'!1110 4444 %%%%'!1110 4444 %M%%!1110 4444 %%%%'
!1110 4444 %%%%'!1110 4444 %%%%'!1110 444 M4 %>#?LX_P#)/?\$/_9>?VJ/_
%HXOUI\$7@W/_/"3WQ#_V7GJJC_UHXOT'M'/_)/?\$/_&7GJJC_-:>^+|>|UX-^SC_
,D|H0_JEY_:H|6GOB_7O-M!1110!(?LSZ9_P4XL_B?XEF_:'_L(>(_@P_AC64!Z?^SA
##|H'P7|M3X/&:>(<=<P_<^)=8^*7Q>|>^%+OPQ%X47Q1!K-CI>A66JS^(9|!NK+4;?3;
M74+_|^|Z**"LC7M-O-8T?4_,T_Q|J_A6|O+@27"@%NJZ'J=KM=BULS!677HH
^)=;^\$7Q#'_Q_&2?|_\$_&Y5O@|_M|T4>#?|"H/B%_T=1|>?">_M9A_^AQH_X5!|0O|
HZCX|_|A/?LP_|T->|T4>#?|*^^(7_1U'OY_|)|H MF'_Z'&C_
(5!|0O^CJ/CS_X3WL/_/P!#C7O-%'_@W_"H/B%_T=1|>?|PGOV M8?|
Z'&C_A4'Q"_Z.H^//_A/?LP_0XU|S10!X_-PJ#XA?|1U'OY_|">_9 MA_|H<:/^%0?
\$+_HZCX|_P#A/?LP_P#T->|T4>#?|"H/B%_T=1|>?">_M9A_^AQH_X5!|0O|HZCX|_|
A/?LP_|T->|T4>#?|*^^(7_1U'OY_|)|H MF'_Z'&C_(5!|0O^CJ/CS_X3WL/_/P!#C7O-%'
'@W_"H/B%_T=1|>?|PGOV M8?|Z'&C_A4'Q"_Z.H^//_A/?LP_0XU|S10!X_-PJ#XA?|
1U'OY_|">_9 MA_|H<:/^%0?\$+_HZCX|_P#A/?LP_P#T->|T4>#?|"H/B%_T=1|>?">_
M9A_^AQH_X5!|0O|HZCX|_|A/?LP_|T->|T4>#?|*^^(7_1U'OY_|)|H MF'_Z'&C_
(5!|0O^CJ/CS_X3WL/_/P!#C7O-%'_R%X*|\$_?%_7_\$OQ>TG5_VF M/CE9:?
X'^(>F>%_"US#X3_9MMI-7T*|^\$_PPl:7.H74UU^SS-!W\$7B;Q?XB
MTL;O3H|2S2UTRVL9+=MOLKZZN?1/^%0?\$+_HZCX|_P#A/?LP_P#T->|T4>M#?|
"H/B%_T=1|>?">_9A_^AQH_X5!|0O|HZCX|_|A/?LP_|T->|T4 M>#?|*^^(7_1U'OY_|)|
H F'_Z'&C_(5!|0O^CJ/CS_X3WL/_/P!#C7O-%'_@ MW_"H/B%_T=1|>?|PGOV8?|
Z'&C_A4'Q"_Z.H^//_A/?LP_0XU|S10!X_-MPJ#XA?|1U'OY_|">_9A_|H<:/^%0?
\$+_HZCX|_P#A/?LP_P#T->|T4>M#?|"H/B%_T=1|>?">_9A_^AQH_X5!|0O|HZCX|_|
A/?LP_|T->|T4 M>#?|*^^(7_1U'OY_|)|H F'_Z'&C_(5!|0O^CJ/CS_X3WL/_/P!#C7O-%'_@
MW_"H/B%_T=1|>?|PGOV8?|Z'&C_A4'Q"_Z.H^//_A/?LP_0XU|S10!X_-MPJ#XA?|
1U'OY_|">_9A_|H<:/^%0?\$+_HZCX|_P#A/?LP_P#T->|T4>M#?|"H/B%_T=1|>?">_
9A^AQH_X5!|0O|HZCX|_|A/?LP_|T->|T4 M>#?|*^^(7_1U'OY_|)|
H F'_Z'&O//B|X(^+_((^\$_QA:;>%OVF/CEJWB;PA
M_|_&OBCPYI5UX3_9MO[74]=T#PUJ>K:1|HS8Z=^SS::A>V|H%I;VTUI8W5M M>7,44
>##X0?\$+_S^U1|>>G_0N_LP_\$.-'_"H/B%_T=1|M>?|PGOV8?|Z'&O>:*_/O^%0?
\$+_HZCX|_&\$|^S#_|#C1_PJ#XA?|1U'O MY_|">_9A_|H<:/YHH|&_X5!|0O^CJ/CS_
.\$|^S#/OXT?|"H/B%_T=M1|>?">_9A_^AQKWF@#P;_A4'Q"_P"CJ/CS_P"\$|^S#_P#0XT?|*^^(7_1U M'OY_|)|
H F'_Z'&O>:*_/O|A4'Q"_Z.H^//_A/?LP_\$.-'_"H/B%_T=1|M>?|PGOV8?|Z'&O>:*
_/O^%0?\$+_HZCX|_&\$|^S#_|#C1_PJ#XA?|1U'O MY_|">_9A_|H<:/YHH
|&_X5!|0O^CJ/CS_.\$|^S#_/OXT?|"H/B%_T=M1|>?">_9A_^AQKWF@#P;_A4'Q"_P"CJ/CS_P"\$|^S#_P#0XT?|*^^(7_1U M'OY_|)|
H F'_Z'&O>:*_/O|A4'Q"_Z.H^//_A/?LP_\$.-'_"H/B%_T=1|M>?|PGOV8?|Z'&O>:*
_/O^%0?\$+_HZCX|_&\$|^S#_|#C1_PJ#XA?|1U'O MY_|">_9A_|H<:/YHH

1& X5!00^CJ/CS_.\$!^S#_ /0XUYWJ?@CXOVGQ M8!\$^"/I:H?XY2^&/\$P!^*B?6-
5:PG^S:JU9:[X0!2?" +2O#FGPWT?[/*Z? M;0:GI C?Q3R:3:S6%Q;06&HOW?UI10!X-
PJ#XA? 1U'OY | M">_9A | H<:/^%0? \$+_ HZCX | P#A/?LP_P#T.->|T4 >#?|
"H/B% T=1|>? M ">_9A ^AQH X5!00| HZCX | | A/?LP | T.->|T4 >#?|* @^(7_1U'OY_ M)|
HF' Z'&C_ (5!00^CJ/CS_X3WL/_ P!#C7O-% '@W_ "H/B% T=1|>?| MPGOV8?|
Z'&C_A4'Q" Z.H^// A/?LP_ 0XU[S10!X- PJ#XA? 1U'OY | M">_9A | H<:/^%0?
\$+_ HZCX | P#A/?LP_P#T.->|T4 >#?| "H/B% T=1|>? M ">_9A ^AQH X5!00| HZCX | |
A/?LP | T.->|T4 >#?|* @^(7_1U'OY_ M)|HF' Z'&C_ (5!00^CJ/CS_X3WL/_ P!#C7O-%
'@W_ "H/B% T=1|>?| MPGOV8?| Z'&C_A4'Q" Z.H^// A/?LP_ 0XU[S10!X- PJ#XA? 1U'OY | M">
9A | H<:/^%0? \$+ HZCX | P#A/?LP_P#T.->|T4 >#?| "H/B% T=1|>?
M ">_9A ^AQH X5!00| HZCX | | A/?LP | T.->|T4 >#?|* @^(7_1U'OY_ M)|HF' Z'&O_ A?
X(^,'B_PWJFJ(^_VE_CEI>H6?Q\$^+OA>VMK;PE^S;91RZ
M#X(^*_C3P9X6U%H; P#9YN9WGU?PSH&D:K=7< MT4 >#?| "H/B% T=1|>?
_">_9A ^AQH X5!00| HZCX | | A/?LP | T.-> M|T4 >#?|* @^(7_1U'OY_ |)HF' Z'&C_
(5!00^CJ/CS_X3WL/_ P!#C7O- M% '@W_ "H/B% T=1|>?| PGOV8?|
Z'&C_A4'Q" Z.H^// A/?LP_ 0XU[S10 M!X- PJ#XA? 1U'OY | ">_9A | H<:/^%0?
\$+_ HZCX | P#A/?LP_P#T.->| MT4 >#?| "H/B% T=1|>?_">_9A ^AQH X5!00| HZCX | |
A/?LP | T.-> M|T4 >#?|* @^(7_1U'OY_ |)HF' Z'&C_ (5!00^CJ/CS_X3WL/_ P!#C7O- M%
'@W_ "H/B% T=1|>?| PGOV8?| Z'&C_A4'Q" Z.H^// A/?LP_ 0XU[S10 M!X- PJ#XA? 1U'OY | ">
9A | H<:/^%0? \$+ HZCX | P#A/?LP_P#T.->| MT4 >#?| "H/B% T=1|>?
_">_9A ^AQH X5!00| HZCX | | A/?LP | T.-> M|T4 >#?|* @^(7_1U'OY_ |)HF' Z'&C_
(5!00^CJ/CS_X3WL/_ P!#C7O- M% 'R-!6?!?Q=|! "OXF>./#/I2?QNU(I)X, ^' C/Q7X?
T/4/"G|.5|8:SKGA MWPYJ6KZ3I5|9:/^ L^Z=JUY::C?V=O9W-KI>H6&HW\$.S06-
Y:W+Q3HJ#?LX |D|!0_P#9>?VJ/_6GOB_7O->#?LX |D|!0 |M9>?VJA UIXOT 'L/_
"3WQ#_V7G|JC UIXOU[S7@W|./)/? \$A V7G| MJC UIXOU[S0 5^>/I7G|5_Q:_9|:_7-
"?PG|)>%?AUJOPZ:V_:!1?! M?
Q(K_B*Z|2W/C70AI7P: ^)OQ2MKCPAI6FOI.A6)63P!:V<^K:SJ/B 72:M<6 MT?
ARQ:PCU&|_0ZOPK X*O^/=1|_ M:_|\$H-6TSX*_M3?%'1/@C^U5K_QL^+G MB'X#_LF?
M(?SP|X|^&FM_?XT?"6TUS60\$P>^&'C31YM5C|6^*--UX'TF M|U+X@0Z&?
|>_X15M,N|+GU_03|K'4?^"@%S)X=|_?L+Z#^ROI&H-I|_K7C M#XH_M:3_!*_P
&6LL<|=KHW@CPG|_@YJ_AWQCJ^M:B!>:GKWBS6_%?AS0 M?#%A%I-OI.E>.=1UC4|?
PM|G?LI?|%' (J_%3|@7X^_M#?'7X)Z)|/_-I+ M|F+XK?M!?'LR>//A7X.UK4-
6^'OQ*_:4^""C.7X8:)X<^#OB'41)J>J>'?BK| M3|SP|X"|+_ :IKVXM?%NI7F@#5-
5&G|JMW|?^WA^V|J7|+\$7@SP;X5^ 'I9'Q M@|4_ \$A+QKKQ?
^S%^R)|8/VDM)^\$ _AFW|Z"|I2:U=>#/'FI^#90&-S<1FS|(^ M#-6UAI_M:/@UJ_CW7|@I_P
(M|0?|L>HV_CVYN/%^N>*/'G| M3?QF|) 'IO&?C""SU'X@^,?@?|4-8M9M;NM.UK4X
#N/VV?C+^WY^RK^S_ Q M\$|_ \$:|C|)' ^ GP&T+7_ BO|6OVN=*|76T7|10Q9T|P|,OA
M=I'PRU?QE?Z;C0;VXA|11:KXL|76'A'PS|,|23|,&H779?M/_ MH?'WX,|
M!'Q)^WCHGP:!*>\$ _CCX8_9-|_ M\$^+?@C|7M0|41Z;|V?\$ES|_|_| ^+_AW
MKD.AV.EZ_K>L^%-9N;GPA+82W?@YY+FWN+^ZU*QDL_|+O>_X*\$ZY^R|>-2
MU|JC?|K_/8\$:_C_&FO#C^#;3Q5X\$|8>#?V//BA|8OAM=^+;_M=:TN#2/AA_M|?|X?
Z=JFF_!'XQ:2%;3Z?=>)?&GBCX::H|EK-K|O|<0Z:J=|+7QW^T7|' M?
VD|@7_P;C^)_ P!E3XPZ3|_ -HO|JO7OV0O\$P#M- ^%?P|^)7|2OQ&U/QY
MXNT;O"W@KP?KD_PB|)>+|J>R|">&OIG@GO!4-7CL_ SWOAZ&>;Q3//KFBMJ
MP|^|&E?\$G2;#X-;|7_B|J>D^&-"L_AC9_\$GOMK,K2VFA>'M)M_"L?B?Q)J<
MC3RW4|M|D.V:7MT|33W,L-G;DR2S.I=ORRUGQW_P6F|6?!CP5XU_9R|_#_L<6_M7B+4-
%W|8=>TC|KM?B(?%_B;7?B=J>O_\$KPQ^SEX,|/?|75/ NA?#NW^""@_MO6_"?P4N/BG|3-
9UO6?&?BS0-2UG7?"<-I:3^./%WKWB+5M9_:6_8R_9=^&/
MA3X= _&;0/#O|26L_#/X2_&72_B9|&OBA|)O%?P|^#O@O2M9|1_M"Z%|6O_OQ
M&|^*_&/%G@C2/B-X6^%/BKX_Z3JGB#2K+1?%&I?%GPEK'A/4/\$7ASQ%H.J;KQ
M_P"WY^W':?#/Q5)^S&W|_G_!0_XE^&/&7A&Y;XM?%7|E'|C3|H/XM:I?A7Q
M!:BTE^'W@?XE^""?#\$.@P>.%&E7=U#J_BSPMX@O+|X;::T_|G7%C|0);"X|_M
'C%K_P5^|3_!&_83_X)U_ '+X4?!W2=&:_A_P""FWCKPA_"#X*?";XBZCJ
MESX(^_BO51XBN/B;|6/&L^DG1?%GBKX+?"|P|X0UWQK;)X=710\$GCO2|2|\$
M:5#=>%CXHN==T/ZN_9%:_Z^*GB_H|G|H|AC|H^W^&LG|17|_ ^A_##XI:'X_
M^'\$A0Q3X\$^&WQU^_P_8K75D|_>_O#OPY|_ ^_B=XG^'_B#P5XJT#6O?Q+M-
7OQ)|=Z:-331-;T+O/=6VN7.DZ#|*?M.>\$O\$Q@^%W_2S_ ;F_9K_91_: % M|!^#/^"?
P"TS#JEW^R3XT^"||#SX|VO|*E_X0|3?LY^-.5|"_L^0W-SXU_M_P"\$A|Z FA>,OAM|_>8=

(A3^*/FFWDNE^&K^_O?#.CZM|C^Q7|-?B#|9/^M"D_[-?|P4:UWX>_\$?
X3_!WQG|!%O@5^R=^SGH7Q=^OBWX2?\$SXD^&OAIJ'B M/QW12_BUXG^%/Q%TO00B-
+|M"N"/B2W1+?#VQ|>/'OB37|&TK5M:3|9_"C_@G#=?'_P_1_LX_LS_ ^7_@H!X!
M_P""67|+G|2.@?M(:QX3_?|.Z+|*_#_(AO/A|K|_X|^'G|.7|./PC|;_!C MX>_M@:Y|+
|GQYJ=AK/C#Q|_M0:Nf@^#_"FC?|(U|,?60\$FJWU|X</_ZNZ*_M**_"BBB@_HHHH ****
"BBB@_K|+?V2_VK?BY|:_VK_ ^"B|/|/Q.|+?#GPH_M_P"QW|1_@#X0|!WW@.Y|3:E>:_I?QF^
7AKXWW%SXHU?Q!)9P7^H:7XMT|1_M(3I/AGP|;*^GWL|Q7:W4!MOT.K|+|^">7Q
Q|8_X*>_||>=7U'X+?M4>_O"?MOY^)'|/C#X_,\$#XL_LE?M)_ "3X;_\$300@O^RO|_#SX+?
\$6?1?'_ ,1_A=X9_M|)VEWT'CSPW>6NDZ7KVK:/J?C31Y|?Q%X'M/\$FB0ZE>Z>_9?|>W|:O|
P54_M8D|>_?VPM0^!W|'7BG|B?X9?%'PWH'BSX'V.N_%K4OVS=7^\$OB3XFZ3|+=(
M^(>@>/_U:|+X)0>_,=34=
M/OIM!U3QO|8_B=X&|3Z+JNG2V&I7N@?'"X@:5:7)MY=0:|MOVCO^"B'@#QA_M|8+|X?|
Q)_8%_X*J_\$KX1_3XEZ'X|_6_PY_X)S?M,>)O!OQJ^*?PXOX|;_M|>_9=500"F@V&M?
#SP#XOM:~7O_%E/'VG^*?'GA|0_!EW'H/A_PV^N?HE^MS=8>+?%'Q\$_.8_:@|+=^
/&O@G5?'FM>&OA)|/_B_28-*|<:;|&V=K'Q|:
MVD&H:.E|=6!U#Q1|=?"Q|2:|K&F:I>:|XQ|!ZO|/M?T+6M9|_W.BZU=@'Q_M_/A_M>?M|>
/V|OV8?@'12?"W|(WB|X6?M-S_\$Z?7OA^|(9_B1=_M2?LJ^#O_M"?@K50%OA0XG?%GQ9?|
C+6?AWXZ|_S:G9:-|A_Q3KVF?#KX:|/X|6:/H_MGA#6?%1>QEUCZ+^,?
|50Q<^&G_!13|BK|DVU|+?#F?X1_M3?#C|J|Q?J/BF>
MY|37WQ'TS5/V;_#/PKU>*VLK>_.32/#.CZ?K6H?%.TMY|/XKN9K/0|B59=+G
MU**.Q_,+XA_#X9?MY?
M7_L8_MGZ(G7O!'@+1|2EF|X_:+^(%_IW_!9#_@EWKEG|!OVJ/%G@_M;X;?#?|;:|'_%?XJ?
#W|DK|H/XC?"P)K0|2_AC|G_3?A#|K'Q_|#?"|7_!M=Q::OJ?
P^U^Q|2ZIH^LZHGPy/V6^^(JWX4TDWFH68!^EG|3GQ+|9^%KKX\$?_M#3X7:A/IWQ(^
?QO|'Z%;WUG9:%JEQ|/PP^?VGXP_'.^EL/\$=K=Z3!'XB^%_MO@+7OA/I6LWBV|6A>..?
BCX*OH|VVO19%_P_O/B)^VC_P51_9;^_OI(>K?M2_M|;|C76/V7_VP/VG_(>_LLIX(^
NM_&'40VC0V>O&7QHCU67X>:SXU|;^*K|
M_#+XL:%X;71=17XEW7@SP)X2M|(VMQ=: '=7FCPKJTWZ,Z5HNO^)OVPOBC|9/
M%7ASQ+IW@7|G?X-6/P6^%ES/X'/C-^T%XG|(Z=:6\$|HXVT(
MZ'X7_9V|%:|JGAJ|TU3_BM?"WQ2|'6,D^MV&LZ9;?FK8_|%\$_!OQJ_..^'/B3
MQS_P3Q_X*NZE>?#CXCZAX:_90TW5?^">WQY|)_#[P|XB|;-)|+GX^>./%_Q
M'TWP9X1|,ZG>^%|)->BT(|E^)'|M:W|7GQ@_:_>_;"_9Z_8+|,?_*=V|/GPYU3XP:U|>/_#_
(|9O|'3XT_%;P_M9J?Q*|+?L|_"1_AK|0_|PSDTGP7IEC#XR^+7BFW^)SZ+XN|7Z5H%O|
(|^/M0|30KWJ?"_|7W|6?|T_P#:#^%S|2/%?C+|KK4_M/'OB/PE|,|3Y-
/T6|^\$UGX&^#VH^&/%WCGQ|XQ'BW0|4|3_P#"1^%?".@VMO@B|OD_M^|US3-
(B^6H;CXP_|\$YOVX_ ^"HWQ)MOV,_@#|6=5|
Z_-4_9;_98^+G|3_AOX0ZQXFU_7OB^0=0U_4?ACX=O?#%_M^?"GB+QA=^\$?^AWGB'3;
|QO=V=GK4D-KX8CU?5+4_S0|G_!8_|:|E_97MK_M7XB?'X:Z|_|%_ =4_X*5:K_
_,\$FO#G@;0?\$WB*?|G7Q-^T-I5Y8S:S|=|_O_M|QC^(9_9X|)>\$;G4_%FOZ9!_J'BN2_|
#TG@E|?M?"WX2_#CH+X=_\$KX*>?%&P|'^7QL^'Q%US7/_M_UYKE|_/'7CSXK^(-
GB7X;?\$WPSJG@00:-S?\$_QE|>OPZAH.NZ3=:9)-JF
MAZ9^6WQ=|+77QR_9|_9|^_W|(W|&?|;|/@ZS_..":_P#P4,^'?|1?C;X4?M'_M
*|1?"3X^_M)^\$_%5KXLF_>|=_#GP'XXN=A?%?3XK2S?%F|^)|OK|_::!
MI7C|Q?;^+O#7A4^)_\$\$?"U|XJ\$6L:A:Z_++3H-0U\$_.6BBB@_HHHH ****_"MBBB@
HHHH ^:_P|L;XM^_.@#^RI^T1|<_AMH7A+Q)XP^#7P7^)|OQ5TO1?'&H
M:S|_AK4&^'G@K7/%|MKJ#Z#:7.J7_NDT8VL=L:S::9WF&|5;\$+YE<)|_/C=|M>?
BW^P9|!%?V@/A|V_A|XJ_:'^_||/'P-^VD>"M8|0ZIX\$^\$|AXZ^+OA'P9
MJVKZAK6LRKXL|3Z9|_O_D_B?4?%&K6&FIXG|;ZCX4/7.B>'HM<|5WNG1W6-_M_P%_
-8N|_X)^?MC:9I7@WXG?\$'Q'XZ_9P^,OPQ|^'^#A|!OB+|9/'7B'Q_M|2OAWXC|!%>\$M-
T|P3|+O#/BSQ1):7.OZU81:IKDFE1Z#X=T|KC6?\$.IZ7I-_MI=7L7AW|(7|1UO|
!C_@D|^SQ|2?\$OP&:_YO/\$?P)_9B^"OPV|8?_P_9.^/_MUM^TC??\$OP%|_
?|G@W6O!OAGX)ZUX_TKQOX@10%\$3;=;>_--TR?X:/91W?B-_M_&B>&=.U+6+0
X+|EW|KW|OK1A_@H'K'|O|= _@#|F77K|O1^S%K|/4_P'
MOCG^R+8_%70/'""^&O"OQ%|+_T|3>_B9X*^+'B;QIKFD>(8=:|3VUYI?B;
M3|>AT'4:7|!9PV+ZCJ%U!H_TIX;^*W|3?QA-?M(^_/@G-|/4M|O|H+Q+|(|M/V>;GXXQ-
8?"_P""_@OX_:1:~#|XK_%+QO#X232_B|X|@O?CUX2^+VG:~X=T_MGQ';#Q'T5I|!8:
|X'|_W_B7QC9?'PL_~LU7Q?KOOK^)^7@7|@/_(*)^VE_M|3O@Y=Z)HGC/XU?L/_&?X3?
|P:/!|=KK|WP2^">F>_/_B+9Z#/_:_#JS^)_CE|_MGQ-KFGZ-/XG|4ZQXH|7_!6|8:-X3^'?AZ'2?

AA^A7Q)U'X9_L.?L@?"WX4^M)?@;|>_VIOA18:'X*_9M|8>&O@Y|
M5_:2|7:YX8UCPCJ&@^*OB+|60A/X5M M-
6|0>*!OB)=/OYOBM>:3X<|8ZEJ>K>+FDOM U>+5=0N(P#S;_@FY^U9^TS^
MTA9_M6>&OV@|#^7B;5_V=?CM-|)?W|0|,40C+2_V=OV@K^!|/#/BZ_N/! MMCXU0?
\$3Q#I.L?#C6M?X>_ \$UI3Q=XQT73?'6FZ|X>TZZGU#PSJT|/|_@GA_M^UA|5/VKM)_.^?
XM^&?A_P"%M<_9Q_!L^/W|*6BVOPZ?Q'<:3J?A?X/6O@A= M/US5+|Q-=RWFHZ_J=
|XAU.6|O+33O#^G&U6P@@T.VE@N+|F|^5A_@F#^RKX<_M_9O^_W|=WQ=_9_|AA|3?
V=OV\$ _C1_P|?6O@Q^SKXP|>_ -!@^*G@|/|'C?_M'GXM?#C|G?09I=G|1/|@UX_|
<|)_@+P_HO@G5O"/A#Q1XGU_PEX@N|?P%IOA" MQ^&|VJ<5_P\$??B?J&@6O_!4"Y|8_
?|KKX)-1T+2M!UCQ-X<^=?V6?^"B?|1WASQ;_P_%/A%_P_%O?P:|+^+?^M"=PU|#_
!^|6_&G|EZ+QP/|@Q|1/|@?X|!|? \$7XC6NH:=X8^)NNZYXJ|!^-?#
M6@_#;6HM7T'6_%E|JJEVEW-|LT&E6\$6HZE|%"17O%?|!7|#/A3XD^-_@)|?O
MC;|?/BAK^L?.\$GQ|)_V>?@K|2?C?XO@^/|00B77?BQXZT?78?A9X5|7:|H7
MPS^%&K>)-1|&V_C#7;=ET_P%X*|.>&M"@UCQ#)X:|+ZA|X?"C5/!W|= _P!_X M*?LR^%?
V_LF^/?V:O#'_B_P?_%GX5R_M?
PU9>%XOB'<7&LW>F^!?"1TO3?!7@7PHGB;3/!/@#P7&WBK7|2|9ZY/KOCD M-I?
#/_@I7^UGH6E?|\$/VC/VGOA_|"/#7|*W_!3?XG>?A5|+_!P|TOQ|!M^|Z=|C>?'
|0|6GP@_X(L?L3ZO^S+|>_@M|0OV M_VB/V3OC9^V5X|^)OPG|9^\$?@MX-
@_8#|ZOH%AHGPK^+.N:=;>/_CG-^T' MX|LO#5S|/GX,^)?B/;>'!_HZA>>.KKPY?
VLCVOUM^U-_P4"!|^+|B|KOP7 M^)|G|'"!4?XG?|+X,?\$'PWKDA^%W_!|H|QEX'^/?Q-
^&WB"R|4^&|I? \$1| M)Z1IFM_!OP|XVT;1M?T2.S-UI_Q9|::#IFK37J?"O0HK;XM
'U_ ^W3^U|H6? MV9KS|A:|^~O@OP-J?AC|J'IMK|G;|F#QZ_Q#|BB'Q;X5|_&F;7;C4;_>/_>
M'=(DTNSM_\$VEZ=X?NK>.YUW6|JTW5+B,7/A558;>6.3|'Z_!3_@K|1_\$6N M^'?
^"6FN:|^SO^UQXOO_ _,%"?V2OVK?B+X4^&'|+7QL^-OB+X2?"X=V
MWB.X^(5U|2Y/|@?X.^)'AOP_XK|'R>,M+M+KP3;>(M3|3>(+FTUD^"=,|4VVE
M75PO|LZ-JMKKNCZ5KEC%J4%EK.FV,JV<&LZ-K'AS6(;74;6*MXXM5|V>(;^2 M|?
T+4HXID2^T;7,T|6-+NA+8ZG8VE|!/:Q@&E1110 4444 %%%%!1110 4 M444 ?
GC^UY^U?|6OV??VE_|@GQ|)_ "7A7X=:K|.OVMOV@?\$7P7|>Z_XBN0\$
MMSXUT(;5|&OB;|4K:X|(;5IKZ3H5B5D|_6MG/JVLZCX@%TFK7%M'X'?#7|'^@_LL:1J#::??
ZUXP^*/|6D_Q*U_P9:RQSQVNC>" M/"?PW^#FK^'?&.KZUJ(%YJ>O>+;|5^'|
!|_6\$6DV^DZ5XYU'6-3M_ "WY|_|M%7_ 'NH^&?VM?^"4&K:9|?%VIOBCHGP1_JU_XV?
%SQ#|_|V3|VD/CYX=|_# M36_@A:/A+:YK7B#X/?##QIH|VJQ^+?%&FFZ|Z3>ZE|0(=#/A
;W_ "MIE MWI<^H?87|>|':VI?LL1>#|!OA7X?MD?&#Q3|2\$O&NO%_P"S%^R)|8/VDM)^
M\$ _AFW|Z"|2:U=>#/'FI^#9O&-S<1FS|(^#-6UAI_M//A7X.UK4-6
M^'OQ*_:4^'"C.7X8:|X<^#OB'41)|J>J>'?BK|3|SP|X"|+_!IKVXM?%NI7F@_M#5-
5&GIJMW?ML_&7|OS|E7|F=_B)X!^(W|&2A_3X#:%K_5_BU^USI7B_MZVB_-
^+.A^'KC_A(O" _P^|+_ "#QE|+M(^&6K^_K_1C<: #>W\$/B*+5?%GBZP M|(^&?AG;Z?
I@U"ZX?|G;Q#X<:_TO|E;X'?|O|D_|K_|F_|9L^'\$O9|8_&/MX@-^UA|#/|"P:U?
Q|KGP4_X1;X@^#8|1M_'MS<>+|<|4>|/VF_C-X3^/3>_ M&\$%GJ/Q|A8_
P"*&L6LVMW6G:UJ<';//0G7/V0_CQJ6O?L;_M?_L"?M1_MM->|!&VGCGP)XP|&_L>? \$?
XQ?#:_|6;W:ZUI<&D?##X_P#P_P!_U33?@C|8 MM/BMH/NO\$OC3Q1|!-T>RUFU^W^.(=
U.IEH |/H_|M#X^!G_ (00^)/V M|= \$^#7A3PG|_>.E? \$G2;#X-;|7_B|J M>D^&-
"L_AC9_\$GQMK.K2VFA>'M)M_"L2B?Q)J\$O%|U/9>|/ #8TSP3X@^*&KQV?@_M9|WP|#/!
XIGGUS16U;|Y|1:MK|/2W|&7|+OPQ|*?#OXS:|X=_:2UGX9_"7XR MZ7|3/|@U|4/A-
XK^'GP=|%Z5K/B/|H70OBUX%^ (WA7PQXL|\$;1|10"WPA|5?
M'2=4|0:59;+XHU+XL^\$M8|)ZAXB|.>(M!U350#R'6??"!/:Q9|&|/7C7|G+ MPA_L<67B+4-
%W|8=>TC|KM?B(?%_B;7?B=J>O_!*,?LY>#|/#WP5U3P+H
M7P|M_@AX+UOPG|%+CXI_\$S6=;UGQGXL|T#4M9UWPG#:6D_CCQ=PUK_P_%?O\$_
MQ&_83_X)U_+'X4?|W2=&:_A_X*;>._O_P@^"GPF^(NHZI<^"/A_XKU4>(KCX
MF_%CQK/D|T7Q9XJ^"WPN|. ^\$=-|VR>'5T;Q)X|TO4O!&E0W7A8^*+G7=#|G
M_|:CM/AGXJD_9C;|F3_@H?|2_#'_C+PG&E MO|HSPEX@^,'PN_X)9_MS?LU_LH_M" ^
!G!/_|:9AU2|_9)|:?!>_ ^'GQW MM?V5+_PAXF_9S|<:KX%_9|AN;GQK_P)#X|T!-"|9?
#;X:2PZ1XG|4>!--O) M=+|_7|>^&='U8_ ^L?@E^VE^TAJQ;_*_8N^)W@7X2?
\$7|L_P#9D|%?#GXI M?"V^^^)|1?|+X,?
M("SXTVNJ6G@;QF=\$|>>*OC%XJ^#|7@/QMHNK>#_ (R6 M" ^_/BU/8VUG9^(?
K^+=1UJ'P;8^1_#?JL;_ (*3?!C|N?X3?LA_MQ_"|JEK MXE:%^U|!&?CY|3OV?
_B+^Q>OQ0|_7&A>*?V<|+PKK7C;X;_%/0_CEXPUJV-O MJFF^_
_ "FF^/B+%JO@|0+GQ)KVC:?=7 MYJ1T#E_@*/%S_MO?|!0;_ (*T M>-?

@S^T7X8^!@_9Z^"G[-!-/7PW?JGKXN)^TK!;/#GPNU'Q!XX^(7Q!L_P!F M:Y!*K|<-%&L?
\$+Q18^#?AGHOB3P9X8U_6-&T!6?%?B;P_P"&O#L%KKEUK?LS M_MX^\$?
BW^T5;_ \$!QU^P;_ P %.O!WOK|7^ ?\$/@BW|9? \$O|@WXY^!_A5!|O@M MX /"/AGPO
MJMEX<^WAS1@""Q3^V/_ ,%2_P!F!|C|D'2?VN_@_|L:>)OV9_VT/V@|!#|
MFC1;|F+5/C3J'QO_9|~)?C/P;XP|<^!/\$V|O_ \$&|M_""?QA|*6VD>!?\$X|:
M>*/"OP|^&T&E66BZEKHLK.%=-TS5OW4K|%?;/!0OPG|*OV?
C=X(^&OP07XE7D'P^|1?&KQUX|^(%IX2|&> M'|=|0>%+NY@U;Q=XFO+"Q^%?
PKU'Q/X;TBX%UX|>W/B?|ZJ_ "BBB@_ HHHH M**** "BBB@_ HHHH_ /'|DO|:M^+GQK_
&K_ /@HC^SS|30"WPY|:~?^QW|1 M_@#X0|%WW@.Y|3:E>:_I?QF^ 7AKXWW%SXHU?
Q!)9P7^H:7^XMT|1(3I/AGP
ML;*^GWL|Q7:W4!MOB;|O;|M7_@H^Q)X<|:_MA:A|#OV.O%|/\$_PR^*/A00/
M%GP/L==^+6I?MFZO|)?\$GQ-TGX6Z|10|!>:=JT7P2@|8ZY?:_H?BNU^%|V/@
MHQ(VEZ+J*:-XOU/Q#!=0P;G_!/+X@7^L?|!3W_ (*|ZOJ/P6_ :H!>\$_CS M|2/V8?
&'P9^('Q9_9*_ :3^\$GPW^(FA?;!|E?X>?;XBSZ+X_ ^(_PN|_ ^\$|2|
MTCQYX;O+72=+U|5M'U/QIH|OXB|#VGB31(=2O=/Q_VCO^"B'@#QA|8+|X?_ M
!)_8%_X*J_ \$KX1_ 3XEZ'XJ|-6_PY_X)S?M;,>)O!OOJ^*?PXOX|;|>_9=5 MOO"F@V&M?
#SP#XQM;:'7O_%E/"VG^*?'GA|O_ 'EW'H/A_P-OK@!'^|Q+^(W MC&7|L;|G/X'^
=7;2HKRQ^)^GOO| C;/'8Z3J*7/P@|\$^&^_ AWP3/)J.GWT MV@ZIXW^,?
Q.|>)|%U73L;#4KW0/A#|0-*M+DV|NH-#|\$3_M>?M|>_ /VJOV8 M?@|12?"W|(WB|X6?M-
S_!_GU|X1_ "&?XD7?|4G|*O@|PGX*U;Q;X;^)^WQ9| M67_C+6?AWXZ| S;G9:-
|/_%_O;9|_OAMH|CWQ9H^B>\$_-9|5%|&76/L#|FZP M|6^*/B)^TQ^U|X|>-?!J^/-:|+
?"3X<>|_%^DP;5XXTWX;?L|6/B"UM(- M0T=+ZZL#J'BCXZ^_/C|XDT#6-_U2|T#QCX#U?
X?;_H6M;SX;N=%U|_ (WXA_ M#X9?MY?M7_L8_M\$M)|+_#;X?Z=X"UCXPZQH<>GZ
M(;G7O!'@+|12EF /T|^,?|5OQ<^&G_!13|BK|DVU|+?#F?X1_M3?#C|H|Q?J
M/BF>Y|37WQ'TS5/V;_ #/PKU>*VLK>_.32/#.CZ?K6H?%.TMY!/#XKN9K/0|B5
M9=+GU**_Q|G_&G/B7XS|+77P(^&GPNU""3OB1|_ CCX/T*WOK.RT+5+C2?A
MA|_ M/QA^.=|+8>(|6|TF.#Q%|+? 6O?"?2M9O%MXM"|<_%'P5?1WMM>BR+_ M
H_ME_\$"_T|_@LA_P \$N|_LE?M)_ M\$;X1^!-=_:7|_?L_Z;|8-
8^)^W@;X7;_X+N+35|3^VOV/B75-'UG5_-^)^ MRWWO'N_"FDF|U"S_ \$*TK1=?3?MA?
%'XR>*O#GB73O_O|_P:L?@M|++F?P MYKCS^*/\$GQ2D|.??&;|H+Q/X|TZVL)
HQM|H1T/PO^SMX*T#5/#5|JG_ %:_%OB MEX.L9)|;L-9TRV
/SF^(G|:/_!5'|EOXZ_LAZM^U+|1%OV=-8_9?_&P/VG_A M|^RRG@CX"ZW|8=2_:_9Z|9?
&B/59?AYK/C7QOXJOS|_OBQH7AM=%U%?B7=> M#/ GA*WLC:W%UH=U>:/|NK3>J?
\$C|M;|KSXP?M?MA?L|?L%^&|@%.G| G@3 MXAZG?7OC5C_P43|&_&K|H|X<^)/!/_!
M_@|H|5Y|_B|J'AK|F_3=5_X)|?'GPG|O#OB+OLTGPTN?CYXX|7_ \$?3?!GA M'PSJ|=
|X7US6|/T?7_&%UH.E?";X8^)?%UUK=_;ZMXDUZ+0LB&X^/_!;|N/_M_@J-
|2;|G+X^_WPC^W%I'P8^/W|+NJ_ X/^/OC%8;G|=_'PIF^\$GC/X M_%G5?_C7.G_
<:_P#\$E>%_%_A;QU|2I?!WPR/@;6=6CU+XDGO)HD^FD^MI?"_|7W|6?
|'M/_:#^%S|2/%?C+|KK4/'OB/P ME|_+|3Y-
/T6|^\$UGX&^#VH^&/%WCGQ|XQ'BW0|4|3_|)'X5|(Z#:^"+V^3^ MW|S7;TB+E?V._VU?
VV?VL_V6OC!)|(|O@'|)_VP_P!GS|K|XM_L=?&+6|?U MKQGK0|+FD>(|@K;Z?J?
BWXY>\$=*AU30_B/XQ^'FHFVJ;?H?A_P #KXOTC7AX MINI8=>|9;-I.D:SJ%C|?L_>(|B!_P
\$9?|_@F5^PO|L?:|!#?VJ/CU|;|+ MX?7=AXXU3|EO|ECXN?M/^&_A#K'B;7|>^(?
Q!U#7|1^&|AV|_7Y|*>(|O&%W MX1|_#Z'>>(|=-OO&|W9V>M20VOAB/5|4M?
8OA=^UM^SQX6_9)O?"B?| \$X_ ^"E% M|^S_.(OB/X@^"?
Q*|_%_3|@KXB^_B#|1|KXRZ)XB|>?&|XL?%7X\$WMKKGO
M<^)/PV|;ZKXBUF#XM>/6^&&NZ'X|9^-+|0++3-9ACU^UT4^@_=""9/|57|0
MO|4G@3X^/^T1H/P5O<^"G|1GC/X+>\$_C;^S4?%L?|/O|0_A;PWHOAK4_P#A
M8/PQM/&VO>+MB^_.0UG3_#6H-|/!6N>+Y;74'T&TN=4N!)=) MHQM8|2WFTTSO_-
VJV(7S*^E*^%_=""FFL7>F2|\$_ /VOM_TKP;|3OB#XC|=?LX M?&7X8^#_9|(|A5|1?C)XZ|0^-
/B5|_ \$?@KPEING>"?A=X9|6>*)+2YU_6 MK"+5-/@;|1M(|%:QXAU3P)|)
|!#QU|7?"/@S5M7U#6M9E7Q9XGTSX;,>| M)_ \$^H^*-6L-
-3Q/XWU'PIX>N=\$|/1;YXKO=.CNOCC|EW|KW|OK1/^"@>L?L" M_MW^
AV9=>OO%|_6L_M3_!|XY_LBV/Q5T#P@OAKPK|1?" PT|3>_B9X*^+ M'B;QIKFD>
(8=;|3VUYI?B;3|>AT'4;7|!9PV+ZCJ%U|H_>_LA?M'6_P8_P"" M3O|/'Q)|2_ ;JKF|1_
G|F+X*_#;QA|_|#|D|X_6W|2_|12_7PU|&>#=: M&^&?@GK7@#2O&_B!&|41-
IUMXXTW3)_AHJE'=^(W|:)X9T|4M8M/E?X6?MV; MKXOUWXU_ \$KP+^P'_
_&%&D_2^)^WP)?A!^SS<_%>)K#X7_#_ M_ %_!C2+;X??%?XI>.(?"2;7|0/'D%|>O"7Q>T|1?

#ND^(I8>(!*M/AX+#7 M?_AV|_SOC&RX'_(ON?M6?M,_M(6?
I5GAKIH/0_@%XFU?IG7X[3?^7P-^T M|^S%+XRT0IG;IH*P/@3PSXNOICP;8^-?
\$'Q\$|0Z3K'PXUK7W^'OQ->T|7>,_= M%TWQUINN^'M.NH0|,ZM ??2?B3J/PS_8<_9
^%OPH2_WX|_M3?"BPT/P5^_MS;XP|_?!SX!;K^TEXNUSPOK'A'4_!5?5\$7XM?"?
PK::MX@|5^#?5\$2Z??S?%:_M|TGPYXQU+4|6|7-)??:!J|6JZA<1_'W_|_!E7PY^S?|_!;|N|XN_L_|
PP^)_MO|_W|"?QH_X40K7P8_9U|8>|O&_@_P?%3P=HGCQOCS|60AQ^SOXL TNS^(GP:
M|^>.\$U?P%X?T7P3JWA'PAXH|3Z_X2|07=OX"TWPA8_#>;5_#ZK_X)X?M8?%3 M|H|2?
VOG^+?AGX?^%M<_9Q_|_L^/W|*6BVOPZ?Q'<:3J?A?X/6O@A=/US5+|Q M-=RWFHZ_J=
|XAU.6|O+330#^G&U6P@@T.VE@N+F|R?B3|6_VRO&GQ;_:'|_? ML?;=|)|?@^%|_P'??
IDOQNNK02_A/X-^,&N^&?\$GOK^,OQ+|;GP?8-|4/' MNE^\$OA?XD^'|@?
P=X#!Z|HJ;A0?'NO1>)-1T+2M!UCQ-X<^?^"/OQ/U#0 M+7_@J|<^,?
@/^UU|.7|3_P#!0;|K7|K;P'9_%3|C|H;X5W7Q(^"CVV|\$7'
M@_60A^OQ\$^%_AF#Q1XMUV30-4M+7X6V,Y^*\$_=S#\$_;KP?|;7=I|5_ML%?
L,^%/B3XW^GO^^-OQ|^*&OZQ|2?'OPG_&>?@K|2?C?XO@^/|00B77? MBQXZT?78?
A9X5|7;IH7PS^%&K>)-1|&V_C#7;=ET_P!>"O#GAK0H-8|0R>& MO"^H'CO|+/_
43_::|>+?^"CGPB_X*/>_@UX7|6_|\$Z/AKX'^/WBWXT_
MLO1>.:|&/B)|#_'O@+XB_\$:UU#30#^Q-UW7/%7@_QKX:T'X::U%J^@ZWXLO8
M=4NTNYM-F@TJPBU'4N%^&?|_P4K_&L|"TK_(OZ?M&?M/?#_P"!AKJE;_@ MIO|
\$|P#|^*OA?X(^FE^/H_CE^S1XD_.*|*:WXZ_9.3XI^/=<|UM_&L|N88+OPHU3P=^W?|_?|
@H|^_MS+X5_9R_|_E^!WO-;_W^7Q@LOC1^TG^U|^R;X|_9|_|>+_'_,6?A7+|!_#5
MEX7B^ (=Q<:S=Z;X%|)'2|+|>|?"FF>)M,|\$^_!<;>*M?U+QGKD^N^.?D7P M|X'|
&A_VM/A!_P18_8GU?|_9E^/?P6^(7|_?|1'|)WOL_.*|>_\$WX3^_"/MP6|&P?
L|^!|7T"PT3X5_%G7-.MO_'OSF_:#|>V7AJY^|S|&?\$OO'M/#_@G4 M=00/'5UX|A|9^'?
AU>^ M\$?&%|8>"KFRMM:U|^_GOO|^G?4G_5#_!|UK|AC|COXC_&CX9>(OB)|=8?
MA%|1/B1|_?AGXK@O|+2+3/ASX6M_\$OC;Q_|5+>PO|_U;3/A_P##>UU+1+7Q
M+;V>IZ5J&O|_C3Q+X'^&.FZUHFO>|_)U>S^6VIO^"@7@/Q9|7==^"_Q_80
M_P""H_Q.^"7P8^(/AO7)#|+O^="W|2WC+PA>_B;|_O\$%EX|_WZ^(CX3TC3 M;^#?
@#QMHVC:_HD=F;K3_BSXTT'3-6FO4^%>A16WQ:|^:|^@IC^S%_P4Q^* M|/+!_!1;XN?#?
6?@=XP|_M0?LVW>FZ%^SUXB_93^-_BW|M/PA|)+?X>1/H7 M|_|?@C5_AW^TOJ|@&U|_-
T_PEL MA_'|P"|>:Q|5|@3|%?B?XAMM-L|?|_BA_"7X<>|_-
:_C>P;|>ZC/%8PWFH7UU%:K\$EQ>7JO_ K5?(W|_AWXR^\$?
MV+|V8?"_|0\$GA9OBWH'P8|_#Z5XIM_|_!@OO5|_|)TJ"RT>"#PSH%WX|_&OBC
MOCXFTCQ3X<|)H6@>.:3J.N%-1|::X@U73|(|_:9?6?AO2?KF@_KP;|G'_DG MOB'_
++S^U1_ZT|7Z|YKP;|G'_DGOB'_LO/|5'_*T|7Z_#|G'_DGOB'_L MO/|5'_K3WQ?
KWFO!OV^ (?!_LO/|5'_K3WQ?KWF@_HHHH **** "BBB@_M HHHH **** "BBB@_HHHH
**** "BBB@_HHHH **** "BBB@_HHHH **** "MBBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "BBB@_HHHH ** M** "BBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "BBB@_HHH MH **** "BBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "BBB@_M HHHH **** "BBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "MBBB@_HHHH *|&_9Q_P"2>^(?^R|_M4?^M/?%^O>:|&_9Q_Y)
|XA_|+S^U1_Z MT|7Z_#|G'_DGOB'_LO/|5'_*T|7Z|YKP;|G'_)|XA_|+S^U1_ZT|7Z
M|YH **** "BBB@_HHHH **** "BBB@_HHKY<_!;|^_P"P|1%|1^.?QSU' M6K7PI:ZUI?
AG2|*|_Z6FL^)_%'B?64O+C3_#WA|3|B|TVPFU&6PTW5=3D?4|_M5TO3|?
3|+OKBXOHO*5).G|X/%9ABL|@<#AZN+QF+JPH8;#4(.I6K5:C484X0
MBFW)M^B5VVD FSEQV.P>6X/\$YAF&)HX/!8.C/\$8K%8B<;=&A1HOK=DDVTG|1T5_.1_P
1/|!_'1(P!KW_P@?@S_//^JGJ/_!SY^PQ%|H) MI/P9_:QO=5CL|H|LM1|
(?!_2|N|02|VLK6^U.V^-NL7.G6=QXBTZ|DC6VE^W7A7XAMI+A3-
+M|_PH|_JVZJ27=MI+=NQ|\$_%|PT2;? M&.462;TG6;TUT2HMM^23;V2N?
TAT5_%E^RA_PT/PROBSX/RP1QV^G>%=(BU|6/'5IXT|+WEI%_'&G?>)O\$
M47B&VU<3ZO9W4|K=OH1>\$ M=!?4+F.UBO|_7Y_"?Q:|6Z|_:9#)*K7=U9>'|0-
M'"GEC\$2.P_2|HOOXQ_%_MX4_L^ZKH|/UGHVK?M;?"5H?@A^ROI&OR6JZ-
|70%VE:QJ|V&JV<_M_A3X+>|_!:'_#QG;7FG7EO?
>%/AOJ^F"VNKJ_M;2X^_SSAG/^&JF'YIE_, MRN>*A4GAEBJ?+&O&DXQJ^SG%RA-
TW.'M(J7-#G@Y)*<6_N,@XJX!WC32|?^%_|1?PUNI?!?QC|'W^MF@>?H5UIWB_3|W6-
!M;R""|AC5_#NIR6L2WL<8_!|2/CA M#Z1|_#|/UT/V MF?VBM2U+P?|_!2MO^R<=8U?
XN^++|6?%|/|%M^W/H?PUB^\$GC'5&O\$O=|
MGP9L;Z'<>#%FM/"EY8W^J6MYHD|K>R0#PCZ_K@HKX\$|(?|!07P5XH|+?#?QQ|
M2_\$;QA!H&G'5XO\$5YI_PM2Q|_|X5|5^\$/'-UX8|8:%=Z".7^&'_4U^&7C MWXZ^%/V>?

&7P':B_9]^(/Q6^%/C'XT_L]Q_';X?^"O#UE^T;X"! QZ?>>+6 M^%UKX.^)?CKQ)I?
C70=&UC1_\$&K_I^+?A[X7_%;11%U2UN]9\%:?(MS!;@ M'Z1T5^&=W_P7P_9PM_V?
-9_JA_99_ZO_V??#7ACXPZ]XH^*EE\!/"A|^& M=8^"?
Q@NO@UXJ!ZIK=S|6+;3M.19:GK\$\$/B+PPDMS_PC6K>';B>QF]2V/CG
MP_XM|^'OHRV_P""IG@2Z^,6E?_1/V6/VR8OBI00@O+!2/V?/#5W|.AA:1 M_M(_#RQU?
1M%UVY|ZY<_&: +0/AJWA>Y|0: +XGTC]H/5/V>[G1;+5=)N;O M:FL:0+|_4"BOS=^'O|
P5&_9]^*'|_OA+|H#PAX2^,NH:CXY^- 'BG]FGPQ^ MSDOA3PU-^T=J/]27@S60%VD>)?
@8_A>Q|:WG@&P|8Z+:^!/%GBW6M;U'XEVG MPX|/_#W0M4^(/B'QUI/@|3M0UFUQO#7_
5<^ 6M?"C]H]Q]K_PY^/?PZ^ (O M|*GQ7^&OP,^,O|,'CCPGX(B_:%T7XL?&_P
1^"?"/P&|*:9IOACXC^*/A9KE MG|3X;:A#JTFKZQXRT/0|+UC4|/_/T|HKYR_9N_:'
MN/VAM'^)%UJOP*^_7|/'B?X4_\$ZX^%7BSX?_!TOX<6?B9M:A|!>_ /B+!KO
MAW5OA)|3/B|/_/%O@S4-!^(VB6^G^)^O#7CG5+*?6;'7|+81SZ3*9/B|XL_|M!7'X7_#+XL?
M2_!+0OV5_P|N+XW?\$_?|_9|T/X: ^+_BOH7P4^"?AGQ&+GP+|3 M=+|^)/B;X/M-?
T;2;'P)>R7>GRRZ=X|]2'5+ ?#?P|X|&F>+F|_M_ 'Z045^\$|7O|5>F_&K2?|_@B;^U-
^RG|>/B1:?!|_:=_X*\$_ WP7?6G@O MQ=KGA+PM|3/A+X_ ^"7|0OC+6/"?
Q_|*6,M|+J5_I/BGX=Z-IFN>%_ \$+R1Z+K M&DZQH NK:8UY!*L'T=|5O^"N?
|/WPE|6;S;Z|+?VB_\$WP4|?'M&^'?V2_B1^ MU?X|\$^"=0_9|^"Q_|
\$/B6S|?2>!=EU3XE: +|8_\$4'AGQM|?GX(|:,>/_A MK|'O'?@7PKXVED|ZOXFM_\$MI?:7;
'ZHT444 %%%!169K6L:9X=T?50\$& MM7D6GZ-H6F7^L:M?S|S#8Z9IEK+>W]Y;
(U>0Q6UK|!+-(\$1W*(=JLV ?SDNO^ M"J?|_M.O<3P1>%_C|>Q12O">6OAOPBE08*1Y
MD*-E1|64|.YYGJK2RC+,5CXX=PC7G0A>%_53F<(RG)QCS249-13|T?I=17 MYE?|6?V>A
H3?C/_X30@?_.>+7C&M?|?%2|_D^,WA35-!T#Q;#|_|P_?V M/BS0+
|2O#">,M4UV|_TEMK.GB/6;NTACTAX_@M;/_A(|6&|M|G6'O%\$S6!M MOH_X;
<:8B56+R3\$X?V>'KU^;\$N%_-1T;Fj%)J4G*O6=J=&%DI3DN:4(J4H M_*XOQ?|
#S"0HR7\$>\$Q7ML5A|_RX15*LJ2Q%2-.6)K)PAR87#Q;JXBHG*4:< M9,?#=A|5-: ^&4GQJ
M^&?Q%|5Z3|_|#|<^<_VQ(N/#_?B2^T2:R'A6WM-5U/5,KXL?MR^(/VW/V3?V
M1OVG/V&_VM/B_P#LLS^+OVO_ ("LR?'KX;Z+|.OV=/'%CKP7KWQ?^_7P_|MA|_%;X8?
%WPK^T|_\$/BOJW@/XO?|EKW5)?|MQHO_"/+J"ZVWB+7|_ ^(/AG M5_!|QI?
R5:C5P|6K0KTYT:U&I.C6I5(N%2E5IR<*E_I"24HSA.+C*,DG&2::
M31|W0KT,50HXX#5:=?#XFE3KX>O2G&I2K4*T(U*56E.+<9TZE.49PG%N,HR3
M3:9^_5%?DI?O^"M7P/_&2_\$7QD|_#^/_AO^U|_ %KPG^Q_!\$=_:Z_:4|(
M>"/A'=_#_P""FH?&70_"VK^#M=^)^5K=?\$+X8^,?\$|S|J?AWQ7H'C7QE)^S_|M|?
QOH7A+3M9W7.F:&L8T>U]J_:C_."A'A3|F;QMXP^'UA^SQ^TW^T=XG^&'
MP*T_]/XO6'|.GACX6:|^%_"OB;6K'XG?:KXP0|_Q7K7 MPL^)%MHWA#X2:?! \$?
QI'#X,U6_UCP|L.GW&CW6IYFI^@-%?D)_P4(_X*:_! MX#|?%M>_?X/?#;|J7XQ?%GX)?
LXZU|0_C'XT_99M? |M%^RV%/|@_6M?^&N MI>.O%OB|XJ?#76_ ^\$KU:PTT>-H? 7P?
L/B|A5K?X?QCQ=-X/M-\$U31K_ %Q M'|B'_@H=>?#/_@GA_P
\$H=*^(/A'|L;|L#|J|C|K;|EVW|8>/'"OP|N|!WC'X ML?\$_-?A;X&|>(?B|0?&'Q|^/?
Q7^%G@F%-#B|8^&GO|WQ;|2H/\$/B'4M=M+ M+0-/UR^,|(!^|-%?F7X9_X*M?
LZ_\$'X#_LS?&GX4^\$/C7|5?\$_O|7VJ>/?#_M_!/_V_-B;X>^&GAW4!|5M_PFMU)XD|_C6/5?
V+?V|AW^VZ?CW8>#OAE|: ?MA'XL_9H^+T_P+^+_
(%^.@>="|3^'OB38^&|%|3:MHJ|_@'X@_\$CPIK-EI M=MKMK9R:YI?
B"ZI74|J.6Z|WVLZ)+8ZO> 'V_17X_ M|>+?VP?"_P#P5&_X M)G_3X2_MV?'+X+_
(_G0/VM="^)^G@'P3|+OV_ \$5|X#O?V;_V:T^*7A'4 M_A1XO^+_.RS|4?
\$E@/_%GB2RGE|>6GCZ^^(4<|=-|/!X1;PE:BTM|*Y^R+^U1 M^TOX_X*I_M_P#!.3XI?
M")^V_|+ _AK^R1X:_.FTGXWO|_OAIX.^+GP4|:: MI2X?_3_+ ,?Q?C^!'AKP7|+?\$_7C'Q'X*?
VT_B7-K_|P40^_G|.7AKX8_M M2Z%XW^/^O?M0ZK|0H3;G|F3X":!::|::
HGPT|*ZU8:YI'PR|>+?\$_AW1_ MA_X)|-:J|_C+Q|HGAG0|0UV"TVW_
."IO@W6|/_|9>G:3^SH?/_#W|4W|?%7P MT?XH_\$|C7XK3?|SP-|5=<|)ZAX>N|?|^*^+_
OX^T#XK^/_ (\$>(OAUKD=A MJ\$=|XS|_ %Q;H)?|E:E92Z!>?)9-"|_-Z?J917X|?LN?
!3CQ;XW_&O MV+/B=|5?V8/VA|?_&G/VG_@IX|)
<^#O@=|K'|GC4_&'QVTS3_@W|*?'WQ2 M_:|^'36G|0B?"_X)/CQJ?|*6E?LZ?|(+:Q?M+_
M^U9HFL:SH^M_LXWW@_3Q"/^#^D?\$_K0_|A'M OB)|/N.XT;_M2_A_X|8Z=XPTF|N=-N-
U"#5K>QO?TX|?'|%/AEXE7|M/3?\$_P4_:|^&7C MW|@_PUX1|<_&?X6>_
O"/P^U'QUJW@#X@^%//%'C3P#XW^'0^&WQ1^(/A/Q+HG MBW0_!7BM|2U00%6A>
(=%O-"U"R|7:'X|)(_N^%U_|\$K|FWXL?\$_WX5>'_"WPN|9W6A?|VW^_.?BKX>3
M:A%X_P|4|6V'C/PSX">_NY-4;P;|/_%5QH NJA_#OXC>_|+6QU2^?|&?|MX*Y_3X+A8?%-|
(_VDO'_|/O|_'Q-'P=_:0_:M^&?@GP'XA^!WPA B)9: MA|F>+|\$_46.H_#0_C?

XLL_AK>:YIMK\3/\$OPC^#/Q)*^"+|H|W2-:UN#6] M'UK3= . /U3HK|= /AA|1?%E
%L_BOX*T3XR?.\$#OG|"O&-' 2S^ O|OGA; MP'> ^/-4UWX4Z7XN|9_M,?&/P9-
XR|"> &\$N|X&T&K6MK-??<#W# M#4'M;OR%Z4_|%C?V;8)_AGXPU3X;_M#;-^RS|9OC
GP)^%G|\$?A|W|+G MC'XC76NZGX2T>""*ZT_XI7_QQ|. ^#?\$WC'2+
|PMX5^*GC/X(>&_A7XDU%(+_1_M_&EYX=O;+6|@_6:BOOI_:?_"VGP#_
&9M)_&|;O_L|_M;?'KX-?LH?%+ M2/@; ^T|>?@7X6^!EU|*OAC|9-4D|.P7?
P|U6|^+|/0/PD|6ZK?>%;OQ=X6T_M_P=>)O#7A#6_A_X*U37|.TKQ)XOT|4FGM(=?
#O_!1_2|1_::^&_P"P=XO_M9(:S^\$OO6^)_P_%=0^/_A^~?B);_LRCX/P>#?#_(>T2_|
&>F#QAX'_::|M;:GXG|9^_&7B'2OA=XM)_#OPUXUU.P|574?BNT6_|@Q)#|5I0#|(:^*4_
MV5_VJK7|JFQ^+FIZ9|#_(V?!_3?A%|9/'WP.N=0^+Z?![#XZ|8_"|Q%J?A_M'Q_>?
#R|^\$WQ?^+%OK'AOPOXLTc4/#&HZOJ|F@'_ (2*QU/1;>UGU+0|>MM+_M_#QA0?
VP;#_@NGIO|,5I^VQ|;E_977|@SQ%^WGJ/P*TKX_LF:I=ZAXA|*M?M\$^'?@|_P*3T?
QO+^SP_Q//PTUO3-8%_?^\$KN?BG)=)-I^F?\$>PFO+74= M_ /WKHK|:_ ' !;G|G#XBZ-
^S5XSTGX#?MC:7|+?VG?VBC^RCX;^+WB3X.>& MJ|^'?
@/X|WOQ@|9?!"PMX*^(6H2_\$F763'XQ|9^#+A_*|1_#S0OB%X7T.+6=
M&TGO|K|@|Q^&W|4OQB^+|P2_9QUK_MX_&|Q|^RS: ^!|;+|EL>*?!^M;_|+=2|=>+?
%WQ4^&NM_P#"5ZM8:./&T|@+_MX/V'Q'^*UO|_#^,>+IO|!HFFJ_-?Z@_?KW17X&_L_|
!175|/W_3F_833 MQ+|/V|VKOVWOVD=<_89^%W|0_Q>TGX06OACXD_%;3?_6J:?.J.E+|5?
B5XK^~7 MQ4^&NEZOJ/C;Q+X:|6:7X0|.6GC'Q)|5_B1JGA7Q/_M/^"T|/|.A#P=^Q|6_#_
_)OVB0BI^SU^WMXA^'?@KX0_M)>_-'^|K|&O|_MC_XD>(KGPUIG@/XU:|1_CC|/?%?
PR|2:./?65|_2ZCX0N|(DN+#5-"|ZMK_M_BO2-5|V0|^OE%?*W|*|4|O^UGX2|5^/_
\$^!_OK^\$G@W0_&OB'P=X3|2_% MP?!TZ1|8;3PSK6JZ#??\$#X2WGPE^,'Q8B|1_#4+
|2D)_OC?5#H&E>._%O_-M-|2>##K_ (=O8M4KZIH_****_"BBOA|HK3_@H)|!|V-M6|_>?
B=%XVU|Q1X
MJTR77+'PUX|T72M5U2TT)+R;3XM9U.37_ '\$AC2|:RO+^TOK2S2/4|H|>73|P
M_9%BA|ONW+LMQ^;8JG@X
MIXLX;X)R7\$|1<69U@, @R3|RHPQ&99E7C0P|.IB:L*%"DF|Rj5:U6<84Z5_,Z
MDFVU%I2: ^X:.*_%O_ (?J_LD?|J|_&C/_ "1^&?| |VOS%_:'_X+!_M*>(_C M#XOUG|G'XF>
(O_/P9O/H_XO|PGXM^&OP=O/\$.D_9_"^BVOB'^T+FZT+QK/)
M|N|50:YJ5IO|3:ELLKRVC7|&BK86OV^5>%O&_9XB="IE|QA+#4<74=:2J.
<8NFHN%.HW-2BHR_G?C3Z9G@-PAE>'S+#<35>_*E? M'TL"|JX+I83'9IAX5
M2^)|GOFU'Q#|.A:>%|HX@>'|^&'P8@U_M?7|!-IKEC/XJT?
2YHO!FARPZCJ>A1W|E92QZWH|D=S/\$Z;H|_7C?'^Z_9^^.'Q#^!GBWX->_!GA'
MPWI_PV^'GQ|T+5O_#>+?.B'3=1TOQ|H/B+2-#+ZMXGCT^#Q9|1F>4YEDV)^
MIYI@J^!Q/LX5E1Q\$""4J4W)0J1W4H2<91YHMKFA.+?-&27|)\$<(<,<);!#|
M(OV8M+|6WSMX|/##?#|X1^'O#.E_|X+? M?\$WQ6^(WC#XBZ9X>U|7?&'BC2?
MAXBQ:9?6FB>_K2UUO4K_.KO!G_!47X%ZOXS_ ;1|6_\$_X??'#|G7Q+_P3_LK_M'5OVB?
A)|8/#7@;4OB/X0T/7OA^?B9X-U|09?@G|1_C%|. '_D>.O"Z7\$OA6_MY|(?
\$#6&N;VUN+|4HM+D5&D||^I/TGHK|XIO^"E?P^|%^?C|X^_:+^'|3O
M|)|O^SYH7PIUS6?#OQL|*?"_6O\$/Q';XWZMXC|_-"WPH|%V^/_Q?^.'ASXD>_M;?
%OB|PZ?|5IX1TKQ%%X@LO&&M;)X>U6PL-1G08K#|1O@A^V|!7?B3_P7G|1_M^!?
&GA#|L#|FKX2:1_P2|,8?&'6OV=?VC/\$GA,^#)O&D|'3_&|!#T_XU>\$O_M'"P?^+_QD^%
<|PW@-|GPS)J4&MKXU|.ZLGCGP|K.C>'|2O|6|_ /Z*J*_*MW|GG_@KA|"OVA?B3|O_4'P?
_:_0^\$>@_M;?#?XD?%G|D|XN_&/PK|,M%^&|/|
M0_@7X4V6GZWXPUP>_@_XN>._/'_@RXM_"6J6GC:PTGXU^?A7JVI^\$9\$U>TL
MI!+;PS%=0|V^I_&S3OC58_#J^N#J_B;2_B3XC^#FB>#_&7@_P| MJFM?
#G5/&;WGARSUX_7JBOG#|K_/_9|\$_L:?.LO_'7|J?XB6FH;GX/^!7PV
M|2_\$+5=&TDQIJWB"71;)FTKPU|HPW%XZ6T4_MKK|?"LJ>"O|_@HI^TH!OAO^U7|6?
VW/\$7|/"Q_^-W@SPY8|!7|/PE^!|/ M/'B7|G|X2^%_'&BVGB+P3|V?
BE>_%3X8>)OVA_BOX@T|0;_2F^)&K^#_ (|? M!_7?B6;6M;|*Q>'|_M+|"|D
A*HK|V+|K0XD?LZ_#?|F?X2?M+>!O%GQ_|MV|?C%|I7CR)?@Q^S|I?P|2_|B"?
A7>9^(/Q3|_W/Q*^(GPQ^%OP|^\$6GZ=JO_MA'4+*|^)_P_3O#.HV8|8^%O"-U)JWCJXO-
/D=Q_P6U_9*M?AQ|_?B|X'_: M274?"|: &A?L>+_ (5I)|6X^+GP)_:BU_7K'0|7X?_!B|
(6WBR:UE|G4_M(=>LKGX=Z|13XGT1)SX)|4:M"VE4_?L'17Y+WO_!7+P-87'|4/A>7|CO|
M;AE^+W|'NFZ#XO|_CE|\$_L:P|_#;CQAH'PG|4^\$|0|;>&OC!IOC>+|H8_/_6O
M"/B#P_HWB&XT3PS9_&0_%|5KSPQXHTNP^&5QJ?AS6;2SV0%W_!7|G?0Y_V_M|?P9|_
/VDOC7+^WQ|)M>^+O|_7_"G/A?IGB5/%VF>'OAH_Q)OO"VI2ZQXQ|M-
Q:|XPAT76=\$M=5MM1=-_|WFI37WCWQ%X4|>?%_B#PZ_?J=17Y@?#7_@K_M?^RIX_|

V: C=^TGKMA\7_@_%^SC\4G^!/?QI^!GQ9^PTC\HSP1\;+O5O#F@
M^\$/A7+|, "VM^,\$U_P4_\$G6_&'A72?AS+X5U\7?#_BN^UR*&SUQ/I.UMM+|MGX/?
!%&OA=|1?CAXX_9H^)OPH^.\W*/O_P#!7P@3\H&+X7?M%:'-X\2\;_!M!-0DTG5?B3\|/?
%/P1^*7QI^'?BG2O#>KB#2O%.A0>,K?QKX?U"Z2UU/PO!);M:B+(-0:BOS+?!(??"?
QR\ZQJMM^S)^VQ\./'C+|F#Q)^TU\)_BOJ\@S MX4MI_P8/(@PLO@_3+/Q\)+KX>_&?
X@>(_#WCC4=,^(GAKQCX<|%?%?PU\O_M'6G^YAKNO>&M'2!8)?BWQ=_P47\3?
LZ_L#?!\\$F/'\|+7PV_:J_:P\|_+7W MQ_:94^#>D?\$OX\|>/?
@AK'\2%YX+|:ZCI6NRV7Q0U#Q\|2_!AWQC\|?|XV>#
M=&|3^%M\$UQ==TCX=Z\K+ZSXI\;?\$_+P?+IWA>Q\5_'-_%?EI=O^"K_PG_9\|
MTOQYXH\7?L\|_M6>(?_P(M_B?M:_\$CX?>_"_A:XO\%_LB>(/&^@>%?%EQX^_M+M\9?
&2+4_&_B?X?>%/&OAKQ\4:?\F72?V@=,|Z#J\AJ>K:J+6_L'NOM+X
MSZ\2/B\|"M3L_V:/C'8?"SQGX\LO!=WX'^_F: X5\;Q>&/'VL>(O#FHZ_X
MR\;:'XM\.;,?|GBC59/A\|KEQX/L/\$.A7_A\5=9N=)CU&XT^PFEU2S_/>:*_MGA
"D7\|+|E_9>(|D?L#VN@:KX-L++1+&|L\|TS0=UMKIKL3>*BF MA2V_1+Q'^VAJG\|+?
#;|FGQ#\A_XX_MP_MA>\$_V\$/A/; ME9Z)96G_B6M?%_7X?B9\1/@A_#S1;?XG>/_#WC%
'PU\ZG>>A_Q&^E_M:Q:>\$/AS-I^E\$1@'Z\45^&7\27_!8:V3\G+|\@7\HK\BCX2>.OVC? ?\|:?
|7O_MP>^4^J:~_##P=XH\|277C_~S>/_A_JW@OXS_\$#X=&W^/_BR'PAX^~%NA6
MVJZGHO@'PAKFG:WX\|6?\$CP\9V?@IO&GK7Q3_P""QOP2^#FL?\$_B/QM^SY^U9_M;^
O@%XU^!OPQ_:F^,>F>%_@MJOPT_9?^)OO\TGP%J_AGP\3IK3X\OXT\6W
MWAB#XF>"H/B\XC^_7@OXT>_?#5SKEF%\7ZA\|!/*?KG17Y"_%Q=|1/#W_!M;3\|D?
P+IOQ2^)<7PP^)/|_#G\6/BGQ3\(_P#A\|77X67GBOX=_\$'X:7X7\5_M\(-#_#HDOB2QL?
%NNVZZS?6\Y>Q1WLB6DMJDDRR\3_P7N^+7\4W_|!7BO\|MJO\90_:|=|:L^>~
O@IXP^\$VFZSH6A?#WX_-\$'PK\3M\^_QU^\$7P>NXO\$IK_M\:/@|3-7TK5_!=OXNNM8\|
(7W@O6O"MD\U\K,'B\3/%B-H'_CX!^V%?%?S\|M^#_VJ?VE/@)_P68^"A
P3RE_:PUK\N_X1?&W\GKXJ?\$_OXH0_\$+P)^SYHGQM_M_8_|0?#BQN+_,,^)?
&/BC\|F3X6_!7P==>"?BGJ<\$'@W3/#OC#X;VGB"QUG5_M*O(-)?A3^S=J7B?
3O#GB%+Q_)XB^(WA#Q_XOO?#7@WQ?X6|=>/_#X&>M?B\|?^/'?B'2=0\86VC7-|_#9_?
IC17XQ_\$:_@IA\9\|_P""D6G?LI_"_P#8_MZ^-'|0GPAA_8?G_:?TWQ1\\$_&7\|)\NL_%6/QG\2?
A_X:|*>/?"R_&?|:~_#M-AI?PW\\$_VMOXQ\|(W5O=Z\|X\|9^+_\$_L>HZ5\|YO_N@Z-
XWUWLO"O_!8;X&>,M?@Q^P^T\|P-_:='PN_X*\$'_=V(SH.L:AX;TC70#|:J
M*_+GQ)_P57^&NE?M#_&G\F/PE^S!^VS\7OB7^SY\0O@CX#^*Y^\$?P/TCQ;X?
M\+6'Q\|L-2U3P\2;049/'^F72_#;RT^PAU#7-8DTZ+6?|+OFUKP_X>|0;)X?
M\9ZCX9\R^%G_6X_9N^+5E^R?XJT3X%?MA:#\|)OVQ/B^?V?_AG\|.M:%|+-&^-%YXB\|
<>&O#7@#Q=J7_"Q\|OO))=^+;_P%JRZ3XD\|^%_'/@?2\JX@_MT#QCX\|+^+--|3>'M
/V3HHHH ****"BBB@ HHHH ****"BBB@ KP;|G'_M_DGOB'_LO\|5'_K3WQ?KWFO!OV^(?
|LO\|5'_K3WQ?H/V^(?^R\|_M4?^M/?%^O>:"BBB@ HHHH ***M*"BBB@ HHHH
*^7VP/V\X+_MP_!24?@9|<|.UJZ*76M:7XFTK5/#_J) MHWB?
POXGT9+RWT_Q#X>U"XL\2L(M1AL-2U73'CU/2M4T^XT_5+ZWN+&7S4:/
MZCHKIP>_Q67XK#X\|XBKA,9A*L*^&Q-;|UJ-6FU%*2\$XM-237HU=---HY<=
M@<'F6#Q.7YAAJ_.P6,HSP^*PN(A&I1KT:D7&=.I"2:E&2?JG9HH-?SD?|0P MW\|'_17VO?_
OO@S_|\X&N/^(':_?LCW"@GO/#|*_C?^T;H_Q&?|1O\|MX0S4?B\XB^&?B3P3;Z^J\|
>)|&|.?"+PKKMYH\TJ_9\|Z5KUC>VJ2_:(1=M_M;_8;G^F>BON:?
BMXATZD*BXJS*3A_.U&HZ%2\$G&2DE.\$Z+C.#M:4))QDKIH MM'Y_4\|_
TJ4YTWPAE454A*#E35>G4BI1Y7*%2%93A-+6,XM2C+WDT\3^!C_MJB+_(((\$?
M(_&K\|H+QOX*_DT#Q9\|O@W\|(M;GT7QKXOT^S76/B+J\|DB?3\|M-
^"VJ:MIN\:'KFFZA:36NJ7'CJ33-5T#2;":*UDL;W7)7TFV_#_ (AAOV"/M^BN?M>_=%\|&?
_G_U_1017JYWXT<>9OC%BL/FT\EI1H4:2P65I4\SPBO:U\|M.LJM6=2M5_|\&V?_!WP'XU\|
>:;WQ3^TA\|M0H/#>L6&L'P=X\|=?#R7PAKSZ?^%K/X>Z=|*O#7CGO(O
M#6F>#?""Q#O_!JOA?QIXNT/PL?V:HKX7_)L_XEJ8>IGN;8S-)X6%2&&>*J
MTDH\T^2"DVH12_0<@X5X\$_VH-+T.+1/B+M6;1_C#^U?
XF^/_C7P\|;_*SL+SQ/KGQ#N;OXX#Q'INBAO"UKH&GB-/@_Q9^R_MO_P46\|:?
LY>+_A1KW_!+?X_WNH^)^O^"Z>I_|\%)M1T%/VE_V\$=\$T\5_V:/\$7\|M1>H?
&_5\|!\$7C+00VO8->T+XMC0Y\|/"4MOIME;Z/8ZI?6>LZ-XZD6&=K#^R:B_MO"/H#^:?
X_LK_MZ>*V5OVV/^"O_P8?@C\7M(_9+|1_!2XB?"+|\@|HM;XG_M_\$W\|F#Q\|X\|_%#/Q+|+
%M?A_|\VA?_PW^_C/Q\JO_1SQ'<0^_#GQ\|M*^'=8G\|=>"|#@_MC2_C1V&H/Z#_
\$/V:/BM/VOG@|XB_\$K_@B\A_L2?L
M6_%C\GOP1XON_\$OQA_9OTG\|C#5OB3^T\XV'@#7?|<7AS\|FT>!O#_(!N/@MH_M?Q-
FU:~|0ZQJGQ:~(_P\BH_~&H0:EX4\3^*O&/AO^A>B@#^2>T_98_P""MB6K?|\&^7\|/_

3U;I@+XFZ'^T[XN];?"PYX&|)H=_P!CK5=|0^%_CW^MTY1/VDK?XA7?
C&'HBMV/Z%HO@730%3>!_ \$VB7=W_XLOO\$@T2^|,Z)K?A_4MM\$_"WC'2|'"UKPS?
>+V);SPY^H?A/|F7Q/X?_8Y_:3U'PY_P M1=_9\$^\$|H:M3^_0A050^"-<|>&\$_
AXSB|3^/-:|.Z!^|=%'Y M:|!,OX5_M/?"F'|H|2?BSHGQ@^'7|_U|1_"TW|&GP-
_:4^+G@|X|_M%?!_MSX?VO@;3;?Q_X=|8_%3P+|2OC3HNI?#VX|<>9_PIWPOJ?
QC^)/BOP=X7L;O3 M|_|0QVEQH^EV'PIH'QB_:&^\$W_!9+@K>/@)^R)XR_:HO/\$?|_=
3AAN9/M"/Q6^"/PVMO_/C#30!/|2X^'_P#PG\$7QE|>^);WX?|_BB74/\$;>)?\$?P_F|
M9^,O",?ANV6Q^"BIO\$\$;Z9_1K7Q?|_~"?OI+WP@_:^*OI8G@'P|4L_:M\$^_|
|2_%GQAJOI3/|3GB|0|/'<4*ZA#H>F:|+&'QAU|X3S:#X'L|4OM,^&'
MAV'P/!H/PIT>9=%^&NG>%=)@M|.(_%/Q9^PC^UK^RK^RA|_|3OV8_@_P#L MW^_
/VM-4_8B_:W|\$_M6?M(>?*A+X^_9Q^'0A01DT_P_?'L?+\$+P5|/=-^/?Q
ME^#.H^)+R7QA^T/J0^&D0LM.TB|!)>"L^+M>|+ZOJ=K:O|S^RA_"K_@IQ^Q
MOXT_:8Z|)_LY^!/?&7|/_Q+_:C^_.OQS^!G|>+?&GX>:3HGPI^'W|17C?5/B MAXAT'XA_
'48-1^*7C7XJ?#;O|X@|11^&X-&|.P_#_OOJUQH^DZUXA|+^&K.M|17'|=%!1110_4444
9FM:/IGB+1|6|/ZU9Q:AHVNZ9?Z/JUA,7\$-HFI MVLME?VO&7B32--5?
#WAO2KWPSK\$^HZWJ%\$!INF"YL=)^'^#7|Z7:WEW%>ZNT#PR)I MEO=>5|',8FK|H?|
A2'QH_Z)#!4/_"-|5_|RIK^NBBOT'(?%_/TCB<;C)TY4J2A";:%.G3HN*BI*80#U|L
MQ"X:P|'#JC+!Y=@:=6%>M|2Y.C>'=/N6@|F|L=3T2T|1_#R>_:
M3|C3KVUAF+WM|Y>I6U|GFB,1(HM?^"4_P"SP&4GQA|9F_050\$7@D*P!R58
MK|/%;!Z':RM@|,#@U^FE%>#C_\$GBW%85\$XG#9OCL!0KUIU:6#I5U4IX;_WS>
MRISG24W3@|J'-K&-HW=FW|1E?A#P+@LOP>\$QF0Y;F>*PV'IT:V85L_*C5QDZ
M<5'V|6E3K.G&K423J%?V9?V+_C%^T! M|_AV?_CEK/Q.|>:YX"^)7|_GA&T|>%-
>_9X_:3^!FH6J1?';X|?"SQ+XH|>MR>
(OCAIWCN>RTS0AX9OM'LM:B_X2O3M9>RT>3Y>_:X)3_\$#4?VV|/@9^V7^
MOGKT'@_3?'O|4?|?B_(*#?-K^UTOP1|:?'#?P1^,7A+Q\$X>_:T&SU&_M
M=&TOXW_#&VT&33O\$#64\$6H?\$(P)J6NI8&3QD;RR|=?OE17PU:M5Q%6K7KU)U
MJU:I.M6JU).=2K5J2%9?B%X
M8A^"^^N>/|#O|_:9U7X@P>)KW3/BQ|1/ASK&DWVF7=EIFE?&;X8Z)H-EI^N?
M6G_!0+X4?M5_+O->:/AW^P#|4M%_:!LOV6-%N/V;?VQOV:OVH?@|?BO^
MSA^T7KGB|XE3ZO|!?'X^Z|XR^/_PQNOB?^SSHNFI_#Q+XP|*Z+X|^/'P|U6
M_P#\$/Q+T310"7C"|N_|3VO|45F:G|WFC?LW?|!1W|GCQ|_P%%_#=_P#L
M_P"C_M<: #_P4;^#7A#Q_0%<_PD|4>*/#EKXK|">(_AW;:>|.1|*!+_J^
M*^C^&!/!.D?|/Q=|7/\$T?Q\$|_O|4/@%HEY%XS;QG|+_AUXU|5+?3W5GK>N^_
MBG|H^D^\$|W^GBB@#^13|D7|B#_@L;^Q-;L ?%OPO^Q1X9|_W?|(^M?|%\$/V M>?
B5^SGX1_:('^^A|O|XA^!O|6_|4.J?'OP+|9?@CJVN:QX=^\$NE:)X*@A|_
MZ8_@WQ=XG|+^_|?TNTETJY)>#7AM)K;|O| ^")6H^(|7^_.O_!|;5/%_ANW|
M'^)M0_X*8^(+S6_"MMKL/B:/P|?W'P1^%,LVCMK|K8Z?::K<6|86|W=V5J+! M|J.86-
Q>6BPWEQ^_E?&G|_O| ?L|/|_ (U^+OO#^_GAOXF>'O%OOYUV3Q5|_M7|1|9?M'_M*?
&6U|>>+H(7G|9ZSHGQI^+GQ"Ts>-)XK>WL)_&%GIEKXEFTF M""19-4;28TL@ ?E+_P
%2OV>OC;^TS_P4_X)V>*|=1_X)D>_P|LC|CO|C^| M_:AUWXY0:YK_ .PCKWA'XNWOQV^
>F>#_AQIG@7X1?M&?M*>|9/\$H^'OO\$MK M'6/%-
W|3M|!"QZ3JGA^VUOP.OBA|/3+^YR?V*_V)OC|*|_@L;XM_:9^_|
M&^I|\$Q_V%Y_@/K7A_XG?LGP?\$SX\$;H_|57QPDO;IO!GC03/@+^SY|4/B5^S
MQ|\$|1|%Z4+>OC|5Z?X_TK5|22WAT9|_|+2?\$OBB|M/Z.Z*/Y)O|W|_#O_41
MU|X8ZE|8;+|D|7OA)^T)^SI_P6T^.'!3OX3_!7XI_&3|G+4M)_-:^!|0OB
MCXBW7BGX0;XZ^\$OQ<^)&A?#_P",&C^\$/&4^GMJ'Q_N_#_@.VUQ=/2SUOQ'I MVJZE?
>%/T1TS|D;X_?M-?M3?MB_MK_\$7X;K^RWJGQ3_.";D?|_P3T^"WP<
M^)/C7X6^,'?6J2ZAXN^*/Q_|6_%;XH:C|_#O&'Q3^'GAC3SXE|7^\$O"G@_2?#
MOQ!|:ZO>:|HVN:WX@M_#|S)I>B-^Y%%_!F&N?L_M=7GP%_X)-?\$OQO_P_\$
MQO@G^U9XO_87_937|A|X_P#|'"O|2WCC|ECQC)|0/"J>!?@GH5M^T|!\$?&GBZ M3X@=
WPGXF|_|>_@P=5T0>(/%5KXNU|P#XMU#PM=VW@NYOM=BN_IKXS?L)_M
M.Z)^SU^RO|=?V0/V_V6_@!|>_V7_P|M^U_;&TK_() ^?"X^\$ _PO| ^ (O F MN_"W4?
@1X|^%5_|%OP9X7|_%#&_ ^/B7P)J+>*KKXG:C|J>\$_#^L7|_SVFL M^,|!|\$^&-
;UW^C6B@#^=K|N?2_|@H^TO|_"|HE+QG%^P%_XG/B+P-^WU^Q|_M^TG=?LW>?\$
VA/V5=5|1_"SX?:LH_\$O|_X6+XYU3X@_%/Q|4?AKX+USXE?&B M>|L_#_@3P1|_
-3^-(7@|PUHW@V#6_%/CGP_K&OWFC/P_B7X8_MW2_MG?|%\$#+XITR3
MIKUQX;T*_N_B2|WHVNW0O;VUT/3?\$\$SEWI=GJ=UINBZM_2|10!_*=H'P_P"" M@\$>@?
|&J>E:E_P_\$|OCK8W?_35T/1/#7|2SQ_&O|A>|L|>/0?V;+3|FV'5 M/LR?

M:Q7'BN&^OJ/'CZ2U^QZ;<6?A2YBLE^U^*SET)/1%_8Z;T^#7[.'!M3I_@F[X_9MB^-?
PP_9^(W|6VO_+-W|5MM|6O@|X6^&_PH|?MMVFNO^*
M_.*|'^*O&6E_&B+Q1|=\$=8|3:YKMC>_!WX1_\$C3/B%G3+:U3PI+|IGMOZ;.*M
/Y^_@1^RA^T!|+|^"E5MH-U^S3|79OV./#O_!)OX'|\$V=#_:GE^(/L.L5K MJVO?!#7?B-
XYD^(%_P##>V^->I?%|2/#/BO2/&%OX(TBXB^&>KZ|9_\$2WBFU M?PE:?
#^YN/&>G_+/AS|@'JO#QE_P3.|?|3_B|^S|^8>\$O_7Q7^\$GA/4/V|
M|J\$^*P>F^#6M_LQ?|SH/PC|=,|7>%/AHWCS4?VA|3XX:OX,|*6WPU@^'^N
M_"G2O!.,OSW6N77QO@T,I!)_5510!_&|4/@W^TM|8?CI^VY-|O^"?OQK_:
MC_X)Y_#|L_6?B3|0/"_/*|<7|&_P_-?V=_VF?%'P%C^'GA;Q-JGC|X9?'+
MPD_QVNOB\$WQM^#VM>'_C2?@5|8_A1X3^(7B#P@/#NMZ5XMO?"[ZEK_ZE?|%)
M3XA_:0_8J_8T_P'''AG|)OVK?AKXZ_9G^/'|&4?O&TTVUYK|S^UM<>:_A
M9KO|.7Q)LM'O|HFW|?&'PA6X?#^CW2|)U98;76=\$TC4)M/|^#GB/PO=?\$'Q-
J7C#Q_P''|O!|?QY_.*|\$?SQWXDUN|MFU'7|3|:_LX>\$?BSHO|/WBQ_\$=Y9'ICN
M_P!AK|E34/VG/#_|8|_|(-*OOVB??"@O3OA_X5|_+K3/#^AK2+;5:'2 ME|_#R?
Q%)|_M#U|3M.US6=)LO&&E^#;7Q?;./JNH:/#KJ:9=SVC@'T'|?P_M3T7|G+X&?"
|X(Z%JM_XBMOAUX0TS0M1|7:PBKK_COQ04:~|9_\$7Q0R23"X|6_M_\$7Q?
>:YXX|67AEE>^|2:_JEY)+(|L.WXY>_#W|9N@?%P8OVR?#O|P3|^M/O!_9L|_|
!/WQ;^Q:_CGPU|7OV|)UOQ%XRU+|H70_CE9>/O"O@?QM^U1 MX4|02?
#^YL/#MOX:C_X2R/P=XP34|1EO+GPG;6%BKWO|H44_?QP'|E#_(*3
MW'_!++|D|HDN|_X)O_&J#XO_S_@I|1#^U-XJM+3X|_L)7GAB|^%-G^V|2OV MI9)-
|07'|6.GF?Q+=:'|2H?|>GZ)<?:12>)=_U2|O|1TS0|C3-0O/T"UKX M#_MS_!OXV_|!4-/?
|*&M?'?X-|%.?A_IWQ|^*=^*_|/W@GQG^SC|;9_M_P|FNP^!^O?"CX_Z-
X|^)FB'6_"TEWH>CZCI?C7X*ZO|6+#0HX|JUM|\$U@:I_M_P'''BUHG|!P&_9*_M^GP^?;
BW|E/6?B%^SU|4/V>M8|77@:QUH?Q%OM M|?
^#O!OB&YUV|U#P|HVORWVLPZ/H6D1_K)|5?V1_B)|7O@E|^?"9/BK|C#_MP-|/?
V_OC#X8|<^)?VM?'7|_I_9T|(?|KJGF.7Q+XH^*_A#|G+X_#W4M0|(
M^.)|30O&XTKP|KW|0W@WX|S:CM>W|;.)H?A/QWX_USQW|_#_W"HH_)?)&
MWW|>GA3X&7_|.W|W?|/_)|_@3|=_%/CO|G?Q)??M!?:0+V|T M3X6:OX|!*_!'XO|Q,N/
_QDT3P3INAV?O#M+I9O#6LWC0:SI7BC5M5NM:MK_M7|:***"BBB@_KX>:_T_X)|_
3|LG5O#/B+XG2^_M!|4>%=,ET.Q|2^=:TK
M2M4N|">|FU"+1M3CU_P_XGTNYLK_N|Z|LWCTV"|@EU"|VMHIO+7|AHKMR_M,L?
E.*IX|+<76P6+I*2A7H3<)|J.XN.XM|2C*+:E&2<6MUL?/<4)|-<;9+B>_M'>+,EP&?
Y)C)4:F(RW,J\$:^'G4PU6->A52=I4ZM&K",Z=6G*%2+32DE*2?XM
M_P##BK|DC_HHG|1G_A7?#A_^=%7XM_M:?!|/GXM?";|H'Q|V_(%?!7|H
MOXE?"O0!X5_X1;QM_P*X|2^,O|:_M7P5XMC^9_\$7Z%W@UO|DF%ROA_)
<+X>XW#YK0_MS"KG7#N"A6QN*PM+"8|/#SRNK'&UYTEA:|7%4<7.45|15L%02?*YI_P
_.'P?_M_&'/VB/%_P_6_A=X2|?_+/'|1?A?P)XH^(O@GP|XU|2_P#"T?_B_|".^\$
MM:|2Z9IOB/7|/9UKPE=:/|/DZ/_M4I*2J5|;0;4HKW4EIR|/3E|_H3^#_!."S+"|0Y?
2|1.V.Q5'\$8?&|28&G1K MY=2IT73GA<,L#7A"5*K-^VFYIR4TDG8_X"P#|-7|GO|C?
Q)K7QO|AH/MQA^+OQ%|>%/\$K>\$|U|QA_#^XUNYO)|NXXC10!:_W-
C|*O!MMXH46AG|-M:=?^./\$VE^;5M6?^T|;T*P>ZU6U^?OAO^Q_J|/|<_P"PI|;?V7?
VZOV3_BM^
MS+>:U^TO^TS|:OAOJVM_\$GX#^*/&_@|7OB_^TY|:OV@/|/H8O@_XW_9_^+WQ
M1_X1+XE?"R^(^D66J-KC:%&?\$\$ LZ#;IXT|#Z|H4VH?
MC17P.9YMF6&M"AJMQ=W=A|0?C!;W4M|.'?^">O|?W MQ#^"Q)T_P#9W^%'C_|9S^"_P
%?B+^Q)^U/^R1^P_^V7|>_AA|;)S^TM^S M9|7=7^(/Q1|_#KXA_#?XJ_'W0OA'^S-
XU|^6_A70_!G@GQCX|U^PMOB-H|S M>V/A/X4>_|0N;2W^O=|^&?|?
WQ5_X*D6W|'IK_@DY|0_V2M-/MOD^,?|/GC*_|&?M\$ZQ|===*^,F@7.IZ-|?B-
|4T|1^|K:|H.6|C:Z|8RQRZK MI|_97NKZ?X;O#J.AZ?|T|44?
R\$^%O^"O#6LZOKOB#X3_-"#X+2+#7TU&_M|30|/+:^0?
VL_P|A+|FC|N"#X5VW|27AGX@^*|;X*>.(B=|;?P7^T|^T+|M\$8/#^Q)L)+";0?B\$|7P*^*?
PVCU?QOQX/ET|9?_7BS7EU37OA_)J&OOX)U#0&_M3>(CJ@|T?|9W|+_
(2_4_93^/O|*7CC5K_/_^&_CO|_O\$OP^NO\$FEP+=Z
MCX8OM6M"VA^*;QODN+2'4;GPSKT&F:|%I=S%OB!XXTSXN?
%WX>?'SX7ZCJ&@:5HD_B_3=%^"WQ2N6U6?4M4T>U=
M)HM!L_V8LK2*PL|2Q@>YD@LK:"TA>|O;S4KQXK:)(8WN|1U&>ZU"_N61-9|V
M^NKF|NI2|U|/_(|C6:/O/_&D?V?|_H|P?^VU^Q;_,%&/AU|_O#O|17B
M;X>_!/XN_LP_M5_L|?"?Q9X3|"^ (G^"Q6|1:|0?#GBSX">(/CSXQ^'?@CQ

M5JOPW!9>'.TWQ5!1/'P!Q!H!K!K'A_00!UWJUUHGA!Q!VA/V_OVYK0Q
MAH!20@_!CKQYX!^ (7OU_P'''U!/'W_!1WXD_!SP!8_V6K+4?@-^SQ^QCH'A_MOP?
X>|'^+_\$/Q\$^-WP||'^*OCW!6K6Z!1^*+73/A?XB|= _#;1+B"?0M?^ (^G
MM9::K/BG^NNB@#^ ^%?#/C2_P#C-9^ ("E! MJKKJT'A3P!J.OBC00#OBB!LO";?
\$O@73?VIOV4/\$? !L!-O'7!"O+O_C_ ^MSY!-P!N/X0>.,?
@#IOQ4_9!;QCXGLO"W!_P^!/^ (&OPZ!;Q?&>|^"VIVAT M>6!1Z!H?C;XH?
#W4M4_LVYTC5)/#UU-83W?|B-?%OQE_P'''?7!+GQ^ _:%^\$ MO!5/Q0!-
_%/+5/CI!"4DC^\$'B!PY^TQ^TY!M!|1WLD::!H'@+X(M!L!73H0#!8?C#_P2^ _;Z_!:"O!
MG!1>FZ#X/^#!'!80Q! _;K_9G_ &Y_@3^SWXK!3>&|3!+^%|/!B31?'A#X1?#_M;XO^ _
\$ _B+PM!2/BKX?|%^ (^/\$/CC5/!'BSQ+X*T;Q?XE! .6:>+|NPL/\$>N MW/U_I'P4 _; _&G?
VZ_A)^WA!2OV8?\$/!+D?|+! (GOP^%7@+X3?%?XC_!#X MA^,?BO! _CM-X8FU(-
+!|_BA!1_!-G!&_!FE>%;S2K#6?\$/?CKPKXS!7:QXHM M!NX!%>\$--TF!DO?VQHH
FO^!|P+ ;7^%'B+Q9XG^"7!'''QH_98^"6L?LI_ & MK2OCG^PQ%|GP!;V/PBO?&UG-
!V!X: _9" _;B_X)3_!\$COAI>_L MJ>*! _; _" P'''>|6!/!&OO)^*WP#N_BM^SM)XJ!|=^
OV>)=>|. ^,==^%GCC3O_MB_? _)/#VC>-OB-X'U"YBTK5=*OTTZ_ _+*&J_TWT4 ?RV>(
MO^">OQG!\$?M@_M3>(\$G_!3!AK_ (*#> ?VQ?B9IOQ_!?"M#?'C4_V9I!/?
M!*WCWQIX!|&>'OBA!(-C&_O_ ^'&N?\$/WXA_!|PMXTV/ZCX!&7WP>T77M833+_M_4K?
^QIM3!2R'PU_3-X|*6_@/P)X*!#V@TE;7P9X2!.>%+8:|X=TKPAH0M_
M#NCV6D0C1?'"6A1Q;)X7TD1V:C30#NC11Z5HEGY.FZ?&E!0J.MHH_!SX2>
M_P!L&O_X+F_M%?M.>*/V(-BW X9_9<^(-LG@/!E7P7!;I_BO^R;JMI<:M!)O
MB%XD!9!4M?^'FC_+0MY!3!&^&GCB/5;JT!(OV?A+6_B1!&WAZZ!8_#WPE-
MJFOV'@_O/'?P8_:L_9=X*A?%O! _; ^"OP#|0_M9_K|K?|9O!A=|*OBU!M/?
AOX!^#'|@7XP_";XM_#4?\$/G_N_%NG6_QY^)'P>|>*/A;X! _>+M2TG78 MMA
&|UXWT77FN=5M!\$OM,M;33M3 _;>B@#^92;_@F=^U)!/V)?V4K?PI! _=M.^+'QW! ?
!%@?"O_4^ ^ _P0! _;\$#P1!OA%XJ_8"!47?|3?PAL/V=_A!&=_M%N_@OXA!7?#7X??"
!6O'_AV31OVFH_\$.B_ \$>R!4?%_O_|!#M?'7AW4S8Z;|M8/#VBZ#X?!)>)_ZSZ*
/Q(^ (/AC!L+Q'_P%?:V)OVBG_8H^ (DOP6! ?LI_%MSX_ %OXD>'OC'^S+J>@>
O'!0WBCX1>*!+:Z'XC^,?@OXF^+ _WPM7X>7.G M>/-7T3X=?VK?W%|)-
!O#OC:WM+=!23_ (+!|!W!J#H!|@#QI^R3^R0^RSX MM_:A7_!7O1!+;KO!J6F^A
!G!P%X+ ^?'AOXA_QQ^\$GQ(_M^"?7Q=|'_MA?M3>)|7_X(W_L8?M_?#7!LOXFZ=^T)!?<
C!^TM<_LI6GQ(_9/ M!;.>./!/@W0?B!|?'C!;.>./"OQ\$!9>-OAI X1!7Z!?'^)O#K_ :!|?R6D%
!K%CI M!FN7'B)=1T+^I*B@#|=H/V9_CW! (?^"J/P!^/'@GX1:;!0?V?3_P3;TW!B?Q
M1XS!&ZQ!+_AAI'P@!6^" _COH'O(M=?U;X67>L:-J-OX#USP5%J=AX-T#XA MA_QB-
&!2:=_I_A?5=+!*>%+A/%>G_)6?"W!B_P#X*9>\$OV3_ /@GC^R)J7!% M^DH?V?^"G?
@'X^ ^ (OBH_P"TI&!X>^,OP@! _&7X^?\$/(>-OAOX?LS>'_VP M?A=_P4E_X*T'_?
QE^PS!6X/@Y!/?#?P)U;X#>,=)^+W!DNIW7Q4U!HD_X3>(
M/AQ<>%=.!.2?'^QU!PE<_&W4KVWU3X0:M!1;3P?I-H4L1^,EQ!(!7%C?:?E
M5X6_9_ X*OZ#_P \$V_|@E!^S?J'_!.7XUS_!=_8J_X*=?#/!J!XNZ1!7OW_M_83N=|N_A!
(/CWX^ ^-\$TWA'Q'J!66DP:OXF!;Z-!5;7P!X5T*[M_-2W!2>_M#/&@!5ZAX:T+_A"!<|:V,44
5K*>6ZL!2ZGLKG39!FV@GFTZ!>SDO+"6:)) M)+*!?
3KN_P!/>YM78P308WU!9M+&YM;NY@*3/9HHH **** "BBB@_HHHH **M** "BBB@
KP;|G'_))|XA_!+S^U1_ZT!7Z!YKP;|G'_DGOB'_LO!H5'_K3 MWQ?H/V^ (?^R!_M4?|
K3WQ?KWFOEGP;HO!17PYLO\$7AS1/A_!|7Q/ MHMU!3/C!XSTC6M5^.'CGPOJESI?
Q)^*_C3XBZ?|J6@VGL_ BJTTZ_P!;M/%4 M.F7D5KXAU:WDN+.2>&Z;.*!&_
MX2'!H_HD'P&_P#\$COB%_P#0KT?)#^T!_T2#X#?^)'?\$+_Z%>@#WFBO!O! MA(?VGO!
HD'P&|_ \$COB%_|0KT?)#^T!_T2#X#?^)'?\$+_ .A7H |YHKP;_M_A(?VGO^B0?;_Q(|XA?
_0KT?)#^T!_T2#X#?|B1WQ" _|H5Z />:.*!&_X M2'!H_HD'P&_!2.^ (7_T*!'_D/!3W_
\$2#X#?^)'?\$+_Z%>@#WFBO!O^\$A_M _;>Z)!|O! Q(|XA?|T*!'_"0_M/?!\$@^
W_B1WQ" ^A7H |YHKP;_ (2'_M!H_*)!|O_! (|XA?_ \$*!'_"0_M/?!\$@^ W_B1WQ" _P#H5Z
/>:.*!&_X2_M'!H_HD'P&_!2.^ (7_T*!'_"0_M/?!\$@^ W_ (D=|0O_ *%>@#WFBO!O^\$A_
M:>_Z)!|O_ \$COB%_|!"O1_P)#^T!_P!\$@^ W_B1WQ" ^A7H |YHKP;_A(?VG MO^B0?;_<
2.^ (7-"O1_PD/!3W_1(!@-_XD=|0O_H5Z />:.*!&_P"\$A _;>M_P"B0?;_P
2.^ (7_P!"O1_PD/!3W_1(!@-_XD=|0O|Z%>@#WFBO!O^\$A _;
M>_Z)!|O_ \$COB%_|!"O1_PD/!3W_1(!@-_P")?'\$+_P"A7H |YHKP;_A(?VGO_M^B0?
;_Q(|XA?_0KT?|_"0_M/?|1(!@-_XD=|0O_H5Z />:.*!&_X2'!H_H MD'P&_P#\$COB%_P#0KT?
!)#^T!_T2#X#?^)'?\$+_Z%>@#WFBO!O! A(?VGO! MHD'P&|_ \$COB%_|0KT?
!)#^T!_T2#X#?^)'?\$+_ .A7H |YHKP;_A(?VGO^ MB0?;_Q(|XA?_0KT?)#^T!_T2#X#?|
B1WQ" _|H5Z />:.*!&_X2'!H_HD M'P&_!2.^ (7_T*!'_D/!3W_ \$2#X#?^)'?

\$+_Z%>@#WFBO!O^\$A_>_Z)!|M!O|Q(IXA?|T*|' "0_M/?|I\$@^W_B1WQ" ^A7H
IYHKP; (2'IH_*)!|O_!(IXA?_ \$*|' "0_M/?|I\$@^W_B1WQ" _P#H5Z />.*|&_X2'IH_HD'
MP&_|2.^ (7_T*|' "0_M/?|I\$@^W_ (D=|00_ %>@#WFBO!O^\$A_>_Z)!|
MO_ \$COB%_ |"O1_P)#^T|_P!\$@^W_B1WQ" ^A7H IYHKP; A(?VGO^B0?; _M_2.^ (7_
"O1_PD/I3W_1(/@-_XD=|00_H5Z />.*|&_P"\$A_>_P"B0?; _M_P
2.^ (7_P!"O1_PD/I3W_1(/@-_XD=|00| Z%>@#WFBO!O^\$A_>_Z)!|O
M_ \$COB%_ |"O1_PD/I3W_1(/@-_P")'?\$+_P"A7H IYHKP; A(?VGO^B0?; _O_M(IXA?_0KT?
"0_M/?|_1(/@-_XD=|00_H5Z />.*|&_X2'IH_HD'P&_P#\$ _MCOB%_P#0KT?)#^T|_T2#X#?
^)'?\$_+_Z%>@#WFBO!O|A(?VGO|HD'P&_|M\$COB%_|0KT?)#^T|_T2#X#?^)'?\$_+_
_A7H IYHKP; A(?VGO^B0?; _O(MIXA?_0KT?)#^T|_T2#X#?|_B1WQ"_|H5Z
/>.*|&_X2'IH_HD'P&_|2.^ _M(7_T*|'_D/I3W_ \$2#X#?^)'?
\$_+_Z%>@#WFBO!O^\$A_>_Z)!|O|Q(IXMA?|T*|' "0_M/?|I\$@^W_B1WQ" ^A7H
IYHKP; (2'IH_*)!|O_!(IMXA?_ \$*|' "0_M/?|I\$@^W_B1WQ" _P#H5Z
/>.*|&_X2'IH_HD'P&_|2.^ (M7_T*|' "0_M/?|I\$@^W_ (D=|00_
%>@#WFBO!O^\$A_>_Z)!|O_ \$COB%_ |M"O1_P)#^T|_P!\$@^W_B1WQ" ^A7H
IYHKP; A(?VGO^B0?; _2.^ (7_M-"O1_PD/I3W_1(/@-_XD=|00_H5Z
/>.*|&_P"\$A_>_P"B0?; _P2.^ (7_M_P!"O1_PD/I3W_1(/@-_XD=|00|
Z%>@#WFBO!O^\$A_>_Z)!|O_ \$COB%_ |M"O1_PD/I3W_1(/@-_P")'?\$+_P"A7H
IYHKP; A(?VGO^B0?; _O(IXA?_0KMT?| "0_M/?|_1(/@-_XD=|00_H5Z
/>.*|&_X2'IH_HD'P&_P#\$ _COB%_P#0MKT?)#^T|_T2#X#?^)'?\$_+_Z%>@#WFBO!O|A(?
VGO|HD'P&_|\$COB%_|M0KT?)#^T|_T2#X#?^)'?\$_+_A7H IYHKP; A(?VGO^B0?
; _O(IXA?_0KT_M?)#^T|_T2#X#?|_B1WQ"_|H5Z />.*|&_X2'IH_HD'P&_|2.^ (7_T*|'_M
D/I3W_ \$2#X#?^)'?\$_+_Z%>@#WFBO!O^\$A_>_Z)!|O|Q(IXA?|T*|'_M_ "0_M/?|I\$@^
W_B1WQ" ^A7H IYHKP; (2'IH_*)!|O_!(IXA?_ \$*|'_M_ "0_M/?|I\$@^W_B1WQ" _P#H5Z
/>.*|&_X2'IH_HD'P&_|2.^ (7_T*|'_M0_M/?|I\$@^W_ (D=|00_
%>@#WFBO!O^\$A_>_Z)!|O_ \$COB%_ |"O1_P)_M#^T|_P!\$@^W_B1WQ" ^A7H
IYHKP; A(?VGO^B0?; _2.^ (7_"O1_PD_M/I3W_1(/@-_XD=|00_H5Z
/>.*|&_P"\$A_>_P"B0?; _P2.^ (7_P!"O1_P_MD/I3W_1(/@-_XD=|00|
Z%>@#WFBO!O^\$A_>_Z)!|O_ \$COB%_ |"O1_PD/I_M3W_1(/@-_P")'?\$+_P"A7H
IYHKP; A(?VGO^B0?; _O(IXA?_0KT?| "0_M_M/?|_1(/@-_XD=|00_H5Z
/>.*|&_X2'IH_HD'P&_P#\$ _COB%_P#0KT?)#^T_M|_T2#X#?^)'?\$_+_Z%>@#WFBO!O|A(?
VGO|HD'P&_|\$COB%_|0KT?)#^_MT|_T2#X#?^)'?\$_+_A7H IYHKP; A(?VGO^B0?
; _O(IXA?_0KT?)#^T|_MT2#X#?|_B1WQ"_|H5Z />.*|&_X2'IH_HD'P&_|2.^ (7_T*|'_
D/I3W_ _M_ \$2#X#?^)'?\$_+_Z%>@#WFBO!O^\$A_>_Z)!|O|Q(IXA?|T*|'_ "0_M/?|_M\$@^
W_B1WQ" ^A7H IYHKP; (2'IH_*)!|O_!(IXA?_ \$*|'_ "0_M/?_M|I\$@^W_B1WQ" _P#H5Z
/>.*|&_X2'IH_HD'P&_|2.^ (7_T*|'_ "0_M/?|I\$@^M^W_ (D=|00_
%>@#WFBO!O^\$A_>_Z)!|O_ \$COB%_ |"O1_P)_#^T|_P!\$ _M@^W_B1WQ" ^A7H
IYHKP; A(?VGO^B0?; _2.^ (7_"O1_PD/I3W_1(/_M@-_XD=|00_H5Z
/>.*|&_P"\$A_>_P"B0?; _P2.^ (7_P!"O1_PD/I3W_1(_M/@-_XD=|00|
Z%>@#WFBO!O^\$A_>_Z)!|O_ \$COB%_ |"O1_PD/I3W_1(/@-_M_P")'?\$+_P"A7H
IYHKP; A(?VGO^B0?; _O(IXA?_0KT?| "0_M/?|_1(/@_M_ _XD=|00_H5Z
/>.*|&_X2'IH_HD'P&_P#\$ _COB%_P#0KT?)#^T|_T2#X#?_M^)'?\$_+_Z%>@#WFO!OV^(?
LO/I5'_K3WQ?H_X2'IH_HD'P&_|2.^ (M7_T*|_WP1|
(>*/|/@)|)9Q:#;^)=3|>_%WQOJ5GX8U?4_?T/3_ %E?%OOO|F1+/3+'6M5T#PM?
ZI_9=AXIM=/N;V?PH/GWEM EX-101.SCH 14 alks-20241231.xsd XBRL TAXONOMY
EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document
- Template Link link:presentationLink link:calculationLink link:definitionLink 100010 -
Document - Document and Entity Information link:presentationLink
link:calculationLink link:definitionLink 100020 - Disclosure - Leases - Summary of
Future Lease Payments Under Non-Cancelable Leases (Details) 2 link:presentationLink
link:calculationLink link:definitionLink 100030 - Statement - CONSOLIDATED
BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink
100040 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)
link:presentationLink link:calculationLink link:definitionLink 100050 - Statement -
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(LOSS) link:presentationLink link:calculationLink link:definitionLink 100060 -
Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
INCOME (LOSS) (Parenthetical) link:presentationLink link:calculationLink

[link:definitionLink 100070 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink](#)
[link:definitionLink 100080 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY \(Parenthetical\) link:presentationLink link:calculationLink](#)
[link:definitionLink 100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 100100 -](#)
[Disclosure - Cybersecurity Risk Management, Strategy, and Governance Disclosure link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure -](#)
[Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant](#)
[Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Discontinued Operations link:presentationLink](#)
[link:calculationLink link:definitionLink 995485 - Disclosure - Revenue from Contracts with Customers link:presentationLink link:calculationLink link:definitionLink 995495 -](#)
[Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Fair Value link:presentationLink link:calculationLink](#)
[link:definitionLink 995515 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Property, Plant and](#)
[Equipment link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink](#)
[link:definitionLink 995545 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Accounts Payable and](#)
[Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Long-term Debt link:presentationLink link:calculationLink](#)
[link:definitionLink 995575 - Disclosure - Earnings \(Loss\) Per Share link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure -](#)
[Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Share-based Compensation link:presentationLink](#)
[link:calculationLink link:definitionLink 995605 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 995615 -](#)
[Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Segment Reporting link:presentationLink](#)
[link:calculationLink link:definitionLink 995635 - Disclosure - Commitments and Contingent Liabilities link:presentationLink link:calculationLink link:definitionLink](#)
[995645 - Disclosure - Summary of Significant Accounting Policies \(Policies\) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure -](#)
[Summary of Significant Accounting Policies \(Tables\) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Discontinued Operations](#)
[\(Tables\) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Revenue from Contracts with Customers \(Tables\) link:presentationLink](#)
[link:calculationLink link:definitionLink 995685 - Disclosure - Investments \(Tables\) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure -](#)
[Fair Value \(Tables\) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Inventory \(Tables\) link:presentationLink link:calculationLink](#)
[link:definitionLink 995715 - Disclosure - Property, Plant and Equipment \(Tables\) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure -](#)
[Intangible Assets and Goodwill \(Tables\) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Leases \(Tables\) link:presentationLink](#)
[link:calculationLink link:definitionLink 995745 - Disclosure - Accounts Payable and Accrued Expenses \(Tables\) link:presentationLink link:calculationLink](#)
[link:definitionLink 995755 - Disclosure - Long-term Debt \(Tables\) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure -](#)
[Earnings \(Loss\) Per Share \(Tables\) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Share-based Compensation \(Tables\)](#)
[link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Income Taxes \(Tables\) link:presentationLink link:calculationLink link:definitionLink](#)
[995795 - Disclosure - Segment Reporting \(Tables\) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Description of Business](#)

and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Summary of Significant Accounting Policies - Schedule of Provisions for Sales and Allowances (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Summary of Significant Accounting Policies - Schedule of Contract Assets and Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Location (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Summary of Significant Accounting Policies - Summary of Location of the Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Fair Value of Stock Option Granted on Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Discontinued Operations - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Discontinued Operations - Schedule of Transfer of Assets and Liabilities Effected in Accordance with Separation Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Discontinued Operations - Summary of Expenses of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Discontinued Operations - Summary of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Discontinued Operations - Summary of Significant Non-cash Items and Capital Expenditures of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Revenue from Contracts with Customers - Schedule of Manufacturing and Royalty Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Revenue from Contracts with Customers - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Investments - Schedule of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Investments - Schedule of Proceeds from Sales and Maturities of Marketable Securities Plus Resulting Realized Gains and Losses (Details) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Investments - Schedule of Contractual Maturities of Available-for-Sale and Held-to-Maturity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Fair Value - Summary of the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Fair Value - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Inventory - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Inventory - Schedule of Inventories (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - Property, Plant and

Equipment - Schedule of Property, Plant and Equipment (Details)
[link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996085 - Disclosure -
Property, Plant and Equipment - Schedule of Property, Plant and Equipment
(Parenthetical) (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#)
996095 - Disclosure - Property, Plant and Equipment - Additional Information (Details)
[link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996105 - Disclosure -
Intangible Assets and Goodwill - Schedule of Goodwill and Intangible Assets (Details)
[link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996115 - Disclosure -
Intangible Assets and Goodwill - Additional Information (Details) [link:presentationLink](#)
[link:calculationLink](#) [link:definitionLink](#) 996125 - Disclosure - Leases - Additional
Information (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#)
996135 - Disclosure - Leases - Summary of Future Lease Payments Under Non-
Cancelable Leases (Details) [link:presentationLink](#) [link:calculationLink](#)
[link:definitionLink](#) 996145 - Disclosure - Accounts Payable and Accrued Expenses -
Schedule of Accounts Payable and Accrued Expenses (Details) [link:presentationLink](#)
[link:calculationLink](#) [link:definitionLink](#) 996155 - Disclosure - Accounts Payable and
Accrued Expenses - Summary of Current Provision for Sales, Discounts, Allowances and
Reserves (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#)
996165 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information
(Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996175 -
Disclosure - Long-term Debt - Schedule of Long-term Debt (Details)
[link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996185 - Disclosure -
Long-term Debt - Additional Information (Details) [link:presentationLink](#)
[link:calculationLink](#) [link:definitionLink](#) 996195 - Disclosure - Long-term Debt -
Scheduled Maturities of Term Loan Facility (Details) [link:presentationLink](#)
[link:calculationLink](#) [link:definitionLink](#) 996205 - Disclosure - Earnings (Loss) Per
Share - Schedule of Basic Earnings (Loss) Per Ordinary Share (Details)
[link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996215 - Disclosure -
Earnings (Loss) Per Share - Schedule of Anti-Dilutive Potential Common Share
Equivalent Excluded from Calculation of Earnings (Loss) Per Share (Details)
[link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996225 - Disclosure -
Shareholders' Equity - Additional Information (Details) [link:presentationLink](#)
[link:calculationLink](#) [link:definitionLink](#) 996235 - Disclosure - Share-based
Compensation - Schedule of Share-based Compensation Expense from Continuing and
Discontinued Operations (Details) [link:presentationLink](#) [link:calculationLink](#)
[link:definitionLink](#) 996245 - Disclosure - Share-based Compensation - Additional
Information (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#)
996255 - Disclosure - Share-based Compensation - Schedule of Stock Option Activity
(Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996265 -
Disclosure - Share-based Compensation - Stock Options - Additional Information
(Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996275 -
Disclosure - Share-based Compensation - Summary of RSU Activity (Details)
[link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996285 - Disclosure -
Share-based Compensation - Time-Based Restricted Stock Units Award - Additional
Information (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#)
996295 - Disclosure - Share-based Compensation - Performance-Based Restricted
Stock Units Awards - Additional Information (Details) [link:presentationLink](#)
[link:calculationLink](#) [link:definitionLink](#) 996305 - Disclosure - Share-based
Compensation - Summary of PRSU Activity (Details) [link:presentationLink](#)
[link:calculationLink](#) [link:definitionLink](#) 996315 - Disclosure - Collaborative
Arrangements - Additional Information (Details) [link:presentationLink](#)
[link:calculationLink](#) [link:definitionLink](#) 996325 - Disclosure - Income Taxes - Schedule
of Provision (Benefit) for Income Taxes from Continuing Operations (Details)
[link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996335 - Disclosure -
Income Taxes - Additional Information (Details) [link:presentationLink](#)
[link:calculationLink](#) [link:definitionLink](#) 996345 - Disclosure - Income Taxes - Schedule
of Income (Loss) Before Provision (Benefit) for Income Taxes by Geographical Area
(Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996355 -

Disclosure - Income Taxes - Schedule of Components of Net Deferred Tax Assets (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996365 - Disclosure - Income Taxes - Schedule of Activity in Valuation Allowance Associated with Deferred taxes (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996375 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Tax Rate to Effective Tax Rate (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996385 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Tax Rate to Effective Tax Rate (Parenthetical) (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996395 - Disclosure - Income Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996405 - Disclosure - Segment Reporting - Additional Information (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996415 - Disclosure - Segment Reporting - Summary of Significant Segment Expenses (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) 996425 - Disclosure - Commitments and Contingent Liabilities - Additional Information (Details) [link:presentationLink](#) [link:calculationLink](#) [link:definitionLink](#) Statement [Line Items]Statement [Line Items]McKesson Corporation.Mc Kesson Corporation [Member]McKessonLand [Member]LandCybersecurity Risk Board of Directors Oversight [Text Block]Plan Name [Domain]Plan NameIncome (loss) from continuing operations before income taxes at statutory rateEffective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, AmountDiscontinued OperationsDiscontinued Operations [Member]Other.Other [Member]OtherEntity Address, Postal Zip CodeEntity Address, Postal Zip CodeSummary of Valuation Allowance [Table Text Block]Schedule of Activity in Valuation Allowance Associated with Deferred taxesCybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]Disposal Group Name [Axis]Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]Schedule of InvestmentsDilutive ordinary share equivalentsWeighted Average Number of Shares Outstanding, Diluted, AdjustmentWeighted Average Number of Shares Outstanding, Diluted, Adjustment, TotalFair Value, Recurring and Nonrecurring [Table]Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]Fair value recurring basis assets or liabilities transfers between level two to level one.Fair Value Recurring Basis Assets Or Liabilities Transfers Between Level Two To Level OneTransfers between Level 2 to Level 1Entity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeBaudax bio, inc.Baudax Bio Inc [Member]BaudaxCosts and Expenses [Abstract]EXPENSES:Interest Paid, Excluding Capitalized Interest, Operating ActivitiesCash paid for interestValuation allowance releasedDeferred Tax Assets, Valuation Allowance ReleasedDeferred tax assets, valuation allowance released.Loss Contingency, Damages Sought, ValueAdditional sought value for damages as part of requested modificationUnrecognized share-based compensation expenseShare-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, AmountNumber of Operating SegmentsNumber of operating segmentRepresents performance based restricted stock units as awarded by a company to their employees as a form of incentive compensation.Performance Based Restricted Stock Unit Awards [Member]Performance-based RSUs AwardsDebt Securities, Available-for-Sale, Amortized Cost, CurrentShort-term investments, Amortized CostShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise PriceExercisable at the end of the period (in dollars per share)Rule 10b5-1 Arrangement Modified [Flag] .Rule 10b5-1 Arr Modified [Flag]Rule 10b5-1 Arrangement ModifiedIncome Tax Authority, Name [Domain]Income Tax Authority, NameShares, OutstandingBALANCE (in shares)BALANCE (in shares)Summary of significant accounting policies.Summary Of Significant Accounting Policies [Line Items]Summary Of Significant Accounting Policies [Line Items]Fair Value Hierarchy and NAV [Axis]Fair Value Hierarchy and NAVIntangible Assets, Net (Including Goodwill)Intangible Assets, Net (Including Goodwill), TotalINTANGIBLE ASSETS, NET AND GOODWILLIntangible assets, net and goodwillAuditor NameAuditor NameDeferred Federal Income Tax Expense (Benefit)U.S. federalCURRENT

ASSETS:Current Assets:Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]Fair Value, Inputs, Level 2 [Member]Level 2Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Share Based Compensation Arrangement By Share Based Payment Award [Line Items]Deferred Tax Liabilities, Gross [Abstract]Deferred tax liabilities:Long-Term Debt, Type [Domain]Long-Term Debt, TypeArea of Real Estate PropertyArea of real estate propertyShare-Based Payment Arrangement, Amount CapitalizedShare based compensation cost capitalizedPercentage of investment securities available for sale unrealized loss positionPercentage Of Investment Securities Available For Sale Unrealized Loss Position2Percentage of investment securities available for sale unrealized loss position.ReductionsContract with Customer Liability ReductionsContract with customer liability reductions.Income tax benefit from discontinued operationsDisposal Group Including Discontinued Operation Income Tax Provision (Benefit)Disposal group including discontinued operation income tax provision (benefit).Segment Reporting, Other Segment Item, AmountOther segment (expenses) incomeOther segment (expenses) incomePrepayment of long-term debtPrepayment Of Long Term DebtPrepayment of long term debt.Reductions based on the lapse of applicable statutes of limitationsUnrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of LimitationsLong-Term Debt, Current Maturities, TotalLong-Term Debt, Current MaturitiesCurrent portion of long-term debtLess: current portionLessee, Operating Leases [Text Block]LeasesDebt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year OneWithin 1 yearCommitments and Contingencies Disclosure [Text Block]Commitments and Contingent LiabilitiesContract with Customer, Basis of Pricing [Axis]Contract with Customer, Basis of PricingWilmington, OhioWilmington, Ohio [Member]Wilmington, Ohio.Product and Service [Axis]Product and ServiceFinite-Lived Intangible Assets by Major Class [Axis]Finite-Lived Intangible Assets by Major ClassDepreciation, Depletion and Amortization, TotalDepreciation, Depletion and AmortizationDepreciation and amortizationTwo thousand and eighteen stock option and incentive plan.Two Thousand And Eighteen Stock Option And Incentive Plan [Member]2018 Stock Option and Incentive PlanCollaborative Arrangement and Arrangement Other than Collaborative [Domain]Collaborative Arrangement and Arrangement Other than CollaborativeStock Repurchased During Period, SharesRepurchase of Alkermes' ordinary shares (in shares)Goodwill [Table]INVESTING ACTIVITIES:Noncash Investing and Financing Items [Abstract]Class of Treasury Stock [Table]Stock Option AwardsEmployee Stock [Member]Cybersecurity Risk Management Processes Integrated [Text Block]Concentration Risk Benchmark [Axis]Concentration Risk BenchmarkInterest Expense, NonoperatingInterest Expense, Nonoperating; TotalInterest expenseEquity [Text Block]Shareholders' EquityTitle and Position [Axis]Title of IndividualRevenue from Contract with Customer [Text Block]Revenue from Contracts with CustomersRepresents the minimum net sales under the collaborative arrangement to determine the know-how royalty percentage.Net Sales Greater Than500 Million [Member]Net sales greater than \$500.0 millionAward Date [Axis]Contract with Customer, Liability [Abstract]Contract Liabilities [Abstract]Sale of Stock [Domain]Cash and Cash Equivalents [Domain]Cash and Cash EquivalentsInventory, Work in Process, Net of ReservesWork in processPension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]Employee Benefit PlansFinite-Lived Intangible Asset, Useful LifeWeighted Amortizable LifeInventory, Policy [Policy Text Block]Inventory852 Winter Street LeaseEight Five Two Winter Street Lease [Member]Eight Five Two Winter Street Lease.Entity Central Index KeyEntity Central Index KeyEntity Central Index KeySEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease), TotalSEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)(Additions)/ ReductionsDebt Securities, Available-for-Sale and Held-to-Maturity, Amortized Cost, before Allowance for Credit LossAmortized CostAmortized CostShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in PeriodForfeited (in shares)Auditor OpinionAuditor Opinion [Text Block]Increase (Decrease) in Operating Capital [Abstract]Changes in assets and liabilities:Advertising

ExpenseAdvertising ExpenseProceeds from the sale of the Athlone FacilityProceeds from Divestiture of BusinessesCommon Stock, Shares, IssuedOrdinary shares, shares issuedShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, MinimumRisk-free interest rate, minimum (as a percent)Total operating expenses from discontinued operationsDisposal Group, Including Discontinued Operation, Operating ExpenseAward Date [Domain]Business Description and Basis of Presentation [Text Block]Description of Business and Basis of PresentationDebt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit LossTotalExternal Research and Development Expenses [Abstract]External research and development expenses [Abstract]External R&D expenses;Income Statement [Abstract]Represents information pertaining to long-term investments.Long Term Investments [Member]Long-term investmentsDebt Instrument, Fair Value Disclosure, TotalDebt Instrument, Fair Value DisclosureAmount to be realized in futureCraig Hopkinson M D.Craig Hopkinson M D [Member]Craig Hopkinson, M.D [Member]Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestOTHER INCOME, NETINCOME (LOSS) BEFORE INCOME TAXESIncome (loss) from continuing operations before provision (benefit) for income taxesIRELANDIrelandAdditional sought value for damages.Additional Sought Value For DamagesAdditional sought value for damagesConcentration Risk Type [Domain]Concentration Risk TypeEquity, Class of Treasury Stock [Line Items]Long-Acting INVEGA Products.Long Acting I N V E G A Products [Member]Long-Acting INVEGA ProductsContract with Customer, Liability, Revenue RecognizedAmounts recognized into revenueRepresents the maximum net sales under the collaborative arrangement to determine the know how royalty percentage.Net Sales Below250 Million [Member]Net sales of below \$250.0 millionCustomer [Axis]CustomerEstimated useful lifeProperty Plant And Equipment Estimated Useful Lives DescriptionProperty, plant and equipment estimated useful lives description.Customer Concentration Risk [Member]Customer Concentration RiskShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares AuthorizedIncrease in number of ordinary shares authorizedDebt Securities, Available-for-Sale, Unrealized Loss Position, TotalDebt Securities, Available-for-Sale, Unrealized Loss PositionAggregate estimated fair value of investments in unrealized loss positionRetirement Plan Name [Domain]Facility and Certain Related Assets [Member]Facility and certain related assets.Facility and Certain Related Assets [Member]Investments Classified by Contractual Maturity Date [Table Text Block]Schedule of Contractual Maturities of Available-for-Sale and Held-to-Maturity SecuritiesMural Oncology plc [Member]Mural Oncology plc [Member]Mural Oncology plcDebt Securities, Held-to-Maturity, Fair Value, NoncurrentEstimated Fair ValueFair value recurring basis assets or liabilities transfers between level one to level two.Fair Value Recurring Basis Assets Or Liabilities Transfers Between Level One To Level TwoTransfers between Level 1 to Level 2Treasury Stock, Common, SharesTreasury sharesCoverCover [Abstract]Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, AmountShare-based compensationComprehensive Income (Loss)Comprehensive Income, Policy [Policy Text Block]Earnings Per Share, BasicBasicEarnings (loss) per ordinary share-basisContract with Customer, Asset, after Allowance for Credit Loss, TotalContract with Customer, Asset, after Allowance for Credit LossContract assetsContract assetsTime based stock options.Time Based Stock Options [Member]Time-Based Stock OptionsRepresents the period after the date of the first commercial sale of the product in a particular country that the agreement will expire.Collaborative Arrangement Period After Date Of First Commercial Sale Of Product For Expiration Of AgreementPeriod after the date of the first commercial sale of the product for license expirationContract with Customer, Liability, CurrentContract liabilities—short-termDocument Annual ReportDocument Annual Report2024 Repurchase ProgramTwo Thousand Twenty Four Repurchase Program [Member]Two thousand twenty four repurchase program.Investments, Debt and Equity Securities [Abstract]License

[Member]License revenueEffective Income Tax Rate Reconciliation, Tax Contingency, Amount, TotalEffective Income Tax Rate Reconciliation, Tax Contingency, AmountUncertain tax positionsChristian Todd Nichols.Christian Todd Nichols
 [Member]Christian Todd Nichols [Member]Represents information pertaining to the manufacturing and supply agreement included under the collaboration agreement.Manufacturing And Supply Agreement [Member]Manufacturing and supply agreementShare-based compensation expenseShare-Based Payment Arrangement, ExpenseTotal share-based compensation expenseReceivables, Net, Current, TotalReceivables, Net, CurrentReceivables, netLong-Term DebtTerm LoansLong-term debtDeferred Tax Assets, Net [Abstract]Deferred tax assets:Increase decrease in accrued sales discount, allowances and reserves.Increase Decrease In Accrued Sales Discount Allowances And ReservesAccrued sales discounts, allowances and reservesRetained Earnings (Accumulated Deficit), TotalRetained Earnings (Accumulated Deficit)Accumulated deficitOperating lease expiration year.Operating Lease Expiration YearLease, expiration yearPlan Name [Axis]Plan NameCapital purchase commitments.Capital Purchase Commitments [Member]Capital CommitmentsSegment Reporting [Abstract]Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, NumberOutstanding at the end of the period (in shares)Outstanding at the beginning of the period (in shares)Outstanding stock optionCurrent assets:Assets, Current [Abstract]CURRENT ASSETS:UNITED STATESU.S.Investment Type [Axis]Deferred Tax Liabilities, Net, TotalDeferred Tax Liabilities, NetTotal deferred tax liabilitiesNet Cash Provided by (Used in) Operating ActivitiesCash flows provided by operating activitiesEntity Address, CountryEntity Address, CountryShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair ValueForfeited (in dollars per share)Product and Service [Domain]Product and ServiceAccumulated Other Comprehensive Income (Loss), Net of Tax, TotalAccumulated Other Comprehensive Income (Loss), Net of TaxAccumulated other comprehensive lossLessee, Operating Lease, Term of ContractLease periodAthlone FacilityAthlone Facility [Member]Athlone facility,Debt Instrument [Line Items]Long-term debtDepreciationDepreciation and Amortization, Discontinued OperationsOperating Loss CarryforwardsOperating loss carryforwardsProperty, Plant and Equipment, NetPROPERTY, PLANT AND EQUIPMENT, NETTotal property, plant and equipment, netProperty, plant and equipment, netLessee, Operating Lease, Liability, to be Paid, Year Four2028Investment, Policy [Policy Text Block]InvestmentsNet Cash Provided by (Used in) Operating Activities [Abstract]CASH FLOWS FROM OPERATING ACTIVITIES:Fair Value, Recurring [Member]Recurring BasisCurrent Income Tax Expense (Benefit); Continuing Operations [Abstract]Current income tax provision (benefit) :Provisions For Sales And Allowancesprovisions for sales and allowances.Beginning balanceEnding BalanceRevenue-related reservesCommon Stock, Par or Stated Value Per ShareOrdinary shares, par value (in dollars per share)Non-employee directors.Non Employee Directors [Member]Non-employee DirectorsStock OptionsCybersecurity Risk Management Positions or Committees Responsible [Text Block]Development Programs [Abstract]Development programs.Development programs:OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after TaxUnrealized gain (loss) on marketable securities, net of tax provision (benefit)Holding gain (loss), net of a tax provision (benefit) of \$292, \$1,195 and \$(973), respectivelyAssets held for saleAsset Held for Sale Not Part of Disposal Group NoncurrentAsset held-for-sale not part of disposal group, noncurrent.Contract liabilitiesContract with Customer, Liability, TotalContract with Customer, LiabilityContract liabilities at end of the periodContract liabilities at beginning of the periodDisposal Groups, Including Discontinued Operations [Table]Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]COMPREHENSIVE INCOME (LOSS) :Accounts Receivable [Policy Text Block]Receivables, netStatement of Cash Flows [Abstract]Counterparty Name [Axis]Counterparty NameRevenue Related Reserves Included In Consolidated Balance

Sheets [Table Text Block]Revenue related reserves included in consolidated balance sheets.Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets9 O-H Risperidone Palimate [Member]9 O-H Risperidone Palimate.O H Risperidone Palimate [Member]Represents royalty as a percentage of net sales under the collaborative agreements.Collaborative Arrangement Royalty RateRoyalty rate (as a percent)Antidilutive Securities, Name [Domain]Antidilutive Securities, NameDiscounts [Member]Discounts.Discountslong-term debt paid offLong-Term Debt, Fair ValueGain on sale of assetsDisposal Group, Not Discontinued Operation, Gain (Loss) on DisposalOccupancy internal research and development expensesOccupancy internal research and development expenses.OccupancySelling, General and Administrative ExpenseSelling, General and Administrative Expenses [Member]Selling, general and administrativeEntity [Domain]Number of investment securities.Number Of Investment SecuritiesNumber of investment securitiesCollaborative arrangement know how royalty rate resets.Collaborative Arrangement Know How Royalty Rate ResetsKnow-how royalty rate resets (as a percent)The limit of annual employee contributions to the plan, as a percentage of compensation.Defined Contribution Plan Employee Contribution Limit As Percentage Of CompensationEmployee contribution limit as a percentage of their eligible compensationDeferred Tax Assets, OtherOtherDistribution of Mural Oncology plcDistribution of BusinessDistribution of BusinessLease agreement, commencement date.Lease Agreement Commencement DateLease, commencement dateEquity Components [Axis]Equity ComponentsBase premises.Base Premises [Member]Base PremisesEntity Address, Address Line OneEntity Address, Address Line OneSchedule of Basic Earnings (Loss) Per Ordinary ShareSchedule of Earnings Per Share, Basic and Diluted [Table Text Block]Employee-related Liabilities, Current, TotalEmployee-related Liabilities, CurrentAccrued compensationShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in PeriodGranted (in shares)Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]Intangible Asset, Finite-Lived [Table]Schedule Of Finite Lived Intangible Assets [Table]Schedules of Concentration of Risk, by Risk Factor [Table Text Block]Schedule of Revenue and Receivables From Customers Exceeding 10% of Total in Each CategoryProperty, Plant and Equipment [Line Items]Property Plant And Equipment [Line Items]Property, plant and equipmentIncome taxes payable on repatriation of unremitted earnings.Income Taxes Payable On Repatriation Of Unremitted EarningsIncome taxes payable on repatriation of unremitted earningsEffective Income Tax Rate Reconciliation, Nondeductible Expense, Other, AmountOther permanent itemsSubsequent Event Type [Axis]Subsequent Event TypeDeferred Income Tax Expense (Benefit), Continuing Operations [Abstract]Deferred income tax provision (benefit):AmerisourceBergen Corporation.Amerisource Bergen Corporation [Member]AmerisourceBergenNonoperating Income (Expense)Total other income (expense), netOTHER INCOME (EXPENSE), NETSchedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]Schedule of Anti-Dilutive Potential Common Share Equivalent Excluded from Calculation of Earnings (Loss) Per ShareArticle or substance produced by labor or machinery, and royalties.Manufactured Product And Royalty [Member]Manufacturing and royalty revenuesInvestments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]InvestmentsShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, NumberUnvested at the end of the period (in shares)Unvested at the beginning of the period (in shares)Entity Voluntary FilersEntity Voluntary FilersRoyalty revenue recognizedRoyalty revenue recognizedAmendment FlagAmendment FlagContract with Customer, Asset, Allowance for Credit LossEnding BalanceBeginning balanceAllowance for doubtful accountsCurrent Federal Tax Expense (Benefit)U.S. federalIncrease (Decrease) in Operating Lease LiabilityDecrease in operating lease liabilityOperating Lease, Liability, NoncurrentOPERATING LEASE LIABILITIES—LONG-TERMRepresents the amount of milestone payments receivable.Milestone Payments ReceivableMilestone payment receivableOther Current Liabilities [Member]Components of Accrued Sales Discounts, Allowances and ReservesProceeds from contingent consideration.Proceeds

From Contingent ConsiderationProceeds from contingent considerationMaximum
percentage of product supplies on net sales.Maximum Percentage Of Product Supplies
On Net SalesMaximum percentage of product supplies on net salesDomestic Tax
Jurisdiction [Member]U.S. federalCorporate Debt Securities [Member]Corporate debt
securitiesInventory, Finished Goods, Net of ReservesFinished goodsAdditional Paid in
Capital, Common StockAdditional paid-in capitalDebt Securities, Available-for-Sale,
NoncurrentLong-term investments, Estimated Fair ValueDeferred Tax Liabilities,
Property, Plant and EquipmentProperty, plant and equipmentRight-of-use assetsRight-
of-use assets, discontinued operating activitiesRight-of-use assets, discontinued
operating activitiesNET INCOME (LOSS)Net income (loss)Lessee, Lease, Description
[Table]Lessee Lease Description [Table]Share-Based Compensation Arrangement by
Share-Based Payment Award, Options, Exercises in PeriodExercised (in shares)Share-
Based Compensation Arrangement by Share-Based Payment Award, Options,
Exercisable, NumberExercisable at the end of the period (in shares)Research and
Development ExpenseResearch and Development Expense [Member]Research and
developmentDefined Contribution Plan, CostEmployer contributionCustomer
[Domain]CustomerSchedule of Debt [Table Text Block]Schedule of Long-term
DebtDebt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity
[Abstract]Available-for-sale, Amortized CostRepresents the information pertaining to
VIVITROL.Vivitrol [Member]VIVITROLEquity Component [Domain]Equity
ComponentStatistical Measurement [Domain]Statistical MeasurementDocument
Financial Statement Error CorrectionDocument Financial Statement Error Correction
[Flag]General and Administrative ExpenseGeneral and Administrative Expense,
TotalGeneral and administrative expenseProceeds from Sale of Property, Plant, and
Equipment, TotalProceeds from Sale of Property, Plant, and EquipmentProceeds from
the sale of equipmentAccrued sales discount allowances and reserves line
items.Accrued Sales Discount Allowances And Reserves [Line Items]Accrued Sales
Discount Allowances And Reserves [Line Items]Long-Lived Assets Held-for-Sale, Name
[Domain]Unbilled Contracts ReceivableUnbilled receivableOther Nonoperating Income
(Expense), TotalOther Nonoperating Income (Expense)Other income (expense),
netOther segment (expenses) incomeDeferred State and Local Income Tax Expense
(Benefit)U.S. stateShare-Based Compensation Arrangement by Share-Based Payment
Award, Expiration PeriodExpiration periodPurchase Commitment, Excluding Long-
Term Commitment [Domain]Purchase Commitment, Excluding Long-Term
CommitmentUndistributed Earnings of Foreign SubsidiariesCumulative unremitted
earnings of overseas subsidiariesCybersecurity Risk Materially Affected or Reasonably
Likely to Materially Affect Registrant [Text Block]Abandonment of NOLsIncome Tax
ReconciliationAbandonment of Net Operating LossIncome tax reconciliation
abandonment of net operating loss.Outstanding Term Loans Principal Amount
DueOutstanding term loans principal amount due.Outstanding term loans principal
amount dueTreasury StockTreasury Stock, Common [Member]Disaggregation of
Revenue [Table]Disaggregation Of Revenue [Table]Cybersecurity Risk Management
Processes Integrated [Flag]Internal R&D expenses:Internal Research and Development
Expenses [Abstract]Internal research and development expenses.Net Income (Loss),
Including Portion Attributable to Noncontrolling Interest, TotalNet Income (Loss),
Including Portion Attributable to Noncontrolling InterestNet income (loss)Debt
Instrument, Variable Interest Rate, Type [Extensible Enumeration]Preferred Stock,
Shares IssuedPreferred stock shares, issuedOperating Lease, PaymentsPayments for
operating leasesRepresents the profit realized on the sale of debt or equity securities
categorized as held-to-maturity, trading securities and available-for-sale.Marketable
Securities Realized GainRealized gainsRepresents the period for resolving default or
breach after the receipt of notice for termination of agreement.Collaborative
Arrangement Period For Resolving Default Or Breach After Receipt Of Notice For
Termination Of AgreementPeriod for resolving default or breach after the receipt of
notice for termination of agreementRodin Therapeutics Incorporation.Rodin
Therapeutics Incorporation [Member]Rodin Therapeutics IncorporationDebt
Securities, Held-to-Maturity, Fair ValueEstimated Fair ValueTotalAdditional award
paid.Additional Award PaidAdditional award paidDiscontinued operation agreement

dateDiscontinued Operation Agreement DateDiscontinued operation agreement
datePayables and Accruals [Abstract]Deferred Tax Liabilities, OtherOtherDisposal
Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or
Comprehensive Income [Extensible Enumeration]Back royalties late payment
interestBack Royalties Late Payment InterestBack royalties late payment
interestOperating Lease, ExpenseOperating lease expensePrepaid Expense and Other
Assets, CurrentPrepaid expenses and other current assetsDebt Securities, Available-
for-Sale, Fair Value, Fiscal Year Maturity [Abstract]Available-for-sale, Estimated Fair
ValueShare-Based Compensation Arrangement by Share-Based Payment Award, Fair
Value Assumptions, Risk Free Interest Rate, MaximumRisk-free interest rate,
maximum (as a percent)Share-Based Compensation Arrangements by Share-Based
Payment Award, Options, Forfeitures in Period, Weighted Average Exercise
PriceForfeited (in dollars per share)Prepaid expenses and other current assetsDisposal
Group, Including Discontinued Operation, Prepaid and Other Assets,
CurrentCollaborative Arrangement and Arrangement Other than Collaborative
[Axis]Collaborative Arrangement and Arrangement Other than CollaborativeContinuing
OperationsContinuing Operations [Member]Summary of Significant Non-cash Items
and Capital Expenditures of Discontinued OperationsSummary of the Significant Non-
cash Items and Capital Expenditures of the Discontinued OperationsCollaborative
Arrangement Disclosure [Text Block]Collaborative ArrangementsComprehensive
Income (Loss), Net of Tax, Attributable to ParentCOMPREHENSIVE INCOME
(LOSS)Common Stock, Shares, Outstanding, Ending BalanceCommon Stock, Shares,
Outstanding, Beginning BalanceCommon Stock, Shares, OutstandingOrdinary shares,
shares outstandingMilestone payments receivedMilestone Payments
ReceivedMilestone payments receivedFinite-Lived Intangible Assets, Major Class Name
[Domain]Finite-Lived Intangible Assets, Major Class NameShare-Based Compensation
Arrangement by Share-Based Payment Award, Options, Outstanding [Roll
Forward]Number of SharesNet amounts written off into other (expense) income,
netContract with customer liability recognized through other expense income
netContract With Customer Liability Recognized Through Other Expense Income
NetNet amounts write off within other income (expense), netSchedule of Components
of Income Tax Expense (Benefit) [Table Text Block]Schedule of Provision (Benefit) for
Income Taxes from Continuing OperationsTwenty twenty six term loansTwenty Twenty
Six Term Loans [Member]2026 Term Loans2026 Term Loans, due March 12,
2026Purchase Commitment, Remaining Minimum Amount CommittedOpen purchase
order commitmentsPreferred Stock, Par or Stated Value Per SharePreferred stock
shares, par value (in dollars per share)Research and development expensesDeferred
Tax Asset, In-Process Research and DevelopmentIncome Tax Expense (Benefit),
Effective Income Tax Rate Reconciliation, Amount [Abstract]Reconciliation of effective
income tax rateAntidilutive Securities [Axis]Antidilutive SecuritiesRepresents the
information pertaining toVUMERITYVumerity [Member]VUMERITYCybersecurity Risk
Process for Informing Management or Committees Responsible [Text Block]Property,
Plant and Equipment, DisposalsCarrying value at the time of dispositionDeferred
Foreign Income Tax Expense (Benefit)IrelandShare-Based Payment Arrangement,
Restricted Stock Unit, Activity [Table Text Block]Summary of RSU ActivityNumber of
significant operating leasesNumber Of Significant Operating LeasesNumber of
significant operating leasesGoodwillFinite-Lived Intangible Assets [Line
Items]Intellectual Property [Member]Capitalized IPDiscontinued Operations and
Disposal Groups [Abstract]Schedule of Transfer of Assets and Liabilities Effected in
Accordance with Separation AgreementsSchedule of the Transfer of Assets and
Liabilities was Effected in Accordance with the Separation Agreements [Table Text
block]Schedule of the transfer of assets and liabilities was effected in accordance with
the separation agreementsEntity Interactive DataCurrentEntity Interactive Data
CurrentDebt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single
Maturity Date, Year OneWithin 1 yearContract liabilities policyContract Liabilities
Policy [Text Block]Contract LiabilitiesProduct [Member]Product sales,
netSummary of significant accounting policiesSummary Of Significant Accounting
Policies [Table]Summary Of Significant Accounting Policies [Table]Cost of goods

~~manufactured~~Cost of Sales [Member]Cost of goods manufactured and soldOperating
Activities [Domain]In-process R&DIncome Tax Reconciliation In Process Research and
DevelopmentIncome tax reconciliation in process research and development.Payment
for Debt Extinguishment or Debt Prepayment CostPayment made for debt
extinguishmentGoodwill [Line Items]Share-Based Compensation Arrangement by
Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period,
Weighted Average Grant Date Fair ValueVested (in dollars per share)Cash, Cash
Equivalents, Restricted Cash, and Restricted Cash Equivalents, TotalCash, Cash
Equivalents, Restricted Cash, and Restricted Cash EquivalentsCASH AND CASH
EQUIVALENTS—End of periodCASH AND CASH EQUIVALENTS—Beginning of
periodStatement of Financial Position Location, Balance [Axis]Balance Sheet
LocationStatistical Measurement [Axis]Statistical MeasurementEquity Method
Investment [Table]Service agreement termDiscontinued Operation, Period of
Continuing Involvement after DisposalUnvested Performance Based Restricted Stock
Units Awards [Member]Unvested:Performance Based Restricted Stock Units
Awards.Unvested Performance-based RSUs AwardsCost of Goods and Services Sold,
TotalCost of Goods and Services SoldCost of goods manufactured and sold (exclusive of
amortization of acquired intangible assets shown below)Assets, Fair Value
DisclosureAssets, TotalProduct discounts.Product Discounts [Member]Product
DiscountsDisaggregation of Revenue [Table Text Block]Schedule of Disaggregation of
RevenuesSelling and Marketing ExpenseSelling and Marketing Expense, TotalSelling
and marketing expenseLessee, Operating Lease, Liability, to be Paid, Maturity [Table
Text Block]Summary of Future Lease Payments Under Non-Cancelable
LeasesCOLLABORATIVE ARRANGEMENTSCollaborative Arrangements Disclosure
[Abstract]Investments determined using Level 3 inputsFair Value, Measurement with
Unobservable Inputs Reconciliation, Recurring Basis, Asset ValueBalance at the end of
the periodBalance at the beginning of the periodFinite-Lived Intangible Assets, Gross,
TotalFinite-Lived Intangible Assets, GrossGross Carrying AmountShare-Based
Compensation Arrangement by Share-Based Payment Award, Number of Shares
Available for GrantShares of common stock available for issuanceShare-Based
Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other
than Options, Grants in Period, Weighted Average Grant Date Fair ValueGranted (in
dollars per share)Weighted average period for unrecognized share-based compensation
expense expected to be recognizedShare-Based Payment Arrangement, Nonvested
Award, Cost Not yet Recognized, Period for RecognitionLoss Contingency Accrual,
ProvisionPotential material losses from claims, legal proceedings probable of
occurringSummary of Location of the AssetsLong-Lived Assets by Geographic Areas
[Table Text Block]Deferred Tax Assets, NetNet deferred tax assetsResearch and
Development Expense, Policy [Policy Text Block]Research and Development
ExpensesRepresents information pertaining to the license agreement included under
the collaboration agreement.License Agreement [Member]License
agreementStatement of Income Location, Balance [Axis]Income Statement
LocationCash and Cash Equivalents [Axis]Cash and Cash EquivalentsExternal Research
and Development expensesExternal research and development expenses.Total external
R&D expensesAssetsTOTAL ASSETSShare-Based Compensation Arrangement by Share-
Based Payment Award, Fair Value Assumptions, Expected TermExpected option
termContract with Customer, Basis of Pricing [Domain]Contract with Customer, Basis
of PricingAmount before allocation of valuation allowances of deferred tax asset
attributable to deductible state tax credit carryforwards.Deferred Tax Assets Tax Credit
Carryforwards StateState tax creditsRoyalty revenue related to back royaltiesRoyalty
Revenue Related to Back RoyaltiesRoyalty revenue related to back royalties.Represents
the provision for extension of operating lease term.Operating Lease Provision For
Extension Of TermLessee operating lease term of option to extendSchedule of Long-
Term Debt Instruments [Table]Debt Instrument [Table]Current Foreign Tax Expense
(Benefit)Rest of worldIrelandShare-Based Compensation Arrangement by Share-Based
Payment Award, Equity Instruments Other than Options, Vested in PeriodVested (in
shares)New Accounting Pronouncements, Policy [Policy Text Block]New Accounting
PronouncementsEntity Address, City or TownEntity Address, City or TownConversion

reissuance (in dollars per share)Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Conversion Reissuance In Period Weighted Average Grant Date Fair ValueShare based compensation arrangement by share based payment award equity instruments other than options conversion reissuance in period weighted average grant date fair value.AOCI Attributable to Parent [Member]Accumulated Other Comprehensive LossEquity [Abstract]Auditor LocationAuditor LocationEffective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, AmountForeign rate differentialSchedule of Maturities of Long-Term Debt [Table Text Block]Scheduled Maturities of Term Loan FacilityCybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in PeriodForfeited (in shares)Contract with Customer, Asset, Reclassified to ReceivableTransferred to receivables, netLuxembourg inland revenue two thousand seventeen.Luxembourg Inland Revenue Two Thousand Seventeen [Member]LTA 2017Disclosure of the entity's accounting policy for geographic information.Geographic Information Policy [Text Block]Geographic InformationCurrent provisions relating to sales in current yearCurrent Provisions Relating To Sales In Current YearCurrent provisions relating to sales in current year.Aggregate revenues, net, during the period in the normal course of business.Revenues Net [Member]Revenues NetShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual TermWeighted average remaining contractual term of stock options exercisableEuropean Union [Member]EUDepreciation, TotalDepreciationDepreciation expenseShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair ValueFair value of RSU's vestedFair value of vesting RSU'sDebt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity [Abstract]Held-to-maturity, Amortized CostAssets related to discontinued operationsAssets related to discontinued operationsTotal current assetsDisposal Group, Including Discontinued Operation, Assets, CurrentReturnsReturns [Member]Returns.Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year OneWithin 1 yearCybersecurity Risk Third Party Oversight and Identification Processes [Flag]Allocation AdjustmentAllocation AdjustmentGoodwill Allocation AdjustmentGoodwill Allocation Adjustment.Share-Based Payment Arrangement [Text Block]Share-based CompensationCybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]Construction in Progress [Member]Construction in ProgressLicensing Agreements [Member]Collaboration agreementsShares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, TotalShares Issued, Shares, Share-Based Payment Arrangement, after ForfeitureIssuance of ordinary shares under employee stock plans (in shares)Current State and Local Tax Expense (Benefit)U.S. stateShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in PeriodExpired (in shares)Discontinuing Operations - DilutedDiscontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted ShareLoss per ordinary share from discontinued operations - dilutedDefined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross PayPercentage of employer contribution matched of the first employee payOperating Lease, Weighted Average Discount Rate, PercentWeighted average incremental borrowing rateOther Assets [Member]Other AssetsFair Value Disclosures [Abstract]Assets held for saleAsset, Held-for-Sale, Not Part of Disposal Group, CurrentAsset, Held-for-Sale, Not Part of Disposal Group, Current, TotalOperating lease liabilities-long-termOPERATING LEASE LIABILITIES-LONG-TERMDisposal Group Including Discontinued Operation Operating Lease Liabilities Non-currentDisposal group including discontinued operation operating lease liabilities non-current.Entity Public FloatEntity Public FloatDeferred Tax Assets, Net of Valuation AllowanceTotal deferred tax assetsNumber of equal annual installments for stock vested.Number Of Equal Annual Installments For Stock VestedNumber of equal annual installments for stock vestedManufacturing

revenue.Manufacturing Revenue [Member]Manufacturing RevenueLessee, Lease,
 Description [Line Items]Lessee Lease Description [Line Items]Liabilities, Current
 [Abstract]CURRENT LIABILITIES:Accounts Receivable [Member]Accounts
 ReceivableReduction of Accounts ReceivableDocument TypeDocument TypeSchedule of
 Intangible Assets and Goodwill [Table Text Block]Schedule of Goodwill and Intangible
 AssetsUS Government Agencies Debt Securities [Member]U.S. government and agency
 debt securitiesRepresents information pertaining to RISPERDAL CONSTA, a product of
 the entity.R I S P E R D A L C O N S T A [Member]RISPERDAL CONSTATitle of 12(b)
 SecurityTitle of 12(b) SecurityCash and Cash Equivalents, at Carrying Value, TotalCash
 and Cash Equivalents, at Carrying ValueCash and cash equivalentsStatement of
 Financial Position Location, Balance [Domain]Balance Sheet LocationOther
 Noncurrent Liabilities [Member]Other Long-Term LiabilitiesComponents of Other
 Long-term LiabilitiesCybersecurity Risk Management, Strategy, and Governance [Line
 Items]Statement of Stockholders' Equity [Abstract]Document Fiscal Period
 FocusDocument Fiscal Period FocusConversion Reissuance (in shares)Share Based
 Compensation Arrangement By Share Based Payment Award Options Conversion
 Reissuance In PeriodShare based compensation arrangement by share based payment
 award options conversion reissuance in period.Share-Based Compensation
 Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic
 ValueAggregate intrinsic value of stock options exercisedDeferred Tax Assets, Tax
 Credit Carryforwards, ResearchFederal research and development creditsResearch and
 Development ExpenseResearch and developmentR&D expensesPayment, Tax
 Withholding, Share-Based Payment ArrangementEmployee taxes paid related to net
 share settlement of equity awardsLong-Term Debt, Excluding Current Maturities,
 TotalLong-Term Debt, Excluding Current MaturitiesLONG-TERM DEBTLong-term
 debtEffective Income Tax Rate Reconciliation, Tax Credit, Research, AmountR&D
 creditShare-Based Compensation Arrangement by Share-Based Payment Award,
 Options, Grants in Period, GrossGranted (in shares)Represents the patent royalty as a
 percentage of net sales under the collaborative agreements.Collaborative Arrangement
 Patent Royalty RatePatent royalty rate (as a percent)Disaggregation of Revenue
 [Abstract]REVENUES:Debt Securities, Held-to-Maturity, Fair Value, Maturity
 [Abstract]Held-to-maturity, Estimated Fair ValueBuilding and Building Improvements
 [Member]Buildings and improvementsBuilding and ImprovementsAsset Class
 [Domain]Asset ClassProperty, Plant and Equipment, Gross, Ending BalanceProperty,
 Plant and Equipment, Gross, Beginning BalanceProperty, Plant and Equipment, Gross,
 TotalProperty, Plant and Equipment, GrossProperty, plant and equipment,
 grossConsolidation, Policy [Policy Text Block]Principles of ConsolidationProduct
 Information [Line Items]Product Information [Line Items]Subsequent Event Type
 [Domain]Subsequent Event TypeIncome taxes.Income Taxes [Table]Income Taxes
 [Table]Schedule of Fair Value of Each Stock Option Granted Estimated on The Grant
 Date Using Weighted-average AssumptionsSchedule of Share-Based Payment Award,
 Stock Options, Valuation Assumptions [Table Text Block]Business Combination,
 Contingent Consideration Arrangements, Change in Amount of Contingent
 Consideration, AssetChange in the fair value of contingent considerationIncrease
 (decrease) in fair value of contingent considerationChange in the fair value of
 contingent considerationDefined contribution 401 (k) plan.Plan401 K [Member]401
 (K) PlanConversion reissuance (in shares)Share Based Compensation Arrangement By
 Share Based Payment Award Equity Instruments Other Than Conversion Reissuance
 Grants In PeriodShare based compensation arrangement by share based payment
 award equity instruments other than conversion reissuance grants in
 period.Discontinued OperationsDisposal Groups, Including Discontinued Operations,
 Disclosure [Text Block]Valuation Allowances and Reserves Type [Axis]SEC Schedule,
 12-09, Valuation Allowances and Reserves Type [Axis]Share-based compensation,
 accounting modification chargeShare-based Compensation Arrangement Accounting
 Modification ChargeShare-based compensation arrangement accounting modification
 charge.Effective Income Tax Rate Reconciliation, State and Local Income Taxes,
 AmountU.S. state income taxes, net of U.S. federal benefitSchedule of Provisions for
 Sales and AllowancesContract with Customer, Asset, Allowance for Credit Loss [Table

Text Block/Financial Instruments [Domain]/Financial InstrumentsNew Non-employee DirectorsNew Non-Employee Directors [Member]/New non-employee directors.Assets related to discontinued operationsASSETS RELATED TO DISCONTINUED OPERATIONS-LONG-TERMDisposal Group, Including Discontinued Operation, Assets, NoncurrentDisposal Group, Including Discontinued Operation, Assets, Noncurrent, TotalLong-term assets:Assets, Noncurrent [Abstract]/Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]/Schedule of Revenues by Geographic Location, as Determined by the Location of the Customer, and the Location of its Long-term AssetsSale of Stock [Axis]/Net Cash Provided by (Used in) Investing Activities [Abstract]/CASH FLOWS FROM INVESTING ACTIVITIES:Investments [Domain]/OtherOther Adjustments [Member]/Other adjustments.RIGHT-OF-USE ASSETSRight-of-use assetsDisposal Group Including Discontinued Operation Right Of Use AssetsDisposal group including discontinued operation right of use assets.Payment for the repurchase of ordinary sharesPayments for Repurchase of Common StockAMPYRAAMPYRA [Member]/AMPYRA [Member]/Cash transferred to Mural Oncology plc at separationPayments Made In Business SeparationPayments made in business separation.Allocation AdjustmentReduction in GoodwillReduction in GoodwillGoodwill, Period Increase (Decrease)Goodwill, Period Increase (Decrease), TotalRoyalty revenueRevenue from Contract with Customer, Excluding Assessed TaxTotal revenuesRevenue by region:Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.Income Taxes [Line Items]/Income Taxes [Line Items]/Distribution of income (loss) before provision for income taxesRetirement Plan Name [Axis]/Summary of Discontinued OperationsDisposal Groups, Including Discontinued Operations [Table Text Block]/Income Tax Disclosure [Text Block]/Income TaxesUnrecognized Tax Benefits, Decrease Resulting from Prior Period Tax PositionsReductions based on tax positions related to prior periodsRepresents Janssen, a collaborative partner of the entity.Janssen [Member]/JanssenSchedule of Reconciliation of Statutory Tax Rate to Effective Tax RateSchedule of Effective Income Tax Rate Reconciliation [Table Text Block]/Cybersecurity Risk Management, Strategy, and Governance [Abstract]/Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale, located at third party warehouse and shipping service provider.Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service ProviderFinished goods inventory located at third-party warehouse and shipping service providerTotal assetsAssetsDisposal Group, Including Discontinued Operation, AssetsCardinal Health.Cardinal Health [Member]/Cardinal HealthSelling, General and Administrative ExpenseSelling, general and administrativeTotal selling, general and administrative expenseAdjustments Relating To Prior YearsAdjustments relating to prior years.Adjustments relating to prior yearsStock Repurchased During Period, ValueRepurchase of Alkermes' ordinary sharesRepresents royalty rate upon termination of related agreement.Collaborative Arrangement Royalty Rate Upon Termination Of Related AgreementRoyalty rate upon termination of manufacturing and supply agreement (as a percent)Intangible assetsFinite-Lived Intangible Assets, Net, Ending BalanceFinite-Lived Intangible Assets, Net, Beginning BalanceFinite-Lived Intangible Assets, NetINTANGIBLE ASSETS, NETNet Carrying AmountOther Accrued Liabilities, CurrentAccrued otherEntity Address, Address Line TwoEntity Address, Address Line TwoShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]/Weighted-average assumptionsLiabilities and Equity [Abstract]/LIABILITIES AND SHAREHOLDERS' EQUITYDocument Period End DateDocument Period End DateDebt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year OneWithin 1 yearNet Cash Provided by (Used in) Financing ActivitiesCash flows used in financing activitiesRepresents the 2018 Stock Option and Incentive Plan which provides for issuance of non-qualified and incentive stock options, restricted stock, restricted stock units, cash-based awards and performance shares to employees, officers and directors of, consultants to the company.Stock

Option And Incentive Plan2018 [Member]2018 PlanWeighted Average Exercise PriceShare-Based Compensation Arrangement By Share-Based Payment Award OptionsWeighted Average Exercise Price [Abstract]Weighted Average Exercise PriceAdditional PremisesAdditional Premises [Member]Additional PremisesICFR Auditor Attestation FlagICFR Auditor Attestation FlagEffective Income Tax Rate Reconciliation, Percent, TotalEffective Income Tax Rate Reconciliation, PercentEffective tax rate (as a percent)Net loss and comprehensive loss from discontinued operationsLOSS FROM DISCONTINUED OPERATIONS, NET OF TAXNet loss from discontinued operationsLOSS ON DISCONTINUED OPERATIONS, NET OF TAXContractual AdjustmentsContractual Adjustments [Member]Contractual AdjustmentsAntidilutive Securities Excluded from Computation of Earnings Per Share, AmountAnti-dilutive potential common share equivalent excluded from calculation of net loss per ordinary shareDebt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through FiveAfter 1 year through 5 yearsAPIC, Share-Based Payment Arrangement, Increase for Cost Recognition, TotalAPIC, Share-Based Payment Arrangement, Increase for Cost RecognitionShare-based compensationThe floor for the variable rate base of the debt instrumentDebt Instrument Variable Rate Basis FloorInterest rate, variable interest rate floor (as a percent)Income Tax Expense (Benefit)INCOME TAX PROVISION (BENEFIT)Total tax provision (benefit)INCOME TAX PROVISION (BENEFIT)Debt Securities, Available-for-Sale [Abstract]Available-for-sale securitiesIncome Tax Authority, Name [Axis]Income Tax Authority, NameNoncash or Part Noncash Acquisition, Value of Liabilities Assumed, TotalNoncash or Part Noncash Acquisition, Value of Liabilities AssumedPurchased capital expenditures included in accounts payable and accrued expensesTrading SymbolTrading SymbolAdditionsContract with Customer, Asset, PurchaseEquity, Attributable to ParentBALANCEBALANCETotal shareholders' equitySummary of Investment Holdings [Line Items]BiogenBiogen [Member]BiogenDebt Instrument, Description of Variable Rate BasisVariable interest rate baseLiabilitiesTotal liabilitiesTotal LiabilitiesDisposal Group, Including Discontinued Operation, LiabilitiesShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]Number of SharesAssignmentAssignment [Member]AssignmentAccrued sales discount allowances and reserves tableAccrued Sales Discount Allowances And Reserves [Table]Accrued Sales Discount Allowances And Reserves [Table]Long-Lived Tangible Asset [Axis]Long-Lived Tangible AssetOther internal research and development expensesOther internal research and development expensesOther internal R&D expensesContract with Customer, Asset, after Allowance for Credit Loss [Abstract]Contract Asset [Abstract]Other Liabilities, NoncurrentOTHER LONG-TERM LIABILITIESShare-Based Payment Arrangement [Policy Text Block]Share-Based CompensationRestricted Stock Units (RSUs) [Member]Restricted Stock Unit AwardsThis element represents receipt of Alkermes' stock for the exercise of stock options or to satisfy minimum tax withholding obligations related to stock based awardsReceipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based AwardsValueReceipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awardsRepayment Of Royalty RevenueRepayment Of Royalty RevenueRepayment of royalty revenueOther Noncash ExpenseOther non-cash chargesProperty, Plant and Equipment [Table]Schedule Of Property Plant And Equipment [Table]Cybersecurity Risk Management, Strategy, and Governance [Table]GoodwillGoodwill, Ending BalanceGoodwill, Beginning BalanceGoodwill, TotalGOODWILLNet Carrying AmountContract liabilitiesContract Liabilities [Member]Contract liabilities-short-termUnrecognized share-based compensation expenseShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, TotalShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, AmountSelling, General and Administrative Expenses, Policy [Policy Text Block]Selling, General and Administrative ExpensesCybersecurity Risk Management Expertise of Management Responsible [Text Block]Share Repurchase Program [Axis]Schedule of Share-based Compensation Expense from Continuing and Discontinued OperationsShare-Based Payment Arrangement, Expensed and

Capitalized, Amount [Table Text Block]Scheduled maturities of term loan two thousand and twenty six.Scheduled Maturities Of Term Loan Two Thousand And Twenty SixTotalDisposal Group Classification [Axis]Deferred Income Tax Expense (Benefit), TotalDeferred Income Tax Expense (Benefit)Deferred income taxesGeographical [Axis]GeographicalShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic ValueAggregate intrinsic value of stock options exercisableReturn of investment.Return Of InvestmentsReturn of Fountain Healthcare Partners II, L.P. investmentLeases [Abstract]Tabular disclosure of net income or loss before provision for income taxes by geographical area of the entity.Schedule Of Net Income Loss Before Provision For Taxes By Geographical Area Table [Text Block]Schedule of Income (Loss) Before Provision (Benefit) for Income Taxes by Geographical AreaContract assets policy.Contract Assets Policy Policy [Text Block]Contract AssetsUse of Estimates, Policy [Policy Text Block]Use of EstimatesDefined Contribution Plan, Maximum Annual Contributions Per Employee, PercentMaximum percentage of employer contribution matched of employee'sConcentration Risk, PercentageConcentration risk percentageCash and Cash Equivalents, Policy [Policy Text Block]Cash and Cash EquivalentsMaximum amount per employee, by the terms of the plan, that the employee may contribute to a defined contribution plan.Defined Contribution Plan Annual Contribution By Per Employee AmountPer employee contribution limitArbitration award amount paid.Arbitration Award Amount PaidArbitration award amount paidAristada and Aristada Initio.Aristada And Aristada Initio [Member]ARISTADA and ARISTADA INITIODeferred Tax Liabilities, Leasing ArrangementsRight-of-use assetsRepresents the period after loss carryforwards have been utilized that tax returns remain open to examination.Period After Loss Carryforwards Utilized That Tax Returns Remain Open To ExaminationPeriod after loss carryforwards utilized that tax returns remain open to examinationInternal research and development expensesInternal research and development expenses.Total internal R&D expensesShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, MinimumExpected stock volatility, minimum (as a percent)Scenario [Axis]ScenarioShare-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend RateExpected annual dividend yieldContract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]Schedule of Contract Assets and Contract LiabilitiesSecurity Exchange NameSecurity Exchange NameConversion reissuance (in dollars per share)Share Based Compensation Arrangements By Share Based Payment Award Options Conversion Reissuance In Period Weighted Average Exercise PriceShare based compensation arrangements by share based payment award options conversion reissuance in period weighted average exercise pricePayments Credits Relating To Sales In Prior YearsPayments credits relating to sales in prior years.Payments/credits relating to sales in prior yearsProceeds from Sale, Maturity and Collection of Investments, TotalProceeds from Sale, Maturity and Collection of InvestmentsSales and maturities of investmentsContinuing Operations - BasicIncome (Loss) from Continuing Operations, Per Basic ShareEarnings (loss) per ordinary share from continuing operations - basicRepresents the manufacturing process period.Manufacturing Process PeriodManufacturing Process periodCounterparty Name [Domain]Counterparty NameDeferred Tax Assets, Tax Credit Carryforwards, TotalDeferred Tax Assets, Tax Credit CarryforwardsTax creditsBusiness Acquisition, Acquiree [Domain]Business Acquisition, AcquireeOperating lease right of use asset remeasurement amount.Operating Lease Right Of Use Asset Remeasurement AmountOperating lease right-of-use asset remeasurement amountSchedule of Revenues by Geographic Location, as Determined by the Location of the CustomerRevenue from External Customers by Geographic Areas [Table Text Block]Long-Lived Tangible Asset [Domain]Long-Lived Tangible AssetOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, TaxTax (benefit) provisionTax provision (benefit)Medicaid rebate.Medicaid Rebate [Member]Medicaid RebateAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending BalanceAccumulated Depreciation, Depletion

and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Legal Entity [Axis] Operating Activities [Axis] Fair Value Disclosures [Text Block] Fair Value Increase decrease in right of use asset. Increase Decrease In Right Of Use Asset Right-of-use assets Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant-date fair value of stock options granted (in dollars per share) Subsequent Event [Member] Subsequent Event Maximum [Member] Maximum Investment Holdings [Table] Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Unrecognized Tax Benefits, Income Tax Penalties Expense Notice of Assessment Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt, Total Loss on debt extinguishment Right-of-use asset Operating Lease, Right-of-Use Asset RIGHT-OF-USE ASSETS This element represents receipt of Alkermes' stock for the exercise of stock options or to satisfy minimum tax withholding obligations related to stock based awards. Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Shares Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards (in shares) Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL CASH FLOW DISCLOSURE: Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location Operating lease liabilities Deferred Tax Assets Operating Lease Liabilities Deferred tax assets, operating lease liabilities. Lease agreement lease renewal term. Lease Agreement Lease Renewal Term Lease agreement option to extend renewal term Earnings Per Share, Diluted Diluted Earnings (loss) per ordinary share - diluted Leasehold Improvements [Member] Leasehold Improvements Leasehold improvements Liabilities Total liabilities Assets Held For Sale [Member] Assets held for sale member. Assets Held For Sale Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Assets, Current Current assets: Total current assets Net Cash Provided by (Used in) Investing Activities Cash flows (used in) provided by investing activities Represents the time-vested restricted stock units awarded by the company to its employees as a form of incentive compensation. Time Based Restricted Stock Unit Awards [Member] Time-based RSU Awards Time-Based RSUs Finite-Lived Intangible Assets, Net [Abstract] Finite-lived intangible assets: Payments/credits relating to sales in current year Payments Credits Relating To Sales In Current Year Payments credits relating to sales in current year. Disclosure of accounting policy for the Contingent consideration Contingent Consideration Policy [Text Block] Contingent Consideration Scenario Forecast Forecast [Member] Forecast Unrecognized Tax Benefits Balance at the end of the period Balance at the beginning of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Lessee operating lease term of option to extend Lessee, Operating Lease, Existence of Option to Extend [true false] Entity Filer Category Entity Filer Category Goodwill and Intangible Assets Disclosure [Text Block] Intangible Assets and Goodwill Property, Plant and Equipment [Abstract] Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent Long-term investments, Amortized Cost Award Granted in February 2021 Award Granted in February Two zero Two One [Member] Award granted in February two zero two one. Payments to Acquire Marketable Securities Purchases of investments Operating lease liabilities Operating lease liabilities, discontinued operating activities Operating lease liabilities, discontinued operating activities Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSE), NET: Current Fiscal Year End Date Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Share-Based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Share-based compensation

~~expense~~~~Increase decrease in operating lease liabilities.~~~~Increase Decrease In Operating Lease Liabilities~~~~Operating lease liabilities~~~~Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in specified foreign income tax contingency.~~~~Effective Income Tax Reconciliation Foreign Income Tax Differential~~~~Irish rate differential~~~~Risk and uncertainties.~~~~Risk And Uncertainties Policy [Text Block]~~~~Risk and Uncertainties~~~~Increase (Decrease) in Receivables, Total~~~~Increase (Decrease) in Receivables~~~~Receivables~~~~Award Granted in February 2023 and 2024~~~~Award Granted in February Two zero Two Three And Two Zero Two Four [Member]~~~~Award granted in february 2023 and 2024.~~~~Registrant Name~~~~Entity Registrant Name~~~~Entity Registrant Name~~~~LYBALVI.L Y B A L V I [Member]~~~~LYBALVI~~~~Number of Reportable Segments~~~~Number of reportable segments~~~~Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]~~~~Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]~~~~Earnings Per Share [Text Block]~~~~Earnings (Loss) Per Share~~~~Due date of loan~~~~Debt Instrument, Maturity Date~~~~Entity Emerging Growth Company~~~~Entity Emerging Growth Company~~~~Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract]~~~~Weighted Average Number of Shares Outstanding, Basic, Total~~~~Weighted Average Number of Shares Outstanding, Basic~~~~Basic~~~~Medicare Part D.~~~~Medicare Part D [Member]~~~~Medicare Part D~~~~Represents the know-how patent royalty as a percentage of net sales under the collaborative agreements.~~~~Collaborative Arrangement Know How Royalty Rate~~~~Know-how royalty rate (as a percent)~~~~Additions based on tax positions related to prior periods~~~~Additions based on tax positions related to prior periods~~~~Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions~~~~Schedule of Equity Method Investments [Line Items]~~~~Actual Credits Received Related To Duplicate Billings~~~~Actual credits received related to duplicate billings.~~~~Actual credits received related to duplicate billings~~~~Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]~~~~Fair Value~~~~Percentage Of Reduction In Work force~~~~Percentage Of Reduction In Work force~~~~Percentage of reduction in work force~~~~Represents the amount of incremental capacity available so long as the entity meets certain conditions.~~~~Debt Instrument Incremental Capacity Subject To Satisfaction Of Certain Conditions~~~~Incremental capacity~~~~Tax benefits included in discontinued operations~~~~Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations~~~~Tax benefits included in discontinued operations~~~~Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum~~~~Expected stock volatility, maximum (as a percent)~~~~Common Stock, Shares Authorized~~~~Ordinary shares, shares authorized~~~~Share Repurchase Program [Domain]~~~~Property, Plant and Equipment, Useful Life~~~~Estimated useful life~~~~Royalty [Member]~~~~Royalty~~~~Proceeds from Sale and Maturity of Marketable Securities~~~~Proceeds from the sales and maturities of investments~~~~Concentration Risk Type [Axis]~~~~Concentration Risk Type~~~~Fair Value, Inputs, Level 1 [Member]~~~~Level 1~~~~Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five~~~~After 1 year through 5 years~~~~Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total~~~~Increase (Decrease) in Accounts Payable and Accrued Liabilities~~~~Accounts payable and accrued expenses~~~~Debt Disclosure [Abstract]~~~~Long-Term Debt [Text Block]~~~~Long-term Debt~~~~Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price~~~~Weighted average exercise price (in dollars per share)~~~~Documents Incorporated by Reference [Text Block]~~~~Documents Incorporated by Reference~~~~Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price~~~~Granted (in dollars per share)~~~~Amortization of Intangible Assets~~~~Amortization of acquired intangible assets~~~~Amortization of acquired intangible assets~~~~Financial Instrument [Axis]~~~~Financial Instrument~~~~Earnings (Loss) Per Share~~~~Earnings Per Share, Policy [Policy Text Block]~~~~Represents the ratio of awards other than stock options counted against the total number of shares available for issuance.~~~~Share Based Compensation Arrangement~~

By Share Based Payment Award Equity Instrument Other Than Options Count Against Number Of Shares Available For Grant RatioRatio of awards other than stock options counted against the total number of shares available for issuanceAccounts payable and accrued expenses.Accounts Payable And Accrued Expenses [Line Items]Accounts Payable And Accrued Expenses [Line Items]Represents the aggregate worldwide net sales tied to know-how royalty under the collaborative agreements.Collaborative Arrangement Net Sales Tied To Know How RoyaltyAggregate worldwide net salesShare-based compensation expense from discontinued operationsShare-based compensation expenseShare-based compensation expense discontinued operationsShare-based compensation expense discontinued operationsOther External Research and Development expensesOther external research and Development expenses.Other external R&D expensesShare-Based Payment Arrangement [Abstract]Luxembourg inland revenue two thousand eighteen.Luxembourg Inland Revenue Two Thousand Eighteen [Member]LTA 2018Collaborative Arrangement and Arrangement Other than Collaborative [Table]Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, TotalShares Issued, Value, Share-Based Payment Arrangement, after ForfeitureIssuance of ordinary shares under employee stock plansDepreciation internal research and development expensesDepreciation internal research and development expenses.DepreciationLease agreement commencement period.Lease Agreement Commencement PeriodLease agreement commencement periodFair value of guaranteeGuarantees, Fair Value DisclosureCash and cash equivalentsDisposal Group, Including Discontinued Operation, Cash and Cash EquivalentsCybersecurity Risk Role of Management [Text Block]Number of transition service agreementNumber of Transition Service AgreementNumber of transition service agreement.Treasury Stock, Common, ValueTreasury shares, at cost (14,493,791 and 5,589,218 shares at December 31, 2024 and 2023, respectively)Net assets transferred to MuralDisposal Group Including Discontinued Operation Assets and Liabilities NetDisposal group including discontinued operation assets and liabilities net.Debt Securities, Available-for-SaleTotalDebt securitiesAccounting Policies [Abstract]Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]Expected amortization of intangible assetsIncome tax reconciliation nondeductible lobbying expenses.Income Tax Reconciliation Nondeductible Lobbying ExpensesNon-deductible lobbying expensesShare-Based Payment Arrangement, Option, Activity [Table Text Block]Schedule of Stock Option ActivityAdditional royalty revenue potentially to be repaid to Acorda.Potential Additional Award To Be PaidPotential additional award to be paidLessee operating lease liability payments due after year four.Lessee Operating Lease Liability Payments Due After Year FourThereafterIncome Tax Disclosure [Abstract]Transaction costs related to the SeparationTransaction costs related to the SeparationUnrecognized Tax Benefits, Increase Resulting from Current Period Tax PositionsAdditions based on tax positions related to the current periodInventory, Raw Materials, Net of ReservesRaw materialsEquity, Attributable to Parent [Abstract]SHAREHOLDERS' EQUITY:Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]Non-cash investing and financing activities:Former Term Loans [Member]Former Term Loans.Former Term Loans, due March 12, 2026Former Term LoansDisposal Group Name [Domain]Statement [Table]Statement [Table]Segment Reporting, Policy [Policy Text Block]Segment InformationProperty, Plant and Equipment [Table Text Block]Schedule of Property, Plant and EquipmentAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to intercompany amounts.Effective Income Tax Reconciliation Change In Deferred Tax Assets Intercompany AmountsIntercompany amountsIncrease (Decrease) in Prepaid Expenses, OtherPrepaid expenses and other assetsShare-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service PeriodNumber of years from the date of the grantShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual TermWeighted average

contractual remaining lifeRepresents the range of net sales under the collaborative arrangement to determine the know-how royalty percentage.Net Sales Between 250 And 500 Million [Member]Net sales between \$250.0 million and 500.0 millionSeparation AgreementSeparation Agreement [Member]Separation agreement .Non-Rule 10b5-1 Arrangement Modified [Flag].Non-Rule 10b5-1 Arr Modified [Flag]Non-Rule 10b5-1 Arrangement ModifiedPreferred Stock, Shares AuthorizedPreferred stock shares, authorizedOther products and services.Other Products And Services [Member]OtherDisposal Group Classification [Domain]Entity File NumberEntity File NumberSegment ReportingSegment Reporting Disclosure [Text Block]Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectNET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTSRevenue from Contract with Customer [Abstract]EARNINGS (LOSS) PER ORDINARY SHARE:Earnings Per Share [Abstract]Contract with Customer, Asset, after Allowance for Credit Loss, Current, TotalContract with Customer, Asset, after Allowance for Credit Loss, CurrentContract assetsContract assets, currentDeferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation CostShare-based compensationMarketable Securities Realized LossRealized lossesRepresents the loss realized on the sale of debt or equity securities categorized as held-to-maturity, trading securities and available-for-sale.State Medicaid RebatesState Medicaid Rebates [Member]State Medicaid rebates.Inventory Disclosure [Abstract]Statement of Financial Position [Abstract]PROPERTY, PLANT AND EQUIPMENT, NETProperty, plant and equipment, netDisposal Group, Including Discontinued Operation, Property, Plant and Equipment, NoncurrentAward Granted in February 2022 and 2023Award Granted in February Two zero Two Two And Two Zero Two Three [Member]Award granted in February two zero two two And two zero two three.CURRENT LIABILITIES:Current Liabilities:Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]Operating Income (Loss)OPERATING INCOME FROM CONTINUING OPERATIONS2024Long-Term Debt, Maturity, Year OneThe minimum percentage of revenues or receivables from a single customer that is used as a threshold for disclosure of a concentration of risk.Threshold For Disclosure PercentageThreshold percentage for disclosure of revenue and receivablesEntity Shell CompanyEntity Shell CompanyAmounts recognized into other (expense) income, netContract with customer liability other (expense) income net recognized.Contract With Customer Liability Other (Expense) Income Net RecognizedDiscontinued OperationsDiscontinued Operations, Policy [Policy Text Block]Employee-relatedEmployee-Related Internal Research and Development ExpensesEmployee-related internal research and development expenses.Entity Tax Identification NumberEntity Tax Identification NumberAssets [Abstract]ASSETSConstruction in Progress, GrossConstruction in progressFair Value of Financial Instruments, Policy [Policy Text Block]Fair Value of Financial InstrumentsEntity Current Reporting StatusEntity Current Reporting StatusAssets Held for SaleAssets Held for Sale [Policy Text Block]Assets held for sale.Represents the number of equity-based compensation plans under which awards are currently made.Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans Under Which Awards Are Currently MadeNumber of share-based compensation plan under which awards are currently madeSchedule of Accounts Payable and Accrued Liabilities [Table Text Block]Schedule of Accounts Payable and Accrued ExpensesProperty, Plant and Equipment Disclosure [Text Block]Property, Plant and EquipmentLong-Term Debt, TypeLong-Term Debt, Type [Axis]852 Winter Street LeaseWinter Street Lease Two [Member]852 winter street lease two.Inventory Disclosure [Text Block]InventoryRevenue from Contract with Customer [Policy Text Block]Revenue from Contracts with CustomersIncrease (Decrease) in Contract with Customer, LiabilityContract liabilitiesGeographical [Domain]GeographicalDocument Fiscal Year FocusDocument Fiscal Year FocusProceeds from sale of development and manufacturing facilityProceeds from Sale, Property, Held-for-SaleCertificates of Deposit [Member]Certificates of depositPreferred Stock, Value, IssuedPreferred shares, par value, \$0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at December 31, 2024 and 2023, respectivelyAccounts payable and

accrued expensesDisposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, CurrentDisposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current, TotalRepayments of Long-Term Debt, TotalRepayments of Long-Term DebtPrincipal payments of long-term debtFinite-Lived Intangible Assets, Accumulated AmortizationAccumulated AmortizationCost of ordinary share acquired during share repurchase programTreasury Stock, Value, Acquired, Cost MethodRepurchase of Alkermes' ordinary sharesSchedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax BenefitsLong-Term Investments, TotalLong-Term InvestmentsINVESTMENTS—LONG-TERMInvestments-long-termForeign derived intangible incomeEffective Income Tax Rate Reconciliation, FDH, AmountDebt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through FiveAfter 1 year through 5 yearsBusiness Acquisition [Axis]Business AcquisitionLong-Lived Asset, Held-for-Sale, Type [Axis]City Area CodeCity Area CodeReclassification, Comparability Adjustment [Policy Text Block]ReclassificationJanssen Pharmaceutica N.V.Janssen Pharmaceutica N.V. [Member]Janssen Pharmaceutica N.V.Liabilities, CurrentTotal current liabilitiesImpairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]Impairment of Long-Lived AssetsThe limit of annual employee contributions to the plan, as a percentage of their total taxable earnings.Defined Contribution Plan Maximum Employee Contribution Limit As Percentage Of Taxable EarningsMaximum employee contribution limit as a percentage of their total taxable earningsGuaranty dateGuaranty DateGuaranty DateEstimated Fair ValueDebt Securities, Available-for-Sale and Held-to-Maturity, Fair ValueInventory, NetInventoryTotal inventoryGOODWILLGoodwillDisposal Group, Including Discontinued Operation, Goodwill, NoncurrentAssets Held for SaleDiscontinued Operations, Held-for-Sale [Member]Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized GainGross Unrealized GainsEffective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, PercentStatutory tax rate (as a percent)Goodwill and Intangible Assets, Policy [Policy Text Block]Goodwill and Intangible AssetsOrganization, Consolidation and Presentation of Financial Statements [Abstract]Local Phone NumberLocal Phone NumberPreferred Stock, Shares Outstanding, Ending BalancePreferred Stock, Shares Outstanding, Beginning BalancePreferred Stock, Shares OutstandingPreferred stock shares, outstandingAntidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]DenominatorRetirement Plan Sponsor Location [Axis]Retirement Plan Sponsor LocationGross Unrealized Losses less than one yearDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated LossTreasury Stock, Value, Acquired, Cost Method Excluding commissionTreasury Stock, Value, Acquired, Cost Method Excluding commission.Shares repurchased valueIncome Tax Jurisdiction [Axis]Income Tax AuthorityIncome Tax, Policy [Policy Text Block]Income TaxesCommitments and Contingencies Disclosure [Abstract]Purchase Commitment, Excluding Long-Term Commitment [Axis]Purchase Commitment, Excluding Long-Term CommitmentShares Acquired, Average Cost Per ShareShares repurchased price per shareDeferred Tax Asset, Valuation Allowance [Table]Debt Securities, Available-for-Sale, Amortized CostTotalSchedule of Deferred Tax Assets and Liabilities [Table Text Block]Schedule of Components of Net Deferred Tax AssetsSchedule of accrued sales discounts allowances and reserves.Schedule Of Accrued Sales Discounts Allowances And Reserves Table [Text Block]Summary of Current Provision for Sales, Discounts, Allowances and ReservesOperating Lease, Liability, CurrentOperating lease liabilities—short-termTotal accrued sales discounts, allowances and reservesCarrying value as of the balance sheet date of obligations relating to sales discounts, allowances and reserves.Accrued Sales Discounts Allowances And ReservesAccrued sales discounts, allowances and reservesIncome Tax Jurisdiction [Domain]Income Tax AuthorityDiscontinuing Operations - BasicDiscontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic ShareLoss per ordinary share from discontinued operations - basicRetained Earnings [Member]Accumulated DeficitSelling, General and Administrative Expense

[Abstract]Selling, general and administrative expenses:Percentage of net sales in royalty payment.Percentage Of Net Sales In Royalty PaymentPercentage of net sales in royalty paymentPayments to Acquire Property, Plant, and Equipment, TotalPayments to Acquire Property, Plant, and EquipmentAdditions of property, plant and equipmentCommitments and contingencies.Commitments And Contingencies [Table]Commitments And Contingencies [Table]Document Transition ReportDocument Transition ReportAdditions of property, plant and equipmentAdditions of property, plant and equipment, discontinued operationsAdditions of property, plant and equipment, discontinued operationsOperating lease liability remeasurement amount.Operating Lease Liability Remeasurement AmountOperating lease liability remeasurement amountRule10b5-1 Trading plan.Rule10 B51 Trading Plan [Member]Stock Repurchase Program Authorized Dollar AmountShare repurchase aggregate amountLessee, Operating Lease, Liability, to be Paid, Year Two2026Valuation Allowances and Reserves Type [Domain]SEC Schedule, 12-09; Valuation Allowances and Reserves [Domain]OPERATING ACTIVITIES:Operating Activities [Abstract]Operating Activities.Antidilutive Security, Excluded EPS Calculation [Table]Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]Tabular disclosure of the proceeds from sales and maturities of marketable securities, plus the resulting realized gains and losses.Proceeds And Realized Gain Loss On Marketable Securities Table [Text Block]Schedule of Proceeds from Sales and Maturities of Marketable Securities Plus Resulting Realized Gains and LossesRelating to research and development.Research And Development [Member]Research and development revenueShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise PriceExercised (in dollars per share)Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued LiabilitiesAccrued expenses and reserves900 Winter Street Lease.Winter Street Lease [Member]900 Winter Street LeaseConcentration Risk, Credit Risk, Policy [Policy Text Block]ConcentrationsDeferred Income Tax Assets, NetDEFERRED TAX ASSETSAuditor Firm IDAuditor Firm IDMinimum [Member]MinimumCommon Stock [Member]Ordinary SharesShare-based compensation ExpenseShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]2025Long-Term Debt, Maturity, Year TwoCommitments and contingencies.Commitments And Contingencies [Line Items]Commitments And Contingencies [Line Items]Accounts Payable and Accrued Liabilities Disclosure [Text Block]Accounts Payable and Accrued ExpensesShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic ValueAggregate intrinsic valueShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair ValueUnvested at the end of the period (in dollars per share)Unvested at the beginning of the period (in dollars per share)Valuation Allowance [Line Items]Additional Paid-in Capital [Member]Additional Paid-In CapitalEntity Well-known Seasoned IssuerEntity Well-known Seasoned IssuerProduct ReturnsProduct Returns [Member]Product returns.Debt Securities, Available-for-Sale, CurrentInvestments—short-termShort-term investments, Estimated Fair ValueForeign Currency Transactions and Translations Policy [Policy Text Block]Foreign CurrencyStock distribution ratio by means of separation of businessStock distribution ratio by means of separation of business.Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Adjustments to reconcile net income (loss) to cash flows from operating activities:Short-Term Investments [Member]Short-term investmentsStatement of Income Location, Balance [Domain]Income Statement LocationLessee, Operating Lease, Liability, to be Paid, Year One2025OtherOther Assets, NoncurrentOTHER ASSETSIncrease (Decrease) in Other Operating Liabilities, TotalIncrease (Decrease) in Other Operating LiabilitiesOther long-term liabilitiesPerformance Shares [Member]Performance-based stock optionsRepresents the notice period required to be served before the termination of the agreement.Collaborative Arrangement Effective Notice Period Required To Be Served For Termination Of AgreementNotice period required to be given before

termination of agreementSchedule of Inventory, Current [Table Text Block]Schedule of InventoriesCorporate Minimum Tax RateCorporate minimum tax rate,Corporate minimum tax rateShare Repurchase Program, Remaining Authorized, AmountShare repurchase program remaining authorized amountOther current assetsOther Assets, CurrentGoodwill and Intangible Assets Disclosure [Abstract]Entity Common Stock, Shares OutstandingEntity Common Stock, Shares OutstandingDisaggregation of Revenue [Line Items]Disaggregation Of Revenue [Line Items]Continuing Operations - DilutedIncome (Loss) from Continuing Operations, Per Diluted ShareEarnings (loss) per ordinary share from continuing operations - dilutedEstimated useful lifeProperty, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]Schedule of Revenues from External Customers and Long-Lived Assets [Table]Schedule Of Revenues From External Customers And Long Lived Assets [Table]2024Finite-Lived Intangible Asset, Expected Amortization, Year OneIncrease in operating lease right of use asset.Increase In Operating Lease Right Of Use AssetIncrease in operating lease right of use assetScenario [Domain]ScenarioRepresents the number of license agreements.Number Of License AgreementsNumber of license agreementsTitle and Position [Domain]Title of IndividualCommon Stock, Value, IssuedOrdinary shares, par value, \$0.01 per share; 450,000,000 shares authorized; 176,670,785 and 172,569,051 shares issued; and 162,176,994 and 166,979,833 shares outstanding at December 31, 2024 and 2023, respectivelyCollaborative Arrangement and Arrangement Other than Collaborative [Line Items]Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]Investment Income, InterestInterest incomeCash and Cash Equivalents, Fair Value DisclosureCash equivalentsOperating lease liabilities-short-termDisposal Group Including Discontinued Operation Operating Lease Liabilities CurrentDisposal group including discontinued operation operating lease liabilities current.Fair Value, Assets Measured on Recurring Basis [Table Text Block]Summary of the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis2026Long-Term Debt, Maturity, Year ThreeLease liabilityOperating Lease, Liability, TotalOperating Lease, LiabilityTotal operating lease liabilitiesMeasurement Frequency [Axis]Measurement FrequencyForeign Plan [Member]Defined Contribution PlanNet operating loss carryforwardsDeferred Tax Assets, Operating Loss Carryforwards, TotalDeferred Tax Assets, Operating Loss CarryforwardsCOMMITMENTS AND CONTINGENT LIABILITIES (Note 19)Commitments and ContingenciesTax benefit related to intercompany transfer of inventoryIncome Tax Expense Benefit Related to Intercompany Transfer of InventoryIncome tax expense benefit related to intercompany transfer of inventory.Incremental share-based compensation expense due to achievement of performance criteriaShare-Based Payment Arrangement, Plan Modification, Incremental CostDebt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, NoncurrentAmortized CostAmortized CostIncome Taxes PaidCash paid for taxesL Y B A L V I External Research And Development Expenses Development ProgramsLYBALVI external research and development expenses development programs.LYBALVIDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated LossGross Unrealized Losses greater than one yearShares used in calculating diluted earnings (loss) per ordinary shareWeighted Average Number of Shares Outstanding, DilutedDilutedShares used in calculating diluted earnings (loss) per ordinary shareSignificant Accounting Policies [Text Block]Summary of Significant Accounting PoliciesSchedule of Segment Reporting Information, by Segment [Table Text Block]Summary of Significant Segment ExpensesShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, NumberStock options expected to vest (in shares)Lessee, Operating Lease, Liability, to be PaidTotal operating lease paymentsIncrease (Decrease) in Inventories, TotalIncrease (Decrease) in InventoriesInventoryCybersecurity Risk Management Third Party Engaged [Flag]Denominator:Weighted Average Number of Shares Outstanding, Diluted [Abstract]WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:Tabular disclosure of the estimated useful life of long-lived, physical

assets that are used in the normal conduct of business to produce goods and services and not intended for resale.Property Plant And Equipment Estimated Useful Lives Table [Text Block]Schedule of Estimated Useful Life of Property, Plant and EquipmentA L K S Two Six Eight Zero External Research and Development Expenses Development ProgramsALKS 2680 external research and development expense development programs.ALKS 2680Concentration Risk Benchmark [Domain]Concentration Risk BenchmarkEntity Small BusinessEntity Small BusinessSegment Reporting Information [Line Items]Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]Debt Instrument, Basis Spread on Variable RateInterest rate added to base rate (as a percent)Amount of increase in contract with customer liability during the period.Contract With Customer Liability AdditionsAdditionsRevenuesRevenues, TotalGain (Loss), Foreign Currency Transaction, before Tax, TotalGain (Loss), Foreign Currency Transaction, before TaxGain (loss) on foreign currency translationIncrease (Decrease) in Contract with Customer, AssetContract assetsLiabilities related to discontinued operationsTotal current liabilitiesDisposal Group, Including Discontinued Operation, Liabilities, CurrentTreasury Stock, Shares, AcquiredShares repurchasedRepurchase of Alkermes' ordinary shares (in shares)Represents designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile, excluding the specified country.Foreign Country Excluding Specified Country [Member]Rest of worldProceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, TotalProceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option ExercisedProceeds from the issuance of ordinary shares under share-based compensation arrangementsRevenues from External Customers and Long-Lived Assets [Line Items]Geographic InformationShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise PriceExpired (in dollars per share)Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through FiveAfter 1 year through 5 yearsNet Cash Provided by (Used in) Financing Activities [Abstract]CASH FLOWS FROM FINANCING ACTIVITIESShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise PriceOutstanding at the end of the period (in dollars per share)Outstanding at the beginning of the period (in dollars per share)Debt Security, Government, Non-US [Member]Non-U.S. government debt securitiesStock distribution by separation of businessStock distribution by separation of business.Goodwill, GrossGross Carrying AmountDebt Securities, Available-for-Sale, Unrealized Loss Position, Number of PositionsNumber of investment securities in an unrealized loss positionAsset Class [Axis]Asset ClassDEFERRED TAX ASSETDeferred tax assetDisposal Group, Including Discontinued Operation, Deferred Tax AssetsState and Local Jurisdiction [Member]U.S. stateMeasurement Frequency [Domain]Measurement FrequencyNature of Operation, Product Information, Concentration of Risk [Table]Schedule Of Product Information [Table]Credit Concentration Risk [Member]Credit Concentration RiskDeferred Tax Assets, Valuation AllowanceValuation allowanceLess: valuation allowanceBalance at End of PeriodBalance at Beginning of PeriodRepresents the number of equity-based compensation plans under which no further awards will be made.Share Based Compensation Arrangement By Share-Based Payment AwardNumber Of Plans Under Which No Further Awards Will Be MadeNumber of share-based compensation plan under which no further awards will be madeNet income (loss) from continuing operationsIncome (Loss) from Continuing Operations, Net of Tax, Attributable to ParentNet income from continuing operationsNET INCOME (LOSS) FROM CONTINUING OPERATIONSFair Value, Inputs, Level 3 [Member]Level 3Operating Lease, Weighted Average Remaining Lease TermWeighted average remaining lease termCencoraCencora Incorporation [Member]Cencora Incorporation.Effective Income Tax Rate Reconciliation, Change in Deferred Tax AssetsValuation Allowance, AmountChange in valuation allowanceCybersecurity Risk Management Positions or Committees Responsible [Flag]Accounts Payable, Current, TotalAccounts Payable, CurrentAccounts payableShare-Based Compensation Arrangement by Share-Based

~~Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]Weighted Average Grant Date Fair ValueDisposal Group, Including Discontinued Operation, Operating Income (Loss), TotalOperating loss from discontinued operationsDisposal Group, Including Discontinued Operation, Operating Income (Loss)Costs and ExpensesTotal expensesRepresents furniture, fixtures and equipment of the entity.Furniture Fixture And Equipment [Member]Furniture, Fixtures and EquipmentFurniture, fixtures and equipmentAccounts Payable and Accrued Liabilities, CurrentAccounts payable and accrued expensesTotal accounts payable and accrued expenses XML 16 R1.htm IDEA: XBRL DOCUMENT~~

Document and Entity Information - USD (\$)		12 Months Ended		Feb. 07, 2025	Jun. 30, 2024
Cover [Abstract]		Dec. 31, 2024			
Entity Registrant Name	Alkermes plc.				
Entity Central Index Key	0001520262				
Document Type	10-K				
Document Period End Date	Dec. 31, 2024				
Amendment Flag	false				
Current Fiscal Year End Date	--12-31				
Entity Small Business	false				
Entity Emerging Growth Company	false				
ICFR Auditor Attestation Flag	true				
Document Financial Statement Error Correction	false				
Entity Shell Company	false				
Entity Current Reporting Status	Yes				
Entity Interactive Data Current	Yes				
Entity Filer Category	Large Accelerated Filer				
Entity Public Float					\$ 3,943,314,276
Entity Common Stock, Shares Outstanding				162,614,067	
Document Fiscal Year Focus	2024				
Document Fiscal Period Focus	FY				
Trading Symbol	ALKS				
Entity Well-known Seasoned Issuer	Yes				
Entity Voluntary Filers	No				
Entity File Number	001-35299				
Entity Incorporation, State or Country Code	L2				
Entity Tax Identification Number	98-1007018				
Entity Address, Address Line One	Connaught House				
Entity Address, Address Line Two	1 Burlington Road				
Entity Address, City or Town	Dublin 4				
Entity Address, Country	IE				
Entity Address, Postal Zip Code	D04 C5Y6				
City Area Code	353				
Local Phone Number	1-772-8000				
Document Annual Report	true				
Document Transition Report	false				
Title of 12(b) Security	Ordinary shares, \$0.01 par value				
Security Exchange Name	NASDAQ				
Auditor Firm ID	238				
Auditor Name	PricewaterhouseCoopers LLP				
Auditor Location	Boston, Massachusetts				
Auditor Opinion	Opinions on the Financial Statements and Internal Control over Financial Reporting				
We have audited the accompanying consolidated balance sheets of Alkermes plc and its subsidiaries (the "Company") as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive income (loss), of shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).					
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.					
Documents Incorporated by Reference	Portions of the definitive proxy statement for our 2025 Annual General Meeting of Shareholders are incorporated by reference into Part III of this report.				

?^"V7_!=/IF#Q?;^ OV@/\$UWX3UFZL5O+?3=9\+PPRO S M,@D"E>A9&&?
537IO_!SHK3O" I 'A_ JK'IHOQ3%9P6W@"WUSQ1JLRB-?I2' M8A?5CA0H&22
DBOY^OVFZ+INF+?:C+%N/^D3O@K&P4J=JC"G/S-Q6;JA P5;."IG_!,IQUI
MEW^V'X6U35=!FU!GDL?%FCJD%_&5"O%!=1J-IQT(SANH/2OLC_@TY^!G@;1?

MV'M?^/\$&B0GQ#KWC:[T^>_DA'F);6\<6U\$?K@F4Y'3(KZ^_X+%_LJZ9^T?)
M!\$V_BMX\$F\+?VOJ-KX3NM2\VZ*-ZZA;(9863WW+@^H)'>@JR.H_X)W_+=_MPK_X*
(?LW:3^T%\,HYK,W&;?6-'N6!FTZ\3B2%L=0#R&'52#ZBOR=_X/%\A_MDIWP)\A_U
J>_P#1UE4'_!G_./==3XG?%[X7K*QTV32-/U'89#A9A)+'D+T_MR5QD]>*_G_X/\$_\
DIOP)_!60?^C!*(@{GZ!?:L_R;?V'OA/Q_S(E_^DZ5^_M;7_!8;_@X;^*/P9^6J?L;?
L)^';>\1:7<1VNM>*I+_ %[XTBWU+5H='U7Q''=7>_
HU*29%KC|H;Q7HWC*WT=\$DFNK;:P|'T=K\$J'='*\
3UO+^QDCDC*21/.A5U(.5.3R.:_FIUCP#I|&W_M_%?'_P+
|>W729_CEI\$.GVT\$G|N''UU2YC@D08_NI@J_M1\6_ \%D_ ^#A_XA?LX?
&O4OV//V)O#VGWGB;2;A;:/Q!XIOH_M2PW+Q'L'M;>%2_M/WL;LGSM D!D*
|&!R/F3Q3^T?_P'_5AX;7|H;6-%\<6FCVZK+)#X;B\$?E!0
MPD:'9NVD'KWK|+^#G_!N7:_'O|O+3OVW?'O|2%OX@BL_&4^OWVCZH6Y;DR.MY".
|D@D%P:Y_J^8WW5^!MU./QQ0'R/RU_X(A_ \!7Q+_:/^,MK^Q|^VW|A'B'6)Y(?")?
BB&W%N9|G<6^Q_M7\$?3>?NQL_9P%(SR?L#_ _(+J?M8?
&K|B_P#8#U3XY_L_^(H|)\16OB33K.*\MEMEE7RI9&#C:P(Y%?B\A*_\A!?\$?
_!QEIT_P;UFSC\7W|1CRZ!?:.5>W-N_M|^|(\6/E*D'(|8K|<_ _@Z!CV_ \!*_+7,|?^\$RT?
G_MJU_*@D\8_X-R_V|VE_V_/_@_M\1/&?|2_C*!6=0T'Q=;V6FS0V,<(CA:U60KA_,Y;U|5|>?
%\%("EE-)'|Y_M\$ET72T)'OAC05;WK'H?Q^_X.!O_|H^U)K&IWO|_
'AJ^ \+>\$6N&338_#OAU_MKBY2,/N7S9\.&DP_#M_&./>OU@_:_6_X*B:1_P3X_X)D?#?|
:+^--G)KGCSO_M% X%T46>@W4H@GU+59;*"299&_RSDY))YYK\+?
^#M|XQ'Q)^U_X&^"-I>W@C_-M^#OM|U;L?W)DNY6VNO\ M;8V!|J_M|QC^!_ ^"F7_
4Q\$'G2ALDA2<\$Y+8Z9_KL/V9?^#B3|O?|CKX\ V_P3
M_P'''F'@"ZOM'_M"&'7+B^TAK35M)BX5IE10!J_C#%;,C\ V"3A:_9/_@GO^SC
M\OV6OV.?/P=^&5AY.GZ?X>MYI9V0+)=W\$J!Y9Y,=7=B3D|!@=_*_ _S_@|H
M_9_ \-7_P#^'G|2MGX:B_M?3/\$K:%>:LA=|>:!Y8HF_O#=%(0>W(|T!H?I5\ M?
O&7Q&^)_P"QKX@^ (?|7B6&3Q)K'@TZGX\$U_-95ED;2Q%5;ABZ<'N17Y_M_- \!&/_
(+T?M2_\$|H>+|E|H|O#Q|HNF^*(Y=+T>:ZTU;62QUM'_=0|EP_M)
<21%6!RYCP0((G|QD4C|GF*!,H|D28^|0)?\$?L_P6!:_;Q7_@GQ^Q)XE^,>AS0MXH
MOHQI?A&WDD4'|=",%GVC|PB7=
(1@Y*J#P,8M1^'|G#_9/ATK|L4'VC4E>.21U*@,52/Y3QC,F,Y%?F/^VQ^W#|9_ ^"|_M
_U%)(?@'X")2:>(X;33+>TW,X%|*%^V7K^D;:6;UV+SS7|7|'I|+ _(' _M8S_9L\(_LU?
#>)FTWPMI;6WVB3&^|G)+SW#?|3RL|^V|':@.A^6O|=O_5D_M_:;^#'_!;|P_ ^QOX" ^)-
O: ^_HQSX5TZZTMM-B9FM|R;V6=-Y!;YA(W.> \5_M^SBQ|3G-?SI? \ %0P?^ (F+PF?
^JG>!O\ TH|J_HOV_P \T#| \WO_ ;5_P#* M8^ ^ _|/B#^=?
T@HVOYOO^#:_O_E,???)@'Q!_.OZ04^|0\$MQ:"C!HHH)&|! MBG_8&***
"HV!^ ^!^%24T_-S0\7_P#|9#_@F3X<_P'''@_P!>Z\6"P_ '\$'PK_M#
<7/A&^5@GFLP3?:RYX*2"-1D_=8_|,@_P_VOCSP)XM^&/C+40A_XYT*XTW6_M-
(O'MM0L+I'LD,JG!4BO|9(=P+XZ_X5^?7_50_P'''&'P_ ;S\967Q> ^&V_MN6WA/Q=)
<)'KU|Y.Z*_MA??91_RU7_P>XZU|66YE|7ER3V/U;P^X\61?| %C6_M_8O9|8O_ "/P%^"?
QJ^*W|WQ)T_XF_! ?Q;>: +K|C(/LMU8MRW8J5Z.HJ00_M?2OWZ_8HUZP_X+.?
L=W&B_MS_LLW&GR6*Q16NO7=J88|2D\$;H;NTD(#1LK>8_M"O(&X=0370?L;?|
!!7|BS|EM|)\4:|X:/C+Q-8P|TNJ:T-T/V@9)=(?NXR>
M,YZ#O7VYI6AZ9H=A'I>D6,=M;PILAMX(PJ1J_.!T%5C\RHU)7I+;9D\;<;9
M7G%;, \3<9Q=U4V?RMK|Y_.Y_P_ %*?|_ @^I^T%^Q_J%U\1/@?:WGCCP#N,@G
MMH=U|H|N\$FC7E@!C|XHP>X|!.*^
YX;RSG>VN8FCDC; \+|!"T!?!OBR|A4)JVBQJD3R+T:2\$* < MCY21@D_=3UWP>=?9K?
>>YPMXL5*,8T,U5U_ _M_FC^;4_N,EL^_K7>?LW?LU?_M%S|K/XLZ7&O@OX:EU+5M1F
9E4^7;1_Q2R-_"BCDGTKZW^*7_!N|^WIX(^_
M6G_ ##PCH=CKNCZM=F.U\40S;,>W0<|H|Q|Y,#\STK|D_ ^"9'_ 3!^\$?_ 3R_M^ \$T>AZ-
:PZEXLU"- \1>(I(QOGD|I'GE(QG_7OU=-N*S2A1|7IN|/L>)?\$K*
M<#EJG@|H|4FM\$NGFR3_@F+_P3+^\$?_!.|X/Q^'_#EG#J7BS4H4?Q/XFDA_EN
MYN3M3^Y&I8A5'4OX%_ "S_ (*E_P#!?SXU>)-=N/BM?RZ/8S++K5|?:B|OI&EY
M(AFWCA4|2V!E5_+\$(S\$GDU^P?_!RKI6|O\ \ \$F?&BZ78RW'V;6M,GG\M"WE_MQ+<
LQOT4=SVKY2_X-(?VD_@SH_Pf^(7|,FO^ (=+TWQA<^+H|9T^VNKA8YM5
MM7MXH"D8;&_RI(_NCD&<<|5?^#/C'_ "\?C\$<_ \RK8_C_I_M)%???'_!=_@I-
 \ \$/V1_V.O&7PIN_\$EG|C3Q|X;OM_T?0;699)(EN(##-/,%_M/[M520XS@EL5^=W_
:#^,+.Q_:F^*7@66WD:XU#P+% =QR\;56"|C5@?H#?
ML_#/_1+U_P#3E=U^WG|\$4:I^Q|H(W^ ^|, _+?|_ @O@K_M|0_ ^#O)@?VV/AB?^J7C_

-.5W7I[??L2"/I&'PCQ_T2_0!_Y3H*_D?._?_<3 MD \ #H?XJ \ 7/2_3E;5\4_ \&>^?I\$^_
-Z>M-!|DKI6_X.*&'_#HCXJ?|_M<|+_/_3E;5\4? \&?##^Q?C1_U|.;_P"@R4!|DYK_
(/&54_\$;X#D_P#0%0?_M^C;&OV\$_8@8?,??#/'_\$(^F \ I.E?CW_P>-9;XB_
<#_H"^(/_1MA7V__M,\$\$O^"CGPO_!:_8O\+_VO_%VGVWC|P+I<6D:_H82!^%E?8W_
;??L\2_L_?A\$J/!E|>V5Q;Z\0_M-200%FJ0SN"%^T.L%LR>BM9VMJ^#W9J^R?
F;)SC_@ZY;Y?^:P:I_Z;|BOU_M>_X+_P#_"B9^+7_
&"H/_2B.OR@^\$|8_P"#KEA_U6#5!_Y3KBOU?_X+_< \ M\$FOBT,?PJ#_-(Z^T?-/_: (L/A
A@?X@X'3XP7/_IKTZOU:N'CCC:65_MU557+_W;WK^>|_@UD_X*#_#S|G/XL^,OV5/C-
XSCT?2_B%/9WOA:ZOI@EM#J_MD*RI)&6/'M/&T*|B0"T"KU:OUU_X*L?
MI_"C|D_|B#Q_XO_\$7CS38=8U'PG_M=VGA?3EOE%Q?75S\$88C\$H.Y@#('W#HJD|J
^T?B9_P_&MK+_/_3H6S_,RA_MJW_HNH/^#B3G_@MUJF?
^>/AG_P!)+>O1O^#2KX":YXO_&P?&7|0DMO(ND^#_M_"K6:W&
|A|N|?;L>._|M96SVV^|>_P#!_#|OC_@H3X&TW|H_X \ Q|NO_M#-
GK;1S6;>);JYNM0NK00GS57)V@KRNX@/'IS7&_ \ %J/^"(O@A_X):_!|PC_M\4_"?QZUGO=
<=>*/%\$FES6^J;/'B)5@>7S_RR,6)*XP>QK|Z/V&?VBO@Q\4_MV_-?
COP=\1='GTVU\&:9%?2_P!H1#|'(L\$<)67+?N\2*R_-C)X%?C!_P<^_
M\%)/A5^U'XZ*_LM?!#Q'9;|H/@>|DU+7-:L6WQ-?R0|5AC?HZK&YW\$?Q"4_M&@<3|5?
^"!S_?A\$F/(@V^H'-_P"E,M?/'!U9^W|+V/OA5H_|"WP\0M#JGB
MQEU+QV^0;B.I\$8|37T|_P_\$<_BQX)^!O_!\$KX=_%SXC:_:Z_M7HOA_P_(W5YJ%|>3!
(XXTGE/)IS@?4U^/7|DFGW/_!9S_@L?D_8L_9&3X_MT_\$R0>.OBI:VVIW4?&|3=,*;
|2VSC*NROYL@SP652,I7G/_=U%?_AA7X_M>\?-_P+_2B_|-|W7Z:V7Q8^"EC:1V-
G\3O#\$4,*!(HX|#+>/5O\A"/\$^GZ|HHL9?,'V,LUM-*FW(8*+@,QZ_M!%8|J^T=G_P;C>
(?!FN?A\$EOAW;>%)K5IM.NM1M-:%O&_401=R.1)ZOY;P_M@5KZ^:_
EAM_@9XRFGD6-5\+W^YV;&T?9WYSVK_E_P#@U);3^\$NG?L|>)_V
M1/&'BJQTO7M+\22ZUI=L,L(O:A41@K,0&96B7Y1SSFOK/_(+S?MG_N_M9V_X)X?
\$CP9J/CFQ7Q5XN\R:'H>BP:DJWA>|7R-"J=P"(OD)XX%?;/SH_MX-"I_:5^+7_
&*%CC_P(DKHO^#Q/_DIOP)_|6O?^C|*MK_(-!@5XFM6^M*G|1FH:=-
%I=ZMGHFFSMPMQ)&7EEQZA=ZC/KQVK\$_P"#Q-@?B;\1_U|>_|M'65
+XC|+?!A!_X(OV_&0.3_TUM7\WG_!;?|CG|H3|MO\:#N/A'^S3\2/_M^\$7\00Z#-?
R:E_,EKFWC=R;X\ -R67C|Q7|-/L,'@>'XF?A\$R/OPXN@OCU_MWX1VVGR"-MIQ-8A./SK\A
A@B?A?|!_X)J_ \ %3VT\A:===!A5;WPGKUQ,I
M9+"Y:9\$#LP_Y9^8@R_0*=W2@2W/IC_B'2_X*^8P?VS%S_P!CC??_!5:O|_
M_IN#^WA,?VS?AK^TA\5OC7X;UD>\$?B)H>NZM)/JTL|U/!9WT,|H"_,+5C(
M)|7|5>*/CC\ (O!W@";XI>)OB1HMI X=A@DF;5Y-2C\AE0\$MM?=ACA6X&3P?2_MOP\A
!0/|H3|N?@O?X3@^!OQL\01^=4^,&GSZ?|_U(EM/H|E*MQ,'C_M'9X(
>WSW_%HO@<,? \ M,R:W_P"B+6OLO_@CC#/_<_P#!%CX5VT\$3-))\+Q(XUZL3-
@J1^/W|/_M_!1K|O'_(*Y?MZM^RM^REXSU?2O#=#YK\VD^\$?
#NBWQM\$N(XG8O>W4BX8G8A_MD8D|%1.G!)H^"7_:_1_\$|Q%817?|2/|6<6EK-;|H:?
X=L7O)O\JQE94(M'JH/TKY:_X(/_M'?|HEG_@KV-6^-MO86=CXBBUGPY#K6J-Y;Z-
>32K)%-D_M_=+&\$VQSC"W3&OZ)OVDVOV/@)^RI'\0^-OQB^(.GZ?H|CIYNH\72-
)>#^%8_M5!S(6/RC&1DT!ML?S:_L??_C3?V8?^"_@S|G;2/\$,VJVO@KX\QZ-|J5Q_(Y
M+I8+O8)&4\$A2VW)&3CI7|&?'\0;?A:H=9%->%E4|L@.N?>OW"_X.1?
AQXC^(W_!)KQY<_M>&K9YI/#NH;:K-Y!'&6^-_ZE?_VO%7PI_P
&DOI4GA>+X0^//V5O\$WC>_MSM|2A\11ZQX?T>XE2.2998?
+G;)RYS%%P.F*|0_X.:/^"A'PU^"|I\$5W^R|_MX\8Z5J_BKXB:E%8WUO8ZA*^FZ?
\$4GFD=5)P6(CB_./|8Q_AH%|HY+_(_M_/V7/BX/_^9^M?A_TA6O@_ \ X+6?A^K"?BP_|3EX-
_P#33I-?=O\ P9|_P_8_MO?%SG_F?K7_TB6OA+_@M8P_XB\$O%@_ZG+P;_.FG2:_^T?
TT:OA_ \ M+Z7X9F^PZUH,FC:IJHC'|H@)+^0|73_!1X_M?^T*MQ9:A#_HF41D|BGREE8
@J0?6OS<_P"#L'|MCX7>./#O@7|D?X=>+|76_M-0T_5IM:\2?
V; >K+':.JF**%|H(SYG.#T!'K0\$3ZF_X-7'5/^"6JX_Z*)JO_M_HJUKS_-(M?VL?
@YX_9\$TO|D/4K6WU/QMXOUFUU73X=A9M)L|:0|KPG/R_M,Y)A4<|E>3^Z2:/^"
(7@*P_83_X(W^'?B#\8KMM-AO-.O\ QIK0NI !:03'_M=\$/JUO""V#SNDQ7Y_"Z#XG?
 \ %|/^"R<&I>*04T.ZU_7^H6|N2FF>&|DU_=+M|L"L8|9)LGO0"^*YA?
!OI^TY/_P!E+_@D)X:O_BSI&FP:~XIM9-!CUC5\$ _M*MIC_ \ M9>%/VO\A
X'^"FTWP|J5O#HWB"2K4);Z?..N)8QC=WDCDH|S\N/_M^"HG'_!S!X3_.RG>!O_
\$HLJ_HNV_SS7\Y_!4)P?_@Y?)?A_93O_W_H^MRK^B_Q^.:|'\WW_!M7_P_IC|H_+
/B#^=?T@HVOYO?A_@VK;_C<MTZB@!"H/:D;)6IU%_\$)MXNZ\^|2+&HZ?
_KIU!|A1>74+O8_H7I1110_4444_M<_ \

\$SX:>#_BY/=8^&'C_1(=0T77M/ELM4L9E#+++#(NUA@\\9f@XX.#VK\\2O
MVE/^#4CXR>"/%T/CS|B#|H*,O`J:RVM|JMP|E=V(_>-YJ7"\$)K|T,U|HMK<2S-
-,A5FN9"6 M=>%)())"O7OG_!`O_@A1XR_X)@?M&>(OC;KOQQT0Q-
::UX6ETB'3|&QDB:(MM2UO+&25I6^U33;P5|8D_Q|5|X? ;X=W'PB^"?
@WX2W>HI>2>=%_M"NGZ3)=QJ569K:VCAW@`D E-V\*Z\_8N,,:0%.HH`_X*6?L@ZO\\
MV?L;,>+O
MV7M#\\86^@W7B5;41ZI=0M)!Y5U%,1Y08\$'=USN_20NYE5^`*/+3^|0!^\$_P>)L
MW_`P\_@/N'\_&\\0?^C;`L.^_X-G?CEJWPX|&_M(?L,?M MIE_KV@V=W)I=YJ\$
MEE0?:@J1^4W|'7_ :A6'A7Q_HOO\$;_#^,MOK|C:B.YOO"^BQN/M-
G!SY4DS=8\\XSC.1Q7|,,:!H&E>`-\$L_#V@:7;V5C8VT=09V=K"(XH(D7:J|J M@!5"@
#@5>\\M/|M.H)/S1|_\\\$(O'A;_(*|M_P4NF^_NER::WC2|UO_`M (1E;&03;|K:6'R|)^
N07#9Z<5|)_P_%_B/^'37Q:|_!4'_I1'7V1\\AY-?`O M_!=KP|XC\\7?\\\$M/BGX>*Z'>:G?
7&FPBWL|'W::63\$Z' 502>|V%|43\\9_\\ M@E'_,\$0M" X*@?L2^(OB|X5^\\)GA?
QMX;^(MUI4\$US&9+6ZM18V\$R*0.497 MDFPPZ|QG&W)|B^'G_!K-^W\\18/\$4;?
M5_M,6-OI^FPPPV,TFJSZI+Y(&BCW
M\$^6%7&!P.W:OK'_@U"\\!>_AU^POX^TCQ_X,U30|J;XM7\$T-OJUA);N?|F: M>
P5P"1D\$9Z<'TK|2-BCH*!|/<\\0_81_8,^!7_!|/X&V_P.^ ^DR);-%%5H&|?=&U|PHX'.2?
B3_@I+_P;Z^//V|?V|+K|K_10V@-)T.UN M%TH?V1=:;+)
(OV2*,_,HQR4R/K7ZE;%|*3"=Q0(;%RQ4_PU\\N_\\%3/^"6GP
M:_X*=?"&S\\%^/+J32/\$6@R22^%?\$UNNY|%|_OF1LO\\4;A\$##J"H(Z5|3:0#D
M"@@,,\$4 ?@%:?.\\&K7|+K_@F'K?Q@TN M;4Y=/:RM_%\$=BZP)\$+_|3&#'|XD*
A/<\\U\\%VG_!H+\\8K3+VG|8VA0LWWFCT MNX4D>AQ7|N;0>U)D>E!)^%@_X-
%OCD!C_\\AM72\\A_P7W-?K/^RC^R=9_`C|BC MPI^Q|\\2|ZS\\56>B^\$O|\\#UF26
F#48F1DD:5^JLK8P:|MINQ3U6@#\\5OVP?\\ M@U(-YXNU3XE_L2?&F/1-
\\S76G>%|7WIY\$IDR(XIU^ZB@D@MR,8YKC/A#_P &
MJW|3GQ8UW_\\A_P|L_P#;BA^U"\\N\\XBAO)M2NKBW2-
!&WG2\$@VKTVT@11T6@+GGG|,O|_7PF_9*^#>C_+^"GA:'2=|T>W\$<,,:-+)CYI7
MA3L>23WKX_."TW_!&7QA_P55\\5^ /\$'AKXRZ;X67P78;A;S17UG)+|H-R
M\\#!E*#C'E'.?6OT\$VCTIOEI_`H X?|G3X877P\\A_@/X1^#M|J<=|+X9_VNF
MR7D:E5F,480L>@..E?|O_!4_P#X-V_\\A+^WS\\3Y/CS*?'\$?@7QAJ&T:SVO MF6=_M7
E*+RLF.I'WL#/2OTJVJ%QMI=BYSMH_`GZMA_@U|_."C6O:Y\\)?
M%7|26FCX>V.J3G3WEUVXFMXTRX6=+,MA'<,20 "-|9|U^D7_2M_P""(7P!
M_P""9\\JUA0;?4#XL>7UOY#>)+ZU4?8(2N'CMU_@W#= M3OKJ22^M'F%P+B.)
|MZ8\\O)^M>^?L" LS:C^QI^Q|X#_9AUCQ-!K5SX/TAK
M*;5+;)D2X)F>3<%/((&'Q7LQ4'DBD*(>2M `Y.?.\\!4+_(-H?!_|5GQ)\\0?M M\$?
LR>/:3PKXDUEVN|PI|=6H6QN+CRC_JRG^J9Y0"21@;B:|^\$'_:U?MA_M%6|T^A
;":H6WT?1Y8|>STV'5)|2D6SVAK!O8I" 0 %X'Y5^\\ "\$8"TNQ? M2@#\\?X/^#7*P_MB>?2
CM\\%/CEI^E>\$?#>I:=-67A^^LY9+J1K2WMTG=W'R M|HHY9?0&7':OUE\\
<^"/'_Q)\\\$ZQ\\.'&C0ZCHOB#2|C3M8L9L|+FUGB:*6) MO9D=E.*W,#TI-B_W: N?
A9^TY_P:M?'+P_%\$ _\$/|@KXYQVMK)J\$DNGV>I: MA)9WNE1L6("W"\$;L
JF003R3BM;X: \\!I5KNL?#++4=;^_W|2PD\\=ZA8|K)+ M6)YK6TN&09,TARTI5B_(X:|7|?
8'7%(0H|4 ?%G_1A_P""6GB7_@EA*/& M7PW\\2?%"Q\\42>*/\$<.I1W%C:O"L*I
(BI#=22,U_`P#|4GIT(X|Z|< Z"FG8XRR|M>Q?L5_P#|JYX2^'7Q,T?X MP?
MB_%V/QHUG=+>WGAFA\$?R;N;:"\$GE8|G429)Q|X#|,FOV(\$:8Z483&"GZ M4 ?
+_P#P4_8G^+G|;G|*|?LM?_XJZ7X#TO4)X8M;DDL699;,"<6L:QC"+N
M"Y&,:5P*X7_@C;_P1|_P#!*_P;XGDU+Q;8^*/*%_BRZB6^UZ&Q\\OR+.)CM
MHRWS!2OWN.S!|6C*?\\L\$?\\%=?@3^WQ_M\\7O&GP\\&>#_!X;4>|XV;5-
*\\00K'(0DY@E_`B20 \$>|`UI*X"\\5XIH M_P"W?\\!_ \$W|95|^PUX;UF:|;Z3HK:CK<<,?
|NP4+&ZQN?|H)*K #M7_`M&? M\\%6?@Y^SY^VKX)_81E\\%:|XB:;>-A;&UCT6-
72T665AF7/("OHTK\$=\$!-?E| M0\\V_\\A|_P|\$|?)
@XM^/'QG^)'A#6M:L;JRM=/6UT*WR8.^F6)W\$?W1B@# M|Z8G_)I^|>N: ^3?
BA_P5Z_9A^#O|'_AW|NGXB'4--TOQ=I_G^&_#\$R@:E?R M\$|1"L?
J, @L>B@Y/:ODI_`#IKP|H*;XE^(G|'GO(T'PUJDG|CQ!=21F)H\\'Y MD&T;NW0T ?
K+M!R2!2#&2<|/2O!_BA_P4*^ W@/|B.X_`YT'5)O\$G@6/1EU* M&;2<&2>
(MLV@'HP;Y2#T(>E?)7CW_@Y3^ 8MM&3|G?|G3QQ\\3+Z^_V NKZU
M9^'HE_XDR3*6\\F8X(WKA=P'0MCM0!^F&\\9Q2|A7Q|_P3\$ _X+%?L^_P#!3FWU MG1/
NBZCX9\\5>'T2740"^LR*TPB9B/,1EX=01@^AK@_V|_@OK\\!OV+OVAQ
M^RUX/^%'B+XF>-K=81J^E^%V0?89)%W+ 20=TNTHQ4=!(N><@`K'_!6;_@H

MDW_!;O\ 9JTHH/ (5ZWB7I?XRM=" L\7(BV^;;W4WfYJOL^,?[5?1G@?Q# M_P);X.T?
Q8;7R?I4TR"[\$.<^7YD:OC_,>K\ '^"UG_5U^#7_4+_P"" M>L?PPL_
>N>!'7AoxN:7<:EX\2*!<"W^PZ@IE4@#(5G53Z97UKI:OCQ^VJ M%_V
/V(=!^/WQNU"1-/M?#VFP6>GVN#<7UP\";(HUIG@GV S0!I&?#!G-/W
MKZU^2A_X.H?"-IH-KX_UH@3XCV?A:ZNO)7Q#)<1?9RNX@D-MPO&UCC/8U^C
M7I/GI5_P_:;5_9UTOIJ/X=>)H7\+ZEI+7TMU/(%^QK&I,J2_W63:=PILT>G M2ME/E-
?K_\!4AT_P""N\7_2I_P""8\$^9HA_:7_"3_:^H_:W9L_#;7S MOXI_X.>/A/=?
\$3Q/H/P+_9">?+\$+PUX90V@D\7:"4^SSQC/I\+M)1#M%_VD?
A)'=1:/KG@*=/LMJ'MFMYHO#D" V6_@K M))\$OB2/Q;KVF:3-XJAD2.UL9IR2-
)BMXNTPNFN6?A%E*V\$JDAH6)!W2+M^91JW(SS0%F?H+N%?)*
M' !0;_@I*_[\$'OO^"OPB'PX.M_\ "W?&MMH/VP77E_8/-N88?-Q_%@RIL>U> M9_L
_P#!>_X_ML?'>;IF#Q;\+O\$7PU\<-YGIDZ-XG93IN:;_O"&4#;*,L0A
M'(103%>1_P#!P(P_X;8_8IR/^:T:;_Z(?MW?MW_W_M ()
I?!.;XW_'34+G|":J.TL=/L\$#W-L.YP\$C7/..!Q/8 FO@FI_X.EO!N@Z? M8^,/ &/I!'O*TOPO?
W2I#XBN)(Q"8B3^ \7*C=E03M!YZ"@-3I9MPHS7F/PJ_: MM^""QG_9RL?VK?!OC6!O!-
YHC:JVK3ML%O"BDR>8/X&3#!EZ@J1S7YYZA_P= M\$?#3Q+XJU03?@+^Q5\10'>B:--
M.O:7L5)4Y&\IM)C'!X/84!J?JOYBIC2I@ M>E?('!;7_@L%_ ^"G>G:UIOPY\ZMX?
\2>'>)=.: \ZPJXD=BJLCKPXXY MP..*XKIOS_@O!\#?V*?
CY#^R[X5^\$OB+XE> .EA1I2T;PPR@V)=0R1L2#F0J0 MQ4#@@\$9H ^I-PHW#K7PK_
_,\$Y_P#@N3\?V\ COJWL,NL_"3Q%\.'6GVL M_&I00@U^TA LO\
C;X5KX@DBCLM8\2E/*5D)-B,P"@A,Y!;MBOTUL+B&YME
MN;>59(Y\$#QR(V0RD9!'L10!P'I6'QP/I-?I.?C3X\G13J7_)Z#-J(L/V^? MY8SMSVS7DO\
P2B_X*\$O_P_%+/V8;C|HG_A #X;\G01=:1_9YN?-SY,<+^9N MI_-Q^%>X?'G4?!>A?!?
Q9XA^(WAY-5T#3/#MY?:QILD8=;FVAA:5XHX.53& M#WKYN_X)I?MM?LG?%'IA+Q-
^T_\ LU?!V;PGX)\-:EJ3W^APV<<+RSVUO%+* MZJGRY92HSWVT ?7ZOE./\$6MW%
MUYWA'2HU^U6,\$+;?/D."-K'H.N.:I0_X)E?%\S_@/_P4D^N)J?!2P^&M>!
M%NFV;7EOI&N3(_VN%=H8HRX^<;LE2,X&:)OBI_P5_/PO_X*P%^ _^"9X^\$;7
M7_"1/9#_(2;I8%KSI4S<[XVX_&ON/<.F: ^./VA_VGOV,?A)_P4Z^%_P"S
MOX_^!":A\5/'NGPWOAWQA'I\3&T3=,K-" +:&^L?VYY@\@62QF5IB>RA 3^%
'6;UJOJVI6N ME:=JM)I@MH6EF?^ZBKDG_*?*Q%_P=0?!ZIU;7KKX,?L=?\$+QEX9T-
E%Q MXEL_+AC"X'S.A!,0W9 W'G&>I?8/I'G_42^!W_4C_9+\3?&/X,<6YL;
M&IL=310QEV\,V3Z"0OW_@H?_P%X?@+^PA\ M:[7]FS2/AIKWQ\$<-
#'+J.B>&G0&R\!DCM:GWEN'K7R%_MP47_"G[?L)?'X?!M?AB=
<_X6MXD@TG\8+OR_L7F744&_'?FY_"O\$?V<
M/^#DCX!_%3IHK3/V)=\$\ _MA_LE^+O\$>HOV>FZ3X\M;S4+R8X2&&+4+5Y')I%4\$GV
MH_82-_EYJ.0X8\ _7K\J_B#_P_0_PX\+KJWC#P7^Q5\0I?)"V_ ^I09^XV
M2&SNU5I@D!9?E!;C!.: ^ ^OV,/VR/A!^W5_) ^/_,%=3:;3-2CV7-K-Q-8W M
^_R#LZGCTZ'00!Y3_P2,_X*5G_(? _I7/C\$?APWAG^QO\$!TSI&;KSO,_M=*^/_L?
A7UIN7'X5^3_P#P:0R*GI#7CAF/_-0FY_[=8J];IH7_(.1/@=\ M.OC_*I
O@%^SGXR^+%IH,DT&K7WAE56*.)V5U3()D4;<IQQ^5!74_2O>O MK2YKX9_X)S?
\%S_V>_\@H#\4;_X"7/@/60'CJS5WA\^-)'40=*APX1E^9
M>I4\@5IR2'Y,XKYJ_:4_X*7?! M|H'IKCX5_L>>./#6K7>O?
%JXABT.^LU4P0&2Y^S@R\$>YXI5I\AM M'ZR\A3=ZD9!KYP^\$W_!33IGKXW?
L,ZM^WC\HR^Z'HJU>ZMI@4+>6KVZY MD@9>@<#IV((-?)&M_P#!TA LVZSH^AR?
/IG3QUX\UG4;":IU;0I)B59=)C MCGFBQ*<'YBL:RX'1)D)YS0!^I!8"DW#UKX@_X)E?
\%P/V>O^"D_CC5/A!HW@ M_5_!?
C33+)KS_A'=B!908H." "ZBORJ^)W_!T9\/'".O:QJW@+IDGQUXI"Z;K,FGVOC^S=
(K&^V\$ MR)N7@9Z9.2I!|UIZ_LG_+9?PB_:I_9ATO\ :M^M);^'M1T^:YGCO&DLS
M\$666.3G_92IS0!'"6_&:QOB!XG'@WP-K/C 0>=_96EW-YY.[&_RXF?;^._*_M+IQ=_P
'2GP@/B3Q!#\%_P!C_P?^?#OA^3;<>);\$I'%MZ;V4@I|DD D\I: M^R_V? \ @H9\O\
@IG^SY?_!9^%=O/'#97\$FG>)/#NH?M%C(4SLD X*!' MR&Z\$;AU!H XW_@CY_P%0_\
AZ3\)?%7Q//PR;PO_P (WXC72OLOVOO.S D MN_/_I^/PKI"W#&:^3_\
@EM^TK^R7^T1X4^(\$I)GP77P7I_A/QM+HNN6J6, M<"W5Y%&H,H"=1MP.>>*E_;
(_P"#@GX"?LV_'^X_9D^\$?P?2_%GQ5I>Y-(AMXY F.EZ-XF93IN:++!>)6_&V45(5'WFD?
9M4=V9:_LSI/W'E'(SBORAU M3_@Z1^&7A35--U3X@_L2?\$_C0?">KW0&G^*+_
&+!<6S_LDR(5&[*\$/M!SS7Z M?"WXE^#OC#\M%^*7@'5XH1=?TV^*TR\C^I+#+
(H96_(_G0!/?_!PM\5O M&'P?_P""5GQ#U?P9=BWN-7:STBXFYW+!<3!)-N.A(_G6U_P1
9P\!?!3@F M5\,+I2?#&FK>>)/#<6L:U=);J7O);@&3,C\$9; ;!X_Z5P7_?\$_X>?

%7!:\,Z%K?A*RO-)\ MPVLY73[=XE*0C#8P@^7WH*^R6O
'@'1_V3/^#I6;P7*;* & OTGOIX-DN|2T^ MUC\N&(SP&5MJ#C.^
\$1C_":\A_8W_X(F_WX#_ /!07PW^V5^T1^W; M9?\$7Q!HNGRVS6=J:NMI/"T+I& 6?
HJR1Q7E_P#P=G?\$_1_%7@3X4?LG^#|/ MCU?QHGB2;6ETZR7S+J&V2%X5^4?;!
(C8_O>5[4!|HN?A\$.?AKXA_-T_P"" M@/Q8_P""NWO.DENM/M=6NM%^""W76(.AC=U\
(2W*Q#_*ZO|: ?^RYX8\>.) M_P#@Z%_:!T|Q-X>L=2MOX=A?R;^U29-W|F: ?@|6!&?
>050\ @UT^._@:Q|_P
M3X;X,V%C9V/B+P!X@N;;7K.-8Y'\$SM+%/ (HY)8;E+'DLC#M7G7|'H?^#I+
M|H(_J2W#_P"FS3Z";Y_@KU\;;H7_ (+J_LL_L77^@VC>#|A-VVMW6CK
M^|@DMWO|QKM J\ F'3E QUS7Z4?M@_LE?!7|HS|DWQ;\ ?&7@RQ32+KPW<0:
M?|GM\$5M/=4+1RPX'RE'5#OC.W%?E|_P60^#'_Q9_:\$_X_."?@Q\)_@9\9+CP#X
MFU7X+PKIWBNU5F>RV76N2-C:0?F1&3Z;|.N?^""*G_!6&YMI+:Z_X+(ZXT,L M++
(LEK/M92,,#\W<4%'S3^QQXGU_Q%_P:R_&C3-7U!IH=%\8:E9:>K=(82MA M,5'
&TED;_@5?>'!N=^R)X4^ W_!-OPE\0;|PSH>(OB);MK6J:D(E:2:U
ME=C;1EB,X6(K\O3<37A?Q8_8 F_X)P_\&'QP^ LWQ5S_P \$N/@,^\$|"UTO0?
%WA.ZUJUT^S4!%MYHXFOC^'|LK8'0,*L_P#! MN)X4\A
I4_I6G|3'I?/CWP9:SZOJ7C01:&UX?.;3|C:\O_!U18?_9#U_DU0/L|X|_OY M4%?
9.\$_X.V/V3?#6E>#OAU^UIX1\)\V-G<-KDN@^);ZUA6-[AY(O.MB^!\YQ# M/R?|H|:W?
^"TOAN?X_?M_L0_LA>(|XQ^%_%207>K0+G|HY:VRE?^!(67VW9 MKU3_ (S;BW'_!-
OPS;&=5D;XP:6RQ|AN(%AJ.2!WZCGW'K7A?_ P6X^'7CK-MXM?M'K00)
|"WTP6;+"F)E#+@?*"2>|?AM^Q|\;/'? M|//_
0@_:T^#NI>*XM/U/POXU'AG3)%D)\$LUU/##=PQ^A:);@^@^@)K| #? \ MX(L? \ %:2&'_#Y?
7NFA CTN/_BJ^;_V|/^"9WBW_()Y_P#|'_XK:3X@^.=C M\1+|Q5\7-(UG5=4TZV96MY-
DL;F7YC\S.P)'+'8|T#U/T(_X((LY?"_XZ/X3L7O/&>A2:KXDNY;96>_DGEF.V0X^8*C",#L?
LL M_P#!U9-\,_EA!9Z/-IFJZK865NNV.V2|T66?R@.P&|'M7Z2_P#!%25/^'4_ MP+&
|_F0|?_T)Z^ (=5B-U_P_/-4C^.\$=_M_!QYI8QRVMQMB->LS?+M/?'- 'WI^P/^QW\?V
/^"=NF_\$SPC*-O/\$5C M\._^\$GU;5)K57N+VZ2S:|'IQ@63G@8QBODW_
(-5_@=9>._AU\3?VW/B7I\$. MK>*_ \$GC2:SC\07JB28R;5N+IAG|H9|A23WS|5^A6N2A?
^"7|T#_T0.3_-,I MK\9/^")W_!/+|N;|JC|D"^^(W|-W_!0|4_A?H,'C2\LYO#-
G#*RM<+!;UQ\ MA'WPZ+_VSH+/-;\
@YB^&_ASX%_M1_LV_M1_"R""P_XKU'Q1=V^H:HL8ADF
M:WELI(I7*XRR^:XR>H)S7J'_7^D6?|MA_8GG@F\$B\A9M,*NIR&!U*RP1|_M5YY\=_\
@W?_&QOC?=Z#+^TU_P5.@\20Z+=O-H\?B.RE(B9C&9/+W..2\$3/ MT%=C_P %S=#?
PW^U-^PGX_M(\%B_V6_V+O\$<.,GAGIUJUW:SL?+NWN;UXV#CH=J6>|!2L*_3/H7|
ME?X2_'G|F7Q1^SUXE\&:8NBZIX:N+"UB6Q3;8DPD1RQ@#Y61L,I&,"5^2W_!
M='X6_\$;XU_\!=3X#_"OX3?Z;P;XBUKP/8V^D^)H%9GTZ4ZAJ&)0%Y.*|HD M_P""*O\
P5GEA,/VV/^""*?QD_ M9"^&OC^TTN;4/%\=I876ILYCM()0DDZJ5.1N,0X"+>M?
H_P35_8G_"P#! M.3|BC0/@QXUD\QZEA,T0BWO_%2*&|N)9G)D>23L%*J_QP,"OD?
X5_"Z|_M_.#=#K_@F-\5/'VG_!7T3XA:Q?:U;R:!)8P;((|QT|I%D&XY Y?V>O_P|C
MG_@C;^V/_P_%3OA!^V3^V+^VIXJTF/XA3+J&EZ':WA_P#!/:P)_/AI_P!
M:S7B"\$:XOC/;JK,3M,MJ?E_|D4#^2M'_@DO^R3X3_8?_P"#A'Q|^SEX(\4: MEK6GZ+\
(KQX=0U9E,\GF7&GMSCC@FOK+_@K|_P \$//_!0BXC^.?PIUE/'?
MQ8TRW46^LPDQQZIL7\$2SLO(9<#;.(0!CI0+YF;^UM_P2U^-OC+_@L7\ (O^"@ M?
|/E|HFDZ-H,E@OCC:XBFN(TFDBN=H4?YEK(4)/KPI|@/X8Z=^UC_P<(_M M#?
&+XN+#JDGPQA6UT&PO(1)%N(@0@-D#8%?A7)JA_P1R_X*4_M:_L|?MAP_
M|\$FO^"B*7<^I7%Q)9>\$?\$.K3?OH98X28H"|?ZZ*81\$1MR2|@?Q<>._!+|D/I MJA
:X_X*|_M4:%^S!^UO>_"6\T76EGU2^LHY&H1/*52,|"/ND\$|Z LS|<
M_P"#F#|G7P3\00\ @G%K'Q<7P_8P^(_ NKV5_I.K+&%GBC,H21 P&2"LAX/
M//6OJK_@F3\5|=^./_!/_P"\$7Q8\1Q*E|K7@6QFN54YPPCV\$_P#CN?QK|?C
M!_P07_X*,?%7P#?>!?C1_P %+=K50#=%\&H6&L6S/|Q1DX!SZT!(U/VRN/V1/BM
MG_HFVN?^D\$|?F#_P0K_Y5_?C|G_H+>*?_3;;U^GW|9?_"\50^R:ZY_P"D M\$U?
F%_P0L!_XA_/C#Q_S%?%' IMMZ"3:_P"#4K|E;P%HO|(6L_M1ZGX9T^X\
M0^(_ \$MUHGJ30|HK>T@VJT63T!;GCK7/?%WX0^#O@U_P=0_#R7X?::FFQ^*O M
D&KZC:V<2QOBX*7EJVU5P_&2V1CZL3ZUIU_P:YG/_!*'1?^QTUK_P!' +7F'
M|6/_!TQ\%?^R2VW_H_5:"OM%+_@I6I_XB6?V2^N6&DSQ^9'.T:IPA4\4?MF?
LY_'?|J'_@XHA0?##|G3|H6Z^&7B+_M (5?%+=+XHLT9G%NBKYD&%
(.&W#_OF@+^Z*_\%A/V7OAU?O^" <_Q+)\)ZWX4T
MUKK1_"=QJ'ARZ:V53874"^9&R%1E1E%RHX(X-?FO_P-)^/;?_@TV>;|6\=U

M?:NO@^ZMIBK1V2ZJNX\$|H\4;1,ZR&O%?^"4WP_N++P-ITWC M;19+|Q++
<6JNU_(T\RX?(.5"@*!VO7G'_!+K_@E|=-^"<_Q%_:4U;Q9XAL;
MGP/XTL9\'+QV;X9A"UTR.Z=%/ER@?G7T#_P0_=?'^4/P2&?^92/_*4SU|(? M\$|E/PV\0
W"|OI_UQ>@6I^90!K#X#\&:W_P3ON=-UGP?I=U?0^/+QH;
MRZT^26,@)C#L"POVYXKT#|@C_@C_P#\$SX"_%%/BU^W#^TAXK\.^+V\;75_
M<>'U^RM)-H\$SWHD1OGR 5@'E\=.V!BN4_P"#4|2?^";=|C_H>KX=?9*^30#_M(G_
&|/^#A+|M3QYH'PQ:;\$U#P'V%? FM-%:R:-=21+#!OD6V8B,JTLTXA=
M\DX7)XP!0%CU+_@ZG^'OP/N_'PO:;(\'^)-%7QYHGO"CT.^32KR%KH>6"6
M96E5#N:B>T 4D<:>:P|*Y_P#X.F?"_H_\$?QK^S9X&L();BZUZ'\!8_(J^"/^"#
HR3SD^M?4O\ P7^EBA_:|_8KEFD557QUIC,S'&T?;|/)/H,4 M!9GZ.^'_=
BOX%:7^OO:_L@1?#?3V*6_A1=+72IK=2&O%C>W',A?YRW7/-? MFI_P:RW_(J^'?
CG|H|HE*Q_9?A'Q=!=<6JLY9TE:2>W89]-MNAX|Y?L.KJ M1O5\ _P!>*_(?_@W2=A
AOS|L9<_S5;_P#I=?T!\$X7_(-_&7B#XXZCW%>Y?&M7|/'A_PS^P+>?M':|H5C
M>:_\10&6H73:H\(>X6WMI&M5B+\$9'IV.X?CJ)!GD5_\\$/BH_X(3_M+D_Z M|5/_
\$WI7,_\\$/CO^"90_4(_:_8.\))%?SX" _\!2K5OAUX7U*U--A)VL M\$S1V;1W\4K
JP'SR(SGW>@+,|<_X*Y?#OPY^RQ_P6K_&6OVE?A#HUIHL>
M,_%MEL.O0P0A(|D37:VCRL%P"WE7#_4J":_9(1\U^1-K_P0/_:TU7|H|X8?
M&;HG_@I?|XT;P'XQFW5]-T_7+.3S)5M|R*=H8BS\%_+V|^2*_79SE&H%U/P
MY_X+%;IX=^\$?_!P3!_BY^T>L8^'ODZ1*MU?QE|6*&.:1)&8\$8VI,?,9>>#D
MCFOL3_@M?_P3D\2?V%(O@=X(\3?LO-H/_"6:K4>HZ/XF\1YLV7<"DB?>!(
M5AZ\$9KV?_@IA_P \$P_@1_P %_A':_#[XKM<.;K&BS/<>%_VGX\ 3Y6V|UP M>'B<
!E/L1R!7Y-?"KX|_P#|0#_@WH_:@T?X#?M(>)HO%7P9\1:E'#;ZE=22
MS6T=H'57N;?) +0NH(S&3C X%|6H|_P5CLKW3? _@M_ ^PQI^HR>9<6|SI<<|
MYSN<:JH)_G7Z-? \!2(\$ _P#!.SX|8\ S1?Q3_Z;FOSK_X*:C;ZI_P71_8 MAU2T?
=#=:AITL+>JM|JZD\C7Z)?\%(G'_#N|X|#/ _%_ %A_Z;:F@78_*7X(
MVFIW7_!HXC72UF:19M4:3RU?5W_0L\2?LC?M2?\\$I-' ^M/@K0|%;^L?
#CZ1\1/#\T;:327S+LDNI\$ZL)#AU?Z#.140_!N;X4\>.O^"-W MA?P?
XMT:WU+2|2U/7+;4+"C#Q7\$+7D@9&4|00: ^OV^O^"*G|4/_!-CX@:A M^W7_, \$N_B-
J|OI&F33ZAJ/ARQG876F0IU11OWQX_X)Q?\!(O|;X/?
&;7;'4+"^TG4|WPO)9MD_9OLCHS..S,0IQ6S_P: MT?
L<^#/A|^P,O|4>KZ)HUYKWQ*US4#;7LEN&EMM-M;AK+|.21QNGMIW.."K+ M6S_
O^"CC?\!2G_((:_&+XJ>(-+M| #01H?@?5-+4VMJP\W MLB95_A61 M..A?HS
"M#_@DWX#T/|K' M_@MI^U+ ^TA9M,M=5U;P)XHOM&.6|Q")(|5C;Q|2.50V1N\$5NO_
)F-8O_M 6NL+W4?^#@3|CF'3K:2:1=< \+2LL*DD(GB0N|U3L(QMAZ_/M#_@Z
M;_9L\>.O^"?EO\ M#:7H^GVNN?#0QA874FI+"%FEL|HQ:~"K*,G|+;O@G
M\$9QBOFO_ (+G:~XF_:0_8?)
V&_#T^H1QZMXRN(|/6ZE)*K//;6\$"NWO4_C3_P0_X*'_%_P'"_X ^_G_5PN-9\+WC1'4--
UNSF-K(R2J\9?#PQE?57_!#;_@JCKO_47_9Y\0>%/
MC+:PV7Q,^'XCL_\$D<8V_VA"T9"7H3^!C(DBNO16 |,* LSP?_@@!\09?A)^R
M|^UY\5XM/6|;PO_%#7|76U9|HG-M9&;9GMN*8SVS67_,&IWP7TGQS\,?B=
M^V+\00#ZZEXMU_Q|):+XDOX5>1SY?G7&PGH6>8%OJ*H_\\$96_X)^_MT9\A MS-
7B|_TU25ZY_P &H5Y:R?\!,C4K:X1H(_BAJAD0,-R@VMEC(|-^5!7S/ M" _\ @XV^'>@?
LT_MY?LR_MA "F.VT'Q-JOB":WU*M(5C\$LEC=6J@_YKE_ ^"C?|/_AK|JS_(.8?AS*?
\$NFIJ6@ZAH>BWN|6S2?+<6L\$ \$U MP5/JK; ".ZDCO7:_\!<\;W-|^S/! A=W\0> (JKU/.E#
JSK5O)#_P_'O'PF MBF#++)\)|\$2*W4,-)N.#0%F?9'_!;;|F#X>_%? \
X)=_3PXWA+38CX3\ _V MEX<*VX46\$EL!MO ^4;|MQTQQ6-_P;H>|/%GQ%_X)*?
#>\67HNI--EU+2|_-MBN-EK;7DL,*>^\$4#|>O:_P#@J:UW_P!;4U|)VO\ P77_
&>_%7|2/_!;XC>"_!PDDU+3;:'6::UACW-<_97 MQH\>Z|C^%>?
\\$1_P#@L!^QW)^P)X4^\$GQR^.NE^%_%WP|T&>TUC3|>D,)> MUM S+-
\$Q&)!Y(3Y1\VI*A2<9_3V\X;VVDL|VV26&9&26-QE74\\$\$=P1Q7P| M\>O^#>#_
()L_'SXA7GO*UCX7W>CZAJ5PIQ?QZ'J#6\LC-EFV#@?04 ?&7| M(|5NH?A%|?
^" ^WB3|J?X;>*|^W^\$?PW\W#WNHW3BC_@EG8R_\%:/^"T'Q_X*/^*M-
:/PAV6ALO"^EW\U#NBDM|-P\33VDS+>:G M"Z%&66>C\$5UG|*'|&'|/?
|S\$GPWN/A1^S;X A\Z/=:E)?W44@&!UH*NC\B?A!K%K_,\$=_P#@X:U;X4ZO?R6'PU^K!
(Y MYE(BC\+/9N,<\$)>9@+=%660|JL6W|5_PC_8?_X.9?C\0OVD=6E\.^?\$.D
MVUK::S>0NL*|H-L@DGW:UX!N/#|K;6NJ6L\$D<,J66I7\$|PN^/D\Z&8!6QN5&QD
X^|/VMO\ M@N?^PC\OV.-2^?PV^FA^*.;UC1;B+POX8L;L:)|TQ|0DBX#1+&S?;QQD
M+\N>M?0VJ?L#?LN:Y^RG;_L6:|+|6^ ^MEIZV=EHUXYD,"*259'/S*ZDDAQ

MR#7S)X+ _.#:O @F)XA=VOC9 AEJ&11VMY|H32=2U1Y+63#;@CK_\$G;:> ", M@I:!
HGO1^SEX<^*NE \&MWQ:A6?%.>^E;Q1X@O14T.XU"X:226Q_P!#MU?Y MN0#+!
@>G/>OU&_X(I%1_P \$M_@*1_T3/2_ \$0*],^*?|+ /P7^,7P&NOV9O
M&/@BV_X0F\T|+&30|' 1XTMT/RQILOM P.E;WP: ^\$7@GX" "W0?@U\-=*-CX M?A-
:;%I^CV;2%)MXUPB|CR<#N:"3UI?*_G_ (J;/_ \$0|?Y-7SS_P22_ : M!^\$G_!)K_@J9^T-
^QG^T!KZ^\$ _#7B'7F'A;6-:9Q&#!=3-9AW(VRVUR29", M;D49QS7Z_7/|/%OP
NOVK(_VTY?!S'XA1Z'_9"ZUIJ? M,?) _17P#_9V\3_)!H?@6^N|K7O\$%CN-
G)>S!8UA0|'V+&Q M#=_LP&1S7MG_7|U+OY\ M;_8_ &X?#EJTMCMX%MH(+I5C_
(V2UGVENV^_ M)U^IK|@(\(?A!!' _OM>%/ @K-\ "&^"GVW2;07(-6O+JZOG-U-
<0Q211YE!W M! LK_ (.,G-?1_P 5?V9?@M\0M?2W MR1HF!XAS&5>6/);
(SM+;3CX&_85_9|_ :+ :? X(_M_ ^-?&>I:E?:Q\1M1F MUW0?
|2CD\ACF:0;:=:U(T!R#A2,\ @9S^%?='@?X:> "_AMX(LOAMX#^*V.E:#IMK|FT_
M2+.\$+;P0_P#/-4Z!>3QWS0'S/S&_X(2_\%>/V1-&_P""<_ASX0_'WXRZ+XA M3?
#&PN|&L|5G\MKRPB=I8;B(8^;|W(L97)'YKB\$QM-9P:/+ #SY4CB^ (_A_HXTOPS M-
3D"3;PY&2-QYQ05\SW/^"R7|: ^@ _\ !2W|N'X\$ _L: _L# ^-W\22;:K,SZMK
M.CZA)#;S3SS1J);C*10VK2L_(Q)QT.?< _\ @OI86VF?MD_L1Z=:*RPV_P_8
MM+BC7=T5=1L0H_5|>_L4? \!(+|B7|@CQ%-XY^!'PP6/Q%/;M;-KVJ3FXN(
MX6?/^"D%K;7<_AW09_M(=)UF2UA+?8S;W;W R?62.XF SCF+_ :%?67|37_!=|@#X>?
LA:M\=/AM?M M+U|5M0TFZA|+>'| %KR;4?)79)"1F-5:2,LS<8W8W8(KZT^.:?
P|^%G|27PR MU3X0?&?P?9ZYX?U>\$OWEC=1Y!_V@>JL#T8-/C)XN
MO=7OH|SXE6NN;:%=2/+(VG6^8'F!9B?+,CD?5#Q7Z'?A\$NO^"Q/I"?A'_@EM
MX+N/B-:|+T/5OA?X)L-%\1Z!>2%;QYK>%;>(PQ|91+L!!7,.-CK7Z":3\'
M/AKHOPSC^#&F>_|+@**0Z6-.C/VQB_95M=NWR?+QC;BOB<_ \&U/_!%O'K^ M-
I/AAJ300=-,=(LR?9^?X<9^|4|\SXA_X(S?M@VG|9?_!PA1/VC+^+^R;_M7Q9V/=5C/V%
|,%D-NMQ8^7&,XWMY<;O@9.%8| 37HW_2" _P""B.L?L|?)
M%"OC|^QQ^W7\9KC3|RI;:7"^&+OO9J3K;V\D%S<_01R2X6..2*0.K' 8!"#@_MC/Z(>
_ ^"5_ |\$ _PR_:(TG|J3P%\';?2O&&AV7V32|RSN&2.&\$6|6VT1#Y? \ M5,PZ=|J:YO\
:7_X(S_L_ MY>,8_B1\;OAGY?B15"7&N:3<-;SW:!0H64K|_ M;J@*3R!Q0%T?G?A
M: _\$|XC.R*#R*SOAQ^TC:?)!*_S_ (./BU+^TOJ,WA_PA M%+= (NN3VC_9VC?;+;SY&?
D5|Z,1G|ZBOT|_8@_X)4?LZG@T!\SX*_X."? \ @J^S|K_ .S+%;LR)8PK(DC!HDX+295%5"?
O'G@BOT4_X)_ G\2 _S M|BSX9_"7Q GK-Q?ZMH?A"SM|2NKK/FO-Y89MV>
<@MC**_9E_P""!7_!;|E MSX@VOQ-)_"235M8TZX6?
2|C7|OKE;611PZHWR|LX8'L0*^TH8GC')ZT"/./ MVRW7_AD3XK>WPUUS_P!
(J)_3_@A4P_XA^_C%_V%/%'_ *_K;OUQ|>#=\$^(M'@_5O
GB6U,VFZUI|AJ\$ (8KYD\$T;1R+D6_?|@G|FS|FW|GO6/V M7_A'X%.F^#=>ENY-
2TLWCOYK7\$;ORG<3D95%'MB@1\I \&NK@? \!)_0R3U
M::U_Z.6O+_VL'!_X.E_@I_V26V_|*-5K|&OV7/V3_@M^QK\H)?@E^S|X7;1_
M#EO>3W4=BURTF)93EVW-SR:RO%_|\$O|.OC;|JC0_VS/\$?@OIOB#X?TE=,TG6
MA=.:!%;JTI";,|3S-)R1_%0!^= _\ P4J8#_@Y9_9+X_YE.V_|*|7KSK_@I#8_M_\$W_
3A_P"#@CP/^V5X\AN|;P'XJ\ _PZ9JFJ1V9;VI5HIXP>|(WE.1UP., MUW'_4;U|2-4_X.:?
V6=-TZ_CFN-\VD-"C?-(9|4D"MZ\$|C?1A7Z4? MM3_L8?LY_MI>|!\$ ^7|1_PRL?
\$>FPR&2T^T+MEM9#C+Q..4) P<=1Q05ML?'/
M_!6|_@LS^R|\+OV&M>L_@S\;="4^+/'WA9H/'-CH-
X)I(EN%9!#V'I%WQQ\=_P#!KGJW@3Q9;7FJ^,O|/?QSHKJ+2?:4@BO5O73
M!W\GV)9@B@?,S*!C-?3'PG_ .#;_P#X)G?"OO|9>/H_AA?:Q+87"S0?:K6I M/-
:EPV06C/#_8Z'@U|VVVBV5GI:::V44=K'"(8|=\$ C6,#_4+TV@<8|* ^9_M^67_
0|_P""NW|&_A#_ (G:/X"^ _Q7TKP?K7PIL9|+4M-U*Y(FN|82EXI MX5QF00YA3;:D%3G
.:Y7_@@\40VE?VFI?VGOVEOBA\2/\$&N>#|YI-A*_VM M,|1&<.:B;R5)PNR*2W#
#_EHH!X-?3'QP_X-W?^":WQO^ (U|\3=4^%5UI| _MJ=Y)=:A#HNH-!|+*
|;F;8.%RP!SC'/I7\$?\&|W|2?P>_X)M?M2_'K| MB|H|H|Q?;^%|8O/\$\$,%GK,J/Y-K)-
HLEW\$T9)SM\Q9A(I)QA<=Q7Z97/_1%_M_P""<R10QWL4JS+(E.T?O%#\$ 8//K3/
MVT_ ^"+/I#7|=GC^/XI?&3X<2P^ (O*6*ZU;1|HV\ETB|MHEV\1N^ \>>,4?D MS_P<9_ \
|4|X3_MK>-_?H/W|_C|M>\&^#16_M+7-;M8V%M>ZG*!' \$J%@_B M.+SL'
R97'.VO5_ ^#K'6;WPOK7|.OB33\$:2ZT^&6YMXU8@F1'A90,+K%YX#O\$N?
#;/_=,JP.KJXW*#AP2BY!XH\$ M>_Z#_P_%UOV_'8BTS|HCQ|\<-,L-2NO#YBG\ (I.9-
2@U2.U1GM/+ !+*TB M/PK9."2"!XC_,&NOPBUX_!3XJ?M?>./#LEK>?%+QY++IMW-
)N:>RBW-@CVF MEE&>XYKV+QO_P;C?\\$RO'/Q4NOBC=_ "F\VO=0-
W<:/8:D\5GN+;F58Q|U"? MX1P!P*^T_AU\-

!WPH&Z\A.OAYX>MM)T72;1+;3["SC"1Q1J, 8'?W[GF@>
MVQ^/7 !NS\J6^,W !'GX\?'?P^W^G:JNHV5EZM*^GH\$7\6P/QJ/_@W' X* M2?
SjFWX*>(?V#_VL_BE;^#O\$7AOOQ<#PY;^(MT\$1BF=1);!R,(PN1*Q#;1B M0G-?
J5^R/^Q!^S[^P[X&OOAQ^S?X,.AZ3J.HF^N[=KIYBTQ0)NRQXX45XS^U M;_P0L_X)Z?
M>>-[CXF?.\$'X1?V?X@OKCSM2U30KIK9KQ\N6:0+PS,7Y;J=JT M?/[6O!6F?^%/?
^"TOP"^\!W!'/C^YO/#'@/Q#:ZAKNN6C.MK>_9[A;R? !! M:/9#Y63P6DZ8KJNB
\$ZU\Z_L2_\!+3[CO\ 8#CNKKJG_P"&\$%KJUXNRZU[4 M^\^9!T02-RJ^PP*^BF0%
<"@3/OJ;,>:_O\ B-^PQ_P<0> /&GOJ^+6OZ? \ M!_O! \A.NG1)<:=U>._LJ_P#!
M!G_@GE^R5\1[7XM>!?A9)J.O.;/YVEWFN7C7 M);\$;T10EW#LV.#0%V?#? \
MP<3/XS_9F_:I 9#_&P1;W'V/PO!JGNH+=F6RN+*YM)_G?!4&19FV*>3Y,A M&
<"O7_!7G_@LE^RO=?\$H<|\$?LX_%?2_%WC#XO>&9-%T/0M)4W,R6IZIM!
M@R(HRCB-Y\$52-Q890 M&"S1D)?^#;?_@F#XB\<2>,5^&6I644M MRLS:39ZM(EJ,'E
N>%/HIT!>Y3?A\$E?#%_#_P \$9?VR?B?;>%VT?0/%K:I<
M^';7YML<"6<@,:DCE4W!00>U=M_P;2_\%4OV?/A]^R;=_L@?M%?%W3/#.H>#
Mj6OK_P+2:Q)Y,,VF3\$W,J+(>"ZW#W#[3R1(,XQ7Z"?MY_"?P%\A\$? _@E1\
M50AA\,/##%IH^AZ+\+J1MM.L+.,*D;+;L!TZDXR2>2: ^%?^"5/_!&WjB/!OW_M
()/?!/XH?"X?S+XCAM]>MYM:TN!:"YA3Q!J@1)-OW\ \ \$ _@_#I0!Q7PD_
M:/L/^"H7_!RKX1^+7P/OI=5\!_"[P_=&SU"2U_=98K.>)Y1TP'N[H%,\G(X MXXSOV1?
VFO#G_! *#_@NA\?/AC^U3K@T7PK\4_?OM5LO\$%Q;NL\$?VNZ>|MI.Y M*8E>\$L,CX)(A
MV4_P&>!T%9'!;W_2^_8^;ZAM9_VA_A=J&J6-N8+'7+60PWD,9_@ \Q>2 MN22->
3F@/(^ _@XB_X*E_"WQQ"\!_84_9"^)/BGQMXR\1Z>VK2>\$YOM
M^V2T1UGBB26(\S2S>1A4)^7>#&G%8_\P6_!\^*_AE\.?^"?/@#QQ/(\^LZ3X M_P!-
MM4:8DN+A3IN\^D\A\@ \GFOMCID_@A7_P \$ _V00'-M\3/ 'PA_M+O!
M87'GZ;JFO73736,-PK*R9#=#1N;UKVSH\A 8I^ 'I6FL^#]>^./@YM5 MNO
>N#5_ "\BW3Q_9+L/&P?Y3W,2'!XXH\$SKOC?A^"B_G_)E74\ TF>O
MPI_X)AO_&%_ ^#?SjJZY^ FYJ50XLLOB-
!QI.BZjJTFI:I9RW+3">XDB2)V.\GJD:#'3B@<3XX_P""-A P5B_
M9D\1_P#!.#0KKjH?jI+2=A %/@>QGM_%W_"2:L!>3CSG=)@'.Z8,KA1MR?E MY_KY_\
^#:.VR7XG?MA_M6?M0>_"4FF^!-HO!:ANY6,' M"YI@=Z^NO@%^S\A(OV8?
A)IGP.^!_@FST'PWI,)CMj&S7&YB/GE<|7D8\ECD MDj: ^9^:_P#P;N>
j&^*7P%:_L^&7B0RKI_B+XO:UI=^87VN(;BU\EH]-M8 MX/:O%? \
@WI_:%^&W_!/#XA?%3_@GM^VAKVG^"=?M?%6^UU#4[PK:RWD;?9W MMPV;
"NKG"E>N*_7CjF+|C#X#?L@6?B2P^_A Z/%XLUZ36=<5KH?/O'&& MD^8\9!7EG!;?
_!&WjACINSQ5#\0/C-\+%C\0HH2;6M'F-K/L22ZjKjG;%K2)Y
MKBW>ZE0D?/'%!;+EC@%FVCU/jWQ>")_P=? _@_#'_%OX=H'_8.NJ^!_V(\^M"7O!(? \
P3j@OY_V=OAM'9:EJD21:AK%[,9jJ5\$+84.W*j=W(&_Z/6?V#OV M<=?_
&LK#j|MO5!/#\A1M-T\65GK?VQ_DAS;QA=F=OW7(Z=Z ^9B_\%39% \ MP3G^,Q'_ \$(
_P#^BZ\!_P"#9:>-/\^"0_@8LW_,>UW_TY35jL_%3X5^\$?C-\
M.M9^%7Q!TWj;HNO:?)9:G:B0KYD+C#+D'F MT;PWIMQ<36EB9VEV--
(9)#ELGEF)H)/1j*3<*6@_HHHH *****"BBB@_HHHH M *****"BBB@_HHHH *****
"B@\$&C/.*"BBB@_HHHH *****"BDW"C<*_%HI M-PHW"@!;*3<*-PH 6BDW"C<*_%HI-
PHW"@!:YGXK^!]>\5_#7Q%X6\+;BMGj M>I!>6NG7A8CR)Y(71'R/IK,&XYXKjJC:\$.
!'QQj7A03V'AV"W>:65KTH(HYI)'/W(XC+A<%;S3+.XNL^7')+ \$55FQS@ \$U MP? \
P2E_9*\;_L+?L"^?V6?B+K=Cj6L>%O!4^V7FFY\F3j3jMY>)MW< \).B
MGW!KZ'DC+FG(NQ=M "T444 %%%!1110 4444 %%%!1110 4444 &?:DW M"LSQ-
XGTOPAH=QXBUZX\FUM8j\G7:N<5PZ_M9_!<\GO_-Y;_"MJ6'K5E>G
M%LX<5F6!PE[A1N%>:?_#6?P6_Z&5O\ P':C_AK/X+?j M#*W_ 'X:C^S\=_Sj?W!;N3_
//Z/WHj+W"C<*T_P"&L_@M_P!#*W_?AJ/^ M&L_@M_T,K? \?
AJ/H/QO_/M_<'jN91_S^CjZ/2jPHW"O-A AK/X+? _0RM_ MX#M1_P-9_!;_H96_P" _#4?V?
C?^?;^X/IE[A1N%>:?_9_!;_M_*&5O^_#4? _#6?P6_Z&5O\ OPU'jGXj_GV_N8?VjD_
#^CjZ/2jPHW"O-/ M^&L_@M_T,K?j^&H_X:S^"W_0RM_WX:C^S\=_Sj?W;/IE[A1N%>
M:_ _#67P7_Z&5O\ ORU)_P-9_!;_H96_P" _#4?V?CO^?;^YA_:F4? _Z/W
MHj+W"C<*T_X:S^"W_0RM_WX:C_AK/X+?j #*W_?AJ/H/QO\ Sj?W!;_F4? \
M/Z/WHj,HKS3_-(R^"W?Q-C_
+8M65XC_ ;A_9Z\+&\$:WXRjGSjWE_P"CNV_!\9A*\;^WLI_Y_1^j&GjL9;_
5jYjGN'K1N'K7AG# MO#jEW_H>V_ _63_H_X>(?LO?j#VW_ ("R?X4?
VIE/_V/WA_:&6_ _5jY MjGN'K1N'K7A?_#Q#jEW_*MO_63_"E_P"B'j+O_0jM_X"R?
X4?VjE/_V M/WA_:V6_ _5jYjGN'K1N'K7AG_#QjEW_H>F_P#

63 "C_AXC^R[P!#TW_@M+) _A1_ ;V4_ \ /V/WC_M;+? \ GZOO/<[P]:-P]:\ _P""B"[+O_0]-
X"R?X4 M?V\$/V7?^A[/@+) _A1_ ;V4_ \ 8_ >+^V,M_Y^K[SW+(_LN_1#V?_63_"C_(>
(_LN?1#VW_@+) _A1_ ;V4_ \ 8_ >^MM?+?^?
J^ \ISW#UHW#UKPS_AXC^R[P!#TW_@)) _A1_P\1_9<_P"A[; P\$D_P MH_MI*? \ G[!IQ?
VOEO\ S\7WGN6X4;A7AO\ P\0_9=_Z'MO_%D_P*5? \ M@H=^RZ>OCP_ ^LG^%A
MS*MO:Q^ \J;_9=*22J+7S/<>31R.J?&&I_ \!>[_M_OJZ5J4VF7?QQ99+>5HY5_LN?
A@V,?=1:B_X? \ O_! ,SK_PO-O_5S_P#Q_M->
I'"XB<5**W/JH< .YY4BIOP\FGK\+V/M/!HP: ^+/_ ^'_+_P3+_Z+FW_(*I
M_P#XFC_A_P" \ \$RQU^.;?^"J?_XFJ^I8K^5E?ZM9]_T#S_ \ 6?:>#1@UA6_M/A
S_@F7_T71O\ P5S_ /Q-'_#_ *_X)F_!%T;_ ,%<_P#\31]3Q7\H?ZMY_M]_T#S_ \
6?:6#2[7_NFOBL_ \%^_ ^"9JG!^ .C_ \ @JG_ /B: \ P7[_X)F? \ M1=&_ \ %4_ _P_31]3Q7\K^XA
5O/O^@>?_ @+/_M3: _JTT;7_NFOBO_(? _P#!_M,S_HNC?^"N?_ .)H_P""_? \
P3, _Z+HW_@KG_P#B:/J>* _E?W!_JWGW_ \$#S_M_P#_6?:>#1@UA6?V_?^"9?_ \$7-O_!3/_ \
\$T?V_?^"9?_ \$7-O_!5/_ \ M\$T?4L5_*P_U9S_ \ Z!_I_ ^L^T\&C!KXL_P""_O\ P3+_
_BYM_X*I_ \ XFC_M_(?^_P#!_O\ Z+FW_@JG_P#B:/J6*_E8?ZM9]_T#S_ \ 6?:>#1@UA6? \ A
MW_@F7_T7-O\ P53_ /Q-'_#_ -_X)E_!%S;_ ,%4_P#\31]2Q7\K#_5K/O\ MH'G_ .
L^T\&C!KXM_X?^? \! ,S_*+FW_@KG_ \ B:/^'_G_3, _P"BYM_X M*Y_
(FCZEBOY6'^K6??] \ _ 6?:>#02< \ 5\86?_! ?+_@F?=R"&/XZ,6;H!_MI4_
_35S_A^S_P3<)Y^ -S?^"N;_ .)JXY;CI*8_-(#_*U/):RHX^SDU> MTM';N?
8>X4;A7O\ P_9_X)M_!%M;_P_%?8.X4;A7O\ P_9_X)M_!M%M;_ ,%R?
G]'S["W"C<*^/O^'[! _O_HM MK? \ @KF_ ^)H_X?
L_ \ \$V_ ^BVM_P""N;_XFC^R\ P_Y\ R^X/I>R?_G]'[S["W"C_M<*^/?^'[_? _!-K_HMK? \
@KF_PH_X?M? \ \$V_ ^BW_ _X*YO_B:/[+S#_GW+[@_M MI*/^?T?O/L+<*_PKX]_X?M?
 \ \$V_ ^BW_ _X*YO_B:/^'[_7_!-K_HMS?^"N;_XF MG_9>8? \ /N7W!_ ;V4?
/_Z/WGV%N%+D>M? '9_P""[_! -T' _" \&_P#!5_ _M37O7[_G]5GP: _ :T\ M\3O@;XE;6-
'2\>U:YAEH\2+C(PV/6LJV!Q>'CS5(-+MS1MA\TR_%SY*51-IDRW^T@#_ ,*3\0\$_ \ ^)Z?
[PKXC&"_5]O_M)J5^"?B? M]_ .) _! "%?\$(0#K7V""KOAYOS_\$/R?Q)%
[1T87_GE0\F!UQ]:V&!\ ^-H]#_P"\$GD\WBZ=Y>_ [8T/IQ;G<^E9RJT: M=E)VOL;4Z.
(JW<(MV,CY>GEBEPG]T4@+8R*7YFVHBEF9L*!SDU=XF<8RE*R# MWPM&T?
W5K4U_P_XO\,6\=JXB\ -7EG#(^V.2XBV@GK5/1M#UOQ%,,/0-&NKR4_M?P6]NSDYK-
;#R\Z:MWN;?5<3]3V?*^;MU*^ /X5_*@'/3;6AXC\
M*>)"4D<'B70[BQ>92T:W\$>W=@XS6:"!SMJX5*=2/-%W1G4IU*,^6::?9CL'
MT6CP78P9Z^E>9?M#Y\ S2/^W@?^BZ]0(R,5YA^T6N)-'(_P"F_P#\3K\Y\5?^
M2+KJW;\ T=6#E)UDCS0!<U?QCS2/KO MASPQXB\7:Q#X?
 *Z)=:A>W!Q#;V<)D9O4X'8=ST%=3/^S_ \ ?]!:KB7X1:\%C_M7N!7=3P>-
KPYX0;7DCHIX7%5H\T(MKR1Q.\$_O4':.1%S#-9W#6UU& MT%O!WBOQKJ0TCP?
X;OM2NMNXPV-NTK*N MX+N.T'
R0,GCD54L+C(U%3<'=1.I3P^(C+D:=^UBAA.P_2EPO3_KK];_&>_MCCX=TJ?
6=:^%>MVUK;1F2XN&L7VOH.K' Z#J3V'/2N,! "OAUQTZGIFIK8;%X
M:WM8./J34HXBC_ \$BUZH?A/6C">M-! ?A:7:1R:QYI;7,>9]PPGK^E _"M2XR
M,!:;%7'45/M)=PYN7J&\$!;-JXXHP,9Q0J@_U//(+ON(0N?O"D<=LT\!(?@ \ ?%?
B+3UX.H;:HLEN3D@@@2 ;6((.0"2. M^.*[93C!7D]'=B,7@ \ "FK245W>AYWDCL:-
_!^!7H?Q<_9%_ :B^VC1^(_C) M\!O%/AS399!&FH:GH\ D<.\!%+XV@GL"03VKB?"WA?Q-
XX\060A3P7X>OM6U2 MIDV6>G::O//.WHB("S'Z"H]I3Y;W)IXI
UJ7M85(N/= -6*62>M%>UWO_!-W_M]O>PL9-2NOV1_'2PPQ&21UT.1L*!D\ 9/X
YI9KQC4K'4=%U*;2-7T^XM+JU ME:*YM;F%HY(75BI5E8
J0000>XI1K4YNR9&'S#+L4VJ52,K=FF1T9]C7I7PI_M_8V_:M^ .7AS_
(2_X0_L] >+/\$&DM*T:ZEIVCR/_J<,%?&&P00<9P>*SOC#^
MS'^T/^SW':3?'#X,^(_ "\=^S+9S:QIDD;M=7^XX:BF\CC=3B#U!K521Z&@?-Z"CYO\
9HH)P,XHN@LA2".H MI#GMB@,/XN*/H:-PT##4;"W'[_:" '&*3: ?
NT:"Y8]BYX>#M4US4KC/DV&DZ?)<3-CJ=J_G_ZD]_ .N*Z3XP?LN_M?M&?
#3K36_C3\&] >\,VE] <&"SN-7L&A6:0+N*#/?'=-WM\&HH-JHZ7/YJ6
M'Q4J3JJ+Y>_0X/+>AHW&NB^&7PB^*?QJ\0KX1^\$GP_U;Q%J3+N^QZ/8O.RJ!
MDL=H.T>YP.W6NX\7_L%_MJ^!- N?\$_BO]F'QE9Z?9KNNKIM#E98U_O':#@>=
M08YQ2GBL+3ERRDD^URZ>#QM6/'#:_I'DNY_2DY]*4EE.UU*D'!!6NV^\$/_I-
MGO_ ^/QO# \ %?A!X@ \ 3+H+]LDT?3))E@W?=#, !@\$^A.:NI6P]*/-I+N9TZ&(MK3Y(1;?
9'\$Y;.,4AR.JUZG\0_P!B;]KOX3^&)O&7Q&_9R\7:1I=N?](U"[T6_M7RHOE)RQ
_T8'WC@#H37EI;'-32KX?\$103: ?H.MA\5AY6J1:J0Q_L49;T:- M'A3PIX\>=>

(K/PAX+\\WFJ:IJ\$PAL;"QMVDFGD/150AQWS>E'S>E&
I')_G3CN_NUHN5I(RYI#;_@VP*G|@>\\!_P"ASO/_\$%*!@+
M@8S7IT_\\&UR#_A@B|_I'2|_!|2OD./^\\17T?=>'SE_;ET_LL^U/VEB?^%);
M_P#|>)_I"%?S=?;G|2W_"1/7_\\KQ/_*\$^*(Z\\3A7_'67K^AZ/B5_OU/T
M"FL1CFE)P.*Z7X-?#MOBAXIM?"YNXX8_19JJ.YO^F:^EKUHX>E*H MID?
GF\$P|3%XB_*&\\G9'6_LW? EOB'J:^,?\$R|'H5C)ND\\PC%PR|5/HH|G*| MW^/,FES_
+/6M7&B&)<K5M/46|0|+MWKC'MZ53^,W@SXA+X\$M?AW\\%|_-@MK22 M-H|Z3S!'B/&
BG_:YW=#OUY-6|;^'?B:|_9M_P"%>I%_':?|DI#L,OR|U89&-M?
PKX'\$8R6+Q4*TY:Y_%/Q+U#2/&,J1P>' M9(VO|>_3=YLC%BJ_P|WY>3^'T?M%^"?
C#X_\\GPCX&TN.WT6%/WF+Q4^T M'TV|@/3O7MYKFD:S6&IRM?=>^7D?(-
\\RH4WCZ\\>9I^|JWY^A2_;G?M_'SO7X|^'&D:%XOF?X=PR6WQ-T2VG&UH|
M:MT;GH1*!6&74J&)<RF5.3ORMNWX7.S/<1C* M-!81K_QXR|\\X5X7;V|U>3+;V5O))
(QPL<2EF/&>E>Z_MU,/^\$FV/GTL9\\A MT(5Q7|+<:3?&O2XIEW*5FX/_
%S:O2RVM+#Y*JJ6R?YL\\'/L+|#;,<6|Q>16|U>|1YCRR\$|2.VT\$C.<\\<^U0?%GXT>&O
M@9XUM_"GASP':EKOEN|2F\\L+\\KM@|<=6PI//&?6N6.=8OF2|ENKK7H=DN\$LM
MA%S>)^&7*W;KV1\\O.DUK*T5S";JQ5HW7#*1U!'J*L)H^MR6@OETFZ,&W=YP
MMVV8|)%_?%?OO\\&W*P"&/7\$G>^C6;9%@17&1ZL&VG.>_,=M.:_Q>_:2C^&GCA
X0'PYX*L9K'3U2.Z^T1D;U(Y5,8_')S6D<\\JUN6-*%Y M;OY&4N\$Z.%|H/\$U;132B|7NV?;
|6.H06T=Y/8S1PR_ZN5XB%?CL<8IM?0'|5 M,NA7OP:|+ZKX;TO|'9W5U'-
;VYM_+9\$;)'F"D#IU^E?/PZ8_M%_?T?\\|_:^TZ^)_M|5?^2+K_"_-'#@_|X1YG_#L|TA+*<
TNSOFD;KR*_C.FDZB/=C|TD??7|%' M@'PE^S|^S!-\\?==TC|1K&I6C77F+#NE:\$G\$,?\$
4X8|2,=2PSTKFM+_;,Y_:1T M76Y=>\\>? >X3PZNY|A8;&19(8L'GZZGZO^
MXPM*AAX5O9MO5DE>|^Y\\V=Q9:VZA?
+M8U&_9RTS3/A5^S_P#"|M0U);)6V6|BSP6D(RHSMZMD XST
MY/6N,7X6>#_A/_P4JT&'P?91VEMK'A^XOIK>/_19F656VCMNV!L#C.<=36|^
MVE^V|JW|_C6U&>\$O UC>7TU@+F:|U)B4"|\\:0JD\$Y/)8G/-@I7J6FY6^"FH?
#OXE?"23 M2|:U15ACOIK,K|Y9'S\$!P?F/.,\$XSV(J|F+|K'X&_L_L_7|Z1X69O&/FJM
MP)AS?2-DJV_&^?NX|>Y)->T^\$/'@7|N|H?7|H|Q?
X'BL;K3_.1HT32LF|E8XER26=NR\\9SC
MZ5X^9ULSP>,HUZ\$U5|H&T7;7^O,\\O'ULQPN*I5Z,O:<\\;1=M5Z^?F?;W|%G|
M:OC|H|XAZMX \\<^&+18O|/|:|M9;6,|8D#*I1\\DY)+\\=.A&*^8_V|/A|X<^|
M|/2>KZ;X8M_)M;R*._,"|Y),EPOL6|;|;' X^F_"FD!O_()O_"J:4_\$^
MHPZGXNU2T9F6%BLEW*,1)P?+C!(&XCIDX8\\5\\0?%/XCZ_\\%GX@Z\\1/\$A_
MT05+LRF-6.V)?X8USSA5P!DUEQ)BI4\\EIX?%RO7?8B<,KIT,3+FK
M7N^Z1EZ;H>N:VLG|C:/=7GD@&8VMNTGEYZ;MHXS@|?0T#P|XB;2SKG|@WWV%
M1DW?V5_*QG&=V,=?>OK;_@D_;Z6S_"XU2T62*.VTYF#+GC%WG%>B?LQ_M6^
M#?V@?B%K'P8_X5A86>AV|DYT?R8P5DMU;|;X,;A@C XY&>|>?E_"^\$Q6%HU M*M?
E=2_*K7NT<>|X?PV*P|*I4|KGLK'P3:>%?%6H6/HJ6/AO4)K4YQ<0V3M M&0.IR|C
P<^F#6?N.< U^@GPZ_:N\\-ZS^TSEK6UT/AN;PG MXLL|:\\NO#&HQ0S,JQ226;A6)Z
\$C|)I#OVJ'4|)%UK1)EM|:TFZM&9=T:W,+ M1EESU^8#BOL+P?\\\\%|8?
B%\\:K/X>^)/A3H?AN^U9;6WS"\\I7\$9WXB<@G&<| M>-
H(ZUR_!5BUM|7XR>'Q;0JN|PZ2=HQ_P MWYKAQO#V#HY?4Q-"JY-9_|"D_\\Z,-8|?
W+EO\\N%+_K|D?ZQ M9#_R)--'T'69VCM+S5K>WNI%?;MC>158Y|<\$U_0!_P M5_
^(/_!)?|DGX;Z)^QQ*_-+N-(NHC9R:M-9M+;Z;#S'L'ELXBPLQD;YB1 MDCC)-?@K|\$?A;K?
QP^,7AGX/^'"5OO\$FN6^GV|*K\$JTD@7=A03P,H_H3_:| M_?_&:O^"2/|,_@|X#_!TA\\0?
\$W6O^\$=+:0|/OK>&22_\\(3|VUS,X"0QE MU5-X61U'(1MM<>9?QH1M??0_,O\$BH3-
\\%2C!U=W|A F7=G/?\\!;?|JOQ/_M_P%:_?V'_P_:'^\$.DKIEJSV8NH;%O;W?E,QDC5B?
FC9>"I/..0>OS_\\A M!M!^S_\\DS?%|XVQ6|EJWBSP_XF.DZ/#G|MWQG_P
%|+7|FV|^!FCR:+/XX30|W2;?39S>6=JU MXL#7+MDX"(\\ADJ|CBN?_P"#BWXX?
_LZ?"3|M_P""GO@\\3^!;>ZM-UGM@A8 EBLCKDYR\$
Z"O;=!_X_/^")O#/CCPW^V'IWCO6-
M:T+7)FTRZTK4;@RIHSE/,B%M\\GRPNPE+!G.'=0H"X"|8;_>(IQY;K|I#V,CA
M&GQ+A83H/#*4&M_CNM_+N=Y^V'_P<3?#X*>!/#/PW_X)U>")G'|GO2WEY|
M6FM%:Z;& FVV2%2NY;MQS@<8SS7OI^_,A?%?7?^"+/C'XO?&SX<0Z?>1>&|M7N
D>'A1:RF6^UJ7\$E8+_%"0?RK|_?VP/VU|'_@GI_P3@^#/Q?\\M!_P@T'Q%XJU72=/T_29-
:M&I4:7M)U'RI7MJ?@KJ_@3Q|X?U:W/Z|X,U:SU"ZQ|EL;S398Y
MIF!_*F^)/!_C#P7|/':>,"FI:3-,A>&+5+"2W9U'4@.!D9XSTK M^@/XP_MV_L|S?\\\$U/#7_
5ED_9GTF\\5_V:UGXVDC,@(-MR/-ANT3LOS% 6"*<#ZU:@^&'Q.N

M;J^L;X6Y<'S&"^8JH&N,@'E<<^@ \ M!/C|N_P=_P%%OV/_C)\0]=^
FD>_%&N@>'6L_\$=H5L#:ZG&,*X>"2-F->M@^>#&Q;8"I#MN(4_M"HGS*.E[%U?
\$+'>QEBZ>&00Y^7F;U;O;;<_GZ5MPS2T
MV/[INTBG=N;|C<_5L/4|M0C/NKE|PY_R%X?Q_!|KJCGH!7*^/^00#^/_*#7 M55|_D_ \
EZ_H?Y?2E_Y+:E_P!>U^9|^?^!|C_(*F>&_V-?!C_*3X*VV MM:[XK\>V)L=8W+%Y<,
|1P2+(^"QV !D4<99@<9S7U9_P="1/GA,^I58+W|7;|4C\OR/%5L;PS7I5FN6/*EZ-G1?"
M/1_@M_P10_X)F6WQXNO"L.H>.?\$.EVTMQ-<1!9KW4+A-\5L2?F2*, 'E?|D|S
MOY#^P9_P<'_\$7XP?M%:=\ (OVH/!NAV^A^*+_ .OZ;?Z7;LALI9'Q\$)-Q.|_Y
M4D<|=-J|2_X.(K:7XA_\\$/ "WQ#\#0-?: (GB"RO6NX%PJ6\T),&/ =O-+J|
|XFLTLD@#;M_FJ, RG, L/A, -I32CHEI*_YGW1_P75_X)^:7\.?VQ?!> ML__PO':6_Q@ODL|?
2|_.\$+ '_&L9TB944<#S/.C8CIN8UIZ?'3OK9?^!|(3|
MCWPC\OV4O@@WBCQ9>%+>UT^QL9)#A7.I1R7T7QBL9+F+S!NVG4-, ?'H2K
>N#Z5Z;_, %;_P#@IF/^ M">'A3PW<>&?AEI_B3Q)XDIFF6Q.I3>7#:Q(H)D(7YWRQ48!
Z_-VKR)XG%8R& M&P|H|^*G>S_R/>IX7_X&IB\5?D>FMMKK6WJ?)%|_P7:_;
|^&7PA0:5^UY^R M-
<6=|JVGR6_A;46TJ2UM6NB&RLRRY!4*1P.3M)Z'C\G;F>_ \0ZS)=;-;>=>7U MV6\FWA"
|Y?'|JHHXR3PJc'8"OWH_X)S_+?/PO_X+"_ "KO:\\$OV@_@C|N:
M39;|8M(+YE^:87*85G4I M5?^!T^?A#5;SQ M-<3Z@L;PQ1|9VV(>7.R-C@=ZAW
XM2SJEB;|1-RO?M&^R/6S'^SX=JX3#T6 ME&UGMS;79^+FCZ'K'B+48|
(\Z1=7UW)_J|6SMVDD?UPJ@DUJWPO^*_J%Y MI%C\.->FO-
/VB^M8M'F:2VW*#^8H7*;ADC.,@<5|_ \!\$&"WNO^"E'@"VNH M%D1FO-RR+D'_
\$=^U?IC\7O^"I_A/X+_ /!4F'|B#P|^SQI#6.I:MI=CXE\2 M-
&! =3W=S;121NBC"E\$BDB7YN<@XP_,_5YEG5?"XIT*4.:ROVT/A|JX>P^P:
MKUJO+>7*M-V?AGX>|>-/%-Q<6?AKP;JVI369 NH=/TV69X0I<6|U"TW_!1_X/_P#!
M+;|H0I0@M+_ -ES19;3Q!<)KGCK5(X5266.:1MX@1WWAQ
MO%=AX&UBXTE8V=M3BTN5|=54D,3(%V@_@YR>,5'="^&6G^'X?%%_P"\$M3AT
MNX(%OJ4NGR+;R\$| LA7:2<'&#S@U^N7|=O\ P6,L/V(OVD+C|COX,_LL>\$)O M!?
@|;>RUJ/4K=PUY\$<_ \8Z7O_H*4N,O^13_VBO#W_D>?|NL^TOVEO\ DB>O M_P#7B?
\T(5\1U|N?M+CX):_P#|>)_| "%? \$=>)PK_NLO7| #TO\$K_?J?H!YX MJYX=\2Z|X1U>/7?
#NH26MU&K":./&1D8/7VS5.BOJ91A4CRR5T?FU.I4HU%. M#LUMZG9-
^T3\;!P?'EU_WRO^%>S:Q^T;HG_"A-EIXZ4^)?|_C^Z|SSLc=_#
MCUKYG^HHP!_#7EXC)\+7<;+EL|Z+?R/HK027\$K>@?)8UD|XKE_P!GOQ)HWA/XM:?
KFOWRVUK"LOF329PN8R.WUKBPI_NT\$ \$XX_P"^ M;JGEI.G@OJH-5C^-
_&/AW4/VE+7QC9Z|')IZZY: M3-=+G;\$61"S=.V*7|H|QAX>\:??'"7/#NIQW5JNGPHTT>
<9#,2.GO7F^/4?Y M_P_XH"8XQ6<,KIQJ1ES/1_)2_X|!O\8?BSINK>* _M6I_#?48|2O\
39)5:WA8C+,(0\$.<=<,*Z;Q=K'PT\;C%>^ .O@IX@EUB%0DD
M<.F.T;,.B>8#M(SW|5|TZ5JNHZ#J4&LZ5F67|8OQ@ MM+1K28Z;<.RX6>2SPZ"4;6
R#SR#FO)Q62U8|GJSZ3+>*,+5YWC M':|K*UUHM_)G"22R60?
NOW1RH|0"0N>GTXKYU MK8\=_ \$?QC\3-635_%^J&XEBC"1*J!%1A\SQ)FE+-
LQ=:FO=M97WT|A7F/|1?W|'_L_ \M.O3J|Q:++^_H_ \VW_ |
MIU\7XJ_ \D77^7YH\O!_ |PCS6FL >,4ZCWQ7\8IN+31|G:Q|= _LA_M<=">\^\$
M\$O|_P" T08X=/AMFBMkJZ#/'<0,Q_=MC)4KP!CL>"*[KP#H/_!|CX:O#\7
M/#_CZUN;|H|Z>LE9VAX((6,#*<"S 5\ \$D9_K2;3T/^? _I7V.%XNJTOHSQ-
XP_8>_,M='U/X@^)K?2|:-OM_>77V:2 M+ +-&SL-N 0<9//;TKX""GJ?
\\4%3C_@.,|_ _J|6&%XJQ5&<_,152,W=IK M2YGAN(L32E/VL5-2=VGL?
KR#5+RX\$T'|F1F59& M78TSR8PQZ8QU(XK9_9+^ -G|)'P<^#FCVC>-=-L=:O=/AN-
=:17:5KID&\\$|3 MP#P_!CCUKX|.D)(/4_Y_P#U4F#C"JZZ?
&F)|XI553C9*T5;1;| #IAQ56CB M?:JFK)62Z+7H?H!\2-:_X)X_%CQ3-XO\=^=
|_ .^O9N/,DNI*,= %&,*/88KY"
M_:BTWX.:7\5)K;X&W,,N@_88BC0LQ7S>=P^;GTKST;QSNL|^IO9IG? \:5-Q|G%.|
|K<^E/^">OQC^'?PHT_QY'X^ \40Z<=4L;.. MQ,P;|Z5%SNQ@'D;U_.N;_P""?
_Q)\%?"SXV3>(O'>OPZ?9MI\$T2SW!-.Y9<# M@>E>'@'| (X8=#D\3ZE(/@KH
MY(D7|XI?)5FVXQSYE?'_7|.GM75?"XT? \$+X&^)F\5
M_#K6%M;R2W\F820I(DL>0=K!|@1U_.1@^ ^":| "SZ5
M.I%3TCSM/\$GP^_9G\40^ (+F^ \UKG5M|EM;:VRQ+SDN
M=N>N|C))XZ5XK_P5A066I?'_3|)%@96DT_P|&L_ER E&:61PI ^Z=I!Y|8/<
M5EWW_!33H:|T=--@DT&WF7(_M""2_WS9SU#.4X|E'X|_ " _\$ _BCQ%XUU^Z\5
M>*|5FOM0OIFENKJ9LL|'OZ>@_&!P.*|//N(L|BO|DRW_<*7^%?DC_6+(?^1+A_ M\$?

R1UWP&^+VL_+XU>%OC5X>MUEO/'^N6^HV\+-@.T3AMOXU^SGQC;:(X(ML_ \!
!6/X3>&|9_ :N\>S>\$|=T-75;>=I;>|M6;:9\$62-&\$D9*C'YX!-?AKC(P M.:<8.*K\$82.(DI-M-
7V))XBX3PV?UH8CVDJ=2&TH|Z|#|ROAA^VM_P \$:?\ M@E#%\%?
\$=|^_Q_XU;Q9XCU2WREK'-/+F<#OUKO/_@DU_P7 M)^?@S_A-
O@K^W|))'HGB_7|2UNS\1>29E22\B&%H?F3(#;22"1SD<5PG M_!1'_@JS^RG^WO\A
M8_ "+X%_:'_X4OH/BO+SQMJJFJ0R01WQ^9% "G=Y*KN/(M!)=3@::_)H|!/-
+M4=O6B.7TXR4G)O\ 0G#^5"-95:^(G4E%-1N_ ANMUYG| M*6J?\%*/^2-
|&)O@7IW|3GA_2?#LVE?V=|CT?|3;-%;00EHR1@|HOD.234+YF;:9D'E>3NQ7XO;
3\QI/ M+%9T\KA3GS*3N<>"\,?|/K.I1Q3R\=QDX_2OT MM_X*Y?MB?LW_=
!U_X)X_!'X4?"GXJZ?K7B#PV+3^V=-M1()+7;8B-MVY0.&& M.M?
F:%P"3UI4JCL1CV%=-U3#QJ2BWT9|MF&0TLP06'K3DU|W2|NUM3|'/B/^
MUM^SOJW_ ;X>#_V6M,^)NGR>;/+61/=^&U5_/B3^U|J7)^7;CRW5NO0UH?A
M\$|_VO?VJ>TOIO?;T/V>_95_ :MSL/CG_P3I) !W_@H5^Q-
X\|8>\$6M8L;PGXF\&^&WU0WB6QV(62 -|U4;0_ M1P"!WKZ4_9H\6_ OX=_L'_%N#X4?
LSZY\)?AKHNAWG|EWWC#37L|H6)I+:4S
MSR0./,0(YCC4ODL!QA0*_(?|E+_@MS^WC^R)X&TKX8>!%6AZSX;T52EAI/B
M31EF6.,Y_=>9\$T?\%BOVYOVT_!L_PW^*?Q!M=-\W5
MY)/<:+X7LS8PS*V<02%6+RQ*&X21GY568LP!'GRR^M*I9;7ON?#8C@',1F#
MI1BH47/FOS.UK_RH'RR0 IW84 8&,45|L=(G|C1H^QIQAV21>\.:Q"/<=_
M@UU5.*_OMC%(1D_ =HQ65T\7C*6(M'ZG\|X|.JV!R^KA06J6N^NA^L/_3/_P""M?
|._CS|FB3|AS_@H.|K#H|M MI7|G:?K5| TD%Y9_P0RA_2DB<;7Q_".A&:|F^%5I_P \$,?A
@G'XD;X|^!OB MML.I:U?6;76D^5JAU2>VBDQ\D*("(F|!7(<G.*_#<(I.&%.
|8_+)Z5YM;A MFC4JR<*DHQD|8IZ/N>SAN,*U&C"-2E&_
MA1XLTC|F'QG9^*/%5|#\$TUGI^J&_GU&958P(|RN8EC7SF!/R,L#SQ7Y7^&O^
M"DWI8OP^5^*/\$?PK^,NJ>&X_%GB"XU;4;#3V0QB>5B>-ZG&!@=NE>\$D9.2-
MW^|3L"M,#D>'PO_*H_:2ENY>1GF'\$V*QG+&D09QCLHZ6/KGX'?A\?7|N5?C
M3X7/Q'_ :IUK_ (1_ ^WK7^VOM B\LVWFCS-P"=-N: ^D?^"XW_ 5%L?B1_P (=
M_P##_P#9_:174?#&M^&|0L?&MAI*GRYUEQ'LD\Q >8V=>".#^7Y;D9.<4!<M-
_G\J<\BP,L7"O%6Y>EM&1'B;_E@9X;4V^;JWKZ'TA_P22^+7PY^""|>?@OX ME?
%;Q5;Z+H=BUS|KU*Z#;(|T+J.|03R>.E>F?M-_M%_!;QC_,%QE_:*\-?S M"RO/!
(:;>'|K_A(8P_D^3#|H'E*^"N|'O&RGCHKXC(!Y*TFT;<5K6RNE6Q4
M|J;UBXV_4PP^=5L/A8T\$E|LE*_Z'VG_P77_:%^#7|2|I7|AX|^"7CVS\1:3' MX7M|=
|ZQ#A%E#;2OSJ.1FOI#_@J#^W|X.^(|I9'|/OQ*_8<^(UMXPUIP_=7\$
M+6.EM)'YKSS0@6|H7Y9_&'MUK\G%7!/'7UK7^'?Q"9_ "?QQI?Q)^'^>NW&E
M:YHMXMUI>H6Y^>&5/@#S.0%."<8O_!Q_ \0|+PW^P7\?A/X3AT>XUO6;.Y&
MD+,N|2Q;6I_<@#JF79D.4BB0!4R>2<9/K_@VO\ ^3!|W_L=+W_T%*!49QS7|U?
&U_)@H_V. ME|_Z"E=G&7_(JM_>1P>'O_(_P"W6?:7|2V?
^%)^(/>7\$ _^A"OB.BB0\$X5_ MW67K^AZ'B5_OU/T"BBBOJS\T"BBB@ HHHH ****
"BBB@ HHHH ",C%-8KB MBBDY,3T!01R:=113D,*Q_:+^_H_ ;?_ -IT45^<^*O_ "1=?
Y?FCJP?^(\ MUHHHK^,3V@HHHH **** "BBB@ HHHH **** "FL)HHH 38?2GC...**
"FR M445MAO\>(>J_ Z,#_OU/_\$OS/R9^('_"/&L_ \84G_ /1AK'HHK^Y_M_W"
ME_A7Y(_UDR#_) \$N'_P1_)!1117<>P% %%% !1110 4444 %%% %%% !1110 4'& M.!110
4444 70#O_ "&8?Q_!|KJJ**^FRC_ =WZ_H?YX_2D_Y+6E_U|7YA111 M7K\PA1110 4444
% %%% !1110 4444 #9QQ1H;N6BB@KF8,68\A.GS&BB ME9"YF SW%?O5_P &U^?^&!
|W'_0Z7O\ Z"E%?((<9?\ (J_|>1|HX> \CS_M \$UG_ V0\$! end GRAPHIC 11
img77546233_2.jpg GRAPHIC begin 644 img77546233_2.jpg M_|C_X 02D9)1@!@\$
W_#<#_VP!# \$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!
0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!
0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!
0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!
P0%!@<("0H+_ \0 M1 @\$# P(\$ P4% M! 0 %| 0(#
01!1(A,4\$&\$U%A!R)Q%#*!D:\$(T*QP152T?D,V)R@&D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM|BYNL+#Q,7&
MQ\ C)RM+3U-76U|C9VN'BX^3EYN?HZ>KQ\O/T|?;W^/GZ_ \0 'P\$ P\$! 0\$! M 0\$! 0 \$"
P0%!@<("0H+_ \0 M1\$ @\$"! 0#! <%! 0 0)W \$" M
Q\$ \$!2\$Q!A)!40=A<1,B,H\$(%\$*1H;!'!2,S4O 58G+1"A8D-.\$E\1<8&1HF M)R@I*C4V-
S@Y.D-\$149'2\$E*4U155E=865IC9&5F9VAI;G-T=79W>'EZ@H.\$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/\$Q<;'R,G*TM/4 MU=;7V-
G: XN/DY>;GZ.G|O/T|?;W^/GZ_ |H #_ ,! (1 Q\$ /P#^_BBBB@ H MHHH **** "BBB@

HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@
HHHH **** "BO. &OQ>^\$ _P-GMX_B)\3_AYX"EO" MPM(O&?
C3PWX8ENV5/,9;6/6]2L7N&"8*K*?<"56TUS0?#UJX>N3P0QBU9E0\,RFO)QV?Y%EC
M<WU*+PAH5E=M&Q6-S-#XIU05X()L;P6T!
IE\$(WVH!X;^\$>@^'=3=T6,^*O%&JZM"03ABMDVA>!/ -4Y&UTU957J0P88^7Q_M'B?
P/0NEG M+\$3Y7*,,)AL9B.>SMROJ4.Z"D^BE5C??;4^PPOA'XA8H_P"K
MM;#0YE&4\;BL#A?9W5^:5*KB5B%)Z N%&=MK7T/V;HK\,M4_X*!?'O7X((+"
M3PGX2NF<,\VB^%WN5*CHC76J7WCZRJ3;!86\<@!)# +E<4H!H;X]^*88(KI
MOJXFMT C<22W>@+INDP]"6E\6_@^]:(G'IN5F0==I)KSY^*_#LN:.%PV;8J
M:47&U"A2IR;MI*4\3[2#2=WS4=/2[7K4_!7BE/?&GBM\$LI7\8ZQX@AB8/)?)
B04+J0LO\6&L7601AUPI&WGV%MI L9# \$8# \YSG:P)7B53JW6'RF5F MO=G6QD8KF?
1Q6':3ZOJN_EH="(*M)1>*SR"=[SIT,OE-\NCTG+%1DFU>W- M1LM'KL?
L\$WQ#!*!;_A-/ "K@_L1%K^ES-@#/"PW3L3CHH!)Z \$US\OQH^&<)
M6*_U"ZD3G(P\$R#N !=BVGLE4ROQFYD"F\Q<'G+/%#!%P3R06&>XZ
M4WQSCY\OL\)\@H-I-_M ZB= TG>-JE)NU^UGW6[UAX897%OVN/S*JMEI+ZK2:=
M_M>/D1N?;FN M30OVJ_ UJLBQ>'_&+SA-HT@J"!T!DZ_-SB
MN*OQGG3;Y)X:ES72Y<,Y);6MSRG9Z_-FUUVL>MA/#CAI17M:>-Q#C;F8
D(K^_J.MYW';,+Z(VTGNHD;J M;Y;4/VV->EB9-(^&,-M/A@D HX@?5K;/
1C#IVGV;N@.=P6X#,"-N"3VMZK M:72(SB_-^D4GJU="!#@Y
Y:ZL'+ +R<*.3UZX/"W""56%I';VP&K"V,_> M_P"0^X!
IXV\$GD;217SV)XQXH3<%F4XJ2>V%R^*Z?\O(82U)=-?KL%X M<\\$249O):=1HJ_-
C\UFIZ:^QJ9A3C-;W3@UY6/I:_P#VW_B09@YT#X>HXZ)- MX=\=Y!J" T>LNN0<
G('.,YSM91!J0!P^6!.Y0_M
>17&7%IJ99MIVL!!(^Q1RL5!&/F7PZ^3@8R&/S\$]@!7S.)XOXH3<5G6-5U MJZ-
2#MWO)_#?5WC&+[(^SP7A[P.]2EPUELFN5KZQ2J*+LT_=HLE=V:G-H M2OK?W?
5/VROVE))'FB\=V6G(N!7":A<^G5EM9FLY^<%8KM""5!(. MH6_S G=CRERV4/3-?
-8KB?B5-VXESF+>MEG6/B]>7[\$*L(+KHFD?9X/@C@QQ MBI<&\.2C=+F?
#>4S5M%=SGAZLY:J9*^JN>V:U^VW^U7>PM;GXOW=M\$V\;H/!
MG@C39P&5H\BZTBTAN5*JS'_R_*VR1,2(I7QG60VF?VC+Z0S7G[07Q MG5G.-
MA9>*] \$BS)M+\$P:3JEM"\$^51&A0K%\WEJH=MW#7=C>3'=:Z]>*?NQSW('WL MC(?
Q A&S^ \AR2O: !%9\$]EJB@F2Y0[CJ#B<^ M XAQ%_ ;YWG-=:6=7,\;56G*TESXF73TVNM-
3Z/'<*)X2WU7AGA["MVO]7R7+ M:#U23O["06NWFGEY;EY^TK\>
(@Q;I3XIH0<*!\6OB#"0><[LZA*/I@>G' M'*7?I47Q_#\$1?M(%Y\ C\$?QK)?
HS"!SA?;Y=VFWH7@C/S^&Y^>H%E;A1P0<2" _E5#D!;_&SQIP.>N;A1V'
8'D_42/18;5.ON--!Z=2",9YYKDJ9MFD-MM)9ICY*ZTEB\2I?=>JE4LVOOZ=2HY'DL'S0R?
*X2VO'+)\)%V>ZNJ*9T<_P 2 M?'5]"IK=>.O'IU;2E/,MISQ/K=W!)M=73S(I-2\$;
I'19\$W+\KHK#D C(N=8U M/4HEAOM9U6]A5Q*L5\IW>1K*JL@D6.;5-
@D57=0X&X(IC.&.+MTQBWB_//IORSI4X6>FONQ6NBUWT78T8_/WP
M]LV#^Q_Z"8X],_3(K9@_X_TA:T_Y<'Z#(\A S% A^G:L6&&I(XNE!?'I1.0;
M'G.+L\$ _3/Y8Q6K!;7I()O(" ?5I+ANV?^?
WGKTIAZ4HK9AK3A^T#&'4@>MKCD=/^7X^OY?IC)97;
M\$ \$WT8Z<(IP!;+O!;)YXZGBOHSX"?LN?&3]HC66TIX>:4TNE6 M!PM?%XJM)118?
#PG4JSE9-VC&[M&-Y3D_=A%.4W&*;7GYCF.7Y5A*V89GCL-
M@<%AX<I;\$XJ" C1I1NOBG-I;+(ZQOQQP M9>5W8*B1QK=N[.I\$!%)8D_#/%?
H^S#_P \$TO&'C-I\9?'H=X%*":UN[M;P#"J0^-?\$EG)9BZ0:S.MQ,/!-BT\UK!=6-S#-
XLE6#5]/GL/"MTNGZN_P"C M?L?
I#WPH_9MBM=:B\$GCWXFQB\67XAZ_;/!-917L,=K):^%O#[7VHV'AFW-J MLT4EY'?/
^(;A-1U6TN=>ETB[BTNU^T*_HK@WP=HX;V68<5N&)KIQJ4GI3Y\
M+2:2DOKU>#MBIQEI+#T9?5;QM.KBJ=1P7\F>('T@,3C/;Y5P,JF#PLE.E5S_ M
!%+DQM>+?WFE&J^*"IRBGRXK\$1>-<;B=.A@:U5)#OAMX:TWP?X M\$\,Z7X7\<
Z3"D-EI>E6XABRD<<3W=W,Q>ZU'4KKRUEU#5M1GN]3U.Y+W>H7=
MS=2R3/UE%%?NM*E2H4X4:-.G1HTH1ITZ5*\$:=.G"*M&\$ (02C"\$4DHQBDD E9)
M(_F>M6K8FM5Q&(K5:]>M.56M7K5)U:U6I-N4ZE6I-RG4G.3&?[00J](I/U35OB#-
X9UZU63+;W1_"/B&!50LBRIDW?E9\7_ M /@X2_:0\1M=6?
P=^\$'PP^%.G7% CIG^V>);K7/BAXNTZ].S.H:=J!/@CPY&H M(?R[75? FKPA7
=Y2FYOAY9X5\>&/'VH:A!;IYDK:9INLZG9W M^ILJXQ%86US*[J1HSNJG^"7XK?\%\$?
VW_C1)*?'W[3?Q5GM;BQ?3;S1?"6N MK\<
O#.H64@C\$D.I^%OAK;^\$O#>IEQ\$N^34=)N)CF3=)F23?;J2>2V,\ \$G+9 MSSR0-

P8GG.\=|G&<_GN9>.^'CS1R?(*U1?9KYEBH4;-)6YL+A8XCFNK|8R/* MTOBNTOT'+/+ ?
\$2Y99QG|&F|>AEN%G73NGMBL5/#\MG:U\')RNU|K1<_1_M^"WO|
G@6\$G0/&OCKXN7D=X|G=:?-OAYK<4EKY4DD\$|!B\$>V4@?
9|7XB_/&O_'RC2#R_P"76W9>6.YS'M+ '#J.0"DJ_M|V_)Z|I%&, G/3HK253)@%6::&\$J
/*#V239|LW9R,ED0G@'&V!4MN5%|DW#_RQ0:&FM0^'_:U.!Y M=E;Z##9HJA4MT4_#Y
T^2X=HU12D_66\$|8TECP1CR7FDW\$|HMC DYX7'%=MI9_MD*RB%@R2'\$MI_)GGA&
"XM8WTS?@|EBDSGO@Y^ S+B?B+-%+^T,|S7%QE>|* MMC\3* @E)=#YK@?
=M|2L4TN)AO MD>9*W SD\Y|0T5UNYFCWM=7R*-T%S##-
)%&N&4P:I8P:I=*Q'"I0W;())KQ
MK2(X0L;EYKFTM@Q\^U^RP75HY'(F@|B&^PNO:/_LU^L6HPM>,\$'V76|.ANK:Z&
|HAF,0@AF<_,?F!!!YOU7'JX.5G'WE%M MQCKNI:-
/F5W&Z5EI*D|VUSRPPZ8\MK>,I^VVL MY J,3R56WGUK4|JDM@*E@>!PA^Z?3M-
VS7D,236FBW M:)LD#,UJT\A)R28-'TP2;FP#B\7)'# GFRY\H@W6JF)<\$+NFL()-F"-
M6'RX('\/V6_E=15YV;NU)646DK72M|-R=KU(3DI7UCK8^-Q\>5-VBVE|K33<
ME*U|2DVZCBKI4YQBXVMS)GJL_DN9(%U8W=O#"H07<5G>7-J_W@',|:M?0XP>
MIMRN"-P(X/I&GPR7"1*%75+&_B6RET:;544*"6B_LZ&<="64.,\$?>' KRWP
MR)K=FCL+V.|MW.'LH%@+1*3C:8-3NX93CIC9G+9'4K7H6D?8|>|S;WLME=DY
M>VO_-.CR,<*=|M;W41|A2'(..2<9'V&#DFHR::YFE*3G%MVY6DI-RA577E4%*
MH)=SX|&HN,7%\B|UZYNYRCY/0)*L)+>55MK"\=5 !-E?SZE&P
M.56N;6YDF8#;=6URVH0<|G*QFV8_GEO7HV2!786J3,B^7#!.F!@&W\$\$\$B|QQ=M-
.#@=:.^DH-M=.9*WNI|:6|U^|K;VB^7K:Q\W6LK7NT|U*4;7TO|T=?=?;RY MO.Y6D=9&
(:6XA#'>|!+DGC*1MZ\8*GGK5.\MKU(M74BVG=-
Z;KW)+9Z)WB|TO>UBZ,K.#|V,;Z)KG@|>: MY:D;WWC?
=Z7.#GM+.>5C+83Z?;#EGM)U2'/8X>6TX((/08##L>>?\$KI>\HZ,_OGRD C;D ?=
MQ79WHU"U8AX|=9,XVSA;R(>8OS#.K++:6FXC)^UV%Y" MQR2?
F9+7;P1G@C&1UW&OGL1%6:ER-O?VD.63:M9<\6I|;=IO3|OK<))KE<93_M4+)KV-
7G@MM?9RC*%O1H)6M;9>>7UKK,&?L^I7URF<@2VUS,,#C'RD|NG<9^ M4
Y+,1RMU-<+G|?91R#H6&B7;G"<|1P.^ NTC<<*M=?J>DQOEX|+2\|08|2 MN;=ASC
\$JQX-' /&W!SM!/'7\$=|:D|+9D_XS#JUO-V P!+T5NFWU>\$<9Q34|EHG>-.G+
|.)N^G\GR> MIQNI3^'9_5N+\$QOSD_V;+\$N3D=)' (!.,GA1&,5Y|J-EX7E+%&:)B",B:*
MW("=COFY.2#NZA<#!:6O4KW4+A_5E:XCQN;+1Z;,N0=N WVX'T.X9P#C_ZUQ&
MH75O)N\$NH649/_/;3+-L_U17+;>UEM*Z0V1TP^9\N<<9P,GYL&N_U)-/EW?A330&W?-
M_MDTQ0<#DY"2NO&">N!MZYX'!ZA:VI8E;|PR@MTNT/ ZI?(!P!K
M/M@UA7\$+C.96)YP(?M.^M-,TG2-)L-6O\ 4|3U&^G2VLM/T_3|_9KJ
MIOKRXEC@M;6VBDN+B:1(HHWD8_37|+_ .Q:7OVH=2BN/"NER>'? %O>16V
MM_\$KQ'9M!X=M_LD@N|;1(EG6Z\5ZU!'#,ITS2_UO:W;V,.OZGH%M?V|Z?Z0_MV:OV-?
@S^S%I<+^\$M&77?',UFMOK7Q\0P6|SXF0F<2&ZM|*(0V_AC1Y6E:+
M^RM&6%KJUAEUR|UR|M\$U!OTK@SPTSSBMTL7.#RS)V|O,<33DW7@K)K_X=N\$
M2V|KVKE3PT6IKVSJ1|E+|EX_P#&#AK@B-7!0FLYS^*:CE.#JQ4<--JZ>9XI_M*
<,&DK/V"C5QDE*#^KQI3|M^T/V6\ @E1-JL6F>-_VEFFTS3IH4O+'X4Z_-M?7-
KK5P/M2-#_P)KKMK/NT>WN+.*1I-_V/S_P!MK'J%|HWK_A|5-.OM'D_<
M/PWX9\>#M\$T_P->\$M!T?POX=TJ.2'3-"T#3;/2-(L(Y9Y;F9+/3|"&"TMQ_M-4O+*
|MN45_4_#7".1*8;V&4X2,;LX1CB<=6M4QN+<;. M|:O96AS+F5"E&G0A*
|A24FV_XJXPX|XDXXQGUK/,=*="G4G/!Y;0YJ678%2T MMA\-
S2O/E|V6(K2JXFI%*-2M**211117TQ\<%%%%%%%%!1110_4444_%%%%%%%%!11_M10_4444
%%%%%%%%!1110_4444_%%%%%%%%!1110_4444_%%%%%%%%!1110_4444_%%%%%%%%>
M4>._C=\/_ARMQ'XE\56":E;"56T/32VK:R+E+4W45I<65B)CI?
\$XO"X.E*OB\11PU&/Q5:|6%*FGJTN:L>,H+RY>U>V9;L-
X=T2XBAL;FVO'0079\0:O9O%\$7GM%_M\W9'^6WQJ_-:(^_GQ/MKNU\9?\$KQ%>:3?
\)_EXU,D_MUG&S^7'^-/B.W022,L;R,Z2SJQ(E_NF?T3P_|C@7*J= M.OF?|H<1XM*,I?
7;_P!4P4:D97YJ>#P,J4^6UN:GB\5BX35|QY79?1OQL_X*_M2?
MH_%V6Y34_C1XA\\$: *US=75KX>^%;|V/+&RANH T@:R&K>'9;+Q-K^E%%.V MU\0>+-
>,Z5QEG;/YMZW//?7-
Q>WMS<7|W>W\$MQ\$G+NR7MP1G)R9EP/O/\$\Q2';!,'_*TBX.U@H) #GJ#2IN|FI?
+U22|H4NU|KN<&(6OE00_/96|=U>Z MN|VOB, I/!)&">H!|YY""H-F.^3G-
-7GMGOMX#\$#NK%22>_!ZX'H^3;_*X
M*D#9@DJC<%D5FP<+ST|XQUR6*3PFYY|:OZ6>G39;Z
M/;:U|UHFCOM|H*\$E3O;"2LN_:0?N2+*6')X|5A@G.>F.@MIOE<#!=""R6I+2_MPR+W,(

9HR1TVL O&3C% =D@#+\$+DCZG)^!>-N(EAW MP_P=Q5GL<7)PPKR;A[-
LT6*FFIOPIP6\$KJM)0QEFPA)PH!R23Q7Z)EGT7 I\$9U" M<\\%X,>(E-
4Y*#_M/AC,LDE)M)WIPSJCE\ZT">5*,XWT;YM#X#,,?I2?1UR2= M.&.\?:
#JHZD;K^S>)\MSN,4FDE4GDM;,
(T976D*LJ&S@F0##>57923P#NS7I6AFU"3K';Y(9#J\$4_D-O8Y!DML
Y)!/%?)\$/QDL;38;+0KAC&"\$=KBVMXGP!M,UG-; MZH"6SEA%=1!#JW=WZ&U_:%O;9
8/#8@D)S,(M;F:UG(4@>;8W6G75MMR5+(B MH" 0-I8,OW>
^@=J*W,HT*E/PJIX:C7Y/WF8<6\"X&5&,G\=?"8CB>&.IJ*= MYP^K.LK-*%I\7C?
V@/T1\IE7I5_%JEB*U!3?L\OX/X^S"-:45\&'QF&X6JX M"i*?#JJVD5MAB 5M-4L8[>XCP2
M=A+9&"<\$XJETUYOI&F\?V=@<"6&X2?Q/IB9!.XW*QW#V_)!/?((I&!\H_+;
MS_6\9V,S2Z=I'ARSR=I5(I7CC:,YPKPV&KV%LS=RP@4,>=@)K?_&J_B,O
MEMINE>"M&FW;I+C3J\$O9I9V!'S3#5=7U.%R,'I\$H.Y@01M" HN5_LX?I,594
MHU\NX,P,9RBI3Q7%F'E&CYU%@,+C*CAT<FFWU5V?G&:_M/OHKX>%6=','^,
M,PE3B^6&\$X.Q,9XAM))4O[0Q>!I1F^DZ_LI6WC9)_KIH-S%;3K=6-L,+21?W
MD>BS65S;[LC*G2[FY%U&>@*B(\$8QC&?6-"1/M7VRQMKBI[DE 9ELY;_2[PDG
M)+VLMDEID=2%FY&,-CD?A2/VK/CL9(YX/&PLI8S\KV'A_P-6H'.<>7%I B;
MCC+1L<'DYP1H'IK/IH&5F,GQ +2,A7SSX6%\%"Z_./N78\."Y1O\ :256&,@\ M5^IY?^S.\>
(^SJM0Q7X3THJ:E*A ;G%U2I33:YI4X+@B5'F2;Y8<JFUK4C>Y M^1YG^U:^CO\
O%1X.\9*TW"48R_U?X+ITJDDKQC4G+C^~;E;23FZ5TM52>Q_
M0HSP?:E(BL5NV4\$VVM"WMIC(/)-Y#J1=B/4P=><9.*I.TV:0R1(@>UE("V
MR_VO9ECR/NZ3^*.1P)R1JTG/(_F0G_:5^/ES,)O^%N>.:1^QTK7+K15&6+?+
M'I#6;A_M_"HPH51\JJ!4D^/7QRN'\$TWQF^*LDF22?T?+_ -FGXA0@GB?.\$?
@RE4T;CA!\G=>%I.;U6=#"U'ZJ.\$I'R*[M^
M59E^U>\,G4<=>)X6<=UJ2IV\3F608:I.WNMTJ>)QE/9:QXN\$X.R66WN !Z;K;
M.\E&".I8\>N_'7C;5&\S5/&/BK4GW.=I_XAU>\8^8\$GS7%W(?W@1_/S! M5#9"C'V&7?
LVN(V_^\%#Q4R3#+I\3X9Q^.=DD[OV^;9=>|U=-O=V=M#X;?-VK_M_"L-
6U7OCB+ZXXK&NLT!W&UM9^<'=;V|<\J5BO6R#SZ|L|#7\>LM_?7!S<7
MEU/USYUQ-+G=H.IV^I_%Z|TROH5^S2E4BG/QGA"35FH^'3J1\7XYI=NW5_MGR|_
&MT:\$[0\ 9U(7NF_%14I/9ZK_B'59=;;G]=%T-1FP,<^@ (P#[\$CS07-
>\.VX9;W5;2QD5FC'D;:W5^64^-ZR7
M3I+MK>|U;LI_M>Z|E|6^C|1H35VI3\4IU5=6UE&'AU00MJN=7?16U_HOO/\$W
MA)*X\8^%PL*L|J3>(K& I&%+LS_&S7W5_%&XEQ@*".G-<=J7Q\$\"*@23Q+
MX8G!R%DA1>\$;A<|UN;DG(.=O7;D=J_*T)Z>X/ZD5T-J0"OOQ^@'|#7'/I
MFCPI"+|KXL9W*5M71X6R^C&3TO:-3\0XW>OO-I.S;W??3_:\<62DG1\$N'8
MP^RJ_&>9UY)7CRWG2R+"IM+1OD2D|NR3:/U\O?&OP_N'8?\ "3Z%"Q'W9+SP-MT2#
I'^0KH|4X)'Y>V.?YUY-7|FGP?&[GXG<23>OPY%ED'TLU?%S2Z: M-/3J>|0_:\?22|EX.\
(TIV24^),XJJRZA V&FV^MHZ:IGW_?>*--C3\$6N M^\$YT)P#%XP@C.
<'!&V>\$X\"GMVPI(X;4/\$5O)D+<:9-D_\ +OXQ5P0.W&JJ_M<=P0,DI,KS7RQ;'#+
I9_/'\ _P!;Z*U^\\OU_J?A &O(K_LVN"DG_;;+XJ;3
M: Y%&3I6TULW)N|T>K|V/8P_|7+Q\$E:WA|P4MO\ F>Y\W|F|NHI*WIZ|3UB|
M08)MW\$C;CSY>OM-D #NNL<^@"\GN.F>=N8(9RY\04N1CY+J27(XZ!=5(IZ8/
M:I0,FLFW/3Z#^1_PKH;J2=QMT\"?) /3G8^>G48'U|^S6W)!SNS;78M+BU\Z8);:Z\27L4
M8WEIJ&M65^MO:7'RF?A T!/?#7AO+ZN:9SXJ9_E^!H.TZ^)R|*XQE)IN-.E".
MG4KUI\LO9T*,*E:HTU3IR:L?7<-_M./%KBW,Z&3Y|X+<,9GF6(UAAL)FV=SE
M&"E",ZU:I*,:6'P|-SC[7%8BI2P|%-K4A%W/S,\.?#'QUXMURP\.>%_"BO
MQ#KVK3FWTW2-)):I=7MW*L;S.(X8=/D)2*"*6XGF.(K:UBFN;B2.&*1T_<| M|DI_()-
:7HC:=XZ_?>VUO5XY+>|T_X3:->Q3:#8D6RR*/'&N:?L_MR\@O) M3OT'PI=CP^KZ?
&;O7/\$^F:EWU_/_%P8X R M/*F)RS\$YQQ%@,.XK!/B"C@/\ "I4A*7-B:N
PBG3E"7NJC0Q%:M%1YIUJ?/. M-.A_4&)^D%XG<1\,TL)FN#R+A/,L4I/'KA?\$8_%5*5*
<8%/ FDOKGB_7M.T#3%9XXY|^;)=W"6UU| MBTZTC\$EYJFH/VUO_-#IVG6IU?
3I#*8;>38V/B3QG^V+>ZM+-8?#;2QIEBI9#_MXCUR."?4)54PGSK'3,SZ?9*I\$^R2^?
5OM\$#+YUHEPA4>+FO\$.4Y,K8W%15> M2O#"TK5<5-
/9JE%^Y%I*E5TZ;LTIWT/H,N6IC:UZ.#IN MIFG7DFJDTVN:E0C5JI--T^74^[M7UO1I
M/MVMZG8Z59I_*6XO|J&UCDF,K!.^RYM9H-(P12""I'M',?
BBY\1ZWXF0GU+7M4OM;U"0 M%&N+Z>2?
RD+O.+:WCDU2:C6Q#26H+V,+|5R5&G:U3>_M_P"F99X;Y=A)0GFM>>854DY4;:EA\
(FI/I,EB*O+TDZE*+UYJ335M|Q|9OB M/XO6XMKWQ!/I^G2I.CZ1HA?
2=,>"XB6WGMKE;9WO|0L;E#M>+5I04K8,\@4Q

MH[+7ROK<2D,#EPI\+D1A>24AW[Q';S%%/E,9YX92X4Q9RI\AU&(D?,1R3M7
M@*7+#A\$MRZR*6.1;SC*KB1//B=<'3Y+NRO\ 0_#:>&O"CZH!<""PO)?&4V@:[%#<.%-
-PA>HBU MBN1-:7%[/%);5^>7C_\X*M_\$O7KFV;P+\+_3X2LH[9HIXO\$NI:WXXO_-<
MOYD=E>V3>"[6+261DVZ7J6EZQY)ZS^T%X"B MN9H-,M-
=U..UN6FL[N.RM[;SD6.;&2*,75[;WZ0;V(99K1#NC(5'C(=_A&'I MQ_SV-;L9S^(!_P
_G7]&\+_LXO_*HPJ9[G/'7%&)]FXU(5\URI*54L?
3FJ451FJN;8B\$U.I4C"G*4/9_S3Q7^T%\9\RT^C;OXWS7,3)9^ M'8K60,YMY)-2,T:
(Y8LDT,=C!+(;[9=PG;"H;H5Y:Z^(GB&\&\$%A9%6+*U MK;.TBECDXDO)KMOC&-%(
'(&<\$>;6MM5%))DY?@;%.>A_(UZ M!X?
^'7Q"\3N(#7@3QEXA=Y!"B:'X8UO5G:8IYHA5;"QN"TIB/F", N8_G V
MU_0&0_1/^C5PM[.>%\^*%JBI5)5^;B*MF/\$L.>5-0?M8\49CFU.=+E5XT*D
M7AX3;JPIQJ-R/YQXC^E'[(GB7VM/\$^)^O\$U-U::H*.04L!P[-1C-3C[.7#> R
MNI"K=V=>G*->4\$J?-ZE1WL?![W[<8VY_M8S_:N'&#GIG;XO#M_P!B?ZU^NY%DGA-
PG*A'A_*/#OAF6&A4CAXY/@.&LFEA MU-OVL;*P5+#.DIRE+VB@H\\$,>WK[?A
UJT8CC;[2/S)%?3% MO^PC^W O7[C7]JP?
7[GCXNC^]Z^\$*OI^PM^VX@W/^QS^U0JJ9\U1<8]Q_/FM).I'M_G^=>P7G[, 'I2VDQQSZ
<[,@D? MRHIM1^\$OCZRBDDV%O+22YV/QHSE5=@@);.I;& 2.%U+P5XST*1([<\
(^)]&D MD,Z)'JN@:KISM);%:VYHQGK[X\ZT4Z ^F1^)(-9D7
M;=]'*TD.0/=O_93[H_'^=9Z_='^>] M7TZ'Z_T%=4/_)+_-M/\$KK?RM?
SU;+2]!;!_*KJ="^_P">*HK]T?YZ<5=C
MY!/J!_6NB'_R7_MIXU;1R7:WZ%VK%5EZ#Z#^56%Z#Z#^5=-,M^KT^[\^OF>;6
M^+^NR+EL?T/I#706K9Q[@Y_G_6N=MCR1[@_TK?M2!M]^/QP*YL3U_K^40#[_M
#_R.DM&P3^GO@YKH;7JOU'\VKF[0\CUQG\P*Z&V/(\^H/Y\$?X_K7S^)^Z_P! ? MRGTN\$?
NP^27RM^B.EM3@C'< ?X_RQ716AY'T_F!7-6IPRY^OY\$_XUT-KRR_4 M?
ID5\ _B>K]/T_I (^EPDK)7Z6LO/S^_6WD=';GD>Y_P-=%;GD>W'YD?XUS5N M>GT'YD'
_M716QQM^HSL#_KY_\$[?Z_E/L(I06WWVT^29TEN<\$?C_,C^ MM>A>"O"?B?
QYXATGPEX.T/4O\$GB77+C[+I>C:3;R7=]=R)#+<3LD48/EVH: M07%[?7'Y="^&OA{)
<7P@;??\$^JS#4_%?B*:W@A@235M7>*+9;CR?M\$6C MZ5;Z9X?L[R>]N[#2+2XO[V2?
^;O%#ORX:X'^L97EJ?;\$^L?;4WE^&K+ZGEM M9-
13S;&0YE3G"7,Y8##\^;;ING7^I1JT0?U7X._1VXM00JN<9G"KPSPC4]
ME569XNB_K^;4':? _BX&IRRJ4ZD.6;'Q?>0N+2"YTJU M*^%%EM]1M+F7QAI=]!-
#^KMM;6UE;6]G9V%\I:6D\$5M:VMM%';6UM!&L4%O M;P1*D4,\$,2+'%%&JQQQJJ(H4
":BOX-XLXSXBXUS&68\09A4Q4TY_5L+"[+
M8&G)K]U@L)%^SHQM&9U'SUZ_+&>)K5JMYO_\$DX*X!X6\LKCE7#&64L'3< M8?
6\94M6S+.;L\$_W^88V257\$3YI3E"FN3#8?GE3PM"A1M311117RQ]D% %%% M!1110
4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 % M%% %!1110
445Y)\;/CE\,/V>? E_P#\$7XL>*+/PSX=LY8]*U\$F;C5==UBX2 M1]/0?#NDP[KS6-
8NTAFF6UM8V2TL;:]U?4IK'1M.U'4+3#%8K#8+#UL7C*]'
M"X7#4YUL1B,14A2HT:5-.4ZE6I-QA"\$4FY2DTDCHPN\$Q6.Q-#!X+#UL7B\55
MA1P^&P]*=:O7K5)*,*5*E34IU)SDTHQC%MO9'K+ND;:)(ZQQQJSN[IL%1\$4%F
M=V8A555!+,2 "20!7YJ?'G_(*(^#?"]S=>\$?@D-! ?^ (USD-UXQ=WN? ^D
M317'ES1:8;:WD\7W:PQR[;JQO+3PY;R7%E<)]JVL%+O2A^1W[3'_40^)?[
M3^H7WAOP]HK^?P974&^Q>%+.X=->\3VEN/*MKCQ[J5D)C49+B4R7J^\$]/9?
M#^G326=O>?V_]>C6NL7-[X%?LS?'?XLMGJ'@WX>;Y_PCUS#%=0^*=9CB\>
M'IRU>^,6.XAQU7(O#]
MIXS\$Q3G"KFM""5: ^+Q\$8R492R_""G*6&H6;3QF)A[9J=X4<+.\$:DOZ=X;\\$<
MMX;R^EQ%XE8[X5VA4I9-6QM+#X+#2E'GA'\8ZD88K\$=?J6%J.A>' +.MBXU
M)4H>I7_C_P 7?\$+6Y/\$7C;Q!J7BC7+E3&;F_N/,C@@\V21[&RMHDBLK#3X[B
MXN7BTO3;2RTNUEF;_1;9I3._HND7\O\$UQ=7\$<<4\$;7\$LK.L,\$,*,*)
_ATD>IO#='PIX,U? MXF:KJ?AYI)\$%QI6K^)-3^'ND^\$O\$<-
VTRP#5O!_Q(T);.*V>33Y7)AB[1?A M@C5^R!XG6I/Q\U/X?M1/-J]GK=A;_&?XS>
(M\A.Z%?V4%Q;1RZ-X ^!\7P: M^&T#2V]P_-
S+=>#KRXF3>&GSV52G#P^+/%_(\NB\!PED\Z=# M]U0G.M3R#
(J<(*SIPKK#8W,%&\$E[.DJ&1SP]11E.&(JZ=2?Y>?%3_@J1^QA M\%8+B"^^+
A\0]=MK.*[@\^-?""!?'UQ?))/-;0>(L.GB^'IE?V\D)N)=/U MGQ?IH!" XD_?0+)\G:K_P%,?
VZOC9#4/V*O\ @G\6/%7A&36;BRM?B1X
MA^&WQ0^)>EZI9&"01*]M/M,T+PUX4UA)7BFF%UX_P#%=E%&86\$GGK+%_6C
M*/V3/V7/@3?6^K?!C]G/X'_LUNVT]=+3Q%X" ^%O@KPOXFFL1 ML\-[XET

MC1;77M1:XA4+>3W^HW-Q>L7DO)9Y7=V^@J_H7(L!X2<,1@Z' 69<88V%I+<=
M9<1SIX-3MRR5/(, @P> PSI62<(X!YCRN_:1^(5IY:700&'O+!)V6E M7B_\WF;P#\?-?
^MJ@{&TUBUD}7-?T'T5X>-!9_%# 'N4J_&6:4W*(_J4<'E MJ2UUC'+L+A8PGK_ \$@HSV!
f1'H8;PXX(PBBJ7#N!GRRYEJ9>(QC;TTD\97KN4 M=/ADW'?35W_(JU_X(0?
\\$Hf.02P_LHVSN,8%U9_VAIV/@Y_U-f6IB(^ ^4Y MZ'BOIKPS_P \$U?A
@GOX2TBWT32OV*?V8+FSM<^5-XD^"G@#QGJH955_TC7_M !AH>NZI=\
(/^/O4IL,6&X?R3#N2M)T,JP%)M;V;IT(MJ^MF?, ^@_L M6?
L<>=%KRWU'PQ^R9^S/X^1WD?8@W.f M.R2 MR^.?@_\"WOG+.S/-)XL^'_A/Q%),
f212LTKZQI%XTC-+!#(S.23)#\$Y):-\" M/.9?V+?V.9VW3?LF_LSS-DG=+\"/A;
(V6.2>3R: ^EZ*]?#9_GV# MIQI83.\WPM*/PT\F6,H4XZ6|V%*M&*T26BV1X^)^X=X?
QM257&9%D^+JRUE4 MQ.68*O4D|WO*=6A.3UUU;U/C_P_3?A\$_/V(?%MFMCIJG[*?
P*M(%;<\".?#KP MYX)O\"?1M1\&66@: @Z^B/%0A 9QM'I7Z4T5|>\"!0\$++H.GE_'?&6
IMW=!/ <49WA8-JW&ACJ M<;ZO6USY_'>&7AMFD_:9EX?
<#YC4LE|3'<)Y#BYV5K+FQ& J2LK*RO9678_) MSQA_P12_8\$\2P1PZ)X
\":_#QT0JUSX/^)GB^ ^GE8L6\QU?W_CfV#@'8!';Q MQ|0"4+98^32?
\\$#OV.G=F3XA_M(P*>D47C+X9LB_0S?\"\".3_+ZD;I|<_MY1 M7TF#|<_&# TE2H>
(W%3X?+J6G:AERPM!/NU33;U;:/YX/\$O\ P;Y_#VZNY\&_M?
M*^,M!L\"3Y5MXG^'FB>+;Q!G@27VE>)?!4,IZY*Z?#GT%>=ZW_P;Y>(+739 MY?
#'|5&CZQK\"@\"VL->^#HXC20<,8EU(IJ^*M>IDKQ4E)*TI*O&I;533U/
MC,=| \$+Z/&/=:=3P|A0JUE+|Y@^).+<*J4I?;I8>EGT<)!O>L8O#RIHZ.FXW3
M_DPG_P\"\"\" [6J2%;3XF?LZSP#[LEQXG^)=K*W7|T,?PHO\$7C'2=^<^G/BWB3
M_@C;^WKH-W):Z7\ -O\"WC2&({4U#PS\2_UK9SC<1NB3QCK/A. \"@_?/L86P
M1A2V0/L.**^RP'TSO&/!S\$LSBXV|GCLCKTX)Z7DGEN99?4YG:S3J.'_* M>I%F7T#O
O'P4,+C3*9*3E|7+N()YX&^4X6>.-B,\$ M
AESY=J|/+|'3GAFRFU3Q'^SG\=M!TNU)^TZGK/PC\?Z;IT 4.Q:6^O/#\ -J
MB|49MS2A2JE@2H)K^ ^.BOK,'|/C50@LTX,X6Q=12_>2P&(S;+H3A=7C\"&(Q
M.:RIRY5;FE4JKF|HDM|H3COV>7_#J5'D_'O&&\"IN/HJ&987)A /,%M=6>TG3
>\"YBD@E7|P^:.54=*:M^S-^S?KUU)?:[^S|S\$=:09I))IKS5OA3X#U&ZEFE8O++)
<7F@S3_M/)(L,TCLY9V8LO)) -?2X7Z;F7UY2_M'P|OF%5ERRP/\$E#'.3:M+FAB,FR_D2
MLK6J5&[N]K7?R.*_9\YGAHP>5>*. QLN9\T,PX4Q&71A%6Y>6IAL^S1U&|>:
M|*DD| -7N|?P|6YR1|>/S|KHK)?^\"=7|%?BN\DOM3^_/A6
MSFEE:5D\.:GXK\ \$V:NS%B(MA&^(-!L((P3A88;.:%PB(JJ%'D/BK_@DG^Q
M|X@D#Z+HWC|P_HCV>5X3|>*J8;.)XF:WM)8-7MJE<^8Q?T'?%C_*I
M!/9WP1FL(2M3ITRS?\"8NK%NW,Z6*R.&\$IM)7<7C|:NR+A'8W|E\ -I9_M/@KPW=QS
MB|6/Q)<*P3QOJ\$2I:V|WH5!/R.=5L;BW\7V,IEJ47Z%_-|FKX0_LU^
M^%OAJ/3Y+N.U_M_Q/J3QZCXN\4W-K\$(XIK7|,,+S*KF:X@TJP@T_0-.N+N| MDTG2-
/0%W<+)|S7_^*GTE,|XJ>(R?
@Q8GAS()7I5TOWM*+G&/IW&1IUJf\$C_3'@U|\$WA|@V.\$SWCYX3BGB6'+6I98H.KPWF
6 MT>7|S6A&6&/@5X\$LOB%a:?\$|K+'X
M5MO\$US>Z+\+O!,+S163^/OB|XILHI+K3O\"6C3SBXM?\"?AQ+|XB_\$6XL|H2?! M6D?
8-*8>+|!>->O##T9UJBFXP5^6E3G5J\$S>T84J5-2G4J3;480A%RE)D)&V M'H3Q-
:G0ING&525N>K4A1I07VJE6K4E&G2IP5Y3G.2C&*;;/\$OVV?V^O@K^Q M'X.^W^_
:V/Q-\2|TZ6f|_\"+1|0A@|3>)V,LUK;ZEJ4WDWO_\"+>\$%08)X+S MQ1?V5PC-
:7UIH6G:_K-M_9\$GX8>?V40V|_\"FGC>T^_WQ|U!_A?V/-67|7X
M6U3Q9IU|IVE:3X6U/R;ZTL?A!\+ #>)K%SHCV4^FW-CKVN7^CV?BRQ1-4F\>=>
M)-62XO;_-/7#X(_\$|?@S|\$?\$7B7|J?|JQOU:~M&?M&RW%|X|<_\"IXPPZ5H M?@?<
P/_8TPU2TU'P5X,OKR;PA\ M(\#Z1I6D0:3KM|/=W?A:WT-IO\"=WX(\.R MIX9T_P'3?VK?
^\"|_,'_\"(<7.J^#OV8O\"I^ -WBJT-W9R>/M=E00#_P *= -OH
M@ (TFTRWC2'Q5X_AM|M)X+M+,>#|%O/(U#0/%NL6DZN?QSC+\"X+,8T\9XC9R
MLFX?A\VN7\ (X#\$2EC,=.#357-:N\$H6Q=.=:1='+T\ -@N: +AF\$6ZM:K^V<%8W
M&Y5*K@O#/) 'G?\$=2'LLPXSS#\"Q6#R^,UK2RBCC%3HX.AJY*OF+6*QZB_:9>X
MJE1H_H+^S|_P3F_9H^ -M8W\"Y1;.7=H7AK|/' MX7T**VO|1KO2|N'2|KQ)9+<-
:3^)+^.)E|'XT_M|?L>?L_7%WIWQ.^/G@73
MO\$%A>7.G7_A+P|>W/CKQCINI6L:O)8ZSX5\#VOB'7/#\S%TC237|'2|4R\$JU
MPHCE,? \&? _\"X*_M@_M0R:G9?\$OXP>(:7P?J@O;>7X: ^\")6\?\$#Z5>
MWD5ZNC:EH.@/;/XMLK&6.%;\"?QU>^*=7ACA0-JG-M7CV
Z\=,UV\5\7LEX>PSRW@7A3!Y?A8\O+6Q<(T55E&ZH5P>\"DJM>;U?UC\$ M9C*M.
f=2*DVC|NEX.9|Q-BHYGO_Q?CLRQ<|U#\"3G7E1C)Q:IT,9C8NE0IK2 M+P^&RV-

"%E[.3BD?U1? \$G_@OY\ \$!*/D?"'X&_ \$KXA7\$=S+!-=>-=9V/_ST
MB2!>..|TV735^(VJWD4V\$D2WU'1|#N C;9A!("M?\$_BI_@N%^U_XNDO|+P=
MX0^#_P_-
/NYW;2|ZR\;|XG\4Z9;&WV112ZEXC\1W'AG49S9*+M7I4OK4NZYL1+E=W%Q=C| (R?
P;X#R|0E_8_-/&U%:_|_J^ (OG/9J7O4 M*M7ZHK=>7#OYH MJ2:T?U%K'!?
O|=GQ(C_L|Q#^T1XULA_-;Y1)+X=^&MQ&4 M_P!)A,M|_M#\+7X=B+CS6CG9Y8H!#
(9(1+|=^S/X;_&O/VMOB!H?@A/C| M;|H_:V6|2>+?\$7Q%\?:MIOA'1--
N|87^I26%SXC6>|FU&*=(|_TA+RR36= M1FL+*ZNM.L7O=5LO)/A%\
_ \$GQ"\5^&/'GA#2C?>(->U_""2+,>4I>9GN|F
MDB@OIOL6AS0W3>)=5^R"QTK21=7#.ZPL1_5O^S?^SCX#_9K\"+X4(V<<^L M:M-
%JOC?Q7.A;50%GB_1%NKF;1|)8-+L0\MOH6CI;(73+1Y7Q-J5|JFH7_O M>'_#?
\$O'F9_6\YS?..F28.=/^T*V(S/'3JXQ_P 2& H5)5I24YR%?#T M2106=E%=%^(?
%&O7:R#2/'7A/2Y;BU&J^(|_FB>*SMY+FTL+.WBO-9UW4=| M.Z7J^L:|?7|?
G_!B^*M;|43+;PQ2-|B?\$>K6TGQ?'O
M%:X/X=KYI"\$*N,JU:>"RZG43=*6,KQJ3C.MRM/V5&C2K5Y13C|1TXT5*#J*< M?M_#
|A)|9|28?*ISE2P5&E4Q^95*M6H4(R:DJ:JR MK.\$U3<)?%?|:O_!07X|_MO>))8?
&&I2>\$A+L.K7FJ^"_@|X?NF'A|1PXC MK M&_|\$M|;V=UXY|4V|E"--=UN+
|+IMS>:TWA/10"UAK>H;:++4V>CM(4VIDD
M#=#C@|E0#SUSD9^I/K75V'A|GE5508;/DF24;49@27=#T9549#43P#_ *ML|0H7DH"-
L<1BE;|KCD|?XDS/-|?F^,K9AF>+K8S&8B7- M5Q%>;G-
VVA%6Y;=*FK0I4J<8TJ4\$H4X0BE%?W?E&0X'*<'0R|*|1P6"P|>6 ME0HP48).W-
*3UE4JS;O<>N:#X-9P"(6?RF5R IWM XY"H|P"FYV<|*HSFO30#?@*60VTHMSL<
MJ&VHJLN&"OL1E;#1GY49U&9 6_#CZ<|(? "_R98I'MPZ*JB91&61|_.=AARGR
M^8D,O(-S*#<:&\$ASU M9*|FU'2|M;O=)W_)7OK;Q/PK|
YY988Q'M=VC\$3^66!E!\$MG,\$"M)*DJ_NXD M'E1^7NGE=4%?5?
@3X17&HWNGV6G;:_NI5,4#06ZE08O#PP6\$+ UN"J(\$9#|_:+&5OW;:5\$'G M/
X7G:4GB"100M:Q2NW|1_LE_LV1_#ROB|?^,-.B7Q?J,1?0M/G3?)X(V|X5RJKBGRSKS4J6
P4 M:BC/%XBR:2T;C2IMQJ8BKRR5*&B4ZM2%.74_LD_LQ:-^S_X.6|U"RM9?B-XD
MM8I|\$>H9@NGT6UD6WE7PGI-Y\$@1_.LY+>|!1>U;RM5U*!+F66ZBM-/DB^NJ*
M*_L3*LKP638##9;E|1%4<+A::ITXJW-)(S|JU))+GJU9-U*LV DY3DW9*R7|*9S
MG&89|F6+S;Z|L1C,95=2K-M|L5M3HTHMR|G0HP4:=&FFU"G&;NS;****| M|P****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * MCS_X*O?LV>(OAO| MB>-
_D^FR#P3|_L_'A#6F-Q>0S:A|H^DZ7XZTBXE:
MTMH(|6TKQ\$;C5AIUO+=_8_#FJ>')Y;@RW-'KX'>"/VA_AGKOPS|
M=V%O<6&I'EYH^J:QW%_X7|26<>WN4AN+9=5T:|U70+ M^232=7U"VG^\$|1.\$)
<9<.U.OH58T\$K5J-5XJA%7 M4ZV%J48553:_>TU5HQ<)>5(U(?P_'^=
TTT4\$@@;|POCD!29A%LV;A(L44J(H M0QRW)P'D8/" 9-
^/H;PK|+I&EC)M@S*ZDJ|2LQ5F4?O%DM6R=|F&8R|4-Q-'
M&%VVSFOK36_V8_\$GP=|ZS|//&5A#'|.E31H!=P;+K3|5TJ0R2:3X@TFX,<" MR:=-
:&24EXK6>VG;48|86TU6"33X/8?"WPU|I8XFM0'MP&,"DL:O|C'E_)++(
MFTB1@2K(S|^)Y;J|+1_QYAN&:_L14HXVC5H5Z%6=&M0JQE&I2K4|LZJ=K|?
|KJ<29?|5:.)R^M2Q&'Q%&G7H8FE)5*=>C5IPG2JTYJZ<)Q: M:29K1,|3|1%?#"3';" &.?
8|O|KMMDP44,(A&=Q7,4A-O*|E2(443B2OI?PI M\55(XS;#S8"QB!0*KH
5FCD92,LJ*48|D)BV@W\$<-KA_5/#W@:*)(U>,F_ MO(\$,\$ERHLZ@R))
MK5|'"%*V4,@(:*V0!&U&Y1A((BEE9^4|SSV/Z7P|PC4Q>(H82A1YZM1I*^D(0
MTEHQC*5HO|VXFXRP^6X3\$8|&5W"A1C=I:SJ5'T"C2A?WZ ME67N*-U9|TIR4%*4;?
|-7|/L(3/'OBBT\$=EIT_VOPGIDJ%9KN;:|NJ7JO&@
M6PMGQ_9ZHJ3:E+&DTY&EVULFI_?-,CCCACCBBC2**)%CBBC54CCC10J1QHH"
MHB*JJH"JH %/K^F|CR7"9#@*>"PL4WI/\$5FK3Q%;E495);VBDE&G!-J\$
M\$E=RYI2_COB3B+|39E4S#&R:BKT|+AE)NGA<.I.4:<N:O|/3_.K_BHIP7_-
&YXH_+N5? (^O|/3^_"BOYHO^"*7Q MX^./Q5_:\$^*.B_%#XS?%;XD:-I_P:N|4L-
|>_\$3Q?XPTRQU-?&_@ZT74:P M|0ZQJ-
K;7RVMU\$2"..16_I=K^60%3PYQOA7QABN#|PS+"YK
MB<+@|!C)8S!TJU&A...H*O""IUVZBE33Y9-Z-ZK0_L+P;|4|O|8^!|'QOEF5
M8S)L)C,=F.!C@<=6HXC\$0GEV(>'G.53#I4W&I)>'?B#XO^%?B/Q'HSP^'/B%X%UK5=
+1^%=?M)X=0T;4 MX+W1;_2|2GTY=1M+:7M)M|1L6U00I=1T@WMG|M^U0|>

HX;\$X!X?&8R.7X M2OBL/1Q6/E1J8F."P!6K"%;%RP!|H7CAJLT5_" + |2/VA/V!A+X|6?
#3Q_ ^T?| M, ^'O&7@K6|W0-?TFZ^.'Q.W M6|
|92%?.MIE|4&& ^TV^A,5_I.J6CS6&K:7=6>IZ?<7%C=V|IG\$_|D?M>?| M1U/I2'_A|?
B= P#-17|LX;Z#W\$F,P| # %X3Q"X8Q.%Q5&EB<-B:&!S"K0Q&'K MPC5HUZ-
6\$Y0|TJM.<:E.I"3A.\$HRBVT)G^?V*.:|\$|*8'%8G!8WPRXNPF,P=>
MMA<7A<1F&64<1AL3AZDJ_?#UZ-2G&I2K4:L)TzM.<8SA.#C)*2:7|^%%?Q_
MLW_|%'/VF/@S|9?!7CWQK|9OB_|%;P/TVH: ^-? ?C?XB>+O&6EZYX4U\$BU
MUH:=IGB3Q%)86WB:QM"?4?#&I^;."TUNTLEOI+C1YM3T^|_M7|%,O#/Q\$|(
M>&?'G@S5K?7?"?C'0M,|2>'8MEFCAU'1M8LXKZPNA#3AB*-2;HN4L/B(TOZ-
|"/I#|)^/&"SJ>2X+&9'F^0UZ M,<;D>9U|-6QD|!B8)X;,-
/ #RY*^\$G7C6PM7EBIX:O2@J|80Q.%E5|I^//P-MT7XOZ)#=#%: ^-
/ #|4LOAS5E\$:-A/FS:%J3,)-.O74/;3,RS:3J(BU"VD| MDZA9ZA^?UGX5_LJ5K:
|M)+&|L97M;B"6.2"X@E@)|@FMIXGPZ20NCQ.CCS4&Z
M*625PTA_7ZO|OBO|'SXUO| #6| #DM;'5FFMK/63,I2.
|T_:X"A&6/2C#\$THQBI8N"Y8PJ7=DZ|&*46 MWK4D)1YKTH1E_:G
7;|JC_8F:XF4I*4HX"H|SG1:2E)86O*|E&/
MNTJ|<^6U:I.'S#|_OAU<=>|.J6RC|RTT:R,=OK6H0HN^&!V;9;6S.C0B^O2DD
M=MO1TA59;EX9TMV@D_0C2|,T_1=/M-*TNUBLM/L85@M;:.\$'9'&N3RS%D)|'8 MM)--*
|S3S:|TTDDL CNV;X6|.:3X/T6UT/1H/*MK<;Y9G"FYOKMU43WU|*JKY MMU<%%W-
A8XHTBMK=(6""&H:|SAW(:62X7WU">.K13Q-9*_M&J%)O54H/=
MZ>TFN>224(P^:XOXIK|28|W'4I9;A|8/#2=G)ZJ6*KQ3LZ|5;+54;:5.+;= M2=0HK|>?
^"NG|<5_ ^S=|,+'X/ _##Q#>:|+|?BW82SC6|&NX|35_A_P##J.YF MLM3|2VEW'*+_
\$O70\$MY;W7ASPGJ-G'|<6:VOBG6|.U72=<|/:1|)/_K_P-MD?M>?|'4_M(?
^'Q^)W_S45_8OA9|%;B_Q.X5H|71SG+>'.OQN)KTLLI9EA<9 M7Q.88;#25*IF%.-!*-
/'SQ"K8>@YR|H6EAZM50C0E1J5?X0|8OIC| #^\$?&5?
M@F>19MQ3F>7X3#5LWK95B| #A|+EN+Q476IY94GB7*57&4|)*AB<0J<53H+\$T
M: +G+\$1Q%.A_?A17|!_|PV1^UY_T=3^TA_X?'XG?_-17|D_|\$A=#_:H_-:^(M^J?
&CXJ_M\$?'_7_@I*+|:;= ^'9^-_Q/NM,|>_\$R2UM+^QT34M+;7I;350#
M/A32|VV|0^)^M/O|NVM|0OK_PCI-UIWB#P_J?B6Q@|GCSZ>9>'G" F;|79|Q_
MD\$*QF(G"C24I1A#F=:M*G0IU:D/
M"|.HJ95XG|9Y'P3PWX:|2RS+.L3|D)XBMFF6_5,NP=*+K8|,|=G2G.G@| #A
MH5:|5OC*|4Y(4*\$*F(K4J\$ _W|07QN M|&>%=(U#P2FD^&?"?Q7|>>?'#^EI=_#/P7?
W2:=HVCZ|9Z=9+)QU"OB*52E0Q^7 M8"5",,U-5)3S&%12?N|M.2>LD?N?
CIXU97X%|*Y9Q5FV28_/)3@Z4:>5U*;BO?+/^B|X M=_| #;F7_P EZ_T|/Y4_XJ*<%_|
1N>*|_#KE7_R/K_3T_OPHK^_P#X;(:_M_Z_I:0_P##X_\$|_P":BC_ALC|KS_HZG|H#_P
/C|3O_FHH_P")%>+/^B|X M=_| #;F7_P EZ_T|_#_BHIP7_-&YXH_|.N5?
_ (^O|/3^_"BOX#_ ^&R/VO^ MHZG|H#_P^/Q_ P#FHH_X;
(_ :|_Z_I:0_P##X_\$|_P":BC_B17BS_HN^'?| MPVYE_P#)>O|_3T/^*BG!?'_1N>*|_ZY5_|
(^O|/3^_"BOX#_|ALC|KS_H MZG|H#_P^/Q_ ^:BO5_AY_P
%+|VY|AFRKHO|17CG7;8SQRW%|H0Y--^)|RW4: M3I-):M>^/| #Q%JMI!.\$,C:9J%A3&?
09XXIX><|!QGPKBL2K M,)OW3^YFBOY^?V4_ ^"Y'AGQ=JFG> M#OVJ_"&F?
#V|OYVM|;XI>!(|4N?|4DAE-K'XG|*7|SK'B+P|;A8X;:37-+U
M:Q/;37|VDUYTAW2(+J_M_WVTG5M+U|2|_US0|2T_6M\$UFPL|5T?6-)O+;4=
M+U72|1MX|O3|2TW4+.2:TOK"^M)H;JSO+6:6WN;>6.>"1XG5C_+O'_ACQMX9
M9E#>+,M*"E"57#RE3Q>'C4I_6!N(,/FL<-R1S#+ZD*F#SC*ZE1/DAF&68F-/ %4 M(3E&
<*. *C" I@L5*E5^J8JNJ/O'6A?'WXZ^ M|A5^+=UO0/_AOXP>-|+T/P?H-H
M\$|NB>&=.L|"U31=+|G1-+-HK7=MI5DVHRVTFH7,VJZG9O/?^&R/VO/^CJ? MVD/_
^/Q_ ^:BO|@PGT&N,JV%PU;|\$|9|X/\$5|D)6_SXQO|0|@2AC,70PO_?
\$V.PM'\$UZ6&QL| %>)/B M|XXUG0_%NA6.H02ZUX;U+3|A7^%|2M|J9|-
>*| #TGQ)X=UBS+-: M:MH6NV%QJFDZE:LZH YM|ZPNK>Z@+HC&*52RJ<@;E?
P_4IU*-2I1K4YTJM*JZD MFGR7J6EJMV|H(6N5MK=9BXAC"_T)5_*7B=P%C|/#+C7-
N"|?F&&S/%93#+IU_ M;A*56CAZRS'+,'F<% "G6O4C|. &+C2ES?%. \$I+1H_LSPD|2,#XM|
Y+Q|EV6X MK*,'G4|TITLOQM:C7Q-!Y7FV-RFHZE6@E2DJM3|3JPY5I"<8RJY,****^!|T
MD**** "BOQI_X+,V/QR)!?P9|=O@G|6OBS|.D^'WB3_A?B-IGP|>^+?"
M&F:EX9|:R6MGH?B76HJ|"1Z7:O/X>|5VNG>'K0HMS>WO_"<_P"D74=KI4\$8 M_FE_X;
(_ :|_Z_I:0_|#X_\$|_YJ*_J7PK^B_FGBOPAA>+^,?TO,H M|&.17P5GW
7\$&|JTL% @,SP.:83,"K1C1Q=+&Y?64U M_O6!K|CE3Y)O^_"BOX#_/ALC|KS_HZG|H#_
/C|3O_)J*_I_."G|4. MO_M_LZZ|X0^('BC6?%WQ-^#7BN;3=;U|Q)JFO>(?

\$FN^\$O&LVI>(O\VN:JX MAUR:f?
4+X7T/BWPM;01WLTMEHWA+2C!|+PYFW#>8XS+I-
M"H8"O>TG\$ 7&BBBOY?/Z|"BBB@ HHHH ** GZ_X+8?M@>///A=??"X%_!_X@
M^+OA|XJNH;OXI>.=|#>(O\$?A'7X|&?^T?"W@00U|0>'5TZ2?3-5ND\7ZGK
MNAW/F Z1H A/42(OY!E !3 ALC|KS_HZG|H#_P/C|3O_FHK^LO#?Z)7%?B) MP=E/&,-
(IR+#9S'\$UL'@%_'6=<#5.%LZXBO60RPM"9AEN.P%#"+&8C"4,76PD(UU*M?
1U/|2'_A?B=_P#-17|C M?
!/:P7|3?|!/*PPNOC)XV|>^_ B7X|TT \$CQ/J7Q\$|6^*O%NMZ4OC".^|
M/>&HY/&%S<:KH4>A>%\$T&TU7P|&8K2S|4CQ#=#\$;B_N9IOF_&+Z.V8>#>0Y?
MG6;791FM;-R66X'+,#@L91Q-5QP|7\$XG%.(FH1PV%A3IPJR2E+VN)PT%&
MU1RA|3X&?2BR5OUXDS/(CWUSIFKZ/J^F?#WO%>Z,JFEZE92P7FGZCHY!#=#V-
|:30W-I&AAx87\$PPTJ=6.)3E*4W/FBXZ)*SUU/|!*_@/_X; M(_!_P"CJ?VD/_#X_\$|_
.:BOZ%?^""WQ>^+/Q9|_M%7'Q4^*Q\$^)<^B:| M|_
H=%F^('C7Q+XRETb*_T_QFH%|H2T.);AK:|H@YAC*_M_4^)WT4^(/#+@K-N-?
Q7DV:87*9Y="I@L)|@L;1Q%9YCF6#RV#A4K-TXJG4Q
M<:LN;>\$&E|S5OC_"/Z97#/BYQ|DW 67<&9|E&+SFGFE2GF&-Q^7U|-065Y5C
M_UJ*=%A%59.K3PZFC|VZ**_,7X^?M+?%|XB?%#XA_L_++7 MBCPW|_-
&^@VGB?|HS|H|Q#H*>|.^\$MC):S:Y_PB7@;P<8KFQ|7^/'T73M
M1GU.VO(KBRL4M=6T/S-)1V4E|H|O|H|+|+9CQ7CJV\$P-3"X3#X/#/'9IFN83 MK4LMRG
*00PJ06.GAJ&*Q4_:XO%87|87"8+"8S,,?CL5AL%@,'B<77I49?U! MQ?
QCE?!F74;F%+&8W\$X_%K+|GR;+*="KFN=9B\B,8'|@(8K\$8/!T_8X+"8
MO'XW&YAC<#EF6Y?A,5F&98|'8/#UJ|TZHK^?KX=ZG^SK|2/\$>AZ!|)/^"Q'
M|5D0QWUF^M4|.3>||%FO'X7ZOX00IQ%!80?"KOYX,|*>&-7M|409Q9Z+X\$;Q
MA*|SF:>+R%(OC=IOA.'QE|_/B9 MX5>'2_"G|07@:U+V>I:OIVB3"T_L;X@:/-
:7EWX|*Z=:VT+0VFNZOHNBV'A MC1XK^^^UXE|)LSR+#8VMAL=6Q>+RS
SS3,,DS7AWB/A//HY12J|I5|IR_+N(M&,SOW|BYWBH1:P5#,,/3R|'U72P>|
MS3\$9AB*#&J?Q 4445_M|?|)^_YO_05_P"3EOB|_P|D,O?_%/O |?U9U_*
M9_P05_Y.6^+O_9#+W_U/O |?U9U_D1|,'D|N;_|B3A|_P|5|_|#;KZ#?_*/V M2?|
90<3_P#J\$F%?%?%?R|?U|?%?%?%?X&?|?%IOV*1XX|() ^UG|_-%\$GB_P#IT
M&F_%_3M*TV66|2^_K,O#."4I*MBLYFX_%?T)?|5\$VV\$|_-R_|'_Q)U>*#0?\$
MM|J&M_|/5=2N|H)IGBJ|=KW7OARC3&:PM;'Q0_VKQ'X:B#:5\$/%@U|3U;6-:
M|::3.V_|HM:&D:OJOA_5M,U|0=3U#1=)P=7%81SC"O)G|8^\$7B;G7A%
MO|DG&V2MU7@:OU?-(PU6E7IMPJ1 M;_Z#.%.*EXVX;R7BSAW%QQV2Y_@*&8Y?
B\$N63HUH^|2KT|MT,5AJJ8;&8: M;|HAL51K8>JHU*4DBO)_CE|9?!?|/GPF|YBJ8K^1S-
(+ \$ M_MI#XZ_%E?
@%X"U1;CX4_!36|N+6KJWCG2'Q;|6;5+O2=+=2@O=8T;4M|N8/T3P0|*|9XM<=8#
((JM1R3|N9<39A3B MU|4RBA4@JE"E5LX0QV8U"!)8)/FE"=2IBW2J4,)72_+_ *0?
C'@/!7P|S'B2 M3H5^(<=SY5PEEE62?UW_|12FZ>
(JTDU.>7Y534LPS!IPC.G2IX)5J6(QN&H3W5W/Y!117^UN P&#RK X++NPU+!Y?
EV%P M^|P.\$H04*&%PF\$|0H8;#T8+2%*C1HPIPBMHQ2A 7,LOQ^<9CC|VS3%U?F
M69XS\$YAF&-Q,W4Q&,QN,K3Q&*Q->H|9UJ|>I.K4D|93DV>P?/X)>?VC/B|
MX'^#7P_MX)?\$OC;5Q8Q75Y(=,T;3+6";4=>|1:K*2'73/#VB6E_K%|%;+-? MW<-
FUEI=I?;I" V?OA/X&^#GP^MKFW|*>_|%CTG3Y+Z2*; M4M2N9)Y|_6-
=U;:"&UMI=8|0ZU>:AKFKR6EI9V3:CJ%S|BLK*T|FUA_,C_@D M|^Q6_P"SF|
(H/C;X_P!)FL_B_P#&O2+*>#3|1MK!;WPA,C.-1T'1(WB6>^L
M|2|9\$6'BSQ3:3WL3110>\$=%U'1=*UWPSJANOV,K_"E^E=XQKC_BU<)>9'BE5
MX2X/Q5:BjM"HYT,YXABIX?9BI1?LZN&P,74RW+9Q4XRC|?QE&M4H9A3C#_9
MCZ&/@6_#7@I;|<0X.5'C7CG!T*SHXBFH8C(N&.)&)R|*W&2|K1Q>8R5+-
|*_MRK^ (W_(*N M?|I/VA_ ^PEX!_|54>|*JKZ#O| R=+B3_L@,Q_|+A@|_|#|H5_R9|A3-
+.5 ME?|ZR_%Q^>-%%?17|DOP" X:A_:"^GP)_X2S_A|O|A/O\$<7_E/|A?|M)-
97"/^\$/\$'BO= 8?|L^'_+=|K_L+|!C^U|/|H^U9F|C|_ _IWFV:X#
M(|S/|UK_5C4J>RH4JM
M:IR|E*G;:C%_Y&9+D^9<19SE/#^3X;ZYF^>YG@,GRK">VH8?ZUF69XJE@L#A
MOK&*JT,+0|OBJJ*E|;\$UJ-"ES<|:K3IQE-?.M%?T@?| \$/K_-7;_P#F|A M|=%'\$/K_P|7;|
F!/_ ,=%?A/_ !-9X!_|%Y_YJ_&?_P!#I_1?_\$FGTDO^MC?_ \$7G_FK|9_|
T.A_Q)H)+_HW'_FX_M|ZH|/ <+
<8X;,,YQ%.K5PV!KY9GF55,5&A!U:L,+,/.,KR^CB:|*49UGAZ%2IB
M/8TZM94G3I5)1^0XW^C?XU^'.0U^)^,,!<5EF0X6K1I8O,&|O5HT7556M2A/X4K|V?</p></div>

^-W\NKKX;?S2_EM?A3<:EVNI:7J MFFW4\|CJ.FZC8SQW5E?V%[:R17-G>V=S%%
<6MU:RQSV\|<A7TEEXI:."UR?PU+)"^HVUS#\\M"HT_6/">\$_"6HZ=?
M+!JOASQ5KT'V:41N\|/U_\$O_,%3M_P!H6A/:#;":?76D7JWG@OX6B/X1>#I8Q!Y-
U;^\$+R^_X2:58IK2\O+/4;M?5?&|HXEN=(U>"16U#PT-,D<9A6-
/Z3^BKP!_KQXKY7C,51HD_!T%Q/C^:M%Z=3%X2K"&2X5R=X*
<|TG1QCISC)5L+@,73LK|T?Y1^F1XE?|0^|&40Q&!56\$HNAC,RP52|MR2_>BBO
M4/@|I)_\$OQT^+7P|^\$A"*1|?^(7BO2?#5K<)8WNHPZ3;7URHU7Q%J-MA4|
MW_8OAG2\$O0\$.07\$49%EHNF7|H*4AMY'7_7S&XS"Y=@|7F&.KT|_@L#AJ^,QF
M)JNU+X7"TIU\17J-)VITJ4)U)NSM&+=C_\$#_8#&9ICL%EF7X>IB|?F.+PV
MP.%HI2JXG&8NM#X;#TDVDZE:M4A3@FTG*25T>7T5U_Q!|#Z_P##+QYXT^"
MBN&"W|3>0%?B#P;X@AM9OM-
K'K/AK5;01M2%I(P|>E)3IUJ%:\$E*K3FKJ4*E.49PDG:46
MFM&98G#8C!XG\$83%T:F'Q6%KU<-B,?-F'"*Q=>6:~%M49Y|JUM+:5XWM/#
<^H:O<>:;P MW)X@CC0"ID-?VS5_D!|*K@%<\$>*^:8S"4?9Y/QC#_6?+Q=6<,[PJD
MDH\|TA7QBIP25"X_"4I.W_P#
<3Z&WB4_\$'P8RC!8VO|7/!|G^J.9>'P.JLY2E7QF6XVJVK\J****_FP_JX****_AW^BB
MBO|H8/^8<_HB_X_?|D9_VH|L_"C_TX>|J_I>K^:'@W|Y&?|:@_|M
/PH_P#3AX^K^EZO|=|I8_|)^.,_P#KOPS_.LKDI_NE|_|E"@|_|"+M?
_6RS|****_G(J8****_/?B|_|/7QI^%WC_X3^+X1+X=^(A36O"VI2+;MV=S"?M\$/PT|
<^,?AUXMM8|+Q1X\$|4:|X\16D,|=U!;ZWX;U2ZT?4XK>|A+07=LMY9
MS"WNX&:"ZA|N>%VBD1C_**=?RA?|%R/V>I?OQ||+?'_2+9CX=^V@Q:7XB_MD5KN?
I%|00-AI^CR-/BQBT|3+/7?!9|_-H|JM_E4JU*5.+;C'Z_E#Q4ZTVW*4|MKP=*\$??;7^?
WT_?#7^W>!:XZM.2Y\$G^E?H_,\$J?V@T^'I8?@)|5N?(|_!95O@|X MK9E5TM1XOO|
3SX4U7,|H8V=DFE^+.'PV=5U;Y:?'^SO#%QXB:&"268*?S@I0
M2I*#2K*058\$@@@Y!!'((Y!K_1SBWAK<8|9|PMF:_P!AS|*|9EE>:BIS_MH?
6J,J=+%4HMI>VPE9T|30;:M6I0E=6|L_"N*|QX%XNX<8'-
ML/30W7BZ71_^\$7^(JI+IYGB|?|A1O|!0W=W9Z;:%!:Z2WB1|>W|8Z?
MI26|'V/1/\$>E*L?EM&|_%W7^#^?9+F'#>=YOP_FM)4,RR3,L;E>.D)MQCBL
M#B*F&K>SDU'GI2G3#S'#4|50|K|2E|.M&G5C&M2K|GO^"QG|1+?|3|DS5/_^B:C%:_^
/C|?R_#BPBCO+:'4;?P M.+;
I=|2M6AL+FR0%U+3H|\$S|":HL9LYK\$_\$"RU&W08KFV@27ZO@;A3'<<|7 M_|
(YU2NL+AISY|=C9JS;I8#!0Q&-K**E+V5"?+&*A#V>7Y?3EHE6S+,*F%P%|R<8*MB8<|
MH1O)?RQ?M5_'|_:2_:'^+'QKN8|BWMO"BNYN?#|E>6|M:WVG>#M)MI?0/!
M.F:C#93W-H-3T|PEI6BV>J2VUQ/%=:E#=#72RR><7;Y|HHK_=[*LLP62Y7EN3
M9;1CALNRG_8/+,!AX_#0P6 P|/"X6C'RI4*4(+RB?
|Y>JXBM4F|=Y'V3^P)^SN_|3O|5'PO^&|Y M8-?>#
|/51XU^)&^WN+BS3P#X0DAU36K#4&M9|>TM_%-PNG>";>_CE|L|3|3
MV\$Y5PI1O|MZ_!W_@A9^SQ'X3^#_C?|H_6|!|KGQ8UB;PAX+N9H;.22W^'_@J
M^EM|80-/O(G>|MXO\$GCF/4-/U?3|E8E=_&BWD:.DD*O\G?I=PO\$.-
PWL<|1,3#B/\$2G'EK1R.G">'X:P|=DI4*F#EB,YP|U?+G+?_6/ST_H?K|_|P!DE5?|BG|O
M6|U9)\$^(H|8?VT)OB^DJNDD'O&_L.<:A;!&58H4BT4Z&_D6H%K'/-<.%6XD
MN!7|H(5^67QR^_QD^""Q3^*OOQ_9X|!V'QL^\$7|0?A^|TH|J|EM=8A|%ZYK
M.K#1;S29OB;|)_ \$5LD2VWB35M+NKQ/%NBPC^V?=\$=|/?W-LFOZ|KNB:AX_S) M|_
L9@JV'SWAK\$8W""9;C(S'\$8;+Y9MEN6X?%XO"PKK\$4_|6SQ6P.84,5PYO7ALOQN;Y?DV
M!XMR+.L+E^\$Q&8XW+L#Q=E6'PE+B7#97@J6(S',GDV.R_"X?'8;*|B|SADN
M:YKBL'@L9/#O#5?@OQ)JOQR^+O|)W|[#7|(WQ%^"PS^%GP6_:'TGX->#/#_|M1-
|XFUGQU>:6WA;0_#OB?PO8VNC0^&-|T|PA4?B+::6VC>\$|(U#6M7MM;%Y
MXA|Q7|O;1ZCKFG_&9_P5-N/'&F:Y^R+K7|/D5Y>?M;6/Q(^)UO|'=L+=+MZZN?
E|)M=7XSS1:?'>*)N3.V<'@LO)>\$7-M%+(UB#ON2O,>,OV@_@9XX^MVG_LW7O_
3H_;R|3^!-\$T|PH'A;X7ZO|?&&@2:8O@M;(^#8KKQ|!XZG|2
M^'|>RGL+"VO/\$|OK5_JT>F/>G44U*VN;VSO/HC|G'X#?&WQE|9KC|K?|K.WT M_P.^-
|*|VZGX%_9_P#@'|>MVOC31?@'X&U-
HHM9UO6/&#I(P6,|:9MQKAE@<)/ZG/,ZSBOA|TP4L%@..XG#K\$<68S/L_4LXRQ97PS/;
|)T445_JT?XSG|F M_P#!!7_DY;XN_P#9#+W_-3|P/7|6=?RF?|!!7_).6^+O_&0R|_|
4^|_# MU_5G7^1'TP?^3VYO_P|B3A|_-5|_#;KZ#?"C|DG_90<3_/JSF%???%?R|M?
U|%%%%!7R|^W#^RCH'|8/P#|2_#&|^Q6'C&QSXF^%_B6|DN8(?#OCS3;:X
MCTQ|Z:SBNIO|!UJWN+KP_P"(HS8ZGY6DZG/J=EA|NMZ9I\$|M|?T5ZV0YYFG#
M.HIQYH_#4I5\$G3KT9J5*O1G4HU8SIU)MQ?B|1V/91Q9D;:1-9_@J689-GF

Q.6YC@ZJO&MAL53E3GRR*E6IW57#XBFX MUL/B(4Z]E
<*M.\$X_YS/B3PYKG@_Q%KWA+Q/IEWHGB7POK6J>?\$.C7\?E7VD
MZWHM/I\NJZ9>1@L(IJQOK:>UN\$#,%EB<D#-8M?TC?!\:3]BIS4A,:(^'VG
M.TJ#2/#?QSL(9E(,*+9Z%X+^(\$%J\(?="!8>#/\$WDWD@,/A PAUY::3\$D'BC
M5G_FYK_,OPH\1K\4^""\U=200PTUC,BS25-TX9SD
M&+G4>79C!6Y%4E&G4PN.ITW.GA\RPN,PL*E2-%5)?9G\["?I7&N_L<'K0?B-M':VI>
=63_A&OBMX3TLV4D_B/P9>R*TDJA,ZELM3XA\,WRVWB+P\ZWNC57= MW82^'KC7-
-T/Q!K9F_NAT76M\2:-I/B+PIJNG:|H&OZ98:UH>MZ1>V^HZ3K
M&CZK:Q7VF:KI>H6DDUI?Z=J%E/!=V5\!RRV\U;313P2/%(K'_.2K^H3_(H
M_MA66L?";Q_^SW\3?SEK\GP,T74?B3X1U_7KX6UE:?!U\H-XOMM2U&73+?3
MM+TKX<>(;VVU!M4U_P_1S7,VD>-[,3--LK/00!*S7A2OBJRC0RO/<-
AYXG,LN56JU##X/,<M%AZF*I1=6%&&X/DH498K.:TY?
6G_!5;H\I_V5_@4?"_@K4OLOQG^,L&K^&_M!LIM/?VHX1\,PV\
<'BWX@075@(C9ZGI\$.H6>E^%"^HZ?=#Q)JUMKMC%JMGX M7UJOA8I?
5/I:/I2^L_M8_M\$>_B\?27D7AZZO&_#G1KU)()?)#WPXT.XN8 M?"VFRV3:EJ\<CJ5\#-
<>(O\$M08ZA\K^+=,V(I9?\$.K,,OPM>XJG\=E-P MC5IX)9?@JO.!\%&/?'NA_?;
@=!\|RSU;Q)#J6G1W6
MB^,O&!Q<^/'A^ZWCK:W\BK*OB'QC;"UU6V_L&TM/#^KVEHGC33+Y?SF^%/PP
M\9?&GXC^#?A5\A_2I=8!8>_M=L\!T6S2.X>&_6Y8M=:EJ,EK;W4MGHFBV\$=
MUK.O:HT#P:1HEA?ZI=;+6TF=?[P/V8/V=-!?!+/P4\&?!OP5#;2P>'K\)_\$?
MB&+3UTZ\;^,;V*)_\$GC'583=7JPMWK-I'_HEI\I>C:?'M'%\9\]*?QC_XASP>^'(\,%
I:@;@C\$X?%XVG6C>AG>?JV(RO_M).62Y*^&HN,%AAL#B*:AFL)KW^BBB0\CC_::*_B-
_X*N?!*0#I_MH?!\'7@'_U5'@2O\?_54>!*_LWZ#O_)TN)/^MR
S'_P\;+A@_@W\H5_R9\A3_+.5E? \ZR_%Q^>_?HI_P2<_Y2"?LI?I?GO&_M_P#50?
\$"OSKK\%_8"^,/@7X!_M<_"#XM_\$O4;K2?!\A"Y\92:YJ%EIM\J\U; MIK'P\|7>'K
Q:=IT,IY&I3K8G%X0%9#CZ&&PV'HTU*I5KUZU2%*E2A&4ZE2<813 MDTC_
"Z\)'P&79=X@!\&_.,=BZT,/A,%@L'Q'EN(Q6+Q5
M>K*_.AA\0IU*U:M4E&%.G"4YR48MG\W=%?EI_P^3_8_P"BC>* _#:>-O\ MY44?
\D_V#/\^BC>* _P#PVGC;_P"5%?XU_P#\$_%O%W_HV?'\A_XC&;_P#S(?|N_M?|1|\\$?^CM>'?
B79'|V^?Y\J?J717Y:?\#Y\I@S_HHWBO_P-IXV_^5%'_M_#Y\I@S_**XK+_
IXV_P#E11_Q\;Q=_P"C9\<_^(QF_P#\R!_Q'OP1_P"C_MM>'?_B79'_|-OG^?9GZEU^_7_!
<>VLI_P\!C#29:I(FGLOC;X'N=-:1\K1WK_M^'O&JGA
(W+YDITZ\OXRF'Q"\K\1LWKW5W_P6:_81MK6XN(?^7C/4)H(9)8K
M&T^&_BM+J\DC0LMM;O?V5E9+-,P\$<;7=Y:VX=@9KB*/VM?
%2Z4/%OB_QA+I#Z='K>NVFE76KV&@6 MOARUU/7\T+2M*U\5%OH-
3OM:UB\>XO-.T?PY^S^/_@CXHTO%/A+.LTX0SSA
MW*_.\TIYOF.8Y\@J^4TE0PD)S6'P\,7&E7Q=?%U'#\#0I8:G5Y55E5KNGAZ=6
MI#\&^DI\('P@K>#O&N09/QOP\Q1G?\$_N3U:C>6FGZ?:7_?W\S:96_M-
C902W5Y>WEU*D%M:6EM_DDUQWB#.21\!;Q100Q@|8H8TB_M0*B'H_1RO!OV7?
A"GP\$_9W^#/P@-EI%AJ/(@7X?>'=)\2QZ#+<7&CW?C66QCU_M#QWJJA<74%M_M9>^;
9SQ?Q+FW"E\NN\$S'.L;C_.,<;CK1K0?NMQ\JS/^C_PRR;&\.>&WA\JP
M\H:Y+2VCZ\!>V5O?PW%M\J_M4GAD37?C.\TMH)?MNC^&M3C(5=TB?
P@SDDDDDDDDDDY))Y))\)/4U^|7_!=7 M\HB3Q3\5_?|\-NA:F\Z'\+M)B\>::,WN;M(OO'
(PL@WA^QU2QEACMI+OP_MSX&EM\4TG4+:6X_M?B-J=H\1RQS1C\%*_P\!;_HB<
ZH>%U'/L70\EF'6(C_MGE64H\M:_.34HSH9\0D\H4JF'EB,VH-7\IS-VF\KEC_B=I-
WQ*_P\!=_%^OPY@L_M3\;)/#O#3X>H1A)2HRSZO.&)XEQ\$5=N-:GBH87)
<1%V7/DB:6O-(K\?^"\$W_M\I.O_D?Q\$^(?|36O6*R:3\K!_AUX
EN+))8I?"BBSBN_%FK:2J":A'-8Z_MAX6\%RVNBW%K-IEQ\J5A\2WDBO+:73'BG_-(DX
R3P_/\I7\Y_|\#_|\<'I
M,7L'PJ^%,VG0V'BFST""Q#\164:/+=7/Q%\48UKQ9'>ZIHD4=IKBZ%?W7_"
M)Z+JKRWL\^&/#VA69O\J&S@D.?TON/GPEX83X?P=?V6;<=XF634U&256.2X9
M4L3GU:">DJ=6C/"9373C*U+-I.+A-0G'7Z#_-(1XU\7H<2X\#NMDWAUA(9\ M4-
SG#OFC>MDL4U.FYP?_/_7*_9\;PA_M'?PE\?!_1+"9=
^_.@QZ1XIN8UU"X@MOB)X\$LI+2EENYFA.F:4FO^"3X<32-M/BG2?
4KOPMXKU,V\,EW.WX;5_<_,%%OV=G_:_9_9,^)G@72K#\?XV\6WN/LRP0
M_#\!79\|GCGY<8^%>#R?%5_:9QP/6CP\B8SDY5994J;K9!B+;J-!8%3RJBK\SE
ME%5N,8N#EP_36\<7P+XQX\,'A099'XA4)<3X2<(*-&.8.
MGG%=I/*HYW0CS2FID7\W_!\O\1\$\|3W\|+7PN^)EOI*7_BZ'1X_!_P_20TIC

M)>P_\$/PG%#I?B&ZU"WT\4M]-E\2A+/QI8:=Y4+V^A^M)9HE\$BY_AK\ZO
M@A7^T4WA7XK^.OV:J=OF71?BHDOC7P-!-=7!BMO'W@ZP=J?T^PL(K22\$7'B
MCP/%JFI:C(X:KR2=Y5JN+GB&+;?
\$OX;0VEK?:AJ\$OC7P7;7EW%I6E:=8W5K\NU3Q=X>N/\$/@:QCN5N\ M>WG\4)?
K9SW5G:J/N6BO;X;S_.%>(EXDRJHZ68Y%F>"S3!RNU&5;!8B%>-
M*JE\="LH.CB*4KPK4*E2E4C*\$Y1?@<5\Y9QCPSGW"F"?
&=ROQ3^"%090Z18V\$/A#QM=W\FE:9I&CW\$T>C:3X3\ M5V7BCP5I-A>0:?=R:9X:M-
12QCL+^QFG^#Z_WAX9X@R_BOAW).Y
M7@LTPKYE*4*6,H0K^QJV^&OAY3E0Q%.2C.E7IU*52,9PE%?X_%O#.9\&<3\
M0<)YS2=+,\^'U-X\^')^EOXY\|V=S=7)MX_'OA"R(2:=IE MA%;2P+?>)O
+ZOJ5_TU%1%U""\FT?4GL)\:J?2-;M8Y\ (UBWAN(FN MI+O;NU9PDS9_T'_A_P'./#_Q-
!'">#/B/X3N);OPQX\|+;!XP\|7%Q";>YET; MQ)I=KJ^G&ZMBS-.W8M+N);JU=C);7
E@D^>-A7^:7TTN /!"XZRWCC\4'# < M9X/V682A\W3S_)Z5'#592Y;1I_7\JPBTI5\1AL?
7YIR=3E_UB^@1XE/B M/P\|S7P\|S#\$*>9^*/'^^DZG<77@GX\$P\A "K1+
M59M9AL&15:7=2S_\$O5?|(U1((+/6/^\$O>Y\WVIZ=;+;Z\I'@?PY>17=_91V
M%Q7\4\87Q^M_P\|F+|F\XK?&%O#K6WA"QN+>.JMK_,=>(JW\.^"MX+ZP;5-
&GO=&A\1ZHU\XDBL=0AU&+PU9ZQ=V*\$S7%LD3_P_#=Q<3W<\|U=3S M7-UWT(>
%B\|VX MC\2,;1;HY32?#>12E%.#S'&TZ6*SC\$P>DHUL'E\|L'A(--PG2S?\$QDN:\$6O\ M-
W\|H-XE\|9+PMX59?72KYU5_UJXBC"352.5X"K5PF1X2I'6.J&.S...QLTU&
M=.MDF\$E%\E2:<=I\./B/XJ?#\$P5\|/'-O%=>*/"WBG00"&@PW#O#;_P\|J M>
(-2MM+LY;VX2.8VNGV\MRMOJ%X8W2SLHI\|J0>7"QKBZ_ =+ _((9?L\2>/_C M=XO_
&B-9M91H7P9T:7P\|X3E=;^!+SX@^/_OM,O)\6XCC_L^B\|^!VURWU
MC3KB4S6USXO\;A'%E\$D3^YO\$|C7#^'? 7\$ _&&(Y)3RC+*L\|1J/W<5FV)<<
M)E.%DD^;V>(S&OAJ=:45*5.@ZM7EDJ;1_GAX1< 8KQ0\2.\$>!\|2-.\VHP
MS*O27OX3)<*I8W.\9%M'Q=2A&;C&KB%1H\|743\ZZCAA,)AJ,5"EA\AJ4:-"A2B
MM(TZ5*\$*<(K2,8I+8^=VP?^32?VIA_LW3XV_|JM/\$U?P%5_?K^V#_,FD M_M2?|FZ?
&W_U6GB:OX"J_P\|)OH*_|DIQW_V4.6 _^JV9_E-^T4_Y+ #PW_.R: MSC_U:40K^F'_(-
O^14:=|&'X5_|IM|=5_|7\|/_!O\|P BI^T\|P\|C M#|*_3;XZK\|>^EC_
_F'XS_Z_P#_#/_K59?*B'T+?^4C>!O\|L%XM_P#6\ST_MH?HHHK_'O_W0"BBB@#_-
_HHHK_H8/^8<_OZLZ_E_X(*_|)RWQ=|(9>_ ^HX^K^K.O\B\|@_|GMS?_L2U\|PG
MXFTRUUKPWXHT;5/#OB#1KZ/S;'5M\$UJQGTW5M,O(LCS+6_L+FXM;B/(WPRNN
M1G-?PO\|I='D)VN_L>_'|O\|KA;V\|\$:JYGBGX5>(|V:UNH>|!ZC>7,6GQ_MZA<6:01?
|)#X?N(+GP\|XBCDL=+DN-0TXZS:;9;Z'K.C2W\|=S7P3_P44_8\|
ML\VP_@#JGAS2\6UC^+'@7\|=XN^\$FK/#IJ7\$NOQ63+?|@JYU*_DM#8Z#X\|MH M(-
+OV.IV%A9ZW:>&?\$FIB^A\1V_P#1_P\|&GQ@EX6\;0PN:XGV?!W%\$|/E^M?
>TE+V.6UU-QR_/8I?#|1J5)TL:TGS9=7Q,W"K6P^&4?Y7^EAX&Q\8?#^IC,
MFPOM..>\$*>)S/AQTH1\OFN'<(RS+AV3>L_|0ITH5<FTX9IA\|+|3I4,3BW/^M'6MO0?
\$FO>%|N\|O0#NKW^C7E_HGB#PW?7&GW#V\|EWH/BK1\|P\|XCTBX*\$>;8
M:SH>IW^F7\|NX*36MU*A&2*".IZ9J6BZEJ&CZQ\|H.KZ3?7>F:KI>I6L\|CJ.
MFZE83R6M\|H_974<5S9WMGG:49*%6C6I5(|-2A4ISB\|FG&47U3A
#6\$Z^\$KQG"5;#8G#U;QG"4Z-M>A6I2T<9)QJ4JM-.W3C.\$ET:"BBOT6_X)H?L:3?
M>_'NT@|2632?|OX8MIGB MOXJ3-+=6Z:Q;R7,O_"/^
::XLU\$Z7GC.H\J*|>.ZTV6V*Z9XFO;'4\;6+; M2H;OQ.*^)\HX,X\|BGI MOAC M97L-
TMUX6^&%XT=PVOB&X\$-O'J?Q%DBMKZRNH\|YD@|V%VND\$Z;JR6_B\|7=-7
M\|UZAM\|>"T@@M;6"&VM::&.WMK:WC2&"W@A18X8((8U6.*&*5CCCC54C1555
M"@|IJ_P^|1N\X\2>,,XXOSJ35?.J\6%P:J2J4G@,MPUU%*EA*"C&4 MXP@|1B)5\|75C\|?
\$592_Z\$?"WPYR\|PIX&R+@C(81>&RK#)XS'.G&GB,WS60:I
MF6;8NSDW7QN)!*_LWZ#O\ R=+B3_L@ M,Q_|:|A@_@W\|H5_R9\A3_LY65_|
K+|7'YXT445_J6?X\A1110 4444 %%%M !7\2?|!%OX"!WXE?'F?XE?
\$#Q\X4G\|?'B6/5OAO\|%+Z'.OZ\|KGV26:+X MD2C6+%=+U'2?|!#|J01;'PS(M M?|(Z\|H'B?
PMK6J>'/\$F@:A:ZKH>O:)?W.F.OI&IV4JSVE_IVH6&|-Q7E^ M0YGO\$KDN*Q%:"QJU*#
<|-B:-6D^3ZU@,OJ6-PM\%4L1@JM>A"EBL\4I3E;_ M \$9Z*^#/_/^"=O\8=I^VA
;#Q7JWV6R^*/@B\|@|&_%32(C309\|>M\|WN;'QE MI^FV*/#NFMJ5MX;.IW?
WG7^&_\$O#F;<(Y_
MFW#6>X;ZIFV2XVM@<;0YE."JTGI4HU%:-7#UZ;A7PU:/NUJ%2G5A\|LT?|J#7" M?%.2\;
<-9+Q9P\BEC\$ _@!HMBVZ M\|:J<75?S\|&UFDM?A\X#O;#53#.GGK?Z?-
K_C)_#ITR\2\K>_L/#GBG3GDY MD0^_X9\|XCO"X\X8X/P/_&.
<9G1IXVM3^/#95AU+%YMBHZ-<^&RVABJM*,K1

MG6C3IN4>=,^;+6N/<+X8^"%W'&))JG.>1916JY?0JNT,7G&<,%DN#G9J7L|
M5FN)PE&M*"E*G1G4JL.N1I S\$ %OXE^(?C+|4/B|450%3J?S'Q#|7:JXMU*&
M*:ZGM;"76|JGO8|)TY[V:|XN8|)T>WEATK2+:2:3|'IEG:6B\$1PH|YY117^ZN
M\$PN'P.%PV"P=&&'PF#P|'"X6A35J=##X>G&C0HTUK:%*E",(|JM&*1_SJXW& M8K,
<9B|PQU>IBL;C|37QF,Q-5|U7\$8K%59U|17J2LKU*M:!=*M;J#3KVREOK
MOQUZ:>T6WF_M1K|@_^^,|I.W_I|IEG_(6=MK6GS6?C|/H/5HO%|YNK?4;*<
|M_A_H'V|2?AU82VMU=264|O>QW/B+QSI>L65 MG9OJ6C^.=/BN'NX=/L95_7RO|?<
OI3|?+CCQ8S:AA*SJY/PC#_5?+N5_NZF(P-M-6I+.<3%)N#=3-
JF*P|*T)25?*"8/"5\$|'O@ODF(QM!4L|XW MG_KAF:&QV.QM)QT>**8:5H-
E.Z%9TDD_N,K|3_/@M_P#L|JM|1?V=O#OQOT2S| M|Q|^"=>/JM-
&2);CX=^.;C3M&U@^3|:37%<.:XG@|)ZA.);B"TTG1)O%>H. M?GDSV_1.X_|J2_%7<
99BJWL|GXVI+AO&*^<6G3S&K457(<5RZ*5;^T\$LM@Y M-1A1S3\$3LY**/A<
IH^&JX|&LRS?!T:YYX?UI<58&4(\$YK M-QH/+&|UFHQ*M%| M5Z4LDUY#:7LVD7T-
U+L.IFPN.:ZGT;6K9)M(UNRCN81J&D7M|8RMY-Q(#Y|1<
M7^NF+PN&QV%Q.!QE&GB,)C,/6PN*P|6/-2KX;\$4Y4:J&I'|5.K2G*\$X|8R:/<
M|2,%C,5EV,PF88&O4PN-P.)H8S!XFC+EJX?%86K"OAZI*7V:E&M"%2\$NDHIG<
M^BEV/_A|XF^!|GO&|)W,MYX7|>>%M|8>'KF>%K:XFF;Q)I=KJ^FM=6LG<
M|RTNOLEW\$+JTEQ+:W DMY0)(V ZZOPT_X(:?M"P^~O@3XM_9|UBZ0>(/@MKL<
MNM^&(7_L^W-YV?'U_?<
ZL|=I&MVVJ:G)O!6(|/.|.N#|0ZDXY/F=6G@J|16GBLJO"CB|IQ<|)153\$<
MY=7PU6K&#E&G6E4IJ4N1L_Z*O"7C|^")_AQPEQQAE3A/O|)%GQM MX.|/_\$3P9XM|<
>+;)M2|^~./#..O>\$/\$NGI)/@?|_%CXA_"~+Q;:%*FO_#WQ9K/<
MAB|N'L;W3XM5ATZ|DCTWQ|HJM|J\$4%V=&|2:6:/7|"N9(PM|HVI6%|)"TD%Q%(<
M_P#|IW|)"CC|9OPCG/A_C:S>-X4Q;S+*8SDKU,BSBM.I7HTHZR:P&;_6*E:)>HJ.<
XRP:RG.I0B|4^(LCH4Z>'KUI645_M_:62?5J5"\$>:3EDN,J5)+VD\$_.J_J|X(?3Q5|<
|:O8WU_X):Z MVH^&HI#;137/P||=WE_JL44*FX:~U*;0?&*>)\$U&|:|:3M.U_PK|JN!Y*5-
M*%7W)_P3F_:(3|FC|K7X9^~J5U\$;;X)|1WC_X^(TTMQ!9V4?@WQG:-V4NJ<
M:I=303F+3|/"GB"#P_P";T0B.>>+PT;5946=|_N/TA>'XB^%?S>48:@J^<9<
M917\$.0Q4.>K+~.HA5K?5Z"Y_9C@9XW*Z>L8J>-C*348L_GKZ,7B4O"|OCX6<
MSO%8CZOD>;5GPOQ))SY*48T|OS>M92DZ>7RC"+E)'|S ME%%8'BOQ1H/|@?<
POXD|:>*M1BT?POX0T#6/%'B35YXYH=*T'P_IUSJVL:C-%<
M:Q3W4L5CIUI<74D=M|~.Z1%88I)"J_-BO2I5:J6G0H4ZE:M6J0I4:-*\$JE6K<
M5J24*~.G3@G.=2*M9M;W1?FE7IC276=%U?0O"|_B/6|C3H|6VU31_'<
M_A|4I;2Y\$&G7,7|J5>O_!^..O?M?&GXF?&7Q'JCU+XA>+M5U^*PN|JM4<
MDT/1I9OL_AOPQ%J#06K7=EX5|.V^E>&|.E-M;YT_2K8"&(-OD%?IE^\$/M/<
MPX|.N%^\$U3IPQN!R^%?.)T^67ML|Q|>,S6;JQ;JM&&,K5,/AZCE*V\$H8>G%J<
MG3A&/_/#XW^(E7Q3|4>+^~/:5)X#;/L,@RV,1^T9^U|!~!U.PAO|P7X<
G;XL>/H;J+3|JSN/#_@N|L)M.TJ|MT_4@UQJNG^(_%|YX8|<
~MIRQ3S/HNKZE=>2T%I_.*?|EAX;|DUG'JTHA7|,M/!O|_R*G|3O_8P_"O|_|<
OCJOYGJ_IA_P"#?|_D5/VG?^QA^%?_*;?'5?K MWTL?^3#|9_|7_AG_P|:K)3|0^A;_P<
I&|~?|@O%O_K'YZ?T/T445_CH?|H! M1110!_F_T445_P!#|_S#G|F_|\$%?<
^3EOB|_V0R|_J3|P/7|6=?RF?|\$%?^3E MOB|_D,O?|_U/O|?U9U_D1|,'):/F_|V):'O_5?<
VZ^@W~H_9)_V M4|\$_JSF%????R|?U|%%%%%%%%!1110 4444 ?R??!|<+|G7P7|*_C7|/_<
(R^M#X|?2I_V@:/QC<>./#EEIT=I8IXO!OX4CU/QA#/#+|~.26;2+3;<
M5WUW1|3|27M|JFI>*+YK3|0*_I_X."O^;2/^Z|_~|7K^;^O|H?HRYIF&<>!MO_~<
S/%U<;BHX/|_J|=J53ZIE/\$><95EU!R27-"Y=@L+A:~IQA!1A\$K^|G|@K|GSPA^S?^R_|<
#/P=X65KB~|1Z#I7Q|!~M:<
|,%%SXB|:>+|'TR_P!5OW")&D5E86ZV.@:);B,26^A:/ID=Y+>:C|MO|O|_MA&K_-\$<
O@Q_R1|X4?|DU|^~HOI5?A7TZ,SQ^~X8X\$R|JABJM++|RSG-|3C|+M"7+3Q5;+<
<)&5@I5K;SCA_KV)E"FW|~U)QJ2BZE*E*|)%_LI(N)_LI"0G52|J4)THSC3K5HS|<
M*HHHK_~P!80HHHH*_B_~X*N?|I/VA_|L)>?_54>!*MRK^(W_@JY_R_MD_~:'|'7@'_<
~51X\$K^S?H._P#)TN)/^R_S'_UHN&#^#?VA7_)GN%/^SE97_M_P"LOQ.O,<
MC89589!PP!(!K|*_13_@DY_P_I|V>O^OSXC?^J@^(%?Z&>+#+|/\$MIM-M<<9-<
~.S37#N9---:H|_S\$|%TI>,7A.FDT_\$O@1--733XIRI~/1HK1|HG M|JW|@:%_T!|=)_P#!=9_<
~|FC^P_~P"@+|/_(+K/_XS6M17^%?MZ_|S^J_~M^#)_YG_1/|7P_P#SXH_~^H?<
~")D_P|@:%_T!|=)_|%UG_P#&:/|T+~H"Z3_M_."ZS_|C-<
~U%'MZ_P#S^J_~#)_YA|7P_P#SXH_~^H?~")D_P|@:%_T!|=)_M|%UG_P#&:~!^~WI(W|/_<
~TGX0UCPI|30AQX;O;G4~+N~.TOQHNCZ7IWCSP<

ME)B2TU/PMXIBLFU'3KFPO\$@O18R/_LM*TG2K*ZU+5-
4U*Z@L=.TW3K&"2ZO;^O;J2*VL/*SMHLBZNBK M6."W@CDEED2-
&8>AE668W+,JRG*|RRG%X>K2QV#S+"8;\$8.MAY0
MDJJKTZ\4^10GRR6I.JN860LH8D#B*|A_!;::+|M2_C_
/!+XC^&CYMN3X|7^~.35<;7RC*J^94W2S&MEN!JX^DX>R=/&U,+2GBJ;I?|
M+MPKNI%P^PUR|/#_FUSVC@,/G><8?JBK970S7,*6U8U;/1JX"EBZT,'457_M
)>J>'C3DJGVT^;J?N7_,\$&?&FL:9^TH6/2:HJG|>+O@O<^(I_2#%;E=M3|3>"O&?
A6S|.W8G:%KN.72|%|9>,T6&&XBMIX|1FDNHIY::S>W_*M:_D:_
MX(6Z/::G^V1XIO;D;9O#WP\$;ZQ8\$8PMW-XR^'&@.6R.GV'7+U1C!W%>V:_K
MEK_*#Z8M'#40&K'SH0C&KB>'L@K8QJG&#GB8X:|AX3G*.M:2P=#"P52?O*,(
MT5|E*!_LH!;OBJW@%EU/\$3E.CA>^):&C*K.HJ>%EBJ.)G"\$)>|0B|=B.9
M4=*G|CG4G7?|RM4"OX8/^"BW|1_M+_M:?\$WQOI>IKJ?@GPI>K|.2AQ-
!E74\$!FTOQ9KTVO^-|,3"6:|/\$YMC,|<\$87^JK_@I7^T0?MV;?V1?B1XHTR^EL?
&GC:W7X6?#Z:WFO;2|@|3^-;2^M|C5K&_L8WDT_4?"_A M:T|2>+-.N96A@?
4|"LK(SQRWD(;^'2OV?Z#_!:/|OB3CJ&LO|C%|@G4C|ME.AC<|Q5-
2767|G8.CB*:5N7,?"A3E^)T@O|<.)*=.?MVI+\$9?P_@ZSAM:/|J8ZOA:C=^?
*|4Z:M0FRBBBO|"C_8TH|:UB)\$BBU;4HX MHT6....ND2-\$5\$1%E"JBJ JH 4 4_~W=;_
_@SJO|X;_O_P"/5E45 ME|"B|Z+_P %P_R-EB*Z5E7K)+1)5)V2|?\$.O|NZW_T&=5_|&-W_
/J9)K.ML310%+JN12Q2*R21R7UT|LT|&G4G9KL_>"BBBM3\$^X?|_@G5^T4?
V9OVL_AGXXU'48M.|M%>)+X_#?XE2W5W:Z?I|?
@CQI";2P@@@U;4|7UF,3ZUJ_BGPE>^%O&6LZC;W%|;VMXBO;)|MK MVSNX8?|/7Z<'
-X|,^).!P^L7_JOG|2G#|+|OC/HX2 MD|)0S7%JGKB*AJZ4445_GB?Z?G^;_1117_0P?
|PY_1%_P;^_|C/^U!_V?A1_M_P"G#O|7|+U?S0_|&_O_"_!4'_&?A1_ZSEN?"FJ:C>->M/?
7_B?P M7#K@*:ES0YH2_#OI&>&R|5/"BOAFAA_K&=8?"?
V|PTHQYJRS_)HSQ6\$H4%9I M5;SH_6LFE)Q?+1S*JX|LU&%
|OPWXNU2>\$RV|>I_>6:3;H(%^7/^"V'|0TWPK_9FTSX1;'=O:~)
M_P|H#7)=%NY(C>PSV_P|OI VM>,9+;|L|JW2"XU/4|OPEX:N;|CN;35O#F
MN^);8P%H_B_K_@AJ^T(P^:~&|1_O6;TQ^&OCEH#SZ)#+YKQVWQ%|~#6M_
MK.FF*22|CL|_@UGPH_B|SOW6UEN|7U6O|)6*R#R(HW^5_P#@J+^T(G|0W|87
MQ#U+2;Z_|&?#5H_A'X)F@^QO;W&F^#;N^77M4M|O3|FZM-5LM;|WWBC5=&
MU=)2|YX=NM\$1PBV|<4?^=G#?@\$L#|*S,*\$L'R|(9\$X^).3IM8>5+'8F;R;+
M*3LXQC@>(UB;=*G/G|IM@|*1SG6OB%XLTPGY%=0V-
SJ*Z/875PKZUXCO;2S5KA|)|+Z)%J/_MB+69\$_%M|EWMS(Z1PNZ_P"A..QN%RW!8S;
<=7AAL#@,+B;C;35;5/#X7"T MIU|17J-)M0I4:CAQ|OP&S7'X*|NP|3%YAF6,PV
P.%|D).KB<M9C*T_/AQ|_V;|<^>L6QC|2_'K7 MS/INH-HV? MUJ>AZ
CVMQ8P365YJOB*;Q=J|TMO=7=FJV@S>\$|M"DD)%? MM17.>#O"6@>?"|A;P+X4L|I?
A;P5XG6=M;B>ZGFN9O+|R>625F=NCK_"_Q&XRQ7B!QQQ-QABU4C+.|TKXC
M#4;K4JF%RVDHX;*L%)Q;BY8++&%PLI1?+*5)R7Q'_1;X6<"X3PTV/>\$N!L&
MZ4X|Y/A|+BZ|&+C3QF:U>;%YQCX1DHR4)J_@*K^_7|L'_)-):D_|-T^O|ZK3Q M-
7|!5?Z6_05_Y)3CO_LH_*?|EAX;_P#9-9Q_ZM*(5_3#_P & M_P!_R*G|3O|V_/PK_|
3;XZK^9ZOZ8?^#?|_D5/VG?^QA^%?_IM|=5^O?2Q_M_P"3#|9_|?|
AG_UJLE/Q#Z%O_*1O_W_&"|6_|K'YZ?T/T445_CH?|H!11 M10!_F_T445_T_|_..>Y_
3H3XU_LQ>)M7|8?|QI_PA'B/7M"?PUJVH_P#"
M_>\$_\$OVO1)-0L=4>R^R>+|!"U^Q@S?;93_::UANQY/E"<0R2QR?5O|P|Q_MX*%?|!|?
^8H^"A|!|OS?HKY#./#|@+B+'3S/B#@CA#/_RJ0ITJF89QPUDV
M9XZ=.C'DI4YXO&X*O7E"E#W:<)5'&\$?>BDM#|?(\$WQ(X7R^&4|>)/&_#N5
M4JE6M3RS(^*|^RG+Z=6O+GK588+_8_#X:%2M-N=6<;2E4E|TVWJ?|H_P|Q_X
M*%?|!|?^8H^"/_SMJA A|C_,"%O^C@O_4?|'_.=M7YOT5Y?_'|"+PG_Z M-AX>?
^(5PW_|#V/^ (W>_|T=WQ/|_|\$^XK_P#GL?|!_P/?^(5PW_M_P#.PA_B-WC/_T=WQ/_
/|\$^XK_>Q^D'_#W'_@H5_T<_%YBCX(_VK^HC_M O U?%SXA_'|C?X/?
%7XJ^(/^\$J|>^*O^%@_P!O:|_9.AZ'|O|_|#^*?C?P MYI?_
!*_#FFZ/HMK|ET71|L_P#0|M_/^S_&BX|Z|FGGE_A7K^V#_@D=_R
MCU_9|_|JO_ZN|XE5_)_TQ.|!>".&/#+(|?PUP=PKP|CJW">68.KCRC*<7
M5PE3A_B>M4PM3\$X#|X>M/#SK8>A5G0E-TI5:%&I*+G3@X_V?!CQ%|0>+O%K
MB++>*^_N,>)NH>'6;XZC@.(>)|SK!4<;2XEX1H4|92PN98|\$T*>*IT,3B:
M_,1"FJL*6(KTXS4*M2,OT@HHHK_-H_U:/YO_/@X*_YM(|KW_|Q>OYOZ_I
M_P"#@K_FTC_NO?|Q>OYOZ_V2^BG_R8|@/_+NC_P!;/B(_PE^F7_RDEXC_M
/_=G_P#K!<+A7^AM|&/^2/?"C_LFO@7_-1?2J_SR:_T-O@Q_P D>^%'_9-? M O|

ZB^E5^%?3N_Y%/AO_P!C'B7_-1LF/Z*_9S?|CKQ5_|%?"?_*EYZ>E4 M445_G\$?ZH!1110
5_\$;_,%7/^4@'10_82|_|JF/E?VY5_\$;_P%7A_ME(!^T/A
|A+P#_ZJCP)7|F_0=_Y.EQ)_V0&8_P#K1<,'|&_M"O|_DSW"G_9R_MLK_|9?BX_/&O1?A-
|6/B!|_|#?B#X>^*?PMU_(1?QYX4?4I-UW^RM%UO| ^MK:/J&@Z@?
|+|1:;J^C77VC2=5O|3%|HUR(OA^_17,4,T?G5%?ZAXO"83'X7_M\$X#'_X;#XW
XW#UL)C,'BZ-/X7%X3\$TY4<1AL3AZT9T: ^'KT9SI5J-6\$Z=6G_M.4)OE&33_P
@L%C<9EN,PF8Y=B|5E^89?BL/CX_P#!0K_HX+_S%'P1_P#G;5^;|%?"?
|0B|)_ ^C8>'G_B%<-_#L/T;_B_M-WC/_P!'=|3_/Q/N*__)|'Z0?
|/Q^D'_#W'_@H5_T<%_YBCX(_P#SMJ|D^,O|?_|87Q_|*2>!OBK|M;_\$&N^\$;AR^H>'|
(T;PCX(T|64)B<6OB"+P'X>|,GO%81RPPW\$.FZXVH6\$%W
M%%=PVT=S&LH^_J*Z|_#X8^&N5XS#YAEGA|P/EV/P=6-?"8|_|Y!A,9A:T/@K_M8?\$X?
+Z=:A5C|FI2G&<>C1Q9CXN>*^;X'%99FWB=XAYIEN-HRP^-R_>-,),
M;@<70G|=#%83\$YE5H8BC|/5.K3G"76+"BBOT'_8\$'_8"|>_MI^A<3#4_"?P-
M!*:I!!|1/B-'B233)';WLG@CP0|Y!|9ZEXWO|&XMY9Y9(+S3/!NF7MIK_B"MWNGO?
#OA_P_4>SQ/Q/D7|N19AQ)Q)F%#+,GRRBZV*Q5=^:C3H4*<;U,1BL14
M<.:%PM&,Z^(KSA2I0E.23|'A'A'B+COB++.%>%,KSIX?"X>%2M6J0IPE)?LA_P0E^-
|X3^\$0Q(-:&UZS
MM4E^+FL67A/P(T^FV3:A#X/^'|WJT'B#5|_|#7(|ZXNTTSQ1XQOKC1;_0YK'3'
MCOOAM:ZE, ^16|YICV7|TUS?@WPAX<^'WA'POX\$|'Z9'HOA/P9X?T?PMX:TB*
M>ZNDTS0= T^WTO2;\$75|/=7UT;6QM8(6NKZZN;VY9#/=W\$|Q))*)_&OXK^&
M_@7|)?B|7_%TB+H'P|!*:OXENK8WEG8SZM<6-LQTOP|HJQ?RPVG|L^)=6>Q_M|Z!' +
(OVO6-2L;1-TDZ*?| \$SQ"XLS/Q9|2,YXBI82M+|%|3YQ0PF399%0E7 MIX6*H97D67)0?
LYXI82CA*->.<.6%?&.K7T=5L_Z_?#?'@K*?!?PJR'A:MC:\$<_M%PED>
(QF>YM)SCAZN,D|1G'\$6:7J)U88.6-KXW\$8>G4YIX;1HX?548H_F" _MX+@?M"2?
\$+|H?P|'|'O-_AGX&:"DNLQ1"1\$NOB+XZM-/UK5&DEBO);/4;:1
MO"J>%+&Q9|2"|TC6+0Q=8O(ZW#HGXF5TWC7Q?KWQ|!9>+?'OB|74/\$_C?Q-
MKWB_Q'?H!#;)>Z|XDU2ZUG5|M;:W2."W6XU"|N)E@C2&\$.(XD5%51S-?|_-^
M&W!F&|N!N&>#|*Z<_|%RNC0Q=>E'EABLSK.6*S7&132DHXO,:^*Q\$(RO*\$*_MD8-
OEN?X-^*W'F+|3?.\$3BWCC%J|_#^W|WKXC!8>M)2J8/*."C@|FP,VFXN>"R
MK#X/#3E"T9U*4ZB2YK%|3-,U+6M2T_1M'L+W5=7U: ^M-,TK2|.M9KW4-2U*_
MN(|6QL+"SMDDN+N|O+J6*WM;6".2:>>1(HD=W53_%1^%A_@@Y^S4/"_AL>M-
OB3|=)?&8T#1QXND|,)>)_A_->&Y/\$XTZW_M|_#UKJ?PJU#4K;0VU7|6VDP:MA?
WM|_#8&WCN|NYG629_RS_X(X_L|A:/VL=,|?:OIRW?@GX_6,7Q!U.6XM?M_M%C-
XVN7GL/AKIAE2Z@ELM2M|9BOO'.F7/E74+/X"N+6:-3?XG_|.'?V0_|HHW|2'_A7_#'
M_P"<_1_PX=_9#_Z*_^TA_P""%?|,?_G/U^V%?"R;_,3">-7_\$<;B+_P=A_M
)G|OS|L_M'_ (EC|O^C6|+_P#@C\$ _#3Y?GW9^)_X=_9#_.BC?M(?M^%?|,?)
YS|'_#AW|D/_**.^TA_X5_PQ_|G/U^V%%"\$PGC5_T<;B+_P'_M8?| ^9_+|^|_#_B6/P"_Z-
_PO_P""_3_|T^7Y|V?@W|1_ ^"\$G|/UK|A_QM=_M"
|QW|W,J63VD\$|W0EQ"4;^6:2.2&22&:-XI8G>.6*1&22.1&*O'(C,CHP*N_MC,K
@@\$5\$ _H^U_%C_P5F_9|_P""#_M@^-0TNV>+P=|:(S|7O#CC|3+%;ZC
MXDO|V/QQ|+W,EK;VBW-KXTM=9U2WTRQ>XCTOPYKGAN&216E"C^N_HD^
W\$W%_MW\$/\$!'O'&?8O.|B|!3SCA|X^=-UH2P\$G2S3+X2A""M|;4*^'QM&*O9QP6_M-
FY2|H%1_B+Z:WT?>\$N">&.&N.#WAS!89?!1C|.3G^9M?MA_P0_|V@S|.VB_\$/P.U>0
MCP|>M_/H/Y7F&R^(_P_L|6U|1R|S/JEK;Z=IFK^%9_&.GWOD:?.J.HZKX@B
M|&V47V>WCN)#^)|=-X*|8>(2AYXQ|)^/O"-|NE^*_B700%_AG4FM;2^73_M
!|X:U2UUG1KUK'4(+JPO%M=1LK:=K2^MKBSN5C,-S!-|QM_8/B1P;AO\$'@_M7B?
@_ \$NG#^V|KK4,+6|JINGA|)R0MH7Q#|);-XGMK: *_LM3DTBYU_M"TC?
5/|_M_=Z?)+:G6?#.K+?>'M=MXV#V6LZ9?V4|<5Q;RQ)Z?7^\$^_P>*R|&
M8O+|;1GAL;@<37P>+P|1)5./BL-5G0Q%&HDVE.E5A.G-)M*479L_Z+;!CL)F_MF!P69Y?
B*>+P&8X3#8|_XJ|DVZ6)PF+HPQ&&Q%-M)NG6HU(5(-I-QDKI|0_S?
MZ***_P"@|_YDCZ)_9_|VK_C|^RU=>*+WX\$>/?|A|;GQG;Z3: ^)9A_A%O!_M?B?^TH-
#DU"72TV>.,?#GB&.S^RR:I?-NL\$M7G|_%PTRQ0B/Z7_X>X_|!OK_M
*_ "_P#;4?|'_P"=M7YOT5|=FWAUX?9_CZV:Y|P+P=G6:8E4EB,RS;AC),QQ
M|=4*4*%5L9C,#6Q%54:%*G1H*=22ITJ<*<+0A&*^ZR7Q1|3.&|MP^3<.^ (O
M'6091A76>%RK)>+N(|JRW#/\$5JF)KO#X'_YA0PM%U|15JUZSITHNK6JU*L^:_M;_
OB|) ^C8>'G_B%<-_#L/5_XC=X\$ _/1W?\$_ _3|BO| ^>Q^D'_#
MW'_@H5_T<%_YBCX(_P#SMJ/^'N/_4*_P"C@O|_S%'P1_|G;5^;|%'_\$(O_M"?|Z-AX>?|
B%<-_P#SL#_B-WC/_P!'=|3_/Q/N*__)|'Z0?|/+O%KB++>*^N,)>)|NH>'6;XZC@.(>)|

JSK!4<;2XEX1H4 M\92PN98[\$T*>*IT,3B:,,1"FJL*6(KTXS4*M2,OT@HHHK-
H_P!6C^*O_@K# M^SY)\! VP_-'HMBUMX,^,F?B/X6E0W,T"7GB:
[NAXXTQ[B2TM]2&ZLO'%OK MM]!IE+,74<2_FG7]@O_6?_9V?XP?LL|"S_\$L7N_&'I/
MKN3>,8A;VUU=W= SX UQ;/2OB%8P10SQV\O#8Q6^@>-M2U*ZAN/LFD^";^&(1
M"ED"!5?I-1IX^7'_A/D&(Q%:VN<<.P_U7SGFDY598C*J5*."Q4Y2?/4EC
M*@I2E2FS_!KZ6/AJ_#7QGXD PV%P_L%M2G MT;Q/X2UW2/\$WAS6+41-1)&Z
M\$J<*BBOWI4J;J3K*G!5JD*==I54(JI.G1E5G2ISJ)K6,XO?{0TK4?#?A"XTG1=
[Z=IEU73?B-J_-O>B33KR_S_%B%4%F8@*H! M))P_.22>!R37H?
[%W]/MK^S#^S1|*_A#|GBC|0:/X?BU;QY%='T*QN;N\;R%Q)_*7TP./
MGP GX8OAW!UO99KQWBI91'E=JD,DP:HXG/:L-;-6%3!976BXR3H9I4;Y9J,E M_9?
T'/#:/&GBXN*,=AW6R;PYP<,[ES101GO!CI5L)P!1J;7C*C.GC|YP|HRB
MUB,GI*2G3E.\$OJ2BBBO\ES_:D****/G3|L'_DTG|J3_+-T^-O_*K3Q-7| M!5?
WZ_M@_P#)I/I4G_9NGQM_!5IXFK^JO|_2WZ"O_)*)<=|E#EO_JMF?Y/? MM%/_^2P|_
P#LFLX!6E\$*_IA_P"#{?|_D5/VG?^QA^%?_*;?'5?S/5_3#_P;_M_?| (J?M_|
8P_"O_TV^J_7O18_P#)A^,_^O\ PS_ZU62GXA|"W_E(W@;_M+!>+?| UC\|/Z'Z***_QT/IT
HHHH_DQ_X<.?M=?|_12/V_7_0NXG_!27%?_*3^3'_APY^UU_T4C|G'_P
*WXF_.BH_P"#{G|7_M7_12/V+OV9_M/V6?A=|_#'_FI>&|7|5^"?^\$V_M74?"-
WJ=|X>N/^\$D^(OB|Q=8_V?=:SI&@Z ME+Y6FZ_9P7?VG2;39?17,
(WCWXA>*>287A_BW%976R!|Y MK0SFC#
Y71P558W#X/'8&G*56G.3E35#,,2G3M9RE&7V\$C|*|+?HV^&/@|Q! MC.)N")G%#-
_=DV(R+\$3S#-ZV/HO+|5C_X5E_PLS^WO^%:@:MXF MTO|7_P
)G_PK|^R_|(X1SPAXJ|_|A|_|GJ/V_|9|@|KS|+|A_:O,G^S_D MQ_PX<_:Z_P"BD?
LX_P#A6_\$W_P"=%7|9U%?OO!7TE/%#>@#AG+.\$>'<7D|+)|L
MI^N_4Z>+R>ABL1'Z_F&*S/\$>TKSFI5+XK&5W&Z7+"48+2*9_?_'-%#PA|2
M^+LVXVXHP6>UL|SKZA|>J8+/*^#PTO|-RS!93A09X:%.4:=L'@;/&=F^>HIU
M'K)H_DQ_X<.?M=?|%(_9O_|"M^)_O_SHJ_J@'^^@7GA3P'X)|+;A+;3W_AKP
MCX;T'^FLGEDLYKS1M&LM.N9;22>&WF>VDFMG>!YK>"5HBC20Q.2B|=17S?B5
MXT|<^+/%#*G7=5TY2|HG'#4N5.W*^9K? M3ZOPG|_#WP7Q&=8K@?#9KAZN?
T<#0S%YCFE7,(RIY?/\$U,,J4:D(>R:EBZW M.U?G3BG|*"BBBOR8_:0HHHH
*_G9_:9_X)&_M'?M)?M0?%3XU^!_&_P2TGPM MXXN_#_QI.G^*_ \$7CNR|06Z:+X)|->&
|H:C:Z1|_.?<)>5L%1S#&Y75RBO+'8.&-I/!5L7@|:
M4C&E4E%1J.O@,,U43NHJ<5|3:,,_%/PFXA_&+(<%PWOK1Q|?+,OS>CG>'AE M^J9?
66/H8/'8"G*=:G&4ITEA|QQ*=-JSFX2O>"Y,?^'#G|77_12/V_7_0NXG_
/\$EQ7_RD_DQ_P"#{G|77_12/VNH37N MR=&O2J)-|E2\$K_?B9|#O^"&O|_
W@&Y@U7XR>,?'&OVU2VN;UDTGRC|/_EQ9 MS00)8"IT/0-
5U;Q=|J.G7*W%SHB^(5O15|)(;>|T*2&&87?|->'?#GA|PAH M>F>&?">@Z-X8|_
Z):1V&C>'_|H=CHNB:18PY\$5EIFE:;|6%A:19/EV|K; MQ0ID|4&:V:.*_\$>,O\$;CCQ!Q-+%
<9<39GGLJ\$ISPU#\$U(4>&.\$JX/@3A/*>'88B,(8K\$X6 ME4KYEC(4|>RIX|_
|=5Q6:XVG2=Y4Z>+QM:%.H7=U?:+)|EYX3T6&V@U:/5+QM_0>BO(X7XCQ_"/\$&
M4|3973P=3,LEQ<,?@%C|.L7A:>,HJ3P|>>'E"*G/#57'\$4&Y6AB*5*HU+EY7 MI?
&'V6|<,YUPEG%7'4LJS_53+LR>78IX/%U,#7E'ZUAH8E0G*G3O=%3P
MN)Y8WGAJU:FG%S4E_)C_..'/VNO^BD?LX_^%;|3?_G14?|_#AS|KK_HI'|. M/_A6_\$W_
_= %7|9U%?T3_P 3B^-7_0?P|_X8,-|L_|H|K?R|_Q(MX!?)|B M?_Q)<5_|H/S^_P"#{J0|_
Z|3?&7BS40%'CG7O"|7-WH MYB@5-(|+;#I&JZGH?A_6|H2-+T6T75/*U338FLO\$?
B+Q,EF9+*6&:7|_*_* MG;B?B7-^,.(,VXGS|\$+%9OG6,J8W&UHPC2INI-
,=&E'W:5"A2A3H8>DKJG M1I4X7?+=_P!1<(<*9)P-PSDO"/#F%>#R7(.#2P&
H2J2JU%2H|HU:|:7O5L M3B:TZN)Q-9I.KB*M2I/-9% % % %>"?1A1110 5^<_!2O|A|5?
VV/A7X.T?P1 MJ7A/P_|_%#X>^+9-7|Z|XRN-=M=&?PWKMC|@|8^)|C0K'6IK;:K-
9>&M:C MO#H&J3?:_"|H|;6%MJ5|=+^C|%?0|)|4YSP5Q%E7%/#V)6\$SC)L0|3@ZTH*
MI3O.E4P|:C6I2LJM#\$X:M6PV(I-I5%*6I|M/^%|YX/XFPCQN1
MY|A5A<=0C4=*I:G6I8G#UJ%:-Y4<3A<50H8K#5DFZ6(HTZB3Y;|FA PX<_
M;Z_Z*1^SC_X5OQ_ _^=%1_P_.'/VNO^BD?LX_^%;|3?|_YT5?UG45_0W_!+
MXU?|!_#W_A@PW_RS^KORM_/_\$BW@%_T+N)_ _\$EQ7_RD_/?_ (P?LW?'G|D
M_P"#{NL_!KXU>)/?B03M-|7WWB#X=WW@CQ+XIUN+2-&|0P17&N^&)|A2>"O
M":Z396OB*"|A264EA<:H-2U#Q7KC7..G_:0R:C^A% % % ?SOQ1Q'F%W\$&;<39
MK#"0S/:L7/'8_P"HX=87#5,75C'ZQ7A0C*4:<|354L17L|3KU:DTHTJ7*OZAX
M/X6RW@GAG>\$LGJ8VIE.08*GEV6O,<2|9BZ>"HRE|6P|3\$RC"52GA:3AAL/>M-
X8>E2IMR<._P_F/_#AS|KK_HI'|/_ (5OQ_ _^=%1_PX<_:Z_Z*1^SC_X5 MOQ-

^=%7I9U%?T1_Q.+XU?|0?P|P"&##? "S^KORM+W!(MX!?"|B?M_P27%?-
"D_DQ_X<.?M=?|12/VK^*!|PFW|JZCX M1N|300#UQ_PDGO%|7>+K'^S|K6=(T'4I?
*TW7|."|T^TZ3;.+Z*YCA|^(KF; MZSHKX#Q&|>_ \$+Q3R3"|A6XK*ZV78/-:&(.9Q-
P7A,XH9ICLFQ&18B>89O6Q|Y? MBL;E^858QHU*
<8QJO\$Y9A7&JG>,%.%K3=BBBBBOQ<_>S(|0;:HOB00=;|+^)-M.LI:|.^(U+0-
>T;4(5N+#5M%UBSFT|5-,OK=|I/9W|C&UOKN!(|B3^K:BOU/PU|9..?"^UH|
M(8|'4*._=4Y8_#X_!4|?0E4P/MUAZU*G5;|C54<36IU)TV0:P<%44O94G#|=M|6/
GP|:|I%EQOE^~O%:(KTWHRGA*%2G M"I%^QJ*|1@E^|>%?A!P3X-Y-
F&1|\$X/%8;'9IF;S7&U M0;=|>:A#+?36EA>W,=LLKP6ES*J00|S\$?|. /VNO|HI'|A
MX50Q_|G15_6=17Z|X;>-'GA3@LRR_A'\$Y;0PV;8JCC;8L=EM+'3E7H4G1
MING.I*+IQ|FVG%:-Z|GXCXK?1|.|.?&:'Y3F7&^%S:OBLEP>(P.!>79K5R^\$:
M&)K1KU55A3A-5).I%.,G9I:|F/_X<:_Z_Z*1^SC_X50Q-_P#G15^OG_!+
M_P#8;^*_I%&B?&+3?BGXB^'GB"?XA:KX+OM&?P!JOB35(:6'PY:>)(+U=3;Q
M%X3|+|/#)*^L6QM5M8|U76.|F@|I|YX>_14|(|#BS+>M-.%
<%GM'/JACJ>\$J8W.Z^,PT8YC@,3EN)IAYTXQFWAL764&VN2;C-:Q044 M45^""|
(A1110 4444 %%%?RL:|:?'C&G !RU%|(4^+|Q,3X3G4='0_#!?'GB ME?AX4D_88L?
\$CJ?|0U4>&MK^(F;7G7^S,-K3-JA!OB9ZN\$.?FUMRPE/UY;.:? MB)NUO-I?>?U3T445
PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **_E(M_P""T|4G_!8?X8_MH?
\$GP=^R-8_M!3? K3M&^TWA:3P%^S-I/Q)|&^O|MP)H%|XE%CXNNOA+XJGU"4>
(9|2%Y"VMW(L;L362L;K+>A|JWJY0<5%M0?, MKI)W:T3L|I%9ZKN).
|>CT=O7^O|NX4445 PHHHH **** "BBB@ HHHH **** M"BBB@ HHK|O^#B7XF?
\$CX5?L1_#GQ%|+_B#XW^&_B"|:;>|Z=Z|X|45Z|
MX/UFZTBY^%_QFO;C2KC4_#U_IU|IL|YHA=S6;D|6LMS8V<|O-+;0NE0CS2
MC&|KNUP>B;|I|TT5|1?|\$V/\$7B#Q=^P3^R9XF|5Z|K/B?Q)KGP1|%.CK7B#Q
M#JE|K6N:QJ%QIRO<7VJ;MJ4|S?ZA>3MTUU=W\$TK?;|L>:^W:35FUV;7W,2
M=TWG5PHHHH#"BBB@ HHHH **** "BBB@ HHK|7O^"T7QC;_K^#GPL^#&J?L*
M6_Q.N/%^L>|I'3<:>=3TV|I\$^~DTBS.IX\$5|EI9-M--HYN)!^ZJHQ%X-'SX+L
M/#K66S0K^T-;IJC?:7OFO+C|PI-6;5T|JZU3L|77EV!.Z3|JX45(|P#! M30Q+XC|'?
|\$_P|J_P4>\$=?UOPMXET3X1;|?+:XB|:K?:'KND7T4UF(|S2
M|7TR>UU"PNHPS!+BTN(ID#\$*XR;_ /W_@W5^)OQ)^*W|\$_P4? \$7Q1^(/CCXD
M^(++|J;QMhMGKOC|Q9KWC'6+31|?X2_!&^M)MM3|17^HWL&F07NHZA>0V\$4
MZ6L5U?WEPD2RW4|O2@W"4|Z1:5O4+ZV|K_B?OA1114#"BBB@ HHHH **** "
MBORT_P""U'C/QA|/?^"9O|2OB_P#XL|2^!_%ND?|*<_LGQ1X0UW5/#7B+2_M M_P?
_A7I=|V=K>BW5EJ=E|MTR|O-.N_LUS%|HL;NZM)M|O/+&Y_P \$5_&? MC#XA?|S?
V:O%_C|Q9XE|<>+=7_X7';WBCQ?KNJ>)?\$6J?8/C_15-+L|I1U
MO6KJHU.|^Q:996>G6GVFFE^S6-I;6D.RW@BC2^3|WSW^WR6_|=YKW%?6WE?|
M3|2Z***@84444 %%%%"1110 4444 %%%%" ,RHK.|!54%F9B%5549+,3@ M DDD 9-
<)X1^*?PO|?WFI:?'X#^(W@/QM?Z/G^U|PCXO|/^(+S2MLOD'^TK
M;1M1O9K'\$W|D_:DBQ+^|/S|5_(E_P4\$|??:_@JO_P%0C_P3C^?\$Q4D|*?L
M_P#PSU^|+>(9K*S|0R^\$+;7O_&B)KWQG^(/Q"T.P@L;GQ9XB|^'*,#4_AEX
M"TG6|0M/'7_"2:/H=OH>M^%G|=^(?%-|J?MH?|I\$"!^R9|M8_:A_90_:I\$^*
M|1/V>_#|Q|3_|\$ICK|:-H&LW%GX.%GK6M^~AOXP|)S>%|_P+J?@C2K#6O%<
M&F7)|2ZGJ4-E%:Z1KUIJG;QZSNJ4?=4JG+*:34>5NUIN9WTO^4CF>ME=*Z MW_K_
O_8K7|AFK?|K3T7_83T7_UW|85^Q_1B_;/A9?MK_L7Z/XP^)|RF
MH_%7X7^,M9^#_CSQ!FUAF|976@Z3H'B#0/&<^GVY)M+K5O#BC2+#6IV6.#5
M/%6C>(M3LH+.TN8M/L_QPU;_)6GH0|L)Z+_P"N_K"BG%QE6B|U2J)_@#=U
M%_WE^I_7G44|I%K!-=74T5M;6T4D|Q<3R)#|!"C22S32R,L<444:L|DCLJ(
MBLS,%!-2U_%#|?|Q9^T/_P6_P#^"D/CO|D+P%|43|/V8?@SK'CB6U73|I^
M)/!EIX3^%>LIX)OOC AJGAFVUCPK%|2_%'C7Q=K.FVW@RS%S'-X5T#QE8;:7
MMOIH XN|3ZKG"".W=J,8J|I/6R|DMV^BZ^NCINUNK>R|I)O""Q.^&WQ!EU*# MP#|00
_C>;1H!%J/A#Q9H/B672I69D6+4H|%U"|>QD+JRA+H1,65E R"!W%_M?QO?MU?|I\$&9?
V/O@OJ?|5?|I"QU^+&H>+O@':_|"P_%D>(|W2=(|96FB>'MI(=0U3X@?
#;QSX)M?"\$WAO5?A_96|S XGO+NI:YO;W1K/4+|I0\$=KK6D6&A^
M)/W/_P"".7|9WC3|M_+8NTXA_\$U5N?B?|_#OQ GKOP:^(('B*&SM|/M/&>M^
M%M'|^(=,|70V-M+);#;7NK^\$ _&'AO_A(Q!'8V_ BV#Q!=Z3I>DZ-<:=IMK4J M:4>>\$N:-
|ZLT^FG5/O|A)N|FK.US|4JXW5_B-|/?#_B71?|FO>_.!NB>./I\$
M>S_A'O"FK^)|\$TWQ+KWF2/#'_8NA7E|JFJ;Y8WB3|#:S|I\$=%RRD#^'C_@H
MEKWQOT#_ (+V_\$C_(9MNK?3_CIXF|1_!CX+;G5;?

6+J*>RT2XLXM7OK:YL[*>WD^/'O_-:77B3X=:W MXE'[8/B;QC^T_J|FM^*.:12>."K3?
#|OIXJU&_ U\$Z=K%X^M:UX_P!.GU77 M)|>/6?B->ZKXMOY4-
|K;>!:BZN4TN"G2C%0X|1_#W3/GBW10AUXY^\$VM:A>WDM_=Z=H>K>
(_#9|%:6T,A|*V>F^M)|\$6|_L.+PUL.C_9'_!33_@B|_P|7^/'A+XV_P##27_"G?|
A%OA'H/PL_X1 MG_A3O_"POMW|B>,O'OBW^W?|_:X6GX'^R_:O^\$X_L_|LO|
LFX|G^R_M?|M:,OVW|_:2Z:C-PG-125U))R3OJM%KK_5|OJ5U=*[|?|
|/W,HK^(|J|L|_@@_'MX>_8S_9D^+|/2GB?|LC40%^G?#31M-N+3PKI|/-
UMIMWXC|0^)?\$6C>#?">C MR:K=?M_74>CZ;?>*/\$6D0ZWK::?|JSHFB-
J.KVFAZ|=64.D7OZ-?&RWP.U|MP5^SA|>OC|KC:C8:7|OB+X=|+^%=-U'1)K"SO?
#OP7TW7H|KQKH^NS71BUS_M2|6|4_\$'Q-X1F2WL(+?2-7^'NK0MJ%|
<7%Q::4Y4H*\$|QJ55M+|WT/Z6=1U'3|L+S5=6O|/2|TZVFO-0U+4;J"RL+&SMXVEN+
MJ|O+EXK>VMH(E:2:>>1(HHU9W=5!-%_"@Q?"|=|M8W.M^(/#OAG4?"7_
C2W1L=7O|_4:C6-0TL7FG0-48IJ\$JG+|I>|RMI-VM%
MN^|O|OFKKF>K2NEU|_U_5MC^U>BO@K_@F9^U?J?|:/|%WP>^.?B<:=%X_P!0
ML=7|)_\$JVTPHML0CGP3K-|X<|_WQ%TA:1|7_P#|_:|:|^'_P"R7XE?P7|=|B3^T)|>?
'A MKQK#J|_:|<>#=#|360BFR^(GBN#6Q#,'M+6XU_M'P+#_P_)I::!|)'*3E*
<6U^P3;OJM'9Z|NM|1N5K:7O|_3_,_ODD^(WPIA|8 MQ?#N;QWX,B^(\$|L+V#P-
)XHT1/&,UF8'NA=Q>&6OAK4EL;6-|D3I9-\$8\$>;? MY:EAV5?R?*M#?|&TB>&O@3K_
(O^!_Q_|9_\$W|H/POHNH>);WP|XO|_:1I?A MOXLZC8Q2WU_H/A1-/O;W6O!/?
B36\$6=O#LFOZ_P"-|+4#=#%EH^L:AHEEJESXH MT;
|F_P"#?'|MKXD_M1_L|_\$|X5?O\$7C?QW^SEXB|*6|EX_P#\$=V^IZGK_M_/?B3:>
(|_"6EZUK5|?WFL:|XC|-ZQX*|8VEUJFHQPAO#=#WX2LDF0;NRU"X M+E3CR.
<)|RBT|DKE:O:S2N|&W;Y;O6PF|V:M?;J?T"t5_(_,:%:?^4|/_|, MW_NS+_UL?XD5^N'_
78_P"45?|4W_=|/_6C?A#2=*WLO>_B6Z?#=#I=|=(=M|+_ "3_%/UFO|^QTNRO-
3U_|M-.T|3|6>|O|0O|B&TLK&SM8FGN;N|N|AX
MX+:UMX4>:>XFD2*&)&DD=44D8/A'QOX*^(&D_P!O>_%_A?QMH?VF:S_+9|M(^(-
)2:3|KMPAGM?|1T:|O:/|3_'0S0>=YL8=-ZKN&?XA/^"87_3T^.' M 4Q_9_TWPS|2?
CQX@^%7|%WP(^ (7B'3/#W@;PC8P7NJ?\$'XJZU\$GBGQ7K3V
M5|J\$.E6>H^'|)6:)867C/O!|7B2"RLKNX|_>%)#M|F|8ZK65^V5^Q3^T5_
MP0U^,/PH::_9G^-FN^)|OASXLUZ|VNO7FDW.B3V>JV4W_"0#X0?&'1M-OV
M|_.?_"_C+P|HCZGIMW;RZ6VLW7AKQ-<+X:|)ZAX8|V:WJ=^QCS.'M%S|%RM) MZ7LW?
=K72|MM63S.U^73U|/'|W%5-0U"PTFOO-4U2|M--TW3K:>|U#4=0N8;
M.QL:;VC::YN|R|N'CM|:VMX4>6>>>1(HHU9Y'55)'F7P&^*VG_'?X'_!|XVZ
M5ILVBZ=|7?AAX#^)=GHES|'2C0=":SA3YG*|Y8P5Y2M>W1*RW;U^X;E:UM6|D?
VN^#?B%X|^ (MC<:A
M/O"@_QUIMI.+6ZU'P;XET7Q/8VUR5+"WN+O1+V^MX9RH+"*219"H)VX&:|"
MOXGOV^O^"1_Q\$X)9^%M!:_=#8R:.\$^),EA|_=>|/6'B^XU:;1-|?>|!%|4:
MC_PC=EXIMO\$&AS:;+I7B|P=X@UO5M#|_#^ (? TOA6:9X=?4ZM%XE|*ZAKZ:|_4
MQ_P3Z:)|/"?AF^M?&&G6|O3XO&O@SQ%K7@7Q?=
M:7:FXNYK#1M6|1>&M1UK0M/NKNZO++1-1TZVN|JZGC>XEUF MI6O9KTU_|I-
B:;LU9VOY?U_5S|)HHK^;C_@X#:_^*OP_T+X5?LJ_L|^)|M?\$_XTV-WXL|>)/|MY?
6'CO2O 46K#P|X3|/>\$|S38?|3L;SX@^*+;Q|.#);L11"#G)16|ZO965V-NRN?
T\$ZK|5OA=H?BNR|":W| M2?_C^.-2-L-|&ZKXQ|.Z?XKOS>FS%EX>N|1AU>Z-
V%8VP@LY//|DQ:P#7 M?5_*)|_?
^#8GP=J/P>MY_BW^TGXVTGX_ZUI5OJ%U/X1|_>'M5^&G@W6|VQM)
MKK1+S2=4E3Q)|0(|(U)KZ";7|3Q=X&76XC#+#I6F>6S7/(-|3\$/VE_CW^S/^
MVE|1_P#@F=^T'XKO?\$V@:5??\$?P|_|&<:WKEGX0^)'PNBO=>U.#P#K.M0Z7
MJ>D_"|O|W|M"|3>+|/T|4M+ATYM2LO#>KZ|T'AS4?%WBUM>T=*+C)PGS."NT
MXM72W:=WIT?|"ZYFFKJU|K_.R?|_7W|G|=8/B;Q5X7|%/Z/=>(O&/B30/"?A M^R,8O-
=|3:QIV@Z/;&5Q'\$+K4|4N+6RMS+(RQO^;FIR%7+\$"OY|_P#@YI_Y M,1^\$G_9VW@7_
-4Y|>*^&?V._P#@CY|6?^"C|/_,%OC_|MD_M)_\$3POX_MM?
A9HOP_9U^\$'AG0!%=>#?A7X#T700_7@;Q"|^*U&@:#8>+--|(#Q#+I7AO
MPG=|X|TJ^V_!!O?";CKUWI|JHTXN"G*?*N9QMRMNZMMKKUOV|PYG=Q2U7
M6_|O|Y_7YHFN:)|XETFP|PYK&E^(-#U2W6|TS6M\$U"TU72=1M7)"7-AJ-A-/
M9WENY5@LUO-) &Q!_8X-:E?PF:;'^T#_P0"X*!^!|/5|5;KQ|^SQ|3+?P?K
MOCMK30|1TWPK|2?A-K&NW'A0Q+JMYX&NM;OM-T+XM_#;ZTW6-1|-7>F>*+W4
M;_%\$T:_UB3P=XY|0^&-2_M?^_GQ5TSX%?!3XO?&O6=/FU?2OA%|,O'?Q+U#1
M|6Z@LKO6;7P/X8U3Q++HJE=7*O!|>ZJNF_V?922I(BW5S#F.3|C\$Z?*X|KYH

MS5XM*U_*W=77ZVV&G??1K='3^,?'_@3X>:=%K'Q|: ^\$O VDW%PMG!JGC'Q)
MH_AG3IKMU9UM8KW6KVRMI+AD5F6!)6E*JS!2_37X!|!RM>6FH|\$_(3W
M^GW5M?6%]^U1.[NRO;.>*YM+RTN?A%|;YK>ZM;F!GAN+>>%TEAFB=XY8W5T
M9E8\$ _CI^PK^PA: _^"UWQ1^+W|5G|47QJ|3:+X"TCQ7_ ,(QJGB'2|:UU;Q%
MXD|3S68|0-|_AU9ZK=W&C?#_P (>- 'U|1+|C|H6IZ=9VNN:1HVAZ'?3WVM M:QH')_!
!5C_ ()X?&W_ ()Q?"WP|X\$|(?&KQ-|5OV)OBU|5K+Q79>'_!#I
M|%E= _#WXZ^&/#/BO3|/#CU>VB^T:2NJ^)?A|K'B+|/XH|(OX>3QM%X?U&R|8^
M\$;4^_O_VI7FL*48U(KVB,/ #USXO_MM7M8S+=)<>&H=1?
687MH@9+A9+)3#&"|@5037|P?_!8WH|_JHS|?|M'X>?| M\$H_V40%.M>\$OK@|_Z-
|8;C2|K6- C|3^(/B'X>3Q1H0>_&-KHZWEC|&J^ (XM=T'6KGPCHT;_&O_:_ ^"8?
A1UNY+/29M%T6?40%O@K3|3O?L%K/KZ^ (O_M'EQHEM|KOD|_Z|
(8=/714HJ,7.IRN:3BN5RT?5ZJR_KH)R=_ =5|/5|?)?U|C M^K>BOYFO^" /|"?%>M^&
("\$>IM?:K9V&K:|H*:I_PC?AO_MPSI.E9O_7O_ ;1^/^D^/_@O_P
\$|V9;S6|!8_ '12/#NK>_ ;15|+:G#HWBK_MQE;_!|:|L_ A|!(M#|1#5+!O#>G^)-
>T35I_ '7FO|FNZ9>>&-&EUJV|*M7WC'2=?7LI>T|G==W+IRVOS?=TOOI?
J',K7^5NM^W|= _A_1U)|5?A?%XO7X? M2_\$CP%%X|8QJO@B3QAX>3Q>S2A6B5?
#3:B-9)E5E;_ "R)<_I7((KO: _E*TK_ _M (-@/_|GP5M+?
6_VFO%=I^T5+I%M=7NKZ5X:TC4/@K8:Z|PW-
WH=KX7CB+Q1+X.L5+^\$%TO^"!G|6|0&B?&WXZ_|!:_| MHS5|0UZ_ ^" ^C>*+KP;-
XG|9V^OZK|_|= ^\$'C#1/AAXX^#^AW9DU5/\$GAM?|1
MM|3|_6^CZ|_9'A*P|%Z|_8UGJ.CZ|L^B-TXN,G"IS#/_&D'Q|X|!7>&!/6@KD"|N=
M_P!FM3J6LW=E9BYN/+D|B_S>;+L?RT;:V/Y1O^#|O_FQ7_NYW_WWJF?'_@B
MW|5_ ^"A?PC|!_M2_ML_M.>--\$|0?+\$+X6^%C|/_AUX-TG1-7TOX:?"5-#LW^%
M<4LVH:G>Z3:;)?|AR6SUUO?A_3|(U96U%|:|8>+|OX@:|XJ2Q%2CR1J2J<_MJE?
3EN|&UIKKM=O2WF#D|M)7:|/Z|N|_6S8WUEJ=E9ZEIMY:ZAI VH6MO?6%
M_8W\$5W97UE=O)/:WEG=O)/!+/%N@>';S69#*D_CTJUUC4+.?47_|D<(2T29C*Z
M1XWLH|!|=XN^ (G|>A_P0I_&:^*G|_O@'XI0:YX9|:>\$;S6O:4VHZ1+JO@/_MQ1H/CBRO-
#|*_&WPM|/=6U'4|'PK|3/#NL:'<:5>VMX-9TR?Q'X/N?#VNI0_M?!-MIESJGZD>\$A
@VTU_P"*?P|O?B|!^TS^UKX|'|4'Q!AMOS_ _B*_CT.S^(_
MC>&O\$FIQP7.JZ:XOUK7O\$|^(_BIK,\$AFAO|_Q'8>)_ "5K)>L5M5U2SM(|0U.
MG1C&TI54HR^%J+;EW=NEK|WVW%\$S-|1UZWZ?E^A_6\$"" 0001D\$<@@|!"#W!HK
M^._W_ ((Z_ '+|HK|BO_@H#X@_X)7_!UU&ZU_P=?GX|T'0|'GU6^O-\$|^+_M
YX2UCXJ:-XV^'=QJHK;W|/P^ ^*GA/3|C4H?#YT_1_|1N?%WAWQ;+8Z|JB>_M(+|/5_NK-
(:./^3#OA+_ _G<>_ _%3?Q|J'2M4C#F34|_.DMXO9VO|_A?YC
MYO=;MMHUYG|%%8_ _B#Q%X?)Z-?|_B+Q5KNC>&?#^E0BXU/7?&\$&IV6C:-IT!D
M2(3W^IZC/:65G"99(XQ)<3QH9'1_VYE!^_ ^"9G_ "CW_8S_ .S<_A7_ .HK MI|?RAW?
AWXT_|%|/^"C/Q0|+|H9)/"G|_OP@/_C:4_6J|H6MZCX;|'_ "#2O\$ MMIX7|)W'A7P3-
>Z?:7/Q0^+|LKZ+X@|3:AXCUG2+R:UAURX6YFT;P+X6|"1D:
M?,YWERQA|4K7ZM*R|NW_ _X.5DM-7:R_X)_3W_P4|3^&O&/!_K|K?Q%X|1
M0Z'XJ|ZA|%O\$;V&N^'-6L-^2.YM(Y&L|3TRXNK*Y5)\$:-VAG<*ZLC\$," M|^?G_!LO_P
F'?%K_L|COY_ZIOX"5^*= _M:|H^GCPK8:_P"\$KF>?7K;6|2TBXUNSL_T9_P"#9?|
Y._ ^+7_9W'CS_P!4 MW|!U<8JA/EES1OZEX4|+? M\$;P'XE|4Z,DDFK^&M
|7^'|9U_2HXI%BE?4M'T|4;G4:|(Y72.1KJVB5)'5&_M(9@#_*U_P6#^_-|2'|9O|??
@C_@DY| ?\$%|X2|()X+L_B/9Q7DVC6/C3Q+X MC|*6WQ9U?7_&U|:7Z3:|_/A?|_+C3?
%4/A&*W#WOB+2_\$&H|IOB77++P/%H MU7|HS_@VYT_X7?L_:M|1OV-9|
UKPW8VNE?\$S4_ "UB MNJZAI'PTT_P=;W'BSP/XMU!K.|N?_EA=ZO|_\$
W^OKHWA>|U/3\$U";QAI>:_IM12CSU.64TG%*/-9/905;_@#D|^ZK|_Y+^G_
)_UUT5^%O|_P06_:J|>_M@_MLS>_!/QF|67?C;XQ?LZ^)-
"|:CXJU*SO&U|Q+|_O%>CW\$ _PWUWQAXAGDDM_M_ %'C:;AX:|= ^'-6UA5BUG4M,+
: #KGBR35O%&M:KXCULO|= ^" ^_O_UOX*_| M!5G|F#XQ^&M/TW5O\$?
PE^#WP%^)GA_2M8CNYM(U/6_?Q|^*_BG2M/U6*PN;
M*_ETV|O|*@MKZ.RO+2|>UDE6VN8)BDJ\$;+=25-NSBF|VO?9KJM|CYE;FZ?|_M!L?
V<>)O%_A/P78PZIXQ|4>'?'>F7-|:Z9;ZCXFUO3=|L9|2OI/*LM/ANI4N
M;6WEOKR7|W:VB2-<7\$GR0QNW%= %7|K7PE_X(4_M&?M'>,""?|6'|?W|67B6;
MXTZ|J.C^.=7^'FD^&|?Q)|GAAH|0L_ \$VC^|S(Q=J&N6'AOPW!HDT|YI5|X|
M#>!O^\$-+|LIT_P):W|ID;3'AA_@Z;_:_%?^|G?_?>J%2C*<(1J)MWYFHN
MT6E>RNUS7L|=|3H'|_I-N-MK)M7U|VO:Q_5OXO|<^"?A|H2Z|X|!8^%O!&B-<
MQ62ZQXO|0Z3X:TIKR<_T-HNH:S=V5H;F98Y&B@\$QED".40A6QT%G>6>HVEKJ

M&GW5M?6%I;PWEE>V<I5U:7EIUKXE MZ%"WP5^)O@;0;F5Y!WBW7/%-
UX5^_Q#:QGU?P-"K>(I'UG4?Z^"-OBW2
M'I*+4E&HI3@FW%1=FEOROK;TU8:KI>A_!\$FOV9M8UO4K#1I
(TVV^.=YJ.J:K>6^GZ=86D'I1 M?Q>>:ZO;ZIDAMK6VA0%I9YY8XHU!9V &:OI
_!=C_E%7^U_-W1#_-:-^\$-?MSI_!\$V?^"87QL_X*4_LU?#O5/C/I?
O"PT_9&^" ^N^,/IWP, ^%_AK07:J77
ME[XE|5^+O'_CO29=86U|'VD,'CCQKJ7AN'QU)I/CW7=:N-%|3>!9U|,V'@W3
M'NW&*E0?--+E2JW;LW|A*R2W>OD)MJ6BO|OZG|JWA;QAX2|F>(-
'GF@;9/%#J>DW5W92R0O|+*B3LT;?*X4|5T5?P;_M M._LV_M'_//
_P#:6^#WQJ^!'QFO'/@'XA7&OC3YKW1KS0--|4Z9X8U'3Y?
M\$OP=^,GA>SU74|SUI|3+|0->TB;2M?@O=,O|O4DU'Q5X0TWP9XF|):=J-A_:: MJ/I1?
@*S_9>OOVM;,>/5|HX86GP\$NOVBX8HK6!:=?O/4'P|?XEQQQV2W4MLNK
MW'AY%5+47LD_O7\$0NGC_ 'IB= /EY7%|T9WY7:SNG9IKO^>HT|W35FCV#Q%XE
M|.>\$-'O?#\$7BSQ!HGA?P_IJ++J.N^(M5L-\$T>PC=UC62|U/4H:RM4:1TC5YY
MXU+IJ@EF-?PMXP|)>.=)CU_P3XI|.>,-"FED@BUKPMK>F>(-)EFB"-+ #'J6
MDW5W9O+&LD;21K,70.A8_N?XE/V2?V4_P!H?_@O-|_ (J_M)_M3_&3Q#X1
M^#7@77ET"SL?#%LIS!8ZEJ|>I6OPE^"NB:Q)>^&O!'A_P (^'OI*U+O3XBU
M2WUS6|0N|1|/7NL:~XQ|2>*O\$?BS2&?M|?|! /CXL_|!%SQA+/VN/V0_V@
M_'FWW@_2=#LDT6PT?6K'5IM1LKZ2_8QNH.HE4=M.5N-W|GF|^?X"YGO;W?77
M>W|++|3^Y&BO"V8/CAIG|2O|.WP5^/FE6=HD'O9^&_A3QK=Z+8ZF-:MO#FM
MZQI-O-XC|++JWV6Q.HR^%O\$ _U/P|/^3|@SX\$?M*_M_M._MB_&/X
_LW_\$NY^#|7Q0|/?\$70/CY|1+2:***?0/V>8OB9X3U3QG"#!= M.:?XBU5M;|2Z?
X)|/KX:|+;KHUWXM?54|*^*_-TCX;ZSXXU"WB%/FY|IR4.2UI
MKSL^O3YW>@W*UM+W_P"!_GY'^AJ|Q'^^FN>)|7|\$Z)X|&:QXS|ASKWA'2
M_%&AZAXGT01LB2'5| M+Z;5=-"/+\$KF|M(0K2(K8+J#V=?QB_MN_|&_%_P#L MM? ?
7OVD0V:~CUXR|8>)O@9H'"Q/&GA|Q+IND>&-:DTGPB@UOQ-X|^'WBO0
M|4TW_A|WP58V-QXHA|-7T.I:I=Z?IIV=&|43>(+ +2|'U|IH?^""|:WCC|L
MG|D"X_X6YKX|2_%WX)>,YOAIXE|07=R;CQ!XN|_-HNE:WX|:;>)"MI;1G5K^
MUO=6|*WEZTU|?Z|>^"|SO'JUJ>L73\$E3BH<|)|ZOROW>5I_>|^JWU!-WL MU9|
=|@_UH?LS1116104444 ?QQ?|!#?QU9?%K_@L#^W1|7-*,|E?;\$?P
M%^TCXZT|6TGG6YLO'/|4'PM|361MYC@RP"VN5|J0CYT*L<\$U_7-|3?|VE?;\$7 MX;?
\$'X?:|90ZGHGCKP|XL|:QIUQ&TL&H:5XGT&_T34+*>)/FDAN|2^F@DC7 MYG21E')%?
QI?|&Q\$\$\$?M6_M!730Q-2UM7FC5@DKVT#.K-
#&5_MDK>O|M733E4;?):\$0V|7_P/T/Y;?| @UIU:_FT MC|MS0D)V;3-.U+|G?
5K.V).R&_UJU^_EGJ,ZC_-UQ;Z|I4:D \$BU3)(YK5_MO^5IZ+_L)Z+_ _N_K"C_(-:J9-
9_::L5*^1<:9^SS=2 KEG-9W?QJA@(:J M%"7UQN7^(E2?NBC5O^5IZ+_L)Z+_
_N_K"M9?QL1_P|!>9?|L|+X8?XE^;/ MZ|Z^)_V;O^"=7|&W|(OC|Q)|4/V>?
@XGP^|=^+O#|HX6|0Z^?'WQ0|6R7^@: MEK6E^(:|3EL?'/C;Q-I=BESK&BZ7>R3:~
8VEUNLXX5G%N9(7^V*_DS_:_J_:_X M_:_B_:_A
VY\$/!_!3_@G;XBU;X;;;7*N|M|H|_P2VTM6O)::Z|C^A3|O|_P"3#OVV/^S1_P|I M'_U3?
C.OQM_X-C9YF_8|^_.ELTTK6|7|2VJ3Q6YD5+>|7+^"*,+|F_'G_@EC_P%4?
7L.OQN^(GQ=_X*??\$#Q?X=|\$_
M|+XH^,OB)|,H/C/^T7XL|. ^+O#7AGP1KVM>)/!;3^)M;TFQUS3O\$NBV-UH|S
M%KGANWT^ZBO|>_L);0R+)|6_P#!L9_R:#|>/^SD;|_U6'PZK5Q4:\$TI*7O1
MU5U::35\$W;E&Z:WW|U^G|6/C'XD(DG_!T|IRNBNI>_"IP'4,|?|&O@^2-P M"" TH_
MD./VO|3_ \$/Y|A @E>S+_P7R_X*#A690^O_+;JN 2_ZC|HPXX5@#AE#HC
MX.1N56QE01_7_7|?W_!+#+E/G_P4\$_|&'|M;_P|!<|/5_8#4UOC7^""_*2A M0V?K^B/Y/?
@YB^_VHZW+^S%^Q7X,L;G7O\$GB;6W^_/B#0-.T+5=0|0WU|/
M+K7PK^#NF^&I;)WCU27Q|J6H?%;UU#P_::?>ZG-J&F^%I+=K?SDAOOZ/V3? MV==
_9>_9>^#|/..EHTUK|_OAUI/AGO!>Z.FH6FG^(O%UY;R:E|0_%=K#>7 M=S?
V*^,O&VI^(_%#6QNLV4NLO!;""&&**A_E_90EM/^"G/_!>OQG|>99M&
M|1_"X)^)M=^+7A>6*_|Z-9:GX%^!;FB_#G|G|6_#\$,D:ZC::SJWCJ;X=?%
MG6O#.M2Z#H^H@>-UO;|X9)/#-|VHU57W8TZ:T:7-)?W|;7|TK^B81U=
MEZ*WYZ'R/^RQ^PG^RK^Q3_PG?_#,OPL_X5I_PLO_ (1C_A-O^*W^(WC+^VO^ M\$-
_X2'_A&|DH'B_P5_P|F_P|F_P#"5Z_ _@G|!|L^W_Z?|J^RV7V;YY_MX+.HC_|!;|K1757
|&^%G_90P#Q_\$SP1)&P!! 9'571N|N|JLI!-?AC|?_M-O#|NK_(*H?M@^(?V2O^"
<'Q#O_A|'_A_>ZS?GXE>%O&&H_#F|4Z'X3U M*R|/E|6?&'Q*|_-
>^,|/^'MWKFI00>#?"G@J\$WVNZ3K>DZAXD|.:OJQAL_# M7&_MM?|!|-+</p></div>

(*3_!/?]D+XM?%;X[?!\!2+X@?%_P+X3\,:#J'COX27GQ6~/
M7BKP]XE^V>)/#VFG2A'XQ\0)H^M66GZS?VU_:7&LZ!;>>-/ANSHE=>7'#4:
M:4X2G47.Y1?*VY2>JLF^C:TU\OD-Z-):6:NMNG^?];K\1?!\@V\Y1ZZS_V<M3\2?
49^'E?E3^R9:P7'!RC\2)9HP\EE\;-K:ZM6+;/*G?X;!LVD_5
M@&)MKNXBVN&7\$A8+O5&7\5O^#;S_)1ZZS_V<3\2?_49^'E?EA^R_RLF_%+
M_LM'[6G_*@/Q%I;Q/^&7YB?_+OY?H?VD5_&W_P;^:7XE^#'_!2K\M3\I\:
MK=MX=|+?#KXHZ7X@L)8FMQJ7B7X+?'OP9X#V\;K=6\|D<\$D-W86/BWQ;"D3P1 M-
%_;%S&T<9\0?V25_(_, \$EO^4V_!3+_NW_UL?X;UG3?|NLN\8O\H:~?F. M6\?7\|
H!_P5I_Y3P_|\$S?^|,O_6Q_B17ZX?!\!=C_)15_M3?|T0_|:-^\$-?D M?_P5I_Y3P_|!,W_
+LR_P#6Q_B17ZX?|V/^45?|4W_'1#_P!:-^\$-:?" M_P#;O_I41O:~?S_|24>+_P#!NJ/^"
<=>E8_&?C3\4B?<^9H0R?4X'T':O+_M_P#@YH_Y_.^\$O_9W'@/_-4W\>Z\0_X-UO\|
E''I/_9:/BE_Z-T*O+_^#FC_M_),.^\$O_&=QX#_|4W\>ZG_F_)B?D_)AH_H?#?@O<=>
(|/\$\XL8OCM<7D(0,94\$46H6#EW18Y M/- C9VBE\$?ZD^!';?_!!7>,\$I_P2_P#%|@TE?V<-
<(S@@XR.<\$?6OYB/^"4 MO_!4;Q7_,\$_? 7Q9\+;!\^RMXA_:#M_B+XOT+7Y\9T?
Q\|7@V'P\|HNC3:=_M9DL%E\|/B#'?2W272W7FO>:
<|*!4^S2AQ*+C%RIUU%7DZB5KI;23W=O/J*|G M"^RC^:/|/#A_@J9X&T7XA_|!O\|L?0-?
@-Q8Z?|"/&_CF"-6VE=:^&%A_PL MOPW/GN+7O%X2TJY9?
XUA*|Z_.+_@VEU6\U'\@7X@V=U/+!H7\4WQ!TK38Y) M&=:;RF^&?
P9UR2"%6)\$43:CK-_O^%P_"XB?"_A_)^%N:|KG_CO_">^\$=7\+7?|?%_X9\T?
M^U_|D.J;_|L_M;3/MWV?|+_&A9^;|HC^|/^#;|0M;V?L;?%;RU_1M5T_|
ME_:Q|=745IK&G7>FW,EL_P'_@3\$EPD%|#!*|RP31+;J&-I(94#%HW EPE" MA-
223%| M1UI=6UO6_P"W=,|:CX+|3XP4W)*#;D\|&UIUNUT|C=DG?8_:OY&I/E_P"#
MJ4;?ES+%G;QG?_P3L3?TQ\|<=W\|D)SG)H^"O_!-W_@MW\>"5A\7OBC_,%# M?BY\;
|XBVQ\8VWP\|U3XW?'FU\8Z!_;U\|>WHL?\$O@#PC>>'O\OPW:2S>RU+3
M_!NA7TTOAFSU"+PYJ_A_PAJ^D7OAZP^7_P|C?X?%KX!_P#!PC\|A|<_B_MK'OZ^*?
A.7Q3_P_)1\6->UCQ+KVK>*_|=8\2^)=^\$^UZMXPO\3\17?|A>'= M9TCPW!_:-
|Y%MH\|M:;>78PVL,>|(1A\6TXR?LH\7TT6M\|M\|N^4MMN.C7O M+?|KS_#UM^K?
_!S3_R8C\)/^SMO_O\ZISX\5^N7\|')AW|\$_&:/^S=_MZIOP97Y&_P#!S3_R8C\)/^SMO
O_*ISX\5^N7\|')AW|\$_9H_|-W_*IO MP963_@P_QS_*(+XY>G^1_:-, '1_P#R_|&Q_|
(K\:_P#T\|_#7_\$_G7\:_M_!/:Q#J7AC_O=_M7:EI4S075SH7PX\2NK,1;3?
%WQG^"A/6825\06XT MC6KZ\U/RNLA1@58BOQ(X.C_/D=_P|C;_L5?C7_.G?
X:5^S7_!=C_E%7^U M_-W1#_UHWX0UKTPO^)^EQ#K/T7Y,|L_X-YO!=CX6_X)L>#-?
RH3HZ>-/%.GZ\|JFK M+(;2_L>J27,J+IMTD?|DU?B=_P5\X)+6_4)T+PK\2?
A:XAT7P5^TG\|-M\|+'AK2+SQ3)=P^"OB'X\FU2?5\|WBF^T\3M5U;0-
3\;AJ.KZ\X*|0Z;87\|MG\|JU77_#OB+2+BVA0;9XH\|_#_)?-7_@LK^VW_P3R\;67\|-
G_!3WX_.\$'QMI M&C6\$::9XOO+;28/C=8^'|&U70\|U\1_\$TFHVOP_
&@O"LFH:!:>6:~+!)O\$T6 MN:IK5YXAU74_BGXFFTR'0%VV MFO?|C^DOX1?L!~?LL_
O\H3XE_M2_#+X?W^@?&SXO2^_90'_BJ;QKXUUBUUJ3 MXC>+|+QWXN;?AS6=?O\|
PYI@U+Q\TUGJ\$;Z7I=F+!8?L=@+:R>2W9/B5_P_\$ M^?V0_B_^T'X/_:H^(WPE?Q\|>?
J>|M:|(^.G^(/Q1TM=&U+X;:O#KW@N>/
MPMHOC;3?!=TFC:O!>FUO_#MU::E)YB:O!~?Q331R>U? C\H#X_-M-?#?2/BW
M\|"?VB?;\$;P|K>S2&ZMY)?QV_P""U_|P5+|;_L1:_X!^"'\|VFI^T;|6=-G\3/
MKM_HD7B*3X;^_%U*XT+1\;T00-6L;K0;A3>_,\$ECK&E>'8M1MM=T\3\?PMX MA?
5\|DFOM E?_*J2GRIR4\6;::26SZD+;Y;E.R5\|*RUT7W6/WKK^_)|@0D M?|'%GOX_)
;|H'\NL\$#@?VG\46P<=1N;GN>HKZ7^&'!*_G_@MAXX\|VGB MCXG?|%+OB?|
"36M(SX>US3/'6EZEI MLK\|FS|*:SXGT7ETM=22*&-'^%?^"2?@WQ=|O\|
@N%K/P_^(C&|^(?COP-MXS_-O\(>-/'^HWFIZC\|CCO9X;TCQ\|HWP'B'Q=?;AK4\|UK-
|>>)-7L\|O6+F\|U; MZN=2N9KQYKZ>;Y>61MHPG&-6TXS?LWHKZ;:W\;NXZ:~?|?
E_7\;?;?_!TW_S8 MK_W<|_|HU7\|*?|'BJG\|C_P"RTB*J\|G\;7P05\$4\;555^&?A@*JJ JJ M
5-9_P=-_|V*_|W_.^~|5_2K^Q\|R;3^RW_V;A\$O_5:>&B?|'"CZS_|M2F-
?'+T_R/Y40^"|\D4<_!6W\|C6&-)H9OA/^SQ%+%*BR1RQR?M+&|)(Y(W
M!5T=25=&!5E)4@@D5_9Q7\97_!=_E+E^QC_-DJ_9U_|.9^+|?V:T5?@H_X
M'^@U\40^W?R/X_|O_-RM+VW_8P>\$O\U@_1J^V/^#FC_DP\X2_|G<=>_P#U M3?
Q\|KXG\3?|*TO;?|C\|X2_|8/T:OMC_(:/^\3#OA+_G<=>_ %3?Q\|JW M_%P_7NG^I+^&?
+B?YH_0C\|A_QC;_#O_@E1^SS\0+OFU\|_L;^&_&-R/BM MO\|',?
#3^VY0\|G(AM_W=BW\|^8B*+_62\$(I-?B9_P:T6+)|I_|^I'!2YO?V<
M\|%.F0UC\|YMH\;>XM_P#@F\|XY MG@G@D>*:";+|G3Q#)%-#+&5>.6-
U5XY\$971U#*00#7YO_P#!K>JCP5^V4P4; MCXI^"2EL#<572?

B854GJ0I9BH)P"S\$=3E6_=8AJYI?=-/118>C_"1^U?|MP5CBCF_X)P_M@I+&DJCX-
ZY%*D174207>GS0R,"|T:2Q:|NCD1)\$ (901^M?|JF_@)7Z/_P#15_|Y1Q_MA?ID810?
^CK*OS@_M_P"#9?|Y.,^+7_9W'CS_P!4W!|*FA_N|3_!Q_0?V_^W?U/A3_()_:8_Q_M7_X.
(VM?&7B.66ZU/X4>-VM|3T2669IFB3PWXO/P&TF/(=PBM0"7B22S@_MA7Y8(4CAC
BB&/|SZ_D1_P""4*JW_!>G_@H|65240_VT&0D_E&/|6G@A"RD|
MJQ1F7(P=K,00D'^NZE6=Y1|J<\$ONO^HH;/U_R/XU?^#:Q9J_@+|HG|KO|GF_M_LO+?
6/AK8>+7E,;(UGJ_P2^(P|K9\$7,<-Y'YQ^+VI,TJ65IJ6F:DW|'AJ.G7|O#=#V-
_8WG|6'CRWN|*MIM+A)(+JTNK>22"XMYXWAGAD>.1&1F4|U_P1#TV#10|
@LG^W7HJ|LEMI7@
M+|H|3;>2X9&G>"P_:G^\$UK"|S1QQ1M*T<:M(R11H7)*QHN%'8?|!5_)3T_M?
|\$_W_P#K|_80_P#6MO'-,IWKR:ZTK_?%"C|/_R-'|=M?R/_P#!TW_S8K_W_M<|_HU7|
<=?R/_|!TW_,V*_P#=#SO|_HU6&'_C0_|>_P#29%3^%_+|T?U0_M?":'X5_#2&&-
(HHOA_X-CBBC54CCC3PYIJI&B*J(B@*JJ_JJ!7|EO_M_7(46OPP_X*|_L'?%F^|Y|P5X-
_9X|4WD<&L,;P)^TW|1/\$ESY|57?SW_M@,OT)D|07R_*_P"A^_W_78_P"45?
|4W_=\$/_6C?A#1_P\$M)|E%7^RS_W6_||:-^+U'_78_P"45?|4W_=\$/_6C?A#1_P\$)|
E%7^MRS_W6_||:-^+U3_,P_<:_L*^W_V|_I1?|!SDJG|C|X\$N54NO|2>G*
MKD##/B_P_\$S?V60A9|1-'/MB'P'00V(O@-
X0|8:\$-2U;1SJ_AS70@=X2T|5M_.M30;_2|:L!>64|L#76EZ_MC97L2N6M|F*0!Q^4?
_!SE_R9Y|"O^SE=,_|57?\$JOUR_8N|6>&_7_!A_M9.|=>,M8LO#OA#P7^Q-|"?
%GBKQ|J4ABT|0_#?ASX\$^%=8US6+^55-?%WVKQ7J>C:|X?OM5_M+QWXC|3Z
MO!Y^D>&_#M/L-M?PZ;%|A^T0V<=U:_^QO|3|<_9>M^
_PH>*|M'TKXB^(_A+:Z|L.N2ZQ;^%KKXG^+_AK%J_COQAXX|:6^B:@UOX:
MTR/5_!F@RZ5.+&TTY(-2|3:OY+_P5&_8!:_L_9G_&:+^XC?M?M|^/?VE?A_M_-
|3/"OAN+X=>)/"WQB|3;:|XBU/20\$MUIWB-=A=^M6T07&F6VG:A:Q7*V
M:WT::C(L\$J1R3J^D*=JD'.HN>Z:B|N5|)I-|H|A_RN*30%V3MT?31K^OZ=OZ_M,?|
@A2S-_P2L_99+,S\$+|:5!8DD*G|1?Q=1%R89X)HUEFAFAE^%GB|8I8G#)|'(C,DD;J5
M=258\$\$BOYXO^#7#_) \$C|LG_+&KX*?^FCXEU_1#^V?_F>?M7_/9M7QU_
M|5=XIK^=|_@UP_Y\$C|LG_L:O@I_Z:/B74P_@506'_I2*?Q1_|>(_JVHHHK_MH****
/XG?|_@VOMM4|)?MT?M'>-5@BBU#3?V?%?=MJRE;A98-4|(_&#X:Z_M+
<01K.D\$BQ>=JET)5N+::X#10@I"PEC|K=U<16=M<7/?!VB:|HGA31;|I-8O/\$WC+
MPSX?CTY=0N);6'^FG|NSXUZ7^SQ^QW^TA|7=1UG3-\$O/"OPA|
<#PI|JO:'Y<0,L|VO>=-1T+2(HHP,M>;Y'B@26:/HK)RJ1:700@UUO?3_M3|OQZD0VUZ-
_(_G)_P"#6:VA:Y;ENV3-Q!|^S5;12;F&R&ZD^/K?|K3T7_83T7_UW|85|I_P;|"R:0_V>?
VD_C+,S1C_MXC_%WPSV|6VDMYXG>S^\$WA)|:;&I0S2(L-S9W5|6|_3XWMV?
R|S1|^&4JZ;_M1|?MG?\$6W_8X_X_)_"W|1'Q8MCH_P-O\$5|(|O\$D6NR^=-#;?
#GQ7|";#|G_M?
Q%XVE@M(B|EL_">OZ1XQO;NTM+>YOKJ'PU<16=O///#"^CUK5TM6Z4DEW?
M+|%6|B^S'_G|K04_L_K^_W_(-A?|^F>)_C#^VA|9|<>|U#QYH'@WX:|^#|7
M5|B|N6::3/BOXH|9>*_&+WD'F?9|N|U'6?A7X6NA>W\$;W-N;|>Y2WDC2^NUE
MK|T#Q|H/BO0|(13^%M;TCQ+X;|0;:9ZSH/B'0-2L|8T/6|(|U&WCN|/U72-6T_MZ:YL
2TV_M98KFSOK*XFM;JWDCF@E>-U8_Q>?|\$"OBG#^R9^WM^T9^QW|7M3
MT/PIK7Q!&I_#6!M0GDD-_P#"X\$>-M:TG3_!6GZI:>=HT9UG2-:^(|EG/>74
M5OK&K;/HFBZ=-7.K:SIMAJ&5.|H5DM|0=NME)M_AO^(Y60#KO^_K'|47|?|_M_P_F'?
ML?|FC_M(_^J|9U^-'!L9_R:|#|>/^SD;|_U6'PZK|\$?^"P?|2GP^_M_9T_8&:"A|8:A/XC^
/PU:|_WX=>%1>I;:QXE|1?|\$|P|?>#|Z|TZ\$PSM)
M9>"|UN_|9:Y+*D%J;'1QI8O(=4UC28;G|O^#8S_DT'X|?|G(WW_JL/AU3B
MG|7F^CFK>=K#;|Z*|7_%'QG|10|E:(T_P#|FOX6_P#K&7A&O|&Z_CD^(W_*
MT|H_8|_"W_UC+PC7|C=*MM1_P"O4?R"/VO|3_0_C^_X)8?|H_|^"@G_&/M|:W
*TYX>K|YO|_@K'^TS_PRG^P7|>OB%IFKR:1XY|2^&G^%'PRGLM(?
NA760_\$FOCMF@GDC|&7_CN|_@+J+|&?|_M@EA_RGS_."@G_8P_MK?^M.>'JO_!|Q;|7?
%/QL_:#_&5/V?A4|ZWX@N-M1T?Q;JWAVRU_2A8:Y15?
BYK:_#OX1^&|7MIY(4T#Q%H&EIKM_!<:S>6T+Z#|
M5|'^9+>R=;NXKEYJT\$|E&\$GZ1BGKZ|?_F+M%VWO9?@?8W_!MI^SF?AM^R#XY
M_:"U.(IK?|2OQ_ECT=XM1%U;2?#CX.7.N^#M">73_L|:7K|^(&H?%9+T>?<=
M"^TB+P|>(OA9^RA^T|30"%Q!:_^+AS^SS|:?'GA>ZN8!=M6UMXB|(?#?
Q+X@T2XN+9F1;B""4M.M|8"RB6-6C+_-D=K|\$A-X=^WP;^%_M?P4|)2W5SX:~\$P^|
(_#S1;V_2S34|2L?":A6.AQ:MJW|GVUE92:QJ_V(ZGJ_M|M:6T5SJ5W=7"PQ^;M|!|=XRE
3J;:V,F6%|G4_\$7P6|Q,5#7%O!H6F?\$C59U1S'F.&|D|16

MYD6.4B:2QB,L:FWA9OV" P""S?| RC' &M/^Q+|,?| JR?!5?@| P &RWQM
M|+>"/BI^TS^S9XRU1O#_ (Z^)&G>"?%_@#0=8:VTLZIJ/PP;QM8?\$3P_0ZA M=VUJ
<>+H-
_12:+K4/A^QT^YOF\/^% &&KW8MK3P|O64/Q(:!U+PEX.!>&8Y|&5KS3M":^&O%_C:
"OA" M|_>:.\$1%ZEKVJB1=/L=0|?>&O'W@|PHMY=(K1Z=:7GC+6O#UA=ZM>F/3-*M
M+J24-4N:/3K:ZO+=I-SQ*6_++|O/_EW|OT|/F*_D*_X(|:S8>(O^"X_4:
M|0:7*)|UW2OVO=9TZ=6C=9K#4 VO/AC>VDH>&26%Q);SQN&BEDC8-F.1U(8
M_P|7?Q.^)/@OX.?#OOM|5OB-K<'AOP)|\\#&L^+_!9K=O',NGZ'H5C-?WT
ML5K:QS7E_>/%"8;#3;""XU#4|Z2WT_3|:YO;F""3^3'_(-B/AS'XC^*7|7W M|06MQ:Q-
X@T7POX""^'.DZS.MR=,U./XE^(O\$/C;QW\$|Y*)O=8M+WX<>|KJX
M59);FTM|626X\$::C TV5-?NZTO*,?+67Z67WCEO'U *OU'_!6G_E/#_P3_-|MLR_|:'^)%?
KA_P%VA E%7^U_-W1#_UHWX0U^1_!6G_E/#_P\$S?|NS+_M_-;'^)%?
KA_P78_Y15_M3?|= \$/_%HWX0UH|+_ -N^E1&H/_P|)1XO_M,&ZW*_./2?^RT?
%+_T;H5>7_P#!S1_R8=|)?^SN/?_*IOX|UZA_P;K?| M*./2?^RT?%+_ -&Z%7E_!S1_P
F'?^7_L|CP'_ZIOX|U^A S\$ _|O/U\$ _@^4 M?T|/X&O\$MG|HTR_="WD^@:G"C#EC8N
M#PJU^TO_3RT'2?%7_!O|9_|.: 91:EH7BA_97^&^@ZUIT^X0W^DZQX"
ML=/U*RF*,KB*ZL|B:"38RMLD.U@<\$?SO?|&W?CW1_@A^TK^U_P#LG_%%9!/W
MOD|8VWA6/2/#VMW.F:>|WB7|GK6OB9H_Q&|#P17=_#?:AXRL(O&LVN0Z)I-E
MJ\$Q|/>#_!KK-T|H9Z#+) *T|T|1|J|J7RYM?NMJ+K!^5OP_X)_8O17P=_P%M+_VJH/V.?
V+OC7|9++O|X;|?KX;G|&?|V8?|(S;|B>;PM/+<^/=G75NWSQ_P\$3_V@/VHOVG_V M-
K|XS_M5>*KQOMXE|3_&3QQ:_#KQ-/X3|%>#XM1^&7A|10""A^,6>G>!/#OA
MC2+JWL_B+IOQ%L&U"YT^74I+NVNK6:|DM::SB@QY'R.I=**ERZO5O?16U^_O
MV+OK;K;Y^O%?OM_|%>;1/BE_P%R?V)OAKXMTBVU;PG+^LB?#GQ!H|&L
M|CKN@>+/VA/\$6H:W:7EO*9898+^P|67&F7:,Q|)K>(1R1NHW/_9)7|:O_!>*_
M^U+|G3_@J1^QK^U8_A6|O_""A>&?@|XXBF&V.V|5>*_@A;==|3^O#UG<.8
MXUO+/PW?>H|E7D'DIKEC(|HD|H=,A O'W<9)>H|;+M=7|+_P##'|E5?R-3 M?|K4J_|
76#_-=V1U_51H7Q3^&_B3X:6'QET;QQX8N_A3J7A!?'|K|0GUBS ML_"2^"O|+;6Y?
\$|YK5|+;66G:/:2DM_J%YJ,MK%IMO!<-J|MC;SBA_B|_9
M%_:.%TG|HG_@XNT;XZ^;FWO_IXP^(OQMT|P5JEM:7VGOZSX#|"?LQ?\$7X>
M>|==:PU.ULM2L|H=|(>%-%UBZM-0L|6|MKJ|HANK>&=)(U**=JSMHJ4T_5VT M_!A+
|A_B7|?B?JM_P'-A_R8C|)A L|;P+_ZISX|5^N7|'_)AW|\$_P#V M:A LW?^J|&5^1O_!S3_P
F("3_L|;P+_ZISX|5^N7|'_ "8=^O/_FC M_LW?^J|&5+_ (A<RB)?'+T_R|YK?
^#H_D=V-O^Q5^?-IW^&E?LU_P M78_Y15_M3?|= \$/_%HWX0U^,O|P=|
/(|L;?|BK|:|T|_#2OZ#_P#@_MJ9|+_P#A<'_|#|KOP6L>ZN+S5?A0|K|5-)L;6VMDDG
MGO+|4_!E|9V<4;SW_|0P036K=HX5O92;^Z40ZS|%^3/G#_@@G?)=|!+G|
MGZW21G;2|: ^-%C*K.&\$+R?&OO_J8C10|&-3|J,5Y-A5UD?YI_X.8O
M^3"OAA_V=AX!_P#53?'&L^X-I/C)HOBG|D#XF?!BXUZRF|9?"KXSZSKD/A
ML;X|ZR^'OC_P|X:O-\$U4B1REU!>>,|+|?6|CVH LS;VJ7<<;W=M+= \$O
GO)|*ZEXBU".)F M.F6=SXC|8Z/IFC27ZPKKDUKX@72OM1|V:Q|BGE:Q-M_WG-
MT;YOP3W""N?| M;MOT_K|3|< ^"6_ "CM_8X_|(+X\$|38M?>U?!/!+?
_E';^OO_P|D%|"? M^FO: ^|JOG|*^@B&K>&M<6SO+&R|5^\$-9\$;7WAK05I=O|j%
|#8:W|7VGW!N-, MU#4+*Z_GOE_X*?M-?LU_P#!: 7?VKZO|A_2=3U|7M3T|1-
#T33KW5|9UG5|VVTW2=(TG3;6|
MU'4|3U&|EAL|/3K"SAFN|VINYHK:UMHI9YY8XHW<.4)0<'?XDI1<;| =M;+5:
M;:70)IW|G9_UV/XX_P#@B)XB|1_LC_|!47|H|O|_82U#Q=J6L>"-4NOB|X(T
MVVN;.&PM_\$?CSX&>*;B?PMX|33R^H-HUQJWPWTWQM/_; M1-+:%?VH-+O-
(V|+*WPR|!>)-5NO|'^&_O&_9UO/#D3,+B.UTGX>?"PK^MT(-
#CAN(YHH|/5_%0)&JL-9O9E::>9IEK?|\$IOL_P"U;_P7|_:6_:?| M)27>H_#CPGJ?
|0OQ+|>)DTC4|'3K_1/&_B&X^&GPXL|W|1:Q_V9K/B#P;XG MO-?
M|U46U|<1Z|KDB6_FZ=Z.L'P2^)|5@MG'\$7O=4E|(_#_,0NEE9>=<&VU;3C M&!
<3H@Z|?O9?SNAK;^?1=E;1=OD9W|U/H|:>GX7ZG|JE?Q/?L" |K%GQW_|L
M|_:K_P#3E|4J_LIU#XF?#K2OAWA7=0|<^\$|X5V_A-?'DOQ%;7|_?P4?|3Z
M8NM1>*XO\$ L=R^D7'A^XTAX|2M=6@NY;*ZLI8KBWFEBC9OXC?^"4'Q/T3XV_
M|%S_!|9?#-JEAX;^+7C_ |KCXE^';#7C:6WUJRT+QUI_Q|A3Z/:Q;V-YJ
M%E|JMMIVJ6T.HQ6=_?6L=XDR6|YJ_I5_8^_Y-) _9;_P"S=|/E_P"JT|T3_@4?6?_
*4P7QRI/AC^57_@_MN_|+|IV_|&#PE_ZP?HU?;'!S1_R8=|) M?^SN/?_
*IOX|U|3^O^5I>V_|&#PE_ZP?HU?;'!S1_P F'?^7_L|CP'_Z MIOX|U;_BX?|ZIT_U)?
PS_QAT?6OP3|_7'C/_@AWX<|V<5Q/=^+A_@G'K MOAJU@M,?:IKC7?@/J^EP16VZ.9?

M\$DMTJ0/H91YC+F-QI+3_@UMN\$;PG^V
MA:#&^#Q%|"KANN=EUIOQ6B3MC&.:3&&)ZY &TM^Z7_!->VBO?^"=G/'EG."T
M%W^S7L;K:8#&3%/X1L8I,@C)1R!D\$>QK^=+_@VZ|>V7P4_:7_:J_9.^)D(M*?
%;Q9I_ AMI#1=7U33+60>*?V?-?^(&@^/O!%E;/=%M8\400^.;G6OL6CM>2
M)H/|@KQ1JKJVGZ9/=0)-NGB(H*7_)/KIR0_Y/3|TC^A#_@J_P#|HX_VPO|
MLC'B#_T=95^<_!LO_R8=|6O^SN/G_JF_@)7V7_,%L?B|X1^\$ _!.#|H2#
MQ'J5C;ZO|3=\$TOX6^"-.%GNX|>_|\$?B/Q7KFFQ7-MI43_-2Z'X:M|>|67T:
M@8TO0+T|A(8D?XT_X-E_ ^3#OBU_V=OX|_P#5_-2IBO|GF^|U^%A_:_|=4^M+_|
@E1=);_!%|?^"B,3%0;|6/VT|6/.CVW5E;WVOZW=+;Z-X=TG|5%
M/K.NW^G:3:%KN|A1E63YH-:|U.%O-VM;|OO%#1-=F|G|AW_!KQ_/&W_59M_;
|)_A|!>?;\$":BPA=;@>)?VC_A%K%M++-:/-9^>1-+.HMYI(90MDKVIR11|Z|2_X*O_
/*>C_@F_P#|?O|%_P#ZUMXYK9_X=?AU?"S_;"^+^I>M&)Q8WUY|
(OAUx4|;3VY%O_)D5/X7|OS1_5^*O^27_#?_+ \$+P?| ^H|HU?QT?|(^B7/B_|
M;I_9D|&:=N.J>(O@7X6T2T5%CD?|3XA^/_C_\$JRVQR30*|<9^K)-!&Y&TS_M(-
SI_5S^QC|9_"|O/I*WP#^+/@K4K#4_)|4_"WP9)>PV%|?#?V#XDL-"L=.
M|5>%-0DA9UCU?PKXBM=2T#5K=CNBOM/F+1E'?|EV_X*""^+-(:D_X+^_LF_M?#?
X:V8|9A_!3Q;^SI-_:Z9>Z;JNFSS^/BAX@^.'O4EAD@N9+4)X&|>M(|3TSQ;H
|C4-.UOPAXBTBZM5OK(V@K#W523: ^&K^5K">L8K2_NVO|_|#^O
MG8_:3_@NQ_RBK_:F_P"Z(?|K1OPAH_X(3_|HJ_V6?|NM_ *T;|7J/^"|"M_**OJJ;_
+HA_P"M&_"&C_@A/_RBK_99_P"ZW_|K1OO>J?^8?|JC?^V#^WM_P|N_J?
\$G_!SE_R9Y|"O^SE=,|57?;\$JO8?VD/'>J?#K_@W<|. ^(-'G>WN|
M0_8)_96|"321EU9M+^*/A?X/_# +7("4!;9=:+XNU"VD!&QHYG60B,L1X|_P<MY?|
)GGP*_|.5TS_-5=|2J^G_B|_|9OB_||\$|O#_@JUAN+F^_X=P?|7QCI
MMG9PW%\$>:AJOPS^#/@7XEZ5IMG;6D4US=7FI:CX1MK"TMHHG;XN+B.'@.6%1
MLH4;|>V= _2|2?M27|W|\$>2_|&VOA.UT'|@+Q/KZ?9Y;WQQ^T1X_UFXF2.V^U
M0V^E>%/A|X7M-.GFBS<-#|!)HEYJ%M!=%3"^K7;L;:QW7F37O^#D/_E'KI'_9
MQ'PV_P#4: ^ (5>|_!&S'Q^|(:S^SY|9/V:KWQ#_OO(\$?%'4/BKI'AR|NK""Z_MO?
AKXS|. ^#|!EO?#|D9EU'4|3P|XR|:D?%-U%;2VVBW'C/PK#=7;.:Y80EW
M_|S'^T%X"TK|GKX2?LT6VN6=Y|4_&'Q4TKXI:AX=M;BONKO00AWXA.>+|\$&
MJZ|;1WO|L;WB/Q/XDTV|*2W.GFTUZ'P|XR6VNEET.>-ZL_K7_:_|DE?|AO
MX/DOP:/T" _X(3_|**OJEG_NM_|ZT;|7J_ _P#X-W_ ^4F7|37_9O_QB_P#5
M_P#P7K|/|^"\$ _P#RBK_99_|K?_ZT;|7J_ _(-W_P#E)E^TU_V;_P#&+_U?M_P
%Z7_05ZO_-+8G_R| ^7Z'|9?|9_|R9Y^U?| |FU?'7_U5WBFOYWO^#7#_M_D2/VR?
^QJ^"G_IH^)=?T0_MG_|)GG|5_|V;5|=?|U5WBFOYWO^#7#_D2_M/VR?
^QJ^"G_IH^)=3#^!6|8?^E(I_%'_+>_(-JVHHHK_H****/O;_X*;?|M\$9/A1^W_
*YIWQ;|^+D^""|06FZ;'I&K>_|PXGB'PU|2|%TVRECT#3?'NA_M6^IZ)=IKVBRI9Z9H_P
0--OIM6L?#F:%K6C>+;#2?|MMX5_N#_((-?MU?M'#6/#NB_MC?|_%+CQG|O"-
VL^AV\$'C#XP_&S6+&U!@M|FS|.Z1|4G|+^!_
MEWJ&EP_8EU6SFUJ/3B(#)|I&KV|'V63^MBBM8UJD4DGHMKI-KT;1+BGKWW|JO
M|OZ9XQ^SQ|_OAO|_LO?|?X?_ _%^\$FEW.E>?AQHS:3HL5_= _;|4O|H|N|N|7
MUO7=9O1%;QW>N>(|>U'4|?UF>VM;*R?4|2NOL%A86(MI*#YW_:_N_X)W?L^?|M%!?
FE>%?C'8ZQHWPB?PF|H<>_ /B=X.N+.Q|9^#KC4#:OJ%G#)J%EJ.F:QX=U_MAK*TCUO0-
6L;B"XBB6YTNYT;6HK+6+|/OHJ%*2ES)M2NW?K=|_?U|CLK6Z'X_MU?|_|+_
O'_P##MWQU|5_%|/I0D_QCL_B9X:T?P|%HDOPN_P"\$ _L+^Q|8
MFU2._DOD^(_C.+5IYHI1.:BZ;I>S:9ED*MY""^3_!%%_ ^"\$7PH_:3^)NJ?'CX
M8_\$B;X"_%SQ+#%)X^@D|+?| "8>?B#JMA9?8K'7KC2(=<|/ZAX0|3WD\$5C: M^(-
;TFZU32M7BT^'4I_"|13WVN^(-9_>VB|JK4YN?F|YJS=EMVM:WX|R|JUK: M;G|R7PH_X-
T=.N;'QWXB_:I_:?| '\$QO^)^FM_"KQ5X_&|S)H.MW_A?X7>(=M;|_| ^(-#V@>_
=0E|1^_IO\$?Q%7P->:OIWB;PGX8BO/A|I5CK&ER+>2ZE'=026_M'ZC?| \$Q?^">?
#N/X0>||A3 _+>_P""R?|_|_;\$F?XA?V|_P@'_KS^S/_M|_|>'#?|D?V7_P)KXY^V|?|
^V_:_|1M-WVO|/B'D>?^D|I%\$JM22:E*Z=MM+*VFUM-/E|Q**5K+;J?CEXC_P""2_|
PD'_5\$M_|@I_ PO| ^R>1KWA; M6_|A3'_JKS|_ _C7P9TCX1?
9O^%B_P#"R(=OVW^RO^\$A|_A|6^S>?|MV3Y4_E?VE)^QM%%3*4I6YG?
E2BM\$K);+1?GJ-)*|NKO|S|? _E?_@E'_P, MS_M|M!M?MQ?|+Z_X37_A>VH_&N_%.8?
|*M_P"\$;_X1;_A_MS_A?L'|C>9_PB6C_P|K^;_..S3/+^PO|M?MS_|!|^3|L_|J_XG
M_M00_M9O|+IOB-)X%EB|'1?_OO%TN@2^"?AUXA_Y_M)U_Q#\$^(_P#I(5K?_B/%_P#-
\$1E?K1_P2_."9.I?|\$XX/C;#J'|0E|H>|/M^%PR_#J6%KSX>3^
O^\$6_P"\$3QORDBQK|1?'_|:O|_|?|PF2%RITG|/_9_M*|A??;P;3|7:*C36RONEMV|

HI.Z7XL G; ;Q P"#?IX? M?M+?% Q'^T%| OB. +ZIM;ZX|5ZJ&
MF:WH6O>!--5U& .IZWX@DBA|66VJ:W=QWFG6/A|A=O=|;|_#=#;PLOA?XM:W
M^T%^TKX@^-?Q|^ (7@340""@SX@Z|X4U/5?#?PJU'5;&/29?%|FA:WX|GUWXF
M>)M,TB.33?#ESK?B7PWI.@VH|=6F@MX@T|P_P"(' I6HH5;JDDI:*UG97L
MK:7M>VBOWV=UH'+ 'MW \$^ ^";O|/#7 #OC|GJ|^ P#PM# A:GVOXB^)/W_M
E7 "\$ _|(#Y? "0Z9X=T|^R?|# . \$N|; _ + ' &!YVW ^V% ^T?; _ + ^QP> M1YDW|E-M^S-
|_VPO^"YW|2O|/'Q-EU:T|*? \$#XL?M312:JH-RMIK6A:QHGA M?
QMXA|.:|H|DB26|MOH^O:5IU^;*|BFL-1A@ET^ AEL|J>-O|TJ BW_9&_Y6 M3?
BE_P!EH_:T_P#4!^ (M72E+|H_ O& @|XM_X*!VGC|'F/PC>V\$7A;3/%>M?&/69/"VF:?
JA:77AOX\$ZGJVH M_ #_ 1|W3M.EFMK#3M. ^ (UG;PP2/9Q:G;P2,U?T7_L0?L8_ "S|@_X":-
|"?A7- MJVJV<>K7_BWOCXMUZ2,ZUXX|=ZU:Z;9:QXFO|6V":?ID:?:H^CZ+I.DZ?& (=
M-T'1=*M;JYU74X|_ %G4OKRBLYU9S2BVK+6R25WM=V_X8M12=U^?3^D?D?|
MM: |\$L?^&|V|V9OVVO^%Z|(- PSI_PIG_ (ME_P*Q_X2;_A,?^%1?&3Q M)|6O^1S-
.%A>'O^\$>_X2'_A(?|A'_ ^14US^R?LGH|_|3+|1_9L'UO^W9^R MO_PVM^RK|4_V9?|
A_ ^%:?!++_XOC_BMO|A&/^\$R_L7_A#?B-X0^(' (M_M)|#X4_M+^TO^\$4_LG_D/V'V/I?
|;|_2OLOV*Y^N**7/+W=?@MRZ+2SNNFN
MW6X66OGO^1|)_P#!.K|BG_A@3|G&T_9^_P"%E| "V|LOC3O3XO_ . \$M_P"\$ M_-X03?|
|)*|BW|G?V#_ ,)7XRV_8OL6/M?|M-|H|W/V:#9A^7_X*:?L"|_M#Q?
X#^\$O@E_PMC_A3O|PBWQ|_:4_9V^)_B_LZ_:4|J#Q!XGM5TB|N?
OC7OQHQ:3:=XZM|K_M0;_3M>^&_C:>2(7GB/O'H%KX@M/\$.JV5EK|^&|'O=?
>)_%/B#|_:.*<9RC)RB_M|2={NRUO|JK;^M_LFK6T/Y/O"|_P;X_M2?'#QKH&O|_|?
G|=&N?\$K0?#)6W_MM;#PYXJ^(_Q:|87>C32H|_HNB>-OC+%IUMX#6Y;-
M*;N#PIXMMW>%8Y-)+". MYB_J'^&/PS|!_!GX?>#_ (5?##PSI_@|X?|_@+0;#PUX3|_
:7Y|6NEZ1|T0B_M@B:XO)KJ_P!0O)VWW6L:MJEW>ZOK&I3W>JZO?
7NI7EU=S=U11*I*=E)Z+9))_M)?6!)+;TN%?#_ |>G|_WP4_X*"?"/AE|5XK|1-
=|/7ESKGPS^)^OAV*S/BWX
M>^ (|BW6WN)K(WD3P:MX9UV*&UM/&'A&|>*P|0V=K8W,%SH_B;1?#/B70?N"B
MI3<6FG9K5-#:OHS^3CP7_P
&T_C^SU(^!_"|*Y;>YMDOG.:@:OX|UGP3X5|0SZ5;B#3O%=S9^/6TVY2V:;0|2MK?R)/T
M'^#G_!\$SX;_ #_ @H%X*;-^\$7Q.L|!GPZ^'VDP:-X9_9ST_X7NT=M;I^SY+|M#
|V|N_BC-|17NM2UG6|4N;|XCZ_K5_X(N-3US7-1U&+5+FZU&^N?\$.O|@45H
MZU1WO+=.+5DDT|7TMN|;|HFB>6*Z>?4_K_@H^P)_P|7^!'A'X)_P#"V|_MA3O_
BWQ;T+XI|)_P@G_"POM_|B^#O'GA+^PO|&_X3+P|E^T_P#";?VA_M_:?|JW'D_P|F?
9|/E^V_::3ZY_9_P#A9_PHOX#_ 3^"7|N_P#"4_|"G?A_M|_A9_PDW|E_P|B?|)%_P
*|&Z-X2_MW^Q?|1U?^R|/7_LC^T|/|_M;5/L_M'VC|)_-|Y7VF7URBL^9V4;Z)MI:O?
SZ#LKWZL_K_@J1_P2>_X>4ZW|&M9_M_P""^?| "E_%^2:5XVTS|_PJS_A8W_"0?|
"8W?AJZ|_P|_A8W@3^RO|_ MX1WR_*|K4OM?VS=YEK|GVS_L)&DJ/%*B21R(TGZ-
!9V>J^*/%U)(O\$ _QOU_P|X@^ (VG:~X5T;PWJ6EZCX%L-*|1_\$G0M?|_%&J:S|HU
MHH>?\$GQ1KXO(M'|*:'X?T+P?X=AN/\$%UK7|0M%:>WJZ>|MI>T;OU=O^'ZW%
MR1|?~^B|P3|EOX'_P#-7|WP;^?| PD_ _FG_ "I?_6A>"A A+|/I%_X1
MS_A(|\$MA;_VG_87|K;|_97VG&_I%_:;I>3|W|7+|ZO>Z**R;::;W;N_5E;'
MY<_I%)/^"57P5_X*::#X?U'Q:K5W|+|C7X*L_P"R?!WQBT'0|/7KH>&Y;^2^
MN?!WC7P|/?*WC'PI%<7>I:GH5DOB#0|1|Z_?WFL|JT%CJ_BC1O\$?XLP?|
M\$!_ ^"A7BS2+X)\$K_@H/9R_LTZ0;*STCPE|XN^-WCG2--TS1WCET1;#X)Z_M=>&O
-B=.E@MY+*PMO%J6^G/%&H%+ _P_2Z|XH|1Z_Q'!_M1+_@G|!?'
^"BOPVT/PKX_P!5UCP1X|!|RZW>_ "XG^'|>'4;|PI>Z_:VD.K6
M&K>|N>ULO%'A75YM+T6ZUC13?;-J_MH|Z|ONMI;:VFP|*UK;=C^4/X>?|
!M7XO_M33?"/OF_6U|Q|_|?#OB9M=LO_MA(X%)ZQI-YK8D6XCN+RUMO\$?
B_6_"7P|07D5S*MOJMIH/CB4137-N&\$V4?VYW_:|'^_QH@C|#:;>_CJS|(?
2V^%|Y:0^%O#?BKPO_M?^%M&T%?B3J/Q2U|4=8;PU874#2:OJ/A=M1U^2V>: ^>&
{NIKL?N515NM4DFG_M+1JS5DD|H-WWW|"Y8KI^+_S/R/_
"TW!+_AY=_PHK_B^O_"E?^%*_P#"MSO|FF/_L?_A)?^%C_/'O?^JA>_|&_L;_A
_ ^HK_&C_&K_ _N/V'_3_M/TK^#_@#_A5'PD^%OPM_M;^W_P#A6OPY|\$>_/I=^P?
V5;_7_AOAG3/#O|M:W|F?;=1_L|^T?|_ ^V?8|/0O_L?G?9_MMUY?
GR>BT5#E)Q46_ =C>RLM+N|UM_M?|QV5|H6?C+^W?|_|\$B_ ^&V?VN?@Q^U1_P-!|
"L ^%1>%/AUX8_X03_A5_M_' "9_P#"0_|_"_ \$WOA|1?MW_"3_/"RO"G|D_VM_P
|7_8_V;_A'M3^P?8/ M|0^T7GVK|#;?LU110Y2DHINZBK1T6B^2U^865V^^^_P_C|?|4_|
@E'_&C_M,%2X_|@I9_POKR?+U#2;_ (4M_P*M|S|H/_>R^"7E?|+_X6*F//^Q_M|)-

O_P"\$#/#>9_8NR39_:S>V?|%-/V!/?^'B_P")?|+_(6Q_P*=_X1;XN: M#|4_ ^\$F_X03_ (6%|N_L3P;X|)|?V%_8Q_"9>|_LOVK_(3C^T/I4_M:X|G^MR_LG|G2_:?M_ I^BE%/GE>_KZP2479:);+;6WG<+ +56W=WZGAOI.OP8_X9T_9_M| ^#/'P'_X23_A_?| A47PY|*^ ^A_A*O|'_X1|_A(?^\$9TJWTS^UOI#_M77/I_M)^V^1Y_V#^V_ 2^S;_*^VW&WS&_\$S_@H;_P\$(+ #|HWXS:E^T|^RK|5=-^?Q_MIUS680%OB? 0=3T_4K#P9K0Q_M|N0Q(?B)H/B?P:|XC^'GBVYOK:XUSQ|J%EH_M/BAO\$GB>=? \$B'0|:DUB_UK^B6BB-2<9.479N|H;M;ZNZV_K0+)JUM#^87P7_P_M;|?%#XIZ5XM|5? MU_MG^+OC=|8;SP%K_(+ ^&EY'/A|J.J6EQ:..? MXKO- <^(WB;1/%7C;+1);V;4=)|'VD|@32|/5X(=00-3U=)|#9P?K-_P_\$R_V!_M? ^='P'|6_!|+_A;_' "XO^\$I^+FO?%A_X2;_(03_A7OV'^V_!O@+PE_87|B M_P#"9>./M7V7_A!_|0_M3^UK?SO|4^R?V=%|B^TW?Z*44Y59R3BW|KMHDDM- MK66GR!12VWM;<_)G_@IK_P_\$F/A3_P_%&;+PUXHN/%U|)|OCAX'TC_A'?#?Q M*L=\$B|3Z=J?A3^T|C5QX1|8>&9-2T2;5=+M+^_UB|T'|T|7-*O=U'6|3O73 M6+2XGTFX_'O_ ^" G_!0'XJOZ!|_/VAO^"@MMKGP*)RP3>&-%?Q7:OB|'X?M? 3-.GT|26T#X7^-[KPCX.T&6"RF?2H)M|A3*=_TZYGCMDN80;..?^NFBG&M.*MY4U9;72? +Z7_.&|A.*;OWWUWV_R_IGS;^R=^RC|'/V+_@IX<^!7P1T.;3/" MNAS76IZ|J^J- 977B000XJU)8\$UCQIXVU>RL=,CU0Q-JD=I96;W2V=K:.=H^F MZ/X=T2RTSP|HFCZ58_#?|5_2L_P"&G_V|V;_-MW_A>_"#_/#/D_P7 MF_X5C_PJ_P#X27_A+O|_A4/Q;USX|?^\$T_X6)X?_L#_(2'^VO|'"S_PB>M? MV3|F_M/&I^=_9|7Z|45"G)2=TV|_H|H|E6_3|_@K^1_(_F_P#FO7_N MYW_WWJOZX*_D?_X.F_|FO7_+N=_P#?>JTP_P#&A_V|_P"DR)G|+^7YH|;Q M5_P0M_:|6@|9_|\$|_VT/%'P&|'_%_0M"U|QE|(I9|=_%/X?Z182:GH5E=7 M%C#XN^&_ ^K7'C+0UN=0U.WTC2?%/A._T321;6-UXB|1S37-Z/M_@EU_P_\$M5O W|!7BF;XV_\$CQKI_QC_:ETF^T;P|J>GZ=+|&?"_3|8M\$LM&|/P_96|_K- WK7|?'?K_DE_PW_P"Q"|_M_/J;=7>TG6J2BXMZ/=V2;MM={O;U>S;".59/T? SLCY';_L_98_X;6_95^*?M|_O_G?_"M/^%E_|(1_Q6W_C_'9?V+_PA00&|(? \$#_D6_P#A(?^G|I?V_ME_PBGI_D_|A^P^Q;_M_ ^E?9?L5R?L)_LL?|_#%/I*OPL_9E_X3O_ (67_P*_MT_X3?_BMO^\$8_P"\$-MK_A.OB-XO^(' _"+?_"0^*_|_LW_(2O^R?^0?_M &S|!|O_-%^U?8K;ZXHJ.9|O)?W>;FM9;VM>^ ^W2|AV5|I;6^1^;7_!3G_@_MGK_P| <^#W@3X3_|"W?^%-_|(5|2|;XB?V_(_#_P_+_#_M/I-X7|2^&O|'_M +*_X37P|BW_P#"1?;?|0_M*[V_8_LWV)OM'GP?9/P_ ^%8^!GP&^"?P1.NC_MQ2/@|H (OAO_|"L^)|CI?|B#Q&A|X-T;PB==.B_VC|_|9_U?^R/I0_LO^UM4_M^P?;/LG|HWOE?:9? 7**7,|*-|S\$VTM-WOY|LKWZL_F)_2_X-QO#VO|_Q;OO_MBY^Q|^T%=?L|"_U=-W&HW? P_P#"AGQ%H^N^'M&M@CEM8|S|+W&B;G/IS"|2'Q5#ISV.F6&|I'!N%|./^%(? \$|PYXM_:U0QA^T_M?|4|6|.7=Y^T!XD^'LNO6'@_1|+|16?B?7M)|,^ KXAVM|?:|XPOK2*S|1^ M/M>|LSZ?:6|MHVG^'K+40%6G^)/Z6:*T|M5LES/2UG97TV3=KM>3WZW%R_MQ|?F? (-|?'|+_#%/I*OPL_9E_X3O_A9?"M/^\$W_P"*V_X1C_A#?|:X3+X_MC>+_(@?|BW_)#XK_LW^S?^\$K_+)_Y#|_H^P?;_|% ^U?8K;X'_X)W_|M|'?_(8):9^)|O|I? _#1/_ "U_P#A8WP_|8^!/?^\$. _P"%1_|""_V_-PEGC_P_M7XY_M3_A(?|A9WC'^T/H|A ^\$0_LO|_|#_8=C|J_M|^|=|LMOLGV2Y;_"BHYY>_M|K|?Q;+76_;37M8=EHML>:.&? X=_P#"WO@|H6/A/;_'"/?|+|^&GCOX=_VM_P#V? _-W|A_|)KX7U7PU;_|JE?;=_M/^S/I3^V_V?|VEI_VWR/LWVVT|SS_MX_SN_P""6_| P3%_X=K;)|9=&_X7=_PNC_A;>J^="3^T_P#"M?|A7/_C_M_/PAUIXEM? (AG_A/'?|J_VC_P)_%YGF^;|OV3|'MANZ^T;H/U;HH4I*,HI^ M|*UU9:V=UK;_W|973|;?;****D84444_%>/_%;|H;X_-9.@CQ?K>CG5QI!U? 2AJAT_P" T?8/43T_|M7Y7VVVWR#_AX3^P+_T? #^R!_P")+?|C_P";603P^2YQBZ,,1A:*E'FA.I&4>;E)720%IK1IGU_17'^ OB%X|^*OA/2?'OPO|<>#_B1X_M%U|I=_8?C3P%XFT7QAX3UG^R|J2O-&U/^R?S? AZ|U'1|1_L|6-.U#2;|I'>3?M9- 2L;RQN/+NK6>).PKSZE.I|J5*56G.E5I3E3JTJD90J4ZD);Z=2\$DI0G"2 M<91DE*,DTTFFCKA.%2\$*E.<:E.I&X3A)2A.\$DI1G"46XRC*+3C)-IHIM,*M***@H**** "BBB@_HK|5/^"SO|?GQQ_8L|)?LU^#_P|F/3|S\$U/X|?M#_!:_O_M_#7AK3_\$/A^+Q|H^J>'? #VF6.EZIHUGI|M|IROQZ|JGC+Q|H-H;NVNUCC@74_M(9\$(N!)%^Q^M;|HO@_PW|JWB? QAX@TC0/#OA;0|H70%/BKQ|?V.@Z|HNBZ)82_MZAK?B#6|3OY|? 3=%TC3K&UNM2U*_O;F"QTZRAFN+F>.WA>1?QG#N8X')LAS MRM&B|)Q)4S2GE=*G4E/%U/I)Q-'!XFI4H*'N4YXFLZ.'DI2=:I1KQ44Z>OEX M?;.'BLOS7+*J+\$9-#|3Q TYP4;_"_XR?"XWZ!>>*O@M|5?AO|70"^G:O/X?

U#Q)\+_'ACQ_H%CKJK96&
MI7.AWFL>%-4U;3K;5L;3M5TN GTV>X2IALM2L+J2!8+RWDDQOC7^T\|#_P!F M_P)-
XZ^//Q7!_";PJ7NH+/5/"B33=" MF_LJ/NM4FT?PW8WJ:Y?)!
(++3[AQMKs8X#'3Q:R^&"Q_A\3M2M+*^U2^|*::JDND>/ 3='TV^L= M_O-
7XRD[5<+CL-6PF)I/M4H5X4ZL'Y2B@PV*PN-HPQ&#Q.'Q>'J*| M*^&K4Zl&:
fPJTl3A)>DF%?DG|+_ ^"27PV^%_/?\ XD_X* :?6O^&J>,_ \$GB MWXG>+9_%
H&@Q>&+:Y^)VB:JHFH6D.HP*-5:#3(M>FGLW<^9+)!\$LY*LI?K M917*I-
TG:F5GYKL;M)VOTV"BBBB,**** "BBB@_HK-UK6M'\:/JWB'O#JV MFZ#H&@Z;?
ZUKFN:U?VNEZ/HVCZ7:RWVIZMJVIWTL%EIFVZ=903WE_?WD\K:
M6L,MQ<2QQ1NXX+X6_&[X,?' +2=1U[X*?%WX8?Q]U\$:1J^L "WQIX4^(&D
MZ5JQMH;P:9J.H^\$16U>SL=1-G<078LKF:*Y-M/#.(O*E1VVCAL1.A4Q,*%>
M&HRA"MB(TIRH4IU-*<*E51=.\$IO2\$923EJE,SE6HQJPHRJTXUJD92ITI3BJM
M2,/CE"FWs2C\3BFHJ;TJ%>6?%_XX?!SjG[PB_CWXX?%#P\)\O!PNVTv#Q! MX_
%&D>%/U#5_-I.U'5XM:T>35KNV?6_\$5WIND:I>: ?X>TA+I6I2BT^L.GV
M%RT\$BKXJ^S?^W;^R!^UUJH@_9U_ : ^'WQ)UFTAU&\NO"%IJ%SX?^(-MIFDSZ
M=:ZAKEQ\./%MGH'CR'PY!:=OIMH/\$DGAQ=!FN[R&VM]1EG8QCKIY1FU; 5G-
V=HSJ1;L1-&<|PP%/%4\#4QV
M#IXVK%RI8.>)HQQ56*M>5/#RFJTXJZNXp:U6NIH:4445YQV!1110 4444 %% M%%
!17XD_"JO+XX6G_!8_!9L_8!^\$?B'P1:_ " Q+L.K?QI;9+[PI)K/BK
M3I9TW1/BI1M2\0:Q+_"?PE)J5KHT?BGXE^-/#?@3PY)JH%E)K?BG4 MM*TOJ2NX;
fFM;%:HW5Q%:W,D43I!*5^@S/AG-4X?.LMPN% M5:OBi8'%XC\$X?
#.K25&+56O/"5ITZ=)U7*ER3NE.-)P6=8"O-?93E"GD^8 M5OI.G06*H4:-.LH5'4:
<*4.;,YS4\$I\T;7BST&BN?|* >+/"OCOPWHO MC'P/XFV^,O""B33I?5O#OBKPIK.G>
(O#>O:5=+OM=3T77-(N;S3-4T^Y3YI M>|L;J>VF7YHY&'-
?.7I2/IT_X<>%K77?'M_X=EU'2-4L7\16?AR;1+:IT^|@N;^&2 MWE5?,PF6YCC\8LOP.
QN-Q\IRIQP.\$PM? \$XR4XOE!8:C3G6C2 M9VU;@|+AWB\5B_
AL(HJ;Q5>O2HX=0DKQDZU2<::C):J3E9K5.Q\6T5Y)\& M?CW\%/VB?";?COX%?
%7P\6?"9DMK:YUGP'XFTKQ%#I.HW>FV.L)HGB&WT^Y MFO/#7B.#3=2L+J_+
^(+;3=?TQ;J*/4=.M96;8I;K# \$8? \$82M4PV*H5L-B*.
MG"M0Q%*=&M2FMX5*52,9PDNL91378UHUIJ6(IPK4*M.M1J14J=6C.-2G4B\I0
MJ0,OB!XHT/P;X5TN34\ZWTS38\I10^((I3=(LGU#4KNTT^R2Y MO(FN\ZZM\I2
27\$T<;A_7Q" _ %7PGI/CWX7^./I_Q(\ "ZHN_L/QIX" \3: M+XP\)\ZS_
&7J5YHVI_V3XC\7NHZ/J\IG:QIVH:3??8IR;D)J5C>6-QY=U:S MQ)MI6Q'U?
ZW\ "MJ5=:ZNL3I?*U?ZQR>T\A\;E\G\;V?O^RYN?D\HEY=3\VU' MVWU?
VM/V_L_;>PH'VWLN;D\KI_-/I/G\SGY>7FIVH\#L**^0\AX3^P+_T M?
#^R!_XDM&/_FUKL/ 7I8_[(GQ5\6:3X" ^%_P"U3^SA\2/'6O?;O\#|%^ O MCC\,?&'BS6?
f+TV\UG4_)\>'O%&HZQJA_9VCZ=J&K7WV.SF^R::8WE\<>
M7:VLJ=J3(<|HTZE;MDV:TJ5*\$JE6K4R\&0ITZ<(\TZE2% % % % !1110
5^8'_!2'_@E_P##_P#X*1?^9_X3KXG^,?AQ_PIG_A8 MGJE_ \ (GI6B;G_:/_L3_A! ?MWJH?
VPK>1_9W_""V?V7I-CS/MUSYW^KBK\// MZ*<9.+4HNS6S\5;A-)Z,Q?
#6B1>&O#F@>'O)Y+F#0-\$TK1(f9526XBTJQ@ ML8YY53Y%DE2_2.J?*&8A>
*VJ_\$O_@F7^WA|=AVUOVL?^"@.@ZIX@| "WW_-MI./Q\$D\#_-!^+PQX6EL-
2\1Z9X@^('Q\$TWPCXFOO\$ES=33ZD\$|'_#9KF\|MQ;V M8EN?%\$%PUO&D.\$/?B
M;X*|'^*O%*:AJ+:/8-X<|/>(=;T\5I;6^U='TNS;3+;Z%SJ*-8PE\|E3\$/H<| MX6S?(1EF>9?
FF70S2A4\|C@9U\1AJ5;%G0C4EAL55P(-+U:70\5T7XC^*/#JMJOA/X7:GIJP3VFJV?
Q'USPM/IK03R7 MR6\\$.LJ>9E^59IFU2='LMQ^95J5.5:I2R_!XC&5*="'
(HX:\$ZDFE&\$95IPC*U_1M1
M@2ZT_5M%UK2KB\TW5=,OK;2.XL\^QN9\6Z@D26"5XV5CN5Q3C*\$I0G&4)PDX
MSA-.,HRBV1E%L.HM--)HHJYTQE&48RC)2C)*491:<91:NI1:NFFFFFG9
MK5!1114C"BBB@_HHHH **** "BBB@#^97_@O#\O""Q:_;(_X(U_"WX@Z1_
M_@3XC_M>_-WC/0OM^IZ5_:/A;Q7\1?V7=#U_2_ \3T2\TW6=.^WZ7?75KJN
MTK4+'4;7S?/LKNVN\$CF3\I_X<* _\$GO^C4_#_.?I27_ , ^&OB_- (+>^(O#
M_A#JNC_@BAXL\6:YH_ACPMX8_:5\4^(? \$OB7Q#J=EHN@>'M T7XG?LLZEK&N
M;YK&I3VVG:3I&DZ=;7%_J6I7\Q;V5C9V\UU=3101.Z_57AS_(-./^"9/B7X
MIVWPTMOC\XGT03K^6QLJ_-^*WB/X<>* _#_P++O4J1NK2SM\N=4U6RMO%/AZ
M*.:ZW7WB#Q9X0T#PCI=K;7=J?B&SL(A=A T" ^ (CRV_#E<#U>,887#Y)Q
M+B=4LNJ591_P!7+I;_XG?B_6-? \ \$5\JM\1: J^H_P#\$QU>| ^S?;_LEIY%C!;6T/K\16\Q!=
MP075K/#I+I%S/#?ZE"E\8_9IP\Q&SRD0IM_).\@R/...>)J&48;\$QKYWG>(QM

M:6*S3\$UV\1BHT,3F&)JXO%.&(KSKXCV-64JLXU)U*ITZLES2FOOLUS/+N&E
MJYA6HNEEN64<-35# T:25&@ZM"4:>'H*5&E&E2H32A%PC"E%J\$7ROB_P!X
M:.*EJ^./C;_@XF\&_#WQ/^VTWBWJG7P%|+_"VDP_%O7/V,]-T+PIK_BWP?M#?
PO;Q:IX@T+Q3J7B7X9+K>J31^&.*O/\$'CN'PI?+;Q@XO-7M?!%OX>UE-
M!:/@?"+"@H#_P%:_O|@K#82A L\$>_@| ^R!X%^%NB>&+?XI?&7XFPCQ9I
MWC3XOSZ?))XB|!>#;S7_
(K7Q%2K&CAI930S.AB*D9NC6G2C[1_/RX^P\$,2L#/.).J>85X>UR| 3RE1Q6 M:8=
<|GB,_%XGV=.G1A!U*ZO|7!5:,7%5*<9OE7!4-%?SK+!/'_(*'_MF>_M'_VXO&7_
3+_P""D-OX0USXS0:1KNM?"GXO^\$=&M-*,Q|=Z1H=YX|!%E+;^# M/#^E>|J7|
(^)_A>FH>*O!_B5/#_PYU?PN?!NH^#/'>CZKX^UZ33O"MC_(*% M_P#!07|L|Q-^W!X-
P""9W-!N/PC7QC;1-\$!1?%_XP^+!-"@UA/AU+JJA9>_M-\$LY(?&'AO6O!6B^\$/#GPWN-
|4>+O\$Q!.\$75O\$|GC?1!?!@72|+|>Z,-| M4<#|+^ (EQ%_J_P#6,F|G_8G^L_|
K#_:#_U;_P!6>3F_M_|M#V'MOI-<_W" MG|3|NZ|5/V%WRJE>?M=+!J\$%%?QZ_MR?
MN?!%P?^";GPR|*>%/C|X|^#GO!U3XD
M>.+77?!7!4_PT|'>%=6TC3K'1|!#|167B|X#^+/"^I_"7P-X?@U6_GN?"/CWP MOKDG@?
0M4-CI?B:QTSQ+X|MWUW30AU_857E|3|\$X_A?Y-F=?;|CS;+<_J9I
M#*|=D>_JXVAB(Y1+!4|74DZN%PLZ4?:XV-&_K"&(C4HUXUJ%%1INKWY)Q+A
M,|Q698&E@LSP&,RF&!ECL-F>&AAJM)YA'\$SH02IUZ|:C|GAI5)3IRE1<*E)T
MZM1N:A_+|^W#=#|^TQ_P<?"|!|G|GA/\$%|=>%/V<_#>E_=-LHKAH_#'_Q'
MT(^./CO=)?/LFMXH/%&A?#;X*6%U,8HEEBO|2S>Y|Z2_1>Q_MI_LW?MV?|!%+
MOVR/'G|*6O|B/5/|@+_P3,^#VN?#"|!>>*_#UF^D>)OV@-2N?7@KXE7N@:%
M+J27T?C74=&|4:|^C:==75L/A1X!U+0K7QAKFB>-?B)X0T7PS?>1_P#!,,W_M.TA_P
%KO|@J3^U7<7&B7FB?"T7GP"TAKE);>Z2|C;QAI?PI!^!)DOH?)
M,=QX"_9KU1;JXACF^VCQ'O-RH=_M/|/5?H7%7\$F)X&S3A7+,NPF J9GPUX=Y
M/@:-7&8>GB?|!#XBSV5/B/,XP5&<%1_M.C#*CA:M:%;%)U%BW&5=67R.19-
M1XHP.>XW&5|5#|9SQ?F.*J0P|6='^U,GRN,LFPF78H|&3J|/5)X5U:|G*G*
M: @|/S*DVW_-|P &OW_)A?Q@_P"SN_'7_JFO@+7@,_PN^&_4C_P"#@#|H M?X;?
M)+K/Q(^"_|)WP5BNOAG|,KJ|&B>%O|9|)R_!S1-7T7Q);Z7:66IZ_X<ME^(7Q+|>>,
|N*34|>|U_4;|PSHVMZEJWP^T|_!Y|P:_?|F%_&#_L|OOU_MZIKX"UY1_P_\$|A
E8<_X*5?|DI^)?|ZM+|G6OK'K5|+6C:KA|0|/*I1C7HSA5A3K58QDE-GS^#C#\$
M<)^%6_KTX5L'C,YP2Q>'JOYZ.)A0PN95:.*O3E>%:BJJA5E2J1E"4Z=.3BW% M'F/_
6S_9>^%O|P3M|4_LL_P#|0K|B_P+!|^S|2?#WQTM/"WB7PO|,3
M4/"W@_Q9++X,N|7T=XO#>B:K8>%_"^A3^'?WBKP9X^|,^&_#UAIGO)T;QH
MG_"3K:>'GA MEF.8XBKCLP6(XVRQX|!%3E7QE3_9?
C%PCI<-8U86A%4L/#%XO#9C#%5Z=&"5.G4Q"MPM!UG",?:SIJL|W*3**_F0_;)_X*1_|%
OA;_P5AF_8Z_9@T;PG|5MA3^! M?#-M.OA#XG|Z|9Z0?&?B3X=R^C;
|Q=XH|8VUOIGB_ (1CP:EOJGC37+*# MQ5L,#Z5HUQ;O?65GYKKY;|R=-?6|1AL-7K-
TL)B<1.E75\$Q'B#E6'J9CS9;GU3"Y M/F-?+,OA-X.|1C3++Q?8_M^%?"?@S7-A
\$FL_H#_P1W_X*1>*O^"@?PA^(^G_!@|*:5X+_)^'BS3_"MGO4T?0_U_2-
%U32O\$B:Q)X,|5)H^NQRS>&;_O+GPUXN|,^)O"2ZWK4MCK7@_M^Y|0XT'3?
%6D^%|!%|S.O#?,FRC,,X_M/A|-89+BL-@^ (L%DV9ROV/X=Q&+J
MRPU"&:TWAJ.'49XR,L%|7!8G&TEBXRI.?NR:|KW_B27PO_MJ'B7;^"?_!0K_@HI?|
P52_9I_8*:MB|%^\$(K+PYKOAGXKR^#_SX>OO" M_P"TI-/@SXL>,"P>|/?B*
|!-66L:|I7C'2MA'6FI-X=NM,TRT|3>%/
M\$<%QX;|"ZG=ZY|.O"WJ5?"#B&C2QRJYOP0#-' M|JG|(_P!BBVU35_@/_P_\$|/|@B?
A|XA^_WQ.T"&XM==^_G MBK7?#'_A_QW8_#01;R_C-EXFU/00|5M#8>'H;6Z|!^
+N)/BA|2T|6>*8?@WX M&F|>_P"#"71!'^RO^T@|@R0G|1\$:GJ0OPY)|@9P,X'.|/7|E?
S&+!KO_M,FM?M)_JG%)_P"J|)U^Y8+B.OF_A!OME,,@|ORS(*GA|1PN%P=)1=?'8G
M%YHLVS?&XB2=;\$X|-*^%HSJ.A1PV\$P|(TZ'-A,,3D|+!_!#X9Q|L M1B,7CZ|>
(O#|_H^JZGX|^,UMXMUSQ/82R:GXBTGX>^\$? VM)=^'K M&R&G%/!P3X6:99>^/V
MK)/X%|8^+=&U6|_VT7_A|C=:A-FTN|M-&T33=,|Z3XN|2VGCVS|3+) M9?
9/|7|F7_E99_X*%?|9H?@|_U&V(=?_P=?|)@OPB_|_P#/_JF/C_7 MV.39MF=#Q#|
(N'Z&.Q%'(<1P1PCA|3DM.HX95B|6>9#|:SB.+R^L)BI9EB.MTZ^J8BE5JUJH3G-
RH4'3^GV&I6ZR)!J%G: MWT*3!5E6*|@2>-951Y\$614D4.\$D=0P(5V&&-RN>|C|
(J>&/^Q>T7_TVUU?MSN?|%&_ ^"C|/V-|8P7WB32/@O|)_/A/ M4M?
T^WUCP_X(|93+|2/!NCZVL<7CG0=3U/4O"FE>(2+XP?|!%UOV_?!^L?M
M7_L9^,O@I^RY^SKJP|5P_|X0>.-+|#:K|6/BKX9|+;AJT.G>+KZ|!9?"KXJ
MZ)H_B3QAJ,%QX:L4UCQE|?"(ETFTOX-/C|,7\$'Q#|4?72|)LRCA<-FLN+!|

M8\8NI/#4N))9[B(Y1_:4)6>534LM69PO_(I8CD>6^P6&A+\$/ \$*DG(!UJM*)4G-V/Z=:*
M_&_((P#1/XG?MP>?C!/?VA?A!>>!/VF/V5?SGA_PA8IDT8>'-(1 MW.O7'C'3-
*OKGPO=7 U7P?| \$#3=4^WBK1_B/X3?3|?0|'5|.RU?P|+8VVN
MW/@OP7|#Z|^W!_P4|_X*_M;_/'X2?|!+|X@?"/X(?;JF#6+WPMXC^,'C? M3O-WB?
3OB+JMYJ5|HFDZS<:GJ_@KXT7%WI7B34?|?C#4OAA'|A_PC8VC^%%
MFU3Q_K27^J>'|T|S*/AGQ_|X@R7'XG)LFCPO0H8G.LYS7,'2R3"X?&^Q>6
M55C,-0Q56M_:RQ.'>74Z.&G7K>VBITJ4HU%#LJ<:Y2LMRG,L+1S',99Y5JT,MMR|
X13S.O6PSJ|+&P>'KU(/GAGQYK7@3P?X900#W|0?@_7->UFMPM/BUH>LZEX?
MM3T*7Q(NG7ND:C|X;LO:5A9:OH_##X-|)WT-J|4A_3U|:
M_B;IGP4^#7Q;^,NM6TM|HWPDP^&7CWXFZM9P;O/N|,|!>%=5|57|M#L21_-GM
M=*EBCV1R-O<;48X4^?Q+P-F_#.(R/#8C\$Y7F8X
M=8:K1JT|/\$#5DZ<:E65J,9N\$V|7G"3IJ=-PJ3_G2_P"";5|^T;_,%Q?^"H M'|4-S;Z/-H?
P@AO_ ("Z<|OLN-VI6OB;00A9X+2:5=0326|)J7@;|G;Q0;J M=#(+E/\$&|"BNRG|J?
V^/@?|ME_MM?LR?M'?|%-OVR-6U;X0_#7X4VWAS1OV
M,/V8M,BGM;6+PIXH^+O@;P3J/Q\$U_3M61KFPTWQ/HFJ2ZBOB74K6#QQ|6=93
M3O\$-HO@SX,>%OA?X>|1_J;_P;A_PJN?#_|&OQ6^.'B#2Y5|6?'KX|Z_<+XH
MNIA<7OBOP3|/|%TG1=(N+B9@9W-A|0M5^+|\$1:>1F>YN+J8|?+2?97_!|=;_E M%|A
M8_|@|X2?^K|^%=?M<^*99#XT8+(LIP^"J?4|TX|X"PF:U:4:V*RW)|H ME@,LSO:Y?
&4JM+#U,UKSK8>OB7S8FA@XUL+3=.IB*LX?FLV M_P#!*K_E'%^QA_V0'P'_
FQ;"G_@B)^R|*|_@H-+^TQ_P4/_&U?#7AW M|HWMX^+|V@=7|%-
H/Q)TF^|1^#?"3Z3X T'7_:N8?#.M:|J?A/Q'HEWHWQ+ M|.>\$|!7A7Q)X7U"P^%FB?
#;04|&75L9K>/2/W6_X)5?|HXOV,A_L@|@/_TV M+7YA?|&O_P#R8+|7?^SO_'W_*ICX
5|M'&XO*|H|&P^_S#PP MPF,HT|5A8Y#F>-
^K5XJKAY8O"Y9DM/#8B="=Z52KAXXFNZ\$JD).E.HZE/EFH MR7S_.'?A1X&_P"";7_!?
WX\$ _!S|FA|!|_ |HK+X&/JOQ\$^%D5<:YX-|_IDU&;5-#DUOQ5X:T2|T_P5J3>'
M%_ |HK^7|IN;_)6-O^""6: XNK4Q.8Y MEP|EL|PQM:7M,3C:V'S3-
|+2Q&+K2O4Q.)6'I4;|16E.M4IT:2G.7(F>KP1
M3IX:MQA@,/""|X/BS&0PF&IKDH8:G6P.7UYT!-'?C+QG|2+Q? N@^&|GQ)HGC^_L|/P
MOXF05|&WMG>^('?"@3,|7_+|4K_(*D?|N_C+J'P4_X*\$^%?_ |5U|0_ MNK^(O@K|0?
AKI6D^%8M9|7RZ9;6GAK2_#NK>%/ O@"PUWPSIOC&+_A%_B+X1 M|0?
#G2/B7|,FNVC'0=6U/PX/"FC>.MO^(<33Q,LMP^;<*8K/7@,/FF'X>H
MYTXYQC;|B,+0Q?UC#T<1A*&&@Z-*M)U<-BL5AL6XX>MB*.K81T,17S_.(D
M9+&C'&UT+Q;X7Z=XEU#P3|/I7&E>,-7|\$_M ^+O\$^ MEZ/!<^(X_&6J;-IFM>+
|/|F_A)_P46^&'Q#_."=%K_P45|1>'M5|#>|;3X7 M^_
?/B3P7J,JZ%)K,'B7X>:WXA|&:WX(|-ZM=W^FZ3K=WXF|>^&KKPW|;G4
M)=!O/%7|L^&#J&D>'M6U6?1;#Y_./#S-LLP.79E@LSR#B; YCFT,AAB.& M0ET/4_#.D:
|+|+|/%_CB2Q|0Z_XEAG@,10^H
M4X2OE.O.I2JNA6K8.G4PV(I2Q:JOIPJ<.#X|RW&8G*L/_9>?86.>5G2RC%8S-M
4J&\$QU)4IUUBZ558J=*,*D%5IT|1.:%E4CAW!RE#^D*BBBORX^X/XS? M^"D_|-
|_T;W|7W@+|LO|;A_VK?&>I_"O|G3|FCQ!X^T;|D?|GW3;&ZT|/|&>
M@^&_B!+|V|I#^)^I:~?W;@TZR|4:=,OB"3OYKMO?>)>OB+'D?|%E?^48O|8'_9-|I#_U-
/'U>;|M!!7_)1/?LI_|US_/6DOC#7|SG_!%BN(O!*E.KAL%@,'EGB5EV697EV7X>
M&'PN"P-#A',*BA|JHB,17KU:V*Q>+Q\$ZE;\$8JO5J-Q@X4X?E>59/0RCQ+G&
MG6Q.*Q&_X,QF-QV,Q=:5:OB<34X@P<;5|E&C2I4Z=##X>E&-.C0I4X)2DI3
ME^*/_!!_@F;^Q%^V;^R)|1OBA^T|I\$ _^%D>.M!_:A %_@+2=<_X61|6_!_ MV3PGI?
PR^\$'B&QTG^S/7CWPMH|_D:QXIUV|^W7.GS:E+|N^SS7DEK:V<%O_M\$?<
7_@DA_P3V_9B^+'A3XX_|HG|_A"/BEX(_MW_A%_%'_M;XW>)?|_=
MX27PUK'A#6_^^))XO^).O^';W|;X=U_5|_XF.D7?V;|7|KM/(OH+:YA_?|MX(E?
|%"_V5OV#?|_@G-|1|6_&^&^(+Z/K7B;|K?XFW"@|P|X;TF|3^/O%R:= M|_%V?_M,FE:'8*(-
/L%D_P!%&O|BC4/#_AK|<5L&U|;UT@;^BO|C'_@I|^R
M5^WI9:NO|/GQ#FU'Q9X9TNSUGQ7|O%>C7WA3Q_X#|6|2:'I=Y?
Z99:CJ=K>:G807'H>+M?Q/A1<:XJCB^X<%?VE
MB&K89TXU5@/J52=2>%JOWC";T;0BIK M|KHHK^3/X7_M|_|!7?J2|
;K;_B_8|_9EU3X7?VEX#^~7CG3/"OQX^)/AC MP_I'@|HFSX6?#KQ|13/#::5 |?'C+Q|12;Q?
F@^&|KQ)HGCZ|H|3PQ MXFO5|&WEG>^('?"@3|DX7X-
S#BNCG.)P>.RC+|+D.&PN,S+%9QC98+#T<+BL
M5""^V514*RFJ+DZM2DK5ZL(^RPE+%8J='#5/OL|XCP>0U,NHXC#9ABZ^:UJ^
M'P5#+|-'\$U:E>A0=?V;@ZM-Q=5)0A_-NH2?/B*E"A&I6A_6917|CWB_(*E M_P#|4?)

X)>?&4/@C_P4(!*^!OVKK;XA>!=6!1!;X@_#32!)*QZSXNGTR MVL_#.E^'M5!*>!?-
AKOAC3?&4#>_%B'X1!0?#C1_B7I4NNVWC#0=7U3PVOA M/10!/'<'KOG_,'/'-
OPRU+JL7QO!3?V?/\$W@#PO-:??\$X@_LQ>!_@_Q_ M?_#GP5.)=:U!00\$QM?
A=IOB34!/P_M<:5XPU?P3^T#XN\3Z7HT%QXDC\9:I MHVF:UXOL_K5X/9TJN
57B7@C#X7.HTWPYF-;/JJP7\$E2HU"=##*>3_3O2K8>O M.EAL3',<+E!*.)K4:,AU1'@?
!1#RUPQ;IX+Q-5KY;*.SG!TJ@!3DT(KGC5 MQ_-BHT'3JTE.M1>#K8N52C3J5%'EBV?
U445^>/PE_P""BWPQ^(7_3GMA M@HMXC\:/MX%!"VOPO!:/.\$?@O4=4T.36(?
\$OP!USQ#X*UOP3X;U>ZOM.TG6 M/KQ-X_|#5UX;^&UU?R:%=^*?/8|MJ&D>'M5U2?
1;#17_V>/C1_P<?MU^% M+SJLXK#_!*_9O!A-!"/:2:MJ/PQ^
'C+0_"\$UIX\T3P%J\$VA:GX:T?6I/ MA=XQ!|=8?\$/B#PWK/AK6-;18?
%7X(I=7U"PY<>_"#EGAWG. M-AG=;,<=DG#. %R#-'D6.QG\$>/G@!-
+/8RK1GD^%GA,/CI8C&PCAZU6IRP6&I M4:#PN9YU7S; K-
+A!GPD<17CE;C3<PLKR:."WU+4_!O@!6/\$&EZ4SRO&A?5=1L+;3H8MX>>>ZCACS)
(BG!+/A M@DA_P4A_:\$:_P#VXOVH?@Y^TA'IG@_00A?X"UZ!C^#UIX6\Z;=?#;X@^&_
MB'X4!% ^)- E!06VG1^)M2BT>_N/\$&G);:JVVJ3Q_QK=W5Y=VPNW^AO! @X6^
M+L'PO_X)F_\$?P_00H-3^_C_&7PBT6!L99(C;SMX@/Q.U!+MXT;-CJ7A#X M9>)-
&N8I'BCF74A"/!MY@AE!/*7A!F>6^(7#O!>:/!U!1F6/R!XAX"O+%X:;!S
M2>'KU9>VY**J^PP?%V"QG"6<<28#ZQ2HX+"YJJ7 MUJDJ%9XK QJTH+V?
-4E>"/AMIUSX5!+V/B;Q)_8Q_P3Q^#D7P!_ M8;_94^%!'TA X1O5/#?
P0!WGBS1<1AK/X@>*M&@!8?S?+1%J SX!U_P-1 MW=P^TL!|CR-)(S.WXL?|'
)PO!(S_LXSQ;_ZF_-U?J_!W'=?,O%CA M"X+#X.%'B7.^,<1COPL*
<_@N(N%Z6#X"RFOB:V(E4R7+N&Z.&P/*&\$P^98K+LRS"5)_A^*7PH!07GA/Q
MHIGAKP;X9T3Q/!EQ=V.L^X?B1!4/_PTUO6-U.PN;34-&12;=H'B_5+KPY
MKNGW4%_H6NQ?K%E*EU8Q&OBG_@F!_P1_P#V%KS!@/X,ZG!6_@;X'^,OCK!H
MSX+^/B=10OB%XHT!6H!%,_"\$/2W^(&@Z%X)U5?\$M!JGPRD!:'XML?!MWKO
MPQU+P9?>-!X>M_\$&00K=W,=E8?07_!>K_E\$!^U9_W0S_-2^#U?7_|P3V_
MY,%_8>|-_9I_|5,>"J_-!FN99+X28>OD^/Q>58C,/;\$'4L;BLNKU,%B!
M51ROA!)L3E!'"MBL/*GB)T,)B<;B<31H.H&.(J>WY'5A3G#!+\$X'!YEQ_5HY
MCAF76MZBU!_3; M7!07_!&?_E*Q_P%F_|LN_Q(-6COBW7!V?MI?
\$CQ=|/V0OVGOBSX U"" M2?'/PT^
GQ8!|=>\$-4N+&RU2#3O\$OA:P1K6M:+>S::J4%SI!_%::C9V!SV=I; MSVMPJ&*XADB=D-
>*N"GF'B0Z%!4H8O.L%PC4JU))4J=3,,TR'*/;XFM!/*Y7 M7Q-65?
\$3A3E*=2=2JXRG)WG@3\$QPG!J!U>>6'RW\$<01A"+@+K/I0_C&;Q'K^JW,OA?
PQ!\$ _B7X>|/>\$ M?AQX6O! P;X-F.F>#!%35/\$!AK=^/'BC49M=|+>L#X0_|!77_(*C^_
M;_M!0?|\$X+|X&>"T_X*00^/'^FG?%OO#;Z/H7@KPAX/TKPSJNH>/OB;100#&GR
M7!/Z!12^\$!;38/&A/Q%X,MK!X;>=!UVRGT/X>ZS-I.A^'OBM=7P9XBA6S3
M"TL!X.Q6-R&M-9_@J&?)8C).#3JRIU,WS#V^\$H48Y;1HOCB,2!6Q&-P=*I"
MGB!%002GAX*GXC91*G@;|KXBH8;-:<7E6)JY5>EF6*G3C.&7X14L15JO&5) M-
TJ*JTZ6&Q\$X2GA!35H.%;7!<5%?R>_\$!JM'_@L5_P_\$I?BE!)O'7_!0GQ=|
M_ VK_P!EOXD:F?"/B35?A#X4!&Z4OAC596N+Z:UV/Z_IGPJ^".I6/Q!LM%TR
M!11^'_#OC.SO?_CK0+37!&L-7TK5!4?S\$O@K!@?^"KW_!1"V_X)W?LT6WQ*
M!+:HGC/XM?\$7Q+!X\$^\$/A76KR;.0^K3:7?SJO3Q)IEKJVE^(-4!&>\$!-L
M8TU./P!)HN?\$.O>\$-"N;11+7Q
VMV'B8SPTS^CF/#67Y=B00I5,TP6:854<90I8B\$IX2K&G0JXFE6AB^2<./H&M.4ZD7%Q
MBW'F_4&BOY;=7!9?!"\$O!WP/U!JGXV?\$/X#?&[P/H/P!U#7_B%|\$&|.;>; M+XH_"W0)-
/&JZUX^:7X?"7P#X8N?\$/PVL+*YNJ3M;3Q_P#\$3PS#;2WUS=^% M/\$UK:276E?HE_P
\$2/VMOCG^VA^OUK7Q=-;#146'B!QW9?&SOKX,M!5T!PWXM?|+0+X?
T;PWX&U'3!0Z9X:T!3-:2&UO47:Z:V-S*LRI+*Z11!7G?ASF&3Y M%C.(Z.?
!YJE&!S'#957Q.09GB;_KV)C5DJ2IUL!A9I4H4E.=2HJ=.I"K3G
MA98B/M'3,LXQPF8YIA!GJ95GN5X_%8.MCZ5'-<%1PR^JT73BYN=%UXMSE4<
M8P@Y3A*G.->-&7(I_L!1117YX?7!1110!_?_P_%P/V5O&W!5!37_!*"SPG9 M?"XH?
\$OX0#XT>,_#OQZUGP!X2!7ZSI!@CX=>-/'O!&GZ!/?^,/%/A?3!J#P M'87?
AFQ!47%OKVK7NF1VUOI&J:C!C!J3^'&D7/Q)N!*\$0V&C):^&-&|
M:PP_A!Q;I^BV!E#JVDZK>;S#?I9WH!4_'S!N3X!?!LU_&3!G!X\$?%'5O\$=C
M!0OVFO\$!AX0^%5H!AJ^UC3+_6M1!3^'O"%K%K&J6S"#1H&UKQ/L3W%R"B0
M237!^2!Z/^"A/_)@O!\$!#Q!Y!S4W>66VTCPL3?&&A^" MM%MI7)+Z;X>|
6_A70=-1<):V6G0V2+;"OSG_X.6H8;FP_8 M!B*.">"XZ^
M+H9X)HUEAFAEA^'Z2Q2Q.&22.1&9)(W4JZDJP()??7_;;N6%Y9_P#!;X<

MW%T7,&J?.\$KXOW^G;Q*%%G'XRN],<1>8H0I.:&G7Q)@+Q>89 6\$XF5?D3_@Y4
M_P"/:,@GW_V7GQ7_.B_A17VG#E&EAOI'8^C048TH<5<:.\$8)1C3YL%GLW3A
M&*2C&G*3A&*245%);'S>;U)UO:I!U*K;_)L/VEO^5EO_O[I?JF@>-?_%%/VX:XG|A?Q!
<=>M,?|@XF_X*2^(+RWCMIY|.^!^M>#XTBD=U:T|
(^)OV9/I|G,=P|ARZL_"EM(M.DF7I%*YC!D_#G_M|&:A_J06EH9?
1WP*AK|WL9<>XMU|*^L;QIYT?7_C#KG@#X/>&9;8J'OIM>|4V7B;Q;
M|S\$A:_EVU3X9^\$/5I>'L5"JO>JT<)MGTZ,%S:4ZJA"">CE))|GS=_P;1_"|:J?L1?
\$#XQ:H|NW7_(|_:O1JUCX_MCGF>YU#Q'X)|"Z3H_A+39+ZXE3SY'L?B!'|4E!DFN-
|ES/.766>9:_HKKX1_
MX)A?""W^!7_!|K|D;X@FDW&+TA:*27TW"&7_P!E<+Y#@7'EJ44?|S|/^5AS
M_@I5_P!DI^)?_JTOV=;_:|Y+Z0_|V3>(P#5KD1^9Y;_,D|X0_|CFA_
MZ@YD>A_|0W_"9+|#_^SI_#O_JI?B|7I*M?S5?|0W_"9+|#_^SI_#O_JI M?B|7I*M?
EO\$?)L/#A_|&WB#_ZD|-GW63_|EOOK_P!@'"7_*8SD_E|U""&
M7_@Z|T.26&*5|;X#S3VSR1H|V|S?L|:Q;--S_F*5K>XN+CN_O9|E'_DD/%C_+'W&A
ZA88_03_O|?F" M_L/?JF@?LT_^J8|5^)'!_*+Q_@C|K#_@X6|:1Q><_A'|H;Q!XG2'89/-
?0_M/B3^V=JJQ>6)|8OYAM_FP7-N6SCSXL^8O|;_//|_DP7|A|_LT#|FG_-4Q_MX*K|A
@EIX?*CUXJ|.6)(C(%YK?Q"_;2TRU)\$MLU0\$0)(L))X(|T:Y=?G,H5)Y?
XTJM9477R)5;Z+V3|1?-8|_X-AHA'^P#|4G(|_JK?X@2G.<\$K|
M(O@3|E<|1B\$#CC<".H_@8-Y|/60Q!B(&/D)^\$OP,FVGCJ1*'YR<..<8_Y7|K
MO_E9*_X)V_|9K|U_P"@_MD5|=C;_P#\$7_%^_P#T27B|JW^KL|?A8|'#V_XA_M|X?
6_P"A|PEMW_M>%_QO?S/Z1|=UO2_#6B:SXCUNZ%CHOA_2M1UO5|UHHEL
M|+TJTF0|Z:&VCFN)1;VD\$LOB@AEFD";(HW)?AMHWQ!?!QQ#|+?B#
<_\$_2_\$VH7UOX2T/5_%MA#X|'Q>&=%MO"O_M
D'A3P|K\$|DGA_Q9XV_L7Q.VD^%'36M*O;SQ?IG|#+HDB-'(JNCJR.CJ&1T_M8%65E8\$,K
D,I!!!((P:_?JG?|X)/_+"G|+'OQU;JH;X+?!F+PY2;R+4_MX/#|U?>)?\$OB#1OAI#K|C-
IWB1?A|JHFMZI>V7AR77|*ZO+&ZNP MW?:=I%_J7_MAWP|=;+X;U/4=&NOQ|AC&
<#8;)>+*/%.4YGF&=XG+HT^\$|5@L1*EALOS'DQ;
M75Q<(XO#*456G@ZLG5I8ZG*A0KTXT:=24?;?H6=X;BBMF60U,CQ^"PF64,9*_M>?
T.32C.MB|'S4&J>'E+#UFI.G'\$07LZF&E&K5I3E4E"+|G^C5?S&_|!KO_M_,FM?
M)_JG%)_P"J|)U_3E7|QO_:_|P#)K7|2?_9Q2?|JN_"=>UPQ_R:_M_P_40^QAX??
^K#/3S<|_.2XX&_|^+O_47*CLOV9?|_E99_X*%?|FA^#O|_MU&V(:?_, '0')@OPB_|_|_|
JF/C_3/V9?|_E99_X*%?|FA^#O|_U&V_M(:?_, '0')@OPB_|_|_|JF/C_7Z%E?|_R=OP=|(|P
//_69I'R&-_Y-_M_P"(?_90|6_^KJ9_0YX1_P"14|_|?B|HO_IMMJ_G*_:#_P"5FC|AG_LUGO=
MZK|JL.OZ-?"/_(J>&A_L7M%_P#3;:5_.5^T'_RLT?L_#9K/B|_P!5G^V'_M7Y|X;_|
(QXY_P"S;:>('JFKGU_&?^Y|_|99<)_P#JRI'VQ_P7J_Y1/?M6_M?|T_P#6DO@|7U7_
_\$WE5?^"??|S@4|1_PRA!6P-S?#+PTS'|LQ+,>I_M8DGDFOE3_@O5_P_HGOVK/^Z&?
^M)?!ZOJS_@G!_RC|_8D_|-3^?_JL/#-95_MO^3.9=_VUJXLX78I;S:K?
21A6N92W_|\$;T;G_|M33_@MG&OWG_:|6(N>F6^/?Q|49_\$UV7_|K_A
)@OQ=_|_P#W_JF/@!7_MZ?Q|VLG|44FUS4/
^,DFUS17#>,DE)=5S)2L|+Q3W2M|3PHD|QX);2;5?Q: MNMG_
&SA5==G9M771M;_|@_X*70Q+_P7S_X)?3B*,3R>%_A5#).\$42R10?&?
MXLO#\$|@&|XX7N)WB1F*QM/_R_&1RWZ)?|YOC%%(?)@F3|=H+?6Y-\$|1?%
MF|!\$?!WPP8B_^JR^+/%6G:CXRT3)D1O+U'X6^_'Z3A!(3_DJM&8R|+^>A_MP4P_Y3W?
|N_^Q;^%_|ZN7XJ5T?_!Q)?;E|8_&G!;?|AO1=8L+\$_M!_M#)
MJ&M.Q\$E_H6H3:IX1^\$7@/6I(2NW^SYA|6/'|EF<"27174J1&2L9;EU+|_|M*>)M|5P?
#_|YQ?^"6/PBM_@=_P3_MN_9!|_00ZA:SGX+>&/'>L66JQS0ZAI_B;XN"X^+7BS3;F"
<^=;MIQB?QOJU@_MEO(\$:WCMTAIN,((U_|_X+K?|HI_VL?|L?"3_U?
GPKK|9|>W@M((+6U@AMK
M6VACM|:VMXTA@MX(46.&""&-5CBABC58XXXU5(T5550H_K|F/^"ZW_**?|JK'
M_L?'?3_U?GPKK|GX5S&KG'BGPWFV(O|?-/(\$#)|OK7ES/VN_XBP^)|J7E9_|\$JO
M^4<7|&'_&0'P'_Z;%K|PO|@U_.3|?B|_-G?^/O_%3'P_KZO&_DYXX
M?|ESPQ_ZN_.#P;-_R/_#+_LE|_|J5_#IYW^W_-RL;?|_|/_+()X5_|2|H|MNOZ@:_E^:_F_Y6-
O^"CP?_R;.>?^RMK_|JLRT_FK_X(:?)|G_6Y_P"SJ_|_6W^UQ3?^"YR
MJ_|/_!\$A'571_VIO\$"NC_K*WQ:_9'#*RD\$,K_D\$\$\$\$@C%_X(:?)|G_M_6Y_P"SJ-
_J6W^UQ1_P7+_.3W/^"(W_9U&O|_JV_V1Z_1H_|G|7_&2B_M_P#7.GQW_-
J/^Z|_|\$0_9K_@H&?V" VVP1D'|D7JL\$'H1_PIKQGP:_E@^'_M-S<2_P#|K?|
'R*:>::U^+NC6UI'+*|B6MNMW|5?P6O&@MT=BL\$+75Q-OAPUY/VE977R;7HV=W';?|
:./M_MU_|^,D_2U#_A_5'|1O|P3?T72=|_P""?|!\$ECHNGVFF6<_|*?P#UJ:VLH4@

MAEU;Q)\.?#/B+7M0=\$ #7>KZYJFHZK?S'Y(B^O;BXD)>5B?P?_X)/0Q0?1%R
M/^"K*0Q1PHVH?'>9DB18U.MO^TCX^(-?1\$ _B;1//A/2'U.ZCGBT?3;1Q5XET
M:WUK6Q9:I-HNCO?ZK;:-K5S9PZ3>?! _2M_P""O?A7_@I9J'Q4\ (W'P@O?
M@M\00AG9:3XC70AXS_X6!HOB7P;K%W+IU:RUX>\$ _!NGZGHNJK;6&K:/>:4
MT>=JEAHGZD?&'X/_S^/WPS\8_!SXQ>#1+|>_#3QH+:+XK_M*ZO\JCM-
2LA<07MM+#+=V%Q9ZGI6J;9J-I9:OH>N:/?6&MZ\K5AI^M:;J%AJ_MMA9WD'SE^QO_
.\$^/V6?V#=#*17Z?^SGX\$O?#M\X^N-/F\9>)->|2:YXJ\1Z\I
M#HL^J\$:#ITU\K%Y/!8:9HB:S?06=EI%GIT5P)!:=I:;&HAKUOA,NOG_M/(@G/
M,'F>4YI7XXK9A0GD6:T*\H9=A<G@:_TL12^N0IRG^|Q_M.?8B=3ZQAHTJM
M!TYU?*U&,PW%\$^)_93_P"ZY_|K27Q_MAKZ*')BZ_|V=G"?^L?C3R)?\G0H_|
9!8C_P!:"GY^_|!NO_P3YD^\$?@_M/XK?M\$_M\$?;QEX%_!?:
XFOX!^'NG_&SX7ZKX1\2^"O_N@^#=_U;Z\8^_:/Q
MIHFFZY80XZU7QOK/AO6/\$5A%Y4\KX+&C:??>Q*_B&VNO.?VH_OAK\B7_(!M?V)_B-
|&/!6F^!O"/\4.EZ\X=|>:%X;#^_"GB\OK\1M>|:?!WOI??"\Z(
MEEID)CLM4^/CR\LEMS9ZO_\$"U/B\5(IM:OKR^E_H7_&_VT?@9^W3\,|=M^+?
|/^J>(-6|&^'?>I_#G4\GQ)X=O?#-|GB;2/#_ACQ->016%|6FFM%TKQ=
MHLD=VIN2:2>\$#=#;07X4_P#|7R>&|_X*|_|!C2K;5)=1L_BC\|4NK123+_M#83_
+0'@YH;IQC_BE_L?4PAR0\1<0\2>*%_ ^LN&Q67ULZX3_MXJRW+DKSQ;:6!PF&X=Q-
:A@G1JN#IPH5%*K34XQ<:M6=96K5)5^YFF3Y1
MD_!#W\|C5J&+IY=GV0XS+|SI1HN>)Q%?;.%KB54@I*\$O_6RRL^KX@_Y*O@'_
+#+^(\A_UG<<'!<MQ5?|MO|X(CHZAE;JJC7U96_965OBW^R."K Y!!!(((((.#7|-?1%N?
V#/V_MVP>G_#(O\2?_*IKQG7XS?|!>?^MJC#S|+_P_C;Q1\,L_193#'
M\L'PYNKB7_@UP^/D4T\TT=M\7=&M;2.65Y\$M;=OVJ_@M>M!;J\%8(6NKBYN6
MBC"H;BXGF*^9-(I?U#_|\X-&TK0?^"??|S\$ECHVGVFF6<_P"RG\|9FMK*%(
M9=5\1_##PSXAU\4'1%:_|U?7-4U'5;^8C?<7U\)(IM0?C?
QC*44VHN2R'(K2:6CDN>=FU=AB@_X+C_|!5I(M8HX4;4?CM,R1(L:F6X_:0\,W%Q*50
&2>>62:9R-TLLCR.6=V8\;_P_%\KFU_M^/O\4G_!;?181BUG4&T\XH_&.W\3?
\$|P_ID4LMU:>&_%_C3P=|_"OB\%O(M)D&DZ(?
C2_G\|(TMK>VO;@SHD4S)RW_!*_+_E.3_P59_Z_?CA_ZT7X;KLM(DO?
MVFO^#F36;HWF7GAO\B7\G^>+3U58;M-OL_ ^%>V>D7\|E\O8ML>L>'_BI^TSJ
M\H*%YK2;PXL\$6\$X@L.323QRX2PN5Y="|A/I
M\+'9G0E1;2E"I"-6\J(6(RF;6ZPKS^MCL9*RZ_F\A_ ^#@?_DX7_@D9_P\G&>+?_4W_
&;J_IPK^8_(!M_P#DX7_@D9_V<9XM_P#4W_9NK\|E\&O\|DXN2?|@?S\$O\|
ZRN=GWOB/_R1^9?|_MA61_ ^K_*S\|R_X+U?|HGOVK/^Z&?^M)?|ZOK_/\X\|?)
)@O\#W_9H\|/_JF_M\!5?(_!>K_E\$|^U9_W0S_UI+X\5\?|_!/_DP7\|A|_+-_9I_14QX*K"O
M_P_F?RO_+;3GW_K+|&M+_DX>_-(S*_P#U>9P?AS_P1G_Y2L?1%F_ ^R\|\$
MC_UH\XMU^V/_4B_P"4?7\;?_9JOQY_15GXD\K\3O^",_P#RE8_X+-_JEW^)
M'_K1WQ;K\JL?^"D7_"CZ;:_S5?CS_ JS\25\|O_,G8R'_KQX=^J;-(MCQN%?
^2!S3_KYQ?_.K'-#Y5_P""O\|RB>_93_|KG_ZTE\8: ^)/V?T1_P#@
MYJ;B9D5FC_9<|)/&64\$QN?A?^R!&70D\$JQCDDC++@E'=<|6(VW_P_\$%?|
ME\$|^RG_W7A\;2^_?S\$W\|O_*S3^W+_FM>\$?_%67\|M>C3_Y+7Z00_8C_M\O/_
%MLI.27_)^\$7_8SX3_/69S_Z3_@YX/_\PP)_\6OP^()&<'_A4_MOQS&1Z'!
(R.Q(Z\$UX#_P5#TK30%_QB_X-T\|46<.OZ1XH^)?A#2Q\$5AJJ;_M;?
6M.UQQ3^Q99Z09ZDDQ8W<.I6US<0WBREO/2:02\$|SGW_|X.=^4?_..?
M^SM/A\|ZJ;XY5X=_P4D=(CI_P&W\$DCK""\6?A\|N\!41%\8?L3,SNS\$*J_MJH)9B0_22
^A\//#_AE*+<9QS'Q@<)>1;4HM<\$UVG%K5--)HHH/<|?B
MU)YOQM&23C+>">'BE%ZQ:_P\9:*.:>C5FT\|&^Y_0)^V\|##<_L7_M>6\|Q%%/;
MS_LO_'V&>":_989H9?A3XL26*6)PR212(S))&ZLK\JO5@02*_ (K_@V?|_ ^4=
MB3_LY;XE?^H;|_*_7G\|M?_DS3\K;_LV3X\?^J\K\5U^0W_!L_P_H\|\$G_9RW
MQ*_10WX85^<91_R9KC'_+++AC_U"S+_ "7W"V>8?|G%X=_DW//_4G!?!YL_
MH4HHHK\G/O_HHHH_G_"Y_P"S9^T1XMF_8Y;_9@|!2?%7XB_L4?%R3Q
MSJ/PUTSPY?>(I:|0Z7=>(?A_XPT'7#I&B;IWB;Q)H7A?Q3|-|+3-?|"WA>M*|07.D^_
K\I7+.72M.T'6M03XE_:8_X+;:O^WU^SYX\|8T_8R_91:-(NOVG_M_(!^&S!-?
B#HFIZ/X;U+0OA\X;U\;?1OBG%INH-Z>JZIK>FFSNM2\%WGB?Q
MKX: ^%6D>&|UFEX\;|=Z)+|B3?UM45^H9%XA9;@,KX?P6=|(X7B'%|(XC%
M8CAG'3S7%9=#"_6<|S>'S7!T*%:&<86EF4I8FG2E6P9*M&\$:D4U\7?|!_JF#5/V-?
V+O@'^S?K^LVVO>)?A\X6U.?Q9J%B3)I@_M\8>./%?
B#XB>+M.T>X>*WEO=#T7Q+XLU31M\$U&XM;ZU+2;"SU"ZL;*YN9;2_M\

< ^#C'P5XR\8VW\!8\(^\$O\$WBDZ5\.,5AZ>9YA+'9MF.*HRJ M?
5*>)Q6;T.;2Q.^>G3J^R2J8ZI6C&-.2\U05D\KT\UX;PV8<-/AFA6G@L)'"
MX#"4*BA\>=&AE\7#3HOY93A\1N&%A3;)M\$U+0;^.PE^#WP'MXKV&SU2VM;B2TDA
M@CN4C:%YK:XB5R\BK_0W17%(@>)9X'A7/^%UA(5*>>YADV/GC'6<9X:63_7.
M6E&BJY5G;Q\$H2R0"9EA8X=4U*-99C\6 MYINKSIP=+ZNK14)<_.\N-M?
YY/VC?"BR\X._V!O&-GX7\177A'2?V2_&6 MGZIXJMM\$U*?PWIM_)X7_&TXX\+4-
T&YTB2Q\>\$/\$?B3PMX0U33/AE\/_&NA_\$*PTSQ# #I_CKP_K^A>
M,3IFB;UX=TCQ7_3=7XT_#? \X*1?*\$\X* _3_@GE\5X/A#X7^&WAKX>Z?K_M_P\$-?
M=* \4Z/A1/'?C35/'OPT=6OA: \U?5?&NJ^% \8D'A7Q3X^O1;Z1X5T
M6XN&\JL5PL\IM\;4.UR?'X6C24\MSNI@(4<-2DJKJ4:U&=# XBE/V\2LL3* @Z;C)_S\? \
M!;+ \K? _+ \VQ?V%?!/A#1_'6F_VC8)>Z+ \J&I>*?+?4\ \4+6 M33O#WZ1? _#%Y>?&KXG_
/_ _ \JA;2_\$%O80?'KX_1ZGXK@B4R;AHDNI:\X.^ M\$?@+Q; \E2JMDEO \1?
B^%OAYH; \J7B>ZT?3O# 'CCX8Z; \ND6KR7MJ/%_C+XC6FA^\$FN M; >_
/_ \$>H: +XCMM(>ZF\ZLEK^HWQ6_P'"<6C_!>_X*_ _K_@H#XF^)\YD7X#^_M
H_!&@_!MO_L; \AJ-& \5QSVVHZ1XI^)\3^)\K_(_"R"3P_I MUBTF)'NXON \Q-
D>3Y/X7\2XC+;_
PSA,KPWBKCN \IPL<=CWB;RKU89ABW#"0J854U*EAJ\$;\$POL<+'\$8\ \$YC&%* @L/OIPP
5*G+"4%+\$2A7K*\$;/%G@O \89^+6E^,?"_B+PGJ=Q^UAXVOX-. \3;)J6@WT\|C+ \
 \(@9;QWL M-IJEM:W\$MD)<6MS ERD;0O-;SQ*Y>&15^=OVJYOC_ P2L_X*T_\$?
@HJGP& \M3%O\ID' \HWX;Z?X6^*7B#XY \2; \X* _+XMU/PEH^OV/B*TU75?"O\5%%?
IW_\$29U.,.*)<7D>'MQ>7<887%Y=G>0SQM>G&IE^,EA*LJ>&S&E3C5P^*HU\%0K8?
&?5JCIM2BZ;E- MGQ/^IL8;+X:T3PQ= \? \ \$; ** \BKBO#Y\A&IX*C\+ TIT<'AL-
@Z=2K&A1H0J56\U;M2K4JU*E2;\$ _\$O\'+ \9+50% @T'5#X9%U_P
*&U&T^S'7OLOJEB? \41; > M2;KS/M!\$.WS""KZQ_P"# @#PUXC \6? \ \$UOB1HOA70-
 \3:Q_ \0?A+-#I/A_2K MI6=3EBM_&MA++/%8;= \PC? \O_J_.C*G""M;5E05/FC)RIN= _;;7?
R7^P-H_ \I/ \M"G\%FEZI97>FZGIO \)? \.6GZCIVH6TUG?Z??V?P> \&V\Y97MG#_
 \7X= _J_P""W.I^(O" _B'0M+ \3_+6= MI? \AS4:T34M,T_Q#I_ "X?VM+AKW1+N^M8+?
5K\ \J% A;BPDN(?)O;24O MY=S"S_T.55OA>&RO!HSV \>H&UN!8R7<+W-
JEX8G^RO#XVP7U*#7&GU-5*KKR7\G?5<_PV>)OBJ+ ^L*(X:O/UF2?#?UCD@J2?
UOV^55LK?;_+V/+&K\9652 MH\FB?OY%_V<=7_&YO^""OQ? \CU^SC8_L;?
&O\H#\IDSX@^/YOB _/\&7P MHTG6M=N\^T+= \ \$TS6-1 \1>\$OAMK5BWC?
7?"OA_PQX; ^ (GP_ \16GAJ32M= \ (MKXB\%??"NHVNI^,?/? \OQ*_:=^,W_! ?G\A_XN?
M0_ ". \^6L? \$3X5ZIX@^% M'P4UC45U/Q1 _/@W% \OVAM%T32?
&TFB>'=3MO%&L>,M) \>=+M2TW7='T\6 MM+7Q;Z?>Z?I8MXM*L?VI_X(W? \
 \23QC_P4/^\$'Q3U;XS6_PL \+?& \X9_\$Z MXT/4OA_ _+ \4: \9_#F_P##?ARY \+>* \1TCQ?
XL \9:HUQJGBI?'FB375OJT M=K\$WAZ&WFTVRG*W&H_?"
C;QUH/Q_P"#F#\GU/A>1XWTWJES\GKQKX%^,6L: M\$J;OHOA#7MA#_M
SZ@-1U&T:XLX#X? \5_&CP+X&UAFE#Z+X^NY?"M\MMMKUC M29-
M7HX2'U;LV=6O1G6A2^O8BG@(1Q+A0K57'#0C>KS.C3 \&> _ \7\G \15EXR \>?)?"5 \>?
M!+=VEIXFT+5- \NKJT_X5_P""H?M5
MM;ZK:VDL \OYL;Q>=\$C1^8CINW*0/Z3.*^FRWB2>7< _ \3\K"1JPXEQ&05YXM
MUG"6\$>18C'5XQC15.2K+\$O&N,FZE/V7LTTAS2 \7&Y_&'9WDFC^&/_
GA+58+R\#;M%I M<-G>_"SP! \2-\$ \6: \#X9\.^ (KR;5_A=?QX; >>#Q1=?G \8? \5?
C_P#X+Z:S M_"V3_V,?@ \46O#GP+ _-%?1?'WOE^GQ2 \+;5:P>_"&?'BGQ5KRZ1?
> \IO%_Q(UJTK0_#FB:3-HJOXH_LBHK \)? _/%' #8 M&&1YE7X3P>_
XPX9RBCDN1 \12S+\$T;+1PN"P \3"996Q^14Z#P^88W+L-4=*CB
M'B \JBA1EB*56=&\$E \SC> \Z^*EF>#I9 \B;_P \G685,RS3)U@J-6O4KXFM#\$8
MVGA:_G3^/?@ \Q== _ \R)^Q_XRM?"WB.Y \(:9^S'XK ML=2 \5V^AZG-
X;T^ \D^" \7\$;=G?: _MI=I=/_J% A\$EO/=1RM)?6:*A:YA#_M_-&=%?# _<1U_.'V<<-
Y \P \3K2I>PAG>"G@YXM-4ZCJ3PZG \2-) MJ*JM1S7 M,X)W4)6L?DQ_P7-T#7?
%'\!+ \J+0O#.B:OXBUN^_P""%)_8M&T+3;S5 \5O/L MW \17PCO+G \+I^GPW%WSY
M5&G' JLJWM6Y.HX>S2BI2(Y/&/\$-;A V\G.KDV'R=X7V:Y8QP^Q6-5?VO/
M=RD \2Z;I^S22@I< \Y5_-U_P \1 \&> _#O_!2C_@LIK7B#PIXET+1_\$? \0GB:
M _ \MK&A:HFF: \2?;XY7276C7 \
 P6NJ6 \VMU;7*3V;L \36 \Q; \&.,% \8 "J \^\$ \$7C/Q.?!>GV= MJJEQX36WU32-\$ _6NG>(=A
#>MR>/_WAWQSH_A_P O>+ _0 \>'_%7A \Q%)
MX9TF%O%? \=QS@XZ \LC(S \C(S \CZU^_'\! \3_@I9XZ;L _?&_P5^T7HWP^ ^
M&G \4/P6^ (VH:7KWPB \)> _/%_@F \T \X>1V.BZ3 \JVH^'/_BSQ9X@FU_1?B;

M>_#/_C..VO((#\$_J>#+#6=+TN^UJQEU7I+PG&&9S3XXXCJLX#-N%JF4I&Y
M1Q3D6(S#&4Y1^H4*67Y)FN&Q."^K8JE5H8O+:DYUU%TL.L<144;PJ'Q=?A-MW
9;/AG*(9UB\GD K4<3I:A4IU:&A&%)R52 ML-1: #C/*4#\BA7?VDOV@/!"VW_!7XS?
M'_L^ZC^S%-XKU#X3:?)\A' MXEOY:|QYI7PJT'Q|XW2'6/'JW6GZ'J-AX@UWQI]?^/+R'3-
8I_!%M5T|1!H5E M-HUQ:P67B/Q|I^>.H)OVG?| @Y>^'VA+H-OJ'AO|BKX#:.??
>)FN9?.MY3:IX\$ MUSQSX=126R1R2*E|HWQ_:(!V #B%X|O0E,B,84|SF?
VJ|0T#JHW_@XX_8M M|\$ #|Q:~^(\$^7PWT:3XE2Z1#+?6?@WQ=V/+SXV_%W6-!U?
4+:UFAANI|*O? M^BW1:=K33M=UZUT*YFLM:%|:1?K?^RS_P\$V=\$_9P_!*_:_O_:1U?
XMZQ|4? M'O|3&H^((J-TW5/'T&@A_!WB'QL/%T_@VTU9/\$6M2^);.SM|A#^'J/O)+
M'0OL^G^#K9A9-JM\$-E|GQ'Q+E&497D^,KX>CD>8XSP5Q>5|Y)A:.958X>7\$
M6=8C!T)0Q%>5:K!T(=;OM/^%(L='T/3KS5M4O#;_-'7X874
MXM=/L(;B|N#:#.P3W,HAA999*HZ;|K74-+U2SN-/U&QNHM-42VUY97<<-
S:SQGB2&>))\$/#*#7| MW|+7|10Q%_X-^?&?QX_9A_!V^"GQ>|??LN^-OB=?
^//@1|>/ACX6T!X? \$VNS M:79:|+M)0:|HGA>|O?%O@?PUX2OM?|
"1^(L7B#X8ZQX9O+==%\2Z;XJ37; M+^Q*BOK,KXYH8;%
<6T|WR&CG.0|98R&/S/*%CJN Q-#%8;'XK'Y?B;!FU+#U MJN'K8.IC,12DY8:I2Q-
"M4IUJ-I+E|'#^<+U:U#(OY?FM3+LUX=PTL)@LP>%A MBZ-
6A6PM#"XREBL!4JTX5:>)AAJ,TE7A4H5:<9TZET|_ ,KW|(B?'+_@JA M|9/
W_!234_@9XD^#G|)?|/?PUU+PC|'-4^(.BSV.J?.\$|37TOXC:9X/DM;F
M2|)%AKWB27Q5|3/%'Q-U75O|J: SX-|&6'A_2/ UWKFKZV|EXA|0?U0T45Y"%W
M%'^M&-P\$Z.74782I7K0C7Q==1J8S%5: ^)KUL1BI
M4Z3JRFE|. *A%'H&Q4*F,JYACT*^|.W^MZ'J>E66OV2?
%:_|JV=KS1;J_M; >#5+58+^QF:XL9)XA%>VDA<)--
A0>'AH7C.QUC1O\$WPR|4ZI9)#::S+L.@>/\$!>(+FWAADCU.TTR: MR>&
|MY; >3^F.OBC_@HM?|XN_LL_L8?'+|H+X&>#M#|>?\$KX7:/X9|0Z9X
M<|3: #XC|2^'I-!;QYX5TWQYK.MZ3X3USPWKKZ7X5|7_ (G|57U_::W86NC6
M^BR:SJLCZ387T,F""O\$>:4|OPG|N3T:-+,LTXTX!X;SC+|9@84/:O
M\$8+\$J&)Q4HM34Y3|CAYTXT8TW|1SLD)V3_K|B3|N3_@HK^P;|!%M\$_8D^*G_M
2X_:_0^-7C7X2:EKGAKX9^,O|L7C%?#VNZ%JFO7FL6&C:UXQL?WQ\$|&ZEH M?
ABZU+4|'2?'O@|Q%<^%H?|UIHFBRZ)8/X;U'7|7|_| ^"\$A^*DG_!5|_@H-
M=_'2|'T+XT:GX4^*6M?%G0O#T|SH6A_\$;7/C|X4U?QGHNCSSVHZQ:RZ;F'
MB&|U#3K-|/6-8LS!;)|DU;4|:RKZ?^C_/_8:_:J'?M=_L@?"K|L>)|/A5I
MJG@:QD^,D>CS/HWA|X?_!0|:~;?|+4T"ZL|;U;4|2|,Z1H6MI?:AHZ>(I5
MN+J:P5=Z|XC?4+|3-6L|4N_PO_X(=Q:=|9?^"CG_5?_J):K%K?PZUCXE M^M"|\$>
((&|M:/Q1H'Q0^,_CGQIH&I:~)"EBJ|7)L/B*>M-I?
5|IH9/6JN1.IA:_.MBZE.BL/1|O6DXP2<%!5*LG+^IVBBBOYGV|D_O|MX*^Z-
K'B'_@FO^UKHN@:3J6N:QJ'P|L8;#2='L;K4|3O9AXQ|,R&*TL+**>Z MN9!&CR%
(8G8(C,1M4D>>?|,\$M UWPO|!\$L_V7="|3:)|J_AW6|'_ (79|MT; M7=-O-(U6S^T_M%?
%R|MOM6GZA#;W=O|: +2XM|J#SH4|VVGAGCW12HS?K/17
MU2XHFN")\|_%_4X>RGQ52XH_M#VS|HITLHK92L|7|GR|CC6==UO;74HJG|.SY
MCPGDD7Q-#B3ZQ+GAD53)/JGLURN-3,*6/^L>VY|AR=-409^SLT^;GNN4_CM_
M9K^/WQ"X+OBA^T#^SA^U%|'_C+|?V1OB)|1&|=/?XS_#G1/#H:7^J?V
M=)|I33|M>D|(^'-6|4>+?|FE>"|:QYX9E|?;J'PIUCP.TND>'_\$&B>*(?F|ME_96TGXN?
|_%8?^"K'|7_(*-^(|@7XC^\$_|G|I.?@=-" ^"E|0|1%N=/U3XGG M19/'3^;JWN5UA-L|6?
\$MIX^|<^(/B-JVJ>#CKG@WP?;>%|#| 7^K:SJ|L/MB'6_ZK:*^TQWBI0Q479
M)+!4(U:=:A7GBL+A|1FGM95<5@<+7J.=/#SP|92A&G2J5IPIQ05_._=P1A
M|WB|PS^V?_P6?U+Q'X6|1^'|.|2?M:/%?>';_6|U/2K+7D)/BM^U;UYHMMU M?
VMO|JEJL%_8S-<6,D|0BO;20N\$N86?^C&BOA)=9PE@UE>;X7-
HSA25.2KNM+*#@XN=+D4W43DX|C^HQ^3QQV:Y%F;KRIRR M.OCZ|:*IJ2Q+QV7UL
XRFYQ=)4U6=5-1GS.*BU%/F7Y_P#P6O|!WB|Q+^VMA_P1?U+PYX6|1^(-.|-M/ZY?>
(K_1-#U/5;+0+)OBM^RE<+>;U=6%K/!I5J MT%A?3+<7TD\$1BLKN0.4MIF3|@?V|
|'^U7|AK|J|2|+LKO4M3U+|E#|HJPT|3
MK"VFO+Z_OKSX0>, +>TLK*TMIDN+J|NKB2."VMH(Y)YI\$BB1G95/U?1776XM
MJ5L|P|@7@817!3QKI5;/R;S#ZYGM;/'|2/LDL|I.=9X=6+DESOVW/&G|9W5.S?)JES/^9O|
X)@? MLCZE^T;_.,\$/BC^RSX^T&_!ZY|3=?^,EGX?B|::?K_ (= &A^-+ #6=&|3_#
M+Q/JMFEO;ZR^CZ'X|T/PYKUW#!;S+J5EIL|F8+J&>2"3QC|B;|N7_@HM^P?|
M%|\$_8E^*W_!+GH'XU^-?A'J.M^&?AGXS|'1^,1X>UW0-2UVAU?3J%UGQC8^M|OB)X-
U+00"USJ6I6&D>///WB*Y|+0>#;/1-\$DT33W|:-CK^K?OI_P%%OC_M/%WJEG|C#XY?

M!/? SP=H?CSXE?"[1_#/B'3/#GB;0?;\$?B7P])H+>/"NF^/M-9UO2?">N>&|=?
2-"O@"_P#\$_BJ^O[6["UT:WT636=5D?2;"^ADM_L_M>>
M#_VNOV0/A3^TF/\$G@^*|U7P+82?&1-'EDT;P|/_ (H>'=&MO^%JZ!=6>MZM
MJ>I>&=(T'7(I^_T=?\$>JW%U-X+NM|1-J_-IFJV>JWGZ%5XMS#,LEXEXBSCA M'+
<^X1XCX/K8R&6ULRS*C6R7BAX"-93I8G+:F\$O"P^_R_\$OPT_:Q@L:|+R4G_M2J8>3?
R4,APF"S/)ISPK)"WO_0HD^*_P""K7_!0J_^.^G;)X>^,E_X2^*>MN_%W1M"N;>;P|X?
^(>L_'OPMK/C;2-*NK?4M7LVTK1M?O-1L+66UUG5|(6UJ MAM=7U*V\$=|/|(-
!O=:7'00^,7_4G_;KU'PX+&T^_7QXDTKP7>W,DDM|H
MZZUXC|9_%GOYX45S)+|GM+/QM* ZK++M_LZV1&6)\$+^_-|F_#_M9_M>_M|%L?
C!|.OB!=^?"|Q=N/BY|*OAE|6|(T2YGEM+/X|_ \$#XG:MX3|=^+6|32
M4O|WPGH/ACPYXBFTBXU'2|TR:|H@0Q:-
>|D_B%XF|:7V@P^&)|M>U_Q#|E12+H4&KZ|'81Z;X:|. ^ M'=% &K79NFTQ|TF#
|3|E@^H|4>(LLP#XZRV6T,-C*4,#@<
M#EM#_LUA&I_C1I^W_L|"+#5:T|3&\$9TW"475G'PN|!GQF*7"^_A&5;)LLS'
MC/,%C*M;#SEB<3BL94RW_2<(OVE2;I?7,0ZT*<:#DXS4T_9QE|XU_-I_P7H
M&>,/%7Q|_P""45WX7|*>)?\$EKH|/0GB|UVYT#0M4UBWT6TD|: ?L|RQW6K3:
M=:W,>G6|QV=W(D|XT,3):W+ABL\$|7^DNBOPS@_B2?"7\$."S^GA(XZ>#HYC26
M&G6="19CE>-RR4G5C3JN/LHXQUDN1|H#<5)R7ZAO#DT>(HQ.53Q\$|L+'\$
M5<%4=>--57!X'/8;')*FYTT_:|/*FWS+E4W)7:L_BA X*/_+,6O?MC_L2? MM ?
LY^%-7M|\$|6^/?"^D7WA*ZO(XVL+009X|!8>'B3X8T+49I9X\$T|3/\$^N M^\$-A-
ZEK.9VT.QU:XUA++47L5L+G|"OV:/^"X&H_L|_+/O@K|CC|LG|DW|
MHNP_:D^!7A&S^%W@+P|H_AWPSI&B?\$7PWX;MI/#_.(O|1EUK4=!U00+::3K
M'2?|8|1>\$O"_Q5L/%%GHH|?:-?Y=Z^_AZT_K1HKUN'N,,MR_(Z_#7\$?#=#/B
M7))9LL|P=*GFE?),=@%IX'\$5(8_#X;%2JX3%X2C1I8G!U*-G*C2K4JM&K M!3//S?
A|&8O-*6=9/G,|ES-8|Y7B*D| #2S+#8K JO+%4H2PM:M0C#\$8?\$5*M
M2CB(5+I5)TZD*E.3B?S|?|\$,?V9/VA?"_H?MB?MI?M0_#UOA5|1_VT?BI_PFMFD?#S5-
#U/PWXA|:6/%'Q|9>*M5F|ZS>W6N>&M#|4^*O'OV+P_P""O\$T<
M/B.'2_!=KK%T;K3=;TF_O/U_P""B.G:AK'|!|/9VE:387NJ:|J7|+_QRL=.
MTW3K6>|O|^|NOAOXBAMK.RL|:6XNKJXF=(H+>"26:5UCC1F8_8|!%<.<|7
MXO.^+UQ;BL)AZ56&-RS\$4K7S"5>KBL5.,>2+E.OB*M1
M05HQBXTT|13/R8_X(9:|KOA?_@EG^R|H7B;1-7|.ZW8_|+L^VZ-KNFWFD:K9_M_:?
VBOBY>6WVK3|0AM|NW^T6EQ:W4'G0IYMM/#!/NBE1F^,O@+X.|76G_!R)
M^VOXRNO"OB.V|:(G^S)X4L=-|5W&AZG#X;U"|"C^&_P"R1#)9V.NR6JZ7=W23 M:??
Q:P74DJRV-Y&R|K:8)_1H17;'CBK'.>AW_LZFY<=X+|L%5H?69TC-U"*#CR/F?
#\$'EW">7_7)VX6Q.58FG5|B MKXUY7EM?+HPG#VEJ"K1KNJW&57D<5!*22,OY|O|
@Y2|(^*_&G|!_P-M*|'_M>&/\$/BS5(?VJO_5_-IOAK1=2UV_BL8OA7|;
():R6STNVNKB.TBGN;:&2X;:0 MI+<01LX>6_-%_P_%3/V\$/BE^UI_P3W_94|6? GP|?
ZA^TG^S#X=^"C3P;I= MEJ-UHGB^|:GX"|.6?Q|:-
>%\$GO|,L8O%|&KZ#X&|96*WC+K,C> KG00#F_
M7=9M|U#^A:OQ|_X*H_|%\$/BM_P3Y|8_L8:|H_@SPGJ?|//Q9^+6J^#_-I3 MQ_XE|'>-
O\$NH>_O#&GZ|_|RWC|_%WOA:O5X?TS3_!H|_@B|^*VM:'IVO:9X MG;6I_!AET_29;?
1|7M|OZ+@?BCB+\$8C@?AOAC_866<|.YSQ:G6_J8K\$R5'-/MKN7*KC,9)?FMI:|M@H_
_%"|VDOV0_C+|X_P#@F|!8?A+10\$?P(^.(@?'#XP^/|A<^"_@SX! M|&Q>|!17XM^,-L?
&_@SP|?6>I:CX0M_%S^"!>I^+__%_0|6GTN"QO/B?J M.E-I>O?
3/_!L_P#|H|_\$G_9RWQ*_J0WX85^C?_!17XV_#;P_P_\$|?VH/B5? M>."?J>&?&?|_
OQ(T3X=^(8|4M=3T/QKXC^)WPZUG10AI8^&|S39YX?\$57B|5
M=:TG^S)|*FGM|C3;A|6^T1Z7;W%|!#|9?|&|PVU#P%_P3-^!^N:B2C?%GXD?
M%/_XDV=K)%<07%HZ>(5^'=F)X|B./(|OX_A|_-G+!YEO<;J=E<12-YK8H|
MLVRW&^\$'\$4|OX8PG"N%Q">2X>CA|B,SQCQF/AEV88G&*6)S*M6E&&%H4Z<
M:>%HJG3PJ;YU*I79@!|C<-X@Y/'%YWB,|KTN%|SJU*U:C@L,L/A)8O!T< M.XT<'3IQ/R|
YKA:F"S"4;A*O+|2AB*<:E.3BU*\$K27NSA)*4)Q:G"
M24HR329^/O|'W_!\$|BG|CGXHP?&OP|!3OC%|4-*EMKOPCXG^_/B;0?\$J^! M-
1AM|^UGU?PMHWA;PEX+T9M8NX+R()JWB:R|2ZEHLVG6-WX8NM!NOM>I*4E",8
M)J,8I%>%>,>B%>%>|1110 4444 %>%% 'XN_M5?|!\$'_P!A|HJGXO:|<;V
M7XM?!7X@>+|RJU?QS-+&P|1:N%EF MUN|+|P|:^(=5O-2|0^(|/6|\$6JZGJUY|4?L_|
|-7|EG_@GOH.MV'P|:- MY>^+/%4"6?B_XJ?\$5|;Q)|10\$^FVVI7FI:=I%U?
V&F:#X>T71|:|B@72_" M/AKPY8ZH-
TN_P#\$\$&L:U9)JA^_^J*^KQG/'&&89+3X>QO\$>;8G):4*%*.7U<

M74E1E1PS3P]"J|^TKT,.U!T:%.=2C2=.DX0BZ-
+D!#|I_\$33|.G!|IX.U#^V=.O|2Z^'FCKKDOC70_*U;Q|#"'+F&E1C6/U"
MKU(H*56G!5?9>TC M&52BZE+GYJ;J.<)QB5^
/f67_!"K|AW|K+XKZK|;M2B^*7P5^)/B:_U#6O&V ML? OQ3X?|:-?
XY|1:E'917/B37_#_BOP?XUT>QUV?|<76|:CX0M?"LWB35|
M7UKQ!XM.OZ_J,^IG|EJ*UR+B//>&<7+'Y!FN-RG%SI2H5:N#K2I>VH3:
M&M.O2YHQFJ=:\$X1J0A4BE4A"2SS3)|KSK#QPN:X'#8^A&I&K"GB*:G|.K&ZC
M4I2TG2J*+E%SIRC)PE*#:A*2?YX?L*?|\$00V4| @G|:^(OX&^'?\$6L^/?%
MMC_8_B7XM?\$K5|'Q+|1=3.)J3:M!X7MKW2|&|. ^'?#OAY+U;.>|T_PKX:T+
M_A(IM(T"|f5RZ_?^'|%N|!#|Z**Y|VSC-,|Q|?-,YQ^*S/,2XNMB|96G6K3
M4(J\$(&_\$6E:AH7B#P_KNGVFKZ)KNB:O:3:2JNCZOI6H0W%AJ> ME:G87%Q9:AH
|:SVE|:3S6US#+#*Z-JT4XRE"49PDXRBU*,HMQE&47=2BU9I MII-----70FE),,DG%HH-
--6::>C36C3T:/Y|?" !M7_P3|4^*-%+WPCI45K:V|(MM+N/B)|./GC&:&:|@DU67_A
M(O%GB% XKZ|N\$|L6LK!+.RM/V._9E_9=^!W|'_.)|)^"W|W@:R|"^!=,O:|6
M+FWBN+O4|9|1>(|5|@:MX|5^(-3GNM7|1>(-=0CM,:T:_P|2NIOL.D:=|AW
M2(M.|.: 'HND:?) 45|3G7""% \$>"P^79|Q%FN:8'#3A4IX;&8J=6FZM.FJ4* MU>|3Q-
>%.|8U|2ZM:-4:FG4J.7AY;POP|D^)|XS*|GP&|Q-:,H3K8>A&\$U3
MG+GG3IVTHTI22(/#^NZ?:.OHFNZ)JH-I^JZ/K&E:A#<
M6&IZ5J=A<7%EJ&GWMO/:7MI/-;7,,L,KHWX#>- ^#:O_ ()^>?*%&N:YX9|5
M_M+?"00-^!|B5X4O?".E16MK;1"VTNX^(GPX|>>,9H9KR"359?^\$B_M|6>
(7BOKNX2Q>RL\$|I*T_H.HKZ/A_B_B;A66(E|G>893|:4%B882LXT:|H/
MFI3JT)J=&=6DW+V59T_:TE.I&\$XQJ34O'S;A_).|5%9OEF\$Q|P|DZ\$J|-.I2
MYTE.-.K%Q|1A4M%SI|7)-Q@Y|A%KY_&9?V7?@=^Q_|)|)^"W|W@:R|"^ M!=,O:
|6+FWBN+O4|9|1>(|5|@:MX|5^(-3GNM7|1>(-=0CM,:T:_U*ZF^PZ1 MIVD>'=
(BT|PYH>BZ1H_T!117B80%XK'XJOC<=B: ^,QF*JSKXG%8FK.OB,16J M2:/J&KZ!J)O-
|UK5|,OO>*Z,|B|5@<30QF"Q-?|XO"U85|M-
BL+6J4,1AZU.2E3JT:U*4*E*I"24H3A*,HM)Hf5>A0Q5&KA|31H8C#UX2I
M5J%>G"K1JTYIQG3JTYJ4)PE%M2C*+C).S31_/7X/_P"#:.,@G_X|2:J_B# MQG^TY|2?
#NAW3W3?#|Q|2?|UGX5UE9HW6XM-5N?/PS|\$>+>+>UFE:*Y=O#? MB;P|?--
:Q"2^EA,L,G|^>'?#V@>\$?#^A^\$ "FAZ1X9|+>&'TSP|X:|+^|
ML|'T'P_H&BV4&FZ/H>B:1|T-OI^E:1L.G6UM8:;IMC;P6=C9V|K;0Q0Q(B|
M%>>YQ!O?Q/O4|,^(L|S#-E@U-86&+K.5*|@ZK3JSIT8J%*-6KRQ56JH>UJ*\$(-MSG*,
O)>7E/#V29\$JRRC+,.)@/K#BZ|J%*-I54\$U",ZDG*I*\$+ODIN7)!RDXQ3
ME)LHHHKYL|D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M|P^
-WQ0TWX(?!CXN_&G6=/N=6T?XO_# #Q|4-6TJRE2"|U/3?'A35O%=|H MI-*DD<-
S>VNDRVT\$LD;|'+(CNC*"H/KSWXM_#3P|:?.A3|3O@YXPDU*+PE|M6?
A|XT^&GBB71KF*RUB/P|X|f-ZEX6UN32KRXMKV"TU)-,U6Z:QN9K.|B@NA
M%+);3HC1/TX)X58S"/* ,C3O|26%56'UA0LXOG=+G4;2B^:UFGJ8X
ME5WAZZPSBL2Z-58=SMR*OR2|DY737*JG+S735KW3V/Y.OV,/|^="WC#_@M;X&
M|3_MQ_|!0G|H#XX+:^+ 'WBW0_@|A_A;K?A?0_?"A'PIH=S8Z;KUYX3L_%M^E?
\$K3O#7A2;Q%97WA&S|*V'AW0=;FO/!-UXO|4>(_% ^H^)|J-?1O_!|*7XF_
M'+|D+ _@HK^T)_P \$E/C|=KSXT_#7P'X\$T|Q+|J9|52ZW?ZQHD^E>#_(:>M)?#7@?
P=)J=Q?7'A?PW\$/V>?A'<>)|KP%X)N?.\$MUH|_C#5+36?.\$#R^*_\$^K^+3^
MVZC8Z9H|K.JZIK=XMJ(|@.5H(87,KHTS_@W^PO8:9^TI_P7Z_X*,M,Z#X8 M>|+?
KPG;?!F'7|6O=,AO="^+NF6/P_ ^"\$H:3H|GJLUQJ6F>*M&^"WQQ?2
M=4CAN|. #P_<63:NFE:MJVF6M?T%_K@^,,)XK87\$QI?ZA9/PWBL5PGESP&P=
M'(L72SK+,#PLL\$E!3P.)Q-*M5IXN%&LY8R4Z|)*L5.#_)?)7EP|7X\$KT74_
MUJS#.*QXG_M&XUC0==|23?%;^UKCP/X@|3Z#KWA_PQX+|6D_AWP?8>)?
M\$'B37=.:XGXN_"/QS_P\$/VH_P|E:QAI?CA6_/'|&7|0?CV^|(?&3X0_\$N MXL/\$-CIQBN/
5AXNUQ|/O(!WA*|H>7WAV|&O_#GQ9H_AGPOXBTBY|3>%_\$M.JZ|X-U/6=(USU#_
f(Z_P#*9C_@KK_V4;|H+_UJG5Z|_P#X:./^27_L7?|M9PNJ?
^H|95|5AL;6P_B#POX7TXX?_4?|*9=AL=D4L'@WA|77S#A6IF.(S2O
M/ZNJLLW>|<,7',%..(C5I049J#E"7A5<-3K|)YUQO-UO|9|+G^+K87-%B;0J
MN'183/:>#HX&E'VO(LO6\$4L.|&XNDZ_9L_ ;M, ^,G|'&I?LR^-?B%XK^'7AGP6GPEG^'?
BN_|1>+ _(|_!:(OA/X7^)?!_P MNTGX>V'PXN7|++=M|1+Y-
0|2MX|27,>F>\$KR;0_"_B+O-K6B>#|K^:>'>%|
M^XKQ6)P/#^7RS'%8/|3S'\$TH5|+0=+!4|1AL+4Q#EBZ|"\$H4ZV,PZJ*\$I2A"
M0T*).S;%QP=#\$8F.#HU)4J|53Q,Z:-O"BE0I59*4Z> M'JN#DE&4HJG%NI4IPE^|= %?

SC>/'^" CWX8?&#P/X ;Z 8+^* J& @?XG7 MLEIX3^)OB'5M?U2QT1=Z/;7-
WJFE^(_AWX(37/#_AY-%)I=N|7|H7 M5+WQGX5T?QAX4|)/>VOBSQE.0:9|)/%>E>&?
#>A:CHOB&'4=4N=:|11Z)8Z5 M)=^+80#.IPZIH&E?
5KPBX_=6G#^QLJ5>G3J8?'O/,@CE.)E5J5*+X7-WF M:RW\$XV=:E5IK
T<5/%_NYS=%4HNHO!B!PHH3E-
-VE**J4(X=||8JHYM1/Z3**^+/V!_VX_A=_P4\$ _9|TGX|
M_###3!:_F'6K|P3|0/!B&)FU3P^1=%T|2-4UKPW_:|4\$&F>)|+;3->T37-M
|2Z0%@U30=:TXZKI_AWQ/#K_A70?RM^(?|P74|<^,OCM|0/A#^P)^O#X_M&V?
#/PGNH|'QI|4_!B+6(_#M|?+=ZI9SR>'H_"O@#QM9#PM?3:5=1>\$O&>MJZ|;Q^_
);749O#^@76E6MGJFJ^_E_/ %N9YGF^48?*94L;D#:SI8_%8'+<+E
MC|K|'""Q>_S#\$X:|4W7J^|ADL1)XJ*=3**K34IKTL7Q7D&"P67YA5Q|;F&S6S
MRWZK0Q_-KXU>S|K)X?"X2C6Q4U2AK7?L5|!VA6Y)M1?|!\$M%?@K^S)_P7)T?|
MI7|LKX'?L;V_|+OC3X:>+_B%X<|:1_%F;X@^:;|1/%?P-^*WP|(|_ \$|Q1XL^M&>H>
:_X;V_ BF.V_P""?6\$5CXCD|0^%;Q|+O7;RZSX5T+7|!\$U;PO'^O7|37 MQ9?X#?
LX_'OXVPP6EW=?"/X_ \$KXCZ?8WTJ0VNI;X;|':QX@TO2I'>2(%M5
MU&PM=.BB619)YKJ.&+,LB|N<<'<1|YIEN39SELL#F;4<-B;|AYXC"5_ ;X M?
&8RO@,-653"5|13A"MB<-6C#GE&4H1C6C%T:M*I/;+N(LGS;XS_|X)%7 M+?
M)_P#|6S_@JM^V#+XFB|0Z?X4U:7X)^|NU@C;3=>|"^(OB!=Z5X\$UJSN6 M@CD5M)|
?LW^&+"W*););379'N@|NK^|TO| @HE^UW^WQ^WA|!#O"|;?@|_&M|/_!GX;>.|\$|
?|CPFGB+4_"OC+XU:_JFO3:|?^_M9D|.2@^+K02KFWFA MUB?^U#|/_>H1_|"O|P-
=>_&A_\$WQ=?M+_P;8_"|!|?|!\$|;SXA:E#8 MM&O#GC_X):#X>|/:#IUGI&AZ#H>D
M:S'I^DZ-HVDZ?#;V&EZ3I=A;V|CIVG6-O!9V5G!#;6T;4,2(O|_AN(KP/C> MLFH91@?|I
M&_"/XL>_.|443ZSK|H|7A+|GSP|XO|3WZB>4W6JZQJZTW@JR|'C:W^C^&H-
(TC180\$>NZMX8O/%'CCQAXF M|1W5YJ%|^TG_#@,_P"|0A|YA7@/A P;9?HXG_P"R_?
%#_P!-G@ROELMQ MF(X8X6|2.+DJ1P/\$, >.
<)>D6&S2%&A/%8'+JU7;L5BJ6|J5:4WA98N<*=/\$S
ML;JE&E3IW2B^;W<9AJ.>9YP;D.9P>*RE|+XC-*V!E4JQH8K&4X8&A0J8J\$*
MD576'C*;K:XNM;|*#2? 6B^,=-T;0;JZUV^?PYX|7P3|_BGPCK M'A: 7/A^V|<^"=-
UCP5H_A*V|1^*AKO|/5?S\$^_^5GGX/?|F|ZG_P"J^*^5_M?
T|5|GXJG7S#A+.71H4L=Q'P'P|GF<3P|&EAZ>+S;\$2QV%Q>.= "A"G1I5<6
ML'2K5U2IPA.O*I444YL|W@1SI83B#+E4JSPN3<59OE>70K5)UIX?+Z4<+7H8
M55;LIU)T|.134ITG.4H1*\$_.9J*"BOYC?A1_P<3>+OV@O"T^C? 7_@GM|4OB
MO^T/;^IN?@_ |O'FL^_|(|/?" 2|_T-)?BEXO| &^E!NSETJWO/%OB&R|+
MZ7H\$'AFZLG>TOKO7_%AFXO?"NF^)|N|^7_!Q|^+O#H^+@_ |MC|G#XL?LH?
M&OX3Z!'KEM|,KN#4|\$F|^)|N+O|I=)|+Z;8>(O#O@'7/"GB_7+;Q%8ZUI%EX MDTW_
(12Y|(QS>*9?&|%JT%D)E7|'?\$?#O\$4Y|.3GBL+*"K9?ALRR?&9G&G4
MK0H0Q.&M+VGM?91E..E+Q\$X.K*E..-VI?^"5'QS^!_P-|5>(-
T(^|6|1>*+76=+>|,JU/;V4/C3X0^
M"/#NO>*VT;3=9U/1?!>KZWX\$NM;BTZXF75K.PM;N^B_>GQ1^U)|#|/_|_G|
M7FM^.;T^/_J_1OB_8^_KJTO|+.K>_"\$^CZ?K/A.33|%UNVT06SKWBR/5
M|'TWP|X5O+"T|1ZEXAU?3?#J;:NM74=C7AYWP%Q7P_|V8|ORM2AG&(E@|MK
M9;CLOSFAB|;"=.G+!4Z^48O'4EC%4J0A'#3G&M4=_90FHR;|3+.*LBS;ZZL'
MC7&6748XC&4|9A<7EU6AAI1E..)E2S"AAJCPSC"4G7C%TXI+GE%M)_05%?S0
M>#_ ^"|G|17C^PU/XS^" ^"6'Q|6?LC:/K&J'4_C#X;UO7|9U6W|!#:#J|S: ^M(O&
<5K9?"^3P;>7WAS2+*^U'Q#X:/K'Q%L;*UN/\$\$7Z\$?| M!-O_ (*C^&?
^"C_C|JC1?!7POE|%>#?V>O\$ _@W2_"7C: ?QG=Z_-|5_#/CK5 M?BA::#XIF|+W_@3P??>
99|*^'=|JTF@7M|XBNX^|0G3KBZ@FTAYK_MSCPRX MUR'+|PS7;LH4L;E*H+
_10S;):L;LOJXC%8?!4L-BZ>"S#\$5J.+EB<50IO"2 MI_6(OE*K*FJ-
*K4AS9=QKPUFN+PF!P685)XK'NK|1I5KBJE;#
MSQ.\$I4ZF'5"A4FJZG|)M1@INI4IPG^J|?DE^VS_P4|3?LG_+9_|%G|^*^D?
M"O0O&6E?M6>,O WA?5O&&H^)M0TG4/!T7B_XK:'.9K03M*MM+O+;5I+*VU=
M|4BBN;RS6:>%;9G2-S*/UMK^#;_@H+ ^VE^TS|8OV^?V?B|2/V/BE|"/B|
M|'_GPZU;X<_ |Q/XIUK4_\$OQTU#1?C/X=|3Z9HGAK4KSX4>%K03+G7|&
MP\$XXVKE>83RJH2I3QN\$Q>
(C#&893K3P|;N'PL8QGCW2H3BY>=Q_Q%/_A_*/P<KR^)|/M+_.RA MO!:6^I?G+H7_
75_:_E^_5OXF^(|?7_2H^_/QF^_7AG5|ROA|>OXDUR'6
MO\$MO:3HDL=KI/A+X8^,='M/\$%K&ZG6/#WAG7?B+HGF0SWMX8)4+>)A/#;C#
M&XG;|+OP&_"X2*F#H8_%U,^R"EE=+\$8^C#\$83"TLXJ9G'!|7BJU*I!_5|)C*

MJ:E*7)6A3FI17I8CC/AI#4,%7JXK%?|"A#\$5,+AX95FT|=,CA:LJ.(KU,OC
M@GCL/0ISC)>VQ&T4YI-AS^UW-XI8>*?%MTVG^-OA+%82^)-\$&K:_)8QW&A>-
WGCLY-5N(MK9)VBC:9(2BR-&A<,44CHO M^">?
-!0:X0-1%\$ @E-PM3X;VIOX5I4^-;VU/-%3X5:QJ5IJ/B+X=^*9I);R
M*%KNWBLCKWA'6XQEZ7:-(I>QU*VFTW1_\$B>(_#VB_R%P#!%'IO M/QW^R?
X+^/'PU^!G/*OO1_:!^,GO5I3^#?%&G>OA\NHV6E>\$O/@G2=:TC7 M?&OB_7-*I-
>+IOM+7_A(O&'AC2--M8I!CTJXDN;T: SXG\W9\V?B3I X/X/
MSVIP9XOI,U,KICO#A,9P'1J87&U<'A'A'1S7:-^)J5:,BZU+!T,/16INL\3+
M\$QPI:AR5(5:D)TW+Y/B'B'*X<2>'>=0QWM,IQ&&XJH0KX:GB,0L0JF P%*C&
M&&PI.IB*M;VTU35%495J=7FC*\$91FH_WT5_,%JOC?QHO_!S9X;I%+XN\3KX-
MD^%DI^!\$EU_51X9>:3J^B^("?-CJ.MVOB2W9M)L-5^\$=6_Y6DO#'_M_9)
IC_UDWQ#7+P9POFW#68^(>6\09?'#8I^\$/%68X9.KA<90KX:O2PM-*<*E-RC4A.,=^(!
IP&=8/A'&Y3BW7H?I!R+"5K0
MKX>K2K4IXA5I+BE6>G>+I/4M=^#7AOPOK4&LVVKV3> M" TU75?!FA>-
=0U#1K'3_!5:0ZO;7P^"X?I #WBWBC!VCDV64Z^#EBG@:%;
M\$YCE>6_7<.QGU;"N3BL1BY8/#8B&\$HN47:>(E332!Y0A8 D!BFTD-D YP:_-3_()2?
M^^(A @HU^SOXS M^-WB3X;Z-+IHPM:/\$7PKBT#0_\$%
IXDM+RTT3PA.O%T>L27U_IVF317%Q-MXXGLGM%MWB2+3X9EF9IW2/D?
VG/^"C7CIP_!&/@%I8?V+?V2?"I>WPU: (I M)>.=74M,TS M0-(U^:Y?6K69I7Q-9Q-
I<*0QW=[HEP[X9YFEG O%&8U,LP,.S MI*,LQ&#A0QF=8//L/C,-
CTF_G\XHR!QQN*>73P&9ULPCA/@WXY:A_:E^%A%K/
MA3X(#V2I/LJBWT">^N+"SU'6I5TIP_XNUAM0UF33M;E_^/#GA+Q#J5_%X? MU.?
6I/#.G3:1J6I'_@/_@NEXI/_&7X>?"S_@H)^PW\2/V*#GQ4NIH-I'_M!;4ZIJUQX3BU-
+_1;)I;MO%?@7P7:1^%=&76;>7QCXLT;Q+K\$WA#I7I\$N ML>&X=,U&;5-
/^3RIPUXTS7*Z;X')O;87%8?;\$8S!498_+*.98_"855'7Q.7Y M17QE/-
<=1@J4W&IA<'5551DZ'M+.W08SC/AO-8ZIE^*S'V=>C6I8?;\$5%A;4 MP6%Q%?
D5*CB\PI8:>!PU63J03A7Q\$'3.\$GTCPOJ&GZ?K5GJ&F:Y)X*A.I_\$C4I!NI*YAU
M7P/X+UJUEC\MG9?G?_@AK^R"^RC^P5\I_7+!8/BA^T*(CQ\0IYEMI+RRM
M/&&FV1^/A5;A]'T76I2U/_I@/WNJ>&I;EU9I^ (7B#X@G3I0:OU&.*/
MX!_X*FZ_P""DG_!6WJFC_@G)IS7VH? 7IF>&#XW?M0VEL/\$2:3JEW2RE\ \$7?@?
X7>\$O&.E_9M>I% ^*?CIXQA\$URL'N0\1_ =YKQG5H\99I;2I#):*K87A/ 5)+2=.LI8_.G3
MERRI/\$86?0I1Y?ALKOG0%N:YQ)\^X.CBI_P I/_!7_E,Q_P5U_I*^T%_P"M4ZO7?_I
!S1_R2_IBI_L MX75/_4>LJX#_ ((Z_P#*9C_@KK_V4;IH+_UJG5ZI_P#X:./^27_L7?I_9PNJ
M?^HJ95^K1_Y2 X_.I\$&0?^L3(^#7_)I^(?I_L;YI_P"M+\$_IWK^7/X3^&M#U
MW_@Z%_:U/5M.@O;_P&?_P_P")?#-S_"9-(URY_9M_9I\ (3ZC:X("SR>I/
M%7B#2B6!'V;4I@ !BK#^HROYC_@C_P.K.WI87_9N?AC_-4C^RU7Y1X93E##
M>)KA*46_"WB"#<6TW&IFO#)Q;5O=G"4H26THR<7=-H^XVC&5;@E22DOI><
MHE9I-;GX:_&&VN%1Q\WES1/B6(GRW9(9&4O#\$R?L3^PIIUIH/I%?I(6EV\$0
M@LM/_9?^ =G:Q LQ2"W^%7A2.,I\$O(Y507D" M?^SH_AS_JI^+U?L7^Q?
_R9W^R=_P!FT_G_P!5=X5KISF4O^ (I%1YGR_Z MW\4>I=VTPV
TVT^.D7MY<7D%C)\+=+_&N) M_#L*%)L+
M: +4/B#^T/XIU9I2%H(IVITK00#@3PMIH+>M!' +=6.GZAI&MR64"S3VEH5E)MR:9I5
MBI*EA,BXUJX:DDE"G4J<55,-V<=+7H1C"RT4(I)))GRGI8O"^A>'_I@Y_M
&4M6TC3K>RU#QQI_O\$7BCQ3&?"AW2 M5=B2+72I:/U% ^P?^#ACXMV_P
_O^"9OQ\I/\$WL>I?&IX@?#X2:-
=6(AI4=7%T41BIEJ'A3X8^(M&GB+I1*-25&=E)BE^7?CW_,K-WI\$ _9L? MBOI I5-
^UQ7-_P#!?":U^A^U1_P3%_82CU?5'TWXG_-IA@I3?%#PH_-
/!OPU_,^+E\AVE1M&T)/C3(EH52RM8+RY\X1I/Y?G8#"0S'CCP/MJXR4Y87*?
#G)\IQ=67--4L)PUCN*,UBY-7IR/U"C0IQDU!N5.DI1E8Z\5B)X M3AGQ.AAE&
(Q_&&8Y7AX+EBYU\YPV1X\AOI??UNI5E** IGO=HG\LM8_\$'O/HMOXN^(XE,0V-/<>
M/=>I1W=PZYWSSR.68L6/YZ?I'%G_"C+I"QU=WE*I;%YFL15?-N4KS MJ2UDW)
IMMW/M>+,+3P/>=X*BK4<'PYB<+25DK4I/@G2@K122IV"T2271)J MG_-
S_O\$#_IYA7@/_!ME_P HXG_I+I4/_39X,KWI_G_9_WB!_I?,*!_X-MLOI'E'\$ _9?
OBA_Z;I!E?58W_DVGBA IG1P/_IK-#PI+_R67!W_&0V*_I M3F/I?<
&_*SS!O^S>=3_P#5%?%*OZ=J_F)_I_*SS!O\ LWG4_P#U17Q2 MK^G:OG?\$/I^%X;_I
9KN&?_4S.3UN"/XG&?I V7.=?^HV6G\MO_!K1X:T2U_9 MU_:28P6\$4?B/7?C5X;I-
I;H8SYIWHGA3P-:ZIH%A)SMK3I_P 9>)+B+ !W MZG-N) 7!_I!6#P_I.H?I%WO^"7CW-
I&SWP_9NE0648^UG0OVFO'.HZ2.1 METIQ1X:T?4&@9C!+=;&VN8Y;6)_P":?

XR_\$[6/!O|P;_LL^&[8M<0?&+MXWZO\,=9DF/FO#H^A_M_M#?
%>R\$;R.618=2^\$VBVD0CSY<&(558LA?Z??|M@|_RCL;4_|-O|
BK_ZBNH5_)K^TU_RK3?|\$_|?^SO/&/_J3_MO5X_A!|. (RM#A:A63J4.?C?D6)ITY-
N\$*|/A3-JT*L8WLIJKAL/-R6LG1HUU!)=_B%)T"M\$NX07C9XV(CF7+1NR,>49E()M_7-
((4_P#)Z|_P6O_.SH/#7_*M?|K:OBMPIXX3K2FIXB/#F(KP
MMI3@ZM5*35USSLUS_.TN84:5+/_PQC3C'EHO.-*225J2X8
MKKECU49*G!M7M|L;WLC^EROY7O|_@LA_RE|_X(|?|E;^"W_K3W@NOZH:_E>_MX+
(?|?/^"/7_96_@M_ZT|X+KF|&/^2TE_V37%O_*SN8'1XC?|_)K_+/_M#_|ZN<\$?
OE^W#^RQI_|:W|+OO0_9DU7QIJ|P|T_XFKX,6Y|7Z7I\$&NWVDKX M/^(/A/Q|BPZ5_!?
V270?A-X\$T/PDNIVFCVN@_P#"2:Q9VPF|3>,KW2;*6>VM-9|;>)KC M5_%VO;+BY>?
6|;U"YFNKF::2>3R;_@H7^U3=_L5?L%)=9@M;|3+^_T'2M=|2V.M^(M-TS4M.U2_
M|/Z9J=KIVHZ?=R17L'XM_LD?|P?CQ^W+|_#?_W|4O|=G|?'|9\$WB_P"._A_3M?
BEX2^'OP<^*&C>!O"G@CPEXQ1M8|,2PV#:/XQ|'6P|4>%|G0_\$J>'O|OA'P
M'I_A4ZHVAV6GW5_9W,B|&295B,HX6BJM.GAX3Q%>HGTYECZ&%XEA3RS(ZE;
M<1U&SL-.TZP^,|7=K96-C:6Z M1P6MG:6T45O;6|;0P0QI%&BHJJ/G;_@U7TJPC|%?
MGZVMN@U2|4_!+2IKL M|R-8:~I/Q*N|6W4G.Q%N-3NY7V8|QG3S-WE1|?6_~"
/@"P^\$_|5G_!8|X6:_M5K7B3Q)I?PU_:\$|">--|1>,M1AUCQ?KUAX-
^(_|5WAVSUKQ5J|J|9:~;ZIXD MU2WTV.^US4;?3|'&^U2>ZN8K*U258(-
/_^#5K_DFG|8W_8|_!|_|L'CN0V+ MC-
QCE'CLJ5:=.F|#X&1C6E&5.5>FLLP3C4G3|+|_6=1MIG1|SPOX<^GPXMKK37C#|
EWH_MQS|5;:=R!_IQ9ZB;>5Y(X8DCX05O^5I+PO_V2>X_|9-|0U|)_P_%JY(S^W|_M
_.\$+8@Z&5/VO+F1XPRF1(Y?C3^R(L;LF=RI(T4JHQ_5VBD"DE&QXWJW_"M)
M>&/^R3W'_K)OB&LN"*DZW!675J005?|B|/BKA_-
>^Z&\$XIKT<-3(_;3P_P#\$'Q=IMA?1@7UA#KNHK93P&ZG|S|Y/V|AC_PNK|F?
M|H3X/H-LWQ/^"?Q0|_V62Q6|T MRW<\$+P1M,J"OY_?
^#@'P%|WQ4_:_I_P""GPPUC6_\$GAK2/B/^T%X|!:_IXC|_M&ZC#|B_P_IWC#XC?
LH^'K|6_"NK7%EJ4&E^)-*MM1EO|_#U&?3K^&RU2"UN9 M+*Z2)H)/H_AP-
!|/^CS_P#@|_XD5X_P#G-5|AB*62?ZB^\$F*S/B:OD-? MT.)L=@J5'(Z^;0K5UQCCN?
%2G2QF&C2J)8/#4I*4)RG3H4DY,P/#0\$F%K MG"\$*FBE""%-0A&VBC%):(|)U7XI?"|H_=
(-00C5|00V|Y=A M#>#OC1|_"&E?!#XG>-H=-T_PGH.L:M.?@|X7MO%|/^(-0G2V|;:_A-
OBM M|)|KQ0|V|-OJE|?VVKRV6BWNJ:A#^S7_4Q_8"TC_@I-^SWX;^#;GQ.A^%<
M^@?|\$OP|4-\$|=P^#%^(0#;9X<|5>'I=.BT>/Q?X+\$MKJ^G^+)I3=KKC0H|K;
M2_8|EQ#)!ZW^V1^PM^S;^W=|;?X??M"^!UUW^Q?|5G|\$>-|N1HGQ#^'6IZ
MQ9I9WVI^#/\$|<%PUJ+G|/H|UJ.@:O::UX/U^|T?0Y_\$OA06CHVFK;?SF^~K; M|N#_(-
|O\$_@#7|/^*VI?M6?|\$W0&'C@>#|GP/XGC2W|4_#&?4Y|H|Q##H^A6 M-
H%PO@_Q+/_H|B2|T'6/"&K0_#7QOK=AKUQXY|%>\$|9U+PLX64XNGQK7X2Q
M_"N=OA_Q+X5R3+,FR_*;RI4JF6YY'(.).C@Z^2X^M3K83#YC7PT6JN59GAXX
M;_%8FI)4:JCSRJ&/P|^&J6?X7/-S+&9A@YSAC;5X3Q%/_L+3
MG3Q%7!TJ|O3Q^"K2KT*,\$ZE-OEC'^L3P%H&J^\$_W@SPMKOB*;Q?KGAKPGX=
MT#6?%EQ9_P|G7'BC5=&T>ST|4?S4^G_;-0^P3:U=VTVI2V?
V^^^ROVM|;_R(S0SH6522|T5?A-=U76K.O%PK.K4=;#|JDX5>=^
MTBZ48P5)QG=.FH14&N51BE9?J5+D|G3|E)2|D/9R4W44H0_M_?%|2OV?O@
M7|8OCGK>FW.M:5|(/AEXX^)-|HEG.MK>:W%X|;:CKXT6TNY(C*B'TNM7DL\$T
MVWNYH9(+6:Y2>=3#&|>O5@^*?"WAGQOX)|+O=#|2>&/\$ MFEV6M^'|?
T74H'M=1TC6M'U*"YT_4|_O|:22WO+&|MYK:Y@D>*:)T9E/1A)8
M:&*PT|92G7PD,11EBJ-.?LZE;#1J1=>E3J:G+)J70QQ\$;TJ%>:|
MG&GB)4:D:%2<>=>%.LX25*|_|_U_:A^*6LZKX@MI?AQXXU>?
00!AU.Y|57|S87O@SX87UAH\$WQ M|!>(>GZ;>:9+;1_T<_/_(*E?L&?MA_Q,T?MX_
G|H#3?'WQ(U^SUB_TCPS;>|OBCH_A/^S!^S|_O&VF07MMIWB_P?|WX?
>\$/\$|A;ZE:2V&HP6>NZ M|X?T_4|:&_L9YK_|CAND2YM9I8)|@|4C*?
U3C3B;PIXKQV;YW'+^~L/G&H*&M HRS'(%DV|EAL)#"Y=A8X6EE?
UF.786G1HT_8T|2JKI0E;JJDG,^&X;R3BW(
M<+E^6/%|_5LNP5RQ52.\$S5YCB56KRKXNNZ|+=|XRO_I5G|2=%TU.203Y(|
M)_M|%OBKX"X);_/_L^+((+2|L+'QIX6#ZD=(T_/6=4TIO_M_5F_:2^%?)
P4Y_:E_88_8F_8Z|8V_Q@OM*^+E|KQO*|=^\$-+OM7|%^'\$_U:
M;PU:"_TKQ#"HB|1Z9X|&:~XU|:>_J4T2V00#|CI4>D16.MZAJT.MZ7T|J27 MQN_9Q^
G|2?AVW|*?'SX0?#WXMZ'8F|?2;QUX7TK7KG0+C4H\$MKZ^|,ZI=V
M|ZKX8U.YMXHH9-4|WNFZB8XXU%T B8YC|G|H_C_|E_|+96L;BQ_9Z^!~PX^%

M4EJ91Z;JNM^&?#MJGBW7-/AN#=#P6/B+QM?"||7^(H6WN6,JM!KFN:A%;RG?
ML9KUL/XF\0QV5\8U\FSFIQYE'#|+).H8O+AO\$80#955R?#9YB82P_UZ-:
MGA:BJSRZE%8>I7A3Y<12C&7/P5>"LXE<;P|2S'+H<+9AFT\SK.6'Q3SFC0K
M8^GF-;+*,U6^JNG.M!TXXR;|K"E*5Z-237+|I(5_,?|S?^5G;|L+_+-S|,?^
MJ1_9:K^G"O+;|X'?|?2_BGK7QRTWX2?#73_C3XCTV+10\$^QN:
M1!8:3I<&EZ0XX@TU/\$NHZ=#IN@Z'T\5E>:G-;QV6CZ7:K&("U2+|ZX5XCH<
M/4>*Z=;#5<0^(>\$LQX'(!_QG^&'P^+7A.UU:VUZV\,?\$GP=X?
|;Z|;ZW96U|9V>L0Z/XD_MT_4M/BU.UM-1U"UM|+=;J&WOKN&.58|B97|31-
\$T;PSHND>&_#FDZ;H/A|P_M_I>GZ)H.A:-96VF.1HNC:5:0V&EZ3I6G6<<-
GI^FZ=8V\%G8V5K#%;6EK#%!M!'!%&BC7'<3X?%\#9#PG'"UH8G*;|S?-
*N+E.#H5J>94L+3ITJ<%^|C.FZ\$G_M-R|UJ2Y=F1AG*CF&69?@84%&7M:
<|'4KSG4G)^XXS59**6JY_M7?<_F"X(C^\$-\$^(/Q|_X+A^?\$MJM|X<;|_!KLO"B"R?
=LN|S|2^-/V|I_M%U6U;:RMMN+|IGB;:RMASA@>1X#_, \$B?V_ (?.
|S\$NM#_:+8_ ;ZE|2?_G_MQY|/?C=X@|9:=XFN_"7C?QCH6K2:5X?|&>' +OPY::9X)|):
|X@|_M+|FV|-67C_M|P7XP%A=>%?'A+Q6FIV.HV\$, &C/XE_J*G|_"_JEKPE|'O\$?
Q1^)|K|_%OAWX/T3X@_%N_|&Z9XD|5>3<_8E|_Q^_, &=/_?Z_'X?/B7
M6H\$FU0Q!=^=JEBNIWMV?D_|9M^)^7|"/_!7/X5Q?M\$M^S3X,^(NG^\$/%?B#X
M56Z_M,?!7X2>*O'/AO4-'L|'|1W^FV;3W7Q&M-/T>|M?;\$^E:|!#8ZHGC:Z,U_MQ9PS?
>_1|3QK@N(|:YCF_#6=XK@?/'P;AL97R|'X;"YEDF=Y#DU'+|!#7HU:
MU#%X.4&|3E+X:P>7YUEM#B;*X|15L/2_MQF\$KU|%F>69IF,|5BJ52G3JX?
\$IX.57"SA.E73C44TXNG5YH_@=|(_VK|*_M_X_+V:OC5X+T+Q%IOP@F|_"_%+P?
|S_ '\$B;P|J?AF|^ (OP^|_7|HC2;|X_M@V%CJC>?+H6N_\$9/'|MH4YBLKN+3--
MM.U|2|'46&NZ39?56B37?|3?_!S'_MKMV=0TF|_.?L2_L_W..F)&L-
TFH6B_#^QT/4M/DWQ*(|6V/_!4_:9UN9F|E_MFM9_#HV2H8U6&/XA7NF^)|O|
@YP_9NT/PA;VTMK|%/V<|5|_>+|2|5;|>U|M)=?+XXZSI=I/!\$%@M; <6'Q-
|&):I#'%!%K.GVZ(#U^X_|@FM_P3|^7L_M_P"U#^WM^TY^T|)|++SQ)^U/1G|4^
(OAYXB|2>)+KPGX'/LL\$|QKO@6VLH;_75%<>&G\$LT*06YG^GXDSC)'LGQ&
(CB<;*'\$7\$698:K4C7=*_@|1B:&2>VQ.*Q\$(:4--ENK_M*;|H:7#VS2V\GSQ.CE*,M:&%KPI
MRITY3|R,YJ-HN6B;U/U?B#+:FOZ;JOA6_P#|+U" |M:C13X;A|07,>OH|7?ASPYX?|
|_A|0?"7A/0|_M(|_>?"VC:7X<|_&|_TZTT?0?#WA_1+-&T/1-)T^&WL-+TC2=.M;:PTW
M3K*"TLK.WAMK:&.&)\$7Y@^/G|!7|&W|4.L0>)/CS^SE|+_B)XJ@DTUO^\$QU
M#0\$TOOI=0:0NS3=-U/QCX>ETCQ/J^B6B9BBT'5-6O-%|IFB>P;-V4_6Y1QED
M<|'Q9D'\$N!S:ID'\$V,@|+C*6(P^*=#\$4JE
M6ER>RC.A*,YRDO|Q_#F9QQ&09KDV)P\$,UR7+JN55:>8T|1+X|'5Z6'C-2GA
MY*OAZE&MAU5HSC"IS<|C5BXQ2/Y^OV./B'8?|%#_/_@03|1OV00@E%J=Y^SM
M^SO)|90#EAX|U'P|J^D0>*7U'P'<_#|+1;=X;V/S|)U#Q=X@|1>.O%?A*RUF#_M2-4O/
O@R>XU+2=*UJ.|TR'^KVO/OAC|)?A:|%/|"EOX%^#WPY|_#_M|%VES_M<7L'A7X?
>%M\$|(:_E_=B,7FHMI6@V5A9RZC?>3\$UJ|S|+WMZ|:R74|K@-7H-_M>#QM-Q-
A>)|LRR^>78*ME^49)D>6<_Y/AL57AB<8LORN%3DK8VO2I4:53%XFO7
MKXBM|.G&G!U52@Y1@I2|3AG):^2X/%QQF)IXO,,SS/&YQF->A2E0P|QF-E#G
MIX:E.=2<_/1|4J5&GSSE.:@ZDN5R<5_,5_P:X?|)IW|1|V:|@+.VM|07EQ%)<"V@A
MA|SRXT45_%OP!^!/?CWQ_X3^*WCGX-"WQC|4/_8T|>|_B+XH|_ ^%M>|<^#QI
M.I7&LZ6/#'BO5-+NM#,4N_M\$,DX;^NX?
V^58S+L54Q/4|C5C@LP^N3C"/QQY%RT4M7H?-G_5_P"4_M=G|:G_9M_P5?
_45U"OPA^'?|_BC|H_@VA|!>"/A_X0N?"Q+|*+|1/BCX_M_|Z?#=#7>M7FI^!/VLOB?
J'B:#PYIUC'/>:QXEO_ (<3>-)T#0K*UNK|7=5_MU&UT?3|>2_O;7'|5OBKPIX7|=>&|
<|&^_O#FA^+_CXFTR|T7Q'X7A3:58Z
MYX>U_1|(^)K>^TK6=&U."YT_4|.O(>&ZLKVWFMKB)FCEC=&(/Q5^U!^TA^SS_M_P
\$L?V:-"|<2_!3Q+IGP/T#QG8>"K/P-^S;X|!V.G^";COM/XD|0MKDWAB_M|2?
#SPQHOAS4?\$L=U;ZE>V-VUW<^+/%.G.VGW,FJ7E|_<;P=Q5C|EN3<.9
M%EM;&|0T_\$3)>+,M4:D50Q4|NR_%8*&63@ITZLI8NK7C&7+.,9T7.G?FDCKX
MBR+"8G&YAG&:8RGALHGPAF>08UN,G5H1QF+P^)^EC8RY9P4:\$*+:O%N-3EG;E
MBS|EOV(^_|O|'7@3|A_X.^%OC#X|8^#_C1|%/|@IX: ^&=|*#;P)XT|8:U|M1-
2^%O@W2_#FD:MX+|4Z-X;C|_0_|+&32|::3|'QCXC|)CP|KEY>Z5K5XFC6
M%IXJU:S3_@V_|2^+_&GQN_X*K>.,?B#X>N/'/CWQ9|5|@|XE|_<^|NPO=*NO#_M'B_7?
%O|4.J>)?#USIFD|J.G7&BZS=7NFS6&H1QWMG);-W2+/'(H_??X4_M"#|D/XLCX=?
MA^"OV=O@JGC?XI>&?"OQC|,?%N|^#GPZL_BXT/CSPO8ZUI6M_MW_C2VT:Z|1P>
(IM"U>&VOKN'7|F<*|UJM|/|S_AY_P;|:W9>.OVCO|_@KQ|_M4_#CC4/_P_0_P|HCP;K?

A+7X"7T_6+*^|=M,>(HWLYBJ&4+I'B;0|UB40^M1J5JY4>9@?:U7M/F883.L+Q-
X=4LUS;+|OHT7GE'+M_P"S|S#5PDJ^%I<.UHK'XR57%8B,Z|XRH0Y^+V@77Q.&'2+;0?
B;|/?'_M,/K>_N%#@09=#L/&6L:5XK|*-XJO;&30|,|077A31|N7^U?.\$6B6&H_TY540I
M"QU6QO=,U.RM-1TW4;2XL-0T^_MX;RQO|&|A>WN|*|M+A)+>ZM+JWDD@N+>>
M.2&>&1XI49&93^1<&<32X1XBP6>?4XYA1HPQF%QN-G6GAUC;|F.#KX#&T%B*
M:E.A5EA|34E0K1C/V5>-.I%*2,90E^@|1Y*N(C.HQ.6?6)82I5EAZ^&Q4:<:S
MP^*P>)I8O#572FU&K!5J,%5IN4?:4I3@IPDU)?SH_P#!0A:_F_9U_X*G?|
M!*O|K;7|D;Q)KGQ)|6_|0?@U|7_|!X/N_#/B;P5KW@&T@|7P>)|I>CU_P#X
M2G2|+T#Q!/H?P|!%?%.|OH?!NN>*.EO?#;,@TG4-2DGT;^TNS_8&_P""QW|_M7A3_()^
JU^)^7QQT3X=>.-?@'|.\$?AO|*O'7PTURRURX|>W&M?#OPW9>|2|_M|(Z%8:1--
XXLO%D/AZU|265QX1;6K30-/URTM/%MWH>H66J06?|2??"|GCX_M_50\$+_-WX'
B^#1|6_P|D_P#"4CX5?#?P=|5|1_V"-2&A_VXGA+1M(35_M/I(C_MC5_|,^VK-
|A.J;B;;RS>W)D|#/|_35_8#_.%DP?%L?LA?_5/'5O.U_MY%?Q?#W0XM'&I-<"
|_ME_|!5NG@V77UO0%%|'X@E|/OK45|F|BOTN293|C#BC_M@"MDN,X5QF5<6QR##9_
*Q"P.9Y7F4ZN#A@7@JU7"N
MMA,5AL,|3AN:#J4|2XU8UOG9Y'Q73S+#+Y|AL=D#S:ME/|CYM3K8/'PR^=.CC
ML1BL%C<'&&(EB5B*5.0R5Z%:K|&LU)0G13A*E^)/_!NW|2KKXS_M\$?|!6WX
MPWWANY|&WOQ7^-_'PN^)^5YX0O+F2|N_"EUXZ|*+CPW=7DMCI;|L_9^_90U#X|?
#;|HSQA|*M(^-.MI^!M3^&_Q%|2V%W;_#R|1>
|77K3O=X3|0>+4\$EEX=U1=,|8^%|8TNYU2&V_MT!;1-3BUG7=)U"||+Z?X@_M%|_#_!/?
X/_R|0^/O%OPX^%GP|_|^*OBKK*^(
M_B=XD|&>#/#OAG7OB)X@6^UG4UUSQOJVC:=97_BK5UU'Q'X@OUU'7)|Z|%YK
MFKW(F|4;MYO%-2_8(|8DU7X?;S|*|C|DO|_9XM0AWK^L6_B/5/'>C_"/P1X_M?TJ7Q-
::7?:)9>*;9-"T;3IM.|56&CZH>EZ?XFTV:TUZPT_4+ZTL|0@@NYT
MD|O%>)W"V:5_\$\$\$YCD&<4C0R_'87Z|E%/A'+X87GA6Q5.K3Q4G7
MITJE&%6,?;T(3I5JM"145:GYE#@G/;#2X3JX/-LOJ9CPS4XGK5*N+PM=X;_)M<08N5?
EE2H3ISH)4IU(5)0D_9591J4X580|G/^=7XW?'CP7_,%3?^"U?|W
M@G|F/7|SQS|_|P|D#4;7XL^+OB7|FAZJOAPZQX%|9Z?|1_&%|974|N99/|FH_M7_|@|X7?
#/2O%5W8Z=I^J^-|/\$+6^EW%|H|WH.MZGTG_!1K5+S_@GY_P_%I?V<
MO^"BGQ\$|^*^,-=9M|>>##X+|5^*O#FEVM|F@>,3|O"PKU3PXB;_"PU'2/#
MUWX6^(H:7ZZ9<>)*|*B|4:9X7&I77AS6GLOZ_V?OV4_V|>,|TKQ1X8U
MNS\$L#P|8QE#
MVTI4^K_4K,,3@<;B;=F6%AQ)B^(|%Q+2QF&P|6IEV#QN64Z5'+|)'#UJD:V(
MP=+#TI49SG*G5DJSU+V<8S_)@O^"T?Q2|_|'S|GG|A;_|@J^-R1KX^+7P|_M95_::O|
4UOF(|^--&TP_P|I^+|/LL&O>);+Q'I?AK7|S|V:5|2O@YX=|W|
ME_|EF|_J7C;24TZY"RQR3_<7QZ_X+I_L;:3^Q|XN^,7PB^6D:U|6/\$_P|+0
MVOPI^\$KZ3J;_|!+TSXJ7^@W=OX>TSQYX1B:"7POH_AOQ%+#+XF|1W>|JP^&|W_M3-
_OI?!FO>*+B|T"+6|UY|*?|KX0^_A_<_|;P1|*_ASX|A7>6NN6-U|/_M'_|@GPUH/|"YL?
\$|7;^)+&?P;I>FVOAV6RU|K^|.LVCZ<;?4_MET+R*83RAOE_M70_^^"77_
30|.>|CXE:1^QQ|!+;Q3<"W*++X#TN^|+Z?-.RK/;7FB>_K|+MKP'X?
U&"9\$EBU+0_#6GZ@DB*RW(*@CEPW%G_6*RS*_HS_)N|J^#X2S3-J_#<
ML'CRPN98/"?4WF.4JG7G/EE0Y(OPN+D|2HTIRKR_MM.,O?|
@B_'^TSXL_8%|+_\$+|H|XD>-_B'XX^7B+Q3|10"MWX_FU&X|3^'_M/A5K6G:-
X:|S\$Z5C^*W_|!(3_M|O'X_|!+|"H|G|@G|O(|_|!&O@_XY:|X|LO&T_A;QMXL|ZYJ>J>&O
7@_MJZ|/I?A3PGJOB6ST_4="|(Z%|0/A_XU_LJZ)|^./OB*?4QJ6B1V_AT^+?|_M&J|6^*_|_I-
W|_|P_>+C2+SXX?;X-?&.|V|Y::!>?%+X8^"O'YH5KJ\$D\$U
M_::+=^*|\$U6XTJ'|FMK:6|BL|+=+F2W@>97;)O)@>|GQ.(XUPO\$6057D'&
MF.P>83PG#V*P^6XO(1E>)Q=?
+%ESJX.K@:U&E0QE;|UZ6(PD55BXXEEC7C%#\$0Q5.K.KAJ>M(I3HXANG)2HM.G*|?
Y^_BK^V;|2/^"=W_|9SX@7G|7?Q-^,L?|S#W|17PLA_MPIFXU;7O&?BOX2^=;?
3OAS=:MKVE>"M-37;_TOO#/C+PGX|&_OI7AS2T|0_MZ-
H_Q#T/Q=JEM%H6O0RWW&?|%JO^"A/P_:_K^!7AG|A3|CWQ-I|3OQP^/?Q
M_'^=NEG|_|O|/\$>B^'-*TG5K;Q#I@L_%JQIH5SXMU_7|;1|'CTS2;Z_|L70#X
MMN_%JYX;2#3;?
6OZ3/C|!#|/S^T#X57PAD1:O:73:/KMOI^IZC96NMZ6UIJMK;7|Y#;W<4=S,K^2_#
M|AC|D'|EJ_N-9^_|/PQ^&OB.ZM|^RF|7:1X?BOO&S;JUMF6R!MX=GHY9QUP9AZ_#?
\$F-X=S5|6|+9?E^\$PV_M'P&*P.&X59MF2=|YC0Q,.6C4Q|'#. <,=7HOJ*|AXR|PJ|6-X7XD
MK4LYR;#9Q@%D&>XO%UZ|;%T<57SG_8;_) *6.P&"?M/J=2C*|6&%J5E&6%I5'

M#DJM0E#T+JFGX6:A\#/VPUC4/AJ
MX\$TPE>ZI8V/P6N(+/4+G2);NVAG8S10S(DI+JOKVRBBOR/\$XBKC,3B,77DI
M5\57JXBM)145*K7J2JU)*,4HQ3G)M1BDELDD?H%"C3P]&CAZ2:I4*5.C33;D
MU3I04(OR=VVHQ2;;NIV%%%%8&H4444 %%% %!1110 4444 %%% %!1110 44 M44
%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!111 M0 4444
%% %!1110 4444 -95=61U5T=2KHP#*RL"&5E((96!(((O)!&* MB3_X*&?#CXY_!\$(?
B#IOB3]@?HJ+QKX%^\$O[56O^-J2MO@IKGA#PMXYT;X;C MPA;^#)6MH-4^)
(!=:9XKG-SKING:#XFN?"B>.=,!(Z=I?A/Q'XK\;7::AKV MHE%?
M'@/BJM7CW+^&1'#XS(.X8JCGF3XJ"87'Y?F4,NRW,,?@'B,+C*->E
M[7"8NG&K0KPC"M3YJM.-14JU:%3|V\4Z\$*?"F+SFC*MA|UR:6'J99F&%Q%?"
MXO!RON-P>\$Q:I5V\4I3Y,1AYNG5I2E_ ;A^(_Q?|&7|07|2_|7OPM| "^+M=^('C"WNM-
D))>"O'_ (?|(^/|0|\$6 MJO
XA1W7B35KGQ#;I9USQEVHQ1WFF^% "FF^&O"_@VWLM>'B7]MJ**_ />;
MAAZ%*%.G2H M4J<%9R<7.4Y2^OX=R_!Y;DV
PV"HJA2EAZ>)FN>I4G4Q&*BJ^(KU:M6=2M5J
MU:LY3G4J3G)W4;J,8I% %%% %?;GM!1110 4444 %%% %!7@_ [3G|/PT_:W^!'
MO'_9W^+UIJUSX^)^FCV^F:M+H&IOH^OZ3?:7JNG^(O#?B/0M1\$5S!#K/ACQ-
MH^C^ (=,BU.QU70|R\TR&Q\0Z+K>A7.HZ1>E%=&\$Q6)P.*PV.P=>KAL9@+11Q
M6%Q-&;IUL/BT^&_AO3-:|Z-:K#P9J%U#X9>[UK7/B/X:T'0E M\0?
9\$|*^&/C%H6DW|O%J,,|D6^O:E,O_85^P)^P|_|_?"G|.VA? 3X;ZEJ MGB6GZ|XG_
+&BN;NQ|:-4+'1=(T/PYX:L M+B[71_#NC:5;ZIJWB7Q&=;|5:X45_0'C+FV_-P!7?
#^C2>\$PE+BOAC+.*^)(M9?EV79=_;?;\$-7#T^?;|Q>
PN&EB*S=>K*,)MT(3DIP1G&\$H_DWAS@,-:=% ME2?
MZ\|ASK&Y#DTL7C,9C|I,RGB4?+@<&L57K*C32I03E%*K*,>651Q GRAPHIC 12
img77546233_3.jpg GRAPHIC begin 644 img77546233_3.jpg M_ |C_X 02D9)1@! @\$ 8
!@ #_VP!# \$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! M 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!
0\$! 0\$! 0\$! MVP!# 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! M 0\$! 0\$!
0\$! 0\$! 0\$! 0\$! 0\$! 0\$! P 1" \$= H # 2(A\$! Q\$! |0 M'P 04! 0\$! 0\$ \$" P0%|@<("0H+_10
M1 @\$# P(\$ P4% M! 0 %| 0(# 01!1(A,4\$&\$U^A!R)Q%#*!D:\$((T*QP152T?
D,V)R@@@D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM|BYNL+#Q,7&
MO|C)RM+3U-76U|C9VN'BX^3EYN?HZ>KQ|O/TI?;W^/GZ_|0 'P\$ P\$! 0\$! M 0\$! 0\$ "
P0%|@<("0H+_10 M1\$ @\$"! 0#! <%! 0 0)W \$" M
Q\$!2\$Q!A)!40=A<1,B,H\$(%\$*1H;!'!2,S4O 58G+1"A8D-.\$E|1<8&1HF M)R@I*C4V-
S@Y.D-\$149'2\$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.\$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;;WN+FZPL/\$Q<;'R,G*TM/4 MU=;7V-
G:XN/DY>;GZ.G|O/TI?;W^/GZ_|H # ,! (1 Q\$ /P#^_BBBB@ H MHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HKGO\$ _B[PGX)TJ;7/&?
B?P|X1T2WSY^L>)|:TW0-* M@P"Q|4-5N;2TCPH+'?;N ">@-?%?C;_ (*>_L(> I9K?
5OVB_"&KW\$1*B/P M38^)?B!%;X_AAU#P3H>O:4P\,K7Z0\$<^;R_|I?%X3#;XG\$X?#I?
WU:G2OZ< M|HW/FL_XSX/X4B\4<5|-|.1E'FB|SS+,I4H|'#Z_|BL/S|+EO=Z*|/O6BQ
MR7NO^"UG|"UO/Y4/B3XBWT>XC|5;_#K5D@P,X;;?36=SM; Q_H^|D;E7G'<^ M\$O|
@KS^P1XKN(K23XOW?A:ZG94BB|6^_'6F0%F_P">NJ6WA^_T:U5?XI+S
M4;>/T8UR1SK*)2Y8YG@;|*^)|I3?9.4DGY6>00^+PWCQX*XNNL-0|5O#^5:4
ME&,9|59-1C.3=E&%6MBZ=*>_#SXM?"|XN:4=<^%O MQ\$|/%?\$/24\$9FOO!OB;1_\$4-
JTH)2*^_LJ|N7L;CAE>VO%@N(W5TDB5T91Z%7
MHPG"i%3A*,X25XRA)2BUW4DVFO1GZAA,9A,PPU'&8#%8;&X/\$052ABL)7I8G
M#5H/13HUZ,ITJD&TTI0E)::A1115'2% %%% %!1110 4444 %%% %!1110 444 M4 %%% %
!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 M 4444 %%% %!1110
4444 %%% %!1110 4444 %%% %!1110 4444 %%% %! M117Y>_|!0/X%?|
!2[XLZ_X#U?]|@?|:-X|?LZ:9H/AW6K3QEX;|=>%=-UN MV|7>(+J_MYM'U%=2O?
AK|19M.M|*O6XM)5AL@_"|JR_99W4,G5@|/V#%8B%"IB M|
@HR4F|1BW55"#C%M*;H4JU1.37+%JFU=KF<8W:X,SQM7+|'5Q='+L=FM2F
MZ:6"RY8:6+JJ/5M'UBSTWQ!I2W>GRZKH|H::GILUW|?R_|!W_ (*X3!0_ M|6|R|5|#OV;

/"(PV99'B,/5CS M4ZU+%8N=.=<VO&4< T|---7NFFG9H?D6,|=N&.+OP%=>"/
NI^,D|*ZNNGZR^C:ZOAGX"6F@6.K M7NCSM#+::9XJU**QDG5#?17"2I#_-\$|U|?
F>70RZI"E',3Z=?P:?:V^9|K=DW9NRO9;OR5|*_MS+M%?
RD_M(?!W_@Y&_9Q^%GC#XL^&?V|?AE|:M"!|:JOB;Q'X:|(?#KX7Q> M/OI
T:WFU/5|1T:1/&/P"MLUOM.TVWN;V73K3Q';MU"!|CT73-4NY(1_P M"M?^" ^G_
5|OY::3++|JV|O+J|FALK.UM/(@-^S?<7UU>61U1 S, ?N(QJ=.5KI3A++U. M-
U=Q,&5<.UZ6%SSACB_+;|>#J4(5L%E,HUJ2C)T:L,ZE3
MJ|LFHS4)2<6X|R7,K_Z6=%?@!_P3;^%/_!<75OB)|+?C;^W?^TUX2M_@S<::
MXAU#Q|LX7G@_X>:?! \$O4(=:\$ZW8>%^A(A/ 7PIT#2O"||B6^|A MB*YTB#QE<:E
FFW.FZW9V=|UWIC?O_7RN98&.7XEX:..P6/<8)SK8"I4JX>, M^:
<7252I1H|H|JDIYOC*FXSC:?:H_H>1904SO K'3RG-LF4ZCC3PN24BBBOR?
_X_P""I_P|_9&N M+KX;^!-
L/BA|=#;+)=Z"UZA7A3P"MS"LMG/XWO;%_M=QJ=Q')%=6WA'3);7
M4IK%ENM3U+0H+K2Y=1|;&8W"Y?0EB<75C1I1TN|N4I--J\$(JIS=G;4W9-N
MR3:|GCCCCSA/PXX>Q7%'&6/?B?XPT+P/X0T>,/?Z|X@O_MHK*T61@QAM+96)N-0U*
|9#%8:7I-UJ6H3|;>RM;B=ECAX/|7' _7^5ZY M<:GX-
_9'T0>\$|5L5_BWXQTRV00%&H@\$H;GPKX2O5NM(T&U?:7M|H|O)#K.I
M7%M,K/HN@7L6!^-|00|47QP_ :C|6'Q=|9O'.I>)|X))_P"Q="C/|G^\$__|M M.PW6?
AKPW:E--TR,QI%/%=B*75=1\$4NK:AJ%RIG/VC^PK_P2T^+?|6%UIOC M?
QO'JOPJ^!.^*X;Q;?6'E>(_&|L&5WM?A|H5_&\$N+:=/W3>+|0A?P_ :S-8Q M>
(+NTNM,3|^QG\$F:9U7^HY)1JT83;7M(V6)E"JG.=1/DPM-75VI'W@!DF;Y%<7*5.69X?
V<.)5A.90GC|=F<)|RP7".64^: M+G6H8KZS3ER7S=.LL(?GQXN|>?
%KXZ>+X=1|>?*?'7Q5|_:O<_9;%M9U+6O% MNN7;|U)E-.TFUFDO;B-.GVI::9IL,<\$:JD-
M;(B(B_7'PM_X)<_MR?%=>YT MSX&:|X0TJ?:6U;XF7>G?#Y(\$?
&R6310\$=S:>*9HV!W|K+0+L|<0 R|OZ_O@ M#^R/^SS^S)I-OIWP=^&7AWPW?
I+:7WBZ>TCU7QSK2|?WS:QXOU!9|;N4N)" M|6\$5U;Z3;O(Z6&G6D&V%?I"NS"
<\$1E^|S/'5:M63YIPPI|DK|>:O6C.=1OJ_ M9P|F|S|?@|Z.#Q=LU|5N/LWS;+7-
8C'8/AIPIP=>23FL1G^=X?'8S;7.5U M4JK+<#4:5H3::FOY5_"O_!
KX|WUNDGC3XV?";PW.Z|FMO#UAXN|7&(D95)) M;
|3/'9<<"3RC+&K9|N250&:_P")O^" OQIM+263P=|>OAAK|ZJYBMO\$>@^*
MO"EO(V,E6N|C|8O'SPI^R."?Q;1DC^IFBO87!^1*/+|7JMVMSO\$UN;ULIJ%
M_P#MRWD?MD?H2_1|CA?J|X9S>=;EY?KTN*<|6*O:W/R0QD<%S7UM|3Y+_8MH M?
QU/_P \$F_|@HS|;\$YO'GPWL|"3Q%X=62|LM6^\$GQ3@TGQ2L<.)6TAKN?P
MIJEQ(R|A86Q-W>;1:PVEQ.Z0A_9O|/_!7#X|?" T/PC^W?| "CQ?IO@O
M4KR|T#3/BS-X#|2^%O\$NF:CH<-GJL&M:-J%C':>-3|HSY UMM%%EXBTJ6XE
MFN;3699H+2/^DBO,OB3|_A+8=(O-"^*P|(|^.=,OK6:SGA|1;)97TPAGM
MYK4M;7KQ"^LKB".>1|*|L|FWN|/NA%>V\$|M>6|_|<4^&YY?+VN39CB,+/>5# M\$N-
?"UFFK*I|1@TG&|7)7FKJ4)1<=>' +/HLX_P_|3_:W@9XF|3<*8Q-5<5P M|Q14H<0|
(9U5A.#A3S+!4,+@J|E.A|;#U:|)5|=3|I2KX|\$X:KA_P|/K_#K
MXD>!/BWX.T3X@_#;Q3|C+P;XCM\$O-(U|1;G|1:7;:<20RHRQW-C?VLFZWU#
M3+^"UU+3;N.6SO|6VNH984|:OO@|5?LA_%+|@SQ3=_|B3QGH^E_NSM(=4
M^,W|WQ5|::FGA/4K2S>*#5/\$?A7Q9XIOY|.T76FTN.W==8|3:YH?|BRZ>TV
MH>)=1|SS>'K?|9/AKX|L/B7X%|,>.M/LKO3+/Q|ZW|H9WS1/(8V:58|BUN M(6..H:9?
QO_VEHNI;8M5T6YLM4BBBBNA&GMX/%5JKEA|90^KXNE%2FH-SPI
M:#T|MAJMDY4W+1PJ*-6G+W91:M.7|WP1QAG6;5L7PYQIP_|ZM<:Y1AJ5?'4
M.'5J8_AO.'|:H+/>%LUG"G4Q&5UL1^|G@LQH3-|MK26'QF&G'V6*K|W111 M7>?
HP4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %?
M!'|67_!3G|B|BNSOX CG|=?"MCXPLXG;+X6^\$;A?&WQ3O)PL-LW@OP|WJ
M&AK=LK1V^I^*V|:.\$9%=9=6AV.5^U?%_A?3/&_A/Q1X+UMKY-&|7^'=;+ZN
M^F7USI>I+IFOZ;G7RVMW*;2^M9(|FTN!'<0.DL:LA/_X M+?|_!(!?
P5_P3IOOAC|4_@KXT|8^*OA!|7==|0^&|S1OB!<:JGB?P3XTTZS
M@URUM5|2::8:1%K^B^ (M,DU:73_MFEPZMIHZEK3W|5S#|3PIE&59UF
M,_%F..Q&&G4?^ST%*/^TN,)5)P>)DYQH248.T949>TU49QGRJ7YYXC|2|1<
M*Y'4S7(|JP6|4\$OKV+Q>)G_)|:E6G1H55@*:ISQ<)5*J4Y0Q4'1:4IT:E M+GG#^B#_
()U_P#!<;70^"BG|>|B'X"^"O@UI7PY^>E?!SQKXVT;5?\$_|=Z MM|7-:U|P|XC|&Z?
H_JDFE:BG@_PH-SIVO7Z77A>SLO\$EW#>+;74?C.:&.2 MSD_27|KG|KOO;|*-5|4?
#CX.:1X00/&?P|^#6O?M\$_' +XG?>U|3:M|+?V=/
M@=H,/B*6'Q=XI|+^"M_&GQ(|: ^,9?"BVW^'OPJ|+;EH&H>((?"OB75|3|3

M:IVEVQU;^+@V%P"4D6N JFT?\$_|J2SX:5_3E^UO;WG@SOY_P47^%>JV
M+GO!^WS^O=J&B_LQ:C*T%K9_ \$+XN>_@K|50AOKO|/NF:G>R6UDGC^7^V_"?
MC7P7X:FN4N?%5CXJ|77&C1S/X7UP0^WQ!DV69?Q(L%A<-&.'HY=A*T*#G.:J
M5)8B%.06JRG*4JCHX>57%S3;IOZO^|BZ"J0?R?!7%6?YUP++-LPQ|ZF.Q6>9
MCA:F+C2I4W0HPP4Z^\$PM""*%\$*=%8K&PPV6TG&*K7QJ5"1%RHU8Y/@|JNC|H M?
2;_%;5XO'7AW|J72_"?PUL?CC|0|/@S??L<_"|C#|H";X\$3WD=CJ/QA_9| M'Q-
|9>+O""QLT30Y)_N/!8MM/U+5)8K72++OQ;ZYJVC:~JW|0>#O%WAOX@>
M\$?"WCSP;JHX@|(>-O#FB>+O"NO6#LJCK?A0Q)IEKK&AZO9.RHSVFL:9>6MY
M;LR*S0S(6522!^&?PUT+5A_@GG|59?C:|<-5^*_Q&|".G_P3|^\$OA#PGK?Q
M4U+2/&7Q"LOC|IOCJ|@O/V1?@G#H^F:5J\$MW|1G0_"5YI7@"PT;5K|5M:V/Q
M:E>ZQ<6&AXTW|2_V(OA1XI^!G|(|-GPB|<1V|OX\$|?!OP)X>|5V%G*DJCH
M_B&VT&T?6-TZ>-WCGTWP|?RSZ)IT|;>7-9:?!*@57"CYW.:&\$5.-?#J"3J4 MH4JU-
*G'%1E1E/\$+V="E0HIX*I&E"4H4*92K3PF.E5 M(JQA4Q56G'ZC*5"-GK4U|
M24445|Z?:A1110_4444 %%%%!1110_4444 %%%%!1110_4444 %%%%!11 M10_4444
%%%%!1110_4444 ?D'_,%POV/;+|KS_@G_/%FTTS1X|0^)_P1 MT^Z^.'PNNHK<2ZF-
1|)\$6-Q>>+_#UGY8%\$*5\$EBE1HY(Y%5XY(W4JZ.C JZ.I*LK JRD@@@U_ME=_%1/V39?
V+/VX_CO|#!.PDLO!5MXHE|9_"QBC"WG^&'CH'Q'X1MK65@/M M0|.VUY-
X.O|D*BR:QX;U;*BA*_9/"-G*GCLEJS;=-_7L*F|VA)QI8F\$;|* M,W|J**ZU*LK+5O|
EWZ0?#G)6RCBG#TDHUT|IS&<8V>TU*OE|6=E|TITEBJ M,IRVC0P|.|O%+_0)_P""-
W|2%I^T|_P3E_9K|:->K=^)O!/?@JT^#/CN-I\$DO_M(/%GPDBB|/6C5JO%X;2R=#\$MU(J-
JU2FZE" M_>DS|G|>(|2<&Y-CG-2Q6'P|2QF C&A.4|6E+\$4E1Q=ND<1'1;(H
MHHKYL^|/FS|LCXK:A#?V3_VC_BYKSQ#3_'P5^(_B\$0S;-NH:C:~%=371='
M0.0CW&MZS)8:1.QN0DES>POLRAB1_!S_&Z_P"R#'^TG^WGI/O-|2Z6+_X=M?
LK:1|6-6^T0".PN_B'=7,NE?";2)B5;R|N#78|3|>6).\$D;X?S0N2LGEO^
M^'_!T!^TZ/AG^Q|V_V;M%U'R/\$?|27C^*|H06L4|QOAE|)I=-|2;JDZ1D2
M0B_|=W_P_%|H6*|M|.UB|\$F|J:R?IG_(-|V21^S1_P3Z|'>=>TP67Q#_M
&G=0_X79XBDFFBVD'@_4K2/3_A5I!E*HSV'"&06_C"WBD0/;7_
(WU:'61<#YECE)PQ6?XKZCA+.S^KTH3IU:RZKE3QD%)?#-TG?5'X;Q!A: M?
&'BWD64."JY?P7EW|L9E=)Q^N8FI1Q&'PTKWC)3E*ZDJ6+9^Z M%?????G)^Y'YV?
|%-_P!KGQ!^R%^SG+XH|\$6:S?\$_+Q_X@C^'W@S5+B*.>Q!*W
M|_I&JZK>^*KFWG1X+VXTG3M+G72+"97@FUFYL)|RWNI-M+ZUF_C|^#7P5^-/
M|6GQ8'A/P%HWB#Q|XV|3:E<:YXIUUVYF:|~P07|^)=;|7^+M?U2Z@MK>#|3=2
M7%U?:IJ\$4VIZA-'9VSW.IWMM;S?WG_%3X0_#+XW^\$+KP'16O:6@^/"5W)+
|7(D5IM2TU-8@U#3?"T:S;ELK+PW;V M*6T"QB>XOKS|1?
W/WL|JB|JB*J(JA550%55485548_4_#_X|.*^DP^%P
M^\$IQI8:C3H4XD)1IPC!.RLG*R3E+JY2;DVVVVVV?U+PUPGPSP=EM'*.%LARK
M(NH4J5&&&RO X?!PG&C'DA.O*C"-3\$UFFY5,1B)U:|6I*=2K4G4G.4BBBBM
MSZ\$****"BBB@!&565E90RL"K*P!5E(P58'((O)!&".#7DUC|~?^\$/S:~9
MHK#PS=:C:3S>#KYYIM)|+0+%/:S7?
PQ\$AGM?!M45\$H1G9M:QORR6DE>UTGV=E=;.RNG9"BL!A<9*E4K4U|?#|
M_P!7Q\$&X8B@|JB|JL:=6-I>S|D/:T9)9+4?VWINFZCH|K?D)-'(-+U6XT^|OK&:-
)%AN8)+K2|"YC^T1_M2O:S0%K5X1<70GUZIR6VDZ%I%J'O=
M8UF|L=L8L|N|AC:|EO^"/|/?_Q8_P""AVE?M@_%KXA3H_A+1_CY9:-|/ MD=AH|
^'GPZN/'=K=:9X>N-3TZQMKW7|5E5(|1UW5M5NKYKC6|J_:3!IVDM9
MZ9:~A0RS%U|OQN9P@E@|~*A3JU9-I2JXBI&G"E2T:G-*2J5%=%%.SDU*=._M%Q6?
Y=A,YRO(*E5RS/-J>+KX>A3Y9.GA|1G6JXC\$7FI4J4W!T:~49.K5YE&
M+C2JRI_MY1117GGM!1110_4444 %%%%!1110_4444 %%%%!1110_5_~A
M|'5,2'|A|X#S%'XD;X2;X1?%YY%QG!W-#\$6%RB7-G/!<1 MI(O|#O|P;_"|H(M=|I-
H^)_J6?#2OJ!^O<|1YSA3J<)2A.&|PDHSA)QE& M2E5:E&2:<6GJFFFGJCY+P+ITZO
_J56\$*M*IF^90J4ZD8SISA*GAE*\$X23C*_M,DVI1DFFG9JQ|H?"W|AO|DWX,^,++XA?
#WX(^%--|=Z3;7%GH/C'6Y=;|;>) MO#%G=Q^3=VGA'6O'&K>(|O|
(VMW!_H|U;~&;C2H;BV_T:9'@_=U|7T45|'6K
MU|1)3Q%:K7FHJ*G6J3JR45=J*E.4FHIMM*|E=|S|BPV#PF"INC@|+A)2"|5U"8C"6/A
M;Q_+<:~;|(K|I+SXF9*NL>Z+^L&O\$?VE/|@7X5_:~^/Q?^'C1\$_X1SXM>/ \$M?
@|JNC"MQ)I%UJVGROZ/XALXG(5M2|~:RNG^(-+9CB/4=-M9#|W%>QD&:2R;
M_#F";Y*~*KI?;PU3|WB(VZOV4L.%|H349;I'R_&?#|.~&WR62C|7%864 ML'5DJ>.H-
5|%/F>L8_6*=.-1HNE*I&H_RE?V:~CKXI_9D:~^#_|O'@Q
MW_X2+X2^/_#GC2UM%F:"/5|/2K^)|9|.W)=;\$;4?#~IA1N?3M3ND!! M;(_UI?AQX_|

"_Q7^'W@;XH>"-135_!00&!(>'/'/A35(JH74/#OB01I/7-&MO-
JLX1KC3I/ZWD>/>QC=FC))4U_D0_\$SX=^*0A%10'GPJ!/?%>F/N)L?
\$/A36+S0I7ME9E0R1QWUC.L,P4+-%LE0;'4U_>W_P;1_M9?I_M"[?V)M7^
/B'4_M7C;IE?Q6WAZSBGFV\N/A5X\EU+Q+X%NG=R)'73-:A!;^M%8(45XK#1I!T*\$2
3111_JOB9ED<5EN#SF@E-X2:HUIPU4L)BFG2J.2WC3K\ML8='I9DS^=?3/YY?GN:
<+8MRI1S*G+\$X:E4O&5/LN4EB**@[.-2MA/:2JW M5UJ1A&R/Z-
J**^+/'^B'4EI^QG^QC|?/VA6N+:+7_!O@B\LO-O%_V9O"MY7\Gf0/I=/CBWN;=
%36;V7X)_#?5M5\RXO+R.6?M3?&7Q;2B>[+RW,H>R>#-
%MM9B8R//!XOT^2X=I+R(?V(UJAQMB*5/&8+(<M++FPF08.EA\$UM4Q=2\$)XJH:
I^Q7MOJ6GW=M>Z=F:C:6NH:9JVE7UEJ6G7UM#=#65U!-&
MKCXZC\^VU+ZPZJH>TAI=T5%UE2YE\1TE-Q@ZBA?D4VHN5E)I79^H8KZRL-B'
M@E0EC/8U?JL<5*I#/\$?P-\OMD.0T%_XX\++&
<9DAFDBV._N/!&;@I\4/'^FF@_M'^*/B+I.?7PXL?A9XV\%Z M3X+TGP5-
XAO;LZ%XLTC7KYX/%&K;[J=U#K.KV5QHF\$U/2=(I-6<I-SL.C1/%
MYLG\8W_!9#_@G[X:_P""=G\73_"SX>ZUJ^N?"KX@>!=(^*WPX/B";*I UW0-'
MUC6_\$7AW4?"KZC#%;)JMQH6M^&=0:QU\$VL,UQH-JHWVY\G4TOKF;^@/_@TW
M_P"27?MG_P#8_?I_W_P!1WQW7ZKG'##?#F#X-K9ME=.MB*E.&!J4.;BJDI5XPJ
MXNA3G'V4?9T:*<>>/O
M1O=:I'J%8B%6IAZJ/#UOJU>I1JPHXCV<:WU>K.\$HTZWL9M0J^RFXU/9S:C/E
MY9.S9_+WJ7_!TM^S)X&-=TR9I;5=%U*V^IHJVF2@-I
MFO=.U3Q5I=Y.S;&1WBN889\$##Y&!#&M#_P_4?I*^I7MKIN@?LP?M+ZSJ5_/M!::?
I*_#DWMJ>7\$JQ16EK:V7B\4)YYY694@BACEEFE98UCR0:C_.#FO\AO M1?
B/^SUH'I:G@KPI;1?CX%ZGI\AKXG:AIH&E\XE^#_(JU&+2-/N15>%#/
MJ%QX#\97^D'3792++0/\$_B>XNIA:6%NL\SG_!\$[XQ^#_@=_P4W_&60%OCJ
MWL&\ZYXLUCX:'4;I(RN@:S\5/'NN?#_...W%/,#%8_9?\$GB'28;Z^D*):Z
M1*E7PU'%.KEZS&NW\9PM)U?JZJVO:M%MTY0GR'-,'PIC^(!#8_9?#YS+
(I'&/U';*!:'MUN6';Y5+#5%6IUJ?ME%SHS:J*\$HR7I^GIWI=I?
MU>&_B)XE'I.GQM_9Z@!MZUH6D6JEI:="AWOBR/7+"IOOJ.@1^1\$EQ9V
LUAO'C>94ENK<I.;^E_MK_M+5D/I&7P+U+XXW/PF^(_P
:+72_\$7A_0KGP9\+-;34_%7DZ\<2V\ZPMM(K1MC3M+H27TLA1(TD0F1.IY,%
I2\$G@/K-65Z<5%3I?6FO:MKVC4GS\MX\UDK)'I#T)FD#J9OI7-70JP6%JTY3=*OI V?
&7U=JC M&4(^RY^6HH7E*FS^76Z_P"#J3ID_3IKJQU7IF7HK3=5LY9;>YTZZA^&T,U
MM/6/%EQX>O=6&FZ>GDL&>XFA4@@MK)U_%7_(+?"2/I NO_
(+G?"SJE7X70V5AXEO/GP;^%?Q%UW2I&"2?3I/M^*K^*WB_QEK A0'4\WP?
I)/%%A=RFY=YVT_P\9:3YB);PQ1?VH_7X""C\I F M;X4>#_@K\%?!"E^"?
A\X)TJWTS2=)TRWACENI8H8TN\;UN\2-)I:2:U.C:A MKVO:@TVHZOJ,TI
I>3R32\$UJ\KG6&X6RW*LMKT\HQ\JHYO@?K=/#SS*NX8*E4B
MU2KSER)U^.;O1@X04U";FXV2G^4*XWO"SSB+/(<)7XEP7\A\9N\MK8RGD6#
MC5S7\$8>:EB;)2I\6%<*=HXFJHM65&56FJ4:CDYT_8*^9?VD_P\LO\EO\ID#0 MI'7_
I/XW>!OA/:ZM#>W&AZ;K^HRW/BGQ'IHA749?# '@O1;25/%_B6.P>Y
MM8\U\T/4%M);JUCN#&JS_LGTU7P3^WG_P\$X/V9_P#@H?X"M?"OOS\747B
MOPU8ZO#\BGX:NY-;#V\U=8#<3Z;.&3I:TFXN+2TEU'PWXB\I2T;IA
M98X+/44MM1MOB>\$C3EB(1:=I056\&E*SED)J'XPG M)*+_
%C.9YO3RS%SR&E@;^;1I\6#HYE.M3P=2:E%RA5G0M43E3YU3M*\$75Y%
M4J4X.4X_B!^U%_P=-?;PE;ZGH7I)7P5\7_%[Q JRV\GXY^*+CX=_#Z&?DPZ
MC9^';*74_'/B6S&)-/U)/AY=L6)6\0(#+^P"P+^T+XL_:N_8X_9^:(I=M:1X>T'QA\5O
=OXD\1Z3X3@U*V\6>JC4M1TVY71+;6-3UG5+;3Y7L//@MK\ M5M2N;=9?)DO;DIYK?
Y8WQQ^%.M?GXT_%SX)>)+JWOO\$'P@^GCKX8ZW?6:/M'9W^J>_\$_^J>%
I Z^LTD9W6SO;G2Y+JU#.I?9Y8\LO^8_Z7O_1C_P"47?I&
M7_9)O_ZD_B&OT7C7AS)%K5(WYFJ<8R<8 M2M3ITU=)VW/P\PJXYXJXJXMSK"
<08J"I8/*JTH9=0PI'#X?"XFF&\$HS:45*MM.<5.I\RK5ZTK-
I2M:WZ=5XW\>_V@O@W^S\I.?\$/QB^_C\0OAS\?#4(:_U MW7+AE:ZNY\$D:ST;1--
MTGU/Q\XAU-HGBTK0-%LH\5\2E5DLI.4J^WV2OBCIL MK_@GQ^RI^WO8^--:9!;
I\XQL?AE=^(HPC;:XW\6^#HK*[\5PZ+;ZQ/=I MX6U?2UU.22'0-
/CM6OQ;.%1="T.0O+KS?S?I\K\RO5%8^>(IX/GOB)86%.IB.
M1)OEI1JSIT^.;2AS2E:"DY\I^7DE^ZYI+,X9?BI9-2P5;-/9VP=/:U:A@G5
ME*,>,\$5;/2K5O9TX.53DIPYJLH*E\2BINK#^#?I X*Z_1%@_B%_P4<I90^"/M!UIJ_P
OV5!&LR7_@OP#=#SHFN^M8@66UM_ _Q)^Q3SV4NL"VEG70/#=K/

M=Z7X3M+NXBBO-4U2Y0-6G|B_X(X_!%COA7_P30^%?Q?^'_Q^\$'Q!^)-!2?
MB#I/C&PO_!VK>'-.M=.M.-!0:.(IG>1ZW/%-)<231&9'A!C\$9_)W9%>2_P#!
M>3|B_P#9^_87_!|'^/PD_9O!*ZGX0|#^(OV;O'''Q%U73=5|4>(?%MQ/XKU?X MG?
&#PS?7R:EXEU#4K^"&72/'".A6ZV44Z6D;VTD|<*S7,|R?<7_!K_@F'^^QW M^WC!%?
CQXS_:5^'^N^,/\$'@7XHZ)X8|-W6D^/?&*A&*ST>|)VVJW%O+:^&=
M9TRWNY'O9'D%Q'-4E62E5E|=N2OJU:)'_7PX_K^*>+H4 O_),K MJL/^";W_ 4&|\$_?
!%)/@=XJ^_7@'P!XJ^'.C^%?BMKGPHN=\$|7WVD:AJ=UJ> MA^\$/
OB^;58)M%DEM5L9|7OU9VD44C"X6XL;IW410\$3|??.I_P2G_.B' M^,O_-|?
Q9_^.ROT;_9" 8O_&?OV%_AKKGPD_9O!*ZGX0|#^(O'.I?\$_75=- MU7Q1XA|6W\$__BO5|
|_&;Z^340\$NH:E?P0RZ1X1T*W6RBG2TC>VDGCA6:YG>
M3|JSG\$<&5, #*.28',Z&/H3<:F*FY409)_O\$U|U;E|S>^JT/Z)X6P7BE M0S:%3BS-
L@QF3JA64Z.74U'\$O\$-+V\$D_|PONIES.?|U:6|V6Q|4U@^)_%/A MCP3H&J^*_&?
B/0?"/A:0K22_UOQ+XGU?3| T#1K&+'FWNJZSJMQ::=H'I'D> M9.O K-97-
|J\$3V45CI_B32-9LM0T:QO+|=8:RC1V0^<
MP%'''5|71H8|%RP.%G*U;%1H2Q#I1L|/V4)1E*|M%M-J?-RRMRO|G.<3F6#R
MW%XG*,NAFV8TJ:EALOGBZ>!CB)N44T|35A.\$_2+E449*/M"V:G!R4U|(_MR M?
|'_*P"R_P# O^U_-|/!*.B' |H_XD6WGVAl7?:+OP|!\$-#O4W1F7_(2 PKK_M(-O*
_V;PI9V/A|4|=MUEX|C8::_7|G?|LW0/%'_!/_X3?MM?M'ZUX)^% M.C^(/@KX?^*Q-
U6T;4K#P;X?N;^UC%|H=IJ-[KFN20WNHM'9^'|!%|KFO7 MJ|>6.BV,FKZI<6XN?
|N'XL?#3Q3|_%BE|2?@|XXAM+;QI|*?'OB_X<>+8+"Y M-
Y81>)?!'B#4/#6N)87ACA^V6(U+3+G|'=B*,7-OY4X11(%'|.W|/'P&:_C_M_"TW|./+G|
_@3Q5+|OV\$ _P!D#X=>"?'''Q*^(VMZ7%_"=O?Z4OBC_A M-
UBWT72EU/5M)T30CJ&J^)+F_U*^UW1="M/U;_ ^"|B MP.79;4HU_JV\$6(5;_LXKU)5:T|
(Z+<8T80CR2J5YRA'#TJ%%MRESRC.,)M_S MEPGXJ<89OGF>4L3@_K^8O
RPN1<,X.C'#X:GF2Q=,ZF)K5)>UIT,)1C6J8W M\$XO%*,80=*\$Z4ZM-'H7|3A P=5?
\$%/&NHZ5^R#^S|X_7P'IEY+:V/C'X_|M_"4ZWKOBRVBD*C4XO!G@3Q7X+A)|07!-
K9W?BGQ)=M!Y=Q=_8;B233;;|D_M^"/7_!8C2O|@I?IOCOP+XW|Z;|+_CY|_-
(T_Q+K>C>'=00-1|&>,_!|_>I MI4GBGPJNIM-K.BOHVLSV6F:|X?
U:|U4V@U;0|VQU|5|J%|:./^&_|7/_:V M_%SP/X>L?\$_G|'Q<@^..HPL(=
<^"Q*@T#X=>)95*_+J'A:Q8VIKX0U\$M(<7 M&D>(&|+_&2!#;/ZUJDSBS3|_?)
@@@Q_P2'^-/!6M?%3X^?M+/H&A_%3XA^ M\$;;X: ^&/AWX(;
|Q1KVD27.@76M:YK6@^'H|L-!O|
M5+33-.TJ>XN=4N+K5S8Z5P9U1X!EPY6JY34HK'4_9QPMJE=9A4K*I|3|M0KM
M3E2E#G%
<5XR0XYPV'XDHXJ645O;3S&^'P4DC|GXHXER|A/)L5G69SDJ&'484J-.WML7B:EU0PM
M"+:3J56FVW|M.E&I6G:G3FU|U?MX_P#!>7|B_P#8EU06/AQIU|JO|0OQLT66
MXLM6^'OPLO=-_L/PIJMN71|_|>?\$_2!:?0M!OX9XI;2_T?0K7Q=XGT:|C|G6O
M#VG|D8_&OPU_X*5_|%U?VKM%M0B'^R_, \$U/@WX3^%VLO+?>'=;^_.GB'7+;
MZMI=QM>SOM'O_GQ3^!5WXGT^ZA8;;WH7A2;2;M_9H9@A53^3G_ ;K?|\$_S
M_"O|5/Q.|5_M8?'?PW;^*?@|!#/\$%EH?@CPIKELEYH/Q ^,CVMOKDL^NVMPL
ML.K:%|_M)N|(UB|T:|3D)K&O>(O#8NS>Z9INLZ5>_P!|*JJJ%4!54!550 JJ M!@<<
#@#@#5|5G<,@X9K_-EX/+J.*X7R3%5*BRG*'_!_?P38^!KR^AL3XQ^%OBG7|!)-
/XC\$DEEH MFJZA8:E?^5(L<, CF>'|.V%O^"VW|\$_|=J:5X\$|_>*=3^\$'QIU4|!8_"7X
MN)I^B:IXAOBK%|7P+XELKV|_|+>.)F*NUH5MJ-CXLNH\$>Y/A>&&*9HOU7|_>
M"_"Q&|)^(? GCWPUHGC'P7XLT|T+Q-X6|2;:::QH6NZ/?Q-#>:=JFF7T4U
MK>6MQ&Q5XIHV&=KKAU5A_FJ_|%C_/_@G;LSW-U+>Z';6=_%XA|
7&K2N;JZUCX>:K+JZJD_|-"BOYA/^#?O_(X>)?VIM&NOV/OVD_\$TNO?
M';P#X>EUKX8?\$_6+G?K/Q8|_:L4>J:-XCNIWWZM|0?!4\$D%TVJ9DU'Q9X4%
MQJVJ1S:MX:|0:YK|/|=??&9OE.+R7'ULOQD4JM)IQG&|HJ4M:=:FVDW":|H.
M,E*\$DI1DE^|_|1Y=Q7DV%SK+)R>'Q*<:E*I95L+B*=E6PM>*,4:M*36S<:D
M)0JTW*G4A)E?S%_|'5'_ "8S|"?^SL/#?_JH/C'7|E?S%_|'5'_ "8S|"?^ MSL/#?_JH/C'7|<'?
|E/DW_86O_3=0|QO_Y(#BC_+%W_NQ0/Q4_X-A?^4D6 MN_|9M'Q/_|4L^&E?Z#|?
Y|'_!L+_RDBUW_+H^)_*EGPTK_\$_Z|KQ) M_P"2D?|V_87ZQ|KX#_
/)"+_L_M!QO!|/HFFV64%YXROK*3X>ZO*LA%M%)8?\$_2Q|-V4^
MI3M'_9VA:QK|^UA2O|
M_VL|R|TZ|M=0L+FXLKZON8+RRO+2:2WNK2|MI5GMKFEVN(F26"X@F1)89HV62
M*1%=&5E!'|HPEB*7\$O"-7*|5+FJ8>C4RNLWK*-V=|'72O|_|NZ;A&#>|3#R M?
O_C3Q*P.(X\$|2|Q%@(HVOQ?|:Z|D).|WJOB3Q#=#

M7_@#X.>&5C@8%K^1I_&NHS:5<[C,=6]*: @L2?Z-*_P#1M_P3|_:IT+JK'AK
MX*_M.:QJ^G6=WJGP|+?%:[FFAM++0?'?@*YTXFSWBM173-.77=#U76[(7
MC"'^IW3KT%K>>*5_Y0?^"9^AZC_P55_X+=_%KJM+Q9875_|"SX.>)|0^,NC
MP:E"S064.AS)X&_9C|*7"L"+35|)L-)T|QF-L<,5S?|_P_U>5UCEN61_SWA3_M_O+2*
"8[%(M)MJ-.E+#JK'|5&5>.MFG_70^PU^S_M+H_|'?|)?
P*_9RTE;5Y_AOX\$TVR|47|FH\$&M>|=7:7Q!|0=>B.T.T&L^--5U
MS4+192\|D%E|;6ID=8%-?5|%%?.\$UZ|3\$UZV(K2K4K590>52K-SG)^LI-_M_6,'A*&
PF%P.%|HEAL'AZ.%P|*.U.AAZ<:5*"|H4X1B00****R.@_A\$ _X.MK_|D|7|G;_LVB#_
-6E|0: ^U?|_@TW_.27?MG_/8_?|W_-1WQW7Q5_P=M7_|)XO|.W_9M\$'_*M+X@UJJ_|
|IO_|DN_|/_.Q^ ^#O_*COCNOV;&_|MFMH?|><'_P"K6F?RYE/_ "D+CO|
K_F7_K/S/ZYJ***_&3^HSS;XR?"OP|<MOA-|2_@SXZM/MO@|XI^!O%'@#O|
JH90|(|5Z->: +>3VC.&\$-_:17AN|/N5Q_M+:7T-OT_M=-9|ZY/9Q:KH||#(1-9SVEY;RLDD-
R#_|14(-XC),3|#\$RBM?J&/G"FIR:U?L,,'#J"VB_ML35E==?Z^?|
@G'^U!'^V3^Q3^S|^T!)=07/B3Q9X&L|^(*0A(_LWQ+|)(33
M>\$ _Z&U3#6<%WXHT;4=5TRWD4,='U#3IU,D,|4LGTW|6?B;X3^"WPO|_B|7_MO'E^_
|%##P5XF|>^*;X;#)!H7A31|S6M2^SQNZ">|DM;*2*RM58275W)#;_M1|I944_R,?|
|JO^U3MD_-#_&_\$.I<2+?:'_X96L|X=|/*|%.?%#3|=I6P_M2RGX>ZM9:?:8(\$?
B343\$V;J9?M#_(.7_P|J;4/A|_R|V/?V1_<|U=?\$7|J_M_P
:V=MJFD:2))|5F^&G@;4|*U&ZT^*"US=QW/B|QY=^#-'T^(+K.G6/BC3
M%2X07,: ^)C>&IOXQED5.+A0KXV-2G):*GE|5?6933M;_&?#^T@VTDYTFM#Z
MO*N/;<:N+P>5RH8B\$G=ULZP|E@*=*2W7UW&NC445=JEB(R5SYU_X_M-
X_AAXJ_:=_:2_*_P""I_Q>L/,U_P=>_-\$O@3X?&!/?WAZZMU,8T?4|>TD&'|+"W|<5?&?
_!/?JEG3_V,?V/_M@/A_L|6|-JNM^"?|5G<^/+NU|MX|4^)7B:27Q-
|0=06Y3+75LWBO5=4M=*DE_MDE>'1+73+-|FUB5?LRO)XCS*:.9OB|11LL+3E""X&\$?
@A@L+%4<.H)|*(<(^MU:Z2J2/I.!LB|68UH3S'-ZL|.I5S7,)O%8V562MS2IU*GU=2LK
MTZ,HHHKPSZX_P_I?_@IE_RD3;_F_P"SLOC|_P"K|A35_H7?|_8_ ^47?|&7_M
&2/FUPIP_%-V=7|-J^C:RZK:ZZVN|>I_+'@M&+|0N,9N*'M>|4Z|,YI_M9/\$?Q9|?^)?
&U|#+,9QIEOK.I33Z5H-JYZ:=X=TC|!H.EQ#Y+?3M.M8\$ 2-1_M7^H^VINH-
^Q=^UXND^8=5;|E_X_+I@A#F;^T#|*?%@LO*\$8,AD^TF/8(P7W_M8V#=#BO|
)7K|B|*L/3Y,XQ;2=7FPN'B^L:=JM6:3|5)|_&OPVM/C'KESY82XU+4OC%=7/Q#M;F|(
DMIH&OZ+HUN|/CA.'|CPV'25##Y1EM&ERVM|.G@Z,8NZWYDKM|/R;:::=PK|?|
M@Y'_&?-/ ^+O_!.;Q|A3(;":Q7^S?X|?'\$72;R.(-?_P#".>)-7M/ASXRT
MJ*3:2NGRVWBG2_\$NI1@H'/A&SF+\$VXCD_?ZOS|_X*NVNGWG_38_8_5_M"QT"YO=
((SQO&JV|D8CU\$@0K|P%=&08BIA,|RFO3;4H9A
MA\$TKWE"=:%.I#36U2G*4'W4FCCXSP-'N\$^(|%72<*V39@TY6:A5HX:I7H5=
M=+T:|.G5CVE!_,S1/V2/CYKO|+G|37P,_"|V/75S;7OPJ^)/ACQ3>I:M(LFI_M^&|?4(|;Q?
X?E|IED>S|2^%+G6O#VH11LKS6.IW,*LI<,A_6YMKF"|MK>|M
M9H|BUNH(KFVGB8/%-!/&LL,T;#AHY(V5T8<,K_CK7^_|7^OY|%K34=|^#GPF_ML-
75TU:R^&?@.TU19%9)%U&V|+:5#>K(C%F5UN4E#*S%E8\$&D@FOTCQ5H4U+
M)L2DE5G'&T)/K*G3>'J4UZ4Y5*C7G4?<_"_HZXRO*GQ3@*3PU.>58RG'|-.MO6CC:-
:26W-6IX>@GY4%V/3*_F+_.#|C_DQGXS_|G8>&_|U4'QCK^G2OYB
M_P#@ZH_Y,9^!/_9V'AO_-5!|8Z^%X_Y*?)O^PM?^FZA^N>*')<4?|B|_M-
V*|^*G_!L+ _P_I(M=|_H^)|_ZEGPTK_0?K_/@_X-A?|_E)%KO_9M'Q/_M_/4L^&E?
Z#|>UXD_|E(^P#"_G6/E? _DA%_P|CG,? _\$C"A1117P|^SA11_M10_4444_%%%%_!1110
4444_%%%%_!1110_4444_%%%%_!1110_4444_%%%%_!1110_4444_%%%%_!1110
UT21&CD571U9'1U#(Z,"K*RL"&5@2&4@@@D\$8_M-?Y97_!5;|DI_P|BW|NOXZ_!C3|_
:3_DWB-_B|A)PL9CM'^&/CXR>(|#5C8_ML0#|/X5>XO|_P|+,LOPT|?
7XD|*ZG|J\$Q!Q9^%?B\$RZ191J5)N?B5WVV:2:4'^OO_(-X/V2/^&;?V|/Q#U_3/L?
Q"-:DU1?C)K_M)?ECBC1|P*^B|1|1A!|266X2*IU|WQ2S7,G%_MZSC0I4|-AXM?
R5:E*57E_P"?M&4|WG*_P_@9@L?G=-Y|F,Q%:'XV<7UJT*&(AA^??
ZMB:=&W+1A;4HHHK|@/Z:"BBB@#^\$3_@ZO|_M^3Q?V=O^S:(/_5I?
\$&OM7_@TW_Y)=^V?_P|C|'?_4=|U^?7_!T;X_|&>+?
MVX/A)X>|+^)=|0:MX"_9XTG1_&5KH^H6NHGPWK>I?+\$+Q|JUMH>L-:2RK8:T_M-
)N+'5)M+N3'>0:J6F79+G58-'O9K*6&L8IAIAU32C=M^4-0MC)^TXVG-
>%U&+A/F6'P|J7-MRM2O9W/Y7RFO1_
MXF#OD_4^26+S*C&7/EE5615*;IJ5|:J1E3Y;|W.G"W-H?V,T445^+|4!_M7Y*?|N?
V3_ ^&MO^">/QG|/:1IG|H_\$#X2V:?:X;K%#YUX^O?#BSU"|U|2|_M*)1YUQ>>(-
YXO|/6%I\$P,^JZEIKE96A2-OUKIKHDJ/|(BR1R*R21NH='1P

M5='5@5964E65@0P)!!!KKP&,JY?C<+CJ#M5PE>E7AK92=.:DX2_NS2<)+9QD
MTI&>:G&68?.LJS'*<6KX?,<'B,'5=DW!5Z) MV;?V(HX;CP9?12)?
>'J3MOA/JUQI/PYFTRJC,EIN?%G2',6W4?" MVD7-JY/V=)*_GD_X*C?LIO\L9?
MT?'WX(V5@UCX,M?%LWC/X7XC9+:3X9>/M5'BCPC:6W"JJ/J_AW4555V;1_:7_P;E_LD?
+.#_!>F?M%CO!IGV+X@?M5ZTGQ2U"2>\$1WUO!.-BN-%^%&ER.!+97>DOK'CW39-
S'R/M'Y1B&3RT_:N+!9@*&51XDPS_-NS/*XY5@*B:O!5!>XXF=336%6CA_:J,TI
MPG4Y&US!F>&>69SC.(I<"XZ-LIR'B"?\$>;T6FXO&Y,I8&E0;=HU*&*QKPD
MTI*U2G0=5*2BS!_****!C^O0HHJK?
7UCIEG=:CJ5Y:Z=JE!)6XNKJX>."W@B0%Y)972-%!9F!-"3;LE=O1);MJA-
DMM))7;>B26!M;Z)^5#_%,O^4B?I&OB!^W3^V-XXI&:S8^(O"7BO!:<^60>&?
\$&EW\$=WI>NZ-M%J?
Q)\1W6EZSI=W"SQ7>FZG9R0WMA=1,T=S:3PSH=L@K_0A_X(:5=
MO\$T%!:1WT,#7NF7ECJ=J);*!MIY/VCC^G-<*9\$G"2=.M@E40%^X_/JQM/3W M7S>
IK;73<_E?P7K4I>(O%IC5IM5!+FDJ+4XOVL?;PTIT?7(U*!KEUVU/
MULHHHK\7/ZI/X\$O^#J'_)2#_!W_+,V^'W_*NWJH:OTW_X-19(S^S?^U3\$
M'4RI;O"LCQ@C MTE3PWXI_9EM!/6E7Q1A!<:YX!^*?
Q%UWQ!:1RD;&ELI#XD^&HD#%HTOH&8 M2*6^;/A @M_P5 ^'7_!/_XN?\$KP+!?
+G4=+^!/_OXL_#+:GXPT_3;_7&^'?C MCP?)JT>B:J?Z-I4%WJUWX;UC2!U32_\$3Z-
8ZCJM02*\$GF&,H5,17:ITJ'U!^*^7#5:LY64*,YU**E5DU"\$*GM9R5. M,I+-
\$4:*(SXP_!%S_ ^"8WPB!\$7?C!VEO#?O/OULGN="!#?"6QU3QEXQU^
MZ\HRPZ;#;1VEGHV@7,V-IG\8ZUX;T^!_W=Q>13%(G^R?V+?V@O'_ .U%^SWX M.^_
_Q&^WBKIG+6/&T^LW^D?#GOEJUIJ^MMX/&I3CPCXGEDAL]*OK.+Q+H1L
M1%AK6B:-J.\$S3216EQI\$VEZKJ/X!7RK,<+AEB!5@Z^%PIJA">)@V/*I4<9
M3M2I5N2K548Q?;G"4*;<5.47***?].83B/(PQIR\$+TPF88R.&EBZE/ U5C
M(4*\$9TZ:EB,1AO:X?#RJ2J1IC2KU:=6LE.5*\$XTYN/U51152_P!0L-*LKK4M
M4O;33=.L8)+JH!^YAL!*SMH5+RW%U=7#QP6!\$2_M)+-(D:*S_,UYZ3;LE
M=O1);MJC6TDVDDKMO1)+=M!\$C_"E_ ^"DO_*0WJNG_+.I_-:16IXNK_1
M%_X(X+*,+IB!_LC>F_ ^G?6*_SEOV!/%_AOX@?MP_MB^.?NL67B'PCXP_:MB^/?
B7POX@TR>.ZTS7?#^M?%+Q3J&CZSIMU\$S1W.GZIHQ:WUC<(Q6>UGBE&M
V!_H=?!\$1_'W@SQO_P3&_91M_"GB71]=N_"P^D!)>*K#3K^VN=0!>.(I%!
M1:Y:7^D:W8Q2M=:7>J46Z@AO8H'N!N+/4;82V5Y;3R_L_B!3FN%LA3A)>SJ
MX_-2!7IC_L^I&T!/?N6SMKIN?ROX*5J3!0.+K5;:JMA,QE1M.+IK%9S0DY
M4I/WXIK4KQNN5J6VI^KM%%?C!_5)DZ_H>E^)!UKPUK=JEIHOB'2=2T/5[*
M0D1WFEZM9S6&H6KE2&"7%I<30L5((5R00>:_R1?VH?@'XK_9<:_'^?I/?C2
M"XBU_P"\$WC!7_"4EQ<0F_ZOI-G=M+X;+36T9P1IWBOPW/I/B72G(4RZ;JUI+MM7?
M'^NA7!VO!>+@CYK!9NA6W!47!-VBV!U^TIX \II'B!P3;^1:3?&O
MP+I0EFT^'3I9#%;R?;\$;PE')/%H8NI(Y/\$^@N/#;73WFD^%I)OO!P_X@H9/F
M5;"XRHJ6#S*_.#K3:4*.)I.7L)U)/2%*J5*M'"TXN57%X'\$QIK%TJ,5K4KTI4*-
>E35Y3A"M3IQE5J0 MC+WC_@W>:_-T_P".?_!-
WX>^#9I+CQC^SGX@!2?!SQ+;/(M2Z5!J\$OBOP% M?"W8^8FG-X.1Z9H%I#X=?
M'^"YI+OI;Q'X7GT34;I-&!)X=N(H-0_X2?X M;ZK=:K'?;+;-;KK0-5!4Z1!9_VS<:=);?
Z1OPZ^)'@+XN^"?#GQ(^&'B_P_MX!|^+M-@U?PUXL!+ZG;:OHFKZ?<[9K6!M))
(R!AX+JVDV75E=136=Y#!= M030IR<<9)6RO.<3BHTV!F56>+PU>*O3H6?
M*!%R7NOG"K*4H10K1E"4;^!MH^EX2<6X7B'A;_Y?
4K1CG&18>EEN.PLY)5W1PL51PF+4:XYIK7XC?!"?QQT_P"#G_!,7XP:(U!>_
(OCCKW@?X-^%X2X\$ES)JWB M"V!5>*E\$0/F/#_P@?A'Q5"!@VQQ3W-J)&)D2*7IG_\$?
B3PI/X/T'6/%7BS7='M!>&/#VG7>L:_P"(O\$&I6>CZ'HFDV\$+W%J>K:KJ\$U08Z?
86=O&+UU=W<15O M!\$C22R*H)K_/_!X+._!0#6?^"HO!6'@;X,_LS:3XF!>?"X8:A?
>"O@WHW MAW1!4OM=^+_Q"!27-K!XD!<:=X=MK^@T'3KG6Y4T
MZ;Q+J6F667!63U:3IK7)6&ZUS4!TX%YIV&*3_%;_M#@_#H.P%?A=_P_\$1_+@E
G_!3X3ZA1/BU;Z;?_M3_&/2K&+OLIG;ZC9_M_#P;-
%J5A!+M&U2!I8+Z!_CMJ6!>:MITK:9JFNV>EZ;ANH9X7T!6M5_
M=&NCCO/Z.=YK"&\$FJF!R^\$Z%&JG>:_K.2EB*T' LZ*J\$LDNYHDA
MFN+ORX7=HY0GG!&QE+B?)^6+E;\$N3LF!1C2J.4G;9)*!;T2W/;4YPAP!Q,Y
MSC!2P\$81)H1A!7:O*3:48K5O1(_ (7_@V%_P"4D6N_JFT?\$_+J2SX M:5_H/U_G5?I
!MO!1?I/P!_X*3:2PV_JH:A8>'373!9I%EO;N*.RM5ENYX(9A_14!!((
M(!!R"#R"".""AKVO\$J,EQ&I.+49X##.,FFE*TJR?*JG9Z.VSW/E?<)<# M2A&
<93IYUCU4BI)R@Y4!+**DD!QYHM25TKK5:"T445^?I2% % % % !1110_44_M44 % % % %

!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !111 M0 4444 %%%
!7BO!1WP.!?M+ 7XN +OL@_X1KXM> ?\$G@B_N?)2XFTF;
M6=.F@TSQ!91.50ZGX;;Z?
M75=4:XU+5AH_AW3M/N;06TEGIPUVVEDDBU1D'!%== MF9YGC4Y-
AOJF"i5*M54W4JUIRJUIN=2=2M6G4JU)-VBG.;Y81A"-H0BD4445P M'LA7Y^_MZ_|-
C!GS_@HQI/PUT3X_:!3-.T_X6:AXGU+P!'.?.\$^D^&FN| MCQ9;.:+ZDNM-
JGAKQ%JMBACT&R:R2 69AD:X:5IQ(BQ_H%171A<5B,%7IXK" M5IX?\$4G)TZU-
!LX.490DXOI>\$!1?DV<689=@F'_@V4_X)IO*0!M"7!)R&F^*NFJPXQ@"W!%0
M+@|>5)ST('%07^P;_!/->?/E7?|1=GG;C|-!4|\$?;CKC|9X"N_O?Q;MW
M^SMK^AVBO8_UKXDW_MK/_ "B?Y;?UYL^8_XAUP*U;_57)?\ PBH_>E?|3Y%
M_8H_8K^\$?|!P9D^!7P4U'QSJ?@N3QAKOC43_\$'7-.!0:|%JOB"VTJTO+;_ MTS0_#|L-
AAT>T%L;M8M-\$QF,ES-O4)|=445XE>O6Q5:IB,14E6KUINI5JS= MYSG+5RD^K?
4^KP>#PN7X6A@L%0IX;"86G&CA\2CRTZ-*"M&\$ (H(Q6B04445 MD=)^&W_!6#_@C-
HO_!2OXG_7XGZ?|2M.^%>M_#FPOO!GQ&O)_#EOKFH>-A MO-K|EKVE:3I-
Q;W|DFE:OX=N;OQF^FW-|>VDLOB@M-\$BV>V?JKO#7AS0_!W
MASP_X1|_:9:Z+X+*Z)I7ASP|H|DGEV6DZ'H=A!IFDZ9:1Y/EVMA86MO:VZ9
M.R*)%R<5MT5W8C,L;BL)@L#7KRJ87+E66\$I-12I*O-3J7DDI3U247-R<(KDA
MRQT/'P60Y5EV9YMF^#PD*.89W+"RS*NI3;KO!TG2HM0E)TZ5HR;J*C&"K5&Z
MM7GJ>|%%<)| 5^-G|6G_!#+|B|JM'X^_,?VC?C+K'QR'CKQO;^&;5M.|*
M>/"T7PK;Q^%|/">C>#M_-LW3+GP5J=|:M+I>A6,|Z9-5G|^_|^9!##(+=/V3
MHKLP.88W+:TJ^ Q;_"5I4W2E4HR<)NG*4)R@VOLN4(-KJXH|S-LERK/<-#!Y MQ@;-
F.%IUH8B%#%4U4IQKPA4IPJJ+TYHPJU(HIR74_GM3_@V7_X)HJJJR?M M 2\$
N_Q6L@SD?Q;(_!Z(">IVHJ^B@<5G3?A&Q?_3>?AUP M*U;_%5R5>F#H_>KA
\$YCP3X3TSP%X,|(^!=%DO)M&|%^&-|)Z3-J,T=Q MJ\$NF>'_*M-
_L)+^XBAMXH|Q|6SB;ZFCMX(Y9S(Z0Q*P1>GHHKP)2|:=VWYMNY|E"\$:
<(PA%1A",80BMHQBE&,5Y))'Q5^W7^P3!|A @H1|M'#|(?CGIFIQ+I>H-
KW@7QUX8N+:P|:_#_P 2FW:T;5?#H=VE|9S6M|:L;/6 M|U2RO=
(UBT\$+3VT>HV&DZEIWR&M_|!HXJ&O2IX<_9\OX8DN&,,^M-
MW4HM>M;1F!2.6TL/B;_H_<0J2C3)>Z;%G&4M92IQKTZGLW)ZR4'&,FW*2;9|=O#X?
<(4XJ&.S MK)Z>)QD(1H0%4L1B'6J4X:1A6E@Z|#VZBO=@ZJG.\$4HPE&A^\$!^O_!|
M?L:_L=>(M&^)7C2;5_VFOB_H,|%|HGB3XDZ3INF^!/?#&JVKD)::SX6^&-G-J
M>GPZM;3(+BSO_%>N>,KG2|N."^T632|^WCNJ_=^BB0.S#;?FM?ZSF&*JXJM
M:RE4DN6\$=^6G3BHTZ4;ZM.\$8WUM=W/_|@_|:\$^,GO+^./O\$UK|H M*?
QA|5/&GB'QWXB M-)^(_A_3_#|HK/B6_?4=0AT2P;P'<7-EIT<|C+:V|_|>
M2I%M66XG958?N;11@;Y M#DV?4J5#.X82#(QR8_E&4.6W?
T+T5Z7^M7\$G_0ZS#YXB;7W;?UYL M'_B'7 O_1*Y+|L%23^|*Y^:G|'"!*O|FO_()W>)?
B)XH^ ^N?%S5+_P") MNB:%H/B"#XD^,-
!3V509^'KZ^U"RDTE/3?"GAZ>UN9)|0G%U)/<7:21K\$L<
M4)4LWZ5T45Y&+Q>)QU>6)QE>IB*|U";ZM5|TY*\$5"";Z|L(J*|DCZ7+)|2@ZM256HXQU
F|^VE_P2 M>_8C_;P>?6_C5|+%TOXDR6J6D'QC^&UY'X*^)|L<4,2P6XU+5K>SO-
!7)9P(ML%A|XZT'Q1;Z="|+T^&U!-?DSX_-X-^?VE/V9-5U_|_8@_X*F_&'X+>|4NV
MNKGP7JO@W4)=+O90OEQ7FO?|(U|0|*)>(M0BA"PQW5Y|.H9H55C#+&KF-?Z
MAZ*|S!|29U@JC!12>N|9|EF? O"
MN;8W^TL5E,*697CG4Q.68C"5:LVM'*M*HVK)NR5OYC_&7_M 0@_:_|_&FVLM-
_:X*O?&'XL^ |6ZM|JX^'/ACP;?:=H5Y-!(LL=Y#!JW
MCV;P=8ZG;NH^S:A<_#K5|F/ADDC"|&_6O|BG_@E_^QO^P-8O+|!AE'__)U
M>61T_6?B|XYNT|6_%+6+60!9|8^(|BUM;3PH|X%C^W:-X,TGPSH=|_|YI
ML|Q\$|LH_06BIOG\$.<8|/_%2MBW3P?7"82C0P6&EM|=|"4J,*BND_WBGJD^B*
MRS@CAC*<9_:6&RU5LS22699CBL9FV/A;1.EBLSQ&+JT&DVKT)4|&UM)W****
M|4^K/FW|K?|_99^&_P"V2!|?&/_OQ:OO%VF^_ '%UX7N|9N_VKV6A>)HWA
M)>*|%|8::EAJ>H:3K=K;QS:IH5G#?!|F::Q>XAB>"61+B+|=|_(-D?^": ML
EN/VB;SY2,W/Q3T9"23GS7A/AK/,3#&9QDF7YEBJ=&. M'A7Q=":-
<:.\$)U*D:2IA<7FE,Q&'J*J4:M:4X349QG'F3WM.\$9+S M7J88#@GA+*|91S#+N|LP6-
P|FZ&)PV&A2JTG4ISI3<)|M;FISG|Z:QDUU"B MBB0&/J HHHH **** "BBB@ HHHH
**** "BBB@ KQ/X_?' X=?LU_#Z;XD_\$
MR|O;:0UUC2="M+32K>*JUG5=3U>YM+72K&:YM\$NY;2OBO|_6;R/|1&T>EZ7 M?
S1B66.."7VROPY_:?DD_+X*)?"7|F+>|W|_|?@M%%XI^(5FC%|&_OA86GB-MSQ)%>A
4EAN|_X1?P/\$2KRZ=?;MJZQR0MNB29)%!\$J_+"N M*(-

J+J+T5>!@5D:JXK\+^%;2'4/%'B30/#=A<2K;V\|KVL:=H\H/.XW)##<
MZCZO+R>*UM,:%!EY MKBXG=(88D'+22.J*.20*+-(S=#P_X(\Z\XMULV,
MNKT:3X>TRYU;43:6QDB%Q<_9+27R(3+&)9=J%UW;A-X>|:>#O%PN#X4|6>&?
M\$XM"!='PIKVEZT+8D\0+@Z;=7/DD\H\$FTDC'6O(VM_ ^35_VD?^R%?%?_U!
MMR*:K;V5Q-+9,+NVN+;,\$ZH?.AEC^C?G1_P1\N; >V_9 M(U%
fF>&W1OC!XQ0//*D2%SH?A\$A0TC**"Q"L0H.< G& : ^>/^"5MY:6_ |2W|9
M+SW50"DNKR&-YIXHUD' GWBPY1G90_!!^4G@@| #5N"3G9OW+6| M+7|R>:
MW+UO_P #_ ,>6BJKWUE%''++>6L<4P)AE>XA2.4#!)C=G"N ""2I/45FZKXF M|
Z%UU75K#3|G5KVXEC@@|L|, @N|B&6_NHYHH8K> MU66:266.-
\$9W53F4;E%8'B'Q7X7|)6D= P"*O\$F@>&;&63RHKSQ#K&G;+:22
MXSY4=QJ5S;0O)@@| %!Y/16LTT<32<@?(KLLD@?*"R0.I% %BBL|5=7TG M0K"?5-|
M,P7LWV>SG|0:UINC0W=P "8+;34;FV2>;#?*B9WP0=O(H Z&BHH)X;F&*YM
MIHKBWN(HYH)X)\$EAF4E4/%++&622*1&5XY\$9E=2&4D\$&LK7?\$GAWPM8G4_\$
MVO;+XWD*D@,\$D)7(SC-;M &)XE| M1Z'XA/:YXL|3ZG;+X<|
+3J&NZ|J|ZS)::9I&E6DM|J%|<,JN_E6UK!+,X MC1Y&";8T=RJG|Y_/_!53|G|XE?\$WPY|
?"?@|XQ7K>*?%NA^#-+|62^&/#M MOX:75/\$6J0Z1I5Y?
L_B|^U| #2KBYGC;SKC2UU%8MO_LOS%,8|D_X*"ZC#;_L M=?'Z&.JAANW|&10^2+B-
+AHKG6|(AFC|K<)"LUO+(C#;|T;MV->2_P#!*2WT M/3_V-/
+6RZ=:ZEK7B7Q|J&J",V|=YJ-J#XPU72|:YNE!\$L|>FZ;H| \$|AF M6VM(T.R-
0+2CR.33;YN5;VMI>Y+;O9::7_'8_2FBL77O\$GAWPM9?VGXGU_1 M?
#FF^8L7|H:|JMC| %EYK E8_M>H3V|F,%8JGF;B 2!@&I=%U|0_\$EA'JOAW
M6=)U_2YF98=2T74;/5+"5DQO6.|L9I|=V3(W!9"5R,@9%04:M%0275K#+'+#+
M&KGQ|HEOXCU M*.6;30#|^K6\$.MW|4\$|S-+9.5)<+?W4<-
M;7%Q*| \$BQP6|KD1Q2,H!MT4
M5B:JXF|.>%;+^T0%'B#1/#>G>8(O|0U|5;#1|+S6!*Q_:M0N+>#S&"DA/,W\$ M D#-
&W167H^N;)XAT^+5M UC2|GS;#A_*O+*;>WDV'A MMDAVGKBKL%U:W08VUS;W
0@.8)HY@A;T,8V::3@XSC.#CI0!/7G'B'XP?"O MPGXST'X=^)_B'X.T#QYXI33Y/#?
A#5M?TVP|1:Y'JVH76DZ8^EZ3<7\$=Y>KJ
M&IV5Y86A@B<3W=M/'NDC91WUS>6=FH:|NK;U5@O5KF>*!6" %R#*Z@A 06(
MX4\$ \$XR* ""|MF|M)?^"IO|' %Q%=6|D\$6E?|/S)HYXGBCV?&KX@.^ ^16*)M4A MFW,-
JD\$X!|JH14FT^S?W">GWK|6D?O/15>"|M;H;::YM|@)@.8)HY@A;T-Y M;_
MW8.,XS@XZ&N;UKO_X\$|-7|&F>(_&OA+0-4N@AM=-UKQ)HVE7|R)3MC,%G M?
7L%Q,)&X0QQL/'Y-2,ZVBD5E=5=&#*P#*RD,K*PR&4C((((O!!R*ACNK
M6662"*Y@DGBSYL,30!/17-6/C3P=j>M7GAS M3?
%GAK4/\$.GF07^@V.NZ7=ZU8F+FB|TNWNI+ZV,>1Y@F@0ID;L9%=+0 5\Q
MZ+^UM)=>:.(US|F"P;Q+ _PL_P |V|SO->TNVUR||T9B^ MRZ3=)?W'FCF/RK=|XY7-?
B1\./^4T'Q4_|!&N?^JO| #%5%)|U^D6UZW7^9
M,FTXI=7^J/W=HJM>7EGIUK/?A=6UC96L3375Y>3Q6UK;0H,O-/<3.D4,2#E
MI)'5%')(%87AWQKX-|7BY;PGXM|, ^*%LV"WA|.ZH6MBU9B0JW)TV|N1 S\$ \$ M
2|'2#@<5)1TU%%&90%,*LTOAJ+7M+DU^)40R.TFC)= M'445\$!=BUL J L2 ,T
>%?"|/K/X3?&OXH?\$KX1>"F|2GQ=|*;K5|/Q6-6T9 M+ #3!-
HGB&3PQ>_V; >K>W#7B_VG\$WDL8(?M|2D*3LKZ;K|*O^"<_)^G|<7_ M &' (C-
/JY;ROW5JH1E9;67XI|J28MM7?? (***KQW=K+,|O%-6+IM9@K;E&&
(|P2!4E%BBL/2_\$ _AO7+S5-.T3Q#H>L:AH:/+C4#*QX6,6Y-"&HZ| \$|QRZ)8>)=&N|7C
MDB)\$B2::;WLEZCQE6#JT(9""& P: .NHHKG?\$|B_PEX1A@N/%GBCP|X8M|IS
M%;3^ (=;TS18;B1<;HX)=2N;9)G&Y-V4X.#Q3=1U+3M'LKC4M6O|+2|.
MM\$|V|U#4;J"RLK6/(7S+BZN9(H(4W,%WR2*N2|G)% %VBN=|. ^+ _GXO@FN MO"?
BCP|XHMK:18KBX|.ZWINM06|K E8YIM-N;F.*1@"521E8@\$@8!KHJ "BB MB@ HHHH
**** "BBB@ HHHH **** "BBB@ K|0/^"8<0^ (W|4|L;'QSOAYM| M<^)Y='TRX?
+F/3O&_C;Q3K|S9V|A!Q!;6_A'0(\$0\$;84ME *KQ^W|?B1_P \$
M;B+:|J;29SC4=A>^\$3>HV?;42)XUMD+Y',|A=C|JG*MD#@"X_!4|(_P#I M7|?
>2_BC|_R.H_X+4_|)O?PO_|++9?^H1XRIOP|_P""<=I^T-|.O#7Q, _:L M^*?C|Q?|0/%?
@01YO"VF^%|7L=*|*_ _PQ?:5:S^'M\$T#3Y|)O8+FI|I%K;_
M4V\$<&EW%|YR26NI72SZ|J3O^"U/_";W|+ _^RRV7_J\$>,J_4'X)_|D9^\$?|
MV3'P%_ZBNDT^9QA!K1WKGKUZ\$V3F|JE^A^1'_ 2#|5>+/#GBC|HW|G?7-9GU M?
1/ASK<%|H,,KRFVTO4K37|=|>* &TV&624VEEK4H=|UDCB&&|AN+E5:XO
M;N66M^T=X9^*7|H> ,? O|/?PLTQM9|075K97FGV_B)M,ATMM\$ _#=Q=C4K#1|&WO-
?L|=H3L|VA_P3"_Y/#_ ;3_|" M_B/_-6CK=?97|8O|?|X=_9RUFQ^%?

P_P##\$WQ6^/6NI9)I_@RP^U36&@R:
MOL71O^\$@73\$FU2^U75?.AGTKPH,,:GJ%D%Z7/?T|^T=F=N*U_E
M;4;RVMW^|\$_=U=DGKUNNWXV|#\XOVV_V-M'_&&M%^'G|1G|_C7Q SX8U/1_
M&>G>&M6M|1UJ*_N8KF^L=1U/3=6M;R"ST\R:?.<2:-/I7B'0M1CU#3M5BU"TC
M^S16:7T%Q^LWQ8\OV2O\$_C*:RB):.RN/\$OPEO-M8N+)26'I M71?@MI"6-G<.:?
ZG.:O/H_J&GZ-936T(L,::*X6%->|3ZYXA@>Z>WO(K.2)D M'ZO6O_**MO|
LQV|_P#5+S42U4&Y*34N6ZUTT=F^MN^VHXOWFDK*R=GNK6_, M^)OV%OV7O
G|6/I"%O|_#_X@:UXMT/2-#_:+|2^,;6Z|'7FCV6I2ZE9>"|,T
M2*WN)=;T/7K5K%K77KN22..TBG,|5NRW"QK+%+|B_L5_L1_"_P#:0^+WQ^'^
M_C3Q'X|TC1_A3?/:Z!=>%|0V/6FI7T:~)I;T0-K\$NK>&=9M9W^RZ9!(396E@
MOVAY6V^64B3|3?|_@CK_,FEZE_V5|QC_P"F3PA7SU_P2H_Y.9_-|'"G_J_M?
^+*IRDG5LVK-->3;28FE|FF|K^>QQO_5C^&^B_!_X"?LE_##PY>:I?Z%X M'N?
&'A|2KW6Y;2?5KFSL=(A.)%+J\$UA9Z=9R7+_O&MK&UB)^|'"M>S? O|A/
MQ+X|UCPS^V;^UY|2_%T7Q\$L=1V/?%K2/!FBFPLM.|'Z-X3N|?Q5X=T77Y-6L
M=8FATVUL|*3^%-_%AT>71K4R6VI875H!OB-=6Q0A7%Q;_#W6982A)4!A(BE26 !P+?
^\$(T;Q(/"_@;P?H>JQV,>GK-\$=4BT"&YFMKV/3=|,Z'=,:.)H-,AANM=U
MC5)M6OKY9DNQJ?7:+X7N_P#@G| MO| PY^%?AGQ/KFO?LZ?M(Q:=I-JX;|5-M7\$-
I%9:EKVI3>%8FNO*M|73I|H0-

+O\$W|9_!O#GA;Q'X@T|PW^T|KM|XBO| \$T/4|5LM_LG^*W|*
M4ZWFM75A:W\$&EVK06%|,MO?201&*RNY_Y2VF9/Z,:*|W_B(E9<=KCA952|JL
MK66?V=|;E|/E_P!4?|4_?;6?J_-?V?\ MO)|&W/^XYN7|Z>7_JA3_P!5O|6/
MKT^3Z|]=^N?5X|_I8/I>|G|'VMK< \ LW-|2_+^|Y;^X?*"|>=A?:K^PU^V
M=I>EV5WJ6IZE^RA^T58:=IUA;37E|?WUYA(/&%O:65E:6Z27%U=W5Q)!;6T M\$